" 10 " auf ||| " 10 " on ||| 0-0 1-1 2-2 3-3
" 10 " ||| " 10 " ||| 0-0 1-1 2-2
" 10 ||| " 10 ||| 0-0 1-1
" 15 " auf ||| " 15 " on ||| 0-0 1-1 2-2 3-3
" 15 " ||| " 15 " ||| 0-0 1-1 2-2
" 15 ||| " 15 ||| 0-0 1-1
" 30 " auf ||| " 30 " on ||| 0-0 1-1 2-2 3-3
" 30 " ||| " 30 " ||| 0-0 1-1 2-2
" 30 ||| " 30 ||| 0-0 1-1
" 5 " auf ||| " 5 " on ||| 0-0 1-1 2-2 3-3
" 5 " ||| " 5 " ||| 0-0 1-1 2-2
" 5 ||| " 5 ||| 0-0 1-1
" 640 " auf der ||| " 640 " on ||| 1-0 0-1 2-1 2-2 3-3 4-3
" 640 " ||| " 640 " ||| 1-0 0-1 2-1 2-2
" 641 " auf der ||| " 641 " on ||| 1-0 0-1 2-1 2-2 3-3 4-3
" 641 " ||| " 641 " ||| 1-0 0-1 2-1 2-2
" 643 " auf der ||| " 643 " on ||| 1-0 0-1 2-1 2-2 3-3 4-3
" 643 " ||| " 643 " ||| 1-0 0-1 2-1 2-2
" A " ||| " A " ||| 0-0 1-1 2-2
" A " ||| " A ||| 0-0 2-0 1-1
" A " über ||| " A " over ||| 0-0 1-1 2-2 3-3
" A ||| " A ||| 0-0 1-1
" A-007 " und " ||| " A-007 " and " ||| 0-0 1-1 2-2 3-3 4-4
" A-007 " und ||| " A-007 " and ||| 0-0 1-1 2-2 3-3
" A-007 " ||| " A-007 " ||| 0-0 1-1 2-2
" A-007 ||| " A-007 ||| 0-0 1-1
" A-008 " und " ||| " A-008 " and " ||| 0-0 1-1 2-2 3-3 4-4
" A-008 " und ||| " A-008 " and ||| 0-0 1-1 2-2 3-3
" A-008 " ||| " A-008 " ||| 0-0 1-1 2-2
" A-008 ||| " A-008 ||| 0-0 1-1
" A-009 " und " ||| " A-009 " and " ||| 0-0 1-1 2-2 3-3 4-4
" A-009 " und ||| " A-009 " and ||| 0-0 1-1 2-2 3-3
" A-009 " ||| " A-009 " ||| 0-0 1-1 2-2
" A-009 ||| " A-009 ||| 0-0 1-1
" A-011 " und " ||| " A-011 " and " ||| 0-0 1-1 2-2 3-3 4-4
" A-011 " und ||| " A-011 " and ||| 0-0 1-1 2-2 3-3
" A-011 " ||| " A-011 " ||| 0-0 1-1 2-2
" A-011 ||| " A-011 ||| 0-0 1-1
" auf der anderen Seite ||| " on the other ||| 0-0 4-0 1-1 2-2 3-3
" auf einer Seite . ||| " on one side . ||| 0-0 1-1 2-2 3-2 3-3 4-4
" auf einer Seite ||| " on one side ||| 0-0 1-1 2-2 3-2 3-3
" auf ||| " on ||| 0-0 1-1
" und " 10 " ||| " and " 10 " ||| 0-0 1-1 2-2 3-3 4-4
" und " 10 ||| " and " 10 ||| 0-0 1-1 2-2 3-3
" und " 15 " ||| " and " 15 " ||| 0-0 1-1 2-2 3-3 4-4
" und " 15 ||| " and " 15 ||| 0-0 1-1 2-2 3-3
" und " 30 " ||| " and " 30 " ||| 0-0 1-1 2-2 3-3 4-4
" und " 30 ||| " and " 30 ||| 0-0 1-1 2-2 3-3
" und " 5 " ||| " and " 5 " ||| 0-0 1-1 2-2 3-3 4-4
" und " 5 ||| " and " 5 ||| 0-0 1-1 2-2 3-3
" und " ||| " and " ||| 0-0 1-1 2-2
" und ||| " and ||| 0-0 1-1
" ||| " ||| 0-0
" über " 640 " ||| " over " 640 " ||| 0-0 1-1 3-2 2-3 4-3 4-4
" über " 641 " ||| " over " 641 " ||| 0-0 1-1 3-2 2-3 4-3 4-4
" über " 643 " ||| " over " 643 " ||| 0-0 1-1 3-2 2-3 4-3 4-4
" über ||| " over ||| 0-0 1-1
% ( 10 ||| % ( 10 ||| 0-0 1-1 2-2
% ( 101 ||| % ( 101 ||| 0-0 1-1 2-2
% ( 141 ||| % ( 141 ||| 0-0 1-1 2-2
% ( 28 % ; ||| % ( 28 % ; ||| 0-0 1-1 2-2 0-3 3-3 4-4
% ( 28 % ||| % ( 28 % ||| 0-0 1-1 2-2 0-3 3-3
% ( 75 ||| % ( 75 ||| 0-0 1-1 2-2
% ( 95 % CI ||| % ( 95 % CI ||| 0-0 1-1 2-2 3-3 4-4
% ( 95 % ||| % ( 95 % ||| 0-0 1-1 2-2 3-3
% ( 95 ||| % ( 95 ||| 0-0 1-1 2-2
% ( 96 ||| % ( 96 ||| 0-0 1-1 2-2
% ( N = 30 ||| % ( N = 30 ||| 0-0 1-1 2-2 3-3 4-4
% ( N = ||| % ( N = ||| 0-0 1-1 2-2 3-3
% ( N ||| % ( N ||| 0-0 1-1 2-2
% ( ||| % ( ||| 0-0 1-1
% ) , jeweils ||| % ) ||| 0-0 1-1
% ) , ||| % ) ||| 0-0 1-1
% ) . ||| % ) . ||| 0-0 1-1 2-2
% ) als ||| % ) than ||| 0-0 1-1 2-2
% ) der ||| % ) of ||| 0-0 1-1 2-2
% ) erhielten kardiovaskuläre ||| % ) were receiving cardiovascular ||| 0-0 1-1 2-2 2-3 3-4
% ) erhielten ||| % ) were receiving ||| 0-0 1-1 2-2 2-3
% ) pro Gewichtsabnahmekategorie für ||| per weight loss category for ||| 2-0 0-1 2-1 3-3 4-4
% ) pro Gewichtsabnahmekategorie ||| per weight loss category ||| 2-0 0-1 2-1 3-3
% ) pro ||| per weight loss ||| 2-0 0-1 2-1
% ) pro ||| per weight ||| 2-0 0-1 2-1
% ) und +0,1 ||| % ) and +0.1 ||| 0-0 1-1 2-2 3-3
% ) und Placebo ( ||| % ) and placebo ( ||| 0-0 1-1 2-2 3-3 4-4
% ) und Placebo ||| % ) and placebo ||| 0-0 1-1 2-2 3-3
% ) und zu einem ||| % ) and a ||| 0-0 1-1 2-2 4-3
% ) und zu ||| % ) and ||| 0-0 1-1 2-2
% ) und ||| % ) and ||| 0-0 1-1 2-2
% ) von EPS einschließlich ||| % ) of EPS including ||| 0-0 1-1 2-2 3-3 4-4
% ) von EPS ||| % ) of EPS ||| 0-0 1-1 2-2 3-3
% ) von ||| % ) of ||| 0-0 1-1 2-2
% ) ||| % ) following the ||| 0-0 1-1
% ) ||| % ) following ||| 0-0 1-1
% ) ||| % ) of ||| 0-0 1-1
% ) ||| % ) ||| 0-0 1-1
% ) ||| 7.8 % ) ||| 0-0 0-1 1-2
% , Suizidgedanken ||| % , and suicidal ideation ||| 0-0 1-1 2-3 2-4
% , ||| % , and ||| 0-0 1-1
% , ||| % , ||| 0-0 1-1
% . ||| % . ||| 0-0 1-1
% ; 0,5 ||| % ; 0.5 ||| 0-0 1-1 2-2
% ; 1,0 ||| % ; 1.0 ||| 0-0 1-1 2-2
% ; 19 ||| % ; 19 % ) ||| 0-0 1-1 2-2 0-3
% ; 19 ||| % ; 19 % ||| 0-0 1-1 2-2 0-3
% ; ||| % ; ||| 0-0 1-1
% Actraphane 20 : lösliches ||| % Actraphane 20 : soluble ||| 0-0 1-1 2-2 3-3 4-4
% Actraphane 20 : ||| % Actraphane 20 : ||| 0-0 1-1 2-2 3-3
% Actraphane 20 ||| % Actraphane 20 ||| 0-0 1-1 2-2
% Actraphane 30 : lösliches ||| % Actraphane 30 : soluble ||| 0-0 1-1 2-2 3-3 4-4
% Actraphane 30 : ||| % Actraphane 30 : ||| 0-0 1-1 2-2 3-3
% Actraphane 30 ||| % Actraphane 30 ||| 0-0 1-1 2-2
% Actraphane 40 : lösliches ||| % Actraphane 40 : soluble ||| 0-0 1-1 2-2 3-3 4-4
% Actraphane 40 : ||| % Actraphane 40 : ||| 0-0 1-1 2-2 3-3
% Actraphane 40 ||| % Actraphane 40 ||| 0-0 1-1 2-2
% Actraphane 50 : lösliches ||| % Actraphane 50 : soluble ||| 0-0 1-1 2-2 3-3 4-4
% Actraphane 50 : ||| % Actraphane 50 : ||| 0-0 1-1 2-2 3-3
% Actraphane 50 ||| % Actraphane 50 ||| 0-0 1-1 2-2
% Actraphane ||| % Actraphane ||| 0-0 1-1
% Aripiprazol wurde unverändert ||| % of unchanged aripiprazole was ||| 0-0 3-2 1-3 2-4 3-4
% CI : ||| % CI : ||| 0-0 1-1 2-2
% CI ] ( Wochen ||| % CI ] ( weeks ||| 0-0 1-1 2-2 3-3 4-4
% CI ] ( ||| % CI ] ( ||| 0-0 1-1 2-2 3-3
% CI ] ||| % CI ] ||| 0-0 1-1 2-2
% CI ||| % CI ||| 0-0 1-1
% Isophan-Insulin . ||| % isophane insulin . ||| 0-0 1-1 1-2 2-3
% Isophan-Insulin ||| % isophane insulin ||| 0-0 1-1 1-2
% Kaukasier und 9 % ||| % Caucasian and 9 % ||| 0-0 1-1 3-1 2-2 3-3 4-4
% Kaukasier und 9 ||| % Caucasian and 9 ||| 0-0 1-1 3-1 2-2 3-3
% ] ) . ||| % ] ) . ||| 0-0 1-1 2-2 3-3
% ] ) und Placebo ||| % ] ) and placebo ||| 0-0 1-1 2-2 3-3 4-4
% ] ) und ||| % ] ) and ||| 0-0 1-1 2-2 3-3
% ] ) ||| % ] ) ||| 0-0 1-1 2-2
% ] ||| % ] ||| 0-0 1-1
% ansteigt . Die Zeit ||| % ansteigt . Die ||| 0-0 1-1 2-2 3-3
% ansteigt . Die ||| % ansteigt . Die ||| 0-0 1-1 2-2 3-3
% ansteigt . ||| % ansteigt . ||| 0-0 1-1 2-2
% ansteigt ||| % ansteigt ||| 0-0 1-1
% bei Aclasta-behandelten Männern im ||| % in men treated with ||| 0-0 1-1 4-1 2-2 3-2 3-3 1-4
% bei Bisphosphonat-naiven Patienten und ||| % in bisphosphonate-naïve patients and ||| 0-0 1-1 2-2 3-3 4-4
% bei Bisphosphonat-naiven Patienten ||| % in bisphosphonate-naïve patients ||| 0-0 1-1 2-2 3-3
% bei Bisphosphonat-naiven ||| % in bisphosphonate-naïve ||| 0-0 1-1 2-2
% bei ||| % for ||| 0-0 1-1
% bei ||| % in ||| 0-0 1-1
% bzw. 73 % ||| % and 73 % ||| 0-0 1-1 2-2 0-3 1-3 3-3
% davon hatten den ||| % being ||| 0-0 2-0
% davon hatten den ||| % ||| 0-0 2-0
% davon hatten ||| % being ||| 0-0 2-0
% davon hatten ||| % ||| 0-0 2-0
% der AUC von Aripiprazol ||| % of aripiprazole AUC ||| 0-0 1-1 3-1 4-2 2-3
% der Patienten ) ||| % of patients ) ||| 0-0 1-1 2-2 3-3
% der Patienten auf . ||| % of the patients . ||| 0-0 1-1 1-2 3-2 2-3 4-4
% der Patienten auf ||| % of the patients ||| 0-0 1-1 1-2 3-2 2-3
% der Patienten beobachtet . ||| % of the patients . ||| 0-0 1-1 1-2 2-3 3-3 4-4
% der Patienten beobachtet ||| % of the patients ||| 0-0 1-1 1-2 2-3 3-3
% der Patienten erhielten das ||| percent received study medicinal product ||| 0-0 1-0 2-1 3-1 1-2 4-3 4-4
% der Patienten erhielten die ||| percent of the patients received ||| 0-0 1-1 1-2 4-2 2-3 3-4
% der Patienten erhielten ||| percent received study ||| 0-0 1-0 2-1 3-1 1-2
% der Patienten gemeldet . ||| % of patients . ||| 0-0 1-1 2-2 3-2 4-3
% der Patienten gemeldet . ||| % of the patients . ||| 0-0 1-1 1-2 2-3 3-3 4-4
% der Patienten gemeldet ||| % of patients ||| 0-0 1-1 2-2 3-2
% der Patienten gemeldet ||| % of the patients ||| 0-0 1-1 1-2 2-3 3-3
% der Patienten hatten einen ||| % of patients had a ||| 0-0 1-1 2-2 3-3 4-3 4-4
% der Patienten hatten vorher ||| percent of the patients had ||| 0-0 3-0 1-1 1-2 2-3 3-4
% der Patienten hatten ||| percent of the patients had ||| 0-0 3-0 1-1 1-2 2-3 3-4
% der Patienten ||| % of patients ||| 0-0 1-1 2-2
% der Patienten ||| % of the patients ||| 0-0 1-1 1-2 2-3
% der Studienpopulation waren ||| % of the population were ||| 0-0 1-1 1-2 2-3 3-4
% der Studienpopulation ||| % of the population ||| 0-0 1-1 1-2 2-3
% der verabreichten Dosis ||| % of the administered dose ||| 0-0 1-1 1-2 2-2 3-4
% der verabreichten ||| % of the administered ||| 0-0 1-1 1-2 2-2
% der verabreichten ||| % of the ||| 0-0 1-1 1-2 2-2
% der ||| % of the ||| 0-0 1-1 1-2
% der ||| % of ||| 0-0 1-1
% der ||| % ||| 0-0
% einen Schlaganfall erlitten ||| % had had a stroke ||| 0-0 3-1 1-2 3-2 1-3 2-4 3-4
% ermittelt ||| % , ||| 0-0 1-0
% ermittelt ||| % ||| 0-0 1-0
% für Aclasta-Patienten , ||| % for Aclasta-treated ||| 0-0 1-1 2-2
% für Aclasta-Patienten ||| % for Aclasta-treated ||| 0-0 1-1 2-2
% für Placebo . ||| % for placebo . ||| 0-0 1-1 2-2 3-3
% für Placebo ||| % for placebo ||| 0-0 1-1 2-2
% für beide Gruppen ) ||| % for both groups ) ||| 0-0 1-1 2-2 3-3 4-4
% für beide Gruppen ||| % for both groups ||| 0-0 1-1 2-2 3-3
% für beide ||| % for both ||| 0-0 1-1 2-2
% für ||| % for ||| 0-0 1-1
% gelöstem Insulin und 50 ||| % dissolved insulin and 50 ||| 0-0 1-1 2-2 3-3 4-4
% gelöstem Insulin und 60 ||| % dissolved insulin and 60 ||| 0-0 1-1 2-2 3-3 4-4
% gelöstem Insulin und 70 ||| % dissolved insulin and 70 ||| 0-0 1-1 2-2 3-3 4-4
% gelöstem Insulin und 80 ||| % dissolved insulin and 80 ||| 0-0 1-1 2-2 3-3 4-4
% gelöstem Insulin und 90 ||| % dissolved insulin and 90 ||| 0-0 1-1 2-2 3-3 4-4
% gelöstem Insulin und ||| % dissolved insulin and ||| 0-0 1-1 2-2 3-3
% gelöstem Insulin ||| % dissolved insulin ||| 0-0 1-1 2-2
% gelöstem ||| % dissolved ||| 0-0 1-1
% geringere ||| % ||| 0-0 1-0
% hatten mehr als 3 ||| % had > 3 sites ||| 0-0 1-1 0-2 4-3
% hatten mehr als 3 ||| % had > 3 ||| 0-0 1-1 0-2 4-3
% hatten mehr als ||| % had > ||| 0-0 1-1 0-2
% hatten mehr ||| % had > ||| 0-0 1-1 0-2
% hatten ||| % had > ||| 0-0 1-1 0-2
% im Vergleich zum Ausgangswert ||| % relative to baseline ||| 0-0 1-1 3-1 3-2 2-3 4-3
% in ||| % in ||| 0-0 1-1
% mit Aripiprazol und 3,0 ||| % with aripiprazole and 3.0 ||| 0-0 1-1 2-2 3-3 4-4
% mit Aripiprazol und 3,2 ||| % with aripiprazole and 3.2 ||| 0-0 1-1 2-2 3-3 4-4
% mit Aripiprazol und ||| % with aripiprazole and ||| 0-0 1-1 2-2 3-3
% mit Aripiprazol ||| % with aripiprazole ||| 0-0 1-1 2-2
% mit Placebo . ||| % with placebo . ||| 0-0 1-1 2-2 3-3
% mit Placebo ||| % with placebo ||| 0-0 1-1 2-2
% mit ||| % with ||| 0-0 1-1
% nach den ersten ||| % after the first ||| 0-0 1-1 2-2 2-3 3-3
% nach ||| % after ||| 0-0 1-1
% schwarzer Hautfarbe . ||| % Black . ||| 0-0 1-1 2-1 3-2
% schwarzer Hautfarbe ||| % Black ||| 0-0 1-1 2-1
% seines Ausgangsgewichtes reduzierte , ||| % seines Ausgangsgewichtes reduzierte , ||| 0-0 3-0 2-1 2-2 2-3 1-4 4-4
% und 10 ||| % und 10 ||| 0-0 1-1 2-2
% und Haloperidol 73 % ||| % and haloperidol 73 % ||| 0-0 1-1 2-2 3-3 4-4
% und Haloperidol 73 ||| % and haloperidol 73 ||| 0-0 1-1 2-2 3-3
% und Haloperidol ||| % and haloperidol ||| 0-0 1-1 2-2
% und Isophan-Insulin 50 ||| % and isophane insulin 50 ||| 0-0 1-1 2-2 2-3 3-4
% und Isophan-Insulin 60 ||| % and isophane insulin 60 ||| 0-0 1-1 2-2 2-3 3-4
% und Isophan-Insulin 70 ||| % and isophane insulin 70 ||| 0-0 1-1 2-2 2-3 3-4
% und Isophan-Insulin 80 ||| % and isophane insulin 80 ||| 0-0 1-1 2-2 2-3 3-4
% und Isophan-Insulin 90 ||| % and isophane insulin 90 ||| 0-0 1-1 2-2 2-3 3-4
% und Isophan-Insulin ||| % and isophane insulin ||| 0-0 1-1 2-2 2-3
% und besteht aus 165 ||| % and consists of 165 ||| 0-0 1-1 2-2 3-2 3-3 4-4
% und besteht aus ||| % and consists of ||| 0-0 1-1 2-2 3-2 3-3
% und die AUC ||| % and AUC ||| 0-0 1-1 3-2
% und die ||| % and ||| 0-0 1-1
% und um 47 % ||| % and 47 % ||| 0-0 1-1 2-2 3-2 4-3
% und um 47 ||| % and 47 ||| 0-0 1-1 2-2 3-2
% und ||| % and ||| 0-0 1-1
% und ||| % und ||| 0-0 1-1
% unterhalb des Ausgangswertes ||| % below baseline levels ||| 0-0 1-1 1-2 3-2 1-3 2-3
% unterhalb des Ausgangswerts ||| % below baseline levels at ||| 0-0 1-1 3-2 2-3 3-3 3-4
% unterhalb ||| % below ||| 0-0 1-1
% zu ||| % ||| 0-0
% ||| % for ||| 0-0
% ||| % in the ||| 0-0
% ||| % in ||| 0-0
% ||| % of the ||| 0-0
% ||| % of ||| 0-0
% ||| % ||| 0-0
% ||| 7.8 % ||| 0-0 0-1
% ||| percent ||| 0-0
% ||| was ||| 0-0
%. ||| % . ||| 0-0 0-1
& Co KG , Kuhloweg ||| & Co KG , Kuhloweg ||| 0-0 1-1 2-2 3-3 4-4
& Co KG , ||| & Co KG , ||| 0-0 1-1 2-2 3-3
& Co KG Kuhloweg 37 ||| & Co KG Kuhloweg 37 ||| 0-0 1-1 2-2 3-3 4-4
& Co KG Kuhloweg ||| & Co KG Kuhloweg ||| 0-0 1-1 2-2 3-3
& Co KG ||| & Co KG ||| 0-0 1-1 2-2
& Co ||| & Co ||| 0-0 1-1
& D Centre ( Europe ||| & D Centre ( Europe ||| 0-0 1-1 2-2 3-3 4-4
& D Centre ( ||| & D Centre ( ||| 0-0 1-1 2-2 3-3
& D Centre Limited ||| & D Centre Limited ||| 0-0 1-1 2-2 3-3
& D Centre ||| & D Centre ||| 0-0 1-1 2-2
& D ||| & D ||| 0-0 1-1
& ||| & ||| 0-0
( % ) pro Gewichtsabnahmekategorie ||| per weight loss category ||| 3-0 1-1 3-1 4-3
( % ) pro ||| per weight loss ||| 3-0 1-1 3-1
( % ) pro ||| per weight ||| 3-0 1-1 3-1
( * ) eingestuft : ||| reactions ( * ) : ||| 1-0 0-1 1-2 3-2 2-3 4-4
( * ) eingestuft ||| reactions ( * ) ||| 1-0 0-1 1-2 3-2 2-3
( 0 ) 241 941-0 ||| ( 0 ) 241 941-0 ||| 0-0 1-1 2-2 3-3 4-4
( 0 ) 241 ||| ( 0 ) 241 ||| 0-0 1-1 2-2 3-3
( 0 ) 30 60 ||| ( 0 ) 30 60 ||| 0-0 1-1 2-2 3-3 4-4
( 0 ) 30 ||| ( 0 ) 30 ||| 0-0 1-1 2-2 3-3
( 0 ) ||| ( 0 ) ||| 0-0 1-1 2-2
( 0 ||| ( 0 ||| 0-0 1-1
( 0)1 46 25 16 ||| ( 0)1 46 25 16 ||| 0-0 1-1 2-2 3-3 4-4
( 0)1 46 25 ||| ( 0)1 46 25 ||| 0-0 1-1 2-2 3-3
( 0)1 46 ||| ( 0)1 46 ||| 0-0 1-1 2-2
( 0)1 47 56 69 ||| ( 0)1 47 56 69 ||| 0-0 1-1 2-2 3-3 4-4
( 0)1 47 56 ||| ( 0)1 47 56 ||| 0-0 1-1 2-2 3-3
( 0)1 47 ||| ( 0)1 47 ||| 0-0 1-1 2-2
( 0)1 580 00 10 ||| ( 0)1 580 00 10 ||| 0-0 1-1 2-2 3-3 4-4
( 0)1 580 00 ||| ( 0)1 580 00 ||| 0-0 1-1 2-2 3-3
( 0)1 580 ||| ( 0)1 580 ||| 0-0 1-1 2-2
( 0)1 ||| ( 0)1 ||| 0-0 1-1
( 0)1628 537 900 ||| ( 0)1628 537 900 ||| 0-0 1-1 2-2 3-3
( 0)1628 537 ||| ( 0)1628 537 ||| 0-0 1-1 2-2
( 0)1628 ||| ( 0)1628 ||| 0-0 1-1
( 0)20 3116 8000 ||| ( 0)20 3116 8000 ||| 0-0 1-1 2-2 3-3
( 0)20 3116 8950 ||| ( 0)20 3116 8950 ||| 0-0 1-1 2-2 3-3
( 0)20 3116 8951 ||| ( 0)20 3116 8951 ||| 0-0 1-1 2-2 3-3
( 0)20 3116 8952 ||| ( 0)20 3116 8952 ||| 0-0 1-1 2-2 3-3
( 0)20 3116 8953 ||| ( 0)20 3116 8953 ||| 0-0 1-1 2-2 3-3
( 0)20 3116 8954 ||| ( 0)20 3116 8954 ||| 0-0 1-1 2-2 3-3
( 0)20 3116 ||| ( 0)20 3116 ||| 0-0 1-1 2-2
( 0)20 ||| ( 0)20 ||| 0-0 1-1
( 0)21 272 16 00 ||| ( 0)21 272 16 00 ||| 0-0 1-1 2-2 3-3 4-4
( 0)21 272 16 ||| ( 0)21 272 16 ||| 0-0 1-1 2-2 3-3
( 0)21 272 ||| ( 0)21 272 ||| 0-0 1-1 2-2
( 0)21 ||| ( 0)21 ||| 0-0 1-1
( 0)810 410 500 ||| ( 0)810 410 500 ||| 0-0 1-1 2-2 3-3
( 0)810 410 ||| ( 0)810 410 ||| 0-0 1-1 2-2
( 0)810 ||| ( 0)810 ||| 0-0 1-1
( 0)9 8545250 ||| ( 0)9 8545250 ||| 0-0 1-1 2-2
( 0)9 ||| ( 0)9 ||| 0-0 1-1
( 0,5 bis ||| ( 0.5 to ||| 0-0 1-1 2-2
( 0,5 ||| ( 0.5 ||| 0-0 1-1
( 0,6 % ) ( ||| ( 0.6 % ) ( ||| 0-0 1-1 2-2 3-3 0-4 4-4
( 0,62 mmol/l ) ||| ( 0.62 mmol/ l ) ||| 0-0 1-1 2-2 2-3 3-4
( 0,62 mmol/l ||| ( 0.62 mmol/ l ||| 0-0 1-1 2-2 2-3
( 0,62 ||| ( 0.62 ||| 0-0 1-1
( 0,7 ml ) ||| ( 0.7 ml ) ||| 0-0 1-1 2-2 3-3
( 0,7 ml ||| ( 0.7 ml ||| 0-0 1-1 2-2
( 0,7 ||| ( 0.7 ||| 0-0 1-1
( 0800 ) 731 1736 ||| ( 0800 ) 731 1736 ||| 0-0 1-1 2-2 3-3 4-4
( 0800 ) 731 ||| ( 0800 ) 731 ||| 0-0 1-1 2-2 3-3
( 0800 ) ||| ( 0800 ) ||| 0-0 1-1 2-2
( 0800 ||| ( 0800 ||| 0-0 1-1
( 1 ) 524 40 ||| ( 1 ) 524 40 ||| 0-0 1-1 2-2 3-3 4-4
( 1 ) 524 ||| ( 1 ) 524 ||| 0-0 1-1 2-2 3-3
( 1 ) ||| ( 1 ) ||| 0-0 1-1 2-2
( 1 800 ) 749 ||| ( 1 800 ) 749 ||| 0-0 1-1 2-2 3-3 4-4
( 1 800 ) ||| ( 1 800 ) ||| 0-0 1-1 2-2 3-3
( 1 800 ||| ( 1 800 ||| 0-0 1-1 2-2
( 1 mg/ml ) ||| ( 1 mg/ ml ) ||| 0-0 1-1 2-2 2-3 3-4
( 1 mg/ml ||| ( 1 mg/ ml ||| 0-0 1-1 2-2 2-3
( 1 ml ) ||| ( 1 ml ) ||| 0-0 1-1 2-2 3-3
( 1 ml ||| ( 1 ml ||| 0-0 1-1 2-2
( 1 ||| ( 1 to ||| 0-0 1-1
( 1 ||| ( 1 ||| 0-0 1-1
( 1,25 mmol/l ) ||| ( 1.25 mmol/ l ) ||| 0-0 1-1 2-2 2-3 3-4
( 1,25 mmol/l ||| ( 1.25 mmol/ l ||| 0-0 1-1 2-2 2-3
( 1,25 ||| ( 1.25 ||| 0-0 1-1
( 1,3 % ) ( ||| ( 1.3 % ) ( ||| 0-0 1-1 2-2 3-3 0-4 4-4
( 1,3 ml ) Aripiprazol ||| ( 1.3 ml ) aripiprazole ||| 0-0 1-1 2-2 3-3 4-4
( 1,3 ml ) für ||| ( 1.3 ml ) for ||| 0-0 1-1 2-2 3-3 4-4
( 1,3 ml ) ||| ( 1.3 ml ) , ||| 0-0 1-1 2-2 3-3
( 1,3 ml ) ||| ( 1.3 ml ) ||| 0-0 1-1 2-2 3-3
( 1,3 ml ||| ( 1.3 ml ||| 0-0 1-1 2-2
( 1,3 ||| ( 1.3 ||| 0-0 1-1
( 1/100 ) ||| ( 1/ 100 ) ||| 0-0 1-1 1-2 2-3
( 1/100 ||| ( 1/ 100 ||| 0-0 1-1 1-2
( 10 000 ||| ( 10 000 ||| 0-0 1-1 2-2
( 10 ||| ( 10 ||| 0-0 1-1
( 1000 I.E. ) ||| ( 1000 IU ) of ||| 0-0 1-1 2-2 3-3 2-4
( 1000 ||| ( 1000 ||| 0-0 1-1
( 101 ||| ( 101 ||| 0-0 1-1
( 139 von 1 062 ||| ( 139 out of 1,062 ||| 0-0 1-1 2-2 2-3 4-4
( 139 von 1 ||| ( 139 out of ||| 0-0 1-1 2-2 2-3
( 139 von ||| ( 139 out of ||| 0-0 1-1 2-2 2-3
( 139 ||| ( 139 ||| 0-0 1-1
( 141 ||| ( 141 ||| 0-0 1-1
( 15 mg Dosis ) ||| ( dose 15 mg ) ||| 0-0 3-1 1-2 2-3 4-4
( 15 mg Dosis ||| ( dose 15 mg ||| 0-0 3-1 1-2 2-3
( 16 % ) der ||| ( 16 % ) of ||| 0-0 1-1 2-2 3-3 4-4
( 16 % ) ||| ( 16 % ) ||| 0-0 1-1 2-2 3-3
( 16 % ||| ( 16 % ||| 0-0 1-1 2-2
( 16 ||| ( 16 ||| 0-0 1-1
( 172 Mammakarzinome , 64 ||| ( 172 breast , 64 ||| 0-0 1-1 2-1 2-2 3-3 4-4
( 172 Mammakarzinome , ||| ( 172 breast , ||| 0-0 1-1 2-1 2-2 3-3
( 172 Mammakarzinome ||| ( 172 breast ||| 0-0 1-1 2-1 2-2
( 1x 10 ||| mg/ ||| 0-0 1-0 2-0
( 2 ) ||| ( 2 ) ||| 0-0 1-1 2-2
( 2 mg Dosis ) ||| ( dose 2 mg ) ||| 0-0 3-1 1-2 2-3 4-4
( 2 mg Dosis ||| ( dose 2 mg ||| 0-0 3-1 1-2 2-3
( 2 ||| ( 2 ||| 0-0 1-1
( 2 ||| 2 ||| 1-0
( 2,1 % ) ||| ( 2.1 % ) ||| 0-0 1-1 2-2 3-3
( 2,1 % ||| ( 2.1 % ||| 0-0 1-1 2-2
( 2,1 ||| ( 2.1 ||| 0-0 1-1
( 2,5 % ) ||| ( 2.5 % ) of ||| 0-0 1-1 2-2 3-3
( 2,5 % ) ||| ( 2.5 % ) ||| 0-0 1-1 2-2 3-3
( 2,5 % ; 0,5 ||| ( 2.5 % ; 0.5 ||| 0-0 1-1 2-2 3-3 4-4
( 2,5 % ; ||| ( 2.5 % ; ||| 0-0 1-1 2-2 3-3
( 2,5 % ||| ( 2.5 % ||| 0-0 1-1 2-2
( 2,5 ||| ( 2.5 ||| 0-0 1-1
( 2000 I.E. ) ||| ( 2000 IU ) of ||| 0-0 1-1 2-2 3-3 2-4
( 2000 ||| ( 2000 ||| 0-0 1-1
( 221 multiple Myelome ||| ( 221 multiple ||| 0-0 1-1 2-1 3-1 2-2
( 23 mg ) Natrium ||| ( 23 mg ) ||| 0-0 1-1 4-1 2-2 3-3
( 24 Stunden ||| ( 24-hour ||| 0-0 1-1
( 24 ||| ( 24-hour ||| 0-0 1-1
( 25 ||| ( 25 ||| 0-0 1-1
( 28 ||| ( 28 ||| 0-0 1-1
( 29 [ 2,7 % ||| ( 29 [ 2.7 % ||| 0-0 1-1 2-2 3-3 4-4
( 29 [ 2,7 ||| ( 29 [ 2.7 ||| 0-0 1-1 2-2 3-3
( 29 [ ||| ( 29 [ ||| 0-0 1-1 2-2
( 29 ||| ( 29 ||| 0-0 1-1
( 2°C - 8°C ) ||| ( 2°C - 8°C ) ||| 0-0 1-1 2-2 3-3 4-4
( 2°C - 8°C ||| ( 2°C - 8°C ||| 0-0 1-1 2-2 3-3
( 2°C - ||| ( 2°C - ||| 0-0 1-1 2-2
( 2°C 8°C ) ||| ( 2°C - 8°C ) ||| 0-0 1-1 1-2 2-3 3-4
( 2°C 8°C ||| ( 2°C - 8°C ||| 0-0 1-1 1-2 2-3
( 2°C ||| ( 2°C - ||| 0-0 1-1 1-2
( 2°C ||| ( 2°C ||| 0-0 1-1
( 3 ml ) . ||| ( 3 ml ) . ||| 0-0 1-1 2-2 3-3 4-4
( 3 ml ) ||| ( 3 ml ) ||| 0-0 1-1 2-2 3-3
( 3 ml ||| ( 3 ml ||| 0-0 1-1 2-2
( 3 ||| ( 3 ||| 0-0 1-1
( 3 ||| , 3 ||| 1-1
( 3 ||| 3 ||| 1-0
( 3,5 ||| ( 3.5 ||| 0-0 1-1
( 30 % ) , ||| ( 30 % ) ||| 0-0 1-1 2-2 3-3
( 30 % ) . ||| ( 30 % ) . ||| 0-0 1-1 2-2 3-3 4-4
( 30 % ) ||| ( 30 % ) ||| 0-0 1-1 2-2 3-3
( 30 % ||| ( 30 % ||| 0-0 1-1 2-2
( 30 mg ) ||| ( 30 mg ) ||| 0-0 1-1 2-2 3-3
( 30 mg ||| ( 30 mg ||| 0-0 1-1 2-2
( 30 ||| ( 30 ||| 0-0 1-1
( 300 mg/m2 ; ||| ( 300 mg/ m2 ; ||| 0-0 1-1 2-2 2-3 3-4
( 300 mg/m2 ||| ( 300 mg/ m2 ||| 0-0 1-1 2-2 2-3
( 300 ||| ( 300 ||| 0-0 1-1
( 3000 I.E. ) ||| ( 3000 IU ) of ||| 0-0 1-1 2-2 3-3 2-4
( 3000 ||| ( 3000 ||| 0-0 1-1
( 31 % ) ||| ( 31 % ) ||| 0-0 1-1 2-2 3-3
( 31 % ||| ( 31 % ||| 0-0 1-1 2-2
( 31 ||| ( 31 ||| 0-0 1-1
( 34 [ 3,2 % ||| ( 34 [ 3.2 % ||| 0-0 1-1 2-2 3-3 4-4
( 34 [ 3,2 ||| ( 34 [ 3.2 ||| 0-0 1-1 2-2 3-3
( 34 [ ||| ( 34 [ ||| 0-0 1-1 2-2
( 34 ||| ( 34 ||| 0-0 1-1
( 3x ) ||| repeated ( ||| 1-0 0-1 2-1
( 4 bis 6 Wochen ||| ( 4 to 6 weeks ||| 0-0 1-1 2-2 3-3 2-4 4-4
( 4 bis 6 Wochen ||| ( 4 to 6 weeks ||| 0-0 1-1 2-2 3-3 4-4
( 4 bis 6 ||| ( 4 to 6 ||| 0-0 1-1 2-2 3-3
( 4 bis ||| ( 4 to ||| 0-0 1-1 2-2
( 4 oder mehr Einheiten ||| ( 4 or more units ||| 0-0 1-1 2-2 3-3 4-4
( 4 oder mehr ||| ( 4 or more ||| 0-0 1-1 2-2 3-3
( 4 oder ||| ( 4 or ||| 0-0 1-1 2-2
( 4 ||| ( 4 ||| 0-0 1-1
( 4000 I.E. ) ||| ( 4000 IU ) of ||| 0-0 1-1 2-2 3-3 2-4
( 4000 ||| ( 4000 ||| 0-0 1-1
( 44-20 ) 74 18 ||| ( 44-20 ) 74 18 ||| 0-0 1-1 2-2 3-3 4-4
( 44-20 ) 74 ||| ( 44-20 ) 74 ||| 0-0 1-1 2-2 3-3
( 44-20 ) ||| ( 44-20 ) ||| 0-0 1-1 2-2
( 44-20 ||| ( 44-20 ||| 0-0 1-1
( 45 % ) wiedergefunden ||| ( 45 % ) ||| 0-0 1-1 4-1 2-2 3-3
( 5 ) 2649600 ||| ( 5 ) 2649600 ||| 0-0 1-1 2-2 3-3
( 5 ) ||| ( 5 ) ||| 0-0 1-1 2-2
( 5 mg in 100 ||| ( 5 mg in 100 ||| 0-0 1-1 2-2 3-3 4-4
( 5 mg in ||| ( 5 mg in ||| 0-0 1-1 2-2 3-3
( 5 mg ||| ( 5 mg ||| 0-0 1-1 2-2
( 5 mg/100 ||| ( 5 mg/ ||| 0-0 1-1 2-1 1-2
( 5 mg/ml ) ||| ( 5 mg/ ml ) ||| 0-0 1-1 2-2 2-3 3-4
( 5 mg/ml ||| ( 5 mg/ ml ||| 0-0 1-1 2-2 2-3
( 5 ||| ( 5 ||| 0-0 1-1
( 5,1 % ) . ||| ( 5.1 % ) . ||| 0-0 1-1 2-2 3-3 4-4
( 5,1 % ) ||| ( 5.1 % ) ||| 0-0 1-1 2-2 3-3
( 5,1 % ||| ( 5.1 % ||| 0-0 1-1 2-2
( 5,1 ||| ( 5.1 ||| 0-0 1-1
( 5,9 - 6,8 ||| ( 5.9 - 6.8 ||| 0-0 1-1 2-2 3-3
( 5,9 - ||| ( 5.9 - ||| 0-0 1-1 2-2
( 5,9 ||| ( 5.9 ||| 0-0 1-1
( 50 ||| ( 50 ||| 0-0 1-1
( 50 ||| ( ||| 0-0
( 5000 I.E. ) ||| ( 5000 IU ) of ||| 0-0 1-1 2-2 3-3 2-4
( 5000 ||| ( 5000 ||| 0-0 1-1
( 53 % ) . ||| ( 53 % ) . ||| 0-0 1-1 2-2 3-3 4-4
( 53 % ) ||| ( 53 % ) ||| 0-0 1-1 2-2 3-3
( 53 % ||| ( 53 % ||| 0-0 1-1 2-2
( 53 ||| ( 53 ||| 0-0 1-1
( 55 % ) und ||| ( 55 % ) and ||| 0-0 1-1 2-2 3-3 4-4
( 55 % ) ||| ( 55 % ) ||| 0-0 1-1 2-2 3-3
( 55 % ||| ( 55 % ||| 0-0 1-1 2-2
( 55 ||| ( 55 ||| 0-0 1-1
( 6 % ) ||| ( 6 % ) ||| 0-0 1-1 2-2 3-3
( 6 % ||| ( 6 % ||| 0-0 1-1 2-2
( 6 , 12 , ||| ( 6 , 12 , ||| 0-0 1-1 2-2 3-3 4-4
( 6 , 12 ||| ( 6 , 12 ||| 0-0 1-1 2-2 3-3
( 6 , ||| ( 6 , ||| 0-0 1-1 2-2
( 6 ||| ( 6 ||| 0-0 1-1
( 6,2 - 7,5 ||| ( 6.2 - 7.5 ||| 0-0 1-1 2-2 3-3
( 6,2 - ||| ( 6.2 - ||| 0-0 1-1 2-2
( 6,2 mmol/l ) ||| ( 6.2 mmol/ l ) ||| 0-0 1-1 2-2 2-3 3-4
( 6,2 mmol/l ||| ( 6.2 mmol/ l ||| 0-0 1-1 2-2 2-3
( 6,2 ||| ( 6.2 ||| 0-0 1-1
( 6000 I.E. ) ||| ( 6000 IU ) of ||| 0-0 1-1 2-2 3-3 2-4
( 6000 ||| ( 6000 ||| 0-0 1-1
( 65 Jahre ) ||| ( 65 years ) ||| 0-0 1-1 2-2 3-3
( 65 Jahre ||| ( 65 years ||| 0-0 1-1 2-2
( 65 ||| ( 65 ||| 0-0 1-1
( 683 Mammakarzinome ||| ( 683 breast ||| 0-0 1-1 2-1 2-2
( 7,5 mg/ml ) ||| ( 7.5 mg/ ml ) ||| 0-0 1-1 2-2 2-3 3-4
( 7,5 mg/ml ||| ( 7.5 mg/ ml ||| 0-0 1-1 2-2 2-3
( 7,5 mmol/l ) gegeben ||| ( 7.5 mmol/ l ) ||| 0-0 1-1 4-1 2-2 2-3 3-4
( 7,5 mmol/l ) steigt ||| ( 7.5 mmol/ l ) ||| 0-0 1-1 2-2 2-3 4-3 3-4
( 7,5 mmol/l ) ||| ( 7.5 mmol/ l ) ||| 0-0 1-1 2-2 2-3 3-4
( 7,5 mmol/l ||| ( 7.5 mmol/ l ||| 0-0 1-1 2-2 2-3
( 7,5 mmol/l ||| ( 7.5 mmol/ ||| 0-0 1-1 2-2
( 7,5 ||| ( 7.5 ||| 0-0 1-1
( 7000 I.E. ) ||| ( 7000 IU ) of ||| 0-0 1-1 2-2 3-3 2-4
( 7000 ||| ( 7000 ||| 0-0 1-1
( 75 von 3.852 ||| ( 75 out of 3,852 ||| 0-0 1-1 3-2 2-3 3-4
( 75 ||| ( 75 ||| 0-0 1-1
( 8,1 mmol/l ) ||| ( 8.1 mmol/ l ) ||| 0-0 1-1 2-2 2-3 3-4
( 8,1 mmol/l ||| ( 8.1 mmol/ l ||| 0-0 1-1 2-2 2-3
( 8,1 ||| ( 8.1 ||| 0-0 1-1
( 8000 I.E. ) ||| ( 8000 IU ) of ||| 0-0 1-1 2-2 3-3 2-4
( 8000 ||| ( 8000 ||| 0-0 1-1
( 9 Wochen ) ||| ( 9 weeks ) ||| 0-0 1-1 2-2 3-3
( 9 Wochen ||| ( 9 weeks ||| 0-0 1-1 2-2
( 9 ||| ( 9 ||| 0-0 1-1
( 9000 I.E. ) ||| ( 9000 IU ) of ||| 0-0 1-1 2-2 3-3 2-4
( 9000 ||| ( 9000 ||| 0-0 1-1
( 91 ) 663 50 ||| ( 91 ) 663 50 ||| 0-0 1-1 2-2 3-3 4-4
( 91 ) 663 ||| ( 91 ) 663 ||| 0-0 1-1 2-2 3-3
( 91 ) ||| ( 91 ) ||| 0-0 1-1 2-2
( 91 ||| ( 91 ||| 0-0 1-1
( 92 ||| ( 92 ||| 0-0 1-1
( 95 % ) ||| ( 95 % ) ||| 0-0 1-1 2-2 3-3
( 95 % CI : ||| ( 95 % CI : ||| 0-0 1-1 2-2 3-3 4-4
( 95 % CI ||| ( 95 % CI ||| 0-0 1-1 2-2 3-3
( 95 % ||| ( 95 % ||| 0-0 1-1 2-2
( 95 ||| ( 95 ||| 0-0 1-1
( 95%-Konfidenzintervall : ||| ( 95 % CI : ||| 0-0 1-1 1-2 1-3 2-4
( 95%-Konfidenzintervall ||| ( 95 % CI ||| 0-0 1-1 1-2 1-3
( 96 ||| ( 96 ||| 0-0 1-1
( > 99 % ) ||| ( > 99 % ) ||| 0-0 1-1 2-2 3-3 4-4
( > 99 % ||| ( > 99 % ||| 0-0 1-1 2-2 3-3
( > 99 ||| ( > 99 ||| 0-0 1-1 2-2
( > ||| ( > ||| 0-0 1-1
( ACE)-Hemmer , Salicylate ||| enzyme ( ACE ) inhibitors ||| 1-0 0-1 2-2 3-2 3-3 3-4
( ACE)-Hemmer ||| enzyme ( ||| 1-0 0-1
( ALT ) , ||| ( ALT ) , ||| 0-0 1-1 2-2 3-3
( ALT ) ||| ( ALT ) ||| 0-0 1-1 2-2
( ALT ||| ( ALT ||| 0-0 1-1
( AQ ) , Italien ||| ( AQ ) , Italy ||| 0-0 1-1 2-2 3-3 4-4
( AQ ) , ||| ( AQ ) , ||| 0-0 1-1 2-2 3-3
( AQ ) ||| ( AQ ) ||| 0-0 1-1 2-2
( AQ ||| ( AQ ||| 0-0 1-1
( AST ) , erhöhte ||| ( AST ) , increased ||| 0-0 1-1 2-2 3-3 4-4
( AST ) , ||| ( AST ) , ||| 0-0 1-1 2-2 3-3
( AST ) ||| ( AST ) ||| 0-0 1-1 2-2
( AST ||| ( AST ||| 0-0 1-1
( AUC ) erhöhte sich ||| ( AUC ) increased ||| 0-0 1-1 2-2 3-3
( AUC ) erhöhte ||| ( AUC ) increased ||| 0-0 1-1 2-2 3-3
( AUC ) ||| ( AUC ) ||| 0-0 1-1 2-2
( AUC ||| ( AUC ||| 0-0 1-1
( Antibiotika). ||| ( antibiotics ||| 0-0 1-1
( Aripiprazol ||| ( aripiprazole ||| 0-0 1-1
( Arzneimittel gegen Pilzinfektionen ) ||| ( anti-fungal medicines ) ||| 0-0 3-1 1-2 2-2 4-3
( Arzneimittel gegen Pilzinfektionen ||| ( anti-fungal medicines ||| 0-0 3-1 1-2 2-2
( Ausgangswert 7,2 % ) ||| ( baseline 7.2 % ) ||| 0-0 1-1 2-2 3-3 4-4
( Ausgangswert 7,2 % ||| ( baseline 7.2 % ||| 0-0 1-1 2-2 3-3
( Ausgangswert 7,2 ||| ( baseline 7.2 ||| 0-0 1-1 2-2
( Ausgangswert 7,3 % ) ||| ( baseline 7.3 % ) ||| 0-0 1-1 2-2 3-3 4-4
( Ausgangswert 7,3 % ||| ( baseline 7.3 % ||| 0-0 1-1 2-2 3-3
( Ausgangswert 7,3 ||| ( baseline 7.3 ||| 0-0 1-1 2-2
( Ausgangswert ||| ( baseline ||| 0-0 1-1
( BSAP ) , das ||| ( BSAP ) , ||| 0-0 1-1 2-2 3-3
( BSAP ) , ||| ( BSAP ) , ||| 0-0 1-1 2-2 3-3
( BSAP ) ||| ( BSAP ) ||| 0-0 1-1 2-2
( BSAP ||| ( BSAP ||| 0-0 1-1
( CB1)- Rezeptoren . ||| ( CB1 ) receptors . ||| 0-0 1-1 0-2 2-3 3-4
( CB1)- Rezeptoren ||| ( CB1 ) receptors ||| 0-0 1-1 0-2 2-3
( CB1)- ||| ( CB1 ) ||| 0-0 1-1 0-2
( CHMP ) ||| ( CHMP ) ||| 0-0 1-1 2-2
( CHMP ||| ( CHMP ||| 0-0 1-1
( CLAS ) . ||| ( CLAS ) . ||| 0-0 1-1 2-2 3-3
( CLAS ) ||| ( CLAS ) ||| 0-0 1-1 2-2
( CLAS ||| ( CLAS ||| 0-0 1-1
( CYP3A4-Substrat ) ||| ( CYP3A4-Substrat ) ||| 0-0 1-1 2-2
( CYP3A4-Substrat ||| ( CYP3A4-Substrat ||| 0-0 1-1
( Chinidin ) die ||| ( quinidine ) ||| 0-0 1-1 3-1 2-2
( Chinidin ) die ||| CYP2D6 ( quinidine ) ||| 1-0 0-1 1-2 3-2 2-3
( Cmax = 196 ||| ( Cmax = ||| 0-0 1-1 2-2
( Cmax = ||| ( Cmax = ||| 0-0 1-1 2-2
( Cmax ||| ( Cmax ||| 0-0 1-1
( Dextromethorphan ) . ||| ( dextromethorphan ) . ||| 0-0 1-1 2-2 3-3
( Dextromethorphan ) ||| ( dextromethorphan ) ||| 0-0 1-1 2-2
( Dextromethorphan ||| ( dextromethorphan ||| 0-0 1-1
( Dextromethorphan/3-Methoxymorphinan-Ratio ) ||| ( dextromethorphan/ 3-methoxymorphinan ratio ) ||| 0-0 1-1 1-2 1-3 2-4
( Dextromethorphan/3-Methoxymorphinan-Ratio ||| ( dextromethorphan/ 3-methoxymorphinan ratio ||| 0-0 1-1 1-2 1-3
( Durchschnittsalter : ||| ( mean age : ||| 0-0 1-1 1-2 2-3
( Durchschnittsalter ||| ( mean age ||| 0-0 1-1 1-2
( E 320 ) 2 ||| ( E 320 ) 2 ||| 0-0 1-1 2-1 2-2 3-3 4-4
( E 320 ) Yarvitan ||| ( E 320 ) Yarvitan ||| 0-0 1-1 2-1 2-2 3-3 4-4
( E 320 ) ||| ( E 320 ) ||| 0-0 1-1 2-1 2-2 3-3
( E 320 ||| ( E 320 ||| 0-0 1-1 2-1 2-2
( E 487 ||| Tablet core : ||| 1-0 2-1
( E 487 ||| Tablet core ||| 1-0 2-1
( E ||| Tablet ||| 1-0
( E132 ) ||| aluminium lake ( E132 ) ||| 0-0 1-1 0-2 1-3 2-4
( E132 ||| aluminium lake ( E132 ||| 0-0 1-1 0-2 1-3
( E216 ) , ||| ( E216 ) , ||| 0-0 1-1 2-2 3-3
( E216 ) Natriumhydroxid ||| ( E216 ) Sodium hydroxide ||| 0-0 1-1 2-2 3-3 3-4
( E216 ) je ||| ( E216 ) per ||| 0-0 1-1 2-2 3-3
( E216 ) ||| ( E216 ) ||| 0-0 1-1 2-2
( E216 ||| ( E216 ||| 0-0 1-1
( E218 ) Propylenglycol ||| ( E218 ) Propylene glycol ||| 0-0 1-1 2-2 3-3 3-4
( E218 ) je ml ||| ( E218 ) per ml ||| 0-0 1-1 2-2 3-3 4-4
( E218 ) je ||| ( E218 ) per ||| 0-0 1-1 2-2 3-3
( E218 ) ||| ( E218 ) ||| 0-0 1-1 2-2
( E218 ||| ( E218 ||| 0-0 1-1
( E951 ) Acesulfam-Kalium ||| ( E951 ) Acesulfame potassium ||| 0-0 1-1 2-2 3-3 3-4
( E951 ) je ||| ( E951 ) per ||| 0-0 1-1 2-2 3-3
( E951 ) ||| ( E951 ) ||| 0-0 1-1 2-2
( E951 ||| ( E951 ||| 0-0 1-1
( EINSCHLIESSLICH BLUE BOX ||| MULTI-PACK ( INCLUDING BLUE BOX ||| 1-0 0-1 1-2 2-3 3-4
( EINSCHLIESSLICH BLUE ||| MULTI-PACK ( INCLUDING BLUE ||| 1-0 0-1 1-2 2-3
( EINSCHLIESSLICH ||| MULTI-PACK ( INCLUDING ||| 1-0 0-1 1-2
( ESA ) folgendes beobachtet ||| ( ESAs ) have shown ||| 0-0 1-1 3-1 2-2 3-3 3-4 4-4
( Eisenmangel , ||| ( iron deficiency , ||| 0-0 1-1 1-2 2-3
( Eisenmangel ||| ( iron deficiency ||| 0-0 1-1 1-2
( Entzündung ||| ( inflammation of ||| 0-0 1-1
( Entzündung ||| ( inflammation ||| 0-0 1-1
( Erkältungen ) ||| ( colds ) ||| 0-0 1-1 2-2
( Erkältungen ||| ( colds ||| 0-0 1-1
( Europe ) , Royaume-Uni ||| ( Europe ) , Royaume-Uni ||| 0-0 1-1 2-2 3-3 4-4
( Europe ) , Storbritannia ||| ( Europe ) , Storbritannia ||| 0-0 1-1 2-2 3-3 4-4
( Europe ) , Storbritannien ||| ( Europe ) , Storbritannien ||| 0-0 1-1 2-2 3-3 4-4
( Europe ) , Te ||| ( Europe ) , Te ||| 0-0 1-1 2-2 3-3 4-4
( Europe ) , Wielka ||| ( Europe ) , Wielka ||| 0-0 1-1 2-2 3-3 4-4
( Europe ) , ||| ( Europe ) , ||| 0-0 1-1 2-2 3-3
( Europe ) , µ ||| ( Europe ) , µ ||| 0-0 1-1 2-2 3-3 4-4
( Europe ) Ltd , ||| ( Europe ) Ltd , ||| 0-0 1-1 2-2 3-3 4-4
( Europe ) Ltd 61 ||| ( Europe ) Ltd 61 ||| 0-0 1-1 2-2 3-3 4-4
( Europe ) Ltd ||| ( Europe ) Ltd ||| 0-0 1-1 2-2 3-3
( Europe ) ||| ( Europe ) ||| 0-0 1-1 2-2
( Europe ||| ( Europe ||| 0-0 1-1
( FACT-An ) General Scale ||| ( FACT-An ) general scale ||| 0-0 1-1 2-2 3-3 3-4 4-4
( FACT-An ) ||| ( FACT-An ) ||| 0-0 1-1 2-2
( FACT-An ||| ( FACT-An ||| 0-0 1-1
( FINLAND ) AB ||| ( FINLAND ) AB ||| 0-0 1-1 2-2 3-3
( FINLAND ) ||| ( FINLAND ) ||| 0-0 1-1 2-2
( FINLAND ||| ( FINLAND ||| 0-0 1-1
( Fachinformation ) , Etikettierung ||| ( SPC ) ||| 0-0 1-1 4-1 2-2
( Fachinformation ) , Etikettierung ||| characteristics ( SPC ) ||| 0-1 1-2 4-2 2-3
( Fieber ) . ||| ( fever ) . ||| 0-0 1-1 2-2 3-3
( Fieber ) ||| ( fever ) ||| 0-0 1-1 2-2
( Fieber ||| ( fever ||| 0-0 1-1
( Flush ) , ||| flushes , ||| 1-0 2-1 3-1
( Flush ||| flushes ||| 1-0
( G-CSF und GM-CSF ||| ( G-CSF and GM-CSF ||| 0-0 1-1 2-2 1-3 3-3
( GGT ) , erhöhte ||| ( GGT ) , increased ||| 0-0 1-1 2-2 3-3 4-4
( GGT ) , ||| ( GGT ) , ||| 0-0 1-1 2-2 3-3
( GGT ) ||| ( GGT ) ||| 0-0 1-1 2-2
( GGT ||| ( GGT ||| 0-0 1-1
( Heparin ) ||| ( heparin ) ||| 0-0 1-1 2-2
( Heparin ||| ( heparin ||| 0-0 1-1
( Heparinisierung ) kann ||| ( heparinisation ) may ||| 0-0 1-1 2-2 3-3
( Heparinisierung ) ||| ( heparinisation ) ||| 0-0 1-1 2-2
( Heparinisierung ||| ( heparinisation ||| 0-0 1-1
( Hydratation ) ||| before and ||| 0-0 1-0
( Hydratation ) ||| before ||| 0-0 1-0
( Hydratation ||| before and ||| 0-0 1-0
( Hydratation ||| before ||| 0-0 1-0
( Hydrolyse- ) Orten auf ||| ( hydrolysis ) sites on ||| 0-0 1-1 3-1 2-2 3-3 4-4
( Hydrolyse- ) Orten ||| ( hydrolysis ) sites ||| 0-0 1-1 3-1 2-2 3-3
( Hypoglykämie ) , Zucker ||| ( hypoglycaemia ) , sugar ||| 0-0 1-1 2-2 3-3 4-4
( Hypoglykämie ) , ||| ( hypoglycaemia ) , ||| 0-0 1-1 2-2 3-3
( Hypoglykämie ) ||| ( hypoglycaemia ) ||| 0-0 1-1 2-2
( Hypoglykämie ||| ( hypoglycaemia ||| 0-0 1-1
( Hämatokrit 33 - ||| ( haematocrit of 33 - ||| 0-0 1-1 2-3 3-4
( Hämatokrit 33 ||| ( haematocrit of 33 ||| 0-0 1-1 2-3
( Hämatokrit ||| ( haematocrit of ||| 0-0 1-1
( Hämatokrit ||| ( haematocrit ||| 0-0 1-1
( I.E. ) , entsprechend ||| ( IU ) corresponding to ||| 0-0 1-1 2-2 3-3 4-3 4-4
( I.E. ) , ||| ( IU ) ||| 0-0 1-1 2-2
( I.E. ) pro ||| ( IU ) per ||| 0-0 1-1 2-2 3-3
( I.E. ) ||| ( IU ) ||| 0-0 1-1 2-2
( I.E. ||| ( IU ||| 0-0 1-1
( Infusion ) ||| ( infusion ) ||| 0-0 1-1 2-2
( Infusion ||| ( infusion ||| 0-0 1-1
( Injektionszubereitung ) ||| ( injection ) ||| 0-0 1-1 2-2
( Injektionszubereitung ||| ( injection ||| 0-0 1-1
( Insulin ||| ( insulin ||| 0-0 1-1
( Internationale Einheitt ) ||| ( International Unit ) ||| 0-0 1-1 1-2 2-2 3-3
( Internationale Einheitt ||| ( International Unit ||| 0-0 1-1 1-2 2-2
( Internationale ||| ( International ||| 0-0 1-1
( Jahr 0-1 ) ||| ( 0 1 year ) ||| 0-0 2-1 2-2 1-3 3-4
( Jahr 0-1 ||| ( 0 1 year ||| 0-0 2-1 2-2 1-3
( Jahr 0-2 ) ||| ( 0 2 year ) ||| 0-0 1-1 2-2 1-3 2-3 3-4
( Jahr 0-2 ||| ( 0 2 year ||| 0-0 1-1 2-2 1-3 2-3
( Ketoconazol ) ||| ( ketoconazole ) ||| 0-0 1-1 2-2
( Ketoconazol ||| ( ketoconazole ||| 0-0 1-1
( Knochenmarkfibrose ||| fibrosis ( bone marrow fibrosis ||| 1-0 0-1 1-2 1-3 1-4
( Lösungsmittel ||| ( ||| 0-0 1-0
( M-II , M-III ||| ( M-II , M-III , ||| 0-0 1-1 2-2 3-3 2-4
( M-II ||| ( M-II ||| 0-0 1-1
( MAO-Hemmer ) , ||| ( MAOI ) , ||| 0-0 1-1 2-2 3-3
( MAO-Hemmer ) ||| ( MAOI ) ||| 0-0 1-1 2-2
( MAO-Hemmer ||| ( MAOI ||| 0-0 1-1
( MIT BLUE BOX ) ||| ( WITH BLUE BOX ) ||| 0-0 1-1 2-2 3-3 4-4
( MIT BLUE BOX ||| ( WITH BLUE BOX ||| 0-0 1-1 2-2 3-3
( MIT BLUE ||| ( WITH BLUE ||| 0-0 1-1 2-2
( MIT ||| ( WITH ||| 0-0 1-1
( MNS ||| ( NMS ||| 0-0 1-1
( MTP ) . ||| ( MTP ) . ||| 0-0 1-1 2-2 3-3
( MTP ) ||| ( MTP ) ||| 0-0 1-1 2-2
( MTP ||| ( MTP ||| 0-0 1-1
( Madrid ) Spanien ||| ( Madrid ) Spain ||| 0-0 1-1 2-2 3-3
( Madrid ) ||| ( Madrid ) ||| 0-0 1-1 2-2
( Madrid ||| ( Madrid ||| 0-0 1-1
( Metformin , Gliclazid ||| ( metformin , gliclazide ||| 0-0 1-1 2-2 3-3
( Metformin , ||| ( metformin , ||| 0-0 1-1 2-2
( Metformin ||| ( metformin ||| 0-0 1-1
( Mittel zur Unterdrückung ||| ( medicine to suppress ||| 0-0 1-0 2-1 2-2 3-3
( Mittel zur ||| ( medicine to ||| 0-0 1-0 2-1 2-2
( Mittel ||| ( ||| 0-0 1-0
( Monotherapie mit 45 mg ||| ( 45 mg monotherapy ||| 0-0 3-1 4-2 1-3 2-3
( Muttersubstanz ||| ( parent ||| 0-0 1-1
( Mäusemilzzellkultur ||| ( mouse spleen cell ||| 0-0 1-1 1-2 1-3
( N = 225 ) ||| ( N = 225 ) ||| 0-0 1-1 2-2 3-3 4-4
( N = 225 ||| ( N = 225 ||| 0-0 1-1 2-2 3-3
( N = 229 ) ||| ( N = 229 ) ||| 0-0 1-1 2-2 3-3 4-4
( N = 229 ||| ( N = 229 ||| 0-0 1-1 2-2 3-3
( N = 30 ) ||| ( N = 30 ) ||| 0-0 1-1 2-2 3-3 4-4
( N = 30 ||| ( N = 30 ||| 0-0 1-1 2-2 3-3
( N = ||| ( N = ||| 0-0 1-1 2-2
( N ||| ( N ||| 0-0 1-1
( N=3.875 ) ||| reduction ( N=3,861 ) ||| 1-0 0-1 1-2 2-3
( N=3.875 ||| reduction ( N=3,861 ||| 1-0 0-1 1-2
( N=789 ) ||| ( N = 789 ) ||| 0-0 1-1 0-2 1-3 2-4
( N=789 ||| ( N = 789 ||| 0-0 1-1 0-2 1-3
( N=82 ) ||| iliac crest 1 ||| 1-0 1-1 0-2
( N=82 ||| iliac crest 1 ||| 1-0 1-1 0-2
( NPH- ) Insulin . ||| ( NPH ) insulin . ||| 0-0 1-1 2-2 3-3 4-4
( NPH- ) Insulin ||| ( NPH ) insulin ||| 0-0 1-1 2-2 3-3
( NPH- ) ||| ( NPH ) ||| 0-0 1-1 2-2
( NPH- ||| ( NPH ||| 0-0 1-1
( NUR ||| THE WEEK ( ||| 1-0 1-1 0-2
( NYHA I bis ||| ( NYHA stages I to ||| 0-0 1-1 2-1 1-2 2-3 3-4
( NYHA I ||| ( NYHA stages I ||| 0-0 1-1 2-1 1-2 2-3
( Niereninsuffizienz ||| ( renal ||| 0-0 1-1
( NovoLet , ||| ( NovoLet , ||| 0-0 1-1 2-2
( NovoLet ||| ( NovoLet ||| 0-0 1-1
( Omeprazol ) ||| ( omeprazole ) ||| 0-0 1-1 2-2
( Omeprazol ||| ( omeprazole ||| 0-0 1-1
( PFT ) Die ||| ( PFT ) The ||| 0-0 1-1 2-2 3-3
( PFT ) ||| ( PFT ) ||| 0-0 1-1 2-2
( PFT ||| ( PFT ||| 0-0 1-1
( PSUR ) eingereicht werden ||| Update Report ( PSUR ) ||| 1-0 1-1 0-2 1-3 3-3 4-3 2-4
( PVC/Aluminium ) Blisterpackung ||| ( PVC/ aluminium ) Blister ||| 0-0 1-1 1-2 2-3 3-4
( PVC/Aluminium ) ||| ( PVC/ aluminium ) ||| 0-0 1-1 1-2 2-3
( PVC/Aluminium ||| ( PVC/ aluminium ||| 0-0 1-1 1-2
( Ph.Eur. ) , Natriumchlorid ||| phosphate dihydrate , sodium chloride ||| 0-0 1-0 1-1 2-1 3-2 4-3 4-4
( Ph.Eur. ) , Natriumhydroxid ||| sodium hydroxide , ||| 0-0 1-0 2-1 4-1 3-2
( Ph.Eur. ) , ||| phosphate dihydrate , ||| 0-0 1-0 1-1 2-1 3-2
( Ph.Eur. ) ||| phosphate dihydrate ||| 0-0 1-0 1-1 2-1
( Ph.Eur. ||| sodium ||| 0-0 1-0
( Plasmakonzentration gegen ||| plasma concentration ||| 1-0 1-1
( Plasmakonzentration ||| plasma concentration ||| 1-0 1-1
( Quincke-Ödem ||| lips ( ||| 1-0 0-1
( RFT ) Die Häufigkeit ||| ( RFT ) The incidence ||| 0-0 1-1 2-2 3-3 4-4
( RFT ) Die ||| ( RFT ) The ||| 0-0 1-1 2-2 3-3
( RFT ) ||| ( RFT ) ||| 0-0 1-1 2-2
( RFT ||| ( RFT ||| 0-0 1-1
( Rhabdomyolyse ) und ||| ( rhabdomyolysis ) , and ||| 0-0 1-1 2-2 1-3 3-4
( Rhabdomyolyse ) ||| ( rhabdomyolysis ) , ||| 0-0 1-1 2-2 1-3
( SBECD ) , Weinsäure ||| tartaric acid , ||| 1-0 4-0 0-1 2-1 4-1 3-2
( SBECD ) Weinsäure ( ||| ( SBECD ) Tartaric acid ||| 0-0 1-1 2-2 3-3 3-4 4-4
( SBECD ) ||| ( SBECD ) ||| 0-0 1-1 2-2
( SBECD ||| ( SBECD ||| 0-0 1-1
( SERENADE ) , ||| ( Serenade ) , ||| 0-0 1-1 2-2 3-3
( SERENADE ) ||| ( Serenade ) ||| 0-0 1-1 2-2
( SERENADE ||| ( Serenade ||| 0-0 1-1
( Safety Specification ) ||| Safety ||| 1-0 2-0
( Safety Specification ||| Safety ||| 1-0 2-0
( Sodbrennen ) , Erbrechen ||| ( heartburn ) , vomiting ||| 0-0 1-1 2-2 3-3 4-4
( Sodbrennen ) , ||| ( heartburn ) , ||| 0-0 1-1 2-2 3-3
( Sodbrennen ) ||| ( heartburn ) ||| 0-0 1-1 2-2
( Sodbrennen ||| ( heartburn ||| 0-0 1-1
( Studie CZOL446M2308 ) ||| ( study CZOL446M2308 ) ||| 0-0 1-1 2-2 3-3
( Studie CZOL446M2308 ||| ( study CZOL446M2308 ||| 0-0 1-1 2-2
( Studie ||| ( study ||| 0-0 1-1
( Sulfonylharnstoffe , Insulin , ||| ( sulphonylureas , insulin , ||| 0-0 1-1 2-2 3-3 4-4
( Sulfonylharnstoffe , Insulin ||| ( sulphonylureas , insulin ||| 0-0 1-1 2-2 3-3
( Sulfonylharnstoffe , ||| ( sulphonylureas , ||| 0-0 1-1 2-2
( Sulfonylharnstoffe ||| ( sulphonylureas ||| 0-0 1-1
( Symptome , Notfallmaßnahmen ||| ( symptoms , emergency procedures ||| 0-0 1-1 2-2 3-3 3-4
( Symptome , ||| ( symptoms , ||| 0-0 1-1 2-2
( Symptome ||| ( symptoms ||| 0-0 1-1
( Tabletten ||| ( tablets ||| 0-0 1-1
( Tag 21 , 14 ||| ( days 21 , 14 ||| 0-0 2-1 1-2 2-2 3-3 4-4
( Tag 21 , ||| ( days 21 , ||| 0-0 2-1 1-2 2-2 3-3
( Tag 21 ||| ( days 21 ||| 0-0 2-1 1-2 2-2
( Thrombozyten ) , ||| platelets ( thrombocytes ) ||| 1-0 0-1 1-2 2-3
( Thrombozyten ) ||| platelets ( thrombocytes ) ||| 1-0 0-1 1-2 2-3
( Thrombozyten ||| platelets ( thrombocytes ||| 1-0 0-1 1-2
( Tropfinfusion in eine Vene ||| ( drip into a vein ||| 0-0 1-1 2-2 4-2 3-3 4-4
( Tropfinfusion ||| ( drip ||| 0-0 1-1
( Typ 1 ) , ||| ( type 1 ) ||| 0-0 1-1 2-2 3-3
( Typ 1 ) ||| ( type 1 ) , ||| 0-0 1-1 2-2 3-3
( Typ 1 ) ||| ( type 1 ) ||| 0-0 1-1 2-2 3-3
( Typ 1 ||| ( type 1 ||| 0-0 1-1 2-2
( Typ III ) mit ||| ( type III ) with ||| 0-0 1-1 2-2 3-3 4-4
( Typ III ) ||| ( type III ) ||| 0-0 1-1 2-2 3-3
( Typ III ||| ( type III ||| 0-0 1-1 2-2
( Typ ||| ( type ||| 0-0 1-1
( Unterzuckerungen ||| ( low blood ||| 0-0 1-1 1-2
( Verwendbar bis : ||| ( EXP ||| 0-0 1-1 2-1 3-1
( Vorhofflimmern ) wurde ||| ( atrial fibrillation ) has ||| 0-0 1-1 1-2 2-3 3-4
( Vorhofflimmern ) ||| ( atrial fibrillation ) ||| 0-0 1-1 1-2 2-3
( Vorhofflimmern ||| ( atrial fibrillation ||| 0-0 1-1 1-2
( Warfarin ) ||| ( warfarin ) ||| 0-0 1-1 2-2
( Warfarin ||| ( warfarin ||| 0-0 1-1
( Wochen ) ||| ( weeks ) ||| 0-0 1-1 2-2
( Wochen ||| ( weeks ||| 0-0 1-1
( Zoledronsäure ) , das ||| ( zoledronic acid ) , ||| 0-0 1-1 1-2 2-3 3-4
( Zoledronsäure ) , ||| ( zoledronic acid ) , ||| 0-0 1-1 1-2 2-3 3-4
( Zoledronsäure ) ||| ( zoledronic acid ) ||| 0-0 1-1 1-2 2-3
( Zoledronsäure ||| ( zoledronic acid ||| 0-0 1-1 1-2
( aller Darreichungsformen ) soll ||| ( all formulations ) should ||| 0-0 1-1 1-2 2-2 3-3 4-4
( aller Darreichungsformen ) ||| ( all formulations ) ||| 0-0 1-1 1-2 2-2 3-3
( aller Darreichungsformen ||| ( all formulations ||| 0-0 1-1 1-2 2-2
( als HCl ) ||| mg tablets ||| 0-0 1-0 2-0 2-1 3-1
( als Hydrchlorid ) . ||| ( as hydrochloride ) . ||| 0-0 1-1 2-2 3-3 4-4
( als Hydrchlorid ) ||| ( as hydrochloride ) ||| 0-0 1-1 2-2 3-3
( als Hydrchlorid ||| ( as hydrochloride ||| 0-0 1-1 2-2
( als Hydrochlorid ) . ||| ( as hydrochloride ) . ||| 0-0 1-1 2-2 3-3 4-4
( als Hydrochlorid ) ||| ( as hydrochloride ) ||| 0-0 1-1 2-2 3-3
( als Hydrochlorid ||| ( as hydrochloride ||| 0-0 1-1 2-2
( als ||| ( as ||| 0-0 1-1
( auch Serotonin genannt ) ||| ( also called serotonin ) ||| 0-0 1-1 3-2 2-3 4-4
( auch Serotonin genannt ||| ( also called serotonin ||| 0-0 1-1 3-2 2-3
( auch bekannt als nicht ||| ( also known as non ||| 0-0 1-1 2-2 3-3
( auch bekannt als nicht ||| ( also known as ||| 0-0 1-1 2-2 3-3
( auch bekannt als ||| ( also known as non ||| 0-0 1-1 2-2 3-3
( auch bekannt als ||| ( also known as ||| 0-0 1-1 2-2 3-3
( auch bekannt ||| ( also known ||| 0-0 1-1 2-2
( auch ||| ( also ||| 0-0 1-1
( auf die Therapie ||| of the ||| 1-1 2-1
( auf die Therapie ||| the ||| 1-0 2-0
( auf die ||| of the ||| 1-1 2-1
( auf die ||| the ||| 1-0 2-0
( behandelte ) Dyslipidämie ||| ( behandelte ) Dyslipidämie eingeschlossen ||| 0-0 1-1 2-2 3-3 3-4
( behandelte ) ||| ( behandelte ) ||| 0-0 1-1 2-2
( behandelte ||| ( behandelte ||| 0-0 1-1
( bei 79 % ||| ( reported in 79 % ||| 0-0 1-1 1-2 2-3 3-4
( bei 79 ||| ( reported in 79 ||| 0-0 1-1 1-2 2-3
( bei ||| ( reported in ||| 0-0 1-1 1-2
( bei ||| ( ||| 0-0
( ca . 16 ||| ( ca . 16 ||| 0-0 1-1 2-2 3-3
( ca . 43-55 % ||| ( approximately 43-55 % ||| 0-0 4-1 1-2 3-2 4-3
( ca . ||| ( ca . Me ||| 0-0 1-1 2-2 1-3
( ca . ||| ( ca . ||| 0-0 1-1 2-2
( ca ||| ( ca ||| 0-0 1-1
( d. ||| ( i. ||| 0-0
( d. ||| ( ||| 0-0
( d.h . ||| ( i. e. ||| 0-0 1-1 1-2 2-2
( die ||| ( ||| 0-0
( dieses sollte ||| ( this should be ||| 0-0 1-1 2-2 2-3
( dieses ||| ( this ||| 0-0 1-1
( durch ||| ( ||| 0-0
( ebenfalls Teil ||| ( also part of ||| 0-0 1-1 1-2 2-2 2-3
( ein Diabetesmedikament ) ||| ( an antidiabetic medicine ) ||| 0-0 1-1 2-2 2-3 3-4
( ein Diabetesmedikament ||| ( an antidiabetic medicine ||| 0-0 1-1 2-2 2-3
( ein Mittel ||| ( ||| 0-0 2-0
( ein P- ||| Digoxin ( ein ||| 0-0 0-1 2-1 1-2
( ein anderes Antipsychotikum ) ||| ( another antipsychotic medicine ) ||| 0-0 2-1 3-2 3-3 4-4
( ein anderes Antipsychotikum ||| ( another antipsychotic medicine ||| 0-0 2-1 3-2 3-3
( ein anderes ||| ( another ||| 0-0 2-1
( ein ||| ( an ||| 0-0 1-1
( ein ||| ( ||| 0-0
( eine Krankheit ||| ( a disease ||| 0-0 1-1 2-2
( eine kumulative Dosis ||| ( for a cumulative dose ||| 0-0 1-2 2-3 3-4
( eine kumulative ||| ( for a cumulative ||| 0-0 1-2 2-3
( eine ||| ( a ||| 0-0 1-1
( eine ||| ( for a ||| 0-0 1-2
( einem ||| ( a ||| 0-0 1-1
( einem ||| ( an ||| 0-0 1-1
( einmal täglich ) ||| ( once daily ) ||| 0-0 1-1 2-2 3-3
( einmal täglich ||| ( once daily ||| 0-0 1-1 2-2
( einmal ||| ( once ||| 0-0 1-1
( einschließlich aller Darreichungsformen von ||| ( including all formulations of ||| 0-0 1-1 2-2 2-3 3-3 4-4
( einschließlich aller Darreichungsformen ||| ( including all formulations ||| 0-0 1-1 2-2 2-3 3-3
( einschließlich ||| ( including ||| 0-0 1-1
( enthält ||| solution ( containing ||| 1-0 0-1 1-2
( gentechnisch hergestellt ||| ( produced by ||| 0-0 1-1 2-1 2-2
( gepoolte Daten* ) : ||| ( pooled data* ) : ||| 0-0 1-1 1-2 2-2 3-3 4-4
( gepoolte Daten* ) ||| ( pooled data* ) ||| 0-0 1-1 1-2 2-2 3-3
( gepoolte Daten* ||| ( pooled data* ||| 0-0 1-1 1-2 2-2
( glykosyliertes Hämoglobin ( ||| ( glycosylated haemoglobin ||| 0-0 3-0 1-1 2-1 2-2
( glykosyliertes Hämoglobin ( ||| substance ( glycosylated haemoglobin ||| 0-1 3-1 1-2 2-2 2-3
( glykosyliertes Hämoglobin , ||| ( glycosylated haemoglobin , ||| 0-0 1-1 2-1 2-2 3-3
( glykosyliertes Hämoglobin , ||| substance ( glycosylated haemoglobin , ||| 0-1 1-2 2-2 2-3 3-4
( glykosyliertes Hämoglobin ||| ( glycosylated haemoglobin ||| 0-0 1-1 2-1 2-2
( glykosyliertes Hämoglobin ||| substance ( glycosylated haemoglobin ||| 0-1 1-2 2-2 2-3
( hauptsächlich ||| ( mostly ||| 0-0 1-1
( human ) . ||| ( human ) . ||| 0-0 1-1 2-2 3-3
( human ) ||| ( human ) ||| 0-0 1-1 2-2
( human ||| ( human ||| 0-0 1-1
( innerhalb von 90 Tagen ||| ( within 90 days ||| 0-0 1-1 2-1 3-2 4-3
( innerhalb von 90 ||| ( within 90 ||| 0-0 1-1 2-1 3-2
( innerhalb von ||| ( within ||| 0-0 1-1 2-1
( insbesondere ||| ( particularly ||| 0-0 1-1
( insbesondere übergewichtigen Patienten ) ||| ( particularly overweight patients ) ||| 0-0 1-1 2-1 2-2 3-3 4-4
( insbesondere übergewichtigen Patienten ) ||| ( particularly overweight patients ) ||| 0-0 1-1 2-2 3-3 4-4
( insbesondere übergewichtigen Patienten ||| ( particularly overweight patients ||| 0-0 1-1 2-1 2-2 3-3
( insbesondere übergewichtigen Patienten ||| ( particularly overweight patients ||| 0-0 1-1 2-2 3-3
( insbesondere übergewichtigen ||| ( particularly overweight ||| 0-0 1-1 2-1 2-2
( insbesondere übergewichtigen ||| ( particularly overweight ||| 0-0 1-1 2-2
( intravenös ) gegeben . ||| ( intravenously ) . ||| 0-0 1-1 3-1 2-2 4-3
( intravenös ) gegeben ||| ( intravenously ) ||| 0-0 1-1 3-1 2-2
( krankhafter ||| ( ||| 0-0
( lokalen ) ||| ( local ) ||| 0-0 1-1 2-2
( lokalen ||| ( local ||| 0-0 1-1
( mehrfach ||| systems ( durable ||| 1-0 0-1 1-2
( mit einem Ausgangswert von ||| ( with a baseline of ||| 0-0 1-1 2-2 2-3 3-3 4-4
( mit einem Ausgangswert ||| ( with a baseline ||| 0-0 1-1 2-2 2-3 3-3
( mit ||| ( with ||| 0-0 1-1
( mit ||| in ||| 1-0
( mittlere Differenz zu Placebo ||| ( mean difference to placebo ||| 0-0 1-1 2-2 3-3 4-4
( mittlere Differenz zu ||| ( mean difference to ||| 0-0 1-1 2-2 3-3
( mittlere Differenz ||| ( mean difference ||| 0-0 1-1 2-2
( mittlere ||| ( mean ||| 0-0 1-1
( möglicherweise auch verzögert ) ||| ( possibly delayed ) ||| 0-0 1-1 3-2 4-3
( möglicherweise auch verzögert ||| ( possibly delayed ||| 0-0 1-1 3-2
( möglicherweise auch ||| ( possibly ||| 0-0 1-1
( möglicherweise verzögert ) . ||| ( possibly delayed ) . ||| 0-0 1-1 2-2 3-3 4-4
( möglicherweise verzögert ) ||| ( possibly delayed ) ||| 0-0 1-1 2-2 3-3
( möglicherweise verzögert ||| ( possibly delayed ||| 0-0 1-1 2-2
( möglicherweise ||| ( possibly ||| 0-0 1-1
( n = 131 ) ||| ( n = 131 ) ||| 0-0 1-1 2-1 2-2 3-3 4-4
( n = 131 ||| ( n = 131 ||| 0-0 1-1 2-1 2-2 3-3
( n = 132 ) ||| ( n = 132 ) ||| 0-0 1-1 2-1 2-2 3-3 4-4
( n = 132 ||| ( n = 132 ||| 0-0 1-1 2-1 2-2 3-3
( n = 135 ) ||| ( n = 135 ) ||| 0-0 1-1 2-1 2-2 3-3 4-4
( n = 135 ||| ( n = 135 ||| 0-0 1-1 2-1 2-2 3-3
( n = 136 ) ||| ( n = 136 ) ||| 0-0 1-1 2-1 2-2 3-3 4-4
( n = 136 ||| ( n = 136 ||| 0-0 1-1 2-1 2-2 3-3
( n = ||| ( n = ||| 0-0 1-1 2-1 2-2
( n= 938 , ||| ( n= 938 ; ||| 0-0 2-1 1-2 2-2 2-3
( n= 938 ||| ( n= 938 ; ||| 0-0 2-1 1-2 2-2 2-3
( nicht ||| ( not ||| 0-0 1-1
( niedrigem Blutcalciumspiegel ||| ( low blood calcium levels ||| 0-0 1-1 2-1
( niedrigem Blutcalciumspiegel ||| ( low blood calcium ||| 0-0 1-1 2-1
( niedrigem Blutcalciumspiegel ||| ( low blood ||| 0-0 1-1 2-1
( niedrigem Blutcalciumspiegel ||| ( low ||| 0-0 1-1 2-1
( normale und anämische Ratten ||| ( normal and anaemic rats ||| 0-0 1-1 2-2 3-3 4-4
( normale und anämische ||| ( normal and anaemic ||| 0-0 1-1 2-2 3-3
( normale und ||| ( normal and ||| 0-0 1-1 2-2
( normale ||| ( normal ||| 0-0 1-1
( oder wenn ||| ( or if ||| 0-0 1-1 2-2
( oder ||| ( or ||| 0-0 1-1
( operative Hodenentfernung ) ||| orchiectomy ( surgical castration ) ||| 1-0 0-1 2-2 2-3 3-4
( operative Hodenentfernung ||| orchiectomy ( surgical castration ||| 1-0 0-1 2-2 2-3
( operative ||| orchiectomy ( ||| 1-0 0-1
( oral ) ||| , oral ||| 1-1
( oral ) ||| oral ||| 1-0
( oral ||| , oral ||| 1-1
( oral ||| oral ||| 1-0
( p=0,01 ) . ||| mortality ( p=0.01 ) . ||| 1-0 0-1 1-2 2-3 3-4
( p=0,01 ) ||| mortality ( p=0.01 ) ||| 1-0 0-1 1-2 2-3
( p=0,01 ||| mortality ( p=0.01 ||| 1-0 0-1 1-2
( periphere arterielle Verschlusskrankheit ||| ( peripheral arterial ||| 0-0 1-1 2-2 3-2
( periphere ||| ( peripheral ||| 0-0 1-1
( rDNA ) , ||| day ; ||| 0-0 3-1
( rDNA ) . ||| ( rDNA ) . ||| 0-0 1-1 2-2 3-3
( rDNA ) oder ||| ( rDNA ) or ||| 0-0 1-1 2-2 3-3
( rDNA ) ||| ( rDNA ) ||| 0-0 1-1 2-2
( rDNA ) ||| day ||| 0-0
( rDNA ||| ( rDNA ||| 0-0 1-1
( rDNA ||| day ||| 0-0
( siehe Abschnitt 4.2 ) ||| ( see section 4.2 ) ||| 0-0 1-1 2-2 3-3 4-4
( siehe Abschnitt 4.2 Behandlung ||| ( see section 4.2 Treatment ||| 0-0 1-1 2-2 3-3 4-4
( siehe Abschnitt 4.2 und ||| ( see section dic ||| 0-0 1-1 2-2 3-2 3-3
( siehe Abschnitt 4.2 ||| ( see also section 4.2 ||| 0-0 1-1 1-2 2-3 3-4
( siehe Abschnitt 4.2 ||| ( see section 4.2 ||| 0-0 1-1 2-2 3-3
( siehe Abschnitt 4.2 ||| ( see section dic ||| 0-0 1-1 2-2 3-2 3-3
( siehe Abschnitt 4.2 ||| populations ( see section 4.2 ||| 0-0 0-1 1-2 2-3 3-4
( siehe Abschnitt 4.3 ) ||| ( see section 4.3 ) ||| 0-0 1-1 2-2 3-3 4-4
( siehe Abschnitt 4.3 ||| ( see section 4.3 ||| 0-0 1-1 2-2 3-3
( siehe Abschnitt 4.3). ||| ( see section 4.3 ) ||| 0-0 1-1 1-2 2-2 3-3 2-4
( siehe Abschnitt 4.4 ) ||| ( See section 4.4 ) ||| 0-0 1-1 2-2 3-3 4-4
( siehe Abschnitt 4.4 ) ||| ( see section 4.4 ) ||| 0-0 1-1 2-2 3-3 4-4
( siehe Abschnitt 4.4 - ||| ( see section 4.4 - ||| 0-0 1-1 2-2 3-3 4-4
( siehe Abschnitt 4.4 und ||| ( see section 4.4 and ||| 0-0 1-1 2-2 3-3 4-4
( siehe Abschnitt 4.4 und ||| ( siehe Abschnitt 4.4 und ||| 0-0 1-1 1-2 2-3 3-3 4-4
( siehe Abschnitt 4.4 ||| ( See section 4.4 ||| 0-0 1-1 2-2 3-3
( siehe Abschnitt 4.4 ||| ( please see section 4.4 ||| 0-0 1-1 1-2 2-3 3-4
( siehe Abschnitt 4.4 ||| ( see section 4.4 ||| 0-0 1-1 2-2 3-3
( siehe Abschnitt 4.4 ||| ( siehe Abschnitt 4.4 ||| 0-0 1-1 1-2 2-3 3-3
( siehe Abschnitt 4.5 ) ||| ( see section 4.5 ) ||| 0-0 1-1 2-2 3-3 4-4
( siehe Abschnitt 4.5 ||| ( see section 4.5 ||| 0-0 1-1 2-2 3-3
( siehe Abschnitt 4.6 ) ||| ( see section 4.6 ) ||| 0-0 1-1 2-2 3-3 4-4
( siehe Abschnitt 4.6 ||| ( see section 4.6 ||| 0-0 1-1 2-2 3-3
( siehe Abschnitt 4.8 ) ||| ( see section 4.8 ) ||| 0-0 1-1 2-2 3-3 4-4
( siehe Abschnitt 4.8 ||| ( see section 4.8 ||| 0-0 1-1 2-2 3-3
( siehe Abschnitt 5.1 ) ||| ( see section 5.1 ) ||| 0-0 1-1 2-2 3-3 4-4
( siehe Abschnitt 5.1 ||| ( see section 5.1 ||| 0-0 1-1 2-2 3-3
( siehe Abschnitt 5.2 ) ||| ( see section 5.2 ) ||| 0-0 1-1 2-2 3-3 4-4
( siehe Abschnitt 5.2 ||| ( see also section 5.2 ||| 0-0 1-1 1-2 2-3 3-4
( siehe Abschnitt 5.2 ||| ( see section 5.2 ||| 0-0 1-1 2-2 3-3
( siehe Abschnitt 5.3 ) ||| ( see section 5.3 ) ||| 0-0 1-1 2-2 3-3 4-4
( siehe Abschnitt 5.3 ||| ( see section 5.3 ||| 0-0 1-1 2-2 3-3
( siehe Abschnitt 6.1 ) ||| ( see section 6.1 ) ||| 0-0 1-1 2-2 3-3 4-4
( siehe Abschnitt 6.1 ||| ( see section 6.1 ||| 0-0 1-1 2-2 3-3
( siehe Abschnitt ||| ( See section ||| 0-0 1-1 2-2
( siehe Abschnitt ||| ( please see section ||| 0-0 1-1 1-2 2-3
( siehe Abschnitt ||| ( see also section ||| 0-0 1-1 1-2 2-3
( siehe Abschnitt ||| ( see section 4.4 ) ||| 0-0 1-1 2-2 2-3 2-4
( siehe Abschnitt ||| ( see section ||| 0-0 1-1 2-2
( siehe Abschnitt ||| ( see sections 4.4 and ||| 0-0 1-1 1-2 2-3
( siehe Abschnitt ||| ( see sections 4.4 ||| 0-0 1-1 1-2 2-3
( siehe Abschnitt ||| Special populations ( see section ||| 0-1 0-2 1-3 2-4
( siehe Abschnitt ||| is ||| 1-0 2-0
( siehe Abschnitt ||| populations ( see section ||| 0-0 0-1 1-2 2-3
( siehe Abschnitte 4.3 und ||| ( see sections 4.3 and ||| 0-0 1-1 2-2 3-3 4-4
( siehe Abschnitte 4.3 ||| ( see sections 4.3 ||| 0-0 1-1 2-2 3-3
( siehe Abschnitte 4.8 und ||| ( see sections 4.8 and ||| 0-0 1-1 2-2 3-3 4-4
( siehe Abschnitte 4.8 ||| ( see sections 4.8 ||| 0-0 1-1 2-2 3-3
( siehe Abschnitte ||| ( see sections ||| 0-0 1-1 2-2
( siehe Anhang I ) ||| ( see Annex I ) ||| 0-0 1-1 2-2 3-2 3-3 4-4
( siehe Anhang I : ||| ( See Annex I : ||| 0-0 1-1 2-1 2-2 3-2 3-3 4-4
( siehe Anhang I ||| ( See Annex I ||| 0-0 1-1 2-1 2-2 3-2 3-3
( siehe Anhang I ||| ( see Annex I ||| 0-0 1-1 2-2 3-2 3-3
( siehe Tabelle 2 ) ||| ( see Table 2 ) ||| 0-0 1-1 2-2 3-3 4-4
( siehe Tabelle 2 ||| ( see Table 2 ||| 0-0 1-1 2-2 3-3
( siehe Tabelle ||| ( see Table ||| 0-0 1-1 2-2
( siehe auch Abschnitt 4.4 ||| ( See also section 4.4 ||| 0-0 1-1 2-2 3-3 4-4
( siehe auch Abschnitt ||| ( See also section ||| 0-0 1-1 2-2 3-3
( siehe auch ||| ( See also ||| 0-0 1-1 2-2
( siehe ||| ( See ||| 0-0 1-1
( siehe ||| ( please see ||| 0-0 1-1 1-2
( siehe ||| ( see also ||| 0-0 1-1 1-2
( siehe ||| ( see sections ||| 0-0 1-1 1-2
( siehe ||| ( see ||| 0-0 1-1
( siehe ||| ( siehe Abschnitt ||| 0-0 1-1 1-2
( siehe ||| Special populations ( see ||| 0-1 0-2 1-3
( siehe ||| populations ( see ||| 0-0 0-1 1-2
( subkutan ) geben ! ||| ( subcutaneously ) . ||| 0-0 1-1 3-1 4-1 2-2 3-3
( subkutan ) geben . ||| ( subcutaneously ) . ||| 0-0 1-1 3-1 2-2 4-3
( subkutan ) geben ||| ( subcutaneously ) ||| 0-0 1-1 3-1 2-2
( subkutan ) gegeben . ||| ( subcutaneously ) . ||| 0-0 1-1 3-1 2-2 4-3
( subkutan ) gegeben ||| ( subcutaneously ) ||| 0-0 1-1 3-1 2-2
( thrombotische vaskuläre Ereignisse ||| ( thrombotic vascular events ||| 0-0 1-1 2-2 3-3
( thrombotische vaskuläre ||| ( thrombotic vascular ||| 0-0 1-1 2-2
( thrombotische vaskuläre ||| clotting disorders ( thrombotic vascular ||| 1-0 1-1 0-2 1-3 2-4
( thrombotische ||| ( thrombotic ||| 0-0 1-1
( thrombotische ||| clotting disorders ( thrombotic ||| 1-0 1-1 0-2 1-3
( tiefe Venenthrombosen ) ||| ( deep venous thrombosis ) ||| 0-0 1-1 2-1 2-2 2-3 3-4
( tiefe Venenthrombosen ||| ( deep venous thrombosis ||| 0-0 1-1 2-1 2-2 2-3
( t½ ) ist daher ||| ( t½ ) is therefore ||| 0-0 1-1 2-2 3-3 4-4
( t½ ) ist ||| ( t½ ) is ||| 0-0 1-1 2-2 3-3
( t½ ) ||| ( t½ ) ||| 0-0 1-1 2-2
( t½ ||| ( t½ ||| 0-0 1-1
( und , mit ||| ( and , with ||| 0-0 1-1 2-2 3-3
( und , ||| ( and , ||| 0-0 1-1 2-2
( und ||| ( and ||| 0-0 1-1
( und ||| , ( and ||| 0-1 1-2
( ungenügende oder ||| following ||| 0-0 1-0
( ungenügende ||| following ||| 0-0 1-0
( unkontrolliertes Zucken ||| ( ||| 0-0 1-0 2-0
( unter 25°C ) . ||| ( below 25°C ) . ||| 0-0 1-1 2-2 3-3 4-4
( unter 25°C ) . ||| ( below 25ºC ) . ||| 0-0 1-1 2-2 3-3 4-4
( unter 25°C ) ||| ( below 25°C ) ||| 0-0 1-1 2-2 3-3
( unter 25°C ) ||| ( below 25ºC ) ||| 0-0 1-1 2-2 3-3
( unter 25°C ||| ( below 25°C ||| 0-0 1-1 2-2
( unter 25°C ||| ( below 25ºC ||| 0-0 1-1 2-2
( unter 30°C ) . ||| ( below 30°C ) . ||| 0-0 1-1 2-1 2-2 3-3 4-4
( unter 30°C ) ||| ( below 30°C ) ||| 0-0 1-1 2-1 2-2 3-3
( unter 30°C ||| ( below 30°C ||| 0-0 1-1 2-1 2-2
( unter die Haut gespritztem ||| ( injection under the skin ||| 0-0 3-1 1-2 2-3 3-4 4-4
( unter ||| ( below ||| 0-0 1-1
( verminderte Empfindlichkeit gegenüber ||| ( decreased sensitivity to a ||| 0-0 1-1 2-2 3-3 3-4
( verminderte Empfindlichkeit ||| ( decreased sensitivity ||| 0-0 1-1 2-2
( verminderte ||| ( decreased ||| 0-0 1-1
( verminderte ||| ( ||| 0-0
( wasserfrei ) . ||| ( anhydrous ) . ||| 0-0 1-1 2-2 3-3
( wasserfrei ) ||| ( anhydrous ) ||| 0-0 1-1 2-2
( wasserfrei ||| ( anhydrous ||| 0-0 1-1
( weniger als 1 von ||| ( affecting less than 1 ||| 0-0 1-1 1-2 2-3 4-3 3-4
( weniger als 10 von ||| ( affecting less than 10 ||| 0-0 1-1 1-2 2-3 4-3 3-4
( weniger als ||| ( less than ||| 0-0 1-1 2-2
( weniger als ||| range ( less than ||| 2-0 0-1 1-2 2-3
( weniger als ||| reference range ( less than ||| 2-1 0-2 1-3 2-4
( weniger ||| ( affecting less ||| 0-0 1-1 1-2
( weniger ||| ( less ||| 0-0 1-1
( wie z.B. ||| ( such as ||| 0-0 1-1 2-1 1-2
( wie ||| ( such as ||| 0-0 1-1 1-2
( z. B. Aminoglykoside oder ||| ( e. g. aminoglycosides or ||| 0-0 1-1 2-1 2-2 3-3 4-4
( z. B. Aminoglykoside ||| ( e. g. aminoglycosides ||| 0-0 1-1 2-1 2-2 3-3
( z. B. Rifampicin ||| ( e. g. rifampicin ||| 0-0 1-1 1-2 2-2 3-3
( z. B. Rifampicin ||| induce ( e. g. rifampicin ||| 0-1 1-2 1-3 2-3 3-4
( z. B. Stenosen ||| ( e. g. stenoses ||| 0-0 1-1 2-1 2-2 3-3
( z. B. Unterfunktion der ||| ( e. g. diminished ||| 0-0 1-1 2-2 3-3
( z. B. Unterfunktion ||| ( e. g. diminished ||| 0-0 1-1 2-2 3-3
( z. B. mehr körperliche ||| ( e. g. increased exercise ||| 0-0 1-1 1-2 2-2 4-4
( z. B. mehr ||| ( e. g. increased ||| 0-0 1-1 1-2 2-2
( z. B. mehr ||| ( e. g. ||| 0-0 1-1 1-2 2-2
( z. B. verminderte ||| ( e. g. ||| 0-0 1-1 2-2 3-2
( z. B. verminderte ||| treated ( e. g. ||| 0-1 1-2 2-3 3-3
( z. B. ||| ( e. g. increased ||| 0-0 1-1 1-2 2-2
( z. B. ||| ( e. g. ||| 0-0 1-1 1-2 2-2
( z. B. ||| ( e. g. ||| 0-0 1-1 2-1 2-2
( z. B. ||| ( e. g. ||| 0-0 1-1 2-2
( z. B. ||| ( e. ||| 0-0 1-1 2-1
( z. B. ||| induce ( e. g. ||| 0-1 1-2 1-3 2-3
( z. ||| ( e. ||| 0-0 1-1
( z. ||| treated ( e. ||| 0-1 1-2
( z.B . : Schlaganfall ||| ( e. g. stroke ||| 0-0 1-1 2-1 1-2 3-3 4-3
( z.B . Gemfibrozil ||| ( e. g. gemfibrozil ||| 0-0 1-1 2-1 1-2 3-3
( z.B . Hypothermie , ||| ( e. g. hypothermia , ||| 0-0 1-1 1-2 2-3 3-3 4-4
( z.B . Hypothermie ||| ( e. g. hypothermia ||| 0-0 1-1 1-2 2-3 3-3
( z.B . ||| ( e. g. , ||| 0-0 1-1 1-2 2-2
( z.B . ||| ( e. g. ||| 0-0 1-1 1-2 2-2
( z.B . ||| ( e. g. ||| 0-0 1-1 2-1 1-2
( z.B . ||| ( e. ||| 0-0 1-1 2-1
( z.B ||| ( e. g. ||| 0-0 1-1 1-2
( z.B. anaphylaktische Reaktion ||| ( e. g. anaphylactic reaction ||| 0-0 1-1 2-2 1-3 2-3 3-4
( z.B. anaphylaktische ||| ( e. g. anaphylactic ||| 0-0 1-1 2-2 1-3 2-3
( zerebrovaskuläre ||| ( cerebrovascular ||| 0-0 1-1
( zum ||| ( zum ||| 0-0 1-1
( zur pH-Einstellung ) , ||| ( for pH-adjustment ) , ||| 0-0 1-1 1-2 2-2 3-3 4-4
( zur pH-Einstellung ) ||| ( for pH-adjustment ) ||| 0-0 1-1 1-2 2-2 3-3
( zur pH-Einstellung ||| ( for pH-adjustment ||| 0-0 1-1 1-2 2-2
( zwei Studien ||| ( two studies ||| 0-0 1-1 2-2
( zwei beziehen ||| ( two relate ||| 0-0 1-1 2-2
( zwei ||| ( two ||| 0-0 1-1
( ||| ( Clcr ||| 0-0
( ||| ( aluminium ||| 0-0 0-1
( ||| ( for ||| 0-0
( ||| ( i. e. ||| 0-0 0-1 0-2
( ||| ( i. ||| 0-0
( ||| ( new ||| 0-0
( ||| ( reduced ||| 0-0
( ||| ( the ||| 0-0
( ||| ( ||| 0-0
( ||| ) ||| 0-0
( ||| , ( ||| 0-1
( ||| 1 ||| 0-0
( ||| 120 ( ||| 0-1
( ||| 22 ( ||| 0-1
( ||| 29 ( ||| 0-0 0-1
( ||| 36 ( ||| 0-1
( ||| 64 ( ||| 0-0 0-1
( ||| Special populations ( ||| 0-1 0-2
( ||| Use ( ||| 0-1
( ||| characteristics ( ||| 0-1
( ||| conditions ( ||| 0-1
( ||| day ||| 0-0
( ||| full ||| 0-0
( ||| index ( ||| 0-1
( ||| induce ( ||| 0-1
( ||| injections of ||| 0-0
( ||| injections ||| 0-0
( ||| populations ( ||| 0-0 0-1
( ||| substance ( ||| 0-1
( ||| system ( ||| 0-1
( ||| treated ( ||| 0-1
( ||| vessels ( ||| 0-1
( Ödeme ) . ||| ( oedema ) . ||| 0-0 1-1 2-2 3-3
( Ödeme ) ||| ( oedema ) ||| 0-0 1-1 2-2
( Ödeme ||| ( oedema ||| 0-0 1-1
( Übelkeit ||| nausea ( feeling ||| 1-0 0-1 1-2
) ) ||| ) ) ||| 0-0 1-1
) ) ||| ) ||| 0-0 1-0
) , 2C9 ( Warfarin ||| ) , 2C9 ( warfarin ||| 0-0 1-1 2-2 3-3 4-4
) , 2C9 ( ||| ) , 2C9 ( ||| 0-0 1-1 2-2 3-3
) , 2C9 ||| ) , 2C9 ||| 0-0 1-1 2-2
) , Anämie ( ||| ) , anaemia ( ||| 0-0 1-1 2-2 3-3
) , Anämie ||| ) , anaemia ||| 0-0 1-1 2-2
) , Brustschmerzen , ||| ) , chest pain , ||| 0-0 1-1 2-2 2-3 3-4
) , Brustschmerzen ||| ) , chest pain ||| 0-0 1-1 2-2 2-3
) , Erbrechen , ||| ) , vomiting , ||| 0-0 1-1 2-2 3-3
) , Erbrechen ||| ) , vomiting ||| 0-0 1-1 2-2
) , Gewichtszunahme ||| ) , weight increase , ||| 0-0 1-1 2-2 2-3 1-4
) , Grand-mal-Anfall ||| ) , grand mal convulsion ||| 0-0 1-1 0-2 2-2 1-3 2-3 2-4
) , Italien ||| ) , Italy ||| 0-0 1-1 2-2
) , Macrogol 3000 . ||| ) , macrogol 3000 ||| 0-0 1-1 2-2 3-3 4-3
) , Macrogol ||| ) , macrogol ||| 0-0 1-1 2-2
) , Monoaminoxidasehemmer ||| ) , monoamine oxidase inhibitors ||| 0-0 1-1 2-2 2-3 2-4
) , Myalgie ( ||| ) , myalgia ( ||| 0-0 1-1 2-2 3-3
) , Myalgie ||| ) , myalgia ||| 0-0 1-1 2-2
) , Natriumhydroxid ( ||| ) , sodium hydroxide ( ||| 0-0 1-1 2-2 2-3 3-4
) , Natriumhydroxid , ||| ) , sodium hydroxide , ||| 0-0 1-1 2-2 2-3 3-4
) , Natriumhydroxid und ||| hydroxide , and ||| 0-0 2-0 1-1 3-2
) , Natriumhydroxid ||| ) , sodium hydroxide ||| 0-0 1-1 2-2 2-3
) , Natriumhydroxid ||| hydroxide , ||| 0-0 2-0 1-1
) , Ritonavir ||| ) , ritonavir ||| 0-0 1-1 2-2
) , Royaume-Uni Tél/Tel ||| ) , Royaume-Uni Tél/ Tel ||| 0-0 1-1 2-2 3-3 3-4
) , Royaume-Uni ||| ) , Royaume-Uni ||| 0-0 1-1 2-2
) , Storbritannia Tlf : ||| ) , Storbritannia Tlf : ||| 0-0 1-1 2-2 3-3 4-4
) , Storbritannia Tlf ||| ) , Storbritannia Tlf ||| 0-0 1-1 2-2 3-3
) , Storbritannia ||| ) , Storbritannia ||| 0-0 1-1 2-2
) , Storbritannien Tel : ||| ) , Storbritannien Tel : ||| 0-0 1-1 2-2 3-3 4-4
) , Storbritannien Tel ||| ) , Storbritannien Tel ||| 0-0 1-1 2-2 3-3
) , Storbritannien Tlf : ||| ) , Storbritannien Tlf : ||| 0-0 1-1 2-2 3-3 4-4
) , Storbritannien Tlf ||| ) , Storbritannien Tlf ||| 0-0 1-1 2-2 3-3
) , Storbritannien ||| ) , Storbritannien ||| 0-0 1-1 2-2
) , Te . : ||| ) , Te . : ||| 0-0 1-1 2-2 3-3 4-4
) , Te . ||| ) , Te . ||| 0-0 1-1 2-2 3-3
) , Te ||| ) , Te ||| 0-0 1-1 2-2
) , Wasser für ||| ) , and water for ||| 0-0 1-1 2-2 2-3 3-4
) , Wasser ||| ) , and water ||| 0-0 1-1 2-2 2-3
) , Weinsäure ( ||| ) , tartaric acid , ||| 0-0 1-1 2-2 2-3 3-3 1-4
) , Wielka Brytania Tel ||| ) , Wielka Brytania Tel ||| 0-0 1-1 2-2 3-3 4-4
) , Wielka Brytania ||| ) , Wielka Brytania ||| 0-0 1-1 2-2 3-3
) , Wielka ||| ) , Wielka ||| 0-0 1-1 2-2
) , Zucker ||| ) , sugar ||| 0-0 1-1 2-2
) , als ||| ) , as ||| 0-0 1-1 2-2
) , das ||| ) , ||| 0-0 1-1
) , die Paclitaxel auflösen ||| ) that dissolve the paclitaxel ||| 0-0 1-1 2-1 4-2 2-3 3-4
) , die durch Diät ||| ) inadequately controlled by diet ||| 0-0 4-1 4-2 2-3 3-3 4-4
) , die normalerweise ||| ) which are normally ||| 0-0 2-1 3-1 3-2 3-3
) , die ||| ) ||| 0-0
) , entsprechend 0,0533 mg ||| , corresponding to 0.0533 mg ||| 1-0 0-1 2-1 2-2 3-3 4-4
) , entsprechend 0,0533 ||| , corresponding to 0.0533 ||| 1-0 0-1 2-1 2-2 3-3
) , entsprechend 16,8 Mikrogramm ||| ) corresponding to 16.8 micrograms ||| 0-0 1-1 2-1 2-2 3-3 4-4
) , entsprechend 16,8 ||| ) corresponding to 16.8 ||| 0-0 1-1 2-1 2-2 3-3
) , entsprechend 25,2 Mikrogramm ||| ) corresponding to 25.2 micrograms ||| 0-0 1-1 2-1 2-2 3-3 4-4
) , entsprechend 25,2 ||| ) corresponding to 25.2 ||| 0-0 1-1 2-1 2-2 3-3
) , entsprechend 33,6 Mikrogramm ||| ) corresponding to 33.6 micrograms ||| 0-0 1-1 2-1 2-2 3-3 4-4
) , entsprechend 33,6 ||| ) corresponding to 33.6 ||| 0-0 1-1 2-1 2-2 3-3
) , entsprechend 42,0 Mikrogramm ||| ) corresponding to 42.0 micrograms ||| 0-0 1-1 2-1 2-2 3-3 4-4
) , entsprechend 42,0 ||| ) corresponding to 42.0 ||| 0-0 1-1 2-1 2-2 3-3
) , entsprechend 5,330 mg ||| , corresponding to 5.330 mg ||| 1-0 0-1 2-1 2-2 3-3 4-4
) , entsprechend 5,330 ||| , corresponding to 5.330 ||| 1-0 0-1 2-1 2-2 3-3
) , entsprechend 50,4 Mikrogramm ||| ) corresponding to 50.4 micrograms ||| 0-0 1-1 2-1 2-2 3-3 4-4
) , entsprechend 50,4 ||| ) corresponding to 50.4 ||| 0-0 1-1 2-1 2-2 3-3
) , entsprechend 58,8 Mikrogramm ||| ) corresponding to 58.8 micrograms ||| 0-0 1-1 2-1 2-2 3-3 4-4
) , entsprechend 58,8 ||| ) corresponding to 58.8 ||| 0-0 1-1 2-1 2-2 3-3
) , entsprechend 67,2 Mikrogramm ||| ) corresponding to 67.2 micrograms ||| 0-0 1-1 2-1 2-2 3-3 4-4
) , entsprechend 67,2 ||| ) corresponding to 67.2 ||| 0-0 1-1 2-1 2-2 3-3
) , entsprechend 75,6 Mikrogramm ||| ) corresponding to 75.6 micrograms ||| 0-0 1-1 2-1 2-2 3-3 4-4
) , entsprechend 75,6 ||| ) corresponding to 75.6 ||| 0-0 1-1 2-1 2-2 3-3
) , entsprechend 8,4 Mikrogramm ||| ) corresponding to 8.4 micrograms ||| 0-0 1-1 2-1 2-2 3-3 4-4
) , entsprechend 8,4 ||| ) corresponding to 8.4 ||| 0-0 1-1 2-1 2-2 3-3
) , entsprechend 84,0 Mikrogramm ||| ) corresponding to 84.0 micrograms ||| 0-0 1-1 2-1 2-2 3-3 4-4
) , entsprechend 84,0 ||| ) corresponding to 84.0 ||| 0-0 1-1 2-1 2-2 3-3
) , entsprechend ||| ) corresponding to ||| 0-0 1-1 2-1 2-2
) , entsprechend ||| , corresponding to ||| 1-0 0-1 2-1 2-2
) , erhöhte Aspartat-Aminotransferase ||| ) , increased Aspartate Aminotransferase ||| 0-0 1-1 2-2 2-3 3-3 3-4
) , erhöhte Gamma- ||| ) , increased Gamma ||| 0-0 1-1 2-2 3-3
) , erhöhte alkalische Phosphatase ||| ) , increased alkaline phosphatase ||| 0-0 1-1 2-2 3-3 4-4
) , erhöhte alkalische ||| ) , increased alkaline ||| 0-0 1-1 2-2 3-3
) , erhöhte ||| ) , increased ||| 0-0 1-1 2-2
) , falls erforderlich ||| ) , if necessary ||| 0-0 1-1 2-2 3-3
) , falls ||| ) , if ||| 0-0 1-1 2-2
) , in der ||| ) , where prophylaxis against ||| 0-0 1-1 2-2
) , in der ||| ) , where prophylaxis ||| 0-0 1-1 2-2
) , in der ||| ) , where ||| 0-0 1-1 2-2
) , in ||| ) , where prophylaxis against ||| 0-0 1-1 2-2
) , in ||| ) , where prophylaxis ||| 0-0 1-1 2-2
) , in ||| ) , where ||| 0-0 1-1 2-2
) , jeweils ||| ) ||| 0-0
) , kontaktieren ||| ) , contact ||| 0-0 1-1 2-2
) , mit einer ||| ) , with an ||| 0-0 1-1 2-2 3-3
) , mit ||| ) , with ||| 0-0 1-1 2-2
) , oder ||| ) or ||| 0-0 2-1
) , siehe Abschnitt 4.5 ||| ) , see section 4.5 ||| 0-0 1-1 2-2 3-3 4-4
) , siehe Abschnitt ||| ) , see section ||| 0-0 1-1 2-2 3-3
) , siehe ||| ) , see ||| 0-0 1-1 2-2
) , versiegelt in einer ||| ) sealed in a ||| 0-0 1-1 2-1 3-2 4-3
) , versiegelt in ||| ) sealed in ||| 0-0 1-1 2-1 3-2
) , versiegelt ||| ) sealed ||| 0-0 1-1 2-1
) , wird ||| ) is ||| 0-0 1-1 2-1
) , ||| ) , ||| 0-0 1-1
) , ||| ) and ||| 0-0
) , ||| ) at ||| 0-0
) , ||| ) ||| 0-0
) , ||| , ||| 0-0 1-0
) , ||| , ||| 1-0
) , ||| ; ||| 1-0
) , ||| move ) , ||| 0-0 0-1 1-2
) , ||| to move ) , ||| 0-1 0-2 1-3
) , µ : +44 ||| ) , µ : +44 ||| 0-0 1-1 2-2 3-3 4-4
) , µ : ||| ) , µ : ||| 0-0 1-1 2-2 3-3
) , µ ||| ) , µ ||| 0-0 1-1 2-2
) . Erbrechen Durchfall weicher ||| ) . vomiting diarrhoea softened ||| 0-0 1-1 2-2 3-3 4-4
) . Erbrechen Durchfall ||| ) . vomiting diarrhoea ||| 0-0 1-1 2-2 3-3
) . Erbrechen ||| ) . vomiting ||| 0-0 1-1 2-2
) . In ||| ) . ||| 0-0 1-1
) . ||| ) . dic ||| 0-0 1-1 0-2
) . ||| ) . no ||| 0-0 1-1
) . ||| ) . ||| 0-0 1-1
) . ||| ) ||| 0-0
) . ||| ) ||| 0-0 1-0
) . ||| . ) . ||| 1-0 0-1 1-2
) . ||| . ||| 1-0
) . ||| received ||| 0-0
) . ||| weight ) . ||| 0-1 1-2
) 2 mg/ml ||| ) 2 mg/ ml ||| 0-0 1-1 2-2 2-3
) 2 ||| ) 2 ||| 0-0 1-1
) 20 501 76 03 ||| ) 20 501 76 03 ||| 0-0 1-1 2-2 3-3 4-4
) 20 501 76 ||| ) 20 501 76 ||| 0-0 1-1 2-2 3-3
) 20 501 ||| ) 20 501 ||| 0-0 1-1 2-2
) 20 ||| ) 20 ||| 0-0 1-1
) 241 941-0 ||| ) 241 941-0 ||| 0-0 1-1 2-2
) 241 ||| ) 241 ||| 0-0 1-1
) 2649600 ||| ) 2649600 ||| 0-0 1-1
) 30 60 25 800 ||| ) 30 60 25 800 ||| 0-0 1-1 2-2 3-3 4-4
) 30 60 25 ||| ) 30 60 25 ||| 0-0 1-1 2-2 3-3
) 30 60 ||| ) 30 60 ||| 0-0 1-1 2-2
) 30 ||| ) 30 ||| 0-0 1-1
) 524 40 64 ||| ) 524 40 64 ||| 0-0 1-1 2-2 3-3
) 524 40 ||| ) 524 40 ||| 0-0 1-1 2-2
) 524 ||| ) 524 ||| 0-0 1-1
) 663 50 00 ||| ) 663 50 00 ||| 0-0 1-1 2-2 3-3
) 663 50 ||| ) 663 50 ||| 0-0 1-1 2-2
) 663 ||| ) 663 ||| 0-0 1-1
) 731 1736 ||| ) 731 1736 ||| 0-0 1-1 2-2
) 731 ||| ) 731 ||| 0-0 1-1
) 74 18 84 00 ||| ) 74 18 84 00 ||| 0-0 1-1 2-2 3-3 4-4
) 74 18 84 16 ||| ) 74 18 84 16 ||| 0-0 1-1 2-2 3-3 4-4
) 74 18 84 ||| ) 74 18 84 ||| 0-0 1-1 2-2 3-3
) 74 18 86 68 ||| ) 74 18 86 68 ||| 0-0 1-1 2-2 3-3 4-4
) 74 18 86 ||| ) 74 18 86 ||| 0-0 1-1 2-2 3-3
) 74 18 ||| ) 74 18 ||| 0-0 1-1 2-2
) 74 ||| ) 74 ||| 0-0 1-1
) 749 749 ||| ) 749 749 ||| 0-0 1-1 2-2
) 749 ||| ) 749 ||| 0-0 1-1
) : Psychiatrische Erkrankungen : ||| Psychiatric disorder : psychotic disorders ||| 2-0 3-1 1-2 4-2 3-3 3-4
) : ||| ) : ||| 0-0 1-1
) ; ||| ) , ||| 0-0 1-1
) AB Puh/Tel : ||| ) AB Puh/ Tel : ||| 0-0 1-1 2-2 2-3 3-4
) AB Puh/Tel ||| ) AB Puh/ Tel ||| 0-0 1-1 2-2 2-3
) AB ||| ) AB ||| 0-0 1-1
) Acesulfam-Kalium Vanille-Aroma ||| ) Acesulfame potassium Vanilla ||| 0-0 1-1 1-2 2-3
) Acesulfam-Kalium ||| ) Acesulfame potassium ||| 0-0 1-1 1-2
) Aclasta ||| ) Aclasta ||| 0-0 1-1
) Aripiprazol . ||| ) aripiprazole . ||| 0-0 1-1 2-2
) Aripiprazol ||| ) aripiprazole ||| 0-0 1-1
) BESTANDTEIL(E ) UND ||| ACTIVE SUBSTANCE(S ) AND ||| 0-0 1-0 1-1 2-2 3-3
) BESTANDTEIL(E ) ||| ACTIVE SUBSTANCE(S ) ||| 0-0 1-0 1-1 2-2
) BESTANDTEIL(E ||| ACTIVE SUBSTANCE(S ||| 0-0 1-0 1-1
) Blisterpackung ( PVC/Aluminium ||| ) Blister ( PVC/ aluminium ||| 0-0 1-1 2-2 3-3 3-4
) Blisterpackung ( ||| ) Blister ( ||| 0-0 1-1 2-2
) Blisterpackung ||| ) Blister ||| 0-0 1-1
) DER ANWENDUNG ||| ) OF ADMINISTRATION ||| 0-0 1-1 2-2
) DER ||| ) OF ||| 0-0 1-1
) Die Häufigkeit von klinischen ||| ) The incidence of clinical ||| 0-0 1-1 2-2 3-3 4-4
) Die Häufigkeit von ||| ) The incidence of ||| 0-0 1-1 2-2 3-3
) Die Häufigkeit ||| ) The incidence ||| 0-0 1-1 2-2
) Die ||| ) The ||| 0-0 1-1
) Dyslipidämie eingeschlossen waren , ||| ) Dyslipidämie eingeschlossen waren , ||| 0-0 1-1 1-2 3-3 2-4 4-4
) Dyslipidämie ||| ) Dyslipidämie eingeschlossen ||| 0-0 1-1 1-2
) Eine Dosisanpassung ist nicht ||| ) No dose adjustment is ||| 0-0 1-1 2-1 2-2 2-3 3-4 4-4
) Eine Dosisanpassung ||| ) No dose adjustment ||| 0-0 1-1 2-1 2-2 2-3
) Erythropoetin berichtet . ||| ) erythropoietin treatment . ||| 0-0 1-1 2-2 3-3
) Erythropoetin berichtet ||| ) erythropoietin treatment ||| 0-0 1-1 2-2
) Erythropoetin ||| ) erythropoietin ||| 0-0 1-1
) General Scale ||| ) general scale ||| 0-0 1-1 1-2 2-2
) In ||| ) In ||| 0-0 1-1
) Insulin . ||| ) insulin . ||| 0-0 1-1 2-2
) Insulin ||| ) insulin ||| 0-0 1-1
) Ltd , 61 Aldwych ||| ) Ltd , 61 Aldwych ||| 0-0 1-1 2-2 3-3 4-4
) Ltd , 61 ||| ) Ltd , 61 ||| 0-0 1-1 2-2 3-3
) Ltd , ||| ) Ltd , ||| 0-0 1-1 2-2
) Ltd 61 Aldwych London ||| ) Ltd 61 Aldwych London ||| 0-0 1-1 2-2 3-3 4-4
) Ltd 61 Aldwych ||| ) Ltd 61 Aldwych ||| 0-0 1-1 2-2 3-3
) Ltd 61 ||| ) Ltd 61 ||| 0-0 1-1 2-2
) Ltd ||| ) Ltd ||| 0-0 1-1
) Natriumhydroxid ( ||| ) Sodium hydroxide ( ||| 0-0 1-1 1-2 2-3
) Natriumhydroxid Sucrose Gereinigtes ||| ) Sodium hydroxide Sucrose Purified ||| 0-0 1-1 1-2 2-3 3-4
) Natriumhydroxid Sucrose ||| ) Sodium hydroxide Sucrose ||| 0-0 1-1 1-2 2-3
) Natriumhydroxid ||| ) Sodium hydroxide ||| 0-0 1-1 1-2
) Pioglitazon bleibt somit unverändert ||| ) pioglitazone concentration is unchanged ||| 0-0 1-1 2-2 2-3 2-4 3-4 4-4
) Pioglitazon ||| ) pioglitazone ||| 0-0 1-1
) Placebo Absolute ||| ) in fracture event ||| 0-0 1-1 1-2 2-2 2-3
) Probanden mit einer ||| with a ||| 0-0 2-0 1-1 3-1
) Propylenglycol Propyl-4-hydroxybenzoat ||| ) Propylene glycol Propyl parahydroxybenzoate ||| 0-0 1-1 1-2 2-3 2-4
) Propylenglycol ||| ) Propylene glycol ||| 0-0 1-1 1-2
) Protaminsulfat Wasser für ||| ) Protamine sulphate Water for ||| 0-0 1-1 1-2 1-3 2-3 3-4
) Protaminsulfat Wasser ||| ) Protamine sulphate Water ||| 0-0 1-1 1-2 1-3 2-3
) Salzsäure ( zur ||| ) Hydrochloric acid ( for ||| 0-0 1-1 1-2 3-2 2-3 3-4
) Spanien ||| ) Spain ||| 0-0 1-1
) UND ETIKETTIERUNG DER FLASCHE ||| ) AND BOTTLE LABEL FOR ||| 0-0 1-1 2-2 3-3 4-3 4-4
) UND ETIKETTIERUNG ||| ) AND BOTTLE ||| 0-0 1-1 2-2
) UND SONSTIGE BESTANDTEILE ||| ) AND OTHER INGREDIENT(S ) ||| 0-0 1-1 2-2 2-3 3-3 3-4
) UND ||| ) AND ||| 0-0 1-1
) Weinsäure ( Ph.Eur. ) ||| ) Tartaric acid Sodium ||| 0-0 1-1 1-2 2-2 3-3 4-3
) Weinsäure ( ||| ) Tartaric acid ||| 0-0 1-1 1-2 2-2
) Yarvitan ist eine farblose ||| ) Yarvitan is a colourless ||| 0-0 1-1 2-2 3-3 4-4
) Yarvitan ist eine ||| ) Yarvitan is a ||| 0-0 1-1 2-2 3-3
) Yarvitan ist ||| ) Yarvitan is ||| 0-0 1-1 2-2
) Yarvitan ||| ) Yarvitan ||| 0-0 1-1
) als bei Patienten ohne ||| ) als bei Patienten ohne ||| 0-0 1-1 2-2 3-3 4-4
) als bei Patienten ||| ) als bei Patienten ||| 0-0 1-1 2-2 3-3
) als bei der Haloperidol-Gruppe ||| ) than for haloperidol ||| 0-0 1-1 4-2 2-3 4-3
) als bei ||| ) als bei ||| 0-0 1-1 2-2
) als bei ||| in ||| 1-0 2-0
) als ||| ) als ||| 0-0 1-1
) als ||| ) as ||| 0-0 1-1
) als ||| ) than ||| 0-0 1-1
) an 384 Patienten untersucht ||| ) in 384 patients ||| 0-0 1-1 2-2 3-3 4-3
) an 384 ||| ) in 384 ||| 0-0 1-1 2-2
) an ||| ) in ||| 0-0 1-1
) auf Humaninsulin ( ||| ) to insulin human ( ||| 0-0 1-1 2-2 2-3 3-4
) auf Humaninsulin ||| ) to insulin human ||| 0-0 1-1 2-2 2-3
) auf Pioglitazon oder einen ||| ) to pioglitazone or any ||| 0-0 1-1 2-2 3-3 4-4
) auf Pioglitazon oder ||| ) to pioglitazone or ||| 0-0 1-1 2-2 3-3
) auf Pioglitazon ||| ) to pioglitazone ||| 0-0 1-1 2-2
) auf ||| ) to ||| 0-0 1-1
) auf ||| to ||| 1-0
) aufweisen . ||| ) . ||| 0-0 2-1
) aufweisen . ||| blood ) . ||| 0-1 2-2
) aufweisen ||| ) ||| 0-0
) aufweisen ||| blood ) ||| 0-1
) bei Patienten ||| ) in patients ||| 0-0 1-1 2-2
) bei der empfohlenen klinischen ||| at the maximum recommended clinical ||| 1-0 3-0 2-1 3-2 3-3 4-4
) bei der empfohlenen ||| at the maximum recommended ||| 1-0 3-0 2-1 3-2 3-3
) bei einer Erhaltungsdosis ||| ) with a maintenance dose ||| 0-0 1-1 2-2 1-3 3-3 3-4
) bei ||| ) in ||| 0-0 1-1
) beobachtet . ||| ) beobachtet . For lp ||| 0-0 1-1 2-2 2-4
) beobachtet ||| ) beobachtet ||| 0-0 1-1
) berichtet ||| ) have been reported ||| 0-0 1-1 1-2 1-3
) bestimmen , ||| ) regularly ||| 0-0 1-1
) bestimmen und ||| ) regularly and ||| 0-0 1-1 2-2
) bestimmen ||| ) regularly ||| 0-0 1-1
) betrugen 2-5 % ||| ) were 2 5 % ||| 0-0 1-1 2-2 2-3 3-4
) betrugen 2-5 ||| ) were 2 5 ||| 0-0 1-1 2-2 2-3
) betrugen ||| ) were ||| 0-0 1-1
) bis 12 g/dl ||| ) to 12 g/ dl ||| 0-0 1-1 2-2 3-3 3-4
) bis 12 ||| ) to 12 ||| 0-0 1-1 2-2
) bis ||| ) to ||| 0-0 1-1
) dem aktuellen ||| ) is the current standard ||| 0-0 1-1 1-2 2-3 1-4
) der ||| ) of ||| 0-0 1-1
) des Harnblasenepithels induziert . ||| up to 2 years . ||| 2-0 1-1 2-2 2-3 3-3 4-4
) des Harnblasenepithels induziert ||| up to 2 years ||| 2-0 1-1 2-2 2-3 3-3
) des ||| to ||| 1-0
) eine signifikant ||| significantly greater ||| 2-0 1-1 2-1
) eingenommen ||| taken ||| 1-0
) einmal täglich . ||| ) once a day . ||| 0-0 1-1 1-2 2-3 3-4
) einmal täglich ||| ) once a day ||| 0-0 1-1 1-2 2-3
) einmal ||| ) once a ||| 0-0 1-1 1-2
) entspricht 0,035 mg ||| ) corresponds to 0.035 mg ||| 0-0 1-1 1-2 2-3 3-4
) entspricht 0,035 ||| ) corresponds to 0.035 ||| 0-0 1-1 1-2 2-3
) entspricht ||| ) corresponds to ||| 0-0 1-1 1-2
) erhielten kardiovaskuläre ||| ) were receiving cardiovascular ||| 0-0 1-1 1-2 2-3
) erhielten ||| ) were receiving ||| 0-0 1-1 1-2
) erhöhte sich linear von ||| ) increased linearly from ||| 0-0 1-1 3-2 4-3
) erhöhte sich linear ||| ) increased linearly ||| 0-0 1-1 3-2
) erhöhte sich ||| ) increased ||| 0-0 1-1
) erhöhte ||| ) increased ||| 0-0 1-1
) für die erste Injektion ||| ) for the first injection ||| 0-0 1-1 2-2 3-3 4-4
) für die erste ||| ) for the first ||| 0-0 1-1 2-2 3-3
) für die ||| ) for the ||| 0-0 1-1 2-2
) für ||| ) for ||| 0-0 1-1
) gegenüber Pioglitazon ||| ) to pioglitazone ||| 0-0 1-1 2-2
) gegenüber ||| ) to ||| 0-0 1-1
) im Kiefer . ||| ) in the jaw . ||| 0-0 1-1 1-2 1-3 2-3 3-4
) im Kiefer ||| ) in the jaw ||| 0-0 1-1 1-2 1-3 2-3
) im Vergleich zu Patienten ||| ) compared with patients ||| 0-0 1-1 2-1 3-1 2-2 4-3
) im Vergleich zu ||| ) , compared ||| 0-0 1-2 2-2 3-2
) im Vergleich zu ||| ) compared with ||| 0-0 1-1 2-1 3-1 2-2
) im ||| ) ||| 0-0
) in Modul ||| ) presented in Module ||| 0-0 2-1 1-2 2-3
) in der Placebo-Gruppe ||| ) in the placebo group ||| 0-0 1-1 2-2 3-3 3-4
) in der ||| ) in the ||| 0-0 1-1 2-2
) in vitro . ||| ) in vitro . ||| 0-0 1-1 2-2 3-3
) in vitro ||| ) in vitro ||| 0-0 1-1 2-2
) in ||| ) in ||| 0-0 1-1
) ist Fieber . ||| ) is fever . ||| 0-0 1-1 2-2 3-3
) ist Fieber ||| ) is fever ||| 0-0 1-1 2-2
) ist daher ||| ) is therefore ||| 0-0 1-1 2-2
) ist ||| ) is ||| 0-0 1-1
) je Schmelztablette . ||| ) per orodispersible tablet ||| 0-0 1-1 2-2 2-3 3-3
) je ml . ||| ) per ml ||| 0-0 1-1 2-2 3-2
) je ml 0,2 mg ||| ) per ml 0.2 mg ||| 0-0 1-1 2-2 3-3 4-4
) je ml 0,2 ||| ) per ml 0.2 ||| 0-0 1-1 2-2 3-3
) je ml ||| ) per ml ||| 0-0 1-1 2-2
) je ||| ) per ||| 0-0 1-1
) kann abhängig vom ||| ) may be ||| 0-0 1-1 2-1 1-2
) kann abhängig ||| ) may be ||| 0-0 1-1 2-1 1-2
) kann ||| ) may ||| 0-0 1-1
) kurz ||| ) shortly ||| 0-0 1-1
) können ||| ) may ||| 0-0 1-1
) lagen , ||| ) ||| 0-0
) lagen ||| ) ||| 0-0
) metabolisiert wird ||| metabolised ||| 1-0
) metabolisiert ||| metabolised ||| 1-0
) mit Frauen mit ||| ) in women with ||| 0-0 2-1 2-2 1-3 3-3
) mit ||| ) with a ||| 0-0 1-1
) mit ||| ) with ||| 0-0 1-1
) nach 6 Monaten ||| ) at six months ||| 0-0 1-1 2-2 1-3 3-3
) nach ||| ) after ||| 0-0 1-1
) oder CYP2D6 ||| ) or CYP2D6 ||| 0-0 1-1 2-2
) oder Koma ||| ) or coma , ||| 0-0 1-1 2-2
) oder Koma ||| ) or coma ||| 0-0 1-1 2-2
) oder Placebo ||| or placebo ( ||| 1-0 2-1
) oder Placebo ||| or placebo ||| 1-0 2-1
) oder anderen ||| ) , or to other ||| 0-0 1-2 2-4
) oder die ||| ) or the ||| 0-0 1-1 2-2
) oder einen ||| ) or to any ||| 0-0 1-1 2-2 2-3
) oder in Fertigpens ||| PenFill ) or pre-filled pens ||| 3-0 0-1 1-2 3-3 3-4
) oder in Form ||| ) , or as ||| 0-0 1-2 3-3
) oder in ||| ) , or ||| 0-0 1-2
) oder in ||| ) or ||| 0-0 1-1
) oder ||| ) , or to ||| 0-0 1-2
) oder ||| ) , or ||| 0-0 1-2
) oder ||| ) or ||| 0-0 1-1
) oder ||| or ||| 1-0
) ohne Finger- , ||| ) Excluding finger , toe ||| 0-0 2-1 1-2 2-2 3-3 2-4
) oral ||| ) ||| 0-0
) pro Kilogramm Körpergewicht . ||| ) per kilogram bodyweight . ||| 0-0 1-1 2-2 2-3 3-3 4-4
) pro Kilogramm Körpergewicht ||| ) per kilogram bodyweight ||| 0-0 1-1 2-2 2-3 3-3
) pro Monat ansteigt oder ||| ) per month , or ||| 0-0 1-1 2-2 3-2 4-4
) pro Monat ansteigt ||| ) per month , ||| 0-0 1-1 2-2 3-2
) pro Monat ansteigt ||| ) per month ||| 0-0 1-1 2-2 3-2
) pro Monat nicht überschreiten ||| ) per month ||| 0-0 1-1 3-1 4-1 2-2
) pro Monat ||| ) per month ||| 0-0 1-1 2-2
) pro ||| ) per ||| 0-0 1-1
) repräsentieren vermutlich die schnelle ||| ) presumably represent rapid ||| 0-0 1-1 2-1 4-2 4-3
) repräsentieren vermutlich die ||| ) presumably ||| 0-0 1-1 2-1
) repräsentieren vermutlich ||| ) presumably ||| 0-0 1-1 2-1
) sind Neutropenie ( ||| ) are neutropenia ( ||| 0-0 1-1 2-2 3-3
) sind Neutropenie ||| ) are neutropenia ||| 0-0 1-1 2-2
) sind darauf hinzuweisen , ||| ) should be alerted about ||| 0-0 1-1 2-1 2-2 3-3 2-4
) sind darauf hinzuweisen ||| ) should be alerted about ||| 0-0 1-1 2-1 2-2 3-3 2-4
) sind extrapyramidale ||| ) are extrapyramidal ||| 0-0 1-1 2-2
) sind nicht ausreichend . ||| , are not sufficient . ||| 1-1 2-2 0-3 3-3 4-4
) sind nicht ausreichend . ||| are not sufficient . ||| 1-0 2-1 0-2 3-2 4-3
) sind nicht ausreichend ||| , are not sufficient ||| 1-1 2-2 0-3 3-3
) sind nicht ausreichend ||| are not sufficient ||| 1-0 2-1 0-2 3-2
) sind ||| ) are ||| 0-0 1-1
) soll ||| ) should ||| 0-0 1-1
) sollte vermieden werden . ||| ) should be avoided . ||| 0-0 1-1 3-2 2-3 4-4
) sollte vermieden werden ||| ) should be avoided ||| 0-0 1-1 3-2 2-3
) sollte ||| ) should ||| 0-0 1-1
) sollten nicht ||| ) should not ||| 0-0 1-1 2-2
) sollten ||| ) should be ||| 0-0 1-1 1-2
) sollten ||| ) should ||| 0-0 1-1
) und +0,1 unter Placebo ||| ) and +0.1 on placebo ||| 0-0 1-1 2-2 3-3 3-4 4-4
) und +0,1 ||| ) and +0.1 ||| 0-0 1-1 2-2
) und 29-mal ( ||| rat ) and 29 ( ||| 2-0 0-1 1-2 3-3 3-4
) und 29-mal ||| rat ) and ||| 2-0 0-1 1-2
) und 6,1 Monate ( ||| ) and 6.1 months ( ||| 0-0 1-1 2-2 3-3 4-4
) und 6,1 Monate ||| ) and 6.1 months ||| 0-0 1-1 2-2 3-3
) und 6,1 ||| ) and 6.1 ||| 0-0 1-1 2-2
) und 802 Patienten mit ||| ) and 802 with ||| 0-0 1-1 2-2 3-2 4-3
) und 802 Patienten ||| ) and 802 ||| 0-0 1-1 2-2 3-2
) und NovoFine Injektionsnadeln vorgesehen ||| ) and NovoFine needles ||| 0-0 1-1 2-2 3-2 3-3 4-3
) und Placebo ( 2,1 ||| ) and placebo ( 2.1 ||| 0-0 1-1 2-2 3-3 4-4
) und Placebo ( 29 ||| ) and placebo ( 29 ||| 0-0 1-1 2-2 3-3 4-4
) und Placebo ( ||| ) and placebo ( ||| 0-0 1-1 2-2 3-3
) und Placebo ||| ) and placebo ||| 0-0 1-1 2-2
) und als ||| ) and as ||| 0-0 1-1 2-2
) und anschließend jährliche ||| ) in September 2005 and ||| 0-0 3-2 3-3 1-4 2-4
) und die Bindung ist ||| ) and binding is ||| 0-0 1-1 3-2 4-3
) und die Bindung ||| ) and binding ||| 0-0 1-1 3-2
) und die ||| ) and ||| 0-0 1-1
) und in-vivo ||| lymphocytes ) and ||| 2-0 0-1 1-2
) und war schnell ||| ) , and was rapidly ||| 0-0 1-2 2-3 3-4
) und war ||| ) , and was ||| 0-0 1-2 2-3
) und zu einem ||| ) and a ||| 0-0 1-1 3-2
) und zu ||| ) and ||| 0-0 1-1
) und ||| ) , and ||| 0-0 1-2
) und ||| ) and ||| 0-0 1-1
) und ||| ) und ||| 0-0 1-1
) und/oder ||| ) and/ ||| 0-0 1-1
) untersucht . ||| ) . ||| 0-0 1-1 2-1
) untersucht werden . ||| ) should be investigated . ||| 0-0 2-1 2-2 1-3 3-4
) untersucht werden ||| ) should be investigated ||| 0-0 2-1 2-2 1-3
) verglichen . ||| ) . ||| 0-0 1-0 2-1
) verglichen ||| ) ||| 0-0 1-0
) von EPS einschließlich Parkinsonismus ||| ) of EPS including parkinsonism ||| 0-0 1-1 2-2 3-3 4-4
) von EPS einschließlich ||| ) of EPS including ||| 0-0 1-1 2-2 3-3
) von EPS ||| ) of EPS ||| 0-0 1-1 2-2
) von ||| ) of ||| 0-0 1-1
) vor dem operativen ||| ) prior to ||| 0-0 1-1 2-1 3-1 1-2
) wird durch ||| ) is ||| 0-0 1-1
) wird ||| ) is ||| 0-0 1-1
) wurde ||| ) has ||| 0-0 1-1
) wurde ||| ) was ||| 0-0 1-1
) wurde ||| ) were ||| 0-0 1-1
) während ||| ) during ||| 0-0 1-1
) zu erreichen . ||| l ) . ||| 1-0 2-0 0-1 3-2
) zu erreichen ||| l ) ||| 1-0 2-0 0-1
) zu hoch sind , ||| ) are too high ||| 0-0 3-1 1-2 2-2 2-3
) zu hoch sind ||| ) are too high ||| 0-0 3-1 1-2 2-2 2-3
) zur ||| for ||| 1-0
) ||| ( ||| 0-0
) ||| ) , ||| 0-0
) ||| ) That ||| 0-0
) ||| ) and ||| 0-0
) ||| ) at ||| 0-0
) ||| ) confirmed ||| 0-0
) ||| ) following the ||| 0-0
) ||| ) following ||| 0-0
) ||| ) in ||| 0-0
) ||| ) low- trauma ||| 0-0
) ||| ) low- ||| 0-0
) ||| ) of ||| 0-0
) ||| ) was ||| 0-0
) ||| ) with ||| 0-0
) ||| ) ||| 0-0
) ||| , ||| 0-0
) ||| . ||| 0-0
) ||| blood ) ||| 0-1
) ||| blood calcium levels ) ||| 0-3
) ||| breaks ) ||| 0-0 0-1
) ||| calcium levels ) ||| 0-2
) ||| factors ( ||| 0-1
) ||| levels ) ||| 0-1
) ||| mouth ) ||| 0-1
) ||| move ) ||| 0-0 0-1
) ||| rabbit ) ||| 0-0 0-1
) ||| received ||| 0-0
) ||| to move ) ||| 0-1 0-2
) ||| weight ) ||| 0-1
) äußern . Symptome einer ||| symptoms of ||| 1-0 3-0 4-1
) äußern . Symptome einer ||| the symptoms of ||| 1-1 3-1 4-2
) äußern . Symptome ||| symptoms ||| 1-0 3-0
) äußern . Symptome ||| the symptoms ||| 1-1 3-1
) über der ||| rabbit ) ||| 0-0 0-1
) über ||| rabbit ) ||| 0-0 0-1
* : in ||| * : in ||| 0-0 1-1 2-2
* : in Übereinstimmung mit ||| * : in line with ||| 0-0 1-1 2-2 3-3 4-4
* : in Übereinstimmung ||| * : in line ||| 0-0 1-1 2-2 3-3
* : ||| * : ||| 0-0 1-1
* Daten von 360 Hunden ||| * data from 360 dogs ||| 0-0 1-1 1-2 2-2 3-3 4-4
* Daten von 360 ||| * data from 360 ||| 0-0 1-1 1-2 2-2 3-3
* Daten von ||| * data from ||| 0-0 1-1 1-2 2-2
* Diese Daten ||| * This data ||| 0-0 1-1 2-2
* Diese ||| * This ||| 0-0 1-1
* Zusätzliche unerwünschte Ereignisse ||| * Additional adverse events ||| 0-0 1-1 2-2 3-3
* Zusätzliche unerwünschte ||| * Additional adverse ||| 0-0 1-1 2-2
* Zusätzliche ||| * Additional ||| 0-0 1-1
* ||| * ||| 0-0
*Die Häufigkeit basiert nur auf ||| *frequency is based only on ||| 0-0 1-0 2-1 2-2 3-3 4-4
*Die Häufigkeit basiert nur ||| *frequency is based only ||| 0-0 1-0 2-1 2-2 3-3
*Die Häufigkeit basiert ||| *frequency is based ||| 0-0 1-0 2-1 2-2
*Die Häufigkeit ||| *frequency ||| 0-0 1-0
*Hergestellt durch rekombinante ||| * Produced in CHO ||| 0-0 0-1 1-1 2-2 2-3
*Hergestellt durch ||| * Produced ||| 0-0 0-1 1-1
*Mediane Zeit bis zur Krankheitsprogression ||| *Median time to disease progression ||| 0-0 1-1 2-2 3-2 4-3 4-4
*Mediane Zeit bis zur ||| *Median time to ||| 0-0 1-1 2-2 3-2
*Mediane Zeit ||| *Median time ||| 0-0 1-1
*Mediane ||| *Median ||| 0-0
*Medianes progressionsfreies ||| *Median Progression Free ||| 0-0 0-1 1-1 1-2
*Medianes progressionsfreies Überleben [ ||| *Median Progression Free Survival [ ||| 0-0 0-1 1-1 1-2 2-3 3-4
*Medianes progressionsfreies Überleben ||| *Median Progression Free Survival ||| 0-0 0-1 1-1 1-2 2-3
*Überleben [ 95 % CI ||| *Survival [ 95 % CI ||| 0-0 1-1 2-2 3-3 4-4
*Überleben [ 95 % ||| *Survival [ 95 % ||| 0-0 1-1 2-2 3-3
*Überleben [ 95 ||| *Survival [ 95 ||| 0-0 1-1 2-2
*Überleben [ ||| *Survival [ ||| 0-0 1-1
*Überleben ||| *Survival ||| 0-0
+ 31 ( 0 ) ||| + 31 ( 0 ) ||| 0-0 1-1 2-2 3-3 4-4
+ 31 ( 0 ||| + 31 ( 0 ||| 0-0 1-1 2-2 3-3
+ 31 ( ||| + 31 ( ||| 0-0 1-1 2-2
+ 31 34 857 42 ||| + 31 34 857 42 ||| 0-0 1-1 2-2 3-3 4-4
+ 31 34 857 ||| + 31 34 857 ||| 0-0 1-1 2-2 3-3
+ 31 34 ||| + 31 34 ||| 0-0 1-1 2-2
+ 31 ||| + 31 ||| 0-0 1-1
+ 32 2 352 74 ||| + 32 2 352 74 ||| 0-0 1-1 2-2 3-3 4-4
+ 32 2 352 ||| + 32 2 352 ||| 0-0 1-1 2-2 3-3
+ 32 2 ||| + 32 2 ||| 0-0 1-1 2-2
+ 32 ||| + 32 ||| 0-0 1-1
+ 33 ( 0)1 47 ||| + 33 ( 0)1 47 ||| 0-0 1-1 2-2 3-3 4-4
+ 33 ( 0)1 ||| + 33 ( 0)1 ||| 0-0 1-1 2-2 3-3
+ 33 ( 0)810 410 ||| + 33 ( 0)810 410 ||| 0-0 1-1 2-2 3-3 4-4
+ 33 ( 0)810 ||| + 33 ( 0)810 ||| 0-0 1-1 2-2 3-3
+ 33 ( ||| + 33 ( ||| 0-0 1-1 2-2
+ 33 ||| + 33 ||| 0-0 1-1
+ 34 ( 91 ) ||| + 34 ( 91 ) ||| 0-0 1-1 2-2 3-3 4-4
+ 34 ( 91 ||| + 34 ( 91 ||| 0-0 1-1 2-2 3-3
+ 34 ( ||| + 34 ( ||| 0-0 1-1 2-2
+ 34 ||| + 34 ||| 0-0 1-1
+ 351 21 412 6600 ||| + 351 21 412 6600 ||| 0-0 1-1 2-2 3-3 4-4
+ 351 21 412 ||| + 351 21 412 ||| 0-0 1-1 2-2 3-3
+ 351 21 ||| + 351 21 ||| 0-0 1-1 2-2
+ 351 ||| + 351 ||| 0-0 1-1
+ 353 ( 1 800 ||| + 353 ( 1 800 ||| 0-0 1-1 2-2 3-3 4-4
+ 353 ( 1 ||| + 353 ( 1 ||| 0-0 1-1 2-2 3-3
+ 353 ( ||| + 353 ( ||| 0-0 1-1 2-2
+ 353 ||| + 353 ||| 0-0 1-1
+ 354 535 7000 ||| + 354 535 7000 ||| 0-0 1-1 2-2 3-3
+ 354 535 ||| + 354 535 ||| 0-0 1-1 2-2
+ 354 ||| + 354 ||| 0-0 1-1
+ 358 ( 0)9 8545250 ||| + 358 ( 0)9 8545250 ||| 0-0 1-1 2-2 3-3 4-4
+ 358 ( 0)9 ||| + 358 ( 0)9 ||| 0-0 1-1 2-2 3-3
+ 358 ( ||| + 358 ( ||| 0-0 1-1 2-2
+ 358 9 251 21 ||| + 358 9 251 21 ||| 0-0 1-1 2-2 3-3 4-4
+ 358 9 251 ||| + 358 9 251 ||| 0-0 1-1 2-2 3-3
+ 358 9 ||| + 358 9 ||| 0-0 1-1 2-2
+ 358 ||| + 358 ||| 0-0 1-1
+ 36(0 ) 20 501 ||| + 36(0 ) 20 501 ||| 0-0 1-1 2-2 3-3 4-4
+ 36(0 ) 20 ||| + 36(0 ) 20 ||| 0-0 1-1 2-2 3-3
+ 36(0 ) ||| + 36(0 ) ||| 0-0 1-1 2-2
+ 36(0 ||| + 36(0 ||| 0-0 1-1
+ 39 06 5026 01 ||| + 39 06 5026 01 ||| 0-0 1-1 2-2 3-3 4-4
+ 39 06 5026 ||| + 39 06 5026 ||| 0-0 1-1 2-2 3-3
+ 39 06 ||| + 39 06 ||| 0-0 1-1 2-2
+ 39 ||| + 39 ||| 0-0 1-1
+ 40 ( 0)21 272 ||| + 40 ( 0)21 272 ||| 0-0 1-1 2-2 3-3 4-4
+ 40 ( 0)21 ||| + 40 ( 0)21 ||| 0-0 1-1 2-2 3-3
+ 40 ( ||| + 40 ( ||| 0-0 1-1 2-2
+ 40 ||| + 40 ||| 0-0 1-1
+ 43 ( 1 ) ||| + 43 ( 1 ) ||| 0-0 1-1 2-2 3-3 4-4
+ 43 ( 1 ||| + 43 ( 1 ||| 0-0 1-1 2-2 3-3
+ 43 ( ||| + 43 ( ||| 0-0 1-1 2-2
+ 43 1 60 14 ||| + 43 1 60 14 ||| 0-0 1-1 2-2 3-3 4-4
+ 43 1 60 ||| + 43 1 60 ||| 0-0 1-1 2-2 3-3
+ 43 1 ||| + 43 1 ||| 0-0 1-1 2-2
+ 43 ||| + 43 ||| 0-0 1-1
+ 43-(0)800 29 5193 ||| + 43-(0)800 29 5193 ||| 0-0 1-1 2-2 3-3
+ 43-(0)800 29 ||| + 43-(0)800 29 ||| 0-0 1-1 2-2
+ 43-(0)800 ||| + 43-(0)800 ||| 0-0 1-1
+ 44 ( 0)1628 537 ||| + 44 ( 0)1628 537 ||| 0-0 1-1 2-2 3-3 4-4
+ 44 ( 0)1628 ||| + 44 ( 0)1628 ||| 0-0 1-1 2-2 3-3
+ 44 ( 0)20 3116 ||| + 44 ( 0)20 3116 ||| 0-0 1-1 2-2 3-3 4-4
+ 44 ( 0)20 ||| + 44 ( 0)20 ||| 0-0 1-1 2-2 3-3
+ 44 ( 0800 ) ||| + 44 ( 0800 ) ||| 0-0 1-1 2-2 3-3 4-4
+ 44 ( 0800 ||| + 44 ( 0800 ||| 0-0 1-1 2-2 3-3
+ 44 ( ||| + 44 ( ||| 0-0 1-1 2-2
+ 44 ||| + 44 ||| 0-0 1-1
+ 45 45 93 05 ||| + 45 45 93 05 ||| 0-0 1-1 2-2 3-3 4-4
+ 45 45 93 ||| + 45 45 93 ||| 0-0 1-1 2-2 3-3
+ 45 45 ||| + 45 45 ||| 0-0 1-1 2-2
+ 45 ||| + 45 ||| 0-0 1-1
+ 46 8 704 71 ||| + 46 8 704 71 ||| 0-0 1-1 2-2 3-3 4-4
+ 46 8 704 ||| + 46 8 704 ||| 0-0 1-1 2-2 3-3
+ 46 8 ||| + 46 8 ||| 0-0 1-1 2-2
+ 46 ||| + 46 ||| 0-0 1-1
+ 47 67 55 53 ||| + 47 67 55 53 ||| 0-0 1-1 2-2 3-3 4-4
+ 47 67 55 ||| + 47 67 55 ||| 0-0 1-1 2-2 3-3
+ 47 67 ||| + 47 67 ||| 0-0 1-1 2-2
+ 47 ||| + 47 ||| 0-0 1-1
+ 49 ( 0 ) ||| + 49 ( 0 ) ||| 0-0 1-1 2-2 3-3 4-4
+ 49 ( 0 ||| + 49 ( 0 ||| 0-0 1-1 2-2 3-3
+ 49 ( ||| + 49 ( ||| 0-0 1-1 2-2
+ 49 ||| + 49 ||| 0-0 1-1
+ ||| + ||| 0-0
+0,1 unter Placebo ( Ausgangswert ||| +0.1 on placebo ( baseline ||| 0-0 1-1 1-2 2-2 3-3 4-4
+0,1 unter Placebo ( ||| +0.1 on placebo ( ||| 0-0 1-1 1-2 2-2 3-3
+0,1 unter Placebo ||| +0.1 on placebo ||| 0-0 1-1 1-2 2-2
+0,1 ||| +0.1 ||| 0-0
+33 ( 0)1 46 25 ||| +33 ( 0)1 46 25 ||| 0-0 1-1 2-2 3-3 4-4
+33 ( 0)1 46 ||| +33 ( 0)1 46 ||| 0-0 1-1 2-2 3-3
+33 ( 0)1 ||| +33 ( 0)1 ||| 0-0 1-1 2-2
+33 ( ||| +33 ( ||| 0-0 1-1
+33 ||| +33 ||| 0-0
+353 1 260 12 55 ||| +353 1 260 12 55 ||| 0-0 1-1 2-2 3-3 4-4
+353 1 260 12 ||| +353 1 260 12 ||| 0-0 1-1 2-2 3-3
+353 1 260 ||| +353 1 260 ||| 0-0 1-1 2-2
+353 1 ||| +353 1 ||| 0-0 1-1
+353 ||| +353 ||| 0-0
+358 9 61 33 22 ||| +358 9 61 33 22 ||| 0-0 1-1 2-2 3-3 4-4
+358 9 61 33 ||| +358 9 61 33 ||| 0-0 1-1 2-2 3-3
+358 9 61 ||| +358 9 61 ||| 0-0 1-1 2-2
+358 9 ||| +358 9 ||| 0-0 1-1
+358 ||| +358 ||| 0-0
+36 1 457 65 00 ||| +36 1 457 65 00 ||| 0-0 1-1 2-2 3-3 4-4
+36 1 457 65 ||| +36 1 457 65 ||| 0-0 1-1 2-2 3-3
+36 1 457 ||| +36 1 457 ||| 0-0 1-1 2-2
+36 1 ||| +36 1 ||| 0-0 1-1
+36 ||| +36 ||| 0-0
+370 ( 5 ) 2649600 ||| +370 ( 5 ) 2649600 ||| 0-0 1-1 2-2 3-3 4-4
+370 ( 5 ) ||| +370 ( 5 ) ||| 0-0 1-1 2-2 3-3
+370 ( 5 ||| +370 ( 5 ||| 0-0 1-1 2-2
+370 ( ||| +370 ( ||| 0-0 1-1
+370 ||| +370 ||| 0-0
+371 7364000 ||| +371 7364000 ||| 0-0 1-1
+371 ||| +371 ||| 0-0
+3726441100 ||| +3726441100 ||| 0-0
+386 ( 0)1 580 00 ||| +386 ( 0)1 580 00 ||| 0-0 1-1 2-2 3-3 4-4
+386 ( 0)1 580 ||| +386 ( 0)1 580 ||| 0-0 1-1 2-2 3-3
+386 ( 0)1 ||| +386 ( 0)1 ||| 0-0 1-1 2-2
+386 ( ||| +386 ( ||| 0-0 1-1
+386 ||| +386 ||| 0-0
+43 1 86 6570 ||| +43 1 86 6570 ||| 0-0 1-1 2-2 3-3
+43 1 86 ||| +43 1 86 ||| 0-0 1-1 2-2
+43 1 ||| +43 1 ||| 0-0 1-1
+43 ||| +43 ||| 0-0
+44 ( 0)20 3116 8000 ||| +44 ( 0)20 3116 8000 ||| 0-0 1-1 2-2 3-3 4-4
+44 ( 0)20 3116 ||| +44 ( 0)20 3116 ||| 0-0 1-1 2-2 3-3
+44 ( 0)20 ||| +44 ( 0)20 ||| 0-0 1-1 2-2
+44 ( ||| +44 ( ||| 0-0 1-1
+44 ||| +44 ||| 0-0
+45 39 16 84 00 ||| +45 39 16 84 00 ||| 0-0 1-1 2-2 3-3 4-4
+45 39 16 84 ||| +45 39 16 84 ||| 0-0 1-1 2-2 3-3
+45 39 16 ||| +45 39 16 ||| 0-0 1-1 2-2
+45 39 ||| +45 39 ||| 0-0 1-1
+45 ||| +45 ||| 0-0
+46 8 732 32 00 ||| +46 8 732 32 00 ||| 0-0 1-1 2-2 3-3 4-4
+46 8 732 32 ||| +46 8 732 32 ||| 0-0 1-1 2-2 3-3
+46 8 732 ||| +46 8 732 ||| 0-0 1-1 2-2
+46 8 ||| +46 8 ||| 0-0 1-1
+46 ||| +46 ||| 0-0
+47 23 05 20 00 ||| +47 23 05 20 00 ||| 0-0 1-1 2-2 3-3 4-4
+47 23 05 20 ||| +47 23 05 20 ||| 0-0 1-1 2-2 3-3
+47 23 05 ||| +47 23 05 ||| 0-0 1-1 2-2
+47 23 ||| +47 23 ||| 0-0 1-1
+47 ||| +47 ||| 0-0
+49 911 273 0 ||| +49 911 273 0 ||| 0-0 1-1 2-2 3-3
+49 911 273 ||| +49 911 273 ||| 0-0 1-1 2-2
+49 911 ||| +49 911 ||| 0-0 1-1
+49 ||| +49 ||| 0-0
, -3A4 sowie ||| , -3A4 , and both ||| 0-0 1-1 0-2 2-3 1-4
, 0010 , ||| , 008 , 010 , ||| 0-0 1-1 2-2 1-3 2-4
, 007 , ||| 150/ 001-003 , ||| 1-0 1-1 2-2
, 007 ||| 150/ 001-003 ||| 1-0 1-1
, 008 , ||| 150/ 004-006 , ||| 1-0 1-1 2-2
, 008 ||| 150/ 004-006 ||| 1-0 1-1
, 009 , ||| , 007 , 009 , ||| 0-0 1-1 2-2 1-3 2-4
, 10 mg , 15 ||| , 10 mg , 15 ||| 0-0 1-1 2-2 3-3 4-4
, 10 mg , ||| , 10 mg , ||| 0-0 1-1 2-2 3-3
, 10 mg ||| , 10 mg ||| 0-0 1-1 2-2
, 10 ||| , 10 ||| 0-0 1-1
, 12 , 24 und ||| , 12 , 24 and ||| 0-0 1-1 2-2 3-3 4-4
, 12 , 24 ||| , 12 , 24 ||| 0-0 1-1 2-2 3-3
, 12 , ||| , 12 , ||| 0-0 1-1 2-2
, 12 ||| , 12 ||| 0-0 1-1
, 14 und 7 ) ||| , 14 and 7 ) ||| 0-0 1-1 2-2 3-3 4-4
, 14 und 7 ||| , 14 and 7 ||| 0-0 1-1 2-2 3-3
, 14 und ||| , 14 and ||| 0-0 1-1 2-2
, 14 ||| , 14 ||| 0-0 1-1
, 15 mg und 30 ||| , 15 mg and 30 ||| 0-0 1-1 2-2 3-3 4-4
, 15 mg und ||| , 15 mg and ||| 0-0 1-1 2-2 3-3
, 15 mg ||| , 15 mg ||| 0-0 1-1 2-2
, 15 ||| , 15 ||| 0-0 1-1
, 150 oder 480 ml ||| , 150 or 480 ml ||| 0-0 1-1 2-2 3-3 4-4
, 150 oder 480 ||| , 150 or 480 ||| 0-0 1-1 2-2 3-3
, 150 oder ||| , 150 or ||| 0-0 1-1 2-2
, 150 ||| , 150 ||| 0-0 1-1
, 17 ||| , 17 ||| 0-0 1-1
, 174 gynäkologische Tumoren ||| , 174 gynaecological ||| 0-0 1-1 3-1 2-2
, 22 Prostatakarzinome ||| , 22 prostate ||| 0-0 1-1 2-2
, 22 ||| , 22 ||| 0-0 1-1
, 23 Bronchialkarzinome , 22 ||| , 23 lung , 22 ||| 0-0 1-1 2-2 3-3 4-4
, 23 Bronchialkarzinome , ||| , 23 lung , ||| 0-0 1-1 2-2 3-3
, 23 Bronchialkarzinome ||| , 23 lung ||| 0-0 1-1 2-2
, 23 ||| , 23 ||| 0-0 1-1
, 24 und 36 Monate ||| , 24 and 36 months ||| 0-0 1-1 2-2 3-3 4-4
, 24 und 36 ||| , 24 and 36 ||| 0-0 1-1 2-2 3-3
, 24 und ||| , 24 and 36 months ||| 0-0 1-1 2-2 1-3 1-4
, 24 und ||| , 24 and ||| 0-0 1-1 2-2
, 24 ||| , 24 ||| 0-0 1-1
, 27 % hatten ||| ; 27 % had ||| 2-0 1-1 2-2 3-3
, 27 % ||| ; 27 % ||| 2-0 1-1 2-2
, 27 ||| 27 ||| 1-0
, 28 , 30 , ||| , 28 , 30 , ||| 0-0 2-0 1-1 4-2 3-3 4-4
, 28 , 30 , ||| , 28 , 30 ||| 0-0 2-0 1-1 4-2 3-3
, 28 , 56 , ||| , 28 , 56 , ||| 0-0 1-1 2-2 3-3 4-4
, 28 , 56 ||| , 28 , 56 ||| 0-0 1-1 2-2 3-3
, 28 , ||| , 28 , ||| 0-0 1-1 2-2
, 28 , ||| , 28 ||| 0-0 2-0 1-1
, 28 ||| , 28 ||| 0-0 1-1
, 29 ||| , ||| 0-0 1-0
, 2C8/9 ||| , 2C8/ 9 ||| 0-0 1-1 1-2
, 2C9 ( Warfarin ) ||| , 2C9 ( warfarin ) ||| 0-0 1-1 2-2 3-3 4-4
, 2C9 ( Warfarin ||| , 2C9 ( warfarin ||| 0-0 1-1 2-2 3-3
, 2C9 ( ||| , 2C9 ( ||| 0-0 1-1 2-2
, 2C9 ||| , 2C9 ||| 0-0 1-1
, 30 oder 45 mg ||| , 30 or 45 mg ||| 0-0 1-1 2-2 3-3 4-4
, 30 oder 45 ||| , 30 or 45 ||| 0-0 1-1 2-2 3-3
, 30 oder ||| , 30 or ||| 0-0 1-1 2-2
, 30 ||| , 30 ||| 0-0 1-1
, 30-36 Avenue Gustave Eiffel ||| , 30-36 Avenue Gustave Eiffel ||| 0-0 1-1 2-2 3-3 4-4
, 30-36 Avenue Gustave ||| , 30-36 Avenue Gustave ||| 0-0 1-1 2-2 3-3
, 30-36 Avenue ||| , 30-36 Avenue ||| 0-0 1-1 2-2
, 30-36 ||| , 30-36 ||| 0-0 1-1
, 300 gastrointestinale ||| , 300 gastro-intestinal , ||| 0-0 1-1 2-2 0-3
, 4 , 8 und ||| , 4 , 8 and ||| 0-0 1-1 0-2 2-2 3-3 4-4
, 4 , 8 ||| , 4 , 8 ||| 0-0 1-1 0-2 2-2 3-3
, 4 , ||| , 4 , ||| 0-0 1-1 0-2 2-2
, 41 ||| , ||| 0-0 1-0
, 49 , 56 , ||| 49 , 56 , ||| 1-0 0-1 3-2 2-3 4-3
, 49 x 1 , ||| , 49 x 1 , ||| 0-0 1-1 2-2 3-3 4-4
, 49 x 1 ||| , 49 x 1 ||| 0-0 1-1 2-2 3-3
, 49 x ||| , 49 x ||| 0-0 1-1 2-2
, 49 ||| , 49 ||| 0-0 1-1
, 49 ||| 49 , ||| 1-0 0-1
, 5 und 10 ||| , 5 and 10 ||| 0-0 1-1 2-2 3-3
, 5 und ||| , 5 and ||| 0-0 1-1 2-2
, 5 ||| , 5 ||| 0-0 1-1
, 56 , 84 , ||| , 56 , 84 , ||| 0-0 1-1 2-2 3-3 4-4
, 56 , 84 UND ||| , 56 , 84 AND ||| 0-0 1-1 2-2 3-3 4-4
, 56 , 84 ||| , 56 , 84 ||| 0-0 1-1 2-2 3-3
, 56 , ||| , 56 , ||| 0-0 1-1 2-2
, 56 , ||| 56 , ||| 1-0 0-1 2-1
, 56 x 1 , ||| , 56 x 1 , ||| 0-0 1-1 2-2 3-3 4-4
, 56 x 1 ||| , 56 x 1 ||| 0-0 1-1 2-2 3-3
, 56 x ||| , 56 x ||| 0-0 1-1 2-2
, 56 ||| , 56 ||| 0-0 1-1
, 61 Aldwych , London ||| , 61 Aldwych , London ||| 0-0 1-1 2-2 3-3 4-4
, 61 Aldwych , ||| , 61 Aldwych , ||| 0-0 1-1 2-2 3-3
, 61 Aldwych ||| , 61 Aldwych ||| 0-0 1-1 2-2
, 61 ||| , 61 ||| 0-0 1-1
, 64 gynäkologische Tumore , ||| , 64 gynaecological , ||| 0-0 1-1 2-2 3-2 4-3
, 64 gynäkologische Tumore ||| , 64 gynaecological ||| 0-0 1-1 2-2 3-2
, 64 ||| , 64 ||| 0-0 1-1
, 67019 Scoppito ( AQ ||| , 67019 Scoppito ( AQ ||| 0-0 1-1 2-2 3-3 4-4
, 67019 Scoppito ( ||| , 67019 Scoppito ( ||| 0-0 1-1 2-2 3-3
, 67019 Scoppito ||| , 67019 Scoppito ||| 0-0 1-1 2-2
, 67019 ||| , 67019 ||| 0-0 1-1
, 79 ||| 79 ||| 1-0
, 84 , 90 oder ||| , 84 , 90 and ||| 0-0 1-1 2-2 3-3
, 84 , 90 oder ||| , 84 , 90 ||| 0-0 1-1 2-2 3-3
, 84 , 90 und ||| , 84 , 90 and ||| 0-0 1-1 2-2 3-3 4-4
, 84 , 90 ||| , 84 , 90 and ||| 0-0 1-1 2-2 3-3
, 84 , 90 ||| , 84 , 90 ||| 0-0 1-1 2-2 3-3
, 84 , ||| , 84 , ||| 0-0 1-1 2-2
, 84 UND 98 ||| , 84 AND 98 ||| 0-0 1-1 2-2 3-3
, 84 UND ||| , 84 AND ||| 0-0 1-1 2-2
, 84 ||| , 84 ||| 0-0 1-1
, 87 % ||| , 87 % ||| 0-0 1-1 2-2
, 87 ||| , 87 ||| 0-0 1-1
, 9,6 für Lorazepam ||| , 9.6 for lorazepam , ||| 0-0 1-1 2-2 3-3 0-4
, 90 oder 98 ||| , 90 and 98 ||| 0-0 1-1 3-3
, 90 oder ||| , 90 and ||| 0-0 1-1
, 90 oder ||| , 90 ||| 0-0 1-1
, 90 und 98 Tabletten ||| , 90 and 98 tablets ||| 0-0 1-1 2-2 3-3 4-4
, 90 und 98 ||| , 90 and 98 ||| 0-0 1-1 2-2 3-3
, 90 und ||| , 90 and ||| 0-0 1-1 2-2
, 90 ||| , 90 and ||| 0-0 1-1
, 90 ||| , 90 ||| 0-0 1-1
, 98 oder 500 ||| , 98 and 500 ||| 0-0 1-1 3-3
, 98 oder ||| , 98 and ||| 0-0 1-1
, 98 oder ||| , 98 ||| 0-0 1-1
, 98 x 1 Tabletten ||| , 98 x 1 tablets ||| 0-0 1-1 2-2 3-3 4-4
, 98 x 1 ||| , 98 x 1 ||| 0-0 1-1 2-2 3-3
, 98 x ||| , 98 x ||| 0-0 1-1 2-2
, 98 ||| , 98 and ||| 0-0 1-1
, 98 ||| , 98 ||| 0-0 1-1
, < 1/10 ||| common ||| 1-0 2-0
, < 1/100 ) . ||| 100 , , 1/ ||| 2-0 0-1 0-2 1-3 2-3 3-3 4-3
, ABILIFY Schmelztabletten ||| , ABILIFY orodispersible tablets , ||| 0-0 1-1 2-2 2-3 0-4
, ART UND DAUER ||| , ROUTE(S ) AND METHOD ||| 0-0 1-1 1-2 2-3 3-4
, ART UND ||| , ROUTE(S ) AND ||| 0-0 1-1 1-2 2-3
, ART ||| , ROUTE(S ) ||| 0-0 1-1 1-2
, Abschnitt 4.2 ) . ||| , Section 4.2 ) . ||| 0-0 1-1 2-2 3-3 4-4
, Abschnitt 4.2 ) . ||| , section 4.2 ) ||| 0-0 1-1 2-2 3-3 4-3
, Abschnitt 4.2 ) ||| , Section 4.2 ) ||| 0-0 1-1 2-2 3-3
, Abschnitt 4.2 ||| , Section 4.2 ||| 0-0 1-1 2-2
, Abschnitt 4.2 ||| , section 4.2 ||| 0-0 1-1 2-2
, Abschnitt ||| , Section ||| 0-0 1-1
, Abschnitt ||| , section ||| 0-0 1-1
, Akathisie , Tremor , ||| , akathisia , tremor , ||| 0-0 1-1 2-2 3-3 4-4
, Akathisie , Tremor , ||| , akathisia , tremor , ||| 0-0 2-0 1-1 4-2 3-3 4-4
, Akathisie , Tremor ||| , akathisia , tremor ||| 0-0 1-1 2-2 3-3
, Akathisie , ||| , akathisia , ||| 0-0 1-1 2-2
, Akathisie , ||| , akathisia ||| 0-0 2-0 1-1
, Akathisie , Übelkeit und ||| , akathisia , nausea and ||| 0-0 1-1 2-2 3-3 4-4
, Akathisie , Übelkeit ||| , akathisia , nausea ||| 0-0 1-1 2-2 3-3
, Akathisie Erkrankungen des Gastrointestinaltrakts ||| , akathisia Gastrointestinal disorders ||| 0-0 1-1 4-2 2-3 3-3
, Akathisie ||| , akathisia ||| 0-0 1-1
, Aneurysmen , etc ||| , aneurysms , etc. ||| 0-0 2-0 1-1 3-1 2-2 3-3
, Aneurysmen ||| , aneurysms ||| 0-0 1-1
, Angiotensin-Converting-Enzyme ( ACE)-Hemmer ||| , angiotensin converting enzyme ( ||| 0-0 1-1 1-2 3-3 2-4
, Angiotensin-Converting-Enzyme ||| , angiotensin converting ||| 0-0 1-1 1-2
, Angioödeme einschließlich geschwollener ||| , angioedema including swollen tongue ||| 0-0 1-1 2-2 1-3 3-3 3-4
, Angstgefühl , ||| , feeling anxious , ||| 0-0 1-1 1-2 2-3
, Angstgefühl ||| , feeling anxious ||| 0-0 1-1 1-2
, Angstzustände ||| in clinical trials . ||| 0-0 1-1 1-2 1-3
, Anorexie , Hyponatriämie ||| , anorexia , hyponatremia ||| 0-0 1-1 2-2 3-3
, Anorexie , ||| , anorexia , ||| 0-0 1-1 2-2
, Anorexie ||| , anorexia ||| 0-0 1-1
, Anämie ( ||| , anaemia ( ||| 0-0 1-1 2-2
, Anämie ||| , anaemia ||| 0-0 1-1
, Apotheker oder das Pflegepersonal ||| , pharmacist or nurse ||| 0-0 1-1 2-2 3-3 4-3
, Apotheker oder das ||| , pharmacist or nurse . ||| 0-0 1-1 2-2 1-3 3-3
, Apotheker oder das ||| , pharmacist or nurse ||| 0-0 1-1 2-2 1-3 3-3
, Apotheker oder ||| , pharmacist or ||| 0-0 1-1 2-2
, Apotheker ||| , pharmacist ||| 0-0 1-1
, Appetitlosigkeit ||| , anorexia ||| 0-0 1-1
, Areflexie , Dyskinesie , ||| , areflexia , dyskinesia , ||| 0-0 1-1 2-2 3-3 4-4
, Areflexie , Dyskinesie ||| , areflexia , dyskinesia ||| 0-0 1-1 2-2 3-3
, Areflexie , ||| , areflexia , ||| 0-0 1-1 2-2
, Areflexie ||| , areflexia ||| 0-0 1-1
, Aripiprazol , ist ein ||| , aripiprazole , is an ||| 0-0 1-1 2-2 3-3 4-4
, Aripiprazol , ist ||| , aripiprazole , is ||| 0-0 1-1 2-2 3-3
, Aripiprazol , ||| , aripiprazole , ||| 0-0 1-1 2-2
, Aripiprazol ||| , aripiprazole ||| 0-0 1-1
, Ataxie , sensorische ||| , ataxia , sensory ||| 0-0 1-1 2-2 3-3
, Ataxie , ||| , ataxia , ||| 0-0 1-1 2-2
, Ataxie ||| , ataxia ||| 0-0 1-1
, Atemfrequenz ||| , respiratory ||| 0-0 1-1
, Auflösung ||| , ||| 0-0 1-0
, Augenschmerz Uveitis , ||| , eye pain Uveitis , ||| 0-0 1-1 2-2 2-3 3-4
, Augenschmerz Uveitis ||| , eye pain Uveitis ||| 0-0 1-1 2-2 2-3
, Augenschmerz ||| , eye ||| 0-0 1-1
, Augenschmerzen , abnormales ||| , eye pain , abnormal ||| 0-0 1-1 2-2 2-3 3-3 3-4
, Augenschmerzen ||| , eye ||| 0-0 1-1
, BP 27166 , F-37071 ||| , BP 27166 , F-37071 ||| 0-0 1-1 2-2 3-3 4-4
, BP 27166 , ||| , BP 27166 , ||| 0-0 1-1 2-2 3-3
, BP 27166 ||| , BP 27166 ||| 0-0 1-1 2-2
, BP ||| , BP ||| 0-0 1-1
, Bauch- ||| , abdominal discomfort , ||| 0-0 1-1 1-2 0-3
, Bauchschmerz , ||| , ||| 0-0 1-0 2-0
, Bauchschmerz ||| sweats , hyperhydrosis ||| 1-0 0-1 1-2
, Belastungsdyspnoe , ||| , exertional dyspnoea , ||| 0-0 1-1 1-2 2-3
, Belastungsdyspnoe ||| , exertional dyspnoea ||| 0-0 1-1 1-2
, Benommenheit , Schlafprobleme ||| , light-headedness , trouble sleeping ||| 0-0 1-1 3-1 2-2 3-3 3-4
, Berichte über ||| , reports of ||| 0-0 1-1 2-1
, Berichte über ||| , reports ||| 0-0 1-1 2-1
, Blut im Harn ||| , blood in urine ||| 0-0 1-1 2-2 2-3 3-3
, Blut ||| , blood ||| 0-0 1-1
, Blutverlust und Hämolyse ||| , blood loss and haemolysis ||| 0-0 1-1 1-2 2-3 1-4 3-4
, Blähungen , Zungenbrennen ||| , flatulence , glossodynia ||| 0-0 1-1 2-2 3-3
, Blähungen , ||| , flatulence , ||| 0-0 1-1 2-2
, Blähungen ||| , flatulence ||| 0-0 1-1
, Bradykardie ||| , bradycardia ||| 0-0 1-1
, Brustschmerz , ||| , joint swelling , ||| 0-0 0-1 0-2 0-3 1-3 2-3
, Brustschmerzen , periphere ||| , chest pain , peripheral ||| 0-0 1-1 1-2 2-3 3-4
, Brustschmerzen , ||| , chest pain , ||| 0-0 1-1 1-2 2-3
, Brustschmerzen , ||| status , chest pain ||| 0-0 0-1 2-1 1-2 1-3
, Brustschmerzen und ||| , chest pain , and ||| 0-0 1-1 1-2 0-3 2-4
, Brustschmerzen ||| , chest pain , ||| 0-0 1-1 1-2 0-3
, Brustschmerzen ||| , chest pain ||| 0-0 1-1 1-2
, County Wicklow . ||| , County Wicklow . ||| 0-0 1-1 2-2 3-3
, County Wicklow ||| , County Wicklow ||| 0-0 1-1 2-2
, County ||| , County ||| 0-0 1-1
, D-58638 Iserlohn , Deutschland ||| , D-58638 Iserlohn , Germany ||| 0-0 1-1 2-2 3-3 4-4
, D-58638 Iserlohn , ||| , D-58638 Iserlohn , ||| 0-0 1-1 2-2 3-3
, D-58638 Iserlohn ||| , D-58638 Iserlohn ||| 0-0 1-1 2-2
, D-58638 ||| , D-58638 ||| 0-0 1-1
, DARREICHUNGSFORM , STÄRKE , ||| NAMES , PHARMACEUTICAL FORM , ||| 1-0 0-1 2-1 3-2 3-3 4-4
, DARREICHUNGSFORM , STÄRKE ||| NAMES , PHARMACEUTICAL FORM ||| 1-0 0-1 2-1 3-2 3-3
, DARREICHUNGSFORM , ||| NAMES , ||| 1-0 0-1 2-1
, DASS DAS ARZNEIMITTEL ||| THAT THE MEDICINAL PRODUCT MUST ||| 0-0 1-0 1-1 2-2 2-3 3-4
, DASS DAS ||| THAT THE MEDICINAL PRODUCT ||| 0-0 1-0 1-1 2-2 2-3
, DASS ||| THAT THE ||| 0-0 1-0 1-1
, DER ABGABE UND/ODER DER ||| , SUPPLY AND/ OR ||| 0-0 2-1 1-2 3-2 4-2 2-3
, DER ||| HOLDER ||| 0-0 1-0
, DER/DIE ||| HOLDER(S ) ||| 0-0 1-0 1-1
, DES ||| , ||| 0-0
, DES ||| OF THE ||| 1-0 1-1
, DIE DEM INHABER DER ||| IMPOSED ON ||| 1-0 2-0 3-0 2-1 4-1
, DIE ||| HOLDERS ||| 0-0 1-0
, Dehydratation und blasse ||| appearance , dehydration and pale ||| 0-0 0-1 1-2 2-3 3-4
, Dehydratation und ||| appearance , dehydration and ||| 0-0 0-1 1-2 2-3
, Dehydratation ||| appearance , dehydration ||| 0-0 0-1 1-2
, Depression ||| with Abraxane at any dose ||| 0-0 1-1 1-2 1-3 1-4
, Deutschland ||| , Germany ||| 0-0 1-1
, Diabetes mellitus , diabetische ||| , diabetes mellitus , diabetic ||| 0-0 1-1 2-2 3-3 4-4
, Diabetes mellitus , ||| , diabetes mellitus , ||| 0-0 1-1 2-2 3-3
, Diabetes mellitus ||| , diabetes mellitus ||| 0-0 1-1 2-2
, Diabetes ||| , diabetes ||| 0-0 1-1
, Diarrhoe ||| , diarrhoea ||| 0-0 1-1
, Diuretika , ||| , nitrates , diuretics ||| 0-0 1-1 2-2 1-3
, Durchfall , Erbrechen , ||| , diarrhoea , vomiting , ||| 0-0 1-1 2-2 3-3 4-4
, Durchfall , Erbrechen ||| , diarrhoea , vomiting ||| 0-0 1-1 2-2 3-3
, Durchfall , ||| , diarrhoea , ||| 0-0 1-1 2-2
, Durchfall ||| , diarrhoea , ||| 0-0 1-1 0-2
, Durchfall ||| , diarrhoea ||| 0-0 1-1
, Durchschnittsalter : ||| mean age : ||| 1-0 1-1 2-2
, Durchschnittsalter ||| mean age ||| 1-0 1-1
, Dysgeusie , Schwindel , ||| , dysgeusia , dizziness , ||| 0-0 1-1 2-2 3-3 4-4
, Dysgeusie , Schwindel ||| , dysgeusia , dizziness ||| 0-0 1-1 2-2 3-3
, Dysgeusie , ||| , dysgeusia , ||| 0-0 1-1 2-2
, Dysgeusie ||| , dysgeusia ||| 0-0 1-1
, Dyskinesie , Hyporeflexie , ||| , dyskinesia , hyporeflexia , ||| 0-0 1-1 2-2 3-3 4-4
, Dyskinesie , Hyporeflexie ||| , dyskinesia , hyporeflexia ||| 0-0 1-1 2-2 3-3
, Dyskinesie , ||| , dyskinesia , ||| 0-0 1-1 2-2
, Dyskinesie ||| , dyskinesia ||| 0-0 1-1
, Dyspepsie , Bauchschmerz ||| , night sweats , hyperhydrosis ||| 0-0 1-1 3-2 2-3 3-4
, Dyspepsie ||| , Gastrointestinal dyspepsia ||| 0-0 1-1 1-2
, Dyspepsie ||| , night ||| 0-0 1-1
, Dysphagie ||| , dysphagia ||| 0-0 1-1
, E218 und E216 ||| E218 , and E216 . ||| 1-0 0-1 2-2 3-3
, E218 und E216 ||| E218 , and E216 ||| 1-0 0-1 2-2 3-3
, E218 und ||| E218 , and ||| 1-0 0-1 2-2
, E218 ||| E218 , ||| 1-0 0-1
, Eisen(III)-hydroxid-oxid ||| , yellow ||| 0-0 1-1
, Entzündungen ||| aluminium intoxication ||| 0-0 1-0 1-1
, Episkleritis , Iritis ||| , episcleritis , iritis ||| 0-0 1-1 2-2 3-3
, Episkleritis , ||| , episcleritis , ||| 0-0 1-1 2-2
, Episkleritis ||| , episcleritis ||| 0-0 1-1
, Erbrechen , Verstopfung , ||| , vomiting , constipation , ||| 0-0 1-1 2-2 3-3 4-4
, Erbrechen , Verstopfung ||| , vomiting , constipation ||| 0-0 1-1 2-2 3-3
, Erbrechen , ein ||| , vomiting , an ||| 0-0 1-1 2-2 3-3
, Erbrechen , ||| , vomiting , ||| 0-0 1-1 2-2
, Erbrechen , Übelkeit , ||| , vomiting , nausea , ||| 0-0 1-1 2-2 3-3 4-4
, Erbrechen , Übelkeit ||| , vomiting , nausea ||| 0-0 1-1 2-2 3-3
, Erbrechen und Durchfall . ||| , vomiting and diarrhoea . ||| 0-0 1-1 2-2 3-3 4-4
, Erbrechen und Durchfall ||| , vomiting and diarrhoea ||| 0-0 1-1 2-2 3-3
, Erbrechen und ||| , vomiting and ||| 0-0 1-1 2-2
, Erbrechen ||| , vomiting ||| 0-0 1-1
, Essstörung , ||| , inflammation of ||| 0-0 1-0 2-0 2-1
, Essstörung , ||| , inflammation ||| 0-0 1-0 2-0 2-1
, F-37071 Tours Cedex 2 ||| , F-37071 Tours Cedex 2 ||| 0-0 1-1 2-2 3-3 4-4
, F-37071 Tours Cedex ||| , F-37071 Tours Cedex ||| 0-0 1-1 2-2 3-3
, F-37071 Tours ||| , F-37071 Tours ||| 0-0 1-1 2-2
, F-37071 ||| , F-37071 ||| 0-0 1-1
, FACT-An Fatigue Scale ||| , FACT-An fatigue scale , ||| 0-0 1-1 2-2 2-3 3-3 0-4
, Fibrate ) . ||| , fibrates ) . ||| 0-0 1-1 2-2 3-3
, Fibrate ) ||| , fibrates ) ||| 0-0 1-1 2-2
, Fibrate ||| , fibrates ||| 0-0 1-1
, Flüssigkeitsretention , Hypoalbuminämie ||| , fluid retention , hypoalbuminaemia ||| 0-0 1-1 1-2 2-3 3-4
, Flüssigkeitsretention , ||| , fluid retention , ||| 0-0 1-1 1-2 2-3
, Flüssigkeitsretention ||| , fluid retention ||| 0-0 1-1 1-2
, Frankreich ||| , France ||| 0-0 1-1
, Gegenmittel ) , falls ||| , antidotes ) , if ||| 0-0 1-1 2-2 3-3 4-4
, Gegenmittel ) , ||| , antidotes ) , ||| 0-0 1-1 2-2 3-3
, Gegenmittel ) ||| , antidotes ) ||| 0-0 1-1 2-2
, Gegenmittel ||| , antidotes ||| 0-0 1-1
, Gelenkschmerz , ||| indigestion , abdominal ||| 0-0 0-1 1-1 2-1 2-2
, Geschlecht und Gesamtkrankheitslast ||| , gender , and ||| 0-0 1-1 3-1 0-2 2-3
, Geschwüre ||| , ||| 0-0 1-0
, Gesichtsödeme ||| , face oedema ||| 0-0 1-1 1-2
, Gewichtsabnahme , Anorexie ||| , weight decreased , anorexia ||| 0-0 1-1 1-2 2-3 3-4
, Gewichtsabnahme , ||| , weight decreased , ||| 0-0 1-1 1-2 2-3
, Gewichtsabnahme ||| , weight decreased ||| 0-0 1-1 1-2
, Gewichtszunahme und ||| , weight increase , and ||| 0-0 1-1 1-2 0-3 2-4
, Gewichtszunahme und Ödeme hin ||| , weight gain and oedema ||| 0-0 1-1 1-2 4-2 2-3 3-4
, Gewichtszunahme ||| , weight increase , ||| 0-0 1-1 1-2 0-3
, Gliclazid ) verglichen . ||| , gliclazide ) . ||| 0-0 1-1 2-2 3-2 4-3
, Gliclazid ) verglichen ||| , gliclazide ) ||| 0-0 1-1 2-2 3-2
, Gliclazid ||| , gliclazide ||| 0-0 1-1
, Glucokortikoide , Schilddrüsenhormone ||| , glucocorticoids , thyroid hormones ||| 0-0 1-1 2-2 3-3 3-4
, Glucokortikoide , ||| , glucocorticoids , ||| 0-0 1-1 2-2
, Glucokortikoide ||| , glucocorticoids ||| 0-0 1-1
, Glucose-Galactose-Malabsorption oder ||| , glucose-galactose malabsorption or ||| 0-0 1-1 1-2 2-3
, Glucose-Galactose-Malabsorption ||| , glucose-galactose malabsorption ||| 0-0 1-1 1-2
, Glycin , ||| , glycine , ||| 0-0 1-1 2-2
, Glycin ||| , glycine ||| 0-0 1-1
, Glycin ||| glycine , ||| 1-0 0-1
, HORIZON ||| , HORIZON ||| 0-0 1-1
, Harninkontinenz Sehr häufig : ||| , polyuria , urinary incontinence ||| 0-0 1-1 0-2 1-3 1-4 2-4 3-4 4-4
, Harnweginfektion , Folliculitis ||| , urinary tract ||| 0-0 2-0 1-1 3-2
, Harnweginfektion , ||| , urinary ||| 0-0 2-0 1-1
, Heiserkeit , ||| , hoarseness , ||| 0-0 1-1 2-2
, Heiserkeit ||| , hoarseness ||| 0-0 1-1
, Hepatitis , ||| , hepatitis , ||| 0-0 1-1 2-2
, Hepatitis ||| , hepatitis ||| 0-0 1-1
, Heptanatriumalz ( SBECD ) ||| -cyclodextrin ( SBECD ) ||| 0-0 1-0 2-1 3-2 4-3
, Heptanatriumalz ( SBECD ||| -cyclodextrin ( SBECD ||| 0-0 1-0 2-1 3-2
, Heptanatriumalz ( ||| -cyclodextrin ( ||| 0-0 1-0 2-1
, Heptanatriumalz ||| -cyclodextrin ||| 0-0 1-0
, Heptanatriumsalz ||| b-cyclodextrin , ||| 1-0 0-1
, Hydroxylierung und N-Dealkylierung ||| , hydroxylation , and N-dealkylation ||| 0-0 1-1 0-2 2-3 3-4
, Hydroxylierung und ||| , hydroxylation , and ||| 0-0 1-1 0-2 2-3
, Hydroxylierung ||| , hydroxylation , ||| 0-0 1-1 0-2
, Hyperglykämie , Hypokalzämie , ||| , hyperglycaemia , hypocalcaemia , ||| 0-0 1-1 2-2 3-3 4-4
, Hyperglykämie , Hypokalzämie ||| , hyperglycaemia , hypocalcaemia ||| 0-0 1-1 2-2 3-3
, Hyperglykämie , ||| , hyperglycaemia , ||| 0-0 1-1 2-2
, Hyperglykämie und Diabetes Mellitus ||| , hyperglycaemia and diabetes mellitus ||| 0-0 1-1 2-2 3-3 4-4
, Hyperglykämie und Diabetes mellitus ||| , hyperglycaemia and diabetes mellitus ||| 0-0 1-1 2-2 3-3 4-4
, Hyperglykämie und Diabetes ||| , hyperglycaemia and diabetes ||| 0-0 1-1 2-2 3-3
, Hyperglykämie und ||| , hyperglycaemia and ||| 0-0 1-1 2-2
, Hyperglykämie ||| , hyperglycaemia ||| 0-0 1-1
, Hypertonie , Lymphödem ||| hypertension , lymphoedema ||| 1-0 0-1 2-1 3-2
, Hypertonie , ||| hypertension , ||| 1-0 0-1 2-1
, Hypoalbuminämie , Polydipsie , ||| , hypoalbuminaemia , polydipsia , ||| 0-0 1-1 2-2 3-3 4-4
, Hypoalbuminämie , Polydipsie ||| , hypoalbuminaemia , polydipsia ||| 0-0 1-1 2-2 3-3
, Hypoalbuminämie , ||| , hypoalbuminaemia , ||| 0-0 1-1 2-2
, Hypoalbuminämie ||| , hypoalbuminaemia ||| 0-0 1-1
, Hypoglykämie , Hyponaträmie Häufig ||| , hypoglycaemia , hyponatraemia Common ||| 0-0 1-1 2-2 3-3 4-4
, Hypoglykämie , Hyponaträmie ||| , hypoglycaemia , hyponatraemia ||| 0-0 1-1 2-2 3-3
, Hypoglykämie , ||| , hypoglycaemia , ||| 0-0 1-1 2-2
, Hypoglykämie ||| , hypoglycaemia ||| 0-0 1-1
, Hypokalzämie , Hypoglykämie , ||| , hypocalcaemia , hypoglycaemia , ||| 0-0 1-1 2-2 3-3 4-4
, Hypokalzämie , Hypoglykämie ||| , hypocalcaemia , hypoglycaemia ||| 0-0 1-1 2-2 3-3
, Hypokalzämie , ||| , hypocalcaemia , ||| 0-0 1-1 2-2
, Hypokalzämie ||| , hypocalcaemia ||| 0-0 1-1
, Hyponatriämie ||| , hyponatremia ||| 0-0 1-1
, Hyponaträmie Häufig : ||| , hyponatraemia Common : ||| 0-0 1-1 2-2 3-3
, Hyponaträmie Häufig ||| , hyponatraemia Common ||| 0-0 1-1 2-2
, Hyponaträmie ||| , hyponatraemia ||| 0-0 1-1
, Hyporeflexie , Neuralgie ||| , hyporeflexia , neuralgia ||| 0-0 1-1 2-2 3-3
, Hyporeflexie , ||| , hyporeflexia , ||| 0-0 1-1 2-2
, Hyporeflexie ||| , hyporeflexia ||| 0-0 1-1
, Hyprolose , Carmellose-Calcium und ||| like and contents of the ||| 0-0 1-0 2-0 4-1 3-2
, Hyprolose , Carmellose-Calcium und ||| like and contents of ||| 0-0 1-0 2-0 4-1 3-2
, Hyprolose , Carmellose-Calcium und ||| like and contents ||| 0-0 1-0 2-0 4-1 3-2
, Hyprolose , Carmellose-Calcium ||| , hyprolose , carmellose calcium ||| 0-0 1-1 0-2 2-2 1-3 3-3 3-4
, Hyprolose , ||| like ||| 0-0 1-0 2-0
, Hyprolose ||| , hydroxypropyl ||| 0-0 1-1
, Hypästhesie , Parästhesie . ||| , hypoaesthesia , paraesthesia . ||| 0-0 1-1 2-2 3-3 4-4
, Hypästhesie , Parästhesie ||| , hypoaesthesia , paraesthesia ||| 0-0 1-1 2-2 3-3
, Hypästhesie , ||| , hypoaesthesia , ||| 0-0 1-1 2-2
, Hypästhesie ||| , hypoaesthesia ||| 0-0 1-1
, Hämolyse , Blutverlust ||| , haemolysis , blood loss ||| 0-0 1-1 3-1 2-2 3-3 3-4
, Hämolyse und Knochenmarkfibrose ||| haemolysis , and bone marrow ||| 1-0 0-1 2-2 3-3 3-4
, Hämolyse und ||| haemolysis , and ||| 1-0 0-1 2-2
, Hämolyse ||| haemolysis , ||| 1-0 0-1
, Hüfte und ||| spine , hip , and ||| 1-0 0-1 1-2 0-3 2-4
, Hüfte ||| spine , hip , ||| 1-0 0-1 1-2 0-3
, Ihr Baby zu stillen ||| to breast-feed your baby ||| 0-0 3-0 1-1 2-1 3-1 4-1 1-2 2-3
, Ihre Dosis von ||| your dose of ||| 1-0 2-1 3-2
, Ihre Dosis ||| your dose ||| 1-0 2-1
, Ihre ||| your ||| 1-0
, Infektion der ||| infection , folliculitis , ||| 1-0 0-1 1-2 0-3
, Infektion ||| infection , folliculitis , ||| 1-0 0-1 1-2 0-3
, Infektionen der oberen Atemwege ||| , upper respiratory tract infection ||| 0-0 3-1 3-2 3-3 4-3 1-4
, Infektionen oder ||| , infection or ||| 0-0 1-1 2-2
, Infektionen ||| , infection ||| 0-0 1-1
, Insulin ( human ) ||| , insulin ( human ) ||| 0-0 1-1 2-2 3-3 4-4
, Insulin ( human ||| , insulin ( human ||| 0-0 1-1 2-2 3-3
, Insulin ( ||| , insulin ( ||| 0-0 1-1 2-2
, Insulin , Metformin ) ||| , insulin , metformin ) ||| 0-0 1-1 2-2 3-3 4-4
, Insulin , Metformin ||| , insulin , metformin ||| 0-0 1-1 2-2 3-3
, Insulin , ||| , insulin , ||| 0-0 1-1 2-2
, Insulin ||| , insulin ||| 0-0 1-1
, Iritis ||| , iritis ||| 0-0 1-1
, Italien ||| , Italy ||| 0-0 1-1
, Jucken , Ausschlag ) ||| , itching , rash ) ||| 0-0 1-1 0-2 2-2 3-3 4-4
, Jucken , Ausschlag ||| , itching , rash ||| 0-0 1-1 0-2 2-2 3-3
, Jucken , ||| , itching , ||| 0-0 1-1 0-2 2-2
, Juckreiz , Nesselsucht , ||| , itching , hives , ||| 0-0 1-1 2-2 3-3 4-4
, Juckreiz , Nesselsucht ||| , itching , hives ||| 0-0 1-1 2-2 3-3
, Juckreiz , ||| , itching , ||| 0-0 1-1 2-2
, Juckreiz ||| , itching ||| 0-0 1-1
, KENNZEICHNUNG UND ||| achieved during the Coordination group ||| 1-0 1-1 1-2 1-3 2-3 1-4
, Keratokonjunktivitis sicca , Madarosis ||| , keratoconjunctivitis sicca , madarosis ||| 0-0 1-1 2-2 3-3 4-4
, Keratokonjunktivitis sicca , ||| , keratoconjunctivitis sicca , ||| 0-0 1-1 2-2 3-3
, Keratokonjunktivitis sicca ||| , keratoconjunctivitis sicca ||| 0-0 1-1 2-2
, Keratokonjunktivitis ||| , keratoconjunctivitis ||| 0-0 1-1
, Ketoazidose ( ||| , ketoacidosis ( ||| 1-1 2-2
, Ketoazidose ( ||| ketoacidosis ( ||| 1-0 2-1
, Ketoazidose ||| , ketoacidosis ||| 1-1
, Ketoazidose ||| ketoacidosis ||| 1-0
, Kilruddey , County Wicklow ||| , Kilruddery , County Wicklow ||| 0-0 1-1 2-2 3-3 4-4
, Kilruddey , County ||| , Kilruddery , County ||| 0-0 1-1 2-2 3-3
, Kilruddey , ||| , Kilruddery , ||| 0-0 1-1 2-2
, Kilruddey ||| , Kilruddery ||| 0-0 1-1
, Km 22 , 67019 ||| , Km 22 , 67019 ||| 0-0 1-1 2-2 3-3 4-4
, Km 22 , ||| , Km 22 , ||| 0-0 1-1 2-2 3-3
, Km 22 ||| , Km 22 ||| 0-0 1-1 2-2
, Km ||| , Km ||| 0-0 1-1
, Konzentration und Proteinbindung ||| , concentrations and protein binding ||| 0-0 1-1 2-2 3-3 3-4
, Konzentration und ||| , concentrations and ||| 0-0 1-1 2-2
, Konzentration ||| , concentrations ||| 0-0 1-1
, Kopfschmerzen , Akathisie , ||| , headache , akathisia , ||| 0-0 1-1 2-2 3-3 4-4
, Kopfschmerzen , Akathisie ||| , headache , akathisia ||| 0-0 1-1 2-2 3-3
, Kopfschmerzen , Dysgeusie , ||| , headache , dysgeusia , ||| 0-0 1-1 2-2 3-3 4-4
, Kopfschmerzen , Dysgeusie ||| , headache , dysgeusia ||| 0-0 1-1 2-2 3-3
, Kopfschmerzen , Müdigkeit , ||| , headache , tiredness , ||| 0-0 1-1 2-2 3-3 4-4
, Kopfschmerzen , Müdigkeit ||| , headache , tiredness ||| 0-0 1-1 2-2 3-3
, Kopfschmerzen , ||| , headache , ||| 0-0 1-1 2-2
, Kopfschmerzen , ||| , headache ||| 0-0 2-0 1-1
, Kopfschmerzen Augenerkrankungen Häufig ||| , headache Eye disorders Common ||| 0-0 1-1 2-2 2-3 3-4
, Kopfschmerzen Augenerkrankungen ||| , headache Eye disorders ||| 0-0 1-1 2-2 2-3
, Kopfschmerzen ||| , headache ||| 0-0 1-1
, Krankheitsgefühl ||| , ||| 0-0 1-0
, Kreatinin und ||| , creatinine and ||| 0-0 1-1 2-2
, Kreatinin ||| , creatinine ||| 0-0 1-1
, Kuhloweg 37 , D-58638 ||| , Kuhloweg 37 , D-58638 ||| 0-0 1-1 2-2 3-3 4-4
, Kuhloweg 37 , ||| , Kuhloweg 37 , ||| 0-0 1-1 2-2 3-3
, Kuhloweg 37 ||| , Kuhloweg 37 ||| 0-0 1-1 2-2
, Kuhloweg ||| , Kuhloweg ||| 0-0 1-1
, Laktation oder der Legeperiode ||| , lactation or lay ||| 0-0 1-1 2-2 4-3
, Laktation oder der ||| , lactation or ||| 0-0 1-1 2-2
, Laktation oder ||| , lactation or ||| 0-0 1-1 2-2
, Laktation ||| , lactation ||| 0-0 1-1
, Lda Tel : + ||| , Lda Tel : + ||| 0-0 1-1 2-2 3-3 4-4
, Lda Tel : ||| , Lda Tel : ||| 0-0 1-1 2-2 3-3
, Lda Tel ||| , Lda Tel ||| 0-0 1-1 2-2
, Lda ||| , Lda ||| 0-0 1-1
, London , WC2B 4AE ||| , London , WC2B 4AE ||| 0-0 1-1 2-2 3-3 4-4
, London , WC2B ||| , London , WC2B ||| 0-0 1-1 2-2 3-3
, London , ||| , London , ||| 0-0 1-1 2-2
, London ||| , London ||| 0-0 1-1
, Lungenembolien , Gefäßerweiterungen ||| pulmonary embolism , ||| 1-0 1-1 0-2 2-2 3-2
, Lungenembolien ||| , pulmonary ||| 0-0 1-1
, Lymphopenie ||| , ||| 0-0
, M-III und M-IV ||| , M-III , and M-IV ||| 0-0 1-1 0-2 2-3 3-4
, M-III und ||| , M-III , and ||| 0-0 1-1 0-2 2-3
, M-III ||| , M-III , ||| 0-0 1-1 0-2
, Macrogol 3000 . ||| , macrogol 3000 ||| 0-0 1-1 2-2 3-2
, Macrogol ||| , macrogol ||| 0-0 1-1
, Madarosis Augenerkrankungen : ||| , madarosis Eye disorders : ||| 0-0 1-1 2-2 2-3 3-4
, Madarosis Augenerkrankungen ||| , madarosis Eye disorders ||| 0-0 1-1 2-2 2-3
, Madarosis ||| , madarosis ||| 0-0 1-1
, Magenverstimmung ||| , ||| 0-0 1-0
, Magnesiumstearat , Eisen(III)-hydroxid-oxid ||| , magnesium stearate , yellow ||| 0-0 1-1 1-2 2-3 3-4
, Magnesiumstearat , Indigocarmin-Aluminiumsalz ||| stearate , indigo carmine ||| 1-0 0-1 2-1 3-2 3-3
, Magnesiumstearat , ||| , magnesium stearate , ||| 0-0 1-1 1-2 2-3
, Magnesiumstearat , ||| magnesium stearate , red ||| 1-0 1-1 0-2 2-2 1-3
, Magnesiumstearat , ||| stearate , ||| 1-0 0-1 2-1
, Magnesiumstearat ||| , magnesium stearate ||| 0-0 1-1 1-2
, Maisstärke , mikrokristalline ||| , maize starch , microcrystalline ||| 0-0 1-1 1-2 0-3 2-3 3-4
, Maisstärke , mikrokristalline ||| , maize starch , microcrystalline ||| 0-0 1-1 1-2 2-3 3-4
, Maisstärke , ||| , maize starch , ||| 0-0 1-1 1-2 0-3 2-3
, Maisstärke , ||| , maize starch , ||| 0-0 1-1 1-2 2-3
, Maisstärke ||| , maize starch , ||| 0-0 1-1 1-2 0-3
, Maisstärke ||| , maize starch ||| 0-0 1-1 1-2
, Malignes Neuroleptisches Syndrom ( ||| , Neuroleptic Malignant Syndrome ( ||| 0-0 1-1 2-2 2-3 3-3 4-4
, Malignes Neuroleptisches Syndrom ||| , Neuroleptic Malignant Syndrome ||| 0-0 1-1 2-2 2-3 3-3
, Malignes ||| , Neuroleptic ||| 0-0 1-1
, Marke ( Hersteller ) ||| , brand ( manufacturer ) ||| 0-0 1-1 2-2 1-3 3-3 4-4
, Marke ( Hersteller ||| , brand ( manufacturer ||| 0-0 1-1 2-2 1-3 3-3
, Maschinen zu bedienen , ||| use machines have ||| 1-0 1-1 3-1 1-2 2-2
, Maschinen zu bedienen ||| use machines have ||| 1-0 1-1 3-1 1-2 2-2
, Metformin ) betrugen ||| , metformin ) were ||| 0-0 1-1 2-2 3-3
, Metformin ) untersucht . ||| , metformin ) . ||| 0-0 1-1 2-2 3-3 4-3
, Metformin ) ||| , metformin ) ||| 0-0 1-1 2-2
, Metformin ||| , metformin ||| 0-0 1-1
, Monoaminoxidasehemmer ( ||| , monoamine oxidase inhibitors ( ||| 0-0 1-1 1-2 1-3 2-4
, Monoaminoxidasehemmer ||| , monoamine oxidase inhibitors ||| 0-0 1-1 1-2 1-3
, Muskelschmerzen , ||| , muscle pain ||| 2-0 1-1 1-2
, Muskelschmerzen ||| muscle pain ||| 1-0 1-1
, Muskelspasmen , ||| Gliedern , Muskelschwäche ||| 0-0 0-1 1-1 2-1 2-2
, Myalgie ( ||| , myalgia ( ||| 0-0 1-1 2-2
, Myalgie ||| , myalgia ||| 0-0 1-1
, Myalgie ||| myalgia ||| 1-0
, Myoglobinurie ( ||| , myoglobinuria ( ||| 0-0 1-1 2-2
, Myoglobinurie ||| , myoglobinuria ||| 0-0 1-1
, Müdigkeit , ||| , tiredness , ||| 0-0 1-1 2-2
, Müdigkeit , Übelkeit , ||| , tiredness , nausea , ||| 0-0 1-1 2-2 3-3 4-4
, Müdigkeit , Übelkeit ||| , tiredness , nausea ||| 0-0 1-1 2-2 3-3
, Müdigkeit ||| , tiredness ||| 0-0 1-1
, Natriumchlorid , Glycin ||| , sodium chloride , glycine ||| 0-0 1-1 1-2 2-3 3-4
, Natriumchlorid , ||| , sodium chloride , ||| 0-0 1-1 1-2 2-3
, Natriumchlorid ||| , sodium chloride ||| 0-0 1-1 1-2
, Natriumcitrat und Wasser ||| , sodium citrate and water ||| 0-0 1-1 1-2 2-3 3-4
, Natriumcitrat und ||| , sodium citrate and ||| 0-0 1-1 1-2 2-3
, Natriumcitrat ||| , sodium citrate ||| 0-0 1-1 1-2
, Natriumhydroxid ( ||| , sodium hydroxide ( ||| 0-0 1-1 1-2 2-3
, Natriumhydroxid , Sucrose ||| , sodium hydroxide , sucrose ||| 0-0 1-1 1-2 2-3 3-4
, Natriumhydroxid , ||| , sodium hydroxide , ||| 0-0 1-1 1-2 2-3
, Natriumhydroxid und ||| hydroxide , and ||| 1-0 0-1 2-2
, Natriumhydroxid ||| , sodium hydroxide ||| 0-0 1-1 1-2
, Natriumhydroxid ||| hydroxide , ||| 1-0 0-1
, Nausea ( Übelkeit ||| , nausea ( feeling sick ||| 0-0 3-1 2-2 3-3 1-4
, Nervosität ; Suizidversuch ||| , nervousness ; suicide attempt ||| 0-0 1-1 2-2 2-3 3-3 3-4
, Nervosität ||| , nervousness ||| 0-0 1-1
, Nesselausschlag ||| difficulty breathing , ||| 0-0 1-0 0-1 0-2
, Nesselsucht , Schwellungen und ||| , hives , swelling and ||| 0-0 1-1 2-2 3-3 4-4
, Nesselsucht , Schwellungen und ||| site within a given area ||| 1-0 1-1 1-2 2-2 3-3 3-4 4-4
, Nesselsucht , Schwellungen ||| , hives , swelling ||| 0-0 1-1 2-2 3-3
, Nesselsucht , ||| , hives , ||| 0-0 1-1 2-2
, Nesselsucht , ||| site within a ||| 1-0 1-1 1-2 2-2
, Nesselsucht ||| , hives ||| 0-0 1-1
, Neuralgie , Verlust des ||| , neuralgia , sensory loss ||| 0-0 1-1 2-2 2-3 3-4 4-4
, Neuralgie , ||| , neuralgia , sensory ||| 0-0 1-1 2-2 2-3
, Neuralgie ||| , neuralgia ||| 0-0 1-1
, Neuropathie , Hypästhesie , ||| , neuropathy , hypoaesthesia , ||| 0-0 1-1 2-2 3-3 4-4
, Neuropathie , Hypästhesie ||| , neuropathy , hypoaesthesia ||| 0-0 1-1 2-2 3-3
, Neuropathie , ||| , neuropathy , ||| 0-0 1-1 2-2
, Neuropathie ||| , neuropathy ||| 0-0 1-1
, Nitrate , ||| channel blockers , ||| 0-0 1-0 1-1 2-2
, Nitrate ||| channel blockers ||| 0-0 1-0 1-1
, Notfallmaßnahmen , Gegenmittel ||| , emergency procedures , antidotes ||| 0-0 1-1 1-2 2-3 3-4
, Notfallmaßnahmen , ||| , emergency procedures , ||| 0-0 1-1 1-2 2-3
, Notfallmaßnahmen ||| , emergency procedures ||| 0-0 1-1 1-2
, Nykturie , Polyurie ||| , nocturia ||| 0-0 2-0 1-1 3-1
, Obstipation ||| , ||| 0-0 1-0
, Osteoporose und QT- Verlängerung ||| , osteoporosis and QT prolongation ||| 0-0 1-1 2-2 0-3 3-3 0-4
, Osteoporose und QT- ||| , osteoporosis and QT prolongation ||| 0-0 1-1 2-2 0-3 3-3 0-4
, Oxford Road Uxbridge - ||| , Oxford Road Uxbridge - ||| 0-0 1-1 2-2 3-3 4-4
, Oxford Road Uxbridge ||| , Oxford Road Uxbridge ||| 0-0 1-1 2-2 3-3
, Oxford Road ||| , Oxford Road ||| 0-0 1-1 2-2
, Oxford ||| , Oxford ||| 0-0 1-1
, Partikel- freie und ||| free from particles and ||| 1-0 2-1 2-2 3-3
, Partikel- freie ||| free from particles ||| 1-0 2-1 2-2
, Partikel- ||| free ||| 1-0
, Parästhesie . ||| , paraesthesia . ||| 0-0 1-1 2-2
, Parästhesie ||| , paraesthesia ||| 0-0 1-1
, Patronen ( ||| , cartridges ( ||| 0-0 1-1 2-2
, Patronen ||| , cartridges ||| 0-0 1-1
, Phenprocoumon und Metformin ausübt ||| , phenprocoumon and metformin ||| 0-0 1-1 4-1 2-2 3-3 4-3
, Phenytoin , ||| , Nevirapin und Johanniskraut ||| 0-0 2-0 1-1 1-2 1-3
, Pleuraerguss , allergische ||| , pleural effusion , allergic ||| 0-0 1-1 1-2 2-2 2-3 3-4
, Pleuraerguss , ||| , pleural effusion , ||| 0-0 1-1 1-2 2-2 2-3
, Pollakisurie , Hämaturie ||| , pollakiuria , haematuria ||| 0-0 1-1 3-1 2-2 3-3
, Polydipsie , Hyperglykämie , ||| , polydipsia , hyperglycaemia , ||| 0-0 1-1 2-2 3-3 4-4
, Polydipsie , Hyperglykämie ||| , polydipsia , hyperglycaemia ||| 0-0 1-1 2-2 3-3
, Polydipsie , ||| , polydipsia , ||| 0-0 1-1 2-2
, Polydipsie ||| , polydipsia ||| 0-0 1-1
, Polysorbat 80 , Salzsäure ||| polysorbate 80 , hydrochloric acid ||| 1-0 2-1 0-2 3-2 1-3 4-3 4-4
, Pruritus oder Urtikaria ||| , pruritus , or urticaria ||| 0-0 1-1 0-2 2-3 3-4
, Pruritus oder ||| , pruritus , or ||| 0-0 1-1 0-2 2-3
, Pruritus ||| , pruritus , ||| 0-0 1-1 0-2
, Puls , Atemfrequenz ||| , pulse , respiratory rate ||| 0-0 1-1 2-2 3-3 1-4
, Pyrexie ) , ||| , pyrexia ) , ||| 0-0 1-1 2-2 3-3
, Pyrexie ) ||| , pyrexia ) ||| 0-0 1-1 2-2
, Pyrexie ||| , pyrexia ||| 0-0 1-1
, RH12 5AB Vereinigtes Königreich ||| , RH12 5AB United Kingdom ||| 0-0 1-1 2-2 3-3 4-4
, RH12 5AB Vereinigtes ||| , RH12 5AB United ||| 0-0 1-1 2-2 3-3
, RH12 5AB ||| , RH12 5AB ||| 0-0 1-1 2-2
, RH12 ||| , RH12 ||| 0-0 1-1
, Raloxifen ||| , raloxifene ||| 0-0 1-1
, Rasse oder Körpergewicht ||| , race or body weight ||| 0-0 1-1 2-2 3-3 3-4
, Rasse oder ||| , race or ||| 0-0 1-1 2-2
, Rasse ||| , race ||| 0-0 1-1
, Rigor , ||| , rigors , ||| 0-0 1-0 1-1 2-2
, Rigor , Ödeme , ||| , rigors , oedema , ||| 0-0 1-0 1-1 2-2 3-3 4-4
, Rigor , Ödeme ||| , rigors , oedema ||| 0-0 1-0 1-1 2-2 3-3
, Rigor ||| , rigors ||| 0-0 1-0 1-1
, Rimonabant , ist ein ||| , rimonabant , is a ||| 0-0 1-1 0-2 2-2 3-3 4-4
, Rimonabant , ist ||| , rimonabant , is ||| 0-0 1-1 0-2 2-2 3-3
, Rimonabant , ||| , rimonabant , ||| 0-0 1-1 0-2 2-2
, Ritonavir ( ein Mittel ||| , ritonavir ( ||| 0-0 1-1 2-2 4-2
, Ritonavir ||| , ritonavir ||| 0-0 1-1
, Royaume-Uni Tél/Tel : ||| , Royaume-Uni Tél/ Tel : ||| 0-0 1-1 2-2 2-3 3-4
, Royaume-Uni Tél/Tel ||| , Royaume-Uni Tél/ Tel ||| 0-0 1-1 2-2 2-3
, Royaume-Uni ||| , Royaume-Uni ||| 0-0 1-1
, Ruhelosigkeit , Angstgefühl ||| , restlessness , feeling anxious ||| 0-0 1-1 2-2 3-3 3-4
, Ruhelosigkeit , ||| , restlessness , ||| 0-0 1-1 2-2
, Ruhelosigkeit ||| , restlessness ||| 0-0 1-1
, Rötungen , Schmerzen und ||| , redness , pain and ||| 0-0 2-0 1-1 2-2 3-3 4-4
, Rötungen , Schmerzen ||| , redness , pain ||| 0-0 2-0 1-1 2-2 3-3
, Rötungen , ||| , redness , ||| 0-0 2-0 1-1 2-2
, S.A. ||| , S. A. ||| 0-0 1-1 1-2
, Salicylate , ||| ACE ) inhibitors , ||| 0-0 1-0 1-1 1-2 2-3
, Salicylate ||| ACE ) inhibitors ||| 0-0 1-0 1-1 1-2
, Schilddrüsenhormone und Betasympathomimetika ||| , thyroid hormones and beta-sympathomimetics ||| 0-0 1-1 1-2 2-3 3-4
, Schilddrüsenhormone und ||| , thyroid hormones and ||| 0-0 1-1 1-2 2-3
, Schilddrüsenhormone ||| , thyroid hormones ||| 0-0 1-1 1-2
, Schlaflosigkeit , ||| , insomnia , ||| 0-0 1-1 2-2
, Schlaflosigkeit ||| , insomnia ||| 0-0 1-1
, Schleimhautentzündung , Schmerzen ||| , mucosal inflammation , pain ||| 0-0 1-1 3-2 2-3 3-4
, Schleimhautentzündung ||| , mucosal ||| 0-0 1-1
, Schläfrigkeit , Sedierung , ||| , somnolence , sedation , ||| 0-0 1-1 2-2 3-3 4-4
, Schläfrigkeit , Sedierung ||| , somnolence , sedation ||| 0-0 1-1 2-2 3-3
, Schläfrigkeit , Tachykardie , ||| , somnolence , tachycardia , ||| 0-0 2-0 1-1 2-2 3-3 4-4
, Schläfrigkeit , Tachykardie ||| , somnolence , tachycardia ||| 0-0 2-0 1-1 2-2 3-3
, Schläfrigkeit , Tremor , ||| , somnolence , tremor , ||| 0-0 1-1 2-2 3-3 4-4
, Schläfrigkeit , Tremor ||| , somnolence , tremor ||| 0-0 1-1 2-2 3-3
, Schläfrigkeit , Zittern und ||| , sleepiness , shaking and ||| 0-0 1-1 3-1 2-2 3-3 4-4
, Schläfrigkeit , Zittern ||| , sleepiness , shaking ||| 0-0 1-1 3-1 2-2 3-3
, Schläfrigkeit , ||| , somnolence , ||| 0-0 1-1 2-2
, Schläfrigkeit , ||| , somnolence , ||| 0-0 2-0 1-1 2-2
, Schläfrigkeit ||| , somnolence ||| 0-0 1-1
, Schmerzen , Rigor ||| inflammation , pain , rigors ||| 1-0 0-1 1-2 2-3 3-3 3-4
, Schmerzen ||| inflammation , pain ||| 1-0 0-1 1-2
, Schwellungen und Entzündungen . ||| , swelling and inflammation . ||| 0-0 1-1 2-2 3-3 4-4
, Schwellungen und Entzündungen ||| , swelling and inflammation ||| 0-0 1-1 2-2 3-3
, Schwellungen und ||| , swelling and ||| 0-0 1-1 2-2
, Schwellungen und/oder Schmerzen ||| , swelling and/ or pain ||| 0-0 1-1 2-2 2-3 3-4
, Schwellungen und/oder ||| , swelling and/ or ||| 0-0 1-1 2-2 2-3
, Schwellungen ||| , swelling ||| 0-0 1-1
, Schwindel , Kopfschmerzen , ||| , dizziness , headache , ||| 0-0 1-1 2-2 3-3 4-4
, Schwindel , Kopfschmerzen ||| , dizziness , headache ||| 0-0 1-1 2-2 3-3
, Schwindel , Schläfrigkeit , ||| , dizziness , somnolence , ||| 0-0 1-1 2-2 3-3 4-4
, Schwindel , Schläfrigkeit ||| , dizziness , somnolence ||| 0-0 1-1 2-2 3-3
, Schwindel , periphere motorische ||| , dizziness , peripheral motor ||| 0-0 1-1 2-2 3-3 4-4
, Schwindel , periphere ||| , dizziness , peripheral ||| 0-0 1-1 2-2 3-3
, Schwindel , ||| , dizziness , ||| 0-0 1-1 2-2
, Schwindel ||| , dizziness ||| 0-0 1-1
, Schwitzen und Herzrhythmusstörungen ||| , diaphoresis and cardiac dysrhythmia ||| 0-0 1-1 3-1 2-2 3-3 3-4
, Schwächegefühl , ||| , feeling of weakness , ||| 0-0 0-1 1-3 2-4
, Schwächegefühl ||| , feeling of weakness ||| 0-0 0-1 1-3
, Sedierung , Kopfschmerzen ||| , sedation , headache ||| 0-0 1-1 2-2 3-3
, Sedierung , ||| , sedation , ||| 0-0 1-1 2-2
, Sedierung ||| , sedation ||| 0-0 1-1
, Sehstörungen , ||| , visual disturbance , ||| 0-0 1-1 1-2 2-3
, Sehstörungen ||| , visual disturbance ||| 0-0 1-1 1-2
, Spanien ||| , Spain ||| 0-0 1-1
, Speichelfluss , Anorexie , ||| , salivation , anorexia , ||| 0-0 0-1 1-2 2-2 3-3 4-4
, Speichelfluss , Anorexie ||| , salivation , anorexia ||| 0-0 0-1 1-2 2-2 3-3
, Speichelfluss , ||| , salivation , ||| 0-0 0-1 1-2 2-2
, Speichelhypersekretion ||| , ||| 0-0 1-0
, Speichelüberproduktion Gefäßerkrankungen ||| , salivary hypersecretion Vascular ||| 0-0 1-1 1-2 2-3
, Speichelüberproduktion ||| , salivary hypersecretion ||| 0-0 1-1 1-2
, Speiseröhrenentzündung ||| taste disturbance , ||| 0-0 0-1 0-2 1-2
, Stomatitis ||| , stomatitis ||| 0-0 1-1
, Storbritannia Tlf : + ||| , Storbritannia Tlf : + ||| 0-0 1-1 2-2 3-3 4-4
, Storbritannia Tlf : ||| , Storbritannia Tlf : ||| 0-0 1-1 2-2 3-3
, Storbritannia Tlf ||| , Storbritannia Tlf ||| 0-0 1-1 2-2
, Storbritannia ||| , Storbritannia ||| 0-0 1-1
, Storbritannien Tel : + ||| , Storbritannien Tel : + ||| 0-0 1-1 2-2 3-3 4-4
, Storbritannien Tel : ||| , Storbritannien Tel : ||| 0-0 1-1 2-2 3-3
, Storbritannien Tel ||| , Storbritannien Tel ||| 0-0 1-1 2-2
, Storbritannien Tlf : + ||| , Storbritannien Tlf : + ||| 0-0 1-1 2-2 3-3 4-4
, Storbritannien Tlf : ||| , Storbritannien Tlf : ||| 0-0 1-1 2-2 3-3
, Storbritannien Tlf ||| , Storbritannien Tlf ||| 0-0 1-1 2-2
, Storbritannien ||| , Storbritannien ||| 0-0 1-1
, Stärke ||| , injection route ||| 0-0 1-1 1-2
, Sucrose , E218 ||| , sucrose , E218 , ||| 0-0 1-1 0-2 3-3 2-4
, Sucrose ||| , sucrose , ||| 0-0 1-1 0-2
, Sucrose ||| , sucrose ||| 0-0 1-1
, Suizidgedanken , und ||| , suicidal ideation , and ||| 0-0 1-1 1-2 2-2 2-3 3-4
, Suizidgedanken , ||| , suicidal ideation , ||| 0-0 1-1 1-2 2-2 2-3
, Suizidgedanken bei ||| , and suicidal ideation in ||| 0-0 1-2 1-3 2-4
, Suizidgedanken ||| , and suicidal ideation ||| 0-0 1-2 1-3
, Synkope ||| , syncope ||| 0-0 1-1
, Tachykardie , ||| , tachycardia , ||| 0-0 1-1 2-2
, Tachykardie , ||| , tachycardia , ||| 0-0 2-0 1-1 2-2
, Tachykardie ||| , tachycardia ||| 0-0 1-1
, Tamoxifen , Hormonersatztherapie ||| , tamoxifen , hormone replacement ||| 0-0 1-1 0-2 2-2 2-3 3-4
, Tamoxifen , ||| , tamoxifen , hormone ||| 0-0 1-1 0-2 2-2 2-3
, Te . : +44 ||| , Te . : +44 ||| 0-0 1-1 2-2 3-3 4-4
, Te . : ||| , Te . : ||| 0-0 1-1 2-2 3-3
, Te . ||| , Te . ||| 0-0 1-1 2-2
, Te ||| , Te ||| 0-0 1-1
, Telithromycin oder Clarithromycin ||| , or telithromycin or clarithromycin ||| 0-0 2-1 3-2 2-3 1-4
, Thiazide , Glucokortikoide , ||| , thiazides , glucocorticoids , ||| 0-0 1-1 2-2 3-3 4-4
, Thiazide , Glucokortikoide ||| , thiazides , glucocorticoids ||| 0-0 1-1 2-2 3-3
, Thiazide , ||| , thiazides , ||| 0-0 1-1 2-2
, Thiazide ||| , thiazides ||| 0-0 1-1
, Tibolon ; ||| , tibolone ; ||| 0-0 1-1 2-2
, Tibolon ||| , tibolone ||| 0-0 1-1
, Toxizität ||| humans ||| 1-0
, Tremor , Schwindel , ||| , tremor , dizziness , ||| 0-0 1-1 2-2 3-3 4-4
, Tremor , Schwindel ||| , tremor , dizziness ||| 0-0 1-1 2-2 3-3
, Tremor , Synkope ||| , tremor , syncope ||| 0-0 1-1 2-2 3-3
, Tremor , ||| , tremor , ||| 0-0 1-1 2-2
, Tremor Häufig : ||| , tremor Common : ||| 0-0 1-1 2-2 3-3
, Tremor Häufig ||| , tremor Common ||| 0-0 1-1 2-2
, Tremor ||| , tremor ||| 0-0 1-1
, Urtikaria und Angioödem ||| , urticaria and angioedema , ||| 0-0 1-1 2-2 3-3 0-4
, Vereinigtes Königreich . ||| , United Kingdom . ||| 0-0 1-1 2-2 3-3
, Vereinigtes Königreich ||| , United Kingdom ||| 0-0 1-1 2-2
, Vereinigtes ||| , United ||| 0-0 1-1
, Verlust des Empfindens , ||| , sensory loss , ||| 0-0 0-1 1-2 2-2 3-3 4-3
, Verlust des ||| , sensory loss ||| 0-0 0-1 1-2 2-2
, Verstopfung , Speichelüberproduktion ||| , constipation , salivary hypersecretion ||| 0-0 1-1 2-2 3-3 3-4
, Verstopfung , Stomatitis ||| , constipation , stomatitis ||| 0-0 1-1 2-2 3-3
, Verstopfung , erhöhte ||| , constipation , increased ||| 0-0 1-1 0-2 2-2 3-3
, Verstopfung , ||| , constipation , ||| 0-0 1-1 0-2 2-2
, Verstopfung , ||| , constipation , ||| 0-0 1-1 2-2
, Verstopfung ||| , constipation ||| 0-0 1-1
, Vitamin-B12- oder ||| , vitamin B12 or ||| 0-0 1-1 1-2 2-3
, Vitamin-B12- ||| , vitamin B12 ||| 0-0 1-1 1-2
, WC2B 4AE , Vereinigtes ||| , WC2B 4AE , United ||| 0-0 1-1 2-2 3-3 4-4
, WC2B 4AE , ||| , WC2B 4AE , ||| 0-0 1-1 2-2 3-3
, WC2B 4AE ||| , WC2B 4AE ||| 0-0 1-1 2-2
, WC2B ||| , WC2B ||| 0-0 1-1
, WENN UNTERSCHIEDLICH , ||| HOLDER ||| 0-0 1-0 2-0
, WENN UNTERSCHIEDLICH ||| HOLDER ||| 0-0 1-0 2-0
, Wachstumshormon und Danazol ||| , growth hormone and danazol ||| 0-0 1-1 1-2 2-3 3-4
, Wachstumshormon und ||| , growth hormone and ||| 0-0 1-1 1-2 2-3
, Wachstumshormon ||| , growth hormone ||| 0-0 1-1 1-2
, Wahn und Paranoia . ||| , delusion and paranoia . ||| 0-0 1-1 2-2 3-3 4-4
, Wahn und Paranoia ||| , delusion and paranoia ||| 0-0 1-1 2-2 3-3
, Wahn und ||| , delusion and ||| 0-0 1-1 2-2
, Wahn ||| , delusion ||| 0-0 1-1
, Warfarin , ||| , warfarin , ||| 0-0 1-1 2-2
, Warfarin ||| , warfarin ||| 0-0 1-1
, Wasser für Injektionszwecke ||| , and water for injections ||| 0-0 1-1 1-2 2-3 3-4
, Wasser für ||| , and water for ||| 0-0 1-1 1-2 2-3
, Wasser ||| , and water ||| 0-0 1-1 1-2
, Weinsäure ( Ph.Eur. ) ||| , tartaric acid , sodium ||| 0-0 1-1 1-2 2-2 0-3 3-4 4-4
, Weinsäure ( ||| , tartaric acid , ||| 0-0 1-1 1-2 2-2 0-3
, Wielka Brytania Tel : ||| , Wielka Brytania Tel : ||| 0-0 1-1 2-2 3-3 4-4
, Wielka Brytania Tel ||| , Wielka Brytania Tel ||| 0-0 1-1 2-2 3-3
, Wielka Brytania ||| , Wielka Brytania ||| 0-0 1-1 2-2
, Wielka ||| , Wielka ||| 0-0 1-1
, Zahnschmerz , Gelenkschmerz , ||| , indigestion , abdominal ||| 0-0 1-0 2-1 2-2 3-2 4-2 4-3
, Zahnschmerz ||| , ||| 0-0 1-0
, Zahnschmerz. # ||| , toothache ||| 0-0 1-1 2-1
, Zoledronsäure , ist ||| , zoledronic acid , is ||| 0-0 1-1 1-2 2-3 3-4
, Zoledronsäure , ||| , zoledronic acid , ||| 0-0 1-1 1-2 2-3
, Zoledronsäure ||| , zoledronic acid ||| 0-0 1-1 1-2
, Zucker ||| , sugar ||| 0-0 1-1
, Zungenbrennen , trockener Mund ||| , glossodynia , dry mouth ||| 0-0 1-1 2-2 3-2 2-3 4-4
, Zungenbrennen , trockener ||| , glossodynia , dry ||| 0-0 1-1 2-2 3-2 2-3
, Zungenbrennen ||| , glossodynia ||| 0-0 1-1
, aber keine ||| but no ||| 1-0 2-1
, aber nicht ||| but not ||| 1-0 2-1
, aber unkonserviertes Produkt und ||| but unpreserved product and ||| 0-0 1-0 2-1 3-2 4-3
, aber unkonserviertes Produkt ||| but unpreserved product ||| 0-0 1-0 2-1 3-2
, aber unkonserviertes ||| but unpreserved ||| 0-0 1-0 2-1
, aber verordnende ||| but prescribers ||| 0-0 1-0 2-1
, aber verordnende Ärzte sollten ||| but prescribers should be alert ||| 0-0 1-0 2-1 4-2 4-3 3-4
, aber ||| , but with ||| 0-0 1-1
, aber ||| , but ||| 0-0 1-1
, aber ||| but ||| 0-0 1-0
, aber ||| but ||| 1-0
, abgemagertes Aussehen , ||| loss , emaciated appearance , ||| 0-0 0-1 1-2 2-2 3-3 3-4
, abgemagertes Aussehen ||| loss , emaciated ||| 0-0 0-1 1-2 2-2
, abgeschwächtes Atemgeräusch , ||| , decreased breath sounds , ||| 0-0 0-1 0-2 1-3 2-3 3-4
, abgeschwächtes Atemgeräusch ||| , decreased breath sounds ||| 0-0 0-1 0-2 1-3 2-3
, abgesetzt werden . ||| , must be discontinued . ||| 0-0 1-1 2-2 1-3 2-3 3-4
, abgesetzt werden ||| , must be discontinued ||| 0-0 1-1 2-2 1-3 2-3
, abnormales Sehen , ||| pain , abnormal vision , ||| 0-0 0-1 1-1 1-2 2-3 3-4
, abnormales Sehen ||| pain , abnormal vision ||| 0-0 0-1 1-1 1-2 2-3
, abnormales ||| pain , abnormal ||| 0-0 0-1 1-1 1-2
, als 10 mg , ||| , as 10 mg , ||| 0-0 1-1 2-2 3-3 4-4
, als 10 mg ||| , as 10 mg ||| 0-0 1-1 2-2 3-3
, als 10 ||| , as 10 ||| 0-0 1-1 2-2
, als ||| , as ||| 0-0 1-1
, als ||| than ||| 1-0
, an der 460 Frauen ||| involving 460 women ||| 1-0 3-1 4-2
, an der 460 ||| involving 460 ||| 1-0 3-1
, an der ||| involving ||| 1-0
, an ||| involving ||| 1-0
, angewendet . ||| . ||| 2-0
, anstrengende körperliche Aktivität können ||| , strenuous physical exercise may ||| 0-0 1-1 2-1 3-2 2-3 4-3 4-4
, arterielle ||| , arterial ||| 0-0 1-1
, auch erlernen , wie ||| to learn how ||| 3-0 2-1 4-2
, auch erlernen , ||| to learn ||| 3-0 2-1
, auch erlernen ||| learn ||| 2-0
, auch ||| , including ||| 0-0 1-1
, auf Anforderung der EMEA ||| the request of the EMEA ||| 1-0 3-0 2-1 3-2 3-3 4-4
, auf Anforderung der ||| the request of the ||| 1-0 3-0 2-1 3-2 3-3
, aufrecht erhalten werden ||| dosing , ||| 3-0 0-1
, aufrecht erhalten ||| , ||| 0-0
, aufrecht ||| , ||| 0-0
, bei 2,3 % der ||| in 2.3 % of ||| 1-0 2-1 3-2 4-3
, bei 2,3 % ||| in 2.3 % ||| 1-0 2-1 3-2
, bei 2,3 ||| in 2.3 ||| 1-0 2-1
, bei 95 % in ||| 95 % in ||| 2-0 3-1 1-2 4-2
, bei denen ein elektiver ||| patients scheduled for major ||| 1-0 2-1 4-2 3-3 4-3
, bei denen ein elektiver ||| scheduled for major ||| 0-0 1-0 2-0 2-1 3-2 4-2
, bei denen ein hohes ||| , having a high ||| 0-0 2-1 4-1 3-2 4-3
, bei denen ein ||| patients scheduled ||| 1-0 2-0 2-1 3-1
, bei denen keine adäquate ||| who for any reason cannot ||| 0-0 2-0 1-1 2-1 2-2 2-3 3-3 4-3 4-4
, bei denen ||| in which ||| 1-0 0-1 2-1
, bei denen ||| patients scheduled ||| 1-0 2-1
, bei denen ||| scheduled for ||| 0-0 1-0 2-0 2-1
, bei denen Übergewicht oder ||| in which overweight or ||| 1-0 0-1 2-1 3-2 4-3
, bei denen Übergewicht ||| in which overweight ||| 1-0 0-1 2-1 3-2
, bei der der Körper ||| in which the body ||| 1-0 0-1 2-2 3-2 4-3
, bei der der ||| in which the ||| 1-0 0-1 2-2 3-2
, bei ||| , ||| 0-0
, bei ||| in which ||| 1-0 0-1
, bei ||| in ||| 1-0
, bei ||| patients ||| 1-0
, beispielsweise ||| , for example ||| 0-0 1-2
, beobachtet . ||| been observed . ||| 1-0 1-1 2-2
, beobachtet ||| been observed ||| 1-0 1-1
, berichtet ( ||| reported ( ||| 1-0 2-1
, berichtet ( ||| were reported ( ||| 1-1 2-2
, berichtet ||| reported ||| 1-0
, berichtet ||| were reported ||| 1-1
, besonders bei Patienten mit ||| , especially in patients ||| 0-0 1-1 2-2 3-3 4-3
, besonders bei ||| , especially in ||| 0-0 1-1 2-2
, besonders wenn ||| , especially when ||| 0-0 1-1 2-2
, besonders ||| , especially ||| 0-0 1-1
, bevor ||| before ||| 1-0
, bevor ||| carefully before ||| 0-0 1-0 1-1
, bis Ihr Zustand unter ||| until your condition ||| 0-0 1-0 2-1 3-2
, bis Ihr Zustand ||| until your condition ||| 0-0 1-0 2-1 3-2
, bis Ihr ||| until your ||| 0-0 1-0 2-1
, bis die ||| of Abraxane until ||| 2-0 1-2
, bis ein stabiler ||| until a stable level ||| 0-0 1-0 2-1 2-2 3-2 3-3
, bis er ||| until it ||| 1-0 2-1
, bis sich der ||| until ||| 1-0 2-0 3-0
, bis sich ||| until ||| 1-0 2-0
, bis ||| Abraxane until ||| 1-1
, bis ||| until ||| 0-0 1-0
, bis ||| until ||| 1-0
, d.h. ||| , i. e. ||| 0-0 1-1 1-2
, da dies zur ||| as this will ||| 0-0 1-0 2-1 2-2 3-2
, da ||| , since ||| 0-0 1-1
, da ||| as ||| 0-0 1-0
, da ||| as ||| 1-0
, daher ||| , and therefore ||| 0-0 1-1 1-2
, darf dieses Arzneimittel ||| , this medicinal product must ||| 0-0 2-1 1-2 2-2 3-3 1-4
, darf ||| should not be ||| 1-0 1-1 0-2 1-2
, das als Mitose-stimulierender Faktor ||| , as a mitosis-stimulating factor ||| 0-0 2-1 3-2 1-3 3-3 4-4
, das als Mitose-stimulierender ||| , as a mitosis-stimulating ||| 0-0 2-1 3-2 1-3 3-3
, das den arzneilich ||| containing the active ||| 0-0 3-0 1-1 2-2 3-2
, das im Umgang mit ||| trained in the handling of ||| 3-0 2-1 4-1 1-2 3-3
, das im Umgang mit ||| trained in the handling ||| 3-0 2-1 4-1 1-2 3-3
, das mit ||| which ||| 0-0 1-0
, das sich ||| risk ||| 1-0
, das ||| , which involved ||| 0-0 1-1
, das ||| , which ||| 0-0 1-1
, das ||| , ||| 0-0
, das ||| containing ||| 0-0 1-0
, das ||| enter ||| 1-0
, das ||| human ||| 0-0 1-0
, das ||| risk ||| 1-0
, das ||| the ||| 1-0
, das ||| which ||| 0-0 1-0
, dass Abseamed ||| that Abseamed ||| 0-0 1-0 2-1
, dass Aripiprazol wie ||| that aripiprazole ||| 0-0 1-0 2-1
, dass Aripiprazol ||| that aripiprazole ||| 0-0 1-0 2-1
, dass Epoetin alfa ||| that epoetin alfa ||| 1-0 2-1 3-2
, dass Epoetin ||| that epoetin ||| 1-0 2-1
, dass Erythropoetine ||| that erythropoietins ||| 0-0 1-0 2-1
, dass Ihr Hämoglobinwert ||| that your haemoglobin ||| 0-0 1-0 2-1 3-2
, dass Ihr ||| that your ||| 0-0 1-0 2-1
, dass Pioglitazon ||| that pioglitazone ||| 0-0 1-0 2-1
, dass Rimonabant ||| that rimonabant is ||| 0-0 1-0 2-1 1-2
, dass Sie ||| make you ||| 0-0 1-0 2-1
, dass Sie ||| that you are ||| 0-0 1-0 2-1 2-2
, dass der Dosisregler ||| that the dose selector returns ||| 0-0 1-0 2-1 3-2 2-3 3-3 3-4
, dass die Wirkung von ||| that the effect of ||| 0-0 1-0 2-1 3-2 4-3
, dass die Wirkung ||| that the effect ||| 0-0 1-0 2-1 3-2
, dass die ||| indicated that ||| 2-0 0-1 1-1 2-1
, dass die ||| that the ||| 0-0 1-0 2-1
, dass die ||| that ||| 0-0 1-0 2-0
, dass ein ||| in exposures is ||| 0-0 0-1 1-2 2-2
, dass es notwendig ist ||| need to ||| 1-0 2-0 1-1
, dass es notwendig ||| need to ||| 1-0 2-0 1-1
, dass es ||| need to ||| 1-0 2-0 1-1
, dass sich der ||| that the ||| 0-0 1-0 2-0 3-1
, dass sich ||| that ||| 0-0 1-0 2-0
, dass ||| containing ||| 0-0
, dass ||| indicate that ||| 1-0 0-1 1-1
, dass ||| make ||| 0-0 1-0
, dass ||| sure ||| 1-0
, dass ||| that the ||| 0-0 1-0
, dass ||| that ||| 0-0 1-0
, dass ||| that ||| 1-0
, dass ||| to ||| 0-0 1-0
, definiert als Verminderung der ||| defined by a decrease in ||| 1-0 3-1 3-2 2-3 3-3
, definiert als Verminderung der ||| defined by a decrease ||| 1-0 3-1 3-2 2-3 3-3
, definiert als Verminderung ||| defined by a decrease in ||| 1-0 3-1 3-2 2-3 3-3
, definiert als Verminderung ||| defined by a decrease ||| 1-0 3-1 3-2 2-3 3-3
, definiert ||| defined ||| 1-0
, dem aktiven Metaboliten , ||| , the active metabolite , ||| 0-0 1-1 2-2 1-3 2-3 3-3 4-4
, dem aktiven Metaboliten ||| , the active metabolite ||| 0-0 1-1 2-2 1-3 2-3 3-3
, den Cannabinoid-Typ 1 ||| , the cannabinoid type 1 ||| 0-0 1-1 2-2 2-3 3-4
, den Cannabinoid-Typ ||| , the cannabinoid type ||| 0-0 1-1 2-2 2-3
, den ||| , the ||| 0-0 1-1
, der Osteoporose bei Männern ||| , osteoporosis in men ||| 0-0 2-1 1-2 3-2 4-3
, der Osteoporose bei ||| , osteoporosis in ||| 0-0 2-1 1-2 3-2
, der auch ||| which also ||| 0-0 2-0 2-1
, der in Actos ||| , ||| 0-0 3-0
, der nach einem Jahr ||| , der nach einem Jahr ||| 0-0 1-1 2-2 2-3 3-3 4-4
, der nach einem ||| , der nach einem ||| 0-0 1-1 2-2 2-3 3-3
, der ||| , der ||| 0-0 1-1
, der ||| , which ||| 0-0 0-1
, der ||| in blood ||| 1-0 0-1 1-1
, der ||| of ||| 1-0
, der ||| the ||| 0-0 1-0
, der ||| the ||| 1-0
, deren Blutzucker trotz einer ||| with insufficient glycaemic ||| 1-0 1-1 2-1 3-1 3-2 4-2
, deren Blutzucker trotz ||| glycaemic control despite ||| 3-0 3-1 1-2 2-2 3-2
, des ||| , non- smoking ||| 0-0 0-1 1-2
, diabetische Ketoazidose , ||| , diabetic ketoacidosis , ||| 0-0 1-1 2-2 3-3
, diabetische Ketoazidose ||| , diabetic ketoacidosis ||| 0-0 1-1 2-2
, diabetische ||| , diabetic ||| 0-0 1-1
, diabetisches hyperosmolares Koma ||| , diabetic hyperosmolar coma ||| 0-0 1-1 1-2 2-2 3-3
, diabetisches hyperosmolares ||| , diabetic hyperosmolar ||| 0-0 1-1 1-2 2-2
, die ( ||| ( ||| 2-0
, die > First-Line-Therapie erhalten ||| receiving > 1st-line therapy ||| 0-0 1-0 4-0 2-1 3-2 4-3
, die Aclasta erhielten , ||| receiving Aclasta ||| 0-0 1-0 3-0 2-1
, die Aclasta erhielten ||| receiving Aclasta ||| 0-0 1-0 3-0 2-1
, die Aripiprazol Injektionslösung erhalten ||| receiving aripiprazole solution for injection ||| 0-0 1-0 4-0 2-1 3-2 3-3 4-3 3-4
, die Entwicklung schwerer ||| , although development of severe ||| 0-0 1-1 2-2 1-3 3-4
, die Entwicklung ||| , although development of ||| 0-0 1-1 2-2 1-3
, die Hämoglobin-Zielkonzentration von ||| the haemoglobin target range of ||| 1-0 2-1 2-2 2-3 3-4
, die Hämoglobin-Zielkonzentration ||| the haemoglobin target range ||| 1-0 2-1 2-2 2-3
, die Ihnen Ihr Arzt ||| to you by your doctor ||| 0-0 1-0 2-1 2-2 3-3 4-3 4-4
, die Ihnen ||| to you by ||| 0-0 1-0 2-1 2-2
, die Paclitaxel auflösen , ||| that dissolve the paclitaxel , ||| 0-0 1-0 3-1 1-2 2-3 4-4
, die Paclitaxel auflösen ||| that dissolve the paclitaxel ||| 0-0 1-0 3-1 1-2 2-3
, die Pharmakovigilanzaktivitäten ||| to performing the ||| 0-0 1-0 2-1 1-2
, die Placebo erhielten ( ||| those receiving placebo ( ||| 1-0 3-0 3-1 2-2 4-3
, die Placebo erhielten ||| receiving placebo ||| 0-0 1-0 3-0 2-1
, die Placebo erhielten ||| those receiving placebo ||| 1-0 3-0 3-1 2-2
, die Umwelt zu schützen ||| to protect the environment ||| 0-0 1-0 2-1 3-1 3-2 4-3
, die Umwelt zu ||| to protect the ||| 0-0 1-0 2-1 3-1 3-2
, die anzeigt , ||| , which gives an indication ||| 0-0 0-1 1-1 2-2 1-3 2-4
, die anzeigt ||| , which gives an indication ||| 0-0 0-1 1-1 2-2 1-3 2-4
, die auf ||| on ||| 1-0 2-0
, die aus ||| , die aus ||| 0-0 1-1 2-2
, die bei 229 Patienten ||| related to 229 patients ||| 1-0 1-1 3-2 2-3 4-3
, die bereits ||| who ||| 0-0 1-0 2-0
, die den Blutdruck senken ||| to lower the blood pressure ||| 0-0 1-0 4-1 2-2 3-3 3-4 4-4
, die drei aktive ||| , which produces three active ||| 0-0 1-1 3-2 2-3 3-4
, die durch Diät und ||| inadequately controlled by diet and ||| 3-0 3-1 1-2 2-2 3-3 4-4
, die durch Diät ||| inadequately controlled by diet ||| 3-0 3-1 1-2 2-2 3-3
, die durch ||| by ||| 1-0 2-0
, die ein Gen ||| as naturally ||| 0-0 1-0 2-1 3-1
, die ein Jahr oder ||| of one year or ||| 1-0 2-1 3-1 3-2 4-3
, die ein Jahr oder ||| of one year or ||| 1-0 3-1 2-2 3-2 4-3
, die ein Jahr ||| of one year ||| 1-0 2-1 3-1 3-2
, die ein Jahr ||| of one year ||| 1-0 3-1 2-2 3-2
, die eine ||| a ||| 2-0
, die einmal wöchentlich ||| , given weekly ||| 0-0 3-1 2-2 3-2
, die im Pharmakovigilanzplan aufgeführten ||| activities detailed in the Pharmacovigilance ||| 1-0 3-0 0-1 3-1 2-2 1-3 2-4 3-4
, die im Pharmakovigilanzplan ||| activities detailed in the Pharmacovigilance ||| 1-0 3-0 0-1 3-1 2-2 1-3 2-4 3-4
, die initial auf die ||| who have shown an ||| 0-0 1-0 2-0 2-1 2-2 3-2 2-3 4-3
, die jedoch aus ||| , but made ||| 0-0 2-1 3-2
, die jedoch ||| , but ||| 0-0 2-1
, die jeweils ||| , each ||| 0-0 2-1
, die kürzlich ( ||| recent ( ||| 2-0 3-1
, die kürzlich ||| recent ||| 2-0
, die mit Abraxane behandelt ||| treated with Abraxane ||| 1-0 4-0 2-1 3-2
, die mit Abseamed behandelt ||| treated with Abseamed ||| 0-0 1-0 4-0 2-1 3-2
, die mit Haloperidol behandelt ||| treated with haloperidol ||| 1-0 4-0 2-1 3-2
, die mit depressiven Störungen ||| 4.3 and ||| 3-0 4-1
, die mit depressiven Störungen ||| section 4.3 and ||| 3-1 4-2
, die mit depressiven ||| 4.3 ||| 3-0
, die mit depressiven ||| section 4.3 ||| 3-1
, die mit einem Brombutyl-/Polyisopren-Gummistopfen ||| with a bromobutyl/ polyisoprene ||| 2-0 3-1 3-2 4-2 4-3
, die mit ||| with ||| 2-0
, die nicht notwendigerweise ||| , not necessarily in association ||| 0-0 2-1 1-2 3-2 3-3 3-4
, die noch nicht ||| insufficiency not yet ||| 1-0 2-0 3-1 2-2
, die normalerweise ||| which are normally ||| 1-0 2-0 2-1 2-2
, die sich einem größeren ||| scheduled for major elective ||| 0-0 4-0 1-1 2-2 4-2 3-3 4-3
, die tödlich enden kann ||| , which is potentially lethal ||| 0-0 1-1 2-1 2-2 2-3 2-4 3-4 4-4
, die wesentlich ||| , which ||| 0-0 1-1
, die zu einer mit ||| , micro-ophthalmia , ||| 0-0 4-1 0-2 3-2
, die zu ||| , ||| 0-0 1-0
, die zum Absetzen führten ||| resulting in discontinuation ||| 1-0 4-0 2-1 3-2
, die ||| ( the ||| 1-1
, die ||| , die ||| 0-0 1-1
, die ||| , that ||| 0-0 1-1
, die ||| , the ||| 0-0 1-1
, die ||| , which ||| 0-0 1-1
, die ||| , who ||| 0-0 1-1
, die ||| , ||| 0-0
, die ||| , ||| 0-0 1-0
, die ||| 58 The ||| 1-1
, die ||| 70 The ||| 1-1
, die ||| The ||| 1-0
, die ||| as ||| 0-0 1-0
, die ||| dose of ||| 1-0 1-1
, die ||| high risk from ||| 0-0
, die ||| high risk ||| 0-0
, die ||| high ||| 0-0
, die ||| of ||| 1-0
, die ||| related to ||| 1-0 1-1
, die ||| that of ||| 1-0
, die ||| that ||| 0-0 1-0
, die ||| that ||| 1-0
, die ||| the ||| 1-0
, die ||| to 15 ||| 1-0
, die ||| to ||| 0-0 1-0
, die ||| to ||| 1-0
, die ||| which ||| 0-0 1-0
, die ||| who ||| 0-0 1-0
, doch es bindet an ||| , but it attaches to ||| 0-0 1-1 2-2 3-3 4-4
, doch es bindet ||| , but it attaches ||| 0-0 1-1 2-2 3-3
, doch es ||| , but it ||| 0-0 1-1 2-2
, doch ||| , but ||| 0-0 1-1
, doppelblinden ||| randomised ||| 1-0
, ein Risiko darstellen . ||| hypoglycaemia whilst driving . ||| 3-0 1-1 2-1 3-1 3-2 4-3
, ein Risiko darstellen ||| hypoglycaemia whilst driving ||| 3-0 1-1 2-1 3-1 3-2
, ein erhöhtes ||| increased risk of ||| 1-0 2-0 2-1
, ein erhöhtes ||| increased risk ||| 1-0 2-0 2-1
, ein ||| , an ||| 0-0 1-1
, eine mittlere ||| a mean total ||| 1-0 2-1 2-2
, eine ||| , a ||| 0-0 1-1
, eine ||| a 0.69 ||| 1-0 0-1
, eine ||| a ||| 1-0
, einem hochwirksamen Induktor ||| , a potent inducer ||| 0-0 1-1 2-2 1-3 3-3
, einen geeichten ||| both a calibrated ||| 1-0 1-1 2-2
, einen ||| both a ||| 1-0 1-1
, einer kardiovaskulären ||| , a cardiovascular ||| 0-0 1-1 2-2
, einer regelmäßigen Kontrolle ||| undergo periodic ||| 1-0 2-0 2-1 3-1
, einer ||| , a ||| 0-0 1-1
, eines charakteristischen Kennzeichens für ||| , a known marker of ||| 0-0 1-1 2-2 2-3 3-3 1-4 4-4
, einschließlich ABILIFY , ||| , including ABILIFY , ||| 0-0 1-1 2-2 3-3
, einschließlich ABILIFY assoziiert worden ||| use , including ABILIFY ||| 4-0 0-1 1-2 3-2 4-2 2-3
, einschließlich ABILIFY ||| , including ABILIFY ||| 0-0 1-1 2-2
, einschließlich Einzelfällen von Angioödemen ||| including isolated cases of angioedema ||| 0-0 1-0 2-1 2-2 3-3 4-4
, einschließlich Einzelfällen von ||| including isolated cases of ||| 0-0 1-0 2-1 2-2 3-3
, einschließlich Einzelfällen ||| including isolated cases ||| 0-0 1-0 2-1 2-2
, einschließlich Zoledronsäure , ||| , including zoledronic acid ||| 0-0 3-0 1-1 2-2 2-3
, einschließlich bei Patienten mit ||| , including those with ||| 0-0 1-1 2-2 3-2 4-3
, einschließlich bei Patienten ||| , including those ||| 0-0 1-1 2-2 3-2
, einschließlich einer Dosisreduzierung , ||| , including dose reduction ||| 0-0 4-0 1-1 2-1 3-2 3-3
, einschließlich seltener Fälle von ||| including rare cases of ||| 0-0 1-0 2-1 3-2 4-3
, einschließlich seltener Fälle ||| including rare cases ||| 0-0 1-0 2-1 3-2
, einschließlich seltener ||| including rare ||| 0-0 1-0 2-1
, einschließlich ||| , including ||| 0-0 1-1
, einschließlich ||| including ||| 0-0 1-0
, endgültige Fassung ( ||| dated Final ( ||| 1-0 1-1 2-1 3-2
, endgültige Fassung ||| dated Final ||| 1-0 1-1 2-1
, entsprechend 16,8 Mikrogramm Epoetin ||| corresponding to 16.8 micrograms epoetin ||| 0-0 1-0 1-1 2-2 3-3 4-4
, entsprechend 16,8 Mikrogramm ||| corresponding to 16.8 micrograms ||| 0-0 1-0 1-1 2-2 3-3
, entsprechend 16,8 ||| corresponding to 16.8 ||| 0-0 1-0 1-1 2-2
, entsprechend 25,2 Mikrogramm Epoetin ||| corresponding to 25.2 micrograms epoetin ||| 0-0 1-0 1-1 2-2 3-3 4-4
, entsprechend 25,2 Mikrogramm ||| corresponding to 25.2 micrograms ||| 0-0 1-0 1-1 2-2 3-3
, entsprechend 25,2 ||| corresponding to 25.2 ||| 0-0 1-0 1-1 2-2
, entsprechend 33,6 Mikrogramm Epoetin ||| corresponding to 33.6 micrograms epoetin ||| 0-0 1-0 1-1 2-2 3-3 4-4
, entsprechend 33,6 Mikrogramm ||| corresponding to 33.6 micrograms ||| 0-0 1-0 1-1 2-2 3-3
, entsprechend 33,6 ||| corresponding to 33.6 ||| 0-0 1-0 1-1 2-2
, entsprechend 42,0 Mikrogramm Epoetin ||| corresponding to 42.0 micrograms epoetin ||| 0-0 1-0 1-1 2-2 3-3 4-4
, entsprechend 42,0 Mikrogramm ||| corresponding to 42.0 micrograms ||| 0-0 1-0 1-1 2-2 3-3
, entsprechend 42,0 ||| corresponding to 42.0 ||| 0-0 1-0 1-1 2-2
, entsprechend 5,330 mg ||| , corresponding to 5.330 mg ||| 0-0 1-1 1-2 2-3 3-4
, entsprechend 5,330 ||| , corresponding to 5.330 ||| 0-0 1-1 1-2 2-3
, entsprechend 50,4 Mikrogramm Epoetin ||| corresponding to 50.4 micrograms epoetin ||| 0-0 1-0 1-1 2-2 3-3 4-4
, entsprechend 50,4 Mikrogramm ||| corresponding to 50.4 micrograms ||| 0-0 1-0 1-1 2-2 3-3
, entsprechend 50,4 ||| corresponding to 50.4 ||| 0-0 1-0 1-1 2-2
, entsprechend 58,8 Mikrogramm Epoetin ||| corresponding to 58.8 micrograms epoetin ||| 0-0 1-0 1-1 2-2 3-3 4-4
, entsprechend 58,8 Mikrogramm ||| corresponding to 58.8 micrograms ||| 0-0 1-0 1-1 2-2 3-3
, entsprechend 58,8 ||| corresponding to 58.8 ||| 0-0 1-0 1-1 2-2
, entsprechend 67,2 Mikrogramm Epoetin ||| corresponding to 67.2 micrograms epoetin ||| 0-0 1-0 1-1 2-2 3-3 4-4
, entsprechend 67,2 Mikrogramm ||| corresponding to 67.2 micrograms ||| 0-0 1-0 1-1 2-2 3-3
, entsprechend 67,2 ||| corresponding to 67.2 ||| 0-0 1-0 1-1 2-2
, entsprechend 75,6 Mikrogramm Epoetin ||| corresponding to 75.6 micrograms epoetin ||| 0-0 1-0 1-1 2-2 3-3 4-4
, entsprechend 75,6 Mikrogramm ||| corresponding to 75.6 micrograms ||| 0-0 1-0 1-1 2-2 3-3
, entsprechend 75,6 ||| corresponding to 75.6 ||| 0-0 1-0 1-1 2-2
, entsprechend 8,4 Mikrogramm Epoetin ||| corresponding to 8.4 micrograms epoetin ||| 0-0 1-0 1-1 2-2 3-3 4-4
, entsprechend 8,4 Mikrogramm ||| corresponding to 8.4 micrograms ||| 0-0 1-0 1-1 2-2 3-3
, entsprechend 8,4 ||| corresponding to 8.4 ||| 0-0 1-0 1-1 2-2
, entsprechend 84,0 Mikrogramm Epoetin ||| corresponding to 84.0 micrograms epoetin ||| 0-0 1-0 1-1 2-2 3-3 4-4
, entsprechend 84,0 Mikrogramm ||| corresponding to 84.0 micrograms ||| 0-0 1-0 1-1 2-2 3-3
, entsprechend 84,0 ||| corresponding to 84.0 ||| 0-0 1-0 1-1 2-2
, entsprechend ||| , corresponding to ||| 0-0 1-1 1-2
, entsprechend ||| corresponding to ||| 0-0 1-0 1-1
, entwickelte ||| experienced the development ||| 1-0 1-2
, ergab keine medizinisch bedeutsamen ||| revealed no medically important ||| 1-0 2-1 3-2 4-3
, ergab keine medizinisch ||| revealed no medically ||| 1-0 2-1 3-2
, ergab keine ||| revealed no ||| 1-0 2-1
, ergab ||| revealed ||| 1-0
, erhalten Sie ||| appropriate you will receive ||| 0-0 0-1 2-1 1-2 1-3
, erhöhen das Risiko von ||| , increase the risk of ||| 0-0 1-1 2-2 2-3 3-3 4-4
, erhöhen das Risiko ||| , increase the risk ||| 0-0 1-1 2-2 2-3 3-3
, erhöhen ||| , increase ||| 0-0 1-1
, erhöht ||| increased ||| 1-0
, erhöhte Alanin-Aminotransferase ( ||| , increased Alanine Aminotransferase ( ||| 0-0 1-1 1-2 2-2 2-3 3-4
, erhöhte Alanin-Aminotransferase ||| , increased Alanine Aminotransferase ||| 0-0 1-1 1-2 2-2 2-3
, erhöhte Aspartat-Aminotransferase ( ||| , increased Aspartate Aminotransferase ( ||| 0-0 1-1 1-2 2-2 2-3 3-4
, erhöhte Aspartat-Aminotransferase ||| , increased Aspartate Aminotransferase ||| 0-0 1-1 1-2 2-2 2-3
, erhöhte Gamma- Glutamyl-Transferase ||| , increased Gamma Glutamyl Transferase ||| 0-0 1-1 2-2 3-3 3-4
, erhöhte Gamma- ||| , increased Gamma ||| 0-0 1-1 2-2
, erhöhte alkalische Phosphatase ||| , increased alkaline phosphatase ||| 0-0 1-1 2-2 3-3
, erhöhte alkalische ||| , increased alkaline ||| 0-0 1-1 2-2
, erhöhte ||| , increased ||| 0-0 1-1
, erhöhtes Risiko ||| , increased risk of ||| 0-0 1-1 2-2
, erhöhtes Risiko ||| , increased risk ||| 0-0 1-1 2-2
, erhöhtes ||| , increased ||| 0-0 1-1
, es sei denn , ||| unless ||| 1-0 2-0 3-0
, es sei denn ||| unless ||| 1-0 2-0 3-0
, evaluiert . ||| . ||| 1-0 2-0
, falls erforderlich ||| , if necessary ||| 0-0 1-1 2-2
, falls ||| , if ||| 0-0 1-1
, farblose , wässrige Lösung ||| , colourless , aqueous solution ||| 0-0 1-1 2-2 3-3 4-4
, farblose , wässrige ||| , colourless , aqueous ||| 0-0 1-1 2-2 3-3
, farblose , ||| , colourless , ||| 0-0 1-1 2-2
, farblose Injektionslösung ||| , colourless solution for injection ||| 0-0 1-1 1-2 2-3 2-4
, farblose ||| , colourless solution ||| 0-0 1-1 1-2
, farblose ||| , colourless ||| 0-0 1-1
, fragen Sie Ihren ||| this product , ask your ||| 1-0 1-1 0-2 1-3 2-3 3-4
, fragen Sie ||| this product , ask ||| 1-0 1-1 0-2 1-3 2-3
, für ||| for ||| 1-0
, gab es keine ||| , there were no ||| 0-0 1-1 2-1 1-2 3-3
, gab es ||| , there were ||| 0-0 1-1 2-1 1-2
, geben ||| , give ||| 0-0 1-1
, gefolgt von ||| , followed by ||| 0-0 1-1 2-1 1-2
, gegeben als intravenöse ||| administered intravenously ||| 1-0 2-0 3-0 1-1
, gegenüber den ||| to ||| 1-0 2-0
, gereinigtes Wasser und ||| , purified water , and ||| 0-0 0-1 2-2 0-3 1-3 3-4
, gereinigtes Wasser ||| , purified water , ||| 0-0 0-1 2-2 0-3 1-3
, grippeähnliche ||| , ||| 0-0 1-0
, gut und ||| was well ||| 1-1
, gut und ||| well ||| 1-0
, gut vertragen ||| well tolerated in ||| 1-0 2-1
, gut vertragen ||| well tolerated ||| 1-0 2-1
, gut ||| was well ||| 1-1
, gut ||| well ||| 1-0
, hatte aber keine Auswirkung ||| , but had no effect ||| 0-0 2-1 1-2 3-3 4-4
, hatte aber keine ||| , but had no ||| 0-0 2-1 1-2 3-3
, hatte aber ||| , but had ||| 0-0 2-1 1-2
, hauptsächlich Albumin , gebunden ||| , binding primarily to albumin ||| 0-0 3-0 2-1 1-2 4-3 2-4 4-4
, häufiger jedoch , 22 ||| , but more frequently ||| 0-0 3-0 4-0 2-1 1-2 1-3
, häufiger jedoch , 35 ||| , but more frequently ||| 0-0 3-0 2-1 1-2 1-3
, häufiger jedoch , wenn ||| , but more frequently when ||| 0-0 3-0 2-1 1-2 1-3 4-4
, häufiger jedoch , ||| , but more frequently ||| 0-0 3-0 2-1 1-2 1-3
, idealerweise bereits bevor die ||| , ideally starting before the ||| 0-0 1-1 2-1 3-3 4-4
, idealerweise bereits bevor ||| , ideally starting before ||| 0-0 1-1 2-1 3-3
, idealerweise bereits ||| , ideally starting ||| 0-0 1-1 2-1
, idealerweise bereits ||| , ideally ||| 0-0 1-1 2-1
, im Vergleich zu ||| , compared ||| 0-0 1-1 2-1 3-1
, im Vergleich zu ||| as compared to ||| 0-0 2-0 1-1 2-1 3-2
, im Vergleich ||| as compared ||| 0-0 2-0 1-1 2-1
, im ||| in patients ||| 0-0 1-0 0-1
, in beiden Gruppen ||| in both groups ||| 1-0 2-1 3-2
, in beiden Gruppen ähnlich ||| similar in both groups ||| 4-0 1-1 2-2 3-3 4-3
, in beiden ||| in both ||| 1-0 2-1
, in denen Midazolam ( ||| , in denen Midazolam ( ||| 0-0 1-1 3-2 3-3 4-4
, in denen Midazolam ||| , in denen Midazolam ||| 0-0 1-1 3-2 3-3
, in denen Pioglitazon mit ||| in which pioglitazone was ||| 1-0 0-1 2-1 3-2 3-3 4-3
, in denen ||| , in ||| 0-0 1-1
, in denen ||| in which ||| 1-0 0-1 2-1
, in der die Pharmakokinetik ||| the pharmacokinetics ||| 1-0 2-0 3-0 4-1
, in der die ||| the ||| 1-0 2-0 3-0
, in der ||| , where prophylaxis against ||| 0-0 1-1
, in der ||| , where prophylaxis ||| 0-0 1-1
, in der ||| , where ||| 0-0 1-1
, in einigen Fällen ||| , in some cases ||| 0-0 1-1 2-2 3-3
, in einigen ||| , in some ||| 0-0 1-1 2-2
, in ||| , in ||| 0-0 1-1
, in ||| , where prophylaxis against ||| 0-0 1-1
, in ||| , where prophylaxis ||| 0-0 1-1
, in ||| , where ||| 0-0 1-1
, in ||| , ||| 0-0
, in ||| in ||| 1-0
, in ||| looking at ||| 0-0 1-1
, indem Sie die ||| by pinching the ||| 1-0 1-1 2-1 3-2
, indem Sie ||| by pinching ||| 1-0 1-1 2-1
, indem ||| by ||| 1-0
, induzierte ||| shown to ||| 1-0
, induzierte ||| shown ||| 1-0
, informieren Sie Ihren Arzt ||| , tell your doctor ||| 0-0 1-1 2-2 3-2 3-3 4-3
, informieren Sie bitte Ihren ||| , inform your ||| 0-0 1-1 2-1 3-1 4-2
, informieren Sie bitte Ihren ||| , please tell your ||| 0-0 2-1 3-1 1-2 3-2 4-3
, informieren Sie bitte ||| , inform ||| 0-0 1-1 2-1 3-1
, informieren Sie bitte ||| , please tell ||| 0-0 2-1 3-1 1-2 3-2
, informieren ||| , tell ||| 0-0 1-1
, inklusive PANSS und die ||| , including PANSS and the ||| 0-0 1-1 1-2 2-2 3-3 4-4
, inklusive PANSS und ||| , including PANSS and ||| 0-0 1-1 1-2 2-2 3-3
, inklusive PANSS ||| , including PANSS ||| 0-0 1-1 1-2 2-2
, insbesondere Infektionen und ||| , especially infections and ||| 0-0 1-1 2-2 3-3
, insbesondere Infektionen ||| , especially infections ||| 0-0 1-1 2-2
, insbesondere der mit ||| , especially those ||| 0-0 1-1 3-2
, insbesondere der ||| , especially ||| 0-0 1-1
, insbesondere wenn ||| , particularly if ||| 0-0 1-1 2-2
, insbesondere ||| , especially ||| 0-0 1-1
, insbesondere ||| , particularly ||| 0-0 1-1
, insbesondere ||| particularly ||| 1-0
, intermediär wirkend kombiniert mit ||| , intermediate-acting combined with ||| 0-0 1-1 2-1 3-2 4-3
, intermediär wirkend kombiniert ||| , intermediate-acting combined ||| 0-0 1-1 2-1 3-2
, intermediär wirkend ||| , intermediate-acting ||| 0-0 1-1 2-1
, intestinale Kalzium-Malabsorption ) ||| , intestinal calcium malabsorption ) ||| 0-0 1-1 1-2 2-3 3-4
, intestinale Kalzium-Malabsorption ||| , intestinal calcium malabsorption ||| 0-0 1-1 1-2 2-3
, intestinale ||| , intestinal calcium ||| 0-0 1-1 1-2
, ist die Behandlung ||| , the treatment ||| 0-0 2-1 1-2 3-2
, ist die Therapie abzusetzen ||| , therapy should be discontinued ||| 0-0 1-1 2-1 3-1 4-2 4-3 4-4
, ist die Therapie ||| , therapy ||| 0-0 1-1 2-1 3-1
, ist ein Bisphosphonat . ||| , is a bisphosphonate . ||| 0-0 1-1 2-2 3-3 4-4
, ist ein Bisphosphonat ||| , is a bisphosphonate ||| 0-0 1-1 2-2 3-3
, ist ein sogenanntes Antipsychotikum ||| , is an antipsychotic medicine ||| 0-0 1-1 2-2 3-3 4-3 3-4
, ist ein ||| , is a ||| 0-0 1-1 2-2
, ist ein ||| , is an ||| 0-0 1-1 2-2
, ist es ||| , it is ||| 0-0 2-1 1-2
, ist ||| , is ||| 0-0 1-1
, ist ||| , ||| 0-0
, ist ||| baseline body weight after ||| 1-0 0-1 1-2
, ist ||| baseline body weight ||| 1-0 0-1 1-2
, ist ||| is ||| 1-0
, jedoch ist dies in ||| , but this is ||| 0-0 1-1 3-2 4-2 2-3
, jedoch keine anderen ||| osteoporosis , but not other ||| 0-0 0-1 1-2 2-3 3-4
, jedoch keine ||| osteoporosis , but not ||| 0-0 0-1 1-2 2-3
, jedoch ||| , but ||| 0-0 1-1
, jedoch ||| but ||| 0-0 1-0
, jedoch ||| osteoporosis , but ||| 0-0 0-1 1-2
, jeweils mit subkutaner Applikation ||| , both via subcutaneous administration ||| 0-0 1-0 3-3 4-4
, jeweils mit subkutaner ||| , both via subcutaneous ||| 0-0 1-0 3-3
, jeweils mit ||| , both via ||| 0-0 1-0
, jeweils mit ||| , both ||| 0-0 1-0
, jeweils mit ||| , ||| 0-0 1-0
, jeweils ||| , both via ||| 0-0 1-0
, jeweils ||| , both ||| 0-0 1-0
, jeweils ||| , ||| 0-0 1-0
, kann die Dosis ||| , the dose may ||| 0-0 2-1 3-2 1-3
, kann diese ||| , it may ||| 0-0 2-1 1-2
, klinischen ||| clinical ||| 1-0
, konnte das ||| , ||| 0-0
, konnte das ||| study , ||| 0-1
, konnte ein Kausalzusammenhang jedoch ||| , causal relationship has ||| 0-0 1-1 2-1 3-1 3-2 4-2 3-3
, konnte ||| , ||| 0-0
, konnte ||| study , ||| 0-1
, kontaktieren ||| , contact ||| 0-0 1-1
, kontrollierten , doppelblinden ||| randomised , controlled , ||| 3-0 2-1 1-2 2-3
, kontrollierten , ||| , controlled , ||| 2-0 1-1 2-2
, kontrollierten , ||| controlled ||| 1-0
, kontrollierten ||| , controlled ||| 1-1
, kontrollierten ||| controlled ||| 1-0
, können auftreten . ||| may occur . ||| 1-0 2-1 3-2
, können auftreten ||| may occur ||| 1-0 2-1
, können die ||| , may ||| 0-0 1-1
, können ||| , may ||| 0-0 1-1
, können ||| may ||| 1-0
, lang wirkendes Insulin ||| , long-acting insulin ||| 0-0 1-1 2-1 3-2
, lang wirkendes ||| , long-acting ||| 0-0 1-1 2-1
, lesen Sie bitte die ||| , read the ||| 0-0 1-1 2-1 3-1 4-2
, lesen Sie bitte ||| , read ||| 0-0 1-1 2-1 3-1
, lesen Sie ||| , lesen Sie bitte ||| 0-0 1-1 2-2 1-3
, lesen Sie ||| , read ||| 0-0 1-1 2-1
, mediane Zeit bis zum ||| , median time to ||| 0-0 1-1 3-1 2-2 4-2 3-3
, migräneartige Kopfschmerzen ||| headaches as a ||| 1-0 2-0 0-1 1-1 1-2
, migräneartige Kopfschmerzen ||| like headaches as ||| 0-0 1-0 1-1 2-1 1-2
, mikrokristalline ||| , microcrystalline ||| 0-0 1-1
, mit Prägung von A-007 ||| , marked with A-007 ||| 0-0 2-1 1-2 3-2 4-3
, mit Prägung von A-008 ||| , marked with A-008 ||| 0-0 2-1 1-2 3-2 4-3
, mit Prägung von A-009 ||| , marked with A-009 ||| 0-0 2-1 1-2 3-2 4-3
, mit Prägung von A-011 ||| , marked with A-011 ||| 0-0 2-1 1-2 3-2 4-3
, mit Prägung von ||| , marked with ||| 0-0 2-1 1-2
, mit Prägung von ||| , marked with ||| 0-0 2-1 1-2 3-2
, mit Prägung ||| , marked with ||| 0-0 2-1 1-2
, mit der Prägung " ||| , engraved with " ||| 0-0 2-1 3-1 1-2 4-3
, mit der Prägung " ||| , marked with " ||| 0-0 2-1 3-1 1-2 4-3
, mit der Prägung ||| , engraved with ||| 0-0 2-1 3-1 1-2
, mit der Prägung ||| , marked with ||| 0-0 2-1 3-1 1-2
, mit einer ||| , with an ||| 0-0 1-1 2-2
, mit oder ||| , with or ||| 0-0 1-1 2-2
, mit ||| , with ||| 0-0 1-1
, muss das Arzneimittel ||| has to be ||| 1-0 2-1 3-1 1-2
, müssen sorgfältig ||| should be carefully ||| 1-0 1-1 2-2
, müssen sorgfältig überwacht werden ||| should be carefully monitored ||| 1-0 1-1 2-2 3-3 4-3
, müssen ||| should be ||| 1-0 1-1
, nachdem Sie ||| you ||| 2-0
, nehmen Sie die ||| , take the ||| 0-0 1-1 2-1 3-2
, nehmen Sie ||| , take ||| 0-0 1-1 2-1
, neuropathische Schmerzen , Tremor ||| , neuropathic pain , tremor ||| 0-0 1-1 2-2 3-3 4-4
, neuropathische Schmerzen , ||| , neuropathic pain , ||| 0-0 1-1 2-2 3-3
, neuropathische Schmerzen ||| , neuropathic pain ||| 0-0 1-1 2-2
, neuropathische ||| , neuropathic ||| 0-0 1-1
, ng Ischialgie , Parästhesie ||| lon Hypoaesthesia Sciatica Paresthesia ||| 1-0 0-1 1-1 2-1 2-2 3-2 4-3
, ng Ischialgie , ||| lon Hypoaesthesia Sciatica ||| 1-0 0-1 1-1 2-1 2-2 3-2
, nicht jedoch bei Affen ||| , but not in monkeys ||| 0-0 2-1 1-2 3-3 4-4
, nicht jedoch bei ||| , but not in ||| 0-0 2-1 1-2 3-3
, nicht jedoch ||| , but not ||| 0-0 2-1 1-2
, nicht ||| not ||| 1-0
, nichtselektive Betarezeptorenblocker ||| , non-selective beta- blocking agents ||| 0-0 1-1 1-2 1-3 2-3 2-4
, nimmt mit den nachfolgenden ||| decreases with subsequent doses ||| 2-1 1-2 3-2 4-2
, nimmt mit den nachfolgenden ||| decreases with subsequent ||| 2-1 1-2 3-2 4-2
, nimmt mit den nachfolgenden ||| with subsequent doses ||| 2-0 1-1 3-1 4-1
, nimmt mit den nachfolgenden ||| with subsequent ||| 2-0 1-1 3-1 4-1
, ob Paclitaxel ||| if paclitaxel ||| 0-0 1-0 2-1
, ob Pioglitazon ||| whether pioglitazone ||| 0-0 1-0 2-1
, ob Zoledronsäure ||| whether zoledronic acid ||| 0-0 1-0 2-1 2-2
, ob das Führen ||| considered ||| 1-0 2-0 3-0
, ob die ||| whether to ||| 0-0 1-0 2-1
, ob es ||| whether or not there ||| 0-0 1-0 2-2 2-3
, ob ||| if ||| 0-0 1-0
, ob ||| whether or ||| 0-0 1-0
, ob ||| whether ||| 0-0 1-0
, obwohl ||| , although ||| 0-0 1-1
, oder wenn Sie ||| , or if you are ||| 0-0 1-1 2-2 3-3 2-4
, oder wenn ||| , or if ||| 0-0 1-1 2-2
, oder ||| , or ||| 0-0 1-1
, oder ||| or ||| 1-0
, offenen Studien wurden 2697 ||| , open-label studies , 2697 ||| 0-0 1-1 2-2 0-3 3-4 4-4
, offenen Studien ||| , open-label studies , ||| 0-0 1-1 2-2 0-3
, ohne ||| without ||| 1-0
, orthostatische Hypotonie Selten : ||| , orthostatic hypotension Rare : ||| 0-0 1-1 2-2 3-3 4-4
, orthostatische Hypotonie Selten ||| , orthostatic hypotension Rare ||| 0-0 1-1 2-2 3-3
, orthostatische Hypotonie ||| , orthostatic hypotension ||| 0-0 1-1 2-2
, orthostatische ||| , orthostatic ||| 0-0 1-1
, p < 0,001 ) ||| in patients who received dic ||| 2-1 0-2 4-3 3-4
, p < 0,001 ) ||| patients who received dic ||| 2-0 0-1 4-2 3-3
, p < ||| in patients who ||| 2-1 0-2
, p < ||| patients who ||| 2-0 0-1
, p ||| who ||| 0-0
, palmar-plantare Erythrodysästhesie gemeldet ||| continuing surveillance of ||| 0-0 1-0 1-1 2-1 3-2
, palmar-plantare Erythrodysästhesie ||| continuing surveillance ||| 0-0 1-0 1-1 2-1
, periphere Kälte , orthostatische ||| , peripheral coldness , orthostatic ||| 0-0 1-1 2-2 3-3 4-4
, periphere Kälte , ||| , peripheral coldness , ||| 0-0 1-1 2-2 3-3
, periphere Kälte ||| , peripheral coldness ||| 0-0 1-1 2-2
, periphere motorische Neuropathie , ||| , peripheral motor neuropathy , ||| 0-0 1-1 2-2 3-3 4-4
, periphere motorische Neuropathie ||| , peripheral motor neuropathy ||| 0-0 1-1 2-2 3-3
, periphere motorische ||| , peripheral motor ||| 0-0 1-1 2-2
, periphere ||| , peripheral ||| 0-0 1-1
, periphere Ödeme ||| , peripheral oedema ||| 0-0 1-1 2-2
, placebokontrollierten Studie , die ||| , placebo-controlled trial ||| 0-0 3-0 1-1 2-2
, placebokontrollierten Studie , ||| , placebo-controlled trial ||| 0-0 3-0 1-1 2-2
, plötzlicher unerklärbarer Tod , ||| , sudden unexplained death , ||| 0-0 4-0 1-1 2-2 3-3 4-4
, plötzlicher unerklärbarer ||| , sudden unexplained ||| 0-0 1-1 2-2
, plötzlicher ||| , sudden ||| 0-0 1-1
, polyzythämische Mäuse ) . ||| , polycythaemic mice ) . ||| 0-0 1-1 2-1 2-2 3-3 4-4
, polyzythämische Mäuse ) ||| , polycythaemic mice ) ||| 0-0 1-1 2-1 2-2 3-3
, polyzythämische Mäuse ||| , polycythaemic mice ||| 0-0 1-1 2-1 2-2
, posturaler Schwindel , neuropathische ||| , postural dizziness , neuropathic ||| 0-0 1-1 2-2 3-3 4-4
, posturaler Schwindel , ||| , postural dizziness , ||| 0-0 1-1 2-2 3-3
, posturaler Schwindel ||| , postural dizziness ||| 0-0 1-1 2-2
, posturaler ||| , postural ||| 0-0 1-1
, r-DNS ( gentechnisch hergestellt ||| , rDNA ( produced by ||| 0-0 1-1 2-2 3-3 4-3 4-4
, r-DNS ( ||| , rDNA ( ||| 0-0 1-1 2-2
, r-DNS ||| , rDNA ||| 0-0 1-1
, randomisierten , doppelblinden ||| , randomised , double-blind ||| 0-0 1-1 3-1 2-2 3-3
, reduzierte Sehschärfe , ||| , reduced visual acuity , ||| 0-0 1-1 2-2 2-3 3-4
, reduzierte Sehschärfe ||| , reduced visual acuity ||| 0-0 1-1 2-2 2-3
, reduzierte ||| , reduced ||| 0-0 1-1
, richtet sich nach Ihrem ||| is based on your ||| 2-0 0-1 1-1 2-2 2-3 3-3 4-3
, richtet ||| based ||| 0-0 1-0
, runden Tabletten enthalten 15 ||| , round tablets contain 15 ||| 0-0 1-1 2-2 3-3 4-4
, runden Tabletten enthalten ||| , round tablets contain ||| 0-0 1-1 2-2 3-3
, runden Tabletten ||| , round tablets ||| 0-0 1-1 2-2
, runden ||| , round ||| 0-0 1-1
, schmerzendes Zahnfleisch ||| , ||| 0-0 1-0 2-0
, schwanger zu werden . ||| plan to become pregnant . ||| 1-0 0-1 2-1 1-2 3-2 1-3 4-4
, schwanger zu werden ||| plan to become pregnant ||| 1-0 0-1 2-1 1-2 3-2 1-3
, schwere Gewichtsabnahme , ||| , severe weight loss , ||| 0-0 1-1 2-2 3-3 3-4
, schwere Gewichtsabnahme ||| , severe weight ||| 0-0 1-1 2-2
, schwere ||| , severe ||| 0-0 1-1
, sehr schnellem Sprechen ||| usual , talking very ||| 3-0 0-1 2-2 3-2 1-3
, sensorische Störung , Somnolenz ||| , sensory disturbance , somnolence ||| 0-0 1-1 3-2 3-3 2-4 4-4
, sensorische ||| , sensory ||| 0-0 1-1
, setzen Sie sich bitte ||| , please contact ||| 0-0 1-1 1-2 2-2 3-2 4-2
, setzen Sie sich bitte ||| , please contact ||| 0-0 1-1 2-1 1-2 3-2 4-2
, setzen Sie sich bitte ||| please contact ||| 0-0 1-0 1-1 2-1 3-1 4-1
, sich etwas anzutun . ||| about hurting yourself . ||| 3-0 1-1 2-1 3-1 3-2 4-3
, sich etwas anzutun ||| about hurting yourself ||| 3-0 1-1 2-1 3-1 3-2
, sich strikt an ||| to adhere strictly ||| 0-0 1-0 1-1 2-1 2-2 3-2
, sie tritt aber sehr ||| but its occurrence is very ||| 0-0 1-0 3-0 2-1 2-2 3-2 4-3 4-4
, sie tritt aber ||| but its occurrence ||| 0-0 1-0 3-0 2-1 2-2 3-2
, siehe Abschnitt 4.5 . ||| , see section 4.5 . ||| 0-0 1-1 2-2 3-3 4-4
, siehe Abschnitt 4.5 ||| , see section 4.5 ||| 0-0 1-1 2-2 3-3
, siehe Abschnitt ||| , see section ||| 0-0 1-1 2-2
, siehe die ||| , see the ||| 0-0 1-1 2-2
, siehe ||| , see ||| 0-0 1-1
, sind die Leberenzymwerte so ||| , liver enzyme levels should ||| 0-0 1-1 3-1 3-2 4-2 2-3 3-3 3-4
, sind unten dargelegt . ||| , are shown below . ||| 0-0 1-1 2-3 3-3 4-4
, sind unten dargelegt ||| , are shown below ||| 0-0 1-1 2-3 3-3
, sind ||| , are shown ||| 0-0 1-1
, sind ||| , are ||| 0-0 1-1
, so ||| , ||| 0-0 1-0
, sobald ||| as soon as ||| 0-0 1-0 1-1 1-2
, sofern erforderlich ||| , if applicable ||| 0-0 1-1 1-2 2-2
, sollte die Aripiprazol-Dosis ||| , the aripiprazole dose should ||| 0-0 2-1 3-2 3-3 1-4
, sollte die Dosis von ||| the dose should ||| 2-0 3-1 4-1 1-2
, sollte die Dosis ||| , the dose should ||| 0-0 2-1 3-2 1-3
, sollte ||| should be ||| 1-0 1-1
, sollte ||| should ||| 1-0
, sollten wegen ||| should be ||| 1-0 1-1 2-1
, sollten ||| , ||| 0-0 1-0
, sollten ||| should ||| 1-0
, sollten ||| treated with antidepressants , ||| 0-0 1-0 1-2 0-3
, sowie ||| and ||| 1-0
, sowie ähnliches Material ||| , and ||| 0-0 2-0 3-0 1-1
, spiegelten Differenzen in ||| reflected differences in ||| 1-0 2-0 1-1 3-2
, spiegelten Differenzen ||| reflected differences ||| 1-0 2-0 1-1
, sterilen ||| , sterile , ||| 0-0 1-1 0-2
, süßen oder fettreichen ||| highly palatable , sweet or ||| 1-0 1-1 0-2 3-3 2-4
, süßen ||| highly palatable , ||| 1-0 1-1 0-2
, teilen ||| Tell ||| 1-0
, tiefe venöse Thrombosen , ||| , deep vein thrombosis , ||| 0-0 1-1 1-2 2-3 3-3 4-4
, tiefe venöse Thrombosen ||| , deep vein thrombosis ||| 0-0 1-1 1-2 2-3 3-3
, tiefe ||| , deep vein ||| 0-0 1-1 1-2
, trockene Nase , Keuchen ||| , nasal dryness , wheezing ||| 0-0 1-1 2-1 2-2 4-2 3-3 4-4
, trockener Mund ||| , dry mouth ||| 0-0 1-0 0-1 2-2
, trockener Mund ||| , pruritus , erythema ||| 0-0 1-1 0-2 1-3 2-3
, trockener ||| , dry ||| 0-0 1-0 0-1
, tropfenförmigen Tabletten erhältlich . ||| , teardrop- shaped tablets . ||| 0-0 1-1 1-2 3-2 2-3 4-4
, tropfenförmigen Tabletten erhältlich ||| , teardrop- shaped tablets ||| 0-0 1-1 1-2 3-2 2-3
, um Harnstoff , Kreatinin ||| to maintain urea , creatinine ||| 0-0 1-0 1-1 2-1 2-2 3-3 4-4
, um Harnstoff , ||| to maintain urea , ||| 0-0 1-0 1-1 2-1 2-2 3-3
, um Harnstoff ||| to maintain urea ||| 0-0 1-0 1-1 2-1 2-2
, um Rückschlüsse ||| draw conclusions regarding ||| 1-0 1-1 2-2
, um das Risiko einer ||| to minimise the risk of ||| 1-0 1-1 2-1 3-1 2-2 3-3 4-4
, um das Risiko ||| accordingly to minimise the risk ||| 1-1 1-2 2-2 3-2 2-3 3-4
, um das Risiko ||| to minimise the risk ||| 1-0 1-1 2-1 3-1 2-2 3-3
, um den Inhalt ||| in order ||| 0-0 1-0 1-1 2-1 3-1
, um die Tablette freizulegen ||| to expose the tablet ||| 0-0 1-0 1-1 4-1 2-2 3-3
, um mikrobielle ||| in order to avoid microbial ||| 1-0 1-1 0-2 1-2 2-3 2-4
, um sicherzustellen , dass ||| to ensure that ||| 0-0 1-0 1-1 2-1 3-2 4-2
, um sicherzustellen ||| to ensure ||| 0-0 1-0 1-1 2-1
, um ||| draw conclusions ||| 1-0 1-1
, um ||| in order to ||| 1-0 1-1 0-2 1-2
, um ||| in order ||| 1-0 1-1
, und Dosierungen ||| , and doses ||| 0-0 1-1 2-2
, und Dosierungen über 45 ||| , and doses above 45 ||| 0-0 1-1 2-2 3-3 4-4
, und Dosierungen über ||| , and doses above ||| 0-0 1-1 2-2 3-3
, und Vantas ||| , and Vantas ||| 0-0 1-1 2-2
, und der mediane Zeitpunkt ||| and the median ||| 1-0 2-1 4-1 3-2
, und die Mehrzahl ||| , and the majority ||| 0-0 1-1 2-2 3-3
, und die ||| , and the ||| 0-0 1-1 2-2
, und eine negative Auswirkung ||| and a negative impact ||| 1-0 2-1 3-2 4-3
, und eine negative ||| and a negative ||| 1-0 2-1 3-2
, und eine ||| and a ||| 1-0 2-1
, und sie ||| , und ||| 0-0 1-1
, und ||| , and ||| 0-0 1-1
, und ||| , und ||| 0-0 1-1
, und ||| , which showed a ||| 0-0 0-1
, und ||| , which showed ||| 0-0 0-1
, und ||| , which ||| 0-0 0-1
, und ||| , ||| 0-0
, und ||| and its ||| 1-0 0-1
, und ||| and ||| 1-0
, unterstützen ||| of sugar ||| 0-1 1-1
, unterstützen ||| sugar ||| 0-0 1-0
, untersucht . ||| . ||| 1-0 2-0
, unzusammenhängende Sprache , ||| , incoherent speech ||| 0-0 3-0 1-1 2-1 2-2
, vaskuläre Ereignisse wie ||| vascular events , such as ||| 1-0 2-1 0-2 3-3 3-4
, vaskuläre Ereignisse ||| vascular events , ||| 1-0 2-1 0-2
, ventrikuläre Arrhythmien , plötzlicher ||| , ventricular arrhythmias , sudden ||| 0-0 1-1 2-2 3-3 4-4
, ventrikuläre Arrhythmien , ||| , ventricular arrhythmias , ||| 0-0 1-1 2-2 3-3
, ventrikuläre Arrhythmien ||| , ventricular arrhythmias ||| 0-0 1-1 2-2
, ventrikuläre ||| , ventricular ||| 0-0 1-1
, verglichen . ||| . ||| 2-0
, verglichen mit ||| compared ||| 1-0
, verglichen ||| compared to ||| 1-0 0-1 1-1
, verglichen ||| compared to ||| 1-0 1-1
, verglichen ||| compared ||| 1-0
, verringerte sich ||| , decreased by ||| 0-0 1-1 2-1 1-2
, verringertem ||| , ||| 1-0
, verringerter ||| of ||| 1-0
, verschlechterter Allgemeinzustand ||| , decreased performance ||| 0-0 1-0 0-1 2-2
, verschlechterter ||| , decreased ||| 0-0 1-0 0-1
, verschwommene Sicht , ||| , blurred vision , ||| 0-0 1-1 1-2 2-3 3-3
, verschwommene ||| , blurred vision ||| 0-0 1-1 1-2
, versiegelt in einer Blisterpackung ||| sealed in a blister ||| 0-0 1-0 2-1 3-2 4-3
, versiegelt in einer ||| sealed in a ||| 0-0 1-0 2-1 3-2
, versiegelt in ||| sealed in ||| 0-0 1-0 2-1
, versiegelt ||| sealed ||| 0-0 1-0
, verteilt auf ||| per week ||| 1-0 1-1 2-1
, verwenden . ||| system . lp ||| 1-0 2-1 1-2
, vor ||| , cases ||| 0-0
, vor ||| , ||| 0-0
, vor ||| to ||| 1-0
, vorübergehende ||| , flushing ||| 0-0 1-0 0-1
, war niedriger in einer ||| was lower in a smaller ||| 1-0 2-1 3-2 4-3 0-4
, war ||| was ||| 1-0
, waren : Übelkeit , ||| were : nausea , ||| 1-0 2-1 3-2 0-3 4-3
, was auf eine weitreichende ||| , indicating extensive ||| 0-0 1-1 2-1 1-2 4-2
, was das ||| , which ||| 0-0 1-1 2-1
, was ||| , however ||| 0-0 1-1
, was ||| , which ||| 0-0 1-1
, weil ||| direct- acting ||| 1-0
, weil ||| direct- ||| 1-0
, welche Art von Futter ||| on the type of food ||| 2-2 1-3 3-3 4-4
, welche Art von Futter ||| the type of food ||| 2-1 1-2 3-2 4-3
, welche Art von Futter ||| type of food ||| 2-0 1-1 3-1 4-2
, welche Art von ||| on the type of ||| 2-2 1-3 3-3
, welche Art von ||| the type of ||| 2-1 1-2 3-2
, welche Art von ||| type of ||| 2-0 1-1 3-1
, welche die Wirksamkeit von ||| to increase the effectiveness of ||| 0-0 1-0 2-1 2-2 3-3 4-4
, welche die Wirksamkeit ||| to increase the effectiveness ||| 0-0 1-0 2-1 2-2 3-3
, welche die ||| to increase the ||| 0-0 1-0 2-1 2-2
, welche ||| to ||| 0-0 1-0
, welcher eine Erholung von ||| that permitted recovery from ||| 0-0 3-1 4-2 4-3
, welcher eine Erholung ||| that permitted ||| 0-0 3-1
, welcher eine ||| that ||| 0-0
, welcher ||| that ||| 0-0
, wenden Sie sich an ||| questions , ask ||| 1-0 0-1 1-2 2-2 3-2 4-2
, weniger als 1 von ||| , less than 1 ||| 0-0 1-1 2-2 3-3
, weniger als 1 ||| , less than 1 ||| 0-0 1-1 2-2 3-3
, weniger als ||| , less than ||| 0-0 1-1 2-2
, weniger ||| , less ||| 0-0 1-1
, wenn ABILIFY zusammen ||| when concomitant administration of ABILIFY ||| 0-0 1-0 3-1 3-2 2-4
, wenn Aclasta ||| when Aclasta ||| 0-0 1-0 2-1
, wenn Erythropoese-stimulierende Wirkstoffe ( ||| when erythropoiesis stimulating agents ( ||| 0-0 1-0 2-1 2-2 3-2 3-3 4-4
, wenn Erythropoese-stimulierende Wirkstoffe ||| when erythropoiesis stimulating agents ||| 0-0 1-0 2-1 2-2 3-2 3-3
, wenn Hämoglobinwerte über 12 ||| when haemoglobin values exceeding 12 ||| 0-0 1-0 2-1 2-2 2-3 3-3 4-4
, wenn Hämoglobinwerte über ||| when haemoglobin values exceeding ||| 0-0 1-0 2-1 2-2 2-3 3-3
, wenn Pioglitazon ||| when pioglitazone ||| 0-0 1-0 2-1
, wenn Pioglitazon ||| when pioglitazone ||| 1-0 2-1
, wenn Sie daran denken ||| if you are having any ||| 0-0 1-0 2-1 3-2 3-3 4-3 4-4
, wenn Sie mit Abseamed ||| while you are using Abseamed ||| 3-0 1-1 2-1 1-2 3-3 4-4
, wenn Sie mit ||| while you are using ||| 3-0 1-1 2-1 1-2 3-3
, wenn Sie schwanger sind ||| if you are pregnant ||| 0-0 1-0 2-1 4-2 3-3
, wenn Sie stillen . ||| if you are breast-feeding . ||| 0-0 1-0 2-1 3-2 3-3 4-4
, wenn Sie stillen ||| if you are breast-feeding ||| 0-0 1-0 2-1 3-2 3-3
, wenn Sie weitere ||| if you are ||| 0-0 1-0 2-1 3-1 1-2
, wenn Sie ||| if you are ||| 0-0 1-0 2-1 1-2
, wenn Sie ||| if you are ||| 1-0 2-1 0-2 1-2
, wenn Sie ||| if you ||| 0-0 1-0 2-1
, wenn Sie ||| if you ||| 1-0 2-1
, wenn Sie ||| you are ||| 1-0 2-0 1-1
, wenn die Behandlung mit ||| when treatment with ||| 0-0 1-0 2-1 3-1 4-2
, wenn die Behandlung ||| when treatment ||| 0-0 1-0 2-1 3-1
, wenn eine schnelle ||| when a rapid ||| 0-0 1-0 2-1 3-2
, wenn eine ||| when a ||| 0-0 1-0 2-1
, wenn sie ||| if they ||| 0-0 1-0 2-1
, wenn ||| behaviour when ||| 0-0 0-1 1-1
, wenn ||| if ||| 0-0 1-0
, wenn ||| if ||| 1-0
, wenn ||| intervals unless ||| 0-0 1-1
, wenn ||| when ||| 0-0 1-0
, wenn ||| when ||| 1-0
, werden Sie gegebenenfalls ||| , you may not ||| 0-0 2-1 3-2 2-3
, werden ||| , ||| 0-0
, wie Ihre Anämie ||| how your anaemia ||| 1-0 2-1 3-2
, wie Ihre ||| how your ||| 1-0 2-1
, wie das das ||| how ||| 1-0 2-0 3-0
, wie das ||| how ||| 1-0 2-0
, wie die Anämie ||| how the anaemia ||| 1-0 2-1 3-2
, wie die ||| how the ||| 1-0 2-1
, wie dieser ||| benefit ||| 2-0
, wie gut der ||| of how well the ||| 3-0 1-1 2-2 3-3
, wie gut ||| how well ||| 1-0 2-1
, wie z.B. Fieber ||| , such as fever ||| 0-0 1-1 2-1 1-2 3-3
, wie z.B. ungewöhnliche ||| such as unusual ||| 1-0 2-0 1-1 3-2
, wie z.B. ||| , such as ||| 0-0 1-1 2-1 1-2
, wie z.B. ||| such as ||| 1-0 2-0 1-1
, wie ||| , as ||| 0-0 1-1
, wie ||| , ||| 0-0
, wie ||| as instructed ||| 0-0 1-0 0-1
, wie ||| as ||| 1-0
, wie ||| decide how ||| 0-0 1-0 1-1
, wie ||| how ||| 0-0 1-0
, wie ||| how ||| 1-0
, wird Ihr Arzt ||| your doctor may ||| 2-0 1-1 3-1 2-2
, wird die Behandlung ||| , the treatment will ||| 0-0 2-1 3-2 1-3
, wird die präoperative Anwendung ||| , the use ||| 0-0 1-1 2-1 3-2 4-2
, wird die ||| , the ||| 0-0 1-1 2-1
, wird keine Information ||| , no information will ||| 0-0 2-1 2-2 1-3 3-3
, wird ||| is ||| 0-0 1-0
, wirksamer als ||| effective than ||| 1-0 2-1
, wirksamer ||| effective ||| 1-0
, wobei diese 4 ||| and this ||| 1-1 2-1
, wobei diese 4 ||| this ||| 1-0 2-0
, wobei diese ||| and this ||| 1-1 2-1
, wobei diese ||| this ||| 1-0 2-0
, wobei jede Tablette separat ||| unit dose blisters ||| 1-0 2-0 2-1 3-2 4-2
, wobei jede ||| unit dose ||| 1-0 2-0 2-1
, wohingegen die Eliminationshalbwertszeit ||| of ||| 1-0 2-0
, wohingegen die relative Wirksamkeit ||| , whilst the relative efficacy ||| 0-0 1-1 2-2 3-3 4-4
, wohingegen die relative ||| , whilst the relative ||| 0-0 1-1 2-2 3-3
, wohingegen die ||| , whilst the ||| 0-0 1-1 2-2
, wohingegen die ||| of ||| 1-0 2-0
, wohingegen ||| , whilst ||| 0-0 1-1
, wurde eine ||| was ||| 1-0 2-0
, wurde in Studien ||| in ||| 1-0 2-0 3-0
, wurden ||| , were ||| 0-0 1-1
, während ca. 86 % ||| , while approximately 86 % ||| 0-0 1-1 2-2 3-3 4-4
, während ca. 86 ||| , while approximately 86 ||| 0-0 1-1 2-2 3-3
, während ca. ||| , while approximately ||| 0-0 1-1 2-2
, während der ||| , while the ||| 0-0 1-1 2-2
, während die zusätzliche Gabe ||| levels , while ||| 2-0 0-1 1-2
, während die zusätzliche ||| levels , while ||| 2-0 0-1 1-2
, während die ||| levels , while ||| 2-0 0-1 1-2
, während ||| , while ||| 0-0 1-1
, während ||| while ||| 1-0
, wässrige Lösung . ||| , aqueous solution . ||| 0-0 1-1 2-2 3-3
, wässrige Lösung ||| , aqueous solution ||| 0-0 1-1 2-2
, wässrige ||| , aqueous ||| 0-0 1-1
, zeigte sich ||| , a ||| 0-0 1-1 2-1
, zerebrovaskuläre ||| , cerebrovascular ||| 0-0 1-1
, zu Pioglitazon oder Placebo ||| to pioglitazone or placebo ||| 0-0 1-0 2-1 3-2 4-3
, zu Pioglitazon oder ||| to pioglitazone or ||| 0-0 1-0 2-1 3-2
, zu Pioglitazon ||| to pioglitazone ||| 0-0 1-0 2-1
, zu einer Hyperglykämie führen ||| , may lead to hyperglycaemia ||| 0-0 4-1 1-2 2-2 4-2 1-3 3-4 4-4
, zu ||| , ||| 0-0
, zu ||| to ||| 0-0 1-0
, zum Serotonin 5HT2c- und ||| , serotonin 5HT2c and 5HT7 ||| 0-0 2-1 1-2 2-2 3-2 4-3 3-4
, ||| , , ||| 0-0 0-1
, ||| , and ||| 0-0
, ||| , around ||| 0-0 0-1
, ||| , as ||| 0-0
, ||| , cases ||| 0-0
, ||| , decreased breath ||| 0-0 0-1 0-2
, ||| , donate ||| 0-0
, ||| , drug interactions ||| 0-0
, ||| , drug ||| 0-0
, ||| , feeling of ||| 0-0 0-1
, ||| , feeling ||| 0-0 0-1
, ||| , for ||| 0-0
, ||| , given the ||| 0-0
, ||| , given ||| 0-0
, ||| , influenza-like ||| 0-0 0-1
, ||| , non- ||| 0-0 0-1
, ||| , pain in the ||| 0-0 0-1
, ||| , pain in ||| 0-0 0-1
, ||| , pain ||| 0-0 0-1
, ||| , reduced ||| 0-0
, ||| , salivation ||| 0-0 0-1
, ||| , sensory ||| 0-0 0-1
, ||| , some ||| 0-0
, ||| , the ||| 0-0
, ||| , typically ||| 0-0 0-1
, ||| , when ||| 0-0 0-1
, ||| , which showed a ||| 0-0 0-1
, ||| , which showed ||| 0-0 0-1
, ||| , which ||| 0-0 0-1
, ||| , ||| 0-0
, ||| 0.69 ||| 0-0
, ||| 3 , and ||| 0-1
, ||| 3 , ||| 0-1
, ||| : ||| 0-0
, ||| ; ||| 0-0
, ||| ACOMPLIA and ||| 0-0
, ||| ACOMPLIA ||| 0-0
, ||| HbA1c , ||| 0-0 0-1
, ||| Human Use ||| 0-0
, ||| Human ||| 0-0
, ||| advised during ||| 0-0
, ||| advised ||| 0-0
, ||| appearance , ||| 0-0 0-1
, ||| appropriate preventive ||| 0-0 0-1
, ||| as ||| 0-0
, ||| at risk of ||| 0-1
, ||| at risk ||| 0-1
, ||| blood ||| 0-0
, ||| body ||| 0-0
, ||| cancer before , ||| 0-0 0-2
, ||| combination ||| 0-0
, ||| containing ||| 0-0
, ||| dated ||| 0-0
, ||| determined , ||| 0-1
, ||| disorder , ||| 0-0 0-1
, ||| disturbance , ||| 0-0 0-1
, ||| enzyme involved ||| 0-0
, ||| enzyme ||| 0-0
, ||| exceeding ||| 0-0
, ||| glycerin , ||| 0-0 0-1
, ||| high risk from ||| 0-0
, ||| high risk ||| 0-0
, ||| high ||| 0-0
, ||| in combination ||| 0-1
, ||| in exposures ||| 0-0 0-1
, ||| in ||| 0-0
, ||| increased , ||| 0-0 0-1
, ||| intervals ||| 0-0
, ||| it , donate ||| 0-1
, ||| it , ||| 0-1
, ||| its ||| 0-0
, ||| looking ||| 0-0
, ||| loss , ||| 0-0 0-1
, ||| necessary for ||| 0-0
, ||| necessary ||| 0-0
, ||| of ACOMPLIA and ||| 0-1
, ||| of ACOMPLIA ||| 0-1
, ||| of ||| 0-0
, ||| osteoporosis , ||| 0-0 0-1
, ||| risk of ||| 0-0
, ||| risk ||| 0-0
, ||| serious ||| 0-0
, ||| shortness of breath ||| 0-0 0-2
, ||| smaller ||| 0-0
, ||| study , ||| 0-1
, ||| that ||| 0-0
, ||| the ||| 0-0
, ||| there is ||| 0-0
, ||| there ||| 0-0
, ||| to be ||| 0-0
, ||| to it , donate ||| 0-2
, ||| to it , ||| 0-2
, ||| to ||| 0-0
, ||| ulceration , ||| 0-0 0-1
, ||| unless ||| 0-0
, ||| use of ACOMPLIA and ||| 0-2
, ||| use of ACOMPLIA ||| 0-2
, ||| well ||| 0-0
, ||| when ||| 0-0
, ||| where there is ||| 0-1
, ||| where there ||| 0-1
, ||| which ||| 0-0
, ||| who ||| 0-0
, ||| with ||| 0-0
, µ : +44 ( ||| , µ : +44 ( ||| 0-0 1-1 2-2 3-3 4-4
, µ : +44 ||| , µ : +44 ||| 0-0 1-1 2-2 3-3
, µ : ||| , µ : ||| 0-0 1-1 2-2
, µ ||| , µ ||| 0-0 1-1
, Ödeme , ||| , oedema , ||| 0-0 1-1 2-2
, Ödeme ||| , oedema ||| 0-0 1-1
, Ösophagitis , Zahnschmerz. # ||| , oesophagitis , toothache ||| 0-0 1-1 2-2 3-3 4-3
, Ösophagitis , ||| , oesophagitis , ||| 0-0 1-1 2-2
, Ösophagitis ||| , oesophagitis ||| 0-0 1-1
, Übelkeit , Erbrechen , ||| , nausea , vomiting , ||| 0-0 1-1 2-2 3-3 4-4
, Übelkeit , Erbrechen und ||| , nausea , vomiting and ||| 0-0 1-1 2-2 3-3 4-4
, Übelkeit , Erbrechen ||| , nausea , vomiting ||| 0-0 1-1 2-2 3-3
, Übelkeit , Verstopfung , ||| , nausea , constipation , ||| 0-0 1-1 2-2 3-3 4-4
, Übelkeit , Verstopfung ||| , nausea , constipation ||| 0-0 1-1 2-2 3-3
, Übelkeit , ||| , nausea , ||| 0-0 1-1 2-2
, Übelkeit und Erbrechen auf ||| , nausea and vomiting ||| 0-0 1-1 2-2 3-3
, Übelkeit und Erbrechen ||| , nausea and vomiting ||| 0-0 1-1 2-2 3-3
, Übelkeit und ||| , nausea and ||| 0-0 1-1 2-2
, Übelkeit ||| , nausea ||| 0-0 1-1
, ähnliche Effekte haben und ||| have similar effects and similar ||| 0-0 3-0 1-1 2-2 4-3 1-4
, ängstlich oder angespannt sein ||| , anxious or tense ||| 0-0 1-1 2-2 3-3 4-3
, ängstlich oder angespannt ||| , anxious or tense . ||| 0-0 1-1 2-2 3-3
, ängstlich oder angespannt ||| , anxious or tense ||| 0-0 1-1 2-2 3-3
, ängstlich oder ||| , anxious or ||| 0-0 1-1 2-2
, ängstlich ||| , anxious ||| 0-0 1-1
, üblicherweise in ||| , usually in ||| 0-0 1-1 2-2
, üblicherweise ||| , usually ||| 0-0 1-1
- 100 ||| - 100 ||| 0-0 1-1
- 14 g/dl ( ||| - 14 g/ dl ( ||| 0-0 1-1 2-2 2-3 3-4
- 14 g/dl . ||| - 14 g/ dl . ||| 0-0 1-1 2-2 2-3 3-4
- 14 g/dl ||| - 14 g/ dl ||| 0-0 1-1 2-2 2-3
- 14 ||| - 14 ||| 0-0 1-1
- 150 30 - 100 ||| - 150 30 - 100 ||| 0-0 1-1 2-2 3-3 4-4
- 150 30 - ||| - 150 30 - ||| 0-0 1-1 2-2 3-3
- 150 30 ||| - 150 30 ||| 0-0 1-1 2-2
- 150 60 - 150 ||| - 150 60 - 150 ||| 0-0 1-1 2-2 3-3 4-4
- 150 60 - ||| - 150 60 - ||| 0-0 1-1 2-2 3-3
- 150 60 ||| - 150 60 ||| 0-0 1-1 2-2
- 150 ml Flasche ||| 034 - 150 ml bottle ||| 3-0 0-1 1-2 2-3 3-4
- 150 ml ||| - 150 ml ||| 0-0 1-1 2-2
- 150 ||| - 150 ||| 0-0 1-1
- 2 g/dl pro Monat ||| 2 g/ dl per month ||| 1-0 0-1 2-1 2-2 3-3 4-4
- 2 g/dl pro ||| 2 g/ dl per ||| 1-0 0-1 2-1 2-2 3-3
- 2 g/dl pro ||| to 2 g/ dl per ||| 1-1 0-2 2-2 2-3 3-4
- 2 g/dl ||| 2 g/ dl ||| 1-0 0-1 2-1 2-2
- 2 g/dl ||| to 2 g/ dl ||| 1-1 0-2 2-2 2-3
- 200 mg ||| - 200 mg ||| 0-0 1-1 2-2
- 200 ||| - 200 ||| 0-0 1-1
- 23 Stunden . ||| to 23 hours . ||| 0-0 1-1 2-2 3-3
- 23 Stunden ||| to 23 hours ||| 0-0 1-1 2-2
- 23 ||| to 23 ||| 0-0 1-1
- 300 mg Fe2+/Tag ||| - 300 mg Fe2+/ day ||| 0-0 1-1 2-2 3-3 3-4
- 300 mg ||| - 300 mg ||| 0-0 1-1 2-2
- 300 ||| - 300 ||| 0-0 1-1
- 39 % ) ||| - 39 % ) ||| 0-0 1-1 2-2 3-3
- 39 % ||| - 39 % ||| 0-0 1-1 2-2
- 39 ||| - 39 ||| 0-0 1-1
- 480 ml Flasche ||| 035 - 480 ml bottle ||| 1-0 0-1 1-2 2-3 3-4
- 480 ml ||| 035 - 480 ml ||| 1-0 0-1 1-2 2-3
- 480 ||| 035 - 480 ||| 1-0 0-1 1-2
- 50 ml Flasche ||| - 50 ml bottle ||| 0-0 1-1 2-2 3-3
- 50 ml ||| - 50 ml ||| 0-0 1-1 2-2
- 50 ||| - 50 ||| 0-0 1-1
- 6,2 Monate ) und ||| 6.2 months ) and ||| 0-0 1-0 2-1 3-2 4-3
- 6,2 Monate ) ||| 6.2 months ) ||| 0-0 1-0 2-1 3-2
- 6,2 Monate ||| 6.2 months ||| 0-0 1-0 2-1
- 6,2 ||| 6.2 ||| 0-0 1-0
- 6,8 mmol/l ) ||| - 6.8 mmol/ l ) ||| 0-0 1-1 2-2 2-3 3-4
- 6,8 mmol/l ||| - 6.8 mmol/ l ||| 0-0 1-1 2-2 2-3
- 6,8 ||| - 6.8 ||| 0-0 1-1
- 7,5 mmol/l ) ||| - 7.5 mmol/ l ) ||| 0-0 1-1 2-2 2-3 3-4
- 7,5 mmol/l ||| - 7.5 mmol/ l ||| 0-0 1-1 2-2 2-3
- 7,5 ||| - 7.5 ||| 0-0 1-1
- 8°C ) . ||| - 8°C ) . ||| 0-0 1-1 2-2 3-3
- 8°C ) ||| - 8°C ) ||| 0-0 1-1 2-2
- 8°C ||| - 8°C ||| 0-0 1-1
- Aclasta 5 mg ||| - Aclasta 5 mg ||| 0-0 1-1 2-2 3-3
- Aclasta 5 ||| - Aclasta 5 ||| 0-0 1-1 2-2
- Aclasta ||| - Aclasta ||| 0-0 1-1
- Allgemein ) ||| - General ) ||| 0-0 1-1 2-2
- Allgemein ||| - General ||| 0-0 1-1
- Arzneimittel für ||| - Keep out of the ||| 0-0 1-1 1-2 2-2 2-3 2-4
- Behandlung der Anämie ||| - Treatment of anaemia associated ||| 0-0 1-1 2-2 3-3 3-4
- Behandlung der ||| - Treatment of ||| 0-0 1-1 2-2
- Behandlung ||| - Treatment ||| 0-0 1-1
- Bei schwangeren ||| - In pregnant or ||| 0-0 1-1 2-2 2-3
- Bei ||| - In ||| 0-0 1-1
- Blutdruckanstieg , der ||| - raised blood pressure which ||| 0-0 1-1 1-2 2-2 1-3 2-4
- Blutdruckanstieg , ||| - raised blood pressure which ||| 0-0 1-1 1-2 2-2 1-3 2-4
- Blutpfropfbildung ( thrombotische ||| - blood clotting ( thrombotic ||| 0-0 1-1 1-2 2-3 3-4
- Blutpfropfbildung ( ||| - blood clotting ( ||| 0-0 1-1 1-2 2-3
- Blutpfropfbildung ||| - blood clotting ||| 0-0 1-1 1-2
- Diabetische Retinopathie Eine langfristige ||| - Diabetic retinopathy Long-term improved ||| 0-0 1-1 2-2 3-3 4-3 4-4
- Diabetische Retinopathie ||| - Diabetic retinopathy ||| 0-0 1-1 2-2
- Diabetische ||| - Diabetic ||| 0-0 1-1
- Die sonstigen Bestandteile sind ||| - The other ingredients are ||| 0-0 1-1 2-2 2-3 3-3 4-4
- Die sonstigen Bestandteile ||| - The other ingredients ||| 0-0 1-1 2-2 2-3 3-3
- Die sonstigen ||| - The other ingredients ||| 0-0 1-1 2-2 2-3
- Die ||| - The ||| 0-0 1-1
- Dieses Arzneimittel wurde ||| - This medicine has been ||| 0-0 1-1 2-2 3-3 3-4
- Dieses Arzneimittel ||| - This medicine ||| 0-0 1-1 2-2
- Dieses ||| - This ||| 0-0 1-1
- Ein Verschluss der Verbindung ||| - Occlusion in the connection ||| 0-0 1-1 2-1 3-3 2-4 4-4
- Erythroblastopenie ) . ||| Pure Red Cell Aplasia ) ||| 1-0 0-1 1-1 1-2 1-3 3-3 2-4
- Für die ungeöffnete Flasche ||| - The unopened bottle does ||| 0-0 1-1 1-2 2-2 3-2 4-3 3-4
- Geringfügige Abnahme der ||| - a small reduction in ||| 0-0 1-1 1-2 2-3 2-4 3-4
- Geringfügige ||| - a small ||| 0-0 1-1 1-2
- Grippeähnliche Symptome ||| - flu-like symptoms , ||| 0-0 1-1 2-2
- Grippeähnliche Symptome ||| - flu-like symptoms ||| 0-0 1-1 2-2
- Grippeähnliche ||| - flu-like ||| 0-0 1-1
- Herzinsuffizienz oder ||| - cardiac failure or ||| 0-0 1-1 1-2 2-3
- Herzinsuffizienz ||| - cardiac failure ||| 0-0 1-1 1-2
- Hinweise zur Anwendung ) ||| Method of administration ) ||| 0-0 1-0 2-0 3-1 3-2 4-3
- Hinweise zur Anwendung ||| Method of administration ||| 0-0 1-0 2-0 3-1 3-2
- Hinweise zur ||| Method ||| 0-0 1-0 2-0
- Kühl lagern und transportieren ||| - Store and transport refrigerated ||| 0-0 1-1 3-2 2-3 3-3 4-3 4-4
- Kühl ||| - Store ||| 0-0 1-1
- Metformin bei Patienten ||| - metformin , in patients ||| 0-0 1-1 2-3 3-4
- Metformin bei ||| - metformin , in ||| 0-0 1-1 2-3
- Metformin und einem Sulfonylharnstoff ||| - metformin and a sulphonylurea ||| 0-0 1-1 2-2 3-3 3-4 4-4
- Metformin und ||| - metformin and ||| 0-0 1-1 2-2
- Metformin ||| - metformin , ||| 0-0 1-1
- Metformin ||| - metformin ||| 0-0 1-1
- Middlesex UB8 1HU - ||| - Middlesex UB8 1HU - ||| 0-0 1-1 2-2 3-3 4-4
- Middlesex UB8 1HU ||| - Middlesex UB8 1HU ||| 0-0 1-1 2-2 3-3
- Middlesex UB8 1HU- ||| - Middlesex UB8 1HU - ||| 0-0 1-1 2-2 2-3 3-3 3-4
- Middlesex UB8 ||| - Middlesex UB8 ||| 0-0 1-1 2-2
- Middlesex ||| - Middlesex ||| 0-0 1-1
- Nach ||| - After ||| 0-0 1-1
- Nach Öffnen der Flasche ||| - After opening the bottle ||| 0-0 1-1 2-2 3-3 4-4
- Nach Öffnen der ||| - After opening the ||| 0-0 1-1 2-2 3-3
- Nach Öffnen ||| - After opening ||| 0-0 1-1 2-2
- Orale Eisensubstitution mit ||| - oral iron substitution of ||| 0-0 1-1 2-2 1-3 2-3 3-3 3-4
- Patienten mit chronischer Niereninsuffizienz ||| - chronic renal failure patients ||| 0-0 1-1 3-1 2-2 4-2 3-3 4-3 1-4
- Periphere Neuropathie ||| - Peripheral neuropathy ||| 0-0 1-1 2-2
- Periphere ||| - Peripheral ||| 0-0 1-1
- Produtos Farmacêuticos , Lda ||| - Produtos Farmacêuticos , Lda ||| 0-0 1-1 2-2 3-3 4-4
- Produtos Farmacêuticos , ||| - Produtos Farmacêuticos , ||| 0-0 1-1 2-2 3-3
- Produtos Farmacêuticos ||| - Produtos Farmacêuticos ||| 0-0 1-1 2-2
- Produtos ||| - Produtos ||| 0-0 1-1
- Refraktionsanomalien ||| - Refraction disorders ||| 0-0 1-1 1-2
- Sie dürfen Aclasta ||| - Do not use Aclasta ||| 0-0 1-1 2-1 2-2 2-3 3-4
- Sie dürfen das ||| - Do not use ||| 0-0 1-1 2-1 2-2 2-3 3-3
- Sie dürfen ||| - Do not use ||| 0-0 1-1 2-1 2-2 2-3
- Vereinigtes Königreich ||| - United Kingdom ||| 0-0 1-1 2-2
- Vereinigtes ||| - United ||| 0-0 1-1
- Verminderter Blutzuckerspiegel ( ||| - decreased blood sugar ( ||| 0-0 1-1 2-2 2-3 3-4
- Verminderter Blutzuckerspiegel ||| - decreased blood sugar ||| 0-0 1-1 2-2 2-3
- Verminderter ||| - decreased ||| 0-0 1-1
- Wenn Sie nicht ||| - if you are ||| 0-0 1-1 2-1 2-2 2-3 3-3
- Wenn Sie ||| - If you are ||| 0-0 1-1 2-2 2-3
- Wenn Sie ||| - If you have ||| 0-0 1-1 2-2 2-3
- Wenn Sie ||| - If you ||| 0-0 1-1 2-2
- Wenn Sie ||| - if you are ||| 0-0 2-1 1-2 2-2 2-3
- Wenn Sie ||| - if you have ||| 0-0 2-1 1-2 2-2 2-3
- Wenn Sie ||| - if you ||| 0-0 1-1 2-1 2-2
- Wenn Sie ||| - if you ||| 0-0 2-1 1-2 2-2
- Wenn bei Ihnen ||| - if you have had ||| 0-0 0-1 1-2 3-2 2-3 3-3 3-4
- Wenn bei Ihnen ||| - if you have ||| 0-0 1-1 1-2 3-2 2-3 3-3
- Wenn ||| - If ||| 0-0 1-1
- bei Patienten ( insbesondere ||| - in patients ( particularly ||| 0-0 1-1 2-2 3-3 4-4
- bei Patienten ( ||| - in patients ( ||| 0-0 1-1 2-2 3-3
- bei Patienten ||| - in patients ||| 0-0 1-1 2-2
- bei ||| - in ||| 0-0 1-1
- einem Sulfonylharnstoff nur ||| - a sulphonylurea , only ||| 0-0 1-1 1-2 2-2 3-4
- einem Sulfonylharnstoff ||| - a sulphonylurea , ||| 0-0 1-1 1-2 2-2
- einem Sulfonylharnstoff ||| - a sulphonylurea ||| 0-0 1-1 1-2 2-2
- erhöhtes ||| - increased risk ||| 0-0 1-1 1-2
- kürzeres Gesamtüberleben und ||| - shortened overall survival and ||| 0-0 1-1 2-2 2-3 3-4
- kürzeres Gesamtüberleben ||| - shortened overall survival ||| 0-0 1-1 2-2 2-3
- kürzeres ||| - shortened ||| 0-0 1-1
- um das Risiko ||| - to minimise the risk ||| 0-0 1-1 1-2 2-2 3-2 2-3 3-4
- verminderte lokoregionale Kontrolle ||| - decreased locoregional control ||| 0-0 1-1 1-2 2-2 2-3 3-3
- wenn Sie unter ||| - if you have high ||| 0-0 1-1 2-2 2-3 3-3 1-4
- wenn Sie ||| - If you ||| 0-0 2-1 1-2 2-2
- wenn Sie ||| - if you are ||| 0-0 1-1 2-2 2-3
- wenn Sie ||| - if you have developed ||| 0-0 1-1 2-2 2-3 1-4
- wenn Sie ||| - if you ||| 0-0 1-1 2-2
- wenn bei Ihnen keine ||| - if you cannot receive ||| 0-0 1-1 3-2 4-3 3-4
- wenn bei ||| - if ||| 0-0 1-1
- wenn die Lösung ||| - if the solution ||| 0-0 1-1 2-2 3-3
- wenn die ||| - if the ||| 0-0 1-1 2-2
- wenn ||| - if ||| 0-0 1-1
- z.B. einige Wochen vor ||| even several weeks prior to ||| 0-0 1-0 2-0 2-1 3-2 4-3 4-4
- z.B. einige Wochen ||| , even several weeks ||| 0-1 1-1 2-1 2-2 3-3
- z.B. einige Wochen ||| even several weeks ||| 0-0 1-0 2-0 2-1 3-2
- z.B. einige ||| , even several ||| 0-1 1-1 2-1 2-2
- z.B. einige ||| even several ||| 0-0 1-0 2-0 2-1
- ||| - if ||| 0-0 0-1
- ||| - in ||| 0-0
- ||| - ||| 0-0
- ||| ACOMPLIA is indicated in ||| 0-0 0-2 0-3
- ||| to ||| 0-0
- ||| works by blocking specific receptors ||| 0-0 0-1 0-2 0-3 0-4
- Ödem Zu ||| - Oedema Oedema may ||| 0-0 1-1 1-2 2-2 2-3
- Überempfindlichkeit ||| - hypersensitivity ||| 0-0 1-1
-0,6 für Rimonabant 20 mg ||| -0.6 for rimonabant 20 mg ||| 0-0 1-1 2-2 3-3 4-4
-0,6 für Rimonabant 20 ||| -0.6 for rimonabant 20 ||| 0-0 1-1 2-2 3-3
-0,6 für Rimonabant ||| -0.6 for rimonabant ||| 0-0 1-1 2-2
-0,6 für ||| -0.6 for ||| 0-0 1-1
-0,6 ||| -0.6 ||| 0-0
-2,9 kg ) . ||| -2.9 kg ) . ||| 0-0 1-1 2-2 3-3
-2,9 kg ) ||| -2.9 kg ) ||| 0-0 1-1 2-2
-2,9 kg ||| -2.9 kg ||| 0-0 1-1
-2,9 ||| -2.9 ||| 0-0
-2C8 und -3A4 . ||| -2C8 and -3A4 respectively . ||| 0-0 1-1 2-2 2-3 3-4
-2C8 und -3A4 ||| -2C8 and -3A4 respectively ||| 0-0 1-1 2-2 2-3
-2C8 und ||| -2C8 and ||| 0-0 1-1
-2C8 ||| -2C8 ||| 0-0
-3A4 . ||| -3A4 respectively . ||| 0-0 0-1 1-2
-3A4 ||| -3A4 respectively ||| 0-0 0-1
-Hydroxypaclitaxel und 3 -p-Hydroxypaclitaxel , ||| -hydroxypaclitaxel and 3 -p-hydroxypaclitaxel , ||| 0-0 1-1 2-2 3-3 4-4
-Hydroxypaclitaxel und 3 -p-Hydroxypaclitaxel ||| -hydroxypaclitaxel and 3 -p-hydroxypaclitaxel ||| 0-0 1-1 2-2 3-3
-Hydroxypaclitaxel und 3 ||| -hydroxypaclitaxel and 3 ||| 0-0 1-1 2-2
-Hydroxypaclitaxel und ||| -hydroxypaclitaxel ; and ||| 0-0 1-2
-Hydroxypaclitaxel und ||| -hydroxypaclitaxel and ||| 0-0 1-1
-Hydroxypaclitaxel ||| -hydroxypaclitaxel ; ||| 0-0
-Hydroxypaclitaxel ||| -hydroxypaclitaxel ||| 0-0
-Induktoren ( z.B ||| inducers ( e. g. rifampicin ||| 0-0 1-1 2-2 2-3 0-4
-ort , ||| g. insulin dosage , ||| 0-0 0-1 0-2 1-3
-ort ||| g. insulin dosage ||| 0-0 0-1 0-2
-p-Dihydroxypaclitaxel ) ||| -3 -p-dihydroxypaclitaxel ||| 0-0 0-1
-p-Dihydroxypaclitaxel ||| -3 -p-dihydroxypaclitaxel ||| 0-0 0-1
-p-Hydroxypaclitaxel , ||| -p-hydroxypaclitaxel , ||| 0-0 1-1
-p-Hydroxypaclitaxel und 6 -3 -p-Dihydroxypaclitaxel ||| -p-hydroxypaclitaxel and 6 -3 -p-dihydroxypaclitaxel ||| 0-0 3-0 1-1 2-2 4-3 4-4
-p-Hydroxypaclitaxel und 6 -3 ||| -p-hydroxypaclitaxel and 6 ||| 0-0 3-0 1-1 2-2
-p-Hydroxypaclitaxel ||| -p-hydroxypaclitaxel ||| 0-0
. ) . ||| ) . ||| 1-0 0-1 2-1
. 16 ||| . 16 ||| 0-0 1-1
. 5.2 ) . ||| 5.2 ) . ||| 1-0 2-1 0-2 3-2
. : + 36(0 ) ||| . : + 36(0 ) ||| 0-0 1-1 2-2 3-3 4-4
. : + 36(0 ||| . : + 36(0 ||| 0-0 1-1 2-2 3-3
. : + ||| . : + ||| 0-0 1-1 2-2
. : +36 1 457 ||| . : +36 1 457 ||| 0-0 1-1 2-2 3-3 4-4
. : +36 1 ||| . : +36 1 ||| 0-0 1-1 2-2 3-3
. : +36 ||| . : +36 ||| 0-0 1-1 2-2
. : +44 ( 0)20 ||| . : +44 ( 0)20 ||| 0-0 1-1 2-2 3-3 4-4
. : +44 ( ||| . : +44 ( ||| 0-0 1-1 2-2 3-3
. : +44 ||| . : +44 ||| 0-0 1-1 2-2
. : ||| . : ||| 0-0 1-1
. Abseamed 3000 I.E./0,3 ml ||| Abseamed 3000 IU/ 0.3 ml ||| 1-0 2-1 3-2 3-3 4-4
. Abseamed 3000 I.E./0,3 ||| Abseamed 3000 IU/ 0.3 ||| 1-0 2-1 3-2 3-3
. Abseamed 3000 ||| Abseamed 3000 ||| 1-0 2-1
. Abseamed 4000 ||| Abseamed 4000 IU/ ||| 1-0 2-1 2-2
. Abseamed 5000 ||| Abseamed 5000 IU/ ||| 1-0 2-1 2-2
. Abseamed 6000 I.E./0,6 ml ||| Abseamed 6000 IU/ 0.6 ml ||| 1-0 2-1 2-2 3-3 4-4
. Abseamed 6000 I.E./0,6 ||| Abseamed 6000 IU/ 0.6 ||| 1-0 2-1 2-2 3-3
. Abseamed 6000 ||| Abseamed 6000 IU/ ||| 1-0 2-1 2-2
. Abseamed 7000 ||| Abseamed 7000 ||| 1-0 2-1
. Abseamed 8000 I.E./0,8 ml ||| Abseamed 8000 IU/ 0.8 ml ||| 1-0 2-1 3-2 3-3 4-4
. Abseamed 8000 I.E./0,8 ||| Abseamed 8000 IU/ 0.8 ||| 1-0 2-1 3-2 3-3
. Abseamed 8000 ||| Abseamed 8000 ||| 1-0 2-1
. Abseamed 9000 ||| Abseamed 9000 ||| 1-0 2-1
. Abseamed ||| Abseamed ||| 1-0
. Auf Anforderung der EMEA ||| the request of the EMEA ||| 1-0 3-0 2-1 3-2 3-3 4-4
. Auf Anforderung der ||| the request of the ||| 1-0 3-0 2-1 3-2 3-3
. Bei der ||| with ||| 1-0
. Bei ||| with ||| 1-0
. Ca. ||| medication . ||| 1-0 0-1
. Datum der letzten ||| Date of last ||| 0-0 1-0 2-1 3-2
. Datum der ||| Date of ||| 0-0 1-0 2-1
. Datum ||| Date ||| 0-0 1-0
. Die ABILIFY-Dosis sollte ||| ABILIFY dose should be reduced ||| 2-0 2-1 1-2 3-2 0-3 3-3 2-4
. Die Patienten sollten auf ||| patients should be ||| 2-0 1-1 3-1 3-2 4-2
. Die Patienten wurden ||| 3 trials ||| 3-1
. Die Patienten wurden ||| trials ||| 3-0
. Die Zeit bis ||| . Die ||| 0-0 1-1
. Die Zeit ||| . Die ||| 0-0 1-1
. Die n ||| . ||| 0-0 2-0
. Die pharmakokinetischen Parameter ||| The pharmacokinetic parameters ||| 1-0 2-1 3-2
. Die pharmakokinetischen ||| The pharmacokinetic ||| 1-0 2-1
. Die ||| . Die ||| 0-0 1-1
. Die ||| . ||| 0-0
. Die ||| The ||| 1-0
. Dies ||| . of ||| 0-0
. Dies ||| . ||| 0-0
. Diese Dosis sollte jedoch ||| but this dose should be ||| 4-0 1-1 2-2 3-3 3-4
. Diese Dosis sollte ||| this dose should be ||| 1-0 2-1 3-2 3-3
. Diese Dosis ||| this dose ||| 1-0 2-1
. Diese Folgeerscheinungen wurden mit ||| as measured ||| 2-0 1-1 2-1 3-1
. Diese Folgeerscheinungen wurden ||| as measured ||| 2-0 1-1 2-1 3-1
. Diese Patienten ||| and such patients ||| 1-1 2-2
. Diese Patienten ||| such patients ||| 1-0 2-1
. Diese ||| and such ||| 1-1
. Diese ||| such ||| 1-0
. Diese ||| this ||| 1-0
. Dieses ||| This ||| 1-0
. Ein Trend zur ||| a trend ||| 1-1 2-1
. Ein Trend zur ||| trend ||| 1-0 2-0
. Ein Trend ||| a trend ||| 1-1 2-1
. Ein Trend ||| trend ||| 1-0 2-0
. Ein Wirkverlust oder andere ||| efficacy or other ||| 2-0 3-1 4-2
. Ein Wirkverlust oder andere ||| loss of efficacy or other ||| 2-2 3-3 4-4
. Ein Wirkverlust oder andere ||| of efficacy or other ||| 2-1 3-2 4-3
. Ein Wirkverlust oder ||| efficacy or ||| 2-0 3-1
. Ein Wirkverlust oder ||| loss of efficacy or ||| 2-2 3-3
. Ein Wirkverlust oder ||| of efficacy or ||| 2-1 3-2
. Ein Wirkverlust ||| efficacy ||| 2-0
. Ein Wirkverlust ||| loss of efficacy ||| 2-2
. Ein Wirkverlust ||| of efficacy ||| 2-1
. Erbrechen Durchfall weicher Stuhl ||| . vomiting diarrhoea softened stools ||| 0-0 1-1 2-2 3-3 4-4
. Erbrechen Durchfall weicher ||| . vomiting diarrhoea softened ||| 0-0 1-1 2-2 3-3
. Erbrechen Durchfall ||| . vomiting diarrhoea ||| 0-0 1-1 2-2
. Erbrechen ||| . vomiting ||| 0-0 1-1
. Es kann ||| . It can be ||| 0-0 1-1 2-2 2-3
. Es ||| . It ||| 0-0 1-1
. Hypothermie , Pyrexie ) ||| hypothermia , pyrexia ) ||| 0-0 1-0 2-1 3-2 4-3
. Hypothermie , Pyrexie ||| hypothermia , pyrexia ||| 0-0 1-0 2-1 3-2
. Hypothermie , ||| hypothermia , ||| 0-0 1-0 2-1
. Hypothermie ||| hypothermia ||| 0-0 1-0
. In ||| . ||| 0-0
. Innerhalb von 60 Tagen ||| Within 60 days of ||| 1-0 3-1 4-2 2-3
. Innerhalb ||| Within ||| 1-0
. Juli ||| . ||| 0-0
. Juni 2006 erteilte ||| European ||| 1-0 2-0 3-0
. Kanzerogenitätstests ergaben keinen ||| testing did not ||| 1-0 2-0 3-1 3-2
. Kanzerogenitätstests ergaben ||| testing ||| 1-0 2-0
. STAND DER INFORMATION 14 ||| OF THE ||| 1-0 2-0 2-1 3-1 4-1
. ||| ) . ||| 0-1
. ||| . For lp ||| 0-0 0-2
. ||| . The ||| 0-0
. ||| . no ||| 0-0
. ||| . of ||| 0-0
. ||| . ||| 0-0
. ||| Me ||| 0-0
. ||| action . ||| 0-1
. ||| be a ||| 0-0
. ||| be ||| 0-0
. ||| between . ||| 0-1
. ||| conditions . ||| 0-1
. ||| day ) . ||| 0-0 0-1 0-2
. ||| days. ||| 0-0
. ||| disorders . ||| 0-1
. ||| effects . ||| 0-1
. ||| for resorption ||| 0-1
. ||| in between . ||| 0-2
. ||| infusion . ||| 0-1
. ||| levels . ||| 0-1
. ||| occur . ||| 0-1
. ||| other . ||| 0-1
. ||| period . ||| 0-1
. ||| prescribed . ||| 0-0 0-1
. ||| resorption ||| 0-0
. ||| studies . ||| 0-1
. ||| swallowing . ||| 0-0 0-1
. ||| to ||| 0-0
. ||| treatment . ||| 0-1
. ||| treatment in between . ||| 0-3
. ||| years . ||| 0-1
/ oder dunkler Harn , ||| and/ or dark urine , ||| 2-0 1-1 0-2 2-2 3-3 4-4
/ oder dunkler Harn ||| and/ or dark urine ||| 2-0 1-1 0-2 2-2 3-3
/ oder dunkler ||| and/ or dark ||| 2-0 1-1 0-2 2-2
/ verfügbar . ||| . europa . eu/ ||| 2-0 0-1 1-1 2-2 1-3
/ ||| / ||| 0-0
/Polyisopren-Gummistopfen . ||| stopper . ||| 0-0 1-1
/Polyisopren-Gummistopfen ||| stopper ||| 0-0
0 ) 241 941-0 ||| 0 ) 241 941-0 ||| 0-0 1-1 2-2 3-3
0 ) 241 ||| 0 ) 241 ||| 0-0 1-1 2-2
0 ) 30 60 25 ||| 0 ) 30 60 25 ||| 0-0 1-1 2-2 3-3 4-4
0 ) 30 60 ||| 0 ) 30 60 ||| 0-0 1-1 2-2 3-3
0 ) 30 ||| 0 ) 30 ||| 0-0 1-1 2-2
0 ) gegeben werden sollte ||| 0 ) ||| 0-0 2-0 3-0 4-0 1-1
0 ) ||| 0 ) ||| 0-0 1-1
0 ||| 0 ||| 0-0
0)1 46 25 16 16 ||| 0)1 46 25 16 16 ||| 0-0 1-1 2-2 3-3 4-4
0)1 46 25 16 ||| 0)1 46 25 16 ||| 0-0 1-1 2-2 3-3
0)1 46 25 ||| 0)1 46 25 ||| 0-0 1-1 2-2
0)1 46 ||| 0)1 46 ||| 0-0 1-1
0)1 47 56 69 00 ||| 0)1 47 56 69 00 ||| 0-0 1-1 2-2 3-3 4-4
0)1 47 56 69 ||| 0)1 47 56 69 ||| 0-0 1-1 2-2 3-3
0)1 47 56 ||| 0)1 47 56 ||| 0-0 1-1 2-2
0)1 47 ||| 0)1 47 ||| 0-0 1-1
0)1 580 00 10 ||| 0)1 580 00 10 ||| 0-0 1-1 2-2 3-3
0)1 580 00 ||| 0)1 580 00 ||| 0-0 1-1 2-2
0)1 580 ||| 0)1 580 ||| 0-0 1-1
0)1 ||| 0)1 ||| 0-0
0)1628 537 900 ||| 0)1628 537 900 ||| 0-0 1-1 2-2
0)1628 537 ||| 0)1628 537 ||| 0-0 1-1
0)1628 ||| 0)1628 ||| 0-0
0)20 3116 8000 ||| 0)20 3116 8000 ||| 0-0 1-1 2-2
0)20 3116 8950 ||| 0)20 3116 8950 ||| 0-0 1-1 2-2
0)20 3116 8951 ||| 0)20 3116 8951 ||| 0-0 1-1 2-2
0)20 3116 8952 ||| 0)20 3116 8952 ||| 0-0 1-1 2-2
0)20 3116 8953 ||| 0)20 3116 8953 ||| 0-0 1-1 2-2
0)20 3116 8954 ||| 0)20 3116 8954 ||| 0-0 1-1 2-2
0)20 3116 ||| 0)20 3116 ||| 0-0 1-1
0)20 ||| 0)20 ||| 0-0
0)21 272 16 00 ||| 0)21 272 16 00 ||| 0-0 1-1 2-2 3-3
0)21 272 16 ||| 0)21 272 16 ||| 0-0 1-1 2-2
0)21 272 ||| 0)21 272 ||| 0-0 1-1
0)21 ||| 0)21 ||| 0-0
0)810 410 500 ||| 0)810 410 500 ||| 0-0 1-1 2-2
0)810 410 ||| 0)810 410 ||| 0-0 1-1
0)810 ||| 0)810 ||| 0-0
0)9 8545250 ||| 0)9 8545250 ||| 0-0 1-1
0)9 ||| 0)9 ||| 0-0
0,001 ) . ||| received dic ||| 1-0 0-1
0,001 ) ||| received dic ||| 1-0 0-1
0,001 ||| dic ||| 0-0
0,0089 µg/ml ||| sulphone 0.0471 µg/ ml ||| 1-0 0-1 0-2 1-2 1-3
0,01 ||| 0.01 ||| 0-0
0,02 mg/kg täglich wurde ||| 0.02 mg/ kg daily was ||| 0-0 1-1 1-2 2-3 3-4
0,02 mg/kg täglich ||| 0.02 mg/ kg daily ||| 0-0 1-1 1-2 2-3
0,02 mg/kg ||| 0.02 mg/ kg ||| 0-0 1-1 1-2
0,02 ||| 0.02 ||| 0-0
0,035 mg wasserfreiem ||| 0.035 mg of anhydrous ||| 0-0 1-1 2-2 2-3
0,035 mg ||| 0.035 mg ||| 0-0 1-1
0,035 ||| 0.035 ||| 0-0
0,05 mg Zoledronsäure ( wasserfrei ||| 0.05 mg zoledronic acid anhydrous ||| 0-0 1-1 2-2 2-3 3-3 4-4
0,05 mg Zoledronsäure ( ||| 0.05 mg zoledronic acid ||| 0-0 1-1 2-2 2-3 3-3
0,05 mg wasserfreie Zoledronsäure ||| 0.05 mg zoledronic acid anhydrous ||| 0-0 1-1 2-1 0-2 3-2 3-3 3-4
0,05 mg ||| 0.05 mg ||| 0-0 1-1
0,05 ||| 0.05 ||| 0-0
0,0533 mg Zoledronsäuremonohydrat ||| 0.0533 mg zoledronic acid monohydrate ||| 0-0 1-1 2-2 2-3 2-4
0,0533 mg ||| 0.0533 mg ||| 0-0 1-1
0,0533 ||| 0.0533 ||| 0-0
0,05330 mg Zoledronsäuremonohydrat ||| 0.05330 mg zoledronic acid monohydrate ||| 0-0 1-1 2-2 2-3 2-4
0,05330 mg ||| 0.05330 mg ||| 0-0 1-1
0,05330 ||| 0.05330 ||| 0-0
0,1 mg/kg ||| 0.1 mg/ kg ||| 0-0 1-1 1-2
0,1 ||| 0.1 ||| 0-0
0,14 % bei ||| 0.14 % in ||| 0-0 1-1 2-2
0,14 % ||| 0.14 % ||| 0-0 1-1
0,14 ||| 0.14 ||| 0-0
0,2 mg Propyl-4-hydroxybenzoat ( ||| 0.2 mg propyl parahydroxybenzoate ( ||| 0-0 1-1 2-2 2-3 3-4
0,2 mg Propyl-4-hydroxybenzoat ||| 0.2 mg propyl parahydroxybenzoate ||| 0-0 1-1 2-2 2-3
0,2 mg ||| 0.2 mg ||| 0-0 1-1
0,2 mg/kg ||| 0.2 mg/ kg ||| 0-0 1-1 1-2
0,2 ||| 0.2 ||| 0-0
0,25 mg/kg ||| 0.25 mg/ kg ||| 0-0 1-1 1-2
0,25 ||| 0.25 ||| 0-0
0,3 ml ( 3000 ||| 0.3 ml ( 3000 ||| 0-0 1-1 2-2 3-3
0,3 ml ( ||| 0.3 ml ( ||| 0-0 1-1 2-2
0,3 ml 6 ||| 0.3 ml 6 ||| 0-0 1-1 2-2
0,3 ml 6 ||| of 0.3 ml 6 ||| 0-1 1-2 2-3
0,3 ml Injektionslösung ||| 0.3 ml solution for injection ||| 0-0 1-1 2-2 2-3 2-4
0,3 ml enthält 3000 Internationale ||| 0.3 ml contains 3000 international ||| 0-0 1-1 2-2 3-3 4-4
0,3 ml enthält 3000 ||| 0.3 ml contains 3000 ||| 0-0 1-1 2-2 3-3
0,3 ml enthält 3000 ||| of 0.3 ml contains 3000 ||| 0-1 1-2 2-3 3-4
0,3 ml enthält ||| 0.3 ml contains ||| 0-0 1-1 2-2
0,3 ml enthält ||| of 0.3 ml contains ||| 0-1 1-2 2-3
0,3 ml ||| 0.3 ml ||| 0-0 1-1
0,3 ml ||| of 0.3 ml ||| 0-1 1-2
0,3 ||| 0.3 ||| 0-0
0,3 ||| of 0.3 ||| 0-1
0,35 % ||| 0.35 % ||| 0-0 1-1
0,35 ||| 0.35 ||| 0-0
0,4 ml ( 4000 ||| 0.4 ml ( 4000 ||| 0-0 1-1 2-2 3-3
0,4 ml ( ||| 0.4 ml ( ||| 0-0 1-1 2-2
0,4 ml 6 ||| of 0.4 ml 6 ||| 0-0 0-1 1-2 2-3
0,4 ml enthält 4000 Internationale ||| 0.4 ml contains 4000 international ||| 0-0 1-1 2-2 3-3 4-4
0,4 ml enthält 4000 ||| 0.4 ml contains 4000 ||| 0-0 1-1 2-2 3-3
0,4 ml enthält 4000 ||| of 0.4 ml contains 4000 ||| 0-0 0-1 1-2 2-3 3-4
0,4 ml enthält 4000 ||| of 0.4 ml contains 4000 ||| 0-1 1-2 2-3 3-4
0,4 ml enthält ||| 0.4 ml contains ||| 0-0 1-1 2-2
0,4 ml enthält ||| of 0.4 ml contains ||| 0-0 0-1 1-2 2-3
0,4 ml enthält ||| of 0.4 ml contains ||| 0-1 1-2 2-3
0,4 ml ||| 0.4 ml ||| 0-0 1-1
0,4 ml ||| of 0.4 ml ||| 0-0 0-1 1-2
0,4 ml ||| of 0.4 ml ||| 0-1 1-2
0,4 ||| 0.4 ||| 0-0
0,4 ||| of 0.4 ||| 0-0 0-1
0,4 ||| of 0.4 ||| 0-1
0,45 ||| 0.45 ||| 0-0
0,45 ||| of 0.45 ||| 0-1
0,5 % ) ||| 0.5 % ) of ||| 0-0 1-1 2-2
0,5 % ) ||| 0.5 % ) ||| 0-0 1-1 2-2
0,5 % ||| 0.5 % ||| 0-0 1-1
0,5 bis ||| 0.5 to ||| 0-0 1-1
0,5 ml ( 1000 ||| 0.5 ml ( 1000 ||| 0-0 1-1 2-2 3-3
0,5 ml ( 5000 ||| 0.5 ml ( 5000 ||| 0-0 1-1 2-2 3-3
0,5 ml ( ||| 0.5 ml ( ||| 0-0 1-1 2-2
0,5 ml 6 ||| 0.5 ml 6 ||| 0-0 1-1 2-2
0,5 ml 6 ||| of 0.5 ml 6 ||| 0-1 1-2 2-3
0,5 ml enthält 1000 Internationale ||| 0.5 ml contains 1000 international ||| 0-0 1-1 2-2 3-3 4-4
0,5 ml enthält 1000 ||| 0.5 ml contains 1000 ||| 0-0 1-1 2-2 3-3
0,5 ml enthält 1000 ||| of 0.5 ml contains 1000 ||| 0-1 1-2 2-3 3-4
0,5 ml enthält 5000 Internationale ||| 0.5 ml contains 5000 international ||| 0-0 1-1 2-2 3-3 4-4
0,5 ml enthält 5000 ||| 0.5 ml contains 5000 ||| 0-0 1-1 2-2 3-3
0,5 ml enthält 5000 ||| of 0.5 ml contains 5000 ||| 0-1 1-2 2-3 3-4
0,5 ml enthält ||| 0.5 ml contains ||| 0-0 1-1 2-2
0,5 ml enthält ||| of 0.5 ml contains ||| 0-1 1-2 2-3
0,5 ml ||| 0.5 ml ||| 0-0 1-1
0,5 ml ||| of 0.5 ml ||| 0-1 1-2
0,5 ||| 0.5 ||| 0-0
0,5 ||| of 0.5 ||| 0-1
0,6 % ) ||| 0.6 % ) ||| 0-0 1-1 2-2
0,6 % ||| 0.6 % ||| 0-0 1-1
0,6 mg/kg ||| 0.6 mg/ kg ||| 0-0 1-1 1-2
0,6 ml ( 6000 ||| 0.6 ml ( 6000 ||| 0-0 1-1 2-2 3-3
0,6 ml ( ||| 0.6 ml ( ||| 0-0 1-1 2-2
0,6 ml 6 ||| of 0.6 ml 6 ||| 0-0 0-1 1-2 2-3
0,6 ml Injektionslösung ||| 0.6 ml solution for injection ||| 0-0 1-1 2-2 2-3 2-4
0,6 ml enthält 6000 Internationale ||| 0.6 ml contains 6000 international ||| 0-0 1-1 2-2 3-3 4-4
0,6 ml enthält 6000 ||| 0.6 ml contains 6000 ||| 0-0 1-1 2-2 3-3
0,6 ml enthält 6000 ||| of 0.6 ml contains 6000 ||| 0-0 0-1 1-2 2-3 3-4
0,6 ml enthält 6000 ||| of 0.6 ml contains 6000 ||| 0-1 1-2 2-3 3-4
0,6 ml enthält ||| 0.6 ml contains ||| 0-0 1-1 2-2
0,6 ml enthält ||| of 0.6 ml contains ||| 0-0 0-1 1-2 2-3
0,6 ml enthält ||| of 0.6 ml contains ||| 0-1 1-2 2-3
0,6 ml ||| 0.6 ml ||| 0-0 1-1
0,6 ml ||| of 0.6 ml ||| 0-0 0-1 1-2
0,6 ml ||| of 0.6 ml ||| 0-1 1-2
0,6 ||| 0.6 ||| 0-0
0,6 ||| of 0.6 ||| 0-0 0-1
0,6 ||| of 0.6 ||| 0-1
0,62 mmol/l ) oder ||| 0.62 mmol/ l ) or ||| 0-0 1-1 1-2 2-3 3-4
0,62 mmol/l ) ||| 0.62 mmol/ l ) ||| 0-0 1-1 1-2 2-3
0,62 mmol/l ||| 0.62 mmol/ l ||| 0-0 1-1 1-2
0,62 ||| 0.62 ||| 0-0
0,63 mg Mitratapid/kg Körpergewicht ||| 0.63 mg mitratapide/ kg bodyweight ||| 0-0 1-1 2-2 3-3 3-4
0,63 mg Mitratapid/kg ||| 0.63 mg mitratapide/ ||| 0-0 1-1 2-2
0,63 mg ||| 0.63 mg ||| 0-0 1-1
0,63 ||| 0.63 ||| 0-0
0,7 ml ( 7000 ||| 0.7 ml ( 7000 ||| 0-0 1-1 2-2 3-3
0,7 ml ( ||| 0.7 ml ( ||| 0-0 1-1 2-2
0,7 ml ) kann abhängig ||| 0.7 ml ) may be ||| 0-0 1-1 2-2 3-3 4-3 3-4
0,7 ml ) ||| 0.7 ml ) ||| 0-0 1-1 2-2
0,7 ml 6 ||| of 0.7 ml 6 ||| 0-0 0-1 1-2 2-3
0,7 ml enthält 7000 ||| of 0.7 ml contains 7000 ||| 0-0 0-1 1-2 2-3 3-4
0,7 ml enthält ||| of 0.7 ml contains ||| 0-0 0-1 1-2 2-3
0,7 ml ||| 0.7 ml ||| 0-0 1-1
0,7 ml ||| of 0.7 ml ||| 0-0 0-1 1-2
0,7 ||| 0.7 ||| 0-0
0,7 ||| of 0.7 ||| 0-0 0-1
0,8 % der ||| 0.8 % of ||| 0-0 1-1 2-2
0,8 % für Placebo . ||| 0.8 % for placebo . ||| 0-0 1-1 2-2 3-3 4-4
0,8 % für Placebo ||| 0.8 % for placebo ||| 0-0 1-1 2-2 3-3
0,8 % für ||| 0.8 % for ||| 0-0 1-1 2-2
0,8 % ||| 0.8 % ||| 0-0 1-1
0,8 ml ( 8000 ||| 0.8 ml ( 8000 ||| 0-0 1-1 2-2 3-3
0,8 ml ( ||| 0.8 ml ( ||| 0-0 1-1 2-2
0,8 ml 6 ||| of 0.8 ml 6 ||| 0-0 0-1 1-2 2-3
0,8 ml Injektionslösung ||| 0.8 ml solution for injection ||| 0-0 1-1 2-2 2-3 2-4
0,8 ml enthält 8000 Internationale ||| 0.8 ml contains 8000 international ||| 0-0 1-1 2-2 3-3 4-4
0,8 ml enthält 8000 ||| 0.8 ml contains 8000 ||| 0-0 1-1 2-2 3-3
0,8 ml enthält 8000 ||| of 0.8 ml contains 8000 ||| 0-1 1-2 2-3 3-4
0,8 ml enthält ||| 0.8 ml contains ||| 0-0 1-1 2-2
0,8 ml enthält ||| of 0.8 ml contains ||| 0-1 1-2 2-3
0,8 ml ||| 0.8 ml ||| 0-0 1-1
0,8 ml ||| of 0.8 ml ||| 0-0 0-1 1-2
0,8 ml ||| of 0.8 ml ||| 0-1 1-2
0,8 ||| 0.8 ||| 0-0
0,8 ||| of 0.8 ||| 0-0 0-1
0,8 ||| of 0.8 ||| 0-1
0,9 ml ( 9000 ||| 0.9 ml ( 9000 ||| 0-0 1-1 2-2 3-3
0,9 ml ( ||| 0.9 ml ( ||| 0-0 1-1 2-2
0,9 ml 6 ||| of 0.9 ml 6 ||| 0-0 0-1 1-2 2-3
0,9 ml enthält 9000 ||| of 0.9 ml contains 9000 ||| 0-0 0-1 1-2 2-3 3-4
0,9 ml enthält ||| of 0.9 ml contains ||| 0-0 0-1 1-2 2-3
0,9 ml ||| 0.9 ml ||| 0-0 1-1
0,9 ml ||| of 0.9 ml ||| 0-0 0-1 1-2
0,9 ||| 0.9 ||| 0-0
0,9 ||| of 0.9 ||| 0-0 0-1
0,94 ||| 0.94 ||| 0-0
0,99- 1,18 ; 42 ||| 0.99 , 1,18 ; 42 ||| 0-0 1-1 1-2 2-2 2-3 3-4
0,99- 1,18 ; ||| 0.99 , 1,18 ; ||| 0-0 1-1 1-2 2-2 2-3
0,99- ||| 0.99 ||| 0-0
0-1 ||| 0 1 ||| 0-0 0-1
00 10 ||| 00 10 ||| 0-0 1-1
00 ||| 00 ||| 0-0
000 I.E. ) Lösung ||| 000 IU ) of solution ||| 0-0 1-1 2-2 1-3 3-4
000 I.E. ) ||| 000 IU ) of ||| 0-0 1-1 2-2 1-3
000 I.E. Epoetin alfa* ||| 000 IU of epoetin alfa* ||| 0-0 1-1 3-2 2-3 3-4
000 I.E. ||| 000 IU ||| 0-0 1-1
000 I.E./1 ml ||| 000 IU/ 1 ml ||| 0-0 1-0 1-1 1-2 2-3
000 I.E./1 ml ||| 000 IU/ 1 ml ||| 0-0 1-1 1-2 1-3 2-3
000 I.E./1 ||| 000 IU/ 1 ||| 0-0 1-0 1-1 1-2
000 I.E./1 ||| 000 IU/ ||| 0-0 1-0 1-1
000 Internationale Einheiten ( I.E. ||| 000 international units ( IU ||| 0-0 1-1 2-2 3-3 4-4
000 Internationale Einheiten ( ||| 000 international units ( ||| 0-0 1-1 2-2 3-3
000 Internationale Einheiten ||| 000 international units ||| 0-0 1-1 2-2
000 Internationale ||| 000 international ||| 0-0 1-1
000 bis 125 000 IE ||| to 125,000 international units ||| 1-0 2-0 1-1 0-2 3-2 3-3 4-3
000 ||| 000 ||| 0-0
000 ältere ||| 8,000 ||| 0-0 1-0
0010 , 019-021 ||| 008 , 010 , 019-021 ||| 0-0 1-1 0-2 1-3 2-4
0010 , ||| 008 , 010 , ||| 0-0 1-1 0-2 1-3
007 , ||| 150/ 001-003 , ||| 0-0 0-1 1-2
007 ||| 150/ 001-003 ||| 0-0 0-1
008 , ||| 150/ 004-006 , ||| 0-0 0-1 1-2
008 ||| 150/ 004-006 ||| 0-0 0-1
009 , 016-018 ||| 007 , 009 , 016-018 ||| 0-0 1-1 0-2 1-3 2-4
009 , ||| 007 , 009 , ||| 0-0 1-1 0-2 1-3
01 ||| 01 ||| 0-0
016-018 ||| 016-018 ||| 0-0
019-021 ||| 019-021 ||| 0-0
03 ||| 03 ||| 0-0
05 06 ||| 05 06 ||| 0-0 1-1
05 20 00 ||| 05 20 00 ||| 0-0 1-1 2-2
05 20 ||| 05 20 ||| 0-0 1-1
05 ||| 05 ||| 0-0
06 5026 01 ||| 06 5026 01 ||| 0-0 1-1 2-2
06 5026 ||| 06 5026 ||| 0-0 1-1
06 ||| 06 ||| 0-0
062 ) . ||| 1,062 ) . ||| 0-0 1-1 2-2
062 ) ||| 1,062 ) ||| 0-0 1-1
062 ||| 1,062 ||| 0-0
0800 ) 731 1736 ||| 0800 ) 731 1736 ||| 0-0 1-1 2-2 3-3
0800 ) 731 ||| 0800 ) 731 ||| 0-0 1-1 2-2
0800 ) ||| 0800 ) ||| 0-0 1-1
0800 ||| 0800 ||| 0-0
1 % der ||| 1 % ||| 0-0 1-1
1 % ||| 1 % of ||| 0-0 1-1
1 % ||| 1 % ||| 0-0 1-1
1 ( CB1)- Rezeptoren ||| 1 ( CB1 ) receptors ||| 0-0 1-1 2-2 1-3 3-4
1 ( CB1)- ||| 1 ( CB1 ) ||| 0-0 1-1 2-2 1-3
1 ) , die ||| 1 ) ||| 0-0 1-1
1 ) , ||| 1 ) ||| 0-0 1-1
1 ) 524 40 64 ||| 1 ) 524 40 64 ||| 0-0 1-1 2-2 3-3 4-4
1 ) 524 40 ||| 1 ) 524 40 ||| 0-0 1-1 2-2 3-3
1 ) 524 ||| 1 ) 524 ||| 0-0 1-1 2-2
1 ) ||| 1 ) , ||| 0-0 1-1
1 ) ||| 1 ) ||| 0-0 1-1
1 , 49 x 1 ||| 1 , 49 x 1 ||| 0-0 1-1 2-2 3-3 4-4
1 , 49 x ||| 1 , 49 x ||| 0-0 1-1 2-2 3-3
1 , 49 ||| 1 , 49 ||| 0-0 1-1 2-2
1 , 5 und 10 ||| 1 , 5 and 10 ||| 0-0 1-1 2-2 3-3 4-4
1 , 5 und ||| 1 , 5 and ||| 0-0 1-1 2-2 3-3
1 , 5 ||| 1 , 5 ||| 0-0 1-1 2-2
1 , 56 x 1 ||| 1 , 56 x 1 ||| 0-0 1-1 2-2 3-3 4-4
1 , 56 x ||| 1 , 56 x ||| 0-0 1-1 2-2 3-3
1 , 56 ||| 1 , 56 ||| 0-0 1-1 2-2
1 , 98 x 1 ||| 1 , 98 x 1 ||| 0-0 1-1 2-2 3-3 4-4
1 , 98 x ||| 1 , 98 x ||| 0-0 1-1 2-2 3-3
1 , 98 ||| 1 , 98 ||| 0-0 1-1 2-2
1 , ||| 1 , ||| 0-0 1-1
1 - 2 g/dl ||| 1 to 2 g/ dl ||| 0-0 2-2 1-3 3-3 3-4
1 062 ) . ||| 1,062 ) . ||| 1-0 2-1 3-2
1 062 ) ||| 1,062 ) ||| 1-0 2-1
1 062 ||| 1,062 ||| 1-0
1 260 12 55 ||| 1 260 12 55 ||| 0-0 1-1 2-2 3-3
1 260 12 ||| 1 260 12 ||| 0-0 1-1 2-2
1 260 ||| 1 260 ||| 0-0 1-1
1 457 65 00 ||| 1 457 65 00 ||| 0-0 1-1 2-2 3-3
1 457 65 ||| 1 457 65 ||| 0-0 1-1 2-2
1 457 ||| 1 457 ||| 0-0 1-1
1 60 14 30 ||| 1 60 14 30 ||| 0-0 1-1 2-2 3-3
1 60 14 ||| 1 60 14 ||| 0-0 1-1 2-2
1 60 ||| 1 60 ||| 0-0 1-1
1 800 ) 749 749 ||| 1 800 ) 749 749 ||| 0-0 1-1 2-2 3-3 4-4
1 800 ) 749 ||| 1 800 ) 749 ||| 0-0 1-1 2-2 3-3
1 800 ) ||| 1 800 ) ||| 0-0 1-1 2-2
1 800 ||| 1 800 ||| 0-0 1-1
1 86 6570 ||| 1 86 6570 ||| 0-0 1-1 2-2
1 86 ||| 1 86 ||| 0-0 1-1
1 BEDINGUNGEN ODER EINSCHRÄNKUNGEN ||| 1 CONDITIONS OR RESTRICTIONS WITH ||| 0-0 1-1 2-2 3-3 3-4
1 BEDINGUNGEN ODER ||| 1 CONDITIONS OR ||| 0-0 1-1 2-2
1 BEDINGUNGEN ||| 1 CONDITIONS ||| 0-0 1-1
1 Diabetes , ||| 1 diabetes , ||| 0-0 1-1 2-2
1 Diabetes ||| 1 diabetes ||| 0-0 1-1
1 Die ||| 1 The ||| 0-0 1-1
1 Durchstechflasche enthält 10 ||| 1 vial contains 10 ||| 0-0 1-1 2-2 3-3
1 Durchstechflasche enthält ||| 1 vial contains ||| 0-0 1-1 2-2
1 Durchstechflasche ||| 1 vial ||| 0-0 1-1
1 Fertigspritze mit 0,3 ||| 1 pre-filled syringe of 0.3 ||| 0-0 1-1 1-2 2-2 3-4
1 Fertigspritze mit 0,4 ||| 1 pre-filled syringe of 0.4 ||| 0-0 1-1 1-2 2-2 3-3 3-4
1 Fertigspritze mit 0,4 ||| 1 pre-filled syringe of 0.4 ||| 0-0 1-1 1-2 2-2 3-4
1 Fertigspritze mit 0,5 ||| 1 pre-filled syringe of 0.5 ||| 0-0 1-1 1-2 2-2 3-4
1 Fertigspritze mit 0,6 ||| 1 pre-filled syringe of 0.6 ||| 0-0 1-1 1-2 2-2 3-3 3-4
1 Fertigspritze mit 0,6 ||| 1 pre-filled syringe of 0.6 ||| 0-0 1-1 1-2 2-2 3-4
1 Fertigspritze mit 0,7 ||| 1 pre-filled syringe of 0.7 ||| 0-0 1-1 1-2 2-2 3-3 3-4
1 Fertigspritze mit 0,8 ||| 1 pre-filled syringe of 0.8 ||| 0-0 1-1 1-2 2-2 3-3 3-4
1 Fertigspritze mit 0,8 ||| 1 pre-filled syringe of 0.8 ||| 0-0 1-1 1-2 2-2 3-4
1 Fertigspritze mit 0,9 ||| 1 pre-filled syringe of 0.9 ||| 0-0 1-1 1-2 2-2 3-3 3-4
1 Fertigspritze mit 1 ||| 1 pre-filled syringe of 1 ||| 0-0 1-1 1-2 2-2 3-4
1 Fertigspritze mit ||| 1 pre-filled syringe of ||| 0-0 1-1 1-2 2-2
1 Fertigspritze mit ||| 1 pre-filled syringe ||| 0-0 1-1 1-2 2-2
1 Filmtablette ||| 1 film-coated ||| 0-0 1-1
1 Flasche , ||| 1 bottle ||| 0-0 1-1
1 Flasche 100 ml ||| 1 bottle - 100 ml ||| 0-0 1-1 2-2 2-3 3-4
1 Flasche 100 ||| 1 bottle - 100 ||| 0-0 1-1 2-2 2-3
1 Flasche enthält 5 mg ||| 1 bottle contains 5 mg ||| 0-0 1-1 2-2 3-3 4-4
1 Flasche enthält 5 ||| 1 bottle contains 5 ||| 0-0 1-1 2-2 3-3
1 Flasche enthält ||| 1 bottle contains ||| 0-0 1-1 2-2
1 Flasche ||| 1 bottle ||| 0-0 1-1
1 Monat nach ||| 1 month after ||| 0-0 1-1 2-2
1 Monat ||| 1 month ||| 0-0 1-1
1 Schmelztabletten 28 x ||| 1 orodispersible tablets 28 x ||| 0-0 1-1 1-2 2-3 3-4
1 Schmelztabletten 28 ||| 1 orodispersible tablets 28 ||| 0-0 1-1 1-2 2-3
1 Schmelztabletten 49 x ||| 1 orodispersible tablets 49 x ||| 0-0 1-1 1-2 2-3 3-4
1 Schmelztabletten 49 ||| 1 orodispersible tablets 49 ||| 0-0 1-1 1-2 2-3
1 Schmelztabletten ||| 1 orodispersible tablets ||| 0-0 1-1 1-2
1 Tabletten . ||| 1 tablets . ||| 0-0 1-1 2-2
1 Tabletten 28 x 1 ||| 1 tablets 28 x 1 ||| 0-0 1-1 2-2 3-3 4-4
1 Tabletten 28 x ||| 1 tablets 28 x ||| 0-0 1-1 2-2 3-3
1 Tabletten 28 ||| 1 tablets 28 ||| 0-0 1-1 2-2
1 Tabletten 49 x 1 ||| 1 tablets 49 x 1 ||| 0-0 1-1 2-2 3-3 4-4
1 Tabletten 49 x ||| 1 tablets 49 x ||| 0-0 1-1 2-2 3-3
1 Tabletten 49 ||| 1 tablets 49 ||| 0-0 1-1 2-2
1 Tabletten 56 x 1 ||| 1 tablets 56 x 1 ||| 0-0 1-1 2-2 3-3 4-4
1 Tabletten 56 x ||| 1 tablets 56 x ||| 0-0 1-1 2-2 3-3
1 Tabletten 56 ||| 1 tablets 56 ||| 0-0 1-1 2-2
1 Tabletten 98 x 1 ||| 1 tablets 98 x 1 ||| 0-0 1-1 2-2 3-3 4-4
1 Tabletten 98 x ||| 1 tablets 98 x ||| 0-0 1-1 2-2 3-3
1 Tabletten 98 ||| 1 tablets 98 ||| 0-0 1-1 2-2
1 Tabletten in ||| 1 tablets in ||| 0-0 1-1 2-2
1 Tabletten ||| 1 tablets ||| 0-0 1-1
1 bis 10 von ||| 1 and 10 ||| 0-0 1-2 2-2
1 bis 10 ||| 1 and 10 ||| 0-0 1-2 2-2
1 g/dl ( 0,62 ||| 1 g/ dl ( 0.62 ||| 0-0 1-1 1-2 2-3 3-4
1 g/dl ( ||| 1 g/ dl ( ||| 0-0 1-1 1-2 2-3
1 g/dl ||| 1 g/ dl ||| 0-0 1-1 1-2
1 mg/ml ) und ||| 1 mg/ ml ) and ||| 0-0 1-1 1-2 2-3 3-4
1 mg/ml ) ||| 1 mg/ ml ) ||| 0-0 1-1 1-2 2-3
1 mg/ml Lösung zum Einnehmen ||| 1 mg/ ml oral solution ||| 0-0 1-1 1-2 3-3 4-3 2-4
1 mg/ml ||| 1 mg/ ml ||| 0-0 1-1 1-2
1 ml ( 10 000 ||| 1 ml ( 10 000 ||| 0-0 1-1 2-2 3-3 4-4
1 ml ( 10 ||| 1 ml ( 10 ||| 0-0 1-1 2-2 3-3
1 ml ( 2000 ||| 1 ml ( 2000 ||| 0-0 1-1 2-2 3-3
1 ml ( ||| 1 ml ( ||| 0-0 1-1 2-2
1 ml ) ||| 1 ml ) ||| 0-0 1-1 2-2
1 ml 6 ||| 1 ml 6 ||| 0-0 1-1 2-2
1 ml 6 ||| of 1 ml 6 ||| 0-1 1-2 2-3
1 ml des Produkts ||| 1 ml of the product ||| 0-0 1-1 2-2 2-3 2-4 3-4
1 ml enthält 10 000 ||| 1 ml contains 10 000 ||| 0-0 1-1 2-2 3-3 4-4
1 ml enthält 10 ||| 1 ml contains 10 ||| 0-0 1-1 2-2 3-3
1 ml enthält 10 ||| of 1 ml contains 10 ||| 0-1 1-2 2-3 3-4
1 ml enthält 100 ||| 1 ml contains 100 ||| 0-0 1-1 2-2 3-3
1 ml enthält 2000 Internationale ||| 1 ml contains 2000 international ||| 0-0 1-1 2-2 3-3 4-4
1 ml enthält 2000 ||| 1 ml contains 2000 ||| 0-0 1-1 2-2 3-3
1 ml enthält 2000 ||| of 1 ml contains 2000 ||| 0-1 1-2 2-3 3-4
1 ml enthält 40 ||| 1 ml contains 40 ||| 0-0 1-1 2-2 3-3
1 ml enthält ||| 1 ml contains ||| 0-0 1-1 2-2
1 ml enthält ||| of 1 ml contains ||| 0-1 1-2 2-3
1 ml ||| 1 ml ||| 0-0 1-1
1 ml ||| of 1 ml ||| 0-1 1-2
1 oder 2 ) , ||| 1 or 2 ) at ||| 0-0 1-1 2-2 3-3
1 oder 2 ) , ||| 1 or 2 ) ||| 0-0 1-1 2-2 3-3
1 oder 2 ) ||| 1 or 2 ) at ||| 0-0 1-1 2-2 3-3
1 oder 2 ) ||| 1 or 2 ) ||| 0-0 1-1 2-2 3-3
1 oder 2 ||| 1 or 2 ||| 0-0 1-1 2-2
1 oder ||| 1 or ||| 0-0 1-1
1 sind ||| 1 ||| 0-0
1 und 5 Durchstechflaschen ||| 1 and 5 vials ||| 0-0 1-1 2-2 3-3
1 und 5 ||| 1 and 5 ||| 0-0 1-1 2-2
1 und ||| 1 and ||| 0-0 1-1
1 von ||| 1 ||| 0-0
1 x/Woche ||| once weekly ||| 0-0 1-0 1-1
1 ||| 1 and ||| 0-0
1 ||| 1 patient ||| 0-0
1 ||| 1 to ||| 0-0
1 ||| 1 ||| 0-0
1 ||| of 1 ||| 0-1
1,0 I.E./kg/Tag . ||| IU/ kg/ day . ||| 0-0 0-1 1-1 1-2 2-3
1,0 I.E./kg/Tag ||| IU/ kg/ day ||| 0-0 0-1 1-1 1-2
1,0 ||| , 1.0 ||| 0-1
1,0 ||| 1.0 ||| 0-0
1,0 ||| of 1.0 ||| 0-1
1,08 zugunsten ||| in favour ||| 1-0 0-1 1-1
1,1 ||| 1.1 ||| 0-0
1,18 ; 42 Studien ||| , 1,18 ; 42 trials ||| 0-0 0-1 1-1 1-2 2-3 3-4
1,18 ; 42 ||| , 1,18 ; 42 ||| 0-0 0-1 1-1 1-2 2-3
1,18 ; ||| , 1,18 ; ||| 0-0 0-1 1-1 1-2
1,2 ||| 1.2 ||| 0-0
1,25 mmol/l ) pro ||| 1.25 mmol/ l ) per ||| 0-0 1-1 1-2 2-3 3-4
1,25 mmol/l ) ||| 1.25 mmol/ l ) ||| 0-0 1-1 1-2 2-3
1,25 mmol/l ||| 1.25 mmol/ l ||| 0-0 1-1 1-2
1,25 und 2,47 zugunsten ||| 1.25 and 2.47 in favour ||| 0-0 1-1 2-2 2-3 3-4
1,25 und 2,47 ||| 1.25 and 2.47 in ||| 0-0 1-1 2-2 2-3
1,25 und ||| 1.25 and ||| 0-0 1-1
1,25 ||| 1.25 ||| 0-0
1,3 % ) ||| 1.3 % ) ||| 0-0 1-1 2-2
1,3 % ||| 1.3 % ||| 0-0 1-1
1,3 ml ) Aripiprazol . ||| 1.3 ml ) aripiprazole . ||| 0-0 1-1 2-2 3-3 4-4
1,3 ml ) Aripiprazol ||| 1.3 ml ) aripiprazole ||| 0-0 1-1 2-2 3-3
1,3 ml ) für die ||| 1.3 ml ) for the ||| 0-0 1-1 2-2 3-3 4-4
1,3 ml ) für ||| 1.3 ml ) for ||| 0-0 1-1 2-2 3-3
1,3 ml ) ||| 1.3 ml ) , ||| 0-0 1-1 2-2
1,3 ml ) ||| 1.3 ml ) ||| 0-0 1-1 2-2
1,3 ml . ||| 1.3 ml ||| 0-0 1-1 2-1
1,3 ml ||| 1.3 ml ||| 0-0 1-1
1,3 ||| 1.3 ||| 0-0
1,35-2,06 ; 35 ||| 1.35 , 2.06 , 35 ||| 0-0 0-1 0-2 1-2 0-3 2-4
1,35-2,06 ; ||| 1.35 , 2.06 , ||| 0-0 0-1 0-2 1-2 0-3
1,4 mg/ml ||| ml ||| 0-0 1-0
1,44 % für Aclasta-Patienten , ||| 1.44 % for Aclasta-treated ||| 0-0 1-1 2-2 3-3
1,44 % für Aclasta-Patienten ||| 1.44 % for Aclasta-treated ||| 0-0 1-1 2-2 3-3
1,44 % für ||| 1.44 % for ||| 0-0 1-1 2-2
1,44 % ||| 1.44 % ||| 0-0 1-1
1,44 ||| 1.44 ||| 0-0
1,5 bis ||| reached ||| 0-0 1-0
1,5 x 109/l angestiegen ist ||| 1.5 x 109/ l ||| 0-0 1-1 2-2 3-2 3-3 4-3
1,5 x ||| 1.5 x ||| 0-0 1-1
1,5 ||| 1.5 ||| 0-0
1,67 ; 95%-Konfidenzintervall : ||| 95 % CI : ||| 0-0 2-1 1-2 2-2 3-3
1,67 ; 95%-Konfidenzintervall ||| 95 % CI ||| 0-0 2-1 1-2 2-2
1,67 ||| 95 ||| 0-0
1,8 % ||| 1.8 % ||| 0-0 1-1
1,8 mg Methyl-4-hydroxybenzoat ( ||| 1.8 mg methyl parahydroxybenzoate ( ||| 0-0 1-1 2-2 2-3 3-4
1,8 mg Methyl-4-hydroxybenzoat ||| 1.8 mg methyl parahydroxybenzoate ||| 0-0 1-1 2-2 2-3
1,8 mg ||| 1.8 mg ||| 0-0 1-1
1,8 ||| 1.8 ||| 0-0
1,87 ||| 1.87 ||| 0-0
1,9 % ( 75 ||| 1.9 % ( 75 ||| 0-0 1-1 2-2 3-3
1,9 % ( ||| 1.9 % ( ||| 0-0 1-1 2-2
1,9 % ||| 1.9 % ||| 0-0 1-1
1,9 ||| 1.9 ||| 0-0
1.000 Patienten betroffen ) ||| in every 1,000 patients ) ||| 0-0 2-1 0-2 1-3 3-4
1.000 Patienten betroffen ||| in every 1,000 patients ||| 0-0 2-1 0-2 1-3
1/1.000 ||| 1/ ||| 0-0
1/100 ) ||| 1/ 100 ) ||| 0-0 0-1 1-2
1/100 ||| 1/ 100 ||| 0-0 0-1
10 " auf einer Seite ||| 10 " on one side ||| 0-0 1-1 2-2 3-3 4-3 4-4
10 " auf ||| 10 " on ||| 0-0 1-1 2-2
10 " ||| 10 " ||| 0-0 1-1
10 % ( 101 ||| 10 % ( 101 ||| 0-0 1-1 2-2 3-3
10 % ( ||| 10 % ( ||| 0-0 1-1 2-2
10 % , ||| 10 % , and ||| 0-0 1-1 2-2
10 % , ||| 10 % , ||| 0-0 1-1 2-2
10 % ; 19 ||| 10 % ; 19 % ||| 0-0 1-1 2-2 3-3 1-4
10 % davon hatten den ||| 10 % being ||| 0-0 1-1 3-1
10 % davon hatten den ||| 10 % ||| 0-0 1-1 3-1
10 % davon hatten ||| 10 % being ||| 0-0 1-1 3-1
10 % davon hatten ||| 10 % ||| 0-0 1-1 3-1
10 % gelöstem Insulin und ||| 10 % dissolved insulin and ||| 0-0 1-1 2-2 3-3 4-4
10 % gelöstem Insulin ||| 10 % dissolved insulin ||| 0-0 1-1 2-2 3-3
10 % gelöstem ||| 10 % dissolved ||| 0-0 1-1 2-2
10 % und Isophan-Insulin ||| 10 % and isophane insulin ||| 0-0 1-1 2-2 3-3 3-4
10 % und ||| 10 % and ||| 0-0 1-1 2-2
10 % ||| 10 % ||| 0-0 1-1
10 000 I.E. ) ||| 10 000 IU ) of ||| 0-0 1-1 2-2 3-3 2-4
10 000 I.E. ||| 10 000 IU ||| 0-0 1-1 2-2
10 000 I.E./1 ml ||| 10 000 IU/ 1 ml ||| 0-0 1-1 2-1 2-2 2-3 3-4
10 000 I.E./1 ml ||| 10 000 IU/ 1 ml ||| 0-0 1-1 2-2 2-3 2-4 3-4
10 000 I.E./1 ||| 10 000 IU/ 1 ||| 0-0 1-1 2-1 2-2 2-3
10 000 I.E./1 ||| 10 000 IU/ ||| 0-0 1-1 2-1 2-2
10 000 Internationale Einheiten ( ||| 10 000 international units ( ||| 0-0 1-1 2-2 3-3 4-4
10 000 Internationale Einheiten ||| 10 000 international units ||| 0-0 1-1 2-2 3-3
10 000 Internationale ||| 10 000 international ||| 0-0 1-1 2-2
10 000 ||| 10 000 ||| 0-0 1-1
10 : lösliches Insulin 10 ||| 10 : soluble insulin 10 ||| 0-0 1-1 2-2 3-3 4-4
10 : lösliches Insulin ||| 10 : soluble insulin ||| 0-0 1-1 2-2 3-3
10 : lösliches ||| 10 : soluble ||| 0-0 1-1 2-2
10 : ||| 10 : ||| 0-0 1-1
10 ACTRAPHANE 20 ACTRAPHANE 30 ||| 10 ACTRAPHANE 20 ACTRAPHANE 30 ||| 0-0 1-1 2-2 3-3 4-4
10 ACTRAPHANE 20 ACTRAPHANE ||| 10 ACTRAPHANE 20 ACTRAPHANE ||| 0-0 1-1 2-2 3-3
10 ACTRAPHANE 20 ||| 10 ACTRAPHANE 20 ||| 0-0 1-1 2-2
10 ACTRAPHANE ||| 10 ACTRAPHANE ||| 0-0 1-1
10 Anpassung der Dosis Begleiterkrankungen ||| Dosage adjustment Concomitant illness ||| 0-0 1-0 1-1 1-2 2-2 4-2 3-3 4-3
10 Effekte auf alle klinischen ||| Effect on all clinical ||| 0-0 1-0 2-1 3-2 4-3
10 Effekte auf alle ||| Effect on all ||| 0-0 1-0 2-1 3-2
10 Effekte auf ||| Effect on ||| 0-0 1-0 2-1
10 Effekte ||| Effect ||| 0-0 1-0
10 In einer ||| 9 In a ||| 1-1 2-2
10 In einer ||| In a ||| 1-0 2-1
10 In ||| 9 In ||| 1-1
10 In ||| In ||| 1-0
10 Nach intravenöser Gabe von ||| Following intravenous administration of ||| 1-0 2-1 3-2 4-3
10 Nach intravenöser Gabe ||| Following intravenous administration ||| 1-0 2-1 3-2
10 Nach intravenöser ||| Following intravenous ||| 1-0 2-1
10 Nach ||| Following ||| 1-0
10 NovoLet 100 ||| 10 NovoLet 100 ||| 0-0 1-1 2-2
10 NovoLet ||| 10 NovoLet ||| 0-0 1-1
10 Patienten ) ist ||| patient in 10 ) is ||| 1-0 1-1 0-2 2-3 3-4
10 Patienten ) ||| patient in 10 ) ||| 1-0 1-1 0-2 2-3
10 Patienten ||| patient in 10 ||| 1-0 1-1 0-2
10 Patronen zu je 3 ||| 10 cartridges x 3 ||| 0-0 1-1 2-1 3-2 4-3
10 Patronen zu je ||| 10 cartridges x ||| 0-0 1-1 2-1 3-2
10 Patronen zu ||| 10 cartridges ||| 0-0 1-1 2-1
10 Penfill 100 ||| 10 Penfill 100 ||| 0-0 1-1 2-2
10 Penfill ||| 10 Penfill ||| 0-0 1-1
10 Tage nach ||| 10 days after ||| 0-0 1-1 2-2
10 Tage nach ||| 10 days following ||| 0-0 1-1 2-2
10 Tage nach ||| days after ||| 1-0 2-1
10 Tage ||| 10 days ||| 0-0 1-1
10 Tage ||| days ||| 1-0
10 Tagen ||| 10 days ||| 0-0 1-1
10 auf einer Seite . ||| 10 on one side . ||| 0-0 1-1 2-2 3-2 3-3 4-4
10 auf einer Seite ||| 10 on one side ||| 0-0 1-1 2-2 3-2 3-3
10 auf ||| 10 on ||| 0-0 1-1
10 besteht aus 10 % ||| 10 consists of 10 % ||| 0-0 1-1 2-1 2-2 3-3 4-4
10 besteht aus 10 ||| 10 consists of 10 ||| 0-0 1-1 2-1 2-2 3-3
10 besteht aus ||| 10 consists of ||| 0-0 1-1 2-1 2-2
10 g/dl ( 6,2 ||| 10 g/ dl ( 6.2 ||| 0-0 1-1 1-2 2-3 3-4
10 g/dl ( ||| 10 g/ dl ( ||| 0-0 1-1 1-2 2-3
10 g/dl und 12 ||| 10 g/ dl - 12 ||| 0-0 1-1 1-2 2-2 3-3 3-4
10 g/dl und ||| 10 g/ dl ||| 0-0 1-1 1-2 2-2
10 g/dl ||| 10 g/ dl ||| 0-0 1-1 1-2
10 kg Körpergewicht 120 ml ||| 10 kg BW 120 ml ||| 0-0 1-1 2-2 3-3 4-4
10 kg Körpergewicht 120 ||| 10 kg BW 120 ||| 0-0 1-1 2-2 3-3
10 kg Körpergewicht ||| 10 kg BW ||| 0-0 1-1 2-2
10 kg ||| 10 kg ||| 0-0 1-1
10 mg , 15 mg ||| 10 mg , 15 mg ||| 0-0 1-1 2-2 3-3 4-4
10 mg , 15 ||| 10 mg , 15 ||| 0-0 1-1 2-2 3-3
10 mg , ||| 10 mg , ||| 0-0 1-1 2-2
10 mg Aripiprazol . ||| 10 mg of aripiprazole . ||| 0-0 1-1 2-3 3-4
10 mg Aripiprazol ||| 10 mg of aripiprazole ||| 0-0 1-1 2-3
10 mg Schmelztabletten sind ||| 10 mg orodispersible tablets are ||| 0-0 1-1 2-2 2-3 3-4
10 mg Schmelztabletten ||| 10 mg orodispersible tablets ||| 0-0 1-1 2-2 2-3
10 mg Tabletten sind rechteckig ||| 10 mg tablets are rectangular ||| 0-0 1-1 2-2 3-3 4-4
10 mg Tabletten sind ||| 10 mg tablets are ||| 0-0 1-1 2-2 3-3
10 mg Tabletten ||| 10 mg tablets ||| 0-0 1-1 2-2
10 mg ||| 10 mg of ||| 0-0 1-1
10 mg ||| 10 mg ||| 0-0 1-1
10 mg/kg ||| 10 mg/ kg ||| 0-0 1-1 1-2
10 ml entsprechend 1000 ||| 10 ml equivalent to 1000 ||| 0-0 1-1 1-2 2-2 2-3 3-4
10 ml entsprechend 400 ||| 10 ml equivalent to 400 ||| 0-0 1-1 1-2 2-2 2-3 3-4
10 ml entsprechend ||| 10 ml equivalent to ||| 0-0 1-1 1-2 2-2 2-3
10 ml und eine Bündelpackung ||| 10 ml and a multipack ||| 0-0 1-1 2-2 3-3 4-4
10 ml und eine ||| 10 ml and a ||| 0-0 1-1 2-2 3-3
10 ml und ||| 10 ml and ||| 0-0 1-1 2-2
10 ml ||| 10 ml ||| 0-0 1-1
10 oder 15 mg/Tag ||| 10 or 15 mg/ day ||| 0-0 1-1 2-2 3-3 3-4
10 oder 15 ml Lösung ||| 10 or 15 ml solution/ ||| 0-0 1-1 2-2 3-3 4-3 2-4
10 oder 15 ||| 10 or 15 ||| 0-0 1-1 2-2
10 oder mehr von ||| 10 or more ||| 0-0 1-1 2-2 3-2
10 oder ||| 10 or ||| 0-0 1-1
10 und 12 g/dl ||| 10 and 12 g/ dl ||| 0-0 1-1 2-2 3-3 3-4
10 und 12 ||| 10 and 12 ||| 0-0 1-1 2-2
10 und 30 mg/Tag ||| 10 to 30 mg/ day ||| 0-0 1-1 2-2 3-3 3-4
10 und 30 ||| 10 to 30 ||| 0-0 1-1 2-2
10 und 30 ||| of 10 to 30 ||| 0-1 1-2 2-3
10 und ||| 10 and ||| 0-0 1-1
10 und ||| 10 to ||| 0-0 1-1
10 und ||| of 10 to ||| 0-1 1-2
10 vorgefüllte Fertigpens zu je ||| 10 pre-filled pens x ||| 0-0 1-1 1-2 2-2 3-2 4-3
10 vorgefüllte Fertigpens zu ||| 10 pre-filled pens ||| 0-0 1-1 1-2 2-2 3-2
10 x ULN ) sollten ||| 10 x ULN ) should ||| 0-0 1-1 2-2 3-3 4-4
10 x ULN ) ||| 10 x ULN ) ||| 0-0 1-1 2-2 3-3
10 x ULN ||| 10 x ULN ||| 0-0 1-1 2-2
10 x ||| 10 x ||| 0-0 1-1
10 ||| 10 ||| 0-0
10 ||| and 10 ||| 0-1
10 ||| of 10 ||| 0-1
10,4 ||| 10.4 ||| 0-0
100 % . ||| 100 % . ||| 0-0 1-1 2-2
100 % ||| 100 % ||| 0-0 1-1
100 , weniger als 1 ||| 100 , less than 1 ||| 0-0 1-1 2-2 3-3 4-4
100 , weniger als ||| 100 , less than ||| 0-0 1-1 2-2 3-3
100 , weniger ||| 100 , less ||| 0-0 1-1 2-2
100 , ||| 100 , ||| 0-0 1-1
100 Es werden möglicherweise nicht ||| Not all pack ||| 0-0 1-0 2-0 3-1 3-2 4-2
100 Es werden ||| Not ||| 0-0 1-0 2-0
100 I.E. Insulin human ||| 100 IU of insulin human ||| 0-0 1-1 1-2 2-3 3-4
100 I.E. Insulin ||| 100 IU of insulin ||| 0-0 1-1 1-2 2-3
100 I.E. ||| 100 IU of ||| 0-0 1-1 1-2
100 Patienten betroffen ) ||| in every 100 patients ) ||| 1-0 2-1 0-2 1-3 3-4
100 Patienten betroffen ||| in every 100 patients ||| 1-0 2-1 0-2 1-3
100 mg Paclitaxel . ||| 100 mg paclitaxel . ||| 0-0 1-1 2-2 3-3
100 mg Paclitaxel ||| 100 mg paclitaxel ||| 0-0 1-1 2-2
100 mg ||| 100 mg ||| 0-0 1-1
100 ml . ||| 100 ml . ||| 0-0 1-1 2-2
100 ml . ||| of 100 ml . ||| 0-1 1-2 2-3
100 ml Fertiginfusionslösung ) ||| 100 ml ready-to-infuse solution ) ||| 0-0 1-1 2-2 1-3 3-4
100 ml Fertiginfusionslösung ||| 100 ml ready-to-infuse solution ||| 0-0 1-1 2-2 1-3
100 ml Lösung enthält ||| 100 ml of solution contains ||| 0-0 1-1 2-2 2-3 3-4
100 ml Lösung enthält ||| 100 ml of solution contains ||| 0-0 1-1 2-3 3-4
100 ml Lösung ||| 100 ml of solution ||| 0-0 1-1 2-2 2-3
100 ml Lösung ||| 100 ml of solution ||| 0-0 1-1 2-3
100 ml Teil ||| - 100 ml Component ||| 0-0 0-1 1-2 2-3
100 ml ||| - 100 ml ||| 0-0 0-1 1-2
100 ml ||| 100 ml of ||| 0-0 1-1
100 ml ||| 100 ml ||| 0-0 1-1
100 ml ||| of 100 ml ||| 0-1 1-2
100 ml-Infusion über ||| 100 ml infusion , lasting ||| 0-0 0-1 1-1 1-2 2-3 1-4
100 ng/ml liegt . ||| 100 ng/ ml ||| 0-0 1-1 2-1 1-2 3-2
100 x ||| 100 x ||| 0-0 1-1
100 ||| - 100 ||| 0-0 0-1
100 ||| 100 ||| 0-0
100 ||| of 100 ||| 0-1
1000 I.E. ) Lösung ||| 1000 IU ) of solution ||| 0-0 1-1 2-2 1-3 3-4
1000 I.E. ) ||| 1000 IU ) of ||| 0-0 1-1 2-2 1-3
1000 I.E. ||| 1000 IU . ||| 0-0 1-1 1-2
1000 I.E./0,5 ml ||| 1000 IU/ 0.5 ml ||| 0-0 0-1 1-2 2-3
1000 I.E./0,5 ||| 1000 IU/ 0.5 ||| 0-0 0-1 1-2
1000 Internationale Einheiten ( I.E. ||| 1000 international units ( IU ||| 0-0 1-1 2-2 3-3 4-4
1000 Internationale Einheiten ( ||| 1000 international units ( ||| 0-0 1-1 2-2 3-3
1000 Internationale Einheiten ||| 1000 international units ||| 0-0 1-1 2-2
1000 Internationale ||| 1000 international ||| 0-0 1-1
1000 ||| 1000 IU/ ||| 0-0 0-1
1000 ||| 1000 ||| 0-0
101 ||| 101 ||| 0-0
102 Bei exzessiv hohen ||| Phlebotomy may be performed ||| 0-0 1-0 2-0 2-1 2-2 3-3
102 Bei exzessiv ||| Phlebotomy may be ||| 0-0 1-0 2-0 2-1 2-2
103 Während ||| During ||| 0-0 1-0
104 In tierexperimentellen Studien mit ||| In animal studies , epoetin ||| 1-0 2-1 3-2 0-3 2-4 4-4
104 statistisch nicht ||| , ||| 0-0
104 statistisch ||| , ||| 0-0
104 ||| , ||| 0-0
105 6.6 Besondere ||| 6.6 Special ||| 0-0 1-0 2-1
105 6.6 ||| 6.6 ||| 0-0 1-0
105 Der H2-Antagonist ||| A gastric ||| 2-0 0-1 1-1 2-1
106 ||| 454 ||| 0-0
107 % , ||| by 107 % , ||| 0-0 0-1 1-2 2-3
107 % ||| by 107 % ||| 0-0 0-1 1-2
107 4.2 Dosierung , ||| 4.2 Posology ||| 0-0 1-0 2-1 3-1
107 4.2 ||| 4.2 ||| 0-0 1-0
107 Die folgenden Nebenwirkungen traten ||| The following undesirable effects occurred ||| 1-0 2-1 4-2 3-3 4-4
107 Die folgenden ||| The following ||| 1-0 2-1
107 Die ||| The ||| 1-0
107 ||| 107 ||| 0-0
107 ||| by 107 ||| 0-0 0-1
109/l angestiegen ist und die ||| 109/ l and ||| 0-0 1-0 1-1 2-1 3-2
109/l angestiegen ist und ||| 109/ l and ||| 0-0 1-0 1-1 2-1 3-2
109/l angestiegen ist ||| 109/ l ||| 0-0 1-0 1-1 2-1
109/l erholt hat . ||| 109/ l. ||| 0-0 1-0 0-1 2-1 3-1
10ml ||| 10 ||| 0-0
11 Bei schon lange ||| Usual warning symptoms may ||| 0-0 1-0 2-0 2-1 3-1 3-2 3-3
11 Die Wirksamkeit ||| The efficacy ||| 0-0 1-0 2-1
11 Die ||| The ||| 0-0 1-0
11 g/dl ( 5,9 ||| 11 g/ dl ( 5.9 ||| 0-0 1-1 1-2 2-3 3-4
11 g/dl ( ||| 11 g/ dl ( ||| 0-0 1-1 1-2 2-3
11 g/dl ||| 11 g/ dl ||| 0-0 1-1 1-2
11 ||| , the ||| 0-0
11 ||| , ||| 0-0
11 ||| 11 ||| 0-0
11,6 63,8 31,0 65,1 26,7 ||| 11.6 63.8 31.0 65.1 26.7 ||| 0-0 1-1 2-2 3-3 4-4
11,6 63,8 31,0 65,1 ||| 11.6 63.8 31.0 65.1 ||| 0-0 1-1 2-2 3-3
11,6 63,8 31,0 ||| 11.6 63.8 31.0 ||| 0-0 1-1 2-2
11,6 63,8 ||| 11.6 63.8 ||| 0-0 1-1
11,6 ||| 11.6 ||| 0-0
11,9 47,3 11,6 63,8 31,0 ||| 11.9 47.3 11.6 63.8 31.0 ||| 0-0 1-1 2-2 3-3 4-4
11,9 47,3 11,6 63,8 ||| 11.9 47.3 11.6 63.8 ||| 0-0 1-1 2-2 3-3
11,9 47,3 11,6 ||| 11.9 47.3 11.6 ||| 0-0 1-1 2-2
11,9 47,3 ||| 11.9 47.3 ||| 0-0 1-1
11,9 ||| 11.9 ||| 0-0
11/21 ANGABEN ||| 10/ 20 PARTICULARS ||| 0-0 0-1 1-2
11/21 ||| 10/ 20 ||| 0-0 0-1
110 Die empfohlene Dosierung wird ||| The recommended dosing regimen is ||| 0-0 1-0 2-1 3-2 2-3 3-3 4-4
110 Die empfohlene Dosierung ||| The recommended dosing regimen ||| 0-0 1-0 2-1 3-2 2-3 3-3
110 Die ||| The ||| 0-0 1-0
110 und Verhaltensstörungen ||| and disturbed behaviours , ||| 1-0 2-1 2-2
110 und Verhaltensstörungen ||| and disturbed behaviours ||| 1-0 2-1 2-2
110 und ||| and ||| 1-0
111 Die empfohlene ||| 104 The recommended ||| 0-0 1-1 2-2
111 Die ||| 104 The ||| 0-0 1-1
111 In ||| In ||| 1-0
111 ||| 104 ||| 0-0
112 4.4 Besondere Warnhinweise und ||| 4.4 Special warnings and ||| 0-0 1-0 2-1 3-2 4-3
112 4.4 Besondere Warnhinweise ||| 4.4 Special warnings ||| 0-0 1-0 2-1 3-2
112 4.4 Besondere ||| 4.4 Special ||| 0-0 1-0 2-1
112 4.4 ||| 4.4 ||| 0-0 1-0
113 Bei Patienten mit ||| In patients with ||| 0-0 1-0 2-1 3-2
113 Bei Patienten ||| In patients ||| 0-0 1-0 2-1
113 Bei ||| In ||| 0-0 1-0
116 A. INHABER DER HERSTELLUNGSERLAUBNIS ||| 106 A MANUFACTURING AUTHORISATION ||| 0-0 1-0 1-1 2-2 3-2 4-3
116 A. INHABER DER ||| 106 A MANUFACTURING ||| 0-0 1-0 1-1 2-2 3-2
116 A. ||| 106 A ||| 0-0 1-0 1-1
117 Bei exzessiv hohen ||| Phlebotomy may be performed ||| 0-0 1-0 2-0 2-1 2-2 3-3
117 Bei exzessiv ||| Phlebotomy may be ||| 0-0 1-0 2-0 2-1 2-2
119 ANGABEN AUF DER ||| 109 PARTICULARS TO ||| 0-0 1-1 2-2 3-2
119 ANGABEN AUF DER ÄUSSEREN ||| 109 PARTICULARS TO APPEAR ||| 0-0 1-1 2-2 3-2 4-3
119 ANGABEN ||| 109 PARTICULARS ||| 0-0 1-1
119 In tierexperimentellen Studien mit ||| In animal studies , epoetin ||| 1-0 0-1 2-1 3-2 2-4 4-4
119 ||| 109 ||| 0-0
11fachen ||| 11 ||| 0-0
11fachen ||| resulting ||| 0-0
12 , 24 und 36 ||| 12 , 24 and 36 ||| 0-0 1-1 2-2 3-3 4-4
12 , 24 und ||| 12 , 24 and ||| 0-0 1-1 2-2 3-3
12 , 24 ||| 12 , 24 ||| 0-0 1-1 2-2
12 , ||| 12 , ||| 0-0 1-1
12 - 14 g/dl ||| 12 - 14 g/ dl ||| 0-0 1-1 2-2 3-3 3-4
12 - 14 ||| 12 - 14 ||| 0-0 1-1 2-2
12 - ||| 12 - ||| 0-0 1-1
12 55 ||| 12 55 ||| 0-0 1-1
12 Bei embryofetalen Toxizitätsstudien an ||| Sporadic malformations ( ||| 0-0 1-0 2-0 3-0 2-1
12 Bei embryofetalen Toxizitätsstudien an ||| Sporadic malformations ||| 0-0 1-0 2-0 3-0 2-1
12 Bei embryofetalen Toxizitätsstudien ||| Sporadic malformations ( ||| 0-0 1-0 2-0 3-0 2-1
12 Bei embryofetalen Toxizitätsstudien ||| Sporadic malformations ||| 0-0 1-0 2-0 3-0 2-1
12 Bei exzessiv hohen ||| Phlebotomy may be performed ||| 0-0 1-0 2-0 2-1 2-2 3-3
12 Bei exzessiv ||| Phlebotomy may be ||| 0-0 1-0 2-0 2-1 2-2
12 Monaten ||| 12 months ||| 0-0 1-1
12 Wochen die Konzentration ||| 12 weeks the level ||| 0-0 1-1 2-2 3-3
12 Wochen die ||| 12 weeks the ||| 0-0 1-1 2-2
12 Wochen ||| 12 weeks ||| 0-0 1-1
12 g/dl ( 6,2 ||| 12 g/ dl ( 6.2 ||| 0-0 1-1 1-2 2-3 3-4
12 g/dl ( 7,5 ||| 12 g/ dl ( 7.5 ||| 0-0 1-1 1-2 2-3 3-4
12 g/dl ( ||| 12 g/ dl ( ||| 0-0 1-1 1-2 2-3
12 g/dl zu halten : ||| - 12 g/ dl : ||| 0-0 0-1 1-2 2-2 1-3 3-3 4-4
12 g/dl zu halten ||| - 12 g/ dl ||| 0-0 0-1 1-2 2-2 1-3 3-3
12 g/dl ||| 12 g/ dl ||| 0-0 1-1 1-2
12 ||| - 12 ||| 0-0 0-1
12 ||| 12 ||| 0-0
12,1 % mit Aripiprazol ||| was 12.1 % with aripiprazole ||| 0-0 0-1 1-2 2-3 3-4
12,1 % mit ||| was 12.1 % with ||| 0-0 0-1 1-2 2-3
12,1 % ||| was 12.1 % ||| 0-0 0-1 1-2
12,1 ||| was 12.1 ||| 0-0 0-1
120 6.6 Besondere ||| 6.6 Special ||| 0-0 1-0 2-1
120 6.6 ||| 6.6 ||| 0-0 1-0
120 ml : 22 kg ||| 120 ml : 22 kg ||| 0-0 1-1 2-2 3-3 4-4
120 ml : 22 ||| 120 ml : 22 ||| 0-0 1-1 2-2 3-3
120 ml : ||| 120 ml : ||| 0-0 1-1 2-2
120 ml ||| 120 ml ||| 0-0 1-1
120 ||| 120 ||| 0-0
121 MINDESTANGABEN AUF ||| 111 MINIMUM PARTICULARS TO APPEAR ||| 0-0 1-1 1-2 2-3 2-4
121 MINDESTANGABEN ||| 111 MINIMUM PARTICULARS ||| 0-0 1-1 1-2
121 ||| 111 ||| 0-0
122 % ( N = ||| 122 % ( N = ||| 0-0 1-1 2-2 3-3 4-4
122 % ( N ||| 122 % ( N ||| 0-0 1-1 2-2 3-3
122 % ( ||| 122 % ( ||| 0-0 1-1 2-2
122 % ||| 122 % ||| 0-0 1-1
122 4.2 Dosierung , ||| 4.2 Posology ||| 0-0 1-0 2-1 3-1
122 4.2 ||| 4.2 ||| 0-0 1-0
122 ANGABEN AUF DER ||| 112 PARTICULARS TO ||| 0-0 1-1 2-2 3-2
122 ANGABEN AUF DER ÄUSSEREN ||| 112 PARTICULARS TO APPEAR ||| 0-0 1-1 2-2 3-2 4-3
122 ANGABEN ||| 112 PARTICULARS ||| 0-0 1-1
122 ||| 112 ||| 0-0
122 ||| 122 ||| 0-0
124 MINDESTANGABEN AUF ||| 114 MINIMUM PARTICULARS TO APPEAR ||| 0-0 1-1 1-2 2-3 2-4
124 MINDESTANGABEN ||| 114 MINIMUM PARTICULARS ||| 0-0 1-1 1-2
124 ||| 114 ||| 0-0
125 ANGABEN AUF DER ||| 115 PARTICULARS TO ||| 0-0 1-1 2-2 3-2
125 ANGABEN AUF DER ÄUSSEREN ||| 115 PARTICULARS TO APPEAR ||| 0-0 1-1 2-2 3-2 4-3
125 ANGABEN ||| 115 PARTICULARS ||| 0-0 1-1
125 Die empfohlene Dosierung wird ||| The recommended dosing regimen is ||| 1-0 2-1 0-2 2-3 3-3 4-4
125 Die empfohlene Dosierung ||| The recommended dosing regimen ||| 1-0 2-1 0-2 2-3 3-3
125 ||| 115 ||| 0-0
125 ||| dosing ||| 0-0
126 Die empfohlene ||| 118 The recommended ||| 0-0 1-1 2-2
126 Die ||| 118 The ||| 0-0 1-1
126 ||| 118 ||| 0-0
127 4.4 Besondere Warnhinweise und ||| 4.4 Special warnings and ||| 0-0 1-0 2-1 3-2 4-3
127 4.4 Besondere Warnhinweise ||| 4.4 Special warnings ||| 0-0 1-0 2-1 3-2
127 4.4 Besondere ||| 4.4 Special ||| 0-0 1-0 2-1
127 4.4 ||| 4.4 ||| 0-0 1-0
127 MINDESTANGABEN AUF ||| 117 MINIMUM PARTICULARS TO APPEAR ||| 0-0 1-1 1-2 2-3 2-4
127 MINDESTANGABEN ||| 117 MINIMUM PARTICULARS ||| 0-0 1-1 1-2
127 Männer ||| 2,127 men ||| 0-0 1-1
127 Männer ||| involved 2,127 men ||| 0-1 1-2
127 ||| 117 ||| 0-0
127 ||| 2,127 ||| 0-0
127 ||| involved 2,127 ||| 0-1
128 ANGABEN AUF DER ||| 118 PARTICULARS TO ||| 0-0 1-1 2-2 3-2
128 ANGABEN AUF DER ÄUSSEREN ||| 118 PARTICULARS TO APPEAR ||| 0-0 1-1 2-2 3-2 4-3
128 ANGABEN ||| 118 PARTICULARS ||| 0-0 1-1
128 Bei Patienten mit ||| In patients with ||| 0-0 1-0 2-1 3-2
128 Bei Patienten ||| In patients ||| 0-0 1-0 2-1
128 Bei ||| In ||| 0-0 1-0
128 ||| 118 ||| 0-0
13 % ( 141 ||| 13 % ( 141 ||| 0-0 1-1 2-2 3-3
13 % ( ||| 13 % ( ||| 0-0 1-1 2-2
13 % der ||| 13 % of the ||| 0-0 1-1 2-2 2-3
13 % ||| 13 % ||| 0-0 1-1
13 . ||| 13 ||| 0-0
13 Tagen ||| 13 days ||| 0-0 1-1
13 g/dl , die ||| 13 g/ dl , the ||| 0-0 1-1 1-2 2-3 3-4
13 g/dl , ||| 13 g/ dl , ||| 0-0 1-1 1-2 2-3
13 g/dl , ||| 13 g/ dl ||| 0-0 1-1 1-2
13 g/dl ||| 13 g/ dl ||| 0-0 1-1 1-2
13 ||| 13 July ||| 0-0
13 ||| 13 ||| 0-0
13,2 [ 7,54 ||| 13.2 [ 7.54 ||| 0-0 1-1 2-2
13,2 [ ||| 13.2 [ ||| 0-0 1-1
13,2 ||| 13.2 ||| 0-0
13/21 MINDESTANGABEN ||| 12/ 20 MINIMUM PARTICULARS TO ||| 0-0 0-1 1-2 1-3 1-4
13/21 ||| 12/ 20 ||| 0-0 0-1
130 MINDESTANGABEN AUF ||| 120 MINIMUM PARTICULARS TO APPEAR ||| 0-0 0-1 1-1 1-2 2-3 2-4
130 MINDESTANGABEN ||| 120 MINIMUM PARTICULARS ||| 0-0 0-1 1-1 1-2
131 ) ||| 131 ) ||| 0-0 1-1
131 ANGABEN AUF DER ||| 121 PARTICULARS TO ||| 0-0 1-1 2-2 3-2
131 ANGABEN AUF DER ÄUSSEREN ||| 121 PARTICULARS TO APPEAR ||| 0-0 1-1 2-2 3-2 4-3
131 ANGABEN ||| 121 PARTICULARS ||| 0-0 1-1
131 ||| 121 ||| 0-0
131 ||| 131 ||| 0-0
132 ) ||| 132 ) ||| 0-0 1-1
132 Bei exzessiv hohen ||| Phlebotomy may be performed ||| 0-0 1-0 2-0 2-1 2-2 3-3
132 Bei exzessiv ||| Phlebotomy may be ||| 0-0 1-0 2-0 2-1 2-2
132 ||| 132 ||| 0-0
133 MINDESTANGABEN ||| 123 MINIMUM PARTICULARS TO ||| 0-0 1-1 1-2 1-3
133 ||| 123 ||| 0-0
134 ANGABEN AUF DER ||| 124 PARTICULARS TO ||| 0-0 1-1 2-2 3-2
134 ANGABEN AUF DER ÄUSSEREN ||| 124 PARTICULARS TO APPEAR ||| 0-0 1-1 2-2 3-2 4-3
134 ANGABEN ||| 124 PARTICULARS ||| 0-0 1-1
134 In tierexperimentellen Studien mit ||| In animal studies , epoetin ||| 1-0 0-1 2-1 3-2 2-4 4-4
134 ||| 124 ||| 0-0
135 ) ||| 135 ) ||| 0-0 1-1
135 6.6 Besondere ||| 6.6 Special ||| 0-0 1-0 2-1
135 6.6 ||| 6.6 ||| 0-0 1-0
135 ||| 135 ||| 0-0
136 ) ||| 136 ) ||| 0-0 1-1
136 MINDESTANGABEN ||| 126 MINIMUM PARTICULARS TO ||| 0-0 1-1 1-2 1-3
136 ||| 126 ||| 0-0
136 ||| 136 ||| 0-0
137 4.2 Dosierung , ||| 4.2 Posology ||| 0-0 1-0 2-1 3-1
137 4.2 ||| 4.2 ||| 0-0 1-0
137 ANGABEN AUF DER ||| 127 PARTICULARS TO ||| 0-0 1-1 2-2 3-2
137 ANGABEN AUF DER ÄUSSEREN ||| 127 PARTICULARS TO APPEAR ||| 0-0 1-1 2-2 3-2 4-3
137 ANGABEN ||| 127 PARTICULARS ||| 0-0 1-1
137 ||| 127 ||| 0-0
139 MINDESTANGABEN ||| 129 MINIMUM PARTICULARS TO ||| 0-0 1-1 1-2 1-3
139 von 1 062 ) ||| 139 out of 1,062 ) ||| 0-0 1-1 1-2 3-3 4-4
139 von 1 062 ||| 139 out of 1,062 ||| 0-0 1-1 1-2 3-3
139 von 1 ||| 139 out of ||| 0-0 1-1 1-2
139 von ||| 139 out of ||| 0-0 1-1 1-2
139 ||| 129 ||| 0-0
139 ||| 139 ||| 0-0
14 , 28 , 56 ||| 14 , 28 , 56 ||| 0-0 1-1 2-2 3-3 4-4
14 , 28 , ||| 14 , 28 , ||| 0-0 1-1 2-2 3-3
14 , 28 , ||| 14 , 28 ||| 0-0 1-1 3-1 2-2
14 , 28 , ||| of 14 , 28 ||| 0-1 1-2 3-2 2-3
14 , 28 ||| 14 , 28 ||| 0-0 1-1 2-2
14 , ||| 14 , ||| 0-0 1-1
14 30 ||| 14 30 ||| 0-0 1-1
14 In tierexperimentellen Studien mit ||| In animal studies , epoetin ||| 1-0 2-1 0-2 3-2 2-4 4-4
14 Patienten mit ||| Patients with ||| 0-0 1-0 2-1
14 Patienten ||| Patients ||| 0-0 1-0
14 Tabletten 28 Tabletten 30 ||| 14 tablets 28 tablets 30 ||| 0-0 1-1 2-2 3-3 4-4
14 Tabletten 28 Tabletten ||| 14 tablets 28 tablets ||| 0-0 1-1 2-2 3-3
14 Tabletten 28 ||| 14 tablets 28 ||| 0-0 1-1 2-2
14 Tabletten ||| 14 tablets ||| 0-0 1-1
14 g/dl ( 7,5 ||| 14 g/ dl ( 7.5 ||| 0-0 1-1 1-2 2-3 3-4
14 g/dl ( ||| 14 g/ dl ( ||| 0-0 1-1 1-2 2-3
14 g/dl . ||| 14 g/ dl . ||| 0-0 1-1 1-2 2-3
14 g/dl ||| 14 g/ dl ||| 0-0 1-1 1-2
14 n la sse ge ||| 12 d ise or uth ||| 0-0 1-1 2-1 3-2 4-3 4-4
14 n la sse ||| 12 d ise ||| 0-0 1-1 2-1 3-2
14 n la ||| 12 d ||| 0-0 1-1 2-1
14 und 7 ) ||| 14 and 7 ) ||| 0-0 1-1 2-2 3-3
14 und 7 ||| 14 and 7 ||| 0-0 1-1 2-2
14 und ||| 14 and ||| 0-0 1-1
14 x 1 , ||| 14 x 1 , ||| 0-0 1-1 2-2 3-3
14 x 1 Schmelztabletten ||| 14 x 1 orodispersible tablets ||| 0-0 1-1 2-2 3-3 3-4
14 x 1 Tabletten 28 ||| 14 x 1 tablets 28 ||| 0-0 1-1 2-2 3-3 4-4
14 x 1 Tabletten in ||| 14 x 1 tablets in ||| 0-0 1-1 2-2 3-3 4-4
14 x 1 Tabletten ||| 14 x 1 tablets ||| 0-0 1-1 2-2 3-3
14 x 1 ||| 14 x 1 ||| 0-0 1-1 2-2
14 x ||| 14 x ||| 0-0 1-1
14 ||| 12 ||| 0-0
14 ||| 14 ||| 0-0
14 ||| Fourteen ||| 0-0
14 ||| of 14 ||| 0-1
14,2 % ( 10 ||| 14.2 % ( 10 ||| 0-0 1-1 2-2 3-3
14,2 % ( ||| 14.2 % ( ||| 0-0 1-1 2-2
14,2 % ||| 14.2 % ||| 0-0 1-1
14,2 ||| 14.2 ||| 0-0
14/21 ANGABEN ||| 13/ 20 PARTICULARS TO ||| 0-0 0-1 1-2 1-3
14/21 ||| 13/ 20 ||| 0-0 0-1
140 ANGABEN AUF DER ||| 130 PARTICULARS TO APPEAR ON ||| 0-0 1-1 2-2 2-3 2-4 3-4
140 ANGABEN ||| 130 PARTICULARS ||| 0-0 1-1
140 Die empfohlene Dosierung wird ||| The recommended dosing regimen is ||| 0-0 1-0 2-1 3-2 2-3 3-3 4-4
140 Die empfohlene Dosierung ||| The recommended dosing regimen ||| 0-0 1-0 2-1 3-2 2-3 3-3
140 Die ||| The ||| 0-0 1-0
140 ||| 130 ||| 0-0
141 Die empfohlene ||| 132 The recommended ||| 0-0 1-1 2-2
141 Die ||| 132 The ||| 0-0 1-1
141 ||| 132 ||| 0-0
141 ||| 141 ||| 0-0
142 4.4 Besondere Warnhinweise und ||| 4.4 Special warnings and ||| 0-0 1-0 2-1 3-2 4-3
142 4.4 Besondere Warnhinweise ||| 4.4 Special warnings ||| 0-0 1-0 2-1 3-2
142 4.4 Besondere ||| 4.4 Special ||| 0-0 1-0 2-1
142 4.4 ||| 4.4 ||| 0-0 1-0
143 Bei Patienten mit ||| In patients with ||| 1-0 0-1 2-1 3-2
143 Bei Patienten ||| In patients ||| 1-0 0-1 2-1
143 mit Aclasta ||| 143 Aclasta-treated ||| 0-0 1-1 2-1
143 ||| 143 ||| 0-0
144 MINDESTANGABEN ||| 134 MINIMUM PARTICULARS TO ||| 0-0 1-1 1-2 1-3
144 ||| 134 ||| 0-0
146 Stunden . ||| 146 hours . ||| 0-0 1-1 2-2
146 Stunden ||| 146 hours ||| 0-0 1-1
146 ||| 146 ||| 0-0
146 ||| of ||| 0-0
147 Bei exzessiv hohen ||| Phlebotomy may be performed ||| 0-0 1-0 2-0 2-1 2-2 3-3
147 Bei exzessiv ||| Phlebotomy may be ||| 0-0 1-0 2-0 2-1 2-2
149 In tierexperimentellen Studien mit ||| In animal studies , epoetin ||| 1-0 0-1 2-1 3-2 2-4 4-4
15 " auf einer Seite ||| 15 " on one side ||| 0-0 1-1 2-2 3-3 4-3 4-4
15 " auf ||| 15 " on ||| 0-0 1-1 2-2
15 " ||| 15 " ||| 0-0 1-1
15 , 30 oder 45 ||| 15 , 30 or 45 ||| 0-0 1-1 2-2 3-3 4-4
15 , 30 oder ||| 15 , 30 or ||| 0-0 1-1 2-2 3-3
15 , 30 ||| 15 , 30 ||| 0-0 1-1 2-2
15 , ||| 15 , ||| 0-0 1-1
15 . ||| 15 ||| 0-0
15 6.6 Besondere ||| 6.6 Special ||| 0-0 1-0 2-1
15 6.6 ||| 6.6 ||| 0-0 1-0
15 Minuten betragen . ||| 15 minutes . ||| 0-0 1-1 2-1 3-2
15 Minuten betragen ||| 15 minutes ||| 0-0 1-1 2-1
15 Minuten dauernde Infusionen von ||| 15-minute infusions of ||| 2-0 2-1 3-1 1-2 4-2
15 Minuten verabreicht . ||| 15 minutes . ||| 0-0 1-1 2-1 3-2
15 Minuten verabreicht ||| 15 minutes ||| 0-0 1-1 2-1
15 Minuten ||| 15 minutes caused ||| 0-0 1-1
15 Minuten ||| 15 minutes ||| 0-0 1-1
15 Spätdyskinesien : in klinischen ||| Tardive Dyskinesia : in clinical ||| 1-0 1-1 2-2 3-3 4-4
15 Spätdyskinesien : in ||| Tardive Dyskinesia : in ||| 1-0 1-1 2-2 3-3
15 Spätdyskinesien : ||| Tardive Dyskinesia : ||| 1-0 1-1 2-2
15 Spätdyskinesien ||| Tardive Dyskinesia ||| 1-0 1-1
15 auf einer Seite . ||| 15 on one side . ||| 0-0 1-1 2-2 3-2 3-3 4-4
15 auf einer Seite ||| 15 on one side ||| 0-0 1-1 2-2 3-2 3-3
15 auf ||| 15 on ||| 0-0 1-1
15 l/h/m2 . ||| 15 l/ hr/ m2 . ||| 0-0 1-1 1-2 1-3 2-4
15 l/h/m2 ||| 15 l/ hr/ m2 ||| 0-0 1-1 1-2 1-3
15 mg , 30 mg ||| 15 mg , 30 ||| 0-0 1-1 4-1 2-2 3-3
15 mg Aripiprazol ) ||| 15 mg aripiprazole ) ||| 0-0 1-1 2-2 3-3
15 mg Aripiprazol . ||| 15 mg of aripiprazole . ||| 0-0 1-1 2-3 3-4
15 mg Aripiprazol ||| 15 mg aripiprazole ||| 0-0 1-1 2-2
15 mg Aripiprazol ||| 15 mg of aripiprazole ||| 0-0 1-1 2-3
15 mg Dosis ) ||| dose 15 mg ) ||| 2-0 0-1 1-2 3-3
15 mg Dosis ||| dose 15 mg ||| 2-0 0-1 1-2
15 mg Pioglitazon ( als ||| 15 mg pioglitazone ( as ||| 0-0 1-1 2-2 3-3 4-4
15 mg Pioglitazon ( als ||| 15mg of pioglitazone ( as ||| 0-0 1-0 2-2 3-3 4-4
15 mg Pioglitazon ( ||| 15 mg pioglitazone ( ||| 0-0 1-1 2-2 3-3
15 mg Pioglitazon ( ||| 15mg of pioglitazone ( ||| 0-0 1-0 2-2 3-3
15 mg Pioglitazon als ||| 15 mg of pioglitazone as ||| 0-0 1-1 2-3 3-4
15 mg Pioglitazon ||| 15 mg of pioglitazone ||| 0-0 1-1 2-3
15 mg Pioglitazon ||| 15 mg pioglitazone ||| 0-0 1-1 2-2
15 mg Pioglitazon ||| 15mg of pioglitazone ||| 0-0 1-0 2-2
15 mg Schmelztabletten sind ||| 15 mg orodispersible tablets are ||| 0-0 1-1 2-2 2-3 3-4
15 mg Schmelztabletten ||| 15 mg orodispersible tablets ||| 0-0 1-1 2-2 2-3
15 mg Tabletten die ||| 15mg tablets ||| 0-0 1-0 2-1
15 mg Tabletten eingenommen ||| 15mg tablets ||| 0-0 1-0 2-1 3-1
15 mg Tabletten ist Pioglitazon ||| 15mg tablets is pioglitazone ||| 0-0 1-0 2-1 3-2 4-3
15 mg Tabletten ist ||| 15mg tablets is ||| 0-0 1-0 2-1 3-2
15 mg Tabletten können ||| 15 mg tablets may ||| 0-0 1-1 2-2 3-3
15 mg Tabletten können ||| 15mg tablets can be ||| 0-0 1-0 2-1 3-2 3-3
15 mg Tabletten mit ||| 15mg tablets with ||| 0-0 1-0 2-1 3-2
15 mg Tabletten sind rund ||| 15 mg tablets are round ||| 0-0 1-1 2-2 3-3 4-4
15 mg Tabletten sind ||| 15 mg tablets are ||| 0-0 1-1 2-2 3-3
15 mg Tabletten werden ||| 15mg tablets are ||| 0-0 1-0 2-1 3-2
15 mg Tabletten ||| 15 mg tablets ||| 0-0 1-1 2-2
15 mg Tabletten ||| 15mg tablets ||| 0-0 1-0 2-1
15 mg einmal täglich ||| 15 mg once a day ||| 0-0 1-1 2-2 2-3 3-4
15 mg einmal ||| 15 mg once a ||| 0-0 1-1 2-2 2-3
15 mg oder 30 mg ||| 15 mg or 30 mg ||| 0-0 1-1 2-2 3-3 4-4
15 mg oder 30 ||| 15 mg or 30 ||| 0-0 1-1 2-2 3-3
15 mg oder ||| 15 mg or ||| 0-0 1-1 2-2
15 mg und 30 mg ||| 15 mg and 30 mg ||| 0-0 1-1 2-2 3-3 4-4
15 mg und 30 ||| 15 mg and 30 ||| 0-0 1-1 2-2 3-3
15 mg und ||| 15 mg and ||| 0-0 1-1 2-2
15 mg waren ||| 15 mg were ||| 0-0 1-1 2-2
15 mg wurde nicht ||| 15 mg has not ||| 0-0 1-1 2-2 3-3
15 mg wurde ||| 15 mg has ||| 0-0 1-1 2-2
15 mg ||| 15 mg of ||| 0-0 1-1
15 mg ||| 15 mg ||| 0-0 1-1
15 mg ||| 15mg of ||| 0-0 1-0
15 mg ||| 15mg ||| 0-0 1-0
15 mg/Tag ( ||| 15 mg/ day ( ||| 0-0 1-1 1-2 2-3
15 mg/Tag ||| 15 mg/ day ||| 0-0 1-1 1-2
15 ml Lösung ( ||| 15 ml solution ( corresponding ||| 0-0 1-1 2-2 3-3 1-4
15 ml Lösung ||| 15 ml solution/ ||| 0-0 1-1 2-1 0-2
15 ||| 15 ||| 0-0
15 ||| 15mg ||| 0-0
15 ||| less than 15 ||| 0-0 0-1 0-2
15,0 ; 18,3 ] ( ||| 15.0 , 18.3 ] ( ||| 0-0 1-0 1-1 2-2 3-3 4-4
15,0 ; 18,3 ] ||| 15.0 , 18.3 ] ||| 0-0 1-0 1-1 2-2 3-3
15,0 ; 18,3 ||| 15.0 , 18.3 ||| 0-0 1-0 1-1 2-2
15,0 ; 19,3 ] ( ||| 15.0 , 19.3 ] ( ||| 0-0 1-0 1-1 2-2 3-3 4-4
15,0 ; 19,3 ] ||| 15.0 , 19.3 ] ||| 0-0 1-0 1-1 2-2 3-3
15,0 ; 19,3 ||| 15.0 , 19.3 ||| 0-0 1-0 1-1 2-2
15,0 ; ||| 15.0 , ||| 0-0 1-0 1-1
15,7 % für ||| 15.7 % for ||| 0-0 1-1 2-2
15,7 % ||| 15.7 % ||| 0-0 1-1
15,7 ; 25,9 ] ( ||| 15.7 , 25.9 ] ( ||| 0-0 1-2 2-2 3-3 4-4
15,7 ; 25,9 ] ||| 15.7 , 25.9 ] ||| 0-0 1-2 2-2 3-3
15,7 ; 25,9 ||| 15.7 , 25.9 ||| 0-0 1-2 2-2
15,7 ||| 15.7 , ||| 0-0
15,7 ||| 15.7 ||| 0-0
15-mg-Dosen verringerten ||| of 10 ||| 0-0 1-0
15-mg-Dosen verringerten ||| of ||| 0-0 1-0
15-minütige Infusion ||| infusion ||| 1-0
150 30 - 100 ||| 150 30 - 100 ||| 0-0 1-1 2-2 3-3
150 30 - ||| 150 30 - ||| 0-0 1-1 2-2
150 30 ||| 150 30 ||| 0-0 1-1
150 6.6 Besondere ||| 6.6 Special ||| 0-0 1-0 2-1
150 6.6 ||| 6.6 ||| 0-0 1-0
150 60 - 150 30 ||| 150 60 - 150 30 ||| 0-0 1-1 2-2 3-3 4-4
150 60 - 150 ||| 150 60 - 150 ||| 0-0 1-1 2-2 3-3
150 60 - ||| 150 60 - ||| 0-0 1-1 2-2
150 60 ||| 150 60 ||| 0-0 1-1
150 I.E./kg dreimal ||| at 150 IU/ kg 3 ||| 2-0 0-1 1-2 2-2 1-3 2-4
150 I.E./kg subkutan ||| 150 IU/ kg given subcutaneously ||| 0-0 1-1 1-2 2-3 2-4
150 I.E./kg ||| 103 150 IU/ kg ||| 0-0 0-1 1-2 1-3
150 I.E./kg ||| 117 150 IU/ kg ||| 0-0 0-1 1-2 1-3
150 I.E./kg ||| 131 150 IU/ kg ||| 0-0 0-1 1-2 1-3
150 I.E./kg ||| 150 IU/ kg ||| 0-0 1-1 1-2
150 I.E./kg ||| 19 150 IU/ kg ||| 0-0 0-1 1-2 1-3
150 I.E./kg ||| 33 150 IU/ kg ||| 1-0 0-1 1-2 1-3
150 I.E./kg ||| 47 150 IU/ kg ||| 0-0 0-1 1-2 1-3
150 I.E./kg ||| 5 150 IU/ kg ||| 0-0 0-1 1-2 1-3
150 I.E./kg ||| 61 150 IU/ kg ||| 0-0 0-1 1-2 1-3
150 I.E./kg ||| 75 150 IU/ kg ||| 0-0 0-1 1-2 1-3
150 I.E./kg ||| 89 150 IU/ kg ||| 0-0 0-1 1-2 1-3
150 Internationale Einheiten ( I.E. ||| 150 International Units ( IU ||| 0-0 1-1 2-2 3-3 4-4
150 Internationale Einheiten ( ||| 150 International Units ( ||| 0-0 1-1 2-2 3-3
150 Internationale Einheiten ||| 150 International Units ||| 0-0 1-1 2-2
150 Internationale ||| 150 International ||| 0-0 1-1
150 ml Lösung zum Einnehmen ||| 150 ml oral solution ||| 0-0 1-1 3-2 4-2 2-3 4-3
150 ml ||| 150 ml ||| 0-0 1-1
150 oder 480 ml pro ||| 150 or 480 ml per ||| 0-0 1-1 2-2 3-3 4-4
150 oder 480 ml ||| 150 or 480 ml ||| 0-0 1-1 2-2 3-3
150 oder 480 ||| 150 or 480 ||| 0-0 1-1 2-2
150 oder ||| 150 or ||| 0-0 1-1
150 ||| 103 150 ||| 0-0 0-1
150 ||| 117 150 ||| 0-0 0-1
150 ||| 131 150 ||| 0-0 0-1
150 ||| 150 ||| 0-0
150 ||| 19 150 ||| 0-0 0-1
150 ||| 47 150 ||| 0-0 0-1
150 ||| 5 150 ||| 0-0 0-1
150 ||| 61 150 ||| 0-0 0-1
150 ||| 75 150 ||| 0-0 0-1
150 ||| 89 150 ||| 0-0 0-1
158 MINDESTANGABEN AUF ||| 148 MINIMUM PARTICULARS TO APPEAR ||| 0-0 1-1 1-2 2-3 2-4
158 MINDESTANGABEN ||| 148 MINIMUM PARTICULARS ||| 0-0 1-1 1-2
158 ||| 148 ||| 0-0
159 MINDESTANGABEN ||| 149 MINIMUM PARTICULARS TO ||| 0-0 0-1 1-2 1-3
159 ||| 149 MINIMUM ||| 0-0 0-1
16 % ) der ||| 16 % ) of ||| 0-0 1-1 2-2 3-3
16 % ) ||| 16 % ) ||| 0-0 1-1 2-2
16 % der verabreichten ||| 16 % of the administered ||| 0-0 1-1 2-2 2-3 3-3
16 % der verabreichten ||| 16 % of the ||| 0-0 1-1 2-2 2-3 3-3
16 % ||| 16 % ||| 0-0 1-1
16 - 23 Stunden . ||| 16 to 23 hours . ||| 0-0 1-1 2-2 3-3 4-4
16 - 23 Stunden ||| 16 to 23 hours ||| 0-0 1-1 2-2 3-3
16 - 23 ||| 16 to 23 ||| 0-0 1-1 2-2
16 - ||| 16 to ||| 0-0 1-1
16 00 ||| 16 00 ||| 0-0 1-1
16 16 ||| 16 16 ||| 0-0 1-1
16 84 00 ||| 16 84 00 ||| 0-0 1-1 2-2
16 84 ||| 16 84 ||| 0-0 1-1
16 Gewichtszunahme : Eine Gewichtszunahme ||| Weight gain : weight gain ||| 1-0 3-0 1-1 0-2 2-2 4-3 4-4
16 Gewichtszunahme : Eine ||| Weight gain : ||| 1-0 3-0 1-1 0-2 2-2
16 mg Zoledronsäure ||| 16 mg zoledronic acid ||| 0-0 1-1 2-2 2-3
16 mg ||| 16 mg ||| 0-0 1-1
16 ||| 16 ||| 0-0
16,1 [ 15,0 ; 18,3 ||| 16.1 [ 15.0 , 18.3 ||| 0-0 1-1 2-2 3-2 3-3 4-4
16,1 [ 15,0 ; 19,3 ||| 16.1 [ 15.0 , 19.3 ||| 0-0 1-1 2-2 3-2 3-3 4-4
16,1 [ 15,0 ; ||| 16.1 [ 15.0 , ||| 0-0 1-1 2-2 3-2 3-3
16,1 [ ||| 16.1 [ ||| 0-0 1-1
16,1 ||| 16.1 ||| 0-0
16,5 ; 10,2 ||| HDL-C and triglycerides in ||| 0-0 2-0 1-1 2-2
16,5 ; 10,2 ||| HDL-C and triglycerides ||| 0-0 2-0 1-1 2-2
16,5 ; 10,2 ||| in HDL-C and triglycerides in ||| 0-1 2-1 1-2 2-3
16,5 ; 10,2 ||| in HDL-C and triglycerides ||| 0-1 2-1 1-2 2-3
16,7 ||| 44.7 ||| 0-0
16,8 Mikrogramm Epoetin alfa ||| 16.8 micrograms epoetin alfa ||| 0-0 1-1 2-2 3-3
16,8 Mikrogramm Epoetin ||| 16.8 micrograms epoetin ||| 0-0 1-1 2-2
16,8 Mikrogramm Epoetin ||| corresponding to 16.8 micrograms epoetin ||| 1-0 0-2 1-3 2-4
16,8 Mikrogramm ||| 16.8 micrograms ||| 0-0 1-1
16,8 Mikrogramm ||| corresponding to 16.8 micrograms ||| 1-0 0-2 1-3
16,8 ||| 16.8 ||| 0-0
16,8 ||| to 16.8 ||| 0-1
160 Patienten , bei denen ||| in 160 patients whose ||| 0-0 3-0 1-2 4-3
160 Patienten , bei ||| in 160 patients ||| 0-0 3-0 1-2
162 MINDESTANGABEN AUF ||| 152 MINIMUM PARTICULARS TO APPEAR ||| 0-0 1-1 1-2 2-3 2-4
162 MINDESTANGABEN ||| 152 MINIMUM PARTICULARS ||| 0-0 1-1 1-2
162 ||| 152 ||| 0-0
163 MINDESTANGABEN ||| 153 MINIMUM PARTICULARS TO ||| 0-0 0-1 1-2 1-3
163 ||| 153 MINIMUM ||| 0-0 0-1
165 Aminosäuren . ||| 165 amino acids . ||| 0-0 1-1 1-2 2-3
165 Aminosäuren ||| 165 amino acids ||| 0-0 1-1 1-2
165 ||| 165 ||| 0-0
166 MINDESTANGABEN AUF ||| 156 MINIMUM PARTICULARS TO APPEAR ||| 0-0 1-1 1-2 2-3 2-4
166 MINDESTANGABEN ||| 156 MINIMUM PARTICULARS ||| 0-0 1-1 1-2
166 ||| 156 ||| 0-0
167 MINDESTANGABEN ||| 157 MINIMUM PARTICULARS TO ||| 0-0 0-1 1-2 1-3
167 ||| 157 MINIMUM ||| 0-0 0-1
16736 ||| 16736 ||| 0-0
17 , Km 22 , ||| 17 , Km 22 , ||| 0-0 1-1 2-2 3-3 4-4
17 , Km 22 ||| 17 , Km 22 ||| 0-0 1-1 2-2 3-3
17 , Km ||| 17 , Km ||| 0-0 1-1 2-2
17 , ||| 17 , ||| 0-0 1-1
17 4.2 Dosierung , ||| 4.2 Posology ||| 0-0 1-0 2-1 3-1
17 4.2 ||| 4.2 ||| 0-0 1-0
17 Wichtige Anzeichen und Symptome ||| signs and symptoms of ||| 2-0 0-1 3-1 4-2 1-3
17 und 33 I.E./kg ||| 17 and 33 IU/ kg ||| 0-0 1-1 2-2 3-3 3-4
17 und 33 ||| 17 and 33 ||| 0-0 1-1 2-2
17 und ||| 17 and ||| 0-0 1-1
17 ||| 17 ||| 0-0
17,1 ||| Incidence of individual ||| 0-0 0-2
17/21 PACKUNGSBEILAGE Yarvitan ||| 16/ 20 PACKAGE LEAFLET Yarvitan ||| 0-0 0-1 1-2 1-3 2-4
17/21 PACKUNGSBEILAGE ||| 16/ 20 PACKAGE LEAFLET ||| 0-0 0-1 1-2 1-3
17/21 ||| 16/ 20 ||| 0-0 0-1
170 MINDESTANGABEN AUF ||| 160 MINIMUM PARTICULARS TO APPEAR ||| 0-0 1-1 1-2 2-3 2-4
170 MINDESTANGABEN ||| 160 MINIMUM PARTICULARS ||| 0-0 1-1 1-2
170 ||| 160 ||| 0-0
171 ) , Macrogol ||| E171 ) , macrogol ||| 0-0 1-1 2-2 3-3
171 ) , ||| E171 ) , ||| 0-0 1-1 2-2
171 ) ||| E171 ) ||| 0-0 1-1
171 MINDESTANGABEN ||| 161 MINIMUM PARTICULARS TO ||| 0-0 1-1 1-2 1-3
171 ||| 161 ||| 0-0
171 ||| E171 ||| 0-0
172 Mammakarzinome , 64 ||| 172 breast , 64 ||| 0-0 1-0 1-1 2-2 3-3
172 Mammakarzinome , ||| 172 breast , ||| 0-0 1-0 1-1 2-2
172 Mammakarzinome ||| 172 breast ||| 0-0 1-0 1-1
1736 ||| 1736 ||| 0-0
174 MINDESTANGABEN AUF ||| 164 MINIMUM PARTICULARS TO APPEAR ||| 0-0 1-1 1-2 2-3 2-4
174 MINDESTANGABEN ||| 164 MINIMUM PARTICULARS ||| 0-0 1-1 1-2
174 gynäkologische Tumoren ||| 174 gynaecological ||| 0-0 2-0 1-1
174 ||| 164 ||| 0-0
175 Ireland BRISTOL-MYERS SQUIBB PHARMACEUTICALS ||| Ireland BRISTOL-MYERS SQUIBB PHARMACEUTICALS ||| 0-0 1-0 2-1 3-2 4-3
175 Ireland BRISTOL-MYERS SQUIBB ||| Ireland BRISTOL-MYERS SQUIBB ||| 0-0 1-0 2-1 3-2
175 Ireland BRISTOL-MYERS ||| Ireland BRISTOL-MYERS ||| 0-0 1-0 2-1
175 Ireland ||| Ireland ||| 0-0 1-0
175 MINDESTANGABEN ||| 165 MINIMUM PARTICULARS TO ||| 0-0 0-1 1-1 1-2 1-3
175 mg/m2 ||| 175 mg/ m2 ||| 0-0 1-1 1-2
175 ||| 175 ||| 0-0
177 Wenn Sie ||| If you ||| 0-0 1-0 2-1
177 Wenn ||| If ||| 0-0 1-0
178 MINDESTANGABEN AUF ||| 168 MINIMUM PARTICULARS TO APPEAR ||| 0-0 1-1 1-2 2-3 2-4
178 MINDESTANGABEN ||| 168 MINIMUM PARTICULARS ||| 0-0 1-1 1-2
178 ||| 168 ||| 0-0
179 MINDESTANGABEN ||| 169 MINIMUM PARTICULARS TO ||| 0-0 0-1 1-2 1-3
179 ||| 169 MINIMUM ||| 0-0 0-1
18 % ||| 18 % ||| 0-0 1-1
18 4.7 Auswirkungen auf ||| 4.7 Effects on ||| 0-0 1-0 2-1 3-2
18 4.7 Auswirkungen ||| 4.7 Effects ||| 0-0 1-0 2-1
18 4.7 ||| 4.7 ||| 0-0 1-0
18 84 00 ||| 18 84 00 ||| 0-0 1-1 2-2
18 84 16 ||| 18 84 16 ||| 0-0 1-1 2-2
18 84 ||| 18 84 ||| 0-0 1-1
18 86 68 ||| 18 86 68 ||| 0-0 1-1 2-2
18 86 ||| 18 86 ||| 0-0 1-1
18 Anpassung der Dosis Begleiterkrankungen ||| Dosage adjustment Concomitant illness ||| 0-0 1-0 1-1 1-2 2-2 4-2 3-3 4-3
18 Jahren . ||| 18 years of age . ||| 0-0 1-1 0-2 1-3 2-4
18 Jahren aufgrund ||| age 18 years due ||| 1-0 0-1 1-2 2-3
18 Jahren ||| 18 years of age due ||| 0-0 1-1 1-3
18 Jahren ||| 18 years of age ||| 0-0 1-1 0-2 1-3
18 Jahren ||| 18 years of age ||| 0-0 1-1 1-3
18 Jahren ||| age 18 years ||| 1-0 0-1 1-2
18 Monate Das Arzneimittel ist ||| 18 months Use product ||| 0-0 1-1 2-2 3-3 4-3
18 Monate Das ||| 18 months Use ||| 0-0 1-1 2-2
18 Monate ||| 18 months ||| 0-0 1-1
18 oder 13 ||| 18 , or 13 ||| 0-0 1-2 2-3
18 oder ||| 18 , or ||| 0-0 1-2
18 ||| 18 , ||| 0-0
18 ||| 18 ||| 0-0
18,3 ] ( n = ||| 18.3 ] ( n = ||| 0-0 1-1 2-2 3-3 4-3 4-4
18,3 ] ( ||| 18.3 ] ( ||| 0-0 1-1 2-2
18,3 ] ||| 18.3 ] ||| 0-0 1-1
18,3 ||| 18.3 ||| 0-0
18,7 ||| 18.7 ||| 0-0
18,93 ||| 18.93 ||| 0-0
18,98 ; 34,05 ] ( ||| , 34.05 ] ( ||| 0-1 2-1 1-2 3-2 4-3
18,98 ; 34,05 ] ( ||| 34.05 ] ( ||| 0-0 2-0 1-1 3-1 4-2
18,98 ; 34,05 ] ||| , 34.05 ] ||| 0-1 2-1 1-2 3-2
18,98 ; 34,05 ] ||| 34.05 ] ||| 0-0 2-0 1-1 3-1
180 mg ||| 180 mg ||| 0-0 1-1
180 ||| 180 ||| 0-0
180-minütigen Infusionen von Abraxane ||| 180-minute infusions of Abraxane ||| 0-0 1-1 2-2 3-3
180-minütigen Infusionen von ||| 180-minute infusions of ||| 0-0 1-1 2-2
180-minütigen Infusionen ||| 180-minute infusions ||| 0-0 1-1
180-minütigen ||| 180-minute ||| 0-0
181 Ireland BRISTOL-MYERS SQUIBB PHARMACEUTICALS ||| Ireland BRISTOL-MYERS SQUIBB PHARMACEUTICALS ||| 0-0 1-0 2-1 3-2 4-3
181 Ireland BRISTOL-MYERS SQUIBB ||| Ireland BRISTOL-MYERS SQUIBB ||| 0-0 1-0 2-1 3-2
181 Ireland BRISTOL-MYERS ||| Ireland BRISTOL-MYERS ||| 0-0 1-0 2-1
181 Ireland ||| Ireland ||| 0-0 1-0
182 MINDESTANGABEN AUF ||| 172 MINIMUM PARTICULARS TO APPEAR ||| 0-0 1-1 1-2 2-3 2-4
182 MINDESTANGABEN ||| 172 MINIMUM PARTICULARS ||| 0-0 1-1 1-2
182 ||| 172 ||| 0-0
183 MINDESTANGABEN ||| 173 MINIMUM PARTICULARS TO ||| 0-0 0-1 1-2 1-3
183 Wenn Sie ||| If you ||| 1-0 0-1 2-1
183 ||| 173 MINIMUM ||| 0-0 0-1
185 Patienten wurde ||| 185 patients ||| 0-0 1-1
185 Patienten ||| 185 patients ||| 0-0 1-1
185 ||| 185 ||| 0-0
186 MINDESTANGABEN AUF ||| 176 MINIMUM PARTICULARS TO APPEAR ||| 0-0 1-1 1-2 2-3 2-4
186 MINDESTANGABEN ||| 176 MINIMUM PARTICULARS ||| 0-0 1-1 1-2
186 ||| 176 ||| 0-0
187 Ireland BRISTOL-MYERS SQUIBB PHARMACEUTICALS ||| Ireland BRISTOL-MYERS SQUIBB PHARMACEUTICALS ||| 0-0 1-0 2-1 3-2 4-3
187 Ireland BRISTOL-MYERS SQUIBB ||| Ireland BRISTOL-MYERS SQUIBB ||| 0-0 1-0 2-1 3-2
187 Ireland BRISTOL-MYERS ||| Ireland BRISTOL-MYERS ||| 0-0 1-0 2-1
187 Ireland ||| Ireland ||| 0-0 1-0
187 MINDESTANGABEN ||| 177 MINIMUM PARTICULARS TO ||| 0-0 0-1 1-2 1-3
187 ||| 177 MINIMUM ||| 0-0 0-1
19 % bei ||| 19 % ||| 0-0 2-0 1-1
19 % ||| 19 % ||| 0-0 1-1
19 . ||| 19 ||| 0-0
19 Bei schon lange ||| Usual warning symptoms may ||| 0-0 1-0 2-0 2-1 3-1 3-2 3-3
19 ||| 19 ||| 0-0
19,3 ] ( n = ||| 19.3 ] ( n = ||| 0-0 1-1 2-2 3-3 4-3 4-4
19,3 ] ( ||| 19.3 ] ( ||| 0-0 1-1 2-2
19,3 ] ||| 19.3 ] ||| 0-0 1-1
19,3 ||| 19.3 ||| 0-0
19,5 % , 10,4 ||| % , 10.4 % , ||| 0-0 1-0 2-1 3-2 1-3 2-4
19/21 Yarvitan sollte ||| Treatment should be ||| 0-0 1-0 2-1 2-2
19/21 Yarvitan ||| Treatment ||| 0-0 1-0
190 MINDESTANGABEN AUF ||| 180 MINIMUM PARTICULARS TO APPEAR ||| 0-0 1-1 1-2 2-3 2-4
190 MINDESTANGABEN ||| 180 MINIMUM PARTICULARS ||| 0-0 1-1 1-2
190 Wichtige Informationen über bestimmte ||| Important information about some ||| 0-0 1-0 4-0 2-1 2-2 3-2 4-3
190 ||| 180 ||| 0-0
191 MINDESTANGABEN ||| 181 MINIMUM PARTICULARS TO ||| 0-0 0-1 1-2 1-3
191 ||| 181 MINIMUM ||| 0-0 0-1
193 Ireland BRISTOL-MYERS SQUIBB PHARMACEUTICALS ||| Ireland BRISTOL-MYERS SQUIBB PHARMACEUTICALS ||| 0-0 1-0 2-1 3-2 4-3
193 Ireland BRISTOL-MYERS SQUIBB ||| Ireland BRISTOL-MYERS SQUIBB ||| 0-0 1-0 2-1 3-2
193 Ireland BRISTOL-MYERS ||| Ireland BRISTOL-MYERS ||| 0-0 1-0 2-1
193 Ireland ||| Ireland ||| 0-0 1-0
194 MINDESTANGABEN AUF ||| 184 MINIMUM PARTICULARS TO APPEAR ||| 0-0 1-1 1-2 2-3 2-4
194 MINDESTANGABEN ||| 184 MINIMUM PARTICULARS ||| 0-0 1-1 1-2
194 ||| 184 ||| 0-0
195 MINDESTANGABEN ||| 185 MINIMUM PARTICULARS TO ||| 0-0 1-1 1-2 1-3
195 ||| 185 ||| 0-0
196 Schwangerschaft und Stillzeit Sie ||| Pregnancy and breast-feeding You ||| 0-0 1-0 3-0 2-1 3-2 3-3 4-3
196 ± 28,1 ng/ml ||| 196 ± 28.1 ng/ ml ||| 1-0 1-1 2-1 1-2 3-3 3-4
196 ± 28,1 ||| 196 ± 28.1 ||| 1-0 1-1 2-1 1-2
199 France BRISTOL-MYERS SQUIBB SARL ||| France BRISTOL-MYERS SQUIBB SARL ||| 0-0 1-0 2-1 3-2 4-3
199 France BRISTOL-MYERS SQUIBB ||| France BRISTOL-MYERS SQUIBB ||| 0-0 1-0 2-1 3-2
199 France BRISTOL-MYERS ||| France BRISTOL-MYERS ||| 0-0 1-0 2-1
199 France ||| France ||| 0-0 1-0
1HU - Vereinigtes Königreich ||| 1HU - United Kingdom ||| 0-0 1-1 2-2 3-3
1HU - Vereinigtes ||| 1HU - United ||| 0-0 1-1 2-2
1HU - ||| 1HU - ||| 0-0 1-1
1HU ||| 1HU ||| 0-0
2 ( ||| 2 ( ||| 0-0 1-1
2 ) , ||| 2 ) at ||| 0-0 1-1
2 ) , ||| 2 ) ||| 0-0 1-1
2 ) . ||| 2 ) . ||| 0-0 1-1 2-2
2 ) ||| 1.4 , 4.0 ) ||| 0-0 0-2 1-3
2 ) ||| 2 ) at ||| 0-0 1-1
2 ) ||| 2 ) ||| 0-0 1-1
2 , 4 , 8 ||| 2 , 4 , 8 ||| 0-0 1-1 2-2 1-3 3-3 4-4
2 , 4 , ||| 2 , 4 , ||| 0-0 1-1 2-2 1-3 3-3
2 , Frankreich ||| 2 , France ||| 0-0 1-1 2-2
2 , ||| 2 , ||| 0-0 1-1
2 127 Männer ||| 2,127 men ||| 1-0 2-1
2 127 Männer ||| involved 2,127 men ||| 1-1 2-2
2 127 ||| 2,127 ||| 1-0
2 127 ||| involved 2,127 ||| 1-1
2 3 Wochen ||| 2 3-week ||| 0-0 1-1 2-1
2 352 74 60 ||| 2 352 74 60 ||| 0-0 1-1 2-2 3-3
2 352 74 ||| 2 352 74 ||| 0-0 1-1 2-2
2 352 ||| 2 352 ||| 0-0 1-1
2 Anpassung der Dosis Begleiterkrankungen ||| Dosage adjustment Concomitant illness ||| 1-0 1-1 1-2 2-2 4-2 3-3 4-3
2 Diabetes mellitus und ||| 2 diabetes mellitus and ||| 0-0 1-1 2-2 3-3
2 Diabetes mellitus ||| 2 diabetes mellitus ||| 0-0 1-1 2-2
2 Diabetes ||| 2 diabetes ||| 0-0 1-1
2 Einheiten ab . ||| 2 units . ||| 0-0 1-1 2-1 3-2
2 Einheiten ab ||| 2 units ||| 0-0 1-1 2-1
2 Jahren betrug ||| two years , ||| 0-0 1-0 1-1 2-1
2 Jahren betrug ||| two years ||| 0-0 1-0 1-1 2-1
2 Jahren ist gezeigt ||| two years ||| 0-0 1-0 1-1
2 Jahren ist ||| two years ||| 0-0 1-0 1-1
2 Jahren ||| 2 years ||| 0-0 1-1
2 Jahren ||| two years ||| 0-0 1-0 1-1
2 Monaten ||| 2 months ||| 0-0 1-1
2 Patienten mit ||| Patients with ||| 0-0 1-0 2-1
2 Patienten ||| Patients ||| 0-0 1-0
2 Studien mit gesunden Probanden ||| 2 studies in healthy subjects ||| 0-0 1-1 2-2 3-2 3-3 4-4
2 Studien mit gesunden ||| 2 studies in healthy ||| 0-0 1-1 2-2 3-2 3-3
2 Studien ||| 2 studies ||| 0-0 1-1
2 Stunden nach Anwendung erreicht ||| achieved 2 hours after administration ||| 4-0 0-1 1-2 2-3 3-4
2 Stunden nach Anwendung ||| 2 hours after administration ||| 0-0 1-1 2-2 3-3
2 Stunden nach ||| 2 hours after ||| 0-0 1-1 2-2
2 Stunden ||| 2 hours ||| 0-0 1-1
2 Vor ||| Patients ||| 0-0 1-0
2 Wochen ||| 2 weeks ||| 0-0 1-1
2 g/dl ( 1,25 ||| 2 g/ dl ( 1.25 ||| 0-0 1-1 1-2 2-3 3-4
2 g/dl ( ||| 2 g/ dl ( ||| 0-0 1-1 1-2 2-3
2 g/dl ||| 2 g/ dl ||| 0-0 1-1 1-2
2 mg Aspartam ( E951 ||| 2 mg aspartame ( E951 ||| 0-0 1-1 2-2 3-3 4-4
2 mg Aspartam ( ||| 2 mg aspartame ( ||| 0-0 1-1 2-2 3-3
2 mg Aspartam ||| 2 mg aspartame ||| 0-0 1-1 2-2
2 mg Dosis ) ||| dose 2 mg ) ||| 2-0 0-1 1-2 3-3
2 mg Dosis ||| dose 2 mg ||| 2-0 0-1 1-2
2 mg ||| 2 mg ||| 0-0 1-1
2 mg/ml ||| 2 mg/ ml ||| 0-0 1-1 1-2
2 ml Tropfpipette abgemessen werden ||| 2 ml calibrated dropper ||| 0-0 1-1 2-2 3-2 2-3
2 ml Tropfpipette abgemessen ||| 2 ml calibrated dropper ||| 0-0 1-1 2-2 3-2 2-3
2 ml ||| 2 ml ||| 0-0 1-1
2 und 78 Einheiten ||| 2-78 units ||| 0-0 1-0 2-0 3-1
2 und 78 ||| 2-78 ||| 0-0 1-0 2-0
2 ||| 1.4 , 4.0 ||| 0-0 0-2
2 ||| 2 ||| 0-0
2 ||| to 2 ||| 0-1
2,1 % ) ||| 2.1 % ) ||| 0-0 1-1 2-2
2,1 % ||| 2.1 % ||| 0-0 1-1
2,1 ||| 2.1 ||| 0-0
2,3 % der ||| 2.3 % of ||| 0-0 1-1 2-2
2,3 % ||| 2.3 % ||| 0-0 1-1
2,3 ||| 2.3 ||| 0-0
2,47 zugunsten der Kontrollen ||| 2.47 in favour of controls ||| 0-0 0-1 1-2 2-3 3-4
2,47 zugunsten der ||| 2.47 in favour of ||| 0-0 0-1 1-2 2-3
2,47 zugunsten ||| 2.47 in favour ||| 0-0 0-1 1-2
2,47 ||| 2.47 in ||| 0-0 0-1
2,49 ||| 2.49 ||| 0-0
2,5 % ( 96 ||| 2.5 % ( 96 ||| 0-0 1-1 2-2 3-3
2,5 % ( ||| 2.5 % ( ||| 0-0 1-1 2-2
2,5 % ) ||| 2.5 % ) of ||| 0-0 1-1 2-2
2,5 % ) ||| 2.5 % ) ||| 0-0 1-1 2-2
2,5 % ; 0,5 ||| 2.5 % ; 0.5 ||| 0-0 1-1 2-2 3-3
2,5 % ; ||| 2.5 % ; ||| 0-0 1-1 2-2
2,5 % ||| 2.5 % ||| 0-0 1-1
2,5 Stunden nach ||| 1.5-2.5 hours after ||| 0-0 1-1 2-2
2,5 Stunden ||| 1.5-2.5 hours ||| 0-0 1-1
2,5 mm geringere ||| 2.5 mm ||| 0-0 1-1 2-1
2,5 ||| 1.5-2.5 ||| 0-0
2,5 ||| 2.5 ||| 0-0
2,7 % ] ) . ||| 2.7 % ] ) . ||| 0-0 1-1 2-2 3-3 4-4
2,7 % ] ) ||| 2.7 % ] ) ||| 0-0 1-1 2-2 3-3
2,7 % ] ||| 2.7 % ] ||| 0-0 1-1 2-2
2,7 % ||| 2.7 % ||| 0-0 1-1
2,7 ||| 2.7 ||| 0-0
2-5 % . ||| 2 5 % . ||| 0-0 0-1 1-2 2-3
2-5 % ||| 2 5 % ||| 0-0 0-1 1-2
2-5 ||| 2 5 ||| 0-0 0-1
2-Stunden Endpunkt war 5,8 für ||| 2-hour endpoint was 5.8 for ||| 0-0 1-1 2-2 3-3 4-4
2-Stunden Endpunkt war 5,8 ||| 2-hour endpoint was 5.8 ||| 0-0 1-1 2-2 3-3
2-Stunden Endpunkt war ||| 2-hour endpoint was ||| 0-0 1-1 2-2
2-Stunden Endpunkt ||| 2-hour endpoint ||| 0-0 1-1
2-Stunden ||| 2-hour ||| 0-0
2. Was muss vor der ||| Before you ||| 0-0 1-0 2-0 1-1 3-1
2. Was muss vor ||| Before you ||| 0-0 1-0 2-0 1-1 3-1
2. Was müssen Sie vor ||| Before you ||| 0-0 1-0 2-0 3-1 4-1
2. Was müssen Sie vor ||| Before you ||| 0-0 1-0 2-0 4-0 3-1
2. Was müssen ||| Before ||| 0-0 1-0 2-0
2/3 Welchen Nutzen hat Abilify ||| What benefit has Abilify ||| 0-0 1-0 2-1 3-2 4-3
2/3 Welchen Nutzen hat ||| What benefit has ||| 0-0 1-0 2-1 3-2
2/3 Welchen Nutzen ||| What benefit ||| 0-0 1-0 2-1
2/3 Welchen ||| What ||| 0-0 1-0
20 % gelöstem Insulin und ||| 20 % dissolved insulin and ||| 0-0 1-1 2-2 3-3 4-4
20 % gelöstem Insulin ||| 20 % dissolved insulin ||| 0-0 1-1 2-2 3-3
20 % gelöstem ||| 20 % dissolved ||| 0-0 1-1 2-2
20 % und Isophan-Insulin ||| 20 % and isophane insulin ||| 0-0 1-1 2-2 3-3 3-4
20 % und ||| 20 % and ||| 0-0 1-1 2-2
20 % ||| 20 % ||| 0-0 1-1
20 00 ||| 20 00 ||| 0-0 1-1
20 501 76 03 ||| 20 501 76 03 ||| 0-0 1-1 2-2 3-3
20 501 76 ||| 20 501 76 ||| 0-0 1-1 2-2
20 501 ||| 20 501 ||| 0-0 1-1
20 : lösliches Insulin 20 ||| 20 : soluble insulin 20 ||| 0-0 1-1 2-2 3-3 4-4
20 : lösliches Insulin ||| 20 : soluble insulin ||| 0-0 1-1 2-2 3-3
20 : lösliches ||| 20 : soluble ||| 0-0 1-1 2-2
20 : ||| 20 : ||| 0-0 1-1
20 ACTRAPHANE 30 ACTRAPHANE 40 ||| 20 ACTRAPHANE 30 ACTRAPHANE 40 ||| 0-0 1-1 2-2 3-3 4-4
20 ACTRAPHANE 30 ACTRAPHANE ||| 20 ACTRAPHANE 30 ACTRAPHANE ||| 0-0 1-1 2-2 3-3
20 ACTRAPHANE 30 ||| 20 ACTRAPHANE 30 ||| 0-0 1-1 2-2
20 ACTRAPHANE ||| 20 ACTRAPHANE ||| 0-0 1-1
20 ANGABEN ||| 18 PARTICULARS ||| 1-0 0-1 1-1
20 Die empfohlene Dosierung wird ||| The recommended dosing regimen is ||| 1-0 0-1 2-1 3-2 2-3 3-3 4-4
20 Die empfohlene Dosierung ||| The recommended dosing regimen ||| 1-0 0-1 2-1 3-2 2-3 3-3
20 NovoLet 100 ||| 20 NovoLet 100 ||| 0-0 1-1 2-2
20 NovoLet ||| 20 NovoLet ||| 0-0 1-1
20 Penfill 100 ||| 20 Penfill 100 ||| 0-0 1-1 2-2
20 Penfill ||| 20 Penfill ||| 0-0 1-1
20 auf einer Seite . ||| 20 on one side . ||| 0-0 1-1 2-2 3-2 3-3 4-4
20 auf einer Seite ||| 20 on one side ||| 0-0 1-1 2-2 3-2 3-3
20 auf ||| 20 on ||| 0-0 1-1
20 besteht aus 20 % ||| 20 consists of 20 % ||| 0-0 1-1 2-1 2-2 3-3 4-4
20 besteht aus 20 ||| 20 consists of 20 ||| 0-0 1-1 2-1 2-2 3-3
20 besteht aus ||| 20 consists of ||| 0-0 1-1 2-1 2-2
20 mg ( Ausgangswert 7,3 ||| 20 mg ( baseline 7.3 ||| 0-0 1-1 2-2 3-3 4-4
20 mg ( Ausgangswert ||| 20 mg ( baseline ||| 0-0 1-1 2-2 3-3
20 mg ( ||| 20 mg ( ||| 0-0 1-1 2-2
20 mg nahezu dosisproportional . ||| 20 mg . ||| 0-0 1-1 2-1 3-1 4-2
20 mg nahezu dosisproportional ||| 20 mg ||| 0-0 1-1 2-1 3-1
20 mg und ||| 20 mg and ||| 0-0 1-1 2-2
20 mg verringerte das Risiko ||| 20 mg reduced the risk ||| 0-0 1-1 2-2 3-3 3-4 4-4
20 mg verringerte ||| 20 mg reduced ||| 0-0 1-1 2-2
20 mg ||| 20 mg ||| 0-0 1-1
20 ||| , 20 ||| 0-1
20 ||| 20 ||| 0-0
200 - 300 mg ||| 200 - 300 mg ||| 0-0 1-1 2-2 3-3
200 - 300 ||| 200 - 300 ||| 0-0 1-1 2-2
200 - ||| 200 - ||| 0-0 1-1
200 Ihr Arzt wird ||| Your doctor will check ||| 1-0 2-1 1-2 3-2 2-3
200 kg ||| 200 kg ||| 0-0 1-1
200 mg Fructose je ml ||| 200 mg fructose per ml ||| 0-0 1-1 2-2 3-3 4-4
200 mg Fructose je ||| 200 mg fructose per ||| 0-0 1-1 2-2 3-3
200 mg Fructose und ||| 200 mg of fructose and ||| 0-0 1-1 2-3 3-4
200 mg Fructose ||| 200 mg fructose ||| 0-0 1-1 2-2
200 mg Fructose ||| 200 mg of fructose ||| 0-0 1-1 2-3
200 mg ||| 200 mg of ||| 0-0 1-1
200 mg ||| 200 mg ||| 0-0 1-1
200 mg ||| of 200 mg ||| 0-1 1-2
200 ||| 200 ||| 0-0
200 ||| not exceed 200 ||| 0-0 0-1 0-2
200 ||| of 200 ||| 0-1
2000 I.E. ) Lösung ||| 2000 IU ) of solution ||| 0-0 1-1 2-2 1-3 3-4
2000 I.E. ) ||| 2000 IU ) of ||| 0-0 1-1 2-2 1-3
2000 I.E. Epoetin alfa* ||| 2000 IU of epoetin alfa* ||| 0-0 1-1 3-2 2-3 3-4
2000 I.E. ||| 2000 IU ||| 0-0 1-1
2000 I.E./1 ml ||| 2000 IU/ 1 ml ||| 0-0 1-0 1-1 1-2 2-3
2000 I.E./1 ml ||| 2000 IU/ 1 ml ||| 0-0 1-1 1-2 1-3 2-3
2000 I.E./1 ||| 2000 IU/ 1 ||| 0-0 1-0 1-1 1-2
2000 I.E./1 ||| 2000 IU/ ||| 0-0 1-0 1-1
2000 Internationale Einheiten ( I.E. ||| 2000 international units ( IU ||| 0-0 1-1 2-2 3-3 4-4
2000 Internationale Einheiten ( ||| 2000 international units ( ||| 0-0 1-1 2-2 3-3
2000 Internationale Einheiten ||| 2000 international units ||| 0-0 1-1 2-2
2000 Internationale ||| 2000 international ||| 0-0 1-1
2000 ||| 2000 ||| 0-0
2005 ||| Chi-squared ||| 0-0
2006 , ||| , ||| 1-0
2006 aktualisiert ||| refer to the relevant modules ||| 0-0 1-3 1-4
2006 ||| refer to the ||| 0-0
2006 ||| refer to ||| 0-0
2006 ||| refer ||| 0-0
2007 ||| 2007 ||| 0-0
2007 ||| July 2007 ||| 0-1
203 Die Menge , ||| The amount ||| 1-0 0-1 2-1
203 Die Menge ||| The amount ||| 1-0 0-1 2-1
207 eská republika OncoEurope Tel ||| eská republika OncoEurope Tel ||| 0-0 1-0 2-1 3-2 4-3
207 eská republika OncoEurope ||| eská republika OncoEurope ||| 0-0 1-0 2-1 3-2
207 eská republika ||| eská republika ||| 0-0 1-0 2-1
207 eská ||| eská ||| 0-0 1-0
21 % der ||| 21 % of ||| 0-0 1-1 2-2
21 % ||| 21 % ||| 0-0 1-1
21 230 ||| 21 230 ||| 0-0 1-1
21 412 6600 ||| 21 412 6600 ||| 0-0 1-1 2-2
21 412 ||| 21 412 ||| 0-0 1-1
21 mit anderen Rezeptoren als ||| Interaction with receptors other than ||| 0-0 3-0 1-1 3-2 2-3 4-4
21 mit anderen Rezeptoren ||| Interaction with receptors other ||| 0-0 3-0 1-1 3-2 2-3
21 ||| 21 ||| 0-0
21-tägigen Behandlung kann ||| 21 days of treatment , ||| 0-0 0-1 1-2 1-3 2-3 2-4
21-tägigen ||| 21 days ||| 0-0 0-1
210 ml : 40 kg ||| 210 ml : 40 kg ||| 0-0 1-1 2-2 3-3 4-4
210 ml : 40 ||| 210 ml : 40 ||| 0-0 1-1 2-2 3-3
210 ml : ||| 210 ml : ||| 0-0 1-1 2-2
210 ml ||| 210 ml ||| 0-0 1-1
210 ||| 210 ||| 0-0
211 Patienten aus der ||| 211 patients in the ||| 0-0 1-1 1-2 2-3 3-3
211 Patienten ||| 211 patients in ||| 0-0 1-1 1-2
211 ||| 211 ||| 0-0
22 , 67019 Scoppito ( ||| 22 , 67019 Scoppito ( ||| 0-0 1-1 2-2 3-3 4-4
22 , 67019 Scoppito ||| 22 , 67019 Scoppito ||| 0-0 1-1 2-2 3-3
22 , 67019 ||| 22 , 67019 ||| 0-0 1-1 2-2
22 , ||| 22 , ||| 0-0 1-1
22 11 ||| 22 11 ||| 0-0 1-1
22 4.4 Besondere Warnhinweise und ||| 4.4 Special warnings and ||| 0-0 1-0 2-1 3-2 4-3
22 4.4 Besondere Warnhinweise ||| 4.4 Special warnings ||| 0-0 1-0 2-1 3-2
22 4.4 Besondere ||| 4.4 Special ||| 0-0 1-0 2-1
22 4.4 ||| 4.4 ||| 0-0 1-0
22 Prostatakarzinome ||| 22 prostate ||| 0-0 1-1
22 bis 143 ||| 22 to 143 ||| 0-0 1-1 2-2
22 bis ||| 22 to ||| 0-0 1-1
22 kg Körpergewicht 210 ml ||| 22 kg BW 210 ml ||| 0-0 1-1 2-2 3-3 4-4
22 kg Körpergewicht 210 ||| 22 kg BW 210 ||| 0-0 1-1 2-2 3-3
22 kg Körpergewicht ||| 22 kg BW ||| 0-0 1-1 2-2
22 kg ||| 22 kg ||| 0-0 1-1
22 von 3.852 ) ||| 22 out of 3,852 ) ||| 0-0 2-1 1-2 2-3 3-4
22 von 3.852 ||| 22 out of 3,852 ||| 0-0 2-1 1-2 2-3
22 ||| , ||| 0-0
22 ||| 22 ||| 0-0
22,5 8,1 41,7 11,9 47,3 ||| 22.5 8.1 41.7 11.9 47.3 ||| 0-0 1-1 2-2 3-3 4-4
22,5 8,1 41,7 11,9 ||| 22.5 8.1 41.7 11.9 ||| 0-0 1-1 2-2 3-3
22,5 8,1 41,7 ||| 22.5 8.1 41.7 ||| 0-0 1-1 2-2
22,5 8,1 ||| 22.5 8.1 ||| 0-0 1-1
22,5 ||| 22.5 ||| 0-0
221 multiple Myelome ||| 221 multiple ||| 0-0 1-0 2-0 1-1
225 ) oder in Form ||| 225 ) , or as ||| 0-0 1-1 2-3 4-4
225 ) oder in ||| 225 ) , or ||| 0-0 1-1 2-3
225 ) oder ||| 225 ) , or ||| 0-0 1-1 2-3
225 ) ||| 225 ) , ||| 0-0 1-1
225 ) ||| 225 ) ||| 0-0 1-1
225 ||| 225 ||| 0-0
229 ) . ||| 229 ) . ||| 0-0 1-1 2-2
229 ) ||| 229 ) ||| 0-0 1-1
229 ||| 229 ||| 0-0
229 ||| 9 229 ||| 0-0 0-1
23 05 20 00 ||| 23 05 20 00 ||| 0-0 1-1 2-2 3-3
23 05 20 ||| 23 05 20 ||| 0-0 1-1 2-2
23 05 ||| 23 05 ||| 0-0 1-1
23 Bei Patienten mit ||| In patients with ||| 1-0 2-1 3-2
23 Bei Patienten ||| In patients ||| 1-0 2-1
23 Bei ||| In ||| 1-0
23 Bronchialkarzinome , 22 Prostatakarzinome ||| 23 lung , 22 prostate ||| 0-0 1-1 2-2 3-3 4-4
23 Bronchialkarzinome , 22 ||| 23 lung , 22 ||| 0-0 1-1 2-2 3-3
23 Bronchialkarzinome , ||| 23 lung , ||| 0-0 1-1 2-2
23 Bronchialkarzinome ||| 23 lung ||| 0-0 1-1
23 Stunden . ||| 23 hours . ||| 0-0 1-1 2-2
23 Stunden ||| 23 hours ||| 0-0 1-1
23 mg ) Natrium pro ||| 23 mg ) per ||| 0-0 3-0 1-1 2-2 4-3
23 mg ) Natrium ||| 23 mg ) ||| 0-0 3-0 1-1 2-2
23 ||| 23 ||| 0-0
230 ||| 230 ||| 0-0
24 % der ||| 24 % of ||| 0-0 1-1 2-2
24 % ||| 24 % ||| 0-0 1-1
24 ANGABEN AUF ||| 22 PARTICULARS TO APPEAR ||| 0-0 1-1 2-2 2-3
24 ANGABEN ||| 22 PARTICULARS ||| 0-0 1-1
24 Monaten ||| 24 months ||| 0-0 1-1
24 Stunden . ||| 24 hours . ||| 0-0 1-1 2-2
24 Stunden können bis zu ||| 24 hours may ||| 0-0 1-0 1-1 3-1 2-2
24 Stunden können bis zu ||| in 24 hours may ||| 0-1 1-1 1-2 3-2 2-3
24 Stunden können bis ||| 24 hours may ||| 0-0 1-0 1-1 3-1 2-2
24 Stunden können bis ||| in 24 hours may ||| 0-1 1-1 1-2 3-2 2-3
24 Stunden nach der ||| 24 hours after the ||| 0-0 1-1 2-2 3-3
24 Stunden nach ||| 24 hours after ||| 0-0 1-1 2-2
24 Stunden ||| 24 hours ||| 0-0 1-1
24 Stunden ||| 24-hour ||| 0-0
24 h ||| 24 hours ||| 0-0 1-0 0-1
24 und 36 Monate ) ||| 24 and 36 months ) ||| 0-0 1-1 2-2 3-3 4-4
24 und 36 Monate ||| 24 and 36 months ||| 0-0 1-1 2-2 3-3
24 und 36 ||| 24 and 36 ||| 0-0 1-1 2-2
24 und ||| 24 and 36 months ||| 0-0 1-1 0-2 0-3
24 und ||| 24 and ||| 0-0 1-1
24 ||| , the ||| 0-1
24 ||| 22 ||| 0-0
24 ||| 24 ||| 0-0
24 ||| 24-hour period ||| 0-0
24 ||| 24-hour ||| 0-0
24 ||| any 24-hour period ||| 0-1
24 ||| any 24-hour ||| 0-1
24 ||| over 24 ||| 0-1
24 ||| the ||| 0-0
24,9 ||| 24.9 ||| 0-0
241 941-0 ||| 241 941-0 ||| 0-0 1-1
241 ||| 241 ||| 0-0
25 % der Patienten auf ||| 25 % of the patients ||| 0-0 1-1 2-2 2-3 4-3 3-4
25 % ||| 25 % ||| 0-0 1-1
25 16 16 ||| 25 16 16 ||| 0-0 1-1 2-2
25 16 ||| 25 16 ||| 0-0 1-1
25 800 ||| 25 800 ||| 0-0 1-1
25 D-90429 Nürnberg Deutschland ||| 25 D-90429 Nuremberg Germany ||| 0-0 1-1 2-2 3-3
25 D-90429 Nürnberg ||| 25 D-90429 Nuremberg ||| 0-0 1-1 2-2
25 D-90429 ||| 25 D-90429 ||| 0-0 1-1
25 und 50 ||| 25 and 50 ||| 0-0 1-1 2-2
25 und ||| 25 and ||| 0-0 1-1
25 ||| 25 ||| 0-0
25 ||| at 25 ||| 0-0 0-1
25 °C ||| 25°C ||| 0-0 1-0
25 °C über ||| above 25°C ||| 2-0 0-1 1-1
25,2 9,5 22,5 8,1 41,7 ||| 25.2 9.5 22.5 8.1 41.7 ||| 0-0 1-1 2-2 3-3 4-4
25,2 9,5 22,5 8,1 ||| 25.2 9.5 22.5 8.1 ||| 0-0 1-1 2-2 3-3
25,2 9,5 22,5 ||| 25.2 9.5 22.5 ||| 0-0 1-1 2-2
25,2 9,5 ||| 25.2 9.5 ||| 0-0 1-1
25,2 Mikrogramm Epoetin alfa ||| 25.2 micrograms epoetin alfa ||| 0-0 1-1 2-2 3-3
25,2 Mikrogramm Epoetin ||| 25.2 micrograms epoetin ||| 0-0 1-1 2-2
25,2 Mikrogramm Epoetin ||| corresponding to 25.2 micrograms epoetin ||| 1-0 0-2 1-3 2-4
25,2 Mikrogramm ||| 25.2 micrograms ||| 0-0 1-1
25,2 Mikrogramm ||| corresponding to 25.2 micrograms ||| 1-0 0-2 1-3
25,2 ||| 25.2 ||| 0-0
25,2 ||| to 25.2 ||| 0-1
251 21 230 ||| 251 21 230 ||| 0-0 1-1 2-2
251 21 ||| 251 21 ||| 0-0 1-1
251 ||| 251 ||| 0-0
25°C ) . ||| 25°C ) . ||| 0-0 1-1 2-2
25°C ) . ||| 25ºC ) . ||| 0-0 1-1 2-2
25°C ) ||| 25°C ) ||| 0-0 1-1
25°C ) ||| 25ºC ) ||| 0-0 1-1
25°C ||| 25°C ||| 0-0
25°C ||| 25ºC ||| 0-0
26 Anpassung der Dosis Begleiterkrankungen ||| Dosage adjustment Concomitant illness ||| 1-0 1-1 1-2 2-2 4-2 3-3 4-3
26 Patienten mit ||| Patients with ||| 1-0 2-1
26 Patienten ||| Patients ||| 1-0
26 Wochen ||| 26-week ||| 0-0 1-0
26,7 ||| 26.7 ||| 0-0
260 12 55 ||| 260 12 55 ||| 0-0 1-1 2-2
260 12 ||| 260 12 ||| 0-0 1-1
260 Bronchialkarzinome , ||| 260 lung , ||| 0-0 1-1 2-2
260 Bronchialkarzinome ||| 260 lung ||| 0-0 1-1
260 mg ||| 260 mg ||| 0-0 1-1
260 mg/m2 ||| 260 mg/ m2 , paclitaxel ||| 0-0 1-1 1-2 1-4
260 ||| 260 ||| 0-0
2649600 ||| 2649600 ||| 0-0
2653 auf 16736 ||| 2653 to 16736 ||| 0-0 1-1 2-2
2653 auf ||| 2653 to ||| 0-0 1-1
2653 ||| 2653 ||| 0-0
268 ||| 268 ||| 0-0
27 % der ||| 27 % of the ||| 0-0 1-1 2-2 2-3
27 % hatten ||| ; 27 % had ||| 1-0 0-1 1-2 2-3
27 % ||| 27 % ||| 0-0 1-1
27 % ||| ; 27 % ||| 1-0 0-1 1-2
27 Bei exzessiv hohen ||| Phlebotomy may be performed ||| 0-0 1-0 2-0 2-1 2-2 3-3
27 Bei exzessiv ||| Phlebotomy may be ||| 0-0 1-0 2-0 2-1 2-2
27 Bei schon lange ||| Usual warning symptoms may ||| 0-0 1-0 2-0 2-1 3-1 3-2 3-3
27 Spätdyskinesien : in klinischen ||| Tardive Dyskinesia : in clinical ||| 0-0 1-0 1-1 2-2 3-3 4-4
27 Spätdyskinesien : in ||| Tardive Dyskinesia : in ||| 0-0 1-0 1-1 2-2 3-3
27 Spätdyskinesien : ||| Tardive Dyskinesia : ||| 0-0 1-0 1-1 2-2
27 Spätdyskinesien ||| Tardive Dyskinesia ||| 0-0 1-0 1-1
27 ||| 27 ||| 0-0
27166 , F-37071 Tours Cedex ||| 27166 , F-37071 Tours Cedex ||| 0-0 1-1 2-2 3-3 4-4
27166 , F-37071 Tours ||| 27166 , F-37071 Tours ||| 0-0 1-1 2-2 3-3
27166 , F-37071 ||| 27166 , F-37071 ||| 0-0 1-1 2-2
27166 , ||| 27166 , ||| 0-0 1-1
27166 ||| 27166 ||| 0-0
272 16 00 ||| 272 16 00 ||| 0-0 1-1 2-2
272 16 ||| 272 16 ||| 0-0 1-1
272 ||| 272 ||| 0-0
273 0 ||| 273 0 ||| 0-0 1-1
273 ||| 273 ||| 0-0
28 % ||| 28 % ||| 0-0 1-1
28 , 56 , 84 ||| 28 , 56 , 84 ||| 0-0 1-1 2-2 3-3 4-4
28 , 56 , ||| 28 , 56 , ||| 0-0 1-1 2-2 3-3
28 , 56 ||| 28 , 56 ||| 0-0 1-1 2-2
28 , ||| 28 , ||| 0-0 1-1
28 Gewichtszunahme : Eine Gewichtszunahme ||| Weight gain : weight gain ||| 1-0 3-0 1-1 2-2 4-3 4-4
28 Gewichtszunahme : Eine ||| Weight gain : ||| 1-0 3-0 1-1 2-2
28 Tabletten 30 Tabletten 50 ||| 28 tablets 30 tablets 50 ||| 0-0 1-1 2-2 3-3 4-4
28 Tabletten 30 Tabletten ||| 28 tablets 30 tablets ||| 0-0 1-1 2-2 3-3
28 Tabletten 30 ||| 28 tablets 30 ||| 0-0 1-1 2-2
28 Tabletten ||| 28 tablets ||| 0-0 1-1
28 x 1 Schmelztabletten ||| 28 x 1 orodispersible tablets ||| 0-0 1-1 2-2 3-3 3-4
28 x 1 Tabletten 49 ||| 28 x 1 tablets 49 ||| 0-0 1-1 2-2 3-3 4-4
28 x 1 Tabletten in ||| 28 x 1 tablets in ||| 0-0 1-1 2-2 3-3 4-4
28 x 1 Tabletten ||| 28 x 1 tablets ||| 0-0 1-1 2-2 3-3
28 x 1 ||| 28 x 1 ||| 0-0 1-1 2-2
28 x ||| 28 x ||| 0-0 1-1
28 ||| 28 ||| 0-0
28%ige Reduktion ||| 28 % reduction in ||| 0-0 1-1 0-2 1-2 1-3
29 % ||| 29 % of the ||| 0-0 1-1
29 % ||| 29 % of ||| 0-0 1-1
29 % ||| 29 % ||| 0-0 1-1
29 5193 ||| 29 5193 ||| 0-0 1-1
29 In tierexperimentellen Studien mit ||| In animal studies , epoetin ||| 1-0 2-1 3-2 0-3 2-4 4-4
29 [ 2,7 % ] ||| 29 [ 2.7 % ] ||| 0-0 1-1 2-2 3-3 4-4
29 [ 2,7 % ||| 29 [ 2.7 % ||| 0-0 1-1 2-2 3-3
29 [ 2,7 ||| 29 [ 2.7 ||| 0-0 1-1 2-2
29 [ ||| 29 [ ||| 0-0 1-1
29 ||| , ||| 0-0
29 ||| 29 ||| 0-0
29-mal ||| rat ||| 0-0
291 Patienten ||| 291 patients ||| 0-0 1-1
291 ||| 291 ||| 0-0
2AQ Vereinigtes Königreich ||| 2AQ United Kingdom ||| 0-0 1-1 2-2
2AQ Vereinigtes ||| 2AQ United ||| 0-0 1-1
2AQ ||| 2AQ ||| 0-0
2C19 ( Omeprazol ) ||| 2C19 ( omeprazole ) ||| 0-0 1-1 2-2 3-3
2C19 ( Omeprazol ||| 2C19 ( omeprazole ||| 0-0 1-1 2-2
2C19 ( ||| 2C19 ( ||| 0-0 1-1
2C19 ||| 2C19 ||| 0-0
2C8 , jedoch ||| 2C8 although ||| 0-0 0-1 2-1
2C8/9 und 3A4 , werden ||| 2C8/ 9 , and 3A4 ||| 0-0 0-1 3-2 1-3 2-4
2C8/9 und 3A4 , ||| 2C8/ 9 , and 3A4 ||| 0-0 0-1 3-2 1-3 2-4
2C8/9 und 3A4 . ||| 2C8/ 9 and 3A4 . ||| 0-0 0-1 1-2 2-3 3-4
2C8/9 und 3A4 ||| 2C8/ 9 and 3A4 ||| 0-0 0-1 1-2 2-3
2C8/9 und ||| 2C8/ 9 and ||| 0-0 0-1 1-2
2C8/9 ||| 2C8/ 9 ||| 0-0 0-1
2C9 ( Warfarin ) ||| 2C9 ( warfarin ) ||| 0-0 1-1 2-2 3-3
2C9 ( Warfarin ||| 2C9 ( warfarin ||| 0-0 1-1 2-2
2C9 ( ||| 2C9 ( ||| 0-0 1-1
2C9 ||| 2C9 ||| 0-0
2°C - 8°C ) . ||| 2°C - 8°C ) . ||| 0-0 1-1 2-2 3-3 4-4
2°C - 8°C ) ||| 2°C - 8°C ) ||| 0-0 1-1 2-2 3-3
2°C - 8°C ||| 2°C - 8°C ||| 0-0 1-1 2-2
2°C - ||| 2°C - ||| 0-0 1-1
2°C 8°C ) . ||| 2°C - 8°C ) . ||| 0-0 0-1 1-2 2-3 3-4
2°C 8°C ) ||| 2°C - 8°C ) ||| 0-0 0-1 1-2 2-3
2°C 8°C ||| 2°C - 8°C ||| 0-0 0-1 1-2
2°C ||| 2°C - ||| 0-0 0-1
2°C ||| 2°C ||| 0-0
3 -p-Hydroxypaclitaxel , ||| 3 -p-hydroxypaclitaxel , ||| 0-0 1-1 2-2
3 -p-Hydroxypaclitaxel und 6 -3 ||| , 3 -p-hydroxypaclitaxel and 6 ||| 0-1 1-2 4-2 2-3 3-4
3 -p-Hydroxypaclitaxel und 6 -3 ||| 3 -p-hydroxypaclitaxel and 6 ||| 0-0 1-1 4-1 2-2 3-3
3 -p-Hydroxypaclitaxel ||| 3 -p-hydroxypaclitaxel ||| 0-0 1-1
3 Beeinträchtigung der ||| pharmacokinetics and safety of ||| 1-0 1-1 2-2 2-3
3 Beeinträchtigung ||| pharmacokinetics and ||| 1-0 1-1
3 Bei schon lange ||| Usual warning symptoms may ||| 0-0 1-0 2-0 2-1 3-1 3-2 3-3
3 Ein erhöhter H-Thymidin-Einbau ||| An increased 3H-thymidine incorporation ||| 3-0 2-1 0-2 1-2 3-2 2-3 3-3
3 Jahre Haltbarkeit nach ||| 3 years Shelf-life after ||| 0-0 1-1 2-2 3-3
3 Jahre Haltbarkeit ||| 3 years Shelf-life ||| 0-0 1-1 2-2
3 Jahre ||| 3 years ||| 0-0 1-1
3 Metastasestellen . ||| 3 sites of metastases . ||| 0-0 1-3 2-4
3 Metastasestellen ||| 3 sites of metastases ||| 0-0 1-3
3 Nierenfunktion wesentlich beeinflussen können ||| can significantly impact renal function ||| 4-0 3-1 2-2 3-2 1-3 1-4
3 Nierenfunktion wesentlich beeinflussen ||| significantly impact renal function ||| 3-0 2-1 3-1 1-2 1-3
3 Nierenfunktion ||| renal function ||| 1-0 1-1
3 Patienten mit ||| 3 patients with ||| 0-0 1-1 2-2
3 Patienten ||| 3 patients ||| 0-0 1-1
3 Spätdyskinesien : in klinischen ||| Tardive Dyskinesia : in clinical ||| 1-0 1-1 2-2 3-3 4-4
3 Spätdyskinesien : in ||| Tardive Dyskinesia : in ||| 1-0 1-1 2-2 3-3
3 Spätdyskinesien : ||| Tardive Dyskinesia : ||| 1-0 1-1 2-2
3 Spätdyskinesien ||| Tardive Dyskinesia ||| 1-0 1-1
3 Tagen ||| 3 days ||| 0-0 1-1
3 Wochen . ||| 3 weeks . ||| 0-0 1-1 2-2
3 Wochen eine ||| 3 weeks ||| 0-0 1-1
3 Wochen ||| 3 weeks ||| 0-0 1-1
3 Wochen ||| 3-week ||| 0-0 1-0
3 aufeinander ||| 3 consecutive ||| 0-0
3 aufeinander ||| 3 ||| 0-0
3 dargestellt . ||| 3 ||| 0-0 1-0 2-0
3 mg Aspartam ( E951 ||| 3 mg aspartame ( E951 ||| 0-0 1-1 2-2 3-3 4-4
3 mg Aspartam ( ||| 3 mg aspartame ( ||| 0-0 1-1 2-2 3-3
3 mg Aspartam ||| 3 mg aspartame ||| 0-0 1-1 2-2
3 mg ||| 3 mg ||| 0-0 1-1
3 ml ( 3,5 ||| 3 ml ( 3.5 ||| 0-0 1-1 2-2 3-3
3 ml ( ||| 3 ml ( ||| 0-0 1-1 2-2
3 ml ) . ||| 3 ml ) . ||| 0-0 1-1 2-2 3-3
3 ml ) ||| 3 ml ) ||| 0-0 1-1 2-2
3 ml . ||| 3 ml . ||| 0-0 1-1 2-2
3 ml Patrone aus Glas ||| 3 ml glass cartridge ||| 0-0 1-1 4-2 2-3 3-3
3 ml entsprechend 300 ||| 3 ml equivalent to 300 ||| 0-0 1-1 1-2 2-2 2-3 3-4
3 ml entsprechend 300 ||| 3 ml equivalent to 300 ||| 0-0 1-1 2-2 2-3 3-4
3 ml entsprechend ||| 3 ml equivalent to ||| 0-0 1-1 1-2 2-2 2-3
3 ml entsprechend ||| 3 ml equivalent to ||| 0-0 1-1 2-2 2-3
3 ml ||| 3 ml ||| 0-0 1-1
3 und ||| 3 and ||| 0-0 1-1
3 x ||| 3 x ||| 0-0 1-1
3 x/Woche oder 450 ||| 3x/ week or 450 ||| 0-0 1-0 1-1 2-2 3-3
3 x/Woche oder ||| 3x/ week or ||| 0-0 1-0 1-1 2-2
3 x/Woche ||| 3x/ week ||| 0-0 1-0 1-1
3 ||| , 3 ||| 0-1
3 ||| 3 consecutive ||| 0-0
3 ||| 3 sites of ||| 0-0
3 ||| 3 sites ||| 0-0
3 ||| 3 ||| 0-0
3 ||| over 3 years ||| 0-0 0-1 0-2
3,0 % mit Placebo . ||| 3.0 % with placebo . ||| 0-0 1-1 2-2 3-3 4-4
3,0 % mit Placebo ||| 3.0 % with placebo ||| 0-0 1-1 2-2 3-3
3,0 % mit ||| 3.0 % with ||| 0-0 1-1 2-2
3,0 % ||| 3.0 % ||| 0-0 1-1
3,0 ||| 3.0 ||| 0-0
3,1 kg ||| 3.1 kg over 2 years ||| 0-0 1-1 1-2 1-3
3,1 kg ||| 3.1 kg over 2 ||| 0-0 1-1 1-2 1-3
3,1 ||| 2.3 , 8.3 ||| 0-0 0-2
3,1 ||| 3.1 ||| 0-0
3,2 % ] ) und ||| 3.2 % ] ) and ||| 0-0 1-1 2-2 3-3 4-4
3,2 % ] ) ||| 3.2 % ] ) ||| 0-0 1-1 2-2 3-3
3,2 % ] ||| 3.2 % ] ||| 0-0 1-1 2-2
3,2 % mit Placebo . ||| 3.2 % with placebo . ||| 0-0 1-1 2-2 3-3 4-4
3,2 % mit Placebo ||| 3.2 % with placebo ||| 0-0 1-1 2-2 3-3
3,2 % mit ||| 3.2 % with ||| 0-0 1-1 2-2
3,2 % ||| 3.2 % ||| 0-0 1-1
3,2 ||| 3.2 ||| 0-0
3,3fach höher als die ||| 3.3-fold higher than those ||| 0-0 1-1 2-2 2-3 3-3
3,3fach höher ||| 3.3-fold higher ||| 0-0 1-1
3,3fach ||| 3.3-fold ||| 0-0
3,5 % der ||| 3.5 % of ||| 0-0 1-1 2-2
3,5 % ||| 3.5 % ||| 0-0 1-1
3,5 Jahre ||| 3.5 years ||| 0-0 1-1
3,5 Stunden ||| 3.5 hours ||| 0-0 1-1
3,5 ||| 3.5 ||| 0-0
3- oder ||| 3 or 5 times ||| 0-0 1-1 0-3
3-Jahres-Osteoporosestudie ||| three-year ||| 0-0
3-fachen ||| 3 X ||| 0-0 0-1
3/21 4.8 Wechselwirkungen mit ||| 4.8 Interaction with ||| 0-0 1-0 2-1 3-2
3/21 4.8 Wechselwirkungen ||| 4.8 Interaction ||| 0-0 1-0 2-1
3/21 4.8 ||| 4.8 ||| 0-0 1-0
30 " auf einer Seite ||| 30 " on one side ||| 0-0 1-1 2-2 3-3 4-3 4-4
30 " auf ||| 30 " on ||| 0-0 1-1 2-2
30 " ||| 30 " ||| 0-0 1-1
30 % ) , jeweils ||| 30 % ) ||| 0-0 1-1 2-2
30 % ) , ||| 30 % ) ||| 0-0 1-1 2-2
30 % ) . ||| 30 % ) . ||| 0-0 1-1 2-2 3-3
30 % ) ||| 30 % ) ||| 0-0 1-1 2-2
30 % der Patienten ) ||| 30 % of patients ) ||| 0-0 1-1 2-2 3-3 4-4
30 % der Patienten ||| 30 % of patients ||| 0-0 1-1 2-2 3-3
30 % der ||| 30 % of ||| 0-0 1-1 2-2
30 % gelöstem Insulin und ||| 30 % dissolved insulin and ||| 0-0 1-1 2-2 3-3 4-4
30 % gelöstem Insulin ||| 30 % dissolved insulin ||| 0-0 1-1 2-2 3-3
30 % gelöstem ||| 30 % dissolved ||| 0-0 1-1 2-2
30 % und Isophan-Insulin ||| 30 % and isophane insulin ||| 0-0 1-1 2-2 3-3 3-4
30 % und ||| 30 % and ||| 0-0 1-1 2-2
30 % ||| 30 % ||| 0-0 1-1
30 %. ||| 30 % . ||| 0-0 1-1 1-2
30 ) . ||| 30 ) . ||| 0-0 1-1 2-2
30 ) ||| 30 ) ||| 0-0 1-1
30 , 50 , ||| , 30 , 50 , ||| 1-0 0-1 1-2 2-3 3-4
30 , 50 , ||| , 30 , 50 ||| 1-0 0-1 3-2 2-3
30 , 50 ||| , 30 , 50 ||| 1-0 0-1 1-2 2-3
30 , 56 , 84 ||| 30 , 56 , 84 ||| 0-0 1-1 2-2 3-3 4-4
30 , 56 , ||| 30 , 56 , ||| 0-0 1-1 2-2 3-3
30 , 56 ||| 30 , 56 ||| 0-0 1-1 2-2
30 , ||| , 30 , ||| 1-0 0-1 1-2
30 , ||| , 30 ||| 1-0 0-1
30 , ||| 30 , ||| 0-0 1-1
30 - 100 ||| 30 - 100 ||| 0-0 1-1 2-2
30 - ||| 30 - ||| 0-0 1-1
30 100 ||| 30 100 ||| 0-0 1-1
30 4.7 Auswirkungen auf ||| 4.7 Effects on ||| 0-0 1-0 2-1 3-2
30 4.7 Auswirkungen ||| 4.7 Effects ||| 0-0 1-0 2-1
30 4.7 ||| 4.7 ||| 0-0 1-0
30 40 ||| 30 40 ||| 0-0 1-1
30 6.6 Besondere ||| 6.6 Special ||| 0-0 1-0 2-1
30 6.6 ||| 6.6 ||| 0-0 1-0
30 60 25 800 ||| 30 60 25 800 ||| 0-0 1-1 2-2 3-3
30 60 25 ||| 30 60 25 ||| 0-0 1-1 2-2
30 60 ||| 30 60 ||| 0-0 1-1
30 : lösliches Insulin 30 ||| 30 : soluble insulin 30 ||| 0-0 1-1 2-2 3-3 4-4
30 : lösliches Insulin ||| 30 : soluble insulin ||| 0-0 1-1 2-2 3-3
30 : lösliches ||| 30 : soluble ||| 0-0 1-1 2-2
30 : ||| 30 : ||| 0-0 1-1
30 ACTRAPHANE 40 ACTRAPHANE 50 ||| 30 ACTRAPHANE 40 ACTRAPHANE 50 ||| 0-0 1-1 2-2 3-3 4-4
30 ACTRAPHANE 40 ACTRAPHANE ||| 30 ACTRAPHANE 40 ACTRAPHANE ||| 0-0 1-1 2-2 3-3
30 ACTRAPHANE 40 ||| 30 ACTRAPHANE 40 ||| 0-0 1-1 2-2
30 ACTRAPHANE ||| 30 ACTRAPHANE ||| 0-0 1-1
30 Minuten alle drei ||| 30 minutes , every three ||| 0-0 1-1 2-3 3-4
30 Minuten alle ||| 30 minutes , every ||| 0-0 1-1 2-3
30 Minuten in dreiwöchigem Abstand ||| 30 minutes every 3 weeks ||| 0-0 1-1 3-2 4-3 3-4
30 Minuten in ||| 30 minutes ||| 0-0 1-1
30 Minuten ||| 30 minutes , ||| 0-0 1-1
30 Minuten ||| 30 minutes ||| 0-0 1-1
30 Minuten ||| 30 ||| 0-0 1-0
30 Monate bei Lagerung ||| 30 months when stored between ||| 0-0 1-1 3-2 2-3 3-3 3-4
30 Monate ||| 30 months ||| 0-0 1-1
30 NovoLet 100 ||| 30 NovoLet 100 ||| 0-0 1-1 2-2
30 NovoLet ||| 30 NovoLet ||| 0-0 1-1
30 Penfill 100 ||| 30 Penfill 100 ||| 0-0 1-1 2-2
30 Penfill ||| 30 Penfill ||| 0-0 1-1
30 Tabletten 50 Tabletten 56 ||| 30 tablets 50 tablets 56 ||| 0-0 1-1 2-2 3-3 4-4
30 Tabletten 50 Tabletten ||| 30 tablets 50 tablets ||| 0-0 1-1 2-2 3-3
30 Tabletten 50 ||| 30 tablets 50 ||| 0-0 1-1 2-2
30 Tabletten ||| 30 tablets ||| 0-0 1-1
30 auf einer Seite . ||| 30 on one side . ||| 0-0 1-1 2-2 3-2 3-3 4-4
30 auf einer Seite ||| 30 on one side ||| 0-0 1-1 2-2 3-2 3-3
30 auf ||| 30 on ||| 0-0 1-1
30 besteht aus 30 % ||| 30 consists of 30 % ||| 0-0 1-1 2-1 2-2 3-3 4-4
30 besteht aus 30 ||| 30 consists of 30 ||| 0-0 1-1 2-1 2-2 3-3
30 besteht aus ||| 30 consists of ||| 0-0 1-1 2-1 2-2
30 kg höhere ||| 30 kg require higher ||| 0-0 1-1 2-2 2-3
30 kg und Erwachsene . ||| 30 kg and adults . ||| 0-0 1-1 2-2 3-3 4-4
30 kg und Erwachsene ||| 30 kg and adults ||| 0-0 1-1 2-2 3-3
30 kg und ||| 30 kg and ||| 0-0 1-1 2-2
30 kg ||| 30 kg ||| 0-0 1-1
30 mg ( d.h . ||| 30 mg ( i. e. ||| 0-0 1-1 2-2 3-3 3-4 4-4
30 mg ( ||| 30 mg ( ||| 0-0 1-1 2-2
30 mg ( ||| of 30 mg ( ||| 0-1 1-2 2-3
30 mg ) ||| 30 mg ) ||| 0-0 1-1 2-2
30 mg Aripiprazol . ||| 30 mg of aripiprazole . ||| 0-0 1-1 2-3 3-4
30 mg Aripiprazol als ||| 30 mg aripiprazole as the ||| 0-0 1-1 2-2 3-3
30 mg Aripiprazol als ||| 30 mg aripiprazole as ||| 0-0 1-1 2-2 3-3
30 mg Aripiprazol ||| 30 mg aripiprazole ||| 0-0 1-1 2-2
30 mg Aripiprazol ||| 30 mg of aripiprazole ||| 0-0 1-1 2-3
30 mg Pioglitazon ( als ||| 30 mg pioglitazone ( as ||| 0-0 1-1 2-2 3-3 4-4
30 mg Pioglitazon ( als ||| 30mg of pioglitazone ( as ||| 0-0 1-0 2-2 3-3 4-4
30 mg Pioglitazon ( ||| 30 mg pioglitazone ( ||| 0-0 1-1 2-2 3-3
30 mg Pioglitazon ( ||| 30mg of pioglitazone ( ||| 0-0 1-0 2-2 3-3
30 mg Pioglitazon als ||| 30 mg of pioglitazone as ||| 0-0 1-1 2-3 3-4
30 mg Pioglitazon ||| 30 mg of pioglitazone ||| 0-0 1-1 2-3
30 mg Pioglitazon ||| 30 mg pioglitazone ||| 0-0 1-1 2-2
30 mg Pioglitazon ||| 30mg of pioglitazone ||| 0-0 1-0 2-2
30 mg Schmelztabletten ( ||| 30 mg orodispersible tablets ( ||| 0-0 1-1 2-2 2-3 3-4
30 mg Schmelztabletten sind ||| 30 mg orodispersible tablets are ||| 0-0 1-1 2-2 2-3 3-4
30 mg Schmelztabletten ||| 30 mg orodispersible tablets ||| 0-0 1-1 2-2 2-3
30 mg Tabletten , als ||| 30 mg tablets , as ||| 0-0 1-1 2-2 3-3 4-4
30 mg Tabletten , ||| 30 mg tablets , ||| 0-0 1-1 2-2 3-3
30 mg Tabletten aufgetreten : ||| 30mg tablets : ||| 0-0 1-0 2-1 3-1 4-2
30 mg Tabletten aufgetreten ||| 30mg tablets ||| 0-0 1-0 2-1 3-1
30 mg Tabletten eingenommen ||| 30mg tablets ||| 0-0 1-0 2-1 3-1
30 mg Tabletten ist Pioglitazon ||| 30mg tablets is pioglitazone ||| 0-0 1-0 2-1 3-2 4-3
30 mg Tabletten ist ||| 30mg tablets is ||| 0-0 1-0 2-1 3-2
30 mg Tabletten können ||| 30 mg tablets may ||| 0-0 1-1 2-2 3-3
30 mg Tabletten können ||| 30mg tablets can be ||| 0-0 1-0 2-1 3-2 3-3
30 mg Tabletten mit ||| 30mg tablets with ||| 0-0 1-0 2-1 3-2
30 mg Tabletten sind rund ||| 30 mg tablets are round ||| 0-0 1-1 2-2 3-3 4-4
30 mg Tabletten sind ||| 30 mg tablets are ||| 0-0 1-1 2-2 3-3
30 mg Tabletten werden ||| 30mg tablets are ||| 0-0 1-0 2-1 3-2
30 mg Tabletten ||| 30 mg tablets ||| 0-0 1-1 2-2
30 mg Tabletten ||| 30mg tablets ||| 0-0 1-0 2-1
30 mg einmal täglich . ||| 30 mg once daily . ||| 0-0 1-1 2-2 3-3 4-4
30 mg einmal täglich ||| 30 mg once daily ||| 0-0 1-1 2-2 3-3
30 mg einmal ||| 30 mg once ||| 0-0 1-1 2-2
30 mg lag . ||| 30 mg . ||| 0-0 1-1 3-2
30 mg lag ||| 30 mg ||| 0-0 1-1
30 mg nicht überschreiten . ||| not exceed 30 mg . ||| 2-0 1-1 3-1 0-2 3-3 4-4
30 mg nicht überschreiten ||| not exceed 30 mg ||| 2-0 1-1 3-1 0-2 3-3
30 mg sollte jedoch ||| 30 mg should be ||| 0-0 3-0 1-1 2-2 2-3
30 mg ||| , 30 mg ||| 0-1 1-2
30 mg ||| 30 mg , ||| 0-0 1-1
30 mg ||| 30 mg of ||| 0-0 1-1
30 mg ||| 30 mg ||| 0-0 1-1
30 mg ||| 30mg of ||| 0-0 1-0
30 mg ||| 30mg ||| 0-0 1-0
30 mg ||| of 30 mg ||| 0-1 1-2
30 mg/Tag ( ||| 30 mg/ day ( ||| 0-0 1-1 1-2 2-3
30 mg/Tag . ||| 30 mg/ day . ||| 0-0 1-1 1-2 2-3
30 mg/Tag ||| 30 mg/ day ||| 0-0 1-1 1-2
30 mit einer ||| 30 to a similar ||| 0-0 1-2 2-2
30 mit einer ||| 30 to a ||| 0-0 1-2 2-2
30 mit einer ähnlichen ||| 30 to a similar mix ||| 0-0 1-2 2-2 3-4
30 oder 45 mg ||| 30 or 45 mg of ||| 0-0 1-1 2-2 3-3
30 oder 45 mg ||| 30 or 45 mg ||| 0-0 1-1 2-2 3-3
30 oder 45 ||| 30 or 45 ||| 0-0 1-1 2-2
30 oder ||| 30 or ||| 0-0 1-1
30 ||| , 30 ||| 0-1
30 ||| 30 to ||| 0-0
30 ||| 30 ||| 0-0
30 ||| 30mg ||| 0-0
30 ||| of 30 ||| 0-1
30 ||| to 30 ||| 0-1
30-36 Avenue Gustave Eiffel , ||| 30-36 Avenue Gustave Eiffel , ||| 0-0 1-1 2-2 3-3 4-4
30-36 Avenue Gustave Eiffel ||| 30-36 Avenue Gustave Eiffel ||| 0-0 1-1 2-2 3-3
30-36 Avenue Gustave ||| 30-36 Avenue Gustave ||| 0-0 1-1 2-2
30-36 Avenue ||| 30-36 Avenue ||| 0-0 1-1
30-36 ||| 30-36 ||| 0-0
30-minütiger Infusion von 260 mg/m2 ||| 260 mg/ m2 over 30 ||| 3-0 4-1 0-2 1-2 4-2 2-3 4-4
300 I.E. pro Kilogramm . ||| 300 IU per kilogram . ||| 0-0 1-1 2-2 3-3 4-4
300 I.E. pro Kilogramm ||| 300 IU per kilogram ||| 0-0 1-1 2-2 3-3
300 I.E. pro ||| 300 IU per ||| 0-0 1-1 2-2
300 I.E. ||| 300 IU . ||| 0-0 1-1 1-2
300 I.E. ||| 300 IU ||| 0-0 1-1
300 I.E./kg an 10 ||| 300 IU/ kg ||| 0-0 1-1 1-2 3-2
300 I.E./kg dreimal ||| 300 IU/ kg 3 ||| 0-0 1-1 2-1 1-2 2-3
300 I.E./kg mittels ||| 300 IU/ kg given by ||| 0-0 1-1 1-2 0-3 2-4
300 I.E./kg ||| 300 IU/ kg given ||| 0-0 1-1 1-2 0-3
300 gastrointestinale ||| 300 gastro-intestinal ||| 0-0 1-1
300 mg Fe2+/Tag wird ||| 300 mg Fe2+/ day is ||| 0-0 1-1 2-2 2-3 3-4
300 mg Fe2+/Tag ||| 300 mg Fe2+/ day ||| 0-0 1-1 2-2 2-3
300 mg ||| 300 mg ||| 0-0 1-1
300 mg/m2 ; 95 ||| 300 mg/ m2 ; 95 ||| 0-0 1-1 1-2 2-3 3-4
300 mg/m2 ; ||| 300 mg/ m2 ; ||| 0-0 1-1 1-2 2-3
300 mg/m2 ||| 300 mg/ m2 ||| 0-0 1-1 1-2
300 ||| 300 ||| 0-0
300-360 mOsm/kg . ||| 300-360 mOsm/ kg . ||| 0-0 0-1 1-1 1-2 2-3
300-360 mOsm/kg ||| 300-360 mOsm/ kg ||| 0-0 0-1 1-1 1-2
3000 . ||| 3000 ||| 0-0 1-0
3000 I.E. ) Lösung ||| 3000 IU ) of solution ||| 0-0 1-1 2-2 1-3 3-4
3000 I.E. ) ||| 3000 IU ) of ||| 0-0 1-1 2-2 1-3
3000 I.E./0,3 ml ||| 3000 IU/ 0.3 ml ||| 0-0 0-1 1-2 2-3
3000 I.E./0,3 ml ||| 3000 IU/ 0.3 ml ||| 0-0 1-1 1-2 2-3
3000 I.E./0,3 ||| 3000 IU/ 0.3 ||| 0-0 0-1 1-2
3000 I.E./0,3 ||| 3000 IU/ 0.3 ||| 0-0 1-1 1-2
3000 Internationale Einheiten ( I.E. ||| 3000 international units ( IU ||| 0-0 1-1 2-2 3-3 4-4
3000 Internationale Einheiten ( ||| 3000 international units ( ||| 0-0 1-1 2-2 3-3
3000 Internationale Einheiten ||| 3000 international units ||| 0-0 1-1 2-2
3000 Internationale ||| 3000 international ||| 0-0 1-1
3000 ||| 3000 IU/ ||| 0-0 0-1
3000 ||| 3000 ||| 0-0
301 ||| 301 ||| 0-0
31 % ) ||| 31 % ) ||| 0-0 1-1 2-2
31 % geringere ||| 31 % ||| 0-0 1-1 2-1
31 % ||| 31 % ||| 0-0 1-1
31 ( 0 ) 30 ||| 31 ( 0 ) 30 ||| 0-0 1-1 2-2 3-3 4-4
31 ( 0 ) ||| 31 ( 0 ) ||| 0-0 1-1 2-2 3-3
31 ( 0 ||| 31 ( 0 ||| 0-0 1-1 2-2
31 ( ||| 31 ( ||| 0-0 1-1
31 34 857 42 22 ||| 31 34 857 42 22 ||| 0-0 1-1 2-2 3-3 4-4
31 34 857 42 ||| 31 34 857 42 ||| 0-0 1-1 2-2 3-3
31 34 857 ||| 31 34 857 ||| 0-0 1-1 2-2
31 34 ||| 31 34 ||| 0-0 1-1
31 ||| 31 ||| 0-0
31,0 65,1 26,7 ||| 31.0 65.1 26.7 ||| 0-0 1-1 2-2
31,0 65,1 ||| 31.0 65.1 ||| 0-0 1-1
31,0 ||| 31.0 ||| 0-0
3116 8000 ||| 3116 8000 ||| 0-0 1-1
3116 8950 ||| 3116 8950 ||| 0-0 1-1
3116 8951 ||| 3116 8951 ||| 0-0 1-1
3116 8952 ||| 3116 8952 ||| 0-0 1-1
3116 8953 ||| 3116 8953 ||| 0-0 1-1
3116 8954 ||| 3116 8954 ||| 0-0 1-1
3116 ||| 3116 ||| 0-0
32 % der ||| 32 % of ||| 0-0 1-1 2-2
32 % und um 47 ||| 32 % and 47 ||| 0-0 1-1 2-2 3-3 4-3
32 % und ||| 32 % and ||| 0-0 1-1 2-2
32 % ||| 32 % ||| 0-0 1-1
32 00 ||| 32 00 ||| 0-0 1-1
32 2 352 74 60 ||| 32 2 352 74 60 ||| 0-0 1-1 2-2 3-3 4-4
32 2 352 74 ||| 32 2 352 74 ||| 0-0 1-1 2-2 3-3
32 2 352 ||| 32 2 352 ||| 0-0 1-1 2-2
32 2 ||| 32 2 ||| 0-0 1-1
32 4.2 Dosierung , ||| 4.2 Posology ||| 0-0 1-0 2-1 3-1
32 4.2 ||| 4.2 ||| 0-0 1-0
32 Deutschland Novartis Pharma GmbH ||| Deutschland Novartis Pharma GmbH ||| 0-0 1-0 2-1 3-2 4-3
32 Deutschland Novartis Pharma ||| Deutschland Novartis Pharma ||| 0-0 1-0 2-1 3-2
32 Deutschland Novartis ||| Deutschland Novartis ||| 0-0 1-0 2-1
32 Deutschland ||| Deutschland ||| 0-0 1-0
32 ||| 32 ||| 0-0
33 % ||| 33 % ||| 0-0 1-1
33 ( 0)1 47 56 ||| 33 ( 0)1 47 56 ||| 0-0 1-1 2-2 3-3 4-4
33 ( 0)1 47 ||| 33 ( 0)1 47 ||| 0-0 1-1 2-2 3-3
33 ( 0)1 ||| 33 ( 0)1 ||| 0-0 1-1 2-2
33 ( 0)810 410 500 ||| 33 ( 0)810 410 500 ||| 0-0 1-1 2-2 3-3 4-4
33 ( 0)810 410 ||| 33 ( 0)810 410 ||| 0-0 1-1 2-2 3-3
33 ( 0)810 ||| 33 ( 0)810 ||| 0-0 1-1 2-2
33 ( ||| 33 ( ||| 0-0 1-1
33 - 39 % ) ||| 33 - 39 % ) ||| 0-0 1-1 2-2 3-3 4-4
33 - 39 % ||| 33 - 39 % ||| 0-0 1-1 2-2 3-3
33 - 39 % ||| of 33 - 39 % ||| 0-1 1-2 2-3 3-4
33 - 39 ||| 33 - 39 ||| 0-0 1-1 2-2
33 - 39 ||| of 33 - 39 ||| 0-1 1-2 2-3
33 - ||| 33 - ||| 0-0 1-1
33 - ||| of 33 - ||| 0-1 1-2
33 22 11 ||| 33 22 11 ||| 0-0 1-1 2-2
33 22 ||| 33 22 ||| 0-0 1-1
33 I.E./kg dreimal ||| 33 IU/ kg 3 times ||| 0-0 1-1 1-2 2-3 2-4
33 I.E./kg ||| 33 IU/ kg , ||| 0-0 1-1 1-2
33 I.E./kg ||| 33 IU/ kg ||| 0-0 1-1 1-2
33 mit anderen Rezeptoren als ||| Interaction with receptors other than ||| 0-0 3-0 1-1 3-2 2-3 4-4
33 mit anderen Rezeptoren ||| Interaction with receptors other ||| 0-0 3-0 1-1 3-2 2-3
33 ||| 33 ||| 0-0
33 ||| of 33 ||| 0-1
33,6 Mikrogramm Epoetin alfa ||| 33.6 micrograms epoetin alfa ||| 0-0 1-1 2-2 3-3
33,6 Mikrogramm Epoetin ||| 33.6 micrograms epoetin ||| 0-0 1-1 2-2
33,6 Mikrogramm Epoetin ||| corresponding to 33.6 micrograms epoetin ||| 1-0 0-2 1-3 2-4
33,6 Mikrogramm ||| 33.6 micrograms ||| 0-0 1-1
33,6 Mikrogramm ||| corresponding to 33.6 micrograms ||| 1-0 0-2 1-3
33,6 ||| 33.6 ||| 0-0
33,6 ||| to 33.6 ||| 0-1
34 % ) ||| 34 % ) ||| 0-0 1-1 2-2
34 % ermittelt ||| 34 % , ||| 0-0 1-1 2-1
34 % ermittelt ||| 34 % ||| 0-0 1-1 2-1
34 % ||| 34 % ||| 0-0 1-1
34 ( 91 ) 663 ||| 34 ( 91 ) 663 ||| 0-0 1-1 2-2 3-3 4-4
34 ( 91 ) ||| 34 ( 91 ) ||| 0-0 1-1 2-2 3-3
34 ( 91 ||| 34 ( 91 ||| 0-0 1-1 2-2
34 ( ||| 34 ( ||| 0-0 1-1
34 857 42 22 ||| 34 857 42 22 ||| 0-0 1-1 2-2 3-3
34 857 42 ||| 34 857 42 ||| 0-0 1-1 2-2
34 857 ||| 34 857 ||| 0-0 1-1
34 Anpassung der Dosis Begleiterkrankungen ||| Dosage adjustment Concomitant illness ||| 0-0 1-0 1-1 1-2 2-2 4-2 3-3 4-3
34 In einer ||| 31 In a ||| 0-0 1-1 2-2
34 In ||| 31 In ||| 0-0 1-1
34 [ 3,2 % ] ||| 34 [ 3.2 % ] ||| 0-0 1-1 2-2 3-3 4-4
34 [ 3,2 % ||| 34 [ 3.2 % ||| 0-0 1-1 2-2 3-3
34 [ 3,2 ||| 34 [ 3.2 ||| 0-0 1-1 2-2
34 [ ||| 34 [ ||| 0-0 1-1
34 ||| 31 ||| 0-0
34 ||| 34 ||| 0-0
34,9 % ( 28 % ||| ( 28 % ||| 2-0 0-1 3-1 1-2 4-2
347 Patienten ||| 347 patients ||| 0-0 1-1
347 ||| 347 ||| 0-0
35 % ||| 35 % ||| 0-0 1-1
35 Bei schon lange ||| Usual warning symptoms may ||| 0-0 1-0 2-0 2-1 3-1 3-2 3-3
35 Die empfohlene Dosierung wird ||| The recommended dosing regimen is ||| 1-0 0-1 2-1 3-2 2-3 3-3 4-4
35 Die empfohlene Dosierung ||| The recommended dosing regimen ||| 1-0 0-1 2-1 3-2 2-3 3-3
35 Studien und ||| 35 trials and ||| 0-0 1-1 2-2
35 Studien ||| 35 trials ||| 0-0 1-1
35 gewogen ||| 35 ||| 0-0 1-0
35 wenn Pioglitazon ||| when pioglitazone was ||| 1-0 2-1 2-2
35 wenn ||| when ||| 1-0
35 ||| 35 ||| 0-0
351 21 412 6600 ||| 351 21 412 6600 ||| 0-0 1-1 2-2 3-3
351 21 412 ||| 351 21 412 ||| 0-0 1-1 2-2
351 21 ||| 351 21 ||| 0-0 1-1
351 ||| 351 ||| 0-0
352 74 60 ||| 352 74 60 ||| 0-0 1-1 2-2
352 74 ||| 352 74 ||| 0-0 1-1
352 ||| 352 ||| 0-0
353 ( 1 800 ) ||| 353 ( 1 800 ) ||| 0-0 1-1 2-2 3-3 4-4
353 ( 1 800 ||| 353 ( 1 800 ||| 0-0 1-1 2-2 3-3
353 ( 1 ||| 353 ( 1 ||| 0-0 1-1 2-2
353 ( ||| 353 ( ||| 0-0 1-1
353 ||| 353 ||| 0-0
354 535 7000 ||| 354 535 7000 ||| 0-0 1-1 2-2
354 535 ||| 354 535 ||| 0-0 1-1
354 ||| 354 ||| 0-0
357 Patienten ||| 357 patients ||| 0-0 1-1
357 ||| 357 ||| 0-0
358 ( 0)9 8545250 ||| 358 ( 0)9 8545250 ||| 0-0 1-1 2-2 3-3
358 ( 0)9 ||| 358 ( 0)9 ||| 0-0 1-1 2-2
358 ( ||| 358 ( ||| 0-0 1-1
358 9 251 21 230 ||| 358 9 251 21 230 ||| 0-0 1-1 2-2 3-3 4-4
358 9 251 21 ||| 358 9 251 21 ||| 0-0 1-1 2-2 3-3
358 9 251 ||| 358 9 251 ||| 0-0 1-1 2-2
358 9 ||| 358 9 ||| 0-0 1-1
358 ||| 358 ||| 0-0
36 % ||| 36 % ||| 0-0 1-1
36 Die empfohlene ||| 34 The recommended ||| 0-0 1-1 2-2
36 Die ||| 34 The ||| 0-0 1-1
36 Monate ) . ||| 36 months ) . ||| 0-0 1-1 2-2 3-3
36 Monate ) ||| 36 months ) ||| 0-0 1-1 2-2
36 Monate ||| 36 months ||| 0-0 1-1
36 ||| 34 ||| 0-0
36 ||| 36 ||| 0-0
36(0 ) 20 501 76 ||| 36(0 ) 20 501 76 ||| 0-0 1-1 2-2 3-3 4-4
36(0 ) 20 501 ||| 36(0 ) 20 501 ||| 0-0 1-1 2-2 3-3
36(0 ) 20 ||| 36(0 ) 20 ||| 0-0 1-1 2-2
36(0 ) ||| 36(0 ) ||| 0-0 1-1
36(0 ||| 36(0 ||| 0-0
360 Hunden ||| 360 dogs ||| 0-0 1-1
360 Hunden über den ||| 360 dogs over the ||| 0-0 1-1 2-2 3-3
360 Hunden über ||| 360 dogs over ||| 0-0 1-1 2-2
360 ||| 360 ||| 0-0
37 ( 16 % ) ||| 37 ( 16 % ) ||| 0-0 1-1 2-2 3-3 4-4
37 ( 16 % ||| 37 ( 16 % ||| 0-0 1-1 2-2 3-3
37 ( 16 ||| 37 ( 16 ||| 0-0 1-1 2-2
37 ( ||| 37 ( ||| 0-0 1-1
37 , D-58638 Iserlohn , ||| 37 , D-58638 Iserlohn , ||| 0-0 1-1 2-2 3-3 4-4
37 , D-58638 Iserlohn ||| 37 , D-58638 Iserlohn ||| 0-0 1-1 2-2 3-3
37 , D-58638 ||| 37 , D-58638 ||| 0-0 1-1 2-2
37 , ||| 37 , ||| 0-0 1-1
37 4.4 Besondere Warnhinweise und ||| 4.4 Special warnings and ||| 0-0 1-0 2-1 3-2 4-3
37 4.4 Besondere Warnhinweise ||| 4.4 Special warnings ||| 0-0 1-0 2-1 3-2
37 4.4 Besondere ||| 4.4 Special ||| 0-0 1-0 2-1
37 4.4 ||| 4.4 ||| 0-0 1-0
37 D-58638 Iserlohn Deutschland ||| 37 D-58638 Iserlohn Germany ||| 0-0 1-1 2-2 3-3
37 D-58638 Iserlohn Deutschland ||| 37 D-58638 Iserlohn ||| 0-0 1-1 2-1 3-2
37 D-58638 Iserlohn ||| 37 D-58638 Iserlohn ||| 0-0 1-1 2-2
37 D-58638 Iserlohn ||| 37 D-58638 ||| 0-0 1-1 2-1
37 D-58638 ||| 37 D-58638 ||| 0-0 1-1
37 ||| 37 ||| 0-0
37 ||| However , the ||| 0-0 0-1
37 ||| However , ||| 0-0 0-1
375 ||| 375 ||| 0-0
38 Bei Patienten mit ||| In patients with ||| 1-0 2-1 0-2 3-2
38 Patienten mit ||| Patients with ||| 0-0 1-0 2-1
38 Patienten ||| Patients ||| 0-0 1-0
3800 ||| 3800 ||| 0-0
384 Patienten untersucht . ||| 384 patients . ||| 0-0 1-1 2-1 3-2
384 Patienten untersucht ||| 384 patients ||| 0-0 1-1 2-1
384 ||| 384 ||| 0-0
39 % ) ||| 39 % ) ||| 0-0 1-1 2-2
39 % ||| 39 % ||| 0-0 1-1
39 06 5026 01 ||| 39 06 5026 01 ||| 0-0 1-1 2-2 3-3
39 06 5026 ||| 39 06 5026 ||| 0-0 1-1 2-2
39 06 ||| 39 06 ||| 0-0 1-1
39 16 84 00 ||| 39 16 84 00 ||| 0-0 1-1 2-2 3-3
39 16 84 ||| 39 16 84 ||| 0-0 1-1 2-2
39 16 ||| 39 16 ||| 0-0 1-1
39 Spätdyskinesien : in klinischen ||| Tardive Dyskinesia : in clinical ||| 0-0 1-0 1-1 2-2 3-3 4-4
39 Spätdyskinesien : in ||| Tardive Dyskinesia : in ||| 0-0 1-0 1-1 2-2 3-3
39 Spätdyskinesien : ||| Tardive Dyskinesia : ||| 0-0 1-0 1-1 2-2
39 Spätdyskinesien ||| Tardive Dyskinesia ||| 0-0 1-0 1-1
39 ||| 39 ||| 0-0
39 ± 16 % ||| 39 ± 16 % ||| 0-0 1-1 2-2 3-3
39 ± 16 ||| 39 ± 16 ||| 0-0 1-1 2-2
39 ± ||| 39 ± ||| 0-0 1-1
39,0 ; 55,3 ] ( ||| 39.0 , 55.3 ] ( ||| 0-0 1-1 2-2 1-3 3-3 4-4
39,0 ; 55,3 ] ||| 39.0 , 55.3 ] ||| 0-0 1-1 2-2 1-3 3-3
39,0 ||| 39.0 ||| 0-0
3A4 ( Dextromethorphan ) . ||| 3A4 ( dextromethorphan ) . ||| 0-0 1-1 2-2 3-3 4-4
3A4 ( Dextromethorphan ) ||| 3A4 ( dextromethorphan ) ||| 0-0 1-1 2-2 3-3
3A4 ( Dextromethorphan ||| 3A4 ( dextromethorphan ||| 0-0 1-1 2-2
3A4 ( ||| 3A4 ( ||| 0-0 1-1
3A4 . ||| 3A4 . ||| 0-0 1-1
3A4 ||| 3A4 ||| 0-0
3XX Vereinigtes Königreich ||| 3XX United Kingdom ||| 0-0 1-1 2-2
3XX Vereinigtes ||| 3XX United ||| 0-0 1-1
3XX ||| 3XX ||| 0-0
3x ||| repeated ||| 0-0
4 Gewichtszunahme : Eine Gewichtszunahme ||| Weight gain : weight gain ||| 1-0 3-0 1-1 2-2 4-3 4-4
4 Gewichtszunahme : Eine ||| Weight gain : ||| 1-0 3-0 1-1 2-2
4 Reproduktionstoxizität gezeigt ( siehe ||| shown reproductive toxicity ( see ||| 2-0 1-1 1-2 3-3 4-4
4 Reproduktionstoxizität gezeigt ( ||| shown reproductive toxicity ( ||| 2-0 1-1 1-2 3-3
4 Reproduktionstoxizität gezeigt ||| shown reproductive toxicity ||| 2-0 1-1 1-2
4 Reproduktionstoxizität ||| reproductive toxicity ||| 1-0 1-1
4 Stunden bei ||| 4 hours in ||| 0-0 1-1 2-2
4 Stunden ||| 4 hours ||| 0-0 1-1
4 Tage nach ||| for four days ||| 1-0 0-1 1-2 2-2
4 Wochen ||| 4 weeks ||| 0-0 1-1
4 bis 6 Wochen ) ||| 4 to 6 weeks ) ||| 0-0 1-1 2-2 1-3 3-3 4-4
4 bis 6 Wochen ) ||| 4 to 6 weeks ) ||| 0-0 1-1 2-2 3-3 4-4
4 bis 6 Wochen ||| 4 to 6 weeks ||| 0-0 1-1 2-2 1-3 3-3
4 bis 6 Wochen ||| 4 to 6 weeks ||| 0-0 1-1 2-2 3-3
4 bis 6 ||| 4 to 6 ||| 0-0 1-1 2-2
4 bis ||| 4 to ||| 0-0 1-1
4 oder mehr Einheiten ||| 4 or more units of ||| 0-0 1-1 2-2 3-3
4 oder mehr Einheiten ||| 4 or more units ||| 0-0 1-1 2-2 3-3
4 oder mehr ||| 4 or more ||| 0-0 1-1 2-2
4 oder ||| 4 or ||| 0-0 1-1
4 ||| 4 ||| 0-0
4 ||| four ||| 0-0
4,6 - 6,2 Monate ) ||| 4.6 6.2 months ) ||| 0-0 1-1 2-1 3-2 4-3
4,6 - 6,2 Monate ||| 4.6 6.2 months ||| 0-0 1-1 2-1 3-2
4,6 - 6,2 ||| 4.6 6.2 ||| 0-0 1-1 2-1
4,6 ||| 4.6 ||| 0-0
4,8 ||| 4.8 ||| 0-0
4. Juni ||| European ||| 0-0 1-0
4. Welche Nebenwirkungen sind ||| Possible side effects 5 How ||| 0-0 1-0 0-1 2-2 1-3 1-4 3-4
4. ||| 4. ||| 0-0
4.10 ||| 4.10 ||| 0-0
4.10 Überdosierung ( Symptome , ||| 4.10 Overdose ( symptoms , ||| 0-0 1-1 2-2 3-3 4-4
4.10 Überdosierung ( Symptome ||| 4.10 Overdose ( symptoms ||| 0-0 1-1 2-2 3-3
4.10 Überdosierung ( ||| 4.10 Overdose ( ||| 0-0 1-1 2-2
4.10 Überdosierung ||| 4.10 Overdose ||| 0-0 1-1
4.2 ) . ||| 4.2 ) . ||| 0-0 1-1 2-2
4.2 ) . ||| 4.2 ) ||| 0-0 1-1 2-1
4.2 ) Die ||| 4.2 ) The ||| 0-0 1-1 2-2
4.2 ) ||| 4.2 ) ||| 0-0 1-1
4.2 - Hinweise zur Anwendung ||| 4.2 Method of administration ||| 0-0 1-1 2-1 3-1 4-2 4-3
4.2 - Hinweise zur ||| 4.2 Method ||| 0-0 1-1 2-1 3-1
4.2 Anwendungsgebiete unter ||| 4.2 Indications for ||| 0-0 1-1 1-2 2-2
4.2 Behandlung von Patienten ||| 4.2 Treatment of patients ||| 0-0 1-1 2-2 3-3
4.2 Behandlung von ||| 4.2 Treatment of ||| 0-0 1-1 2-2
4.2 Behandlung ||| 4.2 Treatment ||| 0-0 1-1
4.2 Dosierung , Art und ||| 4.2 Posology and ||| 0-0 1-1 2-1 3-1 4-2
4.2 Dosierung , Art ||| 4.2 Posology ||| 0-0 1-1 2-1 3-1
4.2 ||| 4.2 ||| 0-0
4.3 ) . ||| 4.3 ) . ||| 0-0 1-1 2-2
4.3 ) ||| 4.3 ) ||| 0-0 1-1
4.3 und 4.4 ||| 4.3 and 4.4 ||| 0-0 1-1 2-2
4.3 und 4.8 ) . ||| . ||| 2-0 4-0
4.3 und 4.8 ) . ||| patient . ||| 2-1 4-1
4.3 und ||| 4.3 and ||| 0-0 1-1
4.3 ||| 4.3 ||| 0-0
4.3). ||| 4.3 ||| 0-0
4.4 ) . In ||| 4.4 ) . ||| 0-0 1-1 2-2
4.4 ) . ||| 4.4 ) . ||| 0-0 1-1 2-2
4.4 ) ||| 4.4 ) ||| 0-0 1-1
4.4 - ||| 4.4 - ||| 0-0 1-1
4.4 und 5.2 ||| 4.4 and 5.2 ||| 0-0 1-1 2-2
4.4 und ||| 4.4 and ||| 0-0 1-1
4.4 ||| 4.4 ||| 0-0
4.4. und 5.2 ) . ||| . and 5.2 ) . ||| 4-0 1-1 0-2 2-2 3-3 4-4
4.4. und 5.2 ) ||| and 5.2 ) ||| 1-0 0-1 2-1 3-2
4.4. und 5.2 ||| and 5.2 ||| 1-0 0-1 2-1
4.5 ) . ||| 4.5 ) . ||| 0-0 1-1 2-2
4.5 ) ||| 4.5 ) ||| 0-0 1-1
4.5 . ||| 4.5 . ||| 0-0 1-1
4.5 Wechselwirkungen mit anderen ||| 4.5 Interaction with other ||| 0-0 0-1 1-1 2-2 3-3
4.5 Wechselwirkungen mit ||| 15 4.5 Interaction with ||| 0-0 0-1 1-2 2-3
4.5 Wechselwirkungen mit ||| 26 4.5 Interaction with ||| 0-0 0-1 1-2 2-3
4.5 Wechselwirkungen mit ||| 37 4.5 Interaction with ||| 0-0 0-1 1-2 2-3
4.5 Wechselwirkungen mit ||| 4 4.5 Interaction with ||| 0-0 0-1 1-2 2-3
4.5 Wechselwirkungen mit ||| 4.5 Interaction with ||| 0-0 0-1 1-1 2-2
4.5 Wechselwirkungen mit ||| 4.5 Interactions with ||| 0-0 1-1 2-2
4.5 Wechselwirkungen ||| 15 4.5 Interaction ||| 0-0 0-1 1-2
4.5 Wechselwirkungen ||| 26 4.5 Interaction ||| 0-0 0-1 1-2
4.5 Wechselwirkungen ||| 37 4.5 Interaction ||| 0-0 0-1 1-2
4.5 Wechselwirkungen ||| 4 4.5 Interaction ||| 0-0 0-1 1-2
4.5 Wechselwirkungen ||| 4.5 Interaction ||| 0-0 0-1 1-1
4.5 Wechselwirkungen ||| 4.5 Interactions ||| 0-0 1-1
4.5 ||| 15 4.5 ||| 0-0 0-1
4.5 ||| 26 4.5 ||| 0-0 0-1
4.5 ||| 37 4.5 ||| 0-0 0-1
4.5 ||| 4 4.5 ||| 0-0 0-1
4.5 ||| 4.5 ||| 0-0
4.5). ||| nefazodone)(see ||| 0-0
4.6 ) . ||| 4.6 ) . ||| 0-0 1-1 2-2
4.6 ) ||| 4.6 ) ||| 0-0 1-1
4.6 ||| 4.6 ||| 0-0
4.7 Anwendung während der Trächtigkeit ||| 4.7 Use during pregnancy ||| 0-0 1-1 2-2 3-2 4-3
4.7 Anwendung während der ||| 4.7 Use during ||| 0-0 1-1 2-2 3-2
4.7 Anwendung ||| 4.7 Use ||| 0-0 1-1
4.7 Auswirkungen auf die ||| 17 4.7 Effects ||| 0-0 0-1 1-1 1-2 2-2 3-2
4.7 Auswirkungen auf die ||| 29 4.7 Effects ||| 0-0 0-1 1-1 1-2 2-2 3-2
4.7 Auswirkungen auf die ||| 4.7 Effects on ||| 0-0 1-1 2-1 2-2 3-2
4.7 Auswirkungen auf die ||| 53 4.7 Effects ||| 0-0 0-1 1-1 1-2 2-2 3-2
4.7 ||| 4.7 ||| 0-0
4.8 ) . ||| . ||| 0-0 2-0
4.8 ) . ||| 4.8 ) . ||| 0-0 1-1 2-2
4.8 ) . ||| patient . ||| 0-1 2-1
4.8 ) ||| 4.8 ) ||| 0-0 1-1
4.8 - Allgemein ) ||| 4.8 - General ) ||| 0-0 1-1 2-2 3-3
4.8 - Allgemein ||| 4.8 - General ||| 0-0 1-1 2-2
4.8 - ||| 4.8 - ||| 0-0 1-1
4.8 und 4.9 ) . ||| 4.8 and 4.9 ) . ||| 0-0 1-1 2-2 3-3 4-4
4.8 und 4.9 ) ||| 4.8 and 4.9 ) ||| 0-0 1-1 2-2 3-3
4.8 und 4.9 ||| 4.8 and 4.9 ||| 0-0 1-1 2-2
4.8 und ||| 4.8 and ||| 0-0 1-1
4.8 ||| 4.8 ||| 0-0
4.9 ) . ||| 4.9 ) . ||| 0-0 1-1 2-2
4.9 ) ||| 4.9 ) ||| 0-0 1-1
4.9 ||| 4.9 ||| 0-0
4/21 ||| It is assumed ||| 0-0 0-1 0-2
40 % der Patienten gemeldet ||| 40 % of the patients ||| 0-0 1-1 2-2 2-3 3-4 4-4
40 % der ||| 40 % of the ||| 0-0 1-1 2-2 2-3
40 % gelöstem Insulin und ||| 40 % dissolved insulin and ||| 0-0 1-1 2-2 3-3 4-4
40 % gelöstem Insulin ||| 40 % dissolved insulin ||| 0-0 1-1 2-2 3-3
40 % gelöstem ||| 40 % dissolved ||| 0-0 1-1 2-2
40 % und Isophan-Insulin ||| 40 % and isophane insulin ||| 0-0 1-1 2-2 3-3 3-4
40 % und ||| 40 % and ||| 0-0 1-1 2-2
40 % ||| 40 % in the ||| 0-0 1-1
40 % ||| 40 % in ||| 0-0 1-1
40 % ||| 40 % ||| 0-0 1-1
40 ( 0)21 272 16 ||| 40 ( 0)21 272 16 ||| 0-0 1-1 2-2 3-3 4-4
40 ( 0)21 272 ||| 40 ( 0)21 272 ||| 0-0 1-1 2-2 3-3
40 ( 0)21 ||| 40 ( 0)21 ||| 0-0 1-1 2-2
40 ( ||| 40 ( ||| 0-0 1-1
40 64 ||| 40 64 ||| 0-0 1-1
40 : lösliches Insulin 40 ||| 40 : soluble insulin 40 ||| 0-0 1-1 2-2 3-3 4-4
40 : lösliches Insulin ||| 40 : soluble insulin ||| 0-0 1-1 2-2 3-3
40 : lösliches ||| 40 : soluble ||| 0-0 1-1 2-2
40 : ||| 40 : ||| 0-0 1-1
40 ACTRAPHANE 50 ||| 40 ACTRAPHANE 50 ||| 0-0 1-1 2-2
40 ACTRAPHANE ||| 40 ACTRAPHANE ||| 0-0 1-1
40 Gewichtszunahme : Eine Gewichtszunahme ||| Weight gain : weight gain ||| 1-0 3-0 1-1 0-2 2-2 4-3 4-4
40 Gewichtszunahme : Eine ||| Weight gain : ||| 1-0 3-0 1-1 0-2 2-2
40 I.E. Insulin human ||| 40 IU of insulin human ||| 0-0 1-1 1-2 2-3 3-4
40 I.E. Insulin ||| 40 IU of insulin ||| 0-0 1-1 1-2 2-3
40 I.E. ||| 40 IU of ||| 0-0 1-1 1-2
40 NovoLet 100 ||| 40 NovoLet 100 ||| 0-0 1-1 2-2
40 NovoLet ||| 40 NovoLet ||| 0-0 1-1
40 Penfill 100 ||| 40 Penfill 100 ||| 0-0 1-1 2-2
40 Penfill ||| 40 Penfill ||| 0-0 1-1
40 besteht aus 40 % ||| 40 consists of 40 % ||| 0-0 1-1 2-1 2-2 3-3 4-4
40 besteht aus 40 ||| 40 consists of 40 ||| 0-0 1-1 2-1 2-2 3-3
40 besteht aus ||| 40 consists of ||| 0-0 1-1 2-1 2-2
40 kg Körpergewicht ||| 40 kg BW ||| 0-0 1-1 2-2
40 kg ||| 40 kg ||| 0-0 1-1
40 ||| 40 ||| 0-0
40-jähriger ||| old ||| 0-0
40.000 Dalton . ||| 40,000 dalton . ||| 0-0 1-1 2-2
40.000 Dalton ||| 40,000 dalton ||| 0-0 1-1
40.000 ||| 40,000 ||| 0-0
40.000/µl oder ||| increase 40,000/ µl or ||| 0-0 0-1 0-2 1-3
40.000/µl ||| increase 40,000/ µl ||| 0-0 0-1 0-2
400 I.E. ||| 400 IU . ||| 0-0 1-1 1-2
400 mg Sucrose . ||| 400 mg of sucrose . ||| 0-0 1-1 2-3 3-4
400 mg Sucrose je ml ||| 400 mg sucrose per ml ||| 0-0 1-1 2-2 3-3 4-4
400 mg Sucrose je ||| 400 mg sucrose per ||| 0-0 1-1 2-2 3-3
400 mg Sucrose ||| 400 mg of sucrose ||| 0-0 1-1 2-3
400 mg Sucrose ||| 400 mg sucrose ||| 0-0 1-1 2-2
400 mg ||| 400 mg of ||| 0-0 1-1
400 mg ||| 400 mg ||| 0-0 1-1
400 ||| 400 ||| 0-0
4000 I.E. ) Lösung ||| 4000 IU ) of solution ||| 0-0 1-1 2-2 1-3 3-4
4000 I.E. ) ||| 4000 IU ) of ||| 0-0 1-1 2-2 1-3
4000 I.E./0,4 ml ||| 4000 IU/ 0.4 ml ||| 0-0 0-1 1-2 2-3
4000 I.E./0,4 ||| 4000 IU/ 0.4 ||| 0-0 0-1 1-2
4000 Internationale Einheiten ( I.E. ||| 4000 international units ( IU ||| 0-0 1-1 2-2 3-3 4-4
4000 Internationale Einheiten ( ||| 4000 international units ( ||| 0-0 1-1 2-2 3-3
4000 Internationale Einheiten ||| 4000 international units ||| 0-0 1-1 2-2
4000 Internationale ||| 4000 international ||| 0-0 1-1
4000 ||| 4000 IU/ ||| 0-0 0-1
4000 ||| 4000 ||| 0-0
41 % ) ||| 41 % ) ||| 0-0 1-1 2-2
41 % ||| 41 % ||| 0-0 1-1
41 ||| 41 ||| 0-0
41,7 11,9 47,3 11,6 63,8 ||| 41.7 11.9 47.3 11.6 63.8 ||| 0-0 1-1 2-2 3-3 4-4
41,7 11,9 47,3 11,6 ||| 41.7 11.9 47.3 11.6 ||| 0-0 1-1 2-2 3-3
41,7 11,9 47,3 ||| 41.7 11.9 47.3 ||| 0-0 1-1 2-2
41,7 11,9 ||| 41.7 11.9 ||| 0-0 1-1
41,7 ||| 41.7 ||| 0-0
410 500 ||| 410 500 ||| 0-0 1-1
410 ||| 410 ||| 0-0
412 6600 ||| 412 6600 ||| 0-0 1-1
412 ||| 412 ||| 0-0
42 % der Patienten ||| Approximately 42 % of patients ||| 0-0 0-1 1-2 2-3 3-4
42 % der ||| Approximately 42 % of ||| 0-0 0-1 1-2 2-3
42 % ||| 42 % ||| 0-0 1-1
42 % ||| Approximately 42 % ||| 0-0 0-1 1-2
42 22 ||| 42 22 ||| 0-0 1-1
42 4.7 Auswirkungen auf ||| 4.7 Effects on ||| 0-0 1-0 2-1 3-2
42 4.7 Auswirkungen ||| 4.7 Effects ||| 0-0 1-0 2-1
42 4.7 ||| 4.7 ||| 0-0 1-0
42 Anpassung der Dosis Begleiterkrankungen ||| Dosage adjustment Concomitant illness ||| 0-0 1-0 1-1 1-2 2-2 4-2 3-3 4-3
42 Bei exzessiv hohen ||| Phlebotomy may be performed ||| 0-0 1-0 2-0 2-1 2-2 3-3
42 Bei exzessiv ||| Phlebotomy may be ||| 0-0 1-0 2-0 2-1 2-2
42 Studien und 8167 Patienten ||| 42 trials and 8167 patients ||| 0-0 1-1 2-2 3-3 4-4
42 Studien und 8167 ||| 42 trials and 8167 ||| 0-0 1-1 2-2 3-3
42 Studien und ||| 42 trials and ||| 0-0 1-1 2-2
42 Studien ||| 42 trials ||| 0-0 1-1
42 ||| 42 ||| 0-0
42 ||| Approximately 42 ||| 0-0 0-1
42,0 Mikrogramm Epoetin alfa ||| 42.0 micrograms epoetin alfa ||| 0-0 1-1 2-2 3-3
42,0 Mikrogramm Epoetin ||| 42.0 micrograms epoetin ||| 0-0 1-1 2-2
42,0 Mikrogramm Epoetin ||| corresponding to 42.0 micrograms epoetin ||| 1-0 0-2 1-3 2-4
42,0 Mikrogramm ||| 42.0 micrograms ||| 0-0 1-1
42,0 Mikrogramm ||| corresponding to 42.0 micrograms ||| 1-0 0-2 1-3
42,0 ||| 42.0 ||| 0-0
42,0 ||| to 42.0 ||| 0-1
425 mg Natrium pro Dosis ||| 425 mg sodium per dose ||| 0-0 1-1 2-2 3-3 4-4
425 mg Natrium pro ||| 425 mg sodium per ||| 0-0 1-1 2-2 3-3
425 mg Natrium ||| 425 mg sodium ||| 0-0 1-1 2-2
425 mg ||| 425 mg ||| 0-0 1-1
425 ||| 425 ||| 0-0
43 ( 1 ) 524 ||| 43 ( 1 ) 524 ||| 0-0 1-1 2-2 3-3 4-4
43 ( 1 ) ||| 43 ( 1 ) ||| 0-0 1-1 2-2 3-3
43 ( 1 ||| 43 ( 1 ||| 0-0 1-1 2-2
43 ( ||| 43 ( ||| 0-0 1-1
43 1 60 14 30 ||| 43 1 60 14 30 ||| 0-0 1-1 2-2 3-3 4-4
43 1 60 14 ||| 43 1 60 14 ||| 0-0 1-1 2-2 3-3
43 1 60 ||| 43 1 60 ||| 0-0 1-1 2-2
43 1 ||| 43 1 ||| 0-0 1-1
43 Bei schon lange ||| Usual warning symptoms may ||| 0-0 1-0 2-0 2-1 3-1 3-2 3-3
43 ||| 43 ||| 0-0
43 ||| to 43 ||| 0-1
43-(0)800 29 5193 ||| 43-(0)800 29 5193 ||| 0-0 1-1 2-2
43-(0)800 29 ||| 43-(0)800 29 ||| 0-0 1-1
43-(0)800 ||| 43-(0)800 ||| 0-0
44 ( 0)1628 537 900 ||| 44 ( 0)1628 537 900 ||| 0-0 1-1 2-2 3-3 4-4
44 ( 0)1628 537 ||| 44 ( 0)1628 537 ||| 0-0 1-1 2-2 3-3
44 ( 0)1628 ||| 44 ( 0)1628 ||| 0-0 1-1 2-2
44 ( 0)20 3116 8950 ||| 44 ( 0)20 3116 8950 ||| 0-0 1-1 2-2 3-3 4-4
44 ( 0)20 3116 8951 ||| 44 ( 0)20 3116 8951 ||| 0-0 1-1 2-2 3-3 4-4
44 ( 0)20 3116 8952 ||| 44 ( 0)20 3116 8952 ||| 0-0 1-1 2-2 3-3 4-4
44 ( 0)20 3116 8953 ||| 44 ( 0)20 3116 8953 ||| 0-0 1-1 2-2 3-3 4-4
44 ( 0)20 3116 8954 ||| 44 ( 0)20 3116 8954 ||| 0-0 1-1 2-2 3-3 4-4
44 ( 0)20 3116 ||| 44 ( 0)20 3116 ||| 0-0 1-1 2-2 3-3
44 ( 0)20 ||| 44 ( 0)20 ||| 0-0 1-1 2-2
44 ( 0800 ) 731 ||| 44 ( 0800 ) 731 ||| 0-0 1-1 2-2 3-3 4-4
44 ( 0800 ) ||| 44 ( 0800 ) ||| 0-0 1-1 2-2 3-3
44 ( 0800 ||| 44 ( 0800 ||| 0-0 1-1 2-2
44 ( ||| 44 ( ||| 0-0 1-1
44 In tierexperimentellen Studien mit ||| In animal studies , epoetin ||| 1-0 2-1 3-2 2-4 4-4
44 In ||| In ||| 1-0
44 ||| 44 ||| 0-0
44-20 ) 74 18 84 ||| 44-20 ) 74 18 84 ||| 0-0 1-1 2-2 3-3 4-4
44-20 ) 74 18 ||| 44-20 ) 74 18 ||| 0-0 1-1 2-2 3-3
44-20 ) 74 ||| 44-20 ) 74 ||| 0-0 1-1 2-2
44-20 ) ||| 44-20 ) ||| 0-0 1-1
44-20 ||| 44-20 ||| 0-0
45 % ) wiedergefunden . ||| 45 % ) . ||| 0-0 3-0 1-1 2-2 4-3
45 % ) wiedergefunden ||| 45 % ) ||| 0-0 3-0 1-1 2-2
45 % der Patienten beobachtet ||| 45 % of the patients ||| 0-0 1-1 2-2 2-3 3-4 4-4
45 % der Patienten ||| 45 % of the patients ||| 0-0 1-1 2-2 2-3 3-4
45 % der ||| 45 % of the ||| 0-0 1-1 2-2 2-3
45 % ||| 45 % ||| 0-0 1-1
45 45 93 05 06 ||| 45 45 93 05 06 ||| 0-0 1-1 2-2 3-3 4-4
45 45 93 05 ||| 45 45 93 05 ||| 0-0 1-1 2-2 3-3
45 45 93 ||| 45 45 93 ||| 0-0 1-1 2-2
45 45 ||| 45 45 ||| 0-0 1-1
45 6.6 Besondere ||| 6.6 Special ||| 0-0 1-0 2-1
45 6.6 ||| 6.6 ||| 0-0 1-0
45 93 05 06 ||| 45 93 05 06 ||| 0-0 1-1 2-2 3-3
45 93 05 ||| 45 93 05 ||| 0-0 1-1 2-2
45 93 ||| 45 93 ||| 0-0 1-1
45 mg ( einmal täglich ||| 45 mg ( once daily ||| 0-0 1-1 2-2 3-3 4-4
45 mg ( einmal ||| 45 mg ( once ||| 0-0 1-1 2-2 3-3
45 mg ( ||| 45 mg ( ||| 0-0 1-1 2-2
45 mg Pioglitazon ( als ||| 45 mg pioglitazone ( as ||| 0-0 1-1 2-2 3-3 4-4
45 mg Pioglitazon ( als ||| 45mg of pioglitazone ( as ||| 0-0 1-0 2-2 3-3 4-4
45 mg Pioglitazon ( ||| 45 mg pioglitazone ( ||| 0-0 1-1 2-2 3-3
45 mg Pioglitazon ( ||| 45mg of pioglitazone ( ||| 0-0 1-0 2-2 3-3
45 mg Pioglitazon . ||| 45 mg of pioglitazone . ||| 0-0 1-1 2-3 3-4
45 mg Pioglitazon als ||| 45 mg of pioglitazone as ||| 0-0 1-1 2-3 3-4
45 mg Pioglitazon ||| 45 mg of pioglitazone ||| 0-0 1-1 2-3
45 mg Pioglitazon ||| 45 mg pioglitazone ||| 0-0 1-1 2-2
45 mg Pioglitazon ||| 45mg of pioglitazone ||| 0-0 1-0 2-2
45 mg Tabletten aufgetreten : ||| 45mg tablets : ||| 0-0 1-0 2-1 3-1 4-2
45 mg Tabletten aufgetreten ||| 45mg tablets ||| 0-0 1-0 2-1 3-1
45 mg Tabletten die ||| 45mg tablets ||| 0-0 1-0 2-1
45 mg Tabletten eingenommen ||| 45mg tablets ||| 0-0 1-0 2-1 3-1
45 mg Tabletten ist Pioglitazon ||| 45mg tablets is pioglitazone ||| 0-0 1-0 2-1 3-2 4-3
45 mg Tabletten ist ||| 45mg tablets is ||| 0-0 1-0 2-1 3-2
45 mg Tabletten können ||| 45 mg tablets may ||| 0-0 1-1 2-2 3-3
45 mg Tabletten können ||| 45mg tablets can be ||| 0-0 1-0 2-1 3-2 3-3
45 mg Tabletten mit ||| 45mg tablets with ||| 0-0 1-0 2-1 3-2
45 mg Tabletten werden ||| 45mg tablets are ||| 0-0 1-0 2-1 3-2
45 mg Tabletten ||| 45 mg tablets ||| 0-0 1-1 2-2
45 mg Tabletten ||| 45mg tablets ||| 0-0 1-0 2-1
45 mg einmal täglich ||| 45 mg once daily ||| 0-0 1-1 2-2 3-2 3-3
45 mg täglich eingenommen haben ||| 45 mg daily ||| 0-0 1-1 2-2 3-2 4-2
45 mg ||| 45 mg of ||| 0-0 1-1
45 mg ||| 45 mg ||| 0-0 1-1
45 mg ||| 45mg of ||| 0-0 1-0
45 mg ||| 45mg ||| 0-0 1-0
45 mit anderen Rezeptoren als ||| Interaction with receptors other than ||| 0-0 3-0 1-1 3-2 2-3 4-4
45 mit anderen Rezeptoren ||| Interaction with receptors other ||| 0-0 3-0 1-1 3-2 2-3
45 ||| 45 ||| 0-0
45 ||| 45mg ||| 0-0
45,1 ; 76,9 ] ( ||| , 76.9 ] ( ||| 0-1 2-1 1-2 3-2 4-3
45,1 ; 76,9 ] ( ||| 76.9 ] ( ||| 0-0 2-0 1-1 3-1 4-2
45,1 ; 76,9 ] ||| , 76.9 ] ||| 0-1 2-1 1-2 3-2
45,1 ; 76,9 ] ||| 76.9 ] ||| 0-0 2-0 1-1 3-1
450 I.E./kg 1 x/Woche ||| 450 IU/ kg once weekly ||| 0-0 1-1 1-2 2-3 3-3 3-4
450 I.E./kg ||| 450 IU/ kg ||| 0-0 1-1 1-2
450 ||| 450 ||| 0-0
457 65 00 ||| 457 65 00 ||| 0-0 1-1 2-2
457 65 ||| 457 65 ||| 0-0 1-1
457 ||| 457 ||| 0-0
46 25 16 16 ||| 46 25 16 16 ||| 0-0 1-1 2-2 3-3
46 25 16 ||| 46 25 16 ||| 0-0 1-1 2-2
46 25 ||| 46 25 ||| 0-0 1-1
46 8 704 71 00 ||| 46 8 704 71 00 ||| 0-0 1-1 2-2 3-3 4-4
46 8 704 71 ||| 46 8 704 71 ||| 0-0 1-1 2-2 3-3
46 8 704 ||| 46 8 704 ||| 0-0 1-1 2-2
46 8 ||| 46 8 ||| 0-0 1-1
46 In einer ||| 42 In a ||| 0-0 1-1 2-2
46 In ||| 42 In ||| 0-0 1-1
46 ||| 42 ||| 0-0
46 ||| 46 ||| 0-0
46,7 [ 39,0 ||| 46.7 [ 39.0 ||| 0-0 1-1 2-2
46,7 [ ||| 46.7 [ ||| 0-0 1-1
46,7 ||| 46.7 ||| 0-0
460 Frauen mit ||| 460 women with ||| 0-0 1-1 2-2
460 Frauen ||| 460 women ||| 0-0 1-1
460 ||| 460 ||| 0-0
460 ||| povidone ||| 0-0
47 4.2 Dosierung , ||| 4.2 Posology ||| 0-0 1-0 2-1 3-1
47 4.2 ||| 4.2 ||| 0-0 1-0
47 56 69 00 ||| 47 56 69 00 ||| 0-0 1-1 2-2 3-3
47 56 69 ||| 47 56 69 ||| 0-0 1-1 2-2
47 56 ||| 47 56 ||| 0-0 1-1
47 67 55 53 50 ||| 47 67 55 53 50 ||| 0-0 1-1 2-2 3-3 4-4
47 67 55 53 ||| 47 67 55 53 ||| 0-0 1-1 2-2 3-3
47 67 55 ||| 47 67 55 ||| 0-0 1-1 2-2
47 67 ||| 47 67 ||| 0-0 1-1
47 ||| 47 ||| 0-0
47,3 11,6 63,8 31,0 65,1 ||| 47.3 11.6 63.8 31.0 65.1 ||| 0-0 1-1 2-2 3-3 4-4
47,3 11,6 63,8 31,0 ||| 47.3 11.6 63.8 31.0 ||| 0-0 1-1 2-2 3-3
47,3 11,6 63,8 ||| 47.3 11.6 63.8 ||| 0-0 1-1 2-2
47,3 11,6 ||| 47.3 11.6 ||| 0-0 1-1
47,3 ||| 47.3 ||| 0-0
48 kg für die ||| 48 kg for the ||| 0-0 1-1 2-2 3-3
48 kg für ||| 48 kg for ||| 0-0 1-1 2-2
48 kg ||| 48 kg ||| 0-0 1-1
48 ||| 48 ||| 0-0
480 ml Lösung zum Einnehmen ||| 480 ml oral solution ||| 0-0 1-1 3-2 4-2 2-3 4-3
480 ml pro ||| 480 ml per ||| 0-0 1-1 2-2
480 ml ||| 480 ml ||| 0-0 1-1
480 ||| 480 ||| 0-0
487 ||| core : ||| 0-0
487 ||| core ||| 0-0
49 ( 0 ) 241 ||| 49 ( 0 ) 241 ||| 0-0 1-1 2-2 3-3 4-4
49 ( 0 ) ||| 49 ( 0 ) ||| 0-0 1-1 2-2 3-3
49 ( 0 ||| 49 ( 0 ||| 0-0 1-1 2-2
49 ( ||| 49 ( ||| 0-0 1-1
49 Schmelztabletten verpackt . ||| 49 orodispersible tablets . ||| 0-0 2-0 1-1 1-2 3-3
49 Schmelztabletten verpackt ||| 49 orodispersible tablets ||| 0-0 2-0 1-1 1-2
49 x 1 , 56 ||| 49 x 1 , 56 ||| 0-0 1-1 2-2 3-3 4-4
49 x 1 , ||| 49 x 1 , ||| 0-0 1-1 2-2 3-3
49 x 1 Schmelztabletten ||| 49 x 1 orodispersible tablets ||| 0-0 1-1 2-2 3-3 3-4
49 x 1 Tabletten 56 ||| 49 x 1 tablets 56 ||| 0-0 1-1 2-2 3-3 4-4
49 x 1 Tabletten in ||| 49 x 1 tablets in ||| 0-0 1-1 2-2 3-3 4-4
49 x 1 Tabletten ||| 49 x 1 tablets ||| 0-0 1-1 2-2 3-3
49 x 1 ||| 49 x 1 ||| 0-0 1-1 2-2
49 x ||| 49 x ||| 0-0 1-1
49 ||| 49 ||| 0-0
4AE , Vereinigtes Königreich . ||| 4AE , United Kingdom . ||| 0-0 1-1 2-2 3-3 4-4
4AE , Vereinigtes Königreich ||| 4AE , United Kingdom ||| 0-0 1-1 2-2 3-3
4AE , Vereinigtes ||| 4AE , United ||| 0-0 1-1 2-2
4AE , ||| 4AE , ||| 0-0 1-1
4AE Vereinigtes Königreich ||| 4AE United Kingdom ||| 0-0 1-1 2-2
4AE Vereinigtes ||| 4AE United ||| 0-0 1-1
4AE ||| 4AE ||| 0-0
5 " auf einer Seite ||| 5 " on one side ||| 0-0 1-1 2-2 3-3 4-3 4-4
5 " auf ||| 5 " on ||| 0-0 1-1 2-2
5 " ||| 5 " ||| 0-0 1-1
5 % ansteigt . Die ||| 5 % ansteigt . Die ||| 0-0 1-1 2-2 3-3 4-4
5 % ansteigt . ||| 5 % ansteigt . ||| 0-0 1-1 2-2 3-3
5 % ansteigt ||| 5 % ansteigt ||| 0-0 1-1 2-2
5 % und 10 ||| 5 % und 10 ||| 0-0 1-1 2-2 3-3
5 % und ||| 5 % und ||| 0-0 1-1 2-2
5 % ||| 5 % ||| 0-0 1-1
5 ) 2649600 ||| 5 ) 2649600 ||| 0-0 1-1 2-2
5 ) ||| 5 ) ||| 0-0 1-1
5 ANHANG ||| 5 The valid Summary of ||| 0-0 0-1 1-2 1-3
5 ANHANG ||| 5 The valid Summary ||| 0-0 0-1 1-2 1-3
5 Die empfohlene Dosierung wird ||| The recommended dosing regimen is ||| 0-0 1-0 2-1 3-2 2-3 3-3 4-4
5 Die empfohlene Dosierung ||| The recommended dosing regimen ||| 0-0 1-0 2-1 3-2 2-3 3-3
5 Die ||| The ||| 0-0 1-0
5 Durchstechflaschen zu je 10 ||| 5 vials x 10 ||| 0-0 1-1 2-2 3-2 4-3
5 Durchstechflaschen zu je ||| 5 vials x ||| 0-0 1-1 2-2 3-2
5 Durchstechflaschen ||| 5 vials ||| 0-0 1-1
5 Flaschen mit jeweils ||| 5 bottles , each bottle ||| 0-0 1-1 3-3 1-4
5 Stunden ||| 5 hours ||| 0-0 1-1
5 auf einer Seite . ||| 5 on one side . ||| 0-0 1-1 2-2 3-2 3-3 4-4
5 auf einer Seite ||| 5 on one side ||| 0-0 1-1 2-2 3-2 3-3
5 auf ||| 5 on ||| 0-0 1-1
5 des ||| 5 of the ||| 0-0 1-1 1-2
5 l/kg . ||| 5 l/ kg . ||| 0-0 1-1 1-2 2-3
5 l/kg ||| 5 l/ kg ||| 0-0 1-1 1-2
5 mg , 10 mg ||| 5 mg , 10 mg ||| 0-0 1-1 2-2 3-3 4-4
5 mg , 10 ||| 5 mg , 10 ||| 0-0 1-1 2-2 3-3
5 mg , ||| 5 mg , ||| 0-0 1-1 2-2
5 mg Aclasta . ||| 5 mg Aclasta . ||| 0-0 1-1 2-2 3-3
5 mg Aclasta ||| 5 mg Aclasta ||| 0-0 1-1 2-2
5 mg Infusionslösung ||| 5 mg solution for infusion ||| 0-0 1-1 2-2 2-3 2-4
5 mg Paclitaxel . ||| 5 mg of paclitaxel . ||| 0-0 1-1 2-3 3-4
5 mg Paclitaxel ||| 5 mg of paclitaxel ||| 0-0 1-1 2-3
5 mg Tabletten sind rechteckig ||| 5 mg tablets are rectangular ||| 0-0 1-1 2-2 3-3 4-4
5 mg Tabletten sind ||| 5 mg tablets are ||| 0-0 1-1 2-2 3-3
5 mg Tabletten ||| 5 mg tablets ||| 0-0 1-1 2-2
5 mg Zoledronsäure ( wasserfrei ||| 5 mg zoledronic acid anhydrous ||| 0-0 1-1 2-2 2-3 3-3 4-4
5 mg Zoledronsäure ( ||| 5 mg zoledronic acid ( ||| 0-0 1-1 2-2 2-3 3-4
5 mg Zoledronsäure ( ||| 5 mg zoledronic acid ||| 0-0 1-1 2-2 2-3 3-3
5 mg Zoledronsäure beurteilt . ||| 5 mg zoledronic acid . ||| 0-0 1-1 2-2 2-3 3-4 4-4
5 mg Zoledronsäure ||| 5 mg zoledronic acid ||| 0-0 1-1 2-2 2-3
5 mg einmal jährlich ||| 5 mg once a year ||| 0-0 1-1 2-2 2-3 3-4
5 mg einmal ||| 5 mg once a ||| 0-0 1-1 2-2 2-3
5 mg in 100 ||| 5 mg in 100 ||| 0-0 1-1 2-2 3-3
5 mg in ||| 5 mg in ||| 0-0 1-1 2-2
5 mg wasserfreie ||| 5 mg ||| 0-0 1-1 2-1
5 mg ||| 5 mg of ||| 0-0 1-1
5 mg ||| 5 mg ||| 0-0 1-1
5 mg/100 ||| 5 mg/ ||| 0-0 1-0 0-1
5 mg/ml ) . ||| 5 mg/ ml ) . ||| 0-0 1-1 1-2 2-3 3-4
5 mg/ml ) ||| 5 mg/ ml ) ||| 0-0 1-1 1-2 2-3
5 mg/ml Butylhydroxyanisol ||| 5 mg/ ml Butylated hydroxyanisole ||| 0-0 1-1 1-2 2-3 2-4
5 mg/ml Lösung zum Eingeben ||| 5 mg/ ml oral solution ||| 0-0 1-1 1-2 3-3 4-3 2-4 4-4
5 mg/ml ||| 5 mg/ ml ||| 0-0 1-1 1-2
5 oder mehr Einheiten ||| or 5 or more units ||| 1-0 0-1 1-2 2-3 3-4
5 oder mehr ||| or 5 or more ||| 1-0 0-1 1-2 2-3
5 oder ||| or 5 or ||| 1-0 0-1 1-2
5 und 10 Patronen zu ||| 5 and 10 cartridges ||| 0-0 1-1 2-2 3-3 4-3
5 und 10 ||| 5 and 10 ||| 0-0 1-1 2-2
5 und 15 ||| 5 and ||| 0-0 1-1
5 und ||| 5 and ||| 0-0 1-1
5 x ULN oder ASL/ALT ||| 5 x ULN or ASL/ ||| 0-0 1-1 2-2 3-3 4-4
5 x ULN oder ||| 5 x ULN or ||| 0-0 1-1 2-2 3-3
5 x ULN ||| 5 x ULN ||| 0-0 1-1 2-2
5 x ||| 5 x ||| 0-0 1-1
5 ||| 5 The ||| 0-0 0-1
5 ||| 5 ||| 0-0
5 ||| The ||| 0-0
5%igen Gewichtsreduktion ||| 5 % ||| 0-0 0-1 1-1
5,1 % ) . ||| 5.1 % ) . ||| 0-0 1-1 2-2 3-3
5,1 % ) ||| 5.1 % ) ||| 0-0 1-1 2-2
5,1 % ||| 5.1 % ||| 0-0 1-1
5,1 ||| 5.1 ||| 0-0
5,25 mg ( 0,7 ml ||| 5.25 mg ( 0.7 ml ||| 0-0 1-1 2-2 3-3 4-4
5,25 mg ( 0,7 ||| 5.25 mg ( 0.7 ||| 0-0 1-1 2-2 3-3
5,25 mg ( ||| 5.25 mg ( ||| 0-0 1-1 2-2
5,25 mg ||| 5.25 mg ||| 0-0 1-1
5,25 ||| 5.25 ||| 0-0
5,3 Monate ( 175 ||| 5.3 months ( 175 ||| 2-0 1-1 2-2 0-3 3-3
5,330 mg Zoledronsäuremonohydrat ||| 5.330 mg zoledronic acid monohydrate ||| 0-0 1-1 2-2 2-3 2-4
5,330 mg ||| 5.330 mg ||| 0-0 1-1
5,330 ||| 5.330 ||| 0-0
5,4 ||| 5.4 ||| 0-0
5,8 für Placebo ||| 5.8 for placebo ||| 0-0 1-1 2-2
5,8 für ||| 5.8 for ||| 0-0 1-1
5,8 ||| 5.8 ||| 0-0
5,9 - 6,8 mmol/l ||| 5.9 - 6.8 mmol/ l ||| 0-0 1-1 2-2 3-3 3-4
5,9 - 6,8 ||| 5.9 - 6.8 ||| 0-0 1-1 2-2
5,9 - ||| 5.9 - ||| 0-0 1-1
5,9 ||| , 5.9 ||| 0-1
5,9 ||| 5.9 ||| 0-0
5-Hydroxytryptamin ( auch Serotonin genannt ||| 5-hydroxytryptamine ( also called serotonin ||| 0-0 1-1 2-2 4-3 3-4
5-Hydroxytryptamin ( auch ||| 5-hydroxytryptamine ( also ||| 0-0 1-1 2-2
5-Hydroxytryptamin ( ||| 5-hydroxytryptamine ( ||| 0-0 1-1
5-Hydroxytryptamin und Dopamin ||| 5-hydroxytryptamine and dopamine ||| 0-0 1-1 2-2
5-Hydroxytryptamin und ||| 5-hydroxytryptamine and ||| 0-0 1-1
5-Hydroxytryptamin ||| 5-hydroxytryptamine are involved ||| 0-0
5-Hydroxytryptamin ||| 5-hydroxytryptamine are ||| 0-0
5-Hydroxytryptamin ||| 5-hydroxytryptamine ||| 0-0
5.1 ) . ||| 5.1 ) . no ||| 0-0 1-1 2-2
5.1 ) . ||| 5.1 ) . ||| 0-0 1-1 2-2
5.1 ) : ||| 5.1 ) : ||| 0-0 1-1 2-2
5.1 ) ||| 5.1 ) , ||| 0-0 1-1
5.1 ) ||| 5.1 ) ||| 0-0 1-1
5.1 ||| 5.1 ||| 0-0
5.2 ) . ||| 5.2 ) . dic ||| 0-0 1-1 2-2 1-3
5.2 ) . ||| 5.2 ) . ||| 0-0 1-1 2-2
5.2 ) . ||| and 5.2 ) . ||| 0-1 1-2 2-3
5.2 ) ||| 5.2 ) ||| 0-0 1-1
5.2 ) ||| and 5.2 ) ||| 0-1 1-2
5.2 ||| 5.2 ||| 0-0
5.2 ||| and 5.2 ||| 0-1
5.3 ) . ||| 5.3 ) . ||| 0-0 1-1 2-2
5.3 ) ||| 5.3 ) ||| 0-0 1-1
5.3 ||| 5.3 ||| 0-0
50 % Isophan-Insulin . ||| 50 % isophane insulin . ||| 0-0 1-1 2-2 2-3 3-4
50 % Isophan-Insulin ||| 50 % isophane insulin ||| 0-0 1-1 2-2 2-3
50 % gelöstem Insulin und ||| 50 % dissolved insulin and ||| 0-0 1-1 2-2 3-3 4-4
50 % gelöstem Insulin ||| 50 % dissolved insulin ||| 0-0 1-1 2-2 3-3
50 % gelöstem ||| 50 % dissolved ||| 0-0 1-1 2-2
50 % und Isophan-Insulin ||| 50 % and isophane insulin ||| 0-0 1-1 2-2 3-3 3-4
50 % und ||| 50 % and ||| 0-0 1-1 2-2
50 % ||| 50 % ||| 0-0 1-1
50 , 150 oder 480 ||| 50 , 150 or 480 ||| 0-0 1-1 2-2 3-3 4-4
50 , 150 oder ||| 50 , 150 or ||| 0-0 1-1 2-2 3-3
50 , 150 ||| 50 , 150 ||| 0-0 1-1 2-2
50 , 56 , 84 ||| 50 , 56 , 84 ||| 0-0 1-1 2-2 3-3 4-4
50 , 56 , ||| , 50 , 56 ||| 1-0 0-1 3-2 2-3
50 , 56 , ||| 50 , 56 , ||| 0-0 1-1 2-2 3-3
50 , 56 ||| 50 , 56 ||| 0-0 1-1 2-2
50 , ||| , 50 ||| 1-0 0-1
50 , ||| 50 , ||| 0-0 1-1
50 00 ||| 50 00 ||| 0-0 1-1
50 80 ||| 50 80 ||| 0-0 1-1
50 : lösliches Insulin 50 ||| 50 : soluble insulin 50 ||| 0-0 1-1 2-2 3-3 4-4
50 : lösliches Insulin ||| 50 : soluble insulin ||| 0-0 1-1 2-2 3-3
50 : lösliches ||| 50 : soluble ||| 0-0 1-1 2-2
50 : ||| 50 : ||| 0-0 1-1
50 Anpassung der Dosis Begleiterkrankungen ||| Dosage adjustment Concomitant illness ||| 1-0 1-1 1-2 2-2 4-2 3-3 4-3
50 Die Schmelztablette ||| The orodispersible tablet ||| 0-0 1-0 2-1 2-2
50 Die empfohlene Dosierung wird ||| The recommended dosing regimen is ||| 0-0 1-0 2-1 3-2 2-3 3-3 4-4
50 Die empfohlene Dosierung ||| The recommended dosing regimen ||| 0-0 1-0 2-1 3-2 2-3 3-3
50 Die ||| The ||| 0-0 1-0
50 I.E./kg dreimal ||| 50 IU/ kg 3 times ||| 0-0 1-1 1-2 2-3 2-4
50 I.E./kg dreimal ||| 50 IU/ kg 3 ||| 0-0 1-1 2-1 1-2 2-3
50 I.E./kg dreimal ||| of 50 IU/ kg 3 ||| 0-1 1-2 2-2 1-3 2-4
50 I.E./kg zweimal pro Woche ||| 50 IU/ kg 2 times ||| 0-0 1-1 2-1 1-2 3-2 2-3 4-4
50 I.E./kg zweimal pro ||| 50 IU/ kg 2 ||| 0-0 1-1 2-1 1-2 3-2 2-3
50 I.E./kg zweimal ||| 50 IU/ kg 2 ||| 0-0 1-1 1-2 2-3
50 I.E./kg ||| 50 IU/ kg ||| 0-0 1-1 1-2
50 Internationale Einheiten ( I.E. ||| 50 International Units ( IU ||| 0-0 1-1 2-2 3-3 4-4
50 Internationale Einheiten ( ||| 50 International Units ( ||| 0-0 1-1 2-2 3-3
50 Internationale Einheiten ||| 50 International Units ||| 0-0 1-1 2-2
50 Internationale ||| 50 International ||| 0-0 1-1
50 MINDESTANGABEN AUF ||| 47 MINIMUM PARTICULARS TO APPEAR ||| 0-0 1-1 1-2 2-3 2-4
50 MINDESTANGABEN ||| 47 MINIMUM PARTICULARS ||| 0-0 1-1 1-2
50 NovoLet 100 ||| 50 NovoLet 100 ||| 0-0 1-1 2-2
50 NovoLet ||| 50 NovoLet ||| 0-0 1-1
50 Penfill 100 ||| 50 Penfill 100 ||| 0-0 1-1 2-2
50 Penfill ||| 50 Penfill ||| 0-0 1-1
50 Tabletten 56 Tabletten 84 ||| 50 tablets 56 tablets 84 ||| 0-0 1-1 2-2 3-3 4-4
50 Tabletten 56 Tabletten ||| 50 tablets 56 tablets ||| 0-0 1-1 2-2 3-3
50 Tabletten 56 ||| 50 tablets 56 ||| 0-0 1-1 2-2
50 Tabletten ||| 50 tablets ||| 0-0 1-1
50 besteht aus 50 % ||| 50 consists of 50 % ||| 0-0 1-1 2-1 2-2 3-3 4-4
50 besteht aus 50 ||| 50 consists of 50 ||| 0-0 1-1 2-1 2-2 3-3
50 besteht aus ||| 50 consists of ||| 0-0 1-1 2-1 2-2
50 ml Flasche ||| 50 ml bottle ||| 0-0 1-1 2-2
50 ml Lösung zum Einnehmen ||| 50 ml oral solution ||| 0-0 1-1 3-2 4-2 2-3 4-3
50 ml ||| 50 ml ||| 0-0 1-1
50 ||| 47 ||| 0-0
50 ||| 50 ||| 0-0
50 ||| of 50 ||| 0-1
50,4 Mikrogramm Epoetin alfa ||| 50.4 micrograms epoetin alfa ||| 0-0 1-1 2-2 3-3
50,4 Mikrogramm Epoetin ||| 50.4 micrograms epoetin ||| 0-0 1-1 2-2
50,4 Mikrogramm Epoetin ||| corresponding to 50.4 micrograms epoetin ||| 1-0 0-2 1-3 2-4
50,4 Mikrogramm ||| 50.4 micrograms ||| 0-0 1-1
50,4 Mikrogramm ||| corresponding to 50.4 micrograms ||| 1-0 0-2 1-3
50,4 ||| 50.4 ||| 0-0
50,4 ||| to 50.4 ||| 0-1
50-95 Jahren ||| aged ||| 1-0
500 Filmtabletten . ||| 500 film-coated tablets . ||| 0-0 1-1 1-2 2-3
500 Filmtabletten . ||| and 500 film-coated tablets . ||| 0-1 1-2 1-3 2-4
500 Filmtabletten ||| 500 film-coated tablets ||| 0-0 1-1 1-2
500 Filmtabletten ||| and 500 film-coated tablets ||| 0-1 1-2 1-3
500 mg Kalzium ||| 500 mg calcium ||| 0-0 1-1 2-2
500 mg elementarem ||| 500 mg elemental ||| 0-0 1-1 2-2
500 mg ||| 500 mg ||| 0-0 1-1
500 ||| 500 ||| 0-0
500 ||| and 500 ||| 0-1
5000 I.E. ) Lösung ||| 5000 IU ) of solution ||| 0-0 1-1 2-2 1-3 3-4
5000 I.E. ) ||| 5000 IU ) of ||| 0-0 1-1 2-2 1-3
5000 I.E./0,5 ml ||| 5000 IU/ 0.5 ml ||| 0-0 0-1 1-2 2-3
5000 I.E./0,5 ||| 5000 IU/ 0.5 ||| 0-0 0-1 1-2
5000 Internationale Einheiten ( I.E. ||| 5000 international units ( IU ||| 0-0 1-1 2-2 3-3 4-4
5000 Internationale Einheiten ( ||| 5000 international units ( ||| 0-0 1-1 2-2 3-3
5000 Internationale Einheiten ||| 5000 international units ||| 0-0 1-1 2-2
5000 Internationale ||| 5000 international ||| 0-0 1-1
5000 ||| 5000 IU/ ||| 0-0 0-1
5000 ||| 5000 ||| 0-0
501 76 03 ||| 501 76 03 ||| 0-0 1-1 2-2
501 76 ||| 501 76 ||| 0-0 1-1
501 ||| 501 ||| 0-0
5026 01 ||| 5026 01 ||| 0-0 1-1
5026 ||| 5026 ||| 0-0
508 Männer ||| 508 men ||| 0-0 1-1
508 ||| 508 ||| 0-0
51 % . Dies deutet ||| about 51 % ||| 2-0 4-0 0-1 3-1 4-1 1-2
51 Bei schon lange ||| Usual warning symptoms may ||| 0-0 1-0 2-0 2-1 3-1 3-2 3-3
51 Die empfohlene ||| 48 The recommended ||| 0-0 1-1 2-2
51 Die ||| 48 The ||| 0-0 1-1
51 MINDESTANGABEN AUF ||| 48 MINIMUM PARTICULARS TO APPEAR ||| 0-0 1-1 1-2 2-3 2-4
51 MINDESTANGABEN ||| 48 MINIMUM PARTICULARS ||| 0-0 1-1 1-2
51 von 3.862 ) ||| 51 out of 3,862 ) ||| 0-0 2-1 1-2 2-3 3-4
51 von 3.862 ||| 51 out of 3,862 ||| 0-0 2-1 1-2 2-3
51 ||| 48 ||| 0-0
51 ||| 51 ||| 0-0
517 bis ||| 517 to ||| 0-0 1-1
517 ||| 517 ||| 0-0
5193 ||| 5193 ||| 0-0
52 % ||| 52 % ||| 0-0 1-1
52 4.4 Besondere Warnhinweise und ||| 4.4 Special warnings and ||| 0-0 1-0 2-1 3-2 4-3
52 4.4 Besondere Warnhinweise ||| 4.4 Special warnings ||| 0-0 1-0 2-1 3-2
52 4.4 Besondere ||| 4.4 Special ||| 0-0 1-0 2-1
52 4.4 ||| 4.4 ||| 0-0 1-0
52 MINDESTANGABEN AUF ||| 49 MINIMUM PARTICULARS TO APPEAR ||| 0-0 0-1 1-1 1-2 2-3 2-4
52 MINDESTANGABEN ||| 49 MINIMUM PARTICULARS ||| 0-0 0-1 1-1 1-2
52 Wochen ||| 52 weeks ||| 0-0 1-1
52 ||| 52 ||| 0-0
5238 Patienten mit Typ 2 ||| 5238 patients with type 2 ||| 0-0 1-1 2-2 3-3 4-4
5238 Patienten mit Typ ||| 5238 patients with type ||| 0-0 1-1 2-2 3-3
5238 Patienten mit ||| 5238 patients with ||| 0-0 1-1 2-2
5238 Patienten ||| 5238 patients ||| 0-0 1-1
5238 ||| 5238 ||| 0-0
524 40 64 ||| 524 40 64 ||| 0-0 1-1 2-2
524 40 ||| 524 40 ||| 0-0 1-1
524 ||| 524 ||| 0-0
53 % ) . ||| 53 % ) . ||| 0-0 1-1 2-2 3-3
53 % ) ||| 53 % ) ||| 0-0 1-1 2-2
53 % ||| 53 % ||| 0-0 1-1
53 50 ||| 53 50 ||| 0-0 1-1
53 Bei Patienten mit ||| In patients with ||| 1-0 0-1 2-1 3-2
53 Bei Patienten ||| In patients ||| 1-0 0-1 2-1
53 ||| 53 ||| 0-0
53,3 % bei ||| 53.3 % for ||| 0-0 1-1 0-2 2-2
53,3 % bei ||| 53.3 % ||| 0-0 2-0 1-1
535 7000 ||| 535 7000 ||| 0-0 1-1
535 ||| 535 ||| 0-0
537 900 ||| 537 900 ||| 0-0 1-1
537 ||| 537 ||| 0-0
54 planen . Aufgrund der ||| Due to ||| 1-0 3-0 4-0 3-1
55 % ) und zu ||| 55 % ) and ||| 0-0 1-1 2-2 3-3
55 % ) und ||| 55 % ) and ||| 0-0 1-1 2-2 3-3
55 % ) ||| 55 % ) ||| 0-0 1-1 2-2
55 % ||| 55 % ||| 0-0 1-1
55 53 50 ||| 55 53 50 ||| 0-0 1-1 2-2
55 53 ||| 55 53 ||| 0-0 1-1
55 In Placebo-kontrollierten Studien ||| In placebo-controlled trials , ||| 1-0 2-1 3-2
55 In Placebo-kontrollierten Studien ||| In placebo-controlled trials ||| 1-0 2-1 3-2
55 In Placebo-kontrollierten ||| In placebo-controlled ||| 1-0 2-1
55 In ||| In ||| 1-0
55 ml : 10 kg ||| 55 ml : 10 kg ||| 0-0 1-1 2-2 3-3 4-4
55 ml : 10 ||| 55 ml : 10 ||| 0-0 1-1 2-2 3-3
55 ml : ||| 55 ml : ||| 0-0 1-1 2-2
55 ml ||| 55 ml ||| 0-0 1-1
55 ||| 55 to ||| 0-0
55 ||| 55 ||| 0-0
55,3 ||| 55.3 ||| 0-0
55- , ||| 55 , ||| 0-0 1-1
55- ||| 55 ||| 0-0
55-ml-Flasche bis zu 36 ||| up to 36 ||| 1-0 2-0 2-1 0-2 3-2
56 , 84 , 90 ||| 56 , 84 , 90 ||| 0-0 1-1 2-2 3-3 4-4
56 , 84 , ||| , 56 , 84 , ||| 1-0 0-1 3-2 2-3 3-4
56 , 84 , ||| 56 , 84 , ||| 0-0 1-1 2-2 3-3
56 , 84 UND 98 ||| 56 , 84 AND 98 ||| 0-0 1-1 2-2 3-3 4-4
56 , 84 UND ||| 56 , 84 AND ||| 0-0 1-1 2-2 3-3
56 , 84 ||| 56 , 84 ||| 0-0 1-1 2-2
56 , ||| , 56 ||| 1-0 0-1
56 , ||| 56 , ||| 0-0 1-1
56 - 99 Jahre ) ||| 56-99 years ) of ||| 0-0 1-0 2-0 3-1 4-2
56 - 99 Jahre ) ||| 56-99 years ) ||| 0-0 1-0 2-0 3-1 4-2
56 - 99 Jahre ||| 56-99 years ||| 0-0 1-0 2-0 3-1
56 - 99 ||| 56-99 ||| 0-0 1-0 2-0
56 69 00 ||| 56 69 00 ||| 0-0 1-1 2-2
56 69 ||| 56 69 ||| 0-0 1-1
56 Tabletten 84 Tabletten 90 ||| 56 tablets 84 tablets 90 ||| 0-0 1-1 2-2 3-3 4-4
56 Tabletten 84 Tabletten ||| 56 tablets 84 tablets ||| 0-0 1-1 2-2 3-3
56 Tabletten 84 ||| 56 tablets 84 ||| 0-0 1-1 2-2
56 Tabletten ||| 56 tablets ||| 0-0 1-1
56 x 1 , 98 ||| 56 x 1 , 98 ||| 0-0 1-1 2-2 3-3 4-4
56 x 1 , ||| 56 x 1 , ||| 0-0 1-1 2-2 3-3
56 x 1 Tabletten 98 ||| 56 x 1 tablets 98 ||| 0-0 1-1 2-2 3-3 4-4
56 x 1 Tabletten ||| 56 x 1 tablets ||| 0-0 1-1 2-2 3-3
56 x 1 ||| 56 x 1 ||| 0-0 1-1 2-2
56 x ||| 56 x ||| 0-0 1-1
56 ||| 56 ||| 0-0
57 Bei exzessiv hohen ||| Phlebotomy may be performed ||| 0-0 1-0 2-0 2-1 2-2 3-3
57 Bei exzessiv ||| Phlebotomy may be ||| 0-0 1-0 2-0 2-1 2-2
58 Anpassung der Dosis Begleiterkrankungen ||| Dosage adjustment Concomitant illness ||| 0-0 1-0 1-1 1-2 2-2 4-2 3-3 4-3
58 In ||| In ||| 1-0
58 ||| 58 ||| 0-0
58,8 Mikrogramm Epoetin alfa ||| 58.8 micrograms epoetin alfa ||| 0-0 1-1 2-2 3-3
58,8 Mikrogramm Epoetin ||| 58.8 micrograms epoetin ||| 0-0 1-1 2-2
58,8 Mikrogramm Epoetin ||| corresponding to 58.8 micrograms epoetin ||| 1-0 0-2 1-3 2-4
58,8 Mikrogramm ||| 58.8 micrograms ||| 0-0 1-1
58,8 Mikrogramm ||| corresponding to 58.8 micrograms ||| 1-0 0-2 1-3
58,8 ||| 58.8 ||| 0-0
58,8 ||| to 58.8 ||| 0-1
580 00 10 ||| 580 00 10 ||| 0-0 1-1 2-2
580 00 ||| 580 00 ||| 0-0 1-1
580 ||| 580 ||| 0-0
59 % der Patienten erhielten ||| Fifty-nine percent received study ||| 0-0 1-1 2-1 3-2 4-2 2-3
59 In tierexperimentellen Studien mit ||| In animal studies , epoetin ||| 1-0 2-1 3-2 0-4 2-4 4-4
59 Patienten ||| Patients ||| 1-0
59 ||| Fifty-nine ||| 0-0
5AB Vereinigtes Königreich ||| 5AB United Kingdom ||| 0-0 1-1 2-2
5AB Vereinigtes ||| 5AB United ||| 0-0 1-1
5AB ||| 5AB ||| 0-0
5HT1a- und 5HT2a-Rezeptor sowie ||| 5HT1a and 5HT2a receptors and ||| 0-0 1-1 2-2 3-2 2-3 1-4
5HT1a- ||| 5HT1a ||| 0-0
5HT2a-Rezeptor sowie ||| 5HT2a receptors ||| 0-0 1-0 0-1
5HT7- , zum alpha-1-adrenergen und ||| , alpha-1 adrenergic and histamine ||| 1-0 0-1 2-2 3-2 4-3 3-4
5HT7- , ||| , alpha-1 ||| 1-0 0-1
5HT7- ||| alpha-1 ||| 0-0
6 % ) ||| 6 % ) ||| 0-0 1-1 2-2
6 % der ||| 6 % of ||| 0-0 1-1 2-2
6 % ||| 6 % ||| 0-0 1-1
6 , 12 , 24 ||| 6 , 12 , 24 ||| 0-0 1-1 2-2 3-3 4-4
6 , 12 , ||| 6 , 12 , ||| 0-0 1-1 2-2 3-3
6 , 12 ||| 6 , 12 ||| 0-0 1-1 2-2
6 , ||| 6 , ||| 0-0 1-1
6 -Hydroxypaclitaxel und 3 -p-Hydroxypaclitaxel ||| 6 -hydroxypaclitaxel and 3 -p-hydroxypaclitaxel ||| 0-0 1-1 2-2 3-3 4-4
6 -Hydroxypaclitaxel und 3 ||| 6 -hydroxypaclitaxel and 3 ||| 0-0 1-1 2-2 3-3
6 -Hydroxypaclitaxel und ||| 6 -hydroxypaclitaxel ; and ||| 0-0 1-1 2-3
6 -Hydroxypaclitaxel und ||| 6 -hydroxypaclitaxel and ||| 0-0 1-1 2-2
6 -Hydroxypaclitaxel ||| 6 -hydroxypaclitaxel ; ||| 0-0 1-1
6 -Hydroxypaclitaxel ||| 6 -hydroxypaclitaxel ||| 0-0 1-1
6 4.7 Auswirkungen auf ||| 4.7 Effects on ||| 0-0 1-0 2-1 3-2
6 4.7 Auswirkungen ||| 4.7 Effects ||| 0-0 1-0 2-1
6 4.7 ||| 4.7 ||| 0-0 1-0
6 Behandlungskursen ||| 6 courses ||| 0-0 1-1
6 Behandlungsmonaten ) ||| six months of therapy ) ||| 0-0 1-0 1-1 1-3 2-4
6 Behandlungsmonaten ||| six months of therapy ||| 0-0 1-0 1-1 1-3
6 Die empfohlene ||| 6 The recommended ||| 0-0 1-1 2-2
6 Die ||| 6 The ||| 0-0 1-1
6 Fertigspritzen mit je 0,3 ||| 6 pre-filled syringes of 0.3 ||| 0-0 1-1 1-2 2-2 3-2 3-3 4-4
6 Fertigspritzen mit je 0,4 ||| 6 pre-filled syringes of 0.4 ||| 0-0 1-1 1-2 2-2 3-2 3-3 4-4
6 Fertigspritzen mit je 0,5 ||| 6 pre-filled syringes of 0.5 ||| 0-0 1-1 1-2 2-2 3-2 3-3 4-4
6 Fertigspritzen mit je 0,6 ||| 6 pre-filled syringes of 0.6 ||| 0-0 1-1 1-2 2-2 3-2 3-3 4-4
6 Fertigspritzen mit je 0,7 ||| 6 pre-filled syringes of 0.7 ||| 0-0 1-1 1-2 2-2 3-2 3-3 4-4
6 Fertigspritzen mit je 0,8 ||| 6 pre-filled syringes of 0.8 ||| 0-0 1-1 1-2 2-2 3-2 3-3 4-4
6 Fertigspritzen mit je 0,9 ||| 6 pre-filled syringes of 0.9 ||| 0-0 1-1 1-2 2-2 3-2 3-3 4-4
6 Fertigspritzen mit je 1 ||| 6 pre-filled syringes of 1 ||| 0-0 1-1 1-2 2-2 3-2 3-3 4-4
6 Fertigspritzen mit je ||| 6 pre-filled syringes of ||| 0-0 1-1 1-2 2-2 3-2 3-3
6 Monate einen PSUR vorzulegen ||| a PSUR at 6 monthly ||| 2-0 3-1 1-2 0-3 4-4
6 Monate einen PSUR ||| a PSUR at 6 ||| 2-0 3-1 1-2 0-3
6 Monate einen PSUR ||| provide a PSUR at 6 ||| 2-1 3-2 1-3 0-4
6 Monate nach Verabreichung ||| 6 months after treatment ||| 0-0 1-1 2-2 3-2
6 Monate nach Verabreichung ||| 6 months after ||| 0-0 1-1 2-2 3-2
6 Monate ||| 6 months ||| 0-0 1-1
6 Monate ||| at 6 ||| 1-0 0-1
6 Monaten ||| 6 months ago ||| 0-0 1-1 1-2
6 Monaten ||| 6 months ||| 0-0 1-1
6 Monaten ||| over 6 months ||| 0-1 1-2
6 Stunden wurde ||| 6 hours has been ||| 0-0 1-1 2-2 2-3
6 Stunden ||| 6 hours ||| 0-0 1-1
6 Wochen ) ||| 6 weeks ) ||| 0-0 1-1 2-2
6 Wochen nach Anbruch oder ||| 6 weeks when used or ||| 0-0 1-1 2-1 3-2 3-3 4-4
6 Wochen nach Anbruch ||| 6 weeks when used ||| 0-0 1-1 2-1 3-2 3-3
6 Wochen nach ||| 6 weeks ||| 0-0 1-1 2-1
6 Wochen nach ||| six weeks after ||| 0-0 1-1 2-2
6 Wochen ||| 6 weeks ||| 0-0 1-1
6 Wochen ||| six weeks ||| 0-0 1-1
6 mg Aspartam ( E951 ||| 6 mg aspartame ( E951 ||| 0-0 1-1 2-2 3-3 4-4
6 mg Aspartam ( ||| 6 mg aspartame ( ||| 0-0 1-1 2-2 3-3
6 mg Aspartam ||| 6 mg aspartame ||| 0-0 1-1 2-2
6 mg ||| 6 mg ||| 0-0 1-1
6 ||| 6 ||| 0-0
6 ||| over 6 ||| 0-1
6 ||| six ||| 0-0
6,1 Monate ( 300 ||| 6.1 months ( 300 ||| 0-0 1-1 2-2 3-3
6,1 Monate ( ||| 6.1 months ( ||| 0-0 1-1 2-2
6,1 Monate ||| 6.1 months ||| 0-0 1-1
6,1 ||| 6.1 ||| 0-0
6,2 % mit Aripiprazol und ||| 6.2 % with aripiprazole and ||| 0-0 1-1 2-2 3-3 4-4
6,2 % mit Aripiprazol ||| 6.2 % with aripiprazole ||| 0-0 1-1 2-2 3-3
6,2 % mit ||| 6.2 % with ||| 0-0 1-1 2-2
6,2 % ||| 6.2 % ||| 0-0 1-1
6,2 - 7,5 mmol/l ||| 6.2 - 7.5 mmol/ l ||| 0-0 1-1 2-2 3-3 3-4
6,2 - 7,5 ||| 6.2 - 7.5 ||| 0-0 1-1 2-2
6,2 - ||| 6.2 - ||| 0-0 1-1
6,2 mmol/l ) bis ||| 6.2 mmol/ l ) to ||| 0-0 1-1 1-2 2-3 3-4
6,2 mmol/l ) ||| 6.2 mmol/ l ) ||| 0-0 1-1 1-2 2-3
6,2 mmol/l ||| 6.2 mmol/ l ||| 0-0 1-1 1-2
6,2 ||| 6.2 ||| 0-0
6,7 ||| 6.7 ||| 0-0
6,8 mmol/l ) . ||| 6.8 mmol/ l ) . ||| 0-0 1-1 1-2 2-3 3-4
6,8 mmol/l ) ||| 6.8 mmol/ l ) ||| 0-0 1-1 1-2 2-3
6,8 mmol/l ||| 6.8 mmol/ l ||| 0-0 1-1 1-2
6,8 ||| 6.8 ||| 0-0
6-7,5 und eine Osmolalität von ||| 6-7.5 and an osmolality of ||| 0-0 1-1 2-2 3-3 4-4
6-7,5 und eine Osmolalität ||| 6-7.5 and an osmolality ||| 0-0 1-1 2-2 3-3
6-7,5 und eine ||| 6-7.5 and an ||| 0-0 1-1 2-2
6-7,5 und ||| 6-7.5 and ||| 0-0 1-1
6-7,5 ||| 6-7.5 ||| 0-0
6-mal ( eine kumulative Dosis ||| ( for a cumulative dose ||| 1-0 2-2 3-3 4-4
6-mal ( eine kumulative ||| ( for a cumulative ||| 1-0 2-2 3-3
6-mal ( eine ||| ( for a ||| 1-0 2-2
6-mal ( ||| ( for ||| 1-0
6-mal ( ||| ( ||| 1-0
6.1 ) . ||| 6.1 ) . ||| 0-0 1-1 2-2
6.1 ) ||| 6.1 ) ||| 0-0 1-1
6.1 . ||| 6.1 . ||| 0-0 1-1
6.1 . ||| 6.1 ||| 0-0 1-0
6.1 ||| 6.1 ||| 0-0
6.6 . ||| 6.6 . ||| 0-0 1-1
6.6 Besondere Vorsichtsmaßnahmen für die ||| 28 6.6 Special precautions ||| 0-0 0-1 1-1 1-2 2-2 2-3 3-3 4-3
6.6 Besondere Vorsichtsmaßnahmen für die ||| 35 6.6 Special precautions ||| 0-0 0-1 1-1 1-2 2-2 2-3 3-3 4-3
6.6 Besondere Vorsichtsmaßnahmen für die ||| 56 6.6 Special precautions ||| 0-0 0-1 1-1 1-2 2-2 2-3 3-3 4-3
6.6 Besondere Vorsichtsmaßnahmen für die ||| 6.6 Special precautions ||| 0-0 1-1 2-1 2-2 3-2 4-2
6.6 Besondere Vorsichtsmaßnahmen für die ||| 63 6.6 Special precautions ||| 0-0 0-1 1-1 1-2 2-2 2-3 3-3 4-3
6.6 Besondere Vorsichtsmaßnahmen für die ||| 70 6.6 Special precautions ||| 0-0 0-1 1-1 1-2 2-2 2-3 3-3 4-3
6.6 Besondere Vorsichtsmaßnahmen für die ||| 77 6.6 Special precautions ||| 0-0 0-1 1-1 1-2 2-2 2-3 3-3 4-3
6.6 Besondere Vorsichtsmaßnahmen für ||| 21 6.6 Special ||| 0-0 0-1 1-1 1-2 2-2 3-2
6.6 aufgeführten ||| 6.6 ||| 0-0
6.6 ||| 5/ 20 6.6 ||| 0-0 0-1 0-2
6.6 ||| 6.6 ||| 0-0
60 % Actraphane 50 : ||| 60 % Actraphane 50 : ||| 0-0 1-1 2-2 3-3 4-4
60 % Actraphane 50 ||| 60 % Actraphane 50 ||| 0-0 1-1 2-2 3-3
60 % Actraphane ||| 60 % Actraphane ||| 0-0 1-1 2-2
60 % Isophan-Insulin . ||| 60 % isophane insulin . ||| 0-0 1-1 2-2 2-3 3-4
60 % Isophan-Insulin ||| 60 % isophane insulin ||| 0-0 1-1 2-2 2-3
60 % in ||| 60 % in ||| 0-0 1-1 2-2
60 % ||| 60 % ||| 0-0 1-1
60 - 150 30 - ||| 60 - 150 30 - ||| 0-0 1-1 2-2 3-3 4-4
60 - 150 30 ||| 60 - 150 30 ||| 0-0 1-1 2-2 3-3
60 - 150 ||| 60 - 150 ||| 0-0 1-1 2-2
60 - ||| 60 - ||| 0-0 1-1
60 14 30 ||| 60 14 30 ||| 0-0 1-1 2-2
60 14 ||| 60 14 ||| 0-0 1-1
60 25 800 ||| 60 25 800 ||| 0-0 1-1 2-2
60 25 ||| 60 25 ||| 0-0 1-1
60 6.6 Besondere ||| 6.6 Special ||| 0-0 1-0 2-1
60 6.6 ||| 6.6 ||| 0-0 1-0
60 Tagen nach Erreichen ||| Within 60 days ||| 2-0 0-1 1-2 2-2
60 Tagen nach ||| Within 60 days ||| 2-0 0-1 1-2 2-2
60 Tagen nachdem ||| 60 days ||| 0-0 1-1
60 Tagen ||| 60 days ||| 0-0 1-1
60 ||| 60 ||| 0-0
600 I.E./kg Körpergewicht ||| 600 IU/ kg body weight ||| 0-0 1-1 1-2 2-3 2-4
600 I.E./kg ||| 600 IU/ kg ||| 0-0 1-1 1-2
600 Internationale Einheiten ( I.E. ||| 600 International Units ( IU ||| 0-0 1-1 2-2 3-3 4-4
600 Internationale Einheiten ( ||| 600 International Units ( ||| 0-0 1-1 2-2 3-3
600 Internationale Einheiten ||| 600 International Units ||| 0-0 1-1 2-2
600 Internationale ||| 600 International ||| 0-0 1-1
600 ||| 600 ||| 0-0
6000 I.E. ) Lösung ||| 6000 IU ) of solution ||| 0-0 1-1 2-2 1-3 3-4
6000 I.E. ) ||| 6000 IU ) of ||| 0-0 1-1 2-2 1-3
6000 I.E./0,6 ml ||| 6000 IU/ 0.6 ml ||| 0-0 0-1 1-2 2-3
6000 I.E./0,6 ||| 6000 IU/ 0.6 ||| 0-0 0-1 1-2
6000 Internationale Einheiten ( I.E. ||| 6000 international units ( IU ||| 0-0 1-1 2-2 3-3 4-4
6000 Internationale Einheiten ( ||| 6000 international units ( ||| 0-0 1-1 2-2 3-3
6000 Internationale Einheiten ||| 6000 international units ||| 0-0 1-1 2-2
6000 Internationale ||| 6000 international ||| 0-0 1-1
6000 ||| 6000 IU/ ||| 0-0 0-1
6000 ||| 6000 ||| 0-0
61 % unterhalb des Ausgangswertes ||| 61 % below baseline levels ||| 0-0 1-1 2-2 2-3 4-3 2-4 3-4
61 % unterhalb ||| 61 % below ||| 0-0 1-1 2-2
61 % ||| 61 % ||| 0-0 1-1
61 33 22 11 ||| 61 33 22 11 ||| 0-0 1-1 2-2 3-3
61 33 22 ||| 61 33 22 ||| 0-0 1-1 2-2
61 33 ||| 61 33 ||| 0-0 1-1
61 Aldwych , London , ||| 61 Aldwych , London , ||| 0-0 1-1 2-2 3-3 4-4
61 Aldwych , London ||| 61 Aldwych , London ||| 0-0 1-1 2-2 3-3
61 Aldwych , ||| 61 Aldwych , ||| 0-0 1-1 2-2
61 Aldwych London WC2B 4AE ||| 61 Aldwych London WC2B 4AE ||| 0-0 1-1 2-2 3-3 4-4
61 Aldwych London WC2B ||| 61 Aldwych London WC2B ||| 0-0 1-1 2-2 3-3
61 Aldwych London ||| 61 Aldwych London ||| 0-0 1-1 2-2
61 Aldwych ||| 61 Aldwych ||| 0-0 1-1
61 Gelegentlich - Diabetische Retinopathie ||| Uncommon - Diabetic retinopathy ||| 0-0 1-0 2-1 3-2 4-3
61 Gelegentlich - Diabetische ||| Uncommon - Diabetic ||| 0-0 1-0 2-1 3-2
61 Gelegentlich - ||| Uncommon - ||| 0-0 1-0 2-1
61 Gelegentlich ||| Uncommon ||| 0-0 1-0
61 ||| 61 ||| 0-0
62 4.2 Dosierung , ||| 4.2 Posology ||| 0-0 1-0 2-1 3-1
62 4.2 ||| 4.2 ||| 0-0 1-0
63 Danmark Takeda Global R ||| Danmark Takeda Global R ||| 0-0 1-0 2-1 3-2 4-3
63 Danmark Takeda Global ||| Danmark Takeda Global ||| 0-0 1-0 2-1 3-2
63 Danmark Takeda ||| Danmark Takeda ||| 0-0 1-0 2-1
63 Danmark ||| Danmark ||| 0-0 1-0
63 Die Schmelztablette ||| The orodispersible tablet ||| 1-0 2-1 0-2 2-2
63 Patienten mit metastasierendem ||| 63 patients with metastatic ||| 0-0 1-1 2-2 3-3
63 Patienten mit ||| 63 patients with ||| 0-0 1-1 2-2
63 Patienten ||| 63 patients ||| 0-0 1-1
63 ||| 63 , 86)** 25 ||| 0-0 0-2 0-3
63 ||| 63 ||| 0-0
63%ige Reduktion ||| 63 % reduction ||| 0-0 1-1 0-2 1-2
63,8 31,0 65,1 26,7 ||| 63.8 31.0 65.1 26.7 ||| 0-0 1-1 2-2 3-3
63,8 31,0 65,1 ||| 63.8 31.0 65.1 ||| 0-0 1-1 2-2
63,8 31,0 ||| 63.8 31.0 ||| 0-0 1-1
63,8 ||| 63.8 ||| 0-0
632 l/m2 ||| 632 ||| 0-0 1-0
64 gynäkologische Tumore , 23 ||| 64 gynaecological , 23 ||| 0-0 1-1 2-1 3-2 4-3
64 gynäkologische Tumore , ||| 64 gynaecological , ||| 0-0 1-1 2-1 3-2
64 gynäkologische Tumore ||| 64 gynaecological ||| 0-0 1-1 2-1
64 ||| 64 ||| 0-0
640 ||| " ||| 0-0
641 ||| " ||| 0-0
643 ||| " ||| 0-0
65 00 ||| 65 00 ||| 0-0 1-1
65 Die empfohlene Dosierung wird ||| The recommended dosing regimen is ||| 0-0 1-0 2-1 3-2 2-3 3-3 4-4
65 Die empfohlene Dosierung ||| The recommended dosing regimen ||| 0-0 1-0 2-1 3-2 2-3 3-3
65 Die ||| The ||| 0-0 1-0
65 Jahre ) ||| 65 years ) ||| 0-0 1-1 2-2
65 Jahre und älter ) ||| age 65 and over ||| 0-0 0-1 1-1 3-1 2-2 3-3 4-3
65 Jahre ||| 65 years ||| 0-0 1-1
65 Jahren ||| 65 years ||| 0-0 1-1
65 auf 200 kg ||| 65 to 200 kg ||| 0-0 1-1 2-2 3-3
65 auf 200 ||| 65 to 200 ||| 0-0 1-1 2-2
65 auf ||| 65 to ||| 0-0 1-1
65 ||| 65 ||| 0-0
65,1 26,7 ||| 65.1 26.7 ||| 0-0 1-1
65,1 ||| 65.1 ||| 0-0
6570 ||| 6570 ||| 0-0
66 Anpassung der Dosis Begleiterkrankungen ||| Dosage adjustment Concomitant illness ||| 0-0 1-0 1-1 1-2 2-2 4-2 3-3 4-3
66 Die empfohlene ||| 62 The recommended ||| 0-0 1-1 2-2
66 Die ||| 62 The ||| 0-0 1-1
66 ||| 62 ||| 0-0
6600 ||| 6600 ||| 0-0
663 50 00 ||| 663 50 00 ||| 0-0 1-1 2-2
663 50 ||| 663 50 ||| 0-0 1-1
663 ||| 663 ||| 0-0
67 % ||| 67 % ||| 0-0 1-1
67 4.4 Besondere Warnhinweise und ||| 4.4 Special warnings and ||| 0-0 1-0 2-1 3-2 4-3
67 4.4 Besondere Warnhinweise ||| 4.4 Special warnings ||| 0-0 1-0 2-1 3-2
67 4.4 Besondere ||| 4.4 Special ||| 0-0 1-0 2-1
67 4.4 ||| 4.4 ||| 0-0 1-0
67 55 53 50 ||| 67 55 53 50 ||| 0-0 1-1 2-2 3-3
67 55 53 ||| 67 55 53 ||| 0-0 1-1 2-2
67 55 ||| 67 55 ||| 0-0 1-1
67 Patienten ||| Patients ||| 1-0
67 Wenn ||| If ||| 1-0
67 planen . Aufgrund der ||| Due to ||| 1-0 3-0 4-0 3-1
67 ||| 67 ||| 0-0
67,2 Mikrogramm Epoetin alfa ||| 67.2 micrograms epoetin alfa ||| 0-0 1-1 2-2 3-3
67,2 Mikrogramm Epoetin ||| 67.2 micrograms epoetin ||| 0-0 1-1 2-2
67,2 Mikrogramm Epoetin ||| corresponding to 67.2 micrograms epoetin ||| 1-0 0-2 1-3 2-4
67,2 Mikrogramm ||| 67.2 micrograms ||| 0-0 1-1
67,2 Mikrogramm ||| corresponding to 67.2 micrograms ||| 1-0 0-2 1-3
67,2 ||| 67.2 ||| 0-0
67,2 ||| to 67.2 ||| 0-1
67019 Scoppito ( AQ ) ||| 67019 Scoppito ( AQ ) ||| 0-0 1-1 2-2 3-3 4-4
67019 Scoppito ( AQ ||| 67019 Scoppito ( AQ ||| 0-0 1-1 2-2 3-3
67019 Scoppito ( ||| 67019 Scoppito ( ||| 0-0 1-1 2-2
67019 Scoppito ||| 67019 Scoppito ||| 0-0 1-1
67019 ||| 67019 ||| 0-0
68 % der ||| 68 % of ||| 0-0 1-1 2-2
68 % ||| 68 % ||| 0-0 1-1
68 Bei Patienten mit ||| In patients with ||| 0-0 1-0 2-1 3-2
68 Bei Patienten ||| In patients ||| 0-0 1-0 2-1
68 Bei ||| In ||| 0-0 1-0
68 Danmark Takeda Global R ||| Danmark Takeda Global R ||| 0-0 1-0 2-1 3-2 4-3
68 Danmark Takeda Global ||| Danmark Takeda Global ||| 0-0 1-0 2-1 3-2
68 Danmark Takeda ||| Danmark Takeda ||| 0-0 1-0 2-1
68 Danmark ||| Danmark ||| 0-0 1-0
68 In Placebo-kontrollierten Studien ||| In placebo-controlled trials , ||| 0-0 1-0 2-1 3-2
68 In Placebo-kontrollierten Studien ||| In placebo-controlled trials ||| 0-0 1-0 2-1 3-2
68 In Placebo-kontrollierten ||| In placebo-controlled ||| 0-0 1-0 2-1
68 In ||| In ||| 0-0 1-0
68 ||| 68 ||| 0-0
683 Mammakarzinome ||| 683 breast ||| 0-0 1-0 1-1
69 % , ||| 69 % , ||| 0-0 1-1 2-2
69 % , ||| to 69 % , ||| 0-1 1-2 2-3
69 % ||| 69 % ||| 0-0 1-1
69 % ||| to 69 % ||| 0-1 1-2
69 00 ||| 69 00 ||| 0-0 1-1
69 Gelegentlich - Diabetische Retinopathie ||| Uncommon - Diabetic retinopathy ||| 0-0 1-0 2-1 3-2 4-3
69 Gelegentlich - Diabetische ||| Uncommon - Diabetic ||| 0-0 1-0 2-1 3-2
69 Gelegentlich - ||| Uncommon - ||| 0-0 1-0 2-1
69 Gelegentlich ||| Uncommon ||| 0-0 1-0
69 ||| 69 ||| 0-0
69 ||| to 69 ||| 0-1
6fache ||| fold ||| 0-0
6fachen der human-therapeutischen ||| therapeutic ||| 2-0
7 % ||| 7 % ||| 0-0 1-1
7 ) vor dem operativen ||| 7 ) prior to ||| 0-0 1-1 2-2 3-2 4-2 2-3
7 ) ||| 7 ) ||| 0-0 1-1
7 4.4 Besondere Warnhinweise und ||| 4.4 Special warnings and ||| 0-0 1-0 2-1 3-2 4-3
7 4.4 Besondere Warnhinweise ||| 4.4 Special warnings ||| 0-0 1-0 2-1 3-2
7 4.4 Besondere ||| 4.4 Special ||| 0-0 1-0 2-1
7 4.4 ||| 4.4 ||| 0-0 1-0
7 In klinischen Studien bei ||| In clinical studies for ||| 0-0 1-0 2-1 3-2 4-3
7 In klinischen Studien ||| In clinical studies ||| 0-0 1-0 2-1 3-2
7 In klinischen ||| In clinical ||| 0-0 1-0 2-1
7 In ||| In ||| 0-0 1-0
7 Patienten ||| 7 patients ||| 0-0 1-1
7 Studie mit ||| In a large clinical trial ||| 0-0 1-0 1-1 2-2 1-3 1-4 2-4
7 ||| 7 ||| 0-0
7,2 % ) . ||| 7.2 % ) . ||| 0-0 1-1 2-2 3-3
7,2 % ) ||| 7.2 % ) ||| 0-0 1-1 2-2
7,2 % ||| 7.2 % ||| 0-0 1-1
7,2 ||| 7.2 ||| 0-0
7,3 % ) und +0,1 ||| 7.3 % ) and +0.1 ||| 0-0 1-1 2-2 3-3 4-4
7,3 % ) und ||| 7.3 % ) and ||| 0-0 1-1 2-2 3-3
7,3 % ) ||| 7.3 % ) ||| 0-0 1-1 2-2
7,3 % ||| 7.3 % ||| 0-0 1-1
7,3 ||| 7.3 ||| 0-0
7,5 % ||| 7.5 % ||| 0-0 1-1
7,5 kg , ||| 7.5 kg over 2 ||| 0-0 1-1 1-2 1-3
7,5 kg ||| 7.5 kg over 2 ||| 0-0 1-1 1-2 1-3
7,5 mg/ml ) ||| 7.5 mg/ ml ) ||| 0-0 1-1 1-2 2-3
7,5 mg/ml ||| 7.5 mg/ ml ||| 0-0 1-1 1-2
7,5 mmol/l ) . ||| 7.5 mmol/ l ) . ||| 0-0 1-1 1-2 2-3 3-4
7,5 mmol/l ) gegeben ||| 7.5 mmol/ l ) ||| 0-0 3-0 1-1 1-2 2-3
7,5 mmol/l ) liegt ||| 7.5 mmol/ l ) ||| 0-0 1-1 1-2 3-2 2-3
7,5 mmol/l ) sollte vermieden ||| 7.5 mmol/ l ) should ||| 0-0 1-1 2-1 4-2 2-3 3-4
7,5 mmol/l ) sollte ||| 7.5 mmol/ l ) should ||| 0-0 1-1 1-2 2-3 3-4
7,5 mmol/l ) steigt . ||| 7.5 mmol/ l ) . ||| 0-0 1-1 1-2 3-2 2-3 4-4
7,5 mmol/l ) steigt ||| 7.5 mmol/ l ) ||| 0-0 1-1 1-2 3-2 2-3
7,5 mmol/l ) zu erreichen ||| 7.5 mmol/ l ) ||| 0-0 1-1 3-2 4-2 2-3
7,5 mmol/l ) ||| 7.5 mmol/ l ) in ||| 0-0 1-1 1-2 2-3
7,5 mmol/l ) ||| 7.5 mmol/ l ) ||| 0-0 1-1 1-2 2-3
7,5 mmol/l ||| 7.5 mmol/ l ||| 0-0 1-1 1-2
7,5 mmol/l ||| 7.5 mmol/ ||| 0-0 1-1
7,5 ||| 7.5 ||| 0-0
7,54 ; 18,93 ] ( ||| 7.54 , 18.93 ] ( ||| 0-0 1-1 2-2 1-3 3-3 4-4
7,54 ; 18,93 ] ||| 7.54 , 18.93 ] ||| 0-0 1-1 2-2 1-3 3-3
7,54 ||| 7.54 ||| 0-0
7,8 % er 27,0 % ||| 34.9 % ||| 0-0 2-0 3-0 1-1 4-1
7,9 % für beide Gruppen ||| 7.9 % for both groups ||| 0-0 1-1 2-2 3-3 4-4
7,9 % für beide ||| 7.9 % for both ||| 0-0 1-1 2-2 3-3
7,9 % für ||| 7.9 % for ||| 0-0 1-1 2-2
7,9 % ||| 7.9 % ||| 0-0 1-1
7,9 ||| 7.9 ||| 0-0
7.400 ||| 7400 ||| 0-0
7.736 Patienten ||| 7,736 patients , ||| 0-0 1-1
7.736 Patienten ||| 7,736 patients ||| 0-0 1-1
7.736 ||| 7,736 ||| 0-0
70 % Actraphane 40 : ||| 70 % Actraphane 40 : ||| 0-0 1-1 2-2 3-3 4-4
70 % Actraphane 40 ||| 70 % Actraphane 40 ||| 0-0 1-1 2-2 3-3
70 % Actraphane ||| 70 % Actraphane ||| 0-0 1-1 2-2
70 % Isophan-Insulin . ||| 70 % isophane insulin . ||| 0-0 1-1 2-2 2-3 3-4
70 % Isophan-Insulin ||| 70 % isophane insulin ||| 0-0 1-1 2-2 2-3
70 % ||| 70 % ||| 0-0 1-1
70 x 1 Filmtablette ||| 70 x 1 film-coated tablets ||| 0-0 1-1 2-2 3-3 1-4
70 ||| 70 ||| 0-0
7000 I.E. ) Lösung ||| 7000 IU ) of solution ||| 0-0 1-1 2-2 1-3 3-4
7000 I.E. ) ||| 7000 IU ) of ||| 0-0 1-1 2-2 1-3
7000 I.E./0,7 ml ||| 7000 IU/ 0.7 ml ||| 0-0 0-1 1-2 2-3
7000 I.E./0,7 ml ||| 7000 IU/ 0.7 ml ||| 0-0 1-1 1-2 2-3
7000 I.E./0,7 ||| 7000 IU/ 0.7 ||| 0-0 0-1 1-2
7000 I.E./0,7 ||| 7000 IU/ 0.7 ||| 0-0 1-1 1-2
7000 Internationale Einheiten ( I.E. ||| 7000 international units ( IU ||| 0-0 1-1 2-2 3-3 4-4
7000 Internationale Einheiten ( ||| 7000 international units ( ||| 0-0 1-1 2-2 3-3
7000 Internationale Einheiten ||| 7000 international units ||| 0-0 1-1 2-2
7000 Internationale ||| 7000 international ||| 0-0 1-1
7000 ||| 7000 IU/ ||| 0-0 0-1
7000 ||| 7000 ||| 0-0
704 71 00 ||| 704 71 00 ||| 0-0 1-1 2-2
704 71 ||| 704 71 ||| 0-0 1-1
704 ||| 704 ||| 0-0
71 % der Patienten gemeldet ||| 71 % of patients ||| 0-0 1-1 2-2 3-3 4-3
71 % der ||| 71 % of ||| 0-0 1-1 2-2
71 % ||| 71 % ||| 0-0 1-1
71 00 ||| 71 00 ||| 0-0 1-1
71 ||| , ||| 0-0
71 ||| 71 ||| 0-0
72 ( 31 % ) ||| 72 ( 31 % ) ||| 0-0 1-1 2-2 3-3 4-4
72 ( 31 % ||| , 72 ( 31 % ||| 0-1 1-2 2-3 3-4
72 ( 31 % ||| 72 ( 31 % ||| 0-0 1-1 2-2 3-3
72 ( 31 ||| , 72 ( 31 ||| 0-1 1-2 2-3
72 ( 31 ||| 72 ( 31 ||| 0-0 1-1 2-2
72 ( ||| , 72 ( ||| 0-1 1-2
72 ( ||| 72 ( ||| 0-0 1-1
72 Bei exzessiv hohen ||| Phlebotomy may be performed ||| 0-0 1-0 2-0 2-1 2-2 3-3
72 Bei exzessiv ||| Phlebotomy may be ||| 0-0 1-0 2-0 2-1 2-2
72 ||| , 72 ||| 0-1
72 ||| 72 ||| 0-0
73 % ) . ||| 73 % ) . ||| 0-0 1-1 2-2 3-3
73 % ) ||| 73 % ) ||| 0-0 1-1 2-2
73 % ||| 73 % ||| 0-0 1-1
73 ||| 73 ||| 0-0
731 1736 ||| 731 1736 ||| 0-0 1-1
731 ||| 731 ||| 0-0
732 32 00 ||| 732 32 00 ||| 0-0 1-1 2-2
732 32 ||| 732 32 ||| 0-0 1-1
732 ||| 732 ||| 0-0
7364000 ||| 7364000 ||| 0-0
74 18 84 00 ||| 74 18 84 00 ||| 0-0 1-1 2-2 3-3
74 18 84 16 ||| 74 18 84 16 ||| 0-0 1-1 2-2 3-3
74 18 84 ||| 74 18 84 ||| 0-0 1-1 2-2
74 18 86 68 ||| 74 18 86 68 ||| 0-0 1-1 2-2 3-3
74 18 86 ||| 74 18 86 ||| 0-0 1-1 2-2
74 18 ||| 74 18 ||| 0-0 1-1
74 60 ||| 74 60 ||| 0-0 1-1
74 Anpassung der Dosis Begleiterkrankungen ||| Dosage adjustment Concomitant illness ||| 0-0 1-0 1-1 1-2 2-2 4-2 3-3 4-3
74 In tierexperimentellen Studien mit ||| In animal studies , epoetin ||| 1-0 2-1 3-2 2-4 4-4
74 In ||| In ||| 1-0
74 ||| 74 ||| 0-0
749 749 ||| 749 749 ||| 0-0 1-1
749 ||| 749 ||| 0-0
75 % bzw. 73 % ||| 75 % and 73 % ||| 0-0 1-1 2-2 3-3 1-4 2-4 4-4
75 - 150 60 - ||| 75 - 150 60 - ||| 0-0 1-1 2-2 3-3 4-4
75 - 150 60 ||| 75 - 150 60 ||| 0-0 1-1 2-2 3-3
75 - 150 ||| 75 - 150 ||| 0-0 1-1 2-2
75 - ||| 75 - ||| 0-0 1-1
75 6.6 Besondere ||| 6.6 Special ||| 0-0 1-0 2-1
75 6.6 ||| 6.6 ||| 0-0 1-0
75 Jahre mit ||| 75 years of age ||| 0-0 1-1 2-2 1-3
75 Jahre und Orientalen/Asiaten ist ||| 75 years and ||| 0-0 1-1 3-1 2-2
75 Jahre und Orientalen/Asiaten ||| 75 years and ||| 0-0 1-1 3-1 2-2
75 und 300 I.E. pro ||| 75 and 300 IU per ||| 0-0 1-1 2-2 3-3 4-4
75 und 300 I.E. ||| 75 and 300 IU ||| 0-0 1-1 2-2 3-3
75 und 300 ||| 75 and 300 ||| 0-0 1-1 2-2
75 und ||| 75 and ||| 0-0 1-1
75 von 3.852 ) ||| 75 out of 3,852 ) ||| 0-0 2-1 1-2 2-3 3-4
75 von 3.852 ||| 75 out of 3,852 ||| 0-0 2-1 1-2 2-3
75 ||| 75 ||| 0-0
75 ± 33 % ||| 75 ± 33 % ||| 0-0 1-1 2-2 3-3
75 ± 33 ||| 75 ± 33 ||| 0-0 1-1 2-2
75 ± ||| 75 ± ||| 0-0 1-1
75,6 Mikrogramm Epoetin alfa ||| 75.6 micrograms epoetin alfa ||| 0-0 1-1 2-2 3-3
75,6 Mikrogramm Epoetin ||| 75.6 micrograms epoetin ||| 0-0 1-1 2-2
75,6 Mikrogramm ||| 75.6 micrograms ||| 0-0 1-1
75,6 ||| 75.6 ||| 0-0
75,6 ||| to 75.6 ||| 0-1
75- jähriger ||| old ||| 0-0 1-0
76 % hatten mehr als ||| 76 % had > ||| 0-0 1-1 2-2 1-3
76 % hatten mehr ||| 76 % had > ||| 0-0 1-1 2-2 1-3
76 % hatten ||| 76 % had > ||| 0-0 1-1 2-2 1-3
76 03 ||| 76 03 ||| 0-0 1-1
76 Die Schmelztablette ||| The orodispersible tablet ||| 1-0 0-1 2-1 2-2
76 ||| 76 ||| 0-0
77 % ||| 77 % ||| 0-0 1-1
77 4.2 Dosierung , ||| 4.2 Posology ||| 0-0 1-0 2-1 3-1
77 4.2 ||| 4.2 ||| 0-0 1-0
77 Gelegentlich - Diabetische Retinopathie ||| Uncommon - Diabetic retinopathy ||| 0-0 1-0 2-1 3-2 4-3
77 Gelegentlich - Diabetische ||| Uncommon - Diabetic ||| 0-0 1-0 2-1 3-2
77 Gelegentlich - ||| Uncommon - ||| 0-0 1-0 2-1
77 Gelegentlich ||| Uncommon ||| 0-0 1-0
77 ||| 77 ||| 0-0
77 ||| Seventy-seven ||| 0-0
789 Patienten berechnet ||| 789 patients ||| 0-0 2-0 1-1
79 % der ||| 79 % of ||| 0-0 1-1 2-2
79 % ||| 79 % ||| 0-0 1-1
79 ||| 79 ||| 0-0
8 704 71 00 ||| 8 704 71 00 ||| 0-0 1-1 2-2 3-3
8 704 71 ||| 8 704 71 ||| 0-0 1-1 2-2
8 704 ||| 8 704 ||| 0-0 1-1
8 732 32 00 ||| 8 732 32 00 ||| 0-0 1-1 2-2 3-3
8 732 32 ||| 8 732 32 ||| 0-0 1-1 2-2
8 732 ||| 8 732 ||| 0-0 1-1
8 Bei Patienten mit ||| In patients with ||| 1-0 2-1 3-2
8 Bei Patienten ||| In patients ||| 1-0 2-1
8 Bei ||| In ||| 1-0
8 Stunden ||| 8 hours ||| 0-0 1-1
8 kg ||| 8 kg ||| 0-0 1-1
8 und 16 mg ||| 8 and 16 mg ||| 0-0 1-1 2-2 3-3
8 und 16 ||| 8 and 16 ||| 0-0 1-1 2-2
8 und ||| 8 and ||| 0-0 1-1
8 ||| 8 ||| 0-0
8,1 41,7 11,9 47,3 11,6 ||| 8.1 41.7 11.9 47.3 11.6 ||| 0-0 1-1 2-2 3-3 4-4
8,1 41,7 11,9 47,3 ||| 8.1 41.7 11.9 47.3 ||| 0-0 1-1 2-2 3-3
8,1 41,7 11,9 ||| 8.1 41.7 11.9 ||| 0-0 1-1 2-2
8,1 41,7 ||| 8.1 41.7 ||| 0-0 1-1
8,1 mmol/l ) ||| 8.1 mmol/ l ) ||| 0-0 1-1 1-2 2-3
8,1 mmol/l ||| 8.1 mmol/ l ||| 0-0 1-1 1-2
8,1 ||| 8.1 ||| 0-0
8,4 Mikrogramm Epoetin alfa ||| 8.4 micrograms epoetin alfa ||| 0-0 1-1 2-2 3-3
8,4 Mikrogramm Epoetin ||| 8.4 micrograms epoetin ||| 0-0 1-1 2-2
8,4 Mikrogramm ||| 8.4 micrograms ||| 0-0 1-1
8,4 ||| 8.4 ||| 0-0
8,4 ||| to 8.4 ||| 0-1
8,7 % bei ||| 8.7 % for ||| 0-0 1-1 2-2
8,7 % ||| 8.7 % ||| 0-0 1-1
8,7 für Aripiprazol . ||| 8.7 for aripiprazole . ||| 0-0 1-1 2-2 3-3
8,7 für Aripiprazol ||| 8.7 for aripiprazole ||| 0-0 1-1 2-2
8,7 für ||| 8.7 for ||| 0-0 1-1
8,7 mmol/l ) angestrebt wurde ||| 8.7 mmol/ l ) , ||| 0-0 3-0 4-0 1-1 1-2 2-3 3-4
8,7 ||| 8.7 ||| 0-0
80 % Actraphane 30 : ||| 80 % Actraphane 30 : ||| 0-0 1-1 2-2 3-3 4-4
80 % Actraphane 30 ||| 80 % Actraphane 30 ||| 0-0 1-1 2-2 3-3
80 % Actraphane ||| 80 % Actraphane ||| 0-0 1-1 2-2
80 % Isophan-Insulin . ||| 80 % isophane insulin . ||| 0-0 1-1 2-2 2-3 3-4
80 % Isophan-Insulin ||| 80 % isophane insulin ||| 0-0 1-1 2-2 2-3
80 % der Studienpopulation ||| 80 % of the population ||| 0-0 1-1 2-2 2-3 3-4
80 % der ||| 80 % of the ||| 0-0 1-1 2-2 2-3
80 % ||| 80 % ||| 0-0 1-1
80 , ||| 80 , ||| 0-0 1-1
80 Die empfohlene Dosierung wird ||| The recommended dosing regimen is ||| 1-0 2-1 0-2 3-2 2-3 3-3 4-4
80 Die empfohlene Dosierung ||| The recommended dosing regimen ||| 1-0 2-1 0-2 3-2 2-3 3-3
80 Wasser für Injektionszwecke ||| Polysorbate 80 Water for injections ||| 0-0 0-1 1-2 2-3 3-4
80 Wasser für ||| Polysorbate 80 Water for ||| 0-0 0-1 1-2 2-3
80 Wasser ||| Polysorbate 80 Water ||| 0-0 0-1 1-2
80 bis 300 mg/m2 ||| 80 to 300 mg/ m2 ||| 0-0 1-1 2-2 3-3 3-4
80 bis 300 ||| 80 to 300 ||| 0-0 1-1 2-2
80 bis 375 ||| 80 to 375 ||| 0-0 1-1 2-2
80 bis ||| 80 to ||| 0-0 1-1
80 planen . Aufgrund der ||| Due to ||| 1-0 3-0 4-0 3-1
80 ||| 80 ||| 0-0
80 ||| Polysorbate 80 ||| 0-0 0-1
800 ) 749 749 ||| 800 ) 749 749 ||| 0-0 1-1 2-2 3-3
800 ) 749 ||| 800 ) 749 ||| 0-0 1-1 2-2
800 ) ||| 800 ) ||| 0-0 1-1
800 ||| 800 ||| 0-0
8000 I.E. ) Lösung ||| 8000 IU ) of solution ||| 0-0 1-1 2-2 1-3 3-4
8000 I.E. ) ||| 8000 IU ) of ||| 0-0 1-1 2-2 1-3
8000 I.E./0,8 ml ||| 8000 IU/ 0.8 ml ||| 0-0 0-1 1-2 2-3
8000 I.E./0,8 ml ||| 8000 IU/ 0.8 ml ||| 0-0 1-1 1-2 2-3
8000 I.E./0,8 ||| 8000 IU/ 0.8 ||| 0-0 0-1 1-2
8000 I.E./0,8 ||| 8000 IU/ 0.8 ||| 0-0 1-1 1-2
8000 Internationale Einheiten ( I.E. ||| 8000 international units ( IU ||| 0-0 1-1 2-2 3-3 4-4
8000 Internationale Einheiten ( ||| 8000 international units ( ||| 0-0 1-1 2-2 3-3
8000 Internationale Einheiten ||| 8000 international units ||| 0-0 1-1 2-2
8000 Internationale ||| 8000 international ||| 0-0 1-1
8000 ||| 8000 IU/ ||| 0-0 0-1
8000 ||| 8000 ||| 0-0
802 Patienten mit Hämoblastosen . ||| 802 with haematological malignancies . ||| 0-0 1-0 2-1 3-2 3-3 4-4
802 Patienten mit Hämoblastosen ||| 802 with haematological malignancies ||| 0-0 1-0 2-1 3-2 3-3
802 Patienten mit ||| 802 with ||| 0-0 1-0 2-1
802 Patienten ||| 802 ||| 0-0 1-0
81 Die empfohlene ||| 76 The recommended ||| 0-0 1-1 2-2
81 Die ||| 76 The ||| 0-0 1-1
81 In Placebo-kontrollierten Studien ||| In placebo-controlled trials , ||| 0-0 1-0 2-1 3-2
81 In Placebo-kontrollierten Studien ||| In placebo-controlled trials ||| 0-0 1-0 2-1 3-2
81 In Placebo-kontrollierten ||| In placebo-controlled ||| 0-0 1-0 2-1
81 In ||| In ||| 0-0 1-0
81 ||| - 81 ||| 0-1
81 ||| 76 ||| 0-0
81 ||| 81 ||| 0-0
81-fachen der empfohlenen Maximaldosis ||| the maximum recommended ||| 1-0 0-1 2-1 3-1 2-2
8167 Patienten ) . ||| 8167 patients ) . ||| 0-0 1-1 2-2 3-3
8167 Patienten ) ||| 8167 patients ) ||| 0-0 1-1 2-2
8167 Patienten ||| 8167 patients ||| 0-0 1-1
8167 ||| 8167 ||| 0-0
82 4.4 Besondere Warnhinweise und ||| 4.4 Special warnings and ||| 0-0 1-0 2-1 3-2 4-3
82 4.4 Besondere Warnhinweise ||| 4.4 Special warnings ||| 0-0 1-0 2-1 3-2
82 4.4 Besondere ||| 4.4 Special ||| 0-0 1-0 2-1
82 4.4 ||| 4.4 ||| 0-0 1-0
82 Anpassung der Dosis Begleiterkrankungen ||| Dosage adjustment Concomitant illness ||| 0-0 1-0 1-1 1-2 2-2 4-2 3-3 4-3
82 Biopsien gefunden . ||| 82 Biopsien gefunden . Microcomputed ||| 0-0 0-1 1-1 1-2 3-3 1-4 2-4
83 Bei Patienten mit ||| In patients with ||| 0-0 1-0 2-1 3-2
83 Bei Patienten ||| In patients ||| 0-0 1-0 2-1
83 Bei ||| In ||| 0-0 1-0
83 ||| It has been ||| 0-0 0-1 0-2
84 , 90 oder 98 ||| 84 , 90 and 98 ||| 0-0 1-1 2-2 4-4
84 , 90 oder ||| , 84 , 90 or ||| 1-0 0-1 1-2 2-3 3-4
84 , 90 oder ||| 84 , 90 and ||| 0-0 1-1 2-2
84 , 90 oder ||| 84 , 90 ||| 0-0 1-1 2-2
84 , 90 und 98 ||| 84 , 90 and 98 ||| 0-0 1-1 2-2 3-3 4-4
84 , 90 und ||| 84 , 90 and ||| 0-0 1-1 2-2 3-3
84 , 90 ||| , 84 , 90 ||| 1-0 0-1 1-2 2-3
84 , 90 ||| 84 , 90 and ||| 0-0 1-1 2-2
84 , 90 ||| 84 , 90 ||| 0-0 1-1 2-2
84 , ||| , 84 , ||| 1-0 0-1 1-2
84 , ||| 84 , ||| 0-0 1-1
84 00 ||| 84 00 ||| 0-0 1-1
84 16 ||| 84 16 ||| 0-0 1-1
84 In ||| In ||| 1-0
84 Tabletten 90 Tabletten 98 ||| 84 tablets 90 tablets 98 ||| 0-0 1-1 2-2 3-3 4-4
84 Tabletten 90 Tabletten ||| 84 tablets 90 tablets ||| 0-0 1-1 2-2 3-3
84 Tabletten 90 ||| 84 tablets 90 ||| 0-0 1-1 2-2
84 Tabletten ||| 017 84 tablets EU/ 1/ ||| 1-0 0-1 1-2 1-3 1-4
84 Tabletten ||| 020 84 tablets EU/ 1/ ||| 1-0 0-1 1-2 1-3 1-4
84 Tabletten ||| 023 84 tablets EU/ 1/ ||| 1-0 0-1 1-2 1-3 1-4
84 Tabletten ||| 84 tablets ||| 0-0 1-1
84 UND 98 TABLETTEN ||| 84 AND 98 TABLETS ONLY ||| 0-0 1-1 2-2 3-3 3-4
84 UND 98 ||| 84 AND 98 ||| 0-0 1-1 2-2
84 UND ||| 84 AND ||| 0-0 1-1
84 ||| 84 ||| 0-0
84 ||| dummy treatment ||| 0-0
84 ||| dummy ||| 0-0
84 ||| of 84 ||| 0-1
84,0 Mikrogramm Epoetin alfa ||| 84.0 micrograms epoetin alfa ||| 0-0 1-1 2-2 3-3
84,0 Mikrogramm Epoetin ||| 84.0 micrograms epoetin ||| 0-0 1-1 2-2
84,0 Mikrogramm ||| 84.0 micrograms ||| 0-0 1-1
84,0 ||| 84.0 ||| 0-0
84,0 ||| to 84.0 ||| 0-1
85 Gelegentlich - Diabetische Retinopathie ||| Uncommon - Diabetic retinopathy ||| 0-0 1-0 2-1 3-2 4-3
85 Gelegentlich - Diabetische ||| Uncommon - Diabetic ||| 0-0 1-0 2-1 3-2
85 Gelegentlich - ||| Uncommon - ||| 0-0 1-0 2-1
85 Gelegentlich ||| Uncommon ||| 0-0 1-0
8545250 ||| 8545250 ||| 0-0
857 42 22 ||| 857 42 22 ||| 0-0 1-1 2-2
857 42 ||| 857 42 ||| 0-0 1-1
857 ||| 857 ||| 0-0
86 % ||| 86 % ||| 0-0 1-1
86 6570 ||| 86 6570 ||| 0-0 1-1
86 68 ||| 86 68 ||| 0-0 1-1
86 ||| 86 ||| 0-0
87 % . ||| 87 % . ||| 0-0 1-1 2-2
87 % Kaukasier und 9 ||| 87 % Caucasian and 9 ||| 0-0 1-1 2-2 4-2 3-3 4-4
87 % ||| 87 % ||| 0-0 1-1
87 Bei exzessiv hohen ||| Phlebotomy may be performed ||| 0-0 1-0 2-0 2-1 2-2 3-3
87 Bei exzessiv ||| Phlebotomy may be ||| 0-0 1-0 2-0 2-1 2-2
87 ||| 87 ||| 0-0
89 In tierexperimentellen Studien mit ||| In animal studies , epoetin ||| 1-0 2-1 3-2 2-4 4-4
89 In ||| In ||| 1-0
89 Prävention des Wiederauftretens manischer ||| Recurrence prevention of manic ||| 0-0 1-0 1-1 2-2 3-3 4-3
89 Prävention des ||| Recurrence prevention of ||| 0-0 1-0 1-1 2-2
89 Prävention ||| Recurrence prevention ||| 0-0 1-0 1-1
89 ||| 89 ||| 0-0
8950 ||| 8950 ||| 0-0
8951 ||| 8951 ||| 0-0
8952 ||| 8952 ||| 0-0
8953 ||| 8953 ||| 0-0
8954 ||| 8954 ||| 0-0
8°C ) . ||| 8°C ) . ||| 0-0 1-1 2-2
8°C ) ||| 8°C ) ||| 0-0 1-1
8°C . ||| 8°C . ||| 0-0 1-1
8°C . ||| 8ºC . ||| 0-0 1-1
8°C ||| 8°C ||| 0-0
8°C ||| 8ºC ||| 0-0
9 % der Patienten ||| 9 % of the patients ||| 0-0 1-1 2-2 2-3 3-4
9 % der ||| , 9 % of the ||| 0-1 1-2 2-3 2-4
9 % der ||| 9 % of the ||| 0-0 1-1 2-2 2-3
9 % ||| , 9 % ||| 0-1 1-2
9 % ||| 9 % ||| 0-0 1-1
9 251 21 230 ||| 9 251 21 230 ||| 0-0 1-1 2-2 3-3
9 251 21 ||| 9 251 21 ||| 0-0 1-1 2-2
9 251 ||| 9 251 ||| 0-0 1-1
9 61 33 22 11 ||| 9 61 33 22 11 ||| 0-0 1-1 2-2 3-3 4-4
9 61 33 22 ||| 9 61 33 22 ||| 0-0 1-1 2-2 3-3
9 61 33 ||| 9 61 33 ||| 0-0 1-1 2-2
9 61 ||| 9 61 ||| 0-0 1-1
9 Gewichtsreduktion und weitere Risikofaktoren ||| conclusions can be drawn with ||| 0-0 0-3 1-3 4-4
9 Gewichtsreduktion und weitere ||| conclusions can be drawn ||| 0-0 0-3 1-3
9 Gewichtsreduktion und ||| conclusions can be drawn ||| 0-0 0-3 1-3
9 Gewichtsreduktion ||| conclusions can be drawn ||| 0-0 0-3 1-3
9 Wochen ) ||| 9 weeks ) ||| 0-0 1-1 2-2
9 Wochen ||| 9 weeks ||| 0-0 1-1
9 mit anderen Rezeptoren als ||| Interaction with receptors other than ||| 0-0 3-0 1-1 3-2 2-3 4-4
9 mit anderen Rezeptoren ||| Interaction with receptors other ||| 0-0 3-0 1-1 3-2 2-3
9 ||| , 9 ||| 0-1
9 ||| 9 ||| 0-0
9 ||| chloride 9 ||| 0-1
9 ||| sodium chloride 9 ||| 0-2
9,5 22,5 8,1 41,7 11,9 ||| 9.5 22.5 8.1 41.7 11.9 ||| 0-0 1-1 2-2 3-3 4-4
9,5 22,5 8,1 41,7 ||| 9.5 22.5 8.1 41.7 ||| 0-0 1-1 2-2 3-3
9,5 22,5 8,1 ||| 9.5 22.5 8.1 ||| 0-0 1-1 2-2
9,5 22,5 ||| 9.5 22.5 ||| 0-0 1-1
9,5 Jahre . ||| 9.5 years . ||| 0-0 1-1 2-2
9,5 Jahre ||| 9.5 years ||| 0-0 1-1
9,5 und 11 g/dl ||| 9.5 and 11 g/ dl ||| 0-0 1-1 2-2 3-3 3-4
9,5 und 11 ||| 9.5 and 11 ||| 0-0 1-1 2-2
9,5 und ||| 9.5 and ||| 0-0 1-1
9,5 ||| 9.5 ||| 0-0
9,6 für Lorazepam ||| 9.6 for lorazepam ||| 0-0 1-1 2-2
9,6 für ||| 9.6 for ||| 0-0 1-1
9,6 ||| 9.6 ||| 0-0
9,75 mg ( 1,3 ml ||| 9.75 mg ( 1.3 ml ||| 0-0 1-1 2-2 3-3 4-4
9,75 mg ( 1,3 ||| 9.75 mg ( 1.3 ||| 0-0 1-1 2-2 3-3
9,75 mg ( ||| 9.75 mg ( ||| 0-0 1-1 2-2
9,75 mg in 1,3 ||| 9.75 mg in 1.3 ||| 0-0 1-1 2-2 3-3
9,75 mg in ||| 9.75 mg in ||| 0-0 1-1 2-2
9,75 mg ||| 9.75 mg ||| 0-0 1-1
9,75 ||| 9.75 ||| 0-0
9,8 ||| sulphone metabolite ||| 0-0 0-1
9,8 ||| the sulphone metabolite ||| 0-1 0-2
90 % Actraphane 20 : ||| 90 % Actraphane 20 : ||| 0-0 1-1 2-2 3-3 4-4
90 % Actraphane 20 ||| 90 % Actraphane 20 ||| 0-0 1-1 2-2 3-3
90 % Actraphane ||| 90 % Actraphane ||| 0-0 1-1 2-2
90 % Isophan-Insulin . ||| 90 % isophane insulin . ||| 0-0 1-1 2-2 2-3 3-4
90 % Isophan-Insulin ||| 90 % isophane insulin ||| 0-0 1-1 2-2 2-3
90 % der ||| 90 % of the ||| 0-0 1-1 2-2 2-3
90 % ||| 90 % ||| 0-0 1-1
90 % ||| was 90 % ||| 1-0 0-1 1-2
90 6.6 Besondere ||| 6.6 Special ||| 0-0 1-0 2-1
90 6.6 ||| 6.6 ||| 0-0 1-0
90 Anpassung der Dosis Begleiterkrankungen ||| Dosage adjustment Concomitant illness ||| 0-0 1-0 1-1 1-2 2-2 4-2 3-3 4-3
90 Tabletten 98 Tabletten ||| 90 tablets 98 tablets ||| 0-0 1-1 2-2 3-3
90 Tabletten 98 ||| 90 tablets 98 ||| 0-0 1-1 2-2
90 Tabletten ||| 90 tablets ||| 0-0 1-1
90 Tagen ) ||| 90 days ) low- trauma ||| 0-0 1-1 2-2
90 Tagen ) ||| 90 days ) low- ||| 0-0 1-1 2-2
90 Tagen ) ||| 90 days ) ||| 0-0 1-1 2-2
90 Tagen ||| 90 days ||| 0-0 1-1
90 oder 98 Filmtabletten ||| 90 and 98 film-coated tablets ||| 0-0 2-2 3-3 3-4
90 oder 98 ||| 90 and 98 ||| 0-0 2-2
90 oder ||| 90 and ||| 0-0
90 oder ||| 90 or ||| 0-0 1-1
90 oder ||| 90 ||| 0-0
90 und 98 Tabletten . ||| 90 and 98 tablets . ||| 0-0 1-1 2-2 3-3 4-4
90 und 98 Tabletten ||| 90 and 98 tablets ||| 0-0 1-1 2-2 3-3
90 und 98 ||| 90 and 98 ||| 0-0 1-1 2-2
90 und ||| 90 and ||| 0-0 1-1
90 ||| 90 and ||| 0-0
90 ||| 90 ||| 0-0
900 Patienten verglichen . ||| 1,900 patients . ||| 0-0 2-0 1-1 3-2
900 Patienten verglichen . ||| of 1,900 patients . ||| 0-1 2-1 1-2 3-3
900 Patienten verglichen ||| 1,900 patients ||| 0-0 2-0 1-1
900 Patienten verglichen ||| of 1,900 patients ||| 0-1 2-1 1-2
900 ||| 900 ||| 0-0
9000 I.E. ) Lösung ||| 9000 IU ) of solution ||| 0-0 1-1 2-2 1-3 3-4
9000 I.E. ) ||| 9000 IU ) of ||| 0-0 1-1 2-2 1-3
9000 I.E./0,9 ml ||| 9000 IU/ 0.9 ml ||| 0-0 1-1 1-2 2-3
9000 I.E./0,9 ||| 9000 IU/ 0.9 ||| 0-0 1-1 1-2
9000 Internationale Einheiten ( I.E. ||| 9000 international units ( IU ||| 0-0 1-1 2-2 3-3 4-4
9000 Internationale Einheiten ( ||| 9000 international units ( ||| 0-0 1-1 2-2 3-3
9000 Internationale Einheiten ||| 9000 international units ||| 0-0 1-1 2-2
9000 Internationale ||| 9000 international ||| 0-0 1-1
9000 ||| 9000 ||| 0-0
91 ) 663 50 00 ||| 91 ) 663 50 00 ||| 0-0 1-1 2-2 3-3 4-4
91 ) 663 50 ||| 91 ) 663 50 ||| 0-0 1-1 2-2 3-3
91 ) 663 ||| 91 ) 663 ||| 0-0 1-1 2-2
91 ) ||| 91 ) ||| 0-0 1-1
91 Patienten ||| Patients ||| 1-0
91 ||| 91 ||| 0-0
91,6 ± 14,1 ng/ml ||| 91.6 ± 14.1 ng/ ml ||| 1-0 0-1 1-1 2-1 1-2 3-3 3-4
91,6 ± 14,1 ||| 91.6 ± 14.1 ||| 1-0 0-1 1-1 2-1 1-2
911 273 0 ||| 911 273 0 ||| 0-0 1-1 2-2
911 273 ||| 911 273 ||| 0-0 1-1
911 ||| 911 ||| 0-0
92 4.2 Dosierung , ||| 4.2 Posology ||| 0-0 1-0 2-1 3-1
92 4.2 ||| 4.2 ||| 0-0 1-0
92 In einer klinischen Studie ||| In a clinical trial ||| 1-0 0-1 2-1 3-2 4-3
92 In einer klinischen ||| In a clinical ||| 1-0 0-1 2-1 3-2
92 In einer ||| In a ||| 1-0 0-1 2-1
92 ||| 92 ||| 0-0
93 05 06 ||| 93 05 06 ||| 0-0 1-1 2-2
93 05 ||| 93 05 ||| 0-0 1-1
93 Gelegentlich - Diabetische Retinopathie ||| Uncommon - Diabetic retinopathy ||| 0-0 1-0 2-1 3-2 4-3
93 Gelegentlich - Diabetische ||| Uncommon - Diabetic ||| 0-0 1-0 2-1 3-2
93 Gelegentlich - ||| Uncommon - ||| 0-0 1-0 2-1
93 Gelegentlich ||| Uncommon ||| 0-0 1-0
93 ||| 93 ||| 0-0
938 , Durchschnittsalter : ||| 938 ; mean age : ||| 0-0 0-1 2-2 2-3 3-4
938 , Durchschnittsalter ||| 938 ; mean age ||| 0-0 0-1 2-2 2-3
938 , ||| 938 ; ||| 0-0 0-1
938 ||| 938 ; ||| 0-0 0-1
941-0 ||| 941-0 ||| 0-0
95 % ) erhielten ||| 95 % ) were receiving ||| 0-0 1-1 2-2 3-3 3-4
95 % ) ||| 95 % ) ||| 0-0 1-1 2-2
95 % CI : ||| 47.6 % ||| 0-0 2-0 3-0 1-1
95 % CI : ||| 95 % CI : ||| 0-0 1-1 2-2 3-3
95 % CI ] ( ||| 95 % CI ] ( ||| 0-0 1-1 2-2 3-3 4-4
95 % CI ] ||| 95 % CI ] ||| 0-0 1-1 2-2 3-3
95 % CI ||| 95 % CI ||| 0-0 1-1 2-2
95 % ||| 95 % ||| 0-0 1-1
95 % ||| Ninety-five percent ||| 0-0 1-1
95 Die empfohlene Dosierung wird ||| The recommended dosing regimen is ||| 0-0 1-0 2-1 3-2 2-3 3-3 4-4
95 Die empfohlene Dosierung ||| The recommended dosing regimen ||| 0-0 1-0 2-1 3-2 2-3 3-3
95 Die ||| The ||| 0-0 1-0
95 ||| 95 ||| 0-0
95 ||| Ninety-five ||| 0-0
95%-Konfidenzintervall : ||| 95 % CI : ||| 0-0 0-1 0-2 1-3
95%-Konfidenzintervall ||| 95 % CI ||| 0-0 0-1 0-2
96 Die empfohlene ||| 90 The recommended ||| 0-0 1-1 2-2
96 Die ||| 90 The ||| 0-0 1-1
96 ||| 90 ||| 0-0
96 ||| 96 ||| 0-0
97 4.4 Besondere Warnhinweise und ||| 4.4 Special warnings and ||| 0-0 1-0 2-1 3-2 4-3
97 4.4 Besondere Warnhinweise ||| 4.4 Special warnings ||| 0-0 1-0 2-1 3-2
97 4.4 Besondere ||| 4.4 Special ||| 0-0 1-0 2-1
97 4.4 ||| 4.4 ||| 0-0 1-0
98 Filmtabletten . ||| 98 film-coated tablets . ||| 0-0 1-1 1-2 2-3
98 Filmtabletten . ||| and 98 film-coated tablets . ||| 0-1 1-2 1-3 2-4
98 Filmtabletten ||| 98 film-coated tablets ||| 0-0 1-1 1-2
98 Filmtabletten ||| and 98 film-coated tablets ||| 0-1 1-2 1-3
98 TABLETTEN ) ||| 98 TABLETS ONLY ) ||| 0-0 1-1 1-2 2-3
98 TABLETTEN ||| 98 TABLETS ONLY ||| 0-0 1-1 1-2
98 Tabletten . ||| 98 tablets . ||| 0-0 1-1 2-2
98 Tabletten verpackt . ||| or 98 tablets . ||| 2-0 0-1 2-1 1-2 3-3
98 Tabletten verpackt ||| or 98 tablets ||| 2-0 0-1 2-1 1-2
98 Tabletten zur Verfügung . ||| 98 tablets . ||| 0-0 2-0 3-0 1-1 4-2
98 Tabletten zur Verfügung ||| 98 tablets ||| 0-0 2-0 3-0 1-1
98 Tabletten ||| 150/ 003 98 tablets ||| 1-0 1-1 0-2 1-3
98 Tabletten ||| 150/ 006 98 tablets ||| 1-0 1-1 0-2 1-3
98 Tabletten ||| 150/ 015 98 tablets ||| 1-0 0-1 0-2 1-3
98 Tabletten ||| 98 tablets ||| 0-0 1-1
98 oder 500 Filmtabletten ||| 98 and 500 film-coated tablets ||| 0-0 2-2 3-3 3-4
98 oder 500 ||| 98 and 500 ||| 0-0 2-2
98 oder ||| 98 and ||| 0-0
98 oder ||| 98 ||| 0-0
98 x 1 Tabletten . ||| 98 x 1 tablets . ||| 0-0 1-1 2-2 3-3 4-4
98 x 1 Tabletten ||| 98 x 1 tablets ||| 0-0 1-1 2-2 3-3
98 x 1 ||| 98 x 1 ||| 0-0 1-1 2-2
98 x ||| 98 x ||| 0-0 1-1
98 ||| , ||| 0-0
98 ||| 015 98 ||| 0-0 0-1
98 ||| 98 and ||| 0-0
98 ||| 98 ||| 0-0
98 ||| and 98 ||| 0-1
99 % ) . ||| 99 % ) . ||| 0-0 1-1 2-2 3-3
99 % ) ||| 99 % ) ||| 0-0 1-1 2-2
99 % ||| 99 % ||| 0-0 1-1
99 ||| 99 ||| 0-0
99 ||| of ||| 0-0
99,9 % ) und ||| 99.9 % ) and ||| 0-0 1-1 2-2 3-3
99,9 % ) ||| 99.9 % ) ||| 0-0 1-1 2-2
99,9 % ||| 99.9 % ||| 0-0 1-1
99,9 ||| 99.9 ||| 0-0
: + 31 ( 0 ||| : + 31 ( 0 ||| 0-0 1-1 2-2 3-3 4-4
: + 31 ( ||| : + 31 ( ||| 0-0 1-1 2-2 3-3
: + 31 34 857 ||| : + 31 34 857 ||| 0-0 1-1 2-2 3-3 4-4
: + 31 34 ||| : + 31 34 ||| 0-0 1-1 2-2 3-3
: + 31 ||| : + 31 ||| 0-0 1-1 2-2
: + 32 2 352 ||| : + 32 2 352 ||| 0-0 1-1 2-2 3-3 4-4
: + 32 2 ||| : + 32 2 ||| 0-0 1-1 2-2 3-3
: + 32 ||| : + 32 ||| 0-0 1-1 2-2
: + 33 ( 0)1 ||| : + 33 ( 0)1 ||| 0-0 1-1 2-2 3-3 4-4
: + 33 ( 0)810 ||| : + 33 ( 0)810 ||| 0-0 1-1 2-2 3-3 4-4
: + 33 ( ||| : + 33 ( ||| 0-0 1-1 2-2 3-3
: + 33 ||| : + 33 ||| 0-0 1-1 2-2
: + 34 ( 91 ||| : + 34 ( 91 ||| 0-0 1-1 2-2 3-3 4-4
: + 34 ( ||| : + 34 ( ||| 0-0 1-1 2-2 3-3
: + 34 ||| : + 34 ||| 0-0 1-1 2-2
: + 351 21 412 ||| : + 351 21 412 ||| 0-0 1-1 2-2 3-3 4-4
: + 351 21 ||| : + 351 21 ||| 0-0 1-1 2-2 3-3
: + 351 ||| : + 351 ||| 0-0 1-1 2-2
: + 353 ( 1 ||| : + 353 ( 1 ||| 0-0 1-1 2-2 3-3 4-4
: + 353 ( ||| : + 353 ( ||| 0-0 1-1 2-2 3-3
: + 353 ||| : + 353 ||| 0-0 1-1 2-2
: + 354 535 7000 ||| : + 354 535 7000 ||| 0-0 1-1 2-2 3-3 4-4
: + 354 535 ||| : + 354 535 ||| 0-0 1-1 2-2 3-3
: + 354 ||| : + 354 ||| 0-0 1-1 2-2
: + 358 ( 0)9 ||| : + 358 ( 0)9 ||| 0-0 1-1 2-2 3-3 4-4
: + 358 ( ||| : + 358 ( ||| 0-0 1-1 2-2 3-3
: + 358 9 251 ||| : + 358 9 251 ||| 0-0 1-1 2-2 3-3 4-4
: + 358 9 ||| : + 358 9 ||| 0-0 1-1 2-2 3-3
: + 358 ||| : + 358 ||| 0-0 1-1 2-2
: + 36(0 ) 20 ||| : + 36(0 ) 20 ||| 0-0 1-1 2-2 3-3 4-4
: + 36(0 ) ||| : + 36(0 ) ||| 0-0 1-1 2-2 3-3
: + 36(0 ||| : + 36(0 ||| 0-0 1-1 2-2
: + 39 06 5026 ||| : + 39 06 5026 ||| 0-0 1-1 2-2 3-3 4-4
: + 39 06 ||| : + 39 06 ||| 0-0 1-1 2-2 3-3
: + 39 ||| : + 39 ||| 0-0 1-1 2-2
: + 40 ( 0)21 ||| : + 40 ( 0)21 ||| 0-0 1-1 2-2 3-3 4-4
: + 40 ( ||| : + 40 ( ||| 0-0 1-1 2-2 3-3
: + 40 ||| : + 40 ||| 0-0 1-1 2-2
: + 43 ( 1 ||| : + 43 ( 1 ||| 0-0 1-1 2-2 3-3 4-4
: + 43 ( ||| : + 43 ( ||| 0-0 1-1 2-2 3-3
: + 43 1 60 ||| : + 43 1 60 ||| 0-0 1-1 2-2 3-3 4-4
: + 43 1 ||| : + 43 1 ||| 0-0 1-1 2-2 3-3
: + 43 ||| : + 43 ||| 0-0 1-1 2-2
: + 43-(0)800 29 5193 ||| : + 43-(0)800 29 5193 ||| 0-0 1-1 2-2 3-3 4-4
: + 43-(0)800 29 ||| : + 43-(0)800 29 ||| 0-0 1-1 2-2 3-3
: + 43-(0)800 ||| : + 43-(0)800 ||| 0-0 1-1 2-2
: + 44 ( 0)1628 ||| : + 44 ( 0)1628 ||| 0-0 1-1 2-2 3-3 4-4
: + 44 ( 0)20 ||| : + 44 ( 0)20 ||| 0-0 1-1 2-2 3-3 4-4
: + 44 ( 0800 ||| : + 44 ( 0800 ||| 0-0 1-1 2-2 3-3 4-4
: + 44 ( ||| : + 44 ( ||| 0-0 1-1 2-2 3-3
: + 44 ||| : + 44 ||| 0-0 1-1 2-2
: + 45 45 93 ||| : + 45 45 93 ||| 0-0 1-1 2-2 3-3 4-4
: + 45 45 ||| : + 45 45 ||| 0-0 1-1 2-2 3-3
: + 45 ||| : + 45 ||| 0-0 1-1 2-2
: + 46 8 704 ||| : + 46 8 704 ||| 0-0 1-1 2-2 3-3 4-4
: + 46 8 ||| : + 46 8 ||| 0-0 1-1 2-2 3-3
: + 46 ||| : + 46 ||| 0-0 1-1 2-2
: + 47 67 55 ||| : + 47 67 55 ||| 0-0 1-1 2-2 3-3 4-4
: + 47 67 ||| : + 47 67 ||| 0-0 1-1 2-2 3-3
: + 47 ||| : + 47 ||| 0-0 1-1 2-2
: + ||| : + ||| 0-0 1-1
: +33 ( 0)1 46 ||| : +33 ( 0)1 46 ||| 0-0 1-1 2-2 3-3 4-4
: +33 ( 0)1 ||| : +33 ( 0)1 ||| 0-0 1-1 2-2 3-3
: +33 ( ||| : +33 ( ||| 0-0 1-1 2-2
: +33 ||| : +33 ||| 0-0 1-1
: +353 1 260 12 ||| : +353 1 260 12 ||| 0-0 1-1 2-2 3-3 4-4
: +353 1 260 ||| : +353 1 260 ||| 0-0 1-1 2-2 3-3
: +353 1 ||| : +353 1 ||| 0-0 1-1 2-2
: +353 ||| : +353 ||| 0-0 1-1
: +358 9 61 33 ||| : +358 9 61 33 ||| 0-0 1-1 2-2 3-3 4-4
: +358 9 61 ||| : +358 9 61 ||| 0-0 1-1 2-2 3-3
: +358 9 ||| : +358 9 ||| 0-0 1-1 2-2
: +358 ||| : +358 ||| 0-0 1-1
: +36 1 457 65 ||| : +36 1 457 65 ||| 0-0 1-1 2-2 3-3 4-4
: +36 1 457 ||| : +36 1 457 ||| 0-0 1-1 2-2 3-3
: +36 1 ||| : +36 1 ||| 0-0 1-1 2-2
: +36 ||| : +36 ||| 0-0 1-1
: +371 7364000 ||| : +371 7364000 ||| 0-0 1-1 2-2
: +371 ||| : +371 ||| 0-0 1-1
: +3726441100 ||| : +3726441100 ||| 0-0 1-1
: +386 ( 0)1 580 ||| : +386 ( 0)1 580 ||| 0-0 1-1 2-2 3-3 4-4
: +386 ( 0)1 ||| : +386 ( 0)1 ||| 0-0 1-1 2-2 3-3
: +386 ( ||| : +386 ( ||| 0-0 1-1 2-2
: +386 ||| : +386 ||| 0-0 1-1
: +43 1 86 6570 ||| : +43 1 86 6570 ||| 0-0 1-1 2-2 3-3 4-4
: +43 1 86 ||| : +43 1 86 ||| 0-0 1-1 2-2 3-3
: +43 1 ||| : +43 1 ||| 0-0 1-1 2-2
: +43 ||| : +43 ||| 0-0 1-1
: +44 ( 0)20 3116 ||| : +44 ( 0)20 3116 ||| 0-0 1-1 2-2 3-3 4-4
: +44 ( 0)20 ||| : +44 ( 0)20 ||| 0-0 1-1 2-2 3-3
: +44 ( ||| : +44 ( ||| 0-0 1-1 2-2
: +44 ||| : +44 ||| 0-0 1-1
: +45 39 16 84 ||| : +45 39 16 84 ||| 0-0 1-1 2-2 3-3 4-4
: +45 39 16 ||| : +45 39 16 ||| 0-0 1-1 2-2 3-3
: +45 39 ||| : +45 39 ||| 0-0 1-1 2-2
: +45 ||| : +45 ||| 0-0 1-1
: +46 8 732 32 ||| : +46 8 732 32 ||| 0-0 1-1 2-2 3-3 4-4
: +46 8 732 ||| : +46 8 732 ||| 0-0 1-1 2-2 3-3
: +46 8 ||| : +46 8 ||| 0-0 1-1 2-2
: +46 ||| : +46 ||| 0-0 1-1
: +47 23 05 20 ||| : +47 23 05 20 ||| 0-0 1-1 2-2 3-3 4-4
: +47 23 05 ||| : +47 23 05 ||| 0-0 1-1 2-2 3-3
: +47 23 ||| : +47 23 ||| 0-0 1-1 2-2
: +47 ||| : +47 ||| 0-0 1-1
: +49 911 273 0 ||| : +49 911 273 0 ||| 0-0 1-1 2-2 3-3 4-4
: +49 911 273 ||| : +49 911 273 ||| 0-0 1-1 2-2 3-3
: +49 911 ||| : +49 911 ||| 0-0 1-1 2-2
: +49 ||| : +49 ||| 0-0 1-1
: 10 kg Körpergewicht 120 ||| : 10 kg BW 120 ||| 0-0 1-1 2-2 3-3 4-4
: 10 kg Körpergewicht ||| : 10 kg BW ||| 0-0 1-1 2-2 3-3
: 10 kg ||| : 10 kg ||| 0-0 1-1 2-2
: 10 ||| : 10 ||| 0-0 1-1
: 22 kg Körpergewicht 210 ||| : 22 kg BW 210 ||| 0-0 1-1 2-2 3-3 4-4
: 22 kg Körpergewicht ||| : 22 kg BW ||| 0-0 1-1 2-2 3-3
: 22 kg ||| : 22 kg ||| 0-0 1-1 2-2
: 22 ||| : 22 ||| 0-0 1-1
: 40 kg Körpergewicht ||| : 40 kg BW ||| 0-0 1-1 2-2 3-3
: 40 kg ||| : 40 kg ||| 0-0 1-1 2-2
: 40 ||| : 40 ||| 0-0 1-1
: Abgeschlagenheit Psychiatrische Erkrankungen Häufig ||| : fatigue Psychiatric disorders Common ||| 0-0 1-1 1-2 2-2 3-3 4-4
: Abgeschlagenheit Psychiatrische Erkrankungen ||| : fatigue Psychiatric disorders ||| 0-0 1-1 1-2 2-2 3-3
: Abgeschlagenheit Psychiatrische ||| : fatigue Psychiatric ||| 0-0 1-1 1-2 2-2
: Abgeschlagenheit* ||| : fatigue* ||| 0-0 1-1
: Anämie bei ||| : anaemia in ||| 0-0 1-1 2-2
: Anämie ||| : anaemia ||| 0-0 1-1
: Ausschlag . ||| : rash . ||| 0-0 1-1 2-2
: Ausschlag ||| : rash ||| 0-0 1-1
: Behandlung der ||| : treatment of ||| 0-0 1-1 2-2
: Behandlung ||| : treatment ||| 0-0 1-1
: Calcitonin , Raloxifen ||| : calcitonin , raloxifene ||| 0-0 1-1 2-2 3-3
: Calcitonin , ||| : calcitonin , ||| 0-0 1-1 2-2
: Calcitonin ||| : calcitonin ||| 0-0 1-1
: Dehydrierung , Hydroxylierung ||| : dehydrogenation , hydroxylation , ||| 0-0 1-1 2-2 3-3 2-4
: Dehydrierung ||| : dehydrogenation ||| 0-0 1-1
: Dysgeusie , ||| : dysgeusia , ||| 0-0 1-1 2-2
: Dysgeusie , Ösophagitis , ||| : dysgeusia , oesophagitis , ||| 0-0 1-1 2-2 3-3 4-4
: Dysgeusie , Ösophagitis ||| : dysgeusia , oesophagitis ||| 0-0 1-1 2-2 3-3
: Dysgeusie ||| : dysgeusia ||| 0-0 1-1
: Dyspepsie , Erbrechen , ||| : dyspepsia , vomiting , ||| 0-0 1-1 2-2 3-3 4-4
: Dyspepsie , Erbrechen ||| : dyspepsia , vomiting ||| 0-0 1-1 2-2 3-3
: Dyspepsie , ||| : dyspepsia , ||| 0-0 1-1 2-2
: Dyspepsie ||| : dyspepsia ||| 0-0 1-1
: Heptakis-O-(4-sulfobutyl)cyclomaltoheptaose , Heptanatriumsalz ( ||| sulfobutylether -cyclodextrin ( ||| 0-0 1-0 3-0 1-1 2-1 4-2
: Heptakis-O-(4-sulfobutyl)cyclomaltoheptaose , Heptanatriumsalz ||| contains sulfobutylether b-cyclodextrin , ||| 0-1 1-1 3-2 2-3
: Heptakis-O-(4-sulfobutyl)cyclomaltoheptaose , Heptanatriumsalz ||| sulfobutylether -cyclodextrin ||| 0-0 1-0 3-0 1-1 2-1
: Heptakis-O-(4-sulfobutyl)cyclomaltoheptaose , Heptanatriumsalz ||| sulfobutylether b-cyclodextrin , ||| 0-0 1-0 3-1 2-2
: Heptakis-O-(4-sulfobutyl)cyclomaltoheptaose ||| contains sulfobutylether ||| 0-1 1-1
: Heptakis-O-(4-sulfobutyl)cyclomaltoheptaose ||| sulfobutylether ||| 0-0 1-0
: Herzinfarkt oder Schlaganfall innerhalb ||| : myocardial infarction or stroke ||| 0-0 1-1 1-2 4-2 2-3 3-4
: Hyperglykämie , in einigen ||| : hyperglycaemia , in some ||| 0-0 1-1 2-2 3-3 4-4
: Hyperglykämie , in ||| : hyperglycaemia , in ||| 0-0 1-1 2-2 3-3
: Hyperglykämie , ||| : hyperglycaemia , ||| 0-0 1-1 2-2
: Hyperglykämie ||| : hyperglycaemia ||| 0-0 1-1
: Im Kühlschrank lagern ||| : store in a refrigerator ||| 0-0 1-1 2-2 3-3 2-4 3-4
: Im ||| : store ||| 0-0 1-1
: In klinischen Studien ||| : in clinical trials ||| 0-0 1-1 1-2 2-2 3-3
: In klinischen ||| : in clinical ||| 0-0 1-1 1-2 2-2
: Lactose-Monohydrat , Maisstärke ||| lactose monohydrate , maize starch ||| 1-0 0-1 1-1 2-2 3-3 3-4
: Lactose-Monohydrat , ||| lactose monohydrate , ||| 1-0 0-1 1-1 2-2
: Lactose-Monohydrat ||| lactose monohydrate ||| 1-0 0-1 1-1
: Nach ||| : after ||| 0-0 1-1
: Osteoporose ( eine Krankheit ||| : osteoporosis ( a disease ||| 0-0 1-1 2-2 3-3 4-4
: Osteoporose ( eine ||| : osteoporosis ( a ||| 0-0 1-1 2-2 3-3
: Osteoporose ( eine ||| diseases : osteoporosis ( a ||| 0-1 1-2 2-3 3-4
: Osteoporose ( ||| : osteoporosis ( ||| 0-0 1-1 2-2
: Osteoporose ( ||| diseases : osteoporosis ( ||| 0-1 1-2 2-3
: Osteoporose ||| : osteoporosis ||| 0-0 1-1
: Osteoporose ||| diseases : osteoporosis ||| 0-1 1-2
: Patienten mit ||| : patients with ||| 0-0 1-1 2-2
: Patienten ||| : patients ||| 0-0 1-1
: Psychiatrische Erkrankungen : ||| Psychiatric disorder : psychotic disorders ||| 1-0 2-1 0-2 3-2 2-3 2-4
: Schizophrenie ||| : schizophrenia ||| 0-0 1-1
: Schlaganfall ||| stroke ||| 0-0 1-0
: Schläfrigkeit , Schwindel , ||| : somnolence , dizziness , ||| 0-0 1-1 2-2 3-3 4-4
: Schläfrigkeit , Schwindel ||| : somnolence , dizziness ||| 0-0 1-1 2-2 3-3
: Schläfrigkeit , ||| : somnolence , ||| 0-0 1-1 2-2
: Schläfrigkeit ||| : somnolence ||| 0-0 1-1
: Schulungsbroschüre ||| : Educational leaflet ||| 0-0 1-1 1-2
: Tachykardie* ||| : tachycardia* ||| 0-0 1-1
: bei Erhalt neuer Informationen ||| new information is received ||| 3-0 4-1 4-2
: bei Erhalt neuer Informationen ||| new information is ||| 3-0 4-1 4-2
: bei Erhalt neuer ||| new ||| 3-0
: bis zu 36 ||| : up to 36 ||| 0-0 1-1 2-1 2-2 3-3
: bis zu ||| : up to ||| 0-0 1-1 2-1 2-2
: die Serumspiegel bleiben gleich ||| : the levels remain the ||| 0-0 1-1 2-2 3-3 4-3 3-4
: die Serumspiegel ||| : the levels ||| 0-0 1-1 2-2
: die ||| : the ||| 0-0 1-1
: ein Maximalvolumen von ||| : a maximum volume of ||| 0-0 1-1 2-2 2-3 3-4
: ein Maximalvolumen ||| : a maximum volume ||| 0-0 1-1 2-2 2-3
: ein ||| : a ||| 0-0 1-1
: extrapyramidale Störung , Akathisie ||| : extrapyramidal disorder , akathisia ||| 0-0 1-1 2-2 3-3 4-4
: extrapyramidale Störung , ||| : extrapyramidal disorder , ||| 0-0 1-1 2-2 3-3
: extrapyramidale Störung ||| : extrapyramidal disorder ||| 0-0 1-1 2-2
: extrapyramidale ||| : extrapyramidal ||| 0-0 1-1
: in klinischen Studien , ||| : in clinical trials ||| 0-0 1-1 2-2 3-3
: in klinischen Studien ||| : in clinical trials ||| 0-0 1-1 2-2 3-3
: in klinischen ||| : in clinical ||| 0-0 1-1 2-2
: in ||| : in ||| 0-0 1-1
: in Übereinstimmung mit dem ||| : in line with the ||| 0-0 1-1 2-2 3-3 4-4
: in Übereinstimmung mit ||| : in line with ||| 0-0 1-1 2-2 3-3
: in Übereinstimmung ||| : in line ||| 0-0 1-1 2-2
: lösliches Insulin 10 % ||| : soluble insulin 10 % ||| 0-0 1-1 2-2 3-3 4-4
: lösliches Insulin 10 ||| : soluble insulin 10 ||| 0-0 1-1 2-2 3-3
: lösliches Insulin 20 % ||| : soluble insulin 20 % ||| 0-0 1-1 2-2 3-3 4-4
: lösliches Insulin 20 ||| : soluble insulin 20 ||| 0-0 1-1 2-2 3-3
: lösliches Insulin 30 % ||| : soluble insulin 30 % ||| 0-0 1-1 2-2 3-3 4-4
: lösliches Insulin 30 ||| : soluble insulin 30 ||| 0-0 1-1 2-2 3-3
: lösliches Insulin 40 % ||| : soluble insulin 40 % ||| 0-0 1-1 2-2 3-3 4-4
: lösliches Insulin 40 ||| : soluble insulin 40 ||| 0-0 1-1 2-2 3-3
: lösliches Insulin 50 % ||| : soluble insulin 50 % ||| 0-0 1-1 2-2 3-3 4-4
: lösliches Insulin 50 ||| : soluble insulin 50 ||| 0-0 1-1 2-2 3-3
: lösliches Insulin ||| : soluble insulin ||| 0-0 1-1 2-2
: lösliches ||| : soluble ||| 0-0 1-1
: orale ||| : oral ||| 0-0 1-1
: orthostatische Hypotonie* , ||| : orthostatic hypotension* , ||| 0-0 1-1 2-2 3-3
: orthostatische Hypotonie* ||| : orthostatic hypotension* ||| 0-0 1-1 2-2
: orthostatische ||| : orthostatic ||| 0-0 1-1
: verschwommenes Sehen ||| : blurred vision ||| 0-0 1-1 2-2
: verschwommenes ||| : blurred ||| 0-0 1-1
: wenn Ihr Hund ||| : if your dog has ||| 0-0 1-1 2-2 3-3
: wenn Ihr Hund ||| : if your dog ||| 0-0 1-1 2-2 3-3
: wenn Ihr ||| : if your ||| 0-0 1-1 2-2
: wenn ||| : if ||| 0-0 1-1
: ||| . ||| 0-0
: ||| : rapid biphasic ||| 0-0
: ||| : rapid ||| 0-0
: ||| : ||| 0-0
: ||| commonly ||| 0-0
: ||| diseases : ||| 0-1
: ||| process : rapid biphasic ||| 0-1
: ||| process : rapid ||| 0-1
: ||| process : ||| 0-1
: ||| stearate . ||| 0-0 0-1
: Übelkeit ||| : nausea ||| 0-0 1-1
; 0,5 ||| ; 0.5 ||| 0-0 1-1
; 1,0 ||| ; 1.0 ||| 0-0 1-1
; 18,93 ] ( ||| , 18.93 ] ( ||| 0-0 1-1 0-2 2-2 3-3
; 18,93 ] ||| , 18.93 ] ||| 0-0 1-1 0-2 2-2
; 19 ||| ; 19 ||| 0-0 1-1
; 25,9 ] ( ||| , 25.9 ] ( ||| 0-1 1-1 2-2 3-3
; 25,9 ] ( ||| 25.9 ] ( ||| 0-0 1-0 2-1 3-2
; 25,9 ] ||| , 25.9 ] ||| 0-1 1-1 2-2
; 25,9 ] ||| 25.9 ] ||| 0-0 1-0 2-1
; 25,9 ||| , 25.9 ||| 0-1 1-1
; 25,9 ||| 25.9 ||| 0-0 1-0
; 34 % ) ||| ; 34 % ) ||| 0-0 1-1 2-2 3-3
; 34 % ||| ; 34 % ||| 0-0 1-1 2-2
; 34 ||| ; 34 ||| 0-0 1-1
; 41 % ) ||| ; 41 % ) ||| 0-0 1-1 2-2 3-3
; 41 % ||| ; 41 % ||| 0-0 1-1 2-2
; 41 ||| ; 41 ||| 0-0 1-1
; 55,3 ] ( ||| , 55.3 ] ( ||| 0-0 1-1 0-2 2-2 3-3
; 55,3 ] ||| , 55.3 ] ||| 0-0 1-1 0-2 2-2
; 86)** ||| 13 , 36)* ||| 1-0 0-1 1-1 1-2
; 95 % CI : ||| ; 95 % CI : ||| 0-0 1-1 2-2 3-3 4-4
; 95 % CI ||| ; 95 % CI ||| 0-0 1-1 2-2 3-3
; 95 % ||| ; 95 % ||| 0-0 1-1 2-2
; 95 ||| ; 95 ||| 0-0 1-1
; 95%-Konfidenzintervall : ||| % CI : ||| 1-0 0-1 1-1 2-2
; 95%-Konfidenzintervall ||| % CI ||| 1-0 0-1 1-1
; ATC-Code : ||| ; ATC code : ||| 0-0 1-1 1-2 2-3
; ATC-Code ||| ; ATC code ||| 0-0 1-1 1-2
; Ctrough = ||| ; Ctrough = ||| 0-0 1-1 2-2
; Ctrough ||| ; Ctrough ||| 0-0 1-1
; Leukopenie ||| ; leukopenia ||| 0-0 1-1
; Leukopenie ||| dependent ; leukopenia ||| 0-1 1-2
; Leukopenie ||| dose dependent ; leukopenia ||| 0-2 1-3
; Suizidversuch , ||| ; suicide attempt , ||| 0-0 0-1 1-1 1-2 2-3
; Suizidversuch ||| ; suicide attempt ||| 0-0 0-1 1-1 1-2
; andere Bisphosphonate waren ausgeschlossen ||| ; but excluded other bisphosphonates ||| 0-0 2-1 4-2 1-3 2-4
; bei Hunden wurde ||| dogs ||| 2-0
; bei Hunden wurde ||| in dogs ||| 2-1
; bei Hunden ||| dogs ||| 2-0
; bei Hunden ||| in dogs ||| 2-1
; daher ||| ; therefore , ||| 0-0 1-1
; daher ||| ; therefore ||| 0-0 1-1
; das ||| ; the large ||| 0-0 1-1 0-2
; der ||| ; the ||| 0-0 1-1
; deshalb ist das Gewicht ||| , therefore weight ||| 0-0 1-1 2-1 3-2 4-2
; deshalb ist ||| , therefore ||| 0-0 1-1 2-1
; die durchschnittliche Dauer des ||| ; the average duration of ||| 0-0 1-1 2-2 3-3 4-4
; die durchschnittliche Dauer ||| ; the average duration ||| 0-0 1-1 2-2 3-3
; die durchschnittliche ||| ; the average ||| 0-0 1-1 2-2
; die systemische Exposition war ||| ; systemic exposure was generally ||| 0-0 2-1 3-2 4-3
; die systemische Exposition war ||| ; systemic exposure was ||| 0-0 2-1 3-2 4-3
; die systemische Exposition ||| ; systemic exposure ||| 0-0 2-1 3-2
; die systemische ||| ; systemic ||| 0-0 2-1
; die ||| ; the ||| 0-0 1-1
; die ||| ; ||| 0-0
; dies ist besonders wichtig ||| ; this is especially important ||| 0-0 1-1 2-2 3-3 4-4
; dies ist besonders ||| ; this is especially ||| 0-0 1-1 2-2 3-3
; dies ist ||| ; this is ||| 0-0 1-1 2-2
; dies ||| ; this ||| 0-0 1-1
; insbesondere bei Patienten ||| , especially in patients ||| 0-0 1-1 2-2 3-3
; insbesondere bei ||| , especially in ||| 0-0 1-1 2-2
; insbesondere ||| , especially ||| 0-0 1-1
; keiner ||| ; none ||| 0-0 1-1
; ||| , and ||| 0-0
; ||| , ||| 0-0
; ||| ; ||| 0-0
; ||| and ||| 0-0
; ||| dependent ; ||| 0-1
; ||| dose dependent ; ||| 0-2
; ||| yellowing of ||| 0-0
; ||| yellowing ||| 0-0
< 1/10 ||| common ||| 0-0 1-0
< ||| in patients ||| 0-1
< ||| patients ||| 0-0
= 196 ||| = ||| 0-0
= 196 ± 28,1 ||| = 196 ± 28.1 ||| 0-0 2-1 2-2 3-2 2-3
= 225 ) oder in ||| = 225 ) , or ||| 0-0 1-1 2-2 3-4
= 225 ) oder ||| = 225 ) , or ||| 0-0 1-1 2-2 3-4
= 225 ) ||| = 225 ) , ||| 0-0 1-1 2-2
= 225 ) ||| = 225 ) ||| 0-0 1-1 2-2
= 225 ||| = 225 ||| 0-0 1-1
= 229 ) . ||| = 229 ) . ||| 0-0 1-1 2-2 3-3
= 229 ) ||| = 229 ) ||| 0-0 1-1 2-2
= 229 ||| = 229 ||| 0-0 1-1
= 30 ) . ||| = 30 ) . ||| 0-0 1-1 2-2 3-3
= 30 ) ||| = 30 ) ||| 0-0 1-1 2-2
= 30 ||| = 30 ||| 0-0 1-1
= 50 80 ||| = 50 80 ||| 0-0 1-1 2-2
= 50 80 ||| Clcr = 50 80 ||| 0-1 1-2 2-3
= 50 ||| = 50 ||| 0-0 1-1
= 50 ||| Clcr = 50 ||| 0-1 1-2
= 91,6 ± 14,1 ||| = 91.6 ± 14.1 ||| 0-0 2-1 1-2 2-2 3-2 2-3
= ||| = ||| 0-0
= ||| Clcr = ||| 0-1
> 0,5 % ) ||| > 0.5 % ) of ||| 0-0 1-1 2-2 3-3
> 0,5 % ) ||| > 0.5 % ) ||| 0-0 1-1 2-2 3-3
> 0,5 % ||| > 0.5 % ||| 0-0 1-1 2-2
> 0,5 ||| > 0.5 ||| 0-0 1-1
> 1,5 x ||| > 1.5 x ||| 0-0 1-1 2-2
> 1,5 ||| > 1.5 ||| 0-0 1-1
> 10 x ULN ||| ALT > 10 x ULN ||| 0-0 0-1 1-2 2-3 3-4
> 10 x ||| ALT > 10 x ||| 0-0 0-1 1-2 2-3
> 10 ||| ALT > 10 ||| 0-0 0-1 1-2
> 100 x ||| > 100 x ||| 0-0 1-1 2-2
> 100 ||| > 100 ||| 0-0 1-1
> 13 g/dl , ||| > 13 g/ dl ; ||| 0-0 1-1 2-2 2-3 0-4
> 13 g/dl nicht angewendet ||| haemoglobin > 13 g/ dl ||| 1-0 0-1 3-1 1-2 4-2 2-3 2-4
> 13 g/dl ||| > 13 g/ dl ; ||| 0-0 1-1 2-2 2-3 0-4
> 27 ||| > 27 ||| 0-0 1-1
> 5 x ULN oder ||| > 5 x ULN or ||| 0-0 1-1 2-2 3-3 4-4
> 5 x ULN ||| > 5 x ULN ||| 0-0 1-1 2-2 3-3
> 5 x ||| > 5 x ||| 0-0 1-1 2-2
> 5 ||| > 5 ||| 0-0 1-1
> 99 % ) . ||| > 99 % ) . ||| 0-0 1-1 2-2 3-3 4-4
> 99 % ) ||| > 99 % ) ||| 0-0 1-1 2-2 3-3
> 99 % ||| > 99 % ||| 0-0 1-1 2-2
> 99 ||| > 99 ||| 0-0 1-1
> First-Line-Therapie 20,6 [ 15,6 ||| 20.6 [ 15.6 , ||| 0-0 1-0 2-0 1-1 3-1 2-2 4-2
> First-Line-Therapie 20,6 [ 15,6 ||| 20.6 [ 15.6 ||| 0-0 1-0 2-0 1-1 3-1 2-2 4-2
> First-Line-Therapie 20,9 [ 15,7 ||| 20.9 [ 15.7 , ||| 0-0 1-0 2-0 1-1 3-1 4-2
> First-Line-Therapie 20,9 [ 15,7 ||| 20.9 [ 15.7 ||| 0-0 1-0 2-0 1-1 3-1 4-2
> First-Line-Therapie 20,9 [ ||| 20.9 [ ||| 0-0 1-0 2-0 1-1 3-1
> First-Line-Therapie 26,5 [ ||| 26.5 [ 18.98 , ||| 0-0 1-0 2-0 1-1 3-1 2-2
> First-Line-Therapie 26,5 [ ||| 26.5 [ 18.98 ||| 0-0 1-0 2-0 1-1 3-1 2-2
> First-Line-Therapie 56,4 [ ||| 56.4 [ 45.1 , ||| 0-0 1-0 2-0 1-1 3-1 2-2
> First-Line-Therapie 56,4 [ ||| 56.4 [ 45.1 ||| 0-0 1-0 2-0 1-1 3-1 2-2
> First-Line-Therapie ||| > 1st-line ||| 0-0 1-1
> ||| > ||| 0-0
> ||| ALT > ||| 0-0 0-1
? 3. ||| 3. ||| 0-0 1-0
? er Die ||| ? er Die ||| 0-0 1-1 2-2
? er ||| ? er ||| 0-0 1-1
? ||| ? ||| 0-0
? ||| for 2. ||| 0-0 0-1
A " ||| A " ||| 0-0 1-1
A " über ||| A " over ||| 0-0 1-1 2-2
A ||| A ||| 0-0
A-007 " und " 5 ||| A-007 " and " 5 ||| 0-0 1-1 2-2 3-3 4-4
A-007 " und " ||| A-007 " and " ||| 0-0 1-1 2-2 3-3
A-007 " und ||| A-007 " and ||| 0-0 1-1 2-2
A-007 " ||| A-007 " ||| 0-0 1-1
A-007 und 5 auf ||| A-007 and 5 on ||| 0-0 1-1 2-2 3-3
A-007 und 5 ||| A-007 and 5 ||| 0-0 1-1 2-2
A-007 und ||| A-007 and ||| 0-0 1-1
A-007 ||| A-007 ||| 0-0
A-008 " und " 10 ||| A-008 " and " 10 ||| 0-0 1-1 2-2 3-3 4-4
A-008 " und " ||| A-008 " and " ||| 0-0 1-1 2-2 3-3
A-008 " und ||| A-008 " and ||| 0-0 1-1 2-2
A-008 " ||| A-008 " ||| 0-0 1-1
A-008 und 10 auf ||| A-008 and 10 on ||| 0-0 1-1 2-2 3-3
A-008 und 10 ||| A-008 and 10 ||| 0-0 1-1 2-2
A-008 und ||| A-008 and ||| 0-0 1-1
A-008 ||| A-008 ||| 0-0
A-009 " und " 15 ||| A-009 " and " 15 ||| 0-0 1-1 2-2 3-3 4-4
A-009 " und " ||| A-009 " and " ||| 0-0 1-1 2-2 3-3
A-009 " und ||| A-009 " and ||| 0-0 1-1 2-2
A-009 " ||| A-009 " ||| 0-0 1-1
A-009 und 15 auf ||| A-009 and 15 on ||| 0-0 1-1 2-2 3-3
A-009 und 15 ||| A-009 and 15 ||| 0-0 1-1 2-2
A-009 und ||| A-009 and ||| 0-0 1-1
A-009 ||| A-009 ||| 0-0
A-011 " und " 30 ||| A-011 " and " 30 ||| 0-0 1-1 2-2 3-3 4-4
A-011 " und " ||| A-011 " and " ||| 0-0 1-1 2-2 3-3
A-011 " und ||| A-011 " and ||| 0-0 1-1 2-2
A-011 " ||| A-011 " ||| 0-0 1-1
A-011 und 30 auf ||| A-011 and 30 on ||| 0-0 1-1 2-2 3-3
A-011 und 30 ||| A-011 and 30 ||| 0-0 1-1 2-2
A-011 und ||| A-011 and ||| 0-0 1-1
A-011 ||| A-011 ||| 0-0
A. INHABER DER HERSTELLUNGSERLAUBNIS ||| A MANUFACTURING AUTHORISATION ||| 0-0 1-1 2-1 3-2
A. INHABER DER ||| A MANUFACTURING ||| 0-0 1-1 2-1
A. ||| A ||| 0-0
A/S Novo Allé DK-2880 ||| A/ S Novo Allé DK-2880 ||| 0-0 0-1 1-2 2-3 3-4
A/S Novo Allé ||| A/ S Novo Allé ||| 0-0 0-1 1-2 2-3
A/S Novo ||| A/ S Novo ||| 0-0 0-1 1-2
A/S Tlf : +45 ||| A/ S Tlf : +45 ||| 0-0 0-1 1-2 2-3 3-4
A/S Tlf : ||| A/ S Tlf : ||| 0-0 0-1 1-2 2-3
A/S Tlf ||| A/ S Tlf ||| 0-0 0-1 1-2
A/S ||| A/ S ||| 0-0 0-1
AB Puh/Tel : + ||| AB Puh/ Tel : + ||| 0-0 1-1 1-2 2-3 3-4
AB Puh/Tel : ||| AB Puh/ Tel : ||| 0-0 1-1 1-2 2-3
AB Puh/Tel ||| AB Puh/ Tel ||| 0-0 1-1 1-2
AB Tel : + 46 ||| AB Tel : + 46 ||| 0-0 1-1 2-2 3-3 4-4
AB Tel : + ||| AB Tel : + ||| 0-0 1-1 2-2 3-3
AB Tel : +46 8 ||| AB Tel : +46 8 ||| 0-0 1-1 2-2 3-3 4-4
AB Tel : +46 ||| AB Tel : +46 ||| 0-0 1-1 2-2 3-3
AB Tel : ||| AB Tel : ||| 0-0 1-1 2-2
AB Tel ||| AB Tel ||| 0-0 1-1
AB ||| AB ||| 0-0
ABFALLMATERIALIEN , SOFERN ERFORDERLICH ||| , IF ANY ||| 1-0 0-1 2-1 2-2 3-2
ABFALLMATERIALIEN ||| APPROPRIATE ||| 0-0
ABILIFY ( aller Darreichungsformen ) ||| ABILIFY ( all formulations ) ||| 0-0 1-1 2-2 2-3 3-3 4-4
ABILIFY ( aller Darreichungsformen ||| ABILIFY ( all formulations ||| 0-0 1-1 2-2 2-3 3-3
ABILIFY ( aller Darreichungsformen ||| of ABILIFY ( all formulations ||| 0-1 1-2 2-3 2-4 3-4
ABILIFY ( ||| ABILIFY ( ||| 0-0 1-1
ABILIFY ( ||| of ABILIFY ( ||| 0-1 1-2
ABILIFY , abgesetzt werden ||| ABILIFY , must be discontinued ||| 0-0 1-1 2-2 3-3 2-4 3-4
ABILIFY , ||| ABILIFY , ||| 0-0 1-1
ABILIFY 1 mg/ml ||| ABILIFY 1 mg/ ml ||| 0-0 1-1 2-2 2-3
ABILIFY 1 ||| ABILIFY 1 ||| 0-0 1-1
ABILIFY 10 mg Tabletten sind ||| ABILIFY 10 mg tablets are ||| 0-0 1-1 2-2 3-3 4-4
ABILIFY 10 mg Tabletten ||| ABILIFY 10 mg tablets ||| 0-0 1-1 2-2 3-3
ABILIFY 10 mg ||| ABILIFY 10 mg ||| 0-0 1-1 2-2
ABILIFY 10 ||| ABILIFY 10 ||| 0-0 1-1
ABILIFY 15 mg Tabletten sind ||| ABILIFY 15 mg tablets are ||| 0-0 1-1 2-2 3-3 4-4
ABILIFY 15 mg Tabletten ||| ABILIFY 15 mg tablets ||| 0-0 1-1 2-2 3-3
ABILIFY 15 mg ||| ABILIFY 15 mg ||| 0-0 1-1 2-2
ABILIFY 15 ||| ABILIFY 15 ||| 0-0 1-1
ABILIFY 30 mg Tabletten sind ||| ABILIFY 30 mg tablets are ||| 0-0 1-1 2-2 3-3 4-4
ABILIFY 30 mg Tabletten ||| ABILIFY 30 mg tablets ||| 0-0 1-1 2-2 3-3
ABILIFY 30 mg ||| ABILIFY 30 mg ||| 0-0 1-1 2-2
ABILIFY 30 ||| ABILIFY 30 ||| 0-0 1-1
ABILIFY 5 mg Tabletten sind ||| ABILIFY 5 mg tablets are ||| 0-0 1-1 2-2 3-3 4-4
ABILIFY 5 mg Tabletten ||| ABILIFY 5 mg tablets ||| 0-0 1-1 2-2 3-3
ABILIFY 5 mg ||| ABILIFY 5 mg ||| 0-0 1-1 2-2
ABILIFY 5 ||| ABILIFY 5 ||| 0-0 1-1
ABILIFY 7,5 mg/ml ||| ABILIFY 7.5 mg/ ml ||| 0-0 1-1 2-2 2-3
ABILIFY 7,5 ||| ABILIFY 7.5 ||| 0-0 1-1
ABILIFY : ||| ABILIFY : ||| 0-0 1-1
ABILIFY Darreichungsformen zum Einnehmen ||| oral formulations of ABILIFY ||| 2-0 3-0 1-1 0-3
ABILIFY Darreichungsformen ||| formulations of ABILIFY ||| 1-0 0-2
ABILIFY Injektionslösung beträgt ||| aripiprazole solution for injection is ||| 2-0 0-1 1-1 1-2 1-3 2-4
ABILIFY Injektionslösung erhalten als ||| ABILIFY solution for injection than ||| 0-0 1-1 1-2 2-2 1-3 3-4
ABILIFY Injektionslösung erhalten ||| ABILIFY solution for injection ||| 0-0 1-1 1-2 2-2 1-3
ABILIFY Injektionslösung ist ||| ABILIFY solution for injection is ||| 0-0 1-1 1-2 1-3 2-4
ABILIFY Injektionslösung sind ||| ABILIFY solution for injection ||| 0-0 1-1 1-2 1-3
ABILIFY Injektionslösung sollte ||| ABILIFY solution for injection should ||| 0-0 1-1 1-2 1-3 2-4
ABILIFY Injektionslösung wird ||| ABILIFY solution for injection is ||| 0-0 1-1 1-2 1-3 2-4
ABILIFY Injektionslösung ||| 182 ABILIFY solution for injection ||| 0-0 0-1 1-2 1-3 1-4
ABILIFY Injektionslösung ||| ABILIFY solution for injection ||| 0-0 1-1 1-2 1-3
ABILIFY Injektionslösung ||| solution for injection ||| 0-0 1-0 1-1 1-2
ABILIFY Jeder ml ABILIFY ||| ABILIFY Each ml of ABILIFY ||| 0-0 1-1 2-2 1-3 3-4
ABILIFY Jeder ml ||| ABILIFY Each ml of ||| 0-0 1-1 2-2 1-3
ABILIFY Lösung zum Einnehmen . ||| ABILIFY oral solution . ||| 0-0 2-1 3-1 1-2 4-3
ABILIFY Lösung zum Einnehmen enthält ||| ABILIFY oral solution contains ||| 0-0 2-1 3-1 1-2 4-3
ABILIFY Lösung zum Einnehmen muss ||| ABILIFY oral solution must be ||| 0-0 2-1 3-1 1-2 4-3 4-4
ABILIFY Lösung zum Einnehmen ||| ABILIFY oral solution ||| 0-0 2-1 3-1 1-2
ABILIFY Lösung zum Einnehmen ||| the ABILIFY oral solution ||| 1-0 0-1 2-2 3-2 1-3 3-3
ABILIFY Schmelztabletten enthalten ||| ABILIFY orodispersible tablets contain ||| 0-0 1-1 1-2 2-3
ABILIFY Schmelztabletten jeden ||| ABILIFY orodispersible tablet at the ||| 0-0 1-1 2-2 2-3 2-4
ABILIFY Schmelztabletten oder ABILIFY ||| orodispersible tablets or ABILIFY ||| 1-0 1-1 2-2 0-3 3-3
ABILIFY Schmelztabletten ||| ABILIFY orodispersible tablets ||| 0-0 1-1 1-2
ABILIFY Schmelztabletten ||| ABILIFY orodispersible ||| 0-0 1-1
ABILIFY Tablette jeden ||| ABILIFY tablet at the ||| 0-0 1-1 2-1 2-2 2-3
ABILIFY Tabletten , ||| ABILIFY tablets , ABILIFY ||| 0-0 1-1 2-2 0-3
ABILIFY Tabletten einnehmen ( siehe ||| ABILIFY tablets ( see also ||| 0-0 2-0 1-1 3-2 4-3 4-4
ABILIFY Tabletten einnehmen ( siehe ||| ABILIFY tablets ( see ||| 0-0 2-0 1-1 3-2 4-3
ABILIFY Tabletten einnehmen ( ||| ABILIFY tablets ( ||| 0-0 2-0 1-1 3-2
ABILIFY Tabletten einnehmen ||| ABILIFY tablets ||| 0-0 2-0 1-1
ABILIFY Tabletten ||| ABILIFY tablets ||| 0-0 1-1
ABILIFY beachten ? 3. ||| ABILIFY 3. ||| 0-0 1-1 2-1 3-1
ABILIFY bei Ihnen wirkt . ||| ABILIFY affects you . ||| 0-0 1-1 2-1 3-1 2-2 4-3
ABILIFY bei Ihnen wirkt ||| ABILIFY affects you ||| 0-0 1-1 2-1 3-1 2-2
ABILIFY beträgt 10 oder 15 ||| ABILIFY is 10 or 15 ||| 0-0 1-1 2-2 3-3 1-4 4-4
ABILIFY beträgt 10 oder 15 ||| ABILIFY is 10 or 15 ||| 0-0 1-1 2-2 3-3 4-4
ABILIFY beträgt 10 oder ||| ABILIFY is 10 or ||| 0-0 1-1 2-2 3-3
ABILIFY beträgt 10 ||| ABILIFY is 10 ||| 0-0 1-1 2-2
ABILIFY beträgt 15 mg ||| ABILIFY is 15 mg ||| 0-0 1-1 1-2 2-2 3-3
ABILIFY beträgt 15 ||| ABILIFY is 15 ||| 0-0 1-1 1-2 2-2
ABILIFY beträgt ||| ABILIFY is ||| 0-0 1-1
ABILIFY darf nicht angewendet ||| Do not use ABILIFY ||| 1-0 1-1 2-1 2-2 0-3
ABILIFY darf nicht eingenommen ||| Do not take ABILIFY ||| 1-0 1-1 2-1 3-2 0-3
ABILIFY darf nicht ||| Do not use ABILIFY ||| 1-0 1-1 2-1 2-2 0-3
ABILIFY enthält Der Wirkstoff ||| ABILIFY contains The active substance ||| 0-0 1-1 2-2 3-3 3-4
ABILIFY enthält Der ||| ABILIFY contains The ||| 0-0 1-1 2-2
ABILIFY enthält ||| ABILIFY contains ||| 0-0 1-1
ABILIFY erhalten . ||| ABILIFY . ||| 0-0 2-1
ABILIFY erhalten ||| ABILIFY ||| 0-0
ABILIFY genau nach Anweisung ||| ABILIFY exactly as your doctor ||| 0-0 1-1 2-1 3-1 1-2 3-3 3-4
ABILIFY in ||| ABILIFY in ||| 0-0 1-1
ABILIFY in ||| ABILIFY ||| 0-0
ABILIFY ist für die ||| ABILIFY is indicated for ||| 0-0 1-1 2-2 2-3 3-3
ABILIFY ist nicht ||| ABILIFY is not ||| 0-0 1-1 2-2
ABILIFY ist wirksam in ||| ABILIFY is effective in ||| 0-0 1-1 2-2 3-3
ABILIFY ist wirksam ||| ABILIFY is effective ||| 0-0 1-1 2-2
ABILIFY ist ||| ABILIFY is ||| 0-0 1-1
ABILIFY kann die Wirkung ||| ABILIFY may increase the effect ||| 0-0 1-1 1-2 2-3 3-4
ABILIFY kann die ||| ABILIFY may increase the ||| 0-0 1-1 1-2 2-3
ABILIFY kann ||| ABILIFY can be ||| 0-0 1-1 1-2
ABILIFY kann ||| ABILIFY may increase ||| 0-0 1-1 1-2
ABILIFY mit Carbamazepin verdoppelt werden ||| ABILIFY occurs with carbamazepine ||| 0-0 3-1 1-2 3-2 2-3 3-3 4-3
ABILIFY nicht anwenden , wenn ||| not use ABILIFY if ||| 1-0 2-1 0-2 3-3 4-3
ABILIFY nicht anwenden ||| not use ABILIFY ||| 1-0 2-1 0-2
ABILIFY nicht einnehmen , wenn ||| not take ABILIFY if ||| 1-0 2-1 3-1 0-2 4-3
ABILIFY nicht einnehmen , ||| not take ABILIFY ||| 1-0 2-1 3-1 0-2
ABILIFY und ||| ABILIFY and ||| 0-0 1-1
ABILIFY wird angewendet bei ||| ABILIFY is used ||| 0-0 1-1 2-2 3-2
ABILIFY wird ||| ABILIFY is ||| 0-0 1-1
ABILIFY zu ändern . ||| ABILIFY . ||| 0-0 1-0 2-0 3-1
ABILIFY zu ändern ||| ABILIFY ||| 0-0 1-0 2-0
ABILIFY zusammen mit ||| concomitant administration of ABILIFY with ||| 1-0 1-1 0-3 2-4
ABILIFY zusammen ||| concomitant administration of ABILIFY ||| 1-0 1-1 0-3
ABILIFY ||| 182 ABILIFY ||| 0-0 0-1
ABILIFY ||| ABILIFY ||| 0-0
ABILIFY ||| of ABILIFY ||| 0-1
ABILIFY ||| on ABILIFY ||| 0-1
ABKÜRZUNGEN FÜR DIE WOCHENTAGE ||| ABBREVIATIONS FOR DAYS OF ||| 0-0 1-1 2-2 3-2 3-3
ABKÜRZUNGEN FÜR ||| ABBREVIATIONS FOR ||| 0-0 1-1
ABKÜRZUNGEN ||| ABBREVIATIONS ||| 0-0
ABSEAMED BEACHTEN ? ||| ABSEAMED ||| 0-0 1-0 2-0
ABSEAMED ||| ABSEAMED ||| 0-0
ACE)-Hemmer ||| enzyme ||| 0-0
ACE-Hemmern ||| carprofen ||| 0-0
ACLASTA ||| ACLASTA ||| 0-0
ACOMPLIA 20 mg ||| , ACOMPLIA 20 mg ||| 0-1 1-2 2-3
ACOMPLIA 20 mg ||| ACOMPLIA 20 mg ||| 0-0 1-1 2-2
ACOMPLIA 20 ||| , ACOMPLIA 20 ||| 0-1 1-2
ACOMPLIA 20 ||| ACOMPLIA 20 ||| 0-0 1-1
ACOMPLIA darf bei Patienten mit ||| ACOMPLIA darf bei Patienten mit ||| 0-0 1-1 2-2 3-3 4-4
ACOMPLIA darf bei Patienten ||| ACOMPLIA darf bei Patienten ||| 0-0 1-1 2-2 3-3
ACOMPLIA darf bei ||| ACOMPLIA darf bei ||| 0-0 1-1 2-2
ACOMPLIA darf ||| ACOMPLIA darf ||| 0-0 1-1
ACOMPLIA darf ||| ACOMPLIA should not be ||| 0-0 1-1 1-2 1-3
ACOMPLIA darf ||| For ||| 0-0 1-0
ACOMPLIA finden Sie hier ||| ACOMPLIA can be found here ||| 0-0 1-1 1-2 1-3 2-4 3-4
ACOMPLIA finden ||| ACOMPLIA can be found ||| 0-0 1-1 1-2 1-3
ACOMPLIA ist ||| or ||| 0-0
ACOMPLIA mit Arzneimitteln ||| ACOMPLIA with some medicines , ||| 0-0 1-1 2-2 2-3
ACOMPLIA mit Arzneimitteln ||| ACOMPLIA with some medicines ||| 0-0 1-1 2-2 2-3
ACOMPLIA mit ||| ACOMPLIA with ||| 0-0 1-1
ACOMPLIA und Placebo ||| ACOMPLIA and placebo ||| 0-0 1-1 2-2
ACOMPLIA und ||| ACOMPLIA and ||| 0-0 1-1
ACOMPLIA wird nicht empfohlen ||| ACOMPLIA is not recommended ||| 0-0 1-1 2-2 3-3
ACOMPLIA wird nicht ||| ACOMPLIA is not ||| 0-0 1-1 2-2
ACOMPLIA wird ||| ACOMPLIA is ||| 0-0 1-1
ACOMPLIA wurden ||| ACOMPLIA were ||| 0-0 1-1
ACOMPLIA ||| , ACOMPLIA ||| 0-1
ACOMPLIA ||| ACOMPLIA in ||| 0-0
ACOMPLIA ||| ACOMPLIA ||| 0-0
ACOMPLIA ||| or ||| 0-0
ACOMPLIA ||| weight ||| 0-0
ACTOS auf der anderen Seite ||| ACTOS on the other face. ||| 0-0 1-1 2-2 3-3 4-4
ACTOS auf der anderen ||| ACTOS on the other ||| 0-0 1-1 2-2 3-3
ACTOS auf der ||| ACTOS on the ||| 0-0 1-1 2-2
ACTOS auf ||| ACTOS on ||| 0-0 1-1
ACTOS ||| ACTOS ||| 0-0
ACTRAPHANE 10 ACTRAPHANE 20 ACTRAPHANE ||| ACTRAPHANE 10 ACTRAPHANE 20 ACTRAPHANE ||| 0-0 1-1 2-2 3-3 4-4
ACTRAPHANE 10 ACTRAPHANE 20 ||| ACTRAPHANE 10 ACTRAPHANE 20 ||| 0-0 1-1 2-2 3-3
ACTRAPHANE 10 ACTRAPHANE ||| ACTRAPHANE 10 ACTRAPHANE ||| 0-0 1-1 2-2
ACTRAPHANE 10 ||| ACTRAPHANE 10 ||| 0-0 1-1
ACTRAPHANE 20 ACTRAPHANE 30 ACTRAPHANE ||| ACTRAPHANE 20 ACTRAPHANE 30 ACTRAPHANE ||| 0-0 1-1 2-2 3-3 4-4
ACTRAPHANE 20 ACTRAPHANE 30 ||| ACTRAPHANE 20 ACTRAPHANE 30 ||| 0-0 1-1 2-2 3-3
ACTRAPHANE 20 ACTRAPHANE ||| ACTRAPHANE 20 ACTRAPHANE ||| 0-0 1-1 2-2
ACTRAPHANE 20 ||| ACTRAPHANE 20 ||| 0-0 1-1
ACTRAPHANE 30 ACTRAPHANE 40 ACTRAPHANE ||| ACTRAPHANE 30 ACTRAPHANE 40 ACTRAPHANE ||| 0-0 1-1 2-2 3-3 4-4
ACTRAPHANE 30 ACTRAPHANE 40 ||| ACTRAPHANE 30 ACTRAPHANE 40 ||| 0-0 1-1 2-2 3-3
ACTRAPHANE 30 ACTRAPHANE ||| ACTRAPHANE 30 ACTRAPHANE ||| 0-0 1-1 2-2
ACTRAPHANE 30 ||| ACTRAPHANE 30 ||| 0-0 1-1
ACTRAPHANE 40 ACTRAPHANE 50 ||| ACTRAPHANE 40 ACTRAPHANE 50 ||| 0-0 1-1 2-2 3-3
ACTRAPHANE 40 ACTRAPHANE ||| ACTRAPHANE 40 ACTRAPHANE ||| 0-0 1-1 2-2
ACTRAPHANE 40 ||| ACTRAPHANE 40 ||| 0-0 1-1
ACTRAPHANE 50 ||| ACTRAPHANE 50 ||| 0-0 1-1
ACTRAPHANE ||| ACTRAPHANE ||| 0-0
ALT ) , ||| ALT ) , ||| 0-0 1-1 2-2
ALT ) ||| ALT ) ||| 0-0 1-1
ALT ||| ALT ||| 0-0
ANGABEN AUF DER ||| PARTICULARS TO APPEAR ON THE ||| 0-0 0-1 1-2 1-3 2-4
ANGABEN AUF DER ||| PARTICULARS TO APPEAR ON ||| 0-0 1-1 1-2 1-3 2-3
ANGABEN AUF DER ||| PARTICULARS TO ||| 0-0 1-1 2-1
ANGABEN AUF DER ÄUSSEREN UMHÜLLUNG ||| PARTICULARS TO APPEAR ON ||| 0-0 1-1 2-1 3-2 4-3
ANGABEN AUF DER ÄUSSEREN ||| PARTICULARS TO APPEAR ||| 0-0 1-1 2-1 3-2
ANGABEN AUF ||| PARTICULARS TO APPEAR ON ||| 0-0 0-1 1-2 1-3
ANGABEN AUF ||| PARTICULARS TO APPEAR ||| 0-0 1-1 1-2
ANGABEN ||| PARTICULARS TO ||| 0-0 0-1
ANGABEN ||| PARTICULARS ||| 0-0
ANGEWENDET ? ||| USED FOR ||| 0-0 0-1 1-1
ANHANG III ||| valid Summary of Product Characteristics ||| 0-0 0-1 1-3 1-4
ANHANG ||| valid Summary of ||| 0-0 0-1
ANHANG ||| valid Summary ||| 0-0 0-1
ANWENDUNG DES TIERARZNEIMITTELS , ||| USE , ||| 0-0 1-0 2-0 3-1
ANWENDUNG DES TIERARZNEIMITTELS ||| EFFECTIVE USE ||| 0-0 1-0 0-1 2-1
ANWENDUNG DES TIERARZNEIMITTELS ||| USE ||| 0-0 1-0 2-0
ANWENDUNG VON ABILIFY BEACHTEN ? ||| USE ABILIFY ||| 0-0 1-0 3-0 2-1 3-1 4-1
ANWENDUNG VON ABSEAMED BEACHTEN ? ||| USE ABSEAMED ||| 0-0 1-0 2-1 3-1 4-1
ANWENDUNG VON ||| USE ||| 0-0 1-0
ANWENDUNG ||| ADMINISTRATION ||| 0-0
ANWENDUNG ||| USE ||| 0-0
AQ ) , Italien ||| AQ ) , Italy ||| 0-0 1-1 2-2 3-3
AQ ) , ||| AQ ) , ||| 0-0 1-1 2-2
AQ ) ||| AQ ) ||| 0-0 1-1
AQ ||| AQ ||| 0-0
ART DER ANWENDUNG ||| ROUTE(S ) OF ADMINISTRATION ||| 0-0 0-1 1-2 2-3
ART DER ||| OF ||| 0-0 1-0
ART DER ||| ROUTE(S ) OF ||| 0-0 0-1 1-2
ART UND DAUER DER ||| ROUTE(S ) AND METHOD OF ||| 0-0 0-1 1-2 2-3 3-4
ART UND DAUER ||| ROUTE(S ) AND METHOD ||| 0-0 0-1 1-2 2-3
ART UND ||| ROUTE(S ) AND ||| 0-0 0-1 1-2
ART ||| ROUTE(S ) ||| 0-0 0-1
ART(EN ) DER ANWENDUNG ||| AND ROUTE(S ) OF ADMINISTRATION ||| 0-0 0-1 1-2 2-3 3-4
ART(EN ) DER ||| AND ROUTE(S ) OF ||| 0-0 0-1 1-2 2-3
ART(EN ) ||| AND ROUTE(S ) ||| 0-0 0-1 1-2
ART(EN ||| AND ROUTE(S ||| 0-0 0-1
ARZNEILICH WIRKSAME(R ) BESTANDTEIL(E ||| STATEMENT OF THE ACTIVE SUBSTANCE(S ||| 0-0 1-0 1-1 1-2 2-3 3-3 3-4
ARZNEILICH WIRKSAME(R ) ||| QUANTITY OF ||| 0-0 1-0 1-1 2-1
ARZNEILICH WIRKSAME(R ||| STATEMENT OF THE ||| 0-0 1-0 1-1 1-2
ARZNEIMITTEL FÜR KINDER UNERREICHBAR ||| MUST BE STORED OUT OF ||| 0-0 1-1 2-1 2-2 3-3 3-4
ARZNEIMITTEL FÜR KINDER ||| MUST BE STORED ||| 0-0 1-1 2-1 2-2
ARZNEIMITTEL ODER ||| PRODUCT OR ||| 0-0 1-1
ARZNEIMITTEL ||| MUST ||| 0-0
ARZNEIMITTEL ||| PRODUCT ||| 0-0
ARZNEIMITTELS , DIE ||| MEDICINAL PRODUCT ||| 0-0 2-0 0-1
ARZNEIMITTELS , ||| MEDICINAL PRODUCT , ||| 0-0 0-1 1-2
ARZNEIMITTELS SOWIE ART ||| MEDICINAL PRODUCT AND ROUTE(S ) ||| 0-0 1-1 1-2 2-3 2-4
ARZNEIMITTELS SOWIE ART(EN ) ||| MEDICINAL PRODUCT AND ROUTE(S ) ||| 0-0 1-1 2-2 2-3 3-4
ARZNEIMITTELS SOWIE ART(EN ||| MEDICINAL PRODUCT AND ROUTE(S ||| 0-0 1-1 2-2 2-3
ARZNEIMITTELS SOWIE ||| MEDICINAL PRODUCT AND ||| 0-0 1-1 1-2
ARZNEIMITTELS SOWIE ||| MEDICINAL PRODUCT ||| 0-0 1-1
ARZNEIMITTELS ||| MEDICINAL PRODUCT ||| 0-0 0-1
ARZNEIMITTELS ||| MEDICINAL ||| 0-0
AS Tlf : +47 23 ||| AS Tlf : +47 23 ||| 0-0 1-1 2-2 3-3 4-4
AS Tlf : +47 ||| AS Tlf : +47 ||| 0-0 1-1 2-2 3-3
AS Tlf : ||| AS Tlf : ||| 0-0 1-1 2-2
AS Tlf ||| AS Tlf ||| 0-0 1-1
AS ||| AS ||| 0-0
ASL/ALT > 10 x ||| ASL/ ALT > 10 x ||| 0-0 1-1 1-2 2-3 3-4
ASL/ALT > 10 ||| ASL/ ALT > 10 ||| 0-0 1-1 1-2 2-3
ASL/ALT > ||| ASL/ ALT > ||| 0-0 1-1 1-2
ASL/ALT ||| ASL/ ||| 0-0
AST ) , erhöhte Gamma- ||| AST ) , increased Gamma ||| 0-0 1-1 2-2 3-3 4-4
AST ) , erhöhte ||| AST ) , increased ||| 0-0 1-1 2-2 3-3
AST ) , ||| AST ) , ||| 0-0 1-1 2-2
AST ) ||| AST ) ||| 0-0 1-1
AST ||| AST ||| 0-0
ATC-Code : ||| ATC code : ||| 0-0 0-1 1-2
ATC-Code ||| ATC code ||| 0-0 0-1
AUC ) erhöhte sich linear ||| AUC ) increased linearly ||| 0-0 1-1 2-2 4-3
AUC ) erhöhte sich ||| AUC ) increased ||| 0-0 1-1 2-2
AUC ) erhöhte ||| AUC ) increased ||| 0-0 1-1 2-2
AUC ) ||| AUC ) ||| 0-0 1-1
AUC hat als ein ||| AUC than a 40 year ||| 0-0 2-1 1-2 3-2 0-3 3-4
AUC ist in den ersten ||| AUC in the first ||| 0-0 2-1 1-2 3-2 3-3 4-3
AUC nach Gabe der gleichen ||| AUC after the same ||| 0-0 1-1 2-1 3-2 4-3
AUC nach Gabe der ||| AUC after the ||| 0-0 1-1 2-1 3-2
AUC nach Gabe ||| AUC after ||| 0-0 1-1 2-1
AUC nach ||| AUC after ||| 0-0 1-1
AUC um ||| in AUC ||| 1-0 0-1 1-1
AUC und Cmax von Dehydro-Aripiprazol ||| AUC and Cmax of dehydro-aripiprazole ||| 0-0 1-1 2-2 3-3 4-4
AUC und Cmax von ||| AUC and Cmax of ||| 0-0 1-1 2-2 3-3
AUC und Cmax ||| AUC and Cmax ||| 0-0 1-1 2-2
AUC und ||| AUC and ||| 0-0 1-1
AUC ||| AUC ||| 0-0
AUF ABGABE UND ANWENDUNG ||| SUPPLY OR USE ||| 0-0 1-0 2-0 1-1 3-2
AUF ABGABE UND ||| SUPPLY OR ||| 0-0 1-0 2-0 1-1
AUF BLISTERPACKUNGEN ODER ||| APPEAR ON SMALL IMMEDIATE PACKAGING ||| 0-0 1-1 2-1 0-2 0-3 0-4
AUF BLISTERPACKUNGEN ODER ||| TO APPEAR ON BLISTERS OR ||| 0-0 0-1 1-2 1-3 2-4
AUF BLISTERPACKUNGEN ||| TO APPEAR ON BLISTERS ||| 0-0 0-1 1-2 1-3
AUF DEM BEHÄLTNIS ||| OUTER PACKAGING ||| 0-0 1-0 2-1
AUF DEM ||| OUTER ||| 0-0 1-0
AUF DEM ||| TO APPEAR ON THE OUTER ||| 0-0 0-1 1-2 1-3 1-4
AUF DER PRIMÄRVERPACKUNG ||| APPEAR ON THE IMMEDIATE PACKAGE ||| 0-0 0-1 1-2 2-3 2-4
AUF DER ||| APPEAR ON THE ||| 0-0 0-1 1-2
AUF DER ||| TO APPEAR ON THE ||| 0-0 0-1 0-2 1-2 1-3
AUF DER ||| TO APPEAR ON ||| 0-0 0-1 0-2 1-2
AUF DER ||| TO ||| 0-0 1-0
AUF DER ÄUSSEREN UMHÜLLUNG UND ||| TO APPEAR ON THE ||| 0-0 1-0 2-1 3-2 4-3
AUF DER ÄUSSEREN UMHÜLLUNG ||| TO APPEAR ON THE OUTER ||| 0-0 0-1 0-2 1-2 1-3 2-4 3-4
AUF DER ÄUSSEREN UMHÜLLUNG ||| TO APPEAR ON ||| 0-0 1-0 2-1 3-2
AUF DER ÄUSSEREN ||| TO APPEAR ||| 0-0 1-0 2-1
AUF KLEINEN ||| APPEAR ON SMALL IMMEDIATE PACKAGING ||| 0-0 0-1 1-2 1-3 1-4
AUF KLEINEN ||| APPEAR ON SMALL IMMEDIATE ||| 0-0 0-1 1-2 1-3
AUF ODER FOLIENSTREIFEN ||| APPEAR ON BLISTERS OR STRIPS ||| 0-0 0-1 1-2 1-3 2-4
AUF ODER ||| APPEAR ON BLISTERS OR ||| 0-0 0-1 1-2 1-3
AUF ||| APPEAR ON ||| 0-0 0-1
AUF ||| ON ||| 0-0
AUF ||| TO APPEAR ||| 0-0 0-1
AUFERLEGT WERDEN ||| AUTHORISATION HOLDER ||| 0-0 0-1 1-1
AUSSER REICH- UND SICHTWEITE ||| KEEP OUT OF THE REACH ||| 0-0 1-0 1-1 1-2 2-3 3-4
AUSSER REICH- UND ||| KEEP OUT OF THE ||| 0-0 1-0 1-1 1-2 2-3
AUSSER REICH- ||| KEEP OUT OF ||| 0-0 1-0 1-1 1-2
Ab Puh/Tel : + ||| Ab Puh/ Tel : + ||| 0-0 1-1 1-2 2-3 3-4
Ab Puh/Tel : ||| Ab Puh/ Tel : ||| 0-0 1-1 1-2 2-3
Ab Puh/Tel ||| Ab Puh/ Tel ||| 0-0 1-1 1-2
Ab ||| Ab ||| 0-0
Abbau ihres inneren ||| break down their internal ||| 0-0 0-1 1-2 1-3 2-3
Abbau ||| break down ||| 0-0 0-1
Abfall der ||| decrease of ||| 0-0
Abfall der ||| decrease ||| 0-0
Abfall ||| decrease of ||| 0-0
Abfall ||| decrease ||| 0-0
Abfallmaterialien sind ||| such veterinary medicinal products ||| 0-0 0-1 1-1 0-2
Abfallmaterialien sind ||| such veterinary medicinal ||| 0-0 0-1 1-1 0-2
Abfälle ||| products ||| 0-0
Abgeschlagenheit Psychiatrische Erkrankungen Häufig : ||| fatigue Psychiatric disorders Common : ||| 0-0 0-1 1-1 2-2 3-3 4-4
Abgeschlagenheit Psychiatrische Erkrankungen Häufig ||| fatigue Psychiatric disorders Common ||| 0-0 0-1 1-1 2-2 3-3
Abgeschlagenheit Psychiatrische Erkrankungen ||| fatigue Psychiatric disorders ||| 0-0 0-1 1-1 2-2
Abgeschlagenheit Psychiatrische ||| fatigue Psychiatric ||| 0-0 0-1 1-1
Abgeschlagenheit* ||| fatigue* ||| 0-0
Abhängig von Ihrer persönlichen Situation ||| Depending on your individual situation ||| 0-0 0-1 1-1 2-2 3-3 3-4 4-4
Abhängig von Ihrer ||| Depending on your ||| 0-0 0-1 1-1 2-2
Abhängig von ||| Depending on ||| 0-0 0-1 1-1
Abilify , Aripiprazol , ist ||| Abilify , aripiprazole , is ||| 0-0 1-1 2-2 3-3 4-4
Abilify , Aripiprazol , ||| Abilify , aripiprazole , ||| 0-0 1-1 2-2 3-3
Abilify , Aripiprazol ||| Abilify , aripiprazole ||| 0-0 1-1 2-2
Abilify , ||| Abilify , ||| 0-0 1-1
Abilify abgebaut ||| Abilify ||| 0-0
Abilify darf nicht ||| Abilify should not ||| 0-0 1-1 1-2 2-2
Abilify finden Sie hier ||| Abilify can be found here ||| 0-0 1-1 1-2 1-3 2-4 3-4
Abilify finden ||| Abilify can be found ||| 0-0 1-1 1-2 1-3
Abilify hatte auch eine ||| Abilify also had a ||| 0-0 2-1 1-2 3-3
Abilify hatte auch eine ähnliche ||| Abilify also had a similar ||| 0-0 2-1 1-2 3-3 4-4
Abilify hatte auch ||| Abilify also had ||| 0-0 2-1 1-2
Abilify in diesen Studien ||| Abilify shown during the studies ||| 0-0 1-1 2-1 2-2 3-4
Abilify in diesen ||| Abilify shown during the ||| 0-0 1-1 2-1 2-2
Abilify in diesen ||| Abilify shown during ||| 0-0 1-1 2-1 2-2
Abilify ist ein Arzneimittel ||| Abilify is a medicine ||| 0-0 1-1 2-2 3-3
Abilify ist ein ||| Abilify is a ||| 0-0 1-1 2-2
Abilify ist ||| Abilify is ||| 0-0 1-1
Abilify und Placebo ||| Abilify and placebo ||| 0-0 1-1 2-2
Abilify und Placebo über drei ||| Abilify and placebo over three ||| 0-0 1-1 2-2 3-3 4-4
Abilify und Placebo über ||| Abilify and placebo over ||| 0-0 1-1 2-2 3-3
Abilify und ||| Abilify and ||| 0-0 1-1
Abilify verhinderte ||| Abilify ||| 0-0 1-0
Abilify wird ||| Abilify is ||| 0-0 1-1
Abilify wurde nicht ||| Abilify has not been ||| 0-0 1-1 2-2 1-3
Abilify ||| , Abilify ||| 0-1
Abilify ||| Abilify at ||| 0-0
Abilify ||| Abilify ||| 0-0
Abilify ||| of Abilify ||| 0-1
Abilify-Injektionen in 10- ||| Injections of Abilify at doses ||| 0-0 2-0 1-1 0-2 1-3 2-4
Abilify-Injektionen ||| Abilify experience ||| 0-0
Abilify-Injektionen ||| Abilify ||| 0-0
Abilify-Injektionen ||| of Abilify experience ||| 0-1
Abilify-Injektionen ||| of Abilify ||| 0-1
Abklingen ||| resolution ||| 0-0
Abnahme der Anzahl roter ||| reduction in red blood cell ||| 0-0 0-1 1-1 2-2 3-2 3-3 3-4
Abnahme der Körpergröße im Vergleich ||| height loss compared ||| 0-0 2-0 3-2 4-2
Abnahme der Körpergröße ||| height loss ||| 0-0 2-0
Abnahme der Körpergröße ||| height ||| 0-0 2-0
Abnahme der ||| decrease in ||| 0-0 0-1
Abnahme der ||| reduction in ||| 0-0 0-1 1-1
Abnahme ||| decrease in ||| 0-0 0-1
Abnehmende Blutspiegel von Geschlechtshormonen ||| Decreased circulating levels of sex ||| 0-0 0-1 1-2 2-3 3-4
Abnehmende Blutspiegel von ||| Decreased circulating levels of ||| 0-0 0-1 1-2 2-3
Abnehmende Blutspiegel ||| Decreased circulating levels ||| 0-0 0-1 1-2
Abnehmende ||| Decreased circulating ||| 0-0 0-1
Abraxane ( ||| Abraxane ( ||| 0-0 1-1
Abraxane 260 ||| Abraxane 260 ||| 0-0 1-1
Abraxane 5 mg/ml ||| Abraxane 5 mg/ ml ||| 0-0 1-1 2-2 2-3
Abraxane 5 ||| Abraxane 5 ||| 0-0 1-1
Abraxane als Erstlinienbehandlung ||| Abraxane as first-line ||| 0-0 1-1 2-2
Abraxane als ||| Abraxane as ||| 0-0 1-1
Abraxane auf ||| Abraxane ||| 0-0 1-0
Abraxane behandelten Patienten ||| patients on Abraxane ||| 2-0 0-2 1-2
Abraxane behandelten ||| Abraxane ||| 0-0 1-0
Abraxane behandelten ||| on Abraxane ||| 0-1 1-1
Abraxane bei jeder Dosis ||| Abraxane at any dose in ||| 0-0 1-1 2-2 3-3 1-4
Abraxane bei ||| Abraxane at ||| 0-0 1-1
Abraxane beträgt 260 ||| Abraxane is 260 ||| 0-0 1-1 2-2
Abraxane beträgt ||| Abraxane is ||| 0-0 1-1
Abraxane darf nicht ||| Abraxane should not be ||| 0-0 1-1 1-2 2-2 1-3
Abraxane enthält Paclitaxel , das ||| Abraxane contains human ||| 0-0 2-0 1-1 3-2 4-2
Abraxane enthält Paclitaxel ||| Abraxane contains ||| 0-0 2-0 1-1
Abraxane hat geringen oder mäßigen ||| Abraxane has minor or moderate ||| 0-0 1-1 2-2 3-3 4-4
Abraxane hat geringen oder ||| Abraxane has minor or ||| 0-0 1-1 2-2 3-3
Abraxane hat geringen ||| Abraxane has minor ||| 0-0 1-1 2-2
Abraxane hat ||| Abraxane has ||| 0-0 1-1
Abraxane in diesen Studien ||| Abraxane shown during the studies ||| 0-0 1-1 2-1 2-2 3-4
Abraxane in diesen ||| Abraxane shown during the ||| 0-0 1-1 2-1 2-2
Abraxane in diesen ||| Abraxane shown during ||| 0-0 1-1 2-1 2-2
Abraxane in ||| Abraxane into ||| 0-0 1-1
Abraxane ist ||| Abraxane is ||| 0-0 1-1
Abraxane kann Nebenwirkungen verursachen ||| Abraxane may cause side effects ||| 0-0 1-1 3-2 2-3 2-4
Abraxane kann ||| Abraxane may ||| 0-0 1-1
Abraxane mit einer Dosis von ||| Abraxane at dose levels of ||| 0-0 1-1 2-1 2-2 3-2 4-4
Abraxane mit einer Dosis ||| Abraxane at dose levels ||| 0-0 1-1 2-1 2-2 3-2
Abraxane mit einer Dosis ||| Abraxane at dose ||| 0-0 1-1 2-1 2-2 3-2
Abraxane nach ||| Abraxane after ||| 0-0 1-1
Abraxane sollte nicht angewendet werden ||| Abraxane should not be administered ||| 0-0 1-1 2-2 4-3 3-4
Abraxane sollte nicht ||| Abraxane should not be ||| 0-0 1-1 2-2 1-3
Abraxane sollte nicht ||| Abraxane should not ||| 0-0 1-1 2-2
Abraxane sollte nur ||| Abraxane should only be administered ||| 0-0 1-1 2-2 1-3
Abraxane sollte nur ||| Abraxane should only be given ||| 0-0 1-1 2-2 1-3
Abraxane sollte nur ||| Abraxane should only be ||| 0-0 1-1 2-2 1-3
Abraxane sollte ||| Abraxane should ||| 0-0 1-1
Abraxane war wirksamer als ||| Abraxane was more effective than ||| 0-0 1-1 2-2 2-3 3-4
Abraxane war wirksamer ||| Abraxane was more effective ||| 0-0 1-1 2-2 2-3
Abraxane war ||| Abraxane was ||| 0-0 1-1
Abraxane wird alleine , ||| Abraxane is ||| 0-0 2-0 1-1 3-1
Abraxane wird nicht empfohlen ||| Abraxane is not recommended ||| 0-0 1-1 2-2 3-3
Abraxane wird nicht ||| Abraxane is not ||| 0-0 1-1 2-2
Abraxane wird ||| Abraxane is ||| 0-0 1-1
Abraxane wirkt auch auf ||| Abraxane also affects ||| 0-0 3-0 2-1 1-2
Abraxane wurde nicht ||| Abraxane has not been ||| 0-0 1-1 2-2 1-3
Abraxane wurde ||| Abraxane has been ||| 0-0 1-1 1-2
Abraxane wurden ||| Abraxane were ||| 0-0 1-1
Abraxane ||| , Abraxane ||| 0-1
Abraxane ||| Abraxane should ||| 0-0
Abraxane ||| Abraxane ||| 0-0
Abraxane-Gabe ||| Abraxane ||| 0-0
Abraxis BioScience Limited West Forest ||| Abraxis BioScience Limited West Forest ||| 0-0 1-1 2-2 3-3 4-4
Abraxis BioScience Limited West ||| Abraxis BioScience Limited West ||| 0-0 1-1 2-2 3-3
Abraxis BioScience Limited ||| Abraxis BioScience Limited ||| 0-0 1-1 2-2
Abraxis BioScience ||| Abraxis BioScience ||| 0-0 1-1
Abraxis ||| Abraxis ||| 0-0
Abschließend ist ||| In conclusion ||| 0-0 0-1
Abschließend ||| In conclusion ||| 0-0 0-1
Abschnitt . 5.2 ) . ||| section 5.2 ) . ||| 0-0 2-1 3-2 1-3 4-3
Abschnitt 4.2 ) . ||| Section 4.2 ) . ||| 0-0 1-1 2-2 3-3
Abschnitt 4.2 ) . ||| section 4.2 ) . ||| 0-0 1-1 2-2 3-3
Abschnitt 4.2 ) . ||| section 4.2 ) ||| 0-0 1-1 2-2 3-2
Abschnitt 4.2 ) Die ||| section 4.2 ) The ||| 0-0 1-1 2-2 3-3
Abschnitt 4.2 ) ||| Section 4.2 ) ||| 0-0 1-1 2-2
Abschnitt 4.2 ) ||| section 4.2 ) ||| 0-0 1-1 2-2
Abschnitt 4.2 - Hinweise zur ||| section 4.2 Method ||| 0-0 1-1 2-2 3-2 4-2
Abschnitt 4.2 Behandlung von Patienten ||| section 4.2 Treatment of patients ||| 0-0 1-1 2-2 3-3 4-4
Abschnitt 4.2 Behandlung von ||| section 4.2 Treatment of ||| 0-0 1-1 2-2 3-3
Abschnitt 4.2 Behandlung ||| section 4.2 Treatment ||| 0-0 1-1 2-2
Abschnitt 4.2 und ||| section dic ||| 0-0 1-0 1-1
Abschnitt 4.2 ||| Section 4.2 ||| 0-0 1-1
Abschnitt 4.2 ||| section 4.2 ||| 0-0 1-1
Abschnitt 4.2 ||| section dic ||| 0-0 1-0 1-1
Abschnitt 4.3 ) . ||| section 4.3 ) . ||| 0-0 1-1 2-2 3-3
Abschnitt 4.3 ) ||| section 4.3 ) ||| 0-0 1-1 2-2
Abschnitt 4.3 ||| section 4.3 ||| 0-0 1-1
Abschnitt 4.4 ) . In ||| section 4.4 ) . ||| 0-0 1-1 2-2 3-3
Abschnitt 4.4 ) . ||| section 4.4 ) . ||| 0-0 1-1 2-2 3-3
Abschnitt 4.4 ) ||| section 4.4 ) ||| 0-0 1-1 2-2
Abschnitt 4.4 - ||| section 4.4 - ||| 0-0 1-1 2-2
Abschnitt 4.4 und 5.2 ) ||| 4.4 und 5.2 ) ||| 0-0 1-0 2-1 3-2 4-3
Abschnitt 4.4 und 5.2 ||| 4.4 und 5.2 ||| 0-0 1-0 2-1 3-2
Abschnitt 4.4 und 5.2 ||| section 4.4 and 5.2 ||| 0-0 1-1 2-2 3-3
Abschnitt 4.4 und Abschnitt 4.8 ||| section 4.4 and section 4.8 ||| 0-0 3-0 1-1 2-2 3-3 4-4
Abschnitt 4.4 und Abschnitt ||| section 4.4 and section ||| 0-0 3-0 1-1 2-2 3-3
Abschnitt 4.4 und ||| 4.4 und ||| 0-0 1-0 2-1
Abschnitt 4.4 und ||| section 4.4 and ||| 0-0 1-1 2-2
Abschnitt 4.4 ||| 4.4 ||| 0-0 1-0
Abschnitt 4.4 ||| section 4.4 ||| 0-0 1-1
Abschnitt 4.5 ) . ||| section 4.5 ) . ||| 0-0 1-1 2-2 3-3
Abschnitt 4.5 ) ||| section 4.5 ) ||| 0-0 1-1 2-2
Abschnitt 4.5 . ||| section 4.5 . ||| 0-0 1-1 2-2
Abschnitt 4.5 ||| section 4.5 ||| 0-0 1-1
Abschnitt 4.6 ) . ||| section 4.6 ) . ||| 0-0 1-1 2-2 3-3
Abschnitt 4.6 ) ||| section 4.6 ) ||| 0-0 1-1 2-2
Abschnitt 4.6 ||| section 4.6 ||| 0-0 1-1
Abschnitt 4.8 ) . ||| section 4.8 ) . ||| 0-0 1-1 2-2 3-3
Abschnitt 4.8 ) ||| section 4.8 ) ||| 0-0 1-1 2-2
Abschnitt 4.8 ||| section 4.8 ||| 0-0 1-1
Abschnitt 5.1 ) . ||| section 5.1 ) . no ||| 0-0 1-1 2-2 3-3
Abschnitt 5.1 ) . ||| section 5.1 ) . ||| 0-0 1-1 2-2 3-3
Abschnitt 5.1 ) : ||| section 5.1 ) : ||| 0-0 1-1 2-2 3-3
Abschnitt 5.1 ) ||| section 5.1 ) , ||| 0-0 1-1 2-2
Abschnitt 5.1 ) ||| section 5.1 ) ||| 0-0 1-1 2-2
Abschnitt 5.1 ||| section 5.1 ||| 0-0 1-1
Abschnitt 5.2 ) . ||| 4.4 and 5.2 ) . ||| 0-0 1-2 2-3 3-4
Abschnitt 5.2 ) . ||| section 5.2 ) . ||| 0-0 1-1 2-2 3-3
Abschnitt 5.2 ) ||| 4.4 and 5.2 ) ||| 0-0 1-2 2-3
Abschnitt 5.2 ) ||| section 5.2 ) ||| 0-0 1-1 2-2
Abschnitt 5.2 ||| 4.4 and 5.2 ||| 0-0 1-2
Abschnitt 5.2 ||| 5.2 ||| 0-0 1-0
Abschnitt 5.2 ||| section 5.2 ||| 0-0 1-1
Abschnitt 5.3 ) . ||| section 5.3 ) . ||| 0-0 1-1 2-2 3-3
Abschnitt 5.3 ) ||| section 5.3 ) ||| 0-0 1-1 2-2
Abschnitt 5.3 ||| section 5.3 ||| 0-0 1-1
Abschnitt 6.1 ) . ||| section 6.1 ) . ||| 0-0 1-1 2-2 3-3
Abschnitt 6.1 ) ||| section 6.1 ) ||| 0-0 1-1 2-2
Abschnitt 6.1 . ||| , see section 6.1 ||| 0-1 0-2 1-3 2-3
Abschnitt 6.1 . ||| section 6.1 . ||| 0-0 1-1 2-2
Abschnitt 6.1 . ||| see section 6.1 ||| 0-0 0-1 1-2 2-2
Abschnitt 6.1 ||| section 6.1 ||| 0-0 1-1
Abschnitt 6.6 . ||| section 6.6 . ||| 0-0 1-1 2-2
Abschnitt 6.6 aufgeführten ||| in section 6.6 ||| 0-1 1-2
Abschnitt 6.6 aufgeführten ||| mentioned in section 6.6 ||| 0-2 1-3
Abschnitt 6.6 aufgeführten ||| section 6.6 ||| 0-0 1-1
Abschnitt 6.6 ||| in section 6.6 ||| 0-1 1-2
Abschnitt 6.6 ||| mentioned in section 6.6 ||| 0-2 1-3
Abschnitt 6.6 ||| section 6.6 ||| 0-0 1-1
Abschnitt ||| , see section ||| 0-1 0-2
Abschnitt ||| 4.4 and ||| 0-0
Abschnitt ||| 4.4 ||| 0-0
Abschnitt ||| Section ||| 0-0
Abschnitt ||| in section ||| 0-1
Abschnitt ||| mentioned in section ||| 0-2
Abschnitt ||| section 4.4 ) ||| 0-0 0-1 0-2
Abschnitt ||| section ||| 0-0
Abschnitt ||| see section ||| 0-0 0-1
Abschnitte 4.3 und 4.4 ||| sections 4.3 and 4.4 ||| 0-0 1-1 2-2 3-3
Abschnitte 4.3 und ||| sections 4.3 and ||| 0-0 1-1 2-2
Abschnitte 4.3 ||| sections 4.3 ||| 0-0 1-1
Abschnitte 4.8 und 4.9 ) ||| sections 4.8 and 4.9 ) ||| 0-0 1-1 2-2 3-3 4-4
Abschnitte 4.8 und 4.9 ||| sections 4.8 and 4.9 ||| 0-0 1-1 2-2 3-3
Abschnitte 4.8 und ||| sections 4.8 and ||| 0-0 1-1 2-2
Abschnitte 4.8 ||| sections 4.8 ||| 0-0 1-1
Abschnitte ||| sections ||| 0-0
Abseamed 10 000 I.E./1 ||| Abseamed 10 000 IU/ 1 ||| 0-0 1-1 2-2 3-2 3-3 3-4
Abseamed 10 000 I.E./1 ||| Abseamed 10 000 IU/ ||| 0-0 1-1 2-2 3-2 3-3
Abseamed 10 000 ||| Abseamed 10 000 ||| 0-0 1-1 2-2
Abseamed 10 ||| Abseamed 10 ||| 0-0 1-1
Abseamed 1000 I.E./0,5 ml ||| Abseamed 1000 IU/ 0.5 ml ||| 0-0 1-1 1-2 2-3 3-4
Abseamed 1000 I.E./0,5 ||| Abseamed 1000 IU/ 0.5 ||| 0-0 1-1 1-2 2-3
Abseamed 1000 ||| Abseamed 1000 IU/ ||| 0-0 1-1 1-2
Abseamed 1000 ||| Abseamed 1000 ||| 0-0 1-1
Abseamed 2000 I.E./1 ml ||| Abseamed 2000 IU/ 1 ml ||| 0-0 1-1 2-1 2-2 2-3 3-4
Abseamed 2000 I.E./1 ml ||| Abseamed 2000 IU/ 1 ml ||| 0-0 1-1 2-2 2-3 2-4 3-4
Abseamed 2000 I.E./1 ||| Abseamed 2000 IU/ 1 ||| 0-0 1-1 2-1 2-2 2-3
Abseamed 2000 I.E./1 ||| Abseamed 2000 IU/ ||| 0-0 1-1 2-1 2-2
Abseamed 2000 ||| Abseamed 2000 ||| 0-0 1-1
Abseamed 3000 I.E./0,3 ml ||| Abseamed 3000 IU/ 0.3 ml ||| 0-0 1-1 1-2 2-3 3-4
Abseamed 3000 I.E./0,3 ml ||| Abseamed 3000 IU/ 0.3 ml ||| 0-0 1-1 2-2 2-3 3-4
Abseamed 3000 I.E./0,3 ||| Abseamed 3000 IU/ 0.3 ||| 0-0 1-1 1-2 2-3
Abseamed 3000 I.E./0,3 ||| Abseamed 3000 IU/ 0.3 ||| 0-0 1-1 2-2 2-3
Abseamed 3000 ||| Abseamed 3000 IU/ ||| 0-0 1-1 1-2
Abseamed 3000 ||| Abseamed 3000 ||| 0-0 1-1
Abseamed 4000 I.E./0,4 ml ||| Abseamed 4000 IU/ 0.4 ml ||| 0-0 1-1 1-2 2-3 3-4
Abseamed 4000 I.E./0,4 ||| Abseamed 4000 IU/ 0.4 ||| 0-0 1-1 1-2 2-3
Abseamed 4000 ||| Abseamed 4000 IU/ ||| 0-0 1-1 1-2
Abseamed 5000 I.E./0,5 ml ||| Abseamed 5000 IU/ 0.5 ml ||| 0-0 1-1 1-2 2-3 3-4
Abseamed 5000 I.E./0,5 ||| Abseamed 5000 IU/ 0.5 ||| 0-0 1-1 1-2 2-3
Abseamed 5000 ||| Abseamed 5000 IU/ ||| 0-0 1-1 1-2
Abseamed 6000 I.E./0,6 ml ||| Abseamed 6000 IU/ 0.6 ml ||| 0-0 1-1 1-2 2-3 3-4
Abseamed 6000 I.E./0,6 ||| Abseamed 6000 IU/ 0.6 ||| 0-0 1-1 1-2 2-3
Abseamed 6000 ||| Abseamed 6000 IU/ ||| 0-0 1-1 1-2
Abseamed 7000 I.E./0,7 ml ||| Abseamed 7000 IU/ 0.7 ml ||| 0-0 1-1 1-2 2-3 3-4
Abseamed 7000 I.E./0,7 ml ||| Abseamed 7000 IU/ 0.7 ml ||| 0-0 1-1 2-2 2-3 3-4
Abseamed 7000 I.E./0,7 ||| Abseamed 7000 IU/ 0.7 ||| 0-0 1-1 1-2 2-3
Abseamed 7000 I.E./0,7 ||| Abseamed 7000 IU/ 0.7 ||| 0-0 1-1 2-2 2-3
Abseamed 7000 ||| Abseamed 7000 IU/ ||| 0-0 1-1 1-2
Abseamed 7000 ||| Abseamed 7000 ||| 0-0 1-1
Abseamed 8000 I.E./0,8 ml ||| Abseamed 8000 IU/ 0.8 ml ||| 0-0 1-1 1-2 2-3 3-4
Abseamed 8000 I.E./0,8 ml ||| Abseamed 8000 IU/ 0.8 ml ||| 0-0 1-1 2-2 2-3 3-4
Abseamed 8000 I.E./0,8 ||| Abseamed 8000 IU/ 0.8 ||| 0-0 1-1 1-2 2-3
Abseamed 8000 I.E./0,8 ||| Abseamed 8000 IU/ 0.8 ||| 0-0 1-1 2-2 2-3
Abseamed 8000 ||| Abseamed 8000 IU/ ||| 0-0 1-1 1-2
Abseamed 8000 ||| Abseamed 8000 ||| 0-0 1-1
Abseamed 9000 I.E./0,9 ml ||| Abseamed 9000 IU/ 0.9 ml ||| 0-0 1-1 2-2 2-3 3-4
Abseamed 9000 I.E./0,9 ||| Abseamed 9000 IU/ 0.9 ||| 0-0 1-1 2-2 2-3
Abseamed 9000 ||| Abseamed 9000 ||| 0-0 1-1
Abseamed Dosis entsprechend ||| dose of Abseamed accordingly ||| 1-0 2-1 0-2
Abseamed Dosis entsprechend ||| dose of Abseamed ||| 1-0 2-1 0-2
Abseamed Eisenpräparate ||| Abseamed ||| 0-0 1-0
Abseamed Fertigspritze ist ||| Abseamed pre-filled syringe is ||| 0-0 1-1 1-2 2-3
Abseamed Fertigspritze ist ||| The Abseamed pre-filled syringe is ||| 0-1 1-2 1-3 2-4
Abseamed Fertigspritze ||| Abseamed pre-filled syringe ||| 0-0 1-1 1-2
Abseamed Fertigspritze ||| The Abseamed pre-filled syringe ||| 0-1 1-2 1-3
Abseamed angewendet haben , als ||| Abseamed than ||| 0-0 1-0 2-1 4-1
Abseamed angewendet ||| Abseamed ||| 0-0 1-0
Abseamed aufgrund einer Nierenerkrankung erhalten ||| a kidney patient Abseamed ||| 1-0 2-0 3-1 1-2 0-3 4-3
Abseamed beachten ? 3. ||| Abseamed 3. ||| 0-0 1-1 2-1 3-1
Abseamed bei Erwachsenen ||| Abseamed in adult patients ||| 0-0 1-1 1-2 2-2 2-3
Abseamed bei Patienten mit ||| Abseamed in patients at ||| 0-0 1-1 2-2 3-2 1-3
Abseamed brauchen . ||| Abseamed . ||| 0-0 2-1
Abseamed brauchen ||| Abseamed ||| 0-0
Abseamed durch ||| Abseamed ||| 0-0
Abseamed enthält ||| Abseamed contains ||| 0-0 1-1
Abseamed hat keinen Einfluss ||| Abseamed has no influence ||| 0-0 1-1 2-2 3-3
Abseamed hat keinen ||| Abseamed has no ||| 0-0 1-1 2-2
Abseamed hat ||| Abseamed has ||| 0-0 1-1
Abseamed injiziert wurde . ||| Abseamed has been injected . ||| 0-0 2-1 2-2 1-3 2-3 3-4
Abseamed injiziert wurde ||| Abseamed has been injected ||| 0-0 2-1 2-2 1-3 2-3
Abseamed ist ein steriles ||| Abseamed is a sterile ||| 0-0 1-1 2-2 3-3
Abseamed ist ein ||| Abseamed is a ||| 0-0 1-1 2-2
Abseamed ist eine ||| Abseamed is presented as a ||| 0-0 1-1 1-2 2-3 2-4
Abseamed ist ||| Abseamed is presented ||| 0-0 1-1 1-2
Abseamed ist ||| Abseamed is ||| 0-0 1-1
Abseamed kann mit ||| Abseamed may be associated with ||| 0-0 1-1 1-2 2-3 2-4
Abseamed kann ||| Abseamed can be ||| 0-0 1-1 1-2
Abseamed kann ||| Abseamed may be ||| 0-0 1-1 1-2
Abseamed nicht erhalten , da ||| not receive Abseamed , since ||| 1-0 2-1 0-2 3-3 4-4
Abseamed nicht erhalten , ||| not receive Abseamed , ||| 1-0 2-1 0-2 3-3
Abseamed nicht erhalten ||| not receive Abseamed ||| 1-0 2-1 0-2
Abseamed oder ||| Abseamed or ||| 0-0 1-1
Abseamed sollte intravenös gegeben werden ||| Abseamed should be administered intravenously ||| 0-0 1-1 1-2 3-3 2-4 3-4 4-4
Abseamed sollte intravenös ||| Abseamed should be given ||| 0-0 1-1 1-2 2-3
Abseamed sollte mit besonderer Vorsicht ||| Take special care with Abseamed ||| 4-0 1-1 3-1 4-2 2-3 0-4
Abseamed sollte ||| Abseamed should be ||| 0-0 1-1 1-2
Abseamed sollte ||| blood , Abseamed should ||| 0-0 0-2 1-3
Abseamed steigern . ||| Abseamed . ||| 0-0 1-0 2-1
Abseamed steigern ||| Abseamed ||| 0-0 1-0
Abseamed von medizinischem ||| Abseamed may be injected by ||| 0-0 1-1 1-2 2-3 2-4
Abseamed von ||| , Abseamed may be ||| 0-1 1-2 1-3
Abseamed von ||| Abseamed may be ||| 0-0 1-1 1-2
Abseamed wird Ihnen in ||| You will receive Abseamed ||| 0-0 1-1 2-1 2-2 0-3
Abseamed wird Ihnen ||| You will receive Abseamed ||| 0-0 1-1 2-1 2-2 0-3
Abseamed wird als Injektion ||| Abseamed is given by injection ||| 0-0 1-1 3-2 2-3 3-3 3-4
Abseamed wird angewendet : ||| Abseamed is used : ||| 0-0 1-1 2-2 3-3
Abseamed wird angewendet ||| Abseamed is used ||| 0-0 1-1 2-2
Abseamed wird ||| Abseamed is ||| 0-0 1-1
Abseamed zu erzielen , ||| to Abseamed adequate ||| 1-0 0-1 2-2 3-2
Abseamed zu ||| to Abseamed ||| 1-0 0-1
Abseamed zwischen 17 und 33 ||| Abseamed between 17 and 33 ||| 0-0 1-1 2-2 3-3 4-4
Abseamed zwischen 17 und ||| Abseamed between 17 and ||| 0-0 1-1 2-2 3-3
Abseamed zwischen 17 ||| Abseamed between 17 ||| 0-0 1-1 2-2
Abseamed zwischen 25 und 50 ||| Abseamed between 25 and 50 ||| 0-0 1-1 2-2 3-3 4-4
Abseamed zwischen 25 und ||| Abseamed between 25 and ||| 0-0 1-1 2-2 3-3
Abseamed zwischen 25 ||| Abseamed between 25 ||| 0-0 1-1 2-2
Abseamed zwischen ||| Abseamed between ||| 0-0 1-1
Abseamed ||| , Abseamed ||| 0-1
Abseamed ||| Abseamed accordingly ||| 0-0
Abseamed ||| Abseamed has ||| 0-0 0-1
Abseamed ||| Abseamed out ||| 0-0
Abseamed ||| Abseamed ||| 0-0
Abseamed ||| The Abseamed ||| 0-1
Abseamed ||| blood , Abseamed ||| 0-0 0-2
Abseamed ||| of Abseamed ||| 0-1
Absetzen ||| discontinuation ||| 0-0
Absolute ||| fracture event ||| 0-0 0-1
Abstand ||| 3 ||| 0-0
Abständen erfolgen . ||| four weeks . ||| 0-0 1-0 1-1 2-2
Abständen erfolgen ||| four weeks ||| 0-0 1-0 1-1
Abteilungen ||| cell-killing ||| 0-0
Acesulfam-Kalium Vanille-Aroma ||| Acesulfame potassium Vanilla ||| 0-0 0-1 1-2
Acesulfam-Kalium ||| Acesulfame potassium ||| 0-0 0-1
Aclasta ( 5 mg in ||| Aclasta ( 5 mg in ||| 0-0 1-1 2-2 3-3 4-4
Aclasta ( 5 mg ||| Aclasta ( 5 mg ||| 0-0 1-1 2-2 3-3
Aclasta ( 5 ||| Aclasta ( 5 ||| 0-0 1-1 2-2
Aclasta ( N=3.875 ||| Placebo Absolute reduction ( N=3,861 ||| 0-0 0-1 2-2 1-3 2-4
Aclasta ( ||| Aclasta ( ||| 0-0 1-1
Aclasta , Zoledronsäure , ||| Aclasta , zoledronic acid , ||| 0-0 1-1 2-2 2-3 3-4
Aclasta , Zoledronsäure ||| Aclasta , zoledronic acid ||| 0-0 1-1 2-2 2-3
Aclasta , ||| Aclasta , ||| 0-0 1-1
Aclasta . ||| Aclasta . ||| 0-0 1-1
Aclasta 5 mg einmal ||| Aclasta 5 mg once a ||| 0-0 1-1 2-2 3-3 3-4
Aclasta 5 mg ||| Aclasta 5 mg ||| 0-0 1-1 2-2
Aclasta 5 ||| Aclasta 5 ||| 0-0 1-1
Aclasta auftreten , kann durch ||| Aclasta can be ||| 0-0 1-1 3-1 3-2 4-2
Aclasta auftreten , kann ||| Aclasta can be ||| 0-0 1-1 3-1 3-2
Aclasta auftritt ( siehe Abschnitt ||| Aclasta ( see section ||| 0-0 2-1 3-2 4-3
Aclasta auftritt ( siehe ||| Aclasta ( see ||| 0-0 2-1 3-2
Aclasta auftritt ( ||| Aclasta ( ||| 0-0 2-1
Aclasta auftritt . ||| Aclasta . ||| 0-0 2-1
Aclasta auftritt ||| Aclasta ||| 0-0
Aclasta behandelten ||| Aclasta-treated ||| 0-0 1-0
Aclasta bei Kindern und ||| Aclasta in children and ||| 0-0 1-1 2-2 3-3
Aclasta bei Kindern ||| Aclasta in children ||| 0-0 1-1 2-2
Aclasta bei ||| Aclasta in ||| 0-0 1-1
Aclasta darf nicht ||| Aclasta must not be ||| 0-0 1-1 2-2 1-3
Aclasta darf nicht ||| Aclasta should not be ||| 0-0 1-1 1-2 2-2 1-3
Aclasta durchgeführt ? ||| administer Aclasta ||| 0-0 1-0 0-1 2-1
Aclasta einmal jährlich empfohlen ||| Aclasta administered once a year ||| 0-0 3-0 1-1 1-2 1-3 2-4
Aclasta enthält ||| Aclasta contains the ||| 0-0 1-1
Aclasta enthält ||| Aclasta contains ||| 0-0 1-1
Aclasta ergriffen ? ||| Aclasta ? ||| 0-0 1-1 2-1
Aclasta finden Sie hier . ||| Aclasta is available here . ||| 0-0 1-1 3-2 1-3 2-3 3-3 4-4
Aclasta finden Sie hier ||| Aclasta is available here ||| 0-0 1-1 3-2 1-3 2-3 3-3
Aclasta hat keine bekannten ||| Aclasta has no known effects ||| 0-0 1-1 2-2 3-3 2-4
Aclasta hat ||| Aclasta has ||| 0-0 1-1
Aclasta herangezogen . ||| assessing Aclasta . ||| 1-0 0-1 2-2
Aclasta herangezogen ||| assessing Aclasta ||| 1-0 0-1
Aclasta im ||| in Aclasta ||| 1-0 0-1
Aclasta in diesen Studien ||| Aclasta shown during the studies ||| 0-0 1-1 2-1 2-2 3-4
Aclasta in diesen ||| Aclasta shown during the ||| 0-0 1-1 2-1 2-2
Aclasta in diesen ||| Aclasta shown during ||| 0-0 1-1 2-1 2-2
Aclasta ist eine klare und ||| Aclasta is a clear and ||| 0-0 1-1 2-2 3-3 4-4
Aclasta ist eine klare ||| Aclasta is a clear ||| 0-0 1-1 2-2 3-3
Aclasta ist eine ||| Aclasta is a ||| 0-0 1-1 2-2
Aclasta ist kontraindiziert bei Patienten ||| Aclasta is contraindicated for patients ||| 0-0 1-1 2-2 3-3 4-4
Aclasta ist kontraindiziert bei ||| Aclasta is contraindicated for ||| 0-0 1-1 2-2 3-3
Aclasta ist kontraindiziert ||| Aclasta is contraindicated ||| 0-0 1-1 2-2
Aclasta ist ||| Aclasta is ||| 0-0 1-1
Aclasta nach ||| Aclasta after ||| 0-0 1-1
Aclasta oder sie erhielten Risedronat ||| Aclasta or they received risedronate ||| 0-0 1-1 2-2 3-3 4-4
Aclasta oder sie erhielten ||| Aclasta or they received ||| 0-0 1-1 2-2 3-3
Aclasta oder sie ||| Aclasta or they ||| 0-0 1-1 2-2
Aclasta oder ||| Aclasta or ||| 0-0 1-1
Aclasta ordnungsgemäß aufbewahrt werden muss ||| store Aclasta properly ||| 1-0 2-0 0-1 3-1 1-2 4-2
Aclasta ordnungsgemäß aufbewahrt werden muss ||| to store Aclasta properly ||| 1-1 2-1 0-2 3-2 1-3 4-3
Aclasta senkte signifikant ||| Aclasta significantly decreased ||| 0-0 1-1 2-1 2-2
Aclasta siehe Abschnitt 6.6 ||| Aclasta , see section 6.6 ||| 0-0 1-2 2-3 3-4
Aclasta siehe Abschnitt ||| Aclasta , see section ||| 0-0 1-2 2-3
Aclasta siehe ||| Aclasta , see ||| 0-0 1-2
Aclasta stellt ||| Aclasta ||| 0-0
Aclasta treten ||| Aclasta tend to ||| 0-0 1-1
Aclasta treten ||| Aclasta tend ||| 0-0 1-1
Aclasta und 0,8 % für ||| Aclasta and 0.8 % for ||| 0-0 1-1 2-2 3-3 4-4
Aclasta und 0,8 % ||| Aclasta and 0.8 % ||| 0-0 1-1 2-2 3-3
Aclasta und 0,8 ||| Aclasta and 0.8 ||| 0-0 1-1 2-2
Aclasta und Risedronat ||| Aclasta and risedronate ||| 0-0 1-1 2-2
Aclasta und ||| Aclasta and ||| 0-0 1-1
Aclasta verabreicht wird . ||| are given Aclasta . ||| 1-0 1-1 2-1 0-2 3-3
Aclasta verabreicht wird ||| are given Aclasta ||| 1-0 1-1 2-1 0-2
Aclasta vor . ||| Aclasta . ||| 0-0 1-0 2-1
Aclasta vor ||| Aclasta ||| 0-0 1-0
Aclasta wies eine ||| Aclasta demonstrated a ||| 0-0 1-1 2-2
Aclasta wies ||| Aclasta demonstrated ||| 0-0 1-1
Aclasta wird als ||| Aclasta is given as a ||| 0-0 1-1 0-2 2-3 2-4
Aclasta wird nicht empfohlen für ||| Aclasta is not recommended for ||| 0-0 1-1 2-2 3-3 4-4
Aclasta wird nicht empfohlen ||| Aclasta is not recommended ||| 0-0 1-1 2-2 3-3
Aclasta wird nicht ||| Aclasta is not ||| 0-0 1-1 2-2
Aclasta wird ||| Aclasta is given ||| 0-0 1-1 0-2
Aclasta wird ||| Aclasta is ||| 0-0 1-1
Aclasta wirkt , indem ||| Aclasta works by ||| 0-0 1-1 3-2
Aclasta wirkt , ||| Aclasta works ||| 0-0 1-1
Aclasta wirkt ||| Aclasta works ||| 0-0 1-1
Aclasta wurde ||| Aclasta was ||| 0-0 1-1
Aclasta ||| , Aclasta ||| 0-1
Aclasta ||| Aclasta , ||| 0-0
Aclasta ||| Aclasta Placebo Absolute ||| 0-0 0-1 0-2
Aclasta ||| Aclasta as ||| 0-0
Aclasta ||| Aclasta ||| 0-0
Aclasta ||| Placebo Absolute ||| 0-0 0-1
Aclasta ||| substances Aclasta ||| 0-1
Aclasta-Gruppe wies ||| Aclasta ||| 0-0 1-0
Aclasta-Infusion normal ernähren . ||| are treated with Aclasta . ||| 1-0 0-1 2-2 0-3 2-3 3-4
Aclasta-Infusion normal ernähren ||| are treated with Aclasta ||| 1-0 0-1 2-2 0-3 2-3
Aclasta-Infusion ||| Aclasta infusion ||| 0-0
Aclasta-Infusion ||| Aclasta ||| 0-0
Aclasta-Infusionen ab . ||| doses of Aclasta . ||| 1-1 0-2 1-2 2-3
Aclasta-Infusionen ab . ||| of Aclasta . ||| 1-0 0-1 1-1 2-2
Aclasta-Infusionen ab ||| doses of Aclasta ||| 1-1 0-2 1-2
Aclasta-Infusionen ab ||| of Aclasta ||| 1-0 0-1 1-1
Aclasta-Patienten , ||| Aclasta-treated ||| 0-0
Aclasta-Patienten ||| Aclasta-treated ||| 0-0
Aclasta-behandelten Männern ||| men treated ||| 0-0 1-0 1-1
Actos . ||| Actos . ||| 0-0 1-1
Actos 15 mg Tabletten Pioglitazon ||| Actos 15 ||| 0-0 2-0 3-0 1-1 4-1
Actos 15 mg Tabletten aufgetreten ||| taking Actos 15mg tablets ||| 0-0 0-1 2-1 1-2 3-3 4-3
Actos 15 mg Tabletten eingenommen ||| Actos 15mg tablets ||| 0-0 1-1 2-1 3-2 4-2
Actos 15 mg Tabletten ist ||| Actos 15mg tablets is ||| 0-0 1-1 2-1 3-2 4-3
Actos 15 mg Tabletten können ||| Actos 15 mg tablets may ||| 0-0 1-1 2-2 3-3 4-4
Actos 15 mg Tabletten können ||| Actos 15mg tablets can be ||| 0-0 1-1 2-1 3-2 4-3 4-4
Actos 15 mg Tabletten mit ||| Actos 15mg tablets with ||| 0-0 1-1 2-1 3-2 4-3
Actos 15 mg Tabletten sind ||| Actos 15 mg tablets are ||| 0-0 1-1 2-2 3-3 4-4
Actos 15 mg Tabletten werden ||| Actos 15 mg Tabletten werden ||| 0-0 1-1 2-2 0-3 3-3 4-4
Actos 15 mg Tabletten werden ||| Actos 15mg tablets are ||| 0-0 1-1 2-1 3-2 4-3
Actos 15 mg Tabletten ||| Actos 15 mg Tabletten ||| 0-0 1-1 2-2 0-3 3-3
Actos 15 mg Tabletten ||| Actos 15 mg tablets ||| 0-0 1-1 2-2 3-3
Actos 15 mg Tabletten ||| Actos 15mg tablets ||| 0-0 1-1 2-1 3-2
Actos 15 mg ||| Actos 15 mg ||| 0-0 1-1 2-2
Actos 15 mg ||| Actos 15mg ||| 0-0 1-1 2-1
Actos 15 mg ||| Actos 15mg ||| 0-0 2-0 1-1
Actos 15 mg ||| taking Actos 15mg ||| 0-0 0-1 2-1 1-2
Actos 15 ||| Actos 15 ||| 0-0 1-1
Actos 30 mg Tabletten Pioglitazon ||| Actos 30 ||| 0-0 2-0 3-0 1-1 4-1
Actos 30 mg Tabletten aufgetreten ||| taking Actos 30mg tablets ||| 0-0 0-1 1-2 2-2 3-3 4-3
Actos 30 mg Tabletten eingenommen ||| Actos 30mg tablets ||| 0-0 1-1 2-1 3-2 4-2
Actos 30 mg Tabletten ist ||| Actos 30mg tablets is ||| 0-0 1-1 2-1 3-2 4-3
Actos 30 mg Tabletten können ||| Actos 30 mg tablets may ||| 0-0 1-1 2-2 3-3 4-4
Actos 30 mg Tabletten können ||| Actos 30mg tablets can be ||| 0-0 1-1 2-1 3-2 4-3 4-4
Actos 30 mg Tabletten mit ||| Actos 30mg tablets with ||| 0-0 1-1 2-1 3-2 4-3
Actos 30 mg Tabletten sind ||| Actos 30 mg tablets are ||| 0-0 1-1 2-2 3-3 4-4
Actos 30 mg Tabletten werden ||| Actos 30 mg Tabletten werden ||| 0-0 1-1 2-2 0-3 3-3 4-4
Actos 30 mg Tabletten werden ||| Actos 30mg tablets are ||| 0-0 1-1 2-1 3-2 4-3
Actos 30 mg Tabletten ||| Actos 30 mg Tabletten ||| 0-0 1-1 2-2 0-3 3-3
Actos 30 mg Tabletten ||| Actos 30 mg tablets ||| 0-0 1-1 2-2 3-3
Actos 30 mg Tabletten ||| Actos 30mg tablets ||| 0-0 1-1 2-1 3-2
Actos 30 mg ||| Actos 30 mg ||| 0-0 1-1 2-2
Actos 30 mg ||| Actos 30mg ||| 0-0 1-1 2-1
Actos 30 mg ||| Actos 30mg ||| 0-0 2-0 1-1
Actos 30 mg ||| taking Actos 30mg ||| 0-0 0-1 1-2 2-2
Actos 30 ||| Actos 30 ||| 0-0 1-1
Actos 45 mg Tabletten Pioglitazon ||| Actos 45 ||| 0-0 2-0 3-0 1-1 4-1
Actos 45 mg Tabletten aufgetreten ||| taking Actos 45mg tablets ||| 0-0 0-1 1-2 2-2 3-3 4-3
Actos 45 mg Tabletten eingenommen ||| Actos 45mg tablets ||| 0-0 1-1 2-1 3-2 4-2
Actos 45 mg Tabletten ist ||| Actos 45mg tablets is ||| 0-0 1-1 2-1 3-2 4-3
Actos 45 mg Tabletten können ||| Actos 45 mg tablets may ||| 0-0 1-1 2-2 3-3 4-4
Actos 45 mg Tabletten können ||| Actos 45mg tablets can be ||| 0-0 1-1 2-1 3-2 4-3 4-4
Actos 45 mg Tabletten mit ||| Actos 45mg tablets with ||| 0-0 1-1 2-1 3-2 4-3
Actos 45 mg Tabletten werden ||| Actos 45 mg Tabletten werden ||| 0-0 1-1 2-2 0-3 3-3 4-4
Actos 45 mg Tabletten werden ||| Actos 45mg tablets are ||| 0-0 1-1 2-1 3-2 4-3
Actos 45 mg Tabletten ||| Actos 45 mg Tabletten ||| 0-0 1-1 2-2 0-3 3-3
Actos 45 mg Tabletten ||| Actos 45 mg tablets ||| 0-0 1-1 2-2 3-3
Actos 45 mg Tabletten ||| Actos 45mg tablets ||| 0-0 1-1 2-1 3-2
Actos 45 mg ||| Actos 45 mg ||| 0-0 1-1 2-2
Actos 45 mg ||| Actos 45mg ||| 0-0 1-1 2-1
Actos 45 mg ||| Actos 45mg ||| 0-0 2-0 1-1
Actos 45 mg ||| taking Actos 45mg ||| 0-0 0-1 1-2 2-2
Actos 45 ||| Actos 45 ||| 0-0 1-1
Actos Tabletten enthalten Lactose-Monohydrat ||| Actos tablets contain lactose monohydrate ||| 0-0 1-1 2-2 3-3 3-4
Actos Tabletten enthalten ||| Actos tablets contain ||| 0-0 1-1 2-2
Actos Tabletten ||| Actos tablets ||| 0-0 1-1
Actos darf weder ||| Actos should not ||| 0-0 1-1 1-2 2-2
Actos enthält Der arzneilich wirksame ||| Actos contains The active ||| 0-0 1-1 2-2 3-3 4-3
Actos enthält Der ||| Actos contains The ||| 0-0 1-1 2-2
Actos enthält ||| Actos contains ||| 0-0 1-1
Actos ist ein Arzneimittel ||| Actos is a medicine ||| 0-0 1-1 2-2 3-3
Actos ist ein ||| Actos is a ||| 0-0 1-1 2-2
Actos ist ||| Actos is ||| 0-0 1-1
Actos oder Placebo ||| Actos or placebo ||| 0-0 1-1 2-2
Actos oder ||| Actos or ||| 0-0 1-1
Actos und Insulin ||| Actos and insulin ||| 0-0 1-1 2-2
Actos und ||| Actos and ||| 0-0 1-1
Actos waren Sehstörungen , ||| Actos are visual disturbance , ||| 0-0 0-1 2-2 2-3 3-4
Actos waren Sehstörungen ||| Actos are visual disturbance ||| 0-0 0-1 2-2 2-3
Actos waren ||| Actos are ||| 0-0 0-1
Actos wird einmal täglich ||| Actos is taken once daily ||| 0-0 1-1 2-2 2-3 3-3 3-4
Actos wird ||| Actos is ||| 0-0 1-1
Actos wurde ||| Actos has been studied ||| 0-0 1-1 1-2 1-3
Actos zur bestehenden Behandlung ||| Actos to the existing treatment ||| 0-0 1-1 2-3 3-4
Actos zur bestehenden ||| Actos to the existing ||| 0-0 1-1 2-3
Actos zur ||| Actos to the ||| 0-0 1-1
Actos zur ||| Actos to ||| 0-0 1-1
Actos ||| Actos 15mg ||| 0-0 0-1
Actos ||| Actos 30mg ||| 0-0 0-1
Actos ||| Actos 45mg ||| 0-0 0-1
Actos ||| Actos are ||| 0-0 0-1
Actos ||| Actos to ||| 0-0
Actos ||| Actos ||| 0-0
Actos ||| taking Actos ||| 0-0 0-1
Actos-Behandlung ||| when starting Actos ||| 0-0 0-1 0-2
Actraphane 10 : lösliches Insulin ||| Actraphane 10 : soluble insulin ||| 0-0 1-1 2-2 3-3 4-4
Actraphane 10 : lösliches ||| Actraphane 10 : soluble ||| 0-0 1-1 2-2 3-3
Actraphane 10 : ||| Actraphane 10 : ||| 0-0 1-1 2-2
Actraphane 10 NovoLet 100 ||| Actraphane 10 NovoLet 100 ||| 0-0 1-1 2-2 3-3
Actraphane 10 NovoLet ||| Actraphane 10 NovoLet ||| 0-0 1-1 2-2
Actraphane 10 Penfill 100 ||| Actraphane 10 Penfill 100 ||| 0-0 1-1 2-2 3-3
Actraphane 10 Penfill ||| Actraphane 10 Penfill ||| 0-0 1-1 2-2
Actraphane 10 besteht aus 10 ||| Actraphane 10 consists of 10 ||| 0-0 1-1 2-2 3-2 3-3 4-4
Actraphane 10 besteht aus ||| Actraphane 10 consists of ||| 0-0 1-1 2-2 3-2 3-3
Actraphane 10 ||| Actraphane 10 ||| 0-0 1-1
Actraphane 20 : lösliches Insulin ||| Actraphane 20 : soluble insulin ||| 0-0 1-1 2-2 3-3 4-4
Actraphane 20 : lösliches ||| Actraphane 20 : soluble ||| 0-0 1-1 2-2 3-3
Actraphane 20 : ||| Actraphane 20 : ||| 0-0 1-1 2-2
Actraphane 20 NovoLet 100 ||| Actraphane 20 NovoLet 100 ||| 0-0 1-1 2-2 3-3
Actraphane 20 NovoLet ||| Actraphane 20 NovoLet ||| 0-0 1-1 2-2
Actraphane 20 Penfill 100 ||| Actraphane 20 Penfill 100 ||| 0-0 1-1 2-2 3-3
Actraphane 20 Penfill ||| Actraphane 20 Penfill ||| 0-0 1-1 2-2
Actraphane 20 besteht aus 20 ||| Actraphane 20 consists of 20 ||| 0-0 1-1 2-2 3-2 3-3 4-4
Actraphane 20 besteht aus ||| Actraphane 20 consists of ||| 0-0 1-1 2-2 3-2 3-3
Actraphane 20 ||| Actraphane 20 ||| 0-0 1-1
Actraphane 30 100 ||| Actraphane 30 100 ||| 0-0 1-1 2-2
Actraphane 30 40 ||| Actraphane 30 40 ||| 0-0 1-1 2-2
Actraphane 30 : lösliches Insulin ||| Actraphane 30 : soluble insulin ||| 0-0 1-1 2-2 3-3 4-4
Actraphane 30 : lösliches ||| Actraphane 30 : soluble ||| 0-0 1-1 2-2 3-3
Actraphane 30 : ||| Actraphane 30 : ||| 0-0 1-1 2-2
Actraphane 30 NovoLet 100 ||| Actraphane 30 NovoLet 100 ||| 0-0 1-1 2-2 3-3
Actraphane 30 NovoLet ||| Actraphane 30 NovoLet ||| 0-0 1-1 2-2
Actraphane 30 Penfill 100 ||| Actraphane 30 Penfill 100 ||| 0-0 1-1 2-2 3-3
Actraphane 30 Penfill ||| Actraphane 30 Penfill ||| 0-0 1-1 2-2
Actraphane 30 besteht aus 30 ||| Actraphane 30 consists of 30 ||| 0-0 1-1 2-2 3-2 3-3 4-4
Actraphane 30 besteht aus ||| Actraphane 30 consists of ||| 0-0 1-1 2-2 3-2 3-3
Actraphane 30 ||| Actraphane 30 ||| 0-0 1-1
Actraphane 40 : lösliches Insulin ||| Actraphane 40 : soluble insulin ||| 0-0 1-1 2-2 3-3 4-4
Actraphane 40 : lösliches ||| Actraphane 40 : soluble ||| 0-0 1-1 2-2 3-3
Actraphane 40 : ||| Actraphane 40 : ||| 0-0 1-1 2-2
Actraphane 40 NovoLet 100 ||| Actraphane 40 NovoLet 100 ||| 0-0 1-1 2-2 3-3
Actraphane 40 NovoLet ||| Actraphane 40 NovoLet ||| 0-0 1-1 2-2
Actraphane 40 Penfill 100 ||| Actraphane 40 Penfill 100 ||| 0-0 1-1 2-2 3-3
Actraphane 40 Penfill ||| Actraphane 40 Penfill ||| 0-0 1-1 2-2
Actraphane 40 besteht aus 40 ||| Actraphane 40 consists of 40 ||| 0-0 1-1 2-2 3-2 3-3 4-4
Actraphane 40 besteht aus ||| Actraphane 40 consists of ||| 0-0 1-1 2-2 3-2 3-3
Actraphane 40 ||| Actraphane 40 ||| 0-0 1-1
Actraphane 50 : lösliches Insulin ||| Actraphane 50 : soluble insulin ||| 0-0 1-1 2-2 3-3 4-4
Actraphane 50 : lösliches ||| Actraphane 50 : soluble ||| 0-0 1-1 2-2 3-3
Actraphane 50 : ||| Actraphane 50 : ||| 0-0 1-1 2-2
Actraphane 50 NovoLet 100 ||| Actraphane 50 NovoLet 100 ||| 0-0 1-1 2-2 3-3
Actraphane 50 NovoLet ||| Actraphane 50 NovoLet ||| 0-0 1-1 2-2
Actraphane 50 Penfill 100 ||| Actraphane 50 Penfill 100 ||| 0-0 1-1 2-2 3-3
Actraphane 50 Penfill ||| Actraphane 50 Penfill ||| 0-0 1-1 2-2
Actraphane 50 besteht aus 50 ||| Actraphane 50 consists of 50 ||| 0-0 1-1 2-2 3-2 3-3 4-4
Actraphane 50 besteht aus ||| Actraphane 50 consists of ||| 0-0 1-1 2-2 3-2 3-3
Actraphane 50 ||| Actraphane 50 ||| 0-0 1-1
Actraphane NovoLet darf ||| Actraphane NovoLet is ||| 0-0 1-1 2-1 1-2
Actraphane NovoLet ist ||| Actraphane NovoLet is ||| 0-0 1-1 2-2
Actraphane NovoLet ||| Actraphane NovoLet ||| 0-0 1-1
Actraphane Penfill darf ||| Actraphane Penfill is ||| 0-0 1-1 2-1 1-2
Actraphane enthält Metacresol , das ||| Actraphane contains metacresol , which ||| 0-0 1-1 2-2 3-3 2-4 4-4
Actraphane enthält den wirksamen Bestandteil ||| Actraphane contains the active ingredient ||| 0-0 1-1 2-2 2-3 3-3 4-3 4-4
Actraphane enthält sowohl schnell wirkendes ||| Actraphane contains both fast-acting ||| 0-0 1-1 2-2 3-3 4-3
Actraphane enthält sowohl ||| Actraphane contains both ||| 0-0 1-1 2-2
Actraphane enthält ||| Actraphane contains ||| 0-0 1-1
Actraphane erforderlich machen . ||| Actraphane . ||| 0-0 1-0 2-0 3-1
Actraphane erforderlich machen ||| Actraphane ||| 0-0 1-0 2-0
Actraphane finden Sie hier ||| Actraphane can be found here ||| 0-0 1-1 1-2 1-3 2-4 3-4
Actraphane finden ||| Actraphane can be found ||| 0-0 1-1 1-2 1-3
Actraphane in diesen Studien ||| Actraphane shown during the studies ||| 0-0 1-1 2-1 2-2 3-4
Actraphane in diesen ||| Actraphane shown during the ||| 0-0 1-1 2-1 2-2
Actraphane in diesen ||| Actraphane shown during ||| 0-0 1-1 2-1 2-2
Actraphane ist eine Mischung ||| Actraphane is a mixture ||| 0-0 1-1 2-2 3-3
Actraphane ist eine Reihe von ||| Actraphane is a range of ||| 0-0 1-1 2-2 3-3 4-4
Actraphane ist eine Reihe ||| Actraphane is a range ||| 0-0 1-1 2-2 3-3
Actraphane ist eine ||| Actraphane is a ||| 0-0 1-1 2-2
Actraphane ist ||| Actraphane is ||| 0-0 1-1
Actraphane kann ||| Actraphane may ||| 0-0 1-1
Actraphane sollte nicht ||| Actraphane should not be ||| 0-0 1-1 2-2 1-3
Actraphane wird normalerweise ||| Actraphane is usually ||| 0-0 1-1 2-2
Actraphane wird subkutan ( ||| Actraphane is given subcutaneously ( ||| 0-0 1-1 2-2 2-3 3-4
Actraphane wird subkutan ||| Actraphane is given subcutaneously ||| 0-0 1-1 2-2 2-3
Actraphane wird ||| Actraphane is ||| 0-0 1-1
Actraphane wurde an ||| Actraphane has been studied in ||| 0-0 1-1 1-2 1-3 2-3 2-4
Actraphane ||| Actraphane ||| 0-0
Adipositas ( ca . ||| Adipositas ( ca . Me ||| 0-0 1-1 2-2 3-3 2-4
Adipositas ( ||| Adipositas ( ||| 0-0 1-1
Adipositas ) höher und ||| obesity ) and ||| 0-0 2-0 1-1 3-2
Adipositas ) höher ||| obesity ) ||| 0-0 2-0 1-1
Adipositas infolge des höheren ||| Adipositas infolge des höheren ||| 0-0 1-1 2-2 1-3
Adipositas infolge des ||| Adipositas infolge des höheren ||| 0-0 1-1 2-2 1-3
Adipositas ist die Eliminationshalbwertszeit wegen ||| Adipositas ist die Eliminationshalbwertszeit wegen ||| 0-0 1-1 2-2 3-3 3-4
Adipositas ist die Eliminationshalbwertszeit ||| Adipositas ist die Eliminationshalbwertszeit wegen ||| 0-0 1-1 2-2 3-3 3-4
Adipositas ist die ||| Adipositas ist die ||| 0-0 1-1 2-2
Adipositas ist eine Erkrankung , ||| ( See section ||| 0-0 0-1 3-1
Adipositas ist eine Erkrankung , ||| ( See ||| 0-0 0-1 3-1
Adipositas ist eine Erkrankung ||| ( See section ||| 0-0 0-1 3-1
Adipositas ist eine Erkrankung ||| ( See ||| 0-0 0-1 3-1
Adipositas ist ||| Adipositas ist ||| 0-0 1-1
Adipositas oder ||| obese or overweight ||| 0-0 1-1 0-2
Adipositas und übergewichtigen ||| in ||| 2-0
Adipositas ||| Adipositas ||| 0-0
Adipositas ||| obese ||| 0-0
Affen , ||| monkeys , ||| 0-0 1-1
Affen nach wiederholter oraler Gabe ||| monkeys after repeated oral ||| 0-0 1-1 2-2 3-3 4-3
Affen nach wiederholter ||| monkeys after repeated ||| 0-0 1-1 2-2
Affen nach ||| monkeys after ||| 0-0 1-1
Affen ||| monkeys ||| 0-0
Affen ||| or monkeys ||| 0-1
Affinität zu Muscarin-Rezeptoren . ||| affinity for muscarinic receptors . ||| 0-0 0-1 1-2 2-2 2-3 3-4
Affinität zu Muscarin-Rezeptoren ||| affinity for muscarinic receptors ||| 0-0 0-1 1-2 2-2 2-3
Affinität ||| affinity for ||| 0-0 0-1
Affinität ||| affinity ||| 0-0
Agitiertheit , Nervosität ||| agitation , nervousness ||| 0-0 1-1 2-2
Agitiertheit , ||| agitation , ||| 0-0 1-1
Agitiertheit 110 und Verhaltensstörungen ||| agitation and disturbed behaviours , ||| 0-0 2-1 3-2 3-3
Agitiertheit 110 und Verhaltensstörungen ||| agitation and disturbed behaviours ||| 0-0 2-1 3-2 3-3
Agitiertheit 110 und ||| agitation and ||| 0-0 2-1
Agitiertheit 110 ||| agitation ||| 0-0
Agitiertheit und Verhaltensstörungen ||| agitation and disturbed behaviours ||| 0-0 1-1 2-2 2-3
Agitiertheit und Verhaltenstörungen ||| agitation and disturbed behaviours ||| 0-0 2-0 1-1 0-2 0-3
Agitiertheit und ||| agitation and ||| 0-0 1-1
Agitiertheit ||| agitation ||| 0-0
Agitiertheit/Verhaltenstörungen ||| agitation/ behavioural ||| 0-0 0-1
Agitiertheit/Verhaltenstörungen ||| in agitation/ behavioural ||| 0-1 0-2
Akathisie , Tremor , Schwindel ||| akathisia , tremor , dizziness ||| 0-0 1-1 2-2 3-3 4-4
Akathisie , Tremor , ||| akathisia , tremor , ||| 0-0 1-1 2-2 3-3
Akathisie , Tremor ||| akathisia , tremor ||| 0-0 1-1 2-2
Akathisie , ||| akathisia , ||| 0-0 1-1
Akathisie , Übelkeit und Erbrechen ||| akathisia , nausea and vomiting ||| 0-0 1-1 2-2 3-3 4-4
Akathisie , Übelkeit und ||| akathisia , nausea and ||| 0-0 1-1 2-2 3-3
Akathisie , Übelkeit ||| akathisia , nausea ||| 0-0 1-1 2-2
Akathisie 6,2 % mit ||| akathisia was 6.2 % with ||| 0-0 0-1 1-2 2-3 3-4
Akathisie 6,2 % ||| akathisia was 6.2 % ||| 0-0 0-1 1-2 2-3
Akathisie 6,2 ||| akathisia was 6.2 ||| 0-0 0-1 1-2
Akathisie Erkrankungen des Gastrointestinaltrakts Häufig ||| akathisia Gastrointestinal disorders Common ||| 0-0 3-1 1-2 2-2 4-3
Akathisie Erkrankungen des Gastrointestinaltrakts ||| akathisia Gastrointestinal disorders ||| 0-0 3-1 1-2 2-2
Akathisie bei bipolaren Patienten ||| akathisia in bipolar patients ||| 0-0 1-1 1-2 2-2 3-3
Akathisie bei bipolaren Patienten ||| akathisia in bipolar patients ||| 0-0 1-1 2-2 3-3
Akathisie bei bipolaren ||| akathisia in bipolar ||| 0-0 1-1 1-2 2-2
Akathisie bei bipolaren ||| akathisia in bipolar ||| 0-0 1-1 2-2
Akathisie bei ||| akathisia in ||| 0-0 1-1
Akathisie kommt ||| Akathisia is ||| 0-0 1-0
Akathisie kommt ||| Akathisia ||| 0-0 1-0
Akathisie ||| akathisia was ||| 0-0 0-1
Akathisie ||| akathisia ||| 0-0
Aktivität , Konzentration und ||| activity , concentrations and ||| 0-0 1-1 2-2 3-3
Aktivität , Konzentration ||| activity , concentrations ||| 0-0 1-1 2-2
Aktivität , ||| activity , ||| 0-0 1-1
Aktivität und ||| activity and ||| 0-0 1-1
Aktivität von Rimonabant wurde ||| activity of rimonabant was ||| 0-0 1-1 2-2 3-3
Aktivität von Rimonabant ||| activity of rimonabant ||| 0-0 1-1 2-2
Aktivität von ||| activity of ||| 0-0 1-1
Aktivität zu erhöhen ||| to increase their physical activity ||| 1-0 2-1 1-2 0-3 0-4
Aktivität ||| activity ||| 0-0
Aktivität ||| physical activity ||| 0-0 0-1
Aktivität ||| physical ||| 0-0
Aktivkohle ( 50 ||| Activated charcoal ( 50 ||| 0-0 0-1 1-2 2-3
Aktivkohle ( ||| Activated charcoal ( ||| 0-0 0-1 1-2
Aktivkohle ||| 52 Activated ||| 0-0 0-1
Aktivkohle ||| 76 Activated ||| 0-1
Aktivkohle ||| 88 Activated ||| 0-0 0-1
Aktivkohle ||| Activated charcoal ||| 0-0 0-1
Aktivkohle ||| Activated ||| 0-0
Aktuelle Werte aus ||| Actual scores ||| 0-0 0-1 1-1 2-1
Akute Toxizität Die höchste ||| Acute toxicity The highest ||| 0-0 1-1 2-2 3-3
Akute Toxizität Die ||| Acute toxicity The ||| 0-0 1-1 2-2
Akute Toxizität ||| Acute toxicity ||| 0-0 1-1
Akute ||| Acute ||| 0-0
Albumin-gebundene Nanopartikelformulierung ||| albumin-bound nanoparticle ||| 0-0 1-1
Albumin-gebundene ||| albumin-bound ||| 0-0
Albuminlösung vom Menschen ( enthält ||| Human albumin solution ( containing ||| 0-0 1-0 2-0 0-1 4-2 3-3 4-4
Albuminlösung vom Menschen ||| Human albumin ||| 0-0 1-0 2-0 0-1
Alcobendas ||| 28108 Alcobendas ||| 0-0 0-1
Aldwych , London , WC2B ||| Aldwych , London , WC2B ||| 0-0 1-1 2-2 3-3 4-4
Aldwych , London , ||| Aldwych , London , ||| 0-0 1-1 2-2 3-3
Aldwych , London ||| Aldwych , London ||| 0-0 1-1 2-2
Aldwych , ||| Aldwych , ||| 0-0 1-1
Aldwych London WC2B 4AE Vereinigtes ||| Aldwych London WC2B 4AE United ||| 0-0 1-1 2-2 3-3 4-4
Aldwych London WC2B 4AE ||| Aldwych London WC2B 4AE ||| 0-0 1-1 2-2 3-3
Aldwych London WC2B ||| Aldwych London WC2B ||| 0-0 1-1 2-2
Aldwych London ||| Aldwych London ||| 0-0 1-1
Aldwych ||| Aldwych ||| 0-0
Alkohol kann ||| Alcohol may ||| 0-0 1-1
Alkohol oder anderen zentral wirksamen ||| alcohol or other CNS ||| 0-0 1-1 2-2 3-3 4-3
Alkohol oder anderen ||| alcohol or other ||| 0-0 1-1 2-2
Alkohol oder ||| alcohol or ||| 0-0 1-1
Alkohol ||| Alcohol ||| 0-0
Alkohol ||| alcohol ||| 0-0
Alkohol- oder ||| alcohol or ||| 0-0 1-0 1-1
Alkoholtupfer . ||| alcohol wipe . ||| 0-0 0-1 1-2
Alkoholtupfer ||| alcohol wipe ||| 0-0 0-1
Alle Frauen erhielten ||| All women received ||| 0-0 1-1 2-2
Alle Frauen ||| All women ||| 0-0 1-1
Alle Patienten , ||| All patients being ||| 0-0 1-1 0-2 2-2
Alle Patienten unter Abseamed ||| Alle Patienten unter Abseamed ||| 0-0 0-1 1-1 0-2 2-2 3-3
Alle Patienten unter ||| Alle Patienten unter ||| 0-0 0-1 1-1 0-2 2-2
Alle Teilnehmer erhielten eine ||| All participants received ||| 0-0 1-1 2-2 3-2
Alle Teilnehmer ||| All participants ||| 0-0 1-1
Alle anderen Anämieursachen ||| All other causes of anaemia ||| 0-0 1-1 2-2 2-3 2-4
Alle anderen ||| All other ||| 0-0 1-1
Alle spezifischen Warnhinweise und ||| All special warnings and ||| 0-0 1-1 1-2 2-2 3-3
Alle spezifischen Warnhinweise ||| All special warnings ||| 0-0 1-1 1-2 2-2
Alle ||| All ||| 0-0
Allerdings ||| However ||| 0-0
Allergische Reaktion ( ||| allergic reaction ( ||| 0-0 0-1 1-1 2-2
Allergische Reaktion ||| allergic reaction ||| 0-0 0-1 1-1
Allgemein ) ||| General ) ||| 0-0 1-1
Allgemein ||| General ||| 0-0
Allgemeine Erkrankungen und Beschwerden ||| General disorders and administration ||| 0-0 3-0 1-1 2-2 3-3
Allgemeinen gut absorbiert . ||| somewhat higher but the systemic ||| 2-0 0-1 2-1 2-2 2-4
Allgemeinen gut absorbiert ||| somewhat higher but the systemic ||| 2-0 0-1 2-1 2-2 2-4
Allgemeinzustand , Brustschmerzen , ||| performance status , chest pain ||| 0-0 1-1 1-2 3-2 2-3 2-4
Allgemeinzustand ||| performance ||| 0-0
Allé DK-2880 Bagsværd Dänemark ||| Allé DK-2880 Bagsværd Denmark ||| 0-0 1-1 2-2 3-3
Allé DK-2880 Bagsværd ||| Allé DK-2880 Bagsværd ||| 0-0 1-1 2-2
Allé DK-2880 ||| Allé DK-2880 ||| 0-0 1-1
Allé ||| Allé ||| 0-0
Alopezie wurde bei 90 ||| Alopecia was observed in 90 ||| 0-0 1-1 1-2 2-3 3-4
Alopezie wurde bei ||| Alopecia was observed in ||| 0-0 1-1 1-2 2-3
Alopezie wurde ||| Alopecia was observed ||| 0-0 1-1 1-2
Alopezie ||| Alopecia ||| 0-0
Als Folge der ||| As a consequence of ||| 0-0 1-1 0-2 1-2 2-3
Als Folge ||| As a consequence ||| 0-0 1-1 0-2 1-2
Als mögliches Warnsignal sollten ||| Attention should be paid ||| 0-0 1-0 1-1 2-2 2-3 3-3
Als mögliches Warnsignal sollten ||| Particular attention should be paid ||| 0-0 1-1 1-2 2-3 2-4 3-4
Als mögliches ||| Attention should ||| 0-0 1-0 1-1
Als mögliches ||| Particular attention should ||| 0-0 1-1 1-2
Als ||| At equivalent doses , ||| 0-0 0-1 0-2
Als ||| At equivalent doses ||| 0-0 0-1 0-2
Als ||| Particular ||| 0-0
Alter , Geschlecht und Gesamtkrankheitslast ||| age , gender , and ||| 0-0 1-1 2-2 4-2 1-3 3-4
Alter , Rasse oder ||| age , race or ||| 0-0 1-1 2-2 3-3
Alter , Rasse ||| age , race ||| 0-0 1-1 2-2
Alter , ||| age , ||| 0-0 1-1
Alter von ||| of age ||| 1-0 0-1
Alter von über 65 Jahren ||| aged over 65 years ||| 3-0 2-1 3-2 0-3 1-3 4-3
Alter ||| age ||| 0-0
Altersgruppe ||| age group ||| 0-0 0-1
Altersgruppe ||| age where ||| 0-0
Altersgruppe ||| age ||| 0-0
Aluminium/Aluminium-Blisterpackung , Packungen mit ||| Aluminium/ aluminium blisters , packs ||| 0-0 2-0 0-1 1-1 2-2 1-3 2-4 3-4
Am Ende eines ||| At the end of a ||| 0-0 1-1 1-2 2-3 0-4 2-4
Amerika ||| American post ||| 0-0 0-1
Amidohydrolase-Stoffwechselwege ( hauptsächlich ||| amidohydrolase ( predominantly ||| 0-0 1-1 0-2 2-2
Aminoglykoside oder Diuretika , die ||| aminoglycosides or diuretics that ||| 0-0 1-1 2-2 3-3 4-3
Aminoglykoside oder Diuretika ||| aminoglycosides or diuretics ||| 0-0 1-1 2-2
Aminoglykoside oder ||| aminoglycosides or ||| 0-0 1-1
Aminoglykoside ||| aminoglycosides ||| 0-0
Aminosäuren . ||| amino acids . ||| 0-0 0-1 1-2
Aminosäuren ||| amino acids ||| 0-0 0-1
Anagni-Frosinone Italien ||| Anagni-Frosinone Italy ||| 0-0 1-1
Anagni-Frosinone ||| Anagni-Frosinone ||| 0-0
Analoga zur Injektion , ||| analogues for injection , ||| 0-0 1-0 1-1 2-2 3-3
Analoga zur Injektion ||| analogues for injection ||| 0-0 1-0 1-1 2-2
Analoga zur ||| analogues for ||| 0-0 1-0 1-1
Analogue Scale ( CLAS ) ||| Analogue Scale ( CLAS ) ||| 0-0 1-0 0-1 2-2 3-3 4-4
Analogue Scale ( CLAS ||| Analogue Scale ( CLAS ||| 0-0 1-0 0-1 2-2 3-3
Analogue Scale ( ||| Analogue Scale ( ||| 0-0 1-0 0-1 2-2
Analogue Scale ||| Analogue Scale ||| 0-0 1-0 0-1
Analyse ||| analysis ||| 0-0
Analysen ( Altersspektrum ||| pharmacokinetic analysis ( ||| 0-0 0-1 2-1 1-2
Analysen ( Altersspektrum ||| population pharmacokinetic analysis ( ||| 0-1 0-2 2-2 1-3
Analysen von Untergruppen ||| subpopulation analyses ||| 0-0 2-1
Analysen von ||| subpopulation ||| 0-0
Analysen zeigten , dass die ||| analysis indicated that ||| 0-0 1-0 4-1 2-2 3-2 4-2
Analysen zeigten ||| analysis ||| 0-0 1-0
Analysen ||| subpopulation ||| 0-0
Anaphylaktische Reaktionen Symptome generalisierter ||| Anaphylactic reactions Symptoms of generalised ||| 0-0 1-1 0-2 2-2 3-4
Anaphylaktische Reaktionen Symptome ||| Anaphylactic reactions Symptoms of ||| 0-0 1-1 0-2 2-2
Anaphylaktische Reaktionen Symptome ||| Anaphylactic reactions Symptoms ||| 0-0 1-1 0-2 2-2
Anbetracht ||| superfluous ||| 0-0
Anbruch innerhalb von 6 ||| within 6 ||| 1-0 0-1 3-1
Anbruch oder bei Aufbewahrung bei ||| when used or stored at ||| 0-0 0-1 1-2 2-3 3-3 3-4 4-4
Anbruch oder ||| when used or ||| 0-0 0-1 1-2
Anbruch ||| when used ||| 0-0 0-1
Andere Störungen des Knochenstoffwechsels ||| Other disturbances of mineral metabolism ||| 0-0 1-1 2-2 3-3 3-4
Andere Störungen des ||| Other disturbances of ||| 0-0 1-1 2-2
Andere Störungen ||| Other disturbances ||| 0-0 1-1
Andere hochwirksame Inhibitoren von CYP3A4 ||| Other potent inhibitors of CYP3A4 ||| 0-0 1-1 2-2 3-3 4-4
Andere hochwirksame Inhibitoren von ||| Other potent inhibitors of ||| 0-0 1-1 2-2 3-3
Andere hochwirksame Inhibitoren ||| Other potent inhibitors ||| 0-0 1-1 2-2
Andere hochwirksame ||| Other potent ||| 0-0 1-1
Andere ||| Other ||| 0-0
Androgensuppression ist ||| androgen suppression is ||| 0-0 0-1 1-2
Androgensuppression ||| androgen suppression ||| 0-0 0-1
Aneurysmen ||| aneurysms ||| 0-0
Anfangsdosierung ||| starting ||| 0-0
Anfangsdosis 50 ||| Starting dose of 50 ||| 0-0 0-1 1-3
Anfangsdosis beträgt 15 mg ||| starting dose is 15 mg ||| 0-0 0-1 1-2 2-3 3-4
Anfangsdosis beträgt 15 ||| starting dose is 15 ||| 0-0 0-1 1-2 2-3
Anfangsdosis beträgt 150 ||| initial dose is 150 ||| 0-0 0-1 1-2 2-3
Anfangsdosis beträgt ||| initial dose is ||| 0-0 0-1 1-2
Anfangsdosis beträgt ||| starting dose is ||| 0-0 0-1 1-2
Anfangsdosis für ABILIFY beträgt ||| starting dose for ABILIFY is ||| 0-0 0-1 1-2 2-3 3-4
Anfangsdosis für ABILIFY ||| starting dose for ABILIFY ||| 0-0 0-1 1-2 2-3
Anfangsdosis für Aripiprazol ||| starting dose for ABILIFY ||| 0-0 0-1 1-2 0-3 2-3
Anfangsdosis für ||| initial dose for ||| 0-0 0-1 1-2
Anfangsdosis für ||| starting dose for ||| 0-0 0-1 1-2
Anfangsdosis ist 150 Internationale ||| starting dose is 150 International ||| 0-0 0-1 1-2 2-3 3-4
Anfangsdosis ist 150 ||| starting dose is 150 ||| 0-0 0-1 1-2 2-3
Anfangsdosis ist 50 Internationale ||| starting dose is 50 International ||| 0-0 0-1 1-2 2-3 3-4
Anfangsdosis ist 50 ||| starting dose is 50 ||| 0-0 0-1 1-2 2-3
Anfangsdosis ist 600 Internationale ||| starting dose is 600 International ||| 0-0 0-1 1-2 2-3 3-4
Anfangsdosis ist 600 ||| starting dose is 600 ||| 0-0 0-1 1-2 2-3
Anfangsdosis ist ||| starting dose is ||| 0-0 0-1 1-2
Anfangsdosis von 50 ||| Starting dose of 50 ||| 0-0 0-1 1-2 2-3
Anfangsdosis von ||| Starting dose of ||| 0-0 0-1 1-2
Anfangsdosis ||| Starting dose of ||| 0-0 0-1
Anfangsdosis ||| Starting dose ||| 0-0 0-1
Anfangsdosis ||| dose ||| 0-0
Anfangsdosis ||| initial dose ||| 0-0 0-1
Anfangsdosis ||| starting dose ||| 0-0 0-1
Anforderung ||| request ||| 0-0
Angaben auf Sie zutrifft ||| applies to you ||| 0-0 3-0 1-1 2-2
Angehörige oder andere nahestehende Personen ||| other relevant persons ||| 1-0 2-0 1-1 0-2 3-2
Angehörige oder andere nahestehende ||| other relevant persons ||| 1-0 2-0 1-1 0-2 3-2
Angesichts dieser ||| Haemoglobin variability ||| 0-0 0-1 1-1
Angina pectoris , erhöhtes Risiko ||| angina pectoris , increased risk ||| 0-0 1-1 2-2 3-3 4-4
Angina pectoris , erhöhtes ||| angina pectoris , increased ||| 0-0 1-1 2-2 3-3
Angina pectoris , ||| angina pectoris , ||| 0-0 1-1 2-2
Angina pectoris ||| angina pectoris ||| 0-0 1-1
Angina ||| angina ||| 0-0
Angina ||| unstable angina pectoris ||| 0-0 0-1 0-2
Angiotensin II-Antagonisten , Calciumantagonisten ||| angiotensin II antagonists , calcium ||| 0-0 1-1 0-2 1-2 3-2 2-3 3-4
Angiotensin-Converting-Enzyme ( ACE)-Hemmer ||| angiotensin converting enzyme ( ||| 0-0 0-1 2-2 1-3
Angiotensin-Converting-Enzyme ||| angiotensin converting ||| 0-0 0-1
Angioödem ||| angioedema ||| 0-0
Angioödeme einschließlich geschwollener ||| angioedema including swollen tongue ||| 0-0 1-1 0-2 2-2 2-3
Angioödemen und anaphylaktischen Reaktionen . ||| angioedema and anaphylactic reaction . ||| 0-0 1-1 2-2 2-3 3-3 4-4
Angioödemen und anaphylaktischen Reaktionen ||| angioedema and anaphylactic reaction ||| 0-0 1-1 2-2 2-3 3-3
Angioödemen und ||| angioedema and ||| 0-0 1-1
Angioödemen ||| angioedema ||| 0-0
Angst und ||| and dizziness . ||| 1-0 0-1
Angst und ||| and dizziness ||| 1-0 0-1
Angst ||| dizziness . ||| 0-0
Angst ||| dizziness ||| 0-0
Angstgefühl , ||| feeling anxious , ||| 0-0 0-1 1-2
Angstgefühl ||| feeling anxious ||| 0-0 0-1
Angstzustände ||| clinical trials . ||| 0-0 0-1 0-2
Anhaltende Schmerzen und/oder nicht heilende ||| Persistent pain and/ or non-healing ||| 0-0 1-1 2-2 2-3 4-4
Anhaltende Schmerzen und/oder nicht ||| Persistent pain and/ or ||| 0-0 1-1 2-2 2-3
Anhaltende Schmerzen und/oder ||| Persistent pain and/ or ||| 0-0 1-1 2-2 2-3
Anhaltende Schmerzen ||| Persistent pain ||| 0-0 1-1
Anhaltende ||| Persistent ||| 0-0
Anhang I ) ||| Annex I ) ||| 0-0 1-0 1-1 2-2
Anhang I ||| Annex I ||| 0-0 1-0 1-1
Anhang ||| Annex ||| 0-0
Annähernd ein Drittel der Patienten ||| Approximately one third of patients ||| 0-0 0-1 1-1 2-2 3-3 4-4
Annähernd ein Drittel der ||| Approximately one third of ||| 0-0 0-1 1-1 2-2 3-3
Annähernd ein Drittel ||| Approximately one third ||| 0-0 0-1 1-1 2-2
Annähernd ein ||| Approximately one ||| 0-0 0-1 1-1
Anorexie , Hyponatriämie ||| anorexia , hyponatremia ||| 0-0 1-1 2-2
Anorexie , schwere Gewichtsabnahme ||| anorexia , severe weight ||| 0-0 1-1 2-2 3-3
Anorexie , schwere ||| anorexia , severe ||| 0-0 1-1 2-2
Anorexie , ||| anorexia , ||| 0-0 1-1
Anorexie ||| anorexia ||| 0-0
Anpassung der Dosis Begleiterkrankungen , ||| Dosage adjustment Concomitant illness , ||| 0-0 0-1 0-2 1-2 3-2 2-3 3-3 4-4
Anpassung der Dosis Begleiterkrankungen ||| Dosage adjustment Concomitant illness ||| 0-0 0-1 0-2 1-2 3-2 2-3 3-3
Anpassung der Dosis notwendig ||| Anpassung der Dosis notwendig ||| 0-0 0-1 1-1 0-2 3-3
Anpassung der Dosis ||| Anpassung der Dosis ||| 0-0 0-1 1-1 0-2
Anpassung der ||| Anpassung der Dosis ||| 0-0 0-1 1-1 0-2
Anpassung einer ||| dosage of medicinal ||| 0-0 1-1 0-2
Anschließend sollte Ihr Hund ||| Thereafter , your dog should ||| 0-0 1-1 2-2 2-3 3-3 1-4
Anschließend stabilisierten sich die Knochenmarker ||| Thereafter bone markers stabilised ||| 0-0 1-1 3-2 4-2 1-3 2-3 4-3
Anschließend ||| Thereafter , ||| 0-0
Anschließend ||| Thereafter ||| 0-0
Anschrift der Hersteller ||| address of ||| 0-0 2-0 1-1
Anschrift der ||| address of ||| 0-0 1-1
Anschrift des Herstellers , der ||| address of the manufacturer ||| 0-0 1-0 1-1 1-2 4-2 2-3 3-3
Anschrift des Herstellers , der ||| address of the manufacturer ||| 0-0 1-0 2-0 1-1 3-2 4-2 2-3
Anschrift des Herstellers ||| address of the manufacturer ||| 0-0 1-1 1-2 2-3
Anschrift des ||| address of the ||| 0-0 1-1 1-2
Anschrift des/der ||| address ||| 0-0 1-0
Anschrift ||| address ||| 0-0
Anschwellen der Hände , ||| swelling of hands , ||| 0-0 1-1 2-2 3-3
Anschwellen der Hände ||| swelling of hands ||| 0-0 1-1 2-2
Anschwellen der ||| swelling of ||| 0-0 1-1
Anschwellen ||| swelling ||| 0-0
Ansprechen bei ||| response ||| 0-0
Ansprechen war definiert als ||| was defined as the patient ||| 0-0 1-0 2-1 3-2
Ansprechen war definiert als ||| was defined as the ||| 0-0 1-0 2-1 3-2
Ansprechen war definiert als ||| was defined as ||| 0-0 1-0 2-1 3-2
Ansprechen war definiert ||| was defined ||| 0-0 1-0 2-1
Ansprechen war ||| was ||| 0-0 1-0
Ansprechen ||| response ||| 0-0
Ansprechrate , ||| rate , ||| 0-0 1-1
Ansprechrate [ 95 ||| Response rate [ 95 ||| 0-0 0-1 1-2 2-3
Ansprechrate [ ||| Response rate [ ||| 0-0 0-1 1-2
Ansprechrate ||| Response rate ||| 0-0 0-1
Ansprechrate ||| rate ||| 0-0
Ansprechraten bei allen Patienten ||| response rates in all patients ||| 0-0 0-1 1-2 2-3 3-4
Ansprechraten bei allen ||| response rates in all ||| 0-0 0-1 1-2 2-3
Ansprechraten bei ||| response rates in ||| 0-0 0-1 1-2
Ansprechraten ||| response rates ||| 0-0 0-1
Anstieg der AUC um ||| increase in AUC ||| 0-0 1-0 3-1 2-2 3-2
Anstieg der ||| increase ||| 0-0 1-0
Anstieg der ||| increases ||| 0-0
Anstieg des Hämatokritwertes ||| the rise in packed ||| 1-0 0-1 1-1 0-2 2-3
Anstieg des Hämoglobins um mehr ||| rise in haemoglobin of greater ||| 0-0 1-0 2-0 0-1 2-2 3-2 1-3 4-4
Anstieg des Hämoglobins um ||| rise in haemoglobin of ||| 0-0 1-0 2-0 0-1 2-2 3-2 1-3
Anstieg des ||| the rise in ||| 1-0 0-1 1-1 0-2
Anstieg von ||| increase of ||| 0-0
Anstieg von ||| increase ||| 0-0
Anstieg ||| increase of ||| 0-0
Anstieg ||| increase ||| 0-0
Anstieg ||| increases ||| 0-0
Antagonist . ||| antagonist . ||| 0-0 1-1
Antagonist ||| antagonist ||| 0-0
Anteil der Patienten , der ||| Anteil der Patienten , der ||| 0-0 1-1 2-2 3-3 4-4
Anteil der Patienten , ||| Anteil der Patienten , ||| 0-0 1-1 2-2 3-3
Anteil der Patienten ||| Anteil der Patienten ||| 0-0 1-1 2-2
Anteil der Patienten ||| proportion of patients ||| 0-0 1-1 2-2
Anteil der ||| Anteil der ||| 0-0 1-1
Anteil der ||| proportion of ||| 0-0 1-1
Anteil von Dehydro-Aripiprazol , ||| , dehydro-aripiprazole , ||| 3-0 0-1 1-1 2-1 3-2
Anteil von Dehydro-Aripiprazol ||| dehydro-aripiprazole ||| 0-0 1-0 2-0
Anteil ||| Anteil ||| 0-0
Anteil ||| proportion ||| 0-0
Anthracyclin ( ||| anthracycline ( ||| 0-0 1-1
Anthracyclin ||| anthracycline ||| 0-0
Anthracyclin-Behandlung oder ||| anthracyclines or ||| 0-0 1-1
Anthracyclin-Behandlung ||| anthracyclines ||| 0-0
Antibiotika). ||| antibiotics ||| 0-0
Antidiabetika ( OAD ) ||| hypoglycaemic agents ( OHA ) ||| 0-0 0-1 1-2 0-3 2-3 3-4
Antidiabetika ( OAD ||| hypoglycaemic agents ( OHA ||| 0-0 0-1 1-2 0-3 2-3
Antimikrotubuli-Wirkstoff ||| antimicrotubule agent ||| 0-0 0-1
Antipsychotika genannt werden . ||| medicines called antipsychotics . ||| 1-0 0-1 1-1 0-2 2-2 3-3
Antipsychotika genannt werden ||| medicines called antipsychotics ||| 1-0 0-1 1-1 0-2 2-2
Antipsychotika in Zusammenhang gebracht wird ||| antipsychotic medicinal products ||| 0-0 1-0 2-0 3-1 3-2 4-2
Antipsychotika in Zusammenhang ||| antipsychotic ||| 0-0 1-0 2-0
Antipsychotika sollte Aripiprazol ||| antipsychotics , aripiprazole should ||| 0-0 2-2 1-3
Antipsychotika ||| antipsychotics , ||| 0-0
Antipsychotika ||| antipsychotics ||| 0-0
Antipsychotikum ) an 384 ||| antipsychotic medicine ) in 384 ||| 0-0 0-1 1-2 2-3 3-4
Antipsychotikum ) an ||| antipsychotic medicine ) in ||| 0-0 0-1 1-2 2-3
Antipsychotikum ) und ||| antipsychotic medicine ) and ||| 0-0 0-1 1-2 2-3
Antipsychotikum ) ||| antipsychotic medicine ) ||| 0-0 0-1 1-2
Antipsychotikum ||| antipsychotic medicine ||| 0-0 0-1
Antipsychotikum ||| antipsychotic ||| 0-0
Antrag auf Anwendung von ||| application for the use of ||| 0-0 1-2 2-3 3-4
Antrag auf Anwendung ||| application for the use ||| 0-0 1-2 2-3
Antrag auf ||| application for the ||| 0-0 1-2
Antrag ||| application for ||| 0-0
Antrag ||| application ||| 0-0
Anweisungen , die Ihnen ||| instructions given to you by ||| 0-0 0-1 1-2 2-2 3-3 3-4
Anweisungen , die ||| instructions given to ||| 0-0 0-1 1-2 2-2
Anweisungen ||| instructions given to ||| 0-0 0-1
Anweisungen ||| instructions given ||| 0-0 0-1
Anweisungen ||| surgeon ||| 0-0
Anwendung ) . ||| of administration ) . ||| 0-0 0-1 1-2 2-3
Anwendung ) ||| of administration ) ||| 0-0 0-1 1-2
Anwendung bei Kindern und ||| use in children and ||| 0-0 1-1 2-2 3-3
Anwendung bei Kindern unter ||| use in children below ||| 0-0 1-1 2-2 3-3
Anwendung bei Kindern ||| use in children ||| 0-0 1-1 2-2
Anwendung bei Tieren Die Sicherheit ||| use in animals The safety ||| 0-0 1-1 2-2 3-3 4-4
Anwendung bei Tieren Die ||| use in animals The ||| 0-0 1-1 2-2 3-3
Anwendung bei Tieren ||| use in animals ||| 0-0 1-1 2-2
Anwendung bei ||| use in ||| 0-0 1-1
Anwendung des Arzneimittels ||| on the use of ||| 2-0 1-1 0-2 2-2 1-3
Anwendung des ||| use ||| 0-0
Anwendung dieses ||| this ||| 0-0 1-0
Anwendung genau ||| use ||| 0-0 1-0
Anwendung in dieser ||| use in this ||| 0-0 1-1 2-2
Anwendung in ||| use in ||| 0-0 1-1
Anwendung kommen . ||| the perisurgical setting ||| 0-0 0-1 1-1 1-2 2-2
Anwendung rekombinanter Erythropoetine sollte ||| recombinant erythropoietins should be based ||| 1-0 0-1 1-1 2-1 3-2 3-3 2-4
Anwendung sollte mittels subkutaner Applikation ||| subcutaneous route of administration should ||| 0-0 3-0 1-1 2-1 3-3 4-3 1-4
Anwendung t lä ||| administration ||| 0-0 1-0 2-0
Anwendung von ABILIFY ||| use ABILIFY ||| 0-0 1-0 2-1
Anwendung von ACOMPLIA ||| as type 2 diabetes or ||| 2-0 1-2 2-4
Anwendung von Abraxane als Erstlinienbehandlung ||| use of Abraxane as first-line ||| 0-0 1-1 2-2 3-3 4-4
Anwendung von Abraxane als ||| use of Abraxane as ||| 0-0 1-1 2-2 3-3
Anwendung von Abraxane ||| use of Abraxane ||| 0-0 1-1 2-2
Anwendung von Abseamed ||| use Abseamed ||| 0-0 1-0 2-1
Anwendung von Abseamed ||| use of Abseamed ||| 0-0 1-1 2-2
Anwendung von Aclasta : ||| are given Aclasta : ||| 0-0 1-1 2-1 2-2 3-3
Anwendung von Aclasta beachtet werden ||| are given Aclasta ||| 0-0 1-1 2-1 2-2 3-2 4-2
Anwendung von Aclasta bei Kindern ||| use of Aclasta in children ||| 0-0 1-1 2-2 3-3 4-4
Anwendung von Aclasta bei ||| use of Aclasta in ||| 0-0 1-1 2-2 3-3
Anwendung von Aclasta ergriffen ? ||| use of Aclasta ? ||| 0-0 1-0 1-1 2-2 3-3 4-3
Anwendung von Aclasta ||| Aclasta administration ||| 2-0 0-1 1-1
Anwendung von Aclasta ||| are given Aclasta ||| 0-0 1-1 2-1 2-2
Anwendung von Aclasta ||| use of Aclasta ||| 0-0 1-0 1-1 2-2
Anwendung von Aclasta ||| use of Aclasta ||| 0-0 1-1 2-2
Anwendung von Actos mit anderen ||| Actos with other ||| 2-0 1-1 3-1 0-2 4-2
Anwendung von Pioglitazon bei Patienten ||| use of pioglitazone in patients ||| 0-0 1-0 1-1 2-2 3-3 4-4
Anwendung von Pioglitazon bei ||| use of pioglitazone in ||| 0-0 1-0 1-1 2-2 3-3
Anwendung von Pioglitazon ||| use of pioglitazone ||| 0-0 1-0 1-1 2-2
Anwendung von Zoledronsäure ||| administration of zoledronic acid ||| 0-0 1-1 2-2 2-3
Anwendung von Zoledronsäure ||| the administration of zoledronic acid ||| 0-1 1-2 2-3 2-4
Anwendung von rekombinantem humanen Erythropoetin ||| administration of recombinant human erythropoietin ||| 0-0 1-1 2-2 3-2 3-3 4-4
Anwendung von rekombinantem humanen ||| administration of recombinant human ||| 0-0 1-1 2-2 3-2 3-3
Anwendung von ||| 2 diabetes ||| 1-0
Anwendung von ||| 2 ||| 1-0
Anwendung von ||| Using ||| 0-0
Anwendung von ||| administration of ||| 0-0 1-1
Anwendung von ||| administration ||| 0-0 1-0
Anwendung von ||| concomitant ||| 0-0
Anwendung von ||| from ||| 1-0
Anwendung von ||| the administration of ||| 0-1 1-2
Anwendung von ||| type 2 diabetes ||| 1-1
Anwendung von ||| type 2 ||| 1-1
Anwendung von ||| use of ||| 0-0 1-0 1-1
Anwendung von ||| use of ||| 0-0 1-1
Anwendung von ||| use ||| 0-0 1-0
Anwendung während der Trächtigkeit , ||| Use during pregnancy , ||| 0-0 1-1 2-1 3-2 4-3
Anwendung während der Trächtigkeit ||| Use during pregnancy ||| 0-0 1-1 2-1 3-2
Anwendung während der ||| Use during ||| 0-0 1-1 2-1
Anwendung ||| Rimonabant is ||| 0-0 0-1
Anwendung ||| Use ||| 0-0
Anwendung ||| Using ||| 0-0
Anwendung ||| administration ||| 0-0
Anwendung ||| are ||| 0-0
Anwendung ||| concomitant ||| 0-0
Anwendung ||| of administration ||| 0-0 0-1
Anwendung ||| the administration ||| 0-1
Anwendung ||| use , ||| 0-0
Anwendung ||| use ||| 0-0
Anwendungen ||| solution ||| 0-0
Anwendungsgebiet schwer ||| difficult ||| 0-0 1-0
Anwendungsgebiete unter ||| Indications for ||| 0-0 0-1 1-1
Anwendungsort ||| gait ||| 0-0
Anwendungsweise des ||| patients and doctors , and ||| 0-0 0-1 0-2 0-4
Anwendungsweise ||| patients and doctors , and ||| 0-0 0-1 0-2 0-4
Anzahl an Patientinnen , die ||| number of patients who ||| 0-0 1-1 2-2 3-3 4-3
Anzahl an Patientinnen ||| number of patients ||| 0-0 1-1 2-2
Anzahl an ||| number of ||| 0-0 1-1
Anzahl roter Blutkörperchen ||| red blood cell count ||| 0-0 1-0 1-1 1-2 2-3
Anzahl roter ||| red blood cell ||| 0-0 1-0 1-1 1-2
Anzahl von ||| number of ||| 0-0 1-1
Anzahl ||| counts ||| 0-0
Anzahl ||| number ||| 0-0
Anzeichen für lokale Infektionen einschließlich ||| signs of local infection including ||| 0-0 1-1 2-2 3-3 4-4
Anzeichen für lokale Infektionen ||| signs of local infection ||| 0-0 1-1 2-2 3-3
Anzeichen für lokale ||| signs of local ||| 0-0 1-1 2-2
Anzeichen für ||| signs of ||| 0-0 1-1
Anzeichen und Symptome die berichtet ||| signs and symptoms reported ||| 0-0 1-1 2-2 3-2 4-3
Anzeichen und Symptome die ||| signs and symptoms ||| 0-0 1-1 2-2 3-2
Anzeichen und Symptome einer Hyperglykämie ||| signs and symptoms of hyperglycaemia ||| 0-0 1-1 2-2 3-3 4-4
Anzeichen und Symptome einer ||| for signs and symptoms of ||| 0-1 1-2 2-3 3-4
Anzeichen und Symptome einer ||| signs and symptoms of ||| 0-0 1-1 2-2 3-3
Anzeichen und Symptome ||| for signs and symptoms ||| 0-1 1-2 2-3
Anzeichen und Symptome ||| signs and symptoms ||| 0-0 1-1 2-2
Anzeichen und ||| for signs and ||| 0-1 1-2
Anzeichen und ||| signs and ||| 0-0 1-1
Anzeichen ||| for signs ||| 0-1
Anzeichen ||| signs of ||| 0-0
Anzeichen ||| signs ||| 0-0
Anzeichen ||| symptoms ||| 0-0
Anzuwenden ||| To ||| 0-0
Anämie ( z. B. ||| anaemia ( e. g. ||| 0-0 1-1 2-2 3-3
Anämie ( z. ||| anaemia ( e. ||| 0-0 1-1 2-2
Anämie ( ||| anaemia ( ||| 0-0 1-1
Anämie ) sind nicht ausreichend ||| anaemia , are not sufficient ||| 0-0 2-2 3-3 1-4 4-4
Anämie bei Kindern und Erwachsenen ||| anaemia in adult and paediatric ||| 0-0 1-1 4-2 3-3 2-4 4-4
Anämie bei chronischer ||| anaemia associated with chronic ||| 0-0 0-1 1-2 2-3
Anämie bei ||| anaemia associated with ||| 0-0 0-1 1-2
Anämie bei ||| anaemia in ||| 0-0 1-1
Anämie mit Epoetin alfa ||| anaemia with epoetin alfa ||| 0-0 1-1 2-2 3-3
Anämie mit Epoetin ||| anaemia with epoetin ||| 0-0 1-1 2-2
Anämie mit ||| anaemia with ||| 0-0 1-1
Anämie muss das Arzneimittel daher ||| anaemia the medicinal product has ||| 0-0 1-0 2-1 3-2 2-3 3-3 4-4
Anämie muss das Arzneimittel ||| anaemia the medicinal product ||| 0-0 1-0 2-1 3-2 2-3 3-3
Anämie muss ||| anaemia ||| 0-0 1-0
Anämie und Reduktion ||| anaemia and reduction ||| 0-0 1-1 2-2
Anämie und ||| anaemia and ||| 0-0 1-1
Anämie ||| anaemia , ||| 0-0
Anämie ||| anaemia associated ||| 0-0 0-1
Anämie ||| anaemia ||| 0-0
Anämie ||| of anaemia ||| 0-1
Anämiesymptome und - folgeerscheinungen können ||| Anaemia symptoms and sequelae may ||| 0-0 3-0 0-1 1-2 2-3 3-3 4-4
Anämiesymptome und - folgeerscheinungen ||| Anaemia symptoms and sequelae ||| 0-0 3-0 0-1 1-2 2-3 3-3
Anämiesymptome und -folgeerscheinungen können ||| Anaemia symptoms and sequelae may ||| 0-0 2-0 0-1 1-2 2-3 3-4
Anämiesymptome und -folgeerscheinungen ||| Anaemia symptoms and sequelae ||| 0-0 2-0 0-1 1-2 2-3
Anämieursachen ( ||| causes of anaemia ( ||| 0-0 0-1 0-2 1-3
Anämieursachen ||| causes of anaemia ||| 0-0 0-1 0-2
Apotheker , wenn Sie weitere ||| pharmacist if you are ||| 0-0 1-1 2-1 3-2 4-2 2-3
Apotheker , wenn Sie ||| nurse if you ||| 0-0 1-1 2-1 3-2
Apotheker , wenn Sie ||| pharmacist if you are ||| 0-0 1-1 2-1 3-2 2-3
Apotheker , wenn ||| nurse if ||| 0-0 1-1 2-1
Apotheker , wie das das ||| pharmacist how ||| 0-0 2-1 3-1 4-1
Apotheker , wie das ||| pharmacist how ||| 0-0 2-1 3-1
Apotheker , ||| pharmacist ||| 0-0
Apotheker . Dieses ||| pharmacist This ||| 0-0 2-1
Apotheker . ||| pharmacist . ||| 0-0 1-1
Apotheker . ||| pharmacist ||| 0-0
Apotheker in ||| pharmacist ||| 0-0
Apotheker oder das Pflegepersonal . ||| pharmacist or nurse . ||| 0-0 1-1 2-2 3-2 4-3
Apotheker oder das Pflegepersonal ||| pharmacist or nurse ||| 0-0 1-1 2-2 3-2
Apotheker oder das ||| pharmacist or nurse . ||| 0-0 1-1 0-2 2-2
Apotheker oder das ||| pharmacist or nurse ||| 0-0 1-1 0-2 2-2
Apotheker oder ||| pharmacist or ||| 0-0 1-1
Apotheker um Rat , bevor ||| pharmacist for advice before ||| 0-0 2-1 1-2 2-2 3-2 4-3
Apotheker um Rat , ||| pharmacist for advice ||| 0-0 2-1 1-2 2-2 3-2
Apotheker wie das ||| pharmacist how ||| 0-0 1-1 2-1
Apotheker ||| nurse ||| 0-0
Apotheker ||| pharmacist ||| 0-0
Appetitlosigkeit ||| , anorexia ||| 0-1
Appetitlosigkeit ||| anorexia ||| 0-0
Appetitlosigkeit ||| appetite ||| 0-0
Appetits kommen . ||| decreased appetite . ||| 0-0 0-1 1-1 2-2
Appetits kommen ||| decreased appetite ||| 0-0 0-1 1-1
Appetitverlust sowie ||| . They include thirst ||| 0-1 0-2 0-3 1-3
Appetitverlust sowie ||| They include thirst ||| 0-0 0-1 0-2 1-2
Applikation , ||| route , ||| 0-0 1-1
Applikation . ||| administration . ||| 0-0 1-1
Applikation . ||| route . ||| 0-0 1-1
Applikation von Epoetin alfa ||| administration of epoetin alfa ||| 0-0 1-1 2-2 3-3
Applikation von Epoetin ||| administration of epoetin ||| 0-0 1-1 2-2
Applikation von ||| administration of ||| 0-0 1-1
Applikation ||| administration ||| 0-0
Applikation ||| route ||| 0-0
Areflexie , Dyskinesie , Hyporeflexie ||| areflexia , dyskinesia , hyporeflexia ||| 0-0 1-1 2-2 3-3 4-4
Areflexie , Dyskinesie , ||| areflexia , dyskinesia , ||| 0-0 1-1 2-2 3-3
Areflexie , Dyskinesie ||| areflexia , dyskinesia ||| 0-0 1-1 2-2
Areflexie , ||| areflexia , ||| 0-0 1-1
Areflexie ||| areflexia ||| 0-0
Aripiprazol ( 15 mg Dosis ||| aripiprazole ( dose 15 mg ||| 0-0 1-1 4-2 2-3 3-4
Aripiprazol ( 30 mg ) ||| aripiprazole ( 30 mg ) ||| 0-0 1-1 2-2 3-3 4-4
Aripiprazol ( 30 mg ||| aripiprazole ( 30 mg ||| 0-0 1-1 2-2 3-3
Aripiprazol ( 30 ||| aripiprazole ( 30 ||| 0-0 1-1 2-2
Aripiprazol ( oral ) ||| , oral aripiprazole ||| 2-1 0-2
Aripiprazol ( oral ) ||| oral aripiprazole ||| 2-0 0-1
Aripiprazol ( oral ||| , oral aripiprazole ||| 2-1 0-2
Aripiprazol ( oral ||| oral aripiprazole ||| 2-0 0-1
Aripiprazol ( siehe Abschnitt 4.8 ||| aripiprazole ( see section 4.8 ||| 0-0 1-1 2-2 3-3 4-4
Aripiprazol ( siehe Abschnitt ||| aripiprazole ( see section ||| 0-0 1-1 2-2 3-3
Aripiprazol ( siehe ||| aripiprazole ( see ||| 0-0 1-1 2-2
Aripiprazol ( ||| aripiprazole ( ||| 0-0 1-1
Aripiprazol ( ||| aripiprazole ||| 0-0
Aripiprazol ) . ||| aripiprazole ) . ||| 0-0 1-1 2-2
Aripiprazol ) einmal täglich ||| aripiprazole ) once a day ||| 0-0 1-1 2-2 2-3 3-4
Aripiprazol ) einmal ||| aripiprazole ) once a ||| 0-0 1-1 2-2 2-3
Aripiprazol ) ||| aripiprazole ) ||| 0-0 1-1
Aripiprazol , gab es keine ||| aripiprazole , there were no ||| 0-0 1-1 2-2 3-2 2-3 4-4
Aripiprazol , gab es ||| aripiprazole , there were ||| 0-0 1-1 2-2 3-2 2-3
Aripiprazol , ist ein ||| aripiprazole , is an ||| 0-0 1-1 2-2 3-3
Aripiprazol , ist ||| aripiprazole , is ||| 0-0 1-1 2-2
Aripiprazol , ||| aripiprazole , ||| 0-0 1-1
Aripiprazol . ||| aripiprazole . ||| 0-0 1-1
Aripiprazol . ||| of aripiprazole . ||| 0-1 1-2
Aripiprazol 77 % ||| aripiprazole 77 % ||| 0-0 1-1 2-2
Aripiprazol 77 ||| aripiprazole 77 ||| 0-0 1-1
Aripiprazol : ||| aripiprazole : ||| 0-0 1-1
Aripiprazol AUC ||| aripiprazole AUC ||| 0-0 1-1
Aripiprazol Injektionslösung nicht ||| lorazepam solution for injection ||| 0-0 1-1 1-2 1-3
Aripiprazol Injektionslösung wird ||| Aripiprazole solution for injection ||| 0-0 2-0 1-1 1-2 1-3
Aripiprazol Injektionslösung ||| aripiprazole solution for injection ||| 0-0 1-1 1-2 1-3
Aripiprazol Injektionslösung ||| lorazepam solution for injection ||| 0-0 1-1 1-2 1-3
Aripiprazol Schmelztabletten können ||| Aripiprazole orodispersible tablets may ||| 0-0 1-1 1-2 2-3
Aripiprazol Schmelztabletten sind bioäquivalent ||| Aripiprazole orodispersible tablet is bioequivalent ||| 0-0 1-1 3-2 3-3 2-4 3-4
Aripiprazol Schmelztabletten ||| Aripiprazole orodispersible tablets ||| 0-0 1-1 1-2
Aripiprazol Schmelztabletten ||| Aripiprazole orodispersible ||| 0-0 1-1
Aripiprazol Tabletten mit ||| aripiprazole tablets , with ||| 0-0 1-1 2-3
Aripiprazol Tabletten ||| aripiprazole tablets , ||| 0-0 1-1
Aripiprazol Tabletten ||| aripiprazole tablets ||| 0-0 1-1
Aripiprazol Zur intramuskulären Anwendung ||| aripiprazole Intramuscular use ||| 0-0 1-1 2-1 3-2
Aripiprazol Zur intramuskulären ||| aripiprazole Intramuscular ||| 0-0 1-1 2-1
Aripiprazol als nicht genotoxisch eingestuft ||| , aripiprazole was considered non-genotoxic ||| 0-1 3-2 3-3 1-4 2-4 3-4 4-4
Aripiprazol als nicht genotoxisch eingestuft ||| aripiprazole was considered non-genotoxic ||| 0-0 3-1 3-2 1-3 2-3 3-3 4-3
Aripiprazol als ||| aripiprazole as the ||| 0-0 1-1
Aripiprazol als ||| aripiprazole as ||| 0-0 1-1
Aripiprazol beeinträchtigte ||| Aripiprazole did not ||| 0-0 1-1 1-2
Aripiprazol begonnen werden . ||| aripiprazole should be initiated . ||| 0-0 2-1 2-2 1-3 2-3 3-4
Aripiprazol begonnen werden ||| aripiprazole should be initiated ||| 0-0 2-1 2-2 1-3 2-3
Aripiprazol behandelten Patienten ||| aripiprazole treated patients ||| 0-0 1-1 2-2
Aripiprazol behandelten ||| aripiprazole treated ||| 0-0 1-1
Aripiprazol bei schwangeren Frauen vor ||| aripiprazole in pregnant women ||| 0-0 1-1 2-2 3-3 4-3
Aripiprazol bei schwangeren ||| aripiprazole in pregnant ||| 0-0 1-1 2-2
Aripiprazol bei ||| aripiprazole in ||| 0-0 1-1
Aripiprazol bei ||| of aripiprazole in ||| 0-1 1-2
Aripiprazol erhalten haben , ||| have been receiving aripiprazole , ||| 2-0 1-1 1-2 0-3 3-4
Aripiprazol erhalten haben ||| have been receiving aripiprazole ||| 2-0 1-1 1-2 0-3
Aripiprazol erhalten ||| been receiving aripiprazole ||| 1-0 1-1 0-2
Aripiprazol erklären . ||| aripiprazole . ||| 0-0 1-0 2-1
Aripiprazol erklären ||| aripiprazole ||| 0-0 1-0
Aripiprazol gleichzeitig mit ||| aripiprazole was administered concomitantly with ||| 0-0 1-1 1-2 1-3 2-4
Aripiprazol gleichzeitig ||| aripiprazole was administered concomitantly ||| 0-0 1-1 1-2 1-3
Aripiprazol in der Galle ||| aripiprazole in the bile ||| 0-0 1-1 2-2 3-3
Aripiprazol in der ||| aripiprazole in the ||| 0-0 1-1 2-2
Aripiprazol in ||| aripiprazole in ||| 0-0 1-1
Aripiprazol ist eine engmaschige medizinische ||| aripiprazole , close medical ||| 0-0 1-2 2-2 3-2 4-2 4-3
Aripiprazol ist für die ||| ABILIFY is indicated for ||| 0-0 1-1 2-2 2-3 3-3
Aripiprazol ist wirksam in ||| ABILIFY is effective in ||| 0-0 2-0 1-1 2-2 3-3
Aripiprazol ist wirksam ||| ABILIFY is effective ||| 0-0 2-0 1-1 2-2
Aripiprazol ist ||| ABILIFY is ||| 0-0 1-1
Aripiprazol macht den Hauptanteil des ||| Aripiprazole is the predominant medicinal ||| 0-0 1-0 1-1 2-2 1-3 3-3 4-3 3-4
Aripiprazol mehr Todesfälle berichtet ||| been reported while taking aripiprazole ||| 3-0 3-1 1-2 2-2 2-3 0-4
Aripiprazol mehr Todesfälle ||| while taking aripiprazole ||| 1-0 2-0 2-1 0-2
Aripiprazol oder einen der ||| aripiprazole or any of the ||| 0-0 1-1 2-2 3-3 3-4
Aripiprazol oder einen ||| aripiprazole or any ||| 0-0 1-1 2-2
Aripiprazol oder ||| aripiprazole or ||| 0-0 1-1
Aripiprazol sollte ||| Aripiprazol sollte ||| 0-0 1-1
Aripiprazol sollte ||| Aripiprazole should be ||| 0-0 1-1 1-2
Aripiprazol sollte ||| aripiprazole ||| 0-0 1-0
Aripiprazol und 3,0 % mit ||| aripiprazole and 3.0 % with ||| 0-0 1-1 2-2 3-3 4-4
Aripiprazol und 3,0 % ||| aripiprazole and 3.0 % ||| 0-0 1-1 2-2 3-3
Aripiprazol und 3,0 ||| aripiprazole and 3.0 ||| 0-0 1-1 2-2
Aripiprazol und 3,2 % mit ||| aripiprazole and 3.2 % with ||| 0-0 1-1 2-2 3-3 4-4
Aripiprazol und 3,2 % ||| aripiprazole and 3.2 % ||| 0-0 1-1 2-2 3-3
Aripiprazol und 3,2 ||| aripiprazole and 3.2 ||| 0-0 1-1 2-2
Aripiprazol und Dehydro-Aripiprazol , aber ||| aripiprazole and dehydro-aripiprazole , but ||| 0-0 1-1 2-2 3-3 4-4
Aripiprazol und Dehydro-Aripiprazol , ||| aripiprazole and dehydro-aripiprazole , ||| 0-0 1-1 2-2 3-3
Aripiprazol und Dehydro-Aripiprazol in vitro ||| aripiprazole and dehydro-aripiprazole did ||| 0-0 1-1 2-2 3-3 4-3
Aripiprazol und Dehydro-Aripiprazol ||| , aripiprazole and dehydro-aripiprazole are ||| 0-1 1-2 2-3 2-4
Aripiprazol und Dehydro-Aripiprazol ||| aripiprazole and dehydro-aripiprazole are ||| 0-0 1-1 2-2 2-3
Aripiprazol und Dehydro-Aripiprazol ||| aripiprazole and dehydro-aripiprazole ||| 0-0 1-1 2-2
Aripiprazol und andere antipsychotischen Arzneimittel ||| Aripiprazole and other antipsychotic drugs ||| 0-0 1-1 2-2 3-3 3-4 4-4
Aripiprazol und andere ||| Aripiprazole and other ||| 0-0 1-1 2-2
Aripiprazol und ||| , aripiprazole and ||| 0-1 1-2
Aripiprazol und ||| Aripiprazole and ||| 0-0 1-1
Aripiprazol und ||| aripiprazole and ||| 0-0 1-1
Aripiprazol wie ||| aripiprazole ||| 0-0
Aripiprazol wies außerdem in ||| Aripiprazole also demonstrated ||| 0-0 1-0 2-1 1-2 2-2 3-2
Aripiprazol wird gut ||| Aripiprazole is well ||| 0-0 1-1 2-2
Aripiprazol wird ||| Aripiprazole is ||| 0-0 1-1
Aripiprazol wird über verschiedene ||| Aripiprazole is metabolised ||| 0-0 1-1 2-2 3-2
Aripiprazol wird überwiegend in ||| Aripiprazole is extensively metabolised ||| 0-0 1-1 2-2 3-2 2-3
Aripiprazol wirkt vermutlich vor ||| Aripiprazole is thought to ||| 0-0 2-1 1-2 2-2 3-3
Aripiprazol wirkt vermutlich ||| Aripiprazole is thought ||| 0-0 2-1 1-2 2-2
Aripiprazol wurde unverändert ||| of unchanged aripiprazole was ||| 2-1 0-2 1-3 2-3
Aripiprazol wurde unverändert ||| unchanged aripiprazole was ||| 2-0 0-1 1-2 2-2
Aripiprazol wurde ||| Aripiprazole was ||| 0-0 1-1
Aripiprazol während ||| aripiprazole during ||| 0-0 1-1
Aripiprazol zeigte im Tiermodell ||| Aripiprazole exhibited antagonist properties in ||| 0-0 1-1 3-2 2-3 3-3 2-4
Aripiprazol zeigte ||| Aripiprazole exhibited ||| 0-0 1-1
Aripiprazol ||| , aripiprazole ||| 0-1
Aripiprazol ||| ABILIFY ||| 0-0
Aripiprazol ||| Aripiprazol ||| 0-0
Aripiprazol ||| Aripiprazole ||| 0-0
Aripiprazol ||| aripiprazole ( Cmax ) ||| 0-0 0-2
Aripiprazol ||| aripiprazole ( Cmax ||| 0-0 0-2
Aripiprazol ||| aripiprazole , ||| 0-0
Aripiprazol ||| aripiprazole . ||| 0-0
Aripiprazol ||| aripiprazole ||| 0-0
Aripiprazol ||| lorazepam ||| 0-0
Aripiprazol ||| of aripiprazole ( Cmax ) ||| 0-1 0-3
Aripiprazol ||| of aripiprazole ( Cmax ||| 0-1 0-3
Aripiprazol ||| of aripiprazole ||| 0-1
Aripiprazol- Behandlung ||| for aripiprazole-treated ||| 0-0 0-1 1-1
Aripiprazol-Behandlung ||| for aripiprazole-treated ||| 0-0 0-1
Aripiprazol-Dosis ||| aripiprazole dose ||| 0-0 0-1
Aripiprazol-Konzentrationen . ||| aripiprazole concentrations . ||| 0-0 0-1 1-2
Aripiprazol-Konzentrationen ||| aripiprazole concentrations ||| 0-0 0-1
Arrhythmien , plötzlicher unerklärbarer ||| arrhythmias , sudden unexplained ||| 0-0 1-1 2-2 3-3
Arrhythmien , plötzlicher ||| arrhythmias , sudden ||| 0-0 1-1 2-2
Arrhythmien , ||| arrhythmias , ||| 0-0 1-1
Arrhythmien . ||| arrhythmias . ||| 0-0 1-1
Arrhythmien ||| arrhythmias ||| 0-0
Art der weißen ||| type of white ||| 0-0 1-1 2-2
Art der weißen ||| type of white ||| 0-0 2-2
Art der ||| Amounts to be ||| 0-0 1-1 1-2
Art der ||| type of ||| 0-0
Art der ||| type of ||| 0-0 1-1
Art der ||| type ||| 0-0
Art und Dauer der Anwendung ||| and method of administration ||| 1-0 0-1 1-1 2-1 3-2 4-3
Art und Dauer der ||| and method of ||| 1-0 0-1 1-1 2-1 3-2
Art und Dauer ||| and method ||| 1-0 0-1 1-1 2-1
Art ||| Amounts ||| 0-0
Art ||| on the type ||| 0-2
Art ||| the type ||| 0-1
Art ||| type of ||| 0-0
Art ||| type ||| 0-0
Arten von Arzneimitteln wurden nicht ||| drug types were not ||| 0-0 1-0 2-0 0-1 3-2 4-3
Arten von Arzneimitteln wurden ||| drug types were ||| 0-0 1-0 2-0 0-1 3-2
Arten von Arzneimitteln ||| drug types ||| 0-0 1-0 2-0 0-1
Arten von Paclitaxel enthalten ||| types of paclitaxel contain ||| 0-0 1-1 2-2 3-3
Arten von Paclitaxel ||| types of paclitaxel ||| 0-0 1-1 2-2
Arten von ||| types of ||| 0-0 1-1
Arten ||| types ||| 0-0
Arthralgie trat bei 32 % ||| Arthralgia occurred in 32 % ||| 0-0 1-1 2-2 3-3 4-4
Arthralgie trat bei 32 ||| Arthralgia occurred in 32 ||| 0-0 1-1 2-2 3-3
Arthralgie trat bei ||| Arthralgia occurred in ||| 0-0 1-1 2-2
Arthralgie trat ||| Arthralgia occurred ||| 0-0 1-1
Arthralgie ||| Arthralgia ||| 0-0
Arz ||| . ||| 0-0
Arz ||| and lp ||| 0-1
Arz ||| kg . ||| 0-1
Arz ||| lp ||| 0-0
Arzneimittel , das den arzneilich ||| medicine containing the active ||| 0-0 1-1 4-1 2-2 3-3 4-3
Arzneimittel , das ||| medicine containing ||| 0-0 1-1 2-1
Arzneimittel : ||| medicinal products : ||| 0-0 0-1 1-2
Arzneimittel Pütter GmbH & Co ||| Arzneimittel Pütter GmbH & Co ||| 0-0 1-0 1-1 2-2 3-3 4-4
Arzneimittel Pütter GmbH & ||| Arzneimittel Pütter GmbH & ||| 0-0 1-0 1-1 2-2 3-3
Arzneimittel Pütter GmbH ||| Arzneimittel Pütter GmbH ||| 0-0 1-0 1-1 2-2
Arzneimittel Pütter ||| Arzneimittel Pütter ||| 0-0 1-0 1-1
Arzneimittel auf eingeschränkte ||| Medicinal product subject to restricted ||| 2-0 0-1 1-2 2-2 1-3 2-4
Arzneimittel auf eingeschränkte ärztliche ||| Arzneimittel auf eingeschränkte ärztliche Verschreibung ||| 0-0 2-1 1-2 2-2 2-3 2-4 3-4
Arzneimittel außer Reich- ||| Keep out of the ||| 0-0 0-1 1-1 2-1 2-2 2-3
Arzneimittel bedarf ||| medicine can only be ||| 0-0 1-1 1-2 1-3
Arzneimittel darf nicht ||| product must not be ||| 0-0 1-1 2-2 1-3
Arzneimittel darf ||| medicinal product must ||| 0-0 0-1 1-2
Arzneimittel einnehmen oder bis ||| taking or ||| 0-0 1-0 2-1
Arzneimittel einnehmen oder ||| taking or ||| 0-0 1-0 2-1
Arzneimittel einnehmen ||| taking ||| 0-0 1-0
Arzneimittel enthält ca. 425 ||| medicinal product contains approximately 425 ||| 0-0 0-1 1-2 2-3 3-4
Arzneimittel enthält ca. ||| medicinal product contains approximately ||| 0-0 0-1 1-2 2-3
Arzneimittel enthält ||| medicinal product contains ||| 0-0 0-1 1-2
Arzneimittel für Kinder ||| Keep out of the reach ||| 0-0 0-1 1-1 1-2 1-3 2-4
Arzneimittel für Kinder ||| Keep out of the reach ||| 0-0 0-1 1-1 1-2 2-3 2-4
Arzneimittel für ||| Keep out of the ||| 0-0 0-1 1-1 1-2 1-3
Arzneimittel für ||| Keep out of ||| 0-0 0-1 1-1 1-2
Arzneimittel gegen Krebs erhältlich . ||| anticancer medicine since 1993. ||| 1-0 2-0 0-1 2-1 3-2 3-3 4-3
Arzneimittel gegen Krebs ||| anticancer medicine ||| 1-0 2-0 0-1 2-1
Arzneimittel gegen Pilzinfektionen ) , ||| anti-fungal medicines ) , ||| 2-0 0-1 1-1 3-2 4-3
Arzneimittel gegen Pilzinfektionen ) ||| anti-fungal medicines ) ||| 2-0 0-1 1-1 3-2
Arzneimittel gegen Pilzinfektionen ||| anti-fungal medicines ||| 2-0 0-1 1-1
Arzneimittel gegen ||| medicines ||| 0-0 1-0
Arzneimittel hat . ||| medicinal products . ||| 0-0 1-1 2-2
Arzneimittel hat ||| medicinal products ||| 0-0 1-1
Arzneimittel ist nur auf ärztliche ||| medicine can only be obtained ||| 0-0 2-1 1-2 2-2 2-3 3-4 4-4
Arzneimittel ist nur ||| medicine can only be ||| 0-0 0-1 1-2 2-2 2-3
Arzneimittel ist nur ||| medicine can only be ||| 0-0 2-1 1-2 2-2 2-3
Arzneimittel ist sofort ||| product immediately ||| 0-0 1-0 2-1
Arzneimittel ist ||| product ||| 0-0 1-0
Arzneimittel muss intravenös ||| intravenous route has to ||| 0-0 2-0 1-1 2-1 2-2 2-3
Arzneimittel nach dem auf der ||| after the expiry ||| 1-0 2-1 4-1 0-2 2-2 3-2
Arzneimittel nach ||| this medicine after ||| 0-0 0-1 1-2
Arzneimittel sofort verwendet werden ||| product should be used immediately ||| 0-0 1-1 3-2 2-3 1-4
Arzneimittel sollten nicht ||| Medicines should not be ||| 0-0 1-1 2-2 1-3
Arzneimittel und wie auch ||| medicinal product and , as ||| 0-0 0-1 1-2 2-4 3-4
Arzneimittel und ||| medicinal product and , ||| 0-0 0-1 1-2
Arzneimittel und ||| medicinal product and ||| 0-0 0-1 1-2
Arzneimittel wurde ||| medicine has been ||| 0-0 1-1 1-2
Arzneimittel zu entsorgen ist , ||| to dispose of ||| 1-0 0-1 1-1 2-1 3-1
Arzneimittel zu entsorgen ist , ||| to dispose of ||| 1-0 0-1 2-1 3-1 4-2
Arzneimittel zu entsorgen ist , ||| to dispose ||| 1-0 0-1 1-1 2-1 3-1
Arzneimittel zu entsorgen ist ||| to dispose of ||| 1-0 0-1 1-1 2-1 3-1
Arzneimittel zu entsorgen ist ||| to dispose ||| 1-0 0-1 1-1 2-1 3-1
Arzneimittel zu entsorgen ist ||| to dispose ||| 1-0 0-1 2-1 3-1
Arzneimittel zur Vorbeugung von Blutpfropfbildung ||| medicinal product to prevent ||| 0-0 0-1 1-2 3-2 2-3 4-3
Arzneimittel ||| Arzneimittel ||| 0-0
Arzneimittel ||| Medicines ||| 0-0
Arzneimittel ||| medicinal product ||| 0-0 0-1
Arzneimittel ||| medicinal products ||| 0-0 0-1
Arzneimittel ||| medicinal ||| 0-0
Arzneimittel ||| medicine can ||| 0-0 0-1
Arzneimittel ||| medicine ||| 0-0
Arzneimittel ||| medicines ||| 0-0
Arzneimittel ||| of medicines ||| 0-1
Arzneimittel ||| product ||| 0-0
Arzneimittel ||| the product ||| 0-1
Arzneimittel ||| this medicine ||| 0-0 0-1
Arzneimittel ||| to the product ||| 0-2
Arzneimittel-Interaktionsstudien ||| drug-drug interaction ||| 0-0 0-1
Arzneimittelbeteiligung sollte erwogen werden ||| product involvement should be considered ||| 0-0 0-1 2-1 1-2 3-3 2-4
Arzneimitteln auf ABILIFY : ||| products to affect ABILIFY : ||| 0-0 1-1 1-2 2-3 3-4
Arzneimitteln auf ABILIFY ||| products to affect ABILIFY ||| 0-0 1-1 1-2 2-3
Arzneimitteln auf ||| products to affect ||| 0-0 1-1 1-2
Arzneimitteln behandelt werden ||| be treated with medicinal products ||| 2-0 1-1 1-2 0-3 0-4 2-4
Arzneimitteln mit ||| medicinal products with ||| 0-0 0-1 1-2
Arzneimitteln und ||| medicinal products and ||| 0-0 0-1 1-2
Arzneimitteln und ||| products and ||| 0-0 1-1
Arzneimitteln verstärken , die ||| medicines used to ||| 0-0 1-0 1-1 2-2 3-2
Arzneimitteln verstärken ||| medicines used ||| 0-0 1-0 1-1
Arzneimitteln wie ||| some medicines , such as ||| 0-0 0-1 1-3 1-4
Arzneimitteln zur Reduzierung der Nebenwirkungen ||| medicines to reduce side effects ||| 0-0 1-1 3-1 4-3 4-4
Arzneimitteln zur Reduzierung der ||| medicines to reduce ||| 0-0 1-1 3-1
Arzneimitteln zur Reduzierung der ||| medicines to ||| 0-0 1-1 3-1
Arzneimitteln ||| drug ||| 0-0
Arzneimitteln ||| medicinal products ||| 0-0 0-1
Arzneimitteln ||| medicines ||| 0-0
Arzneimitteln ||| products ||| 0-0
Arzneimitteln ||| some medicines , ||| 0-0 0-1
Arzneimitteln ||| some medicines ||| 0-0 0-1
Arzneimittels ( ||| medicine ( ||| 0-0 1-1
Arzneimittels , Abschnitt 4.2 ) ||| Characterisitics , Section 4.2 ) ||| 0-0 1-1 2-2 3-3 4-4
Arzneimittels , Abschnitt 4.2 ||| Characterisitics , Section 4.2 ||| 0-0 1-1 2-2 3-3
Arzneimittels , Abschnitt ||| Characterisitics , Section ||| 0-0 1-1 2-2
Arzneimittels , ||| Characterisitics , ||| 0-0 1-1
Arzneimittels im systemischen Kreislauf aus ||| product moiety in systemic circulation ||| 0-0 0-1 1-1 2-1 2-2 2-3 3-3 3-4 4-4
Arzneimittels müssen ||| medicinal product must ||| 1-0 0-1 1-2
Arzneimittels zurück . ||| medicine . ||| 0-0 2-1
Arzneimittels zurück ||| medicine ||| 0-0
Arzneimittels ||| Characterisitics ||| 0-0
Arzneimittels ||| medicine ||| 0-0
Arzneimittels ||| product ||| 0-0
Arzneimittelwirkungen , die in klinischen ||| drug reactions from clinical ||| 0-0 3-0 0-1 1-1 0-2 2-2 4-3
Arzneimittelwirkungen , die in ||| drug reactions from ||| 0-0 3-0 0-1 1-1 0-2 2-2
Arzt , Apotheker oder ||| doctor , pharmacist or ||| 0-0 1-1 2-2 3-3
Arzt , Apotheker ||| doctor , pharmacist ||| 0-0 1-1 2-2
Arzt , ||| doctor , ||| 0-0 1-1
Arzt . ||| doctor . ||| 0-0 1-1
Arzt Patienteninformationspaket ||| Patient information pack ||| 0-0 1-0 1-1 1-2
Arzt benachrichtigen , wenn sie ||| physician if they become ||| 0-0 1-0 2-1 3-1 4-2 1-3
Arzt die Behandlung ||| physicians ||| 0-0 1-0 2-0
Arzt kann Ihnen ein leichtes ||| doctor can recommend a mild ||| 0-0 2-0 1-1 2-2 3-3 4-4
Arzt kann Ihnen ein ||| doctor can recommend a ||| 0-0 2-0 1-1 2-2 3-3
Arzt kann Ihnen ||| doctor can recommend ||| 0-0 2-0 1-1 2-2
Arzt mit ||| doctor ||| 0-0
Arzt mitteilen : ||| medicine : ||| 0-0 1-0 2-1
Arzt mitteilen ||| medicine ||| 0-0 1-0
Arzt muss deshalb mögliche ||| physician must therefore take possible ||| 0-0 2-0 1-1 2-2 3-3 3-4
Arzt muss deshalb ||| physician must therefore ||| 0-0 2-0 1-1 2-2
Arzt oder Apotheker . ||| doctor or pharmacist . ||| 0-0 1-1 2-2 3-3
Arzt oder Apotheker in ||| doctor or pharmacist ||| 0-0 1-1 2-2
Arzt oder Apotheker nach ||| doctor or pharmacist ||| 0-0 1-1 3-1 2-2
Arzt oder Apotheker ||| doctor or pharmacist ||| 0-0 1-1 2-2
Arzt oder ||| doctor or ||| 0-0 1-1
Arzt umgehend , wenn Sie ||| your doctor immediately if you ||| 0-0 0-1 1-2 2-3 3-3 4-4
Arzt umgehend , wenn ||| your doctor immediately if ||| 0-0 0-1 1-2 2-3 3-3
Arzt umgehend ||| your doctor immediately ||| 0-0 0-1 1-2
Arzt unverzüglich , wenn Sie ||| doctor immediately if you ||| 0-0 1-1 2-2 3-2 4-3
Arzt unverzüglich , wenn ||| doctor immediately if ||| 0-0 1-1 2-2 3-2
Arzt unverzüglich ||| doctor immediately ||| 0-0 1-1
Arzt wird Sie bitten , ||| doctor will ask you ||| 0-0 1-1 3-1 3-2 2-3 4-3
Arzt wird dies ||| doctor will take this ||| 0-0 1-1 2-2 2-3
Arzt wird entscheiden , ob ||| doctor will decide when ||| 0-0 1-1 2-1 2-2 4-2 3-3
Arzt wird ||| doctor will ||| 0-0 1-1
Arzt ||| can ||| 0-0
Arzt ||| disorders can ||| 0-1
Arzt ||| doctor ||| 0-0
Arzt ||| medical ||| 0-0
Arzt ||| medicine ||| 0-0
Arzt ||| the medicine ||| 0-1
Arzt ||| use the medicine ||| 0-2
Arzt ||| your doctor ||| 0-0 0-1
Arztes , bevor ||| doctor carefully before ||| 0-0 1-1 2-1 2-2
Arztes ||| doctor ||| 0-0
Arzttermin wahr und besprechen ||| appointment and discuss ||| 0-0 2-1 1-2 3-2
Arzttermin ||| appointment ||| 0-0
Aspart ) bestand . ||| aspart ) . ||| 0-0 2-0 1-1 3-2
Aspart ) bestand ||| aspart ) ||| 0-0 2-0 1-1
Aspartam ( E951 ) je ||| aspartame ( E951 ) per ||| 0-0 1-1 2-2 3-3 4-4
Aspartam ( E951 ) ||| Aspartame ( E951 ) ||| 0-0 1-1 2-2 3-3
Aspartam ( E951 ) ||| aspartame ( E951 ) ||| 0-0 1-1 2-2 3-3
Aspartam ( E951 ||| Aspartame ( E951 ||| 0-0 1-1 2-2
Aspartam ( E951 ||| aspartame ( E951 ||| 0-0 1-1 2-2
Aspartam ( ||| Aspartame ( ||| 0-0 1-1
Aspartam ( ||| aspartame ( ||| 0-0 1-1
Aspartam , ||| , aspartame ||| 1-0 0-1
Aspartam ||| Aspartame ||| 0-0
Aspartam ||| aspartame ||| 0-0
Aspiration sind mit der Einnahme ||| aspiration have been associated with ||| 0-0 1-0 0-1 0-2 3-3 4-3 2-4
Aspiration sind ||| aspiration have been ||| 0-0 1-0 0-1 0-2
Aspirin , Statine , ||| , aspirin , statins , ||| 1-0 0-1 1-2 2-3 3-4
Aspirin , Statine ||| , aspirin , statins ||| 1-0 0-1 1-2 2-3
Aspirin , ||| , aspirin , ||| 1-0 0-1 1-2
Aspirin ||| aspirin ||| 0-0
Assessment of Cancer Therapy Anemia ||| Assessment of Cancer Therapy- Anaemia ||| 0-0 1-0 1-1 2-2 3-3 4-3 4-4
Assessment of Cancer ||| Assessment of Cancer ||| 0-0 1-0 1-1 2-2
Assessment of ||| Assessment of ||| 0-0 1-0 1-1
Asthenie/Müdigkeit wurde bei ||| Asthenia/ Fatigue was reported in ||| 0-0 0-1 1-1 1-2 1-3 2-3 2-4
Ataxie , sensorische ||| ataxia , sensory ||| 0-0 1-1 2-2
Ataxie , ||| ataxia , ||| 0-0 1-1
Ataxie ||| ataxia ||| 0-0
Atembeschwerden ||| in breathing ||| 0-0 0-1
Atemfrequenz ||| respiratory ||| 0-0
Atemnot . ||| breathlessness . ||| 0-0 1-1
Atemnot . ||| or breathlessness . ||| 0-1 1-2
Atemnot ||| breathlessness ||| 0-0
Atemnot ||| or breathlessness ||| 0-1
Attacke/TIA ) , abnormaler Blutdruck ||| , abnormal blood pressure ||| 2-0 0-1 1-1 3-1 4-2 4-3
Attacke/TIA ) , abnormaler ||| , abnormal ||| 2-0 0-1 1-1 3-1
Auch andere Störungen des ||| Other disturbances of ||| 1-0 0-1 2-1 3-2
Auch andere Störungen ||| Other disturbances ||| 1-0 0-1 2-1
Auch wenn Sie ||| 138 Even if you ||| 0-0 0-1 1-2 2-3
Auch wenn Sie ||| 143 Even if you ||| 0-0 0-1 1-2 2-3
Auch wenn Sie ||| 148 Even if you ||| 0-0 0-1 1-2 2-3
Auch wenn Sie ||| 153 Even if you ||| 0-0 0-1 1-2 2-3
Auch wenn Sie ||| Even if you ||| 0-0 1-1 2-2
Auch wenn ||| 138 Even if ||| 0-0 0-1 1-2
Auch wenn ||| 143 Even if ||| 0-0 0-1 1-2
Auch wenn ||| 148 Even if ||| 0-0 0-1 1-2
Auch wenn ||| 153 Even if ||| 0-0 0-1 1-2
Auch wenn ||| Even if ||| 0-0 1-1
Auch ||| 138 Even ||| 0-0 0-1
Auch ||| 143 Even ||| 0-0 0-1
Auch ||| 148 Even ||| 0-0 0-1
Auch ||| 153 Even ||| 0-0 0-1
Auch ||| Even ||| 0-0
Auf Anforderung der EMEA . ||| the request of the EMEA ||| 0-0 2-0 1-1 2-2 2-3 3-4
Auf Anforderung der EMEA ||| the request of the EMEA ||| 0-0 2-0 1-1 2-2 2-3 3-4
Auf Anforderung der ||| the request of the ||| 0-0 2-0 1-1 2-2 2-3
Auf dieser Basis ||| On this basis ||| 0-0 1-1 2-2
Auf dieser ||| On this ||| 0-0 1-1
Auf ||| On ||| 0-0
Auf ||| The printed ||| 0-0 0-1
Aufbau des Immunsystems ||| the immune-system ||| 1-0 0-1
Aufbau des ||| the immune-system ||| 1-0 0-1
Aufbau ||| immune-system ||| 0-0
Aufgrund der potenziell schwerwiegenden ||| Because of potential serious ||| 0-0 1-1 0-2 2-3 3-3
Aufgrund der ||| Because of potential ||| 0-0 1-1 0-2
Aufgrund der ||| Because ||| 0-0
Aufgrund der ||| Due to ||| 0-0 1-0 0-1
Aufgrund des Risikos einer ||| No other erythropoietic therapy ||| 0-0 2-1 1-2 2-2 2-3 3-3
Aufgrund seines 1-adrenergen ||| Due to its 1-adrenergic receptor ||| 0-0 0-1 1-2 1-3 2-3 2-4
Aufgrund ||| Because ||| 0-0
Aufgrund ||| Due to ||| 0-0 0-1
Aufgrund ||| No ||| 0-0
Aufklärungsmaterial für den ||| Physician educational material ||| 0-0 0-1 1-1 0-2 2-2
Aufklärungsmaterial ||| educational ||| 0-0
Aufmerksamkeitsstörungen ||| attention ||| 0-0
Aufmerksamkeitsstörungen ||| in attention ||| 0-1
Aufnahme ||| muscle ||| 0-0
Aufnahme ||| of ||| 0-0
Auftreten einer ||| occurrence of ||| 0-0 1-1
Auftreten ||| occurrence ||| 0-0
Augen ||| eyes ||| 0-0
Augen ||| in the eyes ||| 0-2
Augen ||| the eyes ||| 0-1
Augenerkrankungen : ||| Eye disorders : ||| 0-0 0-1 1-2
Augenerkrankungen Häufig : verschwommenes ||| Eye disorders Common : blurred ||| 0-0 0-1 1-2 2-3 3-4
Augenerkrankungen Häufig : ||| Eye disorders Common : ||| 0-0 0-1 1-2 2-3
Augenerkrankungen Häufig ||| Eye disorders Common ||| 0-0 0-1 1-2
Augenerkrankungen Sehr selten - ||| Eye disorders Very rare - ||| 0-0 0-1 1-2 2-3 3-4
Augenerkrankungen Sehr selten ||| Eye disorders Very rare ||| 0-0 0-1 1-2 2-3
Augenerkrankungen Sehr ||| Eye disorders Very ||| 0-0 0-1 1-2
Augenerkrankungen ||| Eye disorders ||| 0-0 0-1
Augenerkrankungen ||| Eye ||| 0-0
Augenhintergrund . Wenn diese ||| the first ||| 0-0 0-1 2-1 3-1
Augenreizung , Augenschmerzen ||| Eye irritation , eye ||| 0-0 0-1 1-2 2-3
Augenreizung , ||| Eye irritation , ||| 0-0 0-1 1-2
Augenreizung ||| Eye irritation ||| 0-0 0-1
Augenschmerz Uveitis , Episkleritis ||| eye pain Uveitis , episcleritis ||| 0-0 1-1 1-2 2-3 3-4
Augenschmerz Uveitis , ||| eye pain Uveitis , ||| 0-0 1-1 1-2 2-3
Augenschmerz Uveitis ||| eye pain Uveitis ||| 0-0 1-1 1-2
Augenschmerz ||| eye ||| 0-0
Augenschmerzen , abnormales Sehen ||| eye pain , abnormal vision ||| 0-0 1-1 1-2 2-2 2-3 3-4
Augenschmerzen , abnormales ||| eye pain , abnormal ||| 0-0 1-1 1-2 2-2 2-3
Augenschmerzen ||| eye ||| 0-0
Aus diesem ||| Therefore ||| 0-0 1-0
Aus in-vitro-Untersuchungen an ||| No evidence exists ||| 1-0 1-1 0-2 1-2 2-2
Aus ||| 12 From ||| 0-0 0-1
Aus ||| From ||| 0-0
Ausfällungen oder Sinkstoffe sichtbar sind ||| precipitates or settling are visible ||| 0-0 1-1 2-2 3-2 4-3 0-4
Ausführliche Informationen zu ||| 161 Detailed information on ||| 0-0 0-1 2-1 1-2 1-3
Ausführliche Informationen zu ||| 167 Detailed information on ||| 0-0 0-1 2-1 1-2 1-3
Ausführliche Informationen zu ||| 173 Detailed information on ||| 0-0 0-1 2-1 1-2 1-3
Ausführliche Informationen zu ||| 179 Detailed information on ||| 0-0 0-1 2-1 1-2 1-3
Ausführliche Informationen zu ||| Detailed information on ||| 0-0 2-0 1-1 1-2
Ausführliche Informationen zu ||| ge Detailed information on ||| 0-0 0-1 2-1 1-2 0-3
Ausgang berichtet wurde , ||| outcome has been reported , ||| 0-0 0-1 2-2 1-3 3-4
Ausgang berichtet wurde ||| outcome has been reported ||| 0-0 0-1 2-2 1-3
Ausgang ||| outcome has ||| 0-0 0-1
Ausgangsgewichtes ||| seines Ausgangsgewichtes reduzierte ||| 0-0 0-1 0-2
Ausgangswert 7,2 % ) . ||| baseline 7.2 % ) . ||| 0-0 1-1 2-2 3-3 4-4
Ausgangswert 7,2 % ) ||| baseline 7.2 % ) ||| 0-0 1-1 2-2 3-3
Ausgangswert 7,2 % ||| baseline 7.2 % ||| 0-0 1-1 2-2
Ausgangswert 7,2 ||| baseline 7.2 ||| 0-0 1-1
Ausgangswert 7,3 % ) und ||| baseline 7.3 % ) and ||| 0-0 1-1 2-2 3-3 4-4
Ausgangswert 7,3 % ) ||| baseline 7.3 % ) ||| 0-0 1-1 2-2 3-3
Ausgangswert 7,3 % ||| baseline 7.3 % ||| 0-0 1-1 2-2
Ausgangswert 7,3 ||| baseline 7.3 ||| 0-0 1-1
Ausgangswert auf dem PANSS Excitement ||| baseline on the PANSS Excitement ||| 0-0 1-1 2-2 3-3 4-4
Ausgangswert auf dem PANSS ||| baseline on the PANSS ||| 0-0 1-1 2-2 3-3
Ausgangswert auf dem ||| baseline on the ||| 0-0 1-1 2-2
Ausgangswert auf ||| baseline on ||| 0-0 1-1
Ausgangswert ||| above baseline ||| 0-0 0-1
Ausgangswert ||| baseline ||| 0-0
Ausgangswerten . ||| baseline . ||| 0-0 1-1
Ausgangswerten ||| baseline ||| 0-0
Ausgleich ||| gluconate ||| 0-0
Ausmaß ||| extent ||| 0-0
Ausscheidung . ||| excretion . ||| 0-0 1-1
Ausscheidung erfolgt in unveränderter Form ||| and is excreted unchanged ||| 0-0 1-1 2-2 3-2 3-3 4-3
Ausscheidung erfolgt ||| and is ||| 0-0 1-1
Ausscheidung ||| and ||| 0-0
Ausscheidung ||| excretion ||| 0-0
Ausscheidungen , Zellulitis , Flare-up-Reaktion ||| expulsions , cellulitis , flare ||| 1-0 0-1 1-1 1-2 2-3 3-3 3-4 4-4
Ausscheidungen , ||| expulsions , cellulitis ||| 1-0 0-1 1-1 1-2
Ausschlag ) ||| rash ) ||| 0-0 1-1
Ausschlag . ||| rash . ||| 0-0 1-1
Ausschlag ||| rash ||| 0-0
Ausschuss für Humanarzneimittel ||| Committee for Medicinal products for ||| 0-0 1-1 2-2 2-3 1-4
Ausschuss für ||| Ausschuss für ||| 0-0 0-1 1-1
Ausschuss ||| Committee ||| 0-0
Austrocknung zu schützen . ||| prevent dehydration . ||| 0-0 1-0 0-1 2-1 3-2
Austrocknung zu schützen ||| prevent dehydration ||| 0-0 1-0 0-1 2-1
Auswirkung auf das Gesamtüberleben ||| impact on overall survival ||| 0-0 1-1 2-2 3-2 3-3
Auswirkung auf die ||| effect on the ||| 0-0 1-1 2-2
Auswirkung auf ||| effect on ||| 0-0 1-1
Auswirkung auf ||| impact on ||| 0-0 1-1
Auswirkung einer ||| effect of ||| 0-0 1-1
Auswirkung ||| effect ||| 0-0
Auswirkung ||| impact ||| 0-0
Auswirkungen auf die Pharmakokinetik von ||| meal on the pharmacokinetics of ||| 0-0 1-1 2-2 3-3 4-4
Auswirkungen auf die Pharmakokinetik ||| meal on the pharmacokinetics ||| 0-0 1-1 2-2 3-3
Auswirkungen auf die Verkehrstüchtigkeit und ||| Effects on ability ||| 0-0 1-0 1-1 2-1 3-2 4-2
Auswirkungen auf die Verkehrstüchtigkeit und ||| Effects on ability ||| 0-0 1-1 2-2 3-2 4-2
Auswirkungen auf die ||| Effects on ||| 0-0 1-0 1-1 2-1
Auswirkungen auf die ||| meal on the ||| 0-0 1-1 2-2
Auswirkungen auf die ||| on the ||| 0-0 1-0 2-1
Auswirkungen auf ||| Effects on ||| 0-0 1-1
Auswirkungen auf ||| meal on ||| 0-0 1-1
Auswirkungen auf ||| on ||| 0-0 1-0
Auswirkungen ||| Effects ||| 0-0
Auswirkungen ||| meal ||| 0-0
Außerdem erhalten Sie ||| You will also take ||| 2-0 1-1 0-2 2-3
Außerdem erhalten ||| will also ||| 1-0 0-1
Außerdem wird eine Überwachung ||| Moreover , monitoring of ||| 0-0 0-1 1-2 2-2 3-2 2-3
Außerdem wurden Fälle von ||| In addition , cases of ||| 0-0 0-1 1-1 1-2 2-3 3-4
Außerdem wurden Fälle ||| In addition , cases ||| 0-0 0-1 1-1 1-2 2-3
Außerdem wurden ||| In addition , ||| 0-0 0-1 1-1 1-2
Außerdem zeigte Aripiprazol ||| Aripiprazole also exhibited ||| 1-0 2-0 0-1 0-2 1-2
Außerdem zeigten Aripiprazol und Dehydro-Aripiprazol ||| Additionally , aripiprazole and dehydro-aripiprazole ||| 0-0 1-0 0-1 2-2 3-3 4-4
Außerdem zeigten Aripiprazol und ||| Additionally , aripiprazole and ||| 0-0 1-0 0-1 2-2 3-3
Außerdem zeigten Aripiprazol ||| Additionally , aripiprazole ||| 0-0 1-0 0-1 2-2
Außerdem zeigten ||| Additionally , ||| 0-0 1-0 0-1
Außerdem ||| Moreover , ||| 0-0 0-1
Außerdem ||| also ||| 0-0
Avda. de ||| Avda . de ||| 0-0 1-1 1-2
Avda. ||| Avda ||| 0-0
Avenue Gustave Eiffel , BP ||| Avenue Gustave Eiffel , BP ||| 0-0 1-1 2-2 3-3 4-4
Avenue Gustave Eiffel , ||| Avenue Gustave Eiffel , ||| 0-0 1-1 2-2 3-3
Avenue Gustave Eiffel ||| Avenue Gustave Eiffel ||| 0-0 1-1 2-2
Avenue Gustave ||| Avenue Gustave ||| 0-0 1-1
Avenue ||| Avenue ||| 0-0
B-CTx wurde signifikant ||| B-CTx was significantly ||| 0-0 1-1 2-2
B-CTx wurde ||| B-CTx was ||| 0-0 1-1
B-CTx ||| B-CTx ||| 0-0
B. Bluttransfusionen , erhalten . ||| to patients when indicated . ||| 1-0 1-1 1-2 2-2 0-3 1-3 3-3 4-4
B. Bluttransfusionen , erhalten ||| to patients when indicated ||| 1-0 1-1 1-2 2-2 0-3 1-3 3-3
B. Rifampicin ||| e. g. rifampicin ||| 0-0 0-1 1-2
B. Unterfunktion der Nebenschilddrüsen , ||| g. diminished parathyroid reserve , ||| 0-0 1-1 3-2 3-3 4-4
B. Unterfunktion der Nebenschilddrüsen ||| g. diminished parathyroid reserve ||| 0-0 1-1 3-2 3-3
B. Unterfunktion der ||| g. diminished ||| 0-0 1-1
B. Unterfunktion ||| g. diminished ||| 0-0 1-1
B. verminderte ||| g. ||| 0-0 1-0
B. während der ||| e. g. during ||| 0-0 0-1 1-2 2-2
B. ||| e. g. ||| 0-0 0-1
B. ||| g. ||| 0-0
BEACHTET WERDEN ||| GIVEN ||| 0-0 1-0
BEDINGUNGEN ODER BESCHRÄNKUNGEN FÜR EINE ||| CONDITIONS OR RESTRICTIONS ||| 0-0 2-0 1-1 2-2 3-2 4-2
BEDINGUNGEN ODER BESCHRÄNKUNGEN ||| CONDITIONS OR RESTRICTIONS ||| 0-0 1-1 2-2
BEDINGUNGEN ODER EINSCHRÄNKUNGEN FÜR ||| CONDITIONS OR RESTRICTIONS ||| 0-0 1-1 2-2 3-2
BEDINGUNGEN ODER EINSCHRÄNKUNGEN ||| CONDITIONS OR RESTRICTIONS WITH ||| 0-0 1-1 2-2 2-3
BEDINGUNGEN ODER ||| CONDITIONS OR ||| 0-0 1-1
BEDINGUNGEN ||| CONDITIONS ||| 0-0
BEHÄLTNIS ||| PACKAGING ||| 0-0
BEHÄLTNISSEN ||| PACKAGING UNITS ||| 0-0 0-1
BELGIUM S.A./N.V . ||| S. A. / N. V. ||| 0-0 0-1 1-2 1-3 1-4 2-4
BELGIUM ||| S. A. ||| 0-0 0-1
BESCHRÄNKUNGEN DER ||| RESTRICTIONS OF ||| 0-0 1-1
BESCHRÄNKUNGEN ||| RESTRICTIONS ||| 0-0
BESEITIGUNG VON NICHT ||| PRODUCTS OR WASTE MATERIALS ||| 0-0 1-1 1-2 2-3
BESEITIGUNG VON ||| PRODUCTS OR WASTE ||| 0-0 1-1 1-2
BESEITIGUNG ||| PRODUCTS ||| 0-0
BESONDERE VORSICHTSMAßNAHMEN ||| SPECIAL PRECAUTIONS ||| 0-0 0-1 1-1
BESONDERE ||| SPECIAL PRECAUTIONS ||| 0-0 0-1
BESTANDTEILE ||| Enthält Lactosemonohydrat ||| 0-0 0-1
BEURTEILUNG ||| EVALUATION ||| 0-0
BEZEICHNUNG DES ARZNEIMITTELS SOWIE ||| NAME OF THE MEDICINAL PRODUCT ||| 0-0 1-1 1-2 2-3 3-4
BEZEICHNUNG DES ARZNEIMITTELS ||| NAME OF THE MEDICINAL ||| 0-0 1-1 1-2 2-3
BEZEICHNUNG DES ||| NAME OF THE ||| 0-0 1-1 1-2
BEZEICHNUNG ||| NAME ||| 0-0
BEZUG AUF ABGABE UND ANWENDUNG ||| REGARDING SUPPLY OR USE ||| 0-0 1-1 2-1 3-1 2-2 4-3
BEZUG AUF ABGABE UND ||| REGARDING SUPPLY OR ||| 0-0 1-1 2-1 3-1 2-2
BEZUG ||| REGARDING ||| 0-0
BL5 3XX Vereinigtes Königreich ||| BL5 3XX United Kingdom ||| 0-0 1-1 2-2 3-3
BL5 3XX Vereinigtes ||| BL5 3XX United ||| 0-0 1-1 2-2
BL5 3XX ||| BL5 3XX ||| 0-0 1-1
BL5 ||| BL5 ||| 0-0
BLISTERPACKUNGEN ODER FOLIENSTREIFEN ||| ON BLISTERS OR STRIPS ||| 0-0 0-1 1-2 2-3
BLISTERPACKUNGEN ODER ||| ON BLISTERS OR ||| 0-0 0-1 1-2
BLISTERPACKUNGEN ODER ||| ON ||| 0-0 1-0
BLISTERPACKUNGEN ||| ON BLISTERS ||| 0-0 0-1
BLUE BOX ) UND ETIKETTIERUNG ||| BLUE BOX ) AND BOTTLE ||| 0-0 1-1 2-2 3-3 4-4
BLUE BOX ) UND ||| BLUE BOX ) AND ||| 0-0 1-1 2-2 3-3
BLUE BOX ) ||| BLUE BOX ) ||| 0-0 1-1 2-2
BLUE BOX ||| BLUE BOX ||| 0-0 1-1
BLUE ||| BLUE ||| 0-0
BMD ) In ||| BMD ) In ||| 0-0 1-1 2-2
BMD ) ||| BMD ) ||| 0-0 1-1
BMD nach 24 Monaten beurteilt ||| BMD assessed at 24 months ||| 0-0 4-1 0-2 2-3 1-4 3-4
BMD ||| BMD ||| 0-0
BMI ||| BMI ||| 0-0
BOX ) UND ETIKETTIERUNG ||| BOX ) AND BOTTLE ||| 0-0 1-1 2-2 3-3
BOX ) UND ||| BOX ) AND ||| 0-0 1-1 2-2
BOX ) ||| BOX ) ||| 0-0 1-1
BOX ||| BOX ||| 0-0
BP 27166 , F-37071 Tours ||| BP 27166 , F-37071 Tours ||| 0-0 1-1 2-2 3-3 4-4
BP 27166 , F-37071 ||| BP 27166 , F-37071 ||| 0-0 1-1 2-2 3-3
BP 27166 , ||| BP 27166 , ||| 0-0 1-1 2-2
BP 27166 ||| BP 27166 ||| 0-0 1-1
BP ||| BP ||| 0-0
BRISTOL-MYERS SQUIBB ( FINLAND ) ||| BRISTOL-MYERS SQUIBB ( FINLAND ) ||| 0-0 1-1 2-2 3-3 4-4
BRISTOL-MYERS SQUIBB ( FINLAND ||| BRISTOL-MYERS SQUIBB ( FINLAND ||| 0-0 1-1 2-2 3-3
BRISTOL-MYERS SQUIBB ( ||| BRISTOL-MYERS SQUIBB ( ||| 0-0 1-1 2-2
BRISTOL-MYERS SQUIBB AB Tel : ||| BRISTOL-MYERS SQUIBB AB Tel : ||| 0-0 1-1 2-2 3-3 4-4
BRISTOL-MYERS SQUIBB AB Tel ||| BRISTOL-MYERS SQUIBB AB Tel ||| 0-0 1-1 2-2 3-3
BRISTOL-MYERS SQUIBB AB ||| BRISTOL-MYERS SQUIBB AB ||| 0-0 1-1 2-2
BRISTOL-MYERS SQUIBB BELGIUM ||| BRISTOL-MYERS SQUIBB BELGIUM S. A. ||| 0-0 1-1 1-2 2-2 2-3 2-4
BRISTOL-MYERS SQUIBB BELGIUM ||| BRISTOL-MYERS SQUIBB BELGIUM S. A. ||| 0-0 1-1 1-2 2-3 2-4
BRISTOL-MYERS SQUIBB BV Tel : ||| BRISTOL-MYERS SQUIBB BV Tel : ||| 0-0 1-1 2-2 3-3 4-4
BRISTOL-MYERS SQUIBB BV Tel ||| BRISTOL-MYERS SQUIBB BV Tel ||| 0-0 1-1 2-2 3-3
BRISTOL-MYERS SQUIBB BV ||| BRISTOL-MYERS SQUIBB BV ||| 0-0 1-1 2-2
BRISTOL-MYERS SQUIBB GESMBH Tel : ||| BRISTOL-MYERS SQUIBB GESMBH Tel : ||| 0-0 1-1 2-2 3-3 4-4
BRISTOL-MYERS SQUIBB GESMBH Tel ||| BRISTOL-MYERS SQUIBB GESMBH Tel ||| 0-0 1-1 2-2 3-3
BRISTOL-MYERS SQUIBB GESMBH ||| BRISTOL-MYERS SQUIBB GESMBH ||| 0-0 1-1 2-2
BRISTOL-MYERS SQUIBB NORWAY LTD Tlf ||| BRISTOL-MYERS SQUIBB NORWAY LTD Tlf ||| 0-0 1-1 2-2 3-3 4-4
BRISTOL-MYERS SQUIBB NORWAY LTD ||| BRISTOL-MYERS SQUIBB NORWAY LTD ||| 0-0 1-1 2-2 3-3
BRISTOL-MYERS SQUIBB NORWAY ||| BRISTOL-MYERS SQUIBB NORWAY ||| 0-0 1-1 2-2
BRISTOL-MYERS SQUIBB PHARMACEUTICALS LTD Tel ||| BRISTOL-MYERS SQUIBB PHARMACEUTICALS LTD Tel ||| 0-0 1-1 2-2 3-3 4-4
BRISTOL-MYERS SQUIBB PHARMACEUTICALS LTD ||| BRISTOL-MYERS SQUIBB PHARMACEUTICALS LTD ||| 0-0 1-1 2-2 3-3
BRISTOL-MYERS SQUIBB PHARMACEUTICALS ||| BRISTOL-MYERS SQUIBB PHARMACEUTICALS ||| 0-0 1-1 2-2
BRISTOL-MYERS SQUIBB SARL Tél : ||| BRISTOL-MYERS SQUIBB SARL Tél : ||| 0-0 1-1 2-2 3-3 4-4
BRISTOL-MYERS SQUIBB SARL Tél ||| BRISTOL-MYERS SQUIBB SARL Tél ||| 0-0 1-1 2-2 3-3
BRISTOL-MYERS SQUIBB SARL ||| BRISTOL-MYERS SQUIBB SARL ||| 0-0 1-1 2-2
BRISTOL-MYERS SQUIBB Tlf : + ||| BRISTOL-MYERS SQUIBB Tlf : + ||| 0-0 1-1 2-2 3-3 4-4
BRISTOL-MYERS SQUIBB Tlf : ||| BRISTOL-MYERS SQUIBB Tlf : ||| 0-0 1-1 2-2 3-3
BRISTOL-MYERS SQUIBB Tlf ||| BRISTOL-MYERS SQUIBB Tlf ||| 0-0 1-1 2-2
BRISTOL-MYERS SQUIBB ||| BRISTOL-MYERS SQUIBB BELGIUM ||| 0-0 1-1 1-2
BRISTOL-MYERS SQUIBB ||| BRISTOL-MYERS SQUIBB ||| 0-0 1-1
BRISTOL-MYERS ||| BRISTOL-MYERS ||| 0-0
BSAP ) , das ||| BSAP ) , ||| 0-0 1-1 2-2
BSAP ) , ||| BSAP ) , ||| 0-0 1-1 2-2
BSAP ) ||| BSAP ) ||| 0-0 1-1
BSAP ||| BSAP ||| 0-0
BV Tel : + 31 ||| BV Tel : + 31 ||| 0-0 1-1 2-2 3-3 4-4
BV Tel : + ||| BV Tel : + ||| 0-0 1-1 2-2 3-3
BV Tel : ||| BV Tel : ||| 0-0 1-1 2-2
BV Tel ||| BV Tel ||| 0-0 1-1
BV ||| BV ||| 0-0
Bagsværd Dänemark ||| Bagsværd Denmark ||| 0-0 1-1
Bagsværd ||| Bagsværd ||| 0-0
Basierend auf den Ergebnissen der ||| Based on results of ||| 0-0 1-1 2-2 3-2 4-3
Basierend auf den Ergebnissen ||| Based on results ||| 0-0 1-1 2-2 3-2
Basierend auf den konventionellen ||| Non-clinical data reveal no ||| 0-0 1-0 3-1 2-2 3-2 3-3
Basierend auf den konventionellen ||| Non-clinical safety data revealed no ||| 0-0 1-0 2-0 3-1 3-2 3-3 3-4
Basierend auf den ||| Non-clinical ||| 0-0 1-0 2-0
Basierend auf der Bewertung ||| Based on laboratory assessment ||| 0-0 1-1 2-1 2-2 1-3
Basierend auf der ||| Based on laboratory assessment ||| 0-0 1-1 2-1 2-2 1-3
Basierend auf in vitro-Studien ||| Based on in vitro studies ||| 0-0 1-1 2-2 3-3 3-4
Basierend auf in ||| Based on in ||| 0-0 1-1 2-2
Basierend auf ||| Based on ||| 0-0 1-1
Basierend auf ||| Non-clinical ||| 0-0 1-0
Basierend ||| Based ||| 0-0
Basis ||| basis ||| 0-0
Bauch- und Magenbeschwerden , ||| , abdominal and stomach discomfort ||| 3-0 0-1 1-2 2-3 0-4 2-4
Bauch- und Magenbeschwerden ||| abdominal and stomach discomfort , ||| 0-0 1-1 2-2 0-3 2-3
Bauch- und Magenbeschwerden ||| abdominal and stomach discomfort ||| 0-0 1-1 2-2 0-3 2-3
Bauch- ||| abdominal discomfort ||| 0-0 0-1
Bauchspeicheldrüse , ||| of the pancreas ||| 0-2
Bauchspeicheldrüse , ||| pancreas ||| 0-0
Bauchspeicheldrüse , ||| the pancreas ||| 0-1
Bauchspeicheldrüse ||| of the pancreas ||| 0-2
Bauchspeicheldrüse ||| pancreas ||| 0-0
Bauchspeicheldrüse ||| the pancreas ||| 0-1
Beckenkamm entnommen ||| ( N=70 ||| 0-1 1-1
Beckenkamm entnommen ||| N=70 ||| 0-0 1-0
Bedeutung dieses Wirkmechanismus für den ||| relevance of such a mechanism ||| 0-0 1-0 3-0 2-2 0-3 2-4 4-4
Bedienen von Maschinen ) , ||| precautions to avoid ||| 0-0 1-1 2-2 3-2
Bedienen von Maschinen ) ||| precautions to avoid ||| 0-0 1-1 2-2 3-2
Bedienen von Maschinen . ||| use machines . ||| 0-0 1-0 0-1 2-1 3-2
Bedienen von Maschinen . ||| use machines . ||| 0-0 1-0 2-1 3-2
Bedienen von Maschinen durchgeführt ||| use machines have been performed ||| 0-0 0-1 2-1 0-2 1-2 3-3 3-4
Bedienen von Maschinen ||| use machines have ||| 0-0 0-1 2-1 0-2 1-2
Bedienen von Maschinen ||| use machines ||| 0-0 1-0 0-1 2-1
Bedienen von Maschinen ||| use machines ||| 0-0 1-0 2-1
Bedienen von ||| precautions to ||| 0-0 1-1
Bedienen von ||| use ||| 0-0 1-0
Bedienen ||| precautions ||| 0-0
Bedienungsanleitung beigefügt . ||| be followed . ||| 1-0 0-1 1-1 2-2
Bedienungsanleitung beigefügt ||| be followed ||| 1-0 0-1 1-1
Bedingt durch die ||| There may be an increased ||| 0-0 0-1 0-2 0-3 1-3 0-4 2-4
Bedingungen ||| of the ||| 0-1
Bedingungen ||| the ||| 0-0
Beeinträchtigung der Leberfunktion ( siehe ||| hepatic impairment ( see sections ||| 2-0 0-1 2-1 3-2 4-3 4-4
Beeinträchtigung der Leberfunktion ( ||| hepatic impairment ( ||| 2-0 0-1 2-1 3-2
Beeinträchtigung der Leberfunktion ||| hepatic impairment ||| 2-0 0-1 2-1
Beeinträchtigung der Nierenfunktion ( siehe ||| renal impairment ( see ||| 2-0 0-1 2-1 3-2 4-3
Beeinträchtigung der Nierenfunktion ( ||| renal impairment ( ||| 2-0 0-1 2-1 3-2
Beeinträchtigung der Nierenfunktion ||| renal impairment ||| 2-0 0-1 2-1
Beeinträchtigung der ||| however , should ||| 0-0 1-0
Beeinträchtigung der ||| however , ||| 0-0 1-0
Beeinträchtigung der ||| however ||| 0-0 1-0
Beeinträchtigung der ||| pharmacokinetics and safety of ||| 0-0 0-1 1-2 1-3
Beeinträchtigung ||| pharmacokinetics and ||| 0-0 0-1
Beendigung der Behandlung mit Aclasta ||| stopping Aclasta treatment ||| 0-0 1-0 4-1 2-2 3-2
Beendigung der ||| stopping ||| 0-0 1-0
Befolgen Sie sorgfältig alle Anweisungen ||| Follow carefully all instructions given ||| 0-0 1-0 2-1 3-2 4-3 4-4
Befolgen Sie sorgfältig alle ||| Follow carefully all ||| 0-0 1-0 2-1 3-2
Befolgen Sie sorgfältig ||| Follow carefully ||| 0-0 1-0 2-1
Befolgen Sie ||| Follow ||| 0-0 1-0
Befund ||| finding ||| 0-0
Befunde ist nicht bekannt . ||| findings is unknown . ||| 0-0 1-1 2-2 3-2 4-3
Befunde ist nicht bekannt ||| findings is unknown ||| 0-0 1-1 2-2 3-2
Befunde ist ||| findings is ||| 0-0 1-1
Befunde mit Zellen aus ||| findings from ||| 0-0 1-0 2-0 3-1
Befunde mit Zellen ||| findings ||| 0-0 1-0 2-0
Befunde ||| findings ||| 0-0
Beginn Ihrer Behandlung soll ||| the start of your therapy ||| 3-0 0-1 1-2 2-2 1-3 0-4 3-4
Beginn der Actos-Behandlung beibehalten ||| continued when starting Actos ||| 0-0 1-0 3-0 2-1 2-2 2-3
Beginn der Therapie mit Pioglitazon ||| initiation of therapy with pioglitazone ||| 0-0 1-1 2-2 3-3 4-4
Beginn der Therapie mit ||| initiation of therapy with ||| 0-0 1-1 2-2 3-3
Beginn der Therapie mit ||| the initiation of therapy with ||| 1-0 0-1 1-2 2-3 3-4
Beginn der Therapie ||| initiation of therapy ||| 0-0 1-1 2-2
Beginn der Therapie ||| the initiation of therapy ||| 1-0 0-1 1-2 2-3
Beginn der ||| initiation of ||| 0-0 1-1
Beginn der ||| the initiation of ||| 1-0 0-1 1-2
Beginn einer Insulintherapie können Ödeme ||| occur upon initiation of insulin ||| 0-0 0-1 1-1 2-1 2-2 3-2 4-2 4-3 4-4
Beginn ||| initiation ||| 0-0
Beginn ||| start of ||| 0-0
Beginn ||| start ||| 0-0
Beginn ||| starting ||| 0-0
Behandlung ( siehe ||| treatment ( see ||| 0-0 1-1 2-2
Behandlung ( ||| treatment ( ||| 0-0 1-1
Behandlung , ||| treatment , ||| 0-0 1-1
Behandlung . ||| treatment . ||| 0-0 1-1
Behandlung Ihres Diabetes ||| when treating your diabetes ||| 1-0 0-1 1-1 1-2 2-3
Behandlung Ihres ||| when treating your ||| 1-0 0-1 1-1 1-2
Behandlung angesprochen haben . ||| initial treatment response . ||| 1-0 0-1 1-2 2-2 3-3
Behandlung angesprochen haben ||| initial treatment response ||| 1-0 0-1 1-2 2-2
Behandlung auf ||| treatment to ||| 0-0 1-1
Behandlung der Anämie bei ||| Treatment of anaemia associated with ||| 0-0 1-1 2-2 2-3 3-4
Behandlung der Anämie und Reduktion ||| Treatment of anaemia and reduction ||| 0-0 1-1 2-2 3-3 4-4
Behandlung der Anämie und ||| Treatment of anaemia and ||| 0-0 1-1 2-2 3-3
Behandlung der Anämie ||| Treatment of anaemia associated ||| 0-0 1-1 2-2 2-3
Behandlung der Anämie ||| Treatment of anaemia ||| 0-0 1-1 2-2
Behandlung der Osteoporose bei postmenopausalen ||| Treatment of osteoporosis in post-menopausal ||| 0-0 1-1 2-2 3-3 4-4
Behandlung der Osteoporose bei ||| Treatment of osteoporosis in ||| 0-0 1-1 2-2 3-3
Behandlung der Osteoporose ||| Treatment of osteoporosis ||| 0-0 1-1 2-2
Behandlung der Schizophrenie angezeigt . ||| the treatment of schizophrenia . ||| 1-0 0-1 1-1 1-2 2-3 3-3 4-4
Behandlung der Schizophrenie angezeigt ||| the treatment of schizophrenia ||| 1-0 0-1 1-1 1-2 2-3 3-3
Behandlung der bipolaren Störung ||| treatment of bipolar disorder ||| 0-0 1-1 2-2 3-3
Behandlung der bipolaren ||| treatment of bipolar ||| 0-0 1-1 2-2
Behandlung der folgenden Krankheiten ||| the treatment of the following ||| 1-0 0-1 1-2 1-3 3-3 2-4
Behandlung der postmenopausalen Osteoporose ( ||| treatment of post-menopausal osteoporosis ( ||| 0-0 1-1 2-2 3-3 4-4
Behandlung der postmenopausalen Osteoporose ||| treatment of post-menopausal osteoporosis ||| 0-0 1-1 2-2 3-3
Behandlung der postmenopausalen ||| the treatment of post-menopausal ||| 1-0 0-1 1-2 2-3
Behandlung der postmenopausalen ||| treatment of post-menopausal ||| 0-0 1-1 2-2
Behandlung der symptomatischen Anämie bei ||| Treatment of symptomatic anaemia in ||| 0-0 1-1 2-2 3-3 4-4
Behandlung der symptomatischen Anämie ||| Treatment of symptomatic anaemia ||| 0-0 1-1 2-2 3-3
Behandlung der symptomatischen ||| Treatment of symptomatic ||| 0-0 1-1 2-2
Behandlung der ||| Treatment of ||| 0-0 1-1
Behandlung der ||| the treatment of ||| 1-0 0-1 1-1 1-2
Behandlung der ||| the treatment of ||| 1-0 0-1 1-2
Behandlung der ||| treatment of ||| 0-0 1-1
Behandlung des Diabetes ist die ||| treatment of diabetes is ||| 0-0 1-1 2-2 3-3 4-3
Behandlung des Diabetes ||| treatment of diabetes ||| 0-0 1-1 2-2
Behandlung des Morbus Paget ||| treatment of Paget s disease ||| 0-0 1-1 2-2 3-2 1-3 2-3 3-4
Behandlung des ||| treatment of ||| 0-0 1-1
Behandlung die folgenden Erhaltungsdosen festgestellt ||| 6 months of treatment ||| 2-0 3-0 3-1 4-1 4-2 0-3 4-3
Behandlung dieser Patientengruppe abgewogen werden ||| treatment in this patient group ||| 0-0 2-1 1-2 2-2 3-3 3-4 4-4
Behandlung dieser Patientengruppe ||| treatment in this ||| 0-0 2-1 1-2 2-2
Behandlung dieser ||| treatment of ||| 0-0 1-1
Behandlung eingeleitet werden ||| treatment should be initiated ||| 0-0 1-1 2-2 1-3
Behandlung ist Teil ||| treatment is part of ||| 0-0 1-1 2-2 2-3
Behandlung ist ||| treatment is ||| 0-0 1-1
Behandlung kann die ||| of treatment , the ||| 0-0 0-1 1-1 1-2 2-3
Behandlung kann ||| of treatment , ||| 0-0 0-1 1-1 1-2
Behandlung können ||| may ||| 1-0
Behandlung mit Abseamed beendet werden ||| Abseamed treatment should be discontinued ||| 2-0 0-1 1-1 3-2 4-3 3-4 4-4
Behandlung mit Abseamed beginnt . ||| Abseamed treatment begins . ||| 2-0 0-1 1-1 3-2 4-3
Behandlung mit Abseamed beginnt ||| Abseamed treatment begins ||| 2-0 0-1 1-1 3-2
Behandlung mit Abseamed ||| Abseamed treatment ||| 2-0 0-1 1-1
Behandlung mit Aclasta ||| Aclasta treatment ||| 2-0 0-1 1-1
Behandlung mit Aripiprazol ||| aripiprazole treatment ||| 2-0 0-1 1-1
Behandlung mit Aripiprazol ||| treatment with aripiprazole . ||| 0-0 1-1 2-2
Behandlung mit Aripiprazol ||| treatment with aripiprazole ||| 0-0 1-1 2-2
Behandlung mit Epoetin alfa berichtet ||| treatment with epoetin alfa ||| 0-0 1-1 2-2 3-3 4-3
Behandlung mit Epoetin alfa ist ||| treatment with epoetin alfa is ||| 0-0 1-1 2-2 3-3 4-4
Behandlung mit Epoetin alfa ||| treatment with epoetin alfa ||| 0-0 1-1 2-2 3-3
Behandlung mit Epoetin ||| treatment with epoetin ||| 0-0 1-1 2-2
Behandlung mit Lithium ||| treatment with lithium ||| 0-0 1-1 2-2
Behandlung mit Metformin und ||| treatment with metformin and ||| 0-0 1-1 2-2 3-3
Behandlung mit Metformin ||| treatment with metformin ||| 0-0 1-1 2-2
Behandlung mit Pioglitazon ab . ||| with treatment with pioglitazone . ||| 1-0 0-1 1-2 2-3 3-3 4-4
Behandlung mit Pioglitazon ab ||| with treatment with pioglitazone ||| 1-0 0-1 1-2 2-3 3-3
Behandlung mit dem Arzneimittel ||| treatment with the product ||| 0-0 1-1 2-2 3-3
Behandlung mit dem ||| treatment with the ||| 0-0 1-1 2-2
Behandlung mit subkutanem Erythropoetin berichtet ||| of subcutaneous erythropoietin treatment ||| 0-0 1-0 2-1 3-2 0-3 4-3
Behandlung mit zwei anderen ||| treatment with two other ||| 0-0 1-1 2-2 3-3
Behandlung mit zwei ||| treatment with two ||| 0-0 1-1 2-2
Behandlung mit ||| treatment , ||| 0-0 1-0
Behandlung mit ||| treatment with ||| 0-0 1-1
Behandlung mit ||| treatment ||| 0-0 1-0
Behandlung mit ||| with treatment with ||| 1-0 0-1 1-2
Behandlung nicht ||| treatment ||| 0-0
Behandlung postmenopausaler Osteoporose implementiert wurde ||| of treatment of post-menopausal osteoporosis ||| 0-1 2-3 1-4 2-4 3-4 4-4
Behandlung postmenopausaler Osteoporose implementiert wurde ||| treatment of post-menopausal osteoporosis ||| 0-0 2-2 1-3 2-3 3-3 4-3
Behandlung rückläufig . ||| of continued therapy . ||| 0-0 0-1 1-1 1-2 2-3
Behandlung rückläufig ||| of continued therapy ||| 0-0 0-1 1-1 1-2
Behandlung sollte bei diesen Patienten ||| treatment , these patients should ||| 0-0 3-2 2-3 4-3 1-4
Behandlung sollte ||| treatment should be ||| 0-0 1-1 1-2
Behandlung und ||| and ||| 1-0
Behandlung von Diabetes gegenüber ||| treatment of diabetes ||| 0-0 1-1 2-2
Behandlung von Diabetes ||| treatment of diabetes ||| 0-0 1-1 2-2
Behandlung von Erwachsenen , bei ||| Treatment of adult patients ||| 0-0 1-1 2-2 4-3
Behandlung von Erwachsenen , ||| Treatment of adult ||| 0-0 1-1 2-2
Behandlung von Erwachsenen ||| Treatment of adult ||| 0-0 1-1 2-2
Behandlung von Morbus Paget ||| Treatment of Paget s disease ||| 0-0 1-1 2-2 2-3 3-3 3-4
Behandlung von Patienten ||| Treatment of patients ||| 0-0 1-1 2-2
Behandlung von fortgeschrittenem ||| treatment of advanced prostate cancer ||| 0-0 1-1 2-2 2-3 2-4
Behandlung von ||| Treatment of ||| 0-0 1-1
Behandlung von ||| than its ||| 1-0
Behandlung von ||| than ||| 1-0
Behandlung von ||| the treatment of ||| 0-1 1-2
Behandlung von ||| treatment of ||| 0-0 1-1
Behandlung von Übergewicht und Fettleibigkeit ||| management of overweight and obesity ||| 0-0 2-0 1-1 2-2 3-3 4-4
Behandlung von Übergewicht und ||| management of overweight and ||| 0-0 2-0 1-1 2-2 3-3
Behandlung von Übergewicht ||| management of overweight ||| 0-0 2-0 1-1 2-2
Behandlung wieder zurückbildet ||| course of continued therapy ||| 0-0 0-1 0-2 2-2 0-3 1-3
Behandlung zur Vorbeugung ||| treatment for the prevention of ||| 0-0 1-1 1-3 2-3 0-4
Behandlung ||| , treatment ||| 0-1
Behandlung ||| Treatment ||| 0-0
Behandlung ||| be treated ||| 0-0
Behandlung ||| be ||| 0-0
Behandlung ||| experienced ||| 0-0
Behandlung ||| of treatment of ||| 0-1
Behandlung ||| of treatment ||| 0-1
Behandlung ||| palliative treatment ||| 0-0 0-1
Behandlung ||| the treatment ||| 0-1
Behandlung ||| treatment , ||| 0-0
Behandlung ||| treatment of ||| 0-0
Behandlung ||| treatment ||| 0-0
Behandlungsbeginn ||| start of ||| 0-0
Behandlungsbeginn ||| start ||| 0-0
Behandlungsbeginn ||| the start of ||| 0-1
Behandlungsbeginn ||| the start ||| 0-1
Behandlungserfolg zu überprüfen und sicherzugehen ||| being achieved and to ensure ||| 0-0 0-1 2-1 3-2 1-3 4-4
Behandlungserfolg zu überprüfen und ||| being achieved and to ||| 0-0 0-1 2-1 3-2 1-3
Behandlungsgruppen ||| with ||| 0-0
Behandlungskursen ||| courses ||| 0-0
Behandlungsplan eines jeden Patienten sein ||| plan of each patient ||| 0-0 1-1 4-1 2-2 3-3
Behandlungsplan ||| plan ||| 0-0
Behandlungsregime einschließlich Bisphosphonaten ||| regimens including bisphosphonates ||| 0-0 1-1 2-2
Behandlungsregime einschließlich ||| regimens including ||| 0-0 1-1
Behandlungsregime ||| regimens ||| 0-0
Behandlungsschema ||| treatment schedule ||| 0-0 0-1
Behandlungsschemas . ||| schedule . ||| 0-0 1-1
Behandlungsschemas . ||| treatment schedule . ||| 0-1 1-2
Behandlungsschemas ||| schedule ||| 0-0
Behandlungsschemas ||| treatment schedule ||| 0-1
Bei Anwendung von ABILIFY ||| Using ABILIFY ||| 0-0 1-0 2-1 3-1
Bei Anwendung von Aclasta ||| Using Aclasta ||| 0-0 1-0 2-1 3-1
Bei Anwendung ||| Using ||| 0-0 1-0
Bei CYP2D6 ||| In CYP2D6 ||| 0-0 1-1
Bei Einnahme von ABILIFY ||| Taking ABILIFY ||| 0-0 1-0 2-0 3-1
Bei Einnahme von ABILIFY ||| Taking ||| 0-0 1-0 2-0 3-0
Bei Einnahme von ||| Taking ||| 0-0 1-0 2-0
Bei Jungtieren kam es ||| There was ||| 0-0 1-0 2-1 3-1
Bei Jungtieren ||| There ||| 0-0 1-0
Bei Kombination mit Insulin ||| 2 In combination with insulin ||| 0-0 0-1 1-2 2-3 3-4
Bei Kombination mit Insulin ||| In combination with insulin , ||| 0-0 1-1 2-2 3-3
Bei Kombination mit Insulin ||| In combination with insulin ||| 0-0 1-1 2-2 3-3
Bei Kombination mit ||| 2 In combination with ||| 0-0 0-1 1-2 2-3
Bei Kombination mit ||| In combination with ||| 0-0 1-1 2-2
Bei Kombination ||| 2 In combination ||| 0-0 0-1 1-2
Bei Kombination ||| In combination ||| 0-0 1-1
Bei Morbus Paget ||| For Paget s disease , ||| 0-0 1-1 2-1 1-2 2-3
Bei Morbus Paget ||| For Paget s disease ||| 0-0 1-1 2-1 1-2 2-3
Bei Morbus Paget ||| For Paget s disease ||| 0-0 1-1 2-1 2-2 2-3
Bei Morbus Paget ||| In Paget s disease , ||| 0-0 1-1 2-1 1-2 2-3
Bei Morbus Paget ||| In Paget s disease ||| 0-0 1-1 2-1 1-2 2-3
Bei Osteoporose war Aclasta bei ||| In osteoporosis , Aclasta was ||| 0-0 1-1 3-3 2-4 4-4
Bei Osteoporose ||| For osteoporosis ||| 0-0 1-1
Bei Osteoporose ||| In osteoporosis , ||| 0-0 1-1
Bei Osteoporose ||| In osteoporosis ||| 0-0 1-1
Bei Patienten , die ||| For patients who ||| 0-0 1-1 1-2 2-2 3-2
Bei Patienten mit Diabetes mellitus ||| In patients with diabetes mellitus ||| 0-0 1-1 2-2 3-3 4-4
Bei Patienten mit Diabetes ||| In patients with diabetes ||| 0-0 1-1 2-2 3-3
Bei Patienten mit beeinträchtigter Leberfunktion ||| Patients with hepatic impairment ||| 0-0 1-0 2-1 4-2 3-3 4-3
Bei Patienten mit chronischer Niereninsuffizienz ||| In chronic renal failure patients ||| 0-0 1-1 3-1 2-2 4-2 3-3 4-3 1-4
Bei Patienten mit chronischer ||| Serum electrolytes ||| 0-0 1-1 2-1 3-1
Bei Patienten mit einer Adipositas ||| Bei Patienten mit einer Adipositas ||| 0-0 1-1 2-2 3-3 4-4
Bei Patienten mit einer ||| Bei Patienten mit einer ||| 0-0 1-1 2-2 3-3
Bei Patienten mit einer ||| In patients with a ||| 0-0 1-1 2-2 3-3
Bei Patienten mit ||| Bei Patienten mit ||| 0-0 1-1 2-2
Bei Patienten mit ||| In patients with ||| 0-0 1-1 2-2
Bei Patienten mit ||| No dosage adjustment ||| 0-0 0-1 1-1 0-2 2-2
Bei Patienten mit ||| Patients with ||| 0-0 1-0 2-1
Bei Patienten unter Pioglitazon reduzierte ||| Patients receiving pioglitazone had ||| 0-0 1-0 2-1 3-2 4-2 1-3
Bei Patienten ||| Bei Patienten ||| 0-0 1-1
Bei Patienten ||| If patients ||| 0-0 1-1
Bei Patienten ||| In patients ||| 0-0 1-1
Bei Patienten ||| No dosage ||| 0-0 0-1 1-1
Bei Patienten ||| Patients ||| 0-0 1-0
Bei Patientinnen mit chronischer Niereninsuffizienz ||| In chronic renal failure patients ||| 0-0 3-1 4-2 1-3 3-3 4-3 1-4 2-4
Bei Schizophrenie ||| For schizophrenia , ||| 0-0 1-1
Bei Schizophrenie ||| For schizophrenia ||| 0-0 1-1
Bei Tieren lässt ||| In animals , ||| 0-0 1-1 2-1 2-2
Bei Tumorpatienten unter Chemotherapie ||| In cancer patients receiving chemotherapy ||| 0-0 1-1 1-2 2-3 3-3 3-4
Bei Tumorpatienten ||| In cancer patients ||| 0-0 1-1 1-2
Bei Typ 1 ||| In type 1 ||| 0-0 1-1 2-2
Bei Typ ||| In type ||| 0-0 1-1
Bei Wiederauftreten einer schweren Neutropenie ||| Following recurrence of severe neutropenia ||| 1-0 1-1 2-2 3-3 4-4
Bei Wiederauftreten einer schweren ||| Following recurrence of severe ||| 1-0 1-1 2-2 3-3
Bei Wiederauftreten einer ||| Following recurrence of ||| 1-0 1-1 2-2
Bei Wiederauftreten ||| Following recurrence ||| 1-0 1-1
Bei allen Patienten , die ||| In all patients receiving ||| 0-0 1-1 2-2 1-3 3-3 4-3
Bei allen Patienten ||| In all patients ||| 0-0 1-1 2-2
Bei allen ||| All of ||| 1-0 0-1
Bei allen ||| In all ||| 0-0 1-1
Bei beiden Erkrankungen ||| The ||| 0-0
Bei beiden ||| The ||| 0-0
Bei bipolarer Störung ||| Bei bipolarer Störung ||| 0-0 1-1 2-2
Bei bipolarer ||| Bei bipolarer ||| 0-0 1-1
Bei den kombinierten Ergebnissen wurde ||| In the pooled results , ||| 0-0 1-1 2-1 2-2 4-2 1-3 3-3
Bei den kombinierten Ergebnissen wurde ||| In the pooled results ||| 0-0 1-1 2-1 2-2 4-2 1-3 3-3
Bei den meisten dieser Patienten ||| In most of these patients ||| 0-0 1-1 2-1 3-2 3-3 4-4
Bei den meisten dieser ||| In most of these ||| 0-0 1-1 2-1 3-2 3-3
Bei den meisten ||| In most ||| 0-0 1-1 2-1
Bei der Anwendung zur Behandlung ||| When used to treat ||| 0-0 2-1 3-1 1-2 3-2 3-3 4-3
Bei der Einnahme von ABILIFY ||| Taking ABILIFY ||| 0-0 1-0 2-0 3-0 4-1
Bei der Einnahme von ||| Taking ||| 0-0 1-0 2-0 3-0
Bei der ||| with ||| 0-0
Bei diesen Patienten sollte ||| Bei diesen Patienten sollte ||| 0-0 1-1 1-2 2-2 1-3 3-3
Bei diesen Patienten ||| In these patients ||| 0-0 1-1 2-2
Bei diesen Patientinnen besteht die ||| These patients may be at ||| 0-0 1-0 2-1 2-2 3-3 3-4 4-4
Bei diesen Patientinnen ||| These patients may ||| 0-0 1-0 2-1 2-2
Bei diesen ||| In these ||| 0-0 1-1
Bei diesen ||| These ||| 0-0 1-0
Bei einem Kontakt mit ||| If it contacts ||| 0-0 1-1 2-2 3-2
Bei einem ||| If it ||| 0-0 1-1
Bei einer Wirksamkeit von 98-100 ||| With an efficacy of 98-100 ||| 4-0 0-1 1-1 2-2 3-3 4-4
Bei einer Wirksamkeit von ||| an efficacy of ||| 0-0 1-0 2-1 3-2
Bei einer Wirksamkeit ||| an efficacy ||| 0-0 1-0 2-1
Bei einer ||| In ||| 0-0 1-0
Bei einer ||| an ||| 0-0 1-0
Bei einigen Patienten mit langjährigem ||| Some patients with long-standing ||| 4-0 2-1 3-2 0-3 1-3 4-3
Bei erhöhtem oder ||| If an elevated ( or ||| 0-0 1-0 1-1 1-2 1-3 2-4
Bei erhöhtem ||| If an elevated ( ||| 0-0 1-0 1-1 1-2 1-3
Bei gefütterten Hunden ||| In fed dogs , ||| 0-0 1-1 2-2
Bei gefütterten Hunden ||| In fed dogs ||| 0-0 1-1 2-2
Bei gefütterten ||| In fed ||| 0-0 1-1
Bei gleicher Dosierung ||| 90 ||| 0-0 1-0 2-0
Bei mit Aclasta behandelten Patienten ||| In patients treated with Aclasta ||| 0-0 4-1 3-2 1-3 2-4
Bei mit Epoetin ||| Hypertension ||| 0-0 1-0 2-0
Bei pädiatrischen Patienten ||| In paediatric patients ||| 0-0 1-1 2-2
Bei pädiatrischen ||| In paediatric ||| 0-0 1-1
Bei schizophrenen Patienten ||| In schizophrenia patients ||| 0-0 1-1 2-2
Bei schizophrenen ||| In schizophrenia ||| 0-0 1-1
Bei schon lange ||| Usual warning symptoms may ||| 0-0 1-0 1-1 2-1 2-2 2-3
Bei schwangeren ||| In pregnant or ||| 0-0 1-1 1-2
Bei sichtbaren ||| Discard ||| 0-0 1-0
Bei therapeutischen Konzentrationen wird Aripiprazol ||| At therapeutic concentrations , aripiprazole ||| 0-0 1-0 1-1 2-2 3-2 4-4
Bei therapeutischen Konzentrationen wird ||| At therapeutic concentrations , ||| 0-0 1-0 1-1 2-2 3-2
Bei therapeutischen Konzentrationen wird ||| At therapeutic concentrations ||| 0-0 1-0 1-1 2-2 3-2
Bei therapeutischen ||| At therapeutic ||| 0-0 1-0 1-1
Bei versehentlichem Kontakt des ||| If accidental eye contact ||| 0-0 1-0 1-1 1-2 2-2 2-3 3-3
Bei versehentlicher Einnahme ist ||| In case of accidental ||| 0-0 1-1 1-3
Bei versehentlicher Einnahme ist ||| In case of accidental ||| 0-0 1-1 3-2 1-3
Bei versehentlicher Einnahme ||| In case of accidental ||| 0-0 1-1 1-3
Bei versehentlicher ||| In case of accidental ||| 0-0 1-1 1-3
Bei versehentlicher Überdosierung sollte ||| In case of accidental overdosing ||| 0-0 1-1 1-2 1-3 1-4 2-4 3-4
Bei vielen dieser Patienten ||| Many of these patients ||| 0-0 1-0 1-1 2-2 3-3
Bei vielen dieser ||| Many of these ||| 0-0 1-0 1-1 2-2
Bei vielen ||| Many of ||| 0-0 1-0 1-1
Bei zunehmendem Gewicht von 65 ||| As weight increases from 65 ||| 1-0 2-1 1-2 3-3 4-4
Bei zunehmendem Gewicht von ||| As weight increases from ||| 1-0 2-1 1-2 3-3
Bei zunehmendem Gewicht ||| As weight increases ||| 1-0 2-1 1-2
Bei ||| 2 In ||| 0-0 0-1
Bei ||| A ||| 0-0
Bei ||| Bei ||| 0-0
Bei ||| For ||| 0-0
Bei ||| If ||| 0-0
Bei ||| In the ||| 0-0
Bei ||| In ||| 0-0
Bei ||| Pioglitazone ||| 0-0
Bei ||| Serum ||| 0-0
Bei ||| The ||| 0-0
Bei ||| There ||| 0-0
Bei ||| When ||| 0-0
Bei ||| dosage ||| 0-0
Bei ||| of ||| 0-0
Bei ||| with ||| 0-0
Bei älteren Patienten ist keine ||| Bei älteren Patienten ist keine ||| 0-0 1-1 2-2 3-3 4-4
Bei älteren Patienten ist ||| Bei älteren Patienten ist ||| 0-0 1-1 2-2 3-3
Bei älteren Patienten mit ||| In elderly patients with ||| 0-0 1-1 2-2 3-3
Bei älteren Patienten ||| Bei älteren Patienten ||| 0-0 1-1 2-2
Bei älteren Patienten ||| In elderly patients ||| 0-0 1-1 2-2
Bei älteren ||| Bei älteren ||| 0-0 1-1
Bei älteren ||| In elderly ||| 0-0 1-1
Beibehalten der erreichten ||| in maintaining ||| 1-0 0-1 1-1 2-1
Beim Morbus Paget ||| In Paget s disease ||| 1-0 0-1 1-1 2-1 2-2 2-3
Beitrag von ||| contribution ||| 0-0 1-0
Belastungsdyspnoe , ||| exertional dyspnoea , ||| 0-0 0-1 1-2
Belastungsdyspnoe ||| exertional dyspnoea ||| 0-0 0-1
Belgique/België/Belgien BRISTOL-MYERS ||| Belgique/ België/ Belgien BRISTOL-MYERS ||| 0-0 0-1 0-2 1-3
Belgique/België/Belgien ||| Belgique/ België/ Belgien ||| 0-0 0-1 0-2
België/Belgique/Belgien Takeda Global ||| België/ Belgique/ Belgien Takeda Global ||| 0-0 0-1 0-2 1-3 2-4
België/Belgique/Belgien Takeda ||| België/ Belgique/ Belgien Takeda ||| 0-0 0-1 0-2 1-3
België/Belgique/Belgien ||| België/ Belgique/ Belgien ||| 0-0 0-1 0-2
Benazepril ||| enalapril ||| 0-0
Benommenheit , Schlafprobleme , ||| light-headedness , trouble sleeping , ||| 0-0 2-0 1-1 2-2 2-3 3-4
Benommenheit , Schlafprobleme ||| light-headedness , trouble sleeping ||| 0-0 2-0 1-1 2-2 2-3
Benommenheit ||| drowsiness ||| 0-0
Beobachtung wurde klinisch durch spezifische ||| Beobachtung wurde klinisch durch ||| 0-0 1-1 0-2 3-3
Beobachtung wurde klinisch durch ||| Beobachtung wurde klinisch durch ||| 0-0 1-1 0-2 3-3
Beobachtung wurde klinisch ||| Beobachtung wurde klinisch ||| 0-0 1-1 0-2
Beobachtung wurde ||| Beobachtung wurde klinisch ||| 0-0 1-1 0-2
Bereich von 2-60 mg ||| from 2 60 mg ||| 0-0 1-0 2-0 2-1 2-2 3-3
Bereich von 2-60 ||| from 2 60 ||| 0-0 1-0 2-0 2-1 2-2
Bereich zu behalten . ||| the desired range . ||| 0-0 0-1 1-1 2-1 2-2 3-3
Bereich zu behalten ||| the desired range ||| 0-0 0-1 1-1 2-1 2-2
Bereich zu halten . ||| the desired range . ||| 0-0 0-1 1-1 2-1 0-2 3-3
Bereich zu halten : ||| at the desired level : ||| 0-0 0-1 0-2 1-2 2-2 2-3 3-4
Bereich zu halten ||| at the desired level ||| 0-0 0-1 0-2 1-2 2-2 2-3
Bereich zu halten ||| the desired range ||| 0-0 0-1 1-1 2-1 0-2
Bereiche Ihres ||| had sections of your ||| 0-0 0-1 1-3
Bereiche ||| had sections of ||| 0-0 0-1
Bereiche ||| had sections ||| 0-0 0-1
Bereiches kann dabei ||| given area may ||| 0-0 0-1 2-1 1-2
Bereitstellung von Aufklärungspaketen ||| to ||| 1-0
Bereitstellung von ||| to ||| 1-0
Berichte bezieht sich auf Krebspatienten ||| reports refer to cancer patients ||| 0-0 2-0 4-1 1-2 3-2 4-3 4-4
Berichte stützen sich auf in ||| reports are based on in ||| 0-0 1-0 1-1 1-2 2-2 3-3 4-4
Berichte stützen sich auf ||| reports are based on ||| 0-0 1-0 1-1 1-2 2-2 3-3
Berichte stützen sich ||| reports are based ||| 0-0 1-0 1-1 1-2 2-2
Berichte ||| reports ||| 0-0
Berichte über ||| reports of ||| 0-0 1-0
Berichte über ||| reports of ||| 0-0 1-0 1-1
Berichte über ||| reports ||| 0-0 1-0
Berichten von ||| reports ||| 0-0
Berichten ||| reports ||| 0-0
Berkshire RG40 2AQ Vereinigtes Königreich ||| Berkshire RG40 2AQ United Kingdom ||| 0-0 1-1 2-2 3-3 4-4
Berkshire RG40 2AQ Vereinigtes ||| Berkshire RG40 2AQ United ||| 0-0 1-1 2-2 3-3
Berkshire RG40 2AQ ||| Berkshire RG40 2AQ ||| 0-0 1-1 2-2
Berkshire RG40 ||| Berkshire RG40 ||| 0-0 1-1
Berkshire ||| Berkshire ||| 0-0
Berücksichtigung der gängigen medizinischen ||| conducted according to standard medical ||| 0-0 1-1 2-1 1-2 2-3 3-4
Berücksichtigung der gängigen ||| conducted according to standard ||| 0-0 1-1 2-1 1-2 2-3
Berücksichtigung ||| conducted ||| 0-0
Beseitigung und sonstige ||| disposal and ||| 0-0 2-0 1-1
Beseitigung und sonstige ||| for disposal and ||| 0-0 0-1 2-1 1-2
Besondere Vorsicht ||| Take special care with Abseamed ||| 0-0 1-0 0-1 0-2 1-3 0-4
Besondere Vorsichtsmaßnahmen für die Anwendung ||| Special precautions for use ||| 0-0 1-1 3-1 2-2 4-3
Besondere Vorsichtsmaßnahmen für die ||| Special precautions for ||| 0-0 1-1 2-1 2-2 3-2
Besondere Vorsichtsmaßnahmen für die ||| Special precautions for ||| 0-0 1-1 3-1 2-2
Besondere Vorsichtsmaßnahmen für die ||| Special precautions ||| 0-0 1-0 1-1 2-1 3-1
Besondere Warnhinweise und Vorsichtsmaßnahmen ||| Special warnings and precautions ||| 0-0 1-1 2-2 3-3
Besondere Warnhinweise und ||| Special warnings and ||| 0-0 1-1 2-2
Besondere Warnhinweise ||| Special warnings ||| 0-0 1-1
Besondere ||| Special ||| 0-0
Besonderen Depressionen ||| who have no obvious ||| 0-0 0-1 0-2 0-3 1-3
Besonders Patienten ||| Patients , especially those ||| 0-0 1-0 0-2 1-3
Besserung bei ||| greater improvements in ||| 0-0 0-1 1-2
Besserung vom Ausgangswert auf dem ||| improvement from baseline on the ||| 0-0 1-1 2-2 3-3 4-4
Besserung vom Ausgangswert auf ||| improvement from baseline on ||| 0-0 1-1 2-2 3-3
Besserung vom Ausgangswert ||| improvement from baseline ||| 0-0 1-1 2-2
Besserung vom ||| improvement from ||| 0-0 1-1
Besserung ||| greater improvements ||| 0-0 0-1
Besserung ||| improvement in ||| 0-0 0-1
Besserung ||| improvement ||| 0-0
Bestandteil von Actos 15 mg ||| substance in Actos 15mg ||| 0-0 1-1 2-2 3-3 4-3
Bestandteil von Actos 30 mg ||| substance in Actos 30mg ||| 0-0 1-1 2-2 3-3 4-3
Bestandteil von Actos 45 mg ||| substance in Actos 45mg ||| 0-0 1-1 2-2 3-3 4-3
Bestandteil von Actos ||| substance in Actos ||| 0-0 1-1 2-2
Bestandteil von ||| substance in ||| 0-0 1-1
Bestandteil ||| substance ||| 0-0
Bestandteile reagieren , sowie bei ||| ACOMPLIA , see ||| 1-0 2-0 2-1 3-1 0-2
Bestandteile reagieren , sowie ||| ACOMPLIA , see ||| 1-0 2-0 2-1 3-1 0-2
Bestandteile reagieren . ||| ingredients . ||| 0-0 1-0 2-1
Bestandteile reagieren ||| ingredients ||| 0-0 1-0
Bestandteile t lä ||| PARTICULARS ||| 0-0 1-0 2-0
Bestandteile ||| see ||| 0-0
Bestehende schwere depressive Erkrankung ||| Ongoing major depressive illness ||| 0-0 1-0 0-1 2-2 2-3 3-3
Bestehende schwere ||| Ongoing major ||| 0-0 1-0 0-1
Bestimmte Arzneimittel zur ||| agents Certain medicines ||| 0-0 0-1 1-1 2-1 1-2
Betarezeptorenblocker können ||| Beta-blocking agents may ||| 0-0 1-0 0-1 1-2
Betasympathomimetika , Wachstumshormon und ||| beta-sympathomimetics , growth hormone and ||| 0-0 1-1 2-2 2-3 3-4
Betasympathomimetika , Wachstumshormon ||| beta-sympathomimetics , growth hormone ||| 0-0 1-1 2-2 2-3
Betasympathomimetika , ||| beta-sympathomimetics , ||| 0-0 1-1
Betasympathomimetika ||| beta-sympathomimetics ||| 0-0
Beteiligung der Enzyme CYP2D6 und ||| pathways involving the CYP2D6 and ||| 0-0 2-0 0-1 1-2 3-3 4-4
Beteiligung der Enzyme CYP2D6 ||| pathways involving the CYP2D6 ||| 0-0 2-0 0-1 1-2 3-3
Beteiligung der Enzyme ||| pathways involving the ||| 0-0 2-0 0-1 1-2
Betrachtet man nur die ||| When looking only at the ||| 1-0 0-1 2-2 3-3 3-4
Betrachtet man nur ||| When looking only ||| 1-0 0-1 2-2
Betrachtet man ||| When looking ||| 1-0 0-1
Betrachtet ||| looking ||| 0-0
Bevor Sie ||| Tell your doctor ||| 0-0 1-1 1-2
Bevor ||| Tell ||| 0-0
Bewegung ||| be used in patients ||| 0-1
Bewegung ||| be used in ||| 0-1
Bewegung ||| be used ||| 0-1
Bewegung ||| exercise ||| 0-0
Bewegung ||| used in patients ||| 0-0
Bewegung ||| used in ||| 0-0
Bewegung ||| used ||| 0-0
Bewusstlosigkeit und/oder ||| unconsciousness and/ or ||| 0-0 1-1 1-2
Bewusstlosigkeit ||| unconsciousness ||| 0-0
Bewusstseinslagen und Anzeichen autonomer ||| status and evidence of autonomic ||| 0-0 1-1 3-2 0-4 2-4 3-4
Bewusstseinszustand sollten ||| level of consciousness should ||| 0-0 0-2 1-3
Bewusstseinszustand ||| level of consciousness ||| 0-0 0-2
Bezeichnung ||| comparison ||| 0-0
Bezug auf Wirksamkeit und ||| efficacy and ||| 2-0 3-1
Bezug auf Wirksamkeit ||| efficacy ||| 2-0
Bezug ||| with ||| 0-0
Bezüglich Hypokalzämie siehe ||| For hypocalcaemia , see ||| 0-0 0-1 1-1 2-3
Bezüglich Hypokalzämie ||| For hypocalcaemia , ||| 0-0 0-1 1-1
Bezüglich Hypokalzämie ||| For hypocalcaemia ||| 0-0 0-1 1-1
Bildung dieser hydroxylierten Metaboliten ||| formation of these hydroxylated metabolites ||| 0-0 0-1 1-2 2-3 3-4
Bildung dieser hydroxylierten ||| formation of these hydroxylated ||| 0-0 0-1 1-2 2-3
Bildung dieser ||| formation of these ||| 0-0 0-1 1-2
Bildung von Erythrozyten aus Vorläuferzellen ||| formation of erythrocytes from precursors ||| 0-0 1-1 2-2 3-3 4-4
Bildung von Erythrozyten aus ||| formation of erythrocytes from ||| 0-0 1-1 2-2 3-3
Bildung von Erythrozyten ||| formation of erythrocytes ||| 0-0 1-1 2-2
Bildung von Mikrotubulibündeln ||| abnormal arrays or bundles of ||| 0-0 0-1 2-1 1-2 2-3 1-4
Bildung von ||| formation of ||| 0-0 1-1
Bildung von ||| was abnormal ||| 1-0 0-1
Bildung ||| abnormal ||| 0-0
Bildung ||| formation of ||| 0-0 0-1
Bildung ||| formation ||| 0-0
Bindegewebs- und ||| and subcutaneous tissue disorders : ||| 1-0 0-1 0-2 0-3 0-4
Bindegewebs- ||| subcutaneous tissue disorders : ||| 0-0 0-1 0-2 0-3
Bindung ist ||| binding is ||| 0-0 1-1
Bindung ||| binding ||| 0-0
BioScience Limited West Forest Gate ||| BioScience Limited West Forest Gate ||| 0-0 1-1 2-2 3-3 4-4
BioScience Limited West Forest ||| BioScience Limited West Forest ||| 0-0 1-1 2-2 3-3
BioScience Limited West ||| BioScience Limited West ||| 0-0 1-1 2-2
BioScience Limited ||| BioScience Limited ||| 0-0 1-1
BioScience ||| BioScience ||| 0-0
Bioverfügbarkeit der ||| bioavailability of the ||| 0-0 0-1 1-2
Bioverfügbarkeit von Mitratapid ( Muttersubstanz ||| bioavailability of mitratapide ( parent ||| 0-0 1-1 2-2 3-3 4-4
Bioverfügbarkeit von Mitratapid ( ||| bioavailability of mitratapide ( ||| 0-0 1-1 2-2 3-3
Bioverfügbarkeit von Mitratapid ||| bioavailability of mitratapide ||| 0-0 1-1 2-2
Bioverfügbarkeit von Rimonabant ist nicht ||| bioavailability of rimonabant has not ||| 0-0 1-1 2-2 2-3 3-3 4-4
Bioverfügbarkeit von Rimonabant ist ||| bioavailability of rimonabant has ||| 0-0 1-1 2-2 2-3 3-3
Bioverfügbarkeit von ||| bioavailability of ||| 0-0 1-1
Bioverfügbarkeit ||| bioavailability of ||| 0-0 0-1
Bioverfügbarkeit ||| bioavailability ||| 0-0
Bipolar-I-Störung - ||| Bipolar I Disorder - ||| 0-0 0-1 0-2 1-3
Bipolar-I-Störung angewandt , wenn eine ||| Bipolar I Disorder , when ||| 0-0 0-1 0-2 1-3 2-3 3-4 4-4
Bipolar-I-Störung angewandt , ||| Bipolar I Disorder , ||| 0-0 0-1 0-2 1-3 2-3
Bipolar-I-Störung verursacht ||| Bipolar I Disorder ||| 0-0 0-1 0-2
Bipolar-I-Störung zeigte Aripiprazol ||| Bipolar I Disorder , aripiprazole ||| 0-0 0-1 0-2 1-2 1-3 2-4
Bipolar-I-Störung zeigte ||| Bipolar I Disorder , ||| 0-0 0-1 0-2 1-2 1-3
Bipolar-I-Störung ||| Bipolar I Disorder ||| 0-0 0-1 0-2
Bipolar-I-Störung ||| I ||| 0-0
Bipolar-I-Störung ||| of Bipolar I Disorder ||| 0-1 0-2 0-3
Bisphosphonat . ||| bisphosphonate . ||| 0-0 1-1
Bisphosphonat ||| bisphosphonate ||| 0-0
Bisphosphonat-naiven Patienten und 42 % ||| bisphosphonate-naïve patients and 42 % ||| 0-0 1-1 2-2 3-3 4-4
Bisphosphonat-naiven Patienten und 42 ||| bisphosphonate-naïve patients and 42 ||| 0-0 1-1 2-2 3-3
Bisphosphonat-naiven Patienten und ||| bisphosphonate-naïve patients and ||| 0-0 1-1 2-2
Bisphosphonat-naiven Patienten ||| bisphosphonate-naïve patients ||| 0-0 1-1
Bisphosphonat-naiven ||| bisphosphonate-naïve ||| 0-0
Bisphosphonate ( ||| Bisphosphonates ( the ||| 0-0 1-1
Bisphosphonate ( ||| Bisphosphonates ( ||| 0-0 1-1
Bisphosphonate . ||| bisphosphonates . ||| 0-0 1-1
Bisphosphonate oder einen ||| bisphosphonates or any of the ||| 0-0 1-1 2-2 2-4
Bisphosphonate oder ||| bisphosphonates or ||| 0-0 1-1
Bisphosphonate und wirkt ||| bisphosphonates and acts ||| 0-0 1-1 2-2
Bisphosphonate und ||| bisphosphonates and ||| 0-0 1-1
Bisphosphonate ||| Bisphosphonates ||| 0-0
Bisphosphonate ||| bisphosphonates ||| 0-0
Bisphosphonaten , einschließlich Zoledronsäure , ||| bisphosphonates , including zoledronic acid ||| 0-0 1-1 4-1 2-2 3-3 3-4
Bisphosphonaten unterliegen Patienten ||| bisphosphonates , patients taking ||| 0-0 1-2 2-2 0-3
Bisphosphonaten ||| bisphosphonates in ||| 0-0
Bisphosphonaten ||| bisphosphonates ||| 0-0
Bitte fragen Sie bei Ihrem ||| You should check with your ||| 0-0 1-0 2-0 1-1 1-2 3-2 4-2 3-3 4-4
Bitte informieren Sie Ihren Arzt ||| 181 Tell the doctor ||| 0-0 1-0 0-1 2-1 3-3 4-3
Bitte informieren Sie Ihren Arzt ||| Please inform your doctor ||| 0-0 1-1 2-1 3-2 4-3
Bitte informieren Sie Ihren Arzt ||| Please tell your doctor ||| 0-0 1-0 1-1 2-2 3-2 4-3
Bitte informieren Sie Ihren ||| Please inform your ||| 0-0 1-1 2-1 3-2
Bitte informieren Sie Ihren ||| Please tell your ||| 0-0 1-0 1-1 2-2 3-2
Bitte informieren Sie ||| 181 Tell the ||| 0-0 1-0 0-1 2-1
Bitte informieren Sie ||| 181 Tell ||| 0-0 1-0 0-1 2-1
Bitte informieren Sie ||| Please inform ||| 0-0 1-1 2-1
Bitte informieren ||| Please tell ||| 0-0 1-0 1-1
Bitte teilen Sie Ihrem Arzt ||| Tell your doctor ||| 0-0 1-0 2-1 3-1 4-2
Bitte teilen Sie Ihrem ||| Tell your ||| 0-0 1-0 2-1 3-1
Bitte teilen ||| Tell ||| 0-0 1-0
Bitte ||| If ||| 0-0
Bitte ||| Please ||| 0-0
Blisterpackung ( PVC/Aluminium ) ||| Blister ( PVC/ aluminium ) ||| 0-0 1-1 2-2 2-3 3-4
Blisterpackung ( PVC/Aluminium ||| Blister ( PVC/ aluminium ||| 0-0 1-1 2-2 2-3
Blisterpackung ( ||| Blister ( ||| 0-0 1-1
Blisterpackung . ||| blister . ||| 0-0 1-1
Blisterpackung ||| Blister ||| 0-0
Blisterpackung ||| blister ||| 0-0
Blockade ||| blocking ||| 0-0
Blockierung der Lipidaufnahme ||| blockage of the uptake ||| 0-0 1-1 1-2 2-3
Blockierung der ||| blockage of the ||| 0-0 1-1 1-2
Blockierung ||| blockage ||| 0-0
Blut im Harn ||| blood in urine ||| 0-0 1-1 1-2 2-2
Blut ||| blood ||| 0-0
Blutarmut ( Anämie ) ||| anaemia ||| 0-0 2-0
Blutarmut ( Anämie ||| anaemia ||| 0-0 2-0
Blutarmut kann ||| anaemia may ||| 0-0 1-1
Blutarmut ||| anaemia ||| 0-0
Blutdruck , Schläfrigkeit , ||| blood pressure , somnolence , ||| 0-0 0-1 1-2 3-2 2-3 3-4
Blutdruck , Tachykardie , ||| blood pressure , tachycardia , ||| 0-0 0-1 1-2 2-3 3-4
Blutdruck , Tachykardie , ||| blood pressure , tachycardia , ||| 0-0 0-1 1-2 3-2 2-3 3-4
Blutdruck , Tachykardie ||| blood pressure , tachycardia ||| 0-0 0-1 1-2 2-3
Blutdruck , ||| Blood pressure , ||| 0-0 0-1 1-2
Blutdruck , ||| blood pressure , ||| 0-0 0-1 1-2
Blutdruck . ||| blood pressure ||| 0-0 0-1
Blutdruck oder ||| blood pressure or if ||| 0-0 0-1 1-2 1-3
Blutdruck regelmäßig ||| blood pressure regularly ||| 0-0 0-1 1-2
Blutdruck sorgfältig ||| blood pressure ||| 0-0 0-1 1-1
Blutdruck sorgfältig überwacht ||| blood pressure should ||| 0-0 0-1 1-1 2-2
Blutdruck und ||| blood pressure and ||| 0-0 0-1 1-2
Blutdruck und ||| blood ||| 0-0
Blutdruck ||| Blood pressure ||| 0-0 0-1
Blutdruck ||| blood pressure ||| 0-0 0-1
Blutdruck ||| blood ||| 0-0
Blutdruck ||| in blood pressure ||| 0-1 0-2
Blutdruck ||| pressure ||| 0-0
Blutdruck* ||| pressure* ||| 0-0
Blutdruckanstieg , der möglicherweise ||| raised blood pressure which may ||| 0-0 0-1 1-1 0-2 1-3 3-4
Blutdruckanstieg , der ||| raised blood pressure which ||| 0-0 0-1 1-1 0-2 1-3
Blutdruckanstieg , ||| raised blood pressure which ||| 0-0 0-1 1-1 0-2 1-3
Blutdruckanstieges sein , der ||| sudden rise in blood ||| 0-0 1-0 0-1 3-2 2-3 3-3
Blutdruckanstieges sein ||| sudden rise ||| 0-0 1-0 0-1
Blutdruckmitteln ||| require ||| 0-0
Blutdrucks oder die ||| blood pressure or ||| 0-0 0-1 1-2
Blutdrucks oder ||| blood pressure or ||| 0-0 0-1 1-2
Blutdrucks ||| blood pressure ||| 0-0 0-1
Blutfarbstoffes ( Hämoglobin ) bestimmen ||| pigment ( haemoglobin ) regularly ||| 0-0 2-0 1-1 2-2 3-3 4-4
Blutfarbstoffes ( Hämoglobin ) ||| pigment ( haemoglobin ) ||| 0-0 2-0 1-1 2-2 3-3
Blutfarbstoffes ( Hämoglobin ||| pigment ( haemoglobin ||| 0-0 2-0 1-1 2-2
Blutfarbstoffs ( Hämoglobin ) ||| pigment ( haemoglobin ) ||| 0-0 2-0 1-1 2-2 3-3
Blutfarbstoffs ( Hämoglobin ||| pigment ( haemoglobin ||| 0-0 2-0 1-1 2-2
Blutgefäßen ||| blood vessels ||| 0-0 0-1
Bluthochdruck , Gesichtsrötung , ||| , eating disorder , redness ||| 0-0 1-0 1-1 1-2 2-3 3-3 3-4
Bluthochdruck , ||| , eating disorder ||| 0-0 1-0 1-1 1-2
Bluthochdrucktherapie ||| initiate ||| 0-0
Blutkörperchen ||| cell ||| 0-0
Blutkörperchen ||| count ||| 0-0
Blutpfropfbildung ( thrombotische Ereignisse ||| Thrombotic events ( blood clotting ||| 0-0 0-1 3-1 1-2 0-3 0-4 2-4
Blutpfropfbildung ( thrombotische vaskuläre ||| blood clotting ( thrombotic vascular ||| 0-0 0-1 1-2 2-3 3-4
Blutpfropfbildung ( thrombotische ||| blood clotting ( thrombotic ||| 0-0 0-1 1-2 2-3
Blutpfropfbildung ( thrombotisches Ereignis ) ||| clotting ( thrombotic events ) ||| 0-0 1-1 0-2 2-2 0-3 3-3 4-4
Blutpfropfbildung ( thrombotisches Ereignis ||| clotting ( thrombotic events ||| 0-0 1-1 0-2 2-2 0-3 3-3
Blutpfropfbildung ( ||| blood clotting ( ||| 0-0 0-1 1-2
Blutpfropfbildung nach der ||| of blood clotting after the ||| 2-0 0-1 0-2 1-3 2-4
Blutpfropfbildung nach ||| blood clotting after ||| 0-0 0-1 1-2
Blutpfropfbildung ||| blood clotting ||| 0-0 0-1
Blutpfropfbildung/Blutgerinnungsstörungen ||| blood clots/ blood ||| 0-0 0-1 0-2
Blutplasma wurde ||| was shown ||| 1-0 0-1 1-1
Blutspendeprogramm ||| predonation ||| 0-0
Blutspiegel von Geschlechtshormonen ||| levels of sex ||| 0-0 1-1 2-2
Blutspiegel von ||| levels of ||| 0-0 1-1
Blutspiegel ||| levels ||| 0-0
Bluttests , durchführen , ||| blood tests , ||| 0-0 0-1 2-1 1-2 3-2
Blutuntersuchung der ||| the operation ||| 1-0 0-1
Blutuntersuchung ||| operation ||| 0-0
Blutuntersuchungen durchführen , um die ||| blood tests to ||| 1-0 2-0 0-1 1-1 3-2 4-2
Blutuntersuchungen durchführen , ||| blood tests ||| 1-0 2-0 0-1 1-1
Blutuntersuchungen durchführen ||| tests ||| 0-0 1-0
Blutverlust und Hämolyse ) ||| blood loss and haemolysis ) ||| 0-0 0-1 1-2 0-3 2-3 3-4
Blutverlust und Hämolyse ||| blood loss and haemolysis ||| 0-0 0-1 1-2 0-3 2-3
Blutwerte ||| do ||| 0-0
Blutzellen ||| of some blood ||| 0-1 0-2
Blutzellen ||| some blood ||| 0-0 0-1
Blutzucker ) ; ||| blood glucose ) , ||| 0-0 0-1 1-2 2-3
Blutzucker ) ||| blood glucose ) ||| 0-0 0-1 1-2
Blutzucker eingestellt ist . ||| blood glucose is controlled . ||| 0-0 0-1 2-2 1-3 3-4
Blutzucker eingestellt ist ||| blood glucose is controlled ||| 0-0 0-1 2-2 1-3
Blutzucker trotz einer ||| glycaemic control despite ||| 0-0 1-0 1-1 1-2 2-2
Blutzucker ||| blood glucose ||| 0-0 0-1
Blutzuckereinstellung kann jedoch ||| glycaemic control may be ||| 0-0 2-0 0-1 1-2 1-3
Blutzuckerkontrolle geht mit ||| glycaemic control is associated with ||| 0-0 1-0 0-1 1-2 1-3 2-4
Blutzuckerkontrolle geht ||| glycaemic control is associated ||| 0-0 1-0 0-1 1-2 1-3
Blutzuckerkontrolle kann ||| glucose control may ||| 0-0 0-1 1-2
Blutzuckerkontrolle sollte erwogen werden ||| glycaemic control should be considered ||| 0-0 0-1 1-2 3-3 2-4
Blutzuckerkontrolle sollte ||| glycaemic control should ||| 0-0 0-1 1-2
Blutzuckerkontrolle ||| glucose control ||| 0-0 0-1
Blutzuckerkontrolle ||| glycaemic control ||| 0-0 0-1
Blutzuckerschwankung , erhöhtes ||| glucose fluctuation , ||| 0-0 0-1 2-1 1-2
Blutzuckerspiegel ( Hypoglykämie ) ||| blood sugar ( hypoglycaemia ) ||| 0-0 0-1 1-2 2-3 3-4
Blutzuckerspiegel ( Hypoglykämie ||| blood sugar ( hypoglycaemia ||| 0-0 0-1 1-2 2-3
Blutzuckerspiegel ( ||| blood sugar ( ||| 0-0 0-1 1-2
Blutzuckerspiegel . ||| glycaemia ||| 0-0
Blutzuckerspiegel des Patienten sollte ||| patient 's blood sugar should ||| 2-0 1-1 0-2 0-3 3-4
Blutzuckerspiegel des Patienten ||| patient 's blood sugar ||| 2-0 1-1 0-2 0-3
Blutzuckerspiegel des ||| 's blood sugar ||| 1-0 0-1 0-2
Blutzuckerspiegel ||| blood sugar ||| 0-0 0-1
Blutzuckerspiegel ||| blood ||| 0-0
Blutzuckerspiegel ||| glycaemia ||| 0-0
Blutzuckerspiegels produziert . ||| blood sugar . ||| 0-0 0-1 1-1 2-2
Blutzuckerspiegels produziert ||| blood sugar ||| 0-0 0-1 1-1
Blutzuckerwerte ||| glucose ||| 0-0
Blähungen , Zungenbrennen , trockener ||| flatulence , glossodynia , dry ||| 0-0 1-1 2-2 3-3 4-3 3-4
Blähungen , Zungenbrennen ||| flatulence , glossodynia ||| 0-0 1-1 2-2
Blähungen , ||| flatulence , ||| 0-0 1-1
Blähungen ||| flatulence ||| 0-0
Bolus-Verabreichungen ||| bolus ||| 0-0
Bradykardie ||| bradycardia ||| 0-0
Bray Business Park , Kilruddey ||| Bray Business Park , Kilruddery ||| 0-0 1-1 2-2 3-3 4-4
Bray Business Park , ||| Bray Business Park , ||| 0-0 1-1 2-2 3-3
Bray Business Park ||| Bray Business Park ||| 0-0 1-1 2-2
Bray Business ||| Bray Business ||| 0-0 1-1
Bray ||| Bray ||| 0-0
Breite von Epoetin alfa ist ||| margin of epoetin alfa is ||| 0-0 1-1 2-2 3-3 4-4
Breite von Epoetin alfa ||| margin of epoetin alfa ||| 0-0 1-1 2-2 3-3
Breite von Epoetin ||| margin of epoetin ||| 0-0 1-1 2-2
Breite von ||| margin of ||| 0-0 1-1
Breite ||| margin ||| 0-0
Bristol-Myers Squibb Srl Contrada Fontana ||| Bristol-Myers Squibb Srl Contrada Fontana ||| 0-0 1-1 2-2 3-3 4-4
Bristol-Myers Squibb Srl Contrada ||| Bristol-Myers Squibb Srl Contrada ||| 0-0 1-1 2-2 3-3
Bristol-Myers Squibb Srl ||| Bristol-Myers Squibb Srl ||| 0-0 1-1 2-2
Bristol-Myers Squibb ||| Bristol-Myers Squibb ||| 0-0 1-1
Bristol-Myers ||| Bristol-Myers ||| 0-0
Bromobutyl-Gummistopfen ||| aluminium/ ||| 0-0
Bronchialkarzinome , 174 gynäkologische Tumoren ||| lung , 174 gynaecological ||| 0-0 1-1 2-2 4-2 3-3
Bronchialkarzinome , 22 Prostatakarzinome ||| lung , 22 prostate ||| 0-0 1-1 2-2 3-3
Bronchialkarzinome , 22 ||| lung , 22 ||| 0-0 1-1 2-2
Bronchialkarzinome , ||| lung , ||| 0-0 1-1
Bronchialkarzinome ||| lung ||| 0-0
Bronchokonstriktion ||| bronchoconstriction ||| 0-0
Brust ||| abnormaler Gang ||| 0-0 0-1
Brustraums und Mediastinums : ||| and mediastinal disorders : ||| 1-0 0-1 1-1 2-1 2-2 3-3
Brustraums und Mediastinums ||| and mediastinal disorders ||| 1-0 0-1 1-1 2-1 2-2
Brustschmerzen ) ||| chest pain ) ||| 0-0 0-1 1-2
Brustschmerzen , periphere ||| chest pain , peripheral ||| 0-0 0-1 1-2 2-3
Brustschmerzen , periphere Ödeme ||| chest pain , peripheral oedema ||| 0-0 0-1 1-2 2-3 3-4
Brustschmerzen , ||| chest pain , ||| 0-0 0-1 1-2
Brustschmerzen ||| chest pain ||| 0-0 0-1
Brytania Tel : +44 ( ||| Brytania Tel : +44 ( ||| 0-0 1-1 2-2 3-3 4-4
Brytania Tel : +44 ||| Brytania Tel : +44 ||| 0-0 1-1 2-2 3-3
Brytania Tel : ||| Brytania Tel : ||| 0-0 1-1 2-2
Brytania Tel ||| Brytania Tel ||| 0-0 1-1
Brytania ||| Brytania ||| 0-0
Business Park , Kilruddey , ||| Business Park , Kilruddery , ||| 0-0 1-1 2-2 3-3 4-4
Business Park , Kilruddey ||| Business Park , Kilruddery ||| 0-0 1-1 2-2 3-3
Business Park , Oxford Road ||| Business Park , Oxford Road ||| 0-0 1-1 2-2 3-3 4-4
Business Park , Oxford ||| Business Park , Oxford ||| 0-0 1-1 2-2 3-3
Business Park , ||| Business Park , ||| 0-0 1-1 2-2
Business Park ||| Business Park ||| 0-0 1-1
Business ||| Business ||| 0-0
Butylhydroxyanisol ( E 320 ||| Butylated hydroxyanisole ( E 320 ||| 0-0 0-1 1-2 2-3 3-3 3-4
Butylhydroxyanisol ( ||| Butylated hydroxyanisole ( ||| 0-0 0-1 1-2
Butylhydroxyanisol ||| Butylated hydroxyanisole ||| 0-0 0-1
Bündelpackung bestehend aus 5 ||| Multi-pack comprising 5 ||| 0-0 1-1 2-1 3-2
Bündelpackung bestehend aus 5 ||| multi-pack comprising 5 ||| 0-0 0-1 1-1 2-1 3-2
Bündelpackung bestehend aus ||| Multi-pack comprising ||| 0-0 1-1 2-1
Bündelpackung bestehend aus ||| multi-pack comprising ||| 0-0 0-1 1-1 2-1
Bündelpackung mit ||| multipack with ||| 0-0 1-1
Bündelpackung ||| Multi-pack ||| 0-0
Bündelpackung ||| multipack ||| 0-0
CA012-0 Zusatz , endgültige Fassung ||| CA012-0 Addendum dated Final ||| 0-0 0-1 1-1 3-2 3-3 4-3
CA012-0 Zusatz , ||| CA012-0 Addendum ||| 0-0 0-1 1-1
CA012-0 Zusatz ||| CA012-0 Addendum ||| 0-0 0-1 1-1
CB1 ||| pharmakologischen ||| 0-0
CB1)- ||| CB1 ||| 0-0
CB1-Antagonisten unbekannt . ||| CB1 antagonist is unknown . ||| 0-0 0-1 1-2 1-3 2-4
CB1-Antagonisten unbekannt ||| CB1 antagonist is unknown ||| 0-0 0-1 1-2 1-3
CB1-Antagonisten ||| CB1 antagonist ||| 0-0 0-1
CB1-Rezeptoren initiiert wird ||| endocannabinoid signalling via CB1 receptors ||| 0-0 0-1 1-1 1-2 1-3 2-4
CB1-Rezeptoren initiiert ||| endocannabinoid signalling via CB1 ||| 0-0 0-1 1-1 1-2 1-3
CHMP ) ||| CHMP ) ||| 0-0 1-1
CHMP . ||| CHMP . ||| 0-0 1-1
CHMP Guideline ||| CHMP Guideline ||| 0-0 1-1
CHMP hat ||| CHMP has ||| 0-0 1-1
CHMP verlangt die Aufnahme ||| CHMP requests the inclusion , ||| 0-0 1-1 2-2 3-2 1-3
CHMP verlangt die Aufnahme ||| CHMP requests the inclusion ||| 0-0 1-1 2-2 3-2 1-3
CHMP wünschen , lesen Sie ||| CHMP recommendations , read ||| 0-0 1-1 2-2 3-3 4-3
CHMP wünschen , ||| CHMP recommendations , ||| 0-0 1-1 2-2
CHMP wünschen ||| CHMP recommendations ||| 0-0 1-1
CHMP ||| CHMP ||| 0-0
CI ) ||| CI ) ||| 0-0 1-1
CI , 17 ||| CI , 17 ||| 0-0 1-1 2-2
CI , ||| CI , ||| 0-0 1-1
CI : ||| CI : ||| 0-0 1-1
CI ] ( Wochen ) ||| CI ] ( weeks ) ||| 0-0 1-1 2-2 3-3 4-4
CI ] ( Wochen ||| CI ] ( weeks ||| 0-0 1-1 2-2 3-3
CI ] ( ||| CI ] ( ||| 0-0 1-1 2-2
CI ] ||| CI ] ||| 0-0 1-1
CI ||| CI ||| 0-0
CLAS ) . ||| CLAS ) . ||| 0-0 1-1 2-2
CLAS ) ||| CLAS ) ||| 0-0 1-1
CLAS ||| CLAS ||| 0-0
CPK ( ||| CPK ( Creatine ||| 0-0 1-1 0-2
CPK ( ||| CPK ( ||| 0-0 1-1
CPK ||| CPK ||| 0-0
CYP-Enzyme oder P- ||| CYP enzymes or ||| 0-0 2-0 2-1 1-2
CYP2C8 in vitro . ||| CYP2C8 . ||| 0-0 1-0 2-0 3-1
CYP2C8 in vitro ||| CYP2C8 ||| 0-0 1-0 2-0
CYP2C8 in vivo scheint gering ||| CYP2C8 in vivo appears ||| 0-0 1-1 2-2 3-3 4-3
CYP2C8 in vivo ||| CYP2C8 in vivo ||| 0-0 1-1 2-2
CYP2C8 in ||| CYP2C8 in ||| 0-0 1-1
CYP2C8 und ||| CYP2C8 and ||| 0-0 1-1
CYP2C8 ||| CYP2C8 ||| 0-0
CYP2D6 ( Dextromethorphan/3-Methoxymorphinan-Ratio ||| CYP2D6 ( dextromethorphan/ 3-methoxymorphinan ratio ||| 0-0 1-1 2-2 2-3 2-4
CYP2D6 ( ||| CYP2D6 ( ||| 0-0 1-1
CYP2D6 und CYP3A4 , ||| CYP2D6 and CYP3A4 ||| 0-0 1-1 2-2
CYP2D6 und CYP3A4 ||| CYP2D6 and CYP3A4 ||| 0-0 1-1 2-2
CYP2D6 und ||| CYP2D6 and ||| 0-0 1-1
CYP2D6 ||| CYP2D6 ||| 0-0
CYP2D6- oder 3A4-Inhibitors ||| CYP2D6 or 3A4 inhibitor , ||| 0-0 1-1 0-2 2-2 2-3
CYP2D6- oder 3A4-Inhibitors ||| CYP2D6 or 3A4 inhibitor ||| 0-0 1-1 0-2 2-2 2-3
CYP2D6-Inhibitor ||| CYP2D6 inhibitor ||| 0-0 0-1
CYP3A4 ( Ketoconazol ) ||| CYP3A4 ( ketoconazole ) ||| 0-0 1-1 2-2 3-3
CYP3A4 ( Ketoconazol ||| CYP3A4 ( ketoconazole ||| 0-0 1-1 2-2
CYP3A4 ( z.B . ||| CYP3A4 ( e. g. , ||| 0-0 1-1 2-2 2-3 3-3
CYP3A4 ( z.B . ||| CYP3A4 ( e. g. ||| 0-0 1-1 2-2 2-3 3-3
CYP3A4 ( z.B . ||| CYP3A4 ( e. ||| 0-0 1-1 2-2 3-2
CYP3A4 ( ||| CYP3A4 ( ||| 0-0 1-1
CYP3A4 , ||| CYP3A4 , ||| 0-0 1-1
CYP3A4 , ||| CYP3A4 ||| 0-0
CYP3A4 und CYP2D6 ||| CYP3A4 and CYP2D6 ||| 0-0 1-1 2-2
CYP3A4 und ||| CYP3A4 and ||| 0-0 1-1
CYP3A4 ||| CYP3A4 ||| 0-0
CYP3A4- oder CYP2D6-Inhibitor ||| CYP3A4 or CYP2D6 inhibitor ||| 0-0 1-1 2-2 2-3
CYP3A4- oder ||| CYP3A4 or ||| 0-0 1-1
CYP3A4- ||| CYP3A4 ||| 0-0
CYP3A4-Induktor ||| CYP3A4 inducer ||| 0-0 0-1
CYP3A4-Induktoren führt vermutlich zu einer ||| CYP3A4 inducers is expected to ||| 0-0 0-1 2-2 2-3 3-4 4-4
CYP3A4-Induktoren führt vermutlich ||| CYP3A4 inducers is expected ||| 0-0 0-1 2-2 2-3
CYP3A4-Induktoren führt ||| CYP3A4 inducers ||| 0-0 0-1
CYP3A4-Induktoren ||| CYP3A4 inducers ||| 0-0 0-1
CYP3A4-Substrat ) ||| CYP3A4-Substrat ) ||| 0-0 1-1
CYP3A4-Substrat ||| CYP3A4-Substrat ||| 0-0
CZOL446M2308 ) ||| CZOL446M2308 ) ||| 0-0 1-1
CZOL446M2308 ||| CZOL446M2308 ||| 0-0
Ca. ||| medication ||| 0-0
Calcitonin , Raloxifen ||| calcitonin , raloxifene ||| 0-0 1-1 2-2
Calcitonin , ||| calcitonin , ||| 0-0 1-1
Calcitonin ||| calcitonin ||| 0-0
Calciumtrimetasilicat Croscarmellose-Natrium Crospovidon Siliciumdioxid ||| Calcium silicate Croscarmellose sodium Crospovidone ||| 0-0 0-1 1-2 2-3 2-4 3-4
Calciumtrimetasilicat Croscarmellose-Natrium ||| Calcium silicate Croscarmellose ||| 0-0 0-1 1-2
Calciumtrimetasilicat ||| Calcium silicate ||| 0-0 0-1
Canary ||| UK Tel. ||| 0-0 0-1
Cancer Linear Analogue Scale ( ||| Cancer Linear Analogue Scale ( ||| 0-0 1-1 2-2 3-2 2-3 4-4
Cancer Linear Analogue Scale ||| Cancer Linear Analogue Scale ||| 0-0 1-1 2-2 3-2 2-3
Cancer Linear ||| Cancer Linear ||| 0-0 1-1
Cancer Therapy Anemia ( FACT-An ||| Cancer Therapy- Anaemia ( FACT-An ||| 0-0 1-1 2-1 2-2 3-3 4-4
Cancer Therapy Anemia ( ||| Cancer Therapy- Anaemia ( ||| 0-0 1-1 2-1 2-2 3-3
Cancer Therapy Anemia ||| Cancer Therapy- Anaemia ||| 0-0 1-1 2-1 2-2
Cancer ||| Cancer ||| 0-0
Cannabinoid-1-Rezeptor ||| -Antagonist ||| 0-0
Cannabinoid-Rezeptor- Antagonist . ||| cannabinoid receptor antagonist . ||| 0-0 0-1 1-2 2-3
Cannabinoid-Rezeptor- Antagonist ||| cannabinoid receptor antagonist ||| 0-0 0-1 1-2
Cannabinoid-Rezeptor- ||| cannabinoid receptor ||| 0-0 0-1
Cannabinoid-Typ 1 ||| cannabinoid type 1 ||| 0-0 0-1 1-2
Cannabinoid-Typ ||| cannabinoid type ||| 0-0 0-1
Capecitabin ausgesetzt ||| part of ||| 0-0 1-0
Capecitabin ausgesetzt ||| part ||| 0-0 1-0
Carbamazepin ||| carbamazepine ||| 0-0
Carmellose-Calcium und Magnesiumstearat . ||| and contents of the pack ||| 1-0 0-1 2-4
Carmellose-Calcium und Magnesiumstearat ||| and contents of the pack ||| 1-0 0-1 2-4
Carmellose-Calcium und ||| and contents of the ||| 1-0 0-1
Carmellose-Calcium und ||| and contents of ||| 1-0 0-1
Carmellose-Calcium und ||| and contents ||| 1-0 0-1
Carmellose-Calcium ||| contents of the ||| 0-0
Carmellose-Calcium ||| contents of ||| 0-0
Carmellose-Calcium ||| contents ||| 0-0
Carprofen , Meloxicam ||| NSAIDs ||| 0-0 2-0
Cedex 2 , Frankreich ||| Cedex 2 , France ||| 0-0 1-1 2-2 3-3
Cedex 2 , ||| Cedex 2 , ||| 0-0 1-1 2-2
Cedex 2 ||| Cedex 2 ||| 0-0 1-1
Cedex ||| Cedex ||| 0-0
Cellulose , Hyprolose , ||| cellulose , hydroxypropyl cellulose , ||| 0-0 1-1 2-2 0-3 3-4
Cellulose , Hyprolose ||| cellulose , hydroxypropyl cellulose ||| 0-0 1-1 2-2 0-3
Cellulose Aspartam ( E951 ) ||| cellulose Aspartame ( E951 ) ||| 0-0 1-1 2-2 3-3 4-4
Cellulose Aspartam ( E951 ||| cellulose Aspartame ( E951 ||| 0-0 1-1 2-2 3-3
Cellulose Aspartam ( ||| cellulose Aspartame ( ||| 0-0 1-1 2-2
Cellulose Aspartam ||| cellulose Aspartame ||| 0-0 1-1
Cellulose ||| Magnesium stearate ||| 0-0 0-1
Cellulose ||| cellulose ||| 0-0
Centre ( Europe ) , ||| Centre ( Europe ) , ||| 0-0 1-1 2-2 3-3 4-4
Centre ( Europe ) Ltd ||| Centre ( Europe ) Ltd ||| 0-0 1-1 2-2 3-3 4-4
Centre ( Europe ) ||| Centre ( Europe ) ||| 0-0 1-1 2-2 3-3
Centre ( Europe ||| Centre ( Europe ||| 0-0 1-1 2-2
Centre ( ||| Centre ( ||| 0-0 1-1
Centre Limited ||| Centre Limited ||| 0-0 1-1
Centre ||| Centre ||| 0-0
Ceraso I-03012 Anagni-Frosinone Italien ||| Ceraso I-03012 Anagni-Frosinone Italy ||| 0-0 1-1 2-2 3-3
Ceraso I-03012 Anagni-Frosinone ||| Ceraso I-03012 Anagni-Frosinone ||| 0-0 1-1 2-2
Ceraso I-03012 ||| Ceraso I-03012 ||| 0-0 1-1
Ceraso ||| Ceraso ||| 0-0
Charakteristika ||| characteristics ||| 0-0
Chemotherapie ) ||| chemotherapy ) ||| 0-0 1-1
Chemotherapie ||| chemotherapy ||| 0-0
Chinidin ) die ||| quinidine ) ||| 0-0 2-0 1-1
Chinidin gegeben wird . ||| quinidine occurs . ||| 0-0 1-1 2-1 3-2
Chinidin gegeben wird ||| quinidine occurs ||| 0-0 1-1 2-1
Chinidin ||| quinidine ||| 0-0
Ciclosporin ( Mittel zur Unterdrückung ||| cyclosporin ( medicine to suppress ||| 0-0 1-1 2-1 3-2 3-3 4-4
Ciclosporin ( Mittel zur ||| cyclosporin ( medicine to ||| 0-0 1-1 2-1 3-2 3-3
Ciclosporin ( Mittel ||| cyclosporin ( ||| 0-0 1-1 2-1
Ciclosporin angewendet , ||| cyclosporin , ||| 0-0 1-0 2-1
Ciclosporin angewendet ||| cyclosporin ||| 0-0 1-0
Ciclosporin ||| cyclosporin ||| 0-0
Ciclosporin ||| since cyclosporin ||| 0-0 0-1
Circus , Canary ||| Wharf , ||| 0-0 2-0 1-1
Circus ||| E14 4HB ||| 0-0 0-1
Clarithromycin ||| telithromycin ||| 0-0
Clcr ||| of ||| 0-0
Clearance ist daher ||| clearance is therefore ||| 0-0 1-1 2-2
Clearance ist ||| clearance is ||| 0-0 1-1
Clearance ||| clearance ||| 0-0
Cmax = 196 ||| Cmax = ||| 0-0 1-1
Cmax = 196 ± 28,1 ||| Cmax = 196 ± 28.1 ||| 0-0 1-1 3-2 3-3 4-3 3-4
Cmax = ||| Cmax = ||| 0-0 1-1
Cmax korrigiert nach Dosis , ||| Cmax corrected for dose ||| 0-0 1-1 3-3
Cmax korrigiert nach Dosis ||| Cmax corrected for dose ||| 0-0 1-1 3-3
Cmax korrigiert nach ||| Cmax corrected for ||| 0-0 1-1
Cmax korrigiert nach ||| Cmax corrected ||| 0-0 1-1
Cmax korrigiert ||| Cmax corrected for ||| 0-0 1-1
Cmax korrigiert ||| Cmax corrected ||| 0-0 1-1
Cmax und AUC nach ||| Cmax and AUC after ||| 0-0 1-1 2-2 3-3
Cmax und AUC ||| Cmax and AUC ||| 0-0 1-1 2-2
Cmax und eine ||| Cmax and a ||| 0-0 1-1 2-2
Cmax und ||| Cmax and ||| 0-0 1-1
Cmax von Dehydro-Aripiprazol , ||| Cmax of dehydro-aripiprazole , ||| 0-0 1-1 2-2 3-3
Cmax von Dehydro-Aripiprazol ||| Cmax of dehydro-aripiprazole ||| 0-0 1-1 2-2
Cmax von ||| Cmax of ||| 0-0 1-1
Cmax von ||| Cmax ||| 0-0
Cmax von ||| Cmax ||| 0-0 1-0
Cmax ||| Cmax values ||| 0-0
Cmax ||| Cmax ||| 0-0
Cmax-Wert von Paclitaxel wurde ||| Cmax of paclitaxel , which ||| 0-0 1-1 0-2 2-2
Cmax-Wert von Paclitaxel wurde ||| Cmax of paclitaxel , ||| 0-0 1-1 0-2 2-2
Cmax-Wert von Paclitaxel wurde ||| Cmax of paclitaxel ||| 0-0 1-1 0-2 2-2
Cmax-Wert von Paclitaxel ||| Cmax of paclitaxel , which ||| 0-0 1-1 0-2 2-2
Cmax-Wert von Paclitaxel ||| Cmax of paclitaxel , ||| 0-0 1-1 0-2 2-2
Cmax-Wert von Paclitaxel ||| Cmax of paclitaxel ||| 0-0 1-1 0-2 2-2
Co KG , Kuhloweg 37 ||| Co KG , Kuhloweg 37 ||| 0-0 1-1 2-2 3-3 4-4
Co KG , Kuhloweg ||| Co KG , Kuhloweg ||| 0-0 1-1 2-2 3-3
Co KG , ||| Co KG , ||| 0-0 1-1 2-2
Co KG Kuhloweg 37 D-58638 ||| Co KG Kuhloweg 37 D-58638 ||| 0-0 1-1 2-2 3-3 4-4
Co KG Kuhloweg 37 ||| Co KG Kuhloweg 37 ||| 0-0 1-1 2-2 3-3
Co KG Kuhloweg ||| Co KG Kuhloweg ||| 0-0 1-1 2-2
Co KG ||| Co KG ||| 0-0 1-1
Co ||| Co ||| 0-0
Component score bei dem primären ||| Component score at the primary ||| 0-0 0-1 1-1 2-2 3-3 4-4
Component score bei dem ||| Component score at the ||| 0-0 0-1 1-1 2-2 3-3
Component score bei ||| Component score at ||| 0-0 0-1 1-1 2-2
Component score ||| Component score ||| 0-0 0-1 1-1
Contrada Fontana Del Ceraso I-03012 ||| Contrada Fontana Del Ceraso I-03012 ||| 0-0 1-1 2-2 3-3 4-4
Contrada Fontana Del Ceraso ||| Contrada Fontana Del Ceraso ||| 0-0 1-1 2-2 3-3
Contrada Fontana Del ||| Contrada Fontana Del ||| 0-0 1-1 2-2
Contrada Fontana ||| Contrada Fontana ||| 0-0 1-1
Contrada ||| Contrada ||| 0-0
Corpora ||| and controls ||| 0-1
Corpora ||| controls ||| 0-0
County Wicklow . ||| County Wicklow . ||| 0-0 1-1 2-2
County Wicklow ||| County Wicklow ||| 0-0 1-1
County ||| County ||| 0-0
Croscarmellose-Natrium Crospovidon Siliciumdioxid ||| Croscarmellose sodium Crospovidone ||| 0-0 1-1 1-2 2-2
Croscarmellose-Natrium ||| Croscarmellose ||| 0-0
Crospovidon Siliciumdioxid Xylitol ||| sodium Crospovidone Silicon dioxide Xylitol ||| 0-0 0-1 1-1 2-2 2-3 2-4
Crospovidon Siliciumdioxid ||| sodium Crospovidone ||| 0-0 0-1 1-1
Ctrough = 91,6 ± 14,1 ||| Ctrough = 91.6 ± 14.1 ||| 0-0 1-1 3-2 2-3 3-3 4-3 3-4
Ctrough = ||| Ctrough = ||| 0-0 1-1
Ctrough ||| Ctrough ||| 0-0
Cycloolefin-Copolymer ) , ||| polymer ) ||| 0-0 1-1
Cycloolefin-Copolymer ) ||| polymer ) ||| 0-0 1-1
Cycloolefin-Copolymer ||| polymer ||| 0-0
Cytochrom P450 2C8 , jedoch ||| cytochrome P450 2C8 although ||| 0-0 1-1 2-2 2-3 4-3
Cytochrom P450 ||| cytochrome P450 ||| 0-0 1-1
Cytochrom ||| cytochrome ||| 0-0
Cytochrom ||| of cytochrome ||| 0-1
Cytochrom-P450-Enzymsysteme metabolisierten Substanzen ||| of substances ||| 2-1
Cytochrom-P450-Enzymsysteme metabolisierten Substanzen ||| substances ||| 2-0
Cytochroms P450 , 1A , ||| cytochrome P450 , 1A , ||| 1-0 0-1 1-1 2-2 0-3 3-3 2-4 4-4
D ( 50 ||| D ( ||| 0-0 1-1
D ( ||| D ( ||| 0-0 1-1
D , ||| D supplementation , ||| 0-0 0-1 1-2
D Centre ( Europe ) ||| D Centre ( Europe ) ||| 0-0 1-1 2-2 3-3 4-4
D Centre ( Europe ||| D Centre ( Europe ||| 0-0 1-1 2-2 3-3
D Centre ( ||| D Centre ( ||| 0-0 1-1 2-2
D Centre Limited ||| D Centre Limited ||| 0-0 1-1 2-2
D Centre ||| D Centre ||| 0-0 1-1
D pro Tag . ||| D supplementation per day . ||| 0-0 0-1 1-2 2-3 3-4
D pro Tag ||| D supplementation per day ||| 0-0 0-1 1-2 2-3
D pro ||| D supplementation per ||| 0-0 0-1 1-2
D und ||| D and ||| 0-0 1-1
D vor ||| D prior to ||| 0-0 1-1 1-2
D ||| D supplementation ||| 0-0 0-1
D ||| D ||| 0-0
D-58638 Iserlohn , Deutschland ||| D-58638 Iserlohn , Germany ||| 0-0 1-1 2-2 3-3
D-58638 Iserlohn , ||| D-58638 Iserlohn , ||| 0-0 1-1 2-2
D-58638 Iserlohn Deutschland ||| D-58638 Iserlohn Germany ||| 0-0 1-1 2-2
D-58638 Iserlohn Deutschland ||| D-58638 Iserlohn ||| 0-0 1-0 2-1
D-58638 Iserlohn ||| D-58638 Iserlohn ||| 0-0 1-1
D-58638 Iserlohn ||| D-58638 ||| 0-0 1-0
D-58638 ||| D-58638 ||| 0-0
D-90429 Nürnberg Deutschland ||| D-90429 Nuremberg Germany ||| 0-0 1-1 2-2
D-90429 Nürnberg ||| D-90429 Nuremberg ||| 0-0 1-1
D-90429 ||| D-90429 ||| 0-0
D2- und D3-Rezeptor und ||| D2 and D3 , ||| 0-0 2-0 1-1 3-1 2-2
D2- und D3-Rezeptor und ||| D2 and D3 ||| 0-0 2-0 1-1 3-1 2-2
D2/D3-Rezeptor-Liganden ||| caudate ||| 0-0
DARREICHUNGSFORM ||| NAMES ||| 0-0
DAS ARZNEIMITTEL FÜR KINDER ||| MEDICINAL PRODUCT MUST BE STORED ||| 0-0 0-1 1-2 2-3 3-3 3-4
DAS ARZNEIMITTEL ||| MEDICINAL PRODUCT MUST ||| 0-0 0-1 1-2
DAS ||| MEDICINAL PRODUCT ||| 0-0 0-1
DATUM DER ERTEILUNG DER ||| DATE OF FIRST ||| 0-0 1-1 2-2 3-2
DATUM DER ||| DATE OF ||| 0-0 1-1
DATUM ||| DATE ||| 0-0
DAUER DER ANWENDUNG ||| METHOD OF ADMINISTRATION ||| 0-0 1-1 2-2
DAUER DER ||| METHOD OF ||| 0-0 1-1
DAUER ||| METHOD ||| 0-0
DAVON STAMMENDEN ABFALLMATERIALIEN ||| PRODUCTS , IF APPROPRIATE ||| 0-0 1-1 1-2 2-3
DAVON STAMMENDEN ||| PRODUCTS , IF ||| 0-0 1-1 1-2
DAVON ||| PRODUCTS ||| 0-0
DEM UMKARTON FÜR BÜNDELPACKUNG ||| ON THE OUTER CARTON OF ||| 0-0 0-1 0-2 1-3 3-3 2-4
DEM ||| ON THE OUTER ||| 0-0 0-1 0-2
DER ABGABE UND/ODER DER ANWENDUNG ||| SUPPLY AND/ OR USE ||| 1-0 0-1 2-1 3-1 1-2 4-3
DER ABGABE UND/ODER DER ||| SUPPLY AND/ OR ||| 1-0 0-1 2-1 3-1 1-2
DER ANWENDUNG ||| OF ADMINISTRATION ||| 0-0 1-1
DER BEZEICHNUNG , DARREICHUNGSFORM , ||| OF THE NAMES , ||| 0-0 1-0 0-1 3-2 2-3 4-3
DER BEZEICHNUNG ||| OF THE ||| 0-0 1-0 0-1
DER ERTEILUNG DER ||| OF FIRST ||| 0-0 1-1 2-1
DER FLASCHE FÜR PACKUNGSEINHEIT ||| LABEL FOR UNIT PACK ||| 0-0 1-0 1-1 3-2 2-3 3-3
DER FLASCHE FÜR ZWISCHENPACKUNG ||| LABEL FOR INTERMEDIATE PACK ||| 0-0 1-0 1-1 3-2 2-3 3-3
DER FLASCHE ||| LABEL FOR ||| 0-0 1-0 1-1
DER GENEHMIGUNG FÜR DAS INVERKEHRBRINGEN ||| OF THE MARKETING AUTHORISATION ||| 0-0 2-0 3-1 1-2 3-2 4-2 4-3
DER MERKMALE DES ||| ra ||| 0-0 1-0 2-0
DER PRIMÄRVERPACKUNG ||| THE IMMEDIATE PACKAGE ||| 0-0 1-1 1-2
DER PRODUKTEIGENSCHAFTEN , ||| leaflet are the final versions ||| 1-0 1-1 1-2 1-3 1-4
DER PRODUKTEIGENSCHAFTEN ||| leaflet are the final versions ||| 1-0 1-1 1-2 1-3 1-4
DER WISSENSCHAFTLICHEN BEURTEILUNG VON ||| OF THE SCIENTIFIC EVALUATION OF ||| 0-0 0-1 1-2 2-3 0-4 3-4
DER ZULASSUNG ||| THE AUTHORISATION ||| 0-0 1-1
DER ||| HOLDER ||| 0-0
DER ||| OF ||| 0-0
DER ||| THE ||| 0-0
DES ARZNEIMITTELS SOWIE ||| OF THE MEDICINAL PRODUCT AND ||| 0-0 0-1 1-2 2-3 2-4
DES ARZNEIMITTELS SOWIE ||| OF THE MEDICINAL PRODUCT ||| 0-0 0-1 1-2 2-3
DES ARZNEIMITTELS ||| OF THE MEDICINAL ||| 0-0 0-1 1-2
DES ARZNEIMITTELS ||| PRODUCT ||| 0-0 1-0
DES ARZNEIMITTELS ||| THE MEDICINAL PRODUCT ||| 0-0 1-1 1-2
DES VERKAUFS , ||| OF SALE , ||| 0-0 1-1 2-2
DES VERKAUFS ||| OF SALE ||| 0-0 1-1
DES veraltet ||| obsolete ||| 1-0
DES ||| OF THE PRODUCT ||| 0-0 0-1 0-2
DES ||| OF THE ||| 0-0 0-1
DES ||| OF ||| 0-0
DES ||| THE ||| 0-0
DIE ABGABE UND DEN GEBRAUCH ||| REGARDING SUPPLY AND USE ||| 0-0 1-0 3-1 4-1 2-2 4-2 4-3
DIE ABGABE ||| REGARDING ||| 0-0 1-0
DIE DEM INHABER DER ||| IMPOSED ON ||| 0-0 1-0 2-0 1-1 3-1
DIE MITGLIEDSSTAATEN ZU IMPLEMENTIEREN SIND ||| MEMBER STATES ||| 0-0 1-0 2-0 3-0 1-1 4-1
DIE MITGLIEDSSTAATEN ||| MEMBER STATES ||| 0-0 1-0 1-1
DIE WOCHENTAGE ( NUR ||| DAYS OF THE WEEK ( ||| 0-0 1-0 1-1 3-2 3-3 2-4
DIE WOCHENTAGE ||| DAYS OF ||| 0-0 1-0 1-1
DIE ||| FOR ||| 0-0
DK-2880 Bagsværd Dänemark ||| DK-2880 Bagsværd Denmark ||| 0-0 1-1 2-2
DK-2880 Bagsværd ||| DK-2880 Bagsværd ||| 0-0 1-1
DK-2880 ||| DK-2880 ||| 0-0
DNA-Technologie in ||| cell line by ||| 0-0 0-1 1-1 0-2
DNS gegenüber Insulin tierischen Ursprungs ||| DNA versus animal source insulin ||| 0-0 1-1 3-1 3-2 3-3 4-3 2-4
DNS ||| DNA ||| 0-0
DOSIERUNG FÜR JEDE TIERART , ||| DOSAGE FOR EACH SPECIES , ||| 0-0 1-1 2-2 3-3 4-4
DOSIERUNG FÜR JEDE TIERART ||| DOSAGE FOR EACH SPECIES ||| 0-0 1-1 2-2 3-3
DOSIERUNG FÜR JEDE ||| DOSAGE FOR EACH ||| 0-0 1-1 2-2
DOSIERUNG FÜR ||| DOSAGE FOR ||| 0-0 1-1
DOSIERUNG ||| DOSAGE ||| 0-0
DREIFACH-KOMBINATIONSTHERAPIE MIT METFORMIN UND ||| COMBINATION THERAPY WITH METFORMIN AND ||| 0-0 0-1 1-2 2-3 3-4
DREIFACH-KOMBINATIONSTHERAPIE MIT METFORMIN ||| COMBINATION THERAPY WITH METFORMIN ||| 0-0 0-1 1-2 2-3
DREIFACH-KOMBINATIONSTHERAPIE MIT ||| COMBINATION THERAPY WITH ||| 0-0 0-1 1-2
DREIFACH-KOMBINATIONSTHERAPIE ||| COMBINATION THERAPY ||| 0-0 0-1
DURCH ||| BE IMPLEMENTED BY ||| 0-0 0-1 0-2
Da ABILIFY 7,5 mg/ml ||| As ABILIFY 7.5 mg/ ml ||| 0-0 1-1 2-2 3-3 3-4
Da ABILIFY 7,5 ||| As ABILIFY 7.5 ||| 0-0 1-1 2-2
Da ABILIFY ||| As ABILIFY ||| 0-0 1-1
Da Dopamin und 5-Hydroxytryptamin ||| Since dopamine and 5-hydroxytryptamine are ||| 0-0 1-1 2-2 3-3
Da Dopamin und 5-Hydroxytryptamin ||| Since dopamine and 5-hydroxytryptamine ||| 0-0 1-1 2-2 3-3
Da Dopamin und ||| Since dopamine and ||| 0-0 1-1 2-2
Da Dopamin ||| Since dopamine ||| 0-0 1-1
Da Insulin und Pioglitazon ||| Since insulin and pioglitazone ||| 0-0 1-1 2-2 3-3
Da Insulin und ||| Since insulin and ||| 0-0 1-1 2-2
Da Insulin ||| Since insulin ||| 0-0 1-1
Da bei ||| As ||| 0-0 1-0
Da die Schmelztablette ||| Since the orodispersible tablet ||| 0-0 1-1 2-2 2-3
Da die ||| Since the ||| 0-0 1-1
Da diese Ereignisse ||| Because these events ||| 0-0 1-1 2-2
Da diese ||| Because these ||| 0-0 1-1
Da jedoch Ciclosporin ||| However , since cyclosporin ||| 0-0 1-0 1-1 2-2 2-3
Da jedoch ||| However , ||| 0-0 1-0 1-1
Da ||| As ||| 0-0
Da ||| Because ||| 0-0
Da ||| Since ||| 0-0
Dagegen ||| contrast ||| 0-0
Daher darf Pioglitazon nicht ||| Therefore , pioglitazone should not ||| 0-0 0-1 2-2 1-3 1-4 3-4
Daher kann keine ||| Therefore , no ||| 0-0 1-0 0-1 2-2
Daher kann ||| Therefore , ||| 0-0 1-0 0-1
Daher sollte Aripiprazol ||| Therefore , aripiprazole should be ||| 0-0 0-1 2-2 1-3 1-4
Daher sollten Frauen , die ||| Intensified control in the ||| 0-0 1-0 2-0 2-1 2-2 4-3
Daher sollten Frauen , ||| Intensified control in ||| 0-0 1-0 2-0 2-1 2-2
Daher sollten Frauen ||| Intensified control in ||| 0-0 1-0 2-0 2-1 2-2
Daher sollten Hämoglobinwert und ||| Consequently , haemoglobin and ||| 0-0 1-0 0-1 2-2 3-3
Daher sollten Hämoglobinwert ||| Consequently , haemoglobin ||| 0-0 1-0 0-1 2-2
Daher sollten Ihr Hämoglobinwert und ||| Therefore your haemoglobin-levels and ||| 0-0 2-1 1-2 2-2 3-2 4-3
Daher sollten Ihr Hämoglobinwert ||| Therefore your haemoglobin-levels ||| 0-0 2-1 1-2 2-2 3-2
Daher sollten ||| Consequently , ||| 0-0 1-0 0-1
Daher wird eine engmaschige Überwachung ||| Close blood glucose monitoring ||| 0-0 1-0 3-1 2-2 3-2 3-3 4-3
Daher wird ||| Close ||| 0-0 1-0
Daher ||| Therefore , ||| 0-0
Daher ||| Therefore , ||| 0-0 0-1
Daher ||| Therefore ||| 0-0
Dalton . ||| dalton . ||| 0-0 1-1
Dalton ||| dalton ||| 0-0
Danazol . ||| danazol . ||| 0-0 1-1
Danazol ||| danazol ||| 0-0
Danmark BRISTOL-MYERS SQUIBB Tlf : ||| Danmark BRISTOL-MYERS SQUIBB Tlf : ||| 0-0 1-1 2-2 3-3 4-4
Danmark BRISTOL-MYERS SQUIBB Tlf ||| 160 Danmark BRISTOL-MYERS SQUIBB Tlf ||| 0-0 0-1 1-2 2-3 3-4
Danmark BRISTOL-MYERS SQUIBB Tlf ||| 166 Danmark BRISTOL-MYERS SQUIBB Tlf ||| 0-0 0-1 1-2 2-3 3-4
Danmark BRISTOL-MYERS SQUIBB Tlf ||| 172 Danmark BRISTOL-MYERS SQUIBB Tlf ||| 0-0 0-1 1-2 2-3 3-4
Danmark BRISTOL-MYERS SQUIBB Tlf ||| 178 Danmark BRISTOL-MYERS SQUIBB Tlf ||| 0-0 0-1 1-2 2-3 3-4
Danmark BRISTOL-MYERS SQUIBB Tlf ||| Danmark BRISTOL-MYERS SQUIBB Tlf ||| 0-0 1-1 2-2 3-3
Danmark BRISTOL-MYERS SQUIBB ||| 160 Danmark BRISTOL-MYERS SQUIBB ||| 0-0 0-1 1-2 2-3
Danmark BRISTOL-MYERS SQUIBB ||| 166 Danmark BRISTOL-MYERS SQUIBB ||| 0-0 0-1 1-2 2-3
Danmark BRISTOL-MYERS SQUIBB ||| 172 Danmark BRISTOL-MYERS SQUIBB ||| 0-0 0-1 1-2 2-3
Danmark BRISTOL-MYERS SQUIBB ||| 178 Danmark BRISTOL-MYERS SQUIBB ||| 0-0 0-1 1-2 2-3
Danmark BRISTOL-MYERS SQUIBB ||| Danmark BRISTOL-MYERS SQUIBB ||| 0-0 1-1 2-2
Danmark BRISTOL-MYERS ||| 160 Danmark BRISTOL-MYERS ||| 0-0 0-1 1-2
Danmark BRISTOL-MYERS ||| 166 Danmark BRISTOL-MYERS ||| 0-0 0-1 1-2
Danmark BRISTOL-MYERS ||| 172 Danmark BRISTOL-MYERS ||| 0-0 0-1 1-2
Danmark BRISTOL-MYERS ||| 178 Danmark BRISTOL-MYERS ||| 0-0 0-1 1-2
Danmark BRISTOL-MYERS ||| Danmark BRISTOL-MYERS ||| 0-0 1-1
Danmark Novartis Healthcare A/S ||| Danmark Novartis Healthcare A/ S ||| 0-0 1-1 2-2 3-3 3-4
Danmark Novartis Healthcare ||| Danmark Novartis Healthcare ||| 0-0 1-1 2-2
Danmark Novartis ||| Danmark Novartis ||| 0-0 1-1
Danmark Takeda Global R & ||| Danmark Takeda Global R & ||| 0-0 1-1 2-2 3-3 4-4
Danmark Takeda Global R ||| Danmark Takeda Global R ||| 0-0 1-1 2-2 3-3
Danmark Takeda Global ||| Danmark Takeda Global ||| 0-0 1-1 2-2
Danmark Takeda ||| Danmark Takeda ||| 0-0 1-1
Danmark ||| 160 Danmark ||| 0-0 0-1
Danmark ||| 166 Danmark ||| 0-0 0-1
Danmark ||| 172 Danmark ||| 0-0 0-1
Danmark ||| 178 Danmark ||| 0-0 0-1
Danmark ||| Danmark ||| 0-0
Dann sollte die Durchstechflasche ||| Then , the vial should ||| 0-0 2-2 3-3 1-4
Dann ||| Then , ||| 0-0
Dann ||| Then ||| 0-0
Daraus ergibt sich ein erhöhtes ||| The observed excess risk ||| 0-0 0-1 0-2 1-2 2-2 3-3 4-3
Daraus ergibt sich ||| The observed excess ||| 0-0 0-1 0-2 1-2 2-2
Darms entfernt wurden . ||| intestine removed . ||| 0-0 1-0 2-0 1-1 3-2
Darms entfernt wurden ||| intestine removed ||| 0-0 1-0 2-0 1-1
Darreichungsformen zum Einnehmen ||| oral formulations of ABILIFY ||| 1-0 2-0 0-1 2-3
Darreichungsformen zum Einnehmen ||| oral formulations of ||| 1-0 2-0 0-1
Darreichungsformen zum Einnehmen ||| oral formulations ||| 1-0 2-0 0-1
Darreichungsformen ||| formulations of ||| 0-0
Darreichungsformen ||| formulations ||| 0-0
Darüber hinaus kann nicht ||| Moreover , in patients ||| 0-0 1-0 2-0 3-0 1-1 1-2 1-3
Darüber hinaus ||| In addition , ||| 0-0 0-1 1-1 1-2
Das Arzneimittel bedarf ||| The medicine can only be ||| 0-0 1-1 2-2 2-3 2-4
Das Arzneimittel darf nicht ||| Medicines should not be ||| 0-0 1-0 2-1 2-2 3-2 2-3
Das Arzneimittel darf ||| Do not ||| 0-0 1-0 2-0 2-1
Das Arzneimittel ist nur ||| The medicine can only be ||| 0-0 1-1 1-2 2-3 3-3 3-4
Das Arzneimittel ist nur ||| The medicine can only be ||| 0-0 1-1 3-2 2-3 3-3 3-4
Das Arzneimittel ist sofort ||| Use product immediately ||| 0-0 1-1 2-1 3-2
Das Arzneimittel ist ||| Use product ||| 0-0 1-1 2-1
Das Arzneimittel muss intravenös ||| The intravenous route has to ||| 0-0 1-1 3-1 2-2 3-2 3-3 3-4
Das Arzneimittel ||| Medicines ||| 0-0 1-0
Das Arzneimittel ||| The medicine can ||| 0-0 1-1 1-2
Das Arzneimittel ||| The medicine ||| 0-0 1-1
Das Arzneimittel ||| This medicinal product ||| 1-0 1-1 0-2 1-2
Das Auftreten einer ||| The occurrence of ||| 0-0 1-1 2-2
Das Auftreten ||| The occurrence ||| 0-0 1-1
Das Auslassen einer Mahlzeit oder ||| Omission of a meal or ||| 0-0 1-0 1-1 2-2 3-3 4-4
Das Auslassen einer Mahlzeit ||| Omission of a meal ||| 0-0 1-0 1-1 2-2 3-3
Das Auslassen einer ||| Omission of a ||| 0-0 1-0 1-1 2-2
Das Auslassen ||| Omission of ||| 0-0 1-0 1-1
Das Gesamtüberleben ||| Overall survival ||| 0-0 1-0 1-1
Das Maximum liegt immer deutlich ||| The peak is always well ||| 0-0 1-1 2-2 2-3 3-3 4-4
Das Maximum liegt immer ||| The peak is always ||| 0-0 1-1 2-2 2-3 3-3
Das Maximum ||| The peak ||| 0-0 1-1
Das Molekulargewicht von ||| The apparent molecular weight of ||| 0-0 1-1 1-2 2-2 1-3 2-4
Das Schulungsprogramm enthält ||| The educational programme contains the ||| 0-0 1-1 1-2 2-3
Das Schulungsprogramm enthält ||| The educational programme contains ||| 0-0 1-1 1-2 2-3
Das Schulungsprogramm ||| The educational programme ||| 0-0 1-1 1-2
Das Stillen muss während ||| Breastfeeding must be discontinued ||| 0-0 1-0 1-1 2-1 2-2 2-3
Das Stillen muss ||| Breastfeeding must be discontinued ||| 0-0 1-0 1-1 2-1 2-2 2-3
Das Tierarzneimittel sollte ||| Treatment should be ||| 0-0 1-0 2-1 2-2
Das Tierarzneimittel ||| Treatment ||| 0-0 1-0
Das Unternehmen entschied ||| The company decided ||| 0-0 1-1 2-2
Das Unternehmen führte außerdem ||| The company also carried out ||| 0-0 1-1 2-1 3-2 3-3 3-4
Das Unternehmen führte ||| The company ||| 0-0 1-1 2-1
Das Unternehmen legte außerdem Daten ||| The company also presented data ||| 0-0 1-1 2-1 3-2 2-3 4-4
Das Unternehmen legte außerdem ||| The company also presented ||| 0-0 1-1 2-1 3-2 2-3
Das Unternehmen zog daher ||| Therefore , the company withdrew ||| 2-0 3-0 1-2 0-3 1-3 2-4
Das Unternehmen ||| , the company ||| 1-1 0-2 1-2
Das Unternehmen ||| The company ||| 0-0 1-1
Das Unternehmen ||| the company ||| 1-0 0-1 1-1
Das Verfahren zur Rekonstitution ist ||| The procedure for reconstitution is ||| 0-0 1-1 2-2 3-3 4-4
Das Verfahren zur Rekonstitution ||| The procedure for reconstitution ||| 0-0 1-1 2-2 3-3
Das Verfahren zur ||| The procedure for ||| 0-0 1-1 2-2
Das Verfahren ||| The procedure ||| 0-0 1-1
Das Verfalldatum bezieht sich auf ||| The expiry date refers to ||| 0-0 1-1 1-2 2-3 3-3 4-4
Das Verfalldatum bezieht sich ||| The expiry date refers ||| 0-0 1-1 1-2 2-3 3-3
Das Verfalldatum ||| The expiry date ||| 0-0 1-1 1-2
Das Vorgehen ||| 102 avoided ; guidance ||| 1-0 0-1 1-1 1-2 1-3
Das Vorgehen ||| 116 avoided ; guidance ||| 1-0 0-1 1-1 1-2 1-3
Das Vorgehen ||| 130 avoided ; guidance ||| 1-0 0-1 1-1 1-2 1-3
Das Vorgehen ||| 18 avoided ; guidance ||| 0-0 0-1 1-1 1-2 1-3
Das Vorgehen ||| 32 avoided ; guidance ||| 1-0 0-1 1-1 1-2 1-3
Das Vorgehen ||| 4 avoided ; guidance ||| 0-1 1-1 1-2 1-3
Das Vorgehen ||| 46 avoided ; guidance ||| 1-0 0-1 1-1 1-2 1-3
Das Vorgehen ||| 74 avoided ; guidance ||| 1-0 0-1 1-1 1-2 1-3
Das Vorgehen ||| 88 avoided ; guidance ||| 1-0 0-1 1-1 1-2 1-3
Das Vorgehen ||| avoided ; guidance ||| 0-0 1-0 1-1 1-2
Das gentechnologisch gewonnene Epoetin alfa ||| Epoetin alfa obtained by gene ||| 1-0 3-1 4-1 0-2 1-2 2-2 2-3 2-4
Das geschätzte Verteilungsvolumen ||| The estimated volume of distribution ||| 0-0 1-1 1-2 2-3 2-4
Das geschätzte ||| The estimated volume ||| 0-0 1-1 1-2
Das inhibitorische Potenzial auf ||| The potential for inhibition of ||| 0-0 1-1 2-1 2-2 1-3 3-4
Das inhibitorische Potenzial ||| The potential for inhibition ||| 0-0 1-1 2-1 2-2 1-3
Das kontinuierliche Wechseln der ||| 66 ||| 0-0 1-0 2-0 3-0
Das kontinuierliche Wechseln der ||| Continuous rotation of the ||| 0-0 1-0 1-1 2-1 3-2 3-3
Das kontinuierliche Wechseln ||| 31 ||| 0-0 1-0 2-0
Das kontinuierliche Wechseln ||| 38 ||| 0-0 1-0 2-0
Das kontinuierliche Wechseln ||| 59 ||| 0-0 1-0 2-0
Das kontinuierliche Wechseln ||| Continuous rotation ||| 0-0 1-0 1-1 2-1
Das mittlere Verteilungsvolumen ||| The mean volume of distribution ||| 0-0 1-1 2-2 2-3 2-4
Das mittlere ||| The mean ||| 0-0 1-1
Das pharmakokinetische Profil zeigt , ||| ra plateau in exposures ||| 0-0 2-0 1-1 2-1 3-1 4-2 4-3
Das pharmakokinetische Profil zeigt ||| ra plateau ||| 0-0 2-0 1-1 2-1 3-1
Das potenzielle Risiko für ||| The potential risk for ||| 0-0 1-1 2-2 3-3
Das potenzielle Risiko ||| The potential risk ||| 0-0 1-1 2-2
Das potenzielle ||| The potential ||| 0-0 1-1
Das rekonstituierte Arzneimittel enthält ||| The reconstituted medicinal product contains ||| 0-0 1-1 2-2 2-3 3-4
Das rekonstituierte Arzneimittel ||| The reconstituted medicinal product ||| 0-0 1-1 2-2 2-3
Das rekonstituierte ||| The reconstituted ||| 0-0 1-1
Das ||| The ||| 0-0
Das ||| Use ||| 0-0
Das ||| volume ||| 0-0
Daten am Menschen vor , ||| human data to ||| 2-0 0-1 3-1 3-2 4-2
Daten aus der ||| data from the ||| 0-0 1-1 2-2
Daten aus ||| data from ||| 0-0 1-1
Daten basieren auf dem ||| data is based on ||| 0-0 3-1 1-2 2-3 3-3
Daten bei Patienten mit schwerer ||| data in severe ||| 0-0 1-1 2-1 3-1 4-2
Daten bei Patienten mit ||| data in ||| 0-0 1-1 2-1 3-1
Daten der Langzeitverlängerung der Studie ||| data from the Long Term ||| 0-0 0-1 1-2 2-3 3-3 2-4 4-4
Daten der ||| data from the ||| 0-0 0-1 1-2
Daten der ||| data of the ||| 0-0 1-1 1-2
Daten für die Verwendung von ||| data on the use of ||| 0-0 0-1 1-2 2-2 3-3 4-4
Daten für die Verwendung ||| data on the use ||| 0-0 0-1 1-2 2-2 3-3
Daten für die ||| data on the ||| 0-0 0-1 1-2 2-2
Daten von 360 Hunden ||| data from 360 dogs ||| 0-0 0-1 1-1 2-2 3-3
Daten von 360 Hunden über ||| data from 360 dogs over ||| 0-0 0-1 1-1 2-2 3-3 4-4
Daten von 360 ||| data from 360 ||| 0-0 0-1 1-1 2-2
Daten von ||| data from ||| 0-0 0-1 1-1
Daten ||| data , ||| 0-0
Daten ||| data available ||| 0-0 0-1
Daten ||| data from ||| 0-0 0-1
Daten ||| data on ||| 0-0 0-1
Daten ||| data ||| 0-0
Daten ||| of data ||| 0-1
Datum der ||| Datum der letzten Verlängerung ||| 0-0 0-1 0-2 0-3 1-3
Dauer der Anwendung t lä ||| method of administration ||| 0-0 1-1 2-2 3-2 4-2
Dauer der ||| method of ||| 0-0 1-1
Dauer des Diabetes betrug 9,5 ||| duration of diabetes was 9.5 ||| 0-0 1-1 2-2 3-3 4-4
Dauer des Diabetes betrug ||| duration of diabetes was ||| 0-0 1-1 2-2 3-3
Dauer des Diabetes ||| duration of diabetes ||| 0-0 1-1 2-2
Dauer des ||| duration of ||| 0-0 1-1
Dauer ||| average ||| 0-0
Dauer ||| duration ||| 0-0
Dauer ||| method ||| 0-0
Dauer ||| time ||| 0-0
Daumen und Zeigefinger zusammendrücken . ||| thumb and forefinger . ||| 0-0 1-1 2-2 3-2 4-3
Daumen und Zeigefinger zusammendrücken ||| thumb and forefinger ||| 0-0 1-1 2-2 3-2
Daumen und ||| thumb and ||| 0-0 1-1
Daumen ||| thumb ||| 0-0
Dehydratation ) . ||| dehydration ) ||| 0-0 1-1
Dehydratation ) ||| dehydration ) ||| 0-0 1-1
Dehydratation und blasse Schleimhäute . ||| dehydration and pale mucosae . ||| 0-0 1-1 2-2 3-3 4-4
Dehydratation und blasse Schleimhäute ||| dehydration and pale mucosae ||| 0-0 1-1 2-2 3-3
Dehydratation und blasse ||| dehydration and pale ||| 0-0 1-1 2-2
Dehydratation und ||| dehydration and ||| 0-0 1-1
Dehydratation ||| dehydration ||| 0-0
Dehydrierung , Hydroxylierung und ||| dehydrogenation , hydroxylation , and ||| 0-0 1-1 2-2 1-3 3-4
Dehydrierung , Hydroxylierung ||| dehydrogenation , hydroxylation , ||| 0-0 1-1 2-2 1-3
Dehydrierung ||| dehydrogenation ||| 0-0
Dehydro-Aripiprazol , aber ||| dehydro-aripiprazole , but ||| 0-0 1-1 2-2
Dehydro-Aripiprazol , dem aktiven Metaboliten ||| dehydro-aripiprazole , the active metabolite ||| 0-0 1-1 2-2 3-3 2-4 3-4 4-4
Dehydro-Aripiprazol , ||| dehydro-aripiprazole , ||| 0-0 1-1
Dehydro-Aripiprazol die geometrischen Mittel der ||| dehydro-aripiprazole the geometric means of ||| 0-0 1-1 2-2 2-3 3-3 4-4
Dehydro-Aripiprazol die geometrischen Mittel ||| dehydro-aripiprazole the geometric means ||| 0-0 1-1 2-2 2-3 3-3
Dehydro-Aripiprazol die ||| dehydro-aripiprazole the ||| 0-0 1-1
Dehydro-Aripiprazol in vitro ||| dehydro-aripiprazole did ||| 0-0 1-1 2-1
Dehydro-Aripiprazol stiegen um 77 ||| dehydro-aripiprazole increased by 77 ||| 0-0 1-1 1-2 1-3 2-3 3-3
Dehydro-Aripiprazol ||| dehydro-aripiprazole are ||| 0-0 0-1
Dehydro-Aripiprazol ||| dehydro-aripiprazole ||| 0-0
Del Ceraso I-03012 Anagni-Frosinone Italien ||| Del Ceraso I-03012 Anagni-Frosinone Italy ||| 0-0 1-1 2-2 3-3 4-4
Del Ceraso I-03012 Anagni-Frosinone ||| Del Ceraso I-03012 Anagni-Frosinone ||| 0-0 1-1 2-2 3-3
Del Ceraso I-03012 ||| Del Ceraso I-03012 ||| 0-0 1-1 2-2
Del Ceraso ||| Del Ceraso ||| 0-0 1-1
Del ||| Del ||| 0-0
Deltoidregion ||| bottom ||| 0-0
Demenz ( Verlust des ||| dementia ( loss of ||| 0-0 2-0 1-1 2-2 3-2 3-3
Demenz ( Verlust des ||| dementia ( loss of ||| 0-0 2-0 3-0 1-1 2-2 3-3
Den Patienten sollte geraten werden ||| Patients should be advised ||| 0-0 1-0 2-1 4-2 3-3 4-3
Den Patienten sollte ||| Patients should ||| 0-0 1-0 2-1
Den Patienten ||| Patients ||| 0-0 1-0
Den vollständigen Wortlaut des EPAR ||| 2/ 3 The full EPAR ||| 0-0 1-1 1-2 1-3 2-3 2-4 3-4 4-4
Den vollständigen Wortlaut des EPAR ||| The full EPAR for Abraxane ||| 1-0 0-1 1-1 2-2 3-2 4-2 2-3 4-4
Den vollständigen Wortlaut des EPAR ||| The full EPAR for ||| 1-0 0-1 1-1 2-2 3-2 4-2 2-3
Den vollständigen Wortlaut des EPAR ||| The full EPAR ||| 1-0 0-1 1-1 2-2 3-2 4-2
Den vollständigen ||| The full ||| 1-0 0-1 1-1
Den ||| 2/ ||| 0-0
Den ||| Patients ||| 0-0
Dennoch , ||| However , ||| 0-0 1-1
Dennoch ist ||| Dennoch ist ||| 0-0 1-1
Dennoch war die ||| However , in ||| 0-0 2-2
Dennoch war ||| However , ||| 0-0
Dennoch war ||| However ||| 0-0
Dennoch ||| Dennoch ||| 0-0
Dennoch ||| However , ||| 0-0
Dennoch ||| However ||| 0-0
Dentaleingriff ||| procedures ||| 0-0
Dentaleingriffen . ||| dental surgeries . ||| 0-0 0-1 1-2
Dentaleingriffen ||| dental surgeries ||| 0-0 0-1
Depolymerisation stabilisiert . ||| preventing depolymerisation . ||| 0-0 0-1 1-1 2-2
Depolymerisation stabilisiert ||| preventing depolymerisation ||| 0-0 0-1 1-1
Depression , ||| Abraxane at any dose in ||| 0-0 0-1 0-2 0-3 1-4
Depression ||| Abraxane at any dose ||| 0-0 0-1 0-2 0-3
Depressive Erkrankungen ||| Depressive disorders ||| 0-0 1-1
Depressive ||| Depressive ||| 0-0
Der Anteil der Patienten , ||| Der Anteil der Patienten , ||| 0-0 1-1 2-2 3-3 4-4
Der Anteil der Patienten ||| Der Anteil der Patienten ||| 0-0 1-1 2-2 3-3
Der Anteil der ||| Der Anteil der ||| 0-0 1-1 2-2
Der Anteil ||| Der Anteil ||| 0-0 1-1
Der Arzt muss deshalb ||| The physician must therefore ||| 0-0 1-1 3-1 2-2 3-3
Der Arzt sollte eine klinische ||| Physicians should consider clinical ||| 0-0 1-0 2-1 3-2 4-2 4-3
Der Arzt sollte ||| Physicians should ||| 0-0 1-0 2-1
Der Arzt ||| Physicians ||| 0-0 1-0
Der Ausschuss für ||| Der Ausschuss für ||| 0-0 1-1 1-2 2-2
Der Ausschuss ||| The Committee ||| 0-0 1-1
Der Begründung für das ||| Justification for ||| 0-0 1-0 3-0 2-1
Der Blutdruckanstieg ||| These increases in blood pressure ||| 1-0 0-1 1-1 1-2 1-3 1-4
Der Blutzuckerspiegel des Patienten ||| The patient 's blood sugar ||| 0-0 3-1 2-2 1-3 1-4
Der CHMP verlangt die Aufnahme ||| The CHMP requests the inclusion ||| 0-0 1-1 2-2 3-3 4-3 2-4
Der CHMP ||| The CHMP ||| 0-0 1-1
Der Einfluss von Rimonabant ||| of rimonabant ||| 2-0 1-1 3-1
Der H2-Antagonist ||| A gastric ||| 1-0 0-1 1-1
Der Haupteliminationsweg von Paclitaxel besteht ||| Paclitaxel is principally eliminated ||| 0-0 1-0 3-0 4-1 1-2 4-3
Der Hauptindikator für die Wirksamkeit ||| The main measure of effectiveness ||| 0-0 1-1 1-2 2-3 3-3 4-4
Der Hauptindikator für die ||| The main measure of ||| 0-0 1-1 1-2 2-3 3-3
Der Hauptindikator ||| The main measure ||| 0-0 1-1 1-2
Der Hersteller von ||| The Committee ||| 0-0 0-1 1-1
Der Hersteller von ||| The company ||| 0-0 1-1
Der Hersteller ||| The Committee ||| 0-0 0-1 1-1
Der Hersteller ||| The company ||| 0-0 1-1
Der Pharmazeutische Unternehmer verpflichtet sich ||| The Marketing Authorisation Holder commits ||| 0-0 1-1 2-1 2-2 2-3 3-4 4-4
Der Pharmazeutische Unternehmer ||| The Marketing Authorisation Holder ||| 0-0 1-1 2-1 2-2 2-3
Der Proteinanteil des ||| The protein fraction of the ||| 0-0 1-1 1-2 2-2 2-3 2-4
Der Serum-Kreatinin-Wert sollte ||| Patients should have their ||| 1-0 0-1 2-1 1-2 1-3
Der Stoffwechsel von Paclitaxel wird ||| The metabolism of paclitaxel is ||| 0-0 1-1 2-2 3-3 4-4
Der Stoffwechsel von Paclitaxel ||| The metabolism of paclitaxel ||| 0-0 1-1 2-2 3-3
Der Stoffwechsel von ||| The metabolism of ||| 0-0 1-1 2-2
Der Stoffwechsel ||| The metabolism ||| 0-0 1-1
Der Vorschlag ||| The proposal ||| 0-0 1-1
Der Wirkstoff in Abilify ||| The active substance in Abilify ||| 0-0 1-1 1-2 2-3 3-4
Der Wirkstoff in Aclasta ||| The active substance in Aclasta ||| 0-0 1-1 1-2 2-3 3-4
Der Wirkstoff in ||| The active substance in ||| 0-0 1-1 1-2 2-3
Der Wirkstoff ist : Aripiprazol ||| The active substance is aripiprazole ||| 0-0 1-1 1-2 3-2 2-3 4-4
Der Wirkstoff ist : ||| The active substance is ||| 0-0 1-1 1-2 3-2 2-3
Der Wirkstoff ist Aripiprazol ||| The active substance is aripiprazole ||| 0-0 1-1 1-2 2-3 3-4
Der Wirkstoff ist ||| The active substance is ||| 0-0 1-1 1-2 2-3
Der Wirkstoff ||| The active substance ||| 0-0 1-1 1-2
Der arzneilich wirksame Bestandteil von ||| The active substance in ||| 0-0 1-1 2-1 3-2 4-3
Der arzneilich wirksame Bestandteil ||| The active substance in ||| 0-0 1-1 2-2 3-2
Der arzneilich wirksame Bestandteil ||| The active substance ||| 0-0 1-1 2-1 3-2
Der arzneilich wirksame Bestandteil ||| The active substance ||| 0-0 1-1 2-2 3-2
Der arzneilich wirksame ||| The active ||| 0-0 1-1 2-1
Der arzneilich ||| The active ||| 0-0 1-1
Der häufigste ||| The most frequent ||| 0-0 1-1 1-2
Der individuelle Insulinbedarf liegt ||| The individual insulin requirement is ||| 0-0 1-1 2-2 2-3 3-3 3-4
Der individuelle ||| The individual ||| 0-0 1-1
Der mittlere Cmax-Wert von Paclitaxel ||| The mean Cmax of paclitaxel ||| 0-0 1-1 2-2 3-3 2-4 4-4
Der mittlere ||| The mean ||| 0-0 1-1
Der natürliche Verlauf von ||| The natural course of ||| 0-0 1-1 2-2 3-3
Der natürliche Verlauf ||| The natural course ||| 0-0 1-1 2-2
Der natürliche ||| The natural ||| 0-0 1-1
Der primäre Wirksamkeitsparameter war ||| The primary efficacy variable was ||| 0-0 1-1 2-2 2-3 3-4
Der primäre Wirksamkeitsparameter ||| The primary efficacy variable ||| 0-0 1-1 2-2 2-3
Der primäre ||| The primary ||| 0-0 1-1
Der prozentuale Anteil ||| The percentage ||| 0-0 1-1 2-1
Der tägliche Insulinbedarf ||| The daily insulin requirement ||| 0-0 1-1 2-2 2-3
Der tägliche ||| The daily ||| 0-0 1-1
Der ||| Der ||| 0-0
Der ||| The Marketing ||| 0-0 0-1
Der ||| The in ||| 0-0
Der ||| The ||| 0-0
Deshalb ist ||| Therefore ||| 0-0 1-0
Deshalb ist ||| Thus ||| 0-0 1-0
Deshalb ||| Consequently , ||| 0-0 0-1
Detaillierte Angaben zu ||| Detailed information ||| 0-0 2-0 0-1 1-1
Deutschland Takeda Pharma GmbH ||| Deutschland Takeda Pharma GmbH ||| 0-0 1-1 2-2 3-3
Deutschland Takeda Pharma ||| Deutschland Takeda Pharma ||| 0-0 1-1 2-2
Deutschland Takeda ||| Deutschland Takeda ||| 0-0 1-1
Deutschland ||| Deutschland ||| 0-0
Deutschland ||| Germany ||| 0-0
Deutschland ||| Iserlohn ||| 0-0
Development Centre ( Europe ) ||| Development Centre ( Europe ) ||| 0-0 1-1 2-2 3-3 4-4
Development Centre ( Europe ||| Development Centre ( Europe ||| 0-0 1-1 2-2 3-3
Development Centre ( ||| Development Centre ( ||| 0-0 1-1 2-2
Development Centre ||| Development Centre ||| 0-0 1-1
Development ||| Development ||| 0-0
Dexamethason ||| ranitidine ||| 0-0
Dextromethorphan ) . ||| dextromethorphan ) . ||| 0-0 1-1 2-2
Dextromethorphan ) ||| dextromethorphan ) ||| 0-0 1-1
Dextromethorphan ||| dextromethorphan ||| 0-0
Dextromethorphan/3-Methoxymorphinan-Ratio ) , ||| dextromethorphan/ 3-methoxymorphinan ratio ) , ||| 0-0 0-1 0-2 1-3 2-4
Dextromethorphan/3-Methoxymorphinan-Ratio ) ||| dextromethorphan/ 3-methoxymorphinan ratio ) ||| 0-0 0-1 0-2 1-3
Dextromethorphan/3-Methoxymorphinan-Ratio ||| dextromethorphan/ 3-methoxymorphinan ratio ||| 0-0 0-1 0-2
Diabetes , Ketoazidose ( ||| diabetes , ketoacidosis ( ||| 0-0 2-2 3-3
Diabetes , Ketoazidose ||| diabetes , ketoacidosis ||| 0-0 2-2
Diabetes , in welchen ||| in Asian/ Oriental ||| 0-0 2-0 0-1 3-2
Diabetes , in ||| in Asian/ ||| 0-0 2-0 0-1
Diabetes , ||| diabetes , ||| 0-0
Diabetes , ||| diabetes , ||| 0-0 1-1
Diabetes , ||| diabetes ||| 0-0
Diabetes Mellitus ( siehe Abschnitt ||| diabetes mellitus ( see section ||| 0-0 1-1 2-2 3-3 4-4
Diabetes Mellitus ( siehe ||| diabetes mellitus ( see ||| 0-0 1-1 2-2 3-3
Diabetes Mellitus ( ||| diabetes mellitus ( ||| 0-0 1-1 2-2
Diabetes Mellitus : Hyperglykämie , ||| Diabetes Mellitus : hyperglycaemia , ||| 0-0 1-1 3-1 2-2 3-3 4-4
Diabetes Mellitus : Hyperglykämie , ||| diabetes mellitus : hyperglycaemia , ||| 0-0 1-1 2-2 3-3 4-4
Diabetes Mellitus : Hyperglykämie ||| Diabetes Mellitus : hyperglycaemia ||| 0-0 1-1 3-1 2-2 3-3
Diabetes Mellitus : Hyperglykämie ||| diabetes mellitus : hyperglycaemia ||| 0-0 1-1 2-2 3-3
Diabetes Mellitus : ||| diabetes mellitus : ||| 0-0 1-1 2-2
Diabetes Mellitus ||| diabetes mellitus ||| 0-0 1-1
Diabetes betrug 9,5 Jahre . ||| diabetes was 9.5 years . ||| 0-0 1-1 2-2 3-3 4-4
Diabetes betrug 9,5 Jahre ||| diabetes was 9.5 years ||| 0-0 1-1 2-2 3-3
Diabetes betrug 9,5 ||| diabetes was 9.5 ||| 0-0 1-1 2-2
Diabetes betrug ||| diabetes was ||| 0-0 1-1
Diabetes gegenüber ||| diabetes ||| 0-0
Diabetes in der Familienanamnese . ||| family history of diabetes . ||| 0-0 3-0 1-1 3-1 2-2 0-3 4-4
Diabetes in der Familienanamnese ||| family history of diabetes ||| 0-0 3-0 1-1 3-1 2-2 0-3
Diabetes ist die diätetische Kontrolle ||| diabetes is dietary control ||| 0-0 1-1 2-1 3-2 4-3
Diabetes ist die diätetische ||| diabetes is dietary ||| 0-0 1-1 2-1 3-2
Diabetes ist die ||| diabetes is ||| 0-0 1-1 2-1
Diabetes ist eine Krankheit ||| Diabetes is a disease ||| 0-0 1-1 2-2 3-3
Diabetes ist eine ||| Diabetes is a ||| 0-0 1-1 2-2
Diabetes ist ||| Diabetes is ||| 0-0 1-1
Diabetes mellitus ( siehe Abschnitt ||| diabetes mellitus ( see section ||| 0-0 1-1 2-2 3-3 4-4
Diabetes mellitus ( siehe ||| diabetes mellitus ( see ||| 0-0 1-1 2-2 3-3
Diabetes mellitus ( ||| diabetes mellitus ( ||| 0-0 1-1 2-2
Diabetes mellitus , diabetische Ketoazidose ||| diabetes mellitus , diabetic ketoacidosis ||| 0-0 1-1 2-2 3-3 4-4
Diabetes mellitus , diabetische ||| diabetes mellitus , diabetic ||| 0-0 1-1 2-2 3-3
Diabetes mellitus , ||| diabetes mellitus , ||| 0-0 1-1 2-2
Diabetes mellitus : Hyperglykämie , ||| Diabetes Mellitus : hyperglycaemia , ||| 0-0 3-1 2-2 1-3 3-3 4-4
Diabetes mellitus : Hyperglykämie ||| Diabetes Mellitus : hyperglycaemia ||| 0-0 3-1 2-2 1-3 3-3
Diabetes mellitus und Herzkrankheit ||| diabetes mellitus and heart disease ||| 0-0 1-1 2-2 3-3 3-4
Diabetes mellitus und ||| diabetes mellitus and ||| 0-0 1-1 2-2
Diabetes mellitus ||| diabetes mellitus ||| 0-0 1-1
Diabetes ||| Diabetes ||| 0-0
Diabetes ||| diabetes , ||| 0-0
Diabetes ||| diabetes ||| 0-0
Diabetes ||| type 2 ||| 0-0 0-1
Diabetesmedikament ( Dualtherapie ||| antidiabetic medicine ( ||| 0-0 2-0 0-1 1-2
Diabetesmedikament ) bei Patienten ||| antidiabetic medicine ) in patients ||| 0-0 0-1 1-2 2-3 3-4
Diabetesmedikament ) bei ||| antidiabetic medicine ) in ||| 0-0 0-1 1-2 2-3
Diabetesmedikament ) ||| antidiabetic medicine ) ||| 0-0 0-1 1-2
Diabetesmedikament ||| antidiabetic medicine ||| 0-0 0-1
Diabetesmedikamenten ( Metformin , ||| antidiabetic medicines ( metformin , ||| 0-0 0-1 1-2 2-3 3-4
Diabetesmedikamenten ( Metformin ||| antidiabetic medicines ( metformin ||| 0-0 0-1 1-2 2-3
Diabetesmedikamenten ( ||| antidiabetic medicines ( ||| 0-0 0-1 1-2
Diabetesmedikamenten ||| antidiabetic medicines ||| 0-0 0-1
Diabetische Retinopathie Eine langfristige Verbesserung ||| Diabetic retinopathy Long-term improved glycaemic ||| 0-0 1-1 2-2 3-2 3-3 4-3 4-4
Diabetische Retinopathie Eine langfristige Verbesserung ||| Diabetic retinopathy Long-term improved glycaemic ||| 0-0 1-1 2-2 3-2 3-3 4-4
Diabetische Retinopathie Eine langfristige ||| Diabetic retinopathy Long-term improved ||| 0-0 1-1 2-2 3-2 3-3
Diabetische Retinopathie ||| Diabetic retinopathy ||| 0-0 1-1
Diabetische ||| Diabetic ||| 0-0
Diagnose einer ||| a diagnosis ||| 1-0 0-1
Diagnose ||| diagnosis ||| 0-0
Dialyse ||| dialysis ||| 0-0
Dialysepatienten liegen ||| information is ||| 0-0 1-0 1-1
Diarrhoe ||| diarrhoea ||| 0-0
Dichte . ||| dropper . ||| 0-0 1-1
Dichte ||| dropper ||| 0-0
Dichtung ( Aluminium ) . ||| overseal ( aluminium ) . ||| 0-0 2-0 1-1 1-2 3-3 4-4
Dichtung ( Aluminium ) ||| overseal ( aluminium ) ||| 0-0 2-0 1-1 1-2 3-3
Dichtung ( Aluminium ||| overseal ( aluminium ||| 0-0 2-0 1-1 1-2
Die ABILIFY 10 mg Schmelztabletten ||| ABILIFY 10 mg orodispersible tablets ||| 0-0 1-0 2-1 3-2 4-3 4-4
Die ABILIFY 10 mg ||| ABILIFY 10 mg ||| 0-0 1-0 2-1 3-2
Die ABILIFY 10 ||| ABILIFY 10 ||| 0-0 1-0 2-1
Die ABILIFY 15 mg Schmelztabletten ||| ABILIFY 15 mg orodispersible tablets ||| 0-0 1-0 2-1 3-2 4-3 4-4
Die ABILIFY 15 mg ||| ABILIFY 15 mg ||| 0-0 1-0 2-1 3-2
Die ABILIFY 15 ||| ABILIFY 15 ||| 0-0 1-0 2-1
Die ABILIFY 30 mg Schmelztabletten ||| ABILIFY 30 mg orodispersible tablets ||| 0-0 1-0 2-1 3-2 4-3 4-4
Die ABILIFY 30 mg ||| ABILIFY 30 mg ||| 0-0 1-0 2-1 3-2
Die ABILIFY 30 ||| ABILIFY 30 ||| 0-0 1-0 2-1
Die ABILIFY Injektionslösung ||| The ABILIFY solution for injection ||| 0-0 1-1 2-2 2-3 2-4
Die ABILIFY ||| ABILIFY ||| 0-0 1-0
Die ABILIFY ||| The ABILIFY ||| 0-0 1-1
Die ABILIFY-Dosis sollte ||| ABILIFY dose should be reduced ||| 1-0 0-1 1-1 2-2 2-3 1-4
Die ABILIFY-Dosis sollte ||| ABILIFY dose should be ||| 0-0 1-0 1-1 2-2 2-3
Die ABILIFY-Dosis ||| ABILIFY dose ||| 0-0 1-0 1-1
Die AUC und Cmax von ||| The AUC and Cmax of ||| 0-0 1-1 2-2 3-3 4-4
Die AUC und Cmax ||| The AUC and Cmax ||| 0-0 1-1 2-2 3-3
Die AUC und ||| The AUC and ||| 0-0 1-1 2-2
Die AUC ||| The AUC ||| 0-0 1-1
Die Aclasta-Gruppe wies ||| The Aclasta ||| 0-0 1-1 2-1
Die Adipositas ist eine Erkrankung ||| ( See section ||| 1-0 1-1 4-1
Die Adipositas ist eine Erkrankung ||| ( See ||| 1-0 1-1 4-1
Die Androgenablation wird als ||| Androgen ablation is considered to ||| 0-0 1-0 1-1 2-2 3-3
Die Androgenablation wird als ||| Androgen ablation is considered ||| 0-0 1-0 1-1 2-2 3-3
Die Androgenablation wird ||| Androgen ablation is ||| 0-0 1-0 1-1 2-2
Die Androgenablation ||| Androgen ablation ||| 0-0 1-0 1-1
Die Anfangsdosierung ||| The starting ||| 0-0 1-1
Die Anfangsdosis beträgt 150 ||| The initial dose is 150 ||| 0-0 1-1 1-2 2-3 3-4
Die Anfangsdosis beträgt ||| The initial dose is ||| 0-0 1-1 1-2 2-3
Die Anfangsdosis ||| The initial dose ||| 0-0 1-1 1-2
Die Ansprechraten bei allen ||| The response rates in all ||| 0-0 1-1 1-2 2-3 3-4
Die Ansprechraten bei ||| The response rates in ||| 0-0 1-1 1-2 2-3
Die Ansprechraten ||| The response rates ||| 0-0 1-1 1-2
Die Anwendung bei ||| The use in ||| 0-0 1-1 2-2
Die Anwendung von Abraxane ||| The use of Abraxane ||| 0-0 1-1 2-2 3-3
Die Anwendung von Aclasta bei ||| The use of Aclasta in ||| 0-0 1-1 2-2 3-3 4-4
Die Anwendung von Aclasta ||| The use of Aclasta ||| 0-0 1-1 2-2 3-3
Die Anwendung von ||| The use of ||| 0-0 1-1 2-2
Die Anwendung von ||| from ||| 2-0
Die Anwendung ||| Caution ||| 0-0 1-0
Die Anwendung ||| The use ||| 0-0 1-1
Die Aripiprazol AUC ||| The aripiprazole AUC ||| 0-0 1-1 2-2
Die Aripiprazol ||| The aripiprazole ||| 0-0 1-1
Die Ausscheidung erfolgt rasch und ||| Excretion is rapid and ||| 0-0 1-0 2-1 2-2 3-2 4-3
Die Ausscheidung erfolgt rasch ||| Excretion is rapid ||| 0-0 1-0 2-1 2-2 3-2
Die Ausscheidung ||| Excretion ||| 0-0 1-0
Die Auswirkung einer ||| The effect of ||| 0-0 1-1 2-2
Die Auswirkung ||| The effect ||| 0-0 1-1
Die Behandlung ist Teil ||| The treatment is part of ||| 0-0 1-1 2-2 3-3 3-4
Die Behandlung ist ||| The treatment is ||| 0-0 1-1 2-2
Die Behandlung mit Abseamed kann ||| Treatment with Abseamed may be ||| 0-0 1-0 2-1 3-2 4-3 4-4
Die Behandlung mit Abseamed ||| Treatment with Abseamed ||| 0-0 1-0 2-1 3-2
Die Behandlung mit Pioglitazon kann ||| Pioglitazone may be ||| 0-0 1-0 3-0 4-1 2-2 4-2
Die Behandlung mit einer ||| Treatment with a 5 ||| 0-0 1-0 2-1 3-2
Die Behandlung mit einer ||| Treatment with a ||| 0-0 1-0 2-1 3-2
Die Behandlung mit ||| Treatment with ||| 0-0 1-0 2-1
Die Behandlung sollte nur ||| Treatment should only be ||| 0-0 1-0 2-1 3-2 2-3
Die Behandlung sollte ||| The treatment should be ||| 0-0 1-1 2-2 2-3
Die Behandlung sollte ||| Treatment should be directed ||| 0-0 1-0 2-1 2-2 1-3
Die Behandlung sollte ||| Treatment should consist of ||| 0-0 1-0 2-1 1-2 1-3
Die Behandlung ||| The treatment ||| 0-0 1-1
Die Behandlung ||| Treatment ||| 0-0 1-0
Die Bildung dieser hydroxylierten ||| The formation of these hydroxylated ||| 0-0 1-1 1-2 2-3 3-4
Die Bildung dieser ||| The formation of these ||| 0-0 1-1 1-2 2-3
Die Bildung ||| The formation of ||| 0-0 1-1 1-2
Die Blutzucker ||| The blood glucose ||| 0-0 1-1 1-2
Die Clearance ||| The clearance ||| 0-0 1-1
Die Daten der ||| The data from the ||| 0-0 1-1 1-2 2-3
Die Daten der ||| The data of the ||| 0-0 1-1 2-2 2-3
Die Daten zur Immunogenität bei ||| Immunogenicity data for ||| 0-0 3-0 1-1 2-2 4-2
Die Daten ||| The data from ||| 0-0 1-1 1-2
Die Daten ||| The data ||| 0-0 1-1
Die Dialysemodalitäten müssen daher möglicherweise ||| Dialysis prescriptions may ||| 0-0 1-0 1-1 2-1 3-1 4-1 1-2
Die Differenzen zwischen Cmax und ||| Differences in Cmax and ||| 0-0 1-0 1-1 3-2 2-3 4-3
Die Differenzen ||| Differences in ||| 0-0 1-0 1-1
Die Dosierpipette hat eine ||| The dosing pipette has a ||| 0-0 1-1 1-2 2-3 3-4
Die Dosierpipette hat ||| The dosing pipette has ||| 0-0 1-1 1-2 2-3
Die Dosierpipette ||| The dosing pipette ||| 0-0 1-1 1-2
Die Dosierung sollte ||| The dosage should ||| 0-0 1-1 2-2
Die Dosierung ||| The dosage ||| 0-0 1-1
Die Dosis , die Sie ||| The dose you ||| 0-0 1-1 3-1 2-2 4-2
Die Dosis an ABILIFY ||| The dose of ABILIFY ||| 0-0 1-1 2-2 3-3
Die Dosis an ||| The dose of ||| 0-0 1-1 2-2
Die Dosis kann stufenweise auf ||| The dose may be ||| 0-0 1-1 2-2 3-2 2-3 4-3
Die Dosis von 5 mg ||| The dose of 5 mg ||| 0-0 1-1 2-2 3-3 4-4
Die Dosis von 5 ||| The dose of 5 ||| 0-0 1-1 2-2 3-3
Die Dosis von ||| The dose of ||| 0-0 1-1 2-2
Die Dosis wird so angepasst ||| The dose is adjusted ||| 0-0 1-1 2-2 3-2 4-3
Die Dosis wird so ||| The dose is ||| 0-0 1-1 2-2 3-2
Die Dosis wird ||| The dose is ||| 0-0 1-1 2-2
Die Dosis ||| The dose ||| 0-0 1-1
Die Dosisgabe erfolgt ||| It is given ||| 1-0 0-1 2-1 1-2
Die Durchstechflaschen sind zur Verwendung ||| The vials are for use ||| 0-0 1-1 2-2 3-3 4-4
Die Durchstechflaschen sind zur ||| The vials are for ||| 0-0 1-1 2-2 3-3
Die Durchstechflaschen sind ||| The vials are ||| 0-0 1-1 2-2
Die Durchstechflaschen ||| The vials ||| 0-0 1-1
Die Einführung von angemessenen ||| Introducing appropriate ||| 1-0 3-1
Die Einführung von ||| Introducing ||| 1-0
Die Einführung ||| Introducing ||| 1-0
Die Einnahme von Pioglitazon war ||| Pioglitazone was associated ||| 0-0 1-0 3-0 2-1 4-1 1-2
Die Elimination der Zoledronsäure erfolgt ||| Zoledronic acid is eliminated ||| 0-0 1-0 3-0 3-1 4-2 4-3
Die Elimination der Zoledronsäure ||| Zoledronic acid ||| 0-0 1-0 3-0 3-1
Die Entscheidung , ob die ||| The decision whether to ||| 0-0 1-1 2-2 3-2 4-3
Die Entscheidung , ob ||| The decision whether ||| 0-0 1-1 2-2 3-2
Die Entscheidung für die ||| The decision to administer ||| 0-0 1-1 1-2 1-3 2-3 3-3
Die Entscheidung ||| The decision ||| 0-0 1-1
Die Erfahrung bei Patienten ||| Experience in patients ||| 0-0 1-0 2-1 3-2
Die Erfahrung bei Patienten über ||| Experience in patients over ||| 0-0 1-0 2-1 3-2 4-3
Die Erfahrung bei ||| Experience in ||| 0-0 1-0 2-1
Die Erfahrung ||| Experience ||| 0-0 1-0
Die Erfahrungen ||| Experience ||| 0-0 1-0
Die Erhaltungsdosis beträgt 15 ||| The maintenance dose is 15 ||| 0-0 1-1 1-2 2-3 2-4 3-4
Die Erhaltungsdosis ||| The maintenance dose ||| 0-0 1-1 1-2
Die Fertigspritze im Umkarton ||| Keep the pre-filled syringe in ||| 0-0 3-0 2-1 1-2 2-2 1-3 3-3 2-4
Die Fertigspritzen sind ||| The pre-filled syringes are ||| 0-0 1-1 1-2 2-3
Die Fertigspritzen ||| The pre-filled syringes ||| 0-0 1-1 1-2
Die Frauen ||| Women ||| 1-0
Die Genehmigung wurde ||| The marketing authorisation was ||| 0-0 1-1 1-2 2-3
Die Genehmigung ||| The marketing authorisation ||| 0-0 1-1 1-2
Die Gesamtdosis ABILIFY ||| The total dose of ABILIFY ||| 0-0 1-1 1-2 2-4
Die Gesamtdosis ||| The total dose of ||| 0-0 1-1 1-2
Die Gesamtdosis ||| The total dose ||| 0-0 1-1 1-2
Die Gesamtkonzentration von Pioglitazon im ||| Total plasma concentration of pioglitazone ||| 0-0 1-0 1-1 4-1 1-2 2-3 3-4
Die Gesamtmortalität lag bei 10 ||| cause mortality was 10 ||| 1-1 2-2 3-2 4-3
Die Gesamtmortalität lag bei 10 ||| mortality was 10 ||| 1-0 2-1 3-1 4-2
Die Gesamtmortalität lag bei ||| cause mortality was ||| 1-1 2-2 3-2
Die Gesamtmortalität lag bei ||| mortality was ||| 1-0 2-1 3-1
Die Gesamtmortalität ||| cause mortality ||| 1-1
Die Gesamtmortalität ||| mortality ||| 1-0
Die HOMA-Analyse ||| HOMA analysis ||| 0-0 1-0 1-1
Die Hämoglobinspiegel sollten ||| Haemoglobin levels should be ||| 0-0 1-0 1-1 2-2 2-3
Die Hämoglobinspiegel ||| Haemoglobin levels ||| 0-0 1-0 1-1
Die Häufigkeit der ||| The frequency ||| 0-0 1-1 2-1
Die Häufigkeit der ||| The incidence of ||| 0-0 1-1 2-2
Die Häufigkeit dieser Ereignisse ||| The frequency of these events ||| 0-0 1-1 2-2 2-3 3-4
Die Häufigkeit dieser Symptome ||| The incidence of these symptoms ||| 0-0 1-1 2-2 2-3 3-4
Die Häufigkeit dieser ||| The frequency of these ||| 0-0 1-1 2-2 2-3
Die Häufigkeit dieser ||| The incidence of these ||| 0-0 1-1 2-2 2-3
Die Häufigkeit einer Hypokalzämie war ||| The frequency of hypocalcaemia was ||| 0-0 1-1 2-2 2-3 3-3 4-4
Die Häufigkeit einer Hypokalzämie ||| The frequency of hypocalcaemia ||| 0-0 1-1 2-2 2-3 3-3
Die Häufigkeit von Hüftfrakturen ||| The hip fracture event rate ||| 0-0 1-0 3-1 2-2 3-2 3-3 0-4
Die Häufigkeit von klinischen ||| The incidence of clinical ||| 0-0 1-1 2-2 3-3
Die Häufigkeit von ||| The incidence of ||| 0-0 1-1 2-2
Die Häufigkeit ||| The frequency ||| 0-0 1-1
Die Häufigkeit ||| The incidence ||| 0-0 1-1
Die Häufigkeit ||| The rate ||| 0-0 1-0 0-1
Die Häufigkeiten der ||| 5 The frequency of undesirable ||| 0-1 1-2 2-3 1-4
Die Häufigkeiten der ||| The frequency of undesirable ||| 0-0 1-1 2-2 1-3
Die Häufigkeiten von unerwünschten ||| Frequencies of adverse ||| 0-0 1-0 2-1 3-2
Die Häufigkeiten von ||| Frequencies of ||| 0-0 1-0 2-1
Die Häufigkeiten von Ödemen ||| The oedema rates for ||| 0-0 1-1 3-1 3-2 2-3 3-3
Die Häufigkeiten ||| Frequencies ||| 0-0 1-0
Die Infusion muss unter Berücksichtigung ||| The infusion must be conducted ||| 0-0 1-1 2-2 2-3 4-4
Die Infusion muss unter ||| The infusion must be ||| 0-0 1-1 2-2 2-3
Die Infusion muss ||| The infusion must be ||| 0-0 1-1 2-2 2-3
Die Infusion wird ||| The infusion will ||| 0-0 1-1 2-2
Die Infusion ||| The infusion ||| 0-0 1-1
Die Infusionsdauer ||| The infusion time ||| 0-0 1-1 1-2
Die Injektionen werden in ||| The injections are given in ||| 0-0 1-1 1-2 2-2 1-3 3-4
Die Injektionen werden vorzugsweise entweder ||| The injections are given preferably ||| 0-0 1-1 1-2 2-2 1-3 3-4 4-4
Die Injektionen werden ||| The injections are given ||| 0-0 1-1 1-2 2-2 1-3
Die Injektionsnadel muss ||| The needle should be ||| 0-0 1-1 2-1 2-2 2-3
Die Insulinbehandlung der stillenden Mutter ||| Insulin treatment of the nursing ||| 0-0 1-0 1-1 2-2 2-3 3-4 4-4
Die Insulinbehandlung der ||| Insulin treatment of the ||| 0-0 1-0 1-1 2-2 2-3
Die Insulinbehandlung ||| Insulin treatment ||| 0-0 1-0 1-1
Die Interaktion mit anderen ||| Interaction with receptors other ||| 0-0 1-0 2-1 1-2 3-3
Die Interaktion mit ||| Interaction with receptors ||| 0-0 1-0 2-1 1-2
Die Knochenbiopsien zeigten ||| Bone biopsy results showed ||| 0-0 1-0 1-1 1-2 2-3
Die Knochenbiopsien ||| Bone biopsy results ||| 0-0 1-0 1-1 1-2
Die Knochenhistologie wurde bei ||| Bone histology was evaluated in ||| 0-0 1-0 1-1 2-2 2-3 3-4
Die Knochenhistologie wurde ||| Bone histology was evaluated ||| 0-0 1-0 1-1 2-2 2-3
Die Knochenhistologie ||| Bone histology ||| 0-0 1-0 1-1
Die Korrektur Ihrer Blutarmut ||| The correction of your anaemia ||| 0-0 1-1 2-2 2-3 3-4
Die Korrektur Ihrer ||| The correction of your ||| 0-0 1-1 2-2 2-3
Die Korrektur der Anämie kann ||| Correction for anaemia may ||| 0-0 1-0 1-1 2-2 3-2 4-3
Die Korrektur der Anämie ||| Correction for anaemia ||| 0-0 1-0 1-1 2-2 3-2
Die Korrektur ||| Correction for ||| 0-0 1-0 1-1
Die Korrektur ||| The correction ||| 0-0 1-1
Die Leberenzyme sind bei allen ||| Liver enzymes should be checked ||| 0-0 1-0 1-1 2-2 3-3 2-4 4-4
Die Leberenzyme ||| Liver enzymes ||| 0-0 1-0 1-1
Die Lösung muss ||| The solution should be ||| 0-0 1-1 2-2 2-3
Die Lösung zum Einnehmen enthält ||| The oral solution contains ||| 0-0 2-1 3-1 1-2 4-3
Die Lösung zum Einnehmen ||| The oral solution ||| 0-0 2-1 3-1 1-2
Die Lösung ||| The solution ||| 0-0 1-1
Die Maximaldosis von ||| 13 maximum daily dose of ||| 2-0 0-1 1-1 1-2 1-3 2-4
Die Maximaldosis von ||| 2 maximum daily dose of ||| 2-0 0-1 1-1 1-2 1-3 2-4
Die Maximaldosis von ||| 35 maximum daily dose of ||| 0-1 1-1 1-2 1-3 2-4
Die Maximaldosis von ||| maximum daily dose of ||| 0-0 1-0 1-1 1-2 2-3
Die Maximaldosis ||| 35 maximum daily dose ||| 0-1 1-1 1-2 1-3
Die Maximaldosis ||| maximum daily dose ||| 0-0 1-0 1-1 1-2
Die Mehrzahl der berichteten Fälle ||| The majority of reported cases ||| 0-0 1-1 2-2 3-3 4-4
Die Mehrzahl der berichteten ||| The majority of reported ||| 0-0 1-1 2-2 3-3
Die Mehrzahl der ||| The majority of the ||| 0-0 1-1 2-2 2-3
Die Mehrzahl der ||| The majority of ||| 0-0 1-1 2-2
Die Mehrzahl dieser Symptome trat ||| The majority of these symptoms ||| 0-0 1-1 2-1 2-2 4-2 2-3 3-4
Die Mehrzahl dieser Symptome ||| The majority of these symptoms ||| 0-0 1-1 2-2 2-3 3-4
Die Mehrzahl dieser ||| The majority of these ||| 0-0 1-1 2-2 2-3
Die Mehrzahl ||| The majority ||| 0-0 1-1
Die Metaanalyse der ||| Meta-analysis of overall ||| 0-0 1-0 2-1 1-2
Die Mitgliedsstaaten müssen dafür sorgen ||| The Member States shall ||| 0-0 1-1 1-2 3-2 1-3 4-3
Die Möglichkeit von multipler ||| The possibility of multiple medicinal ||| 0-0 1-1 2-2 3-3 3-4
Die Möglichkeit von ||| The possibility of ||| 0-0 1-1 2-2
Die Möglichkeit ||| The possibility ||| 0-0 1-1
Die Nüchtern- und postprandiale ||| 21 Fasting and postprandial ||| 1-0 0-1 1-1 2-2 3-3
Die Nüchtern- und postprandiale ||| 33 Fasting and postprandial ||| 1-0 0-1 1-1 2-2 3-3
Die Nüchtern- und ||| 21 Fasting and ||| 1-0 0-1 1-1 2-2
Die Nüchtern- und ||| 33 Fasting and ||| 1-0 0-1 1-1 2-2
Die Nüchtern- und ||| Fasting and ||| 0-0 1-0 2-1
Die Nüchtern- ||| 21 Fasting ||| 1-0 0-1 1-1
Die Nüchtern- ||| 33 Fasting ||| 1-0 0-1 1-1
Die Nüchtern- ||| Fasting ||| 0-0 1-0
Die Patienten erhielten ||| The patients received ||| 0-0 1-1 2-2
Die Patienten sollten angewiesen werden ||| ge Patients should be instructed ||| 1-0 0-1 1-1 3-1 2-2 4-3 3-4
Die Patienten sollten auf ||| Patients should be ||| 0-0 1-0 2-1 2-2 3-2
Die Patienten sollten auf ||| patients should be ||| 1-0 0-1 2-1 2-2 3-2
Die Patienten sollten in ||| Patients should be ||| 0-0 1-0 2-1 2-2 3-2
Die Patienten sollten ||| Patients should ||| 0-0 1-0 2-1
Die Patienten wurden ohne vorherige ||| Patients were treated without steroid ||| 0-0 1-0 2-1 2-2 3-3 4-4
Die Patienten wurden ohne ||| Patients were treated without ||| 0-0 1-0 2-1 2-2 3-3
Die Patienten wurden ||| 3 trials ||| 2-1
Die Patienten wurden ||| Patients were treated ||| 0-0 1-0 2-1 2-2
Die Patienten wurden ||| trials ||| 2-0
Die Patienten ||| Patients ||| 0-0 1-0
Die Patienten ||| The patients ||| 0-0 1-1
Die Patrone enthält eine ||| The cartridge contains a ||| 0-0 1-1 2-2 3-3
Die Patrone enthält ||| The cartridge contains ||| 0-0 1-1 2-2
Die Patrone ist ||| The cartridge is made ||| 0-0 1-1 2-2 1-3
Die Patrone ||| The cartridge ||| 0-0 1-1
Die Patronen sind für die ||| The cartridges are designed to ||| 0-0 1-1 2-2 1-3 3-3 4-4
Die Patronen sind für ||| The cartridges are designed ||| 0-0 1-1 2-2 1-3 3-3
Die Pharmakokinetik des ||| The pharmacokinetics of total ||| 0-0 1-1 2-2 0-3
Die Pharmakokinetik von Paclitaxel ||| Pharmacokinetics of paclitaxel ||| 0-0 1-0 2-1 3-2
Die Pharmakokinetik von Rimonabant ||| The pharmacokinetics of rimonabant ||| 0-0 1-1 2-2 3-3
Die Pharmakokinetik von Rimonabant ||| or The pharmacokinetics of rimonabant ||| 0-1 1-2 2-3 3-4
Die Pharmakokinetik von ||| Pharmacokinetics of ||| 0-0 1-0 2-1
Die Pharmakokinetik von ||| The pharmacokinetics of ||| 0-0 1-1 2-2
Die Pharmakokinetik von ||| or The pharmacokinetics of ||| 0-1 1-2 2-3
Die Pharmakokinetik ||| Pharmacokinetics ||| 0-0 1-0
Die Pharmakokinetik ||| The pharmacokinetics ||| 0-0 1-1
Die Pharmakokinetik ||| or The pharmacokinetics ||| 0-1 1-2
Die Pipette ||| The pipette ||| 0-0 1-1
Die Proteinbindung ||| The protein binding ||| 0-0 1-1 1-2
Die Reaktionen klingen gewöhnlich ||| Reactions usually resolve in ||| 0-0 1-0 2-0 3-1 2-2 3-2 3-3
Die Resorption von ||| The absorption of ||| 0-0 1-1 2-2
Die Resorption ||| The absorption ||| 0-0 1-1
Die Rezeptoren sind ebenfalls in ||| also found in ||| 0-0 1-0 2-0 3-0 4-1 4-2
Die Rezeptoren sind ebenfalls ||| also ||| 0-0 1-0 2-0 3-0
Die Rimonabant-Exposition im Steady State ||| Steady state rimonabant lon exposures ||| 0-0 1-0 2-1 3-1 4-1 1-2 3-3 4-4
Die Risikoreduktion betrug 51 ||| The risk reduction was 51 ||| 0-0 1-1 3-2 2-3 3-4
Die Risikoreduktion ||| The risk ||| 0-0 1-1
Die Schmelztablette kann mit ||| The orodispersible tablet can be ||| 0-0 1-1 1-2 2-3 3-3 2-4
Die Schmelztablette ||| The orodispersible tablet ||| 0-0 1-1 1-2
Die Schmelztabletten werden auf die ||| Die Schmelztabletten werden auf die ||| 0-0 1-1 2-2 3-3 4-4
Die Schmelztabletten werden auf ||| Die Schmelztabletten werden auf ||| 0-0 1-1 2-2 3-3
Die Schmelztabletten werden ||| Die Schmelztabletten werden ||| 0-0 1-1 2-2
Die Schmelztabletten ||| Die Schmelztabletten ||| 0-0 1-1
Die Sicherheit der Androgensuppression ||| The safety of androgen suppression ||| 0-0 1-1 2-2 3-3 3-4
Die Sicherheit der ||| The safety of ||| 0-0 1-1 2-2
Die Sicherheit ||| The safety ||| 0-0 1-1
Die Spritzen enthalten 0,3 ml ||| The syringes contain 0.3 ml ||| 0-0 1-1 2-2 3-3 4-4
Die Spritzen enthalten 0,3 ||| The syringes contain 0.3 ||| 0-0 1-1 2-2 3-3
Die Spritzen enthalten 0,4 ml ||| The syringes contain 0.4 ml ||| 0-0 1-1 2-2 3-3 4-4
Die Spritzen enthalten 0,4 ||| The syringes contain 0.4 ||| 0-0 1-1 2-2 3-3
Die Spritzen enthalten 0,5 ml ||| The syringes contain 0.5 ml ||| 0-0 1-1 2-2 3-3 4-4
Die Spritzen enthalten 0,5 ||| The syringes contain 0.5 ||| 0-0 1-1 2-2 3-3
Die Spritzen enthalten 0,6 ml ||| The syringes contain 0.6 ml ||| 0-0 1-1 2-2 3-3 4-4
Die Spritzen enthalten 0,6 ||| The syringes contain 0.6 ||| 0-0 1-1 2-2 3-3
Die Spritzen enthalten 0,7 ml ||| The syringes contain 0.7 ml ||| 0-0 1-1 2-2 3-3 4-4
Die Spritzen enthalten 0,7 ||| The syringes contain 0.7 ||| 0-0 1-1 2-2 3-3
Die Spritzen enthalten 0,8 ml ||| The syringes contain 0.8 ml ||| 0-0 1-1 2-2 3-3 4-4
Die Spritzen enthalten 0,8 ||| The syringes contain 0.8 ||| 0-0 1-1 2-2 3-3
Die Spritzen enthalten 0,9 ml ||| The syringes contain 0.9 ml ||| 0-0 1-1 2-2 3-3 4-4
Die Spritzen enthalten 0,9 ||| The syringes contain 0.9 ||| 0-0 1-1 2-2 3-3
Die Spritzen enthalten 1 ml ||| The syringes contain 1 ml ||| 0-0 1-1 2-2 3-3 4-4
Die Spritzen enthalten 1 ||| The syringes contain 1 ||| 0-0 1-1 2-2 3-3
Die Spritzen enthalten ||| The syringes contain ||| 0-0 1-1 2-2
Die Spritzen sind ||| Syringes are ||| 0-0 1-0 2-1
Die Spritzen ||| Syringes ||| 0-0 1-0
Die Spritzen ||| The syringes ||| 0-0 1-1
Die Steady-State-Pharmakokinetik eines oralen Kontrazeptivums ||| Die Steady-State-Pharmakokinetik eines oralen Kontrazeptivums ||| 0-0 1-1 2-2 1-3 4-4
Die Steady-State-Pharmakokinetik eines oralen ||| Die Steady-State-Pharmakokinetik eines oralen ||| 0-0 1-1 2-2 1-3
Die Steady-State-Pharmakokinetik eines ||| Die Steady-State-Pharmakokinetik eines oralen ||| 0-0 1-1 2-2 1-3
Die Studie war nicht ||| The study was not ||| 0-0 1-1 2-2 3-3
Die Studie war ||| The study was ||| 0-0 1-1 2-2
Die Studie ||| The study ||| 0-0 1-1
Die Studienpopulation hatte ein ||| The study population had an ||| 0-0 1-1 1-2 2-3 3-4
Die Studienpopulation hatte ||| The study population had ||| 0-0 1-1 1-2 2-3
Die Studienpopulation ||| The study population ||| 0-0 1-1 1-2
Die Symptome sind ||| The symptoms are ||| 0-0 1-1 2-2
Die Symptome sind üblicherweise ||| The symptoms are usually ||| 0-0 1-1 2-2 3-3
Die Symptome ||| The symptoms ||| 0-0 1-1
Die Tabletten sind weiß ||| The tablets are white ||| 0-0 1-1 2-2 3-3
Die Tabletten sind ||| The tablets are ||| 0-0 1-1 2-2
Die Tabletten ||| The tablets ||| 0-0 1-1
Die Tagesdosis von Abilify ||| The daily dose of Abilify ||| 0-0 1-1 1-2 2-3 3-4
Die Tagesdosis von ||| The daily dose of ||| 0-0 1-1 1-2 2-3
Die Tagesdosis ||| The daily dose ||| 0-0 1-1 1-2
Die Therapie mit Mitratrapid sollte ||| Mitratapide therapy should be restricted ||| 0-0 3-0 1-1 2-1 4-2 4-3 3-4
Die Unbedenklichkeit und Wirksamkeit von ||| The safety and efficacy of ||| 0-0 1-1 2-2 3-3 4-4
Die Unbedenklichkeit und Wirksamkeit ||| The safety and efficacy ||| 0-0 1-1 2-2 3-3
Die Unbedenklichkeit und ||| The safety and ||| 0-0 1-1 2-2
Die Unbedenklichkeit ||| The safety ||| 0-0 1-1
Die Verabreichung von Mitratapid ||| of mitratapide ||| 0-0 1-0 2-0 3-1
Die Verabreichung von ||| of ||| 0-0 1-0 2-0
Die Veränderungen des HDL-Cholesterins und ||| Changes in HDL-C and ||| 1-0 1-1 2-1 3-2 4-3
Die Veränderungen des HDL-Cholesterins ||| Changes in HDL-C ||| 1-0 1-1 2-1 3-2
Die Veränderungen des ||| Changes in ||| 1-0 1-1 2-1
Die Vitamin-D-Spiegel ||| D levels ||| 1-0 0-1 1-1
Die Vorbereitung ||| Aseptic techniques ||| 0-0 1-0 1-1
Die Wirksamkeit und Unbedenklichkeit von ||| The efficacy and safety of ||| 0-0 1-1 2-2 3-3 4-4
Die Wirksamkeit und Unbedenklichkeit ||| The efficacy and safety ||| 0-0 1-1 2-2 3-3
Die Wirksamkeit und ||| The efficacy and ||| 0-0 1-1 2-2
Die Wirksamkeit von Abraxane ||| The effectiveness of Abraxane ||| 0-0 1-1 2-2 3-3
Die Wirksamkeit von ||| The effectiveness of ||| 0-0 1-1 2-2
Die Wirksamkeit ||| The effectiveness ||| 0-0 1-1
Die Wirksamkeit ||| The efficacy ||| 0-0 1-1
Die Wirkstoffexposition ( AUC ||| The drug exposure ( AUC ||| 0-0 1-1 1-2 2-3 3-4
Die Wirkstoffexposition ( ||| The drug exposure ( ||| 0-0 1-1 1-2 2-3
Die Wirkstoffexposition ||| The drug exposure ||| 0-0 1-1 1-2
Die Wirkung beginnt innerhalb von ||| Onset of action is within ||| 0-0 1-0 2-0 4-1 2-2 2-3 3-4 4-4
Die Wirkung der Infusion ||| The effect of the infusion ||| 0-0 1-1 2-2 2-3 3-4
Die Wirkung der ||| The effect of the ||| 0-0 1-1 2-2 2-3
Die Wirkung von Abraxane ( ||| The effects of Abraxane ( ||| 0-0 1-1 2-2 3-3 4-4
Die Wirkung von Abraxane ||| The effects of Abraxane ||| 0-0 1-1 2-2 3-3
Die Wirkung von Pioglitazon ( ||| The effect of pioglitazone ( ||| 0-0 1-1 2-2 3-3 4-4
Die Wirkung von Pioglitazon ||| The effect of pioglitazone ||| 0-0 1-1 2-2 3-3
Die Wirkung von ||| The effect of ||| 0-0 1-1 2-2
Die Wirkung von ||| The effects of ||| 0-0 1-1 2-2
Die Wirkung ||| The effect ||| 0-0 1-1
Die Wirkung ||| The effects ||| 0-0 1-1
Die Wirkungen von ACOMPLIA wurden ||| The effects of ACOMPLIA were ||| 0-0 1-1 2-2 3-3 4-4
Die Wirkungen von ACOMPLIA ||| The effects of ACOMPLIA ||| 0-0 1-1 2-2 3-3
Die Wirkungen von Abraxane wurden ||| The effects of Abraxane were ||| 0-0 1-1 2-2 3-3 4-4
Die Wirkungen von Abraxane ||| The effects of Abraxane ||| 0-0 1-1 2-2 3-3
Die Wirkungen von Pioglitazon werden ||| 9 Pioglitazone effects may be ||| 3-0 0-1 3-1 1-2 2-2 1-3 4-4
Die Wirkungen von Pioglitazon werden ||| Pioglitazone effects may be ||| 0-0 3-0 1-1 1-2 2-2 4-3
Die Wirkungen von Pioglitazon ||| 9 Pioglitazone effects may ||| 3-0 0-1 3-1 1-2 2-2 1-3
Die Wirkungen von Pioglitazon ||| Pioglitazone effects may ||| 0-0 3-0 1-1 1-2 2-2
Die Wirkungen von ||| The effects of ||| 0-0 1-1 2-2
Die Wirkungen ||| The effects ||| 0-0 1-1
Die Zeit bis ||| Die ||| 0-0
Die Zeit ||| Die ||| 0-0
Die Zubereitung ||| Aseptic techniques ||| 0-0 1-0 1-1
Die Zyklen wurden ||| Cycles were ||| 0-0 1-0 2-1
Die Zyklen ||| Cycles ||| 0-0 1-0
Die absolute Bioverfügbarkeit von ||| The absolute bioavailability of ||| 0-0 1-1 2-2 3-3
Die absolute Bioverfügbarkeit ||| The absolute bioavailability ||| 0-0 1-1 2-2
Die absolute orale Bioverfügbarkeit ||| The absolute oral bioavailability of ||| 0-0 1-1 2-2 3-3 3-4
Die absolute orale ||| The absolute oral ||| 0-0 1-1 2-2
Die absolute ||| The absolute ||| 0-0 1-1
Die beobachtete mittlere Besserung vom ||| The observed mean improvement from ||| 0-0 1-1 2-2 3-3 4-4
Die beobachtete mittlere Besserung ||| The observed mean improvement ||| 0-0 1-1 2-2 3-3
Die beobachtete mittlere ||| The observed mean ||| 0-0 1-1 2-2
Die beobachtete ||| The observed ||| 0-0 1-1
Die biologische Wirksamkeit von Epoetin ||| The biological efficacy of epoetin ||| 0-0 1-1 2-2 3-3 4-4
Die biologische Wirksamkeit von ||| The biological efficacy of ||| 0-0 1-1 2-2 3-3
Die biologische Wirksamkeit ||| The biological efficacy ||| 0-0 1-1 2-2
Die biologische ||| The biological ||| 0-0 1-1
Die chemische und physikalische ||| However , chemical and physical ||| 1-0 0-2 1-2 3-2 2-3 3-4
Die chemische und physikalische ||| However chemical and physical ||| 1-0 0-1 1-1 3-1 2-2 3-3
Die dem Injektionssystem beiliegende ||| Detailed instruction accompanying the ||| 0-0 2-0 2-1 1-2 2-2 3-2 3-3
Die empfohlene Anfangsdosis beträgt ||| The recommended starting dose is ||| 0-0 1-1 2-2 2-3 3-4
Die empfohlene Anfangsdosis für ||| The recommended initial dose for ||| 0-0 1-1 2-2 2-3 3-4
Die empfohlene Anfangsdosis für ||| The recommended starting dose for ||| 0-0 1-1 2-2 2-3 3-4
Die empfohlene Anfangsdosis ||| The recommended initial dose ||| 0-0 1-1 2-2 2-3
Die empfohlene Anfangsdosis ||| The recommended starting dose ||| 0-0 1-1 2-2 2-3
Die empfohlene Dosierung beträgt 600 ||| The recommended dose is 600 ||| 0-0 1-1 2-2 3-3 2-4 3-4 4-4
Die empfohlene Dosis für Abraxane ||| The recommended dose of Abraxane ||| 0-0 1-1 2-2 3-3 4-4
Die empfohlene Dosis für ||| The recommended dose of ||| 0-0 1-1 2-2 3-3
Die empfohlene Dosis ist eine ||| The recommended dose is a ||| 0-0 1-1 2-2 3-3 4-4
Die empfohlene Dosis ist ||| The recommended dose is ||| 0-0 1-1 2-2 3-3
Die empfohlene Dosis ||| The recommended dose of ||| 0-0 1-1 2-2
Die empfohlene Dosis ||| The recommended dose ||| 0-0 1-1 2-2
Die empfohlene wöchentliche Dosis ||| The recommended weekly dose ||| 0-0 1-1 2-2 3-3
Die empfohlene wöchentliche Gesamtdosis ||| The recommended total weekly dose ||| 0-0 1-1 2-2 3-2 2-3 3-4
Die empfohlene wöchentliche ||| The recommended weekly ||| 0-0 1-1 2-2
Die empfohlene ||| The recommended ||| 0-0 1-1
Die erhöhte ||| The increased ||| 0-0 1-1
Die folgenden Informationen sind ||| The following information is ||| 0-0 1-1 2-2 3-2 2-3
Die folgenden Nebenwirkungen traten ||| The following undesirable effects occurred ||| 0-0 1-1 2-2 3-2 2-3 3-4
Die folgenden Nebenwirkungen traten ||| The following undesirable effects occurred ||| 0-0 1-1 3-2 2-3 3-4
Die folgenden Reaktionen ||| The following reactions ||| 0-0 1-1 2-2
Die folgenden unerwünschten Ereignisse ||| The following adverse events ||| 0-0 1-1 2-2 3-3
Die folgenden unerwünschten ||| The following adverse ||| 0-0 1-1 2-2
Die folgenden ||| The following ||| 0-0 1-1
Die frühen Verteilungsphasen ( ||| The early disposition phases ( ||| 0-0 1-1 2-2 2-3 3-4
Die frühen Verteilungsphasen ||| The early disposition phases ||| 0-0 1-1 2-2 2-3
Die frühen ||| The early ||| 0-0 1-1
Die geeignete Dosis für Patientinnen ||| The appropriate doses for patients ||| 0-0 1-1 2-1 2-2 3-3 4-4
Die geeignete Dosis für ||| The appropriate dose regimen ||| 0-0 1-1 2-2 0-3
Die geeignete Dosis für ||| The appropriate doses for ||| 0-0 1-1 2-1 2-2 3-3
Die geeignete Dosis ||| The appropriate dose regimen ||| 0-0 1-1 2-2 0-3
Die geeignete Dosis ||| The appropriate doses ||| 0-0 1-1 2-1 2-2
Die gewöhnliche Dosis beträgt zwischen ||| The usual dose is between ||| 0-0 1-1 2-2 3-3 4-4
Die gewöhnliche Dosis beträgt ||| The usual dose is ||| 0-0 1-1 2-2 3-3
Die gewöhnliche Dosis ||| The usual dose ||| 0-0 1-1 2-2
Die gewöhnliche ||| The usual ||| 0-0 1-1
Die gleichzeitige Anwendung von injizierbaren ||| Simultaneous administration of injectable ||| 0-0 1-0 1-1 2-1 3-2 4-3
Die gleichzeitige Anwendung von ||| Simultaneous administration of ||| 0-0 1-0 1-1 2-1 3-2
Die gleichzeitige Anwendung ||| Co- administration ||| 0-0 1-0 1-1 2-1
Die gleichzeitige Anwendung ||| Co-administration ||| 0-0 1-0 2-0
Die gleichzeitige Anwendung ||| Concomitant administration ||| 0-0 1-0 1-1 2-1
Die gleichzeitige Anwendung ||| Simultaneous administration ||| 0-0 1-0 1-1 2-1
Die gleichzeitige Verabreichung von CYP3A4-Induktoren ||| Concomitant administration of CYP3A4 inducers ||| 0-0 1-0 2-1 3-2 4-3 4-4
Die gleichzeitige Verabreichung von ||| Concomitant administration of ||| 0-0 1-0 1-1 2-1 3-2
Die gleichzeitige Verabreichung von ||| Concomitant administration of ||| 0-0 1-0 2-1 3-2
Die gleichzeitige Verabreichung ||| Concomitant administration ||| 0-0 1-0 1-1 2-1
Die gleichzeitige Verabreichung ||| Concomitant administration ||| 0-0 1-0 2-1
Die gleichzeitige ||| Concomitant ||| 0-0 1-0
Die glykämische ||| The rate of ||| 0-0 1-1 1-2
Die histomorphometrische Analyse zeigte eine ||| Histomorphometric analysis showed a ||| 0-0 1-0 2-1 1-2 3-2 4-3
Die histomorphometrische Analyse zeigte ||| Histomorphometric analysis showed ||| 0-0 1-0 2-1 1-2 3-2
Die häufigste Nebenwirkung ||| The most frequent adverse reaction ||| 0-0 1-1 1-2 2-2 2-3 2-4
Die häufigsten Nebenwirkungen im Zusammenhang ||| The most common side effects ||| 0-0 1-1 1-2 2-3 3-3 4-3 2-4
Die häufigsten Nebenwirkungen von ||| The most common side effects ||| 0-0 1-1 1-2 2-3 2-4
Die häufigsten Nebenwirkungen ||| The most common side effects ||| 0-0 1-1 1-2 2-3 2-4
Die häufigsten ||| The most common ||| 0-0 1-1 1-2
Die höchste Exposition in ||| The highest nontumorigenic exposure in ||| 0-0 1-1 1-2 2-2 3-2 2-3 3-4
Die höchste ||| The highest ||| 0-0 1-1
Die inter- bzw. intraindividuelle Variation ||| The inter- and intra-subject variation ||| 0-0 1-1 2-2 3-3 4-3 4-4
Die inter- bzw. ||| The inter- and ||| 0-0 1-1 2-2
Die inter- ||| The inter- ||| 0-0 1-1
Die intrinsische Clearance ist daher ||| Intrinsic clearance is therefore ||| 0-0 1-0 2-1 3-2 4-3
Die intrinsische Clearance ist ||| Intrinsic clearance is ||| 0-0 1-0 2-1 3-2
Die intrinsische Clearance ||| Intrinsic clearance ||| 0-0 1-0 2-1
Die intrinsische ||| Intrinsic ||| 0-0 1-0
Die klinische Relevanz dieser ||| The clinical relevance of these ||| 0-0 1-1 2-2 3-3 3-4
Die klinische Relevanz ||| The clinical relevance ||| 0-0 1-1 2-2
Die klinische ||| The clinical ||| 0-0 1-1
Die lokale Sicherheit von Vantas ||| The local safety of Vantas ||| 0-0 1-1 2-2 3-3 4-4
Die lokale Sicherheit von ||| The local safety of ||| 0-0 1-1 2-2 3-3
Die lokale Sicherheit ||| The local safety ||| 0-0 1-1 2-2
Die lokale ||| The local ||| 0-0 1-1
Die maximale Dosis sollte ||| The maximum dose should ||| 0-0 1-1 2-2 3-3
Die maximale Dosis ||| The maximum dose ||| 0-0 1-1 2-2
Die maximale Tagesdosis sollte ||| The maximum daily dose should ||| 0-0 1-1 2-2 2-3 3-4
Die maximale Tagesdosis ||| The maximum daily dose ||| 0-0 1-1 2-2 2-3
Die maximale ||| Die maximale Tagesdosis ||| 0-0 1-1 1-2
Die maximale ||| The maximum ||| 0-0 1-1
Die mediane Zeit bis zum ||| The median time to ||| 0-0 1-1 3-1 2-2 4-2 3-3
Die meisten Nebenwirkungen von Aclasta ||| Most side effects with Aclasta ||| 1-0 2-1 2-2 3-3 4-4
Die meisten Nebenwirkungen von ||| Most side effects with ||| 1-0 2-1 2-2 3-3
Die meisten Nebenwirkungen ||| Most side effects ||| 1-0 2-1 2-2
Die meisten ||| Most ||| 1-0
Die mittlere Gesamt-Clearance betrug ||| The mean total clearance was ||| 0-0 1-1 2-2 2-3 3-4
Die mittlere Gesamt-Clearance ||| The mean total clearance ||| 0-0 1-1 2-2 2-3
Die mittlere Plasma-Eliminationshalbwertszeit ||| The mean plasma elimination half-life ||| 0-0 1-1 2-2 2-3 2-4
Die mittlere ||| The mean ||| 0-0 1-1
Die pharmakokinetischen Eigenschaften von Aripiprazol ||| The pharmacokinetic characteristics of aripiprazole ||| 0-0 1-1 2-2 3-3 4-4
Die pharmakokinetischen Eigenschaften von Insulinprodukten ||| The pharmacokinetics of insulin products ||| 0-0 1-1 2-1 2-2 3-2 4-3 4-4
Die pharmakokinetischen Eigenschaften von ||| The pharmacokinetic characteristics of ||| 0-0 1-1 2-2 3-3
Die pharmakokinetischen Eigenschaften von ||| The pharmacokinetics of ||| 0-0 1-1 2-1 2-2 3-2
Die pharmakokinetischen Eigenschaften ||| The pharmacokinetic characteristics ||| 0-0 1-1 2-2
Die pharmakokinetischen Parameter ||| The pharmacokinetic parameters ||| 0-0 1-1 2-2
Die pharmakokinetischen ||| The pharmacokinetic ||| 0-0 1-1
Die potenziell medizinisch ernsten Anzeichen ||| The potentially medically serious signs ||| 0-0 1-1 2-2 3-2 3-3 4-4
Die potenziell medizinisch ernsten ||| The potentially medically serious ||| 0-0 1-1 2-2 3-2 3-3
Die potenziell ||| The potentially ||| 0-0 1-1
Die rekonstituierte Suspension hat einen ||| The reconstituted suspension has a ||| 0-0 1-1 2-2 3-3 4-4
Die rekonstituierte Suspension hat ||| The reconstituted suspension has ||| 0-0 1-1 2-2 3-3
Die rekonstituierte Suspension ||| The reconstituted suspension ||| 0-0 1-1 2-2
Die rekonstituierte ||| The reconstituted ||| 0-0 1-1
Die richtige Menge ||| The correct amount ||| 0-0 1-1 2-2
Die richtige ||| The correct ||| 0-0 1-1
Die sonstigen Bestandteile sind : ||| The other ingredients are disodium ||| 0-0 1-1 1-2 2-2 3-3 2-4 4-4
Die sonstigen Bestandteile sind : ||| The other ingredients are lactose ||| 0-0 1-1 1-2 2-2 3-3 1-4 4-4
Die sonstigen Bestandteile sind Mannitol ||| The other ingredients are mannitol ||| 0-0 1-1 1-2 2-2 3-3 4-4
Die sonstigen Bestandteile sind ||| The other ingredients are ||| 0-0 1-1 1-2 2-2 3-3
Die sonstigen Bestandteile ||| The other ingredients ||| 0-0 1-1 1-2 2-2
Die sonstigen ||| The other ingredients ||| 0-0 1-1 1-2
Die subkutane Injektion in ||| Subcutaneous injection into ||| 0-0 1-0 2-1 1-2 3-2
Die terminale Halbwertszeit ( t½ ||| The terminal half-life ( t½ ||| 0-0 1-1 2-2 3-3 4-4
Die terminale Halbwertszeit ( ||| The terminal half-life ( ||| 0-0 1-1 2-2 3-3
Die terminale Halbwertszeit wird ||| The terminal half-life is determined ||| 0-0 1-1 2-2 3-3 1-4
Die terminale Halbwertszeit wird ||| The terminal half-life is determined ||| 0-0 1-1 2-2 3-3 1-4 3-4
Die terminale Halbwertszeit ||| The terminal half-life ||| 0-0 1-1 2-2
Die terminale ||| The terminal ||| 0-0 1-1
Die therapeutische Breite von Epoetin ||| The therapeutic margin of epoetin ||| 0-0 1-1 2-2 3-3 4-4
Die therapeutische Breite von ||| The therapeutic margin of ||| 0-0 1-1 2-2 3-3
Die therapeutische Breite ||| The therapeutic margin ||| 0-0 1-1 2-2
Die therapeutische ||| The therapeutic ||| 0-0 1-1
Die vier Kohlenhydratketten sind ||| The four carbohydrate chains are ||| 0-0 1-1 2-2 2-3 3-4
Die vier Kohlenhydratketten ||| The four carbohydrate chains ||| 0-0 1-1 2-2 2-3
Die vier ||| The four ||| 0-0 1-1
Die vollständige Auflistung der ||| For a full list ||| 0-0 1-0 1-1 1-2 2-2 2-3 3-3
Die vollständige Auflistung der ||| For the full list of ||| 0-0 1-0 3-1 1-2 2-2 2-3 3-3 3-4
Die weißen , runden Tabletten ||| The white , round tablets ||| 0-0 1-1 2-2 3-3 4-4
Die weißen , runden ||| The white , round ||| 0-0 1-1 2-2 3-3
Die weißen , ||| The white , ||| 0-0 1-1 2-2
Die weißen ||| The white ||| 0-0 1-1
Die wichtigste ||| The most ||| 0-0 1-1
Die ||| 5 The ||| 0-1
Die ||| Die ||| 0-0
Die ||| Elderly ||| 0-0
Die ||| For ||| 0-0
Die ||| In ||| 0-0
Die ||| The dosing ||| 0-0 0-1
Die ||| The ||| 0-0
Die ||| Treatment with ||| 0-0
Die ||| Treatment ||| 0-0
Die ||| is ||| 0-0
Die ||| or The ||| 0-1
Die ||| recovery in all cases ||| 0-0
Die ||| recovery in all ||| 0-0
Die ||| recovery in ||| 0-0
Die ||| recovery ||| 0-0
Die Ödeme waren in der ||| The reports of oedema were ||| 0-0 1-1 3-2 4-2 1-3 2-4
Die übliche Anfangsdosis ist ||| The usual starting dose is ||| 0-0 1-1 2-2 2-3 3-4
Die übliche Anfangsdosis ||| The usual starting dose ||| 0-0 1-1 2-2 2-3
Die übliche Dosis beträgt 9,75 ||| The usual dose is 9.75 ||| 0-0 1-1 2-2 3-3 4-4
Die übliche Dosis beträgt ||| The usual dose is ||| 0-0 1-1 2-2 3-3
Die übliche Dosis ist 15 ||| The usual dose is 15 ||| 0-0 1-1 2-2 3-3 4-4
Die übliche Dosis ist 5 ||| The usual dose is 5 ||| 0-0 1-1 2-2 3-3 4-4
Die übliche Dosis ist ||| The usual dose is ||| 0-0 1-1 2-2 3-3
Die übliche Dosis ||| The usual dose ||| 0-0 1-1 2-2
Die übliche ||| The usual ||| 0-0 1-1
Dies bedeutet , dass Aripiprazol ||| This means that aripiprazole ||| 0-0 1-1 2-2 3-2 4-3
Dies bedeutet , dass ||| This means that ||| 0-0 1-1 2-2 3-2
Dies bedeutet ||| This means ||| 0-0 1-1
Dies dient zur ||| This is to check that ||| 0-0 1-1 1-2 1-3 2-3 1-4
Dies entspricht ||| This corresponds to ||| 0-0 1-1 1-2
Dies führt zur Blockierung ||| This results in blockage ||| 0-0 1-1 1-2 2-2 3-3
Dies führt zur ||| This results in ||| 0-0 1-1 1-2 2-2
Dies führte jedoch nicht ||| However , this did not ||| 0-0 2-0 2-1 1-2 1-3 2-3 3-4
Dies führte jedoch ||| However , this did ||| 0-0 2-0 2-1 1-2 1-3 2-3
Dies geschieht hauptsächlich über das ||| This is predominantly via ||| 0-0 1-1 1-2 2-2 1-3 3-3 4-3
Dies ist besonders wichtig bei ||| This is especially important for ||| 0-0 1-1 2-2 3-3 4-4
Dies ist besonders wichtig bei ||| This is especially important in ||| 0-0 1-1 2-2 3-3 4-4
Dies ist besonders wichtig ||| This is especially important ||| 0-0 1-1 2-2 3-3
Dies ist besonders ||| This is especially ||| 0-0 1-1 2-2
Dies ist vergleichbar mit der ||| This is similar to ||| 0-0 1-1 2-2 4-3
Dies ist vergleichbar mit ||| This is similar ||| 0-0 1-1 2-2
Dies ist vergleichbar ||| This is similar ||| 0-0 1-1 2-2
Dies ist zu berücksichtigen bei ||| To be taken into ||| 0-0 1-1 2-1 0-2 3-3 4-3
Dies ist zu ||| To be taken ||| 0-0 1-1 2-1 0-2
Dies ist ||| This is ||| 0-0 1-1
Dies kann ||| This may constitute ||| 0-0 1-1 0-2 1-2
Dies können Warnsignale ||| These may be the warning ||| 2-0 0-1 1-1 1-2 2-4
Dies können ||| may be the ||| 0-0 1-0 1-1
Dies können ||| may be ||| 0-0 1-0 1-1
Dies stellt eine ||| This represents a ||| 0-0 1-1 2-2
Dies stellt ||| This represents ||| 0-0 1-1
Dies wird helfen , Sie ||| This will help ||| 0-0 1-1 4-1 2-2 3-2
Dies wird man mit ||| You will receive appropriate training ||| 0-0 0-1 1-1 2-2 2-3 2-4
Dies wird man ||| You will receive appropriate training ||| 0-0 0-1 1-1 2-2 2-3 2-4
Dies wird ||| You will ||| 0-0 0-1 1-1
Dies ||| 46 ||| 0-0
Dies ||| This can be ||| 0-0 0-1 0-2
Dies ||| This ||| 0-0
Diese Beobachtung wurde klinisch durch ||| Diese Beobachtung wurde klinisch durch ||| 0-0 1-1 2-2 1-3 4-4
Diese Beobachtung wurde klinisch ||| Diese Beobachtung wurde klinisch ||| 0-0 1-1 2-2 1-3
Diese Beobachtung wurde ||| Diese Beobachtung wurde klinisch ||| 0-0 1-1 2-2 1-3
Diese Berichte stützen sich auf ||| These reports are based on ||| 0-0 1-1 2-1 2-2 2-3 3-3 4-4
Diese Berichte stützen sich ||| These reports are based ||| 0-0 1-1 2-1 2-2 2-3 3-3
Diese Daten basieren auf dem ||| This data is based on ||| 0-0 1-1 4-2 2-3 3-4 4-4
Diese Daten ||| This data ||| 0-0 1-1
Diese Diabetesform tritt ||| This is the diabetes ||| 0-0 1-0 1-1 1-2 1-3 2-3
Diese Dosis sollte jedoch ||| but this dose should be ||| 3-0 0-1 1-2 2-3 2-4
Diese Dosis sollte ||| this dose should be ||| 0-0 1-1 2-2 2-3
Diese Dosis wird dreimal ||| This is given 3 ||| 0-0 1-0 2-1 2-2 3-3
Diese Dosis wird zweimal ||| This is given 2 ||| 0-0 1-0 2-1 3-2 3-3
Diese Dosis wird zweimal ||| This is given twice ||| 0-0 1-0 2-1 3-2 3-3
Diese Dosis wird ||| This is given ||| 0-0 1-0 2-1 2-2
Diese Dosis wird ||| This is ||| 0-0 1-0 2-1
Diese Dosis ||| This ||| 0-0 1-0
Diese Dosis ||| this dose ||| 0-0 1-1
Diese Ergebnisse standen im ||| These results were ||| 0-0 1-1 2-1 3-2
Diese Ergebnisse standen ||| These results ||| 0-0 1-1 2-1
Diese Fertigpens dürfen nur zusammen ||| Pens should only be ||| 0-0 1-0 2-0 4-0 2-1 3-2 3-3
Diese Folgeerscheinungen wurden mit ||| as measured ||| 1-0 0-1 1-1 2-1
Diese Folgeerscheinungen wurden ||| as measured ||| 1-0 0-1 1-1 2-1
Diese Gebrauchsinformation wurde zuletzt ||| This leaflet was last ||| 0-0 1-1 2-2 3-3
Diese Gebrauchsinformation wurde zuletzt ||| This leaflet ||| 0-0 1-1 2-1 3-1
Diese Gebrauchsinformation wurde ||| 197 This leaflet was ||| 0-0 0-1 1-2 2-3
Diese Gebrauchsinformation wurde ||| This leaflet was ||| 0-0 1-1 2-2
Diese Gebrauchsinformation ||| 197 This leaflet ||| 0-0 0-1 1-2
Diese Gebrauchsinformation ||| This leaflet ||| 0-0 1-1
Diese Maßnahme hilft , die ||| These measures will help to ||| 0-0 1-1 2-2 2-3 3-4 4-4
Diese Maßnahme hilft die ||| These measures will help ||| 0-0 1-1 2-2 2-3 3-3
Diese Maßnahme hilft ||| These measures will help ||| 0-0 1-1 2-2 2-3
Diese Maßnahme ||| These measures ||| 0-0 1-1
Diese Maßnahmen dienen ||| These measures should help to ||| 0-0 1-1 1-2 2-3 2-4
Diese Maßnahmen ||| These measures should ||| 0-0 1-1 1-2
Diese Nebenwirkungen treten ||| These may be more common ||| 0-0 2-3 1-4 2-4
Diese Patienten ||| and such patients ||| 0-1 1-2
Diese Patienten ||| such patients ||| 0-0 1-1
Diese Reaktionen sind gewöhnlich vorübergehend ||| Most reactions are transitory ||| 0-0 1-1 2-2 3-3 4-3
Diese Reaktionen sind ||| Most reactions are ||| 0-0 1-1 2-2
Diese Reaktionen ||| Most reactions ||| 0-0 1-1
Diese Stabilisierung führt ||| This stability results in ||| 0-0 1-1 2-2 2-3
Diese Stabilisierung ||| This stability ||| 0-0 1-1
Diese Studien beinhalteten Patienten mit ||| These trials included patients with ||| 0-0 1-1 2-2 3-3 4-4
Diese Studien beinhalteten Patienten ||| These trials included patients ||| 0-0 1-1 2-2 3-3
Diese Studien beinhalteten ||| These trials included ||| 0-0 1-1 2-2
Diese Studien ||| Diese Studien ||| 0-0 0-1 1-1
Diese Studien ||| These trials ||| 0-0 1-1
Diese Wirkung hielt ||| This effect was maintained ||| 0-0 1-1 2-2 2-3
Diese Wirkung ||| This effect ||| 0-0 1-1
Diese Wirkungen waren ||| These effects were ||| 0-0 1-1 2-2
Diese Wirkungen ||| These effects ||| 0-0 1-1
Diese ist ||| This is ||| 0-0 1-1
Diese multizentrische Studie wurde ||| This multi-centre trial was ||| 0-0 1-1 2-2 3-3
Diese multizentrische Studie ||| This multi-centre trial ||| 0-0 1-1 2-2
Diese multizentrische ||| This multi-centre ||| 0-0 1-1
Diese verbesserte ||| The improved ||| 1-0 0-1 1-1
Diese ||| 197 This ||| 0-0 0-1
Diese ||| Diese ||| 0-0
Diese ||| Most ||| 0-0
Diese ||| These may be ||| 0-0
Diese ||| These may ||| 0-0
Diese ||| These ||| 0-0
Diese ||| This ||| 0-0
Diese ||| and such ||| 0-1
Diese ||| such ||| 0-0
Diese ||| this ||| 0-0
Dieser ist bei fortgesetzter ||| This regresses during the course ||| 0-0 0-1 1-1 2-2 3-2 3-3 3-4
Dieser ist ||| This regresses ||| 0-0 0-1 1-1
Dieser sollte ||| The rate of ||| 0-0 0-1 1-1
Dieser sollte ||| The rate ||| 0-0 0-1 1-1
Dieses Ansprechen war definiert als ||| This was defined as the ||| 0-0 1-1 2-1 3-2 4-3
Dieses Ansprechen war definiert als ||| This was defined as ||| 0-0 1-1 2-1 3-2 4-3
Dieses Ansprechen war definiert ||| This was defined ||| 0-0 1-1 2-1 3-2
Dieses Ansprechen war ||| This was ||| 0-0 1-1 2-1
Dieses Arzneimittel darf ||| This medicinal product must ||| 0-0 1-1 1-2 2-3
Dieses Arzneimittel enthält ||| This medicinal product contains ||| 0-0 1-1 1-2 2-3
Dieses Arzneimittel wurde ||| This medicine has been ||| 0-0 1-1 2-2 2-3
Dieses Arzneimittel ||| This medicinal product ||| 0-0 0-1 1-2
Dieses Arzneimittel ||| This medicinal product ||| 0-0 1-1 1-2
Dieses Arzneimittel ||| This medicinal ||| 0-0 1-1
Dieses Arzneimittel ||| This medicine ||| 0-0 1-1
Dieses Risiko sollte ||| This risk should be ||| 0-0 1-1 2-2 2-3
Dieses Risiko ||| This risk ||| 0-0 1-1
Dieses ||| This medicinal ||| 0-0 0-1
Dieses ||| This ||| 0-0
Differenz in ||| difference in ||| 0-0 1-1
Differenz zu Placebo -2,9 kg ||| difference to placebo -2.9 kg ||| 0-0 1-1 2-2 3-3 4-4
Differenz zu Placebo -2,9 ||| difference to placebo -2.9 ||| 0-0 1-1 2-2 3-3
Differenz zu Placebo ||| difference to placebo ||| 0-0 1-1 2-2
Differenz zu ||| difference to ||| 0-0 1-1
Differenz ||| Difference ||| 0-0
Differenz ||| difference ||| 0-0
Differenzierungshormon die Bildung ||| differentiating hormone , the formation ||| 0-0 0-1 1-2 1-3 2-4
Differenzierungshormon die ||| differentiating hormone , the ||| 0-0 0-1 1-2 1-3
Differenzierungshormon ||| differentiating hormone ||| 0-0 0-1
Digoxin , Warfarin , ||| digoxin , warfarin , ||| 0-0 1-1 2-2 3-3
Digoxin , Warfarin ||| digoxin , warfarin ||| 0-0 1-1 2-2
Digoxin , ||| digoxin , ||| 0-0 1-1
Digoxin ||| digoxin ||| 0-0
Dinatriumedetat , Fructose ||| edetate , fructose , ||| 2-0 0-1 1-1 2-2 1-3
Diphenhydramin ||| dexamethasone ||| 0-0
Diskussion ( ||| ( ebenfalls ||| 1-0 0-1
Diskussion ||| ebenfalls ||| 0-0
Disposition von Paclitaxel ||| disposition of paclitaxel ||| 0-0 1-1 2-2
Disposition von ||| disposition of ||| 0-0 1-1
Disposition ||| disposition ||| 0-0
Diuretika , die ||| diuretics that ||| 0-0 1-1 2-1
Diuretika , ||| nitrates , diuretics ||| 0-0 1-1 0-2
Diuretika ||| diuretics ||| 0-0
Diät und ||| diet and ||| 0-0 1-1
Diät ||| diet ||| 0-0
Dopamin und 5-Hydroxytryptamin ||| dopamine and 5-hydroxytryptamine are involved ||| 0-0 1-1 2-2
Dopamin und 5-Hydroxytryptamin ||| dopamine and 5-hydroxytryptamine are ||| 0-0 1-1 2-2
Dopamin und 5-Hydroxytryptamin ||| dopamine and 5-hydroxytryptamine ||| 0-0 1-1 2-2
Dopamin und ||| dopamine and ||| 0-0 1-1
Dopamin ||| dopamine ||| 0-0
Doppelblindstudien ||| double-blind ||| 0-0
Dosen von 5,25 ||| at doses of 5.25 ||| 0-1 1-2 2-3
Dosen von 5,25 ||| doses of 5.25 ||| 0-0 1-1 2-2
Dosen von Abseamed zwischen 17 ||| doses of Abseamed between 17 ||| 0-0 1-1 2-2 3-3 4-4
Dosen von Abseamed zwischen 25 ||| doses of Abseamed between 25 ||| 0-0 1-1 2-2 3-3 4-4
Dosen von Abseamed zwischen ||| doses of Abseamed between ||| 0-0 1-1 2-2 3-3
Dosen von Abseamed ||| doses of Abseamed ||| 0-0 1-1 2-2
Dosen von ||| at doses of ||| 0-1 1-2
Dosen von ||| doses of ||| 0-0 1-1
Dosen von ||| doses ||| 0-0 1-0
Dosen ||| at doses ||| 0-1
Dosen ||| doses ||| 0-0
Dosierpipette . ||| dosing pipette . ||| 0-0 0-1 1-2
Dosierpipette hat eine Körpergewichtsabstufung ||| dosing pipette has a gradation ||| 0-0 0-1 1-2 2-3 3-4
Dosierpipette hat eine ||| dosing pipette has a ||| 0-0 0-1 1-2 2-3
Dosierpipette hat ||| dosing pipette has ||| 0-0 0-1 1-2
Dosierpipette ||| dosing pipette ||| 0-0 0-1
Dosierpipetten sind entsprechend des ||| show graduations corresponding to the ||| 0-0 0-1 2-2 2-3 3-4
Dosierpipetten sind entsprechend ||| show graduations corresponding to ||| 0-0 0-1 2-2 2-3
Dosierpipetten sind ||| show graduations ||| 0-0 0-1
Dosierpipetten ||| show graduations ||| 0-0 0-1
Dosierung , Art und Dauer ||| Posology and method ||| 0-0 1-0 2-0 3-1 4-2
Dosierung , Art und Dauer ||| Posology and method ||| 0-0 1-0 3-1 2-2 3-2 4-2
Dosierung , Art und ||| Posology and ||| 0-0 1-0 2-0 3-1
Dosierung , Art ||| Posology ||| 0-0 1-0 2-0
Dosierung , ||| Posology ||| 0-0 1-0
Dosierung Die Dosierung ||| Dosage Dosage ||| 0-0 0-1 1-1 2-1
Dosierung beträgt 600 I.E./kg ||| dose is 600 IU/ kg ||| 0-0 1-1 0-2 1-2 2-2 3-3 3-4
Dosierung beträgt 600 ||| dose is 600 ||| 0-0 1-1 0-2 1-2 2-2
Dosierung kann auch bei ||| dosage may also ||| 0-0 1-1 2-2 3-2
Dosierung kann ||| dosage may ||| 0-0 1-1
Dosierung oder das Unterbrechen der ||| dosage or discontinuation of treatment ||| 0-0 1-1 2-2 3-2 4-3 3-4 4-4
Dosierung oder ||| dosage or ||| 0-0 1-1
Dosierung sollte ||| dosage should ||| 0-0 1-1
Dosierung von ABILIFY ||| dosage of ABILIFY ||| 0-0 1-1 2-2
Dosierung von ||| dosage of ||| 0-0 1-1
Dosierung von ||| of the ||| 0-0 1-0
Dosierung von ||| of ||| 0-0 1-0
Dosierung ||| dosage ||| 0-0
Dosierung ||| dosing ||| 0-0
Dosierungen , ||| at doses ||| 0-0 0-1
Dosierungen , ||| doses ||| 0-0
Dosierungen unter 15 mg waren ||| Doses below 15 mg were ||| 0-0 1-1 2-2 3-3 4-4
Dosierungen unter 15 mg ||| Doses below 15 mg ||| 0-0 1-1 2-2 3-3
Dosierungen unter 15 ||| Doses below 15 ||| 0-0 1-1 2-2
Dosierungen unter ||| Doses below ||| 0-0 1-1
Dosierungen ||| Doses ||| 0-0
Dosierungen ||| at doses ||| 0-0 0-1
Dosierungen ||| doses ||| 0-0
Dosierungen über 45 mg ( ||| doses above 45 mg ( ||| 0-0 1-1 2-2 3-3 4-4
Dosierungen über 45 mg ||| doses above 45 mg ||| 0-0 1-1 2-2 3-3
Dosierungen über 45 ||| doses above 45 ||| 0-0 1-1 2-2
Dosierungen über ||| doses above ||| 0-0 1-1
Dosis , d.h. ||| dose , i. e. ||| 0-0 1-1 2-2 2-3
Dosis , die Sie erhalten ||| dose you receive ||| 0-0 2-0 1-1 3-1 4-2
Dosis , die Sie ||| dose you ||| 0-0 2-0 1-1 3-1
Dosis , spiegelten Differenzen in ||| dose reflected differences in ||| 0-0 2-1 3-1 2-2 4-3
Dosis , spiegelten Differenzen in ||| for dose reflected differences in ||| 0-1 2-2 3-2 2-3 4-4
Dosis , spiegelten Differenzen ||| dose reflected differences ||| 0-0 2-1 3-1 2-2
Dosis , spiegelten Differenzen ||| for dose reflected differences ||| 0-1 2-2 3-2 2-3
Dosis , ||| dose , ||| 0-0 1-1
Dosis , ||| dose ||| 0-0
Dosis , ||| for dose ||| 0-1
Dosis . ||| assay . ||| 0-0 1-1
Dosis . ||| dose . ||| 0-0 1-1
Dosis Ihrer Arzneimittel reduzieren ||| smaller dose of your medicines ||| 1-0 3-0 0-1 1-3 2-4
Dosis an ABILIFY ||| dose of ABILIFY ||| 0-0 1-1 2-2
Dosis an ||| dose of ||| 0-0 1-1
Dosis beträgt 9,75 mg ( ||| dose is 9.75 mg ( ||| 0-0 1-1 2-2 3-3 4-4
Dosis beträgt 9,75 mg ||| dose is 9.75 mg ||| 0-0 1-1 2-2 3-3
Dosis beträgt 9,75 ||| dose is 9.75 ||| 0-0 1-1 2-2
Dosis beträgt zwischen ||| dose is between ||| 0-0 1-1 2-2
Dosis beträgt ||| dose is ||| 0-0 1-1
Dosis bis zu ||| dose to ||| 0-0 1-1 2-1
Dosis des Insulins ||| insulin dose ||| 1-0 2-0 0-1
Dosis des Sulfonylharnstoffs ||| dose of the sulphonylurea ||| 0-0 1-1 1-2 2-3
Dosis des ||| dose of the ||| 0-0 1-1 1-2
Dosis eim ||| . ||| 1-0
Dosis entsprechend ||| dose of ||| 0-0 1-1
Dosis erst ||| dose of ||| 0-0 1-1
Dosis für Abraxane beträgt 260 ||| dose of Abraxane is 260 ||| 0-0 1-1 2-2 3-3 4-4
Dosis für Abraxane beträgt ||| dose of Abraxane is ||| 0-0 1-1 2-2 3-3
Dosis für Abraxane ||| dose of Abraxane ||| 0-0 1-1 2-2
Dosis für ||| dose of ||| 0-0 1-1
Dosis für ||| dose ||| 0-0
Dosis injiziert wurde . ||| dose is injected . ||| 0-0 1-1 1-2 2-2 3-3
Dosis injiziert wurde ||| dose is injected ||| 0-0 1-1 1-2 2-2
Dosis ist 15 mg ||| dose is 15 mg ||| 0-0 1-1 2-2 3-3
Dosis ist 15 ||| dose is 15 ||| 0-0 1-1 2-2
Dosis ist 5 mg , ||| dose is 5 mg , ||| 0-0 1-1 2-2 3-3 4-4
Dosis ist 5 mg ||| dose is 5 mg ||| 0-0 1-1 2-2 3-3
Dosis ist 5 ||| dose is 5 ||| 0-0 1-1 2-2
Dosis ist eine intravenöse ||| dose is a single intravenous ||| 0-0 1-1 2-2 3-3 3-4
Dosis ist eine ||| dose is a ||| 0-0 1-1 2-2
Dosis ist ||| dose is ||| 0-0 1-1
Dosis kann stufenweise auf ||| dose may be ||| 0-0 1-1 2-1 1-2 3-2
Dosis liegt zwischen 75 und ||| dose is between 75 and ||| 0-0 1-1 1-2 2-2 3-3 4-4
Dosis liegt zwischen 75 ||| dose is between 75 ||| 0-0 1-1 1-2 2-2 3-3
Dosis liegt zwischen ||| dose is between ||| 0-0 1-1 1-2 2-2
Dosis notwendig ( siehe Abschnitt ||| ( see section ||| 2-0 3-1 4-2
Dosis notwendig ( siehe ||| ( see ||| 2-0 3-1
Dosis notwendig ( ||| ( ||| 2-0
Dosis notwendig ||| notwendig ||| 1-0
Dosis sollte 200 ||| dose should not exceed 200 ||| 0-0 1-1 2-2 2-3 2-4
Dosis sollte in ||| in dose should ||| 2-0 0-1 1-2
Dosis sollte ||| dose should be ||| 0-0 1-1 1-2
Dosis sollte ||| dose should ||| 0-0 1-1
Dosis von 300 mg/m2 ||| dose of 300 mg/ m2 ||| 0-0 1-1 2-2 3-3 3-4
Dosis von 300 ||| dose of 300 ||| 0-0 1-1 2-2
Dosis von 5 mg ||| dose of 5 mg ||| 0-0 1-1 2-2 3-3
Dosis von 5 ||| dose of 5 ||| 0-0 1-1 2-2
Dosis von 5,25 mg ( ||| dose of 5.25 mg ( ||| 0-0 1-1 2-2 3-3 4-4
Dosis von 5,25 mg ||| dose of 5.25 mg ||| 0-0 1-1 2-2 3-3
Dosis von 5,25 ||| dose of 5.25 ||| 0-0 1-1 2-2
Dosis von 600 I.E./kg ||| dose of 600 IU/ kg ||| 0-0 1-1 2-2 3-3 3-4
Dosis von 600 ||| dose of 600 ||| 0-0 1-1 2-2
Dosis von ABILIFY zu ändern ||| dose of ABILIFY ||| 0-0 1-1 2-2 3-2 4-2
Dosis von ABILIFY ||| dose of ABILIFY ||| 0-0 1-1 2-2
Dosis von ||| dose of ||| 0-0 1-1
Dosis von ||| dose ||| 0-0 1-0
Dosis von ||| same ||| 0-0
Dosis wird so angepasst ||| dose is adjusted ||| 0-0 1-1 2-1 3-2
Dosis wird so ||| dose is ||| 0-0 1-1 2-1
Dosis wird ||| dose is ||| 0-0 1-1
Dosis zu . ||| dose . ||| 0-0 1-0 2-1
Dosis zu ermitteln . ||| lowest effective dose . ||| 2-0 2-1 0-2 3-3
Dosis zu ermitteln ||| lowest effective dose ||| 2-0 2-1 0-2
Dosis zu ||| dose ||| 0-0
Dosis zu ||| dose ||| 0-0 1-0
Dosis ||| administered dose ||| 0-1
Dosis ||| assay ||| 0-0
Dosis ||| dose , ||| 0-0
Dosis ||| dose in ||| 0-0
Dosis ||| dose of ||| 0-0
Dosis ||| dose ||| 0-0
Dosis ||| for dose ||| 0-1
Dosis ||| same ||| 0-0
Dosisanpassung , um die ||| Dose adjustment in order to ||| 0-0 1-0 0-1 2-2 2-3 3-4
Dosisanpassung , um ||| Dose adjustment in order ||| 0-0 1-0 0-1 2-2 2-3
Dosisanpassung , ||| Dose adjustment ||| 0-0 1-0 0-1
Dosisanpassung erforderlich . ||| impairment . ||| 0-0 1-0 2-1
Dosisanpassung erforderlich ||| impairment ||| 0-0 1-0
Dosisanpassung mit dem ||| Dosage adjustment to ||| 0-0 2-0 0-1 1-1 2-2
Dosisanpassung notwendig ist , ||| dose adjustment is necessary , ||| 0-0 0-1 2-2 1-3 3-4
Dosisanpassung notwendig ist ||| dose adjustment is necessary ||| 0-0 0-1 2-2 1-3
Dosisanpassung sollte so ||| Dosisanpassung sollte so gewählt werden ||| 0-0 2-0 2-1 2-2 1-3 2-3 2-4
Dosisanpassung ||| adjustment ||| 0-0
Dosisanpassung ||| dose adjustment ||| 0-0 0-1
Dosisanpassungen bei Patienten mit ||| modifications in patients with ||| 0-0 1-1 1-2 2-2 3-3
Dosisanpassungen bei Patienten mit ||| modifications in patients with ||| 0-0 1-1 2-2 3-3
Dosisanpassungen bei Patienten ||| modifications in patients ||| 0-0 1-1 1-2 2-2
Dosisanpassungen bei Patienten ||| modifications in patients ||| 0-0 1-1 2-2
Dosisanpassungen bei ||| modifications in ||| 0-0 1-1
Dosisanpassungen ||| modifications ||| 0-0
Dosiserhöhungen ||| increases ||| 0-0
Dosismanagement versucht werden , die ||| , with consideration for the ||| 3-0 0-1 0-2 1-2 2-2 1-3 4-4
Dosismanagement versucht werden , die ||| with consideration for the ||| 0-0 0-1 1-1 2-1 1-2 4-3
Dosismanagement versucht werden , ||| , with consideration for ||| 3-0 0-1 0-2 1-2 2-2 1-3
Dosismanagement versucht werden , ||| with consideration for ||| 0-0 0-1 1-1 2-1 1-2
Dosismanagement versucht werden ||| with consideration for ||| 0-0 0-1 1-1 2-1 1-2
Dosisreduzierung ||| dose reduction ||| 0-0 0-1
Dosissenkung . ||| dose reduction . ||| 0-0 0-1 1-2
Dosissenkung ||| dose reduction ||| 0-0 0-1
Drei der sechs identifizierten ||| Three of the six identified ||| 0-0 1-1 1-2 2-3 3-4
Drei der sechs ||| Three of the six ||| 0-0 1-1 1-2 2-3
Drei der ||| Three of the ||| 0-0 1-1 1-2
Drei ||| Three ||| 0-0
Drittel der Patienten erhielt ||| third of patients were receiving ||| 0-0 1-1 2-2 3-3 3-4
Drittel der Patienten ||| third of patients ||| 0-0 1-1 2-2
Drittel der ||| third of ||| 0-0 1-1
Drittel ||| third ||| 0-0
Drücken Sie die Tablette nicht ||| Do not push the tablet ||| 0-0 1-0 4-1 0-2 2-2 2-3 3-4
Durchblutungsstörungen des ||| blood perfusion of the ||| 0-0 0-1 1-2 1-3
Durchblutungsstörungen ||| blood perfusion ||| 0-0 0-1
Durchblutungsstörungen ||| blood ||| 0-0
Durchfall , Erbrechen , Verstopfung ||| diarrhoea , vomiting , constipation ||| 0-0 1-1 2-2 3-3 4-4
Durchfall , Erbrechen , ||| diarrhoea , vomiting , ||| 0-0 1-1 2-2 3-3
Durchfall , Erbrechen ||| diarrhoea , vomiting ||| 0-0 1-1 2-2
Durchfall , ||| diarrhoea , ||| 0-0 1-1
Durchfall . ||| diarrhoea . ||| 0-0 1-1
Durchfall weicher Stuhl ||| diarrhoea softened stools ||| 0-0 1-1 2-2
Durchfall weicher ||| diarrhoea softened ||| 0-0 1-1
Durchfall ||| , diarrhoea ||| 0-1
Durchfall ||| diarrhoea ||| 0-0
Durchschnittsalter : ||| mean age : ||| 0-0 0-1 1-2
Durchschnittsalter von 62 Jahren ||| average age of 62 years ||| 0-0 2-0 0-1 1-2 2-3 3-4
Durchschnittsalter von 62 ||| average age of 62 ||| 0-0 2-0 0-1 1-2 2-3
Durchschnittsalter ||| mean age ||| 0-0 0-1
Durchstechflasche , 50 ||| Vial 50ml ||| 0-0 0-1 2-1
Durchstechflasche . ||| vial . ||| 0-0 1-1
Durchstechflasche enthält 10 ||| vial contains 10 ||| 0-0 1-1 2-2
Durchstechflasche enthält 9,75 mg ( ||| vial contains 9.75 mg ( ||| 0-0 1-1 2-2 3-3 4-4
Durchstechflasche enthält 9,75 mg ||| vial contains 9.75 mg ||| 0-0 1-1 2-2 3-3
Durchstechflasche enthält 9,75 ||| vial contains 9.75 ||| 0-0 1-1 2-2
Durchstechflasche enthält ||| vial contains ||| 0-0 1-1
Durchstechflasche im Umkarton ||| Keep the vial in ||| 1-0 2-0 1-1 0-2 2-2 1-3
Durchstechflasche mit 100 mg Paclitaxel ||| vial of 100 mg paclitaxel ||| 0-0 1-1 2-2 3-3 4-4
Durchstechflasche mit 100 mg ||| vial of 100 mg ||| 0-0 1-1 2-2 3-3
Durchstechflasche mit 100 ||| vial of 100 ||| 0-0 1-1 2-2
Durchstechflasche mit ||| vial of ||| 0-0 1-1
Durchstechflasche ||| the vial ||| 0-1
Durchstechflasche ||| vial ||| 0-0
Durchstechflasche. enthält 9,75 mg in ||| vial provides 9.75 mg in ||| 0-0 1-0 0-1 2-2 3-3 4-4
Durchstechflasche. enthält 9,75 mg ||| vial provides 9.75 mg ||| 0-0 1-0 0-1 2-2 3-3
Durchstechflasche. enthält 9,75 ||| vial provides 9.75 ||| 0-0 1-0 0-1 2-2
Durchstechflasche. enthält ||| vial provides ||| 0-0 1-0 0-1
Durchstechflaschen , Patronen ( ||| vials , cartridges ( ||| 0-0 1-1 2-2 3-3
Durchstechflaschen , Patronen ||| vials , cartridges ||| 0-0 1-1 2-2
Durchstechflaschen , ||| vials , ||| 0-0 1-1
Durchstechflaschen sind zur Verwendung mit ||| vials are for use with ||| 0-0 1-1 2-2 3-3 4-4
Durchstechflaschen sind zur Verwendung ||| vials are for use ||| 0-0 1-1 2-2 3-3
Durchstechflaschen sind zur ||| vials are for ||| 0-0 1-1 2-2
Durchstechflaschen sind ||| vials are ||| 0-0 1-1
Durchstechflaschen zu je 10 ml ||| vials x 10 ml ||| 0-0 1-1 2-1 3-2 4-3
Durchstechflaschen zu je 10 ||| vials x 10 ||| 0-0 1-1 2-1 3-2
Durchstechflaschen zu je ||| vials x ||| 0-0 1-1 2-1
Durchstechflaschen ||| vials ||| 0-0
Dysfunktion ||| dysfunction ||| 0-0
Dysgeusie , Schwindel , periphere ||| dysgeusia , dizziness , peripheral ||| 0-0 1-1 2-2 3-3 4-4
Dysgeusie , Schwindel , ||| dysgeusia , dizziness , ||| 0-0 1-1 2-2 3-3
Dysgeusie , Schwindel ||| dysgeusia , dizziness ||| 0-0 1-1 2-2
Dysgeusie , ||| dysgeusia , ||| 0-0 1-1
Dysgeusie , Ösophagitis , ||| dysgeusia , oesophagitis , ||| 0-0 1-1 2-2 3-3
Dysgeusie , Ösophagitis ||| dysgeusia , oesophagitis ||| 0-0 1-1 2-2
Dysgeusie ||| dysgeusia ||| 0-0
Dyskinesie , Hyporeflexie , Neuralgie ||| dyskinesia , hyporeflexia , neuralgia ||| 0-0 1-1 2-2 3-3 4-4
Dyskinesie , Hyporeflexie , ||| dyskinesia , hyporeflexia , ||| 0-0 1-1 2-2 3-3
Dyskinesie , Hyporeflexie ||| dyskinesia , hyporeflexia ||| 0-0 1-1 2-2
Dyskinesie , ||| dyskinesia , ||| 0-0 1-1
Dyskinesie ||| dyskinesia ||| 0-0
Dyslipidämie ( ||| dyslipidaemia ( abnormal ||| 0-0 1-1 0-2
Dyslipidämie . ||| at inclusion . ||| 0-1 1-2
Dyslipidämie . ||| inclusion . ||| 0-0 1-1
Dyslipidämie eingeschlossen waren , wurde ||| Dyslipidämie eingeschlossen waren , wurde ||| 0-0 0-1 2-2 1-3 3-3 4-4
Dyslipidämie eingeschlossen waren , ||| Dyslipidämie eingeschlossen waren , ||| 0-0 0-1 2-2 1-3 3-3
Dyslipidämie ||| Dyslipidämie eingeschlossen ||| 0-0 0-1
Dyslipidämie ||| at inclusion ||| 0-1
Dyslipidämie ||| dyslipidaemia ||| 0-0
Dyslipidämie ||| inclusion ||| 0-0
Dyspepsie ( Sodbrennen ) , ||| dyspepsia ( heartburn ) , ||| 0-0 1-1 2-2 3-3 4-4
Dyspepsie ( Sodbrennen ) ||| dyspepsia ( heartburn ) ||| 0-0 1-1 2-2 3-3
Dyspepsie ( Sodbrennen ||| dyspepsia ( heartburn ||| 0-0 1-1 2-2
Dyspepsie ( ||| dyspepsia ( ||| 0-0 1-1
Dyspepsie , Bauchschmerz ||| night sweats , hyperhydrosis ||| 0-0 2-1 1-2 2-3
Dyspepsie , Erbrechen , ||| dyspepsia , vomiting , ||| 0-0 1-1 2-2 3-3
Dyspepsie , Erbrechen , Übelkeit ||| dyspepsia , vomiting , nausea ||| 0-0 1-1 2-2 3-3 4-4
Dyspepsie , Erbrechen ||| dyspepsia , vomiting ||| 0-0 1-1 2-2
Dyspepsie , ||| dyspepsia , ||| 0-0 1-1
Dyspepsie ||| Gastrointestinal dyspepsia ||| 0-0 0-1
Dyspepsie ||| dyspepsia ||| 0-0
Dyspepsie ||| night ||| 0-0
Dysphagie , Bauch- ||| dysphagia , abdominal discomfort , ||| 0-0 1-1 2-2 2-3 1-4
Dysphagie : Motilitätsstörungen der Speiseröhre ||| 48 Dysphagia : oesophageal dysmotility ||| 0-0 0-1 2-1 1-2 2-3 3-4 4-4
Dysphagie : Motilitätsstörungen der Speiseröhre ||| 60 Dysphagia : oesophageal dysmotility ||| 1-0 0-1 2-1 1-2 2-3 3-4 4-4
Dysphagie : Motilitätsstörungen der Speiseröhre ||| 72 Dysphagia : oesophageal dysmotility ||| 0-0 0-1 2-1 1-2 2-3 3-4 4-4
Dysphagie : Motilitätsstörungen der Speiseröhre ||| 84 Dysphagia : oesophageal dysmotility ||| 0-0 0-1 2-1 1-2 2-3 3-4 4-4
Dysphagie : Motilitätsstörungen der Speiseröhre ||| Dysphagia : oesophageal dysmotility ||| 0-0 2-0 1-1 2-2 3-3 4-3
Dysphagie : Motilitätsstörungen ||| 48 Dysphagia : oesophageal ||| 0-0 0-1 2-1 1-2 2-3
Dysphagie : Motilitätsstörungen ||| 60 Dysphagia : oesophageal ||| 1-0 0-1 2-1 1-2 2-3
Dysphagie : Motilitätsstörungen ||| 72 Dysphagia : oesophageal ||| 0-0 0-1 2-1 1-2 2-3
Dysphagie : Motilitätsstörungen ||| 84 Dysphagia : oesophageal ||| 0-0 0-1 2-1 1-2 2-3
Dysphagie : Motilitätsstörungen ||| Dysphagia : oesophageal ||| 0-0 2-0 1-1 2-2
Dysphagie ||| dysphagia ||| 0-0
Dystonie und Dyskinesie auf ||| dystonia and dyskinesia ||| 0-0 3-0 1-1 2-2
Dysurie , Pollakisurie , Hämaturie ||| Dysuria , pollakiuria , haematuria ||| 0-0 1-1 2-2 4-2 3-3 4-4
Dysurie , ||| Dysuria , ||| 0-0 1-1
Dysurie ||| Dysuria ||| 0-0
Dänemark ||| Denmark ||| 0-0
E 320 ) 2 ||| E 320 ) 2 ||| 0-0 1-0 1-1 2-2 3-3
E 320 ) Yarvitan ist ||| E 320 ) Yarvitan is ||| 0-0 1-0 1-1 2-2 3-3 4-4
E 320 ) Yarvitan ||| E 320 ) Yarvitan ||| 0-0 1-0 1-1 2-2 3-3
E 320 ) ||| E 320 ) ||| 0-0 1-0 1-1 2-2
E 320 ||| E 320 ||| 0-0 1-0 1-1
E 487 ||| Tablet core : ||| 0-0 1-1
E 487 ||| Tablet core ||| 0-0 1-1
E ||| Tablet ||| 0-0
E14 4HB , ||| E14 4HB , ||| 0-0 1-0 1-1 2-2
E14 4HB ||| E14 4HB ||| 0-0 1-0 1-1
E216 ) , Natriumhydroxid ||| E216 ) , sodium hydroxide ||| 0-0 1-1 2-2 3-3 3-4
E216 ) , ||| E216 ) , ||| 0-0 1-1 2-2
E216 ) Natriumhydroxid Sucrose ||| E216 ) Sodium hydroxide Sucrose ||| 0-0 1-1 2-2 2-3 3-4
E216 ) Natriumhydroxid ||| E216 ) Sodium hydroxide ||| 0-0 1-1 2-2 2-3
E216 ) je ml . ||| E216 ) per ml ||| 0-0 1-1 2-2 3-3 4-3
E216 ) je ||| E216 ) per ||| 0-0 1-1 2-2
E216 ) ||| E216 ) ||| 0-0 1-1
E216 ||| E216 . ||| 0-0
E216 ||| E216 ||| 0-0
E218 ) Propylenglycol ||| E218 ) Propylene glycol ||| 0-0 1-1 2-2 2-3
E218 ) je ml 0,2 ||| E218 ) per ml 0.2 ||| 0-0 1-1 2-2 3-3 4-4
E218 ) je ml ||| E218 ) per ml ||| 0-0 1-1 2-2 3-3
E218 ) je ||| E218 ) per ||| 0-0 1-1 2-2
E218 ) ||| E218 ) ||| 0-0 1-1
E218 ||| E218 ||| 0-0
E951 ) Acesulfam-Kalium Vanille-Aroma ||| E951 ) Acesulfame potassium Vanilla ||| 0-0 1-1 2-2 2-3 3-4
E951 ) Acesulfam-Kalium ||| E951 ) Acesulfame potassium ||| 0-0 1-1 2-2 2-3
E951 ) je Schmelztablette . ||| E951 ) per orodispersible tablet ||| 0-0 1-1 2-2 3-3 3-4 4-4
E951 ) je ||| E951 ) per ||| 0-0 1-1 2-2
E951 ) ||| E951 ) ||| 0-0 1-1
E951 ||| E951 ||| 0-0
EINE SICHERE UND WIRKSAME ||| REGARD TO SAFE AND ||| 0-0 2-1 1-2 2-3 3-3
EINE ||| REGARD ||| 0-0
EINER KOMBINATIONSTHERAPIE ||| THERAPY WITH SULPHONYLUREA ||| 0-0 0-1 1-2
EINER KOMBINATIONSTHERAPIE ||| WITH INSULIN Metabolism ||| 0-0 1-1 1-2
EINER KOMBINATIONSTHERAPIE ||| WITH METFORMIN Blood ||| 0-0 0-1 1-2
EINER ORALEN DREIFACH-KOMBINATIONSTHERAPIE MIT ||| TRIPLE ORAL COMBINATION THERAPY WITH ||| 0-0 1-0 1-1 2-2 2-3 3-4
EINER ORALEN DREIFACH-KOMBINATIONSTHERAPIE ||| TRIPLE ORAL COMBINATION THERAPY ||| 0-0 1-0 1-1 2-2 2-3
EINER ORALEN ||| TRIPLE ORAL ||| 0-0 1-0 1-1
EINER ||| THERAPY WITH ||| 0-0 0-1
EINER ||| WITH METFORMIN ||| 0-0 0-1
EINER ||| WITH ||| 0-0
EINHEITEN ||| BY UNIT ||| 0-0 0-1
EINSCHRÄNKUNGEN FÜR DIE ABGABE ||| RESTRICTIONS REGARDING ||| 0-0 1-0 2-1 3-1
EINSCHRÄNKUNGEN FÜR ||| RESTRICTIONS ||| 0-0 1-0
EINSCHRÄNKUNGEN HINSICHTLICH DER ||| RESTRICTIONS WITH REGARD TO THE ||| 0-0 0-1 1-2 1-3 2-3 2-4
EINSCHRÄNKUNGEN HINSICHTLICH DER ||| RESTRICTIONS WITH REGARD TO ||| 0-0 0-1 1-2 1-3 2-3
EINSCHRÄNKUNGEN ||| RESTRICTIONS WITH ||| 0-0 0-1
EMEA . ||| EMEA ||| 0-0
EMEA ||| EMEA ||| 0-0
ENTSORGUNG VON NICHT ||| THE DISPOSAL OF ||| 0-0 0-1 1-2 2-2
ENTSORGUNG ||| THE DISPOSAL ||| 0-0 0-1
EPAR für die ||| EPAR für die ||| 0-0 0-1 1-1 0-2 2-2
EPS 19 % bei ||| EPS was 19 % ||| 0-0 0-1 1-2 3-2 2-3
EPS einschließlich Parkinsonismus , Akathisie ||| EPS including parkinsonism , akathisia ||| 0-0 1-1 2-2 3-3 4-4
EPS einschließlich Parkinsonismus , ||| EPS including parkinsonism , ||| 0-0 1-1 2-2 3-3
EPS einschließlich Parkinsonismus ||| EPS including parkinsonism ||| 0-0 1-1 2-2
EPS einschließlich ||| EPS including ||| 0-0 1-1
EPS ||| EPS was ||| 0-0 0-1
EPS ||| EPS ||| 0-0
ERSTZULASSUNG / VERLÄNGERUNG DER ZULASSUNG ||| AUTHORISATION/ RENEWAL OF THE AUTHORISATION ||| 0-0 0-1 1-1 2-1 2-2 3-3 4-4
ERSTZULASSUNG / VERLÄNGERUNG DER ||| AUTHORISATION/ RENEWAL OF THE ||| 0-0 0-1 1-1 2-1 2-2 3-3
ERSTZULASSUNG / VERLÄNGERUNG ||| AUTHORISATION/ RENEWAL OF ||| 0-0 0-1 1-1 2-1 2-2
ERTEILUNG DER ERSTZULASSUNG / VERLÄNGERUNG ||| FIRST AUTHORISATION/ RENEWAL OF ||| 0-0 1-0 2-1 2-2 3-2 4-2 4-3
ERTEILUNG DER ||| FIRST ||| 0-0 1-0
ES ANGEWENDET ? ||| IS USED FOR ||| 0-0 1-1 1-2 2-2
ES ||| IS ||| 0-0
ESA ) folgendes beobachtet : ||| ESAs ) have shown : ||| 0-0 2-0 1-1 2-2 2-3 3-3 4-4
ESA ) folgendes beobachtet ||| ESAs ) have shown ||| 0-0 2-0 1-1 2-2 2-3 3-3
ESA sind für ||| ESAs are not indicated for ||| 0-0 1-1 1-2 0-3 2-4
ESA sind ||| ESAs are not indicated ||| 0-0 1-1 1-2 0-3
ETIKETTIERUNG DER FLASCHE FÜR PACKUNGSEINHEIT ||| BOTTLE LABEL FOR UNIT PACK ||| 0-0 1-1 2-1 2-2 4-3 3-4 4-4
ETIKETTIERUNG DER FLASCHE FÜR ZWISCHENPACKUNG ||| BOTTLE LABEL FOR INTERMEDIATE PACK ||| 0-0 1-1 2-1 2-2 4-3 3-4 4-4
ETIKETTIERUNG DER FLASCHE ||| BOTTLE LABEL FOR ||| 0-0 1-1 2-1 2-2
ETIKETTIERUNG ||| BOTTLE ||| 0-0
EU-Nummer ||| EU/ 1/ 06/ 344/ ||| 0-0 0-1 0-2 0-3
EU/0/00/000/001 55 ml EU/0/00/000/002 120 ||| 55 ml 120 ||| 0-0 1-0 2-1 3-2 4-2
EU/0/00/000/001 55 ml ||| 55 ml ||| 0-0 1-0 2-1
EU/0/00/000/001 55 ||| 55 ||| 0-0 1-0
EU/0/00/000/002 120 ml EU/0/00/000/003 210 ||| 120 ml 210 ||| 0-0 1-0 2-1 3-2 4-2
EU/0/00/000/002 120 ml ||| 120 ml ||| 0-0 1-0 2-1
EU/0/00/000/002 120 ||| 120 ||| 0-0 1-0
EU/0/00/000/003 210 ml ||| 210 ml ||| 0-0 1-0 2-1
EU/0/00/000/003 210 ||| 210 ||| 0-0 1-0
EU/1/00/150/001-003 , 007 ||| EU/ 1/ 00/ 150/ 001-003 ||| 0-0 0-1 0-2 2-3 2-4
EU/1/00/150/001-003 , ||| EU/ 1/ 00/ ||| 0-0 0-1 0-2
EU/1/00/150/001-003 ||| EU/ 1/ 00/ ||| 0-0 0-1 0-2
EU/1/00/150/004-006 , 008 ||| EU/ 1/ 00/ 150/ 004-006 ||| 0-0 0-1 0-2 2-3 2-4
EU/1/00/150/004-006 , ||| EU/ 1/ 00/ ||| 0-0 0-1 0-2
EU/1/00/150/004-006 ||| EU/ 1/ 00/ ||| 0-0 0-1 0-2
EU/1/04/276/015 98 x ||| 04/ 276/ 015 98 x ||| 2-0 0-1 2-1 1-2 1-3 2-4
EU/1/04/276/035 ||| 1/ 04/ 276/ ||| 0-0 0-1 0-2
EU/1/05/308/002 ||| 05/ 308/ 002 ||| 0-0 0-1 0-2
EU/1/06/344/003 ||| 06/ 344/ 004 ||| 0-0 0-1 0-2
EU/1/06/344/006 ||| 06/ 344/ 007 ||| 0-0 0-1 0-2
EU/1/06/344/011 ||| 06/ 344/ 011 ||| 0-0 0-1 0-2
EU/1/07/412/002 ||| 07/ 412/ 002 ||| 0-0 0-1 0-2
EU/1/07/412/004 ||| 07/ 412/ 004 ||| 0-0 0-1 0-2
EU/1/07/412/006 ||| 07/ 412/ 006 ||| 0-0 0-1 0-2
EU/1/07/412/008 ||| 07/ 412/ 008 ||| 0-0 0-1 0-2
EU/1/07/412/010 ||| 07/ 412/ 010 ||| 0-0 0-1 0-2
EU/1/07/412/012 ||| 07/ 412/ 012 ||| 0-0 0-1 0-2
EU/1/07/412/014 ||| 07/ 412/ 014 ||| 0-0 0-1 0-2
EU/1/07/412/016 ||| 07/ 412/ 016 ||| 0-0 0-1 0-2
EU/1/07/412/018 ||| 07/ 412/ 018 ||| 0-0 0-1 0-2
EU/1/07/412/020 ||| 07/ 412/ 020 ||| 0-0 0-1 0-2
Ebenso waren für Dehydro-Aripiprazol die ||| Similarly , for dehydro-aripiprazole the ||| 0-0 1-0 2-2 3-3 4-4
Ebenso waren für Dehydro-Aripiprazol ||| Similarly , for dehydro-aripiprazole ||| 0-0 1-0 2-2 3-3
Ebenso waren für ||| Similarly , for ||| 0-0 1-0 2-2
Ebenso waren ||| Similarly , ||| 0-0 1-0
Ebenso waren ||| Similarly ||| 0-0 1-0
Ebenso zeigten sich ||| is there any detectable ||| 0-0 0-1 0-2 0-3 1-3 2-3
Eesti Eli Lilly Holdings Limited ||| Eesti Eli Lilly Holdings Limited ||| 0-0 1-1 2-2 3-3 4-4
Eesti Eli Lilly Holdings ||| Eesti Eli Lilly Holdings ||| 0-0 1-1 2-2 3-3
Eesti Eli Lilly ||| Eesti Eli Lilly ||| 0-0 1-1 2-2
Eesti Eli ||| Eesti Eli ||| 0-0 1-1
Eesti filiaal Tel : +3726441100 ||| Eesti filiaal Tel : +3726441100 ||| 0-0 1-1 2-2 3-3 4-4
Eesti filiaal Tel : ||| Eesti filiaal Tel : ||| 0-0 1-1 2-2 3-3
Eesti filiaal Tel ||| Eesti filiaal Tel ||| 0-0 1-1 2-2
Eesti filiaal ||| Eesti filiaal ||| 0-0 1-1
Eesti ||| Eesti ||| 0-0
Efavirenz , Nevirapin ||| sollten ähnliche Dosiserhöhungen vorgenommen werden ||| 0-0 0-1 0-2 1-2 2-3 2-4
Efavirenz , ||| sollten ähnliche Dosiserhöhungen ||| 0-0 0-1 0-2 1-2
Effekt , der ||| effect , which ||| 0-0 1-1 1-2
Effekt , ||| effect , which ||| 0-0 1-1 1-2
Effekt auf CYP2C8 wurde in ||| inhibitory effect on CYP2C8 has ||| 0-0 2-0 0-1 1-2 2-3 4-3 3-4
Effekt auf die ||| Effect on bone ||| 0-0 1-1 2-1 1-2
Effekt auf ||| effect on ||| 0-0 1-1
Effekt von Rimonabant kann nicht ||| of clinical signs suggestive of ||| 0-0 1-0 2-0 1-1 2-2 2-3 1-4
Effekt von Rimonabant kann ||| of clinical signs suggestive of ||| 0-0 1-0 2-0 1-1 2-2 2-3 1-4
Effekt von Rimonabant ||| effect of rimonabant ||| 0-0 1-1 2-2
Effekt von Rimonabant ||| of clinical signs suggestive of ||| 0-0 1-0 2-0 1-1 2-2 2-3 1-4
Effekt von ||| effect of ||| 0-0 1-1
Effekt ||| Effect ||| 0-0
Effekt ||| effect ||| 0-0
Effekte auf morphometrische Wirbelkörperfrakturen ||| Effect on morphometric vertebral fractures ||| 0-0 1-1 2-2 3-3 3-4
Effekte auf morphometrische ||| Effect on morphometric ||| 0-0 1-1 2-2
Effekte auf ||| Effect on ||| 0-0 1-1
Effekte von Aripiprazol erklären . ||| effects of aripiprazole . ||| 0-0 1-1 2-2 3-2 4-3
Effekte von Aripiprazol erklären ||| effects of aripiprazole ||| 0-0 1-1 2-2 3-2
Effekte von ||| effects of ||| 0-0 1-1
Effekte wurden ||| effects were ||| 0-0 1-1
Effekte ||| Effect ||| 0-0
Effekte ||| Effekte ||| 0-0
Effekte ||| effects ||| 0-0
Effekte ||| similar ||| 0-0
Effkete auf die Körpergröße ||| Effect on height ||| 0-0 1-1 2-1 3-2
Effkete auf die ||| Effect on ||| 0-0 1-1 2-1
Effkete ||| Effect ||| 0-0
Eiffel , BP 27166 , ||| Eiffel , BP 27166 , ||| 0-0 1-1 2-2 3-3 4-4
Eiffel , BP 27166 ||| Eiffel , BP 27166 ||| 0-0 1-1 2-2 3-3
Eiffel , BP ||| Eiffel , BP ||| 0-0 1-1 2-2
Eiffel , ||| Eiffel , ||| 0-0 1-1
Eiffel ||| Eiffel ||| 0-0
Eigenblutspende erfolgen . ||| blood donation procedure . ||| 0-0 0-1 1-1 0-2 2-3
Eigenblutspende erfolgen ||| blood donation procedure ||| 0-0 0-1 1-1 0-2
Eigenblutspenden - ||| autologous ||| 0-0 1-0
Eigenblutspenden - ||| with autologous ||| 0-1 1-1
Eigenblutspendeprogramm ||| predonation programme ||| 0-0 0-1
Eigenschaften bei dopaminerger Hypoaktivität . ||| models of dopaminergic hypoactivity . ||| 0-0 2-0 0-1 1-2 2-2 3-3 4-4
Eigenschaften bei dopaminerger Hypoaktivität ||| models of dopaminergic hypoactivity ||| 0-0 2-0 0-1 1-2 2-2 3-3
Eigenschaften bei dopaminerger ||| models of dopaminergic ||| 0-0 2-0 0-1 1-2 2-2
Eigenschaften von Aripiprazol und ||| characteristics of aripiprazole and ||| 0-0 1-1 2-2 3-3
Eigenschaften von Aripiprazol ||| characteristics of aripiprazole ||| 0-0 1-1 2-2
Eigenschaften von ||| characteristics of ||| 0-0 1-1
Eigenschaften ||| characteristics ||| 0-0
Ein Anstieg des Hämoglobins um ||| A rise in haemoglobin of ||| 0-0 1-1 2-1 3-1 1-2 3-3 4-3 2-4
Ein Teil der Behandlung des ||| Part of the treatment of ||| 0-0 1-0 1-1 2-2 3-3 4-4
Ein Teil der Behandlung ||| Part of the treatment ||| 0-0 1-0 1-1 2-2 3-3
Ein Teil der ||| Part of the ||| 0-0 1-0 1-1 2-2
Ein Teil ||| Part of ||| 0-0 1-0 1-1
Ein Trend zur ||| a trend ||| 0-1 1-1
Ein Trend zur ||| trend ||| 0-0 1-0
Ein Trend ||| a trend ||| 0-1 1-1
Ein Trend ||| trend ||| 0-0 1-0
Ein Verschluss der Verbindung zwischen ||| Occlusion in the connection between ||| 0-0 1-0 2-2 1-3 3-3 4-4
Ein Verschluss der Verbindung ||| Occlusion in the connection ||| 0-0 1-0 2-2 1-3 3-3
Ein Verschluss ||| Occlusion of ||| 0-0 1-0 1-1
Ein Wirkverlust oder andere Symptome ||| efficacy or other symptoms of ||| 1-0 2-1 3-2 4-3
Ein Wirkverlust oder andere Symptome ||| efficacy or other symptoms ||| 1-0 2-1 3-2 4-3
Ein Wirkverlust oder andere Symptome ||| of efficacy or other symptoms ||| 1-1 2-2 3-3 4-4
Ein Wirkverlust oder andere ||| efficacy or other ||| 1-0 2-1 3-2
Ein Wirkverlust oder andere ||| loss of efficacy or other ||| 1-2 2-3 3-4
Ein Wirkverlust oder andere ||| of efficacy or other ||| 1-1 2-2 3-3
Ein Wirkverlust oder ||| efficacy or ||| 1-0 2-1
Ein Wirkverlust oder ||| loss of efficacy or ||| 1-2 2-3
Ein Wirkverlust oder ||| of efficacy or ||| 1-1 2-2
Ein Wirkverlust ||| efficacy ||| 1-0
Ein Wirkverlust ||| loss of efficacy ||| 1-2
Ein Wirkverlust ||| of efficacy ||| 1-1
Ein dauerhafter Hämoglobinwert ||| A sustained haemoglobin level ||| 0-0 1-1 2-2 1-3
Ein direkter Effekt von Rimonabant ||| A direct effect of rimonabant ||| 0-0 1-1 2-2 3-3 4-4
Ein direkter Effekt von ||| A direct effect of ||| 0-0 1-1 2-2 3-3
Ein direkter Effekt ||| A direct effect ||| 0-0 1-1 2-2
Ein direkter ||| A direct ||| 0-0 1-1
Ein direkter ||| Increased incidence and/ or severity ||| 0-0 1-0 1-1 1-2 1-4
Ein geeichter Messbecher und ||| A calibrated measuring cup and ||| 0-0 1-1 2-2 2-3 3-4
Ein geeichter Messbecher ||| A calibrated measuring cup ||| 0-0 1-1 2-2 2-3
Ein geeichter ||| A calibrated ||| 0-0 1-1
Ein gestörter Geburtsverlauf ||| Dystocia ||| 0-0 1-0 2-0
Ein leichtes Absetzen der rekonstituierten ||| Some settling of the reconstituted ||| 1-0 0-1 1-1 2-1 3-2 3-3 4-4
Ein leichtes Absetzen der ||| Some settling of the ||| 1-0 0-1 1-1 2-1 3-2 3-3
Ein leichtes Absetzen ||| Some settling ||| 1-0 0-1 1-1 2-1
Ein ml Lösung enthält ||| One ml solution contains ||| 0-0 1-1 2-2 3-3
Ein ml Lösung ||| One ml solution ||| 0-0 1-1 2-2
Ein ml der Lösung enthält ||| One ml solution contains ||| 0-0 1-1 3-2 4-3
Ein ml der Lösung ||| One ml solution ||| 0-0 1-1 3-2
Ein ml der ||| One ml ||| 0-0 1-1
Ein ml ||| One ml ||| 0-0 1-1
Ein vorgefüllter Fertigpen enthält 3 ||| 1 pre-filled pen contains 3 ||| 1-0 1-1 0-2 1-2 2-2 3-3 4-4
Ein vorgefüllter Fertigpen enthält ||| 1 pre-filled pen contains ||| 1-0 1-1 0-2 1-2 2-2 3-3
Ein vorgefüllter Fertigpen ||| 1 pre-filled pen ||| 1-0 1-1 0-2 1-2 2-2
Ein ||| A ||| 0-0
Ein ||| One ||| 0-0
Eindruck ||| impression ||| 0-0
Eine Anpassung der Dosierung kann ||| 16 Adjustment of dosage may ||| 2-0 0-1 1-1 2-2 3-3 4-4
Eine Anpassung der Dosierung kann ||| 2 Adjustment of dosage may ||| 0-1 1-1 2-2 3-3 4-4
Eine Anpassung der Dosierung kann ||| 23 Adjustment of dosage may ||| 1-0 0-1 1-1 2-2 3-3 4-4
Eine Anpassung der Dosierung kann ||| 30 Adjustment of dosage may ||| 0-1 1-1 2-2 3-3 4-4
Eine Anpassung der Dosierung kann ||| 37 Adjustment of dosage may ||| 1-0 0-1 1-1 2-2 3-3 4-4
Eine Anpassung der Dosierung kann ||| 44 Adjustment of dosage may ||| 1-0 0-1 1-1 2-2 3-3 4-4
Eine Anpassung der Dosierung kann ||| 51 Adjustment of dosage may ||| 1-0 0-1 1-1 2-2 3-3 4-4
Eine Anpassung der Dosierung kann ||| 58 Adjustment of dosage may ||| 1-0 0-1 1-1 2-2 3-3 4-4
Eine Anpassung der Dosierung kann ||| 65 Adjustment of dosage may ||| 0-0 0-1 1-1 2-2 3-3 4-4
Eine Anpassung der Dosierung kann ||| 72 Adjustment of dosage may ||| 1-0 0-1 1-1 2-2 3-3 4-4
Eine Anpassung der Dosierung kann ||| 79 Adjustment of dosage may ||| 1-0 0-1 1-1 2-2 3-3 4-4
Eine Anpassung der Dosierung kann ||| 9 Adjustment of dosage may ||| 1-0 0-1 1-1 2-2 3-3 4-4
Eine Anpassung der Dosierung kann ||| Adjustment of dosage may ||| 0-0 1-0 2-1 3-2 4-3
Eine Anpassung der Dosierung ||| 16 Adjustment of dosage ||| 2-0 0-1 1-1 2-2 3-3
Eine Anpassung der Dosierung ||| 2 Adjustment of dosage ||| 0-1 1-1 2-2 3-3
Eine Anpassung der Dosierung ||| 23 Adjustment of dosage ||| 1-0 0-1 1-1 2-2 3-3
Eine Anpassung der Dosierung ||| 30 Adjustment of dosage ||| 0-1 1-1 2-2 3-3
Eine Anpassung der Dosierung ||| 37 Adjustment of dosage ||| 1-0 0-1 1-1 2-2 3-3
Eine Anpassung der Dosierung ||| 44 Adjustment of dosage ||| 1-0 0-1 1-1 2-2 3-3
Eine Anpassung der Dosierung ||| 51 Adjustment of dosage ||| 1-0 0-1 1-1 2-2 3-3
Eine Anpassung der Dosierung ||| 58 Adjustment of dosage ||| 1-0 0-1 1-1 2-2 3-3
Eine Anpassung der Dosierung ||| 65 Adjustment of dosage ||| 0-0 0-1 1-1 2-2 3-3
Eine Anpassung der Dosierung ||| 72 Adjustment of dosage ||| 1-0 0-1 1-1 2-2 3-3
Eine Anpassung der Dosierung ||| 79 Adjustment of dosage ||| 1-0 0-1 1-1 2-2 3-3
Eine Anpassung der Dosierung ||| 9 Adjustment of dosage ||| 1-0 0-1 1-1 2-2 3-3
Eine Anpassung der Dosierung ||| Adjustment of dosage ||| 0-0 1-0 2-1 3-2
Eine Anpassung der Tagesdosis ||| Adjustments of daily dosage ||| 0-0 1-0 2-1 3-2 1-3
Eine Anpassung der ||| 16 Adjustment of ||| 2-0 0-1 1-1 2-2
Eine Anpassung der ||| 2 Adjustment of ||| 0-1 1-1 2-2
Eine Anpassung der ||| 23 Adjustment of ||| 1-0 0-1 1-1 2-2
Eine Anpassung der ||| 30 Adjustment of ||| 0-1 1-1 2-2
Eine Anpassung der ||| 37 Adjustment of ||| 1-0 0-1 1-1 2-2
Eine Anpassung der ||| 44 Adjustment of ||| 1-0 0-1 1-1 2-2
Eine Anpassung der ||| 51 Adjustment of ||| 1-0 0-1 1-1 2-2
Eine Anpassung der ||| 58 Adjustment of ||| 1-0 0-1 1-1 2-2
Eine Anpassung der ||| 65 Adjustment of ||| 0-0 0-1 1-1 2-2
Eine Anpassung der ||| 72 Adjustment of ||| 1-0 0-1 1-1 2-2
Eine Anpassung der ||| 79 Adjustment of ||| 1-0 0-1 1-1 2-2
Eine Anpassung der ||| 9 Adjustment of ||| 1-0 0-1 1-1 2-2
Eine Anpassung der ||| Adjustment of ||| 0-0 1-0 2-1
Eine Anpassung ||| 2 Adjustment ||| 0-1 1-1
Eine Anpassung ||| 23 Adjustment ||| 1-0 0-1 1-1
Eine Anpassung ||| 30 Adjustment ||| 0-1 1-1
Eine Anpassung ||| 37 Adjustment ||| 1-0 0-1 1-1
Eine Anpassung ||| 44 Adjustment ||| 1-0 0-1 1-1
Eine Anpassung ||| 51 Adjustment ||| 1-0 0-1 1-1
Eine Anpassung ||| 58 Adjustment ||| 1-0 0-1 1-1
Eine Anpassung ||| 65 Adjustment ||| 0-0 0-1 1-1
Eine Anpassung ||| 72 Adjustment ||| 1-0 0-1 1-1
Eine Anpassung ||| 79 Adjustment ||| 1-0 0-1 1-1
Eine Anpassung ||| 9 Adjustment ||| 1-0 0-1 1-1
Eine Anpassung ||| Adjustment ||| 0-0 1-0
Eine Anwendung in der ||| Patients ||| 0-0 1-0 2-0
Eine Anwendung in ||| Patients ||| 0-0 1-0 2-0
Eine Dosisanpassung ist nicht erforderlich ||| No dose adjustment is required ||| 0-0 1-0 1-1 1-2 2-3 3-3 4-4
Eine Dosisanpassung ist nicht notwendig ||| No dose adjustment is necessary ||| 0-0 1-0 1-1 1-2 2-3 3-3 4-4
Eine Dosisanpassung ist nicht ||| No dose adjustment is ||| 0-0 1-0 1-1 1-2 2-3 3-3
Eine Dosisanpassung kann notwendig sein ||| Dosage adjustment may be necessary ||| 0-0 1-0 1-1 2-2 4-3 3-4 4-4
Eine Dosisanpassung kann ||| Dosage adjustment may ||| 0-0 1-0 1-1 2-2
Eine Dosisanpassung ||| Dosage adjustment ||| 0-0 1-0 1-1
Eine Dosisanpassung ||| No dose adjustment ||| 0-0 1-0 1-1 1-2
Eine Durchstechflasche enthält 9,75 mg ||| A vial contains 9.75 mg ||| 0-0 1-1 2-2 3-3 4-4
Eine Durchstechflasche enthält 9,75 ||| A vial contains 9.75 ||| 0-0 1-1 2-2 3-3
Eine Durchstechflasche enthält ||| A vial contains ||| 0-0 1-1 2-2
Eine Durchstechflasche ||| A vial ||| 0-0 1-1
Eine Durchstechflasche. enthält 9,75 mg ||| A vial provides 9.75 mg ||| 0-0 1-1 2-1 1-2 3-3 4-4
Eine Durchstechflasche. enthält 9,75 ||| A vial provides 9.75 ||| 0-0 1-1 2-1 1-2 3-3
Eine Durchstechflasche. enthält ||| A vial provides ||| 0-0 1-1 2-1 1-2
Eine Einzeldosis-Studie bei Probanden ||| A single-dose study in subjects ||| 0-0 1-0 1-1 1-2 2-3 3-4
Eine Einzeldosis-Studie bei ||| A single-dose study in ||| 0-0 1-0 1-1 1-2 2-3
Eine Einzeldosis-Studie ||| A single-dose study ||| 0-0 1-0 1-1 1-2
Eine Erhöhung der Pioglitazondosierung bei ||| The pioglitazone dose may need ||| 0-0 1-1 3-1 3-2 3-3 3-4 4-4
Eine Flasche mit 100 ml ||| Each bottle with 100 ml ||| 0-0 1-1 2-2 3-3 4-4
Eine Flasche mit 100 ||| Each bottle with 100 ||| 0-0 1-1 2-2 3-3
Eine Flasche mit ||| Each bottle with ||| 0-0 1-1 2-2
Eine Flasche ||| Each bottle ||| 0-0 1-1
Eine Gewichtszunahme wurde nach ||| Weight gain has ||| 0-0 1-0 1-1 2-2 3-2
Eine Gewichtszunahme ||| Weight gain ||| 0-0 1-0 1-1
Eine Hypoglykämie kann in Kombination ||| Hypoglycaemia may occur in combination ||| 0-0 1-0 2-1 2-2 3-3 4-4
Eine Hypoglykämie kann in ||| Hypoglycaemia may occur in ||| 0-0 1-0 2-1 2-2 3-3
Eine Hypoglykämie kann ||| Hypoglycaemia may occur ||| 0-0 1-0 2-1 2-2
Eine Hypoglykämie kann ||| Hypoglycaemia may ||| 0-0 1-0 2-1
Eine Hypoglykämie ||| Hypoglycaemia ||| 0-0 1-0
Eine Hypoglykämie ||| The patient s ability ||| 0-0 0-1 0-2 1-2 1-3
Eine I.E. ( Internationale Einheitt ||| One IU ( International Unit ||| 0-0 1-1 2-2 3-3 3-4 4-4
Eine I.E. ( Internationale ||| One IU ( International ||| 0-0 1-1 2-2 3-3
Eine I.E. ( ||| One IU ( ||| 0-0 1-1 2-2
Eine I.E. ||| One IU ||| 0-0 1-1
Eine Mahlzeit ||| There is ||| 0-0 1-0 1-1
Eine Mikrocomputertomographie-(µCT)-Analyse ||| 8 tomography ( CT ) ||| 1-0 1-1 1-3
Eine Mikrocomputertomographie-(µCT)-Analyse ||| 8 tomography ( CT ||| 1-0 1-1 1-3
Eine Nieren- oder Leberfunktionsstörung kann ||| Renal or hepatic impairment may ||| 0-0 1-0 2-1 3-2 3-3 4-4
Eine Nieren- oder Leberfunktionsstörung ||| Renal or hepatic impairment ||| 0-0 1-0 2-1 3-2 3-3
Eine Nieren- oder ||| Renal or ||| 0-0 1-0 2-1
Eine Nieren- ||| Renal ||| 0-0 1-0
Eine Patrone enthält 3 ||| 1 cartridge contains 3 ||| 1-0 0-1 1-1 2-2 3-3
Eine Patrone enthält ||| 1 cartridge contains ||| 1-0 0-1 1-1 2-2
Eine Patrone ||| 1 cartridge ||| 1-0 0-1 1-1
Eine Populations-spezifische Auswertung zur ||| Population pharmacokinetic evaluation has ||| 0-0 1-0 2-0 1-1 2-2 3-2 2-3
Eine Reihe von Spaltungs- ( ||| A number of cleavage ( ||| 0-0 1-0 1-1 2-2 3-3 4-4
Eine Reihe von Spaltungs- ||| A number of cleavage ||| 0-0 1-0 1-1 2-2 3-3
Eine Reihe von ||| A number of ||| 0-0 1-0 1-1 2-2
Eine Reihe ||| A number ||| 0-0 1-0 1-1
Eine Steatosis der Leber und ||| observed ||| 0-0 1-0 2-0 3-0 4-0
Eine Tablette enthält 15 mg ||| Each tablet contains 15 mg ||| 0-0 1-1 2-2 3-3 4-4
Eine Tablette enthält 15 mg ||| Each tablet contains 15mg of ||| 0-0 1-1 2-2 3-3 4-3
Eine Tablette enthält 15 mg ||| Each tablet contains 15mg ||| 0-0 1-1 2-2 3-3 4-3
Eine Tablette enthält 15 ||| Each tablet contains 15 ||| 0-0 1-1 2-2 3-3
Eine Tablette enthält 30 mg ||| Each tablet contains 30 mg ||| 0-0 1-1 2-2 3-3 4-4
Eine Tablette enthält 30 mg ||| Each tablet contains 30mg of ||| 0-0 1-1 2-2 3-3 4-3
Eine Tablette enthält 30 mg ||| Each tablet contains 30mg ||| 0-0 1-1 2-2 3-3 4-3
Eine Tablette enthält 30 ||| Each tablet contains 30 ||| 0-0 1-1 2-2 3-3
Eine Tablette enthält 45 mg ||| Each tablet contains 45 mg ||| 0-0 1-1 2-2 3-3 4-4
Eine Tablette enthält 45 mg ||| Each tablet contains 45mg of ||| 0-0 1-1 2-2 3-3 4-3
Eine Tablette enthält 45 mg ||| Each tablet contains 45mg ||| 0-0 1-1 2-2 3-3 4-3
Eine Tablette enthält 45 ||| Each tablet contains 45 ||| 0-0 1-1 2-2 3-3
Eine Tablette enthält ||| Each tablet contains ||| 0-0 1-1 2-2
Eine Tablette ||| Each tablet ||| 0-0 1-1
Eine Verwendung spezieller DEHP-freier Lösungsbehältnisse ||| The use of specialized DEHP-free ||| 0-0 1-1 0-2 2-3 3-3 4-4
Eine Verwendung spezieller DEHP-freier ||| The use of specialized ||| 0-0 1-1 0-2 2-3 3-3
Eine Verwendung ||| The use of ||| 0-0 1-1 0-2
Eine enge Überwachung ||| Close supervision ||| 0-0 1-0 1-1 2-1
Eine engmaschige Blutzuckerkontrolle ||| Close monitoring of glycaemic control ||| 0-0 1-0 1-1 0-2 2-3 2-4
Eine engmaschige ||| Close monitoring of ||| 0-0 1-0 1-1 0-2
Eine frühzeitige Shuntrevision und ||| Early shunt revision and thrombosis ||| 0-0 1-0 1-1 1-2 2-2 3-3 2-4
Eine gesteigerte Knochenumbaurate ist ||| Elevated bone turnover is a ||| 0-0 1-0 2-0 2-1 2-2 3-3 3-4
Eine gesteigerte Knochenumbaurate ||| Elevated bone turnover ||| 0-0 1-0 2-0 2-1 2-2
Eine gesteigerte Wirksamkeit bei Dosierungen ||| Enhanced efficacy at doses higher ||| 0-0 1-0 2-1 1-2 3-2 4-3 1-4
Eine gleichzeitige Anwendung von Pioglitazon ||| Co-administration of pioglitazone ||| 0-0 1-0 2-0 3-1 4-2
Eine gleichzeitige Anwendung von ||| Co-administration of ||| 0-0 1-0 2-0 3-1
Eine gleichzeitige Anwendung ||| Co-administration ||| 0-0 1-0 2-0
Eine gleichzeitige Osteoporose-Therapie ||| Concomitant osteoporosis therapy ||| 1-0 2-1 2-2
Eine gleichzeitige ||| Concomitant ||| 1-0
Eine hypertensive Krise mit enzephalopathieähnlichen ||| Hypertensive crisis with encephalopathy-like ||| 0-0 1-0 1-1 2-1 3-2 4-3
Eine hypertensive Krise mit ||| Hypertensive crisis with ||| 0-0 1-0 1-1 2-1 3-2
Eine hypertensive Krise ||| Hypertensive crisis ||| 0-0 1-0 1-1 2-1
Eine kardiovaskuläre Outcome-Studie mit ||| A cardiovascular outcome study of ||| 0-0 1-1 2-2 2-3 3-3
Eine kardiovaskuläre Outcome-Studie mit ||| A cardiovascular outcome study ||| 0-0 1-1 2-2 2-3 3-3
Eine kardiovaskuläre ||| A cardiovascular ||| 0-0 1-1
Eine klinische Studie mit Pioglitazon ||| A clinical trial of pioglitazone ||| 0-0 1-1 2-2 3-3 4-4
Eine klinische Studie mit ||| A clinical trial of ||| 0-0 1-1 2-2 3-3
Eine klinische Studie ||| A clinical trial ||| 0-0 1-1 2-2
Eine klinische ||| A clinical ||| 0-0 1-1
Eine langfristige Verbesserung ||| Long-term improved glycaemic ||| 0-0 1-0 1-1 2-1 2-2
Eine langfristige Verbesserung ||| Long-term improved glycaemic ||| 0-0 1-0 1-1 2-2
Eine langfristige ||| Long-term improved ||| 0-0 1-0 1-1
Eine leicht eingeschränkte Leberfunktion ||| Mild hepatic impairment does ||| 0-0 1-1 3-1 2-2 3-2 3-3
Eine niedrigere Dosis von 5,25 ||| A lower dose of 5.25 ||| 0-0 1-1 2-2 3-3 4-4
Eine niedrigere Dosis von ||| A lower dose of ||| 0-0 1-1 2-2 3-3
Eine niedrigere Dosis ||| A lower dose ||| 0-0 1-1 2-2
Eine niedrigere ||| A lower ||| 0-0 1-1
Eine prokonvulsive Aktivität von Rimonabant ||| A proconvulsant activity of rimonabant ||| 0-0 1-1 2-2 3-3 4-4
Eine prokonvulsive Aktivität von ||| A proconvulsant activity of ||| 0-0 1-1 2-2 3-3
Eine prokonvulsive Aktivität ||| A proconvulsant activity ||| 0-0 1-1 2-2
Eine prokonvulsive ||| A proconvulsant ||| 0-0 1-1
Eine rasche Besserung der ||| Fast improvement in blood ||| 0-0 1-0 2-1 2-2 1-3 3-3
Eine unzureichende Dosierung oder ||| Inadequate dosage or ||| 0-0 1-0 2-1 3-2
Eine unzureichende Dosierung ||| Inadequate dosage ||| 0-0 1-0 2-1
Eine unzureichende ||| Inadequate ||| 0-0 1-0
Eine vorbestehende Hypokalzämie muss ||| Pre-existing hypocalcaemia must be ||| 0-0 1-0 2-1 3-2 3-3
Eine vorbestehende Hypokalzämie ||| Pre-existing hypocalcaemia ||| 0-0 1-0 2-1
Eine vorbestehende ||| Pre-existing ||| 0-0 1-0
Eine wiederholte Anwendung ||| Repeated dosing does ||| 0-0 1-0 2-0 1-1 1-2
Eine zusätzliche ||| Eine zusätzliche oder verstärkte antihypertensive ||| 1-0 0-1 1-1 1-2 1-3 1-4
Eine ||| A ||| 0-0
Eine ||| Each ||| 0-0
Eine ||| Mild ||| 0-0
Eine ||| One ||| 0-0
Eine ||| The ||| 0-0
Eine ||| There ||| 0-0
Eine ähnliche Erhöhung der ||| A similar increase ||| 0-0 1-1 2-2 3-2
Eine ähnliche ||| A similar ||| 0-0 1-1
Einfluss auf die Verkehrstüchtigkeit und ||| influence on the ability ||| 0-0 1-1 2-1 2-2 3-3 4-3
Einfluss auf die Verstoffwechselung anderer ||| alters the metabolism of other ||| 0-0 1-0 2-1 3-2 2-3 4-4
Einfluss auf die Verstoffwechselung ||| alters the metabolism of ||| 0-0 1-0 2-1 3-2 2-3
Einfluss auf die ||| influence on the ||| 0-0 1-1 2-1 2-2
Einfluss auf ||| alters ||| 0-0 1-0
Einfluss auf ||| impact on ||| 1-0 0-1 1-1
Einfluss auf ||| may impact on ||| 1-1 0-2 1-2
Einfluss von Rimonabant auf die ||| Effects of rimonabant on ||| 3-0 1-1 0-2 2-2 3-3 4-3
Einfluss von Rimonabant ||| of rimonabant ||| 1-0 0-1 2-1
Einfluss ||| influence ||| 0-0
Einflüsse auf die Verkehrstüchtigkeit ||| effects on ability to ||| 0-0 1-1 0-2 2-2 3-2 1-3
Einführung von angemessenen ||| Introducing appropriate ||| 0-0 2-1
Einführung von ||| Introducing ||| 0-0
Einführung ||| Introducing ||| 0-0
Eingriff und am ||| surgery and ||| 0-0 2-0 1-1
Eingriff vorgesehen ist : ||| orthopaedic surgery : ||| 0-0 1-0 1-1 2-1 3-2
Eingriff vorgesehen ist : ||| orthopaedic surgery ||| 0-0 1-0 1-1 2-1 3-1
Eingriff vorgesehen ist und : ||| orthopaedic surgery and : ||| 0-0 1-0 1-1 2-1 3-2 4-3
Eingriff vorgesehen ist und ||| orthopaedic surgery and ||| 0-0 1-0 1-1 2-1 3-2
Eingriff vorgesehen ist ||| orthopaedic surgery ||| 0-0 1-0 1-1 2-1
Eingriff ||| surgery ||| 0-0
Einheit ) entspricht 0,035 ||| Unit ) corresponds to 0.035 ||| 0-0 1-1 0-2 2-2 2-3 3-4
Einheit ) entspricht ||| Unit ) corresponds to ||| 0-0 1-1 0-2 2-2 2-3
Einheiten ( I.E. ) , ||| units ( IU ) ||| 0-0 1-1 2-2 3-3
Einheiten ( I.E. ) pro ||| Units ( IU ) per ||| 0-0 1-1 2-2 3-3 4-4
Einheiten ( I.E. ) ||| Units ( IU ) ||| 0-0 1-1 2-2 3-3
Einheiten ( I.E. ) ||| units ( IU ) ||| 0-0 1-1 2-2 3-3
Einheiten ( I.E. ||| Units ( IU ||| 0-0 1-1 2-2
Einheiten ( I.E. ||| units ( IU ||| 0-0 1-1 2-2
Einheiten ( ||| Units ( ||| 0-0 1-1
Einheiten ( ||| units ( ||| 0-0 1-1
Einheiten ab . ||| units . ||| 0-0 1-0 2-1
Einheiten ab ||| units ||| 0-0 1-0
Einheiten in Schritten von 2 ||| units in increments of 2 ||| 0-0 1-1 1-2 2-2 3-3 4-4
Einheiten in Schritten von ||| units in increments of ||| 0-0 1-1 1-2 2-2 3-3
Einheiten in Schritten ||| units in increments ||| 0-0 1-1 1-2 2-2
Einheiten ||| Units ||| 0-0
Einheiten ||| units of ||| 0-0
Einheiten ||| units ||| 0-0
Einheitenskala vorgesehen . ||| unit scale . ||| 0-0 0-1 1-1 2-2
Einheitenskala vorgesehen ||| unit scale ||| 0-0 0-1 1-1
Einige Patienten können ||| Some patients may ||| 0-0 1-1 2-2
Einige Patienten ||| Some patients ||| 0-0 1-1
Einige ||| 10 A few ||| 0-1 0-2
Einige ||| 3 A few ||| 0-1 0-2
Einige ||| A few ||| 0-0 0-1
Einige ||| Some ||| 0-0
Einklang mit den biochemischen Markern ||| consistent with biochemical marker ||| 0-0 2-0 1-1 3-2 4-3
Einklang mit den biochemischen ||| consistent with biochemical ||| 0-0 2-0 1-1 3-2
Einklang mit den ||| consistent with ||| 0-0 2-0 1-1
Einmaldosis bei gesunden Probanden ||| single-dose to healthy subjects ||| 0-0 1-0 3-0 2-2 3-3
Einmalgabe und Mehrfachgabe ||| and repeat-dose ||| 1-0 0-1 1-1 2-1
Einmalgabe ||| , ||| 0-0
Einmalige und mehrfache 5 und ||| Single and multiple 5 and ||| 0-0 2-0 1-1 1-2 3-3 4-4
Einmalige und mehrfache 5 ||| Single and multiple 5 ||| 0-0 2-0 1-1 1-2 3-3
Einmalige und mehrfache ||| Single and multiple ||| 0-0 2-0 1-1 1-2
Einnahme . ||| administer . ||| 0-0 1-1
Einnahme dieses ||| taking this ||| 0-0 1-1
Einnahme erreicht . ||| dosing . ||| 0-0 1-0 2-1
Einnahme erreicht ||| dosing ||| 0-0 1-0
Einnahme ist ||| of ||| 1-0
Einnahme von Actos 15 mg ||| Taking Actos 15mg ||| 0-0 1-0 2-1 3-2 4-2
Einnahme von Actos 15mg Tabletten ||| taking Actos 15mg tablets ||| 0-0 3-0 2-1 2-2 4-3
Einnahme von Actos 15mg ||| taking Actos 15mg ||| 0-0 3-0 2-1 2-2
Einnahme von Actos 30 mg ||| Taking Actos 30mg ||| 0-0 1-0 2-1 3-2 4-2
Einnahme von Actos 30mg Tabletten ||| taking Actos 30mg tablets ||| 0-0 3-0 2-1 2-2 4-3
Einnahme von Actos 30mg ||| taking Actos 30mg ||| 0-0 3-0 2-1 2-2
Einnahme von Actos 45 mg ||| Taking Actos 45mg ||| 0-0 1-0 2-1 3-2 4-2
Einnahme von Actos 45mg Tabletten ||| taking Actos 45mg tablets ||| 0-0 3-0 2-1 2-2 4-3
Einnahme von Actos 45mg ||| taking Actos 45mg ||| 0-0 3-0 2-1 2-2
Einnahme von Actos ||| Taking Actos ||| 0-0 1-0 2-1
Einnahme von Kalzium und ||| in association with ||| 1-0 0-1 2-1 3-1 0-2
Einnahme von anderen Osteoporosearzneimitteln ||| allowed to take other medicines ||| 2-0 1-1 0-2 2-3 3-3 2-4
Einnahme von ||| Taking ||| 0-0 1-0
Einnahme von ||| to take ||| 1-0 0-1
Einnahme ||| administer ||| 0-0
Einnahme ||| intake ||| 0-0
Einnahme ||| take ||| 0-0
Einnahme ||| taking ||| 0-0
Einnahme ||| you ||| 0-0
Einnehmen Klare , farblose ||| Clear , colourless ||| 0-0 1-0 2-1 3-2
Einnehmen Klare , ||| Clear , ||| 0-0 1-0 2-1
Einnehmen Klare ||| Clear ||| 0-0 1-0
Einnehmen ||| oral ||| 0-0
Einnistungen ||| still ||| 0-0
Einsatz ||| are ||| 0-0
Einschränkung der Nierenfunktion vor . ||| renal impairment . ||| 0-0 2-0 2-1 3-1 4-2
Einschränkung der Nierenfunktion vor ||| renal impairment ||| 0-0 2-0 2-1 3-1
Einschränkung der Nierenfunktion ||| renal impairment ||| 0-0 2-0 2-1
Einstellung des Rauchens ||| smoking cessation ||| 1-0 2-0 0-1 2-1
Einstellung des pH-Wertes ) ||| pH adjustment ) ||| 0-0 1-0 2-0 2-1 3-2
Einstellung des pH-Wertes ||| pH adjustment ||| 0-0 1-0 2-0 2-1
Einstellung ||| control ||| 0-0
Einstellung ||| diabetic patients ||| 0-0
Einstellung ||| diabetic ||| 0-0
Einstellung ||| the control ||| 0-1
Einstichstelle . ||| pad . ||| 0-0 1-1
Einstichstelle ||| pad ||| 0-0
Einzeldosis ||| single ||| 0-0
Einzelfall ||| case ||| 0-0
Einzelfällen von Angioödemen und ||| isolated cases of angioedema and ||| 0-0 0-1 1-2 2-3 3-4
Einzelfällen von Angioödemen ||| isolated cases of angioedema ||| 0-0 0-1 1-2 2-3
Einzelfällen von ||| isolated cases of ||| 0-0 0-1 1-2
Einzelfällen ||| isolated cases ||| 0-0 0-1
Einzelne ||| There ||| 0-0
Eisen zum Einnehmen , ||| oral doses of iron , ||| 1-0 2-0 0-3 3-4
Eisen zum Einnehmen ||| oral doses of iron ||| 1-0 2-0 0-3
Eisen ||| doses of iron ||| 0-2
Eisen ||| iron ||| 0-0
Eisen ||| of iron ||| 0-1
Eisen(III)- oxid ( E172 ) ||| iron oxide ( E172 ) ||| 0-0 0-1 1-1 3-1 2-2 3-3 4-4
Eisen(III)- oxid ( E172 ||| iron oxide ( E172 ||| 0-0 0-1 1-1 3-1 2-2 3-3
Eisen(III)-hydroxid-oxid x H2O ( E172 ||| yellow iron oxide ( E172 ||| 0-0 4-1 2-2 4-2 1-3 3-3 4-4
Eisen(III)-hydroxid-oxid ||| yellow ||| 0-0
Eisen(III)-oxid ( E172 ||| red iron oxide ( E172 ||| 0-0 0-1 0-2 2-2 1-3 2-4
Eisenmangel , ||| iron deficiency , ||| 0-0 0-1 1-2
Eisenmangel ||| iron deficiency ||| 0-0 0-1
Eisensubstitution ||| substitution of ||| 0-0
Eisensubstitution ||| substitution ||| 0-0
Eli Lilly Finland Ab ||| Eli Lilly Finland Ab ||| 0-0 1-1 2-2 3-3
Eli Lilly Finland ||| Eli Lilly Finland ||| 0-0 1-1 2-2
Eli Lilly Holdings Limited Eesti ||| Eli Lilly Holdings Limited Eesti ||| 0-0 1-1 2-2 3-3 4-4
Eli Lilly Holdings Limited p ||| Eli Lilly Holdings Limited p ||| 0-0 1-1 2-2 3-3 4-4
Eli Lilly Holdings Limited ||| Eli Lilly Holdings Limited ||| 0-0 1-1 2-2 3-3
Eli Lilly Holdings ||| Eli Lilly Holdings ||| 0-0 1-1 2-2
Eli Lilly farmacevtska dru ||| Eli Lilly farmacevtska dru ba ||| 0-0 1-1 1-2 2-2 2-3 3-4
Eli Lilly farmacevtska ||| Eli Lilly farmacevtska dru ||| 0-0 1-1 1-2 2-2 2-3
Eli Lilly farmacevtska ||| Eli Lilly farmacevtska dru ||| 0-0 1-1 2-2 2-3
Eli Lilly ||| Eli Lilly ||| 0-0 1-1
Eli ||| Eli ||| 0-0
Elimination Die ||| 13 Elimination The ||| 0-0 0-1 1-2
Elimination Die ||| 20 Elimination The ||| 0-0 0-1 1-2
Elimination Die ||| 27 Elimination The ||| 0-0 0-1 1-2
Elimination Die ||| 34 Elimination The ||| 0-0 0-1 1-2
Elimination Die ||| 55 Elimination The ||| 0-0 0-1 1-2
Elimination Die ||| 62 Elimination The ||| 0-0 0-1 1-2
Elimination Die ||| 69 Elimination The ||| 0-0 0-1 1-2
Elimination Die ||| 76 Elimination The ||| 0-0 0-1 1-2
Elimination Die ||| Elimination The ||| 0-0 1-1
Elimination per se des Insulins ||| elimination per se of insulin ||| 0-0 1-1 1-2 2-2 3-3 3-4 4-4
Elimination per se ||| elimination per se ||| 0-0 1-1 1-2 2-2
Elimination ||| 13 Elimination ||| 0-0 0-1
Elimination ||| 20 Elimination ||| 0-0 0-1
Elimination ||| 27 Elimination ||| 0-0 0-1
Elimination ||| 34 Elimination ||| 0-0 0-1
Elimination ||| 55 Elimination ||| 0-0 0-1
Elimination ||| 62 Elimination ||| 0-0 0-1
Elimination ||| 69 Elimination ||| 0-0 0-1
Elimination ||| 76 Elimination ||| 0-0 0-1
Elimination ||| Elimination ||| 0-0
Elimination ||| elimination were ||| 0-0
Elimination ||| elimination ||| 0-0
Eliminationshalbwertszeit wegen des größeren ||| Eliminationshalbwertszeit wegen des ||| 0-0 0-1 2-2
Eliminationshalbwertszeit wegen des ||| Eliminationshalbwertszeit wegen des ||| 0-0 0-1 2-2
Eliminationshalbwertszeit wegen ||| Eliminationshalbwertszeit wegen ||| 0-0 0-1
Eliminationshalbwertszeit ||| Eliminationshalbwertszeit wegen ||| 0-0 0-1
Empfehlung von Dosisanpassungen bei Patienten ||| recommend dose modifications in patients ||| 0-0 1-1 2-2 3-3 4-4
Empfehlung von Dosisanpassungen bei ||| recommend dose modifications in ||| 0-0 1-1 2-2 3-3
Empfehlung von Dosisanpassungen ||| recommend dose modifications ||| 0-0 1-1 2-2
Empfehlung von ||| recommend dose ||| 0-0 1-1
Empfehlung ||| recommend ||| 0-0
Empfindens , Synkope , posturaler ||| , syncope , postural ||| 0-0 1-0 2-1 3-2 4-3
Empfindens , Synkope , ||| , syncope , ||| 0-0 1-0 2-1 3-2
Empfindens , Synkope ||| , syncope ||| 0-0 1-0 2-1
Empfindens , ||| , ||| 0-0 1-0
Empfindlichkeit gegenüber Reizen ) ||| sensitivity to a stimulus ) ||| 0-0 1-1 1-2 2-3 3-4
Empfindlichkeit gegenüber Reizen ||| sensitivity to a stimulus ||| 0-0 1-1 1-2 2-3
Empfindlichkeit gegenüber ||| sensitivity to a ||| 0-0 1-1 1-2
Empfindlichkeit ||| sensitivity ||| 0-0
Empfängnisverhütung praktizieren ||| contraception ||| 0-0 1-0
Ende der Behandlung zurückzubilden . ||| the end of treatment . ||| 1-0 0-1 3-1 1-2 2-3 4-4
Ende der Behandlung zurückzubilden ||| the end of treatment ||| 1-0 0-1 3-1 1-2 2-3
Ende der Behandlungzurückzubilden . ||| the end of treatment . ||| 1-0 0-1 2-1 1-2 2-3 3-4
Ende der Behandlungzurückzubilden ||| the end of treatment ||| 1-0 0-1 2-1 1-2 2-3
Ende ||| the end ||| 0-0 0-1
Endothelzellen fördert ||| endothelial ||| 0-0 1-0
Endpunkt war 5,8 für Placebo ||| endpoint was 5.8 for placebo ||| 0-0 1-1 2-2 3-3 4-4
Endpunkt war 5,8 für ||| endpoint was 5.8 for ||| 0-0 1-1 2-2 3-3
Endpunkt war 5,8 ||| endpoint was 5.8 ||| 0-0 1-1 2-2
Endpunkt war ||| endpoint was ||| 0-0 1-1
Endpunkt ||| endpoint ||| 0-0
Energie zu haben ||| having excessive ||| 0-0 0-1 1-1 2-1
Enterozyten . ||| enterocytes . ||| 0-0 1-1
Enterozyten kann es zur Verringerung ||| enterocytes may be followed by ||| 0-0 1-1 2-1 1-2 4-4
Enterozyten kann es zur ||| enterocytes may be followed ||| 0-0 1-1 2-1 1-2
Enterozyten kann es zur ||| enterocytes may be ||| 0-0 1-1 2-1 1-2
Enterozyten kann es ||| enterocytes may be followed ||| 0-0 1-1 2-1 1-2
Enterozyten kann es ||| enterocytes may be ||| 0-0 1-1 2-1 1-2
Enterozyten ||| enterocytes ||| 0-0
Enthält Fructose , Sucrose ||| Contains fructose , sucrose , ||| 0-0 1-1 2-2 3-3 2-4
Enthält Fructose ||| Contains fructose ||| 0-0 1-1
Enthält Lactosemonohydrat . ||| . Contains lactose monohydrate . ||| 2-0 0-1 1-2 1-3 2-4
Enthält Lactosemonohydrat ||| Contains lactose monohydrate ||| 0-0 1-1 1-2
Enthält auch : Heptakis-O-(4-sulfobutyl)cyclomaltoheptaose ||| Also contains sulfobutylether ||| 0-0 1-0 2-2 3-2
Enthält auch ||| Also contains ||| 0-0 1-0
Enthält auch ||| Also ||| 0-0 1-0
Enthält ||| Contains ||| 0-0
Entnahme einer einzelnen Tablette ||| single tablet removal , ||| 0-0 3-1 0-2 1-2 2-2
Entnahme einer einzelnen Tablette ||| single tablet removal ||| 0-0 3-1 0-2 1-2 2-2
Entnehmen Sie ||| Immediately upon ||| 0-0 1-0 0-1
Entnehmen ||| Remove ||| 0-0
Entscheidung , ob die ||| decision whether to ||| 0-0 1-1 2-1 3-2
Entscheidung , ob ||| decision whether ||| 0-0 1-1 2-1
Entscheidung der CHMP . ||| the CHMP . ||| 0-0 1-0 2-1 3-2
Entscheidung der CHMP ||| the CHMP ||| 0-0 1-0 2-1
Entscheidung der ||| the ||| 0-0 1-0
Entscheidung für die ||| decision to administer ||| 0-0 0-1 0-2 1-2 2-2
Entscheidung ||| decision ||| 0-0
Entsorgung ||| unused ||| 0-0
Entwicklung beobachtet worden waren . ||| developmental toxicity . ||| 0-0 1-0 2-0 3-0 0-1 4-2
Entwicklung beobachtet worden waren ||| developmental toxicity ||| 0-0 1-0 2-0 3-0 0-1
Entwicklung ||| development ||| 0-0
Entzündung ) kurz ||| ) shortly ||| 1-0 2-1
Entzündung ) ||| ) ||| 1-0
Entzündung ||| inflammation of ||| 0-0
Entzündung ||| inflammation ||| 0-0
Entzündungen . ||| inflammation . ||| 0-0 1-1
Entzündungen . ||| may help to ||| 0-0 0-1 1-1 0-2
Entzündungen ||| inflammation ||| 0-0
Enzym ||| breakdown of ||| 0-0
Enzym ||| breakdown ||| 0-0
Enzyme CYP3A4 und CYP2D6 ||| CYP3A4 and CYP2D6 enzymes ||| 1-0 2-1 3-2 0-3
Enzyme und ||| enzymes and ||| 0-0 1-1
Enzyme ||| enzymes ||| 0-0
Episkleritis , Iritis ||| episcleritis , iritis ||| 0-0 1-1 2-2
Episkleritis , ||| episcleritis , ||| 0-0 1-1
Episkleritis ||| episcleritis ||| 0-0
Episode bei Patienten angezeigt ||| episode in patients ||| 0-0 3-0 1-1 2-2
Episoden ( ||| episodes ( ||| 0-0 1-1
Episoden bei Bipolar-I-Störung ||| episodes in Bipolar I Disorder ||| 0-0 1-1 1-2 2-2 2-3 2-4
Episoden bei Patienten ||| episodes in patients ||| 0-0 1-0 1-1 2-2
Episoden bei der Bipolar-I-Störung ||| episodes in Bipolar I Disorder ||| 0-0 1-1 1-2 3-2 2-3 3-3 3-4
Episoden bei ||| episodes in ||| 0-0 1-0 1-1
Episoden der Bipolar-I- Störung ||| episodes in Bipolar I Disorder ||| 0-0 2-2 3-2 1-3 2-3 2-4
Episoden der ||| episodes ||| 0-0
Episoden oder ||| episodes or ||| 0-0 1-1
Episoden sollte ||| tongue , ||| 0-0 1-1
Episoden und ||| episodes and ||| 0-0 1-1
Episoden ||| episodes in ||| 0-0
Episoden ||| episodes ||| 0-0
Episoden ||| tongue ||| 0-0
Epoetin alfa , die ||| epoetin alfa , ||| 0-0 1-1 2-2
Epoetin alfa , ||| epoetin alfa , ||| 0-0 1-1 2-2
Epoetin alfa . Abseamed 3000 ||| epoetin alfa Abseamed 3000 ||| 0-0 1-1 3-2 4-3
Epoetin alfa . Abseamed 4000 ||| epoetin alfa Abseamed 4000 IU/ ||| 0-0 1-1 3-2 4-3 4-4
Epoetin alfa . Abseamed 5000 ||| epoetin alfa Abseamed 5000 IU/ ||| 0-0 1-1 3-2 4-3 4-4
Epoetin alfa . Abseamed 6000 ||| epoetin alfa Abseamed 6000 IU/ ||| 0-0 1-1 3-2 4-3 4-4
Epoetin alfa . Abseamed 7000 ||| epoetin alfa Abseamed 7000 ||| 0-0 1-1 3-2 4-3
Epoetin alfa . Abseamed 8000 ||| epoetin alfa Abseamed 8000 ||| 0-0 1-1 3-2 4-3
Epoetin alfa . Abseamed 9000 ||| epoetin alfa Abseamed 9000 ||| 0-0 1-1 3-2 4-3
Epoetin alfa . Abseamed ||| epoetin alfa Abseamed ||| 0-0 1-1 3-2
Epoetin alfa . ||| epoetin alfa ||| 0-0 1-1
Epoetin alfa Einfluss auf ||| epoetin alfa alters ||| 0-0 1-1 2-2 3-2
Epoetin alfa auf ||| epoetin alfa on ||| 0-0 1-1 2-2
Epoetin alfa bei Erwachsenen ||| epoetin alfa in adult patients ||| 0-0 1-1 2-2 2-3 3-3 3-4
Epoetin alfa berichtet , einschließlich ||| reported with epoetin alfa including ||| 2-0 0-1 0-2 1-2 1-3 3-4 4-4
Epoetin alfa berichtet . ||| epoetin alfa . ||| 0-0 1-1 2-1 3-2
Epoetin alfa berichtet ||| epoetin alfa ||| 0-0 1-1 2-1
Epoetin alfa berichtet ||| reported with epoetin alfa ||| 2-0 0-1 0-2 1-2 1-3
Epoetin alfa berücksichtigt werden ||| epoetin alfa in cancer patients ||| 0-0 1-1 2-3 3-3 2-4
Epoetin alfa ist ein ||| epoetin alfa is a ||| 0-0 1-1 2-2 3-3
Epoetin alfa ist sehr groß ||| epoetin alfa is very wide ||| 0-0 1-1 2-2 3-3 4-4
Epoetin alfa ist sehr ||| epoetin alfa is very ||| 0-0 1-1 2-2 3-3
Epoetin alfa ist ||| epoetin alfa is ||| 0-0 1-1 2-2
Epoetin alfa kann ||| epoetin alfa may ||| 0-0 1-1 2-2
Epoetin alfa nicht empfohlen ||| epoetin alfa is not recommended ||| 0-0 0-1 1-1 3-2 2-3 3-4
Epoetin alfa oder ||| epoetin alfa or ||| 0-0 0-1 1-1 2-2
Epoetin alfa sollte ||| Epoetin alfa should be ||| 0-0 1-1 2-2 2-3
Epoetin alfa und anderen Erythropoese-stimulierenden ||| Epoetin alfa and other erythropoiesis-stimulating ||| 0-0 1-1 2-2 3-3 4-4
Epoetin alfa und anderen ||| Epoetin alfa and other ||| 0-0 1-1 2-2 3-3
Epoetin alfa und ||| Epoetin alfa and ||| 0-0 1-1 2-2
Epoetin alfa und ||| epoetin alfa and ||| 0-0 1-1 2-2
Epoetin alfa wird ||| Epoetin alfa is ||| 0-0 1-1 2-2
Epoetin alfa wurde ||| epoetin alfa has been ||| 0-0 1-1 2-2 2-3
Epoetin alfa zu erzielen , ||| to epoetin alfa , adequate ||| 2-0 0-1 1-1 1-2 4-3 3-4
Epoetin alfa zu ||| to epoetin alfa ||| 2-0 0-1 1-1 1-2
Epoetin alfa zusammen ||| epoetin alfa is given concomitantly ||| 0-0 1-1 2-2 2-3 2-4
Epoetin alfa ||| Epoetin alfa ||| 0-0 1-1
Epoetin alfa ||| alfa ||| 0-0 1-0
Epoetin alfa ||| epoetin alfa in ||| 0-0 1-1
Epoetin alfa ||| epoetin alfa ||| 0-0 0-1 1-1
Epoetin alfa ||| epoetin alfa ||| 0-0 1-0 1-1
Epoetin alfa ||| epoetin alfa ||| 0-0 1-1
Epoetin alfa ||| with epoetin alfa ||| 0-0 0-1 1-1 1-2
Epoetin alfa* ||| of epoetin alfa* ||| 1-0 0-1 1-2
Epoetin ||| Epoetin ||| 0-0
Epoetin ||| epoetin ||| 0-0
Er empfahl ||| They recommended ||| 0-0 1-0 1-1
Er stoppt die ||| It stops the ||| 0-0 1-1 2-2
Er stoppt ||| It stops ||| 0-0 1-1
Er wird Ihren ||| Your doctor will ||| 0-0 2-1 1-2
Er wird ||| will use ||| 0-0 1-0 1-1
Er wirkt durch Blockade ||| It acts by blocking ||| 0-0 1-1 2-2 3-3
Er wirkt durch ||| It acts by ||| 0-0 1-1 2-2
Er wirkt ||| It acts ||| 0-0 1-1
Er ||| It ||| 0-0
Er ||| Your ||| 0-0
Er/sie wird ||| He/ she will work ||| 0-0 0-1 1-2 0-3
Erbrechen , Durchfall ||| vomiting , diarrhoea , ||| 0-0 1-1 2-2 1-3
Erbrechen , Speichelfluss , Anorexie ||| vomiting , salivation , anorexia ||| 0-0 1-1 1-2 2-3 3-3 4-4
Erbrechen , Speichelfluss , ||| vomiting , salivation , ||| 0-0 1-1 1-2 2-3 3-3
Erbrechen , Verstopfung , Stomatitis ||| vomiting , constipation , stomatitis ||| 0-0 1-1 2-2 3-3 4-4
Erbrechen , Verstopfung , ||| vomiting , constipation , ||| 0-0 1-1 2-2 3-3
Erbrechen , Verstopfung ||| vomiting , constipation ||| 0-0 1-1 2-2
Erbrechen , ein ||| vomiting , an ||| 0-0 1-1 2-2
Erbrechen , ||| vomiting , salivation ||| 0-0 1-1 1-2
Erbrechen , ||| vomiting , ||| 0-0 1-1
Erbrechen , Übelkeit , Verstopfung ||| vomiting , nausea , constipation ||| 0-0 1-1 2-2 3-3 4-4
Erbrechen , Übelkeit , ||| vomiting , nausea , ||| 0-0 1-1 2-2 3-3
Erbrechen , Übelkeit ||| vomiting , nausea ||| 0-0 1-1 2-2
Erbrechen . ||| vomiting . ||| 0-0 1-1
Erbrechen Durchfall weicher Stuhl ||| vomiting diarrhoea softened stools ||| 0-0 1-1 2-2 3-3
Erbrechen Durchfall weicher ||| vomiting diarrhoea softened ||| 0-0 1-1 2-2
Erbrechen Durchfall ||| vomiting diarrhoea ||| 0-0 1-1
Erbrechen Gelegentlich ||| vomiting Uncommon ||| 0-0 1-1
Erbrechen auf . ||| vomiting . ||| 0-0 2-1
Erbrechen auf ||| vomiting ||| 0-0
Erbrechen und Durchfall . ||| vomiting and diarrhoea . ||| 0-0 1-1 2-2 3-3
Erbrechen und Durchfall ||| vomiting and diarrhoea ||| 0-0 1-1 2-2
Erbrechen und ||| vomiting and ||| 0-0 1-1
Erbrechen ||| vomiting ||| 0-0
Ereignisse ( siehe ||| events ( see ||| 0-0 1-1 2-2
Ereignisse ( ||| events ( ||| 0-0 1-1
Ereignisse ) . ||| events ) . ||| 0-0 1-1 2-2
Ereignisse ) ||| events ) ||| 0-0 1-1
Ereignisse , die ||| events which ||| 0-0 1-1 2-1
Ereignisse : ||| events : ||| 0-0 1-1
Ereignisse bei ||| events in patients ||| 0-0 1-1 1-2
Ereignisse bei ||| events in ||| 0-0 1-1
Ereignisse bestehen kann . ||| events cannot be excluded . ||| 0-0 1-1 1-2 1-3 2-3 3-4
Ereignisse bestehen kann ||| events cannot be excluded ||| 0-0 1-1 1-2 1-3 2-3
Ereignisse im Vergleich zu ||| events compared ||| 0-0 1-1 2-1 3-1
Ereignisse notwendig . ||| events . ||| 0-0 2-1
Ereignisse notwendig ||| events ||| 0-0
Ereignisse wird ||| events is ||| 0-0 1-1
Ereignisse wurden ||| events have been ||| 0-0 1-1 1-2
Ereignisse ||| events ||| 0-0
Ereignissen ||| events ||| 0-0
Ereignissen ||| the events ||| 0-1
Ereignissen ||| to the events ||| 0-2
Ereignisses zurück . ||| event onset . ||| 0-0 0-1 1-1 2-2
Ereignisses zurück ||| event onset ||| 0-0 0-1 1-1
Erfahrung mit der ||| experience with ||| 0-0 1-1
Erfahrung mit ||| experience with ||| 0-0 1-1
Erfahrung seit der Markteinführung Zusätzlich ||| 6 Post-Marketing In addition the ||| 0-0 0-1 1-1 4-2 4-3 2-4 3-4
Erfahrung seit ||| 6 Post-Marketing ||| 0-0 0-1 1-1
Erfahrung ||| experience ||| 0-0
Erfahrung ||| has experience ||| 0-1
Erfahrungen bei Kindern und ||| experience in children and ||| 0-0 1-1 2-2 3-3
Erfahrungen bei Kindern ||| experience in children ||| 0-0 1-1 2-2
Erfahrungen bei ||| experience in ||| 0-0 1-1
Erfahrungen in dieser Patientengruppe vorliegen ||| experience in this patient group ||| 0-0 1-1 2-2 3-2 3-3 4-4
Erfahrungen in dieser Patientengruppe ||| experience in this patient ||| 0-0 1-1 2-2 3-2 3-3
Erfahrungen in ||| experience in ||| 0-0 1-1
Erfahrungen ||| experience ||| 0-0
Ergebnisse einer ||| Results of ||| 0-0 1-0 1-1
Ergebnisse für allgemeine Ansprechrate ||| Results for overall response rate ||| 0-0 2-0 1-1 2-2 2-3 3-4
Ergebnisse für allgemeine ||| Results for overall response ||| 0-0 2-0 1-1 2-2 2-3
Ergebnisse standen im ||| results were ||| 0-0 1-0 2-1
Ergebnisse standen ||| results ||| 0-0 1-0
Erhalt neuer Informationen ||| new information is received ||| 1-0 2-1 2-2
Erhalt neuer Informationen ||| new information is ||| 1-0 2-1 2-2
Erhalt neuer ||| new ||| 1-0
Erhaltungsdosen als Kinder ||| maintenance doses than children ||| 0-0 0-1 1-2 2-3
Erhaltungsdosen als Kinder über ||| maintenance doses than children over ||| 0-0 0-1 1-2 2-3 3-4
Erhaltungsdosen als ||| maintenance doses than ||| 0-0 0-1 1-2
Erhaltungsdosen ||| maintenance doses ||| 0-0 0-1
Erhaltungsdosis 75 - ||| Usual maintenance dose 75 - ||| 0-0 0-1 0-2 1-3 2-4
Erhaltungsdosis 75 ||| Usual maintenance dose 75 ||| 0-0 0-1 0-2 1-3
Erhaltungsdosis beträgt 15 mg ||| maintenance dose is 15 mg ||| 0-0 0-1 1-2 1-3 2-3 3-4
Erhaltungsdosis beträgt 15 ||| maintenance dose is 15 ||| 0-0 0-1 1-2 1-3 2-3
Erhaltungsdosis zwischen 17 und ||| Maintenance dose between 17 and ||| 0-0 0-1 1-2 2-3 3-4
Erhaltungsdosis zwischen 17 ||| Maintenance dose between 17 ||| 0-0 0-1 1-2 2-3
Erhaltungsdosis zwischen 25 und ||| Maintenance dose between 25 and ||| 0-0 0-1 1-2 2-3 3-4
Erhaltungsdosis zwischen 25 ||| Maintenance dose between 25 ||| 0-0 0-1 1-2 2-3
Erhaltungsdosis zwischen ||| Maintenance dose between ||| 0-0 0-1 1-2
Erhaltungsdosis ||| Maintenance dose ||| 0-0 0-1
Erhaltungsdosis ||| Usual maintenance dose ||| 0-0 0-1 0-2
Erhaltungsdosis ||| maintenance dose ||| 0-0 0-1
Erholung von den ||| permitted recovery from the ||| 0-0 1-1 1-2 2-3
Erholung von ||| permitted recovery from ||| 0-0 1-1 1-2
Erholung ||| permitted ||| 0-0
Erhöhte Mortalität : ||| Increased mortality : in ||| 0-0 1-1 2-2 1-3
Erhöhte Tränensekretion , verschwommene ||| Increased lacrimation , blurred vision ||| 0-0 1-1 2-2 3-3 3-4
Erhöhte Tränensekretion , ||| Increased lacrimation , ||| 0-0 1-1 2-2
Erhöhte Tränensekretion ||| Increased lacrimation ||| 0-0 1-1
Erhöhte ||| Increased ||| 0-0
Erhöhter Blutdruck ||| Blood pressure ||| 0-0 1-1
Erhöhter ||| Blood ||| 0-0
Erhöhung der Pioglitazondosierung bei 18 ||| pioglitazone dose may need to ||| 0-0 2-0 2-1 2-2 2-3 3-3
Erhöhung der Pioglitazondosierung bei 18 ||| pioglitazone dose may need ||| 0-0 2-0 2-1 2-2 2-3 3-3
Erhöhung der Pioglitazondosierung bei 5 ||| pioglitazone dose may need to ||| 0-0 2-0 2-1 4-1 2-2 2-3 3-3
Erhöhung der Pioglitazondosierung bei 5 ||| pioglitazone dose may need ||| 0-0 2-0 2-1 4-1 2-2 2-3 3-3
Erhöhung der Pioglitazondosierung bei ||| pioglitazone dose may need to ||| 0-0 2-0 2-1 2-2 2-3 3-3
Erhöhung der Pioglitazondosierung bei ||| pioglitazone dose may need ||| 0-0 2-0 2-1 2-2 2-3 3-3
Erhöhung der ||| increase ||| 0-0 1-0
Erhöhung ||| increase ||| 0-0
Erhöhung ||| increased ||| 0-0
Erhöhungen der CPK ( ||| Elevations of CPK ( Creatine ||| 0-0 1-1 2-2 3-3 2-4
Erhöhungen der CPK ( ||| Elevations of CPK ( ||| 0-0 1-1 2-2 3-3
Erhöhungen der CPK ||| Elevations of CPK ||| 0-0 1-1 2-2
Erhöhungen der ||| Elevations of ||| 0-0 1-1
Erhöhungen ||| Elevations ||| 0-0
Erkenntnissen wird durch die Behandlung ||| date , correction ||| 0-0 1-0 0-2 2-2 3-2 4-2
Erkenntnissen wird durch ||| date , ||| 0-0 1-0 2-0
Erkenntnissen wird durch ||| date ||| 0-0 1-0 2-0
Erkrankung , Unwohlsein , ||| , influenza-like illness , malaise ||| 1-0 1-1 0-2 3-3 2-4
Erkrankung , bei der die ||| , bei der die Bauchspeicheldrüse ||| 0-0 1-0 2-1 3-2 4-3 0-4
Erkrankung , ||| , influenza-like illness ||| 1-0 1-1 0-2
Erkrankung des Nervensystems : ||| Nervous disorders : ||| 2-0 1-1 2-1 3-2
Erkrankung des Nervensystems ||| Nervous disorders ||| 2-0 1-1 2-1
Erkrankung unbehandelt bleibt ||| disease is ||| 0-0 1-0 2-1
Erkrankung unbehandelt ||| disease ||| 0-0 1-0
Erkrankung ||| illness ||| 0-0
Erkrankungen , die ||| conditions ||| 0-0
Erkrankungen , ||| conditions ||| 0-0
Erkrankungen Häufig : ||| disorders Common : ||| 0-0 1-1 2-2
Erkrankungen Häufig ||| disorders Common ||| 0-0 1-1
Erkrankungen der Atemwege , des ||| Respiratory , thoracic ||| 0-0 1-0 2-0 3-1 2-2 3-2 4-2
Erkrankungen des Gastrointestinaltrakts : ||| gastrointestinal disorders : abdominal pain ||| 0-0 0-1 1-1 2-1 3-2 2-3 0-4
Erkrankungen des Gastrointestinaltrakts Häufig : ||| Gastrointestinal disorders Common : ||| 2-0 0-1 1-1 3-2 4-3
Erkrankungen des Gastrointestinaltrakts Häufig ||| Gastrointestinal disorders Common ||| 2-0 0-1 1-1 3-2
Erkrankungen des Gastrointestinaltrakts ||| Gastrointestinal disorders ||| 2-0 0-1 1-1
Erkrankungen des Immunsystems Gelegentlich ||| Immune system disorders Uncommon ||| 0-0 2-0 1-1 2-1 0-2 3-3
Erkrankungen des Immunsystems ||| Immune system disorders ||| 0-0 2-0 1-1 2-1 0-2
Erkrankungen des Nervensystems Gelegentlich - ||| Nervous system disorders Uncommon - ||| 0-0 2-0 1-1 2-1 2-2 3-3 4-4
Erkrankungen des Nervensystems Gelegentlich ||| Nervous system disorders Uncommon ||| 0-0 2-0 1-1 2-1 2-2 3-3
Erkrankungen des Nervensystems ||| Nervous system disorders ||| 0-0 2-0 1-1 2-1 2-2
Erkrankungen des ||| disorders ||| 0-0 1-0
Erkrankungen und affektiven Störungen und ||| illnesses and mood disorders and ||| 0-0 2-0 1-1 2-2 3-2 0-3 4-4
Erkrankungen und affektiven Störungen ||| illnesses and mood disorders and ||| 0-0 2-0 1-1 2-2 3-2 0-3 1-4
Erkrankungen und affektiven Störungen ||| illnesses and mood disorders ||| 0-0 2-0 1-1 2-2 3-2 0-3
Erkrankungen und ||| disorders and ||| 0-0 1-1
Erkrankungen ||| conditions ||| 0-0
Erkrankungen ||| disorders ||| 0-0
Erkrankungen ||| illnesses ||| 0-0
Erkältungen ) ||| colds ) ||| 0-0 1-1
Erkältungen ||| colds ||| 0-0
Ernährung einhalten ||| Bewegung steigern ||| 0-0 1-0 1-1
Ernährung ||| diet ||| 0-0
Ernährungsberater vorgegeben ||| restrictive ||| 0-0 1-0
Ernährungsgewohnheiten oder beides anzupassen . ||| be adjusted . ||| 2-0 0-1 1-1 2-1 3-1 4-2
Ernährungsgewohnheiten oder beides anzupassen ||| be adjusted ||| 2-0 0-1 1-1 2-1 3-1
Ernährungsprogramm ||| nutrition programme ||| 0-0 0-1
Ernährungsstörungen : ||| dry mouth . ||| 0-0 0-1 1-2
Ernährungsstörungen ||| Vascular disorders General disorders ||| 0-0 0-1 0-2 0-3
Ernährungsstörungen ||| dry mouth ||| 0-0 0-1
Ersatzinsulin , das mit ||| replacement insulin which ||| 0-0 0-1 1-2 2-2
Ersatzinsulin , das ||| replacement insulin which ||| 0-0 0-1 1-2 2-2
Ersatzinsulin ||| replacement insulin ||| 0-0 0-1
Erschöpfung , ||| , ||| 0-0 1-0
Erstlinienbehandlung während der Prüfung ||| first-line treatment during the assessment ||| 0-0 1-1 1-2 2-2 2-3 3-3 3-4
Erstlinienbehandlung ||| first-line ||| 0-0
Erteilung ||| granting ||| 0-0
Erwachsene , ||| 192 Adult ||| 0-0 1-0 0-1
Erwachsene . ||| adults . ||| 0-0 1-1
Erwachsene Patienten in ||| Use in adult patients in ||| 0-0 2-1 0-2 1-3 2-4
Erwachsene Tumorpatienten ||| Adult cancer ||| 0-0 1-1
Erwachsene chirurgische Patienten in ||| Adult surgery patients in ||| 0-0 1-1 2-2 3-3
Erwachsene chirurgische Patienten ||| Adult surgery patients ||| 0-0 1-1 2-2
Erwachsene chirurgische ||| Adult surgery ||| 0-0 1-1
Erwachsene und pädiatrische ||| Adult and paediatric haemodialysis patients ||| 0-0 1-1 2-2 2-3 2-4
Erwachsene und ||| Adult and ||| 0-0 1-1
Erwachsene ||| Adult ||| 0-0
Erwachsene ||| adults ||| 0-0
Erwachsenen , bei denen ||| adult patients scheduled ||| 0-0 2-1 3-2
Erwachsenen , bei ||| adult patients ||| 0-0 2-1
Erwachsenen , ||| adult ||| 0-0
Erwachsenen mit ||| adult patients ||| 0-0 0-1 1-1
Erwachsenen unter ||| adult patients on ||| 0-0 0-1 1-2
Erwachsenen zur Behandlung ||| to treat adults ||| 1-0 1-1 2-1 0-2
Erwachsenen ||| adult patients ||| 0-0 0-1
Erwachsenen ||| adult ||| 0-0
Erwachsenen ||| adults , ||| 0-0
Erwachsenen ||| adults ||| 0-0
Erwägung gezogen ; keiner ||| have been proposed ; none ||| 0-0 0-1 0-2 1-2 2-3 3-4
Erwägung gezogen ; ||| have been proposed ; ||| 0-0 0-1 0-2 1-2 2-3
Erwägung gezogen ||| have been proposed ||| 0-0 0-1 0-2 1-2
Erwägung ||| on ABILIFY ||| 0-0 0-1
Erythroblastopenie ( ||| Pure Red Cell Aplasia ( ||| 0-0 0-1 0-2 0-3 1-4
Erythroblastopenie bedeutet , ||| PRCA means the ||| 0-0 1-1
Erythroblastopenie bedeutet , ||| PRCA means ||| 0-0 1-1
Erythroblastopenie bedeutet ||| PRCA means the ||| 0-0 1-1
Erythroblastopenie bedeutet ||| PRCA means ||| 0-0 1-1
Erythroblastopenie kann sich als plötzliche ||| PRCA can result in sudden ||| 0-0 1-1 2-1 1-2 3-3 4-4
Erythroblastopenie kann sich als ||| PRCA can result in ||| 0-0 1-1 2-1 1-2 3-3
Erythroblastopenie kann sich ||| PRCA can result ||| 0-0 1-1 2-1 1-2
Erythroblastopenie ||| PRCA ||| 0-0
Erythroblastopenie ||| Pure Red Cell Aplasia ||| 0-0 0-1 0-2 0-3
Erythropoese-stimulierende Wirkstoffe ( ||| erythropoiesis stimulating agents ( ||| 0-0 0-1 1-1 1-2 2-3
Erythropoese-stimulierende Wirkstoffe ||| erythropoiesis stimulating agents ||| 0-0 0-1 1-1 1-2
Erythropoese-stimulierenden Wirkstoffen ( ||| erythropoiesis-stimulating agents ( ||| 0-0 1-1 2-2
Erythropoese-stimulierenden Wirkstoffen ||| erythropoiesis-stimulating agents ||| 0-0 1-1
Erythropoese-stimulierenden ||| erythropoiesis-stimulating ||| 0-0
Erythropoetin . ||| erythropoietin . ||| 0-0 1-1
Erythropoetin berichtet . ||| erythropoietin treatment . ||| 0-0 1-1 2-2
Erythropoetin berichtet ||| erythropoietin treatment ||| 0-0 1-1
Erythropoetin beträgt 32.000 bis 40.000 ||| erythropoietin is 32,000 to 40,000 ||| 0-0 1-1 1-2 2-2 3-2 3-3 4-4
Erythropoetin beträgt 32.000 bis ||| erythropoietin is 32,000 to ||| 0-0 1-1 1-2 2-2 3-2 3-3
Erythropoetin ist ein ||| Erythropoietin is a ||| 0-0 1-1 2-2
Erythropoetin ist ||| Erythropoietin is ||| 0-0 1-1
Erythropoetin ||| Erythropoietin ||| 0-0
Erythropoetin ||| erythropoietin ||| 0-0
Erythropoetin-Rezeptoren können ||| Erythropoietin receptors may ||| 0-0 0-1 1-2
Erythropoetin-Rezeptoren ||| Erythropoietin receptors ||| 0-0 0-1
Erythropoetine sind Wachstumsfaktoren , ||| Erythropoietins are growth factors ||| 0-0 1-1 2-2 3-2 2-3
Erythropoetine sind ||| Erythropoietins are ||| 0-0 1-1
Erythropoetine ||| Erythropoietins ||| 0-0
Erythropoetine ||| erythropoietins ||| 0-0
Erythropoetinen . ||| tumour proliferators . ||| 0-0 0-1 1-2
Erythropoetinen ||| tumour proliferators ||| 0-0 0-1
Erythropoetinrezeptoren können ||| Erythropoietin receptors may ||| 0-0 0-1 1-2
Erythropoetinrezeptoren ||| Erythropoietin receptors ||| 0-0 0-1
Erythrozyten aus Vorläuferzellen ||| erythrocytes from precursors ||| 0-0 1-1 2-2
Erythrozyten aus ||| erythrocytes from ||| 0-0 1-1
Erythrozyten ||| erythrocytes ||| 0-0
Es besteht ein erhöhtes Risiko ||| There is an increased risk ||| 0-0 1-0 1-1 2-2 3-3 4-4
Es besteht ein erhöhtes ||| There is an increased ||| 0-0 1-0 1-1 2-2 3-3
Es besteht ein ||| There is an ||| 0-0 1-0 1-1 2-2
Es besteht ||| There is ||| 0-0 1-0 1-1
Es darf außerdem nicht ||| It should also not be ||| 0-0 1-1 2-2 1-3 3-3 1-4
Es enthält den Wirkstoff ||| It contains the active substance ||| 0-0 1-1 2-2 2-3 3-3 3-4
Es enthält ||| It contains ||| 0-0 1-1
Es gab jedoch in einer ||| However , in one of ||| 0-0 1-0 2-0 2-1 3-2 4-3 4-4
Es gab jedoch in ||| However , in ||| 0-0 1-0 2-0 2-1 3-2
Es gab jedoch ||| However , ||| 0-0 1-0 2-0 2-1
Es gab keinen ||| and no cases ||| 0-1 1-1 2-1
Es gab keinen ||| and no ||| 0-1 1-1 2-1
Es gab keinen ||| no cases ||| 0-0 1-0 2-0
Es gab keinen ||| no ||| 0-0 1-0 2-0
Es gibt Patienten , ||| Patients have taken ||| 1-0 2-0 2-1 3-1 0-2
Es gibt kein spezifisches Antidot ||| There is no specific antidote ||| 0-0 1-0 0-1 2-2 1-3 2-4 3-4 4-4
Es gibt keine Kumulation : ||| There is no accumulation : ||| 0-0 1-0 3-1 2-2 3-3 4-4
Es gibt keine Kumulation ||| There is no accumulation ||| 0-0 1-0 3-1 2-2 3-3
Es gibt ||| There are ||| 0-0 1-0 1-1
Es gibt ||| There is not ||| 0-0 1-0 0-1
Es gibt ||| There is ||| 0-0 1-0 0-1
Es gibt ||| There ||| 0-0 1-0
Es ist als 5 ||| It is available as 5 ||| 0-0 1-1 0-2 2-3 3-4
Es ist als ||| It is available as ||| 0-0 1-1 0-2 2-3
Es ist besonders ||| It is especially ||| 0-0 1-1 2-2
Es ist in Form von ||| It is available as ||| 0-0 1-1 1-2 3-3
Es ist in Form ||| It is available as ||| 0-0 1-1 1-2 3-3
Es ist in ||| It is available ||| 0-0 1-1 1-2
Es ist nicht bekannt ||| It is not known ||| 0-0 1-1 2-2 3-3
Es ist nicht wichtig , ||| It does not matter ||| 0-0 1-0 3-1 2-2 3-3 4-3
Es ist nicht ||| It is not ||| 0-0 1-1 2-2
Es ist wichtig , dass ||| It is important that ||| 0-0 1-1 2-2 3-3 4-3
Es ist wichtig ||| It is important ||| 0-0 1-1 2-2
Es ist ||| It is available ||| 0-0 1-1 0-2
Es ist ||| It is available ||| 0-0 1-1 1-2
Es ist ||| It is ||| 0-0 1-1
Es ist ||| It ||| 0-0 1-0
Es ist ||| is ||| 0-0 1-0
Es kann schädlich sein , ||| May be harmful for ||| 0-0 1-0 2-0 3-1 2-2 3-2 2-3 4-3
Es kann zusätzlich zu ||| It can be added to ||| 0-0 1-1 1-2 2-3 3-3 3-4
Es kann ||| It can be ||| 0-0 1-1 1-2
Es kann ||| It may ||| 0-0 1-1
Es konnte ||| It could be ||| 0-0 1-1 1-2
Es könnte ein anderer LHRH-Agonist ||| Another LHRH agonist could ||| 4-0 4-1 4-2 0-3 1-3
Es könnte ein anderer ||| could ||| 0-0 1-0
Es könnte ein ||| could ||| 0-0 1-0
Es könnte ||| could ||| 0-0 1-0
Es liegen keine Daten ||| There are no data ||| 0-0 1-0 1-1 2-2 3-3
Es liegen keine Erfahrungen über ||| There is no experience of ||| 0-0 1-0 3-1 2-2 3-3 4-3 4-4
Es liegen keine ausreichenden Daten ||| Data are insufficient ||| 0-0 4-0 1-1 2-1 3-2
Es liegen keine ausreichenden und ||| There are no adequate and ||| 0-0 1-0 1-1 2-2 3-3 4-4
Es liegen keine ausreichenden ||| There are no adequate ||| 0-0 1-0 1-1 2-2 3-3
Es liegen keine hinreichenden und ||| There are no adequate and ||| 0-0 1-0 1-1 2-2 3-3 4-4
Es liegen keine hinreichenden ||| There are no adequate ||| 0-0 1-0 1-1 2-2 3-3
Es liegen keine ||| Es liegen keine ||| 0-0 1-1 2-2
Es liegen keine ||| There are no ||| 0-0 1-0 1-1 2-2
Es liegen ||| Es liegen ||| 0-0 1-1
Es liegen ||| There are ||| 0-0 1-0 1-1
Es liegen ||| There ||| 0-0 1-0
Es sollte nur bei ||| Use should be restricted ||| 0-0 1-1 1-2 2-3 3-3
Es sollte ||| Use should be ||| 0-0 1-1 1-2
Es verhindert auch , dass ||| It also prevents ||| 0-0 2-1 1-2 3-2 4-2
Es werden möglicherweise nicht alle ||| Es werden möglicherweise nicht alle ||| 0-0 1-1 2-2 3-3 4-4
Es werden möglicherweise nicht ||| Es werden möglicherweise nicht ||| 0-0 1-1 2-2 3-3
Es werden möglicherweise nicht ||| Not all pack ||| 0-0 1-0 2-0 2-1 2-2 3-2
Es werden möglicherweise ||| Es werden möglicherweise ||| 0-0 1-1 2-2
Es werden möglicherweise ||| Not all the ||| 0-0 1-0 2-0 2-1
Es werden möglicherweise ||| Not all the ||| 0-0 1-0 2-1
Es werden möglicherweise ||| Not all ||| 0-0 1-0 2-0 2-1
Es werden möglicherweise ||| Not all ||| 0-0 1-0 2-1
Es werden ||| Es werden ||| 0-0 1-1
Es werden ||| Not ||| 0-0 1-0
Es wird angenommen , dass ||| These changes are interpreted ||| 0-0 2-0 1-1 2-1 2-2 2-3 3-3 4-3
Es wird daher empfohlen , ||| It is recommended , therefore ||| 0-0 1-1 3-2 4-3 2-4
Es wird ||| It is ||| 0-0 1-1
Es wird ||| The use of ||| 0-0 1-1
Es wird ||| The use ||| 0-0 1-1
Es wurde kein ||| No ||| 0-0 1-0 2-0
Es wurde ||| No ||| 0-0 1-0
Es wurden keine Studien ||| No studies ||| 0-0 2-0 1-1 3-1
Es wurden keine ||| No ||| 0-0 1-0 2-0
Es ||| A ||| 0-0
Es ||| ACOMPLIA ||| 0-0
Es ||| An ||| 0-0
Es ||| Es ||| 0-0
Es ||| It ||| 0-0
Es ||| No ||| 0-0
Es ||| The ||| 0-0
Es ||| Use ||| 0-0
Es ||| no ||| 0-0
Es ||| taken ||| 0-0
Essen vermischt werden . ||| food prior to administration . ||| 0-0 1-1 2-2 1-3 2-4 3-4
Essen vermischt werden . ||| food prior to administration . ||| 0-0 2-0 1-1 2-2 1-3 3-4
Essen vermischt werden ||| food prior to administration ||| 0-0 2-0 1-1 2-2 1-3
Essen ||| food prior ||| 0-0 0-1
Essen ||| food ||| 0-0
Ethanol oder Lorazepam hatte ||| or lorazepam had ||| 1-0 0-1 2-1 3-2
Ethanol oder Lorazepam ||| or lorazepam ||| 1-0 0-1 2-1
Ethinylestradiol/Levonorgestrel-Kombination wurde durch die ||| Ethinylestradiol/Levonorgestrel-Kombination wurde durch die ||| 0-0 1-1 2-2 3-3
Ethinylestradiol/Levonorgestrel-Kombination wurde durch ||| Ethinylestradiol/Levonorgestrel-Kombination wurde durch ||| 0-0 1-1 2-2
Ethinylestradiol/Levonorgestrel-Kombination wurde ||| Ethinylestradiol/Levonorgestrel-Kombination wurde ||| 0-0 1-1
Ethinylestradiol/Levonorgestrel-Kombination ||| Ethinylestradiol/Levonorgestrel-Kombination ||| 0-0
Ethylvanillin ) Weinsäure ||| vanillin ) Tartaric acid Magnesium ||| 0-0 1-1 0-2 2-2 2-3 2-4
Etikett ||| label ||| 0-0
Etikettierung und ||| and ||| 0-0 1-0
Etwa 80 % der ||| Approximately 80 % of the ||| 0-0 1-1 2-2 3-3 3-4
Etwa 80 % ||| Approximately 80 % ||| 0-0 1-1 2-2
Etwa 80 ||| Approximately 80 ||| 0-0 1-1
Etwa die Hälfte der ||| Approximately half of the ||| 0-0 0-1 1-1 2-1 3-2 3-3
Etwa die Hälfte ||| Approximately half ||| 0-0 0-1 1-1 2-1
Etwa ein Drittel der ||| About one third of the ||| 0-0 1-1 2-1 2-2 3-3 3-4
Etwa ein Drittel ||| About one third ||| 0-0 1-1 2-1 2-2
Etwa ||| About ||| 0-0
Etwa ||| Approximately ||| 0-0
Europe ) , Royaume-Uni ||| Europe ) , Royaume-Uni ||| 0-0 1-1 2-2 3-3
Europe ) , Storbritannia Tlf ||| Europe ) , Storbritannia Tlf ||| 0-0 1-1 2-2 3-3 4-4
Europe ) , Storbritannia ||| Europe ) , Storbritannia ||| 0-0 1-1 2-2 3-3
Europe ) , Storbritannien Tel ||| Europe ) , Storbritannien Tel ||| 0-0 1-1 2-2 3-3 4-4
Europe ) , Storbritannien Tlf ||| Europe ) , Storbritannien Tlf ||| 0-0 1-1 2-2 3-3 4-4
Europe ) , Storbritannien ||| Europe ) , Storbritannien ||| 0-0 1-1 2-2 3-3
Europe ) , Te . ||| Europe ) , Te . ||| 0-0 1-1 2-2 3-3 4-4
Europe ) , Te ||| Europe ) , Te ||| 0-0 1-1 2-2 3-3
Europe ) , Wielka Brytania ||| Europe ) , Wielka Brytania ||| 0-0 1-1 2-2 3-3 4-4
Europe ) , Wielka ||| Europe ) , Wielka ||| 0-0 1-1 2-2 3-3
Europe ) , ||| Europe ) , ||| 0-0 1-1 2-2
Europe ) , µ : ||| Europe ) , µ : ||| 0-0 1-1 2-2 3-3 4-4
Europe ) , µ ||| Europe ) , µ ||| 0-0 1-1 2-2 3-3
Europe ) Ltd , 61 ||| Europe ) Ltd , 61 ||| 0-0 1-1 2-2 3-3 4-4
Europe ) Ltd , ||| Europe ) Ltd , ||| 0-0 1-1 2-2 3-3
Europe ) Ltd 61 Aldwych ||| Europe ) Ltd 61 Aldwych ||| 0-0 1-1 2-2 3-3 4-4
Europe ) Ltd 61 ||| Europe ) Ltd 61 ||| 0-0 1-1 2-2 3-3
Europe ) Ltd ||| Europe ) Ltd ||| 0-0 1-1 2-2
Europe ) ||| Europe ) ||| 0-0 1-1
Europe Ltd verpflichtet sich alle ||| Europe Ltd commits to provide ||| 0-0 1-1 2-2 3-2 3-3 4-3
Europe Ltd verpflichtet sich alle ||| Europe Ltd commits to ||| 0-0 1-1 2-2 3-2 3-3 4-3
Europe Ltd ||| Europe Ltd ||| 0-0 1-1
Europe R & D Centre ||| Europe R & D Centre ||| 0-0 1-1 2-2 3-3 4-4
Europe R & D ||| Europe R & D ||| 0-0 1-1 2-2 3-3
Europe R & ||| Europe R & ||| 0-0 1-1 2-2
Europe R ||| Europe R ||| 0-0 1-1
Europe ||| Europe ||| 0-0
Europharm Limited Wimblehurst Road Horsham ||| Europharm Limited Wimblehurst Road Horsham ||| 0-0 1-1 2-2 3-3 4-4
Europharm Limited Wimblehurst Road ||| Europharm Limited Wimblehurst Road ||| 0-0 1-1 2-2 3-3
Europharm Limited Wimblehurst ||| Europharm Limited Wimblehurst ||| 0-0 1-1 2-2
Europharm Limited ||| Europharm Limited ||| 0-0 1-1
Europharm ||| Europharm ||| 0-0
Europäische ||| marketing ||| 0-0
Europäischen ||| EMEA ||| 0-0
Excitement Component score bei dem ||| Excitement Component score at the ||| 0-0 1-1 1-2 2-2 3-3 4-4
Excitement Component score bei ||| Excitement Component score at ||| 0-0 1-1 1-2 2-2 3-3
Excitement Component score ||| Excitement Component score ||| 0-0 1-1 1-2 2-2
Excitement ||| Excitement ||| 0-0
Exposition gegenüber Rimonabant. ||| exposure of rimonabant ||| 0-0 1-0 2-2
Exposition gegenüber Rimonabant. ||| the exposure of rimonabant ||| 0-1 1-1 2-3
Exposition gegenüber ||| exposure of ||| 0-0 1-0
Exposition gegenüber ||| exposure ||| 0-0 1-0
Exposition gegenüber ||| the exposure of ||| 0-1 1-1
Exposition gegenüber ||| the exposure ||| 0-1 1-1
Exposition haben ||| exposure ||| 0-0
Exposition vergleichbaren Exposition ||| widened brain ventricles and ||| 0-0 0-2 1-2 2-2
Exposition vergleichbaren Exposition ||| widened brain ventricles ||| 0-0 0-2 1-2 2-2
Exposition war ||| exposure was generally ||| 0-0 1-1
Exposition war ||| exposure was ||| 0-0 1-1
Exposition ||| , exposure ||| 0-1
Exposition ||| exposure ||| 0-0
Expositionen ||| exposures ||| 0-0
Expositionen ||| in exposures ||| 0-1
Expositionsplateau bei 180 mg erreicht ||| reached at 180 mg ||| 0-0 4-0 1-1 2-2 3-3
F-37071 Tours Cedex 2 , ||| F-37071 Tours Cedex 2 , ||| 0-0 1-1 2-2 3-3 4-4
F-37071 Tours Cedex 2 ||| F-37071 Tours Cedex 2 ||| 0-0 1-1 2-2 3-3
F-37071 Tours Cedex ||| F-37071 Tours Cedex ||| 0-0 1-1 2-2
F-37071 Tours ||| F-37071 Tours ||| 0-0 1-1
F-37071 ||| F-37071 ||| 0-0
FACT-An ) General Scale ||| FACT-An ) general scale ||| 0-0 1-1 2-2 2-3 3-3
FACT-An ) ||| FACT-An ) ||| 0-0 1-1
FACT-An Fatigue Scale ||| FACT-An fatigue scale ||| 0-0 1-1 1-2 2-2
FACT-An ||| FACT-An ||| 0-0
FALTSCHACHTEL ( MIT BLUE ||| FOLDING BOX ( WITH BLUE ||| 0-0 0-1 1-2 2-3 3-4
FALTSCHACHTEL ( MIT ||| FOLDING BOX ( WITH ||| 0-0 0-1 1-2 2-3
FALTSCHACHTEL ( ||| FOLDING BOX ( ||| 0-0 0-1 1-2
FALTSCHACHTEL ||| FOLDING BOX ||| 0-0 0-1
FINLAND ) AB Puh/Tel ||| FINLAND ) AB Puh/ Tel ||| 0-0 1-1 2-2 3-3 3-4
FINLAND ) AB ||| FINLAND ) AB ||| 0-0 1-1 2-2
FINLAND ) ||| FINLAND ) ||| 0-0 1-1
FINLAND ||| FINLAND ||| 0-0
FOLIENSTREIFEN ||| STRIPS ||| 0-0
FOLIENSTREIFEN ||| UNITS ||| 0-0
Fachinformation ) , Etikettierung ||| SPC ) ||| 0-0 3-0 1-1
Fachpersonal gegeben . ||| medical staff . ||| 0-0 1-0 0-1 2-2
Fachpersonal gegeben ||| medical staff ||| 0-0 1-0 0-1
Faeces gefunden . ||| faeces . ||| 0-0 1-0 2-1
Faeces gefunden ||| faeces ||| 0-0 1-0
Fahrzeugen zu treffen . ||| the warning signs of ||| 1-0 0-1 1-1 2-2 2-3 3-3
Fahrzeugen zu treffen ||| have frequent episodes of hypoglycaemia ||| 0-0 0-1 2-2 1-3 2-3 2-4
Fahrzeugen zu ||| the warning ||| 1-0 0-1 1-1
Fahrzeugen ||| have frequent ||| 0-0 0-1
Faktor und Differenzierungshormon ||| factor and differentiating hormone ||| 0-0 1-1 2-2 2-3
Faktor und ||| factor and ||| 0-0 1-1
Faktor ||| factor ||| 0-0
Faktoren ||| factors ||| 0-0
Fall einer Überdosierung ||| event of an overdose ||| 0-0 1-1 1-2 2-2 2-3
Fall ||| event ||| 0-0
Fall ||| working ||| 0-0
Falle einer Insulinresistenz steigert . ||| case of insulin resistance . ||| 0-0 1-1 2-2 2-3 3-3 4-4
Falle einer Insulinresistenz steigert ||| case of insulin resistance ||| 0-0 1-1 2-2 2-3 3-3
Falle einer ||| case of ||| 0-0 1-1
Falle ||| case ||| 0-0
Falls Sie die Beendigung der ||| If you are considering stopping ||| 0-0 1-1 1-2 2-3 3-4 4-4
Falls Sie die ||| If you are considering ||| 0-0 1-1 1-2 2-3
Falls Sie unter Erythroblastopenie ||| If you develop PRCA ||| 0-0 1-1 2-2 3-2 3-3
Falls Sie ||| If you are ||| 0-0 1-1 1-2
Falls Sie ||| If you ||| 0-0 1-1
Falls Sie ||| You should ||| 0-0 1-0 1-1
Falls bei den Patienten ||| If patients experience ||| 0-0 1-1 3-1
Falls bei den Patienten ||| If patients ||| 0-0 1-1 3-1
Falls die ALT-Spiegel über ||| If ALT levels remain ||| 0-0 2-1 1-2 2-2 2-3 3-3
Falls die Erkrankung unbehandelt bleibt ||| If the disease is ||| 0-0 1-1 2-2 3-2 4-3
Falls die Erkrankung unbehandelt ||| If the disease ||| 0-0 1-1 2-2 3-2
Falls die ||| If the ||| 0-0 1-1
Falls ein Ikterus auftritt , ||| If jaundice is observed , ||| 0-0 1-1 2-1 3-1 2-2 3-3 4-4
Falls ein Ikterus auftritt ||| If jaundice is observed ||| 0-0 1-1 2-1 3-1 2-2 3-3
Falls eine Dosisanpassung ||| When a dose adjustment ||| 0-0 1-1 2-2 2-3
Falls eine ||| If ||| 0-0 1-0
Falls eine ||| When a ||| 0-0 1-1
Falls erforderlich , ||| If necessary ||| 0-0 1-1
Falls erforderlich ||| If necessary ||| 0-0 1-1
Falls indiziert , sollte ||| Appropriate therapy such ||| 0-0 1-0 3-0 1-1 1-2 2-2
Falls medizinisch indiziert , ||| In cases where there ||| 0-0 2-1 0-2 1-2 2-2 2-3
Falls medizinisch indiziert ||| In cases where there ||| 0-0 2-1 0-2 1-2 2-2 2-3
Falls notwendig , erhalten Sie ||| Where appropriate you will receive ||| 0-0 1-0 2-1 2-2 4-2 3-3 3-4
Falls notwendig ||| Where ||| 0-0 1-0
Falls weitere Informationen über ||| For any information ||| 0-0 1-1 2-2 3-2
Falls weitere ||| For any ||| 0-0 1-1
Falls ||| For ||| 0-0
Falls ||| If any ||| 0-0 0-1
Falls ||| If ||| 0-0
Falls ||| When ||| 0-0
Faltschachtel mit 14 x 1 ||| Carton of 14 x 1 ||| 0-0 1-0 0-1 2-2 3-3 4-4
Faltschachtel mit 14 x ||| Carton of 14 x ||| 0-0 1-0 0-1 2-2 3-3
Faltschachtel mit 14 ||| Carton of 14 ||| 0-0 1-0 0-1 2-2
Faltschachtel mit 28 x 1 ||| Carton of 28 x 1 ||| 0-0 1-0 0-1 2-2 3-3 4-4
Faltschachtel mit 28 x ||| Carton of 28 x ||| 0-0 1-0 0-1 2-2 3-3
Faltschachtel mit 28 ||| Carton of 28 ||| 0-0 1-0 0-1 2-2
Faltschachtel mit 49 x 1 ||| Carton of 49 x 1 ||| 0-0 1-0 0-1 2-2 3-3 4-4
Faltschachtel mit 49 x ||| Carton of 49 x ||| 0-0 1-0 0-1 2-2 3-3
Faltschachtel mit 49 ||| Carton of 49 ||| 0-0 1-0 0-1 2-2
Faltschachtel mit ||| Carton of ||| 0-0 1-0 0-1
Faltschachteln mit 14 , 28 ||| 14 , 28 , ||| 2-0 0-1 0-2 1-2 4-2 3-3
Faltschachteln mit 14 , 28 ||| 14 , 28 , ||| 2-0 3-1 0-2 1-2 4-2 3-3
Famotidin , ein ||| acid blocker , ||| 0-0 0-1 2-1 1-2
Farbe des Pulvers ist weiß ||| powder is white ||| 0-0 2-0 3-1 1-2 4-2
Farma - Produtos Farmacêuticos , ||| Farma - Produtos Farmacêuticos , ||| 0-0 1-1 2-2 3-3 4-4
Farma - Produtos Farmacêuticos ||| Farma - Produtos Farmacêuticos ||| 0-0 1-1 2-2 3-3
Farma - Produtos ||| Farma - Produtos ||| 0-0 1-1 2-2
Farma - ||| Farma - ||| 0-0 1-1
Farma ||| Farma ||| 0-0
Farmaceutici SpA Tel : + ||| Farmaceutici SpA Tel : + ||| 0-0 1-1 2-2 3-3 4-4
Farmaceutici SpA Tel : ||| Farmaceutici SpA Tel : ||| 0-0 1-1 2-2 3-3
Farmaceutici SpA Tel ||| Farmaceutici SpA Tel ||| 0-0 1-1 2-2
Farmaceutici SpA ||| Farmaceutici SpA ||| 0-0 1-1
Farmaceutici ||| Farmaceutici ||| 0-0
Farmacêuticos , Lda Tel : ||| Farmacêuticos , Lda Tel : ||| 0-0 1-1 2-2 3-3 4-4
Farmacêuticos , Lda Tel ||| Farmacêuticos , Lda Tel ||| 0-0 1-1 2-2 3-3
Farmacêuticos , Lda ||| Farmacêuticos , Lda ||| 0-0 1-1 2-2
Farmacêuticos , S.A. ||| Farmacêuticos , S. A. ||| 0-0 1-1 2-2 2-3
Farmacêuticos , ||| Farmacêuticos , ||| 0-0 1-1
Farmacêuticos ||| Farmacêuticos ||| 0-0
Fast alle Patienten ( 95 ||| Almost all subjects ( 95 ||| 0-0 1-1 0-2 3-3 4-4
Fast alle Patienten ( ||| Almost all subjects ( ||| 0-0 1-1 0-2 3-3
Fast alle Patienten ||| Almost all subjects ||| 0-0 1-1 0-2
Fast alle ||| Almost all subjects ||| 0-0 1-1 0-2
Fast die Hälfte der Patienten ||| Almost half of the patients ||| 0-0 0-1 1-1 2-1 3-2 3-3 4-4
Fast die Hälfte der ||| Almost half of the ||| 0-0 0-1 1-1 2-1 3-2 3-3
Fast die Hälfte ||| Almost half ||| 0-0 0-1 1-1 2-1
Fatigue Scale ||| fatigue scale ||| 0-0 0-1 1-1
Fe2+/Tag für ||| Fe2+/ day for paediatric ||| 0-0 0-1 1-2 0-3
Fe2+/Tag wird ||| Fe2+/ day is ||| 0-0 0-1 1-2
Fe2+/Tag ||| Fe2+/ day ||| 0-0 0-1
Febrile Neutropenie trat bei vier ||| Febrile neutropenia occurred in four ||| 0-0 1-1 2-2 3-3 4-4
Febrile Neutropenie trat bei ||| Febrile neutropenia occurred in ||| 0-0 1-1 2-2 3-3
Febrile Neutropenie trat ||| Febrile neutropenia occurred ||| 0-0 1-1 2-2
Febrile Neutropenie ||| Febrile neutropenia ||| 0-0 1-1
Febrile ||| Febrile ||| 0-0
Fehlens ||| a lack ||| 0-1
Fehlens ||| lack ||| 0-0
Ferner ||| Furthermore , ||| 0-0
Ferner ||| Furthermore ||| 0-0
Fertiginfusionslösung ||| ready-to-infuse ||| 0-0
Fertigpen ( ||| Pre-filled pen ( ||| 0-0 0-1 1-2
Fertigpen . ||| pre-filled pen . ||| 0-0 0-1 1-2
Fertigpen ||| Pre-filled pen ||| 0-0 0-1
Fertigpen ||| pre-filled pen ||| 0-0 0-1
Fertigspritze ( Injektionszubereitung ) ||| pre-filled syringe ( injection ) ||| 0-0 0-1 1-2 2-3 3-4
Fertigspritze ( Injektionszubereitung ||| pre-filled syringe ( injection ||| 0-0 0-1 1-2 2-3
Fertigspritze ( ||| pre-filled syringe ( ||| 0-0 0-1 1-2
Fertigspritze . ||| pre-filled syringe . ||| 0-0 0-1 1-2
Fertigspritze Die Spritzen enthalten ||| pre-filled syringe The syringes contain ||| 0-0 0-1 1-2 2-3 3-4
Fertigspritze Die Spritzen ||| pre-filled syringe The syringes ||| 0-0 0-1 1-2 2-3
Fertigspritze Die ||| pre-filled syringe The ||| 0-0 0-1 1-2
Fertigspritze Epoetin alfa ||| pre-filled syringe Epoetin alfa ||| 0-0 0-1 1-2 2-3
Fertigspritze Epoetin ||| pre-filled syringe Epoetin ||| 0-0 0-1 1-2
Fertigspritze ist ||| pre-filled syringe is ||| 0-0 0-1 1-2
Fertigspritze mit 0,3 ml ||| pre-filled syringe of 0.3 ml ||| 0-0 0-1 1-1 2-3 3-4
Fertigspritze mit 0,3 ||| pre-filled syringe of 0.3 ||| 0-0 0-1 1-1 2-3
Fertigspritze mit 0,4 ml ||| pre-filled syringe of 0.4 ml ||| 0-0 0-1 1-1 2-2 2-3 3-4
Fertigspritze mit 0,4 ml ||| pre-filled syringe of 0.4 ml ||| 0-0 0-1 1-1 2-3 3-4
Fertigspritze mit 0,4 ||| pre-filled syringe of 0.4 ||| 0-0 0-1 1-1 2-2 2-3
Fertigspritze mit 0,4 ||| pre-filled syringe of 0.4 ||| 0-0 0-1 1-1 2-3
Fertigspritze mit 0,5 ml ||| pre-filled syringe of 0.5 ml ||| 0-0 0-1 1-1 2-3 3-4
Fertigspritze mit 0,5 ||| pre-filled syringe of 0.5 ||| 0-0 0-1 1-1 2-3
Fertigspritze mit 0,6 ml ||| pre-filled syringe of 0.6 ml ||| 0-0 0-1 1-1 2-2 2-3 3-4
Fertigspritze mit 0,6 ml ||| pre-filled syringe of 0.6 ml ||| 0-0 0-1 1-1 2-3 3-4
Fertigspritze mit 0,6 ||| pre-filled syringe of 0.6 ||| 0-0 0-1 1-1 2-2 2-3
Fertigspritze mit 0,6 ||| pre-filled syringe of 0.6 ||| 0-0 0-1 1-1 2-3
Fertigspritze mit 0,7 ml ||| pre-filled syringe of 0.7 ml ||| 0-0 0-1 1-1 2-2 2-3 3-4
Fertigspritze mit 0,7 ||| pre-filled syringe of 0.7 ||| 0-0 0-1 1-1 2-2 2-3
Fertigspritze mit 0,8 ml ||| pre-filled syringe of 0.8 ml ||| 0-0 0-1 1-1 2-2 2-3 3-4
Fertigspritze mit 0,8 ml ||| pre-filled syringe of 0.8 ml ||| 0-0 0-1 1-1 2-3 3-4
Fertigspritze mit 0,8 ||| pre-filled syringe of 0.8 ||| 0-0 0-1 1-1 2-2 2-3
Fertigspritze mit 0,8 ||| pre-filled syringe of 0.8 ||| 0-0 0-1 1-1 2-3
Fertigspritze mit 0,9 ml ||| pre-filled syringe of 0.9 ml ||| 0-0 0-1 1-1 2-2 2-3 3-4
Fertigspritze mit 0,9 ||| pre-filled syringe of 0.9 ||| 0-0 0-1 1-1 2-2 2-3
Fertigspritze mit 1 ml ||| pre-filled syringe of 1 ml ||| 0-0 0-1 1-1 2-3 3-4
Fertigspritze mit 1 ||| pre-filled syringe of 1 ||| 0-0 0-1 1-1 2-3
Fertigspritze mit ||| pre-filled syringe of ||| 0-0 0-1 1-1
Fertigspritze mit ||| pre-filled syringe ||| 0-0 0-1 1-1
Fertigspritze muss ||| pre-filled syringe ||| 0-0 1-0 0-1
Fertigspritze ||| pre-filled syringe ||| 0-0 0-1
Fertigspritzen ( Glasart Typ 1 ||| Pre-filled syringes ( glass type ||| 0-0 2-0 0-1 1-2 2-3 3-4 4-4
Fertigspritzen ( Glasart ||| Pre-filled syringes ( glass ||| 0-0 2-0 0-1 1-2 2-3
Fertigspritzen mit je 0,3 ml ||| pre-filled syringes of 0.3 ml ||| 0-0 0-1 1-1 2-1 2-2 3-3 4-4
Fertigspritzen mit je 0,3 ||| pre-filled syringes of 0.3 ||| 0-0 0-1 1-1 2-1 2-2 3-3
Fertigspritzen mit je 0,4 ml ||| pre-filled syringes of 0.4 ml ||| 0-0 0-1 1-1 2-1 2-2 3-3 4-4
Fertigspritzen mit je 0,4 ||| pre-filled syringes of 0.4 ||| 0-0 0-1 1-1 2-1 2-2 3-3
Fertigspritzen mit je 0,5 ml ||| pre-filled syringes of 0.5 ml ||| 0-0 0-1 1-1 2-1 2-2 3-3 4-4
Fertigspritzen mit je 0,5 ||| pre-filled syringes of 0.5 ||| 0-0 0-1 1-1 2-1 2-2 3-3
Fertigspritzen mit je 0,6 ml ||| pre-filled syringes of 0.6 ml ||| 0-0 0-1 1-1 2-1 2-2 3-3 4-4
Fertigspritzen mit je 0,6 ||| pre-filled syringes of 0.6 ||| 0-0 0-1 1-1 2-1 2-2 3-3
Fertigspritzen mit je 0,7 ml ||| pre-filled syringes of 0.7 ml ||| 0-0 0-1 1-1 2-1 2-2 3-3 4-4
Fertigspritzen mit je 0,7 ||| pre-filled syringes of 0.7 ||| 0-0 0-1 1-1 2-1 2-2 3-3
Fertigspritzen mit je 0,8 ml ||| pre-filled syringes of 0.8 ml ||| 0-0 0-1 1-1 2-1 2-2 3-3 4-4
Fertigspritzen mit je 0,8 ||| pre-filled syringes of 0.8 ||| 0-0 0-1 1-1 2-1 2-2 3-3
Fertigspritzen mit je 0,9 ml ||| pre-filled syringes of 0.9 ml ||| 0-0 0-1 1-1 2-1 2-2 3-3 4-4
Fertigspritzen mit je 0,9 ||| pre-filled syringes of 0.9 ||| 0-0 0-1 1-1 2-1 2-2 3-3
Fertigspritzen mit je 1 ml ||| pre-filled syringes of 1 ml ||| 0-0 0-1 1-1 2-1 2-2 3-3 4-4
Fertigspritzen mit je 1 ||| pre-filled syringes of 1 ||| 0-0 0-1 1-1 2-1 2-2 3-3
Fertigspritzen mit je ||| pre-filled syringes of ||| 0-0 0-1 1-1 2-1 2-2
Fertigspritzen sind ||| pre-filled syringes are ||| 0-0 0-1 1-2
Fertigspritzen ||| pre-filled syringes ||| 0-0 0-1
Fertilität oder Zyklusstörungen ||| or oestrous ||| 1-0 0-1 2-1
Feten ||| corpora ||| 0-0
Fettgewebe vergrößerte . ||| fat mass . ||| 0-0 1-1 2-2
Fettgewebe vergrößerte ||| fat mass ||| 0-0 1-1
Fettgewebe ||| fat ||| 0-0
Fettleibigkeit bei erwachsenen Hunden . ||| obesity in adult dogs . ||| 0-0 1-1 2-2 3-3 4-4
Fettleibigkeit bei erwachsenen Hunden ||| obesity in adult dogs ||| 0-0 1-1 2-2 3-3
Fettleibigkeit bei erwachsenen ||| obesity in adult ||| 0-0 1-1 2-2
Fettleibigkeit bei ||| obesity in ||| 0-0 1-1
Fettleibigkeit durch eine ||| obesity is caused by a ||| 0-0 1-1 1-2 1-3 2-4
Fettleibigkeit durch ||| obesity is caused by ||| 0-0 1-1 1-2 1-3
Fettleibigkeit und ||| obesity and ||| 0-0 1-1
Fettleibigkeit ||| obesity ||| 0-0
Fettsäuren ||| compared with placebo , ||| 0-0 0-2
Fettsäuren ||| compared with placebo ||| 0-0 0-2
Fettzellen die Aufnahme ||| receptors on muscle ||| 0-0 0-1 1-1 2-2
Fettzellen die ||| receptors on ||| 0-0 0-1 1-1
Fettzellen im Fettgewebe ) zu ||| fat tissue ) ||| 0-0 2-0 4-0 2-1 3-2
Fibrate ) . ||| fibrates ) . ||| 0-0 1-1 2-2
Fibrate ) ||| fibrates ) ||| 0-0 1-1
Fibrate ||| fibrates ||| 0-0
Fieber ) . ||| fever ) . ||| 0-0 1-1 2-2
Fieber ) ||| fever ) ||| 0-0 1-1
Fieber , Muskelrigidität , ||| , muscle rigidity , ||| 1-0 0-1 0-2 2-2 1-3 3-3
Fieber . ||| fever . ||| 0-0 1-1
Fieber mit Schüttelfrost , Kopfschmerz ||| Fever and chills , headache ||| 2-0 2-2 3-3 0-4 4-4
Fieber und Schüttelfrost , Muskel- ||| fever and chills , pain ||| 0-0 1-1 4-1 2-2 3-3 3-4
Fieber ||| fever ||| 0-0
Filmtablette ||| film-coated ||| 0-0
Filmtabletten . ||| film-coated tablets . ||| 0-0 0-1 1-2
Filmtabletten ||| film-coated tablets ||| 0-0 0-1
Finland Ab Puh/Tel : ||| Finland Ab Puh/ Tel : ||| 0-0 1-1 2-2 2-3 3-4
Finland Ab Puh/Tel ||| Finland Ab Puh/ Tel ||| 0-0 1-1 2-2 2-3
Finland Ab ||| Finland Ab ||| 0-0 1-1
Finland ||| Finland ||| 0-0
First-Line-Therapie ||| 1st-line ||| 0-0
Fisteln ( z. B. ||| exhibit complications ( e. g. ||| 0-0 0-1 1-2 2-3 3-3 3-4
Fisteln ( ||| exhibit complications ( ||| 0-0 0-1 1-2
Fisteln . ||| complications . ||| 0-0 1-1
Fisteln . ||| has complications . ||| 0-1 1-2
Fisteln ||| complications ||| 0-0
Fisteln ||| exhibit complications ||| 0-0 0-1
Fisteln ||| has complications ||| 0-1
Flasche , ||| bottle ||| 0-0
Flasche 100 ml Teil ||| bottle - 100 ml Component ||| 0-0 1-1 1-2 2-3 3-4
Flasche 100 ml ||| bottle - 100 ml ||| 0-0 1-1 1-2 2-3
Flasche 100 ||| bottle - 100 ||| 0-0 1-1 1-2
Flasche enthält 5 mg ||| bottle contains 5 mg ||| 0-0 1-1 2-2 3-3
Flasche enthält 5 ||| bottle contains 5 ||| 0-0 1-1 2-2
Flasche enthält ||| bottle contains ||| 0-0 1-1
Flasche mit 100 ml ||| bottle with 100 ml of ||| 0-0 1-1 2-2 3-3
Flasche mit 100 ml ||| bottle with 100 ml ||| 0-0 1-1 2-2 3-3
Flasche mit 100 ||| bottle with 100 ||| 0-0 1-1 2-2
Flasche mit ||| bottle with ||| 0-0 1-1
Flasche wieder ||| bottle ||| 0-0
Flasche ||| bottle , ||| 0-0
Flasche ||| bottle ||| 0-0
Flaschen mit jeweils ||| bottles , each bottle of ||| 0-0 0-2 2-2 0-3 1-4
Flaschen mit jeweils ||| bottles , each bottle of ||| 0-0 2-2 0-3
Flaschen mit jeweils ||| bottles , each bottle ||| 0-0 2-2 0-3
Flaschen ||| bottles ||| 0-0
FlexPen oder InnoLet ) erhältlich ||| FlexPen or InnoLet ) ||| 0-0 2-0 1-1 2-2 4-2 3-3
Fluoro- ||| coated ||| 0-0
Fluoxetin ||| fluoxetine ||| 0-0
Flush ) , ||| flushes , ||| 0-0 1-1 2-1
Flush ||| flushes ||| 0-0
Flüssigkeit ||| ( at least one or ||| 0-4
Flüssigkeit ||| at least one or ||| 0-3
Flüssigkeit ||| least one or ||| 0-2
Flüssigkeit ||| one or ||| 0-1
Flüssigkeit ||| or ||| 0-0
Flüssigkeiten verdünnt oder mit ||| liquids or mixed with any ||| 0-0 1-0 2-1 1-2 3-3 1-4
Flüssigkeitsretention , Hypoalbuminämie , ||| fluid retention , hypoalbuminaemia , ||| 0-0 0-1 1-2 2-3 3-4
Flüssigkeitsretention , Hypoalbuminämie ||| fluid retention , hypoalbuminaemia ||| 0-0 0-1 1-2 2-3
Flüssigkeitsretention , ||| fluid retention , ||| 0-0 0-1 1-2
Flüssigkeitsretention ||| fluid retention ||| 0-0 0-1
Flüssigkeitszufuhr ( Hydratation ) ||| fluids before and ||| 0-0 1-1 2-1
Flüssigkeitszufuhr ( Hydratation ) ||| fluids before ||| 0-0 1-1 2-1
Flüssigkeitszufuhr ( Hydratation ||| fluids before and ||| 0-0 1-1 2-1
Flüssigkeitszufuhr ( Hydratation ||| fluids before ||| 0-0 1-1 2-1
Flüssigkeitszufuhr ||| fluids ||| 0-0
Folge der ||| of ||| 0-0 1-0
Folgende Nebenwirkungen sind bei ||| The following side effects have ||| 0-0 0-1 1-2 1-3 2-4 3-4
Folgende Nebenwirkungen wurden im ||| The following adverse reactions were ||| 0-0 0-1 1-2 1-3 2-4 3-4
Folgende Nebenwirkungen ||| The following adverse reactions ||| 0-0 0-1 1-2 1-3
Folgende Nebenwirkungen ||| The following side effects ||| 0-0 0-1 1-2 1-3
Folgende ||| The following ||| 0-0 0-1
Folgende ||| reactions ||| 0-0
Folgenden sind ||| are ||| 0-0 1-0
Folgenden sind ||| following are ||| 0-1 1-1
Folliculitis , Infektion der ||| tract infection , folliculitis , ||| 0-0 2-1 1-2 2-3 1-4
Folliculitis , Infektion ||| tract infection , folliculitis , ||| 0-0 2-1 1-2 2-3 1-4
Folliculitis ||| tract ||| 0-0
Fontana Del Ceraso I-03012 Anagni-Frosinone ||| Fontana Del Ceraso I-03012 Anagni-Frosinone ||| 0-0 1-1 2-2 3-3 4-4
Fontana Del Ceraso I-03012 ||| Fontana Del Ceraso I-03012 ||| 0-0 1-1 2-2 3-3
Fontana Del Ceraso ||| Fontana Del Ceraso ||| 0-0 1-1 2-2
Fontana Del ||| Fontana Del ||| 0-0 1-1
Fontana ||| Fontana ||| 0-0
Forest Gate Wellington Road Wokingham ||| Forest Gate Wellington Road Wokingham ||| 0-0 1-1 2-2 3-3 4-4
Forest Gate Wellington Road ||| Forest Gate Wellington Road ||| 0-0 1-1 2-2 3-3
Forest Gate Wellington ||| Forest Gate Wellington ||| 0-0 1-1 2-2
Forest Gate ||| Forest Gate ||| 0-0 1-1
Forest ||| Forest ||| 0-0
Form gebrauchsfertig . ||| ready for use . ||| 0-0 1-0 1-1 1-2 2-3
Form gebrauchsfertig ||| ready for use ||| 0-0 1-0 1-1 1-2
Form von weißen , ||| as white , ||| 0-0 2-1 3-2
Form von weißen ||| as white ||| 0-0 2-1
Form von ||| as ||| 0-0
Form ||| as ||| 0-0
Formen Sie eine ||| Form a ||| 0-0 1-0 2-1
Formen Sie ||| Form ||| 0-0 1-0
Formulierungen . ||| formulations . ||| 0-0 1-1
Formulierungen ||| formulations ||| 0-0
Fortschreiten der Krankheit betrug ||| disease progression was ||| 2-0 0-1 3-2
Fortschreiten der Krankheit ||| disease progression ||| 2-0 0-1
Fortschreiten der ||| progression , ||| 0-0
Fortschreiten der ||| progression ||| 0-0
Fortschreiten ||| progression , ||| 0-0
Fortschreiten ||| progression ||| 0-0
Fortschreitens einer diabetischen Retinopathie . ||| progression of diabetic retinopathy . ||| 0-0 0-1 1-2 2-2 3-3 4-4
Fortschreitens einer diabetischen Retinopathie ||| progression of diabetic retinopathy ||| 0-0 0-1 1-2 2-2 3-3
Fortschreitens einer diabetischen ||| progression of diabetic ||| 0-0 0-1 1-2 2-2
Fortschreitens ||| progression of ||| 0-0 0-1
Fracture Trial [ PFT ] ||| Fracture Trial [ PFT ] ||| 0-0 1-1 2-2 3-3 4-4
Fracture Trial [ PFT ||| Fracture Trial [ PFT ||| 0-0 1-1 2-2 3-3
Fracture Trial [ RFT ] ||| Fracture Trial [ RFT ] ||| 0-0 1-0 1-1 2-2 3-3 4-4
Fracture Trial [ RFT ||| Fracture Trial [ RFT ||| 0-0 1-0 1-1 2-2 3-3
Fracture Trial [ ||| Fracture Trial [ ||| 0-0 1-0 1-1 2-2
Fracture Trial [ ||| Fracture Trial [ ||| 0-0 1-1 2-2
Fracture Trial ||| Fracture Trial ||| 0-0 1-0 1-1
Fracture Trial ||| Fracture Trial ||| 0-0 1-1
Fracture ||| Fracture ||| 0-0
Fragen Sie Ihren Apotheker , ||| Ask your pharmacist ||| 0-0 1-0 2-1 3-2
Fragen Sie Ihren Apotheker ||| Ask your pharmacist ||| 0-0 1-0 2-1 3-2
Fragen Sie Ihren Arzt oder ||| Ask your doctor or ||| 0-0 1-0 2-1 3-2 4-3
Fragen Sie Ihren Arzt ||| Ask your doctor ||| 0-0 1-0 2-1 3-2
Fragen Sie Ihren Tierarzt ||| Ask your veterinary surgeon ||| 0-0 1-1 2-1 3-2 3-3
Fragen Sie Ihren ||| Ask your ||| 0-0 1-0 2-1
Fragen Sie Ihren ||| Ask your ||| 0-0 1-1 2-1
Fragen Sie vor der ||| Ask your ||| 0-0 1-0 1-1 2-1
Fragen Sie vor ||| Ask your ||| 0-0 1-0 1-1 2-1
Fragen Sie ||| Ask ||| 0-0 1-0
Fragen ||| Ask ||| 0-0
Fraktur ( 92 ||| fracture ( 92 ||| 0-0 1-1 2-2
Fraktur ( ||| fracture ( ||| 0-0 1-1
Fraktur ||| fracture ||| 0-0
Frakturen , einschließlich bei Patienten ||| fracture , including those ||| 0-0 1-1 2-2 3-3 4-3
Frakturen , einschließlich bei Patienten ||| of fracture , including those ||| 0-1 1-2 2-3 3-4 4-4
Frakturen , einschließlich ||| fracture , including ||| 0-0 1-1 2-2
Frakturen , einschließlich ||| of fracture , including ||| 0-1 1-2 2-3
Frakturen , ||| fracture , ||| 0-0 1-1
Frakturen , ||| of fracture , ||| 0-1 1-2
Frakturen Die ||| fractures The incidence ||| 0-0 1-1 0-2
Frakturen betrug 7,5 % ||| fractures was 7.5 % ||| 0-0 1-1 2-2 3-3
Frakturen betrug 7,5 ||| fractures was 7.5 ||| 0-0 1-1 2-2
Frakturen betrug ||| fractures was ||| 0-0 1-1
Frakturen nach einer kürzlich erlittenen ||| fractures following a recent ||| 0-0 1-1 2-2 3-3 4-3
Frakturen nach einer ||| fractures following a ||| 0-0 1-1 2-2
Frakturen nach ||| fractures after ||| 0-0 1-1
Frakturen nach ||| fractures following ||| 0-0 1-1
Frakturen pro 100 Patientenjahre ||| fractures per 100 patient years ||| 0-0 3-0 1-1 2-2 3-3 3-4
Frakturen ||| Frakturen ||| 0-0
Frakturen ||| fracture ||| 0-0
Frakturen ||| fractures ||| 0-0
Frakturen ||| of fracture ||| 0-1
Frakturen über die Zeitdauer ||| fractures over the duration ||| 0-0 1-1 2-2 3-3
Frakturen über die ||| fractures over the ||| 0-0 1-1 2-2
Frakturen über einen Zeitraum von ||| of fractures over ||| 4-0 0-1 1-2 2-2 3-2
Frakturen über einen Zeitraum ||| fractures over ||| 0-0 1-1 2-1 3-1
Frakturen über ||| fractures over ||| 0-0 1-1
Frakturgruppen sind ||| fracture variables are ||| 0-0 0-1 1-2
Frakturgruppen ||| fracture variables ||| 0-0 0-1
Frakturrate ||| observed in ||| 0-0 0-1
France BRISTOL-MYERS SQUIBB SARL Tél ||| France BRISTOL-MYERS SQUIBB SARL Tél ||| 0-0 1-1 2-2 3-3 4-4
France BRISTOL-MYERS SQUIBB SARL ||| France BRISTOL-MYERS SQUIBB SARL ||| 0-0 1-1 2-2 3-3
France BRISTOL-MYERS SQUIBB ||| France BRISTOL-MYERS SQUIBB ||| 0-0 1-1 2-2
France BRISTOL-MYERS ||| France BRISTOL-MYERS ||| 0-0 1-1
France Laboratoires Takeda Tél : ||| France Laboratoires Takeda Tél : ||| 0-0 1-1 2-2 3-3 4-4
France Laboratoires Takeda Tél ||| France Laboratoires Takeda Tél ||| 0-0 1-1 2-2 3-3
France Laboratoires Takeda ||| France Laboratoires Takeda ||| 0-0 1-1 2-2
France Laboratoires ||| France Laboratoires ||| 0-0 1-1
France Therabel Lucien Pharma Tél ||| France Therabel Lucien Pharma Tél ||| 0-0 1-1 2-2 3-3 4-4
France Therabel Lucien Pharma ||| France Therabel Lucien Pharma ||| 0-0 1-1 2-2 3-3
France Therabel Lucien ||| France Therabel Lucien ||| 0-0 1-1 2-2
France Therabel ||| France Therabel ||| 0-0 1-1
France ||| France ||| 0-0
Frankreich ||| France ||| 0-0
Frauen , 87 % ||| women , 87 % ||| 0-0 1-1 2-2 3-3
Frauen , 87 ||| women , 87 ||| 0-0 1-1 2-2
Frauen , der Osteoporose bei ||| women , osteoporosis in ||| 0-0 1-1 3-2 2-3 4-3
Frauen , ||| of women ||| 0-1
Frauen , ||| women , ||| 0-0 1-1
Frauen , ||| women ||| 0-0
Frauen bei Männern ||| women in men ||| 0-0 1-1 2-2
Frauen bei ||| women in ||| 0-0 1-1
Frauen erhielten ||| women received ||| 0-0 1-1
Frauen gleich . ||| and women . ||| 0-1 1-1 2-2
Frauen gleich . ||| women . ||| 0-0 1-0 2-1
Frauen gleich ||| and women ||| 0-1 1-1
Frauen gleich ||| women ||| 0-0 1-0
Frauen in der HORIZON-PFT-Studie ||| women in the HORIZON-PFT ||| 0-0 1-1 2-2 3-3
Frauen in der ||| women in the ||| 0-0 1-1 2-2
Frauen in ||| women in ||| 0-0 1-1
Frauen mit Osteoporose ||| women with osteoporosis ||| 0-0 1-1 2-2
Frauen mit metastasierendem Brustkrebs teilnahmen ||| women with metastatic breast cancer ||| 0-0 1-1 2-2 2-3 3-3 2-4 4-4
Frauen mit ||| women with ||| 0-0 1-1
Frauen und ||| women and ||| 0-0 1-1
Frauen vor . ||| women . ||| 0-0 1-0 2-1
Frauen vor ||| women ||| 0-0 1-0
Frauen ||| Women ||| 0-0
Frauen ||| in women ||| 0-0 0-1
Frauen ||| more ||| 0-0
Frauen ||| of women ||| 0-1
Frauen ||| women , ||| 0-0
Frauen ||| women ||| 0-0
Freihalten der ||| function ||| 0-0 1-0
Fremdblutsparende Maßnahmen ||| Good blood management ||| 0-0 1-0 1-1 1-2
Fruchttod in utero . ||| death in utero . ||| 0-0 1-1 0-2 2-2 3-3
Fruchttod in utero ||| death in utero ||| 0-0 1-1 0-2 2-2
Fructose , Sucrose ||| fructose , sucrose , ||| 0-0 1-1 2-2 1-3
Fructose je ml 400 mg ||| fructose per ml 400 mg ||| 0-0 1-1 2-2 3-3 4-4
Fructose je ml 400 ||| fructose per ml 400 ||| 0-0 1-1 2-2 3-3
Fructose je ml ||| fructose per ml ||| 0-0 1-1 2-2
Fructose je ||| fructose per ||| 0-0 1-1
Fructose und 400 mg ||| fructose and 400 mg of ||| 0-0 1-1 2-2 3-3
Fructose und 400 mg ||| fructose and 400 mg ||| 0-0 1-1 2-2 3-3
Fructose und 400 mg ||| of fructose and 400 mg ||| 0-1 1-2 2-3 3-4
Fructose und 400 ||| fructose and 400 ||| 0-0 1-1 2-2
Fructose und 400 ||| of fructose and 400 ||| 0-1 1-2 2-3
Fructose und ||| fructose and ||| 0-0 1-1
Fructose und ||| of fructose and ||| 0-1 1-2
Fructose ||| fructose ||| 0-0
Fructose ||| of fructose ||| 0-1
Frühstadium ||| Early ||| 0-0
Functional Assessment of Cancer ||| Functional Assessment of Cancer ||| 0-0 1-1 2-1 2-2 3-3
Functional Assessment of ||| Functional Assessment of ||| 0-0 1-1 2-1 2-2
Functional ||| Functional ||| 0-0
Funktionen ||| monitoring ||| 0-0
Funktionsstörung der ||| malfunction of the ||| 0-0 1-2
Funktionsstörung ||| malfunction of ||| 0-0
Funktionsstörung ||| malfunction ||| 0-0
Futter Ihr Hund braucht ||| food your dog will need ||| 0-0 1-1 2-2 1-3 3-4
Futter Ihr Hund ||| food your dog will ||| 0-0 1-1 2-2 1-3
Futter ||| food ||| 0-0
Futters . ||| food . ||| 0-0 1-1
Futters ||| food ||| 0-0
FÜR DIE BESEITIGUNG ||| OF UNUSED MEDICINAL PRODUCTS ||| 0-0 0-1 1-1 1-2 2-3
FÜR DIE CHARGENFREIGABE VERANTWORTLICH IST ||| RESPONSIBLE FOR BATCH RELEASE ||| 0-0 1-0 2-0 2-1 2-2 3-2 3-3 4-3
FÜR DIE CHARGENFREIGABE VERANTWORTLICH IST ||| RESPONSIBLE FOR BATCH RELEASE ||| 0-0 2-0 1-1 2-1 2-2 3-2 3-3 4-3
FÜR DIE CHARGENFREIGABE VERANTWORTLICH IST ||| RESPONSIBLE FOR BATCH RELEASE ||| 0-0 2-0 1-1 2-2 3-2 3-3 4-3
FÜR DIE CHARGENFREIGABE VERANTWORTLICH IST/SIND ||| RESPONSIBLE FOR BATCH RELEASE ||| 0-0 1-0 2-0 2-1 2-2 3-2 4-3
FÜR DIE CHARGENFREIGABE VERANTWORTLICH SIND ||| RESPONSIBLE FOR BATCH RELEASE ||| 0-0 2-0 1-1 2-2 3-2 4-3
FÜR DIE CHARGENFREIGABE VERANTWORTLICH ||| RESPONSIBLE FOR BATCH ||| 0-0 1-0 2-0 2-1 2-2 3-2
FÜR DIE CHARGENFREIGABE VERANTWORTLICH ||| RESPONSIBLE FOR BATCH ||| 0-0 2-0 1-1 2-2 3-2
FÜR DIE ENTSORGUNG VON NICHT ||| FOR THE DISPOSAL OF UNUSED ||| 0-0 1-0 2-1 2-2 3-3 4-3 1-4
FÜR DIE WOCHENTAGE ||| FOR DAYS OF ||| 0-0 1-1 2-1 2-2
FÜR DIE ||| OF UNUSED MEDICINAL ||| 0-0 0-1 1-1 1-2
FÜR JEDE TIERART , ||| FOR EACH SPECIES , ||| 0-0 1-1 2-2 3-3
FÜR JEDE TIERART ||| FOR EACH SPECIES ||| 0-0 1-1 2-2
FÜR JEDE ||| FOR EACH ||| 0-0 1-1
FÜR KINDER UNERREICHBAR UND ||| BE STORED OUT OF THE ||| 0-0 1-0 1-1 2-2 2-3 3-4
FÜR KINDER UNERREICHBAR ||| BE STORED OUT OF ||| 0-0 1-0 1-1 2-2 2-3
FÜR KINDER ||| BE STORED ||| 0-0 1-0 1-1
FÜR PACKUNGSEINHEIT ||| UNIT PACK ||| 1-0 0-1 1-1
FÜR PACKUNGSGRÖßEN MIT 14 , ||| PACK SIZES OF 14 , ||| 0-0 1-0 1-1 2-1 0-2 3-3 4-4
FÜR PACKUNGSGRÖßEN MIT 14 ||| PACK SIZES OF 14 ||| 0-0 1-0 1-1 2-1 0-2 3-3
FÜR PACKUNGSGRÖßEN MIT ||| PACK SIZES OF ||| 0-0 1-0 1-1 2-1 0-2
FÜR TIERE " SOWIE ||| FOR ANIMAL TREATMENT ONLY AND ||| 0-0 1-1 1-2 2-2 3-2 1-3 3-4
FÜR ZWISCHENPACKUNG ||| INTERMEDIATE PACK ||| 1-0 0-1 1-1
FÜR ||| FOR ||| 0-0
FÜR ||| OF ||| 0-0
Fähigkeit zum Bedienen von Maschinen ||| to drive and use machines ||| 0-0 0-1 1-1 1-2 2-3 3-3 2-4 4-4
Fähigkeit zum Fahren oder zum ||| ability to drive or ||| 0-0 1-1 2-1 0-2 1-2 4-2 3-3
Fähigkeit zum ||| to drive and ||| 0-0 0-1 1-1 1-2
Fälle erhöhter Leberenzymwerte ||| cases of elevated liver enzymes ||| 0-0 0-1 1-2 2-2 2-3 2-4
Fälle von Bronchokonstriktion ||| cases of bronchoconstriction ||| 0-0 1-1 2-2
Fälle von Krampfanfällen ||| cases of seizure ||| 0-0 1-1 2-2
Fälle von MNS ||| cases of NMS ||| 0-0 1-1 2-2
Fälle von Schlaganfällen oder ||| cases of stroke or ||| 0-0 1-1 2-2 3-3
Fälle von Schlaganfällen ||| cases of stroke ||| 0-0 1-1 2-2
Fälle von anaphylaktischer Reaktion/Schock ||| cases of anaphylactic reaction/ shock ||| 0-0 1-1 3-2 2-3 3-3 3-4
Fälle von symptomatischer Hypokalzämie ||| symptomatic cases of hypocalcaemia ||| 2-0 0-1 1-2 3-3
Fälle von symptomatischer ||| symptomatic cases of ||| 2-0 0-1 1-2
Fälle von ||| cases of ||| 0-0 1-1
Fälle wurde mit ||| cases have been associated with ||| 0-0 1-1 1-2 2-3 2-4
Fälle wurde ||| cases have been ||| 0-0 1-1 1-2
Fälle ||| cases of ||| 0-0 0-1
Fälle ||| cases ||| 0-0
Fällen ein tödlicher Ausgang ||| cases fatal outcome has ||| 0-0 1-1 2-1 3-2 3-3
Fällen ein tödlicher ||| cases fatal ||| 0-0 1-1 2-1
Fällen extrem und assoziiert mit ||| cases extreme and associated with ||| 0-0 1-1 3-1 2-2 3-3 4-4
Fällen extrem und assoziiert ||| cases extreme and associated ||| 0-0 1-1 3-1 2-2 3-3
Fällen normalisierte . ||| it resolved . ||| 0-0 1-1 2-2
Fällen normalisierte . ||| of whom it resolved . ||| 0-2 1-3 2-4
Fällen normalisierte . ||| whom it resolved . ||| 0-1 1-2 2-3
Fällen normalisierte ||| it resolved ||| 0-0 1-1
Fällen normalisierte ||| of whom it resolved ||| 0-2 1-3
Fällen normalisierte ||| whom it resolved ||| 0-1 1-2
Fällen sind diese Wirkungen ||| cases , these effects are ||| 0-0 0-1 2-2 3-3 1-4
Fällen ||| cases , ||| 0-0 0-1
Fällen ||| cases ||| 0-0
Fällen ||| it ||| 0-0
Fällen ||| of whom it ||| 0-2
Fällen ||| whom it ||| 0-1
Fäzes . ||| faeces . ||| 0-0 1-1
Fäzes ||| faeces ||| 0-0
Föten beobachtet . ||| pioglitazone . ||| 0-0 1-0 2-1
Föten beobachtet . ||| with pioglitazone . ||| 0-1 1-1 2-2
Föten beobachtet ||| pioglitazone ||| 0-0 1-0
Föten beobachtet ||| with pioglitazone ||| 0-1 1-1
Föten ||| pioglitazone ||| 0-0
Füllen Sie die ||| Fill the ||| 0-0 1-1 2-1
Füllen ||| Fill ||| 0-0
Für Dialysepatienten liegen ||| No information is ||| 0-0 1-1 2-1 2-2
Für Insuline gibt es ||| A specific overdose of ||| 0-0 1-0 1-1 2-1 1-2 3-2 3-3
Für Osteonekrosen im Kieferbereich ||| Osteonecrosis of the jaw ||| 1-0 0-1 1-1 2-2 2-3 3-3
Für Osteonekrosen ||| Osteonecrosis of ||| 1-0 0-1 1-1
Für die Behandlung der bipolaren ||| For the treatment of bipolar ||| 0-0 1-1 2-2 3-3 4-4
Für die Behandlung der ||| For the treatment of ||| 0-0 1-1 2-2 3-3
Für die Behandlung ||| For the treatment ||| 0-0 1-1 2-2
Für die ungeöffnete Flasche bestehen ||| The unopened bottle does not ||| 0-0 0-1 1-1 2-1 3-2 2-3 4-3 2-4
Für die ungeöffnete Flasche ||| The unopened bottle does ||| 0-0 0-1 1-1 2-1 3-2 2-3
Für die ||| For the ||| 0-0 1-1
Für die ||| There are no ||| 0-0 0-1 1-1 0-2
Für dieses Arzneimittel ||| This medicinal product ||| 0-0 1-1 2-2
Für dieses Tierarzneimittel ||| This veterinary medicinal product ||| 0-0 2-1 1-2 2-3
Für dieses ||| This medicinal ||| 0-0 1-1
Für ||| 3 Elevated ||| 0-0 0-1
Für ||| For ||| 0-0
Für ||| No ||| 0-0
Für ||| This ||| 0-0
G-CSF oder GM-CSF gezeigt ( ||| G-CSF or GM-CSF ( ||| 0-0 1-1 0-2 2-2 4-3
G-CSF oder GM-CSF gezeigt ||| G-CSF or GM-CSF ||| 0-0 1-1 0-2 2-2
G-CSF oder GM-CSF ||| G-CSF or GM-CSF ||| 0-0 1-1 0-2 2-2
G-CSF und GM-CSF ||| G-CSF and GM-CSF ||| 0-0 1-1 0-2 2-2
GEGEBENENFALLS BESONDERE VORSICHTSMASSNAHMEN ||| SPECIAL PRECAUTIONS FOR DISPOSAL ||| 0-0 0-1 1-1 1-2 2-3
GEGEBENENFALLS BESONDERE ||| SPECIAL PRECAUTIONS FOR ||| 0-0 0-1 1-1 1-2
GENEHMIGUNG FÜR DAS INVERKEHRBRINGEN FÜR ||| THE MARKETING AUTHORISATION ||| 0-0 0-1 1-1 2-1 3-1 3-2 4-2
GENEHMIGUNG FÜR DAS INVERKEHRBRINGEN ||| THE MARKETING AUTHORISATION ||| 0-0 0-1 1-1 2-1 3-1 3-2
GENEHMIGUNG FÜR DAS INVERKEHRBRINGEN ||| THE MARKETING ||| 0-0 0-1 1-1 2-1 3-1
GESMBH Tel : + 43 ||| GESMBH Tel : + 43 ||| 0-0 1-1 2-2 3-3 4-4
GESMBH Tel : + ||| GESMBH Tel : + ||| 0-0 1-1 2-2 3-3
GESMBH Tel : ||| GESMBH Tel : ||| 0-0 1-1 2-2
GESMBH Tel ||| GESMBH Tel ||| 0-0 1-1
GESMBH ||| GESMBH ||| 0-0
GEWICHT , VOLUMEN ODER ||| , BY VOLUME OR BY ||| 0-0 0-1 1-1 2-2 3-3 2-4 3-4
GEWICHT , ||| , BY ||| 0-0 0-1 1-1
GGT ) , erhöhte alkalische ||| GGT ) , increased alkaline ||| 0-0 1-1 2-2 3-3 4-4
GGT ) , erhöhte ||| GGT ) , increased ||| 0-0 1-1 2-2 3-3
GGT ) , ||| GGT ) , ||| 0-0 1-1 2-2
GGT ) ||| GGT ) ||| 0-0 1-1
GGT ||| GGT ||| 0-0
GM-CSF bezüglich ||| proliferation of ||| 0-0 1-0
GM-CSF bezüglich ||| proliferation ||| 0-0 1-0
Gabe , Genotoxizität ||| conventional studies of ||| 0-0 1-0 2-0 2-1
Gabe , Genotoxizität ||| conventional studies ||| 0-0 1-0 2-0 2-1
Gabe von Abraxane auf und ||| Abraxane administration and ||| 2-0 3-0 0-1 1-1 4-2
Gabe von Abraxane auf ||| Abraxane administration ||| 2-0 3-0 0-1 1-1
Gabe von Abraxane ||| administration of Abraxane ||| 0-0 1-1 2-2
Gabe von Aclasta ||| Aclasta administration ||| 2-0 0-1 1-1
Gabe von Alendronat bezogen ||| alendronate ||| 0-0 1-0 2-0
Gabe von Alendronat ||| alendronate ||| 0-0 1-0 2-0
Gabe von Ketoconazol oder anderen ||| administration of ketoconazole or other ||| 0-0 1-1 2-2 3-3 4-4
Gabe von Ketoconazol oder ||| administration of ketoconazole or ||| 0-0 1-1 2-2 3-3
Gabe von Ketoconazol ||| administration of ketoconazole ||| 0-0 1-1 2-2
Gabe von Placebo ||| placebo ||| 2-0
Gabe von ||| administration of ||| 0-0 1-1
Gabe von ||| administration ||| 0-0 1-0
Gabe von ||| of ||| 0-0 1-0
Gabe ||| administration ||| 0-0
Gabe ||| when ||| 0-0
Galle ||| bile ||| 0-0
Gamma- Glutamyl-Transferase ( GGT ||| Gamma Glutamyl Transferase ( GGT ||| 0-0 1-1 1-2 2-3 3-4
Gamma- Glutamyl-Transferase ( ||| Gamma Glutamyl Transferase ( ||| 0-0 1-1 1-2 2-3
Gamma- Glutamyl-Transferase ||| Gamma Glutamyl Transferase ||| 0-0 1-1 1-2
Gamma- ||| Gamma ||| 0-0
Gang ||| Reaktion am Anwendungsort ||| 0-0 0-1 0-2
Ganzen wieder aus dem Mund ||| tablet from the mouth is ||| 0-0 1-1 2-1 3-2 3-3 4-3 3-4
Ganzen wieder aus ||| tablet from ||| 0-0 1-1 2-1
Ganzen ||| tablet ||| 0-0
Gastrointestinaltrakt ||| gastrointestinal ||| 0-0
Gastrointestinaltraktes ||| subcutaneous tissue disorders ||| 0-0 0-1 0-2
Gastrointestinaltrakts ||| Gastrointestinal ||| 0-0
Gate Wellington Road Wokingham Berkshire ||| Gate Wellington Road Wokingham Berkshire ||| 0-0 1-1 2-2 3-3 4-4
Gate Wellington Road Wokingham ||| Gate Wellington Road Wokingham ||| 0-0 1-1 2-2 3-3
Gate Wellington Road ||| Gate Wellington Road ||| 0-0 1-1 2-2
Gate Wellington ||| Gate Wellington ||| 0-0 1-1
Gate ||| Gate ||| 0-0
Geben Sie daher das Arzneimittel ||| Therefore , administer the product ||| 0-0 1-2 3-3 2-4 3-4 4-4
Geben Sie ||| Geben Sie es nicht ||| 0-0 0-1 0-2 1-2 0-3
Geben Sie ||| Therefore , administer ||| 0-0 1-2
Geben Sie ||| and you ||| 1-1
Geben Sie ||| you ||| 1-0
Geben ||| Therefore , ||| 0-0
Geben ||| Therefore ||| 0-0
Gebrauch mit ||| with ||| 0-0 1-0
Gebrauchsinformation wurde zuletzt genehmigt ||| leaflet was last approved on ||| 0-0 1-1 2-2 3-3 3-4
Gebrauchsinformation wurde zuletzt genehmigt ||| leaflet was last approved ||| 0-0 1-1 2-2 3-2 3-3
Gebrauchsinformation wurde zuletzt ||| leaflet was last ||| 0-0 1-1 2-2
Gebrauchsinformation wurde zuletzt ||| leaflet ||| 0-0 1-0 2-0
Gebrauchsinformation wurde ||| leaflet was ||| 0-0 1-1
Gebrauchsinformation ||| leaflet ||| 0-0
Geburt fällt der Insulinbedarf innerhalb ||| delivery , ||| 0-0 1-0 2-0 3-0 4-0
Geburt fällt der Insulinbedarf innerhalb ||| delivery ||| 0-0 1-0 2-0 3-0 4-0
Geeignete Änderungen in der Lebensweise ||| Introducing appropriate lifestyle changes ||| 0-0 1-0 1-1 4-2 1-3 2-3 3-3
Gefahr ||| of ||| 0-0
Gefäßerkrankungen ||| Vascular ||| 0-0
Gefühl ||| feeling ||| 0-0
Gegebenenfalls kann es ||| If convenient it may ||| 0-0 0-1 2-2 1-3
Gegebenenfalls ||| If convenient ||| 0-0 0-1
Gegen ||| There ||| 0-0
Gegenmittel ) , falls erforderlich ||| antidotes ) , if necessary ||| 0-0 1-1 2-2 3-3 4-4
Gegenmittel ) , falls ||| antidotes ) , if ||| 0-0 1-1 2-2 3-3
Gegenmittel ) , ||| antidotes ) , ||| 0-0 1-1 2-2
Gegenmittel ) ||| antidotes ) ||| 0-0 1-1
Gegenmittel ||| antidotes ||| 0-0
Gehirn . ||| brain . ||| 0-0 1-1
Gehirn ||| brain ||| 0-0
Gelegentlich - Diabetische Retinopathie ||| Uncommon - Diabetic retinopathy ||| 0-0 1-1 2-2 3-3
Gelegentlich - Diabetische ||| Uncommon - Diabetic ||| 0-0 1-1 2-2
Gelegentlich - Periphere Neuropathie ||| Uncommon - Peripheral neuropathy ||| 0-0 1-1 2-2 3-3
Gelegentlich - Periphere ||| Uncommon - Peripheral ||| 0-0 1-1 2-2
Gelegentlich - ||| Uncommon - ||| 0-0 1-1
Gelegentlich - Ödem Zu ||| Uncommon - Oedema Oedema may ||| 0-0 1-1 2-2 2-3 3-3 3-4
Gelegentlich : Abgeschlagenheit* ||| Uncommon : fatigue* ||| 0-0 1-1 2-2
Gelegentlich : Depression* ||| anxiety Uncommon : depression* ||| 2-0 0-1 1-2 2-3
Gelegentlich : Dysgeusie , ||| Uncommon : dysgeusia , ||| 0-0 1-1 2-2 3-3
Gelegentlich : Dysgeusie , Ösophagitis ||| Uncommon : dysgeusia , oesophagitis ||| 0-0 1-1 2-2 3-3 4-4
Gelegentlich : Dysgeusie ||| Uncommon : dysgeusia ||| 0-0 1-1 2-2
Gelegentlich : Tachykardie* ||| Uncommon : tachycardia* ||| 0-0 1-1 2-2
Gelegentlich : orthostatische Hypotonie* , ||| Uncommon : orthostatic hypotension* , ||| 0-0 1-1 2-2 3-3 4-4
Gelegentlich : orthostatische Hypotonie* ||| Uncommon : orthostatic hypotension* ||| 0-0 1-1 2-2 3-3
Gelegentlich : orthostatische ||| Uncommon : orthostatic ||| 0-0 1-1 2-2
Gelegentlich : ||| Uncommon : ||| 0-0 1-1
Gelegentlich wurde ||| 6 ||| 1-0
Gelegentlich ||| Uncommon ||| 0-0
Gelegentliche Nebenwirkungen ( ||| Uncommon side effects ( ||| 0-0 1-1 1-2 2-3
Gelegentliche Nebenwirkungen ||| Uncommon side effects ||| 0-0 1-1 1-2
Gelegentliche ||| Uncommon ||| 0-0
Gelenk- ||| joint ||| 0-0
Gelenkschmerzen ||| joints ||| 0-0
Gelenkschwellung , ||| , ||| 0-0 1-0
Gemfibrozil ( einem ||| gemfibrozil ( an ||| 0-0 1-1 0-2 2-2
Gemfibrozil ( einem ||| gemfibrozil ( an ||| 0-0 1-1 2-2
Gemfibrozil ( ||| gemfibrozil ( ||| 0-0 1-1
Gemfibrozil ||| gemfibrozil ||| 0-0
Genehmigung für das Inverkehrbringen von ||| Union , for ||| 0-0 2-0 3-0 1-2
Genehmigung für das Inverkehrbringen ||| Union , for ||| 0-0 2-0 3-0 1-2
Genehmigung wurde ||| marketing authorisation was ||| 0-0 0-1 1-2
Genehmigung ||| marketing authorisation ||| 0-0 0-1
General Scale ||| general scale ||| 0-0 0-1 1-1
Generell ||| In general ||| 0-0 0-1
Genese . ||| any origin . ||| 0-0 0-1 1-2
Genese ||| any origin ||| 0-0 0-1
Genesung von einer Hypoglykämie verzögern ||| delay recovery from hypoglycaemia ||| 0-0 1-0 0-1 2-1 4-2 3-3 4-3
Genesung von einer ||| delay recovery ||| 0-0 1-0 0-1 2-1
Genotoxizität wurde Aripiprazol ||| genotoxicity tests , aripiprazole ||| 0-0 0-1 1-1 2-3
Genotoxizität wurde ||| genotoxicity tests , ||| 0-0 0-1 1-1
Genotoxizität wurde ||| genotoxicity tests ||| 0-0 0-1 1-1
Gereinigtes Wasser ||| Purified water ||| 0-0 1-1
Gereinigtes ||| Purified ||| 0-0
Geringfügige Abnahme der ||| a small reduction in ||| 0-0 0-1 1-2 1-3 2-3
Geringfügige ||| a small ||| 0-0 0-1
Gesamt-Clearance betrug 15 ||| total clearance was 15 ||| 0-0 0-1 1-2 2-3
Gesamt-Clearance betrug ||| total clearance was ||| 0-0 0-1 1-2
Gesamt-Clearance ||| total clearance ||| 0-0 0-1
Gesamt-Paclitaxel nach 30- und 180-minütigen ||| following 30- and 180-minute ||| 1-0 0-1 2-1 3-2 4-3
Gesamt-Paclitaxel nach 30- und ||| following 30- and ||| 1-0 0-1 2-1 3-2
Gesamt-Paclitaxel nach 30- ||| following 30- ||| 1-0 0-1 2-1
Gesamtdosis ABILIFY ( ||| total dose of ABILIFY ( ||| 0-0 0-1 1-3 2-4
Gesamtdosis ABILIFY ||| total dose of ABILIFY ||| 0-0 0-1 1-3
Gesamtdosis und ||| total dose and rate ||| 0-0 0-1 1-2
Gesamtdosis und ||| total dose and ||| 0-0 0-1 1-2
Gesamtdosis ||| total dose of ||| 0-0 0-1
Gesamtdosis ||| total dose ||| 0-0 0-1
Gesamtdosis über mindestens eine bis ||| five minutes , depending ||| 0-0 1-0 0-1 1-2 0-3 2-3 3-3 4-3
Gesamthäufigkeit an Vorhofflimmern ||| atrial fibrillation ||| 0-0 2-1
Gesamthäufigkeit an ||| atrial ||| 0-0
Gesamthäufigkeit von Vorhofflimmern ||| pooled atrial fibrillation incidences ||| 0-0 0-1 1-1 2-2
Gesamthäufigkeit von Vorhofflimmern ||| pooled atrial fibrillation ||| 0-0 0-1 1-1 2-2
Gesamthäufigkeit von ||| pooled atrial ||| 0-0 0-1 1-1
Gesamthäufigkeit ||| atrial ||| 0-0
Gesamtmortalität lag bei 10 % ||| cause mortality was 10 % ||| 0-1 1-2 2-2 3-3 4-4
Gesamtmortalität lag bei 10 % ||| mortality was 10 % ||| 0-0 1-1 2-1 3-2 4-3
Gesamtmortalität lag bei 10 ||| cause mortality was 10 ||| 0-1 1-2 2-2 3-3
Gesamtmortalität lag bei 10 ||| mortality was 10 ||| 0-0 1-1 2-1 3-2
Gesamtmortalität lag bei ||| cause mortality was ||| 0-1 1-2 2-2
Gesamtmortalität lag bei ||| mortality was ||| 0-0 1-1 2-1
Gesamtmortalität ||| cause mortality ||| 0-1
Gesamtmortalität ||| mortality ||| 0-0
Gesamtmortalitätsrisikos ( p=0,01 ||| all cause mortality ( p=0.01 ||| 0-0 0-1 2-2 1-3 2-4
Gesamtmortalitätsrisikos ||| all cause ||| 0-0 0-1
Gesamtüberleben und erhöhte ||| overall survival and increased ||| 0-0 0-1 1-2 2-3
Gesamtüberleben und ||| overall survival and ||| 0-0 0-1 1-2
Gesamtüberleben zwischen den ||| overall survival between ||| 0-0 0-1 2-1 1-2
Gesamtüberleben ||| overall survival ||| 0-0 0-1
Gesamtüberleben ||| survival ||| 0-0
Geschlecht ||| gender ||| 0-0
Geschlechtshormonen ||| sex ||| 0-0
Geschmacksstörung , ||| , tremor ||| 0-0 1-0 1-1
Gesicht ||| face ||| 0-0
Gesicht ||| the face ||| 0-1
Gesichtsrötung , ||| , redness ||| 0-0 1-0 1-1
Gesichtsödeme , Pruritus ||| face oedema , pruritus , ||| 0-0 0-1 1-2 2-3 1-4
Gesichtsödeme ||| face oedema ||| 0-0 0-1
Gesäß ||| gluteal ||| 0-0
Gewichstzunahme , Gewichtsabnahme ||| weight gain , weight decreased ||| 0-0 0-1 1-2 2-3 2-4
Gewichstzunahme , ||| weight gain , ||| 0-0 0-1 1-2
Gewichstzunahme ||| weight gain ||| 0-0 0-1
Gewicht zunimmt , ||| weight increases , ||| 0-0 1-1 2-2
Gewicht zunimmt ||| weight increases ||| 0-0 1-1
Gewicht ||| weight ||| 0-0
Gewichtsabnahme , Anorexie , ||| weight decreased , anorexia , ||| 0-0 0-1 1-2 2-3 3-4
Gewichtsabnahme , Anorexie ||| weight decreased , anorexia ||| 0-0 0-1 1-2 2-3
Gewichtsabnahme , abgemagertes Aussehen ||| weight loss , emaciated ||| 0-0 1-1 1-2 2-3 3-3
Gewichtsabnahme , ||| weight decreased , ||| 0-0 0-1 1-2
Gewichtsabnahme , ||| weight loss , ||| 0-0 1-1 1-2
Gewichtsabnahme ||| weight decreased ||| 0-0 0-1
Gewichtsabnahme ||| weight ||| 0-0
Gewichtsabnahmekategorie für Mitratapid im Vergleich ||| category for mitratapide versus ||| 0-0 1-1 2-2 4-3
Gewichtsabnahmekategorie für Mitratapid im Vergleich ||| loss category for mitratapide versus ||| 0-1 1-2 2-3 4-4
Gewichtsabnahmekategorie für Mitratapid im ||| category for mitratapide ||| 0-0 1-1 2-2
Gewichtsabnahmekategorie für Mitratapid im ||| loss category for mitratapide ||| 0-1 1-2 2-3
Gewichtsabnahmekategorie für Mitratapid ||| category for mitratapide ||| 0-0 1-1 2-2
Gewichtsabnahmekategorie für Mitratapid ||| loss category for mitratapide ||| 0-1 1-2 2-3
Gewichtsabnahmekategorie für ||| category for ||| 0-0 1-1
Gewichtsabnahmekategorie für ||| loss category for ||| 0-1 1-2
Gewichtsabnahmekategorie ||| category ||| 0-0
Gewichtsabnahmekategorie ||| loss category ||| 0-1
Gewichtsreduktion ||| weight loss ||| 0-0 0-1
Gewichtsreduktion ||| weight reduction ||| 0-0 0-1
Gewichtsreduzierung , der ||| overall weight management programme ||| 0-0 2-0 0-1 0-2 0-3
Gewichtsreduzierung ||| weight ||| 0-0
Gewichtsverlust ||| ACOMPLIA ||| 0-0
Gewichtszunahme , die in der ||| that seen in ||| 1-0 2-0 0-1 2-1 3-2 4-2
Gewichtszunahme , die ||| that seen ||| 1-0 2-0 0-1 2-1
Gewichtszunahme : Eine Gewichtszunahme ||| Weight gain : weight gain ||| 0-0 2-0 0-1 1-2 3-3 3-4
Gewichtszunahme : Eine ||| Weight gain : ||| 0-0 2-0 0-1 1-2
Gewichtszunahme : In klinischen ||| Weight gain : in clinical ||| 0-0 0-1 1-2 2-3 2-4 3-4
Gewichtszunahme : ||| Weight gain : ||| 0-0 0-1 1-2
Gewichtszunahme und Ödeme hin ||| weight gain and oedema ||| 0-0 0-1 3-1 1-2 2-3
Gewichtszunahme wird ||| weight gain is ||| 0-0 0-1 1-2
Gewichtszunahme ||| Weight gain ||| 0-0 0-1
Gewichtszunahme ||| weight gain ||| 0-0 0-1
Gewichtszunahme ||| weight increase ||| 0-0 0-1
Gewichtszunahme ||| weight ||| 0-0
Gewährleistung der ||| obese patients and overweight patients ||| 0-0 0-1 0-3 0-4
Gewährleistung ||| obese patients and overweight patients ||| 0-0 0-1 0-3 0-4
Gewährleistung ||| taken ||| 0-0
Glas Wasser ||| glass of water ||| 0-0 1-2
Glas ||| glass of ||| 0-0
Glas ||| glass ||| 0-0
Glaskugel , um die Resuspendierung ||| glass ball to facilitate the ||| 0-0 0-1 1-1 2-1 2-2 3-3 4-3 3-4
Glaskugel , um ||| glass ball to ||| 0-0 0-1 1-1 2-1 2-2
Glibenclamid ||| glibenclamide ||| 0-0
Gliclazid ) verglichen . ||| gliclazide ) . ||| 0-0 1-1 2-1 3-2
Gliclazid ) verglichen ||| gliclazide ) ||| 0-0 1-1 2-1
Gliclazid . ||| gliclazide . ||| 0-0 1-1
Gliclazid als Monotherapie wurde ||| gliclazide as monotherapy was ||| 0-0 1-1 2-2 3-3
Gliclazid als Monotherapie ||| gliclazide as monotherapy ||| 0-0 1-1 2-2
Gliclazid als ||| gliclazide as ||| 0-0 1-1
Gliclazid ||| gliclazide ||| 0-0
Global R & D Centre ||| Global R & D Centre ||| 0-0 1-1 2-2 3-3 4-4
Global R & D ||| Global R & D ||| 0-0 1-1 2-2 3-3
Global R & ||| Global R & ||| 0-0 1-1 2-2
Global R ||| Global R ||| 0-0 1-1
Global Research and Development Centre ||| Global Research and Development Centre ||| 0-0 1-1 2-1 2-2 3-3 4-4
Global Research and Development ||| Global Research and Development ||| 0-0 1-1 2-1 2-2 3-3
Global Research and ||| Global Research and ||| 0-0 1-1 2-1 2-2
Global ||| Global ||| 0-0
Glucokortikoide , Schilddrüsenhormone und ||| glucocorticoids , thyroid hormones and ||| 0-0 1-1 2-2 2-3 3-4
Glucokortikoide , Schilddrüsenhormone ||| glucocorticoids , thyroid hormones ||| 0-0 1-1 2-2 2-3
Glucokortikoide , ||| glucocorticoids , ||| 0-0 1-1
Glucokortikoide ||| glucocorticoids ||| 0-0
Glucose aus der Leber inhibiert ||| glucose output from the liver ||| 0-0 4-1 1-2 2-3 3-4 4-4
Glucose ||| glucose ||| 0-0
Glucose- ||| glucose-galactose ||| 0-0
Glucose-Galactose-Malabsorption oder Sucrase-Isomaltase-Insuffizienz ||| glucose-galactose malabsorption or sucrase-isomaltase insufficiency ||| 0-0 0-1 1-2 2-3 2-4
Glucose-Galactose-Malabsorption oder ||| glucose-galactose malabsorption or ||| 0-0 0-1 1-2
Glucose-Galactose-Malabsorption ||| glucose-galactose malabsorption ||| 0-0 0-1
Glutamyl-Transferase ( GGT ) ||| Glutamyl Transferase ( GGT ) ||| 0-0 0-1 1-2 2-3 3-4
Glutamyl-Transferase ( GGT ||| Glutamyl Transferase ( GGT ||| 0-0 0-1 1-2 2-3
Glutamyl-Transferase ( ||| Glutamyl Transferase ( ||| 0-0 0-1 1-2
Glutamyl-Transferase ||| Glutamyl Transferase ||| 0-0 0-1
Gluteus-maximus-Muskel unter ||| , avoiding ||| 0-1
Gluteus-maximus-Muskel unter ||| avoiding ||| 0-0
Gluteus-maximus-Muskel ||| , avoiding ||| 0-1
Gluteus-maximus-Muskel ||| avoiding ||| 0-0
Glycerol Metacresol Phenol ||| chloride Glycerol Metacresol Phenol ||| 0-0 0-1 1-2 2-2 2-3
Glycerol ||| chloride Glycerol ||| 0-0 0-1
Glycin , ||| glycine , ||| 0-0 1-1
Glycin Polysorbat 80 Wasser für ||| Glycine Polysorbate 80 Water for ||| 0-0 1-0 2-1 2-2 3-3 4-4
Glycin Polysorbat 80 Wasser ||| Glycine Polysorbate 80 Water ||| 0-0 1-0 2-1 2-2 3-3
Glycin Polysorbat 80 ||| Glycine Polysorbate 80 ||| 0-0 1-0 2-1 2-2
Glycin Polysorbat ||| Glycine ||| 0-0 1-0
Glycin ||| glycine ||| 0-0
Glycoprotein ( P-gp ) in ||| P-glycoprotein ( P-gp ) in ||| 0-0 2-0 1-1 2-2 3-3 4-4
Glycoprotein ( P-gp ) ||| P-glycoprotein ( P-gp ) ||| 0-0 2-0 1-1 2-2 3-3
Glycoprotein ( P-gp ||| P-glycoprotein ( P-gp ||| 0-0 2-0 1-1 2-2
GmbH & Co KG , ||| GmbH & Co KG , ||| 0-0 1-1 2-2 3-3 4-4
GmbH & Co KG Kuhloweg ||| GmbH & Co KG Kuhloweg ||| 0-0 1-1 2-2 3-3 4-4
GmbH & Co KG ||| GmbH & Co KG ||| 0-0 1-1 2-2 3-3
GmbH & Co ||| GmbH & Co ||| 0-0 1-1 2-2
GmbH & ||| GmbH & ||| 0-0 1-1
GmbH Roonstraße 25 D-90429 Nürnberg ||| GmbH Roonstraße 25 D-90429 Nuremberg ||| 0-0 1-1 2-2 3-3 4-4
GmbH Roonstraße 25 D-90429 ||| GmbH Roonstraße 25 D-90429 ||| 0-0 1-1 2-2 3-3
GmbH Roonstraße 25 ||| GmbH Roonstraße 25 ||| 0-0 1-1 2-2
GmbH Roonstraße ||| GmbH Roonstraße ||| 0-0 1-1
GmbH Tel : +43 1 ||| GmbH Tel : +43 1 ||| 0-0 1-1 2-2 3-3 4-4
GmbH Tel : +43 ||| GmbH Tel : +43 ||| 0-0 1-1 2-2 3-3
GmbH Tel : +49 911 ||| GmbH Tel : +49 911 ||| 0-0 1-1 2-2 3-3 4-4
GmbH Tel : +49 ||| GmbH Tel : +49 ||| 0-0 1-1 2-2 3-3
GmbH Tel : ||| GmbH Tel : ||| 0-0 1-1 2-2
GmbH Tel ||| GmbH Tel ||| 0-0 1-1
GmbH Tel. + 49 ||| GmbH Tel . + 49 ||| 0-0 1-1 1-2 2-3 3-4
GmbH Tel. + ||| GmbH Tel . + ||| 0-0 1-1 1-2 2-3
GmbH Tel. ||| GmbH Tel . ||| 0-0 1-1 1-2
GmbH Tél/Tel : +49 ||| GmbH Tél/ Tel : +49 ||| 0-0 1-1 1-2 2-3 3-4
GmbH Tél/Tel : ||| GmbH Tél/ Tel : ||| 0-0 1-1 1-2 2-3
GmbH Tél/Tel ||| GmbH Tél/ Tel ||| 0-0 1-1 1-2
GmbH ||| GmbH ||| 0-0
Grad 1 oder 2 ||| Grade 1 or 2 ||| 0-0 1-1 2-2 3-3
Grad 1 oder ||| Grade 1 or ||| 0-0 1-1 2-2
Grad 1 ||| Grade 1 ||| 0-0 1-1
Grad 3 ||| experiencing grade 3 ||| 0-1 1-2
Grad 3 ||| grade 3 ||| 0-0 1-1
Grad für Patienten , die ||| grade for patients experiencing ||| 0-0 1-1 4-1 2-2
Grad für Patienten , die ||| grade for patients ||| 0-0 1-1 4-1 2-2
Grad ||| Grade ||| 0-0
Grad ||| experiencing grade ||| 0-1
Grad ||| grade ||| 0-0
Grippe , Schlaflosigkeit , ||| Flu , sleeplessness , ||| 1-0 0-1 1-1 1-2 2-3 3-3
Grippe , ||| Flu , sleeplessness ||| 1-0 0-1 1-1 1-2
Grippeähnliche Symptome wie ||| flu-like symptoms , such as ||| 0-0 1-1 2-3 2-4
Grippeähnliche Symptome ||| flu-like symptoms , ||| 0-0 1-1
Grippeähnliche Symptome ||| flu-like symptoms ||| 0-0 1-1
Grippeähnliche ||| flu-like ||| 0-0
Grund des Fehlens von Daten ||| a lack of data ||| 2-1 0-2 1-2 3-2 4-3
Grund des Fehlens von Daten ||| lack of data ||| 2-0 0-1 1-1 3-1 4-2
Grund des Fehlens von ||| a lack of ||| 2-1 0-2 1-2 3-2
Grund des Fehlens von ||| lack of ||| 2-0 0-1 1-1 3-1
Grundlage der Empfehlungen des CHMP ||| treatment , read the Package ||| 1-0 0-2 2-2 4-2 3-3 4-4
Gruppe , verglichen ||| group compared to ||| 0-0 2-1 1-2 2-2
Gruppe : orale ||| group : oral blood ||| 0-0 1-1 2-2 0-3
Gruppe ich ||| years ||| 0-0 1-0
Gruppe wurde beobachtet . ||| group . ||| 0-0 1-0 2-0 3-1
Gruppe wurde beobachtet ||| group ||| 0-0 1-0 2-0
Gruppe ||| group ||| 0-0
Gruppen ) nach 6 Monaten ||| groups ) at six months ||| 0-0 1-1 2-2 3-3 2-4 4-4
Gruppen ) ||| groups ) ||| 0-0 1-1
Gruppen ||| groups ||| 0-0
Guideline ||| Guideline ||| 0-0
Gustave Eiffel , BP 27166 ||| Gustave Eiffel , BP 27166 ||| 0-0 1-1 2-2 3-3 4-4
Gustave Eiffel , BP ||| Gustave Eiffel , BP ||| 0-0 1-1 2-2 3-3
Gustave Eiffel , ||| Gustave Eiffel , ||| 0-0 1-1 2-2
Gustave Eiffel ||| Gustave Eiffel ||| 0-0 1-1
Gustave ||| Gustave ||| 0-0
HDL-Cholesterins und der Triglyceride in ||| HDL-C and TG in ||| 0-0 1-1 3-2 2-3 4-3
HDL-Cholesterins und ||| HDL-C and ||| 0-0 1-1
HDL-Cholesterins ||| HDL-C ||| 0-0
HDL-Cholesterinspiegel . ||| gliclazide . ||| 0-0 1-1
HDL-Cholesterinspiegel ||| gliclazide ||| 0-0
HDPE-Flaschen mit 28 , ||| HDPE bottles containing 28 , ||| 0-0 0-1 1-2 2-2 2-3 3-4
HDPE-Flaschen mit 28 ||| HDPE bottles containing 28 ||| 0-0 0-1 1-2 2-2 2-3
HDPE-Flaschen ||| HDPE bottles ||| 0-0 0-1
HERSTELLER DES ||| MANUFACTURER OF ||| 0-0 1-1
HERSTELLER ||| MANUFACTURER ||| 0-0
HERSTELLUNGSERLAUBNIS , DER ||| AUTHORISATION HOLDER ||| 0-0 1-1 2-1
HERSTELLUNGSERLAUBNIS , DER/DIE ||| AUTHORISATION HOLDER(S ) ||| 0-0 1-1 2-1 2-2
HERSTELLUNGSERLAUBNIS , DIE ||| AUTHORISATION HOLDERS ||| 0-0 1-1 2-1
HERSTELLUNGSERLAUBNIS ||| AUTHORISATION ||| 0-0
HF Sími : + 354 ||| HF Sími : + 354 ||| 0-0 1-1 2-2 3-3 4-4
HF Sími : + ||| HF Sími : + ||| 0-0 1-1 2-2 3-3
HF Sími : ||| HF Sími : ||| 0-0 1-1 2-2
HF Sími ||| HF Sími ||| 0-0 1-1
HF ||| HF ||| 0-0
HINSICHTLICH DER SICHEREN UND ||| REGARD TO THE SAFE AND ||| 0-0 0-1 1-1 1-2 2-3 3-4
HINSICHTLICH DER SICHEREN UND ||| REGARD TO THE SAFE AND ||| 0-0 0-1 1-1 3-2 2-3 3-4
HINSICHTLICH DER SICHEREN ||| REGARD TO THE SAFE ||| 0-0 0-1 1-1 1-2 2-3
HINSICHTLICH DER ||| REGARD TO THE ||| 0-0 0-1 1-1 1-2
HINSICHTLICH DER ||| REGARD TO ||| 0-0 0-1 1-1
HIV ) . ||| HIV ) . ||| 0-0 1-1 2-2
HIV ) . ||| of HIV ) . ||| 0-1 1-2 2-3
HIV ) ||| HIV ) ||| 0-0 1-1
HIV ) ||| of HIV ) ||| 0-1 1-2
HIV ||| HIV ||| 0-0
HIV ||| of HIV ||| 0-1
HMGCoA-Reduktasehemmer sind nicht ||| reductase inhibitors are not ||| 0-0 0-1 1-2 2-3
HMGCoA-Reduktasehemmer sind ||| reductase inhibitors are ||| 0-0 0-1 1-2
HMGCoA-Reduktasehemmer ||| reductase inhibitors ||| 0-0 0-1
HORIZON Pivotal Fracture Trial [ ||| HORIZON Pivotal Fracture Trial [ ||| 0-0 1-1 2-2 3-3 4-4
HORIZON Pivotal Fracture Trial ||| HORIZON Pivotal Fracture Trial ||| 0-0 1-1 2-2 3-3
HORIZON Pivotal Fracture ||| HORIZON Pivotal Fracture ||| 0-0 1-1 2-2
HORIZON Pivotal ||| HORIZON Pivotal ||| 0-0 1-1
HORIZON ||| HORIZON ||| 0-0
HORIZON-PFT-Studie ||| HORIZON-PFT ||| 0-0
HORIZON-RFT-Studie ||| HORIZON-RFT study ||| 0-0 0-1
Halbwertszeit ( t½ ) ist ||| half-life ( t½ ) is ||| 0-0 1-1 2-2 3-3 4-4
Halbwertszeit ( t½ ) ||| half-life ( t½ ) ||| 0-0 1-1 2-2 3-3
Halbwertszeit ( t½ ||| half-life ( t½ ||| 0-0 1-1 2-2
Halbwertszeit ( ||| half-life ( ||| 0-0 1-1
Halbwertszeit von ||| half-life of ||| 0-0 1-1
Halbwertszeit war ||| half-life was ||| 0-0 1-1
Halbwertszeit wird ||| half-life is ||| 0-0 1-1
Halbwertszeit ||| half-life ||| 0-0
Halbwertszeit ||| terminal ||| 0-0
Halbwertszeiten t½ 0,24 and t½ ||| of t½ 0.24 and t½ ||| 0-1 1-1 2-1 1-2 3-3 4-4
Halbwertszeiten t½ 0,24 and t½ ||| t½ 0.24 and t½ ||| 0-0 1-0 2-0 1-1 3-2 4-3
Halbwertszeiten t½ 0,24 and ||| of t½ 0.24 and ||| 0-1 1-1 2-1 1-2 3-3
Halbwertszeiten t½ 0,24 and ||| t½ 0.24 and ||| 0-0 1-0 2-0 1-1 3-2
Halbwertszeiten t½ 0,24 ||| of t½ 0.24 ||| 0-1 1-1 2-1 1-2
Halbwertszeiten t½ 0,24 ||| t½ 0.24 ||| 0-0 1-0 2-0 1-1
Halluzinationen ||| hallucinations ||| 0-0
Haloperidol 73 % ) . ||| haloperidol 73 % ) . ||| 0-0 1-1 2-2 3-3 4-4
Haloperidol 73 % ) ||| haloperidol 73 % ) ||| 0-0 1-1 2-2 3-3
Haloperidol 73 % ||| haloperidol 73 % ||| 0-0 1-1 2-2
Haloperidol 73 ||| haloperidol 73 ||| 0-0 1-1
Haloperidol in Woche 12 . ||| haloperidol at week 12. ||| 0-0 0-1 1-1 2-2 0-3 3-3 4-3
Haloperidol ||| haloperidol , ||| 0-0
Haloperidol ||| haloperidol ||| 0-0
Haloperidol-kontrollierten Studie war ||| haloperidol-controlled trial ||| 0-0 2-0 1-1
Haltbarkeit des ||| Shelf-life of the ||| 0-0 1-1 1-2
Haltbarkeit nach erstmaligem Öffnen der ||| Shelf-life after first opening the ||| 0-0 1-1 2-2 2-3 3-3 4-4
Haltbarkeit nach erstmaligem Öffnen ||| Shelf-life after first opening ||| 0-0 1-1 2-2 2-3 3-3
Haltbarkeit nach ||| Shelf-life after ||| 0-0 1-1
Haltbarkeit ||| Shelf-life ||| 0-0
Harn , ||| urine , ||| 0-0 1-1
Harn ||| urine ||| 0-0
Harnweginfektion ||| urinary ||| 0-0
Hauptindikator für die Wirksamkeit war ||| main measure of effectiveness was ||| 0-0 0-1 1-2 2-2 3-3 4-4
Hauptindikator für die Wirksamkeit ||| main measure of effectiveness ||| 0-0 0-1 1-2 2-2 3-3
Hauptindikator für die ||| main measure of ||| 0-0 0-1 1-2 2-2
Hauptindikator ||| The main measure ||| 0-0 0-1 0-2
Hauptindikator ||| main measure ||| 0-0 0-1
Hauptstudie 72 ( ||| main study , 72 ( ||| 0-0 0-1 1-3 2-4
Hauptstudie 72 ||| main study , 72 ||| 0-0 0-1 1-3
Hauptstudie ||| main study , ||| 0-0 0-1
Hauptstudie ||| main study ||| 0-0 0-1
Hauptstudien durchgeführt , in denen ||| main studies looking at ||| 0-0 1-1 4-1 2-2 3-3
Hauptstudien ||| main studies ||| 0-0
Hauptstudien ||| main ||| 0-0
Haupttumoren der Patientinnen um ||| shrunk in size by ||| 0-0 1-1 2-1 0-2 3-3
Haupttumoren der Patientinnen ||| shrunk in size ||| 0-0 1-1 2-1 0-2
Haut ( subkutan ) geben ||| skin ( subcutaneously ) ||| 0-0 1-1 2-2 4-2 3-3
Haut ( subkutan ) gegeben ||| skin ( subcutaneously ) ||| 0-0 1-1 2-2 4-2 3-3
Haut ( ||| skin ( ||| 0-0 1-1
Haut , häufiges Urinieren ||| chest pain , ||| 1-0 0-1 1-1 1-2 2-2 3-2
Haut an der Injektionsstelle ||| skin at the injection site ||| 0-0 0-1 2-2 3-3 1-4 2-4 3-4
Haut in Berührung ||| skin ||| 0-0 1-0 2-0
Haut ||| skin at ||| 0-0 0-1
Haut ||| skin ||| 0-0
Hautausschlag und ||| rash and ||| 0-0 1-1
Hautausschlag ||| rash ||| 0-0
Hautfalte , indem Sie die ||| fold by pinching the ||| 0-0 2-1 2-2 3-2 4-3
Hautfalte , indem Sie ||| fold by pinching ||| 0-0 2-1 2-2 3-2
Hautfalte , ||| fold ||| 0-0
Hautfalte ||| fold ||| 0-0
Hautfarbe war geringer als bei ||| , hypoglyceamia can occur ( ||| 0-1 4-3 2-4
Hautfarbe war geringer als bei ||| hypoglyceamia can occur ( see ||| 0-0 4-2 2-3
Hautfarbe war geringer als bei ||| hypoglyceamia can occur ( ||| 0-0 4-2 2-3
Hautfarbe war ||| , hypoglyceamia can ||| 0-1
Hautfarbe war ||| , hypoglyceamia ||| 0-1
Hautfarbe war ||| hypoglyceamia can ||| 0-0
Hautfarbe war ||| hypoglyceamia ||| 0-0
Hautfarbe ||| , hypoglyceamia can ||| 0-1
Hautfarbe ||| , hypoglyceamia ||| 0-1
Hautfarbe ||| hypoglyceamia can ||| 0-0
Hautfarbe ||| hypoglyceamia ||| 0-0
Hautreaktionen , wie Rötungen ||| Skin reactions such as redness ||| 0-0 0-1 1-1 2-2 2-3 3-4
Hautreaktionen , wie ||| Skin reactions such as ||| 0-0 0-1 1-1 2-2 2-3
Hautreaktionen , ||| Skin reactions ||| 0-0 0-1 1-1
Hautrötung mit Hitzegefühl ( Flush ||| Flushing , hot flushes ||| 0-0 1-0 0-1 2-2 4-3
Hautrötung mit Hitzegefühl ( ||| Flushing , hot ||| 0-0 1-0 0-1 2-2
Hautrötung mit Hitzegefühl ||| Flushing , hot ||| 0-0 1-0 0-1 2-2
Hautrötung mit ||| Flushing , ||| 0-0 1-0 0-1
Hb 10-13 ||| Hb 10 - 13 ||| 0-0 1-0 1-1 1-2 1-3
Hb zwischen 10 und 12 ||| Hb between 10 and 12 ||| 0-0 1-1 2-2 3-3 4-4
Hb zwischen 10 und ||| Hb between 10 and ||| 0-0 1-1 2-2 3-3
Hb zwischen 10 ||| Hb between 10 ||| 0-0 1-1 2-2
Hb zwischen ||| Hb between ||| 0-0 1-1
Hb ||| Hb ||| 0-0
Hb-Anstieg 1 g/dl ||| Hb increase 1 g/ dl ||| 0-0 0-1 1-2 2-3 2-4
Hb-Anstieg 1 ||| Hb increase 1 ||| 0-0 0-1 1-2
Hb-Anstieg ||| Hb increase ||| 0-0 0-1
HbA1c-Spiegels ||| level ||| 0-0
HbA1c-Wertes ( mit einem Ausgangswert ||| HbA1c ( with a baseline ||| 0-0 1-1 2-2 3-3 3-4 4-4
HbA1c-Wertes ( mit ||| HbA1c ( with ||| 0-0 1-1 2-2
HbA1c-Wertes ( ||| HbA1c ( ||| 0-0 1-1
HbA1c-Wertes ||| HbA1c ||| 0-0
HbA1c-Wertes ||| in HbA1c ||| 0-1
Healthcare A/S Tlf : ||| Healthcare A/ S Tlf : ||| 0-0 1-1 1-2 2-3 3-4
Healthcare A/S Tlf ||| Healthcare A/ S Tlf ||| 0-0 1-1 1-2 2-3
Healthcare A/S ||| Healthcare A/ S ||| 0-0 1-1 1-2
Healthcare ||| Healthcare ||| 0-0
Heiserkeit , ||| hoarseness , ||| 0-0 1-1
Heiserkeit ||| hoarseness ||| 0-0
Hemmung von Cytochrom ||| inhibition of any subtype of ||| 0-0 1-1 0-2 1-3 2-3 1-4
Hemmung ||| inhibition ||| 0-0
Heparin ( Heparinisierung ) kann ||| heparin ( heparinisation ) may ||| 0-0 1-1 2-2 3-3 4-4
Heparin ( Heparinisierung ) ||| heparin ( heparinisation ) ||| 0-0 1-1 2-2 3-3
Heparin ( Heparinisierung ||| heparin ( heparinisation ||| 0-0 1-1 2-2
Heparin ( ||| heparin ( ||| 0-0 1-1
Heparin ) ||| heparin ) ||| 0-0 1-1
Heparin ||| heparin ||| 0-0
Heparinisierung ) kann ||| heparinisation ) may ||| 0-0 1-1 2-2
Heparinisierung ) ||| heparinisation ) ||| 0-0 1-1
Heparinisierung ||| heparinisation ||| 0-0
Hepatitis , erhöhte Alanin-Aminotransferase ||| hepatitis , increased Alanine Aminotransferase ||| 0-0 1-1 2-2 2-3 3-3 3-4
Hepatitis , ||| hepatitis , ||| 0-0 1-1
Hepatitis ||| hepatitis ||| 0-0
Heptakis-O-(4-sulfobutyl)cyclomaltoheptaose , Heptanatriumalz ( SBECD ||| Sulfobutylether -cyclodextrin ( SBECD ||| 0-0 1-1 2-1 3-2 4-3
Heptakis-O-(4-sulfobutyl)cyclomaltoheptaose , Heptanatriumalz ( ||| Sulfobutylether -cyclodextrin ( ||| 0-0 1-1 2-1 3-2
Heptakis-O-(4-sulfobutyl)cyclomaltoheptaose , Heptanatriumalz ||| Sulfobutylether -cyclodextrin ||| 0-0 1-1 2-1
Heptakis-O-(4-sulfobutyl)cyclomaltoheptaose ||| Sulfobutylether ||| 0-0
Heptanatriumsalz ||| b-cyclodextrin ||| 0-0
Hersteller Novartis Pharma GmbH Roonstraße ||| Manufacturer Novartis Pharma GmbH Roonstraße ||| 0-0 1-1 2-2 3-3 4-4
Hersteller Novartis Pharma GmbH ||| Manufacturer Novartis Pharma GmbH ||| 0-0 1-1 2-2 3-3
Hersteller Novartis Pharma ||| Manufacturer Novartis Pharma ||| 0-0 1-1 2-2
Hersteller Novartis ||| Manufacturer Novartis ||| 0-0 1-1
Hersteller Pharmazeutischer Unternehmer : ||| Manufacturer Marketing authorisation holder : ||| 0-0 1-1 1-2 2-3 3-4
Hersteller Pharmazeutischer Unternehmer ||| Manufacturer Marketing authorisation holder ||| 0-0 1-1 1-2 2-3
Hersteller Pharmazeutischer ||| Manufacturer Marketing authorisation ||| 0-0 1-1 1-2
Hersteller von ||| company ||| 0-0
Hersteller ||| Manufacturer ||| 0-0
Hersteller ||| company ||| 0-0
Hersteller(s ) ||| batch release ||| 0-0 0-1 1-1
Herstellers , ||| manufacturer ||| 0-0 1-0
Herstellers des ||| manufacturer of the ||| 0-0 1-1 1-2
Herstellers ||| manufacturer ||| 0-0
Herstellungsmethode ( durch rekombinante DNS ||| manufacture ( recombinant DNA ||| 0-0 2-0 3-0 1-1 3-2 4-3
Herstellungsmethode ( durch rekombinante DNS ||| of manufacture ( recombinant DNA ||| 0-1 2-1 3-1 1-2 3-3 4-4
Herstellungsmethode ( durch rekombinante ||| manufacture ( recombinant ||| 0-0 2-0 3-0 1-1 3-2
Herstellungsmethode ( durch rekombinante ||| of manufacture ( recombinant ||| 0-1 2-1 3-1 1-2 3-3
Herzen oder den Blutgefäßen ||| heart or the blood vessels ||| 0-0 1-1 2-2 3-3 3-4
Herzen oder den ||| heart or the ||| 0-0 1-1 2-2
Herzen oder ||| heart or ||| 0-0 1-1
Herzen ||| heart ||| 0-0
Herzens , ||| heart , heart ||| 0-0 1-1 0-2
Herzerkrankungen : ||| Cardiac disorders : ||| 0-0 0-1 1-2
Herzerkrankungen ||| 62 Cardiac ||| 0-1
Herzerkrankungen ||| Cardiac disorders ||| 0-0 0-1
Herzerkrankungen ||| Cardiac ||| 0-0
Herzhypertrophie auf . ||| monkeys . ||| 0-0 2-1
Herzhypertrophie auf ||| monkeys ||| 0-0
Herzhypertrophie ||| monkeys ||| 0-0
Herzinfarkt oder Schlaganfall innerhalb ||| myocardial infarction or stroke in ||| 0-0 0-1 3-1 1-2 2-3
Herzinfarkt oder Schlaganfall innerhalb ||| myocardial infarction or stroke ||| 0-0 0-1 3-1 1-2 2-3
Herzinfarkt oder ||| myocardial infarction or ||| 0-0 0-1 1-2
Herzinfarkt ||| myocardial infarction ||| 0-0 0-1
Herzinsuffizienz , was ||| heart failure , however ||| 0-0 0-1 1-2 2-3
Herzinsuffizienz , ||| heart failure , ||| 0-0 0-1 1-2
Herzinsuffizienz in der Anamnese ( ||| history of cardiac failure ( ||| 1-0 3-0 2-1 0-2 3-2 0-3 4-4
Herzinsuffizienz in der Anamnese ||| history of cardiac failure ||| 1-0 3-0 2-1 0-2 3-2 0-3
Herzinsuffizienz oder diabetischer Ketoazidose ||| heart failure or diabetic ketoacidosis ||| 0-0 0-1 1-2 2-3 3-3 3-4
Herzinsuffizienz oder ||| cardiac failure or ||| 0-0 0-1 1-2
Herzinsuffizienz oder ||| heart failure or ||| 0-0 0-1 1-2
Herzinsuffizienz sein ; deshalb ist ||| cardiac failure , therefore ||| 0-0 1-0 0-1 2-2 3-3 4-3
Herzinsuffizienz sein ; ||| cardiac failure , ||| 0-0 1-0 0-1 2-2
Herzinsuffizienz sein ||| cardiac failure ||| 0-0 1-0 0-1
Herzinsuffizienz ||| cardiac failure ||| 0-0 0-1
Herzinsuffizienz ||| heart failure ||| 0-0 0-1
Herzkrankheit oder früherem Schlaganfall ||| heart disease or previous stroke ||| 0-0 0-1 1-2 2-3 3-4
Herzkrankheit oder früherem ||| heart disease or previous ||| 0-0 0-1 1-2 2-3
Herzkrankheit oder ||| heart disease or ||| 0-0 0-1 1-2
Herzkrankheit ||| heart disease ||| 0-0 0-1
Herzschlag ( Vorhofflimmern ||| heart rhythm ( atrial fibrillation ||| 0-0 0-1 1-2 2-3 2-4
Herzschlag ( ||| heart rhythm ( ||| 0-0 0-1 1-2
Herzschlag leiden . ||| heart beat . ||| 0-0 0-1 1-1 2-2
Herzschlag leiden ||| heart beat ||| 0-0 0-1 1-1
Herzschlag ||| heart rhythm ||| 0-0 0-1
Herztod ||| e. g. heart ||| 0-0 0-1 0-2
Herztod ||| heart failure ||| 0-0 0-1
Hierunter waren ||| Hierunter waren Kopfschmerzen ||| 0-0 0-1 0-2 1-2
Highbridge Business Park , Oxford ||| Highbridge Business Park , Oxford ||| 0-0 1-1 2-2 3-3 4-4
Highbridge Business Park , ||| Highbridge Business Park , ||| 0-0 1-1 2-2 3-3
Highbridge Business Park ||| Highbridge Business Park ||| 0-0 1-1 2-2
Highbridge Business ||| Highbridge Business ||| 0-0 1-1
Highbridge ||| Highbridge ||| 0-0
Hinfallen erlitten ||| a ||| 0-0 1-0
Hinsichtlich der Fortpflanzungsparameter wurden bei ||| Regarding reproductive ||| 0-0 2-0 3-0 2-1
Hinsichtlich der Fortpflanzungsparameter wurden ||| Regarding reproductive ||| 0-0 2-0 3-0 2-1
Hinweis auf klinisch signifikante ||| evidence of clinically significant ||| 0-0 1-0 2-2 3-3
Hinweis auf klinisch ||| evidence of clinically ||| 0-0 1-0 2-2
Hinweis auf ||| evidence of ||| 0-0 1-0
Hinweis auf ||| evidence ||| 0-0 1-0
Hinweise auf eine ||| evidence ||| 0-0 1-0 2-0
Hinweise für die Infusion ||| For information on the infusion ||| 0-0 2-1 2-2 1-3 2-3 3-4
Hinweise für die ||| For information on the ||| 0-0 2-1 2-2 1-3 2-3
Hinweise zur Handhabung ||| other handling ||| 2-0 0-1 1-1 2-1
Hinweise ||| For ||| 0-0
Hitzegefühl ( Flush ) , ||| hot flushes , ||| 0-0 2-1 3-2 4-2
Hitzegefühl ( Flush ||| hot flushes ||| 0-0 2-1
Hitzegefühl ( ||| hot ||| 0-0
Hitzegefühl ||| hot ||| 0-0
Hochdrucktherapie ||| take for high ||| 0-0 0-1 0-2
Hodenentfernung ) ||| surgical castration ) ||| 0-0 0-1 1-2
Hodenentfernung ||| surgical castration ||| 0-0 0-1
Holdings Limited Eesti filiaal Tel ||| Holdings Limited Eesti filiaal Tel ||| 0-0 1-1 2-2 3-3 4-4
Holdings Limited Eesti filiaal ||| Holdings Limited Eesti filiaal ||| 0-0 1-1 2-2 3-3
Holdings Limited Eesti ||| Holdings Limited Eesti ||| 0-0 1-1 2-2
Holdings Limited atstovyb Tel. ||| Holdings Limited atstovyb Tel . ||| 0-0 1-1 2-2 3-2 3-3 3-4
Holdings Limited p rst vniec ||| Holdings Limited p rst vniec ||| 0-0 1-1 2-2 3-3 4-4
Holdings Limited p rst ||| Holdings Limited p rst ||| 0-0 1-1 2-2 3-3
Holdings Limited p ||| Holdings Limited p ||| 0-0 1-1 2-2
Holdings Limited ||| Holdings Limited ||| 0-0 1-1
Holdings ||| Holdings ||| 0-0
Hormon Erythropoetin . ||| hormone erythropoietin . ||| 0-0 1-1 2-2
Hormon Erythropoetin ||| hormone erythropoietin ||| 0-0 1-1
Hormon ||| hormone ||| 0-0
Hormonersatztherapie ||| replacement ||| 0-0
Horsham West Sussex , RH12 ||| Horsham West Sussex , RH12 ||| 0-0 1-1 2-2 3-3 4-4
Horsham West Sussex , ||| Horsham West Sussex , ||| 0-0 1-1 2-2 3-3
Horsham West Sussex ||| Horsham West Sussex ||| 0-0 1-1 2-2
Horsham West ||| Horsham West ||| 0-0 1-1
Horsham ||| Horsham ||| 0-0
House Highbridge Business Park , ||| House Highbridge Business Park , ||| 0-0 1-1 2-2 3-3 4-4
House Highbridge Business Park ||| House Highbridge Business Park ||| 0-0 1-1 2-2 3-3
House Highbridge Business ||| House Highbridge Business ||| 0-0 1-1 2-2
House Highbridge ||| House Highbridge ||| 0-0 1-1
House ||| House ||| 0-0
Humanarzneimittel ||| Medicinal Products ||| 0-0 0-1
Humanarzneimittel ||| Medicinal products ||| 0-0 0-1
Humaninsulin ( rDNA ) ||| insulin human ( rDNA ) ||| 0-0 0-1 1-2 2-3 3-4
Humaninsulin ( rDNA ||| insulin human ( rDNA ||| 0-0 0-1 1-2 2-3
Humaninsulin ( ||| insulin human ( ||| 0-0 0-1 1-2
Humaninsulin ||| human insulin ||| 0-0 0-1
Humaninsulin ||| insulin human ||| 0-0 0-1
Hund Leberfunktionsstörungen ||| dog has impaired liver function ||| 0-0 1-2 1-3 1-4
Hund an ||| your dog ||| 0-0 0-1 1-1
Hund ||| dog has ||| 0-0
Hund ||| dog ||| 0-0
Hunde ( % ) pro ||| dogs per weight loss ||| 0-0 4-1 2-2 4-2
Hunde ( % ) pro ||| dogs per weight ||| 0-0 4-1 2-2 4-2
Hunde ( ||| dogs ||| 0-0
Hunde , ||| , for dogs ||| 1-0 0-1 0-2
Hunde Mitratapid ||| dogs Mitratapide ||| 0-0 1-1
Hunde führt zu einer verringerten ||| to dogs results in reduced ||| 2-0 0-1 1-2 1-3 3-3 4-4
Hunde führt zu einer ||| to dogs results in ||| 2-0 0-1 1-2 1-3 3-3
Hunde resorbieren oral verabreichtes ||| dogs rapidly absorb orally administered ||| 0-0 1-0 1-1 2-2 3-2 3-3 3-4
Hunde resorbieren ||| dogs rapidly ||| 0-0 1-0 1-1
Hunde ||| dogs ||| 0-0
Hunde ||| for dogs ||| 0-0 0-1
Hunden , bei denen ||| dogs in which ||| 0-0 2-1 1-2 3-2
Hunden , bei denen Übergewicht ||| dogs in which overweight ||| 0-0 2-1 1-2 3-2 4-3
Hunden . ||| dogs . ||| 0-0 1-1
Hunden mit Leberfunktionsstörungen ||| dogs with impaired liver function ||| 0-0 1-1 2-2 2-3 2-4
Hunden mit ||| dogs with ||| 0-0 1-1
Hunden und Ratten , ||| dogs and rats , ||| 0-0 1-1 2-2 3-3
Hunden und Ratten ||| dogs and rats ||| 0-0 1-1 2-2
Hunden und ||| dogs and ||| 0-0 1-1
Hunden wurde ||| dogs ||| 0-0
Hunden wurde ||| in dogs ||| 0-1
Hunden ||| dogs , ||| 0-0
Hunden ||| dogs ||| 0-0
Hunden ||| in dogs ||| 0-1
Hunden über den ||| dogs over the ||| 0-0 1-1 2-2
Hunden über ||| dogs over ||| 0-0 1-1
Hunton House Highbridge Business Park ||| Hunton House Highbridge Business Park ||| 0-0 1-1 2-2 3-3 4-4
Hunton House Highbridge Business ||| Hunton House Highbridge Business ||| 0-0 1-1 2-2 3-3
Hunton House Highbridge ||| Hunton House Highbridge ||| 0-0 1-1 2-2
Hunton House ||| Hunton House ||| 0-0 1-1
Hunton ||| Hunton ||| 0-0
Husten , Belastungsdyspnoe , ||| cough , exertional dyspnoea , ||| 0-0 1-1 2-2 2-3 3-4
Husten , Belastungsdyspnoe ||| cough , exertional dyspnoea ||| 0-0 1-1 2-2 2-3
Husten , ||| cough , ||| 0-0 1-1
Husten ||| cough ||| 0-0
Hydrchlorid ) . ||| hydrochloride ) . ||| 0-0 1-1 2-2
Hydrchlorid ) ||| hydrochloride ) ||| 0-0 1-1
Hydrchlorid ||| hydrochloride ||| 0-0
Hydrochlorid ) . ||| hydrochloride ) . ||| 0-0 1-1 2-2
Hydrochlorid ) ||| hydrochloride ) ||| 0-0 1-1
Hydrochlorid ) ||| tablets ||| 0-0 1-0
Hydrochlorid . ||| hydrochloride . ||| 0-0 1-1
Hydrochlorid ||| hydrochloride ||| 0-0
Hydrolyse- ) Orten auf ||| hydrolysis ) sites on ||| 0-0 2-0 1-1 2-2 3-3
Hydrolyse- ) Orten ||| hydrolysis ) sites ||| 0-0 2-0 1-1 2-2
Hydroxy- Metaboliten von ||| conjugates of hydroxy metabolites of ||| 0-0 2-1 0-2 1-3 2-4
Hydroxylierung der aliphatischen Methylengruppen ||| hydroxylation of aliphatic ||| 0-0 1-1 2-1 2-2 3-2
Hydroxylierung von Aripiprazol verantwortlich , ||| hydroxylation of aripiprazole , ||| 0-0 3-0 1-1 2-2 4-3
Hydroxylierung von Aripiprazol verantwortlich ||| hydroxylation of aripiprazole ||| 0-0 3-0 1-1 2-2
Hydroxylierung ||| hydroxylation ||| 0-0
Hyperglykämie ( wie z.B. ||| hyperglycaemia ( such as ||| 0-0 1-1 2-2 3-2 2-3
Hyperglykämie ( ||| hyperglycaemia ( ||| 0-0 1-1
Hyperglykämie , Diabetes mellitus , ||| hyperglycaemia , diabetes mellitus , ||| 0-0 1-1 2-2 3-3 4-4
Hyperglykämie , Diabetes mellitus ||| hyperglycaemia , diabetes mellitus ||| 0-0 1-1 2-2 3-3
Hyperglykämie , Diabetes ||| hyperglycaemia , diabetes ||| 0-0 1-1 2-2
Hyperglykämie , Hypokalzämie , Hypoglykämie ||| hyperglycaemia , hypocalcaemia , hypoglycaemia ||| 0-0 1-1 2-2 3-3 4-4
Hyperglykämie , Hypokalzämie , ||| hyperglycaemia , hypocalcaemia , ||| 0-0 1-1 2-2 3-3
Hyperglykämie , Hypokalzämie ||| hyperglycaemia , hypocalcaemia ||| 0-0 1-1 2-2
Hyperglykämie , in einigen Fällen ||| hyperglycaemia , in some cases ||| 0-0 1-1 2-2 3-3 4-4
Hyperglykämie , in einigen ||| hyperglycaemia , in some ||| 0-0 1-1 2-2 3-3
Hyperglykämie , in ||| hyperglycaemia , in ||| 0-0 1-1 2-2
Hyperglykämie , ||| hyperglycaemia , ||| 0-0 1-1
Hyperglykämie und Diabetes Mellitus ( ||| hyperglycaemia and diabetes mellitus ( ||| 0-0 1-1 2-2 3-3 4-4
Hyperglykämie und Diabetes Mellitus : ||| Hyperglycaemia and diabetes mellitus : ||| 0-0 1-1 2-2 3-3 4-4
Hyperglykämie und Diabetes Mellitus ||| Hyperglycaemia and diabetes mellitus ||| 0-0 1-1 2-2 3-3
Hyperglykämie und Diabetes Mellitus ||| hyperglycaemia and diabetes mellitus ||| 0-0 1-1 2-2 3-3
Hyperglykämie und Diabetes mellitus ( ||| hyperglycaemia and diabetes mellitus ( ||| 0-0 1-1 2-2 3-3 4-4
Hyperglykämie und Diabetes mellitus ||| hyperglycaemia and diabetes mellitus ||| 0-0 1-1 2-2 3-3
Hyperglykämie und Diabetes ||| Hyperglycaemia and Diabetes ||| 0-0 1-1 2-2
Hyperglykämie und Diabetes ||| Hyperglycaemia and diabetes ||| 0-0 1-1 2-2
Hyperglykämie und Diabetes ||| hyperglycaemia and diabetes ||| 0-0 1-1 2-2
Hyperglykämie und ||| Hyperglycaemia and ||| 0-0 1-1
Hyperglykämie und ||| hyperglycaemia and ||| 0-0 1-1
Hyperglykämie ||| Hyperglycaemia ||| 0-0
Hyperglykämie ||| hyperglycaemia ||| 0-0
Hypertonie . ||| hypertension . ||| 0-0 1-1
Hypertonie und/oder ||| hypertension and/ or ||| 0-0 1-1 1-2
Hypertonie ||| hypertension , ||| 0-0
Hypertonie ||| hypertension ||| 0-0
Hypoaktivität . ||| hypoactivity . ||| 0-0 1-1
Hypoaktivität ||| hypoactivity ||| 0-0
Hypoalbuminämie , Polydipsie , Hyperglykämie ||| hypoalbuminaemia , polydipsia , hyperglycaemia ||| 0-0 1-1 2-2 3-3 4-4
Hypoalbuminämie , Polydipsie , ||| hypoalbuminaemia , polydipsia , ||| 0-0 1-1 2-2 3-3
Hypoalbuminämie , Polydipsie ||| hypoalbuminaemia , polydipsia ||| 0-0 1-1 2-2
Hypoalbuminämie , ||| hypoalbuminaemia , ||| 0-0 1-1
Hypoalbuminämie ||| hypoalbuminaemia ||| 0-0
Hypocalcämie ( niedrigem Blutcalciumspiegel ||| hypocalcaemia ( low blood calcium ||| 0-0 1-1 2-2 3-2
Hypocalcämie ( niedrigem Blutcalciumspiegel ||| hypocalcaemia ( low blood ||| 0-0 1-1 2-2 3-2
Hypocalcämie ( niedrigem Blutcalciumspiegel ||| hypocalcaemia ( low ||| 0-0 1-1 2-2 3-2
Hypocalcämie ( ||| hypocalcaemia ( ||| 0-0 1-1
Hypocalcämie ||| hypocalcaemia ||| 0-0
Hypoglykämie ) , Zucker ||| hypoglycaemia ) , sugar ||| 0-0 1-1 2-2 3-3
Hypoglykämie ) , ||| hypoglycaemia ) , ||| 0-0 1-1 2-2
Hypoglykämie ) ||| hypoglycaemia ) ||| 0-0 1-1
Hypoglykämie , Hyponaträmie Häufig : ||| hypoglycaemia , hyponatraemia Common : ||| 0-0 1-1 2-2 3-3 4-4
Hypoglykämie , Hyponaträmie Häufig ||| hypoglycaemia , hyponatraemia Common ||| 0-0 1-1 2-2 3-3
Hypoglykämie , Hyponaträmie ||| hypoglycaemia , hyponatraemia ||| 0-0 1-1 2-2
Hypoglykämie , ||| hypoglycaemia , ||| 0-0 1-1
Hypoglykämie kann ||| hypoglycaemia may ||| 0-0 1-1
Hypoglykämie verzögern . ||| from hypoglycaemia . ||| 1-0 0-1 1-1 2-2
Hypoglykämie verzögern ||| from hypoglycaemia ||| 1-0 0-1 1-1
Hypoglykämie ||| hypoglycaemia ||| 0-0
Hypoglykämie ||| of hypoglycaemia ||| 0-1
Hypoglykämie-Episoden besonders wichtig . ||| hypoglycaemia . ||| 0-0 1-0 2-0 3-1
Hypoglykämie-Episoden besonders wichtig ||| hypoglycaemia ||| 0-0 1-0 2-0
Hypoglykämie-Warnsymptome ||| change in their usual ||| 0-0 0-1 0-2 0-3
Hypoglykämie-Warnsymptome ||| change in their usual ||| 0-0 0-2 0-3
Hypoglykämie-Warnsymptomen oder häufigen ||| episodes of ||| 0-0 1-0 2-0 2-1
Hypoglykämien ( Unterzuckerungen ||| hypoglycaemia ( low blood ||| 0-0 1-1 2-2 2-3
Hypoglykämien ( ||| hypoglycaemia ( ||| 0-0 1-1
Hypoglykämien ||| hypoglycaemia ||| 0-0
Hypokalzämie ( siehe Abschnitt 4.4 ||| hypocalcaemia ( see section 4.4 ||| 0-0 1-1 2-2 3-3 4-4
Hypokalzämie ( siehe Abschnitt ||| hypocalcaemia ( see section ||| 0-0 1-1 2-2 3-3
Hypokalzämie ( siehe ||| hypocalcaemia ( see ||| 0-0 1-1 2-2
Hypokalzämie ( ||| hypocalcaemia ( ||| 0-0 1-1
Hypokalzämie , Hypoglykämie , Hyponaträmie ||| hypocalcaemia , hypoglycaemia , hyponatraemia ||| 0-0 1-1 2-2 3-3 4-4
Hypokalzämie , Hypoglykämie , ||| hypocalcaemia , hypoglycaemia , ||| 0-0 1-1 2-2 3-3
Hypokalzämie , Hypoglykämie ||| hypocalcaemia , hypoglycaemia ||| 0-0 1-1 2-2
Hypokalzämie , ||| hypocalcaemia , ||| 0-0 1-1
Hypokalzämie In einer klinischen ||| Hypocalcaemia In clinical trials ||| 0-0 1-1 2-1 3-2 3-3
Hypokalzämie In einer ||| Hypocalcaemia In ||| 0-0 1-1 2-1
Hypokalzämie beobachtet . ||| hypocalcaemia were observed . ||| 0-0 1-1 1-2 2-3
Hypokalzämie beobachtet ||| hypocalcaemia were observed ||| 0-0 1-1 1-2
Hypokalzämie führt , kann durch ||| hypocalcaemia , reversal may be ||| 0-0 2-1 1-2 3-3 3-4 4-4
Hypokalzämie führt , ||| hypocalcaemia , reversal ||| 0-0 2-1 1-2
Hypokalzämie muss ||| hypocalcaemia must be ||| 0-0 1-1 1-2
Hypokalzämie ||| Hypocalcaemia ||| 0-0
Hypokalzämie ||| hypocalcaemia ||| 0-0
Hyponatriämie ||| hyponatremia ||| 0-0
Hyponaträmie Häufig : ||| hyponatraemia Common : ||| 0-0 1-1 2-2
Hyponaträmie Häufig ||| hyponatraemia Common ||| 0-0 1-1
Hyponaträmie ||| hyponatraemia ||| 0-0
Hypophosphatämie , Flüssigkeitsretention , ||| Hypophosphataemia , fluid retention , ||| 0-0 1-1 2-2 2-3 3-4
Hypophosphatämie , Flüssigkeitsretention ||| Hypophosphataemia , fluid retention ||| 0-0 1-1 2-2 2-3
Hypophosphatämie , ||| Hypophosphataemia , ||| 0-0 1-1
Hypophosphatämie ||| Hypophosphataemia ||| 0-0
Hyporeflexie , Neuralgie , ||| hyporeflexia , neuralgia , sensory ||| 0-0 1-1 2-2 3-3 3-4
Hyporeflexie , Neuralgie ||| hyporeflexia , neuralgia ||| 0-0 1-1 2-2
Hyporeflexie , ||| hyporeflexia , ||| 0-0 1-1
Hyporeflexie ||| hyporeflexia ||| 0-0
Hypotonie , periphere Kälte , ||| Hypotension , peripheral coldness , ||| 0-0 1-1 2-2 3-3 4-4
Hypotonie , periphere Kälte ||| Hypotension , peripheral coldness ||| 0-0 1-1 2-2 3-3
Hypotonie , periphere ||| Hypotension , peripheral ||| 0-0 1-1 2-2
Hypotonie , ||| Hypotension , ||| 0-0 1-1
Hypotonie Selten : ||| hypotension Rare : ||| 0-0 1-1 2-2
Hypotonie Selten ||| hypotension Rare ||| 0-0 1-1
Hypotonie ||| Hypotension ||| 0-0
Hypotonie ||| hypotension ||| 0-0
Hypotonie ||| to hypotension ||| 0-1
Hypotonie* , ||| hypotension* , ||| 0-0 1-1
Hypotonie* ||| hypotension* ||| 0-0
Hypoästhesie ( verminderte Empfindlichkeit ||| hypoaesthesia ( decreased sensitivity ||| 0-0 1-1 2-2 3-3
Hypoästhesie ( verminderte ||| hypoaesthesia ( decreased ||| 0-0 1-1 2-2
Hypoästhesie ( ||| hypoaesthesia ( ||| 0-0 1-1
Hypoästhesie ||| hypoaesthesia ||| 0-0
Hyprolose ||| hydroxypropyl ||| 0-0
Hypästhesie , Parästhesie . ||| hypoaesthesia , paraesthesia . ||| 0-0 1-1 2-2 3-3
Hypästhesie , Parästhesie ||| hypoaesthesia , paraesthesia ||| 0-0 1-1 2-2
Hypästhesie , ||| hypoaesthesia , ||| 0-0 1-1
Hypästhesie ||| hypoaesthesia ||| 0-0
Hälfte der ||| one-half of ||| 0-0 1-1
Hälfte ||| one-half ||| 0-0
Hämatokrit 33 - 39 ||| haematocrit of 33 - 39 ||| 0-0 1-2 2-3 3-4
Hämatokrit 33 - ||| haematocrit of 33 - ||| 0-0 1-2 2-3
Hämatokrit 33 ||| haematocrit of 33 ||| 0-0 1-2
Hämatokrit ||| haematocrit of ||| 0-0
Hämatokrit ||| haematocrit ||| 0-0
Hämatokritwertes abfallen . ||| packed cell volume . ||| 0-0 1-1 1-2 2-3
Hämatokritwertes abfallen ||| packed cell volume ||| 0-0 1-1 1-2
Hämatokritwertes ||| packed ||| 0-0
Hämoblastosen ( 221 multiple Myelome ||| haematological malignancies ( 221 multiple ||| 0-0 0-1 1-2 2-3 3-3 4-3 3-4
Hämoblastosen ( ||| haematological malignancies ( ||| 0-0 0-1 1-2
Hämoblastosen . ||| haematological malignancies . ||| 0-0 0-1 1-2
Hämoblastosen ||| haematological malignancies ||| 0-0 0-1
Hämodialysebehandlung und bei Erwachsenen ||| haemodialysis and adult patients ||| 0-0 1-1 2-2 3-2 3-3
Hämodialysebehandlung und ||| haemodialysis and ||| 0-0 1-1
Hämodialysebehandlung ||| haemodialysis ||| 0-0
Hämoglobin- Zielkonzentration ||| desired haemoglobin level may ||| 0-0 0-1 0-2 1-2 1-3
Hämoglobin-Wert erreicht ist ||| is achieved and periodically thereafter ||| 2-0 0-1 1-1 0-2 0-3 0-4 2-4
Hämoglobin-Zielkonzentration beobachtet werden ||| haemoglobin level may be observed ||| 0-0 0-1 1-2 2-3 1-4
Hämoglobin-Zielkonzentration liegt ||| haemoglobin concentration aimed for is ||| 0-0 0-1 0-2 1-2 1-3 1-4
Hämoglobin-Zielkonzentration von 10 ||| haemoglobin target range of 10 ||| 0-0 0-1 0-2 1-3 2-4
Hämoglobin-Zielkonzentration von ||| haemoglobin target range of ||| 0-0 0-1 0-2 1-3
Hämoglobin-Zielkonzentration ||| haemoglobin level ||| 0-0 0-1
Hämoglobin-Zielkonzentration ||| haemoglobin target range ||| 0-0 0-1 0-2
Hämoglobin-Zielkonzentration ||| target haemoglobin concentration ||| 0-0 0-1 0-2
Hämoglobinkonzentration zwischen ||| haemoglobin concentration should be between ||| 0-0 0-1 0-2 0-3 1-4
Hämoglobinkonzentration ||| haemoglobin concentration should be ||| 0-0 0-1 0-2 0-3
Hämoglobinkonzentration ||| haemoglobin ||| 0-0
Hämoglobinspiegel ||| levels ||| 0-0
Hämoglobinwert um mehr ||| haemoglobin is rising by more ||| 0-0 0-1 0-2 1-2 1-3 2-4
Hämoglobinwert um mehr ||| haemoglobin is rising by more ||| 0-0 0-1 1-2 2-2 1-3 2-4
Hämoglobinwert um ||| haemoglobin is rising by ||| 0-0 0-1 0-2 1-2 1-3
Hämoglobinwert um ||| haemoglobin ||| 0-0 1-0
Hämoglobinwert und Blutdruck ||| haemoglobin and blood pressure ||| 0-0 1-1 2-2 2-3
Hämoglobinwert und ||| haemoglobin and ||| 0-0 1-1
Hämoglobinwert ||| haemoglobin is ||| 0-0 0-1
Hämoglobinwert ||| haemoglobin level ||| 0-0 0-1
Hämoglobinwert ||| haemoglobin ||| 0-0
Hämoglobinwerte ( 1 ||| haemoglobin ( 1 to ||| 0-0 1-1 2-2
Hämoglobinwerte ( 1 ||| haemoglobin ( 1 ||| 0-0 1-1 2-2
Hämoglobinwerte ( 1 ||| in haemoglobin ( 1 to ||| 0-1 1-2 2-3
Hämoglobinwerte ( 1 ||| in haemoglobin ( 1 ||| 0-1 1-2 2-3
Hämoglobinwerte ( ||| haemoglobin ( ||| 0-0 1-1
Hämoglobinwerte ( ||| in haemoglobin ( ||| 0-1 1-2
Hämoglobinwerte im gewünschten ||| maintain haemoglobin values ||| 0-0 1-0 0-1 2-2
Hämoglobinwerte im ||| maintain haemoglobin ||| 0-0 1-0 0-1
Hämoglobinwerte ||| haemoglobin ||| 0-0
Hämoglobinwerte ||| in haemoglobin ||| 0-1
Hämoglobinwerte über 12 ||| haemoglobin values exceeding 12 ||| 0-0 0-1 0-2 1-2 2-3
Hämoglobinwerte über ||| haemoglobin values exceeding ||| 0-0 0-1 0-2 1-2
Hämolyse , Blutverlust , ||| haemolysis , blood loss , ||| 0-0 2-0 1-1 2-2 2-3 3-4
Hämolyse , Blutverlust ||| haemolysis , blood loss ||| 0-0 2-0 1-1 2-2 2-3
Hämolyse ||| haemolysis ||| 0-0
Hände , ||| hands , ||| 0-0 1-1
Hände ||| hands ||| 0-0
Händen ||| hands ||| 0-0
Häufig : Abgeschlagenheit Psychiatrische Erkrankungen ||| Common : fatigue Psychiatric disorders ||| 0-0 1-1 2-2 2-3 3-3 4-4
Häufig : Abgeschlagenheit Psychiatrische ||| Common : fatigue Psychiatric ||| 0-0 1-1 2-2 2-3 3-3
Häufig : Dyspepsie , Erbrechen ||| Common : dyspepsia , vomiting ||| 0-0 1-1 2-2 3-3 4-4
Häufig : Dyspepsie , ||| Common : dyspepsia , ||| 0-0 1-1 2-2 3-3
Häufig : Dyspepsie ||| Common : dyspepsia ||| 0-0 1-1 2-2
Häufig : Schläfrigkeit , Schwindel ||| Common : somnolence , dizziness ||| 0-0 1-1 2-2 3-3 4-4
Häufig : Schläfrigkeit , ||| Common : somnolence , ||| 0-0 1-1 2-2 3-3
Häufig : Schläfrigkeit ||| Common : somnolence ||| 0-0 1-1 2-2
Häufig : extrapyramidale Störung , ||| Common : extrapyramidal disorder , ||| 0-0 1-1 2-2 3-3 4-4
Häufig : extrapyramidale Störung ||| Common : extrapyramidal disorder ||| 0-0 1-1 2-2 3-3
Häufig : extrapyramidale ||| Common : extrapyramidal ||| 0-0 1-1 2-2
Häufig : verschwommenes Sehen ||| Common : blurred vision ||| 0-0 1-1 2-2 3-3
Häufig : verschwommenes ||| Common : blurred ||| 0-0 1-1 2-2
Häufig : ||| Common : ||| 0-0 1-1
Häufig : ||| disorders : ||| 0-0 1-1
Häufig : Übelkeit ||| Common : nausea ||| 0-0 1-1 2-2
Häufig ||| Common ||| 0-0
Häufig ||| disorders ||| 0-0
Häufige Nebenwirkungen ( ||| Common side effects ( ||| 0-0 1-1 1-2 2-3
Häufige Nebenwirkungen ||| Common side effects ||| 0-0 1-1 1-2
Häufige ||| Common ||| 0-0
Häufigkeit der Symptome , welche ||| incidence of post-dose symptoms ||| 0-0 1-1 4-2 2-3 4-3
Häufigkeit der unten aufgeführten Nebenwirkungen ||| frequency listed below ||| 0-0 1-0 2-1 3-1 4-1 2-2
Häufigkeit der ||| frequency ||| 0-0 1-0
Häufigkeit der ||| incidence of ||| 0-0 1-1
Häufigkeit dieser Ereignisse wird ||| frequency of these events is ||| 0-0 1-1 1-2 2-3 3-4
Häufigkeit dieser Ereignisse ||| frequency of these events ||| 0-0 1-1 1-2 2-3
Häufigkeit dieser Symptome nahm ||| incidence of these symptoms decreased ||| 0-0 1-1 1-2 2-3 3-4
Häufigkeit dieser Symptome ||| incidence of these symptoms ||| 0-0 1-1 1-2 2-3
Häufigkeit dieser ||| frequency of these ||| 0-0 1-1 1-2
Häufigkeit dieser ||| incidence of these ||| 0-0 1-1 1-2
Häufigkeit einer Hypokalzämie war ||| frequency of hypocalcaemia was ||| 0-0 1-1 1-2 2-2 3-3
Häufigkeit einer Hypokalzämie ||| frequency of hypocalcaemia ||| 0-0 1-1 1-2 2-2
Häufigkeit und Schwere ||| frequency and severity ||| 0-0 1-1 2-2
Häufigkeit und ||| frequency and ||| 0-0 1-1
Häufigkeit von Wirbelkörperfrakturen ||| incidence of vertebral fractures did ||| 0-0 1-1 2-2 2-3
Häufigkeit von Wirbelkörperfrakturen ||| incidence of vertebral fractures ||| 0-0 1-1 2-2 2-3
Häufigkeit von klinischen Frakturen betrug ||| incidence of clinical fractures was ||| 0-0 1-1 2-2 3-3 4-4
Häufigkeit von klinischen Frakturen ||| incidence of clinical fractures ||| 0-0 1-1 2-2 3-3
Häufigkeit von klinischen Frakturen über ||| incidence of clinical fractures over ||| 0-0 1-1 2-2 3-3 4-4
Häufigkeit von klinischen ||| incidence of clinical ||| 0-0 1-1 2-2
Häufigkeit von ||| incidence of ||| 0-0 1-1
Häufigkeit von ||| incidence ||| 0-0
Häufigkeit ||| frequency ||| 0-0
Häufigkeit ||| incidence ||| 0-0
Häufigkeitdieser Ereignisse wird als ||| frequency of these events is ||| 0-0 1-1 0-2 1-3 3-3 2-4
Häufigkeiten der wichtigsten klinischen ||| rates of key clinical ||| 0-0 1-1 0-2 2-2 3-3
Häufigkeiten der wichtigsten ||| rates of key ||| 0-0 1-1 0-2 2-2
Häufigkeiten der ||| frequency of undesirable ||| 0-0 1-1 0-2
Häufigkeiten für die wichtigsten ||| key ||| 0-0 1-0 2-0 3-0
Häufigkeiten von Ödemen ||| oedema rates for ||| 0-0 2-0 2-1 1-2 2-2
Häufigkeitsgruppe werden die Nebenwirkungen ||| frequency grouping , undesirable effects ||| 0-0 0-1 0-2 0-3 1-3 2-4 3-4
Häufigkeitsgruppe werden die Nebenwirkungen ||| frequency grouping , undesirable effects ||| 0-0 0-1 1-1 0-3 2-3 3-3 3-4
Häufigkeitsgruppe werden ||| frequency grouping , undesirable ||| 0-0 0-1 0-2 0-3 1-3
Höhe von ||| of ||| 0-0 1-0
Hüfte ||| hip ||| 0-0
Hüftfraktur . ||| hip fracture . ||| 0-0 0-1 1-2
Hüftfraktur sollten ||| broken their hip should receive ||| 0-0 0-1 0-2 1-3 1-4
Hüftfraktur wird ||| hip ||| 0-0
Hüftfraktur ||| broken their hip , ||| 0-0 0-1 0-2
Hüftfraktur ||| broken their hip ||| 0-0 0-1 0-2
Hüftfraktur ||| hip fracture , ||| 0-0 0-1
Hüftfraktur ||| hip fracture ||| 0-0 0-1
Hüftfraktur ||| hip ||| 0-0
Hüftfrakturen Aclasta wies eine ||| hip fractures Aclasta demonstrated a ||| 0-0 0-1 1-2 2-3 3-4
Hüftfrakturen Aclasta wies ||| hip fractures Aclasta demonstrated ||| 0-0 0-1 1-2 2-3
Hüftfrakturen Aclasta ||| hip fractures Aclasta ||| 0-0 0-1 1-2
Hüftfrakturen ||| hip fracture , ||| 0-0 0-1
Hüftfrakturen ||| hip fracture ||| 0-0 0-1
Hüftfrakturen ||| hip fractures ||| 0-0 0-1
Hüftfrakturen ||| of hip fractures ||| 0-1 0-2
I-03012 Anagni-Frosinone Italien ||| I-03012 Anagni-Frosinone Italy ||| 0-0 1-1 2-2
I-03012 Anagni-Frosinone ||| I-03012 Anagni-Frosinone ||| 0-0 1-1
I-03012 ||| I-03012 ||| 0-0
I.E pro Kilogramm ||| IU per kilogram , ||| 0-0 1-1 2-2
I.E pro Kilogramm ||| IU per kilogram ||| 0-0 1-1 2-2
I.E pro ||| IU per ||| 0-0 1-1
I.E ||| IU ||| 0-0
I.E. ( Internationale Einheitt ) ||| IU ( International Unit ) ||| 0-0 1-1 2-2 2-3 3-3 4-4
I.E. ( Internationale Einheitt ||| IU ( International Unit ||| 0-0 1-1 2-2 2-3 3-3
I.E. ( Internationale ||| IU ( International ||| 0-0 1-1 2-2
I.E. ( ||| IU ( ||| 0-0 1-1
I.E. ) , entsprechend 16,8 ||| IU ) corresponding to 16.8 ||| 0-0 1-1 2-2 3-2 3-3 4-4
I.E. ) , entsprechend 25,2 ||| IU ) corresponding to 25.2 ||| 0-0 1-1 2-2 3-2 3-3 4-4
I.E. ) , entsprechend 33,6 ||| IU ) corresponding to 33.6 ||| 0-0 1-1 2-2 3-2 3-3 4-4
I.E. ) , entsprechend 42,0 ||| IU ) corresponding to 42.0 ||| 0-0 1-1 2-2 3-2 3-3 4-4
I.E. ) , entsprechend 50,4 ||| IU ) corresponding to 50.4 ||| 0-0 1-1 2-2 3-2 3-3 4-4
I.E. ) , entsprechend 58,8 ||| IU ) corresponding to 58.8 ||| 0-0 1-1 2-2 3-2 3-3 4-4
I.E. ) , entsprechend 67,2 ||| IU ) corresponding to 67.2 ||| 0-0 1-1 2-2 3-2 3-3 4-4
I.E. ) , entsprechend 75,6 ||| IU ) corresponding to 75.6 ||| 0-0 1-1 2-2 3-2 3-3 4-4
I.E. ) , entsprechend 8,4 ||| IU ) corresponding to 8.4 ||| 0-0 1-1 2-2 3-2 3-3 4-4
I.E. ) , entsprechend 84,0 ||| IU ) corresponding to 84.0 ||| 0-0 1-1 2-2 3-2 3-3 4-4
I.E. ) , entsprechend ||| IU ) corresponding to ||| 0-0 1-1 2-2 3-2 3-3
I.E. ) , ||| IU ) ||| 0-0 1-1
I.E. ) Lösung . ||| IU ) of solution . ||| 0-0 1-1 0-2 2-3 3-4
I.E. ) Lösung ||| IU ) of solution ||| 0-0 1-1 0-2 2-3
I.E. ) pro Kilogramm Körpergewicht ||| IU ) per kilogram bodyweight ||| 0-0 1-1 2-2 3-3 3-4 4-4
I.E. ) pro ||| IU ) per ||| 0-0 1-1 2-2
I.E. ) ||| IU ) of ||| 0-0 1-1 0-2
I.E. ) ||| IU ) ||| 0-0 1-1
I.E. Epoetin alfa* ||| IU of epoetin alfa* ||| 0-0 2-1 1-2 2-3
I.E. Insulin human . ||| IU of insulin human . ||| 0-0 0-1 1-2 2-3 3-4
I.E. Insulin human ||| IU of insulin human ||| 0-0 0-1 1-2 2-3
I.E. Insulin ||| IU of insulin ||| 0-0 0-1 1-2
I.E. Vitamin D ||| IU of vitamin D supplementation ||| 0-0 1-2 2-3 2-4
I.E. Vitamin ||| IU of vitamin ||| 0-0 1-2
I.E. pro Kilogramm . ||| IU per kilogram . ||| 0-0 1-1 2-2 3-3
I.E. pro Kilogramm ||| IU per kilogram ||| 0-0 1-1 2-2
I.E. pro ||| IU per ||| 0-0 1-1
I.E. ||| IU . ||| 0-0 0-1
I.E. ||| IU of ||| 0-0
I.E. ||| IU of ||| 0-0 0-1
I.E. ||| IU ||| 0-0
I.E./0,3 ml Injektionslösung ||| 0.3 ml solution for injection ||| 0-0 1-1 2-2 2-3 2-4
I.E./0,3 ml ||| 0.3 ml ||| 0-0 1-1
I.E./0,3 ml ||| IU/ 0.3 ml ||| 0-0 0-1 1-2
I.E./0,3 ||| 0.3 ||| 0-0
I.E./0,3 ||| IU/ 0.3 ||| 0-0 0-1
I.E./0,4 ml Injektionslösung ||| 0.4 ml solution for injection ||| 0-0 1-1 2-2 2-3 2-4
I.E./0,4 ml ||| 0.4 ml ||| 0-0 1-1
I.E./0,4 ||| 0.4 ||| 0-0
I.E./0,5 ml Injektionslösung ||| 0.5 ml solution for injection ||| 0-0 1-1 2-2 2-3 2-4
I.E./0,5 ml ||| 0.5 ml ||| 0-0 1-1
I.E./0,5 ||| 0.5 ||| 0-0
I.E./0,6 ml Injektionslösung ||| 0.6 ml solution for injection ||| 0-0 1-1 2-2 2-3 2-4
I.E./0,6 ml ||| 0.6 ml ||| 0-0 1-1
I.E./0,6 ||| 0.6 ||| 0-0
I.E./0,7 ml Injektionslösung ||| 0.7 ml solution for injection ||| 0-0 1-1 2-2 2-3 2-4
I.E./0,7 ml ||| 0.7 ml ||| 0-0 1-1
I.E./0,7 ml ||| IU/ 0.7 ml ||| 0-0 0-1 1-2
I.E./0,7 ||| 0.7 ||| 0-0
I.E./0,7 ||| IU/ 0.7 ||| 0-0 0-1
I.E./0,8 ml Injektionslösung ||| 0.8 ml solution for injection ||| 0-0 1-1 2-2 2-3 2-4
I.E./0,8 ml ||| 0.8 ml ||| 0-0 1-1
I.E./0,8 ml ||| IU/ 0.8 ml ||| 0-0 0-1 1-2
I.E./0,8 ||| 0.8 ||| 0-0
I.E./0,8 ||| IU/ 0.8 ||| 0-0 0-1
I.E./0,9 ml ||| IU/ 0.9 ml ||| 0-0 0-1 1-2
I.E./0,9 ||| IU/ 0.9 ||| 0-0 0-1
I.E./1 ml ||| IU/ 1 ml ||| 0-0 0-1 0-2 1-2
I.E./kg 1 x/Woche ||| IU/ kg once weekly ||| 0-0 0-1 1-2 2-2 2-3
I.E./kg 3 x/Woche oder ||| IU/ kg 3x/ week or ||| 0-0 0-1 1-2 2-2 2-3 3-4
I.E./kg 3 x/Woche ||| IU/ kg 3x/ week ||| 0-0 0-1 1-2 2-2 2-3
I.E./kg Epoetin alfa , die ||| IU/ kg epoetin alfa , ||| 0-0 0-1 1-2 2-3 3-4
I.E./kg Epoetin alfa , ||| IU/ kg epoetin alfa , ||| 0-0 0-1 1-2 2-3 3-4
I.E./kg Epoetin alfa ||| IU/ kg epoetin alfa ||| 0-0 0-1 1-2 2-3
I.E./kg Epoetin ||| IU/ kg epoetin ||| 0-0 0-1 1-2
I.E./kg Körpergewicht ||| IU/ kg body weight ||| 0-0 0-1 1-2 1-3
I.E./kg an 10 ||| IU/ kg ||| 0-0 0-1 2-1
I.E./kg dreimal pro ||| IU/ kg 3 times per ||| 0-0 0-1 1-2 1-3 2-4
I.E./kg dreimal ||| IU/ kg , three times ||| 0-0 0-1 1-3 1-4
I.E./kg dreimal ||| IU/ kg 3 times ||| 0-0 0-1 1-2 1-3
I.E./kg dreimal ||| IU/ kg 3 ||| 0-0 0-1 1-2
I.E./kg dreimal ||| IU/ kg 3 ||| 0-0 1-0 0-1 1-2
I.E./kg subkutan dreimal ||| IU/ kg given subcutaneously 3 ||| 0-0 0-1 1-2 1-3 2-4
I.E./kg subkutan ||| IU/ kg given subcutaneously ||| 0-0 0-1 1-2 1-3
I.E./kg zweimal pro Woche , ||| IU/ kg 2 times ||| 0-0 1-0 0-1 2-1 1-2 3-3
I.E./kg zweimal pro Woche ||| IU/ kg 2 times ||| 0-0 1-0 0-1 2-1 1-2 3-3
I.E./kg zweimal pro ||| IU/ kg 2 times per ||| 0-0 0-1 1-2 2-3 2-4
I.E./kg zweimal pro ||| IU/ kg 2 ||| 0-0 1-0 0-1 2-1 1-2
I.E./kg zweimal ||| IU/ kg 2 ||| 0-0 0-1 1-2
I.E./kg ||| IU/ kg , ||| 0-0 0-1
I.E./kg ||| IU/ kg ||| 0-0 0-1
I.E./ml Injektionssuspension ||| IU/ ml suspension for injection ||| 0-0 0-1 0-2 1-2 1-3 1-4
II er ng A. ||| lon ANNEX II ||| 1-0 2-0 2-1 3-1 0-2
II ||| II ||| 0-0
III ) mit ||| III ) with a ||| 0-0 1-1 2-2
III ) mit ||| III ) with ||| 0-0 1-1 2-2
III ) ||| III ) ||| 0-0 1-1
III ||| III ||| 0-0
III ||| Product Characteristics , ||| 0-0 0-1
III ||| Product Characteristics ||| 0-0 0-1
III ||| of Product Characteristics , ||| 0-1 0-2
III ||| of Product Characteristics ||| 0-1 0-2
IN EINER KOMBINATIONSTHERAPIE ||| COMBINATION THERAPY WITH INSULIN Metabolism ||| 0-0 0-1 1-2 2-3 2-4
IN EINER KOMBINATIONSTHERAPIE ||| COMBINATION THERAPY WITH METFORMIN Blood ||| 0-0 0-1 1-2 1-3 2-4
IN EINER KOMBINATIONSTHERAPIE ||| COMBINATION THERAPY WITH SULPHONYLUREA ||| 0-0 1-1 1-2 2-3
IN EINER ORALEN DREIFACH-KOMBINATIONSTHERAPIE ||| IN TRIPLE ORAL COMBINATION THERAPY ||| 0-0 1-1 2-1 2-2 3-3 3-4
IN EINER ORALEN ||| IN TRIPLE ORAL ||| 0-0 1-1 2-1 2-2
IN EINER ||| COMBINATION THERAPY WITH METFORMIN ||| 0-0 0-1 1-2 1-3
IN EINER ||| COMBINATION THERAPY WITH ||| 0-0 0-1 1-2
IN EINER ||| COMBINATION THERAPY WITH ||| 0-0 1-1 1-2
IN ||| COMBINATION THERAPY ||| 0-0 0-1
IN ||| COMBINATION ||| 0-0
IN ||| IN ||| 0-0
INHABER DER HERSTELLUNGSERLAUBNIS , DER ||| MANUFACTURING AUTHORISATION HOLDER ||| 0-0 1-0 2-1 3-2 4-2
INHABER DER HERSTELLUNGSERLAUBNIS , DER/DIE ||| MANUFACTURING AUTHORISATION HOLDER(S ) ||| 0-0 1-0 2-1 3-2 4-2 4-3
INHABER DER HERSTELLUNGSERLAUBNIS , DIE ||| MANUFACTURING AUTHORISATION HOLDERS ||| 0-0 1-0 2-1 3-2 4-2
INHABER DER HERSTELLUNGSERLAUBNIS ||| MANUFACTURING AUTHORISATION ||| 0-0 1-0 2-1
INHABER DER ||| MANUFACTURING ||| 0-0 1-0
INHABER ||| INHABER DER HERSTELLUNGSERLAUBNIS ||| 0-0 0-1 0-2
INHABERS ||| APPLICANT ||| 0-0
INHALT NACH GEWICHT , ||| CONTENTS BY WEIGHT , BY ||| 0-0 1-1 1-2 2-2 2-3 2-4 3-4
INHALT NACH GEWICHT , ||| CONTENTS BY WEIGHT , BY ||| 0-0 1-1 1-2 2-3 2-4 3-4
INHALT NACH ||| CONTENTS BY WEIGHT ||| 0-0 1-1 1-2
INHALT ||| CONTENTS ||| 0-0
IST ABILIFY UND WOFÜR WIRD ||| ABILIFY IS AND WHAT IT ||| 1-0 0-1 3-1 2-2 3-3 4-4
IST ABILIFY UND WOFÜR ||| ABILIFY IS AND WHAT ||| 1-0 0-1 3-1 2-2 3-3
IST ABSEAMED UND WOFÜR WIRD ||| ABSEAMED IS AND WHAT IT ||| 1-0 0-1 3-1 2-2 3-3 4-4
IST ABSEAMED UND WOFÜR ||| ABSEAMED IS AND WHAT ||| 1-0 0-1 3-1 2-2 3-3
IST ACLASTA UND WOFÜR WIRD ||| ACLASTA IS AND WHAT IT ||| 1-0 0-1 3-1 2-2 3-3 4-4
IST ACLASTA UND WOFÜR ||| ACLASTA IS AND WHAT ||| 1-0 0-1 3-1 2-2 3-3
IST ACTOS UND WOFÜR WIRD ||| ACTOS IS AND WHAT IT ||| 1-0 0-1 3-1 2-2 3-3 4-4
IST ACTOS UND WOFÜR ||| ACTOS IS AND WHAT ||| 1-0 0-1 3-1 2-2 3-3
IST ||| CHILDREN ||| 0-0
IST/SIND ||| RELEASE ||| 0-0
IV ) ||| IV ) ||| 0-0 1-1
IV ||| IV ||| 0-0
Ibuprofen ( Mittel gegen Entzündung ||| ibuprofen ( anti-inflammation medicines ||| 0-0 1-1 2-1 0-2 3-3
Ibuprofen ( Mittel gegen ||| ibuprofen ( anti-inflammation medicines ||| 0-0 1-1 2-1 0-2 3-3
Ibuprofen ( Mittel ||| ibuprofen ( anti-inflammation ||| 0-0 1-1 2-1 0-2
Ibuprofen kurz nach ||| ibuprofen shortly following ||| 0-0 1-1 2-2
Ibuprofen kurz ||| ibuprofen shortly ||| 0-0 1-1
Ibuprofen oder Paracetamol ||| ibuprofen or paracetamol ||| 0-0 1-1 2-2
Ibuprofen oder ||| ibuprofen or ||| 0-0 1-1
Ibuprofen ||| ibuprofen ||| 0-0
Ideen und manchmal starker Reizbarkeit ||| ideas and sometimes severe irritability ||| 0-0 1-1 2-2 3-3 3-4 4-4
Ideen und manchmal ||| ideas and sometimes ||| 0-0 1-1 2-2
Ideen und ||| ideas and ||| 0-0 1-1
Ideen ||| ideas ||| 0-0
Ihnen Ihr Arzt oder ||| you by your doctor or ||| 0-0 0-1 1-2 2-2 2-3 3-4
Ihnen Ihr Arzt ||| you by your doctor ||| 0-0 0-1 1-2 2-2 2-3
Ihnen eine größere ||| you are due to have ||| 0-0 2-0 0-1 1-2 1-3 0-4
Ihnen keine ||| you cannot receive ||| 0-0 1-1 0-2
Ihnen mitgeteilt ||| you have been told by ||| 0-0 0-1 0-2 0-3 1-3 0-4
Ihnen persönlich verschrieben . ||| prescribed for you . ||| 0-0 1-0 2-0 1-1 2-2 3-3
Ihnen persönlich verschrieben ||| prescribed for you ||| 0-0 1-0 2-0 1-1 2-2
Ihnen sagen , ||| advise you on the ||| 0-0 1-0 0-1
Ihnen sagen , ||| advise you on ||| 0-0 1-0 0-1
Ihnen sagen , ||| advise you ||| 0-0 1-0 0-1
Ihnen sagen ||| advise you on the ||| 0-0 1-0 0-1
Ihnen sagen ||| advise you on ||| 0-0 1-0 0-1
Ihnen sagen ||| advise you ||| 0-0 1-0 0-1
Ihnen ||| for you to ||| 0-1
Ihnen ||| for you ||| 0-1
Ihnen ||| of your ||| 0-1
Ihnen ||| you by ||| 0-0 0-1
Ihnen ||| you to ||| 0-0
Ihnen ||| you ||| 0-0
Ihnen ||| your ||| 0-0
Ihnen üben . ||| you to do this . ||| 0-0 1-2 1-3 2-4
Ihnen üben ||| for you to do this ||| 0-1 1-3 1-4
Ihnen üben ||| you to do this ||| 0-0 1-2 1-3
Ihr Arzt , Apotheker oder ||| Your doctor , pharmacist or ||| 0-0 1-1 2-2 3-3 4-4
Ihr Arzt , Apotheker ||| Your doctor , pharmacist ||| 0-0 1-1 2-2 3-3
Ihr Arzt , ||| Your doctor , ||| 0-0 1-1 2-2
Ihr Arzt kann Ihnen ein ||| Your doctor can recommend a ||| 0-0 1-1 3-1 2-2 3-3 4-4
Ihr Arzt kann Ihnen ||| Your doctor can recommend ||| 0-0 1-1 3-1 2-2 3-3
Ihr Arzt kann auch ||| The doctor may also want ||| 0-1 1-1 2-2 3-3 3-4
Ihr Arzt kann auch ||| doctor may also want ||| 0-0 1-0 2-1 3-2 3-3
Ihr Arzt kann ||| The doctor may ||| 0-1 1-1 2-2
Ihr Arzt kann ||| doctor may ||| 0-0 1-0 2-1
Ihr Arzt kann ||| your doctor may ||| 0-0 1-0 1-1 2-2
Ihr Arzt oder ||| your doctor or ||| 0-0 1-0 1-1 2-2
Ihr Arzt wird Sie beraten ||| Your doctor will advise you ||| 0-0 1-1 0-2 2-2 0-3 4-3 3-4
Ihr Arzt wird Untersuchungen ||| Your doctor will conduct investigations ||| 0-0 1-1 0-2 2-2 3-3 3-4
Ihr Arzt wird dies ||| Your doctor will take this ||| 0-0 1-1 2-2 3-3 3-4
Ihr Arzt wird gegebenenfalls Ihren ||| Your doctor may check your ||| 0-0 2-0 1-1 3-2 1-3 4-4
Ihr Arzt wird gegebenenfalls ||| Your doctor may check ||| 0-0 2-0 1-1 3-2 1-3
Ihr Arzt wird ||| Your doctor may ||| 0-0 2-0 1-1 0-2
Ihr Arzt wird ||| Your doctor will check ||| 0-0 1-1 0-2 2-2 1-3
Ihr Arzt wird ||| Your doctor will consider ||| 0-0 1-1 0-2 2-2 1-3
Ihr Arzt wird ||| Your doctor will ||| 0-0 1-1 0-2 2-2
Ihr Arzt wird ||| Your doctor will ||| 0-0 1-1 2-2
Ihr Arzt ||| The doctor ||| 0-1 1-1
Ihr Arzt ||| Your doctor ||| 0-0 1-1
Ihr Arzt ||| doctor ||| 0-0 1-0
Ihr Arzt ||| your doctor ||| 0-0 1-0 1-1
Ihr Arzt ||| your ||| 0-0 1-0
Ihr Blutdruck sorgfältig ||| your blood pressure ||| 0-0 1-1 1-2 2-2
Ihr Blutdruck sorgfältig überwacht ||| your blood pressure should ||| 0-0 1-1 1-2 2-2 3-3
Ihr Gewicht zunimmt , ||| your weight increases , ||| 0-0 1-1 2-2 3-3
Ihr Gewicht zunimmt ||| your weight increases ||| 0-0 1-1 2-2
Ihr Gewicht ||| your weight ||| 0-0 1-1
Ihr Hund braucht . ||| your dog will need . ||| 0-0 1-1 0-2 2-3 3-4
Ihr Hund braucht ||| your dog will need ||| 0-0 1-1 0-2 2-3
Ihr Hund ||| your dog has ||| 0-0 1-1
Ihr Hund ||| your dog will ||| 0-0 1-1 0-2
Ihr Hund ||| your dog ||| 0-0 0-1 1-1
Ihr Hund ||| your dog ||| 0-0 1-1
Ihr Hämoglobinwert ||| your haemoglobin ||| 0-0 1-1
Ihr Tierarzt sollte ||| Your veterinary surgeon should ||| 0-0 1-1 1-2 2-3
Ihr Tierarzt wird ||| Your veterinary surgeon will ||| 0-0 1-1 1-2 2-3
Ihr Tierarzt ||| Your veterinary surgeon ||| 0-0 1-1 1-2
Ihr Zustand unter Kontrolle ist ||| your condition is controlled ||| 0-0 1-1 4-2 2-3 3-3
Ihr Zustand unter Kontrolle ist ||| your condition is controlled ||| 0-0 1-1 4-2 3-3
Ihr Zustand unter ||| your condition ||| 0-0 1-1
Ihr Zustand ||| your condition ||| 0-0 1-1
Ihr ||| Your ||| 0-0
Ihr ||| your ||| 0-0
Ihre Abseamed Dosis entsprechend anpassen ||| adjust your dose of Abseamed ||| 0-0 0-1 4-1 2-2 3-3 1-4
Ihre Anämie ||| your anaemia ||| 0-0 1-1
Ihre Blutarmut ( Anämie ) ||| your anaemia ||| 0-0 1-1 3-1
Ihre Blutarmut ( Anämie ||| your anaemia ||| 0-0 1-1 3-1
Ihre Dosis von ||| your dose of ||| 0-0 1-1 2-2
Ihre Dosis ||| your dose ||| 0-0 1-1
Ihre Serumelektrolyte sollten während ||| Serum electrolytes should ||| 0-0 1-0 1-1 2-2 3-2
Ihre Serumelektrolyte ||| Serum electrolytes ||| 0-0 1-0 1-1
Ihre Werte des ||| your levels of the ||| 0-0 1-1 2-2 2-3
Ihre Werte ||| your levels ||| 0-0 1-1
Ihre ||| your ||| 0-0
Ihrem Arzt mitteilen : ||| this medicine : ||| 0-0 1-1 2-1 3-2
Ihrem Arzt mitteilen ||| this medicine ||| 0-0 1-1 2-1
Ihrem Arzt ||| doctor ||| 0-0 1-0
Ihrem Arzt ||| your doctor ||| 0-0 1-1
Ihrem Blut ||| your blood ||| 0-0 1-1
Ihrem ||| this ||| 0-0
Ihrem ||| your ||| 0-0
Ihren Apotheker , wie das ||| your pharmacist how ||| 0-0 1-1 3-2 4-2
Ihren Apotheker , ||| your pharmacist ||| 0-0 1-1
Ihren Apotheker wie das ||| your pharmacist how ||| 0-0 1-1 2-2 3-2
Ihren Apotheker ||| your pharmacist ||| 0-0 1-1
Ihren Arzt , Apotheker oder ||| your doctor , pharmacist or ||| 0-0 1-1 2-2 3-3 4-4
Ihren Arzt , Apotheker ||| your doctor , pharmacist ||| 0-0 1-1 2-2 3-3
Ihren Arzt , ||| your doctor , ||| 0-0 0-1 1-1 2-2
Ihren Arzt , ||| your doctor , ||| 0-0 1-1 2-2
Ihren Arzt . ||| your doctor . ||| 0-0 1-1 2-2
Ihren Arzt oder Apotheker . ||| your doctor or pharmacist . ||| 0-0 0-1 1-1 2-2 3-3 4-4
Ihren Arzt oder Apotheker . ||| your doctor or pharmacist . ||| 0-0 1-1 2-2 3-3 4-4
Ihren Arzt oder Apotheker ||| doctor or nurse ||| 0-0 1-0 2-1 3-2
Ihren Arzt oder Apotheker ||| the doctor or nurse ||| 0-1 1-1 2-2 3-3
Ihren Arzt oder Apotheker ||| your doctor or pharmacist ||| 0-0 0-1 1-1 2-2 3-3
Ihren Arzt oder Apotheker ||| your doctor or pharmacist ||| 0-0 1-1 2-2 3-3
Ihren Arzt oder Apotheker ||| your doctor or your pharmacist ||| 0-0 0-1 1-1 2-2 0-3 3-4
Ihren Arzt oder ||| doctor or ||| 0-0 1-0 2-1
Ihren Arzt oder ||| the doctor or ||| 0-1 1-1 2-2
Ihren Arzt oder ||| your doctor or your ||| 0-0 0-1 1-1 2-2 0-3
Ihren Arzt oder ||| your doctor or ||| 0-0 0-1 1-1 2-2
Ihren Arzt oder ||| your doctor or ||| 0-0 1-1 2-2
Ihren Arzt umgehend ||| to tell your doctor immediately ||| 0-0 0-1 1-2 1-3 2-4
Ihren Arzt unverzüglich , wenn ||| tell your doctor immediately if ||| 0-0 0-1 1-2 2-3 3-4 4-4
Ihren Arzt unverzüglich ||| tell your doctor immediately ||| 0-0 0-1 1-2 2-3
Ihren Arzt ||| , tell your doctor ||| 0-1 0-2 0-3 1-3
Ihren Arzt ||| doctor ||| 0-0 1-0
Ihren Arzt ||| for your doctor ||| 0-1 1-2
Ihren Arzt ||| tell your doctor ||| 0-0 0-1 0-2 1-2
Ihren Arzt ||| tell your doctor ||| 0-0 0-1 1-2
Ihren Arzt ||| the doctor ||| 0-1 1-1
Ihren Arzt ||| to tell your doctor ||| 0-0 0-1 1-2 1-3
Ihren Arzt ||| your doctor ||| 0-0 0-1 1-1
Ihren Arzt ||| your doctor ||| 0-0 1-1
Ihren Blutdruck regelmäßig ||| your blood pressure regularly ||| 0-0 1-1 1-2 2-3
Ihren Blutdruck ||| your blood pressure ||| 0-0 1-1 1-2
Ihren Shunt überprüfen und ||| your shunt and ||| 0-0 1-1 2-1 3-2
Ihren Shunt überprüfen ||| your shunt ||| 0-0 1-1 2-1
Ihren ||| doctor ||| 0-0
Ihren ||| for your ||| 0-1
Ihren ||| tell your ||| 0-0 0-1
Ihren ||| to tell ||| 0-0 0-1
Ihren ||| your ||| 0-0
Ihrer ABILIFY Tabletten ||| of your ABILIFY tablets ||| 0-1 1-2 2-3
Ihrer ABILIFY Tabletten ||| your ABILIFY tablets ||| 0-0 1-1 2-2
Ihrer ABILIFY ||| of your ABILIFY ||| 0-1 1-2
Ihrer ABILIFY ||| your ABILIFY ||| 0-0 1-1
Ihrer Behandlung ||| of your ||| 0-0 1-0 0-1
Ihrer Blutarmut kann ||| of your anaemia may ||| 0-0 0-1 1-2 2-3
Ihrer Blutarmut ||| of your anaemia ||| 0-0 0-1 1-2
Ihrer Operation verabreicht . ||| your surgery . ||| 0-0 1-1 2-2 3-2
Ihrer Operation ||| your surgery ||| 0-0 1-1
Ihrer persönlichen Situation ||| your individual situation ||| 0-0 1-1 1-2 2-2
Ihrer ||| of your ||| 0-0 0-1
Ihrer ||| of your ||| 0-1
Ihrer ||| your immune ||| 0-0
Ihrer ||| your ||| 0-0
Ihres Arztes , bevor ||| your doctor carefully before ||| 0-0 1-1 2-2 3-2 3-3
Ihres Arztes ||| your doctor ||| 0-0 1-1
Ihres Darms entfernt wurden . ||| of your intestine removed . ||| 0-1 1-2 2-2 3-2 2-3 4-4
Ihres Darms entfernt wurden . ||| your intestine removed . ||| 0-0 1-1 2-1 3-1 2-2 4-3
Ihres Darms entfernt wurden ||| of your intestine removed ||| 0-1 1-2 2-2 3-2 2-3
Ihres Darms entfernt wurden ||| your intestine removed ||| 0-0 1-1 2-1 3-1 2-2
Ihres ||| of your ||| 0-1
Ihres ||| your ||| 0-0
Ikterus , Hepatitis , ||| jaundice , hepatitis , ||| 0-0 1-1 2-2 3-3
Ikterus , Hepatitis ||| jaundice , hepatitis ||| 0-0 1-1 2-2
Ikterus , ||| jaundice , ||| 0-0 1-1
Ikterus ||| jaundice ||| 0-0
Im Allgemeinen benötigen Kinder unter ||| Generally , children under ||| 0-0 1-0 2-0 1-1 3-2 4-3
Im Allgemeinen benötigen Kinder ||| Generally , children ||| 0-0 1-0 2-0 1-1 3-2
Im Allgemeinen benötigen ||| Generally , ||| 0-0 1-0 2-0 1-1
Im Fall ||| In the event ||| 0-0 0-1 1-2
Im Folgenden sind die ||| The following are the ||| 3-0 1-2 2-2 0-3 3-3
Im Kühlschrank lagern ( ||| Store in a refrigerator ( ||| 0-0 1-1 2-2 1-3 2-3 3-4
Im Kühlschrank lagern ( ||| store in a refrigerator ( ||| 0-0 1-1 2-2 1-3 2-3 3-4
Im Kühlschrank lagern ||| Store in a refrigerator ||| 0-0 1-1 2-2 1-3 2-3
Im Kühlschrank lagern ||| store in a refrigerator ||| 0-0 1-1 2-2 1-3 2-3
Im Rahmen der ||| In ||| 0-0
Im Rahmen ||| In ||| 0-0
Im Steady State beträgt der ||| At steady state ||| 0-0 1-0 1-1 2-1 2-2 3-2 4-2
Im Vergleich ||| There was a ||| 1-1 0-2
Im Vergleich ||| was a ||| 1-0 0-1
Im ersten Trimenon fällt gewöhnlich ||| Insulin requirements usually fall in ||| 0-0 2-0 1-1 3-1 4-2 2-3 3-3 4-3 4-4
Im steady-state ||| At steady ||| 0-0 0-1 1-1
Im ||| In the ||| 0-0 0-1
Im ||| In ||| 0-0
Im ||| Store ||| 0-0
Im ||| a ||| 0-0
Im ||| store ||| 0-0
In 2 Studien mit gesunden ||| In 2 studies in healthy ||| 0-0 1-1 2-2 3-3 4-3 4-4
In 2 Studien ||| In 2 studies ||| 0-0 1-1 2-2
In 2 ||| In 2 ||| 0-0 1-1
In Analysen von Untergruppen ||| In subpopulation analyses ||| 0-0 1-1 3-2
In Analysen von ||| In subpopulation ||| 0-0 1-1
In Analysen ||| In subpopulation ||| 0-0 1-1
In Humanstudien fanden sich ||| Studies in man suggest ||| 0-0 1-0 1-1 1-2 2-2 3-2 2-3
In Interaktionsstudien ||| Interaction studies have ||| 1-0 0-1 1-1 1-2
In Kombination mit einem Sulfonylharnstoff ||| In combination with a sulphonylurea ||| 0-0 1-1 2-2 3-3 3-4 4-4
In Kombination mit ||| In combination with ||| 0-0 1-1 2-2
In Kombination ||| In combination ||| 0-0 1-1
In Kombinationsstudien ||| In combination trials ||| 0-0 1-1 0-2
In Langzeitstudien ||| Longer-term repeat ||| 1-0 1-1
In Placebo-kontrollierten Studien ||| In placebo-controlled trials , ||| 0-0 1-1 2-2
In Placebo-kontrollierten Studien ||| In placebo-controlled trials ||| 0-0 1-1 2-2
In Placebo-kontrollierten ||| In placebo-controlled ||| 0-0 1-1
In Standard-Fertilitätsstudien ||| In standard ||| 0-0 1-1
In Studien in vitro konnten ||| In vitro studies ||| 0-0 2-1 3-1 1-2 4-2
In Studien mit intravenösen Bolus-Verabreichungen ||| In the intravenous bolus studies ||| 0-0 3-2 4-3 1-4
In Tierstudien konnten potenzielle ||| Animal studies could ||| 0-0 1-0 1-1 2-2 3-2
In Tierstudien mit ||| Foetal growth restriction ||| 0-0 1-0 1-1 1-2 2-2
In Tierstudien ||| Animal studies ||| 0-0 1-0 1-1
In beiden Studien ||| In both studies , ||| 0-0 1-1 2-2
In beiden Studien ||| In both studies ||| 0-0 1-1 2-2
In beiden ||| In both ||| 0-0 1-1
In den Langzeitstudien ||| In the long-term studies , ||| 0-0 1-1 0-2 2-3
In den Langzeitstudien ||| In the long-term studies ||| 0-0 1-1 0-2 2-3
In den Neuronen ||| adipocytes ) that affects energy ||| 1-0 2-0 2-3 2-4
In den beobachteten Fällen ||| When seen , it ||| 2-0 0-1 1-1 2-1 3-2 2-3 3-3
In den ersten 24 h ||| Over the first 24 hours ||| 0-0 1-1 2-2 3-3 4-3 3-4
In den ersten ||| Over the first ||| 0-0 1-1 2-2
In den klinischen Studien wurde ||| In the clinical studies , ||| 0-0 1-1 2-2 3-3 4-3
In den klinischen Studien wurde ||| In the clinical studies ||| 0-0 1-1 2-2 3-3 4-3
In den klinischen ||| In the clinical ||| 0-0 1-1 2-2
In den meisten Fällen ||| In most cases , ||| 0-0 1-1 2-1 3-2 3-3
In den meisten klinischen Studien ||| In most clinical trials ||| 0-0 1-1 2-1 3-2 4-3
In den meisten klinischen ||| In most clinical ||| 0-0 1-1 2-1 3-2
In den meisten ||| In most of the ||| 0-0 1-1 2-1 1-2 1-3
In den meisten ||| In most ||| 0-0 1-1 2-1
In den vier placebokontrollierten Studien ||| In the four placebo-controlled studies ||| 0-0 1-1 2-2 3-3 4-4
In den vier placebokontrollierten ||| In the four placebo-controlled ||| 0-0 1-1 2-2 3-3
In den vier ||| In the four ||| 0-0 1-1 2-2
In den ||| If psychiatric illness ||| 1-0 0-1 1-1 1-2
In den ||| In the long-term ||| 0-0 1-1 0-2
In den ||| In the osteoporosis trials ||| 0-0 1-1 0-3
In den ||| In the ||| 0-0 1-1
In den ||| In ||| 0-0
In den ||| Over the ||| 0-0 1-1
In der HORIZON Pivotal Fracture ||| In the HORIZON Pivotal Fracture ||| 0-0 1-1 2-2 3-3 4-4
In der HORIZON Pivotal ||| In the HORIZON Pivotal ||| 0-0 1-1 2-2 3-3
In der HORIZON ||| In the HORIZON ||| 0-0 1-1 2-2
In der Indikation Steigerung ||| In the indication increasing ||| 0-0 1-1 2-2 3-3
In der Indikation ||| In the indication ||| 0-0 1-1 2-2
In der Menopause ||| Osteoporosis Osteoporosis ||| 0-0 2-0 2-1
In der PROactive-Studie , einer ||| In PROactive , a ||| 0-0 1-1 2-1 3-2 4-3
In der PROactive-Studie , ||| In PROactive , ||| 0-0 1-1 2-1 3-2
In der PROactive-Studie ||| In PROactive ||| 0-0 1-1 2-1
In der Studie mit ||| In the study of ||| 0-0 1-1 2-2 1-3 3-3
In der Studie mit älteren ||| In the study of elderly ||| 0-0 1-1 2-2 1-3 3-3 4-4
In der Studie wurde ||| The study ||| 0-0 0-1 1-1 2-1
In der Studie ||| In the study of ||| 0-0 1-1 2-2 1-3
In der Studie ||| The study ||| 0-0 0-1 1-1 2-1
In der Vergangenheit ||| In the past , ||| 0-0 1-1 2-2
In der Vergangenheit ||| In the past ||| 0-0 1-1 2-2
In der limitierten Anzahl von ||| In the limited number of ||| 0-0 1-1 2-2 3-3 4-4
In der limitierten Anzahl ||| In the limited number ||| 0-0 1-1 2-2 3-3
In der limitierten ||| In the limited ||| 0-0 1-1 2-2
In der zweiten Studie ||| The second trial utilised ||| 0-0 2-1 3-2 2-3
In der ||| 28 In the ||| 0-1 1-2
In der ||| In the ||| 0-0 1-1
In der ||| The ||| 0-0
In diesen Fällen sollte überlegt ||| The advisability of driving should ||| 0-0 0-1 1-1 2-1 4-1 4-3 3-4
In diesen Studien ||| These studies have shown ||| 1-0 0-1 2-1 2-2 1-3
In drei Placebo-kontrollierten Studien ( ||| three placebo-controlled trials ( ||| 1-0 0-1 2-1 3-2 4-3
In drei Placebo-kontrollierten Studien ||| three placebo-controlled trials ||| 1-0 0-1 2-1 3-2
In drei Placebo-kontrollierten Studien(n= ||| three placebo-controlled trials ( n= ||| 1-0 0-1 2-1 3-2 3-3 2-4 3-4
In drei Placebo-kontrollierten ||| three placebo-controlled ||| 1-0 0-1 2-1
In drei ||| In three ||| 0-0 1-1
In einem ||| In an ||| 0-0 1-1
In einer Haloperidol-kontrollierten Studie war ||| In a haloperidol-controlled trial ||| 0-0 1-1 2-2 4-2 3-3
In einer Outcome-Studie ||| In controlled clinical trials the ||| 0-0 1-1 2-1 0-2 2-3
In einer Outcome-Studie ||| In controlled clinical trials ||| 0-0 1-1 2-1 0-2 2-3
In einer Studie ||| In a study ||| 0-0 1-1 2-2
In einer anderen ||| In another ||| 0-0 1-1 2-1
In einer kleinen Studie , ||| In a small study ||| 0-0 1-1 2-2 3-3
In einer kleinen Studie ||| In a small study ||| 0-0 1-1 2-2 3-3
In einer kleinen ||| In a small ||| 0-0 1-1 2-2
In einer klinischen Studie bei ||| In clinical trials in ||| 0-0 1-0 2-1 2-2 3-3 4-3
In einer klinischen Studie ||| In a clinical trial ||| 0-0 1-1 2-2 3-3
In einer klinischen ||| In a clinical ||| 0-0 1-1 2-2
In einer klinischen ||| In clinical trials ||| 0-0 1-0 2-1 2-2
In einer prospektiven , ||| In a prospective , ||| 0-0 1-1 2-2 3-3
In einer prospektiven ||| In a prospective ||| 0-0 1-1 2-2
In einer ||| 102 In a ||| 1-0 0-1 1-2
In einer ||| 20 In a ||| 0-1 1-2
In einer ||| 9 In a ||| 0-1 1-2
In einer ||| In a ||| 0-0 1-1
In einer ||| In one ||| 0-0 1-1
In einer ||| In the ||| 0-0 1-0
In einer ||| In ||| 0-0 1-0
In einigen , jedoch ||| In some , but ||| 0-0 1-1 2-2 3-3
In einigen , ||| In some , ||| 0-0 1-1 2-2
In einigen Fällen ||| In some cases ||| 0-0 1-1 2-2
In einigen ||| In some ||| 0-0 1-1
In fünf Kurzzeitstudien wurde ||| There were five short-term studies ||| 0-0 3-1 1-2 2-3 2-4 3-4
In klinischen Prüfungen nahmen ||| In clinical trials ||| 0-0 1-1 1-2 2-2 3-2
In klinischen Prüfungen wurden ||| The following maintenance doses were ||| 0-0 2-1 0-2 1-2 2-2 2-3 3-4
In klinischen Prüfungen ||| In clinical trials ||| 0-0 1-1 1-2 2-2
In klinischen Prüfungen ||| The following maintenance doses ||| 0-0 2-1 0-2 1-2 2-2 2-3
In klinischen Studien hat Aripiprazol ||| In clinical trials aripiprazole has ||| 0-0 1-1 2-2 4-3 3-4
In klinischen Studien mit Aripiprazol ||| In clinical trials of aripiprazole ||| 0-0 1-1 2-2 3-4 4-4
In klinischen Studien mit Aripiprazol ||| In clinical trials with aripiprazole ||| 0-0 1-1 2-2 3-3 4-4
In klinischen Studien mit Pioglitazon ||| In clinical trials with pioglitazone ||| 0-0 1-1 2-2 3-3 4-4
In klinischen Studien mit ||| In clinical trials with ||| 0-0 1-1 2-2 3-3
In klinischen Studien sowie ||| In clinical trials and ||| 0-0 1-1 2-2 3-2 3-3
In klinischen Studien und ||| In clinical trials and ||| 0-0 1-1 2-2 3-3
In klinischen Studien wurden ein ||| In clinical trials , an ||| 0-0 1-1 2-2 3-2 3-3 4-4
In klinischen Studien wurden seltene ||| In clinical trials , rare ||| 0-0 1-1 2-2 3-2 3-3 4-4
In klinischen Studien wurden ||| In clinical trials , ||| 0-0 1-1 2-2 3-2 3-3
In klinischen Studien ||| 53 In clinical trials ||| 0-1 1-2 2-3
In klinischen Studien ||| 58 In clinical trials ||| 0-1 1-2 2-3
In klinischen Studien ||| 63 In clinical trials ||| 0-1 1-2 2-3
In klinischen Studien ||| In clinical studies , ||| 0-0 1-1 2-2
In klinischen Studien ||| In clinical studies ||| 0-0 1-1 2-2
In klinischen Studien ||| In clinical trials of ||| 0-0 1-1 2-2
In klinischen Studien ||| In clinical trials ||| 0-0 1-1 2-2
In klinischen Studien ||| clinical trials ||| 0-0 1-0 2-1
In klinischen Studien ||| in clinical trials ||| 0-0 0-1 1-1 2-2
In klinischen ||| 53 In clinical ||| 0-1 1-2
In klinischen ||| 58 In clinical ||| 0-1 1-2
In klinischen ||| 63 In clinical ||| 0-1 1-2
In klinischen ||| In clinical ||| 0-0 1-1
In klinischen ||| clinical ||| 0-0 1-0
In klinischen ||| in clinical ||| 0-0 0-1 1-1
In kontrollierten Studien versus Vergleichsmedikation ||| In active comparator controlled trials ||| 0-0 3-1 3-2 4-2 1-3 2-4
In kontrollierten klinischen Studien wurde ||| In controlled clinical studies , ||| 0-0 1-1 2-2 3-3 4-3
In kontrollierten klinischen Studien wurde ||| In controlled clinical studies ||| 0-0 1-1 2-2 3-3 4-3
In kontrollierten klinischen ||| In controlled clinical ||| 0-0 1-1 2-2
In kontrollierten ||| In controlled ||| 0-0 1-1
In mehreren kontrollierten Studien ||| In several controlled studies ||| 0-0 1-1 2-2 3-3
In mehreren kontrollierten ||| In several controlled ||| 0-0 1-1 2-2
In mehreren ||| In several ||| 0-0 1-1
In placebokontrollierten Studien ||| In placebo-controlled studies , ||| 0-0 1-1 2-2
In placebokontrollierten Studien ||| In placebo-controlled studies ||| 0-0 1-1 2-2
In placebokontrollierten ||| In placebo-controlled ||| 0-0 1-1
In tierexperimentellen Studien mit Pioglitazon ||| Foetal growth restriction ||| 0-0 1-0 1-1 1-2 2-2 3-2 4-2
In tierexperimentellen Studien mit ||| In animal studies , epoetin ||| 0-0 1-1 2-2 1-4 3-4
In vitro-Studien zeigten ||| In vitro studies have shown ||| 0-0 1-1 1-2 1-3 2-4
In vitro-Studien ||| In vitro studies have ||| 0-0 1-1 1-2 1-3
In zwei großen ||| In two large ||| 0-0 1-1 2-2
In zwei ||| In two ||| 0-0 1-1
In ||| 20 In ||| 0-1
In ||| 28 In ||| 0-1
In ||| 32 In ||| 0-1
In ||| 53 In ||| 0-1
In ||| 58 In ||| 0-1
In ||| 63 In ||| 0-1
In ||| 9 In ||| 0-1
In ||| In the ||| 0-0
In ||| In ||| 0-0
In ||| Over ||| 0-0
In ||| The ||| 0-0
In ||| There ||| 0-0
In ||| d In ||| 0-1
In ||| studies ||| 0-0
In-vivo- ||| battery ||| 0-0
Indigocarmin-Aluminiumsalz ||| indigo carmine ||| 0-0 0-1
Indikation Steigerung ||| indication increasing ||| 0-0 1-1
Indikation ||| indication ||| 0-0
Indikationen . ||| indications . ||| 0-0 1-1
Indikationen . ||| other indications . ||| 0-1 1-2
Indikationen ||| indications , and a ||| 0-0
Indikationen ||| indications , and ||| 0-0
Indikationen ||| indications , ||| 0-0
Indikationen ||| indications ||| 0-0
Indikationen ||| other indications ||| 0-1
Induktion ||| main ||| 0-0
Industrial Park Westhoughton BL5 3XX ||| Industrial Park Westhoughton BL5 3XX ||| 0-0 1-1 2-2 3-3 4-4
Industrial Park Westhoughton BL5 ||| Industrial Park Westhoughton BL5 ||| 0-0 1-1 2-2 3-3
Industrial Park Westhoughton ||| Industrial Park Westhoughton ||| 0-0 1-1 2-2
Industrial Park ||| Industrial Park ||| 0-0 1-1
Industrial ||| Industrial ||| 0-0
Industrie , 30-36 Avenue Gustave ||| Industrie , 30-36 Avenue Gustave ||| 0-0 1-1 2-2 3-3 4-4
Industrie , 30-36 Avenue ||| Industrie , 30-36 Avenue ||| 0-0 1-1 2-2 3-3
Industrie , 30-36 ||| Industrie , 30-36 ||| 0-0 1-1 2-2
Industrie , ||| Industrie , ||| 0-0 1-1
Industrie ||| Industrie ||| 0-0
Infektion , Harnweginfektion , Folliculitis ||| Infection , urinary tract ||| 0-0 1-1 3-1 2-2 4-3
Infektion , Harnweginfektion , ||| Infection , urinary ||| 0-0 1-1 3-1 2-2
Infektion ||| Infection ||| 0-0
Infektion ||| infection ||| 0-0
Infektionen der oberen Atemwege ( ||| upper respiratory tract infection ( ||| 2-0 2-1 2-2 3-2 0-3 4-4
Infektionen der oberen Atemwege ||| upper respiratory tract infection ||| 2-0 2-1 2-2 3-2 0-3
Infektionen der ||| infection ||| 0-0
Infektionen einschließlich Osteomyelitis , und ||| infection including osteomyelitis , and ||| 0-0 1-1 2-2 3-3 4-4
Infektionen einschließlich Osteomyelitis , ||| infection including osteomyelitis , ||| 0-0 1-1 2-2 3-3
Infektionen einschließlich Osteomyelitis ||| infection including osteomyelitis ||| 0-0 1-1 2-2
Infektionen einschließlich ||| infection including ||| 0-0 1-1
Infektionen oder ||| infection or ||| 0-0 1-1
Infektionen und ||| infections and ||| 0-0 1-1
Infektionen ||| infection ||| 0-0
Infektionen ||| infections ||| 0-0
Infiltrationen beobachtet . ||| infiltration were observed . ||| 0-0 0-1 1-2 2-3
Infiltrationen beobachtet ||| infiltration were observed ||| 0-0 0-1 1-2
Infiltrationen ||| infiltration were ||| 0-0 0-1
Infolge der Akkumulierung von Triglyceriden ||| Accumulation of triglycerides inside ||| 0-0 2-0 1-1 3-1 2-2 4-3
Infolge der Akkumulierung von ||| Accumulation of triglycerides ||| 0-0 2-0 1-1 3-1 2-2
Informationen sind ||| information is ||| 0-0 1-0 0-1
Informationen sind ||| more information ||| 0-0 0-1 1-1
Informationen zur ||| more information ||| 0-0 0-1 1-1
Informationen ||| information is received ||| 0-0 0-1
Informationen ||| information is ||| 0-0 0-1
Informationen ||| information on ||| 0-0 0-1
Informationen ||| information ||| 0-0
Informationen ||| more information ||| 0-0 0-1
Informationen über bestimmte ||| information about some ||| 0-0 0-1 1-1 2-2
Informationen über die ||| information on the ||| 0-0 1-0 0-1 2-2
Informationen über ||| information about ||| 0-0 0-1 1-1
Informationen über ||| information about ||| 0-0 1-0 0-1
Informationen über ||| information on ||| 0-0 1-0 0-1
Informationen über ||| information ||| 0-0 1-0
Informationen über ||| more information about ||| 0-0 0-1 1-1 0-2
Informieren Sie Ihren ||| Be sure to tell your ||| 0-0 0-1 1-1 0-2 2-3 2-4
Informieren Sie Ihren ||| Be sure to tell ||| 0-0 0-1 1-1 2-2 2-3
Informieren Sie bitte ||| Be sure to tell ||| 0-0 0-1 1-1 1-2 2-3
Informieren Sie bitte ||| If any of the ||| 0-0 0-1 1-1 2-1 2-3
Informieren Sie bitte ||| If any of ||| 0-0 0-1 1-1 2-1
Informieren Sie bitte ||| If any ||| 0-0 0-1 1-1 2-1
Informieren Sie umgehend Ihren Arzt ||| 137 Tell your doctor immediately ||| 0-0 0-1 1-1 3-2 3-3 4-3 2-4
Informieren Sie umgehend Ihren Arzt ||| 142 Tell your doctor immediately ||| 0-0 0-1 1-1 3-2 3-3 4-3 2-4
Informieren Sie umgehend Ihren Arzt ||| 147 Tell your doctor immediately ||| 0-0 0-1 1-1 3-2 3-3 4-3 2-4
Informieren Sie umgehend Ihren Arzt ||| 152 Tell your doctor immediately ||| 0-0 0-1 1-1 3-2 3-3 4-3 2-4
Informieren Sie umgehend Ihren Arzt ||| 157 Tell your doctor immediately ||| 0-0 0-1 1-1 3-2 3-3 4-3 2-4
Informieren Sie umgehend Ihren Arzt ||| 163 Tell your doctor immediately ||| 0-0 0-1 1-1 3-2 3-3 4-3 2-4
Informieren Sie umgehend Ihren Arzt ||| 169 Tell your doctor immediately ||| 0-0 0-1 1-1 3-2 3-3 4-3 2-4
Informieren Sie umgehend Ihren Arzt ||| 175 Tell your doctor immediately ||| 0-0 0-1 1-1 3-2 3-3 4-3 2-4
Informieren Sie umgehend Ihren Arzt ||| Tell your doctor immediately ||| 0-0 1-1 3-1 3-2 4-2 2-3
Informieren Sie unverzüglich Ihren Arzt ||| Tell your doctor immediately ||| 0-0 1-0 3-1 3-2 4-2 2-3
Informieren Sie unverzüglich Ihren Arzt ||| Tell your doctor immediately ||| 0-0 1-1 3-1 3-2 4-2 2-3
Informieren Sie ||| 137 Tell ||| 0-0 0-1 1-1
Informieren Sie ||| 142 Tell ||| 0-0 0-1 1-1
Informieren Sie ||| 147 Tell ||| 0-0 0-1 1-1
Informieren Sie ||| 152 Tell ||| 0-0 0-1 1-1
Informieren Sie ||| 157 Tell ||| 0-0 0-1 1-1
Informieren Sie ||| 163 Tell ||| 0-0 0-1 1-1
Informieren Sie ||| 169 Tell ||| 0-0 0-1 1-1
Informieren Sie ||| 175 Tell ||| 0-0 0-1 1-1
Informieren Sie ||| Be sure to ||| 0-0 0-1 1-1 0-2
Informieren Sie ||| Be sure to ||| 0-0 0-1 1-1 1-2
Informieren Sie ||| Be sure ||| 0-0 0-1 1-1
Informieren Sie ||| Tell ||| 0-0 1-0
Informieren ||| If ||| 0-0
Informieren ||| Tell ||| 0-0
Infusion ) ||| infusion ) ||| 0-0 1-1
Infusion , ||| infusion ||| 0-0
Infusion . ||| infusion . ||| 0-0 1-1
Infusion auf und sind ||| infusion , becoming ||| 0-0 2-1
Infusion auf und sind ||| infusion , ||| 0-0 2-1
Infusion auf und ||| infusion , becoming ||| 0-0 2-1
Infusion auf und ||| infusion , ||| 0-0 2-1
Infusion auf ||| infusion ||| 0-0
Infusion gegeben oder ||| infusion , or ||| 0-0 1-0 2-2
Infusion gegeben ||| infusion , ||| 0-0 1-0
Infusion gegeben ||| infusion ||| 0-0 1-0
Infusion hält ein Jahr ||| infusion lasts for a year ||| 0-0 1-1 2-2 2-3 3-4
Infusion hält ein ||| infusion lasts for a ||| 0-0 1-1 2-2 2-3
Infusion hält ||| infusion lasts ||| 0-0 1-1
Infusion lag bei ca. 6 ||| infusion was approximately six ||| 0-0 1-1 2-1 3-2 4-3
Infusion lag bei ca. ||| infusion was approximately ||| 0-0 1-1 2-1 3-2
Infusion lag bei ||| infusion was ||| 0-0 1-1 2-1
Infusion muss unter Berücksichtigung ||| infusion must be conducted ||| 0-0 1-1 1-2 3-3
Infusion muss unter ||| infusion must be ||| 0-0 1-1 1-2
Infusion muss ||| infusion must be ||| 0-0 1-1 1-2
Infusion nach ||| after ||| 0-0 1-0
Infusion von 5 mg Aclasta ||| infusion of 5 mg Aclasta ||| 0-0 1-1 2-2 3-3 4-4
Infusion von 5 mg ||| infusion of 5 mg ||| 0-0 1-1 2-2 3-3
Infusion von 5 ||| infusion of 5 ||| 0-0 1-1 2-2
Infusion von Aclasta auftritt ( ||| infusion of Aclasta ( ||| 0-0 1-1 2-2 4-3
Infusion von Aclasta auftritt . ||| infusion of Aclasta . ||| 0-0 1-1 2-2 4-3
Infusion von Aclasta auftritt ||| infusion of Aclasta ||| 0-0 1-1 2-2
Infusion von Aclasta siehe ||| infusion of Aclasta , see ||| 0-0 1-1 2-2 3-4
Infusion von Aclasta ||| dose of Aclasta for ||| 1-0 1-1 0-2 2-2 1-3
Infusion von Aclasta ||| infusion of Aclasta , ||| 0-0 1-1 2-2
Infusion von Aclasta ||| infusion of Aclasta ||| 0-0 1-1 2-2
Infusion von ||| infusion of ||| 0-0 1-1
Infusion wird ||| infusion will ||| 0-0 1-1
Infusion zwei oder mehr Wochen ||| infusion two or more weeks ||| 0-0 1-1 2-2 3-3 4-4
Infusion zwei oder mehr ||| infusion two or more ||| 0-0 1-1 2-2 3-3
Infusion zwei oder ||| infusion two or ||| 0-0 1-1 2-2
Infusion zwei ||| infusion two ||| 0-0 1-1
Infusion ||| infusion , or ||| 0-0
Infusion ||| infusion , ||| 0-0
Infusion ||| infusion ||| 0-0
Infusion ||| single infusion ||| 0-0 0-1
Infusion ||| the infusion ||| 0-1
Infusionen von Abraxane ||| infusions of Abraxane ||| 0-0 1-1 2-2
Infusionen von ||| infusions of ||| 0-0 1-1
Infusionen ||| infusions ||| 0-0
Infusionsbeutel : ||| infusion bag : ||| 0-0 0-1 1-2
Infusionsbeutel gefüllt ||| infusion bag ||| 0-0 0-1 1-1
Infusionsbeutel ||| infusion bag ||| 0-0 0-1
Infusionsdauer darf nicht ||| infusion time must not be ||| 0-0 0-1 1-2 2-3 1-4
Infusionsdauer ||| infusion time ||| 0-0 0-1
Infusionslösung ( Tropfinfusion ||| solution for infusion ( drip ||| 0-0 0-1 0-2 1-3 2-4
Infusionslösung ( ||| solution for infusion ( ||| 0-0 0-1 0-2 1-3
Infusionslösung ist in dieser ||| solution for infusion is ||| 0-0 0-1 0-2 1-3 2-3
Infusionslösung ist in ||| solution for infusion is ||| 0-0 0-1 0-2 1-3 2-3
Infusionslösung ||| solution for infusion ||| 0-0 0-1 0-2
Infusionsrate wider . ||| infusion . ||| 0-0 1-0 2-1
Infusionsrate wider ||| infusion ||| 0-0 1-0
Inhalt der Packung ABILIFY ||| contents of the pack ABILIFY ||| 0-0 2-0 1-1 1-2 2-3 3-4
Inhalt der Packung Aclasta ||| contents of the pack Aclasta ||| 0-0 2-0 1-1 1-2 2-3 3-4
Inhalt der Packung Actos ||| contents of the pack Actos ||| 0-0 2-0 1-1 1-2 2-3 3-4
Inhalt der Packung Die ABILIFY ||| contents of the pack ABILIFY ||| 0-0 2-0 1-1 1-2 2-3 3-4 4-4
Inhalt der Packung ||| contents of the pack ||| 0-0 1-1 1-2 2-3
Inhalt der Packung ||| contents of the pack ||| 0-0 2-0 1-1 1-2 2-3
Inhalt der ||| contents of the ||| 0-0 1-1 1-2
Inhalt ||| contents ||| 0-0
Inhibitor der Osteoklasten-vermittelten Knochenresorption ||| inhibitor of osteoclast-mediated bone resorption ||| 0-0 1-1 2-2 3-3 3-4
Inhibitor der Osteoklasten-vermittelten ||| inhibitor of osteoclast-mediated ||| 0-0 1-1 2-2
Inhibitor der ||| inhibitor of ||| 0-0 1-1
Inhibitor ||| inhibitor ||| 0-0
Inhibitoren von CYP3A4 ( ||| inhibitors of CYP3A4 ( ||| 0-0 1-1 2-2 3-3
Inhibitoren von CYP3A4 , ||| inhibitors of CYP3A4 , ||| 0-0 1-1 2-2 3-3
Inhibitoren von CYP3A4 ||| inhibitors of CYP3A4 ||| 0-0 1-1 2-2
Inhibitoren von ||| inhibitors of ||| 0-0 1-1
Inhibitoren ||| inhibitors ||| 0-0
Initialdosis ||| dose ||| 0-0
Injektion , intermediär wirkend kombiniert ||| injection , intermediate-acting combined ||| 0-0 1-1 2-2 3-2 4-3
Injektion , intermediär wirkend ||| injection , intermediate-acting ||| 0-0 1-1 2-2 3-2
Injektion , ||| injection , ||| 0-0 1-1
Injektion . ||| injection . ||| 0-0 1-1
Injektion : ein Maximalvolumen ||| injection : a maximum volume ||| 0-0 1-1 2-2 3-3 3-4
Injektion : ein ||| injection : a ||| 0-0 1-1 2-2
Injektion : ||| injection : ||| 0-0 1-1
Injektion der notwendigen Menge ||| injection of the necessary amount ||| 0-0 1-1 1-2 2-3 2-4 3-4
Injektion der ||| injection of the ||| 0-0 1-1 1-2
Injektion so vorbereitet ||| before injection so ||| 2-0 0-1 1-2 2-2
Injektion unter die Haut ( ||| injection under the skin ( ||| 0-0 1-1 2-2 3-3 4-4
Injektion unter die Haut ||| injection under the skin ||| 0-0 1-1 2-2 3-3
Injektion unter die ||| injection under the ||| 0-0 1-1 2-2
Injektion unter ||| injection under ||| 0-0 1-1
Injektion ||| injection , ||| 0-0
Injektion ||| injection ||| 0-0
Injektionen . ||| injections . ||| 0-0 1-1
Injektionen in ||| If convenient , ||| 0-0 0-1 1-1
Injektionen in ||| If convenient ||| 0-0 0-1 1-1
Injektionen werden in ||| injections are given in ||| 0-0 0-1 1-1 0-2 2-3
Injektionen werden vorzugsweise entweder ||| injections are given preferably ||| 0-0 0-1 1-1 0-2 2-3 3-3
Injektionen werden ||| injections are given ||| 0-0 0-1 1-1 0-2
Injektionen ||| injections in ||| 0-0
Injektionen ||| injections ||| 0-0
Injektionslösung ( 7,5 ||| for injection ( 7.5 ||| 0-0 0-1 1-2 2-3
Injektionslösung ( ||| for injection ( ||| 0-0 0-1 1-2
Injektionslösung Aripiprazol Zur intramuskulären ||| solution for injection aripiprazole Intramuscular ||| 0-0 0-1 0-2 1-3 2-4 3-4
Injektionslösung Aripiprazol ||| solution for injection aripiprazole ||| 0-0 0-1 0-2 1-3
Injektionslösung Klare , ||| Solution for injection Clear , ||| 0-0 0-1 0-2 1-3 2-4
Injektionslösung Klare ||| Solution for injection Clear ||| 0-0 0-1 0-2 1-3
Injektionslösung enthält 10 ||| solution for injection contains 10 ||| 0-0 0-1 0-2 1-3 2-4
Injektionslösung enthält 1000 ||| solution for injection contains 1000 ||| 0-0 0-1 0-2 1-3 2-4
Injektionslösung enthält 2000 ||| solution for injection contains 2000 ||| 0-0 0-1 0-2 1-3 2-4
Injektionslösung enthält 3000 ||| solution for injection contains 3000 ||| 0-0 0-1 0-2 1-3 2-4
Injektionslösung enthält 4000 ||| solution for injection contains 4000 ||| 0-0 0-1 0-2 1-3 2-4
Injektionslösung enthält 5000 ||| solution for injection contains 5000 ||| 0-0 0-1 0-2 1-3 2-4
Injektionslösung enthält 6000 ||| solution for injection contains 6000 ||| 0-0 0-1 0-2 1-3 2-4
Injektionslösung enthält 7000 ||| solution for injection contains 7000 ||| 0-0 0-1 0-2 1-3 2-4
Injektionslösung enthält 8000 ||| solution for injection contains 8000 ||| 0-0 0-1 0-2 1-3 2-4
Injektionslösung enthält 9000 ||| solution for injection contains 9000 ||| 0-0 0-1 0-2 1-3 2-4
Injektionslösung enthält ||| solution for injection contains ||| 0-0 0-1 0-2 1-3
Injektionslösung erhalten als ||| solution for injection than ||| 0-0 0-1 1-1 0-2 2-3
Injektionslösung erhalten ||| solution for injection ||| 0-0 0-1 1-1 0-2
Injektionslösung in einer ||| Solution for injection in a ||| 0-0 0-1 0-2 1-2 1-3 2-4
Injektionslösung in einer ||| for injection in a ||| 0-0 0-1 1-2 2-3
Injektionslösung in einer ||| solution for injection in a ||| 0-0 0-1 0-2 1-3 2-4
Injektionslösung in ||| Solution for injection in ||| 0-0 0-1 0-2 1-2 1-3
Injektionslösung in ||| for injection in ||| 0-0 0-1 1-2
Injektionslösung in ||| solution for injection in ||| 0-0 0-1 0-2 1-3
Injektionslösung ist eine ||| solution for injection is a ||| 0-0 0-1 0-2 1-3 2-4
Injektionslösung ist gebrauchsfertig ||| solution for injection is ready ||| 0-0 0-1 0-2 1-3 2-4
Injektionslösung ist ||| solution for injection is ||| 0-0 0-1 0-2 1-3
Injektionslösung nicht ||| solution for injection ||| 0-0 0-1 0-2
Injektionslösung sind ||| solution for injection ||| 0-0 0-1 0-2
Injektionslösung sollte nicht ||| solution for injection should not ||| 0-0 0-1 0-2 1-3 2-4
Injektionslösung sollte ||| solution for injection should ||| 0-0 0-1 0-2 1-3
Injektionslösung wird angewendet ||| solution for injection is given ||| 0-0 0-1 0-2 1-3 2-4
Injektionslösung wird ||| solution for injection is ||| 0-0 0-1 0-2 1-3
Injektionslösung wurde durch ||| solution for injection ||| 0-0 0-1 0-2
Injektionslösung wurde ||| solution for injection ||| 0-0 0-1 0-2
Injektionslösung ||| Solution for injection ||| 0-0 0-1 0-2
Injektionslösung ||| for injection ||| 0-0 0-1
Injektionslösung ||| solution for injection ||| 0-0 0-1 0-2
Injektionslösung ||| solution for injection ||| 0-0 0-2
Injektionslösung ||| solution for ||| 0-0 0-1
Injektionsnadel . ||| needle . ||| 0-0 1-1
Injektionsnadel erscheint . ||| needle top . ||| 0-0 1-1 2-2
Injektionsnadel erscheint ||| needle top ||| 0-0 1-1
Injektionsnadel muss ||| needle should be ||| 0-0 1-0 1-1 1-2
Injektionsnadel ||| needle ||| 0-0
Injektionsstelle innerhalb eines bestimmten ||| injection site within a ||| 0-0 0-1 1-2 2-2 3-2 2-3
Injektionsstelle ||| injection site ||| 0-0 0-1
Injektionszubereitung ) ||| injection ) ||| 0-0 1-1
Injektionszubereitung ||| injection ||| 0-0
Injektionszwecke . ||| injections . ||| 0-0 1-1
Injektionszwecke Salzsäure ( ||| injections Hydrochloric acid ( ||| 0-0 1-1 1-2 2-3
Injektionszwecke Salzsäure ||| injections Hydrochloric acid ||| 0-0 1-1 1-2
Injektionszwecke ||| injections ||| 0-0
Innerhalb jeder ||| 5 Within each ||| 0-1 1-2
Innerhalb jeder ||| Within each ||| 0-0 0-1 1-1
Innerhalb jeder ||| Within each ||| 0-0 1-1
Innerhalb von 60 Tagen ||| Within 60 days of ||| 0-0 2-1 3-2 1-3
Innerhalb von ||| An ||| 0-0 1-0
Innerhalb von ||| Up to ||| 0-0 1-1
Innerhalb ||| 5 Within ||| 0-1
Innerhalb ||| Up ||| 0-0
Innerhalb ||| Within ||| 0-0
Insbesondere sind keine ||| In particular , no ||| 0-0 0-1 1-1 1-2 2-3
Insbesondere sind ||| In particular , ||| 0-0 0-1 1-1 1-2
Insgesamt sprachen in der ||| Overall , in the ||| 0-0 1-0 0-1 2-2 3-3
Insgesamt sprachen in ||| Overall , in ||| 0-0 1-0 0-1 2-2
Insgesamt sprachen ||| Overall , ||| 0-0 1-0 0-1
Instabilität ( unregelmäßiger Puls oder ||| instability ( irregular pulse or ||| 0-0 2-0 1-1 2-2 3-3 4-4
Instabilität ( unregelmäßiger Puls ||| instability ( irregular pulse ||| 0-0 2-0 1-1 2-2 3-3
Instabilität ( unregelmäßiger ||| instability ( irregular ||| 0-0 2-0 1-1 2-2
Insulin ( human ) . ||| insulin ( human ) . ||| 0-0 1-1 2-2 3-3 4-4
Insulin ( human ) ||| insulin ( human ) ||| 0-0 1-1 2-2 3-3
Insulin ( human ||| insulin ( human ||| 0-0 1-1 2-2
Insulin ( ||| insulin ( ||| 0-0 1-1
Insulin , Metformin ) ||| insulin , metformin ) ||| 0-0 1-1 2-2 3-3
Insulin , Metformin ||| insulin , metformin ||| 0-0 1-1 2-2
Insulin , ||| insulin , ||| 0-0 1-1
Insulin . ||| insulin . ||| 0-0 1-1
Insulin . ||| insulin ||| 0-0
Insulin 10 % und ||| insulin 10 % and ||| 0-0 1-1 2-2 3-3
Insulin 10 % ||| insulin 10 % ||| 0-0 1-1 2-2
Insulin 10 ||| insulin 10 ||| 0-0 1-1
Insulin 20 % und ||| insulin 20 % and ||| 0-0 1-1 2-2 3-3
Insulin 20 % ||| insulin 20 % ||| 0-0 1-1 2-2
Insulin 20 ||| insulin 20 ||| 0-0 1-1
Insulin 30 % und ||| insulin 30 % and ||| 0-0 1-1 2-2 3-3
Insulin 30 % ||| insulin 30 % ||| 0-0 1-1 2-2
Insulin 30 ||| insulin 30 ||| 0-0 1-1
Insulin 40 % und ||| insulin 40 % and ||| 0-0 1-1 2-2 3-3
Insulin 40 % ||| insulin 40 % ||| 0-0 1-1 2-2
Insulin 40 ||| insulin 40 ||| 0-0 1-1
Insulin 50 % und ||| insulin 50 % and ||| 0-0 1-1 2-2 3-3
Insulin 50 % ||| insulin 50 % ||| 0-0 1-1 2-2
Insulin 50 ||| insulin 50 ||| 0-0 1-1
Insulin auftreten . ||| insulin . ||| 0-0 1-0 2-1
Insulin auftreten ||| insulin ||| 0-0 1-0
Insulin bei ||| insulin in ||| 0-0 1-1
Insulin effektiv ||| insulin effectively ||| 0-0 1-1
Insulin human , r-DNS ( ||| Insulin human , rDNA ( ||| 0-0 1-1 2-2 3-3 4-4
Insulin human , r-DNS ||| Insulin human , rDNA ||| 0-0 1-1 2-2 3-3
Insulin human , ||| Insulin human , ||| 0-0 1-1 2-2
Insulin human . ||| human insulin . ||| 1-0 0-1 2-2
Insulin human . ||| insulin human . ||| 0-0 1-1 2-2
Insulin human ||| Insulin human ||| 0-0 1-1
Insulin human ||| human insulin ||| 1-0 0-1
Insulin human ||| insulin human ||| 0-0 1-1
Insulin in Kombination mit Metformin ||| insulin in combination with metformin ||| 0-0 1-1 2-2 3-3 4-4
Insulin in Kombination mit ||| insulin in combination with ||| 0-0 1-1 2-2 3-3
Insulin in Kombination ||| insulin in combination ||| 0-0 1-1 2-2
Insulin in ||| insulin in ||| 0-0 1-1
Insulin oder ||| insulin or ||| 0-0 1-1
Insulin produzieren ||| insulin ||| 0-0
Insulin und 50 % ||| insulin and 50 % ||| 0-0 1-1 2-2 3-3
Insulin und 50 ||| insulin and 50 ||| 0-0 1-1 2-2
Insulin und 60 % ||| insulin and 60 % ||| 0-0 1-1 2-2 3-3
Insulin und 60 ||| insulin and 60 ||| 0-0 1-1 2-2
Insulin und 70 % ||| insulin and 70 % ||| 0-0 1-1 2-2 3-3
Insulin und 70 ||| insulin and 70 ||| 0-0 1-1 2-2
Insulin und 80 % ||| insulin and 80 % ||| 0-0 1-1 2-2 3-3
Insulin und 80 ||| insulin and 80 ||| 0-0 1-1 2-2
Insulin und 90 % ||| insulin and 90 % ||| 0-0 1-1 2-2 3-3
Insulin und 90 ||| insulin and 90 ||| 0-0 1-1 2-2
Insulin und Isophan- ( NPH- ||| insulin and isophane ( NPH ||| 0-0 1-1 2-2 3-3 4-4
Insulin und Isophan- ( ||| insulin and isophane ( ||| 0-0 1-1 2-2 3-3
Insulin und Isophan- ||| insulin and isophane ||| 0-0 1-1 2-2
Insulin und Pioglitazon ||| insulin and pioglitazone ||| 0-0 1-1 2-2
Insulin und ||| insulin and ||| 0-0 1-1
Insulin wird aus ||| insulin ||| 0-0 1-0 2-0
Insulin zur Regelung des ||| insulin to control the ||| 0-0 1-1 2-2 3-3
Insulin zur Regelung ||| insulin to control ||| 0-0 1-1 2-2
Insulin zur ||| Insulin zur ||| 0-0 1-1
Insulin zur ||| insulin to ||| 0-0 1-1
Insulin ||| Insulin ||| 0-0
Insulin ||| included insulin . ||| 0-0 0-1
Insulin ||| included insulin ||| 0-0 0-1
Insulin ||| insulin , ||| 0-0
Insulin ||| insulin ||| 0-0
Insulin ||| on insulin ||| 0-1
Insulin-Suspensionen zur Injektion . ||| insulin suspensions for injection . ||| 0-0 0-1 1-2 2-3 3-4
Insulin-Suspensionen zur Injektion ||| insulin suspensions for injection ||| 0-0 0-1 1-2 2-3
Insulin-Suspensionen zur ||| insulin suspensions for ||| 0-0 0-1 1-2
Insulin-Suspensionen ||| insulin suspensions ||| 0-0 0-1
Insulinanalogon ||| method of ||| 0-0
Insulinanalogon ||| method ||| 0-0
Insulinantikörpern ( soweit vorhanden ) ||| ( if present ) has ||| 1-0 0-1 0-2 2-2 3-2 4-3 2-4
Insulinbedarf , steigt aber ||| first trimester ||| 2-0 0-1 2-1 3-1
Insulinbedarf kann ||| insulin requirement may be ||| 0-0 0-1 1-2 1-3
Insulinbedarf liegt ||| insulin requirement is ||| 0-0 0-1 1-1 1-2
Insulinbedarf sowohl senken als ||| both decrease and increase ||| 0-0 1-0 1-1 2-1 2-2 2-3 3-3
Insulinbedarf ||| insulin requirement ||| 0-0 0-1
Insuline und Analoga zur Injektion ||| Insulins and analogues for injection ||| 0-0 1-1 2-2 3-2 3-3 4-4
Insuline und Analoga zur ||| Insulins and analogues for ||| 0-0 1-1 2-2 3-2 3-3
Insuline und ||| Insulins and ||| 0-0 1-1
Insuline ||| Insulins ||| 0-0
Insulinprodukten mit schneller ||| insulin products with fast ||| 0-0 0-1 1-2 0-3 2-3
Insulinprodukten unterliegen daher ||| insulin products are therefore affected ||| 0-0 0-1 1-2 2-3 1-4 2-4
Insulinprodukten ||| insulin products , ||| 0-0 0-1
Insulinprodukten ||| insulin products ||| 0-0 0-1
Insulinresistenz des ||| insulin resistance ||| 0-0 1-0 0-1
Insulinresistenz steigert . ||| insulin resistance . ||| 0-0 0-1 1-1 2-2
Insulinresistenz steigert ||| insulin resistance ||| 0-0 0-1 1-1
Insulinresistenz vermittelt . ||| insulin resistance . ||| 0-0 0-1 1-1 2-2
Insulinresistenz vermittelt ||| insulin resistance ||| 0-0 0-1 1-1
Insulinsensitivität einher . ||| insulin sensitivity . ||| 1-0 0-1 1-1 2-2
Insulinsensitivität einher ||| insulin sensitivity ||| 1-0 0-1 1-1
Insulinsensitivität erhöht . ||| increasing insulin sensitivity . ||| 0-0 0-1 0-2 1-2 2-3
Insulinsensitivität erhöht ||| increasing insulin sensitivity ||| 0-0 0-1 0-2 1-2
Insulinsensitivität ||| insulin sensitivity ||| 0-0 0-1
Insulinspritzen mit einer passenden ||| insulin syringes with a corresponding ||| 0-0 0-1 1-2 2-3 3-4
Insulinspritzen mit einer ||| insulin syringes with a ||| 0-0 0-1 1-2 2-3
Insulinspritzen mit ||| insulin syringes with ||| 0-0 0-1 1-2
Insulinspritzen ||| insulin syringes ||| 0-0 0-1
Insulinsuspensionen dürfen nicht ||| Insulin suspensions are not to ||| 0-0 0-1 1-1 1-2 2-3 2-4
Insulinsuspensionen dürfen nicht ||| Insulin suspensions should not ||| 0-0 0-1 1-1 1-2 2-3
Insulinsuspensionen dürfen niemals intravenös ||| Insulin suspensions are never to ||| 0-0 0-1 1-1 2-2 2-3 3-3 3-4
Insulinsuspensionen dürfen ||| Insulin suspensions are ||| 0-0 0-1 1-1 1-2
Insulinsuspensionen dürfen ||| Insulin suspensions should ||| 0-0 0-1 1-1 1-2
Insulinsuspensionen dürfen ||| Insulin suspensions ||| 0-0 0-1 1-1
Insulintherapie ||| insulin therapy ||| 0-0 0-1
Insulintyp oder eine andere ||| type or brand of ||| 0-0 1-1 0-2 2-2 3-2 2-3
Interaktion ||| receptors ||| 0-0
Interaktionen als Folge der Verdrängung ||| interactions resulting from displacement of ||| 0-0 0-1 0-2 1-2 0-3 4-3 2-4 3-4
Interaktionsstudien bestätigt , in denen ||| spezifische Interaktionsstudien bestätigt , in ||| 1-0 1-1 1-2 2-3 3-4
Interaktionsstudien bestätigt , in ||| spezifische Interaktionsstudien bestätigt , in ||| 1-0 1-1 1-2 2-3 3-4
Interaktionsstudien bestätigt , ||| spezifische Interaktionsstudien bestätigt , ||| 1-0 1-1 1-2 2-3
Interaktionsstudien bestätigt ||| spezifische Interaktionsstudien bestätigt ||| 1-0 1-1 1-2
Internationale Einheit ) entspricht ||| International Unit ) corresponds to ||| 0-0 1-1 2-2 1-3 3-3 3-4
Internationale Einheiten ( I.E. ) ||| International Units ( IU ) ||| 0-0 1-1 2-2 3-3 4-4
Internationale Einheiten ( I.E. ) ||| international units ( IU ) ||| 0-0 1-1 2-2 3-3 4-4
Internationale Einheiten ( I.E. ||| International Units ( IU ||| 0-0 1-1 2-2 3-3
Internationale Einheiten ( I.E. ||| international units ( IU ||| 0-0 1-1 2-2 3-3
Internationale Einheiten ( ||| International Units ( ||| 0-0 1-1 2-2
Internationale Einheiten ( ||| international units ( ||| 0-0 1-1 2-2
Internationale Einheiten ||| International Units ||| 0-0 1-1
Internationale Einheiten ||| international units ||| 0-0 1-1
Internationale Einheitt ) entspricht ||| International Unit ) corresponds to ||| 0-0 0-1 1-1 2-2 3-3 3-4
Internationale Einheitt ) ||| International Unit ) ||| 0-0 0-1 1-1 2-2
Internationale Einheitt ||| International Unit ||| 0-0 0-1 1-1
Internationale ||| International ||| 0-0
Internationale ||| international ||| 0-0
Interphase ||| vital ||| 0-0
Intoxikationen mit Aclasta vor . ||| intoxication with Aclasta . ||| 0-0 1-1 2-2 3-2 4-3
Intoxikationen mit Aclasta vor ||| intoxication with Aclasta ||| 0-0 1-1 2-2 3-2
Intoxikationen mit ||| intoxication with ||| 0-0 1-1
Intoxikationen ||| intoxication ||| 0-0
Intravenös verabreichte Zoledronsäure ||| Intravenously administered zoledronic acid ||| 0-0 1-1 2-2 2-3
Intravenös verabreichte ||| Intravenously administered ||| 0-0 1-1
Intravenös ||| Intravenously ||| 0-0
Intravenöse Injektion : ||| Intravenous injection : over ||| 0-0 1-1 2-2 0-3
Inzidenz ( ||| incidence ( ||| 0-0 1-1
Inzidenz von EPS ||| incidence of EPS was ||| 0-0 1-1 2-2 2-3
Inzidenz von EPS ||| incidence of EPS ||| 0-0 1-1 2-2
Inzidenz von ||| incidence of ||| 0-0 1-1
Inzidenz ||| event rate event rate ||| 0-0 0-1 0-2 0-3
Inzidenz ||| incidence of ||| 0-0 0-1
Inzidenz ||| incidence ||| 0-0
Ireland BRISTOL-MYERS SQUIBB PHARMACEUTICALS LTD ||| Ireland BRISTOL-MYERS SQUIBB PHARMACEUTICALS LTD ||| 0-0 1-1 2-2 3-3 4-4
Ireland BRISTOL-MYERS SQUIBB PHARMACEUTICALS ||| Ireland BRISTOL-MYERS SQUIBB PHARMACEUTICALS ||| 0-0 1-1 2-2 3-3
Ireland BRISTOL-MYERS SQUIBB ||| Ireland BRISTOL-MYERS SQUIBB ||| 0-0 1-1 2-2
Ireland BRISTOL-MYERS ||| Ireland BRISTOL-MYERS ||| 0-0 1-1
Ireland Limited Tel : +353 ||| Ireland Limited Tel : +353 ||| 0-0 1-1 2-2 3-3 4-4
Ireland Limited Tel : ||| Ireland Limited Tel : ||| 0-0 1-1 2-2 3-3
Ireland Limited Tel ||| Ireland Limited Tel ||| 0-0 1-1 2-2
Ireland Limited ||| Ireland Limited ||| 0-0 1-1
Ireland Novartis Ireland Limited Tel ||| Ireland Novartis Ireland Limited Tel ||| 0-0 1-1 2-2 3-3 4-4
Ireland Novartis Ireland Limited ||| Ireland Novartis Ireland Limited ||| 0-0 1-1 2-2 3-3
Ireland Novartis Ireland ||| Ireland Novartis Ireland ||| 0-0 1-1 2-2
Ireland Novartis ||| Ireland Novartis ||| 0-0 1-1
Ireland Takeda UK Ltd Tel ||| Ireland Takeda UK Ltd Tel ||| 0-0 1-1 2-2 3-3 4-4
Ireland Takeda UK Ltd ||| Ireland Takeda UK Ltd ||| 0-0 1-1 2-2 3-3
Ireland Takeda UK ||| Ireland Takeda UK ||| 0-0 1-1 2-2
Ireland Takeda ||| Ireland Takeda ||| 0-0 1-1
Ireland ||| Ireland ||| 0-0
Iritis ||| iritis ||| 0-0
Iserlohn , Deutschland ||| Iserlohn , Germany ||| 0-0 1-1 2-2
Iserlohn , ||| Iserlohn , ||| 0-0 1-1
Iserlohn Deutschland ||| Iserlohn Germany ||| 0-0 1-1
Iserlohn ||| Iserlohn ||| 0-0
Isophan- ( NPH- ) Insulin ||| isophane ( NPH ) insulin ||| 0-0 1-1 2-2 3-3 4-4
Isophan- ( NPH- ) ||| isophane ( NPH ) ||| 0-0 1-1 2-2 3-3
Isophan- ( NPH- ||| isophane ( NPH ||| 0-0 1-1 2-2
Isophan- ( ||| isophane ( ||| 0-0 1-1
Isophan- ||| isophane ||| 0-0
Isophan-Insulin . ||| isophane insulin . ||| 0-0 0-1 1-2
Isophan-Insulin 50 % ||| isophane insulin 50 % ||| 0-0 0-1 1-2 2-3
Isophan-Insulin 50 ||| isophane insulin 50 ||| 0-0 0-1 1-2
Isophan-Insulin 60 % Actraphane ||| isophane insulin 60 % Actraphane ||| 0-0 0-1 1-2 2-3 3-4
Isophan-Insulin 60 % ||| isophane insulin 60 % ||| 0-0 0-1 1-2 2-3
Isophan-Insulin 60 ||| isophane insulin 60 ||| 0-0 0-1 1-2
Isophan-Insulin 70 % Actraphane ||| isophane insulin 70 % Actraphane ||| 0-0 0-1 1-2 2-3 3-4
Isophan-Insulin 70 % ||| isophane insulin 70 % ||| 0-0 0-1 1-2 2-3
Isophan-Insulin 70 ||| isophane insulin 70 ||| 0-0 0-1 1-2
Isophan-Insulin 80 % Actraphane ||| isophane insulin 80 % Actraphane ||| 0-0 0-1 1-2 2-3 3-4
Isophan-Insulin 80 % ||| isophane insulin 80 % ||| 0-0 0-1 1-2 2-3
Isophan-Insulin 80 ||| isophane insulin 80 ||| 0-0 0-1 1-2
Isophan-Insulin 90 % Actraphane ||| isophane insulin 90 % Actraphane ||| 0-0 0-1 1-2 2-3 3-4
Isophan-Insulin 90 % ||| isophane insulin 90 % ||| 0-0 0-1 1-2 2-3
Isophan-Insulin 90 ||| isophane insulin 90 ||| 0-0 0-1 1-2
Isophan-Insulin ||| isophane insulin ||| 0-0 0-1
Ist der Blutdruck ||| If blood pressure ||| 0-0 1-1 2-1 2-2
Ist ||| If ||| 0-0
Italia Farmaceutici SpA Tel : ||| Italia Farmaceutici SpA Tel : ||| 0-0 1-1 2-2 3-3 4-4
Italia Farmaceutici SpA Tel ||| Italia Farmaceutici SpA Tel ||| 0-0 1-1 2-2 3-3
Italia Farmaceutici SpA ||| Italia Farmaceutici SpA ||| 0-0 1-1 2-2
Italia Farmaceutici ||| Italia Farmaceutici ||| 0-0 1-1
Italia Takeda Italia Farmaceutici SpA ||| Italia Takeda Italia Farmaceutici SpA ||| 0-0 1-1 2-2 3-3 4-4
Italia Takeda Italia Farmaceutici ||| Italia Takeda Italia Farmaceutici ||| 0-0 1-1 2-2 3-3
Italia Takeda Italia ||| Italia Takeda Italia ||| 0-0 1-1 2-2
Italia Takeda ||| Italia Takeda ||| 0-0 1-1
Italia ||| Italia ||| 0-0
Italien ||| Italy ||| 0-0
JEDE TIERART , ART ||| EACH SPECIES , ROUTE(S ) ||| 0-0 1-1 2-2 3-3 3-4
JEDE TIERART , ||| EACH SPECIES , ||| 0-0 1-1 2-2
JEDE TIERART ||| EACH SPECIES ||| 0-0 1-1
JEDE ||| EACH ||| 0-0
Jahr ) beobachtet ||| Jahr ) beobachtet ||| 0-0 1-1 2-2
Jahr ) ||| Jahr ) ||| 0-0 1-1
Jahr 0-1 ) ||| 0 1 year ) ||| 1-0 1-1 0-2 2-3
Jahr 0-1 ||| 0 1 year ||| 1-0 1-1 0-2
Jahr 0-2 ) ||| 0 2 year ) ||| 0-0 1-1 0-2 1-2 2-3
Jahr 0-2 ||| 0 2 year ||| 0-0 1-1 0-2 1-2
Jahr 5 % und 10 ||| Jahr 5 % und 10 ||| 0-0 1-1 2-2 3-3 4-4
Jahr 5 % und ||| Jahr 5 % und ||| 0-0 1-1 2-2 3-3
Jahr 5 % ||| Jahr 5 % ||| 0-0 1-1 2-2
Jahr 5 ||| Jahr 5 ||| 0-0 1-1
Jahr nach der ||| year after ||| 0-0 1-1
Jahr nach ||| year after ||| 0-0 1-1
Jahr oder länger an . ||| year or more . ||| 0-0 1-1 2-2 3-2 4-3
Jahr oder länger an ||| year or more ||| 0-0 1-1 2-2 3-2
Jahr oder länger benötigen . ||| year or longer . ||| 0-0 1-1 2-2 3-2 4-3
Jahr oder länger benötigen ||| year or longer ||| 0-0 1-1 2-2 3-2
Jahr oder ||| year or ||| 0-0 1-1
Jahr untersucht ||| treatment ||| 1-0
Jahr ||| Jahr ||| 0-0
Jahr ||| year ||| 0-0
Jahre ) Eine Dosisanpassung ||| years ) No dose adjustment ||| 0-0 1-1 2-2 3-2 3-3 3-4
Jahre ) ||| years ) of ||| 0-0 1-1
Jahre ) ||| years ) ||| 0-0 1-1
Jahre . ||| years . ||| 0-0 1-1
Jahre Haltbarkeit nach erstmaligem Öffnen ||| years Shelf-life after first opening ||| 0-0 1-1 2-2 3-3 3-4 4-4
Jahre Haltbarkeit nach ||| years Shelf-life after ||| 0-0 1-1 2-2
Jahre Haltbarkeit ||| years Shelf-life ||| 0-0 1-1
Jahre haben die Aufrechterhaltung dieser ||| have shown maintenance of this ||| 1-0 0-1 3-1 3-2 2-3 4-3 4-4
Jahre mit ||| years of age ||| 0-0 1-1 0-2
Jahre und Orientalen/Asiaten ist ||| years and ||| 0-0 2-0 1-1
Jahre und Orientalen/Asiaten ||| years and ||| 0-0 2-0 1-1
Jahre und darüber ) Aclasta ||| years and over ) Aclasta ||| 0-0 1-1 0-2 3-3 4-4
Jahre und darüber ) ||| years and over ) ||| 0-0 1-1 0-2 3-3
Jahre und darüber ||| years and over ||| 0-0 1-1 0-2
Jahre und ||| years and over ||| 0-0 1-1 0-2
Jahre ||| years of ||| 0-0
Jahre ||| years ||| 0-0
Jahren ; die durchschnittliche Dauer ||| years ; the average duration ||| 0-0 1-1 2-2 3-3 4-4
Jahren ; die durchschnittliche ||| years ; the average ||| 0-0 1-1 2-2 3-3
Jahren ; die ||| years ; the ||| 0-0 1-1 2-2
Jahren ; ||| years ; ||| 0-0 1-1
Jahren untersucht . ||| years . ||| 0-0 1-0 2-1
Jahren untersucht ||| years ||| 0-0 1-0
Jahren ||| age ||| 0-0
Jahren ||| aged ||| 0-0
Jahren ||| years of age due ||| 0-0 0-2
Jahren ||| years of age ||| 0-0 0-2
Jahren ||| years ||| 0-0
Jahres ||| year ||| 0-0
Januar ||| information or procedural aspects please ||| 0-0 0-2 0-3 0-4
Japanern . Arz ||| Japanese subjects . ||| 0-0 2-0 0-1 1-2
Je nachdem , wie Ihre ||| Depending on how your ||| 0-0 1-0 0-1 3-2 4-3
Je nachdem , wie ||| Depending on how ||| 0-0 1-0 0-1 3-2
Je nachdem , ||| Depending on ||| 0-0 1-0 0-1
Je nachdem ||| Depending on ||| 0-0 1-0 0-1
Jede Flasche mit 100 ml ||| Each bottle with 100 ml ||| 0-0 1-1 2-2 3-3 4-4
Jede Flasche mit 100 ||| Each bottle with 100 ||| 0-0 1-1 2-2 3-3
Jede Flasche mit ||| Each bottle with ||| 0-0 1-1 2-2
Jede Flasche ||| Each bottle ||| 0-0 1-1
Jede Packung enthält 1 Flasche ||| Each carton contains 1 bottle ||| 0-0 1-1 2-2 3-3 4-4
Jede Packung enthält 1 ||| Each carton contains 1 ||| 0-0 1-1 2-2 3-3
Jede Packung enthält eine Einzeldosis ||| Each carton contains one single-use ||| 0-0 1-1 2-2 3-3 4-3 4-4
Jede Packung enthält ||| Each carton contains ||| 0-0 1-1 2-2
Jede Packung ||| Each carton ||| 0-0 1-1
Jede Schmelztablette enthält 10 ||| Each orodispersible tablet contains 10 ||| 0-0 1-1 1-2 2-3 3-4
Jede Schmelztablette enthält 15 ||| Each orodispersible tablet contains 15 ||| 0-0 1-1 1-2 2-3 3-4
Jede Schmelztablette enthält 30 ||| Each orodispersible tablet contains 30 ||| 0-0 1-1 1-2 2-3 3-4
Jede Schmelztablette enthält ||| Each orodispersible tablet contains ||| 0-0 1-1 1-2 2-3
Jede Schmelztablette ||| Each orodispersible tablet ||| 0-0 1-1 1-2
Jede ||| At ||| 0-0
Jede ||| Each ||| 0-0
Jede Änderung hinsichtlich Stärke , ||| Changes in strength , ||| 0-0 1-0 2-1 2-2 3-2 4-3
Jede Änderung hinsichtlich Stärke ||| Changes in strength ||| 0-0 1-0 2-1 2-2 3-2
Jede Änderung ||| Changes ||| 0-0 1-0
Jeder ml ABILIFY ||| Each ml of ABILIFY ||| 0-0 1-1 0-2 2-3
Jeder ml Lösung enthält ||| Each ml of solution contains ||| 0-0 1-1 0-2 2-3 3-4
Jeder ml Lösung ||| Each ml of solution ||| 0-0 1-1 0-2 2-3
Jeder ml ||| Each ml of ||| 0-0 1-1 0-2
Jedoch wurden auch Erhöhungen ||| However , elevated creatine ||| 0-0 1-1 1-2 2-2 3-2 3-3
Jedoch ||| However ||| 0-0
Jucken ||| itching ||| 0-0
Juckreiz , Nesselsucht , Schwellungen ||| itching , hives , swelling ||| 0-0 1-1 2-2 3-3 4-4
Juckreiz , Nesselsucht , ||| itching , hives , ||| 0-0 1-1 2-2 3-3
Juckreiz , Nesselsucht ||| itching , hives ||| 0-0 1-1 2-2
Juckreiz , ||| itching , ||| 0-0 1-1
Juckreiz in den ||| pruritus ||| 0-0
Juckreiz in ||| pruritus ||| 0-0
Juckreiz ||| itching ||| 0-0
Juckreiz ||| pruritus ||| 0-0
Jugendlichen ist nicht untersucht worden ||| adolescents has not been studied ||| 0-0 0-1 1-1 2-2 4-3 3-4
Jugendlichen ist nicht ||| adolescents has not ||| 0-0 0-1 1-1 2-2
Jugendlichen ist ||| adolescents has ||| 0-0 0-1 1-1
Jugendlichen unter ||| adolescents under ||| 0-0 0-1 1-1
Juli 2007 ||| 2007 ||| 1-0
Juli 2007 ||| July 2007 ||| 1-1
Juni 2006 erteilte ||| European ||| 0-0 1-0 2-0
KENNZEICHNUNG UND ||| achieved during the Coordination group ||| 0-0 0-1 0-2 0-3 1-3 0-4
KG , Kuhloweg 37 , ||| KG , Kuhloweg 37 , ||| 0-0 1-1 2-2 3-3 4-4
KG , Kuhloweg 37 ||| KG , Kuhloweg 37 ||| 0-0 1-1 2-2 3-3
KG , Kuhloweg ||| KG , Kuhloweg ||| 0-0 1-1 2-2
KG , ||| KG , ||| 0-0 1-1
KG Kuhloweg 37 D-58638 Iserlohn ||| KG Kuhloweg 37 D-58638 Iserlohn ||| 0-0 1-1 2-2 3-3 4-4
KG Kuhloweg 37 D-58638 Iserlohn ||| KG Kuhloweg 37 D-58638 ||| 0-0 1-1 2-2 3-3 4-3
KG Kuhloweg 37 D-58638 ||| KG Kuhloweg 37 D-58638 ||| 0-0 1-1 2-2 3-3
KG Kuhloweg 37 ||| KG Kuhloweg 37 ||| 0-0 1-1 2-2
KG Kuhloweg ||| KG Kuhloweg ||| 0-0 1-1
KG ||| KG ||| 0-0
KINDERN ||| AND SIGHT ||| 0-0 0-1
KINDERWARNHINWEIS " AUSSER REICH- ||| THE WORDS KEEP OUT OF ||| 0-0 0-1 1-1 2-2 3-2 3-3 3-4
KINDERWARNHINWEIS " ||| THE WORDS ||| 0-0 0-1 1-1
KLEINEN BEHÄLTNISSEN ||| SMALL IMMEDIATE PACKAGING UNITS ||| 0-0 0-1 1-2 1-3
KLEINEN PRIMÄRVERPACKUNGEN ||| SMALL IMMEDIATE PACKAGING UNITS ||| 0-0 0-1 0-2 1-3
KLEINEN ||| SMALL IMMEDIATE PACKAGING ||| 0-0 0-1 0-2
KLEINEN ||| SMALL IMMEDIATE ||| 0-0 0-1
KOMBINATIONSTHERAPIE MIT EINEM SULFONYLHARNSTOFF ||| SULPHONYLUREA Ear and labyrinth disorders ||| 0-0 1-1 2-1 1-2 2-3 3-3 3-4
KOMBINATIONSTHERAPIE MIT INSULIN ||| INSULIN Metabolism and nutrition disorders ||| 0-0 0-1 1-2 1-3 2-3 2-4
KOMBINATIONSTHERAPIE MIT METFORMIN ||| Blood and lymphatic system disorders ||| 0-0 1-1 1-2 2-2 2-3 2-4
KOMBINATIONSTHERAPIE ||| Blood ||| 0-0
KOMBINATIONSTHERAPIE ||| INSULIN Metabolism ||| 0-0 0-1
KOMBINATIONSTHERAPIE ||| SULPHONYLUREA ||| 0-0
KOMPLETTE ZUSAMMENFASSUNG ||| OVERALL SUMMARY ||| 0-0 0-1 1-1
Kalium im gewünschten ||| potassium in ||| 0-0 1-0 2-0 1-1
Kaliumspiegel ( ||| ( hyperkalaemia ||| 1-0 0-1
Kaliumspiegel ||| hyperkalaemia ||| 0-0
Kaliumspiegeln ||| potassium level ||| 0-0
Kaliumspiegeln ||| potassium ||| 0-0
Kaliumwerte zu unterbrechen ||| until hyperkalaemia has been corrected ||| 0-0 0-1 1-1 0-2 0-3 2-4
Kaliumwerte zu ||| until hyperkalaemia has been ||| 0-0 0-1 1-1 0-2 0-3
Kalzium und ||| calcium and ||| 0-0 1-1
Kalzium zweimal täglich für ||| calcium twice a day for ||| 0-0 1-1 2-1 2-2 2-3 3-4
Kalzium zweimal täglich ||| calcium twice a day ||| 0-0 1-1 2-1 2-2 2-3
Kalzium ||| calcium ||| 0-0
Kalzium- Spiegels ||| hypocalcaemia ||| 0-0 1-0
Kalzium- Spiegels ||| with hypocalcaemia ||| 0-1 1-1
Kalzium- ||| supplements ||| 0-0
Kalzium-Malabsorption ) . ||| malabsorption ) . ||| 0-0 1-1 2-2
Kalzium-Malabsorption ) ||| malabsorption ) ||| 0-0 1-1
Kalzium-Malabsorption ||| malabsorption ||| 0-0
Kalzium-Spiegel ||| calcium ||| 0-0
Kalzium-Spiegel ||| of calcium ||| 0-1
Kalzium-Tabletten einnehmen können . ||| take daily calcium supplements . ||| 1-0 0-1 0-2 0-3 1-3 2-3 3-4
Kalzium-Tabletten einnehmen können ||| take daily calcium supplements ||| 1-0 0-1 0-2 0-3 1-3 2-3
Kalzium-haltigen Lösungen in ||| come into ||| 0-0 1-0 0-1 2-1
Kaninchen mit Dosierungen ||| ( anencephaly ||| 0-1 2-1
Kaninchen mit Dosierungen ||| anencephaly ||| 0-0 2-0
Kaninchen ||| exposures ||| 0-0
Kanzerogenität ||| and carcinogenicity ||| 0-1
Kanzerogenität ||| carcinogenicity ||| 0-0
Kanzerogenitätstests ergaben keinen ||| testing did not ||| 0-0 1-0 2-1 2-2
Kanzerogenitätstests ergaben ||| testing ||| 0-0 1-0
Kaukasier und 9 % ||| Caucasian and 9 % ||| 0-0 2-0 1-1 2-2 3-3
Kaukasier und 9 ||| Caucasian and 9 ||| 0-0 2-0 1-1 2-2
Keine ||| This medicinal product ||| 0-0 0-1 0-2
Kekse ||| sugar lumps ||| 0-0 0-1
Keratokonjunktivitis sicca , Madarosis ||| keratoconjunctivitis sicca , madarosis ||| 0-0 1-1 2-2 3-3
Keratokonjunktivitis sicca , ||| keratoconjunctivitis sicca , ||| 0-0 1-1 2-2
Keratokonjunktivitis sicca ||| keratoconjunctivitis sicca ||| 0-0 1-1
Keratokonjunktivitis ||| keratoconjunctivitis ||| 0-0
Ketoazidose ( ||| , ketoacidosis ( ||| 0-1 1-2
Ketoazidose ( ||| ketoacidosis ( ||| 0-0 1-1
Ketoazidose , diabetisches hyperosmolares Koma ||| ketoacidosis , diabetic hyperosmolar coma ||| 0-0 1-1 2-2 2-3 3-3 4-4
Ketoazidose , diabetisches hyperosmolares ||| ketoacidosis , diabetic hyperosmolar ||| 0-0 1-1 2-2 2-3 3-3
Ketoazidose , ||| ketoacidosis , ||| 0-0 1-1
Ketoazidose oder hyperosmolarem Koma oder ||| ketoacidosis or hyperosmolar coma or ||| 0-0 1-1 2-2 3-3 4-4
Ketoazidose oder hyperosmolarem Koma ||| ketoacidosis or hyperosmolar coma ||| 0-0 1-1 2-2 3-3
Ketoazidose oder hyperosmolarem ||| ketoacidosis or hyperosmolar ||| 0-0 1-1 2-2
Ketoazidose oder ||| ketoacidosis or ||| 0-0 1-1
Ketoazidose ||| , ketoacidosis ||| 0-1
Ketoazidose ||| ketoacidosis ||| 0-0
Ketoconazol ) ||| ketoconazole ) ||| 0-0 1-1
Ketoconazol oder anderen ||| ketoconazole or other ||| 0-0 1-1 2-2
Ketoconazol oder ||| ketoconazole or ||| 0-0 1-1
Ketoconazol ||| ketoconazole ||| 0-0
Ketonspiegel Säurespiegel ||| acids ||| 0-0 1-0
Kiefer wurden vor allem ||| jaw have ||| 0-0 3-0 1-1 2-1
Kilogramm . ||| kilogram . ||| 0-0 1-1
Kilogramm . ||| kilograms . ||| 0-0 1-1
Kilogramm Körpergewicht . ||| kilogram bodyweight . ||| 0-0 0-1 1-1 2-2
Kilogramm Körpergewicht ||| kilogram bodyweight ||| 0-0 0-1 1-1
Kilogramm dreimal wöchentlich nicht ||| kilogram , three times a ||| 0-0 1-2 1-3 2-3 3-3 2-4
Kilogramm ||| kilogram , ||| 0-0
Kilogramm ||| kilogram ||| 0-0
Kilogramm ||| kilograms ||| 0-0
Kilruddery , ||| Irland.Lilly S.A. , ||| 0-0 0-1 1-2
Kilruddery ||| Irland.Lilly S.A. ||| 0-0 0-1
Kilruddey , County Wicklow . ||| Kilruddery , County Wicklow . ||| 0-0 1-1 2-2 3-3 4-4
Kilruddey , County Wicklow ||| Kilruddery , County Wicklow ||| 0-0 1-1 2-2 3-3
Kilruddey , County ||| Kilruddery , County ||| 0-0 1-1 2-2
Kilruddey , ||| Kilruddery , ||| 0-0 1-1
Kilruddey ||| Kilruddery ||| 0-0
Kind dar . ||| to the baby . ||| 0-0 0-1 0-2 1-2 2-3
Kind dar ||| to the baby ||| 0-0 0-1 0-2 1-2
Kind ||| child ||| 0-0
Kinder und Jugendliche Aclasta wird ||| Children and adolescents Aclasta is ||| 0-0 2-0 1-1 2-2 3-3 4-4
Kinder und Jugendliche Aclasta ||| Children and adolescents Aclasta ||| 0-0 2-0 1-1 2-2 3-3
Kinder und Jugendliche ||| Children and adolescents ||| 0-0 2-0 1-1 2-2
Kinder unter 30 kg ||| children under 30 kg ||| 0-0 1-1 2-2 3-3
Kinder unter 30 ||| children under 30 ||| 0-0 1-1 2-2
Kinder unter ||| children under ||| 0-0 1-1
Kinder unzugänglich aufbewahren ||| reach and sight of children ||| 0-0 1-1 1-2 2-3 2-4
Kinder unzugänglich ||| reach and sight ||| 0-0 1-1 1-2
Kinder unzugänglich ||| the reach and sight ||| 0-0 0-1 1-2 1-3
Kinder ||| anyone ||| 0-0
Kinder ||| children ||| 0-0
Kinder ||| reach ||| 0-0
Kinder ||| the reach ||| 0-0 0-1
Kinder über 30 kg und ||| children over 30 kg and ||| 0-0 1-1 2-2 3-3 4-4
Kinder über 30 kg ||| children over 30 kg ||| 0-0 1-1 2-2 3-3
Kinder über 30 ||| children over 30 ||| 0-0 1-1 2-2
Kinder über ||| children over ||| 0-0 1-1
Kindern , die ||| children ||| 0-0
Kindern , ||| children ||| 0-0
Kindern aufbewahren . ||| children . ||| 0-0 1-0 2-1
Kindern aufbewahren ||| children ||| 0-0 1-0
Kindern und Erwachsenen . ||| adult and paediatric patients : ||| 2-0 1-1 0-2 2-2 2-3 2-4 3-4
Kindern und Erwachsenen unter ||| paediatric and adult patients on ||| 0-0 1-1 2-2 2-3 3-4
Kindern und Erwachsenen ||| adult and paediatric ||| 2-0 1-1 0-2 2-2
Kindern und Erwachsenen ||| paediatric and adult patients ||| 0-0 1-1 2-2 2-3
Kindern und Jugendlichen ist nicht ||| children and adolescents has not ||| 0-0 1-1 2-2 2-3 3-3 4-4
Kindern und Jugendlichen ist ||| children and adolescents has ||| 0-0 1-1 2-2 2-3 3-3
Kindern und Jugendlichen unter ||| children and adolescents under ||| 0-0 1-1 2-2 2-3 3-3
Kindern und ||| children and ||| 0-0 1-1
Kindern und ||| paediatric and ||| 0-0 1-1
Kindern unter 18 Jahren ||| children below age 18 years ||| 0-0 1-1 3-2 2-3 3-4
Kindern unter ||| children below ||| 0-0 1-1
Kindern ||| children ||| 0-0
Kindern ||| in children ||| 0-0 0-1
Kindern ||| paediatric ||| 0-0
Kingdom BRISTOL-MYERS SQUIBB PHARMACEUTICALS LTD ||| Kingdom BRISTOL-MYERS SQUIBB PHARMACEUTICALS LTD ||| 0-0 1-1 2-2 3-3 4-4
Kingdom BRISTOL-MYERS SQUIBB PHARMACEUTICALS ||| Kingdom BRISTOL-MYERS SQUIBB PHARMACEUTICALS ||| 0-0 1-1 2-2 3-3
Kingdom BRISTOL-MYERS SQUIBB ||| Kingdom BRISTOL-MYERS SQUIBB ||| 0-0 1-1 2-2
Kingdom BRISTOL-MYERS ||| Kingdom BRISTOL-MYERS ||| 0-0 1-1
Kingdom Takeda UK Ltd Tel ||| Kingdom Takeda UK Ltd Tel ||| 0-0 1-1 2-2 3-3 4-4
Kingdom Takeda UK Ltd ||| Kingdom Takeda UK Ltd ||| 0-0 1-1 2-2 3-3
Kingdom Takeda UK ||| Kingdom Takeda UK ||| 0-0 1-1 2-2
Kingdom Takeda ||| Kingdom Takeda ||| 0-0 1-1
Kingdom ||| Kingdom ||| 0-0
Klare , farblose , wässrige ||| Clear , colourless , aqueous ||| 0-0 1-1 2-2 3-3 4-4
Klare , farblose , ||| Clear , colourless , ||| 0-0 1-1 2-2 3-3
Klare , farblose ||| Clear , colourless ||| 0-0 1-1 2-2
Klare , ||| Clear , ||| 0-0 1-1
Klare ||| Clear ||| 0-0
Klasse ||| class differs ||| 0-0 0-1
Klasse ||| liver cirrhosis ||| 0-0 0-1
Klasse ||| of liver cirrhosis ||| 0-1 0-2
Klinische Manifestationen ||| Clinical manifestations ||| 0-0 1-0 1-1
Klinische Studien über zwei ||| Two-year clinical studies ||| 0-0 2-0 1-1 1-2 3-2
Klinische Wirksamkeit bei Männern In ||| Clinical efficacy in men In ||| 0-0 1-1 2-2 3-3 4-4
Klinische Wirksamkeit bei Männern ||| Clinical efficacy in men ||| 0-0 1-1 2-2 3-3
Klinische Wirksamkeit bei der Behandlung ||| Clinical efficacy in the treatment ||| 0-0 1-1 2-2 3-3 4-4
Klinische Wirksamkeit bei der ||| Clinical efficacy in the ||| 0-0 1-1 2-2 3-3
Klinische Wirksamkeit bei ||| Clinical efficacy in ||| 0-0 1-1 2-2
Klinische Wirksamkeit ||| Clinical efficacy ||| 0-0 1-1
Klinische ||| 3.0 , 5.8 ||| 0-0 0-1 0-2
Klinische ||| Clinical ||| 0-0
Km 22 , 67019 Scoppito ||| Km 22 , 67019 Scoppito ||| 0-0 1-1 2-2 3-3 4-4
Km 22 , 67019 ||| Km 22 , 67019 ||| 0-0 1-1 2-2 3-3
Km 22 , ||| Km 22 , ||| 0-0 1-1 2-2
Km 22 ||| Km 22 ||| 0-0 1-1
Km ||| Km ||| 0-0
Knochen . ||| bone . ||| 0-0 1-1
Knochen geschwächt hat ||| has made their bones weaker ||| 2-0 1-1 1-2 0-3 1-3 1-4
Knochen geschwächt ||| made their bones weaker ||| 1-0 1-1 0-2 1-2 1-3
Knochen spröde macht ) ||| makes bones fragile ) ||| 0-0 0-1 0-2 1-2 3-3
Knochen spröde macht ||| makes bones fragile ||| 0-0 0-1 0-2 1-2
Knochen spröde ||| makes bones fragile ||| 0-0 0-1 0-2 1-2
Knochen und verringert deshalb ||| bone and therefore makes it ||| 0-0 1-1 2-2 3-2 0-3
Knochen und verringert deshalb ||| bone and therefore makes ||| 0-0 1-1 2-2 3-2 0-3
Knochen und ||| bone and ||| 0-0 1-1
Knochen ||| bone ||| 0-0
Knochen ||| bones ||| 0-0
Knochenbrüchen . ||| break . ||| 0-0 1-1
Knochenbrüchen ||| break ||| 0-0
Knochengewebe ) ||| bone tissue ) ||| 0-0 0-1 1-2
Knochengewebe ||| bone tissue ||| 0-0 0-1
Knochengewebes kennzeichnend . ||| bone . ||| 0-0 1-0 2-1
Knochengewebes kennzeichnend ||| bone ||| 0-0 1-0
Knochenmarkdepression ||| are bone ||| 0-1
Knochenmarkdepression ||| bone ||| 0-0
Knochenmarkfibrose jeglicher ||| bone marrow fibrosis of ||| 0-0 0-1 1-2 1-3
Knochenmarkfibrose ||| bone marrow ||| 0-0 0-1
Knochenmarksfibrose oder Geflechtknochenbildung ||| or woven bone formation ||| 1-0 0-1 2-1 0-2 2-3
Knochenmarksuppression ( insbesondere ||| Bone marrow suppression ( ||| 0-0 0-1 0-2 2-2 1-3
Knochenmarkszellen ||| bone marrow cells ||| 0-0 0-1 0-2
Knochenmineraldichte ( BMD ) ||| mineral density ( BMD ) ||| 1-0 0-1 1-2 2-3 3-4
Knochenmineraldichte ( BMD ||| mineral density ( BMD ||| 1-0 0-1 1-2 2-3
Knochenmineraldichte ( ||| mineral density ( ||| 1-0 0-1 1-2
Knochenmineraldichte ||| density ||| 0-0
Knochenresorption . ||| bone resorption . ||| 0-0 0-1 1-2
Knochenresorption ||| bone resorption ||| 0-0 0-1
Knochens . ||| bone . ||| 0-0 1-1
Knochens Aclasta wurde ||| bone Aclasta was ||| 0-0 1-1 2-2
Knochens Aclasta ||| bone Aclasta ||| 0-0 1-1
Knochens Normalerweise ||| bone ||| 0-0 1-0
Knochens eingesetzt . ||| bone . ||| 0-0 1-0 2-1
Knochens eingesetzt ||| bone ||| 0-0 1-0
Knochens ||| bone ||| 0-0
Knochenstoffwechsels müssen ebenfalls ||| mineral metabolism must also ||| 0-0 0-1 1-2 2-3
Knochenstoffwechsels müssen ||| mineral metabolism must ||| 0-0 0-1 1-2
Knochenstoffwechsels ||| mineral metabolism ||| 0-0 0-1
Knochensubstanz ||| bone ||| 0-0
Knochensubstanz ||| of bone ||| 0-1
Knochenumbau ||| bone remodelling process ||| 0-0 0-1
Knochenumbau ||| bone remodelling ||| 0-0 0-1
Knochenumbaumarker . ||| turnover markers . ||| 0-0 0-1 1-2
Knochenumbaumarker ||| turnover markers ||| 0-0 0-1
Knochenumbaumarkern auf . ||| repeated annual dosing . ||| 0-0 0-1 0-2 2-3
Knochenumbaumarkern auf ||| repeated annual dosing ||| 0-0 0-1 0-2
Knochenumbaumarkern ||| repeated annual dosing ||| 0-0 0-1 0-2
Knochenumbaurate ||| bone turnover ||| 0-0 0-1
Knochenumbaurate ||| of bone turnover ||| 0-1 0-2
Knochenwachstums ||| changed ||| 0-0
Kohlenhydratketten sind ||| carbohydrate chains are ||| 0-0 0-1 1-2
Kohlenhydratketten ||| carbohydrate chains ||| 0-0 0-1
Kolben ||| plunger ||| 0-0
Koma oder Tod ||| coma or death ||| 0-0 1-1 2-2
Koma oder ||| coma or ||| 0-0 1-1
Koma ||| coma , ||| 0-0
Koma ||| coma ||| 0-0
Kombination einer ||| a combination of ||| 1-0 0-1
Kombination einer ||| a combination ||| 1-0 0-1
Kombination mit Insulin ||| combination with insulin , ||| 0-0 1-1 2-2
Kombination mit Insulin ||| combination with insulin ||| 0-0 1-1 2-2
Kombination mit Metformin und/oder ||| combination with metformin and/ or ||| 0-0 1-1 2-2 3-3 3-4
Kombination mit Metformin ||| combination with metformin ||| 0-0 1-1 2-2
Kombination mit Sulfonylharnstoffen oder ||| combination with sulphonylureas or ||| 0-0 1-1 2-2 3-3
Kombination mit Sulfonylharnstoffen ||| combination with sulphonylureas ||| 0-0 1-1 2-2
Kombination mit einem Sulfonylharnstoff ||| combination with a sulphonylurea ||| 0-0 1-1 2-2 2-3 3-3
Kombination mit ||| combination with ||| 0-0 1-1
Kombination von Actos und Insulin ||| combination of Actos and insulin ||| 0-0 1-1 2-2 3-3 4-4
Kombination von Actos und ||| combination of Actos and ||| 0-0 1-1 2-2 3-3
Kombination von Actos ||| combination of Actos ||| 0-0 1-1 2-2
Kombination von Metformin ||| combination of metformin and ||| 0-0 1-1 2-2
Kombination von Metformin ||| combination of metformin ||| 0-0 1-1 2-2
Kombination von ||| combination of ||| 0-0 1-1
Kombination ||| , combination of ||| 0-1
Kombination ||| , combination ||| 0-1
Kombination ||| combination of ||| 0-0
Kombination ||| combination ||| 0-0
Kombinationsstudien ||| combination ||| 0-0
Kombinationstherapie ( siehe Abschnitt ||| combination therapy ( see section ||| 0-0 0-1 1-2 2-3 3-4
Kombinationstherapie ( siehe ||| combination therapy ( see ||| 0-0 0-1 1-2 2-3
Kombinationstherapie ( ||| combination therapy ( ||| 0-0 0-1 1-2
Kombinationstherapie ||| combination therapy ||| 0-0 0-1
Kommission dem Unternehmen ||| authorisation valid throughout the European ||| 0-0 0-1 1-1 2-1 0-2 1-3 2-4
Komplikationen ||| complications ||| 0-0
Konjunktivitis , Augenschmerz Uveitis ||| Conjunctivitis , eye pain Uveitis ||| 0-0 1-1 2-2 3-3 3-4
Konjunktivitis , Augenschmerz ||| Conjunctivitis , eye ||| 0-0 1-1 2-2
Konjunktivitis , ||| Conjunctivitis , ||| 0-0 1-1
Konjunktivitis ||| Conjunctivitis ||| 0-0
Kontakt mit ||| contacts ||| 0-0 1-0
Kontrazeptiva , Thiazide , Glucokortikoide ||| contraeptives , thiazides , glucocorticoids ||| 0-0 1-1 2-2 3-3 4-4
Kontrazeptiva , Thiazide , ||| contraeptives , thiazides , ||| 0-0 1-1 2-2 3-3
Kontrazeptiva , Thiazide ||| contraeptives , thiazides ||| 0-0 1-1 2-2
Kontrazeptiva , ||| contraeptives , ||| 0-0 1-1
Kontrazeptiva ||| contraeptives ||| 0-0
Kontrazeptivums mit einer ng Ethinylestradiol/Levonorgestrel-Kombination ||| Kontrazeptivums mit einer ng Ethinylestradiol/Levonorgestrel-Kombination ||| 0-0 1-1 2-2 3-3 4-4
Kontrazeptivums mit einer ng ||| Kontrazeptivums mit einer ng ||| 0-0 1-1 2-2 3-3
Kontrazeptivums mit einer ||| Kontrazeptivums mit einer ||| 0-0 1-1 2-2
Kontrazeptivums mit ||| Kontrazeptivums mit ||| 0-0 1-1
Kontrazeptivums ||| Kontrazeptivums ||| 0-0
Kontrolle . ||| control . ||| 0-0 1-1
Kontrolle einer normalen Leberfunktion ||| your liver is working normally ||| 0-0 0-1 1-1 2-1 2-2 2-3 3-3 3-4
Kontrolle ist . ||| is controlled . ||| 1-0 0-1 2-2
Kontrolle ist ||| is controlled ||| 1-0 0-1
Kontrolle von gesteigerter Unruhe und ||| control of agitation and ||| 0-0 1-1 2-2 3-2 4-3
Kontrolle von gesteigerter Unruhe ||| control of agitation ||| 0-0 1-1 2-2 3-2
Kontrolle von ||| control of ||| 0-0 1-1
Kontrolle ||| control ||| 0-0
Kontrolle ||| controlled ||| 0-0
Kontrollen ( 95%-Konfidenzintervall ||| controls ( 95 % CI ||| 0-0 1-1 2-2 2-3 2-4
Kontrollen ( ||| controls ( ||| 0-0 1-1
Kontrollen . ||| controls . ||| 0-0 1-1
Kontrollen ||| controls ||| 0-0
Kontrollieren Sie Ihr ||| Your ||| 0-0 1-0 2-0
Kontrollierte klinische Studien haben keinen ||| Controlled clinical trials have not ||| 0-0 1-0 4-0 1-1 2-2 3-3 4-4
Konventionelle Arten von Paclitaxel enthalten ||| Conventional types of paclitaxel contain ||| 0-0 1-1 2-2 3-3 4-4
Konventionelle Arten von Paclitaxel ||| Conventional types of paclitaxel ||| 0-0 1-1 2-2 3-3
Konventionelle Arten von ||| Conventional types of ||| 0-0 1-1 2-2
Konventionelle Arten ||| Conventional types ||| 0-0 1-1
Konventionelle ||| Conventional ||| 0-0
Konvulsionen wurden im ||| observed in ||| 0-0 1-0 2-1
Konvulsionen wurden ||| observed ||| 0-0 1-0
Konvulsionen ||| convulsions ||| 0-0
Konzentration ( ||| ( ||| 0-0 1-0
Konzentration . ||| . ||| 1-0
Konzentration einer Substanz ||| level of a substance ||| 0-0 1-1 2-1 1-2
Konzentration einer Substanz ||| level of a ||| 0-0 1-1 2-1 1-2
Konzentration und Proteinbindung ||| concentrations and protein binding ||| 0-0 1-1 2-2 2-3
Konzentration und ||| concentrations and ||| 0-0 1-1
Konzentration ||| concentration ||| 0-0
Konzentration ||| concentrations ||| 0-0
Konzentration ||| level ||| 0-0
Konzentrationen wird Aripiprazol und ||| concentrations , aripiprazole and ||| 0-0 1-0 2-2 3-3
Konzentrationen wird Aripiprazol ||| concentrations , aripiprazole ||| 0-0 1-0 2-2
Konzentrationen wird ||| concentrations , ||| 0-0 1-0
Konzentrationen wird ||| concentrations ||| 0-0 1-0
Kopfschmerz ||| headache ||| 0-0
Kopfschmerzen ( 5,1 % ) ||| headache ( 5.1 % ) ||| 0-0 1-1 2-2 3-3 4-4
Kopfschmerzen ( 5,1 % ||| headache ( 5.1 % ||| 0-0 1-1 2-2 3-3
Kopfschmerzen ( 5,1 ||| headache ( 5.1 ||| 0-0 1-1 2-2
Kopfschmerzen ( ||| headache ( ||| 0-0 1-1
Kopfschmerzen , Akathisie , ||| headache , akathisia , ||| 0-0 1-1 2-2 3-3
Kopfschmerzen , Akathisie , Übelkeit ||| headache , akathisia , nausea ||| 0-0 1-1 2-2 3-3 4-4
Kopfschmerzen , Akathisie ||| headache , akathisia ||| 0-0 1-1 2-2
Kopfschmerzen , Dysgeusie , Schwindel ||| headache , dysgeusia , dizziness ||| 0-0 1-1 2-2 3-3 4-4
Kopfschmerzen , Dysgeusie , ||| headache , dysgeusia , ||| 0-0 1-1 2-2 3-3
Kopfschmerzen , Dysgeusie ||| headache , dysgeusia ||| 0-0 1-1 2-2
Kopfschmerzen , Müdigkeit , ||| headache , tiredness , ||| 0-0 1-1 2-2 3-3
Kopfschmerzen , Müdigkeit , Übelkeit ||| headache , tiredness , nausea ||| 0-0 1-1 2-2 3-3 4-4
Kopfschmerzen , Müdigkeit ||| headache , tiredness ||| 0-0 1-1 2-2
Kopfschmerzen , ||| headache , ||| 0-0 1-1
Kopfschmerzen , ||| headache in the ||| 0-0
Kopfschmerzen , ||| headache in ||| 0-0
Kopfschmerzen , ||| headache ||| 0-0
Kopfschmerzen Augenerkrankungen Häufig : ||| headache Eye disorders Common : ||| 0-0 1-1 1-2 2-3 3-4
Kopfschmerzen Augenerkrankungen Häufig ||| headache Eye disorders Common ||| 0-0 1-1 1-2 2-3
Kopfschmerzen Augenerkrankungen ||| headache Eye disorders ||| 0-0 1-1 1-2
Kopfschmerzen Augenerkrankungen ||| headache Eye ||| 0-0 1-1
Kopfschmerzen ||| headache in the ||| 0-0
Kopfschmerzen ||| headache in ||| 0-0
Kopfschmerzen ||| headache ||| 0-0
Korrektur Ihrer Blutarmut kann ||| correction of your anaemia may ||| 0-0 1-1 1-2 2-3 3-4
Korrektur Ihrer Blutarmut ||| correction of your anaemia ||| 0-0 1-1 1-2 2-3
Korrektur Ihrer ||| correction of your ||| 0-0 1-1 1-2
Korrektur ||| correction ||| 0-0
Kortikosteroide . ||| corticosteroids . ||| 0-0 1-1
Kortikosteroide ||| corticosteroids ||| 0-0
Kortikosteroiden ||| dentistry ||| 0-0
Krampfanfälle : in klinischen Studien ||| Seizure : in clinical trials ||| 0-0 1-1 2-2 3-3 4-4
Krampfanfälle : in klinischen ||| Seizure : in clinical ||| 0-0 1-1 2-2 3-3
Krampfanfälle : in ||| Seizure : in ||| 0-0 1-1 2-2
Krampfanfälle : ||| Seizure : ||| 0-0 1-1
Krampfanfälle ||| Seizure ||| 0-0
Krampfanfälle ||| Therapy ||| 0-0
Krampfanfällen zwischen eim ||| stopped . du ||| 0-0 2-1 2-2
Krampfanfällen zwischen ||| stopped ||| 0-0
Krampfanfällen ||| seizure ||| 0-0
Krampfanfällen ||| stopped ||| 0-0
Krankenhaus auf und nehmen ||| hospital and take ||| 0-0 1-0 2-1 3-2
Krankenhaus auf und ||| hospital and ||| 0-0 1-0 2-1
Krankenhaus auf ||| hospital ||| 0-0 1-0
Krankenhaus in ||| hospital as ||| 0-0 1-1
Krankenhaus ||| hospital ||| 0-0
Krankheit , bei der der ||| disease in which the ||| 0-0 2-1 1-2 3-3 4-3
Krankheit , bei ||| disease in which ||| 0-0 2-1 1-2
Krankheit können auch ||| condition may also ||| 0-0 1-1 2-2
Krankheit können ||| condition may ||| 0-0 1-1
Krankheit oder ||| Committee ||| 0-0
Krankheit ||| Committee ||| 0-0
Krankheit ||| condition ||| 0-0
Krankheit ||| disease has ||| 0-0
Krankheit ||| disease ||| 0-0
Krankheitsprogression [ 95 % ||| disease progression [ 95 % ||| 0-0 0-1 1-2 2-3 3-4
Krankheitsprogression [ 95 ||| disease progression [ 95 ||| 0-0 0-1 1-2 2-3
Krankheitsprogression [ ||| disease progression [ ||| 0-0 0-1 1-2
Krankheitsprogression ||| disease progression ||| 0-0 0-1
Kreatin-Phosphokinase ) , generell ||| Creatine Phosphokinase ) , generally ||| 0-0 0-1 3-1 1-2 2-3 3-4
Kreatin-Phosphokinase , ||| Creatine Phosphokinase , ||| 0-0 0-1 1-2
Kreatin-Phosphokinase ||| Creatine Phosphokinase ||| 0-0 0-1
Kreatinin und Kalium im gewünschten ||| creatinine and potassium in ||| 0-0 1-1 2-2 3-2 4-2 3-3
Kreatinin und ||| creatinine and ||| 0-0 1-1
Kreatinin ||| creatinine ||| 0-0
Kreatinphosphokinase ) , generell ||| Phosphokinase ) , generally ||| 3-0 1-1 0-2 2-2 3-3
Kreatinphosphokinase ) , ||| ) , ||| 1-0 0-1 2-1
Krebs angewendet werden . ||| anticancer agents . ||| 0-0 1-1 2-1 3-2
Krebs angewendet werden ||| anticancer agents ||| 0-0 1-1 2-1
Krebs ||| anticancer ||| 0-0
Krebsbehandlung ||| treatments ||| 0-0
Krebserkrankung , ||| dental examination ||| 0-0 0-1
Krebserkrankung ||| dental examination ||| 0-0 0-1
Krebserkrankung ||| dental ||| 0-0
Krebszellen zum Abbau ||| cancer cells to break down ||| 0-0 0-1 1-2 2-3 2-4
Krebszellen zum ||| cancer cells to ||| 0-0 0-1 1-2
Krebszellen ||| cancer cells ||| 0-0 0-1
Kreislauf ||| systemic circulation ||| 0-0 0-1
Kreuzreaktion sollte keine andere Erythropoetin ||| should be commenced because of ||| 1-0 1-1 0-2 2-2 0-3 3-3 4-3 3-4
Kribbeln ||| shock-like ||| 0-0
Krise mit enzephalopathieähnlichen Symptomen ( ||| crisis with encephalopathy-like symptoms ( ||| 0-0 1-1 2-2 3-2 3-3 4-4
Krise mit enzephalopathieähnlichen Symptomen ||| crisis with encephalopathy-like symptoms ||| 0-0 1-1 2-2 3-2 3-3
Krise mit ||| crisis with ||| 0-0 1-1
Krise ||| crisis ||| 0-0
Kuhloweg 37 , D-58638 Iserlohn ||| Kuhloweg 37 , D-58638 Iserlohn ||| 0-0 1-1 2-2 3-3 4-4
Kuhloweg 37 , D-58638 ||| Kuhloweg 37 , D-58638 ||| 0-0 1-1 2-2 3-3
Kuhloweg 37 , ||| Kuhloweg 37 , ||| 0-0 1-1 2-2
Kuhloweg 37 D-58638 Iserlohn Deutschland ||| Kuhloweg 37 D-58638 Iserlohn Germany ||| 0-0 1-1 2-2 3-3 4-4
Kuhloweg 37 D-58638 Iserlohn Deutschland ||| Kuhloweg 37 D-58638 Iserlohn ||| 0-0 1-1 2-2 3-2 4-3
Kuhloweg 37 D-58638 Iserlohn ||| Kuhloweg 37 D-58638 Iserlohn ||| 0-0 1-1 2-2 3-3
Kuhloweg 37 D-58638 Iserlohn ||| Kuhloweg 37 D-58638 ||| 0-0 1-1 2-2 3-2
Kuhloweg 37 D-58638 ||| Kuhloweg 37 D-58638 ||| 0-0 1-1 2-2
Kuhloweg 37 ||| Kuhloweg 37 ||| 0-0 1-1
Kuhloweg ||| Kuhloweg ||| 0-0
Kunstoff-Flasche ( Cycloolefin-Copolymer ) , ||| ( cycloolefinic polymer ) ||| 1-0 0-1 2-2 3-3
Kunstoff-Flasche ( Cycloolefin-Copolymer ) ||| ( cycloolefinic polymer ) ||| 1-0 0-1 2-2 3-3
Kunstoff-Flasche ( Cycloolefin-Copolymer ||| ( cycloolefinic polymer ||| 1-0 0-1 2-2
Kunstoff-Flasche ( ||| ( cycloolefinic ||| 1-0 0-1
Kunstoff-Flasche ||| cycloolefinic ||| 0-0
Kurzatmigkeit oder ||| shortness of breath or rapid ||| 0-0 0-2 1-3 0-4
Kurzzeit-Studie ( 24 h ) ||| ( 24-hour ) ||| 1-0 0-1 2-1 3-2 4-2
Kurzzeit-Studie ( 24 ||| ( 24-hour ||| 1-0 0-1 2-1
Kurzzeitstudien ( 24 Stunden ||| ( 24-hour ||| 1-0 2-1
Kurzzeitstudien ( 24 ||| ( 24-hour ||| 1-0 2-1
Kurzzeitstudien ( ||| ( ||| 1-0
Kälte , orthostatische Hypotonie Selten ||| coldness , orthostatic hypotension Rare ||| 0-0 1-1 2-2 3-3 4-4
Kälte , orthostatische Hypotonie ||| coldness , orthostatic hypotension ||| 0-0 1-1 2-2 3-3
Kälte , orthostatische ||| coldness , orthostatic ||| 0-0 1-1 2-2
Kälte , ||| coldness , ||| 0-0 1-1
Kälte ||| coldness ||| 0-0
Königreich . ||| Kingdom . ||| 0-0 1-1
Königreich ||| Kingdom ||| 0-0
Körper nicht genügend ||| body does not produce enough ||| 0-0 1-1 1-2 2-3 2-4
Körper nicht ||| body does not ||| 0-0 1-1 1-2
Körper ||| body ||| 0-0
Körperfettverteilung unter Pioglitazon ||| body fat distribution on pioglitazone ||| 0-0 0-1 0-2 0-3 1-3 2-4
Körperfettverteilung unter ||| body fat distribution on ||| 0-0 0-1 0-2 0-3 1-3
Körperfläche ||| metre ||| 0-0
Körpergewicht ( 1 ml ||| bodyweight ( 1 ml ||| 0-0 1-1 2-2 3-3
Körpergewicht ( 1 ||| bodyweight ( 1 ||| 0-0 1-1 2-2
Körpergewicht ( ||| bodyweight ( ||| 0-0 1-1
Körpergewicht . ||| body weight . ||| 0-0 0-1 1-2
Körpergewicht 120 ml : 22 ||| BW 120 ml : 22 ||| 0-0 1-1 2-2 3-3 4-4
Körpergewicht 120 ml : ||| BW 120 ml : ||| 0-0 1-1 2-2 3-3
Körpergewicht 120 ml ||| BW 120 ml ||| 0-0 1-1 2-2
Körpergewicht 120 ||| BW 120 ||| 0-0 1-1
Körpergewicht 210 ml : 40 ||| BW 210 ml : 40 ||| 0-0 1-1 2-2 3-3 4-4
Körpergewicht 210 ml : ||| BW 210 ml : ||| 0-0 1-1 2-2 3-3
Körpergewicht 210 ml ||| BW 210 ml ||| 0-0 1-1 2-2
Körpergewicht 210 ||| BW 210 ||| 0-0 1-1
Körpergewicht in Kilogramm . ||| body weight in kilograms . ||| 0-0 0-1 1-2 2-3 3-4
Körpergewicht in Kilogramm ||| body weight in kilograms ||| 0-0 0-1 1-2 2-3
Körpergewicht in Relation zu stehen ||| range ||| 0-0 1-0 2-0 3-0 4-0
Körpergewicht in ||| body weight in ||| 0-0 0-1 1-2
Körpergewicht zweimal ||| body weight 2 times ||| 0-0 0-1 1-2 1-3
Körpergewicht ||| BW ||| 0-0
Körpergewicht ||| body weight ||| 0-0 0-1
Körpergewicht ||| bodyweight ||| 0-0
Körpergewicht ||| kg bodyweight results ||| 0-0 0-1
Körpergewicht ||| kg bodyweight ||| 0-0 0-1
Körpergewichts des ||| body weight of the ||| 0-0 0-1 1-2 1-3
Körpergewichts ||| body weight ||| 0-0 0-1
Körpergewichtsabstufung ||| gradation in ||| 0-0
Körpergewichtsabstufung ||| gradation ||| 0-0
Körpergröße ||| height ||| 0-0
Körperliche ||| Paget ||| 0-0
Körpers ||| body ||| 0-0
Kühl aufbewahren und transportieren ( ||| Store and transport refrigerated ( ||| 0-0 2-1 1-2 2-2 3-2 3-3 4-4
Kühl aufbewahren und transportieren ||| Store and transport refrigerated ||| 0-0 2-1 1-2 2-2 3-2 3-3
Kühl lagern und transportieren ( ||| Store and transport refrigerated ( ||| 0-0 2-1 1-2 2-2 3-2 3-3 4-4
Kühl lagern und transportieren ||| Store and transport refrigerated ||| 0-0 2-1 1-2 2-2 3-2 3-3
Kühl ||| Store ||| 0-0
Kühlschrank lagern ( 2°C ||| in a refrigerator ( 2°C ||| 0-0 1-1 0-2 1-2 2-3 3-4
Kühlschrank lagern ( ||| in a refrigerator ( ||| 0-0 1-1 0-2 1-2 2-3
Kühlschrank lagern . Für ||| refrigerate . This ||| 0-0 1-1 2-1 3-2
Kühlschrank lagern . ||| refrigerate . ||| 0-0 1-1 2-1
Kühlschrank lagern ||| in a refrigerator ||| 0-0 1-1 0-2 1-2
Kühlschrank ||| refrigerate ||| 0-0
Kühlschrank ||| refrigerator ||| 0-0
LHRH-Agonist , wobei diese 4 ||| LHRH agonist and this ||| 0-0 0-1 2-3 3-3
LHRH-Agonist , wobei diese ||| LHRH agonist and this ||| 0-0 0-1 2-3 3-3
LHRH-Agonist , ||| LHRH agonist and ||| 0-0 0-1
LHRH-Agonist , ||| LHRH agonist ||| 0-0 0-1
LHRH-Agonist ||| Another LHRH agonist ||| 0-0 0-1 0-2
LHRH-Agonist ||| LHRH agonist and ||| 0-0 0-1
LHRH-Agonist ||| LHRH agonist ||| 0-0 0-1
LTD Tel : + 353 ||| LTD Tel : + 353 ||| 0-0 1-1 2-2 3-3 4-4
LTD Tel : + 44 ||| LTD Tel : + 44 ||| 0-0 1-1 2-2 3-3 4-4
LTD Tel : + ||| LTD Tel : + ||| 0-0 1-1 2-2 3-3
LTD Tel : ||| LTD Tel : ||| 0-0 1-1 2-2
LTD Tel ||| LTD Tel ||| 0-0 1-1
LTD Tlf : + 47 ||| LTD Tlf : + 47 ||| 0-0 1-1 2-2 3-3 4-4
LTD Tlf : + ||| LTD Tlf : + ||| 0-0 1-1 2-2 3-3
LTD Tlf : ||| LTD Tlf : ||| 0-0 1-1 2-2
LTD Tlf ||| LTD Tlf ||| 0-0 1-1
LTD ||| LTD ||| 0-0
Laboratoires Takeda Tél : +33 ||| Laboratoires Takeda Tél : +33 ||| 0-0 1-1 2-2 3-3 4-4
Laboratoires Takeda Tél : ||| Laboratoires Takeda Tél : ||| 0-0 1-1 2-2 3-3
Laboratoires Takeda Tél ||| Laboratoires Takeda Tél ||| 0-0 1-1 2-2
Laboratoires Takeda ||| Laboratoires Takeda ||| 0-0 1-1
Laboratoires ||| Laboratoires ||| 0-0
Laborparameter auftraten , ergab keine ||| laboratory parameters revealed no ||| 0-0 0-1 1-1 3-2 4-3
Laborparameter auftraten , ergab ||| laboratory parameters revealed ||| 0-0 0-1 1-1 3-2
Laborparameter auftraten , ||| laboratory parameters ||| 0-0 0-1 1-1
Laborparameter auftraten ||| laboratory parameters ||| 0-0 0-1 1-1
Laboruntersuchungen ACOMPLIA ||| ACOMPLIA has not ||| 0-0 1-0 0-1 0-2
Laboruntersuchungen haben keine ||| Laboratory tests did not show ||| 0-0 0-1 2-3 1-4 2-4
Laboruntersuchungen ||| Laboratory tests did ||| 0-0 0-1
Laboruntersuchungen ||| Laboratory tests ||| 0-0 0-1
Laborwerten . ||| test values . ||| 0-0 0-1 1-2
Laborwerten ||| test values ||| 0-0 0-1
Lactase-Mangel oder Glucose- ||| lapp lactase deficiency or glucose-galactose ||| 0-0 0-1 0-2 1-3 2-4
Lactase-Mangel oder ||| lapp lactase deficiency or ||| 0-0 0-1 0-2 1-3
Lactase-Mangel ||| lapp lactase deficiency ||| 0-0 0-1 0-2
Lactose : Patienten mit ||| Lactose : patients with ||| 0-0 1-1 2-2 3-3
Lactose : Patienten ||| Lactose : patients ||| 0-0 1-1 2-2
Lactose : ||| Lactose : ||| 0-0 1-1
Lactose ||| Lactose ||| 0-0
Lactose- Monohydrat , Hyprolose , ||| What Actos looks like ||| 0-0 1-1 1-2 2-3 3-3 4-3
Lactose- Monohydrat ||| What Actos looks ||| 0-0 1-1 1-2
Lactose- ||| What ||| 0-0
Lactose-Monohydrat und ||| lactose monohydrate and ||| 0-0 0-1 1-2
Lactose-Monohydrat ||| Lactose monohydrate Maize ||| 0-0 0-1 0-2
Lactose-Monohydrat ||| lactose monohydrate ||| 0-0 0-1
Lactosemonohydrat ||| lactose monohydrate ||| 0-0 0-1
Lagerbedingungen ||| storage ||| 0-0
Lagerungsbedingungen erforderlich . ||| storage conditions . ||| 0-0 1-0 0-1 2-2
Lagerungsbedingungen erforderlich ||| storage conditions ||| 0-0 1-0 0-1
Lagerungsbedingungen für das ||| For storage conditions of the ||| 0-0 0-1 2-1 0-2 1-3 2-3 2-4
Laktation . ||| lactation . ||| 0-0 1-1
Laktation oder der Legeperiode ||| lactation or lay ||| 0-0 1-1 3-2
Laktation oder der ||| lactation or ||| 0-0 1-1
Laktation oder ||| lactation or ||| 0-0 1-1
Laktation ||| lactation ||| 0-0
Lancaster Way Wingates Industrial Park ||| Lancaster Way Wingates Industrial Park ||| 0-0 1-1 2-2 3-3 4-4
Lancaster Way Wingates Industrial ||| Lancaster Way Wingates Industrial ||| 0-0 1-1 2-2 3-3
Lancaster Way Wingates ||| Lancaster Way Wingates ||| 0-0 1-1 2-2
Lancaster Way ||| Lancaster Way ||| 0-0 1-1
Lancaster ||| Lancaster ||| 0-0
Langzeit-Erweiterungsphase über 74 Wochen ||| 74-week extension ||| 0-0 0-1 1-1 2-1 3-1
Langzeitanwendung von Actos . ||| long-term use of Actos . ||| 0-0 0-1 1-2 2-3 3-4
Langzeitanwendung von Actos ||| long-term use of Actos ||| 0-0 0-1 1-2 2-3
Langzeitanwendung von ||| long-term use of ||| 0-0 0-1 1-2
Langzeitanwendung ||| long-term use ||| 0-0 0-1
Langzeitstudien zur Kanzerogenität sind nicht ||| Long-term carcinogenicity studies have not ||| 0-0 0-1 1-1 2-1 2-2 2-3 3-3 4-4
Langzeitstudien zur Kanzerogenität sind ||| Long-term carcinogenicity studies have ||| 0-0 0-1 1-1 2-1 2-2 2-3 3-3
Langzeitstudien ||| Longer-term repeat ||| 0-0 0-1
Langzeitstudien ||| studies , ||| 0-0
Langzeitstudien ||| studies ||| 0-0
Langzeitverlängerung der Studie ||| Long Term ||| 0-0 1-0 0-1 2-1
Langzeitwirkung ||| achieve androgen ||| 0-0 0-1
Langzeitwirkung ||| to achieve androgen ||| 0-1 0-2
Lassen Sie die ||| Keep the ||| 0-0 1-0 2-1
Lassen Sie ||| Keep ||| 0-0 1-0
Latvij Tel : +371 7364000 ||| Latvij Tel : +371 7364000 ||| 0-0 1-1 2-2 3-3 4-4
Latvij Tel : +371 ||| Latvij Tel : +371 ||| 0-0 1-1 2-2 3-3
Latvij Tel : ||| Latvij Tel : ||| 0-0 1-1 2-2
Latvij Tel ||| Latvij Tel ||| 0-0 1-1
Latvij ||| Latvij ||| 0-0
Latvija Eli Lilly Holdings Limited ||| Latvija Eli Lilly Holdings Limited ||| 0-0 1-1 2-2 3-3 4-4
Latvija Eli Lilly Holdings ||| Latvija Eli Lilly Holdings ||| 0-0 1-1 2-2 3-3
Latvija Eli Lilly ||| Latvija Eli Lilly ||| 0-0 1-1 2-2
Latvija Eli ||| Latvija Eli ||| 0-0 1-1
Latvija ||| Latvija ||| 0-0
Lda Tel : + 351 ||| Lda Tel : + 351 ||| 0-0 1-1 2-2 3-3 4-4
Lda Tel : + ||| Lda Tel : + ||| 0-0 1-1 2-2 3-3
Lda Tel : ||| Lda Tel : ||| 0-0 1-1 2-2
Lda Tel ||| Lda Tel ||| 0-0 1-1
Lda ||| Lda ||| 0-0
Lebensweise ||| lifestyle ||| 0-0
Leber , ||| liver , ||| 0-0 1-1
Leber ||| liver ||| 0-0
Leber- ||| a problem with ||| 0-0 0-1 0-2
Leberfunktion Rimonabant ||| with ||| 0-0
Leberfunktion auf die Pharmakokinetik ||| hepatic impairment on the pharmacokinetics ||| 0-0 0-1 1-2 2-3 3-4
Leberfunktion auf die ||| hepatic impairment on the ||| 0-0 0-1 1-2 2-3
Leberfunktion auf ||| hepatic impairment on ||| 0-0 0-1 1-2
Leberfunktion ||| hepatic impairment ||| 0-0 0-1
Leberfunktion ||| with ||| 0-0
Leberfunktionseinschränkung leiden . ||| liver disease . ||| 0-0 1-1 2-2
Leberfunktionseinschränkung leiden ||| liver disease ||| 0-0 1-1
Leberfunktionseinschränkung ||| liver ||| 0-0
Leberfunktionsstörung Eine Dosisanpassung ||| hepatic impairment No dose adjustment ||| 0-0 0-1 1-2 2-2 2-3 2-4
Leberfunktionsstörung kann ||| hepatic impairment may ||| 0-0 0-1 1-2
Leberfunktionsstörung sollten nicht ||| hepatic impairment should not ||| 0-0 0-1 1-2 2-3
Leberfunktionsstörung sollten ||| hepatic impairment should ||| 0-0 0-1 1-2
Leberfunktionsstörung ||| hepatic impairment ||| 0-0 0-1
Leberfunktionsstörungen ( Bilirubin > 5 ||| ( bilirubin > 5 ||| 1-0 0-1 2-1 3-2 4-3
Leberfunktionsstörungen ( Bilirubin > ||| ( bilirubin > ||| 1-0 0-1 2-1 3-2
Leberfunktionsstörungen ( Bilirubin ||| ( bilirubin ||| 1-0 0-1 2-1
Leberfunktionsstörungen . ||| impaired liver function . ||| 0-0 0-1 0-2 1-3
Leberfunktionsstörungen ||| has impaired liver function . ||| 0-1 0-2 0-3
Leberfunktionsstörungen ||| has impaired liver function ||| 0-1 0-2 0-3
Leberfunktionsstörungen ||| impaired liver function . ||| 0-0 0-1 0-2
Leberfunktionsstörungen ||| impaired liver function ||| 0-0 0-1 0-2
Leberinsuffizienz : Bei ||| hepatic impairment : no dosage ||| 0-0 0-1 1-2 0-3 2-4
Leberinsuffizienz : ||| hepatic impairment : no ||| 0-0 0-1 1-2 0-3
Leberinsuffizienz : ||| hepatic impairment : ||| 0-0 0-1 1-2
Leberinsuffizienz ||| hepatic impairment ||| 0-0 0-1
Lebermikrosome und Gewebeschichten ||| liver microsomes and tissue ||| 0-1 2-1 1-2 1-3
Lebermikrosome und Gewebeschichten ||| microsomes and tissue ||| 0-0 2-0 1-1 1-2
Leberproblemen ||| liver problems ||| 0-0 0-1
Legeperiode ||| lay ||| 0-0
Lesen Sie die gesamte ||| Read all of ||| 0-0 1-0 3-0 0-1 2-1 3-2
Lethargie , Hyperpyrexie Gelegentlich : ||| , lethargy , hyperpyrexia ||| 1-0 0-1 2-1 1-2 3-2 4-2 2-3
Leukopenie ||| leukopenia ||| 0-0
Leukopoese nicht beeinflusst . ||| does not affect leucopoiesis . ||| 0-0 1-1 0-2 0-3 2-3 3-4
Leukopoese nicht beeinflusst ||| does not affect leucopoiesis ||| 0-0 1-1 0-2 0-3 2-3
Lietuva Eli Lilly Holdings Limited ||| Lietuva Eli Lilly Holdings Limited ||| 0-0 1-1 2-2 3-3 4-4
Lietuva Eli Lilly Holdings ||| Lietuva Eli Lilly Holdings ||| 0-0 1-1 2-2 3-3
Lietuva Eli Lilly ||| Lietuva Eli Lilly ||| 0-0 1-1 2-2
Lietuva Eli ||| Lietuva Eli ||| 0-0 1-1
Lietuva ||| Lietuva ||| 0-0
Lilly Finland Ab Puh/Tel ||| Lilly Finland Ab Puh/ Tel ||| 0-0 1-1 2-2 3-3 3-4
Lilly Finland Ab ||| Lilly Finland Ab ||| 0-0 1-1 2-2
Lilly Finland ||| Lilly Finland ||| 0-0 1-1
Lilly Holdings Limited Eesti filiaal ||| Lilly Holdings Limited Eesti filiaal ||| 0-0 1-1 2-2 3-3 4-4
Lilly Holdings Limited Eesti ||| Lilly Holdings Limited Eesti ||| 0-0 1-1 2-2 3-3
Lilly Holdings Limited p rst ||| Lilly Holdings Limited p rst ||| 0-0 1-1 2-2 3-3 4-4
Lilly Holdings Limited p ||| Lilly Holdings Limited p ||| 0-0 1-1 2-2 3-3
Lilly Holdings Limited ||| Lilly Holdings Limited ||| 0-0 1-1 2-2
Lilly Holdings ||| Lilly Holdings ||| 0-0 1-1
Lilly Portugal - Produtos Farmacêuticos ||| Lilly Portugal - Produtos Farmacêuticos ||| 0-0 1-1 2-2 3-3 4-4
Lilly Portugal - Produtos ||| Lilly Portugal - Produtos ||| 0-0 1-1 2-2 3-3
Lilly Portugal - ||| Lilly Portugal - ||| 0-0 1-1 2-2
Lilly Portugal ||| Lilly Portugal ||| 0-0 1-1
Lilly farmacevtska dru ||| Lilly farmacevtska dru ba ||| 0-0 0-1 1-1 1-2 2-3
Lilly farmacevtska ||| Lilly farmacevtska dru ||| 0-0 0-1 1-1 1-2
Lilly farmacevtska ||| Lilly farmacevtska dru ||| 0-0 1-1 1-2
Lilly ||| Lilly ||| 0-0
Limited Eesti filiaal Tel : ||| Limited Eesti filiaal Tel : ||| 0-0 1-1 2-2 3-3 4-4
Limited Eesti filiaal Tel ||| Limited Eesti filiaal Tel ||| 0-0 1-1 2-2 3-3
Limited Eesti filiaal ||| Limited Eesti filiaal ||| 0-0 1-1 2-2
Limited Eesti ||| Limited Eesti ||| 0-0 1-1
Limited Tel : +353 1 ||| Limited Tel : +353 1 ||| 0-0 1-1 2-2 3-3 4-4
Limited Tel : +353 ||| Limited Tel : +353 ||| 0-0 1-1 2-2 3-3
Limited Tel : ||| Limited Tel : ||| 0-0 1-1 2-2
Limited Tel ||| Limited Tel ||| 0-0 1-1
Limited West Forest Gate Wellington ||| Limited West Forest Gate Wellington ||| 0-0 1-1 2-2 3-3 4-4
Limited West Forest Gate ||| Limited West Forest Gate ||| 0-0 1-1 2-2 3-3
Limited West Forest ||| Limited West Forest ||| 0-0 1-1 2-2
Limited West ||| Limited West ||| 0-0 1-1
Limited Wimblehurst Road Horsham West ||| Limited Wimblehurst Road Horsham West ||| 0-0 1-1 2-2 3-3 4-4
Limited Wimblehurst Road Horsham ||| Limited Wimblehurst Road Horsham ||| 0-0 1-1 2-2 3-3
Limited Wimblehurst Road ||| Limited Wimblehurst Road ||| 0-0 1-1 2-2
Limited Wimblehurst ||| Limited Wimblehurst ||| 0-0 1-1
Limited atstovyb Tel. +370 ||| Limited atstovyb Tel . +370 ||| 0-0 1-1 2-1 2-2 2-3 3-4
Limited atstovyb Tel. ||| Limited atstovyb Tel . ||| 0-0 1-1 2-1 2-2 2-3
Limited p rst vniec ba ||| Limited p rst vniec ba ||| 0-0 1-1 2-2 3-3 4-4
Limited p rst vniec ||| Limited p rst vniec ||| 0-0 1-1 2-2 3-3
Limited p rst ||| Limited p rst ||| 0-0 1-1 2-2
Limited p ||| Limited p ||| 0-0 1-1
Limited ||| Limited ||| 0-0
Linear Analogue Scale ( CLAS ||| Linear Analogue Scale ( CLAS ||| 0-0 1-1 2-1 1-2 3-3 4-4
Linear Analogue Scale ( ||| Linear Analogue Scale ( ||| 0-0 1-1 2-1 1-2 3-3
Linear Analogue Scale ||| Linear Analogue Scale ||| 0-0 1-1 2-1 1-2
Linear ||| Linear ||| 0-0
Linie die Produktion roter Blutzellen ||| stimulate red blood cell ||| 0-0 1-1 2-1 3-2 3-3 4-3
Linie die Produktion ||| stimulate red ||| 0-0 1-1 2-1
Linie ||| stimulate ||| 0-0
Lipidaufnahme aus der Nahrung . ||| uptake of dietary lipids . ||| 0-0 1-1 1-2 2-2 3-2 3-3 4-4
Lipidaufnahme aus der Nahrung ||| uptake of dietary lipids ||| 0-0 1-1 1-2 2-2 3-2 3-3
Lipidaufnahme ||| uptake ||| 0-0
Literatur ||| literature ||| 0-0
Lithium ( ||| lithium ( ||| 0-0 1-1
Lithium oder Valproat ||| lithium or valproate ||| 0-0 1-1 2-2
Lithium oder ||| lithium or ||| 0-0 1-1
Lithium ||| lithium ||| 0-0
Lithium-Behandlung . ||| with lithium . ||| 0-0 0-1 1-2
Lithium-Behandlung ||| with lithium ||| 0-0 0-1
Lithium-Konzentrationen . ||| lithium concentrations . ||| 0-0 0-1 1-2
Lithium-Konzentrationen ||| lithium concentrations ||| 0-0 0-1
Lockerung ||| tooth . ||| 0-0
Lockerung ||| tooth ||| 0-0
London , WC2B 4AE , ||| London , WC2B 4AE , ||| 0-0 1-1 2-2 3-3 4-4
London , WC2B 4AE ||| London , WC2B 4AE ||| 0-0 1-1 2-2 3-3
London , WC2B ||| London , WC2B ||| 0-0 1-1 2-2
London , ||| London , ||| 0-0 1-1
London WC2B 4AE Vereinigtes Königreich ||| London WC2B 4AE United Kingdom ||| 0-0 1-1 2-2 3-3 4-4
London WC2B 4AE Vereinigtes ||| London WC2B 4AE United ||| 0-0 1-1 2-2 3-3
London WC2B 4AE ||| London WC2B 4AE ||| 0-0 1-1 2-2
London WC2B ||| London WC2B ||| 0-0 1-1
London ||| London ||| 0-0
Lorazepam ( ||| lorazepam ( ||| 0-0 1-1
Lorazepam ( ||| of lorazepam ( ||| 0-1 1-2
Lorazepam ||| lorazepam ||| 0-0
Lorazepam ||| of lorazepam ||| 0-1
Lorazepam- Referenzarm ||| arm ||| 0-0 1-0
Lorazepam- Referenzarm ||| reference arm ||| 0-1 1-1
Lorazepam-Injektionslösung wurde durch ||| solution for injection ||| 0-0 0-1 0-2
Lorazepam-Injektionslösung wurde ||| solution for injection ||| 0-0 0-1 0-2
Lorazepam-Injektionslösung ||| solution for injection ||| 0-0 0-1 0-2
Ltd , 61 Aldwych , ||| Ltd , 61 Aldwych , ||| 0-0 1-1 2-2 3-3 4-4
Ltd , 61 Aldwych ||| Ltd , 61 Aldwych ||| 0-0 1-1 2-2 3-3
Ltd , 61 ||| Ltd , 61 ||| 0-0 1-1 2-2
Ltd , ||| Ltd , ||| 0-0 1-1
Ltd 61 Aldwych London WC2B ||| Ltd 61 Aldwych London WC2B ||| 0-0 1-1 2-2 3-3 4-4
Ltd 61 Aldwych London ||| Ltd 61 Aldwych London ||| 0-0 1-1 2-2 3-3
Ltd 61 Aldwych ||| Ltd 61 Aldwych ||| 0-0 1-1 2-2
Ltd 61 ||| Ltd 61 ||| 0-0 1-1
Ltd Tel : + 44 ||| Ltd Tel : + 44 ||| 0-0 1-1 2-2 3-3 4-4
Ltd Tel : + ||| Ltd Tel : + ||| 0-0 1-1 2-2 3-3
Ltd Tel : ||| Ltd Tel : ||| 0-0 1-1 2-2
Ltd Tel ||| Ltd Tel ||| 0-0 1-1
Ltd verpflichtet sich alle ||| Ltd commits to provide ||| 0-0 1-1 2-1 2-2 3-2
Ltd verpflichtet sich alle ||| Ltd commits to ||| 0-0 1-1 2-1 2-2 3-2
Ltd ||| Ltd ||| 0-0
Lucien Pharma Tél : + ||| Lucien Pharma Tél : + ||| 0-0 1-1 2-2 3-3 4-4
Lucien Pharma Tél : ||| Lucien Pharma Tél : ||| 0-0 1-1 2-2 3-3
Lucien Pharma Tél ||| Lucien Pharma Tél ||| 0-0 1-1 2-2
Lucien Pharma ||| Lucien Pharma ||| 0-0 1-1
Lucien ||| Lucien ||| 0-0
Lungenembolien ) . ||| pulmonary embolism ) . ||| 0-0 0-1 1-2 2-3
Lungenembolien ) ||| pulmonary embolism ) ||| 0-0 0-1 1-2
Lungenembolien ||| pulmonary embolism ||| 0-0 0-1
Lungenembolien ||| pulmonary ||| 0-0
Lungenentzündung , ||| pneumonia , ||| 0-0
Lungenentzündung , ||| pneumonia ||| 0-0
Lungenentzündung ||| pneumonia , ||| 0-0
Lungenentzündung ||| pneumonia ||| 0-0
Luteinisierungshormon-Releasinghormon-Antagonisten ( LH-RHa ) ||| agonists ( LH-RHas ) ||| 0-0 1-1 0-2 2-2 3-3
Luteinisierungshormon-Releasinghormon-Antagonisten ( LH-RHa ||| agonists ( LH-RHas ||| 0-0 1-1 0-2 2-2
Luxembourg/Luxemburg BRISTOL-MYERS SQUIBB ||| Luxembourg/ Luxemburg BRISTOL-MYERS SQUIBB BELGIUM ||| 0-0 0-1 1-2 2-3 2-4
Luxembourg/Luxemburg BRISTOL-MYERS ||| Luxembourg/ Luxemburg BRISTOL-MYERS ||| 0-0 0-1 1-2
Luxembourg/Luxemburg Novartis Pharma GmbH ||| Luxembourg/ Luxemburg Novartis Pharma GmbH ||| 0-0 0-1 1-2 2-3 3-4
Luxembourg/Luxemburg Novartis Pharma ||| Luxembourg/ Luxemburg Novartis Pharma ||| 0-0 0-1 1-2 2-3
Luxembourg/Luxemburg Novartis ||| Luxembourg/ Luxemburg Novartis ||| 0-0 0-1 1-2
Luxembourg/Luxemburg Takeda Global R ||| Luxembourg/ Luxemburg Takeda Global R ||| 0-0 0-1 1-2 2-3 3-4
Luxembourg/Luxemburg Takeda Global ||| Luxembourg/ Luxemburg Takeda Global ||| 0-0 0-1 1-2 2-3
Luxembourg/Luxemburg Takeda ||| Luxembourg/ Luxemburg Takeda ||| 0-0 0-1 1-2
Luxembourg/Luxemburg ||| Luxembourg/ Luxemburg ||| 0-0 0-1
Lymphopenie wurde bei 45 ||| Lymphopenia was observed in 45 ||| 0-0 1-1 1-2 2-3 3-4
Lymphopenie wurde bei ||| Lymphopenia was observed in ||| 0-0 1-1 1-2 2-3
Lymphopenie wurde ||| Lymphopenia was observed ||| 0-0 1-1 1-2
Lymphopenie ||| Lymphopenia ||| 0-0
Lymphozyten ||| chromosome aberrations ||| 0-0 0-1
Lymphödem ||| lymphoedema ||| 0-0
Lösung ( ||| solution ( ||| 0-0 1-1
Lösung . ||| solution . ||| 0-0 1-1
Lösung enthält 0,05 mg ||| solution contains 0.05 mg ||| 0-0 1-1 2-2 3-3
Lösung enthält 0,05 ||| solution contains 0.05 ||| 0-0 1-1 2-2
Lösung enthält 10 000 I.E. ||| solution contains 10 000 IU ||| 0-0 1-1 2-2 3-3 4-4
Lösung enthält 10 000 ||| solution contains 10 000 ||| 0-0 1-1 2-2 3-3
Lösung enthält 10 ||| solution contains 10 ||| 0-0 1-1 2-2
Lösung enthält 2000 I.E. ||| solution contains 2000 IU ||| 0-0 1-1 2-2 3-3
Lösung enthält 2000 ||| solution contains 2000 ||| 0-0 1-1 2-2
Lösung enthält 5 mg wasserfreie ||| of solution contains 5 mg ||| 0-0 0-1 1-2 2-3 3-4 4-4
Lösung enthält 5 mg ||| of solution contains 5 mg ||| 0-1 1-2 2-3 3-4
Lösung enthält 5 mg ||| solution contains 5 mg ||| 0-0 1-1 2-2 3-3
Lösung enthält 5 ||| of solution contains 5 ||| 0-0 0-1 1-2 2-3
Lösung enthält 5 ||| of solution contains 5 ||| 0-1 1-2 2-3
Lösung enthält 5 ||| solution contains 5 ||| 0-0 1-1 2-2
Lösung enthält ||| of solution contains ||| 0-0 0-1 1-2
Lösung enthält ||| of solution contains ||| 0-1 1-2
Lösung enthält ||| solution contains ||| 0-0 1-1
Lösung muss ||| solution should be ||| 0-0 1-1 1-2
Lösung und ||| solution ||| 0-0
Lösung versehentlich eingefroren wurde ||| solution has been accidentally frozen ||| 0-0 1-1 1-2 1-3 2-3 2-4 3-4
Lösung versehentlich eingefroren wurde ||| solution has been accidently frozen ||| 0-0 1-1 1-2 2-3 1-4 2-4 3-4
Lösung zu verwerfen . ||| unused amount . ||| 2-0 0-1 2-1 3-2
Lösung zu verwerfen ||| unused amount ||| 2-0 0-1 2-1
Lösung zum Eingeben für Hunde ||| oral solution for dogs ||| 1-0 2-0 0-1 2-1 3-2 4-3
Lösung zum Eingeben für ||| oral solution for ||| 1-0 2-0 0-1 2-1 3-2
Lösung zum Eingeben ||| oral solution ||| 1-0 2-0 0-1 2-1
Lösung zum Einnehmen . ||| oral solution . ||| 1-0 2-0 0-1 3-2
Lösung zum Einnehmen 150 ml ||| oral solution 150 ml ||| 1-0 2-0 0-1 2-1 3-2 4-3
Lösung zum Einnehmen 150 ||| oral solution 150 ||| 1-0 2-0 0-1 2-1 3-2
Lösung zum Einnehmen 480 ml ||| oral solution 480 ml ||| 1-0 2-0 0-1 2-1 3-2 4-3
Lösung zum Einnehmen 480 ||| oral solution 480 ||| 1-0 2-0 0-1 2-1 3-2
Lösung zum Einnehmen Klare , ||| Oral solution Clear , ||| 0-0 0-1 1-1 2-2 3-2 4-3
Lösung zum Einnehmen Klare ||| Oral solution Clear ||| 0-0 0-1 1-1 2-2 3-2
Lösung zum Einnehmen enthält 200 ||| oral solution contains 200 ||| 1-0 2-0 0-1 3-2 4-3
Lösung zum Einnehmen enthält Methyl-4-hydroxybenzoat ||| oral solution contains methyl parahydroxybenzoate ||| 1-0 2-0 0-1 3-2 4-3 4-4
Lösung zum Einnehmen enthält ||| oral solution contains ||| 1-0 2-0 0-1 3-2
Lösung zum Einnehmen ist eine ||| oral solution is a ||| 1-0 2-0 0-1 3-2 4-3
Lösung zum Einnehmen ist ||| oral solution is ||| 1-0 2-0 0-1 3-2
Lösung zum Einnehmen muss ||| oral solution must be ||| 1-0 2-0 0-1 3-2 3-3
Lösung zum Einnehmen resorbiert ( ||| oral solution ||| 1-0 2-0 3-0 0-1
Lösung zum Einnehmen resorbiert ||| oral solution ||| 1-0 2-0 3-0 0-1
Lösung zum Einnehmen ||| , the oral solution ||| 1-1 1-2 2-2 0-3
Lösung zum Einnehmen ||| oral solution ||| 1-0 2-0 0-1
Lösung zum Einnehmen ||| oral solution ||| 1-0 2-0 0-1 2-1
Lösung zum Einnehmen ||| the oral solution ||| 1-0 1-1 2-1 0-2
Lösung zum ||| Oral solution ||| 0-0 0-1 1-1
Lösung ||| of solution ||| 0-0 0-1
Lösung ||| of solution ||| 0-1
Lösung ||| solution ||| 0-0
Lösungsbehältnisse ||| DEHP-free ||| 0-0
M-II , M-III und ||| M-II , M-III , and ||| 0-0 1-1 2-2 1-3 3-4
M-II , M-III ||| M-II , M-III , ||| 0-0 1-1 2-2 1-3
M-II minimal ausgeprägt ist . ||| M-II is minimal . ||| 0-0 3-1 1-2 2-2 4-3
M-II minimal ausgeprägt ist ||| M-II is minimal ||| 0-0 3-1 1-2 2-2
M-II ||| M-II ||| 0-0
M-III ||| M-III ||| 0-0
M-IV ) . ||| M-IV ) . ||| 0-0 1-1 2-2
M-IV ) ||| M-IV ) ||| 0-0 1-1
M-IV ||| M-IV ||| 0-0
M. deltoideus ||| gluteus ||| 0-0 1-0
MAO-Hemmer ) , ||| MAOI ) , ||| 0-0 1-1 2-2
MAO-Hemmer ) ||| MAOI ) ||| 0-0 1-1
MAO-Hemmer ||| MAOI ||| 0-0
METFORMIN UND SULFONYLHARNSTOFF ||| METFORMIN AND SULPHONYLUREA ||| 0-0 1-1 2-2
METFORMIN UND ||| METFORMIN AND ||| 0-0 1-1
METFORMIN ||| METFORMIN ||| 0-0
MINDESTANGABEN AUF ||| MINIMUM PARTICULARS TO APPEAR ON ||| 0-0 0-1 0-2 1-3 1-4
MINDESTANGABEN AUF ||| MINIMUM PARTICULARS TO APPEAR ||| 0-0 0-1 1-2 1-3
MINDESTANGABEN AUF ||| PARTICULARS TO APPEAR ON ||| 0-0 0-1 1-2 1-3
MINDESTANGABEN ||| MINIMUM PARTICULARS TO ||| 0-0 0-1 0-2
MINDESTANGABEN ||| MINIMUM PARTICULARS ||| 0-0 0-1
MINDESTANGABEN ||| PARTICULARS TO ||| 0-0 0-1
MIT BLUE BOX ) UND ||| WITH BLUE BOX ) AND ||| 0-0 1-1 2-2 3-3 4-4
MIT BLUE BOX ) ||| WITH BLUE BOX ) ||| 0-0 1-1 2-2 3-3
MIT BLUE BOX ||| WITH BLUE BOX ||| 0-0 1-1 2-2
MIT BLUE ||| WITH BLUE ||| 0-0 1-1
MIT EINEM SULFONYLHARNSTOFF ||| Ear and labyrinth disorders ||| 0-0 1-0 0-1 1-2 2-2 2-3
MIT INSULIN ||| and nutrition disorders ||| 0-0 0-1 1-1 1-2
MIT METFORMIN UND SULFONYLHARNSTOFF ||| WITH METFORMIN AND SULPHONYLUREA ||| 0-0 1-1 2-2 3-3
MIT METFORMIN UND ||| WITH METFORMIN AND ||| 0-0 1-1 2-2
MIT METFORMIN ||| WITH METFORMIN ||| 0-0 1-1
MIT METFORMIN ||| and lymphatic system disorders ||| 0-0 0-1 1-1 1-2 1-3
MIT ||| WITH ||| 0-0
MITGLIEDSTAAT Mitgliedstaat ||| MEMBER STATES ||| 0-0 1-1
MITGLIEDSTAAT ||| MEMBER ||| 0-0
MNS ist ein ||| NMS is a ||| 0-0 1-1 2-2
MNS ist ||| NMS is ||| 0-0 1-1
MNS sind ||| NMS are ||| 0-0 1-1
MNS ||| NMS ||| 0-0
MTP ) . ||| MTP ) . ||| 0-0 1-1 2-2
MTP ) ||| MTP ) ||| 0-0 1-1
MTP ||| MTP ||| 0-0
Macrogol 3000 . ||| macrogol 3000 ||| 0-0 1-1 2-1
Macrogol ||| macrogol ||| 0-0
Madarosis Augenerkrankungen : ||| madarosis Eye disorders : ||| 0-0 1-1 1-2 2-3
Madarosis Augenerkrankungen ||| madarosis Eye disorders ||| 0-0 1-1 1-2
Madarosis ||| madarosis ||| 0-0
Madrid ) Spanien ||| Madrid ) Spain ||| 0-0 1-1 2-2
Madrid ) ||| Madrid ) ||| 0-0 1-1
Madrid ||| Madrid ||| 0-0
Magen einnehmen . ||| food . ||| 0-0 1-0 2-1
Magen einnehmen ||| food ||| 0-0 1-0
Magnesiumstearat , Eisen(III)-hydroxid-oxid ||| magnesium stearate , yellow ||| 0-0 0-1 1-2 2-3
Magnesiumstearat , ||| magnesium stearate , ||| 0-0 0-1 1-2
Magnesiumstearat . ||| magnesium stearate . ||| 0-0 0-1 1-2
Magnesiumstearat . ||| of the pack ||| 0-2
Magnesiumstearat . ||| pack ||| 0-0
Magnesiumstearat . ||| the pack ||| 0-1
Magnesiumstearat ||| magnesium stearate ||| 0-0 0-1
Magnesiumstearat ||| of the pack ||| 0-2
Magnesiumstearat ||| pack ||| 0-0
Magnesiumstearat ||| stearate ||| 0-0
Magnesiumstearat ||| the pack ||| 0-1
Magyarország OncoEurope Tel . : ||| Magyarország OncoEurope Tel . : ||| 0-0 1-1 2-2 3-3 4-4
Magyarország OncoEurope Tel . ||| Magyarország OncoEurope Tel . ||| 0-0 1-1 2-2 3-3
Magyarország OncoEurope Tel ||| Magyarország OncoEurope Tel ||| 0-0 1-1 2-2
Magyarország OncoEurope ||| Magyarország OncoEurope ||| 0-0 1-1
Magyarország ||| Magyarország ||| 0-0
Mahlzeit oder ungeplante , ||| meal or unplanned , ||| 0-0 1-1 2-2 3-3
Mahlzeit oder ungeplante ||| meal or unplanned ||| 0-0 1-1 2-2
Mahlzeit oder ||| meal or ||| 0-0 1-1
Mahlzeit ||| fat meal ||| 0-0 0-1
Mahlzeit ||| meal ||| 0-0
Maisstärke , mikrokristalline ||| maize starch , microcrystalline ||| 0-0 0-1 1-2 2-3
Maisstärke , ||| maize starch , ||| 0-0 0-1 1-2
Maisstärke Mikrokristalline ||| starch Microcrystalline cellulose Hydroxypropyl cellulose ||| 0-0 0-1 0-2 1-3 1-4
Maisstärke ||| maize starch ||| 0-0 0-1
Maisstärke ||| starch Microcrystalline cellulose ||| 0-0 0-1 0-2
Malignes Neuroleptisches Syndrom ( MNS ||| Neuroleptic Malignant Syndrome ( NMS ||| 0-0 1-1 1-2 2-2 3-3 4-4
Malignes Neuroleptisches Syndrom ( ||| Neuroleptic Malignant Syndrome ( ||| 0-0 1-1 1-2 2-2 3-3
Malignes Neuroleptisches Syndrom ||| Neuroleptic Malignant Syndrome ||| 0-0 1-1 1-2 2-2
Malignes ||| Neuroleptic ||| 0-0
Malta Takeda Italia Farmaceutici SpA ||| Malta Takeda Italia Farmaceutici SpA ||| 0-0 1-1 2-2 3-3 4-4
Malta Takeda Italia Farmaceutici ||| Malta Takeda Italia Farmaceutici ||| 0-0 1-1 2-2 3-3
Malta Takeda Italia ||| Malta Takeda Italia ||| 0-0 1-1 2-2
Malta Takeda ||| Malta Takeda ||| 0-0 1-1
Malta ||| Malta ||| 0-0
Mammakarzinom ||| breast cancer ||| 0-0 0-1
Man nimmt ||| droplets ||| 0-0 1-0
Management ||| Management ||| 0-0
Mangel oder ||| deficiency or ||| 0-0 1-1
Mangel ||| deficiency ||| 0-0
Manie ||| mania ||| 0-0
Manische Episoden ||| Manic episodes ||| 0-0 1-1
Manische ||| Manic ||| 0-0
Mannitol , Natriumcitrat und ||| Mannitol , sodium citrate and ||| 0-0 1-1 2-2 2-3 3-4
Mannitol , Natriumcitrat und ||| mannitol , sodium citrate and ||| 0-0 1-1 2-2 2-3 3-4
Mannitol , Natriumcitrat ||| Mannitol , sodium citrate ||| 0-0 1-1 2-2 2-3
Mannitol , Natriumcitrat ||| mannitol , sodium citrate ||| 0-0 1-1 2-2 2-3
Mannitol , ||| Mannitol , ||| 0-0 1-1
Mannitol , ||| mannitol , ||| 0-0 1-1
Mannitol ||| Mannitol ||| 0-0
Mannitol ||| mannitol ||| 0-0
Marke ( Hersteller ) , ||| brand ( manufacturer ) , ||| 0-0 1-1 0-2 2-2 3-3 4-4
Marke ( Hersteller ) ||| brand ( manufacturer ) ||| 0-0 1-1 0-2 2-2 3-3
Marke ( Hersteller ||| brand ( manufacturer ||| 0-0 1-1 0-2 2-2
Marker ||| , recovered label ||| 0-1 0-2
Marker ||| recovered label ||| 0-0 0-1
Markern , ||| marker ||| 0-0
Markern ||| marker ||| 0-0
Maschinen ) , ||| avoid ||| 0-0 1-0
Maschinen ) ||| avoid ||| 0-0 1-0
Maschinen . ||| machines . ||| 0-0 1-1
Maschinen auswirken ||| machinery ||| 0-0 1-0
Maschinen bedienen , bis Sie ||| machines , until you ||| 0-0 1-0 2-1 1-2 3-2 4-3
Maschinen bedienen , bis Sie ||| machines until you ||| 0-0 1-0 1-1 2-1 3-1 4-2
Maschinen bedienen , bis ||| machines , until ||| 0-0 1-0 2-1 1-2 3-2
Maschinen bedienen , bis ||| machines until ||| 0-0 1-0 1-1 2-1 3-1
Maschinen bedienen , wenn Sie ||| machines if you ||| 0-0 1-0 2-1 3-1 4-2
Maschinen bedienen , wenn ||| machines if ||| 0-0 1-0 2-1 3-1
Maschinen bedienen ||| machines ||| 0-0 1-0
Maschinen zu bedienen , beobachtet ||| use machines have been observed ||| 0-0 0-1 2-1 0-2 1-2 4-3 4-4
Maschinen zu bedienen , ||| use machines have ||| 0-0 0-1 2-1 0-2 1-2
Maschinen zu bedienen ||| use machines have ||| 0-0 0-1 2-1 0-2 1-2
Maschinen ||| machines ||| 0-0
Materialien ||| pharmacies ||| 0-0
Maternaltoxische Effekte ||| Maternal toxicity ||| 0-0 1-0 0-1
Maximalvolumen von 1 ml ||| maximum volume of 1 ml ||| 0-0 0-1 1-2 2-3 3-4
Maximalvolumen von 1 ||| maximum volume of 1 ||| 0-0 0-1 1-2 2-3
Maximalvolumen von ||| maximum volume of ||| 0-0 0-1 1-2
Maximalvolumen ||| maximum volume ||| 0-0 0-1
Maximum liegt immer deutlich unter ||| peak is always well below ||| 0-0 1-1 1-2 2-2 3-3 4-4
Maximum liegt immer deutlich ||| peak is always well ||| 0-0 1-1 1-2 2-2 3-3
Maximum liegt immer ||| peak is always ||| 0-0 1-1 1-2 2-2
Maximum ||| peak ||| 0-0
Maße beteiligt sein . ||| a lesser degree . ||| 0-0 0-1 1-1 1-2 2-2 3-3
Maße beteiligt sein ||| a lesser degree ||| 0-0 0-1 1-1 1-2 2-2
Maßnahme hilft , die ||| measures will help to ||| 0-0 1-1 1-2 2-3 3-3
Maßnahme hilft die ||| measures will help ||| 0-0 1-1 1-2 2-2
Maßnahme hilft ||| measures will help ||| 0-0 1-1 1-2
Maßnahme ||| measures ||| 0-0
Maßnahmen dienen ||| measures should help to ||| 0-0 0-1 1-2 1-3
Maßnahmen werden zur Gewährleistung ||| measures are being taken to ||| 0-0 1-1 1-2 3-3 2-4
Maßnahmen werden zur ||| , to treat ||| 0-0 2-1 2-2
Maßnahmen werden ||| , ||| 0-0
Maßnahmen werden ||| measures are being ||| 0-0 1-1 1-2
Maßnahmen zu ergreifen . ||| case of overdose . ||| 0-0 2-0 1-1 2-1 2-2 3-3
Maßnahmen zu ergreifen . ||| in case of overdose . ||| 0-1 2-1 1-2 2-2 2-3 3-4
Maßnahmen zu ergreifen ||| case of overdose ||| 0-0 2-0 1-1 2-1 2-2
Maßnahmen zu ergreifen ||| in case of overdose ||| 0-1 2-1 1-2 2-2 2-3
Maßnahmen zur Gewichtsreduzierung ||| weight management programme , ||| 2-0 0-1 1-1 2-2
Maßnahmen zur Gewichtsreduzierung ||| weight management programme , ||| 2-0 0-1 2-2
Maßnahmen zur Gewichtsreduzierung ||| weight management programme ||| 2-0 0-1 1-1 2-2
Maßnahmen zur Gewichtsreduzierung ||| weight management programme ||| 2-0 0-1 2-2
Maßnahmen zur Pharmakovigilanz ||| pharmacovigilance activities ||| 2-0 0-1 1-1 2-1
Maßnahmen zur Vermeidung von ||| measures in order to ||| 0-0 1-3 2-3 3-3
Maßnahmen zur ||| management ||| 0-0
Maßnahmen zur ||| management ||| 0-0 1-0
Maßnahmen ||| , ||| 0-0
Maßnahmen ||| management ||| 0-0
Maßnahmen ||| measures in order ||| 0-0
Maßnahmen ||| measures in ||| 0-0
Maßnahmen ||| measures should ||| 0-0 0-1
Maßnahmen ||| measures ||| 0-0
Medice Arzneimittel Pütter GmbH & ||| Medice Arzneimittel Pütter GmbH & ||| 0-0 1-1 2-1 2-2 3-3 4-4
Medice Arzneimittel Pütter GmbH ||| Medice Arzneimittel Pütter GmbH ||| 0-0 1-1 2-1 2-2 3-3
Medice Arzneimittel Pütter ||| Medice Arzneimittel Pütter ||| 0-0 1-1 2-1 2-2
Medice Arzneimittel ||| Medice Arzneimittel ||| 0-0 0-1 1-1
Medice ||| Medice ||| 0-0
Medikamente einnehmen : ||| your doctor : ||| 0-0 0-1 1-1 2-2
Medikamente einnehmen ||| your doctor ||| 0-0 0-1 1-1
Medikation ||| medications ||| 0-0
Medikation ||| nephrotoxic medications ||| 0-1
Mehrzahl der Nebenwirkungen ||| majority of the side effects ||| 0-0 1-1 1-2 2-3 2-4
Mehrzahl der Patienten eine ||| majority of patients received a ||| 0-0 1-1 2-2 2-3 3-4
Mehrzahl der Patienten ||| majority of patients received ||| 0-0 1-1 2-2 2-3
Mehrzahl der berichteten Fälle ||| majority of reported cases ||| 0-0 1-1 2-2 3-3
Mehrzahl der berichteten ||| majority of reported ||| 0-0 1-1 2-2
Mehrzahl der ||| majority of the ||| 0-0 1-1 1-2
Mehrzahl der ||| majority of ||| 0-0 1-1
Mehrzahl dieser Symptome trat ||| majority of these symptoms ||| 0-0 1-0 1-1 3-1 1-2 2-3
Mehrzahl dieser Symptome war ||| majority of these symptoms were ||| 0-0 1-1 1-2 2-3 3-4
Mehrzahl dieser Symptome ||| majority of these symptoms ||| 0-0 1-1 1-2 2-3
Mehrzahl dieser ||| majority of these ||| 0-0 1-1 1-2
Mehrzahl ||| majority ||| 0-0
Mellitus ( siehe Abschnitt 4.4 ||| mellitus ( see section 4.4 ||| 0-0 1-1 2-2 3-3 4-4
Mellitus ( siehe Abschnitt ||| mellitus ( see section ||| 0-0 1-1 2-2 3-3
Mellitus ( siehe ||| mellitus ( see ||| 0-0 1-1 2-2
Mellitus ( ||| mellitus ( ||| 0-0 1-1
Mellitus : Hyperglykämie , in ||| Mellitus : hyperglycaemia , in ||| 0-0 2-0 1-1 2-2 3-3 4-4
Mellitus : Hyperglykämie , in ||| mellitus : hyperglycaemia , in ||| 0-0 1-1 2-2 3-3 4-4
Mellitus : Hyperglykämie , ||| Mellitus : hyperglycaemia , ||| 0-0 2-0 1-1 2-2 3-3
Mellitus : Hyperglykämie , ||| mellitus : hyperglycaemia , ||| 0-0 1-1 2-2 3-3
Mellitus : Hyperglykämie ||| Mellitus : hyperglycaemia ||| 0-0 2-0 1-1 2-2
Mellitus : Hyperglykämie ||| mellitus : hyperglycaemia ||| 0-0 1-1 2-2
Mellitus : ||| mellitus : ||| 0-0 1-1
Mellitus ||| mellitus ||| 0-0
Meloxicam ||| NSAIDs ||| 0-0
Menge ||| amount ||| 0-0
Menopause ||| menopause , ||| 0-0
Menopause ||| menopause ||| 0-0
Menschen erkennen . ||| to reproduction . ||| 1-0 0-1 1-1 2-2
Menschen erkennen ||| to reproduction ||| 1-0 0-1 1-1
Menschen in die Muttermilch übertritt ||| contraindicated during ||| 0-0 3-0 4-0 4-1
Menschen ist unklar , so ||| in humans is unclear and ||| 0-0 0-1 1-2 2-3 4-3 4-4
Menschen ist ||| in humans is ||| 0-0 0-1 1-2
Menschen mit dieser Krankheit können ||| People with this condition may ||| 0-0 1-1 2-2 3-3 4-4
Menschen mit dieser Krankheit ||| People with this condition ||| 0-0 1-1 2-2 3-3
Menschen mit dieser ||| People with this ||| 0-0 1-1 2-2
Menschen mit ||| People with ||| 0-0 1-1
Menschen n ||| humans . dic ||| 0-0 0-1 1-2
Menschen ||| People ||| 0-0
Menschen ||| ausgeschieden ||| 0-0
Menschen ||| human ||| 0-0
Menschen ||| humans . ||| 0-0 0-1
Menschen ||| in humans ||| 0-0 0-1
Merkmale des Arzneimittels , Abschnitt ||| Product Characterisitics , Section ||| 0-0 1-0 2-1 3-2 4-3
Merkmale des Arzneimittels , Abschnitt ||| Product Characteristics , section ||| 0-0 1-0 0-1 2-1 3-2 4-3
Merkmale des Arzneimittels , ||| Product Characterisitics , ||| 0-0 1-0 2-1 3-2
Merkmale des Arzneimittels , ||| Product Characteristics , ||| 0-0 1-0 0-1 2-1 3-2
Merkmale des Arzneimittels zu ||| Product Characteristics ||| 0-0 1-0 0-1 2-1
Merkmale des Arzneimittels ||| Product Characterisitics ||| 0-0 1-0 2-1
Merkmale des Arzneimittels ||| Product Characteristics ||| 0-0 1-0 0-1 2-1
Merkmale des ||| Product ||| 0-0 1-0
Merkmalen und mit oder ohne ||| features and with or without ||| 0-0 1-1 2-2 3-3 4-4
Merkmalen und mit oder ||| features and with or ||| 0-0 1-1 2-2 3-3
Merkmalen und mit ||| features and with ||| 0-0 1-1 2-2
Merkmalen und ||| features and ||| 0-0 1-1
Merkmalen ||| features ||| 0-0
Messbecher und eine ||| measuring cup and a ||| 0-0 0-1 1-2 2-3
Messbecher und ||| measuring cup and ||| 0-0 0-1 1-2
Messbecher ||| measuring cup ||| 0-0 0-1
Messskalen , die ||| in rating scales ||| 0-0 0-1 1-1 0-2 2-2
Messung ||| Aclasta ||| 0-0
Metaanalyse überflüssig , ||| , orchidectomy ||| 2-0 1-1
Metaanalyse überflüssig ||| orchidectomy ||| 1-0
Metabolisierern die gemeinsame ||| result ||| 0-0 2-0
Metabolismus Es ||| Metabolism Human ||| 0-0 0-1 1-1
Metabolit M-III gleichermaßen zur ||| metabolite M-III contribute equally to ||| 0-0 0-1 1-1 2-2 2-3 3-3 3-4
Metabolit M-III ||| metabolite M-III ||| 0-0 0-1 1-1
Metabolit ||| metabolite ||| 0-0
Metaboliten ( 3 ||| metabolites , 3 ||| 0-0 2-2
Metaboliten ( 3 ||| minor metabolites , 3 ||| 0-1 2-3
Metaboliten ( ||| metabolites , ||| 0-0
Metaboliten ( ||| metabolites ||| 0-0
Metaboliten ( ||| minor metabolites , ||| 0-1
Metaboliten ( ||| minor metabolites ||| 0-1
Metaboliten . ||| metabolites . ||| 0-0 1-1
Metaboliten 6 -Hydroxypaclitaxel und 3 ||| metabolites 6 -hydroxypaclitaxel and 3 ||| 0-0 1-1 2-2 3-3 4-4
Metaboliten 6 -Hydroxypaclitaxel und ||| metabolites 6 -hydroxypaclitaxel and ||| 0-0 1-1 2-2 3-3
Metaboliten 6 -Hydroxypaclitaxel ||| metabolites 6 -hydroxypaclitaxel ||| 0-0 1-1 2-2
Metaboliten 6 ||| metabolites 6 ||| 0-0 1-1
Metaboliten binden in sehr hohem ||| metabolites bind very extensively ||| 0-0 1-1 3-2 4-2 0-3 2-3
Metaboliten erfolgt jeweils ||| metabolites is catalysed ||| 0-0 1-1 1-2
Metaboliten erfolgt jeweils über CYP2C8 ||| metabolites is catalysed by CYP2C8 ||| 0-0 1-1 1-2 3-3 4-4
Metaboliten erfolgt jeweils über ||| metabolites is catalysed by ||| 0-0 1-1 1-2 3-3
Metaboliten erfolgt ||| metabolites is catalysed ||| 0-0 1-1 1-2
Metaboliten erzeugt . ||| metabolites . ||| 0-0 1-0 2-1
Metaboliten erzeugt ||| metabolites ||| 0-0 1-0
Metaboliten liegen überwiegend ||| metabolites are extensively ||| 0-0 1-1 1-2 2-2
Metaboliten sind aktiv ( M-II ||| metabolites are active ( M-II ||| 0-0 1-1 2-2 3-3 4-4
Metaboliten sind aktiv ( ||| metabolites are active ( ||| 0-0 1-1 2-2 3-3
Metaboliten sind aktiv ||| metabolites are active ||| 0-0 1-1 2-2
Metaboliten sind ||| metabolites are ||| 0-0 1-1
Metaboliten ||| metabolites , ||| 0-0
Metaboliten ||| metabolites ||| 0-0
Metaboliten ||| minor metabolites , ||| 0-1
Metaboliten ||| minor metabolites ||| 0-1
Metacresol , das ||| metacresol , which ||| 0-0 1-1 0-2 2-2
Metacresol Phenol ||| Metacresol Phenol ||| 0-0 1-0 1-1
Metastasen ||| metastases ||| 0-0
Metastasestellen . ||| metastases . ||| 0-0 1-1
Metastasestellen . ||| of metastases . ||| 0-1 1-2
Metastasestellen . ||| sites of metastases . ||| 0-2 1-3
Metastasestellen ||| metastases ||| 0-0
Metastasestellen ||| of metastases ||| 0-1
Metastasestellen ||| sites of metastases ||| 0-2
Metformin ) betrugen 2-5 ||| metformin ) were 2 5 ||| 0-0 1-1 2-2 3-3 3-4
Metformin ) betrugen ||| metformin ) were ||| 0-0 1-1 2-2
Metformin ) untersucht . ||| metformin ) . ||| 0-0 1-1 2-2 3-2
Metformin ) ||| metformin ) ||| 0-0 1-1
Metformin , Gliclazid ) verglichen ||| metformin , gliclazide ) ||| 0-0 1-1 2-2 3-3 4-3
Metformin , Gliclazid ||| metformin , gliclazide ||| 0-0 1-1 2-2
Metformin , ||| metformin , ||| 0-0 1-1
Metformin bei Patienten ( insbesondere ||| metformin in patients ( particularly ||| 0-0 1-1 2-2 3-3 4-4
Metformin bei Patienten ( ||| metformin , in patients ( ||| 0-0 1-2 2-3 3-4
Metformin bei Patienten ( ||| metformin in patients ( ||| 0-0 1-1 2-2 3-3
Metformin bei Patienten ||| metformin , in patients ||| 0-0 1-2 2-3
Metformin bei Patienten ||| metformin in patients ||| 0-0 1-1 2-2
Metformin bei ||| metformin , in ||| 0-0 1-2
Metformin bei ||| metformin in ||| 0-0 1-1
Metformin mit einem Sulfonylharnstoff ||| metformin and a sulphonylurea ||| 0-0 1-2 2-2 2-3 3-3
Metformin oder ||| metformin or ||| 0-0 1-1
Metformin und / ||| metformin and / ||| 0-0 1-1 2-2
Metformin und Gliclazid . ||| metformin and gliclazide . ||| 0-0 1-1 2-2 3-3
Metformin und Gliclazid ||| metformin and gliclazide ||| 0-0 1-1 2-2
Metformin und einem Sulfonylharnstoff ||| metformin and a sulphonylurea , ||| 0-0 1-1 2-2 2-3 3-3
Metformin und einem Sulfonylharnstoff ||| metformin and a sulphonylurea ||| 0-0 1-1 2-2 2-3 3-3
Metformin und ||| metformin and ||| 0-0 1-1
Metformin und/oder einem Sulfonylharnstoff ||| metformin and/ or a sulphonylurea ||| 0-0 1-1 1-2 2-3 2-4 3-4
Metformin und/oder ||| metformin and/ or ||| 0-0 1-1 1-2
Metformin unzureichend eingestellt ist ||| monotherapy with metformin ||| 1-0 2-1 0-2 2-2 3-2
Metformin ||| metformin , ||| 0-0
Metformin ||| metformin and ||| 0-0
Metformin ||| metformin ||| 0-0
Methyl-4-hydroxybenzoat ( E218 ) ||| Methyl parahydroxybenzoate ( E218 ) ||| 0-0 0-1 1-2 2-3 3-4
Methyl-4-hydroxybenzoat ( E218 ) ||| methyl parahydroxybenzoate ( E218 ) ||| 0-0 0-1 1-2 2-3 3-4
Methyl-4-hydroxybenzoat ( E218 ||| Methyl parahydroxybenzoate ( E218 ||| 0-0 0-1 1-2 2-3
Methyl-4-hydroxybenzoat ( E218 ||| methyl parahydroxybenzoate ( E218 ||| 0-0 0-1 1-2 2-3
Methyl-4-hydroxybenzoat ( ||| Methyl parahydroxybenzoate ( ||| 0-0 0-1 1-2
Methyl-4-hydroxybenzoat ( ||| methyl parahydroxybenzoate ( ||| 0-0 0-1 1-2
Methyl-4-hydroxybenzoat und ||| methyl parahydroxybenzoate and ||| 0-0 0-1 1-2
Methyl-4-hydroxybenzoat ||| Methyl parahydroxybenzoate ||| 0-0 0-1
Methyl-4-hydroxybenzoat ||| methyl parahydroxybenzoate ||| 0-0 0-1
Midazolam ( CYP3A4-Substrat ) ||| denen Midazolam ( CYP3A4-Substrat ) ||| 0-0 0-1 1-2 2-3 3-4
Midazolam ( CYP3A4-Substrat ||| denen Midazolam ( CYP3A4-Substrat ||| 0-0 0-1 1-2 2-3
Midazolam ( ||| denen Midazolam ( ||| 0-0 0-1 1-2
Midazolam ||| denen Midazolam ||| 0-0 0-1
Middlesex UB8 1HU - Vereinigtes ||| Middlesex UB8 1HU - United ||| 0-0 1-1 2-2 3-3 4-4
Middlesex UB8 1HU - ||| Middlesex UB8 1HU - ||| 0-0 1-1 2-2 3-3
Middlesex UB8 1HU ||| Middlesex UB8 1HU ||| 0-0 1-1 2-2
Middlesex UB8 1HU- Vereinigtes ||| Middlesex UB8 1HU - United ||| 0-0 1-1 1-2 2-2 2-3 3-4
Middlesex UB8 1HU- ||| Middlesex UB8 1HU - ||| 0-0 1-1 1-2 2-2 2-3
Middlesex UB8 ||| Middlesex UB8 ||| 0-0 1-1
Middlesex ||| Middlesex ||| 0-0
Mikrocomputertomographie-(µCT)-Analyse ||| 8 tomography ( CT ) ||| 0-0 0-1 0-3
Mikrocomputertomographie-(µCT)-Analyse ||| 8 tomography ( CT ||| 0-0 0-1 0-3
Mikrogramm Epoetin alfa ||| micrograms epoetin alfa ||| 0-0 1-1 2-2
Mikrogramm Epoetin ||| micrograms epoetin ||| 0-0 1-1
Mikrogramm ||| micrograms ||| 0-0
Mikrokristalline Cellulose Aspartam ( E951 ||| Microcrystalline cellulose Aspartame ( E951 ||| 0-0 1-1 2-2 3-3 4-4
Mikrokristalline Cellulose Aspartam ( ||| Microcrystalline cellulose Aspartame ( ||| 0-0 1-1 2-2 3-3
Mikrokristalline Cellulose Aspartam ||| Microcrystalline cellulose Aspartame ||| 0-0 1-1 2-2
Mikrokristalline Cellulose ||| Hydroxypropyl cellulose Magnesium stearate ||| 0-0 0-1 1-2 1-3
Mikrokristalline Cellulose ||| Microcrystalline cellulose ||| 0-0 1-1
Mikrokristalline ||| Hydroxypropyl cellulose ||| 0-0 0-1
Mikrokristalline ||| Microcrystalline ||| 0-0
Milchsäure Methyl-4-hydroxybenzoat ||| Glycerin Lactic acid Methyl parahydroxybenzoate ||| 0-0 0-1 0-2 1-3 1-4
Milchsäure ||| Glycerin Lactic acid ||| 0-0 0-1 0-2
Minderheit von Patienten ||| women who are breast ||| 0-0 2-1 1-2 2-3
Minderheit ||| women ||| 0-0
Mindestens eine neue ||| At least one new ||| 0-0 0-1 0-2 1-2 2-3
Mindestens eine ||| At least one ||| 0-0 0-1 0-2 1-2
Mineralstoffhaushalts sind wirksam zu ||| mineral metabolism must also be ||| 0-0 0-1 0-2 1-3 3-4
Mineralstoffhaushalts sind wirksam ||| mineral metabolism must also ||| 0-0 0-1 0-2 1-3
Mineralstoffhaushalts sind ||| mineral metabolism must also ||| 0-0 0-1 0-2 1-3
Mineralstoffhaushalts ||| mineral metabolism must ||| 0-0 0-1 0-2
Minute ||| minute ||| 0-0
Minuten ) . ||| minutes ) . ||| 0-0 1-1 2-2
Minuten ) ||| minutes ) ||| 0-0 1-1
Minuten . ||| minutes . ||| 0-0 1-1
Minuten alle drei Wochen ||| minutes , every three weeks ||| 0-0 1-2 2-3 3-4
Minuten alle drei ||| minutes , every three ||| 0-0 1-2 2-3
Minuten alle ||| minutes , every ||| 0-0 1-2
Minuten betragen . ||| minutes . ||| 0-0 1-0 2-1
Minuten betragen ||| minutes ||| 0-0 1-0
Minuten dauernde Infusionen von 2 ||| 15-minute infusions of 2 ||| 1-0 1-1 2-1 0-2 3-2 4-3
Minuten dauernde Infusionen von ||| 15-minute infusions of ||| 1-0 1-1 2-1 0-2 3-2
Minuten in dreiwöchigem Abstand . ||| minutes every 3 weeks . ||| 0-0 2-1 3-2 2-3 4-4
Minuten in dreiwöchigem Abstand ||| minutes every 3 weeks ||| 0-0 2-1 3-2 2-3
Minuten in ||| minutes ||| 0-0
Minuten nach ||| be followed ||| 0-0 0-1 1-1
Minuten verabreicht . ||| minutes . ||| 0-0 1-0 2-1
Minuten verabreicht ||| minutes ||| 0-0 1-0
Minuten ||| minutes , ||| 0-0
Minuten ||| minutes caused ||| 0-0
Minuten ||| minutes ||| 0-0
Mischung aus gelöstem Insulin und ||| mixture of dissolved insulin and ||| 0-0 1-1 1-2 2-2 3-3 4-4
Mischung aus gelöstem Insulin ||| mixture of dissolved insulin ||| 0-0 1-1 1-2 2-2 3-3
Mischung aus gelöstem ||| mixture of dissolved ||| 0-0 1-1 1-2 2-2
Mischung ||| mixture ||| 0-0
Missbildungen ( siehe Abschnitt ||| malformations ( see section ||| 0-0 1-1 2-2 3-3
Missbildungen ( siehe ||| malformations ( see ||| 0-0 1-1 2-2
Missbildungen ( ||| malformations ( ||| 0-0 1-1
Missbildungen und Fruchttod in utero ||| malformations and death in utero ||| 0-0 1-1 2-2 3-3 2-4 4-4
Missbildungen und ||| malformations and ||| 0-0 1-1
Missbildungen ||| malformations ||| 0-0
Mit Rücksicht auf die ||| Owing to the ||| 0-0 1-0 2-0 1-1 3-2
Mit Rücksicht auf ||| Owing to ||| 0-0 1-0 2-0 1-1
Mit der Eisensubstitution sollte ||| Iron supplementation should be ||| 0-0 0-1 1-1 2-1 3-2 3-3
Mit der Eisensubstitution ||| Iron supplementation ||| 0-0 0-1 1-1 2-1
Mit intaktem Skelett können ||| With their skeleton still ||| 0-0 1-0 1-1 3-1 1-2 2-2 2-3
Mitgliedsstaaten müssen dafür sorgen ||| Member States shall ||| 0-0 0-1 2-1 0-2 3-2
Mitgliedstaat ||| STATES ||| 0-0
Mitose . ||| mitosis . ||| 0-0 1-1
Mitose ||| mitosis ||| 0-0
Mitratapid ( Muttersubstanz ||| mitratapide ( parent ||| 0-0 1-1 2-2
Mitratapid ( ||| mitratapide ( ||| 0-0 1-1
Mitratapid 5 mg/ml ||| Mitratapide 5 mg/ ml ||| 0-0 1-1 2-2 2-3
Mitratapid 5 ||| Mitratapide 5 ||| 0-0 1-1
Mitratapid hat auch einen ||| Mitratapide also has a ||| 0-0 2-1 1-2 3-3
Mitratapid hat auch ||| Mitratapide also has ||| 0-0 2-1 1-2
Mitratapid im Vergleich zu Placebo ||| mitratapide versus placebo ||| 0-0 2-1 3-2 4-2
Mitratapid im Vergleich ||| mitratapide versus ||| 0-0 2-1
Mitratapid im ||| mitratapide ||| 0-0
Mitratapid ist ||| Mitratapide is ||| 0-0 1-1
Mitratapid oder ||| mitratapide or ||| 0-0 1-1
Mitratapid rasch . ||| mitratapide . ||| 0-0 1-0 2-1
Mitratapid rasch ||| mitratapide ||| 0-0 1-0
Mitratapid und seine ||| Mitratapide and its ||| 0-0 1-1 2-2
Mitratapid und ||| Mitratapide and ||| 0-0 1-1
Mitratapid wurde nicht untersucht ||| mitratapide has not been investigated ||| 0-0 1-1 2-2 1-3 3-4
Mitratapid wurde nicht ||| mitratapide has not been ||| 0-0 1-1 2-2 1-3
Mitratapid ||| , mitratapide ||| 0-1
Mitratapid ||| Mitratapide ||| 0-0
Mitratapid ||| mitratapide , ||| 0-0
Mitratapid ||| mitratapide ||| 0-0
Mitratapid/kg Körpergewicht ||| mitratapide/ kg bodyweight results ||| 0-0 1-1 1-2
Mitratapid/kg Körpergewicht ||| mitratapide/ kg bodyweight ||| 0-0 1-1 1-2
Mitratapid/kg ||| mitratapide/ ||| 0-0
Mittel ||| kg ||| 0-0
Mitteln ||| constipating ||| 0-0
Molekulargewicht von Erythropoetin ||| apparent molecular weight of erythropoietin ||| 0-0 0-1 1-1 0-2 1-3 2-4
Molekulargewicht von ||| apparent molecular weight of ||| 0-0 0-1 1-1 0-2 1-3
Moleküls ist 58 % ||| molecule contributes about 58 % ||| 0-0 1-1 2-1 2-2 2-3 3-4
Moleküls ist 58 ||| molecule contributes about 58 ||| 0-0 1-1 2-1 2-2 2-3
Moleküls ||| molecule ||| 0-0
Monat ) mit ||| month ) with ||| 0-0 1-1 2-2
Monat ) ||| month ) ||| 0-0 1-1
Monat ansteigt oder wenn der ||| month , or if the ||| 0-0 1-0 2-2 3-3 4-4
Monat ansteigt oder wenn ||| month , or if ||| 0-0 1-0 2-2 3-3
Monat ansteigt oder ||| month , or if the ||| 0-0 1-0 2-2 1-3
Monat ansteigt oder ||| month , or if ||| 0-0 1-0 2-2 1-3
Monat ansteigt oder ||| month , or ||| 0-0 1-0 2-2
Monat ansteigt ||| month , ||| 0-0 1-0
Monat ansteigt ||| month ||| 0-0 1-0
Monat betragen und sollte ||| month and should not exceed ||| 0-0 2-1 3-2 1-3 1-4
Monat nach ||| month after ||| 0-0 1-1
Monat oder ||| month or the ||| 0-0 1-1
Monat oder ||| month or ||| 0-0 1-1
Monat ||| month ||| 0-0
Monate ( 300 mg/m2 ||| months ( 300 mg/ m2 ||| 0-0 1-1 2-2 3-3 3-4
Monate ( 300 ||| months ( 300 ||| 0-0 1-1 2-2
Monate ( ||| 5.3 months ( ||| 1-0 0-1 1-2
Monate ( ||| months ( ||| 0-0 1-1
Monate ) . ||| months ) . ||| 0-0 1-1 2-2
Monate ) und 6,1 Monate ||| months ) and 6.1 months ||| 0-0 1-1 2-2 3-3 4-4
Monate ) und 6,1 ||| months ) and 6.1 ||| 0-0 1-1 2-2 3-3
Monate ) und ||| months ) and ||| 0-0 1-1 2-2
Monate ) ||| months ) ||| 0-0 1-1
Monate Das Arzneimittel ist sofort ||| months Use product immediately ||| 0-0 1-1 2-2 3-2 4-3
Monate Das Arzneimittel ist ||| months Use product ||| 0-0 1-1 2-2 3-2
Monate Das ||| months Use ||| 0-0 1-1
Monate bei Lagerung ||| months when stored between ||| 0-0 2-1 1-2 2-2 2-3
Monate einen PSUR ||| a PSUR at ||| 1-0 2-1 0-2
Monate einen PSUR ||| provide a PSUR at ||| 1-1 2-2 0-3
Monate lang ||| months ||| 0-0 1-0
Monate nach Verabreichung ||| months after treatment ||| 0-0 1-1 2-1
Monate nach Verabreichung ||| months after ||| 0-0 1-1 2-1
Monate ||| at ||| 0-0
Monate ||| months ||| 0-0
Monaten ||| months ago ||| 0-0 0-1
Monaten ||| months ||| 0-0
Monaten. wenn ||| . if ||| 1-1
Monaten. wenn ||| if ||| 1-0
Monats . ||| that month . ||| 0-0 0-1 1-2
Monats vor Ihrer ||| month before your ||| 0-0 1-1 2-2
Monats vor Ihrer ||| the month before your ||| 0-1 1-2 2-3
Monats vor ||| month before ||| 0-0 1-1
Monats vor ||| the month before ||| 0-1 1-2
Monats ||| month ||| 0-0
Monats ||| that month ||| 0-0 0-1
Monats ||| the month ||| 0-1
Monoaminoxidasehemmer ( MAO-Hemmer ||| monoamine oxidase inhibitors ( MAOI ||| 0-0 0-1 0-2 1-3 2-4
Monoaminoxidasehemmer ( ||| monoamine oxidase inhibitors ( ||| 0-0 0-1 0-2 1-3
Monoaminoxidasehemmer ||| monoamine oxidase inhibitors ||| 0-0 0-1 0-2
Monohydrat , Hyprolose , ||| Actos looks like ||| 0-0 0-1 1-2 2-2 3-2
Monohydrat ||| Actos looks ||| 0-0 0-1
Monotherapie mit 45 mg ||| 45 mg monotherapy ||| 2-0 3-1 0-2 1-2
Monotherapie mit Aripiprazol . ||| treatment with aripiprazole alone . ||| 0-0 1-1 2-2 0-3 3-4
Monotherapie mit Aripiprazol ||| treatment with aripiprazole alone ||| 0-0 1-1 2-2 0-3
Monotherapie mit Lithium oder Valproat ||| than lithium or valproate monotherapy ||| 0-0 2-1 3-2 4-3 0-4 1-4
Monotherapie mit maximal verträglichen Dosen ||| control despite maximal tolerated dose ||| 0-0 0-1 1-1 3-1 2-2 3-2 3-3 4-3 3-4
Monotherapie mit ||| monotherapy ||| 0-0 1-0
Monotherapie oder Kombinationstherapie ( ||| monotherapy or combination therapy ( ||| 0-0 1-1 2-2 2-3 3-4
Monotherapie oder Kombinationstherapie ||| monotherapy or combination therapy ||| 0-0 1-1 2-2 2-3
Monotherapie oder ||| monotherapy or ||| 0-0 1-1
Monotherapie wurde ||| monotherapy was ||| 0-0 1-1
Monotherapie ||| administered alone ||| 0-0 0-1
Monotherapie ||| monotherapy ||| 0-0
Monotherapie ||| type 2 diabetes mellitus : ||| 0-0 0-1 0-2 0-3 0-4
Montgomery-Asberg- ||| Montgomery-Asberg ||| 0-0
Morbus Paget 6 Monate ||| Paget s disease 6 months ||| 0-0 1-0 1-1 1-2 2-3 3-4
Morbus Paget 6 ||| Paget s disease 6 ||| 0-0 1-0 1-1 1-2 2-3
Morbus Paget Die ||| 27 Paget s disease The ||| 0-0 0-1 1-1 1-2 1-3 2-4
Morbus Paget des Knochens ||| Paget des ||| 0-0 1-0 3-0 2-1
Morbus Paget des ||| Paget s disease of the ||| 0-0 0-1 1-1 1-2 2-3 2-4
Morbus Paget des ||| Paget s disease of the ||| 0-0 1-0 0-1 1-2 2-3 2-4
Morbus Paget des ||| Paget s disease of the ||| 0-0 1-0 1-1 2-1 1-2 2-3 2-4
Morbus Paget kann Aclasta ||| Paget s disease Aclasta may ||| 0-0 1-0 1-1 1-2 3-3 2-4
Morbus Paget ||| 27 Paget s disease ||| 0-0 0-1 1-1 1-2 1-3
Morbus Paget ||| Paget s disease , ||| 0-0 1-0 0-1 1-2
Morbus Paget ||| Paget s disease ||| 0-0 0-1 1-1 1-2
Morbus Paget ||| Paget s disease ||| 0-0 1-0 0-1 1-2
Morbus Paget ||| Paget s disease ||| 0-0 1-0 1-1 1-2
Mortalität : In drei Placebo-kontrollierten ||| mortality : in three placebo-controlled ||| 0-0 1-1 0-2 3-3 2-4 4-4
Mortalität : ||| mortality : in ||| 0-0 1-1 0-2
Mortalität in der Studie führte ||| in mortality in this study ||| 1-0 0-1 4-1 1-2 2-2 4-3 3-4
Mortalität in dieser Studie ||| in mortality in this study ||| 1-0 0-1 1-2 2-3 3-4
Mortalität in dieser ||| in mortality in this ||| 1-0 0-1 1-2 2-3
Mortalität in ||| in mortality in ||| 1-0 0-1 1-2
Mortalität ||| mortality ||| 0-0
Mortalitätsrisiko , wenn ||| of death when administered ||| 0-0 0-1 1-2 2-2 0-3
Mortalitätsrisiko und Risiko ||| risk of death and ||| 2-0 0-1 0-2 1-3
Mortalitätsrisiko und ||| of death and ||| 0-0 0-1 1-2
Mortalitätsrisiko ||| of death ||| 0-0 0-1
Mukositis ||| marrow suppression ||| 0-0 0-1
Mund , schmerzendes Zahnfleisch ||| mouth , ||| 0-0 1-1 2-1 3-1
Mund . ||| mouth . ||| 0-0 1-1
Mund ||| mouth ||| 0-0
Mund* Gefäßerkrankungen Gelegentlich : orthostatische ||| Vascular disorders Uncommon : orthostatic ||| 1-0 0-1 1-1 2-2 3-3 4-4
Mund* Gefäßerkrankungen Gelegentlich : ||| Vascular disorders Uncommon : ||| 1-0 0-1 1-1 2-2 3-3
Mund* Gefäßerkrankungen Gelegentlich ||| Vascular disorders Uncommon ||| 1-0 0-1 1-1 2-2
Mund* Gefäßerkrankungen ||| Vascular disorders ||| 1-0 0-1 1-1
Mund- ||| ; ||| 0-0
Mundtrockenheit ||| dry mouth ||| 0-0 0-1
Muscarin-Rezeptoren . Die Interaktion ||| for muscarinic receptors . ||| 0-0 0-1 2-1 3-2 1-3
Muskel ||| nurse ||| 0-0
Muskelkrämpfe ||| spasms ||| 0-0
Muskelschmerzen , ||| , muscle pain ||| 1-0 0-1 0-2
Muskelschmerzen ||| muscle pain ||| 0-0 0-1
Mutagenität und ||| Mutagenicity and ||| 0-0 1-1
Mutagenität ||| Mutagenicity ||| 0-0
Mutagenitätstests an Bakterien- und ||| bacterial and mammalian cell ||| 0-0 3-1 1-2 2-2 2-3
Mutagenitätstests ||| bacterial ||| 0-0
Mutter ||| mother ||| 0-0
Muttersubstanz ||| parent substance ||| 0-0 0-1
Muttersubstanz ||| parent ||| 0-0
Myalgie ( ||| myalgia ( ||| 0-0 1-1
Myalgie trat bei 24 % ||| Myalgia occurred in 24 % ||| 0-0 1-1 2-2 3-3 4-4
Myalgie trat bei 24 ||| Myalgia occurred in 24 ||| 0-0 1-1 2-2 3-3
Myalgie trat bei ||| Myalgia occurred in ||| 0-0 1-1 2-2
Myalgie trat ||| Myalgia occurred ||| 0-0 1-1
Myalgie ||| Myalgia ||| 0-0
Myalgie ||| myalgia ||| 0-0
Myelosuppression . ||| from myelosuppression ||| 0-1
Myelosuppression . ||| myelosuppression ||| 0-0
Myelosuppression ||| from myelosuppression ||| 0-1
Myelosuppression ||| myelosuppression ||| 0-0
Myelosuppression ||| profound myelosuppression ||| 0-0 0-1
Myoglobinurie ( Rhabdomyolyse ) ||| myoglobinuria ( rhabdomyolysis ) , ||| 0-0 1-1 2-2 3-3 2-4
Myoglobinurie ( ||| myoglobinuria ( ||| 0-0 1-1
Myoglobinurie ||| myoglobinuria ||| 0-0
Myokardinfarkt und annähernd 20 ||| myocardial infarction and approximately 20 ||| 0-0 0-1 1-2 2-3 3-4
Myokardinfarkt und annähernd ||| myocardial infarction and approximately ||| 0-0 0-1 1-2 2-3
Myokardinfarkt und ||| myocardial infarction and ||| 0-0 0-1 1-2
Myokardinfarkt ||| myocardial infarction ||| 0-0 0-1
Myokardinfarkt ||| of myocardial infarction ||| 0-1 0-2
Myokardinfarkte , zerebrovaskuläre Ereignisse ( ||| infarction , cerebrovascular accidents ( ||| 0-0 1-1 2-2 0-3 3-3 4-4
Myokardinfarkte , zerebrovaskuläre Ereignisse ||| infarction , cerebrovascular accidents ||| 0-0 1-1 2-2 0-3 3-3
Männer ||| men ||| 0-0
Männern ( Studie CZOL446M2308 ) ||| men ( study CZOL446M2308 ) ||| 0-0 1-1 2-2 3-3 4-4
Männern ( Studie CZOL446M2308 ||| men ( study CZOL446M2308 ||| 0-0 1-1 2-2 3-3
Männern ( Studie ||| men ( study ||| 0-0 1-1 2-2
Männern ( ||| men ( ||| 0-0 1-1
Männern ) , die ||| men ) ||| 0-0 1-1
Männern ) , ||| men ) ||| 0-0 1-1
Männern ) ||| men ) ||| 0-0 1-1
Männern . ||| men . ||| 0-0 1-1
Männern In der ||| men In the ||| 0-0 1-1 2-2
Männern In ||| men In ||| 0-0 1-1
Männern erforderlich ( siehe Abschnitt ||| male patients ( see section ||| 0-0 1-0 1-1 2-2 3-3 4-4
Männern erforderlich ( siehe ||| male patients ( see sections ||| 0-0 1-0 1-1 2-2 3-3 3-4
Männern erforderlich ( siehe ||| male patients ( see ||| 0-0 1-0 1-1 2-2 3-3
Männern erforderlich ( ||| male patients ( ||| 0-0 1-0 1-1 2-2
Männern erforderlich ||| male patients ||| 0-0 1-0 1-1
Männern mit ||| men with ||| 0-0 1-1
Männern und Frauen ||| men and women ||| 0-0 1-1 2-2
Männern und des Morbus Paget ||| men and Paget s disease ||| 0-0 1-1 3-2 4-2 2-3 3-3 4-4
Männern und ||| men and ||| 0-0 1-1
Männern wie bei Frauen gleich ||| among men and women ||| 2-0 0-1 2-1 3-3 4-3
Männern wie bei ||| among men and ||| 2-0 0-1 2-1
Männern wie bei ||| among men ||| 2-0 0-1 2-1
Männern ||| 2,127 men ||| 0-1
Männern ||| men , ||| 0-0
Männern ||| men ||| 0-0
Männliche Patienten sollten ||| Male patients should seek ||| 0-0 1-1 2-2
Männliche Patienten sollten ||| Male patients should ||| 0-0 1-1 2-2
Männliche Patienten ||| Male patients ||| 0-0 1-1
Männliche ||| Male ||| 0-0
Männlichen Patienten , ||| Male patients ||| 0-0 1-1
Männlichen Patienten ||| Male patients ||| 0-0 1-1
Männlichen ||| Male ||| 0-0
Mäusemilzzellkultur ||| mouse spleen cell ||| 0-0 0-1 0-2
Mäusen . ||| mice . ||| 0-0 1-1
Mäusen ||| mice ||| 0-0
Möglicher Einfluss von ABILIFY auf ||| Potential for ABILIFY to affect ||| 0-0 1-0 0-1 2-2 3-2 4-3 1-4 4-4
Möglicher Einfluss von anderen Arzneimitteln ||| Potential for other medicinal products ||| 0-0 1-0 0-1 3-2 2-3 3-3 4-4
Möglicher Einfluss von anderen ||| Potential for other medicinal ||| 0-0 1-0 0-1 3-2 2-3 3-3
Möglicher Einfluss ||| Potential for ||| 0-0 1-0 0-1
Möglicherweise sind nur ein ||| Only a few ||| 0-0 3-1 2-2
Möglicherweise sind ||| Only ||| 0-0
Möglicherweise ||| Only ||| 0-0
Möglichkeit einer Schwangerschaft . ||| risk of pregnancy . ||| 0-0 1-1 2-2 3-3
Möglichkeit einer Schwangerschaft ||| risk of pregnancy ||| 0-0 1-1 2-2
Möglichkeit einer ||| risk of ||| 0-0 1-1
Möglichkeit von multipler ||| possibility of multiple medicinal ||| 0-0 1-1 2-2 2-3
Möglichkeit von ||| possibility of ||| 0-0 1-1
Möglichkeit ||| possibility of ||| 0-0
Möglichkeit ||| possibility ||| 0-0
Möglichkeit ||| risk ||| 0-0
Müdigkeit , Schwindel und ||| tiredness , feeling dizzy or ||| 0-0 1-1 2-1 0-2 1-3
Müdigkeit , Schwindel und ||| tiredness , feeling dizzy ||| 0-0 1-1 2-1 0-2 1-3
Müdigkeit , Schwindel ||| tiredness , feeling dizzy or ||| 0-0 1-1 2-1 0-2 1-3
Müdigkeit , Schwindel ||| tiredness , feeling dizzy ||| 0-0 1-1 2-1 0-2 1-3
Müdigkeit , ||| tiredness , ||| 0-0 1-1
Müdigkeit , Übelkeit , Erbrechen ||| tiredness , nausea , vomiting ||| 0-0 1-1 2-2 3-3 4-4
Müdigkeit , Übelkeit , ||| tiredness , nausea , ||| 0-0 1-1 2-2 3-3
Müdigkeit , Übelkeit ||| tiredness , nausea ||| 0-0 1-1 2-2
Müdigkeit vorkommen ||| at the start of treatment ||| 0-0 0-1 0-2 1-2 1-3 1-4
Müdigkeit ||| tiredness ||| 0-0
Müttern nicht angewendet werden . ||| Package Leaflet . ||| 0-0 4-1 3-2 4-2
Müttern nicht angewendet ||| Package ||| 0-0
Müttern nicht ||| Package ||| 0-0
Müttern ||| Package ||| 0-0
N = 225 ) ||| N = 225 ) , ||| 0-0 1-1 2-2 3-3
N = 225 ) ||| N = 225 ) ||| 0-0 1-1 2-2 3-3
N = 225 ||| N = 225 ||| 0-0 1-1 2-2
N = 229 ) . ||| N = 229 ) . ||| 0-0 1-1 2-2 3-3 4-4
N = 229 ) ||| N = 229 ) ||| 0-0 1-1 2-2 3-3
N = 229 ||| N = 229 ||| 0-0 1-1 2-2
N = 30 ) . ||| N = 30 ) . ||| 0-0 1-1 2-2 3-3 4-4
N = 30 ) ||| N = 30 ) ||| 0-0 1-1 2-2 3-3
N = 30 ||| N = 30 ||| 0-0 1-1 2-2
N = ||| N = ||| 0-0 1-1
N ||| N ||| 0-0
N-Dealkylierung . ||| N-dealkylation . ||| 0-0 1-1
N-Dealkylierung wird durch CYP3A4 katalysiert ||| N-dealkylation is catalysed by CYP3A4 ||| 0-0 1-1 2-2 4-2 2-3 3-4
N-Dealkylierung wird ||| N-dealkylation is ||| 0-0 1-1
N-Dealkylierung ||| N-dealkylation ||| 0-0
N-terminale Propeptid ||| N-terminal ||| 0-0 1-0
N=70 ||| 152 post- menopausal ||| 0-0
N=70 ||| 152 post- ||| 0-0
N=70 ||| 152 ||| 0-0
N=70 ||| in 152 post- menopausal ||| 0-1
N=70 ||| in 152 post- ||| 0-1
N=70 ||| in 152 ||| 0-1
N=82 ) ||| iliac crest ||| 0-0 0-1
N=82 ||| iliac crest ||| 0-0 0-1
NACH GEWICHT , VOLUMEN ||| BY WEIGHT , BY VOLUME ||| 0-0 0-1 1-1 1-2 1-3 2-3 3-4
NACH GEWICHT , ||| BY WEIGHT , BY ||| 0-0 0-1 1-1 1-2 1-3 2-3
NACH GEWICHT , ||| BY WEIGHT , BY ||| 0-0 0-1 1-2 1-3 2-3
NACH ||| BY WEIGHT ||| 0-0 0-1
NAME UND ANSCHRIFT DES ZULASSUNGSINHABERS ||| NAME AND ADDRESS OF THE ||| 3-0 1-1 0-2 2-2 3-3 3-4 4-4
NAME UND ANSCHRIFT ||| AND ADDRESS ||| 1-0 0-1 2-1
NICHT SICHTBAR AUFZUBEWAHREN IST ||| REACH AND SIGHT OF CHILDREN ||| 0-0 1-1 1-2 2-2 2-3 3-4
NICHT SICHTBAR AUFZUBEWAHREN ||| REACH AND SIGHT OF ||| 0-0 1-1 1-2 2-2 2-3
NICHT VERWENDETEM ARZNEIMITTEL ODER ||| MATERIALS DERIVED FROM SUCH MEDICINAL ||| 0-0 1-1 1-2 2-2 2-3 3-3 2-4
NICHT ||| MATERIALS ||| 0-0
NICHT ||| REACH ||| 0-0
NORWAY LTD Tlf : + ||| NORWAY LTD Tlf : + ||| 0-0 1-1 2-2 3-3 4-4
NORWAY LTD Tlf : ||| NORWAY LTD Tlf : ||| 0-0 1-1 2-2 3-3
NORWAY LTD Tlf ||| NORWAY LTD Tlf ||| 0-0 1-1 2-2
NORWAY LTD ||| NORWAY LTD ||| 0-0 1-1
NORWAY ||| NORWAY ||| 0-0
NPH- ) Insulin . ||| NPH ) insulin . ||| 0-0 1-1 2-2 3-3
NPH- ) Insulin ||| NPH ) insulin ||| 0-0 1-1 2-2
NPH- ) ||| NPH ) ||| 0-0 1-1
NPH- ||| NPH ||| 0-0
NUR ||| THE WEEK ||| 0-0 0-1
NYHA I bis IV ||| NYHA stages I to IV ||| 0-0 1-0 0-1 1-2 2-3 3-4
NYHA I bis ||| NYHA stages I to ||| 0-0 1-0 0-1 1-2 2-3
NYHA I ||| NYHA stages I ||| 0-0 1-0 0-1 1-2
Nach 2 Jahren betrug ||| At two years , ||| 0-0 1-1 2-1 2-2 3-2
Nach 2 Jahren betrug ||| At two years ||| 0-0 1-1 2-1 2-2 3-2
Nach 24 Monaten ||| At 24 months ||| 0-0 1-1 2-2
Nach 24 ||| At 24 ||| 0-0 1-1
Nach Abbruch der Behandlung können ||| These symptoms can temporally ||| 0-0 1-0 1-1 1-2 1-3 2-3 3-3 4-3
Nach Abbruch der Behandlung ||| These symptoms can temporally ||| 0-0 1-0 1-1 1-2 1-3 2-3 3-3
Nach Absetzen der hochwirksamen ||| Upon discontinuation of potent CYP3A4 ||| 0-0 1-0 1-1 2-2 3-3 3-4
Nach Absetzen der ||| Upon discontinuation of ||| 0-0 1-0 1-1 2-2
Nach Absetzen des ||| 97 Upon discontinuation of the ||| 0-0 0-1 1-1 1-2 2-3 2-4
Nach Absetzen des ||| Upon discontinuation of the ||| 0-0 1-0 1-1 2-2 2-3
Nach Absetzen ||| 97 Upon discontinuation ||| 0-0 0-1 1-1 1-2
Nach Absetzen ||| Upon discontinuation ||| 0-0 1-0 1-1
Nach Applikation von Epoetin alfa ||| After administration of epoetin alfa ||| 0-0 1-1 2-2 3-3 4-4
Nach Applikation von Epoetin ||| After administration of epoetin ||| 0-0 1-1 2-2 3-3
Nach Applikation von ||| After administration of ||| 0-0 1-1 2-2
Nach Applikation ||| After administration ||| 0-0 1-1
Nach Beginn der Therapie mit ||| Following initiation of therapy with ||| 0-0 1-1 2-2 3-3 4-4
Nach Beginn der Therapie ||| Following initiation of therapy ||| 0-0 1-1 2-2 3-3
Nach Beginn der ||| Following initiation of ||| 0-0 1-1 2-2
Nach Beginn ||| Following initiation ||| 0-0 1-1
Nach Injektion der ||| After injection of the ||| 0-0 1-1 2-2 2-3
Nach Injektion ||| After injection ||| 0-0 1-1
Nach Markteinführung wurde über Fälle ||| There have been cases ||| 0-0 1-0 1-1 1-2 2-2 3-2 4-3
Nach Markteinführung wurde über ||| There have been ||| 0-0 1-0 1-1 1-2 2-2 3-2
Nach Rekonstitution enthält Abraxane ||| When reconstituted , Abraxane contains ||| 0-0 0-1 1-1 3-3 2-4
Nach Rekonstitution ||| When reconstituted , ||| 0-0 0-1 1-1
Nach Rekonstitution ||| When reconstituted ||| 0-0 0-1 1-1
Nach dem Öffnen ||| Once opened , ||| 0-0 2-0 1-1 2-1
Nach dem Öffnen ||| Once opened , ||| 0-0 2-0 1-1 2-1 2-2
Nach dem Öffnen ||| Once opened ||| 0-0 2-0 1-1 2-1
Nach der Menopause ||| At the menopause , ||| 0-0 1-1 2-2
Nach der Menopause ||| At the menopause ||| 0-0 1-1 2-2
Nach der Rekonstitution ||| After reconstitution , ||| 0-0 1-1 2-1
Nach der Rekonstitution ||| After reconstitution ||| 0-0 1-1 2-1
Nach der Verabreichung von ||| administration ||| 2-0
Nach der Verabreichung von ||| following the administration ||| 2-2
Nach der Verabreichung von ||| the administration ||| 2-1
Nach der Verabreichung ||| administration ||| 2-0
Nach der Verabreichung ||| following the administration ||| 2-2
Nach der Verabreichung ||| the administration ||| 2-1
Nach der ersten Rekonstitution ||| After first reconstitution , ||| 0-0 1-1 2-1 3-2
Nach der ersten Rekonstitution ||| After first reconstitution ||| 0-0 1-1 2-1 3-2
Nach der ersten ||| After first ||| 0-0 1-1 2-1
Nach der ||| After ||| 0-0 1-0
Nach der ||| At the ||| 0-0 1-1
Nach einer Behandlung ||| After a single treatment ||| 0-0 1-1 0-2 2-3
Nach einer ||| After a single ||| 0-0 1-1 0-2
Nach gemeinsamer Anwendung ||| Following concomitant administration ||| 0-0 1-1 2-2
Nach gemeinsamer ||| Following concomitant ||| 0-0 1-1
Nach intravenöser Gabe von Abraxane ||| Following intravenous administration of Abraxane ||| 0-0 1-1 2-2 3-3 4-4
Nach intravenöser Gabe von ||| Following intravenous administration of ||| 0-0 1-1 2-2 3-3
Nach intravenöser Gabe ||| Following intravenous administration ||| 0-0 1-1 2-2
Nach intravenöser ||| Following intravenous ||| 0-0 1-1
Nach jeder Dosis ||| After each dose , ||| 0-0 1-1 2-2
Nach jeder Dosis ||| After each dose ||| 0-0 1-1 2-2
Nach jeder vorliegenden oder vermuteten ||| Following any confirmed or suspected ||| 0-0 1-1 1-2 2-2 4-2 3-3 4-4
Nach jeder ||| After each ||| 0-0 1-1
Nach mehrfacher Gabe von ||| Following multiple ||| 0-0 2-0 1-1 3-1
Nach oraler Anwendung von ||| Following oral administration of ||| 0-0 1-1 2-2 3-3
Nach oraler Anwendung ||| Following oral administration ||| 0-0 1-1 2-2
Nach oraler Verabreichung ||| Following oral administration , ||| 0-0 1-1 2-2
Nach oraler Verabreichung ||| Following oral administration ||| 0-0 1-1 2-2
Nach oraler ||| Following oral ||| 0-0 1-1
Nach subkutaner Injektion ||| Following subcutaneous injection , ||| 0-0 1-1 2-2
Nach subkutaner Injektion ||| Following subcutaneous injection ||| 0-0 1-1 2-2
Nach subkutaner ||| Following subcutaneous ||| 0-0 1-1
Nach zur Zeit vorliegenden ||| Based on information available to ||| 0-0 1-0 2-0 3-0 3-1 3-2 3-3 1-4
Nach zwei ||| At two ||| 0-0 1-1
Nach ||| After multiple ||| 0-0
Nach ||| After ||| 0-0
Nach ||| At ||| 0-0
Nach ||| Following ||| 0-0
Nach ||| after ||| 0-0
Nach Öffnen der Flasche ||| After opening the bottle , ||| 0-0 1-1 2-2 3-3
Nach Öffnen der Flasche ||| After opening the bottle ||| 0-0 1-1 2-2 3-3
Nach Öffnen der ||| After opening the ||| 0-0 1-1 2-2
Nach Öffnen ||| After opening ||| 0-0 1-1
Nachbeobachtungsphase ||| extended follow-up ||| 0-0 0-1
Nachbeobachtungsstudie ||| observation study ||| 0-0
Nachbeobachtungsstudie ||| observation ||| 0-0
Nachlassen der Wirksamkeit als ||| treated with gliclazide , compared ||| 0-0 0-1 0-2 2-2 2-4 3-4
Nachweisen verifiziert ||| is presented in Table 3. ||| 0-1 1-3 1-4
Nachweisen verifiziert ||| presented in Table 3. ||| 0-0 1-2 1-3
Nachweisen ||| is presented in ||| 0-1
Nachweisen ||| is presented ||| 0-1
Nachweisen ||| presented in ||| 0-0
Nachweisen ||| presented ||| 0-0
Nadel schnell heraus und ||| needle quickly and apply pressure ||| 0-0 1-1 3-2 2-3 3-4
Nadel schnell ||| needle quickly ||| 0-0 1-1
Nadel ||| needle ||| 0-0
Nahrung eingenommen . ||| food . ||| 0-0 1-0 2-1
Nahrung eingenommen ||| food ||| 0-0 1-0
Nahrung mit ||| food with ||| 0-0 1-1
Nahrung mit ||| of food with ||| 0-1 1-2
Nahrung ||| food ||| 0-0
Nahrung ||| of food ||| 0-1
Nahrungsmitteln und Getränken : ||| food and drink : ||| 0-0 1-1 0-2 2-2 3-3
Nahrungsmitteln und Getränken ||| food and drink ||| 0-0 1-1 0-2 2-2
Nahrungsmitteln. eim ||| fatty foods . du ||| 0-0 0-1 1-2 1-3
Nahrungsmitteln. ||| fatty foods ||| 0-0 0-1
Name und Anschrift der Hersteller ||| Name and address of ||| 0-0 1-1 2-2 4-2 3-3
Name und Anschrift der ||| Name and address of ||| 0-0 1-1 2-2 3-3
Name und Anschrift der ||| state the name and address ||| 2-0 3-1 0-2 1-3 2-4
Name und Anschrift des ||| Name and address of the ||| 0-0 1-1 2-2 3-3 3-4
Name und Anschrift des/der ||| Name and address ||| 0-0 1-1 2-2 3-2
Name und Anschrift ||| Name and address ||| 0-0 1-1 2-2
Name und Anschrift ||| and address ||| 1-0 0-1 2-1
Name und ||| Name and ||| 0-0 1-1
Name und ||| name and ||| 0-0 1-1
Name ||| Name ||| 0-0
Name ||| name ||| 0-0
Nanopartikelformulierung ||| nanoparticle ||| 0-0
Nanopartikeln an ||| in ||| 1-0
Nasennebenhöhlen ||| sinus ||| 0-0
Natrium pro Dosis . ||| sodium per dose . ||| 0-0 1-1 2-2 3-3
Natrium pro Dosis ||| sodium per dose ||| 0-0 1-1 2-2
Natrium pro ||| sodium per ||| 0-0 1-1
Natrium ||| sodium ||| 0-0
Natriumchlorid , Glycin , ||| sodium chloride , glycine , ||| 0-0 0-1 1-2 2-3 3-4
Natriumchlorid , Glycin ||| sodium chloride , glycine ||| 0-0 0-1 1-2 2-3
Natriumchlorid , ||| sodium chloride , ||| 0-0 0-1 1-2
Natriumchlorid Glycin Polysorbat 80 ||| Sodium chloride Glycine Polysorbate 80 ||| 0-0 0-1 1-2 2-2 3-3 3-4
Natriumchlorid Glycin Polysorbat ||| Sodium chloride Glycine ||| 0-0 0-1 1-2 2-2
Natriumchlorid ||| Sodium chloride ||| 0-0 0-1
Natriumchlorid ||| chloride ||| 0-0
Natriumchlorid ||| sodium chloride ||| 0-0 0-1
Natriumcitrat und Wasser für ||| sodium citrate and water for ||| 0-0 0-1 1-2 2-3 3-4
Natriumcitrat und Wasser ||| sodium citrate and water ||| 0-0 0-1 1-2 2-3
Natriumcitrat und ||| sodium citrate and ||| 0-0 0-1 1-2
Natriumcitrat ||| sodium citrate ||| 0-0 0-1
Natriumdihydrogenphosphat-Dihydrat ||| dihydrogen phosphate ||| 0-0 0-1
Natriumdihydrogenphosphat-Dihydrat ||| dihydrogen ||| 0-0
Natriumdodecylsulfat ( E 487 ||| ra Tablet core : ||| 0-0 2-1 3-2
Natriumdodecylsulfat ( E 487 ||| ra Tablet core ||| 0-0 2-1 3-2
Natriumdodecylsulfat ( E ||| ra Tablet ||| 0-0 2-1
Natriumdodecylsulfat ( ||| ra ||| 0-0
Natriumdodecylsulfat ||| ra ||| 0-0
Natriumedetat Fructose Glycerol ||| Disodium edetate Fructose ||| 0-0 2-0 0-1 1-1 0-2 1-2
Natriumhydroxid ( zur pH-Einstellung ||| Sodium hydroxide ( for pH-adjustment ||| 0-0 0-1 1-2 2-3 2-4 3-4
Natriumhydroxid ( zur pH-Einstellung ||| sodium hydroxide ( for pH-adjustment ||| 0-0 0-1 1-2 2-3 2-4 3-4
Natriumhydroxid ( ||| Sodium hydroxide ( ||| 0-0 0-1 1-2
Natriumhydroxid ( ||| sodium hydroxide ( ||| 0-0 0-1 1-2
Natriumhydroxid , Sucrose ||| sodium hydroxide , sucrose ||| 0-0 0-1 1-2 2-3
Natriumhydroxid , ||| sodium hydroxide , ||| 0-0 0-1 1-2
Natriumhydroxid Sucrose Gereinigtes Wasser ||| Sodium hydroxide Sucrose Purified water ||| 0-0 0-1 1-2 2-3 3-4
Natriumhydroxid Sucrose Gereinigtes ||| Sodium hydroxide Sucrose Purified ||| 0-0 0-1 1-2 2-3
Natriumhydroxid Sucrose ||| Sodium hydroxide Sucrose ||| 0-0 0-1 1-2
Natriumhydroxid Wasser für Injektionszwecke ||| hydroxide Water for injection ||| 0-0 1-1 3-1 2-2 3-3
Natriumhydroxid ||| Sodium hydroxide ||| 0-0 0-1
Natriumhydroxid ||| hydroxide ||| 0-0
Natriumhydroxid ||| sodium hydroxide ||| 0-0 0-1
Nausea ( Übelkeit ||| nausea ( feeling sick ||| 2-0 1-1 2-2 0-3
Nausea ||| sick ||| 0-0
Nebennieren ||| adrenal ||| 0-0
Nebennierenrinden-Adenomen/Karzinomen bei weiblichen Ratten bei ||| adenomas/ carcinomas in female rats ||| 0-0 1-0 4-0 0-1 1-2 2-3 3-4
Nebenschilddrüsen , intestinale ||| parathyroid reserve , intestinal calcium ||| 0-0 0-1 1-2 2-3 2-4
Nebenschilddrüsen , ||| diminished parathyroid reserve , ||| 0-0 0-1 0-2 1-3
Nebenschilddrüsen , ||| parathyroid reserve , ||| 0-0 0-1 1-2
Nebenschilddrüsen ||| diminished parathyroid reserve ||| 0-0 0-1 0-2
Nebenschilddrüsen ||| parathyroid reserve ||| 0-0 0-1
Nebenschilddrüsen ||| parathyroid ||| 0-0
Nebenwirkung ||| adverse reaction ||| 0-0 0-1
Nebenwirkung ||| adverse ||| 0-0
Nebenwirkung ||| an adverse reaction ||| 0-0 0-1 0-2
Nebenwirkung ||| effect ||| 0-0
Nebenwirkungen ( * ) eingestuft ||| adverse reactions ( * ) ||| 0-0 2-1 1-2 2-3 4-3 3-4
Nebenwirkungen ( 10 ||| side effects ( affecting 10 ||| 0-0 0-1 1-2 0-3 2-4
Nebenwirkungen ( weniger ||| side effects ( affecting less ||| 0-0 0-1 1-2 2-3 2-4
Nebenwirkungen ( ||| side effects ( affecting ||| 0-0 0-1 1-2 0-3
Nebenwirkungen ( ||| side effects ( ||| 0-0 0-1 1-2
Nebenwirkungen , die aus ||| Adverse reactions ||| 0-0 0-1 1-1
Nebenwirkungen , die aus ||| Nebenwirkungen , die aus ||| 0-0 1-1 2-2 3-3
Nebenwirkungen , die ||| Adverse reactions ||| 0-0 0-1 1-1
Nebenwirkungen , die ||| Nebenwirkungen , die ||| 0-0 1-1 2-2
Nebenwirkungen , wie z.B. ||| side effects , such as ||| 0-0 0-1 1-2 2-3 3-3 2-4
Nebenwirkungen , ||| Adverse reactions ||| 0-0 0-1 1-1
Nebenwirkungen , ||| Nebenwirkungen , ||| 0-0 1-1
Nebenwirkungen , ||| side effects , ||| 0-0 0-1 1-2
Nebenwirkungen aufgeführt , die ||| adverse reactions related to ||| 0-0 1-1 3-2 3-3
Nebenwirkungen aufgeführt , ||| adverse reactions ||| 0-0 1-1
Nebenwirkungen aufgeführt ||| adverse reactions ||| 0-0 1-1
Nebenwirkungen bei ||| adverse reactions in ||| 0-0 0-1 1-2
Nebenwirkungen bemerken , die ||| please ||| 0-0 1-0 2-0 3-0
Nebenwirkungen feststellen , ||| notice ||| 0-0 1-0
Nebenwirkungen feststellen ||| notice ||| 0-0 1-0
Nebenwirkungen haben , die ||| cause side effects , ||| 1-0 0-1 0-2 3-2 2-3
Nebenwirkungen im Zusammenhang mit Actos ||| side effects with Actos are ||| 0-0 1-0 2-0 0-1 3-2 4-3 4-4
Nebenwirkungen im Zusammenhang mit ||| side effects with ||| 0-0 1-0 2-0 0-1 3-2
Nebenwirkungen im Zusammenhang ||| side effects ||| 0-0 1-0 2-0 0-1
Nebenwirkungen in Zusammenhang mit der ||| effects related to the ||| 0-0 1-1 2-1 3-1 2-2 4-3
Nebenwirkungen in Zusammenhang mit ||| effects related to ||| 0-0 1-1 2-1 3-1 2-2
Nebenwirkungen sind bei ||| side effects have ||| 0-0 0-1 1-2 2-2
Nebenwirkungen traten häufiger auf ||| undesirable effects occurred more often ||| 1-0 0-1 1-2 2-3 2-4 3-4
Nebenwirkungen traten in ||| undesirable effects occurred ||| 0-0 1-0 0-1 1-2 2-2
Nebenwirkungen traten ||| undesirable effects occurred ||| 0-0 1-0 0-1 1-2
Nebenwirkungen traten ||| undesirable effects occurred ||| 1-0 0-1 1-2
Nebenwirkungen treten insbesondere zu Behandlungsbeginn ||| more common at the start ||| 1-0 0-1 1-1 2-2 3-3 2-4 4-4
Nebenwirkungen treten ||| be more common ||| 1-1 0-2 1-2
Nebenwirkungen treten ||| may be more common ||| 1-2 0-3 1-3
Nebenwirkungen treten ||| more common ||| 1-0 0-1 1-1
Nebenwirkungen verursachen kann . ||| can cause side effects . ||| 2-0 1-1 0-2 0-3 3-4
Nebenwirkungen verursachen kann ||| can cause side effects ||| 2-0 1-1 0-2 0-3
Nebenwirkungen verursachen können . ||| can cause side effects . ||| 2-0 1-1 0-2 0-3 3-4
Nebenwirkungen verursachen können ||| can cause side effects ||| 2-0 1-1 0-2 0-3
Nebenwirkungen verursachen wie ||| cause side effects such as ||| 1-0 0-1 0-2 2-3 2-4
Nebenwirkungen verursachen ||| cause side effects ||| 1-0 0-1 0-2
Nebenwirkungen von Aclasta treten ||| side effects with Aclasta tend ||| 0-0 0-1 1-2 2-3 3-4
Nebenwirkungen von Aclasta ||| side effects with Aclasta ||| 0-0 0-1 1-2 2-3
Nebenwirkungen von ||| side effects with ||| 0-0 0-1 1-2
Nebenwirkungen von ||| side effects ||| 0-0 0-1
Nebenwirkungen wurden im ||| adverse reactions were ||| 0-0 0-1 1-2 2-2
Nebenwirkungen ||| Nebenwirkungen ||| 0-0
Nebenwirkungen ||| adverse reactions ||| 0-0 0-1
Nebenwirkungen ||| adverse ||| 0-0
Nebenwirkungen ||| effects ||| 0-0
Nebenwirkungen ||| reduce side effects ||| 0-1 0-2
Nebenwirkungen ||| side effects ||| 0-0 0-1
Nederland BRISTOL-MYERS SQUIBB BV Tel ||| Nederland BRISTOL-MYERS SQUIBB BV Tel ||| 0-0 1-1 2-2 3-3 4-4
Nederland BRISTOL-MYERS SQUIBB BV ||| Nederland BRISTOL-MYERS SQUIBB BV ||| 0-0 1-1 2-2 3-3
Nederland BRISTOL-MYERS SQUIBB ||| Nederland BRISTOL-MYERS SQUIBB ||| 0-0 1-1 2-2
Nederland BRISTOL-MYERS ||| Nederland BRISTOL-MYERS ||| 0-0 1-1
Nederland ||| Nederland ||| 0-0
Nehmen Sie ABILIFY ||| Always take ABILIFY ||| 0-0 0-1 1-1 2-2
Nehmen Sie die Tablette immer ||| Always take the tablet ||| 0-0 1-0 0-1 2-2 3-3 4-3
Nehmen Sie die ||| Always take the ||| 0-0 1-0 0-1 2-2
Nehmen Sie nicht die ||| Do not take a ||| 0-0 1-0 2-1 0-2 3-3
Nehmen Sie nicht ||| Do not take ||| 0-0 1-0 2-1 0-2
Nehmen Sie ||| Always take ||| 0-0 0-1 1-1
Nehmen Sie ||| Always take ||| 0-0 1-0 0-1
Nervenschädigung ) , ||| touch ) , ||| 2-0 1-1 0-2 2-2
Nervensystem ( ZNS ||| central nervous system ( ||| 2-0 0-1 1-3
Nervensystem ( ||| nervous system ( ||| 0-0 1-2
Nervensystem zu ||| Nervensystem zu finden ||| 0-0 1-1 0-2
Nervensystem ||| nervous system ||| 0-0
Nervensystem ||| nervous ||| 0-0
Nervensystems ||| Nervous ||| 0-0
Nervenzellen im Gehirn ||| nerve cells in the brain ||| 0-0 0-1 1-2 1-3 2-4
Nervenzellen im ||| nerve cells in the ||| 0-0 0-1 1-2 1-3
Nervenzellen ||| nerve cells ||| 0-0 0-1
Nervosität ; Suizidversuch , ||| nervousness ; suicide attempt , ||| 0-0 1-1 1-2 2-2 2-3 3-4
Nervosität ; Suizidversuch ||| nervousness ; suicide attempt ||| 0-0 1-1 1-2 2-2 2-3
Nervosität ||| nervousness ||| 0-0
Nesselsucht , Schwellungen und Entzündungen ||| hives , swelling and inflammation ||| 0-0 1-1 2-2 3-3 4-4
Nesselsucht , Schwellungen und ||| hives , swelling and ||| 0-0 1-1 2-2 3-3
Nesselsucht , Schwellungen und ||| site within a given area ||| 0-0 0-1 0-2 1-2 2-3 2-4 3-4
Nesselsucht , Schwellungen ||| hives , swelling ||| 0-0 1-1 2-2
Nesselsucht , ||| hives , ||| 0-0 1-1
Nesselsucht , ||| site within a ||| 0-0 0-1 0-2 1-2
Nesselsucht ||| hives ||| 0-0
Netzwerkes ||| microtubule network ||| 0-0 0-1
Neuauftreten von derartigen ||| emergence of such ||| 0-0 2-0 1-1
Neuauftreten von derartigen ||| emergence of ||| 0-0 2-0 1-1
Neubildungen ( einschl . Zysten ||| and unspecified ( including cysts ||| 0-0 0-1 2-1 1-2 2-3 3-3 4-4
Neubildungen ( einschl . ||| and unspecified ( including ||| 0-0 0-1 2-1 1-2 2-3 3-3
Neuralgie , Verlust des ||| neuralgia , sensory loss ||| 0-0 1-1 1-2 2-3 3-3
Neuralgie , ||| neuralgia , sensory ||| 0-0 1-1 1-2
Neuralgie ||| neuralgia ||| 0-0
Neuroleptisches Syndrom ( MNS ||| Malignant Syndrome ( NMS ||| 0-0 0-1 1-1 2-2 3-3
Neuroleptisches Syndrom ( ||| Malignant Syndrome ( ||| 0-0 0-1 1-1 2-2
Neuroleptisches Syndrom ||| Malignant Syndrome ||| 0-0 0-1 1-1
Neuropathie , Ataxie , sensorische ||| neuropathy , ataxia , sensory ||| 0-0 1-1 2-2 3-3 4-4
Neuropathie , Ataxie , ||| neuropathy , ataxia , ||| 0-0 1-1 2-2 3-3
Neuropathie , Ataxie ||| neuropathy , ataxia ||| 0-0 1-1 2-2
Neuropathie , Hypästhesie , Parästhesie ||| neuropathy , hypoaesthesia , paraesthesia ||| 0-0 1-1 2-2 3-3 4-4
Neuropathie , Hypästhesie , ||| neuropathy , hypoaesthesia , ||| 0-0 1-1 2-2 3-3
Neuropathie , Hypästhesie ||| neuropathy , hypoaesthesia ||| 0-0 1-1 2-2
Neuropathie , Kopfschmerzen , Dysgeusie ||| neuropathy , headache , dysgeusia ||| 0-0 1-1 2-2 3-3 4-4
Neuropathie , Kopfschmerzen , ||| neuropathy , headache , ||| 0-0 1-1 2-2 3-3
Neuropathie , Kopfschmerzen ||| neuropathy , headache ||| 0-0 1-1 2-2
Neuropathie , Neuropathie , Hypästhesie ||| neuropathy , neuropathy , hypoaesthesia ||| 0-0 1-1 2-2 3-3 4-4
Neuropathie , Neuropathie , ||| neuropathy , neuropathy , ||| 0-0 1-1 2-2 3-3
Neuropathie , Neuropathie ||| neuropathy , neuropathy ||| 0-0 1-1 2-2
Neuropathie , ||| neuropathy , ||| 0-0 1-1
Neuropathie Eine rasche Besserung der ||| neuropathy Fast improvement in blood ||| 0-0 1-1 2-1 3-2 3-3 2-4 4-4
Neuropathie ||| neuropathy , additional ||| 0-0
Neuropathie ||| neuropathy , ||| 0-0
Neuropathie ||| neuropathy ||| 0-0
Neurotoxizität gegenüber Paclitaxel ||| Neurotoxictiy to paclitaxel ||| 0-0 1-0 1-1 2-2
Neurotoxizität gegenüber ||| Neurotoxictiy to ||| 0-0 1-0 1-1
Neurotoxizität ||| neurotoxicity ||| 0-0
Neurotransmitter , ||| neurotransmitters , ||| 0-0 1-1
Neurotransmitter ||| neurotransmitters ||| 0-0
Neutropenie ( ||| neutropenia ( ||| 0-0 1-1
Neutropenie ) tritt ||| primarily neutropenia ) ||| 0-0 0-1 2-1 1-2
Neutropenie oder schweren sensorischen Neuropathie ||| neutropenia or severe sensory neuropathy ||| 0-0 1-1 2-2 3-3 4-4
Neutropenie oder schweren sensorischen ||| neutropenia or severe sensory ||| 0-0 1-1 2-2 3-3
Neutropenie oder schweren ||| neutropenia or severe ||| 0-0 1-1 2-2
Neutropenie oder ||| neutropenia or ||| 0-0 1-1
Neutropenie trat bei vier ||| neutropenia occurred in four ||| 0-0 1-1 2-2 3-3
Neutropenie trat bei ||| neutropenia occurred in ||| 0-0 1-1 2-2
Neutropenie trat ||| neutropenia occurred ||| 0-0 1-1
Neutropenie war die ||| Neutropenia was the most ||| 0-0 1-1 2-2 2-3
Neutropenie war ||| Neutropenia was ||| 0-0 1-1
Neutropenie ||| Neutropenia ||| 0-0
Neutropenie ||| neutropenia ||| 0-0
Neutrophilen , einer Art der ||| , a type of ||| 0-0 1-0 2-1 3-2 4-3
Neutrophilen , einer Art ||| , a type ||| 0-0 1-0 2-1 3-2
Neutrophilen , einer ||| , a ||| 0-0 1-0 2-1
Neutrophilen , ||| , ||| 0-0 1-0
Neutrophilenzahl wieder auf > 1,5 ||| neutrophils recover to > 1.5 ||| 1-0 0-1 1-1 2-1 2-2 3-3 4-4
Neutrophilenzahl wieder auf > ||| neutrophils recover to > ||| 1-0 0-1 1-1 2-1 2-2 3-3
Neutrophilenzahl wieder auf ||| neutrophils recover to ||| 1-0 0-1 1-1 2-1 2-2
Nevirapin ||| vorgenommen werden ||| 0-0 0-1
Nicht als Injektion ||| Do not give by injection ||| 0-0 0-1 2-2 1-3 2-3 2-4
Nicht anwenden bei Hunden im ||| Do not use in dogs ||| 0-0 1-0 1-1 1-2 2-3 4-3 3-4
Nicht anwenden bei Hunden ||| Do not use in dogs ||| 0-0 0-1 1-2 2-3 3-4
Nicht anwenden bei Hunden ||| Do not use in dogs ||| 0-0 1-0 1-1 1-2 2-3 3-4
Nicht anwenden bei Hündinnen ||| Do not use in dogs ||| 0-0 1-0 1-1 1-2 2-3 3-3 3-4
Nicht anwenden bei Tieren mit ||| Do not use in case ||| 0-0 1-0 1-1 3-1 1-2 2-3 4-3 2-4
Nicht anwenden bei ||| Do not use in ||| 0-0 0-1 1-2 2-3
Nicht anwenden bei ||| Do not use in ||| 0-0 1-0 1-1 1-2 2-3
Nicht anwenden ||| Do not use ||| 0-0 0-1 1-2
Nicht anwenden ||| Do not use ||| 0-0 1-0 1-1 1-2
Nicht durch Injektion ||| Do not give by injection ||| 0-0 0-1 2-2 1-3 2-4
Nicht im Kühlschrank lagern . ||| Do not refrigerate . ||| 0-0 1-0 0-1 2-2 3-3 4-3
Nicht im Kühlschrank ||| Do not refrigerate ||| 0-0 1-0 0-1 2-2
Nicht im oder zu nah ||| Do not store them in ||| 0-0 0-1 1-2 2-2 4-2 3-3 4-3 4-4
Nicht im ||| Do not ||| 0-0 1-0 0-1
Nicht verwendetes Arzneimittel ||| Any unused product ||| 0-0 1-1 1-2 2-2
Nicht ||| Any unused ||| 0-0 0-1
Nicht ||| Any ||| 0-0
Nicht ||| Do not ||| 0-0 0-1
Nicht-Aufnehmen der Braille-Schrift wird zugestimmt ||| not including braille accepted ||| 0-0 0-1 0-2 1-2 2-2 3-3 4-3
Nicht-Aufnehmen der Braille-Schrift ||| not including braille ||| 0-0 0-1 0-2 1-2 2-2
Nicht-Krebszellen ||| non-cancer cells ||| 0-0 0-1
Nicht-Rauchens und einer gesunden Ernährung ||| and healthy diet Key ||| 1-0 2-1 3-1 0-2 4-2 4-3
Nichtrauchern ||| non-smoking ||| 0-0
Nichts ||| There ||| 0-0
Nieren schädigen . ||| kidneys . ||| 0-0 1-0 2-1
Nieren schädigen ||| kidneys ||| 0-0 1-0
Nieren wurden ||| kidney have ||| 0-0 0-1 1-1
Nieren ||| kidney have ||| 0-0 0-1
Nieren ||| kidney ||| 0-0
Nieren- oder Leberinsuffizienz auf ||| renal or hepatic dysfunction on ||| 0-0 1-1 0-2 2-2 2-3 3-4
Nieren- oder Leberinsuffizienz ||| renal or hepatic dysfunction ||| 0-0 1-1 0-2 2-2 2-3
Nierenerkrankung , die ||| kidney disease ||| 0-0 0-1 1-1 2-1
Nierenerkrankung oder zusätzlichen Risikofaktoren ( ||| or additional risk factors ( ||| 1-0 2-1 3-2 3-3 4-4
Nierenerkrankung oder zusätzlichen Risikofaktoren ||| compromise or additional risk factors ||| 1-1 2-2 3-3 3-4
Nierenerkrankung oder zusätzlichen Risikofaktoren ||| or additional risk factors ||| 1-0 2-1 3-2 3-3
Nierenerkrankung oder zusätzlichen ||| compromise or additional ||| 1-1 2-2
Nierenerkrankung oder zusätzlichen ||| or additional ||| 1-0 2-1
Nierenerkrankung oder ||| compromise or ||| 1-1
Nierenerkrankung oder ||| or ||| 1-0
Nierenerkrankung ||| kidney ||| 0-0
Nierenfunktion signifikant beeinflussen ( ||| significantly impact renal function ( ||| 1-0 2-1 0-2 0-3 3-4
Nierenfunktion signifikant beeinflussen ||| significantly impact renal function ||| 1-0 2-1 0-2 0-3
Nierenfunktion wesentlich beeinflussen können ||| can significantly impact renal function ||| 3-0 2-1 1-2 2-2 0-3 0-4
Nierenfunktion wesentlich beeinflussen ||| significantly impact renal function ||| 2-0 1-1 2-1 0-2 0-3
Nierenfunktion ||| impaired renal function ||| 0-0 0-1 0-2
Nierenfunktion ||| renal function ||| 0-0 0-1
Nierenfunktionsstörungen ||| Renal dysfunction ||| 0-0 0-1
Niereninsuffizienz , die noch nicht ||| with renal insufficiency not yet ||| 0-0 0-1 2-2 3-2 4-3 3-4
Niereninsuffizienz , ||| renal ||| 0-0
Niereninsuffizienz , ||| with renal ||| 0-0 0-1
Niereninsuffizienz : ||| renal impairment : ||| 0-0 0-1 1-2
Niereninsuffizienz : ||| undergoing dialysis : ||| 0-0 0-1 1-2
Niereninsuffizienz bei Kindern und ||| renal failure in paediatric and ||| 0-0 0-1 1-2 2-3 3-4
Niereninsuffizienz bei Kindern ||| renal failure in paediatric ||| 0-0 0-1 1-2 2-3
Niereninsuffizienz bei ||| renal failure in ||| 0-0 0-1 1-2
Niereninsuffizienz nicht beschleunigt . ||| renal insufficiency . ||| 0-0 1-1 2-1 3-2
Niereninsuffizienz nicht beschleunigt ||| renal insufficiency ||| 0-0 1-1 2-1
Niereninsuffizienz ||| renal failure ||| 0-0 0-1
Niereninsuffizienz ||| renal impairment ||| 0-0 0-1
Niereninsuffizienz ||| renal ||| 0-0
Niereninsuffizienz ||| undergoing dialysis ||| 0-0 0-1
Niereninsuffizienz ||| with renal ||| 0-0 0-1
Nierenproblemen ist unbekannt ||| kidney problems are not known ||| 0-0 0-1 2-1 1-4
Nierenschwäche ||| kidney ||| 0-0
Noch ||| Adult patients with ||| 0-0 0-1 0-2
Nordisk A/S Novo Allé ||| Nordisk A/ S Novo Allé ||| 0-0 1-1 1-2 2-3 3-4
Nordisk A/S Novo ||| Nordisk A/ S Novo ||| 0-0 1-1 1-2 2-3
Nordisk A/S ||| Nordisk A/ S ||| 0-0 1-1 1-2
Nordisk ||| Nordisk ||| 0-0
Norge AS Tlf : +47 ||| Norge AS Tlf : +47 ||| 0-0 1-1 2-2 3-3 4-4
Norge AS Tlf : ||| Norge AS Tlf : ||| 0-0 1-1 2-2 3-3
Norge AS Tlf ||| Norge AS Tlf ||| 0-0 1-1 2-2
Norge AS ||| Norge AS ||| 0-0 1-1
Norge BRISTOL-MYERS SQUIBB NORWAY LTD ||| Norge BRISTOL-MYERS SQUIBB NORWAY LTD ||| 0-0 1-1 2-2 3-3 4-4
Norge BRISTOL-MYERS SQUIBB NORWAY ||| Norge BRISTOL-MYERS SQUIBB NORWAY ||| 0-0 1-1 2-2 3-3
Norge BRISTOL-MYERS SQUIBB ||| Norge BRISTOL-MYERS SQUIBB ||| 0-0 1-1 2-2
Norge BRISTOL-MYERS ||| Norge BRISTOL-MYERS ||| 0-0 1-1
Norge Novartis Norge AS Tlf ||| Norge Novartis Norge AS Tlf ||| 0-0 1-1 2-2 3-3 4-4
Norge Novartis Norge AS ||| Norge Novartis Norge AS ||| 0-0 1-1 2-2 3-3
Norge Novartis Norge ||| Norge Novartis Norge ||| 0-0 1-1 2-2
Norge Novartis ||| Norge Novartis ||| 0-0 1-1
Norge Takeda Global R & ||| Norge Takeda Global R & ||| 0-0 1-1 2-2 3-3 4-4
Norge Takeda Global R ||| Norge Takeda Global R ||| 0-0 1-1 2-2 3-3
Norge Takeda Global ||| Norge Takeda Global ||| 0-0 1-1 2-2
Norge Takeda ||| Norge Takeda ||| 0-0 1-1
Norge ||| Norge ||| 0-0
Normalisierung ||| normalisation ||| 0-0
Normbereich liegen ||| normal ||| 0-0
Normbereich ||| normal ||| 0-0
Notfallmaßnahmen , Gegenmittel ) ||| emergency procedures , antidotes ) ||| 0-0 0-1 1-2 2-3 3-4
Notfallmaßnahmen , Gegenmittel ||| emergency procedures , antidotes ||| 0-0 0-1 1-2 2-3
Notfallmaßnahmen , ||| emergency procedures , ||| 0-0 0-1 1-2
Notfallmaßnahmen ||| emergency procedures ||| 0-0 0-1
Novartis Europharm Limited Wimblehurst Road ||| Novartis Europharm Limited Wimblehurst Road ||| 0-0 1-1 2-2 3-3 4-4
Novartis Europharm Limited Wimblehurst ||| Novartis Europharm Limited Wimblehurst ||| 0-0 1-1 2-2 3-3
Novartis Europharm Limited ||| Novartis Europharm Limited ||| 0-0 1-1 2-2
Novartis Europharm ||| Novartis Europharm ||| 0-0 1-1
Novartis Farma - Produtos Farmacêuticos ||| Novartis Farma - Produtos Farmacêuticos ||| 0-0 1-1 2-2 3-3 4-4
Novartis Farma - Produtos ||| Novartis Farma - Produtos ||| 0-0 1-1 2-2 3-3
Novartis Farma - ||| Novartis Farma - ||| 0-0 1-1 2-2
Novartis Farma ||| Novartis Farma ||| 0-0 1-1
Novartis Finland Oy ||| Finland Novartis Finland Oy ||| 1-0 0-1 1-2 2-3
Novartis Finland ||| Finland Novartis Finland ||| 1-0 0-1 1-2
Novartis Healthcare A/S Tlf ||| Novartis Healthcare A/ S Tlf ||| 0-0 1-1 2-2 2-3 3-4
Novartis Healthcare A/S ||| Novartis Healthcare A/ S ||| 0-0 1-1 2-2 2-3
Novartis Healthcare ||| Novartis Healthcare ||| 0-0 1-1
Novartis Ireland Limited Tel : ||| Novartis Ireland Limited Tel : ||| 0-0 1-1 2-2 3-3 4-4
Novartis Ireland Limited Tel ||| Novartis Ireland Limited Tel ||| 0-0 1-1 2-2 3-3
Novartis Ireland Limited ||| Novartis Ireland Limited ||| 0-0 1-1 2-2
Novartis Ireland ||| Novartis Ireland ||| 0-0 1-1
Novartis Norge AS Tlf : ||| Novartis Norge AS Tlf : ||| 0-0 1-1 2-2 3-3 4-4
Novartis Norge AS Tlf ||| Novartis Norge AS Tlf ||| 0-0 1-1 2-2 3-3
Novartis Norge AS ||| Novartis Norge AS ||| 0-0 1-1 2-2
Novartis Norge ||| Novartis Norge ||| 0-0 1-1
Novartis Pharma GmbH Roonstraße 25 ||| Novartis Pharma GmbH Roonstraße 25 ||| 0-0 1-1 2-2 3-3 4-4
Novartis Pharma GmbH Roonstraße ||| Novartis Pharma GmbH Roonstraße ||| 0-0 1-1 2-2 3-3
Novartis Pharma GmbH Tel : ||| Novartis Pharma GmbH Tel : ||| 0-0 1-1 2-2 3-3 4-4
Novartis Pharma GmbH Tel ||| Novartis Pharma GmbH Tel ||| 0-0 1-1 2-2 3-3
Novartis Pharma GmbH Tél/Tel ||| Novartis Pharma GmbH Tél/ Tel ||| 0-0 1-1 2-2 3-3 3-4
Novartis Pharma GmbH ||| Novartis Pharma GmbH ||| 0-0 1-1 2-2
Novartis Pharma ||| Novartis Pharma ||| 0-0 1-1
Novartis Sverige AB Tel : ||| Novartis Sverige AB Tel : ||| 0-0 1-1 2-2 3-3 4-4
Novartis Sverige AB Tel ||| Novartis Sverige AB Tel ||| 0-0 1-1 2-2 3-3
Novartis Sverige AB ||| Novartis Sverige AB ||| 0-0 1-1 2-2
Novartis Sverige ||| Novartis Sverige ||| 0-0 1-1
Novartis ||| Novartis ||| 0-0
Novo Allé DK-2880 Bagsværd Dänemark ||| Novo Allé DK-2880 Bagsværd Denmark ||| 0-0 1-1 2-2 3-3 4-4
Novo Allé DK-2880 Bagsværd ||| Novo Allé DK-2880 Bagsværd ||| 0-0 1-1 2-2 3-3
Novo Allé DK-2880 ||| Novo Allé DK-2880 ||| 0-0 1-1 2-2
Novo Allé ||| Novo Allé ||| 0-0 1-1
Novo Nordisk A/S Novo ||| Novo Nordisk A/ S Novo ||| 0-0 1-1 2-2 2-3 3-4
Novo Nordisk A/S ||| Novo Nordisk A/ S ||| 0-0 1-1 2-2 2-3
Novo Nordisk ||| Novo Nordisk ||| 0-0 1-1
Novo ||| Novo ||| 0-0
NovoFine Injektionsnadeln vorgesehen . ||| NovoFine needles . ||| 0-0 1-0 1-1 2-1 3-2
NovoFine Injektionsnadeln vorgesehen ||| NovoFine needles ||| 0-0 1-0 1-1 2-1
NovoLet , ||| NovoLet , ||| 0-0 1-1
NovoLet 100 ||| NovoLet 100 ||| 0-0 1-1
NovoLet darf ||| NovoLet is ||| 0-0 1-0 0-1
NovoLet gibt zwischen ||| NovoLet delivers ||| 0-0 0-1 1-1 2-1
NovoLet ist für den Gebrauch ||| NovoLet is designed to be ||| 0-0 1-1 2-2 4-2 3-3 4-4
NovoLet ist ||| NovoLet is ||| 0-0 1-1
NovoLet ||| NovoLet ||| 0-0
Nur ca. 3 ||| an approximate 3 ||| 1-0 0-1 1-1 2-2
Nur ca. ||| an approximate ||| 1-0 0-1 1-1
Nur ||| For animal treatment ||| 0-0 0-1 0-2
Nur ||| Only ||| 0-0
Nutzen . ||| benefit . ||| 0-0 1-1
Nutzen hat ACOMPLIA in ||| in the weight ||| 3-0 0-1 1-1 2-2
Nutzen hat ACOMPLIA ||| the weight ||| 0-0 1-0 2-1
Nutzen hat Abilify in diesen ||| benefit has Abilify shown during ||| 0-0 1-1 2-2 3-3 4-3 4-4
Nutzen hat Abilify ||| benefit has Abilify ||| 0-0 1-1 2-2
Nutzen hat Abraxane in diesen ||| benefit has Abraxane shown during ||| 0-0 1-1 2-2 3-3 4-3 4-4
Nutzen hat Abraxane ||| benefit has Abraxane ||| 0-0 1-1 2-2
Nutzen hat Aclasta in diesen ||| benefit has Aclasta shown during ||| 0-0 1-1 2-2 3-3 4-3 4-4
Nutzen hat Aclasta ||| benefit has Aclasta ||| 0-0 1-1 2-2
Nutzen hat Actos ||| benefit has Actos ||| 0-0 1-1 2-2
Nutzen hat Actraphane in diesen ||| benefit has Actraphane shown during ||| 0-0 1-1 2-2 3-3 4-3 4-4
Nutzen hat Actraphane ||| benefit has Actraphane ||| 0-0 1-1 2-2
Nutzen hat ||| benefit has ||| 0-0 1-1
Nutzen hat ||| the ||| 0-0 1-0
Nutzen ||| benefit ||| 0-0
Nutzen ||| benefits ||| 0-0
Nähere Informationen sind ||| For more information ||| 0-0 1-1 1-2 2-2
Nähere ||| For ||| 0-0
Nürnberg Deutschland ||| Nuremberg Germany ||| 0-0 1-1
Nürnberg ||| Nuremberg ||| 0-0
O-Glykosid-Bindung an das Protein ||| one O-glycosidic bond to the ||| 0-0 0-1 1-1 0-2 2-2 3-2 3-3 2-4
ODER BESCHRÄNKUNGEN DER ||| OR RESTRICTIONS OF ||| 0-0 1-1 2-2
ODER BESCHRÄNKUNGEN ||| OR RESTRICTIONS ||| 0-0 1-1
ODER EINHEITEN ||| OR BY UNIT ||| 0-0 1-1 1-2
ODER EINSCHRÄNKUNGEN FÜR DIE ABGABE ||| OR RESTRICTIONS REGARDING ||| 0-0 1-1 2-1 3-2 4-2
ODER EINSCHRÄNKUNGEN FÜR ||| OR RESTRICTIONS ||| 0-0 1-1 2-1
ODER EINSCHRÄNKUNGEN HINSICHTLICH DER ||| OR RESTRICTIONS WITH REGARD TO ||| 0-0 1-1 1-2 2-3 2-4 3-4
ODER EINSCHRÄNKUNGEN ||| OR RESTRICTIONS WITH ||| 0-0 1-1 1-2
ODER FOLIENSTREIFEN ||| BLISTERS OR STRIPS ||| 0-0 0-1 1-2
ODER FOLIENSTREIFEN ||| OR STRIPS ||| 0-0 1-1
ODER VON ||| OR WASTE MATERIALS ||| 0-0 1-1 1-2
ODER ||| BLISTERS OR ||| 0-0 0-1
ODER ||| OR ||| 0-0
OY BRISTOL-MYERS SQUIBB ( ||| Finland OY BRISTOL-MYERS SQUIBB ( ||| 0-0 0-1 1-2 2-3 3-4
OY BRISTOL-MYERS SQUIBB ||| Finland OY BRISTOL-MYERS SQUIBB ||| 0-0 0-1 1-2 2-3
OY BRISTOL-MYERS ||| Finland OY BRISTOL-MYERS ||| 0-0 0-1 1-2
OY ||| Finland OY ||| 0-0 0-1
Oberfläche von Nervenzellen ||| surface of nerve cells ||| 0-0 1-1 2-2 2-3
Oberfläche von ||| surface of ||| 0-0 1-1
Oberfläche ||| surface ||| 0-0
Obergrenze des Normbereichs bleiben , ||| upper limit of normal , ||| 0-0 1-0 0-1 2-1 1-2 2-3 3-3 4-4
Obergrenze des Normbereichs bleiben ||| upper limit of normal ||| 0-0 1-0 0-1 2-1 1-2 2-3 3-3
Oberschenkel oder in ||| thigh or ||| 0-0 2-0 1-1
Obwohl die ||| , ||| 0-0
Obwohl die ||| Although ||| 0-0
Obwohl es ||| Although ||| 0-0 1-0
Obwohl in sehr seltenen Fällen ||| Although in very rare cases ||| 0-0 1-1 2-2 3-3 4-4
Obwohl in sehr seltenen ||| Although in very rare ||| 0-0 1-1 2-2 3-3
Obwohl in sehr ||| Although in very ||| 0-0 1-1 2-2
Obwohl in ||| Although in ||| 0-0 1-1
Obwohl ||| , ||| 0-0
Obwohl ||| Although ||| 0-0
Octreotid/Lanreotid kann den ||| Octreotide/ lanreotide may ||| 0-0 0-1 1-1 2-1 1-2
Oktober 2000 . Datum der ||| 13-10-2000 Date of ||| 0-0 1-0 2-1 3-1 4-2
Oktober 2000 . Datum ||| 13-10-2000 Date ||| 0-0 1-0 2-1 3-1
Oktober 2000 ||| 13-10-2000 ||| 0-0 1-0
Omeprazol ) ||| omeprazole ) ||| 0-0 1-1
Omeprazol ||| omeprazole ||| 0-0
OncoEurope Tel . : + ||| OncoEurope Tel . : + ||| 0-0 1-1 2-2 3-3 4-4
OncoEurope Tel . : ||| OncoEurope Tel . : ||| 0-0 1-1 2-2 3-3
OncoEurope Tel . ||| OncoEurope Tel . ||| 0-0 1-1 2-2
OncoEurope Tel : + 36(0 ||| OncoEurope Tel : + 36(0 ||| 0-0 1-1 2-2 3-3 4-4
OncoEurope Tel : + ||| OncoEurope Tel : + ||| 0-0 1-1 2-2 3-3
OncoEurope Tel : ||| OncoEurope Tel : ||| 0-0 1-1 2-2
OncoEurope Tel ||| OncoEurope Tel ||| 0-0 1-1
OncoEurope ||| OncoEurope ||| 0-0
Onkologen ||| qualified oncologist ||| 0-0 0-1
Opak weiße HDPE-Flaschen ||| Opaque white HDPE bottles ||| 0-0 1-1 2-2 2-3
Opak weiße ||| Opaque white ||| 0-0 1-1
Opak ||| Opaque ||| 0-0
Operation bevorsteht ||| surgery ||| 0-0 1-0
Operation verabreicht . ||| surgery . ||| 0-0 1-1 2-1
Operation ||| surgery ||| 0-0
Orale Antidiabetika ( OAD ||| Oral hypoglycaemic agents ( OHA ||| 0-0 1-1 1-2 2-3 1-4 3-4
Orale Eisensubstitution , ||| Orale Eisensubstitution , beispielsweise 200 ||| 0-0 0-1 2-2 0-3 1-3 1-4
Orale Eisensubstitution mit 200 ||| oral iron substitution of 200 ||| 0-0 1-1 0-2 1-2 2-2 2-3 3-4
Orale Eisensubstitution mit ||| oral iron substitution of ||| 0-0 1-1 0-2 1-2 2-2 2-3
Orale Kontrazeptiva , Thiazide , ||| Oral contraeptives , thiazides , ||| 0-0 1-1 2-2 3-3 4-4
Orale Kontrazeptiva , Thiazide ||| Oral contraeptives , thiazides ||| 0-0 1-1 2-2 3-3
Orale Kontrazeptiva , ||| Oral contraeptives , ||| 0-0 1-1 2-2
Orale Kontrazeptiva ||| Oral contraeptives ||| 0-0 1-1
Orale ||| Oral ||| 0-0
Orlistat , Ethanol oder Lorazepam ||| orlistat , ethanol or lorazepam ||| 0-0 1-1 0-2 3-3 2-4 4-4
Orlistat , ||| orlistat , ethanol ||| 0-0 1-1 0-2
Ort der Infusion , ||| the infusion ||| 0-0 1-0 2-1
Ort der Infusion ||| the infusion ||| 0-0 1-0 2-1
Ort der ||| the ||| 0-0 1-0
Osmolalität von 300-360 mOsm/kg ||| osmolality of 300-360 mOsm/ kg ||| 0-0 1-1 2-2 2-3 3-3 3-4
Osmolalität von ||| osmolality of ||| 0-0 1-1
Osmolalität ||| osmolality ||| 0-0
Osteoklasten , ||| osteoclasts , ||| 0-0 1-1
Osteoklasten ||| osteoclasts ||| 0-0
Osteoklasten-vermittelten Knochenresorption . ||| osteoclast-mediated bone resorption . ||| 0-0 1-1 1-2 2-3
Osteoklasten-vermittelten Knochenresorption ||| osteoclast-mediated bone resorption ||| 0-0 1-1 1-2
Osteoklasten-vermittelten ||| osteoclast-mediated ||| 0-0
Osteomalazie , ||| osteomalacia , marrow fibrosis ||| 0-0 1-1 0-2 0-3
Osteomyelitis , und die Mehrzahl ||| osteomyelitis , and the majority ||| 0-0 1-1 2-2 3-3 4-4
Osteomyelitis , und die ||| osteomyelitis , and the ||| 0-0 1-1 2-2 3-3
Osteomyelitis , und ||| osteomyelitis , and ||| 0-0 1-1 2-2
Osteomyelitis , ||| osteomyelitis , ||| 0-0 1-1
Osteomyelitis ||| osteomyelitis ||| 0-0
Osteonekrose ( ||| osteonecrosis ( ||| 0-0 1-1
Osteonekrose ||| , osteonecrosis of ||| 0-1
Osteonekrose ||| , osteonecrosis ||| 0-1
Osteonekrose ||| osteonecrosis of ||| 0-0
Osteonekrose ||| osteonecrosis ||| 0-0
Osteonekrosen ||| Osteonecrosis of ||| 0-0 0-1
Osteoporose ( PFT ) Die ||| osteoporosis ( PFT ) The ||| 0-0 1-1 2-2 3-3 4-4
Osteoporose ( PFT ) ||| osteoporosis ( PFT ) ||| 0-0 1-1 2-2 3-3
Osteoporose ( PFT ||| osteoporosis ( PFT ||| 0-0 1-1 2-2
Osteoporose ( eine Krankheit ||| osteoporosis ( a disease ||| 0-0 1-1 2-2 3-3
Osteoporose ( eine ||| osteoporosis ( a ||| 0-0 1-1 2-2
Osteoporose ( ||| osteoporosis ( ||| 0-0 1-1
Osteoporose Die ||| Osteoporosis The ||| 0-0 1-1
Osteoporose Die übliche Dosis ist ||| Osteoporosis The usual dose is ||| 0-0 1-1 2-2 3-3 4-4
Osteoporose Die übliche Dosis ||| Osteoporosis The usual dose ||| 0-0 1-1 2-2 3-3
Osteoporose Die übliche ||| Osteoporosis The usual ||| 0-0 1-1 2-2
Osteoporose bei postmenopausalen Frauen bei ||| osteoporosis in post-menopausal women in ||| 0-0 1-1 2-2 3-3 4-4
Osteoporose bei postmenopausalen Frauen ||| osteoporosis in post-menopausal women ||| 0-0 1-1 2-2 3-3
Osteoporose bei postmenopausalen ||| osteoporosis in post-menopausal ||| 0-0 1-1 2-2
Osteoporose bei ||| osteoporosis in ||| 0-0 1-1
Osteoporose die ||| osteoporosis ||| 0-0
Osteoporose und ||| osteoporosis and ||| 0-0 1-1
Osteoporose war Aclasta bei ||| osteoporosis , Aclasta was ||| 0-0 2-2 1-3 3-3
Osteoporose wiesen ||| osteoporosis , ||| 0-0 1-1
Osteoporose ||| Osteoporose ||| 0-0
Osteoporose ||| Osteoporosis ||| 0-0
Osteoporose ||| osteoporosis , ||| 0-0
Osteoporose ||| osteoporosis ||| 0-0
Osteoporose-Studien ( PFT , HORIZON ||| ( PFT , HORIZON ||| 1-0 0-1 2-1 3-2 4-3
Osteoporose-Studien ( PFT , ||| ( PFT , ||| 1-0 0-1 2-1 3-2
Osteoporose-Studien ( PFT ||| ( PFT ||| 1-0 0-1 2-1
Osteoporose-Therapie ||| osteoporosis therapy ||| 0-0 0-1
Osteoporosebehandlung ||| treatment of ||| 0-0
Osteoporosebehandlung ||| treatment ||| 0-0
Otsuka Pharmaceutical Europe Ltd ||| Otsuka Pharmaceutical Europe Ltd ||| 0-0 1-1 2-2 3-3
Otsuka Pharmaceutical Europe ||| Otsuka Pharmaceutical Europe ||| 0-0 1-1 2-2
Otsuka Pharmaceutical ||| Otsuka Pharmaceutical ||| 0-0 1-1
Otsuka ||| Otsuka ||| 0-0
Outcome-Studie , wurden 5238 Patienten ||| outcome study , 5238 patients ||| 0-0 0-1 2-1 1-2 3-3 4-4
Outcome-Studie , wurden 5238 ||| outcome study , 5238 ||| 0-0 0-1 2-1 1-2 3-3
Outcome-Studie , wurden ||| outcome study , ||| 0-0 0-1 2-1 1-2
Outcome-Studie mit Pioglitazon ||| outcome study of pioglitazone ||| 0-0 0-1 1-1 2-3
Outcome-Studie mit ||| outcome study of ||| 0-0 0-1 1-1
Outcome-Studie mit ||| outcome study ||| 0-0 0-1 1-1
Ovarialsyndrom leiden . ||| syndrome . ||| 0-0 1-0 2-1
Ovarialsyndrom leiden ||| syndrome ||| 0-0 1-0
Ovarialsyndrom ||| syndrome ||| 0-0
Oxford Road Uxbridge - Middlesex ||| Oxford Road Uxbridge - Middlesex ||| 0-0 1-1 2-2 3-3 4-4
Oxford Road Uxbridge - ||| Oxford Road Uxbridge - ||| 0-0 1-1 2-2 3-3
Oxford Road Uxbridge ||| Oxford Road Uxbridge ||| 0-0 1-1 2-2
Oxford Road ||| Oxford Road ||| 0-0 1-1
Oxford ||| Oxford ||| 0-0
Oy Eli Lilly Finland ||| Finland Oy Eli Lilly Finland ||| 0-0 0-1 1-2 2-3 3-4
Oy Eli Lilly ||| Finland Oy Eli Lilly ||| 0-0 0-1 1-2 2-3
Oy Eli ||| Finland Oy Eli ||| 0-0 0-1 1-2
Oy Puh/Tel : +358 ||| Oy Puh/ Tel : +358 ||| 0-0 1-1 1-2 2-3 3-4
Oy Puh/Tel : ||| Oy Puh/ Tel : ||| 0-0 1-1 1-2 2-3
Oy Puh/Tel ||| Oy Puh/ Tel ||| 0-0 1-1 1-2
Oy ||| Finland Oy ||| 0-0 0-1
Oy ||| Oy ||| 0-0
P-Glycoprotein . ||| P-glycoprotein . ||| 0-0 1-1
P-Glycoprotein ||| P-glycoprotein ||| 0-0
P1NP ) ||| P1NP ) ||| 0-0 1-1
P1NP wurde signifikant ||| P1NP was significantly ||| 0-0 1-1 2-2
P1NP wurde ||| P1NP was ||| 0-0 1-1
P1NP ||| P1NP ||| 0-0
P450 2C8 , jedoch ||| P450 2C8 although ||| 0-0 1-1 1-2 3-2
P450 ||| P450 ||| 0-0
P450- ||| systems . ||| 0-0
P450- ||| systems ||| 0-0
P450-Subtypen . ||| cytochrome P450 . ||| 0-0 0-1 1-2
P450-Subtypen ||| cytochrome P450 ||| 0-0 0-1
PACKUNGSBEILAGE Yarvitan 5 ||| PACKAGE LEAFLET Yarvitan 5 ||| 0-0 0-1 1-2 2-3
PACKUNGSBEILAGE Yarvitan ||| PACKAGE LEAFLET Yarvitan ||| 0-0 0-1 1-2
PACKUNGSBEILAGE ||| PACKAGE LEAFLET ||| 0-0 0-1
PACKUNGSBEILAGE ||| procedure . ||| 0-0 0-1
PANSS Excitement Component score bei ||| PANSS Excitement Component score at ||| 0-0 1-1 2-2 2-3 3-3 4-4
PANSS Excitement Component score ||| PANSS Excitement Component score ||| 0-0 1-1 2-2 2-3 3-3
PANSS Excitement ||| PANSS Excitement ||| 0-0 1-1
PANSS ||| PANSS ||| 0-0
PET-Flaschen mit ||| PET-bottles with ||| 0-0 1-1
PET-Flaschen ||| PET-bottles ||| 0-0
PFT ) Die ||| PFT ) The ||| 0-0 1-1 2-2
PFT ) ||| PFT ) ||| 0-0 1-1
PFT ] ( siehe Abschnitt ||| PFT ] ( see section ||| 0-0 1-1 2-2 3-3 4-4
PFT ] ( siehe ||| PFT ] ( see ||| 0-0 1-1 2-2 3-3
PFT ] ( ||| PFT ] ( ||| 0-0 1-1 2-2
PFT ] ||| PFT ] ||| 0-0 1-1
PFT ||| PFT ||| 0-0
PHARMACEUTICALS LTD Tel : + ||| PHARMACEUTICALS LTD Tel : + ||| 0-0 1-1 2-2 3-3 4-4
PHARMACEUTICALS LTD Tel : ||| PHARMACEUTICALS LTD Tel : ||| 0-0 1-1 2-2 3-3
PHARMACEUTICALS LTD Tel ||| PHARMACEUTICALS LTD Tel ||| 0-0 1-1 2-2
PHARMACEUTICALS LTD ||| PHARMACEUTICALS LTD ||| 0-0 1-1
PHARMACEUTICALS ||| PHARMACEUTICALS ||| 0-0
PIOGLITAZON IN EINER ORALEN ||| 19 PIOGLITAZONE IN TRIPLE ORAL ||| 0-0 0-1 1-2 2-3 3-3 3-4
PIOGLITAZON IN EINER ORALEN ||| 31 PIOGLITAZONE IN TRIPLE ORAL ||| 0-0 0-1 1-2 2-3 3-3 3-4
PIOGLITAZON IN EINER ORALEN ||| PIOGLITAZONE IN TRIPLE ORAL ||| 0-0 1-1 2-2 3-2 3-3
PIOGLITAZON IN EINER ||| PIOGLITAZONE IN COMBINATION THERAPY WITH ||| 0-0 0-1 1-2 1-3 2-4
PIOGLITAZON IN EINER ||| PIOGLITAZONE IN COMBINATION THERAPY WITH ||| 0-0 0-1 1-2 2-3 2-4
PIOGLITAZON IN ||| 19 PIOGLITAZONE IN ||| 0-0 0-1 1-2
PIOGLITAZON IN ||| 31 PIOGLITAZONE IN ||| 0-0 0-1 1-2
PIOGLITAZON IN ||| PIOGLITAZONE IN COMBINATION THERAPY ||| 0-0 0-1 1-2 1-3
PIOGLITAZON IN ||| PIOGLITAZONE IN COMBINATION ||| 0-0 0-1 1-2
PIOGLITAZON IN ||| PIOGLITAZONE IN ||| 0-0 1-1
PIOGLITAZON ||| 19 PIOGLITAZONE ||| 0-0 0-1
PIOGLITAZON ||| 31 PIOGLITAZONE ||| 0-0 0-1
PIOGLITAZON ||| PIOGLITAZONE IN ||| 0-0 0-1
PIOGLITAZON ||| PIOGLITAZONE ||| 0-0
PRCA ||| PRCA , ||| 0-0
PRCA ||| PRCA ||| 0-0
PRIMÄRVERPACKUNG ||| IMMEDIATE PACKAGE ||| 0-0 0-1
PRIMÄRVERPACKUNGEN ||| UNITS ||| 0-0
PRODUKTEIGENSCHAFTEN , ||| leaflet are the final versions ||| 0-0 0-1 0-2 0-3 0-4
PRODUKTEIGENSCHAFTEN ||| leaflet are the final versions ||| 0-0 0-1 0-2 0-3 0-4
PSUR ||| PSUR ||| 0-0
PSURs einreichen , bis zu ||| thereafter yearly PSURs unless ||| 3-0 1-1 0-2 2-3
PSURs einreichen , bis ||| thereafter yearly PSURs unless ||| 3-0 1-1 0-2 2-3
PSURs einreichen , ||| yearly PSURs unless ||| 1-0 0-1 2-2
PSURs einreichen ||| yearly PSURs ||| 1-0 0-1
PSURs ||| PSURs ||| 0-0
PVC-Aluminium perforierten Blistern ||| PVC-aluminium perforated ||| 0-0 2-0 1-1
PVC-Aluminium-Blisterpackungen ||| PVC-aluminium blister ||| 0-0 0-1
PVC/Aluminium ) Blisterpackung ( ||| PVC/ aluminium ) Blister ( ||| 0-0 0-1 1-2 2-3 3-4
PVC/Aluminium ) Blisterpackung ||| PVC/ aluminium ) Blister ||| 0-0 0-1 1-2 2-3
PVC/Aluminium ) ||| PVC/ aluminium ) ||| 0-0 0-1 1-2
PVC/Aluminium ||| PVC/ aluminium ||| 0-0 0-1
Paarung ( 9 Wochen ) ||| mating ( 9 weeks ) ||| 0-0 1-1 2-2 3-3 4-4
Paarung ( 9 Wochen ||| mating ( 9 weeks ||| 0-0 1-1 2-2 3-3
Paarung ( 9 ||| mating ( 9 ||| 0-0 1-1 2-2
Paarung ( ||| mating ( ||| 0-0 1-1
Paarung ||| mating ||| 0-0
Packung Die ABILIFY ||| pack The ABILIFY ||| 0-0 1-1 2-2
Packung Die ||| pack The ||| 0-0 1-1
Packung enthalten . ||| carton . ||| 0-0 1-0 2-1
Packung enthalten ||| carton ||| 0-0 1-0
Packung enthält 1 Flasche , ||| carton contains 1 bottle ||| 0-0 1-1 2-2 3-3
Packung enthält 1 Flasche ||| carton contains 1 bottle ||| 0-0 1-1 2-2 3-3
Packung enthält 1 ||| carton contains 1 ||| 0-0 1-1 2-2
Packung enthält eine Einzeldosis in ||| carton contains one single-use ||| 0-0 1-1 2-2 3-2 3-3
Packung enthält eine Einzeldosis ||| carton contains one single-use ||| 0-0 1-1 2-2 3-2 3-3
Packung enthält ||| carton contains ||| 0-0 1-1
Packung mit ||| pack with ||| 0-0 1-1
Packung und ||| pack and ||| 0-0 1-1
Packung ||| carton ||| 0-0
Packung ||| pack ||| 0-0
Packungsbeilage ( ||| Package Leaflet ( ||| 0-0 0-1 1-2
Packungsbeilage . ||| Package Leaflet ||| 0-0 0-1
Packungsbeilage auf . ||| leaflet . ||| 0-0 2-1
Packungsbeilage auf ||| leaflet ||| 0-0
Packungsbeilage beachten . ||| package leaflet before use . ||| 0-0 0-1 1-2 1-3 2-4
Packungsbeilage beachten ||| package leaflet before use ||| 0-0 0-1 1-2 1-3
Packungsbeilage oder ||| package leaflet or ||| 0-0 0-1 1-2
Packungsbeilage sorgfältig durch , bevor ||| this leaflet carefully before ||| 1-0 0-1 2-1 1-2 3-2 4-3
Packungsbeilage sorgfältig durch , ||| this leaflet carefully ||| 1-0 0-1 2-1 1-2 3-2
Packungsbeilage zu entnehmen ) . ||| Package Leaflet ) . ||| 0-0 1-0 2-0 2-1 3-2 4-3
Packungsbeilage zu entnehmen ) ||| Package Leaflet ) ||| 0-0 1-0 2-0 2-1 3-2
Packungsbeilage zu entnehmen ||| Package Leaflet ||| 0-0 1-0 2-0 2-1
Packungsbeilage ||| Package Leaflet ||| 0-0 0-1
Packungsbeilage ||| Package leaflet ||| 0-0 0-1
Packungsbeilage ||| Package ||| 0-0
Packungsbeilage ||| leaflet ||| 0-0
Packungsbeilage ||| package leaflet are ||| 0-0 0-1
Packungsbeilage ||| package leaflet ||| 0-0 0-1
Packungsgröße : eine Durchstechflasche mit ||| Pack size one vial of ||| 0-0 0-1 1-1 2-2 3-3 4-4
Packungsgröße : eine Durchstechflasche ||| Pack size one vial ||| 0-0 0-1 1-1 2-2 3-3
Packungsgröße : eine ||| Pack size one ||| 0-0 0-1 1-1 2-2
Packungsgröße : ||| Pack size ||| 0-0 0-1 1-1
Packungsgrößen bernsteinfarbene Glasflaschen mit 55 ||| Packungsgrößen bernsteinfarbene Glasflaschen mit 55 ||| 0-0 1-1 1-2 2-2 1-3 3-3 4-4
Packungsgrößen bernsteinfarbene Glasflaschen mit ||| Packungsgrößen bernsteinfarbene Glasflaschen mit ||| 0-0 1-1 1-2 2-2 1-3 3-3
Packungsgrößen in ||| Packungsgrößen in ||| 0-0 1-1
Packungsgrößen ||| Packungsgrößen ||| 0-0
Paclitaxel ( 5 mg/ml ||| paclitaxel ( 5 mg/ ml ||| 0-0 1-1 2-2 3-3 3-4
Paclitaxel ( 5 ||| paclitaxel ( 5 ||| 0-0 1-1 2-2
Paclitaxel ( ||| paclitaxel ( ||| 0-0 1-1
Paclitaxel , die wesentlich ||| paclitaxel , which ||| 0-0 1-1 2-2
Paclitaxel , die ||| paclitaxel , which ||| 0-0 1-1 2-2
Paclitaxel , ||| paclitaxel , ||| 0-0 1-1
Paclitaxel . ||| of paclitaxel . ||| 0-1 1-2
Paclitaxel . ||| paclitaxel . ||| 0-0 1-1
Paclitaxel bei Patienten im ||| paclitaxel in patients ||| 0-0 1-1 3-1 1-2 2-2
Paclitaxel blockiert die Fähigkeit von ||| Paclitaxel blocks the ability of ||| 0-0 1-1 2-2 2-3 3-3 4-4
Paclitaxel blockiert die Fähigkeit ||| Paclitaxel blocks the ability ||| 0-0 1-1 2-2 2-3 3-3
Paclitaxel blockiert ||| Paclitaxel blocks ||| 0-0 1-1
Paclitaxel die ||| , paclitaxel ||| 0-1
Paclitaxel die ||| paclitaxel ||| 0-0
Paclitaxel enthalten Substanzen ( Lösungsmittel ||| paclitaxel contain substances ( solvents ||| 0-0 1-1 2-2 3-3 4-3 2-4
Paclitaxel enthalten ||| paclitaxel contain ||| 0-0 1-1
Paclitaxel hat sich ||| Paclitaxel has been shown to ||| 0-0 1-1 0-2 1-3 2-3 2-4
Paclitaxel hin . ||| paclitaxel . ||| 0-0 2-1
Paclitaxel hin ||| paclitaxel ||| 0-0
Paclitaxel in ||| Paclitaxel in ||| 0-0 1-1
Paclitaxel ist ein Antimikrotubuli-Wirkstoff ||| Paclitaxel is an antimicrotubule agent ||| 0-0 1-1 2-2 3-3 3-4
Paclitaxel ist ein zytotoxisches antikarzinogenes ||| Paclitaxel is a cytotoxic anticancer ||| 0-0 1-1 2-2 3-3 4-4
Paclitaxel ist ein zytotoxisches ||| Paclitaxel is a cytotoxic ||| 0-0 1-1 2-2 3-3
Paclitaxel ist ein ||| Paclitaxel is a ||| 0-0 1-1 2-2
Paclitaxel ist ein ||| Paclitaxel is an ||| 0-0 1-1 2-2
Paclitaxel ist seit 1993 ||| Paclitaxel has been available ||| 0-0 1-0 0-1 2-2 3-2 3-3
Paclitaxel ist ||| Paclitaxel has ||| 0-0 1-0 0-1
Paclitaxel ist ||| Paclitaxel is ||| 0-0 1-1
Paclitaxel nach ||| paclitaxel following ||| 0-0 1-1
Paclitaxel oder ||| paclitaxel or ||| 0-0 1-1
Paclitaxel verursacht ||| Paclitaxel ||| 0-0 1-0
Paclitaxel war in-vivo ||| Paclitaxel has been ||| 0-0 2-0 0-1 0-2
Paclitaxel wird ||| paclitaxel is ||| 0-0 1-1
Paclitaxel wurde nicht formell ||| paclitaxel has not been formally ||| 0-0 1-1 2-2 1-3 3-4
Paclitaxel wurde nicht ||| paclitaxel has not been ||| 0-0 1-1 2-2 1-3
Paclitaxel zusammen mit ||| administering paclitaxel concomitantly with ||| 0-1 1-2 2-3
Paclitaxel zusammen mit ||| paclitaxel concomitantly with ||| 0-0 1-1 2-2
Paclitaxel zusammen ||| administering paclitaxel concomitantly ||| 0-1 1-2
Paclitaxel zusammen ||| paclitaxel concomitantly ||| 0-0 1-1
Paclitaxel ||| , paclitaxel ||| 0-1
Paclitaxel ||| Paclitaxel ||| 0-0
Paclitaxel ||| administering paclitaxel ||| 0-1
Paclitaxel ||| of paclitaxel ||| 0-1
Paclitaxel ||| paclitaxel ||| 0-0
Paclitaxel ||| single-agent paclitaxel ||| 0-0 0-1
Paclitaxel-Plasmakonzentration auf multiphasische Weise ab ||| declined in a multiphasic manner ||| 0-0 4-2 2-3 3-4
Paclitaxel-Plasmakonzentration auf ||| declined in ||| 0-0
Paclitaxel-Plasmakonzentration auf ||| declined ||| 0-0
Paclitaxel-Plasmakonzentration ||| declined in ||| 0-0
Paclitaxel-Plasmakonzentration ||| declined ||| 0-0
Pankreatitis , Dysphagie ||| pancreatitis , dysphagia ||| 0-0 1-1 2-2
Pankreatitis , ||| pancreatitis , ||| 0-0 1-1
Pankreatitis ||| pancreatitis ||| 0-0
Paracetamol oder Ibuprofen ( Mittel ||| paracetamol or ibuprofen ( anti-inflammation ||| 0-0 1-1 2-2 3-3 4-3 2-4
Paracetamol oder Ibuprofen kurz nach ||| paracetamol or ibuprofen shortly following ||| 0-0 1-1 2-2 3-3 4-4
Paracetamol oder Ibuprofen kurz ||| paracetamol or ibuprofen shortly ||| 0-0 1-1 2-2 3-3
Paracetamol oder Ibuprofen ||| paracetamol or ibuprofen ||| 0-0 1-1 2-2
Paracetamol oder ||| paracetamol or ||| 0-0 1-1
Paracetamol ||| paracetamol ||| 0-0
Parahydroxybenzoate können allergische Reaktionen verursachen ||| Parahydroxybenzoates may cause allergic reactions ||| 0-0 1-1 4-2 2-3 4-3 3-4
Parahydroxybenzoate können ||| Parahydroxybenzoates may ||| 0-0 1-1
Parahydroxybenzoate ||| Parahydroxybenzoates ||| 0-0
Parameter ||| parameters ||| 0-0
Paranoia . ||| paranoia . ||| 0-0 1-1
Paranoia ||| paranoia ||| 0-0
Parasomnien ||| behaviour ||| 0-0
Park , Kilruddey , County ||| Park , Kilruddery , County ||| 0-0 1-1 2-2 3-3 4-4
Park , Kilruddey , ||| Park , Kilruddery , ||| 0-0 1-1 2-2 3-3
Park , Kilruddey ||| Park , Kilruddery ||| 0-0 1-1 2-2
Park , Oxford Road Uxbridge ||| Park , Oxford Road Uxbridge ||| 0-0 1-1 2-2 3-3 4-4
Park , Oxford Road ||| Park , Oxford Road ||| 0-0 1-1 2-2 3-3
Park , Oxford ||| Park , Oxford ||| 0-0 1-1 2-2
Park , ||| Park , ||| 0-0 1-1
Park Westhoughton BL5 3XX Vereinigtes ||| Park Westhoughton BL5 3XX United ||| 0-0 1-1 2-2 3-3 4-4
Park Westhoughton BL5 3XX ||| Park Westhoughton BL5 3XX ||| 0-0 1-1 2-2 3-3
Park Westhoughton BL5 ||| Park Westhoughton BL5 ||| 0-0 1-1 2-2
Park Westhoughton ||| Park Westhoughton ||| 0-0 1-1
Park ||| Park ||| 0-0
Parkinsonismus , Akathisie ||| parkinsonism , akathisia ||| 0-0 1-1 2-2
Parkinsonismus , ||| parkinsonism , ||| 0-0 1-1
Parkinsonismus ||| parkinsonism ||| 0-0
Paroxetin ||| expected to ||| 0-0 0-1
Partikel- freie und ||| free from particles and ||| 0-0 1-1 1-2 2-3
Partikel- freie ||| free from particles ||| 0-0 1-1 1-2
Partikel- ||| free ||| 0-0
Parästhesie . ||| paraesthesia . ||| 0-0 1-1
Parästhesie ||| Paresthesia ||| 0-0
Parästhesie ||| paraesthesia ||| 0-0
Patient darf nicht ||| patient should not ||| 0-0 1-1 1-2 2-2
Patient ||| patient ||| 0-0
Patienten ( 65 Jahre ) ||| patients ( 65 years ) ||| 0-0 1-1 2-2 3-3 4-4
Patienten ( 65 Jahre ||| patients ( 65 years ||| 0-0 1-1 2-2 3-3
Patienten ( 65 ||| patients ( 65 ||| 0-0 1-1 2-2
Patienten ( 95 % ) ||| ( 95 % ) ||| 1-0 2-1 3-2 4-3
Patienten ( 95 % ||| ( 95 % ||| 1-0 2-1 3-2
Patienten ( 95 ||| ( 95 ||| 1-0 2-1
Patienten ( Durchschnittsalter : ||| patients ( mean age : ||| 0-0 1-1 2-2 2-3 3-4
Patienten ( Durchschnittsalter ||| patients ( mean age ||| 0-0 1-1 2-2 2-3
Patienten ( insbesondere ||| patients ( particularly ||| 0-0 1-1 2-2
Patienten ( insbesondere übergewichtigen Patienten ||| patients ( particularly overweight patients ||| 0-0 1-1 2-2 3-2 3-3 4-4
Patienten ( insbesondere übergewichtigen Patienten ||| patients ( particularly overweight patients ||| 0-0 1-1 2-2 3-3 4-4
Patienten ( insbesondere übergewichtigen ||| patients ( particularly overweight ||| 0-0 1-1 2-2 3-2 3-3
Patienten ( insbesondere übergewichtigen ||| patients ( particularly overweight ||| 0-0 1-1 2-2 3-3
Patienten ( ||| ( ||| 1-0
Patienten ( ||| patients ( ||| 0-0 1-1
Patienten ( ||| patients ||| 0-0
Patienten ) , ||| patients ) ||| 0-0 1-1
Patienten ) . ||| patients ) . ||| 0-0 1-1 2-2
Patienten ) ||| patients ) ||| 0-0 1-1
Patienten , bei denen ein ||| Patients scheduled ||| 0-0 1-0 2-1 3-1 4-1
Patienten , bei denen hypoglykämische ||| patients who have experienced hypoglycaemic ||| 0-0 2-0 1-1 4-1 4-2 3-3 4-3 4-4
Patienten , bei denen ||| 107 Patients scheduled ||| 1-0 0-1 1-1 2-2 3-2
Patienten , bei denen ||| 121 Patients scheduled ||| 0-0 0-1 1-1 2-2 3-2
Patienten , bei denen ||| 135 Patients scheduled ||| 0-0 0-1 1-1 2-2 3-2
Patienten , bei denen ||| 23 Patients scheduled ||| 0-1 1-1 2-2 3-2
Patienten , bei denen ||| 37 Patients scheduled ||| 1-0 0-1 1-1 2-2 3-2
Patienten , bei denen ||| 51 Patients scheduled ||| 0-0 0-1 1-1 2-2 3-2
Patienten , bei denen ||| 65 Patients scheduled ||| 0-0 0-1 1-1 2-2 3-2
Patienten , bei denen ||| 79 Patients scheduled ||| 0-0 0-1 1-1 2-2 3-2
Patienten , bei denen ||| 9 Patients scheduled ||| 0-0 0-1 1-1 2-2 3-2
Patienten , bei denen ||| 93 Patients scheduled ||| 0-0 0-1 1-1 2-2 3-2
Patienten , bei denen ||| Patients scheduled for ||| 0-0 1-1 2-1 3-1 3-2
Patienten , bei denen ||| Patients scheduled ||| 0-0 1-0 2-1 3-1
Patienten , der nach einem ||| Patienten , der nach einem ||| 0-0 1-1 2-2 3-3 3-4 4-4
Patienten , der ||| Patienten , der ||| 0-0 1-1 2-2
Patienten , die Aclasta erhielten ||| patients receiving Aclasta ||| 0-0 1-1 2-1 4-1 3-2
Patienten , die Pioglitazon ||| , patients receiving pioglitazone ||| 1-0 0-1 0-2 3-3
Patienten , die Placebo erhielten ||| patients receiving placebo ||| 0-0 1-1 2-1 4-1 3-2
Patienten , die bereits ||| patients who ||| 0-0 1-1 2-1 3-1
Patienten , die ||| , patients receiving ||| 1-0 0-1 0-2
Patienten , die ||| , that patients ||| 1-0 2-1 0-2
Patienten , die ||| 10 Patients who ||| 0-1 1-2 2-2
Patienten , die ||| 46 The ||| 0-0 2-1
Patienten , die ||| 58 The ||| 2-1
Patienten , die ||| 70 The ||| 2-1
Patienten , die ||| Patients who ||| 0-0 0-1 1-1 2-1
Patienten , die ||| Patients who ||| 0-0 1-1 2-1
Patienten , die ||| The ||| 2-0
Patienten , die ||| patients who have ||| 0-0 0-1 1-1 2-1 0-2
Patienten , die ||| patients who ||| 0-0 0-1 1-1 2-1
Patienten , die ||| patients who ||| 0-0 1-1 2-1
Patienten , die ||| patients ||| 0-0
Patienten , ||| , patients continuing ||| 1-0 0-1 1-2
Patienten , ||| , patients receiving ||| 1-0 0-1 0-2
Patienten , ||| , patients ||| 1-0 0-1
Patienten , ||| 107 Patients ||| 1-0 0-1 1-1
Patienten , ||| 121 Patients ||| 0-0 0-1 1-1
Patienten , ||| 135 Patients ||| 0-0 0-1 1-1
Patienten , ||| 160 patients ||| 0-1
Patienten , ||| 23 Patients ||| 0-1 1-1
Patienten , ||| 37 Patients ||| 1-0 0-1 1-1
Patienten , ||| 46 ||| 0-0
Patienten , ||| 51 Patients ||| 0-0 0-1 1-1
Patienten , ||| 65 Patients ||| 0-0 0-1 1-1
Patienten , ||| 79 Patients ||| 0-0 0-1 1-1
Patienten , ||| 9 Patients ||| 0-0 0-1 1-1
Patienten , ||| 93 Patients ||| 0-0 0-1 1-1
Patienten , ||| Patienten , ||| 0-0 1-1
Patienten , ||| Patients ||| 0-0 1-0
Patienten , ||| in patients ||| 0-1
Patienten , ||| patients , receiving ||| 0-0 1-1 0-2
Patienten , ||| patients , ||| 0-0 1-1
Patienten , ||| patients experiencing ||| 0-0
Patienten , ||| patients ||| 0-0
Patienten . ||| patients . ||| 0-0 1-1
Patienten 12,1 % mit ||| patients was 12.1 % with ||| 0-0 1-1 1-2 2-3 3-4
Patienten 12,1 % ||| patients was 12.1 % ||| 0-0 1-1 1-2 2-3
Patienten 12,1 ||| patients was 12.1 ||| 0-0 1-1 1-2
Patienten anderer ethnischer Populationen . ||| patients of other races . ||| 0-0 1-2 2-3 3-3 4-4
Patienten anderer ethnischer Populationen ||| patients of other races ||| 0-0 1-2 2-3 3-3
Patienten anderer ||| patients of other ||| 0-0 1-2
Patienten angewendet ||| usual ||| 0-0
Patienten auf ||| patient ||| 0-0
Patienten aus der Studienpopulation ||| patients in the study population ||| 0-0 0-1 1-2 2-2 3-3 3-4
Patienten aus der ||| patients in the ||| 0-0 0-1 1-2 2-2
Patienten beobachtet . ||| patients . ||| 0-0 1-0 2-1
Patienten beobachtet . ||| patients . ||| 0-0 1-1 2-1
Patienten beobachtet ||| patients ||| 0-0 1-0
Patienten betrug die Inzidenz von ||| patients the incidence of ||| 0-0 2-1 1-2 2-2 3-2 4-3
Patienten betrug die Inzidenz ||| patients the incidence ||| 0-0 2-1 1-2 2-2 3-2
Patienten betrugen jeweils 39,5 % ||| patients were 39.5 % ||| 0-0 1-1 2-2 3-2 4-3
Patienten betrugen jeweils 39,5 ||| patients were 39.5 ||| 0-0 1-1 2-2 3-2
Patienten betrugen ||| patients were ||| 0-0 1-1
Patienten eine ||| patients received a ||| 0-0 0-1 1-2
Patienten erhielt Insulin in ||| patients were receiving insulin in ||| 0-0 1-1 1-2 2-3 3-4
Patienten erhielt Insulin ||| patients were receiving insulin ||| 0-0 1-1 1-2 2-3
Patienten erhielt ||| patients were receiving ||| 0-0 1-1 1-2
Patienten erhielten zusätzlich eine Chemotherapie ||| patients were also receiving chemotherapy ||| 0-0 1-1 2-1 3-2 1-3 3-3 4-3 4-4
Patienten erhielten ||| patients received ||| 0-0 1-1
Patienten erhielten ||| received ||| 0-0 1-0
Patienten gemeldet . ||| patients . ||| 0-0 1-0 2-1
Patienten gemeldet ||| patients ||| 0-0 1-0
Patienten hatte bereits einen ||| patients had a previous ||| 0-0 1-1 3-1 3-2 1-3 2-3
Patienten hatte ||| patients had ||| 0-0 1-1
Patienten hatten Anzeichen für lokale ||| patients had signs of local ||| 0-0 1-1 2-2 3-3 4-4
Patienten hatten Anzeichen für ||| patients had signs of ||| 0-0 1-1 2-2 3-3
Patienten hatten Anzeichen ||| patients had signs ||| 0-0 1-1 2-2
Patienten hatten einen ||| patients had a ||| 0-0 1-1 2-1 2-2
Patienten hatten ||| patients had ||| 0-0 1-1
Patienten herabsetzen . ||| result of hypoglycaemia . ||| 0-0 1-0 1-1 1-2 2-3
Patienten herabsetzen ||| result of hypoglycaemia ||| 0-0 1-0 1-1 1-2
Patienten hinsichtlich ||| patients ||| 0-0
Patienten im ||| in patients ||| 1-0 0-1
Patienten in ||| patients in ||| 0-0 1-1
Patienten individuelle Hämoglobinwerte über ||| patient above and ||| 0-0 1-0 1-1 2-1 3-1 1-2
Patienten isoliert wurde . ||| anaemic patients . ||| 1-0 2-0 0-1 3-2
Patienten isoliert wurde . ||| of anaemic patients . ||| 1-1 2-1 0-2 3-3
Patienten isoliert wurde ||| anaemic patients ||| 1-0 2-0 0-1
Patienten isoliert wurde ||| of anaemic patients ||| 1-1 2-1 0-2
Patienten ist keine ||| Patienten ist keine ||| 0-0 1-1 2-2
Patienten ist ||| Patienten ist ||| 0-0 1-1
Patienten kein Eisenmangel vorliegt ||| patients are not iron deficient ||| 0-0 3-1 1-2 1-3 2-3 2-4 3-4
Patienten können ||| patients may ||| 0-0 1-1
Patienten mit Agitiertheit und ||| patients with agitation and ||| 0-0 1-1 2-2 3-3
Patienten mit Agitiertheit ||| patients with agitation ||| 0-0 1-1 2-2
Patienten mit Beeinträchtigung der Nierenfunktion ||| patients with renal impairment ||| 0-0 1-1 4-2 2-3 4-3
Patienten mit Diabetes mellitus ||| patients with diabetes mellitus ||| 0-0 1-1 2-2 3-3
Patienten mit Diabetes ||| patients with diabetes ||| 0-0 1-1 2-2
Patienten mit Hypocalcämie ( ||| patients with hypocalcaemia ( ||| 0-0 1-1 2-2 3-3
Patienten mit Hypocalcämie ||| patients with hypocalcaemia ||| 0-0 1-1 2-2
Patienten mit Hypokalzämie ( siehe ||| patients with hypocalcaemia ( see ||| 0-0 1-1 2-2 3-3 4-4
Patienten mit Hypokalzämie ( ||| patients with hypocalcaemia ( ||| 0-0 1-1 2-2 3-3
Patienten mit Hypokalzämie ||| patients with hypocalcaemia ||| 0-0 1-1 2-2
Patienten mit Hämoblastosen ( ||| patients with haematological malignancies ( ||| 0-0 1-1 2-2 2-3 3-4
Patienten mit Hämoblastosen ||| patients with haematological malignancies ||| 0-0 1-1 2-2 2-3
Patienten mit Leberfunktionsstörung ||| Patients with hepatic impairment ||| 0-0 1-1 2-2 2-3
Patienten mit Leberinsuffizienz : ||| Patients with hepatic impairment : ||| 0-0 1-1 2-2 2-3 3-4
Patienten mit Leberinsuffizienz ||| Patients with hepatic impairment ||| 0-0 1-1 2-2 2-3
Patienten mit Leberproblemen ||| patients with liver problems ||| 0-0 1-1 2-2 2-3
Patienten mit Morbus Paget ||| patients with Paget s disease ||| 0-0 1-1 2-2 3-2 3-3 3-4
Patienten mit Niereninsuffizienz : ||| Patients with renal impairment : ||| 0-0 1-1 2-2 2-3 3-4
Patienten mit Niereninsuffizienz ||| Patients with renal impairment ||| 0-0 1-1 2-2 2-3
Patienten mit Phenylketonurie . ||| people with phenylketonuria . ||| 0-0 2-0 1-1 2-2 3-3
Patienten mit Phenylketonurie ||| people with phenylketonuria ||| 0-0 2-0 1-1 2-2
Patienten mit Typ 2 Diabetes ||| patients with type 2 diabetes ||| 0-0 1-1 2-2 3-3 4-4
Patienten mit Typ 2 ||| patients with type 2 ||| 0-0 1-1 2-2 3-3
Patienten mit Typ ||| patients with type ||| 0-0 1-1 2-2
Patienten mit bipolarer Manie aufgrund ||| bipolar mania patients due to ||| 2-0 3-1 0-2 1-2 4-3
Patienten mit bipolarer Manie aufgrund ||| bipolar mania patients due ||| 2-0 3-1 0-2 1-2 4-3
Patienten mit bipolarer Manie ||| bipolar mania patients ||| 2-0 3-1 0-2 1-2
Patienten mit bipolarer Störung ||| patients with bipolar disorder ||| 0-0 1-1 2-2 3-3
Patienten mit bipolarer ||| patients with bipolar ||| 0-0 1-1 2-2
Patienten mit chronischer Niereninsuffizienz ) ||| chronic renal failure patients ) ||| 0-0 2-0 1-1 3-1 2-2 3-2 0-3 4-4
Patienten mit chronischer Niereninsuffizienz ||| chronic renal failure patients ||| 0-0 2-0 1-1 3-1 2-2 3-2 0-3
Patienten mit chronischer Niereninsuffizienz ||| patients with chronic renal failure ||| 0-0 1-1 2-2 3-3 2-4
Patienten mit chronischer Niereninsuffizienz ||| patients with chronic renal failure ||| 0-0 1-1 2-2 3-3 2-4 3-4
Patienten mit chronischer ||| electrolytes ||| 0-0 1-0 2-0
Patienten mit chronischer ||| patients with chronic ||| 0-0 1-1 2-2
Patienten mit den ||| patients with the ||| 0-0 1-1 2-2
Patienten mit diesen Charakteristika ||| patients with these characteristics ||| 0-0 1-1 2-2 3-3
Patienten mit diesen ||| patients with these ||| 0-0 1-1 2-2
Patienten mit einem Ausgangshämoglobinwert von ||| patients with baseline ||| 0-0 1-1 2-2 3-2 4-2
Patienten mit einer Adipositas ist ||| Patienten mit einer Adipositas ist ||| 0-0 1-1 2-2 3-3 4-4
Patienten mit einer Adipositas ||| Patienten mit einer Adipositas ||| 0-0 1-1 2-2 3-3
Patienten mit einer manischen oder ||| patients with a manic or ||| 0-0 1-1 2-2 3-3 4-4
Patienten mit einer manischen ||| patients with a manic ||| 0-0 1-1 2-2 3-3
Patienten mit einer niedrig-traumatischen ||| patients with a recent low-trauma ||| 0-0 1-1 2-2 3-3 3-4
Patienten mit einer ||| Patienten mit einer ||| 0-0 1-1 2-2
Patienten mit einer ||| patients with a ||| 0-0 1-1 2-2
Patienten mit geschätzten Dosen von ||| patients with reported estimated doses ||| 0-0 1-1 2-2 2-3 3-4 4-4
Patienten mit geschätzten ||| patients with reported estimated ||| 0-0 1-1 2-2 2-3
Patienten mit leichter Anämie ( ||| Mildly anaemic patients ( ||| 2-0 3-0 2-1 0-2 1-2 4-3
Patienten mit leichter Anämie ||| Mildly anaemic patients ||| 2-0 3-0 2-1 0-2 1-2
Patienten mit metastasierendem Mammakarzinom ||| patients with metastatic breast cancer ||| 0-0 1-1 2-2 3-2 2-3 2-4
Patienten mit metastasierendem Mammakarzinom ||| patients with metastatic breast cancer ||| 0-0 1-1 2-2 3-3 3-4
Patienten mit metastasierendem ||| patients with metastatic ||| 0-0 1-1 2-2
Patienten mit mittelschwerer Anämie ||| to patients with moderate anaemia ||| 2-0 0-1 1-2 2-3 3-4
Patienten mit mittelschwerer ||| to patients with moderate ||| 2-0 0-1 1-2 2-3
Patienten mit noch vorhandener ||| patients with residual ||| 0-0 1-1 2-2 3-2
Patienten mit normalem oder ||| patients with normal or ||| 0-0 1-1 2-2 3-3
Patienten mit normalem ||| patients with normal ||| 0-0 1-1 2-2
Patienten mit oder ohne psychotischen ||| patients with or without psychotic ||| 0-0 1-1 2-2 3-3 4-4
Patienten mit oder ohne ||| patients with or without ||| 0-0 1-1 2-2 3-3
Patienten mit oder ||| patients with or ||| 0-0 1-1 2-2
Patienten mit renaler Anämie ||| patients with renal anaemia , ||| 0-0 1-1 2-2 3-3
Patienten mit renaler Anämie ||| patients with renal anaemia ||| 0-0 1-1 2-2 3-3
Patienten mit renaler ||| patients with renal ||| 0-0 1-1 2-2
Patienten mit schwarzer Hautfarbe können ||| Black patients may ||| 2-0 3-0 0-1 1-1 4-2
Patienten mit schwarzer Hautfarbe ||| Black patients ||| 2-0 3-0 0-1 1-1
Patienten mit schweren ||| Patients with severe hepatic impairment ||| 0-0 1-1 2-2 0-3 0-4
Patienten mit schwerer Agitiertheit , ||| patients with severe agitation , ||| 0-0 1-1 2-2 3-3 4-4
Patienten mit schwerer Agitiertheit ||| patients with severe agitation ||| 0-0 1-1 2-2 3-3
Patienten mit schwerer Leberfunktionsstörung ||| Patients with severe hepatic impairment ||| 0-0 1-1 2-2 3-3 3-4
Patienten mit schwerer Leberinsuffizienz Dosierungsempfehlungen ||| available are insufficient to establish ||| 0-0 4-0 1-1 4-1 2-2 4-2 2-3 3-4 4-4
Patienten mit schwerer Niereninsuffizienz ||| patients with severe renal ||| 0-0 1-1 2-2 3-3
Patienten mit schwerer ||| Patients with severe ||| 0-0 1-1 2-2
Patienten mit schwerer ||| patients with severe ||| 0-0 1-1 2-2
Patienten mit seltenen Erbkrankheiten ||| Patients with rare hereditary problems ||| 0-0 1-1 2-2 2-3 3-3 3-4
Patienten mit stark eingeschränkter ||| Patienten mit stark eingeschränkter ||| 0-0 1-1 2-2 2-3 3-3
Patienten mit stark ||| patients with severe ||| 0-0 1-1 2-2
Patienten mit ||| , in patients with ||| 0-1 0-2 1-3
Patienten mit ||| , patients with ||| 0-1 1-2
Patienten mit ||| Patienten mit ||| 0-0 1-1
Patienten mit ||| Patients who have ||| 0-0 0-1 1-2
Patienten mit ||| Patients who ||| 0-0 0-1 1-1
Patienten mit ||| Patients with ||| 0-0 1-1
Patienten mit ||| and patients who have ||| 0-1 1-1 0-2
Patienten mit ||| and patients who ||| 0-1 1-1 0-2
Patienten mit ||| in patients with less ||| 0-0 0-1 1-2
Patienten mit ||| in patients with ||| 0-0 0-1 1-2
Patienten mit ||| in patients with ||| 1-0 0-1 1-2
Patienten mit ||| patients . ||| 0-0 1-0
Patienten mit ||| patients who have ||| 0-0 1-0 0-1
Patienten mit ||| patients who ||| 0-0 0-1 1-1
Patienten mit ||| patients who ||| 0-0 1-0 0-1
Patienten mit ||| patients with ||| 0-0 1-1
Patienten mit ||| patients ||| 0-0 1-0
Patienten mit ||| with ||| 0-0 1-0
Patienten ohne Adipositas ( ||| Patienten ohne Adipositas ( ||| 0-0 1-1 2-2 3-3
Patienten ohne Adipositas ||| Patienten ohne Adipositas ||| 0-0 1-1 2-2
Patienten ohne ||| Patienten ohne ||| 0-0 1-1
Patienten routinemäßig Volumenersatz durchzuführen ||| be performed in such patients ||| 0-0 1-0 1-1 2-1 1-2 3-3 3-4
Patienten routinemäßig Volumenersatz ||| be performed in ||| 0-0 1-0 1-1 2-1 1-2
Patienten sichergestellt sein . ||| treatment . ||| 1-0 2-0 3-1
Patienten sichergestellt sein ||| treatment ||| 1-0 2-0
Patienten sollte die Dosierung ||| patients dosing should ||| 0-0 2-1 3-1 1-2
Patienten sollten ||| patients should seek ||| 0-0 1-1
Patienten sollten ||| patients should ||| 0-0 1-1
Patienten sowie ||| that examined the metabolic and ||| 0-0 0-1 1-4
Patienten traten gleichzeitig periphere ||| patients reported concurrent peripheral ||| 0-0 1-1 1-2 2-2 3-2 3-3
Patienten und 42 % ||| patients and 42 % ||| 0-0 1-1 2-2 3-3
Patienten und 42 ||| patients and 42 ||| 0-0 1-1 2-2
Patienten und ||| in patients who ||| 0-0 0-1 0-2
Patienten und ||| patients , ||| 0-0
Patienten und ||| patients and ||| 0-0 1-1
Patienten und ||| patients ||| 0-0
Patienten unter 65 ||| in patients less than 65 ||| 0-0 0-1 1-2 1-3 2-4
Patienten unter Aripiprazol- Behandlung und ||| for aripiprazole-treated patients and ||| 2-0 1-1 2-1 3-1 0-2 4-3
Patienten unter Aripiprazol- Behandlung ||| for aripiprazole-treated patients ||| 2-0 1-1 2-1 3-1 0-2
Patienten unter Haloperidol-Behandlung . ||| haloperidol-treated patients . ||| 1-0 2-0 0-1 3-2
Patienten unter Haloperidol-Behandlung ||| haloperidol-treated patients ||| 1-0 2-0 0-1
Patienten unter Olanzapin-Therapie . ||| olanzapine-treated patients . ||| 1-0 2-0 0-1 3-2
Patienten unter Olanzapin-Therapie ||| olanzapine-treated patients ||| 1-0 2-0 0-1
Patienten unter Risedronat . ||| patients who received risedronate . ||| 0-0 1-0 0-1 0-2 2-3 3-4
Patienten unter Risedronat ||| patients who received risedronate ||| 0-0 1-0 0-1 0-2 2-3
Patienten unter ||| in patients less than ||| 0-0 0-1 1-2 1-3
Patienten unter ||| patients who received ||| 0-0 1-0 0-1 0-2
Patienten unter ||| that in patients less than ||| 0-1 0-2 1-3 1-4
Patienten untersucht . ||| patients . ||| 0-0 1-0 2-1
Patienten untersucht ||| patients ||| 0-0 1-0
Patienten vor Beginn der ||| prior to the initiation of ||| 1-0 0-1 1-1 3-2 2-3 3-4
Patienten vor ||| prior to ||| 1-0 0-1 1-1
Patienten wurde ||| patients ||| 0-0
Patienten wurden Antikörper ||| patients , antibodies ||| 0-0 1-1 1-2 2-2
Patienten wurden ||| 3 trials ||| 1-1
Patienten wurden ||| trials ||| 1-0
Patienten ||| , and a patient ||| 0-3
Patienten ||| , in patients ||| 0-1 0-2
Patienten ||| , patients ||| 0-1
Patienten ||| 10 Patients ||| 0-1
Patienten ||| 160 patients ||| 0-1
Patienten ||| 46 ||| 0-0
Patienten ||| Patienten ||| 0-0
Patienten ||| Patients who ||| 0-0 0-1
Patienten ||| Patients ||| 0-0
Patienten ||| The patients ||| 0-0 0-1
Patienten ||| a patient ||| 0-1
Patienten ||| and a patient ||| 0-2
Patienten ||| available ||| 0-0
Patienten ||| evaluated in patients ||| 0-0 0-1 0-2
Patienten ||| in patients who ||| 0-0 0-1 0-2
Patienten ||| in patients ||| 0-0 0-1
Patienten ||| in patients ||| 0-1
Patienten ||| of patients ||| 0-1
Patienten ||| of ||| 0-0
Patienten ||| patient has ||| 0-0
Patienten ||| patient in ||| 0-0 0-1
Patienten ||| patient ||| 0-0
Patienten ||| patients , ||| 0-0
Patienten ||| patients : ||| 0-0
Patienten ||| patients and ||| 0-0
Patienten ||| patients experiencing ||| 0-0
Patienten ||| patients had ||| 0-0 0-1
Patienten ||| patients in ||| 0-0 0-1
Patienten ||| patients of ||| 0-0
Patienten ||| patients on ||| 0-0
Patienten ||| patients received ||| 0-0 0-1
Patienten ||| patients receiving ||| 0-0 0-1
Patienten ||| patients studied ||| 0-0 0-1
Patienten ||| patients treated ||| 0-0
Patienten ||| patients who ||| 0-0 0-1
Patienten ||| patients ||| 0-0
Patienten ||| receiving ||| 0-0
Patienten ||| that examined the metabolic ||| 0-0 0-1
Patienten ||| that examined the ||| 0-0 0-1
Patienten ||| that examined ||| 0-0 0-1
Patienten ||| that in patients ||| 0-1 0-2
Patienten ||| the patients ||| 0-1
Patienten ||| to that in patients ||| 0-2 0-3
Patienten ||| usual ||| 0-0
Patienten ||| weight ||| 0-0
Patienten über 75 ||| patients over 75 ||| 0-0 1-1 2-2
Patienten über ||| patients over ||| 0-0 1-1
Patientengruppe ||| population , ||| 0-0
Patientengruppe ||| population ||| 0-0
Patientengruppen ( siehe Abschnitt 4.2 ||| populations ( see section 4.2 ||| 1-0 1-1 2-2 3-3 4-4
Patientengruppen ( siehe Abschnitt ||| Special populations ( see section ||| 1-1 1-2 2-3 3-4
Patientengruppen ( siehe Abschnitt ||| populations ( see section ||| 1-0 1-1 2-2 3-3
Patientengruppen ( siehe ||| Special populations ( see ||| 1-1 1-2 2-3
Patientengruppen ( siehe ||| populations ( see ||| 1-0 1-1 2-2
Patientengruppen ( ||| Special populations ( ||| 1-1 1-2
Patientengruppen ( ||| populations ( ||| 1-0 1-1
Patienteninformationspaket soll ||| information pack should ||| 0-0 0-1 1-2
Patienteninformationspaket ||| information pack ||| 0-0 0-1
Patientenkollektiv ||| population ||| 0-0
Patientenpopulation kontraindiziert . ||| this patient population . ||| 0-0 0-1 0-2 1-2 2-3
Patientenpopulation kontraindiziert ||| this patient population ||| 0-0 0-1 0-2 1-2
Patientenzahl festgestellt ||| sample size ||| 0-0 0-1
Patientenzahl ||| sample size ||| 0-0 0-1
Patientin ||| patient ||| 0-0
Patientinnen , die ||| patients who ||| 0-0 1-1 2-1
Patientinnen , ||| fatal ||| 0-0 1-0
Patientinnen , ||| of fatal ||| 0-1 1-1
Patientinnen besteht die Möglichkeit ||| patients may be at risk ||| 0-0 0-1 1-2 1-3 2-3 3-4
Patientinnen besteht die ||| patients may be at ||| 0-0 0-1 1-2 1-3 2-3
Patientinnen mit chronischer Niereninsuffizienz ||| chronic renal failure patients , ||| 2-0 3-1 0-2 2-2 3-2 0-3 1-3
Patientinnen mit chronischer Niereninsuffizienz ||| chronic renal failure patients ||| 2-0 3-1 0-2 2-2 3-2 0-3 1-3
Patientinnen mit leichten oder ||| patients with mild or moderate ||| 0-0 1-1 2-2 3-3 2-4
Patientinnen mit ||| patients with ||| 0-0 1-1
Patientinnen sollten ihren ||| ise their ||| 0-0 1-1 2-1
Patientinnen und Patienten im ||| in male and female patients ||| 3-0 3-1 1-2 0-3 3-3 2-4
Patientinnen ||| fractures , when ||| 0-0
Patientinnen ||| fractures , ||| 0-0
Patientinnen ||| fractures ||| 0-0
Patientinnen ||| ise ||| 0-0
Patientinnen ||| patients may ||| 0-0 0-1
Patientinnen ||| patients ||| 0-0
Patrone ( 3 ml ) ||| cartridge ( 3 ml ) ||| 0-0 1-1 2-2 3-3 4-4
Patrone ( 3 ml ||| cartridge ( 3 ml ||| 0-0 1-1 2-2 3-3
Patrone ( 3 ||| cartridge ( 3 ||| 0-0 1-1 2-2
Patrone ( ||| cartridge ( ||| 0-0 1-1
Patrone . ||| cartridge . ||| 0-0 1-1
Patrone aus Glas ( Typ ||| glass cartridge ( type ||| 2-0 0-1 1-1 3-2 4-3
Patrone aus Glas ( ||| glass cartridge ( ||| 2-0 0-1 1-1 3-2
Patrone aus Glas ||| glass cartridge ||| 2-0 0-1 1-1
Patrone aus ||| cartridge ||| 0-0 1-0
Patrone enthält eine ||| cartridge contains a ||| 0-0 1-1 2-2
Patrone enthält ||| cartridge contains ||| 0-0 1-1
Patrone ist aus Glas ||| cartridge is made of glass ||| 0-0 1-1 0-2 2-3 2-4 3-4
Patrone ist ||| cartridge is made ||| 0-0 1-1 0-2
Patrone ||| cartridge ||| 0-0
Patronen ( ||| cartridges ( ||| 0-0 1-1
Patronen dürfen nur zusammen ||| Cartridges should only ||| 0-0 1-0 3-0 1-1 2-2
Patronen sind für die ||| cartridges are designed to ||| 0-0 1-1 0-2 2-2 3-3
Patronen sind für ||| cartridges are designed ||| 0-0 1-1 0-2 2-2
Patronen zu je 3 ml ||| cartridges x 3 ml ||| 0-0 1-0 2-1 3-2 4-3
Patronen zu je 3 ||| cartridges x 3 ||| 0-0 1-0 2-1 3-2
Patronen zu je ||| cartridges x ||| 0-0 1-0 2-1
Patronen zu ||| cartridges ||| 0-0 1-0
Patronen ||| cartridges ||| 0-0
Penfill 100 ||| Penfill 100 ||| 0-0 1-1
Penfill darf ||| Penfill is ||| 0-0 1-0 0-1
Penfill ||| Penfill ||| 0-0
Perforierte Blisterpackungen zur Abgabe ||| Aluminium perforated unit dose ||| 0-0 1-0 1-1 2-2 3-2 3-3
Perforierte Blisterpackungen ||| Aluminium perforated ||| 0-0 1-0 1-1
Periphere Neuropathie , Neuropathie , ||| Peripheral neuropathy , neuropathy , ||| 0-0 1-1 2-2 3-3 4-4
Periphere Neuropathie , Neuropathie ||| Peripheral neuropathy , neuropathy ||| 0-0 1-1 2-2 3-3
Periphere Neuropathie , ||| Peripheral neuropathy , ||| 0-0 1-1 2-2
Periphere Neuropathie ||| Peripheral neuropathy ||| 0-0 1-1
Periphere sensorische Neuropathie , Kopfschmerzen ||| Peripheral sensory neuropathy , headache ||| 0-0 1-1 2-2 3-3 4-4
Periphere sensorische Neuropathie , ||| Peripheral sensory neuropathy , ||| 0-0 1-1 2-2 3-3
Periphere sensorische Neuropathie ||| Peripheral sensory neuropathy ||| 0-0 1-1 2-2
Periphere sensorische ||| Peripheral sensory ||| 0-0 1-1
Periphere ||| Peripheral ||| 0-0
Periphere Ödeme , Schleimhautentzündung ||| Peripheral oedema , mucosal ||| 0-0 1-1 2-2 3-3
Periphere Ödeme , ||| Peripheral oedema , ||| 0-0 1-1 2-2
Periphere Ödeme ||| Peripheral oedema ||| 0-0 1-1
Permeabilität in vitro und ||| in vitro permeability and ||| 1-0 1-1 2-1 0-2 3-3
Permeabilität in vitro ||| in vitro permeability ||| 1-0 1-1 2-1 0-2
Permeabilität ||| permeability ||| 0-0
Peroxisome Proliferator ||| of specific nuclear receptors ||| 0-1 0-2 1-2 1-3
Peroxisome Proliferator ||| specific nuclear receptors ||| 0-0 0-1 1-1 1-2
Personal zubereitet und angewendet ||| prepared and administered by personnel ||| 0-0 1-0 2-1 3-2 0-3 1-4
Personen ) sind darauf hinzuweisen ||| ) should be alerted about ||| 1-0 2-1 3-1 3-2 4-3 3-4
Personen ) ||| ) ||| 1-0
Pflegepersonal aufgetragen ||| nurse ||| 0-0 1-0
Pflegepersonal verabreicht . ||| nurse . ||| 0-0 1-0 2-1
Pflegepersonal verabreicht ||| nurse ||| 0-0 1-0
Pflegepersonal ||| nurse ||| 0-0
Pfleger darüber . ||| of your concern . ||| 0-1 1-2 2-3
Pfleger darüber . ||| your concern . ||| 0-0 1-1 2-2
Pfleger darüber ||| of your concern ||| 0-1 1-2
Pfleger darüber ||| your concern ||| 0-0 1-1
Pfleger ||| of your ||| 0-1
Pfleger ||| your ||| 0-0
Ph.Eur . ) ) . ||| N-acetyl DL tryptophanate ) . ||| 0-0 0-1 0-2 2-2 3-3 1-4 4-4
Ph.Eur. ) , Natriumhydroxid und ||| sodium hydroxide , and ||| 0-0 1-0 3-1 2-2 4-3
Ph.Eur. ) , Natriumhydroxid ||| sodium hydroxide , ||| 0-0 1-0 3-1 2-2
Ph.Eur. ) Natriumhydroxid ||| Sodium hydroxide ||| 0-0 1-0 2-1
Ph.Eur. ) ||| Sodium ||| 0-0 1-0
Ph.Eur. ) ||| sodium ||| 0-0 1-0
Pharma GmbH Roonstraße 25 D-90429 ||| Pharma GmbH Roonstraße 25 D-90429 ||| 0-0 1-1 2-2 3-3 4-4
Pharma GmbH Roonstraße 25 ||| Pharma GmbH Roonstraße 25 ||| 0-0 1-1 2-2 3-3
Pharma GmbH Roonstraße ||| Pharma GmbH Roonstraße ||| 0-0 1-1 2-2
Pharma GmbH Tel : +43 ||| Pharma GmbH Tel : +43 ||| 0-0 1-1 2-2 3-3 4-4
Pharma GmbH Tel : +49 ||| Pharma GmbH Tel : +49 ||| 0-0 1-1 2-2 3-3 4-4
Pharma GmbH Tel : ||| Pharma GmbH Tel : ||| 0-0 1-1 2-2 3-3
Pharma GmbH Tel ||| Pharma GmbH Tel ||| 0-0 1-1 2-2
Pharma GmbH Tel. + ||| Pharma GmbH Tel . + ||| 0-0 1-1 2-2 2-3 3-4
Pharma GmbH Tel. ||| Pharma GmbH Tel . ||| 0-0 1-1 2-2 2-3
Pharma GmbH Tél/Tel : ||| Pharma GmbH Tél/ Tel : ||| 0-0 1-1 2-2 2-3 3-4
Pharma GmbH Tél/Tel ||| Pharma GmbH Tél/ Tel ||| 0-0 1-1 2-2 2-3
Pharma GmbH ||| Pharma GmbH ||| 0-0 1-1
Pharma Tel . : +36 ||| Pharma Tel . : +36 ||| 0-0 1-1 2-2 3-3 4-4
Pharma Tel . : ||| Pharma Tel . : ||| 0-0 1-1 2-2 3-3
Pharma Tel . ||| Pharma Tel . ||| 0-0 1-1 2-2
Pharma Tel ||| Pharma Tel ||| 0-0 1-1
Pharma Tél : + 33 ||| Pharma Tél : + 33 ||| 0-0 1-1 2-2 3-3 4-4
Pharma Tél : + ||| Pharma Tél : + ||| 0-0 1-1 2-2 3-3
Pharma Tél : ||| Pharma Tél : ||| 0-0 1-1 2-2
Pharma Tél ||| Pharma Tél ||| 0-0 1-1
Pharma ||| Pharma ||| 0-0
Pharmaceutical Europe Ltd ||| Pharmaceutical Europe Ltd ||| 0-0 1-1 2-2
Pharmaceutical Europe ||| Pharmaceutical Europe ||| 0-0 1-1
Pharmaceutical ||| Pharmaceutical ||| 0-0
Pharmakodynamische Effekte ||| Pharmacodynamic effects ||| 0-0 1-1
Pharmakodynamische ||| Pharmacodynamic ||| 0-0
Pharmakokinetik des Sulfonylharnstoffes zu haben ||| pharmacokinetics of the sulphonylurea ||| 0-0 1-1 1-2 3-2 2-3 4-3
Pharmakokinetik des ||| pharmacokinetics of ||| 0-0 1-1
Pharmakokinetik ergab keinen Hinweis auf ||| revealed no evidence of ||| 0-0 1-0 2-1 3-2 4-2
Pharmakokinetik ergab keinen Hinweis auf ||| revealed no evidence ||| 0-0 1-0 2-1 3-2 4-2
Pharmakokinetik ergab keinen ||| revealed no ||| 0-0 1-0 2-1
Pharmakokinetik ergab ||| revealed ||| 0-0 1-0
Pharmakokinetik oder ||| pharmacokinetics or ||| 0-0 1-1
Pharmakokinetik von Aripiprazol . ||| pharmacokinetics of aripiprazole . ||| 0-0 1-1 2-2 3-3
Pharmakokinetik von Aripiprazol ||| pharmacokinetics of aripiprazole ||| 0-0 1-1 2-2
Pharmakokinetik von Rimonabant bei ||| rimonabant pharmacokinetics are ||| 2-0 0-1 1-1 0-2
Pharmakokinetik von Rimonabant ||| pharmacokinetics of rimonabant ||| 0-0 1-1 2-2
Pharmakokinetik von Rimonabant ||| rimonabant pharmacokinetics are ||| 2-0 0-1 1-1 0-2
Pharmakokinetik von ||| pharmacokinetics are ||| 0-0 1-0 0-1
Pharmakokinetik von ||| pharmacokinetics of ||| 0-0 1-1
Pharmakokinetik ||| pharmacokinetics ||| 0-0
Pharmakologie ||| pharmacology ||| 0-0
Pharmakotherapeutische Gruppe : orale ||| Pharmacotherapeutic group : oral blood ||| 0-0 1-1 2-2 3-3 1-4
Pharmakotherapeutische ||| Pharmacotherapeutic ||| 0-0
Pharmakovigilanz-System Der ||| Pharmacovigilance system The ||| 0-0 0-1 1-2
Pharmakovigilanz-System ||| Pharmacovigilance system ||| 0-0 0-1
Pharmakovigilanzaktivitäten ||| performing ||| 0-0
Pharmakovigilanzplan oder ||| Pharmacovigilance Plan or ||| 0-0 0-1 1-2
Pharmakovigilanzplan ||| Pharmacovigilance Plan ||| 0-0 0-1
Pharmazeutische Unternehmer verpflichtet sich ||| Marketing Authorisation Holder commits ||| 0-0 1-0 1-1 1-2 2-3 3-3
Pharmazeutische Unternehmer ||| Marketing Authorisation Holder ||| 0-0 1-0 1-1 1-2
Pharmazeutischer Unternehmer : ||| Marketing authorisation holder : ||| 0-0 0-1 1-2 2-3
Pharmazeutischer Unternehmer Novartis ||| 29 Marketing Authorisation Holder Novartis ||| 0-0 0-1 1-1 1-2 1-3 2-4
Pharmazeutischer Unternehmer und Hersteller ||| Marketing Authorisation Holder and Manufacturer ||| 0-0 1-1 1-2 2-3 3-4
Pharmazeutischer Unternehmer und ||| Marketing Authorisation Holder and ||| 0-0 1-1 1-2 2-3
Pharmazeutischer Unternehmer ||| 29 Marketing Authorisation Holder ||| 0-0 0-1 1-1 1-2 1-3
Pharmazeutischer Unternehmer ||| Marketing Authorisation Holder ||| 0-0 1-1 1-2
Pharmazeutischer Unternehmer ||| Marketing authorisation holder ||| 0-0 0-1 1-2
Pharmazeutischer ||| Marketing authorisation ||| 0-0 0-1
Pharmazeutischer ||| Marketing ||| 0-0
Phase-3-Studien ||| included ||| 0-0
Phasen ||| triphasic process ||| 0-0
Phasen ||| triphasic ||| 0-0
Phenobarbital , Primidon , ||| ähnliche Wirkungen haben und deshalb ||| 0-0 0-1 1-1 2-2 2-3 2-4 3-4
Phenobarbital , ||| ähnliche Wirkungen ||| 0-0 0-1 1-1
Phenprocoumon und Metformin ausübt . ||| phenprocoumon and metformin . ||| 0-0 3-0 1-1 2-2 3-2 4-3
Phenprocoumon und Metformin ausübt ||| phenprocoumon and metformin ||| 0-0 3-0 1-1 2-2 3-2
Phenytoin ||| Nevirapin und Johanniskraut ||| 0-0 0-1 0-2
Phosphatase ( BSAP ) , ||| phosphatase ( BSAP ) , ||| 0-0 1-1 2-2 3-3 4-4
Phosphatase ( BSAP ) ||| phosphatase ( BSAP ) ||| 0-0 1-1 2-2 3-3
Phosphatase ( BSAP ||| phosphatase ( BSAP ||| 0-0 1-1 2-2
Phosphatase ( ||| phosphatase ( ||| 0-0 1-1
Phosphatase ||| alkaline phosphatase ||| 0-0 0-1
Phosphatase ||| phosphatase ||| 0-0
Pilzinfektionen ||| anti-fungal ||| 0-0
Pioglitazon ( als Hydrchlorid ) ||| pioglitazone ( as hydrochloride ) ||| 0-0 1-1 2-2 3-3 4-4
Pioglitazon ( als Hydrchlorid ||| of pioglitazone ( as hydrochloride ||| 0-1 1-2 2-3 3-4
Pioglitazon ( als Hydrchlorid ||| pioglitazone ( as hydrochloride ||| 0-0 1-1 2-2 3-3
Pioglitazon ( als Hydrochlorid ) ||| pioglitazone ( as hydrochloride ) ||| 0-0 1-1 2-2 3-3 4-4
Pioglitazon ( als Hydrochlorid ||| of pioglitazone ( as hydrochloride ||| 0-1 1-2 2-3 3-4
Pioglitazon ( als Hydrochlorid ||| pioglitazone ( as hydrochloride ||| 0-0 1-1 2-2 3-3
Pioglitazon ( als ||| of pioglitazone ( as ||| 0-1 1-2 2-3
Pioglitazon ( als ||| pioglitazone ( as ||| 0-0 1-1 2-2
Pioglitazon ( siehe Abschnitt 4.5 ||| pioglitazone ( see section 4.5 ||| 0-0 1-1 2-2 3-3 4-4
Pioglitazon ( siehe Abschnitt ||| pioglitazone ( see section ||| 0-0 1-1 2-2 3-3
Pioglitazon ( siehe ||| pioglitazone ( see ||| 0-0 1-1 2-2
Pioglitazon ( ||| of pioglitazone ( ||| 0-1 1-2
Pioglitazon ( ||| pioglitazone ( ||| 0-0 1-1
Pioglitazon , der in Actos ||| , ||| 1-0 4-0
Pioglitazon , wohingegen die relative ||| pioglitazone , whilst the relative ||| 0-0 1-1 2-2 3-3 4-4
Pioglitazon , wohingegen die ||| pioglitazone , whilst the ||| 0-0 1-1 2-2 3-3
Pioglitazon , wohingegen ||| pioglitazone , whilst ||| 0-0 1-1 2-2
Pioglitazon , ||| pioglitazone , ||| 0-0 1-1
Pioglitazon . ||| of pioglitazone . ||| 0-1 1-2
Pioglitazon . ||| pioglitazone . ||| 0-0 1-1
Pioglitazon Tabletten werden ||| Pioglitazone tablets are ||| 0-0 1-1 2-2
Pioglitazon Tabletten ||| Pioglitazone tablets ||| 0-0 1-1
Pioglitazon ab . ||| pioglitazone . ||| 0-0 1-0 2-1
Pioglitazon ab ||| pioglitazone ||| 0-0 1-0
Pioglitazon abgesetzt werden . ||| in cardiac status occurs . ||| 0-0 0-1 1-1 1-2 1-3 2-3 3-4
Pioglitazon abgesetzt werden ||| in cardiac status occurs ||| 0-0 0-1 1-1 1-2 1-3 2-3
Pioglitazon als Hydrochlorid . ||| of pioglitazone as hydrochloride . ||| 0-1 1-2 2-3 3-4
Pioglitazon als Hydrochlorid . ||| pioglitazone as hydrochloride . ||| 0-0 1-1 2-2 3-3
Pioglitazon als Hydrochlorid ||| of pioglitazone as hydrochloride ||| 0-1 1-2 2-3
Pioglitazon als Hydrochlorid ||| pioglitazone as hydrochloride ||| 0-0 1-1 2-2
Pioglitazon als ||| of pioglitazone as ||| 0-1 1-2
Pioglitazon als ||| pioglitazone as ||| 0-0 1-1
Pioglitazon behandelten Gruppe wurde beobachtet ||| pioglitazone treated group ||| 0-0 1-1 2-2 3-2 4-2
Pioglitazon behandelten ||| pioglitazone treated ||| 0-0 1-1
Pioglitazon behandelten ||| pioglitazone-treated ||| 0-0 1-0
Pioglitazon bei Patienten ||| pioglitazone in patients ||| 0-0 1-1 2-2
Pioglitazon bei ||| pioglitazone in ||| 0-0 1-1
Pioglitazon beträgt beim Menschen 5-6 ||| pioglitazone in man is 5 ||| 0-0 2-1 2-2 3-2 4-2 1-3 4-4
Pioglitazon bleibt somit unverändert . ||| pioglitazone concentration is unchanged . ||| 0-0 1-1 1-2 1-3 2-3 3-3 4-4
Pioglitazon bleibt somit unverändert ||| pioglitazone concentration is unchanged ||| 0-0 1-1 1-2 1-3 2-3 3-3
Pioglitazon bzw. ||| combination therapy with insulin . ||| 0-0 0-1 0-2 1-3 1-4
Pioglitazon darf nicht ||| Pioglitazone should not be ||| 0-0 1-1 1-2 2-2 1-3
Pioglitazon einnahmen , verglichen ||| taking pioglitazone compared to ||| 1-0 0-1 3-2 3-3
Pioglitazon einnahmen , ||| taking pioglitazone ||| 1-0 0-1
Pioglitazon einnahmen ||| taking pioglitazone ||| 1-0 0-1
Pioglitazon gingen mit ||| pioglitazone have been accompanied ||| 0-0 1-1 1-2 1-3 2-3
Pioglitazon in Kombination ||| pioglitazone was used in combination ||| 0-0 0-1 2-2 1-3 2-4
Pioglitazon ist auch angezeigt ||| Pioglitazone is also indicated ||| 0-0 1-1 2-2 3-3
Pioglitazon ist auch ||| Pioglitazone is also ||| 0-0 1-1 2-2
Pioglitazon ist ||| Pioglitazone is ||| 0-0 1-1
Pioglitazon kann ||| Pioglitazone can ||| 0-0 1-1
Pioglitazon mit Gemfibrozil ( einem ||| pioglitazone with gemfibrozil ( an ||| 0-0 1-1 2-2 3-3 2-4 4-4
Pioglitazon mit Gemfibrozil ( einem ||| pioglitazone with gemfibrozil ( an ||| 0-0 1-1 2-2 3-3 4-4
Pioglitazon mit Gemfibrozil ( ||| pioglitazone with gemfibrozil ( ||| 0-0 1-1 2-2 3-3
Pioglitazon mit Gemfibrozil ||| pioglitazone with gemfibrozil ||| 0-0 1-1 2-2
Pioglitazon mit ||| pioglitazone was ||| 0-0 0-1 1-1
Pioglitazon mit ||| pioglitazone with ||| 0-0 1-1
Pioglitazon oder Placebo ||| pioglitazone or placebo ||| 0-0 1-1 2-2
Pioglitazon oder einen der ||| pioglitazone or any of the ||| 0-0 1-1 2-2 3-3 3-4
Pioglitazon oder einen ||| pioglitazone or any ||| 0-0 1-1 2-2
Pioglitazon oder ||| pioglitazone or ||| 0-0 1-1
Pioglitazon reduzierte ||| pioglitazone ||| 0-0 1-0
Pioglitazon scheint über eine Aktivierung ||| Pioglitazone appears to act via ||| 0-0 1-1 1-2 3-2 4-3 2-4 4-4
Pioglitazon traten ||| was apparent in ||| 0-0 0-1 1-1 1-2
Pioglitazon und alle aktiven Metaboliten ||| Pioglitazone and all active metabolites ||| 0-0 1-1 2-2 3-3 4-4
Pioglitazon und alle aktiven ||| Pioglitazone and all active ||| 0-0 1-1 2-2 3-3
Pioglitazon und alle ||| Pioglitazone and all ||| 0-0 1-1 2-2
Pioglitazon und dem ||| pioglitazone and ||| 0-0 1-1
Pioglitazon und seinen Metaboliten sind ||| pioglitazone and its metabolites are ||| 0-0 1-1 2-2 3-3 4-4
Pioglitazon und seinen Metaboliten ||| pioglitazone and its metabolites ||| 0-0 1-1 2-2 3-3
Pioglitazon und seinen ||| pioglitazone and its ||| 0-0 1-1 2-2
Pioglitazon und ||| Pioglitazone and ||| 0-0 1-1
Pioglitazon und ||| pioglitazone and ||| 0-0 1-1
Pioglitazon und ||| pioglitazone ||| 0-0
Pioglitazon versus Gliclazid als Monotherapie ||| pioglitazone vs. gliclazide as monotherapy ||| 0-0 1-1 2-2 3-3 4-4
Pioglitazon versus Gliclazid als ||| pioglitazone vs. gliclazide as ||| 0-0 1-1 2-2 3-3
Pioglitazon versus Gliclazid ||| pioglitazone vs. gliclazide ||| 0-0 1-1 2-2
Pioglitazon versus ||| pioglitazone vs. ||| 0-0 1-1
Pioglitazon wird Ihre ||| Pioglitazone will ||| 0-0 1-1 2-1
Pioglitazon wird empfohlen , ||| pioglitazone , it is recommended ||| 0-0 3-1 2-2 1-3 2-4
Pioglitazon wird in der Leber ||| Pioglitazone undergoes extensive hepatic metabolism ||| 0-0 1-1 2-1 4-1 4-2 3-3 4-3 4-4
Pioglitazon wurde ||| pioglitazone there was ||| 0-0 1-1 1-2
Pioglitazon während der ||| pioglitazone during ||| 0-0 1-1 2-1
Pioglitazon zu kontrollieren . ||| pioglitazone in all ||| 0-0 1-1 2-2
Pioglitazon zu kontrollieren ||| pioglitazone in all ||| 0-0 0-1 2-2
Pioglitazon zu kontrollieren ||| pioglitazone in all ||| 0-0 1-1 2-2
Pioglitazon zu ||| pioglitazone in ||| 0-0 0-1
Pioglitazon zu ||| pioglitazone in ||| 0-0 1-1
Pioglitazon ||| , pioglitazone ||| 0-1
Pioglitazon ||| Pioglitazone was ||| 0-0 0-1
Pioglitazon ||| Pioglitazone ||| 0-0
Pioglitazon ||| combination therapy with ||| 0-0 0-1 0-2
Pioglitazon ||| in combination therapy with ||| 0-1 0-2 0-3
Pioglitazon ||| of pioglitazone ||| 0-1
Pioglitazon ||| pioglitazone and ||| 0-0
Pioglitazon ||| pioglitazone in ||| 0-0 0-1
Pioglitazon ||| pioglitazone was ||| 0-0 0-1
Pioglitazon ||| pioglitazone ||| 0-0
Pipette ||| pipette ||| 0-0
Pivotal Fracture Trial [ PFT ||| Pivotal Fracture Trial [ PFT ||| 0-0 1-1 2-2 3-3 4-4
Pivotal Fracture Trial [ ||| Pivotal Fracture Trial [ ||| 0-0 1-1 2-2 3-3
Pivotal Fracture Trial ||| Pivotal Fracture Trial ||| 0-0 1-1 2-2
Pivotal Fracture ||| Pivotal Fracture ||| 0-0 1-1
Pivotal ||| Pivotal ||| 0-0
Placebo ( 139 von 1 ||| placebo ( 139 out of ||| 0-0 1-1 2-2 3-3 3-4
Placebo ( 139 von ||| placebo ( 139 out of ||| 0-0 1-1 2-2 3-3 3-4
Placebo ( 139 ||| placebo ( 139 ||| 0-0 1-1 2-2
Placebo ( 2,1 % ) ||| placebo ( 2.1 % ) ||| 0-0 1-1 2-2 3-3 4-4
Placebo ( 2,1 % ||| placebo ( 2.1 % ||| 0-0 1-1 2-2 3-3
Placebo ( 2,1 ||| placebo ( 2.1 ||| 0-0 1-1 2-2
Placebo ( 29 [ 2,7 ||| placebo ( 29 [ 2.7 ||| 0-0 1-1 2-2 3-3 4-4
Placebo ( 29 [ ||| placebo ( 29 [ ||| 0-0 1-1 2-2 3-3
Placebo ( 29 ||| placebo ( 29 ||| 0-0 1-1 2-2
Placebo ( ||| placebo ( ||| 0-0 1-1
Placebo -2,9 kg ) . ||| placebo -2.9 kg ) . ||| 0-0 1-1 2-2 3-3 4-4
Placebo -2,9 kg ) ||| placebo -2.9 kg ) ||| 0-0 1-1 2-2 3-3
Placebo -2,9 kg ||| placebo -2.9 kg ||| 0-0 1-1 2-2
Placebo -2,9 ||| placebo -2.9 ||| 0-0 1-1
Placebo . ||| placebo . ||| 0-0 1-1
Placebo Absolute ||| in fracture event ||| 0-0 0-1 1-1 1-2
Placebo behandelte ||| placebo-treated ||| 0-0 1-0
Placebo behandelten Patienten beobachtet . ||| placebo-treated patients . ||| 0-0 1-0 2-1 3-2 4-2
Placebo behandelten Patienten ||| placebo-treated patients ||| 0-0 1-0 2-1
Placebo behandelten ||| placebo-treated ||| 0-0 1-0
Placebo zu einer bestehenden Behandlung ||| placebo to existing treatment ||| 0-0 1-1 2-2 3-2 4-3
Placebo zu einer bestehenden ||| placebo to existing ||| 0-0 1-1 2-2 3-2
Placebo zu ||| placebo to ||| 0-0 1-1
Placebo ||| Aclasta Placebo ||| 0-0 0-1
Placebo ||| in patients being ||| 0-0 0-1 0-2
Placebo ||| placebo ( ||| 0-0
Placebo ||| placebo , ||| 0-0
Placebo ||| placebo ||| 0-0
Placebo über drei Wochen an ||| placebo over three weeks in ||| 0-0 1-1 2-2 3-3 4-3 4-4
Placebo über drei ||| placebo over three ||| 0-0 1-1 2-2
Placebo über ||| placebo over ||| 0-0 1-1
Placebo-Gruppe . ||| placebo group . ||| 0-0 0-1 1-2
Placebo-Gruppe ||| placebo group ||| 0-0 0-1
Placebo-Gruppe ||| placebo ||| 0-0
Placebo-kontrollierten Studie betrug die Inzidenz ||| placebo-controlled trial , the incidence ||| 0-0 1-1 2-1 3-3 4-4
Placebo-kontrollierten Studie betrug die ||| placebo-controlled trial , the ||| 0-0 1-1 2-1 3-3
Placebo-kontrollierten Studie betrug ||| placebo-controlled trial , ||| 0-0 1-1 2-1
Placebo-kontrollierten Studie betrug ||| placebo-controlled trial ||| 0-0 1-1 2-1
Placebo-kontrollierten Studie über 26 Wochen ||| 26-week , placebo-controlled trial , ||| 2-0 3-0 0-2 1-3 4-3
Placebo-kontrollierten Studie über 26 Wochen ||| 26-week , placebo-controlled trial ||| 2-0 3-0 0-2 1-3 4-3
Placebo-kontrollierten Studie über 26 Wochen ||| 26-week , placebo-controlled trial ||| 2-0 3-0 2-1 0-2 1-3 4-3
Placebo-kontrollierten Studie über 6 Wochen ||| 6-week , placebo-controlled trial involving ||| 0-0 3-0 0-2 1-3 4-3 0-4 2-4
Placebo-kontrollierten Studien betrug die Inzidenz ||| placebo-controlled trials , the incidence ||| 0-0 1-1 2-2 3-3 2-4 4-4
Placebo-kontrollierten Studien betrug die Inzidenz ||| placebo-controlled trials , the incidence ||| 0-0 1-1 3-3 2-4 3-4 4-4
Placebo-kontrollierten Studien ||| placebo-controlled trials , ||| 0-0 1-1
Placebo-kontrollierten Studien ||| placebo-controlled trials ||| 0-0 1-1
Placebo-kontrollierten ||| , placebo-controlled ||| 0-1
Placebo-kontrollierten ||| placebo-controlled ||| 0-0
Placebogruppe . ||| placebo group . ||| 0-0 0-1 1-2
Placebogruppe re-randomisiert . ||| placebo . ||| 0-0 1-0 2-1
Placebogruppe re-randomisiert ||| placebo group ||| 0-0 1-0 0-1
Placebogruppe re-randomisiert ||| placebo ||| 0-0 1-0
Placebogruppe ||| placebo group ||| 0-0 0-1
Plasma bleibt unverändert , aber ||| is unchanged , but with ||| 1-0 0-1 1-1 2-1 3-2 4-3
Plasma bleibt unverändert , aber ||| is unchanged , but ||| 1-0 0-1 1-1 2-1 3-2 4-3
Plasma bleibt unverändert , ||| is unchanged , ||| 1-0 0-1 1-1 2-1 3-2
Plasma bleibt unverändert ||| is unchanged ||| 1-0 0-1 1-1 2-1
Plasma-Eliminationshalbwertszeit von unverändertem ||| plasma elimination half-life of unchanged ||| 0-0 0-1 0-2 1-3 2-4
Plasma-Eliminationshalbwertszeit von ||| plasma elimination half-life of ||| 0-0 0-1 0-2 1-3
Plasma-Eliminationshalbwertszeit ||| plasma elimination half-life ||| 0-0 0-1 0-2
Plasmakomponenten ||| transcytosis ||| 0-0
Plasmakonzentration gegen ||| plasma concentration ||| 0-0 0-1
Plasmakonzentration von Pioglitazon ( ||| plasma concentration of pioglitazone ( ||| 0-0 0-1 1-2 2-3 3-4
Plasmakonzentration von Pioglitazon ||| plasma concentration of pioglitazone ||| 0-0 0-1 1-2 2-3
Plasmakonzentration von ||| plasma concentration of ||| 0-0 0-1 1-2
Plasmakonzentration ||| plasma concentration ||| 0-0 0-1
Plasmakonzentrationen ||| plasma concentrations ||| 0-0 0-1
Plasmaproteinbindung ||| plasma ||| 0-0
Plasmaproteine ||| plasma proteins ||| 0-0 0-1
Plasmaproteine ||| serum proteins ||| 0-0 0-1
Plasmaspiegels bei 1 ||| peak plasma concentrations were 1 ||| 0-1 0-2 0-3 1-3 2-4
Plasmaspiegels bei 1 ||| plasma concentrations were 1 ||| 0-0 0-1 0-2 1-2 2-3
Plasmaspiegels bei ||| peak plasma concentrations were ||| 0-1 0-2 0-3 1-3
Plasmaspiegels bei ||| plasma concentrations were ||| 0-0 0-1 0-2 1-2
Pleuraerguss , allergische Rhinitis ||| pleural effusion , allergic rhinitis ||| 0-0 0-1 1-1 1-2 2-3 3-4
Pleuraerguss , allergische ||| pleural effusion , allergic ||| 0-0 0-1 1-1 1-2 2-3
Pleuraerguss , ||| pleural effusion , ||| 0-0 0-1 1-1 1-2
Pollakisurie , Hämaturie ||| pollakiuria , haematuria ||| 0-0 2-0 1-1 2-2
Polska Takeda Global R & ||| Polska Takeda Global R & ||| 0-0 1-1 2-2 3-3 4-4
Polska Takeda Global R ||| Polska Takeda Global R ||| 0-0 1-1 2-2 3-3
Polska Takeda Global ||| Polska Takeda Global ||| 0-0 1-1 2-2
Polska Takeda ||| Polska Takeda ||| 0-0 1-1
Polska ||| Polska ||| 0-0
Polydipsie , Hyperglykämie , Hypokalzämie ||| polydipsia , hyperglycaemia , hypocalcaemia ||| 0-0 1-1 2-2 3-3 4-4
Polydipsie , Hyperglykämie , ||| polydipsia , hyperglycaemia , ||| 0-0 1-1 2-2 3-3
Polydipsie , Hyperglykämie ||| polydipsia , hyperglycaemia ||| 0-0 1-1 2-2
Polydipsie , ||| polydipsia , ||| 0-0 1-1
Polydipsie ||| polydipsia ||| 0-0
Polyneuropathie , Areflexie , Dyskinesie ||| Polyneuropathy , areflexia , dyskinesia ||| 0-0 1-1 2-2 3-3 4-4
Polyneuropathie , Areflexie , ||| Polyneuropathy , areflexia , ||| 0-0 1-1 2-2 3-3
Polyneuropathie , Areflexie ||| Polyneuropathy , areflexia ||| 0-0 1-1 2-2
Polyneuropathie , ||| Polyneuropathy , ||| 0-0 1-1
Polyneuropathie ||| Polyneuropathy ||| 0-0
Polypen ) : ||| polyps ) : ||| 0-0 1-1 2-2
Polypen ) ||| polyps ) ||| 0-0 1-1
Polypen ||| polyps ||| 0-0
Polyposis ( FAP ) führte ||| adenomatous polyposis ( FAP ) ||| 0-0 0-1 2-1 1-2 2-3 4-3 3-4
Polypropylen/Polyethylen niedriger Dichte . ||| low-density polyethylene dropper . ||| 0-0 0-1 1-1 2-2 3-3
Polypropylen/Polyethylen niedriger Dichte ||| low-density polyethylene dropper ||| 0-0 0-1 1-1 2-2
Polypropylen/Polyethylen niedriger ||| low-density polyethylene ||| 0-0 0-1 1-1
Polysorbat 80 , Salzsäure ||| polysorbate 80 , hydrochloric acid ||| 0-0 1-1 2-2 0-3 3-3 3-4
Population von 789 Patienten berechnet ||| population of 789 patients ||| 0-0 1-1 2-2 4-2 3-3
Population von Patienten mit ||| number of patients . ||| 1-0 1-1 2-2 3-2
Population von Patienten mit ||| number of patients ||| 1-0 1-1 2-2 3-2
Population von ||| number of ||| 1-0 1-1
Population von ||| population of ||| 0-0 1-1
Population ||| population ||| 0-0
Populationen ohne Diabetes ||| non-diabetic ||| 0-0 1-0 2-0
Populationspharmakokinetische Analysen zeigten ||| pharmacokinetic analysis ||| 0-0 1-1 2-1
Populationspharmakokinetische ||| pharmacokinetic ||| 0-0
Populationspharmakokinetische ||| population pharmacokinetic ||| 0-1
Portugal - Produtos Farmacêuticos , ||| Portugal - Produtos Farmacêuticos , ||| 0-0 1-1 2-2 3-3 4-4
Portugal - Produtos Farmacêuticos ||| Portugal - Produtos Farmacêuticos ||| 0-0 1-1 2-2 3-3
Portugal - Produtos ||| Portugal - Produtos ||| 0-0 1-1 2-2
Portugal - ||| Portugal - ||| 0-0 1-1
Portugal Lilly Portugal - Produtos ||| Portugal Lilly Portugal - Produtos ||| 0-0 1-1 2-2 3-3 4-4
Portugal Lilly Portugal - ||| Portugal Lilly Portugal - ||| 0-0 1-1 2-2 3-3
Portugal Lilly Portugal ||| Portugal Lilly Portugal ||| 0-0 1-1 2-2
Portugal Lilly ||| Portugal Lilly ||| 0-0 1-1
Portugal Novartis Farma - Produtos ||| Portugal Novartis Farma - Produtos ||| 0-0 1-1 2-2 3-3 4-4
Portugal Novartis Farma - ||| Portugal Novartis Farma - ||| 0-0 1-1 2-2 3-3
Portugal Novartis Farma ||| Portugal Novartis Farma ||| 0-0 1-1 2-2
Portugal Novartis ||| Portugal Novartis ||| 0-0 1-1
Portugal ||| Portugal ||| 0-0
Post-Marketing ||| Häufigkeit ||| 0-0
Post-Marketing Überwachung ||| Häufigkeit ||| 0-0
Potenziell medizinisch relevante Zeichen ||| The potentially medically important signs ||| 0-0 0-1 1-2 2-2 3-3 3-4
Potenziell medizinisch relevante ||| The potentially medically ||| 0-0 0-1 1-2 2-2
Potenziell ||| The potentially ||| 0-0 0-1
Praxis erfolgen . ||| practice . ||| 0-0 1-0 2-1
Praxis erfolgen ||| practice ||| 0-0 1-0
Primidon , ||| haben und deshalb ||| 0-0 0-1 0-2 1-2
Primärpackung : ||| immediate packaging : ||| 0-0 0-1 1-2
Primärpackung ||| immediate packaging ||| 0-0 0-1
Probanden , ||| healthy subjects ||| 0-0 0-1
Probanden im ||| of ||| 0-0 1-0
Probanden lagen die ||| subjects the ||| 0-0 1-1 2-1
Probanden mit einer 31,1 ||| 31.1 ||| 0-0 1-0 3-0
Probanden mit ||| subjects with ||| 0-0 1-1
Probanden steigerte ein hochwirksamer CYP2D6-Inhibitor ||| subjects , a potent inhibitor ||| 0-0 1-0 1-1 2-2 3-3 2-4 4-4
Probanden steigerte ein hochwirksamer Inhibitor ||| subjects , a potent inhibitor ||| 0-0 1-0 1-1 2-2 3-3 2-4 4-4
Probanden steigerte ||| subjects , ||| 0-0 1-0 1-1
Probanden ||| healthy subjects ||| 0-0 0-1
Probanden ||| subjects , ||| 0-0
Probanden ||| subjects ||| 0-0
Probleme mit dem Herzen oder ||| problem of the heart or ||| 0-0 1-1 2-2 3-3 4-4
Probleme mit dem Herzen ||| problem of the heart ||| 0-0 1-1 2-2 3-3
Probleme mit dem ||| problem of the ||| 0-0 1-1 2-2
Probleme mit ||| problem of ||| 0-0 1-1
Probleme ||| problem , ||| 0-0
Probleme ||| problem ||| 0-0
Produkt und ist ||| product and is ||| 0-0 1-1 2-2
Produkt und ||| product and ||| 0-0 1-1
Produkt ||| product ||| 0-0
Produkte innerhalb ||| members within ||| 0-0 1-1
Produkte ||| members ||| 0-0
Produktiver Husten , Belastungsdyspnoe ||| Productive cough , exertional dyspnoea ||| 0-0 1-1 2-2 3-3 3-4
Produktiver Husten , ||| Productive cough , ||| 0-0 1-1 2-2
Produktiver Husten ||| Productive cough ||| 0-0 1-1
Produktiver ||| Productive ||| 0-0
Produtos Farmacêuticos , Lda Tel ||| Produtos Farmacêuticos , Lda Tel ||| 0-0 1-1 2-2 3-3 4-4
Produtos Farmacêuticos , Lda ||| Produtos Farmacêuticos , Lda ||| 0-0 1-1 2-2 3-3
Produtos Farmacêuticos , S.A. ||| Produtos Farmacêuticos , S. A. ||| 0-0 1-1 2-2 3-3 3-4
Produtos Farmacêuticos , ||| Produtos Farmacêuticos , ||| 0-0 1-1 2-2
Produtos Farmacêuticos ||| Produtos Farmacêuticos ||| 0-0 1-1
Produtos ||| Produtos ||| 0-0
Proportionale Anstiege der ||| Proportional increases of the ||| 0-0 1-0 1-1 2-2 2-3
Proportionale Anstiege ||| Proportional increases ||| 0-0 1-0 1-1
Propyl-4-hydroxybenzoat ( E216 ) ||| Propyl parahydroxybenzoate ( E216 ) ||| 0-0 0-1 1-2 2-3 3-4
Propyl-4-hydroxybenzoat ( E216 ) ||| propyl parahydroxybenzoate ( E216 ) ||| 0-0 0-1 1-2 2-3 3-4
Propyl-4-hydroxybenzoat ( E216 ||| Propyl parahydroxybenzoate ( E216 ||| 0-0 0-1 1-2 2-3
Propyl-4-hydroxybenzoat ( E216 ||| propyl parahydroxybenzoate ( E216 ||| 0-0 0-1 1-2 2-3
Propyl-4-hydroxybenzoat ( ||| Propyl parahydroxybenzoate ( ||| 0-0 0-1 1-2
Propyl-4-hydroxybenzoat ( ||| propyl parahydroxybenzoate ( ||| 0-0 0-1 1-2
Propyl-4-hydroxybenzoat ||| Propyl parahydroxybenzoate ||| 0-0 0-1
Propyl-4-hydroxybenzoat ||| propyl parahydroxybenzoate ||| 0-0 0-1
Propylenglycol Propyl-4-hydroxybenzoat ( ||| Propylene glycol Propyl parahydroxybenzoate ( ||| 0-0 0-1 1-2 1-3 2-4
Propylenglycol Propyl-4-hydroxybenzoat ||| Propylene glycol Propyl parahydroxybenzoate ||| 0-0 0-1 1-2 1-3
Propylenglycol ||| Propylene glycol ||| 0-0 0-1
Propylenglycol ||| glycol ||| 0-0
Prostata- Karzinom eingeführt ||| ago ||| 0-0 1-0 2-0
Prostata-Karzinom ( ||| androgen- independent prostate cancer ( ||| 0-0 0-1 0-2 0-3 1-4
Prostata-Karzinom ||| androgen independent , ||| 0-0 0-1
Prostata-Karzinom ||| androgen independent ||| 0-0 0-1
Prostata-Karzinom ||| androgen- independent prostate cancer ||| 0-0 0-1 0-2 0-3
Prostata-Karzinom ||| prostate cancer which ||| 0-0 0-1
Prostata-Karzinom ||| prostate cancer ||| 0-0 0-1
Prostatakarzinome ||| prostate ||| 0-0
Protaminsulfat Wasser für Injektionszwecke ||| Protamine sulphate Water for injections ||| 0-0 0-1 0-2 1-2 2-3 3-4
Protaminsulfat Wasser für ||| Protamine sulphate Water for ||| 0-0 0-1 0-2 1-2 2-3
Protaminsulfat Wasser ||| Protamine sulphate Water ||| 0-0 0-1 0-2 1-2
Proteinanteil des Moleküls ||| protein fraction of the molecule ||| 0-0 0-1 1-1 1-2 1-3 2-4
Proteinanteil des ||| protein fraction of the ||| 0-0 0-1 1-1 1-2 1-3
Proteinaufnahme führen . ||| protein intake . ||| 0-0 0-1 1-1 2-2
Proteinaufnahme führen ||| protein intake ||| 0-0 0-1 1-1
Proteinbindung ||| protein binding ||| 0-0 0-1
Prozentualer Anteil der Hunde ( ||| Percentages of dogs ||| 0-0 1-0 2-1 3-2
Prozentualer Anteil der Hunde ||| Percentages of dogs ||| 0-0 1-0 2-1 3-2
Prozentualer Anteil der ||| Percentages of ||| 0-0 1-0 2-1
Prozentualer Anteil ||| Percentages ||| 0-0 1-0
Pruritus ||| pruritus ||| 0-0
Prägung von ||| marked ||| 0-0
Prägung ||| marked ||| 0-0
Prävention des Wiederauftretens manischer Episoden ||| Recurrence prevention of manic episodes ||| 0-0 0-1 1-1 2-1 2-2 3-3 4-4
Prävention des Wiederauftretens manischer ||| Recurrence prevention of manic ||| 0-0 0-1 1-1 2-1 2-2 3-3
Prävention des Wiederauftretens manischer ||| preventing recurrence of manic ||| 0-0 1-0 2-1 2-2 3-3
Prävention des Wiederauftretens ||| Recurrence prevention of ||| 0-0 0-1 1-1 2-1 2-2
Prävention des Wiederauftretens ||| preventing recurrence of ||| 0-0 1-0 2-1 2-2
Prävention des ||| preventing ||| 0-0 1-0
Prävention einer neuen manischen ||| prevention of a new manic ||| 0-0 2-0 1-2 2-3 3-4
Prävention einer neuen ||| prevention of a new ||| 0-0 2-0 1-2 2-3
Prävention eines ||| preventing recurrence ||| 0-0 0-1 1-1
Prüfarztes ||| investigator ||| 0-0
Psychiatrische ||| Psychiatric ||| 0-0
Psychosen einschließlich Halluzinationen , Wahn ||| including hallucinations , delusion ||| 1-0 0-1 2-1 3-2 4-3
Psychosen einschließlich Halluzinationen , ||| including hallucinations , ||| 1-0 0-1 2-1 3-2
Psychosen einschließlich Halluzinationen ||| including hallucinations ||| 1-0 0-1 2-1
Pubertät oder wegen ||| puberty or due to ||| 0-0 2-0 1-1 2-2 2-3
Puh/Tel : + 358 ||| Puh/ Tel : + 358 ||| 0-0 0-1 1-2 2-3 3-4
Puh/Tel : + ||| Puh/ Tel : + ||| 0-0 0-1 1-2 2-3
Puh/Tel : +358 9 ||| Puh/ Tel : +358 9 ||| 0-0 0-1 1-2 2-3 3-4
Puh/Tel : +358 ||| Puh/ Tel : +358 ||| 0-0 0-1 1-2 2-3
Puh/Tel : ||| Puh/ Tel : ||| 0-0 0-1 1-2
Puh/Tel ||| Puh/ Tel ||| 0-0 0-1
Puls , Atemfrequenz und ||| pulse , respiratory rate and ||| 0-0 1-1 2-2 0-3 3-4
Puls , Atemfrequenz ||| pulse , respiratory rate ||| 0-0 1-1 2-2 0-3
Puls oder Blutdruck , ||| pulse or blood pressure , ||| 0-0 1-1 2-2 2-3 3-4
Puls oder Blutdruck ||| pulse or blood pressure ||| 0-0 1-1 2-2 2-3
Puls oder ||| pulse or ||| 0-0 1-1
Puls ||| pulse ||| 0-0
Pulver zur Herstellung einer Infusionssuspension ||| powder for suspension for infusion ||| 0-0 2-0 1-1 2-1 4-2 2-3 3-3 4-4
Pulver ||| powder ||| 0-0
Pulvers erfolgt ist ||| powder ||| 0-0
Pulvers erfolgt ||| powder ||| 0-0
Pulvers ||| powder ||| 0-0
Pyrexie ( Fieber ) . ||| pyrexia ( fever ) . ||| 0-0 1-1 2-2 3-3 4-4
Pyrexie ( Fieber ) ||| pyrexia ( fever ) ||| 0-0 1-1 2-2 3-3
Pyrexie ( Fieber ||| pyrexia ( fever ||| 0-0 1-1 2-2
Pyrexie ( ||| pyrexia ( ||| 0-0 1-1
Pyrexie ) , Brustschmerzen ||| pyrexia ) , chest pain ||| 0-0 1-1 2-2 3-3 3-4
Pyrexie ) , ||| pyrexia ) , ||| 0-0 1-1 2-2
Pyrexie ) ||| pyrexia ) ||| 0-0 1-1
Pyrexie ||| pyrexia ||| 0-0
QT-Verlängerung , ventrikuläre Arrhythmien ||| QT prolongation , ventricular arrhythmias ||| 0-0 0-1 1-2 2-3 3-4
QT-Verlängerung , ventrikuläre ||| QT prolongation , ventricular ||| 0-0 0-1 1-2 2-3
QT-Verlängerung , ||| QT prolongation , ||| 0-0 0-1 1-2
QT-Verlängerung ||| QT prolongation ||| 0-0 0-1
Quadratmeter Körperfläche ||| square metre ||| 0-0 1-1
Quadratmeter ||| square ||| 0-0
Quincke-Ödem ||| lips ||| 0-0
R & D Centre ( ||| R & D Centre ( ||| 0-0 1-1 2-2 3-3 4-4
R & D Centre Limited ||| R & D Centre Limited ||| 0-0 1-1 2-2 3-3 4-4
R & D Centre ||| R & D Centre ||| 0-0 1-1 2-2 3-3
R & D ||| R & D ||| 0-0 1-1 2-2
R & ||| R & ||| 0-0 1-1
R ||| R ||| 0-0
RFT ) Die Häufigkeit von ||| RFT ) The incidence of ||| 0-0 1-1 2-2 3-3 4-4
RFT ) Die Häufigkeit ||| RFT ) The incidence ||| 0-0 1-1 2-2 3-3
RFT ) Die ||| RFT ) The ||| 0-0 1-1 2-2
RFT ) ||| RFT ) ||| 0-0 1-1
RFT ] ) ||| RFT ] ) ||| 0-0 1-1 2-2
RFT ] ||| RFT ] ||| 0-0 1-1
RFT ||| RFT ||| 0-0
RG40 2AQ Vereinigtes Königreich ||| RG40 2AQ United Kingdom ||| 0-0 1-1 2-2 3-3
RG40 2AQ Vereinigtes ||| RG40 2AQ United ||| 0-0 1-1 2-2
RG40 2AQ ||| RG40 2AQ ||| 0-0 1-1
RG40 ||| RG40 ||| 0-0
RH12 5AB Vereinigtes Königreich ||| RH12 5AB United Kingdom ||| 0-0 1-1 2-2 3-3
RH12 5AB Vereinigtes ||| RH12 5AB United ||| 0-0 1-1 2-2
RH12 5AB ||| RH12 5AB ||| 0-0 1-1
RH12 ||| RH12 ||| 0-0
RMP sollte ||| RMP should ||| 0-0 1-1
RMP ||| RMP ||| 0-0
Rahmen einer 3-monatigen ||| during a 3 ||| 0-0 1-1 2-1 2-2
Rahmen einer ||| In ||| 1-0
Rahmen ||| during ||| 0-0
Raloxifen , Tamoxifen , ||| raloxifene , tamoxifen , hormone ||| 0-0 1-1 2-2 1-3 3-3 3-4
Raloxifen ||| raloxifene ||| 0-0
Rapid-Cycling Verlauf . ||| a rapid-cycling course . ||| 0-0 0-1 1-1 0-2 2-3
Rapid-Cycling Verlauf ||| a rapid-cycling course ||| 0-0 0-1 1-1 0-2
Rasse oder Körpergewicht . ||| race or body weight . ||| 0-0 1-1 2-2 2-3 3-4
Rasse oder Körpergewicht ||| race or body weight ||| 0-0 1-1 2-2 2-3
Rasse oder ||| race or ||| 0-0 1-1
Rasse ||| race ||| 0-0
Ratte in Dosierungen von ||| rat at doses ||| 0-0 1-1 2-1 2-2 3-2
Ratte ||| rat ||| 0-0
Ratten , nicht jedoch bei ||| rats , but not in ||| 0-0 1-1 3-2 2-3 4-4
Ratten , nicht jedoch ||| rats , but not ||| 0-0 1-1 3-2 2-3
Ratten , polyzythämische Mäuse ) ||| rats , polycythaemic mice ) ||| 0-0 1-1 2-2 3-2 3-3 4-4
Ratten , polyzythämische Mäuse ||| rats , polycythaemic mice ||| 0-0 1-1 2-2 3-2 3-3
Ratten , ||| rats , ||| 0-0 1-1
Ratten nach ||| rats after ||| 0-0 1-1
Ratten ||| rats or ||| 0-0
Ratten ||| rats ||| 0-0
Ratten. ich ||| du ||| 0-0 1-0
Raucher : ||| Smoking status : ||| 0-0 0-1 1-2
Raucher ||| Smoking status ||| 0-0 0-1
Raumtemperatur ( unter 25°C ||| room temperature ( below 25°C ||| 0-0 0-1 1-2 2-3 3-4
Raumtemperatur ( unter 25°C ||| room temperature ( below 25ºC ||| 0-0 0-1 1-2 2-3 3-4
Raumtemperatur ( unter ||| room temperature ( below ||| 0-0 0-1 1-2 2-3
Raumtemperatur ( ||| room temperature ( ||| 0-0 0-1 1-2
Raumtemperatur erreicht haben . ||| room temperature before administration . ||| 0-0 0-1 0-2 1-3 2-3 3-4
Raumtemperatur erreicht haben ||| room temperature before administration ||| 0-0 0-1 0-2 1-3 2-3
Raumtemperatur ||| room temperature before ||| 0-0 0-1 0-2
Raumtemperatur ||| room temperature ||| 0-0 0-1
Reaktion ( z.B . ||| reaction ( e. g. ||| 0-0 1-1 2-2 3-2 2-3
Reaktion ( ||| reaction ( ||| 0-0 1-1
Reaktion , ||| reaction , ||| 0-0 1-1
Reaktion ||| reaction ||| 0-0
Reaktionen an der Injektionsstelle ||| injection site reactions ||| 3-0 1-1 2-1 3-1 0-2
Reaktionen kamen auch bei ||| reactions have also occurred in ||| 0-0 1-1 2-2 1-3 3-4
Reaktionen kamen auch ||| reactions have also occurred ||| 0-0 1-1 2-2 1-3
Reaktionen nach ||| reactions after ||| 0-0 1-1
Reaktionen sind gewöhnlich vorübergehend und ||| reactions are transitory and ||| 0-0 1-1 2-2 3-2 4-3
Reaktionen sind gewöhnlich vorübergehend ||| reactions are transitory ||| 0-0 1-1 2-2 3-2
Reaktionen sind ||| reactions are ||| 0-0 1-1
Reaktionen ||| reactions have ||| 0-0 0-1
Reaktionen ||| reactions ||| 0-0
Reaktionen ||| with ||| 0-0
Reaktionsfähigkeit eines ||| be impaired as a ||| 0-0 0-1 1-1 0-2 1-3
Recurrent Fracture Trial [ RFT ||| Recurrent Fracture Trial [ RFT ||| 0-0 1-1 2-1 2-2 3-3 4-4
Recurrent Fracture Trial [ ||| Recurrent Fracture Trial [ ||| 0-0 1-1 2-1 2-2 3-3
Recurrent Fracture Trial ||| Recurrent Fracture Trial ||| 0-0 1-1 2-1 2-2
Recurrent ||| Recurrent ||| 0-0
Reduktion der Knochenumbaumarker ||| reduction of bone turnover markers ||| 0-0 1-1 0-2 2-3 2-4
Reduktion der ||| reduction of bone ||| 0-0 1-1 0-2
Reduktion der ||| reduction ||| 0-0
Reduktion der ||| reduction ||| 0-0 1-0
Reduktion des Transfusionsbedarfs bei ||| reduction of transfusion requirements in ||| 0-0 1-1 1-2 2-2 2-3 3-4
Reduktion des Transfusionsbedarfs ||| reduction of transfusion requirements ||| 0-0 1-1 1-2 2-2 2-3
Reduktion von neuen ||| reduction in new ||| 0-0 2-2
Reduktion von ||| reduction in ||| 0-0
Reduktion von ||| reduction ||| 0-0
Reduktion ||| reduction in ||| 0-0
Reduktion ||| reduction of ||| 0-0
Reduktion ||| reduction ||| 0-0
Reduzierung ||| reduction ||| 0-0
Refraktionsanomalien Refraktionsanomalien können zu ||| Refraction disorders Refraction anomalies may ||| 0-0 0-1 1-2 1-3 2-3 3-3 2-4
Refraktionsanomalien können zu ||| Refraction anomalies may ||| 0-0 0-1 1-1 2-1 1-2
Refraktionsanomalien ||| Refraction disorders ||| 0-0 0-1
Regel leicht bis mäßig ausgeprägt ||| generally mild to moderate ||| 0-0 1-0 1-1 2-1 2-2 3-3 4-3
Regel leicht bis ||| generally mild to ||| 0-0 1-0 1-1 2-1 2-2
Regelung des Blutzuckerspiegels produziert . ||| control the blood sugar . ||| 0-0 1-1 2-2 2-3 3-3 4-4
Regelung des Blutzuckerspiegels produziert ||| control the blood sugar ||| 0-0 1-1 2-2 2-3 3-3
Regelung des ||| control the ||| 0-0 1-1
Regelung ||| control ||| 0-0
Reihe von Insulin-Suspensionen zur ||| range of insulin suspensions for ||| 0-0 1-1 2-2 2-3 3-4
Reihe von Insulin-Suspensionen ||| range of insulin suspensions ||| 0-0 1-1 2-2 2-3
Reihe von Symptomen ||| number of symptoms ||| 0-0 1-1 2-2
Reihe von anderen ||| number of other ||| 0-0 1-1 2-2
Reihe von ||| number of ||| 0-0 1-1
Reihe von ||| range of ||| 0-0 1-1
Reihe ||| number ||| 0-0
Reihe ||| range ||| 0-0
Reinigen Sie Ihre Haut ||| Clean the skin at ||| 0-0 2-0 1-1 3-2 3-3
Reinigen Sie Ihre ||| Clean the ||| 0-0 2-0 1-1
Reizbarkeit , Nervosität , ||| Aggressiveness ||| 0-0 1-0 2-0 3-0
Reizen ) . ||| stimulus ) . ||| 0-0 1-1 2-2
Reizen ) ||| stimulus ) ||| 0-0 1-1
Reizen ||| stimulus ||| 0-0
Rekonstitution ist ||| reconstitution is ||| 0-0 1-1
Rekonstitution sollte die Suspension ||| reconstitution , the suspension should ||| 0-0 2-2 3-3 1-4
Rekonstitution ||| reconstitution , ||| 0-0
Rekonstitution ||| reconstitution ||| 0-0
Relevanz dieser Befunde ist ||| relevance of these findings is ||| 0-0 1-1 1-2 2-3 3-4
Relevanz dieser Befunde ||| relevance of these findings ||| 0-0 1-1 1-2 2-3
Relevanz dieser ||| relevance of these ||| 0-0 1-1 1-2
Relevanz ||| relevance ||| 0-0
Reproduction and/or distribution of this ||| also looked at how ||| 0-1 1-1 2-1 3-1 4-1
Reproduction and/or distribution of this ||| also looked at ||| 0-1 1-1 2-1 3-1 4-1
Reproduction and/or distribution of this ||| also looked ||| 0-1 1-1 2-1 3-1 4-1
Reproduction and/or distribution of this ||| looked at how ||| 0-0 1-0 2-0 3-0 4-0
Reproduction and/or distribution of this ||| looked at ||| 0-0 1-0 2-0 3-0 4-0
Reproduction and/or distribution of this ||| looked ||| 0-0 1-0 2-0 3-0 4-0
Reproduction and/or distribution of this ||| study also looked at how ||| 0-2 1-2 2-2 3-2 4-2
Reproduction and/or distribution of this ||| study also looked at ||| 0-2 1-2 2-2 3-2 4-2
Reproduction and/or distribution of this ||| study also looked ||| 0-2 1-2 2-2 3-2 4-2
Reproduction is authorised provided the ||| Reproduction is authorised provided the ||| 0-0 1-0 2-1 2-2 3-2 4-2 3-3 4-4
Reproduction is ||| Reproduction ||| 0-0 1-0
Reproduktionstoxizität gezeigt ( siehe ||| shown reproduction toxicity ( see ||| 1-0 0-1 1-1 0-2 2-3 3-4
Reproduktionstoxizität gezeigt ( siehe ||| shown reproductive toxicity ( see ||| 1-0 0-1 0-2 2-3 3-4
Reproduktionstoxizität gezeigt ( ||| shown reproduction toxicity ( ||| 1-0 0-1 1-1 0-2 2-3
Reproduktionstoxizität gezeigt ( ||| shown reproductive toxicity ( ||| 1-0 0-1 0-2 2-3
Reproduktionstoxizität gezeigt ||| shown reproduction toxicity ||| 1-0 0-1 1-1 0-2
Reproduktionstoxizität gezeigt ||| shown reproductive toxicity ||| 1-0 0-1 0-2
Reproduktionstoxizität ||| reproductive toxicity ||| 0-0 0-1
Reproduktionstoxizität ||| toxicity ||| 0-0
Research and Development Centre ( ||| Research and Development Centre ( ||| 0-0 1-0 1-1 2-2 3-3 4-4
Research and Development Centre ||| Research and Development Centre ||| 0-0 1-0 1-1 2-2 3-3
Research and Development ||| Research and Development ||| 0-0 1-0 1-1 2-2
Research and ||| Research and ||| 0-0 1-0 1-1
Resorption Das Resorptionsprofil ||| Absorption The absorption ||| 0-0 1-0 2-0 1-1 0-2
Resorption als ein Maß der ||| absorption rather than of the ||| 0-0 2-1 3-1 1-2 4-3 4-4
Resorption als ein Maß ||| absorption rather than ||| 0-0 2-1 3-1 1-2
Resorption von fettlöslichen Arzneimitteln ||| absorption of lipid soluble drugs ||| 0-0 1-1 2-2 2-3 3-3 2-4
Resorption von ||| absorption of ||| 0-0 1-1
Resorption zu ||| absorption ||| 0-0 1-0
Resorption ||| absorption ||| 0-0
Resorptionsanteil . ||| absorption . ||| 0-0 1-1
Resorptionsanteil ||| absorption ||| 0-0
Resorptionsmarker erreichten ||| nadir for ||| 0-0 1-0
Resorptionsmarker erreichten ||| nadir ||| 0-0 1-0
Resorptionsrate aus dem ||| rate of absorption from the ||| 0-0 1-1 0-2 2-2 1-3 2-4
Resorptionsrate und ||| rate and ||| 0-0 1-1
Resorptionsrate und ähnlichem Resorptionsanteil ||| rate and extent of absorption ||| 0-0 1-1 2-2 2-3 3-4
Resorptionsrate und ähnlichem ||| rate and extent of ||| 0-0 1-1 2-2 2-3
Resorptionsrate ||| rate ||| 0-0
Resuspension des Pulvers erfolgt ist ||| resuspension of any powder ||| 0-0 1-1 1-2 2-3
Resuspension des Pulvers erfolgt ||| resuspension of any powder ||| 0-0 1-1 1-2 2-3
Resuspension des Pulvers ||| resuspension of any powder ||| 0-0 1-1 1-2 2-3
Resuspension des ||| resuspension of any ||| 0-0 1-1 1-2
Resuspension ||| resuspension ||| 0-0
Retikulozytenzahl um 40.000 Zellen/µl ||| reticulocyte count has increased 40,000 ||| 0-0 1-0 2-0 3-1 3-2 3-3 2-4
Retikulozytenzahl ||| well ||| 0-0
Retikulozytenzahl-Anstieg 40.000/µl ||| Reticulocyte count increase 40,000/ µl ||| 0-0 0-1 1-2 1-3 1-4
Retikulozytenzahl-Anstieg ||| Reticulocyte count ||| 0-0 0-1
Retinopathie . ||| retinopathy . ||| 0-0 1-1
Retinopathie Eine langfristige Verbesserung ||| retinopathy Long-term improved glycaemic ||| 0-0 1-1 2-1 2-2 3-2 3-3
Retinopathie Eine langfristige Verbesserung ||| retinopathy Long-term improved glycaemic ||| 0-0 1-1 2-1 2-2 3-3
Retinopathie Eine langfristige ||| retinopathy Long-term improved ||| 0-0 1-1 2-1 2-2
Retinopathie verbunden sein . ||| retinopathy . ||| 0-0 1-0 2-0 3-1
Retinopathie verbunden sein ||| retinopathy ||| 0-0 1-0 2-0
Retinopathie ||| retinopathy ||| 0-0
Rezeptorantagonismus kann Aripiprazol ||| antagonism , aripiprazole has ||| 0-0 1-0 0-1 2-2 0-3
Rezeptoren . ||| receptors . ||| 0-0 1-1
Rezeptoren auf ||| receptors on ||| 0-0 1-1
Rezeptoren ||| receptors ||| 0-0
Rhabdomyolyse ) und ||| rhabdomyolysis ) , and ||| 0-0 1-1 0-2 2-3
Rhabdomyolyse ) ||| rhabdomyolysis ) , ||| 0-0 1-1 0-2
Rhabdomyolyse , ||| rhabdomyolysis , ||| 0-0 1-1
Rhabdomyolyse ||| rhabdomyolysis ||| 0-0
Rhinitis , Heiserkeit , ||| rhinitis , hoarseness , ||| 0-0 1-1 2-2 3-3
Rhinitis , Heiserkeit ||| rhinitis , hoarseness ||| 0-0 1-1 2-2
Rhinitis , ||| rhinitis , ||| 0-0 1-1
Rhinitis ||| rhinitis ||| 0-0
Rifampicin ( einem ||| rifampicin ( an inducer ||| 0-0 1-1 2-2 0-3 2-3
Rifampicin ) sollte Pioglitazon ||| Glycaemic control should ||| 0-0 1-0 3-0 0-1 2-2
Rifampicin ||| rifampicin ||| 0-0
Rimonabant 20 mg ( Ausgangswert ||| rimonabant 20 mg ( baseline ||| 0-0 1-1 2-2 3-3 4-4
Rimonabant 20 mg ( ||| rimonabant 20 mg ( ||| 0-0 1-1 2-2 3-3
Rimonabant 20 mg verringerte ||| Rimonabant 20 mg reduced ||| 0-0 1-1 2-2 3-3
Rimonabant 20 mg ||| Rimonabant 20 mg ||| 0-0 1-1 2-2
Rimonabant 20 mg ||| rimonabant 20 mg ||| 0-0 1-1 2-2
Rimonabant 20 ||| Rimonabant 20 ||| 0-0 1-1
Rimonabant 20 ||| rimonabant 20 ||| 0-0 1-1
Rimonabant : ||| rimonabant : ||| 0-0 1-1
Rimonabant ; daher ||| rimonabant ; therefore , ||| 0-0 1-1 2-2
Rimonabant ; daher ||| rimonabant ; therefore ||| 0-0 1-1 2-2
Rimonabant ; ||| rimonabant ; ||| 0-0 1-1
Rimonabant bei der Behandlung ||| rimonabant treatment in ||| 0-0 3-1 1-2 2-2
Rimonabant bei ||| rimonabant ||| 0-0
Rimonabant ist ein ||| Rimonabant ist ein ||| 0-0 1-1 2-2
Rimonabant ist nicht bestimmt worden ||| rimonabant has not been determined ||| 0-0 0-1 1-1 2-2 4-3 3-4
Rimonabant ist nicht ||| rimonabant has not ||| 0-0 0-1 1-1 2-2
Rimonabant ist ||| Rimonabant ist ||| 0-0 1-1
Rimonabant ist ||| rimonabant has ||| 0-0 0-1 1-1
Rimonabant oder t ||| side ||| 1-0 2-0
Rimonabant weiter ||| rimonabant ||| 0-0
Rimonabant wird hauptsächlich ||| Rimonabant wird hauptsächlich ||| 0-0 1-1 2-2
Rimonabant wird ||| Rimonabant is ||| 0-0 1-1
Rimonabant wird ||| Rimonabant wird ||| 0-0 1-1
Rimonabant wurde in einer ||| rimonabant was found in one ||| 0-0 1-1 2-2 2-3 3-4
Rimonabant wurde in ||| Rimonabant has been detected in ||| 0-0 1-1 1-2 1-3 2-4
Rimonabant wurde in ||| rimonabant was found in ||| 0-0 1-1 2-2 2-3
Rimonabant wurde ||| Rimonabant has been detected ||| 0-0 1-1 1-2 1-3
Rimonabant wurde ||| rimonabant is ||| 0-0 1-0
Rimonabant wurde ||| rimonabant was ||| 0-0 1-1
Rimonabant wurde ||| rimonabant ||| 0-0 1-0
Rimonabant zeigt eine hohe ||| Rimonabant displays high ||| 0-0 1-1 2-2 3-2
Rimonabant zeigt ||| Rimonabant displays ||| 0-0 1-1
Rimonabant ||| ACOMPLIA ||| 0-0
Rimonabant ||| Rimonabant ||| 0-0
Rimonabant ||| Seizures Rimonabant has not ||| 0-0 0-1 0-2 0-3
Rimonabant ||| rimonabant and ||| 0-0
Rimonabant ||| rimonabant ||| 0-0
Rimonabant über einen längeren ||| dosing for a longer ||| 1-1 2-2 3-3
Rimonabant über einen längeren ||| for a longer ||| 1-0 2-1 3-2
Rimonabant über einen ||| dosing for a ||| 1-1 2-2
Rimonabant über einen ||| for a ||| 1-0 2-1
Rimonabant über ||| dosing for ||| 1-1
Rimonabant über ||| for ||| 1-0
Rimonabant-Behandlung abzuschätzen . ||| and suicide . ||| 0-1 1-1 2-2
Rimonabant-Behandlung abzuschätzen . ||| harm and suicide . ||| 0-2 1-2 2-3
Rimonabant-Behandlung abzuschätzen . ||| suicide . ||| 0-0 1-0 2-1
Rimonabant-Behandlung abzuschätzen ||| and suicide ||| 0-1 1-1
Rimonabant-Behandlung abzuschätzen ||| harm and suicide ||| 0-2 1-2
Rimonabant-Behandlung abzuschätzen ||| suicide ||| 0-0 1-0
Rimonabant. n eim Arz ||| of rimonabant . ct ||| 0-1 2-2 1-3 2-3 3-3
Rimonabant. n eim Arz ||| rimonabant . ct ||| 0-0 2-1 1-2 2-2 3-2
Rimonabant. ||| of rimonabant ||| 0-1
Rimonabant. ||| rimonabant ||| 0-0
Risedronat ( ||| risedronate ( ||| 0-0 1-1
Risedronat . ||| risedronate . ||| 0-0 1-1
Risedronat behandelten ||| risedronate-treated ||| 0-0 1-0
Risedronat einmal täglich ||| risedronate once a day ||| 0-0 1-1 1-2 2-3
Risedronat einmal ||| risedronate once a ||| 0-0 1-1 1-2
Risedronat ||| risedronate ||| 0-0
Risiken aufweisen ||| evaluate the potential risks ||| 0-2 0-3
Risiken aufweisen ||| potential risks ||| 0-0 0-1
Risiken aufweisen ||| the potential risks ||| 0-1 0-2
Risiken ||| evaluate the potential risks ||| 0-2 0-3
Risiken ||| potential risks ||| 0-0 0-1
Risiken ||| risks ||| 0-0
Risiken ||| the potential risks ||| 0-1 0-2
Risiken überwiegen ||| its risks ||| 0-1 1-1
Risiken überwiegen ||| risks ||| 0-0 1-0
Risiko für Aspirationspneumonie angewendet werden ||| at risk for aspiration pneumonia ||| 2-0 0-1 1-2 2-3 3-3 2-4 4-4
Risiko für das Kind dar ||| risk to the baby ||| 0-0 1-0 2-0 3-1 3-2 3-3 4-3
Risiko für das ||| risk ||| 0-0 1-0 2-0
Risiko für den Menschen ist ||| risk for humans is ||| 0-0 1-1 2-2 3-2 4-3
Risiko für den Menschen ||| risk for humans ||| 0-0 1-1 2-2 3-2
Risiko für thromboembolische Ereignisse bei ||| risk for thromboembolic events in ||| 0-0 1-1 2-2 3-3 4-4
Risiko für thromboembolische Ereignisse ||| risk for thromboembolic events ||| 0-0 1-1 2-2 3-3
Risiko für thromboembolische ||| risk for thromboembolic ||| 0-0 1-1 2-2
Risiko für thrombotische vaskuläre Ereignisse ||| risk of thrombotic vascular events ||| 0-0 1-0 2-2 3-3 4-4
Risiko für thrombotische vaskuläre ||| risk of thrombotic vascular ||| 0-0 1-0 2-2 3-3
Risiko für thrombotische ||| risk of thrombotic ||| 0-0 1-0 2-2
Risiko für ||| risk for ||| 0-0 1-1
Risiko für ||| risk of ||| 0-0 1-0
Risiko für ||| risk of ||| 0-0 1-0 0-1
Risiko für ||| risk ||| 0-0 1-0
Risiko ist mit ||| Risiko ist mit ||| 0-0 1-1 2-2
Risiko ist ||| Risiko ist ||| 0-0 1-1
Risiko ist ||| is the risk ||| 1-0 1-1 0-2
Risiko sollte ||| risk should be ||| 0-0 1-1 1-2
Risiko thromboembolischer Ereignisse abgewogen werden ||| reported risk of thromboembolic events ||| 1-0 0-1 2-2 1-3 3-3 4-3 2-4
Risiko von Blutpfropfbildung/Blutgerinnungsstörungen ||| risk of blood clots/ blood ||| 0-0 1-1 2-2 2-3 2-4
Risiko von ||| risk of ||| 0-0 1-1
Risiko von ||| risk ||| 0-0
Risiko ||| Risiko ||| 0-0
Risiko ||| risk of ||| 0-0
Risiko ||| risk ||| 0-0
Risikofaktoren ( z. B. ||| risk factors ( e. ||| 0-0 0-1 1-2 2-3 3-3
Risikofaktoren ( ||| risk factors ( ||| 0-0 0-1 1-2
Risikofaktoren , wie Typ-2-Diabetes ||| such as type 2 diabetes ||| 0-0 2-0 1-1 2-1 3-2 3-3 3-4
Risikofaktoren , wie ||| such as ||| 0-0 2-0 1-1 2-1
Risikofaktoren für Diabetes ||| risk factors for diabetes ||| 0-0 0-1 1-2 2-3
Risikofaktoren für ||| risk factors for ||| 0-0 0-1 1-2
Risikofaktoren wie ||| risk factors such as ||| 0-0 0-1 1-2 1-3
Risikofaktoren ||| Risk factors ||| 0-0 0-1
Risikofaktoren ||| risk factors ||| 0-0 0-1
Risikofaktoren ||| risk ||| 0-0
Risikofaktoren ||| with ||| 0-0
Risikomanagement-Plan ||| Risk Management ||| 0-0 0-1
Risikomanagement-Plans , ||| agreed ||| 0-0
Risikomanagement-Plans ||| agreed ||| 0-0
Risikoreduktion betrug 51 % ||| risk reduction was 51 % ||| 0-0 2-1 1-2 2-3 3-4
Risikoreduktion betrug 51 ||| risk reduction was 51 ||| 0-0 2-1 1-2 2-3
Risikoreduktion ||| risk ||| 0-0
Risikozeitspanne ||| adequate clinical monitoring ||| 0-0 0-1 0-2
Ritonavir ( ein Mittel ||| ritonavir ( ||| 0-0 1-1 3-1
Ritonavir ||| ritonavir ||| 0-0
Road Horsham West Sussex , ||| Road Horsham West Sussex , ||| 0-0 1-1 2-2 3-3 4-4
Road Horsham West Sussex ||| Road Horsham West Sussex ||| 0-0 1-1 2-2 3-3
Road Horsham West ||| Road Horsham West ||| 0-0 1-1 2-2
Road Horsham ||| Road Horsham ||| 0-0 1-1
Road Uxbridge - Middlesex UB8 ||| Road Uxbridge - Middlesex UB8 ||| 0-0 1-1 2-2 3-3 4-4
Road Uxbridge - Middlesex ||| Road Uxbridge - Middlesex ||| 0-0 1-1 2-2 3-3
Road Uxbridge - ||| Road Uxbridge - ||| 0-0 1-1 2-2
Road Uxbridge ||| Road Uxbridge ||| 0-0 1-1
Road Wokingham Berkshire RG40 2AQ ||| Road Wokingham Berkshire RG40 2AQ ||| 0-0 1-1 2-2 3-3 4-4
Road Wokingham Berkshire RG40 ||| Road Wokingham Berkshire RG40 ||| 0-0 1-1 2-2 3-3
Road Wokingham Berkshire ||| Road Wokingham Berkshire ||| 0-0 1-1 2-2
Road Wokingham ||| Road Wokingham ||| 0-0 1-1
Road ||| Road ||| 0-0
Rolle ||| play ||| 0-0
Roonstraße 25 D-90429 Nürnberg Deutschland ||| Roonstraße 25 D-90429 Nuremberg Germany ||| 0-0 1-1 2-2 3-3 4-4
Roonstraße 25 D-90429 Nürnberg ||| Roonstraße 25 D-90429 Nuremberg ||| 0-0 1-1 2-2 3-3
Roonstraße 25 D-90429 ||| Roonstraße 25 D-90429 ||| 0-0 1-1 2-2
Roonstraße 25 ||| Roonstraße 25 ||| 0-0 1-1
Roonstraße ||| Roonstraße ||| 0-0
Royaume-Uni Tél/Tel : + ||| Royaume-Uni Tél/ Tel : + ||| 0-0 1-1 1-2 2-3 3-4
Royaume-Uni Tél/Tel : ||| Royaume-Uni Tél/ Tel : ||| 0-0 1-1 1-2 2-3
Royaume-Uni Tél/Tel ||| Royaume-Uni Tél/ Tel ||| 0-0 1-1 1-2
Royaume-Uni ||| Royaume-Uni ||| 0-0
Ruhelosigkeit , Angstgefühl , ||| restlessness , feeling anxious , ||| 0-0 1-1 2-2 2-3 3-4
Ruhelosigkeit , Angstgefühl ||| restlessness , feeling anxious ||| 0-0 1-1 2-2 2-3
Ruhelosigkeit , Schlaflosigkeit , Angstgefühl ||| restlessness , insomnia , ||| 0-0 4-0 1-1 2-2 3-3
Ruhelosigkeit , ||| restlessness , ||| 0-0 1-1
Ruhelosigkeit 1 Die ||| Restlessness 1 The ||| 0-0 1-1 2-2
Ruhelosigkeit 1 ||| Restlessness 1 ||| 0-0 1-1
Ruhelosigkeit ||| Restlessness ||| 0-0
Ruhelosigkeit ||| restlessness ||| 0-0
Rötungen , Schwellungen und/oder ||| redness , swelling and/ or ||| 0-0 1-1 2-2 3-3 3-4
Rötungen , Schwellungen ||| redness , swelling ||| 0-0 1-1 2-2
Rötungen , ||| redness , ||| 0-0 1-1
Rötungen ||| redness ||| 0-0
Rückfall ||| of relapse ||| 0-1
Rückfall ||| relapse ||| 0-0
Rückschlüsse auf die Pharmakokinetik bei ||| regarding pharmacokinetics in ||| 0-0 1-1 3-1 2-2 4-2
Rückschlüsse ||| regarding ||| 0-0
Rückstände aus der ||| residues of the cell line ||| 0-0 1-0 1-1 2-2 0-3 0-4
S.A. ||| S. A. ||| 0-0 0-1
S.A./N.V . ||| / N. V. ||| 0-0 0-1 0-2 1-2
S.p.A. , Strada ||| S. p. A. , ||| 0-0 0-1 2-1 2-2 1-3
SARL Tél : + 33 ||| SARL Tél : + 33 ||| 0-0 1-1 2-2 3-3 4-4
SARL Tél : + ||| SARL Tél : + ||| 0-0 1-1 2-2 3-3
SARL Tél : ||| SARL Tél : ||| 0-0 1-1 2-2
SARL Tél ||| SARL Tél ||| 0-0 1-1
SARL ||| SARL ||| 0-0
SBECD ) Weinsäure ( ||| SBECD ) Tartaric acid ||| 0-0 1-1 2-2 2-3 3-3
SBECD ) ||| SBECD ) ||| 0-0 1-1
SBECD ||| SBECD ||| 0-0
SERENADE ) , ||| Serenade ) , ||| 0-0 1-1 2-2
SERENADE ) ||| Serenade ) ||| 0-0 1-1
SERENADE ||| Serenade ||| 0-0
SICHERE UND WIRKSAME ||| REGARDING SUPPLY AND ||| 0-0 2-1 1-2
SICHERE UND WIRKSAME ||| TO SAFE AND ||| 1-0 0-1 1-2 2-2
SICHERE ||| REGARDING ||| 0-0
SICHERE ||| SAFE ||| 0-0
SICHEREN UND WIRKSAMEN ANWENDUNG ||| SAFE AND EFFECTIVE USE OF ||| 0-0 1-1 2-2 2-3 3-3 3-4
SICHEREN UND WIRKSAMEN ANWENDUNG ||| THE SAFE AND EFFECTIVE USE ||| 1-0 0-1 1-2 2-3 2-4 3-4
SICHEREN UND ||| SAFE AND ||| 0-0 1-1
SICHEREN UND ||| THE SAFE AND ||| 1-0 0-1 1-2
SICHEREN ||| SAFE ||| 0-0
SICHTBAR AUFZUBEWAHREN IST ||| AND SIGHT OF CHILDREN ||| 0-0 0-1 1-1 1-2 2-3
SICHTBAR AUFZUBEWAHREN ||| AND SIGHT OF ||| 0-0 0-1 1-1 1-2
SICHTWEITE VON KINDERN AUFBEWAHREN " ||| REACH AND SIGHT OF CHILDREN ||| 0-0 2-1 2-2 1-3 3-3 3-4 4-4
SICHTWEITE ||| REACH ||| 0-0
SIND ||| RELEASE ||| 0-0
SONSTIGE BESTANDTEILE ||| OTHER INGREDIENT(S ) ||| 0-0 0-1 1-1 1-2
SONSTIGE BESTANDTEILE ||| SONSTIGE BESTANDTEILE Enthält Lactosemonohydrat ||| 0-0 0-1 1-2 1-3
SONSTIGE ||| SONSTIGE BESTANDTEILE ||| 0-0 0-1
SOWIE ART DER ||| PRODUCT AND ROUTE(S ) OF ||| 0-0 0-1 1-2 1-3 2-4
SOWIE ART ||| PRODUCT AND ROUTE(S ) ||| 0-0 0-1 1-2 1-3
SOWIE ART(EN ) DER ||| PRODUCT AND ROUTE(S ) OF ||| 0-0 1-1 1-2 2-3 3-4
SOWIE ART(EN ) ||| PRODUCT AND ROUTE(S ) ||| 0-0 1-1 1-2 2-3
SOWIE ART(EN ||| PRODUCT AND ROUTE(S ||| 0-0 1-1 1-2
SOWIE ||| PRODUCT AND ||| 0-0 0-1
SOWIE ||| PRODUCT ||| 0-0
SQUIBB ( FINLAND ) AB ||| SQUIBB ( FINLAND ) AB ||| 0-0 1-1 2-2 3-3 4-4
SQUIBB ( FINLAND ) ||| SQUIBB ( FINLAND ) ||| 0-0 1-1 2-2 3-3
SQUIBB ( FINLAND ||| SQUIBB ( FINLAND ||| 0-0 1-1 2-2
SQUIBB ( ||| SQUIBB ( ||| 0-0 1-1
SQUIBB AB Tel : + ||| SQUIBB AB Tel : + ||| 0-0 1-1 2-2 3-3 4-4
SQUIBB AB Tel : ||| SQUIBB AB Tel : ||| 0-0 1-1 2-2 3-3
SQUIBB AB Tel ||| SQUIBB AB Tel ||| 0-0 1-1 2-2
SQUIBB AB ||| SQUIBB AB ||| 0-0 1-1
SQUIBB BELGIUM ||| SQUIBB BELGIUM S. A. ||| 0-0 0-1 1-1 1-2 1-3
SQUIBB BELGIUM ||| SQUIBB BELGIUM S. A. ||| 0-0 0-1 1-2 1-3
SQUIBB BV Tel : + ||| SQUIBB BV Tel : + ||| 0-0 1-1 2-2 3-3 4-4
SQUIBB BV Tel : ||| SQUIBB BV Tel : ||| 0-0 1-1 2-2 3-3
SQUIBB BV Tel ||| SQUIBB BV Tel ||| 0-0 1-1 2-2
SQUIBB BV ||| SQUIBB BV ||| 0-0 1-1
SQUIBB GESMBH Tel : + ||| SQUIBB GESMBH Tel : + ||| 0-0 1-1 2-2 3-3 4-4
SQUIBB GESMBH Tel : ||| SQUIBB GESMBH Tel : ||| 0-0 1-1 2-2 3-3
SQUIBB GESMBH Tel ||| SQUIBB GESMBH Tel ||| 0-0 1-1 2-2
SQUIBB GESMBH ||| SQUIBB GESMBH ||| 0-0 1-1
SQUIBB NORWAY LTD Tlf : ||| SQUIBB NORWAY LTD Tlf : ||| 0-0 1-1 2-2 3-3 4-4
SQUIBB NORWAY LTD Tlf ||| SQUIBB NORWAY LTD Tlf ||| 0-0 1-1 2-2 3-3
SQUIBB NORWAY LTD ||| SQUIBB NORWAY LTD ||| 0-0 1-1 2-2
SQUIBB NORWAY ||| SQUIBB NORWAY ||| 0-0 1-1
SQUIBB PHARMACEUTICALS LTD Tel : ||| SQUIBB PHARMACEUTICALS LTD Tel : ||| 0-0 1-1 2-2 3-3 4-4
SQUIBB PHARMACEUTICALS LTD Tel ||| SQUIBB PHARMACEUTICALS LTD Tel ||| 0-0 1-1 2-2 3-3
SQUIBB PHARMACEUTICALS LTD ||| SQUIBB PHARMACEUTICALS LTD ||| 0-0 1-1 2-2
SQUIBB PHARMACEUTICALS ||| SQUIBB PHARMACEUTICALS ||| 0-0 1-1
SQUIBB SARL Tél : + ||| SQUIBB SARL Tél : + ||| 0-0 1-1 2-2 3-3 4-4
SQUIBB SARL Tél : ||| SQUIBB SARL Tél : ||| 0-0 1-1 2-2 3-3
SQUIBB SARL Tél ||| SQUIBB SARL Tél ||| 0-0 1-1 2-2
SQUIBB SARL ||| SQUIBB SARL ||| 0-0 1-1
SQUIBB Tlf : + 45 ||| SQUIBB Tlf : + 45 ||| 0-0 1-1 2-2 3-3 4-4
SQUIBB Tlf : + ||| SQUIBB Tlf : + ||| 0-0 1-1 2-2 3-3
SQUIBB Tlf : ||| SQUIBB Tlf : ||| 0-0 1-1 2-2
SQUIBB Tlf ||| SQUIBB Tlf ||| 0-0 1-1
SQUIBB ||| SQUIBB BELGIUM ||| 0-0 0-1
SQUIBB ||| SQUIBB ||| 0-0
STAMMENDEN ABFALLMATERIALIEN ||| , IF APPROPRIATE ||| 0-0 0-1 1-2
STAMMENDEN ||| , IF ||| 0-0 0-1
STAND DER INFORMATION 14 ||| OF THE ||| 0-0 1-0 1-1 2-1 3-1
STÄRKE , ||| PHARMACEUTICAL FORM , ||| 0-0 0-1 1-2
STÄRKE ||| PHARMACEUTICAL FORM ||| 0-0 0-1
STÜCKZAHL ||| NUMBER OF DOSES ||| 0-0 0-1 0-2
SULFONYLHARNSTOFF ||| SULPHONYLUREA ||| 0-0
Saccharomyces cerevisiae ) . ||| Saccharomyces cerevisiae ) . ||| 0-0 1-1 2-2 3-3
Saccharomyces cerevisiae ) ||| Saccharomyces cerevisiae ) ||| 0-0 1-1 2-2
Saccharomyces cerevisiae ||| Saccharomyces cerevisiae ||| 0-0 1-1
Saccharomyces ||| Saccharomyces ||| 0-0
Safety Specification ) ||| Safety ||| 0-0 1-0
Safety Specification ||| Safety ||| 0-0 1-0
Safety ||| Safety ||| 0-0
Sagen Sie Ihrem Arzt vor ||| Tell your doctor before you ||| 0-0 1-0 1-1 2-1 2-2 3-2 4-3 1-4
Salzsäure ( zur pH-Einstellung ||| Hydrochloric acid ( for pH-adjustment ||| 0-0 0-1 1-2 2-3 2-4 3-4
Salzsäure ( zur ||| Hydrochloric acid ( for ||| 0-0 0-1 2-1 1-2 2-3
Salzsäure ( ||| Hydrochloric acid ( ||| 0-0 0-1 1-2
Salzsäure ||| Hydrochloric acid ||| 0-0 0-1
Sanofi Winthrop Industrie , 30-36 ||| Sanofi Winthrop Industrie , 30-36 ||| 0-0 1-1 2-2 3-3 4-4
Sanofi Winthrop Industrie , ||| Sanofi Winthrop Industrie , ||| 0-0 1-1 2-2 3-3
Sanofi Winthrop Industrie ||| Sanofi Winthrop Industrie ||| 0-0 1-1 2-2
Sanofi Winthrop ||| Sanofi Winthrop ||| 0-0 1-1
Sanofi ||| Sanofi ||| 0-0
Saugreflex unterdrücken ||| is excreted in human milk ||| 0-0 0-1 1-3 1-4
Saugreflex ||| is excreted in ||| 0-0 0-1
Saugreflex ||| is excreted ||| 0-0 0-1
Scale oder ||| scale or ||| 0-0 1-1
Scale ||| scale ||| 0-0
Schaum gesetzt hat . ||| foam subsides . ||| 0-0 1-0 1-1 2-1 3-2
Schaum gesetzt hat ||| foam subsides ||| 0-0 1-0 1-1 2-1
Schaumbildung führt . ||| result in foaming . ||| 1-0 1-1 0-2 1-2 2-3
Schaumbildung führt ||| result in foaming ||| 1-0 1-1 0-2 1-2
Schenkelhals -1,5 ||| femoral neck bone ||| 0-0 0-1
Schenkelhals -1,5 ||| femoral neck ||| 0-0 0-1
Schenkelhals ||| femoral neck bone ||| 0-0 0-1
Schenkelhals ||| femoral neck ||| 0-0 0-1
Schilddrüsenhormone und Betasympathomimetika , ||| thyroid hormones and beta-sympathomimetics , ||| 0-0 0-1 1-2 2-3 3-4
Schilddrüsenhormone und Betasympathomimetika ||| thyroid hormones and beta-sympathomimetics ||| 0-0 0-1 1-2 2-3
Schilddrüsenhormone und ||| thyroid hormones and ||| 0-0 0-1 1-2
Schilddrüsenhormone ||| thyroid hormones ||| 0-0 0-1
Schizophrenie - In ||| Schizophrenia - ||| 0-0 2-0 1-1
Schizophrenie . ||| schizophrenia . ||| 0-0 1-1
Schizophrenie angezeigt . ||| schizophrenia . ||| 0-0 1-0 2-1
Schizophrenie angezeigt ||| schizophrenia ||| 0-0 1-0
Schizophrenie oder ||| schizophrenia or ||| 0-0 1-1
Schizophrenie und Bipolar-I-Störung ||| schizophrenia and Bipolar I Disorder ||| 0-0 1-1 2-2 2-3 2-4
Schizophrenie und manische ||| schizophrenia and manic ||| 0-0 1-1 2-2
Schizophrenie und ||| schizophrenia and ||| 0-0 1-1
Schizophrenie war Abilify ||| schizophrenia , Abilify was ||| 0-0 2-2 1-3
Schizophrenie ||| of schizophrenia ||| 0-1
Schizophrenie ||| schizophrenia , ||| 0-0
Schizophrenie ||| schizophrenia ||| 0-0
Schizophrenie-Patienten ||| 554 ||| 0-0
Schlaflosigkeit , ||| , ||| 0-0 1-0
Schlaflosigkeit , ||| Adverse reactions reported with ||| 0-0 0-1 0-2 1-3
Schlaflosigkeit , ||| insomnia , ||| 0-0 1-1
Schlaflosigkeit ||| Adverse reactions reported ||| 0-0 0-1 0-2
Schlaflosigkeit ||| insomnia ||| 0-0
Schlafstörungen ) ||| ) ||| 0-0 1-0
Schlafstörungen , Schlaflosigkeit , Parasomnien ||| Aggressive behaviour ||| 0-0 1-0 2-0 3-0 4-1
Schlafstörungen , Schlaflosigkeit , ||| Aggressive ||| 0-0 1-0 2-0 3-0
Schlaganfall , die ||| stroke who ||| 0-0 1-1 2-1
Schlaganfall oder eine ||| a stroke or ||| 2-0 0-1 1-2
Schlaganfall oder ||| stroke or ||| 0-0 1-1
Schlaganfall ||| stroke in ||| 0-0
Schlaganfall ||| stroke ||| 0-0
Schlaganfällen oder ||| stroke or ||| 0-0 1-1
Schlaganfällen ||| stroke ||| 0-0
Schleimhautentzündung , Schmerzen ||| mucosal inflammation , pain ||| 0-0 2-1 1-2 2-3
Schleimhautentzündung ||| mucosal ||| 0-0
Schleimhäute . ||| mucosae . ||| 0-0 1-1
Schleimhäute ||| mucosae ||| 0-0
Schluss ||| concluded ||| 0-0
Schläfrigkeit , Schwindel , Kopfschmerzen ||| somnolence , dizziness , headache ||| 0-0 1-1 2-2 3-3 4-4
Schläfrigkeit , Schwindel , ||| somnolence , dizziness , ||| 0-0 1-1 2-2 3-3
Schläfrigkeit , Schwindel ||| somnolence , dizziness ||| 0-0 1-1 2-2
Schläfrigkeit , Sedierung , Kopfschmerzen ||| somnolence , sedation , headache ||| 0-0 1-1 2-2 3-3 4-4
Schläfrigkeit , Sedierung , ||| , somnolence , sedation , ||| 1-0 0-1 3-2 2-3 3-4
Schläfrigkeit , Sedierung , ||| somnolence , sedation , ||| 0-0 1-1 2-2 3-3
Schläfrigkeit , Sedierung ||| somnolence , sedation ||| 0-0 1-1 2-2
Schläfrigkeit , Tremor , Synkope ||| somnolence , tremor , syncope ||| 0-0 1-1 2-2 3-3 4-4
Schläfrigkeit , Tremor , ||| somnolence , tremor , ||| 0-0 1-1 2-2 3-3
Schläfrigkeit , Tremor ||| somnolence , tremor ||| 0-0 1-1 2-2
Schläfrigkeit , Zittern und verschwommenes ||| sleepiness , shaking and blurred ||| 0-0 2-0 1-1 2-2 3-3 4-4
Schläfrigkeit , Zittern und ||| sleepiness , shaking and ||| 0-0 2-0 1-1 2-2 3-3
Schläfrigkeit , Zittern ||| sleepiness , shaking ||| 0-0 2-0 1-1 2-2
Schläfrigkeit , ||| , somnolence ||| 1-0 0-1
Schläfrigkeit , ||| somnolence , ||| 0-0 1-1
Schläfrigkeit ||| somnolence ||| 0-0
Schlüsselelemente ||| That ||| 0-0
Schmelztablette . ||| orodispersible tablet ||| 0-0 0-1 1-1
Schmelztablette Rund und gelb ||| Orodispersible tablet Round and yellow ||| 0-0 1-0 0-1 1-2 2-3 3-4
Schmelztablette Rund und rosafarben ||| Orodispersible tablet Round and pink ||| 0-0 1-0 0-1 1-2 2-3 3-4
Schmelztablette Rund und ||| Orodispersible tablet Round and ||| 0-0 1-0 0-1 1-2 2-3
Schmelztablette Rund ||| Orodispersible tablet Round ||| 0-0 1-0 0-1 1-2
Schmelztablette enthält 10 mg ||| orodispersible tablet contains 10 mg ||| 0-0 0-1 1-2 2-3 3-4
Schmelztablette enthält 10 ||| orodispersible tablet contains 10 ||| 0-0 0-1 1-2 2-3
Schmelztablette enthält 15 mg ||| orodispersible tablet contains 15 mg ||| 0-0 0-1 1-2 2-3 3-4
Schmelztablette enthält 15 ||| orodispersible tablet contains 15 ||| 0-0 0-1 1-2 2-3
Schmelztablette enthält 30 mg ||| orodispersible tablet contains 30 mg ||| 0-0 0-1 1-2 2-3 3-4
Schmelztablette enthält 30 ||| orodispersible tablet contains 30 ||| 0-0 0-1 1-2 2-3
Schmelztablette enthält ||| orodispersible tablet contains ||| 0-0 0-1 1-2
Schmelztablette im Ganzen auf die ||| entire orodispersible tablet on the ||| 2-0 0-1 1-1 2-2 3-3 4-4
Schmelztablette im Ganzen auf ||| entire orodispersible tablet on ||| 2-0 0-1 1-1 2-2 3-3
Schmelztablette im Ganzen ||| entire orodispersible tablet ||| 2-0 0-1 1-1 2-2
Schmelztablette im ||| orodispersible ||| 0-0 1-0
Schmelztablette kann mit ||| orodispersible tablet can be ||| 0-0 0-1 1-2 2-2 1-3
Schmelztablette zerbrechlich ist , ||| orodispersible tablet is fragile , ||| 0-0 0-1 2-2 1-3 3-4
Schmelztablette zerbrechlich ist ||| orodispersible tablet is fragile ||| 0-0 0-1 2-2 1-3
Schmelztablette ||| orodispersible tablet ||| 0-0 0-1
Schmelztablette ||| orodispersible ||| 0-0
Schmelztabletten ( Tabletten ||| orodispersible tablets ( tablets ||| 0-0 0-1 1-2 2-3
Schmelztabletten ( ||| orodispersible tablets ( ||| 0-0 0-1 1-2
Schmelztabletten 28 x 1 ||| orodispersible tablets 28 x 1 ||| 0-0 0-1 1-2 2-3 3-4
Schmelztabletten 28 x ||| orodispersible tablets 28 x ||| 0-0 0-1 1-2 2-3
Schmelztabletten 28 ||| orodispersible tablets 28 ||| 0-0 0-1 1-2
Schmelztabletten 49 x 1 ||| orodispersible tablets 49 x 1 ||| 0-0 0-1 1-2 2-3 3-4
Schmelztabletten 49 x ||| orodispersible tablets 49 x ||| 0-0 0-1 1-2 2-3
Schmelztabletten 49 ||| orodispersible tablets 49 ||| 0-0 0-1 1-2
Schmelztabletten enthalten ||| orodispersible tablets contain ||| 0-0 0-1 1-2
Schmelztabletten jeden Tag zur gleichen ||| orodispersible tablet at the same ||| 0-0 1-1 1-2 1-3 2-4 3-4 4-4
Schmelztabletten jeden ||| orodispersible tablet at the ||| 0-0 1-1 1-2 1-3
Schmelztabletten können ||| orodispersible tablets may ||| 0-0 0-1 1-2
Schmelztabletten oder ||| orodispersible tablets or ||| 0-0 0-1 1-2
Schmelztabletten sind bioäquivalent zu ||| orodispersible tablet is bioequivalent to ||| 0-0 2-1 2-2 1-3 2-3 3-4
Schmelztabletten sind bioäquivalent ||| orodispersible tablet is bioequivalent ||| 0-0 2-1 2-2 1-3 2-3
Schmelztabletten sind rund und ||| orodispersible tablets are round and ||| 0-0 0-1 1-2 2-3 3-4
Schmelztabletten sind rund ||| orodispersible tablets are round ||| 0-0 0-1 1-2 2-3
Schmelztabletten sind ||| orodispersible tablets are ||| 0-0 0-1 1-2
Schmelztabletten und ||| orodispersible tablets and ||| 0-0 0-1 1-2
Schmelztabletten werden auf die ||| Schmelztabletten werden auf die ||| 0-0 1-1 2-2 3-3
Schmelztabletten werden auf ||| Schmelztabletten werden auf ||| 0-0 1-1 2-2
Schmelztabletten werden ||| Schmelztabletten werden ||| 0-0 1-1
Schmelztabletten ||| Schmelztabletten ||| 0-0
Schmelztabletten ||| orodispersible tablets ||| 0-0 0-1
Schmelztabletten ||| orodispersible ||| 0-0
Schmerzen , Juckreiz , Nesselsucht ||| pain , itching , hives ||| 0-0 1-1 2-2 3-3 4-4
Schmerzen , Juckreiz , ||| Continuous rotation of the injection ||| 0-0 0-1 1-1 2-1 2-3 2-4
Schmerzen , Juckreiz , ||| pain , itching , ||| 0-0 1-1 2-2 3-3
Schmerzen , Juckreiz ||| Continuous rotation of the injection ||| 0-0 0-1 1-1 2-1 2-3 2-4
Schmerzen , Juckreiz ||| pain , itching ||| 0-0 1-1 2-2
Schmerzen , Schwellungen ||| pain , swelling ||| 0-0 1-1 2-2
Schmerzen , Tremor Häufig : ||| pain , tremor Common : ||| 0-0 1-1 2-2 3-3 4-4
Schmerzen , Tremor Häufig ||| pain , tremor Common ||| 0-0 1-1 2-2 3-3
Schmerzen , Tremor ||| pain , tremor ||| 0-0 1-1 2-2
Schmerzen , ||| pain , ||| 0-0 1-1
Schmerzen am Ort der Infusion ||| pain at the infusion site ||| 0-0 1-1 2-2 3-2 4-3 1-4
Schmerzen durch Knochenmetastasen ||| into less pain from ||| 1-0 0-2
Schmerzen durch Knochenmetastasen ||| into less pain ||| 1-0 0-2
Schmerzen durch ||| into less pain from ||| 1-0 0-2
Schmerzen durch ||| into less pain ||| 1-0 0-2
Schmerzen und Juckreiz ||| pain and itching ||| 0-0 1-1 2-2
Schmerzen und ||| pain and ||| 0-0 1-1
Schmerzen und/oder nicht heilende Wunden ||| pain and/ or non-healing sores ||| 0-0 1-1 1-2 3-3 4-4
Schmerzen und/oder nicht heilende ||| pain and/ or non-healing ||| 0-0 1-1 1-2 3-3
Schmerzen und/oder nicht ||| pain and/ or ||| 0-0 1-1 1-2
Schmerzen und/oder ||| pain and/ or ||| 0-0 1-1 1-2
Schmerzen ||| Nail disorder , ||| 0-0 0-1 0-2
Schmerzen ||| less pain from ||| 0-1
Schmerzen ||| less pain ||| 0-1
Schmerzen ||| pain from ||| 0-0
Schmerzen ||| pain ||| 0-0
Schmerzmittel wie z.B. Ibuprofen ||| pain reliever such as ibuprofen ||| 1-0 0-1 1-2 2-2 1-3 3-4
Schmerzmittel wie z.B. ||| pain reliever such as ||| 1-0 0-1 1-2 2-2 1-3
Schmerzmittel ||| reliever ||| 0-0
Schreckreflex bei ||| a result of ||| 0-1 1-2
Schreckreflex bei ||| as a result of ||| 0-2 1-3
Schreckreflex bei ||| result of ||| 0-0 1-1
Schreckreflex ||| a result ||| 0-1
Schreckreflex ||| as a result ||| 0-2
Schreckreflex ||| result ||| 0-0
Schritten von 25 I.E./kg ||| be of 25 IU/ kg ||| 0-0 1-1 0-2 2-2 3-3 3-4
Schritten von 25 ||| be of 25 ||| 0-0 1-1 0-2 2-2
Schritten ||| done ||| 0-0
Schritten ||| intervals ||| 0-0
Schulungsbroschüre Zusammenfassung der Merkmale des ||| Educational leaflet Summary of ||| 0-0 0-1 1-2 2-2 3-2 4-3
Schulungsbroschüre Zusammenfassung der Merkmale ||| Educational leaflet Summary ||| 0-0 0-1 1-2 2-2 3-2
Schulungsbroschüre ||| Educational leaflet ||| 0-0 0-1
Schulungsbroschüre ||| leaflet ||| 0-0
Schulungsprogramm enthält ||| educational programme contains the ||| 0-0 0-1 1-2
Schulungsprogramm enthält ||| educational programme contains ||| 0-0 0-1 1-2
Schulungsprogramm ||| educational programme ||| 0-0 0-1
Schutzbrille und Schutzkleidung zu tragen ||| goggles and protective clothing is ||| 0-0 1-1 0-2 2-3 4-3 3-4
Schutzbrille und ||| goggles and protective ||| 0-0 1-1 0-2
Schutzkleidung zu tragen ||| clothing is ||| 0-0 2-0 1-1
Schwangeren vor . ||| pregnant women . ||| 0-0 0-1 1-1 2-2
Schwangeren vor ||| pregnant women ||| 0-0 0-1 1-1
Schwangerschaft . ||| pregnancy . ||| 0-0 1-1
Schwangerschaft und Stillzeit Sie sollten ||| Pregnancy and breast-feeding You should ||| 0-0 2-0 1-1 2-2 2-3 3-3 4-4
Schwangerschaft und Stillzeit Sie ||| Pregnancy and breast-feeding You ||| 0-0 2-0 1-1 2-2 2-3 3-3
Schwangerschaft und Stillzeit Wenn Sie ||| Pregnancy and breast-feeding You ||| 0-0 2-0 1-1 2-2 2-3 3-3 4-3
Schwangerschaft und in der ||| pregnancy and in ||| 0-0 1-1 2-2 3-2
Schwangerschaft und ||| pregnancy and ||| 0-0 1-1
Schwangerschaft wird daher nicht ||| should ||| 0-0 1-0 2-0 3-0
Schwangerschaft zu belegen . ||| pregnancy . ||| 0-0 2-0 3-1
Schwangerschaft zu belegen ||| pregnancy ||| 0-0 2-0
Schwangerschaft zu ||| zu ||| 1-0
Schwangerschaft ||| pregnancy ||| 0-0
Schwangerschaft ||| pregnant ||| 0-0
Schwankungen . ||| variation . ||| 0-0 1-1
Schwankungen ||| variation ||| 0-0
Schwankungsbereiches ( weniger als 2,10 ||| range ( less than 2.10 ||| 3-0 1-1 2-2 3-3 0-4 4-4
Schwellungen , Rötungen , Schmerzen ||| swelling , redness , pain ||| 0-0 1-1 3-1 2-2 3-3 4-4
Schwellungen , Rötungen , ||| swelling , redness , ||| 0-0 1-1 3-1 2-2 3-3
Schwellungen und Entzündungen . ||| given area may help to ||| 0-0 0-1 1-1 2-2 2-3 3-3 2-4
Schwellungen und Entzündungen . ||| swelling and inflammation . ||| 0-0 1-1 2-2 3-3
Schwellungen und Entzündungen ||| swelling and inflammation ||| 0-0 1-1 2-2
Schwellungen und ||| given area ||| 0-0 0-1 1-1
Schwellungen und ||| swelling and ||| 0-0 1-1
Schwellungen und/oder Schmerzen ||| swelling and/ or pain ||| 0-0 1-1 1-2 2-3
Schwellungen und/oder ||| swelling and/ or ||| 0-0 1-1 1-2
Schwellungen ||| swelling ||| 0-0
Schwere Hypoglykämien können ||| Severe hypoglycaemia may ||| 0-0 1-0 1-1 2-2
Schwere Hypoglykämien ||| Severe hypoglycaemia ||| 0-0 1-0 1-1
Schwere ||| severity ||| 0-0
Schwierigkeiten , die ||| difficulty ||| 0-0
Schwierigkeiten , ||| difficulty ||| 0-0
Schwierigkeiten beim Schlucken von ||| be used as an alternative ||| 1-0 2-1 2-2 1-3 0-4 2-4
Schwierigkeiten beim Schlucken ||| be used as an alternative ||| 1-0 2-1 2-2 1-3 0-4 2-4
Schwierigkeiten ||| difficulty ||| 0-0
Schwindel , Kopfschmerzen , Akathisie ||| dizziness , headache , akathisia ||| 0-0 1-1 2-2 3-3 4-4
Schwindel , Kopfschmerzen , ||| dizziness , headache , ||| 0-0 1-1 2-2 3-3
Schwindel , Kopfschmerzen ||| dizziness , headache ||| 0-0 1-1 2-2
Schwindel , Schläfrigkeit , Sedierung ||| dizziness , somnolence , sedation ||| 0-0 1-1 2-2 3-3 4-4
Schwindel , Schläfrigkeit , ||| , dizziness , somnolence ||| 1-0 0-1 3-2 2-3
Schwindel , Schläfrigkeit , ||| dizziness , somnolence , ||| 0-0 1-1 2-2 3-3
Schwindel , Schläfrigkeit ||| dizziness , somnolence ||| 0-0 1-1 2-2
Schwindel , neuropathische Schmerzen , ||| dizziness , neuropathic pain , ||| 0-0 1-1 2-2 3-3 4-4
Schwindel , neuropathische Schmerzen ||| dizziness , neuropathic pain ||| 0-0 1-1 2-2 3-3
Schwindel , neuropathische ||| dizziness , neuropathic ||| 0-0 1-1 2-2
Schwindel , periphere motorische Neuropathie ||| dizziness , peripheral motor neuropathy ||| 0-0 1-1 2-2 3-3 4-4
Schwindel , periphere motorische ||| dizziness , peripheral motor ||| 0-0 1-1 2-2 3-3
Schwindel , periphere ||| dizziness , peripheral ||| 0-0 1-1 2-2
Schwindel , ||| , dizziness ||| 1-0 0-1
Schwindel , ||| dizziness , ||| 0-0 1-1
Schwindel ||| dizziness ||| 0-0
Schwindelgefühl Hypoästhesie ||| Dizziness ||| 0-0 1-0
Schwitzen , ||| , sweating , ||| 1-0 0-1 1-2
Schwitzen und Herzrhythmusstörungen ) ||| diaphoresis and cardiac dysrhythmia ) ||| 0-0 2-0 1-1 2-2 2-3 3-4
Schwitzen und Herzrhythmusstörungen ||| diaphoresis and cardiac dysrhythmia ||| 0-0 2-0 1-1 2-2 2-3
Schwitzen ||| sweating ||| 0-0
Schwäche ) ||| weakness ) ||| 0-0 1-1
Schwäche ||| weakness ||| 0-0
Schwächegefühl , Benommenheit ||| tiredness may occur , especially ||| 0-0 2-0 0-1 0-2 1-3 2-4
Schwächegefühl , ||| of weakness , ||| 0-1 1-2
Schwächegefühl , ||| weakness , ||| 0-0 1-1
Schwächegefühl ||| of weakness ||| 0-1
Schwächegefühl ||| weakness ||| 0-0
Schüttelfrost , ||| Fever and chills , ||| 0-0 0-2 1-3
Schüttelfrost , ||| chills , pain in the ||| 0-0 1-1 1-2
Schüttelfrost , ||| chills , pain in ||| 0-0 1-1 1-2
Schüttelfrost , ||| chills , pain ||| 0-0 1-1 1-2
Schüttelfrost ||| Fever and chills ||| 0-0 0-2
Schüttelfrost ||| chills ||| 0-0
Schütteln sichergestellt werden . ||| agitation before use . ||| 0-0 0-1 1-1 2-3 3-3
Schütteln sichergestellt ||| agitation before use ||| 0-0 0-1 1-1
Schütteln sichergestellt ||| agitation before ||| 0-0 0-1 1-1
Scoppito ( AQ ) , ||| Scoppito ( AQ ) , ||| 0-0 1-1 2-2 3-3 4-4
Scoppito ( AQ ) ||| Scoppito ( AQ ) ||| 0-0 1-1 2-2 3-3
Scoppito ( AQ ||| Scoppito ( AQ ||| 0-0 1-1 2-2
Scoppito ( ||| Scoppito ( ||| 0-0 1-1
Scoppito ||| Scoppito ||| 0-0
Sedierung , Kopfschmerzen Augenerkrankungen ||| , sedation , headache Eye ||| 1-0 0-1 1-2 2-3 3-4
Sedierung , Kopfschmerzen Augenerkrankungen ||| sedation , headache Eye disorders ||| 0-0 1-1 2-2 3-3 3-4
Sedierung , Kopfschmerzen ||| , sedation , headache ||| 1-0 0-1 1-2 2-3
Sedierung , Kopfschmerzen ||| sedation , headache ||| 0-0 1-1 2-2
Sedierung , ||| , sedation , ||| 1-0 0-1 1-2
Sedierung , ||| sedation , ||| 0-0 1-1
Sedierung eingenommen wird ( siehe ||| sedation ( see ||| 0-0 1-0 2-0 3-1 4-2
Sedierung eingenommen wird ( ||| sedation ( ||| 0-0 1-0 2-0 3-1
Sedierung eingenommen wird ||| sedation ||| 0-0 1-0 2-0
Sedierung und kardio-respiratorischer Depression führen ||| sedation and cardiorespiratory depression ||| 0-0 1-1 2-2 3-2 4-2 3-3
Sedierung und ||| sedation and ||| 0-0 1-1
Sedierung ||| excessive sedation and ||| 0-0 0-1
Sedierung ||| excessive sedation ||| 0-0 0-1
Sedierung ||| sedation ||| 0-0
Sehen , reduzierte Sehschärfe ||| vision , reduced visual acuity ||| 0-0 1-1 2-2 3-3 3-4
Sehen , reduzierte ||| vision , reduced ||| 0-0 1-1 2-2
Sehen , ||| vision , ||| 0-0 1-1
Sehen . ||| vision . ||| 0-0 1-1
Sehen Erkrankungen des Gastrointestinaltrakts Häufig ||| vision Gastrointestinal disorders Common ||| 0-0 3-1 1-2 2-2 4-3
Sehen Erkrankungen des Gastrointestinaltrakts ||| vision Gastrointestinal disorders ||| 0-0 3-1 1-2 2-2
Sehen ||| vision ||| 0-0
Sehr häufig > 1/10 ||| Frequencies ||| 0-0 1-0 2-0 3-0
Sehr häufige ||| Very common ||| 0-0 1-1
Sehr selten - Refraktionsanomalien ||| Very rare - Refraction disorders ||| 0-0 1-1 2-2 3-3 3-4
Sehr selten - ||| Very rare - ||| 0-0 1-1 2-2
Sehr selten ||| Very rare ||| 0-0 1-1
Sehr ||| Very ||| 0-0
Sehschärfe , ||| visual acuity , ||| 0-0 0-1 1-2
Sehschärfe ||| visual acuity ||| 0-0 0-1
Sehstörungen , ||| visual disturbance , ||| 0-0 0-1 1-2
Sehstörungen ||| visual disturbance ||| 0-0 0-1
Sein genauer Wirkungsmechanismus ||| Its exact mechanism of action ||| 0-0 0-1 1-1 2-2 2-4
Sein genauer ||| Its exact ||| 0-0 0-1 1-1
Seite . ||| face. . ||| 0-0 1-1
Seite ||| face. ||| 0-0
Selbsttötungsgedanken und entsprechendes ||| Suicidal thoughts and ||| 0-0 0-1 2-1 1-2
Selbsttötungsgedanken ||| thoughts of ||| 0-0
Selbsttötungsgedanken ||| thoughts ||| 0-0
Selten : ||| Rare : ||| 0-0 1-1
Selten wurde über Überempfindlichkeitsreaktionen unter ||| Hypersensitivity reactions have been rarely ||| 0-0 3-1 0-2 1-3 2-4 3-4 4-4
Selten ||| Rare ||| 0-0
Seltene Fälle ||| Rare cases of ||| 0-0 1-1 1-2
Seltene Nebenwirkungen ( ||| Rare side effects ( ||| 0-0 1-1 1-2 2-3
Seltene Nebenwirkungen ||| Rare side effects ||| 0-0 1-1 1-2
Seltene ||| Rare ||| 0-0
Sensorische Neuropathie ||| Sensory neuropathy ||| 0-0 1-1
Sensorische ||| Sensory ||| 0-0
September 2005 einen zusätzlichen 6 ||| submit one additional 6 ||| 0-0 1-0 2-1 3-2 4-3
September 2005 einen zusätzlichen ||| submit one additional ||| 0-0 1-0 2-1 3-2
September 2005 einen ||| submit one ||| 0-0 1-0 2-1
September 2005 ||| submit ||| 0-0 1-0
Serie von In-vivo- ||| a comprehensive battery of ||| 0-0 0-1 2-2 1-3
Serie ||| a comprehensive ||| 0-0 0-1
Serotonin genannt ) . ||| called serotonin ) . ||| 1-0 0-1 2-2 3-3
Serotonin genannt ) ||| called serotonin ) ||| 1-0 0-1 2-2
Serotonin genannt ||| called serotonin ||| 1-0 0-1
Serotonin ||| serotonin ||| 0-0
Serotonin- Wiederaufnahme-Stelle und ||| the serotonin reuptake site and ||| 0-0 0-1 0-2 1-2 1-3 2-4
Serotonin- Wiederaufnahme-Stelle ||| the serotonin reuptake site ||| 0-0 0-1 0-2 1-2 1-3
Serum ||| serum ||| 0-0
Serum-Kalzium-Spiegel ausgeprägt ||| serum calcium ||| 0-0 0-1
Serum-Kalzium-Spiegel ||| serum calcium ||| 0-0 0-1
Serum-Kreatinins ||| creatinine ||| 0-0
Serumspiegel bleiben gleich ||| levels remain the ||| 0-0 1-1 2-1 1-2
Serumspiegel ||| levels ||| 0-0
Sexuell aktive ||| Sexually active ||| 0-0 1-1
Sexuell ||| Sexually ||| 0-0
Shunt überprüfen und ||| shunt and ||| 0-0 1-0 2-1
Shunt überprüfen ||| shunt ||| 0-0 1-0
Shunt-Thrombose ||| occur especially ||| 0-0 0-1
Shunt-Thrombosen können vorkommen , ||| Shunt thromboses may occur , ||| 0-0 0-1 1-1 2-1 1-2 2-3 3-4
Shunt-Thrombosen können vorkommen ||| Shunt thromboses may occur ||| 0-0 0-1 1-1 2-1 1-2 2-3
Sicherheit der Androgensuppression ist ||| safety of androgen suppression is ||| 0-0 1-1 2-2 2-3 3-4
Sicherheit der Androgensuppression ||| safety of androgen suppression ||| 0-0 1-1 2-2 2-3
Sicherheit der ||| safety of ||| 0-0 1-1
Sicherheit er Folgende ||| reactions ||| 2-0
Sicherheit von Aclasta 5 mg ||| safety of Aclasta 5 mg ||| 0-0 1-1 2-2 3-3 4-4
Sicherheit von Aclasta 5 ||| safety of Aclasta 5 ||| 0-0 1-1 2-2 3-3
Sicherheit von Aclasta ||| safety of Aclasta ||| 0-0 1-1 2-2
Sicherheit von Pioglitazon während der ||| safety of pioglitazone during ||| 0-0 1-1 2-2 3-3 4-3
Sicherheit von Pioglitazon ||| safety of pioglitazone ||| 0-0 1-1 2-2
Sicherheit von Vantas wurde hinreichend ||| safety of Vantas is sufficiently ||| 0-0 1-1 2-2 4-4
Sicherheit von Vantas wurde ||| safety of Vantas is ||| 0-0 1-1 2-2
Sicherheit von Vantas wurde ||| safety of Vantas ||| 0-0 1-1 2-2
Sicherheit von Vantas ||| safety of Vantas is ||| 0-0 1-1 2-2
Sicherheit von Vantas ||| safety of Vantas ||| 0-0 1-1 2-2
Sicherheit von ||| safety of ||| 0-0 1-1
Sicherheit ||| Schwangerschaft ||| 0-0
Sicherheit ||| safety ||| 0-0
Sicherheitsbedenken ||| Applicant/ ||| 0-0
Sicherheitsspezifikationen ( Safety Specification ) ||| Safety ||| 2-0 3-0
Sicherheitsspezifikationen ( Safety Specification ||| Safety ||| 2-0 3-0
Sicht , Trockenes-Auge-Syndrom , Keratokonjunktivitis ||| , dry eye , keratoconjunctivitis ||| 0-0 1-0 2-1 2-2 3-3 4-4
Sicht , Trockenes-Auge-Syndrom , ||| , dry eye , ||| 0-0 1-0 2-1 2-2 3-3
Sicht , Trockenes-Auge-Syndrom ||| , dry eye ||| 0-0 1-0 2-1 2-2
Sicht , ||| , ||| 0-0 1-0
Sie ABILIFY einnehmen . ||| taking ABILIFY . ||| 0-0 2-0 1-1 3-2
Sie ABILIFY einnehmen ||| taking ABILIFY ||| 0-0 2-0 1-1
Sie Aclasta erhalten haben ||| after you have received Aclasta ||| 1-0 0-1 3-2 2-3 1-4
Sie Actos 15 mg Tabletten ||| Actos 15mg tablets are ||| 0-0 1-0 2-1 3-1 4-2 1-3
Sie Actos 30 mg Tabletten ||| Actos 30mg tablets are ||| 0-0 1-0 1-1 2-1 3-1 4-2 1-3
Sie Actos 45 mg Tabletten ||| Actos 45mg tablets are ||| 0-0 1-0 2-1 3-1 4-2 1-3
Sie Bedenken haben , dass ||| you are concerned that ||| 0-0 2-0 0-1 1-2 3-2 3-3 4-3
Sie Ihrem Arzt mit ||| your doctor ||| 0-0 1-0 2-1
Sie Ihrem Arzt ||| your doctor ||| 0-0 1-0 2-1
Sie Ihrem ||| your ||| 0-0 1-0
Sie Ihren Arzt , Apotheker ||| your doctor , pharmacist ||| 0-0 1-0 1-1 2-1 3-2 4-3
Sie Ihren Arzt , dass ||| your dentist that ||| 0-0 1-0 2-0 1-1 3-2 4-2
Sie Ihren Arzt , ||| your doctor , ||| 0-0 1-0 1-1 2-1 3-2
Sie Ihren Arzt oder Apotheker ||| your doctor or pharmacist ||| 0-0 1-0 1-1 2-1 3-2 4-3
Sie Ihren Arzt oder Zahnarzt ||| your doctor or dentist ||| 0-0 1-0 1-1 2-1 3-2 4-3
Sie Ihren Arzt oder ||| your doctor or ||| 0-0 1-0 1-1 2-1 3-2
Sie Ihren Arzt ||| your dentist ||| 0-0 1-0 2-0 1-1
Sie Ihren Arzt ||| your doctor ||| 0-0 1-0 1-1 2-1
Sie Ihren Arzt ||| your doctor ||| 0-0 1-0 2-1
Sie Ihren Tierarzt , wie ||| your veterinary surgeon how ||| 0-0 1-0 2-1 2-2 3-3 4-3
Sie Ihren Tierarzt ||| your veterinary surgeon ||| 0-0 1-0 2-1 2-2
Sie Ihren ||| your ||| 0-0 1-0
Sie Leber- ||| you have a problem with ||| 0-0 0-1 1-2 1-3 1-4
Sie an einem polyzystischen ||| you have polycystic ovary ||| 0-0 3-1 1-2 2-2 3-2 3-3
Sie an einer Herzkreislauf-Erkrankung leiden ||| you have cardiovascular disorders ||| 0-0 4-0 1-1 4-1 2-2 3-2
Sie an einer Herzkreislauf-Erkrankung leiden ||| you have cardiovascular ||| 0-0 4-0 1-1 4-1 2-2 3-2
Sie an schweren ||| you have severe ||| 0-0 0-1 1-1 2-2
Sie an ||| you have ||| 0-0 0-1 1-1
Sie anweisen , eine ||| tell you to take a ||| 1-0 0-1 1-2 2-2 1-3 3-4
Sie anweisen , ||| tell you to take ||| 1-0 0-1 1-2 2-2 1-3
Sie bitte mit Ihrem ||| tell your ||| 0-0 1-0 3-1
Sie bitte mit ||| tell ||| 0-0 1-0
Sie bitte ||| tell ||| 0-0 1-0
Sie daher das Arzneimittel mit ||| , administer the product with ||| 0-1 2-2 1-3 2-3 3-3 4-4
Sie daher das Arzneimittel mit ||| administer the product with ||| 0-0 2-1 1-2 2-2 3-2 4-3
Sie daher das Arzneimittel ||| , administer the product ||| 0-1 2-2 1-3 2-3 3-3
Sie daher das Arzneimittel ||| administer the product ||| 0-0 2-1 1-2 2-2 3-2
Sie daran denken ||| you are having any ||| 0-0 1-1 1-2 2-2 2-3
Sie das Arzneimittel zunächst ||| the product orally during ||| 0-0 1-0 1-1 2-1 3-2
Sie das Arzneimittel zunächst ||| the product orally ||| 0-0 1-0 1-1 2-1 3-2
Sie das Arzneimittel ||| the product ||| 0-0 1-0 1-1 2-1
Sie den Eindruck haben ||| you have the impression ||| 0-0 3-1 1-2 2-3
Sie die Beendigung der ||| you are considering stopping ||| 0-0 0-1 1-2 2-3 3-3
Sie die Nadel ||| the needle into the skin ||| 0-0 1-0 2-1 1-2 2-2 1-3 2-4
Sie die Packung mit . ||| the pack with you . ||| 1-0 2-1 3-2 0-3 4-4
Sie die Packung mit ||| the pack with you ||| 1-0 2-1 3-2 0-3
Sie die Spritze , indem ||| the syringe by pulling ||| 0-0 1-0 2-1 4-2 2-3
Sie die ||| the ||| 0-0 1-0
Sie die ||| you are considering ||| 0-0 0-1 1-2
Sie dies mit Ihrem Arzt ||| this with your doctor ||| 1-0 2-1 0-2 3-2 4-3
Sie dies mit Ihrem ||| this with your ||| 1-0 2-1 0-2 3-2
Sie diese Packungsbeilage auf . ||| Keep this leaflet . ||| 0-0 1-1 2-2 4-3
Sie diese Packungsbeilage auf ||| Keep this leaflet ||| 0-0 1-1 2-2
Sie diese Packungsbeilage ||| Keep this leaflet ||| 0-0 1-1 2-2
Sie diese ||| Keep this ||| 0-0 1-1
Sie dieses Arzneimittel einnehmen . ||| taking this medicine . ||| 0-0 3-0 1-1 2-2 4-3
Sie dieses Arzneimittel einnehmen ||| taking this medicine ||| 0-0 3-0 1-1 2-2
Sie dürfen Aclasta nach ||| Do not use Aclasta after ||| 0-0 1-0 1-1 1-2 2-3 3-4
Sie dürfen Aclasta ||| Do not use Aclasta ||| 0-0 1-0 1-1 1-2 2-3
Sie dürfen das Arzneimittel ||| Do not use this medicine ||| 0-0 1-0 1-1 1-2 2-2 3-3 3-4
Sie dürfen das ||| Do not use ABILIFY ||| 0-0 1-0 1-1 1-2 2-2 1-3
Sie dürfen das ||| Do not use ||| 0-0 1-0 1-1 1-2 2-2
Sie dürfen ||| Do not use ||| 0-0 1-0 1-1 1-2
Sie eine Spritze aus der ||| one syringe from the ||| 1-0 2-1 3-2 0-3 4-3
Sie eine größere Menge von ||| you inject more ||| 0-0 1-0 2-1 3-1 2-2 4-2
Sie eine ||| you ||| 0-0 1-0
Sie es nicht mehr benötigen ||| no longer required ||| 1-0 0-1 1-1 2-1 3-1 4-1 4-2
Sie fettleibig ||| you ||| 0-0
Sie gegebenenfalls ||| you may not ||| 0-0 1-1 0-2
Sie glauben , ||| you think ||| 0-0 1-1
Sie glauben ||| you think ||| 0-0 1-1
Sie hier . ||| here . ||| 0-0 1-0 2-1
Sie hier ||| here ||| 0-0 1-0
Sie ist ein Inhibitor der ||| It is an inhibitor of ||| 0-0 1-1 2-2 3-3 4-4
Sie ist ein Inhibitor ||| It is an inhibitor ||| 0-0 1-1 2-2 3-3
Sie ist ein ||| It is an ||| 0-0 1-1 2-2
Sie ist ||| It is ||| 0-0 1-1
Sie kann mit ||| It can be ||| 0-0 1-1 1-2 2-2
Sie kann ||| It may ||| 0-0 1-1
Sie können die Tablette auch ||| Alternatively , disperse the tablet ||| 0-0 3-0 1-1 1-2 3-2 4-2 2-3 3-4
Sie mehr ABILIFY ||| you are given more ABILIFY ||| 0-0 0-1 1-2 1-3 2-4
Sie mehr ||| you are given more ||| 0-0 0-1 1-2 1-3
Sie mit Ihrem Arzt . ||| to your doctor . ||| 0-1 2-1 3-2 4-3
Sie mit Ihrem Arzt . ||| your doctor . ||| 0-0 2-0 3-1 4-2
Sie mit Ihrem Arzt ||| to your doctor ||| 0-1 2-1 3-2
Sie mit Ihrem Arzt ||| your doctor ||| 0-0 2-0 3-1
Sie mit Ihrem ||| to your ||| 0-1 2-1
Sie mit Ihrem ||| your ||| 0-0 2-0
Sie nur soviel injizieren ||| only inject the amount ||| 1-0 0-1 2-1 1-3 3-3
Sie oder ||| you or ||| 0-0 1-1
Sie schwanger sind , ||| you are pregnant , ||| 0-0 2-1 1-2 3-3
Sie schwanger sind , ||| you are pregnant ||| 0-0 2-1 3-1 1-2
Sie schwanger sind ||| you are pregnant ||| 0-0 2-1 1-2
Sie sich , dass ||| that you ||| 1-0 2-0 3-0 0-1
Sie sich besser fühlen . ||| you feel better . ||| 0-0 1-1 3-1 2-2 3-2 4-3
Sie sich besser fühlen ||| you feel better ||| 0-0 1-1 3-1 2-2 3-2
Sie sollten Alkohol meiden , ||| Alcohol should be avoided ||| 0-0 2-0 1-1 3-2 3-3 4-3
Sie sollten Alkohol ||| Alcohol should ||| 0-0 2-0 1-1
Sie sollten sie jedoch nicht ||| However , you should not ||| 3-0 3-1 0-2 1-3 4-4
Sie sollten sie jedoch ||| However , you should ||| 3-0 3-1 0-2 1-3
Sie sollten sie ||| you should ||| 0-0 1-1
Sie sollten ||| You should receive ||| 0-0 1-1 1-2
Sie sollten ||| you should ||| 0-0 1-1
Sie stillen . ||| you are breast-feeding . ||| 0-0 1-1 1-2 2-3
Sie stillen ||| you are breast-feeding ||| 0-0 1-1 1-2
Sie umgehend Ihren Arzt ||| your doctor immediately ||| 0-0 2-0 2-1 3-1 1-2
Sie unter Abschnitt 6.1 . ||| , see section 6.1 ||| 2-1 2-2 3-3 4-3
Sie unter Abschnitt 6.1 . ||| see section 6.1 ||| 2-0 2-1 3-2 4-2
Sie unter Abschnitt ||| , see section ||| 2-1 2-2
Sie unter Abschnitt ||| see section ||| 2-0 2-1
Sie unter Erythroblastopenie ||| you develop PRCA ||| 0-0 1-1 2-1 2-2
Sie unter chronischer Nierenschwäche ||| you have chronic kidney failure ||| 0-0 0-1 2-2 1-3 3-3 2-4
Sie unter diesen Symptomen ||| you experience these symptoms ||| 0-0 0-1 1-1 2-2 3-3
Sie unter diesen ||| you experience these ||| 0-0 0-1 1-1 2-2
Sie unter ||| you experience ||| 0-0 0-1 1-1
Sie unter ||| you have ||| 0-0 0-1 1-1
Sie unverzüglich Ihren Arzt ||| your doctor immediately ||| 0-0 2-0 2-1 3-1 1-2
Sie versehentlich ||| you accidentally ||| 0-0 1-1
Sie versuchen ||| you attempt ||| 0-0 1-1
Sie vor der Anwendung von ||| you use ||| 0-0 1-0 3-1 4-1
Sie vor der ||| you ||| 0-0 1-0
Sie vor ||| , you will ||| 0-1 1-1 0-2
Sie vor ||| you will ||| 0-0 1-0 0-1
Sie vor ||| you ||| 0-0 1-0
Sie weitere Fragen haben ||| you have any further ||| 0-0 3-1 1-2 1-3 2-3 3-3
Sie weitere Fragen haben ||| you have further ||| 0-0 3-1 1-2 2-2 3-2
Sie weitere Informationen über ||| you need more information about ||| 0-0 1-1 2-2 2-3 3-3 2-4
Sie weitere ||| It explains ||| 0-0
Sie weitere ||| It ||| 0-0
Sie weitere ||| you have any ||| 0-0 1-1 1-2
Sie weitere ||| you need ||| 0-0 1-1
Sie weitere ||| you ||| 0-0 1-0
Sie werden sich unter Umständen ||| You will probably need ||| 0-0 0-1 2-2 3-2 4-2 4-3
Sie werden ||| You will ||| 0-0 0-1
Sie werden ||| you will ||| 0-0 0-1
Sie wissen , wie ABILIFY ||| you know how ABILIFY ||| 0-0 1-1 2-1 1-2 3-2 4-3
Sie wissen , wie ||| you know how ||| 0-0 1-1 2-1 1-2 3-2
Sie ||| , administer ||| 0-1
Sie ||| Do ||| 0-0
Sie ||| It explains ||| 0-0
Sie ||| It ||| 0-0
Sie ||| Keep ||| 0-0
Sie ||| Sie ||| 0-0
Sie ||| You will ||| 0-0 0-1
Sie ||| You ||| 0-0
Sie ||| administer ||| 0-0
Sie ||| and you ||| 0-1
Sie ||| if you ||| 0-0 0-1
Sie ||| or no ||| 0-0 0-1
Sie ||| please inform ||| 0-0 0-1
Sie ||| the ||| 0-0
Sie ||| you are on ||| 0-0 0-1
Sie ||| you are ||| 0-0 0-1
Sie ||| you have ||| 0-0 0-1
Sie ||| you will ||| 0-0 0-1
Sie ||| you ||| 0-0
Sie ||| your doctor ||| 0-0 0-1
Sie ||| your ||| 0-0
Siliciumdioxid , Xylitol , ||| , silicon dioxide , ||| 1-0 0-1 2-2 3-3
Siliciumdioxid , Xylitol ||| , silicon dioxide ||| 1-0 0-1 2-2
Siliciumdioxid , ||| , silicon ||| 1-0 0-1
Siliciumdioxid ||| silicon ||| 0-0
Sinkstoffe sichtbar sind ||| settling are ||| 0-0 1-0 2-1
Sinkstoffe sichtbar ||| settling ||| 0-0 1-0
Situationen ||| situations ||| 0-0
Skeletts ||| skeleton that allows ||| 0-0 0-2
Slovenija Eli Lilly farmacevtska ||| Slovenija Eli Lilly farmacevtska dru ||| 0-0 1-1 2-2 2-3 3-3 3-4
Slovenija Eli Lilly farmacevtska ||| Slovenija Eli Lilly farmacevtska dru ||| 0-0 1-1 2-2 3-3 3-4
Slovenija Eli Lilly ||| Slovenija Eli Lilly ||| 0-0 1-1 2-2
Slovenija Eli ||| Slovenija Eli ||| 0-0 1-1
Slovenija ||| Slovenija ||| 0-0
Slovenská republika Eli ||| Slovenská republika Eli ||| 0-0 1-1 2-2
Slovenská republika OncoEurope Tel : ||| Slovenská republika OncoEurope Tel : ||| 0-0 1-1 2-2 3-3 4-4
Slovenská republika OncoEurope Tel ||| Slovenská republika OncoEurope Tel ||| 0-0 1-1 2-2 3-3
Slovenská republika OncoEurope ||| Slovenská republika OncoEurope ||| 0-0 1-1 2-2
Slovenská republika ||| Slovenská republika ||| 0-0 1-1
Slovenská ||| Slovenská ||| 0-0
Sobald Sie ||| When your ||| 0-0 1-1
Sobald der Hund ||| Once the dog ||| 0-0 1-1 2-2
Sobald der Patient ||| Upon regaining ||| 0-0 0-1 1-1 2-1
Sobald der ||| Once the ||| 0-0 1-1
Sobald ||| Once ||| 0-0
Sobald ||| When ||| 0-0
Sodbrennen ) , Erbrechen , ||| heartburn ) , vomiting , ||| 0-0 1-1 2-2 3-3 4-4
Sodbrennen ) , Erbrechen ||| heartburn ) , vomiting ||| 0-0 1-1 2-2 3-3
Sodbrennen ) , ||| heartburn ) , ||| 0-0 1-1 2-2
Sodbrennen ) ||| heartburn ) ||| 0-0 1-1
Sodbrennen ||| heartburn ||| 0-0
Somit ||| Therefore , ||| 0-0
Somit ||| Therefore ||| 0-0
Somnolenz ||| experience somnolence ||| 0-1
Somnolenz ||| somnolence ||| 0-0
Sonstige Bestandteile : ||| Excipients : ||| 0-0 1-0 2-1
Sonstige Bestandteile Das rekonstituierte Arzneimittel ||| Excipients The reconstituted medicinal product ||| 0-0 1-0 2-1 3-2 4-3 4-4
Sonstige Bestandteile Das rekonstituierte ||| Excipients The reconstituted ||| 0-0 1-0 2-1 3-2
Sonstige Bestandteile Das ||| Excipients The ||| 0-0 1-0 2-1
Sonstige Bestandteile ||| Excipients ||| 0-0 1-0
Sowohl bei Frauen als auch ||| In both women and ||| 1-0 3-1 4-1 1-2 2-2 0-3 4-3
SpA Tel : + 39 ||| SpA Tel : + 39 ||| 0-0 1-1 2-2 3-3 4-4
SpA Tel : + ||| SpA Tel : + ||| 0-0 1-1 2-2 3-3
SpA Tel : ||| SpA Tel : ||| 0-0 1-1 2-2
SpA Tel ||| SpA Tel ||| 0-0 1-1
SpA ||| SpA ||| 0-0
Spaltungs- ( Hydrolyse- ) Orten ||| cleavage ( hydrolysis ) sites ||| 0-0 1-1 2-2 4-2 3-3 4-4
Spaltungs- ( ||| cleavage ( ||| 0-0 1-1
Spaltungs- ||| cleavage ||| 0-0
Spanien ||| Spain ||| 0-0
Speichelfluss , Anorexie , schwere ||| , anorexia , severe ||| 0-0 1-0 2-1 3-2 4-3
Speichelfluss , Anorexie , ||| , anorexia , ||| 0-0 1-0 2-1 3-2
Speichelfluss , Anorexie ||| , anorexia ||| 0-0 1-0 2-1
Speichelfluss , ||| , ||| 0-0 1-0
Speichelproduktion , ||| production of saliva , ||| 0-0 0-2 1-3
Speichelproduktion ||| production of saliva ||| 0-0 0-2
Speichelüberproduktion Gefäßerkrankungen ||| salivary hypersecretion Vascular ||| 0-0 0-1 1-2
Speichelüberproduktion ||| salivary hypersecretion ||| 0-0 0-1
Spezies , jeweils mit subkutaner ||| species , both via subcutaneous ||| 0-0 1-1 2-1 4-4
Spezies , jeweils mit ||| species , both via ||| 0-0 1-1 2-1
Spezies , jeweils mit ||| species , both ||| 0-0 1-1 2-1
Spezies , jeweils mit ||| species , ||| 0-0 1-1 2-1
Spezies , jeweils ||| species , both via ||| 0-0 1-1 2-1
Spezies , jeweils ||| species , both ||| 0-0 1-1 2-1
Spezies , jeweils ||| species , ||| 0-0 1-1 2-1
Spezies ||| species ||| 0-0
Spezifische Arzneimittel-Interaktionsstudien ||| Specific drug-drug interaction ||| 0-0 1-1 1-2
Spezifische ||| Specific ||| 0-0
Spongiosa in der Metaphyse der ||| spongiosa in the metaphyses of ||| 0-0 2-0 1-1 2-2 4-2 3-3 4-3 4-4
Sprachstörungen , Malignes ||| speech disorder , Neuroleptic ||| 0-0 0-1 1-2 2-3
Sprachstörungen , ||| speech disorder , ||| 0-0 0-1 1-2
Sprachstörungen ||| speech disorder ||| 0-0 0-1
Spritze , indem ||| syringe by pulling ||| 0-0 2-1 0-2
Spritze auf einen Teil ||| syringe onto a portion of ||| 0-0 0-1 2-2 3-3 3-4
Spritze auf einen ||| syringe onto a ||| 0-0 0-1 2-2
Spritze auf ||| syringe onto ||| 0-0 0-1
Spritze aus ||| syringe from ||| 0-0 1-1
Spritze ||| syringe , ||| 0-0
Spritze ||| syringe onto ||| 0-0 0-1
Spritze ||| syringe ||| 0-0
Spritzen enthalten 0,3 ml ( ||| syringes contain 0.3 ml ( ||| 0-0 1-1 2-2 3-3 4-4
Spritzen enthalten 0,3 ml ||| syringes contain 0.3 ml ||| 0-0 1-1 2-2 3-3
Spritzen enthalten 0,3 ||| syringes contain 0.3 ||| 0-0 1-1 2-2
Spritzen enthalten 0,4 ml ( ||| syringes contain 0.4 ml ( ||| 0-0 1-1 2-2 3-3 4-4
Spritzen enthalten 0,4 ml ||| syringes contain 0.4 ml ||| 0-0 1-1 2-2 3-3
Spritzen enthalten 0,4 ||| syringes contain 0.4 ||| 0-0 1-1 2-2
Spritzen enthalten 0,5 ml ( ||| syringes contain 0.5 ml ( ||| 0-0 1-1 2-2 3-3 4-4
Spritzen enthalten 0,5 ml ||| syringes contain 0.5 ml ||| 0-0 1-1 2-2 3-3
Spritzen enthalten 0,5 ||| syringes contain 0.5 ||| 0-0 1-1 2-2
Spritzen enthalten 0,6 ml ( ||| syringes contain 0.6 ml ( ||| 0-0 1-1 2-2 3-3 4-4
Spritzen enthalten 0,6 ml ||| syringes contain 0.6 ml ||| 0-0 1-1 2-2 3-3
Spritzen enthalten 0,6 ||| syringes contain 0.6 ||| 0-0 1-1 2-2
Spritzen enthalten 0,7 ml ( ||| syringes contain 0.7 ml ( ||| 0-0 1-1 2-2 3-3 4-4
Spritzen enthalten 0,7 ml ||| syringes contain 0.7 ml ||| 0-0 1-1 2-2 3-3
Spritzen enthalten 0,7 ||| syringes contain 0.7 ||| 0-0 1-1 2-2
Spritzen enthalten 0,8 ml ( ||| syringes contain 0.8 ml ( ||| 0-0 1-1 2-2 3-3 4-4
Spritzen enthalten 0,8 ml ||| syringes contain 0.8 ml ||| 0-0 1-1 2-2 3-3
Spritzen enthalten 0,8 ||| syringes contain 0.8 ||| 0-0 1-1 2-2
Spritzen enthalten 0,9 ml ( ||| syringes contain 0.9 ml ( ||| 0-0 1-1 2-2 3-3 4-4
Spritzen enthalten 0,9 ml ||| syringes contain 0.9 ml ||| 0-0 1-1 2-2 3-3
Spritzen enthalten 0,9 ||| syringes contain 0.9 ||| 0-0 1-1 2-2
Spritzen enthalten 1 ml ( ||| syringes contain 1 ml ( ||| 0-0 1-1 2-2 3-3 4-4
Spritzen enthalten 1 ml ||| syringes contain 1 ml ||| 0-0 1-1 2-2 3-3
Spritzen enthalten 1 ||| syringes contain 1 ||| 0-0 1-1 2-2
Spritzen enthalten ||| syringes contain ||| 0-0 1-1
Spritzen ||| syringes ||| 0-0
Spätdyskinesien : in klinischen ||| Tardive Dyskinesia : in clinical ||| 0-0 0-1 1-2 2-3 3-4
Spätdyskinesien : in klinischen ||| Tardive Dyskinesia : in clinical ||| 0-0 0-1 2-1 1-2 2-3 3-4
Spätdyskinesien : in ||| 47 Tardive Dyskinesia : in ||| 0-0 0-1 0-2 2-2 1-3 2-4
Spätdyskinesien : in ||| 59 Tardive Dyskinesia : in ||| 0-0 0-1 0-2 2-2 1-3 2-4
Spätdyskinesien : in ||| 71 Tardive Dyskinesia : in ||| 0-0 0-1 0-2 2-2 1-3 2-4
Spätdyskinesien : in ||| Tardive Dyskinesia : in ||| 0-0 0-1 1-2 2-3
Spätdyskinesien : in ||| Tardive Dyskinesia : in ||| 0-0 0-1 2-1 1-2 2-3
Spätdyskinesien : ||| Tardive Dyskinesia : ||| 0-0 0-1 1-2
Spätdyskinesien ||| 83 Tardive ||| 0-0 0-1
Spätdyskinesien ||| Tardive Dyskinesia ||| 0-0 0-1
Squibb Srl Contrada Fontana Del ||| Squibb Srl Contrada Fontana Del ||| 0-0 1-1 2-2 3-3 4-4
Squibb Srl Contrada Fontana ||| Squibb Srl Contrada Fontana ||| 0-0 1-1 2-2 3-3
Squibb Srl Contrada ||| Squibb Srl Contrada ||| 0-0 1-1 2-2
Squibb Srl ||| Squibb Srl ||| 0-0 1-1
Squibb ||| Squibb ||| 0-0
Srl Contrada Fontana Del Ceraso ||| Srl Contrada Fontana Del Ceraso ||| 0-0 1-1 2-2 3-3 4-4
Srl Contrada Fontana Del ||| Srl Contrada Fontana Del ||| 0-0 1-1 2-2 3-3
Srl Contrada Fontana ||| Srl Contrada Fontana ||| 0-0 1-1 2-2
Srl Contrada ||| Srl Contrada ||| 0-0 1-1
Srl ||| Srl ||| 0-0
Stabilisierung führt ||| stability results in ||| 0-0 1-1 1-2
Stabilisierung ||| stability ||| 0-0
Stabilisierungsphase vor ||| stabilization phase prior to ||| 0-0 0-1 1-2 1-3
Stabilisierungsphase ||| stabilization phase ||| 0-0 0-1
Stabilität der rekonstituierten Suspension ||| Stability of the reconstituted suspension ||| 0-0 1-1 1-2 2-3 3-4
Stabilität der rekonstituierten ||| Stability of the reconstituted ||| 0-0 1-1 1-2 2-3
Stabilität der ||| Stability of the ||| 0-0 1-1 1-2
Stabilität ||| Stability ||| 0-0
Standard-Fertilitätsstudien ||| standard ||| 0-0
Standardbatterie von Untersuchungen zur ||| range of standard ||| 0-0 1-1 2-2 3-2
Standardbatterie von ||| range of ||| 0-0 1-1
Standardbatterie ||| range ||| 0-0
Standardbehandlung mit ||| standard treatment ||| 0-0 1-1
Standardbehandlung ||| standard ||| 0-0
Standardskala für ||| standard scale for ||| 0-0 0-1 1-2
Standardskala ||| standard scale ||| 0-0 0-1
Statale 17 , Km ||| Strada Statale 17 , Km ||| 0-0 0-1 1-2 2-3 3-4
Statale 17 , ||| Strada Statale 17 , ||| 0-0 0-1 1-2 2-3
Statale 17 ||| Strada Statale 17 ||| 0-0 0-1 1-2
Statale ||| Strada Statale ||| 0-0 0-1
Statine , Fibrate ) . ||| statins , fibrates ) . ||| 0-0 1-1 2-2 3-3 4-4
Statine , Fibrate ) ||| statins , fibrates ) ||| 0-0 1-1 2-2 3-3
Statine , Fibrate ||| statins , fibrates ||| 0-0 1-1 2-2
Statine , ||| statins , ||| 0-0 1-1
Statine ||| statins ||| 0-0
Stattdessen ist Paclitaxel in ||| Stattdessen ist Paclitaxel in ||| 0-0 0-1 1-1 2-2 3-3
Stattdessen ist Paclitaxel ||| Stattdessen ist Paclitaxel ||| 0-0 0-1 1-1 2-2
Stattdessen ist ||| Stattdessen ist ||| 0-0 0-1 1-1
Steady State ist bei Patienten ||| Steady State ist bei Patienten ||| 0-0 1-0 0-1 2-2 3-3 4-4
Steady State ist bei ||| Steady State ist bei ||| 0-0 1-0 0-1 2-2 3-3
Steady State ist ||| Steady State ist ||| 0-0 1-0 0-1 2-2
Steady State ||| Steady State ||| 0-0 1-0 0-1
Steady-State-Pharmakokinetik eines oralen Kontrazeptivums mit ||| Steady-State-Pharmakokinetik eines oralen Kontrazeptivums mit ||| 0-0 1-1 0-2 3-3 4-4
Steady-State-Pharmakokinetik eines oralen Kontrazeptivums ||| Steady-State-Pharmakokinetik eines oralen Kontrazeptivums ||| 0-0 1-1 0-2 3-3
Steady-State-Pharmakokinetik eines oralen ||| Steady-State-Pharmakokinetik eines oralen ||| 0-0 1-1 0-2
Steady-State-Pharmakokinetik eines ||| Steady-State-Pharmakokinetik eines oralen ||| 0-0 1-1 0-2
Stechen ||| Insert ||| 0-0
Stehen mit einem Stadiometer gemessen ||| measured annually using a stadiometer ||| 4-0 0-1 1-2 2-2 2-3 3-4 4-4
Stehen mit einem ||| annually using a ||| 0-0 1-1 2-1 2-2
Stehen ||| annually ||| 0-0
Steifheit ||| stiffness ||| 0-0
Steigerung ||| increasing ||| 0-0
Stelle ||| place ||| 0-0
Stenosen , Aneurysmen , etc ||| stenoses , aneurysms , etc. ||| 0-0 1-1 3-1 2-2 4-2 3-3 4-4
Stenosen ||| stenoses ||| 0-0
Sterblichkeit als ||| human ||| 0-0 1-0
Sterblichkeit der jungen Ratten wird ||| pup mortality ||| 1-0 2-0 3-0 0-1
Sterblichkeit der jungen Ratten ||| pup mortality ||| 1-0 2-0 3-0 0-1
Sterblichkeit ||| mortality ||| 0-0
Steroidgabe oder ||| pre- treatment or ||| 0-0 0-1 1-2
Steroidgabe ||| pre- treatment ||| 0-0 0-1
Stimmungslage . ||| flatness . ||| 0-0 1-1
Stimmungslage ||| flatness ||| 0-0
Stimmungsänderungen mit depressiven Symptomen ||| mood alterations with depressive symptoms ||| 2-0 2-1 1-2 0-3 2-3 3-4
Stimmungsänderungen mit depressiven ||| mood alterations with depressive ||| 2-0 2-1 1-2 0-3 2-3
Stoffen ||| compounds , ||| 0-0
Stoffen ||| compounds ||| 0-0
Stoffwechsel von Paclitaxel wird ||| metabolism of paclitaxel is ||| 0-0 1-1 2-2 3-3
Stoffwechsel von Paclitaxel ||| metabolism of paclitaxel ||| 0-0 1-1 2-2
Stoffwechsel von ||| metabolism of ||| 0-0 1-1
Stoffwechsel ||| metabolism ||| 0-0
Stoffwechsel- und ||| disorders : stomach discomfort , ||| 0-0 0-1 0-2 0-3 1-3 1-4
Stoffwechselerkrankungen behandelt ||| groups ||| 0-0
Stoffwechselerkrankungen ||| groups ||| 0-0
Stoffwechsels . ||| vitro . ||| 0-0 1-1
Stoffwechsels ||| vitro ||| 0-0
Stoffwechselumwandlung ist die Sulfoxidation ||| important metabolic transformation is sulphoxidation ||| 0-0 0-1 0-2 3-2 1-3 2-3 3-4
Stomatitis ( Entzündung ||| stomatitis ( inflammation of ||| 0-0 1-1 2-2
Stomatitis ( Entzündung ||| stomatitis ( inflammation ||| 0-0 1-1 2-2
Stomatitis ( ||| stomatitis ( ||| 0-0 1-1
Stomatitis ||| stomatitis ||| 0-0
Stopfen ( Butylkautschuk ||| ( butyl ||| 1-0 0-1 2-1
Storbritannia Tlf : + 44 ||| Storbritannia Tlf : + 44 ||| 0-0 1-1 2-2 3-3 4-4
Storbritannia Tlf : + ||| Storbritannia Tlf : + ||| 0-0 1-1 2-2 3-3
Storbritannia Tlf : ||| Storbritannia Tlf : ||| 0-0 1-1 2-2
Storbritannia Tlf ||| Storbritannia Tlf ||| 0-0 1-1
Storbritannia ||| Storbritannia ||| 0-0
Storbritannien Tel : + 44 ||| Storbritannien Tel : + 44 ||| 0-0 1-1 2-2 3-3 4-4
Storbritannien Tel : + ||| Storbritannien Tel : + ||| 0-0 1-1 2-2 3-3
Storbritannien Tel : ||| Storbritannien Tel : ||| 0-0 1-1 2-2
Storbritannien Tel ||| Storbritannien Tel ||| 0-0 1-1
Storbritannien Tlf : + 44 ||| Storbritannien Tlf : + 44 ||| 0-0 1-1 2-2 3-3 4-4
Storbritannien Tlf : + ||| Storbritannien Tlf : + ||| 0-0 1-1 2-2 3-3
Storbritannien Tlf : ||| Storbritannien Tlf : ||| 0-0 1-1 2-2
Storbritannien Tlf ||| Storbritannien Tlf ||| 0-0 1-1
Storbritannien ||| Storbritannien ||| 0-0
Straßenverkehr ||| ability ||| 0-0
Studie ( ||| study ( ||| 0-0 1-1
Studie ) mit Frauen mit ||| study ) in women with ||| 0-0 1-1 3-2 3-3 2-4 4-4
Studie ) ||| study ) ||| 0-0 1-1
Studie , ||| study , ||| 0-0 1-1
Studie , ||| study ||| 0-0
Studie . ||| study . ||| 0-0 1-1
Studie CZOL446M2308 ) ||| study CZOL446M2308 ) ||| 0-0 1-1 2-2
Studie CZOL446M2308 ||| study CZOL446M2308 ||| 0-0 1-1
Studie bei Männern ( Studie ||| study in men ( study ||| 0-0 1-1 2-2 3-3 4-4
Studie bei Männern ( ||| study in men ( ||| 0-0 1-1 2-2 3-3
Studie bei Männern ||| study in men ||| 0-0 1-1 2-2
Studie bei Osteoporose wiesen ||| in osteoporosis , ||| 0-0 1-0 2-1 3-2
Studie bei Osteoporose ||| in osteoporosis ||| 0-0 1-0 2-1
Studie bei ||| in ||| 0-0 1-0
Studie bei ||| study in ||| 0-0 1-1
Studie bei ||| was ||| 0-0 1-0
Studie betrug die Inzidenz von ||| trial , the incidence of ||| 0-0 1-0 2-2 3-3 4-4
Studie betrug die Inzidenz ||| trial , the incidence ||| 0-0 1-0 2-2 3-3
Studie betrug die ||| trial , the ||| 0-0 1-0 2-2
Studie betrug ||| trial , ||| 0-0 1-0
Studie betrug ||| trial ||| 0-0 1-0
Studie mit Patienten mit fortgeschrittenen ||| study in patients with advanced ||| 0-0 2-1 2-2 1-3 3-3 4-4
Studie mit Patienten mit ||| study in patients with ||| 0-0 2-1 2-2 1-3 3-3
Studie mit Pioglitazon versus Gliclazid ||| trial of pioglitazone vs. gliclazide ||| 0-0 1-1 2-2 3-3 4-4
Studie mit Pioglitazon versus ||| trial of pioglitazone vs. ||| 0-0 1-1 2-2 3-3
Studie mit Pioglitazon ||| trial of pioglitazone ||| 0-0 1-1 2-2
Studie mit fixer Dosierung , ||| fixed-dose trial , ||| 1-0 2-0 3-0 0-1 2-1 4-2
Studie mit fixer Dosierung ||| fixed-dose trial ||| 1-0 2-0 3-0 0-1
Studie mit fixer Dosierung ||| fixed-dose trial ||| 1-0 2-0 3-0 0-1 2-1
Studie mit gesunden Probanden steigerte ||| trial in healthy subjects , ||| 0-0 1-1 2-1 2-2 3-3 4-3 4-4
Studie mit gesunden ||| trial in healthy ||| 0-0 1-1 2-1 2-2
Studie mit ||| trial of ||| 0-0 1-1
Studie umfasste nur 3 Patienten ||| study included only 3 patients ||| 0-0 1-1 2-2 3-3 4-4
Studie umfasste nur 3 ||| study included only 3 ||| 0-0 1-1 2-2 3-3
Studie umfasste nur ||| study included only ||| 0-0 1-1 2-2
Studie umfasste ||| study included ||| 0-0 1-1
Studie war nicht dafür ausgelegt ||| study was not powered ||| 0-0 1-1 2-2 3-3 4-3
Studie war nicht ||| study was not ||| 0-0 1-1 2-2
Studie war ||| study was ||| 0-0 1-1
Studie wurde ||| trial was ||| 0-0 1-1
Studie ||| at study ||| 0-1
Studie ||| study ||| 0-0
Studie ||| trial , ||| 0-0
Studie ||| trial ||| 0-0
Studie über ||| study of ||| 0-0 1-0 1-1
Studien ( n= 938 , ||| trials ( n= 938 ; ||| 0-0 1-1 3-2 2-3 3-3 3-4
Studien ( n= 938 ||| trials ( n= 938 ; ||| 0-0 1-1 3-2 2-3 3-3 3-4
Studien ( ||| trials ( ||| 0-0 1-1
Studien , die ein Jahr ||| trials of one year ||| 0-0 2-1 3-2 4-2 4-3
Studien , die ein Jahr ||| trials of one year ||| 0-0 2-1 4-2 3-3 4-3
Studien , die ||| trials of ||| 0-0 2-1
Studien , eine ||| trials , a ||| 0-0 1-1 2-2
Studien , in denen ||| trials in which ||| 0-0 2-1 1-2 3-2
Studien , ||| trials , ||| 0-0 1-1
Studien , ||| trials ||| 0-0
Studien befassten sich mit der ||| studies also looked at ||| 0-0 1-1 1-2 2-2 3-3 4-3
Studien befassten sich ||| studies also looked ||| 0-0 1-1 1-2 2-2
Studien bei Schwangeren vor . ||| studies in pregnant women . ||| 0-0 1-1 2-2 2-3 3-3 4-4
Studien bei Schwangeren vor ||| studies in pregnant women ||| 0-0 1-1 2-2 2-3 3-3
Studien bei anderen Indikationen ||| studies for other indications ||| 0-0 1-1 2-2 3-3
Studien bei anderen ||| studies for other ||| 0-0 1-1 2-2
Studien bei ||| Studien bei ||| 0-0 1-1
Studien bei ||| studies for ||| 0-0 1-1
Studien bei ||| studies in ||| 0-0 1-1
Studien beinhalteten Patienten mit oder ||| trials included patients with or ||| 0-0 1-1 2-2 3-3 4-4
Studien beinhalteten Patienten mit ||| trials included patients with ||| 0-0 1-1 2-2 3-3
Studien beinhalteten Patienten ||| trials included patients ||| 0-0 1-1 2-2
Studien beinhalteten ||| trials included ||| 0-0 1-1
Studien beobachtet . ||| studies . ||| 0-0 1-0 2-1
Studien beobachtet ||| studies ||| 0-0 1-0
Studien beobachtet ||| trials that ||| 0-0 1-0 1-1
Studien betrug die Inzidenz von ||| trials , the incidence of ||| 0-0 1-1 2-2 1-3 3-3 4-4
Studien betrug die Inzidenz von ||| trials , the incidence of ||| 0-0 2-2 1-3 2-3 3-3 4-4
Studien betrug die Inzidenz ||| trials , the incidence ||| 0-0 1-1 2-2 1-3 3-3
Studien betrug die Inzidenz ||| trials , the incidence ||| 0-0 2-2 1-3 2-3 3-3
Studien gezeigt ? ||| studies ? ||| 0-0 1-1 2-1
Studien gezeigt ? ||| the studies ? ||| 0-1 1-2 2-2
Studien haben ||| trials have ||| 0-0 1-1
Studien hat Aripiprazol nicht ||| trials aripiprazole has not been ||| 0-0 2-1 1-2 3-3 3-4
Studien hat Aripiprazol ||| trials aripiprazole has ||| 0-0 2-1 1-2
Studien in vitro konnten ||| vitro studies ||| 1-0 2-0 0-1 3-1
Studien mit Aripiprazol , ||| trials with aripiprazole , ||| 0-0 1-1 2-2 3-3
Studien mit Aripiprazol bei schwangeren ||| trials of aripiprazole in pregnant ||| 0-0 1-1 2-2 3-3 4-4
Studien mit Aripiprazol bei ||| trials of aripiprazole in ||| 0-0 1-1 2-2 3-3
Studien mit Aripiprazol ||| trials of aripiprazole , ||| 0-0 1-2 2-2
Studien mit Aripiprazol ||| trials of aripiprazole ||| 0-0 1-1 2-2
Studien mit Aripiprazol ||| trials of aripiprazole ||| 0-0 1-2 2-2
Studien mit Aripiprazol ||| trials with aripiprazole ||| 0-0 1-1 2-2
Studien mit Einmalgabe und Mehrfachgabe ||| and repeat-dose studies , the ||| 3-0 2-1 3-1 4-1 0-2
Studien mit Einmalgabe und Mehrfachgabe ||| and repeat-dose studies , ||| 3-0 2-1 3-1 4-1 0-2
Studien mit Einmalgabe und Mehrfachgabe ||| and repeat-dose studies ||| 3-0 2-1 3-1 4-1 0-2
Studien mit Pioglitazon wurde ||| trials with pioglitazone there was ||| 0-0 1-1 2-2 3-3 3-4
Studien mit Pioglitazon ||| trials with pioglitazone ||| 0-0 1-1 2-2
Studien mit gesunden Probanden ||| studies in healthy subjects ||| 0-0 1-1 2-1 2-2 3-3
Studien mit gesunden ||| studies in healthy ||| 0-0 1-1 2-1 2-2
Studien mit intravenösen Bolus-Verabreichungen ||| intravenous bolus studies , ||| 2-0 3-1 0-2
Studien mit intravenösen Bolus-Verabreichungen ||| intravenous bolus studies ||| 2-0 3-1 0-2
Studien mit intravenösen Bolus-Verabreichungen ||| the intravenous bolus studies , ||| 2-1 3-2 0-3
Studien mit intravenösen Bolus-Verabreichungen ||| the intravenous bolus studies ||| 2-1 3-2 0-3
Studien mit oral ||| trials with oral ||| 0-0 1-1 2-2
Studien mit ||| excluded in the studies for ||| 0-1 1-1 0-3
Studien mit ||| excluded in the studies ||| 0-1 1-1 0-3
Studien mit ||| in the studies for ||| 0-0 1-0 0-2
Studien mit ||| in the studies ||| 0-0 1-0 0-2
Studien mit ||| studies , the ||| 0-0
Studien mit ||| studies , ||| 0-0
Studien mit ||| studies ||| 0-0
Studien mit ||| trials of ||| 0-0 1-1
Studien mit ||| trials with ||| 0-0 1-1
Studien sowie ||| trials and ||| 0-0 1-0 1-1
Studien trat unter Aripiprazol ||| trials aripiprazole has not been ||| 0-0 3-1 1-2 1-3 2-4
Studien und 8167 Patienten ) ||| trials and 8167 patients ) ||| 0-0 1-1 2-2 3-3 4-4
Studien und 8167 Patienten ||| trials and 8167 patients ||| 0-0 1-1 2-2 3-3
Studien und 8167 ||| trials and 8167 ||| 0-0 1-1 2-2
Studien und seit der Markteinführung ||| trials and post-marketing experience ||| 0-0 1-1 2-2 4-2 2-3
Studien und zusätzlichen ||| studies and additional ||| 0-0 1-1 2-2
Studien und ||| studies and ||| 0-0 1-1
Studien und ||| trials and ||| 0-0 1-1
Studien war die ||| studies , the patients were ||| 0-0 2-2 1-3 1-4
Studien wurde bei Anwendung von ||| studies , use of ||| 0-0 1-0 2-2 3-2 4-3
Studien wurde bei Anwendung ||| studies , use ||| 0-0 1-0 2-2 3-2
Studien wurde nachgewiesen , dass ||| studies demonstrated that ||| 0-0 1-1 2-1 3-2 4-2
Studien wurde nachgewiesen ||| studies demonstrated ||| 0-0 1-1 2-1
Studien wurde unter ||| studies , ||| 0-0 1-0
Studien wurde unter ||| studies ||| 0-0 1-0
Studien wurde ||| studies , ||| 0-0 1-0
Studien wurde ||| studies looked ||| 0-0 1-1
Studien wurde ||| studies ||| 0-0 1-0
Studien wurden ein erhöhtes ||| trials , an increased ||| 0-0 1-0 1-1 2-2 3-3
Studien wurden ein ||| trials , an ||| 0-0 1-0 1-1 2-2
Studien wurden gelegentlich Fälle von ||| trials , uncommon cases of ||| 0-0 1-1 1-2 2-2 3-3 4-4
Studien wurden gelegentlich Fälle ||| trials , uncommon cases ||| 0-0 1-1 1-2 2-2 3-3
Studien wurden gelegentlich ||| trials , uncommon ||| 0-0 1-1 1-2 2-2
Studien wurden seltene Fälle von ||| trials , rare cases of ||| 0-0 1-0 1-1 2-2 3-3 4-4
Studien wurden seltene Fälle ||| trials , rare cases ||| 0-0 1-0 1-1 2-2 3-3
Studien wurden seltene ||| trials , rare ||| 0-0 1-0 1-1 2-2
Studien wurden unerwünschte zerebrovaskuläre Ereignisse ||| trials , cerebrovascular adverse events ||| 0-0 1-1 2-2 3-2 1-3 2-3 4-4
Studien wurden unerwünschte zerebrovaskuläre ||| trials , cerebrovascular adverse ||| 0-0 1-1 2-2 3-2 1-3 2-3
Studien wurden ||| trials , ||| 0-0 1-0
Studien wurden ||| trials , ||| 0-0 1-0 1-1
Studien wurden ||| trials ||| 0-0 1-0
Studien zur ||| studies ||| 0-0 1-0
Studien ||| Studien ||| 0-0
Studien ||| Studies ||| 0-0
Studien ||| The studies ||| 0-1
Studien ||| studies , the ||| 0-0
Studien ||| studies , where ||| 0-0
Studien ||| studies , ||| 0-0
Studien ||| studies ||| 0-0
Studien ||| the studies ||| 0-1
Studien ||| trials , ||| 0-0
Studien ||| trials in ||| 0-0
Studien ||| trials of ||| 0-0
Studien ||| trials ||| 0-0
Studienarzneimittel als Zweitlinien-Therapie oder in ||| as second or greater than ||| 1-0 0-1 2-1 3-2 1-3 1-4
Studienarzneimittel als Zweitlinien-Therapie oder ||| as second or greater than ||| 1-0 0-1 2-1 3-2 1-3 1-4
Studienlänge : ||| study duration : ||| 0-0 0-1 1-2
Studienlänge ||| study duration ||| 0-0 0-1
Studienpopulation hatte ein ||| study population had an ||| 0-0 0-1 1-2 2-3
Studienpopulation hatte ||| study population had ||| 0-0 0-1 1-2
Studienpopulation waren Frauen , 87 ||| population were women , 87 ||| 0-0 1-1 2-2 3-3 4-4
Studienpopulation waren Frauen , ||| population were women , ||| 0-0 1-1 2-2 3-3
Studienpopulation waren Frauen ||| population were women ||| 0-0 1-1 2-2
Studienpopulation waren ||| population were ||| 0-0 1-1
Studienpopulation wies ||| study population had ||| 0-0 0-1 1-1 0-2
Studienpopulation ||| population ||| 0-0
Studienpopulation ||| study population ||| 0-0 0-1
Stuhl , ||| loose stools , ||| 1-0 0-1 1-2
Stuhl , Ösophagitis ||| loose stools , oesophagitis ||| 1-0 0-1 1-2 2-3
Stuhl ||| stools ||| 0-0
Stunde , ||| hour , ||| 0-0 1-1
Stunde ||| hour ||| 0-0
Stunden , und die der ||| to 6 hours and ||| 1-0 3-0 0-1 0-2 2-3
Stunden , und die ||| to 6 hours and ||| 1-0 3-0 0-1 0-2 2-3
Stunden . ||| hours . ||| 0-0 1-1
Stunden bei ||| hours in ||| 0-0 1-1
Stunden nach Anwendung ||| hours after administration ||| 0-0 1-1 2-2
Stunden nach der ersten Gabe ||| hours after the first ||| 0-0 1-1 2-2 3-3 4-3
Stunden nach der ||| hours after the ||| 0-0 1-1 2-2
Stunden nach subkutaner Injektion erreicht ||| hours after subcutaneous administration ||| 0-0 1-1 2-2 3-2 2-3 4-3
Stunden nach ||| hours after an ||| 0-0 1-1
Stunden nach ||| hours after ||| 0-0 1-1
Stunden wurde ||| hours has been ||| 0-0 1-1 1-2
Stunden ||| 6 hours ||| 0-0 0-1
Stunden ||| hours in ||| 0-0
Stunden ||| hours ||| 0-0
Stärke ||| injection route ||| 0-0 0-1
Stärke ||| strength ||| 0-0
Störung , Akathisie , Tremor ||| disorder , akathisia , tremor ||| 0-0 1-1 2-2 3-3 4-4
Störung , Akathisie , ||| disorder , akathisia , ||| 0-0 1-1 2-2 3-3
Störung , Akathisie , ||| disorder , akathisia ||| 0-0 1-1 3-1 2-2
Störung , Akathisie ||| disorder , akathisia ||| 0-0 1-1 2-2
Störung , Somnolenz . ||| disturbance , somnolence . ||| 1-0 1-1 0-2 2-2 3-3
Störung , Somnolenz ||| disturbance , somnolence ||| 1-0 1-1 0-2 2-2
Störung , ||| disorder , ||| 0-0 1-1
Störung , ||| disorder ||| 0-0
Störung der Temperaturregulation ( ||| temperature regulation disorder ( ||| 2-0 0-1 1-1 2-1 2-2 3-3
Störung der Temperaturregulation ||| temperature regulation disorder ||| 2-0 0-1 1-1 2-1 2-2
Störung eine ||| disorder ||| 0-0
Störung oder ||| bipolar disorder or ||| 0-0 0-1 1-2
Störung wurden acht ||| disorder , there were eight ||| 0-0 1-1 1-2 1-3 2-4
Störung wurden ||| disorder , there were ||| 0-0 1-1 1-2 1-3
Störung ||| Störung ||| 0-0
Störung ||| bipolar disorder ||| 0-0 0-1
Störung ||| disorder ||| 0-0
Störungen , angioneurotisches ||| oedema , difficulties in ||| 0-0 1-1 0-2 2-2 0-3
Störungen auf . ||| . ||| 2-0
Störungen der intrauterinen ||| exclude potential ||| 0-0 1-0 2-0 2-1
Störungen der ||| disturbances in ||| 0-0 0-1 1-1
Störungen des Knochenstoffwechsels müssen ||| disturbances of mineral metabolism must ||| 0-0 1-1 2-2 2-3 3-4
Störungen des Knochenstoffwechsels ||| disturbances of mineral metabolism ||| 0-0 1-1 2-2 2-3
Störungen des ||| disturbances of ||| 0-0 1-1
Störungen ||| and ||| 0-0
Störungen ||| disturbances ||| 0-0
Subchronische und chronische ||| Subchronic and ||| 0-0 2-0 1-1
Subkutane Injektion : ein ||| Subcutaneous injection : a ||| 0-0 1-1 2-2 3-3
Subkutane Injektion : ||| Subcutaneous injection : ||| 0-0 1-1 2-2
Subkutane Injektion ||| Subcutaneous injection ||| 0-0 1-1
Subkutane ||| Subcutaneous ||| 0-0
Substanz widerspiegelt ||| antiresorptive ||| 0-0 1-0
Substanzen ( Lösungsmittel ) ||| substances ( solvents ) ||| 0-0 1-1 2-1 0-2 3-3
Substanzen ( Lösungsmittel ||| substances ( solvents ||| 0-0 1-1 2-1 0-2
Substanzen ||| of substances ||| 0-1
Substanzen ||| substances ||| 0-0
Substrat für das P-Glycoprotein . ||| substrate of P-glycoprotein . ||| 0-0 1-1 2-1 3-2 4-3
Substrat für das P-Glycoprotein ||| substrate of P-glycoprotein ||| 0-0 1-1 2-1 3-2
Substrat für das ||| substrate of ||| 0-0 1-1 2-1
Substrat ||| substrate ||| 0-0
Sucrase-Isomaltase-Insuffizienz sollten ||| sucrase-isomaltase insufficiency should ||| 0-0 0-1 1-2
Sucrase-Isomaltase-Insuffizienz ||| sucrase-isomaltase insufficiency ||| 0-0 0-1
Sucrose , gereinigtes Wasser ||| sucrose , purified water , ||| 0-0 1-1 1-2 3-3 1-4 2-4
Sucrose . ||| of sucrose . ||| 0-1 1-2
Sucrose . ||| sucrose . ||| 0-0 1-1
Sucrose Gereinigtes Wasser ||| Sucrose Purified water ||| 0-0 1-1 2-2
Sucrose Gereinigtes ||| Sucrose Purified ||| 0-0 1-1
Sucrose je ml 1,8 mg ||| sucrose per ml 1.8 mg ||| 0-0 1-1 2-2 3-3 4-4
Sucrose je ml 1,8 ||| sucrose per ml 1.8 ||| 0-0 1-1 2-2 3-3
Sucrose je ml ||| sucrose per ml ||| 0-0 1-1 2-2
Sucrose je ||| sucrose per ||| 0-0 1-1
Sucrose ||| Sucrose ||| 0-0
Sucrose ||| of sucrose ||| 0-1
Sucrose ||| sucrose ||| 0-0
Suizidgedanken , Selbstverletzung und Suizid ||| depressive disorders ||| 0-0 2-0 4-0 2-1 3-1
Suizidgedanken , und ||| suicidal ideation , and ||| 0-0 0-1 1-1 1-2 2-3
Suizidgedanken , ||| suicidal ideation , ||| 0-0 0-1 1-1 1-2
Suizidgedanken bei ||| and suicidal ideation in ||| 0-1 0-2 1-3
Suizidgedanken bei ||| suicidal ideation in ||| 0-0 0-1 1-2
Suizidgedanken ||| and suicidal ideation ||| 0-1 0-2
Suizidgedanken ||| suicidal ideation ||| 0-0 0-1
Sulfonamide . ||| sulphonamides . ||| 0-0 1-1
Sulfonamide ||| sulphonamides ||| 0-0
Sulfonylharnstoff ||| sulphonylurea ||| 0-0
Sulfonylharnstoffe , Insulin , Metformin ||| sulphonylureas , insulin , metformin ||| 0-0 1-1 2-2 3-3 4-4
Sulfonylharnstoffe , Insulin , ||| sulphonylureas , insulin , ||| 0-0 1-1 2-2 3-3
Sulfonylharnstoffe , Insulin ||| sulphonylureas , insulin ||| 0-0 1-1 2-2
Sulfonylharnstoffe , ||| sulphonylureas , ||| 0-0 1-1
Sulfonylharnstoffe ||| sulphonylureas ||| 0-0
Sulfonylharnstoffen oder Insulin auftreten . ||| sulphonylureas or insulin . ||| 0-0 1-1 2-2 3-2 4-3
Sulfonylharnstoffen oder Insulin auftreten ||| sulphonylureas or insulin ||| 0-0 1-1 2-2 3-2
Sulfonylharnstoffen oder ||| sulphonylureas or ||| 0-0 1-1
Sulfonylharnstoffen ||| sulphonylureas ||| 0-0
Sulfonylharnstoffs ||| sulphonylurea ||| 0-0
Suomi/Finland Novartis Finland Oy ||| Suomi/ Finland Novartis Finland Oy ||| 0-0 2-1 1-2 2-3 3-4
Suomi/Finland Novartis Finland ||| Suomi/ Finland Novartis Finland ||| 0-0 2-1 1-2 2-3
Suomi/Finland OY BRISTOL-MYERS SQUIBB ||| Suomi/ Finland OY BRISTOL-MYERS SQUIBB ||| 0-0 1-1 1-2 2-3 3-4
Suomi/Finland OY BRISTOL-MYERS ||| Suomi/ Finland OY BRISTOL-MYERS ||| 0-0 1-1 1-2 2-3
Suomi/Finland OY ||| Suomi/ Finland OY ||| 0-0 1-1 1-2
Suomi/Finland Oy Eli Lilly ||| Suomi/ Finland Oy Eli Lilly ||| 0-0 1-1 1-2 2-3 3-4
Suomi/Finland Oy Eli ||| Suomi/ Finland Oy Eli ||| 0-0 1-1 1-2 2-3
Suomi/Finland Oy ||| Suomi/ Finland Oy ||| 0-0 1-1 1-2
Suomi/Finland ||| Suomi/ ||| 0-0
Suspension getrunken werden . ||| resulting suspension . ||| 1-0 0-1 2-2 3-2
Suspension getrunken ||| resulting suspension ||| 1-0 0-1
Suspension hat einen pH-Wert von ||| suspension has a pH of ||| 0-0 1-1 2-2 3-3 4-4
Suspension hat einen pH-Wert ||| suspension has a pH ||| 0-0 1-1 2-2 3-3
Suspension hat einen ||| suspension has a ||| 0-0 1-1 2-2
Suspension hat ||| suspension has ||| 0-0 1-1
Suspension im Infusionsbeutel ||| suspension in the infusion bag ||| 0-0 1-1 1-2 2-3 2-4
Suspension im ||| suspension in the ||| 0-0 1-1 1-2
Suspension ist möglich . ||| suspension may occur . ||| 0-0 2-1 3-3
Suspension ist möglich ||| suspension may occur ||| 0-0 2-1
Suspension ist möglich ||| suspension may ||| 0-0 2-1
Suspension ist ||| suspension ||| 0-0
Suspension mit der ||| suspension contacts the ||| 0-0 0-1 1-1 2-2
Suspension mit ||| suspension contacts ||| 0-0 0-1 1-1
Suspension trinken . ||| resulting suspension . ||| 1-0 0-1 1-1 2-2
Suspension trinken ||| resulting suspension ||| 1-0 0-1 1-1
Suspension ||| suspension ||| 0-0
Sussex , RH12 5AB Vereinigtes ||| Sussex , RH12 5AB United ||| 0-0 1-1 2-2 3-3 4-4
Sussex , RH12 5AB ||| Sussex , RH12 5AB ||| 0-0 1-1 2-2 3-3
Sussex , RH12 ||| Sussex , RH12 ||| 0-0 1-1 2-2
Sussex , ||| Sussex , ||| 0-0 1-1
Sussex ||| Sussex ||| 0-0
Sverige AB Tel : +46 ||| Sverige AB Tel : +46 ||| 0-0 1-1 2-2 3-3 4-4
Sverige AB Tel : ||| Sverige AB Tel : ||| 0-0 1-1 2-2 3-3
Sverige AB Tel ||| Sverige AB Tel ||| 0-0 1-1 2-2
Sverige AB ||| Sverige AB ||| 0-0 1-1
Sverige BRISTOL-MYERS SQUIBB AB Tel ||| Sverige BRISTOL-MYERS SQUIBB AB Tel ||| 0-0 1-1 2-2 3-3 4-4
Sverige BRISTOL-MYERS SQUIBB AB ||| Sverige BRISTOL-MYERS SQUIBB AB ||| 0-0 1-1 2-2 3-3
Sverige BRISTOL-MYERS SQUIBB ||| Sverige BRISTOL-MYERS SQUIBB ||| 0-0 1-1 2-2
Sverige BRISTOL-MYERS ||| Sverige BRISTOL-MYERS ||| 0-0 1-1
Sverige Novartis Sverige AB Tel ||| Sverige Novartis Sverige AB Tel ||| 0-0 1-1 2-2 3-3 4-4
Sverige Novartis Sverige AB ||| Sverige Novartis Sverige AB ||| 0-0 1-1 2-2 3-3
Sverige Novartis Sverige ||| Sverige Novartis Sverige ||| 0-0 1-1 2-2
Sverige Novartis ||| Sverige Novartis ||| 0-0 1-1
Sverige Takeda Global R & ||| Sverige Takeda Global R & ||| 0-0 1-1 2-2 3-3 4-4
Sverige Takeda Global R ||| Sverige Takeda Global R ||| 0-0 1-1 2-2 3-3
Sverige Takeda Global ||| Sverige Takeda Global ||| 0-0 1-1 2-2
Sverige Takeda ||| Sverige Takeda ||| 0-0 1-1
Sverige ||| Sverige ||| 0-0
Symptome , Notfallmaßnahmen , ||| symptoms , emergency procedures , ||| 0-0 1-1 2-2 2-3 3-4
Symptome , Notfallmaßnahmen ||| symptoms , emergency procedures ||| 0-0 1-1 2-2 2-3
Symptome , welche innerhalb der ||| post-dose symptoms occurring within the ||| 2-0 0-1 2-1 3-2 3-3 4-4
Symptome , welche innerhalb ||| post-dose symptoms occurring within ||| 2-0 0-1 2-1 3-2 3-3
Symptome , welche ||| post-dose symptoms ||| 2-0 0-1 2-1
Symptome , ||| symptoms , ||| 0-0 1-1
Symptome . ||| symptoms . ||| 0-0 1-1
Symptome auf . ||| symptoms . ||| 0-0 1-0 2-1
Symptome auf ||| symptoms ||| 0-0 1-0
Symptome bei sich ||| symptoms ||| 0-0 1-0
Symptome bei ||| such symptoms ||| 0-0 0-1
Symptome bei ||| symptoms ||| 0-0 1-0
Symptome die berichtet ||| symptoms reported ||| 0-0 1-0 2-1
Symptome die ||| symptoms ||| 0-0 1-0
Symptome einer Herzinsuffizienz , ||| symptoms of heart failure , ||| 0-0 1-1 2-2 2-3 3-4
Symptome einer Herzinsuffizienz ||| symptoms of heart failure ||| 0-0 1-1 2-2 2-3
Symptome einer Hyperglykämie ( ||| symptoms of hyperglycaemia ( ||| 0-0 1-1 2-2 3-3
Symptome einer Hyperglykämie ||| symptoms of hyperglycaemia ||| 0-0 1-1 2-2
Symptome einer ||| symptoms of ||| 0-0 1-1
Symptome erstmals bei ||| time ||| 0-0 1-0
Symptome erstmals ||| time ||| 0-0 1-0
Symptome gesteigerter Unruhe als die ||| in symptoms of agitation than ||| 0-1 4-1 1-3 2-3 3-4
Symptome gesteigerter Unruhe als die ||| symptoms of agitation than ||| 0-0 4-0 1-2 2-2 3-3
Symptome gesteigerter Unruhe und ||| symptoms of agitation , and ||| 0-0 2-1 1-2 2-2 3-4
Symptome gesteigerter Unruhe ||| symptoms of agitation , ||| 0-0 2-1 1-2 2-2
Symptome gesteigerter Unruhe ||| symptoms of agitation ||| 0-0 2-1 1-2 2-2
Symptome ist weniger häufig . ||| symptoms is less common . ||| 0-0 1-1 2-2 3-3 4-4
Symptome ist weniger häufig ||| symptoms is less common ||| 0-0 1-1 2-2 3-3
Symptome ist weniger ||| symptoms is less ||| 0-0 1-1 2-2
Symptome ist ||| symptoms is ||| 0-0 1-1
Symptome nahm ||| symptoms decreased ||| 0-0 1-1
Symptome sind ||| symptoms are ||| 0-0 1-1
Symptome sind üblicherweise leicht bis ||| symptoms are usually mild to ||| 0-0 1-1 2-2 3-3 4-3 4-4
Symptome sind üblicherweise ||| symptoms are usually ||| 0-0 1-1 2-2
Symptome war ||| symptoms were ||| 0-0 1-1
Symptome wie ||| symptoms , such as ||| 0-0 1-2 1-3
Symptome ||| not ||| 0-0
Symptome ||| such symptoms ||| 0-0 0-1
Symptome ||| symptoms , ||| 0-0
Symptome ||| symptoms of ||| 0-0
Symptome ||| symptoms ||| 0-0
Symptome über 3 Wochen . ||| symptoms over 3 weeks . ||| 0-0 1-1 2-2 3-3 4-4
Symptome über 3 Wochen ||| symptoms over 3 weeks ||| 0-0 1-1 2-2 3-3
Symptome über 3 ||| symptoms over 3 ||| 0-0 1-1 2-2
Symptome über ||| symptoms over ||| 0-0 1-1
Symptomen kann auftreten . ||| symptoms can occur . ||| 0-0 1-1 2-2 3-3
Symptomen kann auftreten ||| symptoms can occur ||| 0-0 1-1 2-2
Symptomen kann ||| symptoms can ||| 0-0 1-1
Symptomen wurden ||| symptoms have been ||| 0-0 1-1 1-2
Symptomen ||| symptoms of ||| 0-0
Symptomen ||| symptoms ||| 0-0
Synkope , posturaler Schwindel , ||| syncope , postural dizziness , ||| 0-0 1-1 2-2 3-3 4-4
Synkope , posturaler Schwindel ||| syncope , postural dizziness ||| 0-0 1-1 2-2 3-3
Synkope , posturaler ||| syncope , postural ||| 0-0 1-1 2-2
Synkope , ||| syncope , ||| 0-0 1-1
Synkope ||| syncope ||| 0-0
Systemische Chemotherapie führt bei ||| CNS metastases are ||| 0-0 0-1 1-1 2-1 3-2
Systemische Chemotherapie führt ||| CNS metastases ||| 0-0 0-1 1-1 2-1
Säugerzellen bzw. im ||| culture mutagenicity tests and ||| 0-0 0-1 1-1 2-1 0-2 1-3
Sími : + 354 535 ||| Sími : + 354 535 ||| 0-0 1-1 2-2 3-3 4-4
Sími : + 354 ||| Sími : + 354 ||| 0-0 1-1 2-2 3-3
Sími : + ||| Sími : + ||| 0-0 1-1 2-2
Sími : ||| Sími : ||| 0-0 1-1
Sími ||| Sími ||| 0-0
TABLETTEN ) ||| TABLETS ONLY ) ||| 0-0 0-1 1-2
TABLETTEN ||| TABLETS ONLY ||| 0-0 0-1
TIERART , ART UND ||| SPECIES , ROUTE(S ) AND ||| 0-0 1-1 2-2 2-3 3-4
TIERART , ART ||| SPECIES , ROUTE(S ) ||| 0-0 1-1 2-2 2-3
TIERART , ||| SPECIES , ||| 0-0 1-1
TIERART ||| SPECIES ||| 0-0
TIERE " SOWIE ||| ANIMAL TREATMENT ONLY AND ||| 0-0 0-1 1-1 2-1 0-2 2-3
TVEs in der Anamnese ( ||| prior history of TVEs ( ||| 0-0 1-1 3-1 2-2 0-3 4-4
TVEs in der Anamnese ||| prior history of TVEs ||| 0-0 1-1 3-1 2-2 0-3
Tabelle 1 sind ||| Table 1 lists ||| 0-0 1-1 0-2
Tabelle 1 ||| Table 1 lists ||| 0-0 1-1 0-2
Tabelle 1 ||| table 1 ||| 0-0 1-1
Tabelle 2 ) . ||| Table 2 ) . ||| 0-0 1-1 2-2 3-3
Tabelle 2 ) ||| Table 2 ) ||| 0-0 1-1 2-2
Tabelle 2 ||| 2 ||| 0-0 1-0
Tabelle 2 ||| Table 2 ||| 0-0 1-1
Tabelle ||| Table ||| 0-0
Tabelle ||| table ||| 0-0
Tablette ; die systemische Exposition ||| tablet ; systemic exposure ||| 0-0 1-1 3-2 4-3
Tablette ; die systemische ||| tablet ; systemic ||| 0-0 1-1 3-2
Tablette ; die ||| tablet ; ||| 0-0 1-1
Tablette ; ||| tablet ; ||| 0-0 1-1
Tablette Rechteckig und blau , ||| Tablet Rectangular and blue , ||| 0-0 1-0 1-1 2-2 3-3 4-4
Tablette Rechteckig und blau ||| Tablet Rectangular and blue ||| 0-0 1-0 1-1 2-2 3-3
Tablette Rechteckig und rosafarben , ||| Tablet Rectangular and pink , ||| 0-0 1-0 1-1 2-2 3-3 4-4
Tablette Rechteckig und rosafarben ||| Tablet Rectangular and pink ||| 0-0 1-0 1-1 2-2 3-3
Tablette Rechteckig und ||| Tablet Rectangular and ||| 0-0 1-0 1-1 2-2
Tablette Rechteckig ||| Tablet Rectangular ||| 0-0 1-0 1-1
Tablette Rund und gelb , ||| Tablet Round and yellow , ||| 0-0 1-0 1-1 2-2 3-3 4-4
Tablette Rund und gelb ||| Tablet Round and yellow ||| 0-0 1-0 1-1 2-2 3-3
Tablette Rund und rosafarben , ||| Tablet Round and pink , ||| 0-0 1-0 1-1 2-2 3-3 4-4
Tablette Rund und rosafarben ||| Tablet Round and pink ||| 0-0 1-0 1-1 2-2 3-3
Tablette Rund und ||| Tablet Round and ||| 0-0 1-0 1-1 2-2
Tablette Rund ||| Tablet Round ||| 0-0 1-0 1-1
Tablette enthält 15 mg Pioglitazon ||| tablet contains 15 mg pioglitazone ||| 0-0 1-1 2-2 3-3 4-4
Tablette enthält 15 mg Pioglitazon ||| tablet contains 15mg of pioglitazone ||| 0-0 1-1 2-2 3-2 4-4
Tablette enthält 15 mg ||| tablet contains 15 mg of ||| 0-0 1-1 2-2 3-3
Tablette enthält 15 mg ||| tablet contains 15 mg ||| 0-0 1-1 2-2 3-3
Tablette enthält 15 mg ||| tablet contains 15mg of ||| 0-0 1-1 2-2 3-2
Tablette enthält 15 mg ||| tablet contains 15mg ||| 0-0 1-1 2-2 3-2
Tablette enthält 15 ||| tablet contains 15 ||| 0-0 1-1 2-2
Tablette enthält 30 mg Pioglitazon ||| tablet contains 30 mg pioglitazone ||| 0-0 1-1 2-2 3-3 4-4
Tablette enthält 30 mg Pioglitazon ||| tablet contains 30mg of pioglitazone ||| 0-0 1-1 2-2 3-2 4-4
Tablette enthält 30 mg ||| tablet contains 30 mg of ||| 0-0 1-1 2-2 3-3
Tablette enthält 30 mg ||| tablet contains 30 mg ||| 0-0 1-1 2-2 3-3
Tablette enthält 30 mg ||| tablet contains 30mg of ||| 0-0 1-1 2-2 3-2
Tablette enthält 30 mg ||| tablet contains 30mg ||| 0-0 1-1 2-2 3-2
Tablette enthält 30 ||| tablet contains 30 ||| 0-0 1-1 2-2
Tablette enthält 45 mg Pioglitazon ||| tablet contains 45 mg pioglitazone ||| 0-0 1-1 2-2 3-3 4-4
Tablette enthält 45 mg Pioglitazon ||| tablet contains 45mg of pioglitazone ||| 0-0 1-1 2-2 3-2 4-4
Tablette enthält 45 mg ||| tablet contains 45 mg of ||| 0-0 1-1 2-2 3-3
Tablette enthält 45 mg ||| tablet contains 45 mg ||| 0-0 1-1 2-2 3-3
Tablette enthält 45 mg ||| tablet contains 45mg of ||| 0-0 1-1 2-2 3-2
Tablette enthält 45 mg ||| tablet contains 45mg ||| 0-0 1-1 2-2 3-2
Tablette enthält 45 ||| tablet contains 45 ||| 0-0 1-1 2-2
Tablette enthält ||| tablet contains ||| 0-0 1-1
Tablette immer mit Wasser ||| tablet with water ||| 0-0 1-0 2-1 3-2
Tablette immer mit ||| tablet with ||| 0-0 1-0 2-1
Tablette immer ||| tablet ||| 0-0 1-0
Tablette jeden Tag zur gleichen ||| tablet at the same ||| 0-0 1-0 1-1 1-2 2-3 3-3 4-3
Tablette jeden ||| tablet at the ||| 0-0 1-0 1-1 1-2
Tablette separat ||| blisters ||| 0-0 1-0
Tablette ||| tablet ||| 0-0
Tabletten , als 10 mg ||| tablets , as 10 mg ||| 0-0 1-1 2-2 3-3 4-4
Tabletten , als 10 ||| tablets , as 10 ||| 0-0 1-1 2-2 3-3
Tabletten , als ||| tablets , as ||| 0-0 1-1 2-2
Tabletten , ||| tablets , ||| 0-0 1-1
Tabletten . ||| tablets . ||| 0-0 1-1
Tabletten 28 Tabletten 30 Tabletten ||| tablets 28 tablets 30 tablets ||| 0-0 1-1 2-2 3-3 4-4
Tabletten 28 Tabletten 30 ||| tablets 28 tablets 30 ||| 0-0 1-1 2-2 3-3
Tabletten 28 Tabletten ||| tablets 28 tablets ||| 0-0 1-1 2-2
Tabletten 28 x 1 Tabletten ||| tablets 28 x 1 tablets ||| 0-0 1-1 2-2 3-3 4-4
Tabletten 28 x 1 ||| tablets 28 x 1 ||| 0-0 1-1 2-2 3-3
Tabletten 28 x ||| tablets 28 x ||| 0-0 1-1 2-2
Tabletten 28 ||| tablets 28 ||| 0-0 1-1
Tabletten 30 Tabletten 50 Tabletten ||| tablets 30 tablets 50 tablets ||| 0-0 1-1 2-2 3-3 4-4
Tabletten 30 Tabletten 50 ||| tablets 30 tablets 50 ||| 0-0 1-1 2-2 3-3
Tabletten 30 Tabletten ||| tablets 30 tablets ||| 0-0 1-1 2-2
Tabletten 30 ||| tablets 30 ||| 0-0 1-1
Tabletten 49 x 1 Tabletten ||| tablets 49 x 1 tablets ||| 0-0 1-1 2-2 3-3 4-4
Tabletten 49 x 1 ||| tablets 49 x 1 ||| 0-0 1-1 2-2 3-3
Tabletten 49 x ||| tablets 49 x ||| 0-0 1-1 2-2
Tabletten 49 ||| tablets 49 ||| 0-0 1-1
Tabletten 50 Tabletten 56 Tabletten ||| tablets 50 tablets 56 tablets ||| 0-0 1-1 2-2 3-3 4-4
Tabletten 50 Tabletten 56 ||| tablets 50 tablets 56 ||| 0-0 1-1 2-2 3-3
Tabletten 50 Tabletten ||| tablets 50 tablets ||| 0-0 1-1 2-2
Tabletten 50 ||| tablets 50 ||| 0-0 1-1
Tabletten 56 Tabletten 84 Tabletten ||| tablets 56 tablets 84 tablets ||| 0-0 1-1 2-2 3-3 4-4
Tabletten 56 Tabletten 84 ||| tablets 56 tablets 84 ||| 0-0 1-1 2-2 3-3
Tabletten 56 Tabletten ||| tablets 56 tablets ||| 0-0 1-1 2-2
Tabletten 56 x 1 Tabletten ||| tablets 56 x 1 tablets ||| 0-0 1-1 2-2 3-3 4-4
Tabletten 56 x 1 ||| tablets 56 x 1 ||| 0-0 1-1 2-2 3-3
Tabletten 56 x ||| tablets 56 x ||| 0-0 1-1 2-2
Tabletten 56 ||| tablets 56 ||| 0-0 1-1
Tabletten 84 Tabletten 90 Tabletten ||| tablets 84 tablets 90 tablets ||| 0-0 1-1 2-2 3-3 4-4
Tabletten 84 Tabletten 90 ||| tablets 84 tablets 90 ||| 0-0 1-1 2-2 3-3
Tabletten 84 Tabletten ||| tablets 84 tablets ||| 0-0 1-1 2-2
Tabletten 84 ||| tablets 84 ||| 0-0 1-1
Tabletten 90 Tabletten 98 Tabletten ||| tablets 90 tablets 98 tablets ||| 0-0 1-1 2-2 3-3 4-4
Tabletten 90 Tabletten 98 ||| tablets 90 tablets 98 ||| 0-0 1-1 2-2 3-3
Tabletten 90 Tabletten ||| tablets 90 tablets ||| 0-0 1-1 2-2
Tabletten 90 ||| tablets 90 ||| 0-0 1-1
Tabletten 98 Tabletten ||| tablets 98 tablets ||| 0-0 1-1 2-2
Tabletten 98 x 1 Tabletten ||| tablets 98 x 1 tablets ||| 0-0 1-1 2-2 3-3 4-4
Tabletten 98 x 1 ||| tablets 98 x 1 ||| 0-0 1-1 2-2 3-3
Tabletten 98 x ||| tablets 98 x ||| 0-0 1-1 2-2
Tabletten 98 ||| tablets 98 ||| 0-0 1-1
Tabletten an 1 ||| tablets ||| 0-0
Tabletten an ||| tablets ||| 0-0
Tabletten aufgetreten : ||| tablets : ||| 0-0 1-0 2-1
Tabletten aufgetreten ||| tablets ||| 0-0 1-0
Tabletten die ||| tablets ||| 0-0
Tabletten eingenommen ||| tablets ||| 0-0 1-0
Tabletten enthalten 15 , 30 ||| tablets contain 15 , 30 ||| 0-0 1-1 2-2 3-3 4-4
Tabletten enthalten 15 , ||| tablets contain 15 , ||| 0-0 1-1 2-2 3-3
Tabletten enthalten 15 ||| tablets contain 15 ||| 0-0 1-1 2-2
Tabletten enthalten Lactose-Monohydrat und ||| tablets contain lactose monohydrate and ||| 0-0 1-1 2-2 2-3 3-4
Tabletten enthalten Lactose-Monohydrat ||| tablets contain lactose monohydrate ||| 0-0 1-1 2-2 2-3
Tabletten enthalten ||| tablets contain ||| 0-0 1-1
Tabletten in ||| tablets in ||| 0-0 1-1
Tabletten ist Pioglitazon . ||| tablets is pioglitazone . ||| 0-0 1-1 2-2 3-3
Tabletten ist Pioglitazon ||| tablets is pioglitazone ||| 0-0 1-1 2-2
Tabletten ist ||| tablets is ||| 0-0 1-1
Tabletten können ||| tablets can be ||| 0-0 1-1 1-2
Tabletten können ||| tablets may ||| 0-0 1-1
Tabletten mit Nahrungsmitteln und Getränken ||| tablets with food and drink ||| 0-0 1-1 2-2 3-3 2-4 4-4
Tabletten mit der Prägung 20 ||| tablets debossed with 20 ||| 0-0 3-1 1-2 3-2 4-3
Tabletten mit der Prägung ||| tablets debossed with ||| 0-0 3-1 1-2 3-2
Tabletten mit der ||| tablets ||| 0-0
Tabletten mit ||| tablets , with ||| 0-0 1-2
Tabletten mit ||| tablets with ||| 0-0 1-1
Tabletten mit ||| tablets ||| 0-0
Tabletten mit ähnlicher ||| tablets , with a similar ||| 0-0 1-2 2-3 2-4
Tabletten sind rechteckig und blau ||| tablets are rectangular and blue ||| 0-0 1-1 2-2 3-3 4-4
Tabletten sind rechteckig und rosafarben ||| tablets are rectangular and pink ||| 0-0 1-1 2-2 3-3 4-4
Tabletten sind rechteckig und ||| tablets are rectangular and ||| 0-0 1-1 2-2 3-3
Tabletten sind rechteckig ||| tablets are rectangular ||| 0-0 1-1 2-2
Tabletten sind rund und gelb ||| tablets are round and yellow ||| 0-0 1-1 2-2 3-3 4-4
Tabletten sind rund und rosafarben ||| tablets are round and pink ||| 0-0 1-1 2-2 3-3 4-4
Tabletten sind rund und ||| tablets are round and ||| 0-0 1-1 2-2 3-3
Tabletten sind rund ||| tablets are round ||| 0-0 1-1 2-2
Tabletten sind weiß bis weißlich ||| tablets are white to off-white ||| 0-0 1-1 2-2 3-3 3-4 4-4
Tabletten sind weiß ||| tablets are white ||| 0-0 1-1 2-2
Tabletten sind ||| tablets are ||| 0-0 1-1
Tabletten stehen in Blisterpackungen ||| tablets are supplied in blister ||| 0-0 3-1 1-2 2-2 3-2 2-3 3-4
Tabletten werden ||| tablets are ||| 0-0 1-1
Tabletten ||| tablets , ||| 0-0
Tabletten ||| tablets ||| 0-0
Tablettenformulierung beträgt 87 % ||| tablet formulation is 87 % ||| 0-0 0-1 1-1 1-2 2-3 3-4
Tablettenformulierung beträgt 87 ||| tablet formulation is 87 ||| 0-0 0-1 1-1 1-2 2-3
Tablettenformulierung beträgt ||| tablet formulation is ||| 0-0 0-1 1-1 1-2
Tachykardie , ||| tachycardia , ||| 0-0 1-1
Tachykardie , Übelkeit , Erbrechen ||| tachycardia , nausea , vomiting ||| 0-0 1-1 2-2 3-3 4-4
Tachykardie , Übelkeit , ||| tachycardia , nausea , ||| 0-0 1-1 2-2 3-3
Tachykardie , Übelkeit ||| tachycardia , nausea ||| 0-0 1-1 2-2
Tachykardie ||| tachycardia ||| 0-0
Tachykardie* ||| tachycardia* ||| 0-0
Tag . ||| day . ||| 0-0 1-1
Tag 1 und ||| on day 1 and ||| 0-0 0-1 1-2 2-3
Tag 1 ||| on day 1 ||| 0-0 0-1 1-2
Tag 21 , 14 und ||| days 21 , 14 and ||| 1-0 0-1 1-1 2-2 3-3 4-4
Tag 21 , 14 ||| days 21 , 14 ||| 1-0 0-1 1-1 2-2 3-3
Tag 21 , ||| days 21 , ||| 1-0 0-1 1-1 2-2
Tag 21 ||| days 21 ||| 1-0 0-1 1-1
Tag 35 gewogen ||| day 35 ||| 0-0 1-1 2-1
Tag des Monats . ||| day of that month . ||| 0-0 1-1 2-2 2-3 3-4
Tag des Monats ||| day of that month ||| 0-0 1-1 2-2 2-3
Tag des ||| day of ||| 0-0 1-1
Tag vor dem Frühstück eingenommen ||| day , before breakfast ||| 0-0 1-2 3-2 2-3 3-3 4-3
Tag zur gleichen Zeit einzunehmen ||| same time each day ||| 0-0 1-0 2-0 3-1 4-2 4-3
Tag zur gleichen Zeit ||| same time ||| 0-0 1-0 2-0 3-1
Tag zur gleichen ||| same ||| 0-0 1-0 2-0
Tag ||| day , ||| 0-0
Tag ||| day ||| 0-0
Tag ||| on day ||| 0-0 0-1
Tage , ||| days , ||| 0-0 1-1
Tage nach Verabreichung von Aclasta ||| days after administration of Aclasta ||| 0-0 1-1 2-2 3-3 4-4
Tage nach Verabreichung von ||| days after administration of ||| 0-0 1-1 2-2 3-3
Tage nach Verabreichung ||| days after administration ||| 0-0 1-1 2-2
Tage nach der Verabreichung von ||| days after administration of ||| 0-0 1-1 3-2 2-3 4-3
Tage nach der ||| days after ||| 0-0 1-1
Tage nach der ||| days following the ||| 0-0 1-1 2-2
Tage nach ||| days after ||| 0-0 1-1
Tage nach ||| days following ||| 0-0 1-1
Tage unmittelbar ||| days immediately ||| 0-0 1-1
Tage ||| days ||| 0-0
Tagen ) ||| days ) low- trauma ||| 0-0 1-1
Tagen ) ||| days ) low- ||| 0-0 1-1
Tagen ) ||| days ) ||| 0-0 1-1
Tagen . ||| days. ||| 0-0 1-0
Tagen nach Beginn des ||| days of the ||| 0-0 1-0 2-0 3-1 3-2
Tagen nach Beginn ||| days ||| 0-0 1-0 2-0
Tagen nachdem ||| days ||| 0-0
Tagen oder Wochen wieder ab ||| days to a few weeks ||| 0-0 0-1 1-1 2-2 3-3 4-3 2-4 4-4
Tagen oder ||| days to ||| 0-0 0-1 1-1
Tagen vor ||| days prior to ||| 0-0 1-1 1-2
Tagen ||| days ||| 0-0
Tagesdosis sollte ||| daily dose should ||| 0-0 0-1 1-2
Tagesdosis von 15 mg ||| daily dose of 15 mg ||| 0-0 0-1 1-2 2-3 3-4
Tagesdosis von 15 ||| daily dose of 15 ||| 0-0 0-1 1-2 2-3
Tagesdosis von Abilify ||| daily dose of Abilify ||| 0-0 0-1 1-2 2-3
Tagesdosis von ||| daily dose of ||| 0-0 0-1 1-2
Tagesdosis ||| daily dose ||| 0-0 0-1
Tagesdosis ||| daily ||| 0-0
Taillenumfanges , ||| waist circumference , ||| 0-0 0-1 1-2
Taillenumfanges ||| waist circumference ||| 0-0 0-1
Takeda Europe R & D ||| Takeda Europe R & D ||| 0-0 1-1 2-2 3-3 4-4
Takeda Europe R & ||| Takeda Europe R & ||| 0-0 1-1 2-2 3-3
Takeda Europe R ||| Takeda Europe R ||| 0-0 1-1 2-2
Takeda Europe ||| Takeda Europe ||| 0-0 1-1
Takeda Global R & D ||| Takeda Global R & D ||| 0-0 1-1 2-2 3-3 4-4
Takeda Global R & ||| Norge Takeda Global R & ||| 0-0 0-1 1-2 2-3 3-4
Takeda Global R & ||| Takeda Global R & ||| 0-0 1-1 2-2 3-3
Takeda Global R ||| Norge Takeda Global R ||| 0-0 0-1 1-2 2-3
Takeda Global R ||| Takeda Global R ||| 0-0 1-1 2-2
Takeda Global Research and Development ||| Takeda Global Research and Development ||| 0-0 1-1 2-2 3-2 3-3 4-4
Takeda Global Research and ||| Takeda Global Research and ||| 0-0 1-1 2-2 3-2 3-3
Takeda Global ||| Norge Takeda Global ||| 0-0 0-1 1-2
Takeda Global ||| Takeda Global ||| 0-0 1-1
Takeda Ireland Limited ||| Takeda Ireland Limited ||| 0-0 1-1 2-2
Takeda Ireland ||| Takeda Ireland ||| 0-0 1-1
Takeda Italia Farmaceutici SpA Tel ||| Takeda Italia Farmaceutici SpA Tel ||| 0-0 1-1 2-2 3-3 4-4
Takeda Italia Farmaceutici SpA ||| Takeda Italia Farmaceutici SpA ||| 0-0 1-1 2-2 3-3
Takeda Italia Farmaceutici ||| Takeda Italia Farmaceutici ||| 0-0 1-1 2-2
Takeda Italia ||| Takeda Italia ||| 0-0 1-1
Takeda Pharma GmbH Tel. ||| Takeda Pharma GmbH Tel . ||| 0-0 1-1 2-2 3-3 3-4
Takeda Pharma GmbH ||| Deutschland Takeda Pharma GmbH ||| 1-0 0-1 1-2 2-3
Takeda Pharma GmbH ||| Takeda Pharma GmbH ||| 0-0 1-1 2-2
Takeda Pharma ||| Deutschland Takeda Pharma ||| 1-0 0-1 1-2
Takeda Pharma ||| Takeda Pharma ||| 0-0 1-1
Takeda Tél : +33 ( ||| Takeda Tél : +33 ( ||| 0-0 1-1 2-2 3-3 4-4
Takeda Tél : +33 ||| Takeda Tél : +33 ||| 0-0 1-1 2-2 3-3
Takeda Tél : ||| Takeda Tél : ||| 0-0 1-1 2-2
Takeda Tél ||| Takeda Tél ||| 0-0 1-1
Takeda UK Ltd Tel : ||| Takeda UK Ltd Tel : ||| 0-0 1-1 2-2 3-3 4-4
Takeda UK Ltd Tel ||| Takeda UK Ltd Tel ||| 0-0 1-1 2-2 3-3
Takeda UK Ltd ||| Takeda UK Ltd ||| 0-0 1-1 2-2
Takeda UK ||| Takeda UK ||| 0-0 1-1
Takeda ||| Norge Takeda ||| 0-0 0-1
Takeda ||| Takeda ||| 0-0
Tamoxifen ||| tamoxifen ||| 0-0
Taxane ||| anticancer ||| 0-0
Te . : +44 ( ||| Te . : +44 ( ||| 0-0 1-1 2-2 3-3 4-4
Te . : +44 ||| Te . : +44 ||| 0-0 1-1 2-2 3-3
Te . : ||| Te . : ||| 0-0 1-1 2-2
Te . ||| Te . ||| 0-0 1-1
Te ||| Te ||| 0-0
Technologie hergestellt . ||| . ||| 2-0
Technologie hergestellt . ||| action . ||| 2-1
Teil des Futters . ||| portion of the food . ||| 0-0 0-1 1-2 2-3 3-4
Teil des Futters ||| portion of the food ||| 0-0 0-1 1-2 2-3
Teil des körpereigenen ||| Teil des körpereigenen eim The ||| 0-0 1-1 0-2 0-3 2-3
Teil des körpereigenen ||| Teil des körpereigenen eim ||| 0-0 1-1 0-2 0-3 2-3
Teil des ||| portion of the ||| 0-0 0-1 1-2
Teil durch die ||| part , by ||| 0-0 2-1 1-2 2-2
Teil einer Bündelpackung bestehend aus ||| Component of a multi-pack comprising ||| 0-0 1-1 1-2 2-3 2-4 3-4 4-4
Teil einer ||| Component of a ||| 0-0 1-1 1-2
Teil ||| Component ||| 0-0
Teil ||| Teil ||| 0-0
Teil ||| of ||| 0-0
Teil ||| part of ||| 0-0 0-1
Teil ||| part ||| 0-0
Teil ||| portion of ||| 0-0 0-1
Teil ||| some of ||| 0-1
Teile des Körpers ausgebreitet ||| parts of the body ||| 0-0 3-0 1-1 1-2 2-3
Teilnehmer erhielten eine ||| participants received ||| 0-0 1-1 2-1
Teilnehmer ||| participants ||| 0-0
Tel . : + 36(0 ||| Tel . : + 36(0 ||| 0-0 1-1 2-2 3-3 4-4
Tel . : + ||| Tel . : + ||| 0-0 1-1 2-2 3-3
Tel . : +36 1 ||| Tel . : +36 1 ||| 0-0 1-1 2-2 3-3 4-4
Tel . : +36 ||| Tel . : +36 ||| 0-0 1-1 2-2 3-3
Tel . : ||| Tel . : ||| 0-0 1-1 2-2
Tel . ||| Tel . ||| 0-0 1-1
Tel : + 31 ( ||| Tel : + 31 ( ||| 0-0 1-1 2-2 3-3 4-4
Tel : + 31 34 ||| Tel : + 31 34 ||| 0-0 1-1 2-2 3-3 4-4
Tel : + 31 ||| Tel : + 31 ||| 0-0 1-1 2-2 3-3
Tel : + 34 ( ||| Tel : + 34 ( ||| 0-0 1-1 2-2 3-3 4-4
Tel : + 34 ||| Tel : + 34 ||| 0-0 1-1 2-2 3-3
Tel : + 351 21 ||| Tel : + 351 21 ||| 0-0 1-1 2-2 3-3 4-4
Tel : + 351 ||| Tel : + 351 ||| 0-0 1-1 2-2 3-3
Tel : + 353 ( ||| Tel : + 353 ( ||| 0-0 1-1 2-2 3-3 4-4
Tel : + 353 ||| Tel : + 353 ||| 0-0 1-1 2-2 3-3
Tel : + 36(0 ) ||| Tel : + 36(0 ) ||| 0-0 1-1 2-2 3-3 4-4
Tel : + 36(0 ||| Tel : + 36(0 ||| 0-0 1-1 2-2 3-3
Tel : + 39 06 ||| Tel : + 39 06 ||| 0-0 1-1 2-2 3-3 4-4
Tel : + 39 ||| Tel : + 39 ||| 0-0 1-1 2-2 3-3
Tel : + 40 ( ||| Tel : + 40 ( ||| 0-0 1-1 2-2 3-3 4-4
Tel : + 40 ||| Tel : + 40 ||| 0-0 1-1 2-2 3-3
Tel : + 43 ( ||| Tel : + 43 ( ||| 0-0 1-1 2-2 3-3 4-4
Tel : + 43 1 ||| Tel : + 43 1 ||| 0-0 1-1 2-2 3-3 4-4
Tel : + 43 ||| Tel : + 43 ||| 0-0 1-1 2-2 3-3
Tel : + 43-(0)800 29 ||| Tel : + 43-(0)800 29 ||| 0-0 1-1 2-2 3-3 4-4
Tel : + 43-(0)800 ||| Tel : + 43-(0)800 ||| 0-0 1-1 2-2 3-3
Tel : + 44 ( ||| Tel : + 44 ( ||| 0-0 1-1 2-2 3-3 4-4
Tel : + 44 ||| Tel : + 44 ||| 0-0 1-1 2-2 3-3
Tel : + 46 8 ||| Tel : + 46 8 ||| 0-0 1-1 2-2 3-3 4-4
Tel : + 46 ||| Tel : + 46 ||| 0-0 1-1 2-2 3-3
Tel : + ||| Tel : + ||| 0-0 1-1 2-2
Tel : +353 1 260 ||| Tel : +353 1 260 ||| 0-0 1-1 2-2 3-3 4-4
Tel : +353 1 ||| Tel : +353 1 ||| 0-0 1-1 2-2 3-3
Tel : +353 ||| Tel : +353 ||| 0-0 1-1 2-2
Tel : +371 7364000 ||| Tel : +371 7364000 ||| 0-0 1-1 2-2 3-3
Tel : +371 ||| Tel : +371 ||| 0-0 1-1 2-2
Tel : +3726441100 ||| Tel : +3726441100 ||| 0-0 1-1 2-2
Tel : +386 ( 0)1 ||| Tel : +386 ( 0)1 ||| 0-0 1-1 2-2 3-3 4-4
Tel : +386 ( ||| Tel : +386 ( ||| 0-0 1-1 2-2 3-3
Tel : +386 ||| Tel : +386 ||| 0-0 1-1 2-2
Tel : +43 1 86 ||| Tel : +43 1 86 ||| 0-0 1-1 2-2 3-3 4-4
Tel : +43 1 ||| Tel : +43 1 ||| 0-0 1-1 2-2 3-3
Tel : +43 ||| Tel : +43 ||| 0-0 1-1 2-2
Tel : +44 ( 0)20 ||| Tel : +44 ( 0)20 ||| 0-0 1-1 2-2 3-3 4-4
Tel : +44 ( ||| Tel : +44 ( ||| 0-0 1-1 2-2 3-3
Tel : +44 ||| Tel : +44 ||| 0-0 1-1 2-2
Tel : +46 8 732 ||| Tel : +46 8 732 ||| 0-0 1-1 2-2 3-3 4-4
Tel : +46 8 ||| Tel : +46 8 ||| 0-0 1-1 2-2 3-3
Tel : +46 ||| Tel : +46 ||| 0-0 1-1 2-2
Tel : +49 911 273 ||| Tel : +49 911 273 ||| 0-0 1-1 2-2 3-3 4-4
Tel : +49 911 ||| Tel : +49 911 ||| 0-0 1-1 2-2 3-3
Tel : +49 ||| Tel : +49 ||| 0-0 1-1 2-2
Tel : ||| Tel : ||| 0-0 1-1
Tel ||| Tel ||| 0-0
Tel. + 49 ( ||| Tel . + 49 ( ||| 0-0 0-1 1-2 2-3 3-4
Tel. + 49 ||| Tel . + 49 ||| 0-0 0-1 1-2 2-3
Tel. + ||| Tel . + ||| 0-0 0-1 1-2
Tel. ||| Tel . ||| 0-0 0-1
Telithromycin oder Clarithromycin ( ||| or telithromycin or clarithromycin ( ||| 1-0 2-1 1-2 0-3 3-4
Telithromycin oder Clarithromycin ||| or telithromycin or clarithromycin ||| 1-0 2-1 1-2 0-3
Telithromycin ||| clarithromycin ||| 0-0
Testosteronsuppression ||| , testosterone suppression ||| 0-1 0-2
Testosteronsuppression ||| testosterone suppression ||| 0-0 0-1
Tetrazyklin-Markierungen wurden bei allen außer ||| Tetrazyklin-Markierungen wurden bei allen außer ||| 0-0 0-1 1-1 2-2 3-3 4-4
Tetrazyklin-Markierungen wurden bei allen ||| Tetrazyklin-Markierungen wurden bei allen ||| 0-0 0-1 1-1 2-2 3-3
Tetrazyklin-Markierungen wurden bei ||| Tetrazyklin-Markierungen wurden bei ||| 0-0 0-1 1-1 2-2
Tetrazyklin-Markierungen wurden ||| Tetrazyklin-Markierungen wurden ||| 0-0 0-1 1-1
Therabel Lucien Pharma Tél : ||| Therabel Lucien Pharma Tél : ||| 0-0 1-1 2-2 3-3 4-4
Therabel Lucien Pharma Tél ||| Therabel Lucien Pharma Tél ||| 0-0 1-1 2-2 3-3
Therabel Lucien Pharma ||| Therabel Lucien Pharma ||| 0-0 1-1 2-2
Therabel Lucien ||| Therabel Lucien ||| 0-0 1-1
Therabel ||| Therabel ||| 0-0
Therapie begonnen werden . ||| risk of cross-reaction . ||| 1-0 1-1 0-2 1-2 2-2 3-3
Therapie begonnen werden . ||| the risk of cross-reaction . ||| 1-1 1-2 0-3 1-3 2-3 3-4
Therapie begonnen werden ||| risk of cross-reaction ||| 1-0 1-1 0-2 1-2 2-2
Therapie begonnen werden ||| the risk of cross-reaction ||| 1-1 1-2 0-3 1-3 2-3
Therapie kann , insbesondere ||| , especially ||| 2-0 0-1 1-1 3-1
Therapie mit Abseamed ||| Abseamed ||| 2-0
Therapie mit Aclasta Falls Sie ||| Aclasta therapy If you are ||| 2-0 0-1 1-1 3-2 4-3 4-4
Therapie mit Aclasta Falls ||| Aclasta therapy If ||| 2-0 0-1 1-1 3-2
Therapie mit Aclasta ||| Aclasta therapy ||| 2-0 0-1 1-1
Therapie mit Pioglitazon zu kontrollieren ||| therapy with pioglitazone in all ||| 0-0 1-1 2-2 3-3 4-4
Therapie mit Pioglitazon zu ||| therapy with pioglitazone in ||| 0-0 1-1 2-2 3-3
Therapie mit Pioglitazon ||| therapy with pioglitazone ||| 0-0 1-1 2-2
Therapie mit ||| therapy with ||| 0-0 1-1
Therapie mit ||| therapy ||| 0-0 1-0
Therapie nicht angebracht ist . ||| therapy is not appropriate . ||| 0-0 3-1 1-2 2-3 4-4
Therapie nicht angebracht ist ||| therapy is not appropriate ||| 0-0 3-1 1-2 2-3
Therapie ||| therapy , ||| 0-0
Therapie ||| therapy ||| 0-0
Therapieabbruch erforderlich . ||| discontinuation of treatment . ||| 0-0 1-0 0-1 0-2 2-3
Therapieabbruch erforderlich ||| discontinuation of treatment ||| 0-0 1-0 0-1 0-2
Therapieerfolges bei Weiterbehandlung von ||| improvement during continuation therapy in ||| 0-0 0-1 0-2 1-2 2-2 3-2 2-3 1-4
Therapiestandard . ||| care . ||| 0-0 1-1
Therapiestandard . ||| of care . ||| 0-1 1-2
Therapiestandard ||| care ||| 0-0
Therapiestandard ||| of care ||| 0-1
Therapy Anemia ( FACT-An ) ||| Therapy- Anaemia ( FACT-An ) ||| 0-0 1-0 1-1 2-2 3-3 4-4
Therapy Anemia ( FACT-An ||| Therapy- Anaemia ( FACT-An ||| 0-0 1-0 1-1 2-2 3-3
Therapy Anemia ( ||| Therapy- Anaemia ( ||| 0-0 1-0 1-1 2-2
Therapy Anemia ||| Therapy- Anaemia ||| 0-0 1-0 1-1
Thiazide , Glucokortikoide , ||| thiazides , glucocorticoids , ||| 0-0 1-1 2-2 3-3
Thiazide , Glucokortikoide ||| thiazides , glucocorticoids ||| 0-0 1-1 2-2
Thiazide , ||| thiazides , ||| 0-0 1-1
Thiazide ||| thiazides ||| 0-0
Thiazolidindione ; ATC-Code ||| ; Thiazolidinediones ; ATC code ||| 0-0 0-1 1-2 2-3 2-4
Thiazolidindione ; ||| ; Thiazolidinediones ; ||| 0-0 0-1 1-2
Thiazolidindione ||| ; Thiazolidinediones ||| 0-0 0-1
Thromboseprophylaxe durch ||| prophylaxis by ||| 0-0 1-1
Thromboseprophylaxe durchgeführt werden kann . ||| receive adequate antithrombotic prophylaxis . ||| 0-0 0-1 0-2 1-2 2-2 0-3 3-3 4-4
Thromboseprophylaxe durchgeführt werden kann ||| receive adequate antithrombotic prophylaxis ||| 0-0 0-1 0-2 1-2 2-2 0-3 3-3
Thromboseprophylaxe ||| prophylaxis ||| 0-0
Thrombotische Ereignisse können ein ||| Thrombotic events can be a ||| 0-0 1-1 0-2 2-2 0-3 3-4
Thrombotische Ereignisse können ||| Thrombotic events can be ||| 0-0 1-1 0-2 2-2 0-3
Thrombozytenzahl kommen . ||| epoetin alfa . ||| 0-0 1-0 1-1 2-2
Thrombozytenzahl kommen ||| epoetin alfa ||| 0-0 1-0 1-1
Thrombozytose wurde beobachtet ||| Thrombocytosis has been observed ||| 0-0 1-1 1-2 2-3
Thrombozytose wurde ||| Thrombocytosis has been ||| 0-0 1-1 1-2
Thrombozytose ||| Thrombocytosis ||| 0-0
Tibolon ; ||| tibolone ; ||| 0-0 1-1
Tibolon ||| tibolone ||| 0-0
Tierarzneimittel ||| product ||| 0-0
Tierarzneimittel ||| veterinary medicinal product ||| 0-0 0-1 0-2
Tierarzneimittels laut ||| veterinary medicinal product as packaged ||| 0-0 0-1 0-2 1-3 1-4
Tierarzneimittels ||| product ||| 0-0
Tierarzneimittels ||| veterinary medicinal product ||| 0-0 0-1 0-2
Tierarzt , wie ||| veterinary surgeon how ||| 0-0 0-1 1-2 2-2
Tierarzt mit . ||| veterinary surgeon . ||| 0-0 0-1 2-2
Tierarzt mit ||| veterinary surgeon ||| 0-0 0-1
Tierarzt oder ||| veterinary surgeon or ||| 0-0 0-1 1-2
Tierarzt sollte ||| veterinary surgeon should ||| 0-0 0-1 1-2
Tierarzt wird Ihnen sagen , ||| veterinary surgeon will advise you ||| 0-0 0-1 1-2 2-3 3-3 2-4
Tierarzt wird Ihnen sagen ||| veterinary surgeon will advise you ||| 0-0 0-1 1-2 2-3 3-3 2-4
Tierarzt wird ||| veterinary surgeon will ||| 0-0 0-1 1-2
Tierarzt ||| veterinary surgeon ||| 0-0 0-1
Tieren Die Sicherheit ||| animals The safety ||| 0-0 1-1 2-2
Tieren Die ||| animals The ||| 0-0 1-1
Tieren lässt ||| animals , ||| 0-0 1-0 1-1
Tieren ||| animals ||| 0-0
Tierexperimentelle Studien haben eine 4 ||| Studies in animals have ||| 0-0 1-0 0-1 0-2 2-2 3-2 2-3
Tierexperimentelle Studien haben eine ||| Studies in animals have ||| 0-0 1-0 0-1 0-2 2-2 3-2 2-3
Tiermodell der familiären adenomatösen ||| animal model of familial ||| 0-0 0-1 2-1 1-2 2-3 3-3
Tiermodellen gezeigt ||| animal models ||| 0-0 0-1 1-1
Tierversuche ||| Paclitaxel at ||| 0-0 0-1
Titandioxid ( E 171 ) ||| titanium dioxide ( E171 ) ||| 0-0 0-1 2-1 1-2 3-3 4-4
Titandioxid ( E 171 ||| titanium dioxide ( E171 ||| 0-0 0-1 2-1 1-2 3-3
Titandioxid ( E ||| titanium dioxide ( ||| 0-0 0-1 2-1 1-2
Tlf : + 44 ( ||| Tlf : + 44 ( ||| 0-0 1-1 2-2 3-3 4-4
Tlf : + 44 ||| Tlf : + 44 ||| 0-0 1-1 2-2 3-3
Tlf : + 45 45 ||| Tlf : + 45 45 ||| 0-0 1-1 2-2 3-3 4-4
Tlf : + 45 ||| Tlf : + 45 ||| 0-0 1-1 2-2 3-3
Tlf : + 47 67 ||| Tlf : + 47 67 ||| 0-0 1-1 2-2 3-3 4-4
Tlf : + 47 ||| Tlf : + 47 ||| 0-0 1-1 2-2 3-3
Tlf : + ||| Tlf : + ||| 0-0 1-1 2-2
Tlf : +45 39 16 ||| Tlf : +45 39 16 ||| 0-0 1-1 2-2 3-3 4-4
Tlf : +45 39 ||| Tlf : +45 39 ||| 0-0 1-1 2-2 3-3
Tlf : +45 ||| Tlf : +45 ||| 0-0 1-1 2-2
Tlf : +47 23 05 ||| Tlf : +47 23 05 ||| 0-0 1-1 2-2 3-3 4-4
Tlf : +47 23 ||| Tlf : +47 23 ||| 0-0 1-1 2-2 3-3
Tlf : +47 ||| Tlf : +47 ||| 0-0 1-1 2-2
Tlf : ||| Tlf : ||| 0-0 1-1
Tlf ||| Tlf ||| 0-0
Tod enden . ||| or even death . ||| 0-0 1-1 0-2 2-3
Tod enden ||| or even death ||| 0-0 1-1 0-2
Tod ||| death ||| 0-0
Todesfolge beobachtet . ||| no fatalities . ||| 0-0 0-1 1-1 2-2
Todesfolge beobachtet ||| no fatalities ||| 0-0 0-1 1-1
Tolbutamid ) ||| tolbutamide ) ||| 0-0 1-1
Tolbutamid ||| tolbutamide ||| 0-0
Torsades-de-Pointes , Bradykardie ||| de pointes , bradycardia ||| 0-0 0-1 1-2 2-3
Torsades-de-Pointes , ||| de pointes , ||| 0-0 0-1 1-2
Torsades-de-Pointes ||| de pointes ||| 0-0 0-1
Tours Cedex 2 , Frankreich ||| Tours Cedex 2 , France ||| 0-0 1-1 2-2 3-3 4-4
Tours Cedex 2 , ||| Tours Cedex 2 , ||| 0-0 1-1 2-2 3-3
Tours Cedex 2 ||| Tours Cedex 2 ||| 0-0 1-1 2-2
Tours Cedex ||| Tours Cedex ||| 0-0 1-1
Tours ||| Tours ||| 0-0
Toxizität ( bei 79 ||| toxicity ( reported in 79 ||| 0-0 1-1 2-2 2-3 3-4
Toxizität ( bei ||| toxicity ( reported in ||| 0-0 1-1 2-2 2-3
Toxizität ( ||| toxicity ( ||| 0-0 1-1
Toxizität Die höchste ||| toxicity The highest ||| 0-0 1-1 2-2
Toxizität Die ||| toxicity The ||| 0-0 1-1
Toxizität In ||| toxicity In ||| 0-0 1-1
Toxizität eines Zielorgans ||| toxicity ||| 0-0
Toxizität eines ||| toxicity ||| 0-0
Toxizität ||| humans ||| 0-0
Toxizität ||| toxicity ||| 0-0
Transport von Paclitaxel durch ||| transport of paclitaxel ||| 0-0 1-1 3-1 2-2
Transport ||| correct ||| 0-0
Transport ||| transport ||| 0-0
Tremor , Schwindel , Schläfrigkeit ||| tremor , dizziness , somnolence ||| 0-0 1-1 2-2 3-3 4-4
Tremor , Schwindel , ||| , tremor , dizziness , ||| 1-0 0-1 1-2 2-3 3-4
Tremor , Schwindel , ||| tremor , dizziness , ||| 0-0 1-1 2-2 3-3
Tremor , Schwindel ||| , tremor , dizziness ||| 1-0 0-1 1-2 2-3
Tremor , Schwindel ||| tremor , dizziness ||| 0-0 1-1 2-2
Tremor , Synkope ||| tremor , syncope ||| 0-0 1-1 2-2
Tremor , ||| , tremor , ||| 1-0 0-1 1-2
Tremor , ||| tremor , ||| 0-0 1-1
Tremor Häufig : ||| tremor Common : ||| 0-0 1-1 2-2
Tremor Häufig ||| tremor Common ||| 0-0 1-1
Tremor ||| tremor ||| 0-0
Trial [ PFT ] ( ||| Trial [ PFT ] ( ||| 0-0 1-1 2-2 3-3 4-4
Trial [ PFT ] ||| Trial [ PFT ] ||| 0-0 1-1 2-2 3-3
Trial [ PFT ||| Trial [ PFT ||| 0-0 1-1 2-2
Trial [ ||| Trial [ ||| 0-0 1-1
Trial ||| Trial ||| 0-0
Triglycerid-Transportproteins ( MTP ) ||| transfer protein ( MTP ) ||| 0-0 0-1 1-2 2-3 3-4
Triglycerid-Transportproteins ( MTP ||| transfer protein ( MTP ||| 0-0 0-1 1-2 2-3
Triglycerid-Transportproteins ( ||| transfer protein ( ||| 0-0 0-1 1-2
Triglycerid-Transportproteins ||| transfer protein ||| 0-0 0-1
Triglyceride ( zum Zeitpunkt ein ||| ( zum Zeitpunkt ein ||| 1-0 2-1 4-2 0-3 3-3 4-3
Triglyceride ||| TG ||| 0-0
Triglyceriden in den Enterozyten ||| inside the enterocytes ||| 0-0 1-1 2-1 3-2
Triglyceriden in den ||| inside the ||| 0-0 1-1 2-1
Triglyceriden ||| inside ||| 0-0
Triglyceridspiegel , dies ||| prandial hypertriglyceridaemia ||| 0-0 0-1 2-1
Tripletherapie bei ||| in ||| 1-0
Tripletherapie ||| 1,400 ||| 0-0
Trockenes-Auge-Syndrom , Keratokonjunktivitis sicca ||| dry eye , keratoconjunctivitis sicca ||| 0-0 0-1 1-2 2-3 3-4
Trockenes-Auge-Syndrom , Keratokonjunktivitis ||| dry eye , keratoconjunctivitis ||| 0-0 0-1 1-2 2-3
Trockenes-Auge-Syndrom , ||| dry eye , ||| 0-0 0-1 1-2
Trockenes-Auge-Syndrom ||| dry eye ||| 0-0 0-1
Tropf ||| drip ||| 0-0
Tropfinfusion in eine Vene ) ||| drip into a vein ) ||| 0-0 1-1 3-1 2-2 3-3 4-4
Tropfinfusion in eine Vene ||| drip into a vein ||| 0-0 1-1 3-1 2-2 3-3
Tropfinfusion ||| drip ||| 0-0
Tropfpipette abgemessen werden , ||| calibrated dropper ||| 0-0 1-0 0-1
Tropfpipette abgemessen werden ||| calibrated dropper ||| 0-0 1-0 0-1
Tropfpipette abgemessen ||| calibrated dropper ||| 0-0 1-0 0-1
Trough-Plasmakonzentrationen , aber keine Unterschiede ||| but no differences ||| 2-0 3-1 0-2 4-2
Trächtigkeit , Laktation oder der ||| pregnancy , lactation or ||| 0-0 1-1 2-2 3-3
Trächtigkeit , Laktation oder ||| pregnancy , lactation or ||| 0-0 1-1 2-2 3-3
Trächtigkeit , Laktation ||| pregnancy , lactation ||| 0-0 1-1 2-2
Trächtigkeit , ||| pregnancy , ||| 0-0 1-1
Trächtigkeit und Laktation . ||| pregnancy and lactation . ||| 0-0 1-1 2-2 3-3
Trächtigkeit und Laktation ||| pregnancy and lactation ||| 0-0 1-1 2-2
Trächtigkeit und ||| pregnancy and ||| 0-0 1-1
Trächtigkeit ||| pregnancy ||| 0-0
Tränensekretion , verschwommene Sicht , ||| lacrimation , blurred vision , ||| 0-0 1-1 2-2 2-3 3-4 4-4
Tränensekretion , verschwommene ||| lacrimation , blurred vision ||| 0-0 1-1 2-2 2-3
Tränensekretion , ||| lacrimation , ||| 0-0 1-1
Tränensekretion ||| lacrimation ||| 0-0
Tumor induzierte , war ||| was 7 times ||| 0-0 0-1 1-1 3-1 1-2
Tumor negativ beeinflussen ||| negative impact ||| 1-0 2-1
Tumor negativ ||| negative ||| 1-0
Tumoren ( 172 Mammakarzinome , ||| tumours ( 172 breast , ||| 0-0 1-1 2-2 3-2 3-3 4-4
Tumoren ( 172 Mammakarzinome ||| tumours ( 172 breast ||| 0-0 1-1 2-2 3-2 3-3
Tumoren ( 683 Mammakarzinome ||| tumours ( 683 breast ||| 0-0 1-1 2-2 3-2 3-3
Tumoren ( ||| tumours ( ||| 0-0 1-1
Tumoren , ||| tumours , ||| 0-0 1-1
Tumoren auf . ||| either sex . ||| 0-0 0-1 1-1 2-2
Tumoren auf . ||| of either sex . ||| 0-1 0-2 1-2 2-3
Tumoren auf ||| either sex ||| 0-0 0-1 1-1
Tumoren auf ||| of either sex ||| 0-1 0-2 1-2
Tumoren und 478 andere ||| and 478 other tumour types ||| 1-0 0-1 2-1 3-2 2-3 2-4 3-4
Tumoren ||| tumours , ||| 0-0
Tumoren ||| tumours ||| 0-0
Tumorgeweben ergeben sich ||| that indicates an ||| 0-0 0-1 1-1 2-1 0-2
Tumorpatienten ( Erwachsene ) ||| Adult cancer ||| 0-0 1-0 2-0 0-1 3-1
Tumorpatienten , ||| cancer ||| 0-0
Tumorpatienten , ||| in cancer ||| 0-1
Tumorpatienten oder Patienten , ||| 191 Cancer patients or ||| 0-0 0-1 2-2 1-3
Tumorpatienten oder Patienten ||| 191 Cancer patients or ||| 0-0 0-1 2-2 1-3
Tumorpatienten unter Chemotherapie ||| cancer patients receiving chemotherapy , ||| 0-0 0-1 1-2 2-2 2-3
Tumorpatienten unter Chemotherapie ||| cancer patients receiving chemotherapy ||| 0-0 0-1 1-2 2-2 2-3
Tumorpatienten ||| 191 Cancer ||| 0-0 0-1
Tumorpatienten ||| cancer patients ||| 0-0 0-1
Tumorpatienten ||| cancer ||| 0-0
Tumorpatienten ||| in cancer ||| 0-1
Tumorprogression führen , ||| tumour progression , ||| 0-0 0-1 1-2 2-2
Tumorprogression ||| tumour progression ||| 0-0 0-1
Tumorzellen vorhanden sein ||| a variety of tumour cells ||| 0-0 0-1 1-1 1-2 1-3 2-3 1-4
Typ 1 ) , die ||| type 1 ) ||| 0-0 1-1 2-2
Typ 1 ) , ||| type 1 ) ||| 0-0 1-1 2-2
Typ 1 ) ||| type 1 ) , ||| 0-0 1-1 2-2
Typ 1 ) ||| type 1 ) ||| 0-0 1-1 2-2
Typ 1 ||| type 1 ||| 0-0 1-1
Typ 1 ||| type ||| 0-0 1-0
Typ 2 Diabetes mellitus und ||| type 2 diabetes mellitus and ||| 0-0 1-1 2-2 3-3 4-4
Typ 2 Diabetes mellitus ||| type 2 diabetes mellitus ||| 0-0 1-1 2-2 3-3
Typ 2 Diabetes ||| type 2 diabetes ||| 0-0 1-1 2-2
Typ 2 ||| type 2 ||| 0-0 1-1
Typ III ) mit ||| type III ) with a ||| 0-0 1-1 2-2 3-3
Typ III ) mit ||| type III ) with ||| 0-0 1-1 2-2 3-3
Typ III ) ||| type III ) ||| 0-0 1-1 2-2
Typ III ||| type III ||| 0-0 1-1
Typ ||| type ||| 0-0
Typ-2-Diabetes ist eine ||| Typ-2-Diabetes ist eine Erkrankung ||| 0-0 1-1 2-2 0-3
Typ-2-Diabetes oder ||| type 2 diabetes or ||| 0-0 0-1 0-2 1-3
Typ-2-Diabetes ||| Typ-2-Diabetes ||| 0-0
Typ-2-Diabetes ||| control type 2 diabetes ||| 0-1 0-2 0-3
Typ-2-Diabetes ||| type 2 diabetes ||| 0-0 0-1 0-2
Typ-2-Diabetes ||| type 2 ||| 0-0 0-1
Typ-I ||| butyl ||| 0-0
Typ-I- Kollagen ||| propeptide ||| 0-0 1-0
Tätigkeit der Osteoklasten , ||| action of the osteoclasts , ||| 0-0 1-1 0-2 1-2 2-3 3-4
Tätigkeit der Osteoklasten ||| action of the osteoclasts ||| 0-0 1-1 0-2 1-2 2-3
Tätigkeit der ||| action of the ||| 0-0 1-1 0-2 1-2
Tél : + 33 ( ||| Tél : + 33 ( ||| 0-0 1-1 2-2 3-3 4-4
Tél : + 33 ||| Tél : + 33 ||| 0-0 1-1 2-2 3-3
Tél : + ||| Tél : + ||| 0-0 1-1 2-2
Tél : +33 ( 0)1 ||| Tél : +33 ( 0)1 ||| 0-0 1-1 2-2 3-3 4-4
Tél : +33 ( ||| Tél : +33 ( ||| 0-0 1-1 2-2 3-3
Tél : +33 ||| Tél : +33 ||| 0-0 1-1 2-2
Tél : ||| Tél : ||| 0-0 1-1
Tél ||| Tél ||| 0-0
Tél/Tel : + 32 ||| Tél/ Tel : + 32 ||| 0-0 0-1 1-2 2-3 3-4
Tél/Tel : + 44 ||| Tél/ Tel : + 44 ||| 0-0 0-1 1-2 2-3 3-4
Tél/Tel : + ||| Tél/ Tel : + ||| 0-0 0-1 1-2 2-3
Tél/Tel : +49 911 ||| Tél/ Tel : +49 911 ||| 0-0 0-1 1-2 2-3 3-4
Tél/Tel : +49 ||| Tél/ Tel : +49 ||| 0-0 0-1 1-2 2-3
Tél/Tel : ||| Tél/ Tel : ||| 0-0 0-1 1-2
Tél/Tel ||| Tél/ Tel ||| 0-0 0-1
UB8 1HU - Vereinigtes Königreich ||| UB8 1HU - United Kingdom ||| 0-0 1-1 2-2 3-3 4-4
UB8 1HU - Vereinigtes ||| UB8 1HU - United ||| 0-0 1-1 2-2 3-3
UB8 1HU - ||| UB8 1HU - ||| 0-0 1-1 2-2
UB8 1HU ||| UB8 1HU ||| 0-0 1-1
UB8 1HU- Vereinigtes Königreich ||| UB8 1HU - United Kingdom ||| 0-0 0-1 1-1 1-2 2-3 3-4
UB8 1HU- Vereinigtes ||| UB8 1HU - United ||| 0-0 0-1 1-1 1-2 2-3
UB8 1HU- ||| UB8 1HU - ||| 0-0 0-1 1-1 1-2
UB8 ||| UB8 ||| 0-0
UK Ltd Tel : + ||| UK Ltd Tel : + ||| 0-0 1-1 2-2 3-3 4-4
UK Ltd Tel : ||| UK Ltd Tel : ||| 0-0 1-1 2-2 3-3
UK Ltd Tel ||| UK Ltd Tel ||| 0-0 1-1 2-2
UK Ltd ||| UK Ltd ||| 0-0 1-1
UK Tel. ||| UK Tel . ||| 0-0 1-0 1-1 1-2
UK ||| UK ||| 0-0
ULN ) sollten nicht ||| ULN ) should not ||| 0-0 1-1 2-2 3-3
ULN ) sollten ||| ULN ) should ||| 0-0 1-1 2-2
ULN ) ||| ULN ) ||| 0-0 1-1
ULN oder ASL/ALT > ||| ULN or ASL/ ALT > ||| 0-0 1-1 2-2 3-3 3-4
ULN oder ASL/ALT ||| ULN or ASL/ ||| 0-0 1-1 2-2
ULN oder ||| ULN or ||| 0-0 1-1
ULN ||| ULN ||| 0-0
UMHÜLLUNG UND AUF DEM BEHÄLTNIS ||| ON THE OUTER PACKAGING ||| 0-0 1-1 2-2 3-2 4-3
UMHÜLLUNG UND AUF DEM ||| ON THE OUTER ||| 0-0 1-1 2-2 3-2
UMHÜLLUNG UND ||| ON THE ||| 0-0 1-1
UMHÜLLUNG ||| ON ||| 0-0
UMKARTON FÜR BÜNDELPACKUNG ( EINSCHLIESSLICH ||| CARTON OF MULTI-PACK ( INCLUDING ||| 0-0 2-0 1-1 4-2 3-3 4-4
UMKARTON FÜR BÜNDELPACKUNG ||| CARTON OF ||| 0-0 2-0 1-1
UND 98 TABLETTEN ) ||| AND 98 TABLETS ONLY ) ||| 0-0 1-1 2-2 2-3 3-4
UND 98 TABLETTEN ||| AND 98 TABLETS ONLY ||| 0-0 1-1 2-2 2-3
UND 98 ||| AND 98 ||| 0-0 1-1
UND AUF DEM BEHÄLTNIS ||| THE OUTER PACKAGING ||| 0-0 1-1 2-1 3-2
UND AUF DEM ||| THE OUTER ||| 0-0 1-1 2-1
UND AUF ||| AND ON THE ||| 0-0 1-1 0-2
UND DAUER DER ANWENDUNG ||| AND METHOD OF ADMINISTRATION ||| 0-0 1-1 2-2 3-3
UND DAUER DER ||| AND METHOD OF ||| 0-0 1-1 2-2
UND DAUER ||| AND METHOD ||| 0-0 1-1
UND DEN GEBRAUCH , ||| SUPPLY AND USE ||| 1-0 2-0 0-1 2-1 2-2
UND DEN GEBRAUCH ||| SUPPLY AND USE ||| 1-0 2-0 0-1 2-1 2-2
UND ETIKETTIERUNG DER FLASCHE ||| AND BOTTLE LABEL FOR ||| 0-0 1-1 2-2 3-2 3-3
UND ETIKETTIERUNG ||| AND BOTTLE ||| 0-0 1-1
UND NICHT SICHTBAR AUFZUBEWAHREN ||| THE REACH AND SIGHT OF ||| 0-0 1-1 2-2 2-3 3-3 3-4
UND NICHT ||| THE REACH ||| 0-0 1-1
UND SICHTWEITE ||| THE REACH ||| 0-0 1-1
UND SONSTIGE BESTANDTEILE ||| AND OTHER INGREDIENT(S ) ||| 0-0 1-1 1-2 2-2 2-3
UND SULFONYLHARNSTOFF ||| AND SULPHONYLUREA ||| 0-0 1-1
UND WIRKSAME ANWENDUNG DES TIERARZNEIMITTELS ||| SUPPLY AND USE ||| 1-0 0-1 2-2 3-2 4-2
UND WIRKSAME ||| SUPPLY AND ||| 1-0 0-1
UND WIRKSAMEN ANWENDUNG DES ||| AND EFFECTIVE USE OF THE ||| 0-0 1-1 1-2 2-2 2-3 3-4
UND WIRKSAMEN ANWENDUNG ||| AND EFFECTIVE USE OF ||| 0-0 1-1 1-2 2-2 2-3
UND ||| AND THE ||| 0-0 0-1
UND ||| AND ||| 0-0
UND ||| THE ||| 0-0
UNERREICHBAR UND NICHT ||| OUT OF THE REACH ||| 0-0 0-1 1-2 2-3
UNERREICHBAR UND ||| OUT OF THE ||| 0-0 0-1 1-2
UNERREICHBAR ||| OUT OF ||| 0-0 0-1
Um die Resorption zu ||| To enhance absorption ||| 0-0 1-1 2-2 3-2
Um die ||| To enhance ||| 0-0 1-1
Um ein ||| In order ||| 0-0 0-1 1-1
Um eine Lipodystrophie zu ||| Injection sites ||| 0-0 1-1 2-1 3-1
Um ||| In order ||| 0-0 0-1
Um ||| Injection ||| 0-0
Um ||| Iron ||| 0-0
Um ||| To ||| 0-0
Um ||| order ||| 0-0
Umgehung von adipösen Regionen empfohlen ||| adipose regions , is recommended ||| 0-0 0-1 2-1 3-1 4-3 4-4
Umgehung von adipösen Regionen ||| adipose regions , ||| 0-0 0-1 2-1 3-1
Umgehung von adipösen Regionen ||| adipose regions ||| 0-0 0-1 2-1 3-1
Umstellung notwendig ||| several ||| 0-0 1-0
Umständen ||| a small minority ||| 0-1 0-2
Umständen ||| small minority ||| 0-0 0-1
Umwelt zu schützen . ||| protect the environment . ||| 0-0 1-0 1-1 2-2 3-3
Umwelt zu schützen . ||| to protect the environment . ||| 0-0 0-1 1-1 1-2 2-3 3-4
Umwelt zu schützen ||| protect the environment ||| 0-0 1-0 1-1 2-2
Umwelt zu schützen ||| to protect the environment ||| 0-0 0-1 1-1 1-2 2-3
Umwelt zu ||| protect the ||| 0-0 1-0 1-1
Umwelt zu ||| to protect the ||| 0-0 0-1 1-1 1-2
Unbedenklichkeit . ||| safety . ||| 0-0 1-1
Unbedenklichkeit und Wirksamkeit von Rimonabant ||| safety and efficacy of rimonabant ||| 0-0 1-1 2-2 3-3 4-4
Unbedenklichkeit und Wirksamkeit von ||| safety and efficacy of ||| 0-0 1-1 2-2 3-3
Unbedenklichkeit und Wirksamkeit ||| safety and efficacy ||| 0-0 1-1 2-2
Unbedenklichkeit und ||| safety and ||| 0-0 1-1
Unbedenklichkeit von Rimonabant ||| safety of rimonabant ||| 0-0 1-1 2-2
Unbedenklichkeit von ||| safety of ||| 0-0 1-1
Unbedenklichkeit ||| safety ||| 0-0
Unbehagen ||| Unbehagen ||| 0-0
Unerwünschte Wirkungen , die ||| Adverse reactions ||| 0-0 1-0 0-1
Unerwünschte Wirkungen , ||| Adverse reactions ||| 0-0 1-0 0-1
Unerwünschte Wirkungen ||| Adverse reactions ||| 0-0 1-0 0-1
United Kingdom BRISTOL-MYERS SQUIBB PHARMACEUTICALS ||| United Kingdom BRISTOL-MYERS SQUIBB PHARMACEUTICALS ||| 0-0 1-1 2-2 3-3 4-4
United Kingdom BRISTOL-MYERS SQUIBB ||| United Kingdom BRISTOL-MYERS SQUIBB ||| 0-0 1-1 2-2 3-3
United Kingdom BRISTOL-MYERS ||| United Kingdom BRISTOL-MYERS ||| 0-0 1-1 2-2
United Kingdom Takeda UK Ltd ||| United Kingdom Takeda UK Ltd ||| 0-0 1-1 2-2 3-3 4-4
United Kingdom Takeda UK ||| United Kingdom Takeda UK ||| 0-0 1-1 2-2 3-3
United Kingdom Takeda ||| United Kingdom Takeda ||| 0-0 1-1 2-2
United Kingdom ||| United Kingdom ||| 0-0 1-1
United ||| United ||| 0-0
Unregelmäßiger Herzschlag ( ||| Irregular heart rhythm ( ||| 0-0 1-1 1-2 2-3
Unregelmäßiger Herzschlag ||| Irregular heart rhythm ||| 0-0 1-1 1-2
Unregelmäßiger ||| Irregular ||| 0-0
Unruhe ||| agitation ||| 0-0
Unspezifische ||| Non-specific skin ||| 0-0 0-1
Unter Verwendung einer sterilen Spritze ||| Using a sterile syringe , ||| 0-0 1-1 2-1 3-2 4-3
Unter Verwendung einer sterilen Spritze ||| Using a sterile syringe ||| 0-0 1-1 2-1 3-2 4-3
Unter Verwendung einer sterilen ||| Using a sterile ||| 0-0 1-1 2-1 3-2
Unter Verwendung einer ||| Using a ||| 0-0 1-1 2-1
Unter keinen Umständen sollten Sie ||| Under no circumstances should you ||| 0-0 2-0 1-1 2-2 3-3 4-4
Unter keinen Umständen sollten ||| Under no circumstances should ||| 0-0 2-0 1-1 2-2 3-3
Unter keinen Umständen ||| Under no circumstances ||| 0-0 2-0 1-1 2-2
Unter ||| Using ||| 0-0
Unterdrückung ||| suppress ||| 0-0
Unterfunktion der Nebenschilddrüsen , ||| diminished parathyroid reserve , ||| 0-0 2-1 2-2 3-3
Unterfunktion der Nebenschilddrüsen ||| diminished parathyroid reserve ||| 0-0 2-1 2-2
Unterfunktion der ||| diminished ||| 0-0
Unterfunktion ||| diminished ||| 0-0
Untergruppen von 517 bis ||| subsets ranging from 517 to ||| 0-0 1-1 1-2 2-3 3-4
Untergruppen von 517 ||| subsets ranging from 517 ||| 0-0 1-1 1-2 2-3
Untergruppen von ||| subsets ranging from ||| 0-0 1-1 1-2
Untergruppen ||| analyses ||| 0-0
Untergruppen ||| subsets ||| 0-0
Unterhautzellgewebes ||| tissue ||| 0-0
Unternehmen entschied ||| company decided ||| 0-0 1-1
Unternehmen führte außerdem Studien ||| company also carried out studies ||| 0-0 1-0 2-1 2-2 2-3 3-4
Unternehmen führte außerdem ||| company also carried out ||| 0-0 1-0 2-1 2-2 2-3
Unternehmen führte ||| company ||| 0-0 1-0
Unternehmen legte außerdem Daten aus ||| company also presented data from ||| 0-0 1-0 2-1 1-2 3-3 4-4
Unternehmen legte außerdem Daten ||| company also presented data ||| 0-0 1-0 2-1 1-2 3-3
Unternehmen legte außerdem ||| company also presented ||| 0-0 1-0 2-1 1-2
Unternehmen ||| company ||| 0-0
Unternehmer : ||| holder : ||| 0-0 1-1
Unternehmer und Hersteller ||| Authorisation Holder and Manufacturer ||| 0-0 0-1 1-2 2-3
Unternehmer und ||| Authorisation Holder and ||| 0-0 0-1 1-2
Unternehmer ||| Authorisation Holder ||| 0-0 0-1
Unternehmer ||| holder ||| 0-0
Unternehmers in Verbindung . ||| Authorisation Holder . ||| 0-0 1-0 2-1 3-2
Unternehmers in Verbindung . ||| Authorisation Holder : ||| 0-0 1-0 2-1 3-1 2-2
Unternehmers in Verbindung : ||| Authorisation Holder : ||| 0-0 1-0 2-1 3-2
Unternehmers in Verbindung ||| Authorisation Holder ||| 0-0 1-0 2-1
Unternehmers in ||| Authorisation ||| 0-0 1-0
Unterschied im Gesamtüberleben zwischen den ||| difference in overall survival between ||| 0-0 1-0 1-1 2-2 2-3 4-3 3-4
Unterschied im ||| difference in ||| 0-0 1-0 1-1
Unterschiede . ||| differences . ||| 0-0 1-1
Unterschiede bei Hüftfrakturen ||| differences in hip fracture , ||| 0-0 1-1 2-2 2-3
Unterschiede bei Hüftfrakturen ||| differences in hip fracture ||| 0-0 1-1 2-2 2-3
Unterschiede bei ||| differences in ||| 0-0 1-1
Unterschiede ||| differences ||| 0-0
Unterstützung der ||| an aid in the ||| 0-0 0-1 1-2 1-3
Unterstützung ||| an aid ||| 0-0 0-1
Untersuchungen , beispielsweise ||| conduct investigations , for example ||| 0-0 0-1 1-2 2-4
Untersuchungen , ||| conduct investigations , for ||| 0-0 0-1 1-2
Untersuchungen , ||| conduct investigations , ||| 0-0 0-1 1-2
Untersuchungen zum karzinogenen Potential ||| The carcinogenic potential ||| 0-0 1-1 2-1 3-1 2-2
Untersuchungen zur Genotoxizität wurde Aripiprazol ||| standard genotoxicity tests , aripiprazole ||| 0-0 1-0 2-1 2-2 3-2 4-4
Untersuchungen zur Genotoxizität wurde ||| standard genotoxicity tests , ||| 0-0 1-0 2-1 2-2 3-2
Untersuchungen zur Genotoxizität wurde ||| standard genotoxicity tests ||| 0-0 1-0 2-1 2-2 3-2
Untersuchungen zur Sicherheit und ||| The safety and ||| 0-0 1-1 2-1 3-2
Untersuchungen zur Sicherheit ||| The safety ||| 0-0 1-1 2-1
Untersuchungen zur ||| standard ||| 0-0 1-0
Untersuchungen ||| The ||| 0-0
Untersuchungen ||| conduct investigations ||| 0-0 0-1
Unterzuckerungen ||| low blood ||| 0-0 0-1
Unwohlsein , ||| , malaise ||| 1-0 0-1
Unwohlsein ||| malaise ||| 0-0
Unzureichende Blutverdünnung ||| Inadequate thinning ||| 0-0 0-1 1-1
Urin ||| urine ||| 0-0
Urtikaria ) ||| urticaria ) ||| 0-0 1-1
Urtikaria , Exanthem Sehr selten ||| Urticaria , rash Very rare ||| 0-0 2-0 1-1 2-2 3-3 4-4
Urtikaria , Exanthem Sehr ||| Urticaria , rash Very ||| 0-0 2-0 1-1 2-2 3-3
Urtikaria , Exanthem ||| Urticaria , rash ||| 0-0 2-0 1-1 2-2
Urtikaria und Angioödem ||| urticaria and angioedema ||| 0-0 1-1 2-2
Urtikaria und ||| urticaria and ||| 0-0 1-1
Urtikaria ||| urticaria ||| 0-0
Uveitis , Episkleritis , ||| pain Uveitis , episcleritis , ||| 0-0 0-1 1-2 2-3 3-4
Uveitis , Episkleritis ||| pain Uveitis , episcleritis ||| 0-0 0-1 1-2 2-3
Uveitis , ||| pain Uveitis , ||| 0-0 0-1 1-2
Uveitis ||| pain Uveitis ||| 0-0 0-1
Uxbridge - Middlesex UB8 1HU ||| Uxbridge - Middlesex UB8 1HU ||| 0-0 1-1 2-2 3-3 4-4
Uxbridge - Middlesex UB8 ||| Uxbridge - Middlesex UB8 ||| 0-0 1-1 2-2 3-3
Uxbridge - Middlesex ||| Uxbridge - Middlesex ||| 0-0 1-1 2-2
Uxbridge - ||| Uxbridge - ||| 0-0 1-1
Uxbridge ||| Uxbridge ||| 0-0
VANTAS ( siehe Anhang I ||| VANTAS ( see Annex I ||| 0-0 1-1 2-2 3-3 4-3 4-4
VANTAS ( siehe ||| VANTAS ( see ||| 0-0 1-1 2-2
VANTAS ( ||| VANTAS ( ||| 0-0 1-1
VANTAS ||| VANTAS ||| 0-0
VERBOT DES VERKAUFS , ||| PROHIBITION OF SALE , ||| 0-0 1-1 2-2 3-3
VERBOT DES VERKAUFS ||| PROHIBITION OF SALE ||| 0-0 1-1 2-2
VERBOT DES ||| PROHIBITION OF ||| 0-0 1-1
VERBOT ||| PROHIBITION ||| 0-0
VERKAUFS , ||| SALE , ||| 0-0 1-1
VERKAUFS ||| SALE ||| 0-0
VERMERK " NUR FÜR ||| THE WORDS FOR ||| 0-0 0-1 1-1 2-1 3-2
VERMERK " NUR ||| THE WORDS ||| 0-0 0-1 1-1 2-1
VERWENDETEM ARZNEIMITTEL ODER DAVON ||| DERIVED FROM SUCH MEDICINAL PRODUCTS ||| 0-0 0-1 1-1 1-2 2-2 1-3 3-4
VERWENDETEM ARZNEIMITTEL ODER VON ||| PRODUCT OR WASTE MATERIALS ||| 1-0 2-1 3-2 0-3 3-3
VERWENDETEM ARZNEIMITTEL ODER ||| DERIVED FROM SUCH MEDICINAL ||| 0-0 0-1 1-1 1-2 2-2 1-3
VERWENDETEN ARZNEIMITTELN ODER VON ||| PRODUCTS OR WASTE MATERIALS ||| 0-0 1-0 2-1 3-2 3-3
VERWENDETEN ARZNEIMITTELN ODER ||| PRODUCTS OR ||| 0-0 1-0 2-1
VERWENDETEN ARZNEIMITTELN ||| PRODUCTS ||| 0-0 1-0
VERZEICHNIS DER BEZEICHNUNG ||| LIST OF THE ||| 0-0 1-1 2-1 1-2
VERZEICHNIS ||| LIST ||| 0-0
VISTOR HF Sími : + ||| VISTOR HF Sími : + ||| 0-0 1-1 2-2 3-3 4-4
VISTOR HF Sími : ||| VISTOR HF Sími : ||| 0-0 1-1 2-2 3-3
VISTOR HF Sími ||| VISTOR HF Sími ||| 0-0 1-1 2-2
VISTOR HF ||| VISTOR HF ||| 0-0 1-1
VISTOR ||| VISTOR ||| 0-0
VOLUMEN ODER EINHEITEN ||| VOLUME OR BY UNIT ||| 0-0 1-1 2-2 2-3
VOLUMEN ODER ||| VOLUME OR BY ||| 0-0 1-1 0-2 1-2
VOLUMEN ODER ||| VOLUME OR ||| 0-0 1-1
VOLUMEN ||| VOLUME ||| 0-0
VON ABFALLMATERIALIEN , SOFERN ERFORDERLICH ||| WASTE MATERIALS , IF ANY ||| 0-0 0-1 2-2 1-3 3-3 3-4 4-4
VON KINDERN AUFBEWAHREN " ||| AND SIGHT OF CHILDREN ||| 1-0 1-1 0-2 2-2 2-3 3-3
VON NICHT ||| OF ||| 0-0 1-0
VON NICHT ||| OR WASTE MATERIALS ||| 0-0 0-1 1-2
VON ||| OR WASTE ||| 0-0 0-1
VON ||| WASTE MATERIALS ||| 0-0 0-1
VOR DER ANWENDUNG VON ||| YOU USE ||| 0-0 1-0 2-1 3-1
VOR DER ||| YOU ||| 0-0 1-0
VORSICHTSMASSNAHMEN FÜR DIE BESEITIGUNG ||| DISPOSAL OF UNUSED MEDICINAL PRODUCTS ||| 0-0 1-1 1-2 2-2 2-3 3-4
VORSICHTSMASSNAHMEN FÜR DIE ||| DISPOSAL OF UNUSED MEDICINAL ||| 0-0 1-1 1-2 2-2 2-3
VORSICHTSMASSNAHMEN ||| DISPOSAL ||| 0-0
Valproat ( ein anderes Antipsychotikum ||| valproate ( another antipsychotic medicine ||| 0-0 1-1 3-2 4-3 4-4
Valproat ( ein anderes ||| valproate ( another ||| 0-0 1-1 3-2
Valproat ( ein ||| valproate ( ||| 0-0 1-1
Valproat ( ||| valproate ( ||| 0-0 1-1
Valproat oder Lithium eingenommen ||| either valproate or lithium ||| 0-0 0-1 2-1 3-1 1-2 2-3
Valproat oder Lithium ||| valproate or lithium ||| 0-0 1-1 2-2
Valproat oder ||| valproate or ||| 0-0 1-1
Valproat ||| valproate ||| 0-0
Vanille-Aroma künstlich ( ||| Vanilla flavour ( including ||| 0-0 1-1 2-2 1-3
Vanille-Aroma ||| Vanilla ||| 0-0
Vantas , ||| Vantas ||| 0-0
Vantas , ||| unique Vantas ||| 0-1
Vantas ist ein neuer ||| Vantas is a new ||| 0-0 1-1 2-2 3-3
Vantas ist ein ||| Vantas is a ||| 0-0 1-1 2-2
Vantas ist ||| Vantas is ||| 0-0 1-1
Vantas wurde hinreichend untersucht . ||| Vantas is sufficiently investigated and ||| 0-0 2-2 3-3 4-3
Vantas wurde hinreichend untersucht . ||| Vantas is sufficiently investigated ||| 0-0 2-2 3-3 4-3
Vantas wurde hinreichend ||| Vantas is sufficiently ||| 0-0 2-2
Vantas wurde ||| Vantas is ||| 0-0
Vantas wurde ||| Vantas ||| 0-0
Vantas ||| Vantas is ||| 0-0
Vantas ||| Vantas ||| 0-0
Vantas ||| unique Vantas ||| 0-1
Variabilität ||| variability ||| 0-0
Vene ( ||| vein ( ||| 0-0
Vene ( ||| vein ||| 0-0
Vene ||| vein ( ||| 0-0
Vene ||| vein ||| 0-0
Venenthrombosen ergriffen werden . ||| ( DVTs ) . ||| 1-0 0-1 1-1 2-1 1-2 3-3
Venenthrombosen ergriffen werden ||| ( DVTs ) ||| 1-0 0-1 1-1 2-1 1-2
Verabreichen Sie Yarvitan nicht : ||| Do not administer Yarvitan : ||| 1-0 3-1 0-2 2-3 4-4
Verabreichen Sie Yarvitan nicht ||| Do not administer Yarvitan ||| 1-0 3-1 0-2 2-3
Verabreichen Sie Yarvitan ||| Always administer Yarvitan ||| 0-0 1-0 0-1 2-2
Verabreichen Sie das Arzneimittel zunächst ||| Administer the product orally during ||| 0-0 1-1 2-1 2-2 3-2 4-3
Verabreichen Sie das Arzneimittel zunächst ||| Administer the product orally ||| 0-0 1-1 2-1 2-2 3-2 4-3
Verabreichen Sie das Arzneimittel ||| Administer the product ||| 0-0 1-1 2-1 2-2 3-2
Verabreichen Sie ||| Always administer ||| 0-0 1-0 0-1
Verabreichen ||| Administer ||| 0-0
Verabreichen ||| administer ||| 0-0
Verabreichung Plasmavolumen-Vergrößerung mit ||| consistently apparent ||| 0-0 1-0 1-1
Verabreichung Plasmavolumen-Vergrößerung ||| consistently apparent ||| 0-0 1-0 1-1
Verabreichung eines CB1-Antagonisten ||| administration of a CB1 antagonist ||| 0-0 1-1 1-2 2-3 2-4
Verabreichung eines ||| administration of a ||| 0-0 1-1 1-2
Verabreichung soll die gekühlte Lösung ||| refrigerated solution to reach ||| 0-0 1-0 4-1 2-2 3-3
Verabreichung soll ||| refrigerated ||| 0-0 1-0
Verabreichung von Aclasta auf . ||| Aclasta administration . ||| 2-0 0-1 1-1 3-1 4-2
Verabreichung von Aclasta auf . ||| dose of Aclasta . ||| 1-0 1-1 3-1 0-2 2-2 4-3
Verabreichung von Aclasta auf ||| Aclasta administration ||| 2-0 0-1 1-1 3-1
Verabreichung von Aclasta auf ||| dose of Aclasta ||| 1-0 1-1 3-1 0-2 2-2
Verabreichung von Aclasta ||| administration of Aclasta ||| 0-0 1-1 2-2
Verabreichung von CYP3A4-Induktoren führt ||| administration of CYP3A4 inducers ||| 0-0 1-1 2-2 2-3
Verabreichung von CYP3A4-Induktoren ||| administration of CYP3A4 inducers ||| 0-0 1-1 2-2 2-3
Verabreichung von ||| administration of ||| 0-0 1-1
Verabreichung von ||| administration ||| 0-0
Verabreichung von ||| following the administration ||| 0-2
Verabreichung von ||| the administration ||| 0-1
Verabreichung ||| administration , ||| 0-0
Verabreichung ||| administration ||| 0-0
Verabreichung ||| and ||| 0-0
Verabreichung ||| following the administration ||| 0-2
Verabreichung ||| the administration ||| 0-1
Verabreichungen führten nicht zu einer ||| dosing did not lead to ||| 0-0 0-1 1-1 2-2 3-3 4-3 3-4
Verabreichungen führten nicht ||| dosing did not ||| 0-0 0-1 1-1 2-2
Verabreichungen führten ||| dosing did ||| 0-0 0-1 1-1
Verabreichungen ||| dosing ||| 0-0
Verabreichungen ||| markedly ||| 0-0
Verabreichungen ||| multiple dosing ||| 0-1
Verbesserung der Blutzuckereinstellung verringert ||| glycaemic control decreases ||| 0-0 1-1 2-1 2-2 3-2
Verbesserung der Insulinsensitivität einher . ||| improvement in insulin sensitivity . ||| 0-0 1-0 0-1 3-2 2-3 3-3 4-4
Verbesserung der Insulinsensitivität einher ||| improvement in insulin sensitivity ||| 0-0 1-0 0-1 3-2 2-3 3-3
Verbesserung der ||| improvement in ||| 0-0 1-0 0-1
Verbesserung ||| glycaemic ||| 0-0
Verbesserung ||| improvement in ||| 0-0
Verbesserung ||| improvement ||| 0-0
Verbindung , ||| as ||| 0-0 1-0
Verbindung . ||| Holder . ||| 0-0 1-1
Verbindung . ||| Holder : ||| 0-0 1-0 0-1
Verbindung : ||| Holder : ||| 0-0 1-1
Verbindung gebracht . ||| . ||| 1-0 2-0
Verbindung ||| Holder ||| 0-0
Vereinigtes Königreich . ||| United Kingdom . ||| 0-0 1-1 2-2
Vereinigtes Königreich ||| United Kingdom ||| 0-0 1-1
Vereinigtes ||| United ||| 0-0
Verfahren zur Rekonstitution ist ||| procedure for reconstitution is ||| 0-0 1-1 2-2 3-3
Verfahren zur Rekonstitution ||| procedure for reconstitution ||| 0-0 1-1 2-2
Verfahren zur ||| procedure for ||| 0-0 1-1
Verfahren ||| procedure ||| 0-0
Verfalldatum bezieht sich auf den ||| expiry date refers to the ||| 0-0 0-1 1-2 2-2 3-3 4-4
Verfalldatum bezieht sich auf ||| expiry date refers to ||| 0-0 0-1 1-2 2-2 3-3
Verfalldatum bezieht sich ||| expiry date refers ||| 0-0 0-1 1-2 2-2
Verfalldatum ||| expiry date ||| 0-0 0-1
Verfügbarkeit von reversiblen Methoden ||| methods ||| 2-0 3-0
Verfügbarkeit ||| reducing ||| 0-0
Verfügung ||| procedures ||| 0-0
Vergangenheit wurde die Testosteronsuppression ||| past , testosterone suppression was ||| 0-0 3-2 3-3 1-4
Vergangenheit ||| past , ||| 0-0
Vergangenheit ||| past ||| 0-0
Vergewissern Sie sich , dass ||| Ensure that you ||| 0-0 2-1 3-1 4-1 1-2
Vergewissern ||| Ensure ||| 0-0
Vergleich der ||| of ||| 0-0 1-0
Vergleich zu 8,7 % bei ||| versus 8.7 % for ||| 0-0 2-1 3-2 4-3
Vergleich zu 8,7 % ||| versus 8.7 % ||| 0-0 2-1 3-2
Vergleich zu 8,7 ||| versus 8.7 ||| 0-0 2-1
Vergleich zu Placebo : ||| versus placebo : ||| 0-0 1-1 2-1 3-2
Vergleich zu Placebo ||| versus placebo ||| 0-0 1-1 2-1
Vergleich zu Risedronat- behandelten Patienten ||| versus risedronate-treated patients ||| 0-0 2-0 2-1 3-1 4-2
Vergleich zu Risedronat- behandelten ||| versus risedronate-treated ||| 0-0 2-0 2-1 3-1
Vergleich zu den Ausgangswerten . ||| compared to baseline . ||| 0-0 1-0 1-1 2-1 3-2 4-3
Vergleich zu den Ausgangswerten ||| compared to baseline ||| 0-0 1-0 1-1 2-1 3-2
Vergleich zu den ||| compared to ||| 0-0 1-0 1-1 2-1
Vergleich zu ||| compared ||| 0-0
Vergleich zu ||| versus ||| 0-0
Vergleich ||| Between ||| 0-0
Vergleich ||| There was ||| 0-1
Vergleich ||| compared ||| 0-0
Vergleich ||| significantly ||| 0-0
Vergleich ||| versus ||| 0-0
Vergleich ||| was ||| 0-0
Vergleichbare Veränderungen der ||| Similar changes in ||| 0-0 1-1 1-2 2-2
Vergleichbare ||| Similar ||| 0-0
Vergleichsgruppe unter Sulfonylharnstoff beobachtet wurde ||| a sulphonylurea active comparator group ||| 2-0 0-1 1-1 2-1 0-2 2-3 0-4 3-4 4-4
Vergleichsstudien ||| comparative ||| 0-0
Verhalten und ||| and behaviour and ||| 1-0 0-1 1-2
Verhalten ||| behaviour ||| 0-0
Verhaltensstörungen ||| disturbed behaviours , ||| 0-0 0-1
Verhaltensstörungen ||| disturbed behaviours ||| 0-0 0-1
Verhaltensstörungen ||| disturbed ||| 0-0
Verkaufspackung : ||| for sale : ||| 0-0 0-1 1-2
Verkaufspackung ||| for sale ||| 0-0 0-1
Verkehr gebracht . ||| Verkehr gebracht . Me ||| 0-0 0-1 1-1 2-2 1-3 2-3
Verkehr gebracht . ||| be marketed . ||| 0-0 0-1 1-1 2-2
Verkehr gebracht ||| be marketed ||| 0-0 0-1 1-1
Verkehrstüchtigkeit und die Fähigkeit zum ||| ability to drive and ||| 0-0 1-0 2-0 3-1 3-2 4-2 4-3
Verkehrstüchtigkeit und die Fähigkeit zum ||| ability to drive and ||| 0-0 1-0 2-1 3-1 3-2 4-2 4-3
Verkehrstüchtigkeit und die Fähigkeit zum ||| on ability to drive and ||| 0-0 0-1 1-1 2-2 3-2 3-3 4-3 4-4
Verkehrstüchtigkeit und die ||| ability ||| 0-0 1-0 2-0
Verkehrstüchtigkeit und ||| Driving and ||| 0-0 1-1
Verkehrstüchtigkeit und ||| ability ||| 0-0 1-0
Verkehrstüchtigkeit und ||| on ability ||| 0-0 0-1 1-1
Verkehrstüchtigkeit ||| Driving ||| 0-0
Verlangsamung der Tumorprogression führen , ||| slowing of tumour progression , ||| 0-0 1-1 2-2 2-3 3-4 4-4
Verlangsamung der Tumorprogression ||| slowing of tumour progression ||| 0-0 1-1 2-2 2-3
Verlangsamung der ||| slowing of ||| 0-0 1-1
Verlangsamung ||| slowing ||| 0-0
Verlauf der klinischen Prüfungen beoachtet ||| observed during the clinical trials ||| 3-0 0-1 1-1 1-2 2-3 2-4 3-4 4-4
Verlauf der ||| during the ||| 0-0 1-0 1-1
Verlauf von peripherer Neuropathie zum ||| course of peripheral neuropathy to ||| 0-0 1-1 2-2 3-2 3-3 4-4
Verlauf von peripherer Neuropathie ||| course of peripheral neuropathy ||| 0-0 1-1 2-2 3-2 3-3
Verlauf von ||| course of ||| 0-0 1-1
Verlauf ||| course ||| 0-0
Verlauf ||| fall ||| 0-0
Verletzungen , ||| ; intercurrent infections ; inflammatory ||| 0-0 0-1 0-2 0-3 0-4 1-4
Verlust des Bewusstseins und extrapyramidale ||| loss of consciousness and extrapyramidal ||| 0-0 1-1 1-2 2-2 3-3 4-4
Verlust des Bewusstseins und ||| loss of consciousness and ||| 0-0 1-1 1-2 2-2 3-3
Verlust des Bewusstseins ||| loss of consciousness ||| 0-0 1-1 1-2 2-2
Verlust des Empfindens , Synkope ||| loss , syncope ||| 0-0 1-0 2-1 3-1 4-2
Verlust des Empfindens , ||| loss , ||| 0-0 1-0 2-1 3-1
Verlust des ||| loss ||| 0-0 1-0
Verlust ||| loss ||| 0-0
Verlängerung ) . ||| ) . ||| 1-0 2-1
Verlängerung ) ||| ) ||| 1-0
Verlängerung : 13 . ||| renewal : ||| 0-0 2-0 1-1 3-1
Vermehrung . ||| multiply . ||| 0-0 1-1
Vermehrung ||| multiply ||| 0-0
Verminderter Blutzuckerspiegel ( Hypoglykämie ||| decreased blood sugar ( hypoglycaemia ||| 0-0 1-1 1-2 2-3 3-4
Verminderter Blutzuckerspiegel ( ||| decreased blood sugar ( ||| 0-0 1-1 1-2 2-3
Verminderter Blutzuckerspiegel ||| decreased blood sugar ||| 0-0 1-1 1-2
Verminderter ||| decreased ||| 0-0
Verpackung Blisterpackung ( PVC/Aluminium ) ||| Blister ( PVC/ aluminium ) ||| 0-0 1-0 2-1 3-2 3-3 4-4
Verpackung Blisterpackung ( PVC/Aluminium ||| Blister ( PVC/ aluminium ||| 0-0 1-0 2-1 3-2 3-3
Verpackung Blisterpackung ( ||| Blister ( ||| 0-0 1-0 2-1
Verpackung Blisterpackung ||| Blister ||| 0-0 1-0
Verringerung der Insulinresistenz vermittelt . ||| reduction of insulin resistance . ||| 0-0 1-1 2-2 2-3 3-3 4-4
Verringerung der Insulinresistenz vermittelt ||| reduction of insulin resistance ||| 0-0 1-1 2-2 2-3 3-3
Verringerung der klinischen Frakturen bei ||| reduction in clinical fractures in ||| 0-0 1-0 4-1 2-2 3-3 4-4
Verringerung der ||| reduction in ||| 0-0 1-0
Verringerung der ||| reduction of ||| 0-0 1-1
Verringerung der ||| reduction ||| 0-0 1-0
Verringerung des Appetits kommen . ||| by decreased appetite . ||| 0-0 2-1 2-2 3-2 4-3
Verringerung des Appetits kommen . ||| followed by decreased appetite . ||| 0-1 2-2 2-3 3-3 4-4
Verringerung des Appetits kommen ||| by decreased appetite ||| 0-0 2-1 2-2 3-2
Verringerung des Appetits kommen ||| followed by decreased appetite ||| 0-1 2-2 2-3 3-3
Verringerung des ||| by ||| 0-0
Verringerung des ||| followed by ||| 0-1
Verringerung von 35 % ||| 35 % reduction ||| 2-0 3-1 0-2
Verringerung von ||| reduction ||| 0-0
Verringerung ||| by ||| 0-0
Verringerung ||| followed by ||| 0-1
Verringerung ||| reduction ||| 0-0
Verschlechterung der ||| worsening of ||| 0-0 1-1
Verschlechterung einer bestehenden Hypertonie . ||| aggravation of existing hypertension . ||| 0-0 1-0 2-0 1-1 2-2 3-3 4-4
Verschlechterung einer bestehenden Hypertonie ||| aggravation of existing hypertension ||| 0-0 1-0 2-0 1-1 2-2 3-3
Verschlechterung einer bestehenden ||| aggravation of existing ||| 0-0 1-0 2-0 1-1 2-2
Verschlechterung ||| worsening ||| 0-0
Verschluss des Dialysesystems ||| occlusion of the dialysis system ||| 0-0 1-1 1-2 0-3 2-3 1-4 2-4
Verschlusskappe des Fertigpens aufgesetzt ||| pen cap on ||| 0-0 0-1 1-1 2-1 3-1 3-2
Verschlusskrankheit ||| obstructive ||| 0-0
Verschreibung ( siehe Anhang I ||| prescription ( See Annex I ||| 0-0 1-1 2-2 3-2 3-3 4-3 4-4
Verschreibung ( ||| prescription ( ||| 0-0 1-1
Verschreibung erhältlich . ||| a prescription . du ||| 0-0 0-1 1-1 2-2 1-3
Verschreibung erhältlich . ||| with a prescription . ||| 0-0 0-1 0-2 1-2 2-3
Verschreibung erhältlich ||| with a prescription ||| 0-0 0-1 0-2 1-2
Verschreibung ||| prescription ||| 0-0
Verschreibung ||| siehe Anhang ||| 0-0 0-1
Verschreibungspflichtig . ||| on veterinary prescription . ||| 0-0 0-1 0-2 1-3
Verschreibungspflichtig ||| on veterinary prescription ||| 0-0 0-1 0-2
Version 3.0 ||| version 3.0 ||| 0-0 1-0 1-1
Version ||| version ||| 0-0
Verstoffwechselung ||| metabolism ||| 0-0
Verstopfung , Speichelüberproduktion Gefäßerkrankungen ||| constipation , salivary hypersecretion Vascular ||| 0-0 1-1 2-2 2-3 3-4
Verstopfung , Speichelüberproduktion ||| constipation , salivary hypersecretion ||| 0-0 1-1 2-2 2-3
Verstopfung , Stomatitis ||| constipation , stomatitis ||| 0-0 1-1 2-2
Verstopfung , ||| constipation , ||| 0-0 1-1
Verstopfung ||| constipation ||| 0-0
Versuchen Sie , die ABILIFY ||| Try to take the ABILIFY ||| 0-0 1-0 0-1 0-2 2-2 3-3 4-4
Versuchen Sie , die ||| Try to take the ||| 0-0 1-0 0-1 0-2 2-2 3-3
Versuchen Sie , ||| Try to take ||| 0-0 1-0 0-1 0-2 2-2
Versuchen Sie , ||| Try to take ||| 0-0 1-0 0-1 2-1 0-2
Versuchstiere und Hunde resorbieren ||| Laboratory animals and dogs rapidly ||| 0-0 0-1 1-2 2-3 3-3 3-4
Versuchstiere und ||| Laboratory animals and ||| 0-0 0-1 1-2
Versuchstiere ||| Laboratory animals ||| 0-0 0-1
Verteilung Es ||| Distribution No ||| 0-0 1-1
Verteilung ||| Distribution ||| 0-0
Verteilungsphasen ( und , ||| disposition phases ( and , ||| 0-0 0-1 1-2 2-3 3-4
Verteilungsphasen ( und ||| disposition phases ( and ||| 0-0 0-1 1-2 2-3
Verteilungsphasen ( ||| disposition phases ( ||| 0-0 0-1 1-2
Verteilungsphasen ||| disposition phases ||| 0-0 0-1
Verteilungsvolumen beim Menschen ||| of distribution in humans ||| 0-0 0-1 1-2 1-3 2-3
Verteilungsvolumen ||| of distribution ||| 0-0 0-1
Verteilungsvolumen ||| volume of distribution ||| 0-0 0-1 0-2
Verträglichkeit ||| well-tolerated ||| 0-0
Verträglichkeitsstudie ||| single-dose tolerability ||| 0-0 0-1
Verwendbar bis : ||| EXP Use ||| 0-0 1-0 2-0 0-1
Verwendbar bis : ||| EXP ||| 0-0 1-0 2-0
Verwendbar bis { MM/JJJJ } ||| EXP { month/ year } ||| 0-0 1-0 3-1 2-2 3-3 3-4 4-4
Verwendbar bis ||| EXP ||| 0-0 1-0
Verwenden Sie jede Spritze nur ||| Only use each syringe ||| 0-0 4-0 0-1 1-1 2-2 3-2 3-3
Verwenden ||| Use ||| 0-0
Verwendung ) ||| ) ||| 1-0
Verwendung einer sterilen Spritze ||| a sterile syringe , ||| 0-0 1-0 2-1 3-2
Verwendung einer sterilen Spritze ||| a sterile syringe ||| 0-0 1-0 2-1 3-2
Verwendung einer sterilen ||| a sterile ||| 0-0 1-0 2-1
Verwendung einer ||| a ||| 0-0 1-0
Verwendung mit Insulinspritzen mit ||| use with insulin syringes with ||| 0-0 1-1 2-2 2-3 3-4
Verwendung mit Insulinspritzen ||| use with insulin syringes ||| 0-0 1-1 2-2 2-3
Verwendung mit ||| use with ||| 0-0 1-1
Verwendung von Zoledronsäure bei ||| use of zoledronic acid in ||| 0-0 1-1 2-2 2-3 3-4
Verwendung von Zoledronsäure ||| use of zoledronic acid ||| 0-0 1-1 2-2 2-3
Verwendung von ||| use of ||| 0-0 1-1
Verwendung ||| use ||| 0-0
Verwendung ||| using ||| 0-0
Veränderung der Aripiprazol-Konzentrationen . ||| change in aripiprazole concentrations . ||| 0-0 1-0 0-1 2-2 2-3 3-4
Veränderung der Aripiprazol-Konzentrationen ||| change in aripiprazole concentrations ||| 0-0 1-0 0-1 2-2 2-3
Veränderung der Lendenwirbel-BMD ||| change in lumbar spine BMD ||| 0-0 1-0 0-1 1-2 1-3 2-3 1-4
Veränderung der Valproat- oder ||| important change in valproate or ||| 2-0 0-1 1-1 0-2 2-3 3-4
Veränderung der Valproat- ||| important change in valproate ||| 2-0 0-1 1-1 0-2 2-3
Veränderung der ||| change in ||| 0-0 1-0 0-1
Veränderung ||| change in ||| 0-0 0-1
Veränderung ||| in ||| 0-0
Veränderungen der routinemäßig kontrollierten ||| changes in routine ||| 0-0 1-0 2-1 2-2 3-2
Veränderungen der ||| changes in ||| 0-0 0-1 1-1
Veränderungen der ||| changes ||| 0-0 1-0
Veränderungen des HDL-Cholesterins und ||| Changes in HDL-C and ||| 0-0 0-1 1-1 2-2 3-3
Veränderungen des HDL-Cholesterins ||| Changes in HDL-C ||| 0-0 0-1 1-1 2-2
Veränderungen des ||| Changes in ||| 0-0 0-1 1-1
Veränderungen in Mutagenitätstests ||| changes in bacterial ||| 0-0 1-1 2-2
Veränderungen in der Lebensweise ( ||| lifestyle changes ( ||| 3-0 0-1 1-1 2-1 4-2
Veränderungen in der Lebensweise ||| lifestyle changes ||| 3-0 0-1 1-1 2-1
Veränderungen in der ||| changes ||| 0-0 1-0 2-0
Veränderungen in ||| changes in ||| 0-0 1-1
Veränderungen von Laborwerten . ||| alter laboratory test values . ||| 0-0 0-1 1-1 2-2 2-3 3-4
Veränderungen von Laborwerten ||| alter laboratory test values ||| 0-0 0-1 1-1 2-2 2-3
Veränderungen von ||| alter laboratory ||| 0-0 0-1 1-1
Veränderungen ||| changes ||| 0-0
Viele Patienten hatten Anzeichen ||| Many had signs ||| 0-0 1-0 2-1 3-2
Viele Patienten hatten ||| Many had ||| 0-0 1-0 2-1
Viele Patienten ||| Following the menopause bone loss ||| 0-0 0-2 0-3
Viele Patienten ||| Following the menopause bone ||| 0-0 0-2 0-3
Viele Patienten ||| Many ||| 0-0 1-0
Viele dieser Patienten hatten ||| Many of these patients had ||| 0-0 1-1 1-2 2-3 3-4
Viele dieser Patienten ||| Many of these patients ||| 0-0 1-1 1-2 2-3
Viele dieser ||| Many of these ||| 0-0 1-1 1-2
Viele ||| Following the menopause bone loss ||| 0-0 0-2 0-3
Viele ||| Following the menopause bone ||| 0-0 0-2 0-3
Viele ||| Many ||| 0-0
Vielleicht möchten Sie ||| You ||| 0-0 1-0 2-0
Vitamin D , ||| vitamin D supplementation , ||| 0-0 1-1 1-2 2-3
Vitamin D pro Tag ||| vitamin D supplementation per day ||| 0-0 1-1 1-2 2-3 3-4
Vitamin D pro ||| of vitamin D supplementation per ||| 0-1 1-2 1-3 2-4
Vitamin D pro ||| vitamin D supplementation per ||| 0-0 1-1 1-2 2-3
Vitamin D und ||| vitamin D and ||| 0-0 1-1 2-2
Vitamin D vor ||| vitamin D prior to ||| 0-0 1-1 2-2 2-3
Vitamin D ||| of vitamin D supplementation ||| 0-1 1-2 1-3
Vitamin D ||| vitamin D supplementation ||| 0-0 1-1 1-2
Vitamin D ||| vitamin D ||| 0-0 1-1
Vitamin ||| of vitamin ||| 0-1
Vitamin ||| vitamin ||| 0-0
Vitamin-B12- oder Folsäuremangel ||| vitamin B12 or folate deficiency ||| 0-0 0-1 2-1 1-2 2-3 2-4
Vitamin-B12- oder ||| vitamin B12 or ||| 0-0 0-1 1-2
Vitamin-B12- ||| vitamin B12 ||| 0-0 0-1
Vitamin-B12-Mangel ||| have the following causes ||| 0-0 0-2 0-3
Vor Anbruch : Im ||| Before use : store ||| 0-0 1-0 1-1 2-2 3-3
Vor Anbruch : ||| Before use : ||| 0-0 1-0 1-1 2-2
Vor Anbruch ||| Before use ||| 0-0 1-0 1-1
Vor dem Gebrauch ||| Complete ||| 0-0 1-0 2-0
Vor der Anwendung ||| Patients must ||| 0-0 0-1 1-1 2-1
Vor der Beendigung der ||| Before stopping ||| 0-0 1-1 2-1 3-1
Vor der Verabreichung soll ||| Allow the refrigerated ||| 0-0 1-1 2-2 3-2
Vor der ||| Allow the ||| 0-0 1-1
Vor und ||| Iron status ||| 0-0 0-1 1-1
Vor und ||| Patients ||| 0-0
Vor ||| Allow ||| 0-0
Vor ||| Before ||| 0-0
Vor ||| Patients ||| 0-0
Vorbereitung und die Verabreichung von ||| prepare and ||| 0-0 2-0 3-0 1-1
Vorbereitung und die Verabreichung ||| prepare and ||| 0-0 2-0 3-0 1-1
Vorbeugung manischer Episoden ||| prevent manic episodes ||| 0-0 1-1 2-2
Vorbeugung manischer ||| prevent manic ||| 0-0 1-1
Vorbeugung ||| prevent ||| 0-0
Vorbeugung ||| prevention of ||| 0-0
Vorbeugung ||| prevention ||| 0-0
Vorfälle in dem ||| uncommon in the ||| 1-0 1-1 2-2
Vorfälle in ||| uncommon in ||| 1-0 1-1
Vorgemischte Insulinprodukte werden normalerweise ||| Premixed insulin products are usually ||| 0-0 1-0 1-1 1-2 2-2 3-3 3-4
Vorgemischte Insulinprodukte werden ||| Premixed insulin products ||| 0-0 1-0 1-1 1-2 2-2
Vorhofflimmern ) wurde ||| atrial fibrillation ) has ||| 0-0 0-1 1-2 2-3
Vorhofflimmern ) ||| atrial fibrillation ) ||| 0-0 0-1 1-2
Vorhofflimmern , ||| fibrillation serious ||| 0-0 1-1
Vorhofflimmern Kopfschmerz , Schwindel ||| Atrial fibrillation Headache , dizziness ||| 1-0 0-1 1-2 2-3 3-4
Vorhofflimmern Kopfschmerz , ||| Atrial fibrillation Headache , ||| 1-0 0-1 1-2 2-3
Vorhofflimmern Kopfschmerz ||| Atrial fibrillation Headache ||| 1-0 0-1 1-2
Vorhofflimmern ist unbekannt . ||| atrial fibrillation is unknown . ||| 0-0 0-1 1-2 2-3 3-4
Vorhofflimmern ist unbekannt ||| atrial fibrillation is unknown ||| 0-0 0-1 1-2 2-3
Vorhofflimmern ist ||| atrial fibrillation is ||| 0-0 0-1 1-2
Vorhofflimmern ||| atrial fibrillation ||| 0-0 0-1
Vorhofflimmern ||| fibrillation incidences ||| 0-0
Vorhofflimmern ||| fibrillation ||| 0-0
Vorläuferzellen des Stammzellkompartiments ||| precursors of the stem cell ||| 0-0 1-1 1-2 1-3 2-3 2-4
Vorläuferzellen ||| precursors ||| 0-0
Vorschlag ||| proposal ||| 0-0
Vorschriften ||| in accordance ||| 0-0 0-1
Vorsicht anzuwenden ||| Vorsicht anzuwenden ||| 0-0 1-1
Vorsicht bei Patienten mit einem ||| used cautiously in patients ||| 0-0 1-0 0-1 4-1 1-2 2-3 3-3
Vorsicht bei Patienten ||| Vorsicht bei Patienten ||| 0-0 1-1 2-2
Vorsicht bei ||| Vorsicht bei ||| 0-0 1-1
Vorsicht geboten , ||| , caution should be exercised ||| 2-0 0-1 1-1 0-2 0-3 0-4
Vorsicht geboten ||| caution should be exercised ||| 0-0 1-0 0-1 0-2 0-3
Vorsicht ||| Caution ||| 0-0
Vorsicht ||| Vorsicht ||| 0-0
Vorsicht ||| caution ||| 0-0
Vorsichtsmaßnahmen , die ||| precautions ||| 0-0 2-0
Vorsichtsmaßnahmen für die Anwendung bei ||| precautions for use in ||| 0-0 2-0 1-1 3-2 4-3
Vorsichtsmaßnahmen für die Anwendung ||| precautions for use ||| 0-0 1-1 2-1 3-2
Vorsichtsmaßnahmen für die Anwendung ||| precautions for use ||| 0-0 2-0 1-1 3-2
Vorsichtsmaßnahmen für die ||| precautions for ||| 0-0 1-0 1-1 2-1
Vorsichtsmaßnahmen für die ||| precautions for ||| 0-0 1-1 2-1
Vorsichtsmaßnahmen für die ||| precautions for ||| 0-0 2-0 1-1
Vorsichtsmaßnahmen ||| precautions ||| 0-0
WARNHINWEIS , DASS ||| SPECIAL WARNING THAT THE ||| 0-0 0-1 1-2 2-2 2-3
WARNHINWEIS ||| SPECIAL WARNING ||| 0-0 0-1
WAS IST ABILIFY UND WOFÜR ||| WHAT ABILIFY IS AND WHAT ||| 0-0 2-1 1-2 4-2 3-3 4-4
WAS IST ABSEAMED UND WOFÜR ||| WHAT ABSEAMED IS AND WHAT ||| 0-0 2-1 1-2 4-2 3-3 4-4
WAS IST ACLASTA UND WOFÜR ||| WHAT ACLASTA IS AND WHAT ||| 0-0 2-1 1-2 4-2 3-3 4-4
WAS IST ACTOS UND WOFÜR ||| WHAT ACTOS IS AND WHAT ||| 0-0 2-1 1-2 4-2 3-3 4-4
WAS MUSS VOR DER ||| BEFORE YOU ||| 0-0 1-0 2-1 3-1
WAS MUSS ||| BEFORE ||| 0-0 1-0
WAS MÜSSEN SIE VOR DER ||| BEFORE YOU ||| 0-0 1-0 2-0 3-1 4-1
WAS MÜSSEN SIE ||| BEFORE ||| 0-0 1-0 2-0
WAS ||| WHAT ||| 0-0
WC2B 4AE , Vereinigtes Königreich ||| WC2B 4AE , United Kingdom ||| 0-0 1-1 2-2 3-3 4-4
WC2B 4AE , Vereinigtes ||| WC2B 4AE , United ||| 0-0 1-1 2-2 3-3
WC2B 4AE , ||| WC2B 4AE , ||| 0-0 1-1 2-2
WC2B 4AE Vereinigtes Königreich ||| WC2B 4AE United Kingdom ||| 0-0 1-1 2-2 3-3
WC2B 4AE Vereinigtes ||| WC2B 4AE United ||| 0-0 1-1 2-2
WC2B 4AE ||| WC2B 4AE ||| 0-0 1-1
WC2B ||| WC2B ||| 0-0
WIRD ES ANGEWENDET ? ||| IT IS USED FOR ||| 0-0 1-1 2-2 2-3 3-3
WIRD ES ||| IT IS ||| 0-0 1-1
WIRD ||| IT ||| 0-0
WIRKSAME ANWENDUNG DES TIERARZNEIMITTELS ||| EFFECTIVE USE OF THE PRODUCT ||| 1-0 0-1 1-1 3-1 2-2 2-3 2-4
WIRKSAME ||| SUPPLY ||| 0-0
WIRKSAMEN ANWENDUNG DES ||| EFFECTIVE USE OF THE ||| 0-0 0-1 1-1 1-2 2-3
WIRKSAMEN ANWENDUNG ||| EFFECTIVE USE OF ||| 0-0 0-1 1-1 1-2
WIRKSAMEN ANWENDUNG ||| EFFECTIVE USE ||| 0-0 0-1 1-1
WISSENSCHAFTLICHEN BEURTEILUNG ||| SCIENTIFIC EVALUATION ||| 0-0 1-1
WISSENSCHAFTLICHEN ||| SCIENTIFIC ||| 0-0
Wachstum ||| growth ||| 0-0
Wachstumsfaktor , der ||| growth factor ||| 0-0 1-0 0-1 2-1
Wachstumsfaktor für ||| growth ||| 0-0
Wachstumsfaktor ||| growth ||| 0-0
Wachstumsfaktoren , die in erster ||| growth factors that primarily ||| 0-0 1-0 0-1 2-2 4-2 3-3 4-3
Wachstumsfaktoren , ||| growth factors ||| 0-0 1-0 0-1
Wachstumsfaktoren sollte ||| growth factors ||| 0-0 0-1 1-1
Wachstumsfaktoren ||| growth ||| 0-0
Wachstumshormon und Danazol . ||| growth hormone and danazol . ||| 0-0 0-1 1-2 2-3 3-4
Wachstumshormon und Danazol ||| growth hormone and danazol ||| 0-0 0-1 1-2 2-3
Wachstumshormon und ||| growth hormone and ||| 0-0 0-1 1-2
Wachstumshormon ||| growth hormone ||| 0-0 0-1
Wahn und Paranoia . ||| delusion and paranoia . ||| 0-0 1-1 2-2 3-3
Wahn und Paranoia ||| delusion and paranoia ||| 0-0 1-1 2-2
Wahn und ||| delusion and ||| 0-0 1-1
Wahn ||| delusion ||| 0-0
Wahnvorstellungen , unzusammenhängende Sprache , ||| beliefs , incoherent speech ||| 0-0 1-1 4-1 2-2 3-2 3-3
Wahnvorstellungen ||| beliefs ||| 0-0
Wahrnehmung von ||| of ||| 0-0 1-0
Wahrscheinlichkeit , dass ||| experiencing ||| 0-0 1-0
Wahrscheinlichkeit , dass ||| of experiencing ||| 0-1 1-1
Wahrscheinlichkeit , ||| experiencing ||| 0-0 1-0
Wahrscheinlichkeit , ||| of experiencing ||| 0-1 1-1
Wahrscheinlichkeit ||| it less likely ||| 0-2
Wahrscheinlichkeit ||| less likely ||| 0-1
Wahrscheinlichkeit ||| likely ||| 0-0
Warfarin ( CYP2C9-Substrat ) und ||| Warfarin ( CYP2C9-Substrat ) und ||| 1-0 0-1 1-1 2-1 1-2 3-3 4-4
Warfarin ( CYP2C9-Substrat ) ||| Warfarin ( CYP2C9-Substrat ) ||| 1-0 0-1 1-1 2-1 1-2 3-3
Warfarin ( CYP2C9-Substrat ||| Warfarin ( CYP2C9-Substrat ||| 1-0 0-1 1-1 2-1 1-2
Warfarin ) ||| warfarin ) ||| 0-0 1-1
Warfarin , ||| warfarin , ||| 0-0 1-1
Warfarin ||| warfarin ||| 0-0
Warnhinweise und Vorsichtsmaßnahmen für die ||| warnings and precautions for ||| 0-0 1-1 2-2 3-3 4-3
Warnhinweise und Vorsichtsmaßnahmen ||| warnings and precautions ||| 0-0 1-1 2-2
Warnhinweise und ||| warnings and ||| 0-0 1-1
Warnhinweise ||| warnings ||| 0-0
Warnsignal sollten plötzlich auftretende ||| be paid to sudden stabbing ||| 0-0 0-1 1-1 2-2 2-3 3-4
Warnsignal sollten plötzlich ||| be paid to sudden ||| 0-0 0-1 1-1 2-2 2-3
Warnsignal sollten ||| be paid ||| 0-0 0-1 1-1
Was ABILIFY enthält Der ||| What ABILIFY contains The ||| 0-0 1-1 2-2 3-3
Was ABILIFY enthält ||| What ABILIFY contains ||| 0-0 1-1 2-2
Was ABILIFY ||| What ABILIFY ||| 0-0 1-1
Was Actos enthält Der ||| What Actos contains The ||| 0-0 1-1 2-2 3-3
Was Actos enthält ||| What Actos contains ||| 0-0 1-1 2-2
Was Actos ||| What Actos ||| 0-0 1-1
Was ist ABILIFY und ||| What ABILIFY is and ||| 0-0 2-1 1-2 3-3
Was ist ABILIFY ||| What ABILIFY is ||| 0-0 2-1 1-2
Was ist Abseamed und ||| What Abseamed is and ||| 0-0 2-1 1-2 3-3
Was ist Abseamed ||| What Abseamed is ||| 0-0 2-1 1-2
Was ist Aclasta und ||| What Aclasta is and ||| 0-0 2-1 1-2 3-3
Was ist Aclasta ||| What Aclasta is ||| 0-0 2-1 1-2
Was ist Actos und ||| What Actos is and ||| 0-0 2-1 1-2 3-3
Was ist Actos ||| What Actos is ||| 0-0 2-1 1-2
Was ||| What ||| 0-0
Wasser auflösen und ||| water and ||| 0-0 1-0 2-1
Wasser auflösen ||| water ||| 0-0 1-0
Wasser ein und schlucken Sie ||| water and swallow it ||| 0-0 2-1 1-2 3-2 4-2 3-3
Wasser für Injektionszwecke . ||| and water for injections . ||| 0-0 0-1 1-2 2-3 3-4
Wasser für Injektionszwecke . ||| water for injection . ||| 0-0 2-0 1-1 2-2 3-3
Wasser für Injektionszwecke . ||| water for injections . ||| 0-0 1-1 2-2 3-3
Wasser für Injektionszwecke Salzsäure ||| Water for injections Hydrochloric acid ||| 0-0 1-1 2-2 3-3 3-4
Wasser für Injektionszwecke ||| Water for injection ||| 0-0 2-0 1-1 2-2
Wasser für Injektionszwecke ||| Water for injections ||| 0-0 1-1 2-2
Wasser für Injektionszwecke ||| and water for injections ||| 0-0 0-1 1-2 2-3
Wasser für Injektionszwecke ||| water for injection ||| 0-0 2-0 1-1 2-2
Wasser für Injektionszwecke ||| water for injections ||| 0-0 1-1 2-2
Wasser für ||| Water for ||| 0-0 1-1
Wasser für ||| and water for ||| 0-0 0-1 1-2
Wasser für ||| water for ||| 0-0 1-1
Wasser spülen . ||| of water . ||| 0-1 1-1 2-2
Wasser spülen . ||| water . ||| 0-0 1-0 2-1
Wasser spülen ||| of water ||| 0-1 1-1
Wasser spülen ||| water ||| 0-0 1-0
Wasser ||| Water ||| 0-0
Wasser ||| and water ||| 0-0 0-1
Wasser ||| of water ||| 0-1
Wasser ||| water ||| 0-0
Way Wingates Industrial Park Westhoughton ||| Way Wingates Industrial Park Westhoughton ||| 0-0 1-1 2-2 3-3 4-4
Way Wingates Industrial Park ||| Way Wingates Industrial Park ||| 0-0 1-1 2-2 3-3
Way Wingates Industrial ||| Way Wingates Industrial ||| 0-0 1-1 2-2
Way Wingates ||| Way Wingates ||| 0-0 1-1
Way ||| Way ||| 0-0
Wechseljahren ||| menopause ||| 0-0
Wechselwirkung zwischen Epoetin alfa ||| an interaction between epoetin alfa ||| 0-0 0-1 1-2 2-3 3-4
Wechselwirkung zwischen Epoetin ||| an interaction between epoetin ||| 0-0 0-1 1-2 2-3
Wechselwirkung zwischen ||| an interaction between ||| 0-0 0-1 1-2
Wechselwirkung ||| an interaction ||| 0-0 0-1
Wechselwirkungen bei ||| interactions ||| 0-0 1-0
Wechselwirkungen itte ||| interaction ||| 0-0 1-0
Wechselwirkungen mit Arzneimitteln ||| Interactions with ||| 0-0 2-0 1-1
Wechselwirkungen mit anderen Arzneimitteln ||| Interaction with other medicinal products ||| 0-0 1-1 2-2 2-3 2-4 3-4
Wechselwirkungen mit anderen ||| Interactions with other ||| 0-0 1-1 2-2
Wechselwirkungen mit ||| Interaction with ||| 0-0 1-1
Wechselwirkungen mit ||| Interactions with ||| 0-0 1-1
Wechselwirkungen ||| Interaction ||| 0-0
Wechselwirkungen ||| Interactions ||| 0-0
Wechselwirkungen ||| interaction ||| 0-0
Wechselwirkungen ||| interactions ||| 0-0
Wege unter Beteiligung der Enzyme ||| by multiple pathways involving the ||| 0-0 0-1 1-1 2-2 4-2 2-3 3-4
Wege unter ||| by multiple ||| 0-0 0-1 1-1
Wegen ||| Due ||| 0-0
Weinsäure ( Ph.Eur. ) Natriumhydroxid ||| Tartaric acid Sodium hydroxide ||| 0-0 0-1 1-1 2-2 3-2 4-3
Weinsäure ( Ph.Eur. ) ||| Tartaric acid Sodium ||| 0-0 0-1 1-1 2-2 3-2
Weinsäure ( ||| Tartaric acid ||| 0-0 0-1 1-1
Weinsäure ( ||| tartaric acid ||| 0-0 0-1 1-1
Weise ||| manner ||| 0-0
Weitere Studien befassten sich ||| Further studies also looked ||| 0-0 1-1 2-2 2-3 3-3
Weitere Studien ||| Further studies ||| 0-0 1-1
Weitere Symptome können ||| Additional signs may include ||| 0-0 0-1 1-1 2-2 0-3
Weitere Vergleichsstudien sind daher nicht ||| further comparative studies are not ||| 1-0 0-1 1-1 1-2 2-3 3-3 4-4
Weitere Vergleichsstudien sind daher ||| and further comparative studies are ||| 1-1 0-2 1-2 1-3 2-4 3-4
Weitere Vergleichsstudien sind daher ||| further comparative studies are ||| 1-0 0-1 1-1 1-2 2-3 3-3
Weitere Vergleichsstudien ||| and further comparative studies ||| 1-1 0-2 1-2 1-3
Weitere Vergleichsstudien ||| further comparative studies ||| 1-0 0-1 1-1 1-2
Weitere ||| Further ||| 0-0
Welche Maßnahmen werden zur ||| exercise , to treat ||| 0-0 1-1 3-2 3-3
Welche Maßnahmen werden ||| Which measures are being ||| 0-0 1-1 2-2 2-3
Welche Maßnahmen werden ||| exercise , ||| 0-0 1-1
Welche Maßnahmen ||| Which measures ||| 0-0 1-1
Welche Maßnahmen ||| exercise , ||| 0-0 1-1
Welche ||| Which ||| 0-0
Welche ||| exercise ||| 0-0
Welchen Nutzen hat Abraxane ||| What benefit has Abraxane ||| 0-0 1-1 2-2 3-3
Welchen Nutzen hat Aclasta ||| What benefit has Aclasta ||| 0-0 1-1 2-2 3-3
Welchen Nutzen hat Actos ||| What benefit has Actos ||| 0-0 1-1 2-2 3-3
Welchen Nutzen hat Actraphane ||| What benefit has Actraphane ||| 0-0 1-1 2-2 3-3
Welchen Nutzen hat ||| What benefit has ||| 0-0 1-1 2-2
Welchen Nutzen ||| What benefit ||| 0-0 1-1
Welchen ||| What ||| 0-0
Welches Risiko ist mit ||| Welches Risiko ist mit ||| 0-0 1-1 2-2 3-3
Welches Risiko ist ||| Welches Risiko ist ||| 0-0 1-1 2-2
Welches Risiko ||| Welches Risiko ||| 0-0 1-1
Welches ||| 2/ 3 What ||| 0-0 0-1 0-2
Welches ||| Welches ||| 0-0
Wellington Road Wokingham Berkshire RG40 ||| Wellington Road Wokingham Berkshire RG40 ||| 0-0 1-1 2-2 3-3 4-4
Wellington Road Wokingham Berkshire ||| Wellington Road Wokingham Berkshire ||| 0-0 1-1 2-2 3-3
Wellington Road Wokingham ||| Wellington Road Wokingham ||| 0-0 1-1 2-2
Wellington Road ||| Wellington Road ||| 0-0 1-1
Wellington ||| Wellington ||| 0-0
Weniger als 1 % ||| Less than 1 % of ||| 0-0 1-1 2-2 3-3
Weniger als 1 % ||| Less than 1 % ||| 0-0 1-1 2-2 3-3
Weniger als 1 ||| Less than 1 ||| 0-0 1-1 2-2
Weniger als ||| Less than ||| 0-0 1-1
Weniger ||| Less ||| 0-0
Wenn Aktivität , Konzentration und ||| When activity , concentrations and ||| 0-0 1-1 2-2 3-3 4-4
Wenn Aktivität , Konzentration ||| When activity , concentrations ||| 0-0 1-1 2-2 3-3
Wenn Aktivität , ||| When activity , ||| 0-0 1-1 2-2
Wenn Aktivität ||| When activity ||| 0-0 1-1
Wenn Aripiprazol gleichzeitig ||| When aripiprazole was administered concomitantly ||| 0-0 1-1 2-2 2-3 2-4
Wenn Aripiprazol ||| When aripiprazole ||| 0-0 1-1
Wenn Ihre Werte des ||| If your levels of the ||| 0-0 1-1 2-2 3-3 3-4
Wenn Ihre Werte ||| If your levels ||| 0-0 1-1 2-2
Wenn Ihre ||| If your ||| 0-0 1-1
Wenn Sie an einem polyzystischen ||| If you have polycystic ovary ||| 0-0 1-1 4-2 2-3 3-3 4-3 4-4
Wenn Sie den Eindruck haben ||| If you have the impression ||| 0-0 1-1 4-2 2-3 3-4
Wenn Sie eine ||| If you ||| 0-0 1-1 2-1
Wenn Sie eine ||| If you ||| 0-0 2-0 1-1
Wenn Sie nicht ||| if you are ||| 0-0 1-0 1-1 1-2 2-2
Wenn Sie unter diesen Symptomen ||| If you experience these symptoms ||| 0-0 1-1 1-2 2-2 3-3 4-4
Wenn Sie unter diesen ||| If you experience these ||| 0-0 1-1 1-2 2-2 3-3
Wenn Sie unter ||| If you experience ||| 0-0 1-1 1-2 2-2
Wenn Sie versehentlich ||| If you accidentally ||| 0-0 1-1 2-2
Wenn Sie weitere Fragen haben ||| If you have any further ||| 0-0 1-1 4-2 2-3 2-4 3-4 4-4
Wenn Sie weitere Fragen haben ||| If you have further ||| 0-0 1-1 4-2 2-3 3-3 4-3
Wenn Sie weitere ||| If you have any ||| 0-0 1-1 2-2 2-3
Wenn Sie weitere ||| If you need ||| 0-0 1-1 2-2
Wenn Sie ||| If you are ||| 0-0 1-1 1-2
Wenn Sie ||| If you have ||| 0-0 1-1 1-2
Wenn Sie ||| If you ||| 0-0 1-1
Wenn Sie ||| You ||| 0-0 1-0
Wenn Sie ||| if you are ||| 1-0 0-1 1-1 1-2
Wenn Sie ||| if you have ||| 1-0 0-1 1-1 1-2
Wenn Sie ||| if you ||| 0-0 1-0 1-1
Wenn Sie ||| if you ||| 1-0 0-1 1-1
Wenn Sie ||| you ||| 0-0 1-0
Wenn bei Ihnen Bereiche ||| if you have had sections ||| 0-0 0-1 2-1 1-2 2-2 3-3 3-4
Wenn bei Ihnen einige oder ||| you have had some or ||| 0-0 2-0 1-1 2-1 2-2 3-3 4-4
Wenn bei Ihnen einige ||| you have had some ||| 0-0 2-0 1-1 2-1 2-2 3-3
Wenn bei Ihnen ||| if you have ||| 0-0 0-1 2-1 1-2 2-2
Wenn bei Ihnen ||| you have had ||| 0-0 2-0 1-1 2-1 2-2
Wenn der CYP3A4- oder ||| When the CYP3A4 or ||| 0-0 1-1 2-2 3-3
Wenn der CYP3A4- ||| When the CYP3A4 ||| 0-0 1-1 2-2
Wenn der CYP3A4-Induktor ||| When the CYP3A4 inducer ||| 0-0 1-1 2-2 2-3
Wenn der Hämoglobinwert ||| If the haemoglobin is ||| 0-0 1-1 2-2 2-3
Wenn der ||| If the ||| 0-0 1-1
Wenn der ||| When the ||| 0-0 1-1
Wenn die ALT-Spiegel ||| If ALT levels ||| 0-0 2-1 1-2 2-2
Wenn die Suspension mit der ||| If the suspension contacts the ||| 0-0 1-1 2-2 2-3 3-3 4-4
Wenn die Suspension mit ||| If the suspension contacts ||| 0-0 1-1 2-2 2-3 3-3
Wenn die ||| If the ||| 0-0 1-1
Wenn eine allergische Reaktion auftritt ||| If hypersensitivity occurs ||| 0-0 1-0 2-1 3-1 4-2
Wenn eine allergische Reaktion ||| If hypersensitivity ||| 0-0 1-0 2-1 3-1
Wenn eine dieser ||| If any of these ||| 0-0 0-1 1-1 2-2 2-3
Wenn eine psychiatrische Erkrankung während ||| Other psychiatric ||| 0-0 1-0 2-0 2-1 3-1 4-1
Wenn eine ||| If any ||| 0-0 0-1 1-1
Wenn eine ||| If ||| 0-0 1-0
Wenn entweder Valproat oder Lithium ||| When either valproate or lithium ||| 0-0 1-1 2-2 3-3 4-4
Wenn entweder Valproat oder ||| 16 When either valproate or ||| 1-0 0-1 1-2 2-3 3-4
Wenn entweder Valproat oder ||| 27 When either valproate or ||| 1-0 0-1 1-2 2-3 3-4
Wenn entweder Valproat oder ||| 38 When either valproate or ||| 1-0 0-1 1-2 2-3 3-4
Wenn entweder Valproat oder ||| 5 When either valproate or ||| 0-1 1-2 2-3 3-4
Wenn entweder Valproat oder ||| When either valproate or ||| 0-0 1-1 2-2 3-3
Wenn entweder Valproat ||| 16 When either valproate ||| 1-0 0-1 1-2 2-3
Wenn entweder Valproat ||| 27 When either valproate ||| 1-0 0-1 1-2 2-3
Wenn entweder Valproat ||| 38 When either valproate ||| 1-0 0-1 1-2 2-3
Wenn entweder Valproat ||| 5 When either valproate ||| 0-1 1-2 2-3
Wenn entweder Valproat ||| When either valproate ||| 0-0 1-1 2-2
Wenn entweder ||| 16 When either ||| 1-0 0-1 1-2
Wenn entweder ||| 27 When either ||| 1-0 0-1 1-2
Wenn entweder ||| 38 When either ||| 1-0 0-1 1-2
Wenn entweder ||| 5 When either ||| 0-1 1-2
Wenn entweder ||| When either ||| 0-0 1-1
Wenn hochwirksame ||| When concomitant ||| 0-0 1-1
Wenn man die gemeinsame Gabe ||| When considering concomitant administration ||| 0-0 1-0 1-1 2-1 3-1 3-2 4-3
Wenn man die gemeinsame ||| When considering concomitant ||| 0-0 1-0 1-1 2-1 3-1 3-2
Wenn nach ||| If after ||| 0-0 1-1
Wenn notwendig ||| Additional supportive ||| 0-0 1-0 1-1
Wenn präoperativ bei ||| When performing haematologic assessments during ||| 0-0 0-1 1-1 1-2 1-3 2-3 1-4
Wenn schwache Inhibitoren von CYP3A4 ||| When weak inhibitors of CYP3A4 ||| 0-0 1-0 1-1 2-2 3-3 4-4
Wenn schwache Inhibitoren von ||| 85 When weak inhibitors of ||| 1-0 0-1 1-1 1-2 2-3 3-4
Wenn schwache Inhibitoren von ||| When weak inhibitors of ||| 0-0 1-0 1-1 2-2 3-3
Wenn schwache Inhibitoren ||| 85 When weak inhibitors ||| 1-0 0-1 1-1 1-2 2-3
Wenn schwache Inhibitoren ||| When weak inhibitors ||| 0-0 1-0 1-1 2-2
Wenn schwache ||| 85 When weak ||| 1-0 0-1 1-1 1-2
Wenn schwache ||| When weak ||| 0-0 1-0 1-1
Wenn ||| 5 When ||| 0-1
Wenn ||| If ||| 0-0
Wenn ||| In case ||| 0-0 0-1
Wenn ||| When ||| 0-0
Wert ||| mean ||| 0-0
Werte des roten ||| levels of the red blood ||| 0-0 1-1 1-2 2-3 2-4
Werte des ||| levels of the ||| 0-0 1-1 1-2
Werte ||| levels of ||| 0-0
Werte ||| levels ||| 0-0
West Forest Gate Wellington Road ||| West Forest Gate Wellington Road ||| 0-0 1-1 2-2 3-3 4-4
West Forest Gate Wellington ||| West Forest Gate Wellington ||| 0-0 1-1 2-2 3-3
West Forest Gate ||| West Forest Gate ||| 0-0 1-1 2-2
West Forest ||| West Forest ||| 0-0 1-1
West Sussex , RH12 5AB ||| West Sussex , RH12 5AB ||| 0-0 1-1 2-2 3-3 4-4
West Sussex , RH12 ||| West Sussex , RH12 ||| 0-0 1-1 2-2 3-3
West Sussex , ||| West Sussex , ||| 0-0 1-1 2-2
West Sussex ||| West Sussex ||| 0-0 1-1
West ||| West ||| 0-0
Westhoughton BL5 3XX Vereinigtes Königreich ||| Westhoughton BL5 3XX United Kingdom ||| 0-0 1-1 2-2 3-3 4-4
Westhoughton BL5 3XX Vereinigtes ||| Westhoughton BL5 3XX United ||| 0-0 1-1 2-2 3-3
Westhoughton BL5 3XX ||| Westhoughton BL5 3XX ||| 0-0 1-1 2-2
Westhoughton BL5 ||| Westhoughton BL5 ||| 0-0 1-1
Westhoughton ||| Westhoughton ||| 0-0
Wharf , ||| Westferry Circus , ||| 0-0 0-1 1-2
Wharf ||| Westferry Circus ||| 0-0 0-1
Wharf ||| Wharf ||| 0-0
Wichtige Anzeichen und Symptome ||| signs and symptoms of ||| 1-0 2-1 3-2 0-3
Wichtige Informationen ||| Wichtige Informationen über ||| 0-0 0-1 1-1 0-2
Wichtige Informationen über bestimmte ||| Important information about some ||| 0-0 1-1 1-2 2-2 3-3
Wichtige Informationen über bestimmte ||| Important information about some ||| 0-0 3-0 1-1 2-1 1-2 3-3
Wichtige Informationen über ||| Important information about ||| 0-0 1-1 1-2 2-2
Wichtige ||| Important ||| 0-0
Wichtige ||| of ||| 0-0
Wicklow . ||| Wicklow . ||| 0-0 1-1
Wicklow ||| Wicklow ||| 0-0
Wie ABILIFY aussieht und ||| What ABILIFY looks like and ||| 0-0 2-0 1-1 2-2 2-3 3-4
Wie ABILIFY aussieht und ||| What ABILIFY looks like and ||| 2-0 1-1 0-2 2-2 2-3 3-4
Wie ABILIFY aussieht ||| What ABILIFY looks like ||| 0-0 2-0 1-1 2-2 2-3
Wie ABILIFY aussieht ||| What ABILIFY looks like ||| 2-0 1-1 0-2 2-2 2-3
Wie Abseamed aussieht ||| 195 What Abseamed looks like ||| 0-0 0-1 2-1 1-2 2-3 2-4
Wie Aclasta aussieht und ||| What Aclasta looks like and ||| 0-0 2-0 1-1 2-2 2-3 3-4
Wie Aclasta aussieht ||| What Aclasta looks like ||| 0-0 2-0 1-1 2-2 2-3
Wie Actos aussieht und ||| What Actos looks like and ||| 2-0 1-1 0-2 2-2 2-3 3-4
Wie Actos aussieht ||| What Actos looks like ||| 2-0 1-1 0-2 2-2 2-3
Wie alle Arzneimittel ||| Like all medicines ||| 0-0 1-1 2-2
Wie alle ||| Like all ||| 0-0 1-1
Wie bei allen Wachstumsfaktoren sollte ||| As with all growth factors ||| 0-0 1-0 0-1 2-2 3-3 3-4 4-4
Wie bei allen ||| As with all ||| 0-0 1-0 0-1 2-2
Wie bei anderen Antipsychotika ||| As with other antipsychotics , ||| 0-0 1-0 0-1 2-2 3-3
Wie bei anderen Antipsychotika ||| As with other antipsychotics ||| 0-0 1-0 0-1 2-2 3-3
Wie bei anderen Insulinprodukten ||| As for other insulin products ||| 0-0 1-0 1-1 2-2 3-3 3-4
Wie bei anderen ||| As for other ||| 0-0 1-0 1-1 2-2
Wie bei anderen ||| As with other ||| 0-0 1-0 0-1 2-2
Wie bei jeder ||| 52 As with any ||| 0-0 0-1 1-1 0-2 2-3
Wie bei jeder ||| As with any ||| 0-0 1-0 0-1 2-2
Wie bei ||| 52 As with ||| 0-0 0-1 1-1 0-2
Wie bei ||| As for ||| 0-0 1-0 1-1
Wie bei ||| As with ||| 0-0 1-0 0-1
Wie jedoch auch ||| However , as with ||| 0-0 1-0 1-1 0-2 2-2 0-3
Wie wird die ||| How to ||| 0-0 1-0 2-1
Wie wird ||| How ||| 0-0 1-0
Wie ||| Like ||| 0-0
Wiederauftreten einer schweren Neutropenie ||| Following recurrence of severe neutropenia ||| 0-0 0-1 1-2 2-3 3-4
Wiederauftreten einer schweren ||| Following recurrence of severe ||| 0-0 0-1 1-2 2-3
Wiederauftreten einer ||| Following recurrence of ||| 0-0 0-1 1-2
Wiederauftreten ||| Following recurrence ||| 0-0 0-1
Wiederauftreten ||| preventing ||| 0-0
Wiederauftretens manischer Episoden bei ||| recurrence of manic episodes in ||| 0-0 0-1 1-2 2-3 3-3 3-4
Wiederauftretens manischer Episoden ||| manic episodes ||| 0-0 1-0 2-1
Wiederauftretens manischer ||| manic ||| 0-0 1-0
Wiederauftretens manischer ||| recurrence of manic ||| 0-0 0-1 1-2
Wiederauftretens ||| recurrence of ||| 0-0 0-1
Wiederholte Verabreichungen führten nicht ||| Repeat dosing did not ||| 0-0 1-1 1-2 2-2 3-3
Wiederholte Verabreichungen führten ||| Repeat dosing did ||| 0-0 1-1 1-2 2-2
Wiederholte ||| Repeat ||| 0-0
Wielka Brytania Tel : +44 ||| Wielka Brytania Tel : +44 ||| 0-0 1-1 2-2 3-3 4-4
Wielka Brytania Tel : ||| Wielka Brytania Tel : ||| 0-0 1-1 2-2 3-3
Wielka Brytania Tel ||| Wielka Brytania Tel ||| 0-0 1-1 2-2
Wielka Brytania ||| Wielka Brytania ||| 0-0 1-1
Wielka ||| Wielka ||| 0-0
Wimblehurst Road Horsham West Sussex ||| Wimblehurst Road Horsham West Sussex ||| 0-0 1-1 2-2 3-3 4-4
Wimblehurst Road Horsham West ||| Wimblehurst Road Horsham West ||| 0-0 1-1 2-2 3-3
Wimblehurst Road Horsham ||| Wimblehurst Road Horsham ||| 0-0 1-1 2-2
Wimblehurst Road ||| Wimblehurst Road ||| 0-0 1-1
Wimblehurst ||| Wimblehurst ||| 0-0
Wingates Industrial Park Westhoughton BL5 ||| Wingates Industrial Park Westhoughton BL5 ||| 0-0 1-1 2-2 3-3 4-4
Wingates Industrial Park Westhoughton ||| Wingates Industrial Park Westhoughton ||| 0-0 1-1 2-2 3-3
Wingates Industrial Park ||| Wingates Industrial Park ||| 0-0 1-1 2-2
Wingates Industrial ||| Wingates Industrial ||| 0-0 1-1
Wingates ||| Wingates ||| 0-0
Winthrop Industrie , 30-36 Avenue ||| Winthrop Industrie , 30-36 Avenue ||| 0-0 1-1 2-2 3-3 4-4
Winthrop Industrie , 30-36 ||| Winthrop Industrie , 30-36 ||| 0-0 1-1 2-2 3-3
Winthrop Industrie , ||| Winthrop Industrie , ||| 0-0 1-1 2-2
Winthrop Industrie ||| Winthrop Industrie ||| 0-0 1-1
Winthrop ||| Winthrop ||| 0-0
Wirbelkörperfraktur ( ||| vertebral fracture ( ||| 0-0 0-1 1-2
Wirbelkörperfraktur aufgezeigt . ||| vertebral fracture(s ) . ||| 0-0 0-1 1-1 0-2 2-3
Wirbelkörperfraktur aufgezeigt ||| vertebral fracture(s ) ||| 0-0 0-1 1-1 0-2
Wirbelkörperfraktur ||| vertebral fracture ||| 0-0 0-1
Wirbelkörperfrakturen Aclasta senkte signifikant ||| vertebral fractures Aclasta significantly decreased ||| 0-0 0-1 1-2 2-3 3-3 3-4
Wirbelkörperfrakturen Aclasta ||| vertebral fractures Aclasta ||| 0-0 0-1 1-2
Wirbelkörperfrakturen ||| vertebral fractures did ||| 0-0 0-1
Wirbelkörperfrakturen ||| vertebral fractures ||| 0-0 0-1
Wird Epoetin alfa ||| If epoetin alfa ||| 0-0 1-1 2-2
Wird Epoetin ||| If epoetin ||| 0-0 1-1
Wird ||| If ||| 0-0
Wirkmechanismus ||| Mechanism of action ||| 0-0 0-1 0-2
Wirksamkeit . ||| efficacy . ||| 0-0 1-1
Wirksamkeit bei . ||| efficacy . ||| 0-0 1-0 2-1
Wirksamkeit bei Männern In der ||| efficacy in men In the ||| 0-0 1-1 2-2 3-3 4-4
Wirksamkeit bei Männern In ||| efficacy in men In ||| 0-0 1-1 2-2 3-3
Wirksamkeit bei Männern ||| efficacy in men ||| 0-0 1-1 2-2
Wirksamkeit bei der Behandlung der ||| efficacy in the treatment of ||| 0-0 1-1 2-2 3-3 4-4
Wirksamkeit bei der Behandlung ||| efficacy in the treatment ||| 0-0 1-1 2-2 3-3
Wirksamkeit bei der ||| efficacy in the ||| 0-0 1-1 2-2
Wirksamkeit bei ||| efficacy in ||| 0-0 1-1
Wirksamkeit bei ||| efficacy ||| 0-0 1-0
Wirksamkeit der Behandlung bei ||| efficacy in the treatment ||| 0-0 3-1 1-2 2-3
Wirksamkeit einer Infusion von ||| efficacy of one infusion of ||| 0-0 3-1 1-2 2-3 3-4
Wirksamkeit fehlen . ||| efficacy . ||| 0-0 1-0 2-1
Wirksamkeit fehlen ||| efficacy ||| 0-0 1-0
Wirksamkeit und Sicherheit ||| both long-term efficacy and safety ||| 1-0 2-1 0-2 1-3 2-4
Wirksamkeit und Sicherheit ||| efficacy and safety ||| 0-0 1-1 2-2
Wirksamkeit und Unbedenklichkeit von Rimonabant ||| efficacy and safety of rimonabant ||| 0-0 1-1 2-2 3-3 4-4
Wirksamkeit und Unbedenklichkeit von ||| efficacy and safety of ||| 0-0 1-1 2-2 3-3
Wirksamkeit und Unbedenklichkeit ||| efficacy and safety ||| 0-0 1-1 2-2
Wirksamkeit und ||| efficacy and ||| 0-0 1-1
Wirksamkeit von Abraxane wurde ||| effectiveness of Abraxane has been ||| 0-0 1-1 2-2 3-3 3-4
Wirksamkeit von Abraxane ||| effectiveness of Abraxane ||| 0-0 1-1 2-2
Wirksamkeit von Abseamed steigern . ||| effectiveness of Abseamed . ||| 0-0 1-1 2-2 3-2 4-3
Wirksamkeit von Abseamed steigern ||| effectiveness of Abseamed ||| 0-0 1-1 2-2 3-2
Wirksamkeit von Abseamed ||| efficacy of Abseamed ||| 0-0 1-1 2-2
Wirksamkeit von Aripiprazol bei Schizophrenie ||| aripiprazole s efficacy in schizophrenia ||| 2-0 0-1 0-2 3-3 4-4
Wirksamkeit von Aripiprazol bei ||| aripiprazole s efficacy in ||| 2-0 0-1 0-2 3-3
Wirksamkeit von Aripiprazol ||| aripiprazole s efficacy ||| 2-0 0-1 0-2
Wirksamkeit von Epoetin alfa ||| efficacy of epoetin alfa ||| 0-0 1-1 2-2 3-3
Wirksamkeit von Epoetin ||| efficacy of epoetin ||| 0-0 1-1 2-2
Wirksamkeit von M-II ||| efficacy of M-II ||| 0-0 1-1 2-2
Wirksamkeit von Rimonabant ||| efficacy of rimonabant ||| 0-0 1-1 2-2
Wirksamkeit von ||| effectiveness of ||| 0-0 1-1
Wirksamkeit von ||| effectiveness ||| 0-0 1-0
Wirksamkeit von ||| efficacy of ||| 0-0 1-1
Wirksamkeit von ||| s efficacy ||| 0-0 0-1
Wirksamkeit war , ob ||| effectiveness was whether ||| 0-0 1-1 2-2 3-2
Wirksamkeit war die Anzahl an ||| effectiveness was the number of ||| 0-0 1-1 2-2 3-3 4-4
Wirksamkeit war die Anzahl ||| effectiveness was the number ||| 0-0 1-1 2-2 3-3
Wirksamkeit war die ||| effectiveness was the ||| 0-0 1-1 2-2
Wirksamkeit war ||| effectiveness was ||| 0-0 1-1
Wirksamkeit ||| effectiveness ||| 0-0
Wirksamkeit ||| efficacy to ||| 0-0
Wirksamkeit ||| efficacy ||| 0-0
Wirksamkeit ||| of efficacy ||| 0-1
Wirksamkeit ||| s efficacy ||| 0-0 0-1
Wirksamkeitsindikatoren ||| terms of ||| 0-0
Wirksamkeitsindikatoren ||| terms ||| 0-0
Wirksamkeitsparameter war die Häufigkeit ||| efficacy variable was the incidence ||| 0-0 0-1 1-2 2-3 3-4
Wirksamkeitsparameter war die ||| efficacy variable was the ||| 0-0 0-1 1-2 2-3
Wirksamkeitsparameter war ||| efficacy variable was ||| 0-0 0-1 1-2
Wirksamkeitsparameter ||| efficacy variable ||| 0-0 0-1
Wirkstoff in Abilify , ||| active substance in Abilify , ||| 0-0 0-1 1-2 2-3 3-4
Wirkstoff in Abilify ||| active substance in Abilify ||| 0-0 0-1 1-2 2-3
Wirkstoff in Aclasta , ||| active substance in Aclasta , ||| 0-0 0-1 1-2 2-3 3-4
Wirkstoff in Aclasta ||| active substance in Aclasta ||| 0-0 0-1 1-2 2-3
Wirkstoff in ||| active substance in ||| 0-0 0-1 1-2
Wirkstoff ist : Aripiprazol . ||| active substance is aripiprazole . ||| 0-0 0-1 2-1 1-2 3-3 4-4
Wirkstoff ist : Aripiprazol ||| active substance is aripiprazole ||| 0-0 0-1 2-1 1-2 3-3
Wirkstoff ist : ||| active substance is ||| 0-0 0-1 2-1 1-2
Wirkstoff ist Aripiprazol . ||| active substance is aripiprazole . ||| 0-0 0-1 1-2 2-3 3-4
Wirkstoff ist Aripiprazol ||| active substance is aripiprazole ||| 0-0 0-1 1-2 2-3
Wirkstoff ist ||| active substance is ||| 0-0 0-1 1-2
Wirkstoff ||| active substance ||| 0-0 0-1
Wirkstoff ||| of ||| 0-0
Wirkstoffakkumulation ||| multiple doses given ||| 0-0 0-1 0-2
Wirkstoffen ( ||| agents ( ||| 0-0 1-1
Wirkstoffen beobachtet werden . ||| agents . ||| 0-0 1-0 2-0 3-1
Wirkstoffen beobachtet werden ||| agents ||| 0-0 1-0 2-0
Wirkstoffen ||| agents ||| 0-0
Wirkstoffexposition ( AUC ) ||| drug exposure ( AUC ) ||| 0-0 0-1 1-2 2-3 3-4
Wirkstoffexposition ( AUC ||| drug exposure ( AUC ||| 0-0 0-1 1-2 2-3
Wirkstoffexposition ( ||| drug exposure ( ||| 0-0 0-1 1-2
Wirkstoffexposition ||| drug exposure ||| 0-0 0-1
Wirkstoffs biologischen Ursprungs ||| biological active substance ||| 0-0 1-0 1-1 1-2 2-2
Wirkstoffs oder seiner Metaboliten . ||| the compound or metabolites . ||| 0-0 0-1 2-1 1-2 3-3 4-4
Wirkstoffs oder seiner Metaboliten ||| the compound or metabolites ||| 0-0 0-1 2-1 1-2 3-3
Wirkstoffs oder seiner ||| the compound or ||| 0-0 0-1 2-1 1-2
Wirkstoffs ||| active substance ||| 0-0 0-1
Wirkung Ihres ||| possibility of your becoming ||| 0-0 0-1 1-2 0-3 1-3
Wirkung auf Serotonin 5HT2a-Rezeptoren ||| antagonism of serotonin ||| 0-0 1-0 3-0 2-2 3-2
Wirkung belegt . ||| effect . ||| 0-0 1-0 2-1
Wirkung belegt ||| effect ||| 0-0 1-0
Wirkung der Infusion hält ||| effect of the infusion lasts ||| 0-0 1-1 1-2 2-3 3-4
Wirkung der Infusion ||| effect of the infusion ||| 0-0 1-1 1-2 2-3
Wirkung der ||| effect of the ||| 0-0 1-1 1-2
Wirkung einer zusätzlichen Verabreichung von ||| effect of adding ||| 0-0 1-1 3-1 4-1 2-2
Wirkung hielt ||| effect was maintained ||| 0-0 1-1 1-2
Wirkung sollte für ||| desired effects should be ||| 0-0 0-1 1-2 1-3
Wirkung sollte ||| desired effects should be ||| 0-0 0-1 1-2 1-3
Wirkung von ACOMPLIA ||| effect of ACOMPLIA in ||| 0-0 1-1 2-2
Wirkung von ACOMPLIA ||| effect of ACOMPLIA ||| 0-0 1-1 2-2
Wirkung von Abraxane ( ||| effects of Abraxane ( ||| 0-0 1-1 2-2 3-3
Wirkung von Abraxane ||| effects of Abraxane ||| 0-0 1-1 2-2
Wirkung von Actos 15 mg ||| effect of Actos 15mg ||| 0-0 1-1 2-2 3-3 4-3
Wirkung von Actos 30 mg ||| effect of Actos 30mg ||| 0-0 1-1 2-2 3-3 4-3
Wirkung von Actos 45 mg ||| effect of Actos 45mg ||| 0-0 1-1 2-2 3-3 4-3
Wirkung von Actos ||| effect of Actos ||| 0-0 1-1 2-2
Wirkung von Arzneimitteln verstärken ||| effect of medicines used ||| 0-0 1-1 2-2 3-2 3-3
Wirkung von Insulin ||| effect of insulin ||| 0-0 1-1 2-2
Wirkung von Pioglitazon ( ||| effect of pioglitazone ( ||| 0-0 1-1 2-2 3-3
Wirkung von Pioglitazon ||| effect of pioglitazone ||| 0-0 1-1 2-2
Wirkung von Zoledronsäure ||| of effect of zoledronic acid ||| 1-0 0-1 1-2 2-3 2-4
Wirkung von ||| effect of ||| 0-0 1-1
Wirkung von ||| effects of ||| 0-0 1-1
Wirkung von ||| of effect of ||| 1-0 0-1 1-2
Wirkung ||| desired effects ||| 0-0 0-1
Wirkung ||| effect ||| 0-0
Wirkung ||| effects ||| 0-0
Wirkung über drei ||| effect over ||| 0-0 1-1 2-1
Wirkungen von ACOMPLIA wurden ||| effects of ACOMPLIA were ||| 0-0 1-1 2-2 3-3
Wirkungen von ACOMPLIA ||| effects of ACOMPLIA ||| 0-0 1-1 2-2
Wirkungen von Abraxane wurden ||| effects of Abraxane were ||| 0-0 1-1 2-2 3-3
Wirkungen von Abraxane ||| effects of Abraxane ||| 0-0 1-1 2-2
Wirkungen von ||| effects may ||| 0-0 0-1 1-1
Wirkungen von ||| effects may ||| 0-0 1-0 0-1
Wirkungen von ||| effects of ||| 0-0 1-1
Wirkungen waren ||| effects were ||| 0-0 1-1
Wirkungen ||| effects ||| 0-0
Wirkungen ||| foetal effects ||| 0-0 0-1
Wirkungen ||| therapeutic ||| 0-0
Wirkungsmechanismus ist unbekannt ||| mechanism of action is unknown ||| 0-0 0-2 1-3 2-4
Wirkungsmechanismus ist ||| mechanism of action is ||| 0-0 0-2 1-3
Wirkungsmechanismus ||| mechanism of action ||| 0-0 0-2
Wirkverlust oder andere Symptome ||| efficacy or other symptoms of ||| 0-0 1-1 2-2 3-3
Wirkverlust oder andere Symptome ||| efficacy or other symptoms ||| 0-0 1-1 2-2 3-3
Wirkverlust oder andere Symptome ||| of efficacy or other symptoms ||| 0-1 1-2 2-3 3-4
Wirkverlust oder andere ||| efficacy or other ||| 0-0 1-1 2-2
Wirkverlust oder andere ||| loss of efficacy or other ||| 0-2 1-3 2-4
Wirkverlust oder andere ||| of efficacy or other ||| 0-1 1-2 2-3
Wirkverlust oder ||| efficacy or ||| 0-0 1-1
Wirkverlust oder ||| loss of efficacy or ||| 0-2 1-3
Wirkverlust oder ||| of efficacy or ||| 0-1 1-2
Wirkverlust ||| efficacy ||| 0-0
Wirkverlust ||| loss of efficacy ||| 0-2
Wirkverlust ||| of efficacy ||| 0-1
Wissenschaft höchstmöglichen Reinheitsgrad ||| present state of the art ||| 0-0 0-1 1-2 1-3 1-4 2-4
Wissenschaft ||| present state ||| 0-0 0-1
Woche , verteilt auf ||| times per week ||| 0-0 2-1 2-2 3-2
Woche , ||| times ||| 0-0
Woche . ||| week . ||| 0-0 1-1
Woche mittels intravenöser Applikation ||| week by the intravenous route ||| 0-0 1-1 2-2 2-3 3-4
Woche mittels intravenöser ||| week by the intravenous ||| 0-0 1-1 2-2 2-3
Woche mittels ||| week by ||| 0-0 1-1
Woche ||| times ||| 0-0
Woche ||| week ||| 0-0
Wochen ( Tag 21 , ||| weeks ( days 21 , ||| 0-0 1-1 3-2 2-3 3-3 4-4
Wochen ( Tag 21 ||| weeks ( days 21 ||| 0-0 1-1 3-2 2-3 3-3
Wochen ( ||| weeks ( ||| 0-0 1-1
Wochen ) ||| weeks ) ||| 0-0 1-1
Wochen . ||| weeks . ||| 0-0 1-1
Wochen an . ||| weeks . ||| 0-0 1-0 2-1
Wochen an insgesamt 1 ||| weeks in a total of ||| 0-0 1-0 1-1 2-2 3-2 2-3
Wochen an insgesamt 1 ||| weeks in a total ||| 0-0 1-0 1-1 2-2 3-2 2-3
Wochen an ||| weeks in ||| 0-0 1-0 1-1
Wochen an ||| weeks ||| 0-0 1-0
Wochen die Konzentration einer Substanz ||| weeks the level of a ||| 0-0 1-1 2-2 3-3 4-3 3-4
Wochen die Konzentration ||| weeks the level ||| 0-0 1-1 2-2
Wochen die ||| weeks the ||| 0-0 1-1
Wochen eine ||| weeks ||| 0-0
Wochen nach Anbruch oder ||| weeks when used or ||| 0-0 1-0 2-1 2-2 3-3
Wochen nach Anbruch ||| weeks when used ||| 0-0 1-0 2-1 2-2
Wochen nach der ||| weeks after your ||| 0-0 1-1 2-1
Wochen nach der ||| weeks after ||| 0-0 1-1
Wochen nach der ||| weeks after ||| 0-0 1-1 2-1
Wochen nach ||| weeks after ||| 0-0 1-1
Wochen nach ||| weeks following ||| 0-0 1-1
Wochen nach ||| weeks ||| 0-0 1-0
Wochen vor ||| weeks prior to ||| 0-0 1-1 1-2
Wochen wieder ab . ||| a few weeks . ||| 0-0 1-1 2-1 0-2 2-2 3-3
Wochen wieder ab ||| a few weeks ||| 0-0 1-1 2-1 0-2 2-2
Wochen ||| weeks , ||| 0-0
Wochen ||| weeks ||| 0-0
Wokingham Berkshire RG40 2AQ Vereinigtes ||| Wokingham Berkshire RG40 2AQ United ||| 0-0 1-1 2-2 3-3 4-4
Wokingham Berkshire RG40 2AQ ||| Wokingham Berkshire RG40 2AQ ||| 0-0 1-1 2-2 3-3
Wokingham Berkshire RG40 ||| Wokingham Berkshire RG40 ||| 0-0 1-1 2-2
Wokingham Berkshire ||| Wokingham Berkshire ||| 0-0 1-1
Wokingham ||| Wokingham ||| 0-0
Wortlaut des EPAR für ACOMPLIA ||| EPAR for ACOMPLIA ||| 0-0 1-0 2-0 3-1 4-2
Wortlaut des EPAR für Abilify ||| EPAR for Abilify ||| 0-0 1-0 2-0 3-1 4-2
Wortlaut des EPAR für Actraphane ||| EPAR for Actraphane ||| 0-0 1-0 2-0 3-1 4-2
Wortlaut des EPAR für ||| EPAR for ||| 0-0 1-0 2-0 3-1
Wortlaut des EPAR ||| EPAR for Abraxane ||| 0-0 1-0 2-0 0-1 2-2
Wortlaut des EPAR ||| EPAR for ||| 0-0 1-0 2-0 0-1
Wortlaut des EPAR ||| EPAR ||| 0-0 1-0 2-0
Wunden im Mund oder am ||| sores of the mouth or ||| 0-0 4-2 1-3 2-3 3-4
Wunden ||| sores of ||| 0-0
Wunden ||| sores ||| 0-0
Wurde Rimonabant ||| Following dosing ||| 0-0
Wurde Rimonabant ||| Following ||| 0-0
Wurde Rimonabant über einen längeren ||| Following dosing for a longer ||| 0-0 2-2 3-3 4-4
Wurde Rimonabant über einen ||| Following dosing for a ||| 0-0 2-2 3-3
Wurde Rimonabant über ||| Following dosing for ||| 0-0 2-2
Wurde ||| Following dosing ||| 0-0
Wurde ||| Following ||| 0-0
Während der Abraxane-Therapie ||| Frequent monitoring of blood cell ||| 0-0 2-0 2-1 1-2 2-3 2-4
Während der Behandlung ||| Loss of ||| 0-0 1-1 2-1
Während der Behandlung ||| While on treatment , ||| 0-0 1-1 2-2
Während der Behandlung ||| While on treatment ||| 0-0 1-1 2-2
Während der Epoetin-alfa-Behandlung kann ||| There may be a moderate ||| 0-0 3-1 1-2 2-2 2-3 2-4
Während der ersten ||| 18/ 20 During the first ||| 0-0 2-1 0-2 1-3 2-4
Während der ||| During ||| 0-0 1-0
Während der ||| While on ||| 0-0 1-1
Während ||| During ||| 0-0
Während ||| Loss ||| 0-0
Während ||| There ||| 0-0
Während ||| While ||| 0-0
Xylitol , ||| dioxide , ||| 0-0 1-1
Xylitol Mikrokristalline Cellulose ||| Silicon dioxide Xylitol Microcrystalline cellulose ||| 0-0 0-1 0-2 1-3 2-4
Xylitol Mikrokristalline ||| Silicon dioxide Xylitol Microcrystalline ||| 0-0 0-1 0-2 1-3
Xylitol ||| Silicon dioxide Xylitol ||| 0-0 0-1 0-2
Xylitol ||| dioxide ||| 0-0
Yarvitan 5 mg/ml ||| Yarvitan 5 mg/ ml ||| 0-0 1-1 2-2 2-3
Yarvitan 5 ||| Yarvitan 5 ||| 0-0 1-1
Yarvitan ist angezeigt zur ||| Yarvitan is indicated as ||| 0-0 1-1 2-2 2-3 3-3
Yarvitan ist eine farblose ||| Yarvitan is a colourless ||| 0-0 1-1 2-2 3-3
Yarvitan ist eine ||| Yarvitan is a ||| 0-0 1-1 2-2
Yarvitan ist ||| Yarvitan is ||| 0-0 1-1
Yarvitan weiterzuführen . ||| product . ||| 0-0 1-0 2-1
Yarvitan weiterzuführen ||| product ||| 0-0 1-0
Yarvitan ||| Yarvitan ||| 0-0
Yarvitan ||| product ||| 0-0
ZNS ||| central ||| 0-0
ZNS-Metastasen generell nicht zu ||| generally not well ||| 0-0 1-0 2-1 0-2
ZNS-Metastasen generell nicht ||| generally not well ||| 0-0 1-0 2-1 0-2
ZULASSUNG ||| AUTHORISATION ||| 0-0
ZUR UMSETZUNG DURCH ||| TO BE IMPLEMENTED BY ||| 0-0 0-1 0-2 1-2 2-2 2-3
ZUSAMMENFASSUNG DER ||| , labelling and package ||| 0-1 0-3
ZUSAMMENFASSUNG DER ||| labelling and package ||| 0-0 0-2
ZUSAMMENFASSUNG ||| , labelling and package ||| 0-1 0-3
ZUSAMMENFASSUNG ||| labelling and package ||| 0-0 0-2
Zahl der Blutplättchen ||| blood ||| 1-0 2-0
Zahl der Patienten , die ||| at the number of patients ||| 1-0 1-1 4-1 0-2 1-3 2-4
Zahl ||| number of ||| 0-0
Zahl ||| number ||| 0-0
Zahnarzt . ||| dentist . ||| 0-0 1-1
Zahnarzt ||| dentist ||| 0-0
Zahnbehandlung ||| , poor ||| 0-1
Zahnbehandlung ||| poor ||| 0-0
Zahneingriffe ||| prudent ||| 0-0
Zahnextraktionen oder anderen ||| tooth extractions or other ||| 0-0 0-1 1-2 2-3
Zahnextraktionen oder ||| tooth extractions or ||| 0-0 0-1 1-2
Zahnextraktionen ||| tooth extractions ||| 0-0 0-1
Zahnschmerz. # ||| toothache ||| 0-0 1-0
Zahnuntersuchung ||| , ||| 0-0
Zeichen und Symptome ||| important signs and symptoms ||| 0-0 0-1 1-2 2-3
Zeichen und ||| important signs and ||| 0-0 0-1 1-2
Zeichen ||| important signs ||| 0-0 0-1
Zeigefinger zusammendrücken . ||| forefinger . ||| 0-0 1-0 2-1
Zeigefinger zusammendrücken ||| forefinger ||| 0-0 1-0
Zeit ) ||| time ||| 0-0
Zeit bis zum ||| time to ||| 0-0 2-0 1-1
Zeit bis zur Krankheitsprogression [ ||| time to disease progression [ ||| 0-0 1-1 2-1 3-2 3-3 4-4
Zeit bis zur Krankheitsprogression ||| time to disease progression ||| 0-0 1-1 2-1 3-2 3-3
Zeit bis zur ||| time to ||| 0-0 1-1 2-1
Zeit bis zur ||| time until ||| 0-0 2-0 1-1
Zeit einzunehmen . ||| time each day . ||| 0-0 1-1 1-2 2-3
Zeit einzunehmen ||| time each day ||| 0-0 1-1 1-2
Zeit vor ||| period ||| 0-0
Zeit ||| period ||| 0-0
Zeit ||| time ||| 0-0
Zeitdauer der Studie . ||| duration of the study . ||| 0-0 1-1 1-2 2-3 3-4
Zeitdauer der Studie ||| duration of the study ||| 0-0 1-1 1-2 2-3
Zeitdauer der ||| duration of the ||| 0-0 1-1 1-2
Zeitdauer ||| duration ||| 0-0
Zeitperiode ||| failure in patients ||| 0-0 0-2
Zeitpunkt während des klinischen Verlaufs ||| the clinical course , ||| 0-0 2-0 3-1 1-2 2-2 4-2
Zeitpunkt während des klinischen Verlaufs ||| the clinical course ||| 0-0 2-0 3-1 1-2 2-2 4-2
Zeitpunkten ( 6 , 12 ||| timepoints ( 6 , 12 ||| 0-0 1-1 2-2 3-3 4-4
Zeitpunkten ( 6 , ||| timepoints ( 6 , ||| 0-0 1-1 2-2 3-3
Zeitpunkten ( 6 ||| timepoints ( 6 ||| 0-0 1-1 2-2
Zeitpunkten ( ||| timepoints ( ||| 0-0 1-1
Zeitpunkten . ||| timepoints . ||| 0-0 1-1
Zeitpunkten ||| timepoints ||| 0-0
Zeitraum von ||| over ||| 0-0 1-0
Zeitraum ||| Abraxane over ||| 0-1
Zeitraum ||| duration , ||| 0-0
Zeitraum ||| duration ||| 0-0
Zeitraum ||| it ||| 0-0
Zeitraum ||| not ||| 0-0
Zeitraum ||| over a period of ||| 0-0 0-2
Zeitraum ||| over a period ||| 0-0 0-2
Zeitraum ||| over ||| 0-0
Zellen nicht teilen und ||| cells cannot divide and ||| 0-0 1-1 2-2 3-3
Zellen nicht teilen ||| cells cannot divide ||| 0-0 1-1 2-2
Zellen nicht ||| cells cannot ||| 0-0 1-1
Zellen ||| cells ||| 0-0
Zellen/µl ||| count has increased ||| 0-0 0-1 0-2
Zellfunktionen wesentlich ||| mitotic cellular functions ||| 0-0 0-1 1-1 0-2
Zellulitis , Flare-up-Reaktion ||| , flare ||| 0-0 1-0 1-1 2-1
Zellzyklus ||| microtubules throughout ||| 0-0 0-1
Ziehen Sie die Nadel schnell ||| Withdraw the needle quickly ||| 0-0 1-0 2-1 3-2 4-3
Ziehen Sie die Nadel ||| Withdraw the needle ||| 0-0 1-0 2-1 3-2
Ziehen Sie die ||| Withdraw the ||| 0-0 1-0 2-1
Ziehen Sie ||| Withdraw ||| 0-0 1-0
Ziel , den Hämoglobinwert zwischen ||| maintain haemoglobin concentration between ||| 0-0 1-0 3-1 0-2 2-2 4-3
Ziel , den Hämoglobinwert ||| maintain haemoglobin concentration ||| 0-0 1-0 3-1 0-2 2-2
Zielkonzentration von ||| haemoglobin of ||| 0-0 1-1
Zielkonzentration von über 12 ||| haemoglobin of greater than 12 ||| 0-0 1-1 2-2 2-3 3-4
Zielkonzentration von über ||| haemoglobin of greater than ||| 0-0 1-1 2-2 2-3
Zielkonzentration ||| haemoglobin ||| 0-0
Zielorgans nach wiederholter Gabe ||| after repeated dosing ||| 1-0 2-1 3-1 2-2
Zielorgans nach ||| after ||| 1-0
Zinkchlorid Glycerol Metacresol Phenol ||| Zinc chloride Glycerol Metacresol Phenol ||| 0-0 1-1 1-2 2-3 3-3 3-4
Zinkchlorid Glycerol ||| Zinc chloride Glycerol ||| 0-0 1-1 1-2
Zinkchlorid ||| Zinc ||| 0-0
Zoledronsäure ( 5 mg/100 ||| zoledronic acid ( 5 mg/ ||| 0-0 0-1 1-2 2-3 3-3 2-4
Zoledronsäure ( wasserfrei ) ||| zoledronic acid ( anhydrous ) ||| 0-0 0-1 1-2 2-3 3-4
Zoledronsäure ( wasserfrei ||| zoledronic acid ( anhydrous ||| 0-0 0-1 1-2 2-3
Zoledronsäure ( wasserfrei ||| zoledronic acid anhydrous ||| 0-0 0-1 1-1 2-2
Zoledronsäure ( ||| zoledronic acid ( ||| 0-0 0-1 1-2
Zoledronsäure ( ||| zoledronic acid ||| 0-0 0-1 1-1
Zoledronsäure ) , das ||| zoledronic acid ) , ||| 0-0 0-1 1-2 2-3
Zoledronsäure ) , ||| zoledronic acid ) , ||| 0-0 0-1 1-2 2-3
Zoledronsäure ) ||| zoledronic acid ) ||| 0-0 0-1 1-2
Zoledronsäure , ist ein ||| zoledronic acid , is a ||| 0-0 0-1 1-2 2-3 3-4
Zoledronsäure , ist ||| zoledronic acid , is ||| 0-0 0-1 1-2 2-3
Zoledronsäure , ||| zoledronic acid , ||| 0-0 0-1 1-2
Zoledronsäure , ||| zoledronic acid anhydrous , ||| 0-0 0-1 0-2 1-3
Zoledronsäure bei Schwangeren vor ||| zoledronic acid in pregnant women ||| 0-0 0-1 1-2 2-3 2-4 3-4
Zoledronsäure bei ||| zoledronic acid in ||| 0-0 0-1 1-2
Zoledronsäure beurteilt . ||| zoledronic acid . ||| 0-0 0-1 1-2 2-2
Zoledronsäure gehört zur ||| Zoledronic acid belongs to ||| 0-0 0-1 2-1 1-2 2-3
Zoledronsäure muss ||| zoledronic acid must be ||| 0-0 0-1 1-2 1-3
Zoledronsäure wird nicht systemisch ||| Zoledronic acid is not systemically ||| 0-0 0-1 1-2 2-3 3-4
Zoledronsäure wird nicht ||| Zoledronic acid is not ||| 0-0 0-1 1-2 2-3
Zoledronsäure wird ||| Zoledronic acid is ||| 0-0 0-1 1-2
Zoledronsäure wurde ||| Zoledronic acid has been ||| 0-0 0-1 1-2 1-3
Zoledronsäure ||| Zoledronic acid ||| 0-0 0-1
Zoledronsäure ||| zoledronic acid , ||| 0-0 0-1
Zoledronsäure ||| zoledronic acid anhydrous ||| 0-0 0-1 0-2
Zoledronsäure ||| zoledronic acid in ||| 0-0 0-1
Zoledronsäure ||| zoledronic acid ||| 0-0 0-1
Zoledronsäuremonohydrat . ||| zoledronic acid monohydrate . ||| 0-0 0-1 0-2 1-3
Zoledronsäuremonohydrat ||| zoledronic acid monohydrate ||| 0-0 0-1 0-2
Zometa ( Zoledronsäure ) ||| Zometa ( zoledronic acid ) ||| 0-0 1-1 2-2 2-3 3-4
Zometa ( Zoledronsäure ||| Zometa ( zoledronic acid ||| 0-0 1-1 2-2 2-3
Zometa ( ||| Zometa ( ||| 0-0 1-1
Zometa , ||| Zometa , some ||| 0-0 1-1
Zometa , ||| Zometa , ||| 0-0 1-1
Zometa ||| Zometa ||| 0-0
Zu den Nebenwirkungen , die ||| Undesirable effects known to ||| 0-0 1-0 2-1 0-2 3-3 4-3
Zu den Nebenwirkungen ||| Undesirable effects known ||| 0-0 1-0 2-1 0-2
Zu einem späteren ||| Late in ||| 0-0 2-0 1-1
Zuchthunden wurde bisher ||| dogs for breeding purposes has ||| 0-0 0-1 0-2 1-2 0-3 2-3 1-4
Zucker im Harn , Eiweiss ||| sugar in urine , proteins ||| 0-0 1-1 1-2 2-2 4-2 3-3 4-4
Zucker ||| sugar ||| 0-0
Zudem induziert Paclitaxel die ||| In addition , paclitaxel induces ||| 0-0 0-1 2-3 0-4 1-4
Zudem induziert Paclitaxel ||| In addition , paclitaxel induces ||| 0-0 0-1 2-3 0-4 1-4
Zufuhr von Kalzium und Vitamin ||| calcium and vitamin ||| 0-0 1-0 2-0 3-1 4-2
Zufuhr von Kalzium und ||| calcium and ||| 0-0 1-0 2-0 3-1
Zufuhr von Kalzium ||| calcium ||| 0-0 1-0 2-0
Zugabe ||| complete , ||| 0-0
Zugabe ||| complete ||| 0-0
Zunahme ||| an increase ||| 0-0 0-1
Zunge , Zungenödeme , ||| , tongue oedema , ||| 1-0 0-1 2-1 2-2 3-3
Zunge , Zungenödeme ||| , tongue oedema ||| 1-0 0-1 2-1 2-2
Zunge . ||| tongue . ||| 0-0 1-1
Zunge ||| tongue ||| 0-0
Zungenbrennen , trockener Mund ||| glossodynia , dry mouth ||| 0-0 1-1 2-1 1-2 3-3
Zungenbrennen , trockener ||| glossodynia , dry ||| 0-0 1-1 2-1 1-2
Zungenbrennen ||| glossodynia ||| 0-0
Zur Anwendung darf nur eine ||| Only ||| 0-0 2-0 3-0
Zur Anwendung darf nur ||| Only ||| 0-0 2-0 3-0
Zur Behandlung der postmenopausalen ||| For the treatment of post-menopausal ||| 0-0 2-1 1-2 2-3 3-4
Zur Behandlung der ||| For the treatment of ||| 0-0 2-1 1-2 2-3
Zur Entnahme einer einzelnen Tablette ||| For single tablet removal , ||| 0-0 1-1 4-2 1-3 2-3 3-3
Zur Entnahme einer einzelnen Tablette ||| For single tablet removal ||| 0-0 1-1 4-2 1-3 2-3 3-3
Zur Prävention des Wiederauftretens manischer ||| For preventing recurrence of manic ||| 0-0 1-1 2-1 3-2 3-3 4-4
Zur Prävention des Wiederauftretens ||| 82 For preventing recurrence of ||| 0-0 0-1 1-2 2-2 3-3 3-4
Zur Prävention des Wiederauftretens ||| For preventing recurrence of ||| 0-0 1-1 2-1 3-2 3-3
Zur Prävention des ||| 82 For preventing ||| 0-0 0-1 1-2 2-2
Zur Prävention des ||| For preventing ||| 0-0 1-1 2-1
Zur Unterstützung der ||| As an aid in the ||| 0-0 1-0 1-1 1-2 2-3 2-4
Zur Unterstützung ||| As an aid ||| 0-0 1-0 1-1 1-2
Zur Vorbeugung ||| The orodispersible tablets are taken ||| 0-0 1-1 1-2 0-3 1-4
Zur Wiederbehandlung des Morbus Paget ||| Retreatment of Paget s disease ||| 0-0 1-0 2-1 3-2 4-2 2-3 3-3 4-4
Zur Wiederbehandlung ||| Retreatment ||| 0-0 1-0
Zur intramuskulären Anwendung ||| Intramuscular use Read the ||| 0-0 1-0 0-1 2-1 1-2 2-3
Zur intramuskulären Anwendung ||| Intramuscular use ||| 0-0 1-0 2-1
Zur intramuskulären ||| Intramuscular ||| 0-0 1-0
Zur ||| 82 For ||| 0-0 0-1
Zur ||| For ||| 0-0
Zur ||| There is ||| 0-0
Zur ||| There ||| 0-0
Zur ||| Use ||| 0-0
Zusammen mit der Anwendung von ||| 2 Adequate calcium and vitamin ||| 0-0 0-1 1-1 3-1 0-2 2-2 0-4 4-4
Zusammen mit der Anwendung von ||| Adequate calcium and vitamin ||| 0-0 1-0 3-0 0-1 2-1 0-3 4-3
Zusammen mit der Anwendung von ||| Adequate supplements of vitamin ||| 0-0 1-0 3-0 1-1 2-2 4-2 0-3
Zusammen mit der Verabreichung von ||| Adequate calcium and vitamin ||| 0-0 1-0 0-1 2-1 3-2 0-3 4-3
Zusammenfassung der Merkmale des Arzneimittels ||| Summary of Product Characterisitics ||| 0-0 1-1 2-2 3-2 4-3
Zusammenfassung der Merkmale des Arzneimittels ||| Summary of Product Characteristics for ||| 0-0 1-1 2-2 3-2 2-3 4-3 0-4
Zusammenfassung der Merkmale des Arzneimittels ||| Summary of Product Characteristics ||| 0-0 1-1 2-2 3-2 2-3 4-3
Zusammenfassung der Merkmale des ||| Summary of Product ||| 0-0 1-1 2-2 3-2
Zusammenfassung der Merkmale des ||| Summary of ||| 0-0 1-0 2-0 3-1
Zusammenfassung der Merkmale ||| Summary ||| 0-0 1-0 2-0
Zusammenfassung der ||| Summary of ||| 0-0 1-1
Zusammenfassung wurde ||| conditions for the use of ||| 0-0 0-1 1-3 1-4
Zusammenfassung ||| Summary ||| 0-0
Zusammenfassung ||| conditions for the ||| 0-0 0-1
Zusammenfassung ||| conditions for ||| 0-0 0-1
Zusammenhang mit einer antipsychotischen ||| associated with antipsychotic ||| 0-0 2-0 1-1 0-2 3-2
Zusammenhang mit ||| comparable with ||| 0-1 1-1
Zusammenhang mit ||| linked to ||| 0-0 0-1
Zusammenhang mit ||| with ||| 0-0 1-0
Zusammenhang standen . ||| rat . ||| 0-0 1-0 2-1
Zusammenhang standen ||| rat ||| 0-0 1-0
Zusammenhang ||| linked to ||| 0-0 0-1
Zusammenhang ||| side ||| 0-0
Zusammenlagerung ||| promotes ||| 0-0
Zusammensetzung stammen ||| to reliably ||| 0-0 0-1
Zusammensetzung ||| to reliably ||| 0-0 0-1
Zustand unter Kontrolle ist . ||| condition is controlled . ||| 0-0 3-1 1-2 2-2 4-3
Zustand unter Kontrolle ist . ||| condition is controlled . ||| 0-0 3-1 2-2 4-3
Zustand unter Kontrolle ist ||| condition is controlled ||| 0-0 3-1 1-2 2-2
Zustand unter Kontrolle ist ||| condition is controlled ||| 0-0 3-1 2-2
Zustand unter ||| condition ||| 0-0
Zustand ||| condition ||| 0-0
Zuständen , die ||| who have a ||| 0-0 1-0 2-0 0-1 0-2
Zusätzlich sollten ||| In addition ||| 0-0 0-1 1-1
Zusätzlich wurden ||| In addition , ||| 0-0 0-1 1-1 1-2
Zusätzlich ||| In addition ||| 0-0 0-1
Zusätzlich ||| Therapeutic ||| 0-0
Zusätzliche unerwünschte Ereignisse , die ||| Additional adverse events which ||| 0-0 1-1 2-2 3-3 4-3
Zusätzliche unerwünschte Ereignisse ||| Additional adverse events ||| 0-0 1-1 2-2
Zusätzliche unerwünschte ||| Additional adverse ||| 0-0 1-1
Zusätzliche ||| Additional ||| 0-0
Zwar liegen keine ||| Although there is no ||| 0-0 1-0 0-1 0-2 2-3
Zwar liegen ||| Although there is ||| 0-0 1-0 0-1 0-2
Zwei weitere , kleinere ||| Two other smaller , randomised ||| 0-0 0-1 0-2 1-2 3-2 2-3 3-4
Zwischenmahlzeit eingenommen werden . ||| snack containing carbohydrates . ||| 0-0 0-1 0-2 1-2 2-2 3-3
Zwischenmahlzeit eingenommen werden ||| snack containing carbohydrates ||| 0-0 0-1 0-2 1-2 2-2
Zysten und Polypen ) : ||| cysts and polyps ) : ||| 0-0 1-1 2-2 3-3 4-4
Zysten und Polypen ) ||| cysts and polyps ) ||| 0-0 1-1 2-2 3-3
Zysten und Polypen ||| cysts and polyps ||| 0-0 1-1 2-2
Zysten und ||| cysts and ||| 0-0 1-1
Zysten ||| cysts ||| 0-0
Zytostatika angemessen geschult wurde . ||| cytotoxic agents . ||| 0-0 1-0 2-0 2-1 3-1 4-2
Zytostatika angemessen geschult wurde . ||| of cytotoxic agents . ||| 0-1 1-1 2-1 2-2 3-2 4-3
Zytostatika angemessen geschult wurde ||| cytotoxic agents ||| 0-0 1-0 2-0 2-1 3-1
Zytostatika angemessen geschult wurde ||| of cytotoxic agents ||| 0-1 1-1 2-1 2-2 3-2
Zytotoxische Wirkungen von Epoetin alfa ||| Cytotoxic actions of epoetin alfa ||| 0-0 0-1 1-1 2-2 3-3 4-4
Zytotoxische Wirkungen von Epoetin ||| Cytotoxic actions of epoetin ||| 0-0 0-1 1-1 2-2 3-3
Zytotoxische Wirkungen von ||| Cytotoxic actions of ||| 0-0 0-1 1-1 2-2
Zytotoxische Wirkungen ||| Cytotoxic actions ||| 0-0 0-1 1-1
[ 15,0 ; 18,3 ] ||| [ 15.0 , 18.3 ] ||| 0-0 1-1 2-1 2-2 3-3 4-4
[ 15,0 ; 18,3 ||| [ 15.0 , 18.3 ||| 0-0 1-1 2-1 2-2 3-3
[ 15,0 ; 19,3 ] ||| [ 15.0 , 19.3 ] ||| 0-0 1-1 2-1 2-2 3-3 4-4
[ 15,0 ; 19,3 ||| [ 15.0 , 19.3 ||| 0-0 1-1 2-1 2-2 3-3
[ 15,0 ; ||| [ 15.0 , ||| 0-0 1-1 2-1 2-2
[ 2,7 % ] ) ||| [ 2.7 % ] ) ||| 0-0 1-1 2-2 3-3 4-4
[ 2,7 % ] ||| [ 2.7 % ] ||| 0-0 1-1 2-2 3-3
[ 2,7 % ||| [ 2.7 % ||| 0-0 1-1 2-2
[ 2,7 ||| [ 2.7 ||| 0-0 1-1
[ 3,2 % ] ) ||| [ 3.2 % ] ) ||| 0-0 1-1 2-2 3-3 4-4
[ 3,2 % ] ||| [ 3.2 % ] ||| 0-0 1-1 2-2 3-3
[ 3,2 % ||| [ 3.2 % ||| 0-0 1-1 2-2
[ 3,2 ||| [ 3.2 ||| 0-0 1-1
[ 39,0 ; 55,3 ] ||| [ 39.0 , 55.3 ] ||| 0-0 1-1 2-2 3-3 2-4 4-4
[ 39,0 ||| [ 39.0 ||| 0-0 1-1
[ 7,54 ; 18,93 ] ||| [ 7.54 , 18.93 ] ||| 0-0 1-1 2-2 3-3 2-4 4-4
[ 7,54 ||| [ 7.54 ||| 0-0 1-1
[ 95 % CI ] ||| [ 95 % CI ] ||| 0-0 1-1 2-2 3-3 4-4
[ 95 % CI ||| [ 95 % CI ||| 0-0 1-1 2-2 3-3
[ 95 % ||| [ 95 % ||| 0-0 1-1 2-2
[ 95 ||| [ 95 ||| 0-0 1-1
[ PFT ] ( siehe ||| [ PFT ] ( see ||| 0-0 1-1 2-2 3-3 4-4
[ PFT ] ( ||| [ PFT ] ( ||| 0-0 1-1 2-2 3-3
[ PFT ] ||| [ PFT ] ||| 0-0 1-1 2-2
[ PFT ||| [ PFT ||| 0-0 1-1
[ RFT ] ) ||| [ RFT ] ) ||| 0-0 1-1 2-2 3-3
[ RFT ] ||| [ RFT ] ||| 0-0 1-1 2-2
[ RFT ||| [ RFT ||| 0-0 1-1
[ ||| [ ||| 0-0
] ( Wochen ) ||| ] ( weeks ) ||| 0-0 1-1 2-2 3-3
] ( Wochen ||| ] ( weeks ||| 0-0 1-1 2-2
] ( n = 131 ||| ] ( n = 131 ||| 0-0 1-1 2-2 3-2 3-3 4-4
] ( n = 135 ||| ] ( n = 135 ||| 0-0 1-1 2-2 3-2 3-3 4-4
] ( n = ||| ] ( n = ||| 0-0 1-1 2-2 3-2 3-3
] ( siehe Abschnitt 5.1 ||| ] ( see section 5.1 ||| 0-0 1-1 2-2 3-3 4-4
] ( siehe Abschnitt ||| ] ( see section ||| 0-0 1-1 2-2 3-3
] ( siehe ||| ] ( see ||| 0-0 1-1 2-2
] ( ||| ] ( ||| 0-0 1-1
] ) . ||| ] ) . ||| 0-0 1-1 2-2
] ) und Placebo ( ||| ] ) and placebo ( ||| 0-0 1-1 2-2 3-3 4-4
] ) und Placebo ||| ] ) and placebo ||| 0-0 1-1 2-2 3-3
] ) und ||| ] ) and ||| 0-0 1-1 2-2
] ) ||| ] ) ||| 0-0 1-1
] ||| ] ||| 0-0
ab ||| a ||| 0-0
ab ||| in a ||| 0-1
abbauen . ||| tissue . ||| 0-0 1-1
abbauen ||| tissue ||| 0-0
aber Nebenwirkungen verursachen können ||| but can cause side effects ||| 0-0 3-1 2-2 1-3 1-4
aber keine ||| but no ||| 0-0 1-1
aber nicht bei jedem auftreten ||| although not everybody gets ||| 0-0 3-0 1-1 2-2 3-2 3-3 4-3
aber nicht der CYP1A-Enzyme , ||| enzymes but not CYP1A ||| 3-0 0-1 1-2 2-3 3-3 4-3
aber nicht ||| but not ||| 0-0 1-1
aber nur 0,01 ||| but only 0.01 ||| 0-0 1-1 2-2
aber nur ||| but only ||| 0-0 1-1
aber ||| , but a ||| 0-1
aber ||| , but ||| 0-1
aber ||| but a ||| 0-0
aber ||| but with ||| 0-0
aber ||| but ||| 0-0
abfallen . ||| cell volume . ||| 0-0 0-1 1-2
abfallen ||| cell volume ||| 0-0 0-1
abgebaut werden ||| are ||| 1-0
abgemagertes Aussehen , Dehydratation und ||| emaciated appearance , dehydration and ||| 0-0 1-0 2-1 2-2 3-3 4-4
abgemagertes Aussehen , Dehydratation ||| emaciated appearance , dehydration ||| 0-0 1-0 2-1 2-2 3-3
abgemagertes Aussehen , ||| emaciated appearance , ||| 0-0 1-0 2-1 2-2
abgemagertes Aussehen ||| emaciated ||| 0-0 1-0
abgeschwächtes Atemgeräusch , Pleuraerguss , ||| sounds , pleural effusion , ||| 0-0 1-0 2-1 3-2 3-3 4-3 4-4
abgeschwächtes Atemgeräusch , ||| sounds , ||| 0-0 1-0 2-1
abgeschwächtes Atemgeräusch ||| sounds ||| 0-0 1-0
abgesehen . ||| been observed . ||| 0-0 0-1 1-2
abgesehen ||| been observed ||| 0-0 0-1
abgesetzt . ||| . ||| 0-0 1-0
abgesetzt werden . ||| must be discontinued . ||| 0-0 1-1 0-2 1-2 2-3
abgesetzt werden ||| be discontinued ||| 1-0 0-1 1-1
abgesetzt werden ||| must be discontinued ||| 0-0 1-1 0-2 1-2
abgesetzt ||| discontinued ||| 0-0
abgewogen werden . ||| patient group . ||| 0-0 0-1 1-1 2-2
abgewogen werden ||| patient group ||| 0-0 0-1 1-1
abhängig von Alter ||| vary with age ||| 0-0 1-0 0-1 2-2
abhängig von ||| vary with ||| 0-0 1-0 0-1
abnormaler ||| abnormal ||| 0-0
abnorme Blutfettspiegel ||| levels of fat in their ||| 0-0 0-2 1-2 1-4
abrupten Verbesserung der ||| abrupt improvement in ||| 0-0 1-0 1-1 2-1 1-2
absichtliche akute ||| intentional acute ||| 0-0 1-1
absichtliche ||| intentional ||| 0-0
absolute Bioverfügbarkeit von Rimonabant ist ||| absolute bioavailability of rimonabant has ||| 0-0 1-1 2-2 3-3 3-4 4-4
absolute Bioverfügbarkeit von ||| absolute bioavailability of ||| 0-0 1-1 2-2
absolute Bioverfügbarkeit ||| absolute bioavailability ||| 0-0 1-1
absolute Veränderung ||| absolute change in ||| 0-0 1-1 1-2
absolute orale Bioverfügbarkeit der ||| absolute oral bioavailability of the ||| 0-0 1-1 2-2 2-3 3-4
absolute orale Bioverfügbarkeit ||| absolute oral bioavailability of ||| 0-0 1-1 2-2 2-3
absolute orale ||| absolute oral ||| 0-0 1-1
absolute ||| absolute ||| 0-0
absoluten Bioverfügbarkeit von 100 % ||| absolute bioavailability of 100 % ||| 0-0 1-0 1-1 2-2 3-3 4-4
absoluten Bioverfügbarkeit von 100 ||| absolute bioavailability of 100 ||| 0-0 1-0 1-1 2-2 3-3
absoluten Bioverfügbarkeit von ||| absolute bioavailability of ||| 0-0 1-0 1-1 2-2
absoluten Bioverfügbarkeit ||| absolute bioavailability ||| 0-0 1-0 1-1
abzusetzen ( siehe ||| should be discontinued ( see ||| 0-0 0-1 0-2 1-3 2-4
abzusetzen ( ||| should be discontinued ( ||| 0-0 0-1 0-2 1-3
abzusetzen . ||| should be discontinued . ||| 0-0 0-1 0-2 1-3
abzusetzen ||| should be discontinued ||| 0-0 0-1 0-2
acht Hauptstudien ||| eight main ||| 0-0 1-1
acht ||| eight ||| 0-0
achten ||| eighth ||| 0-0
acknowledged . ||| year . ||| 0-0 1-1
acknowledged ||| acknowledged ||| 0-0
acknowledged ||| year ||| 0-0
agonistische ||| properties in animal ||| 0-0 0-1 0-2
aktiv ( M-II ||| active ( M-II ||| 0-0 1-1 2-2
aktiv ( ||| active ( ||| 0-0 1-1
aktiv ||| active ||| 0-0
aktive ||| active ||| 0-0
aktiven Metaboliten liegen überwiegend ||| active metabolites are extensively ||| 0-0 1-1 2-2 2-3 3-3
aktiven Metaboliten ||| active metabolites ||| 0-0 1-1
aktiven ||| active ||| 0-0
aktiver maligner Erkrankung , ||| active malignant disease ||| 0-0 0-1 1-1 2-1 2-2 3-2
aktualisiert . ||| . dic Me ||| 1-0 0-1 0-2 1-2
aktualisiert . ||| relevant modules . ||| 0-0 0-1 1-2
aktualisiert . ||| the relevant modules . ||| 0-1 0-2 1-3
aktualisiert . ||| to the relevant modules . ||| 0-2 0-3 1-4
aktualisiert ||| relevant modules ||| 0-0 0-1
aktualisiert ||| the relevant modules ||| 0-1 0-2
aktualisiert ||| to the relevant modules ||| 0-2 0-3
aktuell ||| current suicidal ideations and/ ||| 0-0 0-1 0-2 0-3
aktuellen Sicherheitsspezifikationen ( Safety Specification ||| current Safety ||| 0-0 3-1 4-1
aktuellen Sicherheitsspezifikationen ( ||| current ||| 0-0
aktuellen Sicherheitsspezifikationen ||| current ||| 0-0
aktuellen ||| current ||| 0-0
akute Intoxikationen mit Aclasta vor ||| acute intoxication with Aclasta ||| 0-0 1-1 2-2 3-3 4-3
akute Intoxikationen mit ||| acute intoxication with ||| 0-0 1-1 2-2
akute Intoxikationen ||| acute intoxication ||| 0-0 1-1
akute ||| acute ||| 0-0
akutem ||| non- ||| 0-0
akutes Nierenversagen sein . ||| acute renal failure . ||| 0-0 1-0 2-0 1-1 1-2 3-3
akutes Nierenversagen sein ||| acute renal failure ||| 0-0 1-0 2-0 1-1 1-2
akutes Nierenversagen ||| acute renal failure ||| 0-0 1-0 1-1 1-2
akutes ||| acute ||| 0-0
akzelerierte ||| antihypertensive medications ||| 0-0 0-1
akzeptiert . ||| SAWP . ||| 0-0 1-1
akzeptiert ||| SAWP ||| 0-0
albuminbindenden ||| accumulation ||| 0-0
alfa , die einmal wöchentlich ||| alfa , given weekly ||| 0-0 1-1 4-2 3-3 4-3
alfa , die ||| alfa , ||| 0-0 1-1
alfa , ||| alfa , ||| 0-0 1-1
alfa . Abseamed 3000 I.E./0,3 ||| alfa Abseamed 3000 IU/ 0.3 ||| 0-0 2-1 3-2 4-3 4-4
alfa . Abseamed 3000 ||| alfa Abseamed 3000 ||| 0-0 2-1 3-2
alfa . Abseamed 4000 ||| alfa Abseamed 4000 IU/ ||| 0-0 2-1 3-2 3-3
alfa . Abseamed 5000 ||| alfa Abseamed 5000 IU/ ||| 0-0 2-1 3-2 3-3
alfa . Abseamed 6000 I.E./0,6 ||| alfa Abseamed 6000 IU/ 0.6 ||| 0-0 2-1 3-2 3-3 4-4
alfa . Abseamed 6000 ||| alfa Abseamed 6000 IU/ ||| 0-0 2-1 3-2 3-3
alfa . Abseamed 7000 ||| alfa Abseamed 7000 ||| 0-0 2-1 3-2
alfa . Abseamed 8000 I.E./0,8 ||| alfa Abseamed 8000 IU/ 0.8 ||| 0-0 2-1 3-2 4-3 4-4
alfa . Abseamed 8000 ||| alfa Abseamed 8000 ||| 0-0 2-1 3-2
alfa . Abseamed 9000 ||| alfa Abseamed 9000 ||| 0-0 2-1 3-2
alfa . Abseamed ||| alfa Abseamed ||| 0-0 2-1
alfa . ||| alfa ||| 0-0
alfa Einfluss auf die Verstoffwechselung ||| alfa alters the metabolism of ||| 0-0 1-1 2-1 3-2 4-3 3-4
alfa Einfluss auf ||| alfa alters ||| 0-0 1-1 2-1
alfa auf Knochenmarkszellen ||| alfa on bone marrow cells ||| 0-0 1-1 2-2 2-3 2-4
alfa auf ||| alfa on ||| 0-0 1-1
alfa behandelten Patienten kann es ||| may occur in epoetin alfa ||| 3-0 1-1 1-2 2-2 0-3 3-3 0-4 4-4
alfa bei Erwachsenen mit ||| alfa in adult patients with ||| 0-0 1-1 1-2 2-2 2-3 3-4
alfa bei Erwachsenen ||| alfa in adult patients ||| 0-0 1-1 1-2 2-2 2-3
alfa berichtet . ||| alfa . ||| 0-0 1-0 2-1
alfa berichtet ||| alfa ||| 0-0 1-0
alfa berücksichtigt werden . ||| alfa in cancer patients . ||| 0-0 1-2 2-2 1-3 3-4
alfa berücksichtigt werden ||| alfa in cancer patients ||| 0-0 1-2 2-2 1-3
alfa ist ein ||| alfa is a ||| 0-0 1-1 2-2
alfa ist sehr groß . ||| alfa is very wide . ||| 0-0 1-1 2-2 3-3 4-4
alfa ist sehr groß ||| alfa is very wide ||| 0-0 1-1 2-2 3-3
alfa ist sehr ||| alfa is very ||| 0-0 1-1 2-2
alfa ist ||| alfa is ||| 0-0 1-1
alfa kann ||| alfa may ||| 0-0 1-1
alfa sollte ||| alfa should be ||| 0-0 1-1 1-2
alfa und G-CSF oder GM-CSF ||| alfa and G-CSF or GM-CSF ||| 0-0 1-1 2-2 3-3 2-4 4-4
alfa und anderen Erythropoese-stimulierenden Wirkstoffen ||| alfa and other erythropoiesis-stimulating agents ||| 0-0 1-1 2-2 3-3 4-4
alfa und anderen Erythropoese-stimulierenden ||| alfa and other erythropoiesis-stimulating ||| 0-0 1-1 2-2 3-3
alfa und anderen ||| alfa and other ||| 0-0 1-1 2-2
alfa und ||| alfa and ||| 0-0 1-1
alfa wird ||| alfa is ||| 0-0 1-1
alfa wurde ||| alfa has been ||| 0-0 1-1 1-2
alfa zeigte keinerlei ||| alfa did not show any ||| 0-0 1-1 2-1 2-2 2-3 2-4
alfa zusammen mit ||| alfa is given concomitantly with ||| 0-0 1-1 1-2 1-3 2-4
alfa zusammen ||| alfa is given concomitantly ||| 0-0 1-1 1-2 1-3
alfa ||| alfa in ||| 0-0
alfa ||| alfa ||| 0-0
alkalische Phosphatase ( BSAP ) ||| alkaline phosphatase ( BSAP ) ||| 0-0 1-1 2-2 3-3 4-4
alkalische Phosphatase ( BSAP ||| alkaline phosphatase ( BSAP ||| 0-0 1-1 2-2 3-3
alkalische Phosphatase ( BSAP ||| specific alkaline phosphatase ( BSAP ||| 0-1 1-2 2-3 3-4
alkalische Phosphatase ( ||| alkaline phosphatase ( ||| 0-0 1-1 2-2
alkalische Phosphatase ( ||| specific alkaline phosphatase ( ||| 0-1 1-2 2-3
alkalische Phosphatase ||| alkaline phosphatase ||| 0-0 1-1
alkalische Phosphatase ||| specific alkaline phosphatase ||| 0-1 1-2
alkalische ||| alkaline ||| 0-0
alkalische ||| specific alkaline ||| 0-1
alkalischen Phosphatase ||| alkaline phosphatase level 2.6 ||| 1-0 0-1 1-1
alkalischen Phosphatase ||| alkaline phosphatase level ||| 1-0 0-1 1-1
alkalischen Phosphatase ||| alkaline phosphatase ||| 1-0 0-1 1-1
alkalischer ||| detected following ||| 0-0
alkalischer ||| detected ||| 0-0
alle 3 Wochen eine ||| every 3 weeks ||| 0-0 1-1 2-2
alle 3 Wochen ||| every 3 weeks ||| 0-0 1-1 2-2
alle 3 ||| every 3 ||| 0-0 1-1
alle Anweisungen , die ||| all instructions given to ||| 0-0 1-1 1-2 2-3 3-3
alle Anweisungen ||| all instructions given to ||| 0-0 1-1 1-2
alle Anweisungen ||| all instructions given ||| 0-0 1-1 1-2
alle Arzneimittel ||| all medicines ||| 0-0 1-1
alle Packungsgrößen in Verkehr gebracht ||| sizes may be marketed ||| 0-0 1-0 1-1 2-2 3-2 3-3 4-3
alle Packungsgrößen in ||| alle Packungsgrößen in ||| 0-0 1-1 2-2
alle Packungsgrößen in ||| sizes may ||| 0-0 1-0 2-0 1-1
alle Packungsgrößen ||| alle Packungsgrößen ||| 0-0 1-1
alle Packungsgrößen ||| sizes may ||| 0-0 1-0 1-1
alle Patienten ||| all ||| 0-0
alle Tumorpatienten ||| all cancer patients ||| 0-0 1-1 1-2
alle aktiven Metaboliten liegen überwiegend ||| all active metabolites are extensively ||| 0-0 1-1 2-2 3-3 3-4 4-4
alle aktiven Metaboliten ||| all active metabolites ||| 0-0 1-1 2-2
alle aktiven ||| all active ||| 0-0 1-1
alle drei Wochen . ||| , every three weeks . ||| 0-1 1-2 2-3 3-4
alle drei Wochen . ||| every three weeks . ||| 0-0 1-1 2-2 3-3
alle drei Wochen ||| , every three weeks ||| 0-1 1-2 2-3
alle drei Wochen ||| every three weeks ||| 0-0 1-1 2-2
alle drei ||| , every three ||| 0-1 1-2
alle drei ||| every three ||| 0-0 1-1
alle klinischen Frakturen Die ||| all clinical fractures The incidence ||| 0-0 1-1 2-2 3-3 2-4
alle klinischen ||| all clinical ||| 0-0 1-1
alle vier Wochen ||| every four weeks ||| 0-0 1-1 2-2
alle vier ||| every four ||| 0-0 1-1
alle ||| , every ||| 0-1
alle ||| all of ||| 0-0
alle ||| all ||| 0-0
alle ||| alle ||| 0-0
alle ||| every ||| 0-0
allein ||| alone ||| 0-0
allein ||| its own ||| 0-1
allein ||| on its own ||| 0-2
allein ||| own ||| 0-0
allem als partieller ||| act mainly by being a ||| 0-0 0-1 1-2 2-3 1-4
allem ||| act mainly ||| 0-0 0-1
allem ||| mainly ||| 0-0
allen Bisphosphonaten unterliegen Patienten ||| all bisphosphonates , patients taking ||| 0-0 1-1 2-3 3-3 1-4
allen Fällen normalisierte ||| all of whom it resolved ||| 0-0 1-3 2-4
allen Fällen ||| all of whom it ||| 0-0 1-3
allen Patienten , die ||| all patients receiving ||| 0-0 1-1 0-2 2-2 3-2
allen Patienten betrugen jeweils 39,5 ||| all patients were 39.5 ||| 0-0 1-1 2-2 3-3 4-3
allen Patienten betrugen ||| all patients were ||| 0-0 1-1 2-2
allen Patienten ||| all patients receiving ||| 0-0 1-1 0-2
allen Patienten ||| all patients ||| 0-0 1-1
allen Wachstumsfaktoren sollte ||| all growth factors ||| 0-0 1-1 1-2 2-2
allen Zeitpunkten ( 6 , ||| all timepoints ( 6 , ||| 0-0 1-1 2-2 3-3 4-4
allen Zeitpunkten ( 6 ||| all timepoints ( 6 ||| 0-0 1-1 2-2 3-3
allen Zeitpunkten ( ||| all timepoints ( ||| 0-0 1-1 2-2
allen Zeitpunkten . ||| all timepoints . ||| 0-0 1-1 2-2
allen Zeitpunkten ||| all timepoints ||| 0-0 1-1
allen außer einer von ||| allen außer einer von ||| 0-0 1-1 2-2 3-3
allen außer einer ||| allen außer einer ||| 0-0 1-1 2-2
allen außer ||| allen außer ||| 0-0 1-1
allen ||| All ||| 0-0
allen ||| all of whom ||| 0-0
allen ||| all of ||| 0-0
allen ||| all ||| 0-0
allen ||| allen ||| 0-0
aller Darreichungsformen ) soll ||| all formulations ) should ||| 0-0 0-1 1-1 2-2 3-3
aller Darreichungsformen ) ||| all formulations ) ||| 0-0 0-1 1-1 2-2
aller Darreichungsformen von Aripiprazol ) ||| all formulations of aripiprazole ) ||| 0-0 0-1 1-1 2-2 3-3 4-4
aller Darreichungsformen von Aripiprazol ||| all formulations of aripiprazole ||| 0-0 0-1 1-1 2-2 3-3
aller Darreichungsformen von ||| all formulations of ||| 0-0 0-1 1-1 2-2
aller Darreichungsformen ||| all formulations ||| 0-0 0-1 1-1
aller ||| all ||| 0-0
allergisch ) ||| of ||| 0-0
allergisch ||| of ||| 0-0
allergische Reaktion ( z.B . ||| allergic reaction ( e. g. ||| 0-0 1-1 2-2 3-3 4-3 3-4
allergische Reaktion ( ||| allergic reaction ( ||| 0-0 1-1 2-2
allergische Reaktion auftritt , ||| hypersensitivity occurs , ||| 0-0 1-0 2-1 3-2
allergische Reaktion auftritt ||| hypersensitivity occurs ||| 0-0 1-0 2-1
allergische Reaktion ||| allergic reaction ||| 0-0 1-1
allergische Reaktion ||| hypersensitivity ||| 0-0 1-0
allergische Reaktionen , ||| reactions have been ||| 0-0 1-0 1-1 2-1
allergische Reaktionen , ||| reactions have ||| 0-0 1-0 1-1 2-1
allergische Reaktionen liegen vor . ||| serious allergic reactions . ||| 1-0 0-1 1-2 4-3
allergische Reaktionen liegen vor ||| serious allergic reactions ||| 1-0 0-1 1-2
allergische Reaktionen liegen ||| serious allergic reactions ||| 1-0 0-1 1-2
allergische Reaktionen verursachen ( möglicherweise ||| cause allergic reactions ( possibly ||| 2-0 0-1 2-1 1-2 3-3 4-4
allergische Reaktionen verursachen ( ||| cause allergic reactions ( ||| 2-0 0-1 2-1 1-2 3-3
allergische Reaktionen verursachen kann . ||| may cause allergic reactions . ||| 0-0 1-1 2-1 0-2 2-2 1-3 3-3 4-4
allergische Reaktionen verursachen kann ||| may cause allergic reactions ||| 0-0 1-1 2-1 0-2 2-2 1-3 3-3
allergische Reaktionen verursachen ||| cause allergic reactions ||| 2-0 0-1 2-1 1-2
allergische Reaktionen ||| serious allergic reactions ||| 1-0 0-1 1-2
allergische Rhinitis , Heiserkeit , ||| allergic rhinitis , hoarseness , ||| 0-0 1-1 2-2 3-3 4-4
allergische Rhinitis , Heiserkeit ||| allergic rhinitis , hoarseness ||| 0-0 1-1 2-2 3-3
allergische Rhinitis , ||| allergic rhinitis , ||| 0-0 1-1 2-2
allergische Rhinitis ||| allergic rhinitis ||| 0-0 1-1
allergische Symptome , ||| allergic symptoms , may ||| 0-0 1-1 2-2 0-3
allergische ||| allergic ||| 0-0
allergischen Reaktion ( N = ||| hypersensitivity ( N = ||| 0-0 1-0 2-1 3-2 4-3
allergischen Reaktion ( N = ||| prevent hypersensitivity ( N = ||| 0-1 1-1 2-2 3-3 4-4
allergischen Reaktion ( N ||| hypersensitivity ( N ||| 0-0 1-0 2-1 3-2
allergischen Reaktion ( N ||| prevent hypersensitivity ( N ||| 0-1 1-1 2-2 3-3
allergischen Reaktion ( ||| hypersensitivity ( ||| 0-0 1-0 2-1
allergischen Reaktion ( ||| prevent hypersensitivity ( ||| 0-1 1-1 2-2
allergischen Reaktion ||| hypersensitivity ||| 0-0 1-0
allergischen Reaktion ||| prevent hypersensitivity ||| 0-1 1-1
allgemeinen ||| contributing ||| 0-0
als 1 % ||| than 1 % of ||| 0-0 1-1 2-2
als 1 % ||| than 1 % ||| 0-0 1-1 2-2
als 1 von 10 Patienten ||| than 1 patient in 10 ||| 0-0 2-0 1-1 4-2 4-3 3-4
als 1 von ||| than 1 ||| 0-0 1-1
als 1 von ||| than 1 ||| 0-0 2-0 1-1
als 1 ||| than 1 patient ||| 0-0 1-1
als 1 ||| than 1 ||| 0-0 1-1
als 10 mg , 15 ||| as 10 mg , 15 ||| 0-0 1-1 2-2 3-3 4-4
als 10 mg , ||| as 10 mg , ||| 0-0 1-1 2-2 3-3
als 10 mg ||| as 10 mg ||| 0-0 1-1 2-2
als 10 von ||| than 10 ||| 0-0 2-0 1-1
als 10 ||| as 10 ||| 0-0 1-1
als 15 Minuten betragen . ||| than 15 minutes . ||| 0-0 1-1 2-2 3-2 4-3
als 15 Minuten betragen ||| than 15 minutes ||| 0-0 1-1 2-2 3-2
als 15 ||| than 15 ||| 0-0 1-1
als 15-minütige ||| as ||| 0-0
als 2 g/dl ( ||| than 2 g/ dl ( ||| 0-0 1-1 2-2 2-3 3-4
als 2 g/dl ||| than 2 g/ dl ||| 0-0 1-1 2-2 2-3
als 2 ||| than 2 ||| 0-0 1-1
als 3 Metastasestellen . ||| 3 sites of metastases . ||| 1-0 2-3 3-4
als 3 Metastasestellen ||| 3 sites of metastases ||| 1-0 2-3
als 3 ||| 3 sites of ||| 1-0
als 3 ||| 3 sites ||| 1-0
als 3 ||| 3 ||| 1-0
als 3-stündige ||| as ||| 0-0 1-0
als 30 % der Patienten ||| than 30 % of patients ||| 0-0 1-1 2-2 3-3 4-4
als 30 % der ||| than 30 % of ||| 0-0 1-1 2-2 3-3
als 30 % ||| than 30 % ||| 0-0 1-1 2-2
als 30 ||| than 30 ||| 0-0 1-1
als 5 mg , 10 ||| as 5 mg , 10 ||| 0-0 1-1 2-2 3-3 4-4
als 5 mg , ||| as 5 mg , ||| 0-0 1-1 2-2 3-3
als 5 mg ||| as 5 mg ||| 0-0 1-1 2-2
als 5 ||| as 5 ||| 0-0 1-1
als 6 Monaten ||| than 6 months ago ||| 0-0 1-1 2-2 2-3
als 6 ||| than 6 ||| 0-0 1-1
als Arzneimittel gegen Krebs ||| as an anticancer medicine ||| 0-0 0-1 2-2 3-2 1-3 3-3
als Erstlinienbehandlung ||| as first-line ||| 0-0 1-1
als Hydrchlorid ) . ||| as hydrochloride ) . ||| 0-0 1-1 2-2 3-3
als Hydrchlorid ) ||| as hydrochloride ) ||| 0-0 1-1 2-2
als Hydrchlorid ||| as hydrochloride ||| 0-0 1-1
als Hydrochlorid ) ) ||| as hydrochloride ) ) ||| 0-0 0-1 1-1 2-2 3-3
als Hydrochlorid ) . ||| as hydrochloride ) . ||| 0-0 1-1 2-2 3-3
als Hydrochlorid ) ||| as hydrochloride ) ||| 0-0 0-1 1-1 2-2
als Hydrochlorid ) ||| as hydrochloride ) ||| 0-0 1-1 2-2
als Hydrochlorid . ||| as hydrochloride . ||| 0-0 1-1 2-2
als Hydrochlorid ||| as hydrochloride ||| 0-0 0-1 1-1
als Hydrochlorid ||| as hydrochloride ||| 0-0 1-1
als Injektion unter die ||| give by injection under the ||| 1-0 0-1 1-1 1-2 2-3 3-4
als Injektion unter die ||| given by injection under the ||| 1-0 0-1 1-1 1-2 2-3 3-4
als Injektion unter ||| give by injection under ||| 1-0 0-1 1-1 1-2 2-3
als Injektion unter ||| given by injection under ||| 1-0 0-1 1-1 1-2 2-3
als Injektion ||| give by injection ||| 1-0 0-1 1-1 1-2
als Injektion ||| given by injection ||| 1-0 0-1 1-1 1-2
als Kinder ||| than children ||| 0-0 1-1
als Kinder über 30 kg ||| than children over 30 kg ||| 0-0 1-1 2-2 3-3 4-4
als Kinder über 30 ||| than children over 30 ||| 0-0 1-1 2-2 3-3
als Kinder über ||| than children over ||| 0-0 1-1 2-2
als Klassenwirkungen ||| as class ||| 0-0 0-1 1-1
als Monotherapie oder Kombinationstherapie ||| as monotherapy or combination therapy ||| 0-0 1-1 2-2 3-3 3-4
als Monotherapie oder ||| as monotherapy or ||| 0-0 1-1 2-2
als Monotherapie wurde ||| as monotherapy was ||| 0-0 1-1 2-2
als Monotherapie ||| administered as a ||| 1-0 0-1 1-1 0-2
als Monotherapie ||| as monotherapy ||| 0-0 1-1
als Risedronat . ||| than risedronate . ||| 0-0 1-1 2-2
als Risedronat ||| than risedronate ||| 0-0 1-1
als Tripletherapie ||| as triple ||| 0-0 0-1
als Verminderung der Hämoglobinwerte ||| by a decrease in haemoglobin ||| 1-0 1-1 0-2 1-2 3-4
als Verminderung der ||| by a decrease in ||| 1-0 1-1 0-2 1-2
als Verminderung der ||| by a decrease ||| 1-0 1-1 0-2 1-2
als Verminderung ||| by a decrease in ||| 1-0 1-1 0-2 1-2
als Verminderung ||| by a decrease ||| 1-0 1-1 0-2 1-2
als Wachstumsfaktoren wirken können ||| may act as growth factor ||| 3-0 2-1 0-2 1-3 2-4
als Wachstumsfaktoren wirken ||| act as growth factor ||| 2-0 0-1 1-2 2-3
als Wachstumsfaktoren ||| as growth ||| 0-0 1-1
als bei Patienten mit Schizophrenie ||| than in those with schizophrenia ||| 0-0 1-1 0-2 2-2 3-3 4-4
als bei Patienten mit ||| than in those with ||| 0-0 1-1 0-2 2-2 3-3
als bei Patienten ohne Adipositas ||| als bei Patienten ohne Adipositas ||| 0-0 1-1 2-2 3-3 4-4
als bei Patienten ohne ||| als bei Patienten ohne ||| 0-0 1-1 2-2 3-3
als bei Patienten ||| als bei Patienten ||| 0-0 1-1 2-2
als bei Patienten ||| than in those ||| 0-0 1-1 0-2 2-2
als bei der Haloperidol-Gruppe ( ||| than for haloperidol ( ||| 0-0 3-1 1-2 3-2 4-3
als bei der Haloperidol-Gruppe ||| than for haloperidol ||| 0-0 3-1 1-2 3-2
als bei ||| als bei ||| 0-0 1-1
als bei ||| can occur ||| 1-1
als bei ||| in ||| 0-0 1-0
als bei ||| occur ||| 1-0
als der ||| than the ||| 0-0 1-1
als die nach der ||| than those observed after the ||| 0-0 0-1 1-1 2-2 2-3 3-4
als die nach ||| than those observed after ||| 0-0 0-1 1-1 2-2 2-3
als die ||| than those ||| 0-0 0-1 1-1
als die ||| than ||| 0-0
als drei ||| than three ||| 0-0 1-1
als ein Jahr wirken , ||| than one year , ||| 0-0 1-1 2-1 2-2 4-3
als ein Jahr wirken ||| than one year ||| 0-0 1-1 2-1 2-2
als ein Jahr ||| than one year ||| 0-0 1-1 2-1 2-2
als ein Maß der Elimination ||| rather than of the elimination ||| 1-0 2-0 0-1 3-2 3-3 4-4
als ein Maß der ||| rather than of the ||| 1-0 2-0 0-1 3-2 3-3
als ein Maß ||| rather than ||| 1-0 2-0 0-1
als einmalige ||| as a single ||| 0-0 1-0 0-1 1-2
als intramuskuläre ||| administered intramuscularly as ||| 1-0 1-1 0-2
als intravenöse Infusion gegeben werden ||| be administered by intravenous infusion ||| 4-0 0-1 1-1 3-1 1-2 1-3 2-4
als intravenöse Infusion gegeben ||| administered by intravenous infusion , ||| 0-0 1-0 1-1 1-2 2-3 3-3
als intravenöse Infusion gegeben ||| administered by intravenous infusion , ||| 0-0 1-0 3-0 1-1 1-2 2-3
als intravenöse Infusion gegeben ||| administered by intravenous infusion ||| 0-0 1-0 1-1 1-2 2-3 3-3
als intravenöse Infusion gegeben ||| administered by intravenous infusion ||| 0-0 1-0 3-0 1-1 1-2 2-3
als intravenöse ||| administered by intravenous ||| 0-0 1-0 1-1 1-2
als konventionelle Paclitaxel enthaltende Arzneimittel ||| than conventional paclitaxel-containing medicines ||| 0-0 1-1 1-2 2-2 3-2 3-3 4-3
als mögliche medizinisch relevante ||| identified as possibly medically relevant ||| 1-0 2-0 0-1 3-2 2-3 3-3 3-4
als nicht bekannt erachtet ( ||| considered not known ( ||| 0-0 3-0 1-1 2-2 3-2 4-3
als nicht bekannt erachtet ||| considered not known ||| 0-0 3-0 1-1 2-2 3-2
als nicht genotoxisch eingestuft . ||| was considered non-genotoxic . ||| 2-0 2-1 0-2 1-2 2-2 3-2 4-3
als nicht genotoxisch eingestuft ||| was considered non-genotoxic ||| 2-0 2-1 0-2 1-2 2-2 3-2
als nicht ||| as non ||| 0-0
als nicht ||| as ||| 0-0
als normal macht . ||| than normal . ||| 0-0 1-1 3-2
als normal macht ||| than normal ||| 0-0 1-1
als normal ||| than normal ||| 0-0 1-1
als notwendig erachtet wird ||| is deemed necessary in ||| 3-0 0-1 2-1 1-2
als notwendig erachtet wird ||| is deemed necessary ||| 3-0 0-1 2-1 1-2
als notwendig erachtet ||| deemed necessary in ||| 0-0 2-0 1-1
als notwendig erachtet ||| deemed necessary ||| 0-0 2-0 1-1
als partieller ||| by being a ||| 0-0 1-1 0-2
als plötzliche ||| in sudden and ||| 0-0 1-1
als plötzliche ||| in sudden ||| 0-0 1-1
als schwerwiegende Nebenwirkung ||| serious adverse events ||| 1-0 2-1 0-2 1-2
als sekundäre Studienziele definiert wurden ||| used as secondary endpoints ||| 1-0 0-1 1-1 2-2 1-3 2-3 3-3 4-3
als sekundäre Studienziele definiert wurden ||| used as secondary endpoints ||| 1-0 0-1 2-2 1-3 2-3 3-3 4-3
als unter Placebo oder wurden ||| than placebo , or were ||| 0-0 1-1 2-1 3-3 4-4
als unter Placebo oder ||| than placebo , or ||| 0-0 1-1 2-1 3-3
als unter Placebo ||| than placebo , ||| 0-0 1-1 2-1
als unter Placebo ||| than placebo ||| 0-0 1-1 2-1
als von ||| than ||| 0-0
als ||| , than ||| 0-1
als ||| a ||| 0-0
als ||| als ||| 0-0
als ||| as a ||| 0-0
als ||| as a ||| 0-0 0-1
als ||| as an ||| 0-0 0-1
als ||| as non ||| 0-0
als ||| as the patient ||| 0-0
als ||| as the ||| 0-0
als ||| as triple ||| 0-0 0-1
als ||| as ||| 0-0
als ||| be ||| 0-0
als ||| conditions other than ||| 0-2
als ||| considered to ||| 0-0
als ||| considered ||| 0-0
als ||| events ||| 0-0
als ||| in ||| 0-0
als ||| more than ||| 0-0 0-1
als ||| other than ||| 0-1
als ||| than ||| 0-0
alternativ zu ||| who have difficulty ||| 0-0 0-1 1-1 0-2
altersabhängigen Effekte ||| in schizophrenic ||| 0-0 0-1 1-1
am Ende der ||| at the end of the ||| 1-0 0-1 0-2 1-2 2-3 2-4
am Ende der ||| at the end of the ||| 1-0 2-1 0-2 1-2 2-3 2-4
am Ende ||| at the end ||| 1-0 0-1 0-2 1-2
am Gefrierfach oder ||| or too near ||| 2-0 1-1 0-2 1-2 2-2
am Menschen ||| human ||| 1-0
am Ort der Infusion , ||| at the infusion site ||| 0-0 1-1 2-1 3-2 0-3
am Ort der Infusion ||| at the infusion site ||| 0-0 1-1 2-1 3-2 0-3
am Putamen . ||| emission tomography . ||| 0-0 1-0 1-1 2-2
am Putamen ||| emission tomography ||| 0-0 1-0 1-1
am Verabreichungsort Gelegentlich - ||| site conditions Uncommon - ||| 1-0 0-1 1-1 2-2 3-3
am Verabreichungsort Gelegentlich : Abgeschlagenheit* ||| site conditions Uncommon : fatigue* ||| 1-0 0-1 1-1 2-2 3-3 4-4
am Verabreichungsort Gelegentlich : ||| site conditions Uncommon : ||| 1-0 0-1 1-1 2-2 3-3
am Verabreichungsort Gelegentlich ||| site conditions Uncommon ||| 1-0 0-1 1-1 2-2
am Verabreichungsort Häufig : ||| site conditions Common : ||| 1-0 0-1 1-1 2-2 3-3
am Verabreichungsort Häufig ||| site conditions Common ||| 1-0 0-1 1-1 2-2
am Verabreichungsort ||| site conditions ||| 1-0 0-1 1-1
am besten ||| best to treat ||| 1-0 0-1 1-2
am häufigsten auftretende Nebenwirkung ||| most frequently occurring undesirable effect ||| 1-0 0-1 1-1 2-2 2-3 3-3 3-4
am häufigsten ||| most frequently ||| 1-0 0-1 1-1
am ||| , rigors ||| 0-0 0-1
am ||| of the ||| 0-1
am ||| the ||| 0-0
am ||| to ||| 0-0
an 1.228 schizophrenen Patienten ||| trials involving 1,228 schizophrenic patients ||| 1-0 1-1 0-2 1-2 2-2 2-3 3-4
an 1.228 schizophrenen ||| trials involving 1,228 schizophrenic ||| 1-0 1-1 0-2 1-2 2-2 2-3
an 375 anämischen Patienten ||| conducted in 375 anaemic patients ||| 0-0 1-0 0-1 1-2 2-2 2-3 3-4
an 375 anämischen ||| conducted in 375 anaemic ||| 0-0 1-0 0-1 1-2 2-2 2-3
an 384 Patienten untersucht . ||| in 384 patients . ||| 0-0 1-1 2-2 3-2 4-3
an 384 Patienten untersucht ||| in 384 patients ||| 0-0 1-1 2-2 3-2
an 384 ||| in 384 ||| 0-0 1-1
an 57 ||| patients participating in ||| 1-0 0-1 1-1 0-2
an 63 Patienten mit metastasierendem ||| in 63 patients with metastatic ||| 0-0 1-1 2-2 3-3 4-4
an 63 Patienten mit ||| in 63 patients with ||| 0-0 1-1 2-2 3-3
an 63 Patienten ||| in 63 patients ||| 0-0 1-1 2-2
an 63 ||| in 63 ||| 0-0 1-1
an ABILIFY Lösung zum Einnehmen ||| of ABILIFY oral solution ||| 0-0 1-1 3-2 4-2 2-3
an ABILIFY ||| of ABILIFY ||| 0-0 1-1
an Bakterien- und ||| and mammalian cell ||| 2-0 0-1 1-1 1-2
an Bakterien- ||| mammalian cell ||| 0-0 1-0 1-1
an Diabetes leidenden Patienten verschwinden ||| disappear in patients with ||| 0-0 1-0 2-0 4-0 2-1 3-2 4-3
an Humanserumalbumin-Nanopartikel gebunden ist . ||| serum albumin-paclitaxel nanoparticles . ||| 0-0 1-0 1-1 1-2 2-2 3-2 4-3
an Humanserumalbumin-Nanopartikel gebunden ist ||| serum albumin-paclitaxel nanoparticles ||| 0-0 1-0 1-1 1-2 2-2 3-2
an Kaninchen mit Dosierungen ||| ( anencephaly ||| 1-1 3-1
an Kaninchen mit Dosierungen ||| anencephaly ||| 1-0 3-0
an Menschen untersucht wurden . ||| studied in humans . ||| 0-0 2-0 0-1 1-2 3-2 4-3
an Menschen untersucht wurden ||| studied in humans ||| 0-0 2-0 0-1 1-2 3-2
an Patientinnen , die ||| of patients who ||| 0-0 1-1 2-2 3-2
an Patientinnen ||| of patients ||| 0-0 1-1
an Plasmaproteine gebunden ( ||| bound to plasma proteins ( ||| 0-0 2-0 0-1 1-2 1-3 3-4
an Plasmaproteine gebunden vor ( ||| bound to plasma protein ( ||| 0-0 1-0 2-0 3-1 1-2 2-3 3-3 4-4
an Plasmaproteine gebunden vor ||| bound to plasma protein ||| 0-0 1-0 2-0 3-1 1-2 2-3 3-3
an Plasmaproteine gebunden ||| bound to plasma proteins ||| 0-0 2-0 0-1 1-2 1-3
an Typ-2-Diabetikern geprüft . ||| in type 2 diabetics . ||| 0-0 1-1 1-2 0-3 1-3 2-3 3-4
an Typ-2-Diabetikern geprüft ||| in type 2 diabetics ||| 0-0 1-1 1-2 0-3 1-3 2-3
an Vorhofflimmern ||| fibrillation ||| 1-0
an den arteriovenösen Fisteln ||| whose arteriovenous fistulae exhibit complications ||| 2-0 0-1 1-1 2-1 2-2 3-3 3-4
an den arteriovenösen ||| whose arteriovenous fistulae ||| 2-0 0-1 1-1 2-1 2-2
an der 460 Frauen mit ||| involving 460 women with ||| 0-0 2-1 3-2 4-3
an der 460 Frauen ||| involving 460 women ||| 0-0 2-1 3-2
an der 460 ||| involving 460 ||| 0-0 2-1
an der Bildung von Blutpfropfen ||| involved in the ||| 2-0 4-0 0-1 3-1 1-2
an der Injektionsstelle mit einem ||| the injection site using an ||| 1-0 2-1 0-2 1-2 2-2 3-3 4-3 4-4
an der Injektionsstelle ||| injection site ||| 2-0 0-1 1-1 2-1
an der Injektionsstelle ||| the injection site ||| 1-0 2-1 0-2 1-2 2-2
an der Ratte ||| in the rat ||| 0-0 1-1 2-2
an der pharmakokinetischen Analyse teilnahmen ||| in the pharmacokinetic analysis ||| 0-0 4-0 1-1 2-2 3-3
an der ||| an ||| 0-0
an der ||| in the ||| 0-0 1-1
an der ||| involving ||| 0-0
an einem polyzystischen Ovarialsyndrom leiden ||| have polycystic ovary syndrome ||| 2-0 0-1 1-1 2-1 2-2 3-3 4-3
an einem polyzystischen ||| have polycystic ovary ||| 2-0 0-1 1-1 2-1 2-2
an einer Injektionsstelle sollte ||| at one injection site should ||| 0-0 1-1 2-1 2-2 0-3 2-3 3-4
an einer Injektionsstelle ||| at one injection site ||| 0-0 1-1 2-1 2-2 0-3 2-3
an einer ||| an ||| 0-0 1-0
an ihren ||| since ||| 0-0
an zwei Spezies , jeweils ||| in two species , both ||| 0-0 1-1 2-2 3-3 4-3
an zwei Spezies , jeweils ||| in two species , ||| 0-0 1-1 2-2 3-3 4-3
an zwei Spezies ||| in two species ||| 0-0 1-1 2-2
an zwei ||| in two ||| 0-0 1-1
an ||| an ||| 0-0
an ||| blood cells ||| 0-0 0-1
an ||| dog infusion ||| 0-0
an ||| dog ||| 0-0
an ||| in ||| 0-0
an ||| involving ||| 0-0
an ||| of ||| 0-0
an ||| since ||| 0-0
an ||| to ||| 0-0
an ||| women ||| 0-0
analog ||| hr/ ||| 0-0
anaphylaktischen Reaktionen . ||| anaphylactic reaction . ||| 0-0 0-1 1-1 2-2
anaphylaktischen Reaktionen ||| anaphylactic reaction ||| 0-0 0-1 1-1
anaphylaktischer Reaktion/Schock ||| anaphylactic reaction/ shock ||| 1-0 0-1 1-1 1-2
and t½ 1,87 ||| and t½ 1.87 ||| 0-0 1-1 2-2
and t½ ||| and t½ ||| 0-0 1-1
and ||| and ||| 0-0
andere Antipsychotika ||| antipsychotic ||| 0-0 1-0
andere Arzneimittel : ||| other medicinal products : ||| 0-0 1-1 1-2 2-3
andere Arzneimittel ||| other medicinal products ||| 0-0 1-1 1-2
andere Bisphosphonate . ||| bisphosphonates . ||| 0-0 1-0 2-1
andere Bisphosphonate waren ausgeschlossen . ||| but excluded other bisphosphonates . ||| 1-0 3-1 0-2 1-3 4-4
andere Bisphosphonate waren ausgeschlossen ||| but excluded other bisphosphonates ||| 1-0 3-1 0-2 1-3
andere Bisphosphonate ||| bisphosphonates ||| 0-0 1-0
andere Bisphosphonate ||| other bisphosphonates ||| 0-0 1-1
andere Dosis einzunehmen . ||| different dose . ||| 0-0 2-0 1-1 3-2
andere Dosis einzunehmen ||| different dose ||| 0-0 2-0 1-1
andere Nicht-Krebszellen , wie beispielsweise ||| non-cancer cells such as blood ||| 1-0 1-1 0-2 3-2 2-3 3-3 4-4
andere Nicht-Krebszellen , wie ||| non-cancer cells such as ||| 1-0 1-1 0-2 3-2 2-3 3-3
andere Symptome ||| other symptoms of ||| 0-0 1-1
andere Symptome ||| other symptoms ||| 0-0 1-1
andere Teile des Körpers ausgebreitet ||| other parts of the body ||| 0-0 1-1 4-1 2-2 2-3 3-4
andere antipsychotischen Arzneimittel sollten mit ||| other antipsychotic drugs should be ||| 0-0 1-1 1-2 2-2 3-3 3-4 4-4
andere antipsychotischen Arzneimittel ||| other antipsychotic drugs ||| 0-0 1-1 1-2 2-2
andere ||| Other ||| 0-0
andere ||| other ||| 0-0
andere ||| taken other ||| 0-0 0-1
anderen . ||| other . ||| 0-0 1-1
anderen Antipsychotika sollte Aripiprazol ||| other antipsychotics , aripiprazole should ||| 0-0 1-1 3-3 2-4
anderen Antipsychotika ||| other antipsychotics , ||| 0-0 1-1
anderen Antipsychotika ||| other antipsychotics ||| 0-0 1-1
anderen Anämieursachen ( ||| other causes of anaemia ( ||| 0-0 1-1 1-2 1-3 2-4
anderen Anämieursachen ||| other causes of anaemia ||| 0-0 1-1 1-2 1-3
anderen Arten von Arzneimitteln wurden ||| other drug types were ||| 0-0 1-1 2-1 3-1 1-2 4-3
anderen Arten von Arzneimitteln ||| other drug types ||| 0-0 1-1 2-1 3-1 1-2
anderen Arzneimitteln , die ||| medicines known to ||| 0-0 1-0 1-1 2-2 3-2
anderen Arzneimitteln , ||| medicines ||| 0-0 1-0
anderen Arzneimitteln angewendet wird ||| medicines known ||| 0-0 1-0 2-0 1-1
anderen Arzneimitteln angewendet ||| medicines known ||| 0-0 1-0 2-0 1-1
anderen Arzneimitteln kann es ||| medicines may ||| 0-0 1-0 3-0 2-1
anderen Arzneimitteln und ||| other medicinal products and other ||| 0-0 0-1 1-2 2-3 0-4
anderen Arzneimitteln und ||| other medicinal products and ||| 0-0 1-1 1-2 2-3
anderen Arzneimitteln zur Reduzierung der ||| other medicines to reduce ||| 0-0 1-1 2-2 4-2
anderen Arzneimitteln zur Reduzierung der ||| other medicines to ||| 0-0 1-1 2-2 4-2
anderen Arzneimitteln ||| benefit from ||| 0-1
anderen Arzneimitteln ||| from ||| 0-0
anderen Arzneimitteln ||| may benefit from ||| 0-2
anderen Arzneimitteln ||| medicines known ||| 0-0 1-0 1-1
anderen Arzneimitteln ||| medicines ||| 0-0 1-0
anderen Arzneimitteln ||| other medicinal products ||| 0-0 0-1 0-2 1-2
anderen Arzneimitteln ||| other medicinal products ||| 0-0 1-1 1-2
anderen Arzneimitteln ||| other medicines ||| 0-0 1-1
anderen Bestandteile reagieren , sowie ||| with ACOMPLIA , see ||| 0-0 2-1 3-1 3-2 4-2 1-3
anderen Bestandteile reagieren . ||| other ingredients . ||| 0-0 1-1 2-1 3-2
anderen Bestandteile reagieren ||| other ingredients ||| 0-0 1-1 2-1
anderen Bisphosphonate . ||| other bisphosphonates . ||| 0-0 1-1 2-2
anderen Bisphosphonate ||| other bisphosphonates ||| 0-0 1-1
anderen CYP-Enzyme oder P- ||| other CYP enzymes or ||| 0-0 1-1 3-1 3-2 2-3
anderen Dentaleingriffen . ||| other dental surgeries . ||| 0-0 1-1 1-2 2-3
anderen Dentaleingriffen ||| other dental surgeries ||| 0-0 1-1 1-2
anderen Diabetesmedikament ( Dualtherapie ||| other antidiabetic medicine ( ||| 0-0 1-1 3-1 1-2 2-3
anderen Diabetesmedikament ) bei ||| another antidiabetic medicine ) in ||| 0-0 1-1 1-2 2-3 3-4
anderen Diabetesmedikament ) ||| another antidiabetic medicine ) ||| 0-0 1-1 1-2 2-3
anderen Diabetesmedikament ||| another antidiabetic medicine ||| 0-0 1-1 1-2
anderen Diabetesmedikamenten ( Metformin ||| other antidiabetic medicines ( metformin ||| 0-0 1-1 1-2 2-3 3-4
anderen Diabetesmedikamenten ( ||| other antidiabetic medicines ( ||| 0-0 1-1 1-2 2-3
anderen Diabetesmedikamenten ( ||| to other antidiabetic medicines ( ||| 0-1 1-2 1-3 2-4
anderen Diabetesmedikamenten ||| other antidiabetic medicines ||| 0-0 1-1 1-2
anderen Diabetesmedikamenten ||| to other antidiabetic medicines ||| 0-1 1-2 1-3
anderen Erythropoese-stimulierenden Wirkstoffen ( ||| other erythropoiesis-stimulating agents ( ||| 0-0 1-1 2-2 3-3
anderen Erythropoese-stimulierenden Wirkstoffen ||| other erythropoiesis-stimulating agents ||| 0-0 1-1 2-2
anderen Erythropoese-stimulierenden ||| other erythropoiesis-stimulating ||| 0-0 1-1
anderen Humaninsulin ||| other human insulin ||| 0-0 1-1 1-2
anderen Indikationen ||| other indications ||| 0-0 1-1
anderen Insulinprodukten ||| other insulin products , ||| 0-0 1-1 1-2
anderen Insulinprodukten ||| other insulin products ||| 0-0 1-1 1-2
anderen Kalzium-haltigen Lösungen in ||| allowed to come into ||| 0-0 0-1 1-2 2-2 1-3 3-3
anderen Seite . ||| other face. . ||| 0-0 1-1 2-2
anderen Seite ||| other face. ||| 0-0 1-1
anderen Studie ||| study ||| 1-0
anderen atypischen antipsychotischen ||| other atypical antipsychotic ||| 0-0 1-1 2-2
anderen atypischen ||| other atypical ||| 0-0 1-1
anderen drei ||| other three ||| 0-0 1-1
anderen hochwirksamen CYP3A4-Inhibitoren mit ||| other potent CYP3A4 inhibitors with ||| 0-0 1-1 2-1 2-2 2-3 3-4
anderen hochwirksamen CYP3A4-Inhibitoren ||| other potent CYP3A4 inhibitors ||| 0-0 1-1 2-1 2-2 2-3
anderen klinischen Effekte von ||| other clinical effects of ||| 0-0 1-1 2-2 3-3
anderen klinischen Effekte ||| other clinical effects ||| 0-0 1-1 2-2
anderen klinischen ||| other clinical ||| 0-0 1-1
anderen oralen ||| other oral ||| 0-0 1-1
anderen oralen ||| to other oral ||| 0-1 1-2
anderen potenziell toxischen Stoffen ||| other potentially toxic compounds , ||| 0-0 1-1 2-2 3-3
anderen potenziell toxischen Stoffen ||| other potentially toxic compounds ||| 0-0 1-1 2-2 3-3
anderen potenziell toxischen ||| other potentially toxic ||| 0-0 1-1 2-2
anderen potenziell ||| other potentially ||| 0-0 1-1
anderen wechseln ( siehe Abschnitt ||| another ( see section ||| 0-0 1-0 2-1 3-2 4-3
anderen wechseln ( siehe ||| another ( see ||| 0-0 1-0 2-1 3-2
anderen wechseln ( ||| another ( ||| 0-0 1-0 2-1
anderen wechseln ||| another ||| 0-0 1-0
anderen zentral wirksamen Arzneimitteln mit ||| other CNS medicinal products with ||| 0-0 1-1 2-1 3-2 3-3 4-4
anderen zentral wirksamen Arzneimitteln ||| other CNS medicinal products ||| 0-0 1-1 2-1 3-2 3-3
anderen zentral wirksamen ||| other CNS ||| 0-0 1-1 2-1
anderen ||| allowed to ||| 0-0 0-1
anderen ||| another ||| 0-0
anderen ||| benefit from ||| 0-1
anderen ||| from ||| 0-0
anderen ||| may benefit from ||| 0-2
anderen ||| other ||| 0-0
anderen ||| to other ||| 0-1
anderen ||| with other ||| 0-0 0-1
anderen ||| with ||| 0-0
anderer Arzneimittel : ||| other medicinal products : ||| 0-0 1-1 0-2 2-3
anderer Arzneimittel hat . ||| other medicinal products . ||| 0-0 1-1 2-2 3-3
anderer Arzneimittel hat ||| other medicinal products ||| 0-0 1-1 2-2
anderer Arzneimittel ||| other medicinal products ||| 0-0 1-1 0-2
anderer Arzneimittel ||| other medicinal ||| 0-0 1-1
anderer Erkrankungen ||| other illnesses ||| 0-0 1-1
anderer LHRH-Agonist ||| Another LHRH agonist ||| 1-0 1-1 1-2
anderer ethnischer Populationen . ||| of other races . ||| 0-1 1-2 2-2 3-3
anderer ethnischer Populationen . ||| other races . ||| 0-0 1-1 2-1 3-2
anderer ethnischer Populationen ||| of other races ||| 0-1 1-2 2-2
anderer ethnischer Populationen ||| other races ||| 0-0 1-1 2-1
anderer ||| of other ||| 0-1
anderer ||| other ||| 0-0
anderes Antipsychotikum ) an ||| another antipsychotic medicine ) in ||| 0-0 1-1 1-2 2-3 3-4
anderes Antipsychotikum ) ||| another antipsychotic medicine ) ||| 0-0 1-1 1-2 2-3
anderes Antipsychotikum ||| another antipsychotic medicine ||| 0-0 1-1 1-2
anderes ||| another ||| 0-0
anders lautenden ||| otherwise decided ||| 0-0 0-1 1-1
anders ||| decided ||| 0-0
anders ||| has ||| 0-0
androgenabhängig . ||| androgen dependent . ||| 0-0 0-1 1-2
androgenabhängig ||| androgen dependent ||| 0-0 0-1
androgenabhängigen ||| androgen dependent ||| 0-0 0-1
angebracht ||| appropriate ||| 0-0
angebracht ||| is ||| 0-0
angebracht ||| it is ||| 0-1
angegeben . ||| seriousness . ||| 0-0 1-1
angegeben werden . ||| be presented . ||| 1-0 0-1 1-1 2-2
angegeben werden ||| be presented ||| 1-0 0-1 1-1
angegeben ||| seriousness ||| 0-0
angehalten , ihre Arz ||| dietician and lp ||| 0-0 2-0 3-2
angehalten , ihre ||| dietician and ||| 0-0 2-0
angehalten , ihre ||| dietician ||| 0-0 2-0
angehoben werden ||| the concomitant ||| 0-0 0-1 1-1
angemessen klinisch überwacht werden . ||| period of risk . ||| 0-0 1-0 2-0 3-0 2-2 4-3
angemessen klinisch überwacht werden ||| period of risk ||| 0-0 1-0 2-0 3-0 2-2
angemessene Änderungen der Ernährung beinhaltet ||| includes appropriate dietary changes ||| 1-0 4-0 1-1 2-2 3-2 4-2 1-3
angemessenen Veränderungen in der Lebensweise ||| appropriate lifestyle changes ||| 0-0 4-1 1-2 2-2 3-2
angemessenen ||| appropriate ||| 0-0
angemessener ||| , ||| 0-0
angemessener ||| adequate ||| 0-0
angepasst , dass ||| adjusted to ||| 0-0 1-1 2-1
angepasst werden , bis Ihr ||| be adjusted until your ||| 1-0 0-1 2-2 3-2 4-3
angepasst werden , bis ||| be adjusted until ||| 1-0 0-1 2-2 3-2
angepasst werden ||| be adjusted ||| 1-0 0-1
angepasst ||| adjusted ||| 0-0
angeraten ||| father ||| 0-0
angespannt sein . ||| tense . ||| 0-0 1-0 2-1
angespannt sein ||| tense ||| 0-0 1-0
angespannt ||| tense . ||| 0-0
angespannt ||| tense ||| 0-0
angestiegen ist , ||| cells/ µl ||| 0-0 0-1 1-1
angestiegen ist ||| cells/ µl ||| 0-0 0-1 1-1
angewandt , wenn eine orale ||| , when oral ||| 0-0 1-0 2-1 3-1 4-2
angewandt , wenn eine ||| , when ||| 0-0 1-0 2-1 3-1
angewandt , ||| , ||| 0-0 1-0
angewendet , wenn die Behandlung ||| given when treatment ||| 0-0 1-1 2-1 3-2 4-2
angewendet , wenn ||| given when ||| 0-0 1-1 2-1
angewendet . ||| . ||| 1-0
angewendet : ||| used : ||| 0-0 1-1
angewendet ? ||| used for 2. ||| 0-0 1-1 1-2
angewendet bei Erwachsenen zur Behandlung ||| used to treat adults ||| 0-0 1-0 3-1 3-2 4-2 2-3
angewendet bei ||| used ||| 0-0 1-0
angewendet werden ( siehe Abschnitt ||| ( see section ||| 2-0 1-1 3-1 4-2
angewendet werden ( siehe ||| ( see ||| 2-0 1-1 3-1
angewendet werden ( siehe ||| angewendet werden ( siehe Abschnitt ||| 0-0 1-1 2-2 3-3 3-4
angewendet werden ( siehe ||| be used ( please see ||| 1-0 0-1 2-2 3-3 3-4
angewendet werden ( ||| angewendet werden ( ||| 0-0 1-1 2-2
angewendet werden ( ||| be used ( ||| 1-0 0-1 2-2
angewendet werden , bis sich ||| be administered until ||| 1-0 0-1 3-2 4-2
angewendet werden , wenn Sie ||| if you are ||| 1-0 2-0 3-0 4-1 3-2
angewendet werden , ||| be administered ||| 1-0 0-1
angewendet werden , ||| be used ||| 1-0 0-1
angewendet werden . ||| . ||| 1-0 2-0
angewendet werden . ||| Leaflet . ||| 2-0 1-1 2-1
angewendet werden . ||| agents . ||| 0-0 1-0 2-1
angewendet werden . ||| closely . ||| 0-0 1-0 2-1
angewendet werden . ||| medicines . ||| 0-0 1-1 2-1
angewendet werden ||| agents ||| 0-0 1-0
angewendet werden ||| angewendet werden ||| 0-0 1-1
angewendet werden ||| be administered ||| 1-0 0-1
angewendet werden ||| be used ||| 1-0 0-1
angewendet werden ||| closely ||| 0-0 1-0
angewendet werden ||| liver ||| 0-0 1-0
angewendet wird . Mit ||| used ||| 0-0 1-0
angewendet wird . ||| used ||| 0-0 1-0
angewendet wird ||| administered ||| 0-0
angewendet wird ||| is on ||| 1-0
angewendet wird ||| is ||| 1-0
angewendet wird ||| used ||| 0-0 1-0
angewendet wurde ||| was used ||| 1-0 0-1
angewendet ||| administered ||| 0-0
angewendet ||| angewendet ||| 0-0
angewendet ||| combination ||| 0-0
angewendet ||| given ||| 0-0
angewendet ||| medicines ||| 0-0
angewendet ||| used on its ||| 0-0
angewendet ||| used on ||| 0-0
angewendet ||| used ||| 0-0
angezeigt für die Kombination ||| indicated for combination ||| 0-0 1-1 2-1 3-2
angezeigt für die ||| indicated for ||| 0-0 1-1 2-1
angezeigt zur Unterstützung ||| indicated as an aid ||| 0-0 0-1 1-1 2-2 2-3
angezeigt zur ||| indicated as ||| 0-0 0-1 1-1
angezeigt ||| indicated ||| 0-0
anhaltenden Wirkung gewünscht wird . ||| long-lasting effect is needed . ||| 0-0 0-1 1-1 2-1 3-2 3-3 4-4
anhaltenden Wirkung gewünscht wird ||| long-lasting effect is needed ||| 0-0 0-1 1-1 2-1 3-2 3-3
anhaltenden Wirkung gewünscht ||| long-lasting effect ||| 0-0 0-1 1-1 2-1
anhand einer Standardskala für ||| using a standard scale for ||| 0-0 1-1 2-2 2-3 3-4
anhand einer Standardskala ||| using a standard scale ||| 0-0 1-1 2-2 2-3
anhand einer ||| using a ||| 0-0 1-1
anhand ||| using ||| 0-0
annähernd 20 % ||| approximately 20 % ||| 0-0 1-1 2-2
annähernd 20 ||| approximately 20 ||| 0-0 1-1
annähernd 6 Stunden wurde ||| approximately 6 hours has been ||| 0-0 1-1 2-2 3-3 3-4
annähernd 6 Stunden ||| approximately 6 hours ||| 0-0 1-1 2-2
annähernd 6 ||| approximately 6 ||| 0-0 1-1
annähernd 60 % in ||| approximately 60 % in ||| 0-0 1-1 2-2 3-3
annähernd 60 % ||| approximately 60 % ||| 0-0 1-1 2-2
annähernd 60 ||| approximately 60 ||| 0-0 1-1
annähernd ||| approximately ||| 0-0
anregen . ||| production . ||| 0-0 1-1
anregen ||| production ||| 0-0
anregt . ||| production . ||| 0-0 1-1
anregt ||| production ||| 0-0
anschließend 180 mg/Tag ||| then 180 mg/ day for ||| 1-0 0-1 1-1 2-2 2-3 1-4
anschließend im Verlauf des ||| and subsequently increase during the ||| 0-0 0-1 1-1 2-1 2-2 3-2 2-3 3-4
anschließende ||| anschließende biliäre ||| 0-0 0-1
anschließender bilärer Exkretion . ||| and biliary excretion . ||| 0-1 1-1 2-1 1-2 3-3
anschließender bilärer Exkretion . ||| biliary excretion . ||| 0-0 1-0 2-0 1-1 3-2
anschließender bilärer Exkretion ||| and biliary excretion ||| 0-1 1-1 2-1 1-2
anschließender bilärer Exkretion ||| biliary excretion ||| 0-0 1-0 2-0 1-1
anschlägt , ||| working , ||| 0-0
anschlägt , ||| working ||| 0-0
anschlägt ||| working , ||| 0-0
anschlägt ||| working ||| 0-0
anspricht ||| responds ||| 0-0
ansteigt . Die Zeit bis ||| ansteigt . Die ||| 0-0 1-1 2-2
ansteigt . Die Zeit ||| ansteigt . Die ||| 0-0 1-1 2-2
ansteigt . Die ||| ansteigt . Die ||| 0-0 1-1 2-2
ansteigt . ||| ansteigt . ||| 0-0 1-1
ansteigt ||| ansteigt ||| 0-0
anstrengende körperliche Aktivität können ||| strenuous physical exercise may ||| 0-0 1-0 2-1 1-2 3-2 3-3
antagonistische Eigenschaften ||| animal models of ||| 0-0 0-1 1-1 1-2
antidepressive Behandlung ( siehe ||| ongoing antidepressive treatment ( see ||| 0-0 0-1 1-2 2-3 3-4
antidepressive Behandlung ( ||| ongoing antidepressive treatment ( ||| 0-0 0-1 1-2 2-3
antidepressive Behandlung ||| ongoing antidepressive treatment ||| 0-0 0-1 1-2
antidepressive ||| ongoing antidepressive ||| 0-0 0-1
antikarzinogenes Arzneimittel und ||| anticancer medicinal product and , ||| 0-0 1-1 1-2 2-3
antikarzinogenes Arzneimittel und ||| anticancer medicinal product and ||| 0-0 1-1 1-2 2-3
antikarzinogenes Arzneimittel ||| anticancer medicinal product ||| 0-0 1-1 1-2
antikarzinogenes ||| anticancer ||| 0-0
antipsychotischen Arzneimittel sollten mit ||| antipsychotic drugs should be ||| 0-0 0-1 1-1 2-2 2-3 3-3
antipsychotischen Arzneimittel ||| antipsychotic drugs ||| 0-0 0-1 1-1
antipsychotischen Arzneimitteln ||| antipsychotic drug ||| 0-0 0-1 1-1
antipsychotischen Wirkstoffen ||| antipsychotic agents ||| 0-0 1-1
antipsychotischen ||| antipsychotic ||| 0-0
antiresorptive ||| compound ||| 0-0
anwenden . ||| . ||| 0-0 1-0
anwenden bei Hunden mit ||| use in dogs with ||| 0-0 1-1 2-2 3-3
anwenden bei Hunden ||| use in dogs ||| 0-0 1-1 2-2
anwenden bei ||| use in ||| 0-0 1-1
anwenden ||| use ||| 0-0
anzuwenden ||| anzuwenden ||| 0-0
anzuwendenden Benzodiazepinen kann ||| benzodiazepine may be ||| 0-0 1-0 2-1 2-2
anzuwendenden Benzodiazepinen ||| benzodiazepine ||| 0-0 1-0
anämische Ratten , polyzythämische Mäuse ||| anaemic rats , polycythaemic mice ||| 0-0 1-1 2-2 3-3 4-3 4-4
anämische Ratten , ||| anaemic rats , ||| 0-0 1-1 2-2
anämische Ratten ||| anaemic rats ||| 0-0 1-1
anämische ||| anaemic ||| 0-0
applikationsfertig ( siehe ||| ready to use ( see ||| 0-0 0-1 0-2 1-3 2-4
applikationsfertig ( ||| ready to use ( ||| 0-0 0-1 0-2 1-3
applikationsfertig ||| ready to use ||| 0-0 0-1 0-2
appliziert werden . ||| by the intravenous route . ||| 0-0 0-1 0-2 0-3 1-3 2-4
appliziert werden ||| by the intravenous route ||| 0-0 0-1 0-2 0-3 1-3
arterielle Verschlusskrankheit ||| arterial ||| 0-0 1-0
arterielle ||| arterial ||| 0-0
arzneilich wirksame Bestandteil von ACOMPLIA ||| active substance in ACOMPLIA ||| 0-0 1-1 2-1 3-3 4-3
arzneilich wirksame Bestandteil von Actos ||| active substance in Actos ||| 0-0 1-0 2-1 3-2 4-3
arzneilich wirksame Bestandteil von ||| active substance in ||| 0-0 1-0 2-1 3-2
arzneilich wirksame Bestandteil ||| active substance in ||| 0-0 1-1 2-1
arzneilich wirksame Bestandteil ||| active substance ||| 0-0 1-0 2-1
arzneilich wirksame Bestandteil ||| active substance ||| 0-0 1-1 2-1
arzneilich wirksame ||| active ||| 0-0 1-0
arzneilich wirksamen Bestandteil oder ||| active substance or to ||| 0-0 1-1 2-1 3-2
arzneilich wirksamen Bestandteil oder ||| active substance or ||| 0-0 1-1 2-1 3-2
arzneilich wirksamen Bestandteil ||| active substance ||| 0-0 1-1 2-1
arzneilich ||| active ||| 0-0
aseptischen Bedingungen ||| followed during preparation of the ||| 0-0 0-1 0-2 1-4
aseptischen ||| followed during preparation of ||| 0-0 0-1 0-2
aseptischen ||| followed during preparation ||| 0-0 0-1 0-2
assoziiert sein kann . Depressive ||| 4.8 ) . ||| 0-0 3-0 3-2 4-2
atstovyb Tel. +370 ( ||| atstovyb Tel . +370 ( ||| 0-0 1-0 1-1 1-2 2-3 3-4
atstovyb Tel. +370 ||| atstovyb Tel . +370 ||| 0-0 1-0 1-1 1-2 2-3
atstovyb Tel. ||| atstovyb Tel . ||| 0-0 1-0 1-1 1-2
atypischen antipsychotischen Wirkstoffen , ||| atypical antipsychotic agents , ||| 0-0 2-0 1-1 2-2 3-3
atypischen antipsychotischen Wirkstoffen ||| atypical antipsychotic agents ||| 0-0 2-0 1-1 2-2
atypischen antipsychotischen ||| atypical antipsychotic ||| 0-0 1-1
atypischen ||| atypical ||| 0-0
auch Abschnitt 4.4 ) . ||| also section 4.4 ) . ||| 0-0 1-1 2-2 3-3 4-4
auch Abschnitt 4.4 ) ||| also section 4.4 ) ||| 0-0 1-1 2-2 3-3
auch Abschnitt 4.4 ||| also section 4.4 ||| 0-0 1-1 2-2
auch Abschnitt ||| also section ||| 0-0 1-1
auch Hyperglykämie , ||| and hyperglycaemia , ||| 0-0 0-1 1-1 2-2
auch Hyperglykämie , ||| hyperglycaemia , ||| 0-0 1-0 2-1
auch Hyperglykämie ||| and hyperglycaemia ||| 0-0 0-1 1-1
auch Hyperglykämie ||| hyperglycaemia ||| 0-0 1-0
auch Serotonin genannt ) . ||| also called serotonin ) . ||| 0-0 2-1 1-2 3-3 4-4
auch Serotonin genannt ) ||| also called serotonin ) ||| 0-0 2-1 1-2 3-3
auch Serotonin genannt ||| also called serotonin ||| 0-0 2-1 1-2
auch angemessene ||| which also ||| 0-0 0-1
auch angezeigt für die Kombination ||| also indicated for combination ||| 0-0 1-1 2-2 3-2 4-3
auch angezeigt für die ||| also indicated for ||| 0-0 1-1 2-2 3-2
auch angezeigt ||| also indicated ||| 0-0 1-1
auch bei einer Änderung ||| also be necessary ||| 0-0 1-0 3-1 2-2 3-2
auch bei ||| also ||| 0-0 1-0
auch bekannt als nicht ||| also known as non ||| 0-0 1-1 2-2
auch bekannt als nicht ||| also known as ||| 0-0 1-1 2-2
auch bekannt als ||| also known as non ||| 0-0 1-1 2-2
auch bekannt als ||| also known as ||| 0-0 1-1 2-2
auch bekannt ||| also known ||| 0-0 1-1
auch erhöhen . ||| insulin requirement . ||| 0-0 1-0 1-1 2-2
auch erhöhen ||| insulin requirement ||| 0-0 1-0 1-1
auch erlernen , wie ||| to learn how ||| 2-0 1-1 3-2
auch erlernen , ||| to learn ||| 2-0 1-1
auch erlernen ||| learn ||| 1-0
auch in ||| also be given in ||| 0-0 0-1 1-2 1-3
auch möglich . ||| also be used . ||| 0-0 1-1 1-2 2-3
auch möglich ||| also be used ||| 0-0 1-1 1-2
auch verzögert ) . ||| delayed ) . ||| 1-0 2-1 3-2
auch verzögert ) ||| delayed ) ||| 1-0 2-1
auch verzögert ||| delayed ||| 1-0
auch ||| also be ||| 0-0 0-1
auch ||| also want ||| 0-0 0-1
auch ||| also ||| 0-0
auch ||| and ||| 0-0
auch ||| auch ||| 0-0
auch ||| both ||| 0-0
auch ||| including ||| 0-0
auch ||| which also ||| 0-0 0-1
auf ( weniger als ||| ( less than ||| 1-0 2-1 3-2
auf ( weniger ||| ( less ||| 1-0 2-1
auf ( ||| ( ||| 1-0
auf , die ||| of ||| 2-0
auf , ||| to ||| 0-0
auf , ||| to ||| 0-0 1-0
auf . ||| . ||| 1-0
auf . ||| conditions . ||| 1-1
auf . ||| of treatment . ||| 0-0 1-2
auf 15 Minuten ||| to 15 minutes caused ||| 0-0 1-1 2-2
auf 15 Minuten ||| to 15 minutes ||| 0-0 1-1 2-2
auf 15 ||| to 15 ||| 0-0 1-1
auf 16736 ||| to 16736 ||| 0-0 1-1
auf 18 Wochen ausgelegten Untersuchung ||| 18-week trial ||| 0-0 1-0 3-0 4-0 2-1 3-1
auf 200 kg ||| to 200 kg ||| 0-0 1-1 2-2
auf 200 ||| to 200 ||| 0-0 1-1
auf ABILIFY : ||| to affect ABILIFY : ||| 0-0 0-1 1-2 2-3
auf ABILIFY Tabletten , ||| to ABILIFY tablets , ABILIFY ||| 0-0 1-1 2-2 3-3 1-4
auf ABILIFY ||| to affect ABILIFY ||| 0-0 0-1 1-2
auf Anforderung der EMEA . ||| the request of the EMEA ||| 0-0 2-0 1-1 2-2 2-3 3-4
auf Anforderung der EMEA ||| the request of the EMEA ||| 0-0 2-0 1-1 2-2 2-3 3-4
auf Anforderung der ||| the request of the ||| 0-0 2-0 1-1 2-2 2-3
auf Anwendung von Abraxane als ||| the use of Abraxane as ||| 0-0 1-1 2-2 3-3 4-4
auf Anwendung von Abraxane ||| for the use of Abraxane ||| 0-1 1-2 2-3 3-4
auf Anwendung von Abraxane ||| the use of Abraxane ||| 0-0 1-1 2-2 3-3
auf Anwendung von ||| for the use of ||| 0-1 1-2 2-3
auf Anwendung von ||| the use of ||| 0-0 1-1 2-2
auf Anwendung ||| for the use ||| 0-1 1-2
auf Anwendung ||| the use ||| 0-0 1-1
auf Berichten von ||| on reports ||| 0-0 1-1
auf Berichten ||| on reports ||| 0-0 1-1
auf Blut- und Nervenzellen , ||| and nerve cells , ||| 2-0 1-1 3-1 0-2 3-2 4-3
auf Blut- und Nervenzellen ||| and nerve cells ||| 2-0 1-1 3-1 0-2 3-2
auf CYP2C8 in vitro . ||| on CYP2C8 . ||| 0-0 1-1 2-1 3-1 4-2
auf CYP2C8 in vitro ||| on CYP2C8 ||| 0-0 1-1 2-1 3-1
auf CYP2C8 in vivo ||| of CYP2C8 in vivo ||| 0-0 1-1 2-2 3-3
auf CYP2C8 in ||| of CYP2C8 in ||| 0-0 1-1 2-2
auf CYP2C8 ||| of CYP2C8 ||| 0-0 1-1
auf Humaninsulin ( rDNA ||| to insulin human ( rDNA ||| 0-0 1-1 1-2 2-3 3-4
auf Humaninsulin ( ||| to insulin human ( ||| 0-0 1-1 1-2 2-3
auf Humaninsulin ||| to insulin human ||| 0-0 1-1 1-2
auf Knochenmarkszellen ||| on bone marrow cells ||| 0-0 1-1 1-2 1-3
auf Null zurückgeht und ||| to zero and ||| 0-0 0-1 1-1 2-1 3-2
auf Null zurückgeht ||| to zero ||| 0-0 0-1 1-1 2-1
auf Pioglitazon oder einen ||| to pioglitazone or any ||| 0-0 1-1 2-2 3-3
auf Pioglitazon oder ||| to pioglitazone or ||| 0-0 1-1 2-2
auf Pioglitazon ||| to pioglitazone ||| 0-0 1-1
auf Rimonabant oder t lä ||| side effects ||| 2-0 3-0 0-1 4-1
auf Sie ||| to you ||| 0-0 1-1
auf Wirksamkeit und ||| efficacy and ||| 1-0 2-1
auf Wirksamkeit ||| efficacy ||| 1-0
auf alle klinischen ||| on all clinical ||| 0-0 1-1 2-2
auf alle ||| on all ||| 0-0 1-1
auf andere ||| to other ||| 0-0 1-1
auf ca. 90 % geschätzt ||| estimated at about 90 % ||| 0-0 4-0 0-1 1-2 2-3 3-4
auf das Gesamtüberleben ||| on overall survival ||| 0-0 1-1 2-1 2-2
auf das Körpergewicht war ||| on body weight appeared to ||| 0-0 2-1 1-2 2-2 3-2 2-3 0-4
auf das ||| of ||| 0-0 1-0
auf dem Humaninsulinmolekül wurden in ||| on the human insulin molecule ||| 0-0 1-1 2-2 2-3 1-4 2-4 3-4 4-4
auf dem PANSS Excitement ||| on the PANSS Excitement ||| 0-0 1-1 2-2 3-3
auf dem PANSS ||| on the PANSS ||| 0-0 1-1 2-2
auf dem ||| on the ||| 0-0 1-1
auf den Ergebnissen der kompletten ||| on results of a full ||| 0-0 1-1 2-1 3-2 4-3 4-4
auf den Ergebnissen der ||| on results of ||| 0-0 1-1 2-1 3-2
auf den Ergebnissen ||| on results ||| 0-0 1-1 2-1
auf den Knochen . ||| on bone . ||| 0-0 1-0 2-1 3-2
auf den Knochen ||| on bone ||| 0-0 1-0 2-1
auf den letzten Tag des ||| to the last day of ||| 0-0 1-1 2-2 3-3 4-4
auf den letzten Tag ||| to the last day ||| 0-0 1-1 2-2 3-3
auf den letzten ||| to the last ||| 0-0 1-1 2-2
auf den ||| on ||| 0-0 1-0
auf den ||| to the ||| 0-0 1-1
auf der Bewertung ||| on laboratory assessment ||| 0-0 1-0 1-1 0-2
auf der anderen . ||| on the other . ||| 0-0 1-1 2-2 3-3
auf der anderen Seite . ||| on the other face. . ||| 0-0 1-1 2-2 3-3 4-4
auf der anderen Seite ||| on the other face. ||| 0-0 1-1 2-2 3-3
auf der anderen ||| on the other ||| 0-0 1-1 2-2
auf der einen Seite und ||| on one side and ||| 0-0 1-0 2-1 3-1 3-2 4-3
auf der einen Seite ||| on one side ||| 0-0 1-0 2-1 3-1 3-2
auf der ||| on laboratory assessment ||| 0-0 1-0 1-1 0-2
auf der ||| on the ||| 0-0 1-1
auf der ||| on ||| 0-0 1-0
auf die Behandlung angesprochen ||| responded to treatment ||| 0-0 1-0 3-0 0-1 2-2
auf die Disposition von Paclitaxel ||| on the disposition of paclitaxel ||| 0-0 1-1 2-2 3-3 4-4
auf die Disposition von ||| on the disposition of ||| 0-0 1-1 2-2 3-3
auf die Disposition ||| on the disposition ||| 0-0 1-1 2-2
auf die Dosishöhe ||| increased to the level ||| 2-0 0-1 1-2 2-3
auf die Einstichstelle . ||| pad . ||| 2-0 3-1
auf die Einstichstelle ||| pad ||| 2-0
auf die Fertilität oder Zyklusstörungen ||| on fertility or oestrous ||| 0-0 1-0 1-1 3-2 2-3 4-3
auf die Knochenmineraldichte ( ||| on bone mineral density ( ||| 0-0 1-0 0-1 3-2 2-3 3-4
auf die Körpergröße ||| on height ||| 0-0 1-0 2-1
auf die Pharmakokinetik bei mäßig ||| pharmacokinetics in moderate ||| 0-0 2-0 1-1 3-1 4-2
auf die Pharmakokinetik bei ||| pharmacokinetics in ||| 0-0 2-0 1-1 3-1
auf die Pharmakokinetik von Aripiprazol ||| on the pharmacokinetics of aripiprazole ||| 0-0 1-1 2-2 3-3 4-4
auf die Pharmakokinetik von ||| on the pharmacokinetics of ||| 0-0 1-1 2-2 3-3
auf die Pharmakokinetik ||| on the pharmacokinetics ||| 0-0 1-1 2-2
auf die Proteinbindung ||| affect protein binding ||| 0-0 2-1 2-2
auf die Therapie ||| of the ||| 0-1 1-1
auf die Therapie ||| the ||| 0-0 1-0
auf die Verkehrstüchtigkeit und die ||| on the ability ||| 0-0 1-0 1-1 2-2 3-2 4-2
auf die Verkehrstüchtigkeit und ||| on ability ||| 0-0 1-1 2-1 3-1
auf die Verkehrstüchtigkeit und ||| on the ability ||| 0-0 1-0 1-1 2-2 3-2
auf die Zunge . ||| on the tongue . ||| 0-0 1-1 2-2 3-3
auf die Zunge ||| on the tongue ||| 0-0 1-1 2-2
auf die am ||| at the major ||| 0-0 2-0 1-1 1-2
auf die einzigartige Zusammensetzung von ||| specifically to the unique ||| 1-0 0-1 3-1 1-2 2-2
auf die einzigartige Zusammensetzung von ||| specifically to the ||| 1-0 0-1 3-1 1-2 2-2
auf die einzigartige Zusammensetzung ||| specifically to the unique ||| 1-0 0-1 3-1 1-2 2-2
auf die einzigartige Zusammensetzung ||| specifically to the ||| 1-0 0-1 3-1 1-2 2-2
auf die ||| affect ||| 0-0
auf die ||| auf die ||| 0-0 1-1
auf die ||| of the ||| 0-1 1-1
auf die ||| on bone ||| 0-0 1-0 0-1
auf die ||| on fertility ||| 0-0 1-0 1-1
auf die ||| on the ||| 0-0 1-0 1-1
auf die ||| on the ||| 0-0 1-1
auf die ||| on ||| 0-0
auf die ||| on ||| 0-0 1-0
auf die ||| the ||| 0-0 1-0
auf die ||| to the ||| 0-0 1-1
auf einem ||| on one ||| 0-0 1-1
auf einen Teil des Futters ||| a portion of the food ||| 1-0 2-1 2-2 3-3 4-4
auf einen Teil des ||| a portion of the ||| 1-0 2-1 2-2 3-3
auf einen Teil ||| a portion of ||| 1-0 2-1 2-2
auf einen ||| a ||| 1-0
auf einer Nutzen-Risiko-Abwägung unter ||| on a benefit-risk assessment with ||| 0-0 1-1 1-2 2-2 3-2 2-3 2-4
auf einer Seite . ||| on one side . ||| 0-0 1-1 2-1 2-2 3-3
auf einer Seite ||| on one side ||| 0-0 1-1 2-1 2-2
auf eingeschränkte ärztliche ||| auf eingeschränkte ärztliche Verschreibung ||| 1-0 0-1 1-1 1-2 1-3 2-3
auf etwa 24 Stunden geschätzt ||| estimated about 24 hours ||| 0-0 1-0 4-0 1-1 2-2 3-3
auf etwa die Hälfte der ||| to approximately one-half of its ||| 0-0 1-1 3-2 2-3 4-3 3-4
auf etwa ||| to approximately ||| 0-0 1-1
auf in vitro ||| on in vitro ||| 0-0 1-1 2-2
auf in vitro-Studien ||| on in vitro studies ||| 0-0 1-1 2-2 2-3
auf in ||| on in ||| 0-0 1-1
auf menschliches Insulin ||| source insulin ||| 0-0 1-0 2-1
auf menschliches ||| source ||| 0-0 1-0
auf mg/m2 ) . ||| on mg/ m ) . ||| 0-0 1-1 1-2 2-3 3-4
auf mg/m2 ) . ||| on mg/ m2 ) . ||| 0-0 1-1 1-2 2-3 3-4
auf mg/m2 ) ||| on mg/ m ) ||| 0-0 1-1 1-2 2-3
auf mg/m2 ) ||| on mg/ m2 ) ||| 0-0 1-1 1-2 2-3
auf mg/m2 ||| on mg/ m ||| 0-0 1-1 1-2
auf mg/m2 ||| on mg/ m2 ||| 0-0 1-1 1-2
auf morphometrische Wirbelkörperfrakturen Aclasta ||| on morphometric vertebral fractures Aclasta ||| 0-0 1-1 2-2 2-3 3-4
auf morphometrische Wirbelkörperfrakturen ||| on morphometric vertebral fractures ||| 0-0 1-1 2-2 2-3
auf morphometrische ||| on morphometric ||| 0-0 1-1
auf multiphasische Weise ab . ||| a multiphasic manner . ||| 3-0 1-1 2-2 4-3
auf multiphasische Weise ab . ||| in a multiphasic manner . ||| 3-1 1-2 2-3 4-4
auf multiphasische Weise ab ||| a multiphasic manner ||| 3-0 1-1 2-2
auf multiphasische Weise ab ||| in a multiphasic manner ||| 3-1 1-2 2-3
auf multiphasische Weise ||| multiphasic manner ||| 1-0 2-1
auf multiphasische ||| multiphasic ||| 1-0
auf nüchternen Magen einnehmen . ||| without food . ||| 0-0 1-0 2-1 3-1 4-2
auf nüchternen Magen einnehmen ||| without food ||| 0-0 1-0 2-1 3-1
auf nüchternen ||| without ||| 0-0 1-0
auf und sind ||| , becoming ||| 1-0
auf und sind ||| , ||| 1-0
auf und ||| , becoming ||| 1-0
auf und ||| , ||| 1-0
auf ||| affect ||| 0-0
auf ||| at ||| 0-0
auf ||| auf ||| 0-0
auf ||| be ||| 0-0
auf ||| for the ||| 0-1
auf ||| of treatment ||| 0-0
auf ||| of ||| 0-0
auf ||| on ||| 0-0
auf ||| the ||| 0-0
auf ||| to affect ||| 0-0 0-1
auf ||| to ||| 0-0
auf ärztliche Verschreibung erhältlich . ||| obtained with a prescription . ||| 0-0 1-0 2-1 2-2 2-3 3-3 4-4
auf ärztliche Verschreibung erhältlich ||| obtained with a prescription ||| 0-0 1-0 2-1 2-2 2-3 3-3
auf ärztliche ||| obtained with ||| 0-0 1-0 1-1
auf ärztliche ||| obtained ||| 0-0 1-0
aufbewahren , um den Inhalt ||| the outer carton in order ||| 3-0 0-1 1-1 2-1 3-2 4-2 4-3 4-4
aufbewahren , um den Inhalt ||| the outer carton in order ||| 3-0 0-1 1-1 2-2 3-2 4-2 4-3 4-4
aufbewahren , um ||| outer ||| 0-0 1-0 2-0
aufbewahren , ||| outer ||| 0-0 1-0
aufbewahren . ||| of children . ||| 0-0 0-1 1-2
aufbewahren und transportieren ( 2°C ||| and transport refrigerated ( 2°C ||| 1-0 0-1 1-1 2-1 2-2 3-3 4-4
aufbewahren und transportieren ( ||| and transport refrigerated ( ||| 1-0 0-1 1-1 2-1 2-2 3-3
aufbewahren und transportieren ||| and transport refrigerated ||| 1-0 0-1 1-1 2-1 2-2
aufbewahren ||| of children ||| 0-0 0-1
auffälligste wichtige hämatologische ||| notable important ||| 0-0 1-0 2-0
auffälligste wichtige hämatologische ||| notable ||| 0-0 1-0 2-0
aufgeführt , die ||| reactions related to ||| 0-0 2-1 2-2
aufgeführt , ||| reactions ||| 0-0
aufgeführt ||| reactions ||| 0-0
aufgeführte Pharmakovigilanzsystem eingerichtet ||| 1.8.1 . ||| 0-0 1-0 2-0
aufgeführte Pharmakovigilanzsystem eingerichtet ||| 1.8.1 ||| 0-0 1-0 2-0
aufgeführten Nebenwirkungen ||| effects listed ||| 1-0 0-1
aufgeführten Studien und zusätzlichen ||| studies and additional ||| 1-0 2-1 3-2
aufgeführten Studien und ||| studies and ||| 1-0 2-1
aufgeführten Studien ||| studies ||| 1-0
aufgeführten ||| listed ||| 0-0
aufgetreten ist ||| have ||| 0-0
aufgetreten ||| have ||| 0-0
aufgetretenen unerwünschten Wirkungen ||| of rimonabant ||| 1-1 2-1
aufgetretenen unerwünschten Wirkungen ||| rimonabant ||| 1-0 2-0
aufgrund einer Herzinsuffizienz beobachtet . ||| heart failure was observed . ||| 0-0 1-0 2-0 2-1 2-2 3-3 4-4
aufgrund einer Herzinsuffizienz beobachtet ||| heart failure was observed ||| 0-0 1-0 2-0 2-1 2-2 3-3
aufgrund einer Herzinsuffizienz ||| heart failure was ||| 0-0 1-0 2-0 2-1 2-2
aufgrund einer Nierenerkrankung ||| a kidney patient ||| 0-0 1-0 2-1 0-2
aufgrund einer ||| assessed by ||| 0-0 0-1 1-1
aufgrund von Komorbiditäten ||| due to co- morbidities ||| 0-0 1-1 2-2 1-3 2-3
aufgrund ||| due to ||| 0-0
aufgrund ||| due to ||| 0-0 0-1
aufgrund ||| due ||| 0-0
aufgrund ||| of tumour due to ||| 0-2
aufgrund ||| of tumour due ||| 0-2
aufgrund ||| tumour due to ||| 0-1
aufgrund ||| tumour due ||| 0-1
auflösen ||| dissolve ||| 0-0
aufrecht erhalten werden ||| dosing ||| 2-0
aufstehen , oder sie können ||| position , or may ||| 0-0 3-0 1-1 2-2 4-3
aufstehen , oder sie ||| position , or ||| 0-0 3-0 1-1 2-2
auftreten , kann durch ||| can be ||| 0-0 2-0 2-1 3-1
auftreten , kann ||| can be ||| 0-0 2-0 2-1
auftreten . ||| occur . ||| 0-0 1-1
auftreten . ||| occur during treatment . ||| 0-0 0-1 0-2 1-3
auftreten . ||| therapy . ||| 0-0 1-1
auftreten . ||| treatment . ||| 0-0 1-1
auftreten können ||| may occur in ||| 1-0 0-1
auftreten können ||| may occur ||| 1-0 0-1
auftreten ||| occur during treatment ||| 0-0 0-1 0-2
auftreten ||| occur in ||| 0-0
auftreten ||| occur ||| 0-0
auftreten ||| therapy ||| 0-0
auftreten ||| treatment ||| 0-0
auftretende Nebenwirkung . ||| occurring undesirable effect . ||| 0-0 0-1 1-1 1-2 2-3
auftretende Nebenwirkung ||| occurring undesirable effect ||| 0-0 0-1 1-1 1-2
auftretende stechende , migräneartige Kopfschmerzen ||| stabbing migraine- like headaches as ||| 0-0 1-0 1-1 2-2 3-2 3-3 4-3 3-4
auftretende stechende , migräneartige Kopfschmerzen ||| stabbing migraine-like headaches as a ||| 0-0 1-1 3-2 4-2 2-3 3-3 3-4
auftretende stechende ||| stabbing migraine- ||| 0-0 1-0 1-1
auftretende stechende ||| stabbing migraine-like ||| 0-0 1-1
auftretende ||| stabbing ||| 0-0
auftritt ( siehe Abschnitt 4.8 ||| ( see section 4.8 ||| 1-0 2-1 3-2 4-3
auftritt ( siehe Abschnitt ||| ( see section ||| 1-0 2-1 3-2
auftritt ( siehe ||| ( see ||| 1-0 2-1
auftritt ( ||| ( ||| 1-0
auftritt , ||| occurs , ||| 0-0 1-1
auftritt . ||| . ||| 1-0
auftritt ||| occurs ||| 0-0
aufweisen . ||| . ||| 1-0
aufwiesen ||| of obese ||| 0-0 0-1
aufzubewahren . ||| children . ||| 0-0 1-1
aufzubewahren ||| children ||| 0-0
aufzubrauchen . ||| opening . ||| 0-0 1-1
aufzubrauchen ||| opening ||| 0-0
aus Aluminium in Faltschachteln ||| in cartons ||| 2-0 0-1 1-1 3-1
aus Glas ( Typ 1 ||| of glass ( type 1 ||| 0-0 0-1 1-1 2-2 3-3 4-4
aus Glas ( Typ ||| of glass ( type ||| 0-0 0-1 1-1 2-2 3-3
aus Glas ( ||| of glass ( ||| 0-0 0-1 1-1 2-2
aus Glas ||| of glass ||| 0-0 0-1 1-1
aus Vorläuferzellen ||| from precursors ||| 0-0 1-1
aus bernsteinfarbenem Glas ||| amber glass ||| 1-0 0-1 2-1
aus dem Beckenkamm entnommen ||| ( N=70 ||| 2-1 3-1
aus dem Beckenkamm entnommen ||| N=70 ||| 2-0 3-0
aus dem großen Kreislauf ||| from the systemic circulation ||| 0-0 1-0 1-1 3-2 3-3
aus dem großen ||| from the ||| 0-0 1-0 1-1
aus dem ||| from the ||| 0-0 1-0 1-1
aus dem ||| from ||| 0-0 1-0
aus der Flasche herausgenommen ||| removed from the bottle ||| 3-0 0-1 1-2 2-3 3-3
aus der Leber inhibiert . ||| output from the liver . ||| 3-0 0-1 1-2 2-3 3-3 4-4
aus der Leber inhibiert ||| output from the liver ||| 3-0 0-1 1-2 2-3 3-3
aus der Nahrung . ||| of dietary lipids . ||| 0-0 0-1 1-1 2-1 2-2 3-3
aus der Nahrung ||| of dietary lipids ||| 0-0 0-1 1-1 2-1 2-2
aus der Studienpopulation ||| the study population ||| 0-0 1-0 2-1 2-2
aus der wissenschaftlichen Literatur vor ||| from the published literature ||| 0-0 1-1 2-2 3-2 3-3 4-3
aus der ||| from the ||| 0-0 1-1
aus der ||| of ||| 0-0 1-0
aus der ||| the ||| 0-0 1-0
aus einer ||| from a ||| 0-0 1-1
aus gelöstem Insulin und Isophan- ||| of dissolved insulin and isophane ||| 0-0 0-1 1-1 2-2 3-3 4-4
aus gelöstem Insulin und ||| of dissolved insulin and ||| 0-0 0-1 1-1 2-2 3-3
aus gelöstem Insulin ||| of dissolved insulin ||| 0-0 0-1 1-1 2-2
aus gelöstem ||| of dissolved ||| 0-0 0-1 1-1
aus humanen Tumorgewebsproben , ||| from human tumour samples , ||| 0-0 1-1 2-2 1-3 2-3 3-4
aus humanen Tumorgewebsproben ||| from human tumour samples ||| 0-0 1-1 2-2 1-3 2-3
aus klinischen ||| clinical ||| 1-0
aus rekombinanter DNS in Saccharomyces ||| recombinant DNA technology in Saccharomyces ||| 0-0 1-0 1-1 2-1 2-2 3-3 4-4
aus rekombinanter DNS in ||| recombinant DNA technology in ||| 0-0 1-0 1-1 2-1 2-2 3-3
aus rekombinanter DNS ||| recombinant DNA technology ||| 0-0 1-0 1-1 2-1 2-2
aus ||| aus ||| 0-0
aus ||| from ||| 0-0
aus ||| made ||| 0-0
aus ||| rate ||| 0-0
ausgeprägte Appetitlosigkeit . ||| loss of appetite . ||| 1-0 0-2 1-2 2-3
ausgeprägte Appetitlosigkeit ||| loss of appetite ||| 1-0 0-2 1-2
ausgeschlossen werden. ln ||| increased tactile hyperesthesia were ro ||| 0-1 1-1 1-2 1-3 2-4
ausgeschlossen werden. ln ||| tactile hyperesthesia were ro ||| 0-0 1-0 1-1 1-2 2-3
ausgeschlossen werden. ||| increased tactile hyperesthesia were ||| 0-1 1-1 1-2 1-3
ausgeschlossen werden. ||| tactile hyperesthesia were ||| 0-0 1-0 1-1 1-2
ausgeschlossen ||| excluded ||| 0-0
ausreichend mit Flüssigkeit ||| of ||| 1-0
ausreichend mit ||| of ||| 1-0
ausreichend überschritten ||| exposure produced ||| 1-0
ausreichend überschritten ||| exposure ||| 1-0
ausreichende ||| adequate supplementation ||| 0-0 0-1
ausreichenden und gut kontrollierten Studien ||| adequate and well-controlled studies ||| 0-0 1-1 2-2 3-2 4-3
ausreichenden und gut kontrollierten ||| adequate and well-controlled ||| 0-0 1-1 2-2 3-2
ausreichenden und ||| adequate and ||| 0-0 1-1
ausreichenden ||| adequate ||| 0-0
ausreichenden ||| ausreichenden Daten am ||| 0-0 0-1 0-2
ausreichenden ||| insufficient ||| 0-0
ausschließlich intravenös angewendet werden ||| has to be administered intravenously ||| 0-0 1-1 3-2 1-3 2-3 1-4 3-4
ausschließlich ||| has ||| 0-0
auszuschließen ||| central ||| 0-0
authorised provided the source ||| is authorised provided the source ||| 0-0 0-1 1-1 2-1 1-2 2-3 3-4
authorised provided the ||| is authorised provided the ||| 0-0 0-1 1-1 2-1 1-2 2-3
autologen ||| autologous ||| 0-0
außer bei pädiatrischen Patienten ||| except in paediatric patients ||| 0-0 1-1 2-2 3-3
außer bei pädiatrischen ||| except in paediatric ||| 0-0 1-1 2-2
außer bei ||| except in ||| 0-0 1-1
außer einer von ||| außer einer von ||| 0-0 1-1 2-2
außer einer ||| außer einer ||| 0-0 1-1
außer ||| außer ||| 0-0
außer ||| except ||| 0-0
außerdem Studien ||| also carried out studies ||| 0-0 0-1 0-2 1-3
außerdem ||| also carried out ||| 0-0 0-1 0-2
außerdem ||| also ||| 0-0
ba , d.o.o. ||| , d. o. o. ||| 1-0 0-1 1-2 2-2 2-3
ba Latvij Tel : +371 ||| ba Latvij Tel : +371 ||| 0-0 1-1 2-2 3-3 4-4
ba Latvij Tel : ||| ba Latvij Tel : ||| 0-0 1-1 2-2 3-3
ba Latvij Tel ||| ba Latvij Tel ||| 0-0 1-1 2-2
ba Latvij ||| ba Latvij ||| 0-0 1-1
ba ||| ba ||| 0-0
ba ||| d. ||| 0-0
basieren auf dem ||| is based on ||| 2-0 0-1 1-2 2-2
basieren ||| based ||| 0-0
basierend auf einem ||| based on one ||| 0-0 1-1 2-2
basierend auf mg/m2 ) ||| based on mg/ m ) ||| 0-0 1-1 2-2 2-3 3-4
basierend auf mg/m2 ) ||| based on mg/ m2 ) ||| 0-0 1-1 2-2 2-3 3-4
basierend auf mg/m2 ||| based on mg/ m ||| 0-0 1-1 2-2 2-3
basierend auf mg/m2 ||| based on mg/ m2 ||| 0-0 1-1 2-2 2-3
basierend auf ||| based on ||| 0-0 1-1
basierend ||| based ||| 0-0
basiert nur auf Berichten von ||| is based only on reports ||| 0-0 0-1 1-2 2-3 3-4
basiert nur auf Berichten ||| is based only on reports ||| 0-0 0-1 1-2 2-3 3-4
basiert nur auf ||| is based only on ||| 0-0 0-1 1-2 2-3
basiert nur ||| is based only ||| 0-0 0-1 1-2
basiert ||| is based ||| 0-0 0-1
beachten . ||| before use . ||| 0-0 0-1 1-2
beachten ? 3. ||| 3. ||| 0-0 1-0 2-0
beachten ||| before use ||| 0-0 0-1
beachtet werden . ||| possible warning signal . ||| 0-0 0-1 0-2 1-2 2-3
beachtet werden ||| possible warning signal ||| 0-0 0-1 0-2 1-2
bedarf ||| can only be ||| 0-0 0-1 0-2
bedenken ||| patient be aware ||| 0-0 0-2
bedeutet , dass Aripiprazol wie ||| means that aripiprazole ||| 0-0 1-1 2-1 3-2
bedeutet , dass Aripiprazol ||| means that aripiprazole ||| 0-0 1-1 2-1 3-2
bedeutet , dass nicht mehr ||| means the inability to ||| 0-0 1-1 0-2 2-2 3-2 4-2 2-3
bedeutet , dass sich der ||| means that the ||| 0-0 1-1 2-1 3-1 4-2
bedeutet , dass sich ||| means that ||| 0-0 1-1 2-1 3-1
bedeutet , dass ||| means that ||| 0-0 1-1 2-1
bedeutet , ||| means the ||| 0-0
bedeutet , ||| means ||| 0-0
bedeutet ||| means the ||| 0-0
bedeutet ||| means ||| 0-0
bedeutsamen Unterschiede . ||| important differences . ||| 0-0 1-1 2-2
bedeutsamen Unterschiede ||| important differences ||| 0-0 1-1
bedeutsamen ||| important ||| 0-0
bedienen , bis sie ||| vehicles , until they ||| 0-0 1-1 0-2 2-2 3-3
bedienen , bis ||| vehicles , until ||| 0-0 1-1 0-2 2-2
beeinflussen ||| impact ||| 0-0
beeinflussen ||| may impact ||| 0-1
beeinflusst . ||| concomitantly . ||| 0-0 1-1
beeinflusst ||| affect ||| 0-0
beeinflusst ||| concomitantly ||| 0-0
beeinträchtigt die Signalübertragung zwischen Gehirnzellen ||| disrupts signals transmitted between brain ||| 0-0 2-0 2-1 2-2 4-2 3-3 4-4
beeinträchtigt oder Sie ||| not listed in this leaflet ||| 0-0 0-1 1-1 0-2 0-3 0-4 2-4
beeinträchtigt ||| serious ||| 0-0
beeinträchtigte die Fruchtbarkeit in Studien ||| did not impair fertility in ||| 0-0 0-1 1-2 2-2 2-3 3-3 4-3 3-4
beeinträchtigte ||| did not ||| 0-0 0-1
beeinträchtigten ||| ECOG ||| 0-0
beeinträchtigter Leberfunktion kann ||| hepatic impairment may be ||| 1-0 0-1 1-1 2-2 2-3
beeinträchtigter Leberfunktion ||| hepatic impairment ||| 1-0 0-1 1-1
beendet werden . ||| should be discontinued . ||| 0-0 1-1 0-2 1-2 2-3
beendet werden ||| should be discontinued ||| 0-0 1-1 0-2 1-2
beendet ||| discontinued ||| 0-0
befassten sich mit der Langzeitanwendung ||| also looked at long-term use ||| 0-0 0-1 1-1 2-2 3-2 4-3 4-4
befassten sich mit der ||| also looked at ||| 0-0 0-1 1-1 2-2 3-2
befassten sich ||| also looked ||| 0-0 0-1 1-1
befolgt werden . ||| be followed . ||| 0-0 1-0 0-1 2-2
befolgt werden ||| be followed ||| 0-0 1-0 0-1
begangener Suizid ( siehe Abschnitt ||| completed suicide ( see section ||| 0-0 1-0 1-1 2-2 3-3 4-4
begangener Suizid ( siehe ||| completed suicide ( see ||| 0-0 1-0 1-1 2-2 3-3
begangener Suizid ( ||| completed suicide ( ||| 0-0 1-0 1-1 2-2
begangener Suizid ||| completed suicide ||| 0-0 1-0 1-1
beginnt . ||| begins . ||| 0-0 1-1
beginnt ||| begins ||| 0-0
begleitender Stoffwechselerkrankungen behandelt ||| groups ||| 1-0
begleitender Stoffwechselerkrankungen ||| groups ||| 1-0
begonnen werden . ||| iron stores . ||| 0-0 0-1 1-1 2-2
begonnen werden . ||| should be initiated . ||| 1-0 1-1 0-2 1-2 2-3
begonnen werden ||| iron stores ||| 0-0 0-1 1-1
begonnen werden ||| should be initiated ||| 1-0 1-1 0-2 1-2
begrenzt . ||| ina ||| 0-0 1-0
begrenzten Anzahl ||| limited number ||| 0-0 1-1
begrenzten Daten ||| limited data , ||| 0-0 1-1
begrenzten Daten ||| limited data ||| 0-0 1-1
begrenzten ||| limited ||| 0-0
behandeln ( siehe Abschnitt 4.3 ||| ( see section 4.3 ||| 0-0 1-0 2-1 3-2 4-3
behandeln ( siehe Abschnitt ||| ( see section ||| 0-0 1-0 2-1 3-2
behandeln ( siehe ||| ( see ||| 0-0 1-0 2-1
behandeln ( ||| ( ||| 0-0 1-0
behandelnde Arzt ||| value ||| 0-0
behandelnde ||| value ||| 0-0
behandelt werden sollten ||| should be treated ||| 2-0 1-1 0-2
behandelt werden ||| be treated ||| 1-0 0-1
behandelt wurden , ||| been treated ||| 1-0 0-1
behandelt wurden , ||| were treated ||| 1-0 0-1
behandelt wurden ||| been treated ||| 1-0 0-1
behandelt wurden ||| cases reported ||| 1-0 1-1
behandelt wurden ||| treated for ||| 0-0 1-0 0-1
behandelt wurden ||| treated ||| 0-0 1-0
behandelt wurden ||| were treated ||| 1-0 0-1
behandelt ||| % of patients treated with ||| 0-0 0-2 0-3 0-4
behandelt ||| being treated ||| 0-0 0-1
behandelt ||| treated , ||| 0-0
behandelt ||| treated with ||| 0-0 0-1
behandelt ||| treated ||| 0-0
behandelte ) Dyslipidämie ||| behandelte ) Dyslipidämie eingeschlossen ||| 0-0 1-1 2-2 2-3
behandelte ) ||| behandelte ) ||| 0-0 1-1
behandelte ||| behandelte ||| 0-0
behandelte ||| for ||| 0-0
behandelten Frauen ||| women treated ||| 1-0 0-1
behandelten Gruppe wurde beobachtet . ||| treated group . ||| 0-0 1-1 2-1 3-1 4-2
behandelten Gruppe wurde beobachtet ||| treated group ||| 0-0 1-1 2-1 3-1
behandelten Patienten wurde ||| patients treated ||| 1-0 0-1
behandelten Patienten ||| occur in ||| 0-0 0-1 1-1
behandelten Patienten ||| patients treated ||| 1-0 0-1
behandelten Patienten ||| treated patients ||| 0-0 1-1
behandelten ||| treated with ||| 0-0
behandelten ||| treated ||| 0-0
behandelten ||| vigilantly ||| 0-0
behandlungsbezogen in der ||| a treatment related increase in ||| 1-0 2-1 0-2 1-2 2-3 1-4
bei 0,1 mg/kg ||| at 0.1 mg/ kg ||| 0-0 1-1 2-2 2-3
bei 0,1 ||| at 0.1 ||| 0-0 1-1
bei 141 ||| 141 ||| 1-0
bei 180 mg ||| at 180 mg ||| 0-0 1-1 2-2
bei 180 ||| at 180 ||| 0-0 1-1
bei 2,3 % der ||| in 2.3 % of ||| 0-0 1-1 2-2 3-3
bei 2,3 % ||| in 2.3 % ||| 0-0 1-1 2-2
bei 2,3 ||| in 2.3 ||| 0-0 1-1
bei 229 Patienten ||| 229 patients ||| 1-0 0-1 2-1
bei 24 % der ||| in 24 % of ||| 0-0 1-1 2-2 3-3
bei 24 % ||| in 24 % ||| 0-0 1-1 2-2
bei 24 ||| in 24 ||| 0-0 1-1
bei 29 % ||| in 29 % of the ||| 0-0 1-1 2-2
bei 29 % ||| in 29 % of ||| 0-0 1-1 2-2
bei 29 % ||| in 29 % ||| 0-0 1-1 2-2
bei 29 ||| in 29 ||| 0-0 1-1
bei 2°C 8°C . ||| 2°C - 8°C . ||| 0-0 1-0 1-1 2-2 3-3
bei 2°C 8°C . ||| 2ºC - 8ºC . ||| 0-0 1-0 1-1 2-2 3-3
bei 2°C 8°C ||| 2°C - 8°C ||| 0-0 1-0 1-1 2-2
bei 2°C 8°C ||| 2ºC - 8ºC ||| 0-0 1-0 1-1 2-2
bei 2°C ||| 2°C - ||| 0-0 1-0 1-1
bei 2°C ||| 2ºC - ||| 0-0 1-0 1-1
bei 3,5 % der mit ||| in 3.5 % of ||| 0-0 4-0 1-1 2-2 3-3
bei 32 % der ||| in 32 % of ||| 0-0 1-1 2-2 3-3
bei 32 % ||| in 32 % ||| 0-0 1-1 2-2
bei 32 ||| in 32 ||| 0-0 1-1
bei 3800 ||| in approximately 3800 ||| 0-0 0-1 1-2
bei 45 % der ||| in 45 % of the ||| 0-0 1-1 2-2 3-3 3-4
bei 45 % ||| in 45 % ||| 0-0 1-1 2-2
bei 45 ||| in 45 ||| 0-0 1-1
bei 64 Patienten ergaben ||| in 64 patients yielded the ||| 0-0 1-1 0-2 2-2 1-3 3-4
bei 64 Patienten ||| in 64 patients yielded ||| 0-0 1-1 0-2 2-2 1-3
bei 68 % der ||| in 68 % of ||| 0-0 1-1 2-2 3-3
bei 68 % ||| in 68 % ||| 0-0 1-1 2-2
bei 68 ||| in 68 ||| 0-0 1-1
bei 7 % ||| in 7 % ||| 0-0 1-1 2-2
bei 7 Patienten ||| in 7 patients ||| 0-0 1-1 2-2
bei 7 ||| in 7 ||| 0-0 1-1
bei 71 % der ||| in 71 % of ||| 0-0 1-1 2-2 3-3
bei 71 % ||| in 71 % ||| 0-0 1-1 2-2
bei 71 ||| in 71 ||| 0-0 1-1
bei 79 % der ||| reported in 79 % of ||| 0-0 0-1 1-2 2-3 3-4
bei 79 % ||| reported in 79 % ||| 0-0 0-1 1-2 2-3
bei 79 ||| reported in 79 ||| 0-0 0-1 1-2
bei 90 % der ||| in 90 % of the ||| 0-0 1-1 2-2 3-3 3-4
bei 90 % ||| in 90 % ||| 0-0 1-1 2-2
bei 90 ||| in 90 ||| 0-0 1-1
bei 95 % in ||| 95 % in ||| 1-0 2-1 0-2 3-2
bei Aclasta-behandelten Männern im ||| in men treated with ||| 0-0 3-0 1-1 2-1 2-2 0-3
bei Affen , ||| in monkeys , ||| 0-0 1-1 2-2
bei Affen ||| in monkeys ||| 0-0 1-1
bei Anwendung der Dosierungen von ||| at doses of ||| 0-0 2-0 3-0 3-1 4-2
bei Anwendung der Dosierungen von ||| reduced at doses of ||| 0-1 2-1 3-1 3-2 4-3
bei Anwendung der Dosierungen ||| at doses ||| 0-0 2-0 3-0 3-1
bei Anwendung der Dosierungen ||| reduced at doses ||| 0-1 2-1 3-1 3-2
bei Anwendung von Epoetin alfa ||| , use of Epoetin alfa ||| 0-1 1-1 2-2 3-3 4-4
bei Anwendung von Epoetin alfa ||| use of Epoetin alfa ||| 0-0 1-0 2-1 3-2 4-3
bei Anwendung von Epoetin ||| , use of Epoetin ||| 0-1 1-1 2-2 3-3
bei Anwendung von Epoetin ||| use of Epoetin ||| 0-0 1-0 2-1 3-2
bei Anwendung von ||| , use of ||| 0-1 1-1 2-2
bei Anwendung von ||| use of ||| 0-0 1-0 2-1
bei Anwendung ||| , use ||| 0-1 1-1
bei Anwendung ||| use ||| 0-0 1-0
bei Aufbewahrung bei Raumtemperatur ( ||| stored at room temperature ( ||| 0-0 1-0 1-1 2-1 3-2 3-3 4-4
bei Aufbewahrung bei Raumtemperatur ||| stored at room temperature ||| 0-0 1-0 1-1 2-1 3-2 3-3
bei Aufbewahrung bei ||| stored at ||| 0-0 1-0 1-1 2-1
bei Behandlung mit Aripiprazol ( ||| treatment with aripiprazole ( ||| 1-0 0-1 2-1 3-2 4-3
bei Behandlung mit Aripiprazol ||| treatment with aripiprazole ||| 1-0 0-1 2-1 3-2
bei Behandlung mit ||| treatment with ||| 1-0 0-1 2-1
bei Bipolar-I-Störung unter ||| in Bipolar I Disorder with ||| 0-0 0-1 1-1 1-2 1-3 2-4
bei Bipolar-I-Störung ||| in Bipolar I Disorder ||| 0-0 0-1 1-1 1-2 1-3
bei Bisphosphonat-naiven Patienten und 42 ||| in bisphosphonate-naïve patients and 42 ||| 0-0 1-1 2-2 3-3 4-4
bei Bisphosphonat-naiven Patienten und ||| in bisphosphonate-naïve patients and ||| 0-0 1-1 2-2 3-3
bei Bisphosphonat-naiven Patienten ||| in bisphosphonate-naïve patients ||| 0-0 1-1 2-2
bei Bisphosphonat-naiven ||| in bisphosphonate-naïve ||| 0-0 1-1
bei Erhalt neuer Informationen ||| new information is received ||| 2-0 3-1 3-2
bei Erhalt neuer Informationen ||| new information is ||| 2-0 3-1 3-2
bei Erhalt neuer ||| new ||| 2-0
bei Erwachsenen mit Niereninsuffizienz , ||| in adult patients with renal ||| 0-0 0-1 1-1 1-2 2-3 3-4
bei Erwachsenen mit Niereninsuffizienz ||| in adult patients with renal ||| 0-0 0-1 1-1 1-2 2-3 3-4
bei Erwachsenen mit ||| in adult patients with ||| 0-0 0-1 1-1 1-2 2-3
bei Erwachsenen mit ||| in adult patients ||| 0-0 1-1 1-2 2-2
bei Erwachsenen ||| adult patients ||| 0-0 1-0 1-1
bei Erwachsenen ||| in adult patients ||| 0-0 0-1 1-1 1-2
bei Frauen , ||| in women ||| 0-0 1-1
bei Frauen ||| in women who ||| 0-0 1-1 0-2
bei Frauen ||| in women ||| 0-0 1-1
bei HIV ) ||| in case of HIV ) ||| 0-0 0-1 1-3 2-4
bei HIV ||| in case of HIV ||| 0-0 0-1 1-3
bei Haloperidol . ||| haloperidol . ||| 0-0 1-0 2-1
bei Haloperidol ||| haloperidol ||| 0-0 1-0
bei Hunden , bei denen ||| in dogs in which ||| 0-0 1-1 3-2 2-3 4-3
bei Hunden im ||| in dogs ||| 0-0 2-0 1-1
bei Hunden mit ||| in dogs with ||| 0-0 1-1 2-2
bei Hunden wurde ||| dogs ||| 1-0
bei Hunden wurde ||| in dogs ||| 1-1
bei Hunden ||| dogs ||| 1-0
bei Hunden ||| in dogs ||| 0-0 1-1
bei Hunden ||| in dogs ||| 1-1
bei Hüftfrakturen ||| in hip fracture , ||| 0-0 1-1 1-2
bei Hüftfrakturen ||| in hip fracture ||| 0-0 1-1 1-2
bei Hündinnen während der Trächtigkeit ||| in dogs during pregnancy ||| 0-0 1-0 1-1 2-2 3-2 4-3
bei Hündinnen während der ||| in dogs during ||| 0-0 1-0 1-1 2-2 3-2
bei Hündinnen ||| in dogs ||| 0-0 1-0 1-1
bei Ihnen keine ||| you cannot receive ||| 1-0 2-1 1-2
bei Ihnen wirkt . ||| affects you . ||| 0-0 1-0 2-0 1-1 3-2
bei Ihnen wirkt ||| affects you ||| 0-0 1-0 2-0 1-1
bei Kindern berichtet . ||| reported in children . ||| 0-0 2-0 1-1 1-2 3-3
bei Kindern berichtet ||| reported in children ||| 0-0 2-0 1-1 1-2
bei Kindern und Erwachsenen ||| in adult and paediatric ||| 0-0 3-1 2-2 1-3 3-3
bei Kindern und Erwachsenen ||| in paediatric and adult patients ||| 0-0 1-1 2-2 3-3 3-4
bei Kindern und Jugendlichen ist ||| in children and adolescents has ||| 0-0 1-1 2-2 3-3 3-4 4-4
bei Kindern und Jugendlichen unter ||| in children and adolescents under ||| 0-0 1-1 2-2 3-3 3-4 4-4
bei Kindern und ||| in children and ||| 0-0 1-1 2-2
bei Kindern und ||| in paediatric and ||| 0-0 1-1 2-2
bei Kindern unter ||| in children below ||| 0-0 1-1 2-2
bei Kindern ||| in children ||| 0-0 1-0 1-1
bei Kindern ||| in children ||| 0-0 1-1
bei Kindern ||| in paediatric ||| 0-0 1-1
bei Krebs- Chemotherapie ||| receiving a chemotherapy for cancer ||| 2-0 2-2 0-3 1-4 2-4
bei Lagerung bei 2°C ||| when stored between 2°C - ||| 1-0 0-1 1-1 1-2 2-3 3-3 3-4
bei Lagerung bei 2°C ||| when stored between 2ºC - ||| 1-0 0-1 1-1 1-2 2-3 3-3 3-4
bei Lagerung ||| when stored between ||| 1-0 0-1 1-1 1-2
bei Morbus Paget ||| in Paget s disease ||| 0-0 1-1 2-1 1-2 2-3
bei Männern ( Studie CZOL446M2308 ||| in men ( study CZOL446M2308 ||| 0-0 1-1 2-2 3-3 4-4
bei Männern ( Studie ||| in men ( study ||| 0-0 1-1 2-2 3-3
bei Männern ( ||| in men ( ||| 0-0 1-1 2-2
bei Männern ) . ||| for males ) . ||| 0-0 0-1 1-1 2-2 3-3
bei Männern ) ||| for males ) ||| 0-0 0-1 1-1 2-2
bei Männern . ||| in men . ||| 0-0 1-1 2-2
bei Männern In der ||| in men In the ||| 0-0 1-1 2-2 3-3
bei Männern In ||| in men In ||| 0-0 1-1 2-2
bei Männern beobachtet ||| observed in men ||| 2-0 0-1 1-2
bei Männern mit ||| in men with ||| 0-0 1-1 2-2
bei Männern stärkt Aclasta die ||| men , Aclasta strengthens the ||| 0-0 1-0 3-2 2-3 4-4
bei Männern stärkt Aclasta ||| men , Aclasta strengthens ||| 0-0 1-0 3-2 2-3
bei Männern wie bei ||| be consistent among men and ||| 0-0 0-1 3-2 1-3 3-3
bei Männern wie bei ||| be consistent among men ||| 0-0 0-1 3-2 1-3 3-3
bei Männern ||| for males ||| 0-0 0-1 1-1
bei Männern ||| in men , ||| 0-0 1-1
bei Männern ||| in men ||| 0-0 1-1
bei Männern ||| men , ||| 0-0 1-0
bei Männern ||| men ||| 0-0 1-0
bei Osteoporose ||| in osteoporosis ||| 0-0 1-1
bei Patienten ( Durchschnittsalter ||| in patients ( mean age ||| 0-0 1-1 2-2 3-3 3-4
bei Patienten ( insbesondere ||| in patients ( particularly ||| 0-0 1-1 2-2 3-3
bei Patienten ( insbesondere übergewichtigen ||| in patients ( particularly overweight ||| 0-0 1-1 2-2 3-3 4-3 4-4
bei Patienten ( insbesondere übergewichtigen ||| in patients ( particularly overweight ||| 0-0 1-1 2-2 3-3 4-4
bei Patienten ( ||| , in patients ( ||| 0-1 1-2 2-3
bei Patienten ( ||| in patients ( ||| 0-0 1-1 2-2
bei Patienten , bei denen ||| in patients ||| 0-0 2-0 3-0 1-1 3-1 4-1
bei Patienten , die ||| the ||| 0-0 1-0 2-0 3-0
bei Patienten , ||| for patients ||| 0-0 1-1
bei Patienten beobachtet , die ||| been seen in patients ||| 2-0 0-1 2-1 4-1 0-2 1-3
bei Patienten berichtet ||| been reported in patients ||| 2-0 2-1 0-2 1-3
bei Patienten im ||| in patients ||| 0-0 2-0 0-1 1-1
bei Patienten mit Agitiertheit und ||| in patients with agitation and ||| 0-0 1-1 2-2 3-3 4-4
bei Patienten mit Agitiertheit ||| in patients with agitation ||| 0-0 1-1 2-2 3-3
bei Patienten mit Hypocalcämie ||| used in patients with hypocalcaemia ||| 0-0 0-1 1-2 2-3 3-4
bei Patienten mit Hypokalzämie ( ||| for patients with hypocalcaemia ( ||| 0-0 1-1 2-2 3-3 4-4
bei Patienten mit Hypokalzämie ||| for patients with hypocalcaemia ||| 0-0 1-1 2-2 3-3
bei Patienten mit Niereninsuffizienz ||| in renal failure patients , ||| 0-0 3-1 3-2 0-3 1-3 2-3
bei Patienten mit Niereninsuffizienz ||| in renal failure patients ||| 0-0 3-1 3-2 0-3 1-3 2-3
bei Patienten mit bipolarer Manie ||| bipolar mania patients ||| 0-0 3-0 4-1 1-2 2-2
bei Patienten mit bipolarer Störung ||| in patients with bipolar disorder ||| 0-0 1-1 2-2 3-3 4-4
bei Patienten mit bipolarer ||| in patients with bipolar ||| 0-0 1-1 2-2 3-3
bei Patienten mit einer Adipositas ||| bei Patienten mit einer Adipositas ||| 0-0 1-1 2-2 3-3 4-4
bei Patienten mit einer kürzlich ||| those with a recent ||| 0-0 1-0 2-1 3-2 4-3
bei Patienten mit einer manischen ||| in patients with a manic ||| 0-0 1-1 2-2 3-3 4-4
bei Patienten mit einer ||| bei Patienten mit einer ||| 0-0 1-1 2-2 3-3
bei Patienten mit einer ||| in patients with a ||| 0-0 1-1 2-2 3-3
bei Patienten mit einer ||| those with a ||| 0-0 1-0 2-1 3-2
bei Patienten mit gemischten Episoden ||| patients with mixed episodes ||| 0-0 1-0 2-1 3-2 4-3
bei Patienten mit gemischten ||| patients with mixed ||| 0-0 1-0 2-1 3-2
bei Patienten mit mittelschwerer Anämie ||| to patients with moderate anaemia ||| 3-0 0-1 1-1 2-2 3-3 4-4
bei Patienten mit mittelschwerer ||| to patients with moderate ||| 3-0 0-1 1-1 2-2 3-3
bei Patienten mit noch vorhandener ||| in patients with residual ||| 0-0 1-1 2-2 3-3 4-3
bei Patienten mit schwerer ||| in severe ||| 0-0 1-0 2-0 3-1
bei Patienten mit stark eingeschränkter ||| bei Patienten mit stark eingeschränkter ||| 0-0 1-1 2-2 3-3 3-4 4-4
bei Patienten mit ||| and patients with ||| 0-1 1-1 2-2
bei Patienten mit ||| bei Patienten mit ||| 0-0 1-1 2-2
bei Patienten mit ||| for patients with ||| 0-0 1-1 2-2
bei Patienten mit ||| in patients at ||| 0-0 1-1 2-1 0-2
bei Patienten mit ||| in patients who ||| 0-0 1-1 1-2 2-2
bei Patienten mit ||| in patients with ||| 0-0 0-1 1-1 2-2
bei Patienten mit ||| in patients with ||| 0-0 1-1 2-2
bei Patienten mit ||| in patients ||| 0-0 1-1 2-1
bei Patienten mit ||| in ||| 0-0 1-0 2-0
bei Patienten mit ||| patients with associated risk ||| 0-0 1-0 2-1 2-2
bei Patienten mit ||| patients with associated ||| 0-0 1-0 2-1 2-2
bei Patienten mit ||| patients with ||| 0-0 1-0 2-1
bei Patienten mit ||| those with ||| 0-0 1-0 2-1
bei Patienten mit ||| used in patients with ||| 0-0 0-1 1-2 2-3
bei Patienten mit ||| with ||| 0-0 1-0 2-0
bei Patienten ohne Adipositas ( ||| bei Patienten ohne Adipositas ( ||| 0-0 1-1 2-2 3-3 4-4
bei Patienten ohne Adipositas ||| bei Patienten ohne Adipositas ||| 0-0 1-1 2-2 3-3
bei Patienten ohne ||| bei Patienten ohne ||| 0-0 1-1 2-2
bei Patienten ||| , in patients ||| 0-1 1-2
bei Patienten ||| and patients ||| 0-1 1-1
bei Patienten ||| bei Patienten ||| 0-0 1-1
bei Patienten ||| for patients ||| 0-0 1-1
bei Patienten ||| in patients who are ||| 0-0 0-1 1-1 1-2 0-3
bei Patienten ||| in patients ||| 0-0 0-1 1-1
bei Patienten ||| in patients ||| 0-0 1-1
bei Patienten ||| patients ||| 0-0 1-0
bei Patienten ||| those ||| 0-0 1-0
bei Patienten ||| used in patients ||| 0-0 0-1 1-2
bei Patienten ||| weight ||| 1-0
bei Patienten über 75 ||| in patients over 75 ||| 0-0 1-1 2-2 3-3
bei Patienten über ||| in patients over ||| 0-0 1-1 2-2
bei Patientinnen ||| in patients ||| 0-0 1-1
bei Probanden mit ||| in subjects with ||| 0-0 1-1 2-2
bei Probanden ||| in subjects ||| 0-0 1-1
bei Ratten ||| 10 in the ||| 1-0 0-1 1-1
bei Ratten ||| 10 in ||| 1-0 0-1 1-1
bei Schizophrenie und ||| in schizophrenia and ||| 0-0 1-1 2-2
bei Schizophrenie ||| in schizophrenia ||| 0-0 1-1
bei Schwangeren vor . ||| in pregnant women . ||| 0-0 1-1 1-2 2-2 3-3
bei Schwangeren vor ||| in pregnant women ||| 0-0 1-1 1-2 2-2
bei Tieren Die Sicherheit ||| in animals The safety ||| 0-0 1-1 2-2 3-3
bei Tieren Die ||| in animals The ||| 0-0 1-1 2-2
bei Tieren ||| in animals ||| 0-0 1-1
bei Wirbelkörperfraktur ||| Summary of vertebral fracture efficacy ||| 1-0 0-1 1-2 1-3 1-4
bei ZNS-Metastasen generell nicht zu ||| are generally not well ||| 0-0 1-1 2-1 3-2 1-3
bei ZNS-Metastasen generell nicht ||| are generally not well ||| 0-0 1-1 2-1 3-2 1-3
bei allen Patienten betrugen ||| in all patients were ||| 0-0 1-1 2-2 3-3
bei allen Patienten ||| in all patients ||| 0-0 1-1 2-2
bei allen außer einer von ||| bei allen außer einer von ||| 0-0 1-1 2-2 3-3 4-4
bei allen außer einer ||| bei allen außer einer ||| 0-0 1-1 2-2 3-3
bei allen außer ||| bei allen außer ||| 0-0 1-1 2-2
bei allen ||| bei allen ||| 0-0 1-1
bei allen ||| in all ||| 0-0 1-1
bei anderen Antipsychotika ||| other antipsychotics ||| 1-0 0-1 2-1
bei anderen Indikationen ||| for other indications ||| 0-0 1-1 2-2
bei anderen potenziell toxischen Stoffen ||| with other potentially toxic compounds ||| 0-0 1-1 2-2 3-3 4-4
bei anderen potenziell toxischen ||| with other potentially toxic ||| 0-0 1-1 2-2 3-3
bei anderen potenziell ||| with other potentially ||| 0-0 1-1 2-2
bei anderen ||| for other ||| 0-0 1-1
bei anderen ||| in other ||| 0-0 1-1
bei anderen ||| with other ||| 0-0 1-1
bei bipolaren Patienten 12,1 ||| in bipolar patients was 12.1 ||| 0-0 0-1 1-1 2-2 3-3 3-4
bei bipolaren Patienten 12,1 ||| in bipolar patients was 12.1 ||| 0-0 1-1 2-2 3-3 3-4
bei bipolaren Patienten ||| in bipolar patients ||| 0-0 0-1 1-1 2-2
bei bipolaren Patienten ||| in bipolar patients ||| 0-0 1-1 2-2
bei bipolaren ||| in bipolar ||| 0-0 0-1 1-1
bei bipolaren ||| in bipolar ||| 0-0 1-1
bei bis zu 10 % ||| in up to 10 % ||| 0-0 1-1 2-1 2-2 3-3 4-4
bei bis zu 10 ||| in up to 10 ||| 0-0 1-1 2-1 2-2 3-3
bei bis zu ||| in up to ||| 0-0 1-1 2-1 2-2
bei chirurgischen ||| and vascular ||| 1-0 0-1 1-1
bei chronischer Niereninsuffizienz bei ||| with chronic renal failure in ||| 0-0 1-1 2-2 2-3 3-4
bei chronischer Niereninsuffizienz ||| with chronic renal failure ||| 0-0 1-1 2-2 2-3
bei chronischer ||| with chronic ||| 0-0 1-1
bei dem primären 2-Stunden Endpunkt ||| at the primary 2-hour endpoint ||| 0-0 1-1 2-2 3-3 4-4
bei dem primären 2-Stunden ||| at the primary 2-hour ||| 0-0 1-1 2-2 3-3
bei dem primären ||| at the primary ||| 0-0 1-1 2-2
bei dem ||| at the ||| 0-0 1-1
bei den Patienten ||| patients experience ||| 0-0 2-0
bei den Patienten ||| patients ||| 0-0 2-0
bei denen die ||| in whom the ||| 0-0 1-1 2-2
bei denen ein elektiver orthopädischer ||| patients scheduled for major elective ||| 0-0 1-1 3-2 2-3 3-3 4-4
bei denen ein elektiver orthopädischer ||| scheduled for major elective ||| 0-0 1-0 3-1 2-2 3-2 4-3
bei denen ein elektiver ||| patients scheduled for major ||| 0-0 1-1 3-2 2-3 3-3
bei denen ein elektiver ||| scheduled for major ||| 0-0 1-0 3-1 2-2 3-2
bei denen ein größerer orthopädischer ||| patients scheduled for major ||| 0-0 1-0 1-1 2-1 4-2 3-3 4-3
bei denen ein hohes ||| having a high ||| 1-0 3-0 2-1 3-2
bei denen ein orthopädischer ||| patients scheduled for ||| 0-0 1-0 1-1 2-1 3-1 3-2
bei denen ein ||| patients scheduled ||| 0-0 1-0 1-1 2-1
bei denen ein ||| scheduled ||| 0-0 1-0 2-0
bei denen ||| in whom ||| 0-0 1-1
bei denen ||| patients scheduled ||| 0-0 1-1
bei denen ||| scheduled ||| 0-0 1-0
bei der Anwendung entstehender ||| from the use of such ||| 1-0 1-1 2-2 1-3 3-4
bei der Anwendung ||| from the use of ||| 1-0 1-1 2-2 1-3
bei der Behandlung der postmenopausalen ||| in the treatment of post-menopausal ||| 0-0 1-1 2-2 3-3 4-4
bei der Behandlung der ||| in the treatment of ||| 0-0 1-1 2-2 3-3
bei der Behandlung ||| in the treatment ||| 0-0 1-1 2-2
bei der Behandlung ||| treatment in ||| 2-0 0-1 1-1
bei der Bipolar-I-Störung : ||| in Bipolar I Disorder : ||| 0-0 0-1 2-1 1-2 2-2 2-3 3-4
bei der Bipolar-I-Störung ||| in Bipolar I Disorder ||| 0-0 0-1 2-1 1-2 2-2 2-3
bei der Haloperidol-Gruppe ( 30 ||| for haloperidol ( 30 ||| 2-0 0-1 2-1 3-2 4-3
bei der Haloperidol-Gruppe ( ||| for haloperidol ( ||| 2-0 0-1 2-1 3-2
bei der Haloperidol-Gruppe ||| for haloperidol ||| 2-0 0-1 2-1
bei der Placebogruppe . ||| in the placebo group . ||| 0-0 1-1 2-2 2-3 3-4
bei der Placebogruppe ||| in the placebo group ||| 0-0 1-1 2-2 2-3
bei der Verringerung manischer Symptome ||| in reduction of manic symptoms ||| 0-0 2-1 1-2 3-3 4-4
bei der Verringerung manischer ||| in reduction of manic ||| 0-0 2-1 1-2 3-3
bei der Verringerung ||| in reduction of ||| 0-0 2-1 1-2
bei der die ||| bei der die ||| 0-0 1-1 2-2
bei der empfohlenen klinischen ||| at the maximum recommended clinical ||| 0-0 2-0 1-1 2-2 2-3 3-4
bei der empfohlenen ||| at the maximum recommended ||| 0-0 2-0 1-1 2-2 2-3
bei der niedrigsten an ||| at the lowest ||| 0-0 1-1 2-2
bei der niedrigsten ||| at the lowest ||| 0-0 1-1 2-2
bei der ||| at the ||| 0-0 1-1
bei der ||| bei der ||| 0-0 1-1
bei der ||| in the ||| 0-0 1-1
bei der ||| in ||| 0-0 1-0
bei der ||| the ||| 1-0
bei diesen Patienten empfohlen . ||| recommended in these patients . ||| 3-0 0-1 1-2 2-3 4-4
bei diesen Patienten empfohlen ||| recommended in these patients ||| 3-0 0-1 1-2 2-3
bei diesen Patienten mit Vorsicht ||| bei diesen Patienten mit Vorsicht ||| 0-0 1-1 1-2 2-2 3-3 4-4
bei diesen Patienten mit ||| bei diesen Patienten mit ||| 0-0 1-1 1-2 2-2 3-3
bei diesen Patienten ||| , these patients ||| 1-1 0-2 2-2
bei diesen Patienten ||| bei diesen Patienten ||| 0-0 1-1 1-2 2-2
bei diesen Patienten ||| in these patients ||| 0-0 1-1 2-2
bei diesen Patienten ||| these patients ||| 1-0 0-1 2-1
bei diesen ||| in these ||| 0-0 1-1
bei dopaminerger Hyperaktivität und ||| dopaminergic hyperactivity and agonist ||| 0-0 1-0 1-1 2-1 3-2 2-3
bei einer Erhaltungsdosis von ||| with a maintenance dose of ||| 0-0 1-1 0-2 2-2 2-3 3-4
bei einer Erhaltungsdosis ||| with a maintenance dose ||| 0-0 1-1 0-2 2-2 2-3
bei einer Rimonabant-Behandlung abzuschätzen . ||| and suicide . ||| 2-1 3-1 4-2
bei einer Rimonabant-Behandlung abzuschätzen . ||| harm and suicide . ||| 2-2 3-2 4-3
bei einer Rimonabant-Behandlung abzuschätzen . ||| suicide . ||| 2-0 3-0 4-1
bei einer Rimonabant-Behandlung abzuschätzen ||| and suicide ||| 2-1 3-1
bei einer Rimonabant-Behandlung abzuschätzen ||| harm and suicide ||| 2-2 3-2
bei einer Rimonabant-Behandlung abzuschätzen ||| suicide ||| 2-0 3-0
bei einer kleinen Minderheit ||| in women ||| 0-0 1-0 2-0 3-1
bei einer kleinen ||| in ||| 0-0 1-0 2-0
bei einzelnen Patienten mit normalem ||| in isolated patients with normal ||| 0-0 1-1 2-2 3-3 4-4
bei einzelnen Patienten mit ||| in isolated patients with ||| 0-0 1-1 2-2 3-3
bei einzelnen Patienten ||| in isolated patients ||| 0-0 1-1 2-2
bei einzelnen ||| in isolated ||| 0-0 1-1
bei erwachsenen Hunden . ||| in adult dogs . ||| 0-0 1-1 2-2 3-3
bei erwachsenen Hunden ||| in adult dogs ||| 0-0 1-1 2-2
bei erwachsenen ||| in adult ||| 0-0 1-1
bei fortgesetzter ||| during the course ||| 0-0 1-0 1-1 1-2
bei gesunden Nichtrauchern vergleichbar ist ||| similar between healthy non-smoking subjects ||| 3-0 1-1 1-2 2-3 1-4
bei gesunden Nichtrauchern vergleichbar ||| similar between healthy non-smoking subjects ||| 3-0 1-1 1-2 2-3 1-4
bei gesunden Nichtrauchern ||| between healthy non-smoking subjects and ||| 1-0 1-1 2-2 1-3
bei gesunden Nichtrauchern ||| between healthy non-smoking subjects ||| 1-0 1-1 2-2 1-3
bei gesunden ||| healthy ||| 1-0
bei gleichzeitiger Anwendung mit Mitratapid ||| used concomitantly with mitratapide ||| 0-0 1-0 2-0 1-1 3-2 4-3
bei gleichzeitiger Anwendung mit ||| used concomitantly with ||| 0-0 1-0 2-0 1-1 3-2
bei gleichzeitiger Anwendung ||| used concomitantly ||| 0-0 1-0 2-0 1-1
bei gleichzeitiger ||| be used ||| 1-0 0-1 1-1
bei ihrem vorhergehenden Insulin waren ||| experienced with their previous insulin ||| 0-0 1-0 1-1 2-2 2-3 4-3 3-4
bei ihrem ||| experienced with ||| 0-0 1-0 1-1
bei jeder Dosis ||| at any dose in ||| 0-0 1-1 2-2 0-3
bei manischen Patienten , die ||| , in manic patients who ||| 3-0 0-1 1-2 2-3 1-4 3-4 4-4
bei manischen ||| in manic ||| 0-0 1-1
bei mehr als 30 % ||| in more than 30 % ||| 0-0 1-1 2-2 3-3 4-4
bei mehr als 30 ||| in more than 30 ||| 0-0 1-1 2-2 3-3
bei mehr als ||| in more than ||| 0-0 1-1 2-2
bei mehr ||| in more ||| 0-0 1-1
bei mit Aripiprazol behandelten Patienten ||| in patients treated with aripiprazole ||| 0-0 0-1 4-1 3-2 1-3 2-4
bei mit Aripiprazol behandelten Patienten ||| in patients treated with aripiprazole ||| 0-0 4-1 3-2 1-3 2-4
bei mit ||| in ||| 0-0 1-0
bei postmenopausalen Frauen bei Männern ||| in post-menopausal women in men ||| 0-0 1-1 2-2 3-3 4-4
bei postmenopausalen Frauen bei ||| in post-menopausal women in ||| 0-0 1-1 2-2 3-3
bei postmenopausalen Frauen in der ||| in post-menopausal women in the ||| 0-0 1-1 2-2 3-3 4-4
bei postmenopausalen Frauen in ||| in post-menopausal women in ||| 0-0 1-1 2-2 3-3
bei postmenopausalen Frauen und bei ||| in post-menopausal women and ||| 0-0 4-0 1-1 2-2 3-3
bei postmenopausalen Frauen ||| in post-menopausal women ||| 0-0 1-1 2-2
bei postmenopausalen ||| in post-menopausal ||| 0-0 1-1
bei pädiatrischen Patienten ||| in paediatric patients ||| 0-0 1-1 2-2
bei pädiatrischen ||| in paediatric ||| 0-0 1-1
bei schwangeren Frauen vor . ||| in pregnant women . ||| 0-0 1-1 2-2 3-2 4-3
bei schwangeren Frauen vor ||| in pregnant women ||| 0-0 1-1 2-2 3-2
bei schwangeren ||| in pregnant ||| 0-0 1-1
bei stillenden Müttern nicht angewendet ||| the Package ||| 1-0 2-1
bei stillenden Müttern nicht ||| the Package ||| 1-0 2-1
bei stillenden Müttern ||| the Package ||| 1-0 2-1
bei stillenden ||| the ||| 1-0
bei vier ||| in four ||| 0-0 1-1
bei wiederholten Infusionen weniger häufig ||| less common with repeated infusions ||| 3-0 4-1 0-2 1-2 1-3 2-4
bei wiederholten Infusionen ||| with repeated infusions ||| 0-0 1-0 1-1 2-2
bei wiederholten ||| with repeated ||| 0-0 1-0 1-1
bei ||| ) for ||| 0-0 0-1
bei ||| , in ||| 0-1
bei ||| are ||| 0-0
bei ||| at ||| 0-0
bei ||| be consistent ||| 0-0 0-1
bei ||| be ||| 0-0
bei ||| bei ||| 0-0
bei ||| by the liver , ||| 0-1 0-2
bei ||| by the liver ||| 0-1 0-2
bei ||| can occur ||| 0-1
bei ||| cases of ||| 0-1
bei ||| for the ||| 0-0
bei ||| for use in ||| 0-0 0-1 0-2
bei ||| for ||| 0-0
bei ||| in approximately ||| 0-0 0-1
bei ||| in case of ||| 0-0 0-1
bei ||| in case ||| 0-0 0-1
bei ||| in patients ||| 0-0 0-1
bei ||| in the ||| 0-0
bei ||| in ||| 0-0
bei ||| into ||| 0-0
bei ||| know ||| 0-0
bei ||| occur ||| 0-0
bei ||| of ||| 0-0
bei ||| patients ||| 0-0
bei ||| regresses ||| 0-0
bei ||| reported in ||| 0-0 0-1
bei ||| seen in ||| 0-0 0-1
bei ||| should carefully ||| 0-0 0-1
bei ||| the liver , ||| 0-0 0-1
bei ||| the liver ||| 0-0 0-1
bei ||| treatment for ||| 0-1
bei ||| used in ||| 0-0 0-1
bei ||| values ||| 0-0
bei ||| when ||| 0-0
bei ||| with ||| 0-0
bei älteren Patienten ist geringfügig ||| patients have slightly ||| 0-0 1-0 2-0 2-1 4-2
bei älteren Patienten ist ||| patients have ||| 0-0 1-0 2-0 2-1
bei älteren Patienten ||| patients have ||| 0-0 1-0 2-0 2-1
bei älteren ||| in elderly ||| 0-0 1-1
beibehalten ||| remain at ||| 0-0 0-1
beide Gruppen ) ||| both groups ) ||| 0-0 1-1 2-2
beide Gruppen ||| both groups ||| 0-0 1-1
beide ||| both ||| 0-0
beiden Arzneimitteln ||| two medicines ||| 0-0 1-1
beiden Gruppen ||| both groups ||| 0-0 1-1
beiden Studien ||| both studies , ||| 0-0 1-1
beiden Studien ||| both studies ||| 0-0 1-1
beiden ||| both ||| 0-0
beiden ||| two ||| 0-0
beim Führen von Fahrzeugen zu ||| awareness of the warning ||| 0-0 1-0 2-1 4-2 3-3 4-3
beim Führen von ||| awareness of ||| 0-0 1-0 2-1
beim Führen ||| awareness ||| 0-0 1-0
beim Hinfallen erlitten ||| a ||| 1-0 2-0
beim Menschen beträgt 0,25 ||| in humans is 0.25 ||| 0-0 0-1 1-1 2-2 2-3 3-3
beim Menschen und könnte ||| in humans and may ||| 1-0 0-1 1-1 3-1 2-2 3-3
beim Menschen und ||| humans and ||| 0-0 1-0 2-1
beim Menschen vorkommendes Protein ||| body ||| 0-0 1-0
beim Menschen vorkommendes ||| body ||| 0-0 1-0
beim Menschen ||| Muttermilch ausgeschieden ||| 0-0 0-1 1-1
beim Menschen ||| body ||| 0-0 1-0
beim Menschen ||| human dose ||| 0-0 1-0 1-1
beim Menschen ||| human ||| 0-0 1-0
beim Menschen ||| humans ||| 0-0 1-0
beim Menschen ||| in human ||| 0-0 0-1 1-1
beim Menschen ||| in humans ||| 0-0 0-1 1-1
beim Typ 1 Diabetes , ||| in type 1 diabetes , ||| 0-0 0-1 1-1 2-2 3-3 4-4
beim Typ 1 Diabetes ||| in type 1 diabetes ||| 0-0 0-1 1-1 2-2 3-3
beim Typ 1 ||| in type 1 ||| 0-0 0-1 1-1 2-2
beim Typ ||| in type ||| 0-0 0-1 1-1
beim ||| 81 ||| 0-0
beinhaltet ||| includes ||| 0-0
beinhalteten Lethargie , erhöhten ||| observed included lethargy , increased ||| 1-0 0-1 1-2 3-2 2-3 3-4
beinhalteten Patienten mit oder ohne ||| included patients with or without ||| 0-0 1-1 2-2 3-3 4-4
beinhalteten Patienten mit oder ||| included patients with or ||| 0-0 1-1 2-2 3-3
beinhalteten Patienten mit ||| included patients with ||| 0-0 1-1 2-2
beinhalteten Patienten ||| included patients ||| 0-0 1-1
beinhalteten ||| included ||| 0-0
beispielsweise Bluttests , durchführen , ||| example blood tests , ||| 0-0 1-1 1-2 3-2 2-3 4-3
beispielsweise Bluttests , durchführen , ||| for example blood tests , ||| 0-1 1-2 1-3 3-3 2-4 4-4
beispielsweise auf Blut- und Nervenzellen ||| blood and nerve cells ||| 0-0 3-1 2-2 4-2 1-3 4-3
beispielsweise schon ||| example , ||| 0-0
beispielsweise schon ||| example ||| 0-0
beispielsweise ||| blood ||| 0-0
beispielsweise ||| e. g. ||| 0-0 0-1
beispielsweise ||| example , ||| 0-0
beispielsweise ||| example ||| 0-0
beispielsweise ||| for example ||| 0-1
bekannt , ob Paclitaxel ||| known if paclitaxel ||| 0-0 1-1 2-1 3-2
bekannt , ob Pioglitazon ||| known whether pioglitazone ||| 0-0 1-1 2-1 3-2
bekannt , ob Zoledronsäure ||| known whether zoledronic acid ||| 0-0 1-1 2-1 3-2 3-3
bekannt , ob ||| known if ||| 0-0 1-1 2-1
bekannt , ob ||| known whether ||| 0-0 1-1 2-1
bekannt , so dass weitere ||| well known and further ||| 1-0 0-1 3-1 2-2 4-3
bekannt , so dass ||| well known and ||| 1-0 0-1 3-1 2-2
bekannt als nicht ||| known as non ||| 0-0 1-1
bekannt als nicht ||| known as ||| 0-0 1-1
bekannt als ||| known as non ||| 0-0 1-1
bekannt als ||| known as ||| 0-0 1-1
bekannt ||| known ||| 0-0
bekannte Komplikation der chronischen ||| known complication of chronic ||| 1-0 0-1 1-1 3-1 2-2 3-3
bekannten ||| and depressive ||| 0-1
bekannten ||| depressive ||| 0-0
bekannten ||| given the known ||| 0-2
bekannten ||| known ||| 0-0
bekannten ||| the known ||| 0-1
bekannter Überempfindlichkeit gegenüber dem arzneilich ||| hypersensitivity to the active ||| 1-0 0-1 2-1 3-2 4-3
bekannter Überempfindlichkeit gegenüber dem arzneilich ||| of hypersensitivity to the active ||| 1-1 0-2 2-2 3-3 4-4
bekannter Überempfindlichkeit gegenüber dem ||| hypersensitivity to the ||| 1-0 0-1 2-1 3-2
bekannter Überempfindlichkeit gegenüber dem ||| of hypersensitivity to the ||| 1-1 0-2 2-2 3-3
bekannter Überempfindlichkeit gegenüber ||| hypersensitivity to ||| 1-0 0-1 2-1
bekannter Überempfindlichkeit gegenüber ||| of hypersensitivity to ||| 1-1 0-2 2-2
bemerken ||| notice any ||| 0-0 0-1
benommen oder ||| drowsy or ||| 0-0 1-1
benommen ||| drowsy ||| 0-0
benötigen ||| need ||| 0-0
benötigen ||| suggest ||| 0-0
beobachtet ( siehe Abschnitte 4.3 ||| observed ( see sections 4.3 ||| 0-0 1-1 2-2 3-3 4-4
beobachtet ( siehe Abschnitte ||| observed ( see sections ||| 0-0 1-1 2-2 3-3
beobachtet ( siehe ||| observed ( see ||| 0-0 1-1 2-2
beobachtet ( ||| observed ( ||| 0-0 1-1
beobachtet , die ||| seen ||| 0-0 2-0
beobachtet , sie tritt aber ||| observed but its occurrence ||| 0-0 1-1 2-1 4-1 3-2 3-3 4-3
beobachtet , wenn Erythropoese-stimulierende Wirkstoffe ||| observed when erythropoiesis stimulating agents ||| 0-0 1-1 2-1 3-2 3-3 4-3 4-4
beobachtet , wenn ||| observed when ||| 0-0 1-1 2-1
beobachtet , ||| observed ||| 0-0
beobachtet . Die absolute Veränderung ||| Me ||| 0-0 1-0 3-0 4-0
beobachtet . Dies ist ||| observed ||| 0-0
beobachtet . Dies ||| observed ||| 0-0
beobachtet . ||| . ||| 0-0 1-0
beobachtet . ||| been observed . ||| 0-0 0-1 1-2
beobachtet . ||| beobachtet . For lp ||| 0-0 1-1 1-3
beobachtet . ||| observed . ||| 0-0 1-1
beobachtet . ||| observed ||| 0-0
beobachtet . ||| were observed . ||| 0-0 0-1 1-2
beobachtet . ||| were ||| 0-0
beobachtet : ||| commonly dic ||| 1-0 0-1
beobachtet bei ||| seen in ||| 0-0 1-0 1-1
beobachtet werden . ||| be observed . ||| 1-0 0-1 2-2
beobachtet werden . ||| may be observed . ||| 0-0 1-1 0-2 2-3
beobachtet werden ||| be observed ||| 1-0 0-1
beobachtet werden ||| may be observed ||| 0-0 1-1 0-2
beobachtet werden ||| observed for ||| 0-0
beobachtet werden ||| observed ||| 0-0
beobachtet werden ||| should be observed ||| 1-0 1-1 0-2
beobachtet ||| been observed ||| 0-0 0-1
beobachtet ||| beobachtet ||| 0-0
beobachtet ||| dic ||| 0-0
beobachtet ||| observed for ||| 0-0
beobachtet ||| observed in ||| 0-0
beobachtet ||| observed over ||| 0-0
beobachtet ||| observed ||| 0-0
beobachtet ||| seen ||| 0-0
beobachtet ||| were observed ||| 0-0 0-1
beobachtet ||| were ||| 0-0
beobachtete mittlere Besserung vom Ausgangswert ||| observed mean improvement from baseline ||| 0-0 1-1 2-2 3-3 4-4
beobachtete mittlere Besserung vom ||| observed mean improvement from ||| 0-0 1-1 2-2 3-3
beobachtete mittlere Besserung ||| observed mean improvement ||| 0-0 1-1 2-2
beobachtete mittlere ||| observed mean ||| 0-0 1-1
beobachtete ||| observed ||| 0-0
bereit , ||| packs ||| 0-0 1-0
bereitgestellt ||| provided ||| 0-0
bereits ||| already ||| 0-0
bereits ||| had already ||| 0-0 0-1
bereits ||| previously ||| 0-0
bereits ||| products you already ||| 0-0 0-1 0-2
berichten ||| report ||| 0-0
berichtet ( ||| reported ( ||| 0-0 1-1
berichtet ( ||| were reported ( ||| 0-1 1-2
berichtet , ||| reported ||| 0-0
berichtet , ||| with ||| 0-0
berichtet . ||| . ||| 0-0 1-0
berichtet . ||| been reported . ||| 0-0 0-1 1-2
berichtet . ||| treatment . ||| 0-0 1-1
berichtet wurde , ||| been reported , ||| 1-0 0-1 2-2
berichtet wurde ||| been reported ||| 1-0 0-1
berichtet ||| been reported ||| 0-0 0-1
berichtet ||| have been reported ||| 0-0 0-1 0-2
berichtet ||| reported ||| 0-0
berichtet ||| treatment ||| 0-0
berichtet ||| were reported ||| 0-1
berichtet ||| with ||| 0-0
berichteten Fälle wurde ||| reported cases have been ||| 0-0 1-1 2-2 2-3
berichteten Fälle ||| reported cases ||| 0-0 1-1
berichteten ||| reported ||| 0-0
bernsteinfarbene Glasflaschen mit 55 ||| bernsteinfarbene Glasflaschen mit 55 ||| 0-0 0-1 1-1 0-2 2-2 3-3
bernsteinfarbene Glasflaschen mit ||| bernsteinfarbene Glasflaschen mit ||| 0-0 0-1 1-1 0-2 2-2
bernsteinfarbenem ||| amber ||| 0-0
berücksichtigen bei ||| into ||| 0-0 1-0
berücksichtigt werden . ||| cancer patients . ||| 0-0 1-0 0-1 2-2
berücksichtigt werden . ||| in cancer patients . ||| 0-1 1-1 0-2 2-3
berücksichtigt werden ||| cancer patients ||| 0-0 1-0 0-1
berücksichtigt werden ||| in cancer patients ||| 0-1 1-1 0-2
berücksichtigt werden ||| treated with ||| 0-0 1-1
berücksichtigt ||| treated ||| 0-0
beschleunigt . ||| insufficiency . ||| 0-0 1-1
beschleunigt ||| insufficiency ||| 0-0
beschleunigter ||| characteristic ||| 0-0
beschrieben vorgebeugt ||| described below ||| 0-0 1-0 0-1
beschrieben ||| described ||| 0-0
beschädigen könnte ||| could damage ||| 1-0 0-1 1-1
besonders beachtet werden . ||| a possible warning signal . ||| 0-0 0-1 1-1 1-2 1-3 2-3 3-4
besonders beachtet werden ||| a possible warning signal ||| 0-0 0-1 1-1 1-2 1-3 2-3
besonders bei Patienten mit ||| especially in patients ||| 0-0 1-1 2-2 3-2
besonders bei ||| especially in ||| 0-0 1-1
besonders beim ||| especially when ||| 0-0 1-0 1-1
besonders wenn ||| especially when ||| 0-0 1-1
besonders wichtig , Ihrem ||| especially important ||| 0-0 1-1 2-1 3-1
besonders wichtig bei Patienten , ||| especially important for patients ||| 0-0 1-1 2-2 3-3
besonders wichtig bei Patienten ||| especially important for patients ||| 0-0 1-1 2-2 3-3
besonders wichtig bei ||| especially important for the ||| 0-0 1-1 2-2
besonders wichtig bei ||| especially important for ||| 0-0 1-1 2-2
besonders wichtig bei ||| especially important in the ||| 0-0 1-1 2-2
besonders wichtig bei ||| especially important in ||| 0-0 1-1 2-2
besonders wichtig ||| especially important ||| 0-0 1-1
besonders ||| especially ||| 0-0
bestehen kann . ||| cannot be excluded . ||| 0-0 0-1 0-2 1-2 2-3
bestehen kann ||| cannot be excluded ||| 0-0 0-1 0-2 1-2
bestehend aus 5 ||| comprising 5 ||| 0-0 1-0 2-1
bestehend aus ||| comprising ||| 0-0 1-0
bestehende Hypertonie und/oder ||| hypertension and/ or dyslipidemia at ||| 1-0 2-1 2-2 0-3
bestehende Hypertonie und/oder ||| hypertension and/ or dyslipidemia ||| 1-0 2-1 2-2 0-3
bestehende ||| dyslipidemia at ||| 0-0
bestehende ||| dyslipidemia ||| 0-0
bestehenden Behandlung mit Metformin und ||| existing treatment with metformin and ||| 0-0 1-1 2-2 3-3 4-4
bestehenden Behandlung mit Metformin ||| existing treatment with metformin ||| 0-0 1-1 2-2 3-3
bestehenden Behandlung mit Metformin ||| the existing treatment with metformin ||| 0-1 1-2 2-3 3-4
bestehenden Behandlung mit ||| existing treatment with ||| 0-0 1-1 2-2
bestehenden Behandlung mit ||| the existing treatment with ||| 0-1 1-2 2-3
bestehenden Behandlung ||| existing treatment ||| 0-0 1-1
bestehenden Behandlung ||| the existing treatment ||| 0-1 1-2
bestehenden Hochdrucktherapie erfordert ||| take for high blood pressure ||| 1-0 1-1 1-2 2-3 0-4 2-4
bestehenden ||| existing ||| 0-0
bestehenden ||| the existing ||| 0-1
besteht aus 10 % gelöstem ||| consists of 10 % dissolved ||| 0-0 1-0 1-1 2-2 3-3 4-4
besteht aus 10 % ||| consists of 10 % ||| 0-0 1-0 1-1 2-2 3-3
besteht aus 10 ||| consists of 10 ||| 0-0 1-0 1-1 2-2
besteht aus 165 Aminosäuren ||| consists of 165 amino acids ||| 0-0 1-0 1-1 2-2 3-3 3-4
besteht aus 165 ||| consists of 165 ||| 0-0 1-0 1-1 2-2
besteht aus 20 % gelöstem ||| consists of 20 % dissolved ||| 0-0 1-0 1-1 2-2 3-3 4-4
besteht aus 20 % ||| consists of 20 % ||| 0-0 1-0 1-1 2-2 3-3
besteht aus 20 ||| consists of 20 ||| 0-0 1-0 1-1 2-2
besteht aus 30 % gelöstem ||| consists of 30 % dissolved ||| 0-0 1-0 1-1 2-2 3-3 4-4
besteht aus 30 % ||| consists of 30 % ||| 0-0 1-0 1-1 2-2 3-3
besteht aus 30 ||| consists of 30 ||| 0-0 1-0 1-1 2-2
besteht aus 40 % gelöstem ||| consists of 40 % dissolved ||| 0-0 1-0 1-1 2-2 3-3 4-4
besteht aus 40 % ||| consists of 40 % ||| 0-0 1-0 1-1 2-2 3-3
besteht aus 40 ||| consists of 40 ||| 0-0 1-0 1-1 2-2
besteht aus 50 % gelöstem ||| consists of 50 % dissolved ||| 0-0 1-0 1-1 2-2 3-3 4-4
besteht aus 50 % ||| consists of 50 % ||| 0-0 1-0 1-1 2-2 3-3
besteht aus 50 ||| consists of 50 ||| 0-0 1-0 1-1 2-2
besteht aus ||| consists of ||| 0-0 1-0 1-1
besteht die Möglichkeit einer Schwangerschaft ||| be at risk of pregnancy ||| 0-0 0-1 1-1 2-2 3-3 4-4
besteht die Möglichkeit einer ||| be at risk of ||| 0-0 0-1 1-1 2-2 3-3
besteht die Möglichkeit ||| be at risk ||| 0-0 0-1 1-1 2-2
besteht die ||| be at ||| 0-0 0-1 1-1
besteht ||| with ||| 0-0
bestimmen , ||| regularly ||| 0-0
bestimmen . Sie wird ||| subcutaneous route and is ||| 0-0 0-1 1-1 2-1 0-2 3-3
bestimmen . Sie ||| subcutaneous route and ||| 0-0 0-1 1-1 2-1 0-2
bestimmen und ||| regularly and ||| 0-0 1-1
bestimmen ||| check ||| 0-0
bestimmen ||| regularly ||| 0-0
bestimmt worden . ||| been determined . ||| 1-0 0-1 2-2
bestimmt worden ||| been determined ||| 1-0 0-1
bestimmt ||| determined ||| 0-0
bestimmt ||| measured ||| 0-0
bestimmte sonstige Bestandteile von ||| some of the ingredients of ||| 0-0 1-1 2-2 1-3 2-3 3-4
bestimmte sonstige Bestandteile ||| some of the ingredients ||| 0-0 1-1 2-2 1-3 2-3
bestimmte ||| some ||| 0-0
bestätigt , in denen ||| spezifische Interaktionsstudien bestätigt , in ||| 0-0 0-1 0-2 1-3 2-4
bestätigt , in ||| spezifische Interaktionsstudien bestätigt , in ||| 0-0 0-1 0-2 1-3 2-4
bestätigt , ||| spezifische Interaktionsstudien bestätigt , ||| 0-0 0-1 0-2 1-3
bestätigt ||| spezifische Interaktionsstudien bestätigt ||| 0-0 0-1 0-2
bestätigte klinische Frakturen hatten . ||| had confirmed clinical fractures . ||| 3-0 0-1 1-2 2-3 4-4
bestätigte klinische Frakturen hatten ||| had confirmed clinical fractures ||| 3-0 0-1 1-2 2-3
bestätigte klinische Frakturen ||| confirmed clinical fractures ||| 0-0 1-1 2-2
bestätigte klinische ||| confirmed clinical ||| 0-0 1-1
bestätigte ||| confirmed ||| 0-0
bestätigtem , vor ||| to ||| 2-0
betrachten ||| considered ||| 0-0
betragen und sollte 2 ||| and should not exceed 2 ||| 1-0 2-1 0-2 0-3 3-4
betragen und sollte ||| and should not exceed ||| 1-0 2-1 0-2 0-3
betragen ||| not exceed ||| 0-0 0-1
betreffenden ||| the ||| 0-0
betroffen ||| every ||| 0-0
betroffen ||| in ||| 0-0
betrug 1,44 % für Aclasta-Patienten ||| was 1.44 % for Aclasta-treated ||| 0-0 1-1 2-2 3-3 4-4
betrug 1,44 % für ||| was 1.44 % for ||| 0-0 1-1 2-2 3-3
betrug 1,44 % ||| was 1.44 % ||| 0-0 1-1 2-2
betrug 1,44 ||| was 1.44 ||| 0-0 1-1
betrug 15 l/h/m2 ||| was 15 l/ hr/ m2 ||| 0-0 1-1 2-2 2-3 2-4
betrug 15 ||| was 15 ||| 0-0 1-1
betrug 18,7 ||| was 18.7 ||| 0-0 1-1
betrug 5,3 Monate ( 175 ||| was 5.3 months ( 175 ||| 0-0 3-1 2-2 3-3 1-4 4-4
betrug 51 % bei ||| reduction was 51 % in ||| 1-0 0-1 1-2 2-3 3-4
betrug 51 % ||| reduction was 51 % ||| 1-0 0-1 1-2 2-3
betrug 51 ||| reduction was 51 ||| 1-0 0-1 1-2
betrug 7,5 % ||| was 7.5 % ||| 0-0 1-1 2-2
betrug 7,5 ||| was 7.5 ||| 0-0 1-1
betrug 9,5 Jahre . ||| was 9.5 years . ||| 0-0 1-1 2-2 3-3
betrug 9,5 Jahre ||| was 9.5 years ||| 0-0 1-1 2-2
betrug 9,5 ||| was 9.5 ||| 0-0 1-1
betrug die Inzidenz von Akathisie ||| , the incidence of akathisia ||| 0-0 1-1 0-2 2-2 3-3 4-4
betrug die Inzidenz von Akathisie ||| , the incidence of akathisia ||| 1-1 0-2 1-2 2-2 3-3 4-4
betrug die Inzidenz von Akathisie ||| the incidence of akathisia was ||| 1-0 0-1 1-1 2-1 3-2 4-3 4-4
betrug die Inzidenz von Akathisie ||| the incidence of akathisia ||| 1-0 0-1 1-1 2-1 3-2 4-3
betrug die Inzidenz von ||| , the incidence of ||| 0-0 1-1 0-2 2-2 3-3
betrug die Inzidenz von ||| , the incidence of ||| 1-1 0-2 1-2 2-2 3-3
betrug die Inzidenz von ||| , the incidence of ||| 1-1 0-2 2-2 3-3
betrug die Inzidenz von ||| the incidence of ||| 1-0 0-1 1-1 2-1 3-2
betrug die Inzidenz von ||| the incidence of ||| 1-0 0-1 2-1 3-2
betrug die Inzidenz ||| , the incidence ||| 0-0 1-1 0-2 2-2
betrug die Inzidenz ||| , the incidence ||| 1-1 0-2 1-2 2-2
betrug die Inzidenz ||| , the incidence ||| 1-1 0-2 2-2
betrug die Inzidenz ||| the incidence ||| 1-0 0-1 1-1 2-1
betrug die Inzidenz ||| the incidence ||| 1-0 0-1 2-1
betrug die mittlere Gewichtszunahme 1,3 ||| of 2.8 ||| 1-0 0-1 2-1 3-1 4-1
betrug die mittlere Gewichtszunahme ||| mean weight increase with ||| 0-0 2-0 3-1 1-2 3-2
betrug die mittlere Gewichtszunahme ||| mean weight increase ||| 0-0 2-0 3-1 1-2 3-2
betrug ||| was ||| 0-0
betrugen 2-5 % . ||| were 2 5 % . ||| 0-0 1-1 1-2 2-3 3-4
betrugen 2-5 % ||| were 2 5 % ||| 0-0 1-1 1-2 2-3
betrugen 2-5 ||| were 2 5 ||| 0-0 1-1 1-2
betrugen jeweils 39,5 % ( ||| were 39.5 % ( ||| 0-0 1-1 2-1 3-2 4-3
betrugen jeweils 39,5 % ||| were 39.5 % ||| 0-0 1-1 2-1 3-2
betrugen jeweils 39,5 ||| were 39.5 ||| 0-0 1-1 2-1
betrugen ||| were ||| 0-0
beträgt 0,25 l/kg . ||| is 0.25 l/ kg . ||| 0-0 0-1 1-1 2-2 2-3 3-4
beträgt 0,25 l/kg ||| is 0.25 l/ kg ||| 0-0 0-1 1-1 2-2 2-3
beträgt 0,25 ||| is 0.25 ||| 0-0 0-1 1-1
beträgt 10 oder 15 ||| is 10 or 15 ||| 0-0 1-1 2-2 0-3 3-3
beträgt 10 oder 15 ||| is 10 or 15 ||| 0-0 1-1 2-2 3-3
beträgt 10 oder ||| is 10 or ||| 0-0 1-1 2-2
beträgt 10 ||| is 10 ||| 0-0 1-1
beträgt 15 mg oder 30 ||| is 15 mg or 30 ||| 0-0 1-1 2-2 3-3 4-4
beträgt 15 mg oder ||| is 15 mg or ||| 0-0 1-1 2-2 3-3
beträgt 15 mg ||| is 15 mg ||| 0-0 0-1 1-1 2-2
beträgt 15 mg ||| is 15 mg ||| 0-0 1-1 2-2
beträgt 15 ||| is 15 ||| 0-0 0-1 1-1
beträgt 15 ||| is 15 ||| 0-0 1-1
beträgt 150 I.E./kg ||| is 150 IU/ kg ||| 0-0 1-1 2-2 2-3
beträgt 150 ||| is 150 ||| 0-0 1-1
beträgt 260 ||| is 260 ||| 0-0 1-1
beträgt 32.000 bis 40.000 Dalton ||| is 32,000 to 40,000 dalton ||| 0-0 0-1 1-1 2-1 2-2 3-3 4-4
beträgt 32.000 bis 40.000 ||| is 32,000 to 40,000 ||| 0-0 0-1 1-1 2-1 2-2 3-3
beträgt 32.000 bis ||| is 32,000 to ||| 0-0 0-1 1-1 2-1 2-2
beträgt 9,75 mg ( 1,3 ||| is 9.75 mg ( 1.3 ||| 0-0 1-1 2-2 3-3 4-4
beträgt 9,75 mg ( ||| is 9.75 mg ( ||| 0-0 1-1 2-2 3-3
beträgt 9,75 mg ||| is 9.75 mg ||| 0-0 1-1 2-2
beträgt 9,75 ||| is 9.75 ||| 0-0 1-1
beträgt beim Menschen 5-6 ||| in man is 5 ||| 1-0 1-1 2-1 3-1 0-2 3-3
beträgt die empfohlene Anfangsdosis zum ||| the recommended starting dose is ||| 1-0 2-1 0-2 3-2 3-3 0-4
beträgt die empfohlene Anfangsdosis ||| the recommended starting dose is ||| 1-0 2-1 0-2 3-2 3-3 0-4
beträgt zwischen ||| is between ||| 0-0 1-1
beträgt ||| is ||| 0-0
beurteilt . ||| . ||| 0-0 1-0
beurteilt ||| assessed ||| 0-0
bevor Sie ABILIFY anwenden . ||| before taking ABILIFY . ||| 0-0 0-1 1-1 3-1 2-2 4-3
bevor Sie ABILIFY anwenden ||| before taking ABILIFY ||| 0-0 0-1 1-1 3-1 2-2
bevor Sie ABILIFY einnehmen . ||| before taking ABILIFY . ||| 0-0 1-1 3-1 2-2 4-3
bevor Sie ABILIFY einnehmen ||| before taking ABILIFY ||| 0-0 1-1 3-1 2-2
bevor Sie dieses Arzneimittel einnehmen ||| before taking this medicine ||| 0-0 1-1 4-1 2-2 3-3
bevor Sie ||| before you ||| 0-0 1-1
bevor die Behandlung mit Abseamed ||| before the Abseamed treatment ||| 0-0 1-1 4-2 2-3 3-3
bevor die Behandlung mit Abseamed ||| starting before the Abseamed treatment ||| 0-1 1-2 4-3 2-4 3-4
bevor die ||| before the ||| 0-0 1-1
bevor die ||| starting before the ||| 0-1 1-2
bevor mit der Anwendung ||| before you are ||| 0-0 0-1 1-1 3-2
bevor mit der ||| before you ||| 0-0 0-1 1-1
bevor mit ||| before you ||| 0-0 0-1 1-1
bevor ||| before ||| 0-0
bevor ||| starting before ||| 0-1
bevorzugen . ||| preferable . ||| 0-0 1-1
bevorzugen ||| preferable ||| 0-0
bewertet : ||| follows : ||| 0-0 1-1
bewertet ||| follows ||| 0-0
bewirken ||| cause ||| 0-0
beziehen ||| relate ||| 0-0
bezieht sich auf den letzten ||| refers to the last ||| 0-0 1-0 2-1 3-2 4-3
bezieht sich auf den ||| refers to the ||| 0-0 1-0 2-1 3-2
bezieht sich auf ||| refers to ||| 0-0 1-0 2-1
bezieht sich ||| refers ||| 0-0 1-0
bilaterale Orchiektomie ( operative Hodenentfernung ||| bilateral orchiectomy ( surgical castration ||| 0-0 1-0 3-1 2-2 4-3 4-4
bilaterale Orchiektomie ( operative ||| bilateral orchiectomy ( ||| 0-0 1-0 3-1 2-2
bilaterale Orchiektomie ||| bilateral ||| 0-0 1-0
biliäre Exkretion eliminiert. itte ||| Exkretion eliminiert. itte Only dic ||| 0-0 0-1 1-1 1-2 2-2 2-3 3-4
biliäre Exkretion eliminiert. ||| Exkretion eliminiert. itte Only ||| 0-0 0-1 1-1 1-2 2-2 2-3
binden ||| bind ||| 0-0
bindet an ||| attaches to ||| 0-0 1-1
bindet ||| attaches ||| 0-0
biochemischen Markern , ||| biochemical marker ||| 0-0 1-1
biochemischen Markern ||| biochemical marker ||| 0-0 1-1
biochemischen ||| biochemical ||| 0-0
biologische Wirksamkeit von Epoetin alfa ||| biological efficacy of epoetin alfa ||| 0-0 1-1 2-2 3-3 4-4
biologische Wirksamkeit von Epoetin ||| biological efficacy of epoetin ||| 0-0 1-1 2-2 3-3
biologische Wirksamkeit von ||| biological efficacy of ||| 0-0 1-1 2-2
biologische Wirksamkeit ||| biological efficacy ||| 0-0 1-1
biologische ||| biological ||| 0-0
biphasisches ||| , ||| 0-0
bipolaren Patienten 12,1 % ||| bipolar patients was 12.1 % ||| 0-0 1-1 2-2 2-3 3-4
bipolaren Patienten 12,1 ||| bipolar patients was 12.1 ||| 0-0 1-1 2-2 2-3
bipolaren Patienten ||| bipolar patients ||| 0-0 1-1
bipolaren Störung wurden ||| bipolar disorder , there were ||| 0-0 1-1 2-2 2-3 2-4
bipolaren Störung ||| bipolar disorder ||| 0-0 1-1
bipolaren ||| bipolar ||| 0-0
bipolarer Manie ||| bipolar mania ||| 0-0 1-1
bipolarer Störung , ||| bipolar disorder ||| 0-0 1-1
bipolarer Störung ||| bipolar disorder ||| 0-0 1-1
bipolarer Störung ||| bipolarer Störung ||| 0-0 1-1
bipolarer ||| bipolar ||| 0-0
bipolarer ||| bipolarer ||| 0-0
bis 10 von ||| 10 ||| 0-0 1-0
bis 10 von ||| and 10 ||| 0-1 1-1
bis 10 ||| 10 ||| 0-0 1-0
bis 10 ||| and 10 ||| 0-1 1-1
bis 12 g/dl ( ||| to 12 g/ dl ( ||| 0-0 1-1 2-2 2-3 3-4
bis 12 g/dl ||| to 12 g/ dl ||| 0-0 1-1 2-2 2-3
bis 12 ||| to 12 ||| 0-0 1-1
bis 125 ||| to 125,000 ||| 0-0 1-0 0-1
bis 143 ||| to 143 ||| 0-0 1-1
bis 3 Stunden nach Anwendung ||| 3 hours after dosing ||| 1-0 0-1 2-1 3-2 3-3 4-3
bis 3 Stunden ||| 3 hours ||| 1-0 0-1 2-1
bis 300 mg/m2 ||| to 300 mg/ m2 ||| 0-0 1-1 2-2 2-3
bis 300 ||| to 300 ||| 0-0 1-1
bis 36 Monate gehalten . ||| at 36 months . ||| 3-0 1-1 3-1 0-2 2-2 4-3
bis 36 Monate gehalten ||| at 36 months ||| 3-0 1-1 3-1 0-2 2-2
bis 375 ||| to 375 ||| 0-0 1-1
bis 6 Wochen ) ||| to 6 weeks ) ||| 0-0 1-1 0-2 2-2 3-3
bis 6 Wochen ) ||| to 6 weeks ) ||| 0-0 1-1 2-2 3-3
bis 6 Wochen ||| to 6 weeks ||| 0-0 1-1 0-2 2-2
bis 6 Wochen ||| to 6 weeks ||| 0-0 1-1 2-2
bis 6 ||| to 6 ||| 0-0 1-1
bis IV ) ||| to IV ) ||| 0-0 1-1 2-2
bis IV ||| to IV ||| 0-0 1-1
bis ca. 20 ||| proportional up to about 20 ||| 0-0 0-1 0-2 1-3 2-4
bis ca. ||| proportional up to about ||| 0-0 0-1 0-2 1-3
bis die ||| of Abraxane until ||| 1-0 0-2
bis er ||| until it ||| 0-0 1-1
bis gelb . ||| to yellow . ||| 0-0 0-1 1-1 2-2
bis gelb ||| to yellow ||| 0-0 0-1 1-1
bis hellgelbe Flüssigkeit ||| to light yellow liquid . ||| 0-0 1-1 0-2 1-2 1-3 2-3 2-4
bis hellgelbe Flüssigkeit ||| to light yellow liquid ||| 0-0 1-1 0-2 1-2 1-3 2-3
bis jahrelanger Behandlung mit ||| to years of treatment with ||| 0-0 0-1 1-1 1-2 2-3 3-4
bis jahrelanger Behandlung ||| to years of treatment ||| 0-0 0-1 1-1 1-2 2-3
bis jahrelanger ||| to years of ||| 0-0 0-1 1-1 1-2
bis leicht gelbe Lösung . ||| to slightly yellow solution . ||| 0-0 1-1 2-1 0-2 2-2 3-3 4-4
bis leicht gelbe Lösung ||| to slightly yellow solution ||| 0-0 1-1 2-1 0-2 2-2 3-3
bis leicht gelbe ||| to slightly yellow ||| 0-0 1-1 2-1 0-2 2-2
bis mäßiger ||| less severe ||| 0-1 1-1
bis mäßiger ||| severe ||| 0-0 1-0
bis sich der ||| until ||| 0-0 1-0 2-0
bis sich die Neutrophilenzahl auf ||| until neutrophil counts recover to ||| 0-0 1-0 3-1 2-2 3-2 3-3 4-3 4-4
bis sich ||| until ||| 0-0 1-0
bis vor kurzem eingenommen haben ||| have recently taken any other ||| 4-0 1-1 2-1 3-2 2-3 2-4
bis vor kurzem eingenommen ||| recently taken any other ||| 1-0 2-0 3-1 2-2 2-3
bis weißlich ||| to off-white ||| 0-0 0-1 1-1
bis zu 10 % , ||| up to 10 % , ||| 0-0 1-0 1-1 2-2 3-3 4-4
bis zu 10 % ||| up to 10 % ||| 0-0 1-0 1-1 2-2 3-3
bis zu 10 ||| up to 10 ||| 0-0 1-0 1-1 2-2
bis zu 2 Jahren untersucht. ||| 2 years ||| 2-0 0-1 3-1 4-1
bis zu 3,5 ||| added to ||| 1-0 2-0 0-1 1-1
bis zu 36 ||| up to 36 ||| 0-0 1-0 1-1 2-2
bis zu 48 kg für ||| up to 48 kg for ||| 0-0 1-0 1-1 2-2 3-3 4-4
bis zu 48 kg ||| up to 48 kg ||| 0-0 1-0 1-1 2-2 3-3
bis zu 48 ||| up to 48 ||| 0-0 1-0 1-1 2-2
bis zu fünf Jahren untersucht ||| up to five years ||| 0-0 1-0 1-1 2-2 3-3 4-3
bis zu fünf ||| up to five ||| 0-0 1-0 1-1 2-2
bis zu zwölf Wochen an ||| for up to 12 weeks ||| 0-0 0-1 1-1 1-2 2-3 3-4 4-4
bis zu zwölf ||| for up to 12 ||| 0-0 0-1 1-1 1-2 2-3
bis zu ||| for up to ||| 0-0 0-1 1-1 1-2
bis zu ||| thereafter ||| 0-0
bis zu ||| to ||| 0-0 1-0
bis zu ||| up to ||| 0-0 1-0 0-1
bis zu ||| up to ||| 0-0 1-0 1-1
bis zum 3-fachen ||| to 3 X ||| 0-0 1-0 2-1 2-2
bis zum ||| to ||| 0-0 1-0
bis zur Krankheitsprogression [ 95 ||| to disease progression [ 95 ||| 0-0 1-0 2-1 2-2 3-3 4-4
bis zur Krankheitsprogression [ ||| to disease progression [ ||| 0-0 1-0 2-1 2-2 3-3
bis zur Krankheitsprogression ||| to disease progression ||| 0-0 1-0 2-1 2-2
bis zur ||| to ||| 0-0 1-0
bis ||| Abraxane until ||| 0-1
bis ||| proportional up to ||| 0-0 0-1 0-2
bis ||| thereafter ||| 0-0
bis ||| to ||| 0-0
bis ||| until ||| 0-0
bis ||| up to ||| 0-0
bis ||| up ||| 0-0
bisher nicht ||| not ||| 0-0 1-0
bitte Ihren Arzt ||| tell your doctor ||| 0-0 1-1 1-2 2-2
bitte die wissenschaftliche Diskussion ( ||| the Scientific Discussion ( ||| 1-0 0-1 1-1 2-1 2-2 3-2 4-3
bitte die wissenschaftliche Diskussion ||| the Scientific Discussion ||| 1-0 0-1 1-1 2-1 2-2 3-2
bitte ||| please ||| 0-0
bitte ||| tell ||| 0-0
blasse Schleimhäute . ||| pale mucosae . ||| 0-0 1-1 2-2
blasse Schleimhäute ||| pale mucosae ||| 0-0 1-1
blasse ||| pale ||| 0-0
blau , mit Prägung von ||| blue , marked with ||| 0-0 1-1 3-2 2-3 4-3
blau , mit der Prägung ||| blue , engraved with ||| 0-0 1-1 3-2 4-2 2-3
blau , ||| blue , ||| 0-0 1-1
blau ||| blue ||| 0-0
bleiben gleich ||| remain the ||| 0-0 1-0 0-1
bleiben ||| remain ||| 0-0
bleibt somit unverändert . ||| concentration is unchanged . ||| 0-0 0-1 0-2 1-2 2-2 3-3
bleibt somit unverändert ||| concentration is unchanged ||| 0-0 0-1 0-2 1-2 2-2
bleibt ||| is ||| 0-0
blockiert die Fähigkeit von ||| blocks the ability of ||| 0-0 1-1 1-2 2-2 3-3
blockiert die Fähigkeit ||| blocks the ability ||| 0-0 1-1 1-2 2-2
blockiert ||| blocks ||| 0-0
blutdrucksenkenden Arzneimitteln ||| hypovolemia ||| 0-0 1-0
blutzuckersenkende Arzneimittel Thiazolidindione ||| glucose lowering drugs ; Thiazolidinediones ||| 0-0 0-1 0-2 1-2 2-3 2-4
blutzuckersenkende Arzneimittel ||| glucose lowering drugs ||| 0-0 0-1 0-2 1-2
brauchen . ||| . ||| 1-0
braucht . ||| need . ||| 0-0 1-1
braucht ||| need ||| 0-0
brechen . ||| break . ||| 0-0 1-1
brechen ||| break ||| 0-0
bzw. 34 % ermittelt ||| and 34 % , respectively ||| 0-0 1-1 2-2 3-2 0-4
bzw. des Insulins ||| insulin ||| 0-0 1-0 2-0
bzw. intraindividuelle Variation ||| and intra-subject variation for ||| 0-0 1-1 2-1 2-2
bzw. intraindividuelle Variation ||| and intra-subject variation ||| 0-0 1-1 2-1 2-2
bzw. senkt die Plasmakonzentration ||| respectively , the plasma concentration ||| 0-0 1-0 2-2 3-3 3-4
bzw. senkt die ||| , respectively , the ||| 0-1 1-1 2-3
bzw. senkt die ||| respectively , the ||| 0-0 1-0 2-2
bzw. senkt ||| , respectively , ||| 0-1 1-1
bzw. senkt ||| , respectively ||| 0-1 1-1
bzw. senkt ||| respectively , ||| 0-0 1-0
bzw. senkt ||| respectively ||| 0-0 1-0
bzw. verzögerter Resorption handelt . ||| and protracted absorption respectively . ||| 0-0 0-1 1-1 3-1 2-2 1-3 4-4
bzw. verzögerter Resorption handelt ||| and protracted absorption respectively ||| 0-0 0-1 1-1 3-1 2-2 1-3
bzw. zuckerhaltigen Lebensmitteln behandelt werden ||| or sugary products ||| 2-0 0-1 1-1 2-1 3-1 2-2 4-2
bzw. ||| , respectively ||| 0-1
bzw. ||| and ||| 0-0
bzw. ||| insulin . ||| 0-0 0-1
bzw. ||| or ||| 0-0
bzw. ||| respectively ||| 0-0
ca . 16 ||| ca . 16 ||| 0-0 1-1 2-2
ca . 43 55 % ||| approximately 43-55 % ||| 4-0 0-1 3-1 2-2 4-2
ca . 43-55 % gebunden ||| approximately 43-55 % bound ||| 3-0 0-1 2-1 3-2 4-3
ca . 43-55 % ||| approximately 43-55 % ||| 3-0 0-1 2-1 3-2
ca . 43-55 ||| 43-55 ||| 0-0 2-0
ca . ||| ca . Me ||| 0-0 1-1 0-2
ca . ||| ca . ||| 0-0 1-1
ca ||| ca ||| 0-0
ca. 1 % der ||| approximately 1 % ||| 0-0 1-1 2-2
ca. 1 % ||| approximately 1 % ||| 0-0 1-1 2-2
ca. 1 ||| approximately 1 ||| 0-0 1-1
ca. 18 % ||| approximately 18 % ||| 0-0 1-1 2-2
ca. 18 ||| approximately 18 ||| 0-0 1-1
ca. 20 mg nahezu dosisproportional ||| about 20 mg ||| 0-0 1-1 2-2 3-2 4-2
ca. 20 ||| about 20 ||| 0-0 1-1
ca. 25 ||| approximately 25 ||| 0-0 1-1
ca. 27 % der ||| approximately 27 % of the ||| 0-0 1-1 2-2 3-3 3-4
ca. 27 % ||| approximately 27 % ||| 0-0 1-1 2-2
ca. 27 ||| approximately 27 ||| 0-0 1-1
ca. 40 % ||| about 40 % ||| 0-0 1-1 2-2
ca. 40 ||| about 40 ||| 0-0 1-1
ca. 425 mg Natrium pro ||| approximately 425 mg sodium per ||| 0-0 1-1 2-2 3-3 4-4
ca. 425 mg Natrium ||| approximately 425 mg sodium ||| 0-0 1-1 2-2 3-3
ca. 425 mg ||| approximately 425 mg ||| 0-0 1-1 2-2
ca. 425 ||| approximately 425 ||| 0-0 1-1
ca. 45 % der ||| approximately 45 % of the ||| 0-0 1-1 2-2 3-3 3-4
ca. 45 % ||| approximately 45 % ||| 0-0 1-1 2-2
ca. 45 ||| approximately 45 ||| 0-0 1-1
ca. 5 l/kg . ||| approximately 5 l/ kg . ||| 0-0 1-1 2-2 2-3 3-4
ca. 5 l/kg ||| approximately 5 l/ kg ||| 0-0 1-1 2-2 2-3
ca. 5 ||| approximately 5 ||| 0-0 1-1
ca. 6 Wochen nach ||| approximately six weeks after ||| 0-0 1-1 2-2 3-3
ca. 6 Wochen ||| approximately six weeks ||| 0-0 1-1 2-2
ca. 6 ||| approximately six ||| 0-0 1-1
ca. 86 % ||| approximately 86 % ||| 0-0 1-1 2-2
ca. 86 ||| approximately 86 ||| 0-0 1-1
ca. 90 % ||| about 90 % ||| 0-0 1-1 2-2
ca. 90 ||| about 90 ||| 0-0 1-1
ca. ||| about ||| 0-0
ca. ||| approximately ||| 0-0
caudatus ||| by positron ||| 0-0 0-1
cerevisiae ) . ||| cerevisiae ) . ||| 0-0 1-1 2-2
cerevisiae ) ||| cerevisiae ) ||| 0-0 1-1
cerevisiae ||| cerevisiae ||| 0-0
charakteristischen Kennzeichens ||| known marker ||| 0-0 0-1 1-1
chemotherapiebedingter Anämie ||| chemotherapy induced anaemia ||| 0-0 0-1 1-2
chemotherapiebedingter ||| chemotherapy induced ||| 0-0 0-1
chinesischen Hamsters . ||| induce ||| 0-0 1-0
chinesischen Hamsters ||| induce ||| 0-0 1-0
chirurgische Patienten in ||| surgery patients in ||| 0-0 1-1 2-2
chirurgische Patienten ||| surgery patients ||| 0-0 1-1
chirurgische ||| surgery ||| 0-0
chronischer Leberfunktionseinschränkung leiden . ||| chronic liver disease . ||| 0-0 1-1 2-2 3-3
chronischer Leberfunktionseinschränkung leiden ||| chronic liver disease ||| 0-0 1-1 2-2
chronischer Leberfunktionseinschränkung ||| chronic liver ||| 0-0 1-1
chronischer Niereninsuffizienz bei Kindern ||| chronic renal failure in paediatric ||| 0-0 1-1 1-2 2-3 3-4
chronischer Niereninsuffizienz bei ||| chronic renal failure in ||| 0-0 1-1 1-2 2-3
chronischer Niereninsuffizienz und klinisch ||| chronic renal failure and clinically ||| 0-0 1-1 0-2 1-2 2-3 3-4
chronischer Niereninsuffizienz und ||| chronic renal failure and ||| 0-0 1-1 0-2 1-2 2-3
chronischer Niereninsuffizienz ||| chronic renal failure , ||| 0-0 1-1 0-2 1-2
chronischer Niereninsuffizienz ||| chronic renal failure ||| 0-0 1-1 0-2
chronischer Niereninsuffizienz ||| chronic renal failure ||| 0-0 1-1 0-2 1-2
chronischer Niereninsuffizienz ||| chronic renal failure ||| 0-0 1-1 1-2
chronischer Nierenschwäche ( Niereninsuffizienz ||| chronic kidney failure ( renal ||| 0-0 1-1 0-2 2-3 3-4
chronischer Nierenschwäche ( ||| chronic kidney failure ( ||| 0-0 1-1 0-2 2-3
chronischer Nierenschwäche ||| chronic kidney failure ||| 0-0 1-1 0-2
chronischer ||| chronic ||| 0-0
commercial purposes only ||| be maintained during ||| 0-1 1-1 2-1
commercial purposes only ||| be maintained ||| 0-1 1-1 2-1
commercial purposes only ||| maintained during ||| 0-0 1-0 2-0
commercial purposes only ||| maintained ||| 0-0 1-0 2-0
d.h . ||| i. e. ||| 0-0 0-1 1-1
d.h. es ist nahezu natriumfrei ||| i. e. essentially sodium- free ||| 0-0 0-1 1-2 2-2 3-2 3-3 4-3 4-4
d.h. ||| i. e. ||| 0-0 0-1
d.o.o. Tel : +386 ||| o. o Tel : +386 ||| 0-0 0-1 1-2 2-3 3-4
d.o.o. Tel : ||| o. o Tel : ||| 0-0 0-1 1-2 2-3
d.o.o. Tel ||| o. o Tel ||| 0-0 0-1 1-2
d.o.o. ||| o. o ||| 0-0 0-1
da Osteoporose die ||| because osteoporosis ||| 0-0 1-1
da Osteoporose ||| because osteoporosis ||| 0-0 1-1
da die Bioverfügbarkeit ||| since bioavailability ||| 0-0 2-1
da die ||| since ||| 0-0
da es das ||| the ||| 2-0
da ||| as ||| 0-0
da ||| because ||| 0-0
da ||| not acceptable ||| 0-0
da ||| not ||| 0-0
da ||| since ||| 0-0
dafür , dass ||| sure ||| 2-0
dafür ausgelegt ||| powered ||| 0-0 1-0
daher das Arzneimittel mit der ||| the product with the ||| 1-0 0-1 1-1 2-1 3-2 4-3
daher das Arzneimittel mit ||| the product with ||| 1-0 0-1 1-1 2-1 3-2
daher das Arzneimittel ||| the product ||| 1-0 0-1 1-1 2-1
daher eher ein Maß der ||| therefore a measure of the ||| 0-0 2-1 1-2 2-2 3-2 4-3 4-4
daher eher ein Maß ||| therefore a measure ||| 0-0 2-1 1-2 2-2 3-2
daher empfohlen , ||| recommended , therefore ||| 1-0 2-1 0-2
daher intravenös gegeben werden ||| has to be administered intravenously ||| 0-0 1-1 3-2 2-3 1-4 3-4
daher verringert , was zu ||| therefore reduced , coupled ||| 0-0 1-1 2-2 1-3 3-3 4-3
daher wird die Anwendung ||| and therefore its use is ||| 0-0 0-1 2-2 2-3 3-3 1-4
daher ||| Therefore ||| 0-0
daher ||| and therefore ||| 0-0 0-1
daher ||| has ||| 0-0
daher ||| therefore , ||| 0-0
daher ||| therefore ||| 0-0
danach fühlen , ||| feelings ||| 0-0 1-0
danach fühlen sich etwas anzutun ||| feelings about hurting yourself ||| 0-0 1-0 4-1 2-2 3-2 4-2 4-3
danach fühlen ||| feelings ||| 0-0 1-0
daran denken oder sich ||| are having any thoughts or ||| 0-0 0-1 1-1 1-2 1-3 3-3 2-4
daran denken ||| are having any ||| 0-0 0-1 1-1 1-2
darauf hin , dass ||| , suggesting that ||| 2-0 0-1 1-1 3-2
darauf hin , ||| , suggesting ||| 2-0 0-1 1-1
darauf hin ||| suggesting ||| 0-0 1-0
darf 30 mg nicht überschreiten ||| should not exceed 30 mg ||| 0-0 0-1 3-1 4-2 1-3 2-4
darf Abseamed nicht ||| Abseamed has not ||| 1-0 1-1 0-2 2-2
darf Aclasta ||| Aclasta must ||| 1-0 0-1
darf Pioglitazon nicht ||| pioglitazone should not ||| 1-0 0-1 0-2 2-2
darf außerdem nicht ||| should also not be ||| 0-0 1-1 0-2 2-2 0-3
darf bei Patienten mit ||| darf bei Patienten mit ||| 0-0 1-1 2-2 3-3
darf bei Patienten ||| darf bei Patienten ||| 0-0 1-1 2-2
darf bei ||| darf bei ||| 0-0 1-1
darf bei ||| should not be used in ||| 0-0 0-1 0-2 1-3 1-4
darf das Arzneimittel ausschließlich ||| the medicinal product has ||| 1-0 0-1 2-1 1-2 2-2 3-3
darf das Arzneimittel ||| the medicinal product ||| 1-0 0-1 2-1 1-2 2-2
darf dieses Arzneimittel nicht ||| this medicinal product must not ||| 1-0 0-1 1-1 2-2 0-3 3-4
darf dieses Arzneimittel ||| , this medicinal product should ||| 1-1 0-2 1-2 2-3 0-4
darf dieses Arzneimittel ||| , this medicinal product should ||| 1-1 0-2 2-2 2-3 0-4
darf dieses Arzneimittel ||| this medicinal product must ||| 1-0 0-1 1-1 2-2 0-3
darf dieses Arzneimittel ||| this medicinal product should ||| 1-0 0-1 1-1 2-2 0-3
darf dieses Arzneimittel ||| this medicinal product should ||| 1-0 0-1 2-1 2-2 0-3
darf nicht angewendet ||| Do not use ||| 0-0 0-1 1-1 1-2
darf nicht bei ||| should not be used in ||| 0-0 0-1 1-1 0-2 2-3 2-4
darf nicht eingenommen ||| Do not take ||| 0-0 0-1 1-1 2-2
darf nicht weniger als ||| must not be less than ||| 0-0 1-1 0-2 2-3 3-4
darf nicht weniger ||| must not be less ||| 0-0 1-1 0-2 2-3
darf nicht ||| Do not use ||| 0-0 0-1 1-1 1-2
darf nicht ||| Do not ||| 0-0 0-1 1-1
darf nicht ||| must not be ||| 0-0 1-1 0-2
darf nicht ||| should not be ||| 0-0 0-1 1-1 0-2
darf nicht ||| should not ||| 0-0 0-1 1-1
darf nur ||| Only solutions ||| 1-0 0-1
darf verwendet werden . ||| should be used . ||| 0-0 2-1 1-2 3-3
darf verwendet werden ||| should be used ||| 0-0 2-1 1-2
darf weder ||| should not ||| 0-0 0-1 1-1
darf ||| darf ||| 0-0
darf ||| must ||| 0-0
darf ||| should not be ||| 0-0 0-1 0-2
darf ||| should ||| 0-0
darf ||| solutions ||| 0-0
darüber ) Aclasta ||| ) Aclasta ||| 1-0 2-1
darüber ) ||| ) ||| 1-0
darüber . ||| concern . ||| 0-0 1-1
darüber ||| concern ||| 0-0
das Absetzen von ||| may require discontinuation of ||| 1-0 0-1 1-1 1-2 2-3
das Absetzen ||| may require discontinuation ||| 1-0 0-1 1-1 1-2
das Anhalten ||| the ||| 0-0 1-0
das Arzneimittel daher ||| the medicinal product has ||| 0-0 1-1 0-2 1-2 2-3
das Arzneimittel gewünscht werden , ||| about this medicinal product , ||| 0-0 2-0 2-1 1-2 3-2 1-3 4-4
das Arzneimittel gewünscht werden , ||| about this medicine , ||| 0-0 2-0 2-1 1-2 2-2 3-2 4-3
das Arzneimittel gewünscht werden ||| about this medicinal product ||| 0-0 2-0 2-1 1-2 3-2 1-3
das Arzneimittel gewünscht werden ||| about this medicine ||| 0-0 2-0 2-1 1-2 2-2 3-2
das Arzneimittel ||| the medicinal product ||| 0-0 1-1 0-2 1-2
das Arzneimittel ||| the product should ||| 0-0 0-1 1-1 1-2
das Arzneimittel ||| to ||| 0-0 1-0
das Bedienen von Maschinen Aclasta ||| using machines Aclasta ||| 0-0 1-0 1-1 2-1 3-1 4-2
das Bedienen von Maschinen beobachtet ||| use machines have been observed ||| 0-0 1-0 1-1 3-1 1-2 2-2 4-3 4-4
das Bedienen von Maschinen durchgeführt ||| use machines have been performed ||| 0-0 1-0 1-1 3-1 2-2 4-2 4-3 4-4
das Bedienen von Maschinen ||| or use machines have ||| 0-1 1-1 1-2 3-2 1-3 2-3
das Bedienen von Maschinen ||| use machines have ||| 0-0 1-0 1-1 3-1 1-2 2-2
das Bedienen von Maschinen ||| using machines ||| 0-0 1-0 1-1 2-1 3-1
das Beibehalten der erreichten Gewichtsreduktion ||| in maintaining weight loss ||| 2-0 1-1 2-1 3-1 0-2 4-2 4-3
das Blut ||| blood ||| 1-0
das Etikett vorzuzeigen ||| the label to the physician ||| 0-0 1-1 0-2 0-3 2-4
das Etikett ||| the label to the ||| 0-0 1-1 0-2 0-3
das Gesamtüberleben ||| overall survival ||| 0-0 1-0 1-1
das Gewicht engmaschig zu kontrollieren ||| weight should be closely monitored ||| 0-0 1-0 2-1 2-2 3-2 2-3 2-4 4-4
das Gewicht ||| weight ||| 0-0 1-0
das Körpergewicht war ||| body weight appeared ||| 1-0 0-1 1-1 2-1 1-2
das N-terminale Propeptid ||| N-terminal ||| 1-0 2-0
das Pflegepersonal , wenn Sie ||| nurse if you are ||| 0-0 1-0 3-1 4-2 2-3 3-3
das Pflegepersonal . ||| nurse . ||| 0-0 1-0 2-1
das Pflegepersonal geben . ||| nurse . ||| 0-0 1-0 2-0 3-1
das Pflegepersonal geben ||| nurse ||| 0-0 1-0 2-0
das Pflegepersonal wissen , wie ||| nurse knows how to ||| 0-0 1-0 2-1 2-2 4-2
das Pflegepersonal wissen , wie ||| nurse knows how ||| 0-0 1-0 2-1 2-2 4-2
das Pflegepersonal ||| nurse ||| 0-0 1-0
das Prostata-Karzinom ||| androgen independent , ||| 1-0 1-1
das Prostata-Karzinom ||| androgen independent ||| 1-0 1-1
das Pulver ||| the powder ||| 0-0 1-1
das Risiko der erneuten Gewichtszunahme ||| the risk of weight regain ||| 0-0 0-1 1-1 2-2 4-3 3-4 4-4
das Risiko der ||| the risk of ||| 0-0 0-1 1-1 2-2
das Risiko des Fortschreitens ||| the risk of progression of ||| 0-0 0-1 1-1 2-2 2-3 3-3 3-4
das Risiko des Fortschreitens ||| the risk of progression of ||| 0-0 0-1 1-1 2-2 3-3 3-4
das Risiko des ||| the risk of ||| 0-0 0-1 1-1 2-2
das Risiko eines Ödems erhöhen ||| increase the risk of oedema ||| 4-0 0-1 0-2 1-2 2-3 2-4 3-4 4-4
das Risiko für ||| reduces the risk ||| 0-0 0-1 0-2 1-2 2-2
das Risiko von Missbildungen und ||| the risk of malformations and ||| 0-0 0-1 1-1 2-2 3-3 4-4
das Risiko von Missbildungen ||| the risk of malformations ||| 0-0 0-1 1-1 2-2 3-3
das Risiko von ||| , the risk of spine ||| 0-1 0-2 1-2 2-3
das Risiko von ||| , the risk of ||| 0-1 0-2 1-2 2-3
das Risiko von ||| risk ||| 1-0
das Risiko von ||| the risk of spine ||| 0-0 0-1 1-1 2-2
das Risiko von ||| the risk of ||| 0-0 0-1 1-1 2-2
das Risiko ||| , the risk ||| 0-1 0-2 1-2
das Risiko ||| risk ||| 0-0 1-0
das Risiko ||| risk ||| 1-0
das Risiko ||| the risk ||| 0-0 0-1 1-1
das Tierarzneimittel ||| the product ||| 0-0 0-1 1-1
das Unterbrechen der ||| discontinuation of treatment ||| 0-0 1-0 2-1 1-2 2-2
das Verteilungsvolumen liegt bei ||| the volume of distribution is ||| 0-0 0-1 1-1 3-1 1-2 1-3 2-4
das Verteilungsvolumen nimmt zu ||| an increased volume of distribution ||| 1-0 2-1 0-2 1-2 2-3 3-3 2-4
das als Mitose-stimulierender Faktor und ||| as a mitosis-stimulating factor and ||| 1-0 2-1 0-2 2-2 3-3 4-4
das als Mitose-stimulierender Faktor ||| as a mitosis-stimulating factor ||| 1-0 2-1 0-2 2-2 3-3
das als Mitose-stimulierender ||| as a mitosis-stimulating ||| 1-0 2-1 0-2 2-2
das als ||| events the ||| 1-0 0-1
das im Umgang mit ||| trained in the handling of ||| 2-0 1-1 3-1 0-2 2-3
das im Umgang mit ||| trained in the handling ||| 2-0 1-1 3-1 0-2 2-3
das in ||| found in ||| 1-0 1-1
das n ||| authorisation . du ||| 0-0 1-2
das nächste Krankenhaus auf und ||| the nearest hospital and ||| 0-0 0-1 1-1 2-2 3-2 4-3
das nächste Krankenhaus auf ||| the nearest hospital ||| 0-0 0-1 1-1 2-2 3-2
das nächste ||| the nearest ||| 0-0 0-1 1-1
das potenzielle Risiko für ||| the potential risk ||| 0-0 1-1 3-1 0-2 2-2
das potenzielle Risiko ||| the potential risk ||| 0-0 1-1 0-2 2-2
das sich ||| risk ||| 0-0
das therapeutische Ansprechen bei ||| therapeutic response ||| 1-0 2-1
das therapeutische Ansprechen ||| therapeutic response ||| 1-0 2-1
das therapeutische ||| therapeutic ||| 1-0
das ||| authorisation . ||| 0-0
das ||| authorisation ||| 0-0
das ||| enter ||| 0-0
das ||| medicinal product ||| 0-0 0-1
das ||| of the ||| 0-1
das ||| risk ||| 0-0
das ||| the ||| 0-0
das ||| these ||| 0-0
das ||| which involved ||| 0-0
das ||| which ||| 0-0
dass Epoetin alfa ||| that epoetin alfa ||| 0-0 1-1 2-2
dass Epoetin ||| that epoetin ||| 0-0 1-1
dass Pioglitazon ||| pioglitazone ||| 0-0 1-0
dass ein ||| is ||| 0-0 1-0
dass es notwendig ist , ||| need to ||| 0-0 1-0 0-1
dass es notwendig ist ||| need to ||| 0-0 1-0 0-1
dass es notwendig ||| need to ||| 0-0 1-0 0-1
dass es ||| need to ||| 0-0 1-0 0-1
dass ||| have ||| 0-0
dass ||| sure ||| 0-0
dass ||| that , ||| 0-0
dass ||| that ||| 0-0
dauerhafte Hämoglobinwert 12 ||| sustained haemoglobin exceeds 12 ||| 0-0 1-1 0-2 2-3
dauerhafte Hämoglobinwert ||| sustained haemoglobin exceeds ||| 0-0 1-1 0-2
dauerhafter Hämoglobinwert ||| sustained haemoglobin level ||| 0-0 1-1 0-2
dauernde Infusionen ||| 15-minute infusions ||| 0-0 0-1 1-1
dauerten , gab es ||| duration , there were ||| 0-0 1-1 2-2 3-2 2-3
dauerten , ||| duration , ||| 0-0 1-1
dauerten ||| duration ||| 0-0
davon stammende ||| materials derived from ||| 0-0 1-0 1-1 1-2
davor gewarnt werden ||| be cautioned ||| 2-0 0-1 1-1
davor gewarnt ||| cautioned ||| 0-0 1-0
de ||| . de ||| 0-0 0-1
definiert als Verminderung der ||| defined by a decrease in ||| 0-0 2-1 2-2 1-3 2-3
definiert als Verminderung der ||| defined by a decrease ||| 0-0 2-1 2-2 1-3 2-3
definiert als Verminderung ||| defined by a decrease in ||| 0-0 2-1 2-2 1-3 2-3
definiert als Verminderung ||| defined by a decrease ||| 0-0 2-1 2-2 1-3 2-3
definiert als ||| defined as the patient ||| 0-0 1-1
definiert als ||| defined as the ||| 0-0 1-1
definiert als ||| defined as ||| 0-0 1-1
definiert ||| defined ||| 0-0
definitiven in Zusammenhang stehenden Fall ||| definitely related ||| 0-0 3-0 4-0 1-1 2-1
dem 16- bis 81fachen der ||| 16 to 81 times the ||| 1-0 0-1 2-1 1-2 2-2 3-2 3-3 4-4
dem 16- bis 81fachen ||| 16 to 81 times ||| 1-0 0-1 2-1 1-2 2-2 3-2 3-3
dem 16- bis ||| 16 to 81 times ||| 1-0 0-1 2-1 1-2 2-2 1-3
dem 3-fachen der ||| > 3 X the ||| 1-0 0-1 1-1 1-2 2-3
dem 3-fachen ||| > 3 X ||| 1-0 0-1 1-1 1-2
dem Arzneimittel ||| the product ||| 0-0 1-1
dem Beckenkamm entnommen ||| ( N=70 ||| 1-1 2-1
dem Beckenkamm entnommen ||| N=70 ||| 1-0 2-0
dem Blutplasma wurde mit 36 ||| was shown to be 36 ||| 2-0 1-1 2-1 0-2 3-3 4-4
dem Blutplasma wurde mit ||| was shown to be ||| 2-0 1-1 2-1 0-2 3-3
dem Blutplasma wurde ||| was shown to ||| 2-0 1-1 2-1 0-2
dem Essen ||| take it ||| 1-0 0-1 1-1
dem Gastrointestinaltrakt ||| the gastrointestinal ||| 0-0 1-1
dem Herzen oder den ||| the heart or the ||| 0-0 1-1 2-2 3-3
dem Herzen oder ||| the heart or ||| 0-0 1-1 2-2
dem Herzen ||| the heart ||| 0-0 1-1
dem Humaninsulinmolekül wurden in ||| the human insulin molecule ||| 0-0 1-1 1-2 0-3 1-3 2-3 3-3
dem Knochengewebe wird der Wirkstoff ||| the bone tissue it is ||| 0-0 3-0 1-1 1-2 2-3 2-4 4-4
dem Lorazepam- Referenzarm ||| the reference arm ||| 0-0 1-2 2-2
dem Mund zu nehmen . ||| the mouth is difficult . ||| 0-0 0-1 1-1 0-2 2-3 3-3 4-4
dem Mund zu nehmen ||| the mouth is difficult ||| 0-0 0-1 1-1 0-2 2-3 3-3
dem Mund ||| the mouth is ||| 0-0 0-1 1-1 0-2
dem PANSS Excitement Component score ||| the PANSS Excitement Component score ||| 0-0 1-1 2-2 3-3 3-4 4-4
dem PANSS Excitement ||| the PANSS Excitement ||| 0-0 1-1 2-2
dem PANSS ||| the PANSS ||| 0-0 1-1
dem Umweltschutz . ||| protect the environment . ||| 1-0 0-1 1-2 2-3
dem Umweltschutz ||| protect the environment ||| 1-0 0-1 1-2
dem Urin eliminiert ||| is eliminated in the urine ||| 0-0 2-1 1-2 0-3 1-4
dem aktiven Metaboliten , ||| the active metabolite , represents ||| 0-0 1-1 0-2 1-2 3-3 1-4 2-4
dem aktiven Metaboliten , ||| the active metabolite , ||| 0-0 1-1 0-2 1-2 2-2 3-3
dem aktiven Metaboliten ||| the active metabolite ||| 0-0 1-1 0-2 1-2 2-2
dem aktuellen ||| is the current standard of ||| 0-0 0-1 1-2 0-3
dem aktuellen ||| is the current standard ||| 0-0 0-1 1-2 0-3
dem arzneilich wirksamen Bestandteil oder ||| the active substance or to ||| 0-0 1-1 2-2 3-2 4-3
dem arzneilich wirksamen Bestandteil oder ||| the active substance or ||| 0-0 1-1 2-2 3-2 4-3
dem arzneilich wirksamen Bestandteil ||| the active substance ||| 0-0 1-1 2-2 3-2
dem arzneilich ||| the active ||| 0-0 1-1
dem empfohlenen Behandlungsschema ||| the recommended treatment schedule ||| 0-0 1-1 2-2 2-3
dem empfohlenen ||| the recommended ||| 0-0 1-1
dem primären 2-Stunden Endpunkt war ||| the primary 2-hour endpoint was ||| 0-0 1-1 2-2 3-3 4-4
dem primären 2-Stunden Endpunkt ||| the primary 2-hour endpoint ||| 0-0 1-1 2-2 3-3
dem primären 2-Stunden ||| the primary 2-hour ||| 0-0 1-1 2-2
dem primären ||| the primary ||| 0-0 1-1
dem ||| at ||| 0-0
dem ||| in the ||| 0-1
dem ||| on ||| 0-0
dem ||| the reference ||| 0-0
dem ||| the ||| 0-0
dem ||| to the ||| 0-0 0-1
dem ||| to ||| 0-0
dementsprechend beraten werden . ||| be advised accordingly . ||| 2-0 1-1 0-2 1-2 3-3
dementsprechend beraten werden ||| be advised accordingly ||| 2-0 1-1 0-2 1-2
dementsprechend beraten ||| advised accordingly ||| 1-0 0-1 1-1
den Adipozyten ( den ||| adipocytes ( ||| 0-0 1-0 3-0 2-1
den Anweisungen Ihres ||| daily ||| 0-0 1-0 2-0
den Anweisungen ||| veterinary surgeon ||| 0-0 1-1
den Augen ||| eyes ||| 1-0
den Augen ||| in the eyes ||| 1-2
den Augen ||| the eyes ||| 1-1
den Blutdruck senken . ||| lower the blood pressure . ||| 2-0 0-1 1-2 1-3 2-3 3-4
den Blutdruck senken ||| lower the blood pressure ||| 2-0 0-1 1-2 1-3 2-3
den Blutgefäßen ||| the blood vessels ||| 0-0 1-1 1-2
den Cannabinoid-Typ 1 ||| the cannabinoid type 1 ||| 0-0 1-1 1-2 2-3
den Cannabinoid-Typ ||| the cannabinoid type ||| 0-0 1-1 1-2
den Eindruck haben , dass ||| have the impression that ||| 2-0 0-1 1-2 3-3 4-3
den Eindruck haben ||| have the impression ||| 2-0 0-1 1-2
den Eindruck ||| the impression ||| 0-0 1-1
den Ergebnissen der kompletten Standardbatterie ||| results of a full range ||| 0-0 1-0 2-1 3-2 3-3 4-4
den Ergebnissen der kompletten Standardbreite ||| results of a full range ||| 0-0 1-0 2-1 3-2 3-3 3-4 4-4
den Ergebnissen der kompletten ||| results of a full ||| 0-0 1-0 2-1 3-2 3-3
den Ergebnissen der ||| results of ||| 0-0 1-0 2-1
den Ergebnissen ||| results ||| 0-0 1-0
den Fötus . ||| to the foetus . ||| 0-0 0-1 0-2 1-2 2-3
den Fötus ||| to the foetus ||| 0-0 0-1 0-2 1-2
den Gesäßbereich oder ||| , the gluteal region or ||| 0-1 0-2 1-2 1-3 2-4
den Gesäßbereich oder ||| the gluteal region or ||| 0-0 0-1 1-1 1-2 2-3
den Gesäßbereich ||| , the gluteal region ||| 0-1 0-2 1-2 1-3
den Gesäßbereich ||| the gluteal region ||| 0-0 0-1 1-1 1-2
den Inhalt vor Feuchtigkeit ||| in order to protect ||| 1-0 0-1 1-1 2-2 2-3 3-3
den Inhalt vor Feuchtigkeit ||| order to protect from ||| 0-0 1-0 2-1 2-2 3-2 3-3
den Inhalt ||| in order ||| 1-0 0-1 1-1
den Inhalt ||| order ||| 0-0 1-0
den Insulinbedarf verringern . ||| reduce insulin requirement . ||| 0-0 2-0 1-1 1-2 2-2 3-3
den Insulinbedarf verringern ||| reduce insulin requirement ||| 0-0 2-0 1-1 1-2 2-2
den Kontrollpatienten . ||| controls . ||| 0-0 1-0 2-1
den Kontrollpatienten ||| controls ||| 0-0 1-0
den Mahlzeiten . ||| regard to meals . ||| 0-0 1-0 0-1 1-2 2-3
den Mahlzeiten als Monotherapie ||| regard to meals as monotherapy ||| 0-0 1-0 0-1 1-2 2-3 3-4
den Mahlzeiten als ||| regard to meals as ||| 0-0 1-0 0-1 1-2 2-3
den Mahlzeiten ||| regard to meals ||| 0-0 1-0 0-1 1-2
den Menschen ist nicht bekannt ||| humans is unknown ||| 0-0 1-0 2-1 3-2 4-2
den Menschen ist ||| humans is ||| 0-0 1-0 2-1
den Menschen ||| humans ||| 0-0 1-0
den Metabolismus der Substrate von ||| the metabolism of substrates of ||| 0-0 0-1 1-1 4-2 1-3 3-3 2-4 4-4
den Morbus Paget des ||| Paget s disease of the ||| 1-0 2-0 0-1 1-1 2-2 3-3 3-4
den Morbus Paget ||| Paget s disease ||| 1-0 2-0 0-1 1-1 2-2
den Morbus-Paget-Studien ||| the Paget s disease ||| 0-0 1-1 0-2 1-2 1-3
den Muskel ||| nurse ||| 1-0
den Neuronen ||| adipocytes ) that affects energy ||| 0-0 1-0 1-3 1-4
den Oberarm sind auch ||| the deltoid region may also ||| 0-0 0-1 1-1 1-2 2-2 1-3 3-4
den Oberarm sind ||| the deltoid region may ||| 0-0 0-1 1-1 1-2 2-2 1-3
den Oberschenkel oder die ||| the thighs or the ||| 0-0 0-1 1-1 2-2 3-3
den Oberschenkel oder ||| the thighs or ||| 0-0 0-1 1-1 2-2
den Oberschenkel ||| the thighs ||| 0-0 0-1 1-1
den Populationen ohne Diabetes ||| the non-diabetic ||| 0-0 1-1 2-1 3-1
den Saugreflex unterdrücken ||| is excreted in human milk ||| 1-0 1-1 2-3 2-4
den Saugreflex ||| is excreted in ||| 1-0 1-1
den Saugreflex ||| is excreted ||| 1-0 1-1
den Schenkelhals -1,5 ||| femoral neck bone ||| 1-0 1-1
den Schenkelhals -1,5 ||| femoral neck ||| 1-0 1-1
den Schenkelhals ||| femoral neck bone ||| 1-0 1-1
den Schenkelhals ||| femoral neck ||| 1-0 1-1
den Studien ||| the studies ||| 0-0 1-1
den Transport ||| correct ||| 1-0
den Verkehr gebracht . ||| be marketed . ||| 1-0 0-1 1-1 2-1 3-2
den Verkehr gebracht ||| be marketed ||| 1-0 0-1 1-1 2-1
den Versuchen ||| the ||| 0-0 1-0
den Wechseljahren ||| den ||| 0-0
den Wechseljahren ||| through the menopause ||| 0-0 0-1 1-2
den Wirkstoff Aripiprazol enthält . ||| the active substance aripiprazole . ||| 0-0 0-1 1-1 1-2 3-2 2-3 4-4
den Wirkstoff Aripiprazol enthält ||| the active substance aripiprazole ||| 0-0 0-1 1-1 1-2 3-2 2-3
den Wirkstoff Paclitaxel ( ||| the active substance paclitaxel ( ||| 0-0 0-1 1-1 1-2 2-3 3-4
den Wirkstoff Paclitaxel ||| the active substance paclitaxel ||| 0-0 0-1 1-1 1-2 2-3
den Wirkstoff Pioglitazon enthält . ||| the active substance pioglitazone . ||| 0-0 0-1 1-1 1-2 3-2 2-3 4-4
den Wirkstoff Pioglitazon enthält ||| the active substance pioglitazone ||| 0-0 0-1 1-1 1-2 3-2 2-3
den Wirkstoff oder ||| the active substance or ||| 0-0 0-1 1-1 1-2 2-3
den Wirkstoff ||| the active substance ||| 0-0 0-1 1-1 1-2
den anschließenden ||| subsequent ||| 0-0 1-0
den ersten 24 h ||| the first 24 hours ||| 0-0 1-1 2-2 3-2 2-3
den ersten ||| the first ||| 0-0 0-1 1-1
den ersten ||| the first ||| 0-0 1-1
den gesamten Behandlungszeitraum . ||| the whole treatment period . ||| 0-0 1-1 2-1 2-2 2-3 3-4
den gesamten Behandlungszeitraum ||| the whole treatment period ||| 0-0 1-1 2-1 2-2 2-3
den gp-60-Albuminrezeptor ||| the gp-60 albumin receptor , ||| 0-0 1-1
den gp-60-Albuminrezeptor ||| the gp-60 albumin receptor ||| 0-0 1-1
den gp-60-Albuminrezeptor ||| the gp-60 albumin ||| 0-0 1-1
den gp-60-Albuminrezeptor ||| the gp-60 ||| 0-0 1-1
den klinischen Studien wurde unter ||| the clinical studies , ||| 0-0 1-1 2-2 3-2
den klinischen Studien wurde unter ||| the clinical studies ||| 0-0 1-1 2-2 3-2
den klinischen Studien wurde ||| the clinical studies , ||| 0-0 1-1 2-2 3-2
den klinischen Studien wurde ||| the clinical studies ||| 0-0 1-1 2-2 3-2
den klinischen ||| the clinical ||| 0-0 1-1
den kombinierten Ergebnissen wurde ||| the pooled results , ||| 0-0 1-0 1-1 3-1 0-2 2-2
den kombinierten Ergebnissen wurde ||| the pooled results ||| 0-0 1-0 1-1 3-1 0-2 2-2
den konventionellen ||| data reveal no ||| 1-0 0-1 1-1 1-2
den letzten Tag des ||| the last day of ||| 0-0 1-1 2-2 3-3
den letzten Tag ||| the last day ||| 0-0 1-1 2-2
den letzten drei Wochen vor ||| during the 3 weeks before ||| 3-0 0-1 1-1 3-2 2-3 3-3 4-4
den letzten drei Wochen ||| during the 3 weeks ||| 3-0 0-1 1-1 3-2 2-3 3-3
den letzten ||| the last ||| 0-0 1-1
den letzten ||| the ||| 0-0 1-0
den meisten Fällen wird ||| most cases , the ferritin ||| 0-0 1-0 2-1 1-2 0-3 2-4 3-4
den meisten Fällen ||| most cases , ||| 0-0 1-0 2-1 2-2
den meisten Fällen ||| most of the cases , ||| 0-0 1-0 0-1 0-2 2-3 2-4
den meisten dieser Patienten ||| most of these patients ||| 0-0 1-0 2-1 2-2 3-3
den meisten dieser ||| most of these ||| 0-0 1-0 2-1 2-2
den meisten klinischen Studien ||| most clinical trials ||| 0-0 1-0 2-1 3-2
den meisten klinischen ||| most clinical ||| 0-0 1-0 2-1
den meisten ||| most of the ||| 0-0 1-0 0-1 0-2
den meisten ||| most ||| 0-0 1-0
den mit Abraxane behandelten ||| Abraxane should be vigilantly ||| 2-0 0-2 1-2 3-3
den mit Abraxane ||| Abraxane should be ||| 2-0 0-2 1-2
den mit ||| be ||| 0-0 1-0
den mit ||| should be ||| 0-1 1-1
den nachfolgenden ||| subsequent ||| 0-0 1-0
den oben genannten Indikationen haben ||| the above indications ||| 0-0 3-1 1-2 2-2 3-2 4-2
den oben genannten ||| values above ||| 0-0 1-1 2-1
den täglichen Bedarf an ||| unable to ||| 1-0 2-0 0-1 3-1
den verordneten Dosierungen . ||| dose regimens . ||| 1-0 0-1 1-1 2-1 3-2
den verordneten Dosierungen ||| dose regimens ||| 1-0 0-1 1-1 2-1
den vier placebokontrollierten Studien ||| the four placebo-controlled studies ||| 0-0 1-1 2-2 3-3
den vier placebokontrollierten ||| the four placebo-controlled ||| 0-0 1-1 2-2
den vier ||| the four ||| 0-0 1-1
den wirksamen Bestandteil Humaninsulin ||| the active ingredient insulin human ||| 0-0 0-1 1-1 2-1 2-2 3-3 3-4
den wirksamen Bestandteil ||| the active ingredient ||| 0-0 0-1 1-1 2-1 2-2
den ||| D ||| 0-0
den ||| For the ||| 0-1
den ||| den ||| 0-0
den ||| regard to effects ||| 0-0 0-1 0-2
den ||| subsequent ||| 0-0
den ||| the individual ||| 0-0 0-1
den ||| the osteoporosis ||| 0-0
den ||| the ||| 0-0
den ||| through the ||| 0-0 0-1
den ||| to the ||| 0-0 0-1
den ||| to ||| 0-0
den ||| used to ||| 0-0
den ||| used ||| 0-0
den ||| values ||| 0-0
den ||| veterinary ||| 0-0
den ||| vitamin D ||| 0-1
denen Metformin kontraindiziert ist , ||| metformin is contraindicated , ||| 0-0 1-0 3-1 2-2 4-3
denen Metformin kontraindiziert ist ||| metformin is contraindicated ||| 0-0 1-0 3-1 2-2
denen Metformin nicht angezeigt ist ||| cannot take metformin ||| 0-0 2-0 2-1 0-2 1-2 3-2 4-2
denen Metformin ||| metformin ||| 0-0 1-0
denen Midazolam ( CYP3A4-Substrat ) ||| denen Midazolam ( CYP3A4-Substrat ) ||| 1-0 1-1 2-2 3-3 4-4
denen Midazolam ( CYP3A4-Substrat ||| denen Midazolam ( CYP3A4-Substrat ||| 1-0 1-1 2-2 3-3
denen Midazolam ( ||| denen Midazolam ( ||| 1-0 1-1 2-2
denen Midazolam ||| denen Midazolam ||| 1-0 1-1
denen das ||| the ||| 1-0
denen die erste Behandlung nicht ||| whose first treatment ||| 0-0 2-1 3-2
denen die erste Behandlung ||| whose first treatment ||| 0-0 2-1 3-2
denen die erste ||| whose first ||| 0-0 2-1
denen die manischen Symptome bereits ||| whose manic symptoms had already ||| 0-0 2-1 1-2 3-2 4-3 4-4
denen die manischen Symptome ||| whose manic symptoms ||| 0-0 2-1 1-2 3-2
denen die ||| whom the ||| 0-0 1-1
denen die ||| whose ||| 0-0
denen ein elektiver orthopädischer ||| scheduled for major elective ||| 0-0 2-1 1-2 2-2 3-3
denen ein elektiver ||| scheduled for major ||| 0-0 2-1 1-2 2-2
denen ein hohes ||| having a high ||| 0-0 2-0 1-1 2-2
denen in der Familienanamnese ||| family history of ||| 0-0 1-0 2-0 3-0 3-1 2-2
denen potenziell klinisch signifikante ||| experiencing potentially clinically significant ||| 0-0 1-0 1-1 2-2 3-3
denen potenziell klinisch ||| experiencing potentially clinically ||| 0-0 1-0 1-1 2-2
denen potenziell ||| experiencing potentially ||| 0-0 1-0 1-1
denen ||| scheduled ||| 0-0
denen ||| where ||| 0-0
denen ||| whom ||| 0-0
denen ||| whose ||| 0-0
denselben Wirkstoff wie ||| same active substance ||| 0-0 2-0 1-1 1-2
denselben Wirkstoff wie ||| the same active substance ||| 0-1 2-1 1-2 1-3
depressive Erkrankung und/oder ||| depressive illness and/ or ||| 0-0 0-1 1-1 2-2 2-3
depressive Erkrankung ||| depressive illness ||| 0-0 0-1 1-1
depressive ||| depressive ||| 0-0
depressiven Störungen ||| 4.3 and ||| 0-0 1-1
depressiven Störungen ||| section 4.3 and ||| 0-1 1-2
depressiven Störungen/Stimmungsänderungen in der ||| history of depressive disorders/ mood ||| 1-0 2-0 3-1 0-2 1-3 0-4
depressiven ||| 4.3 ||| 0-0
depressiven ||| section 4.3 ||| 0-1
der 3-Jahres-Osteoporosestudie ||| the three-year ||| 0-0 1-1
der 460 Frauen mit ||| 460 women with ||| 1-0 2-1 3-2
der 460 Frauen ||| 460 women ||| 1-0 2-1
der 460 ||| 460 ||| 1-0
der ADT auf ein ||| ADT to minimize ||| 1-0 0-1 2-1 1-2
der ADT auf ein ||| for ADT to minimize ||| 1-1 0-2 2-2 1-3
der ADT auf ||| ADT to minimize ||| 1-0 0-1 2-1 1-2
der ADT auf ||| for ADT to minimize ||| 1-1 0-2 2-2 1-3
der AUC von Aripiprazol ||| of aripiprazole AUC ||| 0-0 2-0 3-1 1-2
der Absenkung des Testosteronspiegels ||| serum testosterone reduction ||| 0-0 2-0 1-1 3-1 1-2
der Anamnese auf . ||| pituitary adenoma . ||| 0-0 1-0 1-1 2-1 3-2
der Anamnese auf ||| pituitary adenoma ||| 0-0 1-0 1-1 2-1
der Androgensuppression ist ||| of androgen suppression is ||| 0-0 1-1 1-2 2-3
der Androgensuppression ||| of androgen suppression ||| 0-0 1-1 1-2
der Anteil der Patienten ||| the proportion of patients ||| 0-0 1-1 2-2 3-3
der Anteil der ||| the proportion of ||| 0-0 1-1 2-2
der Anteil ||| the proportion ||| 0-0 1-1
der Anwendung entstehender ||| from the use of such ||| 0-0 0-1 1-2 0-3 2-4
der Anwendung t lä ||| of administration ||| 0-0 1-1 2-1 3-1
der Anwendung von ABILIFY ||| use ABILIFY ||| 1-0 2-0 3-1
der Anwendung von Abseamed ||| use Abseamed ||| 1-0 2-0 3-1
der Anwendung von Aclasta : ||| are given Aclasta : ||| 1-0 2-1 3-1 3-2 4-3
der Anwendung von Aclasta ||| are given Aclasta ||| 1-0 2-1 3-1 3-2
der Anwendung von ||| Using ||| 1-0
der Anwendung von ||| use of ||| 1-0 0-1 2-1
der Anwendung von ||| use ||| 1-0 2-0
der Anwendung zur Behandlung von ||| used to treat ||| 1-0 2-0 0-1 2-1 2-2 3-2 4-2
der Anwendung zur Behandlung ||| used to treat ||| 1-0 2-0 0-1 2-1 2-2 3-2
der Anwendung ||| Using ||| 1-0
der Anwendung ||| are ||| 1-0
der Anwendung ||| from the use of ||| 0-0 0-1 1-2 0-3
der Anwendung ||| of administration ||| 0-0 1-1
der Anämie bei chronischer ||| of anaemia associated with chronic ||| 0-0 1-1 1-2 2-3 3-4
der Anämie bei ||| of anaemia associated with ||| 0-0 1-1 1-2 2-3
der Anämie kann ||| anaemia may ||| 0-0 1-0 2-1
der Anämie mit Epoetin alfa ||| of anaemia with epoetin alfa ||| 0-0 1-1 2-2 3-3 4-4
der Anämie mit Epoetin ||| of anaemia with epoetin ||| 0-0 1-1 2-2 3-3
der Anämie mit ||| of anaemia with ||| 0-0 1-1 2-2
der Anämie und Reduktion ||| of anaemia and reduction ||| 0-0 1-1 2-2 3-3
der Anämie und ||| of anaemia and ||| 0-0 1-1 2-2
der Anämie ||| anaemia ||| 0-0 1-0
der Anämie ||| of anaemia associated ||| 0-0 1-1 1-2
der Anämie ||| of anaemia ||| 0-0 1-1
der Aripiprazol- Konzentrationen gerechnet werden ||| aripiprazole concentrations might be expected ||| 1-0 0-1 2-1 1-2 3-2 4-3 3-4
der Aufrechterhaltung des ||| maintaining the clinical ||| 0-0 1-0 2-1 1-2
der Aufschrift ||| face ||| 0-0 1-0
der Ausfällung von Sulfat-Konjugaten der ||| of precipitation of sulphate ||| 0-0 2-0 1-1 3-1 2-2 4-2 3-3
der Auswirkung des Rauchens auf ||| from smoking upon ||| 0-0 1-0 1-1 2-1 3-1 4-1 3-2
der Bauchspeicheldrüse , ||| of the pancreas ||| 1-2
der Bauchspeicheldrüse , ||| pancreas ||| 1-0
der Bauchspeicheldrüse , ||| the pancreas ||| 1-1
der Bauchspeicheldrüse ||| of the pancreas ||| 1-2
der Bauchspeicheldrüse ||| pancreas ||| 1-0
der Bauchspeicheldrüse ||| the pancreas ||| 1-1
der Beendigung der ||| stopping ||| 0-0 1-0 2-0
der Beginn der Konvulsionen ||| initiation of convulsions ||| 1-0 0-1 2-1 3-2
der Beginn der ||| initiation of ||| 1-0 0-1 2-1
der Behandlung bei ||| in the treatment ||| 2-0 0-1 1-2
der Behandlung der postmenopausalen Osteoporose ||| the treatment of post-menopausal osteoporosis ||| 0-0 1-1 2-2 3-3 4-4
der Behandlung der postmenopausalen ||| the treatment of post-menopausal ||| 0-0 1-1 2-2 3-3
der Behandlung der ||| the treatment of ||| 0-0 1-1 2-2
der Behandlung des Diabetes ||| the treatment of diabetes ||| 0-0 1-1 2-2 3-3
der Behandlung des ||| the treatment of ||| 0-0 1-1 2-2
der Behandlung dieser Patientengruppe ||| the treatment in this ||| 0-0 1-1 3-2 2-3 3-3
der Behandlung dieser ||| the treatment of the ||| 0-0 1-1 2-2 0-3
der Behandlung eingestellt werden ||| for the duration of therapy ||| 2-0 0-1 1-1 2-2 0-3 2-3 3-4
der Behandlung eingestellt ||| for the duration of ||| 2-0 0-1 1-1 2-2 0-3 2-3
der Behandlung kontrolliert werden . ||| be monitored . ||| 0-0 1-0 2-0 2-1 3-1 4-2
der Behandlung kontrolliert werden ||| be monitored ||| 0-0 1-0 2-0 2-1 3-1
der Behandlung mit ||| of the ||| 0-0 0-1 1-1
der Behandlung mit ||| treatment , ||| 0-0 1-0 2-0
der Behandlung mit ||| treatment ||| 0-0 1-0 2-0
der Behandlung von Übergewicht ||| in the management of overweight ||| 0-0 0-1 1-2 3-2 2-3 3-4
der Behandlung ||| , ||| 0-0
der Behandlung ||| of the ||| 0-0 0-1 1-1
der Behandlung ||| of ||| 0-0 1-0
der Behandlung ||| on treatment , ||| 0-0 1-1
der Behandlung ||| on treatment ||| 0-0 1-1
der Behandlung ||| the treatment of ||| 0-0 1-1 0-2
der Behandlung ||| the treatment ||| 0-0 1-1
der Behandlung ||| the ||| 0-0 1-0
der Behandlung ||| treatment of ||| 1-0 0-1
der Behandlung ||| treatment ||| 0-0 1-0
der Behandlung ||| treatment ||| 1-0
der Beitrag von ||| contribution ||| 1-0 2-0
der Bipolar-I- Störung und für ||| Bipolar I Disorder and for ||| 1-0 2-0 0-1 1-1 1-2 3-3 4-4
der Bipolar-I- Störung und ||| Bipolar I Disorder and ||| 1-0 2-0 0-1 1-1 1-2 3-3
der Bipolar-I- Störung und ||| in Bipolar I Disorder and ||| 1-1 2-1 0-2 1-2 1-3 3-4
der Bipolar-I- Störung ||| Bipolar I Disorder ||| 1-0 2-0 0-1 1-1 1-2
der Bipolar-I- Störung ||| in Bipolar I Disorder ||| 1-1 2-1 0-2 1-2 1-3
der Bipolar-I-Störung angewandt , ||| Bipolar I Disorder , ||| 1-0 1-1 1-2 2-3 3-3
der Bipolar-I-Störung zeigte ||| of Bipolar I Disorder , ||| 0-0 1-1 1-2 1-3 2-3 2-4
der Bipolar-I-Störung ||| Bipolar I Disorder ||| 1-0 1-1 1-2
der Blutdruck ||| blood pressure ||| 0-0 1-0 1-1
der Blutplättchen ||| blood ||| 0-0 1-0
der Blutzuckereinstellung verringert das Risiko ||| control decreases the risk ||| 0-0 1-0 1-1 2-1 3-2 3-3 4-3
der Blutzuckereinstellung verringert ||| control decreases ||| 0-0 1-0 1-1 2-1
der CHMP ||| the CHMP ||| 0-0 1-1
der CHMP übereinstimmend der Auffassung ||| the CHMP agrees ||| 0-0 3-0 1-1 2-2 4-2
der CPK ( ||| of CPK ( Creatine ||| 0-0 1-1 2-2 1-3
der CPK ( ||| of CPK ( ||| 0-0 1-1 2-2
der CPK ||| of CPK ||| 0-0 1-1
der CYP3A4- oder CYP2D6-Inhibitor ||| the CYP3A4 or CYP2D6 inhibitor ||| 0-0 1-1 2-2 3-3 3-4
der CYP3A4- oder ||| the CYP3A4 or ||| 0-0 1-1 2-2
der CYP3A4- ||| the CYP3A4 ||| 0-0 1-1
der CYP3A4-Induktor ||| the CYP3A4 inducer ||| 0-0 1-1 1-2
der Clearance von Zoledronsäure aus ||| plasma clearance of zoledronic acid ||| 2-0 1-1 0-2 2-2 4-2 3-3 3-4
der Cmax und AUC nach ||| of Cmax and AUC after ||| 0-0 1-1 2-2 3-3 4-4
der Cmax und AUC ||| of Cmax and AUC ||| 0-0 1-1 2-2 3-3
der Cmax und ||| of Cmax and ||| 0-0 1-1 2-2
der Cmax ||| of Cmax ||| 0-0 1-1
der Dosierung kann auch bei ||| of dosage may also ||| 0-0 1-1 2-2 3-3 4-3
der Dosierung kann ||| of dosage may ||| 0-0 1-1 2-2
der Dosierung ||| of dosage ||| 0-0 1-1
der Dosis notwendig ( siehe ||| ( see ||| 3-0 4-1
der Dosis notwendig ( ||| ( ||| 3-0
der Dosis ||| dose ||| 1-0
der Dosisregler ||| the dose selector returns ||| 0-0 1-1 0-2 1-2 1-3
der Eigenblutspende erfolgen ||| of the blood donation procedure ||| 0-0 0-1 1-2 1-3 2-3 1-4
der Einnahme erreicht . ||| of dosing . ||| 0-0 1-1 2-1 3-2
der Einnahme erreicht ||| of dosing ||| 0-0 1-1 2-1
der Einnahme von Actos 15mg ||| taking Actos 15mg ||| 1-0 4-0 3-1 3-2
der Einnahme von Actos 30mg ||| taking Actos 30mg ||| 1-0 4-0 3-1 3-2
der Einnahme von Actos 45mg ||| taking Actos 45mg ||| 1-0 4-0 3-1 3-2
der Einnahme von ||| associated ||| 0-0 1-0 2-0
der Einnahme ||| associated ||| 0-0 1-0
der Elimination per se ||| of the elimination per se ||| 0-0 0-1 1-2 2-3 2-4 3-4
der Elimination ||| of the elimination ||| 0-0 0-1 1-2
der Epoetin-alfa-Behandlung kann ||| may be a moderate ||| 2-0 0-1 1-1 1-2 1-3
der Epoetin-alfa-Behandlung ||| be a moderate ||| 0-0 1-0 1-1 1-2
der Europäischen ||| Agency ||| 0-0 1-0
der Flasche ||| the bottle , ||| 0-0 1-1
der Flasche ||| the bottle ||| 0-0 1-1
der Gabe von Abraxane auf ||| Abraxane administration ||| 3-0 4-0 1-1 2-1
der Gabe von ||| administration ||| 1-0 2-0
der Gabe von ||| the administration of ||| 0-0 1-1 2-2
der Gabe ||| the administration ||| 0-0 1-1
der Galle ||| the bile ||| 0-0 1-1
der Gehalt der ||| of ||| 0-0 1-0 2-0
der Gesamtdosis und ||| total dose and rate of ||| 1-0 1-1 2-2 0-4
der Gewichtszunahme , die ||| to that seen ||| 0-0 2-1 3-1 1-2 3-2
der Gruppe ich ||| years ||| 1-0 2-0
der HORIZON Pivotal Fracture Trial ||| the HORIZON Pivotal Fracture Trial ||| 0-0 1-1 2-2 3-3 4-4
der HORIZON Pivotal Fracture ||| the HORIZON Pivotal Fracture ||| 0-0 1-1 2-2 3-3
der HORIZON Pivotal ||| the HORIZON Pivotal ||| 0-0 1-1 2-2
der HORIZON ||| the HORIZON ||| 0-0 1-1
der HORIZON-PFT-Studie ||| the HORIZON-PFT ||| 0-0 1-1
der Halbwertszeit war auf ||| half-life was due to ||| 1-0 2-1 0-2 3-3
der Halbwertszeit war ||| half-life was due ||| 1-0 2-1 0-2
der Hauptstudie 72 ||| the main study , 72 ||| 0-0 1-1 1-2 2-4
der Hauptstudie ||| the main study , ||| 0-0 1-1 1-2
der Hauptstudie ||| the main study ||| 0-0 1-1 1-2
der Haut in Berührung ||| the skin ||| 0-0 1-1 2-1 3-1
der Haut ||| the skin ||| 0-0 1-1
der Hund an ||| your dog ||| 1-0 1-1 2-1
der Hund ||| the dog ||| 0-0 1-1
der Hunde ( ||| of dogs ||| 0-0 1-1
der Hunde ||| of dogs ||| 0-0 1-1
der Hydroxy- Metaboliten von ||| conjugates of hydroxy metabolites of ||| 1-0 0-1 3-1 1-2 2-3 3-4
der Hämoglobin- Zielkonzentration ||| the desired haemoglobin level may ||| 0-0 1-1 1-2 1-3 2-3 2-4
der Hämoglobin-Zielkonzentration ||| of the target haemoglobin concentration ||| 0-0 0-1 1-2 1-3 1-4
der Hämoglobinwert um ||| , the haemoglobin ||| 0-1 1-2 2-2
der Hämoglobinwert um ||| the haemoglobin is rising by ||| 0-0 1-1 1-2 1-3 2-3 2-4
der Hämoglobinwert um ||| the haemoglobin ||| 0-0 1-1 2-1
der Hämoglobinwert ||| the haemoglobin is ||| 0-0 1-1 1-2
der Hämoglobinwerte ( 1 ||| haemoglobin ( 1 to ||| 1-0 2-1 3-2
der Hämoglobinwerte ( 1 ||| haemoglobin ( 1 ||| 1-0 2-1 3-2
der Hämoglobinwerte ( 1 ||| in haemoglobin ( 1 to ||| 1-1 2-2 3-3
der Hämoglobinwerte ( 1 ||| in haemoglobin ( 1 ||| 1-1 2-2 3-3
der Hämoglobinwerte ( ||| haemoglobin ( ||| 1-0 2-1
der Hämoglobinwerte ( ||| in haemoglobin ( ||| 1-1 2-2
der Hämoglobinwerte ||| haemoglobin ||| 1-0
der Hämoglobinwerte ||| in haemoglobin ||| 1-1
der Hände , ||| of hands , ||| 0-0 1-1 2-2
der Hände ||| of hands ||| 0-0 1-1
der Hüftfraktur ||| hip fracture ||| 0-0 1-0 1-1
der Indikation Steigerung ||| the indication increasing ||| 0-0 1-1 2-2
der Indikation ||| the indication ||| 0-0 1-1
der Infusion Raumtemperatur ||| reach room temperature ||| 2-0 2-1 0-2 2-2
der Infusion hält ||| of the infusion lasts ||| 0-0 0-1 1-2 2-3
der Infusion lag bei ca. ||| timing of infusion was approximately ||| 0-0 0-1 1-2 2-3 3-3 4-4
der Infusion lag bei ||| timing of infusion was ||| 0-0 0-1 1-2 2-3 3-3
der Infusion ||| infusion ||| 1-0
der Infusion ||| of the infusion ||| 0-0 0-1 1-2
der Infusion ||| the infusion ||| 1-1
der Infusion ||| timing of infusion ||| 0-0 0-1 1-2
der Injektionsnadel . ||| the injection needle . ||| 0-0 0-1 1-2 2-3
der Injektionsnadel ||| the injection needle ||| 0-0 0-1 1-2
der Injektionsstelle ||| of the injection site ||| 0-0 0-1 1-2 1-3
der Injektionsstelle ||| site ||| 0-0 1-0
der Insulinbedarf , steigt aber ||| the first trimester ||| 0-0 3-1 1-2 3-2 4-2
der Insulinresistenz vermittelt . ||| of insulin resistance . ||| 0-0 1-1 1-2 2-2 3-3
der Insulinresistenz vermittelt ||| of insulin resistance ||| 0-0 1-1 1-2 2-2
der Kalzium-Spiegel ||| the level of calcium ||| 0-0 0-1 0-2 1-3
der Knochenumbau ||| bone remodelling ||| 1-0 1-1
der Kontrollen . ||| of controls . ||| 0-0 1-1 2-2
der Kontrollen ||| of controls ||| 0-0 1-1
der Konzentration ||| concentration ||| 1-0
der Krankheit ||| disease ||| 1-0
der Kreatinphosphokinase und Rhabdomyolyse , ||| phosphokinase and rhabdomyolysis , ||| 0-0 1-0 2-1 3-2 4-3
der Kreatinphosphokinase und Rhabdomyolyse ||| phosphokinase and rhabdomyolysis ||| 0-0 1-0 2-1 3-2
der Kreatinphosphokinase und ||| phosphokinase and ||| 0-0 1-0 2-1
der Kreatinphosphokinase ||| phosphokinase ||| 0-0 1-0
der Kurve ( Plasmakonzentration gegen ||| the plasma concentration ||| 0-0 1-0 3-1 3-2
der Kurve ( Plasmakonzentration ||| the plasma concentration ||| 0-0 1-0 3-1 3-2
der Kurve ( ||| the ||| 0-0 1-0
der Kurve ||| the ||| 0-0 1-0
der Körper ||| body ||| 1-0
der Langzeitverlängerung der Studie ||| the Long Term ||| 0-0 1-1 2-1 1-2 3-2
der Leber hauptsächlich ||| by the liver primarily ||| 1-0 0-1 1-2 2-3
der Leber ||| by the liver ||| 1-0 0-1 1-2
der Leberenzyme zu unterziehen . ||| monitoring of liver enzymes . ||| 1-0 0-1 1-2 2-2 1-3 3-3 4-4
der Leberenzyme zu unterziehen ||| monitoring of liver enzymes ||| 1-0 0-1 1-2 2-2 1-3 3-3
der Legeperiode ||| lay ||| 1-0
der Lipidaufnahme ||| of the uptake ||| 0-0 0-1 1-2
der Lösung enthält 0,05 mg ||| solution contains 0.05 mg ||| 1-0 2-1 3-2 4-3
der Lösung enthält 0,05 ||| solution contains 0.05 ||| 1-0 2-1 3-2
der Lösung enthält ||| solution contains ||| 1-0 2-1
der Lösung ||| solution ||| 1-0
der Marker ||| , recovered label ||| 1-1 1-2
der Marker ||| recovered label ||| 1-0 1-1
der Markteinführung Zusätzlich ||| In addition the ||| 2-0 2-1 0-2 1-2
der Markteinführung ||| the ||| 0-0 1-0
der Menopause ||| the menopause , ||| 0-0 1-1
der Menopause ||| the menopause ||| 0-0 1-1
der Merkmale des Arzneimittels , ||| of Product Characterisitics , ||| 0-0 1-1 2-1 3-2 4-3
der Merkmale des Arzneimittels , ||| of Product Characteristics , ||| 0-0 1-1 2-1 1-2 3-2 4-3
der Merkmale des Arzneimittels zu ||| of Product Characteristics ||| 0-0 1-1 2-1 1-2 3-2
der Merkmale des Arzneimittels ||| of Product Characterisitics ||| 0-0 1-1 2-1 3-2
der Merkmale des Arzneimittels ||| of Product Characteristics ||| 0-0 1-1 2-1 1-2 3-2
der Merkmale des ||| of Product ||| 0-0 1-1 2-1
der Mortalität in dieser Studie ||| in mortality in this study ||| 0-0 2-0 1-1 2-2 3-3 4-4
der Mortalität in dieser ||| in mortality in this ||| 0-0 2-0 1-1 2-2 3-3
der Mortalität in ||| in mortality in ||| 0-0 2-0 1-1 2-2
der Muttersubstanz ||| the parent substance ||| 0-0 1-1 1-2
der Möglichkeit ||| the possibility ||| 0-0 1-1
der Nachbeobachtungsstudie ||| observation study ||| 1-0
der Nachbeobachtungsstudie ||| observation ||| 1-0
der Nahrung : ||| Administration of ||| 1-0 0-1 1-1
der Nahrung ||| Administration of ||| 1-0 0-1 1-1
der Nebenschilddrüsen , intestinale ||| parathyroid reserve , intestinal calcium ||| 1-0 1-1 2-2 3-3 3-4
der Nebenschilddrüsen , ||| diminished parathyroid reserve , ||| 1-0 1-1 1-2 2-3
der Nebenschilddrüsen , ||| parathyroid reserve , ||| 1-0 1-1 2-2
der Nebenschilddrüsen ||| diminished parathyroid reserve ||| 1-0 1-1 1-2
der Nebenschilddrüsen ||| parathyroid reserve ||| 1-0 1-1
der Nebenwirkungen , ||| of the side effects , ||| 0-0 0-1 1-2 1-3 2-4
der Nebenwirkungen ||| of the side effects ||| 0-0 0-1 1-2 1-3
der Nierenfunktion ||| of renal function ||| 0-0 1-1 1-2
der Obergrenze des Normbereichs bleiben ||| the upper limit of normal ||| 0-0 1-1 2-1 1-2 3-2 2-3 3-4 4-4
der Osteoklasten-vermittelten Knochenresorption . ||| of osteoclast-mediated bone resorption . ||| 0-0 1-1 2-2 2-3 3-4
der Osteoklasten-vermittelten Knochenresorption ||| of osteoclast-mediated bone resorption ||| 0-0 1-1 2-2 2-3
der Osteoklasten-vermittelten ||| of osteoclast-mediated ||| 0-0 1-1
der Osteoporose bei Männern und ||| osteoporosis in men and ||| 1-0 0-1 2-1 3-2 4-3
der Osteoporose bei Männern ||| osteoporosis in men ||| 1-0 0-1 2-1 3-2
der Osteoporose bei postmenopausalen Frauen ||| of osteoporosis in post-menopausal women ||| 0-0 1-1 2-2 3-3 4-4
der Osteoporose bei postmenopausalen Frauen ||| osteoporosis in post-menopausal women ||| 1-0 0-1 2-1 3-2 4-3
der Osteoporose bei postmenopausalen ||| of osteoporosis in post-menopausal ||| 0-0 1-1 2-2 3-3
der Osteoporose bei postmenopausalen ||| osteoporosis in post-menopausal ||| 1-0 0-1 2-1 3-2
der Osteoporose bei ||| of osteoporosis in ||| 0-0 1-1 2-2
der Osteoporose bei ||| osteoporosis in ||| 1-0 0-1 2-1
der Osteoporose ||| of osteoporosis ||| 0-0 1-1
der PROactive-Studie , einer kardiovaskulären ||| PROactive , a cardiovascular ||| 0-0 1-0 2-1 3-2 4-3
der PROactive-Studie , einer ||| PROactive , a ||| 0-0 1-0 2-1 3-2
der PROactive-Studie , ||| PROactive , ||| 0-0 1-0 2-1
der PROactive-Studie ||| PROactive ||| 0-0 1-0
der Packung Die ABILIFY ||| of the pack The ABILIFY ||| 0-0 0-1 1-2 2-3 3-4
der Packung Die ||| of the pack The ||| 0-0 0-1 1-2 2-3
der Packung enthalten . ||| the carton . ||| 0-0 1-1 2-1 3-2
der Packung enthalten ||| the carton ||| 0-0 1-1 2-1
der Packung ||| of the pack ||| 0-0 0-1 1-2
der Packungsbeilage des ||| package leaflet of the ||| 1-0 1-1 0-2 2-2 2-3
der Packungsbeilage zu entnehmen ) ||| in the Package Leaflet ) ||| 0-1 1-2 2-2 3-2 3-3 4-4
der Packungsbeilage zu entnehmen ) ||| the Package Leaflet ) ||| 0-0 1-1 2-1 3-1 3-2 4-3
der Packungsbeilage zu entnehmen . ||| see the Package Leaflet . ||| 1-0 0-1 1-2 2-2 3-2 3-3 4-4
der Packungsbeilage zu entnehmen ||| , see the Package Leaflet ||| 0-0 1-1 0-2 1-3 2-3 3-3 3-4
der Packungsbeilage zu entnehmen ||| , see the Package Leaflet ||| 1-1 0-2 1-3 2-3 3-3 3-4
der Packungsbeilage zu entnehmen ||| in the Package Leaflet ||| 0-1 1-2 2-2 3-2 3-3
der Packungsbeilage zu entnehmen ||| see the Package Leaflet ||| 1-0 0-1 1-2 2-2 3-2 3-3
der Packungsbeilage zu entnehmen ||| the Package Leaflet ||| 0-0 1-1 2-1 3-1 3-2
der Patient darf nicht ||| patient should not ||| 1-0 2-1 2-2 3-2
der Patient ||| , the patient ||| 0-0 0-1 1-2
der Patient ||| , the patient ||| 0-1 1-2
der Patient ||| patient ||| 1-0
der Patient ||| the patient ||| 0-0 1-1
der Patienten ) ||| of patients ) ||| 0-0 1-1 2-2
der Patienten , der ||| der Patienten , der ||| 0-0 1-1 2-2 3-3
der Patienten , ||| der Patienten , ||| 0-0 1-1 2-2
der Patienten auf . ||| of the patients . ||| 0-0 0-1 2-1 1-2 3-3
der Patienten auf ||| of the patients ||| 0-0 0-1 2-1 1-2
der Patienten beobachtet . ||| of the patients . ||| 0-0 0-1 1-2 2-2 3-3
der Patienten beobachtet ||| of the patients ||| 0-0 0-1 1-2 2-2
der Patienten eine ||| of patients received a ||| 0-0 1-1 1-2 2-3
der Patienten erhielt Insulin ||| of patients were receiving insulin ||| 0-0 1-1 2-2 2-3 3-4
der Patienten erhielt ||| of patients were receiving ||| 0-0 1-1 2-2 2-3
der Patienten erhielten die ||| of the patients received ||| 0-0 0-1 3-1 1-2 2-3
der Patienten gemeldet . ||| of patients . ||| 0-0 1-1 2-1 3-2
der Patienten gemeldet . ||| of the patients . ||| 0-0 0-1 1-2 2-2 3-3
der Patienten gemeldet ||| of patients ||| 0-0 1-1 2-1
der Patienten gemeldet ||| of the patients ||| 0-0 0-1 1-2 2-2
der Patienten hatte ||| of the patients had ||| 0-0 0-1 1-2 2-3
der Patienten hatten einen ||| of patients had a ||| 0-0 1-1 2-2 3-2 3-3
der Patienten hatten einen ||| of the patients had a ||| 0-0 0-1 1-2 2-3 3-3 3-4
der Patienten unter ||| of the patients who received ||| 0-0 0-1 1-2 2-2 1-3 1-4
der Patienten ||| der Patienten ||| 0-0 1-1
der Patienten ||| of patients received ||| 0-0 1-1 1-2
der Patienten ||| of patients ||| 0-0 1-1
der Patienten ||| of the patients ||| 0-0 0-1 1-2
der Patienten ||| of ||| 0-0 1-0
der Patientenpopulation und ||| patient population and ||| 0-0 1-0 1-1 2-2
der Patientenpopulation ||| patient population ||| 0-0 1-0 1-1
der Patientinnen ||| in ||| 0-0 1-0
der Pharmakokinetik ||| the pharmacokinetics of ||| 0-0 1-1 0-2
der Placebo-Gruppe . ||| the placebo group . ||| 0-0 1-1 1-2 2-3
der Placebo-Gruppe ||| the placebo group ||| 0-0 1-1 1-2
der Placebogruppe . ||| the placebo group . ||| 0-0 1-1 1-2 2-3
der Placebogruppe ||| the placebo group ||| 0-0 1-1 1-2
der Primärpackung : ||| the immediate packaging : ||| 0-0 1-1 1-2 2-3
der Primärpackung ||| the immediate packaging ||| 0-0 1-1 1-2
der Prägung ||| engraved ||| 0-0 1-0
der Prägung ||| marked ||| 0-0 1-0
der Ratte in Dosierungen von ||| the rat at doses ||| 0-0 1-1 2-2 3-2 3-3 4-3
der Ratte ||| the rat ||| 0-0 1-1
der Ratte ||| treatment-related ||| 0-0 1-0
der Rekonstitution ||| reconstitution , ||| 0-0 1-0
der Rekonstitution ||| reconstitution ||| 0-0 1-0
der Resorption als ein Maß ||| of the absorption rather than ||| 0-0 0-1 1-2 3-3 4-3 2-4
der Resorption ||| of the absorption ||| 0-0 0-1 1-2
der Schmerzen durch Knochenmetastasen ||| into less pain from ||| 2-0 1-2
der Schmerzen durch Knochenmetastasen ||| into less pain ||| 2-0 1-2
der Schmerzen durch ||| into less pain from ||| 2-0 1-2
der Schmerzen durch ||| into less pain ||| 2-0 1-2
der Schmerzen ||| less pain from ||| 1-1
der Schmerzen ||| less pain ||| 1-1
der Schmerzen ||| pain from ||| 1-0
der Schmerzen ||| pain ||| 1-0
der Schwangerschaft und ||| pregnancy and ||| 1-0 2-1
der Schwangerschaft wird daher nicht ||| should ||| 1-0 2-0 3-0 4-0
der Schwangerschaft ||| pregnancy only if the potential ||| 1-0 1-1 1-2 0-3 1-4
der Schwangerschaft ||| pregnancy ||| 1-0
der Speiseröhre und Aspiration sind ||| dysmotility and aspiration have been ||| 0-0 1-0 2-1 3-2 4-2 3-3 3-4
der Speiseröhre und ||| dysmotility and ||| 0-0 1-0 2-1
der Speiseröhre ||| dysmotility ||| 0-0 1-0
der Spritze auf einen ||| the syringe onto a ||| 0-0 1-1 1-2 3-3
der Spritze auf ||| the syringe onto ||| 0-0 1-1 1-2
der Spritze ||| the syringe onto ||| 0-0 1-1 1-2
der Standardbehandlung mit ||| the standard treatment ||| 0-0 1-1 2-2
der Standardbehandlung ||| the standard ||| 0-0 1-1
der Studie . ||| of the study . ||| 0-0 0-1 1-2 2-3
der Studie mit ||| the study of ||| 0-0 1-1 0-2 2-2
der Studie mit älteren Frauen ||| the study of elderly women ||| 0-0 1-1 0-2 2-2 3-3 4-4
der Studie mit älteren ||| the study of elderly ||| 0-0 1-1 0-2 2-2 3-3
der Studie zur Vermeidung ||| the trial for the prevention ||| 0-0 1-1 2-2 0-3 3-3 2-4
der Studie ||| of the study ||| 0-0 0-1 1-2
der Studie ||| the study of ||| 0-0 1-1 0-2
der Studienpopulation waren Frauen ||| of the population were women ||| 0-0 0-1 1-2 2-3 3-4
der Studienpopulation waren ||| of the population were ||| 0-0 0-1 1-2 2-3
der Studienpopulation wies ||| of the study population had ||| 0-0 0-1 1-2 1-3 2-3 1-4
der Studienpopulation ||| of the population ||| 0-0 0-1 1-2
der Suspension ||| of suspension ||| 0-0 1-1
der Symptome , welche innerhalb ||| of post-dose symptoms occurring within ||| 0-0 3-1 1-2 3-2 4-3 4-4
der Symptome , welche ||| of post-dose symptoms ||| 0-0 3-1 1-2 3-2
der Tablettenformulierung beträgt 87 ||| the tablet formulation is 87 ||| 0-0 1-1 1-2 2-2 2-3 3-4
der Tablettenformulierung beträgt ||| the tablet formulation is ||| 0-0 1-1 1-2 2-2 2-3
der Tagesdosis ||| of daily ||| 0-0 1-1
der Therapie berücksichtigen und ||| into account and should ||| 2-0 0-1 1-1 2-1 3-2 2-3
der Therapie mit Pioglitazon ||| of therapy with pioglitazone ||| 0-0 1-1 2-2 3-3
der Therapie mit itte ||| conditions ct ||| 0-0 1-0 2-0 3-1
der Therapie mit ||| conditions ||| 0-0 1-0 2-0
der Therapie mit ||| of therapy with ||| 0-0 1-1 2-2
der Therapie ||| of therapy ||| 0-0 1-1
der Therapie ||| therapy ||| 1-0
der Triglyceride bei Patienten ||| from weight ||| 0-0 1-0 3-1
der Triglyceride bei ||| from ||| 0-0 1-0
der Triglyceride in dieser ||| TG in this ||| 1-0 0-1 2-1 3-2
der Triglyceride in ||| TG in ||| 1-0 0-1 2-1
der Triglyceride ||| from ||| 0-0 1-0
der Tumorprogression führen , ||| of tumour progression , ||| 0-0 1-1 1-2 2-3 3-3
der Tumorprogression ||| of tumour progression ||| 0-0 1-1 1-2
der Verabreichung soll ||| the refrigerated ||| 0-0 1-1 2-1
der Verabreichung von Aclasta auf ||| the dose of Aclasta ||| 0-0 2-1 2-2 4-2 1-3 3-3
der Verabreichung von Aclasta ||| administration of Aclasta ||| 1-0 0-1 2-1 3-2
der Verabreichung von ||| administration of ||| 1-0 0-1 2-1
der Verabreichung von ||| administration ||| 1-0
der Verabreichung von ||| following the administration ||| 1-2
der Verabreichung von ||| serum creatinine level ||| 0-0 1-0 1-1 0-2
der Verabreichung von ||| the administration ||| 1-1
der Verabreichung ||| administration ||| 1-0
der Verabreichung ||| following the administration ||| 1-2
der Verabreichung ||| serum creatinine level ||| 0-0 1-0 1-1 0-2
der Verabreichung ||| the administration ||| 1-1
der Vergangenheit ||| of ||| 0-0
der Vergangenheit ||| the past , ||| 0-0 1-1
der Vergangenheit ||| the past ||| 0-0 1-1
der Verringerung manischer Symptome ||| reduction of manic symptoms ||| 1-0 0-1 2-2 3-3
der Verringerung manischer Symptome über ||| reduction of manic symptoms over ||| 1-0 0-1 2-2 3-3 4-4
der Verringerung manischer ||| reduction of manic ||| 1-0 0-1 2-2
der Verringerung ||| reduction of ||| 1-0 0-1
der Version 3.0 datiert am ||| the version 3.0 ||| 0-0 3-0 4-0 1-1 2-1 2-2
der Werte ||| the levels of ||| 0-0 1-1
der Werte ||| the levels ||| 0-0 1-1
der Wirkung von Zoledronsäure ||| of effect of zoledronic acid ||| 0-0 2-0 1-1 2-2 3-3 3-4
der Wirkung von ||| of effect of ||| 0-0 2-0 1-1 2-2
der Wissenschaft ||| the present state ||| 0-0 1-1 1-2
der Zustand unter Kontrolle ist ||| the condition is controlled ||| 0-0 1-1 4-2 3-3
der Zustand unter ||| the condition ||| 0-0 1-1
der Zustand ||| the condition ||| 0-0 1-1
der aktualisierte ||| , the ||| 0-1 1-1
der aktualisierte ||| the ||| 0-0 1-0
der aliphatischen Methylengruppen umfassend metabolisiert ||| of aliphatic methylene groups ||| 0-0 1-0 1-1 2-1 3-2 4-2 3-3
der aliphatischen Methylengruppen ||| of aliphatic ||| 0-0 1-0 1-1 2-1
der anderen . ||| the other . ||| 0-0 1-1 2-2
der anderen Bestandteile reagieren . ||| of the other ingredients . ||| 0-0 0-1 1-2 2-3 3-3 4-4
der anderen Bestandteile reagieren ||| of the other ingredients ||| 0-0 0-1 1-2 2-3 3-3
der anderen Seite . ||| the other face. . ||| 0-0 1-1 2-2 3-3
der anderen Seite ||| the other face. ||| 0-0 1-1 2-2
der anderen klinischen Effekte ||| of the other clinical effects ||| 0-0 0-1 1-2 2-3 3-4
der anderen klinischen ||| of the other clinical ||| 0-0 0-1 1-2 2-3
der anderen ||| of the other ||| 0-0 0-1 1-2
der anderen ||| reported with ||| 0-0 1-1
der anderen ||| the other ||| 0-0 1-1
der autologen Blutgewinnung ||| the yield of autologous blood ||| 0-0 2-1 0-2 1-3 2-4
der berichteten Fälle wurde ||| of reported cases have been ||| 0-0 1-1 2-2 3-3 3-4
der berichteten Fälle ||| of reported cases ||| 0-0 1-1 2-2
der berichteten ||| of reported ||| 0-0 1-1
der bipolaren Störung verringerte Abilify ||| bipolar disorder , Abilify was ||| 1-0 0-1 2-1 3-2 4-3 1-4
der bipolaren Störung ||| of bipolar disorder ||| 0-0 1-1 2-2
der bipolaren ||| of bipolar ||| 0-0 1-1
der dauerhafte Hämoglobinwert 12 ||| the sustained haemoglobin exceeds 12 ||| 0-0 1-1 2-2 1-3 3-4
der dauerhafte Hämoglobinwert ||| the sustained haemoglobin exceeds ||| 0-0 1-1 2-2 1-3
der den ||| used ||| 1-0
der der Körper nicht ||| the body does not ||| 0-0 1-0 2-1 3-2 3-3
der der Körper ||| the body ||| 0-0 1-0 2-1
der der ||| the ||| 0-0 1-0
der die Kombination von Actos ||| examining the combination of Actos ||| 1-0 0-1 1-1 2-2 3-3 4-4
der die Kombination von ||| examining the combination of ||| 1-0 0-1 1-1 2-2 3-3
der die Kombination ||| examining the combination ||| 1-0 0-1 1-1 2-2
der die ||| der die ||| 0-0 1-1
der die ||| examining the ||| 1-0 0-1 1-1
der dritten ||| third ||| 1-0
der eines ||| of a ||| 0-0 1-0 1-1
der empfohlenen Maximaldosis beim Menschen ||| the maximum recommended human ||| 0-0 1-1 2-1 1-2 3-3 4-3
der empfohlenen Maximaldosis ||| the maximum recommended ||| 0-0 1-1 2-1 1-2
der erhöhten Insulinsensitivität besteht ||| of increased insulin sensitivity ||| 0-0 1-1 3-1 2-2 2-3
der erneuten Gewichtszunahme . ||| of weight regain . ||| 0-0 2-1 1-2 2-2 3-3
der erneuten Gewichtszunahme ||| of weight regain ||| 0-0 2-1 1-2 2-2
der ersten 21-tägigen ||| the first 21 days of ||| 0-0 1-1 2-2 2-3 0-4
der ersten Gabe . Populations- ||| the first dose . ||| 0-0 1-1 2-1 4-1 1-2 3-3
der ersten Gabe ||| the first ||| 0-0 1-1 2-1
der ersten Infusion ||| first infusion ||| 1-0 2-1
der ersten Infusion ||| the first infusion ||| 0-0 1-1 2-2
der ersten Rekonstitution ||| first reconstitution , ||| 0-0 1-0 2-1
der ersten Rekonstitution ||| first reconstitution ||| 0-0 1-0 2-1
der ersten drei Tage nach ||| the first three days after ||| 0-0 1-1 2-2 3-3 4-4
der ersten drei Tage ||| the first three days ||| 0-0 1-1 2-2 3-3
der ersten drei ||| the first three ||| 0-0 1-1 2-2
der ersten ||| first ||| 0-0 1-0
der ersten ||| first ||| 1-0
der ersten ||| the first ||| 0-0 1-1
der folgenden Tabelle 2 ||| der folgenden Tabelle 2 ||| 0-0 1-1 1-2 2-3 3-3
der folgenden ||| der folgenden Tabelle ||| 0-0 1-1 1-2
der folgenden ||| following ||| 1-0
der gemeinsamen ||| co-administration were ||| 0-0 1-0 1-1
der gesamten aktiven Metaboliten liegt ||| its total active metabolites ||| 2-0 1-1 4-1 2-2 3-3
der gleichen Dosis ||| the same dose ||| 0-0 1-1 2-2
der gleichen ||| the same ||| 0-0 1-1
der gängigen medizinischen Praxis erfolgen ||| according to standard medical practice ||| 0-0 1-0 0-1 1-2 2-3 3-4 4-4
der gängigen medizinischen ||| according to standard medical ||| 0-0 1-0 0-1 1-2 2-3
der gängigen ||| according to standard ||| 0-0 1-0 0-1 1-2
der hochwirksamen ||| of potent CYP3A4 ||| 0-0 1-1 1-2
der human-therapeutischen ||| therapeutic ||| 1-0
der in vitro-Löslichkeit . ||| of in vitro solubility . ||| 0-0 1-1 1-2 2-2 2-3 3-4
der in vitro-Löslichkeit ||| of in vitro solubility ||| 0-0 1-1 1-2 2-2 2-3
der jungen Ratten wird ||| pup ||| 0-0 1-0 2-0
der jungen Ratten ||| pup ||| 0-0 1-0 2-0
der kardiovaskulären ||| of the cardiovascular ||| 0-0 0-1 1-2
der klinischen Exposition vergleichbaren Exposition ||| widened brain ventricles and ||| 2-0 2-2 3-2 4-2
der klinischen Exposition vergleichbaren Exposition ||| widened brain ventricles ||| 2-0 2-2 3-2 4-2
der kompletten Standardbatterie von ||| of a full range of ||| 0-0 1-1 1-2 2-3 3-4
der kompletten Standardbatterie ||| of a full range ||| 0-0 1-1 1-2 2-3
der kompletten Standardbreite von ||| of a full range of ||| 0-0 1-1 1-2 1-3 2-3 3-4
der kompletten Standardbreite ||| of a full range ||| 0-0 1-1 1-2 1-3 2-3
der kompletten ||| of a full ||| 0-0 1-1 1-2
der langen Wirksamkeit von ||| works for a long time ||| 1-0 2-2 3-2 1-3 3-4
der letzten ||| of last ||| 0-0 1-1
der limitierten Anzahl von ||| the limited number of ||| 0-0 1-1 2-2 3-3
der limitierten Anzahl ||| the limited number ||| 0-0 1-1 2-2
der limitierten ||| the limited ||| 0-0 1-1
der mediane Zeitpunkt der Infusion ||| the median timing of infusion ||| 0-0 2-0 1-1 3-2 3-3 4-4
der mediane Zeitpunkt der ||| the median timing of ||| 0-0 2-0 1-1 3-2 3-3
der mediane Zeitpunkt ||| the median ||| 0-0 2-0 1-1
der menschlichen therapeutischen Dosis . ||| ) gene mutation assay . ||| 1-1 2-2 3-3 4-4
der menschlichen therapeutischen Dosis . ||| gene mutation assay . ||| 1-0 2-1 3-2 4-3
der menschlichen therapeutischen Dosis ||| ) gene mutation assay ||| 1-1 2-2 3-3
der menschlichen therapeutischen Dosis ||| gene mutation assay ||| 1-0 2-1 3-2
der menschlichen therapeutischen ||| ) gene mutation ||| 1-1 2-2
der menschlichen therapeutischen ||| gene mutation ||| 1-0 2-1
der menschlichen ||| ) gene ||| 1-1
der menschlichen ||| gene ||| 1-0
der metastasierenden Krankheit ||| metastatic disease has ||| 1-0 2-1
der metastasierenden Krankheit ||| metastatic disease ||| 1-0 2-1
der metastasierenden ||| metastatic ||| 1-0
der mit Abraxane behandelten Patienten ||| of patients on Abraxane with ||| 0-0 4-1 2-3 3-3 1-4
der mit Aclasta behandelten Gruppe ||| the Aclasta-treated group ||| 0-0 1-1 2-1 3-1 4-2
der mit Aclasta behandelten ||| the Aclasta-treated ||| 0-0 1-1 2-1 3-1
der mit EORTC-QLQ-C30 ||| of life parameters on the ||| 0-0 1-1 2-1 2-2 2-3 0-4
der mit ||| of ||| 0-0 1-0
der mit ||| those ||| 1-0
der mittleren Steady-State-Exposition ||| times the mean steady-state ||| 2-0 0-1 1-2 2-3
der mittleren steady-state-Exposition ||| 10 times the mean steady-state ||| 1-0 1-1 0-2 1-3 1-4 2-4
der mittleren steady-state-Exposition ||| 3 times the mean steady-state ||| 1-0 1-1 0-2 1-3 1-4 2-4
der mittleren ||| the mean ||| 0-0 1-1
der möglicherweise ||| may ||| 1-0
der nach einem Jahr 5 ||| der nach einem Jahr 5 ||| 0-0 1-1 1-2 2-2 3-3 4-4
der nach einem Jahr ||| der nach einem Jahr ||| 0-0 1-1 1-2 2-2 3-3
der nach einem ||| der nach einem ||| 0-0 1-1 1-2 2-2
der niedrigsten an ||| the lowest ||| 0-0 1-1
der niedrigsten ||| the lowest ||| 0-0 1-1
der notwendigen Menge ||| of the necessary amount ||| 0-0 0-1 1-2 1-3 2-3
der oberen Atemwege ||| upper respiratory tract ||| 1-0 1-1 1-2 2-2
der offenen Studie bestand ||| the open-label study there was ||| 0-0 1-1 3-1 2-2 3-3 3-4
der operativen Versorgung der Hüftfraktur ||| the hip fracture repair ||| 0-0 3-0 2-1 4-1 4-2 1-3 2-3
der oralen Anwendung von Aripiprazol ||| the use of oral aripiprazole ||| 0-0 2-1 3-2 1-3 4-4
der oralen Anwendung von ||| the use of oral ||| 0-0 2-1 3-2 1-3
der oralen Clearance der ||| oral clearance of ||| 1-0 2-1 0-2 3-2
der pharmakokinetischen Analyse ||| the pharmacokinetic analysis ||| 0-0 1-1 2-2
der pharmakokinetischen ||| the pharmacokinetic ||| 0-0 1-1
der postmenopausalen Osteoporose ( PFT ||| of post-menopausal osteoporosis ( PFT ||| 0-0 1-1 2-2 3-3 4-4
der postmenopausalen Osteoporose ( ||| of post-menopausal osteoporosis ( ||| 0-0 1-1 2-2 3-3
der postmenopausalen Osteoporose ||| of post-menopausal osteoporosis ||| 0-0 1-1 2-2
der postmenopausalen ||| of post-menopausal ||| 0-0 1-1
der rekonstituierten Suspension ist möglich ||| of the reconstituted suspension may ||| 0-0 0-1 1-2 2-3 4-4
der rekonstituierten Suspension ist ||| of the reconstituted suspension ||| 0-0 0-1 1-2 2-3
der rekonstituierten Suspension ||| of the reconstituted suspension ||| 0-0 0-1 1-2 2-3
der rekonstituierten ||| of the reconstituted ||| 0-0 0-1 1-2
der schnellen Kontrolle von ||| the rapid control of ||| 0-0 1-1 2-2 3-3
der schnellen Kontrolle ||| the rapid control ||| 0-0 1-1 2-2
der schnellen ||| the rapid ||| 0-0 1-1
der sechs identifizierten Metaboliten ||| of the six identified metabolites ||| 0-0 0-1 1-2 2-3 3-4
der sechs identifizierten ||| of the six identified ||| 0-0 0-1 1-2 2-3
der sechs ||| of the six ||| 0-0 0-1 1-2
der sicheren Anwendung von ||| ensure the safe use of ||| 1-0 0-1 1-2 2-3 3-3 3-4
der sicheren Anwendung ||| factors such ||| 1-0 1-1
der sicheren Anwendung ||| risk factors such ||| 1-1 1-2
der sicheren Anwendung ||| with risk factors such ||| 1-2 1-3
der sicheren ||| ensure the safe ||| 1-0 0-1 1-2
der sicheren ||| factors such ||| 1-0 1-1
der sicheren ||| risk factors such ||| 1-1 1-2
der sicheren ||| with risk factors such ||| 1-2 1-3
der sonstigen Bestandteile siehe Abschnitt ||| of excipients , see section ||| 0-0 1-1 2-1 2-2 3-3 4-4
der sonstigen Bestandteile siehe ||| of excipients , see ||| 0-0 1-1 2-1 2-2 3-3
der sonstigen Bestandteile sind . ||| of the other ingredients . ||| 0-0 0-1 1-2 1-3 2-3 3-3 4-4
der sonstigen Bestandteile sind ||| of the other ingredients ||| 0-0 0-1 1-2 1-3 2-3 3-3
der sonstigen Bestandteile ||| of excipients , ||| 0-0 1-1 2-1 2-2
der sonstigen Bestandteile ||| of the excipients ||| 0-0 0-1 1-2 2-2
der sonstigen Bestandteile ||| of the other ingredients of ||| 0-0 0-1 1-2 1-3 2-3 1-4
der stillenden Mutter ||| of the nursing ||| 0-0 0-1 1-2 2-2
der symptomatischen Anämie bei ||| of symptomatic anaemia in ||| 0-0 1-1 2-2 3-3
der symptomatischen Anämie ||| of symptomatic anaemia associated with ||| 0-0 1-1 2-2 1-3 2-4
der symptomatischen Anämie ||| of symptomatic anaemia ||| 0-0 1-1 2-2
der symptomatischen ||| of symptomatic ||| 0-0 1-1
der verabreichten Dosis ||| of the administered dose ||| 0-0 0-1 1-1 2-3
der verabreichten ||| of the administered ||| 0-0 0-1 1-1
der verabreichten ||| of the ||| 0-0 0-1 1-1
der veröffentlichten Literatur ||| on the published literature ||| 1-0 0-1 1-2 2-3
der veröffentlichten ||| on the published ||| 1-0 0-1 1-2
der weißen ||| of white ||| 0-0 1-1
der weißen ||| of white ||| 1-1
der weißen ||| white ||| 1-0
der wissenschaftlichen Literatur vor . ||| the published literature . ||| 0-0 1-1 2-1 2-2 3-2 4-3
der wissenschaftlichen Literatur vor ||| the published literature ||| 0-0 1-1 2-1 2-2 3-2
der zur ||| to ||| 0-0 1-0
der zusammengefassten Auflistung enthalten ||| due to the pooled presentation ||| 0-0 0-1 0-2 1-3 1-4 2-4 3-4
der zweiten Studie ||| second trial utilised ||| 1-0 2-1 1-2
der ||| , the ||| 0-0 0-1
der ||| , the ||| 0-1
der ||| , ||| 0-0
der ||| Chest ||| 0-0
der ||| accepted ||| 0-0
der ||| associated with ||| 0-0
der ||| associated ||| 0-0
der ||| become ||| 0-0
der ||| benefits and ||| 0-0
der ||| benefits ||| 0-0
der ||| der ||| 0-0
der ||| due to the ||| 0-0 0-1 0-2
der ||| due ||| 0-0
der ||| in the ||| 0-0 0-1
der ||| in the ||| 0-1
der ||| its benefits and ||| 0-1
der ||| its benefits ||| 0-1
der ||| maintained their ||| 0-1
der ||| occlusive ||| 0-0
der ||| of Abraxane ||| 0-0
der ||| of the ||| 0-0 0-1
der ||| of the ||| 0-1
der ||| of ||| 0-0
der ||| on ||| 0-0
der ||| patient s ||| 0-1
der ||| prior ||| 0-0
der ||| rate of ||| 0-1
der ||| reported ||| 0-0
der ||| s ||| 0-0
der ||| safety of ||| 0-0 0-1
der ||| simultaneously ||| 0-0
der ||| the injection ||| 0-0 0-1
der ||| the level of ||| 0-0 0-1 0-2
der ||| the more ||| 0-0
der ||| the patient s ||| 0-2
der ||| the treatment of osteoporosis ||| 0-0 0-1 0-2
der ||| the treatment of ||| 0-0 0-1 0-2
der ||| the ||| 0-0
der ||| their ||| 0-0
der ||| times ||| 0-0
der ||| timing of ||| 0-0 0-1
der ||| to be ||| 0-0 0-1
der ||| to ||| 0-0
der ||| treatment , ||| 0-0
der ||| treatment ||| 0-0
der ||| via the ||| 0-1
der Überempfindlichkeitsreaktionen wird ||| of hypersensitivity reactions is ||| 0-0 1-1 1-2 2-3
der Überempfindlichkeitsreaktionen ||| of hypersensitivity reactions ||| 0-0 1-1 1-2
der überarbeitete ||| the ||| 0-0 1-0
deren Blutzucker trotz einer ||| insufficient glycaemic control despite ||| 0-0 1-1 2-1 2-2 2-3 3-3
deren Blutzucker trotz einer ||| with insufficient glycaemic ||| 0-0 0-1 1-1 2-1 2-2 3-2
deren Blutzucker trotz ||| glycaemic control despite ||| 2-0 2-1 0-2 1-2 2-2
deren Maximum üblicherweise innerhalb ||| and is usually maximal within ||| 0-1 1-1 2-2 0-3 3-4
deren Maximum üblicherweise innerhalb ||| is usually maximal within ||| 0-0 1-0 2-1 0-2 3-3
deren Maximum üblicherweise ||| and is usually maximal ||| 0-1 1-1 2-2 0-3
deren Maximum üblicherweise ||| is usually maximal ||| 0-0 1-0 2-1 0-2
deren ||| insufficient ||| 0-0
deren ||| whose ||| 0-0
derzeit ||| currently ||| 0-0
des Appetits kommen . ||| decreased appetite . ||| 1-0 1-1 2-1 3-2
des Appetits kommen ||| decreased appetite ||| 1-0 1-1 2-1
des Arzneimittels zurück . ||| of the medicine . ||| 0-0 0-1 1-2 3-3
des Arzneimittels zurück ||| of the medicine ||| 0-0 0-1 1-2
des Arzneimittels ||| a summary of the European ||| 1-1 0-2 0-3 1-3 1-4
des Arzneimittels ||| of the medicine ||| 0-0 0-1 1-2
des Arzneimittels ||| summary of the European ||| 1-0 0-1 0-2 1-2 1-3
des Arztes ein . ||| has told you . ||| 1-0 0-1 1-1 2-1 1-2 3-3
des Arztes ein ||| has told you ||| 1-0 0-1 1-1 2-1 1-2
des Ausgangswerts nach 12 Monaten ||| baseline levels at 12 months ||| 1-0 0-1 1-1 1-2 3-3 2-4 4-4
des Ausgangswerts ||| baseline levels at ||| 1-0 0-1 1-1 1-2
des Bewusstseins und extrapyramidale Symptome ||| of consciousness and extrapyramidal symptoms ||| 0-0 0-1 1-1 2-2 3-3 4-4
des Bewusstseins und extrapyramidale ||| of consciousness and extrapyramidal ||| 0-0 0-1 1-1 2-2 3-3
des Bewusstseins und ||| of consciousness and ||| 0-0 0-1 1-1 2-2
des Bewusstseins ||| of consciousness ||| 0-0 0-1 1-1
des Blutdrucks , ||| the blood pressure is ||| 0-0 0-1 1-1 1-2 1-3
des Blutdrucks ||| the blood pressure is ||| 0-0 0-1 1-1 1-2 1-3
des Blutzuckers empfohlen . ||| is therefore recommended . ||| 1-0 0-1 1-1 2-2 3-3
des Blutzuckers empfohlen ||| is therefore recommended ||| 1-0 0-1 1-1 2-2
des Blutzuckers ||| is therefore ||| 1-0 0-1 1-1
des Blutzuckerspiegels produziert . ||| the blood sugar . ||| 0-0 1-1 1-2 2-2 3-3
des Blutzuckerspiegels produziert ||| the blood sugar ||| 0-0 1-1 1-2 2-2
des CHMP wünschen , ||| of the CHMP recommendations , ||| 0-0 0-1 1-2 2-3 3-4
des CHMP wünschen ||| of the CHMP recommendations ||| 0-0 0-1 1-2 2-3
des CHMP ||| of the CHMP ||| 0-0 0-1 1-2
des Diabetes betrug 9,5 Jahre ||| of diabetes was 9.5 years ||| 0-0 1-1 2-2 3-3 4-4
des Diabetes betrug 9,5 ||| of diabetes was 9.5 ||| 0-0 1-1 2-2 3-3
des Diabetes betrug ||| of diabetes was ||| 0-0 1-1 2-2
des Diabetes ist die diätetische ||| of diabetes is dietary ||| 0-0 1-1 2-2 3-2 4-3
des Diabetes ist die ||| of diabetes is ||| 0-0 1-1 2-2 3-2
des Diabetes ||| of diabetes ||| 0-0 1-1
des Dialysesystems ist bei ||| the dialysis system is possible ||| 0-0 1-1 0-2 1-2 2-3 1-4 3-4
des EPAR ) . ||| the EPAR ) . ||| 0-0 0-1 1-1 2-2 3-3
des EPAR ) ||| the EPAR ) ||| 0-0 0-1 1-1 2-2
des EPAR ist ) . ||| of the EPAR ) . ||| 0-0 0-1 2-1 0-2 1-2 3-3 4-4
des EPAR ist ) ||| of the EPAR ) ||| 0-0 0-1 2-1 0-2 1-2 3-3
des EPAR ist ||| of the EPAR ||| 0-0 0-1 2-1 0-2 1-2
des EPAR ||| the EPAR ||| 0-0 0-1 1-1
des Eintritts einer Schwangerschaft . ||| medicine works . ||| 0-0 1-0 1-1 2-1 3-1 4-2
des Eintritts einer Schwangerschaft ||| medicine works ||| 0-0 1-0 1-1 2-1 3-1
des Ereignisses zurück . ||| of the event onset . ||| 0-0 0-1 1-2 1-3 2-3 3-4
des Ereignisses zurück ||| of the event onset ||| 0-0 0-1 1-2 1-3 2-3
des Fortschreitens einer diabetischen Retinopathie ||| of progression of diabetic retinopathy ||| 0-0 0-1 1-1 1-2 2-3 3-3 4-4
des Fortschreitens einer diabetischen Retinopathie ||| of progression of diabetic retinopathy ||| 0-0 1-1 1-2 2-3 3-3 4-4
des Fortschreitens einer diabetischen ||| of progression of diabetic ||| 0-0 0-1 1-1 1-2 2-3 3-3
des Fortschreitens einer diabetischen ||| of progression of diabetic ||| 0-0 1-1 1-2 2-3 3-3
des Fortschreitens ||| of progression of ||| 0-0 0-1 1-1 1-2
des Fortschreitens ||| of progression of ||| 0-0 1-1 1-2
des Futters . ||| the food . ||| 0-0 1-1 2-2
des Futters ||| the food ||| 0-0 1-1
des Harnblasenepithels induziert . ||| up to 2 years . ||| 1-0 0-1 1-2 1-3 2-3 3-4
des Harnblasenepithels induziert ||| up to 2 years ||| 1-0 0-1 1-2 1-3 2-3
des HbA1c-Spiegels , ||| the level of HbA1c , ||| 0-0 1-1 0-2 2-3 2-4
des HbA1c-Spiegels ||| the level of ||| 0-0 1-1 0-2
des HbA1c-Wertes ||| absolute change in HbA1c ||| 1-0 1-1 0-2 1-3
des Herstellers , der ||| of the manufacturer ||| 0-0 0-1 3-1 1-2 2-2
des Herstellers des ||| of the manufacturer of the ||| 0-0 0-1 1-2 2-3 2-4
des Herstellers ||| of the manufacturer ||| 0-0 0-1 1-2
des Hormons noch ||| of the pharmacological effects ||| 0-0 0-1 0-2 1-2 2-2 1-3
des Immunsystems ) während Ihrer ||| your immune system ) during ||| 4-0 0-2 1-2 2-3 3-4
des Immunsystems ) während ||| immune system ) during ||| 0-1 1-1 2-2 3-3
des Immunsystems ) während ||| system ) during ||| 0-0 1-0 2-1 3-2
des Immunsystems ) ||| immune system ) ||| 0-1 1-1 2-2
des Immunsystems ) ||| system ) ||| 0-0 1-0 2-1
des Immunsystems ||| immune system ||| 0-1 1-1
des Immunsystems ||| system ||| 0-0 1-0
des Immunsystems ||| the ||| 0-0
des Insulins ||| insulin ||| 0-0 1-0
des Insulins ||| of insulin ||| 0-0 0-1 1-1
des Knochens . ||| of the bone . ||| 0-0 0-1 1-2 2-3
des Knochens Normalerweise ||| of the bone ||| 0-0 0-1 1-2 2-2
des Knochens eingesetzt . ||| of the bone . ||| 0-0 0-1 1-2 2-2 3-3
des Knochens eingesetzt ||| of the bone ||| 0-0 0-1 1-2 2-2
des Knochens ||| of the bone ||| 0-0 0-1 1-2
des Knochenstoffwechsels müssen ebenfalls ||| of mineral metabolism must also ||| 0-0 1-1 1-2 2-3 3-4
des Knochenstoffwechsels müssen ||| of mineral metabolism must ||| 0-0 1-1 1-2 2-3
des Knochenstoffwechsels ||| of mineral metabolism ||| 0-0 1-1 1-2
des Knochenumbaus . ||| in bone turnover . ||| 0-0 0-1 1-1 1-2 2-3
des Knochenumbaus ||| bone turnover ||| 1-0 0-1 1-1
des Knochenumbaus ||| in bone turnover ||| 0-0 0-1 1-1 1-2
des Körpers ||| of the body ||| 0-0 0-1 1-2
des Labyrinths ||| mediastinal disorders ||| 0-0 1-0 1-1
des Mineralstoffhaushalts sind wirksam ||| of mineral metabolism must also ||| 0-0 1-1 1-2 1-3 2-4
des Mineralstoffhaushalts sind ||| of mineral metabolism must also ||| 0-0 1-1 1-2 1-3 2-4
des Mineralstoffhaushalts ||| of mineral metabolism must ||| 0-0 1-1 1-2 1-3
des Monats . ||| of that month . ||| 0-0 1-1 1-2 2-3
des Monats ||| of that month ||| 0-0 1-1 1-2
des Morbus Paget des ||| Paget s disease of the ||| 1-0 2-0 0-1 1-1 2-2 3-3 3-4
des Morbus Paget ||| Paget s disease ||| 1-0 2-0 0-1 1-1 2-2
des Morbus Paget ||| of Paget s disease , ||| 0-0 1-1 2-1 0-2 1-2 2-3
des Morbus Paget ||| of Paget s disease : ||| 0-0 1-1 2-1 0-2 1-2 2-3
des Morbus Paget ||| of Paget s disease ||| 0-0 1-1 2-1 0-2 1-2 2-3
des Nervensystems : ||| Nervous disorders : ||| 1-0 0-1 1-1 2-2
des Nervensystems ||| Nervous disorders ||| 1-0 0-1 1-1
des Nervensystems ||| Nervous ||| 0-0 1-0
des Patienten ||| patient 's ||| 1-0 0-1
des Patienten ||| the patient on ||| 0-0 1-1 0-2
des Pharmazeutischen Unternehmers in Verbindung ||| of the Marketing Authorisation Holder ||| 0-0 0-1 0-2 1-2 2-3 3-3 4-4
des Pharmazeutischen Unternehmers in ||| of the Marketing Authorisation ||| 0-0 0-1 0-2 1-2 2-3 3-3
des Pharmazeutischen ||| of the Marketing ||| 0-0 0-1 0-2 1-2
des Produkts pro 8 ||| of the product per 8 ||| 0-0 0-1 0-2 1-2 2-3 3-4
des Produkts pro ||| of the product per ||| 0-0 0-1 0-2 1-2 2-3
des Produkts ||| of the product ||| 0-0 0-1 0-2 1-2
des Prüfarztes ||| by the investigator ||| 0-1 1-2
des Prüfarztes ||| the investigator ||| 0-0 1-1
des Pulvers erfolgt ist ||| of any powder ||| 0-0 0-1 1-2
des Pulvers erfolgt ||| of any powder ||| 0-0 0-1 1-2
des Pulvers ||| of any powder ||| 0-0 0-1 1-2
des Risikos einer ||| other erythropoietic therapy ||| 1-0 0-1 1-1 1-2 2-2
des Stammzellkompartiments stimuliert ||| of the stem cell compartment ||| 0-0 0-1 0-2 1-2 1-3 2-4
des Stammzellkompartiments ||| of the stem cell ||| 0-0 0-1 0-2 1-2 1-3
des Steady State ist bei ||| des Steady State ist bei ||| 0-0 1-1 2-1 1-2 3-3 4-4
des Steady State ist ||| des Steady State ist ||| 0-0 1-1 2-1 1-2 3-3
des Steady State ||| des Steady State ||| 0-0 1-1 2-1 1-2
des Sulfonylharnstoffes zu haben . ||| of the sulphonylurea . ||| 0-0 0-1 2-1 1-2 3-2 4-3
des Sulfonylharnstoffes zu haben ||| of the sulphonylurea ||| 0-0 0-1 2-1 1-2 3-2
des Sulfonylharnstoffs ||| of the sulphonylurea ||| 0-0 0-1 1-2
des Tierarzneimittels ||| of the veterinary medicinal product ||| 0-0 0-1 1-2 1-3 1-4
des Transfusionsbedarfs bei ||| of transfusion requirements in ||| 0-0 0-1 1-1 1-2 2-3
des Transfusionsbedarfs ||| of transfusion requirements ||| 0-0 0-1 1-1 1-2
des Wertes ) . ||| of the value ) . ||| 0-0 0-1 0-2 1-2 2-3 3-4
des Wertes ) ||| of the value ) ||| 0-0 0-1 0-2 1-2 2-3
des Wertes ||| of the value ||| 0-0 0-1 0-2 1-2
des Wiederauftretens manischer Episoden ||| of manic episodes ||| 0-0 1-1 2-1 3-2
des Wiederauftretens manischer ||| of manic ||| 0-0 1-1 2-1
des Wirkstoffs biologischen Ursprungs ||| of the biological active substance ||| 0-0 0-1 1-2 2-2 2-3 2-4 3-4
des Wirkstoffs oder seiner Metaboliten ||| of the compound or metabolites ||| 0-0 1-1 1-2 3-2 2-3 4-4
des Wirkstoffs oder seiner ||| of the compound or ||| 0-0 1-1 1-2 3-2 2-3
des Zellzyklus ||| microtubules throughout the ||| 1-0 1-1 0-2
des größeren ||| des ||| 0-0
des höheren ||| des ||| 0-0
des körpereigenen Insulins herbeiführen ||| of the insulin it produces ||| 0-0 0-1 2-2 1-3 1-4 2-4 3-4
des pharmazeutischen Unternehmers in Verbindung ||| of the Marketing Authorisation Holder ||| 0-0 0-1 0-2 1-2 2-3 3-3 4-4
des pharmazeutischen Unternehmers in ||| of the Marketing Authorisation ||| 0-0 0-1 0-2 1-2 2-3 3-3
des pharmazeutischen ||| of the Marketing ||| 0-0 0-1 0-2 1-2
des prämenopausalen Bereichs . ||| the pre-menopausal range . ||| 0-0 1-1 2-1 2-2 3-3
des prämenopausalen Bereichs ||| the pre-menopausal range ||| 0-0 1-1 2-1 2-2
des roten ||| of the red blood ||| 0-0 0-1 1-2 1-3
des zweiten Jahres in die ||| the second year had ||| 0-0 3-0 4-0 1-1 2-2 4-3
des ||| 's ||| 0-0
des ||| bone metastases ||| 0-0
des ||| bone ||| 0-0
des ||| by the ||| 0-1
des ||| des ||| 0-0
des ||| from bone metastases ||| 0-1
des ||| from bone ||| 0-1
des ||| in ||| 0-0
des ||| of any ||| 0-0 0-1
des ||| of the ||| 0-0 0-1
des ||| of ||| 0-0
des ||| smoking ||| 0-0
des ||| the level of ||| 0-0 0-2
des ||| the peak ||| 0-0
des ||| the ||| 0-0
des ||| to ||| 0-0
deshalb ist das Gewicht ||| therefore weight ||| 0-0 1-0 2-1 3-1
deshalb ist ||| therefore ||| 0-0 1-0
deshalb sollten ||| should therefore ||| 1-0 0-1
deshalb sollten ähnliche Dosisreduktionen ||| dose reductions should therefore ||| 2-0 1-1 2-1 3-1 1-2 0-3
deshalb sollten ähnliche Dosisreduktionen ||| similar dose reductions should therefore ||| 0-0 2-0 2-1 1-2 2-2 3-2 1-3 0-4
deshalb sollten ähnliche Dosisreduktionen ||| similar dose reductions should ||| 0-0 2-0 2-1 1-2 2-2 3-2 1-3
deshalb ||| therefore ||| 0-0
detaillierte Bedienungsanleitung muss befolgt werden ||| delivery system must be followed ||| 0-0 0-1 1-1 2-2 3-3 4-3 3-4
detaillierte Bedienungsanleitung muss ||| delivery system must ||| 0-0 0-1 1-1 2-2
detaillierte Bedienungsanleitung ||| delivery system ||| 0-0 0-1 1-1
deutet darauf hin , dass ||| that ||| 0-0 1-0 2-0 3-0 4-0
deutlich größere Häufigkeit von ||| more ||| 1-0
deutlich größere Häufigkeit ||| more ||| 1-0
deutlich größere ||| more ||| 1-0
deutlich unter ||| well below ||| 0-0 1-1
deutlich ||| well ||| 0-0
diabetische Ketoazidose , diabetisches hyperosmolares ||| diabetic ketoacidosis , diabetic hyperosmolar ||| 0-0 1-1 2-2 3-3 3-4 4-4
diabetische Ketoazidose , ||| diabetic ketoacidosis , ||| 0-0 1-1 2-2
diabetische Ketoazidose ||| diabetic ketoacidosis ||| 0-0 1-1
diabetische ||| diabetic ||| 0-0
diabetischen ||| diabetic ||| 0-0
diabetischer Ketoazidose ||| diabetic ketoacidosis ||| 0-0 1-0 1-1
diabetisches hyperosmolares Koma ||| diabetic hyperosmolar coma ||| 0-0 0-1 1-1 2-2
diabetisches hyperosmolares ||| diabetic hyperosmolar ||| 0-0 0-1 1-1
dialysepflichtig sind ( siehe Abschnitt ||| undergoing dialysis ( See section ||| 0-0 0-1 1-1 2-2 3-3 4-4
dialysepflichtig sind ( siehe ||| undergoing dialysis ( See ||| 0-0 0-1 1-1 2-2 3-3
dialysepflichtig sind ( ||| undergoing dialysis ( ||| 0-0 0-1 1-1 2-2
dialysepflichtig sind ||| undergoing dialysis ||| 0-0 0-1 1-1
dialysepflichtig ||| undergoing dialysis does ||| 0-0 0-1 0-2
die ( ||| ( ||| 1-0
die ABILIFY Schmelztabletten ||| the ABILIFY orodispersible ||| 0-0 1-1 2-2
die ABILIFY Tablette jeden ||| the ABILIFY tablet at the ||| 0-0 1-1 2-2 3-2 3-3 3-4
die ABILIFY ||| the ABILIFY ||| 0-0 1-1
die ALT-Spiegel ||| ALT levels ||| 1-0 0-1 1-1
die ALT-Spiegel über ||| ALT levels remain ||| 1-0 0-1 1-1 1-2 2-2
die AUC nach Gabe der ||| the AUC after the ||| 0-0 1-1 2-2 3-2 4-3
die AUC nach Gabe ||| the AUC after ||| 0-0 1-1 2-2 3-2
die AUC ||| AUC ||| 1-0
die AUC ||| the AUC ||| 0-0 1-1
die Anwendung von rekombinantem humanen ||| the administration of recombinant human ||| 0-0 1-1 2-2 3-3 4-3 4-4
die Anwendung von ||| the administration of ||| 0-0 1-1 2-2
die Anwendung ||| its use ||| 0-0 0-1 1-1
die Anwendung ||| the administration ||| 0-0 1-1
die Anzahl an Patientinnen ||| the number of patients ||| 0-0 1-1 2-2 3-3
die Anzahl an ||| the number of ||| 0-0 1-1 2-2
die Anzahl der ||| at the number ||| 2-0 0-1 2-1 1-2
die Anzahl ||| the number ||| 0-0 1-1
die Anämie ||| the anaemia ||| 0-0 1-1
die Aripiprazol Injektionslösung ||| , aripiprazole solution for injection ||| 1-1 2-2 0-3 2-3 2-4
die Aripiprazol Injektionslösung ||| aripiprazole solution for injection ||| 1-0 2-1 0-2 2-2 2-3
die Aripiprazol-Dosis ||| the aripiprazole dose ||| 0-0 1-1 1-2
die Aufnahme ||| the ||| 0-0 1-0
die Ausscheidung über die Nieren ||| excretion via the kidneys ||| 1-0 2-1 4-1 0-2 3-2 4-3
die Bauchdecke injiziert . ||| abdominal wall . ||| 0-0 1-0 1-1 2-1 3-2
die Bauchdecke injiziert ||| abdominal wall ||| 0-0 1-0 1-1 2-1
die Bauchdecke ||| the abdominal wall ||| 0-0 0-1 1-1 1-2
die Bauchspeicheldrüse ||| pancreas ||| 1-0
die Beendigung der ||| considering stopping ||| 0-0 1-1 2-1
die Behandlung abzubrechen . ||| should be considered . ||| 0-0 2-0 2-1 1-2 2-2 3-3
die Behandlung abzubrechen ||| should be considered ||| 0-0 2-0 2-1 1-2 2-2
die Behandlung anspricht , ||| responds , ||| 0-0 1-0 2-0 3-1
die Behandlung anspricht ||| responds ||| 0-0 1-0 2-0
die Behandlung der Blutarmut ||| , treatment of anaemia ||| 1-1 0-2 2-2 3-3
die Behandlung der Blutarmut ||| treatment of anaemia ||| 1-0 0-1 2-1 3-2
die Behandlung der bipolaren Störung ||| the treatment of bipolar disorder ||| 0-0 1-1 2-2 3-3 4-4
die Behandlung der bipolaren ||| the treatment of bipolar ||| 0-0 1-1 2-2 3-3
die Behandlung der ||| , treatment of ||| 1-1 0-2 2-2
die Behandlung der ||| the treatment of ||| 0-0 1-1 2-2
die Behandlung der ||| treatment of ||| 1-0 0-1 2-1
die Behandlung mit Abseamed beginnt ||| the Abseamed treatment begins ||| 0-0 3-1 1-2 2-2 4-3
die Behandlung mit Abseamed ||| the Abseamed treatment ||| 0-0 3-1 1-2 2-2
die Behandlung mit zwei anderen ||| , treatment with two other ||| 0-0 1-1 2-2 3-3 4-4
die Behandlung mit zwei ||| , treatment with two ||| 0-0 1-1 2-2 3-3
die Behandlung mit ||| , treatment with ||| 0-0 1-1 2-2
die Behandlung mit ||| treatment with ||| 0-0 1-0 2-1
die Behandlung von ||| the treatment of ||| 0-0 1-1 2-2
die Behandlung ||| , treatment ||| 0-0 1-1
die Behandlung ||| the treatment ||| 0-0 1-1
die Behandlung ||| treatment ||| 0-0 1-0
die Behandlung ||| treatment ||| 1-0
die Beseitigung und sonstige ||| precaustions for disposal and ||| 1-0 0-1 1-1 1-2 3-2 2-3
die Bildung von Erythrozyten ||| , the formation of erythrocytes ||| 0-0 0-1 1-2 2-3 3-4
die Bildung von Mikrotubulibündeln ||| abnormal arrays or bundles of ||| 1-0 1-1 3-1 2-2 3-3 2-4
die Bildung von ||| , the formation of ||| 0-0 0-1 1-2 2-3
die Bildung ||| , the formation ||| 0-0 0-1 1-2
die Bindung ist ||| binding is ||| 1-0 2-1
die Bindung ||| binding ||| 1-0
die Bioverfügbarkeit von Mitratapid ( ||| the bioavailability of mitratapide ( ||| 0-0 1-1 2-2 3-3 4-4
die Bioverfügbarkeit von Mitratapid ||| , the bioavailability of mitratapide ||| 0-1 1-2 2-3 3-4
die Bioverfügbarkeit von Mitratapid ||| the bioavailability of mitratapide ||| 0-0 1-1 2-2 3-3
die Bioverfügbarkeit von ||| , the bioavailability of ||| 0-1 1-2 2-3
die Bioverfügbarkeit von ||| the bioavailability of ||| 0-0 1-1 2-2
die Bioverfügbarkeit ||| , the bioavailability ||| 0-1 1-2
die Bioverfügbarkeit ||| bioavailability ||| 1-0
die Bioverfügbarkeit ||| the bioavailability ||| 0-0 1-1
die Blutspiegel von Ciclosporin ||| blood levels of cyclosporin ||| 1-0 0-1 1-1 2-2 1-3 3-3
die Blutzucker senkende Wirkung ||| intensify and prolong the ||| 0-0 1-0 2-0 2-1 2-2 3-2 3-3
die Blutzuckerwerte ||| glucose levels had ||| 1-0 0-1 0-2
die Cmax von ||| Cmax ||| 1-0
die Cmax von ||| Cmax ||| 1-0 2-0
die Cmax ||| Cmax ||| 1-0
die Differenz in der gesamten ||| , the difference in total ||| 0-1 3-1 1-2 2-3 4-4
die Differenz in der gesamten ||| the difference in total ||| 0-0 3-0 1-1 2-2 4-3
die Differenz in der ||| , the difference in ||| 0-1 3-1 1-2 2-3
die Differenz in der ||| the difference in ||| 0-0 3-0 1-1 2-2
die Disposition von Paclitaxel ||| the disposition of paclitaxel ||| 0-0 1-1 2-2 3-3
die Disposition von ||| the disposition of ||| 0-0 1-1 2-2
die Disposition ||| the disposition ||| 0-0 1-1
die Dosierung von ABILIFY ||| , the dosage of ABILIFY ||| 0-1 1-2 2-3 3-4
die Dosierung von ABILIFY ||| the dosage of ABILIFY ||| 0-0 1-1 2-2 3-3
die Dosierung von ||| , the dosage of ||| 0-1 1-2 2-3
die Dosierung von ||| the dosage of ||| 0-0 1-1 2-2
die Dosierung ||| , the dosage ||| 0-1 1-2
die Dosierung ||| dosing ||| 0-0 1-0
die Dosierung ||| the dosage ||| 0-0 1-1
die Dosis des Sulfonylharnstoffs ||| the dose of the sulphonylurea ||| 0-0 1-1 2-2 2-3 3-4
die Dosis des ||| the dose of the ||| 0-0 1-1 2-2 2-3
die Dosis von ||| the dose ||| 0-0 1-1 2-1
die Dosis ||| , additional dose reduction ||| 0-2 1-2 1-3
die Dosis ||| additional dose reduction ||| 0-1 1-1 1-2
die Dosis ||| dose reduction ||| 0-0 1-0 1-1
die Dosis ||| the dose ||| 0-0 1-1
die Durchstechflasche ||| , the vial ||| 0-1 1-2
die Durchstechflasche ||| the vial ||| 0-0 1-1
die EMEA ||| the EMEA ||| 0-0 1-1
die Einnahme ||| the intake ||| 0-0 1-1
die Einnahme ||| you ||| 1-0
die Einstichstelle . ||| pad . ||| 1-0 2-1
die Einstichstelle ||| pad ||| 1-0
die Eliminationshalbwertszeit wegen des größeren ||| die Eliminationshalbwertszeit wegen des ||| 0-0 1-1 1-2 3-3
die Eliminationshalbwertszeit wegen des ||| die Eliminationshalbwertszeit wegen des ||| 0-0 1-1 1-2 3-3
die Eliminationshalbwertszeit wegen ||| die Eliminationshalbwertszeit wegen ||| 0-0 1-1 1-2
die Eliminationshalbwertszeit ||| die Eliminationshalbwertszeit wegen ||| 0-0 1-1 1-2
die Endothelzellen fördert . ||| across endothelial cells . ||| 0-0 1-1 2-1 0-2 3-3
die Endothelzellen fördert ||| across endothelial cells ||| 0-0 1-1 2-1 0-2
die Entwicklung schwerer Symptome ||| although development of severe symptoms ||| 0-0 1-1 0-2 2-3 3-4
die Entwicklung schwerer ||| although development of severe ||| 0-0 1-1 0-2 2-3
die Entwicklung ||| although development of ||| 0-0 1-1 0-2
die Enzyme CYP3A4 und CYP2D6 ||| , CYP3A4 and CYP2D6 enzymes ||| 0-0 2-1 3-2 4-3 1-4
die Epoetin-alfa-Dosis ||| reduce the epoetin alfa ||| 1-0 0-1 1-2 1-3
die Epoetin-alfa-Therapie ||| alfa therapy ||| 1-0 0-1 1-1
die Erfahrung ||| who has experience ||| 0-0 1-2
die Erkrankung unbehandelt bleibt ||| the disease is ||| 0-0 1-1 2-1 3-2
die Erkrankung unbehandelt ||| the disease ||| 0-0 1-1 2-1
die Ernährung nicht eingeschränkt wurde ||| diet was not restricted ||| 1-0 0-1 4-1 2-2 3-3
die Erteilung der ||| the granting of ||| 0-0 2-0 1-1 2-2
die Fruchtbarkeit in Studien ||| impair fertility in ||| 0-0 1-0 1-1 2-1 3-1 2-2
die Fähigkeit , ||| drive ||| 0-0 1-0
die Fähigkeit von Krebszellen ||| the ability of cancer cells ||| 0-0 0-1 1-1 2-2 3-3 3-4
die Fähigkeit von ||| the ability of ||| 0-0 0-1 1-1 2-2
die Fähigkeit zum Bedienen von ||| to drive and use ||| 0-0 1-0 1-1 2-1 2-2 3-3 4-3
die Fähigkeit zum ||| drive ||| 0-0 1-0 2-0
die Fähigkeit zum ||| to drive and ||| 0-0 1-0 1-1 2-1 2-2
die Fähigkeit ||| drive ||| 0-0 1-0
die Fähigkeit ||| the ability ||| 0-0 0-1 1-1
die Fäzes . ||| the faeces . ||| 0-0 1-1 2-2
die Fäzes ||| the faeces ||| 0-0 1-1
die Gesamthäufigkeit von Vorhofflimmern ||| the pooled atrial fibrillation incidences ||| 0-0 1-1 1-2 2-2 3-3
die Gesamthäufigkeit von Vorhofflimmern ||| the pooled atrial fibrillation ||| 0-0 1-1 1-2 2-2 3-3
die Gesamthäufigkeit von ||| the pooled atrial ||| 0-0 1-1 1-2 2-2
die HDL-Cholesterinspiegel . ||| gliclazide . ||| 1-0 2-1
die HDL-Cholesterinspiegel ||| gliclazide ||| 1-0
die Haut ( ||| the skin ( ||| 0-0 1-1 2-2
die Haut ||| the skin ||| 0-0 1-1
die Hypoglykämie-Warnsymptome ||| change in their usual ||| 1-0 1-1 1-2 1-3
die Hypoglykämie-Warnsymptome ||| change in their usual ||| 1-0 1-2 1-3
die Hälfte der ||| one-half of its ||| 1-0 0-1 2-1 1-2
die Hämoglobin-Zielkonzentration von ||| the haemoglobin target range of ||| 0-0 1-1 1-2 1-3 2-4
die Hämoglobin-Zielkonzentration ||| the haemoglobin target range ||| 0-0 1-1 1-2 1-3
die Hämoglobinkonzentration ||| the haemoglobin concentration should be ||| 0-0 1-1 1-2 1-3 1-4
die Hämoglobinwerte im gewünschten ||| to maintain haemoglobin values ||| 0-0 1-1 2-1 1-2 3-3
die Hämoglobinwerte im ||| to maintain haemoglobin ||| 0-0 1-1 2-1 1-2
die Häufigkeit und Schwere ||| , the frequency and severity ||| 0-0 0-1 1-2 2-3 3-4
die Häufigkeit und ||| , the frequency and ||| 0-0 0-1 1-2 2-3
die Häufigkeit von Wirbelkörperfrakturen ||| the incidence of vertebral fractures ||| 0-0 1-1 2-2 3-3 3-4
die Häufigkeit von klinischen Frakturen ||| the incidence of clinical fractures ||| 0-0 1-1 2-2 3-3 4-4
die Häufigkeit von klinischen ||| the incidence of clinical ||| 0-0 1-1 2-2 3-3
die Häufigkeit von ||| the incidence of ||| 0-0 1-1 2-2
die Häufigkeit ||| , the frequency ||| 0-0 0-1 1-2
die Häufigkeit ||| the frequency ||| 0-0 1-1
die Häufigkeit ||| the incidence ||| 0-0 1-1
die Hüfte ||| hip ||| 1-0
die Infusion von Aclasta ||| to give the Aclasta infusion ||| 0-0 2-0 0-1 0-2 3-3 1-4
die Injektion ||| the injection ||| 0-0 1-1
die Insulinsensitivität erhöht . ||| increasing insulin sensitivity . ||| 1-0 1-1 1-2 2-2 3-3
die Insulinsensitivität erhöht ||| increasing insulin sensitivity ||| 1-0 1-1 1-2 2-2
die Inzidenz tödlicher ||| treatment outcomes ||| 2-0 0-1 1-1 2-1
die Inzidenz von EPS ||| , the incidence of EPS ||| 0-1 1-2 2-3 3-4
die Inzidenz von EPS ||| the incidence of EPS was ||| 0-0 1-1 2-2 3-3 3-4
die Inzidenz von EPS ||| the incidence of EPS ||| 0-0 1-1 2-2 3-3
die Inzidenz von ||| , the incidence of ||| 0-1 1-2 2-3
die Inzidenz von ||| the incidence of ||| 0-0 1-1 2-2
die Inzidenz ||| , the incidence ||| 0-1 1-2
die Inzidenz ||| the incidence ||| 0-0 1-1
die Knochen geschwächt hat ||| has made their bones weaker ||| 3-0 2-1 2-2 1-3 2-3 2-4
die Knochen geschwächt ||| made their bones weaker ||| 2-0 2-1 1-2 2-2 2-3
die Knochen und verringert deshalb ||| the bone and therefore makes ||| 0-0 1-1 2-2 3-3 4-3 1-4
die Kombination einer ||| a combination of ||| 2-0 1-1
die Kombination einer ||| a combination ||| 2-0 1-1
die Kombination ||| combination of ||| 1-0
die Kombination ||| combination ||| 1-0
die Konzentration einer Substanz ||| the level of a substance ||| 0-0 1-1 2-2 3-2 2-3
die Konzentration einer Substanz ||| the level of a ||| 0-0 1-1 2-2 3-2 2-3
die Konzentration ||| the level ||| 0-0 1-1
die Leber stattfindet . ||| which is primarily hepatic . ||| 0-0 2-0 2-1 1-2 2-2 2-3 3-4
die Leber stattfindet ||| which is primarily hepatic ||| 0-0 2-0 2-1 1-2 2-2 2-3
die Leberenzymwerte zu ||| liver enzymes should ||| 1-0 2-0 1-1 0-2 1-2
die Lösung nicht einnehmen ||| not take the oral solution ||| 2-0 3-1 0-2 3-3 1-4
die Lösung ||| , the solution ||| 0-1 1-2
die Lösung ||| the solution ||| 0-0 1-1
die Mehrzahl der Patienten ||| the majority of patients received ||| 0-0 1-1 2-2 3-3 3-4
die Mehrzahl der ||| the majority of the ||| 0-0 1-1 2-2 2-3
die Mehrzahl der ||| the majority of ||| 0-0 1-1 2-2
die Mehrzahl ||| the majority ||| 0-0 1-1
die Messung des Serum-Kalzium-Spiegels ||| of Aclasta ||| 0-0 2-0 1-1 3-1
die Messung des ||| of Aclasta ||| 0-0 2-0 1-1
die Montgomery-Asberg- ||| the Montgomery-Asberg ||| 0-0 1-1
die N-Dealkylierung wird ||| N-dealkylation is ||| 1-0 2-1
die N-Dealkylierung ||| N-dealkylation ||| 1-0
die Nadel schnell ||| the needle quickly ||| 0-0 1-1 2-2
die Nadel ||| the needle ||| 0-0 1-1
die Nebenwirkungen ||| effects ||| 0-0 1-0
die Neutrophilenzahl auf > ||| neutrophil counts recover to > ||| 1-0 0-1 1-1 1-2 2-2 2-3 3-4
die Neutrophilenzahl auf ||| neutrophil counts recover to ||| 1-0 0-1 1-1 1-2 2-2 2-3
die Packung mit ||| the pack with ||| 0-0 1-1 2-2
die Packung ||| the pack ||| 0-0 1-1
die Packungsbeilage ( die ||| the Package Leaflet ( ||| 0-0 3-0 1-1 1-2 2-3
die Packungsbeilage oder ||| the package leaflet or ||| 0-0 1-1 1-2 2-3
die Packungsbeilage ||| the Package ||| 0-0 1-1
die Packungsbeilage ||| the package leaflet ||| 0-0 1-1 1-2
die Paclitaxel-Plasmakonzentration auf ||| declined in ||| 1-0
die Paclitaxel-Plasmakonzentration auf ||| declined ||| 1-0
die Paclitaxel-Plasmakonzentration ||| declined in ||| 1-0
die Paclitaxel-Plasmakonzentration ||| declined ||| 1-0
die Patienten eine ||| to ||| 0-0 2-0
die Patienten ||| patients ||| 1-0
die Pharmakokinetik oder Pharmakodynamik ||| either the pharmacokinetics or pharmacodynamics ||| 3-0 0-1 1-2 2-3 3-4
die Pharmakokinetik oder ||| the pharmacokinetics or ||| 0-0 1-1 2-2
die Pharmakokinetik von Aripiprazol . ||| the pharmacokinetics of aripiprazole . ||| 0-0 1-1 2-2 3-3 4-4
die Pharmakokinetik von Aripiprazol ||| the pharmacokinetics of aripiprazole ||| 0-0 1-1 2-2 3-3
die Pharmakokinetik von ||| the pharmacokinetics of ||| 0-0 1-1 2-2
die Pharmakokinetik ||| the pharmacokinetics ||| 0-0 1-1
die Pioglitazon ||| pioglitazone ||| 1-0
die Pipette ||| , the pipette ||| 0-1 1-2
die Pipette ||| the pipette ||| 0-0 1-1
die Placebo erhielten ( siehe ||| those receiving placebo ( see ||| 0-0 2-0 2-1 1-2 3-3 4-4
die Placebo erhielten ( ||| those receiving placebo ( ||| 0-0 2-0 2-1 1-2 3-3
die Placebo erhielten ||| those receiving placebo ||| 0-0 2-0 2-1 1-2
die Plasmakonzentration von Pioglitazon ||| the plasma concentration of pioglitazone ||| 0-0 1-1 1-2 2-3 3-4
die Plasmakonzentration von ||| , the plasma concentration of ||| 0-1 1-2 1-3 2-4
die Plasmakonzentration von ||| the plasma concentration of ||| 0-0 1-1 1-2 2-3
die Plasmakonzentration ||| , the plasma concentration ||| 0-1 1-2 1-3
die Plasmakonzentration ||| plasma concentration ||| 1-0 1-1
die Plasmakonzentration ||| the plasma concentration ||| 0-0 1-1 1-2
die Probleme gelöst wurden . ||| the issues are resolved . ||| 0-0 1-1 2-1 0-2 3-2 2-3 4-4
die Probleme gelöst wurden ||| the issues are resolved ||| 0-0 1-1 2-1 0-2 3-2 2-3
die Produkte innerhalb ||| of the members within ||| 0-1 1-2 2-3
die Produkte innerhalb ||| the members within ||| 0-0 1-1 2-2
die Produkte ||| of the members ||| 0-1 1-2
die Produkte ||| the members ||| 0-0 1-1
die Produktion roter Blutzellen anregen ||| red blood cell production ||| 0-0 1-0 2-1 2-2 3-2 4-3
die Produktion roter Blutzellen anregt ||| stimulates red cell production ||| 0-0 1-0 1-1 2-2 3-2 4-3
die Produktion roter Blutzellen ||| red blood cell ||| 0-0 1-0 2-1 2-2 3-2
die Produktion roter Blutzellen ||| stimulates red cell ||| 0-0 1-0 1-1 2-2 3-2
die Produktion ||| red ||| 0-0 1-0
die Produktion ||| stimulates red ||| 0-0 1-0 1-1
die Proteinbindung ||| protein binding ||| 1-0 1-1
die Prävention einer neuen ||| the prevention of a new ||| 0-0 1-1 3-1 2-3 3-4
die Resorption zu ||| enhance absorption ||| 0-0 1-1 2-1
die Resuspendierung zu erleichtern . ||| facilitate the re- suspension . ||| 0-0 1-0 0-1 2-2 3-2 3-3 4-4
die Resuspendierung zu erleichtern . ||| facilitate the re-suspension . ||| 0-0 1-0 0-1 2-2 3-2 4-3
die Resuspendierung zu erleichtern ||| facilitate the re- suspension ||| 0-0 1-0 0-1 2-2 3-2 3-3
die Resuspendierung zu erleichtern ||| facilitate the re-suspension ||| 0-0 1-0 0-1 2-2 3-2
die Resuspendierung ||| facilitate the ||| 0-0 1-0 0-1
die Schmelztablette im Ganzen auf ||| the entire orodispersible tablet on ||| 0-0 3-1 1-2 2-2 3-3 4-4
die Schmelztablette im Ganzen ||| the entire orodispersible tablet ||| 0-0 3-1 1-2 2-2 3-3
die Schmelztablette zerbrechlich ist ||| the orodispersible tablet is fragile ||| 0-0 1-1 1-2 3-3 2-4
die Schmelztablette ||| the orodispersible tablet ||| 0-0 1-1 1-2
die Serumspiegel bleiben gleich ||| the levels remain the ||| 0-0 1-1 2-2 3-2 2-3
die Serumspiegel von ||| , serum levels of ||| 1-1 0-2 1-2 2-3
die Serumspiegel von ||| serum levels of ||| 1-0 0-1 1-1 2-2
die Serumspiegel ||| , serum levels ||| 1-1 0-2 1-2
die Serumspiegel ||| serum levels ||| 1-0 0-1 1-1
die Serumspiegel ||| the levels ||| 0-0 1-1
die Sicherheit von Pioglitazon ||| the safety of pioglitazone ||| 0-0 1-1 2-2 3-3
die Sicherheit von ||| the safety of ||| 0-0 1-1 2-2
die Sicherheit ||| the safety ||| 0-0 1-1
die Studienmedikation beibehielten , ||| medicinal product at 52-weeks was ||| 1-0 1-1 0-2 1-2 1-3 2-3 2-4
die Studienmedikation beibehielten , ||| product at 52-weeks was ||| 1-0 1-1 0-2 1-2 2-2 2-3
die Studienmedikation beibehielten ||| medicinal product at 52-weeks was ||| 1-0 1-1 0-2 1-2 1-3 2-3 2-4
die Studienmedikation beibehielten ||| product at 52-weeks was ||| 1-0 1-1 0-2 1-2 2-2 2-3
die Suspension mit der ||| the suspension contacts the ||| 0-0 1-1 1-2 2-2 3-3
die Suspension mit ||| the suspension contacts ||| 0-0 1-1 1-2 2-2
die Suspension ||| , the suspension ||| 0-1 1-2
die Suspension ||| the suspension ||| 0-0 1-1
die Symptome einer Hypokalzämie ||| symptoms of hypocalcaemia ||| 0-0 1-0 2-1 2-2 3-2
die Symptome ||| symptoms ||| 0-0 1-0
die Tablette beschädigen könnte . ||| could damage the tablet . ||| 3-0 2-1 3-1 0-2 1-3 4-4
die Tablette beschädigen könnte ||| could damage the tablet ||| 3-0 2-1 3-1 0-2 1-3
die Tablette immer mit Wasser ||| the tablet with water ||| 0-0 1-1 2-1 3-2 4-3
die Tablette immer mit ||| the tablet with ||| 0-0 1-1 2-1 3-2
die Tablette immer ||| the tablet ||| 0-0 1-1 2-1
die Tablette ||| the tablet ||| 0-0 1-1
die Testosteronsuppression ||| , testosterone suppression ||| 1-1 1-2
die Testosteronsuppression ||| testosterone suppression ||| 1-0 1-1
die Tätigkeit der Osteoklasten ||| the action of the osteoclasts ||| 0-0 1-1 2-2 1-3 2-3 3-4
die Tätigkeit der ||| the action of the ||| 0-0 1-1 2-2 1-3 2-3
die Verkehrstüchtigkeit und ||| ability ||| 0-0 1-0 2-0
die Verschlechterung einer bestehenden Hypertonie ||| aggravation of existing hypertension ||| 1-0 2-0 3-0 2-1 3-2 4-3
die Verschlechterung einer bestehenden ||| aggravation of existing ||| 1-0 2-0 3-0 2-1 3-2
die Verschlusskappe des Fertigpens aufgesetzt ||| the pen cap on ||| 0-0 1-1 1-2 2-2 3-2 4-2 4-3
die Verstoffwechselung anderer Arzneimittel ||| the metabolism of other medicinal ||| 0-0 1-1 0-2 2-3 3-4
die Verstoffwechselung anderer ||| the metabolism of other ||| 0-0 1-1 0-2 2-3
die Verstoffwechselung ||| the metabolism of ||| 0-0 1-1 0-2
die Vitamin-D-Spiegel ||| vitamin D levels ||| 1-0 1-1 0-2 1-2
die Vorbereitung und die Verabreichung ||| to prepare and ||| 0-0 1-1 3-1 4-1 2-2
die Wahrscheinlichkeit von Knochenbrüchen . ||| less likely to break . ||| 1-1 0-2 2-2 3-3 4-4
die Wahrscheinlichkeit von Knochenbrüchen . ||| likely to break . ||| 1-0 0-1 2-1 3-2 4-3
die Wahrscheinlichkeit von Knochenbrüchen ||| it less likely to break ||| 1-2 0-3 2-3 3-4
die Wahrscheinlichkeit von Knochenbrüchen ||| less likely to break ||| 1-1 0-2 2-2 3-3
die Wahrscheinlichkeit von Knochenbrüchen ||| likely to break ||| 1-0 0-1 2-1 3-2
die Wahrscheinlichkeit von ||| it less likely to ||| 1-2 0-3 2-3
die Wahrscheinlichkeit von ||| less likely to ||| 1-1 0-2 2-2
die Wahrscheinlichkeit von ||| likely to ||| 1-0 0-1 2-1
die Warnhinweise und Vorsichtsmaßnahmen für ||| warnings and precautions associated with ||| 1-0 2-1 0-2 3-2 4-2 1-3
die Warnhinweise und Vorsichtsmaßnahmen für ||| warnings and precautions associated ||| 1-0 2-1 0-2 3-2 4-2 1-3
die Werte zurück , wie ||| return rapidly ||| 0-0 1-0 2-0 2-1 3-1 4-1
die Wirksamkeit von Abseamed steigern ||| increase the effectiveness of Abseamed ||| 0-0 0-1 1-2 2-3 3-4 4-4
die Wirksamkeit von ||| increase the effectiveness of ||| 0-0 0-1 1-2 2-3
die Wirksamkeit von ||| that compared the effectiveness of ||| 0-0 1-1 0-2 1-3 2-4
die Wirksamkeit ||| increase the effectiveness ||| 0-0 0-1 1-2
die Wirksamkeit ||| that compared the effectiveness ||| 0-0 1-1 0-2 1-3
die Wirkung von Actos ||| the effect of Actos ||| 0-0 1-1 2-2 3-3
die Wirkung von Arzneimitteln verstärken ||| the effect of medicines used ||| 0-0 1-1 2-2 3-3 4-3 4-4
die Wirkung von ||| the effect of ||| 0-0 1-1 2-2
die Wirkung ||| the effect ||| 0-0 1-1
die Zeitdauer der Studie ||| the duration of the study ||| 0-0 1-1 2-2 2-3 3-4
die Zeitdauer der ||| the duration of the ||| 0-0 1-1 2-2 2-3
die Zeitdauer ||| the duration ||| 0-0 1-1
die Zellen nicht teilen und ||| the cells cannot divide and ||| 0-0 1-1 2-2 3-3 4-4
die Zellen nicht teilen ||| the cells cannot divide ||| 0-0 1-1 2-2 3-3
die Zellen nicht ||| the cells cannot ||| 0-0 1-1 2-2
die Zellen ||| the cells ||| 0-0 1-1
die Zunge . ||| the tongue . ||| 0-0 1-1 2-2
die Zunge ||| the tongue ||| 0-0 1-1
die absolute Veränderung des HbA1c-Wertes ||| the absolute change in HbA1c ||| 0-0 3-0 1-1 2-2 2-3 4-4
die absolute Veränderung des ||| the absolute change in ||| 0-0 3-0 1-1 2-2 2-3
die als Makulaödem ||| of the back of the ||| 0-0 0-1 0-2 1-2 2-2 2-3 2-4
die am häufigsten ||| the most frequently ||| 0-0 2-1 1-2 2-2
die an 375 anämischen Patienten ||| conducted in 375 anaemic patients ||| 1-0 2-0 1-1 2-2 3-2 3-3 4-4
die an 375 anämischen ||| conducted in 375 anaemic ||| 1-0 2-0 1-1 2-2 3-2 3-3
die auf ||| on ||| 0-0 1-0
die auffälligste wichtige hämatologische ||| the most notable important ||| 0-0 0-1 1-2 2-2 3-2
die auffälligste wichtige hämatologische ||| the most notable ||| 0-0 0-1 1-2 2-2 3-2
die aus klinischen ||| clinical ||| 2-0
die aus ||| die aus ||| 0-0 1-1
die aus ||| from ||| 1-0
die behandelten ||| , treated ||| 0-0 0-1 1-1
die bei 229 Patienten ||| related to 229 patients ||| 0-0 0-1 2-2 1-3 3-3
die beobachtete ||| where the observed ||| 1-0 0-1 1-2
die bestmögliche Einstellung erreicht wird ||| give the best control ||| 1-0 0-1 1-2 2-2 3-2 2-3 4-3
die dem ||| the ||| 0-0 1-0
die den Wirkstoff Zoledronsäure ||| the active substance zoledronic acid ||| 0-0 1-0 1-1 2-1 2-2 3-3 3-4
die den Wirkstoff ||| the active substance ||| 0-0 1-0 1-1 2-1 2-2
die den ||| where the ||| 0-0 0-1 1-1
die die pharmakologischen Effekte ||| are extensions ||| 2-0 0-1 1-1 2-1 3-1
die drei aktive Metaboliten erzeugt ||| which produces three active metabolites ||| 0-0 2-1 1-2 2-3 3-4 4-4
die drei aktive ||| which produces three active ||| 0-0 2-1 1-2 2-3
die durch Diät und ||| inadequately controlled by diet and ||| 2-0 2-1 0-2 1-2 2-3 3-4
die durch Diät ||| inadequately controlled by diet ||| 2-0 2-1 0-2 1-2 2-3
die durch ||| by ||| 0-0 1-0
die durchschnittliche Dauer des Diabetes ||| the average duration of diabetes ||| 0-0 1-1 2-2 3-3 4-4
die durchschnittliche Dauer des ||| the average duration of ||| 0-0 1-1 2-2 3-3
die durchschnittliche Dauer ||| the average duration ||| 0-0 1-1 2-2
die durchschnittliche ||| the average ||| 0-0 1-1
die ein Ansprechen auf ||| response to ||| 1-0 2-0 3-0 0-1 3-1
die ein Jahr oder weniger ||| of one year or less ||| 0-0 1-1 2-1 2-2 3-3 4-4
die ein Jahr oder weniger ||| of one year or less ||| 0-0 2-1 1-2 2-2 3-3 4-4
die ein Jahr oder ||| of one year or ||| 0-0 1-1 2-1 2-2 3-3
die ein Jahr oder ||| of one year or ||| 0-0 2-1 1-2 2-2 3-3
die ein Jahr ||| of one year ||| 0-0 1-1 2-1 2-2
die ein Jahr ||| of one year ||| 0-0 2-1 1-2 2-2
die eine Strahlentherapie erhielten . ||| receiving radiotherapy . ||| 0-0 1-0 3-0 2-1 3-1 4-2
die eine Strahlentherapie erhielten ||| receiving radiotherapy ||| 0-0 1-0 3-0 2-1 3-1
die eine diuretische Behandlung erhalten ||| receiving diuretic therapy ||| 0-0 1-0 2-0 2-1 4-1 2-2 3-2
die eine diuretische Therapie erhalten ||| receiving diuretic therapy ||| 0-0 1-0 2-0 2-1 4-1 3-2
die eine ||| a ||| 1-0
die einmal wöchentlich ||| given weekly ||| 2-0 1-1 2-1
die einmal wöchentlich über drei ||| given weekly for three ||| 2-0 1-1 2-1 3-2 3-3 4-3
die empfohlene ||| , the recommended ||| 0-1 1-2
die empfohlene ||| recommended ||| 1-0
die empfohlene ||| the recommended ||| 0-0 1-1
die erste Behandlung nicht ||| first treatment ||| 1-0 2-1
die erste Behandlung ||| first treatment ||| 1-0 2-1
die erste Injektion . ||| the first injection . ||| 0-0 1-1 2-2 3-3
die erste Injektion ||| the first injection ||| 0-0 1-1 2-2
die erste ||| first ||| 1-0
die erste ||| the first ||| 0-0 1-1
die etwa ||| about ||| 1-0
die folgenden ||| the following ||| 0-0 1-1
die fortgesetzte Androgensuppression bei Männern ||| androgen suppression in men ||| 2-0 1-1 2-1 3-2 4-3
die fortgesetzte Androgensuppression bei ||| androgen suppression in ||| 2-0 1-1 2-1 3-2
die fortgesetzte Androgensuppression ||| androgen suppression ||| 2-0 1-1 2-1
die für ||| die für ||| 0-0 1-1
die gekühlte Lösung ||| solution to reach ||| 2-0 0-1 1-2
die gekühlte ||| to reach ||| 0-0 1-1
die gemeinsame Anwendung ||| result ||| 1-0 2-0
die geometrischen Mittel der Cmax ||| the geometric means of Cmax ||| 0-0 1-1 1-2 2-2 3-3 4-4
die geometrischen Mittel der ||| the geometric means of ||| 0-0 1-1 1-2 2-2 3-3
die geometrischen Mittel ||| the geometric means ||| 0-0 1-1 1-2 2-2
die gesamte Dosis injiziert wurde ||| the entire dose is injected ||| 0-0 1-1 2-2 3-3 3-4 4-4
die gesamte Dosis ||| the entire dose ||| 0-0 1-1 2-2
die gesamte ||| the entire ||| 0-0 1-1
die gleichzeitige Gabe von Rimonabant ||| die gleichzeitige Gabe von Rimonabant ||| 0-0 1-1 1-2 1-3 3-3 4-4
die gleichzeitige Gabe von ||| die gleichzeitige Gabe von ||| 0-0 1-1 1-2 1-3 3-3
die gleichzeitige ||| , ||| 1-0
die größere Empfindlichkeit dieser ||| the greater sensitivity of this ||| 0-0 2-1 1-2 2-2 3-3 3-4
die größere Empfindlichkeit ||| the greater sensitivity ||| 0-0 2-1 1-2 2-2
die in erster Linie ||| that primarily stimulate ||| 0-0 2-0 1-1 2-1 3-2
die in erster ||| that primarily ||| 0-0 2-0 1-1 2-1
die itte Patienten , die ||| whereas patients re-randomized to ||| 0-0 2-1 3-2 0-3 3-3 4-3
die jedoch aus ||| but made ||| 1-0 2-1
die jedoch ||| but ||| 1-0
die jeweils ||| each ||| 1-0
die kombinierte ||| at combining ||| 0-0 1-1
die kürzlich ( innerhalb von ||| recent ( within ||| 1-0 2-1 3-2 4-2
die kürzlich ( ||| recent ( ||| 1-0 2-1
die kürzlich ||| recent ||| 1-0
die manischen Symptome bereits ||| manic symptoms had already ||| 1-0 0-1 2-1 3-2 3-3
die manischen Symptome ||| manic symptoms ||| 1-0 0-1 2-1
die mit Abraxane behandelt ||| treated with Abraxane ||| 0-0 3-0 1-1 2-2
die mit Aripiprazol behandelt wurden ||| treated with aripiprazole were ||| 0-0 3-0 1-1 2-2 4-3
die mit Aripiprazol behandelt ||| treated with aripiprazole ||| 0-0 3-0 1-1 2-2
die mit Epoetin alfa behandelt ||| treated with epoetin alfa ||| 0-0 4-0 1-1 2-2 3-3
die mit Haloperidol behandelt ||| treated with haloperidol ||| 0-0 3-0 1-1 2-2
die mit depressiven Störungen ||| 4.3 and ||| 2-0 3-1
die mit depressiven Störungen ||| section 4.3 and ||| 2-1 3-2
die mit depressiven ||| 4.3 ||| 2-0
die mit depressiven ||| section 4.3 ||| 2-1
die mit einem Brombutyl-/Polyisopren-Gummistopfen ||| with a bromobutyl/ polyisoprene ||| 1-0 2-1 2-2 3-2 3-3
die mit ||| with ||| 1-0
die nicht notwendigerweise mit ||| not necessarily in association with ||| 1-0 0-1 2-1 2-2 2-3 3-4
die nicht notwendigerweise ||| not necessarily in association ||| 1-0 0-1 2-1 2-2 2-3
die noch nicht dialysepflichtig sind ||| insufficiency not yet undergoing dialysis ||| 0-0 1-0 2-1 1-2 3-3 3-4 4-4
die noch nicht ||| insufficiency not yet ||| 0-0 1-0 2-1 1-2
die normalerweise ||| which are normally ||| 0-0 1-0 1-1 1-2
die nächste Infusion nach ||| the next dose after ||| 0-0 1-0 1-1 0-2 2-3 3-3
die nächste ||| the next dose ||| 0-0 1-0 1-1 0-2
die orale Einnahme des Arzneimittels ||| taking the medicine by mouth ||| 2-0 0-1 3-1 4-2 1-3
die orale Einnahme des Arzneimittels ||| taking the medicine by ||| 2-0 0-1 3-1 4-2 1-3
die periphere ||| increase peripheral ||| 0-0 1-1
die pharmakokinetischen Eigenschaften ||| , the pharmacokinetic characteristics ||| 0-1 1-2 2-3
die pharmakokinetischen Eigenschaften ||| the pharmacokinetic characteristics ||| 0-0 1-1 2-2
die pharmakokinetischen ||| , the pharmacokinetic ||| 0-1 1-2
die pharmakokinetischen ||| the pharmacokinetic ||| 0-0 1-1
die prozentuale ||| the percentage ||| 0-0 1-1
die präklinischen ||| genotoxicity , ||| 0-0 1-0 1-1
die rasche ||| to ||| 0-0
die relative Wirksamkeit von M-II ||| the relative efficacy of M-II ||| 0-0 1-1 2-2 3-3 4-4
die relative Wirksamkeit von ||| the relative efficacy of ||| 0-0 1-1 2-2 3-3
die relative Wirksamkeit ||| the relative efficacy ||| 0-0 1-1 2-2
die relative ||| the relative ||| 0-0 1-1
die richtige Dosis von ||| out the correct dose of ||| 3-0 0-1 1-2 2-3 3-4
die richtige Dosis ||| the correct dose ||| 0-0 1-1 2-2
die richtige ||| the correct ||| 0-0 1-1
die schnelle ||| represent rapid ||| 1-0 1-1
die so hergestellte Suspension getrunken ||| drink the resulting suspension ||| 1-0 2-0 0-1 2-1 4-2 3-3
die so hergestellte Suspension trinken ||| drink the resulting suspension ||| 1-0 2-0 0-1 4-2 3-3 4-3
die so hergestellte ||| drink the ||| 1-0 2-0 0-1
die so hergestellte ||| drink the ||| 1-0 2-0 0-1 2-1
die sowohl schnell wirkendes ||| both fast-acting ||| 0-0 1-0 2-1 3-1
die sowohl ||| both ||| 0-0 1-0
die subkutane Anwendung ist ||| is difficult ||| 0-0 3-0 1-1 2-1
die symptomatische ||| blood transfusions should be the ||| 0-0 1-0 1-1 1-2 1-3 0-4
die systemische Exposition war ||| systemic exposure was generally ||| 1-0 2-1 3-2
die systemische Exposition war ||| systemic exposure was ||| 1-0 2-1 3-2
die systemische Exposition ||| systemic exposure ||| 1-0 2-1
die systemische ||| systemic ||| 1-0
die tödlich enden kann . ||| which is potentially lethal . ||| 0-0 1-0 1-1 1-2 1-3 2-3 3-3 4-4
die tödlich enden kann ||| which is potentially lethal ||| 0-0 1-0 1-1 1-2 1-3 2-3 3-3
die vergessene Dosis ein ||| the missed dose ||| 0-0 1-1 3-1 2-2
die vordere Bauchwand gegeben . ||| the anterior abdominal wall . ||| 0-0 1-1 2-1 2-2 2-3 3-3 4-4
die vordere Bauchwand gegeben ||| part of the abdominal wall ||| 0-0 0-1 0-2 1-3 2-3 2-4 3-4
die vordere Bauchwand gegeben ||| the anterior abdominal wall ||| 0-0 1-1 2-1 2-2 2-3 3-3
die wesentlich ||| which ||| 0-0
die wissenschaftliche Diskussion ( die ||| the Scientific Discussion ( ||| 0-0 1-1 4-1 1-2 2-2 3-3
die zum Absetzen führten ||| resulting in discontinuation ||| 0-0 3-0 1-1 2-2
die zusätzliche Gabe von ||| levels ||| 0-0
die zusätzliche Gabe ||| levels ||| 0-0
die zusätzliche ||| levels ||| 0-0
die ||| ( the ||| 0-1
die ||| , in ||| 0-1
die ||| , the doses that ||| 0-1 0-3
die ||| , the overall ||| 0-1 0-2
die ||| , the ||| 0-0 0-1
die ||| , the ||| 0-1
die ||| , who ||| 0-1
die ||| , ||| 0-0
die ||| 58 The ||| 0-1
die ||| 70 The ||| 0-1
die ||| The potential relevance of ||| 0-0 0-1 0-2 0-3
die ||| The ||| 0-0
die ||| a ||| 0-0
die ||| are at ||| 0-0 0-1
die ||| as low ||| 0-0
die ||| as ||| 0-0
die ||| at the ||| 0-0 0-1
die ||| at ||| 0-0
die ||| back ||| 0-0
die ||| by ||| 0-0
die ||| considering ||| 0-0
die ||| die ||| 0-0
die ||| dose of ||| 0-0 0-1
die ||| dose ||| 0-0
die ||| enhance ||| 0-0
die ||| for ||| 0-0
die ||| give ||| 0-0
die ||| in the ||| 0-1
die ||| in ||| 0-0
die ||| increase the ||| 0-0 0-1
die ||| increase ||| 0-0
die ||| levels had ||| 0-0 0-1
die ||| levels ||| 0-0
die ||| not treated ||| 0-0 0-1
die ||| of Abraxane ||| 0-0
die ||| of the ||| 0-0 0-1
die ||| of the ||| 0-1
die ||| of ||| 0-0
die ||| on ||| 0-0
die ||| part of the ||| 0-0 0-1 0-2
die ||| reduce the ||| 0-0 0-1
die ||| related to ||| 0-0 0-1
die ||| that of ||| 0-0
die ||| that ||| 0-0
die ||| the doses that ||| 0-0 0-2
die ||| the major ||| 0-0 0-1
die ||| the most ||| 0-0 0-1
die ||| the overall ||| 0-0 0-1
die ||| the same ||| 0-0 0-1
die ||| the ||| 0-0
die ||| therapy , the ||| 0-2
die ||| to 15 ||| 0-0
die ||| to ||| 0-0
die ||| which ||| 0-0
die ||| who has ||| 0-0
die ||| who ||| 0-0
die über eine Hypoglykämie berichten ||| report hypoglycaemia ||| 0-0 1-0 2-0 4-0 3-1
dienen dem Umweltschutz ||| help to protect the environment ||| 0-0 0-1 2-2 1-3 2-4
dienen ||| help to ||| 0-0 0-1
dienen ||| to ||| 0-0
dient zur ||| is to check that ||| 0-0 0-1 0-2 1-2 0-3
dies auf eine verminderte ||| as being secondary to decreased ||| 0-0 0-1 0-2 1-2 2-2 1-3 3-4
dies auf eine ||| as being secondary to ||| 0-0 0-1 0-2 1-2 2-2 1-3
dies die Tablette beschädigen könnte ||| this could damage the tablet ||| 0-0 4-1 3-2 4-2 1-3 2-4
dies in ||| this ||| 0-0 1-0
dies ist besonders wichtig bei ||| this is especially important for ||| 0-0 1-1 2-2 3-3 4-4
dies ist besonders wichtig ||| this is especially important ||| 0-0 1-1 2-2 3-3
dies ist besonders ||| this is especially ||| 0-0 1-1 2-2
dies ist ||| this is ||| 0-0 1-1
dies mit ||| this with ||| 0-0 1-1
dies zur Schaumbildung führt ||| this will result in foaming ||| 0-0 0-1 1-1 3-2 3-3 2-4 3-4
dies zur ||| this will ||| 0-0 0-1 1-1
dies ||| based ||| 0-0
dies ||| take this ||| 0-0 0-1
dies ||| this ||| 0-0
diese Befunde ||| these findings ||| 0-0 1-1
diese Enzyme verursacht . ||| by these enzymes . ||| 1-0 0-1 1-2 2-2 3-3
diese Enzyme verursacht ||| by these enzymes ||| 1-0 0-1 1-2 2-2
diese Ereignisse ||| these events ||| 0-0 1-1
diese Nebenwirkungen ||| these side effects ||| 0-0 1-1 1-2
diese Packungsbeilage auf . ||| this leaflet . ||| 0-0 1-1 3-2
diese Packungsbeilage auf ||| this leaflet ||| 0-0 1-1
diese Packungsbeilage ||| this leaflet ||| 0-0 1-1
diese Patientenpopulation kontraindiziert ||| use in this patient population ||| 0-0 0-1 1-2 1-3 1-4 2-4
diese Symptome bei sich feststellen ||| experience these symptoms ||| 4-0 0-1 1-2 2-2
diese Symptome bei sich ||| these symptoms ||| 0-0 1-1 2-1
diese Symptome bei ||| these symptoms ||| 0-0 1-1 2-1
diese Wirkungen ||| that these effects are ||| 1-0 0-1 1-2 0-3
diese Wirkungen ||| these effects ||| 0-0 1-1
diese ||| it ||| 0-0
diese ||| of the ||| 0-1
diese ||| the ||| 0-0
diese ||| these ||| 0-0
diese ||| this ||| 0-0
diese ||| use in ||| 0-0 0-1
diesem Arzneimittel ||| this medicine is available ||| 0-0 1-1 0-2 0-3
diesem Arzneimittel ||| this product is available ||| 0-0 1-1 0-2 0-3
diesem Tierarzneimittel finden ||| on this product is available ||| 0-0 0-1 1-2 0-3 0-4 2-4
diesem ||| in this area ||| 0-1
diesem ||| in this ||| 0-1
diesem ||| this area ||| 0-0
diesem ||| this ||| 0-0
diesen Anweisungen genau zu ||| you follow this advice carefully ||| 1-0 1-1 0-2 3-3 1-4
diesen Charakteristika ||| these characteristics ||| 0-0 1-1
diesen Maßnahmen zur Gewichtsreduzierung ||| this weight management programme , ||| 0-0 3-1 1-2 3-3
diesen Maßnahmen zur Gewichtsreduzierung ||| this weight management programme ||| 0-0 3-1 1-2 3-3
diesen Patienten mit Vorsicht anzuwenden ||| diesen Patienten mit Vorsicht anzuwenden ||| 0-0 0-1 1-1 2-2 3-3 4-4
diesen Patienten mit Vorsicht ||| diesen Patienten mit Vorsicht ||| 0-0 0-1 1-1 2-2 3-3
diesen Patienten mit ||| diesen Patienten mit ||| 0-0 0-1 1-1 2-2
diesen Patienten sollte die Dosierung ||| these patients dosing should ||| 0-0 1-1 3-2 4-2 2-3
diesen Patienten sollte ||| diesen Patienten sollte ||| 0-0 0-1 1-1 0-2 2-2
diesen Patienten ||| diesen Patienten ||| 0-0 0-1 1-1
diesen Patienten ||| these patients ||| 0-0 1-1
diesen Studien gezeigt ? ||| was 3.9 kg . ||| 1-0 0-1 1-1 2-1 3-1 2-2
diesen Studien gezeigt ? ||| was 3.9 kg ||| 1-0 0-1 1-1 2-1 3-1 2-2
diesen Symptomen ||| these symptoms ||| 0-0 1-1
diesen Teil vollständig aufgefressen ||| eaten the complete portion ||| 0-0 1-0 1-1 2-2 3-2 1-3 3-3
diesen beiden Arzneimitteln ||| these two medicines ||| 0-0 1-1 2-2
diesen beiden ||| these two ||| 0-0 1-1
diesen ||| , these ||| 0-1
diesen ||| these ||| 0-0
diesen ||| this ||| 0-0
dieser Altersgruppe ||| of age where ||| 0-0 1-1
dieser Altersgruppe ||| of age ||| 0-0 1-1
dieser Altersgruppe ||| this age group ||| 0-0 1-1 1-2
dieser Angaben auf Sie zutrifft ||| of these applies to you ||| 0-0 0-1 1-2 4-2 2-3 3-4
dieser Basis ||| this basis ||| 0-0 1-1
dieser Befunde ist nicht bekannt ||| of these findings is unknown ||| 0-0 0-1 1-2 2-3 3-4 4-4
dieser Befunde ist ||| of these findings is ||| 0-0 0-1 1-2 2-3
dieser Befunde ||| of these findings ||| 0-0 0-1 1-2
dieser Effekt jedoch ||| but this effect ||| 2-0 0-1 1-2
dieser Effekt ||| this effect ||| 0-0 1-1
dieser Ereignisse wird ||| of these events is ||| 0-0 0-1 1-2 2-3
dieser Ereignisse ||| of these events ||| 0-0 0-1 1-2
dieser Form gebrauchsfertig . ||| ready for use . ||| 1-0 2-0 2-1 2-2 3-3
dieser Form gebrauchsfertig ||| ready for use ||| 1-0 2-0 2-1 2-2
dieser Krankheit können auch ||| this condition may also ||| 0-0 1-1 2-2 3-3
dieser Krankheit können ||| this condition may ||| 0-0 1-1 2-2
dieser Krankheit ||| this condition ||| 0-0 1-1
dieser Nebenwirkungen ||| of these side effects ||| 0-0 0-1 1-2 1-3
dieser Patienten hatten Anzeichen ||| of these patients had signs ||| 0-0 0-1 1-2 2-3 3-4
dieser Patienten hatten ||| of these patients had ||| 0-0 0-1 1-2 2-3
dieser Patienten in Erwägung ziehen ||| for these patients ||| 1-0 0-1 2-1 3-1 4-1 1-2
dieser Patienten traten gleichzeitig periphere ||| these patients reported concurrent peripheral ||| 0-0 1-1 2-2 2-3 3-3 4-3 4-4
dieser Patienten wurden Antikörper ||| of these patients , antibodies ||| 0-0 0-1 1-2 2-3 2-4 3-4
dieser Patienten ||| of these patients ||| 0-0 0-1 1-2
dieser Patienten ||| these patients ||| 0-0 1-1
dieser Patientengruppe abgewogen werden . ||| in this patient group . ||| 1-0 0-1 1-1 2-2 2-3 3-3 4-4
dieser Patientengruppe abgewogen werden ||| in this patient group ||| 1-0 0-1 1-1 2-2 2-3 3-3
dieser Patientengruppe vorliegen . ||| this patient group . ||| 0-0 1-0 1-1 2-2 3-3
dieser Patientengruppe vorliegen ||| this patient group ||| 0-0 1-0 1-1 2-2
dieser Patientengruppe ||| in this ||| 1-0 0-1 1-1
dieser Patientengruppe ||| of this population , ||| 0-0 0-1 1-2
dieser Patientengruppe ||| of this population ||| 0-0 0-1 1-2
dieser Patientengruppe ||| this patient ||| 0-0 1-0 1-1
dieser Studie . ||| this study . ||| 0-0 1-1 2-2
dieser Studie ||| this study ||| 0-0 1-1
dieser Studien , eine ||| these trials , a ||| 0-0 1-1 2-2 3-3
dieser Studien , ||| these trials , ||| 0-0 1-1 2-2
dieser Studien ||| of these trials ||| 0-1 1-2
dieser Studien ||| these trials ||| 0-0 1-1
dieser Symptome nahm ||| of these symptoms decreased ||| 0-0 0-1 1-2 2-3
dieser Symptome war ||| of these symptoms were ||| 0-0 0-1 1-2 2-3
dieser Symptome ||| of these symptoms ||| 0-0 0-1 1-2
dieser Zeit durchgängig engmaschig ||| closely monitored throughout this ||| 0-0 3-0 1-1 3-1 2-2 3-2 2-3
dieser begrenzten Daten ||| these limited data , ||| 0-0 1-1 2-2
dieser begrenzten Daten ||| these limited data ||| 0-0 1-1 2-2
dieser begrenzten ||| these limited ||| 0-0 1-1
dieser hydroxylierten Metaboliten erfolgt jeweils ||| these hydroxylated metabolites is catalysed ||| 0-0 1-1 2-2 3-3 3-4
dieser hydroxylierten Metaboliten erfolgt ||| these hydroxylated metabolites is catalysed ||| 0-0 1-1 2-2 3-3 3-4
dieser hydroxylierten Metaboliten ||| these hydroxylated metabolites ||| 0-0 1-1 2-2
dieser hydroxylierten ||| these hydroxylated ||| 0-0 1-1
dieser ||| benefit ||| 0-0
dieser ||| of these ||| 0-0 0-1
dieser ||| of these ||| 0-1
dieser ||| of this ||| 0-0 0-1
dieser ||| of ||| 0-0
dieser ||| these ||| 0-0
dieser ||| this ||| 0-0
dieses Arzneimittel nicht einnehmen ||| not take this medicinal product ||| 2-0 3-1 0-2 1-3 1-4
dieses Arzneimittel ||| medicinal product ||| 0-0 0-1 1-1
dieses Arzneimittel ||| medicinal product ||| 0-0 1-1
dieses Arzneimittel ||| this medicinal product ||| 0-0 1-1 1-2
dieses Arzneimittel ||| this medicine ||| 0-0 1-1
dieses Arzneimittels begonnen wird . ||| given this medicine . ||| 3-0 0-1 1-2 2-3 4-3
dieses Arzneimittels ||| of this product ||| 0-1 1-2
dieses Arzneimittels ||| this medicine ||| 0-0 1-1
dieses Arzneimittels ||| this product ||| 0-0 1-1
dieses Tierarzneimittel ||| veterinary medicinal product ||| 1-0 0-1 1-2
dieses sollte in Schritten ||| this should be done in ||| 0-0 1-1 1-2 3-3 2-4
dieses sollte ||| this should be ||| 0-0 1-1 1-2
dieses ||| , this ||| 0-1
dieses ||| medicinal ||| 0-0
dieses ||| of this ||| 0-1
dieses ||| this ||| 0-0
direkte ||| direct ||| 0-0
direkter Effekt von Rimonabant ||| direct effect of rimonabant ||| 0-0 1-1 2-2 3-3
direkter Effekt von ||| direct effect of ||| 0-0 1-1 2-2
direkter Effekt ||| direct effect ||| 0-0 1-1
direkter und/oder ||| acting and/ ||| 0-1 1-1
direkter und/oder ||| and/ ||| 0-0 1-0
direkter ||| direct ||| 0-0
distalen Radius ||| distal radius over 3 ||| 0-0 0-1 1-1
distalen Radius ||| distal radius over ||| 0-0 0-1 1-1
distalen Radius ||| distal radius relative ||| 0-0 1-0 1-1
distalen Radius ||| distal radius ||| 0-0 0-1 1-1
distalen Radius ||| distal radius ||| 0-0 1-0 1-1
diätetische Kontrolle . ||| dietary control . ||| 0-0 1-1 2-2
diätetische Kontrolle ||| dietary control ||| 0-0 1-1
diätetische ||| dietary ||| 0-0
doch es bindet an ||| but it attaches to ||| 0-0 1-1 2-2 3-3
doch es bindet ||| but it attaches ||| 0-0 1-1 2-2
doch es ||| but it ||| 0-0 1-1
doch ||| but ||| 0-0
document is authorised for non ||| at how this loss could ||| 0-2 1-2 2-2 3-2 4-2 4-4
document is authorised for non ||| how this loss could be ||| 0-1 1-1 2-1 3-1 4-1 4-3
document is authorised for non ||| how this loss could ||| 0-1 1-1 2-1 3-1 4-1 4-3
document is authorised for non ||| this loss could be ||| 0-0 1-0 2-0 3-0 4-0 4-2
document is authorised for non ||| this loss could ||| 0-0 1-0 2-0 3-0 4-0 4-2
dokumentierte Risikofaktoren ||| documented risk factors ||| 0-0 1-1 1-2
dokumentierte ||| documented ||| 0-0
doppelblinden ||| randomised ||| 0-0
dosis-proportional . ||| dose-proportional . ||| 0-0 1-1
dosis-proportional ||| dose-proportional ||| 0-0
dosisabhängig ; Leukopenie wurde bei ||| ; leukopenia was reported in ||| 1-0 2-1 0-2 3-2 3-3 4-4
dosisabhängig ; Leukopenie wurde ||| ; leukopenia was reported ||| 1-0 2-1 0-2 3-2 3-3
dosisabhängig ; Leukopenie wurde ||| dependent ; leukopenia was reported ||| 1-1 2-2 0-3 3-3 3-4
dosisabhängiger Anstieg des Blutdrucks ||| dose-dependent increase in blood pressure ||| 0-0 1-0 0-1 2-1 1-2 3-3 3-4
dosisabhängiger Anstieg des ||| dose-dependent increase in ||| 0-0 1-0 0-1 2-1 1-2
dosisunabhängig erwiesen . ||| independent . ||| 0-0 1-0 2-1
dosisunabhängig erwiesen ||| independent ||| 0-0 1-0
drei Injektionen ||| three injections in ||| 0-0 1-1
drei Injektionen ||| three injections ||| 0-0 1-1
drei Jahre ||| three years ||| 0-0 1-1
drei Jahren untersucht . ||| three years . ||| 0-0 1-1 2-1 3-2
drei Jahren untersucht ||| three years ||| 0-0 1-1 2-1
drei Jahren ||| three years ||| 0-0 1-1
drei Tage nach Verabreichung von ||| three days after administration of ||| 0-0 1-1 2-2 3-3 4-4
drei Tage nach Verabreichung ||| three days after administration ||| 0-0 1-1 2-2 3-3
drei Tage nach der ||| three days after ||| 0-0 1-1 2-2
drei Tage nach der ||| three days following the ||| 0-0 1-1 2-2 3-3
drei Tage nach ||| three days after ||| 0-0 1-1 2-2
drei Tage nach ||| three days following ||| 0-0 1-1 2-2
drei Tage ||| three days ||| 0-0 1-1
drei Tagen . ||| three days. ||| 0-0 1-1 2-1
drei Tagen nach Beginn des ||| three days of the ||| 0-0 1-1 2-1 3-1 4-2 4-3
drei Tagen nach Beginn ||| three days ||| 0-0 1-1 2-1 3-1
drei Tagen ||| in the three days ||| 0-2 1-3
drei Tagen ||| the three days ||| 0-1 1-2
drei Tagen ||| three days ||| 0-0 1-1
drei Wochen . ||| three weeks . ||| 0-0 1-1 2-2
drei Wochen an insgesamt 1 ||| three weeks in a total ||| 0-0 1-1 2-1 2-2 3-3 4-3 3-4
drei Wochen an ||| three weeks in ||| 0-0 1-1 2-1 2-2
drei Wochen ||| three weeks ||| 0-0 1-1
drei aktive Metaboliten erzeugt . ||| produces three active metabolites . ||| 1-0 0-1 1-2 2-3 3-3 4-4
drei aktive Metaboliten erzeugt ||| produces three active metabolites ||| 1-0 0-1 1-2 2-3 3-3
drei aktive ||| produces three active ||| 1-0 0-1 1-2
drei ||| in the three ||| 0-2
drei ||| the three ||| 0-1
drei ||| three ||| 0-0
dreimal pro Woche durch ||| 3 times a week by ||| 0-0 1-1 2-1 3-2 2-3 3-4
dreimal pro Woche erfolgen . ||| 3 times per week . ||| 0-0 2-1 1-2 2-3 3-3 4-4
dreimal pro Woche erfolgen ||| 3 times per week ||| 0-0 2-1 1-2 2-3 3-3
dreimal pro Woche gegeben . ||| 3 times per week . ||| 0-0 2-1 1-2 2-3 3-3 4-4
dreimal pro Woche gegeben ||| 3 times per week ||| 0-0 2-1 1-2 2-3 3-3
dreimal pro Woche mittels ||| 3 times per week by ||| 0-0 0-1 1-2 2-3 3-4
dreimal pro Woche ||| 3 times per week ||| 0-0 0-1 1-2 2-3
dreimal pro ||| 3 times per ||| 0-0 0-1 1-2
dreimal wöchentlich . ||| three times a week . ||| 0-0 0-1 1-2 1-3 2-4
dreimal wöchentlich nicht ||| , three times a ||| 0-1 0-2 1-2 2-2 1-3
dreimal wöchentlich nicht ||| three times a ||| 0-0 0-1 1-1 2-1 1-2
dreimal wöchentlich nicht überschreiten . ||| three times a week . ||| 0-0 0-1 1-1 2-1 1-2 3-3 4-4
dreimal wöchentlich nicht überschreiten ||| , three times a week ||| 0-1 0-2 1-2 2-2 1-3 3-4
dreimal wöchentlich nicht überschreiten ||| three times a week ||| 0-0 0-1 1-1 2-1 1-2 3-3
dreimal wöchentlich ||| , three times a week ||| 0-1 0-2 1-3 1-4
dreimal wöchentlich ||| three times a week ||| 0-0 0-1 1-2 1-3
dreimal ||| , three times ||| 0-1 0-2
dreimal ||| 3 times ||| 0-0 0-1
dreimal ||| 3 ||| 0-0
dreimal ||| three times ||| 0-0 0-1
dreiwöchigem Abstand . ||| every 3 weeks . ||| 0-0 1-1 0-2 2-3
dreiwöchigem Abstand ||| every 3 weeks ||| 0-0 1-1 0-2
dreiwöchigen ||| three week ||| 0-0 0-1
dringend behandelt werden muss ||| pressure which requires urgent treatment ||| 0-0 1-0 1-1 0-2 0-3 3-3 1-4
dritten Infusion ||| third infusion ||| 0-0 1-1
dritten ||| third ||| 0-0
dru ba , d.o.o. ||| ba , d. o. o ||| 0-0 1-0 2-1 1-2 3-3 3-4
dru ba , d.o.o. ||| ba , d. o. o. ||| 0-0 2-1 1-2 2-3 3-3 3-4
dru ba , ||| ba , d. ||| 0-0 1-0 2-1 1-2
dru ||| ba ||| 0-0
durch Amidohydrolase-Stoffwechselwege ( hauptsächlich ||| amidohydrolase ( predominantly ||| 0-0 1-0 2-1 1-2 3-2
durch Blockade ||| by blocking ||| 0-0 1-1
durch CYP3A und durch ||| metabolized by both CYP3A and ||| 1-0 0-1 1-2 1-3 3-3 2-4
durch CYP3A4 katalysiert . ||| catalysed by CYP3A4 . ||| 0-0 2-0 0-1 1-2 3-3
durch CYP3A4 katalysiert ||| catalysed by CYP3A4 ||| 0-0 2-0 0-1 1-2
durch Cytochrom-P450-Enzymsysteme metabolisierten ||| in ||| 0-0
durch Cytochrom-P450-Enzymsysteme ||| in ||| 0-0
durch Gabe ||| administration ||| 0-0 1-0
durch Heparin ||| of the blood by heparin ||| 0-0 0-1 0-3 1-4
durch Hydroxylierung der aliphatischen Methylengruppen ||| by hydroxylation of aliphatic ||| 0-0 1-1 2-2 3-2 3-3 4-3
durch Hydroxylierung ||| by hydroxylation ||| 0-0 1-1
durch Injektion unter die Haut ||| by injection under the skin ||| 0-0 3-0 1-1 2-2 3-3 4-4
durch Injektion unter die ||| by injection under the ||| 0-0 3-0 1-1 2-2 3-3
durch Injektion unter die ||| give by injection under the ||| 1-0 0-1 1-2 2-3 3-4
durch Injektion unter ||| give by injection under ||| 1-0 0-1 1-2 2-3
durch Injektion ||| by injection ||| 0-0 1-1
durch Injektion ||| give by injection ||| 1-0 0-1 1-2
durch Injektion ||| injection ||| 1-0
durch Knochenmetastasen ||| into less ||| 0-0
durch Knochenmetastasen ||| into ||| 0-0
durch Metabolisierung und anschließende ||| durch Metabolisierung und anschließende biliäre ||| 0-0 1-0 1-1 1-2 2-2 3-3 3-4
durch Metabolisierung und ||| durch Metabolisierung und ||| 0-0 1-0 1-1 1-2 2-2
durch Neurotransmitter , ||| by neurotransmitters , ||| 0-0 1-1 2-2
durch Neurotransmitter ||| by neurotransmitters ||| 0-0 1-1
durch bilaterale Orchiektomie ( operative ||| by bilateral orchiectomy ( ||| 0-0 1-1 2-1 4-2 3-3
durch bilaterale Orchiektomie ||| by bilateral ||| 0-0 1-1 2-1
durch den gp-60-Albuminrezeptor vermittelt ||| mediated by the gp-60 albumin ||| 3-0 0-1 1-2 2-3
durch den gp-60-Albuminrezeptor vermittelt ||| mediated by the gp-60 ||| 3-0 0-1 1-2 2-3
durch den gp-60-Albuminrezeptor ||| by the gp-60 albumin receptor ||| 0-0 1-1 2-2
durch den gp-60-Albuminrezeptor ||| by the gp-60 albumin ||| 0-0 1-1 2-2
durch den gp-60-Albuminrezeptor ||| by the gp-60 ||| 0-0 1-1 2-2
durch den ||| by the ||| 0-0 1-1
durch den ||| durch den ||| 0-0 1-1
durch die EMEA ||| of the EMEA ||| 0-0 1-1 2-2
durch die Folie , weil ||| through the foil because ||| 0-0 2-0 1-1 2-2 4-2 4-3
durch die gleichzeitige Gabe von ||| durch die gleichzeitige Gabe von ||| 0-0 1-1 2-2 2-3 2-4 4-4
durch die orale Zufuhr ||| be treated by oral administration ||| 3-0 1-1 3-1 0-2 2-3 3-3 3-4
durch die ||| , by ||| 1-0 0-1 1-1
durch die ||| by the ||| 0-0 1-1
durch die ||| by ||| 0-0 1-0
durch die ||| durch die ||| 0-0 1-1
durch die ||| of the ||| 0-0 1-1
durch eine optimale glykämische Einstellung ||| onset of late diabetic ||| 0-0 1-0 2-0 2-1 2-2 3-2 4-2 3-3
durch eine ||| is caused by a ||| 0-0 0-1 0-2 1-3
durch leichtes Schütteln sichergestellt ||| by mild agitation before use ||| 0-0 1-1 2-2 2-3 3-3
durch leichtes Schütteln sichergestellt ||| by mild agitation before ||| 0-0 1-1 2-2 2-3 3-3
durch leichtes ||| by mild ||| 0-0 1-1
durch neueres ersetzt ||| replaced with new bone material ||| 1-0 1-2 0-3 2-3 2-4
durch renale Ausscheidung . ||| by renal excretion . ||| 0-0 1-1 2-2 3-3
durch renale Ausscheidung ||| by renal excretion ||| 0-0 1-1 2-2
durch renale ||| by renal ||| 0-0 1-1
durch spezifische Interaktionsstudien bestätigt , ||| durch spezifische Interaktionsstudien bestätigt , ||| 0-0 3-1 3-2 3-3 4-4
durch spezifische Interaktionsstudien bestätigt ||| durch spezifische Interaktionsstudien bestätigt ||| 0-0 3-1 3-2 3-3
durch spezifische Interaktionsstudien ||| durch ||| 0-0
durch spezifische ||| durch ||| 0-0
durch ||| by ||| 0-0
durch ||| durch ||| 0-0
durch ||| in ||| 0-0
durch ||| into less ||| 0-0
durch ||| into ||| 0-0
durch ||| is caused by ||| 0-0 0-1 0-2
durch ||| of the blood by ||| 0-0 0-1 0-3
durch ||| of ||| 0-0
durchgeführt , in denen ||| studies looking at ||| 0-0 3-0 1-1 2-2
durchgeführt . In diesen Studien ||| studies of ||| 0-0 2-0 3-0 4-0
durchgeführt . In diesen Studien ||| studies ||| 0-0 2-0 3-0 4-0
durchgeführt . ||| . ||| 0-0 1-0
durchgeführt . ||| been performed . ||| 0-0 0-1 1-2
durchgeführt worden . ||| been carried out . ||| 0-0 0-1 1-1 1-2 2-3
durchgeführt worden ||| been carried out ||| 0-0 0-1 1-1 1-2
durchgeführt worden ||| been conducted ||| 0-0 1-0 0-1
durchgeführt ||| been conducted ||| 0-0 0-1
durchgeführt ||| been performed ||| 0-0 0-1
durchgeführt ||| conducted ||| 0-0
durchschnittliche Dauer des Diabetes betrug ||| average duration of diabetes was ||| 0-0 1-1 2-2 3-3 4-4
durchschnittliche Dauer des Diabetes ||| average duration of diabetes ||| 0-0 1-1 2-2 3-3
durchschnittliche Dauer des ||| average duration of ||| 0-0 1-1 2-2
durchschnittliche Dauer ||| average duration ||| 0-0 1-1
durchschnittliche ||| average steady-state ||| 0-0
durchschnittliche ||| average ||| 0-0
durchzuführen . ||| such patients . ||| 0-0 0-1 1-2
durchzuführen ||| such patients ||| 0-0 0-1
dynamischen Reorganisation ||| dynamic ||| 0-0 1-0
dürfen nicht ||| should not ||| 0-0 0-1 1-1
ebenfalls Bestandteil ||| also part ||| 0-0 0-1 1-1
ebenfalls Teil des EPAR ist ||| also part of the EPAR ||| 0-0 0-1 1-1 2-2 2-3 4-3 2-4 3-4
ebenfalls Teil des EPAR ||| also part of the EPAR ||| 0-0 0-1 1-1 1-2 2-3 2-4 3-4
ebenfalls Teil ||| also part of ||| 0-0 0-1 1-1 1-2
ebenfalls Teil ||| also part ||| 0-0 0-1 1-1
ebenfalls effektiv behandelt werden ( ||| also be effectively treated ( ||| 0-0 3-1 1-2 2-3 4-4
ebenfalls effektiv behandelt werden ||| also be effectively treated ||| 0-0 3-1 1-2 2-3
ebenfalls ||| also ||| 0-0
effektiv behandelt werden ( z. ||| be effectively treated ( e. ||| 2-0 0-1 1-2 3-3 4-4
effektiv behandelt werden ( ||| be effectively treated ( ||| 2-0 0-1 1-2 3-3
effektiv behandelt werden ||| be effectively treated ||| 2-0 0-1 1-2
effektiv behandelt ||| effectively treated ||| 0-0 1-1
effektiv ||| effectively ||| 0-0
effektive Funktion der Fertigpens ||| pens to function safely ||| 3-0 0-1 1-2 0-3 1-3 2-3 3-3
effektive Funktion der Patrone ||| cartridge to function safely ||| 3-0 0-1 1-2 0-3 1-3 2-3
effektive Funktion der ||| to function safely ||| 0-0 1-1 0-2 1-2 2-2
eher ein Maß der Resorption ||| a measure of the absorption ||| 1-0 0-1 1-1 2-1 3-2 3-3 4-4
eher ein Maß der ||| a measure of the ||| 1-0 0-1 1-1 2-1 3-2 3-3
eher ein Maß ||| a measure ||| 1-0 0-1 1-1 2-1
eim Arz ||| . ||| 0-0 1-0
eim n ||| du ||| 0-0 1-0
eim ||| . du ||| 0-0 0-1
eim ||| . ||| 0-0
eim ||| ina ||| 0-0
ein Anstieg des ||| ein Anstieg des ||| 0-0 1-0 1-1 2-2
ein Anstieg ||| ein Anstieg ||| 0-0 1-0 1-1
ein Antimikrotubuli-Wirkstoff ||| an antimicrotubule agent ||| 0-0 1-1 1-2
ein Arzneimittel , das ||| a medicine containing ||| 0-0 1-1 2-2 3-2
ein Arzneimittel ||| a medicinal product ||| 0-0 1-1 1-2
ein Arzneimittel ||| a medicine ||| 0-0 1-1
ein Arzt ||| medical ||| 1-0
ein Befund ||| a finding ||| 0-0 1-1
ein Behandlungsregime einschließlich Bisphosphonaten ||| regimens including bisphosphonates ||| 1-0 2-1 3-2
ein Behandlungsregime einschließlich ||| regimens including ||| 1-0 2-1
ein Behandlungsregime ||| regimens ||| 1-0
ein Bisphosphonat . ||| a bisphosphonate . ||| 0-0 1-1 2-2
ein Bisphosphonat ||| a bisphosphonate ||| 0-0 1-1
ein Cannabinoid-Rezeptor- Antagonist . ||| a cannabinoid receptor antagonist . ||| 0-0 1-1 1-2 2-3 3-4
ein Cannabinoid-Rezeptor- Antagonist ||| a cannabinoid receptor antagonist ||| 0-0 1-1 1-2 2-3
ein Cannabinoid-Rezeptor- ||| a cannabinoid receptor ||| 0-0 1-1 1-2
ein Diabetesmedikament ) ||| an antidiabetic medicine ) ||| 0-0 1-1 1-2 2-3
ein Diabetesmedikament ||| an antidiabetic medicine ||| 0-0 1-1 1-2
ein Drittel der Patienten ||| one third of the patients ||| 0-0 1-0 1-1 2-2 2-3 3-4
ein Drittel der ||| one third of the ||| 0-0 1-0 1-1 2-2 2-3
ein Drittel ||| one third ||| 0-0 1-0 1-1
ein Durchschnittsalter von 62 ||| an average age of 62 ||| 0-0 1-1 3-1 1-2 2-3 3-4
ein Ernährungsprogramm befolgen . ||| follow a nutrition programme . ||| 1-0 0-1 1-2 2-2 1-3 3-4
ein Ernährungsprogramm befolgen ||| follow a nutrition programme ||| 1-0 0-1 1-2 2-2 1-3
ein Ernährungsprogramm beinhaltet . ||| includes a nutrition programme . ||| 2-0 0-1 1-2 1-3 3-4
ein Ernährungsprogramm beinhaltet ||| includes a nutrition programme ||| 2-0 0-1 1-2 1-3
ein Ernährungsprogramm ||| a nutrition programme ||| 0-0 1-1 1-2
ein Ersatzinsulin , das mit ||| a replacement insulin which ||| 0-0 1-1 1-2 2-3 3-3
ein Ersatzinsulin , das ||| a replacement insulin which ||| 0-0 1-1 1-2 2-3 3-3
ein Ersatzinsulin ||| a replacement insulin ||| 0-0 1-1 1-2
ein Gen ||| naturally ||| 0-0 1-0
ein Glykoprotein , ||| a glycoprotein that stimulates , ||| 0-0 0-1 1-1 1-2 1-3 2-4
ein Glykoprotein ||| a glycoprotein that stimulates ||| 0-0 0-1 1-1 1-2 1-3
ein Hormon ||| a hormone ||| 0-0 1-1
ein Ikterus auftritt , ||| jaundice is observed , ||| 0-0 1-0 2-0 1-1 2-2 3-3
ein Ikterus auftritt ||| jaundice is observed ||| 0-0 1-0 2-0 1-1 2-2
ein Inhibitor der Osteoklasten-vermittelten ||| an inhibitor of osteoclast-mediated ||| 0-0 1-1 2-2 3-3
ein Inhibitor der ||| an inhibitor of ||| 0-0 1-1 2-2
ein Inhibitor ||| an inhibitor ||| 0-0 1-1
ein Jahr nach der ||| year after ||| 1-0 2-1
ein Jahr nach ||| year after ||| 1-0 2-1
ein Jahr oder länger an ||| for a year or more ||| 0-0 0-1 1-2 2-3 3-4 4-4
ein Jahr oder weniger dauerten ||| one year or less duration ||| 0-0 1-0 1-1 2-2 3-3 4-4
ein Jahr oder weniger dauerten ||| one year or less duration ||| 1-0 0-1 1-1 2-2 3-3 4-4
ein Jahr oder weniger ||| one year or less ||| 0-0 1-0 1-1 2-2 3-3
ein Jahr oder weniger ||| one year or less ||| 1-0 0-1 1-1 2-2 3-3
ein Jahr oder ||| for a year or ||| 0-0 0-1 1-2 2-3
ein Jahr oder ||| one year or ||| 0-0 1-0 1-1 2-2
ein Jahr oder ||| one year or ||| 1-0 0-1 1-1 2-2
ein Jahr wirken , ||| one year , ||| 0-0 1-0 1-1 3-2
ein Jahr wirken ||| one year ||| 0-0 1-0 1-1
ein Jahr ||| for a year ||| 0-0 0-1 1-2
ein Jahr ||| one year ||| 0-0 1-0 1-1
ein Jahr ||| one year ||| 1-0 0-1 1-1
ein Jahr ||| year ||| 1-0
ein MNS ||| NMS ||| 0-0 1-0
ein MNS ||| of NMS ||| 0-1 1-1
ein Maximalvolumen von 1 ||| a maximum volume of 1 ||| 0-0 1-1 1-2 2-3 3-4
ein Maximalvolumen von ||| a maximum volume of ||| 0-0 1-1 1-2 2-3
ein Maximalvolumen ||| a maximum volume ||| 0-0 1-1 1-2
ein Maß ||| rather ||| 0-0 1-0
ein Pfleger / ein Verwandter ||| your carer/ relative ||| 1-0 0-1 1-1 2-1 4-1 3-2 4-2
ein Risiko darstellen . ||| hypoglycaemia whilst driving . ||| 2-0 0-1 1-1 2-1 2-2 3-3
ein Risiko darstellen ||| hypoglycaemia whilst driving ||| 2-0 0-1 1-1 2-1 2-2
ein Risiko für ||| a risk ||| 0-0 1-1 2-1
ein Teil ||| of ||| 1-0
ein Teil ||| some of ||| 1-1
ein Wachstumsfaktor , der ||| a growth factor ||| 0-0 1-1 2-1 1-2 3-2
ein anderer LHRH-Agonist ||| Another LHRH agonist ||| 2-0 2-1 2-2
ein anderes Antipsychotikum ) an ||| another antipsychotic medicine ) in ||| 1-0 2-1 2-2 3-3 4-4
ein anderes Antipsychotikum ) ||| another antipsychotic medicine ) ||| 1-0 2-1 2-2 3-3
ein anderes Antipsychotikum ||| another antipsychotic medicine ||| 1-0 2-1 2-2
ein anderes ||| another ||| 1-0
ein beschleunigter ||| a characteristic ||| 0-0 1-1
ein dosisabhängiger Anstieg des ||| a dose-dependent increase in ||| 0-0 1-1 2-1 1-2 3-2 2-3
ein eindeutiger ||| a ||| 0-0
ein eindeutiger Überlebensvorteil ||| a clear-cut ||| 0-0 2-1
ein elektiver orthopädischer ||| for major elective ||| 1-0 0-1 1-1 2-2
ein elektiver orthopädischer ||| major elective ||| 0-0 1-0 2-1
ein elektiver ||| for major ||| 1-0 0-1 1-1
ein elektiver ||| major ||| 0-0 1-0
ein erhöhtes Risiko für thromboembolische ||| an increased risk for thromboembolic ||| 0-0 1-1 2-2 3-3 4-4
ein erhöhtes Risiko für thrombotische ||| an increased risk of thrombotic ||| 0-0 1-1 2-2 3-2 4-4
ein erhöhtes Risiko für ||| an increased risk for ||| 0-0 1-1 2-2 3-3
ein erhöhtes Risiko für ||| an increased risk of ||| 0-0 1-1 2-2 3-2
ein erhöhtes Risiko für ||| an increased risk ||| 0-0 1-1 2-2 3-2
ein erhöhtes Risiko von ||| an increased risk of ||| 0-0 1-1 2-2 3-3
ein erhöhtes Risiko ||| an increased risk ||| 0-0 1-1 2-2
ein erhöhtes Toxizitätsrisiko bestehen ||| increased risk of ||| 0-0 1-0 1-1 2-1 3-1
ein erhöhtes Toxizitätsrisiko bestehen ||| increased risk ||| 0-0 1-0 1-1 2-1 3-1
ein erhöhtes ||| an increased ||| 0-0 1-1
ein erhöhtes ||| increased risk of ||| 0-0 1-0 1-1
ein erhöhtes ||| increased risk ||| 0-0 1-0 1-1
ein erhöhtes ||| risk ||| 0-0 1-0
ein geringer ||| a ||| 0-0
ein hochwirksamer CYP2D6-Inhibitor ||| a potent inhibitor ||| 0-0 1-1 0-2 2-2
ein hochwirksamer Inhibitor von CYP3A4 ||| a potent inhibitor of CYP3A4 ||| 0-0 1-1 0-2 2-2 3-3 4-4
ein hochwirksamer Inhibitor von ||| a potent inhibitor of ||| 0-0 1-1 0-2 2-2 3-3
ein hochwirksamer Inhibitor ||| a potent inhibitor ||| 0-0 1-1 0-2 2-2
ein invasiver Dentaleingriff vermieden ||| avoid invasive dental procedures ||| 0-0 1-1 1-2 3-2 2-3
ein leichtes ||| a mild ||| 0-0 1-1
ein neuer LHRH-Agonist , ||| a new LHRH agonist and ||| 0-0 1-1 2-2 2-3
ein neuer LHRH-Agonist , ||| a new LHRH agonist ||| 0-0 1-1 2-2 2-3
ein neuer LHRH-Agonist ||| a new LHRH agonist and ||| 0-0 1-1 2-2 2-3
ein neuer LHRH-Agonist ||| a new LHRH agonist ||| 0-0 1-1 2-2 2-3
ein neuer ||| a new ||| 0-0 1-1
ein qualitativ normales ||| normal quality ||| 0-0 1-0 1-1 2-1
ein qualitativ normales ||| of normal quality ||| 0-1 1-1 1-2 2-2
ein sogenanntes Antipsychotikum . ||| an antipsychotic medicine . ||| 0-0 1-1 2-1 1-2 3-3
ein sogenanntes Antipsychotikum ||| an antipsychotic medicine ||| 0-0 1-1 2-1 1-2
ein stabiler ||| a stable level ||| 0-0 0-1 1-1 1-2
ein steriles , aber unkonserviertes ||| a sterile but unpreserved ||| 0-0 1-1 2-2 3-2 4-3
ein steriles , aber ||| a sterile but ||| 0-0 1-1 2-2 3-2
ein steriles ||| a sterile ||| 0-0 1-1
ein tödlicher Ausgang berichtet wurde ||| fatal outcome has been reported ||| 0-0 1-0 2-1 2-2 4-3 3-4
ein tödlicher Ausgang ||| fatal outcome has ||| 0-0 1-0 2-1 2-2
ein tödlicher ||| fatal ||| 0-0 1-0
ein und schlucken Sie ||| and swallow it ||| 1-0 0-1 2-1 3-1 2-2
ein verzögertes Wachstum des ||| apparent in animal studies with ||| 1-0 0-1 1-2 2-2 3-2 1-3
ein verzögertes Wachstum des ||| apparent in animal studies ||| 1-0 0-1 1-2 2-2 3-2 1-3
ein zytotoxisches antikarzinogenes Arzneimittel ||| a cytotoxic anticancer medicinal product ||| 0-0 1-1 2-2 3-3 3-4
ein zytotoxisches antikarzinogenes ||| a cytotoxic anticancer ||| 0-0 1-1 2-2
ein zytotoxisches ||| a cytotoxic ||| 0-0 1-1
ein ||| , a ||| 0-1
ein ||| a ||| 0-0
ein ||| an ||| 0-0
ein ||| avoid ||| 0-0
ein ||| clinical ||| 0-0
ein ||| ein ||| 0-0
ein ||| for a ||| 0-0 0-1
ein ||| in ||| 0-0
ein ||| of a ||| 0-1
ein ||| year in ||| 0-0
ein ||| year ||| 0-0
ein ähnlicher signifikanter ||| a similar significant ||| 0-0 1-1 2-2
ein ähnlicher ||| a similar ||| 0-0 1-1
eindeutig ||| cardiotoxicity unequivocally ||| 0-0 0-1
eindeutiger ||| clearly ||| 0-0
eindeutiger Überlebensvorteil ||| clear-cut ||| 1-0
eine 63%ige Reduktion ||| a 63 % reduction ||| 0-0 1-1 2-2 1-3 2-3
eine Albumin-gebundene Nanopartikelformulierung von ||| an albumin-bound nanoparticle formulation of ||| 0-0 1-1 2-2 0-3 3-4
eine Albumin-gebundene Nanopartikelformulierung ||| an albumin-bound nanoparticle formulation ||| 0-0 1-1 2-2 0-3
eine Bündelpackung mit ||| a multipack with ||| 0-0 1-1 2-2
eine Bündelpackung ||| a multipack ||| 0-0 1-1
eine Chemotherapie erhalten ||| receiving chemotherapy ||| 0-0 1-0 1-1 2-1
eine Dehydratation bewirken können ) ||| may cause dehydration ) ||| 3-0 0-1 2-1 1-2 2-2 4-3
eine Dehydratation bewirken können ||| may cause dehydration ||| 3-0 0-1 2-1 1-2 2-2
eine Dehydratation bewirken ||| cause dehydration ||| 0-0 2-0 1-1 2-1
eine Dosis ||| a dose ||| 0-0 1-1
eine Dosisanpassung notwendig ist ||| a dose adjustment is necessary ||| 0-0 1-1 1-2 3-3 2-4
eine Dosisanpassung ||| a dose adjustment ||| 0-0 1-1 1-2
eine Durchstechflasche mit 100 mg ||| one vial of 100 mg ||| 0-0 1-1 2-2 3-3 4-4
eine Durchstechflasche mit 100 ||| one vial of 100 ||| 0-0 1-1 2-2 3-3
eine Durchstechflasche mit ||| one vial of ||| 0-0 1-1 2-2
eine Durchstechflasche ||| one vial ||| 0-0 1-1
eine Einzeldosis in ||| one single-use ||| 0-0 1-0 1-1
eine Einzeldosis ||| one single-use ||| 0-0 1-0 1-1
eine Erholung von den ||| permitted recovery from the ||| 1-0 2-1 2-2 3-3
eine Erholung von ||| permitted recovery from ||| 1-0 2-1 2-2
eine Erholung ||| permitted ||| 1-0
eine Erhöhung der Kreatinphosphokinase , ||| elevated creatine phosphokinase , ||| 0-0 3-0 1-1 3-1 2-2 3-2 4-3
eine Erhöhung der Kreatinphosphokinase ||| elevated creatine phosphokinase ||| 0-0 3-0 1-1 3-1 2-2 3-2
eine Exposition ||| , exposure to ||| 1-1 0-2
eine Exposition ||| exposure to ||| 1-0 0-1
eine Flasche enthalten , geliefert ||| containing 1 bottle ||| 0-0 1-0 3-0 1-1 2-1 1-2 4-2
eine Glaskugel , um ||| a glass ball to ||| 0-0 1-1 1-2 2-2 3-2 3-3
eine Halbwertszeit von annähernd 6 ||| half-life of approximately 6 ||| 0-0 1-0 2-1 3-2 4-3
eine Halbwertszeit von annähernd ||| half-life of approximately ||| 0-0 1-0 2-1 3-2
eine Halbwertszeit von einigen ||| a half-life of a few ||| 0-0 1-1 2-2 0-3 3-4
eine Halbwertszeit von etwa ||| revealed a half-life of approximately ||| 1-0 0-1 1-2 3-2 2-3 3-4
eine Halbwertszeit von ||| a half-life of a ||| 0-0 1-1 2-2 0-3
eine Halbwertszeit von ||| half-life of ||| 0-0 1-0 2-1
eine Halbwertszeit ||| half-life ||| 0-0 1-0
eine Hämoglobin-Zielkonzentration von ||| to target a haemoglobin of ||| 0-0 1-1 0-2 1-3 2-4
eine Hämoglobin-Zielkonzentration ||| to target a haemoglobin ||| 0-0 1-1 0-2 1-3
eine Infusion ||| one infusion of Aclasta ||| 0-0 1-1 0-2 1-3
eine Infusionslösung ( ||| a solution for infusion ( ||| 0-0 1-1 1-2 1-3 2-4
eine Infusionslösung ||| a solution for infusion ||| 0-0 1-1 1-2 1-3
eine Injektion ||| an injection ||| 0-0 0-1 1-1
eine Kompatibilität besteht . ||| to be compatible . ||| 0-0 1-1 0-2 1-2 2-2 3-3
eine Kompatibilität besteht ||| to be compatible ||| 0-0 1-1 0-2 1-2 2-2
eine Krankheit , bei ||| a disease in which ||| 0-0 1-1 3-2 2-3
eine Krankheit ||| a disease ||| 0-0 1-1
eine Körpergewichtsabstufung ||| a gradation in ||| 0-0 1-1
eine Körpergewichtsabstufung ||| a gradation ||| 0-0 1-1
eine Lipodystrophie zu ||| sites ||| 0-0 1-0 2-0
eine Mischung aus gelöstem Insulin ||| a mixture of dissolved insulin ||| 0-0 1-1 2-2 2-3 3-3 4-4
eine Mischung aus gelöstem ||| a mixture of dissolved ||| 0-0 1-1 2-2 2-3 3-3
eine Mischung ||| a mixture ||| 0-0 1-1
eine Nebenwirkung ||| an adverse reaction ||| 0-0 1-1 1-2
eine Osmolalität von ||| an osmolality of ||| 0-0 1-1 2-2
eine Osmolalität ||| an osmolality ||| 0-0 1-1
eine QT-Verlängerung oder ||| QT prolongation or ||| 0-0 1-0 1-1 2-2
eine QT-Verlängerung ||| QT prolongation ||| 0-0 1-0 1-1
eine Reihe von Insulin-Suspensionen ||| a range of insulin suspensions ||| 0-0 1-1 2-2 3-3 3-4
eine Reihe von ||| a range of ||| 0-0 1-1 2-2
eine Reihe ||| a range ||| 0-0 1-1
eine Schwangerschaft planen . ||| planning to become pregnant . ||| 0-0 2-0 0-1 1-2 2-2 2-3 3-4
eine Schwangerschaft planen ||| planning to become pregnant ||| 0-0 2-0 0-1 1-2 2-2 2-3
eine Schwangerschaft ||| to become ||| 0-0 0-1 1-1
eine Spritze aus ||| one syringe from ||| 0-0 1-1 2-2
eine Spritze ||| a syringe ||| 0-0 1-1
eine Spritze ||| one syringe ||| 0-0 1-1
eine Studie mit fixer Dosierung ||| a fixed-dose trial ||| 0-0 2-1 3-1 4-1 1-2 3-2
eine Tablette ||| one tablet ||| 0-0 1-0 1-1
eine Verringerung der Insulinresistenz vermittelt ||| a reduction of insulin resistance ||| 0-0 1-1 2-2 3-3 3-4 4-4
eine Verringerung der ||| a reduction of ||| 0-0 1-1 2-2
eine Verringerung von 35 % ||| a 35 % reduction ||| 0-0 3-1 4-2 1-3
eine Verringerung ||| a reduction ||| 0-0 1-1
eine andere Dosis einzunehmen . ||| a different dose . ||| 0-0 1-1 3-1 2-2 4-3
eine andere Dosis einzunehmen ||| a different dose ||| 0-0 1-1 3-1 2-2
eine angemessene Thromboseprophylaxe erhalten ||| antithrombotic prophylaxis ||| 0-0 1-0 2-0 2-1 3-1
eine anti-Erythropoetin , antikörpervermittelte PRCA ||| anti-erythropoietin , antibody-mediated PRCA is ||| 0-0 1-0 2-1 1-2 3-2 4-3 3-4
eine ausreichende ||| adequate ||| 0-0 1-0
eine bekannte Komplikation der chronischen ||| a known complication of chronic ||| 0-0 2-1 1-2 2-2 4-2 3-3 4-4
eine bis zu 31 ||| up to a 31 ||| 1-0 2-0 1-1 0-2 3-3
eine bis zu ||| up to a ||| 1-0 2-0 1-1 0-2
eine der folgenden ||| following ||| 2-0
eine der ||| of the ||| 0-0 1-0 1-1
eine einzige Injektion . ||| one injection . ||| 0-0 1-0 2-1 3-2
eine einzige Injektion ||| one injection ||| 0-0 1-0 2-1
eine einzige ||| one ||| 0-0 1-0
eine engmaschige Überwachung des Blutzuckers ||| blood glucose monitoring is therefore ||| 1-0 0-1 1-1 1-2 2-2 4-3 3-4 4-4
eine engmaschige Überwachung ||| blood glucose monitoring ||| 1-0 0-1 1-1 1-2 2-2
eine erneute Behandlung benötigen ||| need to be treated ||| 3-0 0-1 1-1 2-2
eine erneute Behandlung benötigen ||| need to be ||| 3-0 0-1 1-1 2-2
eine erneute Behandlung ||| to be treated ||| 0-0 1-0 2-1
eine erneute Behandlung ||| to be ||| 0-0 1-0 2-1
eine erneute ||| to ||| 0-0 1-0
eine farblose bis leicht gelbe ||| a colourless to slightly yellow ||| 0-0 1-1 2-2 3-3 4-3 2-4 4-4
eine farblose ||| a colourless ||| 0-0 1-1
eine geeichte 2 ml Tropfpipette ||| a 2 ml calibrated dropper ||| 0-0 2-1 3-2 1-3 4-3 4-4
eine geeichte Tropfpipette ||| a calibrated ||| 0-0 1-0 1-1 2-1
eine geeichte Tropfpipette ||| a calibrated ||| 0-0 1-1 2-1
eine gegenüber Placebo überlegene Wirksamkeit ||| demonstrated superior efficacy to placebo ||| 0-0 3-0 1-1 3-1 4-2 1-3 2-4
eine gleichzeitig bestehende Hypertonie und/oder ||| with hypertension and/ or dyslipidemia ||| 1-0 3-1 4-2 4-3 2-4
eine gleichzeitig ||| with ||| 1-0
eine hepatische Dysfunktion hinweisen ||| suggesting hepatic dysfunction ||| 1-0 1-1 0-2 1-2 2-2 3-2
eine hohe Permeabilität in vitro ||| high in vitro permeability ||| 0-0 1-0 3-1 3-2 4-2 2-3
eine hohe ||| high ||| 0-0 1-0
eine intravenöse Infusion von ||| a single intravenous infusion of ||| 0-0 1-1 1-2 2-3 3-4
eine intravenöse Infusion ||| a single intravenous infusion ||| 0-0 1-1 1-2 2-3
eine intravenöse ||| a single intravenous ||| 0-0 1-1 1-2
eine kalorienkontrollierte Ernährung zu halten ||| to a calorie-controlled diet ||| 0-0 0-1 1-1 1-2 2-2 3-2 4-2 2-3
eine klare , farblose , ||| a clear , colourless , ||| 0-0 1-1 2-2 3-3 4-4
eine klare , farblose ||| a clear , colourless ||| 0-0 1-1 2-2 3-3
eine klare , ||| a clear , ||| 0-0 1-1 2-2
eine klare , ||| as a clear , ||| 0-0 0-1 1-2 2-3
eine klare und farblose Lösung ||| a clear and colourless solution ||| 0-0 1-1 2-2 3-3 4-4
eine klare und farblose ||| a clear and colourless ||| 0-0 1-1 2-2 3-3
eine klare und ||| a clear and ||| 0-0 1-1 2-2
eine klare ||| a clear ||| 0-0 1-1
eine klare ||| as a clear ||| 0-0 0-1 1-2
eine klinische ||| consider clinical ||| 0-0 1-0 1-1
eine klinische Überwachung ||| consider clinical monitoring ||| 0-0 1-0 1-1 2-2
eine kumulative Dosis ||| a cumulative dose ||| 0-0 1-1 2-2
eine kumulative Dosis ||| for a cumulative dose ||| 0-1 1-2 2-3
eine kumulative ||| a cumulative ||| 0-0 1-1
eine kumulative ||| for a cumulative ||| 0-1 1-2
eine lange Zeit ||| a long time ||| 0-0 1-1 2-2
eine lange ||| a long ||| 0-0 1-1
eine leichte Einschränkung der Nierenfunktion ||| mild renal impairment ||| 1-0 2-1 4-1 4-2
eine leichte ||| mild ||| 1-0
eine mittlere ||| a mean total ||| 0-0 1-1 1-2
eine mäßige Affinität zur ||| moderate binding affinity for ||| 1-0 1-1 0-2 1-2 2-2 3-3
eine mäßige Affinität ||| moderate affinity for ||| 1-0 0-1 1-1 2-1 2-2
eine mäßige Affinität ||| moderate binding affinity for ||| 1-0 1-1 0-2 1-2 2-2 2-3
eine mäßige Affinität ||| moderate binding affinity ||| 1-0 1-1 0-2 1-2 2-2
eine negative Auswirkung auf ||| a negative impact on ||| 0-0 1-1 2-2 3-3
eine negative Auswirkung ||| a negative impact ||| 0-0 1-1 2-2
eine negative ||| a negative ||| 0-0 1-1
eine periphere Neuropathie Grad 3 ||| grade 3 peripheral neuropathy at ||| 3-0 4-1 1-2 2-3 0-4
eine periphere Neuropathie ||| peripheral neuropathy at any ||| 1-0 2-1 0-2
eine periphere Neuropathie ||| peripheral neuropathy at ||| 1-0 2-1 0-2
eine richtige Dosierung zu gewährleisten ||| to allow proper dosing ||| 3-0 0-1 4-1 1-2 4-2 2-3
eine schnelle initiale Wirkung zusammen ||| a rapid initial effect together ||| 0-0 1-1 2-1 2-2 3-3 2-4 4-4
eine schnelle initiale Wirkung zusammen ||| a rapid initial effect together ||| 0-0 1-1 2-2 3-3 2-4 4-4
eine schnelle ||| a rapid ||| 0-0 1-1
eine schnellere Resorption . ||| injection sites . ||| 1-0 0-1 1-1 2-1 3-2
eine schnellere Resorption ||| injection sites ||| 1-0 0-1 1-1 2-1
eine sichere ||| allow the ||| 0-0 1-0 1-1
eine signifikant ||| significantly greater ||| 1-0 0-1 1-1
eine spezifische Behandlung ||| specific treatment ||| 1-0 2-1
eine spezifische ||| specific ||| 1-0
eine statistisch signifikante ||| a statistically significant ||| 0-0 1-1 2-2
eine statistisch ||| a statistically ||| 0-0 1-1
eine strenge ||| by physicians for ||| 0-0 1-1
eine strenge ||| by physicians ||| 0-0 1-1
eine strenge ärztliche ||| by physicians for ||| 0-0 1-1
eine strenge ärztliche ||| by physicians ||| 0-0 1-1
eine strenge ärztliche Überwachung auf ||| by physicians for the occurrence ||| 0-0 1-1 3-3 4-3 4-4
eine symptomatische Behandlung eingeleitet werden ||| symptomatic treatment should be initiated ||| 0-0 1-0 2-1 3-2 4-3 3-4
eine symptomatische Behandlung ||| symptomatic treatment ||| 0-0 1-0 2-1
eine symptomatische Hypokalzämie ||| , symptomatic hypocalcaemia ||| 0-1 1-1 2-2
eine symptomatische Hypokalzämie ||| symptomatic hypocalcaemia ||| 0-0 1-0 2-1
eine symptomatische Therapie erfolgen ||| symptomatic therapy should be administered ||| 0-0 1-0 2-1 1-2 3-3 3-4
eine symptomatische Therapie ||| , symptomatic therapy should ||| 0-1 1-1 2-2 1-3
eine symptomatische Therapie ||| symptomatic therapy should ||| 0-0 1-0 2-1 1-2
eine symptomatische ||| , symptomatic ||| 0-1 1-1
eine symptomatische ||| symptomatic ||| 0-0 1-0
eine systemische Begleiterkrankung ||| a concomitant systemic ||| 0-0 2-1 1-2 2-2
eine t½ von nur wenigen ||| a t½ of a few ||| 0-0 1-1 2-2 0-3 3-4 4-4
eine t½ von ||| a t½ of a ||| 0-0 1-1 2-2 0-3
eine um 27 % höhere ||| a 27 % higher ||| 0-0 2-1 1-2 3-2 4-3
eine um 27 % ||| a 27 % ||| 0-0 2-1 1-2 3-2
eine um 43 % ||| a 43 % ||| 0-0 2-1 1-2 3-2
eine ||| , a ||| 0-1
eine ||| If ||| 0-0
eine ||| a ||| 0-0
eine ||| an ||| 0-0
eine ||| as a ||| 0-0 0-1
eine ||| at any ||| 0-0
eine ||| at ||| 0-0
eine ||| by ||| 0-0
eine ||| demonstrated ||| 0-0
eine ||| due to the ||| 0-0 0-1
eine ||| due to ||| 0-0 0-1
eine ||| eine ||| 0-0
eine ||| for a ||| 0-1
eine ||| of a ||| 0-0 0-1
eine ||| of the ||| 0-0
eine ||| of ||| 0-0
eine ||| one ||| 0-0
eine ||| receiving ||| 0-0
eine ||| revealed ||| 0-0
eine ||| to take ||| 0-0
eine ||| to ||| 0-0
eine ähnliche Abnahme der ||| , a similar decrease in ||| 0-1 1-2 2-3 2-4
eine ähnliche Abnahme der ||| a similar decrease in ||| 0-0 1-1 2-2 2-3
eine ähnliche Abnahme ||| , a similar decrease in ||| 0-1 1-2 2-3 2-4
eine ähnliche Abnahme ||| a similar decrease in ||| 0-0 1-1 2-2 2-3
eine ähnliche Wirksamkeit ||| a similar pattern of efficacy ||| 0-0 1-1 0-2 2-4
eine ähnliche Wirkung ||| a similar effect ||| 0-0 1-1 2-2
eine ähnliche ||| , a similar ||| 0-1 1-2
eine ähnliche ||| a similar pattern of ||| 0-0 1-1 0-2
eine ähnliche ||| a similar pattern ||| 0-0 1-1 0-2
eine ähnliche ||| a similar ||| 0-0 1-1
einem Anstieg der fötalen Sterblichkeit ||| the recommended human weekly dose ||| 2-0 3-1 4-2 0-3 1-3 3-3 4-3 3-4
einem Anthracyclin ( ||| an anthracycline ( ||| 0-0 1-1 2-2
einem Anthracyclin ( ||| including an anthracycline ( ||| 0-1 1-2 2-3
einem Anthracyclin ||| an anthracycline ||| 0-0 1-1
einem Anthracyclin ||| including an anthracycline ||| 0-1 1-2
einem Ausgangshämoglobinwert von ||| baseline ||| 0-0 1-0 2-0
einem Ausgangswert von 7,9 % ||| a baseline of 7.9 % ||| 0-0 0-1 1-1 2-2 3-3 4-4
einem Ausgangswert von 7,9 ||| a baseline of 7.9 ||| 0-0 0-1 1-1 2-2 3-3
einem Ausgangswert von ||| a baseline of ||| 0-0 0-1 1-1 2-2
einem Ausgangswert ||| a baseline ||| 0-0 0-1 1-1
einem Brombutyl- /Polyisopren-Gummistopfen ||| a bromobutyl/ polyisoprene rubber stopper ||| 0-0 0-1 1-1 1-2 1-3 2-4
einem Brombutyl- ||| a bromobutyl/ polyisoprene rubber ||| 0-0 0-1 1-1 1-2 1-3
einem Brombutyl-/Polyisopren-Gummistopfen ||| a bromobutyl/ polyisoprene ||| 0-0 0-1 1-1 1-2
einem Dosisbereich zwischen 10 ||| a dose range of 10 ||| 0-0 1-1 0-2 1-2 2-2 3-4
einem Dosisbereich zwischen ||| a dose range of ||| 0-0 1-1 0-2 1-2 2-2
einem Dosisbereich zwischen ||| a dose range ||| 0-0 1-1 0-2 1-2 2-2
einem Eigenblutspendeprogramm ||| an autologous predonation programme ||| 0-0 0-1 1-2 1-3
einem Fertigpen . ||| a pre-filled pen . ||| 0-0 1-1 1-2 2-3
einem Fertigpen ||| a pre-filled pen ||| 0-0 1-1 1-2
einem Glas Wasser ||| a glass of water ||| 0-0 1-1 2-3
einem Glas ||| a glass of ||| 0-0 1-1
einem Glas ||| a glass ||| 0-0 1-1
einem Kontakt mit ||| it contacts ||| 0-0 1-1 2-1
einem MNS assoziiert waren , ||| NMS , have also ||| 0-0 1-0 2-0 4-1 2-2 2-3 3-3
einem Sulfonylharnstoff ( einem anderen ||| a sulphonylurea ( another ||| 3-0 0-1 1-1 3-1 2-2 4-3
einem Sulfonylharnstoff ( einem ||| a sulphonylurea ( ||| 3-0 0-1 1-1 3-1 2-2
einem Sulfonylharnstoff . ||| a sulphonylurea . ||| 0-0 0-1 1-1 2-2
einem Sulfonylharnstoff nur bei ||| a sulphonylurea , only in ||| 0-0 0-1 1-1 2-3 3-4
einem Sulfonylharnstoff nur ||| a sulphonylurea , only ||| 0-0 0-1 1-1 2-3
einem Sulfonylharnstoff ||| a sulphonylurea , ||| 0-0 0-1 1-1
einem Sulfonylharnstoff ||| a sulphonylurea ||| 0-0 0-1 1-1
einem Sulfonylharnstoff ||| sulphonylurea ||| 0-0 1-0
einem Tiermodell der familiären adenomatösen ||| an animal model of familial ||| 0-0 1-1 1-2 3-2 2-3 3-4 4-4
einem Wechsel von tierischem auf ||| transfer from animal ||| 0-0 1-0 3-0 2-1 3-1 3-2 4-2
einem Wechsel von tierischem ||| transfer from animal ||| 0-0 1-0 3-0 2-1 3-1 3-2
einem Zeitraum von ||| over ||| 1-0 2-0
einem autologen Blutspendeprogramm : ||| an autologous predonation programme : ||| 0-0 0-1 1-1 1-2 2-2 2-3 3-4
einem autologen Blutspendeprogramm ||| an autologous blood predonation ||| 0-0 0-1 1-1 1-2 2-3
einem autologen Blutspendeprogramm ||| an autologous predonation programme ||| 0-0 0-1 1-1 1-2 2-2 2-3
einem autologen ||| an autologous blood ||| 0-0 0-1 1-1 1-2
einem der sonstigen Bestandteile . ||| any of the excipients . ||| 2-0 0-1 1-1 1-2 2-3 3-3 4-4
einem der sonstigen Bestandteile ||| any of the excipients ||| 2-0 0-1 1-1 1-2 2-3 3-3
einem der sonstigen Bestandteile ||| to any of the excipients ||| 2-1 0-2 1-2 1-3 2-4 3-4
einem der ||| of the ||| 0-0 1-0 1-1
einem erhöhten Risiko für Frakturen ||| at increased risk of fracture ||| 2-0 1-1 0-2 2-2 3-2 4-4
einem erhöhten Risiko für ||| an increased risk of ||| 0-0 1-1 2-2 3-2 2-3
einem erhöhten Risiko für ||| at increased risk of ||| 2-0 1-1 0-2 2-2 3-2
einem erhöhten Risiko für ||| at increased risk ||| 2-0 1-1 0-2 2-2 3-2
einem erhöhten ||| an increased ||| 0-0 1-1
einem geringeren Ausmaß im Harn ||| a lesser amount in urine ||| 0-0 1-1 2-1 1-2 3-3 3-4 4-4
einem geringeren Ausmaß ||| a lesser amount ||| 0-0 1-1 2-1 1-2
einem hochwirksamen Induktor ||| a potent inducer ||| 0-0 1-1 0-2 2-2
einem kardiovaskulären ||| a cardiovascular ||| 0-0 1-1
einem scheinbaren Verteilungsvolumen ||| an apparent volume ||| 0-0 1-0 1-1 2-1 2-2
einem solchen Anstieg sollte eine ||| it occurs , appropriate ||| 0-0 1-0 1-1 2-1 2-3 3-3 4-3
einem speziellen gentechnologischen ||| a specialised genetic ||| 0-0 0-1 1-1 2-2
einem speziellen ||| a specialised ||| 0-0 0-1 1-1
einem vor ||| rubber ||| 0-0
einem ||| a body mass index ||| 0-0 0-2
einem ||| a body mass ||| 0-0 0-2
einem ||| a ||| 0-0
einem ||| an autologous ||| 0-0 0-1
einem ||| an ||| 0-0
einem ||| in ||| 0-0
einem ||| including an ||| 0-1
einem ||| it ||| 0-0
einem ||| one ||| 0-0
einem ||| rubber ||| 0-0
einem ||| the ||| 0-0
einem ||| using an ||| 0-0 0-1
einem ||| with ||| 0-0
einen Arzt oder Apotheker . ||| your doctor or pharmacist . ||| 1-0 1-1 0-2 2-2 3-3 4-4
einen Arzt oder Apotheker ||| your doctor or pharmacist ||| 1-0 1-1 0-2 2-2 3-3
einen Arzt oder ||| your doctor or ||| 1-0 1-1 0-2 2-2
einen Brombutyl- /Polyisopren-Gummistopfen ||| a bromobutyl/ polyisoprene rubber stopper ||| 0-0 0-1 1-1 1-2 1-3 2-4
einen Brombutyl- ||| a bromobutyl/ polyisoprene rubber ||| 0-0 0-1 1-1 1-2 1-3
einen Infusionsbeutel gefüllt ||| an infusion bag ||| 0-0 1-1 1-2 2-2
einen Monat ||| one month ||| 0-0 1-1
einen PSUR ||| a PSUR ||| 0-0 1-1
einen PSUR ||| provide a PSUR ||| 0-1 1-2
einen Schlaganfall erlitten . ||| had had a stroke . ||| 2-0 0-1 2-1 0-2 1-3 2-3 3-4
einen Schlaganfall erlitten ||| had had a stroke ||| 2-0 0-1 2-1 0-2 1-3 2-3
einen Seite und " 10 ||| one side and " 10 ||| 0-0 1-0 1-1 2-2 3-3 4-4
einen Seite und " 15 ||| one side and " 15 ||| 0-0 1-0 1-1 2-2 3-3 4-4
einen Seite und " 30 ||| one side and " 30 ||| 0-0 1-0 1-1 2-2 3-3 4-4
einen Seite und " ||| one side and " ||| 0-0 1-0 1-1 2-2 3-3
einen Seite und ||| one side and ||| 0-0 1-0 1-1 2-2
einen Seite ||| one side ||| 0-0 1-0 1-1
einen Teil des Futters ||| a portion of the food ||| 0-0 1-1 1-2 2-3 3-4
einen Teil des ||| a portion of the ||| 0-0 1-1 1-2 2-3
einen Teil ||| a portion of ||| 0-0 1-1 1-2
einen Zeitraum ||| Abraxane over ||| 1-1
einen Zeitraum ||| not ||| 1-0
einen Zeitraum ||| over ||| 1-0
einen beschleunigten Puls feststellen ||| experience a fast heart rate ||| 1-0 0-1 0-2 1-2 2-2 3-2 1-3 2-4
einen der anderen Bestandteile reagieren ||| any of the other ingredients ||| 0-0 1-1 1-2 2-3 3-4 4-4
einen der anderen ||| any of the other ||| 0-0 1-1 1-2 2-3
einen der anderen ||| ge reported with ||| 0-0 1-1 2-2
einen der anderen ||| to any of the other ||| 0-0 0-1 1-2 1-3 2-4
einen der sonstigen Bestandteile . ||| to any of the excipients ||| 0-0 0-1 1-1 2-1 2-2 1-3 2-4 3-4
einen der sonstigen Bestandteile sind ||| any of the other ingredients ||| 0-0 1-1 1-2 2-3 2-4 3-4 4-4
einen der sonstigen Bestandteile ||| any of the other ingredients ||| 0-0 2-0 1-1 1-2 2-3 2-4 3-4
einen der sonstigen Bestandteile ||| to any of the excipients ||| 0-0 0-1 1-1 2-1 2-2 1-3 2-4 3-4
einen der sonstigen Bestandteile ||| to any of the excipients ||| 0-0 0-1 1-2 1-3 2-4 3-4
einen der sonstigen Bestandteile ||| to any of the excipients ||| 0-0 0-1 2-1 1-2 1-3 2-4 3-4
einen der ||| any of the ||| 0-0 1-1 1-2
einen der ||| ge reported ||| 0-0 1-1
einen der ||| to any of the ||| 0-0 0-1 1-2 1-3
einen geeichten ||| both a calibrated ||| 0-0 0-1 1-2
einen geringtraumatischen Hüftbruch ||| a minor trauma ||| 0-0 2-0
einen geringtraumatischen Hüftbruch ||| a minor ||| 0-0 2-0
einen geringtraumatischen Hüftbruch ||| a ||| 0-0 2-0
einen leicht appetitdämpfenden Effekt ||| a slight appetite decreasing effect ||| 0-0 1-1 2-1 2-2 2-3 3-4
einen leicht appetitdämpfenden ||| a slight appetite decreasing ||| 0-0 1-1 2-1 2-2 2-3
einen längeren ||| a longer ||| 0-0 1-1
einen pH-Wert von 6-7,5 und ||| a pH of 6-7.5 and ||| 0-0 1-1 2-2 3-3 4-4
einen pH-Wert von 6-7,5 ||| a pH of 6-7.5 ||| 0-0 1-1 2-2 3-3
einen pH-Wert von ||| a pH of ||| 0-0 1-1 2-2
einen pH-Wert ||| a pH ||| 0-0 1-1
einen zusätzlichen 6 ||| one additional 6 ||| 0-0 1-1 2-2
einen zusätzlichen ||| one additional ||| 0-0 1-1
einen ||| a ||| 0-0
einen ||| an ||| 0-0
einen ||| any of the ||| 0-0 0-2
einen ||| any ||| 0-0
einen ||| both a ||| 0-0 0-1
einen ||| ge ||| 0-0
einen ||| one ||| 0-0
einen ||| or ||| 0-0
einen ||| provide a ||| 0-1
einen ||| to any ||| 0-0 0-1
einen ||| to ||| 0-0
einen ||| were ||| 0-0
einer 3-monatigen ||| a 3 ||| 0-0 1-0 1-1
einer 9 ||| a ||| 0-0
einer 9 ||| in a ||| 0-1
einer Adipositas infolge des höheren ||| einer Adipositas infolge des höheren ||| 0-0 1-1 2-2 3-3 2-4
einer Adipositas infolge des ||| einer Adipositas infolge des höheren ||| 0-0 1-1 2-2 3-3 2-4
einer Adipositas ist die ||| einer Adipositas ist die ||| 0-0 1-1 2-2 3-3
einer Adipositas ist ||| einer Adipositas ist ||| 0-0 1-1 2-2
einer Adipositas ||| einer Adipositas ||| 0-0 1-1
einer Art der weißen ||| a type of white ||| 0-0 1-1 2-2 3-3
einer Art der weißen ||| a type of white ||| 0-0 1-1 3-3
einer Art der ||| a type of ||| 0-0 1-1
einer Art der ||| a type of ||| 0-0 1-1 2-2
einer Art der ||| a type ||| 0-0 1-1
einer Art ||| a type of ||| 0-0 1-1
einer Art ||| a type ||| 0-0 1-1
einer Bipolar-I-Störung , mit ||| Bipolar I Disorder , with ||| 1-0 0-1 1-1 1-2 2-3 3-4
einer Bipolar-I-Störung , ||| Bipolar I Disorder , ||| 1-0 0-1 1-1 1-2 2-3
einer Bipolar-I-Störung , ||| of Bipolar I Disorder , ||| 1-1 0-2 1-2 1-3 2-4
einer Bipolar-I-Störung ||| Bipolar I Disorder ||| 1-0 0-1 1-1 1-2
einer Bipolar-I-Störung ||| of Bipolar I Disorder ||| 1-1 0-2 1-2 1-3
einer Blisterpackung . ||| a blister . ||| 0-0 1-1 2-2
einer Blisterpackung ||| a blister ||| 0-0 1-1
einer Blutdrucksteigerung möglichst gering zu ||| of an increase in blood ||| 0-0 0-1 1-1 0-2 2-2 4-2 4-3 3-4
einer Bündelpackung bestehend aus 5 ||| of a multi-pack comprising 5 ||| 0-0 0-1 1-2 1-3 2-3 3-3 4-4
einer Bündelpackung bestehend aus ||| of a multi-pack comprising ||| 0-0 0-1 1-2 1-3 2-3 3-3
einer CHO-Zelllinie ||| recombinant DNA technology ||| 1-0 0-1 1-1 1-2
einer Dichtung ( Aluminium ) ||| an overseal ( aluminium ) ||| 0-0 1-1 3-1 2-2 2-3 4-4
einer Dichtung ( Aluminium ||| an overseal ( aluminium ||| 0-0 1-1 3-1 2-2 2-3
einer Diät ||| diet ||| 1-0
einer Dosierung von ||| of the ||| 1-0 2-0
einer Dosierung von ||| of ||| 1-0 2-0
einer Dosis von 600 ||| a dose of 600 ||| 0-0 1-1 2-2 3-3
einer Dosis von ||| a dose of ||| 0-0 1-1 2-2
einer Dosis ||| a dose ||| 0-0 1-1
einer Durchstechflasche . ||| a vial . ||| 0-0 1-1 2-2
einer Durchstechflasche ||| a vial ||| 0-0 1-1
einer Einzeldosis ||| a single ||| 0-0 1-1
einer Fertigspritze ( Injektionszubereitung ||| a pre-filled syringe ( injection ||| 0-0 1-1 1-2 2-3 3-4
einer Fertigspritze ( ||| a pre-filled syringe ( ||| 0-0 1-1 1-2 2-3
einer Fertigspritze . ||| a pre-filled syringe . ||| 0-0 1-1 1-2 2-3
einer Fertigspritze Die Spritzen ||| a pre-filled syringe The syringes ||| 0-0 1-1 1-2 2-3 3-4
einer Fertigspritze Die ||| a pre-filled syringe The ||| 0-0 1-1 1-2 2-3
einer Fertigspritze Epoetin alfa ||| a pre-filled syringe Epoetin alfa ||| 0-0 1-1 1-2 2-3 3-4
einer Fertigspritze Epoetin ||| a pre-filled syringe Epoetin ||| 0-0 1-1 1-2 2-3
einer Fertigspritze ||| a pre-filled syringe ||| 0-0 1-1 1-2
einer Flasche erhältlich . ||| each containing 1 bottle . ||| 1-0 0-1 1-1 1-2 1-3 2-3 3-4
einer Flasche erhältlich ||| , each containing 1 bottle ||| 1-1 0-2 1-2 1-3 1-4 2-4
einer Flasche erhältlich ||| each containing 1 bottle ||| 1-0 0-1 1-1 1-2 1-3 2-3
einer Flasche ||| containing one bottle ||| 1-0 0-1 1-2
einer Haloperidol-kontrollierten Studie war ||| a haloperidol-controlled trial ||| 0-0 1-1 3-1 2-2
einer Herzinsuffizienz , ||| of heart failure , ||| 0-0 1-1 1-2 2-3
einer Herzinsuffizienz ||| of heart failure ||| 0-0 1-1 1-2
einer Herzkreislauf-Erkrankung ||| cardiovascular disorders ||| 0-0 1-0
einer Herzkreislauf-Erkrankung ||| cardiovascular ||| 0-0 1-0
einer Hormontherapie resistent . ||| hormonal therapy . ||| 1-0 2-0 0-1 2-1 3-2
einer Hormontherapie resistent ||| hormonal therapy ||| 1-0 2-0 0-1 2-1
einer Hyperglykämie ( wie z.B. ||| of hyperglycaemia ( such as ||| 0-0 1-1 2-2 3-3 4-3 3-4
einer Hyperglykämie ( ||| of hyperglycaemia ( ||| 0-0 1-1 2-2
einer Hyperglykämie ||| of hyperglycaemia ||| 0-0 1-1
einer Hypokalzämie war ||| of hypocalcaemia was ||| 0-0 0-1 1-1 2-2
einer Hypokalzämie ||| hypocalcaemia ||| 0-0 1-0
einer Hypokalzämie ||| of hypocalcaemia ||| 0-0 0-1 1-1
einer Infusion von 5 ||| of one infusion of 5 ||| 2-0 0-1 1-2 2-3 3-4
einer Infusion von ||| of one infusion of ||| 2-0 0-1 1-2 2-3
einer Infusion ||| one infusion ||| 0-0 1-1
einer Initialdosis von 450 ||| an initial dose of 450 ||| 0-0 1-0 1-1 1-2 2-3 1-4 3-4
einer Insulinresistenz steigert . ||| of insulin resistance . ||| 0-0 1-1 1-2 2-2 3-3
einer Insulinresistenz steigert ||| of insulin resistance ||| 0-0 1-1 1-2 2-2
einer Langzeit-Erweiterungsphase über 74 Wochen ||| a 74-week extension ||| 0-0 1-1 1-2 2-2 3-2 4-2
einer Mahlzeit oder ungeplante , ||| a meal or unplanned , ||| 0-0 1-1 2-2 3-3 4-4
einer Mahlzeit oder ungeplante ||| a meal or unplanned ||| 0-0 1-1 2-2 3-3
einer Mahlzeit oder ||| a meal or ||| 0-0 1-1 2-2
einer Mahlzeit ||| a meal ||| 0-0 1-1
einer Nieren- oder Leberinsuffizienz ||| of renal or hepatic dysfunction ||| 0-0 1-1 2-2 1-3 3-3 3-4
einer Nutzen-Risiko-Abwägung unter ||| a benefit-risk assessment with ||| 0-0 0-1 1-1 2-1 1-2 1-3
einer Patrone ( 3 ml ||| a cartridge ( 3 ml ||| 0-0 1-1 2-2 3-3 4-4
einer Patrone ( 3 ||| a cartridge ( 3 ||| 0-0 1-1 2-2 3-3
einer Patrone ( ||| a cartridge ( ||| 0-0 1-1 2-2
einer Patrone . ||| a cartridge . ||| 0-0 1-1 2-2
einer Patrone ||| a cartridge ||| 0-0 1-1
einer QT-Verlängerung ||| QT prolongation ||| 0-0 1-0 1-1
einer Reihe von anderen ||| a number of other ||| 0-0 1-1 2-2 3-3
einer Reihe von ||| a number of ||| 0-0 1-1 2-2
einer Reihe ||| a number ||| 0-0 1-1
einer Rimonabant-Behandlung abzuschätzen . ||| and suicide . ||| 1-1 2-1 3-2
einer Rimonabant-Behandlung abzuschätzen . ||| harm and suicide . ||| 1-2 2-2 3-3
einer Rimonabant-Behandlung abzuschätzen . ||| suicide . ||| 1-0 2-0 3-1
einer Rimonabant-Behandlung abzuschätzen ||| and suicide ||| 1-1 2-1
einer Rimonabant-Behandlung abzuschätzen ||| harm and suicide ||| 1-2 2-2
einer Rimonabant-Behandlung abzuschätzen ||| suicide ||| 1-0 2-0
einer Schwangerschaft . ||| of pregnancy . ||| 0-0 1-1 2-2
einer Schwangerschaft ||| of pregnancy ||| 0-0 1-1
einer Seite . ||| one side . ||| 0-0 1-0 1-1 2-2
einer Seite ||| one side ||| 0-0 1-0 1-1
einer Standardskala für ||| a standard scale for ||| 0-0 1-1 1-2 2-3
einer Standardskala ||| a standard scale ||| 0-0 1-1 1-2
einer Studie mit Patienten mit ||| a study in patients with ||| 0-0 1-1 3-2 3-3 2-4 4-4
einer Studie ||| a study ||| 0-0 1-1
einer Substanz ||| of a substance ||| 0-0 1-0 0-1
einer Substanz ||| of a ||| 0-0 1-0 0-1
einer Tagesdosis von 15 ||| a daily dose of 15 ||| 0-0 1-1 1-2 2-3 3-4
einer Tagesdosis von ||| a daily dose of ||| 0-0 1-1 1-2 2-3
einer Tagesdosis ||| a daily dose ||| 0-0 1-1 1-2
einer Verbesserung der ||| by an improvement in ||| 0-0 0-1 1-2 2-2 1-3
einer Wechselwirkung . ||| an interaction . ||| 0-0 1-0 1-1 2-2
einer Wechselwirkung ||| an interaction ||| 0-0 1-0 1-1
einer Woche . ||| a week . ||| 0-0 1-1 2-2
einer Woche ||| a week ||| 0-0 1-1
einer abrupten Verbesserung der ||| abrupt improvement in ||| 0-0 1-0 2-0 2-1 3-1 2-2
einer anderen ||| a ||| 0-0
einer anderen ||| another ||| 0-0 1-0
einer anders lautenden Entscheidung der ||| otherwise decided by the ||| 1-0 1-1 2-1 0-2 3-3 4-3
einer anders lautenden ||| otherwise decided by ||| 1-0 1-1 2-1 0-2
einer bestehenden Behandlung mit Lithium ||| existing treatment with lithium ||| 0-0 1-0 2-1 3-2 4-3
einer bestehenden Behandlung mit ||| existing treatment with ||| 0-0 1-0 2-1 3-2
einer bestehenden Behandlung ||| existing treatment ||| 0-0 1-0 2-1
einer bestehenden Herzkreislauf-Erkrankung ||| cardiovascular ||| 0-0 1-0 2-0
einer bestehenden Wirbelkörperfraktur aufgezeigt . ||| existing vertebral fracture(s ) . ||| 0-0 1-0 2-1 2-2 3-2 2-3 4-4
einer bestehenden Wirbelkörperfraktur aufgezeigt ||| existing vertebral fracture(s ) ||| 0-0 1-0 2-1 2-2 3-2 2-3
einer bestehenden Wirbelkörperfraktur aufgezeigt ||| of existing vertebral fracture(s ) ||| 0-1 1-1 2-2 2-3 3-3 2-4
einer bestehenden ||| existing ||| 0-0 1-0
einer bestehenden ||| of existing ||| 0-1 1-1
einer diabetischen Retinopathie . ||| diabetic retinopathy . ||| 0-0 1-0 2-1 3-2
einer diabetischen Retinopathie ||| diabetic retinopathy ||| 0-0 1-0 2-1
einer diabetischen ||| diabetic ||| 0-0 1-0
einer dieser Studien , ||| one of these trials , ||| 0-0 0-1 1-2 2-3 3-4
einer dieser Studien ||| one of these trials ||| 0-0 0-1 1-2 2-3
einer dieser ||| one of these ||| 0-0 0-1 1-2
einer dosisabhängigen Senkung von ||| dose dependent decreases in serum ||| 0-0 3-0 1-3 2-3 3-3 3-4
einer fettreichen ||| a ||| 0-0
einer fettreichen ||| with a ||| 0-1
einer gesunden ||| healthy ||| 0-0 1-0
einer großen ||| a large ||| 0-0 1-1
einer guten Kontrolle . ||| controlled by systemic chemotherapy . ||| 2-0 0-1 1-2 1-3 3-4
einer guten Kontrolle ||| controlled by systemic chemotherapy ||| 2-0 0-1 1-2 1-3
einer guten ||| by systemic chemotherapy ||| 0-0 1-1 1-2
einer höheren als der ||| higher than the ||| 0-0 1-0 2-1 3-2
einer höheren als ||| higher than ||| 0-0 1-0 2-1
einer höheren ||| higher ||| 0-0 1-0
einer kardiovaskulären Outcome-Studie , wurden ||| a cardiovascular outcome study , ||| 0-0 1-1 2-2 2-3 4-3 3-4
einer kardiovaskulären ||| a cardiovascular ||| 0-0 1-1
einer kleinen Studie , ||| a small study ||| 0-0 1-1 2-2
einer kleinen Studie ||| a small study ||| 0-0 1-1 2-2
einer kleinen ||| a small ||| 0-0 1-1
einer klinischen Studie mit gesunden ||| a clinical trial in healthy ||| 0-0 1-1 2-2 3-3 4-3 4-4
einer klinischen Studie ||| a clinical trial ||| 0-0 1-1 2-2
einer klinischen ||| a clinical ||| 0-0 1-1
einer kürzlich erlittenen niedrig-traumatischen Hüftfraktur ||| a recent low-trauma hip fracture ||| 0-0 1-1 2-2 3-2 1-3 4-3 2-4
einer kürzlich erlittenen niedrig-traumatischen Hüftfraktur ||| a recent low-trauma hip fracture ||| 0-0 1-1 2-2 3-2 4-3 4-4
einer kürzlich erlittenen niedrig-traumatischen ||| a recent low-trauma ||| 0-0 1-1 2-2 3-2
einer kürzlich erlittenen ||| a recent ||| 0-0 1-1 2-1
einer kürzlich ||| a recent ||| 0-0 1-1
einer länger anhaltenden Wirkung gewünscht ||| a more long-lasting effect ||| 0-0 1-1 2-2 2-3 3-3 4-3
einer länger ||| a more ||| 0-0 1-1
einer lösungsmittelhaltigen Paclitaxel-Injektion ||| a solvent-based ||| 0-0 1-1 2-1
einer manischen oder gemischten Episode ||| a manic or mixed episode ||| 0-0 1-1 2-2 3-3 3-4 4-4
einer manischen oder ||| a manic or ||| 0-0 1-1 2-2
einer manischen ||| a manic ||| 0-0 1-1
einer ng Ethinylestradiol/Levonorgestrel-Kombination wurde durch ||| einer ng Ethinylestradiol/Levonorgestrel-Kombination wurde durch ||| 0-0 1-1 2-2 3-3 4-4
einer ng Ethinylestradiol/Levonorgestrel-Kombination wurde ||| einer ng Ethinylestradiol/Levonorgestrel-Kombination wurde ||| 0-0 1-1 2-2 3-3
einer ng Ethinylestradiol/Levonorgestrel-Kombination ||| einer ng Ethinylestradiol/Levonorgestrel-Kombination ||| 0-0 1-1 2-2
einer ng ||| einer ng ||| 0-0 1-1
einer niedrig-traumatischen Hüftfraktur ||| a recent low-trauma hip fracture ||| 0-0 1-1 1-2 2-3 2-4
einer niedrig-traumatischen ||| a recent low-trauma ||| 0-0 1-1 1-2
einer passenden Einheitenskala vorgesehen . ||| a corresponding unit scale . ||| 0-0 1-1 2-2 2-3 3-3 4-4
einer passenden Einheitenskala vorgesehen ||| a corresponding unit scale ||| 0-0 1-1 2-2 2-3 3-3
einer passenden ||| a corresponding ||| 0-0 1-1
einer prospektiven , ||| a prospective , ||| 0-0 1-1 2-2
einer prospektiven ||| a prospective ||| 0-0 1-1
einer regelmäßigen Kontrolle ||| undergo periodic ||| 0-0 1-0 1-1 2-1
einer schweren Myelosuppression ||| of profound myelosuppression ||| 0-0 1-0 2-1 2-2
einer schweren Neutropenie oder schweren ||| of severe neutropenia or severe ||| 0-0 1-1 2-2 3-3 4-4
einer schweren Neutropenie oder ||| of severe neutropenia or ||| 0-0 1-1 2-2 3-3
einer schweren Neutropenie ||| of severe neutropenia ||| 0-0 1-1 2-2
einer schweren ||| of severe ||| 0-0 1-1
einer schweren ||| of ||| 0-0 1-0
einer signifikanten Gewichtszunahme verbunden . ||| significant weight gain . ||| 1-0 0-1 2-1 2-2 3-2 4-3
einer signifikanten Gewichtszunahme verbunden ||| significant weight gain ||| 1-0 0-1 2-1 2-2 3-2
einer von zwei sicherheitspharmakologischen ||| one of two safety pharmacology ||| 0-0 1-1 2-2 3-3 3-4
einer von zwei ||| one of two ||| 0-0 1-1 2-2
einer von ||| einer von ||| 0-0 1-1
einer von ||| one of ||| 0-0 1-1
einer vor kurzem erlittenen niedrig-traumatischen ||| a recent low-trauma ||| 0-0 1-1 2-1 3-1 3-2 4-2
einer zahnmedizinischen Operation unterziehen ||| undergo dental surgery ||| 0-0 3-0 1-1 2-2
einer zusätzlichen Verabreichung von Abilify ||| of adding Abilify ||| 0-0 2-0 3-0 1-1 4-2
einer zusätzlichen Verabreichung von ||| of adding ||| 0-0 2-0 3-0 1-1
einer ||| , a ||| 0-1
einer ||| 15 and 5 ||| 0-0
einer ||| 15 and ||| 0-0
einer ||| 15 ||| 0-0
einer ||| As an ||| 0-1
einer ||| In ||| 0-0
einer ||| a 5 ||| 0-0
einer ||| a blood ||| 0-0
einer ||| a ||| 0-0
einer ||| an ||| 0-0
einer ||| and a ||| 0-1
einer ||| by an ||| 0-0 0-1
einer ||| by ||| 0-0
einer ||| deterioration ||| 0-0
einer ||| einer kürzlich erlittenen geringtraumatischen Hüftfraktur ||| 0-0
einer ||| einer kürzlich erlittenen geringtraumatischen ||| 0-0
einer ||| einer kürzlich erlittenen ||| 0-0
einer ||| einer kürzlich ||| 0-0
einer ||| einer ||| 0-0
einer ||| in Bipolar I ||| 0-0 0-1 0-2
einer ||| in a ||| 0-1
einer ||| in ||| 0-0
einer ||| incidence of ||| 0-0 0-1
einer ||| of a ||| 0-0 0-1
einer ||| of a ||| 0-1
einer ||| of ||| 0-0
einer ||| one of ||| 0-0 0-1
einer ||| one ||| 0-0
einer ||| ongoing ||| 0-0
einer ||| period ||| 0-0
einer ||| weight ||| 0-0
einer ||| with a ||| 0-0 0-1
einer ||| with a ||| 0-1
einer Änderung ||| be necessary ||| 1-0 0-1 1-1
einer Überdosierung . ||| defined . ||| 0-0 1-0 2-1
einer Überdosierung sollte ||| of overdose should ||| 0-0 0-1 1-1 2-2
einer Überdosierung ||| defined ||| 0-0 1-0
einer Überdosierung ||| of an overdose ||| 0-0 0-1 1-1 1-2
einer Überdosierung ||| of overdose ||| 0-0 0-1 1-1
einer Überdosierung ||| overdose ||| 0-0 1-0
einer ärztlichen Verschreibung . ||| obtained with a prescription . ||| 1-0 2-0 2-1 0-2 2-2 2-3 3-4
einer ärztlichen Verschreibung ||| obtained with a prescription ||| 1-0 2-0 2-1 0-2 2-2 2-3
eines CB1-Antagonisten ||| of a CB1 antagonist ||| 0-0 0-1 1-2 1-3
eines Fahrzeugs ratsam ist . ||| in these circumstances . ||| 1-0 1-1 0-2 1-2 2-2 3-2 4-3
eines Fahrzeugs ratsam ist ||| in these circumstances ||| 1-0 1-1 0-2 1-2 2-2 3-2
eines MNS sind hohes ||| of NMS are hyperpyrexia ||| 0-0 1-1 2-2 0-3 3-3
eines Zielorgans nach wiederholter Gabe ||| after repeated dosing ||| 2-0 3-1 4-1 3-2
eines Zielorgans nach ||| after ||| 2-0
eines Zustands ||| who suffer from a ||| 1-0 0-1 1-1 1-2 0-3
eines charakteristischen Kennzeichens für ||| a known marker of ||| 0-0 1-1 1-2 2-2 0-3 3-3
eines jeden Patienten sein und ||| of each patient ||| 0-0 3-0 1-1 2-2
eines jeden Patienten sein ||| of each patient ||| 0-0 3-0 1-1 2-2
eines oralen ||| eines ||| 0-0
eines plötzlichen Blutdruckanstieges sein ||| signs of a sudden rise ||| 1-0 0-1 0-2 2-3 3-3 2-4
eines plötzlichen ||| signs of a ||| 1-0 0-1 0-2
eines spezifischen Rezeptortyps ||| a specific type of receptor ||| 0-0 1-1 2-2 0-3 2-4
eines vollständigen ||| of a ||| 0-0 0-1
eines vollständigen ||| periods of a ||| 0-1 0-2
eines vollständigen ||| treatment periods of a ||| 0-2 0-3
eines ||| a ||| 0-0
eines ||| eines ||| 0-0
eines ||| of a ||| 0-0 0-1
eines ||| of ||| 0-0
eines ||| periods of a ||| 0-1 0-2
eines ||| size of ||| 0-1
eines ||| treatment periods of a ||| 0-2 0-3
einesMaßnahmenkataloges zur Gewichtsreduzierung ||| an overall weight management programme ||| 0-0 0-1 2-1 2-2 1-3 2-3 2-4
eingeleitet werden ||| should be initiated ||| 0-0 1-1 0-2
eingeleitet ||| initiated ||| 0-0
eingenommen . ||| food . ||| 0-0 1-1
eingenommen ||| food ||| 0-0
eingenommen ||| tablets ||| 0-0
eingenommen ||| take ||| 0-0
eingenommen ||| taken ||| 0-0
eingenommen ||| the tablets ||| 0-1
eingeschlossen waren , die die ||| 2500 ||| 0-0 1-0 3-0 4-0
eingeschlossen waren , wurde ||| waren , wurde ||| 1-0 0-1 2-1 3-2
eingeschlossen waren , ||| waren , ||| 1-0 0-1 2-1
eingeschränkt ||| restricted ||| 0-0
eingeschränkter ||| hepatic impairment . ||| 0-0 0-1
eingeschränkter ||| hepatic impairment ||| 0-0 0-1
eingeschränkter ||| impairment , ||| 0-0
eingeschränkter ||| impairment ||| 0-0
eingeschränkter ||| patients with ||| 0-0 0-1
eingestellt ist . ||| is controlled . ||| 1-0 0-1 2-2
eingestellt ist ||| is controlled ||| 1-0 0-1
eingestellt ||| controlled ||| 0-0
eingestuft ||| adverse ||| 0-0
einheitlichen Ergebnisse ||| results ||| 0-0 1-0
einhergehen ||| levels of the ||| 0-0
einhergehen ||| levels of ||| 0-0
einhergehen ||| levels ||| 0-0
einige Ihrer ABILIFY Tabletten ||| some of your ABILIFY tablets ||| 0-0 1-2 2-3 3-4
einige Ihrer ABILIFY ||| some of your ABILIFY ||| 0-0 1-2 2-3
einige Ihrer ||| some of your ||| 0-0 1-2
einige der anderen klinischen ||| some of the other clinical ||| 0-0 1-1 1-2 2-3 3-4
einige der anderen ||| some of the other ||| 0-0 1-1 1-2 2-3
einige der ||| some of the ||| 0-0 1-1 1-2
einige oder alle ||| some or all of ||| 0-0 1-1 2-2
einige oder alle ||| some or all ||| 0-0 1-1 2-2
einige oder ||| some or ||| 0-0 1-1
einige ||| some of ||| 0-0
einige ||| some ||| 0-0
einigen , jedoch ||| some , but ||| 0-0 1-1 2-2
einigen , ||| some , ||| 0-0 1-1
einigen Fällen extrem und assoziiert ||| some cases extreme and associated ||| 0-0 1-1 2-2 4-2 3-3 4-4
einigen Fällen ||| some cases ||| 0-0 1-1
einigen Minuten . ||| few minutes . ||| 0-0 1-1 2-2
einigen Minuten ||| few minutes ||| 0-0 1-1
einigen Patienten unter Behandlung mit ||| been experienced by some patients ||| 1-0 2-0 3-1 2-2 0-3 1-4 4-4
einigen präklinischen Toxizitätsstudien an ||| some preclinical toxicological studies in ||| 0-0 1-1 2-1 2-2 3-2 2-3 3-4
einigen ||| few ||| 0-0
einigen ||| some ||| 0-0
einmal alle drei ||| once every three ||| 0-0 1-1 2-2
einmal alle ||| once every ||| 0-0 1-1
einmal jährlich für 3 aufeinander ||| once a year for 3 ||| 0-0 0-1 1-2 2-3 3-4
einmal jährlich für 3 ||| once a year for 3 ||| 0-0 0-1 1-2 2-3 3-4
einmal jährlich für ||| once a year for ||| 0-0 0-1 1-2 2-3
einmal jährlich verabreicht , ||| administered once a year , ||| 2-0 0-1 0-2 1-3 3-4
einmal jährlich verabreicht ||| administered once a year ||| 2-0 0-1 0-2 1-3
einmal jährlich ||| administered once a year ||| 0-0 0-1 0-2 1-3
einmal jährlich ||| once a year ||| 0-0 0-1 1-2
einmal oder zweimal täglich angewendet ||| given once or twice daily ||| 2-0 0-1 1-2 2-3 3-3 4-3 3-4
einmal oder zweimal täglich angewendet ||| given once or twice daily ||| 2-0 0-1 3-1 1-2 2-3 4-3 3-4
einmal oder ||| once or ||| 0-0 1-1
einmal pro Jahr ||| once a year ||| 0-0 1-0 0-1 2-2
einmal pro ||| once a ||| 0-0 1-0 0-1
einmal täglich ) ||| once daily ) ||| 0-0 1-1 2-2
einmal täglich , doch ||| once a day , but ||| 0-0 1-0 1-1 1-2 2-3 3-4
einmal täglich , ||| once a day , ||| 0-0 1-0 1-1 1-2 2-3
einmal täglich . ||| once a day . ||| 0-0 0-1 1-2 2-3
einmal täglich . ||| once daily . ||| 0-0 1-1 2-2
einmal täglich mit oder ||| taken once daily with or ||| 0-0 0-1 1-1 1-2 2-3 3-4
einmal täglich mit ||| taken once daily with ||| 0-0 0-1 1-1 1-2 2-3
einmal täglich mit ||| taken orally once daily with ||| 0-0 1-1 0-2 1-2 1-3 2-4
einmal täglich ||| administered once a day ||| 0-0 0-1 1-1 0-2 1-3
einmal täglich ||| once a day ||| 0-0 0-1 1-2
einmal täglich ||| once a day ||| 0-0 1-0 1-1 1-2
einmal täglich ||| once daily ||| 0-0 1-0 1-1
einmal täglich ||| once daily ||| 0-0 1-1
einmal täglich ||| taken once daily ||| 0-0 0-1 1-1 1-2
einmal täglich ||| taken orally once daily ||| 0-0 1-1 0-2 1-2 1-3
einmal wöchentlich ||| given weekly ||| 1-0 0-1 1-1
einmal wöchentlich über drei Wochen ||| given weekly for three weeks ||| 1-0 0-1 1-1 2-2 2-3 3-3 4-4
einmal wöchentlich über drei Wochen ||| given ||| 0-0 1-0 2-0 3-0 4-0
einmal wöchentlich über drei ||| given weekly for three ||| 1-0 0-1 1-1 2-2 2-3 3-3
einmal ||| administered once a ||| 0-0 0-1 0-2
einmal ||| once a ||| 0-0 0-1
einmal ||| once ||| 0-0
einnahmen , ||| taking ||| 0-0
einnahmen ||| taking ||| 0-0
einnehmen , von ||| taking ||| 0-0
einnehmen , ||| take ||| 0-0 1-0
einnehmen , ||| taking ||| 0-0
einnehmen ||| take ||| 0-0
einnehmen ||| taking ||| 0-0
einreichen ||| yearly ||| 0-0
einschließlich ABILIFY , ||| including ABILIFY , ||| 0-0 1-1 2-2
einschließlich ABILIFY ||| including ABILIFY ||| 0-0 1-1
einschließlich Bisphosphonaten ||| including bisphosphonates ||| 0-0 1-1
einschließlich Missbildungen ( siehe Abschnitt ||| including malformations ( see section ||| 0-0 1-1 2-2 3-3 4-4
einschließlich Missbildungen ( siehe ||| including malformations ( see ||| 0-0 1-1 2-2 3-3
einschließlich Missbildungen ( ||| including malformations ( ||| 0-0 1-1 2-2
einschließlich Missbildungen ||| including malformations ||| 0-0 1-1
einschließlich Osteomyelitis , und die ||| including osteomyelitis , and the ||| 0-0 1-1 2-2 3-3 4-4
einschließlich Osteomyelitis , und ||| including osteomyelitis , and ||| 0-0 1-1 2-2 3-3
einschließlich Osteomyelitis , ||| including osteomyelitis , ||| 0-0 1-1 2-2
einschließlich Osteomyelitis ||| including osteomyelitis ||| 0-0 1-1
einschließlich Parkinsonismus , Akathisie ||| including parkinsonism , akathisia ||| 0-0 1-1 2-2 3-3
einschließlich Parkinsonismus , ||| including parkinsonism , ||| 0-0 1-1 2-2
einschließlich Parkinsonismus ||| including parkinsonism ||| 0-0 1-1
einschließlich Zoledronsäure ||| including zoledronic acid ||| 0-0 1-1 1-2
einschließlich aller Darreichungsformen von Aripiprazol ||| including all formulations of aripiprazole ||| 0-0 1-1 1-2 2-2 3-3 4-4
einschließlich aller Darreichungsformen von ||| including all formulations of ||| 0-0 1-1 1-2 2-2 3-3
einschließlich aller Darreichungsformen ||| including all formulations ||| 0-0 1-1 1-2 2-2
einschließlich bei Patienten mit einer ||| including those with a ||| 0-0 1-1 2-1 3-2 4-3
einschließlich bei Patienten mit ||| including those with ||| 0-0 1-1 2-1 3-2
einschließlich bei Patienten ||| including those ||| 0-0 1-1 2-1
einschließlich dem Gastrointestinaltrakt ||| including the gastrointestinal ||| 0-0 1-1 2-2
einschließlich dem ||| including the ||| 0-0 1-1
einschließlich einer Dosisreduzierung ||| including dose reduction ||| 0-0 1-0 2-1 2-2
einschließlich einer ||| including ||| 0-0 1-0
einschließlich generalisierter Hautausschlag ||| may include generalised skin rash ||| 1-0 1-1 0-2 1-2 1-3 2-4
einschließlich generalisierter ||| may include generalised skin ||| 1-0 1-1 0-2 1-2 1-3
einschließlich seltener Fälle von Atemproblemen ||| reported including rare cases of ||| 2-0 0-1 1-2 4-2 2-3 3-4
einschließlich ||| , including ||| 0-1
einschließlich ||| including ||| 0-0
einstellbarem Bluthochdruck . ||| , inadequately treated ||| 0-0 0-1 1-1 2-1 1-2
eintritt , ist die Behandlung ||| occurs , the treatment ||| 0-0 1-1 3-2 2-3 4-3
eintritt , ||| occurs , ||| 0-0 1-1
eintritt ||| occurs ||| 0-0
einzelnen Patienten mit normalem oder ||| isolated patients with normal or ||| 0-0 1-1 2-2 3-3 4-4
einzelnen Patienten mit normalem ||| isolated patients with normal ||| 0-0 1-1 2-2 3-3
einzelnen Patienten mit ||| isolated patients with ||| 0-0 1-1 2-2
einzelnen Patienten ||| isolated patients ||| 0-0 1-1
einzelnen ||| isolated ||| 0-0
einzunehmen . ||| . ||| 0-0 1-0
einzunehmen . ||| each day . ||| 0-0 0-1 1-2
einzunehmen ||| each day ||| 0-0 0-1
einzuschätzen ||| estimate ||| 0-0
elektiven orthopädischen Eingriff vorgesehen ||| elective orthopaedic surgery ||| 2-0 0-1 1-1 2-1 3-1 3-2
elektiven orthopädischen Eingriff ||| orthopaedic surgery ||| 0-0 1-0 2-0 2-1
elementarem ||| elemental ||| 0-0
elementares Kalzium und 400 ||| calcium and 400 ||| 1-0 2-1 0-2 3-2
eliminiert ||| eliminated ||| 0-0
empfehlen , um diese ||| to reduce these side effects ||| 2-0 0-1 3-2 0-3 1-3 3-4
empfohlen ( oder wenn ||| recommended ( or if ||| 0-0 1-1 2-2 3-3
empfohlen ( oder ||| recommended ( or ||| 0-0 1-1 2-2
empfohlen ( siehe Abschnitt 4.2 ||| recommended ( see section 4.2 ||| 0-0 1-1 2-2 3-3 4-4
empfohlen ( siehe Abschnitt ||| recommended ( see section ||| 0-0 1-1 2-2 3-3
empfohlen ( siehe ||| recommended ( see ||| 0-0 1-1 2-2
empfohlen ( ||| recommended ( ||| 0-0 1-1
empfohlen , die ||| recommended that the ||| 0-0 0-1 1-1 2-2
empfohlen , ||| recommended , ||| 0-0 1-1
empfohlen , ||| recommended that ||| 0-0 0-1 1-1
empfohlen . Ein ||| recommended ||| 0-0
empfohlen . ||| , is recommended . ||| 0-1 0-2 1-3
empfohlen . ||| is recommended . ||| 0-0 0-1 1-2
empfohlen . ||| kidneys . ||| 0-0 0-1 1-1
empfohlen . ||| notify ||| 0-0 1-0
empfohlen . ||| recommended . ||| 0-0 1-1
empfohlen . ||| recommended ||| 0-0
empfohlen für Kinder ||| recommended for anyone ||| 0-0 1-1 2-2
empfohlen für die Anwendung bei ||| recommended for use in ||| 0-0 1-1 2-1 3-2 4-3
empfohlen für die Anwendung ||| recommended for use ||| 0-0 1-1 2-1 3-2
empfohlen für die ||| recommended for ||| 0-0 1-1 2-1
empfohlen für ||| recommended for ||| 0-0 1-1
empfohlen ||| , is recommended ||| 0-1 0-2
empfohlen ||| is recommended ||| 0-0 0-1
empfohlen ||| recommended ||| 0-0
empfohlene Anfangsdosis beträgt 15 ||| recommended starting dose is 15 ||| 0-0 1-1 1-2 2-3 3-4
empfohlene Anfangsdosis beträgt ||| recommended starting dose is ||| 0-0 1-1 1-2 2-3
empfohlene Anfangsdosis für ABILIFY ||| recommended starting dose for ABILIFY ||| 0-0 1-1 1-2 2-3 3-4
empfohlene Anfangsdosis für Aripiprazol ||| recommended starting dose for ABILIFY ||| 0-0 1-1 1-2 2-3 1-4 3-4
empfohlene Anfangsdosis für ||| recommended initial dose for ||| 0-0 1-1 1-2 2-3
empfohlene Anfangsdosis für ||| recommended starting dose for ||| 0-0 1-1 1-2 2-3
empfohlene Anfangsdosis ||| recommended initial dose ||| 0-0 1-1 1-2
empfohlene Anfangsdosis ||| recommended starting dose ||| 0-0 1-1 1-2
empfohlene Dosierung beträgt 600 ||| recommended dose is 600 ||| 0-0 1-1 2-2 1-3 2-3 3-3
empfohlene Dosierung wird ||| recommended dosing regimen is ||| 0-0 1-1 0-2 1-2 2-3
empfohlene Dosierung ||| recommended dosing regimen ||| 0-0 1-1 0-2 1-2
empfohlene Dosis für Abraxane beträgt ||| recommended dose of Abraxane is ||| 0-0 1-1 2-2 3-3 4-4
empfohlene Dosis für Abraxane ||| recommended dose of Abraxane ||| 0-0 1-1 2-2 3-3
empfohlene Dosis für ||| recommended dose of ||| 0-0 1-1 2-2
empfohlene Dosis ist eine ||| recommended dose is a ||| 0-0 1-1 2-2 3-3
empfohlene Dosis ist ||| recommended dose is ||| 0-0 1-1 2-2
empfohlene Dosis ||| recommended dose of ||| 0-0 1-1
empfohlene Dosis ||| recommended dose ||| 0-0 1-1
empfohlene wöchentliche Dosis liegt zwischen ||| recommended weekly dose is between ||| 0-0 1-1 2-2 3-3 3-4 4-4
empfohlene wöchentliche Dosis ||| recommended weekly dose ||| 0-0 1-1 2-2
empfohlene wöchentliche Gesamtdosis ||| recommended total weekly dose ||| 0-0 1-1 2-1 1-2 2-3
empfohlene wöchentliche ||| recommended weekly ||| 0-0 1-1
empfohlene ||| recommended ||| 0-0
empfohlenen Behandlungsschema ||| recommended treatment schedule ||| 0-0 1-1 1-2
empfohlenen Maximaldosis beim Menschen ||| maximum recommended human ||| 0-0 1-0 0-1 2-2 3-2
empfohlenen Maximaldosis ||| maximum recommended ||| 0-0 1-0 0-1
empfohlenen human-therapeutischen Exposition ||| recommended human therapeutic exposure ||| 0-0 0-1 1-2 2-3
empfohlenen human-therapeutischen ||| recommended human therapeutic ||| 0-0 0-1 1-2
empfohlenen klinischen ||| maximum recommended clinical dose ||| 0-0 0-1 1-2 0-3
empfohlenen ||| recommended human ||| 0-0 0-1
empfohlenen ||| recommended ||| 0-0
enden ||| even ||| 0-0
endgültige Fassung ( ||| dated Final ( ||| 0-0 0-1 1-1 2-2
endgültige Fassung ||| dated Final ||| 0-0 0-1 1-1
endogenen humanen Erythropoetin , ||| endogenous human erythropoietin that ||| 0-0 1-1 2-2 0-3 3-3
engmaschig zu kontrollieren . ||| should be closely monitored . ||| 0-0 0-1 1-1 0-2 0-3 2-3 3-4
engmaschig zu kontrollieren ||| should be closely monitored ||| 0-0 0-1 1-1 0-2 0-3 2-3
engmaschig ||| closely ||| 0-0
engmaschig überwachen ||| monitor closely ||| 1-0 0-1
engmaschig überwacht werden ||| be monitored closely ||| 2-0 1-1 0-2 2-2
entfernen Sie die Schutzkappe von ||| remove the protective cap from ||| 3-0 2-1 0-2 0-3 1-3 3-3 3-4 4-4
enthalten , jedoch ||| , but ||| 1-0 2-1
enthalten , ||| , ||| 1-0
enthalten 0,3 ml ( 3000 ||| contain 0.3 ml ( 3000 ||| 0-0 1-1 2-2 3-3 4-4
enthalten 0,3 ml ( ||| contain 0.3 ml ( ||| 0-0 1-1 2-2 3-3
enthalten 0,3 ml ||| contain 0.3 ml ||| 0-0 1-1 2-2
enthalten 0,3 ||| contain 0.3 ||| 0-0 1-1
enthalten 0,4 ml ( 4000 ||| contain 0.4 ml ( 4000 ||| 0-0 1-1 2-2 3-3 4-4
enthalten 0,4 ml ( ||| contain 0.4 ml ( ||| 0-0 1-1 2-2 3-3
enthalten 0,4 ml ||| contain 0.4 ml ||| 0-0 1-1 2-2
enthalten 0,4 ||| contain 0.4 ||| 0-0 1-1
enthalten 0,5 ml ( 1000 ||| contain 0.5 ml ( 1000 ||| 0-0 1-1 2-2 3-3 4-4
enthalten 0,5 ml ( 5000 ||| contain 0.5 ml ( 5000 ||| 0-0 1-1 2-2 3-3 4-4
enthalten 0,5 ml ( ||| contain 0.5 ml ( ||| 0-0 1-1 2-2 3-3
enthalten 0,5 ml ||| contain 0.5 ml ||| 0-0 1-1 2-2
enthalten 0,5 ||| contain 0.5 ||| 0-0 1-1
enthalten 0,6 ml ( 6000 ||| contain 0.6 ml ( 6000 ||| 0-0 1-1 2-2 3-3 4-4
enthalten 0,6 ml ( ||| contain 0.6 ml ( ||| 0-0 1-1 2-2 3-3
enthalten 0,6 ml ||| contain 0.6 ml ||| 0-0 1-1 2-2
enthalten 0,6 ||| contain 0.6 ||| 0-0 1-1
enthalten 0,7 ml ( 7000 ||| contain 0.7 ml ( 7000 ||| 0-0 1-1 2-2 3-3 4-4
enthalten 0,7 ml ( ||| contain 0.7 ml ( ||| 0-0 1-1 2-2 3-3
enthalten 0,7 ml ||| contain 0.7 ml ||| 0-0 1-1 2-2
enthalten 0,7 ||| contain 0.7 ||| 0-0 1-1
enthalten 0,8 ml ( 8000 ||| contain 0.8 ml ( 8000 ||| 0-0 1-1 2-2 3-3 4-4
enthalten 0,8 ml ( ||| contain 0.8 ml ( ||| 0-0 1-1 2-2 3-3
enthalten 0,8 ml ||| contain 0.8 ml ||| 0-0 1-1 2-2
enthalten 0,8 ||| contain 0.8 ||| 0-0 1-1
enthalten 0,9 ml ( 9000 ||| contain 0.9 ml ( 9000 ||| 0-0 1-1 2-2 3-3 4-4
enthalten 0,9 ml ( ||| contain 0.9 ml ( ||| 0-0 1-1 2-2 3-3
enthalten 0,9 ml ||| contain 0.9 ml ||| 0-0 1-1 2-2
enthalten 0,9 ||| contain 0.9 ||| 0-0 1-1
enthalten 1 ml ( 10 ||| contain 1 ml ( 10 ||| 0-0 1-1 2-2 3-3 4-4
enthalten 1 ml ( 2000 ||| contain 1 ml ( 2000 ||| 0-0 1-1 2-2 3-3 4-4
enthalten 1 ml ( ||| contain 1 ml ( ||| 0-0 1-1 2-2 3-3
enthalten 1 ml ||| contain 1 ml ||| 0-0 1-1 2-2
enthalten 1 ||| contain 1 ||| 0-0 1-1
enthalten 15 , 30 oder ||| contain 15 , 30 or ||| 0-0 1-1 2-2 3-3 4-4
enthalten 15 , 30 ||| contain 15 , 30 ||| 0-0 1-1 2-2 3-3
enthalten 15 , ||| contain 15 , ||| 0-0 1-1 2-2
enthalten 15 ||| contain 15 ||| 0-0 1-1
enthalten Lactose-Monohydrat und ||| contain lactose monohydrate and ||| 0-0 1-1 1-2 2-3
enthalten Lactose-Monohydrat ||| contain lactose monohydrate ||| 0-0 1-1 1-2
enthalten Substanzen ( Lösungsmittel ) ||| contain substances ( solvents ) ||| 0-0 1-1 2-2 3-2 1-3 4-4
enthalten Substanzen ( Lösungsmittel ||| contain substances ( solvents ||| 0-0 1-1 2-2 3-2 1-3
enthalten ||| contain ||| 0-0
enthaltenden Arzneimitteln ||| medicines ||| 0-0 1-0
enthaltenden ||| paclitaxel- ||| 0-0
enthält 0,05 mg Zoledronsäure ( ||| contains 0.05 mg zoledronic acid ||| 0-0 1-1 2-2 3-3 3-4 4-4
enthält 0,05 mg ||| contains 0.05 mg ||| 0-0 1-1 2-2
enthält 0,05 ||| contains 0.05 ||| 0-0 1-1
enthält 1 Flasche , ||| contains 1 bottle ||| 0-0 1-1 2-2
enthält 1 Flasche ||| contains 1 bottle ||| 0-0 1-1 2-2
enthält 1 ||| contains 1 ||| 0-0 1-1
enthält 10 000 I.E. ||| contains 10 000 IU ||| 0-0 1-1 2-2 3-3
enthält 10 000 Internationale Einheiten ||| contains 10 000 international units ||| 0-0 1-1 2-2 3-3 4-4
enthält 10 000 Internationale ||| contains 10 000 international ||| 0-0 1-1 2-2 3-3
enthält 10 000 ||| contains 10 000 ||| 0-0 1-1 2-2
enthält 10 mg Aripiprazol ||| contains 10 mg of aripiprazole ||| 0-0 1-1 2-2 3-4
enthält 10 mg ||| contains 10 mg of ||| 0-0 1-1 2-2
enthält 10 mg ||| contains 10 mg ||| 0-0 1-1 2-2
enthält 10 ml entsprechend ||| contains 10 ml equivalent to ||| 0-0 1-1 2-2 2-3 3-3 3-4
enthält 10 ||| contains 10 ||| 0-0 1-1
enthält 100 I.E. Insulin ||| contains 100 IU of insulin ||| 0-0 1-1 2-2 2-3 3-4
enthält 100 I.E. ||| contains 100 IU of ||| 0-0 1-1 2-2 2-3
enthält 100 ||| contains 100 ||| 0-0 1-1
enthält 1000 Internationale Einheiten ( ||| contains 1000 international units ( ||| 0-0 1-1 2-2 3-3 4-4
enthält 1000 Internationale Einheiten ||| contains 1000 international units ||| 0-0 1-1 2-2 3-3
enthält 1000 Internationale ||| contains 1000 international ||| 0-0 1-1 2-2
enthält 1000 ||| contains 1000 ||| 0-0 1-1
enthält 15 mg Aripiprazol ||| contains 15 mg of aripiprazole ||| 0-0 1-1 2-2 3-4
enthält 15 mg Pioglitazon ( ||| contains 15 mg pioglitazone ( ||| 0-0 1-1 2-2 3-3 4-4
enthält 15 mg Pioglitazon ( ||| contains 15mg of pioglitazone ( ||| 0-0 1-1 2-1 3-3 4-4
enthält 15 mg Pioglitazon ||| contains 15 mg of pioglitazone ||| 0-0 1-1 2-2 3-4
enthält 15 mg Pioglitazon ||| contains 15 mg pioglitazone ||| 0-0 1-1 2-2 3-3
enthält 15 mg Pioglitazon ||| contains 15mg of pioglitazone ||| 0-0 1-1 2-1 3-3
enthält 15 mg ||| contains 15 mg of ||| 0-0 1-1 2-2
enthält 15 mg ||| contains 15 mg ||| 0-0 1-1 2-2
enthält 15 mg ||| contains 15mg of ||| 0-0 1-1 2-1
enthält 15 mg ||| contains 15mg ||| 0-0 1-1 2-1
enthält 15 ||| contains 15 ||| 0-0 1-1
enthält 200 mg Fructose ||| contains 200 mg of fructose ||| 0-0 1-1 2-2 3-4
enthält 200 mg ||| contains 200 mg of ||| 0-0 1-1 2-2
enthält 200 mg ||| contains 200 mg ||| 0-0 1-1 2-2
enthält 200 ||| contains 200 ||| 0-0 1-1
enthält 2000 I.E. ||| contains 2000 IU ||| 0-0 1-1 2-2
enthält 2000 Internationale Einheiten ( ||| contains 2000 international units ( ||| 0-0 1-1 2-2 3-3 4-4
enthält 2000 Internationale Einheiten ||| contains 2000 international units ||| 0-0 1-1 2-2 3-3
enthält 2000 Internationale ||| contains 2000 international ||| 0-0 1-1 2-2
enthält 2000 ||| contains 2000 ||| 0-0 1-1
enthält 3 ml entsprechend ||| contains 3 ml equivalent to ||| 0-0 1-1 2-2 2-3 3-3 3-4
enthält 3 ml entsprechend ||| contains 3 ml equivalent to ||| 0-0 1-1 2-2 3-3 3-4
enthält 3 ml ||| contains 3 ml ||| 0-0 1-1 2-2
enthält 3 ||| contains 3 ||| 0-0 1-1
enthält 30 mg Aripiprazol ||| contains 30 mg of aripiprazole ||| 0-0 1-1 2-2 3-4
enthält 30 mg Pioglitazon ( ||| contains 30 mg pioglitazone ( ||| 0-0 1-1 2-2 3-3 4-4
enthält 30 mg Pioglitazon ( ||| contains 30mg of pioglitazone ( ||| 0-0 1-1 2-1 3-3 4-4
enthält 30 mg Pioglitazon ||| contains 30 mg of pioglitazone ||| 0-0 1-1 2-2 3-4
enthält 30 mg Pioglitazon ||| contains 30 mg pioglitazone ||| 0-0 1-1 2-2 3-3
enthält 30 mg Pioglitazon ||| contains 30mg of pioglitazone ||| 0-0 1-1 2-1 3-3
enthält 30 mg ||| contains 30 mg of ||| 0-0 1-1 2-2
enthält 30 mg ||| contains 30 mg ||| 0-0 1-1 2-2
enthält 30 mg ||| contains 30mg of ||| 0-0 1-1 2-1
enthält 30 mg ||| contains 30mg ||| 0-0 1-1 2-1
enthält 30 ||| contains 30 ||| 0-0 1-1
enthält 3000 Internationale Einheiten ( ||| contains 3000 international units ( ||| 0-0 1-1 2-2 3-3 4-4
enthält 3000 Internationale Einheiten ||| contains 3000 international units ||| 0-0 1-1 2-2 3-3
enthält 3000 Internationale ||| contains 3000 international ||| 0-0 1-1 2-2
enthält 3000 ||| contains 3000 ||| 0-0 1-1
enthält 40 I.E. Insulin ||| contains 40 IU of insulin ||| 0-0 1-1 2-2 2-3 3-4
enthält 40 I.E. ||| contains 40 IU of ||| 0-0 1-1 2-2 2-3
enthält 40 ||| contains 40 ||| 0-0 1-1
enthält 4000 Internationale Einheiten ( ||| contains 4000 international units ( ||| 0-0 1-1 2-2 3-3 4-4
enthält 4000 Internationale Einheiten ||| contains 4000 international units ||| 0-0 1-1 2-2 3-3
enthält 4000 Internationale ||| contains 4000 international ||| 0-0 1-1 2-2
enthält 4000 ||| contains 4000 ||| 0-0 1-1
enthält 45 mg Pioglitazon ( ||| contains 45 mg pioglitazone ( ||| 0-0 1-1 2-2 3-3 4-4
enthält 45 mg Pioglitazon ( ||| contains 45mg of pioglitazone ( ||| 0-0 1-1 2-1 3-3 4-4
enthält 45 mg Pioglitazon ||| contains 45 mg of pioglitazone ||| 0-0 1-1 2-2 3-4
enthält 45 mg Pioglitazon ||| contains 45 mg pioglitazone ||| 0-0 1-1 2-2 3-3
enthält 45 mg Pioglitazon ||| contains 45mg of pioglitazone ||| 0-0 1-1 2-1 3-3
enthält 45 mg ||| contains 45 mg of ||| 0-0 1-1 2-2
enthält 45 mg ||| contains 45 mg ||| 0-0 1-1 2-2
enthält 45 mg ||| contains 45mg of ||| 0-0 1-1 2-1
enthält 45 mg ||| contains 45mg ||| 0-0 1-1 2-1
enthält 45 ||| contains 45 ||| 0-0 1-1
enthält 5 mg Zoledronsäure ( ||| contains 5 mg zoledronic acid ||| 0-0 1-1 2-2 3-3 3-4 4-4
enthält 5 mg Zoledronsäure ||| contains 5 mg zoledronic acid ||| 0-0 1-1 2-2 3-3 3-4
enthält 5 mg wasserfreie ||| contains 5 mg ||| 0-0 1-1 2-2 3-2
enthält 5 mg ||| contains 5 mg ||| 0-0 1-1 2-2
enthält 5 ||| contains 5 ||| 0-0 1-1
enthält 5000 Internationale Einheiten ( ||| contains 5000 international units ( ||| 0-0 1-1 2-2 3-3 4-4
enthält 5000 Internationale Einheiten ||| contains 5000 international units ||| 0-0 1-1 2-2 3-3
enthält 5000 Internationale ||| contains 5000 international ||| 0-0 1-1 2-2
enthält 5000 ||| contains 5000 ||| 0-0 1-1
enthält 6000 Internationale Einheiten ( ||| contains 6000 international units ( ||| 0-0 1-1 2-2 3-3 4-4
enthält 6000 Internationale Einheiten ||| contains 6000 international units ||| 0-0 1-1 2-2 3-3
enthält 6000 Internationale ||| contains 6000 international ||| 0-0 1-1 2-2
enthält 6000 ||| contains 6000 ||| 0-0 1-1
enthält 7000 Internationale Einheiten ( ||| contains 7000 international units ( ||| 0-0 1-1 2-2 3-3 4-4
enthält 7000 Internationale Einheiten ||| contains 7000 international units ||| 0-0 1-1 2-2 3-3
enthält 7000 Internationale ||| contains 7000 international ||| 0-0 1-1 2-2
enthält 7000 ||| contains 7000 ||| 0-0 1-1
enthält 8000 Internationale Einheiten ( ||| contains 8000 international units ( ||| 0-0 1-1 2-2 3-3 4-4
enthält 8000 Internationale Einheiten ||| contains 8000 international units ||| 0-0 1-1 2-2 3-3
enthält 8000 Internationale ||| contains 8000 international ||| 0-0 1-1 2-2
enthält 8000 ||| contains 8000 ||| 0-0 1-1
enthält 9,75 mg ( 1,3 ||| contains 9.75 mg ( 1.3 ||| 0-0 1-1 2-2 3-3 4-4
enthält 9,75 mg ( ||| contains 9.75 mg ( ||| 0-0 1-1 2-2 3-3
enthält 9,75 mg ||| contains 9.75 mg ||| 0-0 1-1 2-2
enthält 9,75 ||| contains 9.75 ||| 0-0 1-1
enthält 9000 Internationale Einheiten ( ||| contains 9000 international units ( ||| 0-0 1-1 2-2 3-3 4-4
enthält 9000 Internationale Einheiten ||| contains 9000 international units ||| 0-0 1-1 2-2 3-3
enthält 9000 Internationale ||| contains 9000 international ||| 0-0 1-1 2-2
enthält 9000 ||| contains 9000 ||| 0-0 1-1
enthält Abraxane ca. 425 mg ||| Abraxane contains approximately 425 mg ||| 1-0 0-1 2-2 3-3 4-4
enthält Abraxane ca. 425 ||| , Abraxane contains approximately 425 ||| 1-1 0-2 2-3 3-4
enthält Abraxane ca. 425 ||| Abraxane contains approximately 425 ||| 1-0 0-1 2-2 3-3
enthält Abraxane ca. ||| , Abraxane contains approximately ||| 1-1 0-2 2-3
enthält Abraxane ca. ||| Abraxane contains approximately ||| 1-0 0-1 2-2
enthält Abraxane ||| , Abraxane contains ||| 1-1 0-2
enthält Abraxane ||| Abraxane contains ||| 1-0 0-1
enthält Der Wirkstoff ist : ||| contains The active substance is ||| 0-0 1-1 2-2 2-3 4-3 3-4
enthält Der Wirkstoff ist ||| contains The active substance is ||| 0-0 1-1 2-2 2-3 3-4
enthält Der Wirkstoff ||| contains The active substance ||| 0-0 1-1 2-2 2-3
enthält Der arzneilich wirksame Bestandteil ||| contains The active substance ||| 0-0 1-1 2-2 3-2 4-3
enthält Der arzneilich wirksame ||| contains The active ||| 0-0 1-1 2-2 3-2
enthält Der ||| contains The ||| 0-0 1-1
enthält Metacresol , das ||| contains metacresol , which ||| 0-0 1-1 2-2 1-3 3-3
enthält Methyl-4-hydroxybenzoat und ||| contains methyl parahydroxybenzoate and ||| 0-0 1-1 1-2 2-3
enthält Methyl-4-hydroxybenzoat ||| contains methyl parahydroxybenzoate ||| 0-0 1-1 1-2
enthält Vanillin und ||| vanillin and ethyl ||| 0-0 1-0 2-1 1-2
enthält ca. 425 mg Natrium ||| contains approximately 425 mg sodium ||| 0-0 1-1 2-2 3-3 4-4
enthält ca. 425 mg ||| contains approximately 425 mg ||| 0-0 1-1 2-2 3-3
enthält ca. 425 ||| contains approximately 425 ||| 0-0 1-1 2-2
enthält ca. ||| contains approximately ||| 0-0 1-1
enthält den Wirkstoff Paclitaxel ||| contains the active substance paclitaxel ||| 0-0 1-1 1-2 2-2 2-3 3-4
enthält den Wirkstoff ||| contains the active substance ||| 0-0 1-1 1-2 2-2 2-3
enthält den wirksamen Bestandteil ||| contains the active ingredient ||| 0-0 1-1 1-2 2-2 3-2 3-3
enthält denselben Wirkstoff wie ||| contains the same active substance ||| 0-0 1-2 3-2 2-3 2-4
enthält eine Einzeldosis in ||| contains one single-use ||| 0-0 1-1 2-1 2-2
enthält eine Einzeldosis ||| contains one single-use ||| 0-0 1-1 2-1 2-2
enthält eine Glaskugel , um ||| contains a glass ball to ||| 0-0 1-1 2-2 2-3 3-3 4-3 4-4
enthält eine ||| contains a ||| 0-0 1-1
enthält einen Brombutyl-Gummikolben ||| containing a bromobutyl rubber plunger ||| 0-0 1-1 0-2 1-2 2-2 2-3 2-4
enthält folgendes : ||| contains the following : ||| 0-0 2-2 1-3 2-3
enthält jeder ml der Suspension ||| each ml of suspension contains ||| 1-0 2-1 3-2 4-3 0-4
enthält sowohl schnell wirkendes ( ||| contains both fast-acting ( ||| 0-0 1-1 2-2 3-2 4-3
enthält sowohl schnell wirkendes ||| contains both fast-acting ||| 0-0 1-1 2-2 3-2
enthält sowohl ||| contains both ||| 0-0 1-1
enthält ||| contains the ||| 0-0
enthält ||| contains ||| 0-0
entscheiden , wie lange Sie ||| decide how long you ||| 0-0 1-0 2-1 3-2 4-3
entscheiden , wie lange ||| decide how long ||| 0-0 1-0 2-1 3-2
entscheiden , wie ||| decide how ||| 0-0 1-0 2-1
entscheiden , ||| decide ||| 0-0 1-0
entschied ||| decided ||| 0-0
entsorgt werden . ||| household waste . ||| 0-0 0-1 1-1 2-2
entsorgt werden ||| household waste ||| 0-0 0-1 1-1
entsprechend 0,05330 mg ||| corresponding to 0.05330 mg ||| 0-0 0-1 1-2 2-3
entsprechend 0,05330 ||| corresponding to 0.05330 ||| 0-0 0-1 1-2
entsprechend 300 I.E. ||| equivalent to 300 IU . ||| 0-0 0-1 1-2 2-3 2-4
entsprechend 300 ||| equivalent to 300 ||| 0-0 0-1 1-2
entsprechend 5,330 mg ||| corresponding to 5.330 mg ||| 0-0 0-1 1-2 2-3
entsprechend 5,330 ||| corresponding to 5.330 ||| 0-0 0-1 1-2
entsprechend den ||| be disposed ||| 0-0 0-1 1-1
entsprechend den ||| products should be disposed ||| 0-1 0-2 0-3 1-3
entsprechend den ||| should be disposed ||| 0-0 0-1 0-2 1-2
entsprechend des ||| corresponding to the ||| 0-0 0-1 1-2
entsprechend mindestens ||| corresponding to at least ||| 0-0 0-1 1-2 1-3
entsprechend ||| corresponding to ||| 0-0 0-1
entsprechend ||| equivalent to ||| 0-0 0-1
entsprechend ||| of ||| 0-0
entsprechende Dosisanpassung ||| appropriate dose adjustment ||| 0-0 0-1 1-2
entsprechende ||| appropriate dose ||| 0-0 0-1
entspricht 0,035 mg ||| corresponds to 0.035 mg ||| 0-0 0-1 1-2 2-3
entspricht 0,035 ||| corresponds to 0.035 ||| 0-0 0-1 1-2
entspricht 15 mg Aripiprazol ) ||| to 15 mg aripiprazole ) ||| 0-0 1-1 2-2 3-3 4-4
entspricht 15 mg Aripiprazol ||| to 15 mg aripiprazole ||| 0-0 1-1 2-2 3-3
entspricht 15 mg ||| to 15 mg ||| 0-0 1-1 2-2
entspricht 15 ||| to 15 ||| 0-0 1-1
entspricht der Beitrag von M-IV ||| M-IV contribution to ||| 0-0 4-0 2-1 3-1 0-2
entspricht ||| corresponds to ||| 0-0 0-1
entspricht ||| to ||| 0-0
entstehender Abfälle ||| such products ||| 0-0 1-1
entstehender ||| such ||| 0-0
entweder Actos oder Placebo ||| either Actos or placebo ||| 0-0 1-1 2-2 3-3
entweder Actos oder ||| either Actos or ||| 0-0 1-1 2-2
entweder Actos ||| either Actos ||| 0-0 1-1
entweder CYP2C8 ||| either CYP2C8 ||| 0-0 1-1
entweder Valproat oder Lithium ||| either valproate or lithium ||| 0-0 1-1 2-2 3-3
entweder Valproat oder ||| either valproate or ||| 0-0 1-1 2-2
entweder Valproat ||| either valproate ||| 0-0 1-1
entweder eine Infusion mit Aclasta ||| one infusion of Aclasta ||| 0-0 1-0 2-1 1-2 3-2 4-3
entweder eine Infusion mit ||| one infusion of ||| 0-0 1-0 2-1 1-2 3-2
entweder mit ||| either with ||| 0-0 1-1
entweder ||| either ||| 0-0
entwickelte ||| experienced the development ||| 0-0 0-2
enzephalopathieähnlichen Symptomen ( z. B. ||| encephalopathy-like symptoms ( e. g. ||| 0-0 1-0 1-1 2-2 3-3 3-4 4-4
enzephalopathieähnlichen Symptomen ( ||| encephalopathy-like symptoms ( ||| 0-0 1-0 1-1 2-2
enzephalopathieähnlichen Symptomen kann auftreten . ||| encephalopathy-like symptoms can occur . ||| 0-0 1-1 2-2 3-3 4-4
enzephalopathieähnlichen Symptomen kann auftreten ||| encephalopathy-like symptoms can occur ||| 0-0 1-1 2-2 3-3
enzephalopathieähnlichen Symptomen kann ||| encephalopathy-like symptoms can ||| 0-0 1-1 2-2
enzephalopathieähnlichen Symptomen ||| encephalopathy-like symptoms ||| 0-0 1-0 1-1
enzephalopathieähnlichen Symptomen ||| encephalopathy-like symptoms ||| 0-0 1-1
enzephalopathieähnlichen ||| encephalopathy-like ||| 0-0
er Die Erfahrungen ||| uth Experience ||| 0-0 1-1 2-1
er Die Steady-State-Pharmakokinetik eines oralen ||| er Die Steady-State-Pharmakokinetik eines oralen ||| 0-0 1-1 2-2 3-3 2-4
er Die Steady-State-Pharmakokinetik eines ||| er Die Steady-State-Pharmakokinetik eines oralen ||| 0-0 1-1 2-2 3-3 2-4
er Die ||| er Die ||| 0-0 1-1
er Folgende ||| reactions ||| 1-0
er Gedächtnisverlust , Schwindelgefühl Hypoästhesie ||| Memory loss Dizziness ||| 0-0 1-0 1-1 2-1 3-2 4-2
er Gedächtnisverlust , ||| Memory loss ||| 0-0 1-0 1-1 2-1
er des HbA1c-Wertes ||| absolute change in HbA1c ||| 2-0 2-1 1-2 2-3
er des ||| in ||| 1-0
er ng A. ||| lon ANNEX ||| 0-0 1-0 1-1 2-1
er wünschen , ||| er wünschen , ||| 0-0 1-1 2-2
er wünschen ||| er wünschen ||| 0-0 1-1
er ||| er ||| 0-0
er ||| it ||| 0-0
er ||| lon As ||| 0-0
er ||| lon ||| 0-0
er ||| ra The ||| 0-0
er ||| ra ||| 0-0
er ||| uth ||| 0-0
erfolgen , da nur begrenzte ||| because of the limited ||| 0-0 2-0 3-3 4-3
erfolgen , da ||| because of the ||| 0-0 2-0
erfolgen , da ||| because of ||| 0-0 2-0
erfolgen , da ||| because ||| 0-0 2-0
erfolgen . ||| be administered . ||| 0-0 0-1 1-2
erfolgen . ||| be used . ||| 0-0 0-1 1-2
erfolgen ||| be administered ||| 0-0 0-1
erfolgen ||| be used ||| 0-0 0-1
erfolgt der ||| rapid ||| 0-0
erfolgt durch renale Ausscheidung ||| is eliminated by renal excretion ||| 0-0 0-1 1-2 2-3 3-4
erfolgt durch renale ||| is eliminated by renal ||| 0-0 0-1 1-2 2-3
erfolgt durch ||| is eliminated by ||| 0-0 0-1 1-2
erfolgt in unveränderter Form ||| is excreted unchanged ||| 0-0 1-1 2-1 2-2 3-2
erfolgt ist . ||| . ||| 2-0
erfolgt jeweils ||| is catalysed ||| 0-0 0-1
erfolgt jeweils über CYP2C8 ||| is catalysed by CYP2C8 ||| 0-0 0-1 2-2 3-3
erfolgt jeweils über ||| is catalysed by ||| 0-0 0-1 2-2
erfolgt rasch und vorwiegend ||| is rapid and mainly ||| 0-0 0-1 1-1 2-2 3-3
erfolgt rasch und vorwiegend über ||| is rapid and mainly via ||| 0-0 0-1 1-1 2-2 3-3 4-4
erfolgt rasch und ||| is rapid and ||| 0-0 0-1 1-1 2-2
erfolgt rasch ||| is rapid ||| 0-0 0-1 1-1
erfolgt ||| is catalysed ||| 0-0 0-1
erfolgt ||| is eliminated ||| 0-0 0-1
erfolgt ||| is ||| 0-0
erfolgt ||| rapid ||| 0-0
erforderlich ( siehe Abschnitt 5.2 ||| required ( see section 5.2 ||| 0-0 1-1 2-2 3-3 4-4
erforderlich ( siehe Abschnitt ||| required ( see section ||| 0-0 1-1 2-2 3-3
erforderlich ( siehe ||| required ( see ||| 0-0 1-1 2-2
erforderlich ( ||| required ( ||| 0-0 1-1
erforderlich , wird Ihr Arzt ||| necessary your doctor may ||| 0-0 3-1 2-2 4-2 3-3
erforderlich , ||| necessary ||| 0-0
erforderlich . ||| for smokers . ||| 0-0 0-1 1-2
erforderlich . ||| is necessary . ||| 0-0 0-1 1-2
erforderlich . ||| necessary . ||| 0-0 1-1
erforderlich ||| for smokers ||| 0-0 0-1
erforderlich ||| is necessary ||| 0-0 0-1
erforderlich ||| necessary ||| 0-0
erforderlich ||| required ||| 0-0
erfordert ||| not generally ||| 0-0 0-1
erfordert ||| not ||| 0-0
ergab keine medizinisch bedeutsamen Unterschiede ||| revealed no medically important differences ||| 0-0 1-1 2-2 3-3 4-4
ergab keine medizinisch bedeutsamen ||| revealed no medically important ||| 0-0 1-1 2-2 3-3
ergab keine medizinisch ||| revealed no medically ||| 0-0 1-1 2-2
ergab keine ||| revealed no ||| 0-0 1-1
ergab ||| revealed ||| 0-0
ergaben folgende pharmakokinetische Daten ||| the following pharmacokinetic data ||| 0-0 1-1 2-2 3-3
ergaben folgende pharmakokinetische ||| the following pharmacokinetic ||| 0-0 1-1 2-2
ergaben folgende ||| the following ||| 0-0 1-1
ergaben sich die folgenden ||| , the following weight ||| 1-0 0-1 2-1 3-2 2-3
ergaben sich keine ||| , no new ||| 1-0 2-1
ergaben sich keine ||| , no ||| 1-0 2-1
ergaben sich ||| , ||| 1-0
ergaben ||| the ||| 0-0
ergriffen ? ||| ? ||| 0-0 1-0
ergriffen ? ||| dyslipidaemia . ||| 0-0 1-0 0-1
erhalten , ||| , and ||| 1-0
erhalten , ||| , ||| 1-0
erhalten . ||| . ||| 1-0
erhalten haben ||| have been receiving ||| 1-0 0-1 0-2
erhalten haben ||| have received ||| 1-0 0-1
erhalten werden ||| dosing ||| 1-0
erhalten ||| been receiving ||| 0-0 0-1
erhalten ||| receive ||| 0-0
erhalten ||| received ||| 0-0
erhalten ||| will receive ||| 0-0 0-1
erhalten ||| will ||| 0-0
erhielt Insulin in Kombination ||| were receiving insulin in combination ||| 0-0 0-1 1-2 2-3 3-4
erhielt Insulin in ||| were receiving insulin in ||| 0-0 0-1 1-2 2-3
erhielt Insulin ||| were receiving insulin ||| 0-0 0-1 1-2
erhielt ||| were receiving ||| 0-0 0-1
erhielten , eine ||| receiving ||| 0-0 2-0
erhielten Risedronat einmal täglich ||| received risedronate once a day ||| 0-0 1-1 2-2 2-3 3-4
erhielten Risedronat einmal ||| received risedronate once a ||| 0-0 1-1 2-2 2-3
erhielten Risedronat ||| received risedronate ||| 0-0 1-1
erhielten eine ||| received ||| 0-0 1-0
erhielten entweder eine Infusion mit ||| received one infusion of ||| 0-0 1-1 2-1 3-2 2-3 4-3
erhielten kardiovaskuläre ||| were receiving cardiovascular ||| 0-0 0-1 1-2
erhielten zusätzlich eine Chemotherapie und ||| were also receiving chemotherapy and ||| 0-0 1-0 2-1 0-2 2-2 3-2 3-3 4-4
erhielten zusätzlich eine Chemotherapie ||| were also receiving chemotherapy ||| 0-0 1-0 2-1 0-2 2-2 3-2 3-3
erhielten ||| in patients ||| 0-1
erhielten ||| patients received ||| 0-0 0-1
erhielten ||| patients ||| 0-0
erhielten ||| received ||| 0-0
erhielten ||| were receiving ||| 0-0 0-1
erhält . ||| in men . ||| 0-1 1-2
erhält . ||| men . ||| 0-0 1-1
erhält ||| in men ||| 0-1
erhält ||| men ||| 0-0
erhältlich . ||| since 1993. ||| 0-0 0-1 1-1
erhöhen . ||| . ||| 0-0 1-0
erhöhen das Risiko von Missbildungen ||| increase the risk of malformations ||| 0-0 1-1 1-2 2-2 3-3 0-4 4-4
erhöhen das Risiko von Missbildungen ||| increase the risk of malformations ||| 0-0 1-1 1-2 2-2 3-3 4-4
erhöhen das Risiko von ||| increase the risk of ||| 0-0 1-1 1-2 2-2 3-3
erhöhen das Risiko ||| increase the risk ||| 0-0 1-1 1-2 2-2
erhöhen ||| increase ||| 0-0
erhöht . ||| increased . ||| 0-0 1-1
erhöht werden ||| increase ||| 0-0
erhöht ||| increase ||| 0-0
erhöht ||| increased ||| 0-0
erhöht ||| to increase ||| 0-1
erhöhte Alanin-Aminotransferase ( ALT ||| increased Alanine Aminotransferase ( ALT ||| 0-0 0-1 1-1 1-2 2-3 3-4
erhöhte Alanin-Aminotransferase ( ||| increased Alanine Aminotransferase ( ||| 0-0 0-1 1-1 1-2 2-3
erhöhte Alanin-Aminotransferase ||| increased Alanine Aminotransferase ||| 0-0 0-1 1-1 1-2
erhöhte Aspartat-Aminotransferase ( AST ||| increased Aspartate Aminotransferase ( AST ||| 0-0 0-1 1-1 1-2 2-3 3-4
erhöhte Aspartat-Aminotransferase ( ||| increased Aspartate Aminotransferase ( ||| 0-0 0-1 1-1 1-2 2-3
erhöhte Aspartat-Aminotransferase ||| increased Aspartate Aminotransferase ||| 0-0 0-1 1-1 1-2
erhöhte Exposition haben ||| increased exposure ||| 0-0 1-1
erhöhte Exposition ||| increased exposure ||| 0-0 1-1
erhöhte Gamma- Glutamyl-Transferase ( ||| increased Gamma Glutamyl Transferase ( ||| 0-0 1-1 2-2 2-3 3-4
erhöhte Gamma- Glutamyl-Transferase ||| increased Gamma Glutamyl Transferase ||| 0-0 1-1 2-2 2-3
erhöhte Gamma- ||| increased Gamma ||| 0-0 1-1
erhöhte Insulinresistenz des ||| increased insulin resistance ||| 0-0 1-1 2-1 1-2
erhöhte Inzidenz ||| increased incidence of ||| 0-0 1-1 1-2
erhöhte Kreatin-Phosphokinase , ||| increased Creatine Phosphokinase , ||| 0-0 1-1 1-2 2-3
erhöhte Kreatin-Phosphokinase ||| increased Creatine Phosphokinase ||| 0-0 1-1 1-2
erhöhte Speichelproduktion , ||| increased production of saliva , ||| 0-0 1-1 1-3 2-4
erhöhte Speichelproduktion ||| increased production of saliva ||| 0-0 1-1 1-3
erhöhte Sterblichkeit der jungen Ratten ||| increased pup mortality ||| 0-0 2-1 3-1 4-1 1-2
erhöhte Wahrscheinlichkeit ||| how your ||| 0-0 1-0 1-1
erhöhte alkalische Phosphatase ||| increased alkaline phosphatase ||| 0-0 1-1 2-2
erhöhte alkalische ||| increased alkaline ||| 0-0 1-1
erhöhte die ||| increased ||| 0-0
erhöhte postmenopausale ||| elevated post-menopausal ||| 0-0 1-0
erhöhte postmenopausale ||| elevated ||| 0-0 1-0
erhöhte sich linear von 2653 ||| increased linearly from 2653 ||| 0-0 2-1 3-2 4-3
erhöhte sich linear von ||| increased linearly from ||| 0-0 2-1 3-2
erhöhte sich linear ||| increased linearly ||| 0-0 2-1
erhöhte sich ||| increased ||| 0-0
erhöhte ||| increased ||| 0-0
erhöhtem Risiko für ||| at increased risk of ||| 1-0 0-1 1-2 2-2
erhöhtem Risiko für ||| at increased risk ||| 1-0 0-1 1-2 2-2
erhöhtem ||| increased ||| 0-0
erhöhten Auftreten von ||| an increased presence of ||| 0-0 0-1 1-1 2-2 2-3
erhöhten Auftreten ||| an increased ||| 0-0 0-1 1-1
erhöhten Insulinsensitivität besteht ||| increased insulin sensitivity ||| 0-0 2-0 1-1 1-2
erhöhten Risiko für ||| increased risk of ||| 0-0 1-1 2-1 1-2
erhöhten Risiko ||| increased risk of ||| 0-0 1-1
erhöhten Risiko ||| increased risk ||| 0-0 1-1
erhöhten ||| increased ||| 0-0
erhöhter Blutzucker , ||| blood glucose increased , blood ||| 1-0 0-1 1-1 0-2 2-3 1-4
erhöhter Leberenzymwerte und hepatozellulärer ||| elevated liver enzymes and hepatocellular ||| 0-0 1-0 1-1 1-2 2-3 3-4
erhöhter Leberenzymwerte und ||| elevated liver enzymes and ||| 0-0 1-0 1-1 1-2 2-3
erhöhter Leberenzymwerte ||| elevated liver enzymes ||| 0-0 1-0 1-1 1-2
erhöhtes Mortalitätsrisiko und Risiko ||| increased risk of death and ||| 0-0 3-1 1-2 1-3 2-4
erhöhtes Risiko für thromboembolische Ereignisse ||| increased risk for thromboembolic events ||| 0-0 1-1 2-2 3-3 4-4
erhöhtes Risiko für thromboembolische ||| increased risk for thromboembolic ||| 0-0 1-1 2-2 3-3
erhöhtes Risiko für thrombotische vaskuläre ||| increased risk of thrombotic vascular ||| 0-0 1-1 2-1 3-3 4-4
erhöhtes Risiko für thrombotische ||| increased risk of thrombotic ||| 0-0 1-1 2-1 3-3
erhöhtes Risiko für ||| increased risk for ||| 0-0 1-1 2-2
erhöhtes Risiko für ||| increased risk of ||| 0-0 1-1 2-1
erhöhtes Risiko für ||| increased risk ||| 0-0 1-1 2-1
erhöhtes Risiko von ||| increased risk of ||| 0-0 1-1 2-2
erhöhtes Risiko ||| increased risk of ||| 0-0 1-1
erhöhtes Risiko ||| increased risk ||| 0-0 1-1
erhöhtes ||| increased risk ||| 0-0 0-1
erhöhtes ||| increased ||| 0-0
erkennbaren ||| past ||| 0-0
erklärt werden . ||| control group . ||| 0-0 0-1 1-1 2-2
erklärt werden ||| control group ||| 0-0 0-1 1-1
erlaubt . ||| evaluations . ||| 0-0 1-1
erlaubt ||| evaluations ||| 0-0
erlernen , wie ||| to learn how ||| 1-0 0-1 2-2
erlernen , ||| to learn ||| 1-0 0-1
erlernen ||| learn ||| 0-0
erlittenen niedrig-traumatischen Hüftfraktur . ||| low-trauma hip fracture . ||| 0-0 1-0 2-1 2-2 3-3
erlittenen niedrig-traumatischen Hüftfraktur ||| low-trauma hip fracture ||| 0-0 1-0 2-1 2-2
erlittenen niedrig-traumatischen ||| low-trauma ||| 0-0 1-0
ermitteln ||| lowest effective ||| 0-0 0-1
erneut mit Paclitaxel behandelt werden ||| be rechallenged with paclitaxel ||| 4-0 0-1 1-2 3-2 2-3
erneut mit Paclitaxel behandelt ||| rechallenged with paclitaxel ||| 0-0 1-1 3-1 2-2
erneut ||| rechallenged ||| 0-0
erneuten Gewichtszunahme . ||| weight regain . ||| 1-0 0-1 1-1 2-2
erneuten Gewichtszunahme ||| weight regain ||| 1-0 0-1 1-1
erniedrigtem Blutdruck vor : Hypertensive ||| low blood pressure : hypertensive ||| 0-0 1-1 1-2 3-3 0-4 2-4 4-4
errechnete Fraktur-Inzidenz betrug 1,9 ||| fracture incidence calculated was 1.9 ||| 0-0 1-1 2-1 0-2 2-3 0-4 1-4 3-4
errechnete Fraktur-Inzidenz betrug 1,9 ||| fracture incidence calculated was 1.9 ||| 1-0 1-1 2-1 3-2 2-3 0-4 3-4
erreichen maximale ||| reach maximum concentration ||| 0-0 1-1 1-2
erreichen ||| reach ||| 0-0
erreicht haben . ||| administration . ||| 0-0 1-0 2-1
erreicht haben ||| administration ||| 0-0 1-0
erreicht ist ( dieses ||| is achieved ( this ||| 1-0 0-1 2-2 3-3
erreicht ist ( ||| is achieved ( ||| 1-0 0-1 2-2
erreicht ist . ||| is achieved . ||| 1-0 0-1 2-2
erreicht ist ||| is achieved ||| 1-0 0-1
erreicht und betrug 18,7 µg/ml ||| , was 18.7 µg/ ml ||| 1-0 2-1 3-2 0-3 4-3 4-4
erreicht werden . ||| dosing . ||| 0-0 1-0 2-1
erreicht werden ||| dosing ||| 0-0 1-0
erreicht ||| achieved ||| 0-0
erreicht ||| plasma levels achieved ||| 0-0 0-1 0-2
erscheint . ||| top . ||| 0-0 1-1
erscheint ||| top ||| 0-0
erst ||| of ||| 0-0
erste Behandlung nicht ||| first treatment ||| 0-0 1-1
erste Behandlung ||| first treatment ||| 0-0 1-1
erste Injektion . ||| first injection . ||| 0-0 1-1 2-2
erste Injektion ||| first injection ||| 0-0 1-1
erste ||| first ||| 0-0
ersten 10 Tage nach ||| first 10 days after ||| 0-0 1-1 2-2 3-3
ersten 10 Tage ||| first 10 days ||| 0-0 1-1 2-2
ersten 10 ||| first 10 ||| 0-0 1-1
ersten 10 ||| first ||| 0-0
ersten 21-tägigen ||| first 21 days ||| 0-0 1-1 1-2
ersten 24 h ||| first 24 hours ||| 0-0 1-1 2-1 1-2
ersten Aclasta-Infusion ||| first Aclasta infusion ||| 0-0 1-1
ersten Aclasta-Infusion ||| first Aclasta ||| 0-0 1-1
ersten Gabe . Populations- ||| first dose . ||| 0-0 1-0 3-0 0-1 2-2
ersten Gabe ||| first ||| 0-0 1-0
ersten Infusion ||| first infusion ||| 0-0 1-1
ersten drei Tage nach Verabreichung ||| first three days after administration ||| 0-0 1-1 2-2 3-3 4-4
ersten drei Tage nach ||| first three days after ||| 0-0 1-1 2-2 3-3
ersten drei Tage ||| first three days ||| 0-0 1-1 2-2
ersten drei ||| first three ||| 0-0 1-1
ersten ||| first ||| 0-0
erstmaligem Öffnen der Primärpackung ||| first opening the immediate packaging ||| 0-0 0-1 1-1 2-2 3-3 3-4
erstmaligem Öffnen der ||| first opening the ||| 0-0 0-1 1-1 2-2
erstmaligem Öffnen ||| first opening ||| 0-0 0-1 1-1
erstmals ||| first ||| 0-0
erwachsenen Hunden . ||| adult dogs . ||| 0-0 1-1 2-2
erwachsenen Hunden ||| adult dogs ||| 0-0 1-1
erwachsenen Patienten mit ||| with ||| 0-0 1-0 2-0
erwachsenen Patienten ||| adult patients : ||| 0-0 1-1
erwachsenen Patienten ||| adult patients ||| 0-0 1-1
erwachsenen Probanden . ||| adult subjects , nor ||| 0-0 1-1 0-3 2-3
erwachsenen ||| adult ||| 0-0
erwarten . ||| expected . ||| 0-0 1-1
erwarten ||| expected ||| 0-0
erwogen werden ( siehe Abschnitt ||| be considered ( see section ||| 1-0 0-1 2-2 3-3 4-4
erwogen werden ( siehe ||| be considered ( see ||| 1-0 0-1 2-2 3-3
erwogen werden ( ||| be considered ( ||| 1-0 0-1 2-2
erwogen werden ||| be considered ||| 1-0 0-1
erwogen ||| considered ||| 0-0
erzeugt ||| cycle ||| 0-0
erzielen , müssen ausreichende Eisenspeicher ||| , adequate iron stores should ||| 1-0 0-1 3-2 2-3 3-3 4-3 4-4
erzielen , müssen ausreichende Eisenspeicher ||| adequate iron stores should ||| 0-0 1-0 3-1 2-2 3-2 4-2 4-3
erzielen , ||| , adequate ||| 1-0 0-1
erzielen , ||| adequate ||| 0-0 1-0
erzielen ||| adequate ||| 0-0
erzielt ||| nine ||| 0-0
es , ||| In ||| 0-0
es Ihrem Arzt berichten , ||| report it to your doctor ||| 3-0 0-1 4-2 1-3 2-4
es bindet an ||| it attaches to ||| 0-0 1-1 2-2
es bindet ||| it attaches ||| 0-0 1-1
es das ||| the ||| 1-0
es den Knochenumbau ||| the bone remodelling process ||| 0-0 1-0 2-1 2-2
es den Knochenumbau ||| the bone remodelling ||| 0-0 1-0 2-1 2-2
es den ||| the ||| 0-0 1-0
es gibt derzeit ||| are currently ||| 1-0 2-1
es gibt ||| are ||| 1-0
es ist nahezu natriumfrei . ||| essentially sodium- free . ||| 0-0 1-0 2-0 2-1 3-1 3-2 4-3
es ist nahezu natriumfrei ||| essentially sodium- free ||| 0-0 1-0 2-0 2-1 3-1 3-2
es nicht ||| not pass it on ||| 1-0 1-1 0-2
es nicht ||| not pass it ||| 1-0 1-1 0-2
es sei denn , der ||| unless the expected ||| 0-0 1-0 2-0 4-1 2-2
es sei denn , ||| unless ||| 0-0 1-0 2-0
es sei denn ||| unless ||| 0-0 1-0 2-0
es viele gut dokumentierte ||| has multiple well documented ||| 2-0 2-2 3-3
es viele gut ||| has multiple well ||| 2-0 2-2
es ||| In ||| 0-0
es ||| even in ||| 0-0 0-1
es ||| in ||| 0-0
es ||| it on ||| 0-0
es ||| it ||| 0-0
es ||| not there ||| 0-0 0-1
es ||| or not there ||| 0-1 0-2
es ||| recently ||| 0-0
eská ||| eská ||| 0-0
etc. ) ||| , etc. ) ||| 0-0 0-1 1-2
etc. ||| , etc. ||| 0-0 0-1
ethnischer Populationen . ||| races . ||| 0-0 1-0 2-1
ethnischer Populationen ||| races ||| 0-0 1-0
etwa 5-10 Stunden ergeben . ||| about 5-10 hours . ||| 0-0 1-0 1-1 2-1 3-1 2-2 4-3
etwa 5-10 Stunden ergeben ||| about 5-10 hours ||| 0-0 1-0 1-1 2-1 3-1 2-2
etwa alle vier Wochen angepasst ||| adjusted approximately every four weeks ||| 4-0 0-1 1-2 2-3 3-4
etwa alle vier Wochen ||| approximately every four weeks ||| 0-0 1-1 2-2 3-3
etwa alle vier ||| approximately every four ||| 0-0 1-1 2-2
etwa alle ||| approximately every ||| 0-0 1-1
etwa die Hälfte der ||| approximately one-half of its ||| 0-0 2-1 1-2 3-2 2-3
etwa ||| about ||| 0-0
etwa ||| approximately ||| 0-0
etwas anzutun ( ||| about hurting yourself ||| 1-0 0-1 1-1 1-2
etwas anzutun ||| about hurting yourself ||| 1-0 0-1 1-1 1-2
evaluiert . ||| . ||| 0-0 1-0
evaluiert und ist weiterhin unbekannt ||| evaluated and remains unknown ||| 0-0 1-1 3-2 2-3 4-3
evaluiert und ||| evaluated and ||| 0-0 1-1
evaluiert ||| evaluated ||| 0-0
evidenter ||| evident ischaemic heart ||| 0-0 0-1 0-2
exakte ||| 5 ||| 0-0
extrapyramidale Störung , Akathisie , ||| extrapyramidal disorder , akathisia , ||| 0-0 1-1 2-2 3-3 4-4
extrapyramidale Störung , Akathisie , ||| extrapyramidal disorder , akathisia ||| 0-0 1-1 2-2 4-2 3-3
extrapyramidale Störung , Akathisie ||| extrapyramidal disorder , akathisia ||| 0-0 1-1 2-2 3-3
extrapyramidale Störung , ||| extrapyramidal disorder , ||| 0-0 1-1 2-2
extrapyramidale Störung ||| extrapyramidal disorder ||| 0-0 1-1
extrapyramidale Symptome . ||| extrapyramidal symptoms . ||| 0-0 1-1 2-2
extrapyramidale Symptome ||| extrapyramidal symptoms ||| 0-0 1-1
extrapyramidale ||| extrapyramidal ||| 0-0
extravaskuläre Verteilung deutet . ||| extensive extravascular distribution . ||| 0-0 0-1 1-1 2-1 2-2 3-3
extravaskuläre Verteilung deutet ||| extensive extravascular distribution ||| 0-0 0-1 1-1 2-1 2-2
extrem und assoziiert mit Ketoazidose ||| extreme and associated with ketoacidosis ||| 0-0 2-0 1-1 2-2 3-3 4-4
extrem und assoziiert mit ||| extreme and associated with ||| 0-0 2-0 1-1 2-2 3-3
extrem und assoziiert ||| extreme and associated ||| 0-0 2-0 1-1 2-2
falls erforderlich ||| if necessary ||| 0-0 1-1
falls ||| if ||| 0-0
falls ||| indicated ||| 0-0
farblos und ||| colourless and ||| 0-0 1-1
farblos ||| colourless ||| 0-0
farblose , wässrige Lösung . ||| colourless , aqueous solution . ||| 0-0 1-1 2-2 3-3 4-4
farblose , wässrige Lösung ||| colourless , aqueous solution ||| 0-0 1-1 2-2 3-3
farblose , wässrige ||| colourless , aqueous ||| 0-0 1-1 2-2
farblose , ||| colourless , ||| 0-0 1-1
farblose Injektionslösung in ||| colourless solution for injection in ||| 0-0 0-1 1-2 1-3 2-4
farblose Injektionslösung ||| colourless solution for injection ||| 0-0 0-1 1-2 1-3
farblose Lösung . ||| colourless solution . ||| 0-0 1-1 2-2
farblose Lösung ||| colourless solution ||| 0-0 1-1
farblose bis hellgelbe Flüssigkeit ||| colourless to light yellow liquid ||| 0-0 1-1 2-2 1-3 2-3 2-4 3-4
farblose bis leicht gelbe Lösung ||| colourless to slightly yellow solution ||| 0-0 1-1 2-2 3-2 1-3 3-3 4-4
farblose bis leicht gelbe ||| colourless to slightly yellow ||| 0-0 1-1 2-2 3-2 1-3 3-3
farblose ||| colourless solution ||| 0-0 0-1
farblose ||| colourless ||| 0-0
farmacevtska dru ba , ||| farmacevtska dru ba , d. ||| 0-0 0-1 1-2 2-2 3-3 2-4
farmacevtska ||| farmacevtska dru ||| 0-0 0-1
fast ||| almost ||| 0-0
fest auf die Flasche ||| screwed back on ||| 0-0 3-0 0-1 2-1 1-2
fest zugeschraubt werden . ||| screwed back on tightly . ||| 0-0 0-1 1-3 2-3 3-4
fest zugeschraubt werden ||| screwed back on tightly ||| 0-0 0-1 1-3 2-3
fest ||| screwed back on ||| 0-0 0-1
fest ||| screwed back ||| 0-0 0-1
festgesetzt . ||| reference laboratories . ||| 0-0 0-1 1-2
festgesetzt ||| reference laboratories ||| 0-0 0-1
festgestellt . ||| was detected . ||| 0-0 0-1 1-2
festgestellt wurden ||| festgestellt wurden ||| 1-1
festgestellt wurden ||| wurden ||| 1-0
festgestellt ||| was detected ||| 0-0 0-1
festlegen . ||| continue . ||| 0-0 1-1
festlegen ||| continue ||| 0-0
feststellen , inwieweit in ||| decide whether ||| 0-0 1-0 2-0 2-1
feststellen , inwieweit ||| decide whether ||| 0-0 1-0 2-0 2-1
feststellen ||| experience ||| 0-0
festzulegen . ||| recommendations . ||| 0-0 1-1
festzulegen ||| recommendations ||| 0-0
festzustellen , ob ||| decide , if ||| 0-0 2-0 1-1 2-2
fettlöslichen Arzneimitteln bei gleichzeitiger Anwendung ||| lipid soluble drugs used concomitantly ||| 0-0 0-1 1-1 0-2 2-3 3-3 4-3 3-4
fettlöslichen Arzneimitteln ||| lipid soluble drugs ||| 0-0 0-1 1-1 0-2
fettreichen Mahlzeit ||| fat meal ||| 1-0 1-1
fettreichen ||| sweet ||| 0-0
filiaal Tel : +3726441100 ||| filiaal Tel : +3726441100 ||| 0-0 1-1 2-2 3-3
filiaal Tel : ||| filiaal Tel : ||| 0-0 1-1 2-2
filiaal Tel ||| filiaal Tel ||| 0-0 1-1
filiaal ||| filiaal ||| 0-0
finden , und sie ||| , und sie ||| 1-0 2-1 0-2
finden , und ||| , und sie ||| 1-0 2-1 0-2
finden . ||| . ||| 1-0
finden Sie hier . ||| Actos is available here ||| 0-0 0-1 2-2 0-3 1-3 2-3 3-3
finden Sie hier . ||| can be found here . ||| 0-0 0-1 0-2 1-3 2-3 3-4
finden Sie hier . ||| can be found here . ||| 0-0 0-1 0-2 2-2 1-3 2-3 3-4
finden Sie hier . ||| is available here . ||| 0-0 2-1 0-2 1-2 2-2 3-3
finden Sie hier ||| can be found here ||| 0-0 0-1 0-2 1-3 2-3
finden Sie hier ||| can be found here ||| 0-0 0-1 0-2 2-2 1-3 2-3
finden Sie hier ||| is available here ||| 0-0 2-1 0-2 1-2 2-2
finden ||| can be found ||| 0-0 0-1 0-2
finden ||| is ||| 0-0
finden ||| sie ||| 0-0
folgen ||| so ||| 0-0
folgende Nebenwirkungen ||| following side effects ||| 0-0 1-1 1-2
folgende Nebenwirkungen ||| the following side effects ||| 0-1 1-2 1-3
folgende pharmakokinetische Daten ||| following pharmacokinetic data ||| 0-0 1-1 2-2
folgende pharmakokinetische ||| following pharmacokinetic ||| 0-0 1-1
folgende unerwünschten ||| following adverse reactions ||| 0-0 1-1 1-2
folgende ||| following clinical ||| 0-0
folgende ||| following ||| 0-0
folgende ||| the following ||| 0-1
folgenden Informationen sind ||| following information is ||| 0-0 1-1 2-1 1-2
folgenden Nebenwirkungen traten ||| following undesirable effects occurred ||| 0-0 1-1 2-1 1-2 2-3
folgenden Nebenwirkungen traten ||| following undesirable effects occurred ||| 0-0 2-1 1-2 2-3
folgenden Reaktionen kamen auch ||| following reactions have also occurred ||| 0-0 1-1 2-2 3-3 2-4
folgenden Reaktionen ||| following reactions ||| 0-0 1-1
folgenden Tabelle 2 ||| folgenden Tabelle 2 ||| 0-0 0-1 1-2 2-2
folgenden Umständen ||| Before ||| 0-0 1-0
folgenden durch ||| by ||| 1-0
folgenden unerwünschten Ereignisse wurden ||| following adverse events have been ||| 0-0 1-1 2-2 3-3 3-4
folgenden unerwünschten Ereignisse ||| following adverse events ||| 0-0 1-1 2-2
folgenden unerwünschten ||| following adverse ||| 0-0 1-1
folgenden ||| folgenden Tabelle ||| 0-0 0-1
folgenden ||| folgenden ||| 0-0
folgenden ||| following diseases ||| 0-0
folgenden ||| following ||| 0-0
folgenden ||| the following ||| 0-1
folgendes : Aufklärungsmaterial für den ||| following : Physician educational material ||| 1-0 0-1 1-1 2-2 2-3 3-3 2-4 4-4
folgendes : ||| following : ||| 1-0 0-1 1-1
folgendes : ||| the following : ||| 1-1 0-2 1-2
formell untersucht . ||| formally investigated . ||| 0-0 1-1 2-2
formell untersucht ||| formally investigated ||| 0-0 1-1
formell ||| formally ||| 0-0
fortgeschrittenem ||| advanced prostate cancer ||| 0-0 0-1 0-2
fortgeschrittenen soliden Tumoren ||| advanced solid tumours , ||| 0-0 1-1 2-2
fortgeschrittenen soliden Tumoren ||| advanced solid tumours ||| 0-0 1-1 2-2
fortgeschrittenen soliden ||| advanced solid ||| 0-0 1-1
fortgeschrittenen ||| advanced ||| 0-0
fortgesetzt , um das Anhalten ||| to look at the ||| 1-0 2-0 1-1 0-2 2-2 3-3 4-3
fortgesetzt , um ||| to look at ||| 1-0 2-0 1-1 0-2 2-2
fortgesetzte Androgensuppression bei Männern mit ||| androgen suppression in men with ||| 1-0 0-1 1-1 2-2 3-3 4-4
fortgesetzte Androgensuppression bei Männern ||| androgen suppression in men ||| 1-0 0-1 1-1 2-2 3-3
fortgesetzte Androgensuppression bei ||| androgen suppression in ||| 1-0 0-1 1-1 2-2
fortgesetzte Androgensuppression ||| androgen suppression ||| 1-0 0-1 1-1
freie und ||| from particles and ||| 0-0 0-1 1-2
freie ||| from particles ||| 0-0 0-1
freiwilliger ||| voluntarily ||| 0-0
frisst ||| stops eating ||| 0-0 0-1
frühen Verteilungsphasen ( und ||| early disposition phases ( and ||| 0-0 1-1 1-2 2-3 3-4
frühen Verteilungsphasen ( ||| early disposition phases ( ||| 0-0 1-1 1-2 2-3
frühen Verteilungsphasen ||| early disposition phases ||| 0-0 1-1 1-2
frühen ||| early ||| 0-0
früher bereits Anthracycline erhalten ||| been previously exposed to anthracyclines ||| 0-0 1-1 0-2 2-2 2-4 3-4
früher ein ||| had ||| 0-0 1-0
früherem Schlaganfall , die ||| previous stroke who ||| 0-0 1-1 2-2 3-2
früherem Schlaganfall ||| previous stroke ||| 0-0 1-1
früherem ||| previous ||| 0-0
früherer Anthracyclin-Behandlung oder zugrunde ||| anthracyclines or have underlying ||| 1-0 2-1 0-2 3-3
früherer Anthracyclin-Behandlung oder ||| anthracyclines or have ||| 1-0 2-1 0-2
früherer ||| have ||| 0-0
funktionsfähig ||| market ||| 0-0
fördert ||| tubulin ||| 0-0
fötale Wachstumsverzögerungen auf . ||| animal studies with pioglitazone . ||| 0-0 1-0 1-1 1-2 1-3 2-3 3-4
fötale Wachstumsverzögerungen auf ||| animal studies with pioglitazone ||| 0-0 1-0 1-1 1-2 1-3 2-3
führen , dass Sie ||| might make you ||| 0-0 1-1 2-1 3-2
führen , dass ||| might make ||| 0-0 1-1 2-1
führen , ||| , ||| 0-0 1-0
führen kann . ||| . ||| 0-0 2-0
führen ||| might ||| 0-0
führt , kann durch ||| , reversal may be ||| 1-0 0-1 2-2 2-3 3-3
führt , ||| , reversal ||| 1-0 0-1
führt nicht zur Akkumulation des ||| not result in accumulation of ||| 1-0 0-1 3-1 0-2 2-2 3-3 4-4
führt nicht zur Akkumulation ||| not result in accumulation ||| 1-0 0-1 3-1 0-2 2-2 3-3
führt vermutlich zu einer verminderten ||| is expected to reduce the ||| 1-0 1-1 2-2 3-2 4-3
führt vermutlich zu einer verminderten ||| is expected to reduce ||| 1-0 1-1 2-2 3-2 4-3
führt vermutlich zu einer ||| is expected to ||| 1-0 1-1 2-2 3-2
führt vermutlich ||| is expected ||| 1-0 1-1
führt zur Blockierung der ||| results in blockage of the ||| 0-0 0-1 1-1 2-2 3-3 3-4
führt zur Blockierung ||| results in blockage ||| 0-0 0-1 1-1 2-2
führt zur ||| results in ||| 0-0 0-1 1-1
führt ||| führt ||| 0-0
führt ||| results in ||| 0-0 0-1
führt ||| reversal ||| 0-0
führte zu einer Abnahme ||| led to a decrease in ||| 0-0 1-1 2-2 0-3 3-3 3-4
führte zu einer Senkung ||| led to a decrease in ||| 0-0 3-0 1-1 2-2 3-3 3-4
führte zur signifikanten Reduktion des ||| significant reductions in ||| 2-0 3-1 4-1 0-2 4-2
führte ||| resulted in ||| 0-0
führte ||| resulted ||| 0-0
fünf Jahren untersucht . ||| five years . ||| 0-0 1-1 2-1 3-2
fünf Jahren untersucht ||| five years ||| 0-0 1-1 2-1
fünf Kurzzeitstudien wurde ||| were five short-term studies ||| 2-0 0-1 1-2 1-3 2-3
fünf Minuten . ||| on the total dose . ||| 0-0 0-2 1-2 0-3 2-4
fünf Minuten ||| on the total dose ||| 0-0 0-2 1-2 0-3
fünf großen kontrollierten Studien ||| five large controlled studies ||| 0-0 1-1 2-2 3-3
fünf großen kontrollierten ||| five large controlled ||| 0-0 1-1 2-2
fünf großen ||| five large ||| 0-0 1-1
fünf ||| five ||| 0-0
für 3 Wochen ||| for 3 weeks ||| 0-0 1-1 2-2
für 3 aufeinander ||| for 3 consecutive ||| 0-0 1-1
für 3 aufeinander ||| for 3 ||| 0-0 1-1
für 3 ||| for 3 consecutive ||| 0-0 1-1
für 3 ||| for 3 ||| 0-0 1-1
für 4 Wochen bei Ratten ||| for 4 weeks in rats ||| 0-0 3-0 1-1 2-2 3-3 4-4
für 4 Wochen bei ||| for 4 weeks in ||| 0-0 3-0 1-1 2-2 3-3
für ABILIFY beträgt 10 oder ||| for ABILIFY is 10 or ||| 0-0 1-1 2-2 3-3 4-4
für ABILIFY beträgt 10 ||| for ABILIFY is 10 ||| 0-0 1-1 2-2 3-3
für ABILIFY beträgt 15 mg ||| for ABILIFY is 15 mg ||| 0-0 1-1 2-2 2-3 3-3 4-4
für ABILIFY beträgt 15 ||| for ABILIFY is 15 ||| 0-0 1-1 2-2 2-3 3-3
für ABILIFY beträgt ||| for ABILIFY is ||| 0-0 1-1 2-2
für ABILIFY ||| for ABILIFY ||| 0-0 1-1
für ABILIFY ||| für ABILIFY ||| 0-0 1-1
für ACOMPLIA finden ||| for ACOMPLIA can be found ||| 0-0 1-1 2-2 2-3 2-4
für ACOMPLIA ||| for ACOMPLIA ||| 0-0 1-1
für Abilify finden ||| for Abilify can be found ||| 0-0 1-1 2-2 2-3 2-4
für Abilify ||| for Abilify ||| 0-0 1-1
für Abraxane beträgt 260 ||| of Abraxane is 260 ||| 0-0 1-1 2-2 3-3
für Abraxane beträgt ||| of Abraxane is ||| 0-0 1-1 2-2
für Abraxane ||| of Abraxane ||| 0-0 1-1
für Aclasta finden Sie hier ||| for Aclasta is available here ||| 0-0 1-1 2-2 4-3 2-4 3-4 4-4
für Aclasta und Risedronat ||| for Aclasta and risedronate ||| 0-0 1-1 2-2 3-3
für Aclasta und ||| for Aclasta and ||| 0-0 1-1 2-2
für Aclasta ||| for Aclasta ||| 0-0 1-1
für Aclasta-Patienten , ||| for Aclasta-treated ||| 0-0 1-1
für Aclasta-Patienten ||| for Aclasta-treated ||| 0-0 1-1
für Actraphane finden ||| for Actraphane can be found ||| 0-0 1-1 2-2 2-3 2-4
für Actraphane ||| for Actraphane ||| 0-0 1-1
für Aripiprazol . ||| for aripiprazole . ||| 0-0 1-1 2-2
für Aripiprazol ||| for aripiprazole ||| 0-0 1-1
für Dehydro-Aripiprazol die geometrischen Mittel ||| for dehydro-aripiprazole the geometric means ||| 0-0 1-1 2-2 3-3 3-4 4-4
für Dehydro-Aripiprazol die ||| , for dehydro-aripiprazole the ||| 0-1 1-2 2-3
für Dehydro-Aripiprazol die ||| for dehydro-aripiprazole the ||| 0-0 1-1 2-2
für Dehydro-Aripiprazol ||| , for dehydro-aripiprazole ||| 0-1 1-2
für Dehydro-Aripiprazol ||| for dehydro-aripiprazole ||| 0-0 1-1
für Diabetes ||| for diabetes ||| 0-0 1-1
für Humanarzneimittel ||| for Medicinal products for ||| 0-0 1-1 1-2 0-3
für Hunde Mitratapid ||| for dogs Mitratapide ||| 0-0 1-1 2-2
für Hunde ||| for dogs ||| 0-0 1-1
für Hypotonie prädisponieren ||| predispose patients to hypotension ||| 0-0 2-0 2-1 2-2 1-3
für Injektionszwecke . ||| for injections . ||| 0-0 1-1 2-2
für Injektionszwecke Salzsäure ( ||| for injections Hydrochloric acid ( ||| 0-0 1-1 2-2 2-3 3-4
für Injektionszwecke Salzsäure ||| for injections Hydrochloric acid ||| 0-0 1-1 2-2 2-3
für Injektionszwecke ||| for injections ||| 0-0 1-1
für Kinder ||| for anyone ||| 0-0 1-1
für Lorazepam ||| for lorazepam ||| 0-0 1-1
für Mitratapid im Vergleich ||| for mitratapide versus ||| 0-0 1-1 3-2
für Mitratapid im ||| for mitratapide ||| 0-0 1-1
für Mitratapid ||| for mitratapide ||| 0-0 1-1
für Patienten , die zu ||| for patients experiencing ||| 0-0 3-0 1-1
für Patienten , die zu ||| for patients ||| 0-0 3-0 1-1
für Patienten , die ||| for patients experiencing ||| 0-0 3-0 1-1
für Patienten , die ||| for patients ||| 0-0 3-0 1-1
für Patienten mit Phenylketonurie . ||| for people with phenylketonuria . ||| 0-0 1-1 3-1 2-2 3-3 4-4
für Patienten mit Phenylketonurie ||| for people with phenylketonuria ||| 0-0 1-1 3-1 2-2 3-3
für Patienten mit ||| in patients with less ||| 1-0 1-1 2-2
für Patienten mit ||| in patients with ||| 1-0 1-1 2-2
für Patienten ||| for patients ||| 0-0 1-1
für Patienten ||| in patients ||| 1-0 1-1
für Patientinnen mit ||| for patients with ||| 0-0 1-1 2-2
für Patientinnen ||| for patients ||| 0-0 1-1
für Placebo . ||| for placebo . ||| 0-0 1-1 2-2
für Placebo ||| for placebo ||| 0-0 1-1
für Raucher ||| dosage adjustment ||| 0-0 1-0 1-1
für Rimonabant 20 mg ( ||| for rimonabant 20 mg ( ||| 0-0 1-1 2-2 3-3 4-4
für Rimonabant 20 mg ||| for rimonabant 20 mg ||| 0-0 1-1 2-2 3-3
für Rimonabant 20 ||| for rimonabant 20 ||| 0-0 1-1 2-2
für Rimonabant ; daher ||| for rimonabant ; therefore , ||| 0-0 1-1 2-2 3-3
für Rimonabant ; daher ||| for rimonabant ; therefore ||| 0-0 1-1 2-2 3-3
für Rimonabant ; ||| for rimonabant ; ||| 0-0 1-1 2-2
für Rimonabant ||| for rimonabant ||| 0-0 1-1
für Tiere - ||| only to be supplied only ||| 0-0 1-0 1-1 1-2 1-3 1-4 2-4
für Vantas ||| for Vantas ||| 0-0 1-1
für alle Tumorpatienten ||| for all cancer patients ||| 0-0 1-1 2-2 2-3
für alle ||| for all ||| 0-0 1-1
für beide Gruppen ) ||| for both groups ) ||| 0-0 1-1 2-2 3-3
für beide Gruppen ||| for both groups ||| 0-0 1-1 2-2
für beide ||| for both ||| 0-0 1-1
für das P-Glycoprotein . ||| of P-glycoprotein . ||| 0-0 1-0 2-1 3-2
für das P-Glycoprotein ||| of P-glycoprotein ||| 0-0 1-0 2-1
für das ||| of ||| 0-0 1-0
für den Föten rechtfertigt . ||| the foetus . ||| 1-0 0-1 1-1 2-1 3-1 4-2
für den Föten rechtfertigt ||| the foetus ||| 1-0 0-1 1-1 2-1 3-1
für den Fötus . ||| to the foetus . ||| 1-0 1-1 0-2 1-2 2-2 3-3
für den Fötus ||| to the foetus ||| 1-0 1-1 0-2 1-2 2-2
für den Gebrauch ||| designed to be ||| 0-0 2-0 1-1 2-2
für den Menschen ist ||| for humans is ||| 0-0 1-1 2-1 3-2
für den Menschen ||| for humans ||| 0-0 1-1 2-1
für den Morbus Paget ||| of Paget s disease ||| 0-0 2-1 3-1 1-2 2-2 3-3
für den ||| for ||| 0-0
für die Anwendung bei Kindern ||| for use in children ||| 0-0 1-0 2-1 3-2 4-3
für die Anwendung bei ||| for use in ||| 0-0 1-0 2-1 3-2
für die Anwendung ||| for use ||| 0-0 1-0 2-1
für die Behandlung der ||| indicated for the treatment of ||| 0-0 0-1 1-1 3-2 2-3 3-3 3-4
für die Behandlung von ||| for the treatment of ||| 0-0 1-1 2-2 3-3
für die Behandlung ||| for the treatment ||| 0-0 1-1 2-2
für die Chargenfreigabe verantwortlich ist ||| responsible for batch release : ||| 0-0 1-0 2-0 0-1 2-2 3-3 4-3
für die Chargenfreigabe verantwortlich ist ||| responsible for batch release ||| 0-0 1-0 2-0 0-1 2-2 3-2 3-3 4-3
für die Chargenfreigabe verantwortlich ist ||| responsible for batch release ||| 0-0 1-0 2-0 0-1 2-2 3-3 4-3
für die Chargenfreigabe ||| responsible for batch ||| 0-0 1-0 2-0 0-1 2-2
für die Dehydrierung ||| responsible for dehydrogenation ||| 0-0 1-0 2-0 0-1 2-2
für die Empfehlung von Dosisanpassungen ||| to recommend dose modifications ||| 0-0 1-0 2-1 1-2 3-2 4-3
für die Empfehlung von ||| to recommend dose ||| 0-0 1-0 2-1 1-2 3-2
für die Infusion von ||| information on the infusion of ||| 1-0 1-1 0-2 1-2 2-3 3-4
für die Infusion ||| information on the infusion ||| 1-0 1-1 0-2 1-2 2-3
für die Kombination ||| for combination ||| 0-0 1-0 2-1
für die Rezeptoren für die ||| for the receptors for the ||| 0-0 3-0 1-1 4-1 2-2 3-3 4-4
für die Verwendung von Zoledronsäure ||| the use of zoledronic acid ||| 0-0 1-0 2-1 3-2 4-3 4-4
für die Verwendung von ||| the use of ||| 0-0 1-0 2-1 3-2
für die Verwendung ||| the use ||| 0-0 1-0 2-1
für die Wirksamkeit war die ||| of effectiveness was the ||| 0-0 1-0 2-1 3-2 4-3
für die Wirksamkeit war ||| of effectiveness was ||| 0-0 1-0 2-1 3-2
für die Wirksamkeit ||| of effectiveness ||| 0-0 1-0 2-1
für die entsprechende Dosisanpassung ||| for appropriate dose adjustment for ||| 0-0 1-0 2-1 2-2 3-3 0-4
für die erste Injektion . ||| for the first injection . ||| 0-0 1-1 2-2 3-3 4-4
für die erste Injektion ||| for the first injection ||| 0-0 1-1 2-2 3-3
für die erste ||| for the first ||| 0-0 1-1 2-2
für die ||| for the ||| 0-0 1-1
für die ||| for ||| 0-0 1-0
für die ||| indicated for ||| 0-0 0-1 1-1
für die ||| information on the ||| 1-0 1-1 0-2 1-2
für die ||| of ||| 0-0 1-0
für die ||| the incidence of ||| 0-0 1-0 1-1 1-2
für die ||| the ||| 0-0 1-0
für diese ||| for use in ||| 0-0 1-1 1-2
für ein Jahr ||| for one year ||| 0-0 1-1 2-1 2-2
für eine einzige Injektion . ||| for one injection . ||| 0-0 1-1 2-1 3-2 4-3
für eine einzige Injektion ||| for one injection ||| 0-0 1-1 2-1 3-2
für eine einzige ||| for one ||| 0-0 1-1 2-1
für eine lange Zeit wirkt ||| works for a long time ||| 4-0 0-1 1-2 2-3 3-4
für eine lange Zeit ||| for a long time ||| 0-0 1-1 2-2 3-3
für eine lange ||| for a long ||| 0-0 1-1 2-2
für eine ||| for a ||| 0-0 1-1
für lokale Infektionen einschließlich Osteomyelitis ||| of local infection including osteomyelitis ||| 0-0 1-1 2-2 3-3 4-4
für lokale Infektionen einschließlich ||| of local infection including ||| 0-0 1-1 2-2 3-3
für lokale Infektionen ||| of local infection ||| 0-0 1-1 2-2
für lokale ||| of local ||| 0-0 1-1
für metastasierende ||| for ||| 0-0 1-0
für mindestens 2 ||| for at least 2 ||| 0-0 1-1 1-2 2-3
für mindestens ||| for at least ||| 0-0 1-1 1-2
für mit Placebo behandelte Patienten ||| for placebo-treated patients ||| 0-0 2-1 3-1 1-2 4-2
für schwerwiegende Nebenwirkungen ||| serious adverse events When ||| 1-0 2-1 0-2 1-2
für schwerwiegende Nebenwirkungen ||| serious adverse events ||| 1-0 2-1 0-2 1-2
für schwerwiegende kardiovaskuläre Ereignisse beobachtet ||| serious cardiovascular events was observed ||| 1-0 2-1 0-2 3-2 2-3 4-4
für schwerwiegende kardiovaskuläre Ereignisse ||| serious cardiovascular events was ||| 1-0 2-1 0-2 3-2 2-3
für thromboembolische Ereignisse bei ||| for thromboembolic events in ||| 0-0 1-1 2-2 3-3
für thromboembolische Ereignisse ||| for thromboembolic events ||| 0-0 1-1 2-2
für thromboembolische ||| for thromboembolic ||| 0-0 1-1
für unerwünschte zerebrovaskuläre Ereignisse bei ||| for cerebrovascular adverse events in ||| 0-0 1-1 2-1 1-2 3-3 4-4
für unerwünschte zerebrovaskuläre Ereignisse ||| for cerebrovascular adverse events ||| 0-0 1-1 2-1 1-2 3-3
für unerwünschte zerebrovaskuläre ||| for cerebrovascular adverse ||| 0-0 1-1 2-1 1-2
für ||| , for ||| 0-1
für ||| for ||| 0-0
für ||| für ||| 0-0
für ||| of ||| 0-0
für ||| provide ||| 0-0
g/dl ( 0,62 ||| g/ dl ( 0.62 ||| 0-0 0-1 1-2 2-3
g/dl ( 1,25 ||| g/ dl ( 1.25 ||| 0-0 0-1 1-2 2-3
g/dl ( 5,9 - ||| g/ dl ( 5.9 - ||| 0-0 0-1 1-2 2-3 3-4
g/dl ( 5,9 ||| g/ dl ( 5.9 ||| 0-0 0-1 1-2 2-3
g/dl ( 6,2 - ||| g/ dl ( 6.2 - ||| 0-0 0-1 1-2 2-3 3-4
g/dl ( 6,2 ||| g/ dl ( 6.2 ||| 0-0 0-1 1-2 2-3
g/dl ( 7,5 mmol/l ||| g/ dl ( 7.5 mmol/ ||| 0-0 0-1 1-2 2-3 3-4
g/dl ( 7,5 ||| g/ dl ( 7.5 ||| 0-0 0-1 1-2 2-3
g/dl ( 8,1 ||| g/ dl ( 8.1 ||| 0-0 0-1 1-2 2-3
g/dl ( ||| g/ dl ( ||| 0-0 0-1 1-2
g/dl , die ||| g/ dl , the ||| 0-0 0-1 1-2 2-3
g/dl , ||| g/ dl , ||| 0-0 0-1 1-2
g/dl , ||| g/ dl ||| 0-0 0-1
g/dl . ||| g/ dl . ||| 0-0 0-1 1-2
g/dl und 12 ||| g/ dl - 12 ||| 0-0 0-1 1-1 2-2 2-3
g/dl und ||| g/ dl ||| 0-0 0-1 1-1
g/dl zu halten : ||| g/ dl : ||| 0-0 1-0 0-1 2-1 3-2
g/dl zu halten ||| g/ dl ||| 0-0 1-0 0-1 2-1
g/dl ||| g/ dl ||| 0-0 0-1
gab . ||| disorder . ||| 0-0 1-1
gab es keine ||| there were no ||| 0-0 1-0 0-1 2-2
gab es ||| there were ||| 0-0 1-0 0-1
gab ||| disorder ||| 0-0
gar ||| reduce the metabolic ||| 0-1
gar ||| reduce the ||| 0-1
gar ||| the metabolic ||| 0-0
gar ||| the ||| 0-0
gar ||| to reduce the metabolic ||| 0-2
gar ||| to reduce the ||| 0-2
gastrointestinale ||| gastro-intestinal ||| 0-0
gastroösophageale Refluxkrankheit ||| gastrooesophageal reflux ||| 0-0 1-0 1-1
ge Erkrankung des Nervensystems : ||| ise Nervous disorders : ||| 0-0 3-1 2-2 3-2 4-3
ge Erkrankung des Nervensystems ||| ise Nervous disorders ||| 0-0 3-1 2-2 3-2
ge Erkrankung ||| ise ||| 0-0
ge einen ||| Depressive disorders were ||| 0-0 0-1 1-2
ge pharmakokinetische Analysen zeigten ||| Population pharmacokinetic analysis ||| 0-0 1-0 1-1 2-2 3-2
ge pharmakokinetische ||| Population pharmacokinetic ||| 0-0 1-0 1-1
ge zu ANHANG ||| or uth ra ge ||| 0-0 0-1 1-2 2-2 2-3
ge ||| Depressive disorders ||| 0-0 0-1
ge ||| ise ||| 0-0
ge ||| or uth ||| 0-0 0-1
geben ||| give ||| 0-0
gebildet werden , ||| , ||| 0-0 2-0
gebilligt ( zwei beziehen ||| endorsed ( two relate ||| 0-0 1-1 2-2 3-3
gebilligt ( zwei ||| endorsed ( two ||| 0-0 1-1 2-2
gebilligt ( ||| endorsed ( ||| 0-0 1-1
gebilligt ||| endorsed ||| 0-0
geboten , falls Aclasta ||| indicated when Aclasta ||| 2-0 0-1 1-1 3-2
geboten , falls ||| indicated when ||| 2-0 0-1 1-1
geboten , ||| when ||| 0-0 1-0
geboten bei gleichzeitiger ||| be used when ||| 2-0 1-1 2-1 0-2
geboten ||| when ||| 0-0
gebracht . ||| . ||| 0-0 1-0
gebracht . ||| extraction . ||| 0-0 1-1
gebracht wird . ||| medicinal products . ||| 0-0 0-1 1-1 2-2
gebracht wird ||| medicinal products ||| 0-0 0-1 1-1
gebracht ||| extraction ||| 0-0
gebrauchsfertig . ||| ready for use . ||| 0-0 0-1 0-2 1-3
gebrauchsfertig . ||| ready to use . ||| 0-0 0-1 0-2 1-3
gebrauchsfertig ||| ready for use ||| 0-0 0-1 0-2
gebrauchsfertig ||| ready to use ||| 0-0 0-1 0-2
gebrauchsfertig ||| ready ||| 0-0
gebrochen ||| broke ||| 0-0
gebunden ) , ||| bound ) and ||| 0-0 1-1
gebunden ) , ||| bound ) ||| 0-0 1-1
gebunden ) und die Bindung ||| bound ) and binding ||| 0-0 1-1 2-2 4-3
gebunden ) und die ||| bound ) and ||| 0-0 1-1 2-2
gebunden ) und ||| bound ) and ||| 0-0 1-1 2-2
gebunden ) ||| bound ) and ||| 0-0 1-1
gebunden ) ||| bound ) ||| 0-0 1-1
gebunden . ||| . ||| 0-0 1-0
gebunden . ||| paclitaxel . ||| 0-1 1-1
gebunden . ||| protein . ||| 0-0 1-1
gebunden ||| bound ||| 0-0
gebunden ||| protein ||| 0-0
geeichte 2 ml Tropfpipette sind ||| 2 ml calibrated dropper are ||| 1-0 2-1 0-2 3-2 3-3 4-4
geeichte 2 ml Tropfpipette ||| 2 ml calibrated dropper ||| 1-0 2-1 0-2 3-2 3-3
geeichte Tropfpipette ||| calibrated ||| 0-0 1-0
geeichten ||| calibrated ||| 0-0
geeichter Messbecher und eine ||| calibrated measuring cup and a ||| 0-0 1-1 1-2 2-3 3-4
geeichter Messbecher und ||| calibrated measuring cup and ||| 0-0 1-1 1-2 2-3
geeichter Messbecher ||| calibrated measuring cup ||| 0-0 1-1 1-2
geeichter ||| calibrated ||| 0-0
geeignet ||| suitable ||| 0-0
geeignete Dosis für Patientinnen mit ||| appropriate doses for patients with ||| 0-0 1-0 1-1 2-2 3-3 4-4
geeignete Dosis für Patientinnen ||| appropriate doses for patients ||| 0-0 1-0 1-1 2-2 3-3
geeignete Dosis für ||| appropriate dose ||| 0-0 1-1
geeignete Dosis für ||| appropriate doses for ||| 0-0 1-0 1-1 2-2
geeignete Dosis ||| appropriate dose ||| 0-0 1-1
geeignete Dosis ||| appropriate doses ||| 0-0 1-0 1-1
geeignete ||| , appropriate ||| 0-1
geeignete ||| appropriate ||| 0-0
gefallen ist . Anschließend ist ||| and than reinstitute epoetin ||| 0-0 0-1 0-2 1-2 2-2 3-2 4-2 3-3
gefolgt von einer ||| , followed by a ||| 0-1 1-1 0-2 2-3
gefolgt von einer ||| followed by a 74-week extension ||| 0-0 1-0 0-1 2-2 0-3 0-4
gefolgt von einer ||| followed by a ||| 0-0 1-0 0-1 2-2
gefolgt von ||| , followed by ||| 0-1 1-1 0-2
gefolgt von ||| followed by ||| 0-0 1-0 0-1
gefährliche Maschinen ||| about operating hazardous machines ||| 0-0 0-1 0-2 1-3
gefährliche ||| about operating hazardous ||| 0-0 0-1 0-2
gefüttert ||| energy requirements for ||| 0-0 0-1
gefüttert ||| energy requirements ||| 0-0 0-1
gefütterten Hunden ||| fed dogs , ||| 0-0 1-1
gefütterten Hunden ||| fed dogs ||| 0-0 1-1
gefütterten ||| fed ||| 0-0
gegeben als intravenöse ||| administered intravenously ||| 0-0 1-0 2-0 0-1
gegeben werden , ||| occurs , ||| 0-0 1-0 2-1
gegeben werden ||| occurs ||| 0-0 1-0
gegeben wird . ||| occurs . ||| 0-0 1-0 2-1
gegeben wird ||| occurs ||| 0-0 1-0
gegeben ||| administered ||| 0-0
gegeben ||| given ||| 0-0
gegebenen Gesamtdosis mit weniger ||| total administered dose with less ||| 1-0 0-1 1-2 2-3 3-4
gegebenen Gesamtdosis mit ||| total administered dose with ||| 1-0 0-1 1-2 2-3
gegebenen Gesamtdosis ||| total administered dose ||| 1-0 0-1 1-2
gegebenen ||| administered ||| 0-0
gegebenenfalls behandelt werden . ||| controlled as necessary . ||| 0-0 1-0 0-1 0-2 2-2 3-3
gegebenenfalls behandelt werden . ||| treated , if necessary . ||| 1-0 0-2 0-3 2-3 3-4
gegebenenfalls behandelt werden ||| controlled as necessary ||| 0-0 1-0 0-1 0-2 2-2
gegebenenfalls behandelt werden ||| treated , if necessary ||| 1-0 0-2 0-3 2-3
gegebenenfalls bestimmte ||| may ||| 0-0
gegebenenfalls regelmäßige Blutuntersuchungen durchführen , ||| may do regular blood tests ||| 0-0 0-1 0-2 1-2 3-3 4-3 2-4 3-4
gegebenenfalls regelmäßige ||| may do regular ||| 0-0 0-1 0-2 1-2
gegebenenfalls ||| may be ||| 0-0
gegebenenfalls ||| may ||| 0-0
gegen Entzündung ) kurz ||| medicines ) shortly ||| 0-0 2-1 3-2
gegen Entzündung ) ||| medicines ) ||| 0-0 2-1
gegen Entzündung ||| medicines ||| 0-0
gegen Erythropoetine beobachtet ||| to erythropoietins have been observed ||| 0-0 0-1 1-1 1-2 1-3 2-4
gegen Erythropoetine ||| to erythropoietins have been ||| 0-0 0-1 1-1 1-2 1-3
gegen Zeit ) ||| time ||| 1-0
gegen Zeit ||| time ||| 1-0
gegen den Wirkstoff oder ||| to the active substance or ||| 0-0 1-1 0-2 1-2 2-2 2-3 3-4
gegen den Wirkstoff ||| to the active substance ||| 0-0 1-1 0-2 1-2 2-2 2-3
gegen ||| medicines ||| 0-0
gegenüber 0,8 % der ||| versus 0.8 % of ||| 0-0 1-1 2-2 3-3
gegenüber 0,8 % ||| versus 0.8 % ||| 0-0 1-1 2-2
gegenüber 0,8 ||| versus 0.8 ||| 0-0 1-1
gegenüber Insulin tierischen Ursprungs ) ||| versus animal source insulin ) ||| 0-0 2-0 2-1 2-2 3-2 1-3 4-4
gegenüber Insulin tierischen Ursprungs ||| versus animal source insulin ||| 0-0 2-0 2-1 2-2 3-2 1-3
gegenüber Pioglitazon ||| to pioglitazone ||| 0-0 1-1
gegenüber Reizen ) . ||| to a stimulus ) . ||| 0-0 0-1 1-2 2-3 3-4
gegenüber Reizen ) ||| to a stimulus ) ||| 0-0 0-1 1-2 2-3
gegenüber Reizen ||| to a stimulus ||| 0-0 0-1 1-2
gegenüber dem ||| against the ||| 0-0 1-0 1-1
gegenüber dem ||| the way back to ||| 1-0 0-3 1-3
gegenüber den ||| to ||| 0-0 1-0
gegenüber ||| to a ||| 0-0 0-1
gegenüber ||| to ||| 0-0
gegenüber ||| versus ||| 0-0
gehört zu ||| belongs to ||| 0-0 1-1
gehört ||| belongs ||| 0-0
gekühlte ||| reach ||| 0-0
gelangte zu ||| Use ||| 0-0 1-0
gelb , mit Prägung von ||| yellow , marked with ||| 0-0 1-1 3-2 2-3
gelb , mit Prägung von ||| yellow , marked with ||| 0-0 1-1 3-2 2-3 4-3
gelb , mit Prägung ||| yellow , marked with ||| 0-0 1-1 3-2 2-3
gelb , mit der Prägung ||| yellow , engraved with ||| 0-0 1-1 3-2 4-2 2-3
gelb , mit der Prägung ||| yellow , marked with ||| 0-0 1-1 3-2 4-2 2-3
gelb , ||| yellow , ||| 0-0 1-1
gelb ||| yellow ||| 0-0
gelöstem Insulin und 50 % ||| dissolved insulin and 50 % ||| 0-0 1-1 2-2 3-3 4-4
gelöstem Insulin und 50 ||| dissolved insulin and 50 ||| 0-0 1-1 2-2 3-3
gelöstem Insulin und 60 % ||| dissolved insulin and 60 % ||| 0-0 1-1 2-2 3-3 4-4
gelöstem Insulin und 60 ||| dissolved insulin and 60 ||| 0-0 1-1 2-2 3-3
gelöstem Insulin und 70 % ||| dissolved insulin and 70 % ||| 0-0 1-1 2-2 3-3 4-4
gelöstem Insulin und 70 ||| dissolved insulin and 70 ||| 0-0 1-1 2-2 3-3
gelöstem Insulin und 80 % ||| dissolved insulin and 80 % ||| 0-0 1-1 2-2 3-3 4-4
gelöstem Insulin und 80 ||| dissolved insulin and 80 ||| 0-0 1-1 2-2 3-3
gelöstem Insulin und 90 % ||| dissolved insulin and 90 % ||| 0-0 1-1 2-2 3-3 4-4
gelöstem Insulin und 90 ||| dissolved insulin and 90 ||| 0-0 1-1 2-2 3-3
gelöstem Insulin und ||| dissolved insulin and ||| 0-0 1-1 2-2
gelöstem Insulin ||| dissolved insulin ||| 0-0 1-1
gelöstem ||| dissolved ||| 0-0
gemeinsame Anwendung ||| result ||| 0-0 1-0
gemeinsamer Anwendung ||| concomitant administration ||| 0-0 1-1
gemeinsamer ||| concomitant ||| 0-0
gemeldet ||| of ||| 0-0
gemessen , aber ||| measured but a ||| 0-0 1-1 2-1 0-2
gemessen ||| measured annually ||| 0-0 0-1
gemessen ||| measured ||| 0-0
gemischt werden . ||| infusion fluids . ||| 0-0 0-1 1-1 2-2
gemischt werden ||| infusion fluids ||| 0-0 0-1 1-1
gemischten Episode der ||| mixed episode of ||| 0-0 0-1 1-1 2-2
gemischten Episode einer ||| mixed episode of ||| 0-0 0-1 1-1 2-1
gemischten Episode einer ||| mixed episode ||| 0-0 0-1 1-1 2-1
gemischten Episode ||| mixed episode of ||| 0-0 0-1 1-1
gemischten Episode ||| mixed episode ||| 0-0 0-1 1-1
gemischten Episoden oder ||| mixed episodes or ||| 0-0 1-1 2-2
gemischten Episoden ||| mixed episodes ||| 0-0 1-1
gemischten ||| mixed ||| 0-0
genannt ||| called ||| 0-0
genannten Nanopartikeln an ||| in ||| 2-0
genannten ||| of action ||| 0-0
genannten ||| of ||| 0-0
genau nach Anweisung ||| exactly as your doctor ||| 0-0 1-0 2-0 0-1 2-2 2-3
genau zu befolgenden ||| instruction for use to ||| 0-0 2-0 2-1 2-2 1-3
genau zu ||| advice ||| 1-0
genaue Häufigkeit angegeben werden ||| specific frequency can be presented ||| 0-0 1-1 0-2 3-3 2-4 3-4
genaue Häufigkeit ||| specific frequency can ||| 0-0 1-1 0-2
genehmigt im ( MM/JJJJ ) ||| approved on { date } ||| 0-0 0-1 1-2 2-2 3-2 3-3 3-4 4-4
genehmigt im ||| approved in { date } ||| 0-0 1-1 0-2 0-3 0-4 1-4
genehmigt werden . ||| . ||| 1-0 2-0
genehmigt ||| approved on ||| 0-0 0-1
generalisierter ||| generalised ||| 0-0
generalisierter ||| of generalised ||| 0-1
generalisierter Überempfindlichkeit ||| generalised hypersensitivity ||| 0-0 1-1
generalisierter Überempfindlichkeit ||| of generalised hypersensitivity ||| 0-1 1-2
gentechnisch hergestellt aus rekombinanter DNS ||| produced by recombinant DNA technology ||| 0-0 1-0 1-1 2-2 3-2 3-3 4-3 4-4
gentechnisch hergestellt ||| produced by ||| 0-0 1-0 1-1
gentechnologischen ||| genetic ||| 0-0
genügend Insulin zur Regelung ||| produce enough insulin to control ||| 0-0 0-1 1-2 2-3 3-4
genügend Insulin zur ||| Insulin zur ||| 1-0 2-1
genügend Insulin zur ||| produce enough insulin to ||| 0-0 0-1 1-2 2-3
genügend Insulin ||| Insulin ||| 1-0
genügend Insulin ||| produce enough insulin ||| 0-0 0-1 1-2
genügend rote Blutkörperchen ||| produce enough red blood ||| 0-0 0-1 1-1 1-2 2-2 2-3
genügend ||| enough ||| 0-0
genügend ||| produce enough ||| 0-0 0-1
geometrischen Mittel der Cmax und ||| geometric means of Cmax and ||| 0-0 0-1 1-1 2-2 3-3 4-4
geometrischen Mittel der Cmax ||| geometric means of Cmax ||| 0-0 0-1 1-1 2-2 3-3
geometrischen Mittel der ||| geometric means of ||| 0-0 0-1 1-1 2-2
geometrischen Mittel ||| geometric means ||| 0-0 0-1 1-1
geometrischen ||| geometric ||| 0-0
geplante G-CSF-Unterstützung behandelt . ||| planned G-CSF support . ||| 0-0 1-0 1-1 1-2 2-2 3-3
geplante G-CSF-Unterstützung behandelt ||| planned G-CSF support ||| 0-0 1-0 1-1 1-2 2-2
gepoolte Daten* ) : ||| pooled data* ) : ||| 0-0 0-1 1-1 2-2 3-3
gepoolte Daten* ) ||| pooled data* ) ||| 0-0 0-1 1-1 2-2
gepoolte Daten* ||| pooled data* ||| 0-0 0-1 1-1
geraten werden ||| be advised ||| 1-0 0-1 1-1
geraten ||| advised ||| 0-0
geraten ||| important in those ||| 0-0 0-2
gerichtet ||| mucositis ||| 0-0
gering ||| blood ||| 0-0
geringe Menge von ||| small amount of ||| 0-0 0-1 1-1 2-2
geringe Menge ||| small amount ||| 0-0 0-1 1-1
geringen oder mäßigen Einfluss ||| minor or moderate influence ||| 0-0 1-1 2-2 3-3
geringen oder mäßigen ||| minor or moderate ||| 0-0 1-1 2-2
geringen oder ||| minor or ||| 0-0 1-1
geringen ||| minor ||| 0-0
geringer Anstieg der ||| increases ||| 1-0
geringer Anstieg ||| increases ||| 1-0
geringer als bei ||| can occur ( see section ||| 2-1 0-2
geringer als bei ||| can occur ( see ||| 2-1 0-2
geringer als bei ||| can occur ( ||| 2-1 0-2
geringer als bei ||| occur ( see section ||| 2-0 0-1
geringer als bei ||| occur ( see ||| 2-0 0-1
geringer als bei ||| occur ( ||| 2-0 0-1
geringer als ||| ( see section ||| 0-0
geringer als ||| ( see ||| 0-0
geringer als ||| ( ||| 0-0
geringer ||| ( see section ||| 0-0
geringer ||| ( see ||| 0-0
geringer ||| ( ||| 0-0
geringere Wirksamkeit ||| efficacy ||| 1-0
geringeren Ausmaß im Harn ( ||| lesser amount in urine ( ||| 0-0 1-0 0-1 2-2 2-3 3-3 4-4
geringeren Ausmaß im Harn ||| lesser amount in urine ||| 0-0 1-0 0-1 2-2 2-3 3-3
geringeren Ausmaß ||| lesser amount ||| 0-0 1-0 0-1
geringeren ||| a ||| 0-0
geringfügig zwischen ||| slightly between ||| 0-0 1-1
geringfügig ||| slightly ||| 0-0
gesamte Dosis injiziert wurde . ||| entire dose is injected . ||| 0-0 1-1 2-2 2-3 3-3 4-4
gesamte Dosis injiziert wurde ||| entire dose is injected ||| 0-0 1-1 2-2 2-3 3-3
gesamte Dosis ||| entire dose ||| 0-0 1-1
gesamte ||| entire ||| 0-0
gesamten Behandlungszeitraum . ||| whole treatment period . ||| 0-0 1-0 1-1 1-2 2-3
gesamten Behandlungszeitraum ||| whole treatment period ||| 0-0 1-0 1-1 1-2
gesamten Gewichtsreduktion ||| total weight loss ||| 0-0 1-1 1-2
gesamten Hüfte ||| total hip ||| 0-0 1-1
gesamten aktiven Metaboliten liegt bei ||| for its total active metabolites ||| 4-0 1-1 0-2 3-2 1-3 2-4
gesamten aktiven Metaboliten liegt ||| its total active metabolites ||| 1-0 0-1 3-1 1-2 2-3
gesamten ||| Ltd. ||| 0-0
gesamten ||| total ||| 0-0
geschieht hauptsächlich über das Cytochrom ||| is predominantly via cytochrome ||| 0-0 0-1 1-1 0-2 2-2 3-2 4-3
geschieht hauptsächlich über das ||| is predominantly via ||| 0-0 0-1 1-1 0-2 2-2 3-2
geschlechtsabhängigen Effekte ||| in schizophrenic ||| 0-0 0-1 1-1
geschätzt , ||| estimated ||| 0-0
geschätzt ||| estimated ||| 0-0
geschätzte Verteilungsvolumen ||| estimated volume of distribution ||| 0-0 0-1 1-2 1-3
geschätzte ||| estimated volume ||| 0-0 0-1
geschätzten Dosen von ||| reported estimated doses ||| 0-0 0-1 1-2 2-2
geschätzten ||| reported estimated ||| 0-0 0-1
gesteigert werden . ||| be increased . ||| 1-0 0-1 2-2
gesteigert werden ||| be increased ||| 1-0 0-1
gesteigert ||| increased ||| 0-0
gesteigerter Unruhe als ||| agitation than ||| 0-0 1-0 2-1
gesteigerter Unruhe als ||| of agitation than ||| 0-1 1-1 2-2
gesteigerter Unruhe litten , ||| agitation ||| 0-0 1-0
gesteigerter Unruhe litten ||| agitation ||| 0-0 1-0
gesteigerter Unruhe oder Verhaltensstörungen ||| agitation or disturbed ||| 0-0 1-0 2-1 3-2
gesteigerter Unruhe oder ||| agitation or ||| 0-0 1-0 2-1
gesteigerter Unruhe und Verhaltensstörungen ||| agitation and disturbed behaviours ||| 0-0 1-0 2-1 3-2 3-3
gesteigerter Unruhe und ||| agitation and ||| 0-0 1-0 2-1
gesteigerter Unruhe und ||| of agitation , and ||| 1-0 0-1 1-1 2-3
gesteigerter Unruhe ||| agitation ||| 0-0 1-0
gesteigerter Unruhe ||| of agitation , ||| 1-0 0-1 1-1
gesteigerter Unruhe ||| of agitation ||| 0-1 1-1
gesteigerter Unruhe ||| of agitation ||| 1-0 0-1 1-1
gestillten Säuglingen ist Abraxane ||| infants , Abraxane is ||| 0-0 1-0 3-2 2-3
gestillten Säuglingen ||| infants , ||| 0-0 1-0
gestillten Säuglingen ||| infants ||| 0-0 1-0
gestoppt ||| stopped ||| 0-0
gesund erhält . ||| also occur in men . ||| 0-1 1-3 2-4
gesund erhält . ||| occur in men . ||| 0-0 1-2 2-3
gesund erhält ||| also occur in men ||| 0-1 1-3
gesund erhält ||| occur in men ||| 0-0 1-2
gesund ||| also occur in ||| 0-1
gesund ||| also occur ||| 0-1
gesund ||| occur in ||| 0-0
gesund ||| occur ||| 0-0
gesunden Nichtrauchern vergleichbar ist ||| similar between healthy non-smoking subjects ||| 2-0 0-1 0-2 1-3 0-4
gesunden Nichtrauchern vergleichbar ||| similar between healthy non-smoking subjects ||| 2-0 0-1 0-2 1-3 0-4
gesunden Nichtrauchern ||| between healthy non-smoking subjects and ||| 0-0 0-1 1-2 0-3
gesunden Nichtrauchern ||| between healthy non-smoking subjects ||| 0-0 0-1 1-2 0-3
gesunden Probanden ||| healthy subjects ||| 0-0 1-1
gesunden ||| healthy ||| 0-0
gesunden ||| to healthy ||| 0-1
gesunden älteren und jüngeren ||| healthy elderly and younger ||| 0-0 1-1 2-2 3-3
gesunden älteren und ||| healthy elderly and ||| 0-0 1-1 2-2
gesunden älteren ||| healthy elderly ||| 0-0 1-1
getesteten Dosis ||| dose ||| 1-0
getrocknet und der Deckel ||| dried and the cap ||| 0-0 3-0 1-1 2-2 3-3
getrunken ||| resulting ||| 0-0
gewaschen und ||| washed and ||| 0-0 1-1
gewaschen ||| washed ||| 0-0
gewissen Umständen ||| circumstances ||| 0-0 1-0
gewährleisten . ||| effectively . ||| 0-0 1-1
gewährleisten ||| effectively ||| 0-0
gewährleistet sein : ||| be assured : ||| 0-0 0-1 1-1 2-2
gewährleistet sein ||| be assured ||| 0-0 0-1 1-1
gewöhnlich erst im Erwachsenenalter auf ||| that usually develops in adulthood ||| 1-0 0-1 1-2 2-2 3-2 2-3 3-4 4-4
gewöhnlich vorübergehend , ||| usually transient , typically ||| 0-0 1-1 2-2 2-3
gewöhnlich vorübergehend und verschwinden normalerweise ||| transitory and disappear ||| 0-0 1-0 2-1 3-2 4-2
gewöhnlich vorübergehend und ||| transitory and ||| 0-0 1-0 2-1
gewöhnlich vorübergehend ||| transitory ||| 0-0 1-0
gewöhnlich vorübergehend ||| usually transient ||| 0-0 1-1
gewöhnlich ||| usually ||| 0-0
gewöhnliche Dosis beträgt zwischen ||| usual dose is between ||| 0-0 1-1 2-2 3-3
gewöhnliche Dosis beträgt ||| usual dose is ||| 0-0 1-1 2-2
gewöhnliche Dosis ||| usual dose ||| 0-0 1-1
gewöhnliche ||| usual ||| 0-0
gewünschten Bereich zu halten ||| values at the desired level ||| 0-0 1-1 1-2 1-3 2-3 3-3 3-4
gewünschten ||| values ||| 0-0
gezeigt ( G-CSF und GM-CSF ||| ( G-CSF and GM-CSF ||| 1-0 2-1 3-2 2-3 4-3
gezeigt ( ||| ( ||| 1-0
gezeigt , dass Pioglitazon keine ||| shown that pioglitazone has no ||| 0-0 1-1 2-1 3-2 0-3 4-4
gezeigt , dass Pioglitazon ||| shown that pioglitazone has ||| 0-0 1-1 2-1 3-2 0-3
gezeigt , ||| shown ||| 0-0
gezeigt ? ||| ? ||| 0-0 1-0
gezeigt worden . ||| . ||| 1-0 2-0
gezeigt ||| has ||| 0-0
gezeigt ||| shown ||| 0-0
gezogen werden , wenn ||| be considered when ||| 1-0 0-1 2-2 3-2
gezogen werden ||| be considered ||| 1-0 0-1
gezogen ||| considered ||| 0-0
gibt Patienten , ||| Patients have ||| 0-0 1-0 1-1 2-1
gibt derzeit ||| are currently ||| 0-0 1-1
gibt keine Erfahrungen bei Kindern ||| no experience in children ||| 0-0 1-0 2-1 3-2 4-3
gibt keine Erfahrungen bei ||| no experience in ||| 0-0 1-0 2-1 3-2
gibt keine Erfahrungen ||| no experience ||| 0-0 1-0 2-1
gibt keine ||| no ||| 0-0 1-0
gibt ||| are ||| 0-0
gingen mit einer ||| have been accompanied by an ||| 0-0 0-1 0-2 1-2 2-3 2-4
gingen mit ||| have been accompanied ||| 0-0 0-1 0-2 1-2
glauben , ||| think ||| 0-0
glauben schwanger zu sein ||| think you may be pregnant ||| 0-0 1-0 0-1 0-2 2-3 3-3 1-4 3-4
glauben ||| think ||| 0-0
gleich große Injektionen . ||| equal injections . ||| 0-0 1-0 2-1 3-2
gleich große Injektionen ||| equal injections ||| 0-0 1-0 2-1
gleich große ||| equal ||| 0-0 1-0
gleichen Dosis ||| same dose ||| 0-0 1-1
gleichen ||| same ||| 0-0
gleichermaßen zur Wirksamkeit bei . ||| contribute equally to efficacy . ||| 0-0 0-1 1-1 1-2 2-3 3-3 4-4
gleichermaßen zur Wirksamkeit bei ||| contribute equally to efficacy ||| 0-0 0-1 1-1 1-2 2-3 3-3
gleichermaßen zur ||| contribute equally to ||| 0-0 0-1 1-1 1-2
gleichzeitig bestehende Hypertonie und/oder ||| with hypertension and/ or dyslipidemia ||| 0-0 2-1 3-2 3-3 1-4
gleichzeitig mit Aripiprazol eingenommen ||| were administered concomitantly with aripiprazole ||| 0-0 0-1 0-2 3-2 1-3 2-4
gleichzeitig mit ||| was administered concomitantly with ||| 0-0 0-1 0-2 1-3
gleichzeitig verabreicht wird . ||| is concomitantly administered . ||| 2-0 0-1 1-1 1-2 3-3
gleichzeitig verabreicht wird ||| is concomitantly administered ||| 2-0 0-1 1-1 1-2
gleichzeitig verabreicht ||| concomitantly administered ||| 0-0 1-0 1-1
gleichzeitig ||| was administered concomitantly ||| 0-0 0-1 0-2
gleichzeitig ||| with ||| 0-0
gleichzeitige Gabe von Rimonabant ||| gleichzeitige Gabe von Rimonabant ||| 0-0 0-1 0-2 2-2 3-3
gleichzeitige Gabe von ||| gleichzeitige Gabe von ||| 0-0 0-1 0-2 2-2
gleichzeitige Gabe ||| concomitant administration ||| 0-0 0-1 1-1
gleichzeitige Osteoporose-Therapie ||| Concomitant osteoporosis therapy ||| 0-0 1-1 1-2
gleichzeitige ||| , ||| 0-0
gleichzeitige ||| Concomitant ||| 0-0
gleichzeitige ||| concomitant nephrotoxic ||| 0-0
gleichzeitige ||| concomitant ||| 0-0
glykosyliertes Hämoglobin , ||| glycosylated haemoglobin , ||| 0-0 1-0 1-1 2-2
glykosyliertes Hämoglobin ||| glycosylated haemoglobin increased ||| 0-0 1-0 1-1 1-2
glykosyliertes Hämoglobin ||| glycosylated haemoglobin ||| 0-0 1-0 1-1
glykämische ||| rate of ||| 0-0 0-1
gp-60-Albuminrezeptor ||| gp-60 albumin receptor , ||| 0-0
gp-60-Albuminrezeptor ||| gp-60 albumin receptor ||| 0-0
gp-60-Albuminrezeptor ||| gp-60 albumin ||| 0-0
gp-60-Albuminrezeptor ||| gp-60 ||| 0-0
gp-Substrat ) untersucht wurden. ||| P- gp-Substrat ) untersucht wurden. ||| 1-0 0-1 1-2 1-3 3-4
gp-Substrat ) untersucht ||| P- gp-Substrat ) untersucht ||| 1-0 0-1 1-2 1-3
gp-Substrat ) ||| P- gp-Substrat ) untersucht ||| 1-0 0-1 1-2 1-3
gp-Substrat ||| gp-Substrat ||| 0-0
groß . ||| wide . ||| 0-0 1-1
groß ||| wide ||| 0-0
großen , offenen Studien ||| large , open-label studies , ||| 0-0 1-1 2-2 3-3 1-4
großen Kreislauf ||| systemic circulation ||| 1-0 1-1
großen kontrollierten Studien ||| large controlled studies ||| 0-0 1-1 2-2
großen kontrollierten ||| large controlled ||| 0-0 1-1
großen ||| large ||| 0-0
größere Empfindlichkeit dieser Patientengruppe ||| greater sensitivity of this population ||| 1-0 0-1 1-1 2-2 2-3 3-4
größere Empfindlichkeit dieser ||| greater sensitivity of this ||| 1-0 0-1 1-1 2-2 2-3
größere Empfindlichkeit ||| greater sensitivity ||| 1-0 0-1 1-1
größere Häufigkeit von ||| more ||| 0-0
größere Häufigkeit ||| more ||| 0-0
größere Menge von ABILIFY ||| take more ABILIFY ||| 0-0 2-0 0-1 1-1 3-2
größere Menge von Abseamed angewendet ||| inject more Abseamed ||| 0-0 1-0 0-1 2-1 3-2 4-2
größere Menge von Actos ||| take more Actos ||| 0-0 0-1 1-1 2-1 3-2
größere Menge von ||| inject more ||| 0-0 1-0 0-1 2-1
größere Menge von ||| take more ||| 0-0 0-1 1-1 2-1
größere Menge von ||| take more ||| 0-0 2-0 0-1 1-1
größere ||| more ||| 0-0
größerer orthopädischer Eingriff vorgesehen ist ||| for major orthopaedic surgery ||| 1-0 0-1 1-1 2-2 3-2 3-3 4-3
größerer orthopädischer ||| for major ||| 1-0 0-1 1-1
gut dokumentierte ||| has multiple well documented ||| 0-0 0-2 1-3
gut kontrollierten Studien bei ||| well-controlled studies in ||| 0-0 1-0 2-1 3-2
gut kontrollierten Studien ||| well-controlled studies ||| 0-0 1-0 2-1
gut kontrollierten ||| well-controlled ||| 0-0 1-0
gut resorbiert , wobei ||| well absorbed , with ||| 0-0 1-1 3-1 2-2 3-3
gut resorbiert mit ||| is well absorbed and has ||| 1-0 0-1 1-2 0-4
gut resorbiert ||| is well absorbed and has ||| 1-0 0-1 1-2 0-4
gut und ||| was well ||| 0-1
gut und ||| well ||| 0-0
gut vertragen ||| well tolerated in ||| 0-0 1-1
gut vertragen ||| well tolerated ||| 0-0 1-1
gut ||| has multiple well ||| 0-0 0-2
gut ||| was well ||| 0-1
gut ||| well ||| 0-0
guten ||| systemic chemotherapy ||| 0-0 0-1
gynäkologische Tumore , 23 Bronchialkarzinome ||| gynaecological , 23 lung ||| 0-0 1-0 2-1 3-2 4-3
gynäkologische Tumore , 23 ||| gynaecological , 23 ||| 0-0 1-0 2-1 3-2
gynäkologische Tumore , ||| gynaecological , ||| 0-0 1-0 2-1
gynäkologische Tumore ||| gynaecological ||| 0-0 1-0
gynäkologische ||| gynaecological ||| 0-0
h ) ||| ) ||| 0-0 1-0
h ||| longer ||| 0-0
h. chemische Stoffe ||| chemicals ||| 0-0 1-0 2-0
h. ||| on ||| 0-0
haben ( siehe Abschnitt 5.1 ||| ( see section 5.1 ||| 1-0 2-1 3-2 4-3
haben ( siehe Abschnitt ||| ( see section ||| 1-0 2-1 3-2
haben ( siehe ||| ( see ||| 1-0 2-1
haben ( ||| ( ||| 1-0
haben , als Sie sollten ||| than you should ||| 0-0 2-0 1-1 3-1 4-2
haben , als Sie sollten ||| than you should ||| 0-0 2-0 3-1 4-2
haben , als Sie ||| than you ||| 0-0 2-0 1-1 3-1
haben , als Sie ||| than you ||| 0-0 2-0 3-1
haben , als ||| than ||| 0-0 2-0
haben , angewendet ||| have ||| 0-0
haben , ||| effects ||| 0-0
haben , ||| have ||| 0-0
haben . ||| . ||| 1-0
haben . ||| doctor . ||| 0-0 1-1
haben . ||| your doctor . ||| 0-0 0-1 1-2
haben ein erhöhtes Risiko von ||| have an increased risk of ||| 0-0 1-1 2-2 3-3 4-4
haben ein erhöhtes Risiko ||| have an increased risk ||| 0-0 1-1 2-2 3-3
haben ein erhöhtes ||| have an increased ||| 0-0 1-1 2-2
haben ein ||| have an ||| 0-0 1-1
haben gezeigt , dass Pioglitazon ||| have shown that pioglitazone has ||| 0-0 1-1 2-2 3-2 4-3 1-4
haben keine Wechselwirkung zwischen ||| not show an interaction between ||| 1-0 0-1 1-1 2-2 2-3 3-4
haben keine Wechselwirkung ||| did not show an interaction ||| 1-1 0-2 1-2 2-3 2-4
haben keine Wechselwirkung ||| not show an interaction ||| 1-0 0-1 1-1 2-2 2-3
haben keine ||| did not show ||| 1-1 0-2 1-2
haben keine ||| not show ||| 1-0 0-1 1-1
haben ||| cause ||| 0-0
haben ||| doctor ||| 0-0
haben ||| effects ||| 0-0
haben ||| have recently ||| 0-0 0-1
haben ||| have ||| 0-0
haben ||| to have ||| 0-1
haben ||| your doctor ||| 0-0 0-1
halten . ||| . ||| 1-0
halten . ||| pressure . ||| 0-0 1-1
halten ||| pressure ||| 0-0
halten ||| values ||| 0-0
hat . ||| products . ||| 0-0 1-1
hat Abilify in diesen ||| has Abilify shown during the ||| 0-0 1-1 2-2 3-2 3-3
hat Abilify in diesen ||| has Abilify shown during ||| 0-0 1-1 2-2 3-2 3-3
hat Abilify ||| has Abilify ||| 0-0 1-1
hat Abraxane in diesen ||| has Abraxane shown during the ||| 0-0 1-1 2-2 3-2 3-3
hat Abraxane in diesen ||| has Abraxane shown during ||| 0-0 1-1 2-2 3-2 3-3
hat Abraxane ||| has Abraxane ||| 0-0 1-1
hat Aclasta in diesen ||| has Aclasta shown during the ||| 0-0 1-1 2-2 3-2 3-3
hat Aclasta in diesen ||| has Aclasta shown during ||| 0-0 1-1 2-2 3-2 3-3
hat Aclasta ||| has Aclasta ||| 0-0 1-1
hat Actos ||| has Actos ||| 0-0 1-1
hat Actraphane in diesen ||| has Actraphane shown during the ||| 0-0 1-1 2-2 3-2 3-3
hat Actraphane in diesen ||| has Actraphane shown during ||| 0-0 1-1 2-2 3-2 3-3
hat Actraphane ||| has Actraphane ||| 0-0 1-1
hat Aripiprazol nicht ||| aripiprazole has not been ||| 1-0 0-1 2-2 2-3
hat Aripiprazol ||| aripiprazole has ||| 1-0 0-1
hat auch einen ||| also has a ||| 1-0 0-1 2-2
hat auch ||| also has ||| 1-0 0-1
hat eine Körpergewichtsabstufung ||| has a gradation in ||| 0-0 1-1 2-2
hat eine Körpergewichtsabstufung ||| has a gradation ||| 0-0 1-1 2-2
hat eine ||| has a ||| 0-0 1-1
hat einen pH-Wert von 6-7,5 ||| has a pH of 6-7.5 ||| 0-0 1-1 2-2 3-3 4-4
hat einen pH-Wert von ||| has a pH of ||| 0-0 1-1 2-2 3-3
hat einen pH-Wert ||| has a pH ||| 0-0 1-1 2-2
hat einen ||| has a ||| 0-0 1-1
hat geringen oder mäßigen Einfluss ||| has minor or moderate influence ||| 0-0 1-1 2-2 3-3 4-4
hat geringen oder mäßigen ||| has minor or moderate ||| 0-0 1-1 2-2 3-3
hat geringen oder ||| has minor or ||| 0-0 1-1 2-2
hat geringen ||| has minor ||| 0-0 1-1
hat in der Blutbahn ||| in the blood stream has ||| 1-0 2-1 3-2 0-3 2-3 3-3 3-4
hat keine bekannten Auswirkungen auf ||| has no known effects on ||| 0-0 1-1 2-2 1-3 3-4 4-4
hat keine bekannten ||| has no known effects ||| 0-0 1-1 2-2 1-3
hat keinen Einfluss auf die ||| has no influence on the ||| 0-0 1-1 2-2 3-3 4-3 4-4
hat keinen Einfluss ||| has no influence ||| 0-0 1-1 2-2
hat keinen ||| has no ||| 0-0 1-1
hat ||| has ||| 0-0
hat ||| products ||| 0-0
hatte aber keine Auswirkung auf ||| but had no effect on ||| 1-0 0-1 2-2 3-3 4-4
hatte aber keine Auswirkung ||| but had no effect ||| 1-0 0-1 2-2 3-3
hatte aber keine ||| but had no ||| 1-0 0-1 2-2
hatte aber ||| but had ||| 1-0 0-1
hatte auch eine ||| also had a ||| 1-0 0-1 2-2
hatte auch eine ähnliche Wirkung ||| also had a similar effect ||| 1-0 0-1 2-2 3-3 4-4
hatte auch eine ähnliche ||| also had a similar ||| 1-0 0-1 2-2 3-3
hatte auch ||| also had ||| 1-0 0-1
hatte bereits einen Myokardinfarkt ||| had a previous myocardial infarction ||| 0-0 2-0 2-1 0-2 1-2 3-3 3-4
hatte bereits einen ||| had a previous ||| 0-0 2-0 2-1 0-2 1-2
hatte ein ||| had an ||| 0-0 1-1
hatte ||| had ||| 0-0
hatten . ||| one . ||| 0-0 1-1
hatten Anzeichen für lokale Infektionen ||| had signs of local infection ||| 0-0 1-1 2-2 3-3 4-4
hatten Anzeichen für lokale ||| had signs of local ||| 0-0 1-1 2-2 3-3
hatten Anzeichen für ||| had signs of ||| 0-0 1-1 2-2
hatten Anzeichen ||| had signs ||| 0-0 1-1
hatten einen ||| had a ||| 0-0 1-0 1-1
hatten mehr als ||| had ||| 0-0
hatten mehr ||| had ||| 0-0
hatten viszerale Metastasen ||| had visceral metastases ||| 0-0 1-1 2-2
hatten viszerale ||| had visceral ||| 0-0 1-1
hatten ||| had ||| 0-0
hatten ||| one ||| 0-0
hauptsächlich an Knochengewebe gebunden ||| bound to bone tissue ||| 0-0 1-0 3-0 3-1 2-2 2-3
hauptsächlich durch Metabolisierung und ||| hauptsächlich durch Metabolisierung und ||| 0-0 1-1 2-1 2-2 2-3 3-3
hauptsächlich im Fäzes ( 55 ||| mainly in faeces ( 55 ||| 0-0 1-0 2-0 1-1 2-2 3-3 4-4
hauptsächlich im Fäzes ( ||| mainly in faeces ( ||| 0-0 1-0 2-0 1-1 2-2 3-3
hauptsächlich im Fäzes ||| mainly in faeces ||| 0-0 1-0 2-0 1-1 2-2
hauptsächlich ||| hauptsächlich ||| 0-0
hauptsächlich ||| mostly ||| 0-0
hauptsächlich ||| primarily ||| 0-0
hauptsächlich über drei Biotransformations-Wege metabolisiert ||| primarily by three biotransformation pathways ||| 0-0 3-1 1-2 2-2 3-3 3-4 4-4
heilende Wunden ||| non-healing sores of ||| 0-0 1-1
heilende Wunden ||| non-healing sores ||| 0-0 1-1
heilende ||| non-healing ||| 0-0
helfen , ||| help ||| 0-0 1-0
hemmt oder induziert keine ||| does not inhibit or induce ||| 0-0 3-1 0-2 2-2 1-3 3-4
hemmt. ||| peripheral tissues ||| 0-0 0-1
hepatisch ) metabolisiert . ||| hepatic ) pathways in ina ||| 0-0 1-1 0-2 2-2 2-4 3-4
hepatisch ) metabolisiert . ||| hepatic ) pathways in no ||| 0-0 1-1 0-2 2-2
hepatisch ) metabolisiert . ||| hepatic ) pathways in ||| 0-0 1-1 0-2 2-2
hepatisch ) metabolisiert . ||| hepatic ) pathways ||| 0-0 1-1 0-2 2-2
hepatisch ) metabolisiert ||| hepatic ) pathways in no ||| 0-0 1-1 0-2 2-2
hepatisch ) metabolisiert ||| hepatic ) pathways in ||| 0-0 1-1 0-2 2-2
hepatisch ) metabolisiert ||| hepatic ) pathways ||| 0-0 1-1 0-2 2-2
hepatischen Metabolisierung mit ||| hepatic metabolism and ||| 0-0 0-1 1-1
hepatischen Metabolisierung mit ||| hepatic metabolism ||| 0-0 0-1 1-1
hepatischen Metabolisierung ||| hepatic metabolism and ||| 0-0 0-1 1-1
hepatischen Metabolisierung ||| hepatic metabolism ||| 0-0 0-1 1-1
hepatozellulärer Dysfunktion ||| hepatocellular dysfunction ||| 0-0 1-1
hepatozellulärer ||| hepatocellular ||| 0-0
herangezogen ||| assessing ||| 0-0
heraus und ||| and apply pressure ||| 1-0 0-1 1-2
heraus ||| apply ||| 0-0
hergestellt . ||| . ||| 1-0
hergestellt . ||| action . ||| 1-1
hervorrufen kann . ||| feeding . ||| 0-0 2-1
hervorrufen kann ||| feeding ||| 0-0
hervorrufen ||| feeding ||| 0-0
hielt bis zu ||| was maintained for up to ||| 0-0 0-1 1-2 1-3 2-3 2-4
hielt ||| was maintained ||| 0-0 0-1
hilft , die Umwelt zu ||| will help to protect the ||| 0-0 0-1 1-2 2-2 3-3 4-3 4-4
hilft , die ||| will help to ||| 0-0 0-1 1-2 2-2
hilft die Umwelt zu ||| will help to protect the ||| 0-0 0-1 1-1 2-2 2-3 3-3 3-4
hilft die ||| will help ||| 0-0 0-1 1-1
hilft ||| will help ||| 0-0 0-1
hin . ||| . ||| 1-0
hin ||| suggest ||| 0-0
hindeuten ||| presents ||| 0-0
hinlegen müssen , bis Sie ||| to lie down until you ||| 3-0 0-1 1-1 0-2 3-3 4-4
hinlegen müssen , bis ||| to lie down until ||| 3-0 0-1 1-1 0-2 3-3
hinlegen müssen , ||| lie down ||| 0-0 1-0 0-1
hinlegen müssen ||| lie down ||| 0-0 1-0 0-1
hinreichend untersucht . ||| is sufficiently investigated and ||| 0-1 1-2 2-2
hinreichend untersucht . ||| is sufficiently investigated ||| 0-1 1-2 2-2
hinreichend untersucht . ||| sufficiently investigated and ||| 0-0 1-1 2-1
hinreichend untersucht . ||| sufficiently investigated ||| 0-0 1-1 2-1
hinreichend ||| is sufficiently ||| 0-1
hinreichend ||| sufficiently ||| 0-0
hinreichenden Daten für die Verwendung ||| adequate data on the use ||| 0-0 1-1 1-2 2-3 3-3 4-4
hinreichenden Daten für die ||| adequate data on the ||| 0-0 1-1 1-2 2-3 3-3
hinreichenden Daten ||| adequate data on ||| 0-0 1-1 1-2
hinreichenden oder gut ||| hinreichenden oder gut kontrollierten ||| 0-0 1-1 0-2 0-3 2-3
hinreichenden und kontrollierten Studien mit ||| adequate and well-controlled trials of ||| 0-0 1-1 2-2 3-3 4-4
hinreichenden und kontrollierten Studien ||| adequate and well-controlled trials ||| 0-0 1-1 2-2 3-3
hinreichenden und kontrollierten ||| adequate and well-controlled ||| 0-0 1-1 2-2
hinreichenden und ||| adequate and ||| 0-0 1-1
hinreichenden ||| adequate ||| 0-0
hinsichtlich Stärke , ||| in strength , ||| 0-0 0-1 1-1 2-2
hinsichtlich Stärke ||| in strength ||| 0-0 0-1 1-1
hinsichtlich der Absenkung des Testosteronspiegels ||| in serum testosterone reduction ||| 0-0 1-1 3-1 2-2 4-2 2-3
hinsichtlich ||| in ||| 0-0
hinzuweisen , ||| alerted ||| 0-0
hinzuweisen ||| alerted ||| 0-0
hoch ( ||| high ( ||| 0-0 1-1
hoch ist ( siehe ||| the insulin requirement ( see ||| 0-0 0-1 0-2 1-2 2-3 3-4
hoch ist ( ||| the insulin requirement ( ||| 0-0 0-1 0-2 1-2 2-3
hoch ist , ||| too high , ||| 0-0 0-1 1-1 2-2
hoch ist . ||| the insulin requirement . ||| 0-0 0-1 0-2 1-2 2-3
hoch ist ||| the insulin requirement ||| 0-0 0-1 0-2 1-2
hoch ist ||| too high ||| 0-0 0-1 1-1
hoch ||| high ||| 0-0
hochgradig Protein-gebundener Wirkstoffe unwahrscheinlich ||| highly protein-bound drugs are unlikely ||| 0-0 0-1 1-1 2-1 1-2 1-3 3-4
hochgradig Protein-gebundener Wirkstoffe ||| highly protein-bound drugs are ||| 0-0 0-1 1-1 2-1 1-2 1-3
hochgradig Protein-gebundener Wirkstoffe ||| of highly protein-bound drugs are ||| 0-1 0-2 1-2 2-2 1-3 1-4
hochwirksame Inhibitoren von CYP3A4 , ||| potent inhibitors of CYP3A4 , ||| 0-0 1-1 2-2 3-3 4-4
hochwirksame Inhibitoren von CYP3A4 ||| potent inhibitors of CYP3A4 ||| 0-0 1-1 2-2 3-3
hochwirksame Inhibitoren von ||| potent inhibitors of ||| 0-0 1-1 2-2
hochwirksame Inhibitoren ||| potent inhibitors ||| 0-0 1-1
hochwirksame ||| concomitant ||| 0-0
hochwirksame ||| potent ||| 0-0
hochwirksamen CYP3A4-Inhibitoren mit ABILIFY in ||| potent CYP3A4 inhibitors with ABILIFY ||| 0-0 1-0 1-1 1-2 2-3 3-4
hochwirksamen CYP3A4-Inhibitoren mit ABILIFY ||| potent CYP3A4 inhibitors with ABILIFY ||| 0-0 1-0 1-1 1-2 2-3 3-4
hochwirksamen CYP3A4-Inhibitoren mit ||| potent CYP3A4 inhibitors with ||| 0-0 1-0 1-1 1-2 2-3
hochwirksamen CYP3A4-Inhibitoren ||| potent CYP3A4 inhibitors ||| 0-0 1-0 1-1 1-2
hochwirksamen ||| potent CYP3A4 ||| 0-0 0-1
hochwirksamen ||| potent ||| 0-0
hochwirksamer ||| potent ||| 0-0
hohe ||| high ||| 0-0
hohem Fieber ||| high fever ||| 0-0 0-1 1-1
hohen Frakturrisiko ||| of ||| 0-0 1-0
hohen ||| performed ||| 0-0
hohes Fieber ||| high fever ||| 0-0 0-1 1-1
hormonempfindlichem ||| sensitive ||| 0-0
http://www.emea.euopa.eu / ||| . emea . ||| 0-0 0-1 1-1 0-2
http://www.emea.europa.eu / ||| . emea ||| 0-0 0-1 1-1
http://www.emea.europa.eu ||| . emea ||| 0-0 0-1
http://www.emea.europa.eu ||| emea ||| 0-0
human ) . ||| human ) . ||| 0-0 1-1 2-2
human ) ||| human ) ||| 0-0 1-1
human , r-DNS ( ||| human , rDNA ( ||| 0-0 1-1 2-2 3-3
human , r-DNS ||| human , rDNA ||| 0-0 1-1 2-2
human , ||| human , ||| 0-0 1-1
human . ||| human . ||| 0-0 1-1
human ||| human ||| 0-0
human-therapeutischen Exposition ||| therapeutic exposure ||| 0-0 1-1
human-therapeutischen ||| therapeutic ||| 0-0
humanen Erythropoetin ||| human erythropoietin ||| 0-0 1-1
humanen Lebermikrosome und Gewebeschichten ||| human liver microsomes and tissue ||| 0-0 1-2 3-2 2-3 2-4
humanen Tumorgewebsproben , ||| human tumour samples , ||| 0-0 1-1 0-2 1-2 2-3
humanen Tumorgewebsproben ||| human tumour samples ||| 0-0 1-1 0-2 1-2
humanen ||| human liver ||| 0-0
humanen ||| human ||| 0-0
hydroxylierten Metaboliten erfolgt jeweils ||| hydroxylated metabolites is catalysed ||| 0-0 1-1 2-2 2-3
hydroxylierten Metaboliten erfolgt jeweils über ||| hydroxylated metabolites is catalysed by ||| 0-0 1-1 2-2 2-3 4-4
hydroxylierten Metaboliten erfolgt ||| hydroxylated metabolites is catalysed ||| 0-0 1-1 2-2 2-3
hydroxylierten Metaboliten ||| hydroxylated metabolites ||| 0-0 1-1
hydroxylierten ||| hydroxylated ||| 0-0
hyperosmolarem Koma oder Tod ||| hyperosmolar coma or death ||| 0-0 1-1 2-2 3-3
hyperosmolarem Koma oder ||| hyperosmolar coma or ||| 0-0 1-1 2-2
hyperosmolarem Koma ||| hyperosmolar coma ||| 0-0 1-1
hyperosmolarem ||| hyperosmolar ||| 0-0
hält ein Jahr oder ||| lasts for a year or ||| 0-0 1-1 1-2 2-3 3-4
hält ein Jahr ||| lasts for a year ||| 0-0 1-1 1-2 2-3
hält ein ||| lasts for a ||| 0-0 1-1 1-2
hält ||| lasts ||| 0-0
hämatologischer Differenzierung oder Proliferation ||| tumour biopsy specimens in vitro ||| 0-0 0-1 1-1 1-2 2-2 3-2 3-3 3-4
häufig . ||| common . ||| 0-0 1-1
häufig ||| common ||| 0-0
häufige Nebenwirkungen ( ||| common side effects ( affecting ||| 0-0 1-1 1-2 2-3 1-4
häufige ||| common ||| 0-0
häufiger auf ( 1/100 ||| more often ( 1/ 100 ||| 0-0 0-1 1-1 2-2 3-3 3-4
häufiger auf ( ||| more often ( ||| 0-0 0-1 1-1 2-2
häufiger auf ||| more often ||| 0-0 0-1 1-1
häufiger jedoch ||| but more frequently ||| 1-0 0-1 0-2
häufiger vor ||| is more common ||| 0-1 0-2
häufiger vor ||| more common ||| 0-0 0-1
häufiger ||| is more common ||| 0-1 0-2
häufiger ||| more common ||| 0-0 0-1
häufiger ||| more frequently ||| 0-0 0-1
häufigste Nebenwirkung ist ||| most frequent adverse reaction is ||| 0-0 0-1 1-1 1-2 1-3 2-4
häufigste Nebenwirkung während der ||| most frequent adverse reaction during ||| 0-0 0-1 1-1 1-2 1-3 2-4 3-4
häufigste Nebenwirkung ||| most frequent adverse reaction ||| 0-0 0-1 1-1 1-2 1-3
häufigste ||| most frequent ||| 0-0 0-1
häufigsten Nebenwirkungen im Zusammenhang mit ||| most common side effects with ||| 0-0 0-1 1-2 2-2 3-2 1-3 4-4
häufigsten Nebenwirkungen im Zusammenhang ||| most common side effects ||| 0-0 0-1 1-2 2-2 3-2 1-3
häufigsten Nebenwirkungen von ||| most common side effects ||| 0-0 0-1 1-2 1-3
häufigsten Nebenwirkungen ||| most common side effects ||| 0-0 0-1 1-2 1-3
häufigsten unerwünschten Wirkungen , ||| most common adverse lon reactions ||| 0-0 0-1 1-2 2-2 1-4
häufigsten unerwünschten Wirkungen ||| most common adverse lon reactions ||| 0-0 0-1 1-2 2-2 1-4
häufigsten ||| most common ||| 0-0 0-1
höchste Exposition in ||| highest nontumorigenic exposure in ||| 0-0 0-1 1-1 2-1 1-2 2-3
höchste ||| highest ||| 0-0
höchsten Konzentrationen ||| highest concentrations ||| 0-0 0-1 1-1
höchsten ||| at ||| 0-0
höchstmöglichen Reinheitsgrad . ||| of the art . ||| 0-0 0-1 0-2 1-2 2-3
höchstmöglichen Reinheitsgrad ||| of the art ||| 0-0 0-1 0-2 1-2
höher ( 43 % ) ||| ( 43 % ) ||| 1-0 0-1 2-1 3-2 4-3
höher ( 43 % ||| ( 43 % ||| 1-0 0-1 2-1 3-2
höher ( 43 ||| ( 43 ||| 1-0 0-1 2-1
höher ( 53 % ) ||| higher ( 53 % ) ||| 0-0 1-1 2-2 3-3 4-4
höher ( 53 % ||| higher ( 53 % ||| 0-0 1-1 2-2 3-3
höher ( 53 ||| higher ( 53 ||| 0-0 1-1 2-2
höher ( ||| higher ( ||| 0-0 1-1
höher als die nach ||| higher than those observed after ||| 0-0 1-1 1-2 2-2 3-3 3-4
höher als die ||| higher than those ||| 0-0 1-1 1-2 2-2
höher ||| higher ||| 0-0
höhere Cmax und eine ||| higher Cmax and a ||| 0-0 1-1 2-2 3-3
höhere Cmax und ||| higher Cmax and ||| 0-0 1-1 2-2
höhere Cmax ||| higher Cmax ||| 0-0 1-1
höhere Dosis bis zu ||| higher dose to ||| 0-0 1-1 2-2 3-2
höhere Dosis ||| higher dose ||| 0-0 1-1
höhere Erhaltungsdosen als ||| require higher maintenance doses than ||| 0-0 0-1 1-2 1-3 2-4
höhere Erhaltungsdosen ||| require higher maintenance doses ||| 0-0 0-1 1-2 1-3
höhere ||| higher ||| 0-0
höhere ||| require higher ||| 0-0 0-1
höherem ||| fluctuation ||| 0-0
höheren Plasmakonzentrationen ||| higher plasma concentrations ||| 0-0 1-1 1-2
höheren ||| higher ||| 0-0
höheres ||| patients ||| 0-0
ich ln ||| lon ||| 0-0 1-0
ich ||| . ||| 0-0
ich ||| ct ||| 0-0
ich ||| du ||| 0-0
idealerweise bereits bevor die ||| ideally starting before the ||| 0-0 1-0 2-2 3-3
idealerweise bereits bevor ||| ideally starting before ||| 0-0 1-0 2-2
idealerweise bereits ||| ideally starting ||| 0-0 1-0
idealerweise bereits ||| ideally ||| 0-0 1-0
identifizierten Metaboliten sind aktiv ( ||| identified metabolites are active ( ||| 0-0 1-1 2-2 3-3 4-4
identifizierten Metaboliten sind aktiv ||| identified metabolites are active ||| 0-0 1-1 2-2 3-3
identifizierten Metaboliten sind ||| identified metabolites are ||| 0-0 1-1 2-2
identifizierten Metaboliten ||| identified metabolites ||| 0-0 1-1
identifizierten ||| identified ||| 0-0
identisch mit dem ||| carbohydrate composition to ||| 0-0 0-1 1-1 2-1 2-2
ihr Wiederauftreten ||| preventing ||| 1-0
ihres inneren Skeletts ||| their internal skeleton that allows ||| 0-0 0-1 1-1 2-2 2-4
ihres inneren ||| their internal ||| 0-0 0-1 1-1
illegale ||| illicit ||| 0-0
im ( MM/JJJJ ) ||| { date } ||| 0-0 1-0 2-0 2-1 2-2 3-2
im 10-2007 aktualisiert . ||| in 10-2007 . dic Me ||| 0-0 0-1 1-1 3-2 2-3 2-4 3-4
im 10-2007 ||| in 10-2007 ||| 0-0 0-1 1-1
im Abwasser oder Haushaltsabfall ||| disposed of via wastewater or ||| 0-0 1-0 1-1 1-2 2-3 3-3 2-4
im Abwasser ||| disposed of via ||| 0-0 1-0 1-1 1-2
im Allgemeinen bei schizophrenen Patienten ||| commonly seen in schizophrenic ||| 0-0 1-0 3-0 2-1 3-1 2-2 3-3 4-3
im Allgemeinen nicht ||| generally not ||| 0-0 1-0 2-1
im Allgemeinen nicht überschritten werden ||| generally not be exceeded ||| 0-0 1-0 2-1 4-2 3-3 4-3
im Allgemeinen und der ||| therapy in general and the ||| 3-0 0-1 3-1 0-2 1-2 2-3 3-4
im Allgemeinen ||| generally ||| 0-0 1-0
im Bereich ||| in ||| 0-0 1-0
im Einklang mit den biochemischen ||| were consistent with biochemical ||| 0-0 1-1 3-1 2-2 4-3
im Einklang mit den ||| were consistent with ||| 0-0 1-1 3-1 2-2
im Falle einer ||| in the case of ||| 0-0 0-1 1-2 2-3
im Falle ||| in the case ||| 0-0 0-1 1-2
im Gehirn . ||| in the brain . ||| 0-0 0-1 1-2 2-3
im Gehirn ||| in the brain ||| 0-0 0-1 1-2
im Gesicht ||| in the face ||| 0-0 0-1 0-2 1-2
im Harn ( ||| in urine ( ||| 0-0 0-1 1-1 2-2
im Harn , Blut ||| in urine , blood ||| 0-0 0-1 1-1 2-2 3-3
im Harn , Eiweiss ||| in urine , proteins ||| 0-0 0-1 1-1 3-1 2-2 3-3
im Harn , ||| in urine , ||| 0-0 0-1 1-1 2-2
im Harn oder Fäzes nachweisen ||| in either urine or faeces ||| 0-0 4-1 0-2 1-2 2-3 3-4 4-4
im Harn ||| in urine ||| 0-0 0-1 1-1
im Infusionsbeutel : ||| in the infusion bag : ||| 0-0 0-1 1-2 1-3 2-4
im Infusionsbeutel ||| in the infusion bag ||| 0-0 0-1 1-2 1-3
im Januar ||| information or procedural aspects please ||| 1-0 1-2 1-3 1-4
im Kiefer . ||| in the jaw . ||| 0-0 0-1 0-2 1-2 2-3
im Kiefer ||| in the jaw ||| 0-0 0-1 0-2 1-2
im Kieferbereich ||| the jaw ||| 0-0 0-1 1-1
im Knochenmark gebildet werden können ||| cells in the bone marrow ||| 1-0 2-0 0-1 2-2 3-2 1-3 3-4
im Knochenmark gebildet werden ||| cells in the bone marrow ||| 1-0 2-0 0-1 2-2 3-2 1-3 3-4
im Mund oder am ||| of the mouth or ||| 3-1 0-2 1-2 2-3
im Mund oder am ||| the mouth or ||| 3-0 0-1 1-1 2-2
im Mund oder ||| mouth or ||| 0-0 1-0 2-1
im Mund ||| mouth ||| 0-0 1-0
im Mund* Gefäßerkrankungen Gelegentlich : ||| Vascular disorders Uncommon : ||| 2-0 1-1 2-1 3-2 4-3
im Mund* Gefäßerkrankungen Gelegentlich ||| Vascular disorders Uncommon ||| 2-0 1-1 2-1 3-2
im Mund* Gefäßerkrankungen ||| Vascular disorders ||| 2-0 1-1 2-1
im Nervensystem zu ||| im Nervensystem zu finden ||| 0-0 1-1 2-2 1-3
im Plasma . ||| in plasma . ||| 0-0 0-1 1-1 2-2
im Plasma ||| in plasma ||| 0-0 0-1 1-1
im Plasma ||| plasma ||| 0-0 1-0
im Rahmen einer ||| In ||| 2-0
im Tiermodell ||| antagonist properties in ||| 1-0 0-1 1-1 0-2
im Urin , ||| recovered in the urine , ||| 1-0 0-1 0-2 0-3 1-3 2-4
im Urin ausgeschieden und ||| excreted in the urine and ||| 0-0 2-0 0-1 0-2 1-3 3-4
im Urin ausgeschieden ||| excreted in the urine ||| 0-0 2-0 0-1 0-2 1-3
im Urin ||| recovered in the urine ||| 1-0 0-1 0-2 0-3 1-3
im Vergleich zu 21 % ||| compared to 21 % ||| 0-0 1-0 2-1 3-2 4-3
im Vergleich zu 21 ||| compared to 21 ||| 0-0 1-0 2-1 3-2
im Vergleich zu Patienten ||| compared with patients ||| 0-0 1-0 2-0 1-1 3-2
im Vergleich zu Placebo : ||| versus placebo : ||| 1-0 2-1 3-1 4-2
im Vergleich zu Placebo ||| versus placebo ||| 1-0 2-1 3-1
im Vergleich zu den Patientinnen ||| , compared ||| 0-1 1-1 2-1
im Vergleich zu den Patientinnen ||| compared ||| 0-0 1-0 2-0
im Vergleich zu den ||| , compared ||| 0-1 1-1 2-1
im Vergleich zu den ||| compared ||| 0-0 1-0 2-0
im Vergleich zu ||| , compared ||| 0-1 1-1 2-1
im Vergleich zu ||| compared to ||| 0-0 1-0 2-1
im Vergleich zu ||| compared with ||| 0-0 1-0 2-0 1-1
im Vergleich zu ||| compared ||| 0-0 1-0 2-0
im Vergleich zu ||| female patients as compared to ||| 0-0 1-0 1-1 1-2 1-3 2-3 2-4
im Vergleich zu ||| patients as compared to ||| 1-0 1-1 0-2 1-2 2-3
im Vergleich zum Ausgangswert ||| relative to baseline were ||| 2-0 2-1 3-2 0-3 1-3
im Vergleich zum Ausgangswert ||| relative to baseline ||| 0-0 2-0 2-1 1-2 3-2
im Vergleich ||| , compared ||| 0-1 1-1
im Vergleich ||| compared ||| 0-0 1-0
im Vergleich ||| loss compared ||| 0-1 1-1
im Vergleich ||| patients as compared ||| 1-0 1-1 0-2 1-2
im Vergleich ||| versus ||| 1-0
im Vergleich ||| were ||| 0-0 1-0
im Verlauf der Behandlung . ||| during continued treatment . ||| 0-0 1-0 1-1 2-1 3-2 4-3
im Verlauf der Behandlung ||| during continued treatment ||| 0-0 1-0 1-1 2-1 3-2
im Verlauf der ||| during continued ||| 0-0 1-0 1-1 2-1
im gesamten Körper ||| widely distributed throughout the body ||| 0-0 1-0 1-1 2-1 1-2 2-3 2-4
im oder zu nah ||| store them in ||| 0-0 1-0 3-0 2-1 3-1 3-2
im zweiten Jahr aufrechterhalten werden ||| during the ||| 0-0 1-0 2-0 3-0 4-1
im zweiten Jahr aufrechterhalten ||| during ||| 0-0 1-0 2-0 3-0
im { MM/JJJJ } ||| in { MM/ YYYY } ||| 0-0 0-1 1-1 2-1 1-2 2-3 3-3 2-4
im ||| and in ||| 0-1
im ||| im ||| 0-0
im ||| in the ||| 0-0 0-1
im ||| in ||| 0-0
im ||| involved in ||| 0-1
im ||| levels and with ||| 0-0
im ||| levels and ||| 0-0
im ||| levels ||| 0-0
im ||| of ||| 0-0
im ||| plasma ||| 0-0
im ||| state ||| 0-0
im ||| were ||| 0-0
in 1,3 ml . ||| in 1.3 ml ||| 0-0 1-1 2-2 3-2
in 1,3 ||| in 1.3 ||| 0-0 1-1
in 100 ml Fertiginfusionslösung ||| in 100 ml ready-to-infuse solution ||| 0-0 1-1 2-2 3-3 2-4
in 100 ||| in 100 ||| 0-0 1-1
in 6 % der ||| in 6 % of ||| 0-0 1-1 2-2 3-3
in 6 % ||| in 6 % ||| 0-0 1-1 2-2
in 6 ||| in 6 ||| 0-0 1-1
in Abhängigkeit von der ||| at least one to ||| 0-0 1-0 1-1 1-2 2-2 3-3
in Abhängigkeit von ||| at least one ||| 0-0 1-0 1-1 1-2 2-2
in Abilify , Aripiprazol , ||| in Abilify , aripiprazole , ||| 0-0 1-1 2-2 3-3 4-4
in Abilify , Aripiprazol ||| in Abilify , aripiprazole ||| 0-0 1-1 2-2 3-3
in Abilify , ||| in Abilify , ||| 0-0 1-1 2-2
in Abilify ||| in Abilify ||| 0-0 1-1
in Abraxane ||| in Abraxane ||| 0-0 1-1
in Abschnitt 6.6 beschrieben . ||| described in section 6.6 . ||| 3-0 0-1 1-2 2-3 4-4
in Abschnitt 6.6 beschrieben ||| described in section 6.6 ||| 3-0 0-1 1-2 2-3
in Abschnitt 6.6 ||| in section 6.6 ||| 0-0 1-1 2-2
in Abschnitt ||| in section ||| 0-0 1-1
in Aclasta , Zoledronsäure ||| in Aclasta , zoledronic acid ||| 0-0 1-1 2-2 3-3 3-4
in Aclasta , ||| in Aclasta , ||| 0-0 1-1 2-2
in Aclasta ||| in Aclasta ||| 0-0 1-1
in Bezug auf ||| in ||| 0-0
in Bezug ||| in ||| 0-0
in Braille-Schrift angegeben . ||| be included in Braille . ||| 2-0 0-1 0-2 1-3 2-3 3-4
in Braille-Schrift angegeben ||| be included in Braille ||| 2-0 0-1 0-2 1-3 2-3
in Dosierungen von bis zu ||| at doses up to ||| 0-0 1-0 1-1 2-1 3-2 4-2 3-3
in Dosierungen von ||| at doses ||| 0-0 1-0 1-1 2-1
in Durchstechflaschen , Patronen ||| supplied in vials , cartridges ||| 0-0 0-1 1-2 2-3 3-4
in Durchstechflaschen , ||| supplied in vials , ||| 0-0 0-1 1-2 2-3
in Durchstechflaschen ||| supplied in vials ||| 0-0 0-1 1-2
in Flaschen ||| in bottles ||| 0-0 1-1
in Form von weißen , ||| as white , ||| 1-0 3-1 4-2
in Form von weißen ||| as white ||| 1-0 3-1
in Form von ||| as ||| 1-0
in Form ||| as ||| 1-0
in Höhe von ||| of ||| 1-0 2-0
in Kilogramm . ||| in kilograms . ||| 0-0 1-1 2-2
in Kilogramm ||| in kilograms ||| 0-0 1-1
in Kombination mit Alkohol ||| taken in combination with alcohol ||| 1-0 0-1 1-2 2-3 3-4
in Kombination mit Insulin ||| in combination with insulin ||| 0-0 1-1 2-2 3-3
in Kombination mit Insulin ||| used in combination with insulin ||| 1-0 0-1 1-2 2-3 3-4
in Kombination mit Metformin ||| in combination with metformin ||| 0-0 1-1 2-2 3-3
in Kombination mit Sulfonylharnstoffen oder ||| in combination with sulphonylureas or ||| 0-0 1-1 2-2 3-3 4-4
in Kombination mit Sulfonylharnstoffen ||| in combination with sulphonylureas ||| 0-0 1-1 2-2 3-3
in Kombination mit anderen ||| taken in combination with other ||| 1-0 0-1 1-2 2-3 3-4
in Kombination mit ||| in combination with ||| 0-0 1-1 2-2
in Kombination mit ||| taken in combination with ||| 1-0 0-1 1-2 2-3
in Kombination mit ||| used in combination with ||| 1-0 0-1 1-2 2-3
in Kombination ||| in combination ||| 0-0 1-1
in Kombination ||| taken in combination ||| 1-0 0-1 1-2
in Kombination ||| used in combination ||| 1-0 0-1 1-2
in Modul ||| presented in Module ||| 1-0 0-1 1-2
in Mutagenitätstests an Bakterien- und ||| in bacterial and mammalian cell ||| 0-0 1-1 4-2 2-3 3-3 3-4
in Mutagenitätstests ||| in bacterial ||| 0-0 1-1
in PVC-Aluminium perforierten Blistern ||| in PVC-aluminium perforated ||| 0-0 1-1 3-1 2-2
in Prozent angegeben : ||| in Prozent angegeben : Me ||| 0-0 2-0 1-1 1-2 3-3 1-4
in Saccharomyces cerevisiae ) . ||| in Saccharomyces cerevisiae ) . ||| 0-0 1-1 2-2 3-3 4-4
in Saccharomyces cerevisiae ) ||| in Saccharomyces cerevisiae ) ||| 0-0 1-1 2-2 3-3
in Saccharomyces cerevisiae ||| in Saccharomyces cerevisiae ||| 0-0 1-1 2-2
in Saccharomyces ||| in Saccharomyces ||| 0-0 1-1
in Schritten von 2 ||| in increments of 2 ||| 0-0 0-1 1-1 2-2 3-3
in Schritten von ||| in increments of ||| 0-0 0-1 1-1 2-2
in Schritten ||| done in ||| 1-0 0-1
in Schritten ||| in increments ||| 0-0 0-1 1-1
in Situationen , ||| a risk in situations where ||| 0-0 1-1 0-2 1-3 1-4 2-4
in Tabelle 1 aufgeführten Nebenwirkungen ||| effects listed in table 1 ||| 4-0 3-1 0-2 1-3 2-4
in Tabelle 1 aufgeführten ||| listed in table 1 ||| 3-0 0-1 1-2 2-3
in Tabelle 1 ||| in table 1 ||| 0-0 1-1 2-2
in Tabelle 4 dargestellt . ||| presented in Table 4. ||| 3-0 0-1 1-2 2-2 3-2 3-3
in Tabelle 4 dargestellt ||| presented in Table 4. ||| 3-0 0-1 1-2 2-2 3-2 3-3
in Tabelle ||| in table ||| 0-0 1-1
in Untergruppen von 517 ||| in subsets ranging from 517 ||| 0-0 1-1 2-2 2-3 3-4
in Untergruppen von ||| in subsets ranging from ||| 0-0 1-1 2-2 2-3
in Untergruppen ||| in subsets ||| 0-0 1-1
in Verkehr gebracht . ||| be marketed . ||| 0-0 1-0 1-1 2-1 3-2
in Verkehr gebracht . ||| in Verkehr gebracht . Me ||| 0-0 1-1 1-2 2-2 3-3 2-4 3-4
in Verkehr gebracht ||| be marketed ||| 0-0 1-0 1-1 2-1
in Version 3.0 beschriebene und ||| as described in version 3.0 ||| 0-1 0-2 3-2 1-3 2-3 2-4 4-4
in Version 3.0 beschriebene und ||| described in version 3.0 ||| 0-0 0-1 3-1 1-2 2-2 2-3 4-3
in Wasser auflösen und ||| in water and ||| 0-0 1-1 2-1 3-2
in Wasser auflösen ||| in water ||| 0-0 1-1 2-1
in Zusammenhang mit der ersten ||| related to the first ||| 0-0 1-0 2-0 1-1 3-2 4-3
in Zusammenhang mit der ||| related to the ||| 0-0 1-0 2-0 1-1 3-2
in Zusammenhang mit ||| related to ||| 0-0 1-0 2-0 1-1
in Zusammenhang ||| related ||| 0-0 1-0
in allen Fällen ||| in all of whom it ||| 0-0 1-1 2-4
in allen ||| in all of whom ||| 0-0 1-1
in allen ||| in all of ||| 0-0 1-1
in allen ||| in all ||| 0-0 1-1
in beiden Gruppen ||| in both groups ||| 0-0 1-1 2-2
in beiden Gruppen ähnlich ||| similar in both groups ||| 3-0 0-1 1-2 2-3 3-3
in beiden ||| in both ||| 0-0 1-1
in dem ||| uncommon in the ||| 0-0 0-1 1-2
in den Adipozyten ( den ||| found in adipocytes ( ||| 0-0 0-1 1-2 2-2 4-2 3-3
in den Enterozyten kann es ||| the enterocytes may be followed ||| 0-0 1-0 2-1 3-2 4-2 3-3
in den Enterozyten kann es ||| the enterocytes may be ||| 0-0 1-0 2-1 3-2 4-2 3-3
in den Enterozyten ||| the enterocytes ||| 0-0 1-0 2-1
in den Knochen und ||| uptake into bone and ||| 0-0 0-1 1-1 2-2 3-3
in den Knochen ||| uptake into bone ||| 0-0 0-1 1-1 2-2
in den Morbus-Paget-Studien ||| the Paget s disease ||| 1-0 2-1 1-2 2-2 2-3
in den Oberschenkel oder die ||| in the thighs or the ||| 0-0 1-1 1-2 2-2 3-3 4-4
in den Oberschenkel oder ||| in the thighs or ||| 0-0 1-1 1-2 2-2 3-3
in den Oberschenkel ||| in the thighs ||| 0-0 1-1 1-2 2-2
in den Populationen ohne Diabetes ||| of the non-diabetic ||| 0-0 1-1 2-2 3-2 4-2
in den Populationen ohne Diabetes ||| that of the non-diabetic ||| 0-1 1-2 2-3 3-3 4-3
in den Studien gezeigt ? ||| shown during the studies ? ||| 0-0 3-0 4-1 1-2 2-3 3-4 4-4
in den Vergleichsgruppen ( Sulfonylharnstoff ||| comparator groups ( sulphonylurea ||| 2-0 0-1 1-1 2-1 3-2 2-3 4-3
in den Verkehr gebracht . ||| be marketed . ||| 0-0 2-0 1-1 2-1 3-1 4-2
in den Verkehr gebracht ||| be marketed ||| 0-0 2-0 1-1 2-1 3-1
in den einzelnen Studien berichtet ||| reported in the individual studies ||| 4-0 0-1 2-1 1-2 1-3 3-4
in den einzelnen Studien ||| in the individual studies ||| 0-0 2-0 1-1 1-2 3-3
in den einzelnen ||| in the individual ||| 0-0 2-0 1-1 1-2
in den letzten drei Wochen ||| during the 3 weeks ||| 4-0 1-1 2-1 4-2 3-3 4-3
in den letzten ||| the ||| 1-0 2-0
in den systemischen Kreislauf ||| back into the systemic circulation ||| 0-1 1-1 3-1 1-2 2-3 3-3 3-4
in den systemischen Kreislauf ||| into the systemic circulation ||| 0-0 1-0 3-0 1-1 2-2 3-2 3-3
in den ||| in the ||| 0-0 1-1
in den ||| of the ||| 0-0 1-1
in den ||| that of the ||| 0-1 1-2
in den ||| the ||| 0-0 1-0
in den ||| uptake into ||| 0-0 0-1 1-1
in denen Midazolam ( CYP3A4-Substrat ||| in denen Midazolam ( CYP3A4-Substrat ||| 0-0 2-1 2-2 3-3 4-4
in denen Midazolam ( ||| in denen Midazolam ( ||| 0-0 2-1 2-2 3-3
in denen Midazolam ||| in denen Midazolam ||| 0-0 2-1 2-2
in denen ||| in ||| 0-0
in der Anamnese ||| history of ||| 0-0 2-0 1-1
in der Aufrechterhaltung des ||| in maintaining the clinical ||| 0-0 1-1 2-1 3-2 2-3
in der Behandlung ||| in the treatment of ||| 0-0 1-1 2-2 1-3
in der Behandlung ||| in treatment of ||| 0-0 2-1 1-2
in der Galle ||| in the bile ||| 0-0 1-1 2-2
in der HORIZON-PFT-Studie ||| in the HORIZON-PFT ||| 0-0 1-1 2-2
in der Halbwertszeit war auf ||| in half-life was due to ||| 0-0 2-1 3-2 1-3 4-4
in der Halbwertszeit war ||| in half-life was due ||| 0-0 2-1 3-2 1-3
in der Hauptstudie ||| in the main study , ||| 0-0 1-1 2-2 2-3
in der Hauptstudie ||| in the main study ||| 0-0 1-1 2-2 2-3
in der Packung enthalten . ||| included in the carton . ||| 0-0 0-1 1-2 2-3 3-3 4-4
in der Packung enthalten ||| included in the carton ||| 0-0 0-1 1-2 2-3 3-3
in der Pharmakokinetik ||| in the pharmacokinetics of ||| 0-0 1-1 2-2 1-3
in der Placebo-Gruppe . ||| in the placebo group . ||| 0-0 1-1 2-2 2-3 3-4
in der Placebo-Gruppe ||| in the placebo group ||| 0-0 1-1 2-2 2-3
in der Schwangerschaft und ||| in pregnancy and ||| 0-0 2-1 3-2
in der Schwangerschaft ||| in pregnancy ||| 0-0 2-1
in der Stillzeit angewendet werden ||| be administered to breast-feeding women ||| 0-0 1-0 4-0 3-1 3-2 2-3 3-3 2-4 4-4
in der Stillzeit kontraindiziert ( ||| breast-feeding ( ||| 0-0 2-0 3-0 4-1
in der Stillzeit kontraindiziert ||| breast-feeding ||| 0-0 2-0 3-0
in der die Pharmakokinetik ||| the pharmacokinetics ||| 0-0 1-0 2-0 3-1
in der die ||| the ||| 0-0 1-0 2-0
in der hepatischen Metabolisierung mit ||| by hepatic metabolism and ||| 0-0 1-0 2-1 2-2 3-2
in der hepatischen Metabolisierung mit ||| by hepatic metabolism ||| 0-0 1-0 2-1 2-2 3-2
in der hepatischen Metabolisierung ||| by hepatic metabolism and ||| 0-0 1-0 2-1 2-2 3-2
in der hepatischen Metabolisierung ||| by hepatic metabolism ||| 0-0 1-0 2-1 2-2 3-2
in der mit Aclasta behandelten ||| in the Aclasta-treated ||| 0-0 1-1 2-2 3-2 4-2
in der mit Pioglitazon behandelten ||| in the pioglitazone treated ||| 0-0 2-0 1-1 3-2 4-3
in der mit Pioglitazon ||| in the pioglitazone ||| 0-0 2-0 1-1 3-2
in der mit ||| in the ||| 0-0 2-0 1-1
in der randomisierten , ||| in the ||| 0-0 2-0
in der randomisierten , ||| in ||| 0-0 2-0
in der randomisierten ||| in the ||| 0-0 2-0
in der randomisierten ||| in ||| 0-0 2-0
in der ||| by ||| 0-0 1-0
in der ||| in the ||| 0-0 1-1
in der ||| in ||| 0-0
in der ||| in ||| 0-0 1-0
in der ||| included due to the ||| 0-0 1-1 1-2 1-3
in der ||| included in the ||| 0-0 0-1 1-2
in der ||| mentioned in ||| 1-0 0-1 1-1
in der ||| of ||| 0-0 1-0
in der ||| where prophylaxis against ||| 0-0
in der ||| where prophylaxis ||| 0-0
in der ||| where ||| 0-0
in die Muttermilch ausgeschieden wird ||| is excreted in human milk ||| 4-0 2-1 3-1 0-2 1-2 2-3 2-4 4-4
in die Muttermilch ausgeschieden wird ||| is secreted in human milk ||| 4-0 0-1 1-1 2-1 0-2 2-3 2-4 3-4 4-4
in die Muttermilch übergeht ||| excreted into human breast milk ||| 2-0 0-1 1-1 2-1 2-2 2-3 3-3 3-4
in die ||| in ||| 0-0 1-0
in diesen Studien gezeigt ? ||| shown during the studies ? ||| 0-0 1-0 1-1 2-3 3-4 4-4
in diesen Studien ||| shown during the studies ||| 0-0 1-0 1-1 2-3
in diesen ||| shown during the ||| 0-0 1-0 1-1
in diesen ||| shown during ||| 0-0 1-0 1-1
in dieser Altersgruppe ||| in this age group ||| 0-0 1-1 2-2 2-3
in dieser Gebrauchsinformation angegeben sind ||| listed in this leaflet ||| 2-0 3-0 4-0 0-1 1-2 2-3
in dieser Patientengruppe vorliegen . ||| in this patient group . ||| 0-0 1-1 2-1 2-2 3-3 4-4
in dieser Patientengruppe vorliegen ||| in this patient group ||| 0-0 1-1 2-1 2-2 3-3
in dieser Patientengruppe ||| in this patient ||| 0-0 1-1 2-1 2-2
in dieser ||| in this ||| 0-0 1-1
in dreiwöchigem Abstand . ||| every 3 weeks . ||| 1-0 2-1 1-2 3-3
in dreiwöchigem Abstand ||| every 3 weeks ||| 1-0 2-1 1-2
in eine Vene ( ||| into a vein ( ||| 0-0 2-0 1-1 2-2 3-3
in eine Vene ) ||| into a vein ) ||| 0-0 2-0 1-1 2-2 3-3
in eine Vene ||| into a vein ||| 0-0 2-0 1-1 2-2
in eine ||| to ||| 0-0 1-0
in einem Dosisbereich zwischen ||| in a dose range of ||| 0-0 1-1 2-2 1-3 2-3 3-3
in einem Dosisbereich zwischen ||| in a dose range ||| 0-0 1-1 2-2 1-3 2-3 3-3
in einem Fertigpen . ||| in a pre-filled pen . ||| 0-0 1-1 2-2 2-3 3-4
in einem Fertigpen ||| in a pre-filled pen ||| 0-0 1-1 2-2 2-3
in einem autologen Blutspendeprogramm ||| in an autologous predonation programme ||| 0-0 1-1 1-2 2-2 2-3 3-3 3-4
in einem ||| in a ||| 0-0 1-1
in einen Infusionsbeutel gefüllt ||| into an infusion bag ||| 0-0 1-1 2-2 2-3 3-3
in einen ||| into an ||| 0-0 1-1
in einer Blisterpackung . ||| in a blister . ||| 0-0 1-1 2-2 3-3
in einer Blisterpackung ||| in a blister ||| 0-0 1-1 2-2
in einer Fertigspritze . ||| in a pre-filled syringe . ||| 0-0 1-1 2-2 2-3 3-4
in einer Fertigspritze Die ||| in a pre-filled syringe The ||| 0-0 1-1 2-2 2-3 3-4
in einer Fertigspritze Epoetin ||| in a pre-filled syringe Epoetin ||| 0-0 1-1 2-2 2-3 3-4
in einer Fertigspritze ||| in a pre-filled syringe ||| 0-0 1-1 2-2 2-3
in einer Hauptstudie untersucht , ||| studied in one main study ||| 3-0 0-1 1-2 3-2 2-3 2-4
in einer Hauptstudie untersucht ||| studied in one main study ||| 3-0 0-1 1-2 3-2 2-3 2-4
in einer Patrone . ||| in a cartridge . ||| 0-0 1-1 2-2 3-3
in einer Patrone ||| in a cartridge ||| 0-0 1-1 2-2
in einer Population von ||| case in a population of ||| 1-0 0-1 1-2 2-3 3-4
in einer Population ||| case in a population ||| 1-0 0-1 1-2 2-3
in einer dieser Studien ||| in one of these trials ||| 0-0 1-1 1-2 2-3 3-4
in einer dieser ||| in one of these ||| 0-0 1-1 1-2 2-3
in einer großen ||| in a large ||| 0-0 1-1 2-2
in einer kleinen , ||| studied in a small ||| 2-0 0-1 1-2 3-2 2-3
in einer von zwei ||| found in one of two ||| 0-0 0-1 1-2 2-3 3-4
in einer von ||| found in one of ||| 0-0 0-1 1-2 2-3
in einer ||| case in a ||| 1-0 0-1 1-2
in einer ||| found in one ||| 0-0 0-1 1-2
in einer ||| in a ||| 0-0 1-1
in einer ||| in one of ||| 0-0 1-1 1-2
in einigen Fällen ||| in some cases ||| 0-0 1-1 2-2
in einigen ||| in some ||| 0-0 1-1
in erster Linie die Produktion ||| that primarily stimulates red ||| 1-0 0-1 1-1 2-1 3-2 4-2 4-3
in erster Linie ||| that primarily ||| 1-0 0-1 1-1 2-1
in folgendem Diagramm beschrieben ||| described in the following diagram ||| 1-0 0-1 1-2 2-3 1-4 2-4 3-4
in kaltgepressten , perforierten Aluminiumblisterpackungen ||| in cold-formed aluminium perforated ||| 0-0 1-1 3-1 2-2 4-2 4-3
in klinischen Studien , die ||| in clinical trials of ||| 0-0 1-1 2-2 4-3
in klinischen Studien , ||| in clinical trials ||| 0-0 1-1 2-2
in klinischen Studien mit oral ||| in clinical trials with oral ||| 0-0 1-1 2-2 3-3 4-4
in klinischen Studien mit ||| in clinical trials with ||| 0-0 1-1 2-2 3-3
in klinischen Studien wurden gelegentlich ||| in clinical trials , uncommon ||| 0-0 1-1 2-2 3-3 3-4 4-4
in klinischen Studien ||| in clinical trials ||| 0-0 1-1 2-2
in klinischen ||| in clinical ||| 0-0 1-1
in placebokontrollierten Studien ||| did not ||| 0-0
in placebokontrollierten Studien ||| did ||| 0-0
in placebokontrollierten ||| did not ||| 0-0
in placebokontrollierten ||| did ||| 0-0
in regelmäßigen Abständen ||| periodically ||| 0-0 1-0 2-0
in regelmäßigen Abständen überprüft werden ||| achieved and periodically thereafter ||| 0-0 1-0 3-1 1-2 2-2 3-2 3-3 4-3
in regelmäßigen ||| increase in haemoglobin ||| 1-0 0-1 1-2
in regelmäßigen ||| of increase in haemoglobin ||| 1-1 0-2 1-3
in sehr seltenen Fällen ||| in very rare cases ||| 0-0 1-1 2-2 3-3
in sehr seltenen ||| in very rare ||| 0-0 1-1 2-2
in sehr ||| in very ||| 0-0 1-1
in seltenen Fällen ||| in rare cases ||| 0-0 1-1 2-2
in seltenen ||| in rare ||| 0-0 1-1
in späterer Therapie-Linie . ||| second-line therapy . ||| 1-0 2-0 2-1 3-2
in späterer Therapie-Linie ||| second-line therapy ||| 1-0 2-0 2-1
in unmittelbarer Nähe ||| the freezer section or ||| 0-0 0-1 1-1 2-1 2-2 2-3
in unveränderter Form ||| excreted unchanged ||| 0-0 1-0 1-1 2-1
in vitro ( ||| in vitro ( ||| 0-0 1-1 2-2
in vitro . ||| in vitro . ||| 0-0 1-1 2-2
in vitro Befunde mit Zellen ||| in vitro findings ||| 0-0 1-1 2-2 3-2 4-2
in vitro kein Potenzial für ||| did not show potential for ||| 0-0 1-0 2-1 2-2 3-2 3-3 4-3 4-4
in vitro ||| did ||| 0-0 1-0
in vitro ||| in vitro ||| 0-0 0-1 1-1
in vitro ||| in vitro ||| 0-0 1-1
in vitro ||| vitro ||| 0-0 1-0
in vitro-Löslichkeit . ||| in vitro solubility . ||| 0-0 0-1 1-1 1-2 2-3
in vitro-Löslichkeit ||| in vitro solubility ||| 0-0 0-1 1-1 1-2
in vitro-Studien ||| in vitro studies ||| 0-0 1-1 1-2
in vivo scheint gering ||| in vivo appears ||| 0-0 1-1 2-2 3-2
in vivo ||| in vivo ||| 0-0 1-1
in weiteren Indikationen . ||| in other indications . ||| 0-0 2-2 3-3
in weiteren Indikationen ||| in other indications ||| 0-0 2-2
in weiteren ||| in other ||| 0-0
in weiteren ||| in ||| 0-0
in zwei sechsmonatigen Vergleichsstudien ||| in two 6-month comparative trials ||| 0-0 1-1 2-2 3-3 0-4
in ||| , in ||| 0-1
in ||| a ||| 0-0
in ||| are given in the ||| 0-0 0-1 0-2
in ||| are given in ||| 0-0 0-1 0-2
in ||| are ||| 0-0
in ||| as described in ||| 0-1 0-2
in ||| as ||| 0-0
in ||| at ||| 0-0
in ||| described in ||| 0-0 0-1
in ||| did not ||| 0-0
in ||| did ||| 0-0
in ||| found in ||| 0-0 0-1
in ||| given in ||| 0-0 0-1
in ||| in milk ||| 0-0 0-1
in ||| in other ||| 0-0
in ||| in steady ||| 0-0
in ||| in ||| 0-0
in ||| included in ||| 0-0 0-1
in ||| included ||| 0-0
in ||| into ||| 0-0
in ||| of ||| 0-0
in ||| present in ||| 0-0 0-1
in ||| supplied in ||| 0-0 0-1
in ||| that of ||| 0-1
in ||| the ||| 0-0
in ||| uncommon in ||| 0-0 0-1
in ||| where prophylaxis against ||| 0-0
in ||| where prophylaxis ||| 0-0
in ||| where ||| 0-0
in Übereinstimmung mit dem empfohlenen ||| in line with the recommended ||| 0-0 1-1 2-2 3-3 4-4
in Übereinstimmung mit dem ||| in line with the ||| 0-0 1-1 2-2 3-3
in Übereinstimmung mit ||| in line with ||| 0-0 1-1 2-2
in Übereinstimmung ||| in line ||| 0-0 1-1
in-vivo ||| lymphocytes ||| 0-0
indem Sie die ||| by pinching the ||| 0-0 0-1 1-1 2-2
indem Sie ||| by pinching ||| 0-0 0-1 1-1
indem ||| by ||| 0-0
indem ||| six ||| 0-0
individuelle Insulinbedarf liegt ||| individual insulin requirement is ||| 0-0 1-1 1-2 2-2 2-3
individuelle ||| individual ||| 0-0
individuellen klinischen Status ||| basis of individual clinical status ||| 2-0 0-2 1-3 2-4
individuellen klinischen ||| individual clinical ||| 0-0 1-1
individuellen klinischen ||| of individual clinical ||| 0-1 1-2
individuellen ||| individual patient ||| 0-0
individuellen ||| individual ||| 0-0
individuellen ||| of individual ||| 0-1
indiziert für die ||| indicated for the ||| 0-0 1-1 2-2
indiziert für ||| indicated for ||| 0-0 1-1
indiziert ist ||| is indicated ||| 1-0 0-1
indiziert ||| indicated ||| 0-0
induzierte keine Veränderungen von ||| been shown to alter laboratory ||| 0-0 0-1 1-1 1-2 2-3 2-4 3-4
induzierte keine ||| been shown to ||| 0-0 0-1 1-1 1-2
induzierte ||| shown to ||| 0-0
induzierte ||| shown ||| 0-0
infolge des höheren ||| infolge des höheren ||| 0-0 1-1 0-2
infolge des ||| infolge des höheren ||| 0-0 1-1 0-2
infolge ||| consequence ||| 0-0
informieren Sie Ihren Arzt oder ||| inform your doctor or ||| 0-0 1-0 2-1 3-2 4-3
informieren Sie Ihren Arzt oder ||| tell your doctor or ||| 0-0 1-1 2-1 2-2 3-2 4-3
informieren Sie Ihren Arzt ||| inform your doctor ||| 0-0 1-0 2-1 3-2
informieren Sie Ihren Arzt ||| tell your dentist ||| 0-0 1-1 2-1 3-1 2-2
informieren Sie Ihren Arzt ||| tell your doctor ||| 0-0 1-1 2-1 2-2 3-2
informieren Sie Ihren ||| inform your ||| 0-0 1-0 2-1
informieren Sie bitte Ihren Arzt ||| inform your doctor ||| 0-0 1-0 2-0 3-1 4-2
informieren Sie bitte Ihren Arzt ||| please tell your doctor ||| 1-0 2-0 0-1 2-1 3-2 4-3
informieren Sie bitte Ihren ||| inform your ||| 0-0 1-0 2-0 3-1
informieren Sie bitte Ihren ||| please tell your ||| 1-0 2-0 0-1 2-1 3-2
informieren Sie bitte ||| inform ||| 0-0 1-0 2-0
informieren Sie bitte ||| please tell ||| 1-0 2-0 0-1 2-1
informieren Sie bitte ||| tell your ||| 0-0 1-0 2-0 2-1
informieren Sie ||| inform ||| 0-0 1-0
informieren ||| tell ||| 0-0
inhibitorische Potenzial auf CYP2C8 ||| potential for inhibition of CYP2C8 ||| 0-0 1-0 1-1 0-2 2-3 3-4
inhibitorische Potenzial auf ||| potential for inhibition of ||| 0-0 1-0 1-1 0-2 2-3
inhibitorische Potenzial ||| potential for inhibition ||| 0-0 1-0 1-1 0-2
initiale Wirkung zusammen mit einer ||| initial effect together with a ||| 0-0 1-1 0-2 2-2 3-3 4-4
initiale Wirkung zusammen mit ||| initial effect together with ||| 0-0 1-1 0-2 2-2 3-3
initiale Wirkung zusammen ||| initial effect together ||| 0-0 1-1 0-2 2-2
injizierbaren ||| injectable ||| 0-0
injiziert wird , ||| injected ||| 0-0
injiziert wird ||| injected ||| 0-0
injiziert wurde . ||| has been injected . ||| 1-0 1-1 0-2 1-2 2-3
injiziert wurde . ||| is injected . ||| 0-0 0-1 1-1 2-2
injiziert wurde ||| has been injected ||| 1-0 1-1 0-2 1-2
injiziert wurde ||| is injected ||| 0-0 0-1 1-1
injiziert ||| injected ||| 0-0
inklusive PANSS und die Montgomery-Asberg- ||| including PANSS and the Montgomery-Asberg ||| 0-0 0-1 1-1 2-2 3-3 4-4
inklusive PANSS und die ||| including PANSS and the ||| 0-0 0-1 1-1 2-2 3-3
inklusive PANSS und ||| including PANSS and ||| 0-0 0-1 1-1 2-2
inklusive PANSS ||| including PANSS ||| 0-0 0-1 1-1
inklusive kontinuierlicher elektrokardiographischer ||| include continuous electrocardiographic ||| 0-0 0-1 1-1 1-2 2-2
inklusive kontinuierlicher elektrokardiographischer Überwachung ||| include continuous electrocardiographic monitoring ||| 0-0 0-1 1-1 1-2 2-2 3-3
innerhalb der ersten drei ||| occur within the first three ||| 2-0 0-1 1-2 2-3 3-4
innerhalb der ersten drei ||| occurring within the first three ||| 0-0 0-1 1-2 2-3 3-4
innerhalb der ersten ||| occur within the first ||| 2-0 0-1 1-2 2-3
innerhalb der ersten ||| occurring within the first ||| 0-0 0-1 1-2 2-3
innerhalb der ||| occurring within the ||| 0-0 0-1 1-2
innerhalb der ||| within the ||| 0-0 1-1
innerhalb des prämenopausalen Bereichs . ||| within the pre-menopausal range . ||| 0-0 1-1 2-2 3-2 3-3 4-4
innerhalb des prämenopausalen Bereichs ||| within the pre-menopausal range ||| 0-0 1-1 2-2 3-2 3-3
innerhalb des ||| within the ||| 0-0 1-1
innerhalb einer Woche . ||| within a week . ||| 0-0 1-1 2-2 3-3
innerhalb einer Woche ||| within a week ||| 0-0 1-1 2-2
innerhalb einer ||| within a ||| 0-0 1-1
innerhalb eines bestimmten ||| within a ||| 0-0 1-0 2-0 1-1
innerhalb von 3 Monaten verwenden ||| , use within 3 months ||| 1-1 4-1 0-2 2-3 3-4 4-4
innerhalb von 3 Monaten verwenden ||| use within 3 months ||| 1-0 4-0 0-1 2-2 3-3 4-3
innerhalb von 90 Tagen ) ||| within 90 days ) low- ||| 0-0 1-0 2-1 3-2 4-3
innerhalb von 90 Tagen ) ||| within 90 days ) ||| 0-0 1-0 2-1 3-2 4-3
innerhalb von 90 Tagen ||| within 90 days ||| 0-0 1-0 2-1 3-2
innerhalb von 90 ||| within 90 ||| 0-0 1-0 2-1
innerhalb von drei Tagen . ||| away within three days. ||| 0-1 1-1 2-2 3-3 4-3
innerhalb von drei Tagen . ||| within three days. ||| 0-0 1-0 2-1 3-2 4-2
innerhalb von drei ||| away within three ||| 0-1 1-1 2-2
innerhalb von drei ||| within three ||| 0-0 1-0 2-1
innerhalb von zwei Wochen nach ||| within two weeks following ||| 0-0 1-0 2-1 3-2 4-3
innerhalb von zwei Wochen ||| within two weeks ||| 0-0 1-0 2-1 3-2
innerhalb von zwei ||| within two ||| 0-0 1-0 2-1
innerhalb von ||| away within ||| 0-1 1-1
innerhalb von ||| given ||| 0-0 1-0
innerhalb von ||| within ||| 0-0
innerhalb von ||| within ||| 0-0 1-0
innerhalb ||| given ||| 0-0
innerhalb ||| occurring within ||| 0-0 0-1
innerhalb ||| within ||| 0-0
ins ||| part ||| 0-0
insbesondere Infektionen und ||| especially infections and ||| 0-0 1-1 2-2
insbesondere Infektionen ||| especially infections ||| 0-0 1-1
insbesondere auf die einzigartige Zusammensetzung ||| specifically to the unique ||| 2-0 1-1 4-1 2-2 3-2
insbesondere auf die einzigartige Zusammensetzung ||| specifically to the ||| 2-0 1-1 4-1 2-2 3-2
insbesondere bei Patienten ||| especially in patients ||| 0-0 1-1 2-2
insbesondere bei ||| especially in ||| 0-0 1-1
insbesondere der mit ||| especially those ||| 0-0 2-1
insbesondere der ||| especially ||| 0-0
insbesondere im Gesicht ||| especially in the face ||| 0-0 1-1 1-2 1-3 2-3
insbesondere unter ||| particularly ||| 0-0
insbesondere wenn ||| particularly if ||| 0-0 1-1
insbesondere zu Behandlungsbeginn auf ||| at the start of treatment ||| 0-0 1-1 0-2 2-2 3-3
insbesondere zu Behandlungsbeginn auf ||| at the start of ||| 0-0 1-1 0-2 2-2 3-3
insbesondere zu Behandlungsbeginn ||| at the start ||| 0-0 1-1 0-2 2-2
insbesondere ||| especially ||| 0-0
insbesondere ||| particularly ||| 0-0
insbesondere übergewichtigen Patienten ) , ||| particularly overweight patients ) ||| 0-0 1-0 1-1 2-2 3-3
insbesondere übergewichtigen Patienten ) , ||| particularly overweight patients ) ||| 0-0 1-1 2-2 3-3
insbesondere übergewichtigen Patienten ) ||| particularly overweight patients ) ||| 0-0 1-0 1-1 2-2 3-3
insbesondere übergewichtigen Patienten ) ||| particularly overweight patients ) ||| 0-0 1-1 2-2 3-3
insbesondere übergewichtigen Patienten ||| particularly overweight patients ||| 0-0 1-0 1-1 2-2
insbesondere übergewichtigen Patienten ||| particularly overweight patients ||| 0-0 1-1 2-2
insbesondere übergewichtigen ||| particularly overweight ||| 0-0 1-0 1-1
insbesondere übergewichtigen ||| particularly overweight ||| 0-0 1-1
insgesamt 1 900 Patienten verglichen ||| a total of 1,900 patients ||| 0-0 1-0 0-1 2-3 4-3 3-4
insgesamt 1 ||| a total of ||| 0-0 1-0 0-1
insgesamt 1 ||| a total ||| 0-0 1-0 0-1
insgesamt 357 Patienten ||| a total of 357 patients ||| 0-0 0-1 0-2 1-3 2-4
insgesamt 357 ||| a total of 357 ||| 0-0 0-1 0-2 1-3
insgesamt mehr ||| total more ||| 0-0 1-1
insgesamt ||| a total of ||| 0-0 0-1
insgesamt ||| a total of ||| 0-0 0-1 0-2
insgesamt ||| a total ||| 0-0 0-1
insgesamt ||| total ||| 0-0
inter- bzw. intraindividuelle Variation ||| inter- and intra-subject variation for ||| 0-0 1-1 2-2 3-2 3-3
inter- bzw. intraindividuelle Variation ||| inter- and intra-subject variation ||| 0-0 1-1 2-2 3-2 3-3
inter- bzw. ||| inter- and ||| 0-0 1-1
inter- ||| inter- ||| 0-0
interindividuellen Schwankungen . ||| inter-individual variation . ||| 0-0 1-1 2-2
interindividuellen Schwankungen ||| inter-individual variation ||| 0-0 1-1
interindividuellen ||| inter-individual ||| 0-0
intermediär wirkend kombiniert mit ||| intermediate-acting combined with ||| 0-0 1-0 2-1 3-2
intermediär wirkend kombiniert ||| intermediate-acting combined ||| 0-0 1-0 2-1
intermediär wirkend ||| intermediate-acting ||| 0-0 1-0
intestinale Kalzium-Malabsorption ) . ||| intestinal calcium malabsorption ) . ||| 0-0 0-1 1-2 2-3 3-4
intestinale Kalzium-Malabsorption ) ||| intestinal calcium malabsorption ) ||| 0-0 0-1 1-2 2-3
intestinale Kalzium-Malabsorption ||| intestinal calcium malabsorption ||| 0-0 0-1 1-2
intestinale ||| intestinal calcium ||| 0-0 0-1
intraabdominales Fett . ||| intra-abdominal fat . ct ||| 0-0 1-0 0-1 2-2 1-3
intraindividuelle Variation ||| intra-subject variation for ||| 0-0 1-0 1-1
intraindividuelle Variation ||| intra-subject variation ||| 0-0 1-0 1-1
intramuskulär lagen . ||| intramuscular . ||| 0-0 2-1
intramuskulär lagen ||| intramuscular ||| 0-0
intramuskulär ||| intramuscular ||| 0-0
intramuskulär ||| the intramuscular ||| 0-1
intramuskuläre ||| administered intramuscularly ||| 0-0 0-1
intramuskulärer Injektion 90 % größer ||| intramuscular injection was 90 % ||| 0-0 1-0 4-0 1-1 3-2 2-3 3-4
intravenös ) gegeben . ||| intravenously ) . ||| 0-0 2-0 1-1 3-2
intravenös ) gegeben ||| intravenously ) ||| 0-0 2-0 1-1
intravenös angewendet werden ( ||| to be administered intravenously ( ||| 0-0 2-1 0-2 1-2 0-3 2-3 3-4
intravenös angewendet werden ||| to be administered intravenously ||| 0-0 2-1 0-2 1-2 0-3 2-3
intravenös appliziert werden ||| given by the intravenous route ||| 0-0 1-1 1-2 1-3 1-4 2-4
intravenös gegeben werden . ||| to be administered intravenously . ||| 0-0 2-1 1-2 0-3 2-3 3-4
intravenös gegeben werden ||| administered intravenously ||| 1-0 0-1 1-1 2-1
intravenös gegeben werden ||| to be administered intravenously ||| 0-0 2-1 1-2 0-3 2-3
intravenös oder subkutan angewendet werden ||| be administered intravenously or subcutaneously ||| 0-0 2-1 0-2 1-3 2-4 3-4 4-4
intravenös ||| given ||| 0-0
intravenöse Infusion von 5 ||| single intravenous infusion of 5 ||| 0-0 0-1 1-2 2-3 3-4
intravenöse Infusion von ||| single intravenous infusion of ||| 0-0 0-1 1-2 2-3
intravenöse Infusion ||| single intravenous infusion ||| 0-0 0-1 1-2
intravenöse ||| intravenous ||| 0-0
intravenöse ||| single intravenous ||| 0-0 0-1
intravenösen Bolus-Verabreichungen ||| intravenous bolus ||| 0-0 1-1
intravenösen Bolus-Verabreichungen ||| the intravenous bolus ||| 0-1 1-2
intravenösen Infusion von ||| intravenous infusion of ||| 0-0 1-1 2-2
intravenösen Infusion ||| intravenous infusion ||| 0-0 1-1
intravenösen ||| intravenous ||| 0-0
intravenösen ||| the intravenous ||| 0-1
intravenöser Anwendung ||| intravenous ||| 0-0
intravenöser Applikation , ||| the intravenous route , ||| 0-0 0-1 1-2 2-3
intravenöser Applikation . ||| the intravenous route . ||| 0-0 0-1 1-2 2-3
intravenöser Applikation ||| intravenous administration ||| 0-0 1-0 1-1
intravenöser Applikation ||| intravenous route ||| 0-0 1-1
intravenöser Applikation ||| the intravenous route ||| 0-0 0-1 1-2
intravenöser Gabe von Abraxane ||| intravenous administration of Abraxane ||| 0-0 1-1 2-2 3-3
intravenöser Gabe von ||| intravenous administration of ||| 0-0 1-1 2-2
intravenöser Gabe ||| intravenous administration ||| 0-0 1-1
intravenöser ||| intravenous ||| 0-0
intravenöser ||| the intravenous ||| 0-0 0-1
invasiver Dentaleingriff vermieden werden ||| invasive dental procedures if possible ||| 0-0 0-1 2-1 1-2 3-3 3-4
invasiver Dentaleingriff vermieden ||| invasive dental procedures ||| 0-0 0-1 2-1 1-2
irreversible ||| below ||| 0-0
irreversiblen Unfruchtbarkeit ||| infertility ||| 0-0 1-0
is acknowledged . ||| second year . ||| 0-0 1-1 2-2
is acknowledged ||| second year ||| 0-0 1-1
is ||| second ||| 0-0
ischämische Herzerkrankung ||| ischaemic ||| 0-0 1-0
ischämische ||| ischaemic ||| 0-0
isoliert wurde ||| anaemic ||| 0-0 1-0
isoliert wurde ||| of anaemic ||| 0-1 1-1
isotonischer ||| tubing ||| 0-0
ist , sollten ||| should be ||| 2-0 0-1 2-1
ist , wird angenommen ||| , it is ||| 1-0 2-1 0-2 2-2 3-2
ist , ||| , ||| 1-0
ist , ||| is ||| 0-0
ist . Es ||| . It ||| 1-0 0-1 2-1
ist . ||| . ||| 1-0
ist 15 mg einmal ||| is 15 mg once a ||| 0-0 1-1 2-2 3-3 3-4
ist 15 mg ||| is 15 mg ||| 0-0 1-1 2-2
ist 15 ||| is 15 ||| 0-0 1-1
ist 150 Internationale Einheiten ( ||| is 150 International Units ( ||| 0-0 1-1 2-2 3-3 4-4
ist 150 Internationale Einheiten ||| is 150 International Units ||| 0-0 1-1 2-2 3-3
ist 150 Internationale ||| is 150 International ||| 0-0 1-1 2-2
ist 150 ||| is 150 ||| 0-0 1-1
ist 3,3fach höher als die ||| are 3.3-fold higher than those ||| 0-0 1-1 2-2 3-3 3-4 4-4
ist 3,3fach höher ||| are 3.3-fold higher ||| 0-0 1-1 2-2
ist 3,3fach ||| are 3.3-fold ||| 0-0 1-1
ist 5 mg , ||| is 5 mg , ||| 0-0 1-1 2-2 3-3
ist 5 mg ||| is 5 mg ||| 0-0 1-1 2-2
ist 5 ||| is 5 ||| 0-0 1-1
ist 50 Internationale Einheiten ( ||| is 50 International Units ( ||| 0-0 1-1 2-2 3-3 4-4
ist 50 Internationale Einheiten ||| is 50 International Units ||| 0-0 1-1 2-2 3-3
ist 50 Internationale ||| is 50 International ||| 0-0 1-1 2-2
ist 50 ||| is 50 ||| 0-0 1-1
ist 58 % und ||| contributes about 58 % and ||| 0-0 1-0 1-1 1-2 2-3 3-4
ist 58 % ||| contributes about 58 % ||| 0-0 1-0 1-1 1-2 2-3
ist 58 ||| contributes about 58 ||| 0-0 1-0 1-1 1-2
ist 600 Internationale Einheiten ( ||| is 600 International Units ( ||| 0-0 1-1 2-2 3-3 4-4
ist 600 Internationale Einheiten ||| is 600 International Units ||| 0-0 1-1 2-2 3-3
ist 600 Internationale ||| is 600 International ||| 0-0 1-1 2-2
ist 600 ||| is 600 ||| 0-0 1-1
ist ABILIFY und ||| ABILIFY is and ||| 1-0 0-1 2-2
ist ABILIFY ||| ABILIFY is ||| 1-0 0-1
ist Abraxane ||| , Abraxane is ||| 1-1 0-2
ist Abraxane ||| Abraxane is ||| 1-0 0-1
ist Abseamed und ||| Abseamed is and ||| 1-0 0-1 2-2
ist Abseamed ||| Abseamed is ||| 1-0 0-1
ist Aclasta und ||| Aclasta is and ||| 1-0 0-1 2-2
ist Aclasta ||| Aclasta is ||| 1-0 0-1
ist Actos und ||| Actos is and ||| 1-0 0-1 2-2
ist Actos ||| Actos is ||| 1-0 0-1
ist Aripiprazol . ||| is aripiprazole . ||| 0-0 1-1 2-2
ist Aripiprazol ||| is aripiprazole ||| 0-0 1-1
ist Fieber . ||| is fever . ||| 0-0 1-1 2-2
ist Fieber ||| is fever ||| 0-0 1-1
ist Paclitaxel ||| paclitaxel is ||| 1-0 0-1
ist Pioglitazon . ||| is pioglitazone . ||| 0-0 1-1 2-2
ist Pioglitazon ||| is pioglitazone ||| 0-0 1-1
ist Teil ||| is part of ||| 0-0 1-1 1-2
ist Vorsicht ||| Caution is ||| 1-0 0-1
ist angebracht , wenn Aclasta ||| is indicated when Aclasta is ||| 0-0 1-0 0-1 2-2 3-2 4-3 0-4
ist angezeigt zur Unterstützung ||| is indicated as an aid ||| 0-0 1-1 1-2 2-2 3-3 3-4
ist angezeigt zur ||| is indicated as ||| 0-0 1-1 1-2 2-2
ist auch angezeigt für die ||| is also indicated for ||| 0-0 1-1 2-2 3-3 4-3
ist auch angezeigt ||| is also indicated ||| 0-0 1-1 2-2
ist auch ||| is also ||| 0-0 1-1
ist begrenzt . ||| ina ||| 1-0 2-0
ist bei Patienten mit einer ||| ist bei Patienten mit einer ||| 0-0 1-1 2-2 3-3 4-4
ist bei Patienten mit ||| ist bei Patienten mit ||| 0-0 1-1 2-2 3-3
ist bei Patienten ||| ist bei Patienten ||| 0-0 1-1 2-2
ist bei solchen ||| routine volume replacement should ||| 0-0 2-0 1-1 2-1 2-2 2-3
ist bei ||| 4 ||| 0-0 1-0
ist bei ||| ist bei ||| 0-0 1-1
ist bekannt , so dass ||| is well known and ||| 0-0 2-1 1-2 4-2 3-3
ist besonders wichtig , Ihrem ||| is especially important ||| 0-0 1-1 2-2 3-2 4-2
ist besonders wichtig bei Patienten ||| is especially important for patients ||| 0-0 1-1 2-2 3-3 4-4
ist besonders wichtig bei ||| is especially important for the ||| 0-0 1-1 2-2 3-3
ist besonders wichtig bei ||| is especially important for ||| 0-0 1-1 2-2 3-3
ist besonders wichtig bei ||| is especially important in the ||| 0-0 1-1 2-2 3-3
ist besonders wichtig bei ||| is especially important in ||| 0-0 1-1 2-2 3-3
ist besonders wichtig ||| is especially important ||| 0-0 1-1 2-2
ist besonders ||| is especially ||| 0-0 1-1
ist daher eher ein Maß ||| is therefore a measure ||| 0-0 1-1 3-2 2-3 3-3 4-3
ist daher ||| is therefore ||| 0-0 1-1
ist der Packungsbeilage zu entnehmen ||| , see the Package Leaflet ||| 0-0 2-1 1-2 2-3 3-3 4-3 4-4
ist der ||| is available in the ||| 0-0 0-1 1-3
ist der ||| prior ||| 1-0
ist der ||| times ||| 1-0
ist die Behandlung abzusetzen ||| the treatment should be discontinued ||| 1-0 0-1 2-1 3-2 3-3 3-4
ist die Behandlung ||| the treatment ||| 1-0 0-1 2-1
ist die Eliminationshalbwertszeit wegen des ||| ist die Eliminationshalbwertszeit wegen des ||| 0-0 1-1 2-2 2-3 4-4
ist die Eliminationshalbwertszeit wegen ||| ist die Eliminationshalbwertszeit wegen ||| 0-0 1-1 2-2 2-3
ist die Eliminationshalbwertszeit ||| ist die Eliminationshalbwertszeit wegen ||| 0-0 1-1 2-2 2-3
ist die Hypoglykämie im Allgemeinen ||| in general , hypoglycaemia is ||| 3-0 0-1 1-1 3-1 4-1 4-2 2-3 4-4
ist die Therapie abzusetzen . ||| therapy should be discontinued . ||| 0-0 1-0 2-0 3-1 3-2 3-3 4-4
ist die Therapie abzusetzen ||| therapy should be discontinued ||| 0-0 1-0 2-0 3-1 3-2 3-3
ist die Therapie ||| therapy ||| 0-0 1-0 2-0
ist die diätetische Kontrolle . ||| is dietary control . ||| 0-0 1-0 2-1 3-2 4-3
ist die diätetische Kontrolle ||| is dietary control ||| 0-0 1-0 2-1 3-2
ist die diätetische ||| is dietary ||| 0-0 1-0 2-1
ist die ||| is ||| 0-0 1-0
ist die ||| ist die ||| 0-0 1-1
ist dies in Anbetracht ||| this is superfluous ||| 1-0 2-0 0-1 3-2
ist dies in ||| this is ||| 1-0 2-0 0-1
ist durch Symptome ||| by symptoms ||| 1-0 0-1 2-1
ist ein Antimikrotubuli-Wirkstoff ||| is an antimicrotubule agent ||| 0-0 1-1 2-2 2-3
ist ein Arzneimittel , das ||| is a medicine containing ||| 0-0 1-1 2-2 3-3 4-3
ist ein Arzneimittel ||| is a medicine ||| 0-0 1-1 2-2
ist ein Bisphosphonat . ||| is a bisphosphonate . ||| 0-0 1-1 2-2 3-3
ist ein Bisphosphonat ||| is a bisphosphonate ||| 0-0 1-1 2-2
ist ein Cannabinoid-Rezeptor- Antagonist ||| is a cannabinoid receptor antagonist ||| 0-0 1-1 2-2 2-3 3-4
ist ein Cannabinoid-Rezeptor- ||| is a cannabinoid receptor ||| 0-0 1-1 2-2 2-3
ist ein Glykoprotein ||| is a glycoprotein that stimulates ||| 0-0 1-1 1-2 2-2 2-3 2-4
ist ein Inhibitor der Osteoklasten-vermittelten ||| is an inhibitor of osteoclast-mediated ||| 0-0 1-1 2-2 3-3 4-4
ist ein Inhibitor der ||| is an inhibitor of ||| 0-0 1-1 2-2 3-3
ist ein Inhibitor ||| is an inhibitor ||| 0-0 1-1 2-2
ist ein Wachstumsfaktor , der ||| is a growth factor ||| 0-0 1-1 2-2 3-2 2-3 4-3
ist ein beschleunigter ||| is a characteristic ||| 0-0 1-1 2-2
ist ein dosisabhängiger Anstieg des ||| is a dose-dependent increase in ||| 0-0 1-1 2-2 3-2 2-3 4-3 3-4
ist ein neuer LHRH-Agonist , ||| is a new LHRH agonist ||| 0-0 1-1 2-2 3-3 3-4
ist ein neuer LHRH-Agonist ||| is a new LHRH agonist ||| 0-0 1-1 2-2 3-3 3-4
ist ein neuer ||| is a new ||| 0-0 1-1 2-2
ist ein sogenanntes Antipsychotikum . ||| is an antipsychotic medicine . ||| 0-0 1-1 2-2 3-2 2-3 4-4
ist ein sogenanntes Antipsychotikum ||| is an antipsychotic medicine ||| 0-0 1-1 2-2 3-2 2-3
ist ein steriles , aber ||| is a sterile but ||| 0-0 1-1 2-2 3-3 4-3
ist ein steriles ||| is a sterile ||| 0-0 1-1 2-2
ist ein zytotoxisches antikarzinogenes ||| is a cytotoxic anticancer ||| 0-0 1-1 2-2 3-3
ist ein zytotoxisches ||| is a cytotoxic ||| 0-0 1-1 2-2
ist ein ||| is a ||| 0-0 1-1
ist ein ||| is an ||| 0-0 1-1
ist ein ||| ist ein ||| 0-0 1-1
ist eine Albumin-gebundene Nanopartikelformulierung ||| is an albumin-bound nanoparticle formulation ||| 0-0 1-1 2-2 3-3 1-4
ist eine Infusionslösung ||| is a solution for infusion ||| 0-0 1-1 2-2 2-3 2-4
ist eine Krankheit , bei ||| is a disease in which ||| 0-0 1-1 2-2 4-3 3-4
ist eine Krankheit ||| is a disease ||| 0-0 1-1 2-2
ist eine Mischung aus gelöstem ||| is a mixture of dissolved ||| 0-0 1-1 2-2 3-3 3-4 4-4
ist eine Mischung ||| is a mixture ||| 0-0 1-1 2-2
ist eine Reihe von ||| is a range of ||| 0-0 1-1 2-2 3-3
ist eine Reihe ||| is a range ||| 0-0 1-1 2-2
ist eine engmaschige medizinische ||| , close medical ||| 0-1 1-1 2-1 3-1 3-2
ist eine engmaschige medizinische ||| close medical ||| 0-0 1-0 2-0 3-0 3-1
ist eine farblose ||| is a colourless ||| 0-0 1-1 2-2
ist eine intravenöse Infusion ||| is a single intravenous infusion ||| 0-0 1-1 2-2 2-3 3-4
ist eine intravenöse ||| is a single intravenous ||| 0-0 1-1 2-2 2-3
ist eine klare , farblose ||| is a clear , colourless ||| 0-0 1-1 2-2 3-3 4-4
ist eine klare , ||| is a clear , ||| 0-0 1-1 2-2 3-3
ist eine klare und farblose ||| is a clear and colourless ||| 0-0 1-1 2-2 3-3 4-4
ist eine klare und ||| is a clear and ||| 0-0 1-1 2-2 3-3
ist eine klare ||| is a clear ||| 0-0 1-1 2-2
ist eine klare ||| is presented as a clear ||| 0-0 0-1 1-2 1-3 2-4
ist eine langsamere Injektion vorzuziehen ||| treatment with flu-like symptoms ||| 0-0 2-0 2-1 1-2 2-2 3-2 4-2 4-3
ist eine spezifische Behandlung nicht ||| no specific treatment is ||| 0-0 2-1 3-2 0-3 4-3
ist eine ||| is a ||| 0-0 1-1
ist eine ||| is presented as a ||| 0-0 0-1 1-2 1-3
ist eine ||| ist eine ||| 0-0 1-1
ist es ||| it is ||| 1-0 0-1
ist eventuell eine Bluttransfusion zu ||| a blood transfusion may be ||| 0-0 2-0 1-1 1-2 3-2 3-3 4-4
ist eventuell eine Bluttransfusion ||| a blood transfusion may ||| 0-0 2-0 1-1 1-2 3-2 3-3
ist für den Gebrauch ||| is designed to be ||| 0-0 1-1 3-1 2-2 3-3
ist für die ||| is indicated for ||| 0-0 1-1 1-2 2-2
ist gebrauchsfertig . ||| is ready for use . ||| 0-0 1-1 1-2 1-3 2-4
ist gebrauchsfertig . ||| is ready to use . ||| 0-0 1-1 1-2 1-3 2-4
ist gebrauchsfertig ||| is ready for use ||| 0-0 1-1 1-2 1-3
ist gebrauchsfertig ||| is ready to use ||| 0-0 1-1 1-2 1-3
ist gebrauchsfertig ||| is ready ||| 0-0 1-1
ist geringfügig ||| slightly ||| 1-0
ist gezeigt worden . ||| . ||| 2-0 3-0
ist glykosiliert und ||| technology is glycosylated and is ||| 1-0 0-1 1-2 2-3 0-4
ist hoch ( ||| is high ( ||| 0-0 1-1 2-2
ist hoch ||| is high ||| 0-0 1-1
ist in Abschnitt 6.6 beschrieben ||| is described in section 6.6 ||| 0-0 4-1 1-2 2-3 3-4
ist in Durchstechflaschen , ||| is supplied in vials , ||| 0-0 1-1 1-2 2-3 3-4
ist in Durchstechflaschen ||| is supplied in vials ||| 0-0 1-1 1-2 2-3
ist in Form von weißen ||| is available as white ||| 0-0 0-1 2-2 4-3
ist in Form von ||| is available as ||| 0-0 0-1 2-2
ist in Form ||| is available as ||| 0-0 0-1 2-2
ist in den ersten ||| in the first ||| 1-0 0-1 2-1 2-2 3-2
ist in der Stillzeit kontraindiziert ||| breast-feeding ||| 1-0 3-0 4-0
ist in dieser Form gebrauchsfertig ||| is ready for use ||| 0-0 1-0 3-1 4-1 4-2 4-3
ist in dieser ||| is ||| 0-0 1-0
ist in ||| is available ||| 0-0 0-1
ist in ||| is supplied in ||| 0-0 1-1 1-2
ist in ||| is ||| 0-0 1-0
ist indiziert für die ||| is indicated for the ||| 0-0 1-1 2-2 3-3
ist indiziert für ||| is indicated for ||| 0-0 1-1 2-2
ist indiziert ||| is indicated ||| 0-0 1-1
ist kein Substrat für das ||| is not a substrate of ||| 0-0 1-1 0-2 2-3 3-4 4-4
ist kein Substrat ||| is not a substrate ||| 0-0 1-1 0-2 2-3
ist kein ||| is not a ||| 0-0 1-1 0-2
ist keine Anpassung der Dosis ||| ist keine Anpassung der Dosis ||| 0-0 1-1 2-2 2-3 3-3 2-4
ist keine Anpassung der ||| ist keine Anpassung der Dosis ||| 0-0 1-1 2-2 2-3 3-3 2-4
ist keine ||| , the data available are ||| 0-1 1-2 0-3 1-3 1-4
ist keine ||| ist keine ||| 0-0 1-1
ist keine ||| the data available are ||| 0-0 1-1 0-2 1-2 1-3
ist kontraindiziert bei Patienten mit ||| is contraindicated for patients with ||| 0-0 1-1 2-2 3-3 4-4
ist kontraindiziert bei Patienten ||| is contraindicated for patients ||| 0-0 1-1 2-2 3-3
ist kontraindiziert bei ||| is contraindicated for ||| 0-0 1-1 2-2
ist kontraindiziert ||| is contraindicated ||| 0-0 1-1
ist mit ||| ist mit ||| 0-0 1-1
ist möglich . ||| may occur . ||| 1-0 2-2
ist möglich ||| may occur ||| 1-0
ist möglich ||| may ||| 1-0
ist nicht bekannt , ob ||| is not known if ||| 0-0 1-1 2-2 3-3 4-3
ist nicht bekannt , ob ||| is not known whether ||| 0-0 1-1 2-2 3-3 4-3
ist nicht bekannt . ||| is unknown . ||| 0-0 1-1 2-1 3-2
ist nicht bekannt ||| is , therefore , not ||| 0-0 0-1 1-2 1-4 2-4
ist nicht bekannt ||| is not known ||| 0-0 1-1 2-2
ist nicht bekannt ||| is unknown ||| 0-0 1-1 2-1
ist nicht erforderlich ( siehe ||| is required ( see ||| 0-0 1-0 2-1 3-2 4-3
ist nicht erforderlich ( ||| is required ( ||| 0-0 1-0 2-1 3-2
ist nicht erforderlich ||| is required ||| 0-0 1-0 2-1
ist nicht notwendig ||| is necessary ||| 0-0 1-0 2-1
ist nicht ||| is not ||| 0-0 1-1
ist nicht ||| is ||| 0-0 1-0
ist nur auf ärztliche ||| can only be obtained ||| 1-0 0-1 1-1 1-2 2-3 3-3
ist nur auf ärztliche ||| only be obtained with ||| 0-0 1-0 1-1 2-2 3-2 3-3
ist nur ||| can only be ||| 1-0 0-1 1-1 1-2
ist nur ||| only be ||| 0-0 1-0 1-1
ist sehr groß . ||| is very wide . ||| 0-0 1-1 2-2 3-3
ist sehr groß ||| is very wide ||| 0-0 1-1 2-2
ist sehr ||| is very ||| 0-0 1-1
ist typisch für ||| is a characteristic of ||| 0-0 0-1 1-2 2-3
ist typisch ||| is a characteristic ||| 0-0 0-1 1-2
ist unabhängig von der Konzentration ||| is concentration independent ||| 0-0 4-1 1-2
ist unbekannt , doch es ||| is unknown , but it ||| 0-0 1-1 2-2 3-3 4-4
ist unbekannt , doch ||| is unknown , but ||| 0-0 1-1 2-2 3-3
ist unbekannt , ||| is unknown , ||| 0-0 1-1 2-2
ist unbekannt . ||| is unknown . ||| 0-0 1-1 2-2
ist unbekannt ||| is unknown ||| 0-0 1-1
ist unklar , so ||| is unclear and ||| 0-0 1-1 3-1 3-2
ist vergleichbar mit der ||| is similar to ||| 0-0 1-1 3-2
ist vergleichbar mit ||| is similar ||| 0-0 1-1
ist vergleichbar ||| is similar ||| 0-0 1-1
ist vermindert , wenn die ||| skin fold minimises the ||| 1-0 0-1 1-1 1-2 2-2 3-2 4-3
ist vermindert , wenn ||| skin fold minimises ||| 1-0 0-1 1-1 1-2 2-2 3-2
ist weiterhin unbekannt . ||| remains unknown . ||| 1-0 0-1 2-1 3-2
ist weiterhin unbekannt ||| remains unknown ||| 1-0 0-1 2-1
ist weniger häufig . ||| is less common . ||| 0-0 1-1 2-2 3-3
ist weniger häufig ||| is less common ||| 0-0 1-1 2-2
ist weniger ||| is less ||| 0-0 1-1
ist wichtig , dass ||| is important that ||| 0-0 1-1 2-2 3-2
ist wichtig , entsprechend ||| is important to take calcium ||| 0-0 1-1 2-2 3-2 1-3 2-4
ist wichtig ||| is important ||| 0-0 1-1
ist wirksam in ||| is effective in ||| 0-0 1-1 2-2
ist wirksam ||| is effective ||| 0-0 1-1
ist zu ||| be ||| 0-0 1-0
ist ||| , ||| 0-0
ist ||| 25 ||| 0-0
ist ||| After ||| 0-0
ist ||| It ||| 0-0
ist ||| are not known ||| 0-2
ist ||| are ||| 0-0
ist ||| be ||| 0-0
ist ||| is , ||| 0-0 0-1
ist ||| is a ||| 0-0 0-1
ist ||| is available in ||| 0-0 0-1
ist ||| is available ||| 0-0 0-1
ist ||| is presented ||| 0-0 0-1
ist ||| is the ||| 0-0 0-1
ist ||| is ||| 0-0
ist ||| ist ||| 0-0
ist ||| known ||| 0-0
ist ||| not known ||| 0-1
ist ||| of ||| 0-0
itte Patienten ||| patients ||| 1-0
itte ||| . ||| 0-0
itte ||| ct ||| 0-0
itte ||| dic ||| 0-0
jahrelanger ||| years ||| 0-0
je 3 ml . ||| x 3 ml . ||| 0-0 1-1 2-2 3-3
je 3 ml ||| x 3 ml ||| 0-0 1-1 2-2
je 3 ||| x 3 ||| 0-0 1-1
je Quadratmeter Körperfläche ||| per square metre of body ||| 0-0 1-1 2-2 0-3
je Quadratmeter Körperfläche ||| per square metre of ||| 0-0 1-1 2-2 0-3
je Schmelztablette . ||| per orodispersible tablet ||| 0-0 1-1 1-2 2-2
je ml . ||| per ml ||| 0-0 1-1 2-1
je ml 0,2 mg ||| per ml 0.2 mg ||| 0-0 1-1 2-2 3-3
je ml 0,2 ||| per ml 0.2 ||| 0-0 1-1 2-2
je ml 1,8 mg ||| per ml 1.8 mg ||| 0-0 1-1 2-2 3-3
je ml 1,8 ||| per ml 1.8 ||| 0-0 1-1 2-2
je ml 400 mg Sucrose ||| per ml 400 mg sucrose ||| 0-0 1-1 2-2 3-3 4-4
je ml 400 mg ||| per ml 400 mg ||| 0-0 1-1 2-2 3-3
je ml 400 ||| per ml 400 ||| 0-0 1-1 2-2
je ml ||| per ml ||| 0-0 1-1
je ||| per ||| 0-0
je ||| x ||| 0-0
jede Spritze ||| each syringe ||| 0-0 1-0 1-1
jeden Patienten ||| each patient ||| 0-0 1-1
jeden Tag zur gleichen Zeit ||| at the same time ||| 0-0 0-1 1-2 2-2 3-2 4-3
jeden Tag zur gleichen Zeit ||| tablet at the same time ||| 0-0 0-1 0-2 1-3 2-3 3-3 4-4
jeden Tag zur gleichen ||| at the same ||| 0-0 0-1 1-2 2-2 3-2
jeden Tag zur gleichen ||| tablet at the same ||| 0-0 0-1 0-2 1-3 2-3 3-3
jeden ||| at the ||| 0-0 0-1
jeden ||| each ||| 0-0
jeden ||| tablet at the ||| 0-0 0-1 0-2
jeder Dosis ||| , epistaxis , pharyngolaryngeal pain ||| 0-1 0-2 0-3 0-4
jeder Dosis ||| any dose ||| 0-0 1-1
jeder Dosis ||| each dose , ||| 0-0 1-1
jeder Dosis ||| each dose ||| 0-0 1-1
jeder Dosis ||| epistaxis , pharyngolaryngeal pain ||| 0-0 0-1 0-2 0-3
jeder Insulintherapie ||| any insulin therapy , injection ||| 0-0 1-1 1-2 0-3 0-4
jeder ml der Suspension ||| , each ml of suspension ||| 0-1 1-2 2-3 3-4
jeder ml der Suspension ||| each ml of suspension ||| 0-0 1-1 2-2 3-3
jeder ml der ||| , each ml of ||| 0-1 1-2 2-3
jeder ml der ||| each ml of ||| 0-0 1-1 2-2
jeder ml ||| , each ml ||| 0-1 1-2
jeder ml ||| each ml ||| 0-0 1-1
jeder vorliegenden oder vermuteten ||| any confirmed or suspected ||| 0-0 0-1 1-1 3-1 2-2 3-3
jeder vorliegenden oder vermuteten Überdosierung ||| any confirmed or suspected overdose ||| 0-0 0-1 1-1 3-1 2-2 3-3 4-4
jeder ||| , each ||| 0-1
jeder ||| , epistaxis , pharyngolaryngeal pain ||| 0-1 0-2 0-3 0-4
jeder ||| any ||| 0-0
jeder ||| each ||| 0-0
jeder ||| epistaxis , pharyngolaryngeal pain ||| 0-0 0-1 0-2 0-3
jedoch aus ||| but made ||| 0-0 1-1
jedoch eine ||| If ||| 1-0
jedoch ist dies in Anbetracht ||| but this is superfluous ||| 0-0 2-1 3-1 1-2 4-3
jedoch ist dies in ||| but this is ||| 0-0 2-1 3-1 1-2
jedoch keine anderen Bisphosphonate . ||| but not other bisphosphonates . ||| 0-0 1-1 2-2 3-3 4-4
jedoch keine anderen Bisphosphonate ||| but not other bisphosphonates ||| 0-0 1-1 2-2 3-3
jedoch keine anderen ||| but not other ||| 0-0 1-1 2-2
jedoch keine ||| but not ||| 0-0 1-1
jedoch klinisch nicht signifikant ||| but not clinically significant ||| 0-0 2-1 1-2 3-3
jedoch klinisch nicht ||| but not clinically ||| 0-0 2-1 1-2
jedoch nicht ||| did not ||| 0-0 1-1
jedoch ||| , but ||| 0-1
jedoch ||| However , ||| 0-0 0-1
jedoch ||| However ||| 0-0
jedoch ||| but ||| 0-0
jedoch ||| did ||| 0-0
jeglicher Genese . ||| fibrosis of any origin . ||| 0-0 0-1 1-2 1-3 2-4
jeglicher Genese ||| fibrosis of any origin ||| 0-0 0-1 1-2 1-3
jeglicher ||| fibrosis of ||| 0-0 0-1
jeweils 21 ||| , ||| 0-0 1-0
jeweils 39,5 % ( 95 ||| 39.5 % ( 95 ||| 0-0 1-0 2-1 3-2 4-3
jeweils 39,5 % ( ||| 39.5 % ( ||| 0-0 1-0 2-1 3-2
jeweils 39,5 % ||| 39.5 % ||| 0-0 1-0 2-1
jeweils 39,5 ||| 39.5 ||| 0-0 1-0
jeweils ||| , each ||| 0-1
jeweils ||| after ||| 0-0
jeweils ||| each ||| 0-0
jeweils über CYP2C8 ||| by CYP2C8 ||| 1-0 2-1
jeweils über ||| by ||| 1-0
jungen Patienten vergleichbar . ||| young subjects . ||| 0-0 1-0 2-0 0-1 3-2
jungen Patienten vergleichbar ||| young subjects ||| 0-0 1-0 2-0 0-1
jährlich für 3 aufeinander ||| year for 3 consecutive ||| 0-0 1-1 2-2
jährlich für 3 aufeinander ||| year for 3 ||| 0-0 1-1 2-2
jährlich für 3 ||| year for 3 consecutive ||| 0-0 1-1 2-2
jährlich für 3 ||| year for 3 ||| 0-0 1-1 2-2
jährlich für ||| year for ||| 0-0 1-1
jährlich ||| year ||| 0-0
jährliche Verabreichung von Aclasta ||| annual infusion of Aclasta ||| 0-0 3-0 3-1 2-2 1-3 3-3
jährliche ||| September 2005 ||| 0-0 0-1
jährliche ||| in September 2005 ||| 0-1 0-2
jährlichen 5-mg-Dosis ||| annual dose of ||| 0-0 1-0
jährlichen 5-mg-Dosis ||| annual dose ||| 0-0 1-0
jährlichen 5-mg-Dosis ||| annual ||| 0-0 1-0
jüngeren Patienten . Auf Grund ||| young patients . ||| 0-0 1-0 3-0 1-1 4-1 2-2
jüngeren erwachsenen Probanden . ||| younger adult subjects , nor ||| 0-0 1-1 2-2 1-4 3-4
jüngeren ist . ||| younger subjects . ||| 0-0 0-1 2-2
jüngeren ist ||| younger subjects ||| 0-0 0-1
jüngeren ||| younger subjects ||| 0-0 0-1
jüngeren ||| younger ||| 0-0
kaltgepressten , perforierten Aluminiumblisterpackungen ||| cold-formed aluminium perforated ||| 0-0 2-0 1-1 3-1 3-2
kalziumhaltigen Lösungen in ||| allowed to come into ||| 0-0 0-2 1-2 1-3 2-3
kam es ||| was ||| 0-0 1-0
kamen auch bei einzelnen ||| have also occurred in isolated ||| 0-0 1-1 0-2 2-3 3-4
kamen auch bei ||| have also occurred in ||| 0-0 1-1 0-2 2-3
kamen auch ||| have also occurred ||| 0-0 1-1 0-2
kann . ||| . ||| 1-0
kann ABILIFY ||| ABILIFY can ||| 1-0 0-1
kann Abseamed ||| Abseamed can ||| 1-0 0-1
kann Aclasta ||| Aclasta can ||| 1-0 0-1
kann Aclasta ||| Aclasta may ||| 1-0 0-1
kann Ihr Arzt eine ||| , your doctor may consider ||| 1-1 2-1 2-2 0-3 2-4 3-4
kann Ihr Arzt eine ||| your doctor may consider ||| 1-0 2-0 2-1 0-2 2-3 3-3
kann Nebenwirkungen verursachen ||| may cause side effects ||| 0-0 2-1 1-2 1-3
kann abhängig vom ||| may be ||| 0-0 1-0 0-1
kann abhängig ||| may be ||| 0-0 1-0 0-1
kann auch bei einer Änderung ||| may also be necessary ||| 0-0 1-1 2-1 4-2 3-3 4-3
kann auch bei ||| may also ||| 0-0 1-1 2-1
kann auch ||| may also want ||| 0-0 1-1 1-2
kann auftreten . ||| can occur . ||| 0-0 1-1 2-2
kann auftreten ||| can occur ||| 0-0 1-1
kann den Insulinbedarf verringern . ||| may reduce insulin requirement . ||| 0-0 1-1 3-1 2-2 2-3 3-3 4-4
kann den Insulinbedarf verringern ||| may reduce insulin requirement ||| 0-0 1-1 3-1 2-2 2-3 3-3
kann die Blutzucker senkende Wirkung ||| may intensify and prolong the ||| 0-0 1-1 2-1 3-1 3-2 3-3 4-3 4-4
kann die Dosis angepasst werden ||| the dose may be adjusted ||| 1-0 2-1 0-2 4-3 3-4
kann die Dosis ||| the dose may ||| 1-0 2-1 0-2
kann die Konzentrations- und ||| to concentrate and react may ||| 1-0 0-1 1-1 2-1 3-2 2-3 0-4
kann die Wirkung von ||| may increase the effect of ||| 0-0 0-1 1-2 2-3 3-4
kann die Wirkung ||| may increase the effect ||| 0-0 0-1 1-2 2-3
kann die gemeinsame Anwendung ||| may result ||| 0-0 2-1 3-1
kann die ||| may increase the ||| 0-0 0-1 1-2
kann die ||| may ||| 0-0
kann diese ||| it may ||| 1-0 0-1
kann durch ||| may be ||| 0-0 0-1 1-1
kann ein Zusammenhang mit der ||| comparable with the clinical ||| 2-1 3-1 0-2 4-2 1-3
kann ein Zusammenhang mit der ||| with the clinical ||| 2-0 3-0 0-1 4-1 1-2
kann es auch ||| it may also be ||| 1-0 0-1 2-2 2-3
kann es zu Appetitlosigkeit kommen ||| appetite may occur during treatment ||| 3-0 0-1 1-1 1-2 2-2 4-3 4-4
kann es zu Appetitlosigkeit ||| appetite may occur ||| 3-0 0-1 1-1 1-2 2-2
kann es zu ||| may occur ||| 0-0 1-0 1-1 2-1
kann es zur Verringerung des ||| may be followed by ||| 0-0 1-0 0-1 3-3
kann es zur Verringerung ||| may be followed by ||| 0-0 1-0 0-1 3-3
kann es zur ||| may be followed ||| 0-0 1-0 0-1
kann es zur ||| may be ||| 0-0 1-0 0-1
kann es ||| it may ||| 1-0 0-1
kann es ||| may be followed ||| 0-0 1-0 0-1
kann es ||| may be ||| 0-0 1-0 0-1
kann feststellen , inwieweit in ||| can decide whether ||| 0-0 1-1 2-1 3-1 3-2
kann feststellen , inwieweit ||| can decide whether ||| 0-0 1-1 2-1 3-1 3-2
kann in Kombination mit ||| may occur in combination with ||| 0-0 0-1 1-2 2-3 3-4
kann in Kombination ||| may occur in combination ||| 0-0 0-1 1-2 2-3
kann in ||| may occur in ||| 0-0 0-1 1-2
kann mit einem ||| may be associated with an ||| 0-0 0-1 1-2 1-3 2-4
kann mit ||| can be ||| 0-0 0-1 1-1
kann mit ||| can be ||| 0-0 1-0 0-1
kann mit ||| can ||| 0-0 1-0
kann mit ||| may be associated with ||| 0-0 0-1 1-2 1-3
kann nicht ausgeschlossen itte ||| cannot be ruled out . ||| 0-0 1-0 2-0 0-1 2-2 3-2 2-3 3-4
kann nicht ausgeschlossen werden . ||| cannot be excluded . ||| 0-0 1-0 2-0 3-1 2-2 4-3
kann nicht ausgeschlossen werden ||| cannot be excluded ||| 0-0 1-0 2-0 3-1 2-2
kann nicht ausgeschlossen werden. ln ||| increased tactile hyperesthesia were ro ||| 2-1 3-1 3-2 3-3 4-4
kann nicht ausgeschlossen werden. ln ||| tactile hyperesthesia were ro ||| 2-0 3-0 3-1 3-2 4-3
kann nicht ausgeschlossen werden. ||| increased tactile hyperesthesia were ||| 2-1 3-1 3-2 3-3
kann nicht ausgeschlossen werden. ||| tactile hyperesthesia were ||| 2-0 3-0 3-1 3-2
kann notwendig sein , wenn ||| may be necessary when ||| 0-0 2-1 1-2 2-2 3-3 4-3
kann notwendig sein ||| may be necessary ||| 0-0 2-1 1-2 2-2
kann schädlich sein für ||| may be harmful for ||| 0-0 2-1 1-2 2-2 3-3
kann schädlich sein ||| may be harmful ||| 0-0 2-1 1-2 2-2
kann sich als plötzliche ||| can result in sudden and ||| 0-0 1-0 0-1 2-2 3-3
kann sich als plötzliche ||| can result in sudden ||| 0-0 1-0 0-1 2-2 3-3
kann sich als ||| can result in ||| 0-0 1-0 0-1 2-2
kann sich ||| can result ||| 0-0 1-0 0-1
kann stufenweise auf ||| may be ||| 0-0 1-0 0-1 2-1
kann unabhängig von ||| food and drink ||| 0-0 1-0 1-1 1-2 2-2
kann unabhängig von ||| with food and drink ||| 0-1 1-1 1-2 1-3 2-3
kann zu Wirkungen führen , ||| may produce effects that ||| 0-0 1-1 2-1 3-1 2-2 3-3 4-3
kann zur ||| can be translated ||| 0-0 1-0 0-1 1-2
kann zur ||| which can be translated ||| 0-1 1-1 0-2 1-3
kann zusätzlich zu Metformin ||| can be added to metformin ||| 0-0 0-1 1-2 2-2 2-3 3-4
kann zusätzlich zu ||| can be added to ||| 0-0 0-1 1-2 2-2 2-3
kann ||| , may ||| 0-1
kann ||| can be ||| 0-0 0-1
kann ||| can ||| 0-0
kann ||| may be ||| 0-0 0-1
kann ||| may increase ||| 0-0 0-1
kann ||| may occur ||| 0-0 0-1
kann ||| may ||| 0-0
kardiale Ereignisse notwendig . ||| cardiac events . ||| 0-0 1-1 3-2
kardiale Ereignisse notwendig . ||| of cardiac events . ||| 0-1 1-2 3-3
kardiale Ereignisse notwendig ||| cardiac events ||| 0-0 1-1
kardiale Ereignisse notwendig ||| of cardiac events ||| 0-1 1-2
kardiale Ereignisse ||| cardiac events ||| 0-0 1-1
kardiale Ereignisse ||| of cardiac events ||| 0-1 1-2
kardiale ||| cardiac ||| 0-0
kardiale ||| of cardiac ||| 0-1
kardio-respiratorischer Depression führen . ||| cardiorespiratory depression . ||| 0-0 1-0 2-0 1-1 3-2
kardio-respiratorischer Depression führen ||| cardiorespiratory depression ||| 0-0 1-0 2-0 1-1
kardiovaskuläre Outcome-Studie mit Pioglitazon ||| cardiovascular outcome study of pioglitazone ||| 0-0 1-1 1-2 2-2 3-4
kardiovaskuläre Outcome-Studie mit ||| cardiovascular outcome study of ||| 0-0 1-1 1-2 2-2
kardiovaskuläre Outcome-Studie mit ||| cardiovascular outcome study ||| 0-0 1-1 1-2 2-2
kardiovaskuläre ||| cardiovascular ||| 0-0
kardiovaskulären Outcome-Studie , wurden 5238 ||| cardiovascular outcome study , 5238 ||| 0-0 1-1 1-2 3-2 2-3 4-4
kardiovaskulären Outcome-Studie , wurden ||| cardiovascular outcome study , ||| 0-0 1-1 1-2 3-2 2-3
kardiovaskulären Therapie entweder ||| cardiovascular therapy , ||| 0-0 2-0 1-1
kardiovaskulären Therapie entweder ||| cardiovascular therapy ||| 0-0 2-0 1-1
kardiovaskulären ||| cardiovascular ||| 0-0
kein Anstieg der Mortalität ||| increase in mortality from ||| 1-0 1-1 0-2 1-2 3-2 2-3 3-3
kein Eisenmangel vorliegt . ||| are not iron deficient . ||| 2-0 0-1 0-2 1-2 1-3 2-3 3-4
kein Eisenmangel vorliegt ||| are not iron deficient ||| 2-0 0-1 0-2 1-2 1-3 2-3
kein Potenzial für ||| not show potential for ||| 0-0 0-1 1-1 1-2 2-2 2-3
kein Unterschied im ||| no difference in ||| 0-0 1-1 2-1 2-2
kein genotoxisches Potential . ||| vitro genotoxicity assays . ||| 1-0 0-1 2-1 1-2 3-3
kein genotoxisches Potential ||| vitro genotoxicity assays ||| 1-0 0-1 2-1 1-2
kein ||| no ||| 0-0
kein ||| not ||| 0-0
keine Anpassung der Dosis notwendig ||| keine Anpassung der Dosis notwendig ||| 0-0 1-1 1-2 2-2 1-3 4-4
keine Anpassung der Dosis ||| keine Anpassung der Dosis ||| 0-0 1-1 1-2 2-2 1-3
keine Anpassung der ||| keine Anpassung der Dosis ||| 0-0 1-1 1-2 2-2 1-3
keine Auswirkung auf die ||| no effect on the ||| 0-0 1-1 2-2 3-3
keine Auswirkung auf ||| no effect on ||| 0-0 1-1 2-2
keine Auswirkung ||| no effect ||| 0-0 1-1
keine Daten bei Patienten mit ||| no data in ||| 0-0 1-1 2-2 3-2 4-2
keine Daten ||| no data available ||| 0-0 1-1 1-2
keine Daten ||| no data ||| 0-0 1-1
keine Dialyse erhalten ||| receiving dialysis ||| 0-0 2-0 1-1
keine Erfahrungen über akute ||| is no experience of acute ||| 1-0 0-1 1-2 2-2 2-3 3-4
keine Erfahrungen über ||| is no experience of ||| 1-0 0-1 1-2 2-2 2-3
keine Informationen über die ||| no information on the ||| 0-0 1-1 2-1 1-2 3-3
keine Informationen über ||| no information on ||| 0-0 1-1 2-1 1-2
keine Kumulation : die ||| is no accumulation : the ||| 1-0 0-1 1-2 2-3 3-4
keine Kumulation : ||| is no accumulation : ||| 1-0 0-1 1-2 2-3
keine Kumulation ||| is no accumulation ||| 1-0 0-1 1-2
keine Osteomalazie , ||| no osteomalacia , marrow fibrosis ||| 0-0 1-1 2-2 1-3 1-4
keine anderen Bisphosphonate . ||| not other bisphosphonates . ||| 0-0 1-1 2-2 3-3
keine anderen Bisphosphonate ||| not other bisphosphonates ||| 0-0 1-1 2-2
keine anderen ||| not other ||| 0-0 1-1
keine ausreichenden und gut kontrollierten ||| no adequate and well-controlled ||| 0-0 1-1 2-2 3-3 4-3
keine ausreichenden und ||| no adequate and ||| 0-0 1-1 2-2
keine ausreichenden ||| keine ausreichenden Daten am ||| 0-0 1-1 1-2 1-3
keine ausreichenden ||| no adequate ||| 0-0 1-1
keine bekannten Auswirkungen auf die ||| no known effects on the ||| 0-0 1-1 0-2 2-3 3-3 4-4
keine bekannten Auswirkungen auf ||| no known effects on ||| 0-0 1-1 0-2 2-3 3-3
keine bekannten ||| no known effects ||| 0-0 1-1 0-2
keine besonderen Lagerbedingungen ||| require any special storage conditions ||| 0-0 1-0 1-1 1-2 2-3 1-4
keine genaue Häufigkeit ||| no specific frequency can ||| 0-0 1-1 2-2 1-3
keine hinreichenden Daten für die ||| no adequate data on the ||| 0-0 1-1 2-2 2-3 3-4 4-4
keine hinreichenden Daten ||| no adequate data on ||| 0-0 1-1 2-2 2-3
keine hinreichenden und kontrollierten Studien ||| no adequate and well-controlled trials ||| 0-0 1-1 2-2 3-3 4-4
keine hinreichenden und kontrollierten ||| no adequate and well-controlled ||| 0-0 1-1 2-2 3-3
keine hinreichenden und ||| no adequate and ||| 0-0 1-1 2-2
keine hinreichenden ||| no adequate ||| 0-0 1-1
keine klinisch signifikante Veränderung der ||| no clinically significant change in ||| 0-0 1-1 2-2 3-3 4-3 3-4
keine klinisch signifikante ||| no clinically significant ||| 0-0 1-1 2-2
keine klinisch signifikante ||| no clinically ||| 0-0 1-1 2-1
keine klinisch ||| no clinically ||| 0-0 1-1
keine medizinisch bedeutsamen Unterschiede . ||| no medically important differences . ||| 0-0 1-1 2-2 3-3 4-4
keine medizinisch bedeutsamen Unterschiede ||| no medically important differences ||| 0-0 1-1 2-2 3-3
keine medizinisch bedeutsamen ||| no medically important ||| 0-0 1-1 2-2
keine medizinisch ||| no medically ||| 0-0 1-1
keine nennenswerte Affinität zu ||| no appreciable affinity ||| 0-0 1-1 3-1 2-2
keine nennenswerte Affinität ||| no appreciable affinity for ||| 0-0 1-1 2-2 2-3
keine nennenswerte ||| no appreciable ||| 0-0 1-1
keine relevanten ||| no relevant ||| 0-0 1-1
keine sichtbaren Ausfällungen aufweisen . ||| homogenous without visible precipitates . ||| 0-0 1-0 1-1 1-2 2-2 2-3 3-3 4-4
keine sichtbaren Ausfällungen aufweisen ||| homogenous without visible precipitates ||| 0-0 1-0 1-1 1-2 2-2 2-3 3-3
keine signifikante Verbesserung ||| significant improvement in quality ||| 1-0 2-1 2-2 0-3 2-3
keine signifikanten ||| no significant ||| 0-0 1-1
keine spezifische Definition einer Überdosierung ||| insulin cannot be defined ||| 1-0 0-1 1-1 2-1 2-2 3-3 4-3
keine spezifische Definition ||| insulin cannot be ||| 1-0 0-1 1-1 2-1 2-2
keine unerwünschten ||| no adverse ||| 0-0 1-1
keine wirksame Empfängnisverhütung praktizieren ||| not using effective contraception ||| 0-0 1-2 2-3 3-3
keine wirksame ||| not using effective ||| 0-0 1-2
keine ||| , no ||| 0-1
keine ||| No ||| 0-0
keine ||| any ||| 0-0
keine ||| cannot ||| 0-0
keine ||| did not receive ||| 0-1 0-2
keine ||| keine ||| 0-0
keine ||| no information ||| 0-0 0-1
keine ||| no new ||| 0-0
keine ||| no ||| 0-0
keine ||| not receive ||| 0-0 0-1
keine ||| not using ||| 0-0
keine ||| not ||| 0-0
keine ||| of no ||| 0-1
keinen Einfluss auf die ||| no influence on the ||| 0-0 1-1 2-2 3-2 3-3
keinen Einfluss ||| no influence ||| 0-0 1-1
keinen Hinweis auf klinisch signifikante ||| no evidence of clinically significant ||| 0-0 1-1 2-1 3-3 4-4
keinen Hinweis auf klinisch ||| no evidence of clinically ||| 0-0 1-1 2-1 3-3
keinen Hinweis auf ||| no evidence of ||| 0-0 1-1 2-1
keinen Hinweis auf ||| no evidence ||| 0-0 1-1 2-1
keinen relevanten Effekt auf ||| no relevant effect on ||| 0-0 1-1 2-2 3-3
keinen relevanten Effekt ||| no relevant effect ||| 0-0 1-1 2-2
keinen relevanten ||| no relevant ||| 0-0 1-1
keinen signifikanten Effekt auf ||| no significant effect on ||| 0-0 1-1 2-2 3-3
keinen signifikanten Effekt ||| no significant effect ||| 0-0 1-1 2-2
keinen signifikanten ||| no significant ||| 0-0 1-1
keinen ||| did not ||| 0-0 0-1
keinen ||| no ||| 0-0
keiner ||| none ||| 0-0
keinerlei ||| did not ||| 0-0 0-1
kg ) . ||| kg ) . ||| 0-0 1-1 2-2
kg ) ||| kg ) ||| 0-0 1-1
kg , ||| kg over 2 ||| 0-0 0-1 0-2
kg . ||| kg . ||| 0-0 1-1
kg Körpergewicht 120 ml : ||| kg BW 120 ml : ||| 0-0 1-1 2-2 3-3 4-4
kg Körpergewicht 120 ml ||| kg BW 120 ml ||| 0-0 1-1 2-2 3-3
kg Körpergewicht 120 ||| kg BW 120 ||| 0-0 1-1 2-2
kg Körpergewicht 210 ml : ||| kg BW 210 ml : ||| 0-0 1-1 2-2 3-3 4-4
kg Körpergewicht 210 ml ||| kg BW 210 ml ||| 0-0 1-1 2-2 3-3
kg Körpergewicht 210 ||| kg BW 210 ||| 0-0 1-1 2-2
kg Körpergewicht ||| kg BW ||| 0-0 1-1
kg für die ||| kg for the 120 ||| 0-0 1-1 2-2 0-3
kg für die ||| kg for the ||| 0-0 1-1 2-2
kg für ||| kg for ||| 0-0 1-1
kg höhere Erhaltungsdosen ||| kg require higher maintenance doses ||| 0-0 1-1 1-2 2-3 2-4
kg höhere ||| kg require higher ||| 0-0 1-1 1-2
kg und Erwachsene . ||| kg and adults . ||| 0-0 1-1 2-2 3-3
kg und Erwachsene ||| kg and adults ||| 0-0 1-1 2-2
kg und ||| kg and ||| 0-0 1-1
kg ||| kg over 2 years ||| 0-0 0-1 0-2
kg ||| kg over 2 ||| 0-0 0-1 0-2
kg ||| kg ||| 0-0
kg/m² und eine gleichzeitig ||| m² with ||| 0-0 3-1
kg/m² und eine ||| m² ||| 0-0
kg/m² und ||| m² ||| 0-0
kg/m² ||| m² ||| 0-0
kindersicherem Polypropylenverschluss und ||| child resistant polypropylene closure and ||| 0-0 0-1 0-2 0-3 1-3 2-4
kindersicherem Polypropylenverschluss ||| a child resistant polypropylene closure ||| 0-1 0-2 0-3 0-4 1-4
kindersicherem Polypropylenverschluss ||| child resistant polypropylene closure ||| 0-0 0-1 0-2 0-3 1-3
kindersicherem Verschluss aus Polypropylen ||| polypropylene child-resistant closure ||| 0-0 2-0 3-0 0-1 1-1 0-2
klare , farblose , wässrige ||| clear , colourless , aqueous ||| 0-0 1-1 2-2 3-3 4-4
klare , farblose , ||| clear , colourless , ||| 0-0 1-1 2-2 3-3
klare , farblose ||| clear , colourless solution ||| 0-0 1-1 2-2 2-3
klare , farblose ||| clear , colourless ||| 0-0 1-1 2-2
klare , ||| clear , ||| 0-0 1-1
klare und farblose Lösung . ||| clear and colourless solution . ||| 0-0 1-1 2-2 3-3 4-4
klare und farblose Lösung ||| clear and colourless solution ||| 0-0 1-1 2-2 3-3
klare und farblose ||| clear and colourless ||| 0-0 1-1 2-2
klare und ||| clear and ||| 0-0 1-1
klare ||| clear ||| 0-0
kleinen Studie , ||| small study ||| 0-0 1-1
kleinen Studie ||| small study ||| 0-0 1-1
kleinen ||| small ||| 0-0
kleineren Metaboliten ( 3 ||| metabolites , 3 ||| 1-0 3-2
kleineren Metaboliten ( 3 ||| minor metabolites , 3 ||| 1-1 3-3
kleineren Metaboliten ( ||| metabolites , ||| 1-0
kleineren Metaboliten ( ||| metabolites ||| 1-0
kleineren Metaboliten ( ||| minor metabolites , ||| 1-1
kleineren Metaboliten ( ||| minor metabolites ||| 1-1
kleineren Metaboliten ||| metabolites , ||| 1-0
kleineren Metaboliten ||| metabolites ||| 1-0
kleineren Metaboliten ||| minor metabolites , ||| 1-1
kleineren Metaboliten ||| minor metabolites ||| 1-1
kleineren Studie ( ||| study ( 19.5 ||| 1-0 2-1 0-2
kleineren ||| 19.5 ||| 0-0
klinisch angezeigt ist . ||| clinical judgement . ||| 0-0 0-1 1-1 2-1 3-2
klinisch angezeigt ist ||| clinical judgement ||| 0-0 0-1 1-1 2-1
klinisch durch spezifische Interaktionsstudien bestätigt ||| durch spezifische Interaktionsstudien bestätigt ||| 1-0 4-1 4-2 4-3
klinisch durch spezifische Interaktionsstudien ||| durch ||| 1-0
klinisch durch spezifische ||| durch ||| 1-0
klinisch durch ||| durch ||| 1-0
klinisch evidenter ||| clinically evident ischaemic heart ||| 0-0 1-1 1-2 1-3
klinisch nicht signifikant ||| not clinically significant ||| 1-0 0-1 2-2
klinisch nicht ||| not clinically ||| 1-0 0-1
klinisch relevanten Hypokalzämie führt , ||| clinically significant hypocalcaemia , reversal ||| 0-0 1-0 0-1 2-2 4-3 3-4
klinisch relevanten Hypokalzämie ||| clinically significant hypocalcaemia ||| 0-0 1-0 0-1 2-2
klinisch relevanten ||| clinically significant ||| 0-0 1-0 0-1
klinisch signifikante Veränderung der Valproat- ||| clinically important change in valproate ||| 0-0 1-0 4-1 2-2 3-2 2-3 4-4
klinisch signifikante Veränderung der ||| clinically significant change in ||| 0-0 1-1 2-2 3-2 2-3
klinisch signifikante Veränderungen der ||| clinically significant changes ||| 0-0 1-1 2-2 3-2
klinisch signifikante ||| clinically significant ||| 0-0 1-1
klinisch signifikante ||| clinically ||| 0-0 1-0
klinisch signifikante ||| of clinically significant ||| 0-1 1-2
klinisch ||| clinically ||| 0-0
klinisch ||| of clinically ||| 0-1
klinische Faktoren dies rechtfertigen ( ||| clinical factors warrant ( ||| 0-0 1-1 0-2 2-2 3-2 4-3
klinische Faktoren dies rechtfertigen ||| clinical factors warrant ||| 0-0 1-1 0-2 2-2 3-2
klinische Frakturen ||| clinical fractures ||| 0-0 1-1
klinische Relevanz dieser Befunde ||| clinical relevance of these findings ||| 0-0 1-1 2-2 2-3 3-4
klinische Relevanz dieser ||| clinical relevance of these ||| 0-0 1-1 2-2 2-3
klinische Relevanz ||| clinical relevance ||| 0-0 1-1
klinische Studie mit Pioglitazon versus ||| clinical trial of pioglitazone vs. ||| 0-0 1-1 2-2 3-3 4-4
klinische Studie mit Pioglitazon ||| clinical trial of pioglitazone ||| 0-0 1-1 2-2 3-3
klinische Studie mit ||| clinical trial of ||| 0-0 1-1 2-2
klinische Studie ||| clinical trial ||| 0-0 1-1
klinische ||| clinical ||| 0-0
klinische ||| consider clinical ||| 0-0 0-1
klinische Überwachung ||| consider clinical monitoring ||| 0-0 0-1 1-2
klinischen Dosis ||| clinical dose ||| 0-0 1-1
klinischen Effekte von Aripiprazol erklären ||| clinical effects of aripiprazole ||| 0-0 1-1 2-2 3-3 4-3
klinischen Effekte von ||| clinical effects of ||| 0-0 1-1 2-2
klinischen Effekte ||| clinical effects ||| 0-0 1-1
klinischen Exposition vergleichbaren Exposition ||| widened brain ventricles and ||| 1-0 1-2 2-2 3-2
klinischen Exposition vergleichbaren Exposition ||| widened brain ventricles ||| 1-0 1-2 2-2 3-2
klinischen Frakturen Die ||| clinical fractures The incidence ||| 0-0 1-1 2-2 1-3
klinischen Frakturen bei Männern ||| in clinical fractures in men ||| 2-0 0-1 1-2 2-3 3-4
klinischen Frakturen bei ||| in clinical fractures in ||| 2-0 0-1 1-2 2-3
klinischen Frakturen betrug 7,5 % ||| clinical fractures was 7.5 % ||| 0-0 1-1 2-2 3-3 4-4
klinischen Frakturen betrug 7,5 ||| clinical fractures was 7.5 ||| 0-0 1-1 2-2 3-3
klinischen Frakturen betrug ||| clinical fractures was ||| 0-0 1-1 2-2
klinischen Frakturen nach einer ||| clinical fractures following a ||| 0-0 1-1 2-2 3-3
klinischen Frakturen nach ||| clinical fractures following ||| 0-0 1-1 2-2
klinischen Frakturen ||| clinical fractures ||| 0-0 1-1
klinischen Frakturen über die Zeitdauer ||| clinical fractures over the duration ||| 0-0 1-1 2-2 3-3 4-4
klinischen Frakturen über die ||| clinical fractures over the ||| 0-0 1-1 2-2 3-3
klinischen Frakturen über ||| clinical fractures over ||| 0-0 1-1 2-2
klinischen Frakturgruppen sind ||| clinical fracture variables are ||| 0-0 1-1 1-2 2-3
klinischen Frakturgruppen ||| clinical fracture variables ||| 0-0 1-1 1-2
klinischen Pharmakologie ||| clinical pharmacology ||| 0-0 1-1
klinischen Prüfungen nahmen die behandelten ||| clinical trials , treated ||| 0-0 0-1 1-1 2-1 3-2 3-3 4-3
klinischen Prüfungen nahmen ||| clinical trials ||| 0-0 0-1 1-1 2-1
klinischen Prüfungen ||| clinical trials ||| 0-0 0-1 1-1
klinischen Situationen ||| clinical situations ||| 0-0 1-1
klinischen Studie bei Osteoporose wiesen ||| clinical trials in osteoporosis , ||| 0-0 0-1 1-2 2-2 3-3 4-4
klinischen Studie bei Osteoporose ||| clinical trials in osteoporosis ||| 0-0 0-1 1-2 2-2 3-3
klinischen Studie bei ||| clinical trials in ||| 0-0 0-1 1-2 2-2
klinischen Studie mit gesunden ||| clinical trial in healthy ||| 0-0 1-1 2-2 3-2 3-3
klinischen Studie ||| clinical trial ||| 0-0 1-1
klinischen Studien , die ||| clinical trials of ||| 0-0 1-1 3-2
klinischen Studien , in denen ||| clinical trials in which ||| 0-0 1-1 3-2 2-3 4-3
klinischen Studien , ||| clinical trials ||| 0-0 1-1
klinischen Studien bei anderen Indikationen ||| clinical studies for other indications ||| 0-0 1-1 2-2 3-3 4-4
klinischen Studien bei anderen ||| clinical studies for other ||| 0-0 1-1 2-2 3-3
klinischen Studien bei ||| clinical studies for ||| 0-0 1-1 2-2
klinischen Studien beobachtet ||| clinical trials that ||| 0-0 1-1 2-1 2-2
klinischen Studien hat Aripiprazol ||| clinical trials aripiprazole has ||| 0-0 1-1 3-2 2-3
klinischen Studien mit Aripiprazol , ||| clinical trials with aripiprazole , ||| 0-0 1-1 2-2 3-3 4-4
klinischen Studien mit Aripiprazol ||| clinical trials of aripiprazole , ||| 0-0 1-1 2-3 3-3
klinischen Studien mit Aripiprazol ||| clinical trials of aripiprazole ||| 0-0 1-1 2-3 3-3
klinischen Studien mit Aripiprazol ||| clinical trials with aripiprazole ||| 0-0 1-1 2-2 3-3
klinischen Studien mit Pioglitazon ||| clinical trials with pioglitazone ||| 0-0 1-1 2-2 3-3
klinischen Studien mit oral ||| clinical trials with oral ||| 0-0 1-1 2-2 3-3
klinischen Studien mit ||| clinical trials with ||| 0-0 1-1 2-2
klinischen Studien sowie ||| clinical trials and ||| 0-0 1-1 2-1 2-2
klinischen Studien teilnahmen , durchgeführt ||| 57 clinical trials ||| 2-0 4-0 0-1 1-2
klinischen Studien und ||| clinical trials and ||| 0-0 1-1 2-2
klinischen Studien wurde bei Anwendung ||| clinical studies , use ||| 0-0 1-1 2-1 3-3 4-3
klinischen Studien wurde unter ||| clinical studies , ||| 0-0 1-1 2-1
klinischen Studien wurde unter ||| clinical studies ||| 0-0 1-1 2-1
klinischen Studien wurde ||| clinical studies , ||| 0-0 1-1 2-1
klinischen Studien wurde ||| clinical studies ||| 0-0 1-1 2-1
klinischen Studien wurden ein erhöhtes ||| clinical trials , an increased ||| 0-0 1-1 2-1 2-2 3-3 4-4
klinischen Studien wurden ein ||| clinical trials , an ||| 0-0 1-1 2-1 2-2 3-3
klinischen Studien wurden gelegentlich Fälle ||| clinical trials , uncommon cases ||| 0-0 1-1 2-2 2-3 3-3 4-4
klinischen Studien wurden gelegentlich ||| clinical trials , uncommon ||| 0-0 1-1 2-2 2-3 3-3
klinischen Studien wurden seltene Fälle ||| clinical trials , rare cases ||| 0-0 1-1 2-1 2-2 3-3 4-4
klinischen Studien wurden seltene ||| clinical trials , rare ||| 0-0 1-1 2-1 2-2 3-3
klinischen Studien wurden ||| clinical trials , ||| 0-0 1-1 2-1 2-2
klinischen Studien wurden ||| diagnosed ||| 0-0 1-0
klinischen Studien ||| clinical studies , ||| 0-0 1-1
klinischen Studien ||| clinical studies ||| 0-0 1-1
klinischen Studien ||| clinical trials of ||| 0-0 1-1
klinischen Studien ||| clinical trials ||| 0-0 1-1
klinischen Studien ||| diagnosed ||| 0-0 1-0
klinischen Studien über 1 Jahr ||| one year clinical trials ||| 3-0 4-0 2-1 4-1 0-2 1-3
klinischen Studien über ein Jahr ||| one year clinical trials ||| 4-0 2-1 3-1 4-1 0-2 1-3
klinischen Studienbericht : ||| Clinical Study Report : ||| 1-0 0-1 1-1 1-2 2-3
klinischen Studienbericht ||| Clinical Study Report ||| 1-0 0-1 1-1 1-2
klinischen ||| III clinical ||| 0-1
klinischen ||| clinical trials ||| 0-0 0-1
klinischen ||| clinical ||| 0-0
kognitiven Fähigkeiten und ||| cognitive ||| 0-0 1-0
kognitiven Fähigkeiten ||| cognitive ||| 0-0 1-0
kombiniert mit schnell wirkend , ||| combined with fast-acting , ||| 0-0 1-1 2-2 3-2 4-3
kombiniert mit schnell wirkend ||| combined with fast-acting ||| 0-0 1-1 2-2 3-2
kombiniert mit ||| combined with ||| 0-0 1-1
kombiniert ||| combined ||| 0-0
kombinierte ||| combining ||| 0-0
kommen . ||| during treatment . ||| 0-0 0-1 1-2
kommen . ||| used . ||| 0-0 1-1
kommen ||| during treatment ||| 0-0 0-1
kommen ||| epoetin alfa . ||| 0-0 0-1 0-2
kommen ||| used ||| 0-0
kommt , sollte die Haut ||| , the skin should be ||| 1-0 3-1 0-2 4-2 2-3 2-4
kommt , ||| occurs , ||| 0-0 1-1
kommt ||| occurs ||| 0-0
komplette Resuspension des Pulvers erfolgt ||| complete resuspension of any powder ||| 0-0 1-1 2-2 2-3 3-4
komplette Resuspension des Pulvers ||| complete resuspension of any powder ||| 0-0 1-1 2-2 2-3 3-4
komplette Resuspension des ||| complete resuspension of any ||| 0-0 1-1 2-2 2-3
komplette Resuspension ||| complete resuspension ||| 0-0 1-1
komplette ||| complete ||| 0-0
kompletten Standardbatterie von Untersuchungen zur ||| a full range of standard ||| 0-0 0-1 1-2 2-3 3-4 4-4
kompletten Standardbatterie von ||| a full range of ||| 0-0 0-1 1-2 2-3
kompletten Standardbatterie ||| a full range ||| 0-0 0-1 1-2
kompletten Standardbreite von Untersuchungen zur ||| a full range of standard ||| 0-0 0-1 0-2 1-2 2-3 3-4 4-4
kompletten Standardbreite von ||| a full range of ||| 0-0 0-1 0-2 1-2 2-3
kompletten Standardbreite ||| a full range ||| 0-0 0-1 0-2 1-2
kompletten ||| a full ||| 0-0 0-1
konnte das therapeutische Ansprechen bei ||| therapeutic response ||| 2-0 3-1
konnte das therapeutische Ansprechen ||| therapeutic response ||| 2-0 3-1
konnte das therapeutische ||| therapeutic ||| 2-0
konnte ein Kausalzusammenhang jedoch nicht ||| causal relationship has not ||| 0-0 1-0 2-0 2-1 3-1 2-2 4-3
konnte ein Kausalzusammenhang jedoch ||| causal relationship has ||| 0-0 1-0 2-0 2-1 3-1 2-2
konnte ||| could be ||| 0-0 0-1
konnten nicht beobachtet werden . ||| could not be detected . ||| 0-0 1-1 3-2 0-3 2-3 3-3 4-4
konnten nicht beobachtet werden ||| could not be detected ||| 0-0 1-1 3-2 0-3 2-3 3-3
konnten potenzielle ||| could ||| 0-0 1-0
kontaktieren ||| contact ||| 0-0
kontraindiziert bei Patienten mit Hypokalzämie ||| contraindicated for patients with hypocalcaemia ||| 0-0 1-1 2-2 3-3 4-4
kontraindiziert bei Patienten mit ||| contraindicated for patients with ||| 0-0 1-1 2-2 3-3
kontraindiziert bei Patienten ||| contraindicated for patients ||| 0-0 1-1 2-2
kontraindiziert bei ||| contraindicated for ||| 0-0 1-1
kontraindiziert ist , und ||| is contraindicated , ||| 1-0 0-1 2-2
kontraindiziert ist , ||| is contraindicated , ||| 1-0 0-1 2-2
kontraindiziert ist ||| is contraindicated ||| 1-0 0-1
kontraindiziert ||| contraindicated ||| 0-0
kontrollieren . ||| all ||| 0-0
kontrollieren ||| all ||| 0-0
kontrolliert und die ||| be monitored and the ||| 0-0 0-1 1-2 2-3
kontrolliert und ||| be monitored and ||| 0-0 0-1 1-2
kontrolliert werden ||| be monitored ||| 1-0 0-1
kontrolliert ||| be monitored ||| 0-0 0-1
kontrolliert ||| monitored ||| 0-0
kontrollierten , doppelblinden ||| randomised , controlled , ||| 2-0 1-1 0-2 1-3
kontrollierten , ||| , controlled , ||| 1-0 0-1 1-2
kontrollierten , ||| controlled ||| 0-0
kontrollierten Langzeitstudie über 26 Wochen ||| long-term 26-week controlled trial , ||| 0-0 1-0 2-1 3-1 0-2 3-3 4-3
kontrollierten Langzeitstudie über 26 Wochen ||| long-term 26-week controlled trial ||| 0-0 1-0 2-1 3-1 0-2 3-3 4-3
kontrollierten Studien bei ||| Studien bei Schwangeren ||| 1-0 2-1 0-2
kontrollierten Studien mit Aripiprazol bei ||| well-controlled trials of aripiprazole in ||| 0-0 1-1 2-2 3-3 4-4
kontrollierten Studien mit Aripiprazol ||| well-controlled trials of aripiprazole ||| 0-0 1-1 2-2 3-3
kontrollierten Studien mit ||| well-controlled trials of ||| 0-0 1-1 2-2
kontrollierten Studien versus Vergleichsmedikation ||| active comparator controlled trials ||| 2-0 2-1 3-1 0-2 1-3
kontrollierten Studien ||| controlled studies ||| 0-0 1-1
kontrollierten Studien ||| controlled trials ||| 0-0 1-1
kontrollierten Studien ||| well-controlled trials ||| 0-0 1-1
kontrollierten klinischen Studien wurde ||| controlled clinical studies , ||| 0-0 1-1 2-2 3-2
kontrollierten klinischen Studien wurde ||| controlled clinical studies ||| 0-0 1-1 2-2 3-2
kontrollierten klinischen ||| controlled clinical ||| 0-0 1-1
kontrollierten ||| , controlled ||| 0-1
kontrollierten ||| Schwangeren ||| 0-0
kontrollierten ||| controlled ||| 0-0
kontrollierten ||| well-controlled ||| 0-0
konventionelle Paclitaxel enthaltende Arzneimittel . ||| conventional paclitaxel-containing medicines . ||| 0-0 0-1 1-1 2-1 2-2 3-2 4-3
konventionelle Paclitaxel enthaltende Arzneimittel ||| conventional paclitaxel-containing medicines ||| 0-0 0-1 1-1 2-1 2-2 3-2
konventionellen ||| safety data revealed no ||| 0-0 0-1 0-2 0-3
korrigiert nach Dosis , ||| corrected for dose ||| 0-0 2-2
korrigiert nach Dosis ||| corrected for dose ||| 0-0 2-2
korrigiert nach ||| corrected for ||| 0-0
korrigiert nach ||| corrected ||| 0-0
korrigiert ||| corrected for ||| 0-0
korrigiert ||| corrected ||| 0-0
kranialen ||| paresis ||| 0-0
krebshemmender ||| taxanes ||| 0-0
krebshemmender ||| the taxanes ||| 0-1
kräftig in ||| a quick ||| 1-0 0-1
kräftig ||| quick ||| 0-0
kumulative Dosis ||| cumulative dose ||| 0-0 1-1
kumulative Harnausscheidung ||| cumulative ||| 0-0
kumulative ||| cumulative ||| 0-0
kumulativen Toxizität ||| cumulative toxicity ||| 0-0 1-1
kumulativen ||| cumulative ||| 0-0
kurz nach ||| shortly following ||| 0-0 1-1
kurz ||| shortly ||| 0-0
kurzer Zeit auf ||| , insulin requirements ||| 0-1 0-2 1-2 2-2
kurzer Zeit auf ||| insulin requirements ||| 0-0 0-1 1-1 2-1
können ( siehe Abschnitt ||| ( see section ||| 1-0 2-1 3-2
können ( siehe ||| ( see ||| 1-0 2-1
können ( ||| ( ||| 1-0
können . Es kann ||| . It can ||| 1-0 2-1 0-2 3-2
können . ||| . ||| 1-0
können Actos 15 mg Tabletten ||| , Actos 15mg tablets can ||| 0-0 1-1 2-2 3-2 4-3 0-4
können Actos 30 mg Tabletten ||| , Actos 30mg tablets can ||| 0-0 1-1 2-2 3-2 4-3 0-4
können Actos 45 mg Tabletten ||| , Actos 45mg tablets can ||| 0-0 1-1 2-2 3-2 4-3 0-4
können Reaktionen ||| reactions may ||| 1-0 0-1
können abhängig von Alter ||| may vary with age ||| 0-0 1-1 2-1 1-2 3-3
können abhängig von ||| may vary with ||| 0-0 1-1 2-1 1-2
können allergische Reaktionen verursachen ( ||| may cause allergic reactions ( ||| 0-0 3-1 1-2 3-2 2-3 4-4
können allergische Reaktionen verursachen ||| may cause allergic reactions ||| 0-0 3-1 1-2 3-2 2-3
können auch ||| may also ||| 0-0 1-1
können auftreten . ||| may occur . ||| 0-0 1-1 2-2
können auftreten ||| may occur ||| 0-0 1-1
können die ||| may ||| 0-0
können sich schwindelig fühlen , ||| may feel dizzy , ||| 0-0 1-1 3-1 2-2 3-2 4-3
können sich schwindelig fühlen ||| may feel dizzy ||| 0-0 1-1 3-1 2-2 3-2
können ||| can be ||| 0-0 0-1
können ||| can ||| 0-0
können ||| may eat ||| 0-0 0-1
können ||| may have ||| 0-0
können ||| may ||| 0-0
könnte zu schwerwiegenden Komplikationen führen ||| might lead to severe complications ||| 0-0 2-0 1-1 4-1 1-2 2-3 3-4
könnte ||| may ||| 0-0
körpereigenen Insulins herbeiführen . ||| insulin it produces . ||| 1-0 0-1 0-2 1-2 2-2 3-3
körpereigenen Insulins herbeiführen ||| insulin it produces ||| 1-0 0-1 0-2 1-2 2-2
körperliche Bewegung ||| be used in patients ||| 1-1
körperliche Bewegung ||| be used in ||| 1-1
körperliche Bewegung ||| be used ||| 1-1
körperliche Bewegung ||| used in patients ||| 1-0
körperliche Bewegung ||| used in ||| 1-0
körperliche Bewegung ||| used ||| 1-0
körperliche ||| exercise ||| 0-0
körperliche ||| increased exercise ||| 0-1
körperliche ||| they were advised ||| 0-0 0-1 0-2
körperlichen Aktivität , des ||| physical activity , non- smoking ||| 0-0 1-0 1-1 2-2 2-3 3-4
körperlichen Aktivität , ||| physical activity , non- ||| 0-0 1-0 1-1 2-2 2-3
körperlichen Aktivität ||| physical activity ||| 0-0 1-0 1-1
künstlich ( ||| flavour ( including ||| 0-0 1-1 0-2
kürzeres Gesamtüberleben und erhöhte ||| shortened overall survival and increased ||| 0-0 1-1 1-2 2-3 3-4
kürzeres Gesamtüberleben und ||| shortened overall survival and ||| 0-0 1-1 1-2 2-3
kürzeres Gesamtüberleben ||| shortened overall survival ||| 0-0 1-1 1-2
kürzeres ||| shortened ||| 0-0
kürzlich ( innerhalb von 90 ||| recent ( within 90 ||| 0-0 1-1 2-2 3-2 4-3
kürzlich ( innerhalb von ||| recent ( within ||| 0-0 1-1 2-2 3-2
kürzlich ( ||| recent ( ||| 0-0 1-1
kürzlich erlittenen niedrig-traumatischen Hüftfraktur . ||| recent low-trauma hip fracture . ||| 0-0 1-1 2-1 3-2 3-3 4-4
kürzlich erlittenen niedrig-traumatischen Hüftfraktur ||| recent low-trauma hip fracture , ||| 0-0 1-1 2-1 0-2 3-2 1-3
kürzlich erlittenen niedrig-traumatischen Hüftfraktur ||| recent low-trauma hip fracture ||| 0-0 1-1 2-1 0-2 3-2 1-3
kürzlich erlittenen niedrig-traumatischen Hüftfraktur ||| recent low-trauma hip fracture ||| 0-0 1-1 2-1 3-2 3-3
kürzlich erlittenen niedrig-traumatischen ||| recent low-trauma ||| 0-0 1-1 2-1
kürzlich erlittenen ||| recent ||| 0-0 1-0
kürzlich ||| recent ||| 0-0
l/h/m2 . ||| l/ hr/ m2 . ||| 0-0 0-1 0-2 1-3
l/h/m2 ||| l/ hr/ m2 ||| 0-0 0-1 0-2
l/kg . ||| l/ kg . ||| 0-0 0-1 1-2
l/kg ||| l/ kg ||| 0-0 0-1
la Auf ||| The printed ||| 1-0 0-1 1-1
la Auf ||| or The printed ||| 1-1 0-2 1-2
la Depressive Erkrankungen oder ||| or Depressive disorders or ||| 0-0 3-0 1-1 2-2 3-3
la Die vollständige Auflistung der ||| For a full list of ||| 0-0 1-0 2-0 2-1 2-2 3-2 3-3 4-4
la Die vollständige Auflistung ||| For a full list ||| 0-0 1-0 2-0 2-1 2-2 3-2 3-3
la Diese Zusammenfassung wurde zuletzt ||| This summary was last updated ||| 1-0 0-1 2-1 3-2 4-3 4-4
la Diese Zusammenfassung wurde ||| This summary was ||| 1-0 0-1 2-1 3-2
la Diese Zusammenfassung ||| This summary ||| 1-0 0-1 2-1
la Es werden möglicherweise nicht ||| la Es werden möglicherweise nicht ||| 0-0 1-1 2-2 3-3 4-4
la Es werden möglicherweise ||| la Es werden möglicherweise ||| 0-0 1-1 2-2 3-3
la Es werden ||| la Es werden ||| 0-0 1-1 2-2
la Es ||| la Es ||| 0-0 1-1
la Industria 30 28108 Alcobendas ||| la Industria 30 28108 Alcobendas ||| 0-0 1-0 1-1 3-1 2-2 3-3 4-3 4-4
la angewendet ||| d ||| 0-0 1-0
la nicht bekannt ) ||| d ||| 0-0
la nicht bekannt ||| d ||| 0-0
la nicht ||| d ||| 0-0
la ||| d ||| 0-0
la ||| ge ||| 0-0
la ||| la ||| 0-0
lag . ||| . ||| 1-0
lag bei 1,3 % für ||| 1.3 % for ||| 2-0 0-1 3-1 1-2 4-2
lag bei 10 % ( ||| was 10 % ( ||| 0-0 1-0 2-1 3-2 4-3
lag bei 10 % ||| was 10 % ||| 0-0 1-0 2-1 3-2
lag bei 10 ||| was 10 ||| 0-0 1-0 2-1
lag bei ca. 6 Wochen ||| was approximately six weeks ||| 0-0 1-0 2-1 3-2 4-3
lag bei ca. 6 ||| was approximately six ||| 0-0 1-0 2-1 3-2
lag bei ca. ||| was approximately ||| 0-0 1-0 2-1
lag bei ||| was ||| 0-0 1-0
lag ||| was ||| 0-0
lagen , bei 2,3 % ||| in 2.3 % ||| 2-0 3-1 4-2
lagen , bei 2,3 ||| in 2.3 ||| 2-0 3-1
lagen , bei ||| in ||| 2-0
lagen . ||| . ||| 1-0
lagen die ||| the ||| 0-0 1-0
lagern . Für dieses Tierarzneimittel ||| . This veterinary medicinal product ||| 0-0 1-0 2-1 4-2 3-3 4-4
lagern . Für ||| . This ||| 0-0 1-0 2-1
lagern . ||| . ||| 0-0 1-0
lagern . ||| 3 days. ||| 0-0 0-1 1-1
lagern und transportieren ( 2°C ||| and transport refrigerated ( 2°C ||| 1-0 0-1 1-1 2-1 2-2 3-3 4-4
lagern und transportieren ( ||| and transport refrigerated ( ||| 1-0 0-1 1-1 2-1 2-2 3-3
lagern und transportieren ||| and transport refrigerated ||| 1-0 0-1 1-1 2-1 2-2
laktierender ||| and rimonabant may inhibit the ||| 0-1 0-2 0-3
laktierender ||| and rimonabant may inhibit ||| 0-1 0-2 0-3
laktierender ||| rimonabant may inhibit the ||| 0-0 0-1 0-2
laktierender ||| rimonabant may inhibit ||| 0-0 0-1 0-2
lang entweder Actos oder Placebo ||| either Actos or placebo for ||| 1-0 2-1 3-2 4-3 0-4
lang wirkendes Insulin ||| long-acting insulin ||| 0-0 1-0 2-1
lang wirkendes ||| long-acting ||| 0-0 1-0
lang ||| for ||| 0-0
lange Sie ||| long you ||| 0-0 1-1
lange Zeit ||| long time ||| 0-0 1-1
lange ||| long ||| 0-0
langen Knochen ||| long bones ||| 0-0 1-1
langen Wirksamkeit von ||| works for a long time ||| 0-0 1-2 2-2 0-3 2-4
langen ||| long ||| 0-0
langfristige Sicherheit ||| support long-term safety ||| 0-0 1-0 1-1 1-2
langsam und ||| and slowly ||| 1-0 0-1
langsam ||| slowly be ||| 0-0
langsam ||| slowly ||| 0-0
laut Beurteilung des Prüfarztes ||| as assessed by the investigator ||| 0-0 0-1 1-1 2-3 3-4
laut Beurteilung des ||| as assessed by the ||| 0-0 0-1 1-1 2-3
laut Beurteilung ||| as assessed by ||| 0-0 0-1 1-1
laut Beurteilung ||| as assessed ||| 0-0 0-1 1-1
laut Verkaufspackung : ||| as packaged for sale : ||| 0-0 0-1 1-2 1-3 2-4
laut Verkaufspackung ||| as packaged for sale ||| 0-0 0-1 1-2 1-3
laut ||| as packaged ||| 0-0 0-1
leeren , sterilen ||| empty , sterile , ||| 0-0 1-1 2-2 1-3
leeren ||| empty ||| 0-0
legen nahe , dass ||| Limited data suggest ||| 0-0 0-1 1-1 1-2 3-2
leicht appetitdämpfenden Effekt ||| slight appetite decreasing effect ||| 0-0 1-0 1-1 1-2 2-3
leicht appetitdämpfenden ||| slight appetite decreasing ||| 0-0 1-0 1-1 1-2
leicht bis mäßig und ging ||| mild to moderate and resolved ||| 0-0 1-0 2-0 1-1 4-1 2-2 3-3 1-4
leicht bis mäßig und verschwinden ||| mild to moderate and go ||| 0-0 1-0 1-1 2-2 3-3 4-3 4-4
leicht bis mäßig ||| mild to moderate ||| 0-0 1-0 1-1 2-2
leicht bis ||| mild to ||| 0-0 1-0 1-1
leicht eingeschränkte Leberfunktion ||| hepatic impairment does ||| 0-0 2-0 1-1 2-1 2-2
leicht und vorübergehend . ||| mild and transient . ||| 0-0 1-1 2-2 3-3
leicht und vorübergehend ||| mild and transient ||| 0-0 1-1 2-2
leicht und ||| mild and ||| 0-0 1-1
leicht ||| mild and do ||| 0-0 0-2
leicht ||| mild ||| 0-0
leichte ( ||| in mild ( Clcr ||| 0-1 1-2
leichte ( ||| in mild ( ||| 0-1 1-2
leichte ( ||| mild ( Clcr ||| 0-0 1-1
leichte ( ||| mild ( ||| 0-0 1-1
leichte Einschränkung der Nierenfunktion ||| mild renal impairment ||| 0-0 1-1 3-1 3-2
leichte Symptome ||| minor symptoms ||| 0-0 1-1
leichte ||| in mild ||| 0-1
leichte ||| mild ||| 0-0
leichte ||| minor ||| 0-0
leichten oder moderaten Leberproblemen ||| mild or moderate liver problems ||| 0-0 1-1 0-2 3-3 2-4 3-4
leichten oder ||| mild or moderate ||| 0-0 1-1 0-2
leichten ||| normal ||| 0-0
leichter Anämie ||| Mildly anaemic ||| 0-0 1-0 0-1
leichter bis mäßiger ||| mild to moderate ||| 0-0 2-0 1-1 1-2 2-2
leichtes Schmerzmittel wie z.B. ||| mild pain reliever such as ||| 0-0 2-1 1-2 2-3 3-3 2-4
leichtes Schütteln sichergestellt werden . ||| mild agitation before use . ||| 0-0 1-1 1-2 2-2 3-4 4-4
leichtes Schütteln sichergestellt ||| mild agitation before use ||| 0-0 1-1 1-2 2-2
leichtes Schütteln sichergestellt ||| mild agitation before ||| 0-0 1-1 1-2 2-2
leichtes ||| mild ||| 0-0
leiden . ||| disease . ||| 0-0 1-1
leiden ||| disease ||| 0-0
lesen Sie bitte die Packungsbeilage ||| read the Package ||| 0-0 1-0 2-0 3-1 4-2
lesen Sie bitte die ||| read the ||| 0-0 1-0 2-0 3-1
lesen Sie bitte ||| read ||| 0-0 1-0 2-0
lesen Sie ||| lesen Sie bitte ||| 0-0 1-1 0-2
lesen Sie ||| read ||| 0-0 1-0
lesen ||| read ||| 0-0
lesen ||| to read ||| 0-1
letal wirkende ||| non-lethal ||| 0-0 1-0
letzten Tag des Monats ||| last day of that month ||| 0-0 1-1 2-2 3-3 3-4
letzten Tag des ||| last day of ||| 0-0 1-1 2-2
letzten Tag ||| last day ||| 0-0 1-1
letzten Verlängerung : 13 . ||| last renewal : ||| 0-0 1-1 3-1 2-2 4-2
letzten ||| DATE ||| 0-0
letzten ||| last ||| 0-0
liegen . ||| . ||| 1-0
liegen keine ausreichenden ||| are insufficient ||| 0-0 1-0 2-1
liegen keine ausreichenden ||| liegen keine ausreichenden Daten am ||| 0-0 1-1 2-2 2-3 2-4
liegen keine ||| are ||| 0-0 1-0
liegen keine ||| liegen keine ||| 0-0 1-1
liegen nicht vor . ||| not been studied . ||| 0-0 1-0 1-1 1-2 3-3
liegen nicht vor ||| not been studied ||| 0-0 1-0 1-1 1-2
liegen nicht ||| not been studied ||| 0-0 1-0 1-1 1-2
liegen vor . ||| . ||| 2-0
liegen ||| are ||| 0-0
liegen ||| liegen ||| 0-0
liegen überwiegend ||| are extensively ||| 0-0 0-1 1-1
liegt immer deutlich unter ||| is always well below ||| 0-0 0-1 1-1 2-2 3-3
liegt immer deutlich ||| is always well ||| 0-0 0-1 1-1 2-2
liegt immer ||| is always ||| 0-0 0-1 1-1
liegt zwischen 75 und 300 ||| is between 75 and 300 ||| 0-0 0-1 1-1 2-2 3-3 4-4
liegt zwischen 75 und ||| is between 75 and ||| 0-0 0-1 1-1 2-2 3-3
liegt zwischen 75 ||| is between 75 ||| 0-0 0-1 1-1 2-2
liegt zwischen ||| is between ||| 0-0 0-1 1-1
liegt ||| is ||| 0-0
limitierten Anzahl von ||| limited number of ||| 0-0 1-1 2-2
limitierten Anzahl ||| limited number ||| 0-0 1-1
limitierten ||| limited ||| 0-0
linear und dosis-proportional . ||| linear and dose-proportional . ||| 0-0 1-1 2-2 3-3
linear und dosis-proportional ||| linear and dose-proportional ||| 0-0 1-1 2-2
linear und ||| linear and ||| 0-0 1-1
linear von 2653 auf 16736 ||| linearly from 2653 to 16736 ||| 0-0 1-1 2-2 3-3 4-4
linear von 2653 auf ||| linearly from 2653 to ||| 0-0 1-1 2-2 3-3
linear von 2653 ||| linearly from 2653 ||| 0-0 1-1 2-2
linear von ||| linearly from ||| 0-0 1-1
linear ||| linear ||| 0-0
linear ||| linearly ||| 0-0
litten , ||| 805 ||| 0-0
litten und ||| RIO-Diabetes ||| 0-0
litten ||| 805 ||| 0-0
litten ||| RIO-Diabetes ||| 0-0
ln ||| . no ||| 0-0
ln ||| . ||| 0-0
ln ||| ro ||| 0-0
lokale Infektionen einschließlich Osteomyelitis , ||| local infection including osteomyelitis , ||| 0-0 1-1 2-2 3-3 4-4
lokale Infektionen einschließlich Osteomyelitis ||| local infection including osteomyelitis ||| 0-0 1-1 2-2 3-3
lokale Infektionen einschließlich ||| local infection including ||| 0-0 1-1 2-2
lokale Infektionen ||| local infection ||| 0-0 1-1
lokale Sicherheit von Vantas wurde ||| local safety of Vantas is ||| 0-0 1-1 2-2 3-3
lokale Sicherheit von Vantas wurde ||| local safety of Vantas ||| 0-0 1-1 2-2 3-3
lokale Sicherheit von Vantas ||| local safety of Vantas is ||| 0-0 1-1 2-2 3-3
lokale Sicherheit von Vantas ||| local safety of Vantas ||| 0-0 1-1 2-2 3-3
lokale Sicherheit von ||| local safety of ||| 0-0 1-1 2-2
lokale Sicherheit ||| local safety ||| 0-0 1-1
lokale ||| local ||| 0-0
lokalen ) ||| local ) ||| 0-0 1-1
lokalen ||| local ||| 0-0
lutea sowie ein verminderter eim ||| ina ||| 0-0 3-0 4-0
lutea ||| 60 ||| 0-0
lyophilisiertes ||| supplied ||| 0-0
lä ||| 2. ||| 0-0
länger als ein Jahr wirken ||| for longer than one year ||| 0-0 0-1 1-2 2-3 3-3 3-4
länger als ein Jahr ||| for longer than one year ||| 0-0 0-1 1-2 2-3 3-3 3-4
länger als ||| for longer than ||| 0-0 0-1 1-2
länger an . ||| more . ||| 0-0 1-0 2-1
länger an ||| more ||| 0-0 1-0
länger anhaltenden Wirkung gewünscht wird ||| more long-lasting effect is needed ||| 0-0 1-1 1-2 2-2 3-2 4-3 4-4
länger anhaltenden Wirkung gewünscht wird ||| more prolonged effect is desired ||| 0-0 0-1 1-1 3-1 2-2 4-3 3-4
länger anhaltenden Wirkung gewünscht ||| more long-lasting effect ||| 0-0 1-1 1-2 2-2 3-2
länger benötigen . ||| longer . ||| 0-0 1-0 2-1
länger benötigen ||| longer ||| 0-0 1-0
länger ||| for longer ||| 0-0 0-1
länger ||| more ||| 0-0
länger ||| prolonged ||| 0-0
längeren ||| longer ||| 0-0
lösliches Insulin 10 % und ||| soluble insulin 10 % and ||| 0-0 1-1 2-2 3-3 4-4
lösliches Insulin 10 % ||| soluble insulin 10 % ||| 0-0 1-1 2-2 3-3
lösliches Insulin 10 ||| soluble insulin 10 ||| 0-0 1-1 2-2
lösliches Insulin 20 % und ||| soluble insulin 20 % and ||| 0-0 1-1 2-2 3-3 4-4
lösliches Insulin 20 % ||| soluble insulin 20 % ||| 0-0 1-1 2-2 3-3
lösliches Insulin 20 ||| soluble insulin 20 ||| 0-0 1-1 2-2
lösliches Insulin 30 % und ||| soluble insulin 30 % and ||| 0-0 1-1 2-2 3-3 4-4
lösliches Insulin 30 % ||| soluble insulin 30 % ||| 0-0 1-1 2-2 3-3
lösliches Insulin 30 ||| soluble insulin 30 ||| 0-0 1-1 2-2
lösliches Insulin 40 % und ||| soluble insulin 40 % and ||| 0-0 1-1 2-2 3-3 4-4
lösliches Insulin 40 % ||| soluble insulin 40 % ||| 0-0 1-1 2-2 3-3
lösliches Insulin 40 ||| soluble insulin 40 ||| 0-0 1-1 2-2
lösliches Insulin 50 % und ||| soluble insulin 50 % and ||| 0-0 1-1 2-2 3-3 4-4
lösliches Insulin 50 % ||| soluble insulin 50 % ||| 0-0 1-1 2-2 3-3
lösliches Insulin 50 ||| soluble insulin 50 ||| 0-0 1-1 2-2
lösliches Insulin ||| soluble insulin ||| 0-0 1-1
lösliches ||| soluble ||| 0-0
lösungsmittelhaltigem Paclitaxel ||| solvent-based paclitaxel ||| 0-0 1-1
lösungsmittelhaltigem ||| solvent-based ||| 0-0
lösungsmittelhaltigen Paclitaxel-Injektion ||| solvent-based ||| 0-0 1-0
macht ) ||| ) ||| 1-0
macht . ||| . ||| 1-0
machten für gewöhnlich keinen ||| usually did not require ||| 2-0 0-1 1-1 3-1 3-2 0-3
mail@emea.europa.eu http://www.emea.europa.eu ||| emea . europa . eu ||| 1-0 0-1 0-2 0-3 0-4
mail@emea.europa.eu ||| . europa . eu ||| 0-0 0-1 0-2 0-3
man mit Ihnen ||| receive appropriate training for you ||| 0-0 0-1 0-2 2-4
man mit ||| receive appropriate training for ||| 0-0 0-1 0-2
man mit ||| receive appropriate training ||| 0-0 0-1 0-2
man ||| When ||| 0-0
man ||| receive appropriate training for ||| 0-0 0-1 0-2
man ||| receive appropriate training ||| 0-0 0-1 0-2
manchmal starker Reizbarkeit . ||| sometimes severe irritability . ||| 0-0 1-1 1-2 2-2 3-3
manchmal starker Reizbarkeit ||| sometimes severe irritability ||| 0-0 1-1 1-2 2-2
manchmal ||| sometimes ||| 0-0
manische Episoden ( ||| manic episodes ( ||| 0-0 1-1 2-2
manische Episoden ||| manic episodes ||| 0-0 1-1
manische Symptome ||| manic symptoms ||| 0-0 1-1
manische ||| manic ||| 0-0
manischen Episode bei Patienten angezeigt ||| manic episode in patients ||| 0-0 1-1 4-1 2-2 3-3
manischen Episoden der ||| manic episodes ||| 0-0 1-1
manischen Episoden ||| manic episodes in ||| 0-0 1-1
manischen Episoden ||| manic episodes ||| 0-0 1-1
manischen oder gemischten Episode der ||| manic or mixed episode of ||| 0-0 1-1 2-2 2-3 3-3 4-4
manischen oder gemischten Episode einer ||| manic or mixed episode of ||| 0-0 1-1 2-2 2-3 3-3 4-3
manischen oder gemischten Episode einer ||| manic or mixed episode ||| 0-0 1-1 2-2 2-3 3-3 4-3
manischen oder gemischten Episode ||| manic or mixed episode of ||| 0-0 1-1 2-2 2-3 3-3
manischen oder gemischten Episode ||| manic or mixed episode ||| 0-0 1-1 2-2 2-3 3-3
manischen oder ||| manic or ||| 0-0 1-1
manischen ||| manic ||| 0-0
manischer Episoden bei Patienten ||| manic episodes in patients ||| 0-0 1-1 2-1 2-2 3-3
manischer Episoden bei ||| manic episodes in ||| 0-0 1-1 2-1 2-2
manischer Episoden und ||| manic episodes and ||| 0-0 1-1 2-2
manischer Episoden ||| manic episodes ||| 0-0 1-1
manischer Symptome ||| manic symptoms ||| 0-0 1-1
manischer Symptome über 3 Wochen ||| manic symptoms over 3 weeks ||| 0-0 1-1 2-2 3-3 4-4
manischer Symptome über 3 ||| manic symptoms over 3 ||| 0-0 1-1 2-2 3-3
manischer Symptome über ||| manic symptoms over ||| 0-0 1-1 2-2
manischer ||| being placed ||| 0-0 0-1
manischer ||| by being placed ||| 0-1 0-2
manischer ||| manic ||| 0-0
maternale Gewichtszunahme zurückzuführen ist . ||| maternal body weight gain . ||| 0-0 2-0 0-1 1-2 1-3 3-3 4-4
maternale Gewichtszunahme zurückzuführen ist ||| maternal body weight gain ||| 0-0 2-0 0-1 1-2 1-3 3-3
maternaler ||| maternal ||| 0-0
maximal 30 mg ( ||| maximum of 30 mg ( ||| 0-0 1-2 2-3 3-4
maximal 30 mg ||| maximum of 30 mg ||| 0-0 1-2 2-3
maximal 30 ||| maximum of 30 ||| 0-0 1-2
maximal ||| maximum of ||| 0-0
maximal ||| maximum ||| 0-0
maximale Dosis sollte ||| maximum dose should ||| 0-0 1-1 2-2
maximale Dosis ||| maximum dose ||| 0-0 1-1
maximale Plasmaspiegel ||| peak plasma ||| 0-0 1-0 1-1
maximale Tagesdosis sollte ||| maximum daily dose should ||| 0-0 1-1 1-2 2-3
maximale Tagesdosis ||| maximum daily dose ||| 0-0 1-1 1-2
maximale ||| maximale Tagesdosis ||| 0-0 0-1
maximale ||| maximum concentration ||| 0-0 0-1
maximale ||| maximum ||| 0-0
mediane Zeit bis zum ||| median time to ||| 0-0 2-0 1-1 3-1 2-2
mediane ||| median ||| 0-0
medizinisch bedeutsamen Unterschiede . ||| medically important differences . ||| 0-0 1-1 2-2 3-3
medizinisch bedeutsamen Unterschiede ||| medically important differences ||| 0-0 1-1 2-2
medizinisch bedeutsamen ||| medically important ||| 0-0 1-1
medizinisch ernsten Anzeichen und ||| medically serious signs and ||| 0-0 1-0 1-1 2-2 3-3
medizinisch ernsten Anzeichen ||| medically serious signs ||| 0-0 1-0 1-1 2-2
medizinisch ernsten ||| medically serious ||| 0-0 1-0 1-1
medizinisch relevante Zeichen und Symptome ||| medically important signs and symptoms ||| 0-0 1-0 2-1 2-2 3-3 4-4
medizinisch relevante Zeichen und ||| medically important signs and ||| 0-0 1-0 2-1 2-2 3-3
medizinisch relevante Zeichen ||| medically important signs ||| 0-0 1-0 2-1 2-2
medizinisch relevante ||| medically ||| 0-0 1-0
medizinisch ||| medically ||| 0-0
medizinische Fachpersonal in ||| healthcare professionals in ||| 1-0 0-1 1-1 2-2
medizinische Fachpersonal ||| healthcare professionals ||| 1-0 0-1 1-1
medizinischem Fachpersonal gegeben . ||| injected by medical staff . ||| 0-0 0-1 1-2 2-2 1-3 3-4
medizinischem Fachpersonal gegeben ||| injected by medical staff ||| 0-0 0-1 1-2 2-2 1-3
medizinischem ||| injected by ||| 0-0 0-1
medizinischen Praxis erfolgen . ||| medical practice . ||| 0-0 1-1 2-1 3-2
medizinischen Praxis erfolgen ||| medical practice ||| 0-0 1-1 2-1
medizinischen ||| medical ||| 0-0
mehr ABILIFY Lösung zum Einnehmen ||| more ABILIFY oral solution ||| 0-0 1-1 3-2 4-2 2-3
mehr ABILIFY Schmelztabletten ||| more ABILIFY orodispersible tablets ||| 0-0 1-1 2-2 2-3
mehr ABILIFY Tabletten ||| more ABILIFY tablets ||| 0-0 1-1 2-2
mehr ABILIFY ||| given more ABILIFY ||| 0-0 0-1 1-2
mehr ABILIFY ||| more ABILIFY ||| 0-0 1-1
mehr Einheiten ||| more units of ||| 0-0 1-1
mehr Einheiten ||| more units ||| 0-0 1-1
mehr Todesfälle berichtet ||| been reported while taking ||| 2-0 2-1 0-2 1-2 1-3
mehr Todesfälle ||| while taking ||| 0-0 1-0 1-1
mehr Wochen nach der ||| more weeks after your ||| 0-0 1-1 2-2 3-2
mehr Wochen nach der ||| more weeks after ||| 0-0 1-1 2-2
mehr Wochen nach der ||| more weeks after ||| 0-0 1-1 2-2 3-2
mehr Wochen nach ||| more weeks after ||| 0-0 1-1 2-2
mehr Wochen ||| more weeks ||| 0-0 1-1
mehr als 1 von ||| more than 1 ||| 0-0 1-1 3-1 2-2
mehr als 1 ||| more than 1 patient ||| 0-0 1-1 2-2
mehr als 1 ||| more than 1 ||| 0-0 1-1 2-2
mehr als 2 g/dl ||| greater than 2 g/ dl ||| 0-0 1-1 2-2 3-3 3-4
mehr als 2 g/dl ||| more than 2 g/ dl ||| 0-0 1-1 2-2 3-3 3-4
mehr als 2 ||| greater than 2 ||| 0-0 1-1 2-2
mehr als 2 ||| more than 2 ||| 0-0 1-1 2-2
mehr als 3 Metastasestellen . ||| 3 sites of metastases . ||| 2-0 3-3 4-4
mehr als 3 Metastasestellen ||| 3 sites of metastases ||| 2-0 3-3
mehr als 3 ||| 3 sites of ||| 2-0
mehr als 3 ||| 3 sites ||| 2-0
mehr als 3 ||| 3 ||| 2-0
mehr als 30 % der ||| more than 30 % of ||| 0-0 1-1 2-2 3-3 4-4
mehr als 30 % ||| more than 30 % ||| 0-0 1-1 2-2 3-3
mehr als 30 ||| more than 30 ||| 0-0 1-1 2-2
mehr als ||| greater than ||| 0-0 1-1
mehr als ||| more than ||| 0-0 1-1
mehr körperliche ||| exercise ||| 1-0
mehr körperliche ||| increased exercise ||| 1-1
mehr von 100 Patienten betroffen ||| more in every 100 patients ||| 0-0 1-0 3-1 4-2 2-3 3-4
mehr von ||| more ||| 0-0 1-0
mehr ||| given more ||| 0-0 0-1
mehr ||| greater ||| 0-0
mehr ||| has stopped ||| 0-1
mehr ||| more ||| 0-0
mehr ||| stopped ||| 0-0
mehrere Zeitzonen gehen ||| different time zones ||| 1-0 1-1 0-2 1-2 2-2
mehrere ||| in 3.2 ||| 0-0 0-1
mehreren kontrollierten Studien ||| several controlled studies ||| 0-0 1-1 2-2
mehreren kontrollierten ||| several controlled ||| 0-0 1-1
mehreren ||| several ||| 0-0
mehrfacher ||| accumulation ||| 0-0
meiden , wenn Sie ABILIFY ||| be avoided when taking ABILIFY ||| 0-0 0-1 1-1 2-2 0-3 3-3 4-4
meiden , wenn Sie ||| be avoided when taking ||| 0-0 0-1 1-1 2-2 0-3 3-3
meiden , wenn ||| be avoided when ||| 0-0 0-1 1-1 2-2
meiden , ||| be avoided ||| 0-0 0-1 1-1
meist ||| usually ||| 0-0
meisten Nebenwirkungen von Aclasta ||| Most side effects with Aclasta ||| 0-0 1-1 1-2 2-3 3-4
meisten Nebenwirkungen von ||| Most side effects with ||| 0-0 1-1 1-2 2-3
meisten Nebenwirkungen ||| Most side effects ||| 0-0 1-1 1-2
meisten ||| Most ||| 0-0
meisten ||| most of ||| 0-0
meisten ||| most ||| 0-0
mellitus ( siehe Abschnitt 4.4 ||| mellitus ( see section 4.4 ||| 0-0 1-1 2-2 3-3 4-4
mellitus ( siehe Abschnitt ||| mellitus ( see section ||| 0-0 1-1 2-2 3-3
mellitus ( siehe ||| mellitus ( see ||| 0-0 1-1 2-2
mellitus ( ||| mellitus ( ||| 0-0 1-1
mellitus , diabetische Ketoazidose , ||| mellitus , diabetic ketoacidosis , ||| 0-0 1-1 2-2 3-3 4-4
mellitus , diabetische Ketoazidose ||| mellitus , diabetic ketoacidosis ||| 0-0 1-1 2-2 3-3
mellitus , diabetische ||| mellitus , diabetic ||| 0-0 1-1 2-2
mellitus , ||| mellitus , ||| 0-0 1-1
mellitus : Hyperglykämie , in ||| Mellitus : hyperglycaemia , in ||| 2-0 1-1 0-2 2-2 3-3 4-4
mellitus : Hyperglykämie , ||| Mellitus : hyperglycaemia , ||| 2-0 1-1 0-2 2-2 3-3
mellitus : Hyperglykämie ||| Mellitus : hyperglycaemia ||| 2-0 1-1 0-2 2-2
mellitus und Herzkrankheit oder ||| mellitus and heart disease or ||| 0-0 1-1 2-2 2-3 3-4
mellitus und Herzkrankheit ||| mellitus and heart disease ||| 0-0 1-1 2-2 2-3
mellitus und ||| mellitus and ||| 0-0 1-1
mellitus ||| mellitus ||| 0-0
menschlichen therapeutischen Dosis . ||| ) gene mutation assay . ||| 0-1 1-2 2-3 3-4
menschlichen therapeutischen Dosis . ||| gene mutation assay . ||| 0-0 1-1 2-2 3-3
menschlichen therapeutischen Dosis ||| ) gene mutation assay ||| 0-1 1-2 2-3
menschlichen therapeutischen Dosis ||| gene mutation assay ||| 0-0 1-1 2-2
menschlichen therapeutischen ||| ) gene mutation ||| 0-1 1-2
menschlichen therapeutischen ||| gene mutation ||| 0-0 1-1
menschlichen ||| ) gene ||| 0-1
menschlichen ||| gene ||| 0-0
menschlichen ||| human ||| 0-0
menschliches Insulin ||| source insulin ||| 0-0 1-1
menschliches ||| source ||| 0-0
mesolimbischen Systems ||| balance , ||| 0-0
mesolimbischen Systems ||| balance ||| 0-0
mesolimbischen ||| balance , ||| 0-0
mesolimbischen ||| balance ||| 0-0
messen . ||| measure ||| 0-0
messen ||| measure ||| 0-0
metabolische und gewichtsreduzierende Wirkung bei ||| enrolled in ||| 0-0 2-0 3-0 1-1 4-1
metabolisiert , ihre Ausscheidung erfolgt ||| metabolised and is ||| 0-0 2-0 3-1 4-2
metabolisiert , ihre Ausscheidung ||| metabolised and ||| 0-0 2-0 3-1
metabolisiert , ihre ||| metabolised ||| 0-0 2-0
metabolisiert . ||| enzymes . ||| 0-0 1-1
metabolisiert wird ||| metabolised ||| 0-0
metabolisiert ||| enzymes ||| 0-0
metabolisiert ||| metabolised ||| 0-0
metabolisierten Substanzen ||| of substances ||| 1-1
metabolisierten Substanzen ||| substances ||| 1-0
metastasierendem Brustkrebs teilnahmen , ||| metastatic breast cancer , around ||| 0-0 0-1 1-1 0-2 2-2 3-3 3-4
metastasierendem Brustkrebs teilnahmen ||| metastatic breast cancer ||| 0-0 0-1 1-1 0-2 2-2
metastasierendem Brustkrebs ||| metastatic breast cancer ||| 0-0 0-1 1-1 0-2
metastasierendem Mammakarzinom ||| metastatic breast cancer ||| 0-0 1-0 0-1 0-2
metastasierendem Mammakarzinom ||| metastatic breast cancer ||| 0-0 1-0 0-1 1-2
metastasierendem Mammakarzinom ||| metastatic breast cancer ||| 0-0 1-1 1-2
metastasierendem ||| metastatic ||| 0-0
metastasierenden Krankheit ||| metastatic disease has ||| 0-0 1-1
metastasierenden Krankheit ||| metastatic disease ||| 0-0 1-1
metastasierenden ||| metastatic ||| 0-0
mg ( 0,7 ml ) ||| mg ( 0.7 ml ) ||| 0-0 1-1 2-2 3-3 4-4
mg ( 0,7 ml ||| mg ( 0.7 ml ||| 0-0 1-1 2-2 3-3
mg ( 0,7 ||| mg ( 0.7 ||| 0-0 1-1 2-2
mg ( 1,3 ml ) ||| mg ( 1.3 ml ) ||| 0-0 1-1 2-2 3-3 4-4
mg ( 1,3 ml ||| mg ( 1.3 ml ||| 0-0 1-1 2-2 3-3
mg ( 1,3 ||| mg ( 1.3 ||| 0-0 1-1 2-2
mg ( Ausgangswert 7,3 % ||| mg ( baseline 7.3 % ||| 0-0 1-1 2-2 3-3 4-4
mg ( Ausgangswert 7,3 ||| mg ( baseline 7.3 ||| 0-0 1-1 2-2 3-3
mg ( Ausgangswert ||| mg ( baseline ||| 0-0 1-1 2-2
mg ( d.h . ||| mg ( i. e. ||| 0-0 1-1 2-2 2-3 3-3
mg ( einmal täglich ) ||| mg ( once daily ) ||| 0-0 1-1 2-2 3-3 4-4
mg ( einmal täglich ||| mg ( once daily ||| 0-0 1-1 2-2 3-3
mg ( einmal ||| mg ( once ||| 0-0 1-1 2-2
mg ( ||| mg ( ||| 0-0 1-1
mg ) ||| mg ) ||| 0-0 1-1
mg , 10 mg , ||| mg , 10 mg , ||| 0-0 1-1 2-2 3-3 4-4
mg , 10 mg ||| mg , 10 mg ||| 0-0 1-1 2-2 3-3
mg , 10 ||| mg , 10 ||| 0-0 1-1 2-2
mg , 15 mg und ||| mg , 15 mg and ||| 0-0 1-1 2-2 3-3 4-4
mg , 15 mg ||| mg , 15 mg ||| 0-0 1-1 2-2 3-3
mg , 15 ||| mg , 15 ||| 0-0 1-1 2-2
mg , 30 mg ||| mg , 30 ||| 0-0 3-0 1-1 2-2
mg , ||| mg , ||| 0-0 1-1
mg Aclasta . ||| mg Aclasta . ||| 0-0 1-1 2-2
mg Aclasta ||| mg Aclasta ||| 0-0 1-1
mg Aripiprazol ) einmal ||| mg aripiprazole ) once a ||| 0-0 1-1 2-2 3-3 3-4
mg Aripiprazol ) ||| mg aripiprazole ) ||| 0-0 1-1 2-2
mg Aripiprazol . ||| mg of aripiprazole . ||| 0-0 1-2 2-3
mg Aripiprazol als ||| mg aripiprazole as the ||| 0-0 1-1 2-2
mg Aripiprazol als ||| mg aripiprazole as ||| 0-0 1-1 2-2
mg Aripiprazol ||| mg aripiprazole ||| 0-0 1-1
mg Aripiprazol ||| mg of aripiprazole ||| 0-0 1-2
mg Aspartam ( E951 ) ||| mg aspartame ( E951 ) ||| 0-0 1-1 2-2 3-3 4-4
mg Aspartam ( E951 ||| mg aspartame ( E951 ||| 0-0 1-1 2-2 3-3
mg Aspartam ( ||| mg aspartame ( ||| 0-0 1-1 2-2
mg Aspartam ||| mg aspartame ||| 0-0 1-1
mg Fe2+/Tag für ||| mg Fe2+/ day for paediatric ||| 0-0 1-1 1-2 2-3 1-4
mg Fe2+/Tag wird ||| mg Fe2+/ day is ||| 0-0 1-1 1-2 2-3
mg Fe2+/Tag ||| mg Fe2+/ day ||| 0-0 1-1 1-2
mg Fructose je ml 400 ||| mg fructose per ml 400 ||| 0-0 1-1 2-2 3-3 4-4
mg Fructose je ml ||| mg fructose per ml ||| 0-0 1-1 2-2 3-3
mg Fructose je ||| mg fructose per ||| 0-0 1-1 2-2
mg Fructose und 400 ||| mg of fructose and 400 ||| 0-0 1-2 2-3 3-4
mg Fructose und ||| mg of fructose and ||| 0-0 1-2 2-3
mg Fructose ||| mg fructose ||| 0-0 1-1
mg Fructose ||| mg of fructose ||| 0-0 1-2
mg Infusionslösung ist in dieser ||| mg solution for infusion is ||| 0-0 1-1 1-2 1-3 2-4 3-4
mg Infusionslösung ist in ||| mg solution for infusion is ||| 0-0 1-1 1-2 1-3 2-4 3-4
mg Infusionslösung ||| mg solution for infusion ||| 0-0 1-1 1-2 1-3
mg Kalzium zweimal täglich ||| mg calcium twice a day ||| 0-0 1-1 2-2 3-2 3-3 3-4
mg Kalzium ||| mg calcium ||| 0-0 1-1
mg Methyl-4-hydroxybenzoat ( E218 ||| mg methyl parahydroxybenzoate ( E218 ||| 0-0 1-1 1-2 2-3 3-4
mg Methyl-4-hydroxybenzoat ( ||| mg methyl parahydroxybenzoate ( ||| 0-0 1-1 1-2 2-3
mg Methyl-4-hydroxybenzoat ||| mg methyl parahydroxybenzoate ||| 0-0 1-1 1-2
mg Mitratapid/kg Körpergewicht ||| mg mitratapide/ kg bodyweight results ||| 0-0 1-1 2-2 2-3
mg Mitratapid/kg Körpergewicht ||| mg mitratapide/ kg bodyweight ||| 0-0 1-1 2-2 2-3
mg Mitratapid/kg ||| mg mitratapide/ ||| 0-0 1-1
mg Natrium pro Dosis . ||| mg sodium per dose . ||| 0-0 1-1 2-2 3-3 4-4
mg Natrium pro Dosis ||| mg sodium per dose ||| 0-0 1-1 2-2 3-3
mg Natrium pro ||| mg sodium per ||| 0-0 1-1 2-2
mg Natrium ||| mg sodium ||| 0-0 1-1
mg Paclitaxel . ||| mg of paclitaxel . ||| 0-0 1-2 2-3
mg Paclitaxel . ||| mg paclitaxel . ||| 0-0 1-1 2-2
mg Paclitaxel ||| mg of paclitaxel ||| 0-0 1-2
mg Paclitaxel ||| mg paclitaxel ||| 0-0 1-1
mg Pioglitazon ( als Hydrochlorid ||| mg pioglitazone ( as hydrochloride ||| 0-0 1-1 2-2 3-3 4-4
mg Pioglitazon ( als ||| mg pioglitazone ( as ||| 0-0 1-1 2-2 3-3
mg Pioglitazon ( ||| mg pioglitazone ( ||| 0-0 1-1 2-2
mg Pioglitazon . ||| mg of pioglitazone . ||| 0-0 1-2 2-3
mg Pioglitazon als Hydrochlorid ||| mg of pioglitazone as hydrochloride ||| 0-0 1-2 2-3 3-4
mg Pioglitazon als ||| mg of pioglitazone as ||| 0-0 1-2 2-3
mg Pioglitazon ||| mg of pioglitazone ||| 0-0 1-2
mg Pioglitazon ||| mg pioglitazone ||| 0-0 1-1
mg Propyl-4-hydroxybenzoat ( E216 ||| mg propyl parahydroxybenzoate ( E216 ||| 0-0 1-1 1-2 2-3 3-4
mg Propyl-4-hydroxybenzoat ( ||| mg propyl parahydroxybenzoate ( ||| 0-0 1-1 1-2 2-3
mg Propyl-4-hydroxybenzoat ||| mg propyl parahydroxybenzoate ||| 0-0 1-1 1-2
mg Schmelztabletten ( Tabletten ||| mg orodispersible tablets ( tablets ||| 0-0 1-1 1-2 2-3 3-4
mg Schmelztabletten ( ||| mg orodispersible tablets ( ||| 0-0 1-1 1-2 2-3
mg Schmelztabletten sind rund ||| mg orodispersible tablets are round ||| 0-0 1-1 1-2 2-3 3-4
mg Schmelztabletten sind ||| mg orodispersible tablets are ||| 0-0 1-1 1-2 2-3
mg Schmelztabletten ||| mg orodispersible tablets ||| 0-0 1-1 1-2
mg Sucrose . ||| mg of sucrose . ||| 0-0 1-2 2-3
mg Sucrose je ml 1,8 ||| mg sucrose per ml 1.8 ||| 0-0 1-1 2-2 3-3 4-4
mg Sucrose je ml ||| mg sucrose per ml ||| 0-0 1-1 2-2 3-3
mg Sucrose je ||| mg sucrose per ||| 0-0 1-1 2-2
mg Sucrose ||| mg of sucrose ||| 0-0 1-2
mg Sucrose ||| mg sucrose ||| 0-0 1-1
mg Tabletten , als 10 ||| mg tablets , as 10 ||| 0-0 1-1 2-2 3-3 4-4
mg Tabletten , als ||| mg tablets , as ||| 0-0 1-1 2-2 3-3
mg Tabletten , ||| mg tablets , ||| 0-0 1-1 2-2
mg Tabletten können ||| mg tablets may ||| 0-0 1-1 2-2
mg Tabletten sind rechteckig und ||| mg tablets are rectangular and ||| 0-0 1-1 2-2 3-3 4-4
mg Tabletten sind rechteckig ||| mg tablets are rectangular ||| 0-0 1-1 2-2 3-3
mg Tabletten sind rund und ||| mg tablets are round and ||| 0-0 1-1 2-2 3-3 4-4
mg Tabletten sind rund ||| mg tablets are round ||| 0-0 1-1 2-2 3-3
mg Tabletten sind ||| mg tablets are ||| 0-0 1-1 2-2
mg Tabletten ||| mg tablets ||| 0-0 1-1
mg Zoledronsäure ( wasserfrei ||| mg zoledronic acid ( anhydrous ||| 0-0 1-1 1-2 2-3 3-4
mg Zoledronsäure ( wasserfrei ||| mg zoledronic acid anhydrous ||| 0-0 1-1 1-2 2-2 3-3
mg Zoledronsäure ( ||| mg zoledronic acid ( ||| 0-0 1-1 1-2 2-3
mg Zoledronsäure ( ||| mg zoledronic acid ||| 0-0 1-1 1-2 2-2
mg Zoledronsäure beurteilt . ||| mg zoledronic acid . ||| 0-0 1-1 1-2 2-3 3-3
mg Zoledronsäure muss ||| mg zoledronic acid must be ||| 0-0 1-1 1-2 2-3 2-4
mg Zoledronsäure ||| mg zoledronic acid ||| 0-0 1-1 1-2
mg Zoledronsäuremonohydrat . ||| mg zoledronic acid monohydrate . ||| 0-0 1-1 1-2 1-3 2-4
mg Zoledronsäuremonohydrat ||| mg zoledronic acid monohydrate ||| 0-0 1-1 1-2 1-3
mg eingenommen hatten , waren ||| mg ||| 0-0
mg eingenommen hatten , ||| mg ||| 0-0
mg eingenommen hatten ||| mg ||| 0-0
mg eingenommen ||| mg ||| 0-0
mg einmal jährlich für ||| mg once a year for ||| 0-0 1-1 1-2 2-3 3-4
mg einmal jährlich ||| mg once a year ||| 0-0 1-1 1-2 2-3
mg einmal täglich , ||| mg once a day , ||| 0-0 1-1 2-1 2-2 2-3 3-4
mg einmal täglich . ||| mg once a day . ||| 0-0 1-1 1-2 2-3 3-4
mg einmal täglich . ||| mg once daily . ||| 0-0 1-1 2-2 3-3
mg einmal täglich ||| mg administered once a day ||| 0-0 1-1 1-2 2-2 1-3 2-4
mg einmal täglich ||| mg once a day ||| 0-0 1-1 1-2 2-3
mg einmal täglich ||| mg once a day ||| 0-0 1-1 2-1 2-2 2-3
mg einmal täglich ||| mg once daily ||| 0-0 1-1 2-1 2-2
mg einmal täglich ||| mg once daily ||| 0-0 1-1 2-2
mg einmal ||| mg once a ||| 0-0 1-1 1-2
mg einmal ||| mg once ||| 0-0 1-1
mg elementarem ||| mg elemental ||| 0-0 1-1
mg für ||| mg ||| 0-0
mg in 1,3 ml . ||| mg in 1.3 ml ||| 0-0 1-1 2-2 3-3 4-3
mg in 1,3 ||| mg in 1.3 ||| 0-0 1-1 2-2
mg in 100 ||| mg in 100 ||| 0-0 1-1 2-2
mg in ||| mg in ||| 0-0 1-1
mg intramuskulär lagen . ||| mg intramuscular . ||| 0-0 1-1 3-2
mg intramuskulär lagen ||| mg intramuscular ||| 0-0 1-1
mg intramuskulär ||| mg intramuscular ||| 0-0 1-1
mg je Quadratmeter Körperfläche ||| mg per square metre of ||| 0-0 1-1 2-2 3-3 1-4
mg lag . ||| mg . ||| 0-0 2-1
mg lag ||| mg ||| 0-0
mg nahezu dosisproportional . ||| mg . ||| 0-0 1-0 2-0 3-1
mg nahezu dosisproportional ||| mg ||| 0-0 1-0 2-0
mg oder 30 mg einmal ||| mg or 30 mg once ||| 0-0 1-1 2-2 3-3 4-4
mg oder 30 mg ||| mg or 30 mg ||| 0-0 1-1 2-2 3-3
mg oder 30 ||| mg or 30 ||| 0-0 1-1 2-2
mg oder ||| mg or ||| 0-0 1-1
mg sollte ||| mg should be ||| 0-0 1-1 1-2
mg täglich eingenommen haben . ||| mg daily . ||| 0-0 1-1 2-1 3-1 4-2
mg täglich eingenommen haben ||| mg daily ||| 0-0 1-1 2-1 3-1
mg und 30 mg Tabletten ||| mg and 30 mg tablets ||| 0-0 1-1 2-2 3-3 4-4
mg und 30 mg ||| mg and 30 mg ||| 0-0 1-1 2-2 3-3
mg und 30 ||| mg and 30 ||| 0-0 1-1 2-2
mg und ||| mg and ||| 0-0 1-1
mg verringerte das Risiko der ||| mg reduced the risk of ||| 0-0 1-1 2-2 2-3 3-3 4-4
mg verringerte das Risiko ||| mg reduced the risk ||| 0-0 1-1 2-2 2-3 3-3
mg verringerte ||| mg reduced ||| 0-0 1-1
mg waren ||| mg were ||| 0-0 1-1
mg wasserfreie ||| mg ||| 0-0 1-0
mg wasserfreiem Insulin human ||| mg of anhydrous human insulin ||| 0-0 1-1 1-2 3-3 2-4
mg wasserfreiem ||| mg of anhydrous ||| 0-0 1-1 1-2
mg wurde nicht ||| mg has not ||| 0-0 1-1 2-2
mg wurde ||| mg has ||| 0-0 1-1
mg ||| mg , ||| 0-0
mg ||| mg of ||| 0-0
mg ||| mg ||| 0-0
mg- ||| 20 ||| 0-0
mg/Tag ( d.h . ||| mg/ day ( i. e. ||| 0-0 0-1 1-2 2-3 2-4 3-4
mg/Tag ( ||| mg/ day ( ||| 0-0 0-1 1-2
mg/Tag . ||| mg/ day . ||| 0-0 0-1 1-2
mg/Tag ||| mg/ day ||| 0-0 0-1
mg/Tag über vier Tage ||| mg/ day for four days ||| 0-0 0-1 1-2 1-3 2-3 3-4
mg/Tag über vier ||| mg/ day for four ||| 0-0 0-1 1-2 1-3 2-3
mg/kg täglich wurde ||| mg/ kg daily was ||| 0-0 0-1 1-2 2-3
mg/kg täglich ||| mg/ kg daily ||| 0-0 0-1 1-2
mg/kg ||| mg/ kg ||| 0-0 0-1
mg/kg/Tag untersucht . ||| mg/ kg/ day . ||| 0-0 0-1 0-2 1-3 2-3
mg/kg/Tag ||| mg/ kg/ day ||| 0-0 0-1 0-2
mg/m2 ) . ||| mg/ m ) . ||| 0-0 0-1 1-2 2-3
mg/m2 ) . ||| mg/ m2 ) . ||| 0-0 0-1 1-2 2-3
mg/m2 ) ||| mg/ m ) ||| 0-0 0-1 1-2
mg/m2 ) ||| mg/ m2 ) ||| 0-0 0-1 1-2
mg/m2 ; 95 % ||| mg/ m2 ; 95 % ||| 0-0 0-1 1-2 2-3 3-4
mg/m2 ; 95 ||| mg/ m2 ; 95 ||| 0-0 0-1 1-2 2-3
mg/m2 ; ||| mg/ m2 ; ||| 0-0 0-1 1-2
mg/m2 ||| mg/ m ||| 0-0 0-1
mg/m2 ||| mg/ m2 , paclitaxel ||| 0-0 0-1 0-3
mg/m2 ||| mg/ m2 ||| 0-0 0-1
mg/ml ) . ||| mg/ ml ) . ||| 0-0 0-1 1-2 2-3
mg/ml ) 10 vorgefüllte Injektoren ||| mg/ ml ) ||| 0-0 2-0 0-1 3-1 4-1 1-2 4-2
mg/ml ) und als ||| mg/ ml ) and as ||| 0-0 0-1 1-2 2-3 3-4
mg/ml ) und ||| mg/ ml ) and ||| 0-0 0-1 1-2 2-3
mg/ml ) ||| mg/ ml ) ||| 0-0 0-1 1-2
mg/ml Butylhydroxyanisol ( ||| mg/ ml Butylated hydroxyanisole ( ||| 0-0 0-1 1-2 1-3 2-4
mg/ml Butylhydroxyanisol ||| mg/ ml Butylated hydroxyanisole ||| 0-0 0-1 1-2 1-3
mg/ml Injektionslösung ||| mg/ ml solution for injection ||| 0-0 0-1 1-2 1-3 1-4
mg/ml Lösung zum Eingeben für ||| mg/ ml oral solution for ||| 0-0 0-1 2-2 3-2 1-3 3-3 4-4
mg/ml Lösung zum Eingeben ||| mg/ ml oral solution ||| 0-0 0-1 2-2 3-2 1-3 3-3
mg/ml Lösung zum Einnehmen ist ||| mg/ ml oral solution is ||| 0-0 0-1 2-2 3-2 1-3 4-4
mg/ml Lösung zum Einnehmen ||| mg/ ml oral solution ||| 0-0 0-1 2-2 3-2 1-3
mg/ml ||| mg/ ml ||| 0-0 0-1
mikrobielle ||| avoid microbial ||| 0-0 0-1
mikrokristalline Cellulose , Hyprolose ||| microcrystalline cellulose , hydroxypropyl cellulose ||| 0-0 1-1 2-2 3-3 1-4
mikrokristalline ||| microcrystalline ||| 0-0
mikrotubulären ||| reorganisation ||| 0-0
mindestens 10 Tage nach der ||| at least 10 days following ||| 0-0 4-0 0-1 1-2 2-3 3-4
mindestens 15 Minuten dauern ||| take at least 15 minutes ||| 3-0 0-1 0-2 1-3 2-4 3-4
mindestens 15 Minuten verabreicht . ||| at least 15 minutes . ||| 0-0 0-1 1-2 2-3 3-3 4-4
mindestens 15 Minuten verabreicht ||| at least 15 minutes ||| 0-0 0-1 1-2 2-3 3-3
mindestens 15 ||| at least 15 ||| 0-0 0-1 1-2
mindestens 15 ||| for at least 15 ||| 0-1 0-2 1-3
mindestens 2 ||| at least 2 ||| 0-0 0-1 1-2
mindestens 30 %. ||| at least 30 % . ||| 0-0 0-1 1-2 2-3 2-4
mindestens 30 ||| at least 30 ||| 0-0 0-1 1-2
mindestens 500 mg Kalzium ||| at least 500 mg calcium ||| 0-0 0-1 1-2 2-3 3-4
mindestens 500 mg elementarem ||| at least 500 mg elemental ||| 0-0 0-1 1-2 2-3 3-4
mindestens 500 mg ||| at least 500 mg ||| 0-0 0-1 1-2 2-3
mindestens 500 ||| at least 500 ||| 0-0 0-1 1-2
mindestens 6 Sekunden lang unter ||| kept under ||| 0-0 1-0 2-0 3-0 2-1 4-1
mindestens 75 ||| at least 75 ||| 0-0 0-1 1-2
mindestens fünfwöchiger ||| at least five ||| 0-0 0-1 1-1 0-2
mindestens zwei Wochen ||| at least two weeks ||| 0-0 0-1 1-2 2-3
mindestens zwei ||| at least two ||| 0-0 0-1 1-2
mindestens ||| at least ||| 0-0 0-1
mindestens ||| for at least ||| 0-1 0-2
minimal ausgeprägt ist . ||| is minimal . ||| 2-0 0-1 1-1 3-2
minimal ausgeprägt ist ||| is minimal ||| 2-0 0-1 1-1
minimal ausgeprägt ||| minimal ||| 0-0 1-0
mit . ||| . ||| 1-0
mit 0,3 ml Injektionslösung ||| 0.3 ml solution for injection ||| 1-0 2-1 3-2 3-3 3-4
mit 0,3 ml ||| 0.3 ml ||| 1-0 2-1
mit 0,3 ml ||| of 0.3 ml ||| 1-1 2-2
mit 0,3 ||| 0.3 ||| 1-0
mit 0,3 ||| of 0.3 ||| 1-1
mit 0,6 ml Injektionslösung ||| 0.6 ml solution for injection ||| 1-0 2-1 3-2 3-3 3-4
mit 0,6 ml ||| 0.6 ml ||| 1-0 2-1
mit 0,6 ml ||| of 0.6 ml ||| 1-1 2-2
mit 0,6 ||| 0.6 ||| 1-0
mit 0,6 ||| of 0.6 ||| 1-1
mit 0,8 ml Injektionslösung ||| 0.8 ml solution for injection ||| 1-0 2-1 3-2 3-3 3-4
mit 0,8 ml ||| 0.8 ml ||| 1-0 2-1
mit 0,8 ml ||| of 0.8 ml ||| 1-1 2-2
mit 0,8 ||| 0.8 ||| 1-0
mit 0,8 ||| of 0.8 ||| 1-1
mit 1,7 % bei Frauen ||| 1.7 % of women ||| 0-0 1-0 3-0 2-1 4-3
mit 1,7 % bei ||| 1.7 % of ||| 0-0 1-0 3-0 2-1
mit 1,7 % bei ||| 1.7 % ||| 0-0 1-0 3-0 2-1
mit 100 mg Paclitaxel . ||| of 100 mg paclitaxel . ||| 0-0 1-1 2-2 3-3 4-4
mit 100 mg Paclitaxel ||| of 100 mg paclitaxel ||| 0-0 1-1 2-2 3-3
mit 100 mg ||| of 100 mg ||| 0-0 1-1 2-2
mit 100 ml Lösung ||| with 100 ml of solution ||| 0-0 1-1 2-2 3-3 3-4
mit 100 ml Lösung ||| with 100 ml of solution ||| 0-0 1-1 2-2 3-4
mit 100 ml ||| with 100 ml of ||| 0-0 1-1 2-2
mit 100 ml ||| with 100 ml ||| 0-0 1-1 2-2
mit 100 ||| of 100 ||| 0-0 1-1
mit 100 ||| with 100 ||| 0-0 1-1
mit 28 , 98 oder ||| containing 28 , 98 and ||| 0-0 1-0 1-1 2-2 3-3
mit 28 , 98 oder ||| containing 28 , 98 ||| 0-0 1-0 1-1 2-2 3-3
mit 28 , 98 ||| containing 28 , 98 and ||| 0-0 1-0 1-1 2-2 3-3
mit 28 , 98 ||| containing 28 , 98 ||| 0-0 1-0 1-1 2-2 3-3
mit 28 , ||| containing 28 , ||| 0-0 1-0 1-1 2-2
mit 28 ||| containing 28 ||| 0-0 1-0 1-1
mit 36 % ||| be 36 % ||| 0-0 1-1 2-2
mit 36 ||| be 36 ||| 0-0 1-1
mit : ausgeprägte Appetitlosigkeit ||| : significant loss of appetite ||| 1-0 0-1 3-2 2-4 3-4
mit : ||| : significant ||| 1-0 0-1
mit ABILIFY in ||| with ABILIFY ||| 0-0 1-1
mit ABILIFY und anderen ||| with ABILIFY and with other ||| 0-0 1-1 2-2 0-3 3-4
mit ABILIFY und ||| with ABILIFY and with ||| 0-0 1-1 2-2 0-3
mit ABILIFY ||| with ABILIFY ||| 0-0 1-1
mit Abilify verbunden ? ||| associated with Abilify ? ||| 0-0 2-0 2-1 1-2 3-3
mit Abilify verbunden ||| associated with Abilify ||| 0-0 2-0 2-1 1-2
mit Abilify ||| using Abilify ||| 0-0 1-1
mit Abraxane behandelt werden . ||| be treated with Abraxane . ||| 3-0 2-1 0-2 1-3 4-4
mit Abraxane behandelt werden ||| be treated with Abraxane ||| 3-0 2-1 0-2 1-3
mit Abraxane behandelt ||| treated with Abraxane ||| 2-0 0-1 1-2
mit Abraxane behandelten Patienten auf ||| patients on Abraxane ||| 0-0 3-0 4-1 1-2 2-2
mit Abraxane behandelten Patienten beobachtet ||| patients treated with Abraxane ||| 0-0 3-0 2-1 0-2 1-3 4-3
mit Abraxane behandelten Patienten dosisabhängig ||| patients receiving Abraxane ||| 0-0 3-0 3-1 1-2 2-2 4-2
mit Abraxane behandelten Patienten ||| patients on Abraxane with ||| 3-0 1-2 2-2 0-3
mit Abraxane behandelten ||| Abraxane with ||| 1-0 2-0 0-1
mit Abraxane behandelten ||| on Abraxane with ||| 1-1 2-1 0-2
mit Abraxane berichteten ||| reported with Abraxane ||| 2-0 0-1 1-2
mit Abraxane oft auf . ||| occurs frequently with Abraxane . ||| 2-0 2-1 0-2 1-3 3-3 4-4
mit Abraxane oft auf ||| occurs frequently with Abraxane ||| 2-0 2-1 0-2 1-3 3-3
mit Abraxane ||| with Abraxane ||| 0-0 1-1
mit Abseamed kann ||| with Abseamed may be ||| 0-0 1-1 2-2 2-3
mit Abseamed ||| Abseamed ||| 1-0
mit Abseamed ||| with Abseamed ||| 0-0 1-1
mit Aclasta behandelt werden . ||| being treated with Aclasta . ||| 2-0 2-1 0-2 1-3 3-4 4-4
mit Aclasta behandelt werden sollten ||| should be treated with Aclasta ||| 4-0 3-1 2-2 0-3 1-4
mit Aclasta behandelt werden ||| be treated with Aclasta ||| 3-0 2-1 0-2 1-3
mit Aclasta behandelt ||| being treated with Aclasta ||| 2-0 2-1 0-2 1-3
mit Aclasta behandelt ||| treated with Aclasta ||| 2-0 0-1 1-2
mit Aclasta behandelten Gruppe ||| Aclasta-treated group ||| 0-0 1-0 2-0 3-1
mit Aclasta behandelten Patienten wurde ||| patients treated with Aclasta , ||| 3-0 2-1 0-2 1-3
mit Aclasta behandelten Patienten wurde ||| patients treated with Aclasta ||| 3-0 2-1 0-2 1-3
mit Aclasta behandelten Patienten ||| patients treated with Aclasta , ||| 3-0 2-1 0-2 1-3
mit Aclasta behandelten Patienten ||| patients treated with Aclasta ||| 3-0 2-1 0-2 1-3
mit Aclasta behandelten ||| Aclasta-treated ||| 0-0 1-0 2-0
mit Aclasta behandelten ||| treated with Aclasta , ||| 2-0 0-1 1-2
mit Aclasta behandelten ||| treated with Aclasta ||| 2-0 0-1 1-2
mit Aclasta berichteten ||| reported with Aclasta ||| 2-0 0-1 1-2
mit Aclasta vor . ||| with Aclasta . ||| 0-0 1-1 2-1 3-2
mit Aclasta vor ||| with Aclasta ||| 0-0 1-1 2-1
mit Aclasta ||| Aclasta ||| 1-0
mit Aclasta ||| Aclasta-treated ||| 0-0 1-0
mit Aclasta ||| with Aclasta , ||| 0-0 1-1
mit Aclasta ||| with Aclasta ||| 0-0 1-1
mit Actos und Insulin behandelt ||| treated with Actos and insulin ||| 4-0 0-1 1-2 2-3 3-4
mit Actos und Insulin ||| with Actos and insulin ||| 0-0 1-1 2-2 3-3
mit Actos und ||| with Actos and ||| 0-0 1-1 2-2
mit Actos waren Sehstörungen ||| with Actos are visual disturbance ||| 0-0 1-1 1-2 3-3 3-4
mit Actos waren ||| with Actos are ||| 0-0 1-1 1-2
mit Actos ||| with Actos are ||| 0-0 1-1 1-2
mit Actos ||| with Actos ||| 0-0 1-1
mit Adipositas und übergewichtigen ||| in ||| 3-0
mit Agitiertheit 110 und ||| patients presenting with agitation and ||| 0-0 0-1 0-2 1-3 3-4
mit Agitiertheit 110 ||| patients presenting with agitation ||| 0-0 0-1 0-2 1-3
mit Agitiertheit und Verhaltensstörungen ||| with agitation and disturbed behaviours ||| 0-0 1-1 2-2 3-3 3-4
mit Agitiertheit und ||| with agitation and ||| 0-0 1-1 2-2
mit Agitiertheit ||| patients presenting with agitation ||| 0-0 0-1 0-2 1-3
mit Agitiertheit ||| with agitation ||| 0-0 1-1
mit Alkohol oder anderen ||| with alcohol or other ||| 0-0 1-1 2-2 3-3
mit Alkohol oder ||| with alcohol or ||| 0-0 1-1 2-2
mit Alkohol ||| with alcohol ||| 0-0 1-1
mit Aripiprazol ( 30 mg ||| aripiprazole ( 30 mg ||| 0-0 1-0 2-1 3-2 4-3
mit Aripiprazol ( 30 mg ||| aripiprazole ( 30 mg ||| 1-0 2-1 3-2 4-3
mit Aripiprazol ( 30 ||| aripiprazole ( 30 ||| 0-0 1-0 2-1 3-2
mit Aripiprazol ( 30 ||| aripiprazole ( 30 ||| 1-0 2-1 3-2
mit Aripiprazol ( oral ) ||| oral aripiprazole ||| 3-0 1-1
mit Aripiprazol ( oral ||| oral aripiprazole ||| 3-0 1-1
mit Aripiprazol ( ||| aripiprazole ( ||| 0-0 1-0 2-1
mit Aripiprazol ( ||| aripiprazole ( ||| 1-0 2-1
mit Aripiprazol ( ||| aripiprazole ||| 1-0
mit Aripiprazol , gab es ||| with aripiprazole , there were ||| 0-0 1-1 2-2 3-3 4-3 3-4
mit Aripiprazol , ||| with aripiprazole , ||| 0-0 1-1 2-2
mit Aripiprazol allein ||| aripiprazole alone was ||| 1-0 0-1 2-1 2-2
mit Aripiprazol allein ||| of aripiprazole alone was ||| 1-1 0-2 2-2 2-3
mit Aripiprazol behandelten Patienten . ||| patients treated with aripiprazole . ||| 3-0 2-1 0-2 1-3 4-4
mit Aripiprazol behandelten Patienten ||| patients treated with aripiprazole ||| 3-0 2-1 0-2 1-3
mit Aripiprazol behandelten ||| treated with aripiprazole ||| 2-0 0-1 1-2
mit Aripiprazol bei schwangeren ||| of aripiprazole in pregnant ||| 0-0 1-1 2-2 3-3
mit Aripiprazol bei ||| of aripiprazole in ||| 0-0 1-1 2-2
mit Aripiprazol und 3,0 % ||| with aripiprazole and 3.0 % ||| 0-0 1-1 2-2 3-3 4-4
mit Aripiprazol und 3,0 ||| with aripiprazole and 3.0 ||| 0-0 1-1 2-2 3-3
mit Aripiprazol und 3,2 % ||| with aripiprazole and 3.2 % ||| 0-0 1-1 2-2 3-3 4-4
mit Aripiprazol und 3,2 ||| with aripiprazole and 3.2 ||| 0-0 1-1 2-2 3-3
mit Aripiprazol und ||| with aripiprazole and ||| 0-0 1-1 2-2
mit Aripiprazol ||| aripiprazole , ||| 0-0 1-0
mit Aripiprazol ||| aripiprazole ||| 0-0 1-0
mit Aripiprazol ||| aripiprazole ||| 1-0
mit Aripiprazol ||| of aripiprazole , ||| 0-1 1-1
mit Aripiprazol ||| of aripiprazole ||| 0-0 1-1
mit Aripiprazol ||| of aripiprazole ||| 0-1 1-1
mit Aripiprazol ||| of aripiprazole ||| 1-1
mit Aripiprazol ||| with aripiprazole , ||| 0-0 1-1
mit Aripiprazol ||| with aripiprazole . ||| 0-0 1-1
mit Aripiprazol ||| with aripiprazole ||| 0-0 1-1
mit Arzneimitteln ||| with medicinal products ||| 0-0 1-1 1-2
mit Arzneimitteln ||| with some medicines , ||| 0-0 1-1 1-2
mit Arzneimitteln ||| with some medicines ||| 0-0 1-1 1-2
mit Beeinträchtigung der Nierenfunktion ( ||| with renal impairment ( ||| 0-0 3-1 1-2 3-2 4-3
mit Beeinträchtigung der Nierenfunktion ||| with renal impairment ||| 0-0 3-1 1-2 3-2
mit Bisphosphonaten ||| with bisphosphonates ||| 0-0 1-1
mit Carbamazepin , ||| carbamazepine , ||| 0-0 1-0 2-1
mit Carbamazepin verdoppelt werden . ||| occurs with carbamazepine . ||| 2-0 0-1 2-1 1-2 2-2 3-2 4-3
mit Carbamazepin verdoppelt werden ||| occurs with carbamazepine ||| 2-0 0-1 2-1 1-2 2-2 3-2
mit Carbamazepin ||| carbamazepine ||| 0-0 1-0
mit Carbamazepin ||| carbamazepine ||| 1-0
mit Chinidin gegeben wird . ||| with quinidine occurs . ||| 0-0 1-1 2-2 3-2 4-3
mit Chinidin gegeben wird ||| with quinidine occurs ||| 0-0 1-1 2-2 3-2
mit Chinidin ||| with quinidine ||| 0-0 1-1
mit Ciclosporin angewendet , ||| with cyclosporin , ||| 0-0 1-1 2-1 3-2
mit Ciclosporin angewendet ||| with cyclosporin ||| 0-0 1-1 2-1
mit Darreichungsformen zum Einnehmen ||| with oral formulations of ABILIFY ||| 0-0 2-1 3-1 1-2 3-4
mit Diabetes mellitus ||| with diabetes mellitus ||| 0-0 1-1 2-2
mit Diabetes ||| with diabetes ||| 0-0 1-1
mit EORTC-QLQ-C30 ||| life parameters on ||| 0-0 1-0 1-1 1-2
mit Einmalgabe und Mehrfachgabe ||| and repeat-dose ||| 2-0 1-1 2-1 3-1
mit Epoetin alfa Einfluss auf ||| with epoetin alfa alters ||| 0-0 1-1 2-2 3-3 4-3
mit Epoetin alfa berichtet . ||| with epoetin alfa . ||| 0-0 1-1 2-2 3-2 4-3
mit Epoetin alfa berichtet ||| with epoetin alfa ||| 0-0 1-1 2-2 3-2
mit Epoetin alfa ist ein ||| with epoetin alfa is a ||| 0-0 1-1 2-2 3-3 4-4
mit Epoetin alfa ist ||| with epoetin alfa is ||| 0-0 1-1 2-2 3-3
mit Epoetin alfa ||| epoetin alfa ||| 0-0 1-0 1-1 2-1
mit Epoetin alfa ||| with epoetin alfa ||| 0-0 1-1 2-1 2-2
mit Epoetin alfa ||| with epoetin alfa ||| 0-0 1-1 2-2
mit Epoetin ||| with epoetin ||| 0-0 1-1
mit Flüssigkeit ||| of ||| 0-0
mit Frauen mit ||| in women with ||| 1-0 1-1 0-2 2-2
mit Gemfibrozil ( einem ||| with gemfibrozil ( an ||| 0-0 1-1 2-2 1-3 3-3
mit Gemfibrozil ( einem ||| with gemfibrozil ( an ||| 0-0 1-1 2-2 3-3
mit Gemfibrozil ( ||| with gemfibrozil ( ||| 0-0 1-1 2-2
mit Gemfibrozil ||| with gemfibrozil ||| 0-0 1-1
mit Haloperidol ||| with haloperidol ||| 0-0 1-1
mit Hypocalcämie ( niedrigem Blutcalciumspiegel ||| with hypocalcaemia ( low blood ||| 0-0 1-1 2-2 3-3 4-3
mit Hypocalcämie ( niedrigem Blutcalciumspiegel ||| with hypocalcaemia ( low ||| 0-0 1-1 2-2 3-3 4-3
mit Hypocalcämie ( ||| with hypocalcaemia ( ||| 0-0 1-1 2-2
mit Hypocalcämie ||| with hypocalcaemia ||| 0-0 1-1
mit Hypokalzämie ( siehe Abschnitt ||| with hypocalcaemia ( see section ||| 0-0 1-1 2-2 3-3 4-4
mit Hypokalzämie ( siehe ||| with hypocalcaemia ( see ||| 0-0 1-1 2-2 3-3
mit Hypokalzämie ( ||| with hypocalcaemia ( ||| 0-0 1-1 2-2
mit Hypokalzämie ||| with hypocalcaemia ||| 0-0 1-1
mit Hämoblastosen ( ||| with haematological malignancies ( ||| 0-0 1-1 1-2 2-3
mit Hämoblastosen . ||| with haematological malignancies . ||| 0-0 1-1 1-2 2-3
mit Hämoblastosen ||| with haematological malignancies ||| 0-0 1-1 1-2
mit Hüftfraktur ||| have broken their hip ||| 0-0 1-1 1-2 1-3
mit Ihnen ||| for you to ||| 1-1
mit Ihnen ||| for you ||| 1-1
mit Ihnen ||| you to ||| 1-0
mit Ihnen ||| you ||| 1-0
mit Ihnen üben . ||| you to do this . ||| 1-0 2-2 2-3 3-4
mit Ihnen üben ||| for you to do this ||| 1-1 2-3 2-4
mit Ihnen üben ||| you to do this ||| 1-0 2-2 2-3
mit Ihrem Arzt ||| with your doctor ||| 0-0 1-1 2-2
mit Ihrem ||| with your ||| 0-0 1-1
mit Ihrem ||| your ||| 1-0
mit Infusionslösungen gemischt werden ||| be added to infusion fluids ||| 0-0 1-0 1-1 1-2 2-3 2-4 3-4
mit Infusionslösungen ||| be added to ||| 0-0 1-0 1-1 1-2
mit Insulin oder ||| with insulin or ||| 0-0 1-1 2-2
mit Insulin ||| with insulin , ||| 0-0 1-1
mit Insulin ||| with insulin ||| 0-0 1-1
mit Insulinspritzen mit einer ||| with insulin syringes with a ||| 0-0 1-1 1-2 2-3 3-4
mit Insulinspritzen mit ||| with insulin syringes with ||| 0-0 1-1 1-2 2-3
mit Insulinspritzen ||| with insulin syringes ||| 0-0 1-1 1-2
mit Ketoazidose oder hyperosmolarem Koma ||| with ketoacidosis or hyperosmolar coma ||| 0-0 1-1 2-2 3-3 4-4
mit Ketoazidose oder hyperosmolarem ||| with ketoacidosis or hyperosmolar ||| 0-0 1-1 2-2 3-3
mit Ketoazidose oder ||| with ketoacidosis or ||| 0-0 1-1 2-2
mit Ketoazidose ||| with ketoacidosis ||| 0-0 1-1
mit Krampfanfällen ||| of seizure ||| 0-0 1-1
mit Langzeitwirkung ||| used to achieve androgen ||| 0-0 1-2 1-3
mit Leberfunktionsstörung ||| with hepatic impairment ||| 0-0 1-1 1-2
mit Leberfunktionsstörungen . ||| with impaired liver function . ||| 0-0 1-1 1-2 1-3 2-4
mit Leberfunktionsstörungen ||| with impaired liver function ||| 0-0 1-1 1-2 1-3
mit Leberinsuffizienz : ||| with hepatic impairment : no ||| 0-0 1-1 1-2 2-3 1-4
mit Leberinsuffizienz : ||| with hepatic impairment : ||| 0-0 1-1 1-2 2-3
mit Leberinsuffizienz ||| with hepatic impairment ||| 0-0 1-1 1-2
mit Leberproblemen ||| with liver problems ||| 0-0 1-1 1-2
mit Lithium ||| with lithium ||| 0-0 1-1
mit Metformin und / ||| with metformin and / ||| 0-0 1-1 2-2 3-3
mit Metformin und ||| with metformin and ||| 0-0 1-1 2-2
mit Metformin und/oder ||| with metformin and/ or ||| 0-0 1-1 2-2 2-3
mit Metformin ||| with metformin ||| 0-0 1-1
mit Mitratapid wurde nicht ||| with mitratapide has not been ||| 0-0 1-1 2-2 3-3 2-4
mit Mitratapid ||| with mitratapide ||| 0-0 1-1
mit Morbus Paget ||| with Paget s disease ||| 0-0 1-1 2-1 2-2 2-3
mit Nahrungsmitteln und Getränken : ||| with food and drink : ||| 0-0 1-1 2-2 1-3 3-3 4-4
mit Nahrungsmitteln und Getränken ||| with food and drink ||| 0-0 1-1 2-2 1-3 3-3
mit Nierenerkrankung , die ||| with kidney disease ||| 0-0 1-1 1-2 2-2 3-2
mit Niereninsuffizienz , ||| with renal ||| 0-0 1-1
mit Niereninsuffizienz : ||| with renal impairment : ||| 0-0 1-1 1-2 2-3
mit Niereninsuffizienz ||| with renal impairment ||| 0-0 1-1 1-2
mit Niereninsuffizienz ||| with renal ||| 0-0 1-1
mit NovoFine Injektionsnadeln vorgesehen . ||| used with NovoFine needles . ||| 1-0 0-1 1-2 2-2 2-3 3-3 4-4
mit NovoFine Injektionsnadeln vorgesehen ||| used with NovoFine needles ||| 1-0 0-1 1-2 2-2 2-3 3-3
mit Osteoporose ||| with osteoporosis ||| 0-0 1-1
mit Paclitaxel behandelt werden . ||| be treated with paclitaxel . ||| 3-0 2-1 0-2 2-2 1-3 4-4
mit Paclitaxel behandelt werden ||| be treated with paclitaxel ||| 3-0 2-1 0-2 2-2 1-3
mit Paclitaxel behandelt ||| treated with paclitaxel ||| 2-0 0-1 2-1 1-2
mit Paclitaxel behandelt ||| with paclitaxel ||| 0-0 2-0 1-1
mit Patienten mit einer manischen ||| patients with a manic ||| 1-0 0-1 2-1 3-2 4-3
mit Patienten mit einer ||| patients with a ||| 1-0 0-1 2-1 3-2
mit Patienten mit fortgeschrittenen soliden ||| in patients with advanced solid ||| 1-0 1-1 0-2 2-2 3-3 4-4
mit Patienten mit fortgeschrittenen ||| in patients with advanced ||| 1-0 1-1 0-2 2-2 3-3
mit Patienten mit ||| in patients with ||| 1-0 1-1 0-2 2-2
mit Patienten mit ||| patients with ||| 1-0 0-1 2-1
mit Pioglitazon behandelt werden , ||| treated with pioglitazone ||| 2-0 0-1 3-1 1-2
mit Pioglitazon behandelt werden ||| treated with pioglitazone ||| 2-0 0-1 3-1 1-2
mit Pioglitazon behandelten Frauen und ||| women treated with pioglitazone and ||| 3-0 2-1 0-2 1-3 4-4
mit Pioglitazon behandelten Frauen ||| women treated with pioglitazone ||| 3-0 2-1 0-2 1-3
mit Pioglitazon behandelten ||| treated with pioglitazone ||| 2-0 0-1 1-2
mit Pioglitazon versus Gliclazid als ||| of pioglitazone vs. gliclazide as ||| 0-0 1-1 2-2 3-3 4-4
mit Pioglitazon versus Gliclazid ||| of pioglitazone vs. gliclazide ||| 0-0 1-1 2-2 3-3
mit Pioglitazon versus ||| of pioglitazone vs. ||| 0-0 1-1 2-2
mit Pioglitazon wurde ||| with pioglitazone there was ||| 0-0 1-1 2-2 2-3
mit Pioglitazon zu kontrollieren . ||| with pioglitazone in all ||| 0-0 1-1 2-2 3-3
mit Pioglitazon zu kontrollieren ||| with pioglitazone in all patients ||| 0-0 1-1 1-2 3-3 0-4
mit Pioglitazon zu kontrollieren ||| with pioglitazone in all ||| 0-0 1-1 2-2 3-3
mit Pioglitazon zu ||| with pioglitazone in ||| 0-0 1-1 2-2
mit Pioglitazon ||| of pioglitazone ||| 0-0 1-1
mit Pioglitazon ||| with pioglitazone ||| 0-0 1-1
mit Placebo . ||| with placebo . ||| 0-0 1-1 2-2
mit Placebo behandelte Patienten . ||| placebo-treated patients . ||| 1-0 2-0 0-1 3-1 4-2
mit Placebo behandelte Patienten ||| placebo-treated patients ||| 1-0 2-0 0-1 3-1
mit Placebo ||| with placebo ||| 0-0 1-1
mit Produkten verwendet werden ||| used in combination with products ||| 2-0 0-1 1-2 2-2 0-3 1-4 3-4
mit Prägung von A-007 und ||| marked with A-007 and ||| 1-0 0-1 2-1 3-2 4-3
mit Prägung von A-007 ||| marked with A-007 ||| 1-0 0-1 2-1 3-2
mit Prägung von A-008 und ||| marked with A-008 and ||| 1-0 0-1 2-1 3-2 4-3
mit Prägung von A-008 ||| marked with A-008 ||| 1-0 0-1 2-1 3-2
mit Prägung von A-009 und ||| marked with A-009 and ||| 1-0 0-1 2-1 3-2 4-3
mit Prägung von A-009 ||| marked with A-009 ||| 1-0 0-1 2-1 3-2
mit Prägung von A-011 und ||| marked with A-011 and ||| 1-0 0-1 2-1 3-2 4-3
mit Prägung von A-011 ||| marked with A-011 ||| 1-0 0-1 2-1 3-2
mit Prägung von ||| marked with ||| 1-0 0-1
mit Prägung von ||| marked with ||| 1-0 0-1 2-1
mit Prägung ||| marked with ||| 1-0 0-1
mit Rifampicin ( einem ||| with rifampicin ( an inducer ||| 0-0 1-1 2-2 3-3 1-4 3-4
mit Rimonabant ||| with rimonabant was associated with ||| 0-0 1-1 0-2 0-3 0-4
mit Risikofaktoren für Diabetes ||| with risk factors for diabetes ||| 0-0 1-1 1-2 2-3 3-4
mit Risikofaktoren für ||| with risk factors for ||| 0-0 1-1 1-2 2-3
mit Risikofaktoren ||| with risk factors ||| 0-0 1-1 1-2
mit Schizophrenie . ||| with schizophrenia . ||| 0-0 1-1 2-2
mit Schizophrenie ||| with schizophrenia ||| 0-0 1-1
mit Schüttelfrost , ||| Fever and chills , ||| 1-0 1-2 2-3
mit Schüttelfrost ||| Fever and chills ||| 1-0 1-2
mit Sulfonylharnstoffen oder Insulin auftreten ||| with sulphonylureas or insulin ||| 0-0 1-1 2-2 3-3 4-3
mit Sulfonylharnstoffen oder ||| with sulphonylureas or ||| 0-0 1-1 2-2
mit Sulfonylharnstoffen ||| with sulphonylureas ||| 0-0 1-1
mit Typ 2 Diabetes mellitus ||| with type 2 diabetes mellitus ||| 0-0 1-1 2-2 3-3 4-4
mit Typ 2 Diabetes ||| with type 2 diabetes ||| 0-0 1-1 2-2 3-3
mit Typ 2 ||| with type 2 ||| 0-0 1-1 2-2
mit Typ ||| with type ||| 0-0 1-1
mit Valproat oder Lithium eingenommen ||| with either valproate or lithium ||| 0-0 1-1 1-2 3-2 4-2 2-3 3-4
mit Vantas behandelt ||| treated with Vantas ||| 2-0 0-1 1-2
mit Vantas ||| with Vantas ||| 0-0 1-1
mit Vorsicht angewendet werden . ||| be monitored closely . ||| 0-0 1-0 1-1 2-2 3-2 4-3
mit Vorsicht angewendet werden bei ||| used with caution in ||| 2-0 0-1 1-2 3-2 4-3
mit Vorsicht angewendet werden ||| be monitored closely ||| 0-0 1-0 1-1 2-2 3-2
mit Vorsicht angewendet werden ||| used with caution ||| 2-0 0-1 1-2 3-2
mit Vorsicht anzuwenden ||| mit Vorsicht anzuwenden ||| 0-0 1-1 2-2
mit Vorsicht bei Patienten ||| used with caution in patients ||| 1-0 0-1 1-2 2-3 3-4
mit Vorsicht bei ||| used with caution in ||| 1-0 0-1 1-2 2-3
mit Vorsicht ||| be monitored ||| 0-0 1-0 1-1
mit Vorsicht ||| mit Vorsicht ||| 0-0 1-1
mit Vorsicht ||| used with caution ||| 1-0 0-1 1-2
mit Vorsicht ||| with caution ||| 0-0 1-1
mit Wasser ||| with water ||| 0-0 1-1
mit aktiver maligner Erkrankung , ||| with active malignant disease ||| 0-0 1-1 1-2 2-2 3-2 3-3 4-3
mit anderen Arten von Arzneimitteln ||| with other drug types ||| 0-0 1-1 2-2 3-2 4-2 2-3
mit anderen Arzneimitteln , ||| with medicines ||| 0-0 1-1 2-1
mit anderen Arzneimitteln Bitte informieren ||| other medicines Please tell ||| 1-0 2-1 0-2 3-2 4-3
mit anderen Arzneimitteln Bitte ||| other medicines Please ||| 1-0 2-1 0-2 3-2
mit anderen Arzneimitteln angewendet wird ||| with medicines known ||| 0-0 1-1 2-1 3-1 2-2
mit anderen Arzneimitteln angewendet ||| with medicines known ||| 0-0 1-1 2-1 3-1 2-2
mit anderen Arzneimitteln gemischt werden ||| mixed with other medicinal products ||| 1-0 3-0 0-1 1-2 2-3 3-3 3-4 4-4
mit anderen Arzneimitteln und ||| with other medicinal products and ||| 0-0 1-1 2-2 2-3 3-4
mit anderen Arzneimitteln ||| with medicines ||| 0-0 1-1 2-1
mit anderen Arzneimitteln ||| with other medicinal products ||| 0-0 1-1 1-2 1-3 2-3
mit anderen Arzneimitteln ||| with other medicinal products ||| 0-0 1-1 2-2 2-3
mit anderen ||| other ||| 1-0
mit anderen ||| with other ||| 0-0 1-1
mit anschließender bilärer Exkretion . ||| and biliary excretion . ||| 1-1 2-1 3-1 2-2 4-3
mit anschließender bilärer Exkretion . ||| biliary excretion . ||| 1-0 2-0 3-0 2-1 4-2
mit anschließender bilärer Exkretion ||| and biliary excretion ||| 1-1 2-1 3-1 2-2
mit anschließender bilärer Exkretion ||| biliary excretion ||| 1-0 2-0 3-0 2-1
mit atypischen antipsychotischen Wirkstoffen , ||| with atypical antipsychotic agents , ||| 0-0 1-1 3-1 2-2 3-3 4-4
mit atypischen antipsychotischen Wirkstoffen ||| with atypical antipsychotic agents ||| 0-0 1-1 3-1 2-2 3-3
mit beeinträchtigter Leberfunktion kann ||| with hepatic impairment may be ||| 0-0 2-1 1-2 2-2 3-3 3-4
mit beeinträchtigter Leberfunktion ||| with hepatic impairment ||| 0-0 2-1 1-2 2-2
mit bipolarer Störung ||| with bipolar disorder ||| 0-0 1-1 2-2
mit bipolarer ||| with bipolar ||| 0-0 1-1
mit chronischer Niereninsuffizienz : ||| chronic renal failure patients : ||| 1-0 0-1 2-1 1-2 2-2 2-3 3-4
mit chronischer Niereninsuffizienz und ||| with chronic renal failure and ||| 0-0 1-1 2-2 1-3 2-3 3-4
mit chronischer Niereninsuffizienz ||| chronic renal failure patients ||| 1-0 0-1 2-1 1-2 2-2 2-3
mit chronischer Niereninsuffizienz ||| with chronic renal failure , ||| 0-0 1-1 2-2 1-3 2-3
mit chronischer Niereninsuffizienz ||| with chronic renal failure ||| 0-0 1-1 2-2 1-3
mit chronischer Niereninsuffizienz ||| with chronic renal failure ||| 0-0 1-1 2-2 1-3 2-3
mit chronischer ||| with chronic ||| 0-0 1-1
mit dem Arzneimittel mitgelieferten ||| pipettes provided with the product ||| 3-0 1-1 3-1 0-2 1-3 2-4 3-4
mit dem Arzneimittel ||| with the product ||| 0-0 1-1 2-2
mit dem Essen oder ||| take it with or ||| 2-0 1-1 2-1 0-2 3-3
mit dem Essen ||| take it with ||| 2-0 1-1 2-1 0-2
mit dem Herzen oder den ||| of the heart or the ||| 0-0 1-1 2-2 3-3 4-4
mit dem Herzen oder ||| of the heart or ||| 0-0 1-1 2-2 3-3
mit dem Herzen ||| of the heart ||| 0-0 1-1 2-2
mit dem empfohlenen Behandlungsschema ||| with the recommended treatment schedule ||| 0-0 1-1 2-2 3-3 3-4
mit dem empfohlenen ||| with the recommended ||| 0-0 1-1 2-2
mit dem ||| of the ||| 0-0 1-1
mit dem ||| with the ||| 0-0 1-1
mit dem örtlichen Vertreter ||| the local representative ||| 1-0 0-1 2-1 1-2 2-2 3-2
mit dem örtlichen Vertreter ||| the local representative ||| 1-0 2-1 0-2 1-2 2-2 3-2
mit den nachfolgenden Verabreichungen ||| markedly with subsequent ||| 3-0 0-1 1-2 2-2
mit den nachfolgenden ||| with subsequent ||| 0-0 1-1 2-1
mit den ||| with the ||| 0-0 1-1
mit depressiven Störungen ||| 4.3 and ||| 1-0 2-1
mit depressiven Störungen ||| section 4.3 and ||| 1-1 2-2
mit depressiven ||| 4.3 ||| 1-0
mit depressiven ||| section 4.3 ||| 1-1
mit der Behandlung in ||| in the ||| 0-0 3-0 1-1 2-1
mit der Einnahme von ||| associated with ||| 1-0 2-0 3-0 0-1
mit der Einnahme ||| associated with ||| 1-0 2-0 0-1
mit der Gewichtszunahme , die ||| to that seen ||| 1-0 3-1 4-1 2-2 4-2
mit der Langzeitanwendung von Actos ||| at long-term use of Actos ||| 0-0 1-0 2-1 2-2 3-3 4-4
mit der Langzeitanwendung von ||| at long-term use of ||| 0-0 1-0 2-1 2-2 3-3
mit der Langzeitanwendung ||| at long-term use ||| 0-0 1-0 2-1 2-2
mit der Prägung " A ||| marked with " A ||| 1-0 2-0 0-1 3-2 4-3
mit der Prägung " A-007 ||| engraved with " A-007 ||| 1-0 2-0 0-1 3-2 4-3
mit der Prägung " A-008 ||| engraved with " A-008 ||| 1-0 2-0 0-1 3-2 4-3
mit der Prägung " A-009 ||| engraved with " A-009 ||| 1-0 2-0 0-1 3-2 4-3
mit der Prägung " A-011 ||| engraved with " A-011 ||| 1-0 2-0 0-1 3-2 4-3
mit der Prägung " ||| engraved with " ||| 1-0 2-0 0-1 3-2
mit der Prägung " ||| marked with " ||| 1-0 2-0 0-1 3-2
mit der Prägung 20 auf ||| debossed with 20 on ||| 2-0 0-1 2-1 3-2 4-3
mit der Prägung 20 ||| debossed with 20 ||| 2-0 0-1 2-1 3-2
mit der Prägung ||| debossed with ||| 2-0 0-1 2-1
mit der Prägung ||| engraved with ||| 1-0 2-0 0-1
mit der Prägung ||| marked with ||| 1-0 2-0 0-1
mit der Spritze auf einen ||| with the syringe onto a ||| 0-0 1-1 2-2 2-3 4-4
mit der Spritze auf ||| with the syringe onto ||| 0-0 1-1 2-2 2-3
mit der Spritze ||| with the syringe onto ||| 0-0 1-1 2-2 2-3
mit der klinischen ||| micro-ophthalmia ||| 0-0
mit der oralen Anwendung von ||| the use of oral ||| 1-0 3-1 4-2 2-3
mit der ||| at ||| 0-0 1-0
mit der ||| micro-ophthalmia ||| 0-0
mit der ||| the ||| 1-0
mit der ||| to ||| 1-0
mit der ||| treatment with ||| 1-0 0-1
mit der ||| with the ||| 0-0 1-1
mit der ||| with ||| 0-0
mit diesen Charakteristika ||| with these characteristics ||| 0-0 1-1 2-2
mit diesen Maßnahmen zur Gewichtsreduzierung ||| with this weight management programme ||| 0-0 1-0 1-1 4-2 2-3 3-3 4-4
mit diesen Maßnahmen zur Gewichtsreduzierung ||| with this weight management programme ||| 0-0 1-1 4-2 2-3 4-4
mit diesen ||| with these ||| 0-0 1-1
mit diesen ||| with this ||| 0-0 1-0 1-1
mit diesen ||| with this ||| 0-0 1-1
mit dieser Krankheit können auch ||| with this condition may also ||| 0-0 1-1 2-2 3-3 4-4
mit dieser Krankheit können ||| with this condition may ||| 0-0 1-1 2-2 3-3
mit dieser Krankheit ||| with this condition ||| 0-0 1-1 2-2
mit dieser ||| with this ||| 0-0 1-1
mit einem Alkoholtupfer . ||| using an alcohol wipe . ||| 0-0 1-0 1-1 2-2 2-3 3-4
mit einem Alkoholtupfer ||| using an alcohol wipe ||| 0-0 1-0 1-1 2-2 2-3
mit einem Arzt oder Apotheker ||| a doctor or pharmacist ||| 0-0 1-0 2-1 3-2 4-3
mit einem Arzt oder ||| a doctor or ||| 0-0 1-0 2-1 3-2
mit einem Arzt ||| a doctor ||| 0-0 1-0 2-1
mit einem Ausgangshämoglobinwert von ||| with baseline ||| 0-0 1-1 2-1 3-1
mit einem Ausgangswert von 7,9 ||| with a baseline of 7.9 ||| 0-0 1-1 1-2 2-2 3-3 4-4
mit einem Ausgangswert von ||| with a baseline of ||| 0-0 1-1 1-2 2-2 3-3
mit einem Ausgangswert ||| with a baseline ||| 0-0 1-1 1-2 2-2
mit einem Brombutyl-/Polyisopren-Gummistopfen ||| with a bromobutyl/ polyisoprene ||| 0-0 1-1 1-2 2-2 2-3
mit einem Brombutyl-Gummikolben ||| with a bromobutyl rubber plunger ||| 0-0 1-1 2-2 0-3 1-3 2-3 2-4
mit einem Glas Wasser ||| with a glass of water ||| 0-0 1-1 2-2 3-4
mit einem Glas ||| with a glass of ||| 0-0 1-1 2-2
mit einem Glas ||| with a glass ||| 0-0 1-1 2-2
mit einem Sulfonylharnstoff ||| a sulphonylurea ||| 0-0 1-0 1-1 2-1
mit einem Sulfonylharnstoff ||| and a sulphonylurea ||| 0-1 1-1 1-2 2-2
mit einem Sulfonylharnstoff ||| with a sulphonylurea ||| 0-0 1-1 1-2 2-2
mit einem erhöhten Risiko für ||| at increased risk of ||| 0-0 3-0 2-1 1-2 3-2 4-2 4-3
mit einem erhöhten ||| associated with an increased ||| 0-0 0-1 1-2 2-3
mit einem scheinbaren Verteilungsvolumen ||| with an apparent volume ||| 0-0 1-1 2-1 2-2 3-2 3-3
mit einem ||| a ||| 0-0 1-0
mit einem ||| associated with an ||| 0-0 0-1 1-2
mit einem ||| the ||| 1-0
mit einem ||| using a ||| 0-0 1-0 1-1
mit einem ||| using an ||| 0-0 1-0 1-1
mit einem ||| with a ||| 0-0 1-1
mit einem ||| with ||| 0-0
mit einer Adipositas ist die ||| mit einer Adipositas ist die ||| 0-0 1-1 2-2 3-3 4-4
mit einer Adipositas ist ||| mit einer Adipositas ist ||| 0-0 1-1 2-2 3-3
mit einer Adipositas ||| mit einer Adipositas ||| 0-0 1-1 2-2
mit einer Dichtung ( Aluminium ||| with an overseal ( aluminium ||| 0-0 1-1 2-2 4-2 3-3 3-4
mit einer Dosis von 80 ||| at dose levels of 80 ||| 0-0 1-0 1-1 2-1 3-3 4-4
mit einer Dosis von ||| at dose levels of ||| 0-0 1-0 1-1 2-1 3-3
mit einer Dosis ||| at dose levels ||| 0-0 1-0 1-1 2-1
mit einer Dosis ||| at dose ||| 0-0 1-0 1-1 2-1
mit einer Flüssigkeitsretention verbunden ist ||| associated with fluid retention ||| 1-0 3-0 0-1 2-2 3-2 2-3 4-3
mit einer Hämoglobin- Zielkonzentration ||| administered to target a haemoglobin ||| 0-0 2-0 2-2 1-3 3-4
mit einer Hämoglobin- ||| administered to target a ||| 0-0 2-0 2-2 1-3
mit einer Patrone ( 3 ||| with a cartridge ( 3 ||| 0-0 1-1 2-2 3-3 4-4
mit einer Patrone ( ||| with a cartridge ( ||| 0-0 1-1 2-2 3-3
mit einer Patrone ||| with a cartridge ||| 0-0 1-1 2-2
mit einer Reihe von anderen ||| with a number of other ||| 0-0 1-1 2-2 3-3 4-4
mit einer Reihe von ||| with a number of ||| 0-0 1-1 2-2 3-3
mit einer Reihe ||| with a number ||| 0-0 1-1 2-2
mit einer Vergleichsmedikation behandelt wurden ||| treated with comparator ||| 3-0 0-1 1-2 2-2 4-2
mit einer abrupten Verbesserung der ||| with abrupt improvement in ||| 0-0 1-1 2-1 3-1 3-2 4-2 3-3
mit einer kürzlich erlittenen niedrig-traumatischen ||| with a recent low-trauma ||| 0-0 1-1 2-2 3-3 4-3
mit einer kürzlich ||| with a recent ||| 0-0 1-1 2-2
mit einer länger ||| with a more ||| 0-0 1-1 2-2
mit einer manischen oder ||| with a manic or ||| 0-0 1-1 2-2 3-3
mit einer manischen ||| with a manic ||| 0-0 1-1 2-2
mit einer ng Ethinylestradiol/Levonorgestrel-Kombination wurde ||| mit einer ng Ethinylestradiol/Levonorgestrel-Kombination wurde ||| 0-0 1-1 2-2 3-3 4-4
mit einer ng Ethinylestradiol/Levonorgestrel-Kombination ||| mit einer ng Ethinylestradiol/Levonorgestrel-Kombination ||| 0-0 1-1 2-2 3-3
mit einer ng ||| mit einer ng ||| 0-0 1-1 2-2
mit einer niedrig-traumatischen ||| with a recent low-trauma ||| 0-0 1-1 2-2 2-3
mit einer passenden Einheitenskala vorgesehen ||| with a corresponding unit scale ||| 0-0 1-1 2-2 3-3 3-4 4-4
mit einer passenden ||| with a corresponding ||| 0-0 1-1 2-2
mit einer signifikanten Gewichtszunahme verbunden ||| with significant weight gain ||| 0-0 2-1 1-2 3-2 3-3 4-3
mit einer ||| a similar ||| 0-0 1-0
mit einer ||| a ||| 0-0 1-0
mit einer ||| mit einer ||| 0-0 1-1
mit einer ||| to a similar ||| 0-1 1-1
mit einer ||| to a ||| 0-1 1-1
mit einer ||| weight ||| 1-0
mit einer ||| with a 5 ||| 0-0 1-1
mit einer ||| with a ||| 0-0 1-1
mit einer ||| with an ||| 0-0 1-1
mit einer ähnlichen ||| a similar mix ||| 0-0 1-0 2-2
mit einer ähnlichen ||| to a similar mix ||| 0-1 1-1 2-3
mit enzephalopathieähnlichen Symptomen ( ||| with encephalopathy-like symptoms ( ||| 0-0 1-1 2-1 2-2 3-3
mit enzephalopathieähnlichen Symptomen kann auftreten ||| with encephalopathy-like symptoms can occur ||| 0-0 1-1 2-2 3-3 4-4
mit enzephalopathieähnlichen Symptomen kann ||| with encephalopathy-like symptoms can ||| 0-0 1-1 2-2 3-3
mit enzephalopathieähnlichen Symptomen ||| with encephalopathy-like symptoms ||| 0-0 1-1 2-1 2-2
mit enzephalopathieähnlichen Symptomen ||| with encephalopathy-like symptoms ||| 0-0 1-1 2-2
mit enzephalopathieähnlichen ||| with encephalopathy-like ||| 0-0 1-1
mit fixer Dosierung ||| fixed-dose ||| 0-0 1-0 2-0
mit folgenden ||| following ||| 1-0
mit folgenden ||| the following ||| 1-1
mit gemischten Episoden oder ||| with mixed episodes or ||| 0-0 1-1 2-2 3-3
mit gemischten Episoden ||| with mixed episodes ||| 0-0 1-1 2-2
mit gemischten ||| with mixed ||| 0-0 1-1
mit geschätzten Dosen von ||| with reported estimated doses ||| 0-0 1-1 1-2 2-3 3-3
mit geschätzten ||| with reported estimated ||| 0-0 1-1 1-2
mit gesunden Probanden lagen die ||| in healthy subjects the ||| 0-0 1-0 1-1 2-2 3-3 4-3
mit gesunden Probanden steigerte ||| in healthy subjects , ||| 0-0 1-0 1-1 2-2 3-2 3-3
mit gesunden Probanden ||| in healthy subjects ||| 0-0 1-0 1-1 2-2
mit gesunden ||| in healthy ||| 0-0 1-0 1-1
mit hohem Fieber ||| with high fever ||| 0-0 1-1 1-2 2-2
mit intravenösen Bolus-Verabreichungen ||| intravenous bolus ||| 1-0 2-1
mit intravenösen Bolus-Verabreichungen ||| the intravenous bolus ||| 1-1 2-2
mit intravenösen ||| intravenous ||| 1-0
mit intravenösen ||| the intravenous ||| 1-1
mit je 14 ||| packs of 14 ||| 0-0 1-0 1-1 2-2
mit je ||| packs of ||| 0-0 1-0 1-1
mit jeweils ||| , each ||| 1-1
mit jeweils ||| each ||| 1-0
mit kindersicherem Verschluss aus Polypropylen ||| with polypropylene child-resistant closure ||| 0-0 1-1 3-1 4-1 1-2 2-2 1-3
mit leichten oder ||| with mild or moderate ||| 0-0 1-1 2-2 1-3
mit leichter bis mäßiger ||| with mild to moderate ||| 0-0 1-1 3-1 2-2 2-3 3-3
mit metastasierendem Brustkrebs teilnahmen ||| with metastatic breast cancer ||| 0-0 1-1 1-2 2-2 1-3 3-3
mit metastasierendem Mammakarzinom ||| with metastatic breast cancer ||| 0-0 1-1 2-1 1-2 1-3
mit metastasierendem Mammakarzinom ||| with metastatic breast cancer ||| 0-0 1-1 2-2 2-3
mit metastasierendem ||| with metastatic ||| 0-0 1-1
mit mäßig ||| 5.3 ||| 1-0
mit noch vorhandener ||| with residual ||| 0-0 1-1 2-1
mit normalem oder ||| with normal or ||| 0-0 1-1 2-2
mit normalem ||| with normal ||| 0-0 1-1
mit oder ohne Anzeichen ||| 2.5 with or without evidence ||| 3-0 0-1 1-2 2-3 2-4 3-4
mit oder ohne Mahlzeit eingenommen ||| with or without food ||| 0-0 1-1 2-2 3-2 4-3
mit oder ohne Mahlzeit ||| with or without ||| 0-0 1-1 2-2 3-2
mit oder ohne Nahrung eingenommen ||| with or without food ||| 0-0 1-1 2-2 3-3 4-3
mit oder ohne psychotischen Merkmalen ||| with or without psychotic features ||| 0-0 1-1 2-2 3-3 4-4
mit oder ohne psychotischen ||| with or without psychotic ||| 0-0 1-1 2-2 3-3
mit oder ohne ||| with or without ||| 0-0 1-1 2-2
mit oder ||| with or ||| 0-0 1-1
mit oral ||| with oral ||| 0-0 1-1
mit plötzlichem Wirkverlust , ||| developing sudden lack of efficacy ||| 0-0 1-0 1-1 1-2 2-2 2-4
mit plötzlichem Wirkverlust ||| developing sudden lack of efficacy ||| 0-0 1-0 1-1 1-2 2-2 2-4
mit radiologisch bestätigtem , ||| with ||| 0-0
mit radiologisch bestätigtem ||| with ||| 0-0
mit radiologisch ||| with ||| 0-0
mit rekombinantem humanen Erythropoetin behandelten ||| treated with recombinant human erythropoietin ||| 4-0 0-1 1-2 2-2 3-2 4-2 2-3 3-4
mit renaler Anämie ||| with renal anaemia , ||| 0-0 1-1 2-2
mit renaler Anämie ||| with renal anaemia ||| 0-0 1-1 2-2
mit renaler ||| with renal ||| 0-0 1-1
mit schnell wechselnden Ideen und ||| quickly with racing ideas and ||| 1-0 2-0 0-1 2-2 3-2 3-3 4-4
mit schnell wechselnden Ideen ||| quickly with racing ideas ||| 1-0 2-0 0-1 2-2 3-2 3-3
mit schnell wirkend , Insulin ||| with fast-acting , insulin ||| 0-0 1-1 2-1 3-2 4-3
mit schnell wirkend , ||| with fast-acting , ||| 0-0 1-1 2-1 3-2
mit schnell wirkend ||| with fast-acting ||| 0-0 1-1 2-1
mit schweren ||| with severe ||| 0-0 1-1
mit schwerer Agitiertheit , ||| with severe agitation , ||| 0-0 1-1 2-2 3-3
mit schwerer Agitiertheit ||| with severe agitation ||| 0-0 1-1 2-2
mit schwerer Leberfunktionsstörung sollten ||| with severe hepatic impairment should ||| 0-0 1-1 2-2 2-3 3-4
mit schwerer Leberfunktionsstörung ||| with severe hepatic impairment ||| 0-0 1-1 2-2 2-3
mit schwerer Niereninsuffizienz ||| with severe renal ||| 0-0 1-1 2-2
mit schwerer ||| with severe ||| 0-0 1-1
mit seltenen Erbkrankheiten ||| with rare hereditary problems of ||| 0-0 1-1 1-2 2-2 2-3
mit seltenen Erbkrankheiten ||| with rare hereditary problems ||| 0-0 1-1 1-2 2-2 2-3
mit sich überlagernden Nebenwirkungen ||| with overlapping undesirable effects ||| 0-0 1-1 2-1 2-2 3-2 3-3
mit soliden Tumoren ( ||| with solid tumours ( ||| 0-0 1-1 2-2 3-3
mit soliden Tumoren ||| with solid tumours ||| 0-0 1-1 2-2
mit soliden ||| with solid ||| 0-0 1-1
mit stark eingeschränkter ||| mit stark eingeschränkter ||| 0-0 1-1 1-2 2-2
mit stark ||| with severe ||| 0-0 1-1
mit subkutaner Applikation . ||| both via subcutaneous administration . ||| 1-2 2-3 3-4
mit subkutaner Applikation . ||| subcutaneous administration . ||| 1-0 2-1 3-2
mit subkutaner Applikation . ||| via subcutaneous administration . ||| 1-1 2-2 3-3
mit subkutaner Applikation ||| both via subcutaneous administration ||| 1-2 2-3
mit subkutaner Applikation ||| subcutaneous administration ||| 1-0 2-1
mit subkutaner Applikation ||| via subcutaneous administration ||| 1-1 2-2
mit subkutaner ||| both via subcutaneous ||| 1-2
mit subkutaner ||| subcutaneous ||| 1-0
mit subkutaner ||| via subcutaneous ||| 1-1
mit symptomatischer Anämie , die ||| patients with symptomatic anaemia ||| 0-0 1-0 0-1 1-2 2-2 3-2 2-3 4-3
mit symptomatischer Anämie , die ||| patients with symptomatic anaemia ||| 1-0 0-1 1-2 2-2 3-2 2-3 4-3
mit weniger ||| with less ||| 0-0 1-1
mit zunehmender Dosis zu . ||| increased with increasing dose . ||| 1-0 0-1 1-2 2-3 3-3 4-4
mit zunehmender Dosis zu ||| increased with increasing dose ||| 1-0 0-1 1-2 2-3 3-3
mit zunehmender Studienlänge : ||| with increasing study duration : ||| 0-0 1-1 2-2 2-3 3-4
mit zunehmender Studienlänge ||| with increasing study duration ||| 0-0 1-1 2-2 2-3
mit zunehmender ||| increased with increasing ||| 1-0 0-1 1-2
mit zunehmender ||| with increasing ||| 0-0 1-1
mit zwei anderen Diabetesmedikamenten ||| with two other antidiabetic medicines ||| 0-0 1-1 2-2 3-3 3-4
mit zwei anderen ||| with two other ||| 0-0 1-1 2-2
mit zwei ||| with two ||| 0-0 1-1
mit ||| , with ||| 0-1
mit ||| a ||| 0-0
mit ||| administered ||| 0-0
mit ||| agreed with ||| 0-1
mit ||| and treatment with ||| 0-2
mit ||| associated with ||| 0-0 0-1
mit ||| at ||| 0-0
mit ||| be ||| 0-0
mit ||| decreases with ||| 0-1
mit ||| have ||| 0-0
mit ||| in addition to ||| 0-0 0-1
mit ||| in addition ||| 0-0 0-1
mit ||| in patients ||| 0-1
mit ||| in ||| 0-0
mit ||| micro-ophthalmia ||| 0-0
mit ||| mit ||| 0-0
mit ||| of ||| 0-0
mit ||| patients presenting with ||| 0-0 0-1 0-2
mit ||| patients with ||| 0-0 0-1
mit ||| patients ||| 0-0
mit ||| significant ||| 0-0
mit ||| start of ||| 0-0
mit ||| start ||| 0-0
mit ||| supplements ||| 0-0
mit ||| those mentioned in ||| 0-0
mit ||| those mentioned ||| 0-0
mit ||| those ||| 0-0
mit ||| to patients with ||| 0-1 0-2
mit ||| treated with ||| 0-1
mit ||| treatment with ||| 0-1
mit ||| treatment ||| 0-0
mit ||| used to ||| 0-0
mit ||| used ||| 0-0
mit ||| using ||| 0-0
mit ||| with a ||| 0-0
mit ||| with a ||| 0-0 0-1
mit ||| with associated risk ||| 0-0 0-1
mit ||| with associated ||| 0-0 0-1
mit ||| with less ||| 0-0
mit ||| with ||| 0-0
mit ähnlicher Resorptionsrate und ||| with a similar rate and ||| 0-0 1-1 1-2 2-3 3-4
mit ähnlicher Resorptionsrate ||| , with a similar rate ||| 0-1 1-2 1-3 2-4
mit ähnlicher Resorptionsrate ||| with a similar rate ||| 0-0 1-1 1-2 2-3
mit ähnlicher ||| , with a similar ||| 0-1 1-2 1-3
mit ähnlicher ||| with a similar ||| 0-0 1-1 1-2
mit übersteigertem ||| condition with ||| 1-0 0-1
mitotischen ||| interphase ||| 0-0
mitteilen ||| tell ||| 0-0
mittels intravenöser Applikation . ||| by the intravenous route . ||| 0-0 1-1 1-2 2-3 3-4
mittels intravenöser Applikation ||| by the intravenous route ||| 0-0 1-1 1-2 2-3
mittels intravenöser ||| by the intravenous ||| 0-0 1-1 1-2
mittels ||| by ||| 0-0
mittelschweren bestehenden ||| existing ||| 1-0
mittlere Besserung vom Ausgangswert auf ||| mean improvement from baseline on ||| 0-0 1-1 2-2 3-3 4-4
mittlere Besserung vom Ausgangswert ||| mean improvement from baseline ||| 0-0 1-1 2-2 3-3
mittlere Besserung vom ||| mean improvement from ||| 0-0 1-1 2-2
mittlere Besserung ||| mean improvement ||| 0-0 1-1
mittlere Cmax-Wert von Paclitaxel wurde ||| mean Cmax of paclitaxel , ||| 0-0 1-1 2-2 1-3 3-3
mittlere Cmax-Wert von Paclitaxel wurde ||| mean Cmax of paclitaxel ||| 0-0 1-1 2-2 1-3 3-3
mittlere Cmax-Wert von Paclitaxel ||| mean Cmax of paclitaxel , ||| 0-0 1-1 2-2 1-3 3-3
mittlere Cmax-Wert von Paclitaxel ||| mean Cmax of paclitaxel ||| 0-0 1-1 2-2 1-3 3-3
mittlere Differenz zu Placebo -2,9 ||| mean difference to placebo -2.9 ||| 0-0 1-1 2-2 3-3 4-4
mittlere Differenz zu Placebo ||| mean difference to placebo ||| 0-0 1-1 2-2 3-3
mittlere Differenz zu ||| mean difference to ||| 0-0 1-1 2-2
mittlere Differenz ||| mean difference ||| 0-0 1-1
mittlere Gesamt-Clearance betrug 15 ||| mean total clearance was 15 ||| 0-0 1-1 1-2 2-3 3-4
mittlere Gesamt-Clearance betrug ||| mean total clearance was ||| 0-0 1-1 1-2 2-3
mittlere Gesamt-Clearance ||| mean total clearance ||| 0-0 1-1 1-2
mittlere Plasma-Eliminationshalbwertszeit von ||| mean plasma elimination half-life of ||| 0-0 1-1 1-2 1-3 2-4
mittlere Plasma-Eliminationshalbwertszeit ||| mean plasma elimination half-life ||| 0-0 1-1 1-2 1-3
mittlere Verteilungsvolumen ||| mean volume of distribution ||| 0-0 1-1 1-2 1-3
mittlere ||| mean total ||| 0-0 0-1
mittlere ||| mean ||| 0-0
mittleren ||| in mean ||| 0-1
mittleren ||| mean ||| 0-0
ml ( 10 000 ||| ml ( 10 000 ||| 0-0 1-1 2-2 3-3
ml ( 10 ||| ml ( 10 ||| 0-0 1-1 2-2
ml ( 1000 ||| ml ( 1000 ||| 0-0 1-1 2-2
ml ( 2000 ||| ml ( 2000 ||| 0-0 1-1 2-2
ml ( 3,5 ||| ml ( 3.5 ||| 0-0 1-1 2-2
ml ( 3000 ||| ml ( 3000 ||| 0-0 1-1 2-2
ml ( 4000 ||| ml ( 4000 ||| 0-0 1-1 2-2
ml ( 5000 ||| ml ( 5000 ||| 0-0 1-1 2-2
ml ( 6000 ||| ml ( 6000 ||| 0-0 1-1 2-2
ml ( 7000 ||| ml ( 7000 ||| 0-0 1-1 2-2
ml ( 8000 ||| ml ( 8000 ||| 0-0 1-1 2-2
ml ( 9000 ||| ml ( 9000 ||| 0-0 1-1 2-2
ml ( ||| ml ( ||| 0-0 1-1
ml ) . ||| ml ) . ||| 0-0 1-1 2-2
ml ) Aripiprazol . ||| ml ) aripiprazole . ||| 0-0 1-1 2-2 3-3
ml ) Aripiprazol ||| ml ) aripiprazole ||| 0-0 1-1 2-2
ml ) Durchstechflaschen ||| ml ) ||| 0-0 2-0 1-1
ml ) für die erste ||| ml ) for the first ||| 0-0 1-1 2-2 3-3 4-4
ml ) für die ||| ml ) for the ||| 0-0 1-1 2-2 3-3
ml ) für ||| ml ) for ||| 0-0 1-1 2-2
ml ) kann abhängig vom ||| ml ) may be ||| 0-0 1-1 2-2 3-2 2-3
ml ) kann abhängig ||| ml ) may be ||| 0-0 1-1 2-2 3-2 2-3
ml ) ||| ml ) , ||| 0-0 1-1
ml ) ||| ml ) ||| 0-0 1-1
ml . ||| ml . ||| 0-0 1-1
ml . ||| ml ||| 0-0 1-0
ml 0,2 mg Propyl-4-hydroxybenzoat ||| ml 0.2 mg propyl parahydroxybenzoate ||| 0-0 1-1 2-2 3-3 3-4
ml 0,2 mg ||| ml 0.2 mg ||| 0-0 1-1 2-2
ml 0,2 ||| ml 0.2 ||| 0-0 1-1
ml 1,8 mg Methyl-4-hydroxybenzoat ||| ml 1.8 mg methyl parahydroxybenzoate ||| 0-0 1-1 2-2 3-3 3-4
ml 1,8 mg ||| ml 1.8 mg ||| 0-0 1-1 2-2
ml 1,8 ||| ml 1.8 ||| 0-0 1-1
ml 400 mg Sucrose je ||| ml 400 mg sucrose per ||| 0-0 1-1 2-2 3-3 4-4
ml 400 mg Sucrose ||| ml 400 mg sucrose ||| 0-0 1-1 2-2 3-3
ml 400 mg ||| ml 400 mg ||| 0-0 1-1 2-2
ml 400 ||| ml 400 ||| 0-0 1-1
ml 6 Fertigspritzen mit je ||| ml 6 pre-filled syringes of ||| 0-0 1-1 2-2 2-3 3-3 4-3 4-4
ml 6 ||| ml 6 ||| 0-0 1-1
ml : 10 kg Körpergewicht ||| ml : 10 kg BW ||| 0-0 1-1 2-2 3-3 4-4
ml : 10 kg ||| ml : 10 kg ||| 0-0 1-1 2-2 3-3
ml : 10 ||| ml : 10 ||| 0-0 1-1 2-2
ml : 22 kg Körpergewicht ||| ml : 22 kg BW ||| 0-0 1-1 2-2 3-3 4-4
ml : 22 kg ||| ml : 22 kg ||| 0-0 1-1 2-2 3-3
ml : 22 ||| ml : 22 ||| 0-0 1-1 2-2
ml : 40 kg Körpergewicht ||| ml : 40 kg BW ||| 0-0 1-1 2-2 3-3 4-4
ml : 40 kg ||| ml : 40 kg ||| 0-0 1-1 2-2 3-3
ml : 40 ||| ml : 40 ||| 0-0 1-1 2-2
ml : ||| ml : ||| 0-0 1-1
ml EU/0/00/000/002 120 ml ||| ml 120 ml ||| 0-0 1-1 2-1 3-2
ml EU/0/00/000/002 120 ||| ml 120 ||| 0-0 1-1 2-1
ml EU/0/00/000/003 210 ml ||| ml 210 ml ||| 0-0 1-1 2-1 3-2
ml EU/0/00/000/003 210 ||| ml 210 ||| 0-0 1-1 2-1
ml Fertiginfusionslösung ) wird durch ||| ml ready-to-infuse solution ) is ||| 0-0 1-1 0-2 2-3 3-4
ml Fertiginfusionslösung ) wird ||| ml ready-to-infuse solution ) is ||| 0-0 1-1 0-2 2-3 3-4
ml Fertiginfusionslösung ) ||| ml ready-to-infuse solution ) ||| 0-0 1-1 0-2 2-3
ml Fertiginfusionslösung ||| ml ready-to-infuse solution ||| 0-0 1-1 0-2
ml Flasche ||| ml bottle ||| 0-0 1-1
ml Injektionslösung enthält ||| ml solution for injection contains ||| 0-0 1-1 1-2 1-3 2-4
ml Injektionslösung in ||| ml solution for injection in ||| 0-0 1-1 1-2 1-3 2-4
ml Injektionslösung ||| ml solution for injection ||| 0-0 1-1 1-2 1-3
ml Lösung ( entspricht ||| ml solution ( corresponding to ||| 0-0 1-1 2-2 0-3 3-4
ml Lösung ( ||| ml solution ( corresponding ||| 0-0 1-1 2-2 0-3
ml Lösung enthält 5 ||| ml of solution contains 5 ||| 0-0 1-1 1-2 2-3 3-4
ml Lösung enthält 5 ||| ml of solution contains 5 ||| 0-0 1-2 2-3 3-4
ml Lösung enthält ||| ml of solution contains ||| 0-0 1-1 1-2 2-3
ml Lösung enthält ||| ml of solution contains ||| 0-0 1-2 2-3
ml Lösung enthält ||| ml solution contains ||| 0-0 1-1 2-2
ml Lösung zum Einnehmen 150 ||| ml oral solution 150 ||| 0-0 2-1 3-1 1-2 3-2 4-3
ml Lösung zum Einnehmen 480 ||| ml oral solution 480 ||| 0-0 2-1 3-1 1-2 3-2 4-3
ml Lösung zum Einnehmen ||| ml oral solution ||| 0-0 2-1 3-1 1-2 3-2
ml Lösung ||| ml of solution ||| 0-0 1-1 1-2
ml Lösung ||| ml of solution ||| 0-0 1-2
ml Lösung ||| ml solution ||| 0-0 1-1
ml Lösung ||| ml ||| 0-0 1-0
ml Patrone aus Glas ( ||| ml glass cartridge ( ||| 0-0 3-1 1-2 2-2 4-3
ml Patrone aus Glas ||| ml glass cartridge ||| 0-0 3-1 1-2 2-2
ml Teil einer ||| ml Component of a ||| 0-0 1-1 2-2 2-3
ml Teil ||| ml Component ||| 0-0 1-1
ml Tropfpipette abgemessen werden , ||| ml calibrated dropper ||| 0-0 1-1 2-1 1-2
ml Tropfpipette abgemessen werden ||| ml calibrated dropper ||| 0-0 1-1 2-1 1-2
ml Tropfpipette abgemessen ||| ml calibrated dropper ||| 0-0 1-1 2-1 1-2
ml an einer Injektionsstelle ||| ml at one injection site ||| 0-0 1-1 2-2 3-2 3-3 1-4 3-4
ml der Lösung enthält 0,05 ||| ml solution contains 0.05 ||| 0-0 2-1 3-2 4-3
ml der Lösung enthält ||| ml solution contains ||| 0-0 2-1 3-2
ml der Lösung ||| ml solution ||| 0-0 2-1
ml der Suspension ||| ml of suspension ||| 0-0 1-1 2-2
ml der ||| ml of ||| 0-0 1-1
ml der ||| ml ||| 0-0
ml des Produkts pro ||| ml of the product per ||| 0-0 1-1 1-2 1-3 2-3 3-4
ml des Produkts ||| ml of the product ||| 0-0 1-1 1-2 1-3 2-3
ml enthält 10 000 Internationale ||| ml contains 10 000 international ||| 0-0 1-1 2-2 3-3 4-4
ml enthält 10 000 ||| ml contains 10 000 ||| 0-0 1-1 2-2 3-3
ml enthält 10 ||| ml contains 10 ||| 0-0 1-1 2-2
ml enthält 100 I.E. ||| ml contains 100 IU of ||| 0-0 1-1 2-2 3-3 3-4
ml enthält 100 ||| ml contains 100 ||| 0-0 1-1 2-2
ml enthält 1000 Internationale Einheiten ||| ml contains 1000 international units ||| 0-0 1-1 2-2 3-3 4-4
ml enthält 1000 Internationale ||| ml contains 1000 international ||| 0-0 1-1 2-2 3-3
ml enthält 1000 ||| ml contains 1000 ||| 0-0 1-1 2-2
ml enthält 2000 Internationale Einheiten ||| ml contains 2000 international units ||| 0-0 1-1 2-2 3-3 4-4
ml enthält 2000 Internationale ||| ml contains 2000 international ||| 0-0 1-1 2-2 3-3
ml enthält 2000 ||| ml contains 2000 ||| 0-0 1-1 2-2
ml enthält 3000 Internationale Einheiten ||| ml contains 3000 international units ||| 0-0 1-1 2-2 3-3 4-4
ml enthält 3000 Internationale ||| ml contains 3000 international ||| 0-0 1-1 2-2 3-3
ml enthält 3000 ||| ml contains 3000 ||| 0-0 1-1 2-2
ml enthält 40 I.E. ||| ml contains 40 IU of ||| 0-0 1-1 2-2 3-3 3-4
ml enthält 40 ||| ml contains 40 ||| 0-0 1-1 2-2
ml enthält 4000 Internationale Einheiten ||| ml contains 4000 international units ||| 0-0 1-1 2-2 3-3 4-4
ml enthält 4000 Internationale ||| ml contains 4000 international ||| 0-0 1-1 2-2 3-3
ml enthält 4000 ||| ml contains 4000 ||| 0-0 1-1 2-2
ml enthält 5000 Internationale Einheiten ||| ml contains 5000 international units ||| 0-0 1-1 2-2 3-3 4-4
ml enthält 5000 Internationale ||| ml contains 5000 international ||| 0-0 1-1 2-2 3-3
ml enthält 5000 ||| ml contains 5000 ||| 0-0 1-1 2-2
ml enthält 6000 Internationale Einheiten ||| ml contains 6000 international units ||| 0-0 1-1 2-2 3-3 4-4
ml enthält 6000 Internationale ||| ml contains 6000 international ||| 0-0 1-1 2-2 3-3
ml enthält 6000 ||| ml contains 6000 ||| 0-0 1-1 2-2
ml enthält 7000 Internationale Einheiten ||| ml contains 7000 international units ||| 0-0 1-1 2-2 3-3 4-4
ml enthält 7000 Internationale ||| ml contains 7000 international ||| 0-0 1-1 2-2 3-3
ml enthält 7000 ||| ml contains 7000 ||| 0-0 1-1 2-2
ml enthält 8000 Internationale Einheiten ||| ml contains 8000 international units ||| 0-0 1-1 2-2 3-3 4-4
ml enthält 8000 Internationale ||| ml contains 8000 international ||| 0-0 1-1 2-2 3-3
ml enthält 8000 ||| ml contains 8000 ||| 0-0 1-1 2-2
ml enthält 9000 Internationale Einheiten ||| ml contains 9000 international units ||| 0-0 1-1 2-2 3-3 4-4
ml enthält 9000 Internationale ||| ml contains 9000 international ||| 0-0 1-1 2-2 3-3
ml enthält 9000 ||| ml contains 9000 ||| 0-0 1-1 2-2
ml enthält ||| ml contains ||| 0-0 1-1
ml entsprechend 1000 ||| ml equivalent to 1000 ||| 0-0 0-1 1-1 1-2 2-3
ml entsprechend 300 ||| ml equivalent to 300 ||| 0-0 0-1 1-1 1-2 2-3
ml entsprechend 300 ||| ml equivalent to 300 ||| 0-0 1-1 1-2 2-3
ml entsprechend 400 ||| ml equivalent to 400 ||| 0-0 0-1 1-1 1-2 2-3
ml entsprechend ||| ml equivalent to ||| 0-0 0-1 1-1 1-2
ml entsprechend ||| ml equivalent to ||| 0-0 1-1 1-2
ml oder 480 ml ||| or 480 ml per bottle ||| 1-0 2-1 0-2 3-2 0-3 2-4
ml pro ||| ml per ||| 0-0 1-1
ml und eine Bündelpackung mit ||| ml and a multipack with ||| 0-0 1-1 2-2 3-3 4-4
ml und eine Bündelpackung ||| ml and a multipack ||| 0-0 1-1 2-2 3-3
ml und eine ||| ml and a ||| 0-0 1-1 2-2
ml und ||| ml and ||| 0-0 1-1
ml ||| ml of ||| 0-0
ml ||| ml ||| 0-0
mm geringere ||| mm ||| 0-0 1-0
mmol/l ) . ||| mmol/ l ) . ||| 0-0 0-1 1-2 2-3
mmol/l ) bis 12 ||| mmol/ l ) to 12 ||| 0-0 0-1 1-2 2-3 3-4
mmol/l ) bis ||| mmol/ l ) to ||| 0-0 0-1 1-2 2-3
mmol/l ) lagen , ||| mmol/ l ) ||| 0-0 0-1 1-2
mmol/l ) lagen ||| mmol/ l ) ||| 0-0 0-1 1-2
mmol/l ) liegt ||| mmol/ l ) ||| 0-0 0-1 2-1 1-2
mmol/l ) oder die ||| mmol/ l ) or the ||| 0-0 0-1 1-2 2-3 3-4
mmol/l ) oder ||| mmol/ l ) or ||| 0-0 0-1 1-2 2-3
mmol/l ) pro Monat ansteigt ||| mmol/ l ) per month ||| 0-0 0-1 1-2 2-3 3-4 4-4
mmol/l ) pro ||| mmol/ l ) per ||| 0-0 0-1 1-2 2-3
mmol/l ) sollte vermieden ||| mmol/ l ) should ||| 0-0 1-0 3-1 1-2 2-3
mmol/l ) sollte ||| mmol/ l ) should ||| 0-0 0-1 1-2 2-3
mmol/l ) steigt . ||| mmol/ l ) . ||| 0-0 0-1 2-1 1-2 3-3
mmol/l ) steigt ||| mmol/ l ) ||| 0-0 0-1 2-1 1-2
mmol/l ) zu erreichen . ||| mmol/ l ) . ||| 0-0 2-1 3-1 1-2 4-3
mmol/l ) zu erreichen ||| mmol/ l ) ||| 0-0 2-1 3-1 1-2
mmol/l ) ||| mmol/ l ) in ||| 0-0 0-1 1-2
mmol/l ) ||| mmol/ l ) ||| 0-0 0-1 1-2
mmol/l ||| mmol/ l ||| 0-0 0-1
mmol/l ||| mmol/ ||| 0-0
moderaten Leberproblemen oder mit ||| liver problems or with ||| 1-0 0-1 1-1 2-2 3-3
moderaten Leberproblemen oder ||| liver problems or ||| 1-0 0-1 1-1 2-2
moderaten Leberproblemen ||| liver problems ||| 1-0 0-1 1-1
monate- bis ||| months to ||| 0-0 1-0 1-1
monate- ||| rarely reported in ||| 0-0 0-1
monate- ||| rarely reported ||| 0-0 0-1
morphometrische Wirbelkörperfrakturen Aclasta ||| morphometric vertebral fractures Aclasta ||| 0-0 1-1 1-2 2-3
morphometrische Wirbelkörperfrakturen ||| morphometric vertebral fractures ||| 0-0 1-1 1-2
morphometrische ||| morphometric ||| 0-0
motorische Neuropathie , Ataxie , ||| motor neuropathy , ataxia , ||| 0-0 1-1 2-2 3-3 4-4
motorische Neuropathie , Ataxie ||| motor neuropathy , ataxia ||| 0-0 1-1 2-2 3-3
motorische Neuropathie , ||| motor neuropathy , ||| 0-0 1-1 2-2
motorische Neuropathie ||| motor neuropathy ||| 0-0 1-1
motorische ||| motor ||| 0-0
multiphasische Weise ab . ||| a multiphasic manner . ||| 2-0 0-1 1-2 3-3
multiphasische Weise ab . ||| in a multiphasic manner . ||| 2-1 0-2 1-3 3-4
multiphasische Weise ab ||| a multiphasic manner ||| 2-0 0-1 1-2
multiphasische Weise ab ||| in a multiphasic manner ||| 2-1 0-2 1-3
multiphasische Weise ||| multiphasic manner ||| 0-0 1-1
multiphasische ||| multiphasic ||| 0-0
multiple ||| multiple ||| 0-0
multipler ||| multiple medicinal ||| 0-0 0-1
multizentrische Studie wurde ||| multi-centre trial was ||| 0-0 1-1 2-2
multizentrische Studie ||| multi-centre trial ||| 0-0 1-1
multizentrische ||| multi-centre ||| 0-0
muss befolgt werden . ||| must be followed . ||| 0-0 1-1 2-1 1-2 3-3
muss befolgt werden ||| must be followed ||| 0-0 1-1 2-1 1-2
muss das Arzneimittel abgesetzt werden ||| drug therapy should be discontinued ||| 0-0 1-1 3-1 0-2 2-2 4-3 3-4 4-4
muss das Arzneimittel ||| has to be ||| 0-0 1-1 2-1 0-2
muss das Blutbild regelmäßig überwacht ||| counts should be performed during ||| 2-0 0-1 4-1 0-2 1-2 3-2 2-3 3-4
muss die Lösung ||| , the solution must ||| 1-1 2-2 0-3
muss die Lösung ||| the solution must ||| 1-0 2-1 0-2
muss unter Berücksichtigung ||| must be conducted ||| 0-0 0-1 2-2
muss unter ||| must be ||| 0-0 0-1
muss ||| followed ||| 0-0
muss ||| must be ||| 0-0 0-1
muss ||| must ||| 0-0
muss ||| should be ||| 0-0 0-1
myokardiale Ischämien , ||| myocardial ischaemia , myocardial ||| 0-0 0-1 1-1 2-2 1-3
männlichen Patienten ||| male patients ||| 0-0 1-1
männlichen und weiblichen gesunden Probanden ||| healthy male and female subjects ||| 3-0 0-1 1-2 2-3 3-4 4-4
männlichen und weiblichen ||| male and female ||| 0-0 1-1 2-2
männlichen und ||| male and ||| 0-0 1-1
männlichen ||| male ||| 0-0
mäßig ausgeprägt und ||| moderate and ||| 0-0 1-0 2-1
mäßig ausgeprägt ||| moderate ||| 0-0 1-0
mäßig eingeschränkter ||| moderate hepatic impairment . ||| 0-0 1-1 1-2
mäßig eingeschränkter ||| moderate hepatic impairment ||| 0-0 1-1 1-2
mäßig und verschwinden innerhalb von ||| moderate and go away within ||| 0-0 1-1 2-1 2-2 3-4 4-4
mäßig und verschwinden ||| moderate and go away ||| 0-0 1-1 2-1 2-2
mäßig und verschwinden ||| moderate and go ||| 0-0 1-1 2-1 2-2
mäßig ||| 5.3 ||| 0-0
mäßig ||| moderate ||| 0-0
mäßigen Einfluss auf die ||| moderate influence on the ||| 0-0 1-1 2-2 3-2 3-3
mäßigen Einfluss ||| moderate influence ||| 0-0 1-1
mäßigen Einschränkung der Nierenfunktion eine ||| moderate renal impairment ||| 0-0 4-0 1-1 3-1 3-2
mäßigen ||| moderate ||| 0-0
möglich - z.B. einige Wochen ||| possible , even several weeks ||| 0-0 1-2 2-2 3-2 3-3 4-4
möglich - z.B. einige ||| possible , even several ||| 0-0 1-2 2-2 3-2 3-3
möglich . ||| be used . ||| 0-0 0-1 1-2
möglich . ||| may occur . ||| 0-0 1-2
möglich ? 5. ||| to store ABILIFY 6. ||| 0-0 0-1 2-1 2-2 1-3 2-3
möglich ||| be used ||| 0-0 0-1
möglich ||| may occur ||| 0-0
möglich ||| may ||| 0-0
möglich ||| possible , ||| 0-0
möglich ||| possible ||| 0-0
mögliche Nutzen rechtfertigt eindeutig ||| benefit clearly justifies ||| 1-0 0-1 3-1 2-2 3-2
mögliche Wechselwirkungen bei ||| take possible interactions ||| 0-0 0-1 1-2 2-2
mögliche ||| take possible ||| 0-0 0-1
möglichen Blutdruckabfalls beobachtet werden . ||| observed for orthostatic hypotension . ||| 2-0 0-1 1-1 1-2 1-3 3-4 4-4
möglichen Blutdruckabfalls beobachtet ||| observed for orthostatic hypotension ||| 2-0 0-1 1-1 1-2 1-3
möglichen Blutdruckabfalls ||| for orthostatic hypotension ||| 0-0 1-0 1-1 1-2
möglicher ||| possible ||| 0-0
möglicherweise Protein-Disulfid-Isomerase abgebaut wird . ||| possibly protein disulfide isomerase . ||| 0-0 1-0 1-1 1-2 2-2 2-3 3-3 4-4
möglicherweise Protein-Disulfid-Isomerase abgebaut wird ||| possibly protein disulfide isomerase ||| 0-0 1-0 1-1 1-2 2-2 2-3 3-3
möglicherweise auch verzögert ) . ||| possibly delayed ) . ||| 0-0 2-1 3-2 4-3
möglicherweise auch verzögert ) ||| possibly delayed ) ||| 0-0 2-1 3-2
möglicherweise auch verzögert ||| possibly delayed ||| 0-0 2-1
möglicherweise auch ||| possibly ||| 0-0
möglicherweise die üblichen Warnsymptome . ||| longstanding diabetes . ||| 0-0 1-0 2-0 3-0 3-1 4-2
möglicherweise die üblichen Warnsymptome ||| longstanding diabetes ||| 0-0 1-0 2-0 3-0 3-1
möglicherweise nicht alle Packungsgrößen in ||| all pack sizes may ||| 0-0 0-1 1-1 2-2 3-2 4-2 3-3
möglicherweise nicht alle Packungsgrößen in ||| all the pack sizes may ||| 0-0 1-2 2-2 2-3 3-3 4-3 3-4
möglicherweise nicht alle Packungsgrößen in ||| möglicherweise nicht alle Packungsgrößen in ||| 0-0 1-1 2-2 3-3 4-4
möglicherweise nicht alle Packungsgrößen ||| möglicherweise nicht alle Packungsgrößen ||| 0-0 1-1 2-2 3-3
möglicherweise nicht alle ||| möglicherweise nicht alle ||| 0-0 1-1 2-2
möglicherweise nicht ||| all pack ||| 0-0 0-1 1-1
möglicherweise nicht ||| möglicherweise nicht ||| 0-0 1-1
möglicherweise relevant ||| to ||| 0-0
möglicherweise verzögert ) . ||| possibly delayed ) . ||| 0-0 1-1 2-2 3-3
möglicherweise verzögert ) ||| possibly delayed ) ||| 0-0 1-1 2-2
möglicherweise verzögert ||| possibly delayed ||| 0-0 1-1
möglicherweise ||| all the ||| 0-0
möglicherweise ||| all ||| 0-0
möglicherweise ||| may ||| 0-0
möglicherweise ||| möglicherweise ||| 0-0
möglicherweise ||| possibly ||| 0-0
möglicherweise ||| to ||| 0-0
möglicherweise überempfindlich ( allergisch ) ||| full list of all ||| 2-0 1-1 3-2 0-3
möglicherweise überempfindlich ( allergisch ||| full list of all ||| 2-0 1-1 3-2 0-3
mögliches Warnsignal sollten ||| attention should be paid ||| 0-0 0-1 1-2 1-3 2-3
mögliches ||| attention should ||| 0-0 0-1
möglichst gering zu halten ||| blood ||| 0-0 1-0
möglichst gering zu ||| blood ||| 0-0 1-0
möglichst gering ||| blood ||| 0-0 1-0
möglichst ||| it ||| 0-0
müde oder schwindlig ||| tired or ||| 0-0 2-0 1-1
müssen , informieren ||| , tell ||| 0-0 1-0 2-1
müssen , ||| , ||| 0-0 1-0
müssen . ||| them . ||| 0-0 1-1
müssen ausreichende Eisenspeicher gewährleistet sein ||| iron stores should be assured ||| 1-0 0-1 1-1 2-1 2-2 3-3 3-4 4-4
müssen ausreichende Eisenspeicher vorhanden sein ||| iron stores should be ensured ||| 1-0 0-1 1-1 2-1 2-2 4-3 3-4
müssen ausreichende Eisenspeicher ||| iron stores should ||| 1-0 0-1 1-1 2-1 2-2
müssen ebenfalls effektiv behandelt werden ||| must also be effectively treated ||| 0-0 1-1 4-2 2-3 3-4
müssen ebenfalls ||| must also ||| 0-0 1-1
müssen sorgfältig ||| should be carefully ||| 0-0 0-1 1-2
müssen sorgfältig überwacht werden . ||| should be carefully monitored . ||| 0-0 0-1 1-2 2-3 3-3 4-4
müssen sorgfältig überwacht werden ||| should be carefully monitored ||| 0-0 0-1 1-2 2-3 3-3
müssen ||| medicinal ||| 0-0
müssen ||| must ||| 0-0
müssen ||| should be ||| 0-0 0-1
müssen ||| them ||| 0-0
mütterliche ||| marked ||| 0-0
n = 131 ) ||| n = 131 ) ||| 0-0 1-0 1-1 2-2 3-3
n = 131 ||| n = 131 ||| 0-0 1-0 1-1 2-2
n = 132 ) ||| n = 132 ) ||| 0-0 1-0 1-1 2-2 3-3
n = 132 ||| n = 132 ||| 0-0 1-0 1-1 2-2
n = 135 ) ||| n = 135 ) ||| 0-0 1-0 1-1 2-2 3-3
n = 135 ||| n = 135 ||| 0-0 1-0 1-1 2-2
n = 136 ) ||| n = 136 ) ||| 0-0 1-0 1-1 2-2 3-3
n = 136 ||| n = 136 ||| 0-0 1-0 1-1 2-2
n = ||| n = ||| 0-0 1-0 1-1
n Arz ||| . ||| 0-0 1-0
n Für dieses Arzneimittel ||| This medicinal product ||| 0-0 1-0 2-1 2-2 3-2
n Für ||| This ||| 0-0 1-0
n Infektionen ||| reported : infections ||| 0-0 0-1 1-2
n Name und ||| d Name and ||| 0-0 1-1 2-2
n Name ||| d Name ||| 0-0 1-1
n eim Arz ||| . ct ||| 1-0 0-1 1-1 2-1
n eim Arz ||| . ||| 1-0 2-0
n la sse ge zu ||| d ise or ||| 0-0 1-0 2-1 3-1 4-1 3-2
n la sse ge ||| d ise or uth ||| 0-0 1-0 2-1 3-2 3-3
n la sse ||| d ise ||| 0-0 1-0 2-1
n la ||| d ||| 0-0 1-0
n oder ohne ( behandelte ||| n oder ohne ( behandelte ||| 0-0 1-1 2-2 3-3 4-4
n oder ohne ( ||| n oder ohne ( ||| 0-0 1-1 2-2 3-3
n oder ohne ||| n oder ohne ||| 0-0 1-1 2-2
n oder ||| n oder ||| 0-0 1-1
n populationspharmakokinetischer ||| Based ||| 1-0
n ||| . du ||| 0-1
n ||| Renal ||| 0-0
n ||| d ||| 0-0
n ||| dic ||| 0-0
n ||| du ||| 0-0
n ||| in ||| 0-0
n ||| n ||| 0-0
n ||| reported : ||| 0-0 0-1
n= 938 , Durchschnittsalter ||| n= 938 ; mean age ||| 1-0 0-1 1-1 1-2 3-3 3-4
n= 938 , ||| n= 938 ; ||| 1-0 0-1 1-1 1-2
n= 938 ||| n= 938 ; ||| 1-0 0-1 1-1 1-2
nach 12 , ||| at 12 , ||| 0-0 1-1 2-2
nach 12 Monaten ||| 12 months ||| 1-0 0-1 2-1
nach 12 Wochen die Konzentration ||| after 12 weeks the level ||| 0-0 1-1 2-2 3-3 4-4
nach 12 Wochen die ||| after 12 weeks the ||| 0-0 1-1 2-2 3-3
nach 12 Wochen ||| after 12 weeks ||| 0-0 1-1 2-2
nach 12 ||| after 12 ||| 0-0 1-1
nach 12 ||| at 12 ||| 0-0 1-1
nach 24 Monaten ||| 24 months ||| 1-0 0-1 2-1
nach 6 Monaten ||| after 6 months ||| 0-0 1-1 2-2
nach 6 Monaten ||| at six months ||| 0-0 1-1 0-2 2-2
nach 6 ||| after 6 ||| 0-0 1-1
nach Abschluss ||| administered after the completion ||| 1-0 0-1 1-2 1-3
nach Anwendung . ||| after dosing . ||| 0-0 0-1 1-1 2-2
nach Anwendung ||| after administration ||| 0-0 1-1
nach Anwendung ||| after dosing ||| 0-0 0-1 1-1
nach Dosis , spiegelten Differenzen ||| dose reflected differences ||| 1-0 3-1 4-1 3-2
nach Dosis , spiegelten Differenzen ||| for dose reflected differences ||| 1-1 3-2 4-2 3-3
nach Dosis , ||| dose ||| 1-0
nach Dosis , ||| for dose ||| 1-1
nach Dosis ||| dose ||| 1-0
nach Dosis ||| for dose ||| 1-1
nach Ende der Behandlung zurückzubilden ||| following the end of treatment ||| 0-0 2-1 1-2 4-2 2-3 3-4
nach Ende der Behandlungzurückzubilden ||| following the end of treatment ||| 0-0 2-1 1-2 3-2 2-3 3-4
nach Gabe der gleichen Dosis ||| after the same dose ||| 0-0 1-0 2-1 3-2 4-3
nach Gabe der gleichen ||| after the same ||| 0-0 1-0 2-1 3-2
nach Gabe der ||| after the ||| 0-0 1-0 2-1
nach Gabe ||| after ||| 0-0 1-0
nach Monotherapie mit Aripiprazol ||| following treatment with aripiprazole alone ||| 0-0 1-1 2-2 3-3 1-4
nach Verabreichung von Aclasta ||| after administration of Aclasta ||| 0-0 1-1 2-2 3-3
nach Verabreichung von ||| after administration of ||| 0-0 1-1 2-2
nach Verabreichung ||| after administration ||| 0-0 1-1
nach Verabreichung ||| after treatment ||| 0-0 1-0
nach Verabreichung ||| after ||| 0-0 1-0
nach Zahnextraktionen oder anderen ||| following tooth extractions or other ||| 0-0 1-1 1-2 2-3 3-4
nach Zahnextraktionen oder ||| following tooth extractions or ||| 0-0 1-1 1-2 2-3
nach Zahnextraktionen ||| following tooth extractions ||| 0-0 1-1 1-2
nach dem ||| following ||| 0-0
nach den Wechseljahren ||| been through the menopause ||| 0-0 1-1 1-2 2-3
nach den ersten ||| after the first ||| 0-0 1-1 1-2 2-2
nach den ||| been through the ||| 0-0 1-1 1-2
nach der Gabe von ||| following the administration of ||| 0-0 1-1 2-2 3-3
nach der Gabe ||| following the administration ||| 0-0 1-1 2-2
nach der Resuspendierung nicht gleichmäßig ||| do not appear uniformly ||| 0-0 2-0 3-1 1-2 2-2 3-3 4-3
nach der Verabreichung von Aclasta ||| after administration of Aclasta ||| 0-0 2-1 1-2 3-2 4-3
nach der Verabreichung von ||| after administration of ||| 0-0 2-1 1-2 3-2
nach der ersten Gabe ||| after the first ||| 0-0 1-1 2-2 3-2
nach der ersten ||| after the first ||| 0-0 1-1 2-2
nach der ||| after receiving ||| 0-0 1-0
nach der ||| after the ||| 0-0 1-1
nach der ||| after your ||| 0-0 1-0
nach der ||| after ||| 0-0
nach der ||| after ||| 0-0 1-0
nach der ||| following the ||| 0-0 1-1
nach der ||| observed after the ||| 0-0 0-1 1-2
nach ein oder zwei ||| increased after one or two ||| 1-0 0-1 1-2 2-3 3-4
nach ein oder ||| be increased after one or ||| 1-1 0-2 1-3 2-4
nach ein oder ||| increased after one or ||| 1-0 0-1 1-2 2-3
nach ein ||| be increased after one ||| 1-1 0-2 1-3
nach ein ||| increased after one ||| 1-0 0-1 1-2
nach einem Jahr 5 % ||| nach einem Jahr 5 % ||| 0-0 0-1 1-1 2-2 3-3 4-4
nach einem Jahr 5 ||| nach einem Jahr 5 ||| 0-0 0-1 1-1 2-2 3-3
nach einem Jahr ||| nach einem Jahr ||| 0-0 0-1 1-1 2-2
nach einem Wechsel von tierischem ||| after transfer from animal ||| 0-0 1-1 2-1 4-1 3-2 4-2 4-3
nach einem ||| nach einem ||| 0-0 0-1 1-1
nach einer Mahlzeit zu verabreichen ||| be administered after a meal ||| 3-0 0-1 0-2 1-3 2-4 4-4
nach einer kürzlich erlittenen ||| following a recent ||| 0-0 1-1 2-2 3-2
nach einer ||| administered after a ||| 0-0 0-1 1-2
nach einer ||| following a ||| 0-0 1-1
nach einigen Tagen oder ||| a few days to ||| 1-0 0-1 1-1 2-2 2-3 3-3
nach einigen ||| a few ||| 1-0 0-1 1-1
nach erstmaligem Öffnen der ||| after first opening the ||| 0-0 1-1 1-2 2-2 3-3
nach erstmaligem Öffnen ||| after first opening ||| 0-0 1-1 1-2 2-2
nach intravenöser Applikation ergaben ||| intravenous ||| 0-0 1-0 2-0
nach intravenöser Applikation ||| intravenous ||| 0-0 1-0 2-0
nach mindestens fünfwöchiger ||| after at least five weeks ||| 0-0 1-1 1-2 2-2 1-3 0-4
nach monate- bis jahrelanger ||| reported after months to years ||| 1-0 0-1 1-2 2-2 2-3 3-4
nach monate- bis ||| after months to ||| 0-0 1-1 2-1 2-2
nach monate- bis ||| reported after months to ||| 1-0 0-1 1-2 2-2 2-3
nach monate- ||| reported after months ||| 1-0 0-1 1-2
nach sechsmonatiger ||| observed in clinical trials after ||| 1-0 1-1 1-2 1-3 0-4
nach seinem ||| in accordance ||| 0-0 1-1
nach subkutaner Injektion erreicht . ||| after subcutaneous administration . ||| 0-0 1-1 2-1 1-2 3-2 4-3
nach subkutaner Injektion erreicht ||| after subcutaneous administration ||| 0-0 1-1 2-1 1-2 3-2
nach wiederholter Gabe ||| after repeated dosing ||| 0-0 1-1 2-1 1-2
nach wiederholter oraler Gabe ||| after repeated oral ||| 0-0 1-1 2-2 3-2
nach wiederholter ||| after repeated ||| 0-0 1-1
nach ||| administered after ||| 0-0 0-1
nach ||| after an ||| 0-0
nach ||| after ||| 0-0
nach ||| at ||| 0-0
nach ||| been ||| 0-0
nach ||| following ||| 0-0
nach ||| in ||| 0-0
nach ||| observed after ||| 0-0 0-1
nach ||| severity ||| 0-0
nach ||| state ||| 0-0
nach Öffnen zu verwenden und ||| after opening and ||| 0-0 3-0 1-1 4-2
nach Öffnen zu verwenden ||| after opening ||| 0-0 3-0 1-1
nachdem Sie Aclasta erhalten haben ||| after you have received Aclasta ||| 2-0 1-1 4-2 3-3 2-4
nachdem Sie ||| you ||| 1-0
nachfolgenden Abraxane-Zyklen ||| subsequent courses ||| 0-0 0-1 1-1
nachgewiesen , obwohl einzelne Patienten ||| been demonstrated although individual patients ||| 0-0 0-1 2-1 2-2 3-2 3-3 4-4
nachgewiesen , obwohl einzelne ||| been demonstrated although individual ||| 0-0 0-1 2-1 2-2 3-2 3-3
nachgewiesen . ||| been established . ||| 0-0 0-1 1-2
nachgewiesen . ||| dose . ||| 0-0 1-1
nachgewiesen . ||| suckling reflex . ||| 0-0 0-1 1-2
nachgewiesen . ||| the suckling reflex . ||| 0-1 0-2 1-3
nachgewiesen . ||| treatment dose . ||| 0-1 1-2
nachgewiesen werden . ||| been established . ||| 0-0 0-1 1-1 2-2
nachgewiesen werden ||| been established ||| 0-0 0-1 1-1
nachgewiesen ||| been established ||| 0-0 0-1
nachgewiesen ||| demonstrated ||| 0-0
nachgewiesen ||| dose ||| 0-0
nachgewiesen ||| suckling reflex ||| 0-0 0-1
nachgewiesen ||| the suckling reflex ||| 0-1 0-2
nachgewiesen ||| treatment dose ||| 0-1
nachweisbar . ||| used in humans . ||| 0-0 0-1 0-2 1-3
nachweisbar ||| used in humans ||| 0-0 0-1 0-2
nahezu allen ||| all ||| 0-0 1-0
nahm mit den nachfolgenden Verabreichungen ||| decreased markedly with subsequent ||| 0-0 4-1 1-2 2-3 3-3
nahm ||| decreased ||| 0-0
nationalen Anforderungen ||| of in accordance with ||| 0-0 0-1 0-2 1-2 1-3
natürliche Hormon Erythropoetin . ||| natural hormone erythropoietin . ||| 0-0 1-1 2-2 3-3
natürliche Hormon Erythropoetin ||| natural hormone erythropoietin ||| 0-0 1-1 2-2
natürliche Hormon ||| natural hormone ||| 0-0 1-1
natürliche Verlauf von peripherer Neuropathie ||| natural course of peripheral neuropathy ||| 0-0 1-1 2-2 3-3 4-3 4-4
natürliche Verlauf von ||| natural course of ||| 0-0 1-1 2-2
natürliche Verlauf ||| natural course ||| 0-0 1-1
natürliche ||| natural ||| 0-0
neben ||| investigate ||| 0-0
neben ||| treatments ||| 0-0
negativ beeinflussen ||| negative impact ||| 0-0 1-1
negativ ||| negative ||| 0-0
negative Auswirkung auf das Gesamtüberleben ||| negative impact on overall survival ||| 0-0 1-1 2-2 3-3 4-3 4-4
negative Auswirkung auf ||| negative impact on ||| 0-0 1-1 2-2
negative Auswirkung ||| negative impact ||| 0-0 1-1
negative ||| negative ||| 0-0
nehmen Sie die Packung mit ||| take the pack with you ||| 0-0 2-1 3-2 4-3 1-4
nehmen Sie die ||| take the ||| 0-0 1-0 2-1
nehmen Sie ||| take ||| 0-0 1-0
nehmen ||| take ||| 0-0
nennenswerte Affinität zu Muscarin-Rezeptoren ||| appreciable affinity for muscarinic receptors ||| 0-0 1-1 1-2 2-3 3-3 3-4
nennenswerte Affinität zu ||| appreciable affinity ||| 0-0 2-0 1-1
nennenswerte Affinität ||| appreciable affinity for ||| 0-0 1-1 1-2
nennenswerte ||| appreciable ||| 0-0
neue Wirbelkörperfraktur ( ||| new vertebral fracture ( ||| 0-0 1-1 1-2 2-3
neue Wirbelkörperfraktur ||| new vertebral fracture ||| 0-0 1-1 1-2
neue ||| new ||| 0-0
neuen Termin ||| re-schedule ||| 0-0 1-0
neuen ||| in new ||| 0-1
neuen ||| new ||| 0-0
neuer Informationen ||| new information is received ||| 0-0 1-1 1-2
neuer Informationen ||| new information is ||| 0-0 1-1 1-2
neuer LHRH-Agonist , wobei diese ||| new LHRH agonist and this ||| 0-0 1-1 1-2 3-4 4-4
neuer LHRH-Agonist , ||| new LHRH agonist and ||| 0-0 1-1 1-2
neuer LHRH-Agonist , ||| new LHRH agonist ||| 0-0 1-1 1-2
neuer LHRH-Agonist ||| new LHRH agonist and ||| 0-0 1-1 1-2
neuer LHRH-Agonist ||| new LHRH agonist ||| 0-0 1-1 1-2
neuer ||| new ||| 0-0
neueres ||| replaced with new ||| 0-0 0-2
neues ||| new ||| 0-0
neun ||| nine ||| 0-0
neuropathische Schmerzen , Tremor Häufig ||| neuropathic pain , tremor Common ||| 0-0 1-1 2-2 3-3 4-4
neuropathische Schmerzen , Tremor ||| neuropathic pain , tremor ||| 0-0 1-1 2-2 3-3
neuropathische Schmerzen , ||| neuropathic pain , ||| 0-0 1-1 2-2
neuropathische Schmerzen ||| neuropathic pain ||| 0-0 1-1
neuropathische ||| neuropathic ||| 0-0
ng Ethinylestradiol/Levonorgestrel-Kombination wurde durch die ||| ng Ethinylestradiol/Levonorgestrel-Kombination wurde durch die ||| 0-0 1-1 2-2 3-3 4-4
ng Ethinylestradiol/Levonorgestrel-Kombination wurde durch ||| ng Ethinylestradiol/Levonorgestrel-Kombination wurde durch ||| 0-0 1-1 2-2 3-3
ng Ethinylestradiol/Levonorgestrel-Kombination wurde ||| ng Ethinylestradiol/Levonorgestrel-Kombination wurde ||| 0-0 1-1 2-2
ng Ethinylestradiol/Levonorgestrel-Kombination ||| ng Ethinylestradiol/Levonorgestrel-Kombination ||| 0-0 1-1
ng Schlaflosigkeit . ||| . The pharmacokinetic profile demonstrates ||| 2-0 0-2 0-3 0-4 1-4
ng Schlaflosigkeit ||| The pharmacokinetic profile demonstrates that ||| 0-1 0-2 0-3 1-3
ng Schlaflosigkeit ||| The pharmacokinetic profile demonstrates ||| 0-1 0-2 0-3 1-3
ng Schlaflosigkeit ||| pharmacokinetic profile demonstrates that a ||| 0-0 0-1 0-2 1-2
ng Schlaflosigkeit ||| pharmacokinetic profile demonstrates that ||| 0-0 0-1 0-2 1-2
ng Schlaflosigkeit ||| pharmacokinetic profile demonstrates ||| 0-0 0-1 0-2 1-2
ng ||| ng ||| 0-0
ng/ml ; Ctrough = ||| ng/ ml ; Ctrough = ||| 0-0 0-1 1-2 2-3 3-4
ng/ml ; Ctrough ||| ng/ ml ; Ctrough ||| 0-0 0-1 1-2 2-3
ng/ml ; ||| ng/ ml ; ||| 0-0 0-1 1-2
ng/ml liegt . ||| ng/ ml ||| 0-0 1-0 0-1 2-1
ng/ml ||| ng/ ml ||| 0-0 0-1
nicht , und ||| without treatment in between ||| 0-0
nicht , und ||| without treatment in ||| 0-0
nicht , und ||| without treatment ||| 0-0
nicht , und ||| without ||| 0-0
nicht , ||| without treatment in between ||| 0-0
nicht , ||| without treatment in ||| 0-0
nicht , ||| without treatment ||| 0-0
nicht , ||| without ||| 0-0
nicht alle Packungsgrößen in ||| nicht alle Packungsgrößen in ||| 0-0 1-1 2-2 3-3
nicht alle Packungsgrößen in ||| pack sizes may ||| 0-0 1-0 1-1 2-1 3-1 2-2
nicht alle Packungsgrößen in ||| the pack sizes may ||| 0-1 1-1 1-2 2-2 3-2 2-3
nicht alle Packungsgrößen ||| nicht alle Packungsgrößen ||| 0-0 1-1 2-2
nicht alle ||| nicht alle ||| 0-0 1-1
nicht angebracht ist . ||| is not appropriate . ||| 2-0 0-1 1-2 3-3
nicht angebracht ist ||| is not appropriate ||| 2-0 0-1 1-2
nicht angebracht ||| not appropriate ||| 0-0 1-1
nicht angewendet werden ( ||| nicht angewendet werden ( ||| 0-0 1-1 2-2 3-3
nicht angewendet werden , ||| not be administered ||| 0-0 2-1 1-2
nicht angewendet werden , ||| not be used ||| 0-0 2-1 1-2
nicht angewendet werden . ||| Leaflet . ||| 3-0 2-1 3-1
nicht angewendet werden ||| nicht angewendet werden ||| 0-0 1-1 2-2
nicht angewendet werden ||| not be administered ||| 0-0 2-1 1-2
nicht angewendet werden ||| not be used ||| 0-0 2-1 1-2
nicht angewendet ||| nicht angewendet ||| 0-0 1-1
nicht angezeigt ||| not indicated ||| 0-0 1-1
nicht anwenden ||| not use ||| 0-0 1-1
nicht ausgeschlossen werden. ln ||| increased tactile hyperesthesia were ro ||| 1-1 2-1 2-2 2-3 3-4
nicht ausgeschlossen werden. ln ||| tactile hyperesthesia were ro ||| 1-0 2-0 2-1 2-2 3-3
nicht ausgeschlossen werden. ||| increased tactile hyperesthesia were ||| 1-1 2-1 2-2 2-3
nicht ausgeschlossen werden. ||| tactile hyperesthesia were ||| 1-0 2-0 2-1 2-2
nicht ausreichend gezeigt . ||| has not sufficiently Me ||| 2-0 0-1 1-1 1-2 3-3
nicht ausreichend gezeigt ||| has not sufficiently ||| 2-0 0-1 1-1 1-2
nicht ausreichend ist , sprechen ||| is too weak , talk ||| 0-0 2-0 4-1 1-2 4-2 3-3 4-4
nicht ausreichend ||| not sufficiently ||| 0-0 1-0 1-1
nicht ausreichender Daten zur Unbedenklichkeit ||| to insufficient data on safety ||| 3-0 0-1 1-1 2-1 2-2 3-3 3-4 4-4
nicht ausreichender Daten ||| insufficient data ||| 0-0 1-0 2-0 2-1
nicht beeinflusst . ||| concomitantly . ||| 1-0 2-1
nicht beeinflusst ||| concomitantly ||| 1-0
nicht bekannt , ob Paclitaxel ||| not known if paclitaxel ||| 0-0 1-1 2-2 3-2 4-3
nicht bekannt , ob Pioglitazon ||| not known whether pioglitazone ||| 0-0 1-1 2-2 3-2 4-3
nicht bekannt , ob Zoledronsäure ||| not known whether zoledronic acid ||| 0-0 1-1 2-2 3-2 4-3 4-4
nicht bekannt , ob ||| not known if ||| 0-0 1-1 2-2 3-2
nicht bekannt , ob ||| not known whether ||| 0-0 1-1 2-2 3-2
nicht bekannt . ||| unknown . ||| 0-0 1-0 2-1
nicht bekannt erachtet ( ||| considered not known ( ||| 2-0 0-1 1-2 2-2 3-3
nicht bekannt erachtet ||| considered not known ||| 2-0 0-1 1-2 2-2
nicht bekannt ||| not known ||| 0-0 1-1
nicht bekannt ||| therefore , not ||| 0-0 0-2 1-2
nicht bekannt ||| unknown ||| 0-0 1-0
nicht beschleunigt . ||| insufficiency . ||| 0-0 1-0 2-1
nicht beschleunigt ||| insufficiency ||| 0-0 1-0
nicht bestimmt worden . ||| not been determined . ||| 0-0 2-1 1-2 3-3
nicht bestimmt worden ||| not been determined ||| 0-0 2-1 1-2
nicht dafür ausgelegt ||| not powered ||| 0-0 1-1 2-1
nicht dialysepflichtige Erwachsene mit ||| renal insufficiency not yet ||| 1-0 1-1 2-1 0-2 2-3 3-3
nicht durchgeführt worden . ||| not been carried out . ||| 0-0 1-1 1-2 2-2 2-3 3-4
nicht durchgeführt worden ||| not been carried out ||| 0-0 1-1 1-2 2-2 2-3
nicht durchgeführt worden ||| not been conducted ||| 0-0 1-1 2-1 1-2
nicht einer ||| not ||| 0-0
nicht eingeschränkt ||| not restricted ||| 0-0 1-1
nicht einnehmen , ||| not take ||| 0-0 1-1 2-1
nicht einnehmen ||| not take ||| 0-0 1-1
nicht empfohlen . Ein ||| not recommended ||| 0-0 1-1
nicht empfohlen . ||| is not recommended . ||| 1-0 0-1 1-2 2-3
nicht empfohlen . ||| not recommended ||| 0-0 1-1
nicht empfohlen für Kinder ||| not recommended for anyone ||| 0-0 1-1 2-2 3-3
nicht empfohlen für die Anwendung ||| not recommended for use ||| 0-0 1-1 2-2 3-2 4-3
nicht empfohlen für die ||| not recommended for ||| 0-0 1-1 2-2 3-2
nicht empfohlen für ||| not recommended for ||| 0-0 1-1 2-2
nicht empfohlen wird . ||| is not recommended . ||| 2-0 0-1 1-2 2-2 3-3
nicht empfohlen wird ||| is not recommended ||| 2-0 0-1 1-2 2-2
nicht empfohlen ||| is not recommended ||| 1-0 0-1 1-2
nicht empfohlen ||| not recommended ||| 0-0 1-1
nicht erforderlich . ||| not necessary . ||| 0-0 1-1 2-2
nicht erforderlich ||| not necessary ||| 0-0 1-1
nicht erhalten ||| not receive ||| 0-0 1-1
nicht evaluiert und ||| not evaluated and ||| 0-0 1-1 2-2
nicht evaluiert ||| not evaluated ||| 0-0 1-1
nicht geeignet ||| not ||| 0-0 1-0
nicht genügend Insulin ||| does not produce enough insulin ||| 0-0 0-1 1-2 1-3 2-4
nicht genügend ||| does not produce enough ||| 0-0 0-1 1-2 1-3
nicht genügend ||| nicht ||| 0-0
nicht gezeigt ||| do ||| 0-0
nicht heilende Wunden ||| non-healing sores of ||| 1-0 2-1
nicht heilende Wunden ||| non-healing sores ||| 1-0 2-1
nicht heilende ||| non-healing ||| 1-0
nicht in der ||| not included due to the ||| 0-0 1-1 2-2 2-3 2-4
nicht in dieser Gebrauchsinformation angegeben ||| tell your ||| 0-0 1-0 2-0 3-0 4-0 3-1
nicht in dieser Gebrauchsinformation angegeben ||| tell ||| 0-0 1-0 2-0 3-0 4-0
nicht in ||| not included ||| 0-0 1-1
nicht induziert . ||| in man . ||| 0-0 1-0 1-1 2-2
nicht induziert ||| in man ||| 0-0 1-0 1-1
nicht jedoch bei Affen , ||| but not in monkeys , ||| 1-0 0-1 2-2 3-3 4-4
nicht jedoch bei Affen ||| but not in monkeys ||| 1-0 0-1 2-2 3-3
nicht jedoch bei ||| but not in ||| 1-0 0-1 2-2
nicht jedoch ||| but not ||| 1-0 0-1
nicht kontrollierbar , sollte die ||| cannot be controlled , ||| 0-0 1-0 1-1 3-1 1-2 2-3 4-3
nicht kontrollierbar , ||| cannot be controlled , epoetin ||| 0-0 1-0 1-1 1-2 2-3 1-4
nicht letal wirkende intravenöse Einzeldosis ||| non-lethal single intravenous dose ||| 1-0 2-0 0-1 4-1 3-2 4-3
nicht mehr anwenden . ||| carton . ||| 0-0 1-0 2-0 3-1
nicht mehr anwenden ||| carton ||| 0-0 1-0 2-0
nicht metabolisiert , ihre Ausscheidung ||| not metabolised and ||| 0-0 1-1 3-1 4-2
nicht metabolisiert , ihre ||| not metabolised ||| 0-0 1-1 3-1
nicht mit Abraxane behandelt werden ||| not be treated with Abraxane ||| 0-0 4-1 3-2 1-3 2-4
nicht mit Infusionslösungen ||| not be added to ||| 0-0 1-1 2-1 2-2 2-3
nicht mit Paclitaxel behandelt werden ||| not be treated with paclitaxel ||| 0-0 4-1 3-2 1-3 3-3 2-4
nicht möglich ist . ||| is not appropriate . ||| 2-0 0-1 1-1 2-2 3-3
nicht möglich ist . ||| mouth is not appropriate . ||| 2-1 0-2 1-2 2-3 3-4
nicht möglich ist ||| is not appropriate ||| 2-0 0-1 1-1 2-2
nicht möglich ist ||| mouth is not appropriate ||| 2-1 0-2 1-2 2-3
nicht möglich ||| not ||| 0-0 1-0
nicht nachgewiesen , obwohl einzelne ||| not been demonstrated although individual ||| 0-0 1-1 1-2 3-2 3-3 4-3 4-4
nicht nachgewiesen . ||| not been established . ||| 0-0 1-1 1-2 2-3
nicht nachgewiesen werden . ||| not been established . ||| 0-0 1-1 1-2 2-2 3-3
nicht nachgewiesen werden ||| not been established ||| 0-0 1-1 1-2 2-2
nicht nachgewiesen ||| not been established ||| 0-0 1-1 1-2
nicht notwendig . ||| not necessary . ||| 0-0 1-1 2-2
nicht notwendig ||| not necessary ||| 0-0 1-1
nicht optimaler Heparinisierung möglich ||| if heparinisation is not optimum ||| 1-0 0-1 1-1 2-1 1-2 2-3 2-4 3-4
nicht routinemäßig gemessen , aber ||| not routinely measured but a ||| 0-0 1-1 2-2 3-3 4-3 2-4
nicht routinemäßig gemessen ||| not routinely measured ||| 0-0 1-1 2-2
nicht routinemäßig ||| not routinely ||| 0-0 1-1
nicht speziell untersucht . ||| not specifically investigated . ||| 0-0 1-1 2-2 3-3
nicht speziell untersucht ||| not specifically investigated ||| 0-0 1-1 2-2
nicht speziell ||| not specifically ||| 0-0 1-1
nicht stark ||| not highly ||| 0-0 1-1
nicht systemisch ||| not systemically ||| 0-0 1-1
nicht teilen und ||| cannot divide and ||| 0-0 1-1 2-2
nicht teilen ||| cannot divide ||| 0-0 1-1
nicht untersucht . ||| not been evaluated . ||| 0-0 1-1 1-2 2-3
nicht untersucht . ||| not been studied . ||| 0-0 1-1 1-2 2-3
nicht untersucht . ||| not evaluated . ||| 0-0 1-1 2-2
nicht untersucht worden . ||| not been studied . ||| 0-0 2-1 1-2 3-3
nicht untersucht worden ||| has not been studied ||| 1-0 0-1 2-2 1-3
nicht untersucht worden ||| not been studied ||| 0-0 2-1 1-2
nicht untersucht ||| not been evaluated ||| 0-0 1-1 1-2
nicht untersucht ||| not been studied ||| 0-0 1-1 1-2
nicht untersucht ||| not evaluated ||| 0-0 1-1
nicht verwendet werden , wenn ||| not be used if ||| 0-0 2-1 1-2 3-3 4-3
nicht verwendet werden ||| not be used ||| 0-0 2-1 1-2
nicht wichtig , ||| does not matter ||| 1-0 0-1 1-2 2-2
nicht zu einer Zunahme der ||| not lead to an increase ||| 0-0 1-1 2-1 3-1 1-2 3-3 3-4 4-4
nicht zu einer Zunahme ||| not lead to an increase ||| 0-0 1-1 3-1 1-2 2-3 3-3 3-4
nicht zu einer weiteren ||| not lead to further ||| 0-0 1-1 2-1 1-2 3-3
nicht zu einer ||| not lead to ||| 0-0 1-1 2-1 1-2
nicht zu erwarten . ||| not to be expected . ||| 0-0 1-1 1-2 2-3 3-4
nicht zu erwarten ||| not to be expected ||| 0-0 1-1 1-2 2-3
nicht zu ||| not to be ||| 0-0 1-1 1-2
nicht zu ||| not ||| 0-0
nicht zufriedenstellend eingestellt ||| not satisfactorily controlled ||| 0-0 1-1 2-2
nicht zufriedenstellend ||| not satisfactorily ||| 0-0 1-1
nicht ||| cannot ||| 0-0
nicht ||| do not ||| 0-0 0-1
nicht ||| do ||| 0-0
nicht ||| does not ||| 0-0 0-1
nicht ||| is not ||| 0-1
nicht ||| nicht ||| 0-0
nicht ||| not been ||| 0-0 0-1
nicht ||| not pass ||| 0-0 0-1
nicht ||| not take ||| 0-0 0-1
nicht ||| not to ||| 0-0 0-1
nicht ||| not ||| 0-0
nicht ||| with ||| 0-0
nicht ||| without treatment in between ||| 0-0
nicht ||| without treatment in ||| 0-0
nicht ||| without treatment ||| 0-0
nicht ||| without ||| 0-0
nicht über 12 ||| not greater than 12 ||| 0-0 1-1 1-2 2-3
nicht über ||| not greater than ||| 0-0 1-1 1-2
nicht überschritten werden . ||| not be exceeded . ||| 0-0 2-1 1-2 2-2 3-3
nicht überschritten werden ||| not be exceeded ||| 0-0 2-1 1-2 2-2
nicht-platinhaltiger Chemotherapie ||| receiving non-platinum chemotherapy ||| 0-0 0-1 1-2
nicht-platinhaltiger ||| receiving non-platinum ||| 0-0 0-1
nicht-renale Clearance hinweist . ||| non-renal clearance . ||| 0-0 2-0 1-1 3-2
nicht-renale Clearance hinweist ||| non-renal clearance ||| 0-0 2-0 1-1
nichtselektive Betarezeptorenblocker , ||| non-selective beta- blocking agents , ||| 0-0 0-1 0-2 1-2 1-3 2-4
nichtselektive Betarezeptorenblocker ||| non-selective beta- blocking agents ||| 0-0 0-1 0-2 1-2 1-3
nichtsteroidale ||| non-steroidal ||| 0-0
niedrig ||| too low ||| 0-0 0-1
niedrig-traumatischen Hüftfraktur ||| recent low-trauma hip fracture , ||| 0-0 0-1 1-2 1-3
niedrig-traumatischen Hüftfraktur ||| recent low-trauma hip fracture ||| 0-0 0-1 1-2 1-3
niedrig-traumatischen ||| recent low-trauma ||| 0-0 0-1
niedrigem Blutcalciumspiegel ) ||| low blood calcium levels ) ||| 0-0 1-0 2-4
niedrigem Blutcalciumspiegel ||| low blood calcium levels ||| 0-0 1-0
niedrigem Blutcalciumspiegel ||| low blood calcium ||| 0-0 1-0
niedrigem Blutcalciumspiegel ||| low blood ||| 0-0 1-0
niedrigem Blutcalciumspiegel ||| low ||| 0-0 1-0
niedrigen Kalzium- Spiegels ||| associated with hypocalcaemia ||| 0-0 1-2 2-2
niedrigen ||| associated with ||| 0-0
niedrigen ||| associated ||| 0-0
niedrigen ||| low ||| 0-0
niedriger in einer ||| lower in a ||| 0-0 1-1 2-2
niedriger in ||| lower in ||| 0-0 1-1
niedriger ||| lower ||| 0-0
niedrigere Dosis von 5,25 mg ||| lower dose of 5.25 mg ||| 0-0 1-1 2-2 3-3 4-4
niedrigere Dosis von 5,25 ||| lower dose of 5.25 ||| 0-0 1-1 2-2 3-3
niedrigere Dosis von ||| lower dose of ||| 0-0 1-1 2-2
niedrigere Dosis ||| lower dose ||| 0-0 1-1
niedrigere ||| lower ||| 0-0
niedrigsten an ||| lowest ||| 0-0
niedrigsten verfügbaren Dosis ||| lowest available dose ||| 0-0 1-1 2-2
niedrigsten verfügbaren ||| lowest available ||| 0-0 1-1
niedrigsten ||| lowest ||| 0-0
niemals intravenös ||| are never to ||| 0-0 0-1 1-1 1-2
nimmt mit den nachfolgenden ||| decreases with subsequent doses ||| 1-1 0-2 2-2 3-2
nimmt mit den nachfolgenden ||| decreases with subsequent ||| 1-1 0-2 2-2 3-2
nimmt mit den nachfolgenden ||| with subsequent doses ||| 1-0 0-1 2-1 3-1
nimmt mit den nachfolgenden ||| with subsequent ||| 1-0 0-1 2-1 3-1
noch bei Patienten mit Leberproblemen ||| in patients with liver problems ||| 0-0 1-0 2-1 3-2 4-3 4-4
noch bei Patienten mit ||| in patients with ||| 0-0 1-0 2-1 3-2
noch bei Patienten ||| in patients ||| 0-0 1-0 2-1
noch bei ||| in ||| 0-0 1-0
noch keine ||| not ||| 0-0 1-0
noch nicht einer ||| not yet undergoing ||| 1-0 0-1 0-2
noch nicht ||| not yet undergoing ||| 1-0 0-1 0-2
noch vorhandener ||| residual ||| 0-0 1-0
noch ||| yet undergoing ||| 0-0 0-1
normal macht . ||| normal . ||| 0-0 2-1
normal macht ||| normal ||| 0-0
normal ||| are ||| 0-0
normal ||| normal ||| 0-0
normale und anämische Ratten , ||| normal and anaemic rats , ||| 0-0 1-1 2-2 3-3 4-4
normale und anämische Ratten ||| normal and anaemic rats ||| 0-0 1-1 2-2 3-3
normale und anämische ||| normal and anaemic ||| 0-0 1-1 2-2
normale und ||| normal and ||| 0-0 1-1
normale ||| normal ||| 0-0
normalem oder ||| normal or ||| 0-0 1-1
normalem ||| normal ||| 0-0
normalen dynamischen Reorganisation ||| normal dynamic ||| 0-0 1-1 2-1
normalen ||| normal reference ||| 0-0
normalen ||| normal ||| 0-0
normaler ||| normal ||| 0-0
normaler ||| of normal ||| 0-1
normalerweise 200 I.E ||| not normally exceed 200 IU ||| 1-0 0-1 1-2 1-3 2-4
normalerweise 200 ||| not normally exceed 200 ||| 1-0 0-1 1-2 1-3
normalerweise ||| are usually ||| 0-0 0-1
normalerweise ||| normally ||| 0-0
normalerweise ||| usually ||| 0-0
normalgewichtige Probanden. ich ||| normal-weight subjects . lp ||| 0-0 1-0 1-1 2-2 1-3 2-3
normalisieren , ||| brain , ||| 0-0 1-1
normalisieren ||| brain ||| 0-0
normalisierte . ||| resolved . ||| 0-0 1-1
normalisierte ||| of ||| 0-0
normalisierte ||| resolved ||| 0-0
notwendig ( siehe Abschnitt 5.2 ||| ( see section 5.2 ||| 1-0 2-1 3-2 4-3
notwendig ( siehe Abschnitt ||| ( see section ||| 1-0 2-1 3-2
notwendig ( siehe ||| ( see ||| 1-0 2-1
notwendig ( ||| ( ||| 1-0
notwendig . ACOMPLIA sollte ||| ACOMPLIA should be ||| 0-0 2-0 3-1 1-2 3-2
notwendig . ||| . ||| 1-0
notwendig . ||| may be needed . ||| 0-0 0-1 0-2 1-3
notwendig . ||| necessary . ||| 0-0 1-1
notwendig ist , ||| is necessary , ||| 1-0 0-1 2-2
notwendig ist . ||| . ||| 2-0
notwendig ist ||| is necessary ||| 1-0 0-1
notwendig sein , wenn ||| be necessary when ||| 1-0 0-1 1-1 2-2 3-2
notwendig sein ||| be necessary ||| 1-0 0-1 1-1
notwendig ||| may be needed ||| 0-0 0-1 0-2
notwendig ||| necessary in ||| 0-0
notwendig ||| necessary ||| 0-0
notwendig ||| notwendig ||| 0-0
notwendigen Menge ||| necessary amount ||| 0-0 0-1 1-1
nur 0,01 ||| only 0.01 ||| 0-0 1-1
nur 3 Patienten mit ||| only 3 patients with ||| 0-0 1-1 2-2 3-3
nur 3 Patienten ||| only 3 patients ||| 0-0 1-1 2-2
nur 3 ||| only 3 ||| 0-0 1-1
nur auf Berichten von ||| only on reports ||| 0-0 1-1 2-2
nur auf Berichten ||| only on reports ||| 0-0 1-1 2-2
nur auf ||| only on ||| 0-0 1-1
nur begrenzte Erfahrungen in ||| limited experience in ||| 0-0 1-0 2-1 3-2
nur begrenzte Erfahrungen in ||| of the limited experience in ||| 0-2 1-2 2-3 3-4
nur begrenzte Erfahrungen in ||| the limited experience in ||| 0-1 1-1 2-2 3-3
nur begrenzte Erfahrungen ||| limited experience ||| 0-0 1-0 2-1
nur begrenzte Erfahrungen ||| of the limited experience ||| 0-2 1-2 2-3
nur begrenzte Erfahrungen ||| the limited experience ||| 0-1 1-1 2-2
nur begrenzte ||| limited ||| 0-0 1-0
nur begrenzte ||| of the limited ||| 0-2 1-2
nur begrenzte ||| the limited ||| 0-1 1-1
nur bei Morbus Paget ||| in Paget s disease only ||| 1-0 2-1 3-1 2-2 3-3 0-4
nur bei Patienten mit mittelschwerer ||| restricted to patients with moderate ||| 0-0 1-0 4-1 2-2 3-3 4-4
nur bei Patienten mit ||| , only in patients who ||| 0-1 1-2 2-3 2-4 3-4
nur bei Patienten mit ||| only in patients who ||| 0-0 1-1 2-2 2-3 3-3
nur bei ||| , only in ||| 0-1 1-2
nur bei ||| only in ||| 0-0 1-1
nur bei ||| restricted ||| 0-0 1-0
nur die ||| only at the ||| 0-0 1-1 1-2
nur ein ||| a few ||| 1-0 0-1
nur eine Infusion ||| only one infusion of Aclasta ||| 0-0 1-1 2-2 1-3 2-4
nur leichte Symptome ||| only minor symptoms ||| 0-0 1-1 2-2
nur leichte ||| only minor ||| 0-0 1-1
nur von ||| only ||| 0-0
nur wenige Daten über ||| very limited data ||| 3-0 0-1 3-1 1-2 2-2
nur wenigen Minuten ) . ||| few minutes ) . ||| 0-0 1-0 2-1 3-2 4-3
nur wenigen Minuten ) . ||| per se ||| 1-0 0-1 1-1 2-1 3-1
nur wenigen Minuten ) ||| few minutes ) ||| 0-0 1-0 2-1 3-2
nur wenigen Minuten ) ||| per se ||| 1-0 0-1 1-1 2-1 3-1
nur wenigen Minuten ||| few minutes ||| 0-0 1-0 2-1
nur wenigen ||| few ||| 0-0 1-0
nur zur einmaligen Anwendung bestimmt ||| for single use only ||| 1-0 0-1 2-1 3-2 0-3 4-3
nur zur ||| only intended for ||| 0-0 0-1 1-1 1-2
nur ||| , only ||| 0-1
nur ||| Only ||| 0-0
nur ||| few ||| 0-0
nur ||| only be ||| 0-0 0-1
nur ||| only ||| 0-0
nutzen , ||| unable ||| 0-0
nutzen ||| unable ||| 0-0
nächsten Arzttermin wahr und besprechen ||| next appointment and discuss ||| 0-0 1-1 3-2 2-3 4-3
nächsten Arzttermin ||| next appointment ||| 0-0 1-1
nächsten ||| next ||| 0-0
nötig . ||| required . ||| 0-0 1-1
nötig ||| required ||| 0-0
ob Sie sie ||| whether you ||| 0-0 2-0 1-1
ob das Führen ||| considered ||| 0-0 1-0 2-0
ob ||| if ||| 0-0
ob ||| whether ||| 0-0
oben genannten Indikationen haben . ||| above indications . ||| 2-0 0-1 1-1 2-1 3-1 4-2
oben genannten Indikationen haben ||| above indications ||| 2-0 0-1 1-1 2-1 3-1
oben genannten ||| above ||| 0-0 1-0
oberen Atemwege ||| upper respiratory tract ||| 0-0 0-1 0-2 1-2
oberen Atemwege. ||| upper respiratory tract ||| 0-0 0-1 0-2
oberen ||| upper respiratory tract ||| 0-0 0-1 0-2
oberen ||| upper ||| 0-0
obwohl ||| although ||| 0-0
oder 13 ||| , or 13 ||| 0-1 1-2
oder 13 ||| or 13 ||| 0-0 1-1
oder 15 mg/Tag ( ||| or 15 mg/ day ( ||| 0-0 1-1 2-2 2-3 3-4
oder 15 mg/Tag ||| or 15 mg/ day ||| 0-0 1-1 2-2 2-3
oder 15 ml Lösung ||| or 15 ml solution/ ||| 0-0 1-1 2-2 3-2 1-3
oder 15 ||| or 15 ||| 0-0 1-1
oder 15-mg-Dosen verringerten ||| of 10 or 15 ||| 1-0 2-0 0-2
oder 15-mg-Dosen verringerten ||| of 10 or ||| 1-0 2-0 0-2
oder 2 ) , ||| or 2 ) at ||| 0-0 1-1 2-2
oder 2 ) , ||| or 2 ) ||| 0-0 1-1 2-2
oder 2 ) ||| or 2 ) at ||| 0-0 1-1 2-2
oder 2 ) ||| or 2 ) ||| 0-0 1-1 2-2
oder 2 ||| or 2 ||| 0-0 1-1
oder 24 Stunden nach der ||| or 24 hours after the ||| 0-0 1-1 2-2 3-3 4-4
oder 24 Stunden nach ||| or 24 hours after ||| 0-0 1-1 2-2 3-3
oder 24 Stunden ||| or 24 hours ||| 0-0 1-1 2-2
oder 24 ||| or 24 ||| 0-0 1-1
oder 30 mg einmal täglich ||| or 30 mg once daily ||| 0-0 1-1 2-2 3-3 4-4
oder 30 mg einmal ||| or 30 mg once ||| 0-0 1-1 2-2 3-3
oder 30 mg ||| or 30 mg ||| 0-0 1-1 2-2
oder 30 ||| or 30 ||| 0-0 1-1
oder 45 mg Pioglitazon ||| or 45 mg of pioglitazone ||| 0-0 1-1 2-2 3-4
oder 45 mg ||| or 45 mg of ||| 0-0 1-1 2-2
oder 45 mg ||| or 45 mg ||| 0-0 1-1 2-2
oder 45 ||| or 45 ||| 0-0 1-1
oder 450 I.E./kg ||| or 450 IU/ kg ||| 0-0 1-1 2-2 2-3
oder 450 ||| or 450 ||| 0-0 1-1
oder 480 ml pro ||| or 480 ml per ||| 0-0 1-1 2-2 3-3
oder 480 ml ||| or 480 ml ||| 0-0 1-1 2-2
oder 480 ||| or 480 ||| 0-0 1-1
oder 49 Schmelztabletten verpackt . ||| or 49 orodispersible tablets . ||| 0-0 1-1 3-1 2-2 2-3 4-4
oder 49 Schmelztabletten verpackt ||| or 49 orodispersible tablets ||| 0-0 1-1 3-1 2-2 2-3
oder 500 Filmtabletten . ||| 500 film-coated tablets . ||| 1-0 2-1 2-2 3-3
oder 500 Filmtabletten . ||| and 500 film-coated tablets . ||| 1-1 2-2 2-3 3-4
oder 500 Filmtabletten ||| 500 film-coated tablets ||| 1-0 2-1 2-2
oder 500 Filmtabletten ||| and 500 film-coated tablets ||| 1-1 2-2 2-3
oder 500 ||| 500 ||| 1-0
oder 500 ||| and 500 ||| 1-1
oder 98 Filmtabletten . ||| 98 film-coated tablets . ||| 1-0 2-1 2-2 3-3
oder 98 Filmtabletten . ||| and 98 film-coated tablets . ||| 1-1 2-2 2-3 3-4
oder 98 Filmtabletten ||| 98 film-coated tablets ||| 1-0 2-1 2-2
oder 98 Filmtabletten ||| and 98 film-coated tablets ||| 1-1 2-2 2-3
oder 98 Tabletten zur Verfügung ||| or 98 tablets ||| 0-0 1-1 3-1 4-1 2-2
oder 98 ||| 98 ||| 1-0
oder 98 ||| and 98 ||| 1-1
oder ABILIFY Lösung zum Einnehmen ||| or ABILIFY oral solution ||| 0-0 1-1 3-2 4-2 2-3
oder ABILIFY ||| or ABILIFY ||| 0-0 1-1
oder ASL/ALT > 10 ||| or ASL/ ALT > 10 ||| 0-0 1-1 2-2 2-3 3-4
oder ASL/ALT > ||| or ASL/ ALT > ||| 0-0 1-1 2-2 2-3
oder ASL/ALT ||| or ASL/ ||| 0-0 1-1
oder Abfallmaterial ist ||| or waste material should ||| 0-0 0-1 1-1 1-2 2-2 1-3
oder Apotheker , wenn Sie ||| or nurse if you ||| 0-0 1-1 2-2 3-2 4-3
oder Apotheker , wenn Sie ||| or pharmacist if you are ||| 0-0 1-1 2-2 3-2 4-3 3-4
oder Apotheker , wenn ||| or nurse if ||| 0-0 1-1 2-2 3-2
oder Apotheker . ||| or pharmacist . ||| 0-0 1-1 2-2
oder Apotheker in ||| or pharmacist ||| 0-0 1-1
oder Apotheker nach , wenn ||| or pharmacist if ||| 0-0 2-0 1-1 3-2 4-2
oder Apotheker nach ||| or pharmacist ||| 0-0 2-0 1-1
oder Apotheker um Rat , ||| or pharmacist for advice ||| 0-0 1-1 3-2 2-3 3-3 4-3
oder Apotheker ||| or nurse ||| 0-0 1-1
oder Apotheker ||| or pharmacist ||| 0-0 1-1
oder Blutdruck , Tachykardie ||| or blood pressure , tachycardia ||| 0-0 1-1 1-2 2-3 3-4
oder Blutdruck , ||| or blood pressure , ||| 0-0 1-1 1-2 2-3
oder Blutdruck ||| or blood pressure ||| 0-0 1-1 1-2
oder CYP2D6 ||| or CYP2D6 ||| 0-0 1-1
oder CYP2D6-Inhibitor ||| or CYP2D6 inhibitor ||| 0-0 1-1 1-2
oder Clarithromycin ||| or telithromycin or ||| 0-0 1-1 0-2
oder Diuretika , die ||| or diuretics that ||| 0-0 1-1 2-2 3-2
oder Diuretika ||| or diuretics ||| 0-0 1-1
oder Dyslipidämie ( ||| or dyslipidaemia ( abnormal ||| 0-0 1-1 2-2 1-3
oder Exposition beim Menschen ||| human dose or exposure ||| 2-0 3-0 3-1 0-2 1-3
oder Exposition ||| or exposure ||| 0-0 1-1
oder Fettleibigkeit durch ||| or obesity is caused by ||| 0-0 1-1 2-2 2-3 2-4
oder Fettleibigkeit ||| or obesity ||| 0-0 1-1
oder Gefäßkrankheit ||| Cardiovascular ||| 0-0 1-0
oder Gelenkschmerzen ||| or joints ||| 0-0 1-1
oder Glucose- ||| or glucose-galactose ||| 0-0 1-1
oder Haushaltsabfall entsorgt werden . ||| wastewater or household waste . ||| 0-0 1-0 0-1 2-2 2-3 3-3 4-4
oder Haushaltsabfall entsorgt werden ||| wastewater or household waste ||| 0-0 1-0 0-1 2-2 2-3 3-3
oder Haushaltsabfall ||| wastewater or ||| 0-0 1-0 0-1
oder Hb-Anstieg 1 ||| or Hb increase 1 ||| 0-0 1-1 1-2 2-3
oder Hb-Anstieg ||| or Hb increase ||| 0-0 1-1 1-2
oder Herzinsuffizienz in der Anamnese ||| or history of cardiac failure ||| 0-0 2-1 4-1 3-2 1-3 4-3 1-4
oder Herzprobleme haben . ||| your liver or heart . ||| 1-0 1-1 0-2 1-3 2-3 3-4
oder Herzprobleme haben ||| your liver or heart ||| 1-0 1-1 0-2 1-3 2-3
oder Ibuprofen ( Mittel gegen ||| or ibuprofen ( anti-inflammation medicines ||| 0-0 1-1 2-2 3-2 1-3 4-4
oder Ibuprofen ( Mittel ||| or ibuprofen ( anti-inflammation ||| 0-0 1-1 2-2 3-2 1-3
oder Ibuprofen kurz nach ||| or ibuprofen shortly following ||| 0-0 1-1 2-2 3-3
oder Ibuprofen kurz ||| or ibuprofen shortly ||| 0-0 1-1 2-2
oder Ibuprofen ||| or ibuprofen ||| 0-0 1-1
oder Insulin auftreten . ||| or insulin . ||| 0-0 1-1 2-1 3-2
oder Insulin auftreten ||| or insulin ||| 0-0 1-1 2-1
oder Koma ||| or coma , ||| 0-0 1-1
oder Koma ||| or coma ||| 0-0 1-1
oder Kombinationstherapie ( siehe ||| or combination therapy ( see ||| 0-0 1-1 1-2 2-3 3-4
oder Kombinationstherapie ( ||| or combination therapy ( ||| 0-0 1-1 1-2 2-3
oder Kombinationstherapie ||| or combination therapy ||| 0-0 1-1 1-2
oder Krankenhaus in ||| or hospital as ||| 0-0 1-1 2-2
oder Krankenhaus ||| or hospital ||| 0-0 1-1
oder Körpergewicht . ||| or body weight . ||| 0-0 1-1 1-2 2-3
oder Körpergewicht ||| or body weight ||| 0-0 1-1 1-2
oder Leberfunktionsstörung kann ||| or hepatic impairment may ||| 0-0 1-1 1-2 2-3
oder Leberfunktionsstörung ||| or hepatic impairment ||| 0-0 1-1 1-2
oder Lithium ||| or lithium ||| 0-0 1-1
oder Lithium-Konzentrationen . ||| or lithium concentrations . ||| 0-0 1-1 1-2 2-3
oder Lithium-Konzentrationen ||| or lithium concentrations ||| 0-0 1-1 1-2
oder Lungenerkrankung ||| or pulmonary ||| 0-0 0-1 1-1
oder Paracetamol ||| or paracetamol ||| 0-0 1-1
oder Patienten , ||| patients or ||| 1-0 0-1
oder Patienten ||| patients or ||| 1-0 0-1
oder Pflegepersonal aufgetragen ||| or nurse ||| 0-0 1-1 2-1
oder Placebo ||| or placebo ( ||| 0-0 1-1
oder Placebo ||| or placebo ||| 0-0 1-1
oder Schlaganfall ||| or stroke in ||| 0-0 1-1
oder Schlaganfall ||| or stroke ||| 0-0 1-1
oder Sie ||| or if you ||| 0-0 1-1 1-2
oder Sinkstoffe sichtbar sind ||| or settling are ||| 0-0 1-1 2-1 3-2
oder Sinkstoffe sichtbar ||| or settling ||| 0-0 1-1 2-1
oder Sucrase-Isomaltase-Insuffizienz sollten ||| or sucrase-isomaltase insufficiency should ||| 0-0 1-1 1-2 2-3
oder Sucrase-Isomaltase-Insuffizienz ||| or sucrase-isomaltase insufficiency ||| 0-0 1-1 1-2
oder Tod ||| or death ||| 0-0 1-1
oder Urtikaria ) ||| or urticaria ) ||| 0-0 1-1 2-2
oder Urtikaria ||| or urticaria ||| 0-0 1-1
oder Valproat ||| or valproate ||| 0-0 1-1
oder Verhaltensstörungen ||| or disturbed ||| 0-0 1-1
oder Verschlechterung ||| or worsening ||| 0-0 1-1
oder Zahnarzt . ||| or dentist . ||| 0-0 1-1 2-2
oder Zahnarzt ||| or dentist ||| 0-0 1-1
oder Zwischenmahlzeit eingenommen werden . ||| or snack containing carbohydrates . ||| 0-0 1-1 1-2 1-3 2-3 3-3 4-4
oder Zwischenmahlzeit eingenommen werden ||| or snack containing carbohydrates ||| 0-0 1-1 1-2 1-3 2-3 3-3
oder aber ||| or disposed ||| 0-0 0-1
oder absichtliche akute ||| or intentional acute ||| 0-0 1-1 2-2
oder absichtliche ||| or intentional ||| 0-0 1-1
oder alle ||| or all of ||| 0-0 1-1
oder alle ||| or all ||| 0-0 1-1
oder andere Bisphosphonate oder ||| other bisphosphonates or ||| 1-0 2-1 0-2 3-2
oder andere Symptome ||| or other symptoms of ||| 0-0 1-1 2-2
oder andere Symptome ||| or other symptoms ||| 0-0 1-1 2-2
oder andere ||| or other ||| 0-0 1-1
oder andere ||| other relevant ||| 0-0 1-0 0-1
oder anderen Dentaleingriffen . ||| or other dental surgeries . ||| 0-0 1-1 2-2 2-3 3-4
oder anderen Dentaleingriffen ||| or other dental surgeries ||| 0-0 1-1 2-2 2-3
oder anderen Diabetesmedikamenten ||| or to other antidiabetic medicines ||| 0-0 1-2 2-3 2-4
oder anderen hochwirksamen CYP3A4-Inhibitoren ||| or other potent CYP3A4 inhibitors ||| 0-0 1-1 2-2 3-2 3-3 3-4
oder anderen zentral wirksamen Arzneimitteln ||| or other CNS medicinal products ||| 0-0 1-1 2-2 3-2 4-3 4-4
oder anderen zentral wirksamen ||| or other CNS ||| 0-0 1-1 2-2 3-2
oder anderen ||| , or to other ||| 0-1 1-3
oder anderen ||| or other ||| 0-0 1-1
oder anderen ||| or to other ||| 0-0 1-2
oder angespannt sein . ||| or tense . ||| 0-0 1-1 2-1 3-2
oder angespannt sein ||| or tense ||| 0-0 1-1 2-1
oder angespannt ||| or tense . ||| 0-0 1-1
oder angespannt ||| or tense ||| 0-0 1-1
oder auf nüchternen Magen einnehmen ||| or without food ||| 0-0 1-1 2-1 3-2 4-2
oder auf nüchternen ||| or without ||| 0-0 1-1 2-1
oder bei Aufbewahrung bei Raumtemperatur ||| or stored at room temperature ||| 0-0 1-1 2-1 2-2 3-2 4-3 4-4
oder bei Aufbewahrung bei ||| or stored at ||| 0-0 1-1 2-1 2-2 3-2
oder bei HIV ||| or in case of HIV ||| 0-0 1-1 1-2 2-4
oder bei ||| or in case of ||| 0-0 1-1 1-2
oder bei ||| or in case ||| 0-0 1-1 1-2
oder bis ||| or ||| 0-0
oder chronischer Leberfunktionseinschränkung leiden . ||| or chronic liver disease . ||| 0-0 1-1 2-2 3-3 4-4
oder chronischer Leberfunktionseinschränkung leiden ||| or chronic liver disease ||| 0-0 1-1 2-2 3-3
oder chronischer Leberfunktionseinschränkung ||| or chronic liver ||| 0-0 1-1 2-2
oder chronischer ||| or chronic ||| 0-0 1-1
oder das Etikett ||| or the label to the ||| 0-0 1-1 2-2 1-3 1-4
oder das Pflegepersonal . ||| or nurse . ||| 0-0 1-1 2-1 3-2
oder das Pflegepersonal geben . ||| or nurse . ||| 0-0 1-1 2-1 3-1 4-2
oder das Pflegepersonal geben ||| or nurse ||| 0-0 1-1 2-1 3-1
oder das Pflegepersonal ||| or nurse ||| 0-0 1-1 2-1
oder das Unterbrechen der ||| or discontinuation of treatment ||| 0-0 1-1 2-1 3-2 2-3 3-3
oder dem 16- bis 81fachen ||| or 16 to 81 times ||| 0-0 2-1 1-2 3-2 2-3 3-3 4-3 4-4
oder dem 16- bis ||| or 16 to 81 times ||| 0-0 2-1 1-2 3-2 2-3 3-3 2-4
oder den Blutgefäßen ||| or the blood vessels ||| 0-0 1-1 2-2 2-3
oder den Oberarm sind ||| or the deltoid region may ||| 0-0 1-1 1-2 2-2 2-3 3-3 2-4
oder den ||| or the ||| 0-0 1-1
oder der Legeperiode ||| or lay ||| 0-0 2-1
oder der ||| or ||| 0-0
oder diabetischer Ketoazidose ||| or diabetic ketoacidosis ||| 0-0 1-1 2-1 2-2
oder die Verschlechterung einer bestehenden ||| or aggravation of existing ||| 0-0 2-1 3-1 4-1 3-2 4-3
oder die vordere Bauchwand gegeben ||| or the anterior abdominal wall ||| 0-0 1-1 2-2 3-2 3-3 3-4 4-4
oder die ||| or the ||| 0-0 1-1
oder die ||| or ||| 0-0
oder eine ||| or ||| 0-0
oder einen der ||| or any of the ||| 0-0 1-1 2-2 2-3
oder einen der ||| or to any of the ||| 0-0 1-1 1-2 2-3 2-4
oder einen ||| or any of the ||| 0-0 1-1 1-3
oder einen ||| or any ||| 0-0 1-1
oder einen ||| or to any ||| 0-0 1-1 1-2
oder fettleibig ||| or obesity ||| 0-0 0-1
oder fettreichen Nahrungsmitteln. ||| sweet or fatty foods ||| 1-0 0-1 2-2 2-3
oder fettreichen ||| sweet or ||| 1-0 0-1
oder früherem Schlaganfall , die ||| or previous stroke who ||| 0-0 1-1 2-2 3-3 4-3
oder früherem Schlaganfall ||| or previous stroke ||| 0-0 1-1 2-2
oder früherem ||| or previous ||| 0-0 1-1
oder gemischten Episode der ||| or mixed episode of ||| 0-0 1-1 1-2 2-2 3-3
oder gemischten Episode einer ||| or mixed episode of ||| 0-0 1-1 1-2 2-2 3-2
oder gemischten Episode einer ||| or mixed episode ||| 0-0 1-1 1-2 2-2 3-2
oder gemischten Episode ||| or mixed episode of ||| 0-0 1-1 1-2 2-2
oder gemischten Episode ||| or mixed episode ||| 0-0 1-1 1-2 2-2
oder gemischten ||| or mixed ||| 0-0 1-1
oder geplante G-CSF-Unterstützung behandelt . ||| or planned G-CSF support . ||| 0-0 1-1 2-1 2-2 2-3 3-3 4-4
oder geplante G-CSF-Unterstützung behandelt ||| or planned G-CSF support ||| 0-0 1-1 2-1 2-2 2-3 3-3
oder hyperosmolarem Koma oder Tod ||| or hyperosmolar coma or death ||| 0-0 1-1 2-2 3-3 4-4
oder hyperosmolarem Koma oder Tod ||| or hyperosmolar coma or death ||| 0-0 3-0 1-1 2-2 4-2 3-3 4-4
oder hyperosmolarem Koma oder ||| or hyperosmolar coma or ||| 0-0 1-1 2-2 3-3
oder hyperosmolarem Koma ||| or hyperosmolar coma ||| 0-0 1-1 2-2
oder hyperosmolarem ||| or hyperosmolar ||| 0-0 1-1
oder höhere Dosis bis zu ||| or higher dose to ||| 0-0 1-1 2-2 3-3 4-3
oder höhere Dosis ||| or higher dose ||| 0-0 1-1 2-2
oder höhere ||| or higher ||| 0-0 1-1
oder in Form ||| , or as ||| 0-1 2-2
oder in Form ||| or as ||| 0-0 2-1
oder in eine Placebogruppe re-randomisiert ||| or placebo ||| 0-0 2-0 3-1 4-1
oder in eine ||| or ||| 0-0 2-0
oder in ||| , or ||| 0-1
oder in ||| or ||| 0-0
oder keine ||| or of no ||| 0-0 1-2
oder länger an . ||| or more . ||| 0-0 1-1 2-1 3-2
oder länger an ||| or more ||| 0-0 1-1 2-1
oder länger benötigen . ||| or longer . ||| 0-0 1-1 2-1 3-2
oder länger benötigen ||| or longer ||| 0-0 1-1 2-1
oder länger ||| or more ||| 0-0 1-1
oder mehr Einheiten ||| or more units of ||| 0-0 1-1 2-2
oder mehr Einheiten ||| or more units ||| 0-0 1-1 2-2
oder mehr Wochen nach der ||| or more weeks after your ||| 0-0 1-1 2-2 3-3 4-3
oder mehr Wochen nach der ||| or more weeks after ||| 0-0 1-1 2-2 3-3
oder mehr Wochen nach der ||| or more weeks after ||| 0-0 1-1 2-2 3-3 4-3
oder mehr Wochen nach ||| or more weeks after ||| 0-0 1-1 2-2 3-3
oder mehr Wochen ||| or more weeks ||| 0-0 1-1 2-2
oder mehr von ||| or more ||| 0-0 1-1 2-1
oder mehr ||| or more ||| 0-0 1-1
oder mit Risikofaktoren für ||| or with risk factors for ||| 0-0 1-1 2-2 2-3 3-4
oder mit Risikofaktoren ||| or with risk factors ||| 0-0 1-1 2-2 2-3
oder mit ||| or with ||| 0-0 1-1
oder mäßigen Einfluss auf die ||| or moderate influence on the ||| 0-0 1-1 2-2 3-3 4-3 4-4
oder mäßigen Einfluss ||| or moderate influence ||| 0-0 1-1 2-2
oder mäßigen ||| or moderate ||| 0-0 1-1
oder ohne ( behandelte ) ||| oder ohne ( behandelte ) ||| 0-0 1-1 2-2 3-3 4-4
oder ohne ( behandelte ||| oder ohne ( behandelte ||| 0-0 1-1 2-2 3-3
oder ohne ( ||| oder ohne ( ||| 0-0 1-1 2-2
oder ohne Mahlzeit eingenommen . ||| or without food . ||| 0-0 1-1 2-1 3-2 4-3
oder ohne Mahlzeit eingenommen ||| or without food ||| 0-0 1-1 2-1 3-2
oder ohne Mahlzeit ||| or without ||| 0-0 1-1 2-1
oder ohne Nahrung eingenommen . ||| or without food . ||| 0-0 1-1 2-2 3-2 4-3
oder ohne Nahrung eingenommen ||| or without food ||| 0-0 1-1 2-2 3-2
oder ohne Rapid-Cycling Verlauf ||| or without a rapid-cycling course ||| 0-0 1-1 2-2 2-3 3-3 2-4
oder ohne psychotischen Merkmalen und ||| or without psychotic features and ||| 0-0 1-1 2-2 3-3 4-4
oder ohne psychotischen Merkmalen ||| or without psychotic features ||| 0-0 1-1 2-2 3-3
oder ohne psychotischen ||| or without psychotic ||| 0-0 1-1 2-2
oder ohne ||| oder ohne ||| 0-0 1-1
oder ohne ||| or without ||| 0-0 1-1
oder periphere ||| or peripheral ||| 0-0 1-1
oder pflanzliche Arzneimittel , die ||| Antidepressants or herbal ||| 1-0 2-0 0-1 1-2 4-2
oder schlecht einstellbarem Bluthochdruck . ||| untreated , inadequately treated ||| 0-0 1-0 2-1 2-2 3-2 4-2 3-3
oder schlecht ||| untreated ||| 0-0 1-0
oder schweren sensorischen Neuropathie ||| or severe sensory neuropathy , ||| 0-0 1-1 2-2 3-3
oder schweren sensorischen Neuropathie ||| or severe sensory neuropathy ||| 0-0 1-1 2-2 3-3
oder schweren sensorischen ||| or severe sensory ||| 0-0 1-1 2-2
oder schweren ||| or severe ||| 0-0 1-1
oder sehr schnellem oder unregelmäßigem ||| or very rapid or irregular ||| 0-0 1-1 2-2 3-3 4-4
oder sehr schnellem oder ||| or very rapid or ||| 0-0 1-1 2-2 3-3
oder sehr schnellem ||| or very rapid ||| 0-0 1-1 2-2
oder sehr ||| or very ||| 0-0 1-1
oder sich ||| or ||| 0-0
oder sie erhielten Risedronat ||| or they received risedronate ||| 0-0 1-1 2-2 3-3
oder sie erhielten ||| or they received ||| 0-0 1-1 2-2
oder sie ||| or they ||| 0-0 1-1
oder t ||| side ||| 0-0 1-0
oder ungeplante , ||| or unplanned , ||| 0-0 1-1 2-2
oder ungeplante ||| or unplanned ||| 0-0 1-1
oder unregelmäßigem Herzschlag leiden . ||| or irregular heart beat . ||| 0-0 1-1 2-2 2-3 3-3 4-4
oder unregelmäßigem Herzschlag leiden ||| or irregular heart beat ||| 0-0 1-1 2-2 2-3 3-3
oder unregelmäßigem ||| or irregular ||| 0-0 1-1
oder unter der ||| below the ||| 0-0 1-0 2-1
oder unter ||| below ||| 0-0 1-0
oder unzureichend ||| or insufficient ||| 0-0 1-1
oder weniger dauerten , ||| or less duration , ||| 0-0 1-1 2-2 3-3
oder weniger dauerten ||| or less duration ||| 0-0 1-1 2-2
oder weniger ||| or less ||| 0-0 1-1
oder wenn Sie ||| or if you are ||| 0-0 1-1 2-2 1-3
oder wenn der ||| , or if the ||| 0-1 1-2 2-3
oder wenn der ||| or if the ||| 0-0 1-1 2-2
oder wenn sie ||| or if they ||| 0-0 1-1 2-2
oder wenn ||| , or if ||| 0-1 1-2
oder wenn ||| or if ||| 0-0 1-1
oder wurden ||| , or were ||| 0-1 1-2
oder wurden ||| , or were ||| 1-0 0-1 1-2
oder wurden ||| or were ||| 0-0 1-1
oder während der Laktation. ||| or during lactation . ||| 0-0 1-1 2-1 1-2
oder während der Laktation. ||| or during lactation ||| 0-0 1-1 2-1 1-2
oder während der ||| or during lactation . ||| 0-0 1-1 2-1 1-2
oder während der ||| or during lactation ||| 0-0 1-1 2-1 1-2
oder zusätzlichen Risikofaktoren ( ||| or additional risk factors ( ||| 0-0 1-1 2-2 2-3 3-4
oder zusätzlichen Risikofaktoren ||| compromise or additional risk factors ||| 0-1 1-2 2-3 2-4
oder zusätzlichen Risikofaktoren ||| or additional risk factors ||| 0-0 1-1 2-2 2-3
oder zusätzlichen ||| compromise or additional ||| 0-1 1-2
oder zusätzlichen ||| or additional ||| 0-0 1-1
oder zutreffen könnte , ||| , or might apply , ||| 3-0 0-1 1-2 2-2 1-3 3-4
oder zutreffen könnte ||| or might apply ||| 0-0 1-1 2-1 1-2
oder zwei Wochen ||| or two weeks ||| 0-0 1-1 2-2
oder zwei ||| or two ||| 0-0 1-1
oder ||| , or to ||| 0-1
oder ||| , or ||| 0-1
oder ||| 10 or 15 ||| 0-1
oder ||| 10 or ||| 0-1
oder ||| 2 or ||| 0-1
oder ||| ; or ||| 0-1
oder ||| compromise or ||| 0-1
oder ||| oder ||| 0-0
oder ||| or 15 ||| 0-0
oder ||| or 5 ||| 0-0
oder ||| or disposed ||| 0-0 0-1
oder ||| or if ||| 0-0 0-1
oder ||| or in ||| 0-0
oder ||| or liquid faeces ||| 0-0
oder ||| or liquid ||| 0-0
oder ||| or obesity ||| 0-0 0-1
oder ||| or of ||| 0-0
oder ||| or overweight ||| 0-0
oder ||| or the ||| 0-0
oder ||| or to ||| 0-0
oder ||| or ||| 0-0
oder ||| to ||| 0-0
offenen Studie bestand kein ||| open-label study there was no ||| 0-0 2-0 1-1 2-2 2-3 3-4
offenen Studie bestand ||| open-label study there was ||| 0-0 2-0 1-1 2-2 2-3
offenen Studien ||| open-label studies ||| 0-0 1-1
offenen ||| open-label ||| 0-0
oft ||| occurs frequently ||| 0-0 0-1
ohne ( behandelte ) ||| ohne ( behandelte ) ||| 0-0 1-1 2-2 3-3
ohne ( behandelte ||| ohne ( behandelte ||| 0-0 1-1 2-2
ohne ( ||| ohne ( ||| 0-0 1-1
ohne Adipositas ( ||| ohne Adipositas ( ||| 0-0 1-1 2-2
ohne Adipositas ||| ohne Adipositas ||| 0-0 1-1
ohne Diabetes , in welchen ||| or in Asian/ Oriental ||| 0-0 1-1 3-1 1-2 4-3
ohne Diabetes , in welchen ||| years or in Asian/ Oriental ||| 0-1 1-2 3-2 1-3 4-4
ohne Diabetes , in ||| or in Asian/ ||| 0-0 1-1 3-1 1-2
ohne Diabetes , in ||| years or in Asian/ ||| 0-1 1-2 3-2 1-3
ohne Finger- , ||| Excluding finger , toe ||| 1-0 0-1 1-1 2-2 1-3
ohne Mahlzeit eingenommen . ||| without food . ||| 0-0 1-0 2-1 3-2
ohne Mahlzeit eingenommen ||| without food ||| 0-0 1-0 2-1
ohne Mahlzeit ||| without ||| 0-0 1-0
ohne Nahrung eingenommen . ||| without food . ||| 0-0 1-1 2-1 3-2
ohne Nahrung eingenommen ||| without food ||| 0-0 1-1 2-1
ohne Rapid-Cycling Verlauf . ||| without a rapid-cycling course . ||| 0-0 1-1 1-2 2-2 1-3 3-4
ohne Rapid-Cycling Verlauf ||| without a rapid-cycling course ||| 0-0 1-1 1-2 2-2 1-3
ohne psychotischen Merkmalen und mit ||| without psychotic features and with ||| 0-0 1-1 2-2 3-3 4-4
ohne psychotischen Merkmalen und ||| without psychotic features and ||| 0-0 1-1 2-2 3-3
ohne psychotischen Merkmalen ||| without psychotic features ||| 0-0 1-1 2-2
ohne psychotischen ||| without psychotic ||| 0-0 1-1
ohne vorherige Steroidgabe oder ||| without steroid pre- treatment or ||| 0-0 1-1 2-2 2-3 3-4
ohne vorherige Steroidgabe ||| without steroid pre- treatment ||| 0-0 1-1 2-2 2-3
ohne vorherige ||| without steroid ||| 0-0 1-1
ohne ||| ohne ||| 0-0
ohne ||| or ||| 0-0
ohne ||| with no ||| 0-0 0-1
ohne ||| without ||| 0-0
ohne ||| years or ||| 0-1
onkologischen Indikationen ||| oncology indications , and a ||| 0-0 1-1
onkologischen Indikationen ||| oncology indications , and ||| 0-0 1-1
onkologischen Indikationen ||| oncology indications , ||| 0-0 1-1
onkologischen Indikationen ||| oncology indications ||| 0-0 1-1
onkologischen ||| oncology ||| 0-0
operative ||| orchiectomy ||| 0-0
operativen Versorgung der Hüftfraktur vorzunehmen ||| hip fracture repair ||| 2-0 3-0 3-1 0-2 1-2 4-2
operativen Versorgung des Hüftbruchs vorzunehmen ||| hip repair surgery ||| 1-0 0-1 1-1 3-1 4-1 0-2 2-2
operativen Versorgung des Hüftbruchs vorzunehmen ||| your hip repair surgery ||| 1-1 0-2 1-2 3-2 4-2 0-3 2-3
operativen Versorgung ||| repair ||| 0-0 1-0
optimales Ansprechen auf ||| to ensure optimum response ||| 0-0 0-1 0-2 1-2 1-3 2-3
optimales Ansprechen auf ||| to ensure optimum response ||| 0-0 0-1 0-2 1-2 2-2 1-3
oral ) ||| , oral ||| 0-1
oral ) ||| oral ||| 0-0
oral verabreichtes Mitratapid rasch . ||| absorb orally administered mitratapide . ||| 0-0 1-0 1-1 1-2 2-3 3-3 4-4
oral verabreichtes Mitratapid rasch ||| absorb orally administered mitratapide ||| 0-0 1-0 1-1 1-2 2-3 3-3
oral verabreichtes ||| absorb orally administered ||| 0-0 1-0 1-1 1-2
oral ||| , oral ||| 0-1
oral ||| oral ||| 0-0
orale Bioverfügbarkeit der ||| oral bioavailability of the ||| 0-0 1-1 1-2 2-3
orale Bioverfügbarkeit ||| oral bioavailability of ||| 0-0 1-1 1-2
orale Therapie nicht angebracht ist ||| oral therapy is not appropriate ||| 0-0 1-1 4-2 2-3 3-4
orale Therapie ||| oral therapy ||| 0-0 1-1
orale ||| by mouth ||| 0-0
orale ||| by ||| 0-0
orale ||| oral ||| 0-0
oralem Aripiprazol : ||| oral aripiprazole : ||| 0-0 1-1 2-2
oralem Aripiprazol ||| oral aripiprazole ||| 0-0 1-1
oralem ||| oral ||| 0-0
oralen Anwendung von Aripiprazol ||| use of oral aripiprazole ||| 1-0 2-1 0-2 3-3
oralen Anwendung von ||| use of oral ||| 1-0 2-1 0-2
oralen Clearance ||| oral clearance ||| 0-0 1-1
oralen Kontrazeptivums mit einer ng ||| Kontrazeptivums mit einer ng ||| 1-0 2-1 3-2 4-3
oralen Kontrazeptivums mit einer ||| Kontrazeptivums mit einer ||| 1-0 2-1 3-2
oralen Kontrazeptivums mit ||| Kontrazeptivums mit ||| 1-0 2-1
oralen Kontrazeptivums ||| Kontrazeptivums ||| 1-0
oralen ||| oral ||| 0-0
oraler Anwendung von ||| oral administration of ||| 0-0 1-1 2-2
oraler Anwendung ||| oral administration ||| 0-0 1-1
oraler Gabe ||| oral ||| 0-0 1-0
oraler Verabreichung ||| oral administration , ||| 0-0 1-1
oraler Verabreichung ||| oral administration ||| 0-0 1-1
oraler ||| oral ||| 0-0
orthopädischer Eingriff vorgesehen ist : ||| elective orthopaedic surgery : ||| 0-0 1-1 2-1 2-2 3-2 4-3
orthopädischer Eingriff vorgesehen ist ||| elective orthopaedic surgery ||| 0-0 1-1 2-1 2-2 3-2
orthopädischer Eingriff vorgesehen ist ||| for orthopaedic surgery ||| 0-0 0-1 1-1 2-1 2-2 3-2
orthopädischer ||| elective ||| 0-0
orthostatische Hypotonie Selten : ||| orthostatic hypotension Rare : ||| 0-0 1-1 2-2 3-3
orthostatische Hypotonie Selten ||| orthostatic hypotension Rare ||| 0-0 1-1 2-2
orthostatische Hypotonie ||| orthostatic hypotension ||| 0-0 1-1
orthostatische Hypotonie* , ||| orthostatic hypotension* , ||| 0-0 1-1 2-2
orthostatische Hypotonie* ||| orthostatic hypotension* ||| 0-0 1-1
orthostatische ||| orthostatic ||| 0-0
p < ||| in patients ||| 1-1
p < ||| patients ||| 1-0
p rst vniec ba Latvij ||| p rst vniec ba Latvij ||| 0-0 1-1 2-2 3-3 4-4
p rst vniec ba ||| p rst vniec ba ||| 0-0 1-1 2-2 3-3
p rst vniec ||| p rst vniec ||| 0-0 1-1 2-2
p rst ||| p rst ||| 0-0 1-1
p ||| p ||| 0-0
pH-Wert von 6-7,5 und eine ||| pH of 6-7.5 and an ||| 0-0 1-1 2-2 3-3 4-4
pH-Wert von 6-7,5 und ||| pH of 6-7.5 and ||| 0-0 1-1 2-2 3-3
pH-Wert von 6-7,5 ||| pH of 6-7.5 ||| 0-0 1-1 2-2
pH-Wert von ||| pH of ||| 0-0 1-1
pH-Wert ||| pH ||| 0-0
palliative Behandlung betrachtet . ||| be a palliative treatment . ||| 0-0 0-1 0-2 2-2 1-3 3-4
palliative Behandlung betrachtet ||| be a palliative treatment ||| 0-0 0-1 0-2 2-2 1-3
palliative Behandlung betrachtet ||| to be a palliative treatment ||| 0-1 0-2 0-3 2-3 1-4
parasitaere Erkrankungen ||| administration site conditions ||| 0-0 0-1 1-2
parasitaere ||| administration site ||| 0-0 0-1
parenteral anzuwendenden Benzodiazepinen kann ||| parenteral benzodiazepine may be ||| 0-0 1-1 2-1 3-2 3-3
parenteral anzuwendenden Benzodiazepinen ||| parenteral benzodiazepine ||| 0-0 1-1 2-1
parenteral ||| parenteral ||| 0-0
parenterale Therapie mit Benzodiazepinen ||| parenteral benzodiazepine therapy ||| 3-0 0-1 3-1 1-2 2-2
partieller ||| being ||| 0-0
passenden Einheitenskala vorgesehen . ||| corresponding unit scale . ||| 0-0 1-1 1-2 2-2 3-3
passenden Einheitenskala vorgesehen ||| corresponding unit scale ||| 0-0 1-1 1-2 2-2
passenden ||| corresponding ||| 0-0
pectoris , erhöhtes Risiko ||| pectoris , increased risk of ||| 0-0 1-1 2-2 3-3
pectoris , erhöhtes Risiko ||| pectoris , increased risk ||| 0-0 1-1 2-2 3-3
pectoris , erhöhtes ||| pectoris , increased ||| 0-0 1-1 2-2
pectoris , ||| pectoris , ||| 0-0 1-1
pectoris ||| pectoris ||| 0-0
per se des Insulins ||| per se of insulin ||| 0-0 0-1 1-1 2-2 2-3 3-3
per se ||| per se ||| 0-0 0-1 1-1
perforierten ||| perforated ||| 0-0
periodisch angepasst werden ||| have to be adjusted periodically ||| 0-0 0-1 2-2 0-3 1-3 0-4
periphere Kälte , orthostatische Hypotonie ||| peripheral coldness , orthostatic hypotension ||| 0-0 1-1 2-2 3-3 4-4
periphere Kälte , orthostatische ||| peripheral coldness , orthostatic ||| 0-0 1-1 2-2 3-3
periphere Kälte , ||| peripheral coldness , ||| 0-0 1-1 2-2
periphere Kälte ||| peripheral coldness ||| 0-0 1-1
periphere Neuropathie Grad 3 ||| experiencing grade 3 peripheral neuropathy ||| 2-1 3-2 0-3 1-4
periphere Neuropathie Grad 3 ||| grade 3 peripheral neuropathy ||| 2-0 3-1 0-2 1-3
periphere Neuropathie ||| peripheral neuropathy ||| 0-0 1-1
periphere arterielle Verschlusskrankheit ||| peripheral arterial ||| 0-0 1-1 2-1
periphere motorische Neuropathie , Ataxie ||| peripheral motor neuropathy , ataxia ||| 0-0 1-1 2-2 3-3 4-4
periphere motorische Neuropathie , ||| peripheral motor neuropathy , ||| 0-0 1-1 2-2 3-3
periphere motorische Neuropathie ||| peripheral motor neuropathy ||| 0-0 1-1 2-2
periphere motorische ||| peripheral motor ||| 0-0 1-1
periphere ||| peripheral ||| 0-0
periphere Ödeme ||| peripheral oedema ||| 0-0 1-1
peripherer Neuropathie zum Abklingen ||| peripheral neuropathy to resolution ||| 0-0 1-0 1-1 2-2 3-3
peripherer Neuropathie zum ||| peripheral neuropathy to ||| 0-0 1-0 1-1 2-2
peripherer Neuropathie ||| peripheral neuropathy ||| 0-0 1-0 1-1
persönlichen Situation ||| individual situation ||| 0-0 0-1 1-1
pharmakodynamischen ||| genotoxic agent at ||| 0-0 0-1
pharmakodynamischen ||| genotoxic agent ||| 0-0 0-1
pharmakokinetische Daten ||| pharmacokinetic data ||| 0-0 1-1
pharmakokinetische ||| pharmacokinetic ||| 0-0
pharmakokinetischen Analyse ||| pharmacokinetic analysis ||| 0-0 1-1
pharmakokinetischen Eigenschaften von Aripiprazol und ||| pharmacokinetic characteristics of aripiprazole and ||| 0-0 1-1 2-2 3-3 4-4
pharmakokinetischen Eigenschaften von Aripiprazol ||| pharmacokinetic characteristics of aripiprazole ||| 0-0 1-1 2-2 3-3
pharmakokinetischen Eigenschaften von Insulinprodukten ||| pharmacokinetics of insulin products ||| 0-0 1-0 1-1 2-1 3-2 3-3
pharmakokinetischen Eigenschaften von ||| pharmacokinetic characteristics of ||| 0-0 1-1 2-2
pharmakokinetischen Eigenschaften von ||| pharmacokinetics of ||| 0-0 1-0 1-1 2-1
pharmakokinetischen Eigenschaften ||| pharmacokinetic characteristics ||| 0-0 1-1
pharmakokinetischen Parameter ||| pharmacokinetic parameters ||| 0-0 1-1
pharmakokinetischen ||| pharmacokinetic ||| 0-0
pharmakologische ||| pharmacological ||| 0-0
pharmakologischen Wirkungen ||| hemmt. ||| 0-0
pharmakologischen ||| hemmt. ||| 0-0
placebo-kontrollierten Kurzzeitstudien ||| short- ||| 0-0
placebo-kontrollierten ||| short- ||| 0-0
placebokontrollierten Studie ||| placebo-controlled trial ||| 0-0 1-1
placebokontrollierten Studien ||| placebo-controlled studies , ||| 0-0 1-1
placebokontrollierten Studien ||| placebo-controlled studies ||| 0-0 1-1
placebokontrollierten ||| placebo-controlled ||| 0-0
planen . Aufgrund der ||| Due to ||| 0-0 2-0 3-0 2-1
planen ||| is therefore ||| 0-0 0-1
planen ||| planning ||| 0-0
plus 800 bis 1.200 I.E. ||| 800 to 1,200 IU of ||| 1-0 2-1 0-2 2-2 3-2 4-3
plus 800 bis 1.200 I.E. ||| 800 to 1,200 IU ||| 1-0 2-1 0-2 2-2 3-2 4-3
plus 800 bis 1.200 ||| 800 to 1,200 ||| 1-0 2-1 0-2 2-2 3-2
plötzlich auftretende stechende ||| to sudden stabbing migraine- ||| 0-0 0-1 1-2 2-2 2-3
plötzlich auftretende stechende ||| to sudden stabbing migraine-like ||| 0-0 0-1 1-2 2-3
plötzlich auftretende ||| to sudden stabbing ||| 0-0 0-1 1-2
plötzlich ||| to sudden ||| 0-0 0-1
plötzliche ||| sudden and ||| 0-0
plötzliche ||| sudden ||| 0-0
plötzlichen ||| signs ||| 0-0
plötzlicher unerklärbarer Tod ||| sudden unexplained death ||| 0-0 1-1 2-2
plötzlicher unerklärbarer ||| sudden unexplained ||| 0-0 1-1
plötzlicher ||| sudden ||| 0-0
polyzythämische Mäuse ) . ||| polycythaemic mice ) . ||| 0-0 1-0 1-1 2-2 3-3
polyzythämische Mäuse ) ||| polycythaemic mice ) ||| 0-0 1-0 1-1 2-2
polyzythämische Mäuse ||| polycythaemic mice ||| 0-0 1-0 1-1
populationspharmakokinetischer ||| Based ||| 0-0
postmenopausalen Frauen , ||| post-menopausal women , ||| 0-0 1-1 2-2
postmenopausalen Frauen bei Männern ||| post-menopausal women in men ||| 0-0 1-1 2-2 3-3
postmenopausalen Frauen bei ||| post-menopausal women in ||| 0-0 1-1 2-2
postmenopausalen Frauen in der HORIZON-PFT-Studie ||| post-menopausal women in the HORIZON-PFT ||| 0-0 1-1 2-2 3-3 4-4
postmenopausalen Frauen in der ||| post-menopausal women in the ||| 0-0 1-1 2-2 3-3
postmenopausalen Frauen in ||| post-menopausal women in ||| 0-0 1-1 2-2
postmenopausalen Frauen und ||| post-menopausal women and ||| 0-0 1-1 2-2
postmenopausalen Frauen ||| post-menopausal women ||| 0-0 1-1
postmenopausalen Osteoporose ( PFT ) ||| post-menopausal osteoporosis ( PFT ) ||| 0-0 1-1 2-2 3-3 4-4
postmenopausalen Osteoporose ( PFT ||| post-menopausal osteoporosis ( PFT ||| 0-0 1-1 2-2 3-3
postmenopausalen Osteoporose ( ||| post-menopausal osteoporosis ( ||| 0-0 1-1 2-2
postmenopausalen Osteoporose ||| post-menopausal osteoporosis ||| 0-0 1-1
postmenopausalen ||| osteoporosis ||| 0-0
postmenopausalen ||| post-menopausal ||| 0-0
postmenopausaler Osteoporose implementiert wurde , ||| of post-menopausal osteoporosis , ||| 1-1 0-2 1-2 2-2 3-2 4-3
postmenopausaler Osteoporose implementiert wurde , ||| post-menopausal osteoporosis , ||| 1-0 0-1 1-1 2-1 3-1 4-2
postmenopausaler Osteoporose implementiert wurde ||| of post-menopausal osteoporosis ||| 1-1 0-2 1-2 2-2 3-2
postmenopausaler Osteoporose implementiert wurde ||| post-menopausal osteoporosis ||| 1-0 0-1 1-1 2-1 3-1
postmenopausaler Osteoporose ||| post- menopausal osteoporosis ||| 0-0 1-0 0-1 1-2
postnatale Entwicklung wurde an der ||| development were assessed in the ||| 0-0 1-0 2-1 2-2 3-3 4-4
postnatale Entwicklung wurde an ||| development were assessed in ||| 0-0 1-0 2-1 2-2 3-3
postnatale Entwicklung wurde ||| development were assessed ||| 0-0 1-0 2-1 2-2
postnatale Entwicklung ||| development ||| 0-0 1-0
postprandiale ||| postprandial ||| 0-0
posturaler Schwindel , neuropathische Schmerzen ||| postural dizziness , neuropathic pain ||| 0-0 1-1 2-2 3-3 4-4
posturaler Schwindel , neuropathische ||| postural dizziness , neuropathic ||| 0-0 1-1 2-2 3-3
posturaler Schwindel , ||| postural dizziness , ||| 0-0 1-1 2-2
posturaler Schwindel ||| postural dizziness ||| 0-0 1-1
posturaler ||| postural ||| 0-0
potenten ||| CYP3A4 inhibitor ||| 0-0 0-1
potenten ||| CYP3A4 ||| 0-0
potenziell medizinisch ernsten Anzeichen und ||| potentially medically serious signs and ||| 0-0 1-1 2-1 2-2 3-3 4-4
potenziell medizinisch ernsten Anzeichen ||| potentially medically serious signs ||| 0-0 1-1 2-1 2-2 3-3
potenziell medizinisch ernsten ||| potentially medically serious ||| 0-0 1-1 2-1 2-2
potenziell schwerwiegenden Nebenwirkungen bei ||| serious adverse reactions in ||| 0-0 1-0 2-1 2-2 3-3
potenziell schwerwiegenden Nebenwirkungen ||| serious adverse reactions ||| 0-0 1-0 2-1 2-2
potenziell schwerwiegenden ||| serious ||| 0-0 1-0
potenziell toxischen Stoffen ||| potentially toxic compounds , ||| 0-0 1-1 2-2
potenziell toxischen Stoffen ||| potentially toxic compounds ||| 0-0 1-1 2-2
potenziell toxischen ||| potentially toxic ||| 0-0 1-1
potenziell ||| potentially carcinogenic ||| 0-0
potenziell ||| potentially ||| 0-0
potenzielle Risiko für den Menschen ||| potential risk for humans ||| 0-0 1-1 2-2 3-3 4-3
potenzielle Risiko für ||| potential risk for ||| 0-0 1-1 2-2
potenzielle Risiko ||| potential risk ||| 0-0 1-1
potenzielle ||| potential ||| 0-0
potenzielle ||| self harm and ||| 0-0
potenzielle ||| self harm ||| 0-0
potenzielle ||| self ||| 0-0
primäre Wirksamkeitsparameter war die ||| primary efficacy variable was the ||| 0-0 1-1 1-2 2-3 3-4
primäre Wirksamkeitsparameter war ||| primary efficacy variable was ||| 0-0 1-1 1-2 2-3
primäre Wirksamkeitsparameter ||| primary efficacy variable ||| 0-0 1-1 1-2
primäre ||| primary ||| 0-0
primären 2-Stunden Endpunkt war 5,8 ||| primary 2-hour endpoint was 5.8 ||| 0-0 1-1 2-2 3-3 4-4
primären 2-Stunden Endpunkt war ||| primary 2-hour endpoint was ||| 0-0 1-1 2-2 3-3
primären 2-Stunden Endpunkt ||| primary 2-hour endpoint ||| 0-0 1-1 2-2
primären 2-Stunden ||| primary 2-hour ||| 0-0 1-1
primären ||| primary ||| 0-0
pro 100 ||| per 100 ||| 0-0 1-1
pro 8 kg ||| per 8 kg ||| 0-0 1-1 2-2
pro 8 ||| per 8 ||| 0-0 1-1
pro Dosis , d.h. ||| per dose , i. e. ||| 0-0 1-1 2-2 3-3 3-4
pro Dosis , ||| per dose , ||| 0-0 1-1 2-2
pro Dosis . ||| per dose . ||| 0-0 1-1 2-2
pro Dosis ||| per dose ||| 0-0 1-1
pro Kilogramm . ||| per kilogram . ||| 0-0 1-1 2-2
pro Kilogramm Körpergewicht . ||| per kilogram bodyweight . ||| 0-0 1-1 1-2 2-2 3-3
pro Kilogramm Körpergewicht ||| per kilogram bodyweight ||| 0-0 1-1 1-2 2-2
pro Kilogramm ||| per kilogram , ||| 0-0 1-1
pro Kilogramm ||| per kilogram ||| 0-0 1-1
pro Monat ) mit ||| per month ) with ||| 0-0 1-1 2-2 3-3
pro Monat ) ||| per month ) ||| 0-0 1-1 2-2
pro Monat ansteigt oder wenn ||| per month , or if ||| 0-0 1-1 2-1 3-3 4-4
pro Monat ansteigt oder ||| per month , or if ||| 0-0 1-1 2-1 3-3 2-4
pro Monat ansteigt oder ||| per month , or ||| 0-0 1-1 2-1 3-3
pro Monat ansteigt ||| per month , ||| 0-0 1-1 2-1
pro Monat ansteigt ||| per month ||| 0-0 1-1 2-1
pro Monat nicht überschreiten ||| per month ||| 0-0 2-0 3-0 1-1
pro Monat oder ||| per month or the ||| 0-0 1-1 2-2
pro Monat oder ||| per month or ||| 0-0 1-1 2-2
pro Monat ||| per month ||| 0-0 1-1
pro Tag . ||| per day . ||| 0-0 1-1 2-2
pro Tag ||| per day ||| 0-0 1-1
pro Woche ) , ||| times per week ) ||| 1-0 0-1 1-2 2-3
pro Woche ) ||| times per week ) ||| 1-0 0-1 1-2 2-3
pro Woche der ||| times per week , the ||| 1-0 0-1 1-2 2-4
pro Woche durch Injektion ||| times a week by injection ||| 0-0 1-0 2-1 1-2 2-3 3-4
pro Woche durch ||| times a week by ||| 0-0 1-0 2-1 1-2 2-3
pro Woche erfolgen . ||| times per week . ||| 1-0 0-1 1-2 2-2 3-3
pro Woche erfolgen ||| times per week ||| 1-0 0-1 1-2 2-2
pro Woche gegeben . ||| times per week . ||| 1-0 0-1 1-2 2-2 3-3
pro Woche gegeben ||| times per week ||| 1-0 0-1 1-2 2-2
pro Woche mittels intravenöser ||| per week by the intravenous ||| 0-0 1-1 2-2 3-3 3-4
pro Woche mittels ||| per week by ||| 0-0 1-1 2-2
pro Woche mittels ||| times per week by ||| 0-0 0-1 1-2 2-3
pro Woche ||| per week ||| 0-0 1-1
pro Woche ||| times per week , ||| 1-0 0-1 1-2
pro Woche ||| times per week ||| 0-0 0-1 1-2
pro Woche ||| times per week ||| 1-0 0-1 1-2
pro ml ||| per ml ||| 0-0 1-1
pro ||| per ||| 0-0
pro ||| times per ||| 0-0 0-1
produziert ||| sensitive to ||| 0-0
produziert ||| sensitive ||| 0-0
prokonvulsive Aktivität von Rimonabant wurde ||| proconvulsant activity of rimonabant was ||| 0-0 1-1 2-2 3-3 4-4
prokonvulsive Aktivität von Rimonabant ||| proconvulsant activity of rimonabant ||| 0-0 1-1 2-2 3-3
prokonvulsive Aktivität von ||| proconvulsant activity of ||| 0-0 1-1 2-2
prokonvulsive Aktivität ||| proconvulsant activity ||| 0-0 1-1
prokonvulsive ||| proconvulsant ||| 0-0
prospektiven , randomisierten , doppelblinden ||| prospective , randomised , double-blind ||| 0-0 1-1 2-2 4-2 3-3 4-4
prospektiven , ||| prospective , ||| 0-0 1-1
prospektiven ||| prospective ||| 0-0
provided the EMEA is acknowledged ||| during the second year ||| 0-1 1-1 2-1 3-2 4-3
provided the EMEA is acknowledged ||| the second year ||| 0-0 1-0 2-0 3-1 4-2
provided the EMEA is ||| during the second ||| 0-1 1-1 2-1 3-2
provided the EMEA is ||| the second ||| 0-0 1-0 2-0 3-1
provided the EMEA ||| during the ||| 0-1 1-1 2-1
provided the EMEA ||| the ||| 0-0 1-0 2-0
prozentuale Anteil ||| percentage ||| 0-0 1-0
prozentuale ||| percentage ||| 0-0
prozentualen Gewichtsabnahmewerte : ||| loss percentages were obtained : ||| 0-0 0-1 1-1 0-2 1-3 2-4
prozentualen Gewichtsabnahmewerte ||| loss percentages were obtained ||| 0-0 0-1 1-1 0-2 1-3
prä- und postnatale Entwicklung ||| pre- and post-natal development ||| 0-0 1-1 0-2 2-3 3-3
prä- und ||| pre- and post-natal ||| 0-0 1-1 0-2
prä- und ||| the pre- and post-natal ||| 0-1 1-2 0-3
prädisponieren ||| predispose ||| 0-0
präklinischen Toxizitätsstudien an Hunden ||| preclinical toxicological studies in dogs ||| 0-0 1-0 1-1 2-1 1-2 2-3 3-4
präklinischen Toxizitätsstudien an ||| preclinical toxicological studies in ||| 0-0 1-0 1-1 2-1 1-2 2-3
prämenopausalen Bereichs . ||| pre-menopausal range . ||| 0-0 1-0 1-1 2-2
prämenopausalen Bereichs ||| pre-menopausal range ||| 0-0 1-0 1-1
präoperative Anwendung von Epoetin alfa ||| use of epoetin alfa ||| 0-0 1-0 2-1 3-2 3-3 4-3
präoperative Anwendung von ||| use of ||| 0-0 1-0 2-1
präoperative Anwendung ||| use ||| 0-0 1-0
psychiatrischen Erkrankungen ||| ge Depressive reactions may occur ||| 0-0 0-1 0-2 1-2 1-3 1-4
psychotische ||| psychotic features ||| 0-0 0-1
psychotische ||| psychotic ||| 0-0
psychotischen Erkrankungen und affektiven Störungen ||| psychotic illnesses and mood disorders ||| 0-0 1-1 3-1 2-2 3-3 4-3 1-4
psychotischen Merkmalen und mit oder ||| psychotic features and with or ||| 0-0 1-1 2-2 3-3 4-4
psychotischen Merkmalen und mit ||| psychotic features and with ||| 0-0 1-1 2-2 3-3
psychotischen Merkmalen und ||| psychotic features and ||| 0-0 1-1 2-2
psychotischen Merkmalen ||| psychotic features ||| 0-0 1-1
psychotischen Symptome ||| psychotic symptoms ||| 0-0 1-1
psychotischen ||| psychotic ||| 0-0
pädiatrische ||| paediatric haemodialysis patients ||| 0-0 0-1 0-2
pädiatrischen Patienten ||| paediatric patients ||| 0-0 1-1
pädiatrischen ||| paediatric ||| 0-0
r-DNS ( gentechnisch hergestellt ||| rDNA ( produced by ||| 0-0 1-1 2-2 3-2 3-3
r-DNS ( ||| rDNA ( ||| 0-0 1-1
r-DNS ||| rDNA ||| 0-0
rDNA ) , ||| ; ||| 2-0
rDNA ) . ||| rDNA ) . ||| 0-0 1-1 2-2
rDNA ) oder einen ||| rDNA ) or to any ||| 0-0 1-1 2-2 3-3 3-4
rDNA ) oder ||| rDNA ) or ||| 0-0 1-1 2-2
rDNA ) ||| rDNA ) ||| 0-0 1-1
rDNA ||| rDNA ||| 0-0
radioaktiv markiertem Pioglitazon beim Menschen ||| radiolabelled pioglitazone to man , ||| 0-0 1-0 2-1 3-2 1-3 3-3 4-3
radioaktiv markiertem Pioglitazon beim Menschen ||| radiolabelled pioglitazone to man ||| 0-0 1-0 2-1 3-2 1-3 3-3 4-3
radiologisch bestätigtem , vor ||| to ||| 3-0
randomisiert ||| randomised ||| 0-0
randomisierten , doppelblinden ||| randomised , double-blind ||| 0-0 2-0 1-1 2-2
randomisierten ||| randomised ||| 0-0
rauchen . ||| smoke . ||| 0-0 1-1
rauchen ||| smoke ||| 0-0
reagieren , sowie bei ||| ACOMPLIA , ||| 0-0 1-0 1-1 2-1
reagieren , sowie ||| ACOMPLIA , ||| 0-0 1-0 1-1 2-1
rechteckig und blau , ||| rectangular and blue , ||| 0-0 1-1 2-2 3-3
rechteckig und blau ||| rectangular and blue ||| 0-0 1-1 2-2
rechteckig und rosafarben , ||| rectangular and pink , ||| 0-0 1-1 2-2 3-3
rechteckig und rosafarben ||| rectangular and pink ||| 0-0 1-1 2-2
rechteckig und ||| rectangular and ||| 0-0 1-1
rechteckig ||| rectangular ||| 0-0
reduziert . ||| . ||| 0-0 1-0
reduziert werden . ||| be reduced . ||| 1-0 0-1 2-2
reduziert werden ||| be reduced ||| 1-0 0-1
reduziert ||| reduced with ||| 0-0
reduziert ||| reduced ||| 0-0
reduzierte BSAP ||| reduced BSAP ||| 0-0 1-1
reduzierte Pioglitazon im Vergleich ||| pioglitazone reduced total plasma triglycerides ||| 1-0 0-1 0-2 2-3 0-4 3-4
reduzierte Sehschärfe , ||| reduced visual acuity , ||| 0-0 1-1 1-2 2-3
reduzierte Sehschärfe ||| reduced visual acuity ||| 0-0 1-1 1-2
reduzierte schnell ||| rapidly reduced ||| 1-0 0-1
reduzierte ||| reduced ||| 0-0
regelmäßig Ihre Werte des ||| your levels of the ||| 1-0 0-1 2-1 3-2 3-3
regelmäßig Ihre Werte ||| your levels ||| 1-0 0-1 2-1
regelmäßig gemessen werden ||| measured on a regular basis ||| 0-0 1-0 0-1 1-2 1-3 2-3 1-4
regelmäßig kontrolliert werden . ||| be monitored regularly . ||| 2-0 1-1 0-2 3-3
regelmäßig kontrolliert werden ||| be monitored regularly ||| 2-0 1-1 0-2
regelmäßig kontrolliert ||| monitored regularly ||| 1-0 0-1
regelmäßig ||| regularly ||| 0-0
reichlich Wasser spülen . ||| copious amounts of water . ||| 0-0 0-1 1-3 2-3 3-4
reichlich Wasser spülen ||| copious amounts of water ||| 0-0 0-1 1-3 2-3
reichlich ||| copious amounts of ||| 0-0 0-1
reichlich ||| copious amounts ||| 0-0 0-1
rekombinante DNA-Technologie in ||| in CHO cell line by ||| 0-0 0-1 1-2 1-3 2-3 1-4
rekombinante ||| in CHO ||| 0-0 0-1
rekombinantem humanen Erythropoetin ||| recombinant human erythropoietin ||| 0-0 1-0 1-1 2-2
rekombinantem humanen ||| recombinant human ||| 0-0 1-0 1-1
rekonstituierte Arzneimittel enthält ca. ||| reconstituted medicinal product contains approximately ||| 0-0 1-1 1-2 2-3 3-4
rekonstituierte Arzneimittel enthält ||| reconstituted medicinal product contains ||| 0-0 1-1 1-2 2-3
rekonstituierte Arzneimittel ||| reconstituted medicinal product ||| 0-0 1-1 1-2
rekonstituierte Suspension hat einen pH-Wert ||| reconstituted suspension has a pH ||| 0-0 1-1 2-2 3-3 4-4
rekonstituierte Suspension hat einen ||| reconstituted suspension has a ||| 0-0 1-1 2-2 3-3
rekonstituierte Suspension hat ||| reconstituted suspension has ||| 0-0 1-1 2-2
rekonstituierte Suspension ||| reconstituted suspension ||| 0-0 1-1
rekonstituierte ||| reconstituted ||| 0-0
rekonstituierten Suspension im ||| reconstituted suspension in the ||| 0-0 1-1 2-2 2-3
rekonstituierten Suspension ist möglich . ||| reconstituted suspension may occur . ||| 0-0 1-1 3-2 4-4
rekonstituierten Suspension ist möglich ||| reconstituted suspension may occur ||| 0-0 1-1 3-2
rekonstituierten Suspension ist möglich ||| reconstituted suspension may ||| 0-0 1-1 3-2
rekonstituierten Suspension ist ||| reconstituted suspension ||| 0-0 1-1
rekonstituierten Suspension ||| reconstituted suspension ||| 0-0 1-1
rekonstituierten ||| reconstituted ||| 0-0
rektale ||| rectal ||| 0-0
relative Wirksamkeit von M-II ||| relative efficacy of M-II ||| 0-0 1-1 2-2 3-3
relative Wirksamkeit von ||| relative efficacy of ||| 0-0 1-1 2-2
relative Wirksamkeit ||| relative efficacy ||| 0-0 1-1
relative ||| relative ||| 0-0
relevanten Effekt auf ||| relevant effect on ||| 0-0 1-1 2-2
relevanten Effekt ||| relevant effect ||| 0-0 1-1
relevanten ||| relevant ||| 0-0
renale Ausscheidung . ||| renal excretion . ||| 0-0 1-1 2-2
renale Ausscheidung ||| renal excretion ||| 0-0 1-1
renale Beeinflussung ||| renal effects ||| 0-0 1-0
renale Beeinflussung ||| renal ||| 0-0 1-0
renale ||| renal ||| 0-0
renaler Anämie ||| renal anaemia , ||| 0-0 1-1
renaler Anämie ||| renal anaemia ||| 0-0 1-1
renaler ||| renal ||| 0-0
repräsentieren vermutlich die schnelle ||| presumably represent rapid ||| 0-0 1-0 3-1 3-2
repräsentieren vermutlich die ||| presumably ||| 0-0 1-0
repräsentieren vermutlich ||| presumably ||| 0-0 1-0
republika Eli ||| republika Eli ||| 0-0 1-1
republika OncoEurope Tel : + ||| republika OncoEurope Tel : + ||| 0-0 1-1 2-2 3-3 4-4
republika OncoEurope Tel : ||| republika OncoEurope Tel : ||| 0-0 1-1 2-2 3-3
republika OncoEurope Tel ||| republika OncoEurope Tel ||| 0-0 1-1 2-2
republika OncoEurope ||| republika OncoEurope ||| 0-0 1-1
republika ||| republika ||| 0-0
resorbiert , wobei maximale Plasmaspiegel ||| absorbed , with peak plasma ||| 0-0 2-0 1-1 2-2 3-3 4-3 4-4
resorbiert , wobei ||| absorbed , with ||| 0-0 2-0 1-1 2-2
restliche Inhalt verworfen werden ||| , discard any remaining contents ||| 0-0 0-1 1-1 2-2 2-3 2-4 3-4
restliche Inhalt ||| , discard ||| 0-0 0-1 1-1
restliche ||| remaining amount of ||| 0-0 0-1
restliche ||| remaining amount ||| 0-0 0-1
resuspendiert wird ||| time ||| 0-0 1-0
reversibel und ||| reversible and dose dependent ||| 0-0 1-1
reversibel und ||| reversible and dose ||| 0-0 1-1
reversibel und ||| reversible and ||| 0-0 1-1
reversibel ||| reversible ||| 0-0
reversiblen Methoden ||| methods ||| 0-0 1-0
reversibler exzentrischer ||| rats , dogs , ||| 0-0 0-1 0-2 1-2 1-3
richtige Dosis ||| correct dose ||| 0-0 1-1
richtige Menge ||| correct amount ||| 0-0 1-1
richtige ||| correct ||| 0-0
rosafarben , mit Prägung von ||| pink , marked with ||| 0-0 1-1 3-2 2-3
rosafarben , mit Prägung von ||| pink , marked with ||| 0-0 1-1 3-2 2-3 4-3
rosafarben , mit Prägung ||| pink , marked with ||| 0-0 1-1 3-2 2-3
rosafarben , mit der Prägung ||| pink , engraved with ||| 0-0 1-1 3-2 4-2 2-3
rosafarben , mit der Prägung ||| pink , marked with ||| 0-0 1-1 3-2 4-2 2-3
rosafarben , ||| pink , ||| 0-0 1-1
rosafarben ||| pink ||| 0-0
roten Blutfarbstoffes ( Hämoglobin ||| red blood pigment ( haemoglobin ||| 0-0 0-1 1-2 3-2 2-3 3-4
roten Blutfarbstoffs ( Hämoglobin ||| red blood pigment ( haemoglobin ||| 0-0 0-1 1-2 3-2 2-3 3-4
roten ||| red blood ||| 0-0 0-1
roter Blutzellen anregen . ||| blood cell production . ||| 0-0 0-1 1-1 2-2 3-3
roter Blutzellen anregen ||| blood cell production ||| 0-0 0-1 1-1 2-2
roter Blutzellen anregt . ||| cell production . ||| 0-0 1-0 2-1 3-2
roter Blutzellen anregt ||| cell production ||| 0-0 1-0 2-1
roter Blutzellen ||| blood cell ||| 0-0 0-1 1-1
roter Blutzellen ||| cell ||| 0-0 1-0
routinemäßig gemessen , aber ||| routinely measured but a ||| 0-0 1-1 2-2 3-2 1-3
routinemäßig gemessen ||| routinely measured ||| 0-0 1-1
routinemäßig kontrollierten Laborparameter auftraten , ||| in routine laboratory parameters ||| 0-0 0-1 1-1 2-2 2-3 3-3
routinemäßig kontrollierten Laborparameter auftraten ||| in routine laboratory parameters ||| 0-0 0-1 1-1 2-2 2-3 3-3
routinemäßig kontrollierten ||| in routine ||| 0-0 0-1 1-1
routinemäßig ||| routinely ||| 0-0
rst vniec ba Latvij Tel ||| rst vniec ba Latvij Tel ||| 0-0 1-1 2-2 3-3 4-4
rst vniec ba Latvij ||| rst vniec ba Latvij ||| 0-0 1-1 2-2 3-3
rst vniec ba ||| rst vniec ba ||| 0-0 1-1 2-2
rst vniec ||| rst vniec ||| 0-0 1-1
rst ||| rst ||| 0-0
ruhen , ||| minimum ||| 0-0
ruhen ||| minimum ||| 0-0
rund und gelb , ||| round and yellow , ||| 0-0 1-1 2-2 3-3
rund und gelb ||| round and yellow ||| 0-0 1-1 2-2
rund und rosafarben , ||| round and pink , ||| 0-0 1-1 2-2 3-3
rund und rosafarben ||| round and pink ||| 0-0 1-1 2-2
rund und ||| round and ||| 0-0 1-1
rund ||| round ||| 0-0
runde ||| off ||| 0-0
runden Tabletten enthalten 15 , ||| round tablets contain 15 , ||| 0-0 1-1 2-2 3-3 4-4
runden Tabletten enthalten 15 ||| round tablets contain 15 ||| 0-0 1-1 2-2 3-3
runden Tabletten enthalten ||| round tablets contain ||| 0-0 1-1 2-2
runden Tabletten ||| round tablets ||| 0-0 1-1
runden ||| round ||| 0-0
s.c. Anwendung genau ||| sc use ||| 0-0 1-1 2-1
s.c. ||| sc ||| 0-0
sanft invertiert ||| gently inverted ||| 0-0 1-0 1-1
sanofi-aventis S.p.A. , Strada ||| sanofi-aventis S. p. A. , ||| 0-0 1-1 1-2 3-2 3-3 2-4
sanofi-aventis ||| sanofi-aventis ||| 0-0
scheinbar nicht ||| do not seem ||| 1-0 1-1 0-2
scheinbar ||| seem ||| 0-0
scheint gering zu sein . ||| appears to be low . ||| 0-0 1-0 2-1 3-2 2-3 4-4
scheint gering zu sein ||| appears to be low ||| 0-0 1-0 2-1 3-2 2-3
scheint gering ||| appears ||| 0-0 1-0
scheint mit dem ||| concentration ||| 0-0 1-0 2-0
scheint vergleichbar ||| seems comparable to that ||| 0-0 1-1
scheint vergleichbar ||| seems comparable to ||| 0-0 1-1
scheint vergleichbar ||| seems comparable ||| 0-0 1-1
scheint ||| seems ||| 0-0
scheint über eine Aktivierung ||| appears to act via ||| 0-0 0-1 2-1 3-2 1-3 3-3
schienen sich ||| appeared to be reversing , ||| 0-0 1-1 0-2 0-3 1-3 1-4
schizophrenen Patienten betrug die Inzidenz ||| schizophrenia patients the incidence ||| 0-0 1-1 3-2 2-3 3-3 4-3
schizophrenen Patienten ||| schizophrenia patients ||| 0-0 1-1
schizophrenen ||| schizophrenia ||| 0-0
schmackhaften ||| mesolimbic system modulates ||| 0-0 0-2
schmerzhafte ||| painful ||| 0-0
schnell heraus und ||| quickly and apply pressure ||| 0-0 2-1 1-2 2-3
schnell reversibel und ||| rapidly reversible and dose dependent ||| 0-0 1-1 2-2
schnell reversibel und ||| rapidly reversible and dose ||| 0-0 1-1 2-2
schnell reversibel und ||| rapidly reversible and ||| 0-0 1-1 2-2
schnell reversibel ||| rapidly reversible ||| 0-0 1-1
schnell und kräftig in ||| with a quick ||| 0-0 3-1 2-2
schnell und ||| with ||| 0-0
schnell wirkend , Insulin ( ||| fast-acting , insulin ( ||| 0-0 1-0 2-1 3-2 4-3
schnell wirkend , Insulin ||| fast-acting , insulin ||| 0-0 1-0 2-1 3-2
schnell wirkend , ||| fast-acting , ||| 0-0 1-0 2-1
schnell wirkend ||| fast-acting ||| 0-0 1-0
schnell wirkendes ( ||| fast-acting ( ||| 0-0 1-0 2-1
schnell wirkendes ||| fast-acting ||| 0-0 1-0
schnell ||| quickly ||| 0-0
schnell ||| rapidly ||| 0-0
schnell ||| with ||| 0-0
schnelle initiale Wirkung zusammen mit ||| rapid initial effect together with ||| 0-0 1-0 1-1 2-2 1-3 3-3 4-4
schnelle initiale Wirkung zusammen mit ||| rapid initial effect together with ||| 0-0 1-1 2-2 1-3 3-3 4-4
schnelle initiale Wirkung zusammen ||| rapid initial effect together ||| 0-0 1-0 1-1 2-2 1-3 3-3
schnelle initiale Wirkung zusammen ||| rapid initial effect together ||| 0-0 1-1 2-2 1-3 3-3
schnelle ||| rapid ||| 0-0
schnelle ||| represent rapid ||| 0-0 0-1
schnellem oder unregelmäßigem Herzschlag leiden ||| rapid or irregular heart beat ||| 0-0 1-1 2-2 3-3 3-4 4-4
schnellem oder unregelmäßigem ||| rapid or irregular ||| 0-0 1-1 2-2
schnellem oder ||| rapid or ||| 0-0 1-1
schnellem ||| rapid ||| 0-0
schnellen Einsetzens der Wirkung von ||| rapid onset of effect of ||| 0-0 1-0 1-1 2-2 4-2 3-3 4-4
schnellen Einsetzens ||| rapid onset ||| 0-0 1-0 1-1
schnellen Kontrolle von gesteigerter Unruhe ||| rapid control of agitation ||| 0-0 1-1 2-2 3-3 4-3
schnellen Kontrolle von gesteigerter Unruhe ||| the rapid control of agitation ||| 2-0 0-1 1-2 2-3 3-4 4-4
schnellen Kontrolle von ||| rapid control of ||| 0-0 1-1 2-2
schnellen Kontrolle von ||| the rapid control of ||| 0-1 1-2 2-3
schnellen Kontrolle von ||| the rapid control of ||| 2-0 0-1 1-2 2-3
schnellen Kontrolle ||| rapid control ||| 0-0 1-1
schnellen Kontrolle ||| the rapid control ||| 0-1 1-2
schnellen ||| rapid ||| 0-0
schnellen ||| the rapid ||| 0-1
schockartige ||| Quincke ||| 0-0
schon früher ein ||| had ||| 1-0 2-0
schwanger sind , ||| are pregnant , ||| 1-0 0-1 2-2
schwanger sind , ||| are pregnant ||| 1-0 2-0 0-1
schwanger sind oder planen ||| are pregnant or ||| 1-0 0-1 3-1 2-2
schwanger sind ||| are pregnant ||| 1-0 0-1
schwanger ||| pregnant ||| 0-0
schwangeren Frauen vor . ||| pregnant women . ||| 0-0 1-1 2-1 3-2
schwangeren Frauen vor ||| pregnant women ||| 0-0 1-1 2-1
schwangeren ||| pregnant or ||| 0-0 0-1
schwangeren ||| pregnant ||| 0-0
schwarzer Hautfarbe . ||| Black . ||| 0-0 1-0 2-1
schwarzer Hautfarbe ||| Black ||| 0-0 1-0
schwere Dehydratation ) . ||| severe dehydration ) ||| 0-0 1-1 2-2
schwere Dehydratation ) ||| severe dehydration ) ||| 0-0 1-1 2-2
schwere Dehydratation ||| severe dehydration ||| 0-0 1-1
schwere Gewichtsabnahme , abgemagertes Aussehen ||| severe weight loss , emaciated ||| 0-0 1-1 2-2 2-3 3-4 4-4
schwere Gewichtsabnahme , ||| severe weight loss , ||| 0-0 1-1 2-2 2-3
schwere Gewichtsabnahme ||| severe weight ||| 0-0 1-1
schwere ||| and severe ||| 0-1
schwere ||| severe ||| 0-0
schweren Neutropenie oder schweren sensorischen ||| severe neutropenia or severe sensory ||| 0-0 1-1 2-2 3-3 4-4
schweren Neutropenie oder schweren ||| severe neutropenia or severe ||| 0-0 1-1 2-2 3-3
schweren Neutropenie oder ||| severe neutropenia or ||| 0-0 1-1 2-2
schweren Neutropenie ||| severe neutropenia ||| 0-0 1-1
schweren manischen Episoden ||| severe manic episodes in ||| 0-0 1-1 2-2
schweren manischen Episoden ||| severe manic episodes ||| 0-0 1-1 2-2
schweren manischen ||| severe manic ||| 0-0 1-1
schweren sensorischen Neuropathie ||| severe sensory neuropathy , additional ||| 0-0 1-1 2-2
schweren sensorischen Neuropathie ||| severe sensory neuropathy , ||| 0-0 1-1 2-2
schweren sensorischen Neuropathie ||| severe sensory neuropathy ||| 0-0 1-1 2-2
schweren sensorischen ||| severe sensory ||| 0-0 1-1
schweren ||| severe ||| 0-0
schwerer Agitiertheit , ||| severe agitation , ||| 0-0 1-1 2-2
schwerer Agitiertheit ||| severe agitation ||| 0-0 1-1
schwerer Einschränkung der Nierenfunktion vor ||| severe renal impairment ||| 0-0 1-1 3-1 3-2 4-2
schwerer Leberfunktionsstörung sollten nicht ||| severe hepatic impairment should not ||| 0-0 1-1 1-2 2-3 3-4
schwerer Leberfunktionsstörung sollten ||| severe hepatic impairment should ||| 0-0 1-1 1-2 2-3
schwerer Leberfunktionsstörung ||| severe hepatic impairment ||| 0-0 1-1 1-2
schwerer Niereninsuffizienz ||| severe renal ||| 0-0 1-1
schwerer Niereninsuffizienz ||| severe ||| 0-0 1-0
schwerer Symptome ist weniger häufig ||| severe symptoms is less common ||| 0-0 1-1 2-2 3-3 4-4
schwerer Symptome ist weniger ||| severe symptoms is less ||| 0-0 1-1 2-2 3-3
schwerer Symptome ist ||| severe symptoms is ||| 0-0 1-1 2-2
schwerer Symptome ||| severe symptoms ||| 0-0 1-1
schwerer manischer Episoden und ||| severe manic episodes and ||| 0-0 1-1 2-2 3-3
schwerer manischer Episoden ||| severe manic episodes ||| 0-0 1-1 2-2
schwerer manischer ||| severe manic ||| 0-0 1-1
schwerer ||| severe ||| 0-0
schwerwiegende ||| serious ||| 0-0
schwächer als normal macht . ||| weaker than normal . ||| 0-0 1-1 2-2 4-3
schwächer als normal macht ||| weaker than normal ||| 0-0 1-1 2-2
schwächer als normal ||| weaker than normal ||| 0-0 1-1 2-2
schwächer als ||| weaker than ||| 0-0 1-1
schwächer ||| weaker ||| 0-0
schädlich sein für ||| be harmful for ||| 1-0 0-1 1-1 2-2
schädlich sein ||| be harmful ||| 1-0 0-1 1-1
schützen . ||| environment . ||| 0-0 1-1
schützen . ||| from light . ||| 0-0 0-1 1-2
schützen ||| environment ||| 0-0
schützen ||| from light ||| 0-0 0-1
sechs Monaten ||| six months ||| 0-0 1-1
sechs identifizierten Metaboliten sind aktiv ||| six identified metabolites are active ||| 0-0 1-1 2-2 3-3 4-4
sechs identifizierten Metaboliten sind ||| six identified metabolites are ||| 0-0 1-1 2-2 3-3
sechs identifizierten Metaboliten ||| six identified metabolites ||| 0-0 1-1 2-2
sechs identifizierten ||| six identified ||| 0-0 1-1
sechs ||| six ||| 0-0
sechsmonatigen Vergleichsstudien ||| 6-month comparative ||| 0-0 1-1
sechsmonatigen ||| 6-month ||| 0-0
sechsmonatiger ||| observed in clinical trials ||| 0-0 0-1 0-2 0-3
sehr groß . ||| very wide . ||| 0-0 1-1 2-2
sehr groß ||| very wide ||| 0-0 1-1
sehr hohem ||| very ||| 0-0 1-0
sehr schmackhaften ||| mesolimbic system modulates ||| 1-0 1-2
sehr schnellem oder unregelmäßigem ||| very rapid or irregular ||| 0-0 1-1 2-2 3-3
sehr schnellem oder ||| very rapid or ||| 0-0 1-1 2-2
sehr schnellem ||| very rapid ||| 0-0 1-1
sehr selten auf ( siehe ||| is very rare ( see ||| 0-0 0-1 1-2 2-2 3-3 4-4
sehr selten auf ( ||| is very rare ( ||| 0-0 0-1 1-2 2-2 3-3
sehr selten auf ||| is very rare ||| 0-0 0-1 1-2 2-2
sehr seltene Fälle von ||| very rare cases of ||| 0-0 1-1 2-2 3-3
sehr seltene Fälle ||| very rare cases ||| 0-0 1-1 2-2
sehr seltene ||| very rare ||| 0-0 1-1
sehr seltenen Fällen ein tödlicher ||| very rare cases fatal ||| 0-0 1-1 2-2 3-3 4-3
sehr seltenen Fällen ||| very rare cases ||| 0-0 1-1 2-2
sehr seltenen ||| very rare ||| 0-0 1-1
sehr stark ausgeprägt ||| becomes very significant ||| 1-0 0-1 2-1 2-2
sehr stark ist und raschverläuft ||| is severe and rapid ||| 2-0 1-1 3-2 0-3 4-3
sehr ||| is very ||| 0-0 0-1
sehr ||| very ||| 0-0
sein . ||| antihypertensive treatment . ||| 0-0 0-1 1-2
sein ||| antihypertensive treatment ||| 0-0 0-1
sein ||| be ||| 0-0
sein ||| may be ||| 0-0 0-1
sein ||| of ||| 0-0
seine Patienten immer nach ||| always ask his patients ||| 0-0 2-0 0-1 2-2 3-2 1-3
seine ||| its ||| 0-0
seinem ||| accordance ||| 0-0
seinen Antrag auf Anwendung ||| its application for the use ||| 0-0 1-1 2-3 3-4
seinen Antrag auf ||| its application for the ||| 0-0 1-1 2-3
seinen Antrag in Bezug ||| withdraw its application ||| 1-0 3-0 0-1 1-2
seinen Antrag ||| its application for ||| 0-0 1-1
seinen Antrag ||| its application ||| 0-0 1-1
seinen Metaboliten sind ||| its metabolites are ||| 0-0 1-1 2-2
seinen Metaboliten ||| its metabolites ||| 0-0 1-1
seinen ||| its ||| 0-0
seines 1-adrenergen ||| its 1-adrenergic receptor ||| 0-0 0-1 1-1 1-2
seit 1993 als ||| been available as an ||| 0-0 1-0 1-1 2-2 2-3
seit 1993 ||| been available ||| 0-0 1-0 1-1
seit der Markteinführung wurden unbeabsichtigte ||| post-marketing experience , accidental ||| 0-0 2-0 0-1 3-2 3-3 4-3
seit der Markteinführung ||| post-marketing experience ||| 0-0 2-0 0-1
seit ||| postmarketing ||| 0-0
selbst im ||| state ||| 1-0
selbst ||| inject ||| 0-0
selten - Refraktionsanomalien ||| rare - Refraction disorders ||| 0-0 1-1 2-2 2-3
selten - ||| rare - ||| 0-0 1-1
selten auf ( siehe Abschnitt ||| rare ( see section ||| 0-0 1-0 2-1 3-2 4-3
selten auf ( siehe ||| rare ( see ||| 0-0 1-0 2-1 3-2
selten auf ( ||| rare ( ||| 0-0 1-0 2-1
selten auf ||| rare ||| 0-0 1-0
selten ||| rare ||| 0-0
seltene Fälle von MNS ||| rare cases of NMS ||| 0-0 1-1 2-2 3-3
seltene Fälle von ||| rare cases of ||| 0-0 1-1 2-2
seltene Fälle ||| rare cases ||| 0-0 1-1
seltene ||| rare ||| 0-0
seltenen Erbkrankheiten ||| rare hereditary problems of ||| 0-0 0-1 1-1 1-2
seltenen Erbkrankheiten ||| rare hereditary problems ||| 0-0 0-1 1-1 1-2
seltenen Fällen ein tödlicher Ausgang ||| rare cases fatal outcome has ||| 0-0 1-1 2-2 3-2 4-3 4-4
seltenen Fällen ein tödlicher ||| rare cases fatal ||| 0-0 1-1 2-2 3-2
seltenen Fällen ||| rare cases ||| 0-0 1-1
seltenen ||| rare ||| 0-0
seltener Fälle von Bronchokonstriktion ||| rare cases of bronchoconstriction ||| 0-0 1-1 2-2 3-3
seltener Fälle von ||| rare cases of ||| 0-0 1-1 2-2
seltener Fälle ||| rare cases ||| 0-0 1-1
seltener ||| rare ||| 0-0
senkte signifikant ||| significantly decreased ||| 0-0 1-0 1-1
sensorische Neuropathie , Kopfschmerzen , ||| sensory neuropathy , headache , ||| 0-0 1-1 2-2 3-3 4-4
sensorische Neuropathie , Kopfschmerzen ||| sensory neuropathy , headache ||| 0-0 1-1 2-2 3-3
sensorische Neuropathie , ||| sensory neuropathy , ||| 0-0 1-1 2-2
sensorische Neuropathie ||| sensory neuropathy ||| 0-0 1-1
sensorische Störung , Somnolenz . ||| sensory disturbance , somnolence . ||| 0-0 2-1 2-2 1-3 3-3 4-4
sensorische Störung , Somnolenz ||| sensory disturbance , somnolence ||| 0-0 2-1 2-2 1-3 3-3
sensorische ||| sensory ||| 0-0
sensorischen Neuropathie ||| sensory neuropathy , additional ||| 0-0 1-1
sensorischen Neuropathie ||| sensory neuropathy , ||| 0-0 1-1
sensorischen Neuropathie ||| sensory neuropathy ||| 0-0 1-1
sensorischen ||| sensory ||| 0-0
sensorischer Neuropathie Grad 3 ||| grade 3 sensory neuropathy withhold ||| 2-0 3-1 0-2 1-2 1-3 2-4
sensorischer Neuropathie ||| sensory neuropathy ||| 0-0 1-0 1-1
setzen Sie sich bitte ||| please contact ||| 0-0 0-1 1-1 2-1 3-1
setzen Sie sich bitte ||| please contact ||| 0-0 1-0 0-1 2-1 3-1
sicca , Madarosis Augenerkrankungen ||| sicca , madarosis Eye disorders ||| 0-0 1-1 2-2 3-3 3-4
sicca , Madarosis ||| sicca , madarosis ||| 0-0 1-1 2-2
sicca , ||| sicca , ||| 0-0 1-1
sicca ||| sicca ||| 0-0
sich , dass ||| , suggest that ||| 1-0 2-1 0-2 2-2
sich , dass ||| that ||| 0-0 1-0 2-0
sich 39 ||| , 39 ||| 0-0 1-1
sich 39 ± 16 % ||| , 39 ± 16 % ||| 0-0 1-1 2-2 3-3 4-4
sich 39 ± 16 ||| , 39 ± 16 ||| 0-0 1-1 2-2 3-3
sich 39 ± ||| , 39 ± ||| 0-0 1-1 2-2
sich als ||| found to be ||| 0-1 1-2
sich als ||| to be ||| 0-0 1-1
sich am Tag der ||| normally on the day ||| 0-0 0-1 1-1 1-2 3-2 2-3
sich bei ||| regresses ||| 1-0
sich benommen oder schwindelig fühlen ||| feel drowsy or dizzy ||| 0-0 4-0 1-1 2-2 3-3 4-3
sich besser fühlen . ||| feel better . ||| 0-0 2-0 1-1 2-1 3-2
sich besser fühlen ||| feel better ||| 0-0 2-0 1-1 2-1
sich der Möglichkeit ||| to the possibility ||| 0-0 1-1 2-2
sich der ||| to the ||| 0-0 1-1
sich die Masse an extra-abdominalem ||| an increase in extra-abdominal ||| 0-0 1-0 2-0 2-1 3-2 2-3 3-3 4-3
sich die Zellen ||| in place , the cells ||| 0-0 0-1 0-2 1-3 2-4
sich die ||| in place , the ||| 0-0 0-1 0-2 1-3
sich eine Herzinsuffizienz . ||| of heart failure . ||| 1-0 0-1 2-1 2-2 3-3
sich eine Herzinsuffizienz ||| of heart failure ||| 1-0 0-1 2-1 2-2
sich einer zahnmedizinischen Operation unterziehen ||| undergo dental surgery ||| 1-0 4-0 2-1 3-2
sich einer ||| a blood ||| 1-0
sich einer ||| a ||| 1-0
sich etwas anzutun . ||| about hurting yourself . ||| 2-0 0-1 1-1 2-1 2-2 3-3
sich etwas anzutun ||| about hurting yourself ||| 2-0 0-1 1-1 2-1 2-2
sich feststellen ||| experience ||| 1-0
sich in allen Fällen ||| in all of whom it ||| 1-0 2-1 3-4
sich in allen ||| in all of whom ||| 1-0 2-1
sich in allen ||| in all of ||| 1-0 2-1
sich in allen ||| in all ||| 1-0 2-1
sich in den Geweben . ||| to the tissues . ||| 0-0 1-1 2-1 0-2 3-2 4-3
sich in den Geweben ||| to the tissues ||| 0-0 1-1 2-1 0-2 3-2
sich in ||| in ||| 1-0
sich insbesondere ||| formulation ||| 0-0
sich jedoch eine ||| If ||| 2-0
sich keine ||| , no new ||| 0-0 1-1
sich keine ||| , no ||| 0-0 1-1
sich linear von 2653 auf ||| linearly from 2653 to ||| 1-0 2-1 3-2 4-3
sich linear von 2653 ||| linearly from 2653 ||| 1-0 2-1 3-2
sich linear von ||| linearly from ||| 1-0 2-1
sich linear ||| linearly ||| 1-0
sich müde oder schwindlig fühlen ||| feel tired or dizzy ||| 0-0 4-0 1-1 3-1 2-2 4-3
sich nicht ganz sicher sind ||| are not sure ||| 4-0 1-1 0-2 2-2 3-2 4-2
sich schwindelig fühlen , besonders ||| feel dizzy , especially ||| 0-0 2-0 1-1 2-1 3-2 4-3
sich schwindelig fühlen , ||| feel dizzy , ||| 0-0 2-0 1-1 2-1 3-2
sich schwindelig fühlen ||| feel dizzy ||| 0-0 2-0 1-1 2-1
sich unter Umständen ||| probably need ||| 0-0 1-0 2-0 2-1
sich ||| , ||| 0-0
sich ||| a ||| 0-0
sich ||| an ||| 0-0
sich ||| formulation ||| 0-0
sich ||| found to ||| 0-1
sich ||| have an ||| 0-1
sich ||| in place , ||| 0-0 0-1 0-2
sich ||| on treatment ||| 0-0
sich ||| on ||| 0-0
sich ||| or ||| 0-0
sich ||| to ||| 0-0
sich überlagernden Nebenwirkungen wie ||| overlapping undesirable effects such as ||| 0-0 1-0 1-1 2-1 2-2 3-3 3-4
sich überlagernden Nebenwirkungen ||| overlapping undesirable effects ||| 0-0 1-0 1-1 2-1 2-2
sicheren Anwendung ||| factors such ||| 0-0 0-1
sicheren Anwendung ||| risk factors such ||| 0-1 0-2
sicheren Anwendung ||| with risk factors such ||| 0-2 0-3
sicheren ||| factors such ||| 0-0 0-1
sicheren ||| risk factors such ||| 0-1 0-2
sicheren ||| with risk factors such ||| 0-2 0-3
sichergestellt sein . ||| treatment . ||| 0-0 1-0 2-1
sichergestellt sein ||| treatment ||| 0-0 1-0
sicherheitspharmakologischen Studien beobachtet . ||| safety pharmacology studies . ||| 0-0 0-1 1-2 2-2 3-3
sicherheitspharmakologischen Studien beobachtet ||| safety pharmacology studies ||| 0-0 0-1 1-2 2-2
sicherheitspharmakologischen ||| safety pharmacology ||| 0-0 0-1
sicherheitsrelevanten Bedenken ||| concerns ||| 0-0 1-0
sicherstellen , dass Ihr ||| make sure that your haemoglobin ||| 1-0 2-0 2-1 0-2 2-2 3-3 2-4
sicherstellen ||| ensure ||| 0-0
sicherzugehen ||| ensure ||| 0-0
sicherzustellen , dass die gesamte ||| make sure the entire ||| 0-0 1-0 0-1 2-1 3-2 4-3
sicherzustellen , dass die ||| make sure the ||| 0-0 1-0 0-1 2-1 3-2
sicherzustellen , dass ||| ensure that ||| 0-0 1-1 2-1
sicherzustellen , dass ||| make sure ||| 0-0 1-0 0-1 2-1
sicherzustellen , ||| ensure ||| 0-0
sicherzustellen , ||| to ensure ||| 0-1
sicherzustellen ||| ensure ||| 0-0
sicherzustellen ||| to ensure ||| 0-1
sichtbaren ||| visible ||| 0-0
sie die ||| to ||| 0-0 1-0
sie durch den ||| sie durch den ||| 0-0 1-1 2-2
sie durch ||| sie durch ||| 0-0 1-1
sie erhielten Risedronat einmal ||| they received risedronate once a ||| 0-0 1-1 2-2 3-3 3-4
sie erhielten Risedronat ||| they received risedronate ||| 0-0 1-1 2-2
sie erhielten ||| they received ||| 0-0 1-1
sie jedoch ||| However , ||| 1-0 1-1
sie sehr stark ausgeprägt ist ||| it becomes very significant ||| 0-0 4-0 2-1 1-2 3-2 3-3
sie unzerkaut . ||| whole . ||| 0-0 1-0 2-1
sie unzerkaut ||| whole ||| 0-0 1-0
sie ||| it ||| 0-0
sie ||| sie ||| 0-0
sie ||| they ||| 0-0
siehe Abschnitt 4.2 ) . ||| see section 4.2 ) . ||| 0-0 1-1 2-2 3-3 4-4
siehe Abschnitt 4.2 ) Die ||| see section 4.2 ) The ||| 0-0 1-1 2-2 3-3 4-4
siehe Abschnitt 4.2 ) ||| see also section 4.2 ) ||| 0-0 0-1 1-2 2-3 3-4
siehe Abschnitt 4.2 ) ||| see section 4.2 ) ||| 0-0 1-1 2-2 3-3
siehe Abschnitt 4.2 Behandlung von ||| see section 4.2 Treatment of ||| 0-0 1-1 2-2 3-3 4-4
siehe Abschnitt 4.2 Behandlung ||| see section 4.2 Treatment ||| 0-0 1-1 2-2 3-3
siehe Abschnitt 4.2 und ||| see section dic ||| 0-0 1-1 2-1 2-2
siehe Abschnitt 4.2 ||| see also section 4.2 ||| 0-0 0-1 1-2 2-3
siehe Abschnitt 4.2 ||| see section 4.2 ||| 0-0 1-1 2-2
siehe Abschnitt 4.2 ||| see section dic ||| 0-0 1-1 2-1 2-2
siehe Abschnitt 4.3 ) . ||| see section 4.3 ) . ||| 0-0 1-1 2-2 3-3 4-4
siehe Abschnitt 4.3 ) ||| see section 4.3 ) ||| 0-0 1-1 2-2 3-3
siehe Abschnitt 4.3 ||| see section 4.3 ||| 0-0 1-1 2-2
siehe Abschnitt 4.3). itte ||| see section 4.3 ) . ||| 0-0 0-1 1-1 2-2 1-3 3-4
siehe Abschnitt 4.3). ||| see section 4.3 ) ||| 0-0 0-1 1-1 2-2 1-3
siehe Abschnitt 4.4 ) . ||| See section 4.4 ) . ||| 0-0 1-1 2-2 3-3 4-4
siehe Abschnitt 4.4 ) . ||| see section 4.4 ) . ||| 0-0 1-1 2-2 3-3 4-4
siehe Abschnitt 4.4 ) ||| See section 4.4 ) ||| 0-0 1-1 2-2 3-3
siehe Abschnitt 4.4 ) ||| see section 4.4 ) ||| 0-0 1-1 2-2 3-3
siehe Abschnitt 4.4 - ||| please see section 4.4 - ||| 0-0 0-1 1-2 2-3 3-4
siehe Abschnitt 4.4 - ||| see section 4.4 - ||| 0-0 1-1 2-2 3-3
siehe Abschnitt 4.4 und 5.2 ||| see section 4.4 and 5.2 ||| 0-0 1-1 2-2 3-3 4-4
siehe Abschnitt 4.4 und 5.2 ||| siehe Abschnitt 4.4 und 5.2 ||| 0-0 0-1 1-2 2-2 3-3 4-4
siehe Abschnitt 4.4 und Abschnitt ||| see section 4.4 and section ||| 0-0 1-1 4-1 2-2 3-3 4-4
siehe Abschnitt 4.4 und ||| see section 4.4 and ||| 0-0 1-1 2-2 3-3
siehe Abschnitt 4.4 und ||| siehe Abschnitt 4.4 und ||| 0-0 0-1 1-2 2-2 3-3
siehe Abschnitt 4.4 ||| See section 4.4 ||| 0-0 1-1 2-2
siehe Abschnitt 4.4 ||| please see section 4.4 ||| 0-0 0-1 1-2 2-3
siehe Abschnitt 4.4 ||| see section 4.4 ||| 0-0 1-1 2-2
siehe Abschnitt 4.4 ||| siehe Abschnitt 4.4 ||| 0-0 0-1 1-2 2-2
siehe Abschnitt 4.5 ) . ||| see section 4.5 ) . ||| 0-0 1-1 2-2 3-3 4-4
siehe Abschnitt 4.5 ) ||| see section 4.5 ) ||| 0-0 1-1 2-2 3-3
siehe Abschnitt 4.5 . ||| see section 4.5 . ||| 0-0 1-1 2-2 3-3
siehe Abschnitt 4.5 ||| see section 4.5 ||| 0-0 1-1 2-2
siehe Abschnitt 4.5). t lä ||| nefazodone)(see section 4.5 ) ||| 2-0 0-1 1-1 1-2 3-3
siehe Abschnitt 4.5). t ||| nefazodone)(see section 4.5 ) ||| 2-0 0-1 1-1 1-2 3-3
siehe Abschnitt 4.5). ||| nefazodone)(see section 4.5 ||| 2-0 0-1 1-1 1-2
siehe Abschnitt 4.6 ) . ||| see section 4.6 ) . ||| 0-0 1-1 2-2 3-3 4-4
siehe Abschnitt 4.6 ) ||| see section 4.6 ) ||| 0-0 1-1 2-2 3-3
siehe Abschnitt 4.6 ||| see section 4.6 ||| 0-0 1-1 2-2
siehe Abschnitt 4.8 ) . ||| see section 4.8 ) . ||| 0-0 1-1 2-2 3-3 4-4
siehe Abschnitt 4.8 ) ||| see section 4.8 ) ||| 0-0 1-1 2-2 3-3
siehe Abschnitt 4.8 ||| see section 4.8 ||| 0-0 1-1 2-2
siehe Abschnitt 5.1 ) . ||| see section 5.1 ) . ||| 0-0 1-1 2-2 3-3 4-4
siehe Abschnitt 5.1 ) : ||| see section 5.1 ) : ||| 0-0 1-1 2-2 3-3 4-4
siehe Abschnitt 5.1 ) ||| see section 5.1 ) , ||| 0-0 1-1 2-2 3-3
siehe Abschnitt 5.1 ) ||| see section 5.1 ) ||| 0-0 1-1 2-2 3-3
siehe Abschnitt 5.1 ||| see section 5.1 ||| 0-0 1-1 2-2
siehe Abschnitt 5.2 ) . ||| see section 5.2 ) . ||| 0-0 1-1 2-2 3-3 4-4
siehe Abschnitt 5.2 ) ||| see also section 5.2 ) ||| 0-0 0-1 1-2 2-3 3-4
siehe Abschnitt 5.2 ) ||| see section 5.2 ) ||| 0-0 1-1 2-2 3-3
siehe Abschnitt 5.2 ||| see also section 5.2 ||| 0-0 0-1 1-2 2-3
siehe Abschnitt 5.2 ||| see section 5.2 ||| 0-0 1-1 2-2
siehe Abschnitt 5.2 ||| see sections 4.4 and 5.2 ||| 0-0 0-1 1-2 2-4
siehe Abschnitt 5.2 ||| siehe Abschnitt 5.2 ||| 0-0 0-1 1-2 2-2
siehe Abschnitt 5.3 ) . ||| see section 5.3 ) . ||| 0-0 1-1 2-2 3-3 4-4
siehe Abschnitt 5.3 ) ||| see section 5.3 ) ||| 0-0 1-1 2-2 3-3
siehe Abschnitt 5.3 ||| see section 5.3 ||| 0-0 1-1 2-2
siehe Abschnitt 6.1 ) . ||| see section 6.1 ) . ||| 0-0 1-1 2-2 3-3 4-4
siehe Abschnitt 6.1 ) ||| see section 6.1 ) ||| 0-0 1-1 2-2 3-3
siehe Abschnitt 6.1 . ||| see 6.1 . ||| 0-0 1-0 2-1 3-2
siehe Abschnitt 6.1 . ||| see section 6.1 . ||| 0-0 1-1 2-2 3-3
siehe Abschnitt 6.1 ||| see 6.1 ||| 0-0 1-0 2-1
siehe Abschnitt 6.1 ||| see section 6.1 ||| 0-0 1-1 2-2
siehe Abschnitt 6.3 . ||| , see section 6.3 . ||| 2-0 0-1 1-1 1-2 2-3 3-4
siehe Abschnitt 6.3 ||| , see section 6.3 ||| 2-0 0-1 1-1 1-2 2-3
siehe Abschnitt 6.6 . ||| , see section 6.6 . ||| 0-1 1-2 2-3 3-4
siehe Abschnitt 6.6 . ||| see section 6.6 . ||| 0-0 1-1 2-2 3-3
siehe Abschnitt 6.6 ||| , see section 6.6 ||| 0-1 1-2 2-3
siehe Abschnitt 6.6 ||| see section 6.6 ||| 0-0 1-1 2-2
siehe Abschnitt ||| , see section ||| 0-1 1-2
siehe Abschnitt ||| See section ||| 0-0 1-1
siehe Abschnitt ||| is ||| 0-0 1-0
siehe Abschnitt ||| please see section ||| 0-0 0-1 1-2
siehe Abschnitt ||| section 4.5 ||| 0-0 1-0 1-1
siehe Abschnitt ||| see also section ||| 0-0 0-1 1-2
siehe Abschnitt ||| see section 4.4 ) ||| 0-0 1-1 1-2 1-3
siehe Abschnitt ||| see section ||| 0-0 1-0 1-1
siehe Abschnitt ||| see section ||| 0-0 1-1
siehe Abschnitt ||| see sections 4.4 and ||| 0-0 0-1 1-2
siehe Abschnitt ||| see sections 4.4 ||| 0-0 0-1 1-2
siehe Abschnitt ||| see ||| 0-0 1-0
siehe Abschnitte 4.3 und 4.4 ||| see sections 4.3 and 4.4 ||| 0-0 1-1 2-2 3-3 4-4
siehe Abschnitte 4.3 und ||| see sections 4.3 and ||| 0-0 1-1 2-2 3-3
siehe Abschnitte 4.3 ||| see sections 4.3 ||| 0-0 1-1 2-2
siehe Abschnitte 4.8 und 4.9 ||| see sections 4.8 and 4.9 ||| 0-0 1-1 2-2 3-3 4-4
siehe Abschnitte 4.8 und ||| see sections 4.8 and ||| 0-0 1-1 2-2 3-3
siehe Abschnitte 4.8 ||| see sections 4.8 ||| 0-0 1-1 2-2
siehe Abschnitte ||| see sections ||| 0-0 1-1
siehe Anhang I ) ||| see Annex I ) ||| 0-0 1-1 2-1 2-2 3-3
siehe Anhang I : ||| See Annex I : ||| 0-0 1-0 1-1 2-1 2-2 3-3
siehe Anhang I ||| See Annex I ||| 0-0 1-0 1-1 2-1 2-2
siehe Anhang I ||| see Annex I ||| 0-0 1-1 2-1 2-2
siehe Tabelle 2 ) . ||| see Table 2 ) . ||| 0-0 1-1 2-2 3-3 4-4
siehe Tabelle 2 ) ||| see Table 2 ) ||| 0-0 1-1 2-2 3-3
siehe Tabelle 2 ||| see Table 2 ||| 0-0 1-1 2-2
siehe Tabelle ||| see Table ||| 0-0 1-1
siehe auch Abschnitt 4.4 ) ||| See also section 4.4 ) ||| 0-0 1-1 2-2 3-3 4-4
siehe auch Abschnitt 4.4 ||| See also section 4.4 ||| 0-0 1-1 2-2 3-3
siehe auch Abschnitt ||| See also section ||| 0-0 1-1 2-2
siehe auch ||| See also ||| 0-0 1-1
siehe auch ||| siehe auch Abschnitt ||| 0-0 1-1 0-2
siehe die ||| see the ||| 0-0 1-1
siehe ||| , see ||| 0-1
siehe ||| See ||| 0-0
siehe ||| please see ||| 0-0 0-1
siehe ||| see also ||| 0-0 0-1
siehe ||| see sections ||| 0-0 0-1
siehe ||| see ||| 0-0
siehe ||| siehe Abschnitt ||| 0-0 0-1
signifikant beeinflussen ||| significantly impact ||| 0-0 1-1
signifikant höhere ||| significantly ||| 0-0 1-0
signifikant verändert. t lä ||| signifikant verändert. t lä ||| 0-0 1-1 2-2 2-3 3-3
signifikant verändert. ||| signifikant verändert. ||| 0-0 1-1
signifikant ||| improvement in ||| 0-0
signifikant ||| improvement ||| 0-0
signifikant ||| significant ||| 0-0
signifikant ||| significantly ||| 0-0
signifikant ||| signifikant ||| 0-0
signifikante Effekte wurden ||| significant effects were ||| 0-0 1-1 2-2
signifikante Effekte ||| significant effects ||| 0-0 1-1
signifikante Risikofaktoren wie ||| significant risk factors such as ||| 0-0 1-1 1-2 2-3 2-4
signifikante Risikofaktoren ||| significant risk factors ||| 0-0 1-1 1-2
signifikante Unterschiede bei Hüftfrakturen ||| significant differences in hip fracture ||| 0-0 1-1 2-2 3-3 3-4
signifikante Unterschiede bei ||| significant differences in ||| 0-0 1-1 2-2
signifikante Unterschiede ||| significant differences ||| 0-0 1-1
signifikante Veränderung der Aripiprazol-Konzentrationen ||| significant change in aripiprazole concentrations ||| 0-0 1-1 2-1 1-2 3-3 3-4
signifikante Veränderung der ||| significant change in ||| 0-0 1-1 2-1 1-2
signifikante Veränderungen der routinemäßig kontrollierten ||| significant changes in routine ||| 0-0 1-1 2-1 3-2 3-3 4-3
signifikante Veränderungen der ||| significant changes ||| 0-0 1-1 2-1
signifikante ||| significant ||| 0-0
signifikanten Effekt auf ||| significant effect on ||| 0-0 1-1 2-2
signifikanten Effekt ||| significant effect ||| 0-0 1-1
signifikanten Nutzen gezeigt , ||| shown significant benefits ||| 2-0 0-1 1-2
signifikanten Nutzen gezeigt ||| shown significant benefits ||| 2-0 0-1 1-2
signifikanten Nutzen ||| significant benefits ||| 0-0 1-1
signifikanten intra- und interindividuellen ||| by significant intra- and inter-individual ||| 1-0 0-1 1-2 2-3 3-4
signifikanten intra- und ||| by significant intra- and ||| 1-0 0-1 1-2 2-3
signifikanten intra- ||| by significant intra- ||| 1-0 0-1 1-2
signifikanten ||| significant ||| 0-0
signifikanter ||| significant ||| 0-0
sind , ||| are ||| 0-0
sind , ||| are ||| 0-0 1-0
sind . ||| . ||| 1-0
sind . ||| are ||| 0-0
sind : Heptakis-O-(4-sulfobutyl)cyclomaltoheptaose , Heptanatriumsalz ||| are sulfobutylether -cyclodextrin ||| 0-0 1-1 2-1 4-1 2-2 3-2
sind : Lactose-Monohydrat , ||| are lactose monohydrate , ||| 0-0 2-1 1-2 2-2 3-3
sind : Lactose-Monohydrat ||| are lactose monohydrate ||| 0-0 2-1 1-2 2-2
sind : ||| are : ||| 0-0 1-1
sind Interaktionen durch Verdrängung ||| interactions resulting from displacement of ||| 0-0 1-0 1-1 1-2 2-2 1-3 3-3
sind Interaktionen durch Verdrängung ||| interactions resulting from displacement ||| 0-0 1-0 1-1 1-2 2-2 1-3 3-3
sind Mannitol , Natriumcitrat ||| are mannitol , sodium citrate ||| 0-0 1-1 2-2 3-3 3-4
sind Mannitol , ||| are mannitol , ||| 0-0 1-1 2-2
sind Mannitol ||| are mannitol ||| 0-0 1-1
sind Neutropenie ( ||| are neutropenia ( ||| 0-0 1-1 2-2
sind Neutropenie ||| are neutropenia ||| 0-0 1-1
sind Wachstumsfaktoren , ||| are growth factors ||| 0-0 1-1 2-1 1-2
sind aktiv ( M-II ||| are active ( M-II ||| 0-0 1-1 2-2 3-3
sind aktiv ( ||| are active ( ||| 0-0 1-1 2-2
sind aktiv ||| are active ||| 0-0 1-1
sind applikationsfertig ( ||| are ready to use ( ||| 0-0 1-1 1-2 1-3 2-4
sind applikationsfertig ||| are ready to use ||| 0-0 1-1 1-2 1-3
sind auf der Website ||| on the European Medicines Agency ||| 1-0 2-1 0-2 3-2 3-3 2-4 3-4
sind begrenzt . ||| is limited . ||| 1-0 0-1 1-1 2-2
sind begrenzt ||| is limited ||| 1-0 0-1 1-1
sind bei allen Patienten vor ||| should be checked prior to ||| 0-0 1-1 0-2 2-2 4-3 3-4 4-4
sind bei allen Patienten vor ||| should be checked prior to ||| 0-0 1-1 3-1 0-2 2-2 4-3 4-4
sind bei allen Patienten ||| should be checked ||| 0-0 1-1 3-1 0-2 2-2
sind bei allen ||| should be checked ||| 0-0 1-1 0-2 2-2
sind bei wiederholten Infusionen ||| with repeated infusions ||| 1-0 2-0 2-1 3-2
sind bei wiederholten ||| with repeated ||| 1-0 2-0 2-1
sind bei ||| have ||| 0-0 1-0
sind bioäquivalent zu Aripiprazol ||| tablet is bioequivalent to aripiprazole ||| 1-0 1-1 0-2 1-2 2-3 3-4
sind bioäquivalent zu ||| tablet is bioequivalent to ||| 1-0 1-1 0-2 1-2 2-3
sind bioäquivalent ||| tablet is bioequivalent ||| 1-0 1-1 0-2 1-2
sind daher nicht erforderlich . ||| are not necessary . ||| 0-0 1-0 2-1 3-2 4-3
sind daher nicht erforderlich ||| are not necessary ||| 0-0 1-0 2-1 3-2
sind daher nicht ||| are not ||| 0-0 1-0 2-1
sind daher ||| are ||| 0-0 1-0
sind darauf hinzuweisen , ||| should be alerted about ||| 0-0 1-0 1-1 2-2 1-3
sind darauf hinzuweisen ||| should be alerted about ||| 0-0 1-0 1-1 2-2 1-3
sind die Leberenzymwerte so ||| liver enzyme levels should ||| 0-0 2-0 2-1 3-1 1-2 2-2 2-3
sind die Leberenzymwerte zu überprüfen ||| liver enzymes should be checked ||| 2-0 3-0 2-1 1-2 2-2 4-3 0-4 4-4
sind die ||| the ||| 1-0
sind diese Wirkungen leicht und ||| these effects are mild and ||| 1-0 2-1 0-2 3-3 4-4
sind diese Wirkungen leicht ||| these effects are mild ||| 1-0 2-1 0-2 3-3
sind diese Wirkungen ||| these effects are ||| 1-0 2-1 0-2
sind entsprechend des ||| corresponding to the ||| 1-0 1-1 2-2
sind entsprechend ||| corresponding to ||| 1-0 1-1
sind extrapyramidale ||| are extrapyramidal ||| 0-0 1-1
sind gewöhnlich vorübergehend und ||| are transitory and ||| 0-0 1-1 2-1 3-2
sind gewöhnlich vorübergehend ||| are transitory ||| 0-0 1-1 2-1
sind in Tabelle 4 dargestellt ||| are presented in Table 4. ||| 0-0 4-1 1-2 2-3 3-3 4-3 4-4
sind in der Packung enthalten ||| are included in the carton ||| 0-0 1-1 1-2 2-3 3-4 4-4
sind in der ||| are included in the ||| 0-0 1-1 1-2 2-3
sind in ||| are included in ||| 0-0 1-1 1-2
sind keine Daten ||| are no data available ||| 0-0 1-1 2-2 2-3
sind keine besonderen ||| does not require any special ||| 0-0 2-0 1-1 1-2 2-2 2-3 2-4
sind keine besonderen ||| does not require any special ||| 2-0 0-1 0-2 1-2 2-2 2-3 2-4
sind keine besonderen ||| not require any special ||| 0-0 0-1 1-1 2-1 2-2 2-3
sind keine besonderen ||| not require any special ||| 1-0 0-1 1-1 2-1 2-2 2-3
sind keine weiteren besonderen ||| does not require any special ||| 0-0 3-0 1-1 2-1 1-2 3-2 3-3 3-4
sind keine ||| are no ||| 0-0 1-1
sind keine ||| cannot ||| 1-0
sind nach Markteinführung aufgetreten ||| have occurred in post-marketing experience ||| 0-0 3-0 3-1 1-2 1-3 2-3 3-3 3-4
sind nicht zu erwarten ||| are not to be expected ||| 0-0 1-1 2-2 2-3 3-4
sind nicht zu ||| are not to be ||| 0-0 1-1 2-2 2-3
sind nicht ||| , are not ||| 0-1 1-2
sind nicht ||| are not ||| 0-0 1-1
sind nur ein ||| a few ||| 2-0 1-1
sind nur ||| few ||| 1-0
sind rechteckig und blau , ||| are rectangular and blue , ||| 0-0 1-1 2-2 3-3 4-4
sind rechteckig und blau ||| are rectangular and blue ||| 0-0 1-1 2-2 3-3
sind rechteckig und rosafarben , ||| are rectangular and pink , ||| 0-0 1-1 2-2 3-3 4-4
sind rechteckig und rosafarben ||| are rectangular and pink ||| 0-0 1-1 2-2 3-3
sind rechteckig und ||| are rectangular and ||| 0-0 1-1 2-2
sind rechteckig ||| are rectangular ||| 0-0 1-1
sind rund und gelb , ||| are round and yellow , ||| 0-0 1-1 2-2 3-3 4-4
sind rund und gelb ||| are round and yellow ||| 0-0 1-1 2-2 3-3
sind rund und rosafarben , ||| are round and pink , ||| 0-0 1-1 2-2 3-3 4-4
sind rund und rosafarben ||| are round and pink ||| 0-0 1-1 2-2 3-3
sind rund und ||| are round and ||| 0-0 1-1 2-2
sind rund ||| are round ||| 0-0 1-1
sind ungewöhnliche ||| which are unusual ||| 0-0 0-1 1-2
sind unten dargelegt . ||| are shown below . ||| 0-0 1-2 2-2 3-3
sind unten dargelegt ||| are shown below ||| 0-0 1-2 2-2
sind weiß bis weißlich ||| are white to off-white ||| 0-0 1-1 2-2 2-3 3-3
sind weiß ||| are white ||| 0-0 1-1
sind wirksam zu ||| also be ||| 0-0 2-1
sind wirksam ||| also ||| 0-0
sind zu berücksichtigen . ||| respected . ||| 0-0 1-0 2-0 3-1
sind zu berücksichtigen ||| respected ||| 0-0 1-0 2-0
sind zur Verwendung mit ||| are for use with ||| 0-0 1-1 2-2 3-3
sind zur Verwendung ||| are for use ||| 0-0 1-1 2-2
sind zur ||| are for ||| 0-0 1-1
sind ||| , are ||| 0-1
sind ||| also ||| 0-0
sind ||| are not ||| 0-0 0-1
sind ||| are shown ||| 0-0
sind ||| are ||| 0-0
sind ||| have ||| 0-0
sind ||| which are ||| 0-0 0-1
sind üblicherweise leicht bis mäßig ||| are usually mild to moderate ||| 0-0 1-1 2-2 3-2 3-3 4-4
sind üblicherweise leicht bis ||| are usually mild to ||| 0-0 1-1 2-2 3-2 3-3
sind üblicherweise ||| are usually ||| 0-0 1-1
so dass die Wirkung von ||| and the effect of ||| 0-0 0-1 1-1 2-1 3-2 4-3
so dass die Wirkung ||| and the effect ||| 0-0 0-1 1-1 2-1 3-2
so dass die ||| and the ||| 0-0 0-1 1-1 2-1
so früh wie möglich ||| started as soon as possible ||| 1-0 2-1 0-2 1-2 2-2 2-3 3-4
so früh wie ||| started as soon as ||| 1-0 2-1 0-2 1-2 2-2 2-3
so hergestellte ||| drink ||| 0-0 1-0
so ||| and ||| 0-0
sofern erforderlich ||| if applicable ||| 0-0 0-1 1-1
sofort Ihren Arzt . ||| doctor at once . ||| 0-0 1-0 2-0 0-2 3-3
sofort Ihren Arzt ||| doctor at once ||| 0-0 1-0 2-0 0-2
sofort abgesetzt werden . ||| be discontinued immediately . ||| 2-0 1-1 2-1 0-2 3-3
sofort abgesetzt werden ||| be discontinued immediately ||| 2-0 1-1 2-1 0-2
sofort abgesetzt ||| discontinued immediately ||| 1-0 0-1
sofort nach Öffnen zu verwenden ||| immediately after opening ||| 0-0 1-1 4-1 2-2
sofort verwendet werden . ||| should be used immediately . ||| 0-0 2-1 1-2 0-3 2-3 3-4
sofort verwendet werden . ||| should be used immediately . ||| 0-0 2-1 1-2 0-3 3-4
sofort verwendet werden ||| should be used immediately ||| 0-0 2-1 1-2 0-3
sofort verwendet werden ||| should be used immediately ||| 0-0 2-1 1-2 0-3 2-3
sofort ||| immediately ||| 0-0
sogar erst auftreten . ||| discontinuation of treatment . ||| 0-0 1-0 1-1 1-2 2-2 3-3
sogar erst auftreten ||| discontinuation of treatment ||| 0-0 1-0 1-1 1-2 2-2
sogenanntes Antipsychotikum . ||| antipsychotic medicine . ||| 0-0 1-0 0-1 2-2
sogenanntes Antipsychotikum ||| antipsychotic medicine ||| 0-0 1-0 0-1
soliden Tumoren ( 172 Mammakarzinome ||| solid tumours ( 172 breast ||| 0-0 1-1 2-2 3-3 4-3 4-4
soliden Tumoren ( 683 Mammakarzinome ||| solid tumours ( 683 breast ||| 0-0 1-1 2-2 3-3 4-3 4-4
soliden Tumoren ( ||| solid tumours ( ||| 0-0 1-1 2-2
soliden Tumoren ||| solid tumours , ||| 0-0 1-1
soliden Tumoren ||| solid tumours ||| 0-0 1-1
soliden ||| solid ||| 0-0
soll ||| should ||| 0-0
sollte 200 ||| should not exceed 200 ||| 0-0 1-1 1-2 1-3
sollte 30 mg nicht überschreiten ||| should not exceed 30 mg ||| 0-0 3-1 2-2 4-2 1-3 4-4
sollte Abseamed sofort abgesetzt werden ||| Abseamed should be discontinued immediately ||| 1-0 0-1 4-2 3-3 4-3 2-4
sollte Abseamed ||| Abseamed should ||| 1-0 0-1
sollte Aclasta ||| , Aclasta should ||| 1-1 0-2
sollte Aclasta ||| Aclasta should ||| 1-0 0-1
sollte Aripiprazol ||| , aripiprazole should ||| 1-1 0-2
sollte Aripiprazol ||| aripiprazole should be ||| 1-0 0-1 0-2
sollte Aripiprazol ||| aripiprazole should ||| 1-0 0-1
sollte Epoetin alfa ||| epoetin alfa should be used ||| 1-0 1-1 2-1 0-2 0-3 1-4
sollte Epoetin alfa ||| epoetin alfa should ||| 1-0 2-1 0-2
sollte Ihr Hund ||| , your dog should ||| 0-0 1-1 1-2 2-2 0-3
sollte auf der Basis ||| should be considered on ||| 0-0 0-1 2-1 3-2 1-3 3-3
sollte bei diesen Patienten ein ||| , these patients should avoid ||| 2-1 1-2 3-2 0-3 4-4
sollte bei diesen Patienten ein ||| these patients should avoid ||| 2-0 1-1 3-1 0-2 4-3
sollte bei diesen Patienten ||| , these patients should ||| 2-1 1-2 3-2 0-3
sollte bei diesen Patienten ||| these patients should ||| 2-0 1-1 3-1 0-2
sollte das Arzneimittel ||| the medicinal product should be ||| 1-0 2-1 1-2 2-2 0-3 0-4
sollte der Hund nach seinem ||| should be in accordance ||| 0-0 2-0 0-1 1-1 3-2 4-3
sollte der Hund nach ||| should be in ||| 0-0 2-0 0-1 1-1 3-2
sollte der Hund ||| should be ||| 0-0 2-0 0-1 1-1
sollte der Patient ||| the patient should ||| 1-0 2-1 0-2
sollte der ||| should be ||| 0-0 0-1
sollte die Aripiprazol-Dosis ||| the aripiprazole dose should ||| 1-0 2-1 2-2 0-3
sollte die Dosierung ||| dosing should ||| 1-0 2-0 0-1
sollte die Dosis von ||| the dose should ||| 1-0 2-1 3-1 0-2
sollte die Dosis ||| the dose should ||| 1-0 2-1 0-2
sollte die Durchstechflasche ||| , the vial should ||| 1-1 2-2 0-3
sollte die Durchstechflasche ||| the vial should ||| 1-0 2-1 0-2
sollte die Epoetin-alfa-Behandlung beendet werden ||| alfa treatment should be discontinued ||| 1-0 2-0 3-1 0-2 3-2 4-3 2-4 3-4 4-4
sollte die Pipette gewaschen ||| the pipette should be washed ||| 1-0 2-1 0-2 0-3 3-4
sollte die Pipette ||| , the pipette should be ||| 1-1 2-2 0-3 0-4
sollte die Pipette ||| the pipette should be ||| 1-0 2-1 0-2 0-3
sollte die Suspension ||| , the suspension should ||| 1-1 2-2 0-3
sollte die Suspension ||| the suspension should ||| 1-0 2-1 0-2
sollte die komplette Resuspension durch ||| resuspension should be ensured by ||| 3-0 0-1 0-2 1-2 2-3 3-3 4-4
sollte die komplette Resuspension ||| resuspension should be ensured ||| 3-0 0-1 0-2 1-2 2-3 3-3
sollte die rekonstituierte Suspension ||| the reconstituted suspension if ||| 1-0 2-1 0-2 3-2 1-3
sollte die ||| should be ||| 0-0 0-1 1-1
sollte eine klinische ||| should consider clinical ||| 0-0 1-1 2-1 2-2
sollte eine klinische Überwachung ||| should consider clinical monitoring ||| 0-0 1-1 2-1 2-2 3-3
sollte erwogen werden ( siehe ||| should be considered ( see ||| 0-0 2-1 1-2 3-3 4-4
sollte erwogen werden ( ||| should be considered ( ||| 0-0 2-1 1-2 3-3
sollte erwogen werden ||| should be considered ||| 0-0 2-1 1-2
sollte für ||| should be ||| 0-0 0-1
sollte geraten werden ||| should be advised ||| 0-0 0-1 2-1 1-2
sollte geraten werden ||| should be advised ||| 0-0 2-1 1-2 2-2
sollte im Allgemeinen nicht ||| should generally not ||| 0-0 1-1 2-1 3-2
sollte im Allgemeinen ||| should generally ||| 0-0 1-1 2-1
sollte in Schritten ||| should be done in ||| 0-0 0-1 2-2 1-3
sollte intravenös gegeben werden ||| should be administered intravenously ||| 0-0 0-1 2-2 1-3 2-3 3-3
sollte intravenös ||| should be given ||| 0-0 0-1 1-2
sollte mit Vorsicht angewendet werden ||| should be used with caution ||| 0-0 0-1 3-2 1-3 2-4 4-4
sollte mit Vorsicht ||| should be used with caution ||| 0-0 0-1 2-2 1-3 2-4
sollte mit besonderer Vorsicht ||| Take special care with ||| 3-0 0-1 2-1 3-2 1-3
sollte nicht angewendet werden , ||| should not be administered ||| 0-0 1-1 3-2 2-3
sollte nicht angewendet werden ||| should not be administered ||| 0-0 1-1 3-2 2-3
sollte nicht ||| should not be ||| 0-0 1-1 0-2
sollte nicht ||| should not ||| 0-0 1-1
sollte normalerweise 200 ||| should not normally exceed 200 ||| 0-0 2-1 1-2 2-3 2-4
sollte nur bei ||| should be restricted ||| 0-0 0-1 1-2 2-2
sollte nur ||| should only be administered ||| 0-0 1-1 0-2
sollte nur ||| should only be given ||| 0-0 1-1 0-2
sollte nur ||| should only be ||| 0-0 1-1 0-2
sollte sorgfältig ||| should be carefully weighed ||| 0-0 0-1 1-2 1-3
sollte vermieden werden . ||| should be avoided . ||| 0-0 2-1 1-2 3-3
sollte vermieden werden ||| should be avoided ||| 0-0 2-1 1-2
sollte vor Einnahme nicht mit ||| should not be diluted with ||| 0-0 3-1 0-2 1-3 2-3 4-4
sollte vor Einnahme nicht ||| should not be diluted ||| 0-0 3-1 0-2 1-3 2-3
sollte ||| , ||| 0-0
sollte ||| should be weighed ||| 0-0 0-1 0-2
sollte ||| should be ||| 0-0 0-1
sollte ||| should ||| 0-0
sollte ||| sollte ||| 0-0
sollten : ||| should : ||| 0-0 1-1
sollten ABILIFY nicht anwenden ||| should not use ABILIFY ||| 0-0 2-1 3-2 1-3
sollten ABILIFY nicht einnehmen , ||| should not take ABILIFY ||| 0-0 2-1 3-2 4-2 1-3
sollten Ihr Hämoglobinwert und Ihr ||| your haemoglobin-levels and your ||| 1-0 0-1 1-1 2-1 3-2 4-3
sollten Ihr Hämoglobinwert und ||| your haemoglobin-levels and ||| 1-0 0-1 1-1 2-1 3-2
sollten Ihr Hämoglobinwert ||| your haemoglobin-levels ||| 1-0 0-1 1-1 2-1
sollten Sie versuchen ||| should you attempt ||| 0-0 1-1 2-2
sollten Sie ||| should you ||| 0-0 1-1
sollten auf ||| should be ||| 0-0 0-1 1-1
sollten dementsprechend beraten werden . ||| should be advised accordingly . ||| 0-0 3-1 2-2 1-3 2-3 4-4
sollten dementsprechend beraten werden ||| should be advised accordingly ||| 0-0 3-1 2-2 1-3 2-3
sollten deshalb nicht ||| therefore should not be ||| 1-0 0-1 2-2 0-3
sollten deshalb ||| therefore ||| 0-0 1-0
sollten die Blutspiegel von Ciclosporin ||| blood levels of cyclosporin should ||| 2-0 1-1 2-1 3-2 2-3 4-3 0-4
sollten die Patienten ||| patients should ||| 2-0 0-1
sollten die klinische ||| should consider clinical ||| 0-0 1-0 2-1 2-2
sollten die klinische Überwachung ||| should consider clinical monitoring ||| 0-0 1-0 2-1 2-2 3-3
sollten die ||| should ||| 0-0
sollten die ||| should ||| 0-0 1-0
sollten engmaschig überwacht werden ||| should be monitored closely ||| 0-0 3-1 2-2 1-3 3-3
sollten ihren ||| their ||| 0-0 1-0
sollten in ||| should be ||| 0-0 0-1 1-1
sollten mit ||| should be ||| 0-0 0-1 1-1
sollten nicht ||| should not be ||| 0-0 1-1 0-2
sollten nicht ||| should not ||| 0-0 1-1
sollten regelmäßig kontrolliert werden . ||| should be monitored regularly . ||| 0-0 3-1 2-2 1-3 4-4
sollten regelmäßig kontrolliert werden ||| should be monitored regularly ||| 0-0 3-1 2-2 1-3
sollten sie ||| should ||| 0-0
sollten wegen ||| should be ||| 0-0 0-1 1-1
sollten während ||| should ||| 0-0 1-0
sollten ||| should be ||| 0-0 0-1
sollten ||| should receive ||| 0-0 0-1
sollten ||| should seek ||| 0-0
sollten ||| should ||| 0-0
sollten ähnliche Dosisreduktionen ||| dose reductions should ||| 1-0 0-1 1-1 2-1 0-2
somit nicht notwendig . ||| thus not necessary . ||| 0-0 1-1 2-2 3-3
somit nicht notwendig ||| thus not necessary ||| 0-0 1-1 2-2
somit nicht ||| thus not ||| 0-0 1-1
somit ||| thus restoring ||| 0-0 0-1
somit ||| thus ||| 0-0
sonstige Bestandteile von ABILIFY ||| of the ingredients of ABILIFY ||| 0-0 0-2 1-2 2-3 3-4
sonstige Bestandteile von Abseamed ||| of the ingredients of Abseamed ||| 0-0 1-1 0-2 1-2 2-3 3-4
sonstige Bestandteile von ||| of the ingredients of ||| 0-0 0-2 1-2 2-3
sonstige Bestandteile von ||| of the ingredients of ||| 0-0 1-1 0-2 1-2 2-3
sonstige Bestandteile ||| ingredients ||| 0-0 1-0
sonstige Bestandteile ||| of the ingredients ||| 0-0 0-2 1-2
sonstige Bestandteile ||| of the ingredients ||| 0-0 1-1 0-2 1-2
sonstige Wechselwirkungen itte ||| other forms of interaction ||| 0-0 0-1 0-2 1-3 2-3
sonstige Wechselwirkungen ||| forms of interaction ||| 0-0 0-1 1-2
sonstige ||| forms of ||| 0-0 0-1
sonstige ||| other forms of ||| 0-0 0-1 0-2
sonstigen Bestandteile oder andere Bisphosphonate ||| excipients or to any bisphosphonates ||| 0-0 1-0 2-1 0-3 3-4 4-4
sonstigen Bestandteile oder ||| excipients or to any ||| 0-0 1-0 2-1 0-3
sonstigen Bestandteile siehe Abschnitt 6.1 ||| excipients , see section 6.1 ||| 0-0 1-0 1-1 2-2 3-3 4-4
sonstigen Bestandteile siehe Abschnitt 6.1 ||| of excipients , see 6.1 ||| 0-0 0-1 1-1 1-2 2-3 3-3 4-4
sonstigen Bestandteile siehe Abschnitt ||| excipients , see section ||| 0-0 1-0 1-1 2-2 3-3
sonstigen Bestandteile siehe Abschnitt ||| of excipients , see section ||| 0-0 0-1 1-1 1-2 2-3 3-4
sonstigen Bestandteile siehe Abschnitt ||| of excipients , see ||| 0-0 0-1 1-1 1-2 2-3 3-3
sonstigen Bestandteile siehe ||| excipients , see ||| 0-0 1-0 1-1 2-2
sonstigen Bestandteile siehe ||| of excipients , see ||| 0-0 0-1 1-1 1-2 2-3
sonstigen Bestandteile sind . ||| other ingredients . ||| 0-0 0-1 1-1 2-1 3-2
sonstigen Bestandteile sind : Lactose-Monohydrat ||| other ingredients are lactose monohydrate ||| 0-0 0-1 1-1 2-2 4-3 3-4 4-4
sonstigen Bestandteile sind : ||| other ingredients are disodium ||| 0-0 0-1 1-1 2-2 1-3 3-3
sonstigen Bestandteile sind : ||| other ingredients are lactose ||| 0-0 0-1 1-1 2-2 0-3 3-3
sonstigen Bestandteile sind Mannitol , ||| other ingredients are mannitol , ||| 0-0 0-1 1-1 2-2 3-3 4-4
sonstigen Bestandteile sind Mannitol ||| other ingredients are mannitol ||| 0-0 0-1 1-1 2-2 3-3
sonstigen Bestandteile sind ||| other ingredients are ||| 0-0 0-1 1-1 2-2
sonstigen Bestandteile sind ||| other ingredients ||| 0-0 0-1 1-1 2-1
sonstigen Bestandteile von ABILIFY sind ||| other ingredients of ABILIFY ||| 0-0 0-1 1-1 4-1 2-2 3-3
sonstigen Bestandteile von ||| other ingredients of Actos 15mg ||| 0-0 0-1 1-1 2-2 1-3 2-4
sonstigen Bestandteile von ||| other ingredients of Actos 45mg ||| 0-0 0-1 1-1 2-2 1-3 2-4
sonstigen Bestandteile ||| excipients , ||| 0-0 1-0 1-1
sonstigen Bestandteile ||| excipients ||| 0-0 1-0
sonstigen Bestandteile ||| of excipients , ||| 0-0 0-1 1-1
sonstigen Bestandteile ||| of excipients , ||| 0-0 0-1 1-1 1-2
sonstigen Bestandteile ||| of excipients ||| 0-0 0-1 1-1
sonstigen Bestandteile ||| other ingredients of ||| 0-0 0-1 1-1 0-2
sonstigen Bestandteile ||| other ingredients ||| 0-0 0-1 1-1
sonstigen ||| other ingredients ||| 0-0 0-1
sorgfältig alle Anweisungen , die ||| carefully all instructions given to ||| 0-0 1-1 2-2 2-3 3-4 4-4
sorgfältig alle Anweisungen ||| carefully all instructions given ||| 0-0 1-1 2-2 2-3
sorgfältig alle ||| carefully all ||| 0-0 1-1
sorgfältig gegenüber dem ||| carefully weighed against the ||| 0-0 0-1 1-2 2-2 2-3
sorgfältig ||| carefully weighed ||| 0-0 0-1
sorgfältig ||| carefully weighted ||| 0-0
sorgfältig ||| carefully ||| 0-0
sorgfältig überwacht werden . ||| carefully monitored . ||| 0-0 1-1 2-1 3-2
sorgfältig überwacht werden . ||| should be closely monitored . ||| 0-0 2-1 0-2 1-2 2-2 1-3 3-4
sorgfältig überwacht werden ||| carefully monitored ||| 0-0 1-1 2-1
sorgfältig überwacht werden ||| should be closely monitored ||| 0-0 2-1 0-2 1-2 2-2 1-3
source ||| source ||| 0-0
sowie sehr seltene Fälle von ||| and very rare cases of ||| 0-0 1-1 2-2 3-3 4-4
sowie sehr seltene Fälle ||| and very rare cases ||| 0-0 1-1 2-2 3-3
sowie sehr seltene ||| and very rare ||| 0-0 1-1 2-2
sowie sehr ||| and very ||| 0-0 1-1
sowie ||| , and ||| 0-1
sowie ||| and ||| 0-0
sowie ||| as ||| 0-0
sowie ||| metabolic and ||| 0-1
sowie ||| the metabolic and ||| 0-2
sowohl schnell wirkendes ( ||| both fast-acting ( ||| 0-0 1-1 2-1 3-2
sowohl schnell wirkendes ||| both fast-acting ||| 0-0 1-1 2-1
sowohl ||| both ||| 0-0
spenden und : ||| surgery , and : ||| 0-0 1-2 2-3
spenden und ||| surgery , and ||| 0-0 1-2
spenden ||| surgery , ||| 0-0
spenden ||| surgery ||| 0-0
speziell untersucht . ||| specifically investigated . ||| 0-0 1-1 2-2
speziell untersucht . ||| studied specifically . ||| 1-0 0-1 2-2
speziell untersucht ||| specifically investigated ||| 0-0 1-1
speziell untersucht ||| studied specifically ||| 1-0 0-1
speziell ||| specifically ||| 0-0
spezieller DEHP-freier Lösungsbehältnisse ||| specialized DEHP-free ||| 0-0 1-0 2-1
spezieller DEHP-freier ||| specialized ||| 0-0 1-0
spezifische Behandlung ||| specific treatment ||| 0-0 1-1
spezifische Interaktionsstudien bestätigt , in ||| spezifische Interaktionsstudien bestätigt , in ||| 2-0 2-1 2-2 3-3 4-4
spezifische Interaktionsstudien bestätigt , ||| spezifische Interaktionsstudien bestätigt , ||| 2-0 2-1 2-2 3-3
spezifische Interaktionsstudien bestätigt ||| spezifische Interaktionsstudien bestätigt ||| 2-0 2-1 2-2
spezifische ||| specific ||| 0-0
spezifischen Warnhinweise und ||| special warnings and ||| 0-0 0-1 1-1 2-2
spezifischen Warnhinweise ||| special warnings ||| 0-0 0-1 1-1
spezifischen ||| specific ||| 0-0
spezifischer Kernrezeptoren ||| activation of ||| 0-0 1-0
spezifischer Kernrezeptoren ||| activation ||| 0-0 1-0
spiegelten Differenzen in ||| reflected differences in ||| 0-0 1-0 0-1 2-2
spiegelten Differenzen ||| reflected differences ||| 0-0 1-0 0-1
sporadisch ||| rodents ||| 0-0
späterer Therapie-Linie . ||| second-line therapy . ||| 0-0 1-0 1-1 2-2
späterer Therapie-Linie ||| second-line therapy ||| 0-0 1-0 1-1
sse Der Anteil der Patienten ||| sse Der Anteil der Patienten ||| 0-0 1-1 2-2 3-3 4-4
sse Der Anteil der ||| sse Der Anteil der ||| 0-0 1-1 2-2 3-3
sse Der Anteil ||| sse Der Anteil ||| 0-0 1-1 2-2
sse Der ||| sse Der ||| 0-0 1-1
sse Sanofi Winthrop Industrie , ||| ise Sanofi Winthrop Industrie , ||| 0-0 1-1 2-2 3-3 4-4
sse Sanofi Winthrop Industrie ||| ise Sanofi Winthrop Industrie ||| 0-0 1-1 2-2 3-3
sse Sanofi Winthrop ||| ise Sanofi Winthrop ||| 0-0 1-1 2-2
sse Sanofi ||| ise Sanofi ||| 0-0 1-1
sse ge zu ANHANG ||| ise or uth ra ge ||| 0-0 1-1 1-2 2-3 3-3 3-4
sse ge zu ||| ise or ||| 0-0 1-0 2-0 1-1
sse ge ||| ise or uth ||| 0-0 1-1 1-2
sse ||| gastrointestinal ||| 0-0
sse ||| ge ||| 0-0
sse ||| ise ||| 0-0
sse ||| sse ||| 0-0
stabilisiert ||| preventing ||| 0-0
stabilisierten sich die Knochenmarker innerhalb ||| bone markers stabilised within ||| 0-0 2-1 3-1 0-2 1-2 3-2 4-3
stabilisierten sich die Knochenmarker ||| bone markers stabilised ||| 0-0 2-1 3-1 0-2 1-2 3-2
stammen , ||| , ||| 1-0
stark an Plasmaproteine gebunden ||| highly bound to plasma proteins ||| 0-0 1-1 3-1 1-2 2-3 2-4
stark eingeschränkter ||| stark eingeschränkter ||| 0-0 0-1 1-1
stark ist und ||| is severe and ||| 1-0 0-1 2-2
stark ist ||| is severe ||| 1-0 0-1
stark ||| becomes ||| 0-0
stark ||| highly ||| 0-0
stark ||| severe ||| 0-0
starker Reizbarkeit . ||| severe irritability . ||| 0-0 0-1 1-1 2-2
starker Reizbarkeit ||| severe irritability ||| 0-0 0-1 1-1
statistisch signifikant größeren ||| statistically significant greater improvements in ||| 0-0 0-1 1-2 0-3 1-3
statistisch signifikant größeren ||| statistically significant greater improvements ||| 0-0 0-1 1-2 0-3 1-3
statistisch signifikant ||| improvement in ||| 1-0
statistisch signifikant ||| improvement ||| 1-0
statistisch signifikant ||| statistically significant greater improvements in ||| 0-0 0-1 1-2 0-3 1-3
statistisch signifikant ||| statistically significant greater improvements ||| 0-0 0-1 1-2 0-3 1-3
statistisch signifikante ||| statistically significant ||| 0-0 1-1
statistisch ||| statistically ||| 0-0
stechende , migräneartige Kopfschmerzen ||| migraine-like headaches as a ||| 0-0 2-1 3-1 1-2 2-2 2-3
stechende ||| migraine-like ||| 0-0
stehen in Blisterpackungen ||| are supplied in blister ||| 2-0 0-1 1-1 2-1 1-2 2-3
steigt die ||| in proportion to ||| 0-1 1-2
steigt die ||| proportion to ||| 0-0 1-1
steigt ||| in proportion ||| 0-1
steigt ||| proportion ||| 0-0
stellt Aufklärungsmaterial ||| educational ||| 1-0
stellt eine ||| represents a ||| 0-0 1-1
stellt kein Risiko für das ||| mother presents no risk ||| 0-0 0-1 1-1 1-2 2-3 3-3 4-3
stellt kein ||| mother presents no ||| 0-0 0-1 1-1 1-2
stellt ||| represents ||| 0-0
sterben schließlich . ||| they eventually die . ||| 0-0 0-1 1-1 1-2 2-3
sterben schließlich ||| they eventually die ||| 0-0 0-1 1-1 1-2
sterilen Spritze ||| sterile syringe , ||| 0-0 1-1
sterilen Spritze ||| sterile syringe ||| 0-0 1-1
sterilen ||| sterile ||| 0-0
steriles , aber unkonserviertes Produkt ||| sterile but unpreserved product ||| 0-0 1-1 2-1 3-2 4-3
steriles , aber unkonserviertes ||| sterile but unpreserved ||| 0-0 1-1 2-1 3-2
steriles , aber ||| sterile but ||| 0-0 1-1 2-1
steriles ||| sterile ||| 0-0
stiegen um 77 ||| increased by 77 ||| 0-0 0-1 0-2 1-2 2-2
stillen . ||| are breast-feeding . ||| 0-0 0-1 1-2
stillen ||| are breast-feeding ||| 0-0 0-1
stillenden Frauen ||| breast-feeding women ||| 0-0 1-1
stillenden Mutter stellt kein ||| nursing mother presents no ||| 0-0 1-0 2-1 2-2 3-2 3-3
stillenden Mutter ||| nursing ||| 0-0 1-0
stillenden Müttern nicht angewendet ||| the Package ||| 0-0 1-1
stillenden Müttern nicht ||| the Package ||| 0-0 1-1
stillenden Müttern ||| the Package ||| 0-0 1-1
stillenden ||| breast-feeding ||| 0-0
stillenden ||| the ||| 0-0
stimuliert . ||| compartment . ||| 0-0 1-1
stimuliert und ||| specifically and ||| 0-0 1-1
stimuliert ||| compartment ||| 0-0
stimuliert ||| specifically ||| 0-0
stoppt die Tätigkeit der ||| stops the action of the ||| 0-0 1-1 2-2 3-3 2-4 3-4
stoppt die ||| stops the ||| 0-0 1-1
stoppt ||| stops ||| 0-0
strenge ||| physicians for ||| 0-0
strenge ||| physicians ||| 0-0
strenge ärztliche ||| physicians for ||| 0-0
strenge ärztliche ||| physicians ||| 0-0
strenge ärztliche Überwachung auf ||| physicians for the occurrence of ||| 0-0 2-2 3-2 3-3
strenge ärztliche Überwachung auf ||| physicians for the occurrence ||| 0-0 2-2 3-2 3-3
stärkt Aclasta die ||| , Aclasta strengthens the ||| 1-1 0-2 2-3
stärkt Aclasta die ||| Aclasta strengthens the ||| 1-0 0-1 2-2
stärkt Aclasta ||| , Aclasta strengthens ||| 1-1 0-2
stärkt Aclasta ||| Aclasta strengthens ||| 1-0 0-1
stärkt ||| strengthens ||| 0-0
subkutan ( ||| given subcutaneously ( ||| 0-0 0-1 1-2
subkutan ) geben ! ||| subcutaneously ) . ||| 0-0 2-0 3-0 1-1 2-2
subkutan ) geben . ||| subcutaneously ) . ||| 0-0 2-0 1-1 3-2
subkutan ) geben ||| subcutaneously ) ||| 0-0 2-0 1-1
subkutan ) gegeben . ||| subcutaneously ) . ||| 0-0 2-0 1-1 3-2
subkutan ) gegeben ||| subcutaneously ) ||| 0-0 2-0 1-1
subkutan angewendet werden ! ||| to be administered subcutaneously ! ||| 1-0 2-1 0-2 1-2 0-3 2-3 3-3 3-4
subkutan dreimal ||| given subcutaneously 3 ||| 0-0 0-1 1-2
subkutan in den ||| administered subcutaneously in the ||| 0-0 0-1 2-1 1-2 2-3
subkutan ||| given subcutaneously ||| 0-0 0-1
subkutane Anwendung ||| difficult ||| 0-0 1-0
subkutanem ( ||| subcutaneous ( ||| 0-0 1-1
subkutanem Erythropoetin ||| subcutaneous erythropoietin ||| 0-0 1-1
subkutanem ||| subcutaneous ||| 0-0
subkutanen Gewebe bestimmt . ||| subcutaneous tissue . ||| 0-0 1-0 1-1 2-1 3-2
subkutanen Gewebe bestimmt ||| subcutaneous tissue ||| 0-0 1-0 1-1 2-1
subkutaner Anwendung von Abseamed ||| subcutaneous use of Abseamed ||| 0-0 1-1 2-2 3-3
subkutaner Anwendung von ||| subcutaneous use of ||| 0-0 1-1 2-2
subkutaner Anwendung ||| subcutaneous use ||| 0-0 1-1
subkutaner Applikation . ||| both via subcutaneous administration . ||| 0-2 1-3 2-4
subkutaner Applikation . ||| subcutaneous administration . ||| 0-0 1-1 2-2
subkutaner Applikation . ||| via subcutaneous administration . ||| 0-1 1-2 2-3
subkutaner Applikation ||| both via subcutaneous administration ||| 0-2 1-3
subkutaner Applikation ||| subcutaneous administration ||| 0-0 1-1
subkutaner Applikation ||| via subcutaneous administration ||| 0-1 1-2
subkutaner Injektion erreicht . ||| subcutaneous administration . ||| 0-0 1-0 0-1 2-1 3-2
subkutaner Injektion erreicht ||| subcutaneous administration ||| 0-0 1-0 0-1 2-1
subkutaner Injektion ||| subcutaneous injection , ||| 0-0 1-1
subkutaner Injektion ||| subcutaneous injection ||| 0-0 1-1
subkutaner ||| both via subcutaneous ||| 0-2
subkutaner ||| subcutaneous ||| 0-0
subkutaner ||| the subcutaneous ||| 0-1
subkutaner ||| via subcutaneous ||| 0-1
symptomatische ||| symptomatic ||| 0-0
symptomatischen Anämie bei ||| symptomatic anaemia in ||| 0-0 1-1 2-2
symptomatischen Anämie ||| symptomatic anaemia associated with ||| 0-0 1-1 0-2 1-3
symptomatischen Anämie ||| symptomatic anaemia ||| 0-0 1-1
symptomatischen ||| symptomatic ||| 0-0
symptomatischer ||| symptomatic ||| 0-0
systemisch ||| systemically ||| 0-0
systemische Begleiterkrankung wie ||| concomitant systemic disease such as ||| 1-0 0-1 1-1 2-3 2-4
systemische Begleiterkrankung ||| concomitant systemic disease ||| 1-0 0-1 1-1
systemische Begleiterkrankung ||| concomitant systemic ||| 1-0 0-1 1-1
systemische Exposition war ||| systemic exposure was generally ||| 0-0 1-1 2-2
systemische Exposition war ||| systemic exposure was ||| 0-0 1-1 2-2
systemische Exposition ||| systemic exposure ||| 0-0 1-1
systemische ||| systemic ||| 0-0
systemischen ||| systemic ||| 0-0
süßen ||| highly palatable ||| 0-0 0-1
t lä ||| ) ||| 0-0
t lä ||| 2. ||| 1-0
t lä ||| keeping airways ||| 0-0 1-0 1-1
t lä ||| t lä ||| 0-0 0-1 1-1
t ||| ) ||| 0-0
t ||| t lä ||| 0-0 0-1
tatsächlichen ||| made ||| 0-0
teilen und sterben schließlich ||| divide and they eventually die ||| 0-0 1-1 2-2 2-3 3-3 3-4
teilen und ||| divide and ||| 0-0 1-1
teilen ||| Tell ||| 0-0
teilen ||| divide ||| 0-0
teilnahmen , durchgeführt ||| 57 ||| 0-0 2-0
teilnehmen , wird die ||| programme , the ||| 0-0 1-1 2-2 3-2
teilnehmen , ||| programme , ||| 0-0 1-1
teilnehmen . ||| programme . ||| 0-0 1-1
teilnehmen können . ||| 1800 ml . ||| 0-0 1-0 0-1 2-2
teilnehmen können ||| 1800 ml ||| 0-0 1-0 0-1
teilnehmen ||| programme ||| 0-0
teratogenen Wirkungen oder ||| or embryo/ foetal effects ||| 2-0 0-1 1-2 1-3
teratogenen Wirkungen ||| embryo/ foetal effects ||| 0-0 1-1 1-2
teratogenen ||| embryo/ ||| 0-0
terminale Halbwertszeit ( t½ ) ||| terminal half-life ( t½ ) ||| 0-0 1-1 2-2 3-3 4-4
terminale Halbwertszeit ( t½ ||| terminal half-life ( t½ ||| 0-0 1-1 2-2 3-3
terminale Halbwertszeit ( ||| terminal half-life ( ||| 0-0 1-1 2-2
terminale Halbwertszeit wird durch ||| terminal half-life is determined by ||| 0-0 1-1 2-2 0-3 2-3 3-4
terminale Halbwertszeit wird durch ||| terminal half-life is determined by ||| 0-0 1-1 2-2 0-3 3-4
terminale Halbwertszeit wird ||| terminal half-life is determined ||| 0-0 1-1 2-2 0-3
terminale Halbwertszeit wird ||| terminal half-life is determined ||| 0-0 1-1 2-2 0-3 2-3
terminale Halbwertszeit ||| terminal half-life ||| 0-0 1-1
terminale ||| terminal ||| 0-0
therapeutische Ansprechen bei ||| therapeutic response ||| 0-0 1-1
therapeutische Ansprechen ||| therapeutic response ||| 0-0 1-1
therapeutische Breite von Epoetin alfa ||| therapeutic margin of epoetin alfa ||| 0-0 1-1 2-2 3-3 4-4
therapeutische Breite von Epoetin ||| therapeutic margin of epoetin ||| 0-0 1-1 2-2 3-3
therapeutische Breite von ||| therapeutic margin of ||| 0-0 1-1 2-2
therapeutische Breite ||| therapeutic margin ||| 0-0 1-1
therapeutische ||| therapeutic ||| 0-0
therapeutischen Dosis . ||| mutation assay . ||| 0-0 1-1 2-2
therapeutischen Dosis ||| mutation assay ||| 0-0 1-1
therapeutischen ||| mutation ||| 0-0
thromboembolische Ereignisse bei ||| thromboembolic events in ||| 0-0 1-1 2-2
thromboembolische Ereignisse ||| thromboembolic events ||| 0-0 1-1
thromboembolische ||| thromboembolic ||| 0-0
thrombotische Ereignisse ||| thrombotic events ||| 0-0 1-1
thrombotische vaskuläre Ereignisse ||| of thrombotic vascular events ||| 0-1 1-2 2-3
thrombotische vaskuläre Ereignisse ||| thrombotic vascular events ||| 0-0 1-1 2-2
thrombotische vaskuläre ||| of thrombotic vascular ||| 0-1 1-2
thrombotische vaskuläre ||| thrombotic vascular ||| 0-0 1-1
thrombotische ||| of thrombotic ||| 0-1
thrombotische ||| thrombotic ||| 0-0
thrombotisches Ereignis ||| can ||| 0-0 1-0
tief ||| maximus ||| 0-0
tiefe Venenthrombosen ) ||| deep venous thrombosis ) ||| 0-0 1-0 1-1 1-2 2-3
tiefe Venenthrombosen ergriffen werden . ||| thrombosis ( DVTs ) . ||| 0-0 2-1 1-2 2-2 3-2 2-3 4-4
tiefe Venenthrombosen ergriffen werden ||| thrombosis ( DVTs ) ||| 0-0 2-1 1-2 2-2 3-2 2-3
tiefe Venenthrombosen ||| deep vein thrombosis ||| 0-0 1-0 0-1 0-2
tiefe Venenthrombosen ||| deep venous thrombosis ||| 0-0 1-0 1-1 1-2
tiefe venöse Thrombosen , arterielle ||| deep vein thrombosis , arterial ||| 0-0 0-1 1-2 2-2 3-3 4-4
tiefe venöse Thrombosen , ||| deep vein thrombosis , ||| 0-0 0-1 1-2 2-2 3-3
tiefe venöse Thrombosen ||| deep vein thrombosis ||| 0-0 0-1 1-2 2-2
tiefe ||| deep vein ||| 0-0 0-1
tiefe ||| thrombosis ||| 0-0
tierexperimentellen Studien mit ||| animal studies , epoetin ||| 0-0 1-1 0-3 2-3
tierexperimentellen ||| Foetal ||| 0-0
toxische ||| doses ||| 0-0
toxischen Stoffen ||| toxic compounds , ||| 0-0 1-1
toxischen Stoffen ||| toxic compounds ||| 0-0 1-1
toxischen ||| toxic ||| 0-0
tragen ||| zur pharmakologischen Aktivität bei. ln ||| 0-0 0-1 0-2 0-3 0-4
transendotheliale Transport ||| enhanced transendothelial transport ||| 0-0 0-1 1-2
transendotheliale ||| enhanced transendothelial ||| 0-0 0-1
transitorische ischämische Attacken , ||| transient ischaemic attacks , ||| 0-0 1-1 0-2 2-2 3-3
transitorische ischämische Attacken ||| transient ischaemic attacks ||| 0-0 1-1 0-2 2-2
transparente Kunstoff-Flasche ( Cycloolefin-Copolymer ||| transparent plastic ( cycloolefinic polymer ||| 0-0 0-1 2-2 1-3 3-4
transparente Kunstoff-Flasche ( ||| transparent plastic ( cycloolefinic ||| 0-0 0-1 2-2 1-3
transparente ||| transparent plastic ||| 0-0 0-1
trat bei 24 % der ||| occurred in 24 % of ||| 0-0 1-1 2-2 3-3 4-4
trat bei 24 % ||| occurred in 24 % ||| 0-0 1-1 2-2 3-3
trat bei 24 ||| occurred in 24 ||| 0-0 1-1 2-2
trat bei 29 % ||| occurred in 29 % of ||| 0-0 1-1 2-2 3-3
trat bei 29 % ||| occurred in 29 % ||| 0-0 1-1 2-2 3-3
trat bei 29 ||| occurred in 29 ||| 0-0 1-1 2-2
trat bei 32 % der ||| occurred in 32 % of ||| 0-0 1-1 2-2 3-3 4-4
trat bei 32 % ||| occurred in 32 % ||| 0-0 1-1 2-2 3-3
trat bei 32 ||| occurred in 32 ||| 0-0 1-1 2-2
trat bei vier ||| occurred in four ||| 0-0 1-1 2-2
trat bei ||| occurred in ||| 0-0 1-1
trat unter Aripiprazol ||| aripiprazole has not been ||| 2-0 0-1 0-2 1-3
trat unter ||| has not been ||| 0-0 0-1 1-2
trat ||| has been ||| 0-0 0-1
trat ||| has not ||| 0-0 0-1
trat ||| occurred ||| 0-0
traten gleichzeitig periphere ||| reported concurrent peripheral ||| 0-0 0-1 1-1 2-1 2-2
traten gleichzeitig periphere Ödeme auf ||| reported concurrent peripheral oedema ||| 0-0 0-1 1-1 2-1 2-2 3-3 4-3
traten ||| occurred ||| 0-0
traten ||| reported ||| 0-0
treffen . ||| signs of ||| 0-0 0-1 1-1
treten ||| tend to ||| 0-0
treten ||| tend ||| 0-0
tritt mit Abraxane oft auf ||| occurs frequently with Abraxane ||| 0-0 3-0 3-1 1-2 2-3 4-3
trockene Nase , Keuchen ||| nasal dryness , wheezing ||| 0-0 1-0 1-1 3-1 2-2 3-3
tropfenförmigen Tabletten erhältlich . ||| teardrop- shaped tablets . no ||| 0-0 0-1 2-1 1-2 3-3
tropfenförmigen Tabletten erhältlich . ||| teardrop- shaped tablets . ||| 0-0 0-1 2-1 1-2 3-3
tropfenförmigen Tabletten erhältlich ||| teardrop- shaped tablets ||| 0-0 0-1 2-1 1-2
trübe aussehen . ||| cloudy after resuspension . ||| 0-0 0-1 0-2 1-2 2-3
trübe aussehen ||| cloudy after resuspension ||| 0-0 0-1 0-2 1-2
typisch für den Morbus Paget ||| characteristic of Paget s disease ||| 0-0 1-1 3-2 4-2 2-3 3-3 4-4
typisch für ||| characteristic of ||| 0-0 1-1
typisch ||| characteristic ||| 0-0
t½ ) ist daher ||| t½ ) is therefore ||| 0-0 1-1 2-2 3-3
t½ ) ist ||| t½ ) is ||| 0-0 1-1 2-2
t½ ) ||| t½ ) ||| 0-0 1-1
t½ 1,87 ||| t½ 1.87 ||| 0-0 1-1
t½ von ||| t½ of ||| 0-0 1-1
t½ ||| t½ ||| 0-0
täglich ) ||| daily ) ||| 0-0 1-1
täglich . ||| daily . ||| 0-0 1-1
täglich . ||| day . ||| 0-0 1-1
täglich 1.000 bis 1.500 mg ||| 1,000 to 1,500 mg elemental ||| 1-0 2-0 2-1 1-2 3-2 0-3 4-3 3-4
täglich 15 mg oder ||| 15mg or ||| 0-0 1-0 2-0 3-1
täglich 15 mg ||| 15mg ||| 0-0 1-0 2-0
täglich eingenommen haben . ||| daily . ||| 0-0 1-0 2-0 3-1
täglich eingenommen haben ||| daily ||| 0-0 1-0 2-0
täglich wurde ||| daily was ||| 0-0 1-1
täglich zwei Monate lang . ||| day for two months . ||| 0-0 3-1 1-2 2-3 3-3 4-4
täglich zwei Monate lang ||| day for two months ||| 0-0 3-1 1-2 2-3 3-3
täglich ||| daily ||| 0-0
täglich ||| day ||| 0-0
tägliche Insulinbedarf kann ||| daily insulin requirement may be ||| 0-0 1-1 1-2 2-3 2-4
tägliche Insulinbedarf ||| daily insulin requirement ||| 0-0 1-1 1-2
tägliche ||| daily ||| 0-0
täglichen Bedarf ||| unable ||| 0-0 1-0
um 25 % zu reduzieren ||| dose by 25 % ||| 1-0 0-1 1-2 4-2 2-3
um 27 % höhere ||| 27 % higher ||| 1-0 0-1 2-1 3-2
um 27 % ||| 27 % ||| 1-0 0-1 2-1
um 32 % und ||| by 32 % and ||| 0-0 1-1 2-2 3-3
um 32 % ||| by 32 % ||| 0-0 1-1 2-2
um 32 ||| by 32 ||| 0-0 1-1
um 43 % ||| 43 % ||| 1-0 0-1 2-1
um 47 % . ||| 47 % . ||| 0-0 1-0 2-1 3-2
um 47 % ||| 47 % ||| 0-0 1-0 2-1
um 47 ||| 47 ||| 0-0 1-0
um 5 % ansteigt . ||| um 5 % ansteigt . ||| 0-0 1-1 2-2 3-3 4-4
um 5 % ansteigt ||| um 5 % ansteigt ||| 0-0 1-1 2-2 3-3
um 5 % ||| um 5 % ||| 0-0 1-1 2-2
um 5 ||| um 5 ||| 0-0 1-1
um 61 % unterhalb ||| by 61 % below ||| 0-0 1-1 2-2 3-3
um 61 % ||| by 61 % ||| 0-0 1-1 2-2
um 61 ||| by 61 ||| 0-0 1-1
um Rat , bevor ||| for advice before ||| 1-0 0-1 1-1 2-1 3-2
um Rat , ||| for advice ||| 1-0 0-1 1-1 2-1
um Rückschlüsse ||| draw conclusions regarding ||| 0-0 0-1 1-2
um ca. 2,5 mm geringere ||| approximately 2.5 mm less ||| 0-0 1-0 2-1 3-2 4-2 1-3
um ca. 25 ||| by approximately 25 ||| 0-0 1-1 2-2
um ca. ||| by approximately ||| 0-0 1-1
um das Risiko einer ||| to minimise the risk of ||| 0-0 0-1 1-1 2-1 1-2 2-3 3-4
um das Risiko ||| accordingly to minimise the risk ||| 0-1 0-2 1-2 2-2 1-3 2-4
um das Risiko ||| to minimise the risk ||| 0-0 0-1 1-1 2-1 1-2 2-3
um den Inhalt vor Licht ||| carton in order to protect ||| 0-0 1-0 2-0 2-1 2-2 3-3 3-4 4-4
um den Inhalt ||| carton in order ||| 0-0 1-0 2-0 2-1 2-2
um die Hämoglobinwerte im ||| in order to maintain haemoglobin ||| 0-0 0-1 1-2 2-3 3-3 2-4
um die Sicherheit von Pioglitazon ||| determine the safety of pioglitazone ||| 0-0 1-1 2-2 3-3 4-4
um die Sicherheit von ||| determine the safety of ||| 0-0 1-1 2-2 3-3
um die Sicherheit ||| determine the safety ||| 0-0 1-1 2-2
um die Zahl ||| to ||| 0-0 1-0
um die ||| determine the ||| 0-0 1-1
um die ||| in order to ||| 0-0 0-1 1-2
um die ||| to ||| 0-0 1-0
um einen neuen Termin zu ||| possible to re-schedule ||| 1-0 0-1 1-1 4-1 2-2 3-2
um festzustellen , ob ||| to decide , if ||| 0-0 1-1 3-1 2-2 3-3
um mehr als 2 ||| rising by more than 2 ||| 0-0 1-0 0-1 1-2 2-3 3-4
um mehr als ||| rising by more than ||| 0-0 1-0 0-1 1-2 2-3
um mehr ||| rising by more ||| 0-0 1-0 0-1 1-2
um mindestens 30 ||| by at least 30 ||| 0-0 1-1 1-2 2-3
um mindestens 75 ||| fell by at least 75 ||| 0-0 0-1 1-2 1-3 2-4
um mindestens ||| by at least ||| 0-0 1-1 1-2
um mindestens ||| fell by at least ||| 0-0 0-1 1-2 1-3
um ||| 3.6 ||| 0-0
um ||| by ||| 0-0
um ||| determine ||| 0-0
um ||| draw conclusions ||| 0-0 0-1
um ||| fell by ||| 0-0 0-1
um ||| in order ||| 0-0 0-1
um ||| increased ||| 0-0
um ||| to ||| 0-0
um ||| um ||| 0-0
umfassen , ||| of overdoses , such as ||| 0-1 1-2 0-3 1-4
umfassen , ||| overdoses , such as ||| 0-0 1-1 0-2 1-3
umfassend metabolisiert . ||| methylene groups . ||| 0-0 1-0 0-1 2-2
umfassend metabolisiert ||| methylene groups ||| 0-0 1-0 0-1
umfasste nur 3 Patienten mit ||| included only 3 patients with ||| 0-0 1-1 2-2 3-3 4-4
umfasste nur 3 Patienten ||| included only 3 patients ||| 0-0 1-1 2-2 3-3
umfasste nur 3 ||| included only 3 ||| 0-0 1-1 2-2
umfasste nur ||| included only ||| 0-0 1-1
umfasste ||| included ||| 0-0
umgehend , wenn Sie stillen ||| immediately if you are breast-feeding ||| 0-0 1-1 2-1 3-2 4-3 4-4
umgehend , wenn Sie ||| immediately if you ||| 0-0 1-1 2-1 3-2
umgehend , wenn ||| immediately if ||| 0-0 1-1 2-1
umgehend Ihren Arzt , wenn ||| your doctor immediately if ||| 1-0 1-1 2-1 0-2 3-3 4-3
umgehend Ihren Arzt ||| your doctor immediately ||| 1-0 1-1 2-1 0-2
umgehend ||| immediately ||| 0-0
unabhängig von der Konzentration . ||| concentration independent . ||| 3-0 0-1 4-2
unabhängig von der Konzentration ||| concentration independent ||| 3-0 0-1
unabhängig von der ||| independent ||| 0-0
unabhängig von ||| independent ||| 0-0
unabhängig ||| independent ||| 0-0
unangenehmes Gefühl im Magen ||| uncomfortable feeling in the stomach ||| 0-0 1-1 2-2 2-3 0-4 2-4 3-4
unbeeinflusst ||| unaffected ||| 0-0
unbekannt , doch es bindet ||| unknown , but it attaches ||| 0-0 1-1 2-2 3-3 4-4
unbekannt , doch es ||| unknown , but it ||| 0-0 1-1 2-2 3-3
unbekannt , doch ||| unknown , but ||| 0-0 1-1 2-2
unbekannt , ||| unknown , ||| 0-0 1-1
unbekannt . ||| is unknown . ||| 0-0 0-1 1-2
unbekannt . ||| unknown . ||| 0-0 1-1
unbekannt ||| is unknown ||| 0-0 0-1
unbekannt ||| unknown ||| 0-0
unbekannter Größe ||| subject to confounding factors ||| 0-0 0-2 1-2 1-3
und " 10 " auf ||| and " 10 " on ||| 0-0 1-1 2-2 3-3 4-4
und " 10 " ||| and " 10 " ||| 0-0 1-1 2-2 3-3
und " 10 ||| and " 10 ||| 0-0 1-1 2-2
und " 15 " auf ||| and " 15 " on ||| 0-0 1-1 2-2 3-3 4-4
und " 15 " ||| and " 15 " ||| 0-0 1-1 2-2 3-3
und " 15 ||| and " 15 ||| 0-0 1-1 2-2
und " 30 " auf ||| and " 30 " on ||| 0-0 1-1 2-2 3-3 4-4
und " 30 " ||| and " 30 " ||| 0-0 1-1 2-2 3-3
und " 30 ||| and " 30 ||| 0-0 1-1 2-2
und " 5 " auf ||| and " 5 " on ||| 0-0 1-1 2-2 3-3 4-4
und " 5 " ||| and " 5 " ||| 0-0 1-1 2-2 3-3
und " 5 ||| and " 5 ||| 0-0 1-1 2-2
und " ||| and " ||| 0-0 1-1
und +0,1 unter Placebo ( ||| and +0.1 on placebo ( ||| 0-0 1-1 2-2 2-3 3-3 4-4
und +0,1 unter Placebo ||| and +0.1 on placebo ||| 0-0 1-1 2-2 2-3 3-3
und +0,1 ||| and +0.1 ||| 0-0 1-1
und , mit ||| and , with ||| 0-0 1-1 2-2
und , ||| and , ||| 0-0 1-1
und -3A4 . ||| and -3A4 respectively . ||| 0-0 1-1 1-2 2-3
und -3A4 ||| and -3A4 respectively ||| 0-0 1-1 1-2
und / ||| and / ||| 0-0 1-1
und 0,8 % für Placebo ||| and 0.8 % for placebo ||| 0-0 1-1 2-2 3-3 4-4
und 0,8 % für ||| and 0.8 % for ||| 0-0 1-1 2-2 3-3
und 0,8 % ||| and 0.8 % ||| 0-0 1-1 2-2
und 0,8 ||| and 0.8 ||| 0-0 1-1
und 1,1 ||| and 1.1 ||| 0-0 1-1
und 10 Patronen zu je ||| and 10 cartridges x ||| 0-0 1-1 2-2 3-2 4-3
und 10 Patronen zu ||| and 10 cartridges ||| 0-0 1-1 2-2 3-2
und 10 auf einer Seite ||| and 10 on one side ||| 0-0 1-1 2-2 3-3 4-3 4-4
und 10 auf ||| and 10 on ||| 0-0 1-1 2-2
und 10 vorgefüllte Fertigpens zu ||| and 10 pre-filled pens ||| 0-0 1-1 2-2 2-3 3-3 4-3
und 10 ||| and 10 ||| 0-0 1-1
und 10 ||| und 10 ||| 0-0 1-1
und 11 g/dl ( ||| and 11 g/ dl ( ||| 0-0 1-1 2-2 2-3 3-4
und 11 g/dl ||| and 11 g/ dl ||| 0-0 1-1 2-2 2-3
und 11 ||| and 11 ||| 0-0 1-1
und 11 ||| and ||| 0-0
und 11fachen ||| and 11 ||| 0-0 1-1
und 12 g/dl ( ||| and 12 g/ dl ( ||| 0-0 1-1 2-2 2-3 3-4
und 12 g/dl ||| and 12 g/ dl ||| 0-0 1-1 2-2 2-3
und 12 ||| and 12 ||| 0-0 1-1
und 15 auf einer Seite ||| and 15 on one side ||| 0-0 1-1 2-2 3-3 4-3 4-4
und 15 auf ||| and 15 on ||| 0-0 1-1 2-2
und 15 ||| and 15 ||| 0-0 1-1
und 15 ||| and ||| 0-0
und 15,7 % für ||| and 15.7 % for ||| 0-0 1-1 2-2 3-3
und 15,7 % ||| and 15.7 % ||| 0-0 1-1 2-2
und 15,7 ||| and 15.7 ||| 0-0 1-1
und 16 mg Zoledronsäure ||| and 16 mg zoledronic acid ||| 0-0 1-1 2-2 3-3 3-4
und 16 mg ||| and 16 mg ||| 0-0 1-1 2-2
und 16 ||| and 16 ||| 0-0 1-1
und 180-minütigen Infusionen von Abraxane ||| and 180-minute infusions of Abraxane ||| 0-0 1-1 2-2 3-3 4-4
und 180-minütigen Infusionen von ||| and 180-minute infusions of ||| 0-0 1-1 2-2 3-3
und 180-minütigen Infusionen ||| and 180-minute infusions ||| 0-0 1-1 2-2
und 180-minütigen ||| and 180-minute ||| 0-0 1-1
und 19 % ||| and 19 % ||| 0-0 1-1 2-2
und 19 ||| and 19 ||| 0-0 1-1
und 2,47 zugunsten der ||| and 2.47 in favour of ||| 0-0 1-1 1-2 2-3 3-4
und 2,47 zugunsten ||| and 2.47 in favour ||| 0-0 1-1 1-2 2-3
und 2,47 ||| and 2.47 in ||| 0-0 1-1 1-2
und 26 ||| and ||| 0-0
und 3 -p-Hydroxypaclitaxel , ||| and 3 -p-hydroxypaclitaxel , ||| 0-0 1-1 2-2 3-3
und 3 -p-Hydroxypaclitaxel ||| and 3 -p-hydroxypaclitaxel ||| 0-0 1-1 2-2
und 3 ||| and 3 ||| 0-0 1-1
und 3,0 % mit Placebo ||| and 3.0 % with placebo ||| 0-0 1-1 2-2 3-3 4-4
und 3,0 % mit ||| and 3.0 % with ||| 0-0 1-1 2-2 3-3
und 3,0 % ||| and 3.0 % ||| 0-0 1-1 2-2
und 3,0 ||| and 3.0 ||| 0-0 1-1
und 3,2 % mit Placebo ||| and 3.2 % with placebo ||| 0-0 1-1 2-2 3-3 4-4
und 3,2 % mit ||| and 3.2 % with ||| 0-0 1-1 2-2 3-3
und 3,2 % ||| and 3.2 % ||| 0-0 1-1 2-2
und 3,2 ||| and 3.2 ||| 0-0 1-1
und 30 auf einer Seite ||| and 30 on one side ||| 0-0 1-1 2-2 3-3 4-3 4-4
und 30 auf ||| and 30 on ||| 0-0 1-1 2-2
und 30 mg Schmelztabletten ||| and 30 mg orodispersible tablets ||| 0-0 1-1 2-2 3-3 3-4
und 30 mg Tabletten , ||| and 30 mg tablets , ||| 0-0 1-1 2-2 3-3 4-4
und 30 mg Tabletten ||| and 30 mg tablets ||| 0-0 1-1 2-2 3-3
und 30 mg ||| and 30 mg ||| 0-0 1-1 2-2
und 30 mg/Tag ( ||| to 30 mg/ day ( ||| 0-0 1-1 2-2 2-3 3-4
und 30 mg/Tag . ||| to 30 mg/ day . ||| 0-0 1-1 2-2 2-3 3-4
und 30 mg/Tag ||| to 30 mg/ day ||| 0-0 1-1 2-2 2-3
und 30 ||| and 30 ||| 0-0 1-1
und 30 ||| to 30 ||| 0-0 1-1
und 300 I.E. pro Kilogramm ||| and 300 IU per kilogram ||| 0-0 1-1 2-2 3-3 4-4
und 300 I.E. pro ||| and 300 IU per ||| 0-0 1-1 2-2 3-3
und 300 I.E. ||| and 300 IU ||| 0-0 1-1 2-2
und 300 I.E./kg ||| and 300 IU/ kg given ||| 0-0 1-1 2-2 2-3 1-4
und 300 ||| and 300 ||| 0-0 1-1
und 33 I.E./kg ||| and 33 IU/ kg , ||| 0-0 1-1 2-2 2-3
und 33 I.E./kg ||| and 33 IU/ kg ||| 0-0 1-1 2-2 2-3
und 33 ||| and 33 ||| 0-0 1-1
und 36 Monate ) . ||| and 36 months ) . ||| 0-0 1-1 2-2 3-3 4-4
und 36 Monate ) ||| and 36 months ) ||| 0-0 1-1 2-2 3-3
und 36 Monate ||| and 36 months ||| 0-0 1-1 2-2
und 36 ||| and 36 ||| 0-0 1-1
und 3A4 ( Dextromethorphan ) ||| and 3A4 ( dextromethorphan ) ||| 0-0 1-1 2-2 3-3 4-4
und 3A4 ( Dextromethorphan ||| and 3A4 ( dextromethorphan ||| 0-0 1-1 2-2 3-3
und 3A4 ( ||| and 3A4 ( ||| 0-0 1-1 2-2
und 3A4 , werden ||| , and 3A4 ||| 2-0 0-1 1-2
und 3A4 , ||| , and 3A4 ||| 2-0 0-1 1-2
und 3A4 . ||| and 3A4 . ||| 0-0 1-1 2-2
und 3A4 ||| and 3A4 ||| 0-0 1-1
und 4.4 ||| and 4.4 ||| 0-0 1-1
und 4.8 ) . ||| . ||| 1-0 3-0
und 4.8 ) . ||| patient . ||| 1-1 3-1
und 4.9 ) . ||| and 4.9 ) . ||| 0-0 1-1 2-2 3-3
und 4.9 ) ||| and 4.9 ) ||| 0-0 1-1 2-2
und 4.9 ||| and 4.9 ||| 0-0 1-1
und 400 mg Sucrose ||| and 400 mg of sucrose ||| 0-0 1-1 2-2 3-4
und 400 mg ||| and 400 mg of ||| 0-0 1-1 2-2
und 400 mg ||| and 400 mg ||| 0-0 1-1 2-2
und 400 ||| and 400 ||| 0-0 1-1
und 42 % ||| and 42 % ||| 0-0 1-1 2-2
und 42 ||| and 42 ||| 0-0 1-1
und 45 mg gesenkt ||| mg and 45 mg ||| 2-0 0-1 1-2 2-3 3-3
und 45 ||| and 45 ||| 0-0 1-1
und 5 Durchstechflaschen zu je ||| and 5 vials x ||| 0-0 1-1 2-2 3-3 4-3
und 5 Durchstechflaschen ||| and 5 vials ||| 0-0 1-1 2-2
und 5 auf einer Seite ||| and 5 on one side ||| 0-0 1-1 2-2 3-3 4-3 4-4
und 5 auf ||| and 5 on ||| 0-0 1-1 2-2
und 5 ||| and 5 ||| 0-0 1-1
und 5-Hydroxytryptamin ||| and 5-hydroxytryptamine are involved ||| 0-0 1-1
und 5-Hydroxytryptamin ||| and 5-hydroxytryptamine are ||| 0-0 1-1
und 5-Hydroxytryptamin ||| and 5-hydroxytryptamine ||| 0-0 1-1
und 5.2 ) . ||| and 5.2 ) . dic ||| 0-0 1-1 2-2 3-3 2-4
und 5.2 ) . ||| und 5.2 ) . ||| 0-0 1-1 2-2 3-3
und 5.2 ) ||| und 5.2 ) ||| 0-0 1-1 2-2
und 5.2 ||| and 5.2 ||| 0-0 1-1
und 5.2 ||| und 5.2 ||| 0-0 1-1
und 50 % Isophan-Insulin ||| and 50 % isophane insulin ||| 0-0 1-1 2-2 3-3 3-4
und 50 % ||| and 50 % ||| 0-0 1-1 2-2
und 50 I.E./kg zweimal pro ||| and 50 IU/ kg 2 ||| 0-0 1-1 2-2 3-2 2-3 4-3 3-4
und 50 ||| and 50 ||| 0-0 1-1
und 53,3 % bei ||| and 53.3 % for ||| 0-0 1-1 2-2 1-3 3-3
und 53,3 % bei ||| and 53.3 % ||| 0-0 1-1 3-1 2-2
und 5HT2a-Rezeptor sowie ||| and 5HT2a receptors and ||| 0-0 1-1 2-1 1-2 0-3
und 6 ||| and 6 ||| 0-0 1-1
und 6,1 Monate ( 300 ||| and 6.1 months ( 300 ||| 0-0 1-1 2-2 3-3 4-4
und 6,1 Monate ( ||| and 6.1 months ( ||| 0-0 1-1 2-2 3-3
und 6,1 Monate ||| and 6.1 months ||| 0-0 1-1 2-2
und 6,1 ||| and 6.1 ||| 0-0 1-1
und 60 % Isophan-Insulin ||| and 60 % isophane insulin ||| 0-0 1-1 2-2 3-3 3-4
und 60 % ||| and 60 % ||| 0-0 1-1 2-2
und 60 ||| and 60 ||| 0-0 1-1
und 7 ) ||| and 7 ) ||| 0-0 1-1 2-2
und 7 ||| and 7 ||| 0-0 1-1
und 70 % Isophan-Insulin ||| and 70 % isophane insulin ||| 0-0 1-1 2-2 3-3 3-4
und 70 % ||| and 70 % ||| 0-0 1-1 2-2
und 70 ||| and 70 ||| 0-0 1-1
und 76 % hatten mehr ||| and 76 % had > ||| 0-0 1-1 2-2 3-3 2-4
und 76 % hatten ||| and 76 % had > ||| 0-0 1-1 2-2 3-3 2-4
und 76 ||| and 76 ||| 0-0 1-1
und 8,7 für Aripiprazol . ||| and 8.7 for aripiprazole . ||| 0-0 1-1 2-2 3-3 4-4
und 8,7 für Aripiprazol ||| and 8.7 for aripiprazole ||| 0-0 1-1 2-2 3-3
und 8,7 für ||| and 8.7 for ||| 0-0 1-1 2-2
und 8,7 ||| and 8.7 ||| 0-0 1-1
und 80 % Isophan-Insulin ||| and 80 % isophane insulin ||| 0-0 1-1 2-2 3-3 3-4
und 80 % ||| and 80 % ||| 0-0 1-1 2-2
und 80 ||| and 80 ||| 0-0 1-1
und 802 Patienten mit Hämoblastosen ||| and 802 with haematological malignancies ||| 0-0 1-1 2-1 3-2 4-3 4-4
und 802 Patienten mit ||| and 802 with ||| 0-0 1-1 2-1 3-2
und 802 Patienten ||| and 802 ||| 0-0 1-1 2-1
und 8167 Patienten ) . ||| and 8167 patients ) . ||| 0-0 1-1 2-2 3-3 4-4
und 8167 Patienten ) ||| and 8167 patients ) ||| 0-0 1-1 2-2 3-3
und 8167 Patienten ||| and 8167 patients ||| 0-0 1-1 2-2
und 8167 ||| and 8167 ||| 0-0 1-1
und 86 ||| and ||| 0-0
und 90 % Isophan-Insulin ||| and 90 % isophane insulin ||| 0-0 1-1 2-2 3-3 3-4
und 90 % ||| and 90 % ||| 0-0 1-1 2-2
und 90 ||| and 90 ||| 0-0 1-1
und 98 Tabletten . ||| and 98 tablets . ||| 0-0 1-1 2-2 3-3
und 98 Tabletten ||| and 98 tablets ||| 0-0 1-1 2-2
und 98 ||| and 98 ||| 0-0 1-1
und : ||| , and : ||| 0-1 1-2
und : ||| and : ||| 0-0 1-1
und AUC nach ||| and AUC after ||| 0-0 1-1 2-2
und AUC ||| and AUC ||| 0-0 1-1
und Analoga zur Injektion , ||| and analogues for injection , ||| 0-0 1-1 2-1 2-2 3-3 4-4
und Analoga zur Injektion ||| and analogues for injection ||| 0-0 1-1 2-1 2-2 3-3
und Analoga zur ||| and analogues for ||| 0-0 1-1 2-1 2-2
und Angioödem ||| and angioedema ||| 0-0 1-1
und Anschrift der Hersteller ||| and address of ||| 0-0 1-1 3-1 2-2
und Anschrift der ||| and address of ||| 0-0 1-1 2-2
und Anschrift des Herstellers ||| and address of the manufacturer ||| 0-0 1-1 2-2 2-3 3-4
und Anschrift des ||| and address of the ||| 0-0 1-1 2-2 2-3
und Anschrift des/der ||| and address ||| 0-0 1-1 2-1
und Anschrift ||| and address ||| 0-0 1-1
und Anschwellen der Hände , ||| and swelling of hands , ||| 0-0 1-1 2-2 3-3 4-4
und Anschwellen der Hände ||| and swelling of hands ||| 0-0 1-1 2-2 3-3
und Anschwellen der ||| and swelling of ||| 0-0 1-1 2-2
und Anschwellen ||| and swelling ||| 0-0 1-1
und Aspiration sind ||| and aspiration have been ||| 0-0 1-1 2-1 1-2 1-3
und Atemnot . ||| breathlessness . ||| 1-0 2-1
und Atemnot . ||| or breathlessness . ||| 1-1 2-2
und Atemnot ||| breathlessness ||| 1-0
und Atemnot ||| or breathlessness ||| 1-1
und Betasympathomimetika , Wachstumshormon ||| and beta-sympathomimetics , growth hormone ||| 0-0 1-1 2-2 3-3 3-4
und Betasympathomimetika , ||| and beta-sympathomimetics , ||| 0-0 1-1 2-2
und Betasympathomimetika ||| and beta-sympathomimetics ||| 0-0 1-1
und Bewegung ||| and exercise ||| 0-0 1-1
und Bewusstseinszustand sollten ||| and level of consciousness should ||| 0-0 1-1 1-3 2-4
und Bewusstseinszustand ||| and level of consciousness ||| 0-0 1-1 1-3
und Bipolar-I-Störung ||| and Bipolar I Disorder ||| 0-0 1-1 1-2 1-3
und Blutdruck ||| and blood pressure ||| 0-0 1-1 1-2
und CYP2D6 ||| and CYP2D6 ||| 0-0 1-1
und CYP3A4 , ||| and CYP3A4 ||| 0-0 1-1
und CYP3A4 ||| and CYP3A4 ||| 0-0 1-1
und Cancer Linear Analogue Scale ||| and Cancer Linear Analogue Scale ||| 0-0 1-1 2-2 3-3 4-3 3-4
und Cancer Linear ||| and Cancer Linear ||| 0-0 1-1 2-2
und Cancer ||| and Cancer ||| 0-0 1-1
und Cmax von Dehydro-Aripiprazol , ||| and Cmax of dehydro-aripiprazole , ||| 0-0 1-1 2-2 3-3 4-4
und Cmax von Dehydro-Aripiprazol ||| and Cmax of dehydro-aripiprazole ||| 0-0 1-1 2-2 3-3
und Cmax von ||| and Cmax of ||| 0-0 1-1 2-2
und Cmax ||| and Cmax ||| 0-0 1-1
und Danazol . ||| and danazol . ||| 0-0 1-1 2-2
und Danazol ||| and danazol ||| 0-0 1-1
und Dauer der ||| and method of ||| 0-0 1-1 2-2
und Dauer ||| and method ||| 0-0 1-1
und Dehydro-Aripiprazol , aber ||| and dehydro-aripiprazole , but ||| 0-0 1-1 2-2 3-3
und Dehydro-Aripiprazol , ||| and dehydro-aripiprazole , ||| 0-0 1-1 2-2
und Dehydro-Aripiprazol in vitro ||| and dehydro-aripiprazole did ||| 0-0 1-1 2-2 3-2
und Dehydro-Aripiprazol ||| and dehydro-aripiprazole are ||| 0-0 1-1 1-2
und Dehydro-Aripiprazol ||| and dehydro-aripiprazole ||| 0-0 1-1
und Diabetes Mellitus ( siehe ||| and diabetes mellitus ( see ||| 0-0 1-1 2-2 3-3 4-4
und Diabetes Mellitus ( ||| and diabetes mellitus ( ||| 0-0 1-1 2-2 3-3
und Diabetes Mellitus : Hyperglykämie ||| and Diabetes Mellitus : hyperglycaemia ||| 0-0 1-1 2-2 4-2 3-3 4-4
und Diabetes Mellitus : Hyperglykämie ||| and diabetes mellitus : hyperglycaemia ||| 0-0 1-1 2-2 3-3 4-4
und Diabetes Mellitus : ||| and diabetes mellitus : ||| 0-0 1-1 2-2 3-3
und Diabetes Mellitus ||| and diabetes mellitus ||| 0-0 1-1 2-2
und Diabetes in der Familienanamnese ||| and family history of diabetes ||| 0-0 1-1 4-1 2-2 4-2 3-3 1-4
und Diabetes mellitus ( siehe ||| and diabetes mellitus ( see ||| 0-0 1-1 2-2 3-3 4-4
und Diabetes mellitus ( ||| and diabetes mellitus ( ||| 0-0 1-1 2-2 3-3
und Diabetes mellitus : Hyperglykämie ||| and Diabetes Mellitus : hyperglycaemia ||| 0-0 1-1 4-2 3-3 2-4 4-4
und Diabetes mellitus ||| and diabetes mellitus ||| 0-0 1-1 2-2
und Diabetes ||| and Diabetes ||| 0-0 1-1
und Diabetes ||| and diabetes ||| 0-0 1-1
und Differenzierungshormon die ||| and differentiating hormone , the ||| 0-0 1-1 1-2 2-3 2-4
und Differenzierungshormon ||| and differentiating hormone ||| 0-0 1-1 1-2
und Dopamin ||| and dopamine ||| 0-0 1-1
und Dosierpipette . ||| and dosing pipette . ||| 0-0 1-1 1-2 2-3
und Dosierpipette ||| and dosing pipette ||| 0-0 1-1 1-2
und Dosierungen ||| and doses ||| 0-0 1-1
und Dosierungen über 45 mg ||| and doses above 45 mg ||| 0-0 1-1 2-2 3-3 4-4
und Dosierungen über 45 ||| and doses above 45 ||| 0-0 1-1 2-2 3-3
und Dosierungen über ||| and doses above ||| 0-0 1-1 2-2
und Durchfall . ||| and diarrhoea . ||| 0-0 1-1 2-2
und Durchfall bei 25 ||| patients and diarrhoea in 25 ||| 2-0 0-1 1-2 2-3 3-4
und Durchfall bei ||| patients and diarrhoea in ||| 2-0 0-1 1-2 2-3
und Durchfall bei ||| the patients and diarrhoea in ||| 2-1 0-2 1-3 2-4
und Durchfall ||| and diarrhoea ||| 0-0 1-1
und Dyskinesie ||| and dyskinesia ||| 0-0 1-1
und E216 ||| and E216 . ||| 0-0 1-1
und E216 ||| and E216 ||| 0-0 1-1
und Entzündungen . ||| and inflammation . ||| 0-0 1-1 2-2
und Entzündungen ||| and inflammation ||| 0-0 1-1
und Erbrechen . ||| and vomiting . ||| 0-0 1-1 2-2
und Erbrechen auf . ||| and vomiting . ||| 0-0 1-1 3-2
und Erbrechen auf ||| and vomiting ||| 0-0 1-1
und Erbrechen ||| and vomiting ||| 0-0 1-1
und Erwachsene . ||| and adults . ||| 0-0 1-1 2-2
und Erwachsene ||| and adults ||| 0-0 1-1
und Erwachsenen unter ||| and adult patients on ||| 0-0 1-1 1-2 2-3
und Erwachsenen ||| and adult patients ||| 0-0 1-1 1-2
und Fettleibigkeit bei erwachsenen Hunden ||| and obesity in adult dogs ||| 0-0 1-1 2-2 3-3 4-4
und Fettleibigkeit bei erwachsenen ||| and obesity in adult ||| 0-0 1-1 2-2 3-3
und Fettleibigkeit bei erwachsenen ||| overweight and obesity in adult ||| 1-0 0-1 1-2 2-3 3-4
und Fettleibigkeit bei ||| and obesity in ||| 0-0 1-1 2-2
und Fettleibigkeit bei ||| of overweight and obesity in ||| 1-1 0-2 1-3 2-4
und Fettleibigkeit bei ||| overweight and obesity in ||| 1-0 0-1 1-2 2-3
und Fettleibigkeit ||| and obesity ||| 0-0 1-1
und Fettleibigkeit ||| of overweight and obesity ||| 1-1 0-2 1-3
und Fettleibigkeit ||| overweight and obesity ||| 1-0 0-1 1-2
und Frauen ||| and women ||| 0-0 1-1
und Fruchttod in utero . ||| and death in utero . ||| 0-0 1-1 2-2 1-3 3-3 4-4
und Fruchttod in utero ||| and death in utero ||| 0-0 1-1 2-2 1-3 3-3
und G-CSF oder GM-CSF gezeigt ||| and G-CSF or GM-CSF ||| 0-0 1-1 2-2 1-3 3-3
und G-CSF oder GM-CSF ||| and G-CSF or GM-CSF ||| 0-0 1-1 2-2 1-3 3-3
und Gliclazid . ||| and gliclazide . ||| 0-0 1-1 2-2
und Gliclazid ||| and gliclazide ||| 0-0 1-1
und Haloperidol 73 % ) ||| and haloperidol 73 % ) ||| 0-0 1-1 2-2 3-3 4-4
und Haloperidol 73 % ||| and haloperidol 73 % ||| 0-0 1-1 2-2 3-3
und Haloperidol 73 ||| and haloperidol 73 ||| 0-0 1-1 2-2
und Haloperidol ||| and haloperidol ||| 0-0 1-1
und Hersteller Pharmazeutischer Unternehmer ||| and Manufacturer Marketing authorisation holder ||| 0-0 1-1 2-2 2-3 3-4
und Hersteller Pharmazeutischer ||| and Manufacturer Marketing authorisation ||| 0-0 1-1 2-2 2-3
und Hersteller ||| and Manufacturer ||| 0-0 1-1
und Herzkrankheit oder früherem ||| and heart disease or previous ||| 0-0 1-1 1-2 2-3 3-4
und Herzkrankheit oder ||| and heart disease or ||| 0-0 1-1 1-2 2-3
und Herzkrankheit ||| and heart disease ||| 0-0 1-1 1-2
und Hunde resorbieren ||| and dogs rapidly ||| 0-0 1-1 2-1 2-2
und Hypoästhesie ( verminderte Empfindlichkeit ||| and hypoaesthesia ( decreased sensitivity ||| 0-0 1-1 2-2 3-3 4-4
und Hypoästhesie ( verminderte ||| and hypoaesthesia ( decreased ||| 0-0 1-1 2-2 3-3
und Hypoästhesie ( ||| and hypoaesthesia ( ||| 0-0 1-1 2-2
und Hypoästhesie ||| and hypoaesthesia ||| 0-0 1-1
und Ihr Blutdruck sorgfältig ||| and your blood pressure ||| 0-0 1-1 2-2 2-3 3-3
und Ihr Blutdruck sorgfältig überwacht ||| and your blood pressure should ||| 0-0 1-1 2-2 2-3 3-3 4-4
und Ihr Hämoglobinwert ||| and your haemoglobin ||| 0-0 1-1 2-2
und Ihr ||| and your ||| 0-0 1-1
und In-vitro-Studien ||| in vivo and in ||| 1-0 1-1 0-2 1-3
und Infektionen ||| and infections ||| 0-0 1-1
und Infiltrationen beobachtet . ||| and infiltration were observed . ||| 0-0 1-1 1-2 2-3 3-4
und Infiltrationen beobachtet ||| and infiltration were observed ||| 0-0 1-1 1-2 2-3
und Infiltrationen ||| and infiltration were ||| 0-0 1-1 1-2
und Inhalt der Packung ||| and contents of the pack ||| 0-0 1-1 2-2 2-3 3-4
und Inhalt der Packung ||| and contents of the pack ||| 0-0 1-1 3-1 2-2 2-3 3-4
und Inhalt der ||| and contents of the ||| 0-0 1-1 2-2 2-3
und Inhalt ||| and contents ||| 0-0 1-1
und Insulin ||| and insulin ||| 0-0 1-1
und Isophan- ( NPH- ) ||| and isophane ( NPH ) ||| 0-0 1-1 2-2 3-3 4-4
und Isophan- ( NPH- ||| and isophane ( NPH ||| 0-0 1-1 2-2 3-3
und Isophan- ( ||| and isophane ( ||| 0-0 1-1 2-2
und Isophan- ||| and isophane ||| 0-0 1-1
und Isophan-Insulin 50 % ||| and isophane insulin 50 % ||| 0-0 1-1 1-2 2-3 3-4
und Isophan-Insulin 50 ||| and isophane insulin 50 ||| 0-0 1-1 1-2 2-3
und Isophan-Insulin 60 % ||| and isophane insulin 60 % ||| 0-0 1-1 1-2 2-3 3-4
und Isophan-Insulin 60 ||| and isophane insulin 60 ||| 0-0 1-1 1-2 2-3
und Isophan-Insulin 70 % ||| and isophane insulin 70 % ||| 0-0 1-1 1-2 2-3 3-4
und Isophan-Insulin 70 ||| and isophane insulin 70 ||| 0-0 1-1 1-2 2-3
und Isophan-Insulin 80 % ||| and isophane insulin 80 % ||| 0-0 1-1 1-2 2-3 3-4
und Isophan-Insulin 80 ||| and isophane insulin 80 ||| 0-0 1-1 1-2 2-3
und Isophan-Insulin 90 % ||| and isophane insulin 90 % ||| 0-0 1-1 1-2 2-3 3-4
und Isophan-Insulin 90 ||| and isophane insulin 90 ||| 0-0 1-1 1-2 2-3
und Isophan-Insulin ||| and isophane insulin ||| 0-0 1-1 1-2
und Juckreiz ||| and itching ||| 0-0 1-1
und Jugendliche unter 18 Jahren ||| under 18 years of age ||| 2-0 0-1 3-1 1-2 4-2 3-3 4-4
und Jugendlichen ist nicht ||| and adolescents has not ||| 0-0 1-1 1-2 2-2 3-3
und Jugendlichen ist ||| and adolescents has ||| 0-0 1-1 1-2 2-2
und Jugendlichen unter ||| and adolescents under ||| 0-0 1-1 1-2 2-2
und Kalium im gewünschten ||| and potassium in ||| 0-0 1-1 2-1 3-1 2-2
und Knochenmarkfibrose jeglicher ||| and bone marrow fibrosis of ||| 0-0 1-1 1-2 2-3 2-4
und Knochenmarkfibrose ||| and bone marrow ||| 0-0 1-1 1-2
und Kopfschmerzen ( 5,1 % ||| and headache ( 5.1 % ||| 0-0 1-1 2-2 3-3 4-4
und Kopfschmerzen ( 5,1 ||| and headache ( 5.1 ||| 0-0 1-1 2-2 3-3
und Kopfschmerzen ( ||| and headache ( ||| 0-0 1-1 2-2
und Kopfschmerzen , ||| and headache in the ||| 0-0 1-1
und Kopfschmerzen , ||| and headache in ||| 0-0 1-1
und Kopfschmerzen , ||| and headache ||| 0-0 1-1
und Kopfschmerzen ||| and headache in the ||| 0-0 1-1
und Kopfschmerzen ||| and headache in ||| 0-0 1-1
und Kopfschmerzen ||| and headache ||| 0-0 1-1
und Kortikosteroide . ||| and corticosteroids . ||| 0-0 1-1 2-2
und Kortikosteroide ||| and corticosteroids ||| 0-0 1-1
und Laktation . ||| and lactation . ||| 0-0 1-1 2-2
und Laktation ||| and lactation ||| 0-0 1-1
und M-IV ) . ||| and M-IV ) . ||| 0-0 1-1 2-2 3-3
und M-IV ) ||| and M-IV ) ||| 0-0 1-1 2-2
und M-IV ||| and M-IV ||| 0-0 1-1
und Magenbeschwerden , Diarrhoe ||| stomach discomfort , diarrhoea ||| 0-0 1-0 1-1 2-2 3-3
und Magenbeschwerden , ||| stomach discomfort , ||| 0-0 1-0 1-1 2-2
und Magenbeschwerden ||| stomach discomfort ||| 0-0 1-0 1-1
und Magnesiumstearat . ||| and magnesium stearate . ||| 0-0 1-1 1-2 2-3
und Magnesiumstearat ||| and magnesium stearate ||| 0-0 1-1 1-2
und N-Dealkylierung . ||| and N-dealkylation . ||| 0-0 1-1 2-2
und N-Dealkylierung ||| and N-dealkylation ||| 0-0 1-1
und Niere ||| jejunum and kidney ||| 1-0 0-1 1-2
und NovoFine Injektionsnadeln vorgesehen . ||| and NovoFine needles . ||| 0-0 1-1 2-1 2-2 3-2 4-3
und NovoFine Injektionsnadeln vorgesehen ||| and NovoFine needles ||| 0-0 1-1 2-1 2-2 3-2
und Osteonekrose ( ||| and osteonecrosis ( ||| 0-0 1-1 2-2
und Osteonekrose ( ||| infusion and osteonecrosis ( ||| 0-1 1-2 2-3
und Osteonekrose ||| and osteonecrosis ||| 0-0 1-1
und Osteonekrose ||| infusion and osteonecrosis ||| 0-1 1-2
und Packungsbeilage . ||| and Package Leaflet and ||| 0-0 1-1 1-2 0-3
und Packungsbeilage ||| and Package Leaflet and ||| 0-0 1-1 1-2 0-3
und Paranoia . ||| and paranoia . ||| 0-0 1-1 2-2
und Paranoia ||| and paranoia ||| 0-0 1-1
und Patienten mit Diabetes ||| and patients with diabetes ||| 0-0 1-1 2-2 3-3
und Patienten mit bipolarer Manie ||| and bipolar mania patients ||| 0-0 3-1 4-2 1-3 2-3
und Patienten mit ||| and patients with ||| 0-0 1-1 2-2
und Patienten unter 65 ||| in patients less than 65 ||| 1-0 1-1 2-2 2-3 3-4
und Patienten unter ||| in patients less than ||| 1-0 1-1 2-2 2-3
und Patienten unter ||| that in patients less than ||| 1-1 1-2 2-3 2-4
und Patienten ||| and patients ||| 0-0 1-1
und Patienten ||| in patients ||| 1-0 1-1
und Patienten ||| that in patients ||| 1-1 1-2
und Patienten ||| to that in patients ||| 1-2 1-3
und Pioglitazon ||| and pioglitazone ||| 0-0 1-1
und Placebo ( 2,1 % ||| and placebo ( 2.1 % ||| 0-0 1-1 2-2 3-3 4-4
und Placebo ( 2,1 ||| and placebo ( 2.1 ||| 0-0 1-1 2-2 3-3
und Placebo ( 29 [ ||| and placebo ( 29 [ ||| 0-0 1-1 2-2 3-3 4-4
und Placebo ( 29 ||| and placebo ( 29 ||| 0-0 1-1 2-2 3-3
und Placebo ( ||| and placebo ( ||| 0-0 1-1 2-2
und Placebo ||| and placebo ||| 0-0 1-1
und Placebo ||| studied in patients being ||| 0-0 1-1 1-2 1-3
und Placebo über drei ||| and placebo over three ||| 0-0 1-1 2-2 3-3
und Placebo über ||| and placebo over ||| 0-0 1-1 2-2
und Polypen ) : ||| and polyps ) : ||| 0-0 1-1 2-2 3-3
und Polypen ) ||| and polyps ) ||| 0-0 1-1 2-2
und Polypen ||| and polyps ||| 0-0 1-1
und Proteinaufnahme führen . ||| and protein intake . ||| 0-0 1-1 1-2 2-2 3-3
und Proteinaufnahme führen ||| and protein intake ||| 0-0 1-1 1-2 2-2
und Proteinbindung ||| and protein binding ||| 0-0 1-1 1-2
und Ratten , nicht jedoch ||| and rats , but not ||| 0-0 1-1 2-2 4-3 3-4
und Ratten , ||| and rats , ||| 0-0 1-1 2-2
und Ratten ||| and rats ||| 0-0 1-1
und Reduktion des Transfusionsbedarfs ||| and reduction of transfusion requirements ||| 0-0 1-1 2-2 2-3 3-3 3-4
und Reduktion ||| and reduction ||| 0-0 1-1
und Rhabdomyolyse , ||| and rhabdomyolysis , ||| 0-0 1-1 2-2
und Rhabdomyolyse ||| and rhabdomyolysis ||| 0-0 1-1
und Risedronat ||| and risedronate ||| 0-0 1-1
und Schwere ||| and severity ||| 0-0 1-1
und Schwäche ) ||| and weakness ) ||| 0-0 1-1 2-2
und Schwäche ||| and weakness ||| 0-0 1-1
und Schüttelfrost , Muskel- ||| and chills , pain in ||| 0-0 3-0 1-1 2-2 2-3
und Schüttelfrost , Muskel- ||| and chills , pain ||| 0-0 3-0 1-1 2-2 2-3
und Sicherheit von Aclasta 5 ||| and safety of Aclasta 5 ||| 0-0 1-1 2-2 3-3 4-4
und Sicherheit von Aclasta ||| and safety of Aclasta ||| 0-0 1-1 2-2 3-3
und Sicherheit von ||| and safety of ||| 0-0 1-1 2-2
und Sicherheit ||| and safety ||| 0-0 1-1
und Sichtweite von Kindern aufbewahren ||| reach and sight of children ||| 1-0 0-1 1-2 2-3 3-4 4-4
und Sichtweite von ||| reach and sight of ||| 1-0 0-1 1-2 2-3
und Sichtweite ||| reach and sight ||| 1-0 0-1 1-2
und Sie werden ||| and you will ||| 0-0 1-1 1-2
und Sie ||| and you will ||| 0-0 1-1 1-2
und Sulfonamide . ||| and sulphonamides . ||| 0-0 1-1 2-2
und Sulfonamide ||| and sulphonamides ||| 0-0 1-1
und Symptome die berichtet ||| and symptoms reported ||| 0-0 1-1 2-1 3-2
und Symptome die ||| and symptoms ||| 0-0 1-1 2-1
und Symptome einer Herzinsuffizienz ||| and symptoms of heart failure ||| 0-0 1-1 2-2 3-3 3-4
und Symptome einer Hyperglykämie ( ||| and symptoms of hyperglycaemia ( ||| 0-0 1-1 2-2 3-3 4-4
und Symptome einer Hyperglykämie ||| and symptoms of hyperglycaemia ||| 0-0 1-1 2-2 3-3
und Symptome einer ||| and symptoms of ||| 0-0 1-1 2-2
und Symptome ||| and symptoms ||| 0-0 1-1
und Unbedenklichkeit . ||| and safety . ||| 0-0 1-1 2-2
und Unbedenklichkeit von Rimonabant ||| and safety of rimonabant ||| 0-0 1-1 2-2 3-3
und Unbedenklichkeit von ||| and safety of ||| 0-0 1-1 2-2
und Unbedenklichkeit ||| and safety ||| 0-0 1-1
und Vantas ||| and Vantas ||| 0-0 1-1
und Verhaltensstörungen ||| and disturbed behaviours , ||| 0-0 1-1 1-2
und Verhaltensstörungen ||| and disturbed behaviours ||| 0-0 1-1 1-2
und Vermehrung . ||| and multiply . ||| 0-0 1-1 2-2
und Vermehrung ||| and multiply ||| 0-0 1-1
und Verminderung der Fremdblutgabe ||| and ||| 0-0
und Verminderung der ||| and ||| 0-0
und Verminderung ||| and ||| 0-0
und Vitamin D , ||| and vitamin D supplementation , ||| 0-0 1-1 2-2 2-3 3-4
und Vitamin D ||| and vitamin D supplementation ||| 0-0 1-1 2-2 2-3
und Vitamin D ||| and vitamin D ||| 0-0 1-1 2-2
und Vitamin ||| and vitamin ||| 0-0 1-1
und Vorsichtsmaßnahmen , die ||| and precautions ||| 0-0 1-1 3-1
und Vorsichtsmaßnahmen für die Anwendung ||| and precautions for use ||| 0-0 1-1 2-2 3-2 4-3
und Vorsichtsmaßnahmen für die ||| and precautions for ||| 0-0 1-1 2-2 3-2
und Vorsichtsmaßnahmen ||| and precautions ||| 0-0 1-1
und Wasser für Injektionszwecke . ||| and water for injection . ||| 0-0 1-1 3-1 2-2 3-3 4-4
und Wasser für Injektionszwecke . ||| and water for injections . ||| 0-0 1-1 2-2 3-3 4-4
und Wasser für Injektionszwecke ||| and water for injection ||| 0-0 1-1 3-1 2-2 3-3
und Wasser für Injektionszwecke ||| and water for injections ||| 0-0 1-1 2-2 3-3
und Wasser für ||| and water for ||| 0-0 1-1 2-2
und Wasser ||| and water ||| 0-0 1-1
und Wirksamkeit . ||| and efficacy . ||| 0-0 1-1 2-2
und Wirksamkeit fehlen . ||| and efficacy . ||| 0-0 1-1 2-1 3-2
und Wirksamkeit fehlen ||| and efficacy ||| 0-0 1-1 2-1
und Wirksamkeit von Rimonabant ||| and efficacy of rimonabant ||| 0-0 1-1 2-2 3-3
und Wirksamkeit von ||| and efficacy of ||| 0-0 1-1 2-2
und Wirksamkeit ||| and efficacy ||| 0-0 1-1
und Zeigefinger zusammendrücken . ||| and forefinger . ||| 0-0 1-1 2-1 3-2
und Zeigefinger zusammendrücken ||| and forefinger ||| 0-0 1-1 2-1
und Zeit bis zum ||| and time to ||| 0-0 1-1 3-1 2-2
und akutes Nierenversagen sein . ||| and acute renal failure . ||| 0-0 1-1 2-1 3-1 2-2 2-3 4-4
und akutes Nierenversagen sein ||| and acute renal failure ||| 0-0 1-1 2-1 3-1 2-2 2-3
und alle aktiven Metaboliten ||| and all active metabolites ||| 0-0 1-1 2-2 3-3
und alle aktiven ||| and all active ||| 0-0 1-1 2-2
und alle ||| and all ||| 0-0 1-1
und als ||| and as ||| 0-0 1-1
und anaphylaktischen Reaktionen . ||| and anaphylactic reaction . ||| 0-0 1-1 1-2 2-2 3-3
und anaphylaktischen Reaktionen ||| and anaphylactic reaction ||| 0-0 1-1 1-2 2-2
und andere Wechselwirkungen ||| and other forms of interaction ||| 0-0 1-1 0-2 2-2 1-3 2-4
und andere antipsychotischen Arzneimittel ||| and other antipsychotic drugs ||| 0-0 1-1 2-2 2-3 3-3
und andere ||| and other ||| 0-0 1-1
und anderen Erythropoese-stimulierenden Wirkstoffen ( ||| and other erythropoiesis-stimulating agents ( ||| 0-0 1-1 2-2 3-3 4-4
und anderen Erythropoese-stimulierenden Wirkstoffen ||| and other erythropoiesis-stimulating agents ||| 0-0 1-1 2-2 3-3
und anderen Erythropoese-stimulierenden ||| and other erythropoiesis-stimulating ||| 0-0 1-1 2-2
und anderen ||| and other ||| 0-0 1-1
und angewendet ||| and administered ||| 0-0 1-1
und annähernd 20 % ||| and approximately 20 % ||| 0-0 1-1 2-2 3-3
und annähernd 20 ||| and approximately 20 ||| 0-0 1-1 2-2
und annähernd 60 % in ||| and approximately 60 % in ||| 0-0 1-1 2-2 3-3 4-4
und annähernd 60 % ||| and approximately 60 % ||| 0-0 1-1 2-2 3-3
und annähernd 60 ||| and approximately 60 ||| 0-0 1-1 2-2
und annähernd ||| and approximately ||| 0-0 1-1
und anschließend jährliche ||| September 2005 and ||| 2-0 2-1 0-2 1-2
und anschließend jährliche ||| in September 2005 and ||| 2-1 2-2 0-3 1-3
und anschließend ||| and ||| 0-0 1-0
und anämische Ratten , ||| and anaemic rats , ||| 0-0 1-1 2-2 3-3
und anämische Ratten ||| and anaemic rats ||| 0-0 1-1 2-2
und anämische ||| and anaemic ||| 0-0 1-1
und auf ||| on ||| 1-0
und begangener Suizid ( siehe ||| and completed suicide ( see ||| 0-0 1-1 2-1 2-2 3-3 4-4
und begangener Suizid ( ||| and completed suicide ( ||| 0-0 1-1 2-1 2-2 3-3
und begangener Suizid ||| and completed suicide ||| 0-0 1-1 2-1 2-2
und behandelt ||| and treated ||| 0-0 1-1
und bei Erwachsenen ||| and adult patients ||| 0-0 1-1 2-1 2-2
und bei ||| for ||| 1-0
und besteht aus 165 ||| and consists of 165 ||| 0-0 1-1 2-1 2-2 3-3
und besteht aus ||| and consists of ||| 0-0 1-1 2-1 2-2
und betrug 18,7 ||| , was 18.7 ||| 0-0 1-1 2-2
und betrug ||| , was ||| 0-0 1-1
und blasse Schleimhäute . ||| and pale mucosae . ||| 0-0 1-1 2-2 3-3
und blasse Schleimhäute ||| and pale mucosae ||| 0-0 1-1 2-2
und blasse ||| and pale ||| 0-0 1-1
und blau , ||| and blue , ||| 0-0 1-1 2-2
und blau ||| and blue ||| 0-0 1-1
und ca. 18 % ||| and approximately 18 % ||| 0-0 1-1 2-2 3-3
und ca. 18 ||| and approximately 18 ||| 0-0 1-1 2-2
und ca. 45 % ||| and approximately 45 % ||| 0-0 1-1 2-2 3-3
und ca. 45 ||| and approximately 45 ||| 0-0 1-1 2-2
und ca. ||| and approximately ||| 0-0 1-1
und darüber ||| and ||| 0-0
und das Bedienen von Maschinen ||| and using machines ||| 0-0 1-1 2-1 2-2 3-2 4-2
und das Bedienen von Maschinen ||| or use machines have ||| 1-1 2-1 2-2 4-2 2-3 3-3
und das Bedienen von Maschinen ||| use machines have ||| 1-0 2-0 2-1 4-1 2-2 3-2
und das ||| and ||| 0-0
und dass ||| , and that , ||| 0-1 1-2
und dass ||| , and that ||| 0-1 1-2
und dass ||| and that , ||| 0-0 1-1
und dass ||| and that ||| 0-0 1-1
und dem ||| and ||| 0-0
und den Kontrollpatienten . ||| and controls . ||| 0-0 1-1 2-1 3-2
und den Kontrollpatienten ||| and controls ||| 0-0 1-1 2-1
und den verordneten Dosierungen . ||| and dose regimens . ||| 0-0 2-1 1-2 2-2 3-2 4-3
und den verordneten Dosierungen ||| and dose regimens ||| 0-0 2-1 1-2 2-2 3-2
und der Aufschrift ACTOS auf ||| face and ACTOS on ||| 1-0 2-0 0-1 3-2 4-3
und der Aufschrift ACTOS ||| face and ACTOS ||| 1-0 2-0 0-1 3-2
und der Aufschrift ||| face and ||| 1-0 2-0 0-1
und der Triglyceride in dieser ||| and TG in this ||| 0-0 2-1 1-2 3-2 4-3
und der Triglyceride in ||| and TG in ||| 0-0 2-1 1-2 3-2
und der mediane Zeitpunkt der ||| and the median timing of ||| 0-0 1-1 3-1 2-2 4-3 4-4
und der mediane Zeitpunkt ||| and the median ||| 0-0 1-1 3-1 2-2
und der ||| and of the ||| 0-0 1-1 1-2
und der ||| and the ||| 0-0 1-1
und der ||| and ||| 0-0
und deren Blutzucker trotz einer ||| insufficient glycaemic control despite ||| 1-0 2-1 3-1 3-2 3-3 4-3
und deren ||| and whose ||| 0-0 1-1
und deren ||| insufficient ||| 1-0
und des Labyrinths ||| and mediastinal disorders ||| 0-0 1-1 2-1 2-2
und des Morbus Paget ||| and Paget s disease ||| 0-0 2-1 3-1 1-2 2-2 3-3
und deshalb sollten ähnliche Dosisreduktionen ||| and similar dose reductions should ||| 0-0 1-1 3-1 3-2 2-3 3-3 4-3 2-4
und die AUC ||| and AUC ||| 0-0 2-1
und die Bindung ist ||| and binding is ||| 0-0 2-1 3-2
und die Bindung ||| and binding ||| 0-0 2-1
und die Fähigkeit , ||| drive and ||| 1-0 2-0 0-1
und die Fähigkeit zum ||| drive and ||| 1-0 2-0 3-0 0-1
und die Fähigkeit ||| drive and ||| 1-0 2-0 0-1
und die Mehrzahl der ||| and the majority of the ||| 0-0 1-1 2-2 3-3 3-4
und die Mehrzahl ||| and the majority ||| 0-0 1-1 2-2
und die Montgomery-Asberg- ||| and the Montgomery-Asberg ||| 0-0 1-1 2-2
und die so hergestellte ||| and drink the ||| 0-0 2-1 3-1 1-2
und die so hergestellte ||| and drink the ||| 0-0 2-1 3-1 1-2 3-2
und die ||| and the ||| 0-0 1-1
und die ||| and ||| 0-0
und dosis-proportional . ||| and dose-proportional . ||| 0-0 1-1 2-2
und dosis-proportional ||| and dose-proportional ||| 0-0 1-1
und eine Bündelpackung mit ||| and a multipack with ||| 0-0 1-1 2-2 3-3
und eine Bündelpackung ||| and a multipack ||| 0-0 1-1 2-2
und eine Osmolalität von ||| and an osmolality of ||| 0-0 1-1 2-2 3-3
und eine Osmolalität ||| and an osmolality ||| 0-0 1-1 2-2
und eine gleichzeitig ||| with ||| 2-0
und eine negative Auswirkung auf ||| and a negative impact on ||| 0-0 1-1 2-2 3-3 4-4
und eine negative Auswirkung ||| and a negative impact ||| 0-0 1-1 2-2 3-3
und eine negative ||| and a negative ||| 0-0 1-1 2-2
und eine um 27 % ||| and a 27 % ||| 0-0 1-1 3-2 2-3 4-3
und eine um 43 % ||| and a 43 % ||| 0-0 1-1 3-2 2-3 4-3
und eine ||| and a ||| 0-0 1-1
und eine ||| and an ||| 0-0 1-1
und einem Brombutyl- ||| and a bromobutyl/ polyisoprene rubber ||| 0-0 1-1 1-2 2-2 2-3 2-4
und einem Sulfonylharnstoff ||| and a sulphonylurea , ||| 0-0 1-1 1-2 2-2
und einem Sulfonylharnstoff ||| and a sulphonylurea ||| 0-0 1-1 1-2 2-2
und einer gesunden ||| and healthy ||| 0-0 1-1 2-1
und entscheiden , wie lange ||| and decide how long ||| 0-0 1-1 2-1 3-2 4-3
und entscheiden , wie ||| and decide how ||| 0-0 1-1 2-1 3-2
und entscheiden , ||| and decide ||| 0-0 1-1 2-1
und erhöhte ||| and increased ||| 0-0 1-1
und erzeugt multiple ||| cycle and multiple ||| 1-0 0-1 2-2
und erzeugt ||| cycle and ||| 1-0 0-1
und es ||| and a ||| 0-0
und es ||| and ||| 0-0
und extrapyramidale Symptome . ||| and extrapyramidal symptoms . ||| 0-0 1-1 2-2 3-3
und extrapyramidale Symptome ||| and extrapyramidal symptoms ||| 0-0 1-1 2-2
und extrapyramidale ||| and extrapyramidal ||| 0-0 1-1
und farblose Lösung . ||| and colourless solution . ||| 0-0 1-1 2-2 3-3
und farblose Lösung ||| and colourless solution ||| 0-0 1-1 2-2
und farblose ||| and colourless ||| 0-0 1-1
und für die ||| and for the ||| 0-0 1-1 2-2
und für ||| and for ||| 0-0 1-1
und für ||| for ||| 1-0
und gegebenenfalls behandelt werden . ||| and controlled as necessary . ||| 0-0 1-1 2-1 1-2 1-3 3-3 4-4
und gegebenenfalls behandelt werden ||| and controlled as necessary ||| 0-0 1-1 2-1 1-2 1-3 3-3
und gegebenenfalls behandelt werden ||| and treated , if necessary ||| 0-0 2-1 1-3 1-4 3-4
und gelb , mit Prägung ||| and yellow , marked with ||| 0-0 1-1 2-2 4-3 3-4
und gelb , ||| and yellow , ||| 0-0 1-1 2-2
und gelb ||| and yellow ||| 0-0 1-1
und getrocknet und der Deckel ||| and dried and the cap ||| 0-0 1-1 4-1 2-2 3-3 4-4
und gut kontrollierten Studien bei ||| and well-controlled studies in ||| 0-0 1-1 2-1 3-2 4-3
und gut kontrollierten Studien ||| and well-controlled studies ||| 0-0 1-1 2-1 3-2
und gut kontrollierten ||| and well-controlled ||| 0-0 1-1 2-1
und hepatozellulärer Dysfunktion ||| and hepatocellular dysfunction ||| 0-0 1-1 2-2
und hepatozellulärer ||| and hepatocellular ||| 0-0 1-1
und ihr Wiederauftreten verhindert wird ||| and preventing them from returning ||| 0-0 2-1 0-2 3-3 4-3 3-4
und ihr Wiederauftreten ||| and preventing them ||| 0-0 2-1 0-2
und in den Morbus-Paget-Studien ||| and the Paget s disease ||| 0-0 2-1 3-2 2-3 3-3 3-4
und in der ||| and in ||| 0-0 1-1 2-1
und in klinischen ||| and in clinical ||| 0-0 1-1 2-2
und in ||| , and ||| 0-1
und in ||| and in ||| 0-0 1-1
und in ||| and ||| 0-0
und intensivmedizinische Behandlung erforderten ||| physician and intensive medical care ||| 1-0 0-1 1-2 2-2 3-2 3-3 3-4
und interindividuellen Schwankungen . ||| and inter-individual variation . ||| 0-0 1-1 2-2 3-3
und interindividuellen Schwankungen ||| and inter-individual variation ||| 0-0 1-1 2-2
und interindividuellen ||| and inter-individual ||| 0-0 1-1
und ist kein Substrat ||| and is not a substrate ||| 0-0 1-1 2-2 1-3 3-4
und ist kein ||| and is not a ||| 0-0 1-1 2-2 1-3
und ist weiterhin unbekannt . ||| and remains unknown . ||| 0-0 2-1 1-2 3-2 4-3
und ist weiterhin unbekannt ||| and remains unknown ||| 0-0 2-1 1-2 3-2
und ist ||| and is ||| 0-0 1-1
und jungen Patienten vergleichbar . ||| and young subjects . ||| 0-0 1-1 2-1 3-1 1-2 4-3
und jungen Patienten vergleichbar ||| and young subjects ||| 0-0 1-1 2-1 3-1 1-2
und jüngeren ||| and younger ||| 0-0 1-1
und kardio-respiratorischer Depression führen . ||| and cardiorespiratory depression . ||| 0-0 1-1 2-1 3-1 2-2 4-3
und kardio-respiratorischer Depression führen ||| and cardiorespiratory depression ||| 0-0 1-1 2-1 3-1 2-2
und kardiovaskulären Therapie entweder ||| and cardiovascular therapy , ||| 0-0 1-1 3-1 2-2
und kardiovaskulären Therapie entweder ||| and cardiovascular therapy ||| 0-0 1-1 3-1 2-2
und keine nennenswerte Affinität zu ||| and no appreciable affinity ||| 0-0 1-1 2-2 4-2 3-3
und keine nennenswerte Affinität ||| and no appreciable affinity for ||| 0-0 1-1 2-2 3-3 3-4
und keine nennenswerte ||| and no appreciable ||| 0-0 1-1 2-2
und keine ||| and no ||| 0-0 1-1
und klinisch evidenter ||| and clinically evident ischaemic heart ||| 0-0 1-1 2-2 2-3 2-4
und klinisch ||| and clinically ||| 0-0 1-1
und kontrollierten Studien mit Aripiprazol ||| and well-controlled trials of aripiprazole ||| 0-0 1-1 2-2 3-3 4-4
und kontrollierten Studien mit ||| and well-controlled trials of ||| 0-0 1-1 2-2 3-3
und kontrollierten Studien ||| and well-controlled trials ||| 0-0 1-1 2-2
und kontrollierten ||| and well-controlled ||| 0-0 1-1
und kräftig in ||| a quick ||| 2-0 1-1
und kräftig ||| quick ||| 1-0
und machten für gewöhnlich keinen ||| and usually did not require ||| 0-0 3-1 1-2 2-2 4-2 4-3 1-4
und manchmal starker Reizbarkeit . ||| and sometimes severe irritability . ||| 0-0 1-1 2-2 2-3 3-3 4-4
und manchmal starker Reizbarkeit ||| and sometimes severe irritability ||| 0-0 1-1 2-2 2-3 3-3
und manchmal ||| and sometimes ||| 0-0 1-1
und manische ||| and manic ||| 0-0 1-1
und mit der ||| and the ||| 0-0 2-1
und mit oder ohne ||| and with or without ||| 0-0 1-1 2-2 3-3
und mit oder ||| and with or ||| 0-0 1-1 2-2
und mit ||| and with ||| 0-0 1-1
und mit ||| and ||| 0-0
und männlichen Patienten ||| and male patients ||| 0-0 1-1 2-2
und männlichen ||| and male ||| 0-0 1-1
und möglicher ||| and possible ||| 0-0 1-1
und möglicherweise Protein-Disulfid-Isomerase abgebaut wird ||| and possibly protein disulfide isomerase ||| 0-0 1-1 2-1 2-2 2-3 3-3 3-4 4-4
und nach ||| and after ||| 0-0 1-1
und nach ||| and following ||| 0-0 1-1
und nehmen ||| and take ||| 0-0 1-1
und neues ||| and new ||| 0-0 1-1
und normalerweise reversibel sind . ||| is usually reversible . ||| 2-0 1-1 0-2 2-2 3-2 4-3
und normalerweise reversibel sind ||| is usually reversible ||| 2-0 1-1 0-2 2-2 3-2
und ohne Flüssigkeit eingenommen werden ||| taken with or without liquid ||| 0-0 3-0 1-1 2-2 1-3 3-3 2-4 4-4
und ohne ||| with no ||| 1-0 1-1
und parasitaere Erkrankungen ||| and administration site conditions ||| 0-0 1-1 1-2 2-3
und parasitaere ||| and administration site ||| 0-0 1-1 1-2
und parenteral anzuwendenden Benzodiazepinen kann ||| and parenteral benzodiazepine may be ||| 0-0 1-1 2-2 3-2 4-3 4-4
und parenteral anzuwendenden Benzodiazepinen ||| and parenteral benzodiazepine ||| 0-0 1-1 2-2 3-2
und parenteral ||| and parenteral ||| 0-0 1-1
und periphere Neuropathie gerichtet werden ||| mucositis and peripheral neuropathy ||| 3-0 0-1 1-2 2-3 4-3
und periphere ||| and peripheral ||| 0-0 1-1
und postprandiale ||| and postprandial ||| 0-0 1-1
und pädiatrische ||| and paediatric haemodialysis patients ||| 0-0 1-1 1-2 1-3
und reversibler exzentrischer ||| rats , dogs , and ||| 1-0 1-1 1-2 2-2 2-3 0-4
und rosafarben , mit Prägung ||| and pink , marked with ||| 0-0 1-1 2-2 4-3 3-4
und rosafarben , ||| and pink , ||| 0-0 1-1 2-2
und rosafarben ||| and pink ||| 0-0 1-1
und seine ||| and its ||| 0-0 1-1
und seinen Metaboliten sind ||| and its metabolites are ||| 0-0 1-1 2-2 3-3
und seinen Metaboliten ||| and its metabolites ||| 0-0 1-1 2-2
und seinen ||| and its ||| 0-0 1-1
und seit der Markteinführung ||| and post-marketing experience ||| 0-0 1-1 3-1 1-2
und sie ||| und ||| 0-0
und sind ||| , becoming ||| 0-0
und sind ||| , ||| 0-0
und sogar dem Tod enden ||| brain function or even death ||| 0-0 1-0 1-1 2-1 3-2 4-3 3-4
und sogar dem ||| brain function ||| 0-0 1-0 1-1 2-1
und sollte ||| and should ||| 0-0 1-1
und sollten dementsprechend beraten werden ||| and should be advised accordingly ||| 0-0 1-1 4-2 3-3 2-4 3-4
und sollten deshalb nicht ||| and therefore should not be ||| 0-0 2-1 1-2 3-3 1-4
und sollten ||| and should ||| 0-0 1-1
und somit nicht notwendig . ||| and thus not necessary . ||| 0-0 1-1 2-2 3-3 4-4
und somit nicht notwendig ||| and thus not necessary ||| 0-0 1-1 2-2 3-3
und somit nicht ||| and thus not ||| 0-0 1-1 2-2
und somit ||| , thus restoring ||| 0-0 1-1 1-2
und somit ||| and thus ||| 0-0 1-1
und sonstige Wechselwirkungen itte ||| and other forms of interaction ||| 0-0 1-1 1-2 1-3 2-4 3-4
und sonstige ||| and other forms of ||| 0-0 1-1 1-2 1-3
und sterben schließlich . ||| and they eventually die . ||| 0-0 1-1 1-2 2-2 2-3 3-4
und sterben schließlich ||| and they eventually die ||| 0-0 1-1 1-2 2-2 2-3
und trübe aussehen . ||| and cloudy after resuspension . ||| 0-0 1-1 1-2 1-3 2-3 3-4
und trübe aussehen ||| and cloudy after resuspension ||| 0-0 1-1 1-2 1-3 2-3
und um 47 % . ||| and 47 % . ||| 0-0 1-1 2-1 3-2 4-3
und um 47 % ||| and 47 % ||| 0-0 1-1 2-1 3-2
und um 47 ||| and 47 ||| 0-0 1-1 2-1
und ungebrauchte Lösung zu verwerfen ||| and discard any unused amount ||| 0-0 1-1 1-2 4-3 2-4 4-4
und ungebrauchte ||| and discard any ||| 0-0 1-1 1-2
und unter ||| other ||| 0-0
und vaskulären Komplikationen kommen . ||| following repeated phlebotomy . ||| 1-0 0-1 1-1 1-2 2-2 3-2 4-3
und vaskulären Komplikationen kommen ||| following repeated phlebotomy ||| 1-0 0-1 1-1 1-2 2-2 3-2
und verringert deshalb ||| and therefore ||| 0-0 1-1 2-1
und verschwanden innerhalb einer Woche ||| and resolved within a week ||| 0-0 1-1 2-2 3-3 4-4
und verschwanden innerhalb einer ||| and resolved within a ||| 0-0 1-1 2-2 3-3
und verschwanden innerhalb ||| and resolved within ||| 0-0 1-1 2-2
und verschwanden ||| and resolved ||| 0-0 1-1
und verschwinden innerhalb von drei ||| and go away within three ||| 0-0 1-0 1-1 2-3 3-3 4-4
und verschwinden innerhalb von ||| and go away within ||| 0-0 1-0 1-1 2-3 3-3
und verschwinden normalerweise ||| and disappear ||| 0-0 1-1 2-1
und verschwinden ||| and go away ||| 0-0 1-0 1-1
und verschwinden ||| and go ||| 0-0 1-0 1-1
und verschwommenes Sehen . ||| and blurred vision . ||| 0-0 1-1 2-2 3-3
und verschwommenes Sehen ||| and blurred vision ||| 0-0 1-1 2-2
und verschwommenes ||| and blurred ||| 0-0 1-1
und verteilen ||| and distribute ||| 0-0 1-1
und vorwiegend ||| and mainly ||| 0-0 1-1
und vorwiegend über die Fäzes ||| and mainly via the faeces ||| 0-0 1-1 2-2 3-3 4-4
und vorwiegend über die ||| and mainly via the ||| 0-0 1-1 2-2 3-3
und vorwiegend über ||| and mainly via ||| 0-0 1-1 2-2
und vorübergehend . ||| and transient . ||| 0-0 1-1 2-2
und vorübergehend ||| and transient ||| 0-0 1-1
und war schnell reversibel und ||| and was rapidly reversible and ||| 0-0 1-1 2-2 3-3 4-4
und war schnell reversibel ||| , and was rapidly reversible ||| 0-1 1-2 2-3 3-4
und war schnell reversibel ||| and was rapidly reversible ||| 0-0 1-1 2-2 3-3
und war schnell ||| , and was rapidly ||| 0-1 1-2 2-3
und war schnell ||| and was rapidly ||| 0-0 1-1 2-2
und war ||| , and was ||| 0-1 1-2
und war ||| and was ||| 0-0 1-1
und weiblichen ||| and female ||| 0-0 1-1
und weitere 4 Tage nach ||| and for four days ||| 0-0 3-1 2-2 3-3 4-3
und weitere Risikofaktoren ||| with ||| 2-0
und weitere ||| and ||| 0-0
und wenn ||| , and when ||| 0-1 1-2
und wenn ||| and when ||| 0-0 1-1
und wie auch bei anderen ||| and , as with other ||| 0-0 1-2 2-2 3-3 4-4
und wie auch bei ||| and , as with ||| 0-0 1-2 2-2 3-3
und wie auch ||| and , as ||| 0-0 1-2 2-2
und wirkt in ||| and works in ||| 0-0 1-1 2-2
und wirkt ||| and acts ||| 0-0 1-1
und wirkt ||| and works ||| 0-0 1-1
und wofür wird es angewendet ||| and what it is used ||| 0-0 1-1 1-2 3-2 2-3 4-4
und wofür wird es ||| and what it is ||| 0-0 1-1 1-2 3-2 2-3
und wurde ||| and was ||| 0-0 1-1
und wurde ||| which was ||| 0-0 1-1
und ziehen ||| and seek ||| 0-0 1-1
und zu 50 ||| 50 ||| 2-0
und zu einem geringeren Ausmaß ||| and a lesser amount ||| 0-0 2-1 3-2 4-2 3-3
und zu einem ||| and a ||| 0-0 2-1
und zu ||| and ||| 0-0
und zusätzlichen Maßnahmen zur Pharmakovigilanz ||| and additional pharmacovigilance activities ||| 0-0 1-1 4-2 2-3 3-3 4-3
und zusätzlichen ||| and additional ||| 0-0 1-1
und ||| , and ||| 0-1
und ||| , becoming ||| 0-0
und ||| , ||| 0-0
und ||| 1.0 ||| 0-0
und ||| ; and ||| 0-1
und ||| albumin receptor , and ||| 0-3
und ||| and , ||| 0-0
und ||| and 4.3 ||| 0-0
und ||| and a ||| 0-0
und ||| and all ||| 0-0
und ||| and any ||| 0-0
und ||| and dose dependent ||| 0-0
und ||| and dose ||| 0-0
und ||| and in ||| 0-0
und ||| and is ||| 0-0
und ||| and multiple ||| 0-0 0-1
und ||| and rate ||| 0-0
und ||| and the ||| 0-0
und ||| and tissue ||| 0-0 0-1
und ||| and via ||| 0-0
und ||| and vitamin ||| 0-0
und ||| and weight ||| 0-0
und ||| and ||| 0-0
und ||| are ||| 0-0
und ||| brain and ||| 0-1
und ||| disorganised thinking and ||| 0-2
und ||| drug and ||| 0-1
und ||| hormone ||| 0-0
und ||| infusion and ||| 0-1
und ||| other ||| 0-0
und ||| potentially ||| 0-0
und ||| receptor , and ||| 0-2
und ||| reduced and ||| 0-1
und ||| studied ||| 0-0
und ||| thinking and ||| 0-1
und ||| to ||| 0-0
und ||| und ||| 0-0
und ||| which ||| 0-0
und ||| who are ||| 0-1
und ||| worse and ||| 0-1
und Ödeme ||| and oedema ||| 0-0 1-1
und ähnlichem Resorptionsanteil . ||| and extent of absorption . ||| 0-0 1-1 1-2 2-3 3-4
und ähnlichem Resorptionsanteil ||| and extent of absorption ||| 0-0 1-1 1-2 2-3
und ähnlichem ||| and extent of ||| 0-0 1-1 1-2
und über die Nieren eliminiert ||| and eliminated via the kidney ||| 0-0 4-1 1-2 3-2 2-3 3-4
und übergewichtigen ||| in ||| 1-0
und/oder Schmerzen ||| and/ or pain ||| 0-0 0-1 1-2
und/oder antidepressive Behandlung ||| and/ or ongoing antidepressive treatment ||| 0-0 0-1 1-2 1-3 2-4
und/oder antidepressive ||| and/ or ongoing antidepressive ||| 0-0 0-1 1-2 1-3
und/oder einem Sulfonylharnstoff . ||| and/ or a sulphonylurea . ||| 0-0 0-1 1-2 1-3 2-3 3-4
und/oder einem Sulfonylharnstoff ||| and/ or a sulphonylurea ||| 0-0 0-1 1-2 1-3 2-3
und/oder nicht heilende Wunden ||| and/ or non-healing sores of ||| 0-0 0-1 2-2 3-3
und/oder nicht heilende Wunden ||| and/ or non-healing sores ||| 0-0 0-1 2-2 3-3
und/oder nicht heilende ||| and/ or non-healing ||| 0-0 0-1 2-2
und/oder nicht ||| and/ or ||| 0-0 0-1
und/oder ||| and/ or ||| 0-0 0-1
und/oder ||| and/ ||| 0-0
und/oder ||| or ||| 0-0
undvorübergehend . ||| last very long . ||| 0-0 0-1 0-2 1-3
undvorübergehend ||| last very long ||| 0-0 0-1 0-2
unerklärbarer Tod ||| unexplained death ||| 0-0 1-1
unerklärbarer ||| unexplained ||| 0-0
unerwartete ||| unexpected ||| 0-0
unerwünschte Ereignisse , die ||| adverse events which ||| 0-0 1-1 2-2 3-2
unerwünschte Ereignisse : ||| adverse events : in the ||| 0-0 1-1 2-2 0-3
unerwünschte Ereignisse : ||| adverse events : in ||| 0-0 1-1 2-2 0-3
unerwünschte Ereignisse bei ||| adverse events in patients ||| 0-0 1-1 2-2 2-3
unerwünschte Ereignisse ||| adverse events ||| 0-0 1-1
unerwünschte zerebrovaskuläre Ereignisse bei ||| cerebrovascular adverse events in ||| 0-0 1-0 0-1 2-2 3-3
unerwünschte zerebrovaskuläre Ereignisse ||| cerebrovascular adverse events ||| 0-0 1-0 0-1 2-2
unerwünschte zerebrovaskuläre ||| cerebrovascular adverse ||| 0-0 1-0 0-1
unerwünschte ||| adverse ||| 0-0
unerwünschten Arzneimittelwirkungen , die in ||| adverse drug reactions from ||| 0-0 1-1 4-1 1-2 2-2 1-3 3-3
unerwünschten Ereignisse wurden ||| adverse events have been ||| 0-0 1-1 2-2 2-3
unerwünschten Ereignisse ||| adverse events ||| 0-0 1-1
unerwünschten Wirkungen , ||| adverse lon reactions ||| 0-0 1-0 0-2
unerwünschten Wirkungen ||| additional adverse reactions ||| 0-1 1-1 0-2
unerwünschten Wirkungen ||| adverse lon reactions ||| 0-0 1-0 0-2
unerwünschten Wirkungen ||| adverse reactions ||| 0-0 1-0 0-1
unerwünschten Wirkungen ||| of rimonabant ||| 0-1 1-1
unerwünschten Wirkungen ||| rimonabant ||| 0-0 1-0
unerwünschten ||| adverse reactions ||| 0-0 0-1
unerwünschten ||| adverse ||| 0-0
ungebrauchte Lösung zu verwerfen . ||| discard any unused amount . ||| 0-0 0-1 3-2 1-3 3-3 4-4
ungebrauchte Lösung zu verwerfen ||| discard any unused amount ||| 0-0 0-1 3-2 1-3 3-3
ungebrauchte ||| discard any ||| 0-0 0-1
ungefähr ||| approximately ||| 0-0
ungeklärte ||| unexplained ||| 0-0
ungeklärte Übelkeit ||| unexplained nausea ||| 0-0 1-1
ungeordnet aufgebaut ||| a disordered ||| 0-1 1-1
ungeordnet aufgebaut ||| disordered ||| 0-0 1-0
ungeordnet aufgebaut ||| in a disordered ||| 0-2 1-2
ungeplante , ||| unplanned , ||| 0-0 1-1
ungeplante ||| unplanned ||| 0-0
ungewollter Harnabgang ||| ; ||| 0-0 1-0
ungewöhnliche Müdigkeit , Schwindel und ||| unusual tiredness , feeling dizzy ||| 0-0 1-1 2-2 3-2 1-3 2-4
ungewöhnliche Müdigkeit , Schwindel ||| unusual tiredness , feeling dizzy ||| 0-0 1-1 2-2 3-2 1-3 2-4
ungewöhnliche ||| unusual ||| 0-0
unklar , ob es ||| unclear whether or not there ||| 0-0 1-1 2-1 3-3 3-4
unklar , ob ||| unclear whether or ||| 0-0 1-1 2-1
unklar , ob ||| unclear whether ||| 0-0 1-1 2-1
unklar , so dass Pioglitazon ||| unclear and pioglitazone ||| 0-0 2-0 2-1 3-2 4-2
unklar , so ||| unclear and ||| 0-0 2-0 2-1
unklar ||| unclear ||| 0-0
unkonserviertes Produkt und ist ||| unpreserved product and is ||| 0-0 1-1 2-2 3-3
unkonserviertes Produkt und ||| unpreserved product and ||| 0-0 1-1 2-2
unkonserviertes Produkt ||| unpreserved product ||| 0-0 1-1
unkonserviertes ||| unpreserved ||| 0-0
unmittelbar ||| immediately ||| 0-0
unregelmäßigem Herzschlag leiden . ||| irregular heart beat . ||| 0-0 1-1 1-2 2-2 3-3
unregelmäßigem Herzschlag leiden ||| irregular heart beat ||| 0-0 1-1 1-2 2-2
unregelmäßigem ||| irregular ||| 0-0
unregelmäßigen Herzschlag ||| irregular heart rhythm ||| 0-0 1-0 1-1 1-2
unspezifische Neubildungen ( einschl . ||| malignant and unspecified ( including ||| 0-0 1-1 1-2 3-2 2-3 3-4 4-4
unspezifische ||| malignant ||| 0-0
unten aufgeführten Nebenwirkungen ist ||| listed below is ||| 0-0 1-0 2-0 0-1 3-2
unten aufgeführten Nebenwirkungen ||| listed below ||| 0-0 1-0 2-0 0-1
unten dargelegt . ||| below . ||| 0-0 1-0 2-1
unten dargelegt . ||| shown below . ||| 0-1 1-1 2-2
unten dargelegt ||| below ||| 0-0 1-0
unten dargelegt ||| shown below ||| 0-1 1-1
unten dargestellt . ||| listed below . ||| 0-0 0-1 1-1 2-2
unten dargestellt ||| listed below ||| 0-0 0-1 1-1
unter 100 ng/ml liegt . ||| below 100 ng/ ml ||| 0-0 1-1 2-2 3-2 2-3 4-3
unter 100 ||| below 100 ||| 0-0 1-1
unter 12 g/dl ( ||| below 12 g/ dl ( ||| 0-0 1-1 2-2 2-3 3-4
unter 12 g/dl ||| below 12 g/ dl ||| 0-0 1-1 2-2 2-3
unter 12 ||| below 12 ||| 0-0 1-1
unter 15 mg waren ||| below 15 mg were ||| 0-0 1-1 2-2 3-3
unter 15 mg ||| below 15 mg ||| 0-0 1-1 2-2
unter 15 ||| below 15 ||| 0-0 1-1
unter 18 Jahre alt sind ||| are under 18 years of ||| 4-0 0-1 3-1 1-2 3-2 2-3
unter 18 Jahre alt sind ||| are under 18 years ||| 4-0 0-1 3-1 1-2 3-2 2-3
unter 18 Jahre alt ||| under 18 years of ||| 0-0 3-0 1-1 3-1 2-2
unter 18 Jahre alt ||| under 18 years ||| 0-0 3-0 1-1 3-1 2-2
unter 18 Jahren aufgrund ||| below age 18 years due ||| 0-0 2-1 1-2 2-3 3-4
unter 18 Jahren ||| below 18 years of age ||| 0-0 1-1 2-2 2-4
unter 18 Jahren ||| below age 18 years ||| 0-0 2-1 1-2 2-3
unter 18 Monaten ||| less than 18 months ||| 0-0 0-1 0-2 1-2 2-3
unter 18 ||| below 18 ||| 0-0 1-1
unter 18 ||| less than 18 ||| 0-0 0-1 0-2 1-2
unter 25°C ) . ||| below 25°C ) . ||| 0-0 1-1 2-2 3-3
unter 25°C ) . ||| below 25ºC ) . ||| 0-0 1-1 2-2 3-3
unter 25°C ) ||| below 25°C ) ||| 0-0 1-1 2-2
unter 25°C ) ||| below 25ºC ) ||| 0-0 1-1 2-2
unter 25°C ||| below 25°C ||| 0-0 1-1
unter 25°C ||| below 25ºC ||| 0-0 1-1
unter 30 kg höhere ||| under 30 kg require higher ||| 0-0 1-1 2-2 3-3 3-4
unter 30 kg ||| under 30 kg ||| 0-0 1-1 2-2
unter 30 ||| under 30 ||| 0-0 1-1
unter 30°C ) . ||| below 30°C ) . ||| 0-0 1-0 1-1 2-2 3-3
unter 30°C ) ||| below 30°C ) ||| 0-0 1-0 1-1 2-2
unter 30°C ||| below 30°C ||| 0-0 1-0 1-1
unter 65 Jahren ||| less than 65 years ||| 0-0 0-1 1-2 2-3
unter 65 ||| less than 65 ||| 0-0 0-1 1-2
unter Abschnitt 6.1 . ||| , see section 6.1 ||| 1-1 1-2 2-3 3-3
unter Abschnitt 6.1 . ||| see section 6.1 ||| 1-0 1-1 2-2 3-2
unter Abschnitt ||| , see section ||| 1-1 1-2
unter Abschnitt ||| see section ||| 1-0 1-1
unter Aclasta im ||| in Aclasta ||| 2-0 1-1
unter Aclasta ||| Aclasta ||| 1-0
unter Aripiprazol ( 43 % ||| aripiprazole ( 43 % ||| 1-0 2-1 0-2 3-2 4-3
unter Aripiprazol ( 43 ||| aripiprazole ( 43 ||| 1-0 2-1 0-2 3-2
unter Aripiprazol- Behandlung ||| for aripiprazole-treated ||| 1-0 0-1 1-1 2-1
unter Berücksichtigung der gängigen medizinischen ||| conducted according to standard medical ||| 1-0 2-1 3-1 2-2 3-3 4-4
unter Berücksichtigung der gängigen ||| conducted according to standard ||| 1-0 2-1 3-1 2-2 3-3
unter Berücksichtigung ||| conducted ||| 1-0
unter Chemotherapie ||| receiving chemotherapy , ||| 0-0 1-0 1-1
unter Chemotherapie ||| receiving chemotherapy ||| 0-0 1-0 1-1
unter Erythroblastopenie ||| develop PRCA ||| 0-0 1-0 1-1
unter Haloperidol-Behandlung ||| for haloperidol-treated ||| 1-0 0-1 1-1
unter Haloperidol-Behandlung ||| haloperidol-treated ||| 0-0 1-0
unter Kontrolle ist . ||| is controlled . ||| 2-0 0-1 1-1 3-2
unter Kontrolle ist . ||| is controlled . ||| 2-0 1-1 3-2
unter Kontrolle ist ||| is controlled ||| 2-0 0-1 1-1
unter Kontrolle ist ||| is controlled ||| 2-0 1-1
unter Kontrolle ||| controlled ||| 0-0 1-0
unter Kontrolle ||| controlled ||| 1-0
unter Olanzapin-Therapie ||| olanzapine-treated ||| 0-0 1-0
unter Peritonealdialysebehandlung ( siehe ||| on peritoneal dialysis ( See ||| 1-0 0-1 1-1 1-2 2-3 1-4 3-4
unter Pioglitazon . ||| with pioglitazone . ||| 0-0 0-1 1-1 2-2
unter Pioglitazon reduzierte ||| receiving pioglitazone ||| 0-0 1-1 2-1
unter Pioglitazon ||| with pioglitazone ||| 0-0 0-1 1-1
unter Placebo ( 139 ||| receiving placebo ( 139 ||| 0-0 1-1 2-2 3-3
unter Placebo ( Ausgangswert 7,2 ||| on placebo ( baseline 7.2 ||| 0-0 0-1 1-1 2-2 3-3 4-4
unter Placebo ( Ausgangswert ||| on placebo ( baseline ||| 0-0 0-1 1-1 2-2 3-3
unter Placebo ( ||| on placebo ( ||| 0-0 0-1 1-1 2-2
unter Placebo ( ||| receiving placebo ( ||| 0-0 1-1 2-2
unter Placebo oder wurden ||| placebo , or were ||| 0-0 1-0 2-2 3-3
unter Placebo oder wurden ||| placebo , or were ||| 0-0 1-0 3-1 2-2 3-3
unter Placebo oder ||| placebo , or ||| 0-0 1-0 2-2
unter Placebo ||| on placebo ||| 0-0 0-1 1-1
unter Placebo ||| placebo , ||| 0-0 1-0
unter Placebo ||| placebo ||| 0-0 1-0
unter Placebo ||| receiving placebo ||| 0-0 1-1
unter Umgehung von adipösen Regionen ||| adipose regions , ||| 1-0 1-1 3-1 4-1
unter Umgehung von adipösen Regionen ||| adipose regions ||| 1-0 1-1 3-1 4-1
unter Zugrundelegung folgender Kriterien definiert ||| defined using the following convention ||| 1-0 3-0 0-1 2-1 2-2 3-3 3-4 4-4
unter aseptischen Bedingungen ||| followed during preparation of the ||| 1-0 1-1 1-2 2-4
unter aseptischen ||| followed during preparation of ||| 1-0 1-1 1-2
unter aseptischen ||| followed during preparation ||| 1-0 1-1 1-2
unter chronischer Nierenschwäche und klinisch ||| chronic kidney failure and clinically ||| 1-0 0-1 2-1 1-2 3-3 4-4
unter chronischer Nierenschwäche und ||| chronic kidney failure and ||| 1-0 0-1 2-1 1-2 3-3
unter chronischer Nierenschwäche ||| chronic kidney failure ||| 1-0 0-1 2-1 1-2
unter der Aufsicht eines qualifizierten ||| under the supervision of a ||| 0-0 2-0 1-1 2-2 3-2 4-2 3-3 3-4
unter der Kurve ( Plasmakonzentration ||| under the plasma concentration ||| 0-0 1-1 2-1 4-2 4-3
unter der Kurve ( ||| under the ||| 0-0 1-1 2-1
unter der Kurve ||| under the ||| 0-0 1-1 2-1
unter der ||| below the ||| 0-0 1-1
unter die Haut ( ||| under the skin ( ||| 0-0 1-1 2-2 3-3
unter die Haut gespritztem ) ||| injection under the skin ) ||| 2-0 0-1 1-2 2-3 3-3 4-4
unter die Haut gespritztem ||| injection under the skin ||| 2-0 0-1 1-2 2-3 3-3
unter die Haut ||| under the skin ||| 0-0 1-1 2-2
unter die ||| under the ||| 0-0 1-1
unter http://www.emea.europa.eu ||| emea ||| 1-0
unter oralem Aripiprazol : ||| with oral aripiprazole : ||| 0-0 1-1 2-2 3-3
unter oralem Aripiprazol ||| with oral aripiprazole ||| 0-0 1-1 2-2
unter oralem ||| with oral ||| 0-0 1-1
unter ||| % ||| 0-0
unter ||| been ||| 0-0
unter ||| below ||| 0-0
unter ||| less than ||| 0-0 0-1
unter ||| on ||| 0-0
unter ||| receiving ||| 0-0
unter ||| under ||| 0-0
unter ||| with ||| 0-0
unterbrechen . ||| corrected . ||| 0-0 1-1
unterbrechen ||| corrected ||| 0-0
unterbrochen und ||| interrupted and ||| 0-0 1-1
unterbrochen ||| interrupted ||| 0-0
unterdrücken . ||| human milk . ||| 0-0 0-1 1-2
unterdrücken . ||| in human milk . ||| 0-1 0-2 1-3
unterdrücken ||| human milk ||| 0-0 0-1
unterdrücken ||| in human milk ||| 0-1 0-2
unterhalb der menschlichen therapeutischen ||| CHO/ HGPRT ) gene mutation ||| 0-0 0-1 2-3 3-4
unterhalb der menschlichen ||| ( CHO/ HGPRT ) gene ||| 0-1 0-2 2-4
unterhalb der menschlichen ||| CHO/ HGPRT ) gene ||| 0-0 0-1 2-3
unterhalb der ||| ( CHO/ HGPRT ) ||| 0-1 0-2
unterhalb der ||| ( CHO/ HGPRT ||| 0-1 0-2
unterhalb der ||| CHO/ HGPRT ) ||| 0-0 0-1
unterhalb der ||| CHO/ HGPRT ||| 0-0 0-1
unterhalb des Ausgangswertes ||| below baseline levels ||| 0-0 0-1 2-1 0-2 1-2
unterhalb des Ausgangswerts ||| below baseline levels at ||| 0-0 2-1 1-2 2-2 2-3
unterhalb ||| ( CHO/ HGPRT ) ||| 0-1 0-2
unterhalb ||| ( CHO/ HGPRT ||| 0-1 0-2
unterhalb ||| CHO/ HGPRT ) ||| 0-0 0-1
unterhalb ||| CHO/ HGPRT ||| 0-0 0-1
unterhalb ||| below ||| 0-0
unterliegen Patienten ||| , patients ||| 0-1 1-1
unterliegen Patienten ||| patients ||| 0-0 1-0
unterliegen daher ||| are therefore affected ||| 0-0 1-1 0-2 1-2
unterschiedlich sein ; daher ||| overall burden of disease ; ||| 0-0 0-1 1-1 3-1 0-3 2-4
unterschiedlich sein ; ||| overall burden of disease ; ||| 0-0 0-1 1-1 0-3 2-4
unterschiedlich sein ||| overall burden of disease ||| 0-0 0-1 1-1 0-3
unterschiedliche Todesursachen gab ||| causes of deaths were ||| 0-0 0-1 0-2 1-2 2-2 2-3
unterschiedliche Todesursachen ||| causes of deaths ||| 0-0 0-1 0-2 1-2
unterschiedliche periphere Verteilungsvolumina ||| ise peripheral volume of distribution ||| 0-0 1-1 2-2 0-3 2-4
unterstützendes ||| , ||| 0-0
untersucht . Weitere Vergleichsstudien ||| investigated and further comparative studies ||| 0-0 1-0 3-2 2-3 3-3 3-4
untersucht . ||| . ||| 0-0 1-0
untersucht . ||| been evaluated . ||| 0-0 0-1 1-2
untersucht . ||| been studied . ||| 0-0 0-1 1-2
untersucht . ||| evaluated . ||| 0-0 1-1
untersucht . ||| investigated . ||| 0-0 1-1
untersucht . ||| investigated and ||| 0-0 1-0
untersucht . ||| investigated ||| 0-0 1-0
untersucht ; ||| studied ||| 0-0
untersucht werden . ||| should be investigated . ||| 1-0 1-1 0-2 2-3
untersucht werden ||| should be investigated ||| 1-0 1-1 0-2
untersucht worden . ||| been studied . ||| 1-0 0-1 2-2
untersucht worden ||| been studied ||| 1-0 0-1
untersucht wurden. er Die ||| wurden. er Die ||| 1-0 2-1 3-2
untersucht wurden. er ||| wurden. er ||| 1-0 2-1
untersucht wurden. ||| wurden. ||| 1-0
untersucht ||| been evaluated ||| 0-0 0-1
untersucht ||| been studied ||| 0-0 0-1
untersucht ||| evaluated ||| 0-0
untersucht ||| investigated ||| 0-0
untersucht ||| studied ||| 0-0
untersucht ||| treatment ||| 0-0
unverzüglich , wenn Sie ||| immediately if you ||| 0-0 1-1 2-1 3-2
unverzüglich , wenn ||| immediately if ||| 0-0 1-1 2-1
unverzüglich Ihren Arzt , wenn ||| your doctor immediately if ||| 1-0 1-1 2-1 0-2 3-3 4-3
unverzüglich Ihren Arzt ||| your doctor immediately ||| 1-0 1-1 2-1 0-2
unverzüglich ||| immediately ||| 0-0
unverändert bleiben . ||| remain unchanged . ||| 1-0 0-1 2-2
unverändert bleiben ||| remain unchanged ||| 1-0 0-1
unverändert ||| unchanged ||| 0-0
unverändertem Pioglitazon ||| unchanged pioglitazone ||| 0-0 1-1
unverändertem ||| unchanged ||| 0-0
unveränderten Wirkstoffs ||| active substance ||| 1-0 1-1
unwahrscheinlich , ||| unlikely to reduce ||| 0-0
unwahrscheinlich , ||| unlikely to ||| 0-0
unwahrscheinlich , ||| unlikely ||| 0-0
unwahrscheinlich . ||| therefore unlikely . ||| 0-1 1-2
unwahrscheinlich . ||| unlikely . ||| 0-0 1-1
unwahrscheinlich ||| therefore unlikely ||| 0-1
unwahrscheinlich ||| unlikely to reduce ||| 0-0
unwahrscheinlich ||| unlikely to ||| 0-0
unwahrscheinlich ||| unlikely ||| 0-0
unwirksam , und Dosierungen ||| effective , and doses ||| 0-0 1-1 2-2 3-3
unwirksam , und Dosierungen über ||| effective , and doses above ||| 0-0 1-1 2-2 3-3 4-4
unwirksam , und ||| effective , and ||| 0-0 1-1 2-2
unwirksam , ||| effective , ||| 0-0 1-1
unwirksam ||| effective ||| 0-0
unzugänglich aufbewahren . ||| and sight of children . ||| 0-0 0-1 1-2 1-3 2-4
unzugänglich aufbewahren ||| and sight of children ||| 0-0 0-1 1-2 1-3
unzugänglich aufzubewahren . ||| and sight of children . ||| 0-0 0-1 0-2 1-3 2-4
unzugänglich aufzubewahren ||| and sight of children ||| 0-0 0-1 0-2 1-3
unzugänglich ||| and sight of ||| 0-0 0-1 0-2
unzugänglich ||| and sight ||| 0-0 0-1
unzureichend eingestellt sind ||| for whom ||| 0-0 0-1 1-1 2-1
unzureichend ||| blood ||| 0-0
unzureichend ||| insufficient ||| 0-0
unzureichend ||| monotherapy ||| 0-0
unzureichenden Datenlage zur Sicherheit ||| insufficient safety information ||| 0-0 1-0 2-1 3-1 1-2
unzusammenhängende Sprache ||| incoherent speech ||| 0-0 1-0 1-1
utero und ||| utero and via ||| 0-0 1-1
utero und ||| utero and ||| 0-0 1-1
utero ||| utero ||| 0-0
vaskuläre Ereignisse ) . ||| vascular events ) . ||| 0-0 1-1 2-2 3-3
vaskuläre Ereignisse ) ||| vascular events ) ||| 0-0 1-1 2-2
vaskuläre Ereignisse ||| vascular events ||| 0-0 1-1
vaskuläre ||| vascular and ||| 0-0
vaskuläre ||| vascular ||| 0-0
ventrikuläre Arrhythmien , plötzlicher unerklärbarer ||| ventricular arrhythmias , sudden unexplained ||| 0-0 1-1 2-2 3-3 4-4
ventrikuläre Arrhythmien , plötzlicher ||| ventricular arrhythmias , sudden ||| 0-0 1-1 2-2 3-3
ventrikuläre Arrhythmien , ||| ventricular arrhythmias , ||| 0-0 1-1 2-2
ventrikuläre Arrhythmien ||| ventricular arrhythmias ||| 0-0 1-1
ventrikuläre ||| ventricular ||| 0-0
venöse Thrombosen , arterielle ||| thrombosis , arterial ||| 0-0 1-0 2-1 3-2
venöse Thrombosen , ||| thrombosis , ||| 0-0 1-0 2-1
venöse Thrombosen ||| thrombosis ||| 0-0 1-0
verabreichen . ||| . ||| 0-0 1-0
verabreichen . ||| between . ||| 0-1 1-1
verabreicht . ||| . ||| 0-0 1-0
verabreicht . ||| given . ||| 0-0 1-1
verabreicht werden . ||| . ||| 1-0 2-0
verabreicht werden . ||| be administered intravenously . ||| 1-0 0-1 0-2 1-2 2-3
verabreicht werden . ||| be given . ||| 1-0 0-1 2-2
verabreicht werden ||| are ||| 0-0 1-0
verabreicht werden ||| be administered intravenously ||| 1-0 0-1 0-2 1-2
verabreicht werden ||| be given ||| 1-0 0-1
verabreicht wird ||| are given ||| 0-0 0-1 1-1
verabreicht ||| administered ||| 0-0
verabreicht ||| given to ||| 0-0
verabreicht ||| given ||| 0-0
verabreicht über einen Zeitraum von ||| administered over ||| 0-0 1-1 2-1 3-1 4-1
verabreichte Zoledronsäure ||| administered zoledronic acid ||| 0-0 1-1 1-2
verabreichte ||| administered ||| 0-0
veraltet ||| obsolete ||| 0-0
verantwortlich ist ||| release : ||| 0-0 1-0
verantwortlich ist ||| release ||| 0-0 1-0
verbunden ? er Die ||| ? er Die ||| 1-0 2-1 3-2
verbunden ? er ||| ? er ||| 1-0 2-1
verbunden ? ||| ? ||| 1-0
verbunden ||| associated ||| 0-0
vereinbaren . ||| appointment . ||| 0-0 1-1
vereinbaren ||| appointment ||| 0-0
verfügbar . ||| . europa . eu/ ||| 1-0 0-1 1-2 0-3
verfügbar . ||| europa . eu/ ||| 0-0 1-1 0-2
verfügbaren Dosis ||| available dose ||| 0-0 1-1
verfügbaren ||| available ||| 0-0
vergessene Dosis ein , sobald ||| missed dose as soon as ||| 0-0 2-0 1-1 3-2 4-2 4-3 4-4
vergessene Dosis ein ||| missed dose ||| 0-0 2-0 1-1
vergleichbar , ||| similar ||| 0-0
vergleichbar ist ||| similar ||| 0-0
vergleichbar mit der ||| similar to ||| 0-0 2-1
vergleichbar mit ||| similar ||| 0-0
vergleichbar zu Placebo . ||| comparable to placebo . ||| 0-0 1-1 2-2 3-3
vergleichbar zu Placebo ||| comparable to placebo ||| 0-0 1-1 2-2
vergleichbar zu den ||| similar to that ||| 0-0 1-1 2-1
vergleichbar zu den ||| similar to ||| 0-0 1-1 2-1
vergleichbar zu ||| comparable to ||| 0-0 1-1
vergleichbar zwischen ||| comparable between ||| 0-0 1-1
vergleichbar ||| comparable to that ||| 0-0
vergleichbar ||| comparable to ||| 0-0
vergleichbar ||| comparable ||| 0-0
vergleichbar ||| similar ||| 0-0
verglichen . ||| . ||| 1-0
verglichen mit 1,7 % bei ||| compared to 1.7 % of ||| 0-0 0-1 1-2 2-2 4-2 3-3
verglichen mit 1,7 % bei ||| compared to 1.7 % ||| 0-0 0-1 1-2 2-2 4-2 3-3
verglichen mit Patienten , ||| compared with those ||| 0-0 1-1 0-2 2-2
verglichen mit Patienten ||| compared with those ||| 0-0 1-1 0-2 2-2
verglichen mit der ||| treatment with placebo ||| 2-0 1-1 0-2
verglichen mit ||| compared ||| 0-0
verglichen mit ||| with placebo ||| 1-0 0-1
verglichen ||| compared to ||| 0-0 0-1
verglichen ||| compared ||| 0-0
verglichen ||| placebo ||| 0-0
vergrößerte . ||| mass . ||| 0-0 1-1
vergrößerte ||| mass ||| 0-0
verhindern , sollte ||| should be rotated ||| 2-0 2-1 0-2 1-2 2-2
verhindert auch , dass dieser ||| also prevents this ||| 1-0 0-1 2-1 3-1 4-2
verhindert auch , dass ||| also prevents ||| 1-0 0-1 2-1 3-1
verhindert wird . ||| from returning . ||| 0-0 1-0 0-1 2-2
verhindert wird ||| from returning ||| 0-0 1-0 0-1
verifiziert ||| Table 3. ||| 0-0 0-1
verifiziert ||| in Table 3. ||| 0-1 0-2
verlangt die Aufnahme ||| requests the inclusion , ||| 0-0 1-1 2-1 0-2
verlangt die Aufnahme ||| requests the inclusion ||| 0-0 1-1 2-1 0-2
verloren ||| of ||| 0-0
verlängern . ||| insulin . ||| 0-0 1-1
verlängern ||| insulin ||| 0-0
vermehrte Fettablagerungen und ||| increased fatty deposition and ||| 0-0 0-1 1-1 1-2 2-3
vermehrte Fettablagerungen ||| increased fatty deposition ||| 0-0 0-1 1-1 1-2
vermehrte Speichelproduktion , ||| increased production of saliva , ||| 0-0 1-1 0-3 1-3 2-4
vermehrte Speichelproduktion ||| increased production of saliva ||| 0-0 1-1 0-3 1-3
vermehrte primäre ||| increased primary ||| 0-0 1-1
vermehrte primäre ||| of increased primary ||| 0-1 1-2
vermehrte ||| increased ||| 0-0
vermehrte ||| of increased ||| 0-1
vermehrter Kalium- und Proteinaufnahme führen ||| potassium and protein intake ||| 0-0 1-0 2-1 3-2 3-3 4-3
vermehrter Kalium- und ||| potassium and ||| 0-0 1-0 2-1
vermehrter Kalium- ||| potassium ||| 0-0 1-0
vermieden werden . ||| be avoided . ||| 1-0 0-1 2-2
vermieden werden ||| be avoided ||| 1-0 0-1
vermieden ||| avoided ||| 0-0
vermieden ||| l ||| 0-0
verminderte Empfindlichkeit gegenüber Reizen ||| decreased sensitivity to a stimulus ||| 0-0 1-1 2-2 2-3 3-4
verminderte Empfindlichkeit gegenüber ||| decreased sensitivity to a ||| 0-0 1-1 2-2 2-3
verminderte Empfindlichkeit ||| decreased sensitivity ||| 0-0 1-1
verminderte Wahrnehmung von ||| of ||| 1-0 2-0
verminderte lokoregionale Kontrolle ||| decreased locoregional control ||| 0-0 0-1 1-1 1-2 2-2
verminderte maternale Gewichtszunahme zurückzuführen ist ||| decreased maternal body weight gain ||| 0-0 1-1 3-1 1-2 2-3 2-4 4-4
verminderte ||| decreased ||| 0-0
verminderten Exposition gegenüber Rimonabant. ||| reduce the exposure of rimonabant ||| 0-0 1-2 2-2 3-4
verminderten Exposition gegenüber ||| reduce the exposure of ||| 0-0 1-2 2-2
verminderten Exposition gegenüber ||| reduce the exposure ||| 0-0 1-2 2-2
verminderten ||| reduce the ||| 0-0
verminderten ||| reduce ||| 0-0
vermischen , ||| mix ||| 0-0
vermischen ||| mix ||| 0-0
vermischt werden . ||| prior to administration . ||| 0-0 1-1 0-2 1-3 2-3
vermittelt und ||| and ||| 0-0 1-0
vermittelt wird . ||| 5HT2a receptors . ||| 0-0 1-0 0-1 2-2
vermittelt wird ||| 5HT2a receptors ||| 0-0 1-0 0-1
vermittelt ||| mediated ||| 0-0
vermutet , dass die ||| has been proposed that ||| 0-0 0-1 0-2 1-3 2-3 3-3
vermutet wird , ||| suspected , therapy with ||| 0-0 1-0 2-1 0-2 0-3
vermutet ||| has been proposed ||| 0-0 0-1 0-2
vermutlich zu einer verminderten ||| is expected to reduce the ||| 0-0 0-1 1-2 2-2 3-3
vermutlich zu einer verminderten ||| is expected to reduce ||| 0-0 0-1 1-2 2-2 3-3
vermutlich zu einer ||| is expected to ||| 0-0 0-1 1-2 2-2
vermutlich ||| is expected ||| 0-0 0-1
verordnende ||| prescribers ||| 0-0
verordnende Ärzte sollten sich ||| prescribers should be alert to ||| 0-0 2-1 2-2 1-3 3-4
verordnende Ärzte sollten ||| prescribers should be alert ||| 0-0 2-1 2-2 1-3
verpflichtet sich , die Pharmakovigilanzaktivitäten ||| commits to performing the ||| 0-0 1-0 2-1 3-1 4-2 3-3
verpflichtet sich alle ||| commits to provide ||| 0-0 1-0 1-1 2-1
verpflichtet sich alle ||| commits to ||| 0-0 1-0 1-1 2-1
verpflichtet sich ||| commits to performing ||| 0-0 1-0 0-2
verpflichtet sich ||| commits ||| 0-0 1-0
verringern ||| reduce ||| 0-0
verringert , was zu einer ||| reduced , coupled with a ||| 0-0 1-1 0-2 2-2 3-2 4-3 4-4
verringert , was zu ||| reduced , coupled ||| 0-0 1-1 0-2 2-2 3-2
verringert deshalb ||| therefore ||| 0-0 1-0
verringerte Abilify ||| , Abilify ||| 0-0 1-1
verringerte das Risiko der ||| reduced the risk of ||| 0-0 1-1 1-2 2-2 3-3
verringerte das Risiko ||| reduced the risk ||| 0-0 1-1 1-2 2-2
verringerte sich ||| decreased by ||| 0-0 1-0 0-1
verringerte ||| , ||| 0-0
verringerte ||| reduced ||| 0-0
verringertem ||| , ||| 0-0
verringerten Patientenzahl festgestellt werden . ||| reduced sample size . ||| 0-0 3-0 1-1 1-2 4-3
verringerten Patientenzahl festgestellt werden ||| reduced sample size ||| 0-0 3-0 1-1 1-2
verringerten ||| reduced ||| 0-0
verringerter ||| of ||| 0-0
verschiedene Rezeptoren auf der ||| several different receptors on the ||| 3-0 0-1 1-2 2-3 3-4
verschiedene Rezeptoren auf ||| different receptors on ||| 0-0 1-1 2-2
verschiedene Rezeptoren ||| different receptors ||| 0-0 1-1
verschiedene ||| different ||| 0-0
verschiedenen ||| various ||| 0-0
verschlossen ist . ||| tamper-proof cap. ||| 0-0 1-0 0-1 2-1
verschreiben . ||| a day . ||| 0-0 0-1 1-2
verschreiben ||| a day ||| 0-0 0-1
verschreiben ||| prescribe ||| 0-0
verschrieben ||| prescribed ||| 0-0
verschriebenen Dosis ||| prescribed dose when concomitant ||| 0-0 1-1 0-2 0-3
verschwanden innerhalb einer Woche . ||| resolved within a week . ||| 0-0 1-1 2-2 3-3 4-4
verschwanden innerhalb einer Woche ||| resolved within a week ||| 0-0 1-1 2-2 3-3
verschwanden innerhalb einer ||| resolved within a ||| 0-0 1-1 2-2
verschwanden innerhalb ||| resolved within ||| 0-0 1-1
verschwanden ||| resolved ||| 0-0
verschwinden normalerweise im Verlauf der ||| disappear during continued ||| 0-0 1-0 2-1 3-1 3-2 4-2
verschwinden normalerweise ||| disappear ||| 0-0 1-0
verschwommene Sicht , Trockenes-Auge-Syndrom ||| blurred vision , dry eye ||| 0-0 0-1 1-2 2-2 3-3 3-4
verschwommene Sicht , ||| blurred vision , ||| 0-0 0-1 1-2 2-2
verschwommene ||| blurred vision ||| 0-0 0-1
verschwommenes Sehen , Dyspepsie ||| , blurred vision , dyspepsia ||| 2-0 0-1 1-2 2-3 3-4
verschwommenes Sehen , ||| , blurred vision , ||| 2-0 0-1 1-2 2-3
verschwommenes Sehen . ||| blurred vision . ||| 0-0 1-1 2-2
verschwommenes Sehen Erkrankungen des Gastrointestinaltrakts ||| blurred vision Gastrointestinal disorders ||| 0-0 1-1 4-2 2-3 3-3
verschwommenes Sehen aufgrund einer ||| verschwommenes Sehen aufgrund einer Schwellung ||| 0-0 0-1 0-2 1-2 1-3 3-3 1-4 2-4
verschwommenes Sehen ||| blurred vision ||| 0-0 1-1
verschwommenes ||| blurred ||| 0-0
versehene Kühlboxen ||| a visual aid indicating ||| 0-1 1-1 1-2 1-3
versehene Kühlboxen ||| visual aid indicating ||| 0-0 1-0 1-1 1-2
versehene Kühlboxen ||| with a visual aid indicating ||| 0-2 1-2 1-3 1-4
versehentlich eingefroren wurde . ||| has been accidentally frozen . ||| 0-0 0-1 0-2 1-2 1-3 2-3 3-4
versehentlich eingefroren wurde . ||| has been accidently frozen . ||| 0-0 0-1 1-2 0-3 1-3 2-3 3-4
versehentlich eingefroren wurde ||| has been accidentally frozen ||| 0-0 0-1 0-2 1-2 1-3 2-3
versehentlich eingefroren wurde ||| has been accidently frozen ||| 0-0 0-1 1-2 0-3 1-3 2-3
versehentlich ||| accidentally ||| 0-0
versehentlicher Einnahme ist ||| case of accidental ||| 0-0 0-2
versehentlicher Einnahme ist ||| case of accidental ||| 0-0 2-1 0-2
versehentlicher Einnahme ||| case of accidental ||| 0-0 0-2
versehentlicher ||| case of accidental ||| 0-0 0-2
versehentlicher Überdosierung sollte ||| case of accidental overdosing , ||| 0-0 0-1 0-2 0-3 1-3 2-3
versehentlicher Überdosierung sollte ||| case of accidental overdosing ||| 0-0 0-1 0-2 0-3 1-3 2-3
versorgen : Schulungsbroschüre ||| : Educational leaflet ||| 1-0 2-1 2-2
versorgen : ||| : ||| 1-0
verstärken . ||| pressure . ||| 0-0 1-1
verstärken ||| pressure ||| 0-0
verstärkte Brustschmerzen ) ||| chest pain ) ||| 1-0 1-1 2-2
verstärkte Brustschmerzen ||| chest pain ||| 1-0 1-1
verstärkter ||| Benommenheit ||| 0-0
versuchen ||| attempt ||| 0-0
versus Gliclazid als Monotherapie wurde ||| vs. gliclazide as monotherapy was ||| 0-0 1-1 2-2 3-3 4-4
versus Gliclazid als Monotherapie ||| vs. gliclazide as monotherapy ||| 0-0 1-1 2-2 3-3
versus Gliclazid als ||| vs. gliclazide as ||| 0-0 1-1 2-2
versus Gliclazid ||| vs. gliclazide ||| 0-0 1-1
versus Plazebo ) wurde ||| vs. placebo ) was ||| 0-0 1-0 1-1 2-2 3-3
versus Plazebo ) ||| vs. placebo ) ||| 0-0 1-0 1-1 2-2
versus Plazebo ||| vs. placebo ||| 0-0 1-0 1-1
versus Vergleichsmedikation ||| active comparator ||| 0-0 0-1 1-1
versus ||| versus ||| 0-0
versus ||| vs. ||| 0-0
verteilen sich in den Geweben ||| distribute to the tissues ||| 0-0 1-1 2-2 3-2 1-3 4-3
verteilen ||| distribute ||| 0-0
verteilt auf zwei gleich große ||| per week into 2 equal ||| 0-0 0-1 1-1 3-2 3-3 2-4 3-4 4-4
verteilt auf ||| per week ||| 0-0 0-1 1-1
vertragen ||| tolerated in ||| 0-0
vertragen ||| tolerated ||| 0-0
verursachen kann ||| can cause ||| 1-0 0-1
verursachen können ||| can cause ||| 1-0 0-1
verursachen ||| cause ||| 0-0
verursacht wurden ||| been ||| 1-0
verwendbare Injektionssysteme ) ||| devices for repeated use ) ||| 0-0 1-0 0-1 1-2 1-3 2-4
verwendbare Injektionssysteme ||| devices for repeated use ||| 0-0 1-0 0-1 1-2 1-3
verwenden . ||| system . lp ||| 0-0 1-1 0-2
verwendet . ||| used ||| 0-0
verwendet werden , jedoch ||| be used , but ||| 1-0 0-1 2-2 3-3
verwendet werden , wenn sie ||| be used if they ||| 1-0 0-1 2-2 3-2 4-3
verwendet werden , wenn ||| be used if ||| 1-0 0-1 2-2 3-2
verwendet werden , ||| be used , ||| 1-0 0-1 2-2
verwendet werden . ||| be used . ||| 1-0 0-1 2-2
verwendet werden ||| be used ||| 1-0 0-1
verwendet ||| used ||| 0-0
verwendete Tierarzneimittel oder ||| veterinary medicinal product or waste ||| 0-0 1-0 0-1 1-2 2-3 1-4
verwendetes Arzneimittel ||| unused product ||| 0-0 0-1 1-1
verworfen werden . ||| any remaining contents . ||| 0-0 0-1 0-2 1-2 2-3
verworfen werden ||| any remaining contents ||| 0-0 0-1 0-2 1-2
verzögert ) . ||| delayed ) . ||| 0-0 1-1 2-2
verzögert ) ||| delayed ) ||| 0-0 1-1
verzögert . ||| complications . ||| 0-0 1-1
verzögert werden könnte ||| may be ||| 2-0 1-1
verzögert werden ||| be ||| 1-0
verzögert ||| complications ||| 0-0
verzögert ||| delayed ||| 0-0
verzögerten ||| delayed ||| 0-0
verändert die Rimonabant-Exposition nicht . ||| not alter rimonabant exposure . ||| 3-0 0-1 1-1 2-1 2-2 2-3 4-4
verändert die Rimonabant-Exposition nicht ||| not alter rimonabant exposure ||| 3-0 0-1 1-1 2-1 2-2 2-3
verändert die Rimonabant-Exposition ||| alter rimonabant exposure ||| 0-0 1-0 2-0 2-1 2-2
verändert wahrnehmen und ||| warning symptoms of hypoglycaemia and ||| 0-0 1-0 1-1 1-2 1-3 2-4
verändert wahrnehmen ||| warning symptoms of hypoglycaemia ||| 0-0 1-0 1-1 1-2 1-3
verändert. t lä ||| verändert. t lä ||| 0-0 1-1 1-2 2-2
verändert. ||| verändert. ||| 0-0
verändertem Geisteszustand ||| altered mental status ||| 0-0 1-0 0-1 1-2
viel ABILIFY Injektionslösung ||| much ABILIFY solution for injection ||| 0-0 1-1 2-2 2-3 2-4
viel ABILIFY ||| much ABILIFY ||| 0-0 1-1
viel weniger ||| much less ||| 0-0 1-1
viel ||| much ||| 0-0
viele gut dokumentierte ||| has multiple well documented ||| 1-0 1-2 2-3
viele gut ||| has multiple well ||| 1-0 1-2
vier Kohlenhydratketten sind ||| four carbohydrate chains are ||| 0-0 1-1 1-2 2-3
vier Kohlenhydratketten ||| four carbohydrate chains ||| 0-0 1-1 1-2
vier Wochen ||| four weeks ||| 0-0 1-1
vier placebokontrollierten Studien ||| four placebo-controlled studies ||| 0-0 1-1 2-2
vier placebokontrollierten ||| four placebo-controlled ||| 0-0 1-1
vier ||| Four ||| 0-0
vier ||| four of ||| 0-0
vier ||| four week ||| 0-0 0-1
vier ||| four ||| 0-0
viszerale Metastasen ||| visceral metastases ||| 0-0 1-1
viszerale ||| visceral ||| 0-0
vitale ||| essential ||| 0-0
vitro ( Mäusemilzzellkultur ||| vitro ( mouse spleen cell ||| 0-0 1-1 2-2 2-3 2-4
vitro ( ||| vitro ( ||| 0-0 1-1
vitro . ||| vitro . ||| 0-0 1-1
vitro Befunde mit Zellen aus ||| vitro findings from ||| 0-0 1-1 2-1 3-1 4-2
vitro Befunde mit Zellen ||| vitro findings ||| 0-0 1-1 2-1 3-1
vitro ||| vitro ||| 0-0
vitro-Studien zeigten keine ||| vitro studies have shown no ||| 0-0 0-1 0-2 1-3 2-4
vitro-Studien zeigten ||| vitro studies have shown ||| 0-0 0-1 0-2 1-3
vitro-Studien ||| vitro studies have ||| 0-0 0-1 0-2
vitro-Studien ||| vitro studies ||| 0-0 0-1
vivo scheint gering zu sein ||| vivo appears to be low ||| 0-0 1-1 2-1 3-2 4-3 3-4
vivo scheint gering ||| vivo appears ||| 0-0 1-1 2-1
vivo ||| vivo ||| 0-0
vniec ba Latvij Tel : ||| vniec ba Latvij Tel : ||| 0-0 1-1 2-2 3-3 4-4
vniec ba Latvij Tel ||| vniec ba Latvij Tel ||| 0-0 1-1 2-2 3-3
vniec ba Latvij ||| vniec ba Latvij ||| 0-0 1-1 2-2
vniec ba ||| vniec ba ||| 0-0 1-1
vniec ||| vniec ||| 0-0
vollständige Liste ist ||| full list is available in ||| 0-0 1-0 1-1 2-2 2-3
vollständige Liste ist ||| full list is available ||| 0-0 1-0 1-1 2-2 2-3
vollständige Liste ||| full list ||| 0-0 1-0 1-1
vollständigen Behandlungsschemas . ||| schedule . ||| 1-0 2-1
vollständigen Behandlungsschemas . ||| treatment schedule . ||| 1-1 2-2
vollständigen Behandlungsschemas ||| schedule ||| 1-0
vollständigen Behandlungsschemas ||| treatment schedule ||| 1-1
vollständigen Wortlaut des EPAR für ||| 3 The full EPAR for ||| 0-0 0-1 0-2 1-2 1-3 2-3 3-3 4-4
vollständigen Wortlaut des EPAR ||| 3 The full EPAR ||| 0-0 0-1 0-2 1-2 1-3 2-3 3-3
vom Ausgangswert auf dem PANSS ||| from baseline on the PANSS ||| 0-0 1-1 2-2 3-3 4-4
vom Ausgangswert auf dem ||| from baseline on the ||| 0-0 1-1 2-2 3-3
vom Ausgangswert auf ||| from baseline on ||| 0-0 1-1 2-2
vom Ausgangswert ||| from baseline ||| 0-0 1-1
vom individuellen klinischen Status ||| basis of individual clinical status ||| 3-0 1-2 2-3 3-4
vom individuellen klinischen ||| individual clinical ||| 1-0 2-1
vom individuellen klinischen ||| of individual clinical ||| 1-1 2-2
vom individuellen ||| individual ||| 1-0
vom individuellen ||| of individual ||| 1-1
vom ||| by ||| 0-0
vom ||| calculated by ||| 0-0 0-1
vom ||| from ||| 0-0
von " A " ||| " A ||| 1-0 3-0 2-1
von 0,0089 µg/ml ||| sulphone 0.0471 µg/ ml ||| 2-0 1-1 1-2 2-2 2-3
von 0,63 mg Mitratapid/kg ||| of 0.63 mg mitratapide/ ||| 0-0 1-1 2-2 3-3
von 0,63 mg ||| of 0.63 mg ||| 0-0 1-1 2-2
von 0,63 ||| of 0.63 ||| 0-0 1-1
von 1 062 ) . ||| out of 1,062 ) . ||| 0-0 0-1 2-2 3-3 4-4
von 1 062 ) ||| out of 1,062 ) ||| 0-0 0-1 2-2 3-3
von 1 062 ||| out of 1,062 ||| 0-0 0-1 2-2
von 1 ml ||| of 1 ml ||| 0-0 1-1 2-2
von 1 ||| of 1 ||| 0-0 1-1
von 1 ||| out of ||| 0-0 0-1
von 1.000 , weniger als ||| 1,000 , less than ||| 0-0 1-0 2-1 3-2 4-3
von 1.000 , weniger ||| 1,000 , less ||| 0-0 1-0 2-1 3-2
von 1.000 , ||| 1,000 , ||| 0-0 1-0 2-1
von 1.000 ||| 1,000 ||| 0-0 1-0
von 10 g/dl ( ||| of 10 g/ dl ( ||| 0-0 1-1 2-2 2-3 3-4
von 10 g/dl ||| of 10 g/ dl ||| 0-0 1-1 2-2 2-3
von 10 ||| of 10 ||| 0-0 1-1
von 100 % . ||| of 100 % . ||| 0-0 1-1 2-2 3-3
von 100 % ||| of 100 % ||| 0-0 1-1 2-2
von 100 ||| 100 ||| 1-0
von 100 ||| of 100 ||| 0-0 1-1
von 12 - 14 ||| of 12 - 14 ||| 0-0 1-1 2-2 3-3
von 12 - ||| of 12 - ||| 0-0 1-1 2-2
von 12 g/dl ( ||| of 12 g/ dl ( ||| 0-0 1-1 2-2 2-3 3-4
von 12 g/dl ||| of 12 g/ dl ||| 0-0 1-1 2-2 2-3
von 12 ||| of 12 ||| 0-0 1-1
von 15 mg wurde nicht ||| of 15 mg has not ||| 0-0 1-1 2-2 3-3 4-4
von 15 mg wurde ||| of 15 mg has ||| 0-0 1-1 2-2 3-3
von 15 mg ||| of 15 mg ||| 0-0 1-1 2-2
von 15 mg/Tag ||| of 15 mg/ day ||| 0-0 1-1 2-2 2-3
von 15 ||| of 15 ||| 0-0 1-1
von 2 Einheiten ab . ||| of 2 units . ||| 0-0 1-1 2-2 3-2 4-3
von 2 Einheiten ab ||| of 2 units ||| 0-0 1-1 2-2 3-2
von 2 ||| of 2 ||| 0-0 1-1
von 2653 auf 16736 ||| from 2653 to 16736 ||| 0-0 1-1 2-2 3-3
von 2653 auf ||| from 2653 to ||| 0-0 1-1 2-2
von 2653 ||| from 2653 ||| 0-0 1-1
von 3,5 ||| 3.5 ||| 1-0
von 3.852 ) . ||| out of 3,852 ) . ||| 1-0 0-1 1-2 2-3 3-4
von 3.852 ) bei ||| out of 3,852 ) in ||| 1-0 0-1 1-2 2-3 3-4
von 3.852 ) ||| out of 3,852 ) ||| 1-0 0-1 1-2 2-3
von 3.852 ||| out of 3,852 ||| 1-0 0-1 1-2
von 3.862 ) ||| out of 3,862 ) ||| 1-0 0-1 1-2 2-3
von 3.862 ||| out of 3,862 ||| 1-0 0-1 1-2
von 30 Minuten alle ||| of 30 minutes , every ||| 0-0 1-1 2-2 3-4
von 30 Minuten ||| of 30 minutes , ||| 0-0 1-1 2-2
von 30 Minuten ||| of 30 minutes ||| 0-0 1-1 2-2
von 30 mg Risedronat einmal ||| doses of 30 mg risedronate ||| 2-0 0-1 1-2 2-3 4-3 3-4
von 30 mg sollte jedoch ||| of 30 mg should be ||| 0-0 1-1 4-1 2-2 3-3 3-4
von 30 ||| of 30 ||| 0-0 1-1
von 300 mg/m2 ||| of 300 mg/ m2 ||| 0-0 1-1 2-2 2-3
von 300 ||| of 300 ||| 0-0 1-1
von 300-360 mOsm/kg . ||| of 300-360 mOsm/ kg . ||| 0-0 1-1 1-2 2-2 2-3 3-4
von 300-360 mOsm/kg ||| of 300-360 mOsm/ kg ||| 0-0 1-1 1-2 2-2 2-3
von 35 % ||| 35 % ||| 1-0 2-1
von 35 ||| 35 ||| 1-0
von 45 mg ||| of 45 mg ||| 0-0 1-1 2-2
von 45 ||| of 45 ||| 0-0 1-1
von 5 mg Aclasta . ||| of 5 mg Aclasta . ||| 0-0 1-1 2-2 3-3 4-4
von 5 mg Aclasta ||| of 5 mg Aclasta ||| 0-0 1-1 2-2 3-3
von 5 mg Zoledronsäure ||| of 5 mg zoledronic acid ||| 0-0 1-1 2-2 3-3 3-4
von 5 mg ||| of 5 mg ||| 0-0 1-1 2-2
von 5 ||| of 5 ||| 0-0 1-1
von 5,25 mg ( 0,7 ||| of 5.25 mg ( 0.7 ||| 0-0 1-1 2-2 3-3 4-4
von 5,25 mg ( ||| of 5.25 mg ( ||| 0-0 1-1 2-2 3-3
von 5,25 mg ||| of 5.25 mg ||| 0-0 1-1 2-2
von 5,25 ||| of 5.25 ||| 0-0 1-1
von 50 I.E./kg zweimal ||| of 50 IU/ kg 2 ||| 0-0 1-1 2-2 2-3 3-4
von 50 I.E./kg ||| of 50 IU/ kg ||| 0-0 1-1 2-2 2-3
von 50 ||| of 50 ||| 0-0 1-1
von 50-95 Jahren ||| aged ||| 2-0
von 517 bis ||| ranging from 517 to ||| 0-0 0-1 1-2 2-3
von 517 ||| ranging from 517 ||| 0-0 0-1 1-2
von 6-7,5 und eine Osmolalität ||| of 6-7.5 and an osmolality ||| 0-0 1-1 2-2 3-3 4-4
von 6-7,5 und eine ||| of 6-7.5 and an ||| 0-0 1-1 2-2 3-3
von 6-7,5 und ||| of 6-7.5 and ||| 0-0 1-1 2-2
von 6-7,5 ||| of 6-7.5 ||| 0-0 1-1
von 60 Tagen nach Erreichen ||| Within 60 days of ||| 3-0 1-1 2-2 3-2 0-3
von 60 Tagen nach ||| Within 60 days of ||| 3-0 1-1 2-2 3-2 0-3
von 60 Tagen wenn ein ||| 60 days of an ||| 1-0 2-1 0-2 3-3 4-3
von 60 Tagen ||| 60 days of ||| 1-0 2-1 0-2
von 600 I.E./kg ||| of 600 IU/ kg ||| 0-0 1-1 2-2 2-3
von 600 ||| of 600 ||| 0-0 1-1
von 65 auf 200 kg ||| from 65 to 200 kg ||| 0-0 1-1 2-2 3-3 4-4
von 65 auf 200 ||| from 65 to 200 ||| 0-0 1-1 2-2 3-3
von 65 auf ||| from 65 to ||| 0-0 1-1 2-2
von 65 ||| from 65 ||| 0-0 1-1
von 7,9 % für beide ||| of 7.9 % for both ||| 0-0 1-1 2-2 3-3 4-4
von 7,9 % für ||| of 7.9 % for ||| 0-0 1-1 2-2 3-3
von 7,9 % ||| of 7.9 % ||| 0-0 1-1 2-2
von 7,9 ||| of 7.9 ||| 0-0 1-1
von 789 Patienten berechnet ||| of 789 patients ||| 0-0 1-1 3-1 2-2
von 80 bis 375 ||| levels of 80 to 375 ||| 0-1 1-2 2-3 3-4
von 80 bis 375 ||| of 80 to 375 ||| 0-0 1-1 2-2 3-3
von 80 bis ||| levels of 80 to ||| 0-1 1-2 2-3
von 80 bis ||| of 80 to ||| 0-0 1-1 2-2
von 80 ||| levels of 80 ||| 0-1 1-2
von 80 ||| of 80 ||| 0-0 1-1
von ABILIFY Injektionslösung ||| ABILIFY solution for injection ||| 0-0 1-0 2-1 2-2 2-3
von ABILIFY Injektionslösung ||| of ABILIFY solution for injection ||| 0-0 1-1 2-2 2-3 2-4
von ABILIFY Injektionslösung ||| receiving ABILIFY solution for injection ||| 0-1 1-1 2-2 2-3 2-4
von ABILIFY Jeder ml ||| of ABILIFY Each ml of ||| 0-0 1-1 2-2 3-3 2-4
von ABILIFY zu ändern . ||| of ABILIFY . ||| 0-0 1-1 2-1 3-1 4-2
von ABILIFY zu ändern ||| of ABILIFY ||| 0-0 1-1 2-1 3-1
von ABILIFY ||| ABILIFY ||| 0-0 1-0
von ABILIFY ||| ABILIFY ||| 1-0
von ABILIFY ||| of ABILIFY ||| 0-0 1-1
von ABILIFY ||| receiving ABILIFY ||| 0-1 1-1
von ACOMPLIA , Rimonabant , ||| ACOMPLIA , rimonabant , ||| 0-0 1-0 2-1 3-2 2-3 4-3
von ACOMPLIA , Rimonabant , ||| in ACOMPLIA , rimonabant , ||| 0-1 1-1 2-2 3-3 2-4 4-4
von ACOMPLIA gegenüber ||| ACOMPLIA ||| 0-0 1-0
von ACOMPLIA mit Arzneimitteln ||| taking ACOMPLIA with some medicines ||| 0-0 1-1 2-2 3-3 3-4
von ACOMPLIA mit ||| taking ACOMPLIA with ||| 0-0 1-1 2-2
von ACOMPLIA wurden ||| of ACOMPLIA were ||| 0-0 1-1 2-2
von ACOMPLIA ||| ACOMPLIA ||| 0-0 1-0
von ACOMPLIA ||| as type 2 diabetes or ||| 1-0 0-2 1-4
von ACOMPLIA ||| in ACOMPLIA ||| 0-1 1-1
von ACOMPLIA ||| monitor ACOMPLIA ||| 0-0 0-1 1-1
von ACOMPLIA ||| of ACOMPLIA in ||| 0-0 1-1
von ACOMPLIA ||| of ACOMPLIA ||| 0-0 1-1
von ACOMPLIA ||| taking ACOMPLIA ||| 0-0 1-1
von Abilify und Placebo ||| of Abilify and placebo ||| 0-0 1-1 2-2 3-3
von Abilify und Placebo über ||| of Abilify and placebo over ||| 0-0 1-1 2-2 3-3 4-4
von Abilify und ||| of Abilify and ||| 0-0 1-1 2-2
von Abilify ||| of Abilify ||| 0-0 1-1
von Abraxane ( ||| of Abraxane ( ||| 0-0 1-1 2-2
von Abraxane als Erstlinienbehandlung ||| of Abraxane as first-line ||| 0-0 1-1 2-2 3-3
von Abraxane als ||| of Abraxane as ||| 0-0 1-1 2-2
von Abraxane mit einer Dosis ||| of Abraxane at dose levels ||| 0-0 1-1 2-2 3-2 3-3 4-3
von Abraxane mit einer Dosis ||| of Abraxane at dose ||| 0-0 1-1 2-2 3-2 3-3 4-3
von Abraxane wurde nicht ||| of Abraxane has not been ||| 0-0 1-1 2-2 3-3 2-4
von Abraxane wurde ||| of Abraxane has been ||| 0-0 1-1 2-2 2-3
von Abraxane wurden ||| of Abraxane were ||| 0-0 1-1 2-2
von Abraxane ||| Abraxane ||| 1-0
von Abraxane ||| of Abraxane ||| 0-0 1-1
von Abseamed bei Patienten mit ||| of Abseamed in patients at ||| 0-0 1-1 2-2 3-3 4-3 2-4
von Abseamed steigern . ||| of Abseamed . ||| 0-0 1-1 2-1 3-2
von Abseamed steigern ||| of Abseamed ||| 0-0 1-1 2-1
von Abseamed zwischen 17 und ||| of Abseamed between 17 and ||| 0-0 1-1 2-2 3-3 4-4
von Abseamed zwischen 17 ||| of Abseamed between 17 ||| 0-0 1-1 2-2 3-3
von Abseamed zwischen 25 und ||| of Abseamed between 25 and ||| 0-0 1-1 2-2 3-3 4-4
von Abseamed zwischen 25 ||| of Abseamed between 25 ||| 0-0 1-1 2-2 3-3
von Abseamed zwischen ||| of Abseamed between ||| 0-0 1-1 2-2
von Abseamed ||| of Abseamed ||| 0-0 1-1
von Aclasta 5 mg ||| of Aclasta 5 mg ||| 0-0 1-1 2-2 3-3
von Aclasta 5 ||| of Aclasta 5 ||| 0-0 1-1 2-2
von Aclasta : ||| given Aclasta : ||| 0-0 1-0 1-1 2-2
von Aclasta auftreten , kann ||| of Aclasta can be ||| 0-0 1-1 2-2 4-2 4-3
von Aclasta auftritt ( siehe ||| of Aclasta ( see ||| 0-0 1-1 3-2 4-3
von Aclasta auftritt ( ||| of Aclasta ( ||| 0-0 1-1 3-2
von Aclasta auftritt . ||| of Aclasta . ||| 0-0 1-1 3-2
von Aclasta auftritt ||| of Aclasta ||| 0-0 1-1
von Aclasta beachtet werden ||| given Aclasta ||| 0-0 1-0 1-1 2-1 3-1
von Aclasta bei Kindern und ||| of Aclasta in children and ||| 0-0 1-1 2-2 3-3 4-4
von Aclasta bei Kindern ||| of Aclasta in children ||| 0-0 1-1 2-2 3-3
von Aclasta bei ||| of Aclasta in ||| 0-0 1-1 2-2
von Aclasta durchgeführt ? ||| administer Aclasta ||| 1-0 2-0 1-1 3-1
von Aclasta herangezogen . ||| account when assessing Aclasta . ||| 0-0 0-1 2-2 1-3 3-4
von Aclasta herangezogen ||| account when assessing Aclasta ||| 0-0 0-1 2-2 1-3
von Aclasta merklich ab . ||| doses of Aclasta . ||| 2-0 0-1 1-2 2-2 3-2 4-3
von Aclasta merklich ab ||| doses of Aclasta ||| 2-0 0-1 1-2 2-2 3-2
von Aclasta siehe Abschnitt ||| of Aclasta , see section ||| 0-0 1-1 2-3 3-4
von Aclasta siehe ||| of Aclasta , see ||| 0-0 1-1 2-3
von Aclasta stellt ||| Aclasta ||| 1-0
von Aclasta treten ||| with Aclasta tend to ||| 0-0 1-1 2-2
von Aclasta treten ||| with Aclasta tend ||| 0-0 1-1 2-2
von Aclasta ||| Aclasta ||| 0-0 1-0
von Aclasta ||| Aclasta ||| 1-0
von Aclasta ||| given Aclasta ||| 0-0 1-0 1-1
von Aclasta ||| of Aclasta , ||| 0-0 1-1
von Aclasta ||| of Aclasta ||| 0-0 1-1
von Aclasta ||| with Aclasta ||| 0-0 1-1
von Actos . ||| of Actos . ||| 0-0 1-1 2-2
von Actos 15 mg Tabletten ||| in Actos 15mg tablets ||| 0-0 1-1 2-2 3-2 4-3
von Actos 15 mg Tabletten ||| of Actos 15mg tablets ||| 0-0 1-1 2-2 3-2 4-3
von Actos 15 mg ||| in Actos 15mg ||| 0-0 1-1 2-2 3-2
von Actos 15 mg ||| of Actos 15mg ||| 0-0 1-1 2-2 3-2
von Actos 30 mg Tabletten ||| in Actos 30mg tablets ||| 0-0 1-1 2-2 3-2 4-3
von Actos 30 mg Tabletten ||| of Actos 30mg tablets ||| 0-0 1-1 2-2 3-2 4-3
von Actos 30 mg ||| in Actos 30mg ||| 0-0 1-1 2-2 3-2
von Actos 30 mg ||| of Actos 30mg ||| 0-0 1-1 2-2 3-2
von Actos 45 mg Tabletten ||| in Actos 45mg tablets ||| 0-0 1-1 2-2 3-2 4-3
von Actos 45 mg Tabletten ||| of Actos 45mg tablets ||| 0-0 1-1 2-2 3-2 4-3
von Actos 45 mg ||| in Actos 45mg ||| 0-0 1-1 2-2 3-2
von Actos 45 mg ||| of Actos 45mg ||| 0-0 1-1 2-2 3-2
von Actos mit ||| Actos with ||| 1-0 0-1 2-1
von Actos und Insulin ||| of Actos and insulin ||| 0-0 1-1 2-2 3-3
von Actos und ||| of Actos and ||| 0-0 1-1 2-2
von Actos ||| Actos 15mg ||| 1-0 1-1
von Actos ||| Actos 30mg ||| 1-0 1-1
von Actos ||| Actos 45mg ||| 1-0 1-1
von Actos ||| Actos ||| 1-0
von Actos ||| in Actos ||| 0-0 1-1
von Actos ||| of Actos ||| 0-0 1-1
von Actraphane erforderlich machen . ||| of Actraphane . ||| 0-0 1-1 2-1 3-1 4-2
von Actraphane erforderlich machen ||| of Actraphane ||| 0-0 1-1 2-1 3-1
von Actraphane ||| Actraphane ||| 1-0
von Agitiertheit und Verhaltenstörungen ||| of agitation and disturbed behaviours ||| 0-0 1-1 3-1 2-2 1-3 1-4
von Agitiertheit/Verhaltenstörungen ||| agitation/ behavioural ||| 1-0 1-1
von Agitiertheit/Verhaltenstörungen ||| in agitation/ behavioural ||| 1-1 1-2
von Akathisie 6,2 % ||| of akathisia was 6.2 % ||| 0-0 1-1 1-2 2-3 3-4
von Akathisie 6,2 ||| of akathisia was 6.2 ||| 0-0 1-1 1-2 2-3
von Akathisie bei bipolaren Patienten ||| of akathisia in bipolar patients ||| 0-0 1-1 2-2 2-3 3-3 4-4
von Akathisie bei bipolaren Patienten ||| of akathisia in bipolar patients ||| 0-0 1-1 2-2 3-3 4-4
von Akathisie bei bipolaren ||| of akathisia in bipolar ||| 0-0 1-1 2-2 2-3 3-3
von Akathisie bei bipolaren ||| of akathisia in bipolar ||| 0-0 1-1 2-2 3-3
von Akathisie bei ||| of akathisia in ||| 0-0 1-1 2-2
von Akathisie ||| of akathisia was ||| 0-0 1-1 1-2
von Akathisie ||| of akathisia ||| 0-0 1-1
von Angioödemen und anaphylaktischen Reaktionen ||| of angioedema and anaphylactic reaction ||| 0-0 1-1 2-2 3-3 3-4 4-4
von Angioödemen und ||| of angioedema and ||| 0-0 1-1 2-2
von Angioödemen ||| of angioedema ||| 0-0 1-1
von Aripiprazol ) . ||| of aripiprazole ) . ||| 0-0 1-1 2-2 3-3
von Aripiprazol ) ||| of aripiprazole ) ||| 0-0 1-1 2-2
von Aripiprazol . ||| of aripiprazole . ||| 0-0 1-1 2-2
von Aripiprazol erklären . ||| of aripiprazole . ||| 0-0 1-1 2-1 3-2
von Aripiprazol erklären ||| of aripiprazole ||| 0-0 1-1 2-1
von Aripiprazol und ||| of aripiprazole and ||| 0-0 1-1 2-2
von Aripiprazol ||| aripiprazole ||| 1-0
von Aripiprazol ||| of aripiprazole ||| 0-0 1-1
von Arzneimitteln verstärken , die ||| of medicines used to ||| 0-0 1-1 2-1 2-2 3-3 4-3
von Arzneimitteln verstärken ||| of medicines used ||| 0-0 1-1 2-1 2-2
von Aufklärungspaketen ||| to ||| 0-0
von Bisphosphonaten ||| bisphosphonates in ||| 1-0
von Bisphosphonaten ||| bisphosphonates ||| 1-0
von Blutpfropfbildung/Blutgerinnungsstörungen ||| of blood clots/ blood ||| 0-0 1-1 1-2 1-3
von Bronchokonstriktion ||| of bronchoconstriction ||| 0-0 1-1
von CYP3A4 ( Ketoconazol ) ||| of CYP3A4 ( ketoconazole ) ||| 0-0 1-1 2-2 3-3 4-4
von CYP3A4 ( Ketoconazol ||| of CYP3A4 ( ketoconazole ||| 0-0 1-1 2-2 3-3
von CYP3A4 ( z.B . ||| of CYP3A4 ( e. g. ||| 0-0 1-1 2-2 3-3 3-4 4-4
von CYP3A4 ( z.B . ||| of CYP3A4 ( e. ||| 0-0 1-1 2-2 3-3 4-3
von CYP3A4 ( ||| of CYP3A4 ( ||| 0-0 1-1 2-2
von CYP3A4 , ||| of CYP3A4 , ||| 0-0 1-1 2-2
von CYP3A4 ||| of CYP3A4 ||| 0-0 1-1
von CYP3A4-Induktoren führt vermutlich ||| of CYP3A4 inducers is expected ||| 0-0 1-1 1-2 3-3 3-4
von CYP3A4-Induktoren führt ||| of CYP3A4 inducers ||| 0-0 1-1 1-2
von CYP3A4-Induktoren ||| of CYP3A4 inducers ||| 0-0 1-1 1-2
von Dehydro-Aripiprazol , ||| of dehydro-aripiprazole , ||| 0-0 1-1 2-2
von Dehydro-Aripiprazol stiegen um 77 ||| of dehydro-aripiprazole increased by 77 ||| 0-0 1-1 2-2 2-3 2-4 3-4 4-4
von Dehydro-Aripiprazol ||| of dehydro-aripiprazole ||| 0-0 1-1
von Diabetes gegenüber ||| of diabetes ||| 0-0 1-1
von Diabetes ||| of diabetes ||| 0-0 1-1
von Digoxin , Warfarin , ||| of digoxin , warfarin , ||| 0-0 1-1 2-2 3-3 4-4
von Digoxin , Warfarin ||| of digoxin , warfarin ||| 0-0 1-1 2-2 3-3
von Digoxin , ||| of digoxin , ||| 0-0 1-1 2-2
von Digoxin ||| of digoxin ||| 0-0 1-1
von Dosisanpassungen bei Patienten mit ||| dose modifications in patients with ||| 0-0 1-1 2-2 3-3 4-4
von Dosisanpassungen bei Patienten ||| dose modifications in patients ||| 0-0 1-1 2-2 3-3
von Dosisanpassungen bei ||| dose modifications in ||| 0-0 1-1 2-2
von Dosisanpassungen ||| dose modifications ||| 0-0 1-1
von EPS 19 % bei ||| of EPS was 19 % ||| 0-0 1-1 1-2 2-3 4-3 3-4
von EPS einschließlich Parkinsonismus , ||| of EPS including parkinsonism , ||| 0-0 1-1 2-2 3-3 4-4
von EPS einschließlich Parkinsonismus ||| of EPS including parkinsonism ||| 0-0 1-1 2-2 3-3
von EPS einschließlich ||| of EPS including ||| 0-0 1-1 2-2
von EPS ||| of EPS was ||| 0-0 1-1 1-2
von EPS ||| of EPS ||| 0-0 1-1
von Einzeldosen . ||| blisters . ||| 0-0 1-0 2-1
von Einzeldosen ||| blisters ||| 0-0 1-0
von Epoetin alfa auf ||| of epoetin alfa on ||| 0-0 1-1 2-2 3-3
von Epoetin alfa ist sehr ||| of epoetin alfa is very ||| 0-0 1-1 2-2 3-3 4-4
von Epoetin alfa ist ||| of epoetin alfa is ||| 0-0 1-1 2-2 3-3
von Epoetin alfa kann ||| of epoetin alfa may ||| 0-0 1-1 2-2 3-3
von Epoetin alfa und anderen ||| of Epoetin alfa and other ||| 0-0 1-1 2-2 3-3 4-4
von Epoetin alfa und ||| of Epoetin alfa and ||| 0-0 1-1 2-2 3-3
von Epoetin alfa wurde ||| of epoetin alfa has been ||| 0-0 1-1 2-2 3-3 3-4
von Epoetin alfa ||| of Epoetin alfa ||| 0-0 1-1 2-2
von Epoetin alfa ||| of epoetin alfa in ||| 0-0 1-1 2-2
von Epoetin alfa ||| of epoetin alfa ||| 0-0 1-1 1-2 2-2
von Epoetin alfa ||| of epoetin alfa ||| 0-0 1-1 2-2
von Epoetin ||| of Epoetin ||| 0-0 1-1
von Epoetin ||| of epoetin ||| 0-0 1-1
von Erwachsenen , bei denen ||| of adult patients scheduled ||| 0-0 1-1 3-2 4-3
von Erwachsenen , bei ||| of adult patients ||| 0-0 1-1 3-2
von Erwachsenen , ||| of adult ||| 0-0 1-1
von Erwachsenen ||| of adult ||| 0-0 1-1
von Erythrozyten aus Vorläuferzellen ||| of erythrocytes from precursors ||| 0-0 1-1 2-2 3-3
von Erythrozyten aus ||| of erythrocytes from ||| 0-0 1-1 2-2
von Erythrozyten ||| of erythrocytes ||| 0-0 1-1
von Fahrzeugen zu treffen . ||| of the warning signs of ||| 0-0 2-1 1-2 2-2 3-3 3-4 4-4
von Fahrzeugen zu ||| of the warning ||| 0-0 2-1 1-2 2-2
von Geschlechtshormonen ||| of sex ||| 0-0 1-1
von Glucose ||| of glucose ||| 0-0 1-1
von Hüftfrakturen ||| hip fracture event ||| 1-0 0-1 1-1 1-2
von Ihrem Arzt ||| by your doctor ||| 0-0 1-0 1-1 2-2
von Ihrem ||| by your ||| 0-0 1-0 1-1
von In-vivo- ||| battery of ||| 1-0 0-1
von Insulin verstärken und verlängern ||| hypoglycaemic effect of insulin ||| 0-0 1-0 2-0 2-1 2-2 3-2 4-3
von Insulin verstärken und ||| hypoglycaemic effect of ||| 0-0 1-0 2-0 2-1 2-2 3-2
von Insulin ||| of insulin ||| 0-0 1-1
von Insulin-Suspensionen zur Injektion ||| of insulin suspensions for injection ||| 0-0 1-1 1-2 2-3 3-4
von Insulin-Suspensionen zur ||| of insulin suspensions for ||| 0-0 1-1 1-2 2-3
von Insulin-Suspensionen ||| of insulin suspensions ||| 0-0 1-1 1-2
von Insulinprodukten mit schneller ||| of insulin products with fast ||| 0-0 1-1 1-2 2-3 1-4 3-4
von Ketoconazol oder anderen ||| of ketoconazole or other ||| 0-0 1-1 2-2 3-3
von Ketoconazol oder ||| of ketoconazole or ||| 0-0 1-1 2-2
von Ketoconazol ||| of ketoconazole ||| 0-0 1-1
von Kindern aufbewahren . ||| of children . ||| 0-0 1-1 2-1 3-2
von Kindern aufbewahren ||| of children ||| 0-0 1-1 2-1
von Knochengewebe ) ||| of bone tissue ) ||| 0-0 1-1 1-2 2-3
von Knochengewebe ||| of bone tissue ||| 0-0 1-1 1-2
von Knochenumbaumarkern auf . ||| with repeated annual dosing . ||| 0-0 1-1 1-2 1-3 3-4
von Knochenumbaumarkern auf ||| with repeated annual dosing ||| 0-0 1-1 1-2 1-3
von Knochenumbaumarkern ||| with repeated annual dosing ||| 0-0 1-1 1-2 1-3
von Komorbiditäten ||| to co- morbidities ||| 0-0 1-1 0-2 1-2
von Krampfanfällen zwischen eim ||| be stopped . du ||| 0-0 1-1 3-2 3-3
von Krampfanfällen zwischen ||| be stopped ||| 0-0 1-1
von Krampfanfällen ||| be stopped ||| 0-0 1-1
von Krampfanfällen ||| of seizure ||| 0-0 1-1
von Krebszellen zum ||| of cancer cells to ||| 0-0 1-1 1-2 2-3
von Krebszellen ||| of cancer cells ||| 0-0 1-1 1-2
von Kühlelementen lagern . ||| cooling element . ||| 0-0 1-0 1-1 2-1 3-2
von Kühlelementen lagern ||| cooling element ||| 0-0 1-0 1-1 2-1
von Luteinisierungshormon-Releasinghormon-Antagonisten ( LH-RHa ) ||| agonists ( LH-RHas ) ||| 1-0 2-1 1-2 3-2 4-3
von Luteinisierungshormon-Releasinghormon-Antagonisten ( LH-RHa ||| agonists ( LH-RHas ||| 1-0 2-1 1-2 3-2
von M-II minimal ausgeprägt ist ||| of M-II is minimal ||| 0-0 1-1 4-2 2-3 3-3
von M-II ||| of M-II ||| 0-0 1-1
von MNS ||| of NMS ||| 0-0 1-1
von Maschinen ) , ||| to avoid ||| 0-0 1-1 2-1
von Maschinen ) ||| to avoid ||| 0-0 1-1 2-1
von Maschinen nicht beeinträchtigen . ||| operate machinery . ||| 0-0 1-0 2-0 3-0 3-1 4-2
von Maschinen nicht beeinträchtigen ||| operate machinery ||| 0-0 1-0 2-0 3-0 3-1
von Metformin mit einem Sulfonylharnstoff ||| of metformin and a sulphonylurea ||| 0-0 1-1 2-3 3-3 3-4 4-4
von Metformin unzureichend eingestellt ist ||| of monotherapy with metformin ||| 0-0 2-1 3-2 1-3 3-3 4-3
von Metformin ||| of metformin and ||| 0-0 1-1
von Metformin ||| of metformin ||| 0-0 1-1
von Missbildungen und ||| of malformations and ||| 0-0 1-1 2-2
von Missbildungen ||| of malformations ||| 0-0 1-1
von Mitratapid ( Muttersubstanz ||| of mitratapide ( parent ||| 0-0 1-1 2-2 3-3
von Mitratapid ( ||| of mitratapide ( ||| 0-0 1-1 2-2
von Mitratapid ||| of mitratapide ||| 0-0 1-1
von Morbus Paget ||| of Paget s disease ||| 0-0 1-1 1-2 2-2 2-3
von Nervenzellen im ||| of nerve cells in the ||| 0-0 1-1 1-2 2-3 2-4
von Nervenzellen ||| of nerve cells ||| 0-0 1-1 1-2
von Orlistat , ||| of orlistat , ethanol ||| 0-0 1-1 2-2 1-3
von Osteoporose ||| osteoporosis ||| 1-0
von Paclitaxel , die wesentlich ||| of paclitaxel , which ||| 0-0 1-1 2-2 3-3
von Paclitaxel , die ||| of paclitaxel , which ||| 0-0 1-1 2-2 3-3
von Paclitaxel , ||| of paclitaxel , ||| 0-0 1-1 2-2
von Paclitaxel bei Patienten im ||| of paclitaxel in patients ||| 0-0 1-1 2-2 4-2 2-3 3-3
von Paclitaxel durch ||| of paclitaxel ||| 0-0 2-0 1-1
von Paclitaxel enthalten ||| of paclitaxel contain ||| 0-0 1-1 2-2
von Paclitaxel hin . ||| of paclitaxel . ||| 0-0 1-1 3-2
von Paclitaxel hin ||| of paclitaxel ||| 0-0 1-1
von Paclitaxel nach der Abraxane-Gabe ||| of paclitaxel following Abraxane administration ||| 0-0 3-0 1-1 2-2 4-3 3-4
von Paclitaxel wird ||| of paclitaxel is ||| 0-0 1-1 2-2
von Paclitaxel wurde nicht ||| of paclitaxel has not been ||| 0-0 1-1 2-2 3-3 2-4
von Paclitaxel ||| of paclitaxel has ||| 0-0 0-1 1-1 1-2
von Paclitaxel ||| of paclitaxel ||| 0-0 1-1
von Paracetamol oder ||| paracetamol or ||| 1-0 2-1
von Paracetamol ||| paracetamol ||| 1-0
von Patienten mit den ||| of patients with the ||| 0-0 1-1 2-2 3-3
von Patienten mit schwarzer Hautfarbe ||| of Black patients ||| 0-0 3-1 4-1 1-2 2-2
von Patienten mit ||| in patients with ||| 2-0 1-1 2-2
von Patienten mit ||| number of patients . ||| 0-0 0-1 1-2 2-2
von Patienten mit ||| number of patients ||| 0-0 0-1 1-2 2-2
von Patienten mit ||| of patients with ||| 0-0 1-1 2-2
von Patienten ||| of patients ||| 0-0 1-1
von Patienten ||| patients ||| 1-0
von Patienten ||| who are breast ||| 1-0 0-1 1-2
von Pioglitazon ( siehe Abschnitt ||| of pioglitazone ( see section ||| 0-0 1-1 2-2 3-3 4-4
von Pioglitazon ( siehe ||| of pioglitazone ( see ||| 0-0 1-1 2-2 3-3
von Pioglitazon ( ||| of pioglitazone ( ||| 0-0 1-1 2-2
von Pioglitazon und dem ||| pioglitazone and ||| 1-0 2-1
von Pioglitazon und ||| of pioglitazone ||| 0-0 1-1
von Pioglitazon und ||| pioglitazone and ||| 1-0 2-1
von Pioglitazon während der ||| of pioglitazone during ||| 0-0 1-1 2-2 3-2
von Pioglitazon ||| of pioglitazone ||| 0-0 1-1
von Pioglitazon ||| pioglitazone ||| 1-0
von Placebo ( ||| of placebo ( ||| 0-0 1-1 2-2
von Placebo ||| of placebo ||| 0-0 1-1
von Placebo ||| placebo ||| 1-0
von Rimonabant bei der Behandlung ||| of rimonabant treatment in ||| 0-0 1-1 4-2 2-3 3-3
von Rimonabant ist nicht ||| of rimonabant has not ||| 0-0 1-1 1-2 2-2 3-3
von Rimonabant ist ||| of rimonabant has ||| 0-0 1-1 1-2 2-2
von Rimonabant wurde in ||| of rimonabant was found in ||| 0-0 1-1 2-2 3-3 3-4
von Rimonabant wurde ||| of rimonabant was ||| 0-0 1-1 2-2
von Rimonabant ||| failure of ||| 0-1 1-1
von Rimonabant ||| of rimonabant ||| 0-0 1-1
von Rimonabant ||| of ||| 0-0 1-0
von Schlaganfällen oder ||| of stroke or ||| 0-0 1-1 2-2
von Schlaganfällen ||| of stroke ||| 0-0 1-1
von Spaltungs- ( ||| of cleavage ( ||| 0-0 1-1 2-2
von Spaltungs- ||| of cleavage ||| 0-0 1-1
von Studien mit ||| excluded in the studies for ||| 1-1 2-1 1-3
von Studien mit ||| excluded in the studies ||| 1-1 2-1 1-3
von Studien mit ||| in the studies for ||| 1-0 2-0 1-2
von Studien mit ||| in the studies ||| 1-0 2-0 1-2
von Symptomen ||| of symptoms ||| 0-0 1-1
von Untergruppen ||| analyses ||| 1-0
von Untersuchungen zur Genotoxizität wurde ||| of standard genotoxicity tests , ||| 0-0 1-1 2-1 3-2 3-3 4-3
von Untersuchungen zur Genotoxizität wurde ||| of standard genotoxicity tests ||| 0-0 1-1 2-1 3-2 3-3 4-3
von Untersuchungen zur ||| of standard ||| 0-0 1-1 2-1
von Vantas , ||| Vantas ||| 1-0
von Vantas , ||| unique Vantas ||| 1-1
von Vantas wurde hinreichend ||| of Vantas is sufficiently ||| 0-0 1-1 3-3
von Vantas wurde ||| of Vantas is ||| 0-0 1-1
von Vantas wurde ||| of Vantas ||| 0-0 1-1
von Vantas ||| Vantas ||| 1-0
von Vantas ||| of Vantas is ||| 0-0 1-1
von Vantas ||| of Vantas ||| 0-0 1-1
von Vantas ||| unique Vantas ||| 1-1
von Wirbelkörperfrakturen ||| of vertebral fractures did ||| 0-0 1-1 1-2
von Wirbelkörperfrakturen ||| of vertebral fractures ||| 0-0 1-1 1-2
von Zoledronsäure bei ||| of zoledronic acid in ||| 0-0 1-1 1-2 2-3
von Zoledronsäure ||| of zoledronic acid ||| 0-0 1-1 1-2
von Zoledronsäure ||| zoledronic acid ||| 1-0 1-1
von anaphylaktischer Reaktion/Schock ||| of anaphylactic reaction/ shock ||| 0-0 2-1 1-2 2-2 2-3
von anderen Arzneimitteln auf ||| other medicinal products to affect ||| 1-0 0-1 1-1 2-2 3-3 3-4
von anderen Arzneimitteln ||| other medicinal products ||| 1-0 0-1 1-1 2-2
von anderen ||| of other ||| 0-0 1-1
von anderen ||| other medicinal ||| 1-0 0-1 1-1
von angemessenen ||| appropriate ||| 1-0
von annähernd 6 Stunden ||| of approximately 6 hours ||| 0-0 1-1 2-2 3-3
von annähernd 6 ||| of approximately 6 ||| 0-0 1-1 2-2
von annähernd ||| of approximately ||| 0-0 1-1
von den ||| recovery from the ||| 0-0 0-1 1-2
von denen ||| of whom ||| 0-0 1-1
von der Konzentration ||| concentration ||| 2-0
von der veröffentlichten Literatur ||| on the published literature ||| 2-0 1-1 2-2 3-3
von der veröffentlichten ||| on the published ||| 2-0 1-1 2-2
von der ||| of ||| 0-0 1-0
von der ||| the ||| 1-0
von drei ||| three ||| 1-0
von durch Cytochrom-P450-Enzymsysteme metabolisierten ||| in ||| 1-0
von durch Cytochrom-P450-Enzymsysteme ||| in ||| 1-0
von durch ||| in ||| 1-0
von einer höheren Dosis profitieren ||| benefit from a higher dose ||| 0-0 2-0 2-1 1-2 2-3 4-3 3-4
von fettlöslichen Arzneimitteln ||| of lipid soluble drugs ||| 0-0 1-1 1-2 2-2 1-3
von fortgeschrittenem ||| of advanced prostate cancer ||| 0-0 1-1 1-2 1-3
von gesteigerter Unruhe und Verhaltensstörungen ||| of agitation and disturbed behaviours ||| 0-0 1-1 2-1 3-2 4-3 4-4
von gesteigerter Unruhe und ||| of agitation and ||| 0-0 1-1 2-1 3-2
von gesteigerter Unruhe ||| of agitation ||| 0-0 1-1 2-1
von injizierbaren ||| of injectable ||| 0-0 1-1
von klinischen Frakturen betrug 7,5 ||| of clinical fractures was 7.5 ||| 0-0 1-1 2-2 3-3 4-4
von klinischen Frakturen betrug ||| of clinical fractures was ||| 0-0 1-1 2-2 3-3
von klinischen Frakturen nach einer ||| of clinical fractures following a ||| 0-0 1-1 2-2 3-3 4-4
von klinischen Frakturen nach ||| of clinical fractures following ||| 0-0 1-1 2-2 3-3
von klinischen Frakturen ||| of clinical fractures ||| 0-0 1-1 2-2
von klinischen Frakturen über die ||| of clinical fractures over the ||| 0-0 1-1 2-2 3-3 4-4
von klinischen Frakturen über ||| of clinical fractures over ||| 0-0 1-1 2-2 3-3
von klinischen ||| of clinical ||| 0-0 1-1
von lösungsmittelhaltigem Paclitaxel 175 mg/m2 ||| solvent-based paclitaxel 175 mg/ m2 ||| 1-0 0-1 2-1 3-2 4-3 4-4
von lösungsmittelhaltigem Paclitaxel 175 ||| solvent-based paclitaxel 175 ||| 1-0 0-1 2-1 3-2
von lösungsmittelhaltigem Paclitaxel ||| solvent-based paclitaxel ||| 1-0 0-1 2-1
von medizinischem ||| may be injected by ||| 0-0 0-1 1-2 1-3
von multipler ||| of multiple medicinal ||| 0-0 1-1 1-2
von neuen ||| in new ||| 1-1
von neuen ||| new ||| 1-0
von peripherer Neuropathie zum Abklingen ||| of peripheral neuropathy to resolution ||| 0-0 1-1 2-1 2-2 3-3 4-4
von peripherer Neuropathie zum ||| of peripheral neuropathy to ||| 0-0 1-1 2-1 2-2 3-3
von peripherer Neuropathie ||| of peripheral neuropathy ||| 0-0 1-1 2-1 2-2
von rekombinantem humanen Erythropoetin ||| of recombinant human erythropoietin ||| 0-0 1-1 2-1 2-2 3-3
von rekombinantem humanen ||| of recombinant human ||| 0-0 1-1 2-1 2-2
von reversiblen Methoden ||| methods ||| 1-0 2-0
von roten ||| with ||| 0-0 1-0
von unerwünschten ||| of adverse ||| 0-0 1-1
von unter 18 Monaten ||| less than 18 months of ||| 1-0 1-1 1-2 2-2 3-3 0-4
von unverändertem Pioglitazon ||| of unchanged pioglitazone ||| 0-0 1-1 2-2
von unverändertem ||| of unchanged ||| 0-0 1-1
von weißen , ||| white , ||| 1-0 2-1
von weißen ||| white ||| 1-0
von zwei sicherheitspharmakologischen Studien beobachtet ||| of two safety pharmacology studies ||| 0-0 1-1 2-2 2-3 3-4 4-4
von zwei sicherheitspharmakologischen ||| of two safety pharmacology ||| 0-0 1-1 2-2 2-3
von zwei ||| of two ||| 0-0 1-1
von ||| . of ||| 0-1
von ||| 2 diabetes ||| 0-0
von ||| 2 ||| 0-0
von ||| account when ||| 0-0 0-1
von ||| are ||| 0-0
von ||| be ||| 0-0
von ||| dose ||| 0-0
von ||| for ||| 0-0
von ||| from ||| 0-0
von ||| greater than ||| 0-0
von ||| greater ||| 0-0
von ||| have ||| 0-0
von ||| in ||| 0-0
von ||| infusions of ||| 0-1
von ||| is not ||| 0-0
von ||| is ||| 0-0
von ||| levels of ||| 0-1
von ||| may be ||| 0-0 0-1
von ||| may result in loss of ||| 0-0 0-1 0-4
von ||| may ||| 0-0
von ||| months of ||| 0-1
von ||| number of ||| 0-0 0-1
von ||| of on ||| 0-0
von ||| of spine ||| 0-0
von ||| of such ||| 0-0
von ||| of the ||| 0-0
von ||| of the ||| 0-0 0-1
von ||| of whom ||| 0-0
von ||| of ||| 0-0
von ||| out of ||| 0-0 0-1
von ||| over ||| 0-0
von ||| presence of ||| 0-0 0-1
von ||| ranging from ||| 0-0 0-1
von ||| recovery from ||| 0-0 0-1
von ||| taking ||| 0-0
von ||| ten ||| 0-0
von ||| than its ||| 0-0
von ||| than ||| 0-0
von ||| to ||| 0-0
von ||| type 2 diabetes ||| 0-1
von ||| type 2 ||| 0-1
von ||| von ||| 0-0
von ||| was ||| 0-0
von ||| with ||| 0-0
von über 12 ||| of greater than 12 ||| 0-0 1-1 1-2 2-3
von über ||| of greater than ||| 0-0 1-1 1-2
vor , die ||| established related to conditions other ||| 0-0 2-1 0-2 2-2
vor , die ||| established related to conditions ||| 0-0 2-1 0-2 2-2
vor , die ||| established related to ||| 0-0 2-1 0-2 2-2
vor , um Rückschlüsse ||| to draw conclusions regarding ||| 0-0 2-1 2-2 3-3
vor , um ||| to draw conclusions ||| 0-0 2-1 2-2
vor , ||| to ||| 0-0
vor . ||| . ||| 1-0
vor Austrocknung zu schützen . ||| to prevent dehydration . ||| 0-0 1-1 2-1 1-2 3-2 4-3
vor Austrocknung zu schützen ||| to prevent dehydration ||| 0-0 1-1 2-1 1-2 3-2
vor Beginn der ||| prior to the initiation of ||| 0-0 0-1 2-2 1-3 2-4
vor Einnahme ||| diluted ||| 0-0 1-0
vor Feuchtigkeit zu schützen . ||| to protect from moisture . ||| 0-0 0-1 1-1 1-2 2-3 3-3 4-4
vor Feuchtigkeit zu schützen . ||| to protect from moisture . ||| 0-0 0-1 1-1 3-2 2-3 3-3 4-4
vor Feuchtigkeit zu schützen ||| to protect from moisture ||| 0-0 0-1 1-1 1-2 2-3 3-3
vor Feuchtigkeit zu schützen ||| to protect from moisture ||| 0-0 0-1 1-1 3-2 2-3 3-3
vor Feuchtigkeit ||| to protect from ||| 0-0 0-1 1-1 1-2
vor Feuchtigkeit ||| to protect ||| 0-0 0-1 1-1
vor Ihrer Operation verabreicht . ||| before your surgery . ||| 0-0 1-1 2-2 3-3 4-3
vor Ihrer Operation ||| before your surgery ||| 0-0 1-1 2-2
vor Ihrer ||| before your ||| 0-0 1-1
vor Licht zu schützen . ||| to protect from light . ||| 0-0 0-1 1-1 1-2 2-3 3-3 4-4
vor Licht zu schützen . ||| to protect from light . ||| 0-0 0-1 1-1 2-1 3-2 3-3 4-4
vor Licht zu schützen . ||| to protect from light . ||| 0-0 0-1 1-1 3-2 2-3 3-3 4-4
vor Licht zu schützen ||| to protect from light ||| 0-0 0-1 1-1 1-2 2-3 3-3
vor Licht zu schützen ||| to protect from light ||| 0-0 0-1 1-1 2-1 3-2 3-3
vor Licht zu schützen ||| to protect from light ||| 0-0 0-1 1-1 3-2 2-3 3-3
vor Licht zu ||| to protect ||| 0-0 0-1 1-1 2-1
vor Licht ||| to protect from ||| 0-0 0-1 1-1 1-2
vor Licht ||| to protect ||| 0-0 0-1 1-1
vor allem ||| mainly ||| 1-0
vor allem ||| to act mainly ||| 0-0 1-1 1-2
vor als bei Patienten mit ||| than in those with ||| 1-0 2-1 1-2 3-2 4-3
vor als bei Patienten ||| than in those ||| 1-0 2-1 1-2 3-2
vor dem Frühstück eingenommen . ||| , before breakfast . ||| 0-1 2-1 1-2 2-2 3-2 4-3
vor dem Frühstück eingenommen . ||| before breakfast . ||| 0-0 2-0 1-1 2-1 3-1 4-2
vor dem Frühstück eingenommen ||| , before breakfast ||| 0-1 2-1 1-2 2-2 3-2
vor dem Frühstück eingenommen ||| before breakfast ||| 0-0 2-0 1-1 2-1 3-1
vor dem operativen Eingriff erhalten ||| prior to surgery ||| 0-0 1-0 2-0 4-0 0-1 3-2
vor dem operativen ||| prior to ||| 0-0 1-0 2-0 0-1
vor der Verwendung rekonstituiert ||| for reconstitution before use ||| 2-0 0-1 1-1 0-2 3-2 2-3
vor der ||| before ||| 0-0
vor einer Operation Eigenblut ||| donating your own blood before ||| 0-0 2-1 3-2 2-3 0-4 2-4 3-4
vor kurzem die ||| recently ||| 0-0 1-0
vor kurzem eingenommen haben ||| have recently taken any other ||| 3-0 0-1 1-1 2-2 1-3 1-4
vor kurzem eingenommen ||| recently taken any other ||| 0-0 1-0 2-1 1-2 1-3
vor kurzem erlittenen niedrig-traumatischen Hüftfraktur ||| recent low-trauma hip fracture , ||| 0-0 1-0 2-0 2-1 3-1 4-2 2-3
vor kurzem erlittenen niedrig-traumatischen Hüftfraktur ||| recent low-trauma hip fracture ||| 0-0 1-0 2-0 2-1 3-1 4-2 2-3
vor kurzem erlittenen niedrig-traumatischen Hüftfraktur ||| recent low-trauma hip fracture ||| 0-0 1-0 2-0 2-1 3-1 4-2 4-3
vor kurzem erlittenen niedrig-traumatischen ||| recent low-trauma ||| 0-0 1-0 2-0 2-1 3-1
vor kurzem ||| recently ||| 0-0 1-0
vor mehr ||| more ||| 1-0
vor und ||| before and ||| 0-0 1-1
vor ||| before ||| 0-0
vor ||| prior to ||| 0-0 0-1
vor ||| prior ||| 0-0
vor ||| to ||| 0-0
vorbestehender Nierenerkrankung ||| pre-existing ||| 0-0
vorbestehender ||| pre-existing ||| 0-0
vorbestehender ||| reports of ||| 0-0
vorbestehender ||| reports ||| 0-0
vordere Bauchwand gegeben . ||| abdominal wall . ||| 0-0 1-0 1-1 2-1 3-2
vordere Bauchwand gegeben . ||| anterior abdominal wall . ||| 0-0 1-0 1-1 1-2 2-2 3-3
vordere Bauchwand gegeben ||| abdominal wall ||| 0-0 1-0 1-1 2-1
vordere Bauchwand gegeben ||| anterior abdominal wall ||| 0-0 1-0 1-1 1-2 2-2
vorgefüllte Fertigpens zu je 3 ||| pre-filled pens x 3 ||| 0-0 0-1 1-1 2-1 3-2 4-3
vorgefüllte Fertigpens zu je ||| pre-filled pens x ||| 0-0 0-1 1-1 2-1 3-2
vorgefüllte Fertigpens zu ||| pre-filled pens ||| 0-0 0-1 1-1 2-1
vorgenommen werden . ||| be applied . ||| 1-0 0-1 1-1 2-2
vorgenommen werden . ||| be applied . ||| 1-0 0-1 2-2
vorgenommen werden . ||| therefore be applied . ||| 0-0 1-1 0-2 2-3
vorgenommen werden ||| be applied ||| 1-0 0-1
vorgenommen werden ||| be applied ||| 1-0 0-1 1-1
vorgenommen werden ||| therefore be applied ||| 0-0 1-1 0-2
vorgenommen ||| applied ||| 0-0
vorhanden sein . ||| be ensured . ||| 1-0 0-1 2-2
vorhanden sein ||| be ensured ||| 1-0 0-1
vorhanden ||| ensured ||| 0-0
vorher noch keine ||| not ||| 1-0 2-0
vorhergehenden Insulin waren . ||| their previous insulin . ||| 0-0 0-1 2-1 1-2 3-3
vorhergehenden Insulin waren ||| their previous insulin ||| 0-0 0-1 2-1 1-2
vorherige Steroidgabe oder ||| steroid pre- treatment or ||| 0-0 1-1 1-2 2-3
vorherige Steroidgabe ||| steroid pre- treatment ||| 0-0 1-1 1-2
vorherige ||| steroid ||| 0-0
vorliegen . ||| group . ||| 0-0 1-1
vorliegen ||| group ||| 0-0
vorsichtig eingestellt werden . ||| be managed cautiously . ||| 2-0 0-1 1-1 1-2 2-2 3-3
vorsichtig eingestellt werden ||| be managed cautiously ||| 2-0 0-1 1-1 1-2 2-2
vorwiegend ||| mainly ||| 0-0
vorwiegend über die Fäzes . ||| mainly via the faeces . ||| 0-0 1-1 2-2 3-3 4-4
vorwiegend über die Fäzes ||| mainly via the faeces ||| 0-0 1-1 2-2 3-3
vorwiegend über die ||| mainly via the ||| 0-0 1-1 2-2
vorwiegend über ||| mainly via ||| 0-0 1-1
vorzugsweise entweder ||| preferably ||| 0-0 1-0
vorzulegen , wenn ||| monthly intervals unless ||| 0-0 1-1 2-2
vorzulegen , ||| monthly intervals ||| 0-0 1-1
vorzulegen ||| monthly ||| 0-0
vorzuzeigen . ||| physician . ||| 0-0 1-1
vorzuzeigen ||| physician ||| 0-0
vorübergehend , ||| transient , typically ||| 0-0 1-1 1-2
vorübergehend . ||| transient . ||| 0-0 1-1
vorübergehend und asymptomatisch , wurden ||| transient and asymptomatic , were ||| 0-0 2-0 1-1 2-2 3-3 4-4
vorübergehend und asymptomatisch , ||| transient and asymptomatic , ||| 0-0 2-0 1-1 2-2 3-3
vorübergehend und asymptomatisch ||| transient and asymptomatic ||| 0-0 2-0 1-1 2-2
vorübergehend ||| transient ||| 0-0
vorübergehende Mangeldurchblutung des Gehirns hatten ||| " mini " stroke ||| 1-0 0-1 1-1 2-1 3-1 1-2 3-3 4-3
vorübergehende ||| temporary ||| 0-0
vorübergehende ||| transient ||| 0-0
vorübergehenden Verlust des Bewusstseins und ||| transient loss of consciousness and ||| 0-0 1-1 2-2 2-3 3-3 4-4
vorübergehenden Verlust des Bewusstseins ||| transient loss of consciousness ||| 0-0 1-1 2-2 2-3 3-3
vorübergehenden Verlust ||| transient loss ||| 0-0 1-1
vorübergehenden ||| transient ||| 0-0
vorübergehender Mangeldurchblutung des Gehirns ||| " mini " stroke have ||| 0-0 0-1 1-1 1-2 1-3 2-3 3-3 3-4
wahr und besprechen ||| and discuss ||| 1-0 0-1 2-1
wahrscheinlich ||| androgen- ||| 0-0
wahrscheinlich über eine Verringerung der ||| mediated by a reduction of ||| 0-0 1-0 0-1 2-2 3-3 4-4
wahrscheinlich über eine Verringerung ||| mediated by a reduction ||| 0-0 1-0 0-1 2-2 3-3
wahrscheinlich über eine ||| mediated by a ||| 0-0 1-0 0-1 2-2
wahrscheinlich über ||| mediated by ||| 0-0 1-0 0-1
war , ob ||| was whether ||| 0-0 1-1 2-1
war 5,8 für Placebo ||| was 5.8 for placebo ||| 0-0 1-1 2-2 3-3
war 5,8 für ||| was 5.8 for ||| 0-0 1-1 2-2
war 5,8 ||| was 5.8 ||| 0-0 1-1
war Abilify ||| , Abilify was ||| 1-1 0-2
war Abilify ||| Abilify was ||| 1-0 0-1
war Aclasta bei ||| , Aclasta was ||| 1-1 0-2 2-2
war Aclasta bei ||| Aclasta was ||| 1-0 0-1 2-1
war Aclasta wirksamer als ||| Aclasta was more effective than ||| 1-0 0-1 2-2 2-3 3-4
war Aclasta wirksamer ||| , Aclasta was more effective ||| 1-1 0-2 2-3 2-4
war Aclasta wirksamer ||| Aclasta was more effective ||| 1-0 0-1 2-2 2-3
war Aclasta ||| , Aclasta was ||| 1-1 0-2
war Aclasta ||| Aclasta was ||| 1-0 0-1
war die Anzahl an Patientinnen ||| was the number of patients ||| 0-0 1-1 2-2 3-3 4-4
war die Anzahl an ||| was the number of ||| 0-0 1-1 2-2 3-3
war die Anzahl ||| was the number ||| 0-0 1-1 2-2
war die Aripiprazol Injektionslösung ||| aripiprazole solution for injection was ||| 2-0 3-1 1-2 3-2 3-3 0-4
war die Gewichtsreduktion geringer ||| weight loss was less pronounced ||| 2-0 2-1 0-2 1-2 0-3 1-4 3-4
war die Häufigkeit von klinischen ||| was the incidence of clinical ||| 0-0 1-1 2-2 3-3 4-4
war die Häufigkeit von ||| was the incidence of ||| 0-0 1-1 2-2 3-3
war die Häufigkeit ||| was the incidence ||| 0-0 1-1 2-2
war die auffälligste wichtige hämatologische ||| was the most notable important ||| 0-0 1-1 1-2 2-3 3-3 4-3
war die auffälligste wichtige hämatologische ||| was the most notable ||| 0-0 1-1 1-2 2-3 3-3 4-3
war die ||| , in ||| 1-1
war die ||| , the patients were ||| 1-1 0-2 0-3
war die ||| in ||| 1-0
war die ||| the patients were ||| 1-0 0-1 0-2
war die ||| was the most ||| 0-0 1-1 1-2
war die ||| was the same ||| 0-0 1-1 1-2
war die ||| was the ||| 0-0 1-1
war die ||| was ||| 0-0 1-0
war geringer als bei ||| can occur ( see section ||| 3-1 1-2
war geringer als bei ||| can occur ( see ||| 3-1 1-2
war geringer als bei ||| can occur ( ||| 3-1 1-2
war geringer als bei ||| occur ( see section ||| 3-0 1-1
war geringer als bei ||| occur ( see ||| 3-0 1-1
war geringer als bei ||| occur ( ||| 3-0 1-1
war geringer als ||| ( see section ||| 1-0
war geringer als ||| ( see ||| 1-0
war geringer als ||| ( ||| 1-0
war geringer ||| ( see section ||| 1-0
war geringer ||| ( see ||| 1-0
war geringer ||| ( ||| 1-0
war linear und dosis-proportional . ||| were linear and dose-proportional . ||| 0-0 1-1 2-2 3-3 4-4
war linear und dosis-proportional ||| were linear and dose-proportional ||| 0-0 1-1 2-2 3-3
war linear und ||| were linear and ||| 0-0 1-1 2-2
war linear ||| were linear ||| 0-0 1-1
war nicht dafür ausgelegt ||| was not powered ||| 0-0 1-1 2-2 3-2
war nicht ||| was not ||| 0-0 1-1
war niedriger in einer ||| was lower in a ||| 0-0 1-1 2-2 3-3
war niedriger in ||| was lower in ||| 0-0 1-1 2-2
war niedriger ||| was lower ||| 0-0 1-1
war schnell reversibel und ||| was rapidly reversible and dose ||| 0-0 1-1 2-2 3-3
war schnell reversibel und ||| was rapidly reversible and ||| 0-0 1-1 2-2 3-3
war schnell reversibel ||| was rapidly reversible ||| 0-0 1-1 2-2
war schnell ||| was rapidly ||| 0-0 1-1
war statistisch signifikant ||| improvement in ||| 2-0
war statistisch signifikant ||| improvement ||| 2-0
war vergleichbar zwischen ||| healing was comparable between ||| 0-1 1-2 2-3
war vergleichbar zwischen ||| was comparable between ||| 0-0 1-1 2-2
war vergleichbar ||| healing was comparable ||| 0-1 1-2
war vergleichbar ||| was comparable ||| 0-0 1-1
war wirksamer als ||| was more effective than ||| 0-0 1-1 1-2 2-3
war wirksamer ||| was more effective ||| 0-0 1-1 1-2
war ||| area was ||| 0-1
war ||| healing was ||| 0-1
war ||| patients were ||| 0-0 0-1
war ||| was generally ||| 0-0
war ||| was ||| 0-0
war ||| were ||| 0-0
war ähnlich zwischen den beiden ||| was generally similar between the ||| 0-0 1-2 4-2 2-3 3-4
waren : ||| were : ||| 0-0 1-1
waren : Übelkeit ||| were : nausea ||| 0-0 1-1 2-2
waren Frauen , 87 % ||| were women , 87 % ||| 0-0 1-1 2-2 3-3 4-4
waren Frauen , 87 ||| were women , 87 ||| 0-0 1-1 2-2 3-3
waren Frauen , ||| were women , ||| 0-0 1-1 2-2
waren Frauen ||| were women ||| 0-0 1-1
waren Sehstörungen , ||| visual disturbance , ||| 1-0 1-1 2-2
waren Sehstörungen ||| visual disturbance ||| 1-0 1-1
waren ausgeschlossen ||| excluded ||| 1-0
waren fast ||| almost ||| 1-0
waren gewöhnlich vorübergehend , ||| were usually transient , typically ||| 0-0 1-1 2-2 3-3 3-4
waren gewöhnlich vorübergehend ||| were usually transient ||| 0-0 1-1 2-2
waren gewöhnlich ||| were usually ||| 0-0 1-1
waren im ||| and were ||| 0-0 0-1 1-1
waren vergleichbar zu den Veränderungen ||| were similar to that ||| 0-0 4-0 1-1 2-2 3-2
waren vergleichbar zu den Veränderungen ||| were similar to ||| 0-0 4-0 1-1 2-2 3-2
waren von Studien mit ||| were excluded in the studies ||| 0-0 2-2 3-2 2-4
waren von ||| were excluded ||| 0-0
waren von ||| were ||| 0-0
waren ||| of which were ||| 0-1 0-2
waren ||| waren ||| 0-0
waren ||| were excluded ||| 0-0
waren ||| were ||| 0-0
waren ||| which were ||| 0-0 0-1
was Nebenwirkungen verursachen kann ||| which can cause side effects ||| 0-0 3-1 2-2 1-3 1-4
was auf eine weitreichende ||| indicating extensive ||| 0-0 1-0 0-1 3-1
was das ||| which ||| 0-0 1-0
was ||| however ||| 0-0
was ||| indicating ||| 0-0
was ||| which ||| 0-0
wasserfrei ) , entsprechend 0,0533 ||| anhydrous , corresponding to 0.0533 ||| 0-0 2-1 1-2 3-2 3-3 4-4
wasserfrei ) , entsprechend 5,330 ||| anhydrous , corresponding to 5.330 ||| 0-0 2-1 1-2 3-2 3-3 4-4
wasserfrei ) , entsprechend ||| anhydrous , corresponding to ||| 0-0 2-1 1-2 3-2 3-3
wasserfrei ) . ||| anhydrous ) . ||| 0-0 1-1 2-2
wasserfrei ) ||| anhydrous ) ||| 0-0 1-1
wasserfrei ||| anhydrous ||| 0-0
wasserfreiem Insulin human . ||| of anhydrous human insulin . ||| 0-0 0-1 2-2 1-3 3-4
wasserfreiem Insulin human ||| of anhydrous human insulin ||| 0-0 0-1 2-2 1-3
wasserfreiem ||| of anhydrous ||| 0-0 0-1
wechselnde ||| altered mental ||| 0-0 0-1
wechselnde ||| unregelmäßiger Puls oder ||| 0-0 0-1 0-2
wegen Erbrechen ||| due to vomiting ||| 0-0 0-1 1-2
wegen begleitender Stoffwechselerkrankungen behandelt ||| groups ||| 2-0
wegen begleitender Stoffwechselerkrankungen ||| groups ||| 2-0
wegen des größeren ||| des ||| 1-0
wegen des ||| des ||| 1-0
wegen ||| due to ||| 0-0 0-1
weiblichen Ratten , die keinen ||| female rats ||| 0-0 2-0 3-0 4-0 1-1
weiblichen Ratten ||| female rats ||| 0-0 1-1
weiblichen und männlichen Patienten ||| female and male patients ||| 0-0 1-1 2-2 3-3
weiblichen und männlichen ||| female and male ||| 0-0 1-1 2-2
weiblichen und ||| female and ||| 0-0 1-1
weiblichen ||| female ||| 0-0
weicher Stuhl ||| softened stools ||| 0-0 1-1
weicher ||| softened ||| 0-0
weil sie ||| irreversible metabolism-dependent ||| 0-0 0-1
weil ||| direct- acting ||| 0-0
weil ||| direct- ||| 0-0
weil ||| irreversible metabolism-dependent ||| 0-0 0-1
weisen die Patienten gewöhnlich ||| is usually in those with ||| 0-0 0-1 3-1 3-2 0-3 1-3 2-3 2-4
weiter einzunehmen . ||| medicine . ||| 0-0 1-0 2-1
weiter einzunehmen ||| medicine ||| 0-0 1-0
weiter verstärken können . ||| of the hormone . ||| 1-0 1-1 0-2 1-2 2-2 3-3
weiter verstärken können ||| of the hormone ||| 1-0 1-1 0-2 1-2 2-2
weitere 4 Tage nach ||| for four days ||| 2-0 1-1 2-2 3-2
weitere 4 ||| four ||| 1-0
weitere Dosis erst ||| need another dose of ||| 0-0 0-1 1-2 2-3
weitere Dosis ||| need another dose ||| 0-0 0-1 1-2
weitere Fragen haben ||| have any further ||| 2-0 0-1 0-2 1-2 2-2
weitere Fragen haben ||| have further ||| 2-0 0-1 1-1 2-1
weitere Informationen ||| further information is ||| 0-0 1-1 1-2
weitere Informationen über ||| any information ||| 0-0 1-1 2-1
weitere Informationen über ||| need more information about ||| 0-0 1-1 1-2 2-2 1-3
weitere Risikofaktoren ||| with ||| 1-0
weitere ||| any ||| 0-0
weitere ||| further ||| 0-0
weitere ||| have any ||| 0-0 0-1
weitere ||| need another ||| 0-0 0-1
weitere ||| need ||| 0-0
weiteren Indikationen . ||| indications . ||| 1-0 2-1
weiteren Indikationen . ||| other indications . ||| 1-1 2-2
weiteren Indikationen ||| indications ||| 1-0
weiteren Indikationen ||| other indications ||| 1-1
weiteren Reduktion der ||| further reduction of bone ||| 0-0 1-1 2-2 1-3
weiteren ||| further ||| 0-0
weiterer Behandlung wieder zurückbildet . ||| course of continued therapy . ||| 1-0 1-1 1-2 3-2 1-3 2-3 0-4 4-4
weiterhin gut ||| continuing to ||| 0-0
weiterhin gut ||| continuing ||| 0-0
weiterhin ||| continuing to ||| 0-0
weiterhin ||| continuing ||| 0-0
weiterhin ||| remains ||| 0-0
weiß bis weißlich ||| white to off-white ||| 0-0 1-1 1-2 2-2
weiß und trübe aussehen ||| white and cloudy after resuspension ||| 0-0 1-1 2-2 2-3 2-4 3-4
weiß und ||| white and ||| 0-0 1-1
weiß ||| white ||| 0-0
weiße HDPE-Flaschen mit 28 ||| white HDPE bottles containing 28 ||| 0-0 1-1 1-2 2-3 3-3 3-4
weiße HDPE-Flaschen ||| white HDPE bottles ||| 0-0 1-1 1-2
weiße Tabletten mit der Prägung ||| white tablets debossed with ||| 0-0 1-1 4-2 2-3 4-3
weiße Tabletten ||| white tablets ||| 0-0 1-1
weiße ||| white ||| 0-0
weißen , runden Tabletten enthalten ||| white , round tablets contain ||| 0-0 1-1 2-2 3-3 4-4
weißen , runden Tabletten ||| white , round tablets ||| 0-0 1-1 2-2 3-3
weißen , runden ||| white , round ||| 0-0 1-1 2-2
weißen , tropfenförmigen Tabletten erhältlich ||| white , teardrop- shaped tablets ||| 0-0 1-1 2-2 2-3 4-3 3-4
weißen , ||| white , ||| 0-0 1-1
weißen ||| of white ||| 0-1
weißen ||| white ||| 0-0
welche Art von Futter ||| on the type of food ||| 1-2 0-3 2-3 3-4
welche Art von Futter ||| the type of food ||| 1-1 0-2 2-2 3-3
welche Art von Futter ||| type of food ||| 1-0 0-1 2-1 3-2
welche Art von ||| on the type of ||| 1-2 0-3 2-3
welche Art von ||| the type of ||| 1-1 0-2 2-2
welche Art von ||| type of ||| 1-0 0-1 2-1
welche sich ||| of ||| 0-0
welche ||| conjunction ||| 0-0
welche ||| in conjunction ||| 0-1
welche ||| of ||| 0-0
welchen ||| Oriental ||| 0-0
welcher eine Erholung von den ||| permitted recovery from the ||| 2-0 3-1 3-2 4-3
welcher eine Erholung von ||| permitted recovery from ||| 2-0 3-1 3-2
welcher eine Erholung ||| permitted ||| 2-0
wenden ||| , ||| 0-0
wenig ||| little , ||| 0-0
wenig ||| little ||| 0-0
wenige Daten ||| data ||| 0-0 1-0
weniger als 1 von ||| affecting less than 1 ||| 0-0 0-1 1-2 3-2 2-3
weniger als 1 von ||| less than 1 ||| 0-0 1-1 2-2
weniger als 1 ||| less than 1 ||| 0-0 1-1 2-2
weniger als 10 von ||| affecting less than 10 ||| 0-0 0-1 1-2 3-2 2-3
weniger als 15 Minuten betragen ||| less than 15 minutes ||| 0-0 1-1 2-2 3-3 4-3
weniger als 15 ||| less than 15 ||| 0-0 1-1 2-2
weniger als 6 Monaten ||| less than 6 months ago ||| 0-0 1-1 2-2 3-3 3-4
weniger als 6 ||| less than 6 ||| 0-0 1-1 2-2
weniger als drei ||| less than three ||| 0-0 1-1 2-2
weniger als ||| less than ||| 0-0 1-1
weniger dauerten , gab es ||| less duration , there were ||| 0-0 1-1 2-2 3-3 4-3 3-4
weniger dauerten , ||| less duration , ||| 0-0 1-1 2-2
weniger dauerten ||| less duration ||| 0-0 1-1
weniger des Plasmaspiegels bei klinischer ||| species at plasma ||| 0-0 1-0 2-0 4-0 2-1 3-1 2-2
weniger häufig . ||| less common . ||| 0-0 1-1 2-2
weniger häufig ||| becoming less common ||| 0-1 1-2
weniger häufig ||| less common ||| 0-0 1-1
weniger ||| affecting less ||| 0-0 0-1
weniger ||| becoming less ||| 0-1
weniger ||| less ||| 0-0
wenigstens 211 Patienten ||| at least 211 patients in ||| 0-0 0-1 1-2 2-3 2-4
wenigstens 211 ||| at least 211 ||| 0-0 0-1 1-2
wenigstens ||| at least ||| 0-0 0-1
wenn Ihr Hund ||| if your dog has ||| 0-0 1-1 2-2
wenn Ihr Hund ||| if your dog ||| 0-0 1-1 2-2
wenn Ihr ||| . if your ||| 0-1 1-2
wenn Ihr ||| if your ||| 0-0 1-1
wenn Paclitaxel zusammen mit ||| when administering paclitaxel concomitantly with ||| 0-0 1-2 2-3 3-4
wenn Paclitaxel zusammen ||| when administering paclitaxel concomitantly ||| 0-0 1-2 2-3
wenn Paclitaxel ||| when administering paclitaxel ||| 0-0 1-2
wenn Pioglitazon ||| when pioglitazone was ||| 0-0 1-1 1-2
wenn Pioglitazon ||| when pioglitazone ||| 0-0 1-1
wenn Sie ABILIFY einnehmen . ||| when taking ABILIFY . ||| 0-0 1-1 3-1 2-2 4-3
wenn Sie ABILIFY einnehmen ||| when taking ABILIFY ||| 0-0 1-1 3-1 2-2
wenn Sie eine Phenylketonurie haben ||| people with phenylketonuria ||| 0-0 1-0 3-0 3-1 2-2 3-2 4-2
wenn Sie mit Abseamed ||| while you are using Abseamed ||| 2-0 0-1 1-1 0-2 2-3 3-4
wenn Sie mit ||| while you are using ||| 2-0 0-1 1-1 0-2 2-3
wenn Sie schwanger sind , ||| if you are pregnant ||| 0-0 1-1 3-2 4-2 2-3
wenn Sie unter unzureichend ||| if you have high blood ||| 0-0 1-1 1-2 2-2 0-3 3-4
wenn Sie unter ||| if you have high ||| 0-0 1-1 1-2 2-2 0-3
wenn Sie ||| If you ||| 1-0 0-1 1-1
wenn Sie ||| if you are ||| 0-0 1-1 0-2
wenn Sie ||| if you are ||| 0-0 1-1 1-2
wenn Sie ||| if you have developed ||| 0-0 1-1 1-2 0-3
wenn Sie ||| if you ||| 0-0 1-1
wenn Sie ||| you are ||| 0-0 1-0 0-1
wenn Sie ||| you ||| 0-0 1-0
wenn bei Ihnen beispielsweise schon ||| for example , if you ||| 1-0 3-1 0-3 2-4
wenn bei Ihnen beispielsweise ||| for example , if you ||| 1-0 3-1 0-3 2-4
wenn bei Ihnen keine ||| if you cannot receive ||| 0-0 2-1 3-2 2-3
wenn bei ||| if ||| 0-0
wenn der dauerhafte Hämoglobinwert ||| if the sustained haemoglobin exceeds ||| 0-0 1-1 2-2 3-3 2-4
wenn der ||| if the ||| 0-0 1-1
wenn die Lösung ||| if the solution ||| 0-0 1-1 2-2
wenn die ||| if the ||| 0-0 1-1
wenn ein ||| an ||| 0-0 1-0
wenn eine orale Therapie ||| when oral therapy ||| 0-0 1-0 2-1 3-2
wenn eine orale ||| when oral ||| 0-0 1-0 2-1
wenn eine ||| when ||| 0-0 1-0
wenn sie ||| if they ||| 0-0 1-1
wenn ||| , if ||| 0-1
wenn ||| . if ||| 0-1
wenn ||| if ||| 0-0
wenn ||| the treatment of obese ||| 0-0 0-1 0-2 0-3
wenn ||| unless ||| 0-0
wenn ||| when administering ||| 0-0
wenn ||| when ||| 0-0
werden ( siehe Abschnitt 4.2 ||| ( see section 4.2 ||| 1-0 2-1 3-2 0-3 4-3
werden ( siehe Abschnitt 4.4 ||| ( see section 4.4 ||| 1-0 0-1 2-1 3-2 4-3
werden ( siehe Abschnitt 4.4 ||| werden ( siehe Abschnitt 4.4 ||| 0-0 1-1 2-2 2-3 3-4 4-4
werden ( siehe Abschnitt 5.2 ||| ( see section 5.2 ||| 1-0 0-1 2-1 2-2 3-2 4-3
werden ( siehe Abschnitt 5.3 ||| ( see section 5.3 ||| 1-0 0-1 2-1 3-2 4-3
werden ( siehe Abschnitt ||| ( see section ||| 1-0 0-1 2-1 2-2 3-2
werden ( siehe Abschnitt ||| ( see section ||| 1-0 0-1 2-1 3-2
werden ( siehe ||| ( see ||| 1-0 0-1 2-1
werden ( siehe ||| werden ( siehe Abschnitt ||| 0-0 1-1 2-2 2-3
werden ( ||| werden ( ||| 0-0 1-1
werden , dass Pioglitazon ||| that pioglitazone ||| 1-0 2-0 3-1
werden , dass ||| that ||| 1-0 2-0
werden , insbesondere ||| , particularly at ||| 1-0 0-1 2-1 2-2
werden , ob das Führen ||| be considered ||| 0-0 2-1 3-1 4-1
werden , sollte der ||| should be ||| 2-0 0-1 2-1 3-1
werden , wenn Sie an ||| if you have ||| 0-0 1-0 2-0 3-1 3-2 4-2
werden , wenn Sie ||| if you are ||| 0-0 1-0 2-0 3-1 2-2
werden , wenn ||| be ||| 0-0 2-0
werden , wenn ||| if ||| 0-0 1-0 2-0
werden , wie ||| , ||| 1-0
werden , wird ||| are advised ||| 0-0 2-0 0-1
werden , ||| , ||| 1-0
werden , ||| be ||| 0-0
werden . ||| ) . ||| 0-1 1-1
werden . ||| . ||| 0-0 1-0
werden . ||| Abraxane therapy . ||| 0-0 0-1 1-2
werden . ||| Leaflet . ||| 1-0 0-1 1-1
werden . ||| are observed . ||| 0-0 0-1 1-2
werden . ||| be ||| 0-0 1-0
werden . ||| before swallowing . ||| 0-0 1-1 1-2
werden . ||| if possible . ||| 0-0 0-1 1-2
werden . ||| period . ||| 0-0 1-1
werden . ||| therapy . ||| 0-0 1-1
werden . ||| use . ||| 0-1 1-1
werden : bei Erhalt ||| be ||| 0-0
werden : bei ||| be ||| 0-0
werden : ||| be ||| 0-0
werden Sie gegebenenfalls ||| you may not ||| 1-0 2-1 1-2
werden auf die ||| werden auf die ||| 0-0 1-1 2-2
werden auf ||| werden auf ||| 0-0 1-1
werden die nächste Infusion nach ||| the next dose after ||| 1-0 2-0 2-1 1-2 3-3 4-3
werden die nächste ||| the next dose ||| 1-0 2-0 2-1 1-2
werden einmal täglich ||| are taken orally once daily ||| 0-0 1-1 2-2 1-3 2-3 2-4
werden kann ||| cancer ||| 0-0
werden können ( siehe Abschnitt ||| ( see section ||| 2-0 3-1 4-2
werden können ( siehe ||| ( see ||| 2-0 3-1
werden können ( ||| ( ||| 2-0
werden können . Es kann ||| . It can be ||| 2-0 3-1 1-2 4-2 0-3
werden könnte ||| may be ||| 1-0 0-1
werden langsam ||| for infusion should slowly be ||| 0-2 1-3
werden langsam ||| for infusion should slowly ||| 0-2 1-3
werden langsam ||| infusion should slowly be ||| 0-1 1-2
werden langsam ||| infusion should slowly ||| 0-1 1-2
werden langsam ||| should slowly be ||| 0-0 1-1
werden langsam ||| should slowly ||| 0-0 1-1
werden mit ||| werden mit ||| 0-0 1-1
werden möglicherweise nicht alle Packungsgrößen ||| werden möglicherweise nicht alle Packungsgrößen ||| 0-0 1-1 2-2 3-3 4-4
werden möglicherweise nicht alle ||| werden möglicherweise nicht alle ||| 0-0 1-1 2-2 3-3
werden möglicherweise nicht ||| werden möglicherweise nicht ||| 0-0 1-1 2-2
werden möglicherweise ||| werden möglicherweise ||| 0-0 1-1
werden nicht induziert . ||| in man . ||| 1-0 2-0 2-1 3-2
werden nicht induziert ||| in man ||| 1-0 2-0 2-1
werden sich unter Umständen ||| probably need ||| 1-0 2-0 3-0 3-1
werden sollten ||| should be ||| 1-0 0-1
werden und Patienten mit Diabetes ||| and patients with diabetes ||| 1-0 2-1 3-2 4-3
werden und Patienten mit ||| and patients with ||| 1-0 2-1 3-2
werden und Patienten ||| and patients ||| 1-0 2-1
werden und ihr Wiederauftreten ||| and preventing them ||| 1-0 3-1 1-2
werden und ||| and ||| 1-0
werden und ||| be ||| 0-0
werden wahrscheinlich über eine Verringerung ||| be mediated by a reduction ||| 0-0 1-1 2-1 1-2 3-3 4-4
werden wahrscheinlich über eine ||| be mediated by a ||| 0-0 1-1 2-1 1-2 3-3
werden wahrscheinlich über ||| be mediated by ||| 0-0 1-1 2-1 1-2
werden zur Gewährleistung ||| are being taken to ||| 0-0 0-1 2-2 1-3
werden zur ||| to treat ||| 1-0 1-1
werden ||| . ||| 0-0
werden ||| Abraxane therapy ||| 0-0 0-1
werden ||| all ||| 0-0
werden ||| are being ||| 0-0 0-1
werden ||| are observed ||| 0-0 0-1
werden ||| are ||| 0-0
werden ||| be ||| 0-0
werden ||| become ||| 0-0
werden ||| before ||| 0-0
werden ||| cancer ||| 0-0
werden ||| dosing ||| 0-0
werden ||| for infusion should ||| 0-2
werden ||| if possible ||| 0-0 0-1
werden ||| infusion should ||| 0-1
werden ||| period ||| 0-0
werden ||| should be ||| 0-0 0-1
werden ||| should ||| 0-0
werden ||| the ||| 0-0
werden ||| therapy ||| 0-0
werden ||| werden ||| 0-0
werden ||| with ||| 0-0
werden. itte ||| . lp ||| 0-0 0-1 1-1
wesentlich beeinflussen können ||| can significantly impact ||| 2-0 1-1 0-2 1-2
wesentlich beeinflussen ||| significantly impact ||| 1-0 0-1 1-1
wichtig , Ihrem ||| important ||| 0-0 1-0 2-0
wichtig , dass ||| important that ||| 0-0 1-1 2-1
wichtig , entsprechend ||| important to take calcium ||| 0-0 1-1 2-1 0-2 1-3
wichtig bei Patienten , ||| important for patients ||| 0-0 1-1 2-2
wichtig bei Patienten ||| important for patients ||| 0-0 1-1 2-2
wichtig bei ||| important for the ||| 0-0 1-1
wichtig bei ||| important for ||| 0-0 1-1
wichtig bei ||| important in the ||| 0-0 1-1
wichtig bei ||| important in ||| 0-0 1-1
wichtig ||| important ||| 0-0
wichtigste ||| most ||| 0-0
wichtigsten vorkommenden Toxizitäten ||| anticipated toxicities ||| 0-0 1-0 1-1 2-1
wie 5-Hydroxytryptamin und Dopamin ||| 5-hydroxytryptamine and dopamine ||| 1-0 2-1 3-2
wie 5-Hydroxytryptamin und ||| 5-hydroxytryptamine and ||| 1-0 2-1
wie 5-Hydroxytryptamin ||| 5-hydroxytryptamine ||| 1-0
wie Freihalten der ||| function ||| 1-0 2-0
wie Fructoseintoleranz , Glucose-Galactose-Malabsorption ||| fructose intolerance , glucose-galactose malabsorption ||| 0-0 1-0 1-1 2-2 3-3 3-4
wie Fructoseintoleranz , ||| fructose intolerance , ||| 0-0 1-0 1-1 2-2
wie Fructoseintoleranz , ||| of fructose intolerance , ||| 0-1 1-1 1-2 2-3
wie Fructoseintoleranz sollten ||| fructose intolerance should ||| 0-0 1-0 1-1 2-2
wie Fructoseintoleranz sollten ||| of fructose intolerance should ||| 0-1 1-1 1-2 2-3
wie Fructoseintoleranz ||| fructose intolerance ||| 0-0 1-0 1-1
wie Fructoseintoleranz ||| of fructose intolerance ||| 0-1 1-1 1-2
wie Haloperidol . ||| haloperidol . ||| 0-0 1-0 2-1
wie Haloperidol und ||| haloperidol and ||| 0-0 1-0 2-1
wie Haloperidol ||| haloperidol ||| 0-0 1-0
wie Ihre Anämie ||| how your anaemia ||| 0-0 1-1 2-2
wie Ihre Blutarmut ( Anämie ||| how your anaemia ||| 0-0 1-1 2-2 4-2
wie Ihre ||| how your ||| 0-0 1-1
wie Itraconazol und ||| such as itraconazole and HIV ||| 0-0 0-1 0-2 1-2 2-3 1-4
wie Ketoconazol oder ||| , such as ketoconazole or ||| 0-1 0-2 1-3 2-4
wie Ketoconazol oder ||| such as ketoconazole or ||| 0-0 0-1 1-2 2-3
wie Ketoconazol ||| , such as ketoconazole ||| 0-1 0-2 1-3
wie Ketoconazol ||| such as ketoconazole ||| 0-0 0-1 1-2
wie Metformin und Gliclazid . ||| as metformin and gliclazide . ||| 0-0 1-1 2-2 3-3 4-4
wie Metformin und Gliclazid ||| as metformin and gliclazide ||| 0-0 1-1 2-2 3-3
wie Metformin und ||| as metformin and ||| 0-0 1-1 2-2
wie Metformin ||| as metformin ||| 0-0 1-1
wie Müdigkeit ||| such as tiredness ||| 0-0 0-1 1-2
wie Rötungen , Schwellungen ||| such as redness , swelling ||| 0-0 0-1 1-2 2-3 3-4
wie Rötungen , ||| such as redness , ||| 0-0 0-1 1-2 2-3
wie Rötungen ||| such as redness ||| 0-0 0-1 1-2
wie Sedierung eingenommen wird ( ||| such as sedation ( ||| 0-0 0-1 1-2 2-2 3-2 4-3
wie Sedierung eingenommen wird ||| such as sedation ||| 0-0 0-1 1-2 2-2 3-2
wie auch bei anderen potenziell ||| , as with other potentially ||| 0-1 1-1 2-2 3-3 4-4
wie auch bei anderen potenziell ||| as with other potentially ||| 0-0 1-0 2-1 3-2 4-3
wie auch bei anderen ||| , as with other ||| 0-1 1-1 2-2 3-3
wie auch bei anderen ||| as with other ||| 0-0 1-0 2-1 3-2
wie auch bei ||| , as with ||| 0-1 1-1 2-2
wie auch bei ||| as with ||| 0-0 1-0 2-1
wie auch ||| , as ||| 0-1 1-1
wie auch ||| as ||| 0-0 1-0
wie beim Hinfallen erlitten ||| such as a ||| 0-0 0-1 2-2 3-2
wie beim ||| such as ||| 0-0 0-1
wie das das ||| how ||| 0-0 1-0 2-0
wie das ||| how ||| 0-0 1-0
wie der Ausschuss ||| zu Empfehlungen bezüglich der ||| 2-0 0-1 2-1 2-2 1-3 2-3
wie die Anämie ||| how the anaemia ||| 0-0 1-1 2-2
wie die ||| how the ||| 0-0 1-1
wie dieser ||| benefit ||| 1-0
wie gut der ||| of how well the ||| 2-0 0-1 1-2 2-3
wie gut ||| how well ||| 0-0 1-1
wie in ||| in milk ||| 1-0 1-1
wie lange Sie ||| how long you ||| 0-0 1-1 2-2
wie lange ||| how long ||| 0-0 1-1
wie möglich ||| as possible ||| 0-0 1-1
wie sie ||| as ||| 0-0
wie weit sich diese Ergebnisse ||| these outcomes might apply ||| 3-0 0-1 1-1 1-2 1-3 2-3 3-3 4-3
wie z.B. Fieber ||| such as fever ||| 0-0 1-0 0-1 2-2
wie z.B. ungewöhnliche ||| such as unusual ||| 0-0 1-0 0-1 2-2
wie z.B. ||| such as ||| 0-0 1-0 0-1
wie ||| , such as ||| 0-1 0-2
wie ||| as ||| 0-0
wie ||| disease such as ||| 0-1 0-2
wie ||| how ||| 0-0
wie ||| may include ||| 0-0 0-1
wie ||| same as ||| 0-0 0-1
wie ||| such as ||| 0-0 0-1
wieder aus dem Mund ||| from the mouth is ||| 0-0 1-0 2-1 2-2 3-2 2-3
wieder aus ||| from ||| 0-0 1-0
wieder fest zugeschraubt werden . ||| screwed back on tightly . ||| 1-0 1-1 2-3 3-3 4-4
wieder fest zugeschraubt werden ||| screwed back on tightly ||| 1-0 1-1 2-3 3-3
wieder fest ||| screwed back on ||| 1-0 1-1
wieder fest ||| screwed back ||| 1-0 1-1
wiederholter Anwendung ||| repeat-dose ||| 0-0
wiederholter Anwendung ||| the repeat-dose ||| 0-1
wiederholter Gabe , Genotoxizität ||| based on conventional studies of ||| 0-0 0-1 1-2 2-2 3-2 3-3
wiederholter Gabe , Genotoxizität ||| based on conventional studies ||| 0-0 0-1 1-2 2-2 3-2 3-3
wiederholter Gabe ||| repeated dosing ||| 0-0 1-0 0-1
wiederholter oraler Gabe ||| repeated oral ||| 0-0 1-1 2-1
wiederholter ||| based on ||| 0-0 0-1
wiederholter ||| repeat-dose ||| 0-0
wiederholter ||| repeated ||| 0-0
wiederholter ||| the repeat-dose ||| 0-1
wies eine ||| demonstrated a ||| 0-0 1-1
wies ||| demonstrated ||| 0-0
wiesen ||| , ||| 0-0
wird ( etwa 1/20 ||| ( approximately 1/ 20th ||| 1-0 2-1 3-2 0-3 2-3 3-3
wird , die ||| to ||| 1-0 2-0
wird , ist ||| , ||| 1-0
wird , und wird ||| and is ||| 2-0 0-1 3-1
wird , ||| , ||| 1-0
wird , ||| when ||| 1-0
wird . ||| . ||| 1-0
wird . ||| is needed . ||| 0-0 0-1 1-2
wird . ||| receptors . ||| 0-0 1-1
wird Ihnen in ||| will receive ||| 0-0 1-0 1-1
wird Ihnen sagen , ||| will advise you on the ||| 0-0 1-1 2-1 1-2
wird Ihnen sagen , ||| will advise you on ||| 0-0 1-1 2-1 1-2
wird Ihnen sagen , ||| will advise you ||| 0-0 1-1 2-1 1-2
wird Ihnen sagen ||| will advise you on the ||| 0-0 1-1 2-1 1-2
wird Ihnen sagen ||| will advise you on ||| 0-0 1-1 2-1 1-2
wird Ihnen sagen ||| will advise you ||| 0-0 1-1 2-1 1-2
wird Ihnen ||| will receive ||| 0-0 1-0 1-1
wird Ihr Arzt ||| your doctor may ||| 1-0 0-1 2-1 1-2
wird Ihre ||| will ||| 0-0 1-0
wird Ihren ||| doctor will ||| 1-0 0-1
wird Pioglitazon schnell ||| pioglitazone is rapidly ||| 1-0 0-1 2-2
wird Pioglitazon ||| pioglitazone is ||| 1-0 0-1
wird Sie bitten , ||| will ask you ||| 0-0 2-0 2-1 1-2 3-2
wird als Injektion unter ||| is given by injection under ||| 0-0 2-1 1-2 2-2 2-3 3-4
wird als Injektion ||| is given by injection ||| 0-0 2-1 1-2 2-2 2-3
wird als nicht bekannt erachtet ||| is considered not known ||| 0-0 1-1 4-1 2-2 3-3 4-3
wird als ||| is considered to ||| 0-0 1-1
wird als ||| is considered ||| 0-0 1-1
wird angewendet , wenn ||| is given when ||| 0-0 1-1 2-2 3-2
wird angewendet : ||| is used : ||| 0-0 1-1 2-2
wird angewendet bei ||| is used ||| 0-0 1-1 2-1
wird angewendet ||| is given ||| 0-0 1-1
wird angewendet ||| is used ||| 0-0 1-1
wird bei diesen Patienten empfohlen ||| is recommended in these patients ||| 0-0 4-1 1-2 2-3 3-4
wird berichtet ||| is reported ||| 0-0 1-1
wird daher empfohlen , ||| is recommended , therefore ||| 0-0 2-1 3-2 1-3
wird das Auftreten diabetischer Spätfolgen ||| optimised glycaemic control delays the ||| 0-0 1-0 2-0 3-0 3-1 3-2 3-3 4-3 4-4
wird die Anwendung ||| its use is ||| 1-0 1-1 2-1 0-2
wird die Behandlung ||| the treatment will ||| 1-0 2-1 0-2
wird die Messung des Serum-Kalzium-Spiegels ||| of Aclasta is ||| 1-0 3-0 2-1 4-1 0-2
wird die Messung des ||| of Aclasta is ||| 1-0 3-0 2-1 0-2
wird die präoperative Anwendung von ||| the use of ||| 0-0 1-0 2-1 3-1 4-2
wird die präoperative Anwendung ||| the use ||| 0-0 1-0 2-1 3-1
wird die ||| the ||| 0-0 1-0
wird dies ||| will take this ||| 0-0 1-1 1-2
wird dreimal ||| is given 3 ||| 0-0 0-1 1-2
wird durch CYP3A4 katalysiert . ||| is catalysed by CYP3A4 . ||| 0-0 1-1 3-1 1-2 2-3 4-4
wird durch CYP3A4 katalysiert ||| is catalysed by CYP3A4 ||| 0-0 1-1 3-1 1-2 2-3
wird durch ||| is ||| 0-0
wird eine ||| , a ||| 1-1
wird eine ||| a ||| 1-0
wird eine ||| recommended dose is a ||| 0-0 1-1 0-2 1-3
wird eine Überwachung ||| monitoring of ||| 0-0 1-0 2-0 1-1
wird einmal täglich mit ||| is taken once daily with ||| 0-0 1-1 1-2 2-2 2-3 3-4
wird einmal täglich ||| is taken once daily ||| 0-0 1-1 1-2 2-2 2-3
wird empfohlen , ||| , it is recommended ||| 2-0 1-1 0-2 1-3
wird empfohlen ||| it is recommended ||| 1-0 0-1 1-2
wird entscheiden , ob Sie ||| will decide when you ||| 0-0 1-0 1-1 3-1 2-2 4-3
wird entscheiden , ob ||| will decide when ||| 0-0 1-0 1-1 3-1 2-2
wird gebilligt ( zwei beziehen ||| is endorsed ( two relate ||| 0-0 1-1 2-2 3-3 4-4
wird gebilligt ( zwei ||| is endorsed ( two ||| 0-0 1-1 2-2 3-3
wird gebilligt ( ||| is endorsed ( ||| 0-0 1-1 2-2
wird gebilligt ||| is endorsed ||| 0-0 1-1
wird geschätzt , ||| is estimated ||| 0-0 1-1
wird geschätzt ||| is estimated ||| 0-0 1-1
wird gut resorbiert , wobei ||| is well absorbed , with ||| 0-0 1-1 2-2 4-2 3-3 4-4
wird gut ||| is well ||| 0-0 1-1
wird hauptsächlich durch Metabolisierung und ||| wird hauptsächlich durch Metabolisierung und ||| 0-0 1-1 2-2 3-2 3-3 3-4 4-4
wird hauptsächlich ||| wird hauptsächlich ||| 0-0 1-1
wird helfen , Sie vor ||| will help to ||| 0-0 3-0 1-1 2-1 4-2
wird helfen , Sie ||| will help ||| 0-0 3-0 1-1 2-1
wird in der Leber durch ||| undergoes extensive hepatic metabolism by ||| 0-0 1-0 3-0 3-1 2-2 3-2 3-3 4-4
wird in der Leber ||| undergoes extensive hepatic metabolism ||| 0-0 1-0 3-0 3-1 2-2 3-2 3-3
wird in der folgenden ||| wird in der folgenden Tabelle ||| 0-0 1-0 1-1 2-2 3-3 3-4
wird in der ||| wird in der ||| 0-0 1-0 1-1 2-2
wird in drei Phasen eliminiert ||| is eliminated by a triphasic ||| 0-0 4-1 0-2 1-2 2-2 1-3 3-4
wird in ||| wird in ||| 0-0 1-0 1-1
wird individuell ||| is individual and determined ||| 0-0 1-1 1-2 0-3 1-3
wird keine Information ||| no information will ||| 1-0 1-1 0-2 2-2
wird nicht empfohlen für Kinder ||| is not recommended for anyone ||| 0-0 1-1 2-2 3-3 4-4
wird nicht empfohlen für die ||| is not recommended for ||| 0-0 1-1 2-2 3-3 4-3
wird nicht empfohlen für ||| is not recommended for ||| 0-0 1-1 2-2 3-3
wird nicht empfohlen ||| is not recommended ||| 0-0 1-1 2-2
wird nicht metabolisiert , ihre ||| is not metabolised ||| 0-0 1-1 2-2 4-2
wird nicht systemisch ||| is not systemically ||| 0-0 1-1 2-2
wird nicht ||| is not ||| 0-0 1-1
wird normalerweise ||| is usually ||| 0-0 1-1
wird so angepasst , dass ||| is adjusted to ||| 0-0 1-0 2-1 3-2 4-2
wird so angepasst ||| is adjusted ||| 0-0 1-0 2-1
wird so ||| is ||| 0-0 1-0
wird subkutan ( ||| is given subcutaneously ( ||| 0-0 1-1 1-2 2-3
wird subkutan in den ||| is administered subcutaneously in the ||| 0-0 1-1 1-2 3-2 2-3 3-4
wird subkutan ||| is given subcutaneously ||| 0-0 1-1 1-2
wird zugestimmt . ||| accepted . ||| 0-0 1-0 2-1
wird zugestimmt ||| accepted ||| 0-0 1-0
wird zweimal ||| is given 2 ||| 0-0 1-1 1-2
wird zweimal ||| is given twice ||| 0-0 1-1 1-2
wird ||| , approximately ||| 0-1
wird ||| activity ||| 0-0
wird ||| approximately ||| 0-0
wird ||| by ||| 0-0
wird ||| given ||| 0-0
wird ||| is given ||| 0-0 0-1
wird ||| is needed ||| 0-0 0-1
wird ||| is on ||| 0-0
wird ||| is ||| 0-0
wird ||| receptors ||| 0-0
wird ||| there is ||| 0-1
wird ||| use of ||| 0-0
wird ||| use ||| 0-0
wird ||| will ||| 0-0
wird ||| wird ||| 0-0
wird über verschiedene Wege unter ||| is metabolised by multiple ||| 0-0 1-1 2-1 3-2 3-3 4-3
wird über verschiedene ||| is metabolised ||| 0-0 1-1 2-1
wird überwiegend in ||| is extensively metabolised ||| 0-0 1-1 2-1 1-2
wirken , ||| , ||| 1-0
wirksam in der Aufrechterhaltung des ||| effective in maintaining the clinical ||| 0-0 1-1 2-2 3-2 4-3 3-4
wirksam in einem Dosisbereich zwischen ||| effective in a dose range ||| 0-0 1-1 2-2 3-3 2-4 3-4 4-4
wirksam in ||| effective in ||| 0-0 1-1
wirksam wie Metformin und Gliclazid ||| effective as metformin and gliclazide ||| 0-0 1-1 2-2 3-3 4-4
wirksam wie Metformin und ||| effective as metformin and ||| 0-0 1-1 2-2 3-3
wirksam wie Metformin ||| effective as metformin ||| 0-0 1-1 2-2
wirksam wie ||| effective as ||| 0-0 1-1
wirksam zu ||| be ||| 1-0
wirksam ||| effective ||| 0-0
wirksame Bestandteil von ACOMPLIA ||| substance in ACOMPLIA ||| 0-0 1-0 2-2 3-2
wirksame Bestandteil ||| substance in ||| 0-0 1-0
wirksame Bestandteil ||| substance ||| 0-0 1-0
wirksame Empfängnisverhütung praktizieren ||| effective contraception ||| 0-0 1-1 2-1
wirksame Empfängnisverhütung praktizieren ||| using effective contraception ||| 0-1 1-2 2-2
wirksame ||| effective ||| 0-0
wirksame ||| using effective ||| 0-1
wirksamen Bestandteil Rimonabant enthält . ||| substance rimonabant . ||| 0-0 1-0 3-0 2-1 4-2
wirksamen Bestandteil Rimonabant enthält ||| substance rimonabant ||| 0-0 1-0 3-0 2-1
wirksamen Bestandteil oder ||| substance or to ||| 0-0 1-0 2-1
wirksamen Bestandteil oder ||| substance or ||| 0-0 1-0 2-1
wirksamen Bestandteil ||| substance ||| 0-0 1-0
wirksamer als Risedronat . ||| more effective than risedronate . ||| 0-0 0-1 1-2 2-3 3-4
wirksamer als Risedronat ||| more effective than risedronate ||| 0-0 0-1 1-2 2-3
wirksamer als ||| effective than ||| 0-0 1-1
wirksamer als ||| more effective than ||| 0-0 0-1 1-2
wirksamer ||| effective ||| 0-0
wirksamer ||| more effective ||| 0-0 0-1
wirkt , indem ||| works by ||| 0-0 2-1
wirkt , ||| works ||| 0-0
wirkt Aclasta ? ||| fall ||| 0-0 1-0 2-0
wirkt Aclasta für ein Jahr ||| Aclasta works for one year ||| 1-0 0-1 2-2 3-3 4-3 4-4
wirkt Aclasta für ||| Aclasta works for ||| 1-0 0-1 2-2
wirkt Aclasta ||| Aclasta works ||| 1-0 0-1
wirkt auch ||| also affects ||| 1-0 0-1
wirkt durch Blockade ||| acts by blocking ||| 0-0 1-1 2-2
wirkt durch ||| acts by ||| 0-0 1-1
wirkt in ||| works in ||| 0-0 1-1
wirkt vermutlich vor allem ||| is thought to act mainly ||| 1-0 0-1 1-1 2-2 3-3 3-4
wirkt vermutlich vor ||| is thought to ||| 1-0 0-1 1-1 2-2
wirkt vermutlich ||| is thought ||| 1-0 0-1 1-1
wirkt ||| acts ||| 0-0
wirkt ||| affects ||| 0-0
wirkt ||| works ||| 0-0
wirres Verhalten und verflachte Stimmungslage ||| and behaviour and emotional flatness ||| 2-0 1-1 2-2 0-3 3-3 4-4
wirres Verhalten und verflachte ||| and behaviour and emotional ||| 2-0 1-1 2-2 0-3 3-3
wirres ||| speech ||| 0-0
wissen , ob ||| know if ||| 0-0 1-0 2-1
wissen , wie ABILIFY ||| know how ABILIFY ||| 0-0 1-0 0-1 2-1 3-2
wissen , wie ||| know how ||| 0-0 1-0 0-1 2-1
wissen , wie ||| knows how to ||| 0-0 0-1 2-1
wissen , wie ||| knows how ||| 0-0 0-1 2-1
wissen , ||| know ||| 0-0 1-0
wissenschaftliche Diskussion ( die ||| Scientific Discussion ( ||| 0-0 3-0 0-1 1-1 2-2
wissenschaftlichen Literatur vor . ||| published literature . ||| 0-0 1-0 1-1 2-1 3-2
wissenschaftlichen Literatur vor ||| published literature ||| 0-0 1-0 1-1 2-1
wissenschaftlichen ||| scientific advice from ||| 0-0
wissenschaftlichen ||| scientific advice ||| 0-0
wissenschaftlichen ||| scientific ||| 0-0
wobei die Zusammenfassung der ||| the Summary of ||| 0-0 1-0 2-1 3-2
wobei die Zusammenfassung ||| the Summary ||| 0-0 1-0 2-1
wobei die ||| the ||| 0-0 1-0
wobei diese 4 ||| and this ||| 0-1 1-1
wobei diese 4 ||| this ||| 0-0 1-0
wobei diese ||| and this ||| 0-1 1-1
wobei diese ||| this ||| 0-0 1-0
wobei jede Tablette separat ||| unit dose blisters ||| 0-0 1-0 1-1 2-2 3-2
wobei jede ||| unit dose ||| 0-0 1-0 1-1
wofür wird es angewendet ||| what it is used ||| 0-0 0-1 2-1 1-2 3-3
wofür wird es ||| what it is ||| 0-0 0-1 2-1 1-2
wohingegen die Eliminationshalbwertszeit ||| of ||| 0-0 1-0
wohingegen die relative Wirksamkeit von ||| whilst the relative efficacy of ||| 0-0 1-1 2-2 3-3 4-4
wohingegen die relative Wirksamkeit ||| whilst the relative efficacy ||| 0-0 1-1 2-2 3-3
wohingegen die relative ||| whilst the relative ||| 0-0 1-1 2-2
wohingegen die ||| of ||| 0-0 1-0
wohingegen die ||| whilst the ||| 0-0 1-1
wohingegen ||| whilst ||| 0-0
worden . ||| . ||| 0-0 1-0
worden waren , verglichen ||| been ||| 0-0 1-0
worden waren , ||| been ||| 0-0 1-0
worden waren , ||| similar ||| 0-0 1-0
worden waren ||| been ||| 0-0 1-0
worden waren ||| similar ||| 0-0 1-0
worden ||| been ||| 0-0
wurde , auf Anforderung der ||| the request of the ||| 2-0 4-0 3-1 4-2 4-3
wurde , gab es keine ||| , there was no ||| 1-0 2-1 3-1 0-2 2-2 4-3
wurde , gab es ||| , there was ||| 1-0 2-1 3-1 0-2 2-2
wurde . Auf Anforderung der ||| the request of the ||| 2-0 4-0 3-1 4-2 4-3
wurde . Die Patienten ||| prescribed by ||| 0-0
wurde . Die Patienten ||| prescribed ||| 0-0
wurde . Die ||| prescribed by ||| 0-0
wurde . Die ||| prescribed ||| 0-0
wurde . ||| , ||| 0-0
wurde . ||| . ||| 1-0
wurde . ||| patients , ||| 0-1
wurde . ||| prescribed by ||| 0-0
wurde . ||| prescribed ||| 0-0
wurde ACOMPLIA 20 mg ||| , ACOMPLIA 20 mg was ||| 1-1 2-2 3-3 0-4
wurde ACOMPLIA 20 mg ||| ACOMPLIA 20 mg was ||| 1-0 2-1 3-2 0-3
wurde Abilify ||| Abilify ||| 0-0 1-0
wurde Aclasta ||| , Aclasta has been ||| 1-1 0-2 0-3
wurde Aclasta ||| Aclasta has been ||| 1-0 0-1 0-2
wurde Ihnen persönlich verschrieben ||| has been prescribed for you ||| 0-0 0-1 1-2 2-2 3-2 2-3 3-4
wurde am Ende der ||| at the end of the ||| 2-0 3-1 1-2 2-2 3-3 3-4
wurde an der Ratte ||| were assessed in the rat ||| 0-0 0-1 1-2 2-3 3-4
wurde an der ||| were assessed in the ||| 0-0 0-1 1-2 2-3
wurde an ||| has been studied in ||| 0-0 0-1 0-2 1-2 1-3
wurde an ||| were assessed in ||| 0-0 0-1 1-2
wurde auch die kombinierte ||| also looked at combining ||| 1-0 0-1 2-2 3-3
wurde auch die ||| also looked at ||| 1-0 0-1 2-2
wurde auch ||| also looked ||| 1-0 0-1
wurde bei 45 % ||| was observed in 45 % ||| 0-0 0-1 1-2 2-3 3-4
wurde bei 45 ||| was observed in 45 ||| 0-0 0-1 1-2 2-3
wurde bei 7 Patienten ||| was evaluated in 7 patients ||| 0-0 0-1 1-2 2-3 3-4
wurde bei 7 ||| was evaluated in 7 ||| 0-0 0-1 1-2 2-3
wurde bei 90 % ||| was observed in 90 % ||| 0-0 0-1 1-2 2-3 3-4
wurde bei 90 ||| was observed in 90 ||| 0-0 0-1 1-2 2-3
wurde bei Kindern berichtet ||| has been reported in children ||| 0-0 0-1 1-2 3-2 2-3 2-4
wurde bei Patienten berichtet ||| has been reported in patients ||| 0-0 3-1 3-2 1-3 2-4
wurde bei ||| was evaluated in ||| 0-0 0-1 1-2
wurde bei ||| was observed in ||| 0-0 0-1 1-2
wurde beobachtet ||| has been observed ||| 0-0 0-1 1-2
wurde berichtet . ||| . ||| 1-0 2-0
wurde bisher nicht ||| has not been established ||| 0-0 1-1 2-1 0-2 0-3
wurde das ||| osteoporosis ||| 0-0
wurde der Marker ||| , recovered label was ||| 2-1 2-2 0-3
wurde der Marker ||| recovered label was ||| 2-0 2-1 0-2
wurde der ||| was ||| 0-0
wurde die Anzahl der ||| and looked at the number ||| 0-1 3-2 1-3 3-3 2-4
wurde die Anzahl der ||| looked at the number ||| 0-0 3-1 1-2 3-2 2-3
wurde die Testosteronsuppression ||| , testosterone suppression was ||| 2-1 2-2 0-3
wurde die Testosteronsuppression ||| testosterone suppression was ||| 2-0 2-1 0-2
wurde die ||| was ||| 0-0
wurde durch die ||| wurde durch die ||| 0-0 1-1 2-2
wurde durch ||| wurde durch ||| 0-0 1-1
wurde ein Anstieg des ||| wurde ein Anstieg des ||| 0-0 1-1 2-1 2-2 3-3
wurde ein Anstieg ||| wurde ein Anstieg ||| 0-0 1-1 2-1 2-2
wurde ein verzögertes Wachstum des ||| was apparent in animal studies ||| 0-0 2-1 1-2 2-3 3-3 4-3 2-4
wurde ein ähnlicher signifikanter Anstieg ||| a similar significant increase ||| 1-0 2-1 3-2 0-3 4-3
wurde eine ||| was ||| 0-0 1-0
wurde hinreichend untersucht . ||| is sufficiently investigated and ||| 1-1 2-2 3-2
wurde hinreichend untersucht . ||| is sufficiently investigated ||| 1-1 2-2 3-2
wurde hinreichend untersucht . ||| sufficiently investigated and ||| 1-0 2-1 3-1
wurde hinreichend untersucht . ||| sufficiently investigated ||| 1-0 2-1 3-1
wurde hinreichend ||| is sufficiently ||| 1-1
wurde hinreichend ||| sufficiently ||| 1-0
wurde in Studien ||| in ||| 0-0 1-0 2-0
wurde in einer kleinen , ||| was studied in a small ||| 0-0 3-1 1-2 2-3 4-3 3-4
wurde in einer von ||| was found in one of ||| 0-0 1-1 1-2 2-3 3-4
wurde in einer ||| was found in one ||| 0-0 1-1 1-2 2-3
wurde in klinischen Studien ermittelt ||| were determined in clinical studies ||| 0-0 1-2 4-2 2-3 0-4 3-4
wurde in ||| has been detected in ||| 0-0 0-1 0-2 1-3
wurde in ||| was found in ||| 0-0 1-1 1-2
wurde keine Osteomalazie , ||| no osteomalacia , marrow fibrosis ||| 1-0 2-1 3-2 2-3 2-4
wurde keine ||| , no ||| 1-1
wurde keine ||| no ||| 1-0
wurde klinisch ||| wurde ||| 0-0
wurde mit ||| has been associated with ||| 0-0 0-1 1-2 1-3
wurde mit ||| have been associated with ||| 0-0 0-1 1-2 1-3
wurde nach ||| has ||| 0-0 1-0
wurde nachgewiesen , dass ||| demonstrated that ||| 0-0 1-0 2-1 3-1
wurde nachgewiesen ||| demonstrated ||| 0-0 1-0
wurde nicht evaluiert und ||| treatment was not evaluated and ||| 0-1 1-2 2-3 3-4
wurde nicht evaluiert und ||| was not evaluated and ||| 0-0 1-1 2-2 3-3
wurde nicht evaluiert ||| treatment was not evaluated ||| 0-1 1-2 2-3
wurde nicht evaluiert ||| was not evaluated ||| 0-0 1-1 2-2
wurde nicht formell untersucht ||| has not been formally investigated ||| 0-0 1-1 0-2 2-3 3-4
wurde nicht formell ||| has not been formally ||| 0-0 1-1 0-2 2-3
wurde nicht nachgewiesen . ||| has not been established . ||| 0-0 1-1 2-2 2-3 3-4
wurde nicht nachgewiesen ||| has not been established ||| 0-0 1-1 2-2 2-3
wurde nicht speziell untersucht ||| has not been studied specifically ||| 0-0 1-1 0-2 3-3 2-4
wurde nicht untersucht . ||| has not been investigated . ||| 0-0 1-1 0-2 2-3 3-4
wurde nicht untersucht ||| has not been investigated ||| 0-0 1-1 0-2 2-3
wurde nicht ||| has not been ||| 0-0 1-1 0-2
wurde nicht ||| has not ||| 0-0 1-1
wurde nicht ||| treatment was not ||| 0-1 1-2
wurde nicht ||| was not ||| 0-0 1-1
wurde signifikant ||| was significantly ||| 0-0 1-1
wurde zuletzt genehmigt ||| was last approved on ||| 0-0 1-1 2-2 2-3
wurde zuletzt genehmigt ||| was last approved ||| 0-0 1-1 2-1 2-2
wurde zuletzt im 10-2007 ||| was last updated in 10-2007 ||| 0-0 1-1 1-2 2-3 2-4 3-4
wurde zuletzt ||| was last updated ||| 0-0 1-1 1-2
wurde zuletzt ||| was last ||| 0-0 1-1
wurde ||| , ||| 0-0
wurde ||| 6 ||| 0-0
wurde ||| Four studies ||| 0-0 0-1
wurde ||| and looked ||| 0-1
wurde ||| been ||| 0-0
wurde ||| has been detected ||| 0-0 0-1 0-2
wurde ||| has been studied ||| 0-0 0-1 0-2
wurde ||| has been ||| 0-0 0-1
wurde ||| has ||| 0-0
wurde ||| have been ||| 0-0 0-1
wurde ||| looked ||| 0-0
wurde ||| osteoporosis ||| 0-0
wurde ||| patients , ||| 0-1
wurde ||| population was ||| 0-1
wurde ||| prescribed by ||| 0-0
wurde ||| prescribed ||| 0-0
wurde ||| the use of ||| 0-1 0-2
wurde ||| there was ||| 0-0 0-1
wurde ||| treatment was ||| 0-1
wurde ||| use of ||| 0-0 0-1
wurde ||| was assessed ||| 0-0 0-1
wurde ||| was evaluated ||| 0-0 0-1
wurde ||| was observed ||| 0-0 0-1
wurde ||| was ||| 0-0
wurde ||| were assessed ||| 0-0 0-1
wurde ||| were ||| 0-0
wurde ||| wurde ||| 0-0
wurde über einen Zeitraum von ||| have not been evaluated beyond ||| 0-0 3-1 0-2 4-2 0-3 1-4
wurden ( 57,3 % ) ||| ( 57.3 % ) ||| 1-0 0-1 2-1 3-2 4-3
wurden ( 57,3 % ||| ( 57.3 % ||| 1-0 0-1 2-1 3-2
wurden ( 57,3 ||| ( 57.3 ||| 1-0 0-1 2-1
wurden , beinhalteten Schläfrigkeit , ||| included somnolence , ||| 0-0 2-0 3-1 1-2 4-2
wurden , ||| been ||| 0-0
wurden , ||| were ||| 0-0
wurden . ||| study . ||| 0-0 1-1
wurden 2697 ||| 2697 ||| 0-0 1-0
wurden 508 Männer randomisiert ||| 508 men were randomised ||| 1-0 2-1 0-2 3-3
wurden 508 Männer ||| 508 men were ||| 1-0 2-1 0-2
wurden Antikörper ||| , antibodies ||| 0-0 0-1 1-1
wurden acht Hauptstudien ||| , there were eight main ||| 0-0 0-1 0-2 1-3 2-4
wurden acht ||| , there were eight ||| 0-0 0-1 0-2 1-3
wurden auch Erhöhungen der Kreatinphosphokinase ||| , elevated creatine phosphokinase ||| 0-0 0-1 1-1 2-1 2-2 3-3 4-3
wurden auch Erhöhungen ||| , elevated creatine ||| 0-0 0-1 1-1 2-1 2-2
wurden auf ||| were ||| 0-0 1-0
wurden folgende unerwünschten Wirkungen ||| following adverse reactions were ||| 1-0 2-1 2-2 0-3 3-3
wurden gelegentlich Fälle von Krampfanfällen ||| , uncommon cases of seizure ||| 0-0 0-1 1-1 2-2 3-3 4-4
wurden gelegentlich Fälle von ||| , uncommon cases of ||| 0-0 0-1 1-1 2-2 3-3
wurden gelegentlich Fälle ||| , uncommon cases ||| 0-0 0-1 1-1 2-2
wurden gelegentlich ||| , uncommon ||| 0-0 0-1 1-1
wurden im ||| were ||| 0-0 1-0
wurden nach ||| studies , ||| 0-0 0-1
wurden nicht speziell untersucht . ||| were not specifically investigated . ||| 0-0 1-1 2-2 3-3 4-4
wurden nicht speziell untersucht ||| were not specifically investigated ||| 0-0 1-1 2-2 3-3
wurden nicht speziell ||| were not specifically ||| 0-0 1-1 2-2
wurden nicht untersucht . ||| were not evaluated . ||| 0-0 1-1 2-2 3-3
wurden nicht untersucht ||| were not evaluated ||| 0-0 1-1 2-2
wurden nicht ||| were not ||| 0-0 1-1
wurden nicht ||| were ||| 0-0
wurden ohne vorherige ||| were treated without steroid ||| 0-0 0-1 1-2 2-3
wurden ohne ||| were treated without ||| 0-0 0-1 1-2
wurden unbeabsichtigte oder absichtliche akute ||| , accidental or intentional acute ||| 0-0 0-1 1-1 2-2 3-3 4-4
wurden unbeabsichtigte oder absichtliche ||| , accidental or intentional ||| 0-0 0-1 1-1 2-2 3-3
wurden unbeabsichtigte oder ||| , accidental or ||| 0-0 0-1 1-1 2-2
wurden unbeabsichtigte ||| , accidental ||| 0-0 0-1 1-1
wurden unerwünschte zerebrovaskuläre Ereignisse ( ||| , cerebrovascular adverse events ( ||| 0-0 1-1 2-1 0-2 1-2 3-3 4-4
wurden unerwünschte zerebrovaskuläre Ereignisse ||| , cerebrovascular adverse events ||| 0-0 1-1 2-1 0-2 1-2 3-3
wurden unerwünschte zerebrovaskuläre ||| , cerebrovascular adverse ||| 0-0 1-1 2-1 0-2 1-2
wurden unverändert in den ||| was recovered unchanged in the ||| 1-0 0-1 1-1 3-1 1-2 2-3 3-4
wurden vor ||| have ||| 0-0 1-0
wurden ||| , there were ||| 0-0 0-1 0-2
wurden ||| 3 trials ||| 0-1
wurden ||| been reduced ||| 0-0
wurden ||| been ||| 0-0
wurden ||| cases reported ||| 0-0 0-1
wurden ||| festgestellt wurden ||| 0-1
wurden ||| have been ||| 0-0 0-1
wurden ||| have ||| 0-0
wurden ||| studies , ||| 0-0 0-1
wurden ||| studies ||| 0-0
wurden ||| study ||| 0-0
wurden ||| trials ||| 0-0
wurden ||| were carried out , ||| 0-0 0-3
wurden ||| were observed ||| 0-0 0-1
wurden ||| were treated ||| 0-0 0-1
wurden ||| were ||| 0-0
wurden ||| wurden ||| 0-0
wurden. er Die ||| wurden. er Die ||| 0-0 1-1 2-2
wurden. er ||| wurden. er ||| 0-0 1-1
wurden. ||| wurden. ||| 0-0
während 2 Monaten wurde ||| 2 months was ||| 1-0 2-1 0-2 3-2
während ca. 86 % ||| while approximately 86 % ||| 0-0 1-1 2-2 3-3
während ca. 86 ||| while approximately 86 ||| 0-0 1-1 2-2
während ca. ||| while approximately ||| 0-0 1-1
während der Behandlung eingestellt werden ||| for the duration of therapy ||| 3-0 1-1 2-1 3-2 1-3 3-3 4-4
während der Behandlung eingestellt ||| for the duration of ||| 3-0 1-1 2-1 3-2 1-3 3-3
während der Behandlung mit Aripiprazol ||| during treatment with aripiprazole . ||| 0-0 1-0 2-1 3-2 4-3
während der Behandlung mit Aripiprazol ||| during treatment with aripiprazole ||| 0-0 1-0 2-1 3-2 4-3
während der Behandlung mit Epoetin ||| during treatment with epoetin ||| 0-0 1-0 2-1 3-2 4-3
während der Behandlung mit ||| during treatment with ||| 0-0 1-0 2-1 3-2
während der Behandlung ||| during treatment ||| 0-0 1-0 2-1
während der Laktation. ||| during lactation . ||| 0-0 1-0 0-1
während der Laktation. ||| during lactation ||| 0-0 1-0 0-1
während der Post-Marketing Überwachung berichtet ||| reported during post-marketing surveillance ||| 2-0 0-1 1-1 2-1 2-2 2-3 3-3 4-3
während der Prüfung ||| treatment during the assessment ||| 0-0 0-1 1-1 1-2 2-2 2-3
während der Pubertät oder wegen ||| during puberty or due to ||| 0-0 1-0 2-1 4-1 3-2 4-3 4-4
während der Risikozeitspanne ||| adequate clinical monitoring during the ||| 2-0 2-1 2-2 0-3 1-3 1-4
während der Schwangerschaft angewendet wird ||| administered during pregnancy ||| 3-0 0-1 1-1 2-2
während der Schwangerschaft angewendet ||| administered during pregnancy ||| 3-0 0-1 1-1 2-2
während der Schwangerschaft und ||| during pregnancy and ||| 0-0 1-0 2-1 3-2
während der Schwangerschaft zu belegen ||| during pregnancy ||| 0-0 1-0 2-1 4-1
während der Schwangerschaft ||| during pregnancy ||| 0-0 1-0 2-1
während der Schwangerschaft ||| während der ||| 0-0 0-1 1-1
während der Therapie ||| during therapy ||| 0-0 2-1
während der Trächtigkeit , Laktation ||| during pregnancy , lactation ||| 0-0 1-0 2-1 3-2 4-3
während der Trächtigkeit , ||| during pregnancy , ||| 0-0 1-0 2-1 3-2
während der Trächtigkeit und Laktation ||| during pregnancy and lactation ||| 0-0 1-0 2-1 3-2 4-3
während der Trächtigkeit und ||| during pregnancy and ||| 0-0 1-0 2-1 3-2
während der Trächtigkeit ||| during pregnancy ||| 0-0 1-0 2-1
während der ||| during lactation . ||| 0-0 1-0 0-1
während der ||| during lactation ||| 0-0 1-0 0-1
während der ||| during the ||| 0-0 1-0 1-1
während der ||| during ||| 0-0
während der ||| during ||| 0-0 1-0
während der ||| while the ||| 0-0 1-1
während der ||| während der ||| 0-0 0-1 1-1
während die Cmax unverändert blieb ||| while Cmax was unchanged ||| 0-0 1-0 4-0 2-1 3-2 3-3 4-3
während und ||| during and ||| 0-0 1-1
während ||| develop such ||| 0-0
während ||| develop ||| 0-0
während ||| during ||| 0-0
während ||| while ||| 0-0
während ||| whilst ||| 0-0
wässrige Lösung . ||| aqueous solution . ||| 0-0 1-1 2-2
wässrige Lösung ||| aqueous solution ||| 0-0 1-1
wässrige ||| aqueous ||| 0-0
wöchentlich . ||| a week . ||| 0-0 0-1 1-2
wöchentlich durch Injektion ||| week by injection ||| 0-0 1-1 2-2
wöchentlich durch ||| week by ||| 0-0 1-1
wöchentlich ||| a week ||| 0-0 0-1
wöchentlich ||| week ||| 0-0
wöchentliche Dosis liegt zwischen 75 ||| weekly dose is between 75 ||| 0-0 1-1 2-2 2-3 3-3 4-4
wöchentliche Dosis liegt zwischen ||| weekly dose is between ||| 0-0 1-1 2-2 2-3 3-3
wöchentliche Dosis ||| weekly dose ||| 0-0 1-1
wöchentliche Gesamtdosis liegt zwischen ||| total weekly dose is between ||| 0-0 1-0 0-1 1-2 2-3 2-4 3-4
wöchentliche Gesamtdosis ||| total weekly dose ||| 0-0 1-0 0-1 1-2
wöchentliche ||| weekly ||| 0-0
wünschen , lesen Sie bitte ||| recommendations , read ||| 0-0 1-1 2-2 3-2 4-2
wünschen , lesen Sie ||| recommendations , read ||| 0-0 1-1 2-2 3-2
wünschen , lesen Sie ||| wünschen , lesen Sie bitte ||| 0-0 1-1 2-2 3-3 2-4
wünschen , ||| recommendations , ||| 0-0 1-1
wünschen , ||| wünschen , ||| 0-0 1-1
wünschen ||| recommendations ||| 0-0
wünschen ||| wünschen ||| 0-0
x 1 , 49 x ||| x 1 , 49 x ||| 0-0 1-1 2-2 3-3 4-4
x 1 , 49 ||| x 1 , 49 ||| 0-0 1-1 2-2 3-3
x 1 , 56 x ||| x 1 , 56 x ||| 0-0 1-1 2-2 3-3 4-4
x 1 , 56 ||| x 1 , 56 ||| 0-0 1-1 2-2 3-3
x 1 , 98 x ||| x 1 , 98 x ||| 0-0 1-1 2-2 3-3 4-4
x 1 , 98 ||| x 1 , 98 ||| 0-0 1-1 2-2 3-3
x 1 , ||| x 1 , ||| 0-0 1-1 2-2
x 1 Filmtablette in ||| x 1 film-coated tablets in ||| 0-0 1-1 2-2 0-3 3-4
x 1 Filmtablette ||| x 1 film-coated tablets ||| 0-0 1-1 2-2 0-3
x 1 Schmelztabletten 28 ||| x 1 orodispersible tablets 28 ||| 0-0 1-1 2-2 2-3 3-4
x 1 Schmelztabletten 49 ||| x 1 orodispersible tablets 49 ||| 0-0 1-1 2-2 2-3 3-4
x 1 Schmelztabletten ||| x 1 orodispersible tablets ||| 0-0 1-1 2-2 2-3
x 1 Tabletten . ||| x 1 tablets . ||| 0-0 1-1 2-2 3-3
x 1 Tabletten 28 x ||| x 1 tablets 28 x ||| 0-0 1-1 2-2 3-3 4-4
x 1 Tabletten 28 ||| x 1 tablets 28 ||| 0-0 1-1 2-2 3-3
x 1 Tabletten 49 x ||| x 1 tablets 49 x ||| 0-0 1-1 2-2 3-3 4-4
x 1 Tabletten 49 ||| x 1 tablets 49 ||| 0-0 1-1 2-2 3-3
x 1 Tabletten 56 x ||| x 1 tablets 56 x ||| 0-0 1-1 2-2 3-3 4-4
x 1 Tabletten 56 ||| x 1 tablets 56 ||| 0-0 1-1 2-2 3-3
x 1 Tabletten 98 x ||| x 1 tablets 98 x ||| 0-0 1-1 2-2 3-3 4-4
x 1 Tabletten 98 ||| x 1 tablets 98 ||| 0-0 1-1 2-2 3-3
x 1 Tabletten in ||| x 1 tablets in ||| 0-0 1-1 2-2 3-3
x 1 Tabletten ||| x 1 tablets ||| 0-0 1-1 2-2
x 1 ||| x 1 ||| 0-0 1-1
x 109/l angestiegen ist und ||| x 109/ l and ||| 0-0 1-1 2-1 2-2 3-2 4-3
x 109/l angestiegen ist ||| x 109/ l ||| 0-0 1-1 2-1 2-2 3-2
x 109/l erholt hat . ||| x 109/ l. ||| 0-0 1-1 2-1 1-2 3-2 4-2
x H2O ( E172 ) ||| iron oxide ( E172 ) ||| 3-0 1-1 3-1 0-2 2-2 3-3 4-4
x H2O ( E172 ||| iron oxide ( E172 ||| 3-0 1-1 3-1 0-2 2-2 3-3
x ULN ) sollten nicht ||| x ULN ) should not ||| 0-0 1-1 2-2 3-3 4-4
x ULN ) sollten ||| x ULN ) should ||| 0-0 1-1 2-2 3-3
x ULN ) ||| x ULN ) ||| 0-0 1-1 2-2
x ULN oder ASL/ALT ||| x ULN or ASL/ ||| 0-0 1-1 2-2 3-3
x ULN oder ||| x ULN or ||| 0-0 1-1 2-2
x ULN ||| x ULN ||| 0-0 1-1
x ||| x ||| 0-0
z. B. Aminoglykoside oder Diuretika ||| e. g. aminoglycosides or diuretics ||| 0-0 1-0 1-1 2-2 3-3 4-4
z. B. Aminoglykoside oder ||| e. g. aminoglycosides or ||| 0-0 1-0 1-1 2-2 3-3
z. B. Aminoglykoside ||| e. g. aminoglycosides ||| 0-0 1-0 1-1 2-2
z. B. Rifampicin ||| e. g. rifampicin ||| 0-0 0-1 1-1 2-2
z. B. Stenosen ||| e. g. stenoses ||| 0-0 1-0 1-1 2-2
z. B. Unterfunktion der Nebenschilddrüsen ||| e. g. diminished parathyroid reserve ||| 0-0 1-1 2-2 4-3 4-4
z. B. Unterfunktion der ||| e. g. diminished ||| 0-0 1-1 2-2
z. B. Unterfunktion ||| e. g. diminished ||| 0-0 1-1 2-2
z. B. mehr körperliche ||| e. g. increased exercise ||| 0-0 0-1 1-1 3-3
z. B. mehr ||| e. g. increased ||| 0-0 0-1 1-1
z. B. mehr ||| e. g. ||| 0-0 0-1 1-1
z. B. verminderte ||| e. g. ||| 0-0 1-1 2-1
z. B. ||| . ||| 0-0 1-0
z. B. ||| e. g. increased ||| 0-0 0-1 1-1
z. B. ||| e. g. ||| 0-0 0-1 1-1
z. B. ||| e. g. ||| 0-0 1-0 1-1
z. B. ||| e. g. ||| 0-0 1-1
z. B. ||| e. ||| 0-0 1-0
z. B. ||| swelling and inflammation . ||| 0-0 0-1 0-2 1-2 0-3
z. ||| e. ||| 0-0
z.B . : Schlaganfall ||| e. g. stroke ||| 0-0 1-0 0-1 2-2 3-2
z.B . Gemfibrozil ||| e. g. gemfibrozil ||| 0-0 1-0 0-1 2-2
z.B . Hypothermie , Pyrexie ||| e. g. hypothermia , pyrexia ||| 0-0 0-1 1-2 2-2 3-3 4-4
z.B . Hypothermie , ||| e. g. hypothermia , ||| 0-0 0-1 1-2 2-2 3-3
z.B . Hypothermie ||| e. g. hypothermia ||| 0-0 0-1 1-2 2-2
z.B . ||| e. g. , ||| 0-0 0-1 1-1
z.B . ||| e. g. ||| 0-0 0-1 1-1
z.B . ||| e. g. ||| 0-0 1-0 0-1
z.B . ||| e. ||| 0-0 1-0
z.B ||| e. g. ||| 0-0 0-1
z.B. anaphylaktische Reaktion , ||| e. g. anaphylactic reaction , ||| 0-0 1-1 0-2 1-2 2-3 3-4
z.B. anaphylaktische Reaktion ||| e. g. anaphylactic reaction ||| 0-0 1-1 0-2 1-2 2-3
z.B. anaphylaktische ||| e. g. anaphylactic ||| 0-0 1-1 0-2 1-2
z.B. ||| e. g. prior ||| 0-0 0-1 0-2
zahnmedizinischen Operation ||| dental surgery ||| 0-0 1-1
zahnmedizinischen ||| dental ||| 0-0
zahnärztlicher Behandlung befinden oder sich ||| dental treatment or ||| 0-0 2-0 1-1 3-2
zahnärztlicher Behandlung befinden oder ||| dental treatment or ||| 0-0 2-0 1-1 3-2
zahnärztlicher Behandlung befinden ||| dental treatment ||| 0-0 2-0 1-1
zeigen ; die Häufigkeit von ||| ; the incidence of ||| 1-0 0-1 2-1 3-2 4-3
zeigen ; die Häufigkeit ||| ; the incidence ||| 1-0 0-1 2-1 3-2
zeigen ; die ||| ; the ||| 1-0 0-1 2-1
zeigt , dass Pioglitazon ||| shows that pioglitazone improves ||| 0-0 1-1 2-1 3-2 0-3 2-3
zeigt eine hohe ||| displays high ||| 0-0 1-1 2-1
zeigt ||| displays ||| 0-0
zeigte Aripiprazol ||| , aripiprazole failed ||| 0-0 1-1 0-2
zeigte Aripiprazol ||| , aripiprazole failed ||| 1-1 0-2
zeigte Aripiprazol ||| aripiprazole failed ||| 1-0 0-1
zeigte im Tiermodell ||| exhibited antagonist properties in ||| 0-0 2-1 1-2 2-2 1-3
zeigte in einer umfangreichen ||| devoid of genotoxic potential in ||| 0-0 3-0 2-1 1-2 2-2 3-2 3-3 1-4
zeigte keinerlei Veränderungen ||| did not show any changes ||| 0-0 1-0 1-1 1-2 1-3 2-4
zeigte keinerlei ||| did not show any ||| 0-0 1-0 1-1 1-2 1-3
zeigte sich unter Pioglitazon durchgängig ||| , pioglitazone consistently gave ||| 1-0 3-1 0-2 1-2 4-2 2-3 4-3
zeigte sich ||| a ||| 0-0 1-0
zeigte ||| exhibited ||| 0-0
zeigte ||| failed ||| 0-0
zeigte ||| in ||| 0-0
zeigte ||| showed ||| 0-0
zeigte ||| substance in ||| 0-1
zeigten keine ||| shown no ||| 0-0 1-1
zeigten ||| showed ||| 0-0
zeigten ||| shown ||| 0-0
zentral wirksamen Arzneimitteln mit ||| CNS medicinal products with ||| 0-0 1-0 2-1 2-2 3-3
zentral wirksamen Arzneimitteln ||| CNS medicinal products ||| 0-0 1-0 2-1 2-2
zentral wirksamen ||| CNS ||| 0-0 1-0
zerbrechlich ist , ||| is fragile , ||| 1-0 0-1 2-2
zerbrechlich ist ||| is fragile ||| 1-0 0-1
zerbrechlich ||| fragile ||| 0-0
zerebrovaskuläre ||| cerebrovascular ||| 0-0
ziehen ||| seek ||| 0-0
zu ( kg ||| Subjects ||| 0-0 1-0 2-0
zu 2 ||| 2 ||| 1-0
zu 21 % der ||| to 21 % of ||| 0-0 1-1 2-2 3-3
zu 21 % ||| to 21 % ||| 0-0 1-1 2-2
zu 21 ||| to 21 ||| 0-0 1-1
zu 25 °C ) , ||| up to 25°C ) ||| 0-0 2-0 0-1 4-1 1-2 2-2 3-3
zu 50 ||| 50 ||| 1-0
zu 8,7 % bei ||| 8.7 % for ||| 1-0 2-1 3-2
zu 8,7 % ||| 8.7 % ||| 1-0 2-1
zu 8,7 ||| 8.7 ||| 1-0
zu ABILIFY Tabletten ||| ABILIFY tablets ||| 1-0 2-1
zu ABILIFY ||| ABILIFY ||| 1-0
zu ANHANG ||| ra ge ||| 0-0 1-0 1-1
zu Aripiprazol Tabletten mit ||| to aripiprazole tablets , with ||| 0-0 1-1 2-2 3-4
zu Aripiprazol Tabletten ||| to aripiprazole tablets , ||| 0-0 1-1 2-2
zu Aripiprazol Tabletten ||| to aripiprazole tablets ||| 0-0 1-1 2-2
zu Aripiprazol ||| to aripiprazole ||| 0-0 1-1
zu Bluthochdruck kommen . ||| treated patients . ||| 0-0 1-0 2-0 1-1 3-2
zu Bluthochdruck kommen ||| treated patients ||| 0-0 1-0 2-0 1-1
zu Die folgende ||| resulted in recovery in all ||| 0-0 0-1 2-1 1-2
zu Die folgende ||| resulted in recovery in ||| 0-0 0-1 2-1 1-2
zu Die folgende ||| resulted in recovery ||| 0-0 0-1 2-1 1-2
zu Die ||| The ||| 1-0
zu Diät ||| to diet ||| 0-0 1-1
zu Erbrechen , Durchfall ||| vomiting , diarrhoea , ||| 1-0 2-1 3-2 2-3
zu Erbrechen ||| vomiting ||| 1-0
zu Expositionen ||| exposures ||| 1-0
zu Expositionen ||| in exposures ||| 1-1
zu Laboruntersuchungen ACOMPLIA ||| or ACOMPLIA has not ||| 0-0 1-1 2-1 1-2 1-3
zu Muscarin-Rezeptoren . ||| muscarinic receptors . ||| 0-0 1-0 1-1 2-2
zu Muscarin-Rezeptoren ||| muscarinic receptors ||| 0-0 1-0 1-1
zu Männern erforderlich ( ||| to male patients ( ||| 0-0 1-1 2-1 2-2 3-3
zu Männern erforderlich ||| to male patients ||| 0-0 1-1 2-1 2-2
zu Placebo -2,9 kg ) ||| to placebo -2.9 kg ) ||| 0-0 1-1 2-2 3-3 4-4
zu Placebo -2,9 kg ||| to placebo -2.9 kg ||| 0-0 1-1 2-2 3-3
zu Placebo -2,9 ||| to placebo -2.9 ||| 0-0 1-1 2-2
zu Placebo . ||| to placebo . ||| 0-0 1-1 2-2
zu Placebo : ||| placebo : ||| 0-0 1-0 2-1
zu Placebo ||| placebo ||| 0-0 1-0
zu Placebo ||| to placebo ||| 0-0 1-1
zu Plazebo ||| free fatty ||| 1-0 0-1 1-1
zu Störungen ||| Obesity is ||| 0-0 1-0 0-1
zu Wirkungen führen , ||| produce effects that ||| 0-0 1-0 2-0 1-1 2-2 3-2
zu anderen ||| other ||| 1-0
zu bevorzugen . ||| be preferable . ||| 0-0 1-1 2-2
zu bevorzugen ||| be preferable ||| 0-0 1-1
zu den ||| to that ||| 0-0 1-0
zu den ||| to ||| 0-0 1-0
zu der von Tabletten . ||| to tablets . ||| 0-0 1-0 2-0 3-1 4-2
zu der von Tabletten ||| to tablets ||| 0-0 1-0 2-0 3-1
zu der von ||| to ||| 0-0 1-0 2-0
zu drei Injektionen ||| three injections in ||| 1-0 2-1
zu drei Injektionen ||| three injections ||| 1-0 2-1
zu drei ||| three ||| 1-0
zu einem geringeren Ausmaß ||| a lesser amount ||| 1-0 2-1 3-1 2-2
zu einem ||| a ||| 1-0
zu einem ||| one ||| 1-0
zu einer Dosis von 80 ||| following dosing from 80 ||| 3-0 3-1 0-2 1-2 3-2 4-3
zu einer Dosis von ||| following dosing from ||| 3-0 3-1 0-2 1-2 3-2
zu einer Hemmung der normalen ||| the inhibition of the normal ||| 0-0 3-0 2-1 1-2 3-2 3-3 4-4
zu einer Hemmung der ||| the inhibition of the ||| 0-0 3-0 2-1 1-2 3-2 3-3
zu einer Hyperglykämie führen . ||| may lead to hyperglycaemia . ||| 3-0 0-1 1-1 3-1 0-2 2-3 3-3 4-4
zu einer Hyperglykämie führen ||| may lead to hyperglycaemia ||| 3-0 0-1 1-1 3-1 0-2 2-3 3-3
zu einer Hypoglykämie führen . ||| lead to hypoglycaemia . ||| 0-0 1-0 3-0 0-1 2-2 4-3
zu einer Hypoglykämie führen ||| lead to hypoglycaemia ||| 0-0 1-0 3-0 0-1 2-2
zu einer Zunahme der ||| lead to an increase ||| 0-0 1-0 2-0 0-1 2-2 2-3 3-3
zu einer Zunahme ||| lead to an increase ||| 0-0 2-0 0-1 1-2 2-2 2-3
zu einer anders lautenden ||| otherwise decided by ||| 2-0 2-1 3-1 1-2
zu einer bestehenden Behandlung mit ||| to existing treatment with ||| 0-0 1-1 2-1 3-2 4-3
zu einer bestehenden Behandlung ||| to existing treatment ||| 0-0 1-1 2-1 3-2
zu einer bestehenden ||| to existing ||| 0-0 1-1 2-1
zu einer dosisabhängigen Senkung von ||| dose dependent decreases in serum ||| 1-0 4-0 2-3 3-3 4-3 4-4
zu einer guten Kontrolle . ||| controlled by systemic chemotherapy . ||| 3-0 1-1 2-2 2-3 4-4
zu einer guten Kontrolle ||| controlled by systemic chemotherapy ||| 3-0 1-1 2-2 2-3
zu einer guten ||| by systemic chemotherapy ||| 1-0 2-1 2-2
zu einer verminderten Exposition gegenüber ||| to reduce the exposure of ||| 0-0 1-0 2-1 3-3 4-3
zu einer verminderten Exposition gegenüber ||| to reduce the exposure ||| 0-0 1-0 2-1 3-3 4-3
zu einer verminderten ||| to reduce the ||| 0-0 1-0 2-1
zu einer verminderten ||| to reduce ||| 0-0 1-0 2-1
zu einer weiteren ||| lead to further ||| 0-0 1-0 0-1 2-2
zu einer ||| by ||| 1-0
zu einer ||| greater ||| 0-0
zu einer ||| lead to ||| 0-0 1-0 0-1
zu einer ||| to a ||| 0-0 1-1
zu einer ||| to ||| 0-0 1-0
zu enthalten , jedoch ||| , but ||| 2-0 3-1
zu enthalten , ||| , ||| 2-0
zu entsorgen . ||| local requirements . ||| 0-0 1-0 1-1 2-2
zu entsorgen ||| local requirements ||| 0-0 1-0 1-1
zu erhöhen ||| to increase their ||| 0-0 1-1 0-2
zu erleichtern . ||| re- suspension . ||| 0-0 1-0 1-1 2-2
zu erleichtern . ||| re-suspension . ||| 0-0 1-0 2-1
zu erleichtern ||| re- suspension ||| 0-0 1-0 1-1
zu erleichtern ||| re-suspension ||| 0-0 1-0
zu ermitteln ||| lowest effective ||| 1-0 1-1
zu erreichen ||| l ||| 0-0 1-0
zu erwarten , dass ||| unlikely to ||| 1-0 3-0 0-1 2-1
zu erwarten . ||| to be expected . ||| 0-0 0-1 1-2 2-3
zu erwarten ||| to be expected ||| 0-0 0-1 1-2
zu erwartenden Vorteil ||| benefit to be derived from ||| 1-0 0-1 1-2 1-3 2-3 2-4
zu exzessiver Sedierung und ||| with excessive sedation and ||| 0-0 0-1 1-1 2-2 3-3
zu exzessiver Sedierung ||| with excessive sedation ||| 0-0 0-1 1-1 2-2
zu exzessiver ||| with excessive ||| 0-0 0-1 1-1
zu gelangen ||| Public Assessment Report ( EPAR ||| 0-0 1-0 1-1 1-2 1-3 1-4
zu geringen inhibitorischen Effekt auf ||| mild inhibitory effect on ||| 0-0 1-0 1-1 2-1 3-1 3-2 4-3
zu geringen inhibitorischen Effekt ||| mild inhibitory effect ||| 0-0 1-0 1-1 2-1 3-1 3-2
zu halten . ||| . ||| 2-0
zu halten ||| values ||| 1-0
zu hoch ist ( ||| to the insulin requirement ( ||| 0-0 1-1 1-2 1-3 2-3 3-4
zu hoch ist . ||| to the insulin requirement . ||| 0-0 1-1 1-2 1-3 2-3 3-4
zu hoch ist ||| to the insulin requirement ||| 0-0 1-1 1-2 1-3 2-3
zu hoch ist ||| too high . ||| 0-0 1-0 1-1 2-1 0-2
zu hoch sind , ||| are too high ||| 2-0 0-1 1-1 1-2
zu hoch sind ||| are too high ||| 2-0 0-1 1-1 1-2
zu hoch ||| too high ||| 0-0 1-0 1-1
zu je 10 ml und ||| x 10 ml and ||| 0-0 1-0 2-1 3-2 4-3
zu je 10 ml ||| x 10 ml ||| 0-0 1-0 2-1 3-2
zu je 10 ||| x 10 ||| 0-0 1-0 2-1
zu je ||| x ||| 0-0 1-0
zu kontrollieren . ||| in all ||| 0-0 1-1
zu kontrollieren . ||| therapy . ||| 0-0 1-0 2-1
zu kontrollieren ||| all ||| 1-0
zu kontrollieren ||| in all ||| 0-0 1-1
zu kontrollieren ||| therapy ||| 0-0 1-0
zu legen nahe , dass ||| Limited data suggest ||| 1-0 1-1 2-1 2-2 4-2
zu nehmen . ||| difficult . ||| 0-0 1-0 2-1
zu nehmen ||| difficult ||| 0-0 1-0
zu niedrigen ||| to low ||| 0-0 1-1
zu schützen . ||| from light . ||| 1-0 0-1 1-1 2-2
zu schützen . ||| from moisture . ||| 1-0 0-1 1-1 2-2
zu schützen . ||| light . ||| 0-0 1-0 2-1
zu schützen . ||| moisture . ||| 0-0 1-0 2-1
zu schützen ||| from light ||| 1-0 0-1 1-1
zu schützen ||| from moisture ||| 1-0 0-1 1-1
zu schützen ||| light ||| 0-0 1-0
zu schützen ||| moisture ||| 0-0 1-0
zu sein . ||| to be low . ||| 0-0 1-1 0-2 2-3
zu sein ||| to be low ||| 0-0 1-1 0-2
zu treffen . ||| episodes of hypoglycaemia . ||| 1-0 0-1 1-1 1-2 2-3
zu treffen ||| episodes of hypoglycaemia ||| 1-0 0-1 1-1 1-2
zu um 5 % ansteigt ||| zu um 5 % ansteigt ||| 0-0 1-1 2-2 3-3 4-4
zu um 5 % ||| zu um 5 % ||| 0-0 1-1 2-2 3-3
zu um 5 ||| zu um 5 ||| 0-0 1-1 2-2
zu um ||| zu um ||| 0-0 1-1
zu verabreichen . ||| treatment in between . ||| 0-0 0-1 1-3 2-3
zu verabreichen . ||| without treatment in between . ||| 0-1 0-2 1-4 2-4
zu viele Tabletten eingenommen haben ||| take too many tablets ||| 3-0 0-1 1-1 1-2 3-2 2-3 4-3
zu wissen , ob ||| to know if ||| 0-0 1-1 2-1 3-2
zu wissen , ||| to know ||| 0-0 1-1 2-1
zu ||| Packungsbeilage zu entnehmen . ||| 0-1
zu ||| Packungsbeilage zu entnehmen ||| 0-1
zu ||| Packungsbeilage zu ||| 0-1
zu ||| advice ||| 0-0
zu ||| be ||| 0-0
zu ||| greater ||| 0-0
zu ||| high ||| 0-0
zu ||| in ||| 0-0
zu ||| is ||| 0-0
zu ||| or the ||| 0-1
zu ||| or ||| 0-0
zu ||| ra This document is a ||| 0-0 0-1 0-2 0-3
zu ||| ra This document is ||| 0-0 0-1 0-2 0-3
zu ||| relative to ||| 0-1
zu ||| show ||| 0-0
zu ||| the ||| 0-0
zu ||| this to ||| 0-0 0-1
zu ||| to be ||| 0-0 0-1
zu ||| to ||| 0-0
zu ||| too ||| 0-0
zu ||| treatment in between ||| 0-0 0-1
zu ||| treatment in ||| 0-0 0-1
zu ||| with ||| 0-0
zu ||| without treatment in between ||| 0-1 0-2
zu ||| without treatment in ||| 0-1 0-2
zu ||| zu entnehmen . ||| 0-0
zu ||| zu entnehmen ||| 0-0
zu ||| zu ||| 0-0
zufriedenstellend eingestellt ||| satisfactorily controlled ||| 0-0 1-1
zufriedenstellend ||| satisfactorily ||| 0-0
zugelassen , jedoch keine ||| for osteoporosis , but not ||| 0-0 1-1 1-2 2-3 3-4
zugelassen , jedoch ||| for osteoporosis , but ||| 0-0 1-1 1-2 2-3
zugelassen , ||| for osteoporosis , ||| 0-0 1-1 1-2
zugelassen . ||| psychosis . ||| 0-0 1-1
zugelassen ||| for ||| 0-0
zugelassen ||| psychosis ||| 0-0
zugelassene Indikation ||| indication of ||| 0-0 1-0
zugelassene Indikation ||| indication ||| 0-0 1-0
zugeschraubt werden . ||| on tightly . ||| 0-1 1-1 2-2
zugeschraubt werden . ||| tightly . ||| 0-0 1-0 2-1
zugeschraubt werden ||| on tightly ||| 0-1 1-1
zugeschraubt werden ||| tightly ||| 0-0 1-0
zugrunde ||| underlying ||| 0-0
zugunsten der Kontrollen . ||| favour of controls . ||| 0-0 1-1 2-2 3-3
zugunsten der Kontrollen ||| favour of controls ||| 0-0 1-1 2-2
zugunsten der ||| favour of ||| 0-0 1-1
zugunsten ||| favour ||| 0-0
zulassen . ||| comparisons . ||| 0-0 1-1
zulassen ||| comparisons ||| 0-0
zuletzt genehmigt ||| last approved on ||| 0-0 1-1 1-2
zuletzt genehmigt ||| last approved ||| 0-0 1-0 1-1
zuletzt im 10-2007 ||| last updated in 10-2007 ||| 0-0 0-1 1-2 1-3 2-3
zuletzt im ||| product , scientific ||| 0-0 0-2
zuletzt ||| last updated ||| 0-0 0-1
zuletzt ||| last ||| 0-0
zuletzt ||| product , scientific ||| 0-0 0-2
zum Abbau ihres inneren ||| to break down their internal ||| 0-0 1-1 1-2 2-3 2-4 3-4
zum Abbau ||| to break down ||| 0-0 1-1 1-2
zum Abklingen ||| to resolution ||| 0-0 1-1
zum Absetzen ||| in discontinuation ||| 0-0 1-1
zum Ausgangswert ||| relative to baseline ||| 0-0 0-1 1-2
zum Dopamin D4- , ||| dopamine D4 , ||| 1-0 0-1 2-1 3-2
zum Dopamin D4- ||| dopamine D4 ||| 1-0 0-1 2-1
zum Dopamin ||| dopamine ||| 0-0 1-0
zum Einnehmen resorbiert ( ||| oral ||| 0-0 1-0 2-0
zum Einnehmen resorbiert ||| oral ||| 0-0 1-0 2-0
zum Einnehmen ||| , the oral ||| 0-1 0-2 1-2
zum Einnehmen ||| oral doses of ||| 0-0 1-0
zum Einnehmen ||| oral doses ||| 0-0 1-0
zum Einnehmen ||| oral ||| 0-0 1-0
zum Einnehmen ||| the oral ||| 0-0 0-1 1-1
zum Histamin-H1Rezeptor . ||| H1 receptors . ||| 0-0 1-0 1-1 2-2
zum Histamin-H1Rezeptor ||| H1 receptors ||| 0-0 1-0 1-1
zum Serotonin 5HT1a- ||| , serotonin 5HT1a ||| 0-1 1-1 2-2
zum Serotonin 5HT1a- ||| serotonin 5HT1a ||| 0-0 1-0 2-1
zum Serotonin 5HT2c- und ||| serotonin 5HT2c and 5HT7 ||| 1-0 0-1 1-1 2-1 3-2 2-3
zum Serotonin ||| , serotonin ||| 0-1 1-1
zum Serotonin ||| serotonin ||| 0-0 1-0
zum Teil durch die ||| , in part , by ||| 0-1 1-2 3-3 2-4 3-4
zum Teil durch die ||| in part , by ||| 0-0 1-1 3-2 2-3 3-3
zum Teil ||| , in part ||| 0-1 1-2
zum Teil ||| in part ||| 0-0 1-1
zum alpha-1-adrenergen und zum Histamin-H1Rezeptor ||| adrenergic and histamine H1 receptors ||| 0-0 1-0 2-1 1-2 3-3 4-3 4-4
zum alpha-1-adrenergen und ||| adrenergic and histamine ||| 0-0 1-0 2-1 1-2
zum karzinogenen Potential von Paclitaxel ||| carcinogenic potential of paclitaxel has ||| 0-0 1-0 2-0 1-1 3-2 3-3 4-3 4-4
zum karzinogenen Potential ||| carcinogenic potential ||| 0-0 1-0 2-0 1-1
zum ||| , in ||| 0-1
zum ||| in ||| 0-0
zum ||| relative to ||| 0-0 0-1
zum ||| to ||| 0-0
zum ||| zum Einnehmen ||| 0-0 0-1
zum ||| zum ||| 0-0
zunehmendem Gewicht von 65 ||| As weight increases from 65 ||| 0-0 1-1 0-2 2-3 3-4
zunehmendem Gewicht von ||| As weight increases from ||| 0-0 1-1 0-2 2-3
zunehmendem Gewicht ||| As weight increases ||| 0-0 1-1 0-2
zunehmender Studienlänge : ||| increasing study duration : ||| 0-0 1-1 1-2 2-3
zunehmender Studienlänge ||| increasing study duration ||| 0-0 1-1 1-2
zunehmender ||| increasing ||| 0-0
zunimmt , informieren Sie bitte ||| increases , inform ||| 0-0 1-1 2-2 3-2 4-2
zunimmt , ||| increases , ||| 0-0 1-1
zunimmt ||| increases ||| 0-0
zunächst ||| orally during ||| 0-0
zunächst ||| orally ||| 0-0
zur Abgabe von Einzeldosen . ||| unit dose blister packs . ||| 0-0 1-0 3-0 1-1 2-1 3-2 3-3 4-4
zur Abgabe von Einzeldosen . ||| unit dose blisters . ||| 0-0 1-0 1-1 2-2 3-2 4-3
zur Abgabe von Einzeldosen ||| unit dose blister packs ||| 0-0 1-0 3-0 1-1 2-1 3-2 3-3
zur Abgabe von Einzeldosen ||| unit dose blisters ||| 0-0 1-0 1-1 2-2 3-2
zur Abgabe ||| unit dose ||| 0-0 1-0 1-1
zur Aripiprazol Injektionslösung ||| to aripiprazole solution for injection ||| 0-0 1-1 2-2 2-3 2-4
zur Aripiprazol ||| to aripiprazole ||| 0-0 1-1
zur Behandlung der Osteoporose bei ||| used to treat osteoporosis in ||| 0-0 0-1 0-2 1-2 3-3 2-4 4-4
zur Behandlung von Diabetes ||| used to treat diabetes ||| 0-0 0-1 0-2 1-2 2-2 3-3
zur Behandlung von Typ-2-Diabetes ||| to treat type 2 ||| 0-0 0-1 1-1 2-1 3-2 3-3
zur Behandlung von metastasierendem Brustkrebs ||| to treat metastatic breast cancer ||| 0-0 0-1 1-1 2-1 3-2 3-3 4-3 3-4
zur Behandlung von ||| for the treatment of ||| 0-0 1-2 2-3
zur Behandlung von ||| to treat ||| 0-0 0-1 1-1 2-1
zur Behandlung von ||| used to treat ||| 0-0 0-1 0-2 1-2 2-2
zur Behandlung ||| for the treatment ||| 0-0 1-2
zur Behandlung ||| to treat ||| 0-0 0-1 1-1
zur Behandlung ||| used to treat ||| 0-0 0-1 0-2 1-2
zur Empfehlung von Dosisanpassungen bei ||| to recommend dose modifications in ||| 0-0 1-1 2-2 3-3 4-4
zur Empfehlung von Dosisanpassungen ||| to recommend dose modifications ||| 0-0 1-1 2-2 3-3
zur Empfehlung von ||| to recommend dose ||| 0-0 1-1 2-2
zur Empfehlung ||| to recommend ||| 0-0 1-1
zur Gewährleistung der sicheren ||| taken to ensure the safe ||| 1-0 0-1 3-2 2-3 3-4
zur Gewährleistung ||| taken to ||| 1-0 0-1
zur Identifizierung möglicher Arrhythmien . ||| to detect possible arrhythmias . ||| 0-0 0-1 1-1 2-1 2-2 3-3 4-4
zur Identifizierung möglicher Arrhythmien ||| to detect possible arrhythmias ||| 0-0 0-1 1-1 2-1 2-2 3-3
zur Identifizierung möglicher ||| to detect possible ||| 0-0 0-1 1-1 2-1 2-2
zur Infusion ||| for infusion ||| 0-0 1-1
zur Injektion . ||| for injection . ||| 0-0 1-1 2-2
zur Injektion ||| for injection ||| 0-0 1-1
zur Reduktion von neuen ||| reduction in new ||| 1-0 3-2
zur Reduktion von ||| reduction in ||| 1-0
zur Reduktion von ||| reduction ||| 1-0
zur Reduktion ||| reduction in ||| 1-0
zur Reduktion ||| reduction ||| 1-0
zur Reduzierung der Nebenwirkungen ||| to reduce side effects ||| 0-0 2-0 3-2 3-3
zur Reduzierung der ||| to reduce ||| 0-0 2-0
zur Reduzierung der ||| to ||| 0-0 2-0
zur Regelung des Blutzuckerspiegels produziert ||| to control the blood sugar ||| 0-0 1-1 2-2 3-3 3-4 4-4
zur Regelung des ||| to control the ||| 0-0 1-1 2-2
zur Regelung ||| to control ||| 0-0 1-1
zur Rekonstitution ist ||| for reconstitution is ||| 0-0 1-1 2-2
zur Rekonstitution ||| for reconstitution ||| 0-0 1-1
zur Reproduktionstoxizität nicht . ||| reproductive toxicity studies . ||| 0-0 1-0 1-1 2-1 1-2 3-3
zur Reproduktionstoxizität nicht ||| reproductive toxicity studies ||| 0-0 1-0 1-1 2-1 1-2
zur Risikominimierung ||| minimisation ||| 0-0 1-0
zur Serotonin- Wiederaufnahme-Stelle und ||| the serotonin reuptake site and ||| 1-0 1-1 0-2 1-2 2-2 2-3 3-4
zur Serotonin- Wiederaufnahme-Stelle ||| for the serotonin reuptake site ||| 0-0 1-1 1-2 1-3 2-3 2-4
zur Serotonin- Wiederaufnahme-Stelle ||| the serotonin reuptake site ||| 1-0 1-1 0-2 1-2 2-2 2-3
zur Sicherheit und ||| safety and ||| 0-0 1-0 2-1
zur Sicherheit ||| safety ||| 0-0 1-0
zur Teilnahme am Straßenverkehr ||| not affect your ability ||| 1-0 0-1 1-1 2-1 1-2 3-3
zur Teilnahme am ||| not affect your ||| 1-0 0-1 1-1 2-1 1-2
zur Teilung und Vermehrung ||| them to divide and multiply ||| 1-0 0-1 1-2 2-3 3-4
zur Teilung und ||| them to divide and ||| 1-0 0-1 1-2 2-3
zur Teilung ||| them to divide ||| 1-0 0-1 1-2
zur Unterdrückung ||| medicine to suppress ||| 0-0 0-1 1-2
zur Verbesserung ||| improvement ||| 1-0
zur Verfügung stehen . ||| to starting Abseamed therapy . ||| 0-0 0-1 1-1 2-1 1-2 1-3 3-4
zur Verfügung stehen ||| to starting Abseamed therapy ||| 0-0 0-1 1-1 2-1 1-2 1-3
zur Verhütung ||| to prevent ||| 0-0
zur Verhütung ||| to ||| 0-0
zur Vermeidung von ||| in order to ||| 0-2 1-2 2-2
zur Vermeidung von ||| order to ||| 0-1 1-1 2-1
zur Vermeidung von ||| to ||| 0-0 1-0 2-0
zur Verringerung des Appetits kommen ||| by decreased appetite ||| 1-0 3-1 3-2 4-2
zur Verringerung des Appetits kommen ||| followed by decreased appetite ||| 1-1 3-2 3-3 4-3
zur Verringerung des ||| by ||| 1-0
zur Verringerung des ||| followed by ||| 1-1
zur Verringerung ||| by ||| 1-0
zur Verringerung ||| followed by ||| 1-1
zur Verwendung mit Insulinspritzen ||| for use with insulin syringes ||| 0-0 1-1 2-2 3-3 3-4
zur Verwendung mit ||| for use with ||| 0-0 1-1 2-2
zur Verwendung ||| for use ||| 0-0 1-1
zur Vorbeugung von Blutpfropfbildung ||| to prevent ||| 0-0 2-0 1-1 3-1
zur Vorbeugung ||| for the prevention ||| 0-0 0-2 1-2
zur Wirksamkeit und Unbedenklichkeit . ||| efficacy and safety . ||| 0-0 1-0 2-1 3-2 4-3
zur Wirksamkeit und Unbedenklichkeit ||| efficacy and safety ||| 0-0 1-0 2-1 3-2
zur Wirksamkeit und ||| efficacy and ||| 0-0 1-0 2-1
zur Wirksamkeit ||| efficacy ||| 0-0 1-0
zur bestehenden Behandlung mit ||| to the existing treatment with ||| 0-0 1-2 2-3 3-4
zur bestehenden Behandlung ||| to the existing treatment ||| 0-0 1-2 2-3
zur bestehenden ||| to the existing ||| 0-0 1-2
zur pH-Einstellung ) , ||| for pH-adjustment ) , ||| 0-0 0-1 1-1 2-2 3-3
zur pH-Einstellung ) Natriumhydroxid ||| for pH-adjustment ) Sodium hydroxide ||| 0-0 0-1 1-1 2-2 3-3 3-4
zur pH-Einstellung ) ||| for pH-adjustment ) ||| 0-0 0-1 1-1 2-2
zur pH-Einstellung ||| for pH-adjustment ||| 0-0 0-1 1-1
zur signifikanten ||| significant ||| 1-0
zur ||| acid ||| 0-0
zur ||| for the ||| 0-0
zur ||| for ||| 0-0
zur ||| in ||| 0-0
zur ||| medicine to ||| 0-0 0-1
zur ||| of ||| 0-0
zur ||| to prevent ||| 0-0
zur ||| to the ||| 0-0
zur ||| to treat ||| 0-0 0-1
zur ||| to ||| 0-0
zur ||| used ||| 0-0
zur ||| zur ||| 0-0
zur Überdosierung mit Rimonabant ||| with rimonabant in overdosage ||| 2-0 3-1 0-2 1-2 2-2 3-3
zurück . ||| . ||| 1-0
zurück in den systemischen Kreislauf ||| back into the systemic circulation ||| 1-1 2-1 4-1 2-2 3-3 4-3 4-4
zurück in den systemischen Kreislauf ||| into the systemic circulation ||| 1-0 2-0 4-0 2-1 3-2 4-2 4-3
zusammen mit Ciclosporin angewendet ||| is given concomitantly with cyclosporin ||| 0-0 0-1 0-2 1-3 2-4 3-4
zusammen mit Nahrungsmitteln und Getränken ||| with food and drink ||| 1-0 0-1 2-1 3-2 2-3 4-3
zusammen mit anderen Arzneimitteln angewendet ||| concomitantly with medicines known ||| 0-0 1-1 2-2 3-2 4-2 3-3
zusammen mit zwei anderen ||| together with two other ||| 0-0 1-1 2-2 3-3
zusammen mit zwei ||| together with two ||| 0-0 1-1 2-2
zusammen mit ||| concomitantly with ||| 0-0 1-1
zusammen mit ||| is given concomitantly with ||| 0-0 0-1 0-2 1-3
zusammen mit ||| together with ||| 0-0 1-1
zusammen ||| concomitant administration of ||| 0-0 0-1
zusammen ||| concomitant administration ||| 0-0 0-1
zusammen ||| concomitantly ||| 0-0
zusammen ||| is given concomitantly ||| 0-0 0-1 0-2
zusammen ||| together ||| 0-0
zusammengefassten Auflistung enthalten sind : ||| pooled presentation are : ||| 0-0 0-1 1-1 2-1 3-2 4-3
zusammengefassten Auflistung enthalten sind ||| pooled presentation are ||| 0-0 0-1 1-1 2-1 3-2
zusammengefassten Auflistung enthalten ||| pooled presentation ||| 0-0 0-1 1-1 2-1
zusätzlich zu Metformin bei Patienten ||| added to metformin in patients ||| 0-0 1-0 1-1 2-2 3-3 4-4
zusätzlich zu Metformin bei ||| added to metformin in ||| 0-0 1-0 1-1 2-2 3-3
zusätzlich zu Metformin ||| added to metformin ||| 0-0 1-0 1-1 2-2
zusätzlich zu ||| added to ||| 0-0 1-0 1-1
zusätzlich zu ||| to ||| 0-0 1-0
zusätzlich zur Aripiprazol ||| addition to aripiprazole ||| 0-0 1-1 2-2
zusätzlich zur Aripiprazol ||| in addition to aripiprazole ||| 0-1 1-2 2-3
zusätzlich zur ||| addition to ||| 0-0 1-1
zusätzlich zur ||| in addition to ||| 0-1 1-2
zusätzlich ||| addition ||| 0-0
zusätzlich ||| in addition ||| 0-1
zusätzliche Gabe von Placebo ||| placebo ||| 3-0
zusätzlichen 6 ||| additional 6 ||| 0-0 1-1
zusätzlichen Maßnahmen zur Pharmakovigilanz ||| additional pharmacovigilance activities ||| 0-0 3-1 1-2 2-2 3-2
zusätzlichen Nutzen . ||| additional benefit . ||| 0-0 1-1 2-2
zusätzlichen Nutzen bieten . ||| provide additional benefits . ||| 2-0 0-1 1-2 2-2 3-3
zusätzlichen Nutzen bieten ||| provide additional benefits ||| 2-0 0-1 1-2 2-2
zusätzlichen Nutzen ||| additional benefit ||| 0-0 1-1
zusätzlichen Risikofaktoren ( z. B. ||| additional risk factors ( e. ||| 0-0 1-1 1-2 2-3 3-4 4-4
zusätzlichen Risikofaktoren ( ||| additional risk factors ( ||| 0-0 1-1 1-2 2-3
zusätzlichen Risikofaktoren ||| additional risk factors ||| 0-0 1-1 1-2
zusätzlichen ||| adding ||| 0-0
zusätzlichen ||| additional ||| 0-0
zutreffen könnte ||| might apply ||| 0-0 1-0 0-1
zuviel Abseamed injiziert wurde ||| much Abseamed has been injected ||| 0-0 1-1 3-2 3-3 2-4 3-4
zuviel Abseamed ||| much Abseamed ||| 0-0 1-1
zuviel ||| much ||| 0-0
zwei Hauptstudien ||| in two main studies ||| 0-1 1-2
zwei Hauptstudien ||| in two main ||| 0-1 1-2
zwei Hauptstudien ||| two main studies ||| 0-0 1-1
zwei Hauptstudien ||| two main ||| 0-0 1-1
zwei Jahre ||| two years ||| 0-0 1-1
zwei Jahren ||| two years ||| 0-0 1-1
zwei Monate lang . ||| for two months . ||| 2-0 0-1 1-2 2-2 3-3
zwei Monate lang ||| for two months ||| 2-0 0-1 1-2 2-2
zwei Spezies , jeweils mit ||| two species , both via ||| 0-0 1-1 2-2 3-2
zwei Spezies , jeweils mit ||| two species , both ||| 0-0 1-1 2-2 3-2
zwei Spezies , jeweils mit ||| two species , ||| 0-0 1-1 2-2 3-2
zwei Spezies , jeweils ||| two species , both via ||| 0-0 1-1 2-2 3-2
zwei Spezies , jeweils ||| two species , both ||| 0-0 1-1 2-2 3-2
zwei Spezies , jeweils ||| two species , ||| 0-0 1-1 2-2 3-2
zwei Spezies ||| two species ||| 0-0 1-1
zwei Studien war die ||| in two studies was ||| 1-0 0-1 1-2 2-3 3-3
zwei Studien ||| in two studies ||| 1-0 0-1 1-2
zwei Studien ||| two studies , where ||| 0-0 1-1
zwei Studien ||| two studies , ||| 0-0 1-1
zwei Studien ||| two studies ||| 0-0 1-1
zwei Wochen nach ||| two weeks following ||| 0-0 1-1 2-2
zwei Wochen ||| two weeks ||| 0-0 1-1
zwei anderen Diabetesmedikamenten ||| two other antidiabetic medicines ||| 0-0 1-1 2-2 2-3
zwei anderen ||| two other ||| 0-0 1-1
zwei aufeinanderfolgenden Tage ||| for two consecutive days ||| 1-0 0-1 1-2 2-3
zwei aufeinanderfolgenden Tagen ||| for two consecutive days ||| 1-0 0-1 1-2 2-3
zwei aufeinanderfolgenden ||| for two consecutive ||| 1-0 0-1 1-2
zwei beziehen ||| two relate ||| 0-0 1-1
zwei der kardiovaskulären ||| two of the cardiovascular ||| 0-0 1-1 1-2 2-3
zwei der ||| two of the ||| 0-0 1-1 1-2
zwei gleich große Injektionen . ||| in two equal injections . ||| 0-1 1-2 2-2 3-3 4-4
zwei gleich große Injektionen . ||| into 2 equal injections . ||| 1-0 1-1 0-2 1-2 2-2 3-3 4-4
zwei gleich große Injektionen . ||| two equal injections . ||| 0-0 1-1 2-1 3-2 4-3
zwei gleich große Injektionen ||| in two equal injections ||| 0-1 1-2 2-2 3-3
zwei gleich große Injektionen ||| into 2 equal injections ||| 1-0 1-1 0-2 1-2 2-2 3-3
zwei gleich große Injektionen ||| two equal injections ||| 0-0 1-1 2-1 3-2
zwei gleich große ||| in two equal ||| 0-1 1-2 2-2
zwei gleich große ||| into 2 equal ||| 1-0 1-1 0-2 1-2 2-2
zwei gleich große ||| two equal ||| 0-0 1-1 2-1
zwei großen ||| two large ||| 0-0 1-1
zwei kleineren Metaboliten ( 3 ||| two minor metabolites , 3 ||| 0-0 2-2 4-4
zwei kleineren Metaboliten ( ||| two minor metabolites , ||| 0-0 2-2
zwei kleineren Metaboliten ( ||| two minor metabolites ||| 0-0 2-2
zwei kleineren Metaboliten ||| two minor metabolites , ||| 0-0 2-2
zwei kleineren Metaboliten ||| two minor metabolites ||| 0-0 2-2
zwei kleineren ||| two minor ||| 0-0
zwei kleineren ||| two ||| 0-0
zwei oder mehr Wochen nach ||| two or more weeks after ||| 0-0 1-1 2-2 3-3 4-4
zwei oder mehr Wochen ||| two or more weeks ||| 0-0 1-1 2-2 3-3
zwei oder mehr ||| two or more ||| 0-0 1-1 2-2
zwei oder ||| two or ||| 0-0 1-1
zwei placebo-kontrollierten Kurzzeitstudien ||| two short- ||| 0-0 1-1
zwei placebo-kontrollierten ||| two short- ||| 0-0 1-1
zwei sechsmonatigen Vergleichsstudien ||| two 6-month comparative ||| 0-0 1-1 2-2
zwei sechsmonatigen ||| two 6-month ||| 0-0 1-1
zwei sicherheitspharmakologischen Studien beobachtet . ||| two safety pharmacology studies . ||| 0-0 1-1 1-2 2-3 3-3 4-4
zwei sicherheitspharmakologischen Studien beobachtet ||| two safety pharmacology studies ||| 0-0 1-1 1-2 2-3 3-3
zwei sicherheitspharmakologischen ||| two safety pharmacology ||| 0-0 1-1 1-2
zwei ||| comparing ||| 0-0
zwei ||| in two ||| 0-1
zwei ||| two minor ||| 0-0
zwei ||| two ||| 0-0
zweimal pro Woche mittels ||| 2 times per week by ||| 0-0 1-1 1-2 2-3 3-4
zweimal pro Woche ||| 2 times per week ||| 0-0 1-1 1-2 2-3
zweimal pro ||| 2 times per ||| 0-0 1-1 1-2
zweimal täglich für ||| twice a day for ||| 0-0 1-0 1-1 1-2 2-3
zweimal täglich ||| twice a day ||| 0-0 1-0 1-1 1-2
zweimal täglich ||| twice daily is ||| 0-0 1-0 1-1
zweimal täglich ||| twice daily ||| 0-0 1-0 1-1
zweimal ||| 2 times ||| 0-0 0-1
zweimal ||| 2 ||| 0-0
zweimal ||| given 2 ||| 0-0 0-1
zweimal ||| given twice ||| 0-0 0-1
zweimal ||| twice a ||| 0-0
zweimal ||| twice ||| 0-0
zweiten Jahres ||| second year ||| 0-0 1-1
zweiten Studie ||| second trial utilised ||| 0-0 1-1 0-2
zweiten Studie ||| second trial ||| 0-0 1-1
zweiten ||| second ||| 0-0
zwischen 1,25 und 2,47 ||| between 1.25 and 2.47 in ||| 0-0 1-1 2-2 3-3 3-4
zwischen 1,25 und ||| between 1.25 and ||| 0-0 1-1 2-2
zwischen 1,25 ||| between 1.25 ||| 0-0 1-1
zwischen 10 g/dl und ||| between 10 g/ dl ||| 0-0 1-1 2-2 2-3 3-3
zwischen 10 g/dl und ||| between 10 g/ dl ||| 0-0 3-0 1-1 2-2 2-3
zwischen 10 und 12 ||| between 10 and 12 ||| 0-0 1-1 2-2 3-3
zwischen 10 und ||| between 10 and ||| 0-0 1-1 2-2
zwischen 10 ||| between 10 ||| 0-0 1-1
zwischen 17 und 33 ||| between 17 and 33 ||| 0-0 1-1 2-2 3-3
zwischen 17 und ||| between 17 and ||| 0-0 1-1 2-2
zwischen 17 ||| between 17 ||| 0-0 1-1
zwischen 25 und 50 ||| between 25 and 50 ||| 0-0 1-1 2-2 3-3
zwischen 25 und ||| between 25 and ||| 0-0 1-1 2-2
zwischen 25 ||| between 25 ||| 0-0 1-1
zwischen 9,5 und 11 ||| between 9.5 and 11 ||| 0-0 1-1 2-2 3-3
zwischen 9,5 und ||| between 9.5 and ||| 0-0 1-1 2-2
zwischen 9,5 ||| between 9.5 ||| 0-0 1-1
zwischen Cmax und Cmax korrigiert ||| Cmax and Cmax corrected for ||| 1-0 0-1 2-1 3-2 4-3
zwischen Cmax und Cmax korrigiert ||| Cmax and Cmax corrected ||| 1-0 0-1 2-1 3-2 4-3
zwischen Cmax und Cmax ||| Cmax and Cmax ||| 1-0 0-1 2-1 3-2
zwischen Cmax und ||| Cmax and ||| 1-0 0-1 2-1
zwischen Daumen und Zeigefinger zusammendrücken ||| between thumb and forefinger ||| 0-0 1-1 2-2 3-3 4-3
zwischen Daumen und ||| between thumb and ||| 0-0 1-1 2-2
zwischen Daumen ||| between thumb ||| 0-0 1-1
zwischen Epoetin alfa und ||| between epoetin alfa and ||| 0-0 1-1 2-2 3-3
zwischen Epoetin alfa ||| between epoetin alfa ||| 0-0 1-1 2-2
zwischen Epoetin ||| between epoetin ||| 0-0 1-1
zwischen den ||| between the ||| 0-0 1-1
zwischen den ||| between ||| 0-0 1-0
zwischen der ||| between ||| 0-0
zwischen eim ||| . du ||| 1-0 1-1
zwischen gesunden ||| between healthy ||| 0-0 1-1
zwischen gesunden älteren und jüngeren ||| between healthy elderly and younger ||| 0-0 1-1 2-2 3-3 4-4
zwischen gesunden älteren und ||| between healthy elderly and ||| 0-0 1-1 2-2 3-3
zwischen gesunden älteren ||| between healthy elderly ||| 0-0 1-1 2-2
zwischen ||| between ||| 0-0
zwischen ||| concentration ||| 0-0
zwölf Wochen an . ||| 12 weeks . ||| 0-0 1-1 2-1 3-2
zwölf Wochen an ||| 12 weeks ||| 0-0 1-1 2-1
zwölf ||| 12 ||| 0-0
zytotoxisches antikarzinogenes Arzneimittel und ||| cytotoxic anticancer medicinal product and ||| 0-0 1-1 2-2 2-3 3-4
zytotoxisches antikarzinogenes Arzneimittel ||| cytotoxic anticancer medicinal product ||| 0-0 1-1 2-2 2-3
zytotoxisches antikarzinogenes ||| cytotoxic anticancer ||| 0-0 1-1
zytotoxisches ||| cytotoxic ||| 0-0
{ MM/JJJJ } ||| { month/ year } ||| 1-0 0-1 1-2 1-3 2-3
{ ||| month/ ||| 0-0
©EMEA 2007 ||| One study also ||| 0-0 1-0
©EMEA 2007 ||| One study ||| 0-0 1-0
©EMEA 2007 ||| One ||| 0-0 1-0
± 16 % der verabreichten ||| ± 16 % of the ||| 0-0 1-1 2-2 3-3 3-4 4-4
± 16 % ||| ± 16 % ||| 0-0 1-1 2-2
± 16 ||| ± 16 ||| 0-0 1-1
± 2,5 ||| ± 2.5 ||| 0-0 1-1
± 28,1 ng/ml ||| 196 ± 28.1 ng/ ml ||| 0-0 0-1 1-1 0-2 2-3 2-4
± 28,1 ||| 196 ± 28.1 ||| 0-0 0-1 1-1 0-2
± 33 % ||| ± 33 % ||| 0-0 1-1 2-2
± 33 ||| ± 33 ||| 0-0 1-1
± ||| ± ||| 0-0
µ : +44 ( 0)20 ||| µ : +44 ( 0)20 ||| 0-0 1-1 2-2 3-3 4-4
µ : +44 ( ||| µ : +44 ( ||| 0-0 1-1 2-2 3-3
µ : +44 ||| µ : +44 ||| 0-0 1-1 2-2
µ : ||| µ : ||| 0-0 1-1
µ ||| µ ||| 0-0
ÄUSSEREN UMHÜLLUNG UND AUF DEM ||| APPEAR ON THE OUTER ||| 0-0 1-1 2-2 3-3 4-3
ÄUSSEREN UMHÜLLUNG UND ||| APPEAR ON THE ||| 0-0 1-1 2-2
ÄUSSEREN UMHÜLLUNG ||| APPEAR ON ||| 0-0 1-1
ÄUSSEREN UMHÜLLUNG ||| OUTER ||| 0-0 1-0
ÄUSSEREN UMHÜLLUNG ||| THE OUTER PACKAGE ||| 0-0 0-1 1-1 1-2
ÄUSSEREN ||| APPEAR ||| 0-0
Ältere Patienten ( 65 Jahre ||| Elderly patients ( 65 years ||| 0-0 1-1 2-2 3-3 4-4
Ältere Patienten ( 65 ||| Elderly patients ( 65 ||| 0-0 1-1 2-2 3-3
Ältere Patienten ( ||| Elderly patients ( ||| 0-0 1-1 2-2
Ältere Patienten : Die Wirksamkeit ||| Elderly : the effectiveness ||| 0-0 1-0 2-1 0-2 0-3 3-3 4-3
Ältere Patienten Die Wirksamkeit und ||| Elderly The efficacy and ||| 0-0 1-0 2-1 3-2 4-3
Ältere Patienten Die Wirksamkeit ||| Elderly The efficacy ||| 0-0 1-0 2-1 3-2
Ältere Patienten Die ||| Elderly The ||| 0-0 1-0 2-1
Ältere Patienten ||| Elderly patients ||| 0-0 1-1
Ältere Patienten ||| Elderly ||| 0-0 1-0
Ältere ||| Elderly ||| 0-0
Änderung ||| deterioration of ||| 0-0
Änderung ||| deterioration ||| 0-0
Änderung ||| of deterioration of ||| 0-1
Änderung ||| of deterioration ||| 0-1
Änderungen der Ernährung beinhaltet . ||| includes appropriate dietary changes . ||| 0-0 3-0 0-1 1-2 2-2 3-2 0-3 4-4
Änderungen der Ernährung beinhaltet ||| includes appropriate dietary changes ||| 0-0 3-0 0-1 1-2 2-2 3-2 0-3
Ärzte bzw. medizinisches Fachpersonal bestimmt ||| medical or healthcare professionals ||| 0-0 3-0 1-1 2-2 3-2 3-3 4-3
Ärzte sollten die klinische ||| Physicians should consider clinical ||| 0-0 1-1 2-1 3-2 3-3
Ärzte sollten die klinische Überwachung ||| Physicians should consider clinical monitoring ||| 0-0 1-1 2-1 3-2 3-3 4-4
Ärzte sollten die ||| Physicians should ||| 0-0 1-1 2-1
Ärzte sollten sich der ||| should be alert to the ||| 1-0 1-1 0-2 2-3 3-4
Ärzte sollten sich ||| should be alert to ||| 1-0 1-1 0-2 2-3
Ärzte sollten ||| should be alert ||| 1-0 1-1 0-2
Ärzte ||| Physicians ||| 0-0
Ärzte ||| alert ||| 0-0
Ísland VISTOR HF Sími : ||| Ísland VISTOR HF Sími : ||| 0-0 1-1 2-2 3-3 4-4
Ísland VISTOR HF Sími ||| Ísland VISTOR HF Sími ||| 0-0 1-1 2-2 3-3
Ísland VISTOR HF ||| Ísland VISTOR HF ||| 0-0 1-1 2-2
Ísland VISTOR ||| Ísland VISTOR ||| 0-0 1-1
Ísland ||| Ísland ||| 0-0
Ödem Zu ||| Oedema Oedema may ||| 0-0 0-1 1-1 1-2
Ödeme ) . ||| oedema ) . ||| 0-0 1-1 2-2
Ödeme ) ||| oedema ) ||| 0-0 1-1
Ödeme , Schleimhautentzündung ||| oedema , mucosal ||| 0-0 1-1 2-2
Ödeme , ||| oedema , ||| 0-0 1-1
Ödeme auf . ||| oedema . ||| 0-0 1-0 2-1
Ödeme auf ||| oedema ||| 0-0 1-0
Ödeme waren in der ||| reports of oedema were ||| 0-0 2-1 3-1 0-2 1-3
Ödeme ||| oedema ||| 0-0
Öffnen Sie ||| 158 Do ||| 0-0 0-1 1-1
Öffnen Sie ||| 164 Do ||| 0-0 0-1 1-1
Öffnen Sie ||| 170 Do ||| 0-0 0-1 1-1
Öffnen der Flasche ||| opening the bottle , ||| 0-0 1-1 2-2
Öffnen der Flasche ||| opening the bottle ||| 0-0 1-1 2-2
Öffnen der ||| opening the ||| 0-0 1-1
Öffnen zu ||| opening ||| 0-0
Öffnen ||| opening ||| 0-0
Ösophagitis , Zahnschmerz. # ||| oesophagitis , toothache ||| 0-0 1-1 2-2 3-2
Ösophagitis , ||| oesophagitis , ||| 0-0 1-1
Ösophagitis ||| oesophagitis ||| 0-0
Österreich BRISTOL-MYERS SQUIBB GESMBH Tel ||| BRISTOL-MYERS SQUIBB GESMBH Tel ||| 0-0 1-0 2-1 3-2 4-3
Österreich BRISTOL-MYERS SQUIBB GESMBH Tel ||| Österreich BRISTOL-MYERS SQUIBB GESMBH Tel ||| 0-0 1-1 2-2 3-3 4-4
Österreich BRISTOL-MYERS SQUIBB GESMBH ||| BRISTOL-MYERS SQUIBB GESMBH ||| 0-0 1-0 2-1 3-2
Österreich BRISTOL-MYERS SQUIBB GESMBH ||| Österreich BRISTOL-MYERS SQUIBB GESMBH ||| 0-0 1-1 2-2 3-3
Österreich BRISTOL-MYERS SQUIBB ||| BRISTOL-MYERS SQUIBB ||| 0-0 1-0 2-1
Österreich BRISTOL-MYERS SQUIBB ||| Österreich BRISTOL-MYERS SQUIBB ||| 0-0 1-1 2-2
Österreich BRISTOL-MYERS ||| BRISTOL-MYERS ||| 0-0 1-0
Österreich BRISTOL-MYERS ||| Österreich BRISTOL-MYERS ||| 0-0 1-1
Österreich Medice Arzneimittel Ges.mbH ||| Medice Arzneimittel Ges . mbH ||| 1-0 1-1 2-1 0-2 3-2 3-4
Österreich Novartis Pharma GmbH Tel ||| Österreich Novartis Pharma GmbH Tel ||| 0-0 1-1 2-2 3-3 4-4
Österreich Novartis Pharma GmbH ||| Österreich Novartis Pharma GmbH ||| 0-0 1-1 2-2 3-3
Österreich Novartis Pharma ||| Österreich Novartis Pharma ||| 0-0 1-1 2-2
Österreich Novartis ||| Österreich Novartis ||| 0-0 1-1
Österreich ||| Österreich ||| 0-0
Übelkeit , Durchfall , Erbrechen ||| Nausea , diarrhoea , vomiting ||| 0-0 1-1 2-2 3-3 4-4
Übelkeit , Durchfall , ||| Nausea , diarrhoea , ||| 0-0 1-1 2-2 3-3
Übelkeit , Durchfall ||| Nausea , diarrhoea ||| 0-0 1-1 2-2
Übelkeit , Erbrechen , ein ||| nausea , vomiting , an ||| 0-0 1-1 2-2 3-3 4-4
Übelkeit , Erbrechen , ||| nausea , vomiting , ||| 0-0 1-1 2-2 3-3
Übelkeit , Erbrechen und Durchfall ||| nausea , vomiting and diarrhoea ||| 0-0 1-1 2-2 3-3 4-4
Übelkeit , Erbrechen und ||| nausea , vomiting and ||| 0-0 1-1 2-2 3-3
Übelkeit , Erbrechen ||| nausea , vomiting ||| 0-0 1-1 2-2
Übelkeit , Verstopfung , ||| nausea , constipation , ||| 0-0 1-1 2-2 3-3
Übelkeit , Verstopfung ||| nausea , constipation ||| 0-0 1-1 2-2
Übelkeit , ||| Nausea , ||| 0-0 1-1
Übelkeit , ||| nausea , ||| 0-0 1-1
Übelkeit trat bei 29 % ||| Nausea occurred in 29 % ||| 0-0 1-1 2-2 3-3 4-4
Übelkeit trat bei 29 ||| Nausea occurred in 29 ||| 0-0 1-1 2-2 3-3
Übelkeit trat bei ||| Nausea occurred in ||| 0-0 1-1 2-2
Übelkeit trat ||| Nausea occurred ||| 0-0 1-1
Übelkeit und Erbrechen auf . ||| nausea and vomiting . ||| 0-0 1-1 2-2 4-3
Übelkeit und Erbrechen auf ||| nausea and vomiting ||| 0-0 1-1 2-2
Übelkeit und Erbrechen ||| nausea and vomiting ||| 0-0 1-1 2-2
Übelkeit und ||| nausea and ||| 0-0 1-1
Übelkeit ||| Nausea ||| 0-0
Übelkeit ||| experience nausea ||| 0-1
Übelkeit ||| nausea ||| 0-0
Über Osteonekrosen ||| Osteonecrosis of ||| 0-0 1-0 1-1
Über allergische Reaktionen , ||| Allergic reactions have been ||| 0-0 1-1 2-1 2-2 3-2
Über allergische Reaktionen , ||| Allergic reactions have ||| 0-0 1-1 2-1 2-2 3-2
Über eine Halbwertszeit von annähernd ||| A half-life of approximately ||| 0-0 1-1 2-1 3-2 4-3
Über eine Halbwertszeit von ||| A half-life of ||| 0-0 1-1 2-1 3-2
Über eine Halbwertszeit ||| A half-life ||| 0-0 1-1 2-1
Über einen ||| Pioglitazone or ||| 0-0 1-1
Über thrombotische , vaskuläre Ereignisse ||| Thrombotic/ vascular events , ||| 0-0 1-0 3-1 4-2 2-3
Über thrombotische ||| Thrombotic/ ||| 0-0 1-0
Über ||| , little ||| 0-0
Über ||| , ||| 0-0
Über ||| A ||| 0-0
Über ||| Allergic ||| 0-0
Über ||| Pioglitazone ||| 0-0
Überdosierung ( Symptome , ||| Overdose ( symptoms , ||| 0-0 1-1 2-2 3-3
Überdosierung ( Symptome ||| Overdose ( symptoms ||| 0-0 1-1 2-2
Überdosierung ( ||| Overdose ( ||| 0-0 1-1
Überdosierung mit Aripiprazol ||| overdose with aripiprazole , ||| 0-0 1-1 2-2
Überdosierung mit Aripiprazol ||| overdose with aripiprazole ||| 0-0 1-1 2-2
Überdosierung mit ||| overdose with ||| 0-0 1-1
Überdosierung von Epoetin alfa kann ||| Overdose of epoetin alfa may ||| 0-0 1-1 2-2 3-3 4-4
Überdosierung von Epoetin alfa ||| Overdose of epoetin alfa ||| 0-0 1-1 2-2 3-3
Überdosierung von Epoetin ||| Overdose of epoetin ||| 0-0 1-1 2-2
Überdosierung von ||| Overdose of ||| 0-0 1-1
Überdosierung ||| Overdose ||| 0-0
Überdosierung ||| of overdose ||| 0-1
Überdosierung ||| overdose ||| 0-0
Überdosierung ||| overdosing ||| 0-0
Übereinstimmung mit dem empfohlenen ||| line with the recommended ||| 0-0 1-1 2-2 3-3
Übereinstimmung mit dem ||| line with the ||| 0-0 1-1 2-2
Übereinstimmung mit ||| line with ||| 0-0 1-1
Übereinstimmung ||| line ||| 0-0
Überempfindlichkeit : ||| Hypersensitivity : ||| 0-0 1-1
Überempfindlichkeit gegen den Wirkstoff ||| Hypersensitivity to the active substance ||| 0-0 1-0 1-1 2-2 2-3 3-3 3-4
Überempfindlichkeit gegen den Wirkstoff ||| hypersensitivity to the active substance ||| 0-0 1-1 2-2 1-3 2-3 3-3 3-4
Überempfindlichkeit gegen ||| Hypersensitivity to ||| 0-0 1-0 1-1
Überempfindlichkeit ||| Hypersensitivity ||| 0-0
Überempfindlichkeit ||| hypersensitivity ||| 0-0
Überempfindlichkeit ||| of hypersensitivity ||| 0-1
Überempfindlichkeitsreaktionen , einschließlich seltener Fälle ||| Hypersensitivity reactions including rare cases ||| 0-0 0-1 1-2 2-2 3-3 4-4
Überempfindlichkeitsreaktionen , einschließlich seltener ||| Hypersensitivity reactions including rare ||| 0-0 0-1 1-2 2-2 3-3
Überempfindlichkeitsreaktionen , einschließlich ||| Hypersensitivity reactions including ||| 0-0 0-1 1-2 2-2
Überempfindlichkeitsreaktionen , ||| hypersensitivity reactions , ||| 0-0 0-1 1-2
Überempfindlichkeitsreaktionen wird ||| hypersensitivity reactions is ||| 0-0 0-1 1-2
Überempfindlichkeitsreaktionen ||| Hypersensitivity reactions ||| 0-0 0-1
Überempfindlichkeitsreaktionen ||| hypersensitivity reactions ||| 0-0 0-1
Übergewicht oder Fettleibigkeit ||| overweight or obesity ||| 0-0 1-1 2-2
Übergewicht oder ||| overweight or ||| 0-0 1-1
Übergewicht ||| overweight ||| 0-0
Überleben [ 95 % CI ||| Survival [ 95 % CI ||| 0-0 1-1 2-2 3-3 4-4
Überleben [ 95 % ||| Survival [ 95 % ||| 0-0 1-1 2-2 3-3
Überleben [ 95 ||| Survival [ 95 ||| 0-0 1-1 2-2
Überleben [ ||| Survival [ ||| 0-0 1-1
Überleben und ||| Survival and ||| 0-0 1-1
Überleben ||| Survival ||| 0-0
Überlebensvorteil ||| clear-cut ||| 0-0
Überwachung auf kardiale Ereignisse notwendig ||| the occurrence of cardiac events ||| 0-0 1-0 1-1 2-3 3-4
Überwachung auf kardiale Ereignisse ||| the occurrence of cardiac events ||| 0-0 1-0 1-1 2-3 3-4
Überwachung auf kardiale ||| for the occurrence of cardiac ||| 0-1 1-1 1-2 2-4
Überwachung auf kardiale ||| the occurrence of cardiac ||| 0-0 1-0 1-1 2-3
Überwachung auf ||| for the occurrence of ||| 0-1 1-1 1-2
Überwachung auf ||| for the occurrence ||| 0-1 1-1 1-2
Überwachung auf ||| the occurrence of ||| 0-0 1-0 1-1
Überwachung auf ||| the occurrence ||| 0-0 1-0 1-1
Überwachung solange angezeigt , ||| supervision and monitoring should ||| 0-0 1-0 1-1 0-2 2-2 1-3
Überwachung solange angezeigt ||| supervision and monitoring should ||| 0-0 1-0 1-1 0-2 2-2 1-3
Überwachung zur Identifizierung möglicher Arrhythmien ||| monitoring to detect possible arrhythmias ||| 0-0 1-1 1-2 2-2 3-2 3-3 4-4
Überwachung zur Identifizierung möglicher ||| monitoring to detect possible ||| 0-0 1-1 1-2 2-2 3-2 3-3
Überwachung ||| monitoring ||| 0-0
ähnlich wie ||| similar ||| 0-0 1-0
ähnlich wie ||| were similar ||| 0-1 1-1
ähnlich zwischen den beiden ||| generally similar between the ||| 0-1 3-1 1-2 2-3
ähnlich zwischen den beiden ||| similar between the ||| 0-0 3-0 1-1 2-2
ähnliche Abnahme der ||| similar decrease in ||| 0-0 1-1 1-2
ähnliche Abnahme ||| similar decrease in ||| 0-0 1-1 1-2
ähnliche Erhöhung der ||| similar increase ||| 0-0 1-1 2-1
ähnliche Wirkung ||| similar effect ||| 0-0 1-1
ähnliche ||| similar ||| 0-0
ähnlichem Resorptionsanteil . ||| extent of absorption . ||| 0-0 0-1 1-2 2-3
ähnlichem Resorptionsanteil ||| extent of absorption ||| 0-0 0-1 1-2
ähnlichem ||| extent of ||| 0-0 0-1
ähnlichen ||| mix ||| 0-0
ähnlichen ||| similar mix ||| 0-1
ähnlicher Resorptionsrate und ||| a similar rate and ||| 0-0 0-1 1-2 2-3
ähnlicher Resorptionsrate ||| a similar rate ||| 0-0 0-1 1-2
ähnlicher signifikanter ||| similar significant ||| 0-0 1-1
ähnlicher ||| a similar ||| 0-0 0-1
ähnlicher ||| similar ||| 0-0
älteren Frauen ||| elderly women , ||| 0-0 1-1
älteren Frauen ||| elderly women ||| 0-0 1-1
älteren Patienten ist keine ||| älteren Patienten ist keine ||| 0-0 1-1 2-2 3-3
älteren Patienten ist ||| älteren Patienten ist ||| 0-0 1-1 2-2
älteren Patienten mit ||| elderly patients with ||| 0-0 1-1 2-2
älteren Patienten ||| among elderly patients who ||| 1-0 0-1 1-2 1-3
älteren Patienten ||| elderly patients ||| 0-0 1-1
älteren Patienten ||| patients ||| 0-0 1-0
älteren Patienten ||| älteren Patienten ||| 0-0 1-1
älteren und jüngeren ||| elderly and younger ||| 0-0 1-1 2-2
älteren und ||| elderly and ||| 0-0 1-1
älteren ||| elderly ||| 0-0
älteren ||| älteren ||| 0-0
älteres ||| old ||| 0-0
ängstlich oder angespannt sein . ||| anxious or tense . ||| 0-0 1-1 2-2 3-2 4-3
ängstlich oder angespannt sein ||| anxious or tense ||| 0-0 1-1 2-2 3-2
ängstlich oder angespannt ||| anxious or tense . ||| 0-0 1-1 2-2
ängstlich oder angespannt ||| anxious or tense ||| 0-0 1-1 2-2
ängstlich oder ||| anxious or ||| 0-0 1-1
ängstlich ||| anxious ||| 0-0
ärztliche Verschreibung ( ||| medical prescription ( ||| 0-0 1-1 2-2
ärztliche Verschreibung ||| medical prescription ||| 0-0 1-1
ärztliche ||| attention ||| 0-0
ärztliche ||| medical ||| 0-0
ärztliche Überwachung auf kardiale Ereignisse ||| the occurrence of cardiac events ||| 1-0 2-0 2-1 3-3 4-4
ärztliche Überwachung auf kardiale ||| for the occurrence of cardiac ||| 1-1 2-1 2-2 3-4
ärztliche Überwachung auf kardiale ||| the occurrence of cardiac ||| 1-0 2-0 2-1 3-3
ärztliche Überwachung auf ||| for the occurrence of ||| 1-1 2-1 2-2
ärztliche Überwachung auf ||| for the occurrence ||| 1-1 2-1 2-2
ärztliche Überwachung auf ||| the occurrence of ||| 1-0 2-0 2-1
ärztliche Überwachung auf ||| the occurrence ||| 1-0 2-0 2-1
ärztlichen ||| seek medical ||| 0-0
ärztlichen ||| seek ||| 0-0
äußern . Symptome einer ||| symptoms of ||| 0-0 2-0 3-1
äußern . Symptome einer ||| the symptoms of ||| 0-1 2-1 3-2
äußern . Symptome ||| symptoms ||| 0-0 2-0
äußern . Symptome ||| the symptoms ||| 0-1 2-1
üben . ||| do this . ||| 0-0 0-1 1-2
üben . ||| to do this . ||| 0-1 0-2 1-3
üben ||| do this ||| 0-0 0-1
üben ||| to do this ||| 0-1 0-2
über " 640 " ||| over " 640 " ||| 0-0 2-1 1-2 3-2 3-3
über " 641 " ||| over " 641 " ||| 0-0 2-1 1-2 3-2 3-3
über " 643 " ||| over " 643 " ||| 0-0 2-1 1-2 3-2 3-3
über 1 Jahr ||| one year ||| 1-0 2-0 0-1 2-1
über 12 g/dl ||| greater than 12 g/ dl ||| 0-0 0-1 1-2 2-3 2-4
über 12 ||| greater than 12 ||| 0-0 0-1 1-2
über 12 ||| of greater than 12 ||| 0-0 0-1 0-2 1-3
über 14 g/dl ||| greater than 14 g/ dl ||| 0-0 0-1 1-2 2-3 2-4
über 14 ||| greater than 14 ||| 0-0 0-1 1-2
über 2 Wochen ||| for 2 weeks ||| 0-0 1-1 2-2
über 2 ||| for 2 ||| 0-0 1-1
über 24 ||| 24 ||| 1-0
über 24 ||| over 24 ||| 1-1
über 26 ||| 26-week , ||| 0-0 1-0
über 26 ||| 26-week , ||| 0-0 1-0 0-1
über 26 ||| 26-week ||| 0-0 1-0
über 3 Wochen . ||| over 3 weeks . ||| 0-0 1-1 2-2 3-3
über 3 Wochen ||| over 3 weeks ||| 0-0 1-1 2-2
über 3 ||| over 3 ||| 0-0 1-1
über 30 Minuten in ||| over 30 minutes ||| 0-0 1-1 2-2
über 30 Minuten ||| over 30 minutes ||| 0-0 1-1 2-2
über 30 kg und Erwachsene ||| over 30 kg and adults ||| 0-0 1-1 2-2 3-3 4-4
über 30 kg und ||| over 30 kg and ||| 0-0 1-1 2-2 3-3
über 30 kg ||| over 30 kg ||| 0-0 1-1 2-2
über 30 ||| over 30 ||| 0-0 1-1
über 45 mg ( einmal ||| above 45 mg ( once ||| 0-0 1-1 2-2 3-3 4-4
über 45 mg ( ||| above 45 mg ( ||| 0-0 1-1 2-2 3-3
über 45 mg ||| above 45 mg ||| 0-0 1-1 2-2
über 45 ||| above 45 ||| 0-0 1-1
über 50 Jahre , ||| aged over 50 years ||| 2-0 0-1 1-2 2-3
über 50 Jahre ||| aged over 50 years ||| 2-0 0-1 1-2 2-3
über 50 ||| over 50 ||| 0-0 1-1
über 65 ||| aged over 65 ||| 1-0 0-1 1-2
über 75 Jahre mit ||| over 75 years of age ||| 0-0 1-1 2-2 3-3 2-4
über 75 Jahre und Orientalen/Asiaten ||| over 75 years and ||| 0-0 1-1 2-2 4-2 3-3
über 75 ||| over 75 ||| 0-0 1-1
über CYP2C8 ||| by CYP2C8 ||| 0-0 1-1
über CYP2D6 . ||| CYP2D6 . ||| 0-0 1-0 2-1
über CYP2D6 ||| CYP2D6 ||| 0-0 1-0
über bestimmte sonstige Bestandteile von ||| bestimmte sonstige Bestandteile von ||| 0-0 1-0 1-1 1-2 2-2 3-2 1-3 4-3
über den gesamten Behandlungszeitraum ||| over the whole treatment period ||| 0-0 1-1 2-2 3-2 3-3 3-4
über den ||| over the ||| 0-0 1-1
über der ||| the ||| 1-0
über die Fäzes . ||| via the faeces . ||| 0-0 1-1 2-2 3-3
über die Fäzes ||| via the faeces ||| 0-0 1-1 2-2
über die Kombination einer partiell ||| mediated through a combination of ||| 0-0 4-0 4-1 3-2 2-3
über die Kombination einer partiell ||| mediated through a combination ||| 0-0 4-0 4-1 3-2 2-3
über die Nieren . ||| via the kidney . ||| 0-0 2-0 1-1 2-2 3-3
über die Nieren eliminiert . ||| eliminated via the kidney . ||| 3-0 0-1 2-1 1-2 2-3 4-4
über die Nieren eliminiert ||| eliminated via the kidney ||| 3-0 0-1 2-1 1-2 2-3
über die Nieren ||| via the kidney ||| 0-0 2-0 1-1 2-2
über die Zeitdauer der ||| over the duration of the ||| 0-0 1-1 2-2 3-3 3-4
über die Zeitdauer ||| over the duration ||| 0-0 1-1 2-2
über die ||| over the ||| 0-0 1-1
über die ||| via the ||| 0-0 1-1
über drei Biotransformations-Wege metabolisiert : ||| by three biotransformation pathways : ||| 2-0 0-1 1-1 2-2 2-3 3-3 4-4
über drei Biotransformations-Wege metabolisiert ||| by three biotransformation pathways ||| 2-0 0-1 1-1 2-2 2-3 3-3
über drei Wochen ( ||| for three weeks ( ||| 0-0 0-1 1-1 2-2 3-3
über drei Wochen an ||| over three weeks in ||| 0-0 1-1 2-2 3-2 3-3
über drei Wochen ||| for three weeks ||| 0-0 0-1 1-1 2-2
über drei ||| for three ||| 0-0 0-1 1-1
über drei ||| over three ||| 0-0 1-1
über drei ||| over ||| 0-0 1-0
über drei ||| three ||| 0-0 1-0
über ein Jahr ||| one year ||| 2-0 0-1 1-1 2-1
über ein Jahr ||| over one year ||| 0-0 2-1 1-2 2-2
über einen Zeitraum von 15 ||| over 15 ||| 0-0 1-0 2-0 3-0 4-1
über einen Zeitraum von 30 ||| over a period of 30 ||| 0-0 1-0 2-0 1-1 2-2 3-3 4-4
über einen Zeitraum von drei ||| over three ||| 0-0 1-0 2-0 3-0 4-1
über einen Zeitraum von mindestens ||| over at least ||| 0-0 1-0 2-0 3-0 4-1 4-2
über einen Zeitraum von ||| over a period of ||| 0-0 1-0 2-0 1-1 2-2 3-3
über einen Zeitraum von ||| over ||| 0-0 1-0 2-0 3-0
über einen Zeitraum ||| over a period ||| 0-0 1-0 2-0 1-1 2-2
über einen Zeitraum ||| over ||| 0-0 1-0 2-0
über einen längeren ||| dosing for a longer ||| 0-1 1-2 2-3
über einen längeren ||| for a longer ||| 0-0 1-1 2-2
über einen ||| beyond ||| 0-0
über einen ||| dosing for a ||| 0-1 1-2
über einen ||| for a ||| 0-0 1-1
über einen ||| through ||| 0-0 1-0
über einer Tagesdosis von ||| than a daily dose of ||| 0-0 1-1 2-2 2-3 3-4
über einer Tagesdosis ||| than a daily dose ||| 0-0 1-1 2-2 2-3
über einer ||| than a ||| 0-0 1-1
über verschiedene Wege unter ||| metabolised by multiple ||| 0-0 1-0 2-1 2-2 3-2
über verschiedene ||| metabolised ||| 0-0 1-0
über vier Tage , ||| for four days , ||| 0-0 0-1 1-1 2-2 3-3
über vier Tage ||| for four days ||| 0-0 0-1 1-1 2-2
über vier ||| for four ||| 0-0 0-1 1-1
über zwölf Wochen an ||| over 12 weeks ||| 0-0 1-1 2-2 3-2
über zwölf ||| over 12 ||| 0-0 1-1
über ||| , ||| 0-0
über ||| above ||| 0-0
über ||| beyond ||| 0-0
über ||| by ||| 0-0
über ||| dosing for ||| 0-1
über ||| for ||| 0-0
über ||| greater than ||| 0-0 0-1
über ||| of greater than ||| 0-0 0-1 0-2
über ||| over ||| 0-0
über ||| than ||| 0-0
über ||| via ||| 0-0
überempfindlich ( allergisch ) gegen ||| allergic ( hypersensitive ) to ||| 0-0 1-1 0-2 2-2 4-2 3-3 4-4
überempfindlich ( allergisch ) ||| are hypersensitive ( allergic ) ||| 0-0 0-1 2-1 1-2 2-3 3-4
überempfindlich ( allergisch ) ||| full list of ||| 1-0 0-1 2-2
überempfindlich ( allergisch ||| are hypersensitive ( allergic ||| 0-0 0-1 2-1 1-2 2-3
überempfindlich ( allergisch ||| full list of ||| 1-0 0-1 2-2
überempfindlich ( ||| full list ||| 1-0 0-1
überempfindlich ||| list ||| 0-0
überflüssig , ||| , orchidectomy ||| 1-0 0-1
überflüssig ||| orchidectomy ||| 0-0
übergewichtig oder fettleibig ||| overweight or obesity ||| 0-0 1-1 1-2
übergewichtig oder ||| overweight or obesity ||| 0-0 1-1 1-2
übergewichtig ||| overweight ||| 0-0
übergewichtigen Patienten ) , ||| overweight patients ) ||| 0-0 1-1 2-2
übergewichtigen Patienten ) ||| overweight patients ) ||| 0-0 1-1 2-2
übergewichtigen Patienten ||| overweight patients ||| 0-0 1-1
übergewichtigen ||| in ||| 0-0
übergewichtigen ||| overweight and ||| 0-0
übergewichtigen ||| overweight ||| 0-0
übermäßige ||| " high " ||| 0-0 0-1 0-2
überschreiten . ||| exceed ||| 0-0
überschreiten . ||| week . ||| 0-0 1-1
überschreiten ||| exceed ||| 0-0
überschreiten ||| week ||| 0-0
überschritten werden . ||| be exceeded . ||| 1-0 0-1 1-1 2-2
überschritten werden . ||| in section 4.2 . ||| 0-0 0-1 0-2 1-2 2-3
überschritten werden ||| be exceeded ||| 1-0 0-1 1-1
überschritten werden ||| in section 4.2 ||| 0-0 0-1 0-2 1-2
überschritten ||| exposure produced ||| 0-0
überschritten ||| exposure ||| 0-0
übersteigertem ||| condition ||| 0-0
überwachen . ||| therapy . ||| 0-0 1-1
überwachen ||| monitor ||| 0-0
überwachen ||| therapy ||| 0-0
überwacht und gegebenenfalls behandelt werden ||| monitored and controlled as necessary ||| 0-0 1-1 2-2 3-2 2-3 2-4 4-4
überwacht und ||| monitored and ||| 0-0 1-1
überwacht werden . ||| monitored . ||| 0-0 1-0 2-1
überwacht werden . ||| period . ||| 0-0 1-0 2-1
überwacht werden ||| monitored ||| 0-0 1-0
überwacht werden ||| period ||| 0-0 1-0
überwacht ||| monitored ||| 0-0
überwacht ||| should ||| 0-0
überwiegen . ||| . ||| 0-0 1-0
überwiegend in der Leber ||| extensively metabolised by the liver ||| 0-0 1-0 0-1 3-2 2-3 3-4
überwiegend in ||| extensively metabolised ||| 0-0 1-0 0-1
überwiegend ||| predominantly ||| 0-0
übliche Anfangsdosis ist 150 ||| usual starting dose is 150 ||| 0-0 1-1 1-2 2-3 3-4
übliche Anfangsdosis ist 50 ||| usual starting dose is 50 ||| 0-0 1-1 1-2 2-3 3-4
übliche Anfangsdosis ist 600 ||| usual starting dose is 600 ||| 0-0 1-1 1-2 2-3 3-4
übliche Anfangsdosis ist ||| usual starting dose is ||| 0-0 1-1 1-2 2-3
übliche Anfangsdosis ||| usual starting dose ||| 0-0 1-1 1-2
übliche Dosis beträgt 9,75 mg ||| usual dose is 9.75 mg ||| 0-0 1-1 2-2 3-3 4-4
übliche Dosis beträgt 9,75 ||| usual dose is 9.75 ||| 0-0 1-1 2-2 3-3
übliche Dosis beträgt ||| usual dose is ||| 0-0 1-1 2-2
übliche Dosis ist 15 mg ||| usual dose is 15 mg ||| 0-0 1-1 2-2 3-3 4-4
übliche Dosis ist 15 ||| usual dose is 15 ||| 0-0 1-1 2-2 3-3
übliche Dosis ist 5 mg ||| usual dose is 5 mg ||| 0-0 1-1 2-2 3-3 4-4
übliche Dosis ist 5 ||| usual dose is 5 ||| 0-0 1-1 2-2 3-3
übliche Dosis ist ||| usual dose is ||| 0-0 1-1 2-2
übliche Dosis ||| usual dose ||| 0-0 1-1
übliche ||| usual ||| 0-0
üblichen ||| employed ||| 0-0
üblicherweise in ||| usually in ||| 0-0 1-1
üblicherweise leicht bis mäßig ||| usually mild to moderate ||| 0-0 1-1 2-1 2-2 3-3
üblicherweise leicht bis ||| usually mild to ||| 0-0 1-1 2-1 2-2
üblicherweise ||| usually ||| 0-0
